RU2771624C2 - Compositions and methods for immune oncology - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, specifically to genome editing technologies; it can be used in medicine in the treatment of a disease related to tumor antigen expression, and in transplantation. nRNA molecule is proposed that includes tracr and crRNA, where crRNA includes a guiding domain containing any of SEQ ID NO: 1-SEQ ID NO:83 or SEQ ID NO: 5492-SEQ ID NO: 5527.

EFFECT: invention allows for using nRNA for mediating B2M editing in the cell using Cas9, while the cell is not a human germ cell or a human embryo cell.

63 cl, 66 dwg, 43 tbl, 18 ex

Description

RELATED APPLICATIONS

This application claims priority of U.S. Provisional Application 62/263,169 filed December 4, 2015, U.S. Provisional Application 62/316,784 filed April 1, 2016, and U.S. Provisional Application 62/394,290 filed September 14, 2016. All contents of these applications are incorporated into this application by reference.

BACKGROUND OF THE INVENTION

CRISPR (regularly clustered short palindromic repeats) evolved in bacteria as an adaptive immune system to protect against attack by viruses. Upon exposure to a virus, short segments of viral DNA are integrated into the CRISPR locus of the bacterial genome. The RNA is transcribed from a portion of the CRISPR locus that includes the viral sequence. This RNA, which contains a complementary sequence to the viral genome, mediates the directed interaction of the Cas9 protein with a sequence in the viral genome. The Cas9 protein cleaves and thus causes silencing of the viral target.

Recently, the CRISPR/Cas system has been adapted for genome editing in eukaryotic cells. The introduction of site-specific single-strand breaks (SSBs) or double-strand breaks (DSBs) allows alteration of the target sequence, for example by non-homologous end joining (NHEJ) or directed homologous repair (HDR).

SUMMARY OF THE INVENTION

The invention described in this application relates to compositions and methods for immuno-oncology, for example, cells modified in certain target sequences in their genome, including those modified by the introduction of CRISPR systems, which include nRNA molecules that interact with the specified sequences - targets, as well as methods for their preparation and use. For example, the present disclosure relates to nRNA molecules, CRISPR systems, cells, and methods useful for editing the genome of cells, e.g., T cells, e.g., T cells further modified to express a chimeric antigen receptor, and applicable for the treatment of diseases such as cancer. diseases.

In a first aspect of the invention, there is provided an nRNA molecule comprising tracr and crRNA, wherein the crRNA includes a guide domain that is complementary to an allogeneic T cell target sequence selected from B2M, CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, TRBC2, HLA- A, HLA-B, HLA-C, DCK, CD52, FKBP1A, CIITA, NLRC5, RFXANK, RFX5, RFXAP, or NR3C1.

In embodiments, the nRNA molecules:

2(a) the target of the allogeneic T cell is B2M and the targeting domain comprises any of SEQ ID NO: 1 - SEQ ID NO: 83 or SEQ ID NO: 5492 - SEQ ID NO: 5527;

2(b) the target of the allogeneic T cell is TRAC and the targeting domain comprises any of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965;

2(c) the target of the allogeneic T cell is TRBC1 and the targeting domain comprises any of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097;

2(d) the target of the allogeneic T cell is TRBC2 and the targeting domain comprises any of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226;

2(e) the target of the allogeneic T cell is CD247 and the targeting domain comprises any of SEQ ID NO: 84 - SEQ ID NO: 392;

2(f) the target of the allogeneic T cell is CD3D and the targeting domain comprises any of SEQ ID NO: 393 - SEQ ID NO: 532 or SEQ ID NO: 10780 - SEQ ID NO: 10794;

2(g) the target of the allogeneic T cell is CD3E and the targeting domain comprises any of SEQ ID NO: 533 - SEQ ID NO: 839 or SEQ ID NO: 10677 - SEQ ID NO: 10764;

2(h) the target of the allogeneic T cell is CD3G and the targeting domain comprises any of SEQ ID NO: 840 - SEQ ID NO: 968 or SEQ ID NO: 10765 - SEQ ID NO: 10779;

2(i) the target of the allogeneic T cell is HLA-A and the targeting domain comprises any of SEQ ID NO: 969 - SEQ ID NO: 1345;

2(j) the target of the allogeneic T cell is HLA-B and the targeting domain includes any of SEQ ID NO: 1346 - SEQ ID NO: 1698;

2(k) the target of the allogeneic T cell is HLA-C and the targeting domain comprises any of SEQ ID NO: 1699 - SEQ ID NO: 2068;

2(l) the target of the allogeneic T cell is DCK and the targeting domain comprises any of SEQ ID NO: 5278 - SEQ ID NO: 5491;

2(m) the target of the allogeneic T cell is CD52 and the targeting domain includes any of SEQ ID NO: 6227 - SEQ ID NO: 6324;

2(n) the target of the allogeneic T cell is FKBP1A and the targeting domain comprises any of SEQ ID NO: 6325 - SEQ ID NO: 6583 or SEQ ID NO: 6662 - SEQ ID NO: 6749;

2(o) the target of the allogeneic T cell is NR3C1 and the targeting domain includes any of SEQ ID NO: 2069 - SEQ ID NO: 2941;

2(p) the target of the allogeneic T cell is CIITA and the targeting domain comprises any of SEQ ID NO: 6750 - SEQ ID NO: 7716 or SEQ ID NO: 7717 - SEQ ID NO: 7804; or

2(q), the target of the allogeneic T cell is NLRC5 and the targeting domain includes any of SEQ ID NO: 8622 - SEQ ID NO: 10089.

In embodiments of the nRNA molecule, the target of the allogeneic T cell is TRAC and the targeting domain comprises SEQ ID NO: 5569, SEQ ID NO: 5585, SEQ ID NO: 5587, SEQ ID NO: 5592, SEQ ID NO: 5601, SEQ ID NO : 5589, SEQ ID NO: 5600, SEQ ID NO: 5594, SEQ ID NO: 5571, SEQ ID NO: 5593, SEQ ID NO: 5574, SEQ ID NO: 5598, SEQ ID NO: 5586, SEQ ID NO: 5599 , SEQ ID NO: 5591, SEQ ID NO: 5610, SEQ ID NO: 5608, SEQ ID NO: 5617, SEQ ID NO: 5619 or SEQ ID NO: 5620, for example, the targeting domain includes SEQ ID NO: 5569, SEQ ID NO: 5586, SEQ ID NO: 5587, SEQ ID NO: 5592, SEQ ID NO: 5599 or SEQ ID NO: 5600, e.g., the targeting domain includes SEQ ID NO: 5569, SEQ ID NO: 5587, SEQ ID NO: 5592 or SEQ ID NO: 5586, for example, the targeting domain includes SEQ ID NO: 5569.

In embodiments of the nRNA molecule, the target of the allogeneic T cell is TRBC2 and the targeting domain comprises SEQ ID NO: 5719, SEQ ID NO: 5694, SEQ ID NO: 5706, SEQ ID NO: 5696, SEQ ID NO: 5711, SEQ ID NO : 5708, SEQ ID NO: 5709, SEQ ID NO: 5712, SEQ ID NO: 5703, SEQ ID NO: 5707, SEQ ID NO: 5687, SEQ ID NO: 5705, SEQ ID NO: 5713, SEQ ID NO: 5715 or SEQ ID NO: 5710.

In embodiments of the nRNA molecule, the target of the allogeneic T cell is B2M and the targeting domain comprises SEQ ID NO: 5519, SEQ ID NO: 5497, SEQ ID NO: 5499, SEQ ID NO: 5498, SEQ ID NO: 5503, SEQ ID NO : 5496, SEQ ID NO: 5507, SEQ ID NO: 5515, SEQ ID NO: 5493, SEQ ID NO: 5506, SEQ ID NO: 5509, SEQ ID NO: 5517, SEQ ID NO: 5521, SEQ ID NO: 5520 , SEQ ID NO: 5500, SEQ ID NO: 5494, SEQ ID NO: 5508, SEQ ID NO: 5514 or SEQ ID NO: 5492, for example, the targeting domain includes SEQ ID NO: 5496, SEQ ID NO: 5498 or SEQ ID NO: 5509.

In embodiments of the nRNA molecule, the target of the allogeneic T cell is CIITA and the targeting domain comprises SEQ ID NO: 7771, SEQ ID NO: 7769, SEQ ID NO: 7773, SEQ ID NO: 7726, SEQ ID NO: 7758, SEQ ID NO : 7739, SEQ ID NO: 7779, SEQ ID NO: 7770, SEQ ID NO: 7749, SEQ ID NO: 7754, SEQ ID NO: 7745, SEQ ID NO: 7785, SEQ ID NO: 7731, SEQ ID NO: 7772 , SEQ ID NO: 7743 or SEQ ID NO: 7750, for example, the targeting domain includes SEQ ID NO: 7769, SEQ ID NO: 7771, SEQ ID NO: 7739 or SEQ ID NO: 7785.

In embodiments of the nRNA molecule, the target of the allogeneic T cell is CD3E and the targeting domain comprises SEQ ID NO: 10729, SEQ ID NO: 10719, SEQ ID NO: 10764, SEQ ID NO: 10789, SEQ ID NO: 10701, SEQ ID NO : 10700 or SEQ ID NO: 10722.

In embodiments of the gRNA molecule, the target of the allogeneic T cell is FKBP1A and the targeting domain comprises SEQ ID NO: 6693, SEQ ID NO: 6705, SEQ ID NO: 6694, SEQ ID NO: 6708, or SEQ ID NO: 6699.

In a second aspect of the invention, there is provided an nRNA molecule comprising tracr and crRNA, wherein the crRNA includes a targeting domain that is complementary to a target sequence of an inhibitory molecule or a downstream signaling effector via an inhibitory molecule, which is selected from CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4 , CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGF-beta or PTPN11.

In embodiments, the nRNA molecules:

15(a) the inhibitory molecule is CD274 (PD-L1) and the targeting domain includes any of SEQ ID NO: 2942 - SEQ ID NO: 3270;

15(b) the inhibitory molecule is HAVCR2 (TIM3) and the targeting domain includes any of SEQ ID NO: 3271 - SEQ ID NO: 3541;

15(c) the inhibitory molecule is LAG3 and the targeting domain includes any of SEQ ID NO: 3542 - SEQ ID NO: 4032;

15(d) the inhibitory molecule is PDCD1 (PD-1) and the targeting domain includes any of SEQ ID NO: 4033 - SEQ ID NO: 4589 or SEQ ID NO: 5720 - SEQ ID NO: 5815; or

15(e), the downstream signaling effector via an inhibitory molecule is PTPN1, and the targeting domain includes any of SEQ ID NO: 4590 - SEQ ID NO: 5277.

In embodiments of the gRNA molecule, the inhibitory molecule is PDCD1 and the targeting domain comprises SEQ ID NO: 5743, SEQ ID NO: 5798, SEQ ID NO: 5748, SEQ ID NO: 5722, SEQ ID NO: 5800, SEQ ID NO: 5735, SEQ ID NO: 5724, SEQ ID NO: 5731, SEQ ID NO: 5725, SEQ ID NO: 5775, SEQ ID NO: 5766, SEQ ID NO: 5727, SEQ ID NO: 5744, SEQ ID NO: 5751 or SEQ ID NO: 5734, for example, the targeting domain includes SEQ ID NO: 5775.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, the targeting domain includes 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in the reference sequence), 24 (if present in the reference sequence) or 25 (if present in the reference sequence) consecutive nucleic acids of any of the indicated targeting domain sequences. In other embodiments of the nRNA molecule, including any of the above aspects and embodiments, the targeting domain consists of 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in the reference sequence) or 24 (if present in the reference sequence) or 25 (if present in the reference sequence) consecutive nucleic acids of any of the indicated targeting domain sequences. In embodiments, the nRNA molecules, including any of the above aspects and embodiments, 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in the reference sequence) sequence) or 24 (if present in the reference sequence) or 25 (if present in the reference sequence) consecutive nucleic acids of any of the specified targeting domain sequences are 17, 18, 19, 20, 21 (if present in the reference sequence), 22 ( if present in the reference sequence), 23 (if present in the reference sequence) or 24 (if present in the reference sequence), or 25 (if present in the reference sequence) contiguous nucleic acids located at the 3' end of said targeting domain sequence. In other embodiments, the implementation of the nRNA molecules, including in any of the above aspects and embodiments, 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in reference sequence) or 24 (if present in the reference sequence) or 25 (if present in the reference sequence) consecutive nucleic acids of any of the specified targeting domain sequences are 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in the reference sequence) or 24 (if present in the reference sequence) or 25 (if present in the reference sequence) contiguous nucleic acids located at the 5' end of said targeting domain sequence. In other embodiments, the implementation of the nRNA molecules, including in any of the above aspects and embodiments, 17, 18, 19, 20, 21 (if present in the reference sequence), 22 (if present in the reference sequence), 23 (if present in reference sequence) or 24 (if present in the reference sequence) or 25 (if present in the reference sequence) consecutive nucleic acids of any of the specified targeting domain sequences do not include the 5' or 3' nucleic acids of the specified targeting domain sequence.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, the targeting domain consists of the specified targeting domain sequence.

The following general aspects of an nRNA molecule may be combined, alone or in combination, with any of the nRNAs comprising the targeting domain described herein, such as the targeting domain specified in any of the above aspects and embodiments.

In embodiments, the nRNA molecules, including any of the above aspects and embodiments, the crRNA portion and the tracr portion hybridize to form a flagpole comprising SEQ ID NO: 6584 or SEQ ID NO: 6585. In other embodiments, the flagpole further comprises a first extension of the flagpole portion located 3' to the crRNA of the flagpole portion, wherein said first flagpole extension comprises SEQ ID NO: 6586. In other embodiments, the flagpole further comprises a second flagpole extension located 3' to the crRNA of the flagpole portion and, if present, relative to the first flagpole extension where said second flagpole extension includes SEQ ID NO: 6587.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, tracr includes, for example consists of:

(a) SEQ ID NO: 7820 optionally further comprising, at the 3' end, an additional 1, 2, 3, 4, 5, 6 or 7 uracil nucleotides (U);

(b) SEQ ID NO: 6660; or

(c) SEQ ID NO: 6661. In such embodiments, the crRNA portion of the flagpole includes SEQ ID NO: 6607 or SEQ ID NO: 6608.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, the tracr includes SEQ ID NO: 6589 or SEQ ID NO: 6590, and optionally, if a first flagpole extension is present, the first tracr extension located 5' relative to SEQ ID NO: 6589 or SEQ ID NO: 6590, wherein said first tracr extension includes SEQ ID NO: 6591.

In embodiments, the nRNA molecules, including any of the above aspects and embodiments, the targeting domain and tracr are located on separate nucleic acid molecules.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, the crRNA comprises (e.g., consists of), 5' to 3', [guide domain]-:

a) SEQ ID NO: 6584;

b) SEQ ID NO: 6585;

c) SEQ ID NO: 6605;

d) SEQ ID NO: 6606;

e) SEQ ID NO: 6607;

f) SEQ ID NO: 6608; or

g) SEQ ID NO: 7806.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, tracr includes (e.g., consists of), 5' to 3':

a) SEQ ID NO: 6589;

b) SEQ ID NO: 6590;

c) SEQ ID NO: 6609;

d) SEQ ID NO: 6610;

e) SEQ ID NO: 6660;

f) SEQ ID NO: 6661;

g) SEQ ID NO: 7820;

h) SEQ ID NO: 7807;

i) SEQ ID NO: 7808;

j) SEQ ID NO: 7809;

k) any of a) to j) above, further comprising, at the 3' end, at least 1, 2, 3, 4, 5, 6, or 7 uracil nucleotides (U), e.g., 1, 2, 3 , 4, 5, 6 or 7 uracil nucleotides (U);

l) any of a) to k) above, further comprising, at the 3' end, at least 1, 2, 3, 4, 5, 6, or 7 adenine (A) nucleotides, e.g., 1, 2, 3 , 4, 5, 6 or 7 adenine (A) nucleotides; or

m) any of a) to l) above, further comprising, at the 5' end (e.g., 5' ends), at least 1, 2, 3, 4, 5, 6, or 7 adenine (A) nucleotides eg 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides.

In preferred embodiments, the nRNA molecules, including any of the above aspects and embodiments, the targeting domain and tracr are located on separate nucleic acid molecules, and the nucleic acid molecule comprising the targeting domain comprises SEQ ID NO: 6607, optionally located directly 3 ' relative to the targeting domain, and a nucleic acid molecule comprising tracr includes, for example, consists of SEQ ID NO: 6660.

In other embodiments, the implementation of the nRNA molecules, including any of the above aspects and embodiments, the targeting domain and tracr are located on the same nucleic acid molecule, and the tracr is located 3' relative to the targeting domain. In such embodiments, the implementation of the nRNA molecule, including any of the above aspects and embodiments, the nRNA molecule further includes a loop located 3' relative to the targeting domain and 5' relative to tracr, for example, a loop that includes (for example, consists of), SEQ ID NO: 6588.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, the nRNA molecule comprises (e.g., consists of), 5' to 3', [guide domain]-:

(a) SEQ ID NO: 6601;

(b) SEQ ID NO: 6602;

(c) SEQ ID NO: 6603;

(d) SEQ ID NO: 6604;

(e) SEQ ID NO: 7811; or

(f) any of (a) - (e), above, further comprising, at the 3' end, 1, 2, 3, 4, 5, 6, or 7 uracil (U) nucleotides.

In preferred embodiments, the implementation of the nRNA molecules, including in any of the above aspects and embodiments, the guide domain and tracr are located on the same nucleic acid molecule, and while the specified nucleic acid molecule includes, for example consists of, the specified guide domain and SEQ ID NO : 6601, optionally located directly 3' relative to the specified guide domain.

In preferred embodiments, the implementation of the nRNA molecules, including in any of the above aspects and embodiments, the guide domain and tracr are located on the same nucleic acid molecule, and while the specified nucleic acid molecule includes, for example consists of, the specified guide domain and SEQ ID NO : 7811, optionally located directly 3' relative to the specified guide domain.

In embodiments, the nRNA molecule consists of unmodified RNA nucleotides and nucleic acid linkages. In other embodiments, the implementation of the nRNA molecule contains one or more modifications, for example, as described in this application. In embodiments of the nRNA molecule, including any of the above aspects and embodiments, one or optionally more than one nucleic acid molecule of the nRNA molecule comprises:

a) a phosphothioate modification, eg three phosphothioate modifications, at the 3' end of said nucleic acid molecule or molecules;

b) a phosphothioate modification, eg three phosphothioate modifications, at the 5' end of said nucleic acid molecule or molecules;

c) a 2'-O-methyl modification, eg three 2'-O-methyl modifications, at the 3' end of said nucleic acid molecule or molecules;

d) a 2'-O-methyl modification, eg three 2'-O-methyl modifications, at the 5' end of said nucleic acid molecule or molecules;

e) a 2'-O-methyl modification at each of the 4th from the end, 3rd from the end and 2nd from the end of the 3'-terminal residues of the indicated nucleic acid molecule or molecules; or

f) any combination of them.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, upon administration of a CRISPR system (e.g., RNP as described herein, e.g. RNP that includes a Cas9 molecule, e.g. as described herein) , including the nRNA molecule (for example, as described in this application), into the cell, the indel is formed at or near the target sequence complementary to the directing domain of the nRNA molecule. In embodiments, the indel is a frameshift mutation. In embodiments, the indel is the indel listed in any of Figure 34A, Figure 34B, Figure 36, Figure 38, Figure 41, Figure 44, Figure 48, Figure 49, Figure 50, or Figure 53.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, upon administration of a CRISPR system (e.g., RNP as described herein, e.g. RNP that includes a Cas9 molecule, e.g. as described herein) , including an nRNA molecule (for example, as described in this application), into a population of cells, the indel is formed at or near the target sequence, complementary to the directing domain of the nRNA molecule by at least about 40%, for example, at least about 50%, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., at least about 90%, e.g., at least about 95%, e.g., at least about 96%, such as at least about 97%, such as at least about 98%, such as at least about 99%, of the cells in the population. In embodiments, an indel that is a frameshift mutation is generated at or near a target sequence that is at least about 20%, such as at least about 30%, such as at least about 35%, such as at least about 40%, such as at least about 45%, such as at least about 50%, such as at least about 55%, such as at least about 60%, such as at least about 65%, such as at least about 70%, such as at least about 75%, such as at least about 80%, such as at least about 85%, such as at least about 90 %, such as at least about 95%, such as at least about 99%, of the cells in the population. In embodiments, at least about 30%, such as the least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 95%, such as at least about 96%, such as at least about 97%, such as at least about 98% , for example, at least about 99% of the cells in the population, the indel is the indel listed in any of Figure 34A, Figure 34B, Figure 36, Figure 38, Figure 41, Figure 44, Figure 48, Figure 49, Figure 50, or Figure 53. In embodiments, the five most commonly found indels in said cell population include three or more, such as four, such as five, indels associated with any of the nRNAs listed in any of Figure 34A, Figure 34B, Figures 36, Figures 38, Figures 41, Figures 44, Figures 48, Figures 49, Figures 50, or Figures 53. The indel or indel profile is as measured and/or quantified, for example, by next generation sequencing (NGS).

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, upon administration of a CRISPR system (e.g., RNP as described herein, e.g. RNP that includes a Cas9 molecule, e.g. as described herein) , including an nRNA molecule (for example, as described in this application), into a cell (or population of cells), as described in this application, the expression of a gene that includes a target sequence complementary to the directing domain of the nRNA molecule is reduced or eliminated in the specified cell. In embodiments, expression of said gene is reduced or eliminated by at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 95%, such as at least about 96%, such as at least about 97%, such as at least about 98%, such as at least about 99% of the cells in the population. In embodiments, reduced or abolished expression is measured by flow cytometry. In other embodiments, for example, in the case of FKBP1A, reduced or eliminated expression is measured using functional analysis, for example, as described in this application.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, upon administration of a CRISPR system (e.g., RNP as described herein, e.g. RNP that includes a Cas9 molecule, e.g. as described herein) , including an nRNA molecule (for example, as described in this application), into a cell, as described in this application, no off-target indels are formed in the specified cell, for example, as detected using next generation sequencing and/or nucleotide insertion analysis, for example, as described in this application.

In embodiments of the nRNA molecule, including any of the above aspects and embodiments, upon administration of a CRISPR system (e.g., RNP as described herein, e.g. RNP that includes a Cas9 molecule, e.g. as described herein) , including an nRNA molecule (for example, as described in this application), in a population of cells, as described in this application, the non-target indel is found in no more than about 5%, for example, no more than about 1%, for example, no more than about 0.1%, for example, not more than about 0.01%, of cells in a population of cells, for example, as detected by next generation sequencing and/or nucleotide insertion analysis.

In any of the above aspects and embodiments in which a cell is specified, the cell is (or the cell population includes) a mammalian, primate or human cell, for example, is a human cell. In any of the above aspects and embodiments where the cell is specified, the cell is (or the cell population includes) an immune effector cell, e.g., T cell or NK cell, e.g., is a T cell, e.g. CD4+ T cell, CD8+ T cell or combination thereof.

In any of the above aspects and embodiments in which a cell is indicated, the cell (or population of cells) has been or will be modified to express a chimeric antigen receptor (CAR). In embodiments, CAR is:

(a) CD19CAR; or

(b) BCMA CAR. In embodiments:

(a) CAR is a CD19 CAR comprising an antigen binding domain comprising any of SEQ ID NO: 7883 - SEQ ID NO: 7898;

(b) CAR is a CD19 CAR comprising SEQ ID NO: 7909 or SEQ ID NO: 7920;

(c) CAR is a BCMA CAR comprising an antigen-binding domain comprising any of SEQ ID NO: 7939 - SEQ ID NO: 8112, for example, comprising the antigen-binding domain of SEQ ID NO: 7949; or

(d) CAR is a BCMA CAR including any of SEQ ID NO: 8549 - SEQ ID NO: 8621, for example, including SEQ ID NO: 8559.

In any of the above aspects and embodiments in which said cell is indicated, the cell is allogeneic with respect to the patient to whom said cell is to be administered. In other embodiments, the implementation of the cell is autologous in relation to the patient who is supposed to enter the specified cell.

In another aspect of the invention, a composition is provided comprising a first nRNA molecule of any of the previous aspects and embodiments, further comprising a Cas9 molecule. In embodiments, the Cas9 molecule includes, for example consists of, any of SEQ ID NO: 6611 or SEQ ID NO: 7821 to SEQ ID NO: 7831. In embodiments, the Cas9 molecule is active or inactive S. pyogenes Cas9. In preferred embodiments, the first nRNA molecule and the Cas9 molecule are present in a ribonucleoprotein complex (RNP).

In aspects, the composition may include more than one nRNA molecule, for example more than one nRNA molecule, each of which is complexed with the Cas9 molecule described in this application. For example, in embodiments, the composition further comprises a second nRNA molecule; a second nRNA molecule and a third nRNA molecule; or a second nRNA molecule, a third nRNA molecule, and a fourth nRNA molecule, where the second nRNA molecule, the third nRNA molecule (if present) and the fourth nRNA molecule (if present) are an nRNA molecule as described herein, for example, an nRNA molecule of any of the previous aspects and embodiments, and wherein each nRNA molecule of the composition is complementary to a different target sequence (i.e., includes a different guide domain). In embodiments, the first nRNA molecule, the second nRNA molecule, the third nRNA molecule (if present) and the fourth nRNA molecule (if present) are complementary to target sequences in the same gene. In such embodiments, the first nRNA molecule, the second nRNA molecule, the third nRNA molecule (if present), and the fourth nRNA molecule (if present) are complementary to the target sequences except for no more than 20,000 nucleotides, no more than 10,000 nucleotides, no more than 6000, not more than 5000 nucleotides, not more than 4000, not more than 1000 nucleotides, not more than 500 nucleotides, not more than 400 nucleotides, not more than 300 nucleotides, not more than 200 nucleotides, not more than 100 nucleotides, not more than 90 nucleotides, not more than 80 nucleotides, not more than 70 nucleotides, not more than 60 nucleotides, not more than 50 nucleotides, not more than 40 nucleotides, not more than 30 nucleotides, not more than 20 nucleotides, or not more than 10 nucleotides. In other embodiments, the first nRNA molecule, the second nRNA molecule, the third nRNA molecule (if present), and the fourth nRNA molecule (if present) are complementary to the target sequence at different genes or loci, e.g., different genes, as described herein.

In embodiments, the first nRNA molecule is an nRNA molecule according to any one of 2(b), 2(c), 2(d), 2(d), 2(e), 2(f), 2(g) or 2(h ); and the second nRNA molecule is an nRNA molecule according to any one of 2(a), 2(i), 2(j), 2(k), or 2(q); and the third nRNA molecule is an nRNA molecule according to any one of 15(a), 15(b), 15(c), 15(d) or 15(e). In other embodiments, the first nRNA molecule is an nRNA molecule according to any one of 2(b), 2(c), 2(d), 2(d), 2(e), 2(f), 2(g), or 2( h); and the second nRNA molecule is an nRNA molecule according to any one of 2(l), 2(m), 2(n) or 2(o); and the third nRNA molecule is an nRNA molecule according to any one of 15(a), 15(b), 15(c), 15(d) or 15(e). In other embodiments, the first nRNA molecule is an nRNA molecule according to any one of 2(b), 2(c), 2(d), 2(d), 2(e), 2(f), 2(g), or 2( h); and the second nRNA molecule is an nRNA molecule according to any one of 2(l), 2(m), 2(n) or 2(o). In other embodiments, the first nRNA molecule is an nRNA molecule according to any one of 2(b), 2(c), 2(d), 2(d), 2(e), 2(f), 2(g), or 2( h); and the second nRNA molecule is an nRNA molecule according to any one of 2(a), 2(i), 2(j), or 2(k). In other embodiments, the first nRNA molecule is an nRNA molecule according to any one of 2(b), 2(c), 2(d), 2(d), 2(e), 2(f), 2(g), or 2( h); and the second nRNA molecule is an nRNA molecule according to any one of 15(a), 15(b), 15(c), 15(d) or 15(e). In other embodiments, the first nRNA molecule is an nRNA molecule according to any one of 15(a), 15(b), 15(c), 15(d), or 7(e); and the second nRNA molecule is an nRNA molecule according to any one of 15(a), 15(b), 15(c), 15(d) or 15(e). In embodiments according to any of the above embodiments, a third nRNA is present and the third nRNA molecule is the nRNA molecule according to any of 15(a), 15(b), 15(c), 15(d), or 15(e). In embodiments, the composition consists of two nRNA molecules according to any of the above aspects and embodiments of the nRNA molecule. In embodiments, the composition consists of three nRNA molecules according to any of the above aspects and embodiments of the nRNA molecule. In embodiments, the composition consists of a first nRNA molecule according to any of the above aspects and embodiments, wherein the targeting domain of said first nRNA molecule is a targeting domain according to any of 2(a), 2(i), 2(j), or 2(k) ; and a second nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, wherein the targeting domain of said second nRNA molecule is a targeting domain according to any of 2(b), 2(c), 2(d), 2(f), 2( g), 2(h) or 2(i).

In embodiments, the composition comprises two molecules of nRNA, and the targeting domain of said first nRNA molecule includes, for example, consists of, SEQ ID NO: 5519, SEQ ID NO: 5497, SEQ ID NO: 5499, SEQ ID NO: 5498, SEQ ID NO: 5503, SEQ ID NO: 5496, SEQ ID NO: 5507, SEQ ID NO: 5515, SEQ ID NO: 5493, SEQ ID NO: 5506, SEQ ID NO: 5509, SEQ ID NO: 5517, SEQ ID NO: 5521, SEQ ID NO: 5520, SEQ ID NO: 5500, SEQ ID NO: 5494, SEQ ID NO: 5508, SEQ ID NO: 5514 or SEQ ID NO: 5492; and the targeting domain of said second gRNA molecule includes, for example, consists of, SEQ ID NO: 5569, SEQ ID NO: 5585, SEQ ID NO: 5587, SEQ ID NO: 5592, SEQ ID NO: 5601, SEQ ID NO: 5589, SEQ ID NO: 5600, SEQ ID NO: 5594, SEQ ID NO: 5571, SEQ ID NO: 5593, SEQ ID NO: 5574, SEQ ID NO: 5598, SEQ ID NO: 5586, SEQ ID NO: 5599, SEQ ID NO : 5591, SEQ ID NO: 5610, SEQ ID NO: 5608, SEQ ID NO: 5617, SEQ ID NO: 5619 or SEQ ID NO: 5620.

In embodiments, the composition comprises two molecules of nRNA, and the targeting domain of said first nRNA molecule includes, for example, consists of, SEQ ID NO: 5496, SEQ ID NO: 5498, or SEQ ID NO: 5509; and the targeting domain of said second gRNA molecule includes, for example, consists of SEQ ID NO: 5569, SEQ ID NO: 5586, SEQ ID NO: 5587, SEQ ID NO: 5592, SEQ ID NO: 5599, or SEQ ID NO: 5600.

In embodiments, the composition comprises two molecules of nRNA, and the targeting domain of said first nRNA molecule includes, for example, consists of, SEQ ID NO: 5496, SEQ ID NO: 5498, or SEQ ID NO: 5509; and the targeting domain of said second nRNA molecule includes, for example, consists of SEQ ID NO: 5569.

In embodiments, the composition comprises two molecules of nRNA, and the targeting domain of said first nRNA molecule includes, for example, consists of, SEQ ID NO: 5496, SEQ ID NO: 5498, or SEQ ID NO: 5509; and the targeting domain of said second gRNA molecule includes, for example, consists of, SEQ ID NO: 10729, SEQ ID NO: 10719, SEQ ID NO: 10764, SEQ ID NO: 10789, SEQ ID NO: 10701, SEQ ID NO: 10700, or SEQ ID NO: 10722.

In embodiments, including any of the above aspects and embodiments, the composition further comprises a third nRNA molecule described herein, for example in any of the above aspects and embodiments of the nRNA molecule, wherein the targeting domain of said third nRNA molecule is the targeting domain. according to any of 2(n) or 2(q). In embodiments, the targeting domain of said third nRNA molecule includes, for example, consists of, SEQ ID NO: 7771, SEQ ID NO: 7769, SEQ ID NO: 7773, SEQ ID NO: 7726, SEQ ID NO: 7758, SEQ ID NO: 7739 , SEQ ID NO: 7779, SEQ ID NO: 7770, SEQ ID NO: 7749, SEQ ID NO: 7754, SEQ ID NO: 7745, SEQ ID NO: 7785, SEQ ID NO: 7731, SEQ ID NO: 7772, SEQ ID NO: 7743 or SEQ ID NO: 7750; for example, includes (for example, consists of), SEQ ID NO: 7769, SEQ ID NO: 7771, SEQ ID NO: 7739, or SEQ ID NO: 7785.

In embodiments, including any of the above aspects and embodiments, the composition further comprises a fourth nRNA molecule described herein, for example in any of the above aspects and embodiments of the nRNA molecule, wherein the targeting domain of said fourth nRNA molecule is complementary to the sequence - target of a target of an NK inhibitory molecule, for example, LILRB1. In embodiments, the targeting domain of said fourth nRNA molecule includes, for example consists of, the following:

a) any of SEQ ID NO: 10090 - SEQ ID NO: 10673;

b) 17, 18, 19, 20, 21, 22, 23 or 24 consecutive nucleotides, preferably 20 consecutive nucleotides, of any of SEQ ID NO: 10090 - SEQ ID NO: 10673.

c) 5' 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides, preferably 20 nucleotides, of any of SEQ ID NO: 10090 - SEQ ID NO: 10673; or

d) 3' 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides, preferably 20 nucleotides, of any of SEQ ID NO: 10090 - SEQ ID NO: 10673.

In embodiments of the composition (including any of the above aspects and embodiments), the targeting domain of the first nRNA molecule (described herein), the targeting domain of the second nRNA molecule (described herein) and, if present, the targeting domain of the third nRNA molecule (described in this application) includes, for example consists of, the sequence of any of:

a) Combinations A1 - combinations A72 of Table 33;

b) Combinations B1 - combinations B84 of Table 34;

c) Combinations C1 - combinations C42 of Table 35;

d) Combinations D1 - combinations D36 of Table 36;

e) Combinations E1 - combinations E30 of Table 37; or

f) F1 combinations - F60 combinations of Table 38.

In any of the above aspects and embodiments, each of these nRNA molecules is in a ribonucleoprotein complex (RNP) with the Cas9 molecule described in this application.

In embodiments, the nRNA molecule or composition is included in a growth medium suitable for electroporation.

In embodiments where each of said nRNA molecules is present in the Cas9 RNP described herein, each of said RNP complexes is present at a concentration of less than about 10 μM, such as less than about 3 μM, such as less than about 1 µM, eg, less than about 0.5 µM, eg, less than about 0.3 µM, eg, less than about 0.1 µM.

In embodiments, the composition further comprises a cell, eg, a population of cells, eg, an immune effector cell, eg, a CAR-expressing immune effector cell, eg, as described herein.

In another aspect of the invention, a nucleic acid is provided that encodes an nRNA molecule according to any of the previous aspects or embodiments of the nRNA molecule, or (e.g., all) component(s) of a composition according to any of the above aspects and embodiments of the composition. In embodiments, the nucleic acid includes a promoter operably linked to a sequence that encodes an nRNA molecule. In embodiments, the promoter is a promoter recognized by RNA polymerase II or RNA polymerase III. In other embodiments, the promoter is a U6 promoter or a HI promoter. In embodiments, the nucleic acid also encodes a Cas9 molecule. In embodiments, the nucleic acid comprises a promoter operably linked to a sequence that encodes a Cas9 molecule, such as an EF-1 promoter, a CMV IE gene promoter, an EF-1α promoter, a ubiquitin C promoter, or a phosphoglycerate kinase (PGK) promoter.

In another aspect of the invention, a vector is provided that includes a nucleic acid according to any of the above nucleic acid aspects and embodiments. In embodiments, the vector is selected from the group consisting of a lentiviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes simplex virus (HSV) vector, a plasmid, a minicircle, a nanoplasmid, and an RNA vector.

In another aspect of the invention, a composition is provided that includes an nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule and a nucleic acid encoding a Cas9 molecule, for example, as described herein.

In another aspect of the invention, a composition is provided that includes a nucleic acid encoding an nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, and a Cas9 molecule, for example, as described herein.

In embodiments of any of the compositions of the invention, the composition further comprises a template nucleic acid. In embodiments, the template nucleic acid comprises a nucleotide that corresponds to a nucleotide in the target sequence of the gRNA molecule. In embodiments, the template nucleic acid comprises a nucleic acid encoding a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the CAR is: (a) a CD19 CAR, eg as described in WO2012/079000 or WO2014/153270; or (b) a BCMA CAR, e.g., as described herein, e.g., a BCMA CAR comprising SEQ ID NO: 8559. In embodiments, the template nucleic acid comprises a nucleic acid encoding an NK inhibitory molecule, e.g., as described herein .

In another aspect of the invention, a method is provided for modifying, for example, changing the structure, for example, a sequence, of a target sequence of a cell, comprising contacting said cell with: a) an nRNA molecule, for example, more than one nRNA molecule, according to any of the previous aspects and embodiments of the nRNA molecule, and a Cas9 molecule, for example, as described in this application; b) an nRNA molecule, eg more than one nRNA molecule according to any of the previous aspects and embodiments of the nRNA molecule, and a nucleic acid encoding a Cas9 molecule, eg as described herein; c) a nucleic acid encoding an nRNA molecule, for example, more than one nRNA molecule, according to any of the previous aspects and embodiments of the nRNA molecule, and a Cas9 molecule, for example, as described in this application; d) a nucleic acid encoding an nRNA molecule, eg, more than one nRNA molecule, according to any of the previous aspects and embodiments of the nRNA molecule, and a nucleic acid encoding a Cas9 molecule, eg, as described herein; e) any of a) to d) above and a template nucleic acid; f) any of a) to d) above and a nucleic acid comprising a sequence encoding a template nucleic acid; g) a composition according to any of the previous aspects and embodiments of the composition; or h) a vector according to any of the previous aspects and embodiments of the vector. In embodiments, an nRNA molecule or nucleic acid encoding an nRNA molecule and a Cas9 molecule or nucleic acid encoding a Cas9 molecule are included in the same composition. In other embodiments, an nRNA molecule or nucleic acid encoding an nRNA molecule and a Cas9 molecule or nucleic acid encoding a Cas9 molecule are included in more than one composition. In embodiments, more than one composition is delivered, for example delivered to the cell described in this application, simultaneously or sequentially. In embodiments, the cell is an animal cell, such as a mammalian, primate, or human cell. In embodiments, the cell is an immune effector cell (e.g., a population of immune effector cells), e.g., a T cell or a NK cell, e.g., a T cell, e.g., a CD4+ T cell, a CD8+ T cell, or a combination thereof. In embodiments, the cell has been or will be modified to express a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the cell includes or will include a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the cell includes or will include a nucleic acid encoding a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the CAR is: (a) CD19 CAR; or (b) BCMA CAR. In embodiments, the CAR is a CD19 CAR comprising an antigen binding domain comprising any of SEQ ID NO: 7883 - SEQ ID NO: 7898. In embodiments, the CAR is a CD19 CAR and includes any of SEQ ID NO: 7908 - SEQ ID NO: 7920. In embodiments, the CAR is a BCMA CAR including any of SEQ ID NO: 7939 - SEQ ID NO: 8112. In embodiments, the CAR is a BCMA CAR and includes any of SEQ ID NO: 8549 - SEQ ID NO: 8621, for example, includes SEQ ID NO: 8559. In embodiments, the implementation of the cell is allogeneic in relation to the patient who intends to enter the specified cell. In embodiments, the cell is isolated from a healthy human donor. In embodiments, the cell is autologous to the patient to whom said cell is to be administered.

In another aspect of the invention, there is provided a cell modified by a method according to any of the above aspects and embodiments of the method, for example, modified by the method described in this application. In another aspect of the invention, a cell is provided that comprises a first nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, or a composition according to any of the above aspects and embodiments of the composition, a nucleic acid according to any of the above nucleic acid aspects and embodiments, or a vector according to any of the above aspects and embodiments of the vector. In embodiments, the nRNA molecule, composition, nucleic acid, or vector is introduced into said cell ex vivo. In other embodiments, the implementation of the nRNA molecule, composition, nucleic acid or vector is introduced into the specified cell in vivo. In embodiments, the cell is an animal cell, such as a mammalian, primate, or human cell. In embodiments, the cell is an immune effector cell (eg, a population of immune effector cells), eg, T cells or NK cells, eg, T cells, eg, CD4+ T cells, CD8+ T cells, or combinations thereof. In embodiments, the cell has been or will be modified to express a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the cell includes or will include a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the cell includes or will include a nucleic acid encoding a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the CAR is: (a) CD19 CAR; or (b) BCMA CAR. In embodiments, the CAR is a CD19 CAR comprising an antigen binding domain comprising any of SEQ ID NO: 7883 - SEQ ID NO: 7898. In embodiments, the CAR is a CD19 CAR and includes any of SEQ ID NO: 7908 - SEQ ID NO: 7920. In embodiments, the CAR is a BCMA CAR including any of SEQ ID NO: 7939 - SEQ ID NO: 8112. In embodiments, the CAR is a BCMA CAR and includes any of SEQ ID NO: 8549 - SEQ ID NO: 8621, for example, includes SEQ ID NO: 8559. In embodiments, the implementation of the cell is allogeneic in relation to the patient who intends to enter the specified cell. In embodiments, the cell is isolated from a healthy human donor. In embodiments, the cell is autologous to the patient to whom said cell is to be administered. In embodiments, the cell includes, has included or will include a second nRNA molecule according to any one of paragraphs. 1-60 or a nucleic acid encoding a second nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, wherein the first nRNA molecule and the second nRNA molecule comprise non-identical guide domains. In embodiments, the first nRNA molecule includes a targeting domain that is complementary to the target sequence of the allogeneic T cell target (e.g., the targeting domain described in Tables 1, 3, 4, or 5) and the second nRNA molecule includes a targeting domain that is complementary to the inhibitory target sequence. molecule or downstream signaling effector through an inhibitory molecule (eg, includes a targeting domain as described in Table 2 or Table 6). In embodiments, the inhibitory molecule or downstream signaling effector through the inhibitory molecule is CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF -beta or PTPN11. In embodiments, the first nRNA molecule includes a targeting domain complementary to the TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E, or CD3G target sequence, and the second nRNA molecule includes a targeting domain that is complementary to the NLRC5 target sequence, e.g., includes a targeting domain including ( for example, consisting of) any of SEQ ID NO: 8622 - SEQ ID NO: 10089. In embodiments, the first nRNA molecule includes a guide domain complementary to the TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E, or CD3G target sequence, and the second molecule The nRNA includes a guide domain complementary to the B2M, HLA-A, HLA-B, or HLA-C target sequence. In embodiments, the cell further comprises, has included or will include a third nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, or a nucleic acid encoding a third nRNA molecule according to any of the above aspects and embodiments of the nRNA molecule, wherein the first nRNA molecule, the second molecule The nRNA and the third nRNA molecule include non-identical targeting domains. In embodiments, the third nRNA molecule includes a targeting domain complementary to the CIITA, RFXANK, RFX5, or RFXAP target sequence, e.g., CIITA, for example, includes a targeting domain, including, for example, consisting of, any of SEQ ID NO: 7717 - SEQ ID NO: 7804, for example, includes a targeting domain, including, for example, consisting of, any of SEQ ID NO: 7769, SEQ ID NO: 7771, or SEQ ID NO: 7785. a domain complementary to the TRAC target sequence; the second nRNA molecule includes a guide domain complementary to the B2M target sequence; and the third nRNA molecule includes a guide domain complementary to the CIITA target sequence. In embodiments, the cell includes three nRNA molecules, wherein the first nRNA molecule includes a guide domain complementary to the TRAC target sequence; the second nRNA molecule includes a guide domain complementary to the NLRC5 target sequence; and the third nRNA molecule includes a guide domain complementary to the CIITA target sequence. In embodiments, the cell includes two nRNA molecules, wherein the first nRNA molecule includes a targeting domain complementary to the TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E, or CD3G target sequences, and the second nRNA molecule includes a targeting domain complementary to the NR3C1 target sequence, DCK, CD52 or FKBP1A.

In embodiments of a cell that includes an nRNA molecule (for example, more than one nRNA molecule as described herein):

(1) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(2) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(3) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(4) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(5) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(6) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(7) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(8) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(9) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(10) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(11) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(12) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(13) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(14) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(15) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(16) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(17) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(18) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(19) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(20) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(21) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(22) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(23) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(24) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(25) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(26) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(27) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(28) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(29) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(30) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(31) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(32) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(33) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(34) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(35) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(36) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(37) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(38) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(39) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(40) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(41) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(42) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(43) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(44) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(45) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(46) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(47) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324;

(48) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583;

(49) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527;

(50) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345;

(51) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698;

(52) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068;

(53) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941;

(54) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491;

(55) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; or

(56) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583.

In embodiments, including any of the above aspects and embodiments of the cell, the cell further comprises a third nRNA molecule comprising a guide domain complementary to the target sequence of the inhibitory molecule or downstream signaling effector via the inhibitory molecule, wherein the inhibitory molecule or downstream signaling effector via the inhibitory molecule is CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF-beta or PTPN11, e.g. third nRNA molecule , includes a guide domain according to any of 15(a) - 15(e).

In embodiments of a cell that includes an nRNA molecule (for example, more than one nRNA molecule as described herein):

(1) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(2) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(3) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(4) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(5) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(6) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(7) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(8) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(9) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(10) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(11) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(12) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(13) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(14) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(15) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(16) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(17) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(18) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(19) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(20) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(21) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(22) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(23) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(24) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(25) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(26) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(27) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(28) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(29) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815;

(30) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277;

(31) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270;

(32) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541;

(33) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032;

(34) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; or

(35) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277.

In cell embodiments, the targeting domain of the first nRNA molecule, the targeting domain of the second nRNA molecule, and, if present, the targeting domain of the third nRNA molecule, comprises, for example, consists of, the sequence of any of:

g) Combinations A1 - combinations A72 of Table 33;

h) Combinations B1 - combinations B84 of Table 34;

i) Combinations C1 - combinations C42 of Table 35;

j) Combinations D1 - combinations D36 of Table 36;

k) Combinations E1 - combinations E30 of Table 37; or

l) F1 combinations - F60 combinations of Table 38.

In cell embodiments, the first nRNA molecule includes a targeting domain comprising SEQ ID NO: 5569, SEQ ID NO: 5592, or SEQ ID NO: 5586, and the second nRNA molecule includes a targeting domain comprising SEQ ID NO: 5775.

In any of the above aspects and cell embodiments, a gene comprising a target sequence complementary to the guide domain of the first nRNA molecule, and optionally a gene comprising a target sequence complementary to the guide domain of the second nRNA molecule, and/or a gene comprising the sequence - the target complementary to the guide domain of the third nRNA molecule have been altered so that the expression of the functional product of the gene comprising the target sequence complementary to the guide domain of the first nRNA molecule and optionally the gene comprising the target sequence complementary to the guide domain of the second nRNA molecule, and/or a functional gene product comprising a target sequence complementary to the targeting domain of a third nRNA molecule has been reduced or eliminated.

In another aspect of the invention, there is provided a method of conferring antitumor immunity in a subject, comprising administering to the subject an effective amount of a cell as described herein, eg, a cell according to any of the above aspects and embodiments of the cell.

In another aspect of the invention, a method of treating cancer in a subject is provided, comprising administering to the subject an effective amount of a cell as described herein, eg, a cell according to any of the above aspects and embodiments of the cell.

In another aspect of the invention, there is provided a method of treating a subject having a disease associated with the expression of a tumor antigen, e.g., a proliferative disease, a precancerous condition, cancer, and a non-cancer related indication associated with the expression of a tumor antigen, wherein the method comprises administering to the subject an effective amount of a cell as described in this application, for example, cells according to any of the above aspects and cell embodiments. In embodiments, the disease associated with tumor antigen expression is cancer or a non-cancer indication. In embodiments, Th disease is a cancer selected from colon cancer, rectal cancer, renal cell cancer, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer, childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis carcinoma, central nervous neoplasia system (CNS), primary CNS lymphoma, tumor angiogenesis, tumors of the spinal canal, glioma of the brainstem brain, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell carcinoma, T-cell lymphoma, environmental cancers, combinations of these cancers, and metastatic lesions of these cancers. In embodiments, the cancer is a hemoblastosis selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T -ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, Waldenström's macroglobulinemia and preleukemia.

In embodiments of any of the above methods, the method further comprises administering a chemotherapeutic agent, such as cyclophosphamide, fludarabine, or cyclophosphamide and fludarabine. In embodiments of the methods, the method includes administering a lymph-depleting agent or immunosuppressant prior to administering to the subject an effective amount of a cell as described herein, eg, a cell according to any of the above aspects and embodiments of the cell.

In another aspect of the invention, a method is provided for obtaining cells (e.g., a population of cells) for immunotherapy, comprising: (a) modifying the cells by reducing or eliminating the expression of a T cell receptor (TCR) component, for example, by introducing into said cells an nRNA molecule (described in present application), for example, more than one nRNA molecule, according to any one of paragraphs. 3, 4, 5, 10, 11 or 12; (b) modification of cells by reducing or eliminating the expression of HLA (for example, HLA-A, HLA-B and/or HLA-C) or B2M, for example, by introducing into these cells an nRNA molecule (described in this application), for example, more than one nRNA molecule, according to any of 2a, 2i, 2j or 2k, for example, an nRNA molecule, for example, more than one nRNA molecule, according to any one of paragraphs. 6 or 7; and (c) propagating said cells. In embodiments, the method further comprises modifying said cells by reducing or eliminating the expression of CIITA, for example by introducing into said cells an nRNA molecule (described herein), for example more than one nRNA molecule according to 2p, for example an nRNA molecule, for example more than one molecule of nRNA, according to any one of paragraphs. 8 or 9, where said modification optionally takes place before the step of expanding said cells.

In another aspect of the invention, a method is provided for obtaining cells (e.g., a population of cells) for immunotherapy, comprising: (a) modifying the cells by reducing or eliminating the expression of a T cell receptor (TCR) component, for example, by introducing into said cells an nRNA molecule (described in this application), for example, more than one nRNA molecule, according to any of 2b-2h, for example, an nRNA molecule (described in this application), for example, more than one nRNA molecule, according to any one of paragraphs. 3, 4, 5, 10, 11 or 12; (b) modifying cells by reducing or eliminating the expression of the immunosuppressant target, for example, by introducing into said cells an nRNA molecule (described in this application), for example, more than one nRNA molecule (described in this application), according to any of 2l, 2m, 2n or 2o, for example, an nRNA molecule (described in this application), for example, more than one nRNA molecule, according to paragraph 13; and (c) propagating said cells.

In embodiments of any of the above methods for producing cells, the method further comprises: (d) modifying the cells by reducing or eliminating the expression of the first inhibitory molecule or downstream signaling effector via the inhibitory molecule, for example, by introducing into said cells an nRNA molecule (described herein), for example, more than one nRNA molecule, according to paragraphs. 14 or 15; where the specified modification optionally takes place before the stage of reproduction of these cells.

In another aspect of the invention, a method is provided for obtaining cells (for example, a population of cells) for immunotherapy, including: (a) modifying cells by reducing or eliminating the expression of a first inhibitory molecule or a downstream signaling effector through an inhibitory molecule, for example, by introducing an nRNA molecule into said cells ( described in this application), for example, more than one nRNA molecule, according to paragraph 14, for example, an nRNA molecule, for example, more than one nRNA molecule, according to any one of paragraphs. 15-17; and (c) expanding said cells.

In embodiments of any of the above cell production methods, the method further comprises: (e) modifying the cells by reducing or eliminating the expression of the second inhibitory molecule or downstream signaling effector via the inhibitory molecule, for example, by introducing into said cells an nRNA molecule, eg, more than one nRNA molecule. , according to paragraphs. 14 or 15, wherein the first inhibitory molecule or downstream signaling effector via the inhibitory molecule and the second inhibitory molecule or downstream signaling effector via the inhibitory molecule are different.

In embodiments of any of the above methods for obtaining cells, the introduction of each of the molecules of nRNA is simultaneous or sequential. In embodiments, administration of each of the nRNA molecules is sequential and separated by a period of at least 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days.

In embodiments of any of the above methods for obtaining cells, the method further comprises introducing into the cells a nucleic acid encoding a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, a nucleic acid encoding a CAR is located on a template nucleic acid. In embodiments, a nucleic acid encoding a CAR is located on an RNA vector. In embodiments, a nucleic acid encoding a CAR is located on a lentiviral vector.

In embodiments of any of the above cell production methods, the method further comprises isolating cells that are negative for TCR expression. In embodiments, isolation results in a cell population that is greater than about 75%, such as greater than about 80%, 85%, 90%, 91%, 92%, 93, 94%, 95%, 96%, 97%, 98 %, 99% or 99.5% of cells are negative for TCR expression. In embodiments, the step of isolating cells that are negative for TCR expression comprises contacting a cell population with a composition comprising an antibody specific for a T cell receptor (TCR) component, optionally associated with a solid support or a detectable label, and isolating cells that do not bind to the specified antibody. In embodiments, the cells are immune effector cells, eg T cells, or NK cells, eg T cells. In embodiments, the cells are allogeneic to the subject to whom they are to be administered, eg, the cells are isolated from a healthy donor, eg, a donor that does not suffer from a condition associated with tumor antigen expression. In embodiments, the cells are autologous to the subject to whom they are to be administered. In embodiments of any of the above cell production methods, steps (a) and/or (b) are performed ex vivo. In embodiments, step (c) is performed ex vivo. In embodiments, propagation in step (c) is performed for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days, or a period of 2 -15, 2-14, 2-13, 2-12, 2-11, 2-10, 3-10, 2-9, 3-9, 2-8, 3-8, 2-7, 3-7 , 2-6, 3-6, 2-5 or 3-5 days.

In embodiments of any of the above cell production methods, the nRNA molecules are the nRNA molecules described herein, and the targeting domains of each of the nRNA molecules (e.g., used in combination) include, e.g., consist of sequences from any of the combinations listed in Table 33, Table 34, Table 35, Table 36, Table 37, or Table 38. In embodiments, the targeting domains of each of the nRNA molecules include, for example, consist of sequences of any of:

a) Combinations A1 - combinations A72 of Table 33, for example combinations A1-A4, combinations A5-A8, combinations A37-A40 or combinations A41-A44;

b) Combinations B1 - combinations B84 of Table 34;

c) Combinations C1 - combinations C42 of Table 35;

d) D1 combinations - D36 combinations of Table 36, eg D2 combinations, D4 combinations, D20 combinations or D22 combinations;

e) Combinations E1 - combinations E30 of Table 37, eg combinations E2, combinations E4, combinations E8 or combinations E10; or

f) F1 combinations - F60 combinations of Table 38, for example, any F1-F4 combination, F5-F8 combination, F13-F16 combination or F17-F20 combination.

In another aspect of the invention, a method of treating a subject in need thereof is provided, which comprises administering cells (e.g., a population of cells) obtained by a cell production method described herein, for example, a method according to any of the above aspects and cell production method embodiments. In embodiments, especially embodiments that include an nRNA molecule that binds to an immunosuppressant target sequence, the method further comprises administering an immunosuppressant, eg, rapamycin, rapalogue, or an mTor inhibitor, eg, RAD001. In embodiments, the subject has a disease associated with the expression of a tumor antigen, e.g., a proliferative disease, a precancerous condition, cancer, and a non-cancer related indication associated with the expression of a tumor antigen, wherein said administration allows treatment of said disease associated with the expression of the tumor antigen. In embodiments, the disease associated with tumor antigen expression is cancer or a non-cancer indication. In embodiments, the disease is a cancer selected from colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head cancer or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer, childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis carcinoma, neoplasia of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, tumors of the spinal canal, glioma of the brainstem brain, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell carcinoma, T-cell lymphoma, environmental cancers, combinations of these cancers, and metastatic lesions of these cancers. In embodiments, the cancer is a hemoblastosis selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T -ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, Waldenström macroglobulinemia, and preleukemia

In another aspect of the invention, a method of treating a patient suffering from a disease is provided, comprising:

(a) obtaining a population of cells from an allogeneic donor;

(b) introducing into cells a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in a gene selected from CD247, CD3D , CD3E, CD3G, TRAC, TRBC1 and TRBC2;

(c) optionally, selecting those cells in which the expression of a functional TCR has been reduced or abolished;

(d) transducing the cells with a nucleic acid encoding a CAR; and

(e) administering the cells to a patient in need thereof, for example, a patient who has a disease associated with the expression of an antigen recognized by CAR. In embodiments, the first anti-CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, or TRBC2 nRNA molecule is an nRNA molecule according to any one of 2(b)-2(h), e.g., is an nRNA molecule according to any one of paragraphs. 3, 4, 5, 10, 11 or 12.

In embodiments, the method of treating a patient suffering from a disease further comprises introducing into cells a CRISPR system (e.g., the S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to the sequence targets in a gene selected from B2M, HLA-A, HLA-B or HLA-C. In embodiments, the second nRNA to B2M, HLA-A, HLA-B, or HLA-C is an nRNA molecule according to any of 2(a) or 2(i)-2(k), for example, is an nRNA molecule according to any one of paragraphs. 6 or 7. In embodiments, the method further comprises administering to cells a CRISPR system (e.g., S. pyogenes CRISPR Cas9 system) comprising a third nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a guide domain complementary to the target sequence in a gene selected from CIITA, RFXANK, RFXAP, RFX5, HLA-DM, HLA-DO, HLA-DR, HLA-DQ and HLA-DP. In embodiments, the third nRNA molecule is an nRNA molecule according to any one of 2(a) or 2(i)-2(k), for example, is an nRNA molecule according to any one of paragraphs. 6 or 7.

In other embodiments, the method of treating a patient suffering from a disease further comprises introducing into cells a CRISPR system (e.g., the S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to the sequence target in a gene selected from DCK, CD52, FKBP1A or NR3C1. In embodiments, the second nRNA molecule to DCK, CD52, FKBP1A, or NR3C1 is the second nRNA molecule according to any of 2(l)-2(o), e.g., is the second nRNA molecule according to paragraph 13. In embodiments where the second nRNA molecule is directed on DCK, the method further comprises administering to said patient a nucleoside analog drug, for example a nucleoside analog drug such as cytarabine or gemcitabine. In embodiments where the second nRNA is directed to CD52, the method further comprises administering to said patient an anti-CD52 antibody or antigen-binding fragment thereof, for example, the anti-CD52 antibody or antigen-binding fragment thereof is alemtuzumab (Campas®). In embodiments where the second nRNA is directed to FKBP1A, the method further comprises administering to said patient FK506, cyclosporine, rapamycin, or rapalogue, or an mTor inhibitor such as RAD001. In embodiments where the second nRNA is directed to NR3C1, the method further comprises administering to said patient a corticosteroid, for example, the corticosteroid is dexamethasone.

In embodiments of any of the above methods of treating a patient suffering from a disease, the nRNA molecules are the nRNA molecules described herein, and the targeting domains of each of the nRNA molecules (e.g., used in combination) include, e.g., consist of, the sequence of any of the combinations listed in Table 33, Table 34, Table 35, Table 36, Table 37, or Table 38. In embodiments, the targeting domains of each of the nRNA molecules include, for example, consist of sequences of any of:

a) Combinations A1 - combinations A72 of Table 33, for example combinations A1-A4, combinations A5-A8, combinations A37-A40 or combinations A41-A44;

b) Combinations B1 - combinations B84 of Table 34;

c) Combinations C1 - combinations C42 of Table 35;

d) D1 combinations - D36 combinations of Table 36, eg D2 combinations, D4 combinations, D20 combinations or D22 combinations;

e) Combinations E1 - combinations E30 of Table 37, eg combinations E2, combinations E4, combinations E8 or combinations E10; or

f) F1 combinations - F60 combinations of Table 38, for example, any F1-F4 combination, F5-F8 combination, F13-F16 combination or F17-F20 combination.

In embodiments of any of the above methods of treating a patient suffering from a disease, the method further comprises administering to cells a CRISPR system (e.g., S. pyogenes CRISPR Cas9 system) comprising a fourth nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a guide domain , complementary to a target sequence in a gene selected from CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1 , CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF-beta or PTPN11, e.g., a fourth nRNA molecule that targets CD274, HAVCR2, LAG3, PDCD1, or PTPN11, e.g. 16-17.

In another aspect of the invention, a method of treating a patient suffering from a disease is provided, comprising:

(a) obtaining a population of cells (as described in this application), for example, immune effector cells;

(b) introducing into the cell population a CRISPR system (e.g., the S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in a gene selected from CD247, CD3D, CD3E, CD3G, TRAC, TRBC1 and TRBC2;

(c) introducing into the cell population a CRISPR system (e.g., the S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule (or a nucleic acid encoding said nRNA molecule) comprising a target domain complementary to a target sequence in a gene selected from B2M, HLA-A, HLA-B and HLA-C;

(d) optionally, selecting those cells in which the expression of functional TCR, functional B2M, or functional TCR and B2M has been reduced or abolished;

(d) introducing into the cell population a nucleic acid encoding a CAR; and

(e) administering the cell population to a patient in need thereof, for example, a patient who has a disease associated with the expression of an antigen recognized by CAR. In embodiments of the method, the method further comprises: (f) introducing into the cell population of cells a CRISPR system (e.g., the S. pyogenes CRISPR Cas9 system) comprising a third nRNA molecule (or nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to target sequences in a gene selected from CIITA, RFXANK, RFX5 and RFXAP. In embodiments, the first nRNA molecule includes a targeting domain complementary to a target sequence in a gene selected from TRAC, TRBC1 and TRBC2, for example, as described in this application, for example, TRAC, for example, includes (for example, consists of) a targeting domain selected of SEQ ID NO: 5569, SEQ ID NO: 5585, SEQ ID NO: 5592, SEQ ID NO: 5601, SEQ ID NO: 5589, SEQ ID NO: 5600, SEQ ID NO: 5594, SEQ ID NO: 5571, SEQ ID NO: 5593, SEQ ID NO: 5574, SEQ ID NO: 5598, SEQ ID NO: 5586, SEQ ID NO: 5599, SEQ ID NO: 5591, SEQ ID NO: 5610, SEQ ID NO: 5608, SEQ ID NO : 5617, SEQ ID NO: 5619, and SEQ ID NO: 5620, for example, selected from SEQ ID NO: 5569, SEQ ID NO: 5592, SEQ ID NO: 5587, SEQ ID NO: 5599, SEQ ID NO: 5600 and SEQ ID NO: 5586, e.g., selected from SEQ ID NO: 5569, SEQ ID NO: 5586, and SEQ ID NO: 5592. In other embodiments, the first nRNA molecule includes a targeting domain complementary to a target sequence in a gene selected from CD3E, CD3G and CD3D, for example, as op isano in this application. In embodiments, the second nRNA molecule includes a targeting domain complementary to a target sequence in the B2M gene, e.g., as described herein, e.g., includes (e.g., consists of) a targeting domain selected from SEQ ID NO: 5519, SEQ ID NO: 5497, SEQ ID NO: 5499, SEQ ID NO: 5498, SEQ ID NO: 5503, SEQ ID NO: 5496, SEQ ID NO: 5507, SEQ ID NO: 5515, SEQ ID NO: 5493, SEQ ID NO: 5506, SEQ ID NO: 5509, SEQ ID NO: 5517, SEQ ID NO: 5521, SEQ ID NO: 5520, SEQ ID NO: 5500, SEQ ID NO: 5494, SEQ ID NO: 5508, SEQ ID NO: 5514 and SEQ ID NO: 5492, e.g., selected from SEQ ID NO: 5496, SEQ ID NO: 5498, and SEQ ID NO: 5509. In embodiments, the third nRNA molecule includes a targeting domain complementary to a target sequence in the CIITA gene, e.g., as described herein application, for example, includes (for example, consists of) a targeting domain selected from SEQ ID NO: 7771, SEQ ID NO: 7769, SEQ ID NO: 7773, SEQ ID NO: 7726, SEQ ID NO: 7758, SEQ ID NO: 7739 SEQ ID NO: 7779, SEQ ID NO: 7770, SEQ ID NO: 7749, SEQ ID NO: 7754, SEQ ID NO: 7745, SEQ ID NO: 7785, SEQ ID NO: 7731, SEQ ID NO: 7772, SEQ ID NO : 7743 or SEQ ID NO: 7750, e.g. selected from SEQ ID NO: 7769, SEQ ID NO: 7771, SEQ ID NO: 7739, or SEQ ID NO: 7785. In preferred embodiments, the targeting domains of each of the nRNA molecules (e.g., used in combination) include, for example consist of, sequences of any of the combinations listed in Table 33, Table 34, or Table 38. In embodiments, the targeting domains of each of the nRNA molecules include, for example, consist of sequences of any of:

a) Combinations A1 - combinations A72 of Table 33, for example combinations A1-A4, combinations A5-A8, combinations A37-A40 or combinations A41-A44;

b) Combinations B1 - combinations B84 of Table 34; or

c) F1-F60 combinations of Table 38, for example, any F1-F4 combination, F5-F8 combination, F13-F16 combination or F17-F20 combination.

In embodiments of the method for treating a patient suffering from a disease, the method further comprises administering to said cells a nucleic acid molecule encoding an NK inhibitory molecule (e.g., as described herein), e.g., a nucleic acid molecule encoding an HLA-G:B2M fusion. , for example, a nucleic acid molecule encoding SEQ ID NO: 10674. In embodiments of a method of treating a patient suffering from a disease, the cell (or population of cells) is an immune effector cell (or population of immune effector cells), for example, a T cell (or population T cells). In embodiments, the cell (or population of cells) is allogeneic to the patient, eg, isolated from a healthy human donor. In other embodiments, the implementation of the cell (or population of cells) is autologous in relation to the patient. In embodiments, the CAR is a CD19 CAR (e.g., as described herein), e.g., a CD19 CAR comprising an antigen binding domain comprising any of SEQ ID NO: 7883 - SEQ ID NO: 7898. In other embodiments, the CAR is a BCMA CAR, e.g. , including an antigen recognition domain, including any of SEQ ID NO: 7939 - SEQ ID NO: 8112 or SEQ ID NO: 8155 - SEQ ID NO: 8166, for example, includes an antigen recognition domain, including, for example, consisting of, SEQ ID NO: 7949, for example, including any of SEQ ID NO: 8549 - SEQ ID NO: 8621, for example, including, for example, consisting of, SEQ ID NO: 8559.

In another aspect of the invention, a modified cell is provided in which the expression of: a) a T-cell receptor component is reduced or eliminated; b) B2M; and/or c) CIITA, compared to an unmodified cell of the same type. In embodiments, the T-cell receptor component is a TCR alpha chain or a TCR beta chain, such as the TCR alpha chain. In other embodiments, the TCR component is CD3 delta, CD3 epsilon, or CD3 gamma, eg CD3 epsilon. In embodiments, the modified cell (or cell population) has reduced or abolished expression of the T-cell receptor component, B2M and CIITA.

In another aspect of the invention, a modified cell is provided, comprising the insertion or deletion of a nitrogen base pair, eg, more than one nitrogen base pair, at or near: a) a gene encoding a T-cell receptor component; b) B2M; and/or c) CIITA; compared to an unmodified cell of the same type. In embodiments, each of said insertions or deletions is an indel. In embodiments, each specified insertion or deletion is a frameshift mutation. In embodiments, the modified cell (or population of cells) contains an insertion or deletion of a nitrogen base pair, e.g., more than one nitrogen base pair, at or near the gene encoding the T-cell receptor component, B2M and CIITA.

In another aspect of the invention, a population of cells is provided, comprising a modified cell according to any of the above aspects and embodiments of the cell (e.g., modified cell), wherein at least about 30% of the cells, at least one of said insertion or deletion is a frameshift mutation. , for example, as measured by NGS.

In another aspect of the invention, a cell is provided, comprising (e.g., a cell population comprising a cell, e.g., more than one cell, comprising):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) Optionally, a nucleic acid sequence encoding an NK inhibitory molecule, for example, as described in this application, for example, a nucleic acid encoding an HLA-G or HLA-G:B2M fusion construct, as described in this application;

(c) An indel at or near the sequence of a gene encoding a TCR component (e.g. TRAC, TRBC1 TRBC2, CD3E, CD3D or CD3G, e.g. TRAC) or its regulatory elements, e.g. an indel at or near the target nRNA sequence, comprising a guide domain to a TCR component (e.g., TRAC, TRBC1, TRBC2, CD3E, CD3D, or CD3G, e.g., TRAC), e.g., including the guide domain listed in Table 1, Table 4, Table 5, Table 6e, Table 6f, or Table 6g;

(d) An indel at or near the sequence of a B2M-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a B2M guide domain, e.g. including the guide domain listed in Table 1 or Table 3 ;

(e) Optionally, an indel at or near the sequence of the CIITA-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a CIITA targeting domain, e.g., including the targeting domain listed in Table 1 or Table 6c; and

(f) Optionally, an indel at or near the sequence of the gene encoding LILRB1 or its regulatory elements, for example, an indel at or near the target sequence of an nRNA comprising a LILRB1 targeting domain, such as including the targeting domain listed in Table 6d;

Wherein the cell (or a population of cells including said cell) expresses a CAR and optionally a NK inhibitory molecule, and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1, TRBC2, CD3D , CD3E or CD3G, eg TRAC), ii) B2M, iii) CIITA and/or iv) LILRB1. In embodiments, the sequences of the targeting domain of the nRNA molecules (described herein) to the TCR, B2M, and CIITA component include, for example, consist of the targeting domains listed in any combination listed in Table 33, Table 34, or Table 38, for example:

a) Combinations A1 - combinations A72 of Table 33, for example combinations A1-A4, combination A5-A8, combinations A37-A40 or combinations A41-A44;

b) Combinations B1 - combinations B84 of Table 34; or

c) F1 combinations - F60 combinations of Table 38, for example any F1-F4 combination, F5-F8 combination, F13-F16 combination or F17-F20 combination.

In another aspect of the invention, a cell is provided, comprising (e.g., a cell population comprising a cell, e.g., more than one cell, comprising):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) Optionally, a nucleic acid sequence encoding an NK inhibitory molecule, for example, as described in this application, for example, a nucleic acid encoding HLA-G, as described in this application;

(c) an indel at or near the sequence of a gene encoding a TCR component (e.g. TRAC, TRBC1 TRBC2, CD3D, CD3E or CD3G, e.g. TRAC) or its regulatory elements, e.g. an indel at or near the target nRNA sequence, including a guide domain to a TCR component (e.g., TRAC, TRBC1 TRBC2, CD3D, CD3E, or CD3G, e.g., TRAC), e.g., including the guide domain listed in Table 1, Table 4, Table 5, Table 6e, Table 6f, or Table 6g ;

(d) An indel at or near the NLRC5 encoding gene sequence or regulatory elements thereof, eg an indel at or near an nRNA target sequence comprising an NLRC5 guide domain, eg comprising the guide domain listed in Table 1;

(e) Optionally, an indel at or near the sequence of the CIITA-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a CIITA targeting domain, e.g., including the targeting domain listed in Table 1 or Table 6c; and

(f) Optionally, an indel at or near the sequence of the gene encoding LILRB1 or its regulatory elements, for example, an indel at or near the target sequence of an nRNA comprising a LILRB1 targeting domain, such as including the targeting domain listed in Table 6d;

Wherein the cell (or cell population comprising one or more of said cells) expresses a CAR and optionally an NK inhibitory molecule, and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1 TRBC2, CD3D, CD3E or CD3G, e.g. TRAC), ii) B2M, iii) NLRC5 and/or iv) LILRB1.

In another aspect of the invention, a cell is provided, comprising (e.g., a cell population comprising a cell, e.g., more than one cell, comprising):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) an indel at or near the sequence of a gene encoding a TCR component (e.g. TRAC, TRBC1 TRBC2, CD3D, CD3E or CD3G, e.g. TRAC) or its regulatory elements, e.g. an indel at or near the target nRNA sequence, including a guide domain to a TCR component (e.g., TRAC, TRBC1 TRBC2, CD3D, CD3E, or CD3G, e.g., TRAC), e.g., including the guide domain listed in Table 1, Table 4, Table 5, Table 6e, Table 6f, or Table 6g ; and

(c) An indel at or near the sequence of a gene encoding FKBP1A or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising an FKBP1A guide domain, e.g. comprising the guide domain listed in Table 1 or Table 6b ;

Where the cell (or population of cells including a cell, e.g., more than one cell including) expresses a CAR and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1, TRBC2, CD3D, CD3E or CD3G, eg TRAC), and/or ii) FKBP12. In embodiments, the sequences of the targeting domain of the nRNA molecules (described herein) to the TCR and FKBP1A component include, for example, consist of the targeting domains listed in any combination listed in Table 35, Table 36 or Table 37, for example:

a) Combinations C1 - combinations C42 of Table 35;

b) D1 combinations - D36 combinations of Table 36, eg D2 combinations, D4 combinations, D20 combinations or D22 combinations; or

c) E1 combinations - E30 combinations of Table 37, eg E2 combinations, E4 combinations, E8 combinations or E10 combinations.

In another aspect of the invention, a cell is provided, comprising (e.g., a cell population comprising a cell, e.g., more than one cell, comprising):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) A nucleic acid sequence encoding a rapamycin-resistant mTor, eg as described herein, eg a nucleic acid sequence encoding an mTor comprising an S2035 mutation, eg an S2035I mutation; and;

(c) an indel at or near the sequence of a gene encoding a TCR component (e.g. TRAC, TRBC1 TRBC2, CD3D, CD3E or CD3G, e.g. TRAC) or its regulatory elements, e.g. an indel at or near the target nRNA sequence, including a guide domain to a TCR component (e.g., TRAC, TRBC1 TRBC2, CD3D, CD3E, or CD3G, e.g., TRAC), e.g., including the guide domain listed in Table 1, Table 4, Table 5, Table 6e, Table 6f, or Table 6g ;

Wherein a cell (or cell population comprising said cell, e.g., more than one of said cell) expresses CAR and rapamycin-resistant mTor, and exhibits reduced or abolished expression and/or function of a TCR component (e.g., TRAC, TRBC1 TRBC2, CD3D, CD3E or CD3G, such as TRAC).

In embodiments that include an indel at or near the gene encoding the TCR component, B2M, and CIITA, the targeting domain of the nRNA molecule to the TCR component, targeting the nRNA molecule to B2M, and targeting the nRNA molecule to CIIRA include, for example, consist of, respectively: a) the sequence of the targeting domain for the indicated molecules of nRNA listed in any combination of A1-A72 in Table 33; b) the sequence of the targeting domain for the indicated molecules of nRNA listed in any combination of F1-F60 in Table 38; or c) the sequence of the targeting domain for each nRNA molecule listed in any combination of B1-B84 in Table 34.

In embodiments that include an indel at or near the gene encoding the TCR component and FKBP1A, the targeting domain of the nRNA molecule to the TCR component and the targeting domain of the nRNA molecule(s) to FKBP1A include, for example, consist of, respectively: a) a targeting domain sequence for the specified nRNA molecules listed in any combination of C1-C42 in Table 35; b) the sequence of the directing domain for the indicated molecules of nRNA listed in any combination of D1-D36 in Table 36; or c) the sequences of the targeting domain for the indicated nRNA molecules listed in any combination of E1-E30 in Table 37.

In embodiments of any of the aspects and cell embodiments described above, each of said indels in said cell is obtained by introducing into said cell an nRNA molecule, e.g., more than one nRNA molecule (e.g., a CRISPR system, e.g., more than one CRISPR system). , including the specified nRNA molecule, for example, each of the specified more than one nRNA molecule), each of which includes a directing domain that is complementary to the target sequence at or near each of the specified indels.

In another aspect of the invention, a population of cells is provided wherein at least about 30%, such as at least about 50%, such as at least about 75%, such as at least about 90%, of the cells in the population is a cell according to any one of the above aspects or cell embodiments. In embodiments, at least about 30% of said cells (e.g., at least about 40%, e.g., at least about 50%, e.g., at least about 60%, e.g., at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 95%, such as at least about 99% of said cells), each of said indels is a frameshift mutation. In embodiments of the invention, including any of the above aspects and cell embodiments, a cell (or population of cells) is provided that includes an indel listed in Figure 34A, Figure 34B, or Figure 49. In embodiments of the invention, including in any of the above aspects and cell embodiments, a cell (or cell population) is provided that includes the indel listed in Figure 36 or Figure 48. In embodiments of the invention, including any of the above cell aspects and embodiments, a cell ( or cell population) that includes an indel listed in Figure 38, Figure 41, Figure 44, or Figure 50. In embodiments of the invention, including any of the above aspects and cell embodiments, a cell (or cell population) is provided that includes the indel listed in Figure 53.

In another aspect of the invention, a population of cells is provided, which includes a cell according to any of the above aspects and cell embodiments. In embodiments, at least about 20% of the cells in the cell population are a cell according to any of the above aspects and cell embodiments. In embodiments, at least about 50% of the cells in the cell population are a cell according to any of the above aspects and cell embodiments. In embodiments, less than about 5%, eg, less than about 1%, eg, less than about 0.01% of the cells in the cell population comprise a non-target indel. In embodiments, a cell in a cell population is modified to express a chimeric antigen receptor (CAR). In embodiments, the CAR is a CD19 CAR (e.g., as described herein), e.g., a CD19 CAR comprising an antigen-binding domain comprising any of SEQ ID NO: 7883 - SEQ ID NO: 7898, or comprising the sequence of SEQ ID NO: 7909 or SEQ ID NO: 7920. In other embodiments, the CAR is a BCMA CAR, for example, including an antigen recognition domain, including any of SEQ ID NO: 7939 - SEQ ID NO: 8112 or SEQ ID NO: 8155 - SEQ ID NO: 8166, for example, including an antigen recognition domain comprising, for example consisting of, SEQ ID NO: 7949, for example, including any of SEQ ID NO: 8549 - SEQ ID NO: 8621, for example, including, for example, consisting of, SEQ ID NO: 8559. In embodiments, the cell is an animal cell, eg a mammalian, primate or human cell, eg a human cell. In embodiments, the cell is an immune effector cell (e.g., a population of immune effector cells), e.g., a T cell or a NK cell, e.g., a T cell, e.g., a CD4+ T cell, a CD8+ T cell, or a combination thereof. In embodiments, the cell is allogeneic with respect to the patient to whom said cell is to be administered, for example, the cell is isolated from a healthy individual. In other embodiments, the implementation of the cell is autologous in relation to the patient who is supposed to enter the specified cell.

In another aspect of the invention, there is provided a method for treating a disease, such as cancer, in a patient in need thereof, comprising administering a cell according to any of the above aspects and embodiments of the cell. In embodiments, especially embodiments in which the expression or function of the immunosuppressant target has been reduced or abolished, the method further comprises administering an immunosuppressant, eg, RAD001.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described in this application (for example, in any of the above aspects and embodiments of a cell (for example, a modified cell) or a population of cells), for use as a medicine.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described in this application (for example, in any of the above aspects and embodiments of a cell (eg, a modified cell) or a population of cells), for use in the manufacture of a drug.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described in this application (for example, in any of the above aspects and embodiments of a cell (eg, a modified cell) or a population of cells), for use in the treatment of a disease.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described herein (e.g., in any of the above aspects and embodiments of a cell (e.g., a modified cell) or cell population), for use in the treatment of a disease, where the disease is a tumor antigen expression-associated disease, e.g., a proliferative disease , precancerous condition, cancer and non-cancer indication associated with tumor antigen expression.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described herein (e.g., in any of the above aspects and embodiments of a cell (e.g., a modified cell) or population of cells), for use in the treatment of cancer, wherein the cancer is a hemoblastosis selected from the group consisting of chronic lymphocytic leukemia ( CLL), acute leukemia, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell prolymphatic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse B- large cell lymphoma, follicular lymphoma, hairy cell leukemia, small or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid neoplasia cells, macroglobulinemia Waldenström and preleukemia.

In another aspect of the invention, an nRNA molecule as described herein (for example, in any of the above aspects and embodiments of the nRNA molecule), a composition as described in this application (for example, in any of the above aspects and embodiments of the composition), a nucleic an acid as described herein (for example in any of the above aspects and embodiments of a nucleic acid), a vector as described herein (for example in any of the above aspects and embodiments of a vector), or a cell (or population of cells) , as described in this application (for example, in any of the above aspects and embodiments of a cell (for example, a modified cell) or a population of cells), for use in the treatment of cancer, for example, where the cancer is selected from the group consisting of mesothelioma, adenocarcinoma, glioblastoma , colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell carcinoma small bowel cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, cancer testicular, fallopian tube carcinoma, endometrial carcinoma, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis carcinoma, central nervous system (CNS) neoplasia, primary CNS lymphoma, tumor angiogenesis, spinal canal tumor, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell carcinoma, T-cell lymphoma, forms of cancer due to environmental factors, combinations of these forms cancer and metastatic lesions of these forms of cancer.

In addition to certain features of the invention described above, the following general features of gRNA molecules, Cas9 molecules, and cells are intended to apply to any aspect and embodiment of the invention described herein, including the aspects and embodiments described above.

In any of the aspects and embodiments disclosed in this application, an nRNA molecule (for example, an nRNA molecule or a combination of nRNA molecules, including the guide domain described in this application), may include one or more of the following features:

In some embodiments, the nRNA molecule (e.g., an nRNA molecule, or one or more nRNA molecules in a combination of nRNA molecules comprising a guide domain described herein) is a lncRNA molecule, where the guide domain and tracr are located on separate nucleic acid molecules.

In embodiments, the crRNA comprises, 5' to 3', [guide domain]-:

a) SEQ ID NO: 6584;

b) SEQ ID NO: 6585;

c) SEQ ID NO: 6605;

d) SEQ ID NO: 6606;

e) SEQ ID NO: 6607;

f) SEQ ID NO: 6608; or

g) SEQ ID NO: 7806. In a preferred embodiment, the crRNA comprises, 5' to 3', [guide domain]-[SEQ ID NO: 6607]. In embodiments, tracr comprises more than 15, such as 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, or 80 or more nucleotides of the S. pyogenes tracr sequence (GUUGGAACCAUUCAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCG UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC). In embodiments, tracr further comprises 1 or more, eg 1, 2, 3, 4, 5, 6 or 7, eg preferably 4 or 7, U nucleotides at the 3' end. In preferred embodiments, lncRNA tracr comprises SEQ ID NO: 7820. In embodiments, tracr further comprises 1 or more, such as 1, 2, 3, 4, 5, 6, or 7, such as preferably 4 or 7, U nucleotides per 3' -end. In preferred embodiments, lncRNA tracr includes, for example, consists of SEQ ID NO: 6660. In preferred lncRNA embodiments, crRNA includes, for example, consists of [guide domain]-SEQ ID NO: 6607, and tracr includes SEQ ID NO: 7820, e.g. includes, e.g. consists of, SEQ ID NO: 6660.

In other embodiments, the nRNA molecule (e.g., an nRNA molecule or one or more nRNA molecules in a combination of nRNA molecules comprising a guide domain described herein) is an sRNA molecule, where the guide domain and tracr are located on the same nucleic acid molecule. In embodiments, the sRNA molecule includes, for example consists of: [guide domain]-

(a) SEQ ID NO: 6601;

(b) SEQ ID NO: 6602;

(c) SEQ ID NO: 6603;

(d) SEQ ID NO: 6604; or

(e) any of (a)-(d) above, further comprising, at the 3' end, 1, 2, 3, 4, 5, 6, or 7 uracil (U) nucleotides. In a preferred embodiment, the sRNA molecule comprises [guide domain]-SEQ ID NO: 6601. In a preferred embodiment, the sRNA molecule includes, for example, consists of, [guide domain]-SEQ ID NO: 7811.

In embodiments, including any of the above aspects and embodiments, one or more nucleic acid molecules of the nRNA molecule described herein, for example, all nucleic acid molecules of the nRNA molecule described herein, do not include a nucleotide or internucleotide modification. connections. In other embodiments, including any of the above aspects and embodiments, one or more nucleic acid molecules of the nRNA molecule described herein include one or more nucleotide or internucleotide linkage modifications, for example, as described herein. In embodiments, said modification includes the 2'O-methyl modification. In embodiments, said modification includes a phosphothioate modification. In embodiments, said modification includes a 2' O-methyl modification at each of 1, 2, 3 or more, eg 3, 3', nucleic acid nucleotides of the nRNA molecule. In embodiments, said modification includes a 2'O-methyl modification at each of the 4th from the end, 3rd from the end, and 2nd from the end of the 3' nucleic acid nucleotide of the gRNA molecule. In embodiments, said modification includes a 2' O-methyl modification at each of 1, 2, 3 or more, eg 3, 5', nucleic acid nucleotides of the nRNA molecule. In embodiments, said modification includes a 2' O-methyl modification in each of the 4th from the end, 3rd from the end, and 2nd from the end of the 3' nucleic acid nucleotides of the nRNA molecule and , 2, 3 or more, for example 3, 5' nucleic acid nucleotides of the nRNA molecule. In embodiments, said modification includes one or more, eg 1, 2, 3 or more, eg 3, phosphothioate bonds at the 3' end of the nRNA nucleic acid molecule. In embodiments, said modification includes one or more, eg 1, 2, 3 or more, eg 3, phosphothioate bonds at the 5' end of the nRNA nucleic acid molecule. In embodiments, said modification includes one or more, eg 1, 2, 3 or more, eg 3, phosphothioate bonds at the 3' end and at the 5' end of the nRNA nucleic acid molecule. In embodiments involving the lncRNA molecule, the tracr molecule and the crRNA molecule are modified as described herein. In other embodiments that include a lncRNA molecule, the tracr molecule is unmodified and the crRNA molecule is modified as described herein. In other embodiments that include a lncRNA molecule, the crRNA molecule is unmodified and the tracr molecule is modified as described herein.

In aspects of the invention that include more than one nRNA molecule, each nRNA molecule can independently be a lncRNA molecule or an ssRNA molecule, for example, as described herein. In embodiments, all nRNA molecules in the combination described herein are lncRNA molecules. In embodiments, all nRNA molecules in the combination described herein are sRNA molecules. In embodiments, one or more nRNA molecules in the combination described herein are lncRNA molecules, and one or more other nRNA molecules in the combination described herein are ssRNA molecules.

In embodiments, an nRNA molecule of the invention is an nRNA molecule that creates an indel at or near a target nRNA sequence when introduced into a cell described herein. In embodiments, an nRNA molecule of the invention is an nRNA molecule that creates an indel of at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 95 %, for example, at least about 96%, for example, at least about 97%, for example, at least about 98%, for example, at least about 99% or more cells, for example, as described in of the present application, in the population of cells into which the nRNA molecule is introduced. In embodiments, the indel frequency is measured by NGS, for example, as described herein. In embodiments, said indel or indels are or include frameshift mutations. In embodiments, an nRNA molecule of the invention is an nRNA molecule that creates a frameshift mutation of at least about 30%, such as at least about 40%, such as at least about 50%, such as at least at least about 60%, such as at least about 70%, such as at least about 75%, such as at least about 80%, such as at least about 85%, such as at least at least about 90%, for example, at least about 95% or more of the cells, for example, as described in this application, in the population of cells into which the nRNA molecule is introduced. In embodiments, the frameshift mutation rate is measured by NGS, for example, as described herein. In embodiments, said indel, indel frequency, frameshift mutation, and/or frameshift mutation frequency is measured in a cell (or cell population) following administration of the Cas9 RNP RNA molecule described herein. In embodiments, said indel, indel frequency, frameshift mutation, and/or frameshift mutation frequency is measured in a cell (or cell population) after the introduction of the nRNA molecule by electroporation.

In embodiments, the nRNA molecule of the invention is an nRNA molecule that creates an indel at a non-target site at a frequency of at least 50 times, such as at least 100 times, such as at least 1000 times lower than at or near from the target nRNA sequence, when introduced into a cell or population of cells described in this application. In preferred embodiments, the implementation of the nRNA does not create a detectable indel at any non-target site when introduced into the cell or population of cells described in this application. In embodiments, the analysis of off-target indels is measured by targeted off-target sequencing of predicted off-target binding sites, for example, as described herein. In embodiments, the analysis of non-target indels is measured using nucleotide insertion analysis, for example, as described in this application. In embodiments, a non-targeted assay is measured in a cell (or population of cells) following administration of the nRNA molecule as RNP with the Cas9 molecule described herein. In embodiments, the off-target assay is measured in a cell (or population of cells) after the introduction of the nRNA molecule by electroporation.

In embodiments, the RNP or combination of RNPs is delivered to cells by a single electroporation. In embodiments, the cells of the invention are subjected to only one electroporation step.

In aspects and embodiments of the invention that include a combination of nRNA molecules, each of the nRNA molecules in the combination may independently include any of the above features.

In any of the aspects and embodiments disclosed in this application, the Cas9 molecule may include one or more of the following features:

In aspects, the Cas9 molecule is S. pyogenes Cas9, eg, a modified or unmodified S. pyogenes Cas9 molecule, as described herein. In embodiments, the Cas9 molecule includes, for example, SEQ ID NO: 6611. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7821. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7822. embodiments, the Cas9 molecule includes, for example consists of, SEQ ID NO: 7823. In other embodiments, the Cas9 molecule includes, for example, consists of SEQ ID NO: 7824. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7825. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7826. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7827. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7828. In other embodiments, the Cas9 molecule includes, for example consists of, SEQ ID NO: 7829. In other embodiments, the Cas9 molecule includes, for example, consists of, S EQ ID NO: 7830. In other embodiments, the Cas9 molecule includes, for example, consists of, SEQ ID NO: 7831. Preferred Cas9 molecules are Cas9 molecules, which include, for example, consist of, SEQ ID NO: 7821, SEQ ID NO: 7822, SEQ ID NO: 7825 and SEQ ID NO: 7828.

In aspects and embodiments that include one or more RNP complexes, for example, one or more RNP complexes that include the Cas9 molecule described in this application, each of these RNP complexes is present at a concentration of less than about 10 μM, for example, less than about 3 µM, eg, less than about 1 µM, eg, less than about 0.5 µM, eg, less than about 0.3 µM, eg, less than about 0.1 µM. In embodiments, said concentration is the concentration of the RNP complex in the composition comprising the cell (e.g., cell populations), e.g., as described herein, into which the RNP is intended to be administered, e.g., as described herein, e.g., by electroporation. In embodiments, the medium of the composition is suitable for electroporation.

In aspects and embodiments of the invention that include a combination of nRNA molecules, such as a combination of RNPs that include different nRNA molecules, each of the Cas9 molecules in the combination may independently include any of the above features.

In any of the aspects and embodiments disclosed in this application, a cell (for example, a population of cells) may include one or more of the following features:

In aspects, a cell (eg, a population of cells) includes one or more cells that have reduced or abolished expression of a T cell receptor (TCR) component. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished TRAC expression. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished expression of TRBC1. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished expression of TRBC2. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished expression of CD3G. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished expression of CD3D. In embodiments, reduced or abolished expression of a T cell receptor (TCR) component includes reduced or abolished expression of CD3E. In embodiments, said reduced or abolished expression of said TCR component results from the introduction into said cell of one or more, eg one or two, eg one, nRNA molecule described herein to said TCR component. In embodiments, the cell includes an indel, eg, a frameshift mutation, eg, as described herein, at or near the target sequence of the directing domain of the nRNA molecule to the specified TCR component. In embodiments, the cell population comprises at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, or more cells (as described herein) that show reduced or abolished expression of the TCR component. In embodiments, said reduced or abolished expression of a TCR component is measured by flow cytometry, for example, as described herein.

In aspects (including as an alternative to, or in addition to, reduced or eliminated expression of a TCR component), a cell (eg, cell population) includes one or more cells that have reduced or eliminated expression of beta-2-microglobulin (B2M). In embodiments, said reduced or abolished expression of said B2M results from the introduction into said cell of one or more, eg one or two, eg one, nRNA molecule described herein to B2M. In embodiments, the cell includes an indel, eg, a frameshift mutation, eg, as described herein, at or near the target sequence of the directing domain of the nRNA molecule to the specified B2M. In embodiments, the cell population comprises at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, or more cells (as described herein) that show reduced or abolished B2M expression. In embodiments, said reduced or eliminated B2M expression is measured by flow cytometry, for example, as described herein.

In aspects (including as an alternative to, or in addition to, reduced or eliminated expression of a TCR and/or B2M component), a cell (eg, cell population) includes one or more cells that have reduced or eliminated expression of CIITA. In embodiments, said reduced or abolished expression of said CIITA results from the introduction into said cell of one or more, eg one or two, eg one, nRNA molecule to said CIITA as described herein. In embodiments, the cell includes an indel, eg, a frameshift mutation, eg, as described herein, at or near the target sequence of the directing domain of the nRNA molecule to the specified CIITA. In embodiments, the cell population comprises at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, or more cells (as described herein) that show reduced or abolished expression of CIITA. In embodiments, said reduced or eliminated B2M expression is measured by flow cytometry, for example, as described herein.

In aspects (including as an alternative to, or in addition to, reduced or abolished expression of a TCR component), a cell (eg, a population of cells) includes one or more cells in which expression of an immunosuppressant target, such as FKBP1A, is reduced or abolished. In embodiments, said reduced or abolished expression of said FKBP1A results from the introduction into said cell of one or more, eg one or two, eg one, molecule of the nRNA described herein to said FKBP1A. In embodiments, the cell includes an indel, eg, a frameshift mutation, eg, as described herein, at or near the target sequence of the directing domain of the nRNA molecule to said FKBP1A. In embodiments, the cell population comprises at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, or more cells (as described herein) that show reduced or abolished FKBP1A expression. In embodiments, said reduced or eliminated FKBP1A expression is measured by flow cytometry, for example, as described herein.

In some aspects, it is desirable that the cells show reduced or eliminated expression of more than one gene. In an aspect, the cells show reduced or abolished expression of a TCR component (eg, TRAC, TRBC1, TRBC2, CD3E, CD3G, and/or CD3D), reduced or abolished expression of B2M, and reduced or abolished expression of CIITA. In embodiments, reduced or abolished expression results from the introduction into the cell of a combination of nRNA molecules, where the nRNA molecules in the combination comprise the targeting domain sequences listed in any of the combinations A1-A72. In embodiments, reduced or abolished expression results from the introduction into the cell of a combination of nRNA molecules, where the nRNA molecules in the combination comprise the targeting domain sequences listed in any of the combinations B1-B84. In embodiments, said cell includes an indel, e.g., a frameshift mutation, at or near the target sequences of each of the targeting domains of the nRNA molecules listed in Table 33, Table 34, or Table 38 (e.g., nRNA molecules in any of the combinations of A1-A72 , B1-B84 or F1-F60).

In some aspects, it is desirable that the cells show reduced or eliminated expression of more than one gene. In an aspect, the cells show reduced or abolished expression of a TCR component (eg, TRAC, TRBC1, TRBC2, CD3E, CD3G, and/or CD3D) and reduced or abolished expression of an immunosuppressant target, eg, FKBP1A. In embodiments, the reduced or abolished expression results from the introduction into the cell of a combination of nRNA molecules, where the nRNA molecules in the combination comprise the targeting domain sequences listed in any of the combinations C1-C42. In embodiments, reduced or abolished expression results from the introduction into the cell of a combination of nRNA molecules, where the nRNA molecules in the combination comprise the targeting domain sequences listed in any of the combinations D1-D36. In embodiments, said cell includes an indel, e.g., a frameshift mutation, at or near the target sequences of each of the targeting domains of the nRNA molecules listed in Table 35, Table 36, or Table 37 (e.g., nRNA molecules in any of the combinations of C1-C42 , D1-D36 or E1-E30).

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and B2M (including embodiments where the expression or function of an additional target, e.g. more than one additional target, e.g. CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRAC is selected from SEQ ID NO: 7833, SEQ ID NO: 7834, SEQ ID NO: 7835, lncRNA, including, for example consisting of, SEQ ID NO: 7836 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with B2M is selected from SEQ ID NO: 7853, SEQ ID NO: 7854, SEQ ID NO: 7855, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7857 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7857 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and B2M (including embodiments where the expression or function of an additional target, e.g. more than one additional target, e.g. CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRAC is selected from SEQ ID NO: 7833, SEQ ID NO: 7834, SEQ ID NO: 7835, lncRNA, including, for example consisting of, SEQ ID NO: 7836 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 10798, and the nRNA molecule that is directed to B2M is selected from SEQ ID NO: 7858, SEQ ID NO: 7859, SEQ ID NO: 7860, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 6660, lncRNA, including, for example, with consisting of, SEQ ID NO: 7862 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7862 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and B2M (including embodiments where the expression or function of an additional target, e.g. more than one additional target, e.g. CIITA, is also reduced or eliminated ), the nRNA molecule that interacts directionally with TRAC is selected from SEQ ID NO: 7838, SEQ ID NO: 7839, SEQ ID NO: 7840, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 10798, and an nRNA molecule that interacts directedly with B2M is selected from SEQ ID NO: 7853, SEQ ID NO: 7854, SEQ ID NO: 7855, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7857 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7857 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and B2M (including embodiments where the expression or function of an additional target, e.g. more than one additional target, e.g. CIITA, is also reduced or eliminated ), the nRNA molecule that interacts directionally with TRAC is selected from SEQ ID NO: 7838, SEQ ID NO: 7839, SEQ ID NO: 7840, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with B2M is selected from SEQ ID NO: 7858, SEQ ID NO: 7859, SEQ ID NO: 7860, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7862 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7862 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments that reduce or eliminate the expression of a T cell receptor component, e.g. TRBC, and B2M (including embodiments where the expression or function of an additional target, e.g., more than one additional target, e.g., CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRBC is selected from SEQ ID NO: 7843, SEQ ID NO: 7844, SEQ ID NO: 7845, lncRNA, including, for example consisting of, SEQ ID NO: 7846 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 10798, and the nRNA molecule that is directed to B2M is selected from SEQ ID NO: 7853, SEQ ID NO: 7854, SEQ ID NO: 7855, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7857 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7857 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments that reduce or eliminate the expression of a T cell receptor component, e.g. TRBC, and B2M (including embodiments where the expression or function of an additional target, e.g., more than one additional target, e.g., CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRBC is selected from SEQ ID NO: 7843, SEQ ID NO: 7844, SEQ ID NO: 7845, lncRNA, including, for example consisting of, SEQ ID NO: 7846 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 10798, and the nRNA molecule that is directed to B2M is selected from SEQ ID NO: 7858, SEQ ID NO: 7859, SEQ ID NO: 7860, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7862 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7862 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments that reduce or eliminate the expression of a T cell receptor component, e.g. TRBC, and B2M (including embodiments where the expression or function of an additional target, e.g., more than one additional target, e.g., CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRBC is selected from SEQ ID NO: 7848, SEQ ID NO: 7849, SEQ ID NO: 7850, lncRNA including, for example consisting of, SEQ ID NO: 7851 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 10798, and the nRNA molecule that is directed to B2M is selected from SEQ ID NO: 7853, SEQ ID NO: 7854, SEQ ID NO: 7855, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7857 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7856 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7857 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments that reduce or eliminate the expression of a T cell receptor component, e.g. TRBC, and B2M (including embodiments where the expression or function of an additional target, e.g., more than one additional target, e.g., CIITA, is also reduced or eliminated ), the nRNA molecule that is directed to TRBC is selected from SEQ ID NO: 7848, SEQ ID NO: 7849, SEQ ID NO: 7850, lncRNA including, for example consisting of, SEQ ID NO: 7851 and SEQ ID NO: 6660 , lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 10798, and an nRNA molecule that interacts directedly with B2M is selected from SEQ ID NO: 7858, SEQ ID NO: 7859, SEQ ID NO: 7860, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 6660, lncRNA including, for example consisting of, SEQ ID NO: 7862 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7861 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7862 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRAC, is selected from SEQ ID NO: 7833, SEQ ID NO: 7834, SEQ ID NO: 7835, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7837 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7863, SEQ ID NO: 7864, SEQ ID NO: 7865, lncRNA, including, for example consisting of, SEQ ID NO: 7866 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7867 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7866 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7867 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRAC, is selected from SEQ ID NO: 7833, SEQ ID NO: 7834, SEQ ID NO: 7835, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7837 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7836 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7837 and SEQ ID NO: 10798, and the nRNA molecule that is directed to interact with FKBP1A is selected from SEQ ID NO: 7868, SEQ ID NO: 7869, SEQ ID NO: 7870, lncRNA, including, for example consisting of, SEQ ID NO: 7871 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7872 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7871 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7872 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRAC, is selected from SEQ ID NO: 7838, SEQ ID NO: 7839, SEQ ID NO: 7840, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7842 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7863, SEQ ID NO: 7864, SEQ ID NO: 7865, lncRNA, including, for example consisting of, SEQ ID NO: 7866 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7867 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7866 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7867 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRAC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRAC, is selected from SEQ ID NO: 7838, SEQ ID NO: 7839, SEQ ID NO: 7840, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7842 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7841 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7842 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7868, SEQ ID NO: 7869, SEQ ID NO: 7870, lncRNA, including, for example consisting of, SEQ ID NO: 7871 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7872 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7871 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7872 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRBC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which directly interacts with TRBC, is selected from SEQ ID NO: 7843, SEQ ID NO: 7844, SEQ ID NO: 7845, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7847 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7863, SEQ ID NO: 7864, SEQ ID NO: 7865, lncRNA, including, for example consisting of, SEQ ID NO: 7866 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7867 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7866 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7867 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRBC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which directly interacts with TRBC, is selected from SEQ ID NO: 7843, SEQ ID NO: 7844, SEQ ID NO: 7845, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7847 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7846 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7847 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7868, SEQ ID NO: 7869, SEQ ID NO: 7870, lncRNA, including, for example consisting of, SEQ ID NO: 7871 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7872 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7871 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7872 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRBC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRBC, is selected from SEQ ID NO: 7848, SEQ ID NO: 7849, SEQ ID NO: 7850, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7852 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7863, SEQ ID NO: 7864, SEQ ID NO: 7865, lncRNA, including, for example consisting of, SEQ ID NO: 7866 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7867 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7866 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7867 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In preferred embodiments, which provide for the reduction or elimination of the expression of a T cell receptor component, e.g. TRBC, and FKBP1A (including embodiments where the expression or function of an additional target, e.g. more than one additional target, is also reduced or eliminated), the nRNA molecule , which is directed to interact with TRBC, is selected from SEQ ID NO: 7848, SEQ ID NO: 7849, SEQ ID NO: 7850, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 6660, lncRNA, including , for example consisting of, SEQ ID NO: 7852 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7851 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7852 and SEQ ID NO: 10798, and the nRNA molecule that interacts directedly with FKBP1A is selected from SEQ ID NO: 7868, SEQ ID NO: 7869, SEQ ID NO: 7870, lncRNA, including, for example consisting of, SEQ ID NO: 7871 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of and h, SEQ ID NO: 7872 and SEQ ID NO: 6660, lncRNA, including, for example, consisting of, SEQ ID NO: 7871 and SEQ ID NO: 10798, and lncRNA, including, for example, consisting of, SEQ ID NO: 7872 and SEQ ID NO: 10798. As described herein, in embodiments of any of the combinations, each of said nRNA molecules is provided as a RNP with a Cas9 molecule, eg, the Cas9 molecule described herein.

In one aspect, the cell shows reduced or abolished expression of only one TCR component (although it may show reduced or abolished expression of one or more other targets that are not a TCR component). In embodiments, the cell includes an indel at or near the target sequence in only one gene (or its regulatory elements) that is a component of the TCR (although the cell may include an indel at or near the target sequence in one or more additional genes (or their regulatory elements) that are not a component of the TCR). Thus, in embodiments, the cell does not include an indel in more than one gene that is a component of the TCR. In embodiments, the cell does not include an indel in TRAC and in the gene encoding the second TCR component, eg, TRBC1 or TRBC2.

In one aspect, the cell does not show reduced or abolished expression of a gene comprising a target sequence of an inhibitory molecule or a downstream signaling effector via an inhibitory molecule (although it may show reduced or abolished expression of one or more other genes). In embodiments, the cell does not include an indel at or near a target sequence in the gene (or regulatory elements thereof) of an inhibitory molecule or a downstream signaling effector via an inhibitory molecule (although it may include an indel in one or more other genes (or regulatory elements thereof)) . In embodiments, the cell does not include an indel in PDCD1 or its regulatory elements.

In aspects, the cell is an animal cell, such as a mammalian, primate, or human cell, such as a human cell. In aspects, the cell is an immune effector cell (e.g., a population of cells including one or more immune effector cells), e.g., a T cell or an NK cell, e.g., a T cell, e.g., a CD4+ T cell, a CD8+ T cell, or a combination thereof. .

In aspects, the cell is autologous to the patient to whom said cell is to be administered. In other aspects, the cell is allogeneic with respect to the patient to whom said cell is to be administered. In embodiments, the cell is allogeneic to the patient to whom said cell is to be administered, and is or is a cell derived from an induced pluripotent stem cell. In embodiments, the cell is allogeneic to the patient to whom said cell is to be administered and is an immune effector cell, such as a T cell, isolated from a healthy human donor.

In aspects, a cell (or population of cells), for example, as described herein, for example, a CAR-expressing cell, as described in this application, is modified and/or altered, for example, using the methods described in this application, ex vivo. In other aspects, a cell (or population of cells), for example, as described in this application, for example, a CAR-expressing cell, as described in this application, is modified and/or changed, for example, using the methods described in this application, in vivo . In aspects of the CRISPR system, the nRNA molecules (including those in an RNP complex with a Cas9 molecule as described herein) and/or compositions (e.g. compositions comprising more than one nRNA molecule according to the invention) according to the invention are introduced into a cell, e.g. , as described in this application, for example, a CAR-expressing cell, as described in this application, ex vivo. In other aspects, CRISPR systems, nRNA molecules (including RNP complexed with a Cas9 molecule as described herein) and/or compositions (e.g., compositions comprising more than one nRNA molecule according to the invention) according to the invention are introduced into a cell, for example, as described in this application, for example, a CAR-expressing cell, as described in this application, in vivo.

In aspects, the cell has been or will be modified to express a chimeric antigen receptor (CAR) as described herein (eg, the cell includes or will include a nucleic acid sequence encoding a CAR). In embodiments, the CAR recognizes an antigen selected from the following: CD19; CD123; CD22; CD30; CD171; CS-1 (also called CD2 subgroup 1, CRACC, SLAMF7, CD319 and 19A24); lectin-like molecule 1 C-type (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); B cell maturation antigen, a member of the TNF receptor (BCMA) family; Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor associated glycoprotein 72 (TAG72); CD38; CD44v6; cancer embryonic antigen (CEA); epitheliocyte adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); alpha-2 subunit of the interleukin-13 receptor (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostatic stem cell antigen (PSCA); serine protease 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis antigen (Y); CD24; platelet growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen 4 (SSEA-4); CD20; folate receptor alpha; receptor tyrosine protein kinase ERBB2 (Her2/neu); mucin 1 associated with the cell surface (MUC1); epidermal growth factor receptor (EGFR); nerve cell adhesion molecule (NCAM); prostasis; prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); proteasome subunit (prosoma, macropain), beta type, 9 (LMP2); glycoprotein 100 (gp100); an oncogenic fusion protein consisting of a clustered punctate break region (BCR) and Abelson murine leukemia virus (Abl) oncogene homologue 1 (bcr-abl); tyrosinase; ephrin type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); melanoma-associated high molecular weight antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid-stimulating hormone receptor (TSHR); group 5 G-protein coupled receptor class C, member D (GPRC5D); X chromosome open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); the hexasaccharide portion of glycoceramide globoH (GloboH); breast differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cell receptor 1 (HAVCR1); beta-3 adrenoreceptor (ADRB3); pannexin 3 (PANX3); G-protein coupled receptor 20 (GPR20); lymphocyte antigen complex 6, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternative reading frame protein (TARP); Wilms tumor protein (WT1); cancer/testicular antigen 1 (NY-ESO-1); cancer/testicular antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); translocation variant of the ETS 6 gene located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); antigen family X, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); cancer-testicular melanoma antigen 1 (MAD-CT-1); cancer-testicular melanoma antigen 2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); mutant p53; protein; survivin; telomerase; prostate carcinoma tumor antigen 1 (PCTA-1 or galectin-8), T cell-recognized melanoma antigen 1 (MelanA or MART1); rat sarcoma (Ras) mutant oncogene; human telomerase reverse transcriptase (hTERT); point breaks in the translocation of the sarcoma; melanoma apoptosis inhibitor (ML-IAP); ERG (transmembrane serine protease 2 (TMPRSS2) ETS fusion gene); N-acetyl-glucosaminyl transferase V (NA17); paired box-containing protein Pax-3 (PAX3); androgen receptor; cyclin B1; a homologue of the v-myc viral oncogene of avian myelocytomatosis from neuroblastoma (MYCN); member C of the Ras homologue family (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B1 (CYP1B1); CCCTC-binding factor (zinc-finger protein)-like (BORIS or Brother of the Regulator of Imprinted Sites), T-cell-recognized squamous cell carcinoma antigen 3 (SART3); Containing paired boxing protein Pax-5 (PAX5); proacrosin-binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); anchor protein A-kinase 4 (AKAP-4); synovial sarcoma, X break point 2 (SSX2); glycation end products receptor (RAGE-1); renal common 1 (RU1); renal common 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); IgA Fc receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily member 2 (LILRA2); member f of the CD300 family of molecule-like proteins (CD300LF); a member of the A family of 12 proteins with C-type lectin domains (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocytic antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin-lambda-like polypeptide 1 (IGLL1), for example, as described in this application.

In embodiments, the CAR includes an antigen recognition domain that binds CD19, for example, as described herein. In embodiments, the CAR includes an anti-CD19 binding domain, which includes, for example, consists of SEQ ID NO: 7895. In embodiments, the CAR includes an anti-CD19 binding domain, which includes, for example, consists of SEQ ID NO: 7884.

In embodiments, the CAR includes an antigen recognition domain that binds BCMA, for example, as described herein. In embodiments, the CAR includes an anti-BCMA binding domain that includes, for example, consists of SEQ ID NO: 7949.

In embodiments, the CAR includes an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. In embodiments, the transmembrane domain includes the sequence of SEQ ID NO: 6644. In embodiments, the intracellular signaling domain includes a primary signaling domain and/or a costimulatory signaling domain. In embodiments, the primary signaling domain includes, for example, consists of, the sequence of SEQ ID NO: 6648 or SEQ ID NO: 6650. In embodiments, the co-stimulatory signaling domain includes, for example, consists of, the sequence of SEQ ID NO: 6646 or SEQ ID NO: 6636, for example, includes, for example consists of, the sequence of SEQ ID NO: 6646. In other embodiments, the implementation of the co-stimulatory signaling domain includes a sequence from the intracellular signaling domain of CD28.

In embodiments, the CAR is a CD19 CAR, and includes, for example, consists of, the sequence of SEQ ID NO: 7920. In embodiments, the CAR is a CD19 CAR, and includes, for example, consists of, the sequence of SEQ ID NO: 7909. In embodiments, a cell, for example , described in this application, includes a nucleic acid sequence encoding the CD19 CAR described in this application, for example, CD19 CAR, which includes the sequence of SEQ ID NO: 7920 or SEQ ID NO: 7909.

In embodiments, the CAR is a BCMA CAR, and includes, for example, consists of, the sequence of SEQ ID NO: 8559. In embodiments, a cell, for example, described in this application, includes a nucleic acid sequence encoding a BCMA CAR, described in this application, for example, BCMA CAR which includes SEQ ID NO: 8559. In embodiments, the nucleic acid sequence encoding the BCMA CAR includes, for example consists of, SEQ ID NO: 8574.

In aspects, a cell of the invention (eg, a population of cells of the invention), eg as described herein, further comprises a nucleic acid sequence encoding an NK inhibitory molecule. Such cells are preferred when the cells show reduced or abolished expression of one or more major histocompatibility complex class I (MHC I) molecules (e.g., as a result of reduced or abolished B2M expression, for example, obtained using the methods described herein), and/ or reduced or abolished expression of one or more major histocompatibility complex class II (MHC II) molecules (eg, as a result of reduced or abolished CIITA expression, eg, obtained using the methods described herein). In embodiments, the NK inhibitory molecule is an HLA-G molecule, eg an HLA-G molecule that does not require B2M, eg HLA-G2, HLA-G3, HLA-G4. In other embodiments, the NK inhibitory molecule is an HLA-G:B2M fusion molecule. An exemplary HLA-G:B2M fusion molecule is SEQ ID NO: 10674. An exemplary nucleic acid sequence encoding said HLA-G:B2M fusion construct is SEQ ID NO: 10675.

In embodiments, a cell (eg, a population of cells) exhibits reduced or abolished expression of a target NK inhibitory molecule, such as reduced or abolished expression of LILRB1.

In embodiments, a CAR-expressing cell of the invention (e.g., a cell in which the expression or function of one or more proteins has been reduced or abolished, e.g., using the methods described herein) retains the ability to proliferate in response to stimulation, e.g. , the binding of the CAR to its target antigen. In embodiments, proliferation occurs ex vivo. In embodiments, proliferation takes place in vivo. In embodiments, proliferation occurs ex vivo and in vivo. In embodiments, the level of proliferation is substantially the same as the level of proliferation exhibited by a cell of the same type (e.g., a CAR-expressing cell of the same type), but in which the expression or function of one or more proteins has not been reduced or abolished, e.g. , using the methods described in this application. In embodiments, the level of proliferation is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or more of the level of proliferation exhibited by the same cell type (e.g., CAR-expressing cell of the same type), but which has not been reduced or eliminated the expression or function of one or more proteins, for example, using the methods described in this application.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as they are commonly understood by a person skilled in the art to which the present invention pertains. While methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other sources referenced herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative and should not be construed as limiting. Headings, subheadings, or items marked with numbers or letters, such as (a), (b), (i), etc., are provided merely for ease of reading. The use of headings or numeric or lettered elements in this document does not require that steps or elements be performed in alphabetical order, or that steps or elements are necessarily separate from each other. Other features, objects and advantages of the invention will become apparent from the description and drawings, as well as from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Cas9 editing of the B2M locus. The editing region was detected by NGS in HEK-293 Cas9GFP 24 h after delivery of crRNA interacting with the B2M locus and trRNA by lipofection. Each dot represents a different crRNA, trRNA was left unchanged. Genomic coordinates indicate position on chromosome 15. (n=3).

Figure 2: Histogram of TCR expression after editing with nRNA molecules including TCR-alpha targeting domains listed in Table 1. Shown are %mCherry+TCR- cells after 7 days in Jurkat cells using three different concentrations of lentivirus.

Figure 3: %TCR primary T cells are shown 6 and 12 days after administration of the lentivirus encoding the shown nRNA and Cas9/mCherry. Data represents %mCherry+TCR- edited cells.

Figure 4: Showing %PD1 primary T cells in an mCherry+ sorted population 3 days after re-stimulation (with CD3/CD28 spheres) and 8 days after activation, in cells transfected with lentivirus encoding said nRNA and Cas9/mCherry.

Figure 5A and 5B: TCR expression on culture day 7 with TRAC-8 nRNA (FIG. 5A) and PD-1 culture day 8 with PD1-6 nRNA (FIG. 5B) is shown in histogram form.

Figure 6: Expression profiles of primary T cells modified to express the CD19 CAR and treated with an RNP comprising an nRNA that targets TCR-alpha. Pre-enrichment shows cell populations that are CAR+/- and TCR+/- after 11 days in culture. Subsequent enrichment shows >98% TCR-T cells after isolation using a negative selection step with CD3 microspheres.

Figure 7: Cytotoxic activity of CD19 CAR transduced T cells against target-positive (Nalm6-luc) and target-negative (K562-luc) cell lines is shown. "T1" and "T8" refer to TRAC-1 and TRAC-8 nRNA, respectively. Lentivirus or RNP-introduced Cas9/nRNA shown and results for unsorted and TCR-sorted ("sorted") T cell populations

Figure 8: Excision of the B2M gene segment using the CRISPR system, including two molecules of nRNA. In each experiment, cells were exposed to the CR00442 targeting domain nRNA and a second nRNA molecule as indicated. The estimated size of the cut product is shown.

Figure 9: Results of exposing an nRNA pair to the B2M gene with expected excised products less than 100. An * indicates an observed expected excised product (green arrow); ?=expected cut product could not be determined from analysis. The yellow arrow indicates the wild-type fragment.

Figure 10: Results of exposing an nRNA pair to the B2M gene with expected excised products of ~4000 base pairs. A red * indicates the observed expected cut product (green box); Purple *=editing efficiency is less than 10%. Orange frames indicate the wild-type fragment.

Figure 11: Results of exposing an nRNA pair to the B2M gene with expected excised products of ~6000 base pairs. A red * indicates the observed expected cut product (green box); Purple *=editing efficiency is less than 10%. Orange frames indicate the wild-type fragment.

Figure 12: Mean (n≥3) editing of CRISPR systems with lncRNA as indicated to TRAC in HEK cells (stably expressing Cas9) or primary human CD3+ T cells (lncRNA:Cas9 RNP delivery by electroporation). Also shown is the % of cells with TCR loss, as determined by flow cytometry using an anti-TCRa/b antibody.

Figure 13: Mean (n≥3) editing of CRISPR systems with lncRNA as indicated to TRBC1 and TRBC2 coding regions in HEK cells (stably expressing Cas9). Also shown is the % of T-cells with TCR loss, as determined by flow cytometry using anti-TCR a/b antibody.

Figure 14: Mean (n≥3) editing of CRISPR systems with lncRNA as indicated to B2M in HEK cells (stably expressing Cas9), in CD34+ primary human hematopoietic stem cells, and % loss of B2M in primary CD3+ T cells as measured by flow cytometry. NGS analyzes were performed 24 hours after the introduction of CRISPR systems into these cells; flow cytometric analysis was performed 3-5 days after the introduction of CRISPR systems into CD3+ T cells.

Figure 15: Editing, as measured by TCR loss (flow cytometry), by CRISPR systems comprising the indicated nRNA molecule in primary human CD3+ T cells from three different donors. For each nRNA, left column=donor 1; middle column=donor 2; right column=donor 3.

Figure 16: Mean (n≥3) editing of CRISPR systems with lncRNA as indicated to PDCD1 in HEK cells (stably expressing Cas9), as measured by NGS, and in primary human CD3+ cells (RNP electroporation), as measured by loss PD-1 (flow cytometry, using anti-PD-1 antibody).

Figure 17A: Expression (flow cytometry) of TCR and/or B2M after electroporation of nRNA to TRAC and/or B2M at the indicated ratios.

Figure 17B: % cells negative for B2M and for TCR at the indicated ratios of nRNA.

Figure 17C: Editing B2M or TCR as measured by flow cytometry.

Figure 17D: Cell viability 24 hours after electroporation.

Figure 18: Editing (%) when using lncRNAs containing targeting domains to PDCD1 (targeting domain with the indicated sequence CRxxxx) in primary CD3+ T cells as measured by NGS (yellow bars) or loss of PD-1 according to flow cytometry (if using antibodies against PD-1). NGS sequencing was performed 24 hours after RNP delivery; flow cytometry was performed on day 5 after RNP delivery.

Figure 19: Edit % (n≥3) using lncRNAs containing targeting domains to PDCD1 (targeting domain with the specified CRxxxx sequence) in primary CD3+ T cells, as measured by loss of PD-1 by flow cytometry (using an antibody against PD-1), from three different donors (donor 4, left column; donor 5, middle column; donor 6, right column). Systems with targeting domains to some targets show >50% loss of PD-1, with results confirmed with various donors. nRNAs including the targeting domain CR00852, CR00828, CR00870, CR00848, CR00855 and CR00838 show editing greater than 50% with at least 2 donors.

Figure 20: Editing % (n≥3) using lncRNAs containing targeting domains to B2M (targeting domain with the indicated CRxxxx sequence) in primary CD3+ T cells as measured by B2M loss by flow cytometry in three different donors (donor 1 , left column; donor 4, middle column; donor 5, right column). Systems with guide domains to some target sequences show >40% loss of B2M, with confirmed results with various donors. nRNAs including the targeting domain CR00442, CR00444 and CR00455 show editing greater than 40% with at least 2 donors.

Figure 21: % edit (N=3) as measured by NGS in HEK293 cells stably expressing Cas9 using lncRNAs that include a guide domain to FKBP1A as indicated (each unchecked bar uses an odd-numbered CRxxxx guide domain that hits between marked numbers (for example, data for lncRNA that includes the targeting domain CR002073 is presented in a column falling between marked CR002072 and CR002074).

Figure 22: % edit (N=3) and % edit frameshift (FS) as measured by NGS in HEK293 cells stably expressing Cas9 using lncRNAs that include a guide domain to FKBP1A as indicated.

Figure 23: % edit (N=3) and % edit frameshift (FS) as measured by NGS in HEK293 cells stably expressing Cas9 using lncRNAs that include a guide domain to FKBP1A as indicated.

Figure 24: % edit (N=3) and % frameshift edit (FS edit) as measured by NGS in CD3+ T cells using RNPs that include lncRNA that include a guide domain to the indicated FKBP1A.

Figure 25: % of CD3+ T cells that are B2M-, TCR- (as measured with anti-CD3 Ab) or B2M-/TCR- (double negative) as measured by FACS (day 4 after first electroporation) after serial electroporation of RNPs, including nRNA to targets, or after simultaneous electroporation of RNPs, including nRNA to targets.

Figure 26: % of CD3+ T cells that are B2M-, TCR- (as measured with Anti-CD3 Ab) or B2M-/TCR- (double negative) as measured by NGS (48 hours after first electroporation) after one electroporation, sequential electroporation of RNPs including nRNA to targets, or after simultaneous ("Simultaneous") electroporation of RNPs including nRNA to targets (B2M and TRAC).

Figure 27: Gene-edited gene-edited CAR transduced TCR-/B2M-BCMA T cells.

Figure 28: Surface expression of TCR (using anti-CD3-PercpCy5.5 antibody) and B2M (using anti-B2M-APC antibody) five days after electroporation (RNP). T cells transduced with RNPs containing anti-B2M nRNA are designated "B2M"; T cells transduced with RNPs containing anti-TRAC mRNA are designated "TCR". T cells transduced with BCMA CAR are designated "CAR". Non-transduced cells are designated "UTD". Cells electroporated with Cas9 but without guide RNA are referred to as "no nRNA". Staining for CD4 using the anti-CD4-V450 antibody is shown in the lower panel to confirm that the lack of staining for CD3 is due to loss of TCR and not loss of T cells.

Figure 29: Surface expression of TCR and B2M when compared in total T cells and CAR+ T cells from each population. "CAR" means CAR transduction; "Without nRNA" means electroporation of Cas9 without nRNA; "B2M" means electroporation of RNP containing B2M-specific nRNA; "TCR" means electroporation of RNPs containing TRAC-specific nRNA.

Figure 30: CAR expression levels in cells of electroporated RNPs containing B2M-specific ("B2M") and TRAC ("TCR")-specific nRNAs or electroporated Cas9 without nRNA ("nRNA-free").

Figure 31: Evaluation of T cell proliferation in response to tumor cell lines expressing high BCMA (KMS11), low BCMA (RPMI8226), or which are BCMA-(Nalm6). T cells were electroporated with cas9 without nRNA ("No nRNA") or RNP containing anti-B2M and TRAC nRNA ("B2M+TCR"); and/or transduced with a lentiviral vector encoding the BCMA CAR ("BCMA CAR") or not transduced ("UTD") as indicated.

Figure 32: Proliferation of CAR+ CD4+ and/or CD8+ T cells in response to tumor cell lines expressing high BCMA (KMS11), low BCMA (RPMI8226), or which are BCMA- (Nalm6). Cells were electroporated with cas9 without nRNA ("Without nRNA") or electroporated with RNP containing anti-B2M and TRAC nRNA ("B2M+TCR"); and/or transduced with a lentiviral vector encoding a BCMA CAR ("BCMA CAR") or not transduced ("UTD") as indicated.

Figure 33A and 33B: Evaluation of the effect of TRAC-targeted nRNAs on TCR expression on the cell surface. Figure 33A shows the loss of CD3 staining for RNPs containing nRNA CR000961 (961), CR000978 (978), CR000984 (984), CR000992 (992), CR000985 (985), and CR000960 (nRNA1) and CR000979 (nRNA8). Figure 33B shows the loss of CD3 staining for RNPs containing nRNAs CR000991 (991), CR000992 (992), CR000993 (993) and CR000978 (978). 991 and 992 are almost the same.

Figure 33C: Shows genomic editing of the TRAC locus by electroporation of primary human T cells with RNP containing the indicated nRNA targeting the TRAC locus. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that results in a frameshift of the coding sequence is shown (% frameshifted edits).

Figure 34A and 34B: Showing in detail the 5 most commonly observed sequence changes for each TRAC-targeted nRNA used to edit primary human T cells. Figures 34A and 34B are the result of 2 independently conducted electroporation experiments. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data for each experiment are the average of triplicate PCR products. In Figure 34A to 34B, SEQ ID NOs: 10845-10899 are disclosed, respectively, in order of appearance.

Figure 35: Evaluation of the effect of B2M-targeted nRNAs on B2M expression on the cell surface. The nRNA numbers indicate the identifier CR00xxx of the targeting domain.

Figure 36: Genomic editing of the B2M locus by electroporation of primary human T cells with RNP containing the indicated nRNAs targeting the B2M locus. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence (% frameshift edits) is shown in the top panel. The bottom panel details the 10 most commonly observed sequence changes for each B2M-targeted nRNA used to edit primary human T cells. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 36 discloses SEQ ID NOs: 10900-10919, respectively, in order of appearance.

Figure 37: % editing on Day 3 post-electroporation (Day 5 cell culture) in primary human T cells when exposed to RNPs that include the indicated anti-CIITA lncRNAs (the number indicates the guide domain identifier CRxxxxx) at the indicated concentration as measured by flow cytometry at using an anti-HLA-DR reagent.

Figure 38: Shows genomic editing of the CIITA locus by electroporation of primary human T cells with RNP containing the indicated CIITA targeting nRNA. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown (% frameshift edits). The bottom panel shows in detail the 5 most commonly observed sequence changes. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 38 discloses SEQ ID NOs: 10920-10939, respectively, in order of appearance.

Figure 39: % post electroporation Day 3 editing in primary human T cells exposed to RNPs that include the indicated anti-CIITA lncRNA (number indicates targeting domain identifier CR00xxxx) at indicated concentration as measured by flow cytometry using anti-HLA-DR reagent . The % edit represents the expression of HLA-DR on the cell surface after electroporation of the nRNA to CIITA compared to the expression in electroporated cells without guide RNA.

Figure 40: Shows genomic editing of the CIITA locus by electroporation of primary human T cells with RNP containing the indicated nRNA targeting the CIITA locus. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown (% frameshift edits).

Figure 41: The 5 most commonly observed sequence changes (indels) for each CIITA-targeted nRNA used to edit primary human T cells. Data are the average of triplicate PCR products. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Figure 41 discloses SEQ ID NO 10940-10974, respectively, in order of appearance.

Figure 42: % post-electroporation Day 3 editing in primary human T cells exposed to RNPs that include the indicated anti-CIITA lncRNA (number indicates targeting domain identifier CR00xxxx) at indicated concentration as measured by flow cytometry using anti-HLA-DR reagent . The % edit represents the expression of HLA-DR on the cell surface after electroporation of the nRNA to CIITA compared to the expression in cells electroporated without guide RNA.

Figure 43: Shows genomic editing of the CIITA locus by electroporation of primary human T cells with RNP containing the indicated nRNA targeting the CIITA locus. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown (% frameshift edits).

Figure 44. The 5 most commonly observed sequence changes for each CIITA-targeted nRNA used to edit primary human T cells. Data are the average of triplicate PCR products. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Figure 44 discloses SEQ ID NOs: 10975-11014, respectively, in order of appearance.

Figure 45: Schematic of a procedure for obtaining primary human T cells edited at the B2M, TRAC and CIITA loci (cells edited in triplicate).

Figure 46: Evaluation of TRAC, B2M and CIITA editing by analysis of cell surface expression of CD3 epsilon, B2M and HLA-DR, respectively, by flow cytometry. Cell surface expression was examined in cells that were electroporated with a single targeted RNP (single B2M 442, single TRAC 961 or single CIITA 991) or 3 RNPs simultaneously (Triple 1, Triple 2, Triple 3, Triple 4; as detailed in Figure 45) . Cells without electroporation are designated as "without EPO". Cells electroporated with Cas9 but without guide RNA are labeled "No nRNA".

Figure 47: Genomic editing of the B2M, TRAC and CIITA loci by electroporation of primary human T cells simultaneously with 3 RNPs containing nRNAs targeting the B2M, TRAC and CIITA loci. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown in parentheses.

Figure 48: The 10 most frequently observed sequence changes at the B2M locus in primary human T cells for the B2M targeted nRNA CR00442 in a 3 loci simultaneous edit (triple edit) with different concentrations of each RNP, as shown schematically in Figure 45. Unmodified wild bases type (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 48 discloses SEQ ID NOs: 11015-11054, respectively, in order of appearance.

Figure 49: The 10 most frequently observed sequence changes at the TRAC locus in primary human T cells for the TRAC-targeted nRNA CR000961 in a 3-loci simultaneous edit (triple edit) with different concentrations of each RNP, as shown schematically in Figure 45. Unmodified wild bases type (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 49 discloses SEQ ID NOs: 11055-11094, respectively, in order of appearance.

Figure 50: The 10 most frequently observed sequence changes at the CIITA locus in primary human T cells for the CIITA targeted nRNA CR002991 in a 3 loci simultaneous edit (triple edit) with different concentrations of each RNP, as shown schematically in Figure 45. Unmodified wild bases type (wt) are shown in capital letters. Deletions relative to the wt sequence are shown with "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 50 discloses SEQ ID NOs: 11095-11134, respectively, in order of appearance.

Figure 51: The guide RNA format was evaluated for editing efficiency. Anti-TRAC (CR000961; upper panel) or B2M (CR00442; lower panel) target RNA was synthesized in single target or dual target format, with or without designated chemical modifications (PS or OMePS). RNP was introduced by electroporation into primary human T cells at the indicated concentrations. Editing efficiency was assessed in the analysis of cell surface staining for CD3 epsilon in the case of TRAC editing (top) and for B2M protein in the case of B2M editing (bottom) by flow cytometry.

Figure 52: Genomic editing of the FKBP1A locus by electroporation of primary human RNP T cells containing these nRNAs targeting FKBP1A. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown.

Figure 53: Shows the 5 most frequently observed sequence changes for each FKBP1A directed nRNA used to edit primary human T cells. Unmodified wild-type bases (wt) are shown in capital letters. Deletions relative to the wt sequence are shown "-"; insertions relative to the wt sequence are shown in lower case. Data are the average of triplicate PCR products. Figure 53 discloses SEQ ID NOs: 11135-11159, respectively, in order of appearance.

Figure 54: T cells were edited with RNPs containing nRNAs including targeting domains to FKBP1A (CR002086, CR002097, CR002122; labeled 2086, 2097 and 2112, respectively) or negative controls: 442 (irrelevant nRNA CR00442 targeting B2M); Cas9 (only Cas9 without trRNA or crRNA); trRNA (indicator RNA, but without crRNA or Cas9 protein); Cas9+trRNA (Cas9 and indicator RNA, but without crRNA); EP (only cells with electroporation); without EPO (only cells without electroporation). After electroporation, cells were treated with 2.5 nM RAD001 (upper panel) or left untreated (lower panel) and the effect on mTOR pathway inhibition was assessed by S6 phosphorylation (pS6) analysis by flow cytometry. The Y-axis indicates the forward scatter (FSC) and the X-axis indicates the pS6 level. Positive staining for pS6 (shown in indicator gating) was determined by gating above the level of fluorescence seen in the isotype antibody stained control (not shown). Quantification of S6 phosphorylation based on flow cytometry data is shown in the graph in the bottom panel.

Figure 55A and 55B: Cytokine production by edited CART cells in response to antigen exposure. Gene editing was performed on CART cells using CR000961 nRNA to target the TRAC locus and/or CR002097 and CR002086 nRNA to target the FKBP1A locus (as indicated by cr961, 2097 and 2086, respectively). CART cells electroporated with RNP containing guide RNA were prepared as a negative control. CART cells expressing CART-CD19, CART-BCMA-10, or non-transduced (UTD) (as indicated) were mixed with the indicated cancer cell (KMS11 (BCMA positive), Nalm6 (CD19 positive), or RPMI8226 (BCMA positive)) at an effector ratio of to the target 1:1 or 1:2.5 (as indicated). Cell culture supernatants were collected and interferon-gamma was measured (Figure A) or IL-2 was measured (Figure B).

Figure 56: Killing of antigen-positive cancer cell lines with edited CART cells. Gene editing was performed on CART cells using CR000961 nRNA to target the TRAC locus and/or CR002097 and CR002086 nRNA to target the FKBP1A locus (as designated by cr961, 2097 and 2086, respectively). CART cells electroporated with RNP containing guide RNA were prepared as a negative control. CART cells expressing CART-CD19, CART-BCMA-10, or non-transduced (UTD) (as indicated) were mixed with indicated cancer cell lines that stably express reporter luciferase (KMS11 (BCMA positive), Nalm6 (CD19 positive) or RPMI8226 ( BCMA positive)), with an effector to target ratio of 1:1. The luciferase signal was measured and cell killing was defined as the loss of luciferase activity.

Figure 57: Proliferation of edited CART cells in response to antigen exposure. Gene editing was performed on CART cells using CR000961 nRNA to target the TRAC locus and/or CR002097 and CR002086 nRNA to target the FKBP1A locus (as indicated by 961, 2097 and 2086, respectively). CART cells electroporated with RNP containing guide RNA were prepared as a negative control. CART cells expressing CART-CD19 (designated CD19CAR), CART-BCMA-10 (designated BCMA10CAR) or non-transduced (UTD) (as indicated) were mixed with the indicated cancer cell lines (KMS11 (BCMA positive), Nalm6 (CD19 positive) or RPMI8226 (BCMA positive)) at an effector to target ratio of 1:1. Proliferation was measured by counting the number of CD4+ and CD8+ cells, which are CAR+, compared to a constant number of counting microspheres.

Figure 58: Sensitivity of edited (for TRAC and/or FKBP1A genes) CART cells to RAD001. Received CART cells expressing BCMA CAR10 (A), CD19 CAR (B) or no CAR (C; UTD). Gene editing was performed on CART cells or UTD cells using CR000961 nRNA to target the TRAC locus and/or CR002097 and CR002086 nRNA to target the FKBP1A locus (as indicated by 961, 2097 and 2086, respectively). CART cells electroporated with RNP containing guide RNA were prepared as a negative control. After RNP electroporation, cells were treated with 2.5 nM RAD001 (upper panel, indicated as +RAD001) or left untreated (lower panel, indicated as -RAD001) and assessed for effect on inhibition of the mTOR pathway by analyzing S6 phosphorylation (pS6) by flow cytometry . The Y-axis indicates the side scatter (SSC) and the X-axis indicates the level of phosphorylated S6 protein (pS6). Positive staining for pS6, shown in the lower right square of the FACS diagrams, was determined by gating above the level of fluorescence observed in the isotype antibody stained control (not shown). The percentage of cells with S6 phosphorylation is shown in histograms (upper panels) and graphically (lower panel).

Figure 59: Expression of the HLA-G/B2M fusion protein in SupT1 cells as detected by HLA-G flow cytometry. Light gray histogram indicates background fluorescence in the PE channel in non-transduced cells. The dark gray histogram indicates fluorescence in the PE channel from cells transduced with HLA-G/B2M.

Figure 60: Efficiency of editing at the B2M target locus in CD34+ hematopoietic stem cells using various Cas9 variants as assessed by NGS and flow cytometry. NLS=SV40 NLS; His6 (SEQ ID NO: 10795) or His8 (SEQ ID NO: 10796) refers to 6 or 8 histidine residues, respectively; TEV=tobacco etch virus cleavage site; Cas9=Cas9 S. pyogenes wild-type - mutations or variants indicated).

Figure 61: Efficiency of editing at the B2M target locus in primary human T cells using various Cas9 variants and a set of concentrations as measured by flow cytometry.

Figure 62: Editing efficiency of two different Cas9 variants at various concentrations in primary human T cells using two different nRNAs targeting B2M (left panel) or TRAC (right panel). Editing efficiency (% edit) was measured by flow cytometry by measuring the loss of B2M expression on the cell surface (left panel) or TCR (right panel).

Figure 63: Non-targeted activity of nRNA to TRAC and B2M was assessed using the oligo-dsDNA insertion method in HEK-293 cells overexpressing Cas9. The detected target area (triangle) and potential non-target areas (circles) are indicated; the y-axis indicates the frequency of detection. All nRNAs were tested in lncRNA format with the guide domain designated as CRxxxxx. If indicated, each nRNA has been modified such that three 5' internucleotide bonds and three 3' internucleotide bonds are phosphothioate bonds ("PS").

Figure 64: Off-target activity for CIITA, FKBP1A, PDCD1, TRAC and TRBC2 directed guide RNA molecules was assessed using the oligo-dsDNA insertion method in Cas9 overexpressing HEK-293 cells. The detected target area (triangle) and potential non-target areas (circles) are indicated; the y-axis indicates the frequency of detection. All nRNAs were tested in lncRNA format with the guide domain designated as CRxxxxx.

Figure 65: % editing in primary human CD3+ T cells as measured by loss of CD3 surface expression (as measured by flow cytometry) 72 hours after administration of CRISPR systems targeting CD3 delta (lncRNA comprising the indicated targeting domain). Each % of CD3 negative cells is the average of three independent experiments (SD=standard deviation).

Figure 66: % editing in primary human CD3+ T cells as measured by loss of CD3 surface expression (as measured by flow cytometry) 72 hours after administration of CRISPR systems targeting CD3 gamma (lncRNA comprising the indicated targeting domain). Each mean of % CD3-negative cells is the mean of three independent experiments (SD=tolerance).

DEFINITIONS

The terms "CRISPR system", "Cas system", or "CRISPR/Cas system" refer to a set of molecules, including an RNA-targeted nuclease or other effector molecule and an gRNA molecule, which together are necessary and sufficient to direct and effect nucleic acid modification. in the target sequence when exposed to an RNA-directed nuclease or other effector molecule. In one embodiment, the CRISPR system includes an nRNA and a Cas protein, such as the Cas9 protein. Such systems comprising a Cas9 molecule or a modified Cas9 molecule are referred to herein as "Cas9 systems" or "CRISPR/Cas9 systems". In one example, an nRNA molecule and a Cas molecule can bind to form a ribonucleoprotein (RNP) complex.

The terms "guide RNA", "guide RNA molecule", "nRNA molecule", or "nRNA" are used interchangeably and refer to a set of nucleic acid molecules that provide specific targeting for an RNA-directed nuclease or other effector molecule (usually in combination with a molecule nRNA) to the target sequence. In some embodiments, said targeting is achieved by hybridization of a portion of the nRNA to DNA (e.g., via an nRNA guide domain) and by binding of a portion of the nRNA molecule to an RNA-directed nuclease or other effector molecule (e.g., via at least a tracr nRNA). In embodiments, the nRNA molecule consists of a single, contiguous polynucleotide molecule, referred to herein as "single guide RNA" or "onRNA" and the like. In other embodiments, an nRNA molecule consists of a plurality, usually two, of polynucleotide molecules that are themselves capable of association, usually by hybridization, and are referred to herein as "double guide RNA" or "lncRNA" and the like. The nRNA molecules are described in more detail below, but typically include a guide domain and tracr. In embodiments, the targeting domain and tracr are located on the same polynucleotide. In other embodiments, the targeting domain and tracr are located on separate polynucleotides.

The term "guide domain" when used in relation to an nRNA is the part of an nRNA molecule that recognizes, eg is complementary, a target sequence, eg a target sequence in a nucleic acid of a cell, eg a gene.

The term "crRNA" when used in relation to an nRNA molecule is the part of an nRNA molecule that includes a guide domain and a region that interacts with tracr to form a flagpole region.

The term "target sequence" refers to a nucleic acid sequence that is complementary, eg fully complementary, to the directing domain of an nRNA. In embodiments, the target sequence is located on genomic DNA. In an embodiment, the target sequence is contiguous (or co-located or on a complementary strand of DNA) to a protospacer adjacent motif (PAM) sequence recognized by a protein having nuclease or other effector activity, e.g., a PAM sequence recognized by Cas9. In embodiments, the target sequence is an allogeneic T cell target sequence. In embodiments, the target sequence is the target sequence of an inhibitory molecule. In embodiments, the target sequence is the target sequence of a downstream effector of an inhibitory molecule.

The term "flagpole", when used in this application in relation to an nRNA molecule, refers to the part of the nRNA in which crRNA and tracr bind or hybridize with each other.

The term "tracr", when used herein in relation to an nRNA molecule, refers to the portion of the nRNA that binds to a nuclease or other effector molecule. In embodiments, tracr includes a nucleic acid sequence that specifically binds to Cas9. In embodiments, tracr includes a nucleic acid sequence that is part of the flagpole.

The terms "Cas9" or "Cas9 molecule" refer to an enzyme from the bacterial type II CRISPR/Cas system that cleaves DNA. Cas9 also includes the wild-type protein, as well as its functional and non-functional mutants.

The term "complementary" when used in relation to a nucleic acid refers to the base pairing, A with T or U and G with C. The term complementary refers to nucleic acid molecules that are fully complementary, that is, form an A with T or U pair and a G pair. with C throughout the reference sequence, as well as molecules that are at least 80%, 85%, 90%, 95%, 99% complementary.

"Matrix nucleic acid", when used in relation to homology-guided repair or homologous recombination, refers to a nucleic acid inserted at the site of modification by a donor sequence of a CRISPR system for gene repair (insert) at the cleavage site. In one aspect, the template nucleic acid comprises a nucleic acid sequence encoding a chimeric antigen receptor (CAR), for example, as described herein. In one aspect, the template nucleic acid comprises a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), for example, as described herein.

"Indel", as the term is used in this application, refers to a nucleic acid comprising one or more nucleotide insertions, one or more nucleotide deletions, or a combination of nucleotide insertions and deletions relative to a reference nucleic acid, which is obtained by exposure to a composition comprising an nRNA molecule, such as the CRISPR system. Indels can be determined by sequencing the nucleic acid after exposure to a composition comprising an nRNA molecule, for example, using NGS. With respect to the indel region, an indel is said to be located "at or near" a reference region (e.g., a region complementary to the targeting domain of an nRNA molecule) if it includes at least one insertion or deletion of approximately 10, 9, 8, 7 , 6, 5, 4, 3, 2, or 1 nucleotide(s) of the reference region or overlaps with part or all of the indicated reference region (e.g., includes at least one insertion or deletion overlapping with or at 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 nucleotides of the region complementary to the targeting domain of the nRNA molecule, for example, the nRNA molecule described in this application).

"Indel profile", as the term is used in this application, refers to the set of indels that are formed after exposure to a composition comprising an nRNA molecule. In an embodiment, the indel profile consists of the top three indels by frequency of occurrence. In an embodiment, the indel profile consists of the top five indels by frequency of occurrence. In an embodiment, the indel profile consists of indels that are present at greater than about 5% frequency relative to all sequencing reads. In an embodiment, the indel profile consists of indels that are present at more than about 10% frequency relative to the total number of indel sequencing reads (ie, those reads that do not consist of an unmodified reference nucleic acid sequence). In an embodiment, the indel profile includes any 3 of the top five most frequently observed indels. The indel profile can be determined, for example, by sequencing cells in a population of cells that have been exposed to an nRNA molecule.

"Off-target indel", as used herein, refers to an indel at or near a site that differs from the target sequence of the directing domain of an nRNA molecule. Such regions may include, for example, 1, 2, 3, 4, 5 or more mismatched nucleotides relative to the sequence of the nRNA guide domain. In exemplary embodiments, such regions are detected using targeted sequencing in in silico predicted non-target regions or using an insertion method known in the art.

The term "inhibitory molecule" refers to a molecule that, when activated, causes or contributes to the inhibition of cell survival, activation, proliferation and/or function; as well as to the gene encoding the specified molecule, and related regulatory elements, such as promoters. In embodiments, the inhibitory molecule is a molecule expressed on an immune effector cell, such as a T cell. Non-limiting examples of inhibitory molecules are PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGF-beta. It should be understood that the term inhibitory molecule refers to a gene (and its associated regulatory elements) encoding an inhibitory molecule protein when the term is used in relation to a target sequence or nRNA molecule. In an embodiment, the gene encoding the inhibitory molecule is CD274. In an embodiment, the gene encoding the inhibitory molecule is HAVCR2. In an embodiment, the gene encoding the inhibitory molecule is LAG3. In an embodiment, the gene encoding the inhibitory molecule is PDCD1.

The term "downstream signaling effector via an inhibitory molecule" refers to a molecule that mediates the inhibitory effect of an inhibitory molecule; as well as to the gene encoding the specified molecule, and related regulatory elements, such as promoters. It should be understood that the term downstream signaling effector via an inhibitory molecule refers to a gene (and its associated regulatory elements) encoding a downstream signaling effector via an inhibitory molecule protein when the term is used in relation to a target sequence or gRNA molecule. In an embodiment, the gene encoding the downstream signaling effector via an inhibitory molecule is PTPN11.

The terms "allogeneic T cell target" and "allogeneic T cell target" are used interchangeably herein and refer to a protein that mediates or promotes a host-versus-graft reaction, mediates or promotes a graft-versus-host reaction, or is the target of an immunosuppressant; as well as to the gene encoding the specified molecule, and related regulatory elements, such as promoters. It is to be understood that the term allogeneic T cell target refers to the gene (and associated regulatory elements) encoding an allogeneic T cell target protein when the term is used in relation to a target sequence or an nRNA molecule. Without being limited by theory, inhibition or elimination of one or more targets of an allogeneic T cell, for example, using the methods and compositions disclosed in this application, can increase the efficiency, survival, function and / or viability of an allogeneic cell, for example, an allogeneic T cell, for example, by reducing or eliminating unwanted immunogenicity (such as host versus graft or graft versus host).

In a non-limiting example, a protein that mediates or promotes graft versus host or host versus graft is one or more components of a T cell receptor. In an embodiment, the T cell receptor component is T cell receptor alpha, eg, the TCR alpha constant domain. In an embodiment, the T cell receptor component is the T cell receptor beta chain, eg constant domain 1 or constant domain 2 of TCR beta. In an embodiment, the T cell receptor component is the T cell receptor delta chain. In an embodiment, the T cell receptor component is the T cell receptor epsilon chain. In an embodiment, the T cell receptor component is the T cell receptor zeta chain. In an embodiment, the T cell receptor component is the T cell receptor gamma chain. Thus, in embodiments in which the protein encoded by the allogeneic T cell target is a component of the TCR, the gene encoding the allogeneic T cell target may be, for example, TRAC, TRBC1, TRBC2, CD3D, CD3E, CD3G, or CD247, and their combinations.

In a non-limiting example, a protein that mediates or promotes graft versus host or host versus graft is an HLA or B2M protein. Examples of HLA proteins include HLA-A, HLA-B and HLA-C. Thus, in embodiments where the allogeneic T cell target protein is an HLA or B2M protein, the gene encoding the allogeneic T cell target may be, for example, HLA-A, HLA-B, HLA-C, or B2M and their combinations. In other embodiments, the allogeneic T cell target protein is NLRC5, and the gene encoding the allogeneic T cell target can be, for example, NLRC5.

In a non-limiting example, a protein that mediates or promotes graft-versus-host disease or host-versus-graft disease is a major histocompatibility complex class II (MHC II) molecule (e.g., HLA-Dx (where x refers to the MHC II protein designator letter, e.g., HLA-DM, HLA-DO, HLA-DR, HLA-DQ and/or HLA-DP)) or MHC II expression regulatory factor and combinations thereof. A non-limiting example is CIITA (also referred to in this application as C2TA). Thus, in embodiments where the allogeneic T cell target protein is CIITA, the gene encoding the allogeneic T cell target may be, for example, CIITA. In another non-limiting example, a protein that mediates or promotes graft versus host or host versus graft is RFXANK. In another non-limiting example, a protein that mediates or promotes graft versus host or host versus graft is RFXAP. In another non-limiting example, a protein that mediates or promotes graft versus host or host versus graft is RFX5.

The term "target of an immunosuppressant" as used herein refers to the molecular target, e.g., receptor or other protein, of an immunosuppressant agent (the terms "immunosuppressant" and "immunosuppressive" are used interchangeably herein with respect to agent or agent target). An immunosuppressant agent is a substance that suppresses immune function through one of several mechanisms of action. In other words, the function of an immunosuppressant agent is performed by a compound that demonstrates the ability to reduce the degree and/or intensity of the immune response. One example of the type of activity exhibited by an immunosuppressant agent is the activity of eliminating T cells, eg, activated T cells. Another example of the type of activity exhibited by an immunosuppressant agent is the activity of reducing the level of activity or activation of T cells. As a non-limiting example, an immunosuppressant agent can be a calcineurin inhibitor, a rapamycin target, an interleukin-2 a-chain blocker, an inosine monophosphate dehydrogenase inhibitor, a dihydrofolate reductase inhibitor, a corticosteroid, cyclosporine, or an immunosuppressive antimetabolite. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through T cell activation or by inhibiting helper cell activation. As non-limiting examples, immunosuppressant agent targets can be immunosuppressant agent receptors such as: deoxycytidine kinase, CD52, glucocorticoid receptor (GR), a member of the FKBP gene family, such as FKBP12, and a member of the cyclophilin gene family. In an embodiment, the target of the immunosuppressant is deoxycytidine kinase (DCK) and the immunosuppressant is a nucleoside analog drug such as cytarabine (cytosine arabinoside) or gemcitabine. In an embodiment, the target of the immunosuppressant is GR and the immunosuppressant is a corticosteroid such as dexamethasone. In an embodiment, the target of the immunosuppressant is CD52 and the immunosuppressant is an anti-CD52 antibody or antigen-binding fragment thereof, such as alemtuzumab (Campas®). In an embodiment, the target of the immunosuppressant is FKBP12 and the immunosuppressant is FK506 (or an analogue or FKBP12 binding fragment thereof), cyclosporine, rapamycin, or rapalog, or an mTor inhibitor such as RAD001. Thus, in embodiments where the allogeneic T cell target is an immunosuppressant protein target, the gene encoding the allogeneic T cell target can be, for example, NR3C1, FKBP1A, CD52, or DCK, and combinations thereof.

The term "rapamycin-resistant mTor" refers to an mTor protein (and the gene encoding said mTor protein) that has reduced or eliminated binding to FKBP12 (including in the presence of rapamycin, FK506, rapalogue, cyclosporine, and/or another mTor inhibitor such as as RAD001). In exemplary embodiments, rapamycin-resistant mTor includes one or more mutations in the FRB domain. In an exemplary embodiment, rapamycin-resistant mTor includes, for example, consists of, a mutation in S2035, for example, includes, for example, consists of, the S2035I mutation.

The terms "a" and "an" refer to one or more than one (i.e. at least one) grammatical object of the article. As an example, "an element" means one element or more than one element.

The term "approximately" when referring to a measurable value such as amount, duration, etc. is intended to cover changes of ±20% or in some cases ±10% or in some cases ±5% or , in some cases, ±1% or, in some cases, ±0.1% of the specified value, if such options are suitable for the implementation of the disclosed methods.

The term "chimeric antigen receptor" or alternatively "CAR" refers to a set of polypeptides, typically two in the simplest embodiments, which, when present in an immune effector cell, confer on the cell specificity for a target cell, typically a cancer cell. , and generation of an intracellular signal. In some embodiments, a CAR includes at least an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain") comprising a functional signaling domain derived from a stimulatory molecule and/or a costimulatory molecule, as defined below. In some aspects, the polypeptides in the set are adjacent to each other. In some embodiments, the set of polypeptides includes a dimerization switch, which, in the presence of a dimerization molecule, can connect polypeptides to each other, for example, can connect an antigen-binding domain to an intracellular signaling domain. In one aspect, the stimulatory molecule is a zeta chain associated with a T-cell receptor complex. In one aspect, the cytoplasmic signaling domain further includes one or more functional signaling domains derived from at least one costimulatory molecule, as defined below. In one aspect, the co-stimulatory molecule is selected from the co-stimulatory molecules described herein, eg 4 1BB (ie CD137), CD27 and/or CD28. In one aspect, CAR includes a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a stimulatory molecule. In one aspect, a CAR includes a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a costimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, CAR includes a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising two functional signaling domains derived from one or more co-stimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one aspect, a CAR includes a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR includes an optional leader sequence at the N-terminus (N-ter) of the CAR fusion protein. In one aspect, the CAR further includes a leader sequence at the N-terminus of the extracellular antigen-binding domain, where the leader sequence is optionally cleaved from the antigen-binding domain (eg, scFv) during cellular processing and localization of the CAR to the cell membrane.

A CAR that includes an antigen-binding domain (eg, scFv or TCR) that interacts specifically with a specific tumor marker X, such as those described herein, is also referred to as XCAR. For example, a CAR that includes an antigen binding domain that targets CD19 is referred to as CD19CAR. As another example, a CAR that includes an antigen binding domain that interacts directedly with BCMA is referred to as BCMA CAR.

The term "signaling domain" refers to a functional portion of a protein that acts by transmitting information within the cell, regulating cellular activity through certain signaling pathways by generating second messengers or acting as effectors in response to such messengers.

The term "antibody" as used herein refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. The antibodies may be polyclonal or monoclonal, multi or single chain, or intact immunoglobulins, and may be obtained from natural sources or from recombinant sources. The antibodies may be tetramers of immunoglobulin molecules.

The term "antibody fragment" refers to at least one portion of an antibody that retains the ability to interact specifically (eg, through binding, steric hindrance, stabilization/destabilization, spatial distribution) with an antigen epitope. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, antibody scFv fragments, disulfide-linked Fv fragments (sdFv), Fd fragment consisting of VH and CH1 domains , linear antibodies, single domain antibodies such as sdAb (or VL or VH), camelid VHH domains, multispecific antibodies formed from antibody fragments such as a bivalent fragment comprising two Fab fragments linked by a disulfide bridge in the hinge region and an isolated CDR or other epitope-binding antibody fragments. The antigen binding fragment can also be incorporated into single domain antibodies, maxibody, minibody, nanobody, intrabody, diabody, triabody, tetrabody, v-NAR, and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005 ). Antigen-binding fragments can also be grafted onto scaffolds based on polypeptides such as type III fibronectin (Fn3) (see US Pat. No. 6,703,199, which describes fibronectin-based polypeptide minibodies).

The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light and heavy chain variable regions are linked, for example, through a synthetic a linker, for example, a short flexible polypeptide linker, and which can be expressed as a single chain polypeptide, and where the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, when used herein, scFvs may contain the VL and VH variable regions in any order, e.g., relative to the N-terminus and C-terminus of the polypeptide, the scFv may include a VL-linker-VH, or may include a VH-linker-VL.

The portion of the CAR of the invention comprising an antibody or antibody fragment may exist in a variety of forms, wherein the antigen-binding domain is expressed as part of a continuous polypeptide chain, including, for example, a single-domain antibody fragment (sdAb), a single-chain antibody (scFv), a humanized antibody, or a bispecific antibody ( Harlow et al., 1999, in Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, in Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al. al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of a CAR composition of the invention comprises an antibody fragment. In another aspect, the CAR includes an antibody fragment that includes scFv. The exact boundaries of the amino acid sequence of a given CDR can be determined using any of many known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (Kabat's numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (Chothia's numbering scheme), or combinations thereof.

As used herein, the term "binding domain" or "antibody molecule" refers to a protein, such as an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. The term "binding domain" or "antibody molecule" encompasses antibodies and antibody fragments. In an embodiment, the antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, the multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence that has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.

The portion of the CAR of the invention comprising an antibody or antibody fragment may exist in a variety of forms, wherein the antigen-binding domain is expressed as part of a continuous polypeptide chain, including, for example, a single-domain antibody fragment (sdAb), a single-chain antibody (scFv), a humanized antibody, or a bispecific antibody ( Harlow et al., 1999, in Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, in Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al. al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of a CAR composition of the invention comprises an antibody fragment. In another aspect, the CAR includes an antibody fragment that includes scFv.

The term "antibody heavy chain" refers to the larger of the two types of polypeptide chains found in antibody molecules in their natural conformations, and which generally defines the class to which the antibody belongs.

The term "antibody light chain" refers to the smaller of the two types of polypeptide chains present in antibody molecules in their natural conformations. Kappa (κ) and lambda (λ) light chains are the two main light chain isotypes of antibodies.

The term "recombinant antibody" refers to an antibody that is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage or a yeast expression system. It should also be understood that the term means an antibody that has been obtained by synthesizing a DNA molecule encoding an antibody, wherein such DNA molecule expresses an antibody protein or an amino acid sequence that defines an antibody, where the DNA or amino acid sequence was obtained using recombinant DNA or amino acid technology. sequences that are available and known in the art.

The term "antigen" or "Ag" refers to a molecule that elicits an immune response. Such an immune response may include antibody production and/or activation of specific immunocompetent cells. It will be apparent to those skilled in the art that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. In addition, antigens can be obtained from recombinant or genomic DNA. It will be apparent to those skilled in the art that any DNA that includes nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response would thus encode an "antigen" as the term is used herein. In addition, it will be obvious to a person skilled in the art that an antigen need not necessarily be encoded by the full nucleotide sequence of a gene alone. It should be obvious that the present invention includes, without limitation, the use of incomplete nucleotide sequences of more than one gene, and that such nucleotide sequences are present in various combinations, encoding polypeptides that elicit the desired immune response. In addition, it will be obvious to one skilled in the art that an antigen need not be encoded by a "gene" at all. It should be obvious that the antigen may be obtained by synthesis or may be obtained from a biological sample, or may be another macromolecule in addition to the polypeptide. Such a biological sample may include, without limitation, a tissue sample, a tumor sample, a cell or fluid with other biological components.

The term "anti-cancer effect" refers to a biological effect that can be manifested in a variety of ways, including, but not limited to, for example, reduction in tumor volume, reduction in the number of cancer cells, reduction in the number of metastases, increase in life expectancy, reduction in cancer cell proliferation, reduction in cancer cell survival. or reducing the severity of various physiological symptoms associated with cancer. "Anti-cancer activity" can also be manifested in the ability of peptides, polynucleotides, cells and antibodies to prevent the primary occurrence of cancer. The term "antitumor activity" refers to a biological effect that can be manifested in a variety of ways, including, but not limited to, for example, shrinking tumor volume, reducing tumor cell numbers, decreasing tumor cell proliferation, or decreasing tumor cell survival.

The term "autologous" refers to any material obtained from the same individual to whom it is intended to be reintroduced at a later date.

The term "allogeneic" refers to any material obtained from another animal of the same species as the individual to whom such material is administered. Two or more individuals are said to be allogeneic to each other when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may be genetically different enough to interact antigenically.

The term "xenogeneic" refers to a graft obtained from an animal of another species.

The term "cancer" refers to a disease characterized by the uncontrolled growth of aberrant cells. Cancer cells can spread locally or, through the bloodstream and lymphatic system, to other parts of the body. Examples of various forms of cancer are described herein and include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colon and rectal cancer, kidney cancer, liver cancer, cancer brain, lymphoma, leukemia, lung cancer, etc. The terms "tumor" and "cancer" are used interchangeably in this application, for example, both terms cover solid and hemoblastic, for example, diffuse or circulating tumors. As used herein, the term "cancer" or "tumor" includes premalignant tumors as well as cancer and malignant tumors.

"Derived from" when using this term in this application indicates the relationship between the first and second molecule. It usually refers to the structural similarity between the first molecule and the second molecule and does not mean or include a process or original limitation on the first molecule that is derived from the second molecule. For example, in the case of an intracellular signaling domain that is derived from a CD3 zeta molecule, the intracellular signaling domain retains sufficient structure of CD3 zeta such that it has the required function, namely the ability to generate a signal under appropriate conditions. This does not imply or include a limitation to a particular process for producing an intracellular signaling domain, for example, it does not mean that in order to obtain an intracellular signaling domain, one must start with a CD3-zeta sequence and delete an undesired sequence or introduce mutations to obtain an intracellular signaling domain.

The phrase "a disease associated with the expression of a tumor antigen as described herein" includes, without limitation, a disease associated with the expression of a tumor antigen as described herein or a condition associated with cells that express a tumor antigen as described in the present application, including, for example, proliferative diseases such as cancer or malignancy or a precancerous condition such as myelodysplasia, myelodysplastic syndrome or preleukemia; or a non-cancer indication associated with cells that express a tumor antigen as described herein. In one aspect, cancer associated with the expression of a tumor antigen, as described in this application, is hemoblastosis. In one aspect, the cancer associated with tumor antigen expression as described is a solid cancer. Other diseases associated with the expression of the tumor antigen described in this application include, without limitation, for example, atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with the expression of the tumor antigen, as described in this application. Non-cancer indications associated with tumor antigen expression as described herein include, but are not limited to, for example, autoimmune disease (eg, lupus), inflammatory disorders (allergy and asthma), and transplantation. In some embodiments, tumor antigen-expressing cells express, or have at any time expressed, an mRNA encoding a tumor antigen. In an embodiment, the tumor antigen-expressing cells produce a tumor antigen protein (eg, wild-type or mutant), wherein the tumor antigen protein may be present at normal levels or reduced levels. In an embodiment, the tumor antigen expressing cells produce detectable levels of tumor antigen protein at a certain point and then do not produce substantially detectable tumor antigen protein.

The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody or an antibody fragment containing an amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody or antibody fragment of the invention using standard methods known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (eg, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (eg, threonine, valine, isoleucine), and aromatic side chains (eg, tyrosine, phenylalanine , tryptophan, histidine). Thus, one or more amino acid residues in a CAR of the invention may be replaced with other amino acid residues from the same side chain family, and the altered CAR may be tested using the functional assays described herein.

The term "stimulation" refers to the primary response induced by the binding of a stimulatory molecule (e.g., TCR/CD3 or CAR complex) to its cognate ligand (or tumor antigen in the case of CAR) that mediates signal transduction, such as, without limitation, signal transduction via the TCR/CD3 complex or signal transduction via the corresponding NK receptor or CAR signaling regions. Stimulation may mediate altered expression of certain molecules.

The term "stimulatory molecule" refers to a molecule expressed by an immune cell (e.g., T cell, NK cell, B cell) that provides cytoplasmic signal sequence(s) that regulates immune cell activation in a stimulatory manner at at least some aspect of the immune cell signaling pathway. In one aspect, a signal is a primary signal that initiates, for example, the binding of a TCR/CD3 complex to a peptide-loaded MHC molecule and that results in the mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, etc. P. The primary cytoplasmic signaling sequence (also referred to as "primary signaling region") that acts in a stimulatory manner may contain a signaling motif, which is known as an immunoreceptor tyrosine activating motif or ITAM. Examples of an ITAM containing a cytoplasmic signal sequence that is particularly useful in the invention include, but are not limited to, ITAMs that are derived from CD3-zeta, FcR-gamma generic (FCER1G), Fc-gamma RIIa, FcR-beta (Fc-epsilon R1b), CD3-gamma, CD3-delta, CD3-epsilon, CD79a, CD79b, DAP10 and DAP12. In a particular CAR according to the invention, the intracellular signaling domain in any one or more CAR receptors according to the invention contains an intracellular signal sequence, for example, the primary signal sequence of CD3-zeta. In a particular CAR of the invention, the primary CD3-zeta signal sequence is the sequence shown as SEQ ID NO: 18, or equivalent residues from non-human species, e.g., mouse, rodent, monkey, great ape, and the like. In a particular CAR of the invention, the primary CD3-zeta signal sequence is the sequence shown in SEQ ID NO: 20, or equivalent residues from a non-human species, e.g., mouse, rodent, monkey, great ape, and the like.

The term "antigen presenting cell" or "APC" refers to a cell of the immune system, such as a helper cell (e.g., B cell, dendritic cell, etc.), which displays a foreign antigen associated with major histocompatibility complexes (MHC) on its surface. T cells can recognize such complexes using their T cell receptors (TCRs). APCs process antigens and present them to T cells.

"Intracellular signaling domain", when using this term in this application, refers to the intracellular part of the molecule. The intracellular signaling domain generates a signal that stimulates the immunoeffector function of a CAR containing cell, such as a CART cell. Examples of immunoeffector function, for example in a CART cell, include cytolytic activity and helper activity, including cytokine secretion.

In one embodiment, the intracellular signaling domain may comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include signaling domains that are derived from molecules that provide primary stimulation or antigen-dependent spoof. In one embodiment, the intracellular signaling domain may comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include signaling domains that are derived from molecules that provide costimulatory signals or antigen-independent stimulation. For example, in the case of CART, the primary intracellular signaling domain may contain the cytoplasmic sequence of the T-cell receptor, and the costimulatory intracellular signaling domain may contain the cytoplasmic sequence from the co-receptor or costimulatory molecule.

The primary intracellular signaling domain may contain a signaling motif, which is known as an immunoreceptor tyrosine activating motif or ITAM. Examples of ITAMs containing primary cytoplasmic signal sequences include, but are not limited to, ITAMs that are derived from CD3-zeta, FcR-gamma general type (FCER1G), Fc-gamma RIIa, FcR-beta (Fc-epsilon R1b), CD3- gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10 and DAP12.

The term "zeta" or, alternatively, "zeta chain", "CD3-zeta" or "TCR-zeta" is defined as a protein represented under reg. GenBan number BAG36664.1, or equivalent residues from a non-human species, e.g. mouse, rodent, monkey, great ape, etc., and a "zeta-stimulating domain" or alternatively "CD3-zeta-stimulating domain" or "TCR-zeta-stimulating domain" is defined as amino acid residues from the cytoplasmic domain of the zeta chain, or functional derivatives thereof, that are sufficient for functional transmission of the primary signal required for T-cell activation. In one aspect, the cytoplasmic zeta domain contains residues 52 to 164 of reg. GenBank numbers BAG36664.1 or equivalent residues from non-human species, eg mouse, rodent, monkey, great ape, etc., which are functional orthologues. In one aspect, a "zeta-stimulating domain" or "CD3 zeta-stimulating domain" is the sequence shown as SEQ ID NO: 18. In one aspect, a "zeta-stimulating domain" or "CD3 zeta-stimulating domain" is the sequence shown as SEQ ID NO: 20.

The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand that mediates a costimulatory response of the T cell, such as, without limitation, proliferation. Costimulatory molecules are cell surface molecules, other than antigen receptors or their ligands, that promote an effective immune response. Costimulatory molecules include, but are not limited to, the MHC class I molecule, BTLA, and the Toll Ligand receptor, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4- 1BB (CD137). Other examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8-alpha, CD8-beta, IL2R- beta, IL2R, IL7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229) CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT , GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds to CD83.

The costimulatory intracellular signaling domain may be an intracellular portion of a costimulatory molecule. The costimulatory molecule can be present in the following protein families: TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte-activating molecules (SLAM proteins), and activating NK cell receptors. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, ICAM-1, lymphocytic function-associated antigen-1 (LFA-1), CD2, CDS, CD7, CD287, LIGHT, NKG2C, NKG2D, SLAMF7, NKp80, NKp30, NKp44, NKp46, CD160, B7-H3, and a ligand that specifically binds to CD83, and the like.

An intracellular signaling domain may include the entire intracellular portion or the entire native intracellular signaling domain of the molecule from which it is derived, or a functional fragment or derivative thereof.

The term "4-1BB" refers to a member of the TNFR superfamily whose amino acid sequence is provided under Reg. GenBank number AAA62478.2 or equivalent non-human species, eg mouse, rodent, monkey, great ape, etc.; and "costimulatory domain 4-1BB" is defined as amino acid residues 214-255 from GenBank AAA62478.2 or equivalent residues from non-human species, eg, mouse, rodent, monkey, great ape, and the like. In one aspect, a "4-1BB co-stimulatory domain" is a sequence represented by SEQ ID NO: 14 or equivalent residues from a non-human species, e.g., mouse, rodent, monkey, great ape, and the like.

"Immune effector cell", when used in this application, refers to a cell that is involved in the immune response, for example, in the stimulation of the immune effector response. Examples of immune effector cells include T cells, such as alpha/beta T cells and gamma/delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and phagocytes of myeloid origin.

"Immunoeffector function or immune effector response", as used herein, refers to a function or response, eg, to an immune effector cell, that enhances or promotes an immune attack on a target cell. For example, immunoeffector function or response refers to a property of a T or NK cell that contributes to killing or inhibiting the growth or proliferation of a target cell. In the case of a T cell, primary stimulation and costimulation are examples of an immune effector function or response.

The term "coding" refers to the characteristic property of specific nucleotide sequences in a polynucleotide, such as a gene, cDNA or mRNA, for use as templates for the synthesis of other polymers and macromolecules in biological processes, having either a specific nucleotide sequence (for example, rRNA, tRNA and mRNA ), or a specific amino acid sequence, and the resulting biological properties. Thus, a gene, cDNA, or RNA codes for a protein if the transcription and translation of the mRNA corresponding to that gene results in a protein in a cell or other biological system. A coding strand whose nucleotide sequence is identical to that of an mRNA and is usually provided in sequence listings, and a non-coding strand used as a template for transcription of a gene or cDNA may be listed as encoding a protein or other product of that gene or cDNA.

Unless otherwise specified, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate variants of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that codes for a protein or RNA may also include introns, to the extent that a nucleotide sequence that codes for a protein may, in some embodiment, contain intron(s).

The term "effective amount" or "therapeutically effective amount" is used interchangeably herein and refers to an amount of a compound, dosage form, material or composition as described herein effective to produce a particular biological result.

The term "endogenous" refers to any material from, or produced in an organism, cell, tissue, or system.

The term "exogenous" refers to any material introduced from or produced outside the body, cell, tissue or system.

The term "expression" refers to the transcription and/or translation of a particular nucleotide sequence that is regulated by a promoter.

The term "transfer vector" refers to a composition of substances which contains an isolated nucleic acid and which can be used to deliver the isolated nucleic acid into a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides linked to ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "transfer vector" includes an autonomously replicating plasmid or virus. It is also to be understood that the term also includes non-plasmid and non-viral compounds that facilitate the transfer of a nucleic acid into cells, such as, for example, a polylysine compound, a liposome, and the like. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and the like.

The term "expression vector" refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operably linked to an expressed nucleotide sequence. The expression vector includes sufficient cis-acting elements for expression; other elements for expression may be provided by the host cell or in an in vitro expression system. Expression vectors include all vectors known in the art, including cosmids, plasmids (eg, naked or contained in liposomes), and viruses (eg, lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that include the recombinant polynucleotide.

The term "homologous" or "identity" refers to subunit sequence identity between two polymeric molecules, for example between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. When the position of a subunit in both molecules is occupied by the same monomeric subunit; for example, if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position. Homology between two sequences is a direct function of the number of matching or homologous positions; for example, if half (eg, five positions in a 10 subunit long polymer) positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (eg, 9 out of 10) are the same or homologous, the two sequences are 90% homologous.

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding antibody subsequences) that contain a minimum sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from the complementarity determining region (CDR) of the recipient are replaced by CDR residues from a non-human species (donor antibody) such as mouse, rat, or rabbit having the required specificity, affinity and activity. In some cases, Fv framework region (FR) residues of a human immunoglobulin are replaced with corresponding non-human residues. In addition, the humanized antibody/antibody fragment may contain residues that are not present in either the recipient antibody or the imported CDR or framework sequences. Such modifications can further improve and optimize the performance of antibodies or antibody fragments. In general, a humanized antibody or fragment thereof will contain substantially all of at least one, and typically two, variable domains in which all or substantially all of the CDRs correspond to non-human immunoglobulin CDRs and all or a significant portion of the FR -regions are FR regions from the human immunoglobulin sequence. The humanized antibody or antibody fragment may also contain at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin. For more information, see Jones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332:323-329, 1988; Presta, Curr. Op. Struct. Biol., 2:593-596, 1992.

"Fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, where the entire molecule is of human origin or consists of an amino acid sequence identical to the human form of the antibody or immunoglobulin.

The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally present in the body of a living animal is not "isolated", but the same nucleic acid or peptide that is partially or completely separated from accompanying materials in its natural state is "isolated". The isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-native environment such as, for example, a host cell.

The term "operably linked" or "transcriptional regulation" refers to a functional relationship between a regulatory sequence and a heterologous nucleic acid sequence that results in the expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in operable linkage to a second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Functionally related DNA sequences can be adjacent to each other and, for example, if it is necessary to connect two protein-coding regions, be in the same reading frame.

The term "parenteral" administration of an immunogenic composition includes, for example, subcutaneous (SC), intravenous (IV), intramuscular (IM) or intrasternal injection, intratumoral, or infusion methods.

The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and their polymers in single or double stranded form. Unless otherwise limited, this term encompasses nucleic acids containing known analogs of naturally occurring nucleotides that have similar binding properties as the reference nucleic acid and are metabolized similarly to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses its conservatively modified variants (eg, degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence as expressly specified. In particular, degenerate codon substitutions can be made by generating sequences in which the third position of one or more selected (or all) codons is replaced by mixed base residues and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991 ); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

The terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to a compound consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that a protein or peptide sequence may contain. Polypeptides include any peptide or protein containing two or more amino acids connected to each other by peptide bonds. As used herein, the term refers to both short chains, which are also commonly referred to in the art as peptides, oligopeptides, and oligomers, for example, and longer chains, which are commonly referred to in the art as proteins, which come in many types. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins, and others. The polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof.

The term "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell or introduced by the synthetic machinery required to initiate a specific transcription of a polynucleotide sequence.

The term "promoter/regulatory sequence" refers to a nucleic acid sequence that is required for the expression of a gene operably linked to a promoter/regulatory sequence. In some cases, this sequence may be the main promoter sequence, and in other cases, this sequence may also include an enhancer sequence and other regulatory elements that are necessary for the expression of the gene product. The promoter/regulatory sequence may, for example, be one that expresses the gene product in a tissue-specific manner.

The term "constitutive" promoter refers to a nucleotide sequence which, when operably linked to a polynucleotide that encodes or defines a gene product, causes the production of the gene product in a cell under most or all physiological conditions of the cell.

The term "inducible" promoter refers to a nucleotide sequence which, when operably linked to a polynucleotide that encodes or defines a gene product, causes the gene product to be produced in a cell substantially only when an inducer is present in the cell that matches the promoter.

The term "tissue-specific" promoter refers to a nucleotide sequence which, when operably linked to a polynucleotide that encodes for or is defined by a gene, causes the gene product to be produced in a cell substantially only when the cell is a cell of the type of tissue that matches the promoter.

The terms "cancer-associated antigen" or "tumor antigen" alternately refer to a molecule (usually a protein, carbohydrate, or lipid) that is expressed on the surface of a cancer cell, either entirely or as a fragment (e.g., MHC/peptide), and which can be used for selective targeting of a pharmacological agent to a cancer cell. In some embodiments, the tumor antigen is a marker expressed by both normal cells and cancer cells, such as a lineage marker, such as CD19 on B cells. In some embodiments, the tumor antigen is a cell surface molecule that is overexpressed in a cancer cell compared to a normal cell, e.g., 1-fold overexpression, 2-fold overexpression, 3-fold overexpression or more compared to a normal cell. In some embodiments, the tumor antigen is a cell surface molecule that is improperly synthesized in a cancer cell, such as a molecule that contains deletions, additions, or mutations compared to a molecule expressed in a normal cell. In some embodiments, the tumor antigen is expressed exclusively on the cell surface of the cancer cell, in whole or as a fragment (eg, MHC/peptide) and is not synthesized or expressed on the surface of a normal cell. In some embodiments, the CAR receptors of the present invention include CAR receptors containing an antigen binding domain (eg, an antibody or antibody fragment) that binds to a peptide presented by the MHC. Typically, peptides derived from endogenous proteins fill the cavities of major histocompatibility complex (MHC) class I molecules and are recognized by T cell receptors (TCRs) on CD8+ T lymphocytes. MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and/or tumor-specific peptide/MHC complexes represent a unique class of cell surface targets for immunotherapy. TCR-like antibodies targeting peptides derived from viral or tumor antigens have been described in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 (see, for example, Sastry et al., J Virol. 2011 85( 5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8 (21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, a TCR-like antibody can be identified by screening a library, such as a human scFv phage display library.

The term "tumor-supporting antigen" or "cancer-supporting antigen" refers interchangeably to a molecule (usually a protein, carbohydrate, or lipid) that is expressed on the surface of a cell that is not itself cancerous but supports cancer cells, for example, by promoting their growth. or survival, such as immune cell resistance. Examples of cells of this type include stromal cells and myeloid suppressor cells (MDSC). The tumor-supporting antigen itself should not play a role in supporting tumor cells as long as the antigen is present in the cell that supports the cancer cells.

The term "flexible polypeptide linker" or "linker" when used in relation to scFv refers to a peptide linker that consists of amino acids, such as glycine and/or serine residues, used alone or in combination to link heavy chain variable regions and light chain variable regions together. . In one embodiment, the flexible polypeptide linker is a Gly/Ser linker and includes the amino acid sequence (Gly-Gly-Gly-Ser)n, where n is a positive integer greater than or equal to 1. For example, n=1, n=2, n =3, n=4, n=5 and n=6, n=7, n=8, n=9 and n=10 (SEQ ID NO: 6592). In one embodiment, flexible polypeptide linkers include, but are not limited to, (Gly4Ser)4 (SEQ ID NO: 6593) or (Gly4Ser)3 (SEQ ID NO: 6594). In another embodiment, the linkers include multiple repeats of (Gly2Ser), (GlySer) or (Gly3Ser) (SEQ ID NO: 6595). Also included within the scope of the invention are the linkers described in WO2012/138475, incorporated herein by reference.

When used herein in relation to messenger RNA (mRNA), the 5' cap (also referred to as RNA cap, RNA 7-methylguanosine cap, or m7G RNA cap) is a modified guanine nucleotide that is attached to the "front" or 5' end of the eukaryotic messenger RNA shortly after the start of transcription. The 5' cap consists of an end group that is linked to the first nucleotide to be transcribed. Its presence is extremely important for recognition by the ribosome and protection from the action of RNases. Attachment of the cap is associated with transcription and occurs co-transcriptionally, with each process affecting the other. Shortly after the start of transcription, the 5' end of the synthesized mRNA is bound by a cap-synthesizing complex associated with RNA polymerase. This enzyme complex catalyzes the chemical reactions that are required for mRNA capping. The synthesis continues as a multi-stage biochemical reaction. The capping group can be modified to modulate the functionality of the mRNA, such as its stability or translation efficiency.

As used herein, "in vitro transcribed RNA" refers to RNA, preferably mRNA, that has been synthesized in vitro. Typically, in vitro transcribed RNA is obtained from an in vitro transcription vector. An in vitro transcription vector includes a template that is used to generate in vitro transcribed RNA.

As used herein, "poly(A)" is the addition of a large amount of adenosines to mRNA by polyadenylation. In a preferred embodiment of the construct for transient expression, the polyA comprises between 50 and 5000 (SEQ ID NO: 6596), preferably greater than 64, more preferably greater than 100, most preferably greater than 300 or 400. Poly(A) sequences may be modified chemically or enzymatically to modulate mRNA functionality such as localization, stability, or translation efficiency.

As used herein, "polyadenylation" refers to the covalent bonding of a polyadenyl group, or a modified variant thereof, to a messenger RNA molecule. In eukaryotic organisms, most messenger or messenger RNA (mRNA) molecules are polyadenylated at the 3' end. The 3' poly(A) tail is a long sequence of adenine nucleotides (often several hundred) attached to pre-mRNA by the action of the enzyme, polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is attached to transcripts that contain a specific sequence, the polyadenylation signal. The poly(A) tail and the protein associated with it contribute to the protection of mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, mRNA export from the nucleus, and translation. Polyadenylation occurs in the nucleus immediately after the transcription of DNA into RNA, but additionally can also take place later in the cytoplasm. After transcription is terminated, the mRNA chain is cleaved by the endonuclease complex associated with RNA polymerase. The cleavage site is typically characterized by the presence of the base sequence AAUAAA near the cleavage site. After mRNA cleavage, adenosine residues are attached to the free 3' ends at the cleavage site.

As used herein, "transient" refers to the expression of a non-integrated transgene over a period of hours, days, or weeks, where the expression time period is less than the gene expression time period if the gene is integrated into the genome or contained in a stable plasmid replicon in host cell.

As used herein, the terms "treat" and "treatment" refer to reducing or reducing the progression, severity and/or duration of a proliferative disorder, or alleviating one or more symptoms (preferably one or more overt symptoms) of a proliferative disorder resulting from the use of one or more therapies (eg, one or more therapeutic agents such as CAR according to the invention). In specific embodiments, the terms "treat" and "treatment" refer to improvement in at least one measurable physical parameter of a proliferative disorder, such as tumor growth, not necessarily apparent to the patient. In other embodiments, the terms "treat" and "treatment" refer to inhibiting the progression of a proliferative disorder physically, eg by stabilizing a recognizable symptom, and/or physiologically, eg by stabilizing a physical parameter. In other embodiments, the terms "treat" and "treatment" refer to reducing or stabilizing the size of a tumor or the number of malignant cells.

The term "signaling pathway" refers to the biochemical relationship between various signaling molecules that play a role in signaling from one part of a cell to another part of the cell. The phrase "cell surface receptor" includes molecules and complexes of molecules capable of receiving a signal and transmitting a signal across the cell membrane.

The term "subject" is intended to include living organisms in which an immune response can be elicited (eg, mammal, human).

The term "substantially clear" cell refers to a cell that is essentially free of other types of cells. A substantially purified cell also refers to a cell that has been separated from other cell types with which it is normally associated in its natural state. In some cases, the population of essentially purified cells refers to a homogeneous population of cells. In other cases, the term simply refers to a cell that has been separated from the cells with which it is normally associated in its natural state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro.

The term "therapeutic" as used in this application means treatment. The therapeutic effect is obtained by reduction, suppression, remission or elimination of the pathological condition.

The term "prophylaxis" as used herein means the prevention or protective treatment of a disease or condition.

As used herein, "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with hyperproliferative disorder" refers to antigens that are prevalent in certain hyperproliferative disorders. In some aspects, the hyperproliferative disorder antigens of the present invention are derived from cancers, including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemias, uterine cancer, cervical cancer , bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like.

The term "transfected" or "transformed" or "transduced" refers to a process in which an exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" or "transformed" or "transduced" cell is a cell that has been transfected, transformed, or transduced with an exogenous nucleic acid. A cell includes a subject's primary cell and its progeny.

The term "specifically binds" refers to a molecule that recognizes and binds to a binding partner (eg, protein or nucleic acid) present in a sample, but such molecule does not substantially recognize or bind other molecules in the sample.

"Membrane anchor" or "membrane-binding domain", as used herein, refers to a polypeptide or group, such as a myristoyl group, sufficient to bind an extracellular or intracellular domain to a plasma membrane.

The term "bioequivalent" refers to the amount of an agent other than the reference compound (eg, RAD001) required to produce an effect equivalent to that obtained with the reference dose or reference amount of the reference compound (eg, RAD001). In one embodiment, the effect is the level of mTOR inhibition, e.g. as measured by P70 S6 kinase inhibition, e.g. as measured in an in vivo or in vitro assay, e.g. as measured by an assay described herein, e.g. . In one embodiment, the effect is a change in the ratio of PD-1 positive/PD-1 negative T cells as measured by cell sorting. In one embodiment, the bioequivalent amount or dose of the mTOR inhibitor is the amount or dose that provides the same level of P70 S6 kinase inhibition as the reference dose or reference amount of the reference compound. In one embodiment, the bioequivalent amount or dose of the mTOR inhibitor is the amount or dose that achieves the same level of change in the ratio of PD-1 positive/PD-1 negative T cells as the reference dose or reference amount of the reference compound.

The term "low immunostimulatory dose" when used in relation to an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g. measuring inhibition of P70 S6 kinase activity. Methods for assessing mTOR activity, for example, by inhibition of P70 S6 kinase, are discussed in this application. The dose is not sufficient to provide complete immunosuppression, but sufficient to enhance the immune response. In an embodiment, a low immunostimulatory dose of an mTOR inhibitor results in a decrease in the number of PD-1 positive T cells and/or an increase in the number of PD-1 negative T cells or an increase in the ratio of PD-1 negative T cells/PD-1 positive T cells. In an embodiment, a low immunostimulatory dose of an mTOR inhibitor results in an increase in naïve T cells. In an embodiment, a low immunostimulatory dose of an mTOR inhibitor results in one or more of the following:

increased expression of one or more of the following markers: CD62Lhigh, CD127high, CD27+ and BCL2, eg on memory T cells, eg memory T cell precursors;

decrease in expression of KLRG1, for example, on T-memory cells, for example, precursors of T-memory cells; and

an increase in memory T cell precursors, eg, cells with any or combination of the following: increased CD62Lhigh, increased CD127high, increased CD27+, decreased KLRG1, and increased BCL2;

where there is any of the changes described above, for example, at least temporarily, for example, compared with an untreated subject.

"Refractory" as used herein refers to a disease, such as cancer, that does not respond to treatment. In embodiments, refractory cancer may be treatment-resistant prior to treatment or at the start of treatment. In other embodiments, refractory cancer may become resistant during treatment. Refractory cancer is also called resistant cancer.

"Recurrent" as used herein refers to the recurrence of a disease (eg, cancer) or signs and symptoms of a disease, such as cancer, after a period of improvement, eg, after previous treatment with a therapy, eg, cancer therapy.

Ranges: Throughout this specification, various aspects of the invention may be presented in range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Thus, a description of a range should be considered to include all possible expressly disclosed subranges, as well as individual numerical values within that range. For example, a description of a range such as 1 to 6 should be considered as expressly disclosed subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6 and so on, as well as individual numbers within a given range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity, includes anything with 95%, 96%, 97%, 98%, or 99% identity, and also includes sub-ranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97- 98% and 98-99% identity. This applies regardless of the latitude of the range.

DETAILED DESCRIPTION

The nRNA molecules, compositions, and methods described herein relate to genome editing in eukaryotic cells using a CRISPR/Cas system, such as the Cas9 system. In particular, the nRNA molecules, compositions, and methods described herein relate to the regulation of the expression (or expression of functional variants) of target molecules that affects the function of a transplanted cell, such as a cell for cancer immunotherapy. In an aspect, the transplanted cell is an immune effector cell, such as an NK cell or a T cell. In an aspect, the cell is an allogeneic cell. In an aspect, the cell has been or will be modified to express a chimeric antigen receptor. Thus, the present application provides compositions and methods for altering, e.g., inhibiting or reducing, expression and/or function (e.g., level of expression of a functional variant) of a gene product, which can increase efficacy (e.g., reducing or eliminating unwanted immunogenicity (such as host-versus-graft or graft-versus-host)), function, proliferation, stimulation, or survival of a transplanted cell, such as a transplanted immune effector cell, such as an NK cell, or a T cell, such as a T cell modified to express a chimeric antigen receptor ( CAR), for example, an allogeneic CAR-expressing T cell for immunotherapy.

In aspects, the gene products are allogeneic T cell targets, such as a T cell receptor component, eg CD3 zeta, CD3 epsilon, CD3 gamma, CD3 delta, T cell receptor alpha (TCR) or TCR beta; an HLA molecule or beta-2 microglobulin (B2M), such as HLA-A, HLA-B, HLA-C or B2M; a CIITA molecule; or an immunosuppressant target, eg, glucocorticoid receptor, deoxycytidine kinase, FKBP, CD52, or a member of the cyclophilin family; and their combinations. Without being limited by theory, it is believed that inhibiting or eliminating the level of an allogeneic T cell target or the expression level of an allogeneic T cell targeting gene product (e.g., by altering a gene) can improve the function of a cell, e.g., a transplanted cell, e.g., a transplanted immune effector cell eg CART cells, eg allogeneic CART cell, by reducing or eliminating graft versus host, host versus graft, or render said transplanted cell resistant to immunosuppressive therapy.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host-versus-graft or graft-versus-host)), survival, proliferation, and/or efficacy by altering the T-cell receptor (TCR) component gene, e.g., CD3-zeta, CD3-epsilon, CD3-gamma, CD3- delta, T-cell receptor alpha (TCR), eg, TCR-alpha or TCR-beta constant region, eg, constant region 1 or constant region 2 of the TCR-beta gene. Without being bound by theory, reduced or absent expression of functional T-cell receptor components is believed to reduce or abolish the presence of a TCR on the surface of said cell, which reduces or prevents graft-versus-host disease by abolishing T-cell receptor recognition and response against host tissues. This approach can thus be used to generate T cells ready for mass application (Torikai et al., 2012 Blood 119, 5697-5705).

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host-versus-graft or graft-versus-host)), survival, proliferation, and/or efficacy by altering the gene for a major histocompatibility complex component, e.g., HLA or B2M protein, e.g., HLA-A, HLA-B, HLA-C, or B2M (encoded by the B2M gene), or a protein that regulates the expression of one or more major histocompatibility complex components, such as NLRC5. Without being bound by theory, reduced or absent expression of a mismatched (e.g., one that does not match the type of a subject receiving cell therapy) HLA protein (or component) is believed to reduce or abolish the host's anti-graft response by abolishing host T-cell receptor recognition and response to mismatched (eg, allogeneic) graft tissue. Thus, this approach can be used to create T cells ready for mass application.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host-versus-graft or graft-versus-host disease)), survival, proliferation, and/or efficacy by modifying the class II major histocompatibility complex component gene or class II MHC expression regulator, e.g., CIITA (encoded by the CIITA gene), RFXANK, RFX5 , or RFXAP and combinations thereof, such as CIITA. Without being bound by theory, it is believed that reducing or eliminating the expression of an MHC class II expression regulator, such as CIITA, will reduce or eliminate the expression of MHC class II molecules on an allogeneic cell, thereby reducing or eliminating the expression of a mismatched (e.g., one that does not matches the type in the subject receiving cell therapy) of MHC class II protein (or component), thereby reducing or eliminating host anti-graft response, e.g., eliminating host T-cell receptor recognition and response to mismatched (e.g., allogeneic) graft tissue , for example, an allogeneic T cell, for example, an allogeneic CART cell, as described in this application. This approach can thus be used to create T cells ready for mass application.

In one aspect, it may be beneficial to reduce or eliminate the expression of both one or more MHC class I molecules and one or more MHC II molecules, e.g., in a T cell, e.g., an allogeneic T cell, e.g., an allogeneic CART cell , for example, as described herein, to further reduce or eliminate the host's anti-graft response and response when the cell is introduced. Thus, in an embodiment of the cells and methods of the invention, cells may be contacted with a composition of the invention (e.g., a composition comprising an nRNA and a Cas9 molecule) comprising an nRNA molecule, e.g., as described herein, to B2M (e.g., thus that the expression of one or more MHC class I molecules is reduced or eliminated in said cell), and a composition according to the invention (for example, a composition containing an nRNA and a Cas9 molecule) containing an nRNA molecule, for example, as described in this application, to CIITA (for example , such that the expression of one or more MHC class II molecules is reduced or abolished). In embodiments of the cells and methods of the invention, the cell may also be contacted with a composition of the invention (e.g., a composition comprising an nRNA and a Cas9 molecule) containing an nRNA molecule, e.g., as described herein, a TCR component, e.g., TRAC and /or TRBC (for example, in such a way that the expression of the T-cell receptor, for example one or more components of the TCR, is reduced or eliminated). In one embodiment, the cell of the invention has reduced or abolished TCR expression (e.g., as detected by flow cytometry), reduced or abolished expression of one or more MHC class I molecules (e.g., as detected by flow cytometry), and reduced or abolished expression one or more MHC class II molecules (eg, as detected by flow cytometry). In one embodiment, the cell of the invention reduces or eliminates TRAC expression, reduces or eliminates B2M expression, and reduces or eliminates CIITA expression. In one embodiment, the cell of the invention reduces or eliminates TRAC expression, reduces or eliminates NLRC5 expression, and reduces or eliminates CIITA expression. In embodiments, reduced or abolished expression is measured relative to a similar cell that has not been treated with a composition or CRISPR system of the invention. In embodiments, the cell is an immune effector cell, eg, a T cell, or a NK cell, eg, a T cell, eg, as described herein. In embodiments, the cell is a T cell that has been modified to express a chimeric antigen receptor (CAR), for example, as described herein. In embodiments, the implementation of the CAR is BCMA CAR, for example, as described in this application. In one embodiment, the invention provides a cell, such as an immune effector cell, such as a T cell or NK cell, such as a T cell modified to express a BCMA CAR that is TCR-/ B2M-/CIITA- or TCR-/ NLRC5-/CIITA-. In embodiments, the cell is a human cell. In embodiments, the cell is allogeneic with respect to the subject to whom said cell is to be administered. In embodiments, reduced or abolished expression of TCR, B2M, NLRC5 and/or CIITA is achieved by introducing into said cell a composition, CRISPR system, or nRNA according to the invention, for example, as described herein, or using the method described herein.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host-versus-graft or graft-versus-host)), survival, proliferation, and/or efficacy by altering an immunosuppressant target gene, eg, glucocorticoid receptor (GR) (encoded by NR3C1). Without being limited by theory, it is believed that the absent or reduced expression of functional GR on a cell therapy product allows such a cell therapy product to function in the presence of an immunosuppressive agent such as a corticosteroid such as dexamethasone, where said immunosuppressive agent is administered, for example, to reduce or eliminate the response of the host against transplant. This approach can thus be used to create T cells ready for mass application.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host versus graft or graft versus host)), survival, proliferation and/or efficacy by altering the target gene of an immunosuppressant, eg CD52 (encoded by CD52). Without being limited by theory, it is believed that absent or reduced expression of functional CD52 on a cell therapy product allows that cell therapy product to function in the presence of an immunosuppressive agent, such as an anti-CD52 antibody or antigen-binding fragment thereof, such as alemtuzumab (Campas®), wherein said immunosuppressive agent administered, for example, to reduce or eliminate the reaction of the host against the transplant. This approach can thus be used to create T cells ready for mass application.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host versus graft or graft versus host)), survival, proliferation and/or efficacy by altering the target gene of an immunosuppressant, eg a member of the FKBP family, eg FKBP12 (encoded by FKBP1A). Without being limited by theory, it is believed that absent or reduced expression of functional FKBP12 on a cell therapy product allows such a cell therapy product to function in the presence of an immunosuppressive agent such as FK506 (or a FKBP12 binding fragment or analogue thereof), cyclosporine, rapamycin or rapalogue, or an inhibitor mTor, such as RAD001, wherein said immunosuppressive agent is administered, for example, to reduce or eliminate host anti-graft response. This approach can thus be used to create T cells ready for mass application.

In an aspect, the compositions and methods described herein can be used to improve a cell, such as a T cell, such as a CAR-modified T cell, such as the function of an allogeneic CAR-modified T cell (for example, by reducing or eliminating undesirable immunogenicity (such as host versus graft or graft versus host)), survival, proliferation and/or efficacy by altering the target gene of an immunosuppressant, eg deoxycytidine kinase (encoded by DCK). Without being limited by theory, it is believed that absent or reduced expression of a functional deoxycytidine kinase on a cell therapy product allows such cell therapy product to function in the presence of a nucleoside analog immunosuppressive agent such as cytarabine (cytosine arabinoside) or gemcitabine, where said immunosuppressive agent is administered, for example, to reduce or eliminate host anti-graft response or to treat cancer. This approach can thus be used to create T cells ready for mass application.

In aspects, the gene products are inhibitory molecules, e.g. immune checkpoint proteins e.g. PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC Class I, MHC class II, GAL9, adenosine and TGF-beta. Without being limited by theory, it is believed that inhibiting or eliminating the level of an inhibitory molecule or the level of expression of an inhibitory molecule gene product (e.g., by altering a gene) can improve the function of a cell, e.g., a transplanted cell, e.g., a transplanted immune effector cell, e.g., a CART cell, for example, an allogeneic CART cell, by reducing or eliminating the inhibitory effects mediated by said inhibitory molecule.

In one aspect, the compositions and methods described in this application can be used to reduce the effect of immune inhibitory factors on cells, for example, CAR-modified T cells, by changing the gene of an inhibitory molecule, for example, PD-1. Without being limited by theory, reduced or absent expression of programmed cell death protein 1 (PD-1) (encoded by PDCD1) is believed to abolish the induction of a suppressed or inactive state ("anergy").

In one aspect, the compositions and methods described in this application can be used to reduce the effect of immune inhibitory factors on cells, for example, CAR-modified T cells, by changing the gene of the inhibitory molecule, for example, Tim3. Without being bound by theory, reduced or absent expression of Tim3 (encoded by HAVCR2) is believed to abolish the induction of a suppressed or inactive state ("anergy").

In one aspect, the compositions and methods described in this application can be used to reduce the effect of immune inhibitory factors on cells, for example, CAR-modified T cells, by changing the gene of the inhibitory molecule, for example, the CTLA4 gene. Without being bound by theory, reduced or absent expression of the cytotoxic T cell antigen 4 (encoded by CTLA4) is believed to abolish the induction of a suppressed or inactive state ("anergy").

In one aspect, the compositions and methods described in this application can be used to reduce the effect of immune inhibitory factors on cells, for example, CAR-modified T cells, by changing the gene of the inhibitory molecule, for example, the Lag3 gene. Without being limited by theory, reduced or absent expression of the lymphocyte activation gene 3 (Lag3) (encoded by LAG3) is believed to abolish the induction of a suppressed or inactive state ("anergy").

In one aspect, the compositions and methods described in this application can be used to reduce the effect of immune inhibitory factors on cells, for example, CAR-modified T cells, by changing the gene of the inhibitory molecule, for example, the PD-L1 gene. Without being bound by theory, reduced or absent expression of programmed death ligand 1 (PD-L1, also known as CD274 and B7-H1) (encoded by CD274) is believed to abolish the induction of a suppressed or inactive state ("anergy").

In one aspect, the compositions and methods described herein can be used to reduce the effect of immune inhibitory factors on cells, e.g., CAR-modified T cells, by altering the inhibitory molecule's downstream effector molecule gene, e.g., the non-receptor type 1 tyrosine protein phosphatase gene. Without being limited by theory, reduced or absent expression of functional non-receptor type 1 protein tyrosine phosphatase, also known as tyrosine protein phosphatase 1B (encoded by PTPN1), is believed to abolish the induction of a suppressed or inactive state (“anergy”) by affecting signaling through an inhibitory molecule .

In aspects, the compositions and methods described herein can be used in combination to produce cells, e.g. transplantable cells, e.g. allogeneic cells, e.g. immune effector cells, e.g. NK cells or T cells, e.g. CAR-modified T cells with increased efficiency (eg, by reducing or eliminating unwanted immunogenicity (such as host versus graft or graft versus host)), survival, proliferation and/or stimulation compared to unmodified cells.

In one approach, the compositions and methods described in this application can be used to obtain cells in which the levels or expression levels of the functional TCR component have been reduced or eliminated, and in which the levels or expression levels of the functional MHC have been reduced or eliminated. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-alpha and HLA-A. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-alpha and HLA-B. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-alpha and HLA-C. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-alpha and B2M. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-alpha and NLRC5. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-beta and HLA-A. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-beta and HLA-B. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-beta and HLA-C. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-beta and B2M. In one embodiment, the cells are reduced or eliminated levels or levels of expression of TCR-beta and NLRC5. In one embodiment, the levels or expression levels of CD3-zeta and HLA-A are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3-zeta and HLA-B are reduced or eliminated in the cells. In one embodiment, the cells are reduced or eliminated levels or levels of expression of CD3-zeta and HLA-C. In one embodiment, the levels or expression levels of CD3-zeta and B2M are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3-zeta and NLRC5 are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 epsilon and HLA-A are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3 epsilon and HLA-B are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 epsilon and HLA-C are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3 epsilon and B2M are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 epsilon and NLRC5 are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3-gamma and HLA-A are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3-gamma and HLA-B are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3-gamma and HLA-C are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3-gamma and B2M are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3-gamma and NLRC5 are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 delta and HLA-A are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 delta and HLA-B are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 delta and HLA-C are reduced or eliminated in the cells. In one embodiment, the levels or levels of expression of CD3 delta and B2M are reduced or eliminated in the cells. In one embodiment, the levels or expression levels of CD3 delta and NLRC5 are reduced or eliminated in the cells. In any of the above embodiments, levels or expression levels of CIITA can be reduced or eliminated in cells. In an embodiment, the levels or expression levels of TRAC, B2M and CIITA are reduced or eliminated in the cells. In an embodiment, the levels or expression levels of TRBC, B2M and CIITA are reduced or eliminated in the cells. In an embodiment, the levels or expression levels of TRAC, TRBC, B2M, and CIITA are reduced or eliminated in the cells. In an embodiment, the levels or expression levels of TRAC, NLRC5 and CIITA are reduced or eliminated in the cells. In an embodiment, the levels or expression levels of TRBC, NLRC5 and CIITA are reduced or eliminated in the cells. In an embodiment, the levels or expression levels of TRAC, TRBC, NLRC5 and CIITA are reduced or eliminated in the cells. In any of the above embodiments, the levels or levels of expression of one or more inhibitory molecules or downstream effectors of an inhibitory molecule can be further reduced or eliminated in cells. In one aspect, one or more inhibitory molecules include PD-1. In one aspect, one or more inhibitory molecules include PD-L1. In one aspect, one or more inhibitory molecules include Lag3. In one aspect, one or more inhibitory molecules include Tim3. In one aspect, one or more inhibitory molecules include CTLA4. In one aspect, one or more inhibitory molecules include PTPN1. In one aspect, one or more inhibitory molecules include PD-1 and PD-L1. In one aspect, one or more inhibitory molecules include PD-1 and Lag3. In one aspect, one or more inhibitory molecules include PD-1 and Tim3. In one aspect, one or more inhibitory molecules include PD-1 and CTLA4. In one aspect, one or more inhibitory molecules include PD-L1 and Lag3. In one aspect, one or more inhibitory molecules include PD-L1 and Tim3. In one aspect, one or more inhibitory molecules include PD-L1 and CTLA4. In one aspect, one or more inhibitory molecules include Tim3 and Lag3. In one aspect, one or more inhibitory molecules include Tim3 and CTLA4. In one aspect, one or more inhibitory molecules include Lag3 and CTLA4. In one aspect, one or more inhibitory molecules include PD-1, PD-L1 and Lag3. In one aspect, one or more inhibitory molecules include PD-1, PD-L1 and Tim3. In one aspect, one or more inhibitory molecules include PD-1, PD-L1 and CTLA-4. In one aspect, one or more inhibitory molecules include PD-1, Tim3 and Lag3. In one aspect, one or more inhibitory molecules include PD-L1, Tim3 and Lag3. In one aspect, one or more inhibitory molecules include CTLA4, Tim3 and Lag3.

In one aspect, the compositions and methods described in this application can be used to obtain cells, for example, T-cells, for example, CAR-modified T-cells, in which the levels or levels of expression of two or more, for example 2, for example 3, for example 4, inhibitory molecules have been reduced or eliminated. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1 and PD-L1. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1 and Tim3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1 and CTLA4. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-L1 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-L1 and Tim3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-L1 and CTLA4. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include Tim3 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include Tim3 and CTLA4. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include Lag3 and CTLA4. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1, PD-L1 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1, PD-L1 and Tim3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1, PD-L1 and CTLA-4. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-1, Tim3 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include PD-L1, Tim3 and Lag3. In one aspect, two or more, eg 2, eg 3, eg 4 inhibitory molecules include CTLA4, Tim3 and Lag3.

In embodiments in which TCR-alpha expression levels or levels are reduced or eliminated in the cells, the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: SEQ ID NO: 5816 - SEQ ID NO: 5965 or SEQ ID NO: 5528 - SEQ ID NO: 5623, e.g. SEQ ID NO: 5569, SEQ ID NO: 5587, SEQ ID NO: 5592 or SEQ ID NO: 5586, or an nRNA molecule comprising a guide domain consisting of 17 , 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: SEQ ID NO: 5816 - SEQ ID NO: 5965 or SEQ ID NO: 5528 - SEQ ID NO : 5623.

In embodiments in which TCR-beta expression levels or levels are reduced or eliminated in the cells, the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 5966 - SEQ ID NO: 6097 or SEQ ID NO : 5624 - SEQ ID NO: 5643, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 5966 - SEQ ID NO: 6097 or SEQ ID NO: 5624 - SEQ ID NO: 5643. In embodiments in which the levels or levels of TCR-beta expression are reduced or eliminated in the cells, the cells preferably include or once included an nRNA molecule comprising a guide domain comprising SEQ ID NO: 6098 - SEQ ID NO: 6226 or SEQ ID NO: 5644 - SEQ ID NO: 5719, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive whole nucleotides, from SEQ ID NO: 6098 - SEQ ID NO: 6226 or SEQ ID NO: 5644 - SEQ ID NO: 5719.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of CD3-zeta (encoded by the CD247 gene), the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 84 - SEQ ID NO: 392, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 84 - SEQ ID NO: 392.

In embodiments in which the cells have reduced or eliminated CD3-epsilon (encoded by the CD3E gene) expression levels or levels, the cells preferably include or once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 533 - SEQ ID NO: 839, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 533 - SEQ ID NO: 839.

In embodiments in which the cells have reduced or eliminated levels or expression levels of CD3 delta (encoded by the CD3D gene), the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 393 - SEQ ID NO: 532, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 393 - SEQ ID NO: 532.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of CD3-gamma (encoded by the CD3G gene), the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 840 - SEQ ID NO: 968, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 840 - SEQ ID NO: 968.

In embodiments in which the cells have reduced or eliminated B2M (encoded by the B2M gene) expression levels or levels, the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 1 - SEQ ID NO: 83 or SEQ ID NO: 5492 - SEQ ID NO: 5527, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 1 - SEQ ID NO: 83 or SEQ ID NO: 5492 - SEQ ID NO: 5527.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of NLRC5 (encoded by the NLRC5 gene), the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 8622 - SEQ ID NO: 10089, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19 or 20 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 8622 - SEQ ID NO: 10089.

In embodiments in which the cells have reduced or eliminated HLA-A (encoded by the HLA-A gene) expression levels or levels, the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 969 - SEQ ID NO: 1345, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 969 - SEQ ID NO: 1345.

In embodiments in which the cells have reduced or eliminated HLA-B (encoded by the HLA-B gene) expression levels or levels, the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 1346 - SEQ ID NO: 1698, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 1346 - SEQ ID NO: 1698.

In embodiments in which the cells have reduced or eliminated HLA-C (encoded by the HLA-C gene) expression levels or levels, the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 1699 - SEQ ID NO: 2068, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 1699 - SEQ ID NO: 2068.

In embodiments in which the cells have reduced or eliminated CIITA (encoded by the CTIIA gene) expression levels or levels, the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising any of SEQ ID NO: 6750 - SEQ ID NO: 7716, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 6750 - SEQ ID NO: 7716. In embodiments, the nRNA molecule includes a targeting domain that includes any of SEQ ID NO: 7717 - SEQ ID NO: 7804.

In embodiments in which cells have reduced or eliminated levels or levels of expression of GR (encoded by the NR3C1 gene), the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 2069 - SEQ ID NO: 2941, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 2069 - SEQ ID NO: 2941.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of FKBP12 (encoded by the FKBP1A gene), the cells preferably include or once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 6325 - SEQ ID NO: 6583, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 6325 - SEQ ID NO: 6583.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of CD52 (encoded by the CD52 gene), the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 6227 - SEQ ID NO: 6324, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 6227 - SEQ ID NO: 6324.

In embodiments in which the cells have reduced or eliminated DCK (encoded by the DCK gene) expression levels or levels, the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 5278 - SEQ ID NO: 5491, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 5278 - SEQ ID NO: 5491.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of PD-L1 (encoded by the CD274 gene), the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 2942 - SEQ ID NO: 3270, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 2942 - SEQ ID NO: 3270.

In embodiments in which the cells have reduced or eliminated Tim3 (encoded by the HAVCR2 gene) expression levels or levels, the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 3271 - SEQ ID NO: 3541, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 3271 - SEQ ID NO: 3541.

In embodiments in which the cells have reduced or eliminated Lag3 (encoded by the LAG3 gene) expression levels or levels, the cells preferably include or have once included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 3542 - SEQ ID NO: 4032, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 3542 - SEQ ID NO: 4032.

In embodiments in which the cells have reduced or eliminated levels or levels of expression of PD-1 (encoded by the PDCD1 gene), the cells preferably include, or once included, an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 4033 - SEQ ID NO: 4589 or SEQ ID NO: 5720 - SEQ ID NO: 5815, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, of SEQ ID NO: 4033 - SEQ ID NO: 4589 or SEQ ID NO: 5720 - SEQ ID NO: 5815. In one embodiment, the nRNA molecule includes a targeting domain, including SEQ ID NO: 5775, or includes a targeting domain, including or consisting of 17, 18 or 19 consecutive nucleotides from SEQ ID NO: 5775.

In embodiments in which cells have reduced or eliminated levels or levels of expression of non-receptor tyrosine protein phosphatase type 1 (encoded by the PTPN1 gene), the cells preferably include or have formerly included an nRNA molecule comprising a targeting domain comprising SEQ ID NO: 4590 - SEQ ID NO: 5277, or an nRNA molecule comprising a guide domain consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 consecutive nucleotides, preferably 20 consecutive nucleotides, from SEQ ID NO: 4590 - SEQ ID NO : 5277.

In any of the above aspects and embodiments, the cell is an autologous cell. In any of the above aspects and embodiments, the cell is an allogeneic cell. In any of the above embodiments and aspects, the cell is or will be modified to express a chimeric antigen receptor (CAR), for example, as described herein. In any of the above aspects and embodiments, the cell is a T cell.

Additional features of the nRNA molecule, CRISPR systems, Cas9 molecules, cells, CAR molecules, and methods of the invention are detailed below.

I. nRNA molecules

An nRNA molecule may have a plurality of domains, as described in more detail below, however, an nRNA molecule typically includes at least a crRNA domain (including a guide domain) and tracr. The nRNA molecules of the invention used as a component of a CRISPR system can be used to modify (eg, sequence modify) DNA at or near a target site. Such modifications include deletions and/or insertions that result, for example, in the reduction or elimination of the expression of a functional gene product comprising the target region. Such uses and additional uses are described in more detail below.

In an embodiment, the monomolecular or sRNA comprises, preferably 5' to 3': crRNA (which contains a guide domain complementary to the target sequence and the region that is part of the flagpole (ie, the crRNA flagpole region)); loop; and tracr (which contains a domain complementary to the crRNA flagpole region and a domain that additionally binds a nuclease or other effector molecule, e.g. a Cas molecule, e.g. aCas9 molecule), and may have the following format (from 5' to 3'):

[guiding domain]-[crRNA flagpole region]-[optional first flagpole extension]-[loop]-[optional first tracr extension]-[tracr flagpole region]-[tracr nuclease-binding domain].

In embodiments, the tracr nuclease binding domain binds to a Cas protein, such as the Cas9 protein.

In an embodiment, the bimolecular or lncRNA comprises two polynucleotides; first, preferably 5' to 3': crRNA (which contains a targeting domain complementary to the target sequence and the region that forms part of the flagpole; and second, preferably 5' to 3': tracr (which contains a domain complementary to the flagpole region of the crRNA , and a domain that further binds a nuclease or other effector molecule, such as a Cas molecule, such as a Cas9 molecule), and may have the following format (from 5' to 3'):

Polynucleotide 1 (crRNA): [guide domain]-[crRNA flagpole region]-[optional first flagpole extension]-[optional second flagpole extension]

Polynucleotide 2 (tracr): [optional first tracr extension]-[tracr flagpole region]-[tracr nuclease-binding domain]

In embodiments, the tracr nuclease binding domain binds to a Cas protein, such as the Cas9 protein.

In some aspects, a guide domain includes or consists of a sequence of a guide domain described in this application, for example, a guide domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c, or a guide domain including or consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 (preferably 20) consecutive nucleotides of the targeting domain sequence described in Table 1, 2, 3, 4, 5, 6, 6b or 6c.

In some aspects, the flagpole, eg the crRNA flagpole region, includes, 5' to 3': GUUUUAGAGCUA (SEQ ID NO: 6584).

In some aspects, the flagpole, eg the crRNA flagpole region, includes, 5' to 3': GUUUAAGAGCUA (SEQ ID NO: 6585).

In some aspects, the loop includes, from 5' to 3': GAAA (SEQ ID NO: 6588).

In some aspects, tracr includes, 5' to 3': UAGCAAGUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6589) and is preferably used in an nRNA molecule comprising SEQ ID NO: 6584.

In some aspects, tracr includes, 5' to 3': UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6590) and is preferably used in an nRNA molecule comprising SEQ ID NO: 6585.

In some aspects, the nRNA may also include, at the 3' end, additional U nucleic acids. For example, the nRNA may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 U nucleic acids per 3 -end (SEQ ID NO: 10806). In an embodiment, the nRNA includes an additional 4 U nucleic acids at the 3' end. In the case of lncRNA, one or more lncRNA polynucleotides (e.g., a polynucleotide comprising a guide domain and a polynucleotide including tracr) may include, at the 3' end, additional U nucleic acids. For example, in the case of lncRNA, one or more lncRNA polynucleotides (e.g., a polynucleotide comprising a guide domain and a polynucleotide comprising tracr) may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 U nucleic acids at the 3' end (SEQ ID NO: 10806). In an embodiment, in the case of lncRNA, one or more lncRNA polynucleotides (eg, a polynucleotide comprising a guide domain and a polynucleotide comprising tracr) include an additional 4 U nucleic acids at the 3' end. In an embodiment, lncRNA only polynucleotide comprising tracr comprises additional U nucleic acid(s), e.g. 4 U nucleic acids. In an embodiment lncRNA only polynucleotide comprising guide domain comprises additional U nucleic acid(s). , including the guide domain, and polynucleotide, including tracr, include additional U nucleic acids, for example 4 U nucleic acids.

In some aspects, the nRNA may also include, at the 3' end, additional nucleic acids. For example, the nRNA may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 A nucleic acids at the 3' end (SEQ ID NO: 10809). In an embodiment, the nRNA includes an additional 4 A nucleic acids at the 3' end. In the case of lncRNA, one or more lncRNA polynucleotides (eg, a polynucleotide comprising a guide domain and a polynucleotide comprising tracr) may include, at the 3' end, additional nucleic acids. For example, in the case of lncRNA, one or more lncRNA polynucleotides (e.g., a polynucleotide comprising a guide domain and a polynucleotide comprising tracr) may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 A nucleic acids. at the 3' end (SEQ ID NO: 10809). In an embodiment, in the case of lncRNA, one or more lncRNA polynucleotides (eg, a polynucleotide comprising a guide domain and a polynucleotide comprising tracr) include an additional 4 A nucleic acids at the 3' end. In an lncRNA embodiment, only the polynucleotide comprising tracr includes additional nucleic acid(s), e.g., 4 A nucleic acids. In an embodiment, lncRNA only the polynucleotide comprising the targeting domain includes additional nucleic acid(s). In an embodiment, the lncRNA polynucleotide comprising the guide domain and the polynucleotide comprising tracr comprise additional U nucleic acids, e.g. 4 A nucleic acids.

In embodiments, one or more polynucleotides of the nRNA molecule may include a cap at the 5' end.

In an embodiment, the monomolecular or sRNA comprises, preferably 5' to 3': crRNA (which contains a guide domain complementary to the target sequence; a crRNA flagpole region; a first flagpole extension; a loop; a first tracr extension (which contains a domain complementary to at least part of the first flagpole extension); and tracr (which contains a domain complementary to the flagpole region of the crRNA and a domain that further binds the Cas9 molecule).In some aspects, the targeting domain includes a targeting domain sequence as described herein, described in Table 1, 2, 3, 4, 5, 6, 6b or 6c, or a targeting domain comprising or consisting of 17, 18, 19, 20, 21, 22, 23, 24 or 25 (preferably 20) consecutive nucleotides from the sequence of the guide domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c, for example 3' 17, 18, 19, 20, 21, 22, 23, 24 or 25 (preferably whole nucleotides from the sequence of the guide domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c.

In aspects involving the first flagpole extension and/or the first tracr extension, the flagpole, loop, and tracr sequences may be as described above. In general, any first flagpole extension and first tracr extension may be used, provided they are complementary. In embodiments, the first flagpole extension and the first tracr extension consist of 3, 4, 5, 6, 7, 8, 9, 10 or more complementary nucleotides.

In some aspects, the first flagpole extension includes, 5' to 3': UGCUG (SEQ ID NO: 6586). In some aspects, the first flagpole extension consists of SEQ ID NO: 6586.

In some aspects, the first tracr extension includes, 5' to 3': CAGCA (SEQ ID NO: 6591). In some aspects, the first tracr extension consists of SEQ ID NO: 6591.

In an embodiment, lncRNA includes two nucleic acid molecules. In some aspects, lncRNA includes a first nucleic acid that contains, preferably from 5' to 3': a targeting domain complementary to the target sequence; crRNA flagpole region; optionally a first flagpole extension; and optionally a second flagpole extension; and a second nucleic acid (which may be referred to in this application as tracr), and includes at least a domain that binds a Cas molecule, for example, a Cas9 molecule, including, preferably from 5' to 3': optionally the first extension of tracr; and tracr (which contains a domain complementary to the crRNA flagpole region and a domain that additionally binds Cas, such as the Cas9 molecule). The second nucleic acid may further include, at the 3' end (e.g., 3' to tracr) additional U nucleic acids. For example, tracr may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleic acids U at the 3' end (eg 3' to tracr) (SEQ ID NO: 10806). The second nucleic acid may additionally or alternately include, at the 3' end (eg, 3' to tracr), additional nucleic acids. For example, tracr may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 A nucleic acids at the 3' end (eg, 3' to tracr) (SEQ ID NO: 10809). In some aspects, the directing domain includes a directing domain sequence described in this application, for example, a directing domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c, or a directing domain including or consisting of 17, 18 , 19, 20, 21, 22, 23, 24 or 25 (preferably 20) consecutive nucleotides from the sequence of the targeting domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c.

In aspects involving lncRNA, the crRNA flagpole region, optional flagpole first extension, optional tracr first extension, and tracr sequences may be as described above.

In some aspects, the optional second flagpole extension includes, 5' to 3': UUUUG (SEQ ID NO: 6587).

In embodiments, 3' 1, 2, 3, 4, or 5 nucleotides, 5' 1, 2, 3, 4, or 5 nucleotides, or 3' and 5' 1, 2, 3, 4, or 5 nucleotides of the nRNA molecule (and in the case lncRNA molecules, a polynucleotide comprising a guide domain, and/or a polynucleotide comprising tracr) are modified nucleic acids, as described in more detail in section XIII, below.

The domains are briefly described below:

1) Referring domain:

Guidance on the choice of target domains can be found, for example, in Fu Y el al. NAT BIOTECHNOL 2014 (doi: 10.1038/nbt.2808) and Sternberg SH el al. NATURE 2014 (doi: 10.1038/naturel3011).

The targeting domain includes a nucleotide sequence that is complementary, eg at least 80%, 85%, 90%, 95% or 99% complementary, eg fully complementary to the target sequence on the target nucleic acid. The targeting domain is part of an RNA molecule and will therefore include a uracil (U) base, while any DNA encoding an nRNA molecule will include a thymine (T) base. Without being limited by theory, it is believed that the complementarity of the targeting domain with the target sequence contributes to the specificity of the interaction of the complex of the nRNA molecule/Cas9 molecule with the target nucleic acid. It should be understood that in a guide domain and target sequence pair, uracil bases in the guide domain will pair with adenine bases in the target sequence.

In an embodiment, the targeting domain is 5-50, eg 10-40, eg 10-30, eg 15-30, eg 15-25 nucleotides in length. In an embodiment, the targeting domain is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In an embodiment, the targeting domain is 16 nucleotides in length. In an embodiment, the targeting domain is 17 nucleotides in length. In an embodiment, the targeting domain is 18 nucleotides in length. In an embodiment, the targeting domain is 19 nucleotides in length. In an embodiment, the guide domain is 20 nucleotides long. In an embodiment, the guide domain is 21 nucleotides in length. In an embodiment, the targeting domain is 22 nucleotides in length. In an embodiment, the targeting domain is 23 nucleotides in length. In an embodiment, the guide domain is 24 nucleotides in length. In an embodiment, the guide domain is 25 nucleotides in length. In embodiments, the above 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides include 5'-16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides from the guide the domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c. In embodiments, the above 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides include 3'-16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides from the guide the domain described in Table 1, 2, 3, 4, 5, 6, 6b or 6c.

Without being limited by theory, it is believed that the 8, 9, or 10 targeting domain nucleic acids located at the 3' end of the targeting domain are important for targeting interaction with the target sequence and thus can be referred to as the "core" region of the targeting domain. In an embodiment, the core domain is fully complementary to the target sequence.

The target nucleic acid chain that is complementary to the targeting domain is referred to herein as the target sequence. In some aspects, the target sequence is located on a chromosome, for example, is a target in a gene. In some aspects, the target sequence is located in the exon of the gene. In some aspects, the target sequence is located in the intron of the gene. In some aspects, the target sequence includes or is located near (e.g., within 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1000 nucleic acids) a binding site of a regulatory element, e.g., a promoter or site binding transcription factor, target gene. Some or all of the nucleotides of the domain may have a modification, for example, the modification specified in section XIII of this description.

2) The region of the crRNA flagpole:

The flagpole contains parts of crRNA and tracr. The flagpole region of the crRNA is complementary to the tracr portion, and in an embodiment has sufficient complementarity to the tracr portion to form a double-stranded region under at least some physiological conditions, eg, normal physiological conditions. In an embodiment, the crRNA flagpole region is 5-30 nucleotides in length. In an embodiment, the crRNA flagpole region is 5-25 nucleotides in length. The crRNA flagpole region may share homology or may be derived from a natural portion of the repeat-containing sequence from the bacterial CRISPR system. In an embodiment, it shares at least 50% homology with the flagpole region of the crRNA disclosed herein, eg, with the flagpole region of the crRNA of S. pyogenes or S. thermophilus.

In an embodiment, a flagpole, e.g., a crRNA flagpole region, comprises SEQ ID NO: 6584. In an embodiment, a flagpole, e.g., a crRNA flagpole region, comprises a sequence having at least 50%, 60%, 70%, 80%, 85% , 90%, 95%, or 99% homology to SEQ ID NO: 6584. In an embodiment, the flagpole, e.g., the crRNA flagpole region, comprises at least 5, 6, 7, 8, 9, 10, or 11 nucleotides of SEQ ID NO: 6584. In an embodiment, a flagpole, e.g., a crRNA flagpole region, comprises SEQ ID NO: 6585. In an embodiment, the flagpole comprises a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95 % or 99% homology to SEQ ID NO: 6585. In an embodiment, the flagpole, e.g., crRNA flagpole region, comprises at least 5, 6, 7, 8, 9, 10, or 11 nucleotides of SEQ ID NO: 6585.

Some or all of the nucleotides in a domain may have a modification, such as the modification described in Section XIII of this specification.

3) First flagpole extension

When using a tracr including a first tracr extension, the crRNA may include a first flagpole extension. In general, any first flagpole extension and first tracr extension may be used, provided they are complementary. In embodiments, the first flagpole extension and the first tracr extension consist of 3, 4, 5, 6, 7, 8, 9, 10 or more complementary nucleotides.

The first flagpole extension may include nucleotides that are 80%, 85%, 90%, 95%, or 99% complementary, eg, fully complementary with the nucleotides of the first tracr extension. In some aspects, the nucleotides of the first flagpole extension that hybridize to the complementary nucleotides of the first tracr extension are contiguous. In some aspects, the nucleotides of the first flagpole extension that hybridize to the complementary nucleotides of the first tracr extension are spaced, for example, include two or more hybridization regions separated by nucleotides that do not base pair with the nucleotides of the first tracr extension. In some aspects, the first flagpole extension comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides . In some aspects, the first flagpole extension includes, 5' to 3': UGCUG (SEQ ID NO: 6586). In some aspects, the first flagpole extension consists of SEQ ID NO: 6586. In some aspects, the first flagpole extension includes a nucleic acid that shares at least 80%, 85%, 90%, 95%, or 99% homology with SEQ ID NO: 6586 .

Some or all of the nucleotides of the first tracr extension may have a modification, for example, the modification specified in section XIII of this description.

3) Loop

The loop serves to link the flagpole region of the crRNA (or optionally the first flagpole extension if present) to tracr (or optionally the first tracr extension if present) in the sRNA. The loop can link the flagpole region of crRNA and tracr covalently or non-covalently. In an embodiment, the bond is covalent. In an embodiment, the loop covalently connects the flagpole region of crRNA and tracr. In an embodiment, the loop covalently connects the first flagpole extension and the first tracr extension. In an embodiment, the loop is or includes a covalent bond located between the crRNA flagpole region and a tracr domain that hybridizes to the crRNA flagpole region. Typically, the loop includes one or more, for example 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides.

In lncRNA molecules, the two molecules can be linked by hybridization between at least a portion of a crRNA (eg, a crRNA flagpole region) and at least a portion of a tracr (eg, a tracr domain that is complementary to a crRNA flagpole region).

A number of loops are suitable for use in sRNA. The loops may consist of a covalent bond or be only one or a few nucleotides in length, such as 1, 2, 3, 4 or 5 nucleotides. In an embodiment, the loop is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 or more nucleotides in length. In an embodiment, the loop is 2-50, 2-40, 2-30, 2-20, 2-10, or 2-5 nucleotides in length. In an embodiment, the loop has homology or is derived from a natural sequence. In an embodiment, the loop has at least 50% homology with the loop disclosed in this application. In an embodiment, the loop includes SEQ ID NO: 6588.

Some or all of the nucleotides in a domain may have a modification, such as the modification described in Section XIII of this specification.

4) Second flagpole extension

In an embodiment, the lncRNA may include an additional sequence, 3' from the flagpole region of the crRNA, or, if present, the first flagpole extension referred to herein as the second flagpole extension. In an embodiment, the second flagpole extension is 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, or 2-4 nucleotides in length. In an embodiment, the second flagpole extension is 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides in length. In an embodiment, the second flagpole extension comprises SEQ ID NO: 6587.

5) Tracr:

Tracr is a nucleic acid sequence required to bind a nuclease, eg Cas9. Without being limited by theory, each Cas9 species is believed to be associated with a specific tracr sequence. The tracr sequences are used in both sRNA and lncRNA systems. In an embodiment, tracr includes a sequence from, or derived from, S. pyogenes tracr. In some aspects, tracr has a moiety that hybridizes to a portion of the crRNA flagpole, e.g., has sufficient complementarity with the crRNA flagpole region to form a double-stranded region under at least some physiological conditions (sometimes referred to herein as the tracr flagpole region or the tracr domain , complementary to the crRNA flagpole region). In embodiments, the tracr domain that hybridizes to the crRNA flagpole region comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides, that hybridize with complementary nucleotides of the crRNA flagpole region. In some aspects, the tracr nucleotides that hybridize to the complementary nucleotides of the crRNA flagpole region are contiguous. In some aspects, tracr nucleotides that hybridize to complementary nucleotides of the crRNA flagpole region are spaced, eg, includes two or more hybridization regions separated by nucleotides that do not base pair with nucleotides of the crRNA flagpole region. In some aspects, the portion of tracr that hybridizes to the crRNA flagpole region includes, 5' to 3': UAGCAAGUUAAAA (SEQ ID NO: 6597). In some aspects, the portion of tracr that hybridizes to the crRNA flagpole region includes, 5' to 3': UAGCAAGUUUAAA (SEQ ID NO: 6598). In embodiments, the sequence that hybridizes to the flagpole region of the crRNA is located tracr 5'- from the tracr sequence that further binds a nuclease, eg a Cas molecule, eg a Cas9 molecule.

Tracr further includes a domain that further binds to a nuclease, eg a Cas molecule, eg a Cas9 molecule. Without being bound by theory, it is believed that Cas9s from different species bind to different tracr sequences. In some aspects, tracr includes a sequence that binds to an S. pyogenes Cas9 molecule. In some aspects, tracr includes a sequence that binds to the Cas9 molecule disclosed in this application. In some aspects, the domain that further binds the Cas9 molecule includes, 5' to 3': UAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6599). In some aspects, the domain that further binds the Cas9 molecule includes, 5' to 3': UAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 6600).

In some embodiments, tracr includes SEQ ID NO: 6589. In some embodiments, tracr includes SEQ ID NO: 6590.

Some or all of the tracr nucleotides may have a modification, for example, the modification specified in section XIII of this specification. In embodiments, the nRNA (e.g., ssRNA or tracr and/or crRNA in lncRNA), for example, any of the nRNA or nRNA components described above, includes an inverted residue without a nitrogenous base at the 5' end, 3' end, or 5' and 3' ends of the nRNA. In embodiments, the nRNA (e.g., sRNA or tracr and/or crRNA in lncRNA), for example, any of the nRNA or components of the nRNA described above, includes one or more phosphothioate bonds between residues at the 5' end of the polynucleotide, for example, a phosphothioate bond between the first two 5' residues, between each of the first three 5' residues, between each of the first four 5' residues, or between each of the first five 5' residues. In embodiments, the nRNA or nRNA component may alternatively or additionally include one or more phosphothioate bonds between residues at the 3' end of the polynucleotide, e.g., a phosphothioate bond between the first two 3' residues, between each of the first three 3' residues, between each of the first four 3' residues or between each of the first five 3' residues. In an nRNA embodiment (e.g., ssRNA or tracr and/or crRNA in lncRNA), for example, any of the nRNA or components of the nRNA described above includes a phosphothioate bond between each of the first four 5' residues (e.g., includes, e.g. consists of, three phosphothioate bonds at the 5' end(s)) and a phosphothioate bond between each of the first four 3' residues (eg includes, eg consists of, three phosphothioate bonds at the 3' end(s)). In an embodiment, any of the phosphothioate modifications described above is combined with an inverted residue without a nitrogenous base at the 5' end, 3' end, or 5' and 3' ends of the polynucleotide. In such embodiments, the inverted nucleotide without a nitrogenous base may be linked to the 5' and/or 3' nucleotides by a phosphate bond or a phosphothioate bond. In embodiments of the nRNA (eg, sRNA or tracr and/or crRNA in lncRNA), for example, any of the nRNA or nRNA components described above includes one or more nucleotides that include 2'-O-methyl modifications. In embodiments, each of the first 1, 2, 3 or more 5' residues includes 2'-O-methyl modifications. In embodiments, each of the first 1, 2, 3 or more 3' residues includes 2'-O-methyl modifications. In embodiments, 4 from the end, 3 from the end, and 2 from the end of the 3' residues include 2'-O-methyl modifications. In embodiments, each of the first 1, 2, 3 or more 5' residues includes 2'-O-methyl modifications, and each of the first 1, 2, 3 or more 3' residues include 2'-O-methyl modifications. In an embodiment, each of the first 3 5' residues includes 2'-O-methyl modifications, and each of the first 3 3' residues includes 2'-O-methyl modifications. In embodiments, each of the first 3 5' residues includes 2'-O-methyl modifications, and 4 from the end, 3 from the end, and 2 from the end of the 3' residue include 2'-O-methyl modifications. In embodiments, any 2'-O-methyl modifications, for example, as described above, can be combined with one or more phosphothioate modifications, for example, as described above, and/or one or more inverted modifications without a nitrogenous base, for example, as described higher. In an embodiment, the nRNA (e.g., ssRNA or tracr and/or crRNA in lncRNA), e.g., any of the nRNA or nRNA components described above, includes, e.g., consists of, a phosphothioate bond between each of the first four 5' residues (e.g., includes , e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s)), a phosphothioate bond between each of the first four 3' residues (e.g., includes, e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s) ), a 2'-O-methyl modification in each of the first three 5' residues, and a 2'-O-methyl modification in each of the first three 3' residues. In an embodiment, the nRNA (e.g., ssRNA or tracr and/or crRNA in lncRNA), e.g., any of the nRNA or nRNA components described above, includes, e.g., consists of, a phosphothioate bond between each of the first four 5' residues (e.g., includes , e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s)), a phosphothioate bond between each of the first four 3' residues (e.g., includes, e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s) ), a 2'-O-methyl modification at each of the first three 5' residues, and a 2'-O-methyl modification at each of 4 from the end, 3 from the end, and 2 from the end of the 3' residues.

In an embodiment, the nRNA (e.g., ssRNA or tracr and/or crRNA in lncRNA), e.g., any of the nRNA or components of the nRNA described above, includes, e.g., consists of, a phosphothioate bond between each of the first four 5' residues (e.g., includes , e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s)), a phosphothioate bond between each of the first four 3' residues (e.g., includes, e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s) ), a 2'-O-methyl modification at each of the first three 5' residues, a 2'-O-methyl modification at each of the first three 3' residues, and an additional invert residue without a nitrogenous base at each of the 5' and 3' ends .

In an embodiment, the nRNA (e.g., ssRNA or tracr and/or crRNA in lncRNA), e.g., any of the nRNA or components of the nRNA described above, includes, e.g., consists of, a phosphothioate bond between each of the first four 5' residues (e.g., includes , e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s)), a phosphothioate bond between each of the first four 3' residues (e.g., includes, e.g., consists of, three phosphothioate bonds at the 5' end of the polynucleotide(s) ), a 2'-O-methyl modification at each of the first three 5' residues, and a 2'-O-methyl modification at each of 4 from the end, 3 from the end, and 2 from the end of the 3' residues, and an additional inverted residue without a nitrogenous base at each of the 5' and 3' ends.

In embodiments, the nRNA is lncRNA and includes, for example, consists of:

crRNA:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAU*mG*mC*mU (SEQ ID NO: 10797), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain, for example, as described in this application, (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end); and

tracer:

AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660) (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end).

In embodiments, the nRNA is lncRNA and includes, for example, consists of:

crRNA:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAU*mG*mC*mU (SEQ ID NO: 10797), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain, for example, as described in this application, (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end); and

tracer:

mA*mA*mC*AGCAUAGCAAGUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain (optionally with the residue inverted without a nitrogenous base at the 5' and/or 3' end).

In embodiments, the nRNA is lncRNA and includes, for example, consists of:

crRNA:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO:), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain, for example, as described in the present application, (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end); and

tracer:

AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660) (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end).

In embodiments, the nRNA is lncRNA and includes, for example, consists of:

crRNA:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO:), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain, for example, as described in the present application, (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end); and

tracer:

mA*mA*mC*AGCAUAGCAAGUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798), where m is a base with a 2'-O-methyl modification, and * is a phosphothioate bond (optionally with an inverted residue without a nitrogenous base at 5' and/or 3' end).

In embodiments, the nRNA is an sRNA and includes, for example, consists of:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 10799), where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is a guide domain residue, e.g., as described in this application, (optionally with an inverted residue without a nitrogenous base at the 5' and/or 3' end).

In embodiments, the nRNA is an sRNA and includes, for example, consists of:

mN*mN*mN*NNNNNNNNNNNNNNNGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U, where m is a base with a 2'-O-methyl modification, * is a phosphothioate bond, and N is residues of the targeting domain, e.g., as described herein (optional) with an inverted residue without a nitrogenous base at the 5' and/or 3' end).

6) First extension of Tracr

In the case where the nRNA includes a first flagpole extension, tracr may include a first tracr extension. The first tracr extension may include nucleotides that are eg 80%, 85%, 90%, 95% or 99% complementary, eg fully complementary to the nucleotides of the first flagpole extension. In some aspects, the nucleotides of the first tracr extension that hybridize to the complementary nucleotides of the first flagpole extension are contiguous. In some aspects, the nucleotides of the first tracr extension that hybridize to the complementary nucleotides of the first flagpole extension are spaced, for example, includes two or more hybridization regions separated by nucleotides that do not base pair with the nucleotides of the first flagpole extension. In some aspects, the first tracr extension comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides . In some aspects, the first tracr extension includes SEQ ID NO: 6591. In some aspects, the first tracr extension includes a nucleic acid that shares at least 80%, 85%, 90%, 95% or 99% homology with SEQ ID NO: 6591.

Some or all of the nucleotides of the first tracr extension may have a modification, for example, the modification specified in section XIII of this description.

In some embodiments, the sRNA may include, 5' to 3', located 3' relative to the targeting domain:

a) GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6601);

b) GUUUAAGAGCUAGAAAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6602);

c) GUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6603);

d) GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6604);

e) any of a) to d) above, further comprising, at the 3' end, at least 1, 2, 3, 4, 5, 6 or 7 uracil (U) nucleotides, e.g. 1, 2, 3, 4, 5, 6 or 7 uracil (U) nucleotides;

f) any of a) to d) above, further comprising, at the 3' end, at least 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides, e.g. 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides; or

g) any of a) to f) above, further comprising, at the 5' end (e.g., 5' end, e.g., 5' relative to the targeting domain), at least 1, 2, 3, 4, 5 , 6 or 7 adenine (A) nucleotides, for example 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides.

In an embodiment, the sRNA of the invention comprises, for example, consists of, 5' to 3': [guide domain]-GUUUUAGAGCUAGAAAUAGCAAGUUAAAUAAGGCUAGUCCGUUAUC AACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7811).

In an embodiment, the sRNA of the invention comprises, for example, consists of, 5' to 3': [guide domain]-GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAG UCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7807).

In embodiments, any of a) - g) above is located immediately 3' relative to the targeting domain.

In some embodiments, lncRNA may include:

crRNA, including, from 5' to 3', preferably located directly 3' relative to the targeting domain:

a) GUUUUAGAGCUA (SEQ ID NO: 6584);

b) GUUUAAGAGCUA (SEQ ID NO: 6585);

c) GUUUUAGAGCUAUGCUG (SEQ ID NO: 6605);

d) GUUUAAGAGCUAUGCUG (SEQ ID NO: 6606);

e) GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 6607);

f) GUUUAAGAGCUAUGCUGUUUUG (SEQ ID NO: 6608); or

g) GUUUUAGAGCUAUGCU (SEQ ID NO: 7806):

and tracr, including, from 5' to 3':

a) UAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6589);

b) UAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6590);

c) CAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6609);

d) CAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 6610);

e) AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660);

f) AACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6661);

g) GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7807);

h) AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 7808);

i) GUUGGAACCAUUCAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 7809);

j) AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 7820);

k) any of a) to j) above, further comprising, at the 3' end, at least 1, 2, 3, 4, 5, 6 or 7 uracil (U) nucleotides, e.g. 1, 2, 3, 4, 5, 6 or 7 uracil (U) nucleotides;

l) any of a) - j), above, further comprising, at the 3'-end, at least 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides, for example 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides; or

m) any of a) - l), above, further comprising, at the 5'-end (for example, at the 5'-end), at least 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides, for example 1, 2, 3, 4, 5, 6 or 7 adenine (A) nucleotides.

In an embodiment, the sequence k) above includes the 3' sequence UUUUUU, for example if the U6 promoter is used for transcription. In an embodiment, the sequence k) above includes the 3' sequence UUUU, for example if the HI promoter is used for transcription. In an embodiment, the sequence k) above includes variable amounts of 3' U, depending, for example, on the termination signal of the pol-III promoter used. In an embodiment, sequence k) above includes a variable 3' sequence derived from a DNA template if the T7 promoter is used. In an embodiment, the sequence k) above includes a variable 3' sequence derived from a DNA template, for example if in vitro transcription is used to produce the RNA molecule. In an embodiment, the sequence k) above includes a variable 3' sequence derived from a DNA template, for example if the pol-II promoter is used to direct transcription.

In an embodiment, the crRNA comprises SEQ ID NO: 6607 and tracr includes, for example, consists of, AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In an embodiment, the crRNA comprises SEQ ID NO: 6608 and tracr includes, for example consists of, AACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6661).

In an embodiment, the crRNA includes, e.g., consists of, a guide domain and, located 3' to the guide domain (e.g., located immediately 3' to the guide domain), a sequence including, e.g., consisting of, GUUUUAGAGCUAUGCU (SEQ ID NO: 7806), and tracr includes, for example consists of, GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7807).

In an embodiment, the crRNA includes, e.g., consists of, a guide domain and, located 3' to the guide domain (e.g., located immediately 3' to the guide domain), a sequence including, e.g., consisting of, GUUUUAGAGCUAUGCU (SEQ ID NO: 7806), and tracr includes, for example consists of, AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 7808).

In an embodiment, the crRNA includes, e.g., consists of, a guide domain and, located 3' to the guide domain (e.g., located immediately 3' to the guide domain), a sequence including, e.g., consisting of, GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 6607), and tracr includes, for example consists of, GUUGGAACCAUUCAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 7809).

7) Targeting domains used to alter the expression of allogeneic T cell targets, inhibitory molecules and/or downstream inhibitory molecule effectors

The tables below show the targeting domains for the nRNA molecules for use in the compositions and methods of the present invention, for example, when changing the expression or changing the allogeneic T cell target gene, inhibitory molecule gene and/or downstream inhibitory molecule gene effectors.

Table 1: nRNA targeting domains for exemplary allogeneic T cell targets ID Target Target region (e.g. exon) Chain Position in the genome (hg38) nRNA guide domain sequence SEQID NO: 567_1_1 B2M Exon 1 + xp15:44711469-44711494 UGGCUGGGCACGCGUUUAAUAUAG one 567_1_2 B2M Exon 1 + xp15:44711472-44711497 CUGGGCACGCGUUUAAUAUAAGUGG 2 567_1_3 B2M Exon 1 + xp15:44711483-44711508 UUUAAUAUAAGUGGAGGCGUCGCGC 3 567_1_4 B2M Exon 1 + xp15:44711486-44711511 AAUAUAAGUGGAGGCGUCGCGCUGG 4 567_1_5 B2M Exon 1 + xp15:44711487-44711512 AUAUAAGUGGAGGCGUCGCGCUGGC 5 567_1_6 B2M Exon 1 + xp15:44711512-44711537 GGGCAUUCCUGAAGCUGACAGCAUU 6 567_1_7 B2M Exon 1 + xp15:44711513-44711538 GGCAUUCCUGAAGCUGACAGCAUUC 7 567_1_8 B2M Exon 1 + xp15:44711534-44711559 AUUCGGGCCGAGAUGUCUCGCUCCCG eight 567_1_9 B2M Exon 1 + xp15:44711568-44711593 CUGUGCUCGCGCUACUCUCUCUUUC nine 567_1_10 B2M Exon 1 + xp15:44711573-44711598 CUCGCGCUACUCUCUCUUUCUGCC ten 567_1_11 B2M Exon 1 + xp15:44711576-44711601 GCGCUACUCUCUCUUUCUGGCCUGG eleven 567_1_12 B2M Exon 1 - xp15:44711466-44711491 AUAUUAAAACGCGUGCCCAGCCAAUC 12 567_1_13 B2M Exon 1 - xp15:44711522-44711547 UCUCGGCCCGAAUGCUGUCAGCUUC thirteen 567_1_14 B2M Exon 1 - xp15:44711544-44711569 GCUAAGGCCACGGAGCGAGACAUCU fourteen 567_1_15 B2M Exon 1 - xp15:44711559-44711584 AGUAGCGCGAGCACAGCUAAGGCCA fifteen 567_1_16 B2M Exon 1 - xp15:44711565-44711590 AGAGAGAGUAGCGCGAGCACAGCUA sixteen 567_1_17 B2M Exon 1 - xp15:44711599-44711624 GAGAGACUCACGCUGGAUAGCCUCC 17 567_1_18 B2M Exon 1 - xp15:44711611-44711636 GCGGGAGGGUAGGAGAGACUCACGC eighteen 567_2_1 B2M Exon 2 + xp15:44715412-44715437 UAUUCCUCAGGUACUCCAAAAGAUUC nineteen 567_2_2 B2M Exon 2 + xp15:44715440-44715465 UUUACUCACGUCAUCCAGCAGAGAA 20 567_2_3 B2M Exon 2 + xp15:44715473-44715498 CAAAUUUCCUGAAUUGCUAUGUGUC 21 567_2_4 B2M Exon 2 + xp15:44715474-44715499 AAAUUUCCUGAAUUGCUAUGUGUCU 22 567_2_5 B2M Exon 2 + xp15:44715515-44715540 ACAUUGAAGUUGACUUACUGAAGAA 23 567_2_6 B2M Exon 2 + xp15:44715535-44715560 AAGAAUGGAGAGAGAAUUGAAAAAAG 24 567_2_7 B2M Exon 2 + xp15:44715562-44715587 GAGCAUUCAGCACUUGUCUUUCAGCA 25 567_2_8 B2M Exon 2 + xp15:44715567-44715592 UUCAGACUGUCUUUCAGCAAGGAC 26 567_2_9 B2M Exon 2 + xp15:44715672-44715697 UUUGUCACAGCCCAAGAUAGUUAAG 27 567_2_10 B2M Exon 2 + xp15:44715673-44715698 UUGUCACAGCCCAAGAUAGUUAAGU 28 567_2_11 B2M Exon 2 + xp15:44715674-44715699 UGUCACAGCCCAAGAUAGUUAAGUG 29 567_2_12 B2M Exon 2 - xp15:44715410-44715435 AUCUUUGGAGUACCUGAGGAAUAUUC thirty 567_2_13 B2M Exon 2 - xp15:44715411-44715436 AAUCUUUGGAGUACCUGAGGAAUAU 31 567_2_14 B2M Exon 2 - xp15:44715419-44715444 UAAACCUGAAUCUUUGGAGUACCUG 32 567_2_15 B2M Exon 2 - xp15:44715430-44715455 GAUGACGUGAGUAAACCUGAAUCUU 33 567_2_16 B2M Exon 2 - xp15:44715457-44715482 GGAAAUUUGACUUUCCAUUCUCUGC 34 567_2_17 B2M Exon 2 - xp15:44715483-44715508 AUGAACCCAGACACAUAGCAAUUC 35 567_2_18 B2M Exon 2 - xp15:44715511-44715536 UCAGUAAGUCAACUUCAAUGUCGGA 36 567_2_19 B2M Exon 2 - xp15:44715515-44715540 UUCUUCAGUAAGUCAACUUCAAUGU 37 567_2_20 B2M Exon 2 - xp15:44715629-44715654 CAGGCAUACUCAUCUUUUUCAGGG 38 567_2_21 B2M Exon 2 - xp15:44715630-44715655 GCAGGCAUACUCAUCUUUUUCAGUG 39 567_2_22 B2M Exon 2 - xp15:44715631-44715656 GGCAGGCAUACUCAUCUUUUUCAGU 40 567_2_23 B2M Exon 2 - xp15:44715632-44715657 CGGCAGGCAUACUCAUCUUUUUCAG 41 567_2_24 B2M Exon 2 - xp15:44715653-44715678 GACAAAGUCACAUGGUUCACACGGC 42 567_2_25 B2M Exon 2 - xp15:44715657-44715682 CUGUGACAAAAGUCACAUGGUUCACA 43 567_2_26 B2M Exon 2 - xp15:44715666-44715691 UAUCUUGGGCUGUGACAAAGUCACA 44 567_2_27 B2M Exon 2 - xp15:44715685-44715710 AAGACUUACCCCCACUUAACUAUCUU 45 567_2_28 B2M Exon 2 - xp15:44715686-44715711 UAAGACUUACCCCCACUUAACUAUCU 46 567_3_1 B2M Exon 3 + xp15:44716326-44716351 AGAUCGAGACAUGUAAGCAGCAUCA 47 567_3_2 B2M Exon 3 + xp15:44716329-44716354 UCGAGACAUGUAAGCAGCAUCAUGG 48 567_3_3 B2M Exon 3 - xp15:44716313-44716338 AUGUCUCGAUCUAUGAAAAAAGACAG 49 567_4_1 B2M Exon 4 + xp15:44717599-44717624 UUUUCAGGUUUGAAGAUGCCGCAUU fifty 567_4_2 B2M Exon 4 + xp15:44717604-44717629 AGGUUUGAAGAUGCCGCAUUUGGAU 51 567_4_3 B2M Exon 4 + xp15:44717681-44717706 CACUUACACUUUAUGCACAAAAUGU 52 567_4_4 B2M Exon 4 + xp15:44717682-44717707 ACUUACACUUUAUGCACAAAAUGUA 53 567_4_5 B2M Exon 4 + xp15:44717702-44717727 AUGUAGGGUUAUAAUAAUGUUAACA 54 567_4_6 B2M Exon 4 + xp15:44717764-44717789 GUCUCCAUGUUUGAUGUAUCUGAGC 55 567_4_7 B2M Exon 4 + xp15:44717776-44717801 GAUGUAUCUGAGCAGGUUGCUCCAC 56 567_4_8 B2M Exon 4 + xp15:44717786-44717811 AGCAGGUUGCUCCACAGGUAGCUCU 57 567_4_9 B2M Exon 4 + xp15:44717789-44717814 AGGUUGCUCCACAGGUAGCUCUAGG 58 567_4_10 B2M Exon 4 + xp15:44717790-44717815 GGUUGCUCCACAGGUAGCUCUAGGA 59 567_4_11 B2M Exon 4 + xp15:44717794-44717819 GCUCCACAGGUAGCUCUAGGAGGGC 60 567_4_12 B2M Exon 4 + xp15:44717805-44717830 AGCUCUAGGAGGGCUGGCAACUUAG 61 567_4_13 B2M Exon 4 + xp15:44717808-44717833 UCUAGGAGGGCUGGCAACUUAGAGG 62 567_4_14 B2M Exon 4 + xp15:44717809-44717834 CUAGGAGGGCUGGCAACUUAGAGGU 63 567_4_15 B2M Exon 4 + xp15:44717810-44717835 UAGGAGGGCUGGCAACUUAGAGGUG 64 567_4_16 B2M Exon 4 + xp15:44717846-44717871 AUUCUCUUAUCCAACAUCAACAUCU 65 567_4_17 B2M Exon 4 + xp15:44717945-44717970 CAAUUUACAUACUCUGCUUAGAAUU 66 567_4_18 B2M Exon 4 + xp15:44717946-44717971 AAUUUACAUACUCUGCUUAGAAUUU 67 567_4_19 B2M Exon 4 + xp15:44717947-44717972 AUUUACAUACUCUGCUUAGAAUUUG 68 567_4_20 B2M Exon 4 + xp15:44717948-44717973 UUUACAUACUCUGCUUAGAAUUUGG 69 567_4_21 B2M Exon 4 + xp15:44717973-44717998 GGGAAAAUUUAGAAAUAUAAUUGAC 70 567_4_22 B2M Exon 4 + xp15:44717981-44718006 UUAGAAAUAUAAUUGACAGGAUUAU 71 567_4_23 B2M Exon 4 + xp15:44718056-44718081 UACUUCUUAUACAUUUGAUAAAGUA 72 567_4_24 B2M Exon 4 + xp15:44718061-44718086 CUUAUACAUUUGAUAAAAGUAAGGCA 73 567_4_25 B2M Exon 4 + xp15:44718067-44718092 CAUUUGAUAAAAGUAAGGCAUGGUUG 74 567_4_26 B2M Exon 4 + xp15:44718076-44718101 AAGUAAGGCAUGGUUGUGGUUAAUUC 75 567_4_27 B2M Exon 4 - xp15:44717589-44717614 CUUCAAACCUGAAAAAGAAAAGAAAA 76 567_4_28 B2M Exon 4 - xp15:44717620-44717645 AUUUGGAAUUCAUCCAAUCCAAAUG 77 567_4_29 B2M Exon 4 - xp15:44717642-44717667 UAUUAAAAAAGCAAGCAAGCAGAAUU 78 567_4_30 B2M Exon 4 - xp15:44717771-44717796 GCAACCUGCUCAGAUACAUCAAACA 79 567_4_31 B2M Exon 4 - xp15:44717800-44717825 UUGCCAGCCCUCCUAGAGCUACCUG 80 567_4_32 B2M Exon 4 - xp15:44717859-44717884 UCAAAUCUGACCAAAGAUGUUGAUGU 81 567_4_33 B2M Exon 4 - xp15:44717947-44717972 CAAAUUCUAAGCAGAGUAUGUAAAU 82 567_4_34 B2M Exon 4 - xp15:44718119-44718144 CAAGUUUUAUGAUUUAUUUAACUUG 83 919_8_1 CD247 Exon 8 + xp1:167430647-167430672 CACUGAAGCAUUUAUUAUGCAAAAU 84 919_8_2 CD247 Exon 8 + xp1:167430651-167430676 GAAGCAUUUAUUAUGCAAAAUAGGA 85 919_8_3 CD247 Exon 8 + xp1:167430719-167430744 CAGAGUAGAGAGCGUUUUCCAUCCA 86 919_8_4 CD247 Exon 8 + xp1:167430763-167430788 ACGCAGCAGUAUCCUAGUACAUUGA 87 919_8_5 CD247 Exon 8 + xp1:167430764-167430789 CGCAGCAGUAUCCUAGUACAUUGAC 88 919_8_6 CD247 Exon 8 + xp1:167430792-167430817 UUUUUCCUGUCCUGCCACUGUCCGC 89 919_8_7 CD247 Exon 8 + xp1:167430793-167430818 UUUUCCUGUCCUGCCACUGUCCGCU 90 919_8_8 CD247 Exon 8 + xp1:167430803-167430828 CUGCCACUGUCCGCUGGGCAGUUAU 91 919_8_9 CD247 Exon 8 + xp1:167430816-167430841 CUGGGCAGUUAUAGGUCCCAUGUGU 92 919_8_10 CD247 Exon 8 + xp1:167430817-167430842 UGGGCAGUUAUAGGUCCCAUGUGUU 93 919_8_11 CD247 Exon 8 + xp1:167430830-167430855 GUCCCAUGUGUUGGGUCUUCCUGCG 94 919_8_12 CD247 Exon 8 + xp1:167430882-167430907 UCGCUGAAAGCGUGAAGUGAAUCAA 95 919_8_13 CD247 Exon 8 + xp1:167430962-167430987 AUGCCACUUUGUGCACAGCUCAUCA 96 919_8_14 CD247 Exon 8 + xp1:167430982-167431007 CAUCAAGGUCAGUCUGUUCAUCUUC 97 919_8_15 CD247 Exon 8 + xp1:167430998-167431023 UUCAUCUUCUGGCCCCUGUAGCACA 98 919_8_16 CD247 Exon 8 + xp1:167431011-167431036 CCCUGUAGCACAUGGUACAGUUCAA 99 919_8_17 CD247 Exon 8 + xp1:167431016-167431041 UAGCACAUGGUACAGGUUCAAUGGUG 100 919_8_18 CD247 Exon 8 + xp1:167431024-167431049 GGUACAGUUCAAUGGUGCGGCACAG 101 919_8_19 CD247 Exon 8 + xp1:167431031-167431056 UUCAAUGGUGCGGCACAGAGGCCUG 102 919_8_20 CD247 Exon 8 + xp1:167431035-167431060 AUGGUGCGGCACAGAGGCCUGAGGC 103 919_8_21 CD247 Exon 8 + xp1:167431036-167431061 UGGUGCGGCACAGAGGCCUGAGGCA 104 919_8_22 CD247 Exon 8 + xp1:167431039-167431064 UGCGGCACAGAGGCCUGAGGCAGGG 105 919_8_23 CD247 Exon 8 + xp1:167431058-167431083 GCAGGGAGGCUCCCGCUGCCCUCGC 106 919_8_24 CD247 Exon 8 + xp1:167431064-167431089 AGGCCCCGCUGCCCUCGCAGGCCC 107 919_8_25 CD247 Exon 8 + xp1:167431113-167431138 ACCUUCCCAUGCCCCUGCAGCUCCC 108 919_8_26 CD247 Exon 8 + xp1:167431123-167431148 GCCCCUGCAGCUCCCUGGUUGCACC 109 919_8_27 CD247 Exon 8 + xp1:167431129-167431154 GCAGCUCCCUGGUUGCACCUGGCCU 110 919_8_28 CD247 Exon 8 + xp1:167431156-167431181 GCUCCUUUCCAUCUGCCCCUCUGCC 111 919_8_29 CD247 Exon 8 + xp1:167431169-167431194 UGCCCCUCUGCCCGGCCCUCUCACC 112 919_8_30 CD247 Exon 8 + xp1:167431170-167431195 GCCCCUCUGCCCGGCCCUCUCACCA 113 919_8_31 CD247 Exon 8 + xp1:167431173-167431198 CCUCUGCCCGGCCCUCUCACCAGGG 114 919_8_32 CD247 Exon 8 + xp1:167431183-167431208 GCCCUCUCACCAGGGAGGCACAACA 115 919_8_33 CD247 Exon 8 + xp1:167431206-167431231 CAUGGCCCAGUACAGUUACCUUGAA 116 919_8_34 CD247 Exon 8 + xp1:167431209-167431234 GGCCCAGUACAGUUACCUUGAAAGG 117 919_8_35 CD247 Exon 8 + xp1:167431215-167431240 GUACAGUUACCUUGAAAGGAGGUGA 118 919_8_36 CD247 Exon 8 + xp1:167431243-167431268 UGACAACAGAAGCCAAAUUUACAGC 119 919_8_37 CD247 Exon 8 + xp1:167431282-167431307 UCAGACACAGAGUGAUACAGACAUU 120 919_8_38 CD247 Exon 8 + xp1:167431283-167431308 CAGACACAGAGUGAUACAGACAUUA 121 919_8_39 CD247 Exon 8 + xp1:167431311-167431336 CAUGUGCUAGCAUCUGCCGCUUUCUC 122 919_8_40 CD247 Exon 8 + xp1:167431312-167431337 AUGUGCUAGCAUCUGCCGCUUUCUCU 123 919_8_41 CD247 Exon 8 + xp1:167431313-167431338 UGUGCUAGCAUCUGCGCUUUCUCUG 124 919_8_42 CD247 Exon 8 + xp1:167431351-167431376 ACAGACUCAACAACUCAGCUGUGAG 125 919_8_43 CD247 Exon 8 + xp1:167431371-167431396 GUGAGAGGCAGUGCGCCCCGCCUCCC 126 919_8_44 CD247 Exon 8 + xp1:167431372-167431397 UGAGAGGCAGUGCGCCCGCCUCCCA 127 919_8_45 CD247 Exon 8 + xp1:167431381-167431406 GUGCGCCCCGCCUCCCAGGGAGAACG 128 919_8_46 CD247 Exon 8 + xp1:167431391-167431416 CUCCCAGGGAGAACGAGGAACCGCC 129 919_8_47 CD247 Exon 8 + xp1:167431398-167431423 GGAGAACGAGGAACCGCCAGGAGAC 130 919_8_48 CD247 Exon 8 + xp1:167431415-167431440 CAGGAGACAGGUCUACCUGCACCAC 131 919_8_49 CD247 Exon 8 + xp1:167431426-167431451 UCUACCUGCACCACCGGCAAAACCAG 132 919_8_50 CD247 Exon 8 + xp1:167431427-167431452 CUACCUGCACCACCGGCAAACCAGA 133 919_8_51 CD247 Exon 8 + xp1:167431434-167431459 CACCACCGGCCAAACCAGAGGGCCCA 134 919_8_52 CD247 Exon 8 + xp1:167431439-167431464 CCGGCAAACCAGAGGGCCCAAGGCC 135 919_8_53 CD247 Exon 8 + xp1:167431440-167431465 CGGCAAACCAGAGGGCCCAAGGCCA 136 919_8_54 CD247 Exon 8 + xp1:167431453-167431478 GGCCCAAGGCCAGGGCCGUAAGCCC 137 919_8_55 CD247 Exon 8 + xp1:167431454-167431479 GCCCAAGGCCAGGGCCGUAAGCCCU 138 919_8_56 CD247 Exon 8 + xp1:167431479-167431504 GGGAGUACACCUCCCUUAAAGAGUGC 139 919_8_57 CD247 Exon 8 + xp1:167431480-167431505 GGAGUACACCUCCCUUAAAGAGUGCA 140 919_8_58 CD247 Exon 8 + xp1:167431501-167431526 UGCAGGGACAACAGUCUGUGUGUGA 141 919_8_59 CD247 Exon 8 + xp1:167431506-167431531 GGACAACAGGUCUGUGUGUGAAGGUU 142 919_8_60 CD247 Exon 8 + xp1:167431541-167431566 UAUAACCAAAGCAUCCUGUACAUAA 143 919_8_61 CD247 Exon 8 + xp1:167431542-167431567 AUAACCAAAAGCAUCCUGUACAUAAAA 144 919_8_62 CD247 Exon 8 + xp1:167431543-167431568 UAACCAAAGCAUCCUGUACAUAAAG 145 919_8_63 CD247 Exon 8 + xp1:167431556-167431581 CUGUACAUAAAGGGGAAUACUUCAG 146 919_8_64 CD247 Exon 8 + xp1:167431574-167431599 ACUUCAGUGGCUGAGAAGAGUGAAC 147 919_8_65 CD247 Exon 8 + xp1:167431575-167431600 CUUCAGUGGCUGAGAAGAGUGAACC 148 919_8_66 CD247 Exon 8 + xp1:167431609-167431634 AUGCUUCAUCCUGUGUCUCAUAAUAC 149 919_8_67 CD247 Exon 8 + xp1:167431610-167431635 UGCUUCAUCCUGUGUCUCAUAAUCU 150 919_8_68 CD247 Exon 8 + xp1:167431620-167431645 UGUGUCUCAUAAUCUGGGCGUCUGC 151 919_8_69 CD247 Exon 8 + xp1:167431625-167431650 CUCAUAAUCUGGGCGUCUGCAGGUC 152 919_8_70 CD247 Exon 8 + xp1:167431636-167431661 GGCGUCUGCAGGUCUGGCCUUUGAG 153 919_8_71 CD247 Exon 8 + xp1:167431649-167431674 CUGGCCUUUGAGUGGUGAAAUCCCC 154 919_8_72 CD247 Exon 8 + xp1:167431661-167431686 UGGUGAAAUCCCCUGGCUGUUAGCG 155 919_8_73 CD247 Exon 8 + xp1:167431662-167431687 GGUGAAAUCCCCUGGCUGUUAGCGA 156 919_8_74 CD247 Exon 8 + xp1:167431663-167431688 GUGAAAUCCCCUGGCUGUUAGCGAG 157 919_8_75 CD247 Exon 8 + xp1:167431664-167431689 UGAAAUCCCCUGGCUGUUAGCGAGG 158 919_8_76 CD247 Exon 8 + xp1:167431668-167431693 AUCCCCUGGCUGUUAGCGAGGGGGC 159 919_8_77 CD247 Exon 8 + xp1:167431669-167431694 UCCCCUGGCUGUUAGCGAGGGGGCA 160 919_8_78 CD247 Exon 8 + xp1:167431683-167431708 GCGAGGGGGCAGGGCCUGCAUGUGA 161 919_8_79 CD247 Exon 8 + xp1:167431684-167431709 CGAGGGGGCAGGGCCUGCAUGUGAA 162 919_8_80 CD247 Exon 8 + xp1:167431693-167431718 AGGGCCUGCAUGUGAAGGGCGUCGU 163 919_8_81 CD247 Exon 8 + xp1:167431702-167431727 AUGUGAAGGGCGUCGUAGGUGUCCU 164 919_8_82 CD247 Exon 8 + xp1:167431705-167431730 UGAAGGGCCGUCGUAGGUGUCCUUGG 165 919_8_83 CD247 Exon 8 + xp1:167431722-167431747 GUCCUUGGUGGCUGUACUGAGACCCC 166 919_8_84 CD247 Exon 8 - xp1:167430692-167430717 UUUUUUCUACUGUUUUAAUUUAUAC 167 919_8_85 CD247 Exon 8 - xp1:167430740-167430765 GUCAUUACAGGGCACAGGCCAUGGA 168 919_8_86 CD247 Exon 8 - xp1:167430744-167430769 CUGCGUCAUUACAGGGCACAGGCCA 169 919_8_87 CD247 Exon 8 - xp1:167430750-167430775 AUACUGCUGCCGUCAUUACAGGGCAC 170 919_8_88 CD247 Exon 8 - xp1:167430756-167430781 ACUAGGAUACUGCUGCGUCAUUACA 171 919_8_89 CD247 Exon 8 - xp1:167430757-167430782 UACUAGGAUACUGCUGCGUCAUUAC 172 919_8_90 CD247 Exon 8 - xp1:167430778-167430803 GACAGGAAAAAACCCGUCAAUGUACU 173 919_8_91 CD247 Exon 8 - xp1:167430800-167430825 ACUGCCCAGCGGACAGUGGCAGGAC 174 919_8_92 CD247 Exon 8 - xp1:167430805-167430830 CUAUAACUGCCCAGCGGACAGUGGC 175 919_8_93 CD247 Exon 8 - xp1:167430809-167430834 GGACCUAUAACUGCCCAGCGGACAG 176 919_8_94 CD247 Exon 8 - xp1:167430816-167430841 ACACAUGGGACCUAUAACUGCCCAG 177 919_8_95 CD247 Exon 8 - xp1:167430835-167430860 GGCCUCGCAGGAAGACCCAACACAU 178 919_8_96 CD247 Exon 8 - xp1:167430836-167430861 AGGCCUCGCAGGAAGACCCAACACACA 179 919_8_97 CD247 Exon 8 - xp1:167430852-167430877 AAAAUCAUCUUUGUGAAGGCCUCGC 180 919_8_98 CD247 Exon 8 - xp1:167430861-167430886 GCGAAUGACAAAAUCAUCUUUGUGA 181 919_8_99 CD247 Exon 8 - xp1:167430913-167430938 GAAUAAAGUGCUGCGGAGCAAGAGG 182 919_8_100 CD247 Exon 8 - xp1:167430916-167430941 UGUGAAUAAAAGUGCUGCGGAGCAAG 183 919_8_101 CD247 Exon 8 - xp1:167430925-167430950 GUUACACAGUGUGAAUAAAAGUGCUG 184 919_8_102 CD247 Exon 8 - xp1:167430952-167430977 UGCACAAAGUGGCAUAAAAAACAUG 185 919_8_103 CD247 Exon 8 - xp1:167430968-167430993 UGACCUUGAUGAGCUGUGCACAAAG 186 919_8_104 CD247 Exon 8 - xp1:167431013-167431038 CAUUGAACUGUACCAUGUGCUACAG 187 919_8_105 CD247 Exon 8 - xp1:167431014-167431039 CCAUUGAACUGUACCAUGUGCUACA 188 919_8_106 CD247 Exon 8 - xp1:167431015-167431040 ACCAUUGAACUGUACCAUGUGCUAC 189 919_8_107 CD247 Exon 8 - xp1:167431055-167431080 AGGGCAGCGGGAGCCUCCCUGCCUC 190 919_8_108 CD247 Exon 8 - xp1:167431072-167431097 GUCAGCCAGGGCCUGCGAGGGCAGC 191 919_8_109 CD247 Exon 8 - xp1:167431073-167431098 GGUCAGCCAGGGCCUGCGAGGGCAG 192 919_8_110 CD247 Exon 8 - xp1:167431079-167431104 GGGGAGGGUCAAGCCAGGGCCUGCGA 193 919_8_111 CD247 Exon 8 - xp1:167431080-167431105 AGGGGAGGGUCAAGCCAGGGCCUGCG 194 919_8_112 CD247 Exon 8 - xp1:167431089-167431114 UGGGCGGGCAGGGGAGGGUCAGCCA 195 919_8_113 CD247 Exon 8 - xp1:167431090-167431115 GUGGGCGGGCAGGGGAGGGUCAGCC 196 919_8_114 CD247 Exon 8 - xp1:167431099-167431124 CAUGGGAAGGUGGGCGGGCAGGGGA 197 919_8_115 CD247 Exon 8 - xp1:167431100-167431125 GCAUGGGAAGGUGGGCGGGCAGGGG 198 919_8_116 CD247 Exon 8 - xp1:167431103-167431128 GGGGCAUGGGAAGGUGGGCGGGCAG 199 919_8_117 CD247 Exon 8 - xp1:167431104-167431129 AGGGGCAUGGGAAGGUGGGCGGGCA 200 919_8_118 CD247 Exon 8 - xp1:167431105-167431130 CAGGGGCAUGGGAAGGUGGGCGGGC 201 919_8_119 CD247 Exon 8 - xp1:167431109-167431134 GCUGCAGGGGCAUGGGAAGGUGGGC 202 919_8_120 CD247 Exon 8 - xp1:167431110-167431135 AGCUGCAGGGGCAUGGGAAGGUGGG 203 919_8_121 CD247 Exon 8 - xp1:167431113-167431138 GGGAGCUGCAGGGGCAUGGGAAGGU 204 919_8_122 CD247 Exon 8 - xp1:167431114-167431139 AGGGAGCUGCAGGGGCAUGGGAAGG 205 919_8_123 CD247 Exon 8 - xp1:167431117-167431142 ACCAGGGAGCUGCAGGGGCAUGGGA 206 919_8_124 CD247 Exon 8 - xp1:167431121-167431146 UGCAACCAGGGAGCUGCAGGGGCAU 207 919_8_125 CD247 Exon 8 - xp1:167431122-167431147 GUGCAACCAGGGAGCUGCAGGGGCA 208 919_8_126 CD247 Exon 8 - xp1:167431127-167431152 GCCAGGUGCAACCAGGGAGCUGCAG 209 919_8_127 CD247 Exon 8 - xp1:167431128-167431153 GGCCAGGUGCAACCAGGGAGCUGCA 210 919_8_128 CD247 Exon 8 - xp1:167431129-167431154 AGGCCAGGUGCAACCAGGGAGCUGC 211 919_8_129 CD247 Exon 8 - xp1:167431138-167431163 AAGGAGCCUAGGCCAGGUGCAACCA 212 919_8_130 CD247 Exon 8 - xp1:167431139-167431164 AAAGGAGCCUAGGCCAGGUGCAACC 213 919_8_131 CD247 Exon 8 - xp1:167431149-167431174 GGGCAGAUGGAAAGGAGCCUAGGCC 214 919_8_132 CD247 Exon 8 - xp1:167431154-167431179 CAGAGGGGCAGAUGGAAAGGAGCCU 215 919_8_133 CD247 Exon 8 - xp1:167431162-167431187 GGGCCGGGCAGAGGGGCAGAUGGAA 216 919_8_134 CD247 Exon 8 - xp1:167431167-167431192 UGAGAGGGCCGGGCAGAGGGGCAGA 217 919_8_135 CD247 Exon 8 - xp1:167431174-167431199 UCCCUGGUGAGAGGGCCGGGCAGAG 218 919_8_136 CD247 Exon 8 - xp1:167431175-167431200 CUCCCUGGUGAGAGGGCCGGGCAGA 219 919_8_137 CD247 Exon 8 - xp1:167431176-167431201 CCUCCCUGGUGAGAGGGCCGGGCAG 220 919_8_138 CD247 Exon 8 - xp1:167431182-167431207 GUUGUGCCUCCCUGGUGAGAGGGCC 221 919_8_139 CD247 Exon 8 - xp1:167431183-167431208 UGUUGUGCCUCCCUGGUGAGAGGGC 222 919_8_140 CD247 Exon 8 - xp1:167431187-167431212 GCCAUGUUGUGCCUCCCUGGUGAGA 223 919_8_141 CD247 Exon 8 - xp1:167431188-167431213 GGCCAUGUUGUGCCUCCCUGGUGAG 224 919_8_142 CD247 Exon 8 - xp1:167431195-167431220 UGUACUGGGCCAUGUUGUGCCUCCC 225 919_8_143 CD247 Exon 8 - xp1:167431214-167431239 CACCUCCUUUCAAGGUAACUGUACU 226 919_8_144 CD247 Exon 8 - xp1:167431215-167431240 UCACCUCCUUUCAAGGUAACUGUAC 227 919_8_145 CD247 Exon 8 - xp1:167431227-167431252 CUGUUGUCACCUUCACCUCCUUUCA 228 919_8_146 CD247 Exon 8 - xp1:167431258-167431283 AGUGGCUUCACUCCUGCUGUAAAUU 229 919_8_147 CD247 Exon 8 - xp1:167431281-167431306 AUGUCUGUAUCACUCUGUGUCUGAG 230 919_8_148 CD247 Exon 8 - xp1:167431389-167431414 CGGUUCCUCGUUCUCCCCUGGGAGGC 231 919_8_149 CD247 Exon 8 - xp1:167431390-167431415 GCGGUUCCUCGUUCUCCCCUGGGAGG 232 919_8_150 CD247 Exon 8 - xp1:167431393-167431418 CUGGCGGUUCCUCGUUCUCCCCUGGG 233 919_8_151 CD247 Exon 8 - xp1:167431396-167431421 CUCCUGGCGGUUCCUCGUUCUCCCU 234 919_8_152 CD247 Exon 8 - xp1:167431397-167431422 UCUCCUGGCGGUUCCUCGUUCUCCC 235 919_8_153 CD247 Exon 8 - xp1:167431414-167431439 UGGUGCAGGUAGACCUGUCUCCUGG 236 919_8_154 CD247 Exon 8 - xp1:167431417-167431442 CGGUGGUGCAGGUAGACCUGUCUCC 237 919_8_155 CD247 Exon 8 - xp1:167431433-167431458 GGGCCCUCUGGUUUGCCGGUGGUGC 238 919_8_156 CD247 Exon 8 - xp1:167431439-167431464 GGCCUUGGGCCCUCUGGUUUGCCGG 239 919_8_157 CD247 Exon 8 - xp1:167431442-167431467 CCUGGCCUUGGGCCCUCUGGUUUGC 240 919_8_158 CD247 Exon 8 - xp1:167431450-167431475 CUUACGGCCCUGGCCUUGGGCCCUC 241 919_8_159 CD247 Exon 8 - xp1:167431458-167431483 UCCCAGGGCUUACGGCCCUGGCCUU 242 919_8_160 CD247 Exon 8 - xp1:167431459-167431484 CUCCCAGGGCUUACGGCCCUGGCCU 243 919_8_161 CD247 Exon 8 - xp1:167431465-167431490 AGUGUACUCCCAGGGCUUACGGCCC 244 919_8_162 CD247 Exon 8 - xp1:167431471-167431496 UAAGGGAGUGUACUCCCAGGGCUUA 245 919_8_163 CD247 Exon 8 - xp1:167431478-167431503 CACUCUUUAAGGGAGUGUACUCCCCA 246 919_8_164 CD247 Exon 8 - xp1:167431479-167431504 GCACUCUUUAAGGGAGUGUACUCCC 247 919_8_165 CD247 Exon 8 - xp1:167431493-167431518 AGACUGUUGUCCCUGCACUCUUUAA 248 919_8_166 CD247 Exon 8 - xp1:167431494-167431519 CAGACUGUUGUCCCUGCACUCUUUA 249 919_8_167 CD247 Exon 8 - xp1:167431549-167431574 AUUCCCCUUUAUGUACAGGAUGCUU 250 919_8_168 CD247 Exon 8 - xp1:167431558-167431583 CACUGAAGUAUUCCCCUUUAUGUAC 251 919_8_169 CD247 Exon 8 - xp1:167431601-167431626 GACACAGGAUGAAGCAUUUACAACC 252 919_8_170 CD247 Exon 8 - xp1:167431621-167431646 UGCAGACGCCCAGAUUAUGAGACAC 253 919_8_171 CD247 Exon 8 - xp1:167431656-167431681 ACAGCCAGGGGAUUUCACCACUCAA 254 919_8_172 CD247 Exon 8 - xp1:167431673-167431698 GCCCUGCCCCCUCGCUAACAGCCAG 255 919_8_173 CD247 Exon 8 - xp1:167431674-167431699 GGCCCUGCCCCCUCGCUAACAGCCCA 256 919_8_174 CD247 Exon 8 - xp1:167431675-167431700 AGGCCCUGCCCCCUCGCUAACAGCC 257 919_8_175 CD247 Exon 8 - xp1:167431700-167431725 GACACCUACGACGCCCUUCACAUGC 258 919_8_176 CD247 Exon 8 - xp1:167431727-167431752 CGCCAGGGUCUCAGUACAGCCACCA 259 919_7_1 CD247 Exon 7 + xp1:167432999-167433024 UGAAGGGACGCCGGCAGCUCCUACC 260 919_7_2 CD247 Exon 7 + xp1:167433005-167433030 GACGCCGGCAGCUCCUACCUGGUAA 261 919_7_3 CD247 Exon 7 + xp1:167433029-167433054 AAGGCCAUCGUGCCCCUUGCCCCUC 262 919_7_4 CD247 Exon 7 + xp1:167433035-167433060 AUCGUGCCCCUUGCCCCUCCGGCGC 263 919_7_5 CD247 Exon 7 + xp1:167433043-167433068 CCUUGCCCCUCCGGCGCUGGUUGUU 264 919_7_6 CD247 Exon 7 + xp1:167433044-167433069 CUUGCCCCUCCGGCGCUGGUUGUUU 265 919_7_7 CD247 Exon 7 - xp1:167433012-167433037 AUGGCCUUUACCAGGUAGGAGCUGC 266 919_7_8 CD247 Exon 7 - xp1:167433021-167433046 AGGGGCACGAUGGCCUUUACCAGGU 267 919_7_9 CD247 Exon 7 - xp1:167433025-167433050 GGCAAGGGGCACGAUGGCCUUUACC 268 919_7_10 CD247 Exon 7 - xp1:167433036-167433061 AGCGCCGGAGGGGCAAGGGGCACGA 269 919_7_11 CD247 Exon 7 - xp1:167433044-167433069 AAACAACCAGCGCCGGAGGGGCAAG 270 919_7_12 CD247 Exon 7 - xp1:167433045-167433070 CAAACAACCAGCGCCGGAGGGGCAA 271 919_7_13 CD247 Exon 7 - xp1:167433046-167433071 CCAAACAACCAGCGCCGGAGGGGCA 272 919_7_14 CD247 Exon 7 - xp1:167433051-167433076 CACUCCCAAACAACCAGCGCCGGAG 273 919_7_15 CD247 Exon 7 - xp1:167433052-167433077 UCACUCCCAAACAACCAGCGCCGGA 274 919_7_16 CD247 Exon 7 - xp1:167433053-167433078 UUCACUCCCAAACAACCAGCGCCGG 275 919_7_17 CD247 Exon 7 - xp1:167433056-167433081 CAUUUCACUCCCAAACAACCAGGCGC 276 919_6_1 CD247 Exon 6 + xp1:167434020-167434045 UCGCCUUUCAUCCCAAUCUCACUGU 277 919_6_2 CD247 Exon 6 + xp1:167434060-167434085 UAUCUUUCUGCAGUUCCUGCAGAAG 278 919_6_3 CD247 Exon 6 + xp1:167434061-167434086 AUCUUUCUGCAGUUCCUGCAGAAGA 279 919_6_4 CD247 Exon 6 + xp1:167434066-167434091 UCUGCAGUUCCUGCAGAAGAGGGCG 280 919_6_5 CD247 Exon 6 - xp1:167434021-167434046 UACAGUGAGAUUGGGAUGAAAGGCG 281 919_6_6 CD247 Exon 6 - xp1:167434026-167434051 AGGCCUACAGUGAGAUUGGGAUGAA 282 919_6_7 CD247 Exon 6 - xp1:167434034-167434059 GAUGGCGGAGGCCUACAGUGAGAUU 283 919_6_8 CD247 Exon 6 - xp1:167434035-167434060 AGAUGGCGGAGGCCUACAGUGAGAU 284 919_6_9 CD247 Exon 6 - xp1:167434051-167434076 GAACUGCAGAAAAGAUAAGAUGGCGG 285 919_6_10 CD247 Exon 6 - xp1:167434054-167434079 CAGGAACUGCAGAAAGAUAAGAUGG 286 919_6_11 CD247 Exon 6 - xp1:167434057-167434082 CUGCAGGAACUGCAGAAAGAUAAGA 287 919_5_1 CD247 Exon 5 + xp1:167435380-167435405 GAGGUCUCCUCUACUCACAUUGUAC 288 919_5_2 CD247 Exon 5 + xp1:167435391-167435416 UACUCACAUUGUACAGGCCUUCCUG 289 919_5_3 CD247 Exon 5 + xp1:167435392-167435417 ACUCACAUUGUACAGGCCUUCCUGA 290 919_5_4 CD247 Exon 5 + xp1:167435411-167435436 UCCUGAGGGUUCUUCCUUCUCUGCU 291 919_5_5 CD247 Exon 5 + xp1:167435422-167435447 CUUCCUUCUCUGCUAGGAAAGACAA 292 919_5_6 CD247 Exon 5 + xp1:167435423-167435448 UUCCUUCUCUGCUAGGAAAGACAAC 293 919_5_7 CD247 Exon 5 - xp1:167435390-167435415 AGGAAGGCCUGUACAUGUGAGUAG 294 919_5_8 CD247 Exon 5 - xp1:167435411-167435436 AGCAGAGAAGGAAGAACCCUCAGGA 295 919_5_9 CD247 Exon 5 - xp1:167435415-167435440 UCCUAGCAGAGAAGGAAGAACCCUC 296 919_5_10 CD247 Exon 5 - xp1:167435428-167435453 UUCCCGUUGUCUUUCCUAGCAGAGA 297 919_4_1 CD247 Exon 4 + xp1:167438544-167438569 CACAGGAAGGUAGAGGAACCCCUAC 298 919_4_2 CD247 Exon 4 + xp1:167438562-167438587 CCCCUACCGGCUUUCCCCCCAUCUC 299 919_4_3 CD247 Exon 4 + xp1:167438563-167438588 CCCUACCGGCUUUCCCCCCAUCCA 300 919_4_4 CD247 Exon 4 + xp1:167438569-167438594 CGGCUUUCCCCCCAUCUCAGGGUCC 301 919_4_5 CD247 Exon 4 - xp1:167438565-167438590 CCUGAGAUGGGGGGAAAGCCGGUAG 302 919_4_6 CD247 Exon 4 - xp1:167438566-167438591 CCCUGAGAUGGGGGGAAAGCCGGUA 303 919_4_7 CD247 Exon 4 - xp1:167438567-167438592 ACCCUGAGAUGGGGGGAAAGCCGGU 304 919_4_8 CD247 Exon 4 - xp1:167438571-167438596 CGGGACCCUGAGAUGGGGGAAAGC 305 919_4_9 CD247 Exon 4 - xp1:167438579-167438604 GACGUGGCCGGGACCCUGAGAUGGG 306 919_4_10 CD247 Exon 4 - xp1:167438580-167438605 AGACGUGGCCGGGACCCUGAGAUGG 307 919_4_11 CD247 Exon 4 - xp1:167438581-167438606 GAGACGUGGCCGGGACCCUGAGAUG 308 919_4_12 CD247 Exon 4 - xp1:167438582-167438607 AGAGACGUGGCCGGGACCCUGAGAU 309 919_4_13 CD247 Exon 4 - xp1:167438583-167438608 AAGAGACGUGGCCGGGACCCUGAGA 310 919_4_14 CD247 Exon 4 - xp1:167438595-167438620 GAUGUUUUGGACAAGAGACGUGGCC 311 919_4_15 CD247 Exon 4 - xp1:167438596-167438621 CGAUGUUUUGGACAAGAGACGUGGC 312 919_4_16 CD247 Exon 4 - xp1:167438600-167438625 AGUACGAUGUUUUGGACAAGAGACG 313 919_4_17 CD247 Exon 4 - xp1:167438613-167438638 GGACGAAGAGAGGAGUACGAUGUUU 314 919_4_18 CD247 Exon 4 - xp1:167438628-167438653 UAGGAGCUCAAUCUAGGACGAAGAG 315 919_4_19 CD247 Exon 4 - xp1:167438639-167438664 CUUAUCUGUUAUAGGAGCUCAAUCU 316 919_3_1 CD247 Exon 3 + xp1:167439328-167439353 GCGAGGCUGACUUACGUUAUAGAGC 317 919_3_2 CD247 Exon 3 + xp1:167439334-167439359 CUGACUUACGUUAUAGAGCUGGUUC 318 919_3_3 CD247 Exon 3 + xp1:167439343-167439368 GUUAUAGAGCUGGUUCUGGCCCUGC 319 919_3_4 CD247 Exon 3 + xp1:167439350-167439375 AGCUGGUUCUGGCCCUGCUGGUACG 320 919_3_5 CD247 Exon 3 + xp1:167439351-167439376 GCUGGUUCUGGCCCUGCUGGUACGC 321 919_3_6 CD247 Exon 3 + xp1:167439352-167439377 CUGGUUCUGGCCCUGCUGGUACGCG 322 919_3_7 CD247 Exon 3 + xp1:167439353-167439378 UGGUUCUGGCCCUGCUGGUACGCGG 323 919_3_8 CD247 Exon 3 - xp1:167439365-167439390 GCGCAGACGCCCCCGCGUACCAGCA 324 919_3_9 CD247 Exon 3 - xp1:167439366-167439391 AGCGCAGACGCCCCCGCGUACCAGC 325 919_3_10 CD247 Exon 3 - xp1:167439394-167439419 UUUGCUUUCUGUGUUGCAGUUCAGGC 326 919_2_1 CD247 Exon 2 + xp1:167440648-167440673 CCCAGUGGUACCCACCUUCACUCUC 327 919_2_2 CD247 Exon 2 + xp1:167440655-167440680 GUACCCACCUUCACUCUCAGGAACA 328 919_2_3 CD247 Exon 2 + xp1:167440684-167440709 AGUGAGAAUGACACCAUAGAUGAAG 329 919_2_4 CD247 Exon 2 + xp1:167440699-167440724 AUAGAUGAAGAGGAUUCCAUCCAGC 330 919_2_5 CD247 Exon 2 + xp1:167440712-167440737 AUUCCAUCCAGCAGGUAGCAGAGUU 331 919_2_6 CD247 Exon 2 + xp1:167440713-167440738 UUCCAUCCAGCAGGUAGCAGAGUUU 332 919_2_7 CD247 Exon 2 + xp1:167440723-167440748 CAGGUAGCAGAGUUUGGGAUCCAGC 333 919_2_8 CD247 Exon 2 + xp1:167440761-167440786 GUGCCUCUGUGCCAAGAGAUAAAGC 334 919_2_9 CD247 Exon 2 - xp1:167440641-167440666 AAGGUGGGUACCACUGGGCUUUGGG 335 919_2_10 CD247 Exon 2 - xp1:167440644-167440669 GUGAAGGUGGGUACCACUGGGCUUU 336 919_2_11 CD247 Exon 2 - xp1:167440645-167440670 AGUGAAGGUGGGUACCACUGGGCUU 337 919_2_12 CD247 Exon 2 - xp1:167440651-167440676 CCUGAGAGUGAAGGUGGGUACCACU 338 919_2_13 CD247 Exon 2 - xp1:167440652-167440677 UCCUGAGAGUGAAGGUGGGUACAC 339 919_2_14 CD247 Exon 2 - xp1:167440661-167440686 CUGCCUUGUUCCUGAGAGUGAAGGU 340 919_2_15 CD247 Exon 2 - xp1:167440662-167440687 ACUGCCUUGUUCCUGAGAGUGAAGG 341 919_2_16 CD247 Exon 2 - xp1:167440665-167440690 CUCACUGCCUUGUUCCUGAGAGUGA 342 919_2_17 CD247 Exon 2 - xp1:167440700-167440725 UGCUGGAUGGAAUCCUCUUCAUCUA 343 919_2_18 CD247 Exon 2 - xp1:167440718-167440743 AUCCCAAACUCUGCUACCUGCUGGA 344 919_2_19 CD247 Exon 2 - xp1:167440722-167440747 CUGGAUCCCCAAACUCUGCUACCUGC 345 919_2_20 CD247 Exon 2 - xp1:167440746-167440771 ACAGAGGCACAGAGCUUUGGCCUGC 346 919_2_21 CD247 Exon 2 - xp1:167440754-167440779 CUCUUGGCACAGAGGCACAGAGCUU 347 919_2_22 CD247 Exon 2 - xp1:167440767-167440792 UGACCAGCUUUAUCUCUUGGCACAG 348 919_1_1 CD247 Exon 1 + xp1:167518389-167518414 UCGACACGUCGGCCCUACCUGUAAU 349 919_1_2 CD247 Exon 1 + xp1:167518405-167518430 ACCUGUAAUCGGCAACUGUGCCUGC 350 919_1_3 CD247 Exon 1 + xp1:167518409-167518434 GUAAUCGGCAACUGUGCCUGCAGGA 351 919_1_4 CD247 Exon 1 + xp1:167518415-167518440 GGCAACUGUGCCUGCAGGAUGGCCG 352 919_1_5 CD247 Exon 1 + xp1:167518461-167518486 UCAUCUUGUCCUUUCCCUCAGAAAG 353 919_1_6 CD247 Exon 1 + xp1:167518465-167518490 CUUGUCCCUUUCCCUCAGAAAGAGGC 354 919_1_7 CD247 Exon 1 + xp1:167518466-167518491 UUGUCCUUUCCCUCAGAAAGAGGCU 355 919_1_8 CD247 Exon 1 + xp1:167518469-167518494 UCCUUUCCCUCAGAAAGAGGCUGGG 356 919_1_9 CD247 Exon 1 + xp1:167518475-167518500 CCCUCAGAAAGAGGCUGGGAGGCAG 357 919_1_10 CD247 Exon 1 + xp1:167518481-167518506 GAAAGAGGCUGGGAGGCAGAGGCUG 358 919_1_11 CD247 Exon 1 + xp1:167518487-167518512 GGCUGGGAGGCAGAGGCUGAGGCAG 359 919_1_12 CD247 Exon 1 + xp1:167518490-167518515 UGGGAGGCAGAGGCUGAGGCAGCGG 360 919_1_13 CD247 Exon 1 + xp1:167518494-167518519 AGGCAGAGGCUGAGGCAGCGGUGGC 361 919_1_14 CD247 Exon 1 + xp1:167518495-167518520 GGCAGAGGCUGAGGCAGCGGUGGCC 362 919_1_15 CD247 Exon 1 + xp1:167518499-167518524 GAGGCUGAGGCAGCGGUGGCCGGGA 363 919_1_16 CD247 Exon 1 + xp1:167518504-167518529 UGAGGCAGCGGUGGCCGGGACGGUU 364 919_1_17 CD247 Exon 1 + xp1:167518512-167518537 CGGUGGCCGGGACGGUUAGGAGAAA 365 919_1_18 CD247 Exon 1 + xp1:167518524-167518549 CGGUUAGGAGAAAAGGAGUCUCUGC 366 919_1_19 CD247 Exon 1 + xp1:167518550-167518575 GGUUUUAUUCUGCAGCUACCUCCCC 367 919_1_20 CD247 Exon 1 + xp1:167518556-167518581 AUUCUGCAGCUACCUCCCCAGGAAG 368 919_1_21 CD247 Exon 1 + xp1:167518559-167518584 CUGCAGCUACCUCCCCAGGAAGUGG 369 919_1_22 CD247 Exon 1 + xp1:167518566-167518591 UACCUCCCCAGGAAGUGGAGGACUG 370 919_1_23 CD247 Exon 1 + xp1:167518567-167518592 ACCUCCCCAGGAAGUGGAGGACUGU 371 919_1_24 CD247 Exon 1 + xp1:167518568-167518593 CCUCCCCAGGAAGUGGAGGACUGUG 372 919_1_25 CD247 Exon 1 + xp1:167518594-167518619 GGCCUUUGAGAAAGCACCUGCCGAC 373 919_1_26 CD247 Exon 1 + xp1:167518595-167518620 GCCUUUGAGAAAGCACCUGCCGACA 374 919_1_27 CD247 Exon 1 - xp1:167518385-167518410 CAGGUAGGGCCGACGUGUGUCGACGGC 375 919_1_28 CD247 Exon 1 - xp1:167518389-167518414 AUUACAGGUAGGGCCGACGUGUCGA 376 919_1_29 CD247 Exon 1 - xp1:167518404-167518429 CAGGCACAGGUUGCCGAUUACAGGUA 377 919_1_30 CD247 Exon 1 - xp1:167518405-167518430 GCAGGCACAGGUUGCCGAUUACAGGU 378 919_1_31 CD247 Exon 1 - xp1:167518409-167518434 UCCUGCAGGCCACAGUUGCCGAUUAC 379 919_1_32 CD247 Exon 1 - xp1:167518428-167518453 GCGCUUUUCACCGCGGCCAUCCUGC 380 919_1_33 CD247 Exon 1 - xp1:167518440-167518465 AUGAAGUGGAAGGCGCUUUUCACCG 381 919_1_34 CD247 Exon 1 - xp1:167518455-167518480 GAGGGAAAGGACAAGAUGAAGUGGA 382 919_1_35 CD247 Exon 1 - xp1:167518459-167518484 UUCUGAGGGAAAGGACAAGAUGAAG 383 919_1_36 CD247 Exon 1 - xp1:167518473-167518498 GCCUCCCAGCCUCUUUCUGAGGGAA 384 919_1_37 CD247 Exon 1 - xp1:167518478-167518503 CCUCUGCCUCCCAGCCUCUUUCUGA 385 919_1_38 CD247 Exon 1 - xp1:167518479-167518504 GCCUCUGCCUCCCAGCCUCUUUCUG 386 919_1_39 CD247 Exon 1 - xp1:167518521-167518546 GAGACUCCUUUUCUCCUAACCGUCC 387 919_1_40 CD247 Exon 1 - xp1:167518571-167518596 CCCCACAGUCCUCCACUUCCUGGGG 388 919_1_41 CD247 Exon 1 - xp1:167518574-167518599 AGGCCCCACAGUCCUCCACUUCCUG 389 919_1_42 CD247 Exon 1 - xp1:167518575-167518600 AAGGCCCCACAGUCCUCCACUUCCU 390 919_1_43 CD247 Exon 1 - xp1:167518576-167518601 AAAGGCCCCACAGUCCUCCACUUCC 391 919_1_44 CD247 Exon 1 - xp1:167518599-167518624 GCCCUGUCGGCAGGUGCUUUCUCAA 392 915_5_1 CD3D Exon 5 + xp11:118339059-118339084 AGCCCAGGCACCUGCUGAGUGAAAG 393 915_5_2 CD3D Exon 5 + xp11:118339072-118339097 GCUGAGUGAAAAGAGGAUAUAUUUAU 394 915_5_3 CD3D Exon 5 + xp11:118339085-118339110 GGAUAUAUUUAUUGGCUGAGCAAGA 395 915_5_4 CD3D Exon 5 + xp11:118339086-118339111 GAUAUAUUUAUUGGCUGAGCAAGAA 396 915_5_5 CD3D Exon 5 + xp11:118339090-118339115 UAUUUAUUGGCUGAGCAAGAAGGGA 397 915_5_6 CD3D Exon 5 + xp11:118339099-118339124 GCUGAGCAAGAAGGGAAGGUACGU 398 915_5_7 CD3D Exon 5 + xp11:118339105-118339130 CAAGAAGGGAAGGUACAGUUGGUAA 399 915_5_8 CD3D Exon 5 + xp11:118339132-118339157 GCUGCUUCUAGAAGCCACCAGUCUC 400 915_5_9 CD3D Exon 5 + xp11:118339164-118339189 CUUGUUCCGAGCCCAGUUUCCUCA 401 915_5_10 CD3D Exon 5 + xp11:118339167-118339192 GUUCCGAGCCCAGUUUCCUCCAAGG 402 915_5_11 CD3D Exon 5 + xp11:118339194-118339219 GCUGUACUGAGCAUCAUCUCGAUCU 403 915_5_12 CD3D Exon 5 + xp11:118339197-118339222 GUACUGAGCAUCAUCUCGAUCUCGG 404 915_5_13 CD3D Exon 5 + xp11:118339198-118339223 UACUGAGCAUCAUCUCGAUCUCGGA 405 915_5_14 CD3D Exon 5 + xp11:118339199-118339224 ACUGAGCAUCAUCUCGAUCUCGGAG 406 915_5_15 CD3D Exon 5 + xp11:118339209-118339234 AUCUCGAUCUCGGAGGGGCUAAGAG 407 915_5_16 CD3D Exon 5 + xp11:118339223-118339248 GGGGCUAAGAGAGGAGAAGAGAAAA 408 915_5_17 CD3D Exon 5 - xp11:118339054-118339079 ACUCAGCAGGUGCCUGGGCUUCUUA 409 915_5_18 CD3D Exon 5 - xp11:118339064-118339089 AUCCUCUUUCACUCAGCAGGUGCCU 410 915_5_19 CD3D Exon 5 - xp11:118339065-118339090 UAUCCUCUUUCACUCAGCAGGUGCC 411 915_5_20 CD3D Exon 5 - xp11:118339072-118339097 AUAAAUAUAUCCUCUUUCACUCAGGC 412 915_5_21 CD3D Exon 5 - xp11:118339149-118339174 UCGGAACAAGUGAACCUGAGACUGG 413 915_5_22 CD3D Exon 5 - xp11:118339152-118339177 GGCCUCGGAACAAGUGAACCUGAGAC 414 915_5_23 CD3D Exon 5 - xp11:118339173-118339198 CAGCCACCUUGGAGGAAACUGGGCU 415 915_5_24 CD3D Exon 5 - xp11:118339178-118339203 CAGUACAGCCACCUUGGAGGAAACU 416 915_5_25 CD3D Exon 5 - xp11:118339179-118339204 UCAGUACAGCCACCUUGGAGGAAAC 417 915_5_26 CD3D Exon 5 - xp11:118339186-118339211 AUGAUGCUCAGUACAGCCACCUUGG 418 915_5_27 CD3D Exon 5 - xp11:118339189-118339214 GAGAUGAUGCUCAGUACAGCCACCU 419 915_4_1 CD3D Exon 4 + xp11:118339435-118339460 CCCCUCAACGCUCACCUGAUAGACC 420 915_4_2 CD3D Exon 4 + xp11:118339463-118339488 UCAUUCCUCAACAGAGCUUGUGUGU 421 915_4_3 CD3D Exon 4 - xp11:118339431-118339456 UAUCAGGUGAGCGUUGAGGGGAAGG 422 915_4_4 CD3D Exon 4 - xp11:118339434-118339459 GUCUAUCAGGUGAGCGUUGAGGGGA 423 915_4_5 CD3D Exon 4 - xp11:118339438-118339463 CCAGGUCUAUCAGGUGAGCGUUGAG 424 915_4_6 CD3D Exon 4 - xp11:118339439-118339464 ACCAGGUCUAUCAGGUGAGCGUUGA 425 915_4_7 CD3D Exon 4 - xp11:118339440-118339465 GACCAGGUCUAUCAGGUGAGCGUUG 426 915_4_8 CD3D Exon 4 - xp11:118339452-118339477 CUGUUGAGGAAUGACCAGGUCUAUUC 427 915_4_9 CD3D Exon 4 - xp11:118339461-118339486 ACACAAGCUCUGUUGAGGAAUGACC 428 915_4_10 CD3D Exon 4 - xp11:118339471-118339496 AGCUGCCGACACACAAGCUCUGUUG 429 915_3_1 CD3D Exon 3 + xp11:118339802-118339827 AGCAAAGCAGAAGACUCCCAAAGCA 430 915_3_2 CD3D Exon 3 + xp11:118339812-118339837 AAGACUCCCAAAGCAAGGAGCAGAG 431 915_3_3 CD3D Exon 3 + xp11:118339845-118339870 ACAUCAGUGACAAUGAUGCCAGCCA 432 915_3_4 CD3D Exon 3 + xp11:118339848-118339873 UCAGUGACAAUGAUGCCAGCCACGG 433 915_3_5 CD3D Exon 3 + xp11:118339852-118339877 UGACAAUGAUGCCAGCCACGGUGGC 434 915_3_6 CD3D Exon 3 + xp11:118339874-118339899 GGCUGGAUCCAGCUCCACACAGCUC 435 915_3_7 CD3D Exon 3 + xp11:118339884-118339909 AGCUCCACACAGCUCUGGCACACUG 436 915_3_8 CD3D Exon 3 + xp11:118339885-118339910 GCUCCACACAGCUCUGGCACACUGU 437 915_3_9 CD3D Exon 3 + xp11:118339886-118339911 CUCCACACAGCUCUGGCACACUGUG 438 915_3_10 CD3D Exon 3 + xp11:118339887-118339912 UCCACACAGCUCUGGCACACUGUGG 439 915_3_11 CD3D Exon 3 + xp11:118339891-118339916 CACAGCUCUGGCACACUGUGGGGGA 440 915_3_12 CD3D Exon 3 + xp11:118339892-118339917 ACAGCUCUGGCACACCUGUGGGGGAA 441 915_3_13 CD3D Exon 3 + xp11:118339895-118339920 GCUCUGGCACACUGUGGGGGAAGGG 442 915_3_14 CD3D Exon 3 + xp11:118339902-118339927 CACACUGUGGGGGAAGGGAGGAGAG 443 915_3_15 CD3D Exon 3 - xp11:118339769-118339794 GACUGGAAGGCUGUCUGGGGGUUAG 444 915_3_16 CD3D Exon 3 - xp11:118339776-118339801 GACAUGAGACUGGAAGGCUGUCUGG 445 915_3_17 CD3D Exon 3 - xp11:118339777-118339802 GGACAUGAGACUGGAAGGCUGUCUG 446 915_3_18 CD3D Exon 3 - xp11:118339778-118339803 UGGACAUGAGACUGGAAGGCUGUCU 447 915_3_19 CD3D Exon 3 - xp11:118339779-118339804 CUGGACAUGAGACUGGAAGGCUGUC 448 915_3_20 CD3D Exon 3 - xp11:118339787-118339812 CUGCUUUGCUGGACAUGAGACUGGA 449 915_3_21 CD3D Exon 3 - xp11:118339791-118339816 UCUUCUGCUUUGCUGGACAUGAGAC 450 915_3_22 CD3D Exon 3 - xp11:118339803-118339828 UUGCUUUGGGAGUCUUCUGCUUUGC 451 915_3_23 CD3D Exon 3 - xp11:118339821-118339846 UCAUUGCCACUCUGCUCCUUGCUUU 452 915_3_24 CD3D Exon 3 - xp11:118339822-118339847 GUCAUUGCCACUCUGCUCCUUGCUU 453 915_3_25 CD3D Exon 3 - xp11:118339866-118339891 UGGAGCUGGAUCCAGCCACCGUGGC 454 915_3_26 CD3D Exon 3 - xp11:118339870-118339895 UGUGUGGAGCUGGAUCCAGCCACCG 455 915_3_27 CD3D Exon 3 - xp11:118339885-118339910 ACAGUGUGCCAGAGCUGUGUGGAGC 456 915_3_28 CD3D Exon 3 - xp11:118339891-118339916 UCCCCCACAGUGUGCCAGAGCUGUG 457 915_2_1 CD3D Exon 2 + xp11:118340367-118340392 CACGUACUUCGAUAAUGAACUUGCA 458 915_2_2 CD3D Exon 2 + xp11:118340422-118340447 UCCCAUUACACCCUAUAUAUUCCUCG 459 915_2_3 CD3D Exon 2 + xp11:118340423-118340448 CCCAUUACACCUAUAUAUUCCUCGU 460 915_2_4 CD3D Exon 2 + xp11:118340429-118340454 ACACCUAUAUAUUCCUCGUGGGUCC 461 915_2_5 CD3D Exon 2 + xp11:118340444-118340469 UCGUGGGUCCAGGAUGCGUUUUCCC 462 915_2_6 CD3D Exon 2 + xp11:118340505-118340530 ACCGUUCCCCUCUACCCAUGUGAUGC 463 915_2_7 CD3D Exon 2 + xp11:118340548-118340573 ACACUCUGUCCUCAAGUUCCUCUAU 464 915_2_8 CD3D Exon 2 + xp11:118340559-118340584 UCAAGUUCCUCUAUAGGUAUCUUGA 465 915_2_9 CD3D Exon 2 + xp11:118340560-118340585 CAAGUUCCUCUAUAGGUAUCUUGAA 466 915_2_10 CD3D Exon 2 + xp11:118340561-118340586 AAGUUCCUCUAUAGGUAUCUUGAAG 467 915_2_11 CD3D Exon 2 + xp11:118340572-118340597 UAGGUAUCUUGAAGGGGCUCACUAA 468 915_2_12 CD3D Exon 2 + xp11:118340573-118340598 AGGUAUCUUGAAGGGGCUCACUAAA 469 915_2_13 CD3D Exon 2 + xp11:118340574-118340599 GGUAUCUUGAAGGGGCUCACUAAAG 470 915_2_14 CD3D Exon 2 - xp11:118340352-118340377 GAAGUACGUGCUUCCUGAACCCUUU 471 915_2_15 CD3D Exon 2 - xp11:118340353-118340378 CGAAGUACGUGCUUCCUGAACCCUU 472 915_2_16 CD3D Exon 2 - xp11:118340410-118340435 AGGUGUAAUGGGACAGAUAUAUACA 473 915_2_17 CD3D Exon 2 - xp11:118340426-118340451 CCCACGAGGAAUAUAUAGGUGUAAU 474 915_2_18 CD3D Exon 2 - xp11:118340427-118340452 ACCCACGAGGAAUAUAUAGGUGUAA 475 915_2_19 CD3D Exon 2 - xp11:118340435-118340460 CAUCCUGGACCCACGAGGAAUAUAU 476 915_2_20 CD3D Exon 2 - xp11:118340445-118340470 UGGGAAAACCGCAUCCUGGACCCACG 477 915_2_21 CD3D Exon 2 - xp11:118340455-118340480 AGACUGGACCUGGGAAAACGCAUCC 478 915_2_22 CD3D Exon 2 - xp11:118340469-118340494 UCUCAGACAUUACAAGACCUGGACCU 479 915_2_23 CD3D Exon 2 - xp11:118340470-118340495 CUCUCAGACAUUACAAGACUGGACC 480 915_2_24 CD3D Exon 2 - xp11:118340476-118340501 ACACUGCUCUCAGACAUUACAAGAC 481 915_2_25 CD3D Exon 2 - xp11:118340505-118340530 GCAUCACAUGGGUAGAGGGAACGGU 482 915_2_26 CD3D Exon 2 - xp11:118340506-118340531 AGCAUCACAUGGGUAGAGGGAACGG 483 915_2_27 CD3D Exon 2 - xp11:118340509-118340534 ACCAGCAUCACAUGGGUAGAGGGAA 484 915_2_28 CD3D Exon 2 - xp11:118340514-118340539 GCAAUACCAGCAUCACAUGGGUAGA 485 915_2_29 CD3D Exon 2 - xp11:118340515-118340540 UGCAAUACCAGCAUCACAUGGGUAG 486 915_2_30 CD3D Exon 2 - xp11:118340521-118340546 GUGAAUUGCAAUACCAGCAUCACAU 487 915_2_31 CD3D Exon 2 - xp11:118340522-118340547 UGUGAAUUGCAAUACCAGCAUCACA 488 915_2_32 CD3D Exon 2 - xp11:118340560-118340585 UUCAAGAAUACCUAUAGAGGAACUUG 489 915_2_33 CD3D Exon 2 - xp11:118340569-118340594 GUGAGCCCCUUCAAGAUACCUAUAG 490 915_1_1 CD3D Exon 1 + xp11:118342538-118342563 UGGAGUAGCCUUACCUUGCGAGAGA 491 915_1_2 CD3D Exon 1 + xp11:118342539-118342564 GGAGUAGCCUUACCUUGCGAGAGAA 492 915_1_3 CD3D Exon 1 + xp11:118342553-118342578 UUGCGAGAGAAGGGUAGCCAGUACC 493 915_1_4 CD3D Exon 1 + xp11:118342589-118342614 AAACGUGCUAUGUUCCAUCUCCCAG 494 915_1_5 CD3D Exon 1 + xp11:118342614-118342639 CGGAACUCAUCCAGUAAGAUAAAGCC 495 915_1_6 CD3D Exon 1 + xp11:118342634-118342659 AAGCCAGGUCACCGAACUAUCAGCC 496 915_1_7 CD3D Exon 1 + xp11:118342635-118342660 AGCCAGGUCACCGAACUAUCAGCCU 497 915_1_8 CD3D Exon 1 + xp11:118342667-118342692 AGCUGCCCUCCCCUAGCUGACUCAC 498 915_1_9 CD3D Exon 1 + xp11:118342673-118342698 CCUCCCCUAGCUGACUCAGAGUAC 499 915_1_10 CD3D Exon 1 + xp11:118342680-118342705 UAGCUGACUCACAGGUACCGGAAAG 500 915_1_11 CD3D Exon 1 + xp11:118342687-118342712 CUCACAGGUACCGGAAAAGAGGAGAG 501 915_1_12 CD3D Exon 1 + xp11:118342688-118342713 UCACAGGUACCGGAAAAGAGGAGAGU 502 915_1_13 CD3D Exon 1 + xp11:118342689-118342714 CACAGGUACCGGAAAAGAGGAGAGUG 503 915_1_14 CD3D Exon 1 + xp11:118342690-118342715 ACAGGUACCGGAAAAGAGGAGAGUGG 504 915_1_15 CD3D Exon 1 + xp11:118342693-118342718 GGUACCGGAAAAGAGGAGAGUGGGGG 505 915_1_16 CD3D Exon 1 + xp11:118342734-118342759 CUGCUUCUCUGCUUUCUGCCGUUGA 506 915_1_17 CD3D Exon 1 + xp11:118342737-118342762 CUUCUCUGCUUUCUGCCGUUGAUGG 507 915_1_18 CD3D Exon 1 + xp11:118342738-118342763 UUCUCUGCUUUCUGCCGUUGAUGGU 508 915_1_19 CD3D Exon 1 - xp11:118342530-118342555 AAGGUAAGGCUACUCCAGGUGGGUG 509 915_1_20 CD3D Exon 1 - xp11:118342531-118342556 CAAGGUAAGGCUACUCCAGGUGGGU 510 915_1_21 CD3D Exon 1 - xp11:118342532-118342557 GCAAGGUAAGGCUACUCCAGGUGGG 511 915_1_22 CD3D Exon 1 - xp11:118342535-118342560 CUCGCAAGGUAAGGCUACUCCAGGU 512 915_1_23 CD3D Exon 1 - xp11:118342536-118342561 UCUCGCAAGGUAAGGCUACUCCAGG 513 915_1_24 CD3D Exon 1 - xp11:118342539-118342564 UUUCUCCGCAAGGUAAGGCUACUCC 514 915_1_25 CD3D Exon 1 - xp11:118342549-118342574 CUGGCUACCCUUCUCUCGCAAGGUA 515 915_1_26 CD3D Exon 1 - xp11:118342554-118342579 UGGUACUGGCUACCCUUCUCUCGCA 516 915_1_27 CD3D Exon 1 - xp11:118342573-118342598 AGCACGUUUCUCUCUGGCCUGGUAC 517 915_1_28 CD3D Exon 1 - xp11:118342579-118342604 GAACAUAGCACGUUUCUCUCUGCC 518 915_1_29 CD3D Exon 1 - xp11:118342584-118342609 AGAUGGAACAUAGCACGUUUCUCUC 519 915_1_30 CD3D Exon 1 - xp11:118342606-118342631 CUACUGGAUGAGUUCCGCUGGGAGA 520 915_1_31 CD3D Exon 1 - xp11:118342612-118342637 CUUUAUCUACUGGAUGAGUUCCGCU 521 915_1_32 CD3D Exon 1 - xp11:118342613-118342638 GCUUUAUCUACUGGAUGAGUUCGCGC 522 915_1_33 CD3D Exon 1 - xp11:118342627-118342652 AGUUCGGUGACCUGGCUUUAUCUAC 523 915_1_34 CD3D Exon 1 - xp11:118342640-118342665 CACCCAGGCUGAUAGUUCGGUGACC 524 915_1_35 CD3D Exon 1 - xp11:118342648-118342673 GCAGCUCUCACCCAGGCUGAUAGUU 525 915_1_36 CD3D Exon 1 - xp11:118342660-118342685 AGCUAGGGGAGGGCAGCUCUCACCC 526 915_1_37 CD3D Exon 1 - xp11:118342675-118342700 CGGUACCUGUGAGUCAGCUAGGGGA 527 915_1_38 CD3D Exon 1 - xp11:118342676-118342701 CCGGUACCUGUGAGUCAGCUAGGGG 528 915_1_39 CD3D Exon 1 - xp11:118342679-118342704 UUUCCGGUACCUGUGAGUCAGCUAG 529 915_1_40 CD3D Exon 1 - xp11:118342680-118342705 CUUUCCGGUACCUGUGAGUCAGCUA 530 915_1_41 CD3D Exon 1 - xp11:118342681-118342706 UCUUUCCGGUACCUGUGAGUCAGCU 531 915_1_42 CD3D Exon 1 - xp11:118342700-118342725 AGUUCCUCCCCCACUCUCCUCUUUC 532 916_1_1 CD3E Exon 1 + xp11:118304575-118304600 CAGGUAUUGUCAGAGUCCUCUUGUU 533 916_1_2 CD3E Exon 1 + xp11:118304584-118304609 UCAGAGUCCUCUUGUUUGGCCUUCU 534 916_1_3 CD3E Exon 1 + xp11:118304588-118304613 AGUCCUCUUGUUUGGCCUUCUAGGA 535 916_1_4 CD3E Exon 1 + xp11:118304594-118304619 CUUGUUUGGCCUUCUAGGAAGGCUG 536 916_1_5 CD3E Exon 1 + xp11:118304595-118304620 UUGUUUGGCCUUCUAGGAAGGCUGU 537 916_1_6 CD3E Exon 1 + xp11:118304621-118304646 GGACCCAGCUUUCUUCAACCAGUCC 538 916_1_7 CD3E Exon 1 + xp11:118304624-118304649 CCCAGCUUUCUUCAACCAGUCCAGG 539 916_1_8 CD3E Exon 1 + xp11:118304627-118304652 AGCUUUCUUCAACCAGUCCAGGUGG 540 916_1_9 CD3E Exon 1 + xp11:118304655-118304680 CCUCUGCCUUGAACGUUUCCAAGUG 541 916_1_10 CD3E Exon 1 + xp11:118304668-118304693 CGUUUCCAAGUGAGGUAAAAACCCGC 542 916_1_11 CD3E Exon 1 + xp11:118304676-118304701 AGUGAGGUAAAAACCCGCAGGCCCAG 543 916_1_12 CD3E Exon 1 + xp11:118304696-118304721 CCCAGAGGCCUCUCUACUUCCUGUG 544 916_1_13 CD3E Exon 1 + xp11:118304697-118304722 CCAGAGGCCUCUCUACUUCCUGUGU 545 916_1_14 CD3E Exon 1 + xp11:118304698-118304723 CAGAGGCCUCUCUACUUCCUGUGUG 546 916_1_15 CD3E Exon 1 + xp11:118304730-118304755 GAAACCCUCCUCCCCUCCCAGCCUC 547 916_1_16 CD3E Exon 1 + xp11:118304749-118304774 AGCCUCAGGUGCCUGCUUCAGAAAA 548 916_1_17 CD3E Exon 1 - xp11:118304572-118304597 AAGAGGACUCUGACAAUACCUGGAG 549 916_1_18 CD3E Exon 1 - xp11:118304573-118304598 CAAGAGGACUCUGACAAUACCUGGA 550 916_1_19 CD3E Exon 1 - xp11:118304574-118304599 ACAAGAGGACUCUGACAAUACCUGG 551 916_1_20 CD3E Exon 1 - xp11:118304577-118304602 CAAACAAGAGGACUCUGACAAUACC 552 916_1_21 CD3E Exon 1 - xp11:118304594-118304619 CAGCCUUCCUAGAAGGCCAAACAAG 553 916_1_22 CD3E Exon 1 - xp11:118304606-118304631 AGCUGGGUCCCACAGCCUUCCUAGA 554 916_1_23 CD3E Exon 1 - xp11:118304627-118304652 CCACCUGGACUGGUUGAAGAAAGCU 555 916_1_24 CD3E Exon 1 - xp11:118304628-118304653 UCCACCUGGACUGGUUGAAGAAAGC 556 916_1_25 CD3E Exon 1 - xp11:118304642-118304667 UCAAGGCAGAGGCCUCCACCUGGAC 557 916_1_26 CD3E Exon 1 - xp11:118304647-118304672 AACGUUCAAGGCAGAGGCCUCCACC 558 916_1_27 CD3E Exon 1 - xp11:118304658-118304683 CCUCACUUGGAAACGUUCAAGGCAG 559 916_1_28 CD3E Exon 1 - xp11:118304664-118304689 GUUUUACCUCACUUGGAAACGUUCA 560 916_1_29 CD3E Exon 1 - xp11:118304676-118304701 CUGGGCCUGCGGGUUUUACCUCACU 561 916_1_30 CD3E Exon 1 - xp11:118304691-118304716 GAAGUAGAGAGGCCUCUGGGCCUGC 562 916_1_31 CD3E Exon 1 - xp11:118304692-118304717 GGAAGUAGAGAGGCCUCUGGGCCUG 563 916_1_32 CD3E Exon 1 - xp11:118304699-118304724 CCACACAGGAAGUAGAGAGGCCUCU 564 916_1_33 CD3E Exon 1 - xp11:118304700-118304725 CCCACACAGGAAGUAGAGAGGCCUC 565 916_1_34 CD3E Exon 1 - xp11:118304707-118304732 UCUGAACCCCCACACAGGAAGUAGAG 566 916_1_35 CD3E Exon 1 - xp11:118304718-118304743 GGAGGAGGGUUUCUGAACCCCAACAC 567 916_1_36 CD3E Exon 1 - xp11:118304737-118304762 GGCACCUGAGGCUGGGAGGGGAGGA 568 916_1_37 CD3E Exon 1 - xp11:118304738-118304763 AGGCACCUGAGGCUGGGAGGGGAGG 569 916_1_38 CD3E Exon 1 - xp11:118304741-118304766 AGCAGGCACCUGAGGCUGGGAGGGG 570 916_1_39 CD3E Exon 1 - xp11:118304744-118304769 UGAAGCAGGCACCUGAGGCUGGGAG 571 916_1_40 CD3E Exon 1 - xp11:118304745-118304770 CUGAAGCAGGCACCUGAGGCUGGGA 572 916_1_41 CD3E Exon 1 - xp11:118304746-118304771 UCUGAAGCAGGCACCUGAGGCUGGG 573 916_1_42 CD3E Exon 1 - xp11:118304749-118304774 UUUUCUGAAGCAGGCACCUGAGGCU 574 916_1_43 CD3E Exon 1 - xp11:118304750-118304775 AUUUUCUGAAGCAGGCACCUGAGGC 575 916_1_44 CD3E Exon 1 - xp11:118304754-118304779 CACCAUUUUCUGAAGCAGGCACCUG 576 916_1_45 CD3E Exon 1 - xp11:118304763-118304788 AGAGAGACUCACCAUUUUCUGAAGC 577 916_2_1 CD3E Exon 2 + xp11:118304883-118304908 UUUUUUCCAGAAGUAGUAAGUCUGC 578 916_2_2 CD3E Exon 2 + xp11:118304934-118304959 CAGUCCCAUGAAAACAAAGAUGCAGU 579 916_2_3 CD3E Exon 2 + xp11:118304935-118304960 AGUCCCAUGAAAACAAAGAUGCAGUC 580 916_2_4 CD3E Exon 2 + xp11:118304945-118304970 AACAAAGAUGCAGUCGGGCACUCAC 581 916_2_5 CD3E Exon 2 + xp11:118304955-118304980 CAGUCGGGCACUCACUGGAGAGUUC 582 916_2_6 CD3E Exon 2 + xp11:118304956-118304981 AGUCGGGCACUCACUGGAGAGUUCU 583 916_2_7 CD3E Exon 2 + xp11:118304974-118304999 GAGUUCUGGGCCUCUGCCUCUUAUC 584 916_2_8 CD3E Exon 2 + xp11:118304982-118305007 GGCCUCUGCCUCUUAUCAGGUGAGU 585 916_2_9 CD3E Exon 2 + xp11:118304986-118305011 UCUGCCUCUUAUCAGGUGAGUAGGA 586 916_2_10 CD3E Exon 2 + xp11:118304991-118305016 CUCUUAUCAGGUGAGUAGGAUGGAG 587 916_2_11 CD3E Exon 2 + xp11:118304996-118305021 AUCAGGUGAGUAGGAUGGAGUGGAA 588 916_2_12 CD3E Exon 2 + xp11:118304997-118305022 UCAGGUGAGUAGGAUGGAGUGGAAA 589 916_2_13 CD3E Exon 2 - xp11:118304892-118304917 CGGAGGCCAGCAGACUUACUACUUC 590 916_2_14 CD3E Exon 2 - xp11:118304914-118304939 GACUGUUACUUUACUAAAGAUGGCGG 591 916_2_15 CD3E Exon 2 - xp11:118304917-118304942 UGGGACUGUUACUUUACUAAAGAUGG 592 916_2_16 CD3E Exon 2 - xp11:118304920-118304945 UCAUGGGACUGUUACUUUACUAAGA 593 916_2_17 CD3E Exon 2 - xp11:118304941-118304966 GUGCCCGACUGCAUCUUUGUUUCAU 594 916_2_18 CD3E Exon 2 - xp11:118304942-118304967 AGUGCCCGACUGCAUCUUUGUUUCA 595 916_2_19 CD3E Exon 2 - xp11:118304987-118305012 AUCCUACUCACCUGAUAAGAGGCAG 596 916_2_20 CD3E Exon 2 - xp11:118304993-118305018 CACUCCAUCCUACUCACCUGAUAAG 597 916_3_1 CD3E Exon 3 + xp11:118307263-118307288 UUUUUUUUCUUAUUUAUUUUCUAGU 598 916_3_2 CD3E Exon 3 + xp11:118307270-118307295 UCUUAUUUAUUUUCUAGUUGGCGUU 599 916_3_3 CD3E Exon 3 + xp11:118307271-118307296 CUUAUUUAUUUUCUAGUUGGCGUUU 600 916_3_4 CD3E Exon 3 + xp11:118307272-118307297 UUAUUUAUUUUCUAGUUGGCGUUUG 601 916_3_5 CD3E Exon 3 + xp11:118307273-118307298 UAUUUAUUUUCUAGUUGGCGUUUGG 602 916_3_6 CD3E Exon 3 + xp11:118307281-118307306 UUCUAGUUGGCGUUUGGGGGCAAGA 603 916_4_1 CD3E Exon 4 + xp11:118308413-118308438 GUUUCCUUUUCAGGUAAUGAAGAAAA 604 916_4_2 CD3E Exon 4 + xp11:118308414-118308439 UUUCCUUUUCAGGUAAUGAAGAAAU 605 916_4_3 CD3E Exon 4 - xp11:118308420-118308445 UUACCCAUUUCUUCAUUACCUGAAA 606 916_5_1 CD3E Exon 5 + xp11:118312128-118312153 GCUGUUUCCUUUUUUCAUUUUCAGG 607 916_5_2 CD3E Exon 5 + xp11:118312155-118312180 GUAUUACACAGACACGUGAGUUUAU 608 916_5_3 CD3E Exon 5 - xp11:118312138-118312163 UGUAAUACCACCUGAAAAUGAAAAA 609 916_6_1 CD3E Exon 6 + xp11:118312611-118312636 CCCCAGCAUAUAAAGUCUCCAUCUC 610 916_6_2 CD3E Exon 6 + xp11:118312647-118312672 UAAUAUUGACAUGCCCUCAGUAUCC 611 916_6_3 CD3E Exon 6 + xp11:118312663-118312688 UCAGUAUCCUGGAUCUGAAAUACUA 612 916_6_4 CD3E Exon 6 + xp11:118312686-118312711 UAUGGCAACACAAUGAUAAAAAACAU 613 916_6_5 CD3E Exon 6 + xp11:118312689-118312714 GGCAACACAAUGAUAAAAAACAUAGG 614 916_6_6 CD3E Exon 6 + xp11:118312697-118312722 AAUGAUAAAAAACAUAGGCGGUGAUG 615 916_6_7 CD3E Exon 6 + xp11:118312713-118312738 GCGGUGAUGAGGAUGAUAAAAAACAU 616 916_6_8 CD3E Exon 6 + xp11:118312724-118312749 GAUGAUAAAAAACAUAGGCAGUGAUG 617 916_6_9 CD3E Exon 6 + xp11:118312742-118312767 AGUGAUGAGGAUCACCUGUCACUGA 618 916_6_10 CD3E Exon 6 + xp11:118312757-118312782 CUGUCACUGAAGGAAUUUUCAGAAU 619 916_6_11 CD3E Exon 6 + xp11:118312767-118312792 AGGAAUUUUCAGAAUUGGAGCAAAG 620 916_6_12 CD3E Exon 6 + xp11:118312791-118312816 GUGGUUAUUAUGUCUGCUACCCCAG 621 916_6_13 CD3E Exon 6 + xp11:118312831-118312856 AGAUGCGAACUUUUAUCUCUACCUG 622 916_6_14 CD3E Exon 6 + xp11:118312832-118312857 GAUGCGAACUUUUAUCUCUACCUGA 623 916_6_15 CD3E Exon 6 + xp11:118312839-118312864 ACUUUUAUCUCUACCUGAGGGCAAG 624 916_6_16 CD3E Exon 6 + xp11:118312848-118312873 UCUACCUGAGGGCAAGAGGUAAUCC 625 916_6_17 CD3E Exon 6 + xp11:118312861-118312886 AAGAGGUAAUCCAGGUCUCCAGAC 626 916_6_18 CD3E Exon 6 - xp11:118312596-118312621 UAUGCUGGGGAGAAAGAAGGGAAAU 627 916_6_19 CD3E Exon 6 - xp11:118312603-118312628 GACUUUAUAUGCUGGGGAGAAAGAA 628 916_6_20 CD3E Exon 6 - xp11:118312604-118312629 AGACUUUAUAUGCUGGGGAGAAAGA 629 916_6_21 CD3E Exon 6 - xp11:118312614-118312639 CCAGAGAUGGAGACUUUAUAUGCUG 630 916_6_22 CD3E Exon 6 - xp11:118312615-118312640 UCCAGAGAUGGAGACUUUAUAUGCU 631 916_6_23 CD3E Exon 6 - xp11:118312616-118312641 UUCCAGAAUGGAGACUUUAUAUGC 632 916_6_24 CD3E Exon 6 - xp11:118312632-118312657 GUCAAUAUUACUGUGGUUCCAGAGA 633 916_6_25 CD3E Exon 6 - xp11:118312644-118312669 UACUGAGGGCAUGUCAAUAUUACUG 634 916_6_26 CD3E Exon 6 - xp11:118312663-118312688 UAGUAUUUCAGAUCCAGGAUACUGA 635 916_6_27 CD3E Exon 6 - xp11:118312664-118312689 AUAGUAUUUCAGAUCCAGGAUACUG 636 916_6_28 CD3E Exon 6 - xp11:118312673-118312698 UGUGUUGCCAUAGUAUUUCAGAUCC 637 916_6_29 CD3E Exon 6 - xp11:118312759-118312784 CAAUUCUGAAAAUUCCUUCAGUGAC 638 916_6_30 CD3E Exon 6 - xp11:118312813-118312838 CGCAUCUUCUGGUUUGCUUCCUCUG 639 916_6_31 CD3E Exon 6 - xp11:118312814-118312839 UCGCAUCUUCUGGUUUGCUUCCUCU 640 916_6_32 CD3E Exon 6 - xp11:118312815-118312840 UUCGCAUCUUCUGGUUUGCUUCCUC 641 916_6_33 CD3E Exon 6 - xp11:118312829-118312854 GGUAGAGAUAAAAGUUCGCAUCUUC 642 916_6_34 CD3E Exon 6 - xp11:118312855-118312880 GAGACCUGGAUUACCUCUUGCCCUC 643 916_7_1 CD3E Exon 7 + xp11:118313696-118313721 CCCCCCACAGUGUGUGAGAACUGCA 644 916_7_2 CD3E Exon 7 + xp11:118313702-118313727 ACAGUGUGUGAGAACUGCAUGGAGA 645 916_7_3 CD3E Exon 7 + xp11:118313714-118313739 AACUGCAUGGAGAUGGAUGUGAUGU 646 916_7_4 CD3E Exon 7 + xp11:118313717-118313742 UGCAUGGAGAUGGAUGUGAUGUCGG 647 916_7_5 CD3E Exon 7 + xp11:118313735-118313760 AUGUCGGUGGCCACAAUUGUCAUAG 648 916_7_6 CD3E Exon 7 + xp11:118313751-118313776 UUGUCAUAGUGGACAUCUGCAUCAC 649 916_7_7 CD3E Exon 7 + xp11:118313752-118313777 UGUCAUAGUGGACAUCUGCAUCACU 650 916_7_8 CD3E Exon 7 + xp11:118313753-118313778 GUCAUAGUGGACAUCUGCAUCACUG 651 916_7_9 CD3E Exon 7 + xp11:118313754-118313779 UCAUAGUGGACAUCUGCAUCACUGG 652 916_7_10 CD3E Exon 7 + xp11:118313768-118313793 UGCAUCACUGGGGGCUUGCUGCUGC 653 916_7_11 CD3E Exon 7 + xp11:118313779-118313804 GGGCUUGCUGCUGCUGGUUUACUAC 654 916_7_12 CD3E Exon 7 + xp11:118313795-118313820 GUUUACUACUGGAGCAAGAAUAGAA 655 916_7_13 CD3E Exon 7 + xp11:118313801-118313826 UACUGGAGCAAGAAUAGAAAGGCCA 656 916_7_14 CD3E Exon 7 + xp11:118313820-118313845 AGGCCAAGGCCAAGCCUGUGACACG 657 916_7_15 CD3E Exon 7 + xp11:118313825-118313850 AAGGCCAAGCCUGUGACACGAGGAG 658 916_7_16 CD3E Exon 7 + xp11:118313826-118313851 AGGCCAAGCCUGUGACACGAGGAGC 659 916_7_17 CD3E Exon 7 + xp11:118313832-118313857 AGCCUGUGACACGAGGAGCGGGUGC 660 916_7_18 CD3E Exon 7 + xp11:118313835-118313860 CUGUGACACGAGGAGCGGGUGCUGG 661 916_7_19 CD3E Exon 7 + xp11:118313839-118313864 GACACGAGGAGCGGGUGCUGGCGGC 662 916_7_20 CD3E Exon 7 + xp11:118313845-118313870 AGGAGCGGGUGCUGGCGGCAGGCAA 663 916_7_21 CD3E Exon 7 + xp11:118313846-118313871 GGAGCGGGUGCUGGCGGCAGGCAAA 664 916_7_22 CD3E Exon 7 + xp11:118313847-118313872 GAGCGGGUGCUGGCGGCAGGCAAAG 665 916_7_23 CD3E Exon 7 + xp11:118313852-118313877 GGUGCUGGCGGCAGGCAAAGGGGUA 666 916_7_24 CD3E Exon 7 + xp11:118313858-118313883 GGCGGCAGGCAAAGGGGUAAGGCUG 667 916_7_25 CD3E Exon 7 - xp11:118313684-118313709 ACACUGUGGGGGGUGGGGUGGGGAG 668 916_7_26 CD3E Exon 7 - xp11:118313689-118313714 CUCACACACUGUGGGGGGUGGGGUG 669 916_7_27 CD3E Exon 7 - xp11:118313690-118313715 UCUCACACACUGUGGGGGGUGGGGU 670 916_7_28 CD3E Exon 7 - xp11:118313691-118313716 UUCUCACACACUGUGGGGGGUGGGG 671 916_7_29 CD3E Exon 7 - xp11:118313694-118313719 CAGUUCUCACACACUGUGGGGGGUG 672 916_7_30 CD3E Exon 7 - xp11:118313695-118313720 GCAGUUCUCACACACUGUGGGGGGU 673 916_7_31 CD3E Exon 7 - xp11:118313696-118313721 UGCAGUUCUCACACACUGUGGGGGG 674 916_7_32 CD3E Exon 7 - xp11:118313699-118313724 CCAUGCAGUUCUCACACACCUGUGGG 675 916_7_33 CD3E Exon 7 - xp11:118313700-118313725 UCCAUGCAGUUCUCACACACUGUGG 676 916_7_34 CD3E Exon 7 - xp11:118313701-118313726 CUCCAUGCAGUUCUCACACACUGUG 677 916_7_35 CD3E Exon 7 - xp11:118313702-118313727 UCUCCAUGCAGUUCUCACACACUGU 678 916_7_36 CD3E Exon 7 - xp11:118313703-118313728 AUCUCCAUGCAGUUCUCACACACUG 679 916_7_37 CD3E Exon 7 - xp11:118313748-118313773 AUGCAGAUGUCCCACUAUGACAAUUG 680 916_7_38 CD3E Exon 7 - xp11:118313826-118313851 GCUCCUCGUGUCACAAGGCUUGGCCU 681 916_7_39 CD3E Exon 7 - xp11:118313832-118313857 GCACCCGCUCCUCGUGUCACAGGCU 682 916_7_40 CD3E Exon 7 - xp11:118313837-118313862 CGCCAGCACCCGCUCCUCGUGUCAC 683 916_8_1 CD3E Exon 8 + xp11:118314431-118314456 CCUCCUUCCUCCGCAGGACAAAAACA 684 916_8_2 CD3E Exon 8 + xp11:118314436-118314461 UUCCUCCGCAGGACAAAAACAAGGAG 685 916_8_3 CD3E Exon 8 + xp11:118314467-118314492 CCACCUGUUCCCAACCCAGACUAUG 686 916_8_4 CD3E Exon 8 + xp11:118314475-118314500 UCCCAACCCAGACUAUGAGGUAACG 687 916_8_5 CD3E Exon 8 + xp11:118314476-118314501 CCCAACCCAGACUAUGAGGUAACGU 688 916_8_6 CD3E Exon 8 + xp11:118314486-118314511 ACUAUGAGGUAACGUGGGAUAGAAA 689 916_8_7 CD3E Exon 8 + xp11:118314487-118314512 CUAUGAGGUAACGUGGGAUAGAAAU 690 916_8_8 CD3E Exon 8 - xp11:118314432-118314457 UUGUUUUGUCCUGCGGAGGAAGGAG 691 916_8_9 CD3E Exon 8 - xp11:118314433-118314458 CUUGUUUUGUCCUGCGGAGGAAGGA 692 916_8_10 CD3E Exon 8 - xp11:118314434-118314459 CCUUGUUUUGUCCUGCGGAGGAAGG 693 916_8_11 CD3E Exon 8 - xp11:118314437-118314462 UCUCCUUGUUUUGUCCUGCGGAGGA 694 916_8_12 CD3E Exon 8 - xp11:118314441-118314466 GGCCUUCCUUGUUUUGUCCUGCGG 695 916_8_13 CD3E Exon 8 - xp11:118314444-118314469 GGUGGCCCUCCUUGUUUUGUCCUG 696 916_8_14 CD3E Exon 8 - xp11:118314467-118314492 CAUAGUCUGGGUUGGGAACAGGUGG 697 916_8_15 CD3E Exon 8 - xp11:118314470-118314495 CCUCAUAGUCUGGGUUGGGAACAGG 698 916_8_16 CD3E Exon 8 - xp11:118314473-118314498 UUACCUCAUAGUCUGGGUUGGGAAC 699 916_8_17 CD3E Exon 8 - xp11:118314479-118314504 CCCACGUUACCUCAUAGUCUGGGUU 700 916_8_18 CD3E Exon 8 - xp11:118314480-118314505 UCCCACGUUACCUCAUAGUCUGGU 701 916_8_19 CD3E Exon 8 - xp11:118314484-118314509 UCUUAUCCCACGUUACCUCAUAGCU 702 916_8_20 CD3E Exon 8 - xp11:118314485-118314510 UUCUAUCCCACGUUACCUCAUAGUC 703 916_9_1 CD3E Exon 9 + xp11:118315466-118315491 CUCUCUAUUUCACCCCCAGCCCAUC 704 916_9_2 CD3E Exon 9 + xp11:118315471-118315496 UAUUUCACCCCCAGCCCAUCCGGAA 705 916_9_3 CD3E Exon 9 + xp11:118315478-118315503 CCCCCAGCCCAUCCGGAAAGGCCAG 706 916_9_4 CD3E Exon 9 + xp11:118315479-118315504 CCCCAGCCCAUCCGGAAAGGCCAGC 707 916_9_5 CD3E Exon 9 + xp11:118315492-118315517 GGAAAGGCCAGCGGGACCUGUAUUC 708 916_9_6 CD3E Exon 9 + xp11:118315522-118315547 UGAAUCAGAGACGCAUCUGACCCUC 709 916_9_7 CD3E Exon 9 + xp11:118315542-118315567 CCCUCUGGAGAACACUGCCUCCCGC 710 916_9_8 CD3E Exon 9 + xp11:118315548-118315573 GGAGAACACCUGCCUCCCGCUGGCCC 711 916_9_9 CD3E Exon 9 + xp11:118315586-118315611 AGUCCCCCUGCGACUCCCUGUUUCC 712 916_9_10 CD3E Exon 9 + xp11:118315587-118315612 GUCCCCCUGCGACUCCCUGUUUCCU 713 916_9_11 CD3E Exon 9 + xp11:118315597-118315622 GACUCCCUGUUUCCUGGGCUAGUCU 714 916_9_12 CD3E Exon 9 + xp11:118315632-118315657 GAGAGAGAAUCGUUCCUCAGCCUCA 715 916_9_13 CD3E Exon 9 + xp11:118315689-118315714 GCUCCCUCCUCCCUGCCUUCUCUGC 716 916_9_14 CD3E Exon 9 + xp11:118315760-118315785 UCAUCAGUAGUCACACCCUCACAGC 717 916_9_15 CD3E Exon 9 + xp11:118315777-118315802 CUCACAGCUGGCCUGCCCUCUUGCC 718 916_9_16 CD3E Exon 9 + xp11:118315812-118315837 UUUGUGCUAUUCACUCCCUUCCCUU 719 916_9_17 CD3E Exon 9 + xp11:118315921-118315946 CGCCGUCCCCUUUUGCAGCCCUCUC 720 916_9_18 CD3E Exon 9 + xp11:118315922-118315947 GCCGUCCCCUUUUGCAGCCCUCUCU 721 916_9_19 CD3E Exon 9 + xp11:118315923-118315948 CCGUCCCCUUUUGCAGCCCUCUCUG 722 916_9_20 CD3E Exon 9 + xp11:118315927-118315952 CCCCUUUUGCAGCCCUCUCUGGGGA 723 916_9_21 CD3E Exon 9 + xp11:118315932-118315957 UUUGCAGCCCUCUCUGGGGAUGGAC 724 916_9_22 CD3E Exon 9 + xp11:118315933-118315958 UUGCAGCCCUCUCUGGGGAUGGACU 725 916_9_23 CD3E Exon 9 + xp11:118315949-118315974 GGAUGGACUGGGUAAAUGUUGACAG 726 916_9_24 CD3E Exon 9 + xp11:118315973-118315998 GAGGCCCUGCCCCGUUCACAGAUCC 727 916_9_25 CD3E Exon 9 + xp11:118316062-118316087 ACUCCCUCCACCCCCCCUCCACUGU 728 916_9_26 CD3E Exon 9 + xp11:118316069-118316094 CCACCCCCCCUCCACUGUAGGCCAC 729 916_9_27 CD3E Exon 9 + xp11:118316073-118316098 CCCCCCUCCACUGUAGGCCACUGGA 730 916_9_28 CD3E Exon 9 + xp11:118316139-118316164 GAGAGAGAAAAAAAUAAACUGUAUU 731 916_9_29 CD3E Exon 9 - xp11:118315465-118315490 AUGGGCUGGGGGUGAAAUAGAGAGG 732 916_9_30 CD3E Exon 9 - xp11:118315466-118315491 GAUGGGCUGGGGGUGAAAUAGAGAG 733 916_9_31 CD3E Exon 9 - xp11:118315467-118315492 GGAUGGGCUGGGGGUGAAAUAGAGA 734 916_9_32 CD3E Exon 9 - xp11:118315468-118315493 CGGAUGGGCUGGGGGUGAAAUAGAG 735 916_9_33 CD3E Exon 9 - xp11:118315481-118315506 CCGCUGGCCUUUCCGGAUGGGCUGG 736 916_9_34 CD3E Exon 9 - xp11:118315482-118315507 CCCGCUGGCCUUUCCGGAUGGGCUG 737 916_9_35 CD3E Exon 9 - xp11:118315483-118315508 UCCCGCUGGCCUUUCCGGAUGGGCU 738 916_9_36 CD3E Exon 9 - xp11:118315484-118315509 GUCCCGCUGGCCUUUCCGGAUGGGC 739 916_9_37 CD3E Exon 9 - xp11:118315488-118315513 ACAGGUCCCGCUGGCCUUUCCGGAU 740 916_9_38 CD3E Exon 9 - xp11:118315489-118315514 UACAGGUCCCGCUGGCCUUUCCGGA 741 916_9_39 CD3E Exon 9 - xp11:118315493-118315518 AGAAUACAGGUCCCGCUGGCCUUUC 742 916_9_40 CD3E Exon 9 - xp11:118315502-118315527 AUUCAGGCCAGAAUACAGGUCCCGC 743 916_9_41 CD3E Exon 9 - xp11:118315511-118315536 GCGUCUCUGAUUCAGGCCAGAAUAC 744 916_9_42 CD3E Exon 9 - xp11:118315523-118315548 AGAGGGUCAGAUGCGUCUCUGAUUC 745 916_9_43 CD3E Exon 9 - xp11:118315545-118315570 CCAGCGGGAGGCAGUGUUCUCCAGA 746 916_9_44 CD3E Exon 9 - xp11:118315546-118315571 GCCAGCGGGAGGCAGUGUUCUCCAG 747 916_9_45 CD3E Exon 9 - xp11:118315562-118315587 UGGAGAGGAGACCUGGGCCAGCGGG 748 916_9_46 CD3E Exon 9 - xp11:118315565-118315590 GACUGGAGAGGAGACCUGGGCCAGC 749 916_9_47 CD3E Exon 9 - xp11:118315566-118315591 GGACUGGAGAGGAGACCUGGGCCAG 750 916_9_48 CD3E Exon 9 - xp11:118315573-118315598 CGCAGGGGGACUGGAGAGGAGACCU 751 916_9_49 CD3E Exon 9 - xp11:118315574-118315599 UCGCAGGGGGACUGGAGAGGAGACC 752 916_9_50 CD3E Exon 9 - xp11:118315582-118315607 ACAGGGAGUCCGCAGGGGGACUGGAG 753 916_9_51 CD3E Exon 9 - xp11:118315587-118315612 AGGAAAACAGGGAGUCCGCAGGGGGAC 754 916_9_52 CD3E Exon 9 - xp11:118315592-118315617 AGCCCAGGAAAACAGGGAGUCCGCAGG 755 916_9_53 CD3E Exon 9 - xp11:118315593-118315618 UAGCCCAGGAAAACAGGGAGUCCGCAG 756 916_9_54 CD3E Exon 9 - xp11:118315594-118315619 CUAGCCCAGGAAAACAGGGAGUCGCA 757 916_9_55 CD3E Exon 9 - xp11:118315595-118315620 ACUAGCCCAGGAAAACAGGGAGUCGC 758 916_9_56 CD3E Exon 9 - xp11:118315604-118315629 GGGUCCAAGACUAGCCCAGGAAACA 759 916_9_57 CD3E Exon 9 - xp11:118315605-118315630 GGGGUCCAAGACUAGCCCAGGAAAC 760 916_9_58 CD3E Exon 9 - xp11:118315612-118315637 CUCUCGUGGGGUCCAAGACUAGCCCC 761 916_9_59 CD3E Exon 9 - xp11:118315629-118315654 GGCUGAGGAACGAUUCUCUCUCGUG 762 916_9_60 CD3E Exon 9 - xp11:118315630-118315655 AGGCUGAGGAACGAUUCUCUCGU 763 916_9_61 CD3E Exon 9 - xp11:118315631-118315656 GAGGCUGAGGAACGAUUUCUCUCCG 764 916_9_62 CD3E Exon 9 - xp11:118315649-118315674 UCCCGCGGAGUUCACCAUGAGGCUG 765 916_9_63 CD3E Exon 9 - xp11:118315655-118315680 CCGACCUCCCGCGGAGUUCACCAUG 766 916_9_64 CD3E Exon 9 - xp11:118315722-118315747 GAGGAAGCAGCAAUAUUUUAGGACU 767 916_9_65 CD3E Exon 9 - xp11:118315723-118315748 AGAGGAAGCAGCAAUAUUUUAGGAC 768 916_9_66 CD3E Exon 9 - xp11:118315728-118315753 AAGGAAGAGGAAGCAGCAAUAUUUU 769 916_9_67 CD3E Exon 9 - xp11:118315746-118315771 ACUACUGAUGAUGCUUCAAAGGAAG 770 916_9_68 CD3E Exon 9 - xp11:118315752-118315777 GGUGUGACUACUGAUGAUGCUUCAA 771 916_9_69 CD3E Exon 9 - xp11:118315778-118315803 UGGCAAGAGGGCAGGCCAGCUGUGA 772 916_9_70 CD3E Exon 9 - xp11:118315779-118315804 CUGGCAAGAGGGCAGGCCAGCUGUG 773 916_9_71 CD3E Exon 9 - xp11:118315791-118315816 CAAAUAAAUAUCCUGGCAAGAGGGC 774 916_9_72 CD3E Exon 9 - xp11:118315795-118315820 AGCACAAAUAAAUAUCCUGGCAAGA 775 916_9_73 CD3E Exon 9 - xp11:118315796-118315821 UAGCACAAAUAAAUAUCCUGGCAAG 776 916_9_74 CD3E Exon 9 - xp11:118315803-118315828 GAGUGAAUAGCACAAAAUAAAUAUCC 777 916_9_75 CD3E Exon 9 - xp11:118315830-118315855 ACGGAGAAGUUACAUCCAAAGGGAA 778 916_9_76 CD3E Exon 9 - xp11:118315831-118315856 AACGGAGAAGUUACAUCCAAAGGGA 779 916_9_77 CD3E Exon 9 - xp11:118315835-118315860 ACUGAACGGAGAAGUUACAUCCAAA 780 916_9_78 CD3E Exon 9 - xp11:118315836-118315861 AACUGAACGGAGAAGUUACAUCCAA 781 916_9_79 CD3E Exon 9 - xp11:118315854-118315879 CAUGCAAGAAAAGGAGGGAACUGAA 782 916_9_80 CD3E Exon 9 - xp11:118315864-118315889 GGACAACUUCAUGCAAGAAAAGGA 783 916_9_81 CD3E Exon 9 - xp11:118315865-118315890 GGGACAAACUUACAUGCAAGAAAAGG 784 916_9_82 CD3E Exon 9 - xp11:118315868-118315893 UGGGGGACAACUUACAUGCAAGAAA 785 916_9_83 CD3E Exon 9 - xp11:118315890-118315915 AAGUAGAUGGAAUACUUUGGGAUGG 786 916_9_84 CD3E Exon 9 - xp11:118315891-118315916 AAAGUAGAUGGAAUACUUUGGGAUG 787 916_9_85 CD3E Exon 9 - xp11:118315892-118315917 AAAAGUAGAUGGAAUACUUUGGGAU 788 916_9_86 CD3E Exon 9 - xp11:118315893-118315918 GAAAAGUAGAUGGAAUACUUUGGGA 789 916_9_87 CD3E Exon 9 - xp11:118315897-118315922 GAUGAAAAAGUAGAUGGAAUACUUU 790 916_9_88 CD3E Exon 9 - xp11:118315898-118315923 CGAUGAAAAAGUAGAUGGAAUACUU 791 916_9_89 CD3E Exon 9 - xp11:118315908-118315933 AAGGGGACGGCGAUAGAAAAGUAGA 792 916_9_90 CD3E Exon 9 - xp11:118315926-118315951 CCCCAGAGAGGGCUGCAAAAGGGGA 793 916_9_91 CD3E Exon 9 - xp11:118315930-118315955 CCAUCCCCAGAGAGGGCUGCAAAAG 794 916_9_92 CD3E Exon 9 - xp11:118315931-118315956 UCCAUCCCCAGAGAGGGCUGCAAAA 795 916_9_93 CD3E Exon 9 - xp11:118315932-118315957 GUCCAUCCCCAGAGAGGGCUGCAAA 796 916_9_94 CD3E Exon 9 - xp11:118315942-118315967 CAUUUACCCAGUCCAUCCCAGAGA 797 916_9_95 CD3E Exon 9 - xp11:118315943-118315968 ACAUUUACCCAGUCCAUCCCCAGAG 798 916_9_96 CD3E Exon 9 - xp11:118315980-118316005 AGGGCCAGGAUCUGUGAACGGGGCA 799 916_9_97 CD3E Exon 9 - xp11:118315981-118316006 CAGGGCCAGGAUCUGUGAACGGGGC 800 916_9_98 CD3E Exon 9 - xp11:118315985-118316010 GGCUCAGGGCCAGGAUCUGUGAACG 801 916_9_99 CD3E Exon 9 - xp11:118315986-118316011 UGGCUCAGGGCCAGGAUCUGUGAAC 802 916_9_100 CD3E Exon 9 - xp11:118315987-118316012 CUGGCUCAGGGCCAGGAUCUGUGAA 803 916_9_101 CD3E Exon 9 - xp11:118315999-118316024 AGGAGCACAGGGCUGGCUCAGGGCC 804 916_9_102 CD3E Exon 9 - xp11:118316004-118316029 GAGGGAGGAGCACAGGGCUGGCUCA 805 916_9_103 CD3E Exon 9 - xp11:118316005-118316030 GGAGGGAGGAGCACAGGGCUGGCUC 806 916_9_104 CD3E Exon 9 - xp11:118316011-118316036 GUUGGGGGAGGGAGGAGCACAGGGC 807 916_9_105 CD3E Exon 9 - xp11:118316015-118316040 GAGUGUUGGGGGAGGGAGGAGCACA 808 916_9_106 CD3E Exon 9 - xp11:118316016-118316041 GGAGUGUUGGGGGAGGGAGGAGCAC 809 916_9_107 CD3E Exon 9 - xp11:118316024-118316049 GUUGGUAGGGAGUGUUGGGGGAGGG 810 916_9_108 CD3E Exon 9 - xp11:118316027-118316052 GGGGUUGGUAGGGAGUGUUGGGGGA 811 916_9_109 CD3E Exon 9 - xp11:118316028-118316053 GGGGGUUGGUAGGGAGUGUUGGGGG 812 916_9_110 CD3E Exon 9 - xp11:118316031-118316056 UUAGGGGGUUGGUAGGGAGUGUUGG 813 916_9_111 CD3E Exon 9 - xp11:118316032-118316057 AUUAGGGGGUUGGUAGGGAGUGUUG 814 916_9_112 CD3E Exon 9 - xp11:118316033-118316058 GAUUAGGGGGUUGGUAGGGAGUGUU 815 916_9_113 CD3E Exon 9 - xp11:118316034-118316059 GGAUUAGGGGGUUGGUAGGGAGUGU 816 916_9_114 CD3E Exon 9 - xp11:118316042-118316067 GGAGUAGGGGAUUAGGGGGUUGGUA 817 916_9_115 CD3E Exon 9 - xp11:118316043-118316068 GGGAGUAGGGGAUUAGGGGGUUGGU 818 916_9_116 CD3E Exon 9 - xp11:118316047-118316072 UGGAGGGAGUAGGGGAUUAGGGGGU 819 916_9_117 CD3E Exon 9 - xp11:118316051-118316076 GGGGUGGAGGGAGUAGGGGAUUAGG 820 916_9_118 CD3E Exon 9 - xp11:118316052-118316077 GGGGGUGGAGGGAGUAGGGGAUUAG 821 916_9_119 CD3E Exon 9 - xp11:118316053-118316078 GGGGGGUGGAGGGAGUAGGGGAUUA 822 916_9_120 CD3E Exon 9 - xp11:118316054-118316079 GGGGGGGUGGAGGGAGUAGGGGAUU 823 916_9_121 CD3E Exon 9 - xp11:118316060-118316085 AGUGGAGGGGGGGUGGAGGGAGUAG 824 916_9_122 CD3E Exon 9 - xp11:118316061-118316086 CAGUGGAGGGGGGGUGGAGGGAGUA 825 916_9_123 CD3E Exon 9 - xp11:118316062-118316087 ACAGUGGAGGGGGGGUGGAGGGAGU 826 916_9_124 CD3E Exon 9 - xp11:118316068-118316093 UGGCCUACAGUGGAGGGGGGGUGGA 827 916_9_125 CD3E Exon 9 - xp11:118316069-118316094 GUGGCCUACAGUGGAGGGGGGGUGG 828 916_9_126 CD3E Exon 9 - xp11:118316072-118316097 CCAGUGGCCUACAGUGGAGGGGGGG 829 916_9_127 CD3E Exon 9 - xp11:118316075-118316100 CAUCCAGUGGCCUACAGUGGAGGGG 830 916_9_128 CD3E Exon 9 - xp11:118316076-118316101 CCAUCCAGUGGCCUACAGUGGAGGG 831 916_9_129 CD3E Exon 9 - xp11:118316077-118316102 ACCAUCCAGUGGCCUACAGUGGAGG 832 916_9_130 CD3E Exon 9 - xp11:118316078-118316103 GACCAUCCAGUGGCCUACAGUGGAG 833 916_9_131 CD3E Exon 9 - xp11:118316079-118316104 UGACCAUCCAGUGGCCUACAGUGGA 834 916_9_132 CD3E Exon 9 - xp11:118316080-118316105 AUGACCAUCCAGUGGCCUACAGUGG 835 916_9_133 CD3E Exon 9 - xp11:118316083-118316108 CAAAUGACCAUCCAGUGGCCUACAG 836 916_9_134 CD3E Exon 9 - xp11:118316093-118316118 UACGGAGAUGCAAAUGACCAUCCAG 837 916_9_135 CD3E Exon 9 - xp11:118316116-118316141 UCAGCUGAGGAGCAGAGCACAUUUA 838 916_9_136 CD3E Exon 9 - xp11:118316134-118316159 AGUUUAUUUUUUUCUCUCUCAGCUG 839 917_1_1 CD3G Exon 1 + xp11:118344359-118344384 AGGCUGGCUGGCUGGCUGGCUGCUA 840 917_1_2 CD3G Exon 1 + xp11:118344360-118344385 GGCUGGCUGGCUGGCUGGCUGCUAA 841 917_1_3 CD3G Exon 1 + xp11:118344380-118344405 GCUAAGGGCUGCUCCACGCUUUUGC 842 917_1_4 CD3G Exon 1 + xp11:118344383-118344408 AAGGGCUGCUCCACGCUUUUGCCGG 843 917_1_5 CD3G Exon 1 + xp11:118344399-118344424 UUUUGCCGGAGGACAGAGACUGACA 844 917_1_6 CD3G Exon 1 + xp11:118344405-118344430 CGGAGGACAGAGACUGACAUGGAAC 845 917_1_7 CD3G Exon 1 + xp11:118344406-118344431 GGAGGACAGAGACUGACAUGGAACA 846 917_1_8 CD3G Exon 1 + xp11:118344407-118344432 GAGGACAGAGACUGACAUGGAACAG 847 917_1_9 CD3G Exon 1 + xp11:118344411-118344436 ACAGAGACUGACAUGGAACAGGGGA 848 917_1_10 CD3G Exon 1 + xp11:118344412-118344437 CAGAGACUGACAUGGAACAGGGGAA 849 917_1_11 CD3G Exon 1 + xp11:118344417-118344442 ACUGACAUGGAACAGGGGAAGGGCC 850 917_1_12 CD3G Exon 1 + xp11:118344432-118344457 GGGAAGGGCCUGGCUGUCCUCAUCC 851 917_1_13 CD3G Exon 1 + xp11:118344451-118344476 UCAUCCUGGCUAUCAUUCUUCUUCA 852 917_1_14 CD3G Exon 1 + xp11:118344456-118344481 CUGGCUAUCAUUCUUCUUCAAGGUA 853 917_1_15 CD3G Exon 1 + xp11:118344457-118344482 UGGCUAUCAUUCUUCUUCAAGGUAA 854 917_1_16 CD3G Exon 1 + xp11:118344466-118344491 UUCUUCUUCAAGGUAAGGGCCUACU 855 917_1_17 CD3G Exon 1 + xp11:118344467-118344492 UCUUCUUCAAGGUAAGGGCCUACUA 856 917_1_18 CD3G Exon 1 + xp11:118344468-118344493 CUUCUUCAAGGUAAGGGCCUACUAG 857 917_1_19 CD3G Exon 1 + xp11:118344473-118344498 UCAAGGUAAGGGCCUACUAGGGGUC 858 917_1_20 CD3G Exon 1 - xp11:118344323-118344348 UCACUGGCUCCACCCAUCACUGUUG 859 917_1_21 CD3G Exon 1 - xp11:118344324-118344349 AUCACUGGCUCCACCCAUCACUGUU 860 917_1_22 CD3G Exon 1 - xp11:118344325-118344350 GAUCACUGGCUCCACCCAUCACUGU 861 917_1_23 CD3G Exon 1 - xp11:118344344-118344369 GUCGGUCGGACACGUCGUCGAUCAC 862 917_1_24 CD3G Exon 1 - xp11:118344396-118344421 CAGUCUCUGUCCUCCGGCAAAAGCG 863 917_1_25 CD3G Exon 1 - xp11:118344407-118344432 CUGUUCCAUGUCAGUCUCUGUCCUC 864 917_1_26 CD3G Exon 1 - xp11:118344443-118344468 AAUGAUAGCCAGGAUGAGGACAGCC 865 917_1_27 CD3G Exon 1 - xp11:118344452-118344477 UUGAAGAAGAAUGAUAGCCAGGAUG 866 917_1_28 CD3G Exon 1 - xp11:118344458-118344483 CUUACCUUGAAGAAGAAUGAUAGCC 867 917_2_1 CD3G Exon 2 + xp11:118349007-118349032 CUCUCUUCUGUCUUUACAGGUACUU 868 917_2_2 CD3G Exon 2 + xp11:118349023-118349048 CAGGUACCUUUGGCCCAGUCAAUCAA 869 917_2_3 CD3G Exon 2 + xp11:118349027-118349052 UACUUUGGCCCAGUCAAUCAAAGGU 870 917_2_4 CD3G Exon 2 + xp11:118349035-118349060 CCCAGUCAAUCAAAGGUAGGAGAAA 871 917_2_5 CD3G Exon 2 - xp11:118349038-118349063 CCAUUUCUCCUACCUUUGAUUGACU 872 917_2_6 CD3G Exon 2 - xp11:118349039-118349064 GCCAUUUCUCCUACCUUUGAUUGAC 873 917_3_1 CD3G Exon 3 + xp11:118349726-118349751 GCUUUUCUCAUUUCAGGAAACCACU 874 917_3_2 CD3G Exon 3 + xp11:118349732-118349757 CUCAUUUCAGGAAACCCACUUGGUUA 875 917_3_3 CD3G Exon 3 + xp11:118349754-118349779 UUAAGGUGUAUGACUAUCAAGAAGA 876 917_3_4 CD3G Exon 3 + xp11:118349759-118349784 GUGUAUGACUAUCAAGAGAUGGUU 877 917_3_5 CD3G Exon 3 + xp11:118349800-118349825 UGAUGCAGAAGCCAAAAAUAUCACA 878 917_3_6 CD3G Exon 3 + xp11:118349811-118349836 CCAAAAAUAUCACAUGGUUUAAAGA 879 917_3_7 CD3G Exon 3 + xp11:118349812-118349837 CAAAAUAUCACAUGGUUUAAAGAU 880 917_3_8 CD3G Exon 3 + xp11:118349823-118349848 CAUGGUUUAAAGAUGGGAAGAUGAU 881 917_3_9 CD3G Exon 3 + xp11:118349851-118349876 CUUCCUAACUGAAGAUAAAAAAAAAA 882 917_3_10 CD3G Exon 3 + xp11:118349858-118349883 ACUGAAGAUAAAAAAAAAUGGAAUUC 883 917_3_11 CD3G Exon 3 + xp11:118349859-118349884 CUGAAGAUAAAAAAAAAUGGAAUCU 884 917_3_12 CD3G Exon 3 + xp11:118349873-118349898 AAAUGGAAUCUGGGAAGUAAUGCCA 885 917_3_13 CD3G Exon 3 + xp11:118349883-118349908 UGGGAAGUAAUGCCAAGGACCCUCG 886 917_3_14 CD3G Exon 3 + xp11:118349884-118349909 GGGAAGUAAUGCCAAGGACCCUCGA 887 917_3_15 CD3G Exon 3 + xp11:118349901-118349926 ACCCUCGAGGGAUGUAUCAGUGUAA 888 917_3_16 CD3G Exon 3 + xp11:118349960-118349985 UAUUACAGAAGUAUGUAAUCCCCUU 889 917_3_17 CD3G Exon 3 - xp11:118349724-118349749 UGGUUUCCUGAAAUGAGAAAAGCCG 890 917_3_18 CD3G Exon 3 - xp11:118349749-118349774 UUGAUAGUCAUACACCUUAACCAAG 891 917_3_19 CD3G Exon 3 - xp11:118349814-118349839 CCAUCUUUAAACCAUGUGAUAUUUU 892 917_3_20 CD3G Exon 3 - xp11:118349857-118349882 AUUCCAUUUUUUUUUAUCUUCAGUU 893 917_3_21 CD3G Exon 3 - xp11:118349898-118349923 CACUGAUACAUCCCUCGAGGGUCCU 894 917_3_22 CD3G Exon 3 - xp11:118349905-118349930 UCCUUUACACUGAUACAUCCCUCGA 895 917_3_23 CD3G Exon 3 - xp11:118349906-118349931 AUCCUUUACACUGAUACAUCCCUCG 896 917_3_24 CD3G Exon 3 - xp11:118349951-118349976 ACAUACUUCUGUAAUACACUUGGAG 897 917_3_25 CD3G Exon 3 - xp11:118349956-118349981 GGAUUACAUACUUCUGUAAUACACU 898 917_4_1 CD3G Exon 4 + xp11:118350566-118350591 UUGAACUAAAUGCAGCCACCAUAUC 899 917_4_2 CD3G Exon 4 + xp11:118350611-118350636 UCGUCAGCAUUUUCGUCCUUGCUGU 900 917_4_3 CD3G Exon 4 + xp11:118350612-118350637 CGUCAGCAUUUUCGUCCUUGCUGUU 901 917_4_4 CD3G Exon 4 + xp11:118350613-118350638 GUCAGCAUUUUCGUCCUUGCUGUUG 902 917_4_5 CD3G Exon 4 + xp11:118350629-118350654 UUGCUGUUGGGGUCUACUUCAUUGC 903 917_4_6 CD3G Exon 4 + xp11:118350634-118350659 GUUGGGGUCUACUUCAUUGCUGGAC 904 917_4_7 CD3G Exon 4 + xp11:118350638-118350663 GGGUCUACUUCAUUGCUGGACAGGA 905 917_4_8 CD3G Exon 4 + xp11:118350656-118350681 GACAGGAUGGAGUUCGCCAGUCGAG 906 917_4_9 CD3G Exon 4 - xp11:118350540-118350565 GCAGUUCUGACACACUGUAGGGAAA 907 917_4_10 CD3G Exon 4 - xp11:118350546-118350571 UUCAAUGCAGUUCUGACACACUGUA 908 917_4_11 CD3G Exon 4 - xp11:118350547-118350572 GUUCAAUGCAGUUCUGACACACUGU 909 917_4_12 CD3G Exon 4 - xp11:118350584-118350609 UCAGCAAAGAGAAAGCCAGAUAUGG 910 917_4_13 CD3G Exon 4 - xp11:118350587-118350612 AUUUCAGCAAAGAGAAAGCCAGAUA 911 917_4_14 CD3G Exon 4 - xp11:118350630-118350655 AGCAAUGAAGUAGACCCCCAACAGCA 912 917_4_15 CD3G Exon 4 - xp11:118350675-118350700 UAAGAGCAUUCUUUUACCCUCGAC 913 917_5_1 CD3G Exon 5 + xp11:118351644-118351669 CUGUUGCCCAAUGACCAGCUCUACC 914 917_5_2 CD3G Exon 5 + xp11:118351649-118351674 GCCCAAUGACCAGCUCUACCAGGUA 915 917_5_3 CD3G Exon 5 + xp11:118351650-118351675 CCCAAUGACCAGCUCUACCAGGUAA 916 917_5_4 CD3G Exon 5 + xp11:118351651-118351676 CCAAUGACCAGCUCUACCAGGUAAG 917 917_5_5 CD3G Exon 5 - xp11:118351653-118351678 CCCUUACCUGGUAGAGCUGGUCAUU 918 917_5_6 CD3G Exon 5 - xp11:118351654-118351679 CCCCUUACCUGGUAGAGCUGGUCAU 919 917_5_7 CD3G Exon 5 - xp11:118351661-118351686 UCUUCAUCCCCCUUACCUGGUAGAGGC 920 917_5_8 CD3G Exon 5 - xp11:118351670-118351695 CUCUUUUAUUCUUCAUCCCCUUACC 921 917_6_1 CD3G Exon 6 + xp11:118352385-118352410 CUGUGCUGUCCUUUCCAGCCCCUCA 922 917_6_2 CD3G Exon 6 + xp11:118352419-118352444 AAGAUGACCCAGUACAGCCACCUUCA 923 917_6_3 CD3G Exon 6 + xp11:118352432-118352457 CAGCCACCUUCAAGGAAACCAGUUG 924 917_6_4 CD3G Exon 6 + xp11:118352435-118352460 CCACCUUCAAGGAAAACCAGUUGAGG 925 917_6_5 CD3G Exon 6 + xp11:118352448-118352473 AACCAGUUGAGGAGGAAUUGAACUC 926 917_6_6 CD3G Exon 6 + xp11:118352460-118352485 AGGAAUUGAACUCAGGACUCAGAGU 927 917_6_7 CD3G Exon 6 + xp11:118352463-118352488 AAUUGAACUCAGGACUCAGAGUAGG 928 917_6_8 CD3G Exon 6 + xp11:118352464-118352489 AUUGAACUCAGGACUCAGAGUAGGU 929 917_6_9 CD3G Exon 6 - xp11:118352397-118352422 CUUCUCGAUCCUUGAGGGGCUGGAA 930 917_6_10 CD3G Exon 6 - xp11:118352402-118352427 GUCAUCUUCUCGAUCCUUGAGGGGC 931 917_6_11 CD3G Exon 6 - xp11:118352406-118352431 ACUGGUCAUCUUCUCGAUCCUUGAG 932 917_6_12 CD3G Exon 6 - xp11:118352407-118352432 UACUGGUCAUCUUCUCGAUCCUUGA 933 917_6_13 CD3G Exon 6 - xp11:118352408-118352433 GUACUGGUCAUCUUCUCGAUCCUUG 934 917_6_14 CD3G Exon 6 - xp11:118352429-118352454 CUGGUUUCCUUGAAGGUGGCUGUAC 935 917_6_15 CD3G Exon 6 - xp11:118352438-118352463 CCUCCUCAACUGGUUUCCUUGAAGG 936 917_6_16 CD3G Exon 6 - xp11:118352441-118352466 AUUCCUCCUCAACUGGUUUCCUUGA 937 917_6_17 CD3G Exon 6 - xp11:118352453-118352478 GUCCUGAGUUCAAUUCCUCCUCAAC 938 917_7_1 CD3G Exon 7 + xp11:118353096-118353121 AUUGCAAUUUUUCUUUUUUCAGUCC 939 917_7_2 CD3G Exon 7 + xp11:118353142-118353167 UUCCCAGAAUCAAAGCAAUGCAUUU 940 917_7_3 CD3G Exon 7 + xp11:118353188-118353213 ACUUUCAGCCCUAAAUCUAGACUCCA 941 917_7_4 CD3G Exon 7 + xp11:118353208-118353233 ACUCAAGGUUCCCAGAGAUGACAAA 942 917_7_5 CD3G Exon 7 + xp11:118353218-118353243 CCCAGAGAUGACAAAUGGAGAAGAA 943 917_7_6 CD3G Exon 7 + xp11:118353236-118353261 AGAAAAAGGCCAUCAGAGCAAAUU 944 917_7_7 CD3G Exon 7 + xp11:118353237-118353262 GAAGAAAGGCCAUCAGAGCAAAUUU 945 917_7_8 CD3G Exon 7 + xp11:118353238-118353263 AAGAAAGGCCAUCAGAGCAAAUUUG 946 917_7_9 CD3G Exon 7 + xp11:118353239-118353264 AGAAAGGCCAUCAGCAAAUUUGG 947 917_7_10 CD3G Exon 7 + xp11:118353298-118353323 ACUGUGUUUCAGAAGCGCCACCUAU 948 917_7_11 CD3G Exon 7 + xp11:118353299-118353324 CUGUGUUUCAGAAGCGCCACCUAUU 949 917_7_12 CD3G Exon 7 + xp11:118353300-118353325 UGUGUUUCAGAAGCGCCACCUAUUG 950 917_7_13 CD3G Exon 7 + xp11:118353342-118353367 AAAAUGAAAAGAUCAAAUAACCCCC 951 917_7_14 CD3G Exon 7 - xp11:118353122-118353147 GGGAACUGAAUAGGAGGAGAACACCC 952 917_7_15 CD3G Exon 7 - xp11:118353133-118353158 GCUUUGAUUCUGGGAACUGAAUAGG 953 917_7_16 CD3G Exon 7 - xp11:118353136-118353161 AUUGCUUUGAUUCUGGGAACUGAAU 954 917_7_17 CD3G Exon 7 - xp11:118353147-118353172 UUCCAAAAUGCAUUGCUUUGAUUCCU 955 917_7_18 CD3G Exon 7 - xp11:118353148-118353173 UUUCCAAAAUGCAUUGCUUUGAUUC 956 917_7_19 CD3G Exon 7 - xp11:118353179-118353204 AUUUAGGGCUGAAAGUCUCUCUGCU 957 917_7_20 CD3G Exon 7 - xp11:118353199-118353224 UCUGGGAACCUUGAGUCUAGAUUUA 958 917_7_21 CD3G Exon 7 - xp11:118353200-118353225 CUCUGGGAACCUUGAGUCUAGAUUU 959 917_7_22 CD3G Exon 7 - xp11:118353221-118353246 CCUUUCUUCUCCAUUUGUCAUCUCU 960 917_7_23 CD3G Exon 7 - xp11:118353222-118353247 GCCUUUCUUCUCCAUUUGUCAUCUC 961 917_7_24 CD3G Exon 7 - xp11:118353249-118353274 UGAGAAACCCCCAAAUUUGCUCUGA 962 917_7_25 CD3G Exon 7 - xp11:118353318-118353343 UUCUUUUACAAUUUUCCCCAAUAGG 963 917_7_26 CD3G Exon 7 - xp11:118353321-118353346 UUUUUCUUUUACAAUUUUCCCCAAU 964 917_7_27 CD3G Exon 7 - xp11:118353365-118353390 ACAAAAAAUUAUAUUCAAAUCCAGG 965 917_7_28 CD3G Exon 7 - xp11:118353366-118353391 CACAAAAAAUUAUAUUCAAAUCCAG 966 917_7_29 CD3G Exon 7 - xp11:118353367-118353392 ACACAAAAAAUUAUAUUCAAAUUCCA 967 917_7_30 CD3G Exon 7 - xp11:118353368-118353393 AACACAAAAAAUUAUAUUCAAAUCC 968 3105_1_1 HLA-A Exon 1 + xp6:29942466-29942491 CCAGAGAAGCCAAUCAGUGUCGUCG 969 3105_1_2 HLA-A Exon 1 + xp6:29942498-29942523 UGUUCUAAAGCCCGCACGCACCCAC 970 3105_1_3 HLA-A Exon 1 + xp6:29942499-29942524 GUUCUAAAGCCCGCACGCACCCACC 971 3105_1_4 HLA-A Exon 1 + xp6:29942525-29942550 GGACUCAGAUUCUCCCCAGACGCCG 972 3105_1_5 HLA-A Exon 1 + xp6:29942529-29942554 UCAGAUUCUCCCCAGACGCCGAGGA 973 3105_1_6 HLA-A Exon 1 + xp6:29942538-29942563 CCCCAGACGCCGAGGAUGGCCGUCA 974 3105_1_7 HLA-A Exon 1 + xp6:29942568-29942593 CCCCGAACCCUCCUCCUGCUACUCU 975 3105_1_8 HLA-A Exon 1 + xp6:29942569-29942594 CCCGAACCCUCCUCCUGCUACUCUC 976 3105_1_9 HLA-A Exon 1 + xp6:29942570-29942595 CCGAACCCUCCUCCUGCUACUCUCG 977 3105_1_10 HLA-A Exon 1 + xp6:29942571-29942596 CGAACCCUCCUCCUGCUACUCUCGG 978 3105_1_11 HLA-A Exon 1 + xp6:29942577-29942602 CUCCUCCUGCUACUCUCGGGGGCCC 979 3105_1_12 HLA-A Exon 1 + xp6:29942594-29942619 GGGGGCCCUGGCCCUGACCCAGACC 980 3105_1_13 HLA-A Exon 1 + xp6:29942595-29942620 GGGGCCCUGGCCCUGACCCAGACCCU 981 3105_1_14 HLA-A Exon 1 + xp6:29942598-29942623 GCCCUGGCCCUGACCCAGACCCUGGG 982 3105_1_15 HLA-A Exon 1 + xp6:29942599-29942624 CCCUGGCCCUGACCCAGACCCUGGGC 983 3105_1_16 HLA-A Exon 1 + xp6:29942608-29942633 UGACCCAGACCCUGGGCGGGUGAGUG 984 3105_1_17 HLA-A Exon 1 + xp6:29942609-29942634 GACCCAGACCUGGGCGGGUGAGUGC 985 3105_1_18 HLA-A Exon 1 + xp6:29942610-29942635 ACCCAGACCUGGGCGGGUGAGUGCG 986 3105_1_19 HLA-A Exon 1 + xp6:29942614-29942639 AGACCUGGGCGGGUGAGUGCGGGGU 987 3105_1_20 HLA-A Exon 1 + xp6:29942615-29942640 GACCUGGGCGGGUGAGUGCGGGGUC 988 3105_1_21 HLA-A Exon 1 + xp6:29942618-29942643 CUGGGCGGGUGAGUGCGGGGUCGGG 989 3105_1_22 HLA-A Exon 1 + xp6:29942619-29942644 UGGGCGGGUGAGUGCGGGGUCGGGA 990 3105_1_23 HLA-A Exon 1 - xp6:29942450-29942475 CUUCUCUGGAAACCCGACACCCAAU 991 3105_1_24 HLA-A Exon 1 - xp6:29942451-29942476 GCUUCUCUGGAAACCCGACACCCAA 992 3105_1_25 HLA-A Exon 1 - xp6:29942469-29942494 CCGCGACGACACUGAUUGGCUUCUC 993 3105_1_26 HLA-A Exon 1 - xp6:29942478-29942503 GAACAGCGACCGCGACGACACUGAU 994 3105_1_27 HLA-A Exon 1 - xp6:29942511-29942536 AAUCUGAGUCCCGGUGGGUGCGUGC 995 3105_1_28 HLA-A Exon 1 - xp6:29942512-29942537 GAAUCUGAGUCCCGGUGGGUGCGUG 996 3105_1_29 HLA-A Exon 1 - xp6:29942521-29942546 GUCUGGGGAGAAUCUGAGUCCCGGU 997 3105_1_30 HLA-A Exon 1 - xp6:29942522-29942547 CGUCUGGGGAGAAUCUGAGUCCCGG 998 3105_1_31 HLA-A Exon 1 - xp6:29942525-29942550 CGGCGUCUGGGGAGAAUCUGAGUCC 999 3105_1_32 HLA-A Exon 1 - xp6:29942541-29942566 CCAUGACGGCCAUCCUCGGCGUCUG 1000 3105_1_33 HLA-A Exon 1 - xp6:29942542-29942567 GCCAUGACGGCCAUCCUCGGCGUCU 1001 3105_1_34 HLA-A Exon 1 - xp6:29942543-29942568 CGCCAUGACGGCCAUCCUCGGCGUC 1002 3105_1_35 HLA-A Exon 1 - xp6:29942550-29942575 UUCGGGGCCGCCAUGACGGCCAUCCU 1003 3105_1_36 HLA-A Exon 1 - xp6:29942560-29942585 AGGAGGAGGGUUCGGGGCGCCAUGA 1004 3105_1_37 HLA-A Exon 1 - xp6:29942571-29942596 CCGAGAGUAGCAGGAGGAGGGUUCG 1005 3105_1_38 HLA-A Exon 1 - xp6:29942572-29942597 CCCGAGAGUAGCAGGAGGAGGGUUC 1006 3105_1_39 HLA-A Exon 1 - xp6:29942573-29942598 CCCCGAGAGUAGCAGGAGGAGGGUU 1007 3105_1_40 HLA-A Exon 1 - xp6:29942578-29942603 AGGGCCCCCGAGAGUAGCAGGAGGA 1008 3105_1_41 HLA-A Exon 1 - xp6:29942579-29942604 CAGGGCCCCCGAGAGUAGCAGGAGG 1009 3105_1_42 HLA-A Exon 1 - xp6:29942582-29942607 GGCCAGGGCCCCCGAGAGUAGCAGG 1010 3105_1_43 HLA-A Exon 1 - xp6:29942585-29942610 CAGGGCCAGGGCCCCCGAGAGUAGGC 1011 3105_1_44 HLA-A Exon 1 - xp6:29942602-29942627 CCCGCCCAGGUCUGGGUCAGGGCCA 1012 3105_1_45 HLA-A Exon 1 - xp6:29942603-29942628 ACCCGCCCAGGUCUGGGUCAGGGCC 1013 3105_1_46 HLA-A Exon 1 - xp6:29942608-29942633 CACUCACCCGCCCAGGUCUGGGUCA 1014 3105_1_47 HLA-A Exon 1 - xp6:29942609-29942634 GCACUCACCCGCCCAGGUCUGGGUC 1015 3105_1_48 HLA-A Exon 1 - xp6:29942614-29942639 ACCCCGCACUCACCCGCCCAGGUCU 1016 3105_1_49 HLA-A Exon 1 - xp6:29942615-29942640 GACCCCGCACUCACCCGCCCAGGUC 1017 3105_1_50 HLA-A Exon 1 - xp6:29942620-29942645 CUCCCGACCCCGCACUCACCCGCCC 1018 3105_2_1 HLA-A Exon 2 + xp6:29942745-29942770 CUCGCCCCCAGGCUCCCACUCCAUG 1019 3105_2_2 HLA-A Exon 2 + xp6:29942769-29942794 GAGGUAUUUCUUCACAUCCGUGUCC 1020 3105_2_3 HLA-A Exon 2 + xp6:29942774-29942799 AUUUCUUCACAUCCGUGUCCCGGCC 1021 3105_2_4 HLA-A Exon 2 + xp6:29942780-29942805 UCACAUCCGUGUCCCGGCCCGGCCG 1022 3105_2_5 HLA-A Exon 2 + xp6:29942781-29942806 CACAUCCGUGUCCCGGCCCGGCCGC 1023 3105_2_6 HLA-A Exon 2 + xp6:29942782-29942807 ACAUCCGUGUCCCGGCCCGGCCGCG 1024 3105_2_7 HLA-A Exon 2 + xp6:29942803-29942828 CGCGGGGAGCCCCGCUUCAUCGCCG 1025 3105_2_8 HLA-A Exon 2 + xp6:29942804-29942829 GCGGGGAGCCCCGCUUCAUCGCCGU 1026 3105_2_9 HLA-A Exon 2 + xp6:29942812-29942837 CCCCGCUUCAUCGCCGUGGGCUACG 1027 3105_2_10 HLA-A Exon 2 + xp6:29942832-29942857 CUACGUGGACGACACGCAGUUCGUG 1028 3105_2_11 HLA-A Exon 2 + xp6:29942859-29942884 GUUCGACAGCGACGCCGCGAGCCAG 1029 3105_2_12 HLA-A Exon 2 + xp6:29942863-29942888 GACAGCGACGCCGCGAGCCAGAGGA 1030 3105_2_13 HLA-A Exon 2 + xp6:29942871-29942896 CGCCGCGAGCCAGAGGAUGGAGCCG 1031 3105_2_14 HLA-A Exon 2 + xp6:29942872-29942897 GCCGCGAGCCAGAGGAUGGAGCCGC 1032 3105_2_15 HLA-A Exon 2 + xp6:29942880-29942905 CCAGAGGAUGGAGCCGCGGGCGCCG 1033 3105_2_16 HLA-A Exon 2 + xp6:29942890-29942915 GAGCCGCGGGCCGCCGUGGAUAGAGC 1034 3105_2_17 HLA-A Exon 2 + xp6:29942893-29942918 CCGCGGGCCGCCGUGGAUAGAGCAGG 1035 3105_2_18 HLA-A Exon 2 + xp6:29942894-29942919 CGCGGGCCGCCGUGGAUAGAGCAGGA 1036 3105_2_19 HLA-A Exon 2 + xp6:29942895-29942920 GCGGGCCGCCGUGGAUAGAGCAGGAG 1037 3105_2_20 HLA-A Exon 2 + xp6:29942899-29942924 GCGCCGUGGAUAGAGCAGGAGGGGC 1038 3105_2_21 HLA-A Exon 2 + xp6:29942907-29942932 GAUAGAGCAGGAGGGGCCGGAGUAU 1039 3105_2_22 HLA-A Exon 2 + xp6:29942908-29942933 AUAGAGCAGGAGGGCCGGAGUAUU 1040 3105_2_23 HLA-A Exon 2 + xp6:29942914-29942939 CAGGAGGGGCCGGAGUAUUGGGACC 1041 3105_2_24 HLA-A Exon 2 + xp6:29942922-29942947 GCCGGAGUAUUGGGACCAGGAGACA 1042 3105_2_25 HLA-A Exon 2 + xp6:29942932-29942957 UGGGACCAGGAGACACGGAAUGUGA 1043 3105_2_26 HLA-A Exon 2 + xp6:29942956-29942981 AAGGCCCAGUCACAGACUGACCGAG 1044 3105_2_27 HLA-A Exon 2 + xp6:29942962-29942987 CAGUCACAGACUGACCGAGUGGACC 1045 3105_2_28 HLA-A Exon 2 + xp6:29942963-29942988 AGUCACAGACUGACCGAGUGGACCU 1046 3105_2_29 HLA-A Exon 2 + xp6:29942964-29942989 GUCACAGACUGACCGAGUGGACCUG 1047 3105_2_30 HLA-A Exon 2 + xp6:29942975-29943000 ACCGAGUGGACCUGGGGACCCUGCG 1048 3105_2_31 HLA-A Exon 2 + xp6:29942995-29943020 CUGCGCGGCUACUACAACCAGAGCG 1049 3105_2_32 HLA-A Exon 2 + xp6:29942999-29943024 GCGGCUACUACAACCAGCGAGGC 1050 3105_2_33 HLA-A Exon 2 + xp6:29943012-29943037 CCAGAGCGAGGCCGGUGAGUGACCCC 1051 3105_2_34 HLA-A Exon 2 + xp6:29943016-29943041 AGCGAGGCCGGUGAGUGACCCCGGC 1052 3105_2_35 HLA-A Exon 2 + xp6:29943017-29943042 GCGAGGCCGGUGAGUGACCCCGGCC 1053 3105_2_36 HLA-A Exon 2 + xp6:29943018-29943043 CGAGGCCGGUGAGUGACCCCGGCCG 1054 3105_2_37 HLA-A Exon 2 + xp6:29943019-29943044 GAGGCCGGUGAGUGACCCCGGCCGG 1055 3105_2_38 HLA-A Exon 2 - xp6:29942742-29942767 GGAGUGGGAGCCUGGGGGCGAGCAG 1056 3105_2_39 HLA-A Exon 2 - xp6:29942752-29942777 AAUACCUCAUGGAGUGGGAGCCUGG 1057 3105_2_40 HLA-A Exon 2 - xp6:29942753-29942778 AAAUACCUCAUGGAGUGGGAGCCUG 1058 3105_2_41 HLA-A Exon 2 - xp6:29942754-29942779 GAAAUACCUCAUGGAGUGGGAGCCU 1059 3105_2_42 HLA-A Exon 2 - xp6:29942755-29942780 AGAAAUACCUCAUGGAGUGGGAGCC 1060 3105_2_43 HLA-A Exon 2 - xp6:29942762-29942787 GAUGUGAAGAAAUACCUCAUGGAGU 1061 3105_2_44 HLA-A Exon 2 - xp6:29942763-29942788 GGAUGUGAAGAAAUACCUCAUGGAG 1062 3105_2_45 HLA-A Exon 2 - xp6:29942768-29942793 GACACGGAUGUGAAGAAAUACCUCA 1063 3105_2_46 HLA-A Exon 2 - xp6:29942789-29942814 GGCUCCCCGCGGCCGGGCCGGGACA 1064 3105_2_47 HLA-A Exon 2 - xp6:29942795-29942820 AAGCGGGGCUCCCCGCGGCCGGGCC 1065 3105_2_48 HLA-A Exon 2 - xp6:29942796-29942821 GAAGCGGGGCUCCCCGCGGCCGGGC 1066 3105_2_49 HLA-A Exon 2 - xp6:29942800-29942825 CGAUGAAGCGGGGCUCCCCGCGGCC 1067 3105_2_50 HLA-A Exon 2 - xp6:29942801-29942826 GCGAUGAAGCGGGGCUCCCCGCGGC 1068 3105_2_51 HLA-A Exon 2 - xp6:29942805-29942830 CACGGCGAUGAAGCGGGGCUCCCCG 1069 3105_2_52 HLA-A Exon 2 - xp6:29942815-29942840 CCACGUAGCCCACGGCGAUGAAGCG 1070 3105_2_53 HLA-A Exon 2 - xp6:29942816-29942841 UCCACGUAGCCCACGGCGAUGAAGC 1071 3105_2_54 HLA-A Exon 2 - xp6:29942817-29942842 GUCCACGUAGCCCACGGCGAUGAAG 1072 3105_2_55 HLA-A Exon 2 - xp6:29942828-29942853 AACUGCGUGUCGUCCACGUAGCCCA 1073 3105_2_56 HLA-A Exon 2 - xp6:29942876-29942901 GCCCGCGGCUCCAUCCUCUGGCCUCG 1074 3105_2_57 HLA-A Exon 2 - xp6:29942883-29942908 CCACGGCGCCCGCGGCUCCAUCCUC 1075 3105_2_58 HLA-A Exon 2 - xp6:29942896-29942921 CCUCCUGCUCUAUCCACGGCGCCCG 1076 3105_2_59 HLA-A Exon 2 - xp6:29942905-29942930 ACUCCGGCCCCUCCUGCUCUAUCCA 1077 3105_2_60 HLA-A Exon 2 - xp6:29942926-29942951 UCCGUGUCUCCUGGUCCCAAUACUC 1078 3105_2_61 HLA-A Exon 2 - xp6:29942940-29942965 CUGGGCCUUCACAUUCCGUGUCUCC 1079 3105_2_62 HLA-A Exon 2 - xp6:29942963-29942988 AGGUCCACUCGGUCAGUCUGUGACU 1080 3105_2_63 HLA-A Exon 2 - xp6:29942964-29942989 CAGGUCCACUCGGUCAGUCUGUGAC 1081 3105_2_64 HLA-A Exon 2 - xp6:29942979-29943004 GCCGCGCAGGGUCCCCAGGUCCCACU 1082 3105_2_65 HLA-A Exon 2 - xp6:29942988-29943013 GUUGUAGUAGCCGCGCAGGGUCCCC 1083 3105_2_66 HLA-A Exon 2 - xp6:29942996-29943021 UCGCUCUGGUUGUAGUAGCCGCGCA 1084 3105_2_67 HLA-A Exon 2 - xp6:29942997-29943022 CUCGCUCUGGUUGUAGUAGCCGCGC 1085 3105_2_68 HLA-A Exon 2 - xp6:29943015-29943040 CCGGGGUCACUCACCGGCCUCGCUC 1086 3105_2_69 HLA-A Exon 2 - xp6:29943026-29943051 UGCGCCCCCGGCCGGGGUCACUCAC 1087 3105_3_1 HLA-A Exon 3 + xp6:29943267-29943292 GUUCUCACACCAUCCAGAUAAUGUA 1088 3105_3_2 HLA-A Exon 3 + xp6:29943278-29943303 AUCCAGAUAAUGUAUGGCUGCGACG 1089 3105_3_3 HLA-A Exon 3 + xp6:29943279-29943304 UCCAGAUAAUGUAUGGCUGCGACGU 1090 3105_3_4 HLA-A Exon 3 + xp6:29943280-29943305 CCAGAUAAUGUAUGGCUGCGACGUG 1091 3105_3_5 HLA-A Exon 3 + xp6:29943284-29943309 AUAAUGUAUGGCUGCGACGUGGGGU 1092 3105_3_6 HLA-A Exon 3 + xp6:29943288-29943313 UGUAUGGCUGCGACGUGGGGUCGGA 1093 3105_3_7 HLA-A Exon 3 + xp6:29943289-29943314 GUAUGGCUGCGACGUGGGGUCGGAC 1094 3105_3_8 HLA-A Exon 3 + xp6:29943303-29943328 UGGGGUCGGACGGGCGCUUCCUCCG 1095 3105_3_9 HLA-A Exon 3 + xp6:29943304-29943329 GGGGUCGGACGGGCGCUUCCUCCGC 1096 3105_3_10 HLA-A Exon 3 + xp6:29943310-29943335 GGACGGGCGCUUCCUCCGCGGGUAC 1097 3105_3_11 HLA-A Exon 3 + xp6:29943314-29943339 GGGCGCUUCCUCCGCGGGUACCGGC 1098 3105_3_12 HLA-A Exon 3 + xp6:29943327-29943352 GCGGGUACCGGCAGGACGCCUACGA 1099 3105_3_13 HLA-A Exon 3 + xp6:29943332-29943357 UACCGGCAGGACGCCUACGACGGCA 1100 3105_3_14 HLA-A Exon 3 + xp6:29943353-29943378 GGCAAGGAUUACAUCCGCCCUGAACG 1101 3105_3_15 HLA-A Exon 3 + xp6:29943367-29943392 CGCCCUGAACGAGGACCUGCCGCUCU 1102 3105_3_16 HLA-A Exon 3 + xp6:29943374-29943399 AACGAGGACCUGCCGCUCUUGGACCG 1103 3105_3_17 HLA-A Exon 3 + xp6:29943377-29943402 GAGGACCUGCGCUCUUGGACCGCGG 1104 3105_3_18 HLA-A Exon 3 + xp6:29943383-29943408 CUGCGCUCUUGGACCGCGGCGGACA 1105 3105_3_19 HLA-A Exon 3 + xp6:29943386-29943411 CGCUCUUGGACCGCGGCGGACAUGG 1106 3105_3_20 HLA-A Exon 3 + xp6:29943409-29943434 GGCGGCUCAGAUCACCAAGCGCAAG 1107 3105_3_21 HLA-A Exon 3 + xp6:29943410-29943435 GCGGCUCAGAUCACCAAGCGCAAGU 1108 3105_3_22 HLA-A Exon 3 + xp6:29943413-29943438 GCUCAGAUCACCAAGCGCAAGUGGG 1109 3105_3_23 HLA-A Exon 3 + xp6:29943416-29943441 CAGAUCACCAAGCGCAAGUGGGAGG 1110 3105_3_24 HLA-A Exon 3 + xp6:29943425-29943450 AAGCGCAAGUGGGAGGCGGCCCAUG 1111 3105_3_25 HLA-A Exon 3 + xp6:29943428-29943453 CGCAAGUGGGAGGCGGCCCAUGAGG 1112 3105_3_26 HLA-A Exon 3 + xp6:29943449-29943474 GAGGCGGAGCAGUUGAGAGCCUACC 1113 3105_3_27 HLA-A Exon 3 + xp6:29943453-29943478 CGGAGCAGUUGAGAGCCUACCUGGA 1114 3105_3_28 HLA-A Exon 3 + xp6:29943464-29943489 AGAGCCUACCUGGAUGGCACGUGCG 1115 3105_3_29 HLA-A Exon 3 + xp6:29943469-29943494 CUACCUGGAUGGCACGUGCGUGGAG 1116 3105_3_30 HLA-A Exon 3 + xp6:29943485-29943510 UGCGUGGAGUGGCUCCGCAGAUACC 1117 3105_3_31 HLA-A Exon 3 + xp6:29943492-29943517 AGUGGCUCCGCAGAUACCUGGAGAA 1118 3105_3_32 HLA-A Exon 3 + xp6:29943493-29943518 GUGGCUCCGCAGAUACCUGGAGAAC 1119 3105_3_33 HLA-A Exon 3 + xp6:29943497-29943522 CUCCGCAGAUACCUGGAGAACGGGA 1120 3105_3_34 HLA-A Exon 3 + xp6:29943515-29943540 AACGGGAAGGAGACGCUGCAGCGCA 1121 3105_3_35 HLA-A Exon 3 + xp6:29943516-29943541 ACGGGAAGGAGACGCUGCAGCGCAC 1122 3105_3_36 HLA-A Exon 3 + xp6:29943523-29943548 GGAGACGCUGCAGCGCACGGGUAC 1123 3105_3_37 HLA-A Exon 3 + xp6:29943524-29943549 GAGACGCUGCAGCGCACGGGUACCA 1124 3105_3_38 HLA-A Exon 3 + xp6:29943525-29943550 AGACGCUGCAGCGCACGGGUACAG 1125 3105_3_39 HLA-A Exon 3 + xp6:29943531-29943556 UGCAGCGCACGGGUACCAGGGGCCA 1126 3105_3_40 HLA-A Exon 3 + xp6:29943532-29943557 GCAGCGCACGGGUACCAGGGGCCAC 1127 3105_3_41 HLA-A Exon 3 + xp6:29943533-29943558 CAGCGCACGGGUACCAGGGGCCACG 1128 3105_3_42 HLA-A Exon 3 - xp6:29943252-29943277 GUGUGAGAACCUGGCCCCGACCCCG 1129 3105_3_43 HLA-A Exon 3 - xp6:29943266-29943291 ACAUUAUCUGGAUGGUGUGAGAACC 1130 3105_3_44 HLA-A Exon 3 - xp6:29943279-29943304 ACGUCGCAGCCAUACAUUAUCUGGA 1131 3105_3_45 HLA-A Exon 3 - xp6:29943283-29943308 CCCCACGUCGCAGCCAUACAUUAUC 1132 3105_3_46 HLA-A Exon 3 - xp6:29943325-29943350 GUAGGCGUCCCUGCCGGUACCCGCGG 1133 3105_3_47 HLA-A Exon 3 - xp6:29943328-29943353 GUCGUAGGCCGUCCUGCCGGUACCCG 1134 3105_3_48 HLA-A Exon 3 - xp6:29943337-29943362 AUCCUUGCCGUCGUAGGCGUCCCUGC 1135 3105_3_49 HLA-A Exon 3 - xp6:29943348-29943373 AGGGCGAUGUAAUCCUUGCCGUCGU 1136 3105_3_50 HLA-A Exon 3 - xp6:29943372-29943397 GUCCAAGAGCGCAGGUCCUCGUUCA 1137 3105_3_51 HLA-A Exon 3 - xp6:29943373-29943398 GGUCCAAGAGCGCAGGUCCUCGUUC 1138 3105_3_52 HLA-A Exon 3 - xp6:29943385-29943410 CAUGUCCGCCGCGGUCCAAGAGCGC 1139 3105_3_53 HLA-A Exon 3 - xp6:29943399-29943424 GUGAUCUGAGCCGCCAUGUCCGCCG 1140 3105_3_54 HLA-A Exon 3 - xp6:29943426-29943451 UCAUGGGCCGCCUCCCACUUGCGCU 1141 3105_3_55 HLA-A Exon 3 - xp6:29943447-29943472 UAGGCUCUCAACUGCUCCGCCUCAU 1142 3105_3_56 HLA-A Exon 3 - xp6:29943448-29943473 GUAGGCUCUCAACUGCUCCGCCUCA 1143 3105_3_57 HLA-A Exon 3 - xp6:29943471-29943496 CACUCCACGCACGUGCCAUCCAGGU 1144 3105_3_58 HLA-A Exon 3 - xp6:29943475-29943500 GAGCCACUCCACGCACGUGCCAUCC 1145 3105_3_59 HLA-A Exon 3 - xp6:29943502-29943527 CUCCUUCCCGUUCUCCAGGUAUCUG 1146 3105_3_60 HLA-A Exon 3 - xp6:29943511-29943536 CUGCAGCGUCUCCUUCCCGUUCUCC 1147 3105_4_1 HLA-A Exon 4 + xp6:29944141-29944166 ACCCACCACCCCAUCUCUGACCAUG 1148 3105_4_2 HLA-A Exon 4 + xp6:29944152-29944177 CAUCUCUGACCAUGAGGCCACCCUG 1149 3105_4_3 HLA-A Exon 4 + xp6:29944158-29944183 UGACCAUGAGGCCACCCUGAGGUGC 1150 3105_4_4 HLA-A Exon 4 + xp6:29944159-29944184 GACCAUGAGGCCACCCUGAGGUGCU 1151 3105_4_5 HLA-A Exon 4 + xp6:29944165-29944190 GAGGCCACCCUGAGGUGCUGGGCCC 1152 3105_4_6 HLA-A Exon 4 + xp6:29944166-29944191 AGGCCACCCUGAGGUGCUGGGCCCU 1153 3105_4_7 HLA-A Exon 4 + xp6:29944180-29944205 UGCUGGGCCCUGGGCUUCUACCCUG 1154 3105_4_8 HLA-A Exon 4 + xp6:29944197-29944222 CUACCCUGCGGAGAUCACACCUGACC 1155 3105_4_9 HLA-A Exon 4 + xp6:29944203-29944228 UGCGGAGAUCACACCUGACCUGGCAG 1156 3105_4_10 HLA-A Exon 4 + xp6:29944204-29944229 GCGGAGAUCACACCUGACCUGGCAGC 1157 3105_4_11 HLA-A Exon 4 + xp6:29944208-29944233 AGAUCACACUGACCUGGCAGCGGGA 1158 3105_4_12 HLA-A Exon 4 + xp6:29944209-29944234 GAUCACACUGACCUGGCAGCGGGAU 1159 3105_4_13 HLA-A Exon 4 + xp6:29944210-29944235 AUCACACUGACCUGGCAGCGGGAUG 1160 3105_4_14 HLA-A Exon 4 + xp6:29944213-29944238 ACACUGACCUGGCAGCGGGAUGGGG 1161 3105_4_15 HLA-A Exon 4 + xp6:29944225-29944250 CAGCGGGAUGGGGAGGACCAGACCC 1162 3105_4_16 HLA-A Exon 4 + xp6:29944231-29944256 GAUGGGGAGGACCAGACCCAGGACA 1163 3105_4_17 HLA-A Exon 4 + xp6:29944240-29944265 GACCAGACCCAGGACACGGAGCUCG 1164 3105_4_18 HLA-A Exon 4 + xp6:29944248-29944273 CCAGGACACGGAGCUCGUGGAGACC 1165 3105_4_19 HLA-A Exon 4 + xp6:29944256-29944281 CGGAGCUCGUGGAGACCAGGCCUGC 1166 3105_4_20 HLA-A Exon 4 + xp6:29944257-29944282 GGAGCUCGUGGAGACCAGGCCUGCA 1167 3105_4_21 HLA-A Exon 4 + xp6:29944258-29944283 GAGCUCGUGGAGACCAGGCCUGCAG 1168 3105_4_22 HLA-A Exon 4 + xp6:29944262-29944287 UCGUGGAGACCAGGCCUGCAGGGGA 1169 3105_4_23 HLA-A Exon 4 + xp6:29944278-29944303 UGCAGGGGAUGGAACCUUCCAGAAG 1170 3105_4_24 HLA-A Exon 4 + xp6:29944279-29944304 GCAGGGGAUGGAACCUUCCAGAAGU 1171 3105_4_25 HLA-A Exon 4 + xp6:29944282-29944307 GGGGAUGGAACCUUCCAGAAGUGGG 1172 3105_4_26 HLA-A Exon 4 + xp6:29944288-29944313 GGAACCUUCCAGAAGUGGGCGGCUG 1173 3105_4_27 HLA-A Exon 4 + xp6:29944291-29944316 ACCUUCCAGAAGUGGGCGGCUGUGG 1174 3105_4_28 HLA-A Exon 4 + xp6:29944301-29944326 AGUGGGCGGCUGUGGUGGUGCCUUC 1175 3105_4_29 HLA-A Exon 4 + xp6:29944306-29944331 GCGGCUGUGGUGGUGCCUUCUGGAG 1176 3105_4_30 HLA-A Exon 4 + xp6:29944339-29944364 AGAUACACCUGCCAUGUGCAGCAUG 1177 3105_4_31 HLA-A Exon 4 + xp6:29944340-29944365 GAUACACCUGCCAUGUGCAGCAUGA 1178 3105_4_32 HLA-A Exon 4 + xp6:29944368-29944393 UCUGCCCAAGCCCCUCACCCUGAGA 1179 3105_4_33 HLA-A Exon 4 + xp6:29944369-29944394 CUGCCCAAGCCCCUCACCCUGAGAU 1180 3105_4_34 HLA-A Exon 4 + xp6:29944370-29944395 UGCCCAAGCCCCUCACCCUGAGAUG 1181 3105_4_35 HLA-A Exon 4 + xp6:29944375-29944400 AAGCCCCUCACCCUGAGAUGGGGUA 1182 3105_4_36 HLA-A Exon 4 + xp6:29944378-29944403 CCCCUCACCCUGAGAUGGGGUAAGG 1183 3105_4_37 HLA-A Exon 4 + xp6:29944379-29944404 CCCUCACCCUGAGAUGGGGUAAGGA 1184 3105_4_38 HLA-A Exon 4 + xp6:29944385-29944410 CCCUGAGAUGGGGUAAGGAGGGAGA 1185 3105_4_39 HLA-A Exon 4 + xp6:29944386-29944411 CCUGAGAUGGGGUAAGGAGGGAGAU 1186 3105_4_40 HLA-A Exon 4 + xp6:29944387-29944412 CUGAGAUGGGGUAAGGAGGGAGAUG 1187 3105_4_41 HLA-A Exon 4 + xp6:29944388-29944413 UGAGAUGGGGUAAGGAGGGAGAUGG 1188 3105_4_42 HLA-A Exon 4 - xp6:29944116-29944141 CAUAUGUGUCUUGGGGGGUCUGAC 1189 3105_4_43 HLA-A Exon 4 - xp6:29944117-29944142 UCAUAUGUGUCUUGGGGGGUCUGA 1190 3105_4_44 HLA-A Exon 4 - xp6:29944125-29944150 GUGGUGGGUCAUAUGUGUCUUGGGG 1191 3105_4_45 HLA-A Exon 4 - xp6:29944126-29944151 GGUGGUGGGUCAUAUGUGUCUUGGG 1192 3105_4_46 HLA-A Exon 4 - xp6:29944127-29944152 GGGUGGUGGGUCAUAUGUGUCUUGG 1193 3105_4_47 HLA-A Exon 4 - xp6:29944128-29944153 GGGGUGGUGGGUCAUAUGUGUCUUG 1194 3105_4_48 HLA-A Exon 4 - xp6:29944129-29944154 UGGGGUGGUGGGUCAUAUGUGUCUU 1195 3105_4_49 HLA-A Exon 4 - xp6:29944130-29944155 AUGGGGUGGUGGGUCAUAUGUGUCU 1196 3105_4_50 HLA-A Exon 4 - xp6:29944145-29944170 GCCUCAUGGUCAGAGAAUGGGGUGGU 1197 3105_4_51 HLA-A Exon 4 - xp6:29944146-29944171 GGCCUCAUGGUCAGAGAAUGGGGUGG 1198 3105_4_52 HLA-A Exon 4 - xp6:29944149-29944174 GGUGGCCUCAUGGUCAGAGAAUGGGG 1199 3105_4_53 HLA-A Exon 4 - xp6:29944152-29944177 CAGGGUGGCCUCAUGGUCAGAGAUG 1200 3105_4_54 HLA-A Exon 4 - xp6:29944153-29944178 UCAGGGUGGCCUCAUGGUCAGAGAU 1201 3105_4_55 HLA-A Exon 4 - xp6:29944154-29944179 CUCAGGGUGGCCUCAUGGUCAGAGA 1202 3105_4_56 HLA-A Exon 4 - xp6:29944164-29944189 GGCCCAGCACCUCAGGGUGGCCUCA 1203 3105_4_57 HLA-A Exon 4 - xp6:29944172-29944197 AAGCCCAGGGCCCAGCACCUCAGGG 1204 3105_4_58 HLA-A Exon 4 - xp6:29944175-29944200 UAGAAGCCCAGGGCCCAGCACCUCCA 1205 3105_4_59 HLA-A Exon 4 - xp6:29944176-29944201 GUAGAAGCCCAGGGCCCAGCACCUC 1206 3105_4_60 HLA-A Exon 4 - xp6:29944190-29944215 GUGAUCUCCCGCAGGGUAGAAGCCCA 1207 3105_4_61 HLA-A Exon 4 - xp6:29944191-29944216 UGUGAUCUCCCGCAGGGUAGAAGCCC 1208 3105_4_62 HLA-A Exon 4 - xp6:29944203-29944228 CUGCCAGGUCAGUGUGAUCUCCGCA 1209 3105_4_63 HLA-A Exon 4 - xp6:29944204-29944229 GCUGCCAGGUCAGUGUGAUCUCCGC 1210 3105_4_64 HLA-A Exon 4 - xp6:29944223-29944248 GUCUGGUCCUCCCCAUCCCGCUGCC 1211 3105_4_65 HLA-A Exon 4 - xp6:29944245-29944270 CUCCACGAGCUCCGUGUCCUGGGUC 1212 3105_4_66 HLA-A Exon 4 - xp6:29944250-29944275 CUGGUCUCCACGAGCUCCGUGUCCU 1213 3105_4_67 HLA-A Exon 4 - xp6:29944251-29944276 CCUGGUCUCCACGAGCUCCGUGUCC 1214 3105_4_68 HLA-A Exon 4 - xp6:29944274-29944299 UGGAAGGUUCCAUCCCCUGCAGGCC 1215 3105_4_69 HLA-A Exon 4 - xp6:29944279-29944304 ACUUCUGGAAGGUUCCAUCCCCUGC 1216 3105_4_70 HLA-A Exon 4 - xp6:29944295-29944320 ACCACCACAGCCCGCCCACUUCUGGA 1217 3105_4_71 HLA-A Exon 4 - xp6:29944299-29944324 AGGCACCACCACAGCCCGCCCACUUC 1218 3105_4_72 HLA-A Exon 4 - xp6:29944324-29944349 AGGUGUAUCUCUGCUCCUCUCCAGA 1219 3105_4_73 HLA-A Exon 4 - xp6:29944349-29944374 GGCAGACCCUCAUGCUGCACAUGGC 1220 3105_4_74 HLA-A Exon 4 - xp6:29944353-29944378 CUUGGGCAGACCCUCAUGCUGCACA 1221 3105_4_75 HLA-A Exon 4 - xp6:29944375-29944400 UACCCCAUCUCAGGGUGAGGGGCUU 1222 3105_4_76 HLA-A Exon 4 - xp6:29944376-29944401 UUACCCCAUCUCAGGGUGAGGGGCU 1223 3105_4_77 HLA-A Exon 4 - xp6:29944381-29944406 CCUCCUUACCCCAUCUCAGGGUGAG 1224 3105_4_78 HLA-A Exon 4 - xp6:29944382-29944407 CCCUCCUUACCCCAUCUCAGGGUGA 1225 3105_4_79 HLA-A Exon 4 - xp6:29944383-29944408 UCCCUCCUUACCCCAUCUCAGGGUG 1226 3105_4_80 HLA-A Exon 4 - xp6:29944388-29944413 CCAUCUCCCUCCUUACCCCAUCUCA 1227 3105_4_81 HLA-A Exon 4 - xp6:29944389-29944414 CCCAUCUCCCUCCUUACCCCAUCUC 1228 3105_5_1 HLA-A Exon 5 + xp6:29944504-29944529 UCUUCCCAGCCCACCAUCCCCAUCG 1229 3105_5_2 HLA-A Exon 5 + xp6:29944505-29944530 CUUCCCAGCCCACCAUCCCAUCGU 1230 3105_5_3 HLA-A Exon 5 + xp6:29944517-29944542 CCAUCCCCAUCGUGGGCAUCAUUGC 1231 3105_5_4 HLA-A Exon 5 + xp6:29944522-29944547 CCCAUCGUGGGCAUCAUUGCUGGCC 1232 3105_5_5 HLA-A Exon 5 + xp6:29944532-29944557 GCAUCAUUGCUGGCCUGGUUCUCCU 1233 3105_5_6 HLA-A Exon 5 + xp6:29944547-29944572 UGGUUCUCCUUGGAGCUGUGAUCAC 1234 3105_5_7 HLA-A Exon 5 + xp6:29944555-29944580 CUUGGAGCUGUGAUCACCUGGAGCUG 1235 3105_5_8 HLA-A Exon 5 + xp6:29944572-29944597 UGGAGCUGUGGUCGCUGCCGUGAUG 1236 3105_5_9 HLA-A Exon 5 + xp6:29944575-29944600 AGCUGUGGUCGCUGCCGUGAUGUGG 1237 3105_5_10 HLA-A Exon 5 + xp6:29944578-29944603 UGUGGUCGCUGCCGUGAUGUGGAGG 1238 3105_5_11 HLA-A Exon 5 + xp6:29944589-29944614 CCGUGAUGUGGAGGAGGAAGAGCUC 1239 3105_5_12 HLA-A Exon 5 + xp6:29944592-29944617 UGAUGUGGAGGAGGAAGAGCUCAGG 1240 3105_5_13 HLA-A Exon 5 + xp6:29944598-29944623 GGAGGAGGAAGAGCUCAGGUGGAGA 1241 3105_5_14 HLA-A Exon 5 + xp6:29944599-29944624 GAGGAGGAAGAGCUCAGGUGGAGAA 1242 3105_5_15 HLA-A Exon 5 + xp6:29944600-29944625 AGGAGGAAGAGCUCAGGUGGAGAAG 1243 3105_5_16 HLA-A Exon 5 + xp6:29944606-29944631 AAGAGCUCAGGUGGAGAAGGGGUGA 1244 3105_5_17 HLA-A Exon 5 + xp6:29944607-29944632 AGAGCUCAGGUGGAGAAGGGGUGAA 1245 3105_5_18 HLA-A Exon 5 + xp6:29944610-29944635 GCUCAGGUGGAGAAGGGGUGAAGGG 1246 3105_5_19 HLA-A Exon 5 + xp6:29944611-29944636 CUCAGGUGGAGAAGGGGUGAAGGGU 1247 3105_5_20 HLA-A Exon 5 + xp6:29944612-29944637 UCAGGUGGAGAAGGGGUGAAGGGUG 1248 3105_5_21 HLA-A Exon 5 - xp6:29944477-29944502 GCUCUGGGAAAAGAGGGGAAGGUGA 1249 3105_5_22 HLA-A Exon 5 - xp6:29944478-29944503 AGCUCUGGGAAAAGAGGGGAAGGUG 1250 3105_5_23 HLA-A Exon 5 - xp6:29944483-29944508 AAGACAGCUCUGGGAAAAGAGGGGA 1251 3105_5_24 HLA-A Exon 5 - xp6:29944487-29944512 UGGGAAGACAGCUCUGGGAAAAGAG 1252 3105_5_25 HLA-A Exon 5 - xp6:29944488-29944513 CUGGGAAGACAGCUCUGGGAAAAAGA 1253 3105_5_26 HLA-A Exon 5 - xp6:29944489-29944514 GCUGGGAAGACAGCUCUGGGAAAAG 1254 3105_5_27 HLA-A Exon 5 - xp6:29944497-29944522 GAUGGUGGGCUGGGAAGACAGCUCU 1255 3105_5_28 HLA-A Exon 5 - xp6:29944498-29944523 GGAUGGUGGGCUGGGAAGACAGCUC 1256 3105_5_29 HLA-A Exon 5 - xp6:29944511-29944536 AUGCCCACGAUGGGGAUGGUGGGCU 1257 3105_5_30 HLA-A Exon 5 - xp6:29944512-29944537 GAUGCCCACGAUGGGGAUGGUGGGC 1258 3105_5_31 HLA-A Exon 5 - xp6:29944516-29944541 CAAUGAUGCCCACGAUGGGGAUGGU 1259 3105_5_32 HLA-A Exon 5 - xp6:29944517-29944542 GCAAUGAUGCCCACGAUGGGGAUGG 1260 3105_5_33 HLA-A Exon 5 - xp6:29944520-29944545 CCAGCAAUGAUGCCCACGAUGGGGA 1261 3105_5_34 HLA-A Exon 5 - xp6:29944524-29944549 CAGGCCAGCAAUGAUGCCCACGAUG 1262 3105_5_35 HLA-A Exon 5 - xp6:29944525-29944550 CCAGGCCAGCAAUGAUGCCCACGAU 1263 3105_5_36 HLA-A Exon 5 - xp6:29944526-29944551 ACCAGGCCAGCAAUGAUGCCCACGA 1264 3105_5_37 HLA-A Exon 5 - xp6:29944548-29944573 AGUGAUCACAGCUCCAAGGAGAACC 1265 3105_5_38 HLA-A Exon 5 - xp6:29944557-29944582 CACAGCUCCAGUGAUCACAGCUCCA 1266 3105_5_39 HLA-A Exon 5 - xp6:29944592-29944617 CCUGAGCUCUUCCUCCCUCCACAUCA 1267 3105_6_1 HLA-A Exon 6 + xp6:29945040-29945065 GACAUUUUCUUCUCACAGAUGAAA 1268 3105_6_2 HLA-A Exon 6 + xp6:29945043-29945068 AUUUUCUUCUCACAGAUAGAAAGG 1269 3105_6_3 HLA-A Exon 6 + xp6:29945044-29945069 UUUUCUUCUCACAGAUAGAAAAAGGA 1270 3105_6_4 HLA-A Exon 6 + xp6:29945057-29945082 GAUAGAAAAGGAGGGAGUUACACUC 1271 3105_6_5 HLA-A Exon 6 + xp6:29945076-29945101 ACACUCAGGCUGCAAGUAAGUAUGA 1272 3105_6_6 HLA-A Exon 6 + xp6:29945079-29945104 CUCAGGCUGCAAGUAAGUAUGAAGG 1273 3105_7_1 HLA-A Exon 7 + xp6:29945223-29945248 UCUACCCCAGGCAGUGACAGUGCCC 1274 3105_7_2 HLA-A Exon 7 + xp6:29945224-29945249 CUACCCCAGGCAGUGACAGUGCCCA 1275 3105_7_3 HLA-A Exon 7 + xp6:29945254-29945279 CUGAUGUGUCCCUCACAGCUUGUAA 1276 3105_7_4 HLA-A Exon 7 + xp6:29945265-29945290 CUCACAGCUUGUAAAGGUGAGAGCU 1277 3105_7_5 HLA-A Exon 7 + xp6:29945268-29945293 ACAGCUUGUAAAGGUGAGAGCUUGG 1278 3105_7_6 HLA-A Exon 7 - xp6:29945230-29945255 GAGCCCUGGGCACUGUCACUGCCUG 1279 3105_7_7 HLA-A Exon 7 - xp6:29945231-29945256 AGAGCCCUGGGCACUGUCACUGCCU 1280 3105_7_8 HLA-A Exon 7 - xp6:29945232-29945257 CAGAGCCCUGGGCACUGUCACUGCC 1281 3105_7_9 HLA-A Exon 7 - xp6:29945248-29945273 GCUGUGAGGGACACAUCAGAGCCCU 1282 3105_7_10 HLA-A Exon 7 - xp6:29945249-29945274 AGCUGUGAGGGACACAUCAGAGCCCC 1283 3105_7_11 HLA-A Exon 7 - xp6:29945266-29945291 AAGCUCUCACCUUUACAAGCUGUGA 1284 3105_7_12 HLA-A Exon 7 - xp6:29945267-29945292 CAAGCUCUCACCUUUACAAGCUGUG 1285 3105_8_1 HLA-A Exon 8 + xp6:29945445-29945470 UAUAGUGUGAGACAGCUGCCUUGUG 1286 3105_8_2 HLA-A Exon 8 + xp6:29945446-29945471 AUAGUGUGAGACAGCUGCCUUGUGU 1287 3105_8_3 HLA-A Exon 8 + xp6:29945455-29945480 GACAGCUGCCUUGUGUGGGACUGAG 1288 3105_8_4 HLA-A Exon 8 + xp6:29945517-29945542 AAGAACCCUGACUUUGUUUCCUGCAA 1289 3105_8_5 HLA-A Exon 8 + xp6:29945545-29945570 CACCUGCAUGUGUCUGUGUUCGUGU 1290 3105_8_6 HLA-A Exon 8 + xp6:29945557-29945582 UCUGUGUUCGUGUAGGCAUAAUGUG 1291 3105_8_7 HLA-A Exon 8 + xp6:29945560-29945585 GUGUUCGUGUAGGCAUAAUGUGAGG 1292 3105_8_8 HLA-A Exon 8 + xp6:29945563-29945588 UUCGUGUAGGCAUAAUGUGAGGAGG 1293 3105_8_9 HLA-A Exon 8 + xp6:29945564-29945589 UCGUGUAGGCAUAAUGUGAGGAGGU 1294 3105_8_10 HLA-A Exon 8 + xp6:29945565-29945590 CGUGUAGGCAUAAUGUGAGGAGGUG 1295 3105_8_11 HLA-A Exon 8 + xp6:29945652-29945677 CCCAAUCAUCUUUCCUGUUCCAGAG 1296 3105_8_12 HLA-A Exon 8 + xp6:29945655-29945680 AAUCAUCUUUCCUGUUCCAGAGAGG 1297 3105_8_13 HLA-A Exon 8 + xp6:29945656-29945681 AUCAUCUUUCCUGUUCCAGAGAGGU 1298 3105_8_14 HLA-A Exon 8 + xp6:29945657-29945682 UCAUCUUUCCUGUUCCAGAGAGGUG 1299 3105_8_15 HLA-A Exon 8 + xp6:29945663-29945688 UUCCUGUUCCAGAGAGGUGGGGCUG 1300 3105_8_16 HLA-A Exon 8 + xp6:29945691-29945716 UGUCUCCAUCUCUGUCUCAACUUCA 1301 3105_8_17 HLA-A Exon 8 + xp6:29945775-29945800 UACUUUCUCAAAUUCUUGCCAUGAG 1302 3105_8_18 HLA-A Exon 8 + xp6:29945794-29945819 CAUGAGAGGUUGAUGAGUUAAUUAA 1303 3105_8_19 HLA-A Exon 8 + xp6:29945830-29945855 CCUAAAAUUUGAGAGACAAAAUAAAA 1304 3105_8_20 HLA-A Exon 8 - xp6:29945466-29945491 AACUCUUGCCUCUCAGUCCCACACA 1305 3105_8_21 HLA-A Exon 8 - xp6:29945497-29945522 UUCUUCAAGUCACAAAGGGAAGGGC 1306 3105_8_22 HLA-A Exon 8 - xp6:29945501-29945526 AGGGUUCUUCAAGUCACAAAGGGAA 1307 3105_8_23 HLA-A Exon 8 - xp6:29945502-29945527 CAGGGUUCUUCAAGUCACAAAGGGA 1308 3105_8_24 HLA-A Exon 8 - xp6:29945506-29945531 AAGUCAGGGUUCUUCAAGUCACAAA 1309 3105_8_25 HLA-A Exon 8 - xp6:29945507-29945532 AAAGUCAGGGUUCUUCAAGUCACAA 1310 3105_8_26 HLA-A Exon 8 - xp6:29945525-29945550 AGGUGCCUUUGCAGAAACAAAGUCA 1311 3105_8_27 HLA-A Exon 8 - xp6:29945526-29945551 CAGGUGCCUUUGCAGAAACAAAGUC 1312 3105_8_28 HLA-A Exon 8 - xp6:29945550-29945575 UGCCUACACGAACACAGACACAUGC 1313 3105_8_29 HLA-A Exon 8 - xp6:29945599-29945624 GGUCAUGGUGGACAUGGGGGUGGGG 1314 3105_8_30 HLA-A Exon 8 - xp6:29945602-29945627 GAGGGUCAUGGUGGACAUGGGGGUG 1315 3105_8_31 HLA-A Exon 8 - xp6:29945603-29945628 AGAGGGUCAUGGUGGACAUGGGGGU 1316 3105_8_32 HLA-A Exon 8 - xp6:29945604-29945629 AAGAGGGUCAUGGUGGACAUGGGGG 1317 3105_8_33 HLA-A Exon 8 - xp6:29945607-29945632 GGGAAGAGGGUCAUGGUGGACAUGG 1318 3105_8_34 HLA-A Exon 8 - xp6:29945608-29945633 UGGGAAGAGGGUCAUGGUGGACAUG 1319 3105_8_35 HLA-A Exon 8 - xp6:29945609-29945634 GUGGGAAGAGGGUCAUGGUGGACAU 1320 3105_8_36 HLA-A Exon 8 - xp6:29945610-29945635 CGUGGGAAGAGGGUCAUGGUGGACA 1321 3105_8_37 HLA-A Exon 8 - xp6:29945616-29945641 GGUCAGCGUGGGAAGAGGGUCAUGG 1322 3105_8_38 HLA-A Exon 8 - xp6:29945619-29945644 ACAGGUCAGCGUGGGAAGAGGGUCA 1323 3105_8_39 HLA-A Exon 8 - xp6:29945625-29945650 GGGAGCACAGGUCAGCGUGGGAAGA 1324 3105_8_40 HLA-A Exon 8 - xp6:29945626-29945651 AGGGAGCACAGGUCAGCGUGGGAAG 1325 3105_8_41 HLA-A Exon 8 - xp6:29945632-29945657 UUGGGGAGGGAGCACAGGUCAGCGU 1326 3105_8_42 HLA-A Exon 8 - xp6:29945633-29945658 AUUGGGGAGGGAGCACAGGUCAAGCG 1327 3105_8_43 HLA-A Exon 8 - xp6:29945642-29945667 GGAAAGAUGAUUGGGGAGGGAGCAC 1328 3105_8_44 HLA-A Exon 8 - xp6:29945650-29945675 CUGGAACAGGAAAGAUGAUUGGGGA 1329 3105_8_45 HLA-A Exon 8 - xp6:29945651-29945676 UCUGGAACAGGAAAGAUGAUUGGGG 1330 3105_8_46 HLA-A Exon 8 - xp6:29945654-29945679 CUCUCUGGAACAGGAAAAGAUGAUUG 1331 3105_8_47 HLA-A Exon 8 - xp6:29945655-29945680 CCUCUCUGGAACAGGAAAAGAUGAUU 1332 3105_8_48 HLA-A Exon 8 - xp6:29945656-29945681 ACCUCUCUGGAACAGGAAAAGAUGAU 1333 3105_8_49 HLA-A Exon 8 - xp6:29945668-29945693 CACCUCAGCCCCACCUCUCUGGAAC 1334 3105_8_50 HLA-A Exon 8 - xp6:29945674-29945699 UGGAGACACCUCAGCCCCACCUCUC 1335 3105_8_51 HLA-A Exon 8 - xp6:29945699-29945724 GUGCACCAUGAAGUUGAGACAGAGA 1336 3105_8_52 HLA-A Exon 8 - xp6:29945743-29945768 ACUAAGGUUCUAAUUUUAAUAGGGA 1337 3105_8_53 HLA-A Exon 8 - xp6:29945747-29945772 UUAUACUAAGGUUCUAAUUUUAAUA 1338 3105_8_54 HLA-A Exon 8 - xp6:29945748-29945773 UUUAUACUAAGGUUCUAAUUUUAAU 1339 3105_8_55 HLA-A Exon 8 - xp6:29945764-29945789 AAUUUGAGAAAGUAAAUUUAUACUA 1340 3105_8_56 HLA-A Exon 8 - xp6:29945796-29945821 CUUUAAUUAACUCAUCAACCUCUCA 1341 3105_8_57 HLA-A Exon 8 - xp6:29945833-29945858 CCAUUUAUUUUGUCUCUCAAAUUUU 1342 3105_8_58 HLA-A Exon 8 - xp6:29945873-29945898 GCACAAGAAACACGUGGACUCUGGA 1343 3105_8_59 HLA-A Exon 8 - xp6:29945877-29945902 AUCAGCACAAGAAACACGUGGACUC 1344 3105_8_60 HLA-A Exon 8 - xp6:29945884-29945909 GCAACAAAUCAGCACAAGAAAACCG 1345 3106_8_1 HLA-B Exon 8 + xp6:31353849-31353874 CUCAGCACAGCGAACAUGCAGAUUC 1346 3106_8_2 HLA-B Exon 8 + xp6:31353853-31353878 GCACAGCGAACAUGCAGAUUCUGGA 1347 3106_8_3 HLA-B Exon 8 + xp6:31353861-31353886 AACAUGCAGAUUCUGGAAGGUUCUC 1348 3106_8_4 HLA-B Exon 8 + xp6:31353888-31353913 GUCUUUAUUUGCUCUCUCAAAAUUCC 1349 3106_8_5 HLA-B Exon 8 + xp6:31353974-31353999 UUAUAUUCAGAUUCUUAUUUUCAGU 1350 3106_8_6 HLA-B Exon 8 + xp6:31353975-31354000 UAUAUUCAGAUUCUUAUUUUCAGUA 1351 3106_8_7 HLA-B Exon 8 + xp6:31354022-31354047 AGUGCACGUAAAGUUGAGACAGAGA 1352 3106_8_8 HLA-B Exon 8 + xp6:31354046-31354071 AUGGAGACAUCCAGCCCCACCUCUC 1353 3106_8_9 HLA-B Exon 8 + xp6:31354064-31354089 ACCUCUCUGGAACAAGAAAAGAUGAC 1354 3106_8_10 HLA-B Exon 8 + xp6:31354065-31354090 CCUCUCUGGAACAAGAAAAGAUGACU 1355 3106_8_11 HLA-B Exon 8 + xp6:31354066-31354091 CUCUCUGGAACAAGAAAAGAUGACUG 1356 3106_8_12 HLA-B Exon 8 + xp6:31354069-31354094 UCUGGAACAAGAAAAGAUGACUGGGG 1357 3106_8_13 HLA-B Exon 8 + xp6:31354078-31354103 AGAAAGAUGACUGGGGAGGAAACAC 1358 3106_8_14 HLA-B Exon 8 + xp6:31354087-31354112 ACUGGGGAGGAAAACACAGGUCAGCA 1359 3106_8_15 HLA-B Exon 8 + xp6:31354088-31354113 CUGGGGAGGAAAACACAGGUCAGCAU 1360 3106_8_16 HLA-B Exon 8 + xp6:31354094-31354119 AGGAAAACACAGGUCAGCAUGGGAAC 1361 3106_8_17 HLA-B Exon 8 + xp6:31354095-31354120 GGAAACACAGGUCAGCAUGGGAACA 1362 3106_8_18 HLA-B Exon 8 + xp6:31354096-31354121 GAAACACAGGUCAGCAUGGGAACAG 1363 3106_8_19 HLA-B Exon 8 + xp6:31354105-31354130 GUCAGCAUGGGAACAGGGGUCACAG 1364 3106_8_20 HLA-B Exon 8 + xp6:31354113-31354138 GGGAACAGGGGUCACAGUGGACACA 1365 3106_8_21 HLA-B Exon 8 + xp6:31354114-31354139 GGAACAGGGGUCACAGUGGACACAAA 1366 3106_8_22 HLA-B Exon 8 + xp6:31354117-31354142 ACAGGGGUCACAGUGGACACAAGGG 1367 3106_8_23 HLA-B Exon 8 + xp6:31354118-31354143 CAGGGGUCACAGUGGACACAAGGGU 1368 3106_8_24 HLA-B Exon 8 + xp6:31354152-31354177 CUCCACCUCCUCACAUUAUGCUAAC 1369 3106_8_25 HLA-B Exon 8 + xp6:31354153-31354178 UCCACCUCCUCACAUUAUGCUAACA 1370 3106_8_26 HLA-B Exon 8 + xp6:31354170-31354195 UGCUAACAGGGACGCAGACACAUUC 1371 3106_8_27 HLA-B Exon 8 + xp6:31354197-31354222 GUGCCUUUGCAGAAAGAGAUGCCAG 1372 3106_8_28 HLA-B Exon 8 + xp6:31354215-31354240 AUGCCAGAGGCUCUUGAAGUCACAA 1373 3106_8_29 HLA-B Exon 8 + xp6:31354216-31354241 UGCCAGAGGCUCUUGAAGUCACAAAA 1374 3106_8_30 HLA-B Exon 8 + xp6:31354217-31354242 GCCAGAGGCUCUUGAAGUCACAAAG 1375 3106_8_31 HLA-B Exon 8 + xp6:31354220-31354245 AGAGGCUCUUGAAGUCACAAAGGGG 1376 3106_8_32 HLA-B Exon 8 + xp6:31354268-31354293 CAGUCCCUCACAAGACAGCUGUCUC 1377 3106_8_33 HLA-B Exon 8 - xp6:31353914-31353939 UGGAUUAAUUAAAAUAAGUCAAUUCC 1378 3106_8_34 HLA-B Exon 8 - xp6:31353939-31353964 UCAAAUAUUUGCUAUGAGAGGUUGA 1379 3106_8_35 HLA-B Exon 8 - xp6:31353946-31353971 UGUUUUCUCAAAUAUUUGCUAUGAG 1380 3106_8_36 HLA-B Exon 8 - xp6:31354059-31354084 CUUUCUUGUUCCAGAGAGGUGGGGC 1381 3106_8_37 HLA-B Exon 8 - xp6:31354063-31354088 UCAUCUUUCUUGUUCCAGAGAGGUG 1382 3106_8_38 HLA-B Exon 8 - xp6:31354064-31354089 GUCAUCUUUCUUGUUCCAGAGAGGU 1383 3106_8_39 HLA-B Exon 8 - xp6:31354065-31354090 AGUCAUCUUUCUUGUUCCAGAGAGG 1384 3106_8_40 HLA-B Exon 8 - xp6:31354068-31354093 CCCAGUCAUCUUUCUUGUUCCAGAG 1385 3106_8_41 HLA-B Exon 8 - xp6:31354157-31354182 UCCCUGUUAGCAUAAUGUGAGGAGG 1386 3106_8_42 HLA-B Exon 8 - xp6:31354160-31354185 GCGUCCCUGUUAGCAUAAUGUGAGG 1387 3106_8_43 HLA-B Exon 8 - xp6:31354163-31354188 UCUGCGUCCCUGUUAGCAUAAUGUG 1388 3106_8_44 HLA-B Exon 8 - xp6:31354203-31354228 GAGCCUCUGGCAUCUCUUUCGCAA 1389 3106_8_45 HLA-B Exon 8 - xp6:31354221-31354246 UCCCCUUUGUGACUUCAAGAGCCUC 1390 3106_8_46 HLA-B Exon 8 - xp6:31354262-31354287 GCUGUCUUGUGAGGGACUGAGAUGC 1391 3106_8_47 HLA-B Exon 8 - xp6:31354275-31354300 GUAGCCUGAGACAGCUGUCUUGUGA 1392 3106_8_48 HLA-B Exon 8 - xp6:31354276-31354301 UGUAGCCUGAGACAGCUGUCUUGUG 1393 3106_7_1 HLA-B Exon 7 + xp6:31354485-31354510 AGCUGUGAGAGACACAUCAGAGCCCC 1394 3106_7_2 HLA-B Exon 7 + xp6:31354486-31354511 GCUGUGAGAGACACAUCAGAGCCCU 1395 3106_7_3 HLA-B Exon 7 + xp6:31354502-31354527 CAGAGCCCUGGGCACUGUCGCUGCC 1396 3106_7_4 HLA-B Exon 7 + xp6:31354519-31354544 UCGCUGCCUGGAGUAGAAAAAAAC 1397 3106_7_5 HLA-B Exon 7 - xp6:31354466-31354491 ACAGCUUGAAAAGGUGAGAUUCUUG 1398 3106_7_6 HLA-B Exon 7 - xp6:31354467-31354492 CACAGCUUGAAAAGGUGAGAUUCUU 1399 3106_7_7 HLA-B Exon 7 - xp6:31354468-31354493 UCACAGCUUGAAAAGGUGAGAUUCU 1400 3106_7_8 HLA-B Exon 7 - xp6:31354480-31354505 CUGAUGUGUCUCUCACAGCUUGAAA 1401 3106_7_9 HLA-B Exon 7 - xp6:31354510-31354535 CUACUCCAGGCAGCGACAGUGCCCA 1402 3106_7_10 HLA-B Exon 7 - xp6:31354511-31354536 UCUACUCCAGGCAGCGACAGUGCCC 1403 3106_6_1 HLA-B Exon 6 + xp6:31354643-31354668 GAGUAGCUCCCUCCUUUUCCACCUG 1404 3106_6_2 HLA-B Exon 6 + xp6:31354644-31354669 AGUAGCUCCCUCCUUUUCCACCUGU 1405 3106_6_3 HLA-B Exon 6 - xp6:31354610-31354635 CGUGUAAGUGGUGGGGGUGGGAGUG 1406 3106_6_4 HLA-B Exon 6 - xp6:31354617-31354642 CAGGCUGCGUGUAAGUGGUGGGGGU 1407 3106_6_5 HLA-B Exon 6 - xp6:31354618-31354643 UCAGGCUGCGUGUAAGUGGUGGGGG 1408 3106_6_6 HLA-B Exon 6 - xp6:31354621-31354646 CUCUCAGGCUGCGUGUAAGUGGUGG 1409 3106_6_7 HLA-B Exon 6 - xp6:31354622-31354647 ACUCUCAGGCUGCGUGUAAGUGGUG 1410 3106_6_8 HLA-B Exon 6 - xp6:31354623-31354648 UACUCUCAGGCUGCGUGUAAGUGGU 1411 3106_6_9 HLA-B Exon 6 - xp6:31354624-31354649 CUACUCUCAGGCUGCGUGUAAGUGG 1412 3106_6_10 HLA-B Exon 6 - xp6:31354627-31354652 GAGCUACUCUCAGGCUGCGUGUAAG 1413 3106_6_11 HLA-B Exon 6 - xp6:31354641-31354666 GGUGGAAAAGGAGGGAGCUACUCUC 1414 3106_6_12 HLA-B Exon 6 - xp6:31354654-31354679 UUUUCUUCCCACAGGUGGAAAAGGA 1415 3106_6_13 HLA-B Exon 6 - xp6:31354655-31354680 AUUUUCUUCCCACAGGUGGAAAAGG 1416 3106_6_14 HLA-B Exon 6 - xp6:31354658-31354683 GACAUUUUCUUCCCACAGGUGGAAA 1417 3106_6_15 HLA-B Exon 6 - xp6:31354664-31354689 UCACAGGACAUUUUCUUCCCACAGG 1418 3106_5_1 HLA-B Exon 5 + xp6:31355140-31355165 CACAGCUCCGAUGACCACAACUGCU 1419 3106_5_2 HLA-B Exon 5 + xp6:31355149-31355174 GAUGACCACAACUGCUAGGACAGCC 1420 3106_5_3 HLA-B Exon 5 + xp6:31355171-31355196 GCCAGGCCAGCAACAAUGCCCACGA 1421 3106_5_4 HLA-B Exon 5 + xp6:31355172-31355197 CCAGGCCAGCAACAAUGCCCACGAU 1422 3106_5_5 HLA-B Exon 5 + xp6:31355173-31355198 CAGGCCAGCAACAAUGCCCACGAUG 1423 3106_5_6 HLA-B Exon 5 + xp6:31355177-31355202 CCAGCAACAAUGCCCACGAUGGGGA 1424 3106_5_7 HLA-B Exon 5 + xp6:31355180-31355205 GCAACAAUGCCCACGAUGGGGACGG 1425 3106_5_8 HLA-B Exon 5 + xp6:31355185-31355210 AAUGCCCACGAUGGGGACGGUGGAC 1426 3106_5_9 HLA-B Exon 5 + xp6:31355186-31355211 AUGCCCACGAUGGGGACGGUGGACU 1427 3106_5_10 HLA-B Exon 5 + xp6:31355193-31355218 CGAUGGGGACGGUGGACUGGGAAGA 1428 3106_5_11 HLA-B Exon 5 + xp6:31355199-31355224 GGACGGUGGACUGGGAAGACGGCUC 1429 3106_5_12 HLA-B Exon 5 + xp6:31355200-31355225 GACGGUGGACUGGGAAGACGGCUCU 1430 3106_5_13 HLA-B Exon 5 + xp6:31355205-31355230 UGGACUGGGAAGACGGCUCUGGGAA 1431 3106_5_14 HLA-B Exon 5 + xp6:31355208-31355233 ACUGGGAAGACGGCUCUGGGAAAGG 1432 3106_5_15 HLA-B Exon 5 + xp6:31355209-31355234 CUGGGAAGACGGCUCUGGGAAAGGA 1433 3106_5_16 HLA-B Exon 5 + xp6:31355210-31355235 UGGGAAGACGGCUCUGGGAAAGGAG 1434 3106_5_17 HLA-B Exon 5 + xp6:31355219-31355244 GGCUCUGGGAAAGGAGGGGAAGAUG 1435 3106_5_18 HLA-B Exon 5 + xp6:31355220-31355245 GCUCUGGGAAAGGAGGGGAAGAUGA 1436 3106_5_19 HLA-B Exon 5 - xp6:31355085-31355110 UCAGGUAGGGAAGGGGUGAGGGGUG 1437 3106_5_20 HLA-B Exon 5 - xp6:31355086-31355111 UUCAGGUAGGGAAGGGGUGAGGGGU 1438 3106_5_21 HLA-B Exon 5 - xp6:31355087-31355112 GUUCAGGUAGGGAAGGGGUGAGGGG 1439 3106_5_22 HLA-B Exon 5 - xp6:31355090-31355115 AGAGUUCAGGUAGGGAAGGGGUGAG 1440 3106_5_23 HLA-B Exon 5 - xp6:31355091-31355116 AAGAGUUCAGGUAGGGAAGGGGUGA 1441 3106_5_24 HLA-B Exon 5 - xp6:31355092-31355117 GAAGAGUUCAGGUAGGGAAGGGGUG 1442 3106_5_25 HLA-B Exon 5 - xp6:31355097-31355122 AGGAGGAAGAGUUCAGGUAGGGAAG 1443 3106_5_26 HLA-B Exon 5 - xp6:31355098-31355123 UAGGAGGAAGAGUUCAGGUAGGGAA 1444 3106_5_27 HLA-B Exon 5 - xp6:31355099-31355124 GUAGGAGGAAGAGUUCAGGUAGGGA 1445 3106_5_28 HLA-B Exon 5 - xp6:31355103-31355128 AUGUGUAGGAGGAAGAGUUCAGGUA 1446 3106_5_29 HLA-B Exon 5 - xp6:31355104-31355129 GAUGUGUAGGAGGAAGAGUUCAGGU 1447 3106_5_30 HLA-B Exon 5 - xp6:31355108-31355133 CUGUGAUGUGUAGGAGGAAGAGUUC 1448 3106_5_31 HLA-B Exon 5 - xp6:31355119-31355144 UGUGGUCGCUGCUGUGAUGUGUAGG 1449 3106_5_32 HLA-B Exon 5 - xp6:31355122-31355147 AGCUGUGGUCGCUGCUGUGAUGUGU 1450 3106_5_33 HLA-B Exon 5 - xp6:31355142-31355167 CUAGCAGUUGUGGUCAUCGGAGCUG 1451 3106_5_34 HLA-B Exon 5 - xp6:31355150-31355175 UGGCUGUCCUAGCAGUUGUGGUCAU 1452 3106_5_35 HLA-B Exon 5 - xp6:31355157-31355182 GCUGGCCUGGCUGUCCUAGCAGUUG 1453 3106_5_36 HLA-B Exon 5 - xp6:31355175-31355200 CCCAUCGUGGGCAUUGUUGCUGGCC 1454 3106_5_37 HLA-B Exon 5 - xp6:31355180-31355205 CCGUCCCCAUCGUGGGCAUUGUUGC 1455 3106_5_38 HLA-B Exon 5 - xp6:31355192-31355217 CUUCCCAGUCCACCGUCCCCAUCGU 1456 3106_5_39 HLA-B Exon 5 - xp6:31355193-31355218 UCUUCCCAGUCCACCGUCCCCAUCG 1457 3106_4_1 HLA-B Exon 4 + xp6:31355299-31355324 CUCAUCCCCCUCCUUACCCCAUUCUC 1458 3106_4_2 HLA-B Exon 4 + xp6:31355300-31355325 UCAUCCCCCUCCUUACCCCAUCUCA 1459 3106_4_3 HLA-B Exon 4 + xp6:31355305-31355330 CCCCUCCUUACCCCAUCUCAGGGUG 1460 3106_4_4 HLA-B Exon 4 + xp6:31355306-31355331 CCCUCCUUACCCCAUCUCAGGGUGA 1461 3106_4_5 HLA-B Exon 4 + xp6:31355307-31355332 CCUCCUUACCCCAUCUCAGGGUGAG 1462 3106_4_6 HLA-B Exon 4 + xp6:31355313-31355338 UACCCCAUCUCAGGGUGAGGGGCUU 1463 3106_4_7 HLA-B Exon 4 + xp6:31355335-31355360 CUUCGGCAGCCCCUCAUGCUGUAC 1464 3106_4_8 HLA-B Exon 4 + xp6:31355364-31355389 AUGUGUAUCUCUGCUCUUCUCCAGA 1465 3106_4_9 HLA-B Exon 4 + xp6:31355389-31355414 AGGCACCACCACAGCUGCCCACUUC 1466 3106_4_10 HLA-B Exon 4 + xp6:31355393-31355418 ACCACCACAGCUGCCCACUUCUGGA 1467 3106_4_11 HLA-B Exon 4 + xp6:31355409-31355434 ACUUCUGGAAGGUUCUAUCUCCUGC 1468 3106_4_12 HLA-B Exon 4 + xp6:31355414-31355439 UGGAAGGUUCUAUCUCCUGCUGGUC 1469 3106_4_13 HLA-B Exon 4 + xp6:31355443-31355468 CUCCACAAGCUCAGUGUCCUGAGUU 1470 3106_4_14 HLA-B Exon 4 + xp6:31355465-31355490 GUUUGGUCCUCCGCCAUCCCGCUGCC 1471 3106_4_15 HLA-B Exon 4 + xp6:31355484-31355509 GCUGCCAGGUCAGUGUGAUCUCCGC 1472 3106_4_16 HLA-B Exon 4 + xp6:31355485-31355510 CUGCCAGGUCAGUGUGAUCUCCGCA 1473 3106_4_17 HLA-B Exon 4 + xp6:31355497-31355522 UGUGAUCUCCCGCAGGGUAGAAACCC 1474 3106_4_18 HLA-B Exon 4 + xp6:31355498-31355523 GUGAUCUCCCGCAGGGUAGAAACCCCA 1475 3106_4_19 HLA-B Exon 4 + xp6:31355512-31355537 GUAGAAACCCAGGGCCCAGCACCUC 1476 3106_4_20 HLA-B Exon 4 + xp6:31355513-31355538 UAGAAACCCAGGGCCCAGCACCUCCA 1477 3106_4_21 HLA-B Exon 4 + xp6:31355516-31355541 AAACCCAGGGCCCAGCACCUCAGGG 1478 3106_4_22 HLA-B Exon 4 + xp6:31355524-31355549 GGCCCAGCACCUCAGGGUGGCCUCA 1479 3106_4_23 HLA-B Exon 4 + xp6:31355534-31355559 CUCAGGGUGGCCUCAUGGUCAGAGA 1480 3106_4_24 HLA-B Exon 4 + xp6:31355535-31355560 UCAGGGUGGCCUCAUGGUCAGAGAU 1481 3106_4_25 HLA-B Exon 4 + xp6:31355536-31355561 CAGGGUGGCCUCAUGGUCAGAGAUG 1482 3106_4_26 HLA-B Exon 4 + xp6:31355539-31355564 GGUGGCCUCAUGGUCAGAGAAUGGGG 1483 3106_4_27 HLA-B Exon 4 + xp6:31355542-31355567 GGCCUCAUGGUCAGAGAAUGGGGUGG 1484 3106_4_28 HLA-B Exon 4 + xp6:31355543-31355568 GCCUCAUGGUCAGAGAAUGGGGUGGU 1485 3106_4_29 HLA-B Exon 4 + xp6:31355559-31355584 UGGGGUGGUGGGUCACGUGUGUCUU 1486 3106_4_30 HLA-B Exon 4 + xp6:31355560-31355585 GGGGUGGUGGGUCACGUGUGUCUUU 1487 3106_4_31 HLA-B Exon 4 + xp6:31355561-31355586 GGGUGGUGGGUCACGUGUGUCUUUG 1488 3106_4_32 HLA-B Exon 4 + xp6:31355562-31355587 GGUGGUGGGUCACGUGUGUCUUUGG 1489 3106_4_33 HLA-B Exon 4 + xp6:31355563-31355588 GUGGUGGGUCACGUGUGUCUUUGGG 1490 3106_4_34 HLA-B Exon 4 + xp6:31355571-31355596 UCACGUGUGUCUUUGGGGGGUCUGA 1491 3106_4_35 HLA-B Exon 4 + xp6:31355572-31355597 CACGUGUGUCUUUGGGGGUCUGAU 1492 3106_4_36 HLA-B Exon 4 - xp6:31355299-31355324 GAGAUGGGGUAAGGAGGGGGAUGAG 1493 3106_4_37 HLA-B Exon 4 - xp6:31355300-31355325 UGAGAUGGGGUAAGGAGGGGGAUGA 1494 3106_4_38 HLA-B Exon 4 - xp6:31355301-31355326 CUGAGAUGGGGUAAGGAGGGGGAUG 1495 3106_4_39 HLA-B Exon 4 - xp6:31355307-31355332 CUCACCCUGAGAUGGGGUAAGGAGG 1496 3106_4_40 HLA-B Exon 4 - xp6:31355308-31355333 CCUCACCCUGAGAUGGGGUAAGGAG 1497 3106_4_41 HLA-B Exon 4 - xp6:31355309-31355334 CCCUCACCCUGAGAUGGGGUAAGGA 1498 3106_4_42 HLA-B Exon 4 - xp6:31355310-31355335 CCCCUCACCCUGAGAUGGGGUAAGG 1499 3106_4_43 HLA-B Exon 4 - xp6:31355313-31355338 AAGCCCCUCACCCUGAGAUGGGGUA 1500 3106_4_44 HLA-B Exon 4 - xp6:31355318-31355343 UGCCGAAGCCCCUCACCCUGAGAUG 1501 3106_4_45 HLA-B Exon 4 - xp6:31355319-31355344 CUGCCGAAGCCCCUCACCCUGAGAU 1502 3106_4_46 HLA-B Exon 4 - xp6:31355320-31355345 GCUGCCGAAGCCCCUCACCCUGAGA 1503 3106_4_47 HLA-B Exon 4 - xp6:31355347-31355372 AUACACAUGCCAUGUACAGCAUGAG 1504 3106_4_48 HLA-B Exon 4 - xp6:31355348-31355373 GAUACACAUGCCAUGUACAGCAUGA 1505 3106_4_49 HLA-B Exon 4 - xp6:31355349-31355374 AGAUACACAUGCCAUGUACAGCAUG 1506 3106_4_50 HLA-B Exon 4 - xp6:31355387-31355412 AGUGGGCAGCUGUGGUGGUGCCUUC 1507 3106_4_51 HLA-B Exon 4 - xp6:31355397-31355422 ACCUUCCAGAAGUGGGCAGCUGUGG 1508 3106_4_52 HLA-B Exon 4 - xp6:31355400-31355425 AGAACCUUCCAGAAGUGGGCAGCUG 1509 3106_4_53 HLA-B Exon 4 - xp6:31355409-31355434 GCAGGAGAUAGAACCUUCCAGAAGU 1510 3106_4_54 HLA-B Exon 4 - xp6:31355410-31355435 AGCAGGAGAUAGAACCUUCCAGAAG 1511 3106_4_55 HLA-B Exon 4 - xp6:31355432-31355457 CUGAGCUUGUGGAGACCAGACCAGC 1512 3106_4_56 HLA-B Exon 4 - xp6:31355448-31355473 GACCAAACUCAGGACACUGAGCUUG 1513 3106_4_57 HLA-B Exon 4 - xp6:31355463-31355488 CAGCGGGAUGGCGAGGACCAAACUC 1514 3106_4_58 HLA-B Exon 4 - xp6:31355475-31355500 ACACUGACCUGGCAGCGGGAUGGCG 1515 3106_4_59 HLA-B Exon 4 - xp6:31355480-31355505 AGAUCACACUGACCUGGCAGCGGGA 1516 3106_4_60 HLA-B Exon 4 - xp6:31355484-31355509 GCGGAGAUCACACCUGACCUGGCAGC 1517 3106_4_61 HLA-B Exon 4 - xp6:31355485-31355510 UGCGGAGAUCACACCUGACCUGGCAG 1518 3106_4_62 HLA-B Exon 4 - xp6:31355491-31355516 CUACCCUGCGGAGAUCACACCUGACC 1519 3106_4_63 HLA-B Exon 4 - xp6:31355508-31355533 UGCUGGGCCCUGGGUUUCUACCCUG 1520 3106_4_64 HLA-B Exon 4 - xp6:31355522-31355547 AGGCCACCCUGAGGUGCUGGGCCCU 1521 3106_4_65 HLA-B Exon 4 - xp6:31355523-31355548 GAGGCCACCCUGAGGUGCUGGGCCC 1522 3106_4_66 HLA-B Exon 4 - xp6:31355529-31355554 GACCAUGAGGCCACCCUGAGGUGCU 1523 3106_4_67 HLA-B Exon 4 - xp6:31355530-31355555 UGACCAUGAGGCCACCCUGAGGUGC 1524 3106_4_68 HLA-B Exon 4 - xp6:31355536-31355561 CAUCUCUGACCAUGAGGCCACCCUG 1525 3106_4_69 HLA-B Exon 4 - xp6:31355547-31355572 ACCCACCACCCCAUCUCUGACCAUG 1526 3106_3_1 HLA-B Exon 3 + xp6:31356173-31356198 CUCCAGCUUGUCCUUCCCGUUCUCC 1527 3106_3_2 HLA-B Exon 3 + xp6:31356182-31356207 GUCCUUCCCGUUCUCCAGGUAUCUG 1528 3106_3_3 HLA-B Exon 3 + xp6:31356209-31356234 GAGCCACUCCACGCACUCGCCCUCC 1529 3106_3_4 HLA-B Exon 3 + xp6:31356213-31356238 CACUCCACGCACUCGCCCUCCAGGU 1530 3106_3_5 HLA-B Exon 3 + xp6:31356236-31356261 GUAGGCUCUCCGCUGCUCCGCCUCA 1531 3106_3_6 HLA-B Exon 3 + xp6:31356237-31356262 UAGGCUCUCCGCUGCUCCGCCUCAC 1532 3106_3_7 HLA-B Exon 3 + xp6:31356257-31356282 CUCACGGGCCGCCUCCCACUUGCGC 1533 3106_3_8 HLA-B Exon 3 + xp6:31356258-31356283 UCACGGGCCCGCCUCCCACUUGCGCU 1534 3106_3_9 HLA-B Exon 3 + xp6:31356282-31356307 UGGGUGAUCUGAGCCGCCGUGUCCCG 1535 3106_3_10 HLA-B Exon 3 + xp6:31356285-31356310 GUGAUCUGAGCCGCCGUGUCCGCGG 1536 3106_3_11 HLA-B Exon 3 + xp6:31356291-31356316 UGAGCCGCCGUGUCCGCGGCGGUCC 1537 3106_3_12 HLA-B Exon 3 + xp6:31356299-31356324 CGUGUCCGCGGCGGUCCAGGAGCGC 1538 3106_3_13 HLA-B Exon 3 + xp6:31356311-31356336 GGUCCAGGAGCGCAGGUCCUCGUUC 1539 3106_3_14 HLA-B Exon 3 + xp6:31356312-31356337 GUCCAGGAGCGCAGGUCCUCGUUCA 1540 3106_3_15 HLA-B Exon 3 + xp6:31356336-31356361 AGGGCGAUGUAAUCCUUGCCGUCGU 1541 3106_3_16 HLA-B Exon 3 + xp6:31356344-31356369 GUAAUCCUUGCCGUCGUAGGCGUAC 1542 3106_3_17 HLA-B Exon 3 + xp6:31356356-31356381 GUCGUAGGCGUACUGGUCAUGCCCG 1543 3106_3_18 HLA-B Exon 3 + xp6:31356359-31356384 GUAGGCGUACUGGUCAUGCCCGCGG 1544 3106_3_19 HLA-B Exon 3 + xp6:31356362-31356387 GGCGUACUGGUCAUGCCCGCGGAGG 1545 3106_3_20 HLA-B Exon 3 + xp6:31356373-31356398 CAUGCCCGCGGAGGAGGCGCCCGUC 1546 3106_3_21 HLA-B Exon 3 + xp6:31356401-31356426 CCCCACGUCGCAGCCGUACAUGCUC 1547 3106_3_22 HLA-B Exon 3 + xp6:31356404-31356429 CACGUCGCAGCCGUACAUGCUCUGG 1548 3106_3_23 HLA-B Exon 3 + xp6:31356405-31356430 ACGUCGCAGCCGUACAUGCUCUGGA 1549 3106_3_24 HLA-B Exon 3 - xp6:31356151-31356176 GAGCGCGCUGGUACCAGGGGCAGUG 1550 3106_3_25 HLA-B Exon 3 - xp6:31356152-31356177 GGAGCGCGCUGGUACCAGGGGCAGU 1551 3106_3_26 HLA-B Exon 3 - xp6:31356153-31356178 UGGAGCGCCGCUGGUACCAGGGGCAG 1552 3106_3_27 HLA-B Exon 3 - xp6:31356159-31356184 ACAAGCUGGAGCGCCGCUGGUACAG 1553 3106_3_28 HLA-B Exon 3 - xp6:31356160-31356185 GACAAGCUGGAGCGCCGCUGGUACCA 1554 3106_3_29 HLA-B Exon 3 - xp6:31356161-31356186 GGACAAGCUGGAGCGCCGCUGGUAC 1555 3106_3_30 HLA-B Exon 3 - xp6:31356168-31356193 ACGGGAAGGACAAGCUGGAGCGCGC 1556 3106_3_31 HLA-B Exon 3 - xp6:31356178-31356203 UACCUGGAGAACGGGAAGGACAAGC 1557 3106_3_32 HLA-B Exon 3 - xp6:31356187-31356212 CUCCGCAGAUACCUGGAGAACGGGA 1558 3106_3_33 HLA-B Exon 3 - xp6:31356191-31356216 GUGGCUCCGCAGAUACCUGGAGAAC 1559 3106_3_34 HLA-B Exon 3 - xp6:31356192-31356217 AGUGGCUCCGCAGAUACCUGGAGAA 1560 3106_3_35 HLA-B Exon 3 - xp6:31356199-31356224 UGCGUGGAGUGGCUCCGCAGAUACC 1561 3106_3_36 HLA-B Exon 3 - xp6:31356215-31356240 CUACCUGGAGGGCGAGUGCGUGGAG 1562 3106_3_37 HLA-B Exon 3 - xp6:31356220-31356245 AGAGCCUACCUGGAGGGCGAGUGCG 1563 3106_3_38 HLA-B Exon 3 - xp6:31356231-31356256 CGGAGCAGCGGAGAGCCUACCUGGA 1564 3106_3_39 HLA-B Exon 3 - xp6:31356232-31356257 GCGGAGCAGCGGAGAGCCUACCUGG 1565 3106_3_40 HLA-B Exon 3 - xp6:31356235-31356260 GAGGCGGAGCAGCGGAGAGCCUACC 1566 3106_3_41 HLA-B Exon 3 - xp6:31356248-31356273 GGAGGCGGCCCGUGAGGCGGAGCAG 1567 3106_3_42 HLA-B Exon 3 - xp6:31356256-31356281 CGCAAGUGGGAGGCGGCCCGUGAGG 1568 3106_3_43 HLA-B Exon 3 - xp6:31356259-31356284 CAGCGCAAGUGGGAGGCGGCCCGUG 1569 3106_3_44 HLA-B Exon 3 - xp6:31356268-31356293 CAGAUCACCCAGCGCAAGUGGGAGG 1570 3106_3_45 HLA-B Exon 3 - xp6:31356271-31356296 GCUCAGAUCACCCAGCGCAAGUGGG 1571 3106_3_46 HLA-B Exon 3 - xp6:31356274-31356299 GCGGCUCAGAUCACCCAGCGCAAGU 1572 3106_3_47 HLA-B Exon 3 - xp6:31356275-31356300 GGCGGCUCAGAUCACCCAGCGCAAG 1573 3106_3_48 HLA-B Exon 3 - xp6:31356298-31356323 CGCUCCUGGACCGCCGCGGACACGG 1574 3106_3_49 HLA-B Exon 3 - xp6:31356301-31356326 CUGCGCUCCUGGACCGCCGCGGACA 1575 3106_3_50 HLA-B Exon 3 - xp6:31356307-31356332 GAGGACCCUGCGCUCCUGGACCGCCG 1576 3106_3_51 HLA-B Exon 3 - xp6:31356317-31356342 CGCCCUGAACGAGGACCUGCCGCUCC 1577 3106_3_52 HLA-B Exon 3 - xp6:31356331-31356356 GGCAAGGAUUACAUCCGCCCUGAACG 1578 3106_3_53 HLA-B Exon 3 - xp6:31356352-31356377 CAUGACCAGUAACGCCUACGACGGCA 1579 3106_3_54 HLA-B Exon 3 - xp6:31356357-31356382 GCGGGCAUGACCAGUAACGCCUACGA 1580 3106_3_55 HLA-B Exon 3 - xp6:31356380-31356405 GGGGCCGGACGGGCCGCCUCCUCCGC 1581 3106_3_56 HLA-B Exon 3 - xp6:31356381-31356406 UGGGGCCGGACGGGCGCCUCCUCCG 1582 3106_3_57 HLA-B Exon 3 - xp6:31356395-31356420 GUACGGCUGCGACGUGGGGCCGGAC 1583 3106_3_58 HLA-B Exon 3 - xp6:31356396-31356421 UGUACGGCUGCGACGUGGGGCCGGA 1584 3106_3_59 HLA-B Exon 3 - xp6:31356400-31356425 AGCAUGUACGGCUGCGACGUGGGGC 1585 3106_3_60 HLA-B Exon 3 - xp6:31356404-31356429 CCAGAGCAUGUACGGCUGCGACGUG 1586 3106_3_61 HLA-B Exon 3 - xp6:31356405-31356430 UCCAGAGCAUGUACGGCUGCGACGU 1587 3106_3_62 HLA-B Exon 3 - xp6:31356406-31356431 CUCCAGAGCAUGUACGGCUGCGACG 1588 3106_3_63 HLA-B Exon 3 - xp6:31356417-31356442 CCUCUCACACCCUCCAGAGCAUGUA 1589 3106_2_1 HLA-B Exon 2 + xp6:31356662-31356687 UGCGCCCCGGGCCGGGGUCACUCAC 1590 3106_2_2 HLA-B Exon 2 + xp6:31356673-31356698 CCGGGGUCACUCACCGGCCUCGCUC 1591 3106_2_3 HLA-B Exon 2 + xp6:31356691-31356716 CUCGCUCUGGUUGUAGUAGCCGCGC 1592 3106_2_4 HLA-B Exon 2 + xp6:31356700-31356725 GUUGUAGUAGCCGCGCAGGUUCGCGC 1593 3106_2_5 HLA-B Exon 2 + xp6:31356709-31356734 GCCGCGCAGGUUCCGCAGGCUCUCU 1594 3106_2_6 HLA-B Exon 2 + xp6:31356724-31356749 CAGGCUCUCUCGGUCAGUCUGUGCC 1595 3106_2_7 HLA-B Exon 2 + xp6:31356725-31356750 AGGCUCUCUCGGUCAGUCUGUGCCU 1596 3106_2_8 HLA-B Exon 2 + xp6:31356748-31356773 CUGGGCCUUGUAGAUCUGUGUGUUC 1597 3106_2_9 HLA-B Exon 2 + xp6:31356762-31356787 UCUGUGUGUUCCGGUCCCAAUACUC 1598 3106_2_10 HLA-B Exon 2 + xp6:31356783-31356808 ACUCCGGCCCCUCCUGCUCUAUCCA 1599 3106_2_11 HLA-B Exon 2 + xp6:31356792-31356817 CCUCCUGCUCUAUCCACGGCGCCCG 1600 3106_2_12 HLA-B Exon 2 + xp6:31356804-31356829 UCCACGGCGCCCGCCGGCUCCUCUCU 1601 3106_2_13 HLA-B Exon 2 + xp6:31356812-31356837 GCCCGCGGCUCCUCUCUCGGACUCG 1602 3106_2_14 HLA-B Exon 2 + xp6:31356838-31356863 GGCGUCGCUGUCGAACCUCACGAAC 1603 3106_2_15 HLA-B Exon 2 + xp6:31356839-31356864 GCGUCGCUGUCGAACCUCACGAACU 1604 3106_2_16 HLA-B Exon 2 + xp6:31356871-31356896 GUCCACGUAGCCCACUGAGAUGAAG 1605 3106_2_17 HLA-B Exon 2 + xp6:31356872-31356897 UCCACGUAGCCCACUGAGAUGAAGC 1606 3106_2_18 HLA-B Exon 2 + xp6:31356873-31356898 CCACGUAGCCCACUGAGAUGAAGCG 1607 3106_2_19 HLA-B Exon 2 + xp6:31356883-31356908 CACUGAGAUGAAGCGGGGCUCCCCG 1608 3106_2_20 HLA-B Exon 2 + xp6:31356887-31356912 GAGAUGAAGCGGGGCUCCCCGCGGC 1609 3106_2_21 HLA-B Exon 2 + xp6:31356888-31356913 AGAUGAAGCGGGGCUCCCCGCGGCC 1610 3106_2_22 HLA-B Exon 2 + xp6:31356892-31356917 GAAGCGGGGCUCCCCGCGGCCGGGC 1611 3106_2_23 HLA-B Exon 2 + xp6:31356893-31356918 AAGCGGGGCUCCCCGCGGCCGGGCC 1612 3106_2_24 HLA-B Exon 2 + xp6:31356899-31356924 GGCUCCCCGCGGCCGGGCCGGGACA 1613 3106_2_25 HLA-B Exon 2 + xp6:31356902-31356927 UCCCCGCGGCCGGGCCGGGACACGG 1614 3106_2_26 HLA-B Exon 2 + xp6:31356920-31356945 GACACGGAGGUGUAGAAAUACCUCA 1615 3106_2_27 HLA-B Exon 2 + xp6:31356925-31356950 GGAGGUGUAGAAAUACCUCAUGGAG 1616 3106_2_28 HLA-B Exon 2 + xp6:31356926-31356951 GAGGUGUAGAAAUACCUCAUGGAGU 1617 3106_2_29 HLA-B Exon 2 + xp6:31356933-31356958 AGAAAUACCUCAUGGAGUGGGAGCC 1618 3106_2_30 HLA-B Exon 2 + xp6:31356934-31356959 GAAAUACCUCAUGGAGUGGGAGCCU 1619 3106_2_31 HLA-B Exon 2 + xp6:31356935-31356960 AAAUACCUCAUGGAGUGGGAGCCUG 1620 3106_2_32 HLA-B Exon 2 + xp6:31356936-31356961 AAUACCUCAUGGAGUGGGAGCCUGG 1621 3106_2_33 HLA-B Exon 2 + xp6:31356941-31356966 CUCAUGGAGUGGGAGCCUGGGGGUG 1622 3106_2_34 HLA-B Exon 2 + xp6:31356944-31356969 AUGGAGUGGGAGCCUGGGGGUGAGG 1623 3106_2_35 HLA-B Exon 2 + xp6:31356945-31356970 UGGAGUGGGAGCCUGGGGGUGAGGA 1624 3106_2_36 HLA-B Exon 2 + xp6:31356946-31356971 GGAGUGGGAGCCUGGGGGUGAGGAG 1625 3106_2_37 HLA-B Exon 2 - xp6:31356669-31356694 GAGGCCGGUGAGUGACCCCGGCCCG 1626 3106_2_38 HLA-B Exon 2 - xp6:31356670-31356695 CGAGGCCGGUGAGUGACCCCGGCCC 1627 3106_2_39 HLA-B Exon 2 - xp6:31356671-31356696 GCGAGGCCGGUGAGUGACCCCGGCC 1628 3106_2_40 HLA-B Exon 2 - xp6:31356676-31356701 CCAGAGCGAGGCCGGUGAGUGACCCC 1629 3106_2_41 HLA-B Exon 2 - xp6:31356689-31356714 GCGGCUACUACAACCAGCGAGGC 1630 3106_2_42 HLA-B Exon 2 - xp6:31356693-31356718 CUGCGCGGCUACUACAACCAGAGCG 1631 3106_2_43 HLA-B Exon 2 - xp6:31356713-31356738 ACCGAGAGGCCUGCGGAACCUGCG 1632 3106_2_44 HLA-B Exon 2 - xp6:31356724-31356749 GGCACAGACUGACCGAGAGAGCCUG 1633 3106_2_45 HLA-B Exon 2 - xp6:31356750-31356775 CGGAACACACAGAUCUACAAAGGCCC 1634 3106_2_46 HLA-B Exon 2 - xp6:31356756-31356781 UGGGACCGGAACACACAGAUCUACA 1635 3106_2_47 HLA-B Exon 2 - xp6:31356775-31356800 GCAGGAGGGGCCGGAGUAUUGGGAC 1636 3106_2_48 HLA-B Exon 2 - xp6:31356780-31356805 AUAGAGCAGGAGGGCCGGAGUAUU 1637 3106_2_49 HLA-B Exon 2 - xp6:31356781-31356806 GAUAGAGCAGGAGGGGCCGGAGUAU 1638 3106_2_50 HLA-B Exon 2 - xp6:31356789-31356814 GCGCCGUGGAUAGAGCAGGAGGGGC 1639 3106_2_51 HLA-B Exon 2 - xp6:31356793-31356818 GCGGGCCGCCGUGGAUAGAGCAGGAG 1640 3106_2_52 HLA-B Exon 2 - xp6:31356794-31356819 CGCGGGCCGCCGUGGAUAGAGCAGGA 1641 3106_2_53 HLA-B Exon 2 - xp6:31356795-31356820 CCGCGGGCCGCCGUGGAUAGAGCAGG 1642 3106_2_54 HLA-B Exon 2 - xp6:31356798-31356823 GAGCCGCGGGCCGCCGUGGAUAGAGC 1643 3106_2_55 HLA-B Exon 2 - xp6:31356808-31356833 UCCGAGAGAGGAGCCGCGGGCGCCG 1644 3106_2_56 HLA-B Exon 2 - xp6:31356816-31356841 GCCGCGAGUCCGAGAGAGGAGCCGC 1645 3106_2_57 HLA-B Exon 2 - xp6:31356817-31356842 CGCCGCGAGUCCGAGAGAGGAGCCG 1646 3106_2_58 HLA-B Exon 2 - xp6:31356825-31356850 GACAGCGACGCCGCGAGUCCGAGAG 1647 3106_2_59 HLA-B Exon 2 - xp6:31356856-31356881 CUACGUGGACGACACCCAGUUCGUG 1648 3106_2_60 HLA-B Exon 2 - xp6:31356876-31356901 CCCCGCUUCAUCUCAGUGGGCUACG 1649 3106_2_61 HLA-B Exon 2 - xp6:31356884-31356909 GCGGGGAGCCCCGCUUCAUCUCAGU 1650 3106_2_62 HLA-B Exon 2 - xp6:31356885-31356910 CGCGGGGAGCCCCGCUUCAUCUCAG 1651 3106_2_63 HLA-B Exon 2 - xp6:31356906-31356931 ACCUCCGUGUCCCGGCCCGGCCGCG 1652 3106_2_64 HLA-B Exon 2 - xp6:31356907-31356932 CACCUCCGUGUCCCGGCCCGGCCGC 1653 3106_2_65 HLA-B Exon 2 - xp6:31356908-31356933 ACACCUCCGUGUCCCGGCCCGGCCG 1654 3106_2_66 HLA-B Exon 2 - xp6:31356914-31356939 AUUUCUACACCUCCGUGUCCCGGCC 1655 3106_2_67 HLA-B Exon 2 - xp6:31356919-31356944 GAGGUAUUUCUACACCUCCGUGUCC 1656 3106_2_68 HLA-B Exon 2 - xp6:31356943-31356968 CUCACCCCCAGGCUCCCACUCCAUG 1657 3106_1_1 HLA-B Exon 1 + xp6:31357060-31357085 CAUUUCCCUCCCGACCCGCACUCAC 1658 3106_1_2 HLA-B Exon 1 + xp6:31357066-31357091 CCUCCCGACCCGCACUCACCGGCCC 1659 3106_1_3 HLA-B Exon 1 + xp6:31357072-31357097 GACCCGCACUCACCGGCCCAGGUCU 1660 3106_1_4 HLA-B Exon 1 + xp6:31357077-31357102 GCACUCACCGGCCCAGGUCUCGGUC 1661 3106_1_5 HLA-B Exon 1 + xp6:31357078-31357103 CACUCACCGGCCCAGGUCUCGGUCA 1662 3106_1_6 HLA-B Exon 1 + xp6:31357083-31357108 ACCGGCCCAGGUCUCGGUCAGGGCC 1663 3106_1_7 HLA-B Exon 1 + xp6:31357084-31357109 CCGGCCCAGGUCUCGGUCAGGGCCA 1664 3106_1_8 HLA-B Exon 1 + xp6:31357101-31357126 CAGGGCCAGGGCCGCCGAGAGCAGC 1665 3106_1_9 HLA-B Exon 1 + xp6:31357104-31357129 GGCCAGGGCCGCCGAGAGCAGCAGG 1666 3106_1_10 HLA-B Exon 1 + xp6:31357108-31357133 AGGGCCGCCGAGAGCAGCAGGAGGA 1667 3106_1_11 HLA-B Exon 1 + xp6:31357113-31357138 CGCCGAGAGCAGCAGGAGGACGGUU 1668 3106_1_12 HLA-B Exon 1 + xp6:31357114-31357139 GCCGAGAGCAGCAGGAGGACGGUUC 1669 3106_1_13 HLA-B Exon 1 + xp6:31357115-31357140 CCGAGAGCAGCAGGAGGACGGUUCG 1670 3106_1_14 HLA-B Exon 1 + xp6:31357135-31357160 GUUCGGGGCGCCAUGACCAGCAUCU 1671 3106_1_15 HLA-B Exon 1 + xp6:31357144-31357169 GCCAUGACCAGCAUCUCCGGCGUCUG 1672 3106_1_16 HLA-B Exon 1 + xp6:31357159-31357184 UCGGCGUCUGAGGAGACUCUGAGUC 1673 3106_1_17 HLA-B Exon 1 + xp6:31357160-31357185 CGGCGUCUGAGGAGACUCUGAGUCC 1674 3106_1_18 HLA-B Exon 1 + xp6:31357163-31357188 CGUCUGAGGAGACUCUGAGUCCGGG 1675 3106_1_19 HLA-B Exon 1 + xp6:31357164-31357189 GUCUGAGGAGACUCUGAGUCCGGGU 1676 3106_1_20 HLA-B Exon 1 + xp6:31357171-31357196 GAGACUCUGAGUCCGGGUGGGUGCG 1677 3106_1_21 HLA-B Exon 1 + xp6:31357172-31357197 AGACUCUGAGUCCGGGUGGGUGCGU 1678 3106_1_22 HLA-B Exon 1 + xp6:31357173-31357198 GACUCUGAGUCCGGGUGGGUGCGUG 1679 3106_1_23 HLA-B Exon 1 + xp6:31357186-31357211 GGUGGGUGCGUGGGGACUUUAGAAC 1680 3106_1_24 HLA-B Exon 1 + xp6:31357187-31357212 GUGGGUGCGUGGGGACUUUAGACU 1681 3106_1_25 HLA-B Exon 1 + xp6:31357194-31357219 CGUGGGGACUUUAGAACUGGGACCG 1682 3106_1_26 HLA-B Exon 1 + xp6:31357207-31357232 GAACUGGGACCGCGGCGACGCUGAU 1683 3106_1_27 HLA-B Exon 1 - xp6:31357068-31357093 CUGGGCCGGUGAGUGCGGGUCGGGA 1684 3106_1_28 HLA-B Exon 1 - xp6:31357069-31357094 CCUGGGCCGGUGAGUGCGGGUCGGG 1685 3106_1_29 HLA-B Exon 1 - xp6:31357072-31357097 AGACCUGGGCCGGUGAGUGCGGGUC 1686 3106_1_30 HLA-B Exon 1 - xp6:31357073-31357098 GAGACCUGGGCCGGUGAGUGCGGGU 1687 3106_1_31 HLA-B Exon 1 - xp6:31357077-31357102 GACCGAGACCUGGGCCGGUGAGUGC 1688 3106_1_32 HLA-B Exon 1 - xp6:31357078-31357103 UGACCGAGACCUGGGCCGGUGAGUG 1689 3106_1_33 HLA-B Exon 1 - xp6:31357087-31357112 CCCUGGCCCUGACCGAGACCUGGGC 1690 3106_1_34 HLA-B Exon 1 - xp6:31357091-31357116 GCGGCCCUGGCCCUGACCGAGACCU 1691 3106_1_35 HLA-B Exon 1 - xp6:31357092-31357117 GGCGGCCCUGGCCCUGACCGAGACC 1692 3106_1_36 HLA-B Exon 1 - xp6:31357109-31357134 GUCCUCCUGCUGCUCUCGGCGGCCC 1693 3106_1_37 HLA-B Exon 1 - xp6:31357115-31357140 CGAACCGUCCUCCUGCUGCUCUCGG 1694 3106_1_38 HLA-B Exon 1 - xp6:31357118-31357143 CCCCGAACCGUCCUCCUGCUGCUCU 1695 3106_1_39 HLA-B Exon 1 - xp6:31357148-31357173 UCCUCAGACGCCGAGAUGCUGGUCA 1696 3106_1_40 HLA-B Exon 1 - xp6:31357154-31357179 AGAGUCUCCUCAGACGCCGAGAUGC 1697 3106_1_41 HLA-B Exon 1 - xp6:31357186-31357211 GUUCUAAAGUCCCCACCGCACCCACC 1698 3107_8_1 HLA-C Exon 8 + xp6:31268726-31268751 CUCAGCACAGCGAACAUGCAAAUUC 1699 3107_8_2 HLA-C Exon 8 + xp6:31268730-31268755 GCACAGCGAACAUGCAAAUUCUGGA 1700 3107_8_3 HLA-C Exon 8 + xp6:31268738-31268763 AACAUGCAAAUUCUGGAAGGUUCUC 1701 3107_8_4 HLA-C Exon 8 + xp6:31268765-31268790 GUCUUUAUUUGCUCUCUCAACUUCU 1702 3107_8_5 HLA-C Exon 8 + xp6:31268834-31268859 UAUUUGAGAACACAAAUUUAUAUUC 1703 3107_8_6 HLA-C Exon 8 + xp6:31268851-31268876 UUAUAUUCAGGUUCUUAACUUCAUU 1704 3107_8_7 HLA-C Exon 8 + xp6:31268852-31268877 UAUAUUCAGGUUCUUAACUUCAUUA 1705 3107_8_8 HLA-C Exon 8 + xp6:31268900-31268925 GUGCACCAUGAAUUUGAGACAGAGA 1706 3107_8_9 HLA-C Exon 8 + xp6:31268924-31268949 AUGGAGACAUCCAGCCCCACCUCUC 1707 3107_8_10 HLA-C Exon 8 + xp6:31268930-31268955 ACAUCCAGCCCCACCUCUCUGGAAC 1708 3107_8_11 HLA-C Exon 8 + xp6:31268942-31268967 ACCUCUCUGGAACAGGAAAAGAUGAU 1709 3107_8_12 HLA-C Exon 8 + xp6:31268943-31268968 CCUCUCUGGAACAGGAAAGAUGAUC 1710 3107_8_13 HLA-C Exon 8 + xp6:31268944-31268969 CUCUCUGGAACAGGAAAAGAUGAUCG 1711 3107_8_14 HLA-C Exon 8 + xp6:31268947-31268972 UCUGGAACAGGAAAGAUGAUCGGGG 1712 3107_8_15 HLA-C Exon 8 + xp6:31268948-31268973 CUGGAACAGGAAAGAUGAUCGGGGA 1713 3107_8_16 HLA-C Exon 8 + xp6:31268956-31268981 GGAAAGAUGAUCGGGGAGGGAACAC 1714 3107_8_17 HLA-C Exon 8 + xp6:31268965-31268990 AUCGGGGAGGGAACACAGGUCAGUG 1715 3107_8_18 HLA-C Exon 8 + xp6:31268966-31268991 UCGGGGAGGGAACACAGGUCAGUGU 1716 3107_8_19 HLA-C Exon 8 + xp6:31268967-31268992 CGGGGAGGGAACACAGGUCAGUGUG 1717 3107_8_20 HLA-C Exon 8 + xp6:31268972-31268997 AGGGAACACAGGUCAGUGUGGGGAC 1718 3107_8_21 HLA-C Exon 8 + xp6:31268973-31268998 GGGAACACAGGUCAGUGUGGGGACA 1719 3107_8_22 HLA-C Exon 8 + xp6:31268974-31268999 GGAACACAGGUCAGUGUGGGGACAG 1720 3107_8_23 HLA-C Exon 8 + xp6:31268980-31269005 CAGGUCAGUGUGGGGACAGGGGUCA 1721 3107_8_24 HLA-C Exon 8 + xp6:31268983-31269008 GUCAGUGUGGGGACAGGGGUCACGG 1722 3107_8_25 HLA-C Exon 8 + xp6:31268989-31269014 GUGGGGACAGGGGUCACGGUGGACA 1723 3107_8_26 HLA-C Exon 8 + xp6:31268990-31269015 UGGGGACAGGGGUCACGGUGGACAC 1724 3107_8_27 HLA-C Exon 8 + xp6:31268991-31269016 GGGGACAGGGGUCACGGUGGACACG 1725 3107_8_28 HLA-C Exon 8 + xp6:31268992-31269017 GGGACAGGGGUCACGGUGGACACGG 1726 3107_8_29 HLA-C Exon 8 + xp6:31268995-31269020 ACAGGGGUCACGGUGGACACGGGGG 1727 3107_8_30 HLA-C Exon 8 + xp6:31268996-31269021 CAGGGGUCACGGUGGACACGGGGGU 1728 3107_8_31 HLA-C Exon 8 + xp6:31269030-31269055 CUCCACCUCCUCACAUUAUGCUAAC 1729 3107_8_32 HLA-C Exon 8 + xp6:31269048-31269073 UGCUAACAGGAACGCAGACACAUUC 1730 3107_8_33 HLA-C Exon 8 + xp6:31269075-31269100 GUGCCUUUGCAGAAAGAGAUGCCAG 1731 3107_8_34 HLA-C Exon 8 + xp6:31269093-31269118 AUGCCAGAGGCUCUUGAAGUCACAA 1732 3107_8_35 HLA-C Exon 8 + xp6:31269098-31269123 AGAGGCUCUUGAAGUCACAAAGGAG 1733 3107_8_36 HLA-C Exon 8 + xp6:31269132-31269157 GAAAUCCUGCAUCUCAGUCCCACAC 1734 3107_8_37 HLA-C Exon 8 + xp6:31269145-31269170 UCAGUCCCACACAGGCAGCUGUCUC 1735 3107_8_38 HLA-C Exon 8 - xp6:31268816-31268841 UCAAAUAUUUGCUAUGAAGCGUUGA 1736 3107_8_39 HLA-C Exon 8 - xp6:31268908-31268933 UGUCUCCAUCUCUGUCUCAAAUUCA 1737 3107_8_40 HLA-C Exon 8 - xp6:31268937-31268962 CUUUCCUGUUCCAGAGAGGUGGGGC 1738 3107_8_41 HLA-C Exon 8 - xp6:31268941-31268966 UCAUCUUUCCUGUUCCAGAGAGGUG 1739 3107_8_42 HLA-C Exon 8 - xp6:31268942-31268967 AUCAUCUUUCCUGUUCCAGAGAGGU 1740 3107_8_43 HLA-C Exon 8 - xp6:31268943-31268968 GAUCAUCUUUCCUGUUCCAGAGAGG 1741 3107_8_44 HLA-C Exon 8 - xp6:31268946-31268971 CCCGAUCAUCUUUCCUGUUCCAGAG 1742 3107_8_45 HLA-C Exon 8 - xp6:31269035-31269060 UUCCUGUUAGCAUAAUGUGAGGAGG 1743 3107_8_46 HLA-C Exon 8 - xp6:31269038-31269063 GCGUUCCUGUUAGCAUAAUGUGAGG 1744 3107_8_47 HLA-C Exon 8 - xp6:31269041-31269066 UCUGCGUUCCUGUUAGCAUAAUGUG 1745 3107_8_48 HLA-C Exon 8 - xp6:31269081-31269106 GAGCCUCUGGCAUCUCUUUCGCAA 1746 3107_8_49 HLA-C Exon 8 - xp6:31269099-31269124 UCUCCUUUGUGACUUCAAGAGCCUC 1747 3107_8_50 HLA-C Exon 8 - xp6:31269140-31269165 AGCUGCCUGUGUGGGACUGAGAUGC 1748 3107_8_51 HLA-C Exon 8 - xp6:31269153-31269178 UGUAGCCUGAGACAGCUGCCUGUGU 1749 3107_8_52 HLA-C Exon 8 - xp6:31269154-31269179 CUGUAGCCUGAGACAGCUGCCUGUG 1750 3107_7_1 HLA-C Exon 7 + xp6:31269344-31269369 AGUGAUGAGAGACUCAUCAGAGCCCC 1751 3107_7_2 HLA-C Exon 7 + xp6:31269345-31269370 GUGAUGAGAGACUCAUCAGAGCCCU 1752 3107_7_3 HLA-C Exon 7 + xp6:31269361-31269386 CAGAGCCCUGGGCACUGUUGCUGCC 1753 3107_7_4 HLA-C Exon 7 + xp6:31269362-31269387 AGAGCCCUGGGCACUGUUGCUGCCU 1754 3107_7_5 HLA-C Exon 7 + xp6:31269363-31269388 GAGCCCUGGGCACUGUUGCUGCCUG 1755 3107_7_6 HLA-C Exon 7 - xp6:31269315-31269340 AAGGUGAGAUUCUGGGGAGCUGAAG 1756 3107_7_7 HLA-C Exon 7 - xp6:31269326-31269351 CAUCACUUGUAAAGGUGAGAUUCUG 1757 3107_7_8 HLA-C Exon 7 - xp6:31269327-31269352 UCAUCACUUGUAAAGGUGAGAUUCU 1758 3107_7_9 HLA-C Exon 7 - xp6:31269328-31269353 CUCAUCACUUGUAAAGGUGAGAUUC 1759 3107_7_10 HLA-C Exon 7 - xp6:31269339-31269364 CUGAUGAGUCUCUCAUCAUCACUUGUAA 1760 3107_7_11 HLA-C Exon 7 - xp6:31269369-31269394 CUACCCCAGGCAGCAACAGUGCCCA 1761 3107_7_12 HLA-C Exon 7 - xp6:31269370-31269395 UCUACCCCAGGCAGCAACAGUGCCC 1762 3107_6_1 HLA-C Exon 6 + xp6:31269503-31269528 GAGCAGCUCCCUCCUUUUCCACCUG 1763 3107_6_2 HLA-C Exon 6 + xp6:31269504-31269529 AGCAGCUCCCUCCUUUUCCACCUGU 1764 3107_6_3 HLA-C Exon 6 - xp6:31269470-31269495 CGUGUAAGUGAUGGCGGCGGGCGUG 1765 3107_6_4 HLA-C Exon 6 - xp6:31269477-31269502 CAGGCUGCGUGUAAGUGAUGGCGGC 1766 3107_6_5 HLA-C Exon 6 - xp6:31269478-31269503 UCAGGCUGCGUGUAAGUGAUGGCGG 1767 3107_6_6 HLA-C Exon 6 - xp6:31269481-31269506 CUCUCAGGCUGCGUGUAAGUGAUGG 1768 3107_6_7 HLA-C Exon 6 - xp6:31269484-31269509 CUGCUCUCAGGCUGCGUGUAAGUGA 1769 3107_6_8 HLA-C Exon 6 - xp6:31269501-31269526 GGUGGAAAAGGAGGGAGCUGCUCUC 1770 3107_6_9 HLA-C Exon 6 - xp6:31269514-31269539 UUUUCUUCCCACAGGUGGAAAAGGA 1771 3107_6_10 HLA-C Exon 6 - xp6:31269515-31269540 AUUUUCUUCCCACAGGUGGAAAAGG 1772 3107_6_11 HLA-C Exon 6 - xp6:31269518-31269543 GGCAUUUUCUUCCCACAGGUGGAAA 1773 3107_6_12 HLA-C Exon 6 - xp6:31269524-31269549 UCAUAGGGCAUUUUCUUCCCACAGG 1774 3107_5_1 HLA-C Exon 5 + xp6:31269967-31269992 GAGCUCUUCCUCCUACACAUCAUAG 1775 3107_5_2 HLA-C Exon 5 + xp6:31269984-31270009 CAUCAUAGCGGUGACCACAGCUCCA 1776 3107_5_3 HLA-C Exon 5 + xp6:31269993-31270018 GGUGACCACAGCUCCAAGGACAGCU 1777 3107_5_4 HLA-C Exon 5 + xp6:31270002-31270027 AGCUCCAAGGACAGCUAGGACAACC 1778 3107_5_5 HLA-C Exon 5 + xp6:31270011-31270036 GACAGCUAGGACAACCAGGACAGCC 1779 3107_5_6 HLA-C Exon 5 + xp6:31270033-31270058 GCCAGGCCAGCAACGAUGCCCAUGA 1780 3107_5_7 HLA-C Exon 5 + xp6:31270034-31270059 CCAGGCCAGCAACGAUGCCCAUGAU 1781 3107_5_8 HLA-C Exon 5 + xp6:31270035-31270060 CAGGCCAGCAACGAUGCCCAUGAUG 1782 3107_5_9 HLA-C Exon 5 + xp6:31270039-31270064 CCAGCAACGAUGCCCAUGAUGGGGA 1783 3107_5_10 HLA-C Exon 5 + xp6:31270042-31270067 GCAACGAUGCCCAUGAUGGGGAUGG 1784 3107_5_11 HLA-C Exon 5 + xp6:31270043-31270068 CAACGAUGCCCAUGAUGGGGAUGGU 1785 3107_5_12 HLA-C Exon 5 + xp6:31270047-31270072 GAUGCCCAUGAUGGGGAUGGUGGGC 1786 3107_5_13 HLA-C Exon 5 + xp6:31270048-31270073 AUGCCCAUGAUGGGGAUGGUGGGCU 1787 3107_5_14 HLA-C Exon 5 + xp6:31270055-31270080 UGAUGGGGAUGGUGGGCUGGGAAGA 1788 3107_5_15 HLA-C Exon 5 + xp6:31270061-31270086 GGAUGGUGGGCUGGGAAGAUGGCUC 1789 3107_5_16 HLA-C Exon 5 + xp6:31270062-31270087 GAUGGUGGGCUGGGAAGAUGGCUCU 1790 3107_5_17 HLA-C Exon 5 + xp6:31270067-31270092 UGGGCUGGGAAGAUGGCUCUGGGAA 1791 3107_5_18 HLA-C Exon 5 + xp6:31270070-31270095 GCUGGGAAGAUGGCUCUGGGAAAGG 1792 3107_5_19 HLA-C Exon 5 + xp6:31270076-31270101 AAGAUGGCUCUGGGAAAGGAGGAGA 1793 3107_5_20 HLA-C Exon 5 + xp6:31270081-31270106 GGCUCUGGGAAAGGAGGAGAAGGUG 1794 3107_5_21 HLA-C Exon 5 + xp6:31270082-31270107 GCUCUGGGAAAGGAGGAGAAGGUGA 1795 3107_5_22 HLA-C Exon 5 - xp6:31269944-31269969 UCAGGUAGGGAAGGGGUGAAGAGCG 1796 3107_5_23 HLA-C Exon 5 - xp6:31269945-31269970 CUCAGGUAGGGAAGGGGUGAAGAGC 1797 3107_5_24 HLA-C Exon 5 - xp6:31269946-31269971 GCUCAGGUAGGGAAGGGGUGAAGAG 1798 3107_5_25 HLA-C Exon 5 - xp6:31269956-31269981 AGGAGGAAGAGCUCAGGUAGGGAAG 1799 3107_5_26 HLA-C Exon 5 - xp6:31269957-31269982 UAGGAGGAAGAGCUCAGGUAGGGAA 1800 3107_5_27 HLA-C Exon 5 - xp6:31269958-31269983 GUAGGAGGAAGAGCUCAGGUAGGGA 1801 3107_5_28 HLA-C Exon 5 - xp6:31269962-31269987 AUGUGUAGGAGGAAGAGCUCAGGUA 1802 3107_5_29 HLA-C Exon 5 - xp6:31269963-31269988 GAUGUGUAGGAGGAAGAGCUCAGGU 1803 3107_5_30 HLA-C Exon 5 - xp6:31269967-31269992 CUAUGAUGUGUAGGAGGAAGAGCUC 1804 3107_5_31 HLA-C Exon 5 - xp6:31269978-31270003 UGUGGUCACCGCUAUGAUGUGUAGG 1805 3107_5_32 HLA-C Exon 5 - xp6:31269981-31270006 AGCUGUGGUCACCGCUAUGAUGUGU 1806 3107_5_33 HLA-C Exon 5 - xp6:31270001-31270026 GUUGUCCUAGCUGUCCUUGGAGCUG 1807 3107_5_34 HLA-C Exon 5 - xp6:31270009-31270034 CUGUCCUGGUUGUCCUAGCUGUCCU 1808 3107_5_35 HLA-C Exon 5 - xp6:31270028-31270053 GGCAUCGUUGCUGGCCUGGCUGUCC 1809 3107_5_36 HLA-C Exon 5 - xp6:31270037-31270062 CCCAUCAUGGGCAUCGUUGCUGGCC 1810 3107_5_37 HLA-C Exon 5 - xp6:31270042-31270067 CCAUCCCCAUCAUGGGCAUCGUUGC 1811 3107_5_38 HLA-C Exon 5 - xp6:31270054-31270079 CUUCCCAGCCCACCAUCCCAUCAU 1812 3107_5_39 HLA-C Exon 5 - xp6:31270055-31270080 UCUUCCCAGCCCACCAUCCCCAUCA 1813 3107_4_1 HLA-C Exon 4 + xp6:31270192-31270217 CCCAUUCCCCCUCCUUACCCCAGCUC 1814 3107_4_2 HLA-C Exon 4 + xp6:31270193-31270218 CCAUUCCCCCUCCUUACCCCAGCUCA 1815 3107_4_3 HLA-C Exon 4 + xp6:31270198-31270223 CCCCUCCUUACCCCAGCUCAGGGUG 1816 3107_4_4 HLA-C Exon 4 + xp6:31270199-31270224 CCCUCCUUACCCCAGCUCAGGGUGA 1817 3107_4_5 HLA-C Exon 4 + xp6:31270200-31270225 CCUCCUUACCCCAGCUCAGGGUGAG 1818 3107_4_6 HLA-C Exon 4 + xp6:31270228-31270253 CUCUUGCAGCCCCUCGUGCUGCAUA 1819 3107_4_7 HLA-C Exon 4 + xp6:31270257-31270282 ACGUGUAUCUCUGCUCUUGUCCCAGA 1820 3107_4_8 HLA-C Exon 4 + xp6:31270282-31270307 AGGCACCACCACAGCUGCCCACUUC 1821 3107_4_9 HLA-C Exon 4 + xp6:31270286-31270311 ACCACCACAGCUGCCCACUUCUGGA 1822 3107_4_10 HLA-C Exon 4 + xp6:31270302-31270327 ACUUCUGGAAGGUUCCAUCUCCUGC 1823 3107_4_11 HLA-C Exon 4 + xp6:31270307-31270332 UGGAAGGUUCCAUCUCCUGCUGGCC 1824 3107_4_12 HLA-C Exon 4 + xp6:31270322-31270347 CCUGCUGGCCUGGUCUCCCAAGCU 1825 3107_4_13 HLA-C Exon 4 + xp6:31270330-31270355 CCUGGUCUCCCACAAGCUCGGUGUCC 1826 3107_4_14 HLA-C Exon 4 + xp6:31270331-31270356 CUGGUCUCCCACAAGCUCGGUGUCCU 1827 3107_4_15 HLA-C Exon 4 + xp6:31270336-31270361 CUCCACAAGCUCGGUGUCCUGGGUC 1828 3107_4_16 HLA-C Exon 4 + xp6:31270358-31270383 GUCUGGUCCUCCCCAUCCCGCUGCC 1829 3107_4_17 HLA-C Exon 4 + xp6:31270377-31270402 GCUGCCAGGUCAGUGUGAUCUCCGC 1830 3107_4_18 HLA-C Exon 4 + xp6:31270378-31270403 CUGCCAGGUCAGUGUGAUCUCCGCA 1831 3107_4_19 HLA-C Exon 4 + xp6:31270390-31270415 UGUGAUCUCCCGCAGGGUAGAAGCCC 1832 3107_4_20 HLA-C Exon 4 + xp6:31270391-31270416 GUGAUCUCCCGCAGGGUAGAAGCCCA 1833 3107_4_21 HLA-C Exon 4 + xp6:31270405-31270430 GUAGAAGCCCAGGGCCCAGCACCUC 1834 3107_4_22 HLA-C Exon 4 + xp6:31270406-31270431 UAGAAGCCCAGGGCCCAGCACCUCCA 1835 3107_4_23 HLA-C Exon 4 + xp6:31270409-31270434 AAGCCCAGGGCCCAGCACCUCAGGG 1836 3107_4_24 HLA-C Exon 4 + xp6:31270417-31270442 GGCCCAGCACCUCAGGGUGGCCUCA 1837 3107_4_25 HLA-C Exon 4 + xp6:31270426-31270451 CCUCAGGGUGGCCUCAUGGUCAGAG 1838 3107_4_26 HLA-C Exon 4 + xp6:31270427-31270452 CUCAGGGUGGCCUCAUGGUCAGAGA 1839 3107_4_27 HLA-C Exon 4 + xp6:31270428-31270453 UCAGGGUGGCCUCAUGGUCAGAGAG 1840 3107_4_28 HLA-C Exon 4 + xp6:31270429-31270454 CAGGGUGGCCUCAUGGUCAGAGAGG 1841 3107_4_29 HLA-C Exon 4 + xp6:31270432-31270457 GGUGGCCUCAUGGUCAGAGAGGGGG 1842 3107_4_30 HLA-C Exon 4 + xp6:31270435-31270460 GGCCUCAUGGUCAGAGAGGGGGUGG 1843 3107_4_31 HLA-C Exon 4 + xp6:31270436-31270461 GCCUCAUGGUCAGAGAGGGGGUGGU 1844 3107_4_32 HLA-C Exon 4 + xp6:31270452-31270477 GGGGGUGGUGGGUCACGUGUGUCUU 1845 3107_4_33 HLA-C Exon 4 + xp6:31270453-31270478 GGGGUGGUGGGUCACGUGUGUCUUU 1846 3107_4_34 HLA-C Exon 4 + xp6:31270454-31270479 GGGUGGUGGGUCACGUGUGUCUUUG 1847 3107_4_35 HLA-C Exon 4 + xp6:31270455-31270480 GGUGGUGGGUCACGUGUGUCUUUGG 1848 3107_4_36 HLA-C Exon 4 + xp6:31270464-31270489 UCACGUGUGUCUUUGGGGGUUCUGA 1849 3107_4_37 HLA-C Exon 4 + xp6:31270465-31270490 CACGUGUGUCUUUGGGGGUUCUGAC 1850 3107_4_38 HLA-C Exon 4 - xp6:31270192-31270217 GAGCUGGGGUAAGGAGGGGAAUGGG 1851 3107_4_39 HLA-C Exon 4 - xp6:31270193-31270218 UGAGCUGGGGUAAGGAGGGGAAUGG 1852 3107_4_40 HLA-C Exon 4 - xp6:31270194-31270219 CUGAGCUGGGGUAAGGAGGGGAAUG 1853 3107_4_41 HLA-C Exon 4 - xp6:31270195-31270220 CCUGAGCUGGGGUAAGGAGGGGAAU 1854 3107_4_42 HLA-C Exon 4 - xp6:31270196-31270221 CCCUGAGCUGGGGUAAGGAGGGGAA 1855 3107_4_43 HLA-C Exon 4 - xp6:31270201-31270226 CCUCACCCUGAGCUGGGGUAAGGAG 1856 3107_4_44 HLA-C Exon 4 - xp6:31270202-31270227 CCCUCACCCUGAGCUGGGGUAAGGA 1857 3107_4_45 HLA-C Exon 4 - xp6:31270203-31270228 CCCCUCACCCUGAGCUGGGGUAAGG 1858 3107_4_46 HLA-C Exon 4 - xp6:31270206-31270231 GAGCCCCUCACCCUGAGCUGGGGUA 1859 3107_4_47 HLA-C Exon 4 - xp6:31270211-31270236 UGCAAGAGCCCCUCACCCUGAGCUG 1860 3107_4_48 HLA-C Exon 4 - xp6:31270212-31270237 CUGCAAGAGCCCCUCACCCUGAGCU 1861 3107_4_49 HLA-C Exon 4 - xp6:31270213-31270238 GCUGCAAGAGCCCCUCACCCUGAGC 1862 3107_4_50 HLA-C Exon 4 - xp6:31270240-31270265 AUACACGUGCCAUAUGCAGCACGAG 1863 3107_4_51 HLA-C Exon 4 - xp6:31270241-31270266 GAUACACGUGCCAUAUGCAGCACGA 1864 3107_4_52 HLA-C Exon 4 - xp6:31270242-31270267 AGAUACACGUGCCAUAUGCAGCACG 1865 3107_4_53 HLA-C Exon 4 - xp6:31270280-31270305 AGUGGGCAGCUGUGGUGGUGCCUUC 1866 3107_4_54 HLA-C Exon 4 - xp6:31270290-31270315 ACCUUCCAGAAGUGGGCAGCUGUGG 1867 3107_4_55 HLA-C Exon 4 - xp6:31270293-31270318 GGAACCUUCCAGAAGUGGGCAGCUG 1868 3107_4_56 HLA-C Exon 4 - xp6:31270302-31270327 GCAGGAGAUGGAACCUUCCAGAAGU 1869 3107_4_57 HLA-C Exon 4 - xp6:31270303-31270328 AGCAGGAGAUGGAACCUUCCAGAAG 1870 3107_4_58 HLA-C Exon 4 - xp6:31270319-31270344 UUGUGGAGACCAGGCCAGCAGGAGA 1871 3107_4_59 HLA-C Exon 4 - xp6:31270325-31270350 CCGAGCUUGUGGAGACCAGGCCAGC 1872 3107_4_60 HLA-C Exon 4 - xp6:31270333-31270358 CCAGGACACCGAGCUUGUGGAGACC 1873 3107_4_61 HLA-C Exon 4 - xp6:31270341-31270366 GACCAGACCCAGGACACCGAGCUUG 1874 3107_4_62 HLA-C Exon 4 - xp6:31270356-31270381 CAGCGGGAUGGGGAGGACCAGACCC 1875 3107_4_63 HLA-C Exon 4 - xp6:31270368-31270393 ACACUGACCUGGCAGCGGGAUGGGG 1876 3107_4_64 HLA-C Exon 4 - xp6:31270371-31270396 AUCACACUGACCUGGCAGCGGGAUG 1877 3107_4_65 HLA-C Exon 4 - xp6:31270372-31270397 GAUCACACUGACCUGGCAGCGGGAU 1878 3107_4_66 HLA-C Exon 4 - xp6:31270373-31270398 AGAUCACACUGACCUGGCAGCGGGA 1879 3107_4_67 HLA-C Exon 4 - xp6:31270377-31270402 GCGGAGAUCACACCUGACCUGGCAGC 1880 3107_4_68 HLA-C Exon 4 - xp6:31270378-31270403 UGCGGAGAUCACACCUGACCUGGCAG 1881 3107_4_69 HLA-C Exon 4 - xp6:31270384-31270409 CUACCCUGCGGAGAUCACACCUGACC 1882 3107_4_70 HLA-C Exon 4 - xp6:31270401-31270426 UGCUGGGCCCUGGGCUUCUACCCUG 1883 3107_4_71 HLA-C Exon 4 - xp6:31270415-31270440 AGGCCACCCUGAGGUGCUGGGCCCU 1884 3107_4_72 HLA-C Exon 4 - xp6:31270416-31270441 GAGGCCACCCUGAGGUGCUGGGCCC 1885 3107_4_73 HLA-C Exon 4 - xp6:31270422-31270447 GACCAUGAGGCCACCCUGAGGUGCU 1886 3107_4_74 HLA-C Exon 4 - xp6:31270423-31270448 UGACCAUGAGGCCACCCUGAGGUGC 1887 3107_4_75 HLA-C Exon 4 - xp6:31270429-31270454 CCUCUCUGACCAUGAGGCCACCCUG 1888 3107_4_76 HLA-C Exon 4 - xp6:31270440-31270465 ACCCACCACCCCCUCUCUGACCAUG 1889 3107_3_1 HLA-C Exon 3 + xp6:31271079-31271104 CUGCAGCGUCUCCUUCCCGUUCUCC 1890 3107_3_2 HLA-C Exon 3 + xp6:31271088-31271113 CUCCUUCCCGUUCUCCAGGUAUCUG 1891 3107_3_3 HLA-C Exon 3 + xp6:31271115-31271140 GAGCCACUCCACGCACGUGCCCUCC 1892 3107_3_4 HLA-C Exon 3 + xp6:31271119-31271144 CACUCCACGCACGUGCCCUCCAGGU 1893 3107_3_5 HLA-C Exon 3 + xp6:31271142-31271167 GUAGGCUCUCAGCUGCUCCGCCGCA 1894 3107_3_6 HLA-C Exon 3 + xp6:31271143-31271168 UAGGCUCUCAGCUGCUCCGCCGCAC 1895 3107_3_7 HLA-C Exon 3 + xp6:31271163-31271188 CGCACGGGCCGCCUCCAACUUGCGC 1896 3107_3_8 HLA-C Exon 3 + xp6:31271164-31271189 GCACGGGCCCGCCUCCAACUUGCCGCU 1897 3107_3_9 HLA-C Exon 3 + xp6:31271179-31271204 AACUUGCCGCUGGGUGAUCUGAGCCG 1898 3107_3_10 HLA-C Exon 3 + xp6:31271188-31271213 UGGGUGAUCUGAGCCGCGGUGUCCG 1899 3107_3_11 HLA-C Exon 3 + xp6:31271191-31271216 GUGAUCUGAGCCGCGGUGUCCGCGG 1900 3107_3_12 HLA-C Exon 3 + xp6:31271197-31271222 UGAGCCGCGGUGUCCGCGGCGGUCC 1901 3107_3_13 HLA-C Exon 3 + xp6:31271205-31271230 GGUGUCCGCGGCGGUCCAGGAGCGC 1902 3107_3_14 HLA-C Exon 3 + xp6:31271217-31271242 GGUCCAGGAGCGCAGGUCCUCGUUC 1903 3107_3_15 HLA-C Exon 3 + xp6:31271218-31271243 GUCCAGGAGCGCAGGUCCUCGUUCA 1904 3107_3_16 HLA-C Exon 3 + xp6:31271242-31271267 AGGGCGAUGUAAUCCUUGCCGUCGU 1905 3107_3_17 HLA-C Exon 3 + xp6:31271245-31271270 GCGAUGUAAUCCUUGCCGUCGUAGG 1906 3107_3_18 HLA-C Exon 3 + xp6:31271250-31271275 GUAAUCCUUGCCGUCGUAGGCGGAC 1907 3107_3_19 HLA-C Exon 3 + xp6:31271262-31271287 GUCGUAGGCGGACUGGUCAUACCCG 1908 3107_3_20 HLA-C Exon 3 + xp6:31271265-31271290 GUAGGCGGACUGGUCAUACCCGCGG 1909 3107_3_21 HLA-C Exon 3 + xp6:31271268-31271293 GGCGGACUGGUCAUACCCGCGGAGG 1910 3107_3_22 HLA-C Exon 3 + xp6:31271278-31271303 UCAUACCCGCGGAGGAGGCGCCCGU 1911 3107_3_23 HLA-C Exon 3 + xp6:31271279-31271304 CAUACCCGCGGAGGAGGCGCCCGUC 1912 3107_3_24 HLA-C Exon 3 + xp6:31271286-31271311 GCGGAGGAGGCGCCCGUCGGGCCCC 1913 3107_3_25 HLA-C Exon 3 + xp6:31271307-31271332 CCCCAGGUCCGCAGCCAGACAUCCUC 1914 3107_3_26 HLA-C Exon 3 + xp6:31271310-31271335 CAGGUCGCAGCCAGACAUCCUCUGG 1915 3107_3_27 HLA-C Exon 3 + xp6:31271311-31271336 AGGUCGCAGCCAGACAUCCUCUGGA 1916 3107_3_28 HLA-C Exon 3 + xp6:31271324-31271349 ACAUCCUCUGGAGGGUGUGAGACCCC 1917 3107_3_29 HLA-C Exon 3 + xp6:31271338-31271363 GUGUGAGACCCUGGCCCCGCCCCCG 1918 3107_3_30 HLA-C Exon 3 - xp6:31271057-31271082 CAGCGCGCAGGUACCAGGGGCAGUG 1919 3107_3_31 HLA-C Exon 3 - xp6:31271058-31271083 GCAGCGCGCAGGUACCAGGGGCAGU 1920 3107_3_32 HLA-C Exon 3 - xp6:31271059-31271084 UGCAGCGCGCAGGUACCAGGGGCAG 1921 3107_3_33 HLA-C Exon 3 - xp6:31271065-31271090 AGACGCUGCAGCGGCGCAGGUACAG 1922 3107_3_34 HLA-C Exon 3 - xp6:31271066-31271091 GAGACGCUGCAGCGCGCAGGUACCA 1923 3107_3_35 HLA-C Exon 3 - xp6:31271067-31271092 GGAGACGCUGCAGCGGCGCAGGUAC 1924 3107_3_36 HLA-C Exon 3 - xp6:31271074-31271099 ACGGGAAGGAGACGCUGCAGCGCGC 1925 3107_3_37 HLA-C Exon 3 - xp6:31271093-31271118 CUCCGCAGAUACCUGGAGAACGGGA 1926 3107_3_38 HLA-C Exon 3 - xp6:31271097-31271122 GUGGCUCCGCAGAUACCUGGAGAAC 1927 3107_3_39 HLA-C Exon 3 - xp6:31271098-31271123 AGUGGCUCCGCAGAUACCUGGAGAA 1928 3107_3_40 HLA-C Exon 3 - xp6:31271105-31271130 UGCGUGGAGUGGCUCCGCAGAUACC 1929 3107_3_41 HLA-C Exon 3 - xp6:31271121-31271146 CUACCUGGAGGGCACGUGCGUGGAG 1930 3107_3_42 HLA-C Exon 3 - xp6:31271126-31271151 AGAGCCUACCUGGAGGGCACGUGCG 1931 3107_3_43 HLA-C Exon 3 - xp6:31271137-31271162 CGGAGCAGCUGAGAGCCUACCUGGA 1932 3107_3_44 HLA-C Exon 3 - xp6:31271138-31271163 GCGGAGCAGCUGAGAGCCUACCUGG 1933 3107_3_45 HLA-C Exon 3 - xp6:31271141-31271166 GCGGCGGAGCAGCUGAGAGCCUACC 1934 3107_3_46 HLA-C Exon 3 - xp6:31271162-31271187 CGCAAGUUGGAGGCGGCCCGUGCGG 1935 3107_3_47 HLA-C Exon 3 - xp6:31271165-31271190 CAGCGCAAGUUGGAGGCGGCCCGUG 1936 3107_3_48 HLA-C Exon 3 - xp6:31271174-31271199 CAGAUCACCCAGCGCAAGUUGGAGG 1937 3107_3_49 HLA-C Exon 3 - xp6:31271177-31271202 GCUCAGAUCACCCAGCGCAAGUUGG 1938 3107_3_50 HLA-C Exon 3 - xp6:31271180-31271205 GCGGCUCAGAUCACCCAGCGCAAGU 1939 3107_3_51 HLA-C Exon 3 - xp6:31271204-31271229 CGUCCUGGACCGCCGCGGACACCG 1940 3107_3_52 HLA-C Exon 3 - xp6:31271213-31271238 GAGGACCCUGCGCUCCUGGACCGCCG 1941 3107_3_53 HLA-C Exon 3 - xp6:31271223-31271248 CGCCCUGAACGAGGACCUGCCGCUCC 1942 3107_3_54 HLA-C Exon 3 - xp6:31271237-31271262 GGCAAGGAUUACAUCCGCCCUGAACG 1943 3107_3_55 HLA-C Exon 3 - xp6:31271258-31271283 UAUGACCAGUCCCGCCUACGACGGCA 1944 3107_3_56 HLA-C Exon 3 - xp6:31271263-31271288 GCGGGUAUGACCAGUCCCGCCUACGA 1945 3107_3_57 HLA-C Exon 3 - xp6:31271286-31271311 GGGGCCCGACGGGCGCCCUCCCGC 1946 3107_3_58 HLA-C Exon 3 - xp6:31271287-31271312 UGGGGCCCGACGGGCGCCUCCUCCG 1947 3107_3_59 HLA-C Exon 3 - xp6:31271301-31271326 GUCUGGCUGCGACCUGGGGCCCGAC 1948 3107_3_60 HLA-C Exon 3 - xp6:31271302-31271327 UGUCUGGCUGCGACCUGGGGCCCGA 1949 3107_3_61 HLA-C Exon 3 - xp6:31271310-31271335 CCAGAGGAUGUCUGGCUGCGACCUG 1950 3107_3_62 HLA-C Exon 3 - xp6:31271311-31271336 UCCAGAGGAUGUCUGGCUGCGACCU 1951 3107_3_63 HLA-C Exon 3 - xp6:31271312-31271337 CUCCAGAGGAUGUCUGGCUGCGACC 1952 3107_3_64 HLA-C Exon 3 - xp6:31271323-31271348 GGUCUCACACCCUCCAGAGGAUGUC 1953 3107_3_65 HLA-C Exon 3 - xp6:31271331-31271356 GGGGCCAGGGUCUCACACCCUCCAG 1954 3107_2_1 HLA-C Exon 2 + xp6:31271584-31271609 CCGGGGUCACUCACCGUCCUCGCUC 1955 3107_2_2 HLA-C Exon 2 + xp6:31271602-31271627 CUCGCUCUGGUUGUAGUAGCCGCGC 1956 3107_2_3 HLA-C Exon 2 + xp6:31271611-31271636 GUUGUAGUAGCCGCGCAGGUUCGCGC 1957 3107_2_4 HLA-C Exon 2 + xp6:31271620-31271645 GCCGCGCAGGUUCCGCAGGCUCACU 1958 3107_2_5 HLA-C Exon 2 + xp6:31271635-31271660 CAGGCUCACUCGGUCAGCCUGUGCC 1959 3107_2_6 HLA-C Exon 2 + xp6:31271659-31271684 CUGGCGCUUGUACUUCUGUGUCUCC 1960 3107_2_7 HLA-C Exon 2 + xp6:31271673-31271698 UCUGUGUCUCCCGGUCCCAAUACUC 1961 3107_2_8 HLA-C Exon 2 + xp6:31271694-31271719 ACUCCGGCCCCCUCCUGCUCCACCCA 1962 3107_2_9 HLA-C Exon 2 + xp6:31271703-31271728 CCUCCUGCUCCACCCACGGCGCCCG 1963 3107_2_10 HLA-C Exon 2 + xp6:31271715-31271740 CCCACGGCGCCCGCCGGCUCCCCUCU 1964 3107_2_11 HLA-C Exon 2 + xp6:31271723-31271748 GCCCGCGGCUCCCCUCUCGGACUCG 1965 3107_2_12 HLA-C Exon 2 + xp6:31271782-31271807 GUCCACGUAGCCCACUGAGAUGAAG 1966 3107_2_13 HLA-C Exon 2 + xp6:31271783-31271808 UCCACGUAGCCCACUGAGAUGAAGC 1967 3107_2_14 HLA-C Exon 2 + xp6:31271784-31271809 CCACGUAGCCCACUGAGAUGAAGCG 1968 3107_2_15 HLA-C Exon 2 + xp6:31271794-31271819 CACUGAGAUGAAGCGGGGCUCUCCG 1969 3107_2_16 HLA-C Exon 2 + xp6:31271798-31271823 GAGAUGAAGCGGGGCUCUCCGCGGC 1970 3107_2_17 HLA-C Exon 2 + xp6:31271799-31271824 AGAUGAAGCGGGGCUCUCCGCGGCC 1971 3107_2_18 HLA-C Exon 2 + xp6:31271803-31271828 GAAGCGGGGCUCUCCGCGGCCGGGC 1972 3107_2_19 HLA-C Exon 2 + xp6:31271804-31271829 AAGCGGGGCUCUCCGCGGCCGGGCC 1973 3107_2_20 HLA-C Exon 2 + xp6:31271810-31271835 GGCUCUCCGCGGCCGGGCCGGGACA 1974 3107_2_21 HLA-C Exon 2 + xp6:31271813-31271838 UCUCCGCGGCCGGGCCGGGACACGG 1975 3107_2_22 HLA-C Exon 2 + xp6:31271831-31271856 GACACGGCGGUGUCGAAAUACCUCA 1976 3107_2_23 HLA-C Exon 2 + xp6:31271836-31271861 GGCGGUGUGUCGAAAUACCUCAUGGAG 1977 3107_2_24 HLA-C Exon 2 + xp6:31271837-31271862 GCGGUGUGUCGAAAUACCUCAUGGAGU 1978 3107_2_25 HLA-C Exon 2 + xp6:31271844-31271869 CGAAAUACCUCAUGGAGUGGGAGCC 1979 3107_2_26 HLA-C Exon 2 + xp6:31271845-31271870 GAAAUACCUCAUGGAGUGGGAGCCU 1980 3107_2_27 HLA-C Exon 2 + xp6:31271846-31271871 AAAUACCUCAUGGAGUGGGAGCCUG 1981 3107_2_28 HLA-C Exon 2 + xp6:31271847-31271872 AAUACCUCAUGGAGUGGGAGCCUGG 1982 3107_2_29 HLA-C Exon 2 + xp6:31271852-31271877 CUCAUGGAGUGGGAGCCUGGGGGCG 1983 3107_2_30 HLA-C Exon 2 + xp6:31271855-31271880 AUGGAGUGGGAGCCUGGGGGCGAG 1984 3107_2_31 HLA-C Exon 2 + xp6:31271856-31271881 UGGAGUGGGAGCCUGGGGGCGAGGA 1985 3107_2_32 HLA-C Exon 2 + xp6:31271857-31271882 GGAGUGGGAGCCUGGGGGCGAGGAG 1986 3107_2_33 HLA-C Exon 2 - xp6:31271580-31271605 GAGGACGGUGAGUGACCCCGGCCCG 1987 3107_2_34 HLA-C Exon 2 - xp6:31271581-31271606 CGAGGACGGUGAGUGACCCCGGCCC 1988 3107_2_35 HLA-C Exon 2 - xp6:31271582-31271607 GCGAGGACGGUGAGUGACCCCGGCC 1989 3107_2_36 HLA-C Exon 2 - xp6:31271587-31271612 CCAGAGCGAGGACGGUGAGUGACCCC 1990 3107_2_37 HLA-C Exon 2 - xp6:31271600-31271625 GCGGCUACUACAACCAGAGCGAGGA 1991 3107_2_38 HLA-C Exon 2 - xp6:31271604-31271629 CUGCGCGGCUACUACAACCAGAGCG 1992 3107_2_39 HLA-C Exon 2 - xp6:31271624-31271649 ACCGAGUGAGCCUGCGGAACCUGCG 1993 3107_2_40 HLA-C Exon 2 - xp6:31271635-31271660 GGCACAGGCUGACCGAGUGAGCCUG 1994 3107_2_41 HLA-C Exon 2 - xp6:31271655-31271680 ACACAGAAGUACAAGCGCCAGGCAC 1995 3107_2_42 HLA-C Exon 2 - xp6:31271661-31271686 CGGGAGACACAGAAGUACAAGCGCC 1996 3107_2_43 HLA-C Exon 2 - xp6:31271685-31271710 CAGGAGGGGCCGGAGUAUUGGGACC 1997 3107_2_44 HLA-C Exon 2 - xp6:31271686-31271711 GCAGGAGGGGCCGGAGUAUUGGGAC 1998 3107_2_45 HLA-C Exon 2 - xp6:31271691-31271716 GUGGAGCAGGAGGGCCGGAGUAUU 1999 3107_2_46 HLA-C Exon 2 - xp6:31271692-31271717 GGUGGAGCAGGAGGGGCCGGAGUAU 2000 3107_2_47 HLA-C Exon 2 - xp6:31271700-31271725 GCGCCGUGGGUGGAGCAGGAGGGGC 2001 3107_2_48 HLA-C Exon 2 - xp6:31271704-31271729 GCGGGCCGCCGUGGGUGGAGCAGGAG 2002 3107_2_49 HLA-C Exon 2 - xp6:31271705-31271730 CGCGGGCCGCCGUGGGUGGAGCAGGA 2003 3107_2_50 HLA-C Exon 2 - xp6:31271706-31271731 CCGCGGGCCGCCGUGGGUGGAGCAGG 2004 3107_2_51 HLA-C Exon 2 - xp6:31271709-31271734 GAGCCGCGGGCCGCCGUGGGUGGAGC 2005 3107_2_52 HLA-C Exon 2 - xp6:31271715-31271740 AGAGGGGAGCCGCGGGCCGCCGUGGG 2006 3107_2_53 HLA-C Exon 2 - xp6:31271718-31271743 CCGAGAGGGGAGCCGCGGGCGCCGU 2007 3107_2_54 HLA-C Exon 2 - xp6:31271719-31271744 UCCGAGAGGGGAGCCGCGGGCGCCG 2008 3107_2_55 HLA-C Exon 2 - xp6:31271727-31271752 GCCGCGAGUCCGAGAGGGGAGCCGC 2009 3107_2_56 HLA-C Exon 2 - xp6:31271728-31271753 CGCCGCGAGUCCGAGAGGGGAGCCG 2010 3107_2_57 HLA-C Exon 2 - xp6:31271736-31271761 GACAGCGACGCCGCGAGUCCGAGAG 2011 3107_2_58 HLA-C Exon 2 - xp6:31271737-31271762 CGACAGCGACGCCGCGAGUCCGAGA 2012 3107_2_59 HLA-C Exon 2 - xp6:31271738-31271763 UCGACAGCGACGCCGCGAGUCCGAG 2013 3107_2_60 HLA-C Exon 2 - xp6:31271767-31271792 CUACGUGGACGACACGCAGUUCGUG 2014 3107_2_61 HLA-C Exon 2 - xp6:31271787-31271812 CCCCGCUUCAUCUCAGUGGGCUACG 2015 3107_2_62 HLA-C Exon 2 - xp6:31271795-31271820 GCGGAGAGCCCCGCUUCAUCUCAGU 2016 3107_2_63 HLA-C Exon 2 - xp6:31271796-31271821 CGCGGAGAGCCCCGCUUCAUCUCAG 2017 3107_2_64 HLA-C Exon 2 - xp6:31271819-31271844 ACACCGCCGUGUCCCGGCCCGGCCG 2018 3107_2_65 HLA-C Exon 2 - xp6:31271825-31271850 AUUUCGACACCGCCGUGUCCCGGCC 2019 3107_2_66 HLA-C Exon 2 - xp6:31271830-31271855 GAGGUAUUUCGACACCGCCGUGUCC 2020 3107_2_67 HLA-C Exon 2 - xp6:31271854-31271879 CUCGCCCCCAGGCUCCCACUCCAUG 2021 3107_1_1 HLA-C Exon 1 + xp6:31271973-31271998 GCUUCCCUCCCAACCCCGCACUCAC 2022 3107_1_2 HLA-C Exon 1 + xp6:31271979-31272004 CUCCCAACCCCGCACUCACAGGCCC 2023 3107_1_3 HLA-C Exon 1 + xp6:31271985-31272010 ACCCCGCACUCACAGGCCCAGGUCU 2024 3107_1_4 HLA-C Exon 1 + xp6:31271990-31272015 GCACUCACAGGCCCAGGUCUCGGUC 2025 3107_1_5 HLA-C Exon 1 + xp6:31271991-31272016 CACUCACAGGCCCAGGUCUCGGUCA 2026 3107_1_6 HLA-C Exon 1 + xp6:31271996-31272021 ACAGGCCCAGGUCUCGGUCAGGGCC 2027 3107_1_7 HLA-C Exon 1 + xp6:31272014-31272039 CAGGGCCAGGCCUCCCGAGAGCAGC 2028 3107_1_8 HLA-C Exon 1 + xp6:31272017-31272042 GGCCAGGCCUCCCGAGAGCAGCAGG 2029 3107_1_9 HLA-C Exon 1 + xp6:31272020-31272045 CAGGCCUCCCGAGAGCAGCAGGAGG 2030 3107_1_10 HLA-C Exon 1 + xp6:31272021-31272046 AGGCCUCCCGAGAGCAGCAGGAGGA 2031 3107_1_11 HLA-C Exon 1 + xp6:31272026-31272051 UCCCGAGAGCAGCAGGAGGAGGGCU 2032 3107_1_12 HLA-C Exon 1 + xp6:31272027-31272052 CCCGAGAGCAGCAGGAGGAGGGCUC 2033 3107_1_13 HLA-C Exon 1 + xp6:31272028-31272053 CCGAGAGCAGCAGGAGGAGGGCUCCG 2034 3107_1_14 HLA-C Exon 1 + xp6:31272048-31272073 GCUCGGGGCCGCCAUGACCCCGCAUCU 2035 3107_1_15 HLA-C Exon 1 + xp6:31272055-31272080 GCGCCAUGACCCGCAUCUCGGCCUC 2036 3107_1_16 HLA-C Exon 1 + xp6:31272056-31272081 CGCCAUGACCCGCAUCUCCGGCCUCU 2037 3107_1_17 HLA-C Exon 1 + xp6:31272057-31272082 GCCAUGACCCGCAUCUCCGGCCUCUG 2038 3107_1_18 HLA-C Exon 1 + xp6:31272072-31272097 UCGGCCUCUGGGGAGAAUGUGAGUC 2039 3107_1_19 HLA-C Exon 1 + xp6:31272073-31272098 CGGCCUCUGGGGAGAAUGUGAGUCC 2040 3107_1_20 HLA-C Exon 1 + xp6:31272076-31272101 CCUCUGGGGAGAAUGUGAGUCCGGG 2041 3107_1_21 HLA-C Exon 1 + xp6:31272077-31272102 CUCUGGGGAGAAUGUGAGUCCGGGU 2042 3107_1_22 HLA-C Exon 1 + xp6:31272084-31272109 GAGAAUGUGAGUCCGGGUGGGUGAC 2043 3107_1_23 HLA-C Exon 1 + xp6:31272085-31272110 AGAAUGUGAGUCCGGGUGGGUGACU 2044 3107_1_24 HLA-C Exon 1 + xp6:31272086-31272111 GAAUGUGAGUCCGGGUGGGUGACUG 2045 3107_1_25 HLA-C Exon 1 + xp6:31272099-31272124 GGUGGGUGACUGGGGACUUUAGAAC 2046 3107_1_26 HLA-C Exon 1 + xp6:31272100-31272125 GUGGGUGACUGGGGACUUUAGAACC 2047 3107_1_27 HLA-C Exon 1 + xp6:31272107-31272132 ACUGGGGACUUUAGAACCGGGACUG 2048 3107_1_28 HLA-C Exon 1 + xp6:31272120-31272145 GAACCGGGACUGCGGAGACGCUGAU 2049 3107_1_29 HLA-C Exon 1 - xp6:31271980-31272005 UGGGCCUGUGAGUGCGGGGUUGGGA 2050 3107_1_30 HLA-C Exon 1 - xp6:31271981-31272006 CUGGGCCUGUGAGUGCGGGGUUGGG 2051 3107_1_31 HLA-C Exon 1 - xp6:31271984-31272009 GACCUGGGCCUGUGAGUGCGGGGUU 2052 3107_1_32 HLA-C Exon 1 - xp6:31271985-31272010 AGACCUGGGCCUGUGAGUGCGGGGU 2053 3107_1_33 HLA-C Exon 1 - xp6:31271989-31272014 ACCGAGACCUGGGCCUGUGAGUGCG 2054 3107_1_34 HLA-C Exon 1 - xp6:31271990-31272015 GACCGAGACCUGGGCCUGUGAGUGC 2055 3107_1_35 HLA-C Exon 1 - xp6:31271991-31272016 UGACCGAGACCUGGGCCUGUGAGUG 2056 3107_1_36 HLA-C Exon 1 - xp6:31272004-31272029 GGAGGCCUGGCCCUGACCGAGACCU 2057 3107_1_37 HLA-C Exon 1 - xp6:31272005-31272030 GGGAGGCCUGGCCCUGACCGAGACC 2058 3107_1_38 HLA-C Exon 1 - xp6:31272022-31272047 CUCCUCCUGCUGCUCUCGGGAGGCC 2059 3107_1_39 HLA-C Exon 1 - xp6:31272027-31272052 GAGCCCUCCUCCUGCUGCUCUCGGG 2060 3107_1_40 HLA-C Exon 1 - xp6:31272030-31272055 CCCGAGCCCUCCUCCUGCUGCUCUC 2061 3107_1_41 HLA-C Exon 1 - xp6:31272031-31272056 CCCCGAGCCCUCCUCCUGCUGCUCU 2062 3107_1_42 HLA-C Exon 1 - xp6:31272061-31272086 UCCCCAGAGGCCGAGAUGCGGGUCA 2063 3107_1_43 HLA-C Exon 1 - xp6:31272067-31272092 ACAUUCUCCCCCAGAGGCCGAGAUGC 2064 3107_1_44 HLA-C Exon 1 - xp6:31272068-31272093 CACAUUCUCCCCAGAGGCCGAGAUG 2065 3107_1_45 HLA-C Exon 1 - xp6:31272079-31272104 CCACCCGGACUCACAUUCUCCCAG 2066 3107_1_46 HLA-C Exon 1 - xp6:31272099-31272124 GUUCUAAAGUCCCCAGUCACCCACC 2067 3107_1_47 HLA-C Exon 1 - xp6:31272126-31272151 AAGCCAAUCAGCGUCUCCGCAGUCC 2068 2908_11_1 NR3C1 Exon 11 + xp5:143277948-143277973 UUUUAUUAUGAUGUUUCUCCAUAUU 2069 2908_11_2 NR3C1 Exon 11 + xp5:143277963-143277988 UCUCCAUAUUUGGCAUUGCUGUAAAA 2070 2908_11_3 NR3C1 Exon 11 + xp5:143277985-143278010 AAAUGGCUAACAUUUACUGCCAAUU 2071 2908_11_4 NR3C1 Exon 11 + xp5:143277998-143278023 UUACUGCCAAUUCGGUACAAAUGUG 2072 2908_11_5 NR3C1 Exon 11 + xp5:143278003-143278028 GCCAAUUCGGUACAAAUGUGUGGUU 2073 2908_11_6 NR3C1 Exon 11 + xp5:143278061-143278086 AAUAAAAGUUAAAACAUUUCCACACA 2074 2908_11_7 NR3C1 Exon 11 + xp5:143278090-143278115 UUUACAGUCUGACAUUUCACUGCGU 2075 2908_11_8 NR3C1 Exon 11 + xp5:143278167-143278192 AAAACUACAACUUUUAUUUUUAAC 2076 2908_11_9 NR3C1 Exon 11 + xp5:143278176-143278201 ACUUUUAUUUUUAAAACAGGAGUCAC 2077 2908_11_10 NR3C1 Exon 11 + xp5:143278346-143278371 UAUAUGUAGUUAAGCAAGUUAUUUG 2078 2908_11_11 NR3C1 Exon 11 + xp5:143278349-143278374 AUGUAGUUAAGCAAGUUAUUUGAGG 2079 2908_11_12 NR3C1 Exon 11 + xp5:143278350-143278375 UGUAGUUAAGCAAGUUAUUUGAGGA 2080 2908_11_13 NR3C1 Exon 11 + xp5:143278433-143278458 AGAAGCAAAUCCUUUCCUGAAAACC 2081 2908_11_14 NR3C1 Exon 11 + xp5:143278446-143278471 UUCCUGAAAACCUGGUCACUAAAUCC 2082 2908_11_15 NR3C1 Exon 11 + xp5:143278447-143278472 UCCUGAAAACCUGGUCACUAAUCCU 2083 2908_11_16 NR3C1 Exon 11 + xp5:143278450-143278475 UGAAAACCUGGUCACUAAUCCUGGG 2084 2908_11_17 NR3C1 Exon 11 + xp5:143278456-143278481 CCUGGUCACUAAUCCUGGGUGGACC 2085 2908_11_18 NR3C1 Exon 11 + xp5:143278475-143278500 UGGACCAGGUUGCUUGAAAAUAGUC 2086 2908_11_19 NR3C1 Exon 11 + xp5:143278476-143278501 GGACCAGGUUGCUUGAAAAUAGCU 2087 2908_11_20 NR3C1 Exon 11 + xp5:143278500-143278525 UGGGAAAUUACGAAACUCCACCCAA 2088 2908_11_21 NR3C1 Exon 11 + xp5:143278501-143278526 GGGAAAUUACGAAACUCCACCCAAA 2089 2908_11_22 NR3C1 Exon 11 + xp5:143278594-143278619 AACACAUUCACCUACAGCUACAGUC 2090 2908_11_23 NR3C1 Exon 11 + xp5:143278595-143278620 ACACAUUCACCUACAGCUACAGUCA 2091 2908_11_24 NR3C1 Exon 11 + xp5:143278613-143278638 ACAGUCAGGGAGUGACCAGCCAAGA 2092 2908_11_25 NR3C1 Exon 11 + xp5:143278628-143278653 CCAGCCAAGAUGGAAAUCUCACUGA 2093 2908_11_26 NR3C1 Exon 11 + xp5:143278637-143278662 AUGGAAAUCUCACUGAAGGCUACCA 2094 2908_11_27 NR3C1 Exon 11 + xp5:143278643-143278668 AUCUCACUGAAGGCUACCAUGGUUC 2095 2908_11_28 NR3C1 Exon 11 + xp5:143278691-143278716 UUGUAUAACAAUAUUUUUCAUUCCA 2096 2908_11_29 NR3C1 Exon 11 + xp5:143278707-143278732 UUCAUUCCAUGGUGAUGUAGUUUUC 2097 2908_11_30 NR3C1 Exon 11 + xp5:143278708-143278733 UCAUUCCAUGGUGAUGUAGUUUUCA 2098 2908_11_31 NR3C1 Exon 11 + xp5:143278719-143278744 UGAUGUAGUUUUCAGGGUUUUUAAA 2099 2908_11_32 NR3C1 Exon 11 + xp5:143278720-143278745 GAUGUAGUUUUCAGGGUUUUAAAA 2100 2908_11_33 NR3C1 Exon 11 + xp5:143278742-143278767 AAAGGGAACUAAAAUUAUGAGACUU 2101 2908_11_34 NR3C1 Exon 11 + xp5:143278751-143278776 UAAAUUAUGAGACUUAGGUGAAAC 2102 2908_11_35 NR3C1 Exon 11 + xp5:143278780-143278805 AUUGCUCCCUGCCUCUGAAUUCUGA 2103 2908_11_36 NR3C1 Exon 11 + xp5:143278781-143278806 UUGCUCCCUGCCUCUGAAUUCUGAA 2104 2908_11_37 NR3C1 Exon 11 + xp5:143278788-143278813 CUGCCUCUGAAUUCUGAAGGGAGCG 2105 2908_11_38 NR3C1 Exon 11 + xp5:143278801-143278826 CUGAAGGGAGCGUGGCUUUCCUUCA 2106 2908_11_39 NR3C1 Exon 11 + xp5:143278873-143278898 ACACAAAUCAUGUUAGUUUUCCUUU 2107 2908_11_40 NR3C1 Exon 11 + xp5:143278874-143278899 CACAAAUCAUGUUAGUUUUCCUUUU 2108 2908_11_41 NR3C1 Exon 11 + xp5:143278875-143278900 ACAAAUCAUGUUAGUUUUCCUUUUG 2109 2908_11_42 NR3C1 Exon 11 + xp5:143278878-143278903 AAUCAUGUUAGUUUUCCUUUUGGGG 2110 2908_11_43 NR3C1 Exon 11 + xp5:143278884-143278909 GUUAGUUUUCCUUUUGGGGUGGCCA 2111 2908_11_44 NR3C1 Exon 11 + xp5:143278904-143278929 GGCCAAGGUUUCCUCCCAUAGUUUU 2112 2908_11_45 NR3C1 Exon 11 + xp5:143278911-143278936 GUUUCCUCCCAUAGUUUUAGGCAUU 2113 2908_11_46 NR3C1 Exon 11 + xp5:143279007-143279032 CCUACAAACACUAAAAAUACUUUUC 2114 2908_11_47 NR3C1 Exon 11 + xp5:143279062-143279087 GAAGUUACUACAAAACUUCAACAGUU 2115 2908_11_48 NR3C1 Exon 11 + xp5:143279063-143279088 AAGUUACUACAAAACUUCAACAGUUU 2116 2908_11_49 NR3C1 Exon 11 + xp5:143279067-143279092 UACUACAAACUUCAACAGUUUGGGU 2117 2908_11_50 NR3C1 Exon 11 + xp5:143279068-143279093 ACUACAAACUUCAACAGUUUGGGUU 2118 2908_11_51 NR3C1 Exon 11 + xp5:143279072-143279097 CAAACUUCAACAGUUUGGGUUGGGA 2119 2908_11_52 NR3C1 Exon 11 + xp5:143279092-143279117 UGGGAUGGCCAGAUAACACAUACAU 2120 2908_11_53 NR3C1 Exon 11 + xp5:143279190-143279215 UUUCUUUUCCCCCACGUAUCCUAAA 2121 2908_11_54 NR3C1 Exon 11 + xp5:143279191-143279216 UUCUUUUCCCCCACGUAUCCUAAAAA 2122 2908_11_55 NR3C1 Exon 11 + xp5:143279327-143279352 UCUAUUUUUUGAGCGCCAAGAUUGU 2123 2908_11_56 NR3C1 Exon 11 + xp5:143279328-143279353 CUAUUUUUUGAGCGCCAAGAUUGUU 2124 2908_11_57 NR3C1 Exon 11 + xp5:143279365-143279390 AGAUUAAUGUGUGAGAUGUGCUUUC 2125 2908_11_58 NR3C1 Exon 11 + xp5:143279392-143279417 GUUUUAACCACAUAACAUUCUAUAA 2126 2908_11_59 NR3C1 Exon 11 + xp5:143279471-143279496 AUAAGAAUAUUCAAGCAGUUUUCUU 2127 2908_11_60 NR3C1 Exon 11 + xp5:143279493-143279518 CUUAGGCACCAAAAAAUUUAUCCAGC 2128 2908_11_61 NR3C1 Exon 11 + xp5:143279494-143279519 UUAGGCACCAAAAAAUUUAUCCAGCC 2129 2908_11_62 NR3C1 Exon 11 + xp5:143279651-143279676 AACAAAAACAUGUCCUCAUUUUAUU 2130 2908_11_63 NR3C1 Exon 11 + xp5:143279671-143279696 UUAUUUGGAAAUAAACUCUUGUUGU 2131 2908_11_64 NR3C1 Exon 11 + xp5:143279680-143279705 AAUAAACUCUUGUUGUAGGAUAGAA 2132 2908_11_65 NR3C1 Exon 11 + xp5:143279697-143279722 GGAUAGAAAGGAAUUAGUGUAUUAU 2133 2908_11_66 NR3C1 Exon 11 + xp5:143279734-143279759 AGAUUCUGCACUAUUUACAUAUUGC 2134 2908_11_67 NR3C1 Exon 11 + xp5:143279792-143279817 GAAGCUUCUGUUGUCAUUCAACUGC 2135 2908_11_68 NR3C1 Exon 11 + xp5:143279793-143279818 AAGCUUCUGUUGUCAUUCAACUGCU 2136 2908_11_69 NR3C1 Exon 11 + xp5:143279794-143279819 AGCUUCUGUUGUCAUUCAACUGCUG 2137 2908_11_70 NR3C1 Exon 11 + xp5:143279795-143279820 GCUUCUGUUGUCAUUCAACUGCUGG 2138 2908_11_71 NR3C1 Exon 11 + xp5:143279798-143279823 UCUGUUGUCAUUCAACUGCUGGGGG 2139 2908_11_72 NR3C1 Exon 11 + xp5:143279799-143279824 CUGUUGUCAUUCAACUGCUGGGGGA 2140 2908_11_73 NR3C1 Exon 11 + xp5:143279830-143279855 UAUGUGAAAGUAACCCGCUAUUAGA 2141 2908_11_74 NR3C1 Exon 11 + xp5:143279841-143279866 AACCCGCUAUUAGAUGGUGCCUUUA 2142 2908_11_75 NR3C1 Exon 11 + xp5:143279898-143279923 UACAUACUUUACAUACUUUAGUGCA 2143 2908_11_76 NR3C1 Exon 11 + xp5:143279899-143279924 ACAUACUUUACAUACUUUAGUGCAA 2144 2908_11_77 NR3C1 Exon 11 + xp5:143279900-143279925 CAUACUUUACAUACUUUAGUGCAAG 2145 2908_11_78 NR3C1 Exon 11 + xp5:143279942-143279967 AAACCUGCCGCUGACAGACUCACUGU 2146 2908_11_79 NR3C1 Exon 11 + xp5:143279952-143279977 UGACAGACUCACUGUUGGAAUGAGA 2147 2908_11_80 NR3C1 Exon 11 + xp5:143279953-143279978 GACAGACUCACUGUUGGAAUGAGAA 2148 2908_11_81 NR3C1 Exon 11 + xp5:143279956-143279981 AGACUCACUGUUGGAAUGAGAAGGG 2149 2908_11_82 NR3C1 Exon 11 + xp5:143279965-143279990 GUUGGAAUGAGAAGGGUGGUCAGAA 2150 2908_11_83 NR3C1 Exon 11 + xp5:143279966-143279991 UUGGAAUGAGAAGGGUGGUCAGAAU 2151 2908_11_84 NR3C1 Exon 11 + xp5:143279969-143279994 GAAUGAGAAGGGUGGUCAGAAUGGG 2152 2908_11_85 NR3C1 Exon 11 + xp5:143279975-143280000 GAAGGGUGGUCAGAAUGGGAGGCAG 2153 2908_11_86 NR3C1 Exon 11 + xp5:143280000-143280025 AGGAUAACCUUCCUCUGUAAUCUCAC 2154 2908_11_87 NR3C1 Exon 11 + xp5:143280001-143280026 GGAUAAACUUCCUCUGUAAUCUCACU 2155 2908_11_88 NR3C1 Exon 11 + xp5:143280033-143280058 AGCCUCAGCAACCUUCACUGCACAC 2156 2908_11_89 NR3C1 Exon 11 + xp5:143280075-143280100 CCCUCUUCCCCUAGAGCAAACUGUU 2157 2908_11_90 NR3C1 Exon 11 + xp5:143280131-143280156 UGCAUGUACAAACUAAAUCAUAU 2158 2908_11_91 NR3C1 Exon 11 + xp5:143280404-143280429 UCAGUUUUCUAUUACACAAAUAAUU 2159 2908_11_92 NR3C1 Exon 11 + xp5:143280435-143280460 CCUUGAAUAGAAAUCAAAUUUCUUG 2160 2908_11_93 NR3C1 Exon 11 + xp5:143280475-143280500 GUUAAGUUUUGAGUUUACAGAAAGU 2161 2908_11_94 NR3C1 Exon 11 + xp5:143280480-143280505 GUUUUGAGUUUACAGAAAGUUGGUA 2162 2908_11_95 NR3C1 Exon 11 + xp5:143280494-143280519 GAAAGUUGGUAAGGUGCACACAGAA 2163 2908_11_96 NR3C1 Exon 11 + xp5:143280495-143280520 AAAGUUGGUAAGGUGCACACAGAAA 2164 2908_11_97 NR3C1 Exon 11 + xp5:143280551-143280576 AAUUUUCAACAGUGAAGAAAUUCAC 2165 2908_11_98 NR3C1 Exon 11 + xp5:143280571-143280596 UUCACAGGACUUGUGUGUUAAACUCUUA 2166 2908_11_99 NR3C1 Exon 11 + xp5:143280582-143280607 UGUGUUAAACUCUAUGGCACACAUU 2167 2908_11_100 NR3C1 Exon 11 + xp5:143280583-143280608 GUGUUAAACUCUAUGGCACACAUUA 2168 2908_11_101 NR3C1 Exon 11 + xp5:143280605-143280630 UUAGGGAUGUGUAGUUUUACAAACA 2169 2908_11_102 NR3C1 Exon 11 + xp5:143280666-143280691 AGUAGCUGAGCUUUCCUGUACCAUC 2170 2908_11_103 NR3C1 Exon 11 + xp5:143280683-143280708 GUACCAUCAGGAAAGAUUAACCAAU 2171 2908_11_104 NR3C1 Exon 11 + xp5:143280693-143280718 GAAAGAUUAACCAAUUGGUGACAGA 2172 2908_11_105 NR3C1 Exon 11 + xp5:143280694-143280719 AAAGAUUAACCAAUUGGUGACAGAU 2173 2908_11_106 NR3C1 Exon 11 + xp5:143280707-143280732 UUGGUGACAGAAUGGGAAUGUGAAAAA 2174 2908_11_107 NR3C1 Exon 11 + xp5:143280708-143280733 UGGUGACAGAAUGGGAAUGUGAAAAU 2175 2908_11_108 NR3C1 Exon 11 + xp5:143280748-143280773 UUUGCCAUAUUAGAGAUUUAGUUUU 2176 2908_11_109 NR3C1 Exon 11 + xp5:143280749-143280774 UUGCCAUAUUAGAGAUUUAGUUUUU 2177 2908_11_110 NR3C1 Exon 11 + xp5:143280766-143280791 UAGUUUUUGGGUAAAGUUUAGUGAG 2178 2908_11_111 NR3C1 Exon 11 + xp5:143280811-143280836 AAAAGUCUCUCAGCUGUGUUACAGC 2179 2908_11_112 NR3C1 Exon 11 + xp5:143280819-143280844 CUCAGCUGUGUUACAGCUGGUUAUC 2180 2908_11_113 NR3C1 Exon 11 + xp5:143280860-143280885 AAGAAGUUAUACAAACUACUUCAAAA 2181 2908_11_114 NR3C1 Exon 11 + xp5:143280917-143280942 CUUGCCAUAUAGCCAUUGCAAAAAU 2182 2908_11_115 NR3C1 Exon 11 + xp5:143280918-143280943 UUGCCAUAUAGCCAUUGCAAAAAUA 2183 2908_11_116 NR3C1 Exon 11 + xp5:143280925-143280950 AUAGCCAUUGCAAAAAUAGGGCGUU 2184 2908_11_117 NR3C1 Exon 11 + xp5:143280935-143280960 CAAAAAUAGGGCGUUAGGUACAGAC 2185 2908_11_118 NR3C1 Exon 11 + xp5:143280936-143280961 AAAAAUAGGGCGUUAGGUACAGACA 2186 2908_11_119 NR3C1 Exon 11 + xp5:143280944-143280969 GGCGUUAGGUACAGACAGGGCCUCU 2187 2908_11_120 NR3C1 Exon 11 + xp5:143280999-143281024 AACCAUCAUCCACAGUUUACCCAGC 2188 2908_11_121 NR3C1 Exon 11 + xp5:143281006-143281031 AUCCACAGUUUACCCAGCAGGUCAC 2189 2908_11_122 NR3C1 Exon 11 + xp5:143281012-143281037 AGUUUACCCAGCAGGUCACUGGACU 2190 2908_11_123 NR3C1 Exon 11 + xp5:143281030-143281055 CUGGACUAGGUGCUCUAUACCAGUU 2191 2908_11_124 NR3C1 Exon 11 + xp5:143281123-143281148 UUUUUUUUUUUUUGACAAGAAUAC 2192 2908_11_125 NR3C1 Exon 11 + xp5:143281145-143281170 UACUGGAGAUUUGAGUCAAUUUUUG 2193 2908_11_126 NR3C1 Exon 11 + xp5:143281171-143281196 GGUCUUCUGAUAGCUAAGUGCCAUC 2194 2908_11_127 NR3C1 Exon 11 + xp5:143281229-143281254 GAUUGAUUAAUGUUUAGAGUUUAUU 2195 2908_11_128 NR3C1 Exon 11 + xp5:143281230-143281255 AUUGAUUAAUGUUUAGAGUUUAUUU 2196 2908_11_129 NR3C1 Exon 11 + xp5:143281331-143281356 AGCAAGCGUAGUUCACUAAAAUAUAA 2197 2908_11_130 NR3C1 Exon 11 + xp5:143281367-143281392 AAAACCAGACAGUAAUAGCUAUAAA 2198 2908_11_131 NR3C1 Exon 11 + xp5:143281412-143281437 GAUAUACACUUGUAAAACUUUUUUUC 2199 2908_11_132 NR3C1 Exon 11 + xp5:143281453-143281478 AUCAAAAAUGCUAUCCUAACUAUAC 2200 2908_11_133 NR3C1 Exon 11 + xp5:143281454-143281479 UCAAAAAUGCUAUCCUAACUAUACA 2201 2908_11_134 NR3C1 Exon 11 + xp5:143281455-143281480 CAAAAAUGCUAUCCUAACUAUACAG 2202 2908_11_135 NR3C1 Exon 11 + xp5:143281456-143281481 AAAAAUGCUAUCCUAACUAUACAGG 2203 2908_11_136 NR3C1 Exon 11 + xp5:143281457-143281482 AAAAUGCUAUCCUAACUAUACAGGG 2204 2908_11_137 NR3C1 Exon 11 + xp5:143281458-143281483 AAAUGCUAUCCUAACUAUACAGGGG 2205 2908_11_138 NR3C1 Exon 11 + xp5:143281459-143281484 AAUGCUAUCCUAACUAUACAGGGGG 2206 2908_11_139 NR3C1 Exon 11 + xp5:143281543-143281568 AAGAGAAAGUUCAUCACACAGACUU 2207 2908_11_140 NR3C1 Exon 11 + xp5:143281544-143281569 AGAGAAAGUUCAUCACACAGACUUU 2208 2908_11_141 NR3C1 Exon 11 + xp5:143281550-143281575 AGUUCAUCACACAGACUUUGGGCAC 2209 2908_11_142 NR3C1 Exon 11 + xp5:143281553-143281578 UCAUCACACAGACUUUGGGCACUGG 2210 2908_11_143 NR3C1 Exon 11 + xp5:143281559-143281584 CACAGACUUUGGGCACUGGUGGUUU 2211 2908_11_144 NR3C1 Exon 11 + xp5:143281581-143281606 UUUAGGUGCCAUCCUUCUUUGACUG 2212 2908_11_145 NR3C1 Exon 11 + xp5:143281603-143281628 CUGUGGAGAUUACGUCCACAUAUUA 2213 2908_11_146 NR3C1 Exon 11 + xp5:143281617-143281642 UCCACAUAUUAAGGUUUCUAAUUUC 2214 2908_11_147 NR3C1 Exon 11 + xp5:143281618-143281643 CCACAUAUUAAGGUUUCUAAUUUCUCU 2215 2908_11_148 NR3C1 Exon 11 + xp5:143281703-143281728 CUCAACUGCUUCUGUUGCCAAGUCU 2216 2908_11_149 NR3C1 Exon 11 + xp5:143281788-143281813 AAAAAUAAAACAACAAAACCUCUAC 2217 2908_11_150 NR3C1 Exon 11 + xp5:143281839-143281864 AAAGCUAUUAAUUCGACUUUCUUUA 2218 2908_11_151 NR3C1 Exon 11 + xp5:143281857-143281882 UUCUUUAAGGCAACCAUUCUUAUUA 2219 2908_11_152 NR3C1 Exon 11 + xp5:143281911-143281936 UUUUGAUAUUUCCAUUUGAAUAUUU 2220 2908_11_153 NR3C1 Exon 11 + xp5:143281922-143281947 CCAUUUGAAUAUUUUGGUAUCUGAU 2221 2908_11_154 NR3C1 Exon 11 + xp5:143281946-143281971 UUGGUGAUGAUUUCAGCUAACAUCU 2222 2908_11_155 NR3C1 Exon 11 + xp5:143281947-143281972 UGGUGAUGAUUUCAGCUAACAUCUC 2223 2908_11_156 NR3C1 Exon 11 + xp5:143281948-143281973 GGUGAUGAUUUCAGCUAAACAUCUCG 2224 2908_11_157 NR3C1 Exon 11 + xp5:143281964-143281989 AACAUCUCGGGGAAUUCAAUACUCA 2225 2908_11_158 NR3C1 Exon 11 + xp5:143281984-143282009 ACUCAUGGUCUUAUCCAAAAAAUGUU 2226 2908_11_159 NR3C1 Exon 11 + xp5:143281999-143282024 CAAAAAUGUUUGGAAGCAAUAGUUA 2227 2908_11_160 NR3C1 Exon 11 + xp5:143282031-143282056 UUUCAACCACCUGCAAGAGAAGAUA 2228 2908_11_161 NR3C1 Exon 11 - xp5:143277969-143277994 UAGCCAUUUACAGCAAUGCCAAAUA 2229 2908_11_162 NR3C1 Exon 11 - xp5:143278007-143278032 ACCAAACCACACAUUUGUACCGAAU 2230 2908_11_163 NR3C1 Exon 11 - xp5:143278039-143278064 AUUUUUUCAUUUAAAUUUGCUGUUC 2231 2908_11_164 NR3C1 Exon 11 - xp5:143278082-143278107 AAAUGUCAGACUGUAAAAACCUUGUG 2232 2908_11_165 NR3C1 Exon 11 - xp5:143278271-143278296 GGACAAAAUCUAUAUUAUACUGUGUA 2233 2908_11_166 NR3C1 Exon 11 - xp5:143278297-143278322 UUUGUAUAUUAAAUGCUAUAUAAUG 2234 2908_11_167 NR3C1 Exon 11 - xp5:143278298-143278323 UUUUGUAUAUUAAAUGCUAUAUAAUAU 2235 2908_11_168 NR3C1 Exon 11 - xp5:143278299-143278324 AUUUUGUAUAUUAAAUGCUAUAUAA 2236 2908_11_169 NR3C1 Exon 11 - xp5:143278394-143278419 UGAAAGGAUUUUAUUUUCUGAUGAA 2237 2908_11_170 NR3C1 Exon 11 - xp5:143278415-143278440 UGCUUCUCUCUAGAAAAUGUCUGAA 2238 2908_11_171 NR3C1 Exon 11 - xp5:143278446-143278471 GGAUUAGUGACCAGGUUUUCAGGAA 2239 2908_11_172 NR3C1 Exon 11 - xp5:143278451-143278476 ACCCAGGAUUAGUGACCAGGUUUUC 2240 2908_11_173 NR3C1 Exon 11 - xp5:143278459-143278484 CCUGGUCCACCCAGGAUUAGUGACC 2241 2908_11_174 NR3C1 Exon 11 - xp5:143278472-143278497 UAUUUUCAAGCAACCUGGUCCACCC 2242 2908_11_175 NR3C1 Exon 11 - xp5:143278482-143278507 UUUCCAGACUAUUUUCAAGCAACC 2243 2908_11_176 NR3C1 Exon 11 - xp5:143278520-143278545 AGGAGGACACUUUAAACCCUUUGGG 2244 2908_11_177 NR3C1 Exon 11 - xp5:143278523-143278548 GUAAGGAGGACACUUUAAACCCUUU 2245 2908_11_178 NR3C1 Exon 11 - xp5:143278524-143278549 UGUAAAGGAGGACACUUUAAACCCUU 2246 2908_11_179 NR3C1 Exon 11 - xp5:143278542-143278567 UCAGAAGGGAAAAUAAAAGUGUAAGG 2247 2908_11_180 NR3C1 Exon 11 - xp5:143278545-143278570 GUGUCAGAAGGGAAAAUAAAAGUGUGUA 2248 2908_11_181 NR3C1 Exon 11 - xp5:143278561-143278586 ACACACAGACGUUUUAGUGUCAGAA 2249 2908_11_182 NR3C1 Exon 11 - xp5:143278562-143278587 CACACACAGACGUUUUAGUGUCAGA 2250 2908_11_183 NR3C1 Exon 11 - xp5:143278607-143278632 CUGGUCACUCCCUGACUGUAGCUGU 2251 2908_11_184 NR3C1 Exon 11 - xp5:143278631-143278656 CCUUCAGUGAGAUUUCCAUCUUGGC 2252 2908_11_185 NR3C1 Exon 11 - xp5:143278635-143278660 GUAGCCUUCAGUGAGAUUUCCAUCU 2253 2908_11_186 NR3C1 Exon 11 - xp5:143278662-143278687 UUGAUCUGUCAAACUUCCAGAACCA 2254 2908_11_187 NR3C1 Exon 11 - xp5:143278716-143278741 AAAAACCCUGAAAACUACAUCACCA 2255 2908_11_188 NR3C1 Exon 11 - xp5:143278789-143278814 ACGCUCCCUUCAGAAUUCAGAGGCA 2256 2908_11_189 NR3C1 Exon 11 - xp5:143278790-143278815 CACGCUCCCUUCAGAAUUCAGAGGC 2257 2908_11_190 NR3C1 Exon 11 - xp5:143278794-143278819 AAGCCACCGCUCCCUUCAGAAUUCAG 2258 2908_11_191 NR3C1 Exon 11 - xp5:143278823-143278848 GGGAUGAGCUCUGGGCAUGCCAUGA 2259 2908_11_192 NR3C1 Exon 11 - xp5:143278836-143278861 GGAUAAUUAGCAUGGGAUGAGCUCU 2260 2908_11_193 NR3C1 Exon 11 - xp5:143278837-143278862 UGGAUAAUUAGCAUGGGAUGAGCUC 2261 2908_11_194 NR3C1 Exon 11 - xp5:143278848-143278873 CUAUGAAGUGCUGGAUAAUUAGCAU 2262 2908_11_195 NR3C1 Exon 11 - xp5:143278849-143278874 UCUAUGAAGUGCUGGAUAAUUAGCA 2263 2908_11_196 NR3C1 Exon 11 - xp5:143278862-143278887 AACAUGAUUUGUGUCUAUGAAGUGC 2264 2908_11_197 NR3C1 Exon 11 - xp5:143278896-143278921 GGGAGGAAACCUUGGCCACCCCAAA 2265 2908_11_198 NR3C1 Exon 11 - xp5:143278909-143278934 UGCCUAAAACUAUGGGAGGAAACCU 2266 2908_11_199 NR3C1 Exon 11 - xp5:143278918-143278943 AUAUCCAAAUGCCUAAAACUAUGGG 2267 2908_11_200 NR3C1 Exon 11 - xp5:143278921-143278946 UAUAUAUCCAAAUGCCUAAAACUAU 2268 2908_11_201 NR3C1 Exon 11 - xp5:143278922-143278947 AUAUAUAUCCAAAUGCCUAAAACUA 2269 2908_11_202 NR3C1 Exon 11 - xp5:143278951-143278976 AGGCACUUAGGACAAUAACACUUUUG 2270 2908_11_203 NR3C1 Exon 11 - xp5:143278952-143278977 GAGGCACUUAGGACAAUAACACUUUU 2271 2908_11_204 NR3C1 Exon 11 - xp5:143278953-143278978 UGAGGCACUUAGGACAUAAACACUUU 2272 2908_11_205 NR3C1 Exon 11 - xp5:143278968-143278993 CUAUACAAGCAGAACUGAGGCACUU 2273 2908_11_206 NR3C1 Exon 11 - xp5:143278976-143279001 GUGGGAUACUAUACAAGCAGAACUG 2274 2908_11_207 NR3C1 Exon 11 - xp5:143278999-143279024 UUUUUAGUGUUUGUAGGUAUUCUGU 2275 2908_11_208 NR3C1 Exon 11 - xp5:143279000-143279025 AUUUUUAGUGUUUGUAGGUAUUCUG 2276 2908_11_209 NR3C1 Exon 11 - xp5:143279010-143279035 CCUGAAAAAGUAUUUUUAGUGUUUGU 2277 2908_11_210 NR3C1 Exon 11 - xp5:143279053-143279078 AGUUUGUAGUACUUCAGUGAGAGU 2278 2908_11_211 NR3C1 Exon 11 - xp5:143279103-143279128 AUUUAUUUCCUAUGUAUGUGUUAUC 2279 2908_11_212 NR3C1 Exon 11 - xp5:143279147-143279172 AAUUGUGGAUUUAAGGUGCUAUAUGG 2280 2908_11_213 NR3C1 Exon 11 - xp5:143279150-143279175 UUUAAUUGUGGAUUUAAGUGCUAUA 2281 2908_11_214 NR3C1 Exon 11 - xp5:143279167-143279192 AAGUCAUCUUAAUUAUGUUUAAUUG 2282 2908_11_215 NR3C1 Exon 11 - xp5:143279201-143279226 AGCUGUGCCCUUUUAGGAUACGUGG 2283 2908_11_216 NR3C1 Exon 11 - xp5:143279202-143279227 AAGCUGUGCCCUUUUAGGAUACGUG 2284 2908_11_217 NR3C1 Exon 11 - xp5:143279203-143279228 GAAGCUGUGCCCUUUUAGGAUACGU 2285 2908_11_218 NR3C1 Exon 11 - xp5:143279204-143279229 AGAAGCUGUGCCCUUUUAGGAUACG 2286 2908_11_219 NR3C1 Exon 11 - xp5:143279212-143279237 AUGGGAAAAAGAAGCUGUGCCCUUUU 2287 2908_11_220 NR3C1 Exon 11 - xp5:143279235-143279260 AACUAUAGGAGGCUUUUCAUUAAAU 2288 2908_11_221 NR3C1 Exon 11 - xp5:143279236-143279261 CAACUAUAGGAGGCUUUUCAUUAAA 2289 2908_11_222 NR3C1 Exon 11 - xp5:143279251-143279276 ACUGAUGCUCAUCGACAACUAUAGG 2290 2908_11_223 NR3C1 Exon 11 - xp5:143279254-143279279 UCAACUGAUGCUCAUCGACAACUAU 2291 2908_11_224 NR3C1 Exon 11 - xp5:143279345-143279370 AAUCUGAUUUUCAUCCCAACAAUCU 2292 2908_11_225 NR3C1 Exon 11 - xp5:143279402-143279427 UAUCAUUCCUUUAUAGAAUGUUAUG 2293 2908_11_226 NR3C1 Exon 11 - xp5:143279504-143279529 UGUGUAACCCGGCUGGAUAAAUUUU 2294 2908_11_227 NR3C1 Exon 11 - xp5:143279516-143279541 AUUUUAAGAUGGUGUGUAACCCGGC 2295 2908_11_228 NR3C1 Exon 11 - xp5:143279520-143279545 UAAUAUUUUAAGAUGGUGUGUAACC 2296 2908_11_229 NR3C1 Exon 11 - xp5:143279532-143279557 UAAAAGGGAAUGUAAUAUUUUAAAGA 2297 2908_11_230 NR3C1 Exon 11 - xp5:143279552-143279577 UUUGCUUUUUGAAUGCUCUCUAAAA 2298 2908_11_231 NR3C1 Exon 11 - xp5:143279553-143279578 AUUUGCUUUUUGAAUGCUCUCUAAA 2299 2908_11_232 NR3C1 Exon 11 - xp5:143279607-143279632 AUGUUAUUUGUUAUUUUCAGUAUUU 2300 2908_11_233 NR3C1 Exon 11 - xp5:143279667-143279692 CAAGAGUUUAUUUCCAAAUAAAAUG 2301 2908_11_234 NR3C1 Exon 11 - xp5:143279731-143279756 AUAUGUAAAUAGUGCAGAAUCUCAU 2302 2908_11_235 NR3C1 Exon 11 - xp5:143279767-143279792 AGAAGUUUGGCAAUAGUUUGCAUAG 2303 2908_11_236 NR3C1 Exon 11 - xp5:143279785-143279810 AAUGACAACAGAAGCUUCAGAAGUU 2304 2908_11_237 NR3C1 Exon 11 - xp5:143279846-143279871 AUCCUUAAGGCACCAUCUAAUAGC 2305 2908_11_238 NR3C1 Exon 11 - xp5:143279847-143279872 CAUCCUUAAAGGCACCAUCUAAUAG 2306 2908_11_239 NR3C1 Exon 11 - xp5:143279863-143279888 AGGAAGGUGGUGCUUACAUCCUUAA 2307 2908_11_240 NR3C1 Exon 11 - xp5:143279881-143279906 AGUAUGUAAACAGGAGACAGGAAGG 2308 2908_11_241 NR3C1 Exon 11 - xp5:143279884-143279909 UAAAGUAUGUAAACAGGAGACAGGA 2309 2908_11_242 NR3C1 Exon 11 - xp5:143279888-143279913 UAUGUAAAAGUAUGUAAACAGGAGAC 2310 2908_11_243 NR3C1 Exon 11 - xp5:143279895-143279920 ACUAAAGUAUGUAAAAGUAUGUAAAC 2311 2908_11_244 NR3C1 Exon 11 - xp5:143279948-143279973 AUUCCAACAGUGAGUCUGUCAGCGC 2312 2908_11_245 NR3C1 Exon 11 - xp5:143280013-143280038 AGGCUCUGACCCAGUGAGAUUCAG 2313 2908_11_246 NR3C1 Exon 11 - xp5:143280038-143280063 GUCCUGUGUGCAGUGAAGGUUGCUG 2314 2908_11_247 NR3C1 Exon 11 - xp5:143280047-143280072 UGGAGACUGGUCCUGUGUGCAGUGA 2315 2908_11_248 NR3C1 Exon 11 - xp5:143280065-143280090 UCUAGGGGAAGAGGGAGAUGGAGAC 2316 2908_11_249 NR3C1 Exon 11 - xp5:143280072-143280097 AGUUUGCUCUAGGGGAAGAGGGAGA 2317 2908_11_250 NR3C1 Exon 11 - xp5:143280078-143280103 CCAAACAGUUUGCUCUAGGGGAAGA 2318 2908_11_251 NR3C1 Exon 11 - xp5:143280079-143280104 ACCAAACAGUUUGCUCUAGGGGAAG 2319 2908_11_252 NR3C1 Exon 11 - xp5:143280085-143280110 UCAGAAACCAAACAGUUUGCUCUAG 2320 2908_11_253 NR3C1 Exon 11 - xp5:143280086-143280111 CUCAGAAACCAAACAGUUUGCUCUA 2321 2908_11_254 NR3C1 Exon 11 - xp5:143280087-143280112 UCUCAGAAACCAAACAGUUUGCUCU 2322 2908_11_255 NR3C1 Exon 11 - xp5:143280115-143280140 GUACAUGCAUUCAUACAGGCAGCGA 2323 2908_11_256 NR3C1 Exon 11 - xp5:143280124-143280149 UUAUAGUUUGUACAUGCAUUCAUAC 2324 2908_11_257 NR3C1 Exon 11 - xp5:143280166-143280191 UUUGUAGGGGUCAAAGAAAUGCUGA 2325 2908_11_258 NR3C1 Exon 11 - xp5:143280184-143280209 AUGACAGUUAUAUAUUUUUUGUAG 2326 2908_11_259 NR3C1 Exon 11 - xp5:143280185-143280210 CAUGACAGUUAUAUAUUUUUUGUA 2327 2908_11_260 NR3C1 Exon 11 - xp5:143280186-143280211 UCAUGACAUGUUAUAUAUUUUUUGU 2328 2908_11_261 NR3C1 Exon 11 - xp5:143280305-143280330 CCAUAACACUAAUCUGGGAAGGGAA 2329 2908_11_262 NR3C1 Exon 11 - xp5:143280306-143280331 ACCAUAACACUAAUCUGGGAAGGGA 2330 2908_11_263 NR3C1 Exon 11 - xp5:143280310-143280335 UAUAACCAUAACACUAAUCUGGGAA 2331 2908_11_264 NR3C1 Exon 11 - xp5:143280311-143280336 GUAUAACCAUAACACUAAUCUGGA 2332 2908_11_265 NR3C1 Exon 11 - xp5:143280315-143280340 UAUAGUAUAACCAUAACACUAAUCU 2333 2908_11_266 NR3C1 Exon 11 - xp5:143280316-143280341 AUAUAGUAUAACCAUAACACUAAUC 2334 2908_11_267 NR3C1 Exon 11 - xp5:143280385-143280410 AACUGAAAAUCUAAUAUUAAAAAUA 2335 2908_11_268 NR3C1 Exon 11 - xp5:143280435-143280460 CAAGAAAUUUGAUUUCUAUUCAAGG 2336 2908_11_269 NR3C1 Exon 11 - xp5:143280438-143280463 CCACAAGAAAUUUGAUUUCUAUUCA 2337 2908_11_270 NR3C1 Exon 11 - xp5:143280683-143280708 AUUGGUUAAUCUUUCCUGAUGGUAC 2338 2908_11_271 NR3C1 Exon 11 - xp5:143280689-143280714 UCACCAAUUGGUUAAUCUUUCCUGA 2339 2908_11_272 NR3C1 Exon 11 - xp5:143280706-143280731 UUUCACAUUCCCAUCUGUCACCAAU 2340 2908_11_273 NR3C1 Exon 11 - xp5:143280746-143280771 AACUAAAUCUCUAAUAUGGCAAAAA 2341 2908_11_274 NR3C1 Exon 11 - xp5:143280755-143280780 UUACCCAAAAACUAAAUCUCUAAUA 2342 2908_11_275 NR3C1 Exon 11 - xp5:143280892-143280917 AAAGCUGGUAAAACUAUUUGUCUUUC 2343 2908_11_276 NR3C1 Exon 11 - xp5:143280912-143280937 UGCAAUGGCUAUAUGGCAAGAAAGC 2344 2908_11_277 NR3C1 Exon 11 - xp5:143280924-143280949 ACGCCCUAUUUUUGCAAUGGCUAUA 2345 2908_11_278 NR3C1 Exon 11 - xp5:143280932-143280957 UGUACCUAACGCCCUAUUUUUGCAA 2346 2908_11_279 NR3C1 Exon 11 - xp5:143280967-143280992 ACUAAUUUAAAAAAUAACUACCAAG 2347 2908_11_280 NR3C1 Exon 11 - xp5:143281004-143281029 GACCUGCUGGGUAAAACUGUGGAUGA 2348 2908_11_281 NR3C1 Exon 11 - xp5:143281011-143281036 GUCCAGUGACCUGCUGGGUAAACCUG 2349 2908_11_282 NR3C1 Exon 11 - xp5:143281021-143281046 AGAGCACCUAGUCCAGUGACCUGCU 2350 2908_11_283 NR3C1 Exon 11 - xp5:143281022-143281047 UAGAGCACCUAGUCCAGUGACCUGC 2351 2908_11_284 NR3C1 Exon 11 - xp5:143281052-143281077 GGUUGUGCAAAUUAACAGUCCUAAC 2352 2908_11_285 NR3C1 Exon 11 - xp5:143281078-143281103 UAUCUGCUUCAGUGGAGAAUUAUAU 2353 2908_11_286 NR3C1 Exon 11 - xp5:143281091-143281116 CAUAUUUUGUAUAUAUCUGCUUCAG 2354 2908_11_287 NR3C1 Exon 11 - xp5:143281194-143281219 AAAUGGGUUGGUGCUUCUAACCUGA 2355 2908_11_288 NR3C1 Exon 11 - xp5:143281211-143281236 AUCAAUCAUCUGUGUGAAAAUGGGU 2356 2908_11_289 NR3C1 Exon 11 - xp5:143281215-143281240 AUUAAUCAAUCACUGUGUGAAAAU 2357 2908_11_290 NR3C1 Exon 11 - xp5:143281216-143281241 CAUUAAUCAAUCAUCUGUGUGAAAAA 2358 2908_11_291 NR3C1 Exon 11 - xp5:143281279-143281304 AAGUUAUUGUACAGCUGUUUAAGAU 2359 2908_11_292 NR3C1 Exon 11 - xp5:143281280-143281305 CAAGUUAUUGUACAGCUGUUUAAGA 2360 2908_11_293 NR3C1 Exon 11 - xp5:143281374-143281399 UGUGCCUUUUAUAGCUAUUACUGUC 2361 2908_11_294 NR3C1 Exon 11 - xp5:143281406-143281431 AAGUUUACAAGUGUAUAUCAGAAAAA 2362 2908_11_295 NR3C1 Exon 11 - xp5:143281407-143281432 AAAGUUUACAAGUGUAUAUCAGAAA 2363 2908_11_296 NR3C1 Exon 11 - xp5:143281446-143281471 UAGGAUAGCAUUUUUGAUUUAUGCA 2364 2908_11_297 NR3C1 Exon 11 - xp5:143281470-143281495 UGGUGUAUCCCCCCCCCUGUAUAGUU 2365 2908_11_298 NR3C1 Exon 11 - xp5:143281495-143281520 GGAUGAAAUUUUCUAGACUUUCUGU 2366 2908_11_299 NR3C1 Exon 11 - xp5:143281521-143281546 CUUCAUACUUUUUUUCACAGUUGGC 2367 2908_11_300 NR3C1 Exon 11 - xp5:143281525-143281550 UUCUCUUCAUACUUUUUUUCACAGGU 2368 2908_11_301 NR3C1 Exon 11 - xp5:143281592-143281617 CGUAAUCUCCACAGUCAAAGAAGGA 2369 2908_11_302 NR3C1 Exon 11 - xp5:143281596-143281621 UGGACGUAAUCUCCACAGUCAAGA 2370 2908_11_303 NR3C1 Exon 11 - xp5:143281621-143281646 CCCAGAAAUUAGAAACCUUAAUAUG 2371 2908_11_304 NR3C1 Exon 11 - xp5:143281671-143281696 CACUUUUCAGUGAUGGGAGAGUAGA 2372 2908_11_305 NR3C1 Exon 11 - xp5:143281682-143281707 UGAGUCGUCAUCACUUUUCAGUGAU 2373 2908_11_306 NR3C1 Exon 11 - xp5:143281683-143281708 UUGAGUCGUCAUCACUUUUCAGUGA 2374 2908_11_307 NR3C1 Exon 11 - xp5:143281723-143281748 AUGUGGUUUAUAGAGGGCCAAGACU 2375 2908_11_308 NR3C1 Exon 11 - xp5:143281734-143281759 AUACGCACUACAUGUGGUUUAUAGA 2376 2908_11_309 NR3C1 Exon 11 - xp5:143281735-143281760 AAUACGCACUACAUGUGGUUUAUAG 2377 2908_11_310 NR3C1 Exon 11 - xp5:143281745-143281770 UUUUGUUUUAAAUACGCACUACAUG 2378 2908_11_311 NR3C1 Exon 11 - xp5:143281809-143281834 UAUAAACUAUCAGUUUGUCCUGUAG 2379 2908_11_312 NR3C1 Exon 11 - xp5:143281873-143281898 UCAAAAGUGACUGCCUUAAUAAGAA 2380 2908_11_313 NR3C1 Exon 11 - xp5:143281925-143281950 CCAAUCAGAUACCAAAAUAUUCAAAA 2381 2908_11_314 NR3C1 Exon 11 - xp5:143282001-143282026 CUUAACCUAUUGCUUCCAAAACAUUUU 2382 2908_11_315 NR3C1 Exon 11 - xp5:143282040-143282065 UCAUUACCAUAUCUUCUCUUGCAGG 2383 2908_10_1 NR3C1 Exon 10 + xp5:143282594-143282619 CAGUUGAUAAAACCGCUGCCAGUUC 2384 2908_10_2 NR3C1 Exon 10 + xp5:143282598-143282623 UGAUAAAACCGCUGCCAGUUCUGGC 2385 2908_10_3 NR3C1 Exon 10 + xp5:143282622-143282647 CUGGAGUUUCCUUCCCUCUUGACAAA 2386 2908_10_4 NR3C1 Exon 10 + xp5:143282646-143282671 AUGGCUUUUCCUAGCUCUUUGAUGU 2387 2908_10_5 NR3C1 Exon 10 + xp5:143282675-143282700 CAUUCUAAUUUCAUCAAUAGCUCU 2388 2908_10_6 NR3C1 Exon 10 + xp5:143282695-143282720 GCUCUUGGCUCUUCAGACCGUCCUU 2389 2908_10_7 NR3C1 Exon 10 + xp5:143282705-143282730 CUUCAGACCGUCCUUAGGAACUAAA 2390 2908_10_8 NR3C1 Exon 10 - xp5:143282584-143282609 CGGUUUUAUCAACUGACAAAAACUCU 2391 2908_10_9 NR3C1 Exon 10 - xp5:143282609-143282634 AGGAAACUCCAGCCAGAACUGGCAG 2392 2908_10_10 NR3C1 Exon 10 - xp5:143282615-143282640 GAGGGAAGGAAACUCCAGCCCAGAAC 2393 2908_10_11 NR3C1 Exon 10 - xp5:143282634-143282659 UAGGAAAAGCCAUUGUCAAGAGGGA 2394 2908_10_12 NR3C1 Exon 10 - xp5:143282638-143282663 GAGCUAGGAAAAGCCAUUGUCAAAGA 2395 2908_10_13 NR3C1 Exon 10 - xp5:143282639-143282664 AGAGCUAGGAAAAGCCAUUGUCAAG 2396 2908_10_14 NR3C1 Exon 10 - xp5:143282658-143282683 UUAGAAUGACCUACAUCAAAGAGCU 2397 2908_10_15 NR3C1 Exon 10 - xp5:143282715-143282740 AUCUUAACCUUUUAGUUCCUAAGGA 2398 2908_10_16 NR3C1 Exon 10 - xp5:143282719-143282744 CUUCAUCUUAACCUUUUAGUUCCUA 2399 2908_9_1 NR3C1 Exon 9 + xp5:143293879-143293904 UAAACAAGUAAAGUUGUUAGUAUCC 2400 2908_9_2 NR3C1 Exon 9 + xp5:143293900-143293925 AUCCAGGCACUGAAUUAUACCUUCA 2401 2908_9_3 NR3C1 Exon 9 + xp5:143293972-143293997 ACUUCUUUAACAAGUGUACCGCUAC 2402 2908_9_4 NR3C1 Exon 9 + xp5:143294007-143294032 AAACGUCUCUAGCAAUGAUCUUUAU 2403 2908_9_5 NR3C1 Exon 9 + xp5:143294008-143294033 AACGUCUCUAGCAAUGAUCUUUAUC 2404 2908_9_6 NR3C1 Exon 9 + xp5:143294119-143294144 AAAACAUUAAGAUGAAUGUGCCGCUU 2405 2908_9_7 NR3C1 Exon 9 + xp5:143294194-143294219 GCAACAUCCAUAGCUUACAGUUAUU 2406 2908_9_8 NR3C1 Exon 9 + xp5:143294221-143294246 GCAACUAUGAAACCCACAGUUACUAA 2407 2908_9_9 NR3C1 Exon 9 + xp5:143294273-143294298 AAAUGUACCUUAUUUGUAUAUGAAG 2408 2908_9_10 NR3C1 Exon 9 + xp5:143294332-143294357 AUUGAUAUGUAAUUUUUACUUGAAA 2409 2908_9_11 NR3C1 Exon 9 + xp5:143294339-143294364 UGUAAUUUUUACUUGAAAUGGCCUA 2410 2908_9_12 NR3C1 Exon 9 + xp5:143295014-143295039 AAUAGUAAUUAAGCACACCUUUUCU 2411 2908_9_13 NR3C1 Exon 9 + xp5:143295063-143295088 UUUCUCAUACAUGCUAAUACUCAUU 2412 2908_9_14 NR3C1 Exon 9 + xp5:143295098-143295123 AAUUUUUAACCAAAAUAACAGUAG 2413 2908_9_15 NR3C1 Exon 9 + xp5:143295157-143295182 AUGUCUUCCCAUGAUCAAAGAUCAAA 2414 2908_9_16 NR3C1 Exon 9 + xp5:143295161-143295186 CUUCCCAUGAUCAAAGAUCAAGGA 2415 2908_9_17 NR3C1 Exon 9 + xp5:143295165-143295190 CCAUGAUCAAAGAUCAAAAGGAAGGA 2416 2908_9_18 NR3C1 Exon 9 + xp5:143295261-143295286 CCAUACCUAUUUGUCUUAUUAAUCU 2417 2908_9_19 NR3C1 Exon 9 + xp5:143295319-143295344 CAUUCAUAAAAAUCAUCUGACUAGU 2418 2908_9_20 NR3C1 Exon 9 + xp5:143295337-143295362 GACUAGUAGGAAAUAAUAGUAGACU 2419 2908_9_21 NR3C1 Exon 9 + xp5:143295382-143295407 UGUAUAUAAAUUAACCUUUGUUUCU 2420 2908_9_22 NR3C1 Exon 9 + xp5:143295411-143295436 CUUCAUAUUUCAUGCUUUUGACAUA 2421 2908_9_23 NR3C1 Exon 9 + xp5:143295419-143295444 UUCAUGCUUUUGACAUAAGGUGAAA 2422 2908_9_24 NR3C1 Exon 9 + xp5:143295452-143295477 UACCAACCUGAAGAGAGAAGCAGUA 2423 2908_9_25 NR3C1 Exon 9 + xp5:143295506-143295531 GAUACCUGAAGCCUGUGUAACUCAG 2424 2908_9_26 NR3C1 Exon 9 + xp5:143295532-143295557 GGAAACAUACAGCAUGUGUUUACAU 2425 2908_9_27 NR3C1 Exon 9 + xp5:143295545-143295570 AUGUGUUUACAUUGGUCGUACAUGC 2426 2908_9_28 NR3C1 Exon 9 + xp5:143295546-143295571 UGUGUUUACAUUGGUCGUACAUGCA 2427 2908_9_29 NR3C1 Exon 9 + xp5:143295583-143295608 UCUCUGCCUGUGAAAGAUAAAUAGC 2428 2908_9_30 NR3C1 Exon 9 + xp5:143295584-143295609 CUCUGCCUGUGAAAGAAUAAAUAGCA 2429 2908_9_31 NR3C1 Exon 9 - xp5:143293861-143293886 UUGUUUUUUUUUUUUUUUUUUUUCUU 2430 2908_9_32 NR3C1 Exon 9 - xp5:143293905-143293930 UACCAUGAAGGUAUAAUUCAGUGCC 2431 2908_9_33 NR3C1 Exon 9 - xp5:143293922-143293947 AUCAUAGCUUUGAUUGAUACCAUGA 2432 2908_9_34 NR3C1 Exon 9 - xp5:143293993-143294018 UAGAGACGUUUAAUGUUACCUGUAG 2433 2908_9_35 NR3C1 Exon 9 - xp5:143294047-143294072 AGAAGUAUUAAUAAUAUUUCAGUCA 2434 2908_9_36 NR3C1 Exon 9 - xp5:143294080-143294105 UCAACAAAAAGUUAUUUUAUGUUAA 2435 2908_9_37 NR3C1 Exon 9 - xp5:143294204-143294229 AUAGUUGCCAAAUAACUGUAAGCUA 2436 2908_9_38 NR3C1 Exon 9 - xp5:143294236-143294261 AAAGUCUUAAUUCCAUUAGUAACUG 2437 2908_9_39 NR3C1 Exon 9 - xp5:143294363-143294388 UGAACUAGUUGGUAUUAUAAACCUU 2438 2908_9_40 NR3C1 Exon 9 - xp5:143294379-143294404 AAAUUUUAAAAGCUCUAUGAACUAGU 2439 2908_9_41 NR3C1 Exon 9 - xp5:143294957-143294982 UGUCAGAGAUUCAUUAUCUAGAAAA 2440 2908_9_42 NR3C1 Exon 9 - xp5:143294987-143295012 GGAUUGGUUAACAUAGCAUGGGAGC 2441 2908_9_43 NR3C1 Exon 9 - xp5:143294993-143295018 UAUUGGGGAUUGGUUAACAUAGCAU 2442 2908_9_44 NR3C1 Exon 9 - xp5:143294994-143295019 CUAUUGGGGAUUGGUUAACAUAGCA 2443 2908_9_45 NR3C1 Exon 9 - xp5:143295008-143295033 GGUGUGCUUAAUUACUAUUGGGGAU 2444 2908_9_46 NR3C1 Exon 9 - xp5:143295013-143295038 GAAAAGGUGUGCUUAAUUACUAUUG 2445 2908_9_47 NR3C1 Exon 9 - xp5:143295014-143295039 AGAAAAGGUGUGCUUAAUUACUAUU 2446 2908_9_48 NR3C1 Exon 9 - xp5:143295015-143295040 UAGAAAAGGUGUGCUUAAUUACUAU 2447 2908_9_49 NR3C1 Exon 9 - xp5:143295034-143295059 GGGAGAAAAAAGGCGCAUCCUAGAAA 2448 2908_9_50 NR3C1 Exon 9 - xp5:143295050-143295075 AUGUAUGAGAAAUUAUGGGAGAAAAA 2449 2908_9_51 NR3C1 Exon 9 - xp5:143295059-143295084 AGUAUUAGCAUGUAUGAGAAAUUAU 2450 2908_9_52 NR3C1 Exon 9 - xp5:143295060-143295085 GAGUAUUAGCAUGUAUGAGAAAUUA 2451 2908_9_53 NR3C1 Exon 9 - xp5:143295110-143295135 UGAUUUUGUCCACUACACUGUUAUU 2452 2908_9_54 NR3C1 Exon 9 - xp5:143295158-143295183 UUUGAUCUUUGAUCAUGGGAAGACA 2453 2908_9_55 NR3C1 Exon 9 - xp5:143295167-143295192 CUUCCUUCCUUUGAUCUUUGAUCAU 2454 2908_9_56 NR3C1 Exon 9 - xp5:143295168-143295193 CCUUCCUUCCUUUGAUCUUUGAUCA 2455 2908_9_57 NR3C1 Exon 9 - xp5:143295232-143295257 AACAGAGAGGUAUAUGAGCUGCAUA 2456 2908_9_58 NR3C1 Exon 9 - xp5:143295233-143295258 AAACAGAGAGGUAUAUGAGCUGCAU 2457 2908_9_59 NR3C1 Exon 9 - xp5:143295250-143295275 ACAAAUAGGUAUGGCAGAAACAGAG 2458 2908_9_60 NR3C1 Exon 9 - xp5:143295264-143295289 CCAAGAUUAAUAAAGACAAAUAGGUA 2459 2908_9_61 NR3C1 Exon 9 - xp5:143295269-143295294 UGACACCAAAGAUUAAUAAAGACAAAU 2460 2908_9_62 NR3C1 Exon 9 - xp5:143295306-143295331 UUUUUAUGAAUGUAAAAAUAUUAGAA 2461 2908_9_63 NR3C1 Exon 9 - xp5:143295399-143295424 AUGAAAUAUGAAGGCCUAGAAACAA 2462 2908_9_64 NR3C1 Exon 9 - xp5:143295413-143295438 CUUAUGUCAAAAGCAUGAAAUAUGA 2463 2908_9_65 NR3C1 Exon 9 - xp5:143295457-143295482 AACCUUACUGCUUCUCUCUUCAGGU 2464 2908_9_66 NR3C1 Exon 9 - xp5:143295461-143295486 UGAAAACCUUACUGCUUCUCUCUUC 2465 2908_9_67 NR3C1 Exon 9 - xp5:143295513-143295538 GUUUCCUCUGAGUUACACAGGCUUC 2466 2908_9_68 NR3C1 Exon 9 - xp5:143295520-143295545 GCUGUAUGUUUCCUCUGAGUUACAC 2467 2908_8_1 NR3C1 Exon 8 + xp5:143298659-143298684 CAACUUACUCAUUAAUAAUCAGAUC 2468 2908_8_2 NR3C1 Exon 8 + xp5:143298675-143298700 AAUCAGAUCAGGAGCAAAACACAGC 2469 2908_8_3 NR3C1 Exon 8 + xp5:143298736-143298761 AGAGCAAAUGCCAUAAGAAACAUCC 2470 2908_8_4 NR3C1 Exon 8 + xp5:143298750-143298775 AAGAAACAUCCAGGAGUACUGCAGU 2471 2908_8_5 NR3C1 Exon 8 + xp5:143298751-143298776 AGAAACAUCCAGGAGUACUGCAGUA 2472 2908_8_6 NR3C1 Exon 8 + xp5:143298759-143298784 CCAGGAGUACUGCAGUAGGGUCAUU 2473 2908_8_7 NR3C1 Exon 8 + xp5:143298768-143298793 CUGCAGUAGGGUCAUUUGGUCAUCC 2474 2908_8_8 NR3C1 Exon 8 + xp5:143298805-143298830 CUGAAACCUGAAUUAAGAGAAAUAA 2475 2908_8_9 NR3C1 Exon 8 - xp5:143298732-143298757 GUUUCUUAUGGCAUUUGCUCUGGGG 2476 2908_8_10 NR3C1 Exon 8 - xp5:143298735-143298760 GAUGUUUCUUAUGGCAUUUGCUCUG 2477 2908_8_11 NR3C1 Exon 8 - xp5:143298736-143298761 GGAUGUUUCUUAUGGCAUUUGCUCU 2478 2908_8_12 NR3C1 Exon 8 - xp5:143298737-143298762 UGGAUGUUUCUUAUGGCAUUUGCUC 2479 2908_8_13 NR3C1 Exon 8 - xp5:143298749-143298774 CUGCAGUACUCCUGGAUGUUUCUUA 2480 2908_8_14 NR3C1 Exon 8 - xp5:143298762-143298787 CCAAAUGACCCUACUGCAGUACUCC 2481 2908_8_15 NR3C1 Exon 8 - xp5:143298794-143298819 AAUUCAGGUUUCAGGAACUUACACC 2482 2908_8_16 NR3C1 Exon 8 - xp5:143298807-143298832 CUUUAUUUCUCUUAAUUCAGGUUUC 2483 2908_7_1 NR3C1 Exon 7 + xp5:143300460-143300485 GCUCUUUUAUGUUUUGCAUCUUACC 2484 2908_7_2 NR3C1 Exon 7 + xp5:143300547-143300572 UAGUCAUGAUCCUCCAAGUUGAGUC 2485 2908_7_3 NR3C1 Exon 7 + xp5:143300583-143300608 UAUCAUAUCCUGCAUAUAACACUUC 2486 2908_7_4 NR3C1 Exon 7 + xp5:143300611-143300636 UUCAAUAACCUCCAACAGUGACACC 2487 2908_7_5 NR3C1 Exon 7 + xp5:143300612-143300637 UCAAUAACCUCCAACAGUGACACCA 2488 2908_7_6 NR3C1 Exon 7 + xp5:143300616-143300641 UAACCUCCAACAGUGACACCAGGGU 2489 2908_7_7 NR3C1 Exon 7 + xp5:143300617-143300642 AACCUCCAACAGUGACACCAGGGUA 2490 2908_7_8 NR3C1 Exon 7 + xp5:143300618-143300643 ACCUCCAACAGUGACACCAGGGUAG 2491 2908_7_9 NR3C1 Exon 7 + xp5:143300628-143300653 GUGACACCAGGGUAGGGGUGAGUUG 2492 2908_7_10 NR3C1 Exon 7 + xp5:143300640-143300665 UAGGGGUGAGUUGUGGUAACGUUGC 2493 2908_7_11 NR3C1 Exon 7 + xp5:143300661-143300686 UUGCAGGAACUAUUGUUUUGUUACC 2494 2908_7_12 NR3C1 Exon 7 + xp5:143300672-143300697 AUUGUUUUGUUACCAGGAUUUUCAG 2495 2908_7_13 NR3C1 Exon 7 + xp5:143300696-143300721 GAGGUUUCUUGUGAGACUCCUGUAG 2496 2908_7_14 NR3C1 Exon 7 + xp5:143300741-143300766 AUUUUUUUCUUUGUUUUUCGAGCUG 2497 2908_7_15 NR3C1 Exon 7 + xp5:143300742-143300767 UUUUUUUCUUUGUUUUUCGAGCUGU 2498 2908_7_16 NR3C1 Exon 7 - xp5:143300486-143300511 CAGUGAAAUGGGCAAAGGCAAUACC 2499 2908_7_17 NR3C1 Exon 7 - xp5:143300496-143300521 GUGAUUGCAGCAGUGAAAUGGGCAA 2500 2908_7_18 NR3C1 Exon 7 - xp5:143300502-143300527 CGGCAAGUGAUUGCAGCAGUGAAU 2501 2908_7_19 NR3C1 Exon 7 - xp5:143300503-143300528 GCGGCAAGUGAUUGCAGCAGUGAAA 2502 2908_7_20 NR3C1 Exon 7 - xp5:143300527-143300552 GACUACGCUCAACAUGUUAGGAGGG 2503 2908_7_21 NR3C1 Exon 7 - xp5:143300530-143300555 CAUGACUACCGCUCAACAUGUUAGGA 2504 2908_7_22 NR3C1 Exon 7 - xp5:143300531-143300556 UCAUGACUACGCUCAACAUGUUAGG 2505 2908_7_23 NR3C1 Exon 7 - xp5:143300534-143300559 GGAUCAUGACUACGCUCAACAUGUU 2506 2908_7_24 NR3C1 Exon 7 - xp5:143300560-143300585 UAGCUCUGUUCCAGACUCAACUUGG 2507 2908_7_25 NR3C1 Exon 7 - xp5:143300563-143300588 UGAUAGCUCUGUUCCAGACUCAACU 2508 2908_7_26 NR3C1 Exon 7 - xp5:143300594-143300619 UUAUUGAACCUGAAGUGUUAUAUGC 2509 2908_7_27 NR3C1 Exon 7 - xp5:143300622-143300647 ACCCCUACCCUGGUGUCACUGUUGG 2510 2908_7_28 NR3C1 Exon 7 - xp5:143300625-143300650 CUCACCCCUACCCUGGUGUCACUGU 2511 2908_7_29 NR3C1 Exon 7 - xp5:143300637-143300662 ACGUUACCACAACUCACCCCUACCC 2512 2908_7_30 NR3C1 Exon 7 - xp5:143300687-143300712 UCUCACAAGAAACCUCUGAAAAUCC 2513 2908_7_31 NR3C1 Exon 7 - xp5:143300717-143300742 UAAAAGGAAUUCAGCAGGCCACUAC 2514 2908_7_32 NR3C1 Exon 7 - xp5:143300727-143300752 AAGAAAAAAAUAAAAGGAAUUCAGC 2515 2908_7_33 NR3C1 Exon 7 - xp5:143300738-143300763 CUCGAAAAACAAAGAAAAAAAUAAA 2516 2908_6_1 NR3C1 Exon 6 + xp5:143310076-143310101 CUUUCAGAUAUUUAUAUUACCUUCC 2517 2908_6_2 NR3C1 Exon 6 + xp5:143310109-143310134 UCCAGCCUGAAGACAUUUUCGAUAG 2518 2908_6_3 NR3C1 Exon 6 + xp5:143310117-143310142 GAAGACAUUUUCGAUAGCGGCAUGC 2519 2908_6_4 NR3C1 Exon 6 + xp5:143310118-143310143 AAGACAUUUUCGAUAGCGGCAUGCU 2520 2908_6_5 NR3C1 Exon 6 + xp5:143310172-143310197 GAUGCAAUCAUUCCUUCCAGCACAU 2521 2908_6_6 NR3C1 Exon 6 + xp5:143310193-143310218 ACAUAGGUAAUUGUGCUGUCCUAUA 2522 2908_6_7 NR3C1 Exon 6 + xp5:143310202-143310227 AUUGUGCUGUCCUAUAUGGAAUAAAA 2523 2908_6_8 NR3C1 Exon 6 - xp5:143310098-143310123 GUCUUCAGGCUGGAAUGAACCUGGA 2524 2908_6_9 NR3C1 Exon 6 - xp5:143310102-143310127 AAAUGUCUUCAGGCUGGAAUGAACC 2525 2908_6_10 NR3C1 Exon 6 - xp5:143310113-143310138 GCCGCUAUCGAAAAUGUCUUCAGGC 2526 2908_6_11 NR3C1 Exon 6 - xp5:143310117-143310142 GCAUGCCCGCUAUCGAAAAUGUCUUC 2527 2908_6_12 NR3C1 Exon 6 - xp5:143310187-143310212 ACAGCACAAUUACCUAUGUGCUGGA 2528 2908_6_13 NR3C1 Exon 6 - xp5:143310191-143310216 UAGGACAGCACAAUUACCUAUGUGC 2529 2908_5_1 NR3C1 Exon 5 + xp5:143314062-143314087 UCCUGAAGCUUCAUCAGAGCACACC 2530 2908_5_2 NR3C1 Exon 5 + xp5:143314072-143314097 UCAUCAGAGCACACCAGGCAGAGUU 2531 2908_5_3 NR3C1 Exon 5 + xp5:143314073-143314098 CAUCAGAGCACACCAGGCAGAGUUU 2532 2908_5_4 NR3C1 Exon 5 + xp5:143314076-143314101 CAGAGCACACCAGGCAGAGUUUGGG 2533 2908_5_5 NR3C1 Exon 5 + xp5:143314079-143314104 AGCACACCAGGCAGAGUUUGGGAGG 2534 2908_5_6 NR3C1 Exon 5 + xp5:143314099-143314124 GGAGGUGGUCCUGUUGUUGCUGUUG 2535 2908_5_7 NR3C1 Exon 5 + xp5:143314105-143314130 GGUCCUGUUGUUGCUGUUGAGGAGC 2536 2908_5_8 NR3C1 Exon 5 + xp5:143314109-143314134 CUGUUGUUGCUGUUGAGGAGCUGGA 2537 2908_5_9 NR3C1 Exon 5 + xp5:143314112-143314137 UUGUUGCUGUUGAGGAGCUGGAUGG 2538 2908_5_10 NR3C1 Exon 5 + xp5:143314127-143314152 AGCUGGAUGGAGGAGAGCUUACAUC 2539 2908_5_11 NR3C1 Exon 5 + xp5:143314138-143314163 GGAGAGCUUACAUCUGGUCUCAUGC 2540 2908_5_12 NR3C1 Exon 5 + xp5:143314139-143314164 GAGAGCUUACAUCUGGUCUCAUGCU 2541 2908_5_13 NR3C1 Exon 5 + xp5:143314140-143314165 AGAGCUUACAUCUGGUCUCAUGCUG 2542 2908_5_14 NR3C1 Exon 5 + xp5:143314150-143314175 UCUGGUCUCAUGCUGGGGCUAAAGA 2543 2908_5_15 NR3C1 Exon 5 + xp5:143314151-143314176 CUGGUCUCAUGCUGGGGCUAAAGAA 2544 2908_5_16 NR3C1 Exon 5 + xp5:143314152-143314177 UGGUCUCAUGCUGGGGCUAAAGAAG 2545 2908_5_17 NR3C1 Exon 5 - xp5:143314003-143314028 AAGUUUUCUUCAAAAGAGCAGUGGA 2546 2908_5_18 NR3C1 Exon 5 - xp5:143314007-143314032 UGUAAAAGUUUUCUUCAAAAGAGCAG 2547 2908_5_19 NR3C1 Exon 5 - xp5:143314039-143314064 GAUGUCAUUAUGGAGUCUUAACUUG 2548 2908_5_20 NR3C1 Exon 5 - xp5:143314054-143314079 CUGAUGAAGCUUCAGGAUGUCAUUA 2549 2908_5_21 NR3C1 Exon 5 - xp5:143314066-143314091 GCCUGGUGUGCUCUGAUGAAGCUUC 2550 2908_5_22 NR3C1 Exon 5 - xp5:143314088-143314113 ACAGGACCACCUCCCAAACUCUGCC 2551 2908_5_23 NR3C1 Exon 5 - xp5:143314111-143314136 CAUCCAGCUCCUCAACAGCAACAAC 2552 2908_4_1 NR3C1 Exon 4 + xp5:143399662-143399687 AGCCAUUAGAAAAAAACUGUUCGACC 2553 2908_4_2 NR3C1 Exon 4 + xp5:143399663-143399688 GCCAUUAGAAAAAAACUGUUCGACCA 2554 2908_4_3 NR3C1 Exon 4 + xp5:143399711-143399736 AGUCAAGUUGUCAUCUCCAGAUCCU 2555 2908_4_4 NR3C1 Exon 4 + xp5:143399730-143399755 GAUCCUUGGCACCUAUUCCAAUUUU 2556 2908_4_5 NR3C1 Exon 4 + xp5:143399739-143399764 CACCUAUUCCAAUUUUCGGAACCAA 2557 2908_4_6 NR3C1 Exon 4 + xp5:143399740-143399765 ACCUAUUCCAAUUUUCGGAACCAAC 2558 2908_4_7 NR3C1 Exon 4 + xp5:143399746-143399771 UCCAAUUUUCGGAACCAACGGGAAU 2559 2908_4_8 NR3C1 Exon 4 + xp5:143399749-143399774 AAUUUUCGGAACCAACGGGAAUUGG 2560 2908_4_9 NR3C1 Exon 4 + xp5:143399767-143399792 GAAUUGGUGGAAUGACAUUAAAAAAU 2561 2908_4_10 NR3C1 Exon 4 + xp5:143399792-143399817 AGGCUUCUGAUCCUGCUGUUGAGAA 2562 2908_4_11 NR3C1 Exon 4 + xp5:143399793-143399818 GGCUUCUGAUCCUGCUGUUGAGAAA 2563 2908_4_12 NR3C1 Exon 4 + xp5:143399816-143399841 AAGGGAUGCUGUAUUCAUGUCAUAG 2564 2908_4_13 NR3C1 Exon 4 + xp5:143399835-143399860 UCAUAGUGGUACAUCUGUCCUCCAG 2565 2908_4_14 NR3C1 Exon 4 + xp5:143399859-143399884 GAGGUACUCCACCAUGAACAGAAA 2566 2908_4_15 NR3C1 Exon 4 + xp5:143399893-143399918 UUUUAUUACCAAUUAUAUUUGCUCC 2567 2908_4_16 NR3C1 Exon 4 + xp5:143399947-143399972 CCAGUUUCUCUUGCUUAAUUACCCC 2568 2908_4_17 NR3C1 Exon 4 + xp5:143399948-143399973 CAGUUUCUCUUGCUUAAUUACCCCA 2569 2908_4_18 NR3C1 Exon 4 + xp5:143399949-143399974 AGUUUCUCUUGCUUAAUUACCCCAG 2570 2908_4_19 NR3C1 Exon 4 + xp5:143399990-143400015 GAAAUCUUCUUUUUCUGUUUUCACU 2571 2908_4_20 NR3C1 Exon 4 + xp5:143399991-143400016 AAAUCUUCUUUUUCUGUUUUCACUU 2572 2908_4_21 NR3C1 Exon 4 + xp5:143399992-143400017 AAUCUUCUUUUUCUGUUUUCACUUG 2573 2908_4_22 NR3C1 Exon 4 + xp5:143400009-143400034 UUCACUUGGGGCAGUGUUACAUUAC 2574 2908_4_23 NR3C1 Exon 4 + xp5:143400010-143400035 UCACUUGGGGCAGUGUUACAUUACU 2575 2908_4_24 NR3C1 Exon 4 + xp5:143400011-143400036 CACUUGGGGCAGUGUUACAUUACUG 2576 2908_4_25 NR3C1 Exon 4 + xp5:143400048-143400073 ACCAGAUCUCCAUUAUCCUUAAUUU 2577 2908_4_26 NR3C1 Exon 4 + xp5:143400049-143400074 CCAGAUCUCCAUUAUCCUUAAUUUU 2578 2908_4_27 NR3C1 Exon 4 + xp5:143400061-143400086 UAUCCUUAAUUUUGGGUUUAGUGUC 2579 2908_4_28 NR3C1 Exon 4 + xp5:143400073-143400098 UGGGUUUAGUGUCCGGUAAAAAUGAG 2580 2908_4_29 NR3C1 Exon 4 + xp5:143400107-143400132 GUCCUCAUUCGAGUUUCCUUCCAAA 2581 2908_4_30 NR3C1 Exon 4 + xp5:143400133-143400158 GGAAUGAAUCGCUUCUCCCCGCCAG 2582 2908_4_31 NR3C1 Exon 4 + xp5:143400164-143400189 AAGCAAACAGUUUUCAUCUAUCAAC 2583 2908_4_32 NR3C1 Exon 4 + xp5:143400178-143400203 CAUCUAUCAACAGGUCUGAUCUCCA 2584 2908_4_33 NR3C1 Exon 4 + xp5:143400202-143400227 AAGGACUCUCAUUCGUCUCUUUACC 2585 2908_4_34 NR3C1 Exon 4 + xp5:143400203-143400228 AGGACUCUCAUUCGUCUCUUUACCU 2586 2908_4_35 NR3C1 Exon 4 + xp5:143400204-143400229 GGACUCUCAUUCGUCUCUUUACCUG 2587 2908_4_36 NR3C1 Exon 4 + xp5:143400243-143400268 AACUCCAAAUCCUGCAAAAUGUCAA 2588 2908_4_37 NR3C1 Exon 4 + xp5:143400251-143400276 AUCCUGCAAAAUGUCAAAGGUGCUU 2589 2908_4_38 NR3C1 Exon 4 + xp5:143400258-143400283 AAAAUGUCAAAGGUGCUUUGGUCUG 2590 2908_4_39 NR3C1 Exon 4 + xp5:143400285-143400310 GUAUACAAUUUCACAUUGCCACCGU 2591 2908_4_40 NR3C1 Exon 4 + xp5:143400296-143400321 CACAUUGCCACCGUUGGUGCCAGUC 2592 2908_4_41 NR3C1 Exon 4 + xp5:143400343-143400368 CUGAAGAUACAUCAGAGUGAGUUUU 2593 2908_4_42 NR3C1 Exon 4 + xp5:143400360-143400385 UGAGUUUUUGGAAAACUCCUUCUCUG 2594 2908_4_43 NR3C1 Exon 4 + xp5:143400361-143400386 GAGUUUUUGGAAAACUCCUUCUCUGU 2595 2908_4_44 NR3C1 Exon 4 + xp5:143400362-143400387 AGUUUUUGGAAAACUCCUUCUCUGUG 2596 2908_4_45 NR3C1 Exon 4 + xp5:143400363-143400388 GUUUUUGGAAAACUCCUUCUCUGUGG 2597 2908_4_46 NR3C1 Exon 4 + xp5:143400381-143400406 UCUGUGGGGGCAGCAGACACAGCAG 2598 2908_4_47 NR3C1 Exon 4 + xp5:143400396-143400421 GACACAGCAGUGGAUGCUGAACUCU 2599 2908_4_48 NR3C1 Exon 4 + xp5:143400397-143400422 ACACAGCAGUGGAUGCUGAACUCUU 2600 2908_4_49 NR3C1 Exon 4 + xp5:143400398-143400423 CACAGCAGUGGAUGCUGAACUCUUG 2601 2908_4_50 NR3C1 Exon 4 + xp5:143400406-143400431 UGGAUGCUGAACUCUUGGGGUUCUC 2602 2908_4_51 NR3C1 Exon 4 + xp5:143400414-143400439 GAACUCUUGGGGUUCUCUGGAACAC 2603 2908_4_52 NR3C1 Exon 4 + xp5:143400428-143400453 CUCUGGAACCUGGUCGACCUAUUG 2604 2908_4_53 NR3C1 Exon 4 + xp5:143400474-143400499 AAAAGCUUUAAGCUGUUUCCCCCCG 2605 2908_4_54 NR3C1 Exon 4 + xp5:143400479-143400504 CUUUAAGCUGUUUCCCCCGAGGAA 2606 2908_4_55 NR3C1 Exon 4 + xp5:143400488-143400513 UGUUUCCCCCGAGGAAAGGCUGAUU 2607 2908_4_56 NR3C1 Exon 4 + xp5:143400499-143400524 AGGAAAGGCUGAUUUGGCCCUGCUG 2608 2908_4_57 NR3C1 Exon 4 + xp5:143400500-143400525 GGAAAGGCUGAUUUGGCCCUGCUGU 2609 2908_4_58 NR3C1 Exon 4 + xp5:143400509-143400534 GAUUUGGCCCUGCUGUGGGAAUCCCC 2610 2908_4_59 NR3C1 Exon 4 + xp5:143400576-143400601 AGUCCCAUUGAGAGUGAAACUGCUU 2611 2908_4_60 NR3C1 Exon 4 + xp5:143400586-143400611 AGAGUGAAACUGCUUUGGACAGAUC 2612 2908_4_61 NR3C1 Exon 4 + xp5:143400616-143400641 GCUGCGCAUUGCUUACUGAGCCUUU 2613 2908_4_62 NR3C1 Exon 4 + xp5:143400645-143400670 AAAUCAACCAAAAGUCUUCGCUGCU 2614 2908_4_63 NR3C1 Exon 4 + xp5:143400675-143400700 UCUGAUUGAGAAGCGACAGCCAGUG 2615 2908_4_64 NR3C1 Exon 4 + xp5:143400676-143400701 CUGAUUGAGAAGCGACAGCCAGUGA 2616 2908_4_65 NR3C1 Exon 4 + xp5:143400716-143400741 AACCUUCACAGGUAGCUCCUCCUCUU 2617 2908_4_66 NR3C1 Exon 4 + xp5:143400717-143400742 ACCUUCACAGGUAGCUCCUCCUCUUA 2618 2908_4_67 NR3C1 Exon 4 + xp5:143400768-143400793 CCCCUCUCCUGAGCAAGCACACUGC 2619 2908_4_68 NR3C1 Exon 4 + xp5:143400769-143400794 CCCUUCCUGAGCAAGCACACUGCU 2620 2908_4_69 NR3C1 Exon 4 + xp5:143400770-143400795 CCUCUCCUGAGCAAGCACACUGCUG 2621 2908_4_70 NR3C1 Exon 4 + xp5:143400787-143400812 CACUGCUGGGGUUUUCUUCUCUACC 2622 2908_4_71 NR3C1 Exon 4 + xp5:143400804-143400829 UCCUUACCAGGAGUUAAUGAUUCUU 2623 2908_4_72 NR3C1 Exon 4 + xp5:143400848-143400873 UCAACUACAAAACAAAAAACAAAAA 2624 2908_4_73 NR3C1 Exon 4 + xp5:143400849-143400874 CAACUACAAAACAAAAAACAAAAAC 2625 2908_4_74 NR3C1 Exon 4 - xp5:143399657-143399682 AACAGUUUUUUCUAAUGGCUAUUCA 2626 2908_4_75 NR3C1 Exon 4 - xp5:143399667-143399692 UCCCUGGUCGAACAGUUUUUUCUAA 2627 2908_4_76 NR3C1 Exon 4 - xp5:143399688-143399713 CUUCUCUGGGGACUCUGAACUUCCC 2628 2908_4_77 NR3C1 Exon 4 - xp5:143399705-143399730 UGGAGAUGACAACUUGACUUCUCUG 2629 2908_4_78 NR3C1 Exon 4 - xp5:143399706-143399731 CUGGAGAUGACAACUUGACUUCUCU 2630 2908_4_79 NR3C1 Exon 4 - xp5:143399707-143399732 UCUGGAGAUGACAACUUGACUUCUC 2631 2908_4_80 NR3C1 Exon 4 - xp5:143399730-143399755 AAAAUUGGAAUAGGUGCCAAGGAUC 2632 2908_4_81 NR3C1 Exon 4 - xp5:143399736-143399761 GUUCCGAAAAUUGGAAUAGGUGCCA 2633 2908_4_82 NR3C1 Exon 4 - xp5:143399744-143399769 UCCCGUUGGUUCCGAAAAUUGGAAU 2634 2908_4_83 NR3C1 Exon 4 - xp5:143399750-143399775 ACCAAUUCCCGUUGGUUCCGAAAAU 2635 2908_4_84 NR3C1 Exon 4 - xp5:143399763-143399788 UUAAUGUCAUUCCACCCAAUUCCCGU 2636 2908_4_85 NR3C1 Exon 4 - xp5:143399806-143399831 AAUACAGCAUCCCUUUCUCAACAGC 2637 2908_4_86 NR3C1 Exon 4 - xp5:143399856-143399881 CUGUUCAUGGUGUGAGUACCUCUGG 2638 2908_4_87 NR3C1 Exon 4 - xp5:143399859-143399884 UUUCUGUUCAUGGUGUGAGUACCUC 2639 2908_4_88 NR3C1 Exon 4 - xp5:143399874-143399899 AUAAAAUGUCUGCCAUUUCUGUUCA 2640 2908_4_89 NR3C1 Exon 4 - xp5:143399904-143399929 CAAGCUUUCCUGGAGCAAAUAUAUAU 2641 2908_4_90 NR3C1 Exon 4 - xp5:143399919-143399944 CAGUUUACUGUCAGGCAAGCUUUCC 2642 2908_4_91 NR3C1 Exon 4 - xp5:143399932-143399957 GAGAAACUGGGCACAGUUUACUGUC 2643 2908_4_92 NR3C1 Exon 4 - xp5:143399949-143399974 CUGGGGUAAUUAAGCAAGAGAAACU 2644 2908_4_93 NR3C1 Exon 4 - xp5:143399950-143399975 CCUGGGGUAAUUAAGCAAGAGAAAC 2645 2908_4_94 NR3C1 Exon 4 - xp5:143399971-143399996 GAUUUCAUCGAACUCUGCACCCCUG 2646 2908_4_95 NR3C1 Exon 4 - xp5:143399972-143399997 AGAUUUCAUCGAACUCUGCACCCCU 2647 2908_4_96 NR3C1 Exon 4 - xp5:143399973-143399998 AAGAUUUCAUCGAACUCUGCACCCC 2648 2908_4_97 NR3C1 Exon 4 - xp5:143400052-143400077 CCCAAAAUUAAGGAUAAUGGAUC 2649 2908_4_98 NR3C1 Exon 4 - xp5:143400060-143400085 ACACUAAACCCAAAAUUAAGGAUAA 2650 2908_4_99 NR3C1 Exon 4 - xp5:143400067-143400092 UUACCGGACACUAAACCCCAAAAUUA 2651 2908_4_100 NR3C1 Exon 4 - xp5:143400088-143400113 GAGGACUGCAAGCCUCUCAUUUUAC 2652 2908_4_101 NR3C1 Exon 4 - xp5:143400112-143400137 UUCCUUUUGGAAGGAAAACUCGAAUG 2653 2908_4_102 NR3C1 Exon 4 - xp5:143400126-143400151 GAGAAGACGAUUCAUUCCUUUUGGA 2654 2908_4_103 NR3C1 Exon 4 - xp5:143400130-143400155 GCGGGAGAAGACGAUUCAUUCCUUU 2655 2908_4_104 NR3C1 Exon 4 - xp5:143400153-143400178 AAAACUGUUUGCUUUCUCCUCUGGC 2656 2908_4_105 NR3C1 Exon 4 - xp5:143400154-143400179 GAAAACUGUUUGCUUUCUCCUCUGG 2657 2908_4_106 NR3C1 Exon 4 - xp5:143400157-143400182 GAUGAAAAACUGUUUGCUUUUCUCCUC 2658 2908_4_107 NR3C1 Exon 4 - xp5:143400203-143400228 AGGUAAAGAGACGAAUGAGAGUCCU 2659 2908_4_108 NR3C1 Exon 4 - xp5:143400228-143400253 AUUUGGAGUUUUCUUCUGGGUCCCC 2660 2908_4_109 NR3C1 Exon 4 - xp5:143400236-143400261 UUUGCAGGAUUUGGAGUUUUCUUCU 2661 2908_4_110 NR3C1 Exon 4 - xp5:143400237-143400262 UUUUGCAGGAUUUGGAGUUUUCUUC 2662 2908_4_111 NR3C1 Exon 4 - xp5:143400250-143400275 AGCACCUUUGACAUUUUGCAGGAUU 2663 2908_4_112 NR3C1 Exon 4 - xp5:143400256-143400281 GACCAAAGCACCUUUGACAUUUUGC 2664 2908_4_113 NR3C1 Exon 4 - xp5:143400306-143400331 UGAAGGGCCAGACUGGCACCAACGG 2665 2908_4_114 NR3C1 Exon 4 - xp5:143400309-143400334 AUUUGAAGGGCCAGACUGGCACCA 2666 2908_4_115 NR3C1 Exon 4 - xp5:143400318-143400343 AACAGCAACAUUUGAAGGGCCAGAC 2667 2908_4_116 NR3C1 Exon 4 - xp5:143400327-143400352 UAUCUUCAGAACAGCAACAUUUGAA 2668 2908_4_117 NR3C1 Exon 4 - xp5:143400328-143400353 GUAUCUUCAGAACAGCAACAUUUGA 2669 2908_4_118 NR3C1 Exon 4 - xp5:143400379-143400404 GCUGUGUCUGCUGCCCCCACAGAGA 2670 2908_4_119 NR3C1 Exon 4 - xp5:143400449-143400474 GGAAGAAAGCAUUGCAAACCUCAAU 2671 2908_4_120 NR3C1 Exon 4 - xp5:143400475-143400500 UCGGGGGAAACAGACUUAAAGCUUU 2672 2908_4_121 NR3C1 Exon 4 - xp5:143400496-143400521 CAGGGCCAAAAUCAGCCUUUCCUCGG 2673 2908_4_122 NR3C1 Exon 4 - xp5:143400497-143400522 GCAGGGCCAAAAUCAGCCUUUCCUCG 2674 2908_4_123 NR3C1 Exon 4 - xp5:143400498-143400523 AGCAGGGCCAAAAUCAGCCUUUCCUC 2675 2908_4_124 NR3C1 Exon 4 - xp5:143400499-143400524 CAGCAGGGCCAAAAUCAGCCUUUCCU 2676 2908_4_125 NR3C1 Exon 4 - xp5:143400519-143400544 GAAAUGACCUGGGAUUCCCACAGCA 2677 2908_4_126 NR3C1 Exon 4 - xp5:143400520-143400545 GGAAAUGACCUGGGAUUCCCACAGGC 2678 2908_4_127 NR3C1 Exon 4 - xp5:143400534-143400559 AAAAAAAGUGAUGGGAAAUGACCU 2679 2908_4_128 NR3C1 Exon 4 - xp5:143400535-143400560 GAAACAAAAGUGAUGGGAAAUGACC 2680 2908_4_129 NR3C1 Exon 4 - xp5:143400546-143400571 UGGGAGAGACAGAAAACAAAAGUGAU 2681 2908_4_130 NR3C1 Exon 4 - xp5:143400547-143400572 AUGGGAGAGACAGAAAACAAAAGUGA 2682 2908_4_131 NR3C1 Exon 4 - xp5:143400570-143400595 UUUCACUCUCAAUGGGACUGUAUAU 2683 2908_4_132 NR3C1 Exon 4 - xp5:143400571-143400596 GUUUCACUCUCAAUGGGACUGUUAUA 2684 2908_4_133 NR3C1 Exon 4 - xp5:143400582-143400607 UGUCCAAAGCAGUUUCACCUCAAU 2685 2908_4_134 NR3C1 Exon 4 - xp5:143400583-143400608 CUGUCCAAAGCAGUUUCACUCUCAA 2686 2908_4_135 NR3C1 Exon 4 - xp5:143400639-143400664 GAAGACUUUUGGUUGAUUUUCCAAA 2687 2908_4_136 NR3C1 Exon 4 - xp5:143400655-143400680 UCAGACUCCAAGCAGCGAAGACUUU 2688 2908_4_137 NR3C1 Exon 4 - xp5:143400697-143400722 AAGGUUUCUGCGUCUUCACCCUCAC 2689 2908_4_138 NR3C1 Exon 4 - xp5:143400721-143400746 ACCCUAAGAGGAGGAGCUACUGUGA 2690 2908_4_139 NR3C1 Exon 4 - xp5:143400735-143400760 UGGACUUCUAUAAAACCCUAAGAGG 2691 2908_4_140 NR3C1 Exon 4 - xp5:143400738-143400763 UGAUGGACUUCUAUAAAACCCUAAG 2692 2908_4_141 NR3C1 Exon 4 - xp5:143400760-143400785 CUUGCUCAGGAGAGGGGAGAUGUGA 2693 2908_4_142 NR3C1 Exon 4 - xp5:143400771-143400796 CCAGCAGUGUGCUUGCUCAGGAGAG 2694 2908_4_143 NR3C1 Exon 4 - xp5:143400772-143400797 CCCAGCAGUGUGCUUGCUCAGGAGA 2695 2908_4_144 NR3C1 Exon 4 - xp5:143400773-143400798 CCCCAGCAGUGUGCUUGCUCAGGAG 2696 2908_4_145 NR3C1 Exon 4 - xp5:143400778-143400803 GAAAACCCCAGCAGUGUGCUUGCUC 2697 2908_4_146 NR3C1 Exon 4 - xp5:143400813-143400838 UGGACUCCAAAGAAUCAUUAACUCCC 2698 2908_4_147 NR3C1 Exon 4 - xp5:143400838-143400863 UUGUUUUGUAGUUGAUAUUCACUGA 2699 2908_3_1 NR3C1 Exon 3 + xp5:143403188-143403213 CCCCCCCCGCCUCGCUUCUUACCUC 2700 2908_3_2 NR3C1 Exon 3 + xp5:143403194-143403219 CCGCCUCGCUUCUUACCUCUGGCAG 2701 2908_3_3 NR3C1 Exon 3 + xp5:143403267-143403292 AAACAACUUAGCUUGUGAACGCAGA 2702 2908_3_4 NR3C1 Exon 3 + xp5:143403273-143403298 CUUAGCUUGUGAACGCAGAAGGAGC 2703 2908_3_5 NR3C1 Exon 3 + xp5:143403276-143403301 AGCUUGUGAACGCAGAAGGAGCAGG 2704 2908_3_6 NR3C1 Exon 3 + xp5:143403277-143403302 GCUUGUGAACGCAGAAGGAGCAGGA 2705 2908_3_7 NR3C1 Exon 3 + xp5:143403305-143403330 AAAUAUAUUUUUUUUUUCUAAAAAAA 2706 2908_3_8 NR3C1 Exon 3 + xp5:143403333-143403358 AAGUAAACAGCCGCCCCUUUCUCCA 2707 2908_3_9 NR3C1 Exon 3 + xp5:143403334-143403359 AGUAAACAGCCGCCCCUUUCUCCAU 2708 2908_3_10 NR3C1 Exon 3 + xp5:143403337-143403362 AAACAGCCGCCCCUUUCUCCAUGGG 2709 2908_3_11 NR3C1 Exon 3 + xp5:143403338-143403363 AACAGCCGCCCCUUUCUCCAUGGGU 2710 2908_3_12 NR3C1 Exon 3 + xp5:143403339-143403364 ACAGCCGCCCCUUUCUCCAUGGGUG 2711 2908_3_13 NR3C1 Exon 3 + xp5:143403340-143403365 CAGCCGCCCCUUUCUCCAUGGGUGG 2712 2908_3_14 NR3C1 Exon 3 + xp5:143403341-143403366 AGCCGCCCCUUUCUCCAUGGGUGGG 2713 2908_3_15 NR3C1 Exon 3 + xp5:143403406-143403431 GACAAGCCAGCCCUCCGCCCCCGCGC 2714 2908_3_16 NR3C1 Exon 3 + xp5:143403407-143403432 ACAAGCCAGCCCUCCGCCCCGCGCC 2715 2908_3_17 NR3C1 Exon 3 + xp5:143403415-143403440 GCCCUCCGCCCCGCGCCGGGCUCCG 2716 2908_3_18 NR3C1 Exon 3 + xp5:143403416-143403441 CCCUCCGCCCCGCGCCGGGCUCCGC 2717 2908_3_19 NR3C1 Exon 3 + xp5:143403422-143403447 GCCCCGCGCCGGGCUCCGCGGGUCG 2718 2908_3_20 NR3C1 Exon 3 + xp5:143403428-143403453 CGCCGGGCUCCGCGGGUCGAGGUUC 2719 2908_3_21 NR3C1 Exon 3 + xp5:143403429-143403454 GCCGGGCUCCGCGGGUCGAGGUUCC 2720 2908_3_22 NR3C1 Exon 3 + xp5:143403448-143403473 GGUUCCGGGCGCGCGUGCCCCGUCC 2721 2908_3_23 NR3C1 Exon 3 + xp5:143403463-143403488 UGCCCCGUCCCGGUCCCAGCUGCUU 2722 2908_3_24 NR3C1 Exon 3 + xp5:143403472-143403497 CCGGUCCAGCUGCUUCGGCCGCUC 2723 2908_3_25 NR3C1 Exon 3 + xp5:143403478-143403503 CCAGCUGCUUCGGCCGCUCCGGCUG 2724 2908_3_26 NR3C1 Exon 3 + xp5:143403513-143403538 UUCCACCCACAGAAUCCGUCCCCGA 2725 2908_3_27 NR3C1 Exon 3 + xp5:143403514-143403539 UCCACCCACAGAAUCCGUCCCCGAC 2726 2908_3_28 NR3C1 Exon 3 + xp5:143403518-143403543 CCCACAGAAUCCGUCCCCGACGGGC 2727 2908_3_29 NR3C1 Exon 3 + xp5:143403521-143403546 ACAGAAUCCGUCCCCGACGGGCAGG 2728 2908_3_30 NR3C1 Exon 3 + xp5:143403529-143403554 CGUCCCCGACGGGCAGGCGGUGACU 2729 2908_3_31 NR3C1 Exon 3 + xp5:143403530-143403555 GUCCCCGACGGGCAGGCGGUGACUC 2730 2908_3_32 NR3C1 Exon 3 + xp5:143403561-143403586 CCGUCACAGACACGAGCUCGCAAAA 2731 2908_3_33 NR3C1 Exon 3 + xp5:143403564-143403589 UCACAGACACGAGCUCGCAAAAUGG 2732 2908_3_34 NR3C1 Exon 3 + xp5:143403567-143403592 CAGACACGAGCUCGCAAAAUGGAGG 2733 2908_3_35 NR3C1 Exon 3 + xp5:143403570-143403595 ACACGAGCUCGCAAAAUGGAGGAGG 2734 2908_3_36 NR3C1 Exon 3 + xp5:143403573-143403598 CGAGCUCGCAAAAUGGAGGAGGCGG 2735 2908_3_37 NR3C1 Exon 3 + xp5:143403576-143403601 GCUCGCAAAAUGGAGGAGGCGGCGG 2736 2908_3_38 NR3C1 Exon 3 + xp5:143403579-143403604 CGCAAAAUGGAGGAGGCGGCGGCGG 2737 2908_3_39 NR3C1 Exon 3 + xp5:143403580-143403605 GCAAAAUGGAGGAGGCGGCGGCGGA 2738 2908_3_40 NR3C1 Exon 3 + xp5:143403592-143403617 AGGCGGCGGCGGAGGGAAGAGAGCG 2739 2908_3_41 NR3C1 Exon 3 + xp5:143403604-143403629 AGGGAAGAGAGCGCGGACACGCGAA 2740 2908_3_42 NR3C1 Exon 3 + xp5:143403605-143403630 GGGAAGAGAGCGCGGACACGCGAAA 2741 2908_3_43 NR3C1 Exon 3 + xp5:143403613-143403638 AGCGCGGACACGCGAAAGGGCAGCC 2742 2908_3_44 NR3C1 Exon 3 + xp5:143403618-143403643 GGACACGCGAAAGGGCAGCCCGGCC 2743 2908_3_45 NR3C1 Exon 3 + xp5:143403619-143403644 GACACGCGAAAGGGCAGCCCGGCCU 2744 2908_3_46 NR3C1 Exon 3 + xp5:143403630-143403655 GGGCAGCCCGGCCUGGGCGAGCGAG 2745 2908_3_47 NR3C1 Exon 3 + xp5:143403631-143403656 GGCAGCCCGGCCUGGGCGAGCGAGC 2746 2908_3_48 NR3C1 Exon 3 + xp5:143403640-143403665 GCCUGGGCGAGCGAGCGGGACCGAG 2747 2908_3_49 NR3C1 Exon 3 + xp5:143403641-143403666 CCUGGGCGAGCGAGCGGGACCGAGC 2748 2908_3_50 NR3C1 Exon 3 + xp5:143403642-143403667 CUGGGCGAGCGAGCGGACCGAGCG 2749 2908_3_51 NR3C1 Exon 3 + xp5:143403647-143403672 CGAGCGAGCGGGACCGAGCGGGGAG 2750 2908_3_52 NR3C1 Exon 3 + xp5:143403648-143403673 GAGCGAGCGGGACCGAGCGGGGAGC 2751 2908_3_53 NR3C1 Exon 3 + xp5:143403651-143403676 CGAGCGGGACCGAGCGGGGAGCGGG 2752 2908_3_54 NR3C1 Exon 3 + xp5:143403654-143403679 GCGGGACCGAGCGGGGAGCGGGUGG 2753 2908_3_55 NR3C1 Exon 3 + xp5:143403657-143403682 GGACCGAGCGGGGAGCGGGUGGAGG 2754 2908_3_56 NR3C1 Exon 3 + xp5:143403665-143403690 CGGGGAGCGGGUGGAGGCGGCGCCA 2755 2908_3_57 NR3C1 Exon 3 - xp5:143403190-143403215 CAGAGGUAAGAAGCGAGGCGGGAGG 2756 2908_3_58 NR3C1 Exon 3 - xp5:143403191-143403216 CCAGAGGUAAGAAGCGAGGCGGGAG 2757 2908_3_59 NR3C1 Exon 3 - xp5:143403192-143403217 GCCAGAGGUAAGAAGCGAGGCGGGA 2758 2908_3_60 NR3C1 Exon 3 - xp5:143403193-143403218 UGCCAGAGGUAAGAAGCGAGGCGGG 2759 2908_3_61 NR3C1 Exon 3 - xp5:143403196-143403221 CUCUGCCAGAGGUAAGAAGCGAGGC 2760 2908_3_62 NR3C1 Exon 3 - xp5:143403197-143403222 CCUCUGCCAGAGGUAAGAAGCGAGG 2761 2908_3_63 NR3C1 Exon 3 - xp5:143403200-143403225 GCUCCUCUGCCAGAGGUAAGAAGCG 2762 2908_3_64 NR3C1 Exon 3 - xp5:143403212-143403237 GGCGGGCGAGCGGCUCCUCUGCCAG 2763 2908_3_65 NR3C1 Exon 3 - xp5:143403227-143403252 GGAACUGCGGACGGUGGCGGGCGAG 2764 2908_3_66 NR3C1 Exon 3 - xp5:143403234-143403259 UGCGGCGGGAACUGCGGACGGUGGC 2765 2908_3_67 NR3C1 Exon 3 - xp5:143403235-143403260 CUGCGGCGGGAACUGCGGACGGUGG 2766 2908_3_68 NR3C1 Exon 3 - xp5:143403238-143403263 CGGCUGCGGCGGGAACUGCGGACGG 2767 2908_3_69 NR3C1 Exon 3 - xp5:143403241-143403266 UCUCGGCUGCGGCGGGAACUGCGGA 2768 2908_3_70 NR3C1 Exon 3 - xp5:143403245-143403270 UUUAUCUCGGCUGCGGCGGGAACUG 2769 2908_3_71 NR3C1 Exon 3 - xp5:143403253-143403278 CUAAGUUGUUUAUCUCGGCUGCGGC 2770 2908_3_72 NR3C1 Exon 3 - xp5:143403254-143403279 GCUAAGUUGUUUAUCUCGGCUGCGG 2771 2908_3_73 NR3C1 Exon 3 - xp5:143403257-143403282 CAAGCUAAGUUGUUUAUCUCGGCUG 2772 2908_3_74 NR3C1 Exon 3 - xp5:143403263-143403288 CGUUCACAAGCUAAGUUGUUUAUCU 2773 2908_3_75 NR3C1 Exon 3 - xp5:143403346-143403371 CUCCCCCCACCCAUGGAGAAAGGGG 2774 2908_3_76 NR3C1 Exon 3 - xp5:143403349-143403374 GCUCUCCCCCCACCCAUGGAGAAAG 2775 2908_3_77 NR3C1 Exon 3 - xp5:143403350-143403375 GGCUCUCCCCCCACCCAUGGAGAAA 2776 2908_3_78 NR3C1 Exon 3 - xp5:143403351-143403376 GGGCUCUCCCCCCACCCAUGGAGAA 2777 2908_3_79 NR3C1 Exon 3 - xp5:143403358-143403383 UAAAUAGGGGCUCUCCCCCCACCCA 2778 2908_3_80 NR3C1 Exon 3 - xp5:143403376-143403401 GGCAAUGGGAGACUUUCUUAAAUAG 2779 2908_3_81 NR3C1 Exon 3 - xp5:143403377-143403402 GGGCAAUGGGAGACUUUCUUAAAUA 2780 2908_3_82 NR3C1 Exon 3 - xp5:143403378-143403403 UGGGCAAUGGGAGACUUUCUUAAAU 2781 2908_3_83 NR3C1 Exon 3 - xp5:143403395-143403420 AGGGCUGGCUUGUCAGCUGGGCAAU 2782 2908_3_84 NR3C1 Exon 3 - xp5:143403396-143403421 GAGGGCUGGCUUGUCAGCUGGGCAA 2783 2908_3_85 NR3C1 Exon 3 - xp5:143403402-143403427 GGGGCGGAGGGCUGGCUUGUCAGCU 2784 2908_3_86 NR3C1 Exon 3 - xp5:143403403-143403428 CGGGGCGGAGGGCUGGCUUGUCAGC 2785 2908_3_87 NR3C1 Exon 3 - xp5:143403415-143403440 CGGAGCCCGGCGCGGGGCGGAGGGC 2786 2908_3_88 NR3C1 Exon 3 - xp5:143403419-143403444 CCCGCGGAGCCCGGCGCGGGGCGGA 2787 2908_3_89 NR3C1 Exon 3 - xp5:143403420-143403445 ACCCGCGGAGCCCGGCGCGGGGCGG 2788 2908_3_90 NR3C1 Exon 3 - xp5:143403423-143403448 UCGACCCGCGGAGCCCGGCGCGGGG 2789 2908_3_91 NR3C1 Exon 3 - xp5:143403426-143403451 ACCUCGACCCGCGGAGCCCGGCGCG 2790 2908_3_92 NR3C1 Exon 3 - xp5:143403427-143403452 AACCUCGACCCGCGGAGCCCGGCGC 2791 2908_3_93 NR3C1 Exon 3 - xp5:143403428-143403453 GAACCUGACCCGCGGAGCCCGGCG 2792 2908_3_94 NR3C1 Exon 3 - xp5:143403433-143403458 GCCCGGAACCUCGACCCGCGGAGCC 2793 2908_3_95 NR3C1 Exon 3 - xp5:143403440-143403465 CACGCGCGCCCGGAACCUCGACCCG 2794 2908_3_96 NR3C1 Exon 3 - xp5:143403455-143403480 GGGACCGGGACGGGGCACGCGCGCC 2795 2908_3_97 NR3C1 Exon 3 - xp5:143403468-143403493 GGCCGAAGCAGCUGGGACCGGGACG 2796 2908_3_98 NR3C1 Exon 3 - xp5:143403469-143403494 CGGCCGAAGCAGCUGGGACCGGGAC 2797 2908_3_99 NR3C1 Exon 3 - xp5:143403470-143403495 GCGGCCGAAGCAGCUGGGACCGGGA 2798 2908_3_100 NR3C1 Exon 3 - xp5:143403474-143403499 CGGAGCGGCCGAAGCAGCUGGGACC 2799 2908_3_101 NR3C1 Exon 3 - xp5:143403475-143403500 CCGGAGCGGCCGAAGCAGCUGGGAC 2800 2908_3_102 NR3C1 Exon 3 - xp5:143403480-143403505 CGCAGCCGGAGCGGCCGAAGCAGCU 2801 2908_3_103 NR3C1 Exon 3 - xp5:143403481-143403506 CCGCAGCCGGAGCGGCCGAAGCAGC 2802 2908_3_104 NR3C1 Exon 3 - xp5:143403494-143403519 GUGGAAGGAGACGCCGCAGCCGGAG 2803 2908_3_105 NR3C1 Exon 3 - xp5:143403499-143403524 UGUGGGUGGAAGGAGACGCCGCAGC 2804 2908_3_106 NR3C1 Exon 3 - xp5:143403514-143403539 GUCGGGGACGGAUUCUGUGGGUGGA 2805 2908_3_107 NR3C1 Exon 3 - xp5:143403518-143403543 GCCCGUCGGGGACGGAUUCUGUGGG 2806 2908_3_108 NR3C1 Exon 3 - xp5:143403521-143403546 CCUGCCCGUCGGGGACGGAUUCUGU 2807 2908_3_109 NR3C1 Exon 3 - xp5:143403522-143403547 GCCUGCCCGUCGGGGACGGAUUCUG 2808 2908_3_110 NR3C1 Exon 3 - xp5:143403531-143403556 CGAGUCACCGCCUGCCCGUCGGGGA 2809 2908_3_111 NR3C1 Exon 3 - xp5:143403535-143403560 AGCCCGAGUCACCGCCUGCCCGUCG 2810 2908_3_112 NR3C1 Exon 3 - xp5:143403536-143403561 GAGCCCGAGUCACCGCCUGCCCGUC 2811 2908_3_113 NR3C1 Exon 3 - xp5:143403537-143403562 GGAGCCCGAGUCACCGCCUGCCCGU 2812 2908_3_114 NR3C1 Exon 3 - xp5:143403563-143403588 CAUUUUGCGAGCUCGUGUCUGUGAC 2813 2908_3_115 NR3C1 Exon 3 - xp5:143403564-143403589 CCAUUUUGCGAGCUCGUGUCUGUGA 2814 2908_3_116 NR3C1 Exon 3 - xp5:143403639-143403664 UCGGUCCCGCUCGCUCGCCCAGGCC 2815 2908_3_117 NR3C1 Exon 3 - xp5:143403640-143403665 CUCGGUCCCGCUCGCUCGCCAGGC 2816 2908_3_118 NR3C1 Exon 3 - xp5:143403644-143403669 CCCGCUCGGUCCCGCUCGCUCCGCCC 2817 2908_3_119 NR3C1 Exon 3 - xp5:143403663-143403688 GCGCCGCCUCCACCCGCUCCCCGCU 2818 2908_2_1 NR3C1 Exon 2 + xp5:143404352-143404377 AGCGGGGGUCGGCGCAUACGUACUU 2819 2908_2_2 NR3C1 Exon 2 + xp5:143404353-143404378 GCGGGGGUCGGCGCAUACGUACCUUU 2820 2908_2_3 NR3C1 Exon 2 + xp5:143404358-143404383 GGUCGGCGCAUACGUACUUUGGGCC 2821 2908_2_4 NR3C1 Exon 2 + xp5:143404359-143404384 GUCGGCGCAUACGUACUUUGGGCCC 2822 2908_2_5 NR3C1 Exon 2 + xp5:143404360-143404385 UCGGCGCAUACGUACUUUGGGCCCG 2823 2908_2_6 NR3C1 Exon 2 + xp5:143404361-143404386 CGGCGCAUACGUACUUUGGGCCCGG 2824 2908_2_7 NR3C1 Exon 2 + xp5:143404362-143404387 GGCGCAUACGUACUUUGGGCCCGGG 2825 2908_2_8 NR3C1 Exon 2 + xp5:143404375-143404400 UUUGGGCCCGGGGGGAGUCCGCGUGC 2826 2908_2_9 NR3C1 Exon 2 + xp5:143404379-143404404 GGCCCGGGGGGAGUCCGCGUGCCGGC 2827 2908_2_10 NR3C1 Exon 2 + xp5:143404402-143404427 GCAGGUCCCCCCACCACCGCAUCAUC 2828 2908_2_11 NR3C1 Exon 2 + xp5:143404403-143404428 CAGGUCCCCCACCACCGCAUCAUCU 2829 2908_2_12 NR3C1 Exon 2 + xp5:143404406-143404431 GUCCCCCACCACCGCAUCAUCUGGG 2830 2908_2_13 NR3C1 Exon 2 + xp5:143404410-143404435 CCCACCACCGCAUCAUCUGGGCGGC 2831 2908_2_14 NR3C1 Exon 2 + xp5:143404411-143404436 CCACCACCGCAUCAUCUGGGCGGCC 2832 2908_2_15 NR3C1 Exon 2 + xp5:143404444-143404469 AGCUGCCGCCGCCGCGCUCUCGCAC 2833 2908_2_16 NR3C1 Exon 2 + xp5:143404445-143404470 GCUGCCGCCGCCGCGCUCUCGCACU 2834 2908_2_17 NR3C1 Exon 2 - xp5:143404384-143404409 GACCUGCCGGCACGCGACUCCCCCC 2835 2908_2_18 NR3C1 Exon 2 - xp5:143404385-143404410 GGACCUGCCGGCACGCGACUCCCCC 2836 2908_2_19 NR3C1 Exon 2 - xp5:143404402-143404427 GAUGAUGCGGUGGUGGGGGACCUGC 2837 2908_2_20 NR3C1 Exon 2 - xp5:143404411-143404436 GGCCGCCCAGAUGAUGCGGUGGUGG 2838 2908_2_21 NR3C1 Exon 2 - xp5:143404412-143404437 CGGCCGCCCAGAUGAUGCGGUGGUG 2839 2908_2_22 NR3C1 Exon 2 - xp5:143404413-143404438 CCGGCCGCCCAGAUGAUGCGGUGGU 2840 2908_2_23 NR3C1 Exon 2 - xp5:143404414-143404439 CCCGGCCCGCCCAGAUGAUGCGGUGG 2841 2908_2_24 NR3C1 Exon 2 - xp5:143404417-143404442 AGACCCGGCCCGCCCAGAUGAUGCGG 2842 2908_2_25 NR3C1 Exon 2 - xp5:143404420-143404445 UGAAGACCCGGCCGCCCAGAUGAUG 2843 2908_2_26 NR3C1 Exon 2 - xp5:143404437-143404462 AGCGCGGCGGCGGCAGCUGAAGACC 2844 2908_2_27 NR3C1 Exon 2 - xp5:143404452-143404477 CUCUCCCAGUGCGAGAGCGCGGCGG 2845 2908_2_28 NR3C1 Exon 2 - xp5:143404455-143404480 CUUCUCUCCCAGUGCGAGAGCGCGG 2846 2908_2_29 NR3C1 Exon 2 - xp5:143404458-143404483 CAACUUCUCUCCCAGUGCGAGAGCG 2847 2908_1_1 NR3C1 Exon 1 + xp5:143434553-143434578 GAAGCAAAGUCUUCUUUGUUCUUUG 2848 2908_1_2 NR3C1 Exon 1 + xp5:143434558-143434583 AAAGUCUUCUUUGUUCUUUGAGGAA 2849 2908_1_3 NR3C1 Exon 1 + xp5:143434565-143434590 UCUUUGUUCUUUGAGGAAAGGAGCC 2850 2908_1_4 NR3C1 Exon 1 + xp5:143434590-143434615 AGGCAGAUGAAAAUUCCUGUUAUUA 2851 2908_1_5 NR3C1 Exon 1 + xp5:143434608-143434633 GUUAUUAAGGUACAACUAAAGCCCG 2852 2908_1_6 NR3C1 Exon 1 + xp5:143434611-143434636 AUUAAGGUACAACUAAAGCCCGAGG 2853 2908_1_7 NR3C1 Exon 1 + xp5:143434612-143434637 UUAAGGUACAACUAAAGCCCGAGGA 2854 2908_1_8 NR3C1 Exon 1 + xp5:143434616-143434641 GGUACAACUAAAGCCCGAGGAGGGU 2855 2908_1_9 NR3C1 Exon 1 + xp5:143434655-143434680 GUUCCUCCCCAUUCUCCGCACAGAGA 2856 2908_1_10 NR3C1 Exon 1 + xp5:143434691-143434716 AAGUGCUUAUCAAAGUUAAUAUCUG 2857 2908_1_11 NR3C1 Exon 1 + xp5:143434736-143434761 CCUCUGCAGCAGUCGUCACAGAAGC 2858 2908_1_12 NR3C1 Exon 1 + xp5:143434748-143434773 UCGUCACAGAAGCUGGCCCCUUUCC 2859 2908_1_13 NR3C1 Exon 1 + xp5:143434749-143434774 CGUCACAGAAGCUGGCCCCUUUCCU 2860 2908_1_14 NR3C1 Exon 1 + xp5:143434923-143434948 UUUCAGAUCAGAAGAUCCUGUCUCU 2861 2908_1_15 NR3C1 Exon 1 + xp5:143434924-143434949 UUCAGAUCAGAAGAUCCUGUCUCUC 2862 2908_1_16 NR3C1 Exon 1 + xp5:143434944-143434969 CUCUCGGGUAUAACUUUUUUUUUUU 2863 2908_1_17 NR3C1 Exon 1 + xp5:143434974-143434999 AGAAAUACAGUGACUCUCCUAAUUA 2864 2908_1_18 NR3C1 Exon 1 + xp5:143435026-143435051 CCACUGAUUCAGCAGAAUAUUCCCCC 2865 2908_1_19 NR3C1 Exon 1 + xp5:143435039-143435064 AGAUAUUCCCCCAGGCAGAUCCUAA 2866 2908_1_20 NR3C1 Exon 1 + xp5:143435055-143435080 AGAUCCUAAUGGAAACCCAACAUGUG 2867 2908_1_21 NR3C1 Exon 1 + xp5:143435066-143435091 GAAACCAACAUGUGAGGUCUGAUGC 2868 2908_1_22 NR3C1 Exon 1 + xp5:143435067-143435092 AAACCAACAUGUGAGGUCUGAUGCU 2869 2908_1_23 NR3C1 Exon 1 + xp5:143435089-143435114 GCUGGGAAUUUUAUCAUGCUCAACA 2870 2908_1_24 NR3C1 Exon 1 + xp5:143435226-143435251 CCCAUCAUGCCCCAGUGCUUCCGU 2871 2908_1_25 NR3C1 Exon 1 + xp5:143435245-143435270 UUCCGUUGGACACAAUGCGCAUUUUA 2872 2908_1_26 NR3C1 Exon 1 + xp5:143435254-143435279 ACACAUGCGCAUUUUACGGUCCUGC 2873 2908_1_27 NR3C1 Exon 1 + xp5:143435255-143435280 CACAUGCGCAUUUUACGGUCCUGCA 2874 2908_1_28 NR3C1 Exon 1 + xp5:143435281-143435306 GGCUUGAAAAGAUUUCUGACCUUCUA 2875 2908_1_29 NR3C1 Exon 1 + xp5:143435294-143435319 UCUGACCUUCUAAGGUCCAGUGAUU 2876 2908_1_30 NR3C1 Exon 1 + xp5:143435458-143435483 AGAAGAGGAAGAGGUACCUUUUGAA 2877 2908_1_31 NR3C1 Exon 1 + xp5:143435459-143435484 GAAGAGGAAGAGGUACCUUUUGAAU 2878 2908_1_32 NR3C1 Exon 1 + xp5:143435460-143435485 AAGAGGAAGAGGUACCUUUUGAAUG 2879 2908_1_33 NR3C1 Exon 1 + xp5:143435498-143435523 CCCUUACAUAACCUGACCACCAAU 2880 2908_1_34 NR3C1 Exon 1 + xp5:143435501-143435526 UUACAUAACCUGACCACCAAUAGG 2881 2908_1_35 NR3C1 Exon 1 - xp5:143434537-143434562 CUUUGCUUCAUUAAAGUGUCUGAGA 2882 2908_1_36 NR3C1 Exon 1 - xp5:143434591-143434616 UUAAUAAACAGGAAUUUUCAUCUGCC 2883 2908_1_37 NR3C1 Exon 1 - xp5:143434608-143434633 CGGGCUUUAGUUGUACCUUAAUAAC 2884 2908_1_38 NR3C1 Exon 1 - xp5:143434632-143434657 ACAAAAUGCAGCUCCUACCCUCCUC 2885 2908_1_39 NR3C1 Exon 1 - xp5:143434633-143434658 AACAAAAUGCAGCUCCUACCCUCCU 2886 2908_1_40 NR3C1 Exon 1 - xp5:143434661-143434686 GUGCCUUCUCUGUGCGAGAAUGGGG 2887 2908_1_41 NR3C1 Exon 1 - xp5:143434664-143434689 UGAGUGCCUUCUCUGUGCGAGAAUG 2888 2908_1_42 NR3C1 Exon 1 - xp5:143434665-143434690 AUGAGUGCCUUCUCUGUGCGAGAAU 2889 2908_1_43 NR3C1 Exon 1 - xp5:143434666-143434691 AAUGAGUGCCUUCUCUGUGCGAGAA 2890 2908_1_44 NR3C1 Exon 1 - xp5:143434735-143434760 CUUCUGUGACGACUGCUGCAGAGGC 2891 2908_1_45 NR3C1 Exon 1 - xp5:143434739-143434764 CCAGCUUCUGUGACGACUGCUGCAG 2892 2908_1_46 NR3C1 Exon 1 - xp5:143434767-143434792 UUCUCAGAGCAGUUAGCCCAGGAAAG 2893 2908_1_47 NR3C1 Exon 1 - xp5:143434768-143434793 CUCUCAGAGCAGUUAGCCCAGGAAA 2894 2908_1_48 NR3C1 Exon 1 - xp5:143434769-143434794 GCUCUCAGAGCAGUUAGCCCAGGAA 2895 2908_1_49 NR3C1 Exon 1 - xp5:143434774-143434799 CUGGUGCUCUCAGAGCAGUUAGCCC 2896 2908_1_50 NR3C1 Exon 1 - xp5:143434798-143434823 GUCAUAUCUAAGUCAGAUUUCAUUC 2897 2908_1_51 NR3C1 Exon 1 - xp5:143434833-143434858 UGUGUAGCUGGCUUCUUCUGAAAAA 2898 2908_1_52 NR3C1 Exon 1 - xp5:143434850-143434875 AUUUGUUCAUCAAGAGGUUGUGUAGGC 2899 2908_1_53 NR3C1 Exon 1 - xp5:143434883-143434908 AAAUUCCUCUGGUUUGUGCUCAUCGU 2900 2908_1_54 NR3C1 Exon 1 - xp5:143434900-143434925 AAUUUUCUUCACUUCUGAAAUUCUC 2901 2908_1_55 NR3C1 Exon 1 - xp5:143434942-143434967 AAAAAAAAAGUUAUACCCGAGAGAC 2902 2908_1_56 NR3C1 Exon 1 - xp5:143434994-143435019 CUGAACCUAGGAAAUUCACCAUAAUU 2903 2908_1_57 NR3C1 Exon 1 - xp5:143435012-143435037 UGAAUCAGUGGCUCUGAGCUGAACU 2904 2908_1_58 NR3C1 Exon 1 - xp5:143435029-143435054 CCUGGGGGAAUAUCUGCUGAAUCAG 2905 2908_1_59 NR3C1 Exon 1 - xp5:143435049-143435074 UUGGUUUCCAUUAGGAUCUGCCUGG 2906 2908_1_60 NR3C1 Exon 1 - xp5:143435050-143435075 GUUGGUUUCCAUUAGGAUCUGCCUG 2907 2908_1_61 NR3C1 Exon 1 - xp5:143435051-143435076 UGUUGGUUUCCAUUAGGAUCUGCCU 2908 2908_1_62 NR3C1 Exon 1 - xp5:143435052-143435077 AUGUUGGUUUCCAUUAGGAUCUGCC 2909 2908_1_63 NR3C1 Exon 1 - xp5:143435062-143435087 CAGACCUCACAUGUUGGUUUCCAUU 2910 2908_1_64 NR3C1 Exon 1 - xp5:143435073-143435098 AUUCCCAGCAUCAGACCUCAGUGU 2911 2908_1_65 NR3C1 Exon 1 - xp5:143435166-143435191 AAAAGGGAAAGUGGUGAAGGCAGGG 2912 2908_1_66 NR3C1 Exon 1 - xp5:143435169-143435194 GAAAAAAGGGAAAGUGGUGAAGGCA 2913 2908_1_67 NR3C1 Exon 1 - xp5:143435170-143435195 AGAAAAAAGGGAAAGUGGUGAAGGC 2914 2908_1_68 NR3C1 Exon 1 - xp5:143435174-143435199 GAGAAGAAAAAAGGGAAAGUGGUGA 2915 2908_1_69 NR3C1 Exon 1 - xp5:143435180-143435205 GGGUAAGAGAAGAAAAAAAGGGAAAG 2916 2908_1_70 NR3C1 Exon 1 - xp5:143435187-143435212 AGAAAGAGGGUAAGAGAAGAAAAAA 2917 2908_1_71 NR3C1 Exon 1 - xp5:143435188-143435213 CAGAAAGAGGGUAAGAGAAGAAAAAA 2918 2908_1_72 NR3C1 Exon 1 - xp5:143435205-143435230 UGGGGAAGGAAUAGAAACAGAAGA 2919 2908_1_73 NR3C1 Exon 1 - xp5:143435206-143435231 GUGGGGAAGGAAUAGAAACAGAAAG 2920 2908_1_74 NR3C1 Exon 1 - xp5:143435224-143435249 GGAAGCACUGGGGCAUGAGUGGGGA 2921 2908_1_75 NR3C1 Exon 1 - xp5:143435228-143435253 CAACGGAAGCACUGGGGCAUGAGUG 2922 2908_1_76 NR3C1 Exon 1 - xp5:143435229-143435254 CCAACGGAAGCACUGGGGCAUGAGU 2923 2908_1_77 NR3C1 Exon 1 - xp5:143435230-143435255 UCCAACGGAAGCACUGGGGCAUGAG 2924 2908_1_78 NR3C1 Exon 1 - xp5:143435239-143435264 GCGCAUGUGUCCAACGGAAGCACUG 2925 2908_1_79 NR3C1 Exon 1 - xp5:143435240-143435265 UGCGCAUGUGUCCAACGGAAGCACU 2926 2908_1_80 NR3C1 Exon 1 - xp5:143435241-143435266 AUGCGCAUGUGUCCAACGGAAGCAC 2927 2908_1_81 NR3C1 Exon 1 - xp5:143435250-143435275 GACCGUAAAAAUGCGCAUGUGUCCAA 2928 2908_1_82 NR3C1 Exon 1 - xp5:143435277-143435302 AGGUCAGAAAUCUUUCAAGCCCUGC 2929 2908_1_83 NR3C1 Exon 1 - xp5:143435302-143435327 UGAUACCAAAUCACUGGACCUUAGA 2930 2908_1_84 NR3C1 Exon 1 - xp5:143435313-143435338 CUUAGAUCUUCUGAUACCAAAUCAC 2931 2908_1_85 NR3C1 Exon 1 - xp5:143435347-143435372 CACGCUUCUUUAAAUGGCAGAGAGA 2932 2908_1_86 NR3C1 Exon 1 - xp5:143435358-143435383 GGAAAUUGCAACACGCUUCUUUAAA 2933 2908_1_87 NR3C1 Exon 1 - xp5:143435384-143435409 AGGCGAAUCACUUUCACUUCUGCUG 2934 2908_1_88 NR3C1 Exon 1 - xp5:143435385-143435410 GAGGCGAAUCACUUUCACUUCUGCU 2935 2908_1_89 NR3C1 Exon 1 - xp5:143435386-143435411 AGAGGCGAAUCACUUUCACUUCUGC 2936 2908_1_90 NR3C1 Exon 1 - xp5:143435409-143435434 ACACGGAAUGCAGACAUUUGAGUAG 2937 2908_1_91 NR3C1 Exon 1 - xp5:143435477-143435502 AGGGUUUGCUUUCACCCCCAUUCAAAA 2938 2908_1_92 NR3C1 Exon 1 - xp5:143435501-143435526 CCUAUUGUGUGGUCAGGUUAUGUAA 2939 2908_1_93 NR3C1 Exon 1 - xp5:143435502-143435527 UCCUAUUGUGUGGUCAGGUUAUGUA 2940 2908_1_94 NR3C1 Exon 1 - xp5:143435512-143435537 UUUCAUUUCCUCCUAUUGUGUGGUC 2941 1633_1_1 DCK Exon 1 + xp4:70993523-70993548 CCCGGCCUUCACGUGACCUGGCGUG 5278 1633_1_2 DCK Exon 1 + xp4:70993536-70993561 UGACCUGGCGUGCGGAGCGCGCACG 5279 1633_1_3 DCK Exon 1 + xp4:70993537-70993562 GACCUGGCGUGCGGAGCGCGCACGC 5280 1633_1_4 DCK Exon 1 + xp4:70993549-70993574 GGAGCGCGCACGCGGGAACCCGCGC 5281 1633_1_5 DCK Exon 1 + xp4:70993552-70993577 GCGCGCACGCGGGAACCCGCCGCUGG 5282 1633_1_6 DCK Exon 1 + xp4:70993555-70993580 CGCACGCGGGAACCCGCCGCUGGAGG 5283 1633_1_7 DCK Exon 1 + xp4:70993556-70993581 GCACGCGGGAACCCGCCGCUGGAGGC 5284 1633_1_8 DCK Exon 1 + xp4:70993561-70993586 CGGGAACCCGCCGCUGGAGGCGGGCG 5285 1633_1_9 DCK Exon 1 + xp4:70993562-70993587 GGGAACCCGCGCUGGAGGCGGGCGA 5286 1633_1_10 DCK Exon 1 + xp4:70993568-70993593 CCGCGCUGGAGGCGGGCGAGGGCCG 5287 1633_1_11 DCK Exon 1 + xp4:70993569-70993594 CGCGCUGGAGGCGGGCGAGGGCCGA 5288 1633_1_12 DCK Exon 1 + xp4:70993570-70993595 GCGCUGGAGGCGGGCGAGGGCCGAG 5289 1633_1_13 DCK Exon 1 + xp4:70993578-70993603 GGCGGGCGAGGGCCGAGGGGCAGCU 5290 1633_1_14 DCK Exon 1 + xp4:70993579-70993604 GCGGGCGAGGGCCGAGGGGCAGCUA 5291 1633_1_15 DCK Exon 1 + xp4:70993586-70993611 AGGGCCGAGGGGCAGCUAGGGAGCG 5292 1633_1_16 DCK Exon 1 + xp4:70993593-70993618 AGGGGCAGCUAGGGAGCGCGGCUUG 5293 1633_1_17 DCK Exon 1 + xp4:70993596-70993621 GGCAGCUAGGGAGCGCGGCUUGAGG 5294 1633_1_18 DCK Exon 1 + xp4:70993597-70993622 GCAGCUAGGGAGCGCGGCUUGAGGA 5295 1633_1_19 DCK Exon 1 + xp4:70993600-70993625 GCUAGGGAGCGCGGCUUGAGGAGGG 5296 1633_1_20 DCK Exon 1 + xp4:70993601-70993626 CUAGGGAGCGCGGCUUGAGGAGGGC 5297 1633_1_21 DCK Exon 1 + xp4:70993602-70993627 UAGGGAGCGCGGCUUGAGGAGGGCG 5298 1633_1_22 DCK Exon 1 + xp4:70993614-70993639 CUUGAGGAGGGCGGGGCCGCCCCGC 5299 1633_1_23 DCK Exon 1 + xp4:70993671-70993696 GCCAAAGUCAAACCCCGACACCCGC 5300 1633_1_24 DCK Exon 1 + xp4:70993674-70993699 AAAGUCAAACCCCGACACCCGCCGG 5301 1633_1_25 DCK Exon 1 + xp4:70993675-70993700 AAGUCAAACCCCGACACCCGCCGGC 5302 1633_1_26 DCK Exon 1 + xp4:70993679-70993704 CAAACCCCGACACCCGCCGGCGGGC 5303 1633_1_27 DCK Exon 1 + xp4:70993700-70993725 GGGCCGGUGAGCUCACUAGCUGACC 5304 1633_1_28 DCK Exon 1 + xp4:70993704-70993729 CGGUGAGCUCACUAGCUGACCCGGC 5305 1633_1_29 DCK Exon 1 + xp4:70993709-70993734 AGCUCACUAGCUGACCCGGCAGGUC 5306 1633_1_30 DCK Exon 1 + xp4:70993715-70993740 CUAGCUGACCCGGCAGGUCAGGAUC 5307 1633_1_31 DCK Exon 1 + xp4:70993723-70993748 CCCGGCAGGUCAGGAUCUGGCUUAG 5308 1633_1_32 DCK Exon 1 + xp4:70993753-70993778 CCGCGAGCUCCAGUGCGCGCACCCCG 5309 1633_1_33 DCK Exon 1 + xp4:70993777-70993802 GUGGCCGCCUCCCAGCCCUCUUUGC 5310 1633_1_34 DCK Exon 1 + xp4:70993788-70993813 CCAGCCCUCUUUGCCGGACGAGCUC 5311 1633_1_35 DCK Exon 1 + xp4:70993789-70993814 CAGCCCUCUUUGCCGGACGAGCUCU 5312 1633_1_36 DCK Exon 1 + xp4:70993806-70993831 CGAGCUCUGGGCCGCCACAAGACUA 5313 1633_1_37 DCK Exon 1 + xp4:70993811-70993836 UCUGGGCCGCCACAAGACUAAGGAA 5314 1633_1_38 DCK Exon 1 + xp4:70993859-70993884 UGCCCGUCUUUCUCAGCCAGCUCUG 5315 1633_1_39 DCK Exon 1 + xp4:70993860-70993885 GCCCGUCUUUCUCAGCCAGCUCUGA 5316 1633_1_40 DCK Exon 1 + xp4:70993861-70993886 CCCGUCUUUCUCAGCCAGCUCUGAG 5317 1633_1_41 DCK Exon 1 + xp4:70993890-70993915 CCCGCAUCAAGAAAAUCUCCAUCGA 5318 1633_1_42 DCK Exon 1 + xp4:70993891-70993916 CCGCAUCAAGAAAAUCUCCAUCGAA 5319 1633_1_43 DCK Exon 1 + xp4:70993899-70993924 AGAAAAUCUCCAUCGAAGGGAACAU 5320 1633_1_44 DCK Exon 1 + xp4:70993904-70993929 AUCUCCAUCGAAGGGAACAUCGGUA 5321 1633_1_45 DCK Exon 1 + xp4:70993913-70993938 GAAGGGAACAUCGGUAAGGAGCCUC 5322 1633_1_46 DCK Exon 1 + xp4:70993921-70993946 CAUCGGUAAGGAGCCUCCGGAAAUG 5323 1633_1_47 DCK Exon 1 + xp4:70993922-70993947 AUCGGUAAGGAGCCUCCGGAAAUGU 5324 1633_1_48 DCK Exon 1 - xp4:70993525-70993550 CGCACGCCAGGUCACGUGAAGGCCG 5325 1633_1_49 DCK Exon 1 - xp4:70993526-70993551 CCGCACGCCAGGUCACGUGAAGGCC 5326 1633_1_50 DCK Exon 1 - xp4:70993527-70993552 UCCGCACGCCAGGUCACGUGAAGGC 5327 1633_1_51 DCK Exon 1 - xp4:70993531-70993556 GCGCUCCGCACGCCAGGUCACGUGA 5328 1633_1_52 DCK Exon 1 - xp4:70993542-70993567 UUCCCGCGUGCGCGCUCCGCACGCC 5329 1633_1_53 DCK Exon 1 - xp4:70993570-70993595 CUCGGCCCUCGCCCGCCUCCAGGCGC 5330 1633_1_54 DCK Exon 1 - xp4:70993571-70993596 CCUCGGCCCUCGCCCGCCUCCAGCG 5331 1633_1_55 DCK Exon 1 - xp4:70993593-70993618 CAAGCCGCCGCUCCCUAGCUGCCCCU 5332 1633_1_56 DCK Exon 1 - xp4:70993633-70993658 UGAGGACACUGGCGGGCCUGCGGGG 5333 1633_1_57 DCK Exon 1 - xp4:70993636-70993661 AGCUGAGGACACUGGCGGGCCUGCG 5334 1633_1_58 DCK Exon 1 - xp4:70993637-70993662 CAGCUGAGGACACUGGCGGGCCUGC 5335 1633_1_59 DCK Exon 1 - xp4:70993638-70993663 GCAGCUGAGGACACUGGCGGGCCUG 5336 1633_1_60 DCK Exon 1 - xp4:70993645-70993670 CGCGGAGGCAGCUGAGGACACUGGC 5337 1633_1_61 DCK Exon 1 - xp4:70993646-70993671 GCGCGGAGGCAGCUGAGGACACUGG 5338 1633_1_62 DCK Exon 1 - xp4:70993649-70993674 GGCGCGCGGAGGCAGCUGAGGACAC 5339 1633_1_63 DCK Exon 1 - xp4:70993656-70993681 UGACUUUGGCGCGCGGAGGCAGCUG 5340 1633_1_64 DCK Exon 1 - xp4:70993665-70993690 GUCGGGGUUUGACUUUGGCGCGCGG 5341 1633_1_65 DCK Exon 1 - xp4:70993668-70993693 GGUGUCGGGGUUUGACUUUGGCGCG 5342 1633_1_66 DCK Exon 1 - xp4:70993675-70993700 GCCGGCGGGUGUCGGGGUUUGACUU 5343 1633_1_67 DCK Exon 1 - xp4:70993686-70993711 CUCACCGGCCCGCCGGCGGGUGUCG 5344 1633_1_68 DCK Exon 1 - xp4:70993687-70993712 GCUCACCGGCCCGCCGGCGGGUGUC 5345 1633_1_69 DCK Exon 1 - xp4:70993688-70993713 AGCUCACCGGCCCGCCGGCGGGUGU 5346 1633_1_70 DCK Exon 1 - xp4:70993694-70993719 CUAGUGAGCUCACCGGCCCGCCGGC 5347 1633_1_71 DCK Exon 1 - xp4:70993695-70993720 GCUAGUGAGCUCACCGGCCCGCCGG 5348 1633_1_72 DCK Exon 1 - xp4:70993698-70993723 UCAGCUAGUGAGCUCACCGGCCCGC 5349 1633_1_73 DCK Exon 1 - xp4:70993706-70993731 CUGCCGGGUCAGCUAGUGAGCUCAC 5350 1633_1_74 DCK Exon 1 - xp4:70993726-70993751 CCGCUAAGCCAGAUCCUGACCUGCC 5351 1633_1_75 DCK Exon 1 - xp4:70993727-70993752 GCCGCUAAGCCAGAUCCUGACCUGC 5352 1633_1_76 DCK Exon 1 - xp4:70993756-70993781 CCACGGGUGCGCCGCACUGGAGCUCG 5353 1633_1_77 DCK Exon 1 - xp4:70993765-70993790 GGGAGGCGGCCACGGGUGCGCGCAC 5354 1633_1_78 DCK Exon 1 - xp4:70993777-70993802 GCAAAGAGGGCUGGGAGGCGGCCAC 5355 1633_1_79 DCK Exon 1 - xp4:70993778-70993803 GGCAAAGAGGGCUGGGAGGCGGCCA 5356 1633_1_80 DCK Exon 1 - xp4:70993784-70993809 UCGUCCGGCAAAGAGGGCUGGGAGG 5357 1633_1_81 DCK Exon 1 - xp4:70993787-70993812 AGCUCGUCCGGCAAAGAGGGCUGGG 5358 1633_1_82 DCK Exon 1 - xp4:70993790-70993815 CAGAGCUCGUCCGGCAAAGAGGGCU 5359 1633_1_83 DCK Exon 1 - xp4:70993791-70993816 CCAGAGCUCGUCCGGCAAAGAGGGC 5360 1633_1_84 DCK Exon 1 - xp4:70993795-70993820 CGGCCCAGAGCUCGUCCGGCAAAGA 5361 1633_1_85 DCK Exon 1 - xp4:70993796-70993821 GCGGCCCAGAGCUCGUCCGGCAAAG 5362 1633_1_86 DCK Exon 1 - xp4:70993804-70993829 GUCUUGUGGCGGCCCAGAGCUCGUC 5363 1633_1_87 DCK Exon 1 - xp4:70993820-70993845 GGGUGGCCAUUCCUUAGUCUUGUGG 5364 1633_1_88 DCK Exon 1 - xp4:70993823-70993848 GCGGGGUGGCCAUUCCUUAGUCUUG 5365 1633_1_89 DCK Exon 1 - xp4:70993842-70993867 GACGGGCAGCUUCUCUUGGGCGGGG 5366 1633_1_90 DCK Exon 1 - xp4:70993845-70993870 AAAGACGGGCAGCUUCUCUUGGGCG 5367 1633_1_91 DCK Exon 1 - xp4:70993846-70993871 GAAAGACGGGCAGCUUCUCUUGGGC 5368 1633_1_92 DCK Exon 1 - xp4:70993847-70993872 AGAAAGACGGGCAGCUUCUCUUGGG 5369 1633_1_93 DCK Exon 1 - xp4:70993850-70993875 CUGAGAAAGACGGGCAGCUUCUCUU 5370 1633_1_94 DCK Exon 1 - xp4:70993851-70993876 GCUGAGAAAGACGGGCAGCUUCUCU 5371 1633_1_95 DCK Exon 1 - xp4:70993864-70993889 CCCCUCAGAGCUGGCUGAGAAAAGAC 5372 1633_1_96 DCK Exon 1 - xp4:70993865-70993890 UCCCCUCAGAGCUGGCUGAGAAAGA 5373 1633_1_97 DCK Exon 1 - xp4:70993878-70993903 UUCUUGAUGCGGGUCCCCUCAGAGGC 5374 1633_1_98 DCK Exon 1 - xp4:70993893-70993918 CCUUCGAUGGAGAUUUUCUUGAUGC 5375 1633_1_99 DCK Exon 1 - xp4:70993894-70993919 CCCUUCGAUGGAGAUUUUCUUGAUG 5376 1633_1_100 DCK Exon 1 - xp4:70993911-70993936 GGCUCCUUACCGAUGUUCCCUUCGA 5377 1633_2_1 DCK Exon 2 + xp4:70998045-70998070 UUUUAUCUUUCCUCACAACAGCUGC 5378 1633_2_2 DCK Exon 2 + xp4:70998046-70998071 UUUAUCUUUCCUCACAACAGCUGCA 5379 1633_2_3 DCK Exon 2 + xp4:70998091-70998116 UAUCCUUAAACAAUUGUGUGAAGAU 5380 1633_2_4 DCK Exon 2 + xp4:70998092-70998117 AUCCUUAAACAAUUGUGUGAAGAUU 5381 1633_2_5 DCK Exon 2 + xp4:70998098-70998123 AAACAAUUGUGUGAAGAUUGGGAAG 5382 1633_2_6 DCK Exon 2 + xp4:70998121-70998146 AGUGGUUCCUGAACCUGUUGCCAGA 5383 1633_2_7 DCK Exon 2 + xp4:70998155-70998180 GUUCAAAGUACUCAAGAUGAAUUUG 5384 1633_2_8 DCK Exon 2 - xp4:70998058-70998083 UGUUGACUUCCCUGCAGCUGUUGUG 5385 1633_2_9 DCK Exon 2 - xp4:70998097-70998122 UUCCAAUCUUCACACAAUUGUUUA 5386 1633_2_10 DCK Exon 2 - xp4:70998131-70998156 CAUUGCACCAUCUGGCAACAGGUUC 5387 1633_2_11 DCK Exon 2 - xp4:70998137-70998162 UUUGAACAUUGCACCAUCUGGCAAC 5388 1633_2_12 DCK Exon 2 - xp4:70998144-70998169 UGAGUACCUUUGAACAUUGCACCAUC 5389 1633_3_1 DCK Exon 3 + xp4:71022364-71022389 AGGAACUUACAAUGUCUCAGAAAAA 5390 1633_3_2 DCK Exon 3 + xp4:71022367-71022392 AACUUACAAUGUCUCAGAAAAAAUGG 5391 1633_3_3 DCK Exon 3 + xp4:71022368-71022393 ACUUACAAUGUCUCAGAAAAAAUGGU 5392 1633_3_4 DCK Exon 3 + xp4:71022407-71022432 GAUGAUGUAUGAGAAACCUGAACGA 5393 1633_3_5 DCK Exon 3 + xp4:71022472-71022497 UAAGAGCUCAGCUUGCCUCUCUGAA 5394 1633_3_6 DCK Exon 3 + xp4:71022533-71022558 UUUUGAACGAUCUGUGUAUAGUGAC 5395 1633_3_7 DCK Exon 3 + xp4:71022546-71022571 GUGUAUAGUCAGGUAUGUAUAAAA 5396 1633_3_8 DCK Exon 3 + xp4:71022557-71022582 CAGGUAUGUAUAAAUGGCUUGUACG 5397 1633_3_9 DCK Exon 3 - xp4:71022426-71022451 UUUGGAAGGUAAAAAGACCAUCGUUC 5398 1633_3_10 DCK Exon 3 - xp4:71022445-71022470 CGACUGAGACAGGCAUAUGUUUGGA 5399 1633_3_11 DCK Exon 3 - xp4:71022449-71022474 UAUUCGACUGAGACAGGCAUAUGUU 5400 1633_3_12 DCK Exon 3 - xp4:71022460-71022485 AGCUGAGCUCUUAUUCGACUGAGAC 5401 1633_3_13 DCK Exon 3 - xp4:71022490-71022515 GCAUCUUUGAGCUUGCCAUUCAGAG 5402 1633_3_14 DCK Exon 3 - xp4:71022525-71022550 ACACAGAUCGUUCAAAAAAUAAUAC 5403 1633_4_1 DCK Exon 4 + xp4:71023585-71023610 AUCUGAAUGCAUGAAUGAGACAGAG 5404 1633_4_2 DCK Exon 4 + xp4:71023603-71023628 GACAGAGUGGACAAUUUAUCAAGAC 5405 1633_4_3 DCK Exon 4 + xp4:71023612-71023637 GACAAUUUAUCAAGACUGGCAUGAC 5406 1633_4_4 DCK Exon 4 + xp4:71023629-71023654 GGCAUGACUGGAUGAAUAACCAAUU 5407 1633_4_5 DCK Exon 4 + xp4:71023646-71023671 AACCAAUUUGGCCAAAGCCUUGAAU 5408 1633_4_6 DCK Exon 4 + xp4:71023650-71023675 AAUUUGGCCAAAGCCUUGAAUUGGA 5409 1633_4_7 DCK Exon 4 + xp4:71023679-71023704 AUCAUUUAUCUUCAAGCCACUCCAG 5410 1633_4_8 DCK Exon 4 - xp4:71023651-71023676 AUCCAAUUCAAGGCUUUGGCCAAAAU 5411 1633_4_9 DCK Exon 4 - xp4:71023660-71023685 AAUGAUUCCAUCCAAUUCAAGGCUU 5412 1633_4_10 DCK Exon 4 - xp4:71023666-71023691 AAGAUAAAUGAUUCCAUCCAAUUCA 5413 1633_4_11 DCK Exon 4 - xp4:71023698-71023723 UUUUUAUUGGGUUUUACCUCUGGAG 5414 1633_4_12 DCK Exon 4 - xp4:71023703-71023728 ACACAUUUUUAUUGGGUUUUACCUC 5415 1633_5_1 DCK Exon 5 + xp4:71025814-71025839 GACAUGCUUACAUAGAAUAUAUUUA 5416 1633_5_2 DCK Exon 5 + xp4:71025815-71025840 ACAUGCUUACAUAGAAUAUAUUUAC 5417 1633_5_3 DCK Exon 5 + xp4:71025816-71025841 CAUGCUUACAUAGAAUAUAUUUACG 5418 1633_5_4 DCK Exon 5 + xp4:71025834-71025859 AUUUACGGGGAAGAAAUGAAGAGCA 5419 1633_5_5 DCK Exon 5 + xp4:71025883-71025908 GAAGCUUCAUUAUAAACAUGAAAGC 5420 1633_5_6 DCK Exon 5 + xp4:71025895-71025920 UAAACAUGAAAAGCUGGCUCCUGCAU 5421 1633_5_7 DCK Exon 5 - xp4:71025794-71025819 AUGUCUAAAAAGCAAGUAAUAAGAGA 5422 1633_5_8 DCK Exon 5 - xp4:71025869-71025894 AAUGAAGCUUCUCUAAAUAUUCAAG 5423 1633_5_9 DCK Exon 5 - xp4:71025916-71025941 UAAGUCUUACUUCAGUGUCCUAUGC 5424 1633_6_1 DCK Exon 6 + xp4:71026662-71026687 AGAACCAACUUCGAUUAUCUUCAAG 5425 1633_6_2 DCK Exon 6 + xp4:71026680-71026705 CUUCAAGAGGUGCCUAUCUUAACAC 5426 1633_6_3 DCK Exon 6 + xp4:71026719-71026744 GACUUUAAAGACAAAAUAUGAAAGUC 5427 1633_6_4 DCK Exon 6 + xp4:71026728-71026753 GACAAAUAUGAAAGUCUGGUUGAAA 5428 1633_6_5 DCK Exon 6 - xp4:71026669-71026694 GGCACCUCUUGAAGAUAAUCGAAGU 5429 1633_6_6 DCK Exon 6 - xp4:71026695-71026720 CUUCAUUAACAUCCAGUGUUAAGAU 5430 1633_7_1 DCK Exon 7 + xp4:71029369-71029394 ACUUUGUGAUCUUGCUGAAGACCUAC 5431 1633_7_2 DCK Exon 7 + xp4:71029380-71029405 UUGCUGAAGACUACAGGCAGCCAAA 5432 1633_7_3 DCK Exon 7 + xp4:71029473-71029498 CAAGUUUUUAAUCGUUUUUGUUUUA 5433 1633_7_4 DCK Exon 7 + xp4:71029705-71029730 UCCUCAGCAGGUUGGCUUUUUUCCC 5434 1633_7_5 DCK Exon 7 + xp4:71029723-71029748 UUUUCCCUGGUGCCUCUCACUUCGU 5435 1633_7_6 DCK Exon 7 + xp4:71029769-71029794 GAAAGCUUUAAUGUUACAUAGUAAA 5436 1633_7_7 DCK Exon 7 + xp4:71029817-71029842 AGUGUACCUAUUAAAAAGUUGCAAAG 5437 1633_7_8 DCK Exon 7 + xp4:71029826-71029851 AUUAAAAAGUUGCAAAGUGGAAUUAA 5438 1633_7_9 DCK Exon 7 + xp4:71029842-71029867 UGGAAUUAAAGGAAUCCCUAGAAUA 5439 1633_7_10 DCK Exon 7 + xp4:71029932-71029957 GCCUCAGUCUGCUUUCUCUACUGUC 5440 1633_7_11 DCK Exon 7 + xp4:71029942-71029967 GCUUUCUCUACUGUCUGGAUUAAUU 5441 1633_7_12 DCK Exon 7 + xp4:71030131-71030156 CUGAAAGCAUUAUUUUUUGUUGAAU 5442 1633_7_13 DCK Exon 7 + xp4:71030155-71030180 UAGGAAAUAAAAUUAAUGAAGACAG 5443 1633_7_14 DCK Exon 7 + xp4:71030241-71030266 UGUGAAUAUUUGUAAAAAUAAAUGAA 5444 1633_7_15 DCK Exon 7 + xp4:71030296-71030321 AUUUUCUUUCUAGUUUGUUUAGUUA 5445 1633_7_16 DCK Exon 7 + xp4:71030370-71030395 AGAAAAUUUUAUGUAUUUUAAAAUA 5446 1633_7_17 DCK Exon 7 + xp4:71030371-71030396 GAAAAUUUUAUGUAUUUUAAAAUAA 5447 1633_7_18 DCK Exon 7 + xp4:71030372-71030397 AAAAUUUUAUGUAUUUUAAAAUAG 5448 1633_7_19 DCK Exon 7 + xp4:71030430-71030455 UUUCUUUCCAAGUCAUUUUUGUUUU 5449 1633_7_20 DCK Exon 7 + xp4:71030459-71030484 UUCUUAUUCAAAGAUGAUAAUUUAG 5450 1633_7_21 DCK Exon 7 + xp4:71030494-71030519 AGUCCAGACGCACUGAUCUUUGCAA 5451 1633_7_22 DCK Exon 7 + xp4:71030575-71030600 UGCAUUUUUUAGUUUGUUUUUGUU 5452 1633_7_23 DCK Exon 7 + xp4:71030633-71030658 UAAGUAUAAACCUUAUGAACCUACAG 5453 1633_7_24 DCK Exon 7 + xp4:71030734-71030759 CUUUUAAAAUAAAUUAUGAAUAUUAA 5454 1633_7_25 DCK Exon 7 + xp4:71030773-71030798 UAAAUUACUUUGAUUCCAUUUUAAG 5455 1633_7_26 DCK Exon 7 + xp4:71030901-71030926 UCAUGACUCAAAAGGUUGUCUCAGUG 5456 1633_7_27 DCK Exon 7 + xp4:71030904-71030929 UGACUCAAAAAGUUGUCUCAGUGUGG 5457 1633_7_28 DCK Exon 7 - xp4:71029343-71029368 CUCAAAAACUCUUUGACCUGAGGAA 5458 1633_7_29 DCK Exon 7 - xp4:71029348-71029373 AAGUACUCAAAAACUCUUUGACCUG 5459 1633_7_30 DCK Exon 7 - xp4:71029403-71029428 CAAAGCUGAAGUAUCUGGAACCAUU 5460 1633_7_31 DCK Exon 7 - xp4:71029413-71029438 CGAAGAUACACAAAGCUGAAGUAUC 5461 1633_7_32 DCK Exon 7 - xp4:71029474-71029499 UUAAAAAAAAAACGAUUAAAAACUU 5462 1633_7_33 DCK Exon 7 - xp4:71029475-71029500 CUUAAAACAAAAACGAUUAAAAACU 5463 1633_7_34 DCK Exon 7 - xp4:71029545-71029570 UUUUUUUUUUGUUUUCUUUUCUUUC 5464 1633_7_35 DCK Exon 7 - xp4:71029730-71029755 GUCACCAACGAAGUGAGAGGCACCA 5465 1633_7_36 DCK Exon 7 - xp4:71029731-71029756 GGUCACCAACGAAGUGAGAGGCACC 5466 1633_7_37 DCK Exon 7 - xp4:71029738-71029763 AGAAACUGGUCACCAACGAAGUGAG 5467 1633_7_38 DCK Exon 7 - xp4:71029757-71029782 CAUUAAAAGCUUUCAGUUUAAGAAAC 5468 1633_7_39 DCK Exon 7 - xp4:71029808-71029833 UUUUAAUAGGUACACUAAUUUACAC 5469 1633_7_40 DCK Exon 7 - xp4:71029826-71029851 UUAAUUCCACUUUGCAACUUUUAAU 5470 1633_7_41 DCK Exon 7 - xp4:71029860-71029885 AUAAAACUUCAGAAUCCUUAUUCUA 5471 1633_7_42 DCK Exon 7 - xp4:71029861-71029886 AAUAAAACUUCAGAAUCCUUAUUCU 5472 1633_7_43 DCK Exon 7 - xp4:71029918-71029943 CAGACUGAGGCAGGAAGUAAGAGGU 5473 1633_7_44 DCK Exon 7 - xp4:71029919-71029944 GCAGACUGAGGCAGGAAGUAAGAGG 5474 1633_7_45 DCK Exon 7 - xp4:71029922-71029947 AAAGCAGACUGAGGCAGGAAGUAAG 5475 1633_7_46 DCK Exon 7 - xp4:71029932-71029957 GACAGUAGAGAAAGCAGACUGAGGC 5476 1633_7_47 DCK Exon 7 - xp4:71029936-71029961 UCCAGACAGUAGAGAAAGCAGACUG 5477 1633_7_48 DCK Exon 7 - xp4:71029976-71030001 AAAUGUGUGACUUUAACUUUAUAGC 5478 1633_7_49 DCK Exon 7 - xp4:71030133-71030158 CUAUUCAACAAAAAAUAAUGCUUUC 5479 1633_7_50 DCK Exon 7 - xp4:71030197-71030222 UAGUUAAGGUGUCUCAUUAAUUAA 5480 1633_7_51 DCK Exon 7 - xp4:71030237-71030262 UUAUUUUUCAAAUAUUCACAUGA 5481 1633_7_52 DCK Exon 7 - xp4:71030341-71030366 CGUAAAAUGGAAAGGUUUAAUACAC 5482 1633_7_53 DCK Exon 7 - xp4:71030354-71030379 AAAUUUUCUAAAACGUAAAAAUGGAA 5483 1633_7_54 DCK Exon 7 - xp4:71030359-71030384 ACAUAAAAUUUUCUAAAACGUAAAA 5484 1633_7_55 DCK Exon 7 - xp4:71030440-71030465 UAAGAAACCAAAAACAAAAAUGACU 5485 1633_7_56 DCK Exon 7 - xp4:71030495-71030520 UUUGCAAAGAUCAGUGCGUCUGGAC 5486 1633_7_57 DCK Exon 7 - xp4:71030500-71030525 UCUCCUUUGCAAAGAUCAGUGCGUC 5487 1633_7_58 DCK Exon 7 - xp4:71030550-71030575 UACGUAUAAUGAGACAGUUUAUGUA 5488 1633_7_59 DCK Exon 7 - xp4:71030646-71030671 GAGUGUAGCUCCACCUGUAGUUCAUA 5489 1633_7_60 DCK Exon 7 - xp4:71030791-71030816 CACUGAAAUAUGUCUCCACUAAAA 5490 1633_7_61 DCK Exon 7 - xp4:71030830-71030855 UUUAAAAGUCAUUAUACAUUUUUAA 5491 TRAC-1a TRAC EXON-1 + UCUCAAACAAAUGUGUCACAAAAGUA 5816 TRAC-2a TRAC EXON-1 + CACAGACAAAACUGUGCUAGACAUG 5817 TRAC-3a TRAC EXON-1 + AAAACUGUGCUAGACAUGAGGUCUA 5818 TRAC-4a TRAC EXON-1 + AUGGACUUCAAGAGCAACAGUGCUG 5819 TRAC-5a TRAC EXON-1 + CUUCAAGAGCAACAGUGCUGUGGCC 5820 TRAC-6a TRAC EXON-1 - CUGGGCUGGGGAAGAAGGUGUCUUC 5821 TRAC-7a TRAC EXON-1 - UCUUCUGGAAUAAUGCUGUUGUUGA 5822 TRAC-8a TRAC EXON-1 - CAUGCAAAGUCAGAUUUGUUGCUCC 5823 TRAC-9a TRAC EXON-1 - GACACAUUUGUUUGAGAAUCAAAAU 5824 TRAC-10a TRAC EXON-1 - UGUUUGAGAAUCAAAAUCGGUGAAU 5825 TRAC-11 TRAC EXON-1 - GUGAAUAGGCAGACAGACUUGUCAC 5826 TRAC-12 TRAC EXON-1 - GUCACUGGAUUUAGAGUCUCUCAGC 5827 TRAC-13 TRAC EXON-1 - GAUUUAGAGUCUCUCAGCUGGUAC 5828 TRAC-14 TRAC EXON-1 - UAGAGUCUCUCAGCUGGUACACGGC 5829 TRAC-15 TRAC EXON-1 - AGAGUCUCUCAGCUGGUACACGGCA 5830 TRAC-16 TRAC EXON-1 - CUCUCAGCUGGUACACGGCAGGGUC 5831 TRAC-17 TRAC EXON-1 - UCUCAGCUGGUACACGGCAGGGUCA 5832 TRAC-18 TRAC EXON-1 - CUGGUACACGGCAGGGUCAGGGUUC 5833 TRAC-19 TRAC EXON-1 - GCAGGGUCAGGGUUCUGGAUAUCUG 5834 TRAC-20 TRAC EXON-1 - CAGGGUCAGGGUUCUGGAUAUCUGU 5835 TRAC-21 TRAC EXON-1 - GGGUUCUGGAUAUCUGUGGGACAAG 5836 TRAC-22 TRAC EXON-1 - UGGAUAUCUGUGGGACAAGAGGAUC 5837 TRAC-23 TRAC EXON-1 - GGAUAUCUGUGGGACAAGAGGAUCA 5838 TRAC-24 TRAC EXON-1 - UCUGUGGGACAAGAGGAUCAGGGUU 5839 TRAC-25 TRAC EXON-2 + UUAGAAAGUUCCUGUGAUGUCAAGC 5840 TRAC-26 TRAC EXON-2 + AGCUGGUCGAGAAAAGCUUUGAAAC 5841 TRAC-27 TRAC EXON-2 + AGAAAGCUUUGAAAACAGGUAAGAC 5842 TRAC-28 TRAC EXON-2 + GAAAAGCUUUGAAAACAGGUAAGACA 5843 TRAC-29 TRAC EXON-2 + AAAAGCUUUGAAAACAGGUAAGACAG 5844 TRAC-30 TRAC EXON-2 + AAACAGGUAAAGACAGGGGUCUAGCC 5845 TRAC-31 TRAC EXON-2 + AACAGGUAAAGACAGGGGUCUAGCCU 5846 TRAC-32 TRAC EXON-2 - CUUUUCUCGACCAGCUUGACAUCAC 5847 TRAC-33 TRAC EXON-2 - CUUGACAUCACAGGAACUUUCUAAA 5848 TRAC-34 TRAC EXON-3 + UAAACUUUCAAAAACCUGUCAGUGAU 5849 TRAC-35 TRAC EXON-3 + AAACUUUCAAAAACCUGUCAGUGAUU 5850 TRAC-36 TRAC EXON-3 + GGGUUCCGAAUCCUCCUCCUGAAG 5851 TRAC-37 TRAC EXON-3 + UCCGAAUCCUCCUCCUGAAAGUGGC 5852 TRAC-38 TRAC EXON-3 + CCGAAUCCUCCUCCUGAAAGUGGCC 5853 TRAC-39 TRAC EXON-3 + CGGGUUUAAUCUGCUCAUGACGCUG 5854 TRAC-40 TRAC EXON-3 + UAAUCUGCUCAUGACGCUGCGGCUG 5855 TRAC-41 TRAC EXON-3 + UGACGCUGCGGCUGUGGUCCAGCUG 5856 TRAC-42 TRAC EXON-3 + CUGCGGCUGUGGUCCAGCUGAGGUG 5857 TRAC-43 TRAC EXON-3 + UGCGGCUGUGGUCCAGCUGAGGUGA 5858 TRAC-44 TRAC EXON-3 + GCGGCUGUGGUCCAGCUGAGGUGAG 5859 TRAC-45 TRAC EXON-3 + CAGCUGAGGUGAGGGGCCUUGAAGC 5860 TRAC-46 TRAC EXON-3 + AGCUGAGGUGAGGGGCCUUGAAGCU 5861 TRAC-47 TRAC EXON-3 - CAGCUUCAAGGCCCCUCACCUCAGGC 5862 TRAC-48 TRAC EXON-3 - CGCAGCGUCAUGAGCAGAUUAAACC 5863 TRAC-49 TRAC EXON-3 - GAGCAGAUUAAACCCGGCCACUUUC 5864 TRAC-50 TRAC EXON-3 - CAGAUUAAACCCGGCCACUUUCAGG 5865 TRAC-51 TRAC EXON-3 - AUUAAACCCGGCCACUUUCAGGAGG 5866 TRAC-52 TRAC EXON-3 - CCCGGCCACUUUCAGGAGGAGGAUU 5867 TRAC-53 TRAC EXON-3 - GAGGAUUCGGAACCCAAUCACUGAC 5868 TRAC-54 TRAC EXON-3 - AAUCACUGACAGGUUUUGAAAGUUU 5869 TRAC-55 TRAC EXON-3 - UUAGGUUCGUAUCUGUAAAAACCAAG 5870 TRAC-56 TRAC EXON-3 - UAUCUGUAAAAACCAAGAGGCCACAG 5871 TRAC-57 TRAC EXON-4 + GCCCCUCUUCUCCCCUCCAAACAG 5872 TRAC-58 TRAC EXON-4 + CCCCUCUUCUCCCUCUCCAAACAGA 5873 TRAC-59 TRAC EXON-4 + AACAGAGGGAACUCUCCUACCCCA 5874 TRAC-60 TRAC EXON-4 + AGAGGGAACUCUCCUACCCCCCAAGG 5875 TRAC-61 TRAC EXON-4 + AGCUGCUACCACCUCUGUGCCCCCC 5876 TRAC-62 TRAC EXON-4 + GUGCCCCCCCGGCAAUGCCACCAAC 5877 TRAC-63 TRAC EXON-4 + GCUGCUUGUCACUGCCUGACAUUCA 5878 TRAC-64 TRAC EXON-4 + UGUCACUGCCUGACAUUCACGGCAG 5879 TRAC-65 TRAC EXON-4 + CUGCCUGACAUUCACCGGCAGAGGCA 5880 TRAC-66 TRAC EXON-4 + GAGGCAAGGCUGCUGCAGCCUCCCC 5881 TRAC-67 TRAC EXON-4 + ACUGCCUCCGCCAUCCCACAGAUGA 5882 TRAC-68 TRAC EXON-4 + CAUCCCACAGAUGAUGGAUCUUCAG 5883 TRAC-69 TRAC EXON-4 + AUCCCACAGAUGAUGGAUCUCUCAGU 5884 TRAC-70 TRAC EXON-4 + AUGAUGGAUCUCUCAGUGGGUUCUCUCU 5885 TRAC-71 TRAC EXON-4 + UGAUGGAUCUUCAGUGGGUUCUCUU 5886 TRAC-72 TRAC EXON-4 + UCUUCAGUGGGUUCUCUUGGGCUCU 5887 TRAC-73 TRAC EXON-4 + GCUCUAGGUCCCUGCAGAAUGUUGUG 5888 TRAC-74 TRAC EXON-4 + CUCUAGGUCCCUGCAGAAUGUUGUGA 5889 TRAC-75 TRAC EXON-4 + UCUAGGUCCCUGCAGAAUGUUGUGAG 5890 TRAC-76 TRAC EXON-4 + ACAUAGUAUUCUUCUUCUCAAGACG 5891 TRAC-77 TRAC EXON-4 + CAUAGUAUUCUUCUUCUCAAGACGU 5892 TRAC-78 TRAC EXON-4 + AUAGUAUUCUUCUUCUCAAGACGUG 5893 TRAC-79 TRAC EXON-4 + UAGUAUUCUUCUUCUCAAGACGUGG 5894 TRAC-80 TRAC EXON-4 + AGUAUUCUUCUUCUCAAGACGUGGG 5895 TRAC-81 TRAC EXON-4 + GUGGGGGGAAAUUAUCUCAUUAUCG 5896 TRAC-82 TRAC EXON-4 + UCGAGGCCCUGCUAUGCUGUGUAUUC 5897 TRAC-83 TRAC EXON-4 + CGAGGCCCUGCUAUGCUGUGUAUCU 5898 TRAC-84 TRAC EXON-4 + UGCCGAUGCCUUCAUUAAAAUGAUU 5899 TRAC-85 TRAC EXON-4 + AGCAGAGACUGUGCCUCUGUUUGAC 5900 TRAC-86 TRAC EXON-4 + GCAGAGACUGUGCCUCUGUUUGACU 5901 TRAC-87 TRAC EXON-4 + GACUGUGCCUCUGUUUGACUGGGUU 5902 TRAC-88 TRAC EXON-4 + GUGCCUCUGUUUGACUGGGUUUGGU 5903 TRAC-89 TRAC EXON-4 - ACUCCUACCAAACCCAGUCAAACAG 5904 TRAC-90 TRAC EXON-4 - CUGCUCUUCCAAAUCAUUUUAAUGA 5905 TRAC-91 TRAC EXON-4 - UUCCAAAUCAUUUUAAUGAAGGCAU 5906 TRAC-92 TRAC EXON-4 - UCAUUUUAAUGAAGGCAUCGGCAGC 5907 TRAC-93 TRAC EXON-4 - AACACGCCCAGAUACACAGCAUAGC 5908 TRAC-94 TRAC EXON-4 - ACACGCCCAGAUACACAGCAAUAGCA 5909 TRAC-95 TRAC EXON-4 - AAAUAAACCCCUCACAACAUUCUGC 5910 TRAC-96 TRAC EXON-4 - GAACCCACUGAAGAUCCAUCACUG 5911 TRAC-97 TRAC EXON-4 - AACCCACUGAAGAUCCAUCACUGUGU 5912 TRAC-98 TRAC EXON-4 - CACUGAAGAUCCAUCAUCUGGGA 5913 TRAC-99 TRAC EXON-4 - UGAAGAUCCAUCAUCUGUGGGAUGG 5914 TRAC-100 TRAC EXON-4 - AGAUCCAUCAUCUGUGGGAUGGCGG 5915 TRAC-101 TRAC EXON-4 - UCUGUGGGAUGGCGGAGGCAGUCUC 5916 TRAC-102 TRAC EXON-4 - CUGUGGGAUGGCGGAGGCAGUCUCU 5917 TRAC-103 TRAC EXON-4 - UGUGGGAUGGCGGAGGCAGUCUCUG 5918 TRAC-104 TRAC EXON-4 - AUGGCGGAGGCAGUCUCUGGGGAGC 5919 TRAC-105 TRAC EXON-4 - GCGGAGGCAGCUCUGGGGAGCAGG 5920 TRAC-106 TRAC EXON-4 - CGGAGGCAGCUCUGGGGAGCAGGA 5921 TRAC-107 TRAC EXON-4 - GGAGCAGGAGGGAAUGUGCACAGCC 5922 TRAC-108 TRAC EXON-4 - GAGCAGGAGGGAAUGUGCACAGCCA 5923 TRAC-109 TRAC EXON-4 - AGCAGGAGGGAAUGUGCACAGCCAG 5924 TRAC-110 TRAC EXON-4 - AGGAGGGAAUGUGCACAGCCAGGGG 5925 TRAC-111 TRAC EXON-4 - CAGCCUUGCCUCUGCCGUGAAUGUC 5926 TRAC-112 TRAC EXON-4 - UGUCAGGCAGUGACAAGCAGCAAUA 5927 TRAC-113 TRAC EXON-4 - GUCAGGCAGUGACAAGCAGCAAUAA 5928 TRAC-114 TRAC EXON-4 - GUGACAAGCAGCAAUAAGGGAACAG 5929 TRAC-115 TRAC EXON-4 - UGACAAGCAGCAAUAAGGGAACAGA 5930 TRAC-116 TRAC EXON-4 - GACAAGCAGCAAUAAGGGAACAGAG 5931 TRAC-117 TRAC EXON-4 - ACAAGCAGCAAUAAGGGAACAGAGG 5932 TRAC-118 TRAC EXON-4 - AGCAGCAAUAAGGGAACAGAGGGGG 5933 TRAC-119 TRAC EXON-4 - GAACAGAGGGGGUGGCAGCAGUGUU 5934 TRAC-120 TRAC EXON-4 - UCUUCAGCAAUCUUAAUCAUAAAAUU 5935 TRAC-121 TRAC EXON-4 - CUUCAGCAAUCUUAAUCAAUAAAUUC 5936 TRAC-122 TRAC EXON-4 - AGCAAUCUUAAUCAAUAAAUUCGGGU 5937 TRAC-123 TRAC EXON-4 - AUCAUAAAUUCGGGUAGGAUCCAGU 5938 TRAC-124 TRAC EXON-4 - AUAAAUUCGGGUAGGAUCCAGUUGG 5939 TRAC-125 TRAC EXON-4 - GGUAGGAUCCAGUUGGUGGCAUUGC 5940 TRAC-126 TRAC EXON-4 - GUAGGAUCCAGUUGGUGGCAUUGCC 5941 TRAC-127 TRAC EXON-4 - UAGGAUCCAGUUGGUGGCAUUGCCG 5942 TRAC-128 TRAC EXON-4 - AGGAUCCAGUUGGUGGCAUUGCCGG 5943 TRAC-129 TRAC EXON-4 - GGAUCCAGUUGGUGGCAUUGCCGGG 5944 TRAC-130 TRAC EXON-4 - GAUCCAGUUGGUGGCAUUGCCGGGG 5945 TRAC-131 TRAC EXON-4 - UGGUGGCAUUGCCGGGGGGGCACAG 5946 TRAC-132 TRAC EXON-4 - UGGCAUUGCCGGGGGGGCACAGAGG 5947 TRAC-133 TRAC EXON-4 - GAGGUGGUAGCAGCUUUCACCUCCU 5948 TRAC-134 TRAC EXON-4 - AGGUGGUAGCAGCUUUCACCUCCUU 5949 TRAC-135 TRAC EXON-4 - GGUGGUAGCAGCUUUCACCUCCUUG 5950 TRAC-136 TRAC EXON-4 - GUGGUAGCAGCUUUCACCCUCCUUGG 5951 TRAC-137 TRAC EXON-4 - UAGCAGCUUUCACCUCCUUGGGGGU 5952 TRAC-138 TRAC EXON-4 - UGGGGGUAGGAGAGUUCCCUCUGUU 5953 TRAC-139 TRAC EXON-4 - GUAGGAGAGUUCCCUCUGUUUGGAG 5954 TRAC-140 TRAC EXON-4 - UAGGAGAGUUCCCUCUGUUUGGAGA 5955 TRAC-141 TRAC EXON-4 - UUCCCUCUGUUUGGAGAGGGAGAAG 5956 TRAC-142 TRAC EXON-4 - UCCCUCUGUUUGGAGAGGGAGAAGA 5957 TRAC-143 TRAC EXON-4 - CCCUCUGUUUGGAGAGGGAGAAGAG 5958 TRAC-144 TRAC EXON-4 - GAGAGGGAGAAGAGGGGCAAUGCAG 5959 TRAC-145 TRAC EXON-4 - GGGAGAAGAGGGGCAAUGCAGAGGA 5960 TRAC-146 TRAC EXON-4 - GAGGGGCAAUGCAGAGGAAGGAGCG 5961 TRAC-147 TRAC EXON-4 - AGGGGCAAUGCAGAGGAAGGAGCGA 5962 TRAC-148 TRAC EXON-4 - UGCAGAGGAAGGAGCGAGGGAGCAC 5963 TRAC-149 TRAC EXON-4 - AGGCUGUCUUACAAUCUUGCAGAUC 5964 TRAC-150 TRAC EXON-4 - CUUACAAUCUUGCAGAUCUGGAAUG 5965 TRBC1-1 TRBC EXON-1 + CUUCCCUUUCCAGAGGACCUGAACA 5966 TRBC1-2 TRBC EXON-1 + GACCUGAACAAGGUGUUCCCACCCCG 5967 TRBC1-3 TRBC EXON-1 + GAAGCAGAGAUCUCCCACACCCAAA 5968 TRBC1-4 TRBC EXON-1 + AUCUCCCACACCCAAAAGGCCACAC 5969 TRBC1-5 TRBC EXON-1 + ACCCAAAAGGCCACACUGGUGUGCC 5970 TRBC1-6 TRBC EXON-1 + AGGCCACACUGGUGUGCCUGGCCAC 5971 TRBC1-7 TRBC EXON-1 + GCCACAGGCUUCUUCCCCGACCACG 5972 TRBC1-8 TRBC EXON-1 + CUUCCCCCGACCACGUGGAGCUGAGC 5973 TRBC1-9 TRBC EXON-1 + CCCCGACCACGUGGAGCUGAGCUGG 5974 TRBC1-10 TRBC EXON-1 + CCCGACCACGUGGAGCUGAGCUGGU 5975 TRBC1-11 TRBC EXON-1 + ACGUGGAGCUGAGCUGGUGGGUGAA 5976 TRBC1-12 TRBC EXON-1 + CGUGGAGCUGAGCUGGUGGGUGAAU 5977 TRBC1-13 TRBC EXON-1 + GAGCUGAGCUGGUGGGUGAAUGGGA 5978 TRBC1-14 TRBC EXON-1 + CUGAGCUGGUGGGUGAAUGGGAAGG 5979 TRBC1-15 TRBC EXON-1 + GGGUGAAUGGGAAGGAGGUGCACAG 5980 TRBC1-16 TRBC EXON-1 + GGUGAAUGGGAAGGAGGUGCACAGU 5981 TRBC1-17 TRBC EXON-1 + GUGAAUGGGAAGGAGGUGCACAGUG 5982 TRBC1-18 TRBC EXON-1 + GUCAGCACAGACCCGCAGCCCCUCA 5983 TRBC1-19 TRBC EXON-1 + CAGAUACUGCCUGAGCAGCCGCCUG 5984 TRBC1-20 TRBC EXON-1 + AGAUACUGCCUGAGCAGCCGCCUGA 5985 TRBC1-21 TRBC EXON-1 + UGCCUGAGCAGCCGCCUGAGGGUCU 5986 TRBC1-22 TRBC EXON-1 + CCGCCUGAGGGUCUCGGCCACCUUC 5987 TRBC1-23 TRBC EXON-1 + ACUUCCGCUGUCAAGUCCAGUUCUA 5988 TRBC1-24 TRBC EXON-1 + CUUCCGCUGUCAAGUCCAGUUCUAC 5989 TRBC1-25 TRBC EXON-1 + UGUCAAGUCCAGUUCUACGGGCUCU 5990 TRBC1-26 TRBC EXON-1 + CUACGGGCUCUCGGAGAAUGACGAG 5991 TRBC1-27 TRBC EXON-1 + CUCUCGGAGAAUGACGAGUGGACCCC 5992 TRBC1-28 TRBC EXON-1 + GGAGAAUGACGAGUGGACCCAGGAU 5993 TRBC1-29 TRBC EXON-1 + GAGAAUGACGAGUGGACCCAGGAUA 5994 TRBC1-30 TRBC EXON-1 + CCCGUCACCCAGAUCGUCAGCGCCG 5995 TRBC1-31 TRBC EXON-1 + CACCCAGAUCGUCAGCGCCGAGGCC 5996 TRBC1-32 TRBC EXON-1 + ACCCAGAUCGUCAGCGCCGAGGCCU 5997 TRBC1-33 TRBC EXON-1 + CCCAGAUCGUCAGCGCCGAGGCCUG 5998 TRBC1-34 TRBC EXON-1 + UCAGCGCCGAGGCCUGGGGUAGAGGC 5999 TRBC1-35 TRBC EXON-1 + CGAGGCCUGGGGUAGAGCAGGUGAG 6000 TRBC1-36 TRBC EXON-1 + GAGGCCUGGGGUAGAGCAGGUGAGU 6001 TRBC1-37 TRBC EXON-1 + AGGCCUGGGGUAGAGCAGGUGAGUG 6002 TRBC1-38 TRBC EXON-1 + UGGGGUAGAGCAGGUGAGUGGGGCC 6003 TRBC1-39 TRBC EXON-1 + GGGGUAGAGCAGGUGAGUGGGGCCU 6004 TRBC1-40 TRBC EXON-1 + GGGUAGAGCAGGUGAGUGGGGCCUG 6005 TRAC1-41 TRBC EXON-1 - AGGCCCCACUCACCUGCUCUACCCC 6006 TRAC1-42 TRBC EXON-1 - CACUCACCUGCUCUACCCCAGGCCU 6007 TRAC1-43 TRBC EXON-1 - ACCCCAGGCCUCGGCGCUGACGAUC 6008 TRAC1-44 TRBC EXON-1 - CCCCAGGCCUCGGCGCUGACGAUCU 6009 TRAC1-45 TRBC EXON-1 - GCCUCGGCGCUGACGAUCUGGGUGA 6010 TRAC1-46 TRBC EXON-1 - CCUCGGCGCUGACGAUCUGGGUGAC 6011 TRAC1-47 TRBC EXON-1 - GCGCUGACGAUCUGGGUGACGGGUU 6012 TRAC1-48 TRBC EXON-1 - CUGGGUGACGGGUUUGGCCCUAUCC 6013 TRAC1-49 TRBC EXON-1 - UGGGUGACGGGUUUGGCCCUAUCCU 6014 TRAC1-50 TRBC EXON-1 - GUCAUUCUCCGAGAGCCCGUAGAAC 6015 TRAC1-51 TRBC EXON-1 - GAGCCCGUAGAACUGGACUUGACAG 6016 TRAC1-52 TRBC EXON-1 - GUAGAACUGGACUUGACAGCGGAAG 6017 TRAC1-53 TRBC EXON-1 - CUGGACUUGACAGCGGAAGUGGUUG 6018 TRAC1-54 TRBC EXON-1 - UGGACUUGACAGCGGAAGUGGUUGC 6019 TRAC1-55 TRBC EXON-1 - GGACUUGACAGCGGAAGUGGUUGCG 6020 TRAC1-56 TRBC EXON-1 - GACUUGACAGCGGAAGUGGUUGCGG 6021 TRAC1-57 TRBC EXON-1 - AAGUGGUUGCGGGGGUUCUGCCAGA 6022 TRAC1-58 TRBC EXON-1 - UGGUUGCGGGGGUUCUGCCAGAAGG 6023 TRAC1-59 TRBC EXON-1 - CUGCCAGAAGGUGGCCGAGACCCUC 6024 TRAC1-60 TRBC EXON-1 - CCAGAAGGUGGCCGAGACCCUCAGG 6025 TRAC1-61 TRBC EXON-1 - GGCCGAGACCCUCAGGCGGCUGCUC 6026 TRAC1-62 TRBC EXON-1 - CUCAGGCGGCUGCUCAGGCAGUAUC 6027 TRAC1-63 TRBC EXON-1 - GCUCAGGCAGUAUCUGGAGUCAUUG 6028 TRAC1-64 TRBC EXON-1 - CUCAGGCAGUAUCUGGAGUCAUUGA 6029 TRAC1-65 TRBC EXON-1 - AGGCAGUAUCUGGAGUCAUUGAGGG 6030 TRAC1-66 TRBC EXON-1 - GGCAGUAUCUGGAGUCAUUGAGGGC 6031 TRAC1-67 TRBC EXON-1 - GUCAUUGAGGGCGGGCUGCUCCUUG 6032 TRAC1-68 TRBC EXON-1 - UCAUUGAGGGCGGGCUGCUCCUUGA 6033 TRAC1-69 TRBC EXON-1 - CAUUGAGGGCGGGCUGCUCCUUGAG 6034 TRAC1-70 TRBC EXON-1 - GGGCGGGCUGCUCCUUGAGGGGCUG 6035 TRAC1-71 TRBC EXON-1 - GGCGGGCUGCUCCUUGAGGGGCUGC 6036 TRAC1-72 TRBC EXON-1 - AUUCACCCACCAGCUCAGCUCCACCG 6037 TRAC1-73 TRBC EXON-1 - ACCCACCAGCUCAGCUCCACGUGGU 6038 TRAC1-74 TRBC EXON-1 - CCCACCAGCUCAGCUCCACGUGGUC 6039 TRAC1-75 TRBC EXON-1 - CCACCAGCUCAGCUCCACGUGGUCG 6040 TRAC1-76 TRBC EXON-1 - UCCACGUGGUCGGGGAAGAAGCCUG 6041 TRAC1-77 TRBC EXON-1 - GUGGUCGGGGAAGAAGCCUGUGGCC 6042 TRAC1-78 TRBC EXON-1 - AAGCCUGUGGCCAGGCACACCAGUG 6043 TRAC1-79 TRBC EXON-1 - GGCCAGGCACACCAGUGUGGCCUUU 6044 TRAC1-80 TRBC EXON-1 - GCCAGGCACACCAGUGUGGCCUUUU 6045 TRAC1-81 TRBC EXON-1 - GCACACCAGUGUGGCCUUUUGGGUG 6046 TRAC1-82 TRBC EXON-1 - CACACCAGUGUGGCCUUUUGGGUGU 6047 TRAC1-83 TRBC EXON-1 - GGGUGUGGGAGAUCUCUGCUUCUGA 6048 TRAC1-84 TRBC EXON-1 - UCUGAUGGCUCAAACACAGCGACCU 6049 TRAC1-85 TRBC EXON-1 - CUGAUGGCUCAAACACAGCGACCUC 6050 TRAC1-86 TRBC EXON-1 - AUGGCUCAAACACAGCGACCUCGGG 6051 TRAC1-87 TRBC EXON-1 - UGGCUCAAACACAGCGACCUCGGGU 6052 TRAC1-88 TRBC EXON-1 - GACCUCGGGUGGGAACACCUUGUUC 6053 TRAC1-89 TRBC EXON-1 - GUGGGAACACCUUGUUCAGGUCCUC 6054 TRAC1-90 TRBC EXON-1 - AACACCUUGUUCAGGUCCUCUGGAA 6055 TRAC1-91 TRBC EXON-1 - ACACCUUGUUCAGGUCCUCUGGAAA 6056 TRAC1-92 TRBC EXON-1 - UGUUCAGGUCCCUGGAAAGGGAAG 6057 TRAC1-93 TRBC EXON-1 - GUUCAGGUCCCUCUGGAAAGGGAAGA 6058 TRAC1-94 TRBC EXON-1 - UUCAGGUCCCUCUGGAAAGGGAAGAG 6059 TRBC1-95 TRBC EXON-2 + UUUCUUUCAGACUGUGGCUUUACCU 6060 TRBC1-96 TRBC EXON-2 + UUCUUUCAGACUGUGGCUUUACCUC 6061 TRAC1-97 TRBC EXON-2 - GUAAAGCCACAGUCUGAAAGAAAGC 6062 TRAC1-98 TRBC EXON-2 - UAAAGCCACAGUCUGAAAGAAAAGCA 6063 TRBC1-99 TRBC EXON-3 + CCGUGCCAACAGUGUCCUACCAGCA 6064 TRBC1-100 TRBC EXON-3 + CGUGCCAACAGGUGUCCUACCAGCAA 6065 TRBC1-101 TRBC EXON-3 + GUGCCAACAGUGUCCUACCAGCAAG 6066 TRBC1-102 TRBC EXON-3 + CCACCAUCCUCUAUGAGAUCCUGCU 6067 TRBC1-103 TRBC EXON-3 + CACCAUCCUCUAUGAGAUCCUGCUA 6068 TRBC1-104 TRBC EXON-3 + AUCCUCUAUGAGAUCCUGCUAGGGA 6069 TRBC1-105 TRBC EXON-3 + GGGAAGGCCACCCUGUAUGCUGUGC 6070 TRBC1-106 TRBC EXON-3 + GUGCUGGUCAAGCGCCCUUGUGUUGA 6071 TRBC1-107 TRBC EXON-3 + GUCAGCGCCCUUGUGUUGAUGGCCA 6072 TRBC1-108 TRBC EXON-3 + CCUUGUGUUGAUGGCCAUGGUAAGC 6073 TRBC1-109 TRBC EXON-3 + UGUGUUGAUGGCCAUGGUAAGCAGG 6074 TRBC1-110 TRBC EXON-3 + GUGUUGAUGGCCAUGGUAAGCAGGA 6075 TRBC1-111 TRBC EXON-3 + UGAUGGCCAUGGUAAGCAGGAGGGC 6076 TRBC1-112 TRBC EXON-3 + GGCCAUGGUAAGCAGGAGGGCAGGA 6077 TRBC1-113 TRBC EXON-3 + GCCAUGGUAAGCAGGAGGGCAGGAU 6078 TRBC1-114 TRBC EXON-3 + CCAUGGUAAGCAGGAGGGCAGGAUG 6079 TRAC1-115 TRBC EXON-3 - CCCCAUCCUGCCCUCCUGCUUACCA 6080 TRAC1-116 TRBC EXON-3 - CCUGCUUACCAUGGCCAUCAACACA 6081 TRAC1-117 TRBC EXON-3 - CUGCUUACCAUGGCCAUCAACACAA 6082 TRAC1-118 TRBC EXON-3 - AAGGGCGCUGACCAGCACAGCAUAC 6083 TRAC1-119 TRBC EXON-3 - AGGGCGCUGACCAGCACAGCAUACA 6084 TRAC1-120 TRBC EXON-3 - GCGCUGACCAGCACAGCAUACAGGG 6085 TRAC1-121 TRBC EXON-3 - AGCAUACAGGGUGGCCUUCCCUAGC 6086 TRAC1-122 TRBC EXON-3 - GGCCUUCCCUAGCAGGAUCUCAUAG 6087 TRAC1-123 TRBC EXON-3 - UUCCCUAGCAGGAUCUCAUAGAGGA 6088 TRAC1-124 TRBC EXON-3 - CCUAGCAGGAUCUCAUAGAGGAUGG 6089 TRAC1-125 TRBC EXON-3 - GAUCUCAUAGAGGAUGGUGGCAGAC 6090 TRAC1-126 TRBC EXON-3 - GAUGGUGGCAGACAGGACCCCUUGC 6091 TRAC1-127 TRBC EXON-3 - GUGGCAGACAGGACCCCUUGCUGGU 6092 TRAC1-128 TRBC EXON-3 - GGACCCCCUUGCUGGUAGGACACUGU 6093 TRAC1-129 TRBC EXON-3 - CCUUGCUGGUAGGACACUGUUGGCA 6094 TRAC1-130 TRBC EXON-3 - UGCUGGUAGGACACUGUUGGCACGG 6095 TRBC1-131 TRBC EXON-4 + GCAGGUCAAGAGAAAGGAUUUCUGA 6096 TRBC1-132 TRBC EXON-4 + GAGAAAGGAUUUCUGAAGGCAGCCC 6097 TRBC2-1 TRBC2 EXON-1 + GACCUGAAAAAACGUGUUCCCACCCCG 6098 TRBC2-2 TRBC2 EXON-1 + GAAGCAGAGAUCUCCCACACCCAAA 6099 TRBC2-3 TRBC2 EXON-1 + AUCUCCCACACCCAAAAGGCCACAC 6100 TRBC2-4 TRBC2 EXON-1 + ACCCAAAAGGCCACACUGGUAUGCC 6101 TRBC2-5 TRBC2 EXON-1 + AGGCCACACUGGUAUGCCUGGCCAC 6102 TRBC2-6 TRBC2 EXON-1 + GCCACAGGCUUCUACCCCGACCACG 6103 TRBC2-7 TRBC2 EXON-1 + CUACCCCGACCACGUGGAGCUGAGC 6104 TRBC2-8 TRBC2 EXON-1 + CCCCGACCACGUGGAGCUGAGCUGG 6105 TRBC2-9 TRBC2 EXON-1 + CCCGACCACGUGGAGCUGAGCUGGU 6106 TRBC2-10 TRBC2 EXON-1 + ACGUGGAGCUGAGCUGGUGGGUGAA 6107 TRBC2-11 TRBC2 EXON-1 + CGUGGAGCUGAGCUGGUGGGUGAAU 6108 TRBC2-12 TRBC2 EXON-1 + GAGCUGAGCUGGUGGGUGAAUGGGA 6109 TRBC2-13 TRBC2 EXON-1 + CUGAGCUGGUGGGUGAAUGGGAAGG 6110 TRBC2-14 TRBC2 EXON-1 + GGGUGAAUGGGAAGGAGGUGCACAG 6111 TRBC2-15 TRBC2 EXON-1 + GGUGAAUGGGAAGGAGGUGCACAGU 6112 TRBC2-16 TRBC2 EXON-1 + GUGAAUGGGAAGGAGGUGCACAGUG 6113 TRBC2-17 TRBC2 EXON-1 + GUCAGCACAGACCCGCAGCCCCUCA 6114 TRBC2-18 TRBC2 EXON-1 + CAGAUACUGCCUGAGCAGCCGCCUG 6115 TRBC2-19 TRBC2 EXON-1 + AGAUACUGCCUGAGCAGCCGCCUGA 6116 TRBC2-20 TRBC2 EXON-1 + UGCCUGAGCAGCCGCCUGAGGGUCU 6117 TRBC2-21 TRBC2 EXON-1 + CCGCCUGAGGGUCUCGGCCACCUUC 6118 TRBC2-22 TRBC2 EXON-1 + ACUUCCGCUGUCAAGUCCAGUUCUA 6119 TRBC2-23 TRBC2 EXON-1 + CUUCCGCUGUCAAGUCCAGUUCUAC 6120 TRBC2-24 TRBC2 EXON-1 + UGUCAAGUCCAGUUCUACGGGCUCU 6121 TRBC2-25 TRBC2 EXON-1 + CUACGGGCUCUCGGAGAAUGACGAG 6122 TRBC2-26 TRBC2 EXON-1 + CUCUCGGAGAAUGACGAGUGGACCCC 6123 TRBC2-27 TRBC2 EXON-1 + GGAGAAUGACGAGUGGACCCAGGAU 6124 TRBC2-28 TRBC2 EXON-1 + GAGAAUGACGAGUGGACCCAGGAUA 6125 TRBC2-29 TRBC2 EXON-1 + CCCGUCACCCAGAUCGUCAGCGCCG 6126 TRBC2-30 TRBC2 EXON-1 + CACCCAGAUCGUCAGCGCCGAGGCC 6127 TRBC2-31 TRBC2 EXON-1 + ACCCAGAUCGUCAGCGCCGAGGCCU 6128 TRBC2-32 TRBC2 EXON-1 + CCCAGAUCGUCAGCGCCGAGGCCUG 6129 TRBC2-33 TRBC2 EXON-1 + UCAGCGCCGAGGCCUGGGGUAGAGGC 6130 TRBC2-34 TRBC2 EXON-1 + CGAGGCCUGGGGUAGAGCAGGUGAG 6131 TRBC2-35 TRBC2 EXON-1 + GAGGCCUGGGGUAGAGCAGGUGAGU 6132 TRBC2-36 TRBC2 EXON-1 + AGGCCUGGGGUAGAGCAGGUGAGUG 6133 TRBC2-37 TRBC2 EXON-1 + UGGGGUAGAGCAGGUGAGUGGGGCC 6134 TRBC2-38 TRBC2 EXON-1 + GGGGUAGAGCAGGUGAGUGGGGCCU 6135 TRBC2-39 TRBC2 EXON-1 + GGGUAGAGCAGGUGAGUGGGGCCUG 6136 TRAC2-40 TRBC2 EXON-1 - AGGCCCCACUCACCUGCUCUACCCC 6137 TRAC2-41 TRBC2 EXON-1 - CACUCACCUGCUCUACCCCAGGCCU 6138 TRAC2-42 TRBC2 EXON-1 - ACCCCAGGCCUCGGCGCUGACGAUC 6139 TRAC2-43 TRBC2 EXON-1 - CCCCAGGCCUCGGCGCUGACGAUCU 6140 TRAC2-44 TRBC2 EXON-1 - GCCUCGGCGCUGACGAUCUGGGUGA 6141 TRAC2-45 TRBC2 EXON-1 - CCUCGGCGCUGACGAUCUGGGUGAC 6142 TRAC2-46 TRBC2 EXON-1 - GCGCUGACGAUCUGGGUGACGGGUU 6143 TRAC2-47 TRBC2 EXON-1 - CUGGGUGACGGGUUUGGCCCUAUCC 6144 TRAC2-48 TRBC2 EXON-1 - UGGGUGACGGGUUUGGCCCUAUCCU 6145 TRAC2-49 TRBC2 EXON-1 - GUCAUUCUCCGAGAGCCCGUAGAAC 6146 TRAC2-50 TRBC2 EXON-1 - GAGCCCGUAGAACUGGACUUGACAG 6147 TRAC2-51 TRBC2 EXON-1 - GUAGAACUGGACUUGACAGCGGAAG 6148 TRAC2-52 TRBC2 EXON-1 - CUGGACUUGACAGCGGAAGUGGUUG 6149 TRAC2-53 TRBC2 EXON-1 - UGGACUUGACAGCGGAAGUGGUUGC 6150 TRAC2-54 TRBC2 EXON-1 - GGACUUGACAGCGGAAGUGGUUGCG 6151 TRAC2-55 TRBC2 EXON-1 - GACUUGACAGCGGAAGUGGUUGCGG 6152 TRAC2-56 TRBC2 EXON-1 - AAGUGGUUGCGGGGGUUCUGCCAGA 6153 TRAC2-57 TRBC2 EXON-1 - UGGUUGCGGGGGUUCUGCCAGAAGG 6154 TRAC2-58 TRBC2 EXON-1 - CUGCCAGAAGGUGGCCGAGACCCUC 6155 TRAC2-59 TRBC2 EXON-1 - CCAGAAGGUGGCCGAGACCCUCAGG 6156 TRAC2-60 TRBC2 EXON-1 - GGCCGAGACCCUCAGGCGGCUGCUC 6157 TRAC2-61 TRBC2 EXON-1 - CUCAGGCGGCUGCUCAGGCAGUAUC 6158 TRAC2-62 TRBC2 EXON-1 - GCUCAGGCAGUAUCUGGAGUCAUUG 6159 TRAC2-63 TRBC2 EXON-1 - CUCAGGCAGUAUCUGGAGUCAUUGA 6160 TRAC2-64 TRBC2 EXON-1 - AGGCAGUAUCUGGAGUCAUUGAGGG 6161 TRAC2-65 TRBC2 EXON-1 - GGCAGUAUCUGGAGUCAUUGAGGGC 6162 TRAC2-66 TRBC2 EXON-1 - GUCAUUGAGGGCGGGCUGCUCCUUG 6163 TRAC2-67 TRBC2 EXON-1 - UCAUUGAGGGCGGGCUGCUCCUUGA 6164 TRAC2-68 TRBC2 EXON-1 - CAUUGAGGGCGGGCUGCUCCUUGAG 6165 TRAC2-69 TRBC2 EXON-1 - GGGCGGGCUGCUCCUUGAGGGGCUG 6166 TRAC2-70 TRBC2 EXON-1 - GGCGGGCUGCUCCUUGAGGGGCUGC 6167 TRAC2-71 TRBC2 EXON-1 - AUUCACCCACCAGCUCAGCUCCACCG 6168 TRAC2-72 TRBC2 EXON-1 - ACCCACCAGCUCAGCUCCACGUGGU 6169 TRAC2-73 TRBC2 EXON-1 - CCCACCAGCUCAGCUCCACGUGGUC 6170 TRAC2-74 TRBC2 EXON-1 - CCACCAGCUCAGCUCCACGUGGUCG 6171 TRAC2-75 TRBC2 EXON-1 - UCCACGUGGUCGGGGUAGAAGCCUG 6172 TRAC2-76 TRBC2 EXON-1 - GUGGUCGGGGUAGAAGCCUGUGGCC 6173 TRAC2-77 TRBC2 EXON-1 - AAGCCUGUGGCCAGGCAUACCAGUG 6174 TRAC2-78 TRBC2 EXON-1 - GGCCAGGCAUACCAGUGUGGCCUUU 6175 TRAC2-79 TRBC2 EXON-1 - GCCAGGCAUACCAGUGUGGCCUUUU 6176 TRAC2-80 TRBC2 EXON-1 - GCAUACCAGUGUGGCCUUUUGGGUG 6177 TRAC2-81 TRBC2 EXON-1 - CAUACCAGUGUGGCCUUUUGGGUGU 6178 TRAC2-82 TRBC2 EXON-1 - GGGUGUGGGAGAUCUCUGCUUCUGA 6179 TRAC2-83 TRBC2 EXON-1 - UCUGAUGGCUCAAACACAGCGACCU 6180 TRAC2-84 TRBC2 EXON-1 - CUGAUGGCUCAAACACAGCGACCUC 6181 TRAC2-85 TRBC2 EXON-1 - AUGGCUCAAACACAGCGACCUCGGG 6182 TRAC2-86 TRBC2 EXON-1 - UGGCUCAAACACAGCGACCUCGGGU 6183 TRAC2-87 TRBC2 EXON-1 - GACCUCGGGUGGGAACACGUUUUUC 6184 TRAC2-88 TRBC2 EXON-1 - GUGGGAACACGUUUUUCAGGUCCUC 6185 TRAC2-89 TRBC2 EXON-1 - AACACGUUUUUCAGGUCCUCUGGAA 6186 TRAC2-90 TRBC2 EXON-1 - ACACGUUUUUCAGGUCCUCUGGAAA 6187 TRAC2-91 TRBC2 EXON-1 - UUUUCAGGUCCCUCUGGAAAGGGAAG 6188 TRAC2-92 TRBC2 EXON-1 - GGUCCCUCUGGAAAGGGAAGAGGUAA 6189 TRAC2-93 TRBC2 EXON-1 - GUCCUCUGGAAAGGGAAGAGGUAAU 6190 TRAC2-94 TRBC2 EXON-1 - UCCUCUGGAAAGGGAAGAGGUAAUG 6191 TRBC2-95 TRBC2 EXON-2 + UUCUUUCAGACUGUGGCUUCACCCUC 6192 TRAC2-96 TRBC2 EXON-2 - GUGAAGCCACAGUCUGAAAGAAAAC 6193 TRAC2-97 TRBC2 EXON-2 - UGAAGCCCAGUCUGAAAGAAAAACA 6194 TRAC2-98 TRBC2 EXON-2 - GAAGCCACAGUCUGAAAGAAAACAG 6195 TRBC2-99 TRBC2 EXON-3 + UCUUGUCAACAGCAGUCUUACCAGCA 6196 TRBC2-100 TRBC2 EXON-3 + CUUGUCAACAGAGUCUUACCAGCAA 6197 TRBC2-101 TRBC2 EXON-3 + UUGUCAACAGCAGUCUUACCAGCAAG 6198 TRBC2-102 TRBC2 EXON-3 + CCACCAUCCUCUAUGAGAUCUUGCU 6199 TRBC2-103 TRBC2 EXON-3 + CACCAUCCUCUAUGAGAUCUUGCUA 6200 TRBC2-104 TRBC2 EXON-3 + AUCCUCUAUGAGAUCUUGCUAGGGA 6201 TRBC2-105 TRBC2 EXON-3 + GGGAAGGCCACCUUGUAUGCCGUGC 6202 TRBC2-106 TRBC2 EXON-3 + GUGCUGGUCAGUGCCCUCGUGCUGA 6203 TRBC2-107 TRBC2 EXON-3 + GUCAGUGCCCUCGUGCUGAUGGCCA 6204 TRBC2-108 TRBC2 EXON-3 + UGCCCUCGUGCUGAUGGCCAUGGUA 6205 TRBC2-109 TRBC2 EXON-3 + CCUCGUGCUGAUGGCCAUGGUAAGG 6206 TRBC2-110 TRBC2 EXON-3 + CGUGCUGAUGGCCAUGGUAAGGAGG 6207 TRBC2-111 TRBC2 EXON-3 + GUGCUGAUGGCCAUGGUAAGGAGGA 6208 TRBC2-112 TRBC2 EXON-3 + CUGAUGGCCAUGGUAAGGAGGAGGG 6209 TRBC2-113 TRBC2 EXON-3 + UGAUGGCCAUGGUAAGGAGGAGGGU 6210 TRBC2-114 TRBC2 EXON-3 + GCCAUGGUAAGGAGGAGGGUGGGAU 6211 TRBC2-115 TRBC2 EXON-3 + CCAUGGUAAGGAGGAGGGUGGGAUA 6212 TRAC2-116 TRBC2 EXON-3 - CCCUAUCCCACCCUCCUCCUUACCCA 6213 TRAC2-117 TRBC2 EXON-3 - CCUCCUUACCAUGGCCAUCAGCACG 6214 TRAC2-118 TRBC2 EXON-3 - CUCCUUACCAUGGCCAUCAGCACGA 6215 TRAC2-119 TRBC2 EXON-3 - AUCAGCACGAGGGCACUGACCAGCA 6216 TRAC2-120 TRBC2 EXON-3 - AGGGCACUGACCAGCACGGCAUACA 6217 TRAC2-121 TRBC2 EXON-3 - GCACUGACCAGCACGGCAUACAAGG 6218 TRAC2-122 TRBC2 EXON-3 - GGCCUUCCCUAGCAAGAUCUCAUAG 6219 TRAC2-123 TRBC2 EXON-3 - UUCCCUAGCAAGAUCUCAUAGAGGA 6220 TRAC2-124 TRBC2 EXON-3 - CCUAGCAAGAUCUCAUAGAGGAUGG 6221 TRAC2-125 TRBC2 EXON-3 - GAUCUCAUAGAGGAUGGUGGCAGAC 6222 TRAC2-126 TRBC2 EXON-3 - GAUGGUGGCAGACAGGACCCCUUGC 6223 TRBC2-127 TRBC2 EXON-4 + UUCUCUCUUCCACAGGUCAAGAGAA 6224 TRBC2-128 TRBC2 EXON-4 + CACAGGUCAAGAGAAAGGAUUCCAG 6225 TRAC2-129 TRBC2 EXON-4 - CUCUGGAAUCCUUUCUCUUGACCUG 6226 CD52-1 CD52 EXON-1 + UUCCUCCUACUCACCAUCAGCCUCC 6227 CD52-2 CD52 EXON-1 + CUACUCACCAUCAGCCUCCUGGUUA 6228 CD52-3 CD52 EXON-1 + ACCAUCAGCCUCCUGGUUAUGGUAC 6229 CD52-4 CD52 EXON-1 + UUAUGGUACAGGUAAGAGCAACGCC 6230 CD52-5 CD52 EXON-1 - CGUUGCUCUUACCUGUACCAUAAACC 6231 CD52-6 CD52 EXON-1 - UGCUCUUACCUGUACCAUAAACCAGG 6232 CD52-7 CD52 EXON-1 - ACCUGUACCAUAAACCAGGAGGCUGA 6233 CD52-8 CD52 EXON-1 - CAUAACCAGGAGGCUGAUGGUGAGU 6234 CD52-9 CD52 EXON-1 - AACCAGGAGGCUGAUGGUGAGUAGG 6235 CD52-10 CD52 EXON-1 - GAGGCUGAUGGUGAGUAGGAGGAAG 6236 CD52-11 CD52 EXON-1 - AGGAGGAAGAGGAAGCGCUUCAUUU 6237 CD52-12 CD52 EXON-1 - GGAAGAGGAAGCGCUUCAUUUUGGU 6238 CD52-13 CD52 EXON-1 - GCGCUUCAUUUUGGUAGGAUCUUCG 6239 CD52-14 CD52 EXON-1 - UUUGGUAGGAUCUUCGUGGCUGUCU 6240 CD52-15 CD52 EXON-1 - GUGGCUGUCUUGGUAGCAGCUUUUU 6241 CD52-16 CD52 EXON-1 - UGGUAGCAGCUUUUUAGGUGAUCUC 6242 CD52-17 CD52 EXON-1 - GGUAGCAGCUUUUUAGGUGAUCUCA 6243 CD52-18 CD52 EXON-1 - CUUUUUAGGUGAUCUCAGGGCUGUC 6244 CD52-19 CD52 EXON-1 - UUUAGGUGAUCUCAGGGCUGUCUGG 6245 CD52-20 CD52 EXON-1 - CUCAGGGCUGUCUGGAGGCUUCUUU 6246 CD52-21 CD52 EXON-1 - CUUUUGGUUUAGCUGCUUUUGAACC 6247 CD52-22 CD52 EXON-1 - UUGGUUUAGCUGCUUUUGAACCAGG 6248 CD52-23 CD52 EXON-1 - UAGCUGCUUUUGAACCAGGAGGCAG 6249 CD52-24 CD52 EXON-1 - CUGCUUUUGAACCAGGAGGCAGAGG 6250 CD52-25 CD52 EXON-1 - CUUUUGAACCAGGAGGCAGAGGAGG 6251 CD52-26 CD52 EXON-2 + CACUUCUCCCUCCUACAGAUACAAAC 6252 CD52-27 CD52 EXON-2 + UCCUACAGAUACAAACUGGACUCUC 6253 CD52-28 CD52 EXON-2 + GCCCCUCAGCAUCCAGCAACAUAAG 6254 CD52-29 CD52 EXON-2 + CCUCAGCAUCCAGCAACAUAAGCGG 6255 CD52-30 CD52 EXON-2 + AGCGGAGGCAUUUUCCUUUUCUUCG 6256 CD52-31 CD52 EXON-2 + UAAUCCACCUCUUCUGCUUCAGUUG 6257 CD52-32 CD52 EXON-2 + CUCGCAAGAGAAUCCCCCCUCCAUCUU 6258 CD52-33 CD52 EXON-2 + UCGCAAGAGAAUCCCCUCCAUCUUU 6259 CD52-34 CD52 EXON-2 + CAAGAGAAUCCCCUCCAUCUUUGGG 6260 CD52-35 CD52 EXON-2 + AAGAGAAUCCCCUCCAUCUUUGGGA 6261 CD52-36 CD52 EXON-2 + AGAGAAUCCCCUCCAUCUUUGGGAG 6262 CD52-37 CD52 EXON-2 + GGAGGGGUUGAUGCCAGACAUCACC 6263 CD52-38 CD52 EXON-2 + ACAUCACCAGGUUGUAGAAGUUGAC 6264 CD52-39 CD52 EXON-2 + UUGUAGAAGUUGACAGGCAGUGCCA 6265 CD52-40 CD52 EXON-2 + UGUAGAAGUUGACAGGCAGUGCCAU 6266 CD52-41 CD52 EXON-2 + GUAGAAGUUGACAGGCAGUGCCAUG 6267 CD52-42 CD52 EXON-2 + UAGAAGUUGACAGGCAGUGCCAUGG 6268 CD52-43 CD52 EXON-2 + GUGCCAUGGGGGCAACAGCCAAAAU 6269 CD52-44 CD52 EXON-2 + UGCCAUGGGGGCAACAGCCAAAAUA 6270 CD52-45 CD52 EXON-2 + GCCAUGGGGGCAACAGCCAAAAUAG 6271 CD52-46 CD52 EXON-2 + CCAUGGGGGCAACAGCCAAAAUAGG 6272 CD52-47 CD52 EXON-2 + CAUGGGGGCAACAGCCAAAAUAGGG 6273 CD52-48 CD52 EXON-2 + AGCCAAAAUAGGGGGGUAAUGAUGU 6274 CD52-49 CD52 EXON-2 + GCCAAAAUAGGGGGGUAAUGAUGUA 6275 CD52-50 CD52 EXON-2 + CCAAAAUAGGGGGGUAAUGAUGUAG 6276 CD52-51 CD52 EXON-2 + AUGUAGGGGCCAAGCAGUGCCCAGC 6277 CD52-52 CD52 EXON-2 + UGUAGGGGCCAAGCAGUGCCCAGCU 6278 CD52-53 CD52 EXON-2 + GUAGGGGCCAAGCAGUGCCCAGCUG 6279 CD52-54 CD52 EXON-2 + UAGGGGCCAAGCAGUGCCCAGCUGG 6280 CD52-55 CD52 EXON-2 + AAUAAAGUUACCCUUGUACUUGCAG 6281 CD52-56 CD52 EXON-2 + AUAAAGUUACCCUUGUACUUGCAGU 6282 CD52-57 CD52 EXON-2 + UAAAGUUACCCUUGUACUUGCAGUG 6283 CD52-58 CD52 EXON-2 + UGUACUUGCAGUGGGGUCCUGCUUG 6284 CD52-59 CD52 EXON-2 + GCAGUGGGGUCCUGCUUGUGGUUAC 6285 CD52-60 CD52 EXON-2 - GUAGGGAUGUCCAGUAACCACAAGC 6286 CD52-61 CD52 EXON-2 - CAAGCAGGACCCCCACUGCAAGUACA 6287 CD52-62 CD52 EXON-2 - AAGCAGGACCCCCACUGCAAGUACAA 6288 CD52-63 CD52 EXON-2 - AAGGGUAACUUUAUUGACCCCCAGC 6289 CD52-64 CD52 EXON-2 - AGGGUAACUUUAUUGACCCCCCAGCU 6290 CD52-65 CD52 EXON-2 - UAUUGACCCCAGCUGGGCACUGCU 6291 CD52-66 CD52 EXON-2 - CCCCUACAUCAUUACCCCCCUAUUU 6292 CD52-67 CD52 EXON-2 - CCCCCUAUUUUGGCUGUUGCCCCCA 6293 CD52-68 CD52 EXON-2 - GCACUGCCUGUCAACUUCUACAAC 6294 CD52-69 CD52 EXON-2 - UCAACUUCUACAACCUGGUGAUGUC 6295 CD52-70 CD52 EXON-2 - GUCUGGCAUCAACCCCUCCCAAAGA 6296 CD52-71 CD52 EXON-2 - UGGCAUCAACCCCUCCCAAAAGAUGG 6297 CD52-72 CD52 EXON-2 - GGCAUCAACCCCUCCCAAAAGAUGGA 6298 CD52-73 CD52 EXON-2 - GCAUCAACCCCUCCCAAAGAUGGAG 6299 CD52-74 CD52 EXON-2 - AUGGAGGGGAUUCUCUUGCGAGUGA 6300 CD52-75 CD52 EXON-2 - GAGGGGAUUCUCUUGCGAGUGAUGG 6301 CD52-76 CD52 EXON-2 - UGCGAGUGAUGGUGGCAGCUGUUUC 6302 CD52-77 CD52 EXON-2 - GCGAGUGAUGGUGGCAGCUGUUUCA 6303 CD52-78 CD52 EXON-2 - CGAGUGAUGGUGGCAGCUGUUUCAG 6304 CD52-79 CD52 EXON-2 - GAGUGAUGGUGGCAGCUGUUUCAGG 6305 CD52-80 CD52 EXON-2 - UGGUGGCAGCUGUUUCAGGGGGCAC 6306 CD52-81 CD52 EXON-2 - GGUGGCAGCUGUUUCAGGGGGCACA 6307 CD52-82 CD52 EXON-2 - AGCUGUUUCAGGGGGCACAGGGCUA 6308 CD52-83 CD52 EXON-2 - CGUGUCACCUCAACUGAAGCAGAAG 6309 CD52-84 CD52 EXON-2 - GUCACCUCAACUGAAGCAGAAGAGG 6310 CD52-85 CD52 EXON-2 - CAACUGAAGCAGAAGAGGUGGAUUA 6311 CD52-86 CD52 EXON-2 - AAGCAGAAGAGGUGGAUUAUGGCAU 6312 CD52-87 CD52 EXON-2 - GAUUAUGGCAUUGGCCACGAAGAAA 6313 CD52-88 CD52 EXON-2 - AGGAAAAUGCCUCCGCUUAUGUUGC 6314 CD52-89 CD52 EXON-2 - CCUCCGCUUAUGUUGCUGGAUGCUG 6315 CD52-90 CD52 EXON-2 - CUCCGCUUAUGUUGCUGGAUGCUGA 6316 CD52-91 CD52 EXON-2 - UCCGCUUAUGUUGCUGGAUGCUGAG 6317 CD52-92 CD52 EXON-2 - AUGUUGCUGGAUGCUGAGGGGCUGC 6318 CD52-93 CD52 EXON-2 - GCUGGAUGCUGAGGGGCUGCUGGUU 6319 CD52-94 CD52 EXON-2 - GAUGCUGAGGGGCUGCUGGUUUGGC 6320 CD52-95 CD52 EXON-2 - UCCUGAGAGUCCCAGUUUGUAUCUGU 6321 CD52-96 CD52 EXON-2 - UGAGAGUCCCAGUUUGUAUCUGUAGG 6322 CD52-97 CD52 EXON-2 - CAGUUUGUAUCUGUAGGAGGAGAAG 6323 CD52-98 CD52 EXON-2 - AGUUUGUAUCUGUAGGAGGAGAGU 6324 FKBP1A-1 FKBP1A EXON-1 + CGCGCGCCGUGUGGGGCGCGCACGC 6325 FKBP1A-2 FKBP1A EXON-1 + GCGCGCCGUGUGGGGCGCGCACCGCA 6326 FKBP1A-3 FKBP1A EXON-1 + GCCGUGUGGGGCGCGCACGCAGGGC 6327 FKBP1A-4 FKBP1A EXON-1 + CCGUGUGGGGCGCGCACGCAGGGCU 6328 FKBP1A-5 FKBP1A EXON-1 + GGGCGCGCACGCAGGGCUGGGCGUG 6329 FKBP1A-6 FKBP1A EXON-1 + GGCGCGCACGCAGGGCUGGGCGUGA 6330 FKBP1A-7 FKBP1A EXON-1 + GCGCGCACGCAGGGCUGGGCGUGAG 6331 FKBP1A-8 FKBP1A EXON-1 + CGCGCACGCAGGGCUGGGCGUGAGG 6332 FKBP1A-9 FKBP1A EXON-1 + GGCGUGAGGGGGCGUGCGCGUGCGC 6333 FKBP1A-10 FKBP1A EXON-1 + GUGCGCGUGCGCAGGCGACGCGCCG 6334 FKBP1A-11 FKBP1A EXON-1 + UGCGCAGGCGACGCGCCGAGGUACU 6335 FKBP1A-12 FKBP1A EXON-1 + CGCGCCGAGGUACUAGGCAGAGCCG 6336 FKBP1A-13 FKBP1A EXON-1 + UAGGCAGAGCCGUGGAACCGCCGCC 6337 FKBP1A-14 FKBP1A EXON-1 + CGUGGAACCGCCGCCAGGUCGCUGU 6338 FKBP1A-15 FKBP1A EXON-1 + GCCCGCUCAGCGUCCGCCGCCGCCA 6339 FKBP1A-16 FKBP1A EXON-1 + CCCGCUCAGCGUCCGCCGCCGCCAU 6340 FKBP1A-17 FKBP1A EXON-1 + GCGUCCGCCGCCGCCAUGGGAGUGC 6341 FKBP1A-18 FKBP1A EXON-1 + UCCGCCGCCGCCAUGGGAGUGCAGG 6342 FKBP1A-19 FKBP1A EXON-1 + GAGUGCAGGUGGAAACCAUCUCCCC 6343 FKBP1A-20 FKBP1A EXON-1 + AGGUGGAAACCAUCUCCCCAGGAGA 6344 FKBP1A-21 FKBP1A EXON-1 + CAUCUCCCCAGGAGACGGUGAGUAG 6345 FKBP1A-22 FKBP1A EXON-1 + CCAGGAGACGGUGAGUAGUGGCGCG 6346 FKBP1A-23 FKBP1A EXON-1 + GGAGACGGUGAGUAGUGGCGCGCGG 6347 FKBP1A-24 FKBP1A EXON-1 - CCGCGCGCCACUACUCACCGUCUCC 6348 FKBP1A-25 FKBP1A EXON-1 - CGCGCGCCACUACUCACCGUCUCCU 6349 FKBP1A-26 FKBP1A EXON-1 - GCGCGCCACUACUCACCGUCUCCUG 6350 FKBP1A-27 FKBP1A EXON-1 - CACUACUCACCGUCUCCUGGGGAGA 6351 FKBP1A-28 FKBP1A EXON-1 - GAGAUGGUUUCCACCCUGCACUCCCA 6352 FKBP1A-29 FKBP1A EXON-1 - AUGGUUUCCACCUGCACUCCCAUGG 6353 FKBP1A-30 FKBP1A EXON-1 - GUUUCCACCCUGCACUCCCAUGGCGG 6354 FKBP1A-31 FKBP1A EXON-1 - UCCACCUGCACUCCCAUGGCGGCGG 6355 FKBP1A-32 FKBP1A EXON-1 - UCCCAUGGCGGCGGCGGACGCUGAG 6356 FKBP1A-33 FKBP1A EXON-1 - CCCAUGGCGGCGGCGGACGCUGAGC 6357 FKBP1A-34 FKBP1A EXON-1 - AUGGCGGCGGCGGACGCUGAGCGGG 6358 FKBP1A-35 FKBP1A EXON-1 - UGGCGGCGGCGGACGCUGAGCGGGC 6359 FKBP1A-36 FKBP1A EXON-1 - CGGCGGCGGACGCUGAGCGGGCGGG 6360 FKBP1A-37 FKBP1A EXON-1 - GACGCUGAGCGGGCGGGCGGCGCGA 6361 FKBP1A-38 FKBP1A EXON-1 - ACGCUGAGCGGGCGGGCGGCGCGAC 6362 FKBP1A-39 FKBP1A EXON-1 - CUGAGCGGGCGGGCGGCGCGACGGG 6363 FKBP1A-40 FKBP1A EXON-1 - CGGGCGGGCGGCGCGACGGGCGGCG 6364 FKBP1A-41 FKBP1A EXON-1 - CGGGCGGCGUGGACCAACAGCGACC 6365 FKBP1A-42 FKBP1A EXON-1 - GCGGCGUGGACCAACAGCGACCUGG 6366 FKBP1A-43 FKBP1A EXON-1 - GCGUGGACCAACAAGCGACCUGGCGG 6367 FKBP1A-44 FKBP1A EXON-1 - CAACAGCGACCUGGCGGCGGUUCCA 6368 FKBP1A-45 FKBP1A EXON-1 - GGUUCCACGGCUCUGCCUAGUACCU 6369 FKBP1A-46 FKBP1A EXON-1 - CCCAGCCCUGCGUGCGCGCCCCACA 6370 FKBP1A-47 FKBP1A EXON-2 + CCUCAGGGCGCACCUUCCCCAAGCG 6371 FKBP1A-48 FKBP1A EXON-2 + UUCCCCAAGCGCGGCCAGACCUGCG 6372 FKBP1A-49 FKBP1A EXON-2 + GCCAGACCUGCGUGGUGCACUACAC 6373 FKBP1A-50 FKBP1A EXON-2 + UGCGUGGUGCACUACACCGGUGAGU 6374 FKBP1A-51 FKBP1A EXON-2 + GCGUGGUGCACUACACCGGUGAGUC 6375 FKBP1A-52 FKBP1A EXON-2 + CGUGGUGCACUACACCGGUGAGUCG 6376 FKBP1A-53 FKBP1A EXON-2 + GUGGUGCACUACACCGGUGAGUCGG 6377 FKBP1A-54 FKBP1A EXON-2 + CUACACCGGUGAGUCGGGGGCCCAG 6378 FKBP1A-55 FKBP1A EXON-2 + UACACCGGUGAGUCGGGGGCCCAGGC 6379 FKBP1A-56 FKBP1A EXON-2 + ACACCGGUGAGUCGGGGGCCCAGCG 6380 FKBP1A-57 FKBP1A EXON-2 + CCGGUGAGUCGGGGGCCCAGCGGGG 6381 FKBP1A-58 FKBP1A EXON-2 - GACUCACCGGUGUAGUGCACCACGC 6382 FKBP1A-59 FKBP1A EXON-2 - ACCGGUGUAGUGCACCACGCAGGUC 6383 FKBP1A-60 FKBP1A EXON-2 - UGCACCCACGCAGGUCUGGCCGCGCU 6384 FKBP1A-61 FKBP1A EXON-2 - GCACCACGCAGGUCUGGCCGCGCUU 6385 FKBP1A-62 FKBP1A EXON-2 - CACCACGCAGGUCUGGCCGCGCUUG 6386 FKBP1A-63 FKBP1A EXON-2 - ACGCAGGUCUGGCCGCGCUUGGGGA 6387 FKBP1A-64 FKBP1A EXON-2 - CCGCGCUUGGGGAAGGUGCCGCCCUG 6388 FKBP1A-65 FKBP1A EXON-2 - AAGGUGCCGCCCUGAGGAGACAGAGA 6389 FKBP1A-66 FKBP1A EXON-2 - AGGUGCCGCCCUGAGGAGACAGAGAC 6390 FKBP1A-67 FKBP1A EXON-3 + UCUUUUUCACAGGGAUGCUUGAAGA 6391 FKBP1A-68 FKBP1A EXON-3 + AGAUGGAAAGAAAUUUGAUUCCUCC 6392 FKBP1A-69 FKBP1A EXON-3 + GAUGGAAAGAAAUUUGAUUCCUCCCC 6393 FKBP1A-70 FKBP1A EXON-3 + GAAACAAGCCCUUUAAGUUUAUGCU 6394 FKBP1A-71 FKBP1A EXON-3 + CCCUUUAAGUUUAUGCUAGGCAAGC 6395 FKBP1A-72 FKBP1A EXON-3 + UUUAAGUUUAUGCUAGGCAAGCAGG 6396 FKBP1A-73 FKBP1A EXON-3 + UGCUAGGCAAGCAGGAGGUGAUCCG 6397 FKBP1A-74 FKBP1A EXON-3 + AGGCAAGCAGGAGGUGAUCCGAGGC 6398 FKBP1A-75 FKBP1A EXON-3 + GGCAAGCAGGAGGUGAUCCGAGGCU 6399 FKBP1A-76 FKBP1A EXON-3 + AGGAGGUGAUCCGAGGCUGGGAAGA 6400 FKBP1A-77 FKBP1A EXON-3 + GGAGGUGAUCCGAGGCUGGGAAGAA 6401 FKBP1A-78 FKBP1A EXON-3 + GAGGUGAUCCGAGGCUGGGAAGAAG 6402 FKBP1A-79 FKBP1A EXON-3 + CGAGGCUGGGAAGAAGGGGUUGCCC 6403 FKBP1A-80 FKBP1A EXON-3 - AACAAAACAAAUGAGAGAGCAUACC 6404 FKBP1A-81 FKBP1A EXON-3 - ACAAAACAAAUGAGAGAGCAUACCU 6405 FKBP1A-82 FKBP1A EXON-3 - CUGGGCAACCCCUUCUUCCCAGCCU 6406 FKBP1A-83 FKBP1A EXON-3 - UCCUGCUUGCCUAGCAUAAACUUAA 6407 FKBP1A-84 FKBP1A EXON-3 - CCUGCUUGCCUAGCAUAAACUUAAA 6408 FKBP1A-85 FKBP1A EXON-3 - AAACUUAAAAGGGCUUGUUUCUGUCC 6409 FKBP1A-86 FKBP1A EXON-3 - AACUUAAAGGGCUUGUUUCUGUCCC 6410 FKBP1A-87 FKBP1A EXON-3 - UUAAAGGGCUUGUUUCUGUCCCGGG 6411 FKBP1A-88 FKBP1A EXON-4 + UCCUUGUUCUUUUCACAGAUGAGUG 6412 FKBP1A-89 FKBP1A EXON-4 + CCUUGUUCUUUUCACAGAUGAGUGU 6413 FKBP1A-90 FKBP1A EXON-4 + UGACUAUAUCUCCAGAUUAUGCCUA 6414 FKBP1A-91 FKBP1A EXON-4 + CUCCAGAUUAUGCCUAUGGUGCCAC 6415 FKBP1A-92 FKBP1A EXON-4 + UCCAGAUUAUGCCUAUGGUGCCACU 6416 FKBP1A-93 FKBP1A EXON-4 + AUGCCUAUGGUGCCACUGGGCACCC 6417 FKBP1A-94 FKBP1A EXON-4 + CCACAUGCCCACUCUCGUCUUCGAUG 6418 FKBP1A-95 FKBP1A EXON-4 + GUCUUCGAUGUGGAGCUUCUAAAAC 6419 FKBP1A-96 FKBP1A EXON-4 + GUGGAGCUUCUAAAAACUGGAAUGAC 6420 FKBP1A-97 FKBP1A EXON-4 + GCUUCUAAAAACUGGAAUGACAGGAA 6421 FKBP1A-98 FKBP1A EXON-4 + GCCUCCUCCCUUAGCUCCCUGUUCU 6422 FKBP1A-99 FKBP1A EXON-4 + CCUCCUCCCUUAGCUCCCUGUUCUU 6423 FKBP1A-100 FKBP1A EXON-4 + UCCCUUAGCUCCCUGUUCUUGGGUA 6424 FKBP1A-101 FKBP1A EXON-4 + AGCUCCCUGUUCUUGGGUAAGGAAA 6425 FKBP1A-102 FKBP1A EXON-4 + CUUGGGUAAGGAAAUGGAAUACUGA 6426 FKBP1A-103 FKBP1A EXON-4 + UUGGGUAAGGAAAUGGAAUACUGAA 6427 FKBP1A-104 FKBP1A EXON-4 - GUAUUCCAUUUCCUUACCCAAAGAAC 6428 FKBP1A-105 FKBP1A EXON-4 - UAUUCCAUUCCUUACCCAAGAACA 6429 FKBP1A-106 FKBP1A EXON-4 - UUCCUUACCCAAAGAACAGGGAGCUA 6430 FKBP1A-107 FKBP1A EXON-4 - UCCUUACCCAAAGAACAGGGAGCUAA 6431 FKBP1A-108 FKBP1A EXON-4 - UUACCCAAAGAACAGGGAGCUAAGGG 6432 FKBP1A-109 FKBP1A EXON-4 - CCCAAGAACAGGGAGCUAAGGGAGG 6433 FKBP1A-110 FKBP1A EXON-4 - AGAAGCUCCACAUCGAAGACGAGAG 6434 FKBP1A-111 FKBP1A EXON-4 - CCACAUCGAAGACGAGAGUGGCAUG 6435 FKBP1A-112 FKBP1A EXON-4 - CAUCGAAGACGAGAGUGGCAUGUGG 6436 FKBP1A-113 FKBP1A EXON-4 - AUCGAAGACGAGAGUGGCAUGUGGU 6437 FKBP1A-114 FKBP1A EXON-4 - GAGUGGCAUGUGGUGGGAUGAUGCC 6438 FKBP1A-115 FKBP1A EXON-4 - AGUGGCAUGUGGUGGGAUGAUGCCU 6439 FKBP1A-116 FKBP1A EXON-4 - GGUGGGAUGAUGCCUGGGUGCCCAG 6440 FKBP1A-117 FKBP1A EXON-4 - AUGCCUGGGUGCCCAGUGGCACCAU 6441 FKBP1A-118 FKBP1A EXON-4 - GCCCAGUGGCACCAAUAGGCAUAAUC 6442 FKBP1A-119 FKBP1A EXON-4 - GCAUAAUCUGGAGAUAUAGUCAGUU 6443 FKBP1A-120 FKBP1A EXON-4 - CCCACACUCAUCUGUGAAAAGAACA 6444 FKBP1A-121 FKBP1A EXON-5 + UUUUCUGUCCCCCAACAGAUCUGCCA 6445 FKBP1A-122 FKBP1A EXON-5 + UCUGUCCCCCAACAGAUCUGCCAUGG 6446 FKBP1A-123 FKBP1A EXON-5 + CUGUCCCCCAACAGAUCUGCCAUGGA 6447 FKBP1A-124 FKBP1A EXON-5 + CCAACAGAUCUGCCAUGGAGGGAUC 6448 FKBP1A-125 FKBP1A EXON-5 + CCAGACAUGUGCACAUGAAUCCAUA 6449 FKBP1A-126 FKBP1A EXON-5 + UAUUCAUUUUAUUUUGUUUUCAUUU 6450 FKBP1A-127 FKBP1A EXON-5 + AUUCAUUUUAUUUUGUUUUCAUUUU 6451 FKBP1A-128 FKBP1A EXON-5 + UUCAUUUUAUUUUGUUUUCAUUUUG 6452 FKBP1A-129 FKBP1A EXON-5 + GGGUGAAGAUUCAGUUUCAGUCUUU 6453 FKBP1A-130 FKBP1A EXON-5 + GAUUCAGUUUCAGUCUUUUGGAUAU 6454 FKBP1A-131 FKBP1A EXON-5 + GGAUAUAGGUUUCCAAUUAAGUACA 6455 FKBP1A-132 FKBP1A EXON-5 + CAUGGUCAAGUAUUAACAGCACAAG 6456 FKBP1A-133 FKBP1A EXON-5 + GUCAAGUAUUAACAGCACAAGGUGGU 6457 FKBP1A-134 FKBP1A EXON-5 + ACAAGUGGUAGGUUAACAUUAGAAU 6458 FKBP1A-135 FKBP1A EXON-5 + GGUAGGUUAACAUUAGAAUAGGAAU 6459 FKBP1A-136 FKBP1A EXON-5 + UUAACAUUAGAAUAGGAAUUGGUGU 6460 FKBP1A-137 FKBP1A EXON-5 + UAACAUUAGAAUAGGAAUUGGUGUU 6461 FKBP1A-138 FKBP1A EXON-5 + AACAUUAGAAUAGGAAUUGGUGUUG 6462 FKBP1A-139 FKBP1A EXON-5 + ACAUUAGAAUAGGAAUUGGUGUUGG 6463 FKBP1A-140 FKBP1A EXON-5 + CAUUAGAAUAGGAAUUGGUGUUGGG 6464 FKBP1A-141 FKBP1A EXON-5 + AUUAGAAUAGGAAUUGGUGUUGGGG 6465 FKBP1A-142 FKBP1A EXON-5 + UUAGAAUAGGAAUUGGUGUUGGGGG 6466 FKBP1A-143 FKBP1A EXON-5 + UAGAAUAGGAAUUGGUGUUGGGGGG 6467 FKBP1A-144 FKBP1A EXON-5 + AGAAUAGGAAUUGGUGUUGGGGGGG 6468 FKBP1A-145 FKBP1A EXON-5 + GCAAGAAUAUUUUAUUUUAAUUUUU 6469 FKBP1A-146 FKBP1A EXON-5 + GCGCUGCAAAGCCAUAGCAGAUUUG 6470 FKBP1A-147 FKBP1A EXON-5 + CCAUAGCAGAUUUGAGGCGCUGUUG 6471 FKBP1A-148 FKBP1A EXON-5 + UACUCUCCAAGUUGAGAGAUGUCUU 6472 FKBP1A-149 FKBP1A EXON-5 + ACUCUCCAAGUUGAGAGAUGUCUUU 6473 FKBP1A-150 FKBP1A EXON-5 + AAAUUAAAAGCCCUACCUAAAACUG 6474 FKBP1A-151 FKBP1A EXON-5 + UUAAAAGCCCUACCUAAAACUGAGG 6475 FKBP1A-152 FKBP1A EXON-5 + UAAAAGCCCUACCUAAAACUGAGGU 6476 FKBP1A-153 FKBP1A EXON-5 + AAAAGCCCUACCUAAAACUGAGGUG 6477 FKBP1A-154 FKBP1A EXON-5 + GCCCUACCUAAAACUGAGGUGGGGA 6478 FKBP1A-155 FKBP1A EXON-5 + CCCUACCUAAAACUGAGGUGGGGAU 6479 FKBP1A-156 FKBP1A EXON-5 + CCUACCUAAAACUGAGGUGGGGAUG 6480 FKBP1A-157 FKBP1A EXON-5 + AAGUAGAUCAUGUUCACUGCAAUGC 6481 FKBP1A-158 FKBP1A EXON-5 + UGUUCACUGCAAUGCUGGACACUAC 6482 FKBP1A-159 FKBP1A EXON-5 + GCUGGACACUACAGGUAUCUGUCCC 6483 FKBP1A-160 FKBP1A EXON-5 + CUGGACACUACAGGUAUCUGUCCCU 6484 FKBP1A-161 FKBP1A EXON-5 + UACAGGUAUCUGUCCCUGGGCCAGC 6485 FKBP1A-162 FKBP1A EXON-5 + ACAGGUAUCUGUCCCUGGGCCAGCA 6486 FKBP1A-163 FKBP1A EXON-5 + GCAGGGACCUCUGAAGCCUUCUUUG 6487 FKBP1A-164 FKBP1A EXON-5 + GUGGCCUUUUUUUUUUUUCAUCCUG 6488 FKBP1A-165 FKBP1A EXON-5 + UUUUUUCAUCCUGUGGUUUUUCUAA 6489 FKBP1A-166 FKBP1A EXON-5 + CCUGUGGUUUUUCUAAUGGACUUUC 6490 FKBP1A-167 FKBP1A EXON-5 + AACUUUAAUUGACAGUUUCAAUUGA 6491 FKBP1A-168 FKBP1A EXON-5 + GAAUGUUCUCUUAAGAAAAAUGAUGC 6492 FKBP1A-169 FKBP1A EXON-5 + UCAGCAUCUCCUGUUUUUUGAUGCU 6493 FKBP1A-170 FKBP1A EXON-5 + GCUCCCUCUGCUGAUCUCAGUUUCC 6494 FKBP1A-171 FKBP1A EXON-5 + CCCUUUGCUGUCCUGUGUAGUGAUU 6495 FKBP1A-172 FKBP1A EXON-5 + UUAUUGCAAUAAAAGUGCUUUAUGC 6496 FKBP1A-173 FKBP1A EXON-5 + GCCGGCUUUUCUCAGCUCUGUGUCA 6497 FKBP1A-174 FKBP1A EXON-5 + GGCUUUUCUCAGCUCUGUGUGUCAUGG 6498 FKBP1A-175 FKBP1A EXON-5 + GCUCUGUGUCAUGGUGGUUAUUUUC 6499 FKBP1A-176 FKBP1A EXON-5 + AUUUUCAGGUGCCUCCCCUGCCAUU 6500 FKBP1A-177 FKBP1A EXON-5 - ACCAUGACACAGAAGCUGAGAAAAGC 6501 FKBP1A-178 FKBP1A EXON-5 - AAUAAUAAAACUUGAGACUCAUAAA 6502 FKBP1A-179 FKBP1A EXON-5 - AAAACUUGAGACUCAUAAAAUGGUGC 6503 FKBP1A-180 FKBP1A EXON-5 - AAACUUGAGACUCAAUAAAUGGUGCU 6504 FKBP1A-181 FKBP1A EXON-5 - AACUUGAGACUCAAUAAAUGGUGCUG 6505 FKBP1A-182 FKBP1A EXON-5 - ACUUGAGACUCAAUAAAUGGUGCUGG 6506 FKBP1A-183 FKBP1A EXON-5 - GAGACUCAUAAAUGGUGCUGGGGGA 6507 FKBP1A-184 FKBP1A EXON-5 - AGACUCAUAAAUGGUGCUGGGGGAA 6508 FKBP1A-185 FKBP1A EXON-5 - ACGAUUUCUCACCAAAAUCACUACAC 6509 FKBP1A-186 FKBP1A EXON-5 - ACCAAAUCACUACACAGGACAGCAA 6510 FKBP1A-187 FKBP1A EXON-5 - CCAAAUCACUACACAGGACAGCAAA 6511 FKBP1A-188 FKBP1A EXON-5 - CAAAUCACUACACAGGACAGCAAAG 6512 FKBP1A-189 FKBP1A EXON-5 - UACACAGGACAGCAAAGGGGUGAGA 6513 FKBP1A-190 FKBP1A EXON-5 - ACACAGGACAGCAAAGGGGUGAGAA 6514 FKBP1A-191 FKBP1A EXON-5 - CACAGGACAGCAAAGGGGUGAGAAG 6515 FKBP1A-192 FKBP1A EXON-5 - ACAGCAAAGGGGUGAGAAGGGGCUG 6516 FKBP1A-193 FKBP1A EXON-5 - CAGCAAAGGGGUGAGAAGGGGCUGA 6517 FKBP1A-194 FKBP1A EXON-5 - CAAAGGGGUGAGAAGGGGCUGAGGG 6518 FKBP1A-195 FKBP1A EXON-5 - AGAAGGGGCUGAGGGAGGAAAAGCC 6519 FKBP1A-196 FKBP1A EXON-5 - AAAGCCAGGAAACUGAGAUCAGCAG 6520 FKBP1A-197 FKBP1A EXON-5 - AAGCCAGGAAACUGAGAUCAGCAGA 6521 FKBP1A-198 FKBP1A EXON-5 - CAGAGGGAGCCAAGCAUCAAAAAAAC 6522 FKBP1A-199 FKBP1A EXON-5 - CAUCAUUUUCUUAAGAGAACAUUCA 6523 FKBP1A-200 FKBP1A EXON-5 - GAGAACAUUCAAGGAUUUGUCAUGA 6524 FKBP1A-201 FKBP1A EXON-5 - ACAUUCAAGGAUUUGUCAUGAUGGC 6525 FKBP1A-202 FKBP1A EXON-5 - CAUUCAAGGAUUUGUCAUGAUGGCU 6526 FKBP1A-203 FKBP1A EXON-5 - UUUGUCAUGAUGGCUGGGCUUUCAC 6527 FKBP1A-204 FKBP1A EXON-5 - UUGUCAUGAUGGCUGGGCUUUCACU 6528 FKBP1A-205 FKBP1A EXON-5 - CUGUCAAUUAAAGUUCUUAAGAUUU 6529 FKBP1A-206 FKBP1A EXON-5 - AUUAAAGUUCUUAAGAUUUAGGAAG 6530 FKBP1A-207 FKBP1A EXON-5 - AAAGUUCUUAAGAUUUAGGAAGUGG 6531 FKBP1A-208 FKBP1A EXON-5 - UUAAGAUUUAGGAAGUGGUGGAGCU 6532 FKBP1A-209 FKBP1A EXON-5 - CCUGAAAGUCCAUUAGAAAAACCAC 6533 FKBP1A-210 FKBP1A EXON-5 - AAAACCACAGGAUGAAAAAAAAAAA 6534 FKBP1A-211 FKBP1A EXON-5 - UGAAAAAAAAAAAAGGCCACAAAGA 6535 FKBP1A-212 FKBP1A EXON-5 - AAAAAGGCCACAAAGAAGGCUUCAG 6536 FKBP1A-213 FKBP1A EXON-5 - CAAAGAAGGCUUCAGAGGUCCCUGC 6537 FKBP1A-214 FKBP1A EXON-5 - AGGCUUCAGAGGUCCCUGCUGGCCC 6538 FKBP1A-215 FKBP1A EXON-5 - GGCUUCAGAGGUCCCUGCUGGCCCA 6539 FKBP1A-216 FKBP1A EXON-5 - UGCAGUGAACAUGAUCUACUUUCAA 6540 FKBP1A-217 FKBP1A EXON-5 - GAACAUGAUCUACUUUCAAAGGCAG 6541 FKBP1A-218 FKBP1A EXON-5 - AACAUGAUCUACUUUCAAAGGCAGA 6542 FKBP1A-219 FKBP1A EXON-5 - UCUACUUUCAAAGGCAGAGGGUUUA 6543 FKBP1A-220 FKBP1A EXON-5 - CUACUUUCAAAGGCAGAGGGUUUAA 6544 FKBP1A-221 FKBP1A EXON-5 - UACUUUCAAAGGCAGAGGGUUUAAG 6545 FKBP1A-222 FKBP1A EXON-5 - UUUCAAAGGCAGAGGGUUUAAGGGG 6546 FKBP1A-223 FKBP1A EXON-5 - UUCAAAGGCAGAGGGUUUAAGGGGA 6547 FKBP1A-224 FKBP1A EXON-5 - AAAGGCAGAGGGUUUAAGGGGAGGG 6548 FKBP1A-225 FKBP1A EXON-5 - AAGGCAGAGGGUUUAAGGGGAGGGU 6549 FKBP1A-226 FKBP1A EXON-5 - GCAGAGGGUUUAAGGGGAGGGUGGG 6550 FKBP1A-227 FKBP1A EXON-5 - CAGAGGGUUUAAGGGGAGGGUGGGU 6551 FKBP1A-228 FKBP1A EXON-5 - GGUUUAAGGGGAGGGUGGGUGGGAA 6552 FKBP1A-229 FKBP1A EXON-5 - UUAAGGGGAGGGUGGGUGGGAAUGG 6553 FKBP1A-230 FKBP1A EXON-5 - AGGGGAGGGUGGGUGGGAAUGGUGG 6554 FKBP1A-231 FKBP1A EXON-5 - GGGUGGGUGGGAAUGGUGGAGGCAA 6555 FKBP1A-232 FKBP1A EXON-5 - CUCUCCCCAUCCCCACCUCAGUUUU 6556 FKBP1A-233 FKBP1A EXON-5 - CCCCAUCCCCACCUCAGUUUUAGGU 6557 FKBP1A-234 FKBP1A EXON-5 - CCCAUCCCCACCUCAGUUUUAGGUA 6558 FKBP1A-235 FKBP1A EXON-5 - UUUAACCCAAAGACAUCUCUCAACCU 6559 FKBP1A-236 FKBP1A EXON-5 - CCUCAACAGCGCCUCAAAUCUGCUA 6560 FKBP1A-237 FKBP1A EXON-5 - GUUAAUACUUGACCAUGUACUUAAU 6561 FKBP1A-238 FKBP1A EXON-5 - AAAACAAAAUAAAAUGAAUAACUUG 6562 FKBP1A-239 FKBP1A EXON-5 - AAUAAAAUGAAUAACUUGAGGUUUA 6563 FKBP1A-240 FKBP1A EXON-5 - ACUUGAGGUUUAUGGCAUAUAGUUU 6564 FKBP1A-241 FKBP1A EXON-5 - UAUAGUUUAGGUAAACACACAUACG 6565 FKBP1A-242 FKBP1A EXON-5 - UAGGUAAACACACAUACGAGGAGAA 6566 FKBP1A-243 FKBP1A EXON-5 - AGGUAAACACACAUACGAGAGAAA 6567 FKBP1A-244 FKBP1A EXON-5 - GGUAAACACACAUACGAGGAGAAAG 6568 FKBP1A-245 FKBP1A EXON-5 - CACACAUACGAGGAGAAAGGGGAAG 6569 FKBP1A-246 FKBP1A EXON-5 - GAGGAGAAAGGGGAAGAGGAAACAG 6570 FKBP1A-247 FKBP1A EXON-5 - AAAGGGGAAGAGGAAAACAGAGGUGU 6571 FKBP1A-248 FKBP1A EXON-5 - GCUGAGUGACAGAACACAUUCAGUC 6572 FKBP1A-249 FKBP1A EXON-5 - CUGAGUGACAGAACACAUUCAGUCA 6573 FKBP1A-250 FKBP1A EXON-5 - AGUCAGGGCAGAUGUCUAUACAAAG 6574 FKBP1A-251 FKBP1A EXON-5 - GGGCAGAUGUCUAUACAAAGGUGGAG 6575 FKBP1A-252 FKBP1A EXON-5 - UCUAUACAAAGUGGAGUGGAACAUC 6576 FKBP1A-253 FKBP1A EXON-5 - GUGGAACAUCAGGAAAAGCUCCAUA 6577 FKBP1A-254 FKBP1A EXON-5 - CCAUAUGGAUUCAUGUGCACAUGUC 6578 FKBP1A-255 FKBP1A EXON-5 - UAUGGAUUCAUGUGCACAUGUCUGG 6579 FKBP1A-256 FKBP1A EXON-5 - UGUCUGGAGGCACCAGAUCCCUCCA 6580 FKBP1A-257 FKBP1A EXON-5 - CCAGAUCCCUCCAUGGCAGAUCUGU 6581 FKBP1A-258 FKBP1A EXON-5 - CAGAUCCCUCCAUGGCAGAUCUGUU 6582 FKBP1A-259 FKBP1A EXON-5 - AGAUCCCUCCAUGGCAGAUCUGUUG 6583 4261_1_3 CIITA one + xp16_10877214_10877239 GUGAUGAGGCUGUGUGCUUCUGAGC 6750 4261_1_4 CIITA one + xp16_10877215_10877240 UGAUGAGGCUGUGUGCUUCUGAGCU 6751 4261_1_6 CIITA one + xp16_10877225_10877250 GUGUGCUUCUGAGCUGGGCAUCCGA 6752 4261_1_9 CIITA one + xp16_10877234_10877259 UGAGCUGGGCAUCCGAAGGCAUCCU 6753 4261_1_12 CIITA one + xp16_10877235_10877260 GAGCUGGGCAUCCGAAGGCAUCCUU 6754 4261_1_14 CIITA one + xp16_10877236_10877261 AGCUGGGCAUCCGAAGGCAUCCUUG 6755 4261_1_17 CIITA one + xp16_10877245_10877270 UCCGAAGGCAUCCUUGGGGAAGCUG 6756 4261_1_18 CIITA one + xp16_10877246_10877271 CCGAAGGCAUCCUUGGGGAAGCUGA 6757 4261_1_21 CIITA one + xp16_10877253_10877278 CAUCCUUGGGGAAGCUGAGGGCACG 6758 4261_1_25 CIITA one + xp16_10877256_10877281 CCUUGGGGAAGCUGAGGGCACGAGG 6759 4261_1_26 CIITA one + xp16_10877257_10877282 CUUGGGGAAGCUGAGGGCACGAGGA 6760 4261_1_27 CIITA one + xp16_10877258_10877283 UUGGGGAAGCUGAGGGCACGAGGAG 6761 4261_1_30 CIITA one + xp16_10877272_10877297 GGCACGAGGAGGGGCUGCCAGACUC 6762 4261_1_33 CIITA one + xp16_10877273_10877298 GCACGAGGAGGGGCUGCCAGACUCC 6763 4261_1_34 CIITA one + xp16_10877286_10877311 CUGCCAGACUCCGGGAGCUGCUGCC 6764 4261_1_37 CIITA one + xp16_10877290_10877315 CAGACUCCGGGAGCUGCUGCCUGGC 6765 4261_1_38 CIITA one + xp16_10877291_10877316 AGACUCCGGGAGCUGCUGCCUGGCU 6766 4261_1_39 CIITA one + xp16_10877315_10877340 UGGGAUUCCUACACAAUGCGUUGCC 6767 4261_1_42 CIITA one + xp16_10877331_10877356 UGCGUUGCCUGGCUCCACGCCCUGC 6768 4261_1_43 CIITA one + xp16_10877332_10877357 GCGUUGCCUGGCUCCACGCCCUGCU 6769 4261_1_46 CIITA one + xp16_10877355_10877380 CUGGGUCCCUACCUGUCAGAGCCCCA 6770 4261_1_47 CIITA one + xp16_10877363_10877388 UACCUGUCAGAGCCCCAAGGUAAAA 6771 4261_1_50 CIITA one + xp16_10877367_10877392 UGUCAGAGCCCCAAGGUAAAAAGGC 6772 4261_1_52 CIITA one + xp16_10877368_10877393 GUCAGAGCCCCAAGGUAAAAAGGCC 6773 4261_1_53 CIITA one - xp16_10877186_10877211 GGAGUAGUGAUACCAGUCACCAGUU 6774 4261_1_56 CIITA one - xp16_10877187_10877212 CGGAGUAGUGAUACCAGUCACCAGU 6775 4261_1_62 CIITA one - xp16_10877249_10877274 CCCUCAGCUUCCCCAAGGAUGCCUU 6776 4261_1_64 CIITA one - xp16_10877259_10877284 CCUCCUCGUGCCCUCAGCUUCCCCA 6777 4261_1_66 CIITA one - xp16_10877292_10877317 CAGCCAGGCAGCAGCUCCCGGAGUC 6778 4261_1_68 CIITA one - xp16_10877299_10877324 GGAAUCCCAGCCAGGCAGCAGCUCC 6779 4261_1_71 CIITA one - xp16_10877312_10877337 AACGCAUUGUGUAGGAAUCCCAGCC 6780 4261_1_72 CIITA one - xp16_10877325_10877350 CGUGGAGCCAGGCAACGCAUUGUGU 6781 4261_1_75 CIITA one - xp16_10877341_10877366 GUAGGACCCAGCAGGGCGUGGAGCC 6782 4261_1_76 CIITA one - xp16_10877348_10877373 CUGACAGGUAGGACCCAGCAGGGCG 6783 4261_1_79 CIITA one - xp16_10877353_10877378 GGGCUCUGACAGGUAGGACCCAGCA 6784 4261_1_80 CIITA one - xp16_10877354_10877379 GGGGCUCUGACAGGUAGGACCCAGC 6785 4261_1_87 CIITA one - xp16_10877364_10877389 UUUUUACCUUGGGGCUCUGACAGGU 6786 4261_1_89 CIITA one - xp16_10877368_10877393 GGCCUUUUUACCUUGGGGCUCUGAC 6787 4261_2_4 CIITA 2 + xp16_10895277_10895302 CCAGGCAGCUCACAGUGUGCCACCA 6788 4261_2_7 CIITA 2 + xp16_10895283_10895308 AGCUCACAGUGUGCCACCAUGGAGU 6789 4261_2_9 CIITA 2 + xp16_10895284_10895309 GCUCACAGUGUGCCACCAUGGAGUU 6790 4261_2_10 CIITA 2 + xp16_10895285_10895310 CUCACAGUGUGCCACCAUGGAGUUG 6791 4261_2_12 CIITA 2 + xp16_10895296_10895321 CCACCAUGGAGUUGGGGCCCCUAGA 6792 4261_2_13 CIITA 2 + xp16_10895299_10895324 CCAUGGAGUUGGGGCCCCUAGAAGG 6793 4261_2_16 CIITA 2 + xp16_10895307_10895332 UUGGGGCCCCUAGAAGGUGGCUACC 6794 4261_2_21 CIITA 2 + xp16_10895364_10895389 UGCCUCUACCACUUCUAUGACCAGA 6795 4261_2_22 CIITA 2 + xp16_10895370_10895395 UACCACUUCUAUGACCAGAUGGACC 6796 4261_2_24 CIITA 2 + xp16_10895374_10895399 ACUUCUAUGACCAGAUGGACCUGGC 6797 4261_2_31 CIITA 2 + xp16_10895401_10895426 GAGAAGAAGAGAUUGAGCUCUACUC 6798 4261_2_33 CIITA 2 + xp16_10895404_10895429 AAGAAGAGAUUGAGCUCUACUCAGG 6799 4261_2_34 CIITA 2 + xp16_10895405_10895430 AGAAGAGAUUGAGCUCUACUCAGGU 6800 4261_2_36 CIITA 2 + xp16_10895420_10895445 CUACUCAGGUGGGCCCUCCUCCCUC 6801 4261_2_38 CIITA 2 - xp16_10895275_10895300 GUGGCACACUGUGAGCUGCCUGGGA 6802 4261_2_40 CIITA 2 - xp16_10895276_10895301 GGUGGCACACUGUGAGCUGCCUGGG 6803 4261_2_43 CIITA 2 - xp16_10895279_10895304 CAUGGUGGCACACUGUGAGCUGCCU 6804 4261_2_44 CIITA 2 - xp16_10895280_10895305 CCAUGGUGGCACACUGUGAGCUGCC 6805 4261_2_49 CIITA 2 - xp16_10895299_10895324 CCUUCUAGGGGCCCCAACUCCAUGG 6806 4261_2_50 CIITA 2 - xp16_10895302_10895327 CCACCUUCUAGGGGCCCCAACUCCA 6807 4261_2_51 CIITA 2 - xp16_10895316_10895341 GAAGCUCCAGGUAGCCACCUUCUAG 6808 4261_2_52 CIITA 2 - xp16_10895317_10895342 AGAAGCUCCAGGUAGCCACCUUCUA 6809 4261_2_54 CIITA 2 - xp16_10895318_10895343 AAGAAGCUCCAGGUAGCCACCUUCU 6810 4261_2_57 CIITA 2 - xp16_10895333_10895358 GUCAGCAUCGCUGUUAAGAGCUCC 6811 4261_2_60 CIITA 2 - xp16_10895360_10895385 GUCAUAGAAGUGGUAGAGGCACAGG 6812 4261_2_61 CIITA 2 - xp16_10895361_10895386 GGUCAAUAGAAGUGGUAGAGGCACAG 6813 4261_2_62 CIITA 2 - xp16_10895362_10895387 UGGUCAAUAGAAGUGGUAGAGGCACA 6814 4261_2_64 CIITA 2 - xp16_10895363_10895388 CUGGUCAAUAGAAGUGGUAGAGGCAC 6815 4261_2_67 CIITA 2 - xp16_10895369_10895394 GUCCAUCUGGUCAAUAGAAGUGGUAG 6816 4261_2_69 CIITA 2 - xp16_10895375_10895400 AGCCAGGUCCAUCUGGUCAUAGAAG 6817 4261_2_74 CIITA 2 - xp16_10895387_10895412 CUCUUCUUCUCCAGCCAGGUCCAUC 6818 4261_2_75 CIITA 2 - xp16_10895396_10895421 GAGCUCAAUCUCUUCUUCUCCAGCC 6819 4261_3_4 CIITA 3 + xp16_10895681_10895706 CACCAUCAACUGCGACCAGUUCAGC 6820 4261_3_7 CIITA 3 + xp16_10895697_10895722 CAGUUCAGCAGGCUGUUGUGUGACA 6821 4261_3_8 CIITA 3 + xp16_10895701_10895726 UCAGCAGGCUGUUGUGUGACAUGGA 6822 4261_3_15 CIITA 3 + xp16_10895717_10895742 UGACAUGGAAGGUGAUGAAGAGAC 6823 4261_3_16 CIITA 3 + xp16_10895718_10895743 GACAUGGAAGGUGAUGAAGAGACCA 6824 4261_3_18 CIITA 3 + xp16_10895721_10895746 AUGGAAGGUGAUGAAGAGACAGGG 6825 4261_3_19 CIITA 3 + xp16_10895737_10895762 AGACCAGGGAGGCUUAUGCCAAUAU 6826 4261_3_23 CIITA 3 + xp16_10895742_10895767 AGGGAGGCUUAUGCCAAUAUCGGUG 6827 4261_3_26 CIITA 3 - xp16_10895663_10895688 GAUGGUGUCUGUGUCGGGUUCUGGG 6828 4261_3_30 CIITA 3 - xp16_10895666_10895691 GUUGAUGGUGUCUGUGUCGGGUUCU 6829 4261_3_32 CIITA 3 - xp16_10895667_10895692 AGUUGAUGGUGUCUGUGUCGGGUUC 6830 4261_3_35 CIITA 3 - xp16_10895673_10895698 GGUCGCAGUUGAUGGUGUCUGUGUC 6831 4261_3_36 CIITA 3 - xp16_10895674_10895699 UGGUCGCAGUUGAUGGUGUCUGUGU 6832 4261_3_38 CIITA 3 - xp16_10895686_10895711 AGCCUGCUGAACUGGUCGCAGUUGA 6833 4261_3_39 CIITA 3 - xp16_10895699_10895724 CAUGUCACACAACAGCCUGCUGAAC 6834 4261_3_44 CIITA 3 - xp16_10895743_10895768 UCACCGAUAUUGGCAUAAGCCUCCC 6835 4261_3_46 CIITA 3 - xp16_10895758_10895783 GGCUCAGGUGCUUCUCACCGAUAU 6836 4261_4_2 CIITA 4 + xp16_10898650_10898675 CUUUUCCUUGUCUGGGCAGCGGAAC 6837 4261_4_8 CIITA 4 + xp16_10898668_10898693 GCGGAACUGGACCAGUAUGUCUUCC 6838 4261_4_10 CIITA 4 + xp16_10898680_10898705 CAGUAUGUCUUCCAGGACUCCCAGC 6839 4261_4_13 CIITA 4 + xp16_10898683_10898708 UAUGUCUUCCAGGACUCCCAGCUGG 6840 4261_4_14 CIITA 4 + xp16_10898684_10898709 AUGUCUUCCAGGACUCCCAGCUGGA 6841 4261_4_18 CIITA 4 + xp16_10898695_10898720 GACUCCCAGCUGGAGGGCCUGAGCA 6842 4261_4_19 CIITA 4 + xp16_10898716_10898741 AGCAAGGACAUUUUCAGUAAGUUUG 6843 4261_4_21 CIITA 4 + xp16_10898719_10898744 AAGGACAUUUUCAGUAAGUUUGUGG 6844 4261_4_22 CIITA 4 + xp16_10898720_10898745 AGGACAUUUUCAGUAAGUUUGUGGU 6845 4261_4_24 CIITA 4 + xp16_10898723_10898748 ACAUUUUCAGUAAGUUUGUGGUGGG 6846 4261_4_25 CIITA 4 + xp16_10898724_10898749 CAUUUUCAGUAAGUUUGUGGUGGGU 6847 4261_4_28 CIITA 4 - xp16_10898658_10898683 CUGGUCCCAGUUCCGCUGCCCAGACA 6848 4261_4_30 CIITA 4 - xp16_10898682_10898707 CAGCUGGGAGUCCCUGGAAGACAUAC 6849 4261_4_31 CIITA 4 - xp16_10898694_10898719 GCUCAGGCCCUCCAGCUGGGAGUCC 6850 4261_4_35 CIITA 4 - xp16_10898702_10898727 AUGUCCUUGCUCAGGCCCUCCAGCU 6851 4261_4_38 CIITA 4 - xp16_10898703_10898728 AAUGUCCUUGCUCAGGCCCUCCAGC 6852 4261_4_41 CIITA 4 - xp16_10898715_10898740 AAACUUACUGAAAAUGUCCUUGCUC 6853 4261_5_2 CIITA 5 + xp16_10898906_10898931 UGGUUUUUCUCAAAGUAGAGCACAU 6854 4261_5_8 CIITA 5 + xp16_10898924_10898949 AGCACAUAGGACCAGAUGAAGUGAU 6855 4261_5_12 CIITA 5 + xp16_10898935_10898960 CCAGAUGAAGUGAUCGGUGAGAGUA 6856 4261_5_16 CIITA 5 + xp16_10898954_10898979 AGAGUAUGGAGAUGCCAGCAGAAGU 6857 4261_5_17 CIITA 5 + xp16_10898955_10898980 GAGUAUGGAGAUGCCAGCAGAAGUU 6858 4261_5_29 CIITA 5 - xp16_10898938_10898963 CCAUACUCUCACCGAUCACUUCAUC 6859 4261_5_34 CIITA 5 - xp16_10898971_10898996 UCUGACUUUUCUGCCCAACUUCUGC 6860 4261_6_3 CIITA 6 + xp16_10901497_10901522 CAUGUUUUCCUGCAGCCUUCCCAG 6861 4261_6_8 CIITA 6 + xp16_10901506_10901531 UCUGCAGCCUUCCCAGAGGAGCUUC 6862 4261_6_12 CIITA 6 + xp16_10901523_10901548 GGAGCUUCCGGCAGACCUGAAGCAC 6863 4261_6_15 CIITA 6 + xp16_10901531_10901556 CGGCAGACCUGAAGCACUGGAAGCC 6864 4261_6_17 CIITA 6 + xp16_10901539_10901564 CUGAAGCACUGGAAGCCAGGUGUGC 6865 4261_6_18 CIITA 6 + xp16_10901540_10901565 UGAAGCACUGGAAGCCAGGUGUGCA 6866 4261_6_19 CIITA 6 + xp16_10901544_10901569 GCACUGGAAGCCAGGUGUGCAGGGC 6867 4261_6_21 CIITA 6 + xp16_10901547_10901572 CUGGAAGCCAGGUGUGCAGGGCAGG 6868 4261_6_22 CIITA 6 + xp16_10901548_10901573 UGGAAGCCAGGUGUGCAGGGCAGGU 6869 4261_6_25 CIITA 6 - xp16_10901516_10901541 AGGUCUGCCGGAAGCUCCUCUGGA 6870 4261_6_28 CIITA 6 - xp16_10901520_10901545 CUUCAGGUCUGCCGGAAGCUCCUCU 6871 4261_6_29 CIITA 6 - xp16_10901521_10901546 GCUUCAGGUCUGCCGGAAGCUCCUC 6872 4261_6_33 CIITA 6 - xp16_10901533_10901558 CUGGCUUCCAGUGCUUCAGGUCUGC 6873 4261_6_36 CIITA 6 - xp16_10901541_10901566 CUGCACACCUGGCUUCCAGUGCUUC 6874 4261_7_1 CIITA 7 + xp16_10902027_10902052 UUCCUCACAGCUGAGCCCCCCACUG 6875 4261_7_3 CIITA 7 + xp16_10902034_10902059 CAGCUGAGCCCCCCACUGUGGUGAC 6876 4261_7_5 CIITA 7 + xp16_10902048_10902073 ACUGUGGUGACUGGCAGUCUCCUAG 6877 4261_7_7 CIITA 7 + xp16_10902049_10902074 CUGUGGUGACUGGCAGUCUCCUAGU 6878 4261_7_11 CIITA 7 + xp16_10902108_10902133 CUGCCACUGCCUGCCGCUGUUCAACC 6879 4261_7_12 CIITA 7 + xp16_10902121_10902146 CGCUGUUCAACCAGGAGCCAGCCUC 6880 4261_7_16 CIITA 7 + xp16_10902135_10902160 GAGCCAGCCUCCGGCCAGAAUGCGCC 6881 4261_7_20 CIITA 7 + xp16_10902166_10902191 AAACCGACCAGAUUCCCAGUAUGUU 6882 4261_7_22 CIITA 7 + xp16_10902167_10902192 AACCGACCAGAUUCCCAGUAUGUUA 6883 4261_7_24 CIITA 7 + xp16_10902168_10902193 ACCGACCAGAUUCCCAGUAUGUUAG 6884 4261_7_25 CIITA 7 + xp16_10902169_10902194 CCGACCAGAUUCCCAGUAUGUUAGG 6885 4261_7_28 CIITA 7 + xp16_10902174_10902199 CAGAUUCCCCAGUAUGUUAGGGGGCU 6886 4261_7_30 CIITA 7 - xp16_10902025_10902050 GUGGGGGGCUCAGCUGUGAGGAAGU 6887 4261_7_31 CIITA 7 - xp16_10902026_10902051 AGUGGGGGGCUCAGCUGUGAGGAAG 6888 4261_7_33 CIITA 7 - xp16_10902032_10902057 CACCACAGUGGGGGGCUCAGCUGUG 6889 4261_7_37 CIITA 7 - xp16_10902045_10902070 GGAGACUGCCAGUCACCACAGUGGG 6890 4261_7_38 CIITA 7 - xp16_10902046_10902071 AGGAGACUGCCAGUCACCACAGUGG 6891 4261_7_40 CIITA 7 - xp16_10902047_10902072 UAGGAGACUGCCAGUCACCACAGUG 6892 4261_7_42 CIITA 7 - xp16_10902048_10902073 CUAGGAGACUGCCAGUCACCACAGU 6893 4261_7_43 CIITA 7 - xp16_10902049_10902074 ACUAGGAGACUGCCAGUCACCACAG 6894 4261_7_47 CIITA 7 - xp16_10902071_10902096 GGAGCAGUCCGCUCACUGGUCCCACU 6895 4261_7_49 CIITA 7 - xp16_10902081_10902106 AGGGCAGGGUGGAGCAGUCGCUCAC 6896 4261_7_50 CIITA 7 - xp16_10902097_10902122 GCAGGCAGUGGCAGGCAGGGCAGGG 6897 4261_7_53 CIITA 7 - xp16_10902100_10902125 AGCGCAGGCAGUGGCAGGCAGGGCA 6898 4261_7_54 CIITA 7 - xp16_10902101_10902126 CAGCGCAGGCAGUGGCAGGCAGGGC 6899 4261_7_57 CIITA 7 - xp16_10902105_10902130 UGAACAGGCGCAGGCAGUGGCAGGCA 6900 4261_7_58 CIITA 7 - xp16_10902106_10902131 UUGAACAGCGGCAGGCAGUGGCAGGC 6901 4261_7_60 CIITA 7 - xp16_10902110_10902135 CUGGUUGAACAGCGCAGGCAGUGGC 6902 4261_7_61 CIITA 7 - xp16_10902114_10902139 GCUCCUGGUUGAACAGCGGCAGGCAG 6903 4261_7_62 CIITA 7 - xp16_10902120_10902145 AGGCUGGCUCCUGGUUGAACAGGCGC 6904 4261_7_64 CIITA 7 - xp16_10902134_10902159 GCGCAUCUGGCCGGAGGCUGGCUCC 6905 4261_7_66 CIITA 7 - xp16_10902141_10902166 UCUCCAGGCGCAUCUGGCCGGAGGC 6906 4261_7_69 CIITA 7 - xp16_10902145_10902170 GUUUUCUCCAGGCGCAUCUGGCCGG 6907 4261_7_70 CIITA 7 - xp16_10902148_10902173 UCGGUUUUCUCCAGGCGCAUCUGGC 6908 4261_7_73 CIITA 7 - xp16_10902152_10902177 CUGGUCGGUUUUCUCCAGGCGCAUC 6909 4261_7_74 CIITA 7 - xp16_10902161_10902186 ACUGGGAAUCUGGUCGGUUUUCUCC 6910 4261_7_75 CIITA 7 - xp16_10902172_10902197 CCCCCUAACAUACUGGGAAUCUGGU 6911 4261_7_76 CIITA 7 - xp16_10902176_10902201 CAAGCCCCCUAACAUACUGGGAAUC 6912 4261_8_11 CIITA eight + xp16_10902674_10902699 UCGUUGAGCUGCCUGAAUCUCCCUG 6913 4261_8_13 CIITA eight + xp16_10902675_10902700 CGUUGAGCUGCCUGAAUCUCCCUGA 6914 4261_8_17 CIITA eight + xp16_10902717_10902742 UCCCCACCAUCUCCACUCUGCCCCA 6915 4261_8_19 CIITA eight + xp16_10902718_10902743 CCCCACCAUCUCCACUCUGCCCCAU 6916 4261_8_20 CIITA eight + xp16_10902724_10902749 CAUCUCCACUCUGCCCCAUGGGCUC 6917 4261_8_22 CIITA eight + xp16_10902737_10902762 CCCCAUGGGCUCUGGCAAAUCUCUG 6918 4261_8_25 CIITA eight + xp16_10902741_10902766 AUGGGCUCUGGCAAAUCUCUGAGGC 6919 4261_8_27 CIITA eight + xp16_10902747_10902772 UCUGGCAAAUCUCUGAGGCUGGAAC 6920 4261_8_29 CIITA eight + xp16_10902748_10902773 CUGGCAAAUCUCUGAGGCUGGAACA 6921 4261_8_30 CIITA eight + xp16_10902749_10902774 UGGCAAAUCUCUGAGGCUGGAACAG 6922 4261_8_31 CIITA eight + xp16_10902774_10902799 GGGUCUCCAGUAAUAUUCAUCUACCA 6923 4261_8_34 CIITA eight + xp16_10902783_10902808 GUAUAUUCAUCUACCAUGGUGAGUG 6924 4261_8_36 CIITA eight + xp16_10902784_10902809 UAUAUUCAUCUACCAUGGUGAGUGC 6925 4261_8_37 CIITA eight + xp16_10902785_10902810 AUAUUCAUCUACCAUGGUGAGUGCG 6926 4261_8_38 CIITA eight + xp16_10902790_10902815 CAUCUACCAUGGUGAGUGCGGGGCC 6927 4261_8_40 CIITA eight - xp16_10902644_10902669 UGGAGAAAGGCACUGCAAGAGACAA 6928 4261_8_42 CIITA eight - xp16_10902662_10902687 GGCAGCUCAACGAGGAACUGGAGAA 6929 4261_8_45 CIITA eight - xp16_10902669_10902694 AGAUUCAGGCAGCUCAACGAGGAAC 6930 4261_8_48 CIITA eight - xp16_10902675_10902700 UCAGGGAGAUUCAGGCAGCUCAACG 6931 4261_8_52 CIITA eight - xp16_10902688_10902713 CUGGAUGGGUCCCUCAGGGAGAUUC 6932 4261_8_54 CIITA eight - xp16_10902697_10902722 GGGGACAAACUGGAUGGGUCCCUCA 6933 4261_8_56 CIITA eight - xp16_10902698_10902723 UGGGGACAAACUGGAUGGGUCCCUC 6934 4261_8_58 CIITA eight - xp16_10902707_10902732 UGGAGAUGGUGGGGACAAACUGGAU 6935 4261_8_59 CIITA eight - xp16_10902708_10902733 GUGGAGAUGGUGGGGACAAACUGGA 6936 4261_8_61 CIITA eight - xp16_10902712_10902737 CAGAGUGGAGAUGGUGGGGACAAAAC 6937 4261_8_63 CIITA eight - xp16_10902721_10902746 CCCAUGGGGCAGAGUGGAGAUGGUG 6938 4261_8_64 CIITA eight - xp16_10902722_10902747 GCCCAUGGGGCAGAGUGGAGAUGGU 6939 4261_8_67 CIITA eight - xp16_10902723_10902748 AGCCCAUGGGGCAGAGUGGAGAUGG 6940 4261_8_69 CIITA eight - xp16_10902726_10902751 CAGAGCCCAUGGGGCAGAGUGGAGA 6941 4261_8_72 CIITA eight - xp16_10902732_10902757 AUUUGCCAGAGCCCAUGGGGCAGAG 6942 4261_8_76 CIITA eight - xp16_10902740_10902765 CCUCAGAGAUUUUGCCAGAGCCCAUG 6943 4261_8_77 CIITA eight - xp16_10902741_10902766 GCCUCAGAGAUUUGCCAGAGCCCAU 6944 4261_8_78 CIITA eight - xp16_10902742_10902767 AGCCUCAGAGAUUUGCCAGAGCCCA 6945 4261_8_84 CIITA eight - xp16_10902783_10902808 CACUCACCAUGGUAGAUGAAUAUAC 6946 4261_9_1 CIITA nine + xp16_10903717_10903742 ACCCCCAAUGUAGGUGAGGUGCCCC 6947 4261_9_3 CIITA nine + xp16_10903742_10903767 AGGCCAGCCAAGUACCCCCUCCCAG 6948 4261_9_4 CIITA nine + xp16_10903757_10903782 CCCCUCCCAGUGGAUUCACUGUCCA 6949 4261_9_6 CIITA nine + xp16_10903779_10903804 CCACGGCCUCCCAACAUCUCCAGAC 6950 4261_9_7 CIITA nine + xp16_10903784_10903809 GCCUCCCAACAUCUCCAGACCGGCC 6951 4261_9_10 CIITA nine + xp16_10903868_10903893 CCCUGACCUCCCGAGCAAACAUGAC 6952 4261_9_12 CIITA nine + xp16_10903873_10903898 ACCUCCCGAGCAAACAUGACAGGUA 6953 4261_9_14 CIITA nine + xp16_10903882_10903907 GCAAAACAUGACAGGUAAGGACCCUU 6954 4261_9_15 CIITA nine + xp16_10903883_10903908 CAAACAUGACAGGUAAGGACCCUUA 6955 4261_9_18 CIITA nine - xp16_10903718_10903743 UGGGGCACCUACCUACAUUGGGGG 6956 4261_9_20 CIITA nine - xp16_10903721_10903746 GCCUGGGGCACCCUCACCUACAUUGG 6957 4261_9_21 CIITA nine - xp16_10903722_10903747 GGCCUGGGGCACCUACCUACAUUG 6958 4261_9_22 CIITA nine - xp16_10903723_10903748 UGGCCUGGGGCACCUCACCUACAUU 6959 4261_9_25 CIITA nine - xp16_10903724_10903749 CUGGCCUGGGGCACCUCACCUACAU 6960 4261_9_28 CIITA nine - xp16_10903741_10903766 UGGGAGGGGGUACUUGGCUGGCCUG 6961 4261_9_29 CIITA nine - xp16_10903742_10903767 CUGGGAGGGGGUACUUGGCUGGCCU 6962 4261_9_31 CIITA nine - xp16_10903743_10903768 ACUGGGAGGGGGUACUUGGCUGGCC 6963 4261_9_33 CIITA nine - xp16_10903748_10903773 AAUCCACUGGGAGGGGGUACUUGGC 6964 4261_9_34 CIITA nine - xp16_10903752_10903777 AGUGAAUCCACCUGGGAGGGGGUACU 6965 4261_9_35 CIITA nine - xp16_10903759_10903784 CGUGGACAGUGAAUCCACUGGGAGG 6966 4261_9_36 CIITA nine - xp16_10903760_10903785 CCGUGGACAGUGAAUCCACUGGGAG 6967 4261_9_37 CIITA nine - xp16_10903761_10903786 GCCGUGGACAGUGAAUCCACUGGGA 6968 4261_9_39 CIITA nine - xp16_10903762_10903787 GGCCGUGGACAGUGAAUCCACUGGG 6969 4261_9_43 CIITA nine - xp16_10903765_10903790 GGAGGCCGUGGACAGUGAAUCCACU 6970 4261_9_45 CIITA nine - xp16_10903766_10903791 GGGAGGCCGUGGACAGUGAAUCCAC 6971 4261_9_49 CIITA nine - xp16_10903782_10903807 CCGGUCUGGAGAUGUUGGGAGGCCG 6972 4261_9_51 CIITA nine - xp16_10903788_10903813 GCCUGGCCGGUCUGGAGAUGUUGGG 6973 4261_9_53 CIITA nine - xp16_10903791_10903816 GGAGCCUGGCCGGUCUGGAGAUGUU 6974 4261_9_55 CIITA nine - xp16_10903792_10903817 UGGAGCCUGGCCGGUCUGGAGAUGU 6975 4261_9_58 CIITA nine - xp16_10903801_10903826 AGGGGCUGGUGGAGCCUGGCCGGUC 6976 4261_9_60 CIITA nine - xp16_10903806_10903831 AGCGAAGGGGCUGGUGGAGCCUGGC 6977 4261_9_61 CIITA nine - xp16_10903810_10903835 AUGGAGCGAAGGGGCUGGUGGAGCC 6978 4261_9_62 CIITA nine - xp16_10903817_10903842 CUGGCUGAUGGAGCGAAGGGGCUGG 6979 4261_9_65 CIITA nine - xp16_10903820_10903845 AGUCUGGCUGAUGGAGCGAAGGGGC 6980 4261_9_66 CIITA nine - xp16_10903824_10903849 GUCCAGUCUGGCUGAUGGAGCGAAG 6981 4261_9_67 CIITA nine - xp16_10903825_10903850 CGUCCAGUCUGGCUGAUGGAGCGAA 6982 4261_9_68 CIITA nine - xp16_10903826_10903851 CCGUCCAGUCUGGCUGAUGGAGCGA 6983 4261_9_72 CIITA nine - xp16_10903834_10903859 CGUACGACCCGUCCAGUCUGGCUGA 6984 4261_9_75 CIITA nine - xp16_10903841_10903866 CCAAGUCCGUACGACCCGUCCAGUC 6985 4261_9_79 CIITA nine - xp16_10903880_10903905 GGGUCCUUACCUGUCAUGUUUGCUC 6986 4261_9_80 CIITA nine - xp16_10903881_10903906 AGGGUCCUUACCUGUCAUGUUUGCU 6987 4261_10_2 CIITA ten + xp16_10904745_10904770 CACAAGACGUCCCCCACCCAAUGCC 6988 4261_10_4 CIITA ten + xp16_10904752_10904777 CGUCCCCCACCCAAUGCCCGGCAGC 6989 4261_10_7 CIITA ten + xp16_10904757_10904782 CCCACCCAAUGCCCGGCAGCUGGAG 6990 4261_10_8 CIITA ten + xp16_10904780_10904805 AGAGGUCUCCAACAAGCUUCCAAAAA 6991 4261_10_9 CIITA ten + xp16_10904785_10904810 UCUCCAACAAGCUUCCAAAAUGGCC 6992 4261_10_13 CIITA ten + xp16_10904797_10904822 UUCCAAAAUGGCCUGGUGAGUGAUG 6993 4261_10_14 CIITA ten + xp16_10904798_10904823 UCCAAAAUGGCCUGGUGAGUGAUGC 6994 4261_10_17 CIITA ten - xp16_10904727_10904752 UCUUGUGCUCUGGAGAUGGAGAAGC 6995 4261_10_20 CIITA ten - xp16_10904736_10904761 UGGGGGACGUCUUGUGCUCUGGAGA 6996 4261_10_24 CIITA ten - xp16_10904742_10904767 AUUGGGUGGGGGACGUCUUGUGCUC 6997 4261_10_27 CIITA ten - xp16_10904758_10904783 UCUCCAGCUGCCGGGCAUUGGGUGG 6998 4261_10_29 CIITA ten - xp16_10904759_10904784 CUCUCCAGCUGCCGGGCAUUGGGUG 6999 4261_10_31 CIITA ten - xp16_10904760_10904785 CCUCUCCAGCUGCCGGGCAUUGGGU 7000 4261_10_33 CIITA ten - xp16_10904761_10904786 ACCUCUCCAGCUGCCGGGCAUUGGG 7001 4261_10_35 CIITA ten - xp16_10904764_10904789 GAGACCUCUCCAGCUGCCGGGCAUU 7002 4261_10_36 CIITA ten - xp16_10904765_10904790 GGAGACCUCUCCAGCUGCCGGGCAU 7003 4261_10_40 CIITA ten - xp16_10904771_10904796 CUUGUUGGAGACCUCUCCAGCUGCC 7004 4261_10_41 CIITA ten - xp16_10904772_10904797 GCUUGUUGGAGACCUCUCCAGCUGC 7005 4261_10_46 CIITA ten - xp16_10904791_10904816 UCACCAGGCCAUUUUGGAAGCUUGU 7006 4261_10_50 CIITA ten - xp16_10904802_10904827 UCCCGCAUCACUCACCAGGCCAUUU 7007 4261_11_3 CIITA eleven + xp16_10906479_10906504 ACGCCCCUGGCCUUUGCAGACCCGG 7008 4261_11_7 CIITA eleven + xp16_10906503_10906528 GUGGAGCAGUUCUACCCGCUCACUGC 7009 4261_11_8 CIITA eleven + xp16_10906513_10906538 UCUACCGCUCACUGCAGGACACGUA 7010 4261_11_11 CIITA eleven + xp16_10906528_10906553 AGGACACGUAUGGUGCCGAGCCCGC 7011 4261_11_13 CIITA eleven + xp16_10906533_10906558 ACGUAUGGUGCCGAGCCCGCAGGCC 7012 4261_11_14 CIITA eleven + xp16_10906537_10906562 AUGGUGCCGAGCCCGCAGGCCCGGA 7013 4261_11_16 CIITA eleven + xp16_10906620_10906645 AGCCUGGAGCGGGAACUGGCCACCC 7014 4261_11_18 CIITA eleven + xp16_10906625_10906650 GGAGCGGGAACUGGCCACCCCGGAC 7015 4261_11_19 CIITA eleven + xp16_10906626_10906651 GAGCGGGAACUGGCCACCCCGGACU 7016 4261_11_21 CIITA eleven + xp16_10906634_10906659 ACUGGCCACCCCGGACUGGGCAGAA 7017 4261_11_22 CIITA eleven + xp16_10906641_10906666 ACCCCGGACUGGGCAGAACGGCAGC 7018 4261_11_25 CIITA eleven + xp16_10906648_10906673 ACUGGGCAGAACGGCAGCUGGCCCA 7019 4261_11_26 CIITA eleven + xp16_10906651_10906676 GGGCAGAACGGCAGCUGGCCCAAGG 7020 4261_11_27 CIITA eleven + xp16_10906656_10906681 GAACGGCAGCUGGCCCAAGGAGGCC 7021 4261_11_29 CIITA eleven + xp16_10906662_10906687 CAGCUGGCCCAAGGAGGCCUGGCUG 7022 4261_11_30 CIITA eleven + xp16_10906671_10906696 CAAGGAGGCCUGGCUGAGGUGCUGU 7023 4261_11_33 CIITA eleven + xp16_10906680_10906705 CUGGCUGAGGUGCUGUUGGCUGCCA 7024 4261_11_34 CIITA eleven + xp16_10906688_10906713 GGUGCUGUUGGCUGCCAAGGAGCAC 7025 4261_11_35 CIITA eleven + xp16_10906691_10906716 GCUGUUGGCUGCCAAGGAGCACCGG 7026 4261_11_40 CIITA eleven + xp16_10906722_10906747 CGUGAGACACGAGUGAUUGCUGUGC 7027 4261_11_41 CIITA eleven + xp16_10906723_10906748 GUGAGACACGAGUGAUUGCUGUGCU 7028 4261_11_42 CIITA eleven + xp16_10906732_10906757 GAGUGAUUGCUGUGCUGGGCAAAGC 7029 4261_11_44 CIITA eleven + xp16_10906737_10906762 AUUGCUGUGCUGGGCAAAGCUGGUC 7030 4261_11_45 CIITA eleven + xp16_10906738_10906763 UUGCUGUGCUGGGCAAAGCUGGUCA 7031 4261_11_49 CIITA eleven + xp16_10906751_10906776 CAAAGCUGGUCAGGGCAAGAGCUAU 7032 4261_11_50 CIITA eleven + xp16_10906752_10906777 AAAGCUGGUCAGGGCAAGAGCUAUU 7033 4261_11_52 CIITA eleven + xp16_10906756_10906781 CUGGUCAGGGCAAGAGCUAUUGGGC 7034 4261_11_54 CIITA eleven + xp16_10906757_10906782 UGGUCAGGGCAAGAGCUAUUGGGCU 7035 4261_11_55 CIITA eleven + xp16_10906758_10906783 GGUCAGGGCAAGAGCUAUUGGGCUG 7036 4261_11_58 CIITA eleven + xp16_10906769_10906794 GAGCUAUUGGGCUGGGGCAGUGAGC 7037 4261_11_59 CIITA eleven + xp16_10906770_10906795 AGCUAUUGGGCUGGGGCAGUGAGCC 7038 4261_11_61 CIITA eleven + xp16_10906775_10906800 UUGGGCUGGGGCAGUGAGCCGGGCC 7039 4261_11_62 CIITA eleven + xp16_10906776_10906801 UGGGCUGGGGCAGUGAGCCGGGCCU 7040 4261_11_64 CIITA eleven + xp16_10906783_10906808 GGGCAGUGAGCCGGGCCUGGGCUUG 7041 4261_11_65 CIITA eleven + xp16_10906787_10906812 AGUGAGCCGGGCCUGGGCUUGUGGC 7042 4261_11_73 CIITA eleven + xp16_10906842_10906867 GUCCCCUGCCAUUGCUUGAACCGUC 7043 4261_11_76 CIITA eleven + xp16_10906843_10906868 UCCCCUGCCAUUGCUUGAACCGUCC 7044 4261_11_77 CIITA eleven + xp16_10906844_10906869 CCCCUGCCAUUGCUUGAACCGUCCG 7045 4261_11_79 CIITA eleven + xp16_10906845_10906870 CCCUGCCAUUGCUUGAACCGUCCGG 7046 4261_11_80 CIITA eleven + xp16_10906855_10906880 GCUUGAACCGUCCGGGGGAUGCCUA 7047 4261_11_84 CIITA eleven + xp16_10906863_10906888 CGUCCGGGGGAUGCCUAUGGCCUGC 7048 4261_11_86 CIITA eleven + xp16_10906881_10906906 GGCCUGCAGGAUCUGCUCUUCUCCC 7049 4261_11_87 CIITA eleven + xp16_10906882_10906907 GCCUGCAGGAUCUGCUCUUCUCCCU 7050 4261_11_88 CIITA eleven + xp16_10906899_10906924 UUUCCCCUGGGCCCACAGCCACUCCG 7051 4261_11_89 CIITA eleven + xp16_10906902_10906927 UCCCUGGGCCCACAGCCACUCGUGG 7052 4261_11_92 CIITA eleven + xp16_10906911_10906936 CCACAGCCACUCGUGGCGGCCGAUG 7053 4261_11_99 CIITA eleven + xp16_10906963_10906988 CUGACCGCGUUCUGCUCAUCCUAGA 7054 4261_11_102 CIITA eleven + xp16_10906971_10906996 GUUCUGCUCAUCCUAGACGGCUUCG 7055 4261_11_107 CIITA eleven + xp16_10906977_10907002 CUCAUCCUAGACGGCUUCGAGGAGC 7056 4261_11_108 CIITA eleven + xp16_10906990_10907015 GCUUCGAGGAGCUGGAAGCGCAAGA 7057 4261_11_111 CIITA eleven + xp16_10907011_10907036 AAGAUGGCUUCCUGCACAGCACGUG 7058 4261_11_112 CIITA eleven + xp16_10907016_10907041 GGCUUCCUGCACAGCACGGUGCGGAC 7059 4261_11_113 CIITA eleven + xp16_10907022_10907047 CUGCACAGCACGUGCGGACCGGCAC 7060 4261_11_117 CIITA eleven + xp16_10907025_10907050 CACAGCACGUGCGGACCGGCACCGG 7061 4261_11_119 CIITA eleven + xp16_10907042_10907067 GGCACCGGCGGAGCCCUGCUCCCUC 7062 4261_11_121 CIITA eleven + xp16_10907043_10907068 GCACCGGCGGAGCCCUGCUCCCUCC 7063 4261_11_123 CIITA eleven + xp16_10907044_10907069 CACCGGCGGAGCCCUGCUCCCUCCG 7064 4261_11_124 CIITA eleven + xp16_10907045_10907070 ACCGGCGGAGCCCUGCUCCCUCCGG 7065 4261_11_125 CIITA eleven + xp16_10907052_10907077 GAGCCCUGCUCCCUCCGGGGGCUGC 7066 4261_11_126 CIITA eleven + xp16_10907056_10907081 CCUGCUCCCUCCGGGGGCUGCUGGC 7067 4261_11_130 CIITA eleven + xp16_10907083_10907108 GCCUUUUCCAGAAGAAGCUGCUCCG 7068 4261_11_134 CIITA eleven + xp16_10907108_10907133 AGGUUGCACCCUCCUCCUCACAGCC 7069 4261_11_136 CIITA eleven + xp16_10907114_10907139 CACCCUCCUCCUCACAGCCCGGCCC 7070 4261_11_139 CIITA eleven + xp16_10907115_10907140 ACCCUCCUCCUCACAGCCCGGCCCC 7071 4261_11_140 CIITA eleven + xp16_10907116_10907141 CCCUCCUCCUCACAGCCCGGCCCCG 7072 4261_11_141 CIITA eleven + xp16_10907124_10907149 CUCACAGCCCGGCCCCGGGGCCGCC 7073 4261_11_144 CIITA eleven + xp16_10907142_10907167 GGCCGCCUGGUCCAGAGCCUGAGCA 7074 4261_11_146 CIITA eleven + xp16_10907167_10907192 AGGCCGACGCCCUAUUUGAGCUGUC 7075 4261_11_148 CIITA eleven + xp16_10907178_10907203 CUAUUUGAGCUGUCCGGCUUCUCCA 7076 4261_11_150 CIITA eleven + xp16_10907184_10907209 GAGCUGUCCGGCUUCUCCAUGGAGC 7077 4261_11_153 CIITA eleven + xp16_10907190_10907215 UCCGGCUUCUCCAUGGAGCAGGCCC 7078 4261_11_158 CIITA eleven + xp16_10907221_10907246 ACGUGAUGCGCUACUUUGAGAGCUC 7079 4261_11_160 CIITA eleven + xp16_10907222_10907247 CGUGAUGCGCUACUUUGAGAGCUCA 7080 4261_11_166 CIITA eleven + xp16_10907261_10907286 CCAAGACAGAGCCCUGACGCUCCUC 7081 4261_11_168 CIITA eleven + xp16_10907262_10907287 CAAGACAGAGCCCUGACGCUCCUCCC 7082 4261_11_169 CIITA eleven + xp16_10907267_10907292 CAGAGCCCUGACGCUCCUCCGGGAC 7083 4261_11_173 CIITA eleven + xp16_10907309_10907334 UCACAGCCACAGCCCUACUUUGUGC 7084 4261_11_174 CIITA eleven + xp16_10907310_10907335 CACAGCCACAGCCCUACUUUGUGCC 7085 4261_11_177 CIITA eleven + xp16_10907331_10907356 UGCCGGGCAGUGUGCCAGCUCUCAG 7086 4261_11_181 CIITA eleven + xp16_10907340_10907365 GUGUGCCAGCUCUCAGAGGCCCUGC 7087 4261_11_183 CIITA eleven + xp16_10907347_10907372 AGCUCUCAGAGGCCCUGCUGGAGCU 7088 4261_11_186 CIITA eleven + xp16_10907348_10907373 GCUCUCAGAGGCCCUGCUGGAGCUU 7089 4261_11_188 CIITA eleven + xp16_10907349_10907374 CUCUCAGAGGCCCUGCUGGAGCUUG 7090 4261_11_190 CIITA eleven + xp16_10907352_10907377 UCAGAGGCCCUGCUGGAGCUUGGGG 7091 4261_11_193 CIITA eleven + xp16_10907379_10907404 GACGCCAAGCUGCCCUCCACGCUCA 7092 4261_11_195 CIITA eleven + xp16_10907380_10907405 ACGCCAAGCUGCCCUCCACGCUCAC 7093 4261_11_196 CIITA eleven + xp16_10907392_10907417 CCUCCACGCUCACGGGACUCUAUGU 7094 4261_11_198 CIITA eleven + xp16_10907400_10907425 CUCACGGGACUCUAUGUCGGCCUGC 7095 4261_11_199 CIITA eleven + xp16_10907401_10907426 UCACGGGACUCUAUGUCGGCCUGCU 7096 4261_11_201 CIITA eleven + xp16_10907428_10907453 GCCGUGCAGCCCUCGACAGCCCCCC 7097 4261_11_203 CIITA eleven + xp16_10907429_10907454 CCGUGCAGCCCUCGACAGCCCCCCC 7098 4261_11_204 CIITA eleven + xp16_10907430_10907455 CGUGCAGCCCUCGACAGCCCCCCCG 7099 4261_11_205 CIITA eleven + xp16_10907436_10907461 GCCCUCGACAGCCCCCCCGGGGCCC 7100 4261_11_207 CIITA eleven + xp16_10907445_10907470 AGCCCCCCCGGGGCCCUGGCAGAGC 7101 4261_11_208 CIITA eleven + xp16_10907454_10907479 GGGGCCCUGGCAGAGCUGGCCAAGC 7102 4261_11_210 CIITA eleven + xp16_10907459_10907484 CCUGGCAGAGCUGGCCAAGCUGGCC 7103 4261_11_213 CIITA eleven + xp16_10907460_10907485 CUGGCAGAGCUGGCCAAGCUGGCCU 7104 4261_11_215 CIITA eleven + xp16_10907466_10907491 GAGCUGGCCAAGCUGGCCUGGGAGC 7105 4261_11_216 CIITA eleven + xp16_10907467_10907492 AGCUGGCCAAGCUGGCCUGGGAGCU 7106 4261_11_219 CIITA eleven + xp16_10907493_10907518 GGCCGCAGACAUCAAAGUACCCUAC 7107 4261_11_221 CIITA eleven + xp16_10907496_10907521 CGCAGACAUCAAAGUACCCUACAGG 7108 4261_11_224 CIITA eleven + xp16_10907522_10907547 GGACCAGUUCCCAUCCGCAGACGUG 7109 4261_11_226 CIITA eleven + xp16_10907528_10907553 GUUCCCAUCCGCAGACGUGAGGACC 7110 4261_11_227 CIITA eleven + xp16_10907529_10907554 UUCCCAUCCGCAGACGUGAGGACCU 7111 4261_11_229 CIITA eleven + xp16_10907535_10907560 UCCGCAGACGUGAGGACCUGGGCGA 7112 4261_11_230 CIITA eleven + xp16_10907542_10907567 ACGUGAGGACCUGGGCGAUGGCCAA 7113 4261_11_232 CIITA eleven + xp16_10907564_10907589 CAAAGGCUUAGUCCAACACCCACCCG 7114 4261_11_233 CIITA eleven + xp16_10907565_10907590 AAAGGCUUAGUCCAACACCCACCGC 7115 4261_11_237 CIITA eleven + xp16_10907583_10907608 CCACCGCGGGCCGCAGAGUCCGAGC 7116 4261_11_240 CIITA eleven + xp16_10907616_10907641 CCCAGCUUCCUCCUGCAAUGCUUCC 7117 4261_11_242 CIITA eleven + xp16_10907617_10907642 CCAGCUUCCUCCCUGCAAUGCUUCCU 7118 4261_11_244 CIITA eleven + xp16_10907618_10907643 CAGCUUCCUCCUGCAAUGCUUCCUG 7119 4261_11_245 CIITA eleven + xp16_10907619_10907644 AGCUUCCUCCUGCAAUGCUUCCUGG 7120 4261_11_247 CIITA eleven + xp16_10907627_10907652 CCUGCAAUGCUUCCUGGGGGCCCUG 7121 4261_11_248 CIITA eleven + xp16_10907631_10907656 CAAUGCUUCCUGGGGGCCCUGUGGC 7122 4261_11_251 CIITA eleven + xp16_10907641_10907666 UGGGGGCCCUGUGGCUGGCUCUGAG 7123 4261_11_254 CIITA eleven + xp16_10907652_10907677 UGGCUGGCUCUGAGUGGCGAAAUCA 7124 4261_11_256 CIITA eleven + xp16_10907658_10907683 GCUCUGAGUGGCGAAAUCAAGGACA 7125 4261_11_259 CIITA eleven + xp16_10907690_10907715 CCCGCAGUACCUAGCAUUGACCCA 7126 4261_11_263 CIITA eleven + xp16_10907699_10907724 CCUAGCAUUGACCCCCAAGGAAGAAG 7127 4261_11_265 CIITA eleven + xp16_10907714_10907739 AAGGAAGAGAGGCCCUAUGACAAC 7128 4261_11_268 CIITA eleven + xp16_10907718_10907743 AAGAAGAGGCCCUAUGACAACUGGC 7129 4261_11_270 CIITA eleven + xp16_10907721_10907746 AAGAGGCCCUAUGACAACUGGCUGG 7130 4261_11_271 CIITA eleven + xp16_10907722_10907747 AGAGGCCCUAUGACAACUGGCUGGA 7131 4261_11_272 CIITA eleven + xp16_10907739_10907764 UGGCUGGAGGGCGUGCCACGCUUUC 7132 4261_11_274 CIITA eleven + xp16_10907743_10907768 UGGAGGGCGUGCCACGCUUUCUGGC 7133 4261_11_275 CIITA eleven + xp16_10907744_10907769 GGAGGGCGUGCCACGCUUUCUGGCU 7134 4261_11_280 CIITA eleven + xp16_10907775_10907800 AUCUUCCAGCCUCCCGCCCGCUGCC 7135 4261_11_282 CIITA eleven + xp16_10907776_10907801 UCUUCCAGCCUCCCGCCCGCUGCCU 7136 4261_11_285 CIITA eleven + xp16_10907788_10907813 CCGCCCGCUGCCUGGGAGCCCUACU 7137 4261_11_286 CIITA eleven + xp16_10907789_10907814 CGCCCGCUGCCUGGGAGCCCUACUC 7138 4261_11_287 CIITA eleven + xp16_10907796_10907821 UGCCUGGGAGCCCUACUCGGGCCAU 7139 4261_11_288 CIITA eleven + xp16_10907799_10907824 CUGGGAGCCCUACUCGGGCCAUCGG 7140 4261_11_289 CIITA eleven + xp16_10907808_10907833 CUACUCGGGCCAUCGGCGGCUGCCU 7141 4261_11_291 CIITA eleven + xp16_10907811_10907836 CUCGGGCCAUCGGCGGCUGCCUCGG 7142 4261_11_294 CIITA eleven + xp16_10907816_10907841 GCCAUCGGCGGCUGCCUCGGUGGAC 7143 4261_11_296 CIITA eleven + xp16_10907826_10907851 GCUGCCUCGGUGGACAGGAAGCAGA 7144 4261_11_298 CIITA eleven + xp16_10907837_10907862 GGACAGGAAGCAGAAGGUGCUUGCG 7145 4261_11_300 CIITA eleven + xp16_10907849_10907874 GAAGGUGCUUGCGAGGUACCUGAAG 7146 4261_11_303 CIITA eleven + xp16_10907859_10907884 GCGAGGUACCUGAAGCGGCUGCAGC 7147 4261_11_305 CIITA eleven + xp16_10907860_10907885 CGAGGUACCUGAAGCGGCUGCAGCC 7148 4261_11_307 CIITA eleven + xp16_10907861_10907886 GAGGUACCUGAAGCGGCUGCAGCCG 7149 4261_11_309 CIITA eleven + xp16_10907870_10907895 GAAGCGGCUGCAGCCGGGGACACUG 7150 4261_11_310 CIITA eleven + xp16_10907871_10907896 AAGCGGCUGCAGCCGGGGACACUGC 7151 4261_11_311 CIITA eleven + xp16_10907876_10907901 GCUGCAGCCGGGGACACUGCGGGCG 7152 4261_11_314 CIITA eleven + xp16_10907886_10907911 GGGACACUGCGGGCGCGGCAGCUGC 7153 4261_11_316 CIITA eleven + xp16_10907910_10907935 CUGGAGCUGCUGCACUGCGCCCCACG 7154 4261_11_320 CIITA eleven + xp16_10907916_10907941 CUGCUGCACUGCGCCCACGAGGCCG 7155 4261_11_321 CIITA eleven + xp16_10907919_10907944 CUGCACUGCGCCCACGAGGCCGAGG 7156 4261_11_324 CIITA eleven + xp16_10907923_10907948 ACUGCGCCCACGAGGCCGAGGAGGC 7157 4261_11_325 CIITA eleven + xp16_10907930_10907955 CCACGAGGCCGAGGAGGCUGGAAUU 7158 4261_11_326 CIITA eleven + xp16_10907940_10907965 GAGGAGGCUGGAAUUUGGCAGCACG 7159 4261_11_328 CIITA eleven + xp16_10907946_10907971 GCUGGAAUUUGGCAGCACGUGGUAC 7160 4261_11_331 CIITA eleven + xp16_10907956_10907981 GGCAGCACGGUGGUACAGGAGCUCCC 7161 4261_11_334 CIITA eleven + xp16_10907973_10907998 GAGCUCCCCGGCCGCCUCUCUUUUC 7162 4261_11_335 CIITA eleven + xp16_10907974_10907999 AGCUCCCCGGCCGCCUCUCUUUUCU 7163 4261_11_340 CIITA eleven + xp16_10908009_10908034 CUCACGCCUCCUGAUGCACAUGUAC 7164 4261_11_341 CIITA eleven + xp16_10908010_10908035 UCACGCCUCCUGAUGCACAUGUACU 7165 4261_11_342 CIITA eleven + xp16_10908015_10908040 CCUCCUGAUGCACAUGUACUGGGCA 7166 4261_11_345 CIITA eleven + xp16_10908021_10908046 GAUGCACAUGUACUGGGCAAGGCCU 7167 4261_11_346 CIITA eleven + xp16_10908024_10908049 GCACAUGUACUGGGCAAGGCCUUGG 7168 4261_11_347 CIITA eleven + xp16_10908027_10908052 CAUGUACUGGGCAAGGCCUUGGAGG 7169 4261_11_349 CIITA eleven + xp16_10908030_10908055 GUACUGGGCAAGGCCUUGGAGGCGG 7170 4261_11_350 CIITA eleven + xp16_10908031_10908056 UACUGGGCAAGGCCUUGGAGGCGGC 7171 4261_11_353 CIITA eleven + xp16_10908048_10908073 GAGGCGGCGGGCCAAGACUUCUCCC 7172 4261_11_354 CIITA eleven + xp16_10908064_10908089 ACUUCUCCCCUGGACCUCCGCAGCAC 7173 4261_11_357 CIITA eleven + xp16_10908079_10908104 UCCGCAGCACUGGCAUUUGCCCCUC 7174 4261_11_360 CIITA eleven + xp16_10908084_10908109 AGCACUGGCAUUUGCCCCUCUGGAU 7175 4261_11_362 CIITA eleven + xp16_10908085_10908110 GCACUGGCAUUUGCCCCUCUGGAUU 7176 4261_11_364 CIITA eleven + xp16_10908086_10908111 CACUGGCAUUUGCCCCUCUGGAUUG 7177 4261_11_366 CIITA eleven + xp16_10908096_10908121 UGCCCCUCUGGAUUGGGGAGCCUCG 7178 4261_11_368 CIITA eleven + xp16_10908097_10908122 GCCCCUCUGGAUUGGGGAGCCUCGU 7179 4261_11_372 CIITA eleven + xp16_10908122_10908147 GGGACUCAGCUGUGUGUCACCCGUUUC 7180 4261_11_374 CIITA eleven + xp16_10908125_10908150 ACUCAGCUGUGUGCACCCGUUUCAGG 7181 4261_11_376 CIITA eleven + xp16_10908126_10908151 CUCAGCUGUGUGCACCCGUUUCAGGU 7182 4261_11_377 CIITA eleven + xp16_10908127_10908152 UCAGCUGUGUCACCCGUUUCAGGUG 7183 4261_11_381 CIITA eleven + xp16_10908132_10908157 UGUGUCACCCGUUUCAGGUGGGGUG 7184 4261_11_382 CIITA eleven + xp16_10908133_10908158 GUGUCACCCGUUUCAGGUGGGGUGA 7185 4261_11_383 CIITA eleven + xp16_10908134_10908159 UGUUCACCCGUUUCAGGUGGGGUGAG 7186 4261_11_385 CIITA eleven + xp16_10908139_10908164 CCCGUUUCAGGUGGGGUGAGGGGCU 7187 4261_11_387 CIITA eleven + xp16_10908140_10908165 CCGUUUCAGGUGGGGUGAGGGGCUU 7188 4261_11_388 CIITA eleven + xp16_10908141_10908166 CGUUUCAGGUGGGGUGAGGGGCUUG 7189 4261_11_390 CIITA eleven - xp16_10906485_10906510 GCUCCACCGGCUCUGCAAAGGCCAG 7190 4261_11_391 CIITA eleven - xp16_10906486_10906511 UGCUCCACCGGCUCUGCAAAGGCCA 7191 4261_11_393 CIITA eleven - xp16_10906487_10906512 CUGCUCCACCGGCUCUGCAAAGGCC 7192 4261_11_395 CIITA eleven - xp16_10906492_10906517 UAGAACUGCUCCACCGGCUCUGCAA 7193 4261_11_396 CIITA eleven - xp16_10906503_10906528 GCAGUGAGCGGUAGAACUGCUCCAC 7194 4261_11_399 CIITA eleven - xp16_10906520_10906545 GGCACCAUACGUGUCCUGCAGUGAG 7195 4261_11_401 CIITA eleven - xp16_10906546_10906571 AGGAUGCCAUCCGGGCCUGCGGGCU 7196 4261_11_402 CIITA eleven - xp16_10906551_10906576 GGUCUAGGAUGCCAUCCGGGCCUGC 7197 4261_11_403 CIITA eleven - xp16_10906552_10906577 AGGUCUAGGAUGCCAUCCGGGCCUG 7198 4261_11_405 CIITA eleven - xp16_10906559_10906584 UAGGUGGAGGUCUAGGAUGCCAUCC 7199 4261_11_406 CIITA eleven - xp16_10906560_10906585 CUAGGUGGAGGUCUAGGAUGCCAUC 7200 4261_11_408 CIITA eleven - xp16_10906571_10906596 CCGGACGUGGUCUAGGUGGAGGUCU 7201 4261_11_411 CIITA eleven - xp16_10906642_10906667 AGCUGCCGUUCUGCCCAGUCCGGGG 7202 4261_11_412 CIITA eleven - xp16_10906645_10906670 GCCAGCUGCCGUUCUGCCCAGUCCG 7203 4261_11_413 CIITA eleven - xp16_10906646_10906671 GGCCAGCUGCCGUUCUGCCCAGUCC 7204 4261_11_415 CIITA eleven - xp16_10906647_10906672 GGGCCAGCUGCCGUUCUGCCCAGUC 7205 4261_11_418 CIITA eleven - xp16_10906672_10906697 AACAGCACCUCAGCCAGGCCUCCUU 7206 4261_11_419 CIITA eleven - xp16_10906673_10906698 CAACAGCACCUCAGCCAGGCCUCCU 7207 4261_11_422 CIITA eleven - xp16_10906682_10906707 CUUGGCAGCCCAACAGCACCUCAGCC 7208 4261_11_423 CIITA eleven - xp16_10906705_10906730 GUCUCACGCGGCCCGCCGGUGCUCCU 7209 4261_11_424 CIITA eleven - xp16_10906715_10906740 AAUCACUCGUGUCUCACGCGGCCGC 7210 4261_11_425 CIITA eleven - xp16_10906722_10906747 GCACAGCAAUCACUCGUGUCUCACG 7211 4261_11_429 CIITA eleven - xp16_10906796_10906821 GGGAAGCCGGCCACAAGCCAGGCC 7212 4261_11_430 CIITA eleven - xp16_10906801_10906826 UACUGGGGAAGCCGGCCACAAGCCC 7213 4261_11_431 CIITA eleven - xp16_10906814_10906839 GAAGACAAAGUCGUACUGGGGAAGC 7214 4261_11_433 CIITA eleven - xp16_10906821_10906846 GGACAGAGAAGACAAAGUCGUACUG 7215 4261_11_434 CIITA eleven - xp16_10906822_10906847 GGGACAGAGAAGACAAAGUCGUACCU 7216 4261_11_437 CIITA eleven - xp16_10906823_10906848 GGGGACAGAGAAGACAAAGUCGUAC 7217 4261_11_443 CIITA eleven - xp16_10906847_10906872 CCCCGGACGGUUCAAGCAAUGGCAG 7218 4261_11_444 CIITA eleven - xp16_10906848_10906873 CCCCCGGACGGUUCAAGCAAUGGCA 7219 4261_11_447 CIITA eleven - xp16_10906849_10906874 UCCCCCGGACGGUUCAAGCAAUGGC 7220 4261_11_449 CIITA eleven - xp16_10906853_10906878 GGCAUCCCCCGGACGGUUCAAGCAA 7221 4261_11_450 CIITA eleven - xp16_10906865_10906890 CUGCAGGCCAUAGGCAUCCCCCGGA 7222 4261_11_451 CIITA eleven - xp16_10906869_10906894 GAUCCUGCAGGCCAUAGGCAUCCCC 7223 4261_11_453 CIITA eleven - xp16_10906879_10906904 GAGAAGAGCAGAUCCUGCAGGCCAU 7224 4261_11_454 CIITA eleven - xp16_10906886_10906911 GCCCAGGGAGAAGAGCAGAUCCUGC 7225 4261_11_458 CIITA eleven - xp16_10906906_10906931 GCCGCCACGAGUGGCUGUGGGCCCA 7226 4261_11_461 CIITA eleven - xp16_10906907_10906932 GGCCGCCACGAGUGGCUGUGGGCCC 7227 4261_11_463 CIITA eleven - xp16_10906913_10906938 CUCAUCGGCCGCCACGAGUGGCUGU 7228 4261_11_464 CIITA eleven - xp16_10906914_10906939 CCUCAUCGGCCGCCACGAGUGGCUG 7229 4261_11_466 CIITA eleven - xp16_10906920_10906945 UGAAAACCUCAUCGGCCGCCACGAG 7230 4261_11_469 CIITA eleven - xp16_10906933_10906958 UUCAAGAUGUGGCUGAAAACCUCAU 7231 4261_11_471 CIITA eleven - xp16_10906949_10906974 AACGCGGUCAGGUCUCUUCAAGAUG 7232 4261_11_472 CIITA eleven - xp16_10906965_10906990 CGUCUAGGAUGAGCAGAACGCGGUC 7233 4261_11_473 CIITA eleven - xp16_10906970_10906995 GAAGCCGUCUAGGAUGAGCAGAACG 7234 4261_11_478 CIITA eleven - xp16_10906985_10907010 CGCUUCCAGCUCCUCGAAGCCGUCU 7235 4261_11_482 CIITA eleven - xp16_10907024_10907049 CGGUGCCGGUCCGCACGUGCUGUGC 7236 4261_11_485 CIITA eleven - xp16_10907043_10907068 GGAGGGAGCAGGGCUCCGCCGGUGC 7237 4261_11_486 CIITA eleven - xp16_10907049_10907074 GCCCCCGGAGGGAGCAGGGCUCCGC 7238 4261_11_487 CIITA eleven - xp16_10907058_10907083 CGGCCAGCAGCCCCCGGAGGGAGCA 7239 4261_11_488 CIITA eleven - xp16_10907059_10907084 CCGGCCAGCAGCCCCCGGAGGGAGC 7240 4261_11_490 CIITA eleven - xp16_10907065_10907090 AAAAGGCCGGCCAGCAGCCCCCGGA 7241 4261_11_492 CIITA eleven - xp16_10907066_10907091 GAAAAGGCCGGCCAGCAGCCCCCGG 7242 4261_11_495 CIITA eleven - xp16_10907069_10907094 CUGGAAAAGGCCGGCCAGCAGCCCC 7243 4261_11_500 CIITA eleven - xp16_10907083_10907108 CGGAGCAGCUUCUUCUGGAAAAGGC 7244 4261_11_501 CIITA eleven - xp16_10907087_10907112 ACCUCGGAGCAGCUUCUUCUGGAAA 7245 4261_11_502 CIITA eleven - xp16_10907093_10907118 GGUGCAACCUCGGAGCAGCUUCUUC 7246 4261_11_506 CIITA eleven - xp16_10907108_10907133 GGCUGUGAGGAGGAGGGUGCAACCU 7247 4261_11_508 CIITA eleven - xp16_10907119_10907144 CCCCGGGGCCGGGCUGUGAGGAGGA 7248 4261_11_509 CIITA eleven - xp16_10907120_10907145 GCCCCGGGGCCGGGCUGUGAGGAGG 7249 4261_11_511 CIITA eleven - xp16_10907123_10907148 GCGGCCCCGGGGCCGGGCUGUGAGG 7250 4261_11_515 CIITA eleven - xp16_10907126_10907151 CAGGCGGCCCCGGGGCCGGGCUGUG 7251 4261_11_518 CIITA eleven - xp16_10907134_10907159 CUCUGGACCAGGCGGCCCCGGGGCC 7252 4261_11_519 CIITA eleven - xp16_10907135_10907160 GCUCUGGACCAGGCGGCCCCGGGGC 7253 4261_11_521 CIITA eleven - xp16_10907139_10907164 UCAGGCUCUGGACCAGGCGGCCCCG 7254 4261_11_522 CIITA eleven - xp16_10907140_10907165 CUCAGGCUCUGGACCAGGCGGCCCC 7255 4261_11_523 CIITA eleven - xp16_10907141_10907166 GCUCAGGCUCUGGACCAGGCGGCCC 7256 4261_11_527 CIITA eleven - xp16_10907147_10907172 GGCCUUGCUCAGGCUCUGGACCAGG 7257 4261_11_528 CIITA eleven - xp16_10907150_10907175 GUCGGCCUUGCUCAGGCUCUGGACC 7258 4261_11_529 CIITA eleven - xp16_10907156_10907181 UAGGGCGUCGGCCUUGCUCAGGCUC 7259 4261_11_531 CIITA eleven - xp16_10907162_10907187 CUCAAAUAGGGCGUCGGCCUUGCUC 7260 4261_11_532 CIITA eleven - xp16_10907173_10907198 AAGCCGGACAGCUCAAAUAGGGCGU 7261 4261_11_533 CIITA eleven - xp16_10907179_10907204 AUGGAGAAGCCGGACAGCUCAAAUA 7262 4261_11_534 CIITA eleven - xp16_10907180_10907205 CAUGGAGAAGCCGGACAGCUCAAAU 7263 4261_11_536 CIITA eleven - xp16_10907194_10907219 GCCUGGGCCUGCUCCAUGGAGAAGC 7264 4261_11_541 CIITA eleven - xp16_10907203_10907228 AUCACGUAUGCCUGGGCCUGCUCCA 7265 4261_11_543 CIITA eleven - xp16_10907215_10907240 UCAAAGUAGCGCAUCACGUAUGCCU 7266 4261_11_544 CIITA eleven - xp16_10907216_10907241 CUCAAAGUAGCGCAUCACGUAUGCC 7267 4261_11_548 CIITA eleven - xp16_10907264_10907289 CCGGAGGAGCGUCUAGGGCUCUGUCU 7268 4261_11_549 CIITA eleven - xp16_10907275_10907300 AGUGGCCGGUCCCGGAGGAGCGUCA 7269 4261_11_550 CIITA eleven - xp16_10907276_10907301 AAGUGGCCGGUCCCGGAGGAGCUC 7270 4261_11_553 CIITA eleven - xp16_10907285_10907310 ACUGAGAAGAAGUGGCCGGUCCCGG 7271 4261_11_555 CIITA eleven - xp16_10907288_10907313 GUGACUGAGAAGAAGUGGCCGGUCC 7272 4261_11_558 CIITA eleven - xp16_10907294_10907319 GUGGCUGUGACUGAGAAGAAGUGGC 7273 4261_11_559 CIITA eleven - xp16_10907298_10907323 GGCUGUGGCUGUGACUGAGAAGAG 7274 4261_11_565 CIITA eleven - xp16_10907318_10907343 CACUGCCCGGCACAAAGUAGGGCUG 7275 4261_11_566 CIITA eleven - xp16_10907324_10907349 CUGGCACACCUGCCCGGCACAAAGUA 7276 4261_11_567 CIITA eleven - xp16_10907325_10907350 GCUGGCACACUGCCCGGCACAAAGU 7277 4261_11_569 CIITA eleven - xp16_10907336_10907361 GGCCUCUGAGAGCUGGCACACUGCC 7278 4261_11_570 CIITA eleven - xp16_10907348_10907373 AAGCUCCAGCAGGGCCUCUGAGAGC 7279 4261_11_574 CIITA eleven - xp16_10907362_10907387 UUGGCGUCCUCCCCAAGCUCCAGCA 7280 4261_11_575 CIITA eleven - xp16_10907363_10907388 CUUGGCGUCCUCCCCAAGCUCCAGGC 7281 4261_11_577 CIITA eleven - xp16_10907386_10907411 AGUCCCGUGAGCGUGGAGGGCAGCU 7282 4261_11_578 CIITA eleven - xp16_10907394_10907419 CGACAUAGAGUCCCGUGAGCGUGGA 7283 4261_11_579 CIITA eleven - xp16_10907395_10907420 CCGACAUAGAGUCCCGUGAGCGUGG 7284 4261_11_582 CIITA eleven - xp16_10907398_10907423 AGGCCGACAUAGAGUCCCGUGAGCG 7285 4261_11_586 CIITA eleven - xp16_10907423_10907448 GCUGUCGAGGGCUGCACGGCCCAGGC 7286 4261_11_587 CIITA eleven - xp16_10907432_10907457 CCCGGGGGGGCUGUCGAGGGCUGCA 7287 4261_11_588 CIITA eleven - xp16_10907440_10907465 GCCAGGGCCCCGGGGGGGCUGUCGA 7288 4261_11_589 CIITA eleven - xp16_10907441_10907466 UGCCAGGGCCCCGGGGGGGCUGUCG 7289 4261_11_592 CIITA eleven - xp16_10907450_10907475 GGCCAGCUCUGCCAGGGCCCCGGGG 7290 4261_11_593 CIITA eleven - xp16_10907451_10907476 UGGCCAGCUCUGCCAGGGCCCCGGG 7291 4261_11_595 CIITA eleven - xp16_10907452_10907477 UUGGCCAGCUCUGCCAGGGCCCCGG 7292 4261_11_598 CIITA eleven - xp16_10907453_10907478 CUUGGCCAGCUCUGCCAGGGCCCCG 7293 4261_11_600 CIITA eleven - xp16_10907454_10907479 GCUUGGCCAGCUCUGCCAGGGCCCC 7294 4261_11_602 CIITA eleven - xp16_10907455_10907480 AGCUUGGCCAGCUCUGCCAGGGCCC 7295 4261_11_604 CIITA eleven - xp16_10907461_10907486 CAGGCCAGCUUGGCCAGCUCUGCCA 7296 4261_11_605 CIITA eleven - xp16_10907462_10907487 CCAGGCCAGCUUGGCCAGCUCUGCC 7297 4261_11_607 CIITA eleven - xp16_10907476_10907501 CUGCGGCCCAGCUCCCAGGCCAGCU 7298 4261_11_610 CIITA eleven - xp16_10907485_10907510 CUUUGAUGUCUGCGGCCCAGCUCCCC 7299 4261_11_611 CIITA eleven - xp16_10907498_10907523 CUCCUGUAGGGUACUUUGAUGUCUG 7300 4261_11_612 CIITA eleven - xp16_10907515_10907540 GCGGAUGGGAACUGGUCCUCCUGUA 7301 4261_11_613 CIITA eleven - xp16_10907516_10907541 UGCGGAUGGGAACUGGUCCUCCUGU 7302 4261_11_615 CIITA eleven - xp16_10907528_10907553 GGUCCUCACGUCUGCGGAUGGGAAC 7303 4261_11_617 CIITA eleven - xp16_10907534_10907559 CGCCCAGGUCCUCACGUCUGCGGAU 7304 4261_11_619 CIITA eleven - xp16_10907535_10907560 UCGCCCAGGUCCUCACGUCUGCGGA 7305 4261_11_621 CIITA eleven - xp16_10907539_10907564 GCCAUCGCCCAGGUCCUCACGUCUG 7306 4261_11_625 CIITA eleven - xp16_10907554_10907579 UGGACUAAGCCUUUGGCCAUCGCCC 7307 4261_11_627 CIITA eleven - xp16_10907566_10907591 CGCGGUGGGUGUUGGACUAAGCCUU 7308 4261_11_628 CIITA eleven - xp16_10907579_10907604 GGACUCUGCGGCCCGCGGUGGGUGU 7309 4261_11_630 CIITA eleven - xp16_10907585_10907610 CAGCUCGGACUCUGCGGCCCGCGGU 7310 4261_11_631 CIITA eleven - xp16_10907586_10907611 CCAGCUCGGACUCUGCGGCCCGCGG 7311 4261_11_633 CIITA eleven - xp16_10907589_10907614 AGGCCAGCUCGGACUCUGCGGCCCG 7312 4261_11_634 CIITA eleven - xp16_10907596_10907621 CUGGGGAAGGCCAGCUCGGACUCUG 7313 4261_11_635 CIITA eleven - xp16_10907605_10907630 AGGAGGAAGCUGGGGAAGGCCAGCU 7314 4261_11_638 CIITA eleven - xp16_10907614_10907639 AAGCAUUGCAGGAGGAAGCUGGGGA 7315 4261_11_640 CIITA eleven - xp16_10907618_10907643 CAGGAAGCAUUGCAGGAGGAAGCUG 7316 4261_11_642 CIITA eleven - xp16_10907619_10907644 CCAGGAAGCAUUGCAGGAGGAAGCU 7317 4261_11_644 CIITA eleven - xp16_10907620_10907645 CCCAGGAAGCAUUGCAGGAGGAAGC 7318 4261_11_646 CIITA eleven - xp16_10907627_10907652 CAGGGCCCCCAGGAAGCAUUGCAGG 7319 4261_11_649 CIITA eleven - xp16_10907630_10907655 CCACAGGGCCCCCAGGAAGCAUUGC 7320 4261_11_652 CIITA eleven - xp16_10907642_10907667 ACUCAGAGCCAGCCACAGGGCCCCC 7321 4261_11_657 CIITA eleven - xp16_10907650_10907675 AUUUCGCCACUCAGAGCCAGCCACA 7322 4261_11_658 CIITA eleven - xp16_10907651_10907676 GAUUUCCGCCACUCAGAGCCAGCCAC 7323 4261_11_665 CIITA eleven - xp16_10907693_10907718 CCUUGGGGUCAAUGCUAGGUACUGC 7324 4261_11_666 CIITA eleven - xp16_10907694_10907719 UCCUUGGGGUCAAUGCUAGGUACUG 7325 4261_11_671 CIITA eleven - xp16_10907702_10907727 CCUCUUCUUCCUUGGGGUCAAUGCU 7326 4261_11_673 CIITA eleven - xp16_10907713_10907738 UUGUCAUAGGGCCUCUUCUUCCUUG 7327 4261_11_674 CIITA eleven - xp16_10907714_10907739 GUUGUCAUAGGGCCUCUUCUUCCUU 7328 4261_11_676 CIITA eleven - xp16_10907715_10907740 AGUUGUCAUAGGGCCUCUUCUUCCU 7329 4261_11_678 CIITA eleven - xp16_10907730_10907755 GCACGCCCUCCAGCCAGUUGUCAUA 7330 4261_11_679 CIITA eleven - xp16_10907731_10907756 GGCACGCCCUCCAGCCAGUUGUCAU 7331 4261_11_681 CIITA eleven - xp16_10907757_10907782 GGAAGAUCAGCCCAGCCAGAAAGCG 7332 4261_11_683 CIITA eleven - xp16_10907783_10907808 GGCUCCCAGGCAGCGGGCGGGAGGC 7333 4261_11_686 CIITA eleven - xp16_10907787_10907812 GUAGGGCUCCCAGGCAGCGGGCGGG 7334 4261_11_688 CIITA eleven - xp16_10907790_10907815 CGAGUAGGGCUCCCAGGCAGCGGGC 7335 4261_11_689 CIITA eleven - xp16_10907791_10907816 CCGAGUAGGGCUCCCAGGCAGCGGG 7336 4261_11_692 CIITA eleven - xp16_10907794_10907819 GGCCCGAGUAGGGCUCCCAGGCAGC 7337 4261_11_693 CIITA eleven - xp16_10907795_10907820 UGGCCCGAGUAGGGCUCCCAGGCAG 7338 4261_11_695 CIITA eleven - xp16_10907801_10907826 CGCCGAUGGCCCGAGUAGGGCUCCC 7339 4261_11_696 CIITA eleven - xp16_10907809_10907834 GAGGCAGCCGCCGAUGGCCCGAGUA 7340 4261_11_697 CIITA eleven - xp16_10907810_10907835 CGAGGCAGCCGCCGAUGGCCCGAGU 7341 4261_11_700 CIITA eleven - xp16_10907820_10907845 UCCUGUCCACCGAGGCAGCCGCCGA 7342 4261_11_703 CIITA eleven - xp16_10907833_10907858 AGCACCUUCUGCUUCCUGUCCACCG 7343 4261_11_706 CIITA eleven - xp16_10907870_10907895 CAGUGUCCCCGGCUGCAGCCGCUUC 7344 4261_11_707 CIITA eleven - xp16_10907886_10907911 GCAGCUGCCGCGCCCGCAGUGUCCC 7345 4261_11_709 CIITA eleven - xp16_10907932_10907957 CAAAUUCCAGCCUCCUCGGCCUCGU 7346 4261_11_710 CIITA eleven - xp16_10907933_10907958 CCAAAUUCCAGCCUCCUCGGCCUCG 7347 4261_11_712 CIITA eleven - xp16_10907941_10907966 ACGUGCUGCCAAAUUCCAGCCUCCU 7348 4261_11_713 CIITA eleven - xp16_10907981_10908006 GGUGCCCAGAAAAGAGAGGCGGCCG 7349 4261_11_715 CIITA eleven - xp16_10907982_10908007 GGGUGCCCCAGAAAAGAGAGGCGGCC 7350 4261_11_717 CIITA eleven - xp16_10907983_10908008 CGGGUGCCCCAGAAAAGAGAGGCGGC 7351 4261_11_720 CIITA eleven - xp16_10907987_10908012 GAGGCGGGUGCCCAGAAAAGAGAGG 7352 4261_11_721 CIITA eleven - xp16_10907990_10908015 CGUGAGGCGGGUGCCCAGAAAAGAG 7353 4261_11_725 CIITA eleven - xp16_10908007_10908032 ACAUGUGCAUCAGGAGGCGUGAGGC 7354 4261_11_726 CIITA eleven - xp16_10908008_10908033 UACAUGUGCAUCAGGAGGCGUGAGG 7355 4261_11_728 CIITA eleven - xp16_10908011_10908036 CAGUACAUGUGCAUCAGGAGGCGUG 7356 4261_11_731 CIITA eleven - xp16_10908018_10908043 CCUUGCCCAGUACAUGUGCAUCAGG 7357 4261_11_733 CIITA eleven - xp16_10908021_10908046 AGGCCUUGCCCAGUACAUGUGCAUC 7358 4261_11_736 CIITA eleven - xp16_10908046_10908071 GAGAAGUCUUGGCCCGCCGCCUCCA 7359 4261_11_737 CIITA eleven - xp16_10908062_10908087 GCUGCGGAGGUCCAGGGAGAAGCU 7360 4261_11_740 CIITA eleven - xp16_10908073_10908098 CAAAUGCCAGUGCUGCGGAGGUCCA 7361 4261_11_742 CIITA eleven - xp16_10908074_10908099 GCAAAUGCCAGUGCUGCGGAGGUCC 7362 4261_11_745 CIITA eleven - xp16_10908080_10908105 AGAGGGGCAAAUGCCAGUGCUGCGG 7363 4261_11_746 CIITA eleven - xp16_10908083_10908108 UCCAGAGGGGCAAAUGCCAGUGCUG 7364 4261_11_749 CIITA eleven - xp16_10908101_10908126 UCCCACGAGGCUCCCCAAUCCAGAG 7365 4261_11_750 CIITA eleven - xp16_10908102_10908127 GUCCCACGAGGCUCCCCAAUCCAGA 7366 4261_11_751 CIITA eleven - xp16_10908103_10908128 AGUCCCACGAGGCUCCCCAAUCCAG 7367 4261_11_755 CIITA eleven - xp16_10908119_10908144 ACGGGUGACACAGCUGAGUCCCACG 7368 4261_11_758 CIITA eleven - xp16_10908142_10908167 CCAAGCCCCUCACCCCACCUGAAC 7369 4261_11_759 CIITA eleven - xp16_10908143_10908168 CCCAAGCCCCUCACCCCACCUGAAA 7370 4261_12_1 CIITA 12 + xp16_10908965_10908990 GCUGCCCUUCCAUUAAGGUCUAGCC 7371 4261_12_4 CIITA 12 + xp16_10908978_10909003 UAAGGUCUAGCCUGGUCACCGUGCC 7372 4261_12_5 CIITA 12 + xp16_10908979_10909004 AAGGUCUAGCCUGGUCACCGUGCCU 7373 4261_12_8 CIITA 12 + xp16_10908986_10909011 AGCCUGGUCACCGUGCCUGGGUCUG 7374 4261_12_10 CIITA 12 + xp16_10909001_10909026 CCUGGGUCUGAGGCCCUCCCUCCAC 7375 4261_12_11 CIITA 12 + xp16_10909002_10909027 CUGGGUCUGAGGCCCUCCCUCCACA 7376 4261_12_13 CIITA 12 + xp16_10909020_10909045 CUCCACAGGGCUGCCUUGAGCGACA 7377 4261_12_14 CIITA 12 + xp16_10909023_10909048 CACAGGGCUGCCUUGAGCGACACGG 7378 4261_12_16 CIITA 12 + xp16_10909031_10909056 UGCCUUGAGCGACACGGUGGCGCUG 7379 4261_12_19 CIITA 12 + xp16_10909032_10909057 GCCUUGAGCGACACGGUGGCGCUGU 7380 4261_12_22 CIITA 12 + xp16_10909051_10909076 CGCUGUGGGAGUCCCUGCAGCAGCA 7381 4261_12_24 CIITA 12 + xp16_10909052_10909077 GCUGUGGGAGUCCCUGCAGCAGCAU 7382 4261_12_27 CIITA 12 + xp16_10909053_10909078 CUGUGGGAGUCCCUGCAGCAGCAUG 7383 4261_12_28 CIITA 12 + xp16_10909071_10909096 CAGCAUGGGGAGACCAAGCUACUUC 7384 4261_12_31 CIITA 12 + xp16_10909080_10909105 GAGACCAAGCUACUUCAGGCAGCAG 7385 4261_12_39 CIITA 12 + xp16_10909122_10909147 GAGCCUUUCAAAGCCAAGUCCCUGA 7386 4261_12_41 CIITA 12 + xp16_10909128_10909153 UUCAAAGCCAAGUCCCUGAAGGAUG 7387 4261_12_46 CIITA 12 + xp16_10909137_10909162 AAGUCCCUGAAGGAUGUGGAAGAC 7388 4261_12_48 CIITA 12 + xp16_10909138_10909163 AGUCCCUGAAGGAUGUGGAAGACCU 7389 4261_12_51 CIITA 12 + xp16_10909160_10909185 CCUGGGAAAGCUUGUGCAGACUCAG 7390 4261_12_55 CIITA 12 + xp16_10909167_10909192 AAGCUUGUGCAGACUCAGAGGUGAG 7391 4261_12_58 CIITA 12 + xp16_10909172_10909197 UGUGCAGACUCAGAGGUGAGAGGAG 7392 4261_12_61 CIITA 12 + xp16_10909175_10909200 GCAGACUCAGAGGUGAGAGGAGAGG 7393 4261_12_62 CIITA 12 + xp16_10909179_10909204 ACUCAGAGGUGAGAGGAGAGGCGGA 7394 4261_12_63 CIITA 12 - xp16_10908972_10908997 GUGACCAGGCUAGACCUUAAUGGAA 7395 4261_12_64 CIITA 12 - xp16_10908973_10908998 GGUGACCAGGCUAGACCUUAAUGGA 7396 4261_12_67 CIITA 12 - xp16_10908977_10909002 GCACGGUGACCAGGCUAGACCUUAA 7397 4261_12_69 CIITA 12 - xp16_10908991_10909016 GGCCUCAGACCCAGGCACGGUGACC 7398 4261_12_70 CIITA 12 - xp16_10908999_10909024 GGAGGGAGGGCCUCAGACCCAGGCA 7399 4261_12_71 CIITA 12 - xp16_10909004_10909029 CCUGUGGAGGGAGGGCCUCAGACCC 7400 4261_12_72 CIITA 12 - xp16_10909017_10909042 CGCUCAAGGCAGCCCUGUGGAGGGA 7401 4261_12_73 CIITA 12 - xp16_10909018_10909043 UCGCUCAAGGCAGCCCUGUGGAGGG 7402 4261_12_75 CIITA 12 - xp16_10909021_10909046 GUGUCGCUCAAGGCAGCCCUGUGGA 7403 4261_12_78 CIITA 12 - xp16_10909022_10909047 CGUGUCGCUCAAGGCAGCCCUGUGG 7404 4261_12_80 CIITA 12 - xp16_10909025_10909050 CACCGUGUCGCUCAAGGCAGCCCUG 7405 4261_12_83 CIITA 12 - xp16_10909036_10909061 UCCCACAGCGCCACCGUGUCGCUCA 7406 4261_12_85 CIITA 12 - xp16_10909066_10909091 AGCUUGGUCUCCCCAUGCUGCUGCA 7407 4261_12_87 CIITA 12 - xp16_10909067_10909092 UAGCUUGGUCUCCCCAUGCUGCUGC 7408 4261_12_90 CIITA 12 - xp16_10909087_10909112 UUCUCCUCUGCUGCCUGAAGCUGCU 7409 4261_12_96 CIITA 12 - xp16_10909120_10909145 AGGGACUUGGCUUUGAAAGGCUCGA 7410 4261_12_98 CIITA 12 - xp16_10909128_10909153 CAUCCUUCAGGGACUUGGCUUUGAA 7411 4261_12_101 CIITA 12 - xp16_10909138_10909163 AGGUCUUCCACAUCCUUCAGGGACU 7412 4261_12_104 CIITA 12 - xp16_10909144_10909169 UUUCCCAGGUCUUCCACAUCCUUCA 7413 4261_12_105 CIITA 12 - xp16_10909145_10909170 CUUUCCCAGGUCUUCCACAUCCUUC 7414 4261_12_108 CIITA 12 - xp16_10909163_10909188 CCUCUGAGUCUGCACAAGCUUUCCC 7415 4261_13_3 CIITA thirteen + xp16_10910176_10910201 GUUCUCUCCAGGACGAGAAGUUCCU 7416 4261_13_7 CIITA thirteen + xp16_10910189_10910214 CGAGAAGUUCCUCGGAAGACACAGC 7417 4261_13_10 CIITA thirteen + xp16_10910190_10910215 GAGAAGUUCCUCGGAAGACACAGCU 7418 4261_13_12 CIITA thirteen + xp16_10910191_10910216 AGAAGUUCCUCGGAAGACACAGCUG 7419 4261_13_16 CIITA thirteen + xp16_10910208_10910233 CACAGCUGGGGAGCUCCCUGCUGUU 7420 4261_13_17 CIITA thirteen + xp16_10910209_10910234 ACAGCUGGGGAGCUCCCUGCUGUUC 7421 4261_13_21 CIITA thirteen + xp16_10910224_10910249 CCUGCUGUUCGGGACCUAAAGAAAAC 7422 4261_13_25 CIITA thirteen + xp16_10910242_10910267 AAGAAACUGGAGUUUGCGUAAGCAA 7423 4261_13_27 CIITA thirteen + xp16_10910243_10910268 AGAACUGGAGUUUGCGUAAGCAAA 7424 4261_13_28 CIITA thirteen + xp16_10910244_10910269 GAAACUGGAGUUUGCGUAAGCAAAG 7425 4261_13_30 CIITA thirteen + xp16_10910247_10910272 ACUGGAGUUUGCGUAAGCAAAGGGG 7426 4261_13_32 CIITA thirteen - xp16_10910176_10910201 AGGAACUUCUCCGUCCUGGAGAGAAC 7427 4261_13_38 CIITA thirteen - xp16_10910186_10910211 GUGUCUUCCGAGGAACUUCUCGUCC 7428 4261_13_41 CIITA thirteen - xp16_10910201_10910226 GGGAGCUCCCCAGCUGUGUCUUCCG 7429 4261_13_49 CIITA thirteen - xp16_10910226_10910251 CAGUUUCUUUAGGUCCCCGAACAGCA 7430 4261_13_50 CIITA thirteen - xp16_10910227_10910252 CCAGUUUCUUUAGGUCCCGAACAGC 7431 4261_13_55 CIITA thirteen - xp16_10910241_10910266 UGCUUACGCAAAACUCCAGUUUCUUU 7432 4261_14_2 CIITA fourteen + xp16_10915559_10915584 UGCCUCCUAGGCUGGGCCCUGUCUC 7433 4261_14_5 CIITA fourteen + xp16_10915567_10915592 AGGCUGGGCCCUGUCUCAGGCCCCC 7434 4261_14_6 CIITA fourteen + xp16_10915582_10915607 UCAGGCCCCCAGGCUUUCCCCAAAAC 7435 4261_14_8 CIITA fourteen + xp16_10915587_10915612 CCCCCAGGCUUUCCCCAAACUGGUG 7436 4261_14_9 CIITA fourteen + xp16_10915597_10915622 UUCCCCAAACUGGUGCGGAUCCUCA 7437 4261_14_13 CIITA fourteen + xp16_10915621_10915646 ACGGCCUUUUCCUCCCUGCAGCAUC 7438 4261_14_21 CIITA fourteen + xp16_10915639_10915664 CAGCAUCUGGAGUGAGUAUAGACUC 7439 4261_14_22 CIITA fourteen + xp16_10915640_10915665 AGCAUCUGGAGUGAGUAUAGACUCU 7440 4261_14_23 CIITA fourteen - xp16_10915552_10915577 GGCCCAGCCCUAGGAGGCAAAGAGCA 7441 4261_14_25 CIITA fourteen - xp16_10915564_10915589 GGCCUGAGACAGGGCCCAGCCUAGG 7442 4261_14_27 CIITA fourteen - xp16_10915567_10915592 GGGGGCCUGAGACAGGGCCCAGCCU 7443 4261_14_29 CIITA fourteen - xp16_10915578_10915603 GGGGAAAGCCUGGGGCCUGAGACA 7444 4261_14_31 CIITA fourteen - xp16_10915579_10915604 UGGGGAAAGCCUGGGGGCCUGAGAC 7445 4261_14_35 CIITA fourteen - xp16_10915590_10915615 CCGCACCAGUUUGGGGAAAGCCUGG 7446 4261_14_36 CIITA fourteen - xp16_10915591_10915616 UCCGCACCAGUUUGGGGAAAGCCUG 7447 4261_14_37 CIITA fourteen - xp16_10915592_10915617 AUCCGCACCAGUUUGGGGAAAGCCU 7448 4261_14_39 CIITA fourteen - xp16_10915593_10915618 GAUCCGCACCAGUUUGGGGAAAGCC 7449 4261_14_42 CIITA fourteen - xp16_10915602_10915627 GGCCGUGAGGAUCCCGCACCAGUUUG 7450 4261_14_44 CIITA fourteen - xp16_10915603_10915628 AGGCCGUGAGGAUCCCGCACCAGUUU 7451 4261_14_46 CIITA fourteen - xp16_10915604_10915629 AAGGCCGUGAGGAUCCCGCACCAGUU 7452 4261_14_49 CIITA fourteen - xp16_10915620_10915645 AUGCUGCAGGGAGGAAAAGGCCGUG 7453 4261_14_52 CIITA fourteen - xp16_10915628_10915653 CACUCCAGAUGCUGCAGGGAGGAAA 7454 4261_14_53 CIITA fourteen - xp16_10915634_10915659 UAUACUCACUCCAGAUGCUGCAGGG 7455 4261_14_57 CIITA fourteen - xp16_10915637_10915662 GUCUAUACUCACUCCAGAUGCUGCA 7456 4261_14_58 CIITA fourteen - xp16_10915638_10915663 AGUCUAUACUCACUCCAGAUGCUGC 7457 4261_15_6 CIITA fifteen + xp16_10916368_10916393 UGGAUGCCGCUGAGUGAGAACAAGAU 7458 4261_15_9 CIITA fifteen + xp16_10916369_10916394 GGAUGCCGCUGAGUGAGAACAAGAUC 7459 4261_15_10 CIITA fifteen + xp16_10916370_10916395 GAUGCCGCUGAGUGAGAACAAAGAUCG 7460 4261_15_13 CIITA fifteen + xp16_10916376_10916401 CUGAGUGAGAACAAGAUCGGGGACG 7461 4261_15_14 CIITA fifteen + xp16_10916377_10916402 UGAGUGAGAACAAGAUCGGGGACGA 7462 4261_15_17 CIITA fifteen + xp16_10916421_10916446 GCCACCUUCCCCCAGCUGAAGUCCU 7463 4261_15_23 CIITA fifteen + xp16_10916444_10916469 CUUGGAAACCCUCAAGUGAGUGAGC 7464 4261_15_24 CIITA fifteen + xp16_10916445_10916470 UUGGAAACCCUCAAGUGAGUGAGCU 7465 4261_15_26 CIITA fifteen - xp16_10916349_10916374 CAUCCAGGCUGCAGGUGGAAUCAGA 7466 4261_15_28 CIITA fifteen - xp16_10916359_10916384 UCACUCAGCGCAUCCAGGCUGCAGG 7467 4261_15_31 CIITA fifteen - xp16_10916362_10916387 UUCUCACUCAGCGGCAUCCAGGCUGC 7468 4261_15_33 CIITA fifteen - xp16_10916369_10916394 GAUCUUGUUCUCACUCAGCGCAUCC 7469 4261_15_38 CIITA fifteen - xp16_10916425_10916450 UCCAAGGACUUCAGCUGGGGGAAGG 7470 4261_15_41 CIITA fifteen - xp16_10916428_10916453 GUUUCCAAGGACUUCAGCUGGGGGA 7471 4261_15_43 CIITA fifteen - xp16_10916432_10916457 GAGGGUUUCCAAGGACUUCAGCUGG 7472 4261_15_44 CIITA fifteen - xp16_10916433_10916458 UGAGGGUUUCCAAGGACUUCAGCUG 7473 4261_15_48 CIITA fifteen - xp16_10916434_10916459 UUGAGGGUUUCCAAGGACUUCAGCU 7474 4261_15_49 CIITA fifteen - xp16_10916435_10916460 CUUGAGGGUUUCCAAGGACUUCAGGC 7475 4261_15_52 CIITA fifteen - xp16_10916446_10916471 CAGCUCACUCACUUGAGGGUUUCCA 7476 4261_16_3 CIITA sixteen + xp16_10918440_10918465 CUGUCCCAGAACAAACAUCACUGACC 7477 4261_16_4 CIITA sixteen + xp16_10918441_10918466 UGUCCCAGAACAAACAUCACUGACCU 7478 4261_16_6 CIITA sixteen + xp16_10918461_10918486 GACCUGGGUGCCUACAAACUCGCCG 7479 4261_16_7 CIITA sixteen + xp16_10918493_10918518 GCCUUCCGCUCGCUGCAUCCCUGCUC 7480 4261_16_9 CIITA sixteen + xp16_10918499_10918524 GCUCGCUGCAUCCCUGCUCAGGCUA 7481 4261_16_13 CIITA sixteen + xp16_10918506_10918531 GCAUCCCUGCUCAGGCUAAGGUGAG 7482 4261_16_14 CIITA sixteen + xp16_10918507_10918532 CAUCCCUGCUCAGGCUAAGGUGAGU 7483 4261_16_15 CIITA sixteen + xp16_10918508_10918533 AUCCCUGCUCAGGCUAAGGUGAGUG 7484 4261_16_17 CIITA sixteen + xp16_10918514_10918539 GCUCAGGCUAAGGUGAGUGGGGCCC 7485 4261_16_18 CIITA sixteen - xp16_10918422_10918447 GGGACAGACUGCGGGGACACAGUGA 7486 4261_16_19 CIITA sixteen - xp16_10918423_10918448 UGGGACAGACUGCGGGGACACAGUG 7487 4261_16_24 CIITA sixteen - xp16_10918434_10918459 UGAUGUUGUUCUGGGACAGACUGCG 7488 4261_16_26 CIITA sixteen - xp16_10918435_10918460 GUGAUGUUGUUCUGGGACAGACUGC 7489 4261_16_27 CIITA sixteen - xp16_10918436_10918461 AGUGAUGUUGUUCUGGGACAGACUG 7490 4261_16_30 CIITA sixteen - xp16_10918447_10918472 GCACCCAGGUCAGUGAUGUUGUUCU 7491 4261_16_31 CIITA sixteen - xp16_10918448_10918473 GGCACCCAGGUCAGUGAUGUUGUUC 7492 4261_16_36 CIITA sixteen - xp16_10918466_10918491 GGCCUCGGCGAGUUUGUAGGCACCC 7493 4261_16_37 CIITA sixteen - xp16_10918474_10918499 GAAGGCAGGGCCUCGGCGAGUUUGU 7494 4261_16_39 CIITA sixteen - xp16_10918486_10918511 GAUGCAGCGGAGCGAAGGCAGGGCCU 7495 4261_16_40 CIITA sixteen - xp16_10918492_10918517 AGCAGGGAUGCAGCGAGCGAAGGCA 7496 4261_16_41 CIITA sixteen - xp16_10918493_10918518 GAGCAGGGAUGCAGCGGAGCGAAGGC 7497 4261_16_43 CIITA sixteen - xp16_10918497_10918522 GCCUGAGCAGGGAUGCAGCGGAGCGA 7498 4261_16_47 CIITA sixteen - xp16_10918513_10918538 GGCCCCACUCACCUUAGCCUGAGCA 7499 4261_16_48 CIITA sixteen - xp16_10918514_10918539 GGGCCCCACUCACCUUAGCCUGAGC 7500 4261_17_4 CIITA 17 + xp16_10922167_10922192 UUGUACAUAACUGCAUCUGCGACG 7501 4261_17_6 CIITA 17 + xp16_10922168_10922193 UGUACAUAACUGCAUCUGCGACGU 7502 4261_17_11 CIITA 17 + xp16_10922182_10922207 AUCUGCGACGUGGGAGCCGAGAGCU 7503 4261_17_13 CIITA 17 + xp16_10922197_10922222 GCCGAGAGCUUGGCUCGUGUGCUUC 7504 4261_17_14 CIITA 17 + xp16_10922203_10922228 AGCUUGGCUCGUGUGCUUCCGGACA 7505 4261_17_17 CIITA 17 + xp16_10922214_10922239 UGUGCUUCCGGACAUGGUGUCCUCUC 7506 4261_17_18 CIITA 17 + xp16_10922215_10922240 GUGCUUCCGGACAUGGUGUCCCUCC 7507 4261_17_20 CIITA 17 + xp16_10922221_10922246 CCGGACAUGGUGUCCCUCCGGGUGA 7508 4261_17_26 CIITA 17 + xp16_10922232_10922257 GUCCCUCCGGGUGAUGGAGUGAGUG 7509 4261_17_28 CIITA 17 + xp16_10922233_10922258 UCCCUCCGGGUGAUGGAGUGAGUGU 7510 4261_17_30 CIITA 17 + xp16_10922240_10922265 GGGUGAUGGAGUGAGUGUGGGAGUC 7511 4261_17_31 CIITA 17 + xp16_10922241_10922266 GGUGAUGGAGUGAGUGUGGGAGUCU 7512 4261_17_34 CIITA 17 - xp16_10922153_10922178 UUAUUGUACAGCUGUCGGAAACAG 7513 4261_17_36 CIITA 17 - xp16_10922162_10922187 CAGAUGCAGUUAUUGUACAGCUGU 7514 4261_17_39 CIITA 17 - xp16_10922201_10922226 UCCGGAAGCACAGAGCCAAGCUCU 7515 4261_17_41 CIITA 17 - xp16_10922224_10922249 CCAUCACCCGGAGGGACACCAUGUC 7516 4261_17_44 CIITA 17 - xp16_10922237_10922262 UCCCACACUCACUCCAUCACCCGGA 7517 4261_17_46 CIITA 17 - xp16_10922238_10922263 CUCCCACACUCACUCCAUCACCCGG 7518 4261_17_48 CIITA 17 - xp16_10922241_10922266 AGACUCCCACACUCACUCCAUCACC 7519 4261_18_3 CIITA eighteen + xp16_10922401_10922426 GCCAGCGUCCAGUACAACAAGUUCA 7520 4261_18_7 CIITA eighteen + xp16_10922408_10922433 UCCAGUACAACAGUUCACGGCUGC 7521 4261_18_8 CIITA eighteen + xp16_10922409_10922434 CCAGUACAACAAGUUCACGGCUGCC 7522 4261_18_9 CIITA eighteen + xp16_10922410_10922435 CAGUACAACAAGUUCACGGCUGCCG 7523 4261_18_13 CIITA eighteen + xp16_10922436_10922461 GGCCCAGCAGCCUCGCUGCCAGCCUU 7524 4261_18_14 CIITA eighteen + xp16_10922439_10922464 CCAGCAGCUCGCUGCCAGCCUUCGG 7525 4261_18_16 CIITA eighteen + xp16_10922452_10922477 GCCAGCCUUCGGAGGUGUCCUCAUG 7526 4261_18_18 CIITA eighteen + xp16_10922461_10922486 CGGAGGUGUCCUCAUGUGGAGACGC 7527 4261_18_20 CIITA eighteen + xp16_10922473_10922498 CAUGUGGAGACGCUGGCGUAAGUCC 7528 4261_18_21 CIITA eighteen + xp16_10922482_10922507 ACGCUGGCGUAAGUCCAGGCAACCC 7529 4261_18_26 CIITA eighteen - xp16_10922405_10922430 GCCGUGAACUUGUUGUACUGGACGC 7530 4261_18_27 CIITA eighteen - xp16_10922412_10922437 CCCGGCAGCCGUGAACUUGUUGUAC 7531 4261_18_30 CIITA eighteen - xp16_10922435_10922460 AGGCUGGCAGCGAGCUGCUGGGCCC 7532 4261_18_31 CIITA eighteen - xp16_10922441_10922466 CUCCGAAGGCUGGCAGCGAGCUGCU 7533 4261_18_32 CIITA eighteen - xp16_10922442_10922467 CCUCCGAAGGCUGGCAGCGAGCUGC 7534 4261_18_35 CIITA eighteen - xp16_10922456_10922481 UCCACAUGAGGACACCCUCCGAAGGC 7535 4261_18_36 CIITA eighteen - xp16_10922460_10922485 CGUCUCCACAUGAGGACACCUCCGA 7536 4261_18_39 CIITA eighteen - xp16_10922473_10922498 GGACUUACGCCAGCGGUCUCCACAUG 7537 4261_19_4 CIITA nineteen + xp16_10923234_10923259 ACGCCCACCAUCCCAUUCAGUGUCC 7538 4261_19_7 CIITA nineteen + xp16_10923252_10923277 AGUGUCCAGGAACACCUGCAACAAC 7539 4261_19_9 CIITA nineteen + xp16_10923260_10923285 GGAACACCUGCAACAACAGGAUUCA 7540 4261_19_13 CIITA nineteen + xp16_10923292_10923317 GCCUGAGAUGAUCCCAGCUGUGCUC 7541 4261_19_15 CIITA nineteen + xp16_10923297_10923322 AGAUGAUCCCAGCUGUGCUCUGGAC 7542 4261_19_16 CIITA nineteen + xp16_10923298_10923323 GAUGAUCCCAGCUGUGCUCUGGACA 7543 4261_19_18 CIITA nineteen + xp16_10923306_10923331 CAGCUGUGCUCUGGACAGGGUAACC 7544 4261_19_19 CIITA nineteen + xp16_10923307_10923332 AGCUGUGCUCUGGACAGGGUAACCA 7545 4261_19_21 CIITA nineteen + xp16_10923310_10923335 UGUGCUCUGGACAGGGUAACCAGGG 7546 4261_19_22 CIITA nineteen + xp16_10923311_10923336 GUGCUCUGGACAGGGUAACCAGGGU 7547 4261_19_24 CIITA nineteen + xp16_10923316_10923341 CUGGACAGGGUAACCAGGGUGGGCU 7548 4261_19_25 CIITA nineteen + xp16_10923317_10923342 UGGACAGGGUAACCAGGGUGGGCUU 7549 4261_19_26 CIITA nineteen - xp16_10923213_10923238 GCGUCCACAUCCUGCAAGGGGGGAU 7550 4261_19_28 CIITA nineteen - xp16_10923214_10923239 GGCGUCCACAUCCUGCAAGGGGGGA 7551 4261_19_30 CIITA nineteen - xp16_10923218_10923243 GGUGGGCGUCCACAUCCUGCAAGGG 7552 4261_19_32 CIITA nineteen - xp16_10923219_10923244 UGGUGGGCGUCCACAUCCUGCAAGG 7553 4261_19_33 CIITA nineteen - xp16_10923220_10923245 AUGGUGGGCGUCCACAUCCUGCAAG 7554 4261_19_36 CIITA nineteen - xp16_10923221_10923246 GAUGGUGGGCGUCCACAUCCUGCAA 7555 4261_19_37 CIITA nineteen - xp16_10923222_10923247 GGAUGGUGGGCGUCCACAUCCUGCA 7556 4261_19_41 CIITA nineteen - xp16_10923240_10923265 GUUCCUGGACACUGAAUGGGAUGGU 7557 4261_19_42 CIITA nineteen - xp16_10923241_10923266 UGUUCCUGGACACUGAAUGGGAUGG 7558 4261_19_44 CIITA nineteen - xp16_10923244_10923269 AGGUGUUCCUGGACACUGAAUGGGA 7559 4261_19_46 CIITA nineteen - xp16_10923248_10923273 UUGCAGGUGUUCCUGGACACUGAAU 7560 4261_19_48 CIITA nineteen - xp16_10923249_10923274 GUUGCAGGUGUUCCUGGACACUGAA 7561 4261_19_52 CIITA nineteen - xp16_10923260_10923285 UGAAUCCUGUUGUUGCAGGUGUUCC 7562 4261_19_54 CIITA nineteen - xp16_10923269_10923294 GCUGAUCCGUGAAUCCUGUUGUUGC 7563 4261_19_56 CIITA nineteen - xp16_10923296_10923321 UCCAGAGCACAGCUGGGAUCAUCUC 7564 4261_19_58 CIITA nineteen - xp16_10923307_10923332 UGGUUACCCUGUCCAGAGCACAGCU 7565 4261_19_60 CIITA nineteen - xp16_10923308_10923333 CUGGUUACCCUGUCCAGAGCACAGC 7566 4261_20_3 CIITA 20 + xp16_10923863_10923888 UCCUCCCGCUACAGCAUGUUCUCUG 7567 4261_20_5 CIITA 20 + xp16_10923879_10923904 UGUUCUCUGAGGACACUAACCACGC 7568 4261_20_9 CIITA 20 + xp16_10923891_10923916 ACACUAACCACGCUGGACCUUGAAC 7569 4261_20_10 CIITA 20 + xp16_10923892_10923917 CACUAACCACGCUGGACCUUGAACU 7570 4261_20_12 CIITA 20 + xp16_10923901_10923926 CGCUGGACCUUGAACUGGGUACUUG 7571 4261_20_14 CIITA 20 + xp16_10923919_10923944 GUACUUGUGGACACAGCUCUUCUCC 7572 4261_20_18 CIITA 20 + xp16_10923947_10923972 CUGUAUUCCCAUGAGCCUCAGCAUCC 7573 4261_20_19 CIITA 20 + xp16_10923954_10923979 CCAUGAGCCUCAGCAUCCUGGCAC 7574 4261_20_20 CIITA 20 + xp16_10923964_10923989 CAGCAUCCUGGCACCCGGCCCCUGC 7575 4261_20_22 CIITA 20 + xp16_10923970_10923995 CCUGGCACCCGGCCCCUGCUGGUUC 7576 4261_20_23 CIITA 20 + xp16_10923971_10923996 CUGGCACCCGGCCCCUGCUGGUUCA 7577 4261_20_24 CIITA 20 + xp16_10923975_10924000 CACCCGGCCCCUGCUGGUUCAGGGU 7578 4261_20_25 CIITA 20 + xp16_10923986_10924011 UGCUGGUUCAGGGUUGGCCCCUGCC 7579 4261_20_27 CIITA 20 + xp16_10923992_10924017 UUCAGGGUUGGCCCCUGCCCGGCUG 7580 4261_20_32 CIITA 20 + xp16_10924027_10924052 CACAUCUUGCUCUGCUGACAGACAC 7581 4261_20_33 CIITA 20 + xp16_10924032_10924057 CUUGCUCUGCUGACAGACACAGGCC 7582 4261_20_35 CIITA 20 + xp16_10924039_10924064 UGCUGACAGACACAAGGCCCGGCUCC 7583 4261_20_37 CIITA 20 + xp16_10924059_10924084 GCUCCAGGCUCCUUUAGCCGCCCAGU 7584 4261_20_38 CIITA 20 + xp16_10924060_10924085 CUCCAGGCUCCUUUAGCCGCCCAGUU 7585 4261_20_40 CIITA 20 + xp16_10924063_10924088 CAGGCUCCUUUAGCCGCCCAGUUGGG 7586 4261_20_41 CIITA 20 + xp16_10924071_10924096 UUUAGCCGCCCAGUUGGGUGGAUGCC 7587 4261_20_43 CIITA 20 + xp16_10924074_10924099 AGCGCCCAGUUGGGUGGAUGCCUGG 7588 4261_20_45 CIITA 20 + xp16_10924083_10924108 UUGGGUGGAUGCCUGGUGGCAGCUG 7589 4261_20_49 CIITA 20 + xp16_10924093_10924118 GCCUGGUGGCAGCUGCGGUCCACCC 7590 4261_20_51 CIITA 20 + xp16_10924103_10924128 AGCUGCGGUCCACCCAGGAGCCCCG 7591 4261_20_54 CIITA 20 + xp16_10924116_10924141 CCAGGAGCCCCGAGGCCUUCUCUGA 7592 4261_20_56 CIITA 20 + xp16_10924125_10924150 CCGAGGCCUUCUCUGAAGGACAUUG 7593 4261_20_57 CIITA 20 + xp16_10924135_10924160 CUCUGAAGGACAUUGCGGACAGCCA 7594 4261_20_59 CIITA 20 + xp16_10924140_10924165 AAGGACAUUGCGGACAGCCACGGCC 7595 4261_20_62 CIITA 20 + xp16_10924147_10924172 UUGCGGACAGCCACGGCCAGGCCAG 7596 4261_20_65 CIITA 20 + xp16_10924148_10924173 UGCGGACAGCCACGGCCAGGCCAGA 7597 4261_20_68 CIITA 20 + xp16_10924159_10924184 ACGGCCAGGCCAGAGGGAGUGACAG 7598 4261_20_69 CIITA 20 + xp16_10924182_10924207 AGAGGCAGCCCCAUUCUGCCUGCCC 7599 4261_20_71 CIITA 20 + xp16_10924197_10924222 CUGCCUGCCCAGGCCCCUGCCACCC 7600 4261_20_73 CIITA 20 + xp16_10924198_10924223 UGCCUGCCCAGGCCCCUGCCACCCU 7601 4261_20_77 CIITA 20 + xp16_10924199_10924224 GCCUGCCCAGGCCCCUGCCACCCUG 7602 4261_20_85 CIITA 20 + xp16_10924554_10924579 CUGCUCUCCGACCAGACACCUUGAC 7603 4261_20_86 CIITA 20 + xp16_10924555_10924580 UGCUCUCCGACCAGACACCUUGACA 7604 4261_20_88 CIITA 20 + xp16_10924563_10924588 GACCAGACACCUUGACAGGGCACAC 7605 4261_20_89 CIITA 20 + xp16_10924564_10924589 ACCAGACACCUUGACAGGGCACACC 7606 4261_20_93 CIITA 20 + xp16_10924584_10924609 ACACCGGGCACUCAGAAGACACUGA 7607 4261_20_94 CIITA 20 + xp16_10924585_10924610 CACCGGGCACUCAGAAGACACUGAU 7608 4261_20_95 CIITA 20 + xp16_10924622_10924647 GCCUGCUAAUUCCCCAGAUUGCAAC 7609 4261_20_97 CIITA 20 + xp16_10924626_10924651 GCUAAUUCCCCCAGAUUGCAACAGGC 7610 4261_20_98 CIITA 20 + xp16_10924627_10924652 CUAAUUCCCCCAGAUUGCAACAGGCU 7611 4261_20_100 CIITA 20 + xp16_10924636_10924661 CAGAUUGCAACAGGCUGGGCUUCAG 7612 4261_20_104 CIITA 20 + xp16_10924655_10924680 CUUCAGUGGCAGCUGCUUUUGUCUUA 7613 4261_20_105 CIITA 20 + xp16_10924656_10924681 UUCAGGUGGCAGCUGCUUUUGUCUAU 7614 4261_20_110 CIITA 20 + xp16_10924679_10924704 AUGGGACUCAAUGCACUGACAUUGU 7615 4261_20_111 CIITA 20 + xp16_10924696_10924721 GACAUUGUUGGCCAAAGCCAAAGCU 7616 4261_20_112 CIITA 20 + xp16_10924701_10924726 UGUUGGCCAAAAGCCAAAGCUAGGCC 7617 4261_20_116 CIITA 20 + xp16_10924725_10924750 CUGGCCAGAUGCACCAGCCCUUAGC 7618 4261_20_118 CIITA 20 + xp16_10924726_10924751 UGGCCAGAUGCACCAGCCCUUAGCA 7619 4261_20_122 CIITA 20 + xp16_10924739_10924764 CAGCCCUUAGCAGGGAAACAGCUAA 7620 4261_20_123 CIITA 20 + xp16_10924740_10924765 AGCCCUUAGCAGGGAAACAGCUAAU 7621 4261_20_126 CIITA 20 + xp16_10924750_10924775 AGGGAAACAGCUAAUGGGACACUAA 7622 4261_20_128 CIITA 20 + xp16_10924751_10924776 GGGAAACAGCUAAUGGGACACUAAU 7623 4261_20_129 CIITA 20 + xp16_10924752_10924777 GGAAACAGCUAAUGGGACACUAAUG 7624 4261_20_130 CIITA 20 + xp16_10924755_10924780 AACAGCUAAUGGGACACUAAUGGGG 7625 4261_20_135 CIITA 20 + xp16_10924762_10924787 AAUGGGACACUAAUGGGGCGGUGAG 7626 4261_20_136 CIITA 20 + xp16_10924763_10924788 AUGGGACACUAAUGGGGCGGUGAGA 7627 4261_20_138 CIITA 20 + xp16_10924764_10924789 UGGGACACUAAUGGGGCGGUGAGAG 7628 4261_20_141 CIITA 20 + xp16_10924774_10924799 AUGGGGCGGUGAGAGGGGAACAGAC 7629 4261_20_151 CIITA 20 + xp16_10924838_10924863 AUUAAUAAAUGUCUCUUUAAUGUCAC 7630 4261_20_152 CIITA 20 + xp16_10924842_10924867 UAAAUGUCUCUUUAAUGUCACAGGC 7631 4261_20_155 CIITA 20 + xp16_10924848_10924873 UCUCUUUAAUGUCACAAGGCAGGUCC 7632 4261_20_156 CIITA 20 + xp16_10924849_10924874 CUCUUUAAUGUCACAAGGCAGGUCCA 7633 4261_20_162 CIITA 20 + xp16_10924878_10924903 UUGAGUUCAUACCCUGUUACCAUUU 7634 4261_20_163 CIITA 20 + xp16_10924879_10924904 UGAGUUCAUACCUGUUACCAUUUU 7635 4261_20_165 CIITA 20 + xp16_10924880_10924905 GAGUUCAUACCUGUUACCAUUUUG 7636 4261_20_172 CIITA 20 - xp16_10923860_10923885 AGAACAUGCUGUAGCGGGAGGAGCC 7637 4261_20_173 CIITA 20 - xp16_10923867_10923892 UCCUCAGAGAACAUGCUGUAGCGGG 7638 4261_20_176 CIITA 20 - xp16_10923870_10923895 GUGUCCUCCAGAGAACAUGCUGUAGGC 7639 4261_20_179 CIITA 20 - xp16_10923871_10923896 AGUGUCCUCAGAGAACAUGCUGUAG 7640 4261_20_186 CIITA 20 - xp16_10923901_10923926 CAAGUACCCAGUUCAAGGUCCAGCG 7641 4261_20_187 CIITA 20 - xp16_10923911_10923936 GCUGUGUGCCACAAGUACCCAGUUCA 7642 4261_20_191 CIITA 20 - xp16_10923945_10923970 AUGCUGAGGCUCAUGGGAUACAGCC 7643 4261_20_194 CIITA 20 - xp16_10923956_10923981 CGGGUGCCAGGAUGCUGAGGCUCAU 7644 4261_20_195 CIITA 20 - xp16_10923957_10923982 CCGGGUGCCAGGAUGCUGAGGCUCA 7645 4261_20_198 CIITA 20 - xp16_10923964_10923989 GCAGGGGCCGGGUGCCAGGAUGCUG 7646 4261_20_200 CIITA 20 - xp16_10923973_10923998 CCUGAACCAGCAGGGGCCGGGUGCC 7647 4261_20_202 CIITA 20 - xp16_10923980_10924005 GGCCAACCCUGAACCAGCAGGGGCC 7648 4261_20_203 CIITA 20 - xp16_10923981_10924006 GGGCCAACCCUGAACCAGCAGGGGC 7649 4261_20_205 CIITA 20 - xp16_10923985_10924010 GCAGGGGCCAAACCCUGAACCAGCAG 7650 4261_20_206 CIITA 20 - xp16_10923986_10924011 GGCAGGGGCCAAACCCUGAACCAGCA 7651 4261_20_207 CIITA 20 - xp16_10923987_10924012 GGGCAGGGGCCAACCCUGAACCAGC 7652 4261_20_213 CIITA 20 - xp16_10924006_10924031 UGUGGUUCAUUCCGCAGCCGGGCAG 7653 4261_20_214 CIITA 20 - xp16_10924007_10924032 AUGUGGUUCAUUCCGCAGCCGGGCA 7654 4261_20_215 CIITA 20 - xp16_10924008_10924033 GAUGUGGUUCAUUCCGCAGCCGGGC 7655 4261_20_218 CIITA 20 - xp16_10924012_10924037 GCAAGAUGUGGUUCAUUCCGCAGCC 7656 4261_20_219 CIITA 20 - xp16_10924013_10924038 AGCAAGAUGUGGUUCAUUCCGCAGC 7657 4261_20_221 CIITA 20 - xp16_10924029_10924054 CUGUGUCUGUCAGCAGAGCAAGAUG 7658 4261_20_223 CIITA 20 - xp16_10924058_10924083 CUGGGCCGCUAAAGGAGCCUGGAGCC 7659 4261_20_224 CIITA 20 - xp16_10924059_10924084 ACUGGGCCGCUAAAGGAGCCUGGAGC 7660 4261_20_227 CIITA 20 - xp16_10924065_10924090 CACCCAACUGGGCCGCUAAAGGAGCC 7661 4261_20_230 CIITA 20 - xp16_10924072_10924097 AGGCAUCCACCCAACUGGGCCGCUAA 7662 4261_20_232 CIITA 20 - xp16_10924081_10924106 GCUGCCACCAGGCAUCCACCCAACU 7663 4261_20_233 CIITA 20 - xp16_10924082_10924107 AGCUGCCACCAGGCAUCCACCCAAC 7664 4261_20_235 CIITA 20 - xp16_10924097_10924122 UCCUGGGUGGACCGCAGCUGCCACC 7665 4261_20_236 CIITA 20 - xp16_10924115_10924140 CAGAGAAGGCCUCGGGGCUCCUGGG 7666 4261_20_239 CIITA 20 - xp16_10924118_10924143 CUUCAGAGAAGGCCUCGGGGCUCCU 7667 4261_20_240 CIITA 20 - xp16_10924119_10924144 CCUUCAGAGAAGGCCUCGGGGCUCC 7668 4261_20_242 CIITA 20 - xp16_10924126_10924151 GCAAUGUCCUUCAGAGAAGGCCUCG 7669 4261_20_243 CIITA 20 - xp16_10924127_10924152 CGCAAUGUCCUUCAGAGAAGGCCUC 7670 4261_20_245 CIITA 20 - xp16_10924128_10924153 CCGCAAUGUCCUUCAGAGAAGGCCU 7671 4261_20_247 CIITA 20 - xp16_10924134_10924159 GGCUGUCCCGCAAUGUCCUUCAGAGA 7672 4261_20_251 CIITA 20 - xp16_10924160_10924185 UCUGUCACUCCCUCUGGCCUGGCCG 7673 4261_20_252 CIITA 20 - xp16_10924166_10924191 GCUGCCUCUGUCACUCCCUCUGCC 7674 4261_20_253 CIITA 20 - xp16_10924171_10924196 AUGGGGCUGCCUCUGUCACUCCUCUC 7675 4261_20_254 CIITA 20 - xp16_10924193_10924218 GGCAGGGGCCUGGGCAGGCAGAAUG 7676 4261_20_255 CIITA 20 - xp16_10924194_10924219 UGGCAGGGGCCUGGGCAGGCAGAAU 7677 4261_20_257 CIITA 20 - xp16_10924195_10924220 GUGGCAGGGGCCUGGGCAGGCAGAA 7678 4261_20_260 CIITA 20 - xp16_10924203_10924228 UCCCCAGGGUGGCAGGGGCCUGGGC 7679 4261_20_263 CIITA 20 - xp16_10924207_10924232 UUUCUCCCCAGGGUGGCAGGGGCCU 7680 4261_20_264 CIITA 20 - xp16_10924208_10924233 CUUUCUCCCCAGGGUGGCAGGGGCC 7681 4261_20_266 CIITA 20 - xp16_10924213_10924238 UUGUACUUUUCUCCCAGGGUGGCAG 7682 4261_20_267 CIITA 20 - xp16_10924214_10924239 CUUGUACUUUUCUCCCAGGGUGGCA 7683 4261_20_268 CIITA 20 - xp16_10924215_10924240 UCUUGUACUUUUCUCCCAGGGUGGC 7684 4261_20_271 CIITA 20 - xp16_10924219_10924244 UUUUUCUUGUACUUUCUCCCCCAGGG 7685 4261_20_272 CIITA 20 - xp16_10924222_10924247 UUUUUUUUCUUGUACUUUCUCCCCA 7686 4261_20_273 CIITA 20 - xp16_10924223_10924248 UUUUUUUUUCUUGUACUUUCUCCCCC 7687 4261_20_279 CIITA 20 - xp16_10924552_10924577 CAAGGUGUCUGGUCGGAGAGCAGGG 7688 4261_20_282 CIITA 20 - xp16_10924555_10924580 UGUCAAGGUGUCUGGUCGGAGAGCA 7689 4261_20_283 CIITA 20 - xp16_10924556_10924581 CUGUCAAGGUGUCUGGUCGGAGAGC 7690 4261_20_286 CIITA 20 - xp16_10924564_10924589 GGUGUGCCCUGUCAAGGUGUCUGGU 7691 4261_20_289 CIITA 20 - xp16_10924568_10924593 GCCCGGUGUGCCCUGUCAAGGUGUC 7692 4261_20_291 CIITA 20 - xp16_10924575_10924600 UCUGAGUGCCCGGUGUGCCCUGUCA 7693 4261_20_293 CIITA 20 - xp16_10924590_10924615 UGCCCAUCAGUGUCUUCUGAGUGCC 7694 4261_20_296 CIITA 20 - xp16_10924619_10924644 GCAAUCUGGGGAAUUAGCAGGCUGG 7695 4261_20_298 CIITA 20 - xp16_10924620_10924645 UGCAAUCUGGGGAAUUAGCAGGCUG 7696 4261_20_299 CIITA 20 - xp16_10924621_10924646 UUGCAAUCUGGGGAAUUAGCAGGCU 7697 4261_20_302 CIITA 20 - xp16_10924622_10924647 GUUGCAAUCUGGGGAAUUAGCAGGC 7698 4261_20_304 CIITA 20 - xp16_10924626_10924651 GCCUGUUGCAAUCUGGGGAAUUAGC 7699 4261_20_306 CIITA 20 - xp16_10924636_10924661 CUGAAGCCCAGCCUGUUGCAAUCUG 7700 4261_20_307 CIITA 20 - xp16_10924637_10924662 ACUGAAGCCCAGCCUGUUGCAAUCU 7701 4261_20_310 CIITA 20 - xp16_10924638_10924663 CACUGAAGCCCAGCCUGUUGCAAUC 7702 4261_20_319 CIITA 20 - xp16_10924710_10924735 AUCUGGCCAGGCCUAGCUUUGGCUU 7703 4261_20_320 CIITA 20 - xp16_10924716_10924741 UGGUGCAUCUGGCCAGGCCUAGCUU 7704 4261_20_321 CIITA 20 - xp16_10924727_10924752 CUGCUAAGGGCUGGUGCAUCUGGCC 7705 4261_20_324 CIITA 20 - xp16_10924732_10924757 UUUCCCUGCUAAGGGCUGGUGCAUC 7706 4261_20_326 CIITA 20 - xp16_10924741_10924766 CAUUAGCUGUUUCCCUGCUAAGGGC 7707 4261_20_327 CIITA 20 - xp16_10924745_10924770 GUCCCAUUAGCUGUUUCCCUGCUAA 7708 4261_20_328 CIITA 20 - xp16_10924746_10924771 UGUCCCAUUAGCUGUUUCCCUGCUA 7709 4261_20_336 CIITA 20 - xp16_10924821_10924846 UUUAUAAUGUAGUGAAAAAAGACAC 7710 4261_20_342 CIITA 20 - xp16_10924874_10924899 GGUAAACAGGGUAUGAACUCAAACCC 7711 4261_20_345 CIITA 20 - xp16_10924892_10924917 GUGUGGGUACCCCAAAAUGGUAACA 7712 4261_20_346 CIITA 20 - xp16_10924893_10924918 CGUGUGGGUACCCCAAAAUGGUAAC 7713 4261_20_348 CIITA 20 - xp16_10924900_10924925 UUGGUCUCGUGUGGGUACCCCAAAAA 7714 4261_20_349 CIITA 20 - xp16_10924913_10924938 AAUGUAUAAAUCUAUUGGUCUCGUGU 7715 4261_20_350 CIITA 20 - xp16_10924914_10924939 CAAUGUAUAAAUCUAUUGGUCUCGUG 7716 84166_1_4 NLRC5 EXON + xp16:57017065-57017085 CCCCUUAGGAGUCUGCACUA 8622 84166_1_6 NLRC5 EXON + xp16:57017091-57017111 CAACCUGUCAAUCCAGCUCA 8623 84166_1_9 NLRC5 EXON + xp16:57017129-57017149 CACCCAUGAGACCCUCCCG 8624 84166_1_11 NLRC5 EXON + xp16:57017130-57017150 ACCCAUGAGACCCUCUCCGU 8625 84166_1_13 NLRC5 EXON + xp16:57017131-57017151 CCCAUGAGACCCUCUCCGUG 8626 84166_1_19 NLRC5 EXON + xp16:57017158-57017178 UAGAGCACCUAUCAUGAACG 8627 84166_1_20 NLRC5 EXON + xp16:57017170-57017190 CAUGAACGAGGAGACCAAGU 8628 84166_1_21 NLRC5 EXON - xp16:57017056-57017076 CUCCUAAGGGGAGAGAAGAC 8629 84166_1_28 NLRC5 EXON - xp16:57017068-57017088 CCAUAGUGCAGACUCCUAAG 8630 84166_1_30 NLRC5 EXON - xp16:57017069-57017089 UCCAUAGUGCAGACUCCUAA 8631 84166_1_33 NLRC5 EXON - xp16:57017070-57017090 UUCCAUAGUGCAGACUCCUA 8632 84166_1_37 NLRC5 EXON - xp16:57017097-57017117 GUGCCUUGAGCUGGAUUGAC 8633 84166_1_38 NLRC5 EXON - xp16:57017106-57017126 GGGCUAUGUGUGCCUUGAGC 8634 84166_1_41 NLRC5 EXON - xp16:57017126-57017146 AGAGGGUCUCAUGGGUGUCU 8635 84166_1_42 NLRC5 EXON - xp16:57017127-57017147 GAGAGGGUCUCAUGGGUGUC 8636 84166_1_44 NLRC5 EXON - xp16:57017134-57017154 CCCCACGGAGAGGGUCUCAU 8637 84166_1_45 NLRC5 EXON - xp16:57017135-57017155 UCCCCACGGAGAGGGUCUCA 8638 84166_1_47 NLRC5 EXON - xp16:57017143-57017163 CUCUAGGGUCCCCACGGAGA 8639 84166_1_48 NLRC5 EXON - xp16:57017144-57017164 GCUCUAGGGUCCCCACGGAG 8640 84166_1_52 NLRC5 EXON - xp16:57017149-57017169 UAGGUGCUCUAGGGUCCCCCA 8641 84166_1_55 NLRC5 EXON - xp16:57017158-57017178 CGUUCAUGAUAGGUGCUCUA 8642 84166_1_56 NLRC5 EXON - xp16:57017159-57017179 UCGUUCAUGAUAGGUGCUCU 8643 84166_1_59 NLRC5 EXON - xp16:57017168-57017188 UUGGUCUCCUCGUUCAUGAU 8644 84166_1_60 NLRC5 EXON - xp16:57017187-57017207 GGAGAGAAAAAAUCACCUACU 8645 84166_2_1 NLRC5 EXON + xp16:57020683-57020703 CUUCCCUGUCCCUCCAGGGC 8646 84166_2_4 NLRC5 EXON + xp16:57020693-57020713 CCUCCAGGGCUGGCUCCUCA 8647 84166_2_5 NLRC5 EXON + xp16:57020703-57020723 UGGCUCCUCAUGGACCCCGU 8648 84166_2_6 NLRC5 EXON + xp16:57020715-57020735 GACCCCGUUGGCCUCCAGCU 8649 84166_2_11 NLRC5 EXON + xp16:57020731-57020751 AGCUCGGCAACAAGAACCUG 8650 84166_2_13 NLRC5 EXON + xp16:57020746-57020766 ACCUGUGGAGCUGUCUUGUG 8651 84166_2_17 NLRC5 EXON + xp16:57020770-57020790 UGCUCACCAAAGACCCAGAA 8652 84166_2_21 NLRC5 EXON + xp16:57020807-57020827 GAAGUUCUUCCUCCCCAACA 8653 84166_2_23 NLRC5 EXON + xp16:57020813-57020833 CUUCCUCCCCAACACGGACC 8654 84166_2_27 NLRC5 EXON + xp16:57020821-57020841 CCAACACGGACCUGGAUUCC 8655 84166_2_31 NLRC5 EXON + xp16:57020834-57020854 GGAUUCCAGGAACGAGACCU 8656 84166_2_38 NLRC5 EXON + xp16:57020882-57020902 ACUCAACAAGCUGCAUGUCC 8657 84166_2_39 NLRC5 EXON + xp16:57020883-57020903 CUCAACAAGCUGCAUGUCCA 8658 84166_2_41 NLRC5 EXON + xp16:57020888-57020908 CAAGCUGCAUGUCCAGGGUU 8659 84166_2_42 NLRC5 EXON + xp16:57020896-57020916 AUGUCCAGGGUUCGGACACC 8660 84166_2_49 NLRC5 EXON + xp16:57020973-57020993 GUGCUGCUGCUGAGUACUUU 8661 84166_2_50 NLRC5 EXON + xp16:57020985-57021005 AGUACUUUUGGCUAUGAUGA 8662 84166_2_52 NLRC5 EXON + xp16:57020990-57021010 UUUUGGCUAUGAUGAUGGUA 8663 84166_2_53 NLRC5 EXON + xp16:57020991-57021011 UUUGGCUAUGAUGAUGGUAA 8664 84166_2_57 NLRC5 EXON + xp16:57020995-57021015 GCUAUGAUGAUGGUAAGGGC 8665 84166_2_61 NLRC5 EXON - xp16:57020689-57020709 GAGCCAGCCCUGGAGGGACA 8666 84166_2_63 NLRC5 EXON - xp16:57020690-57020710 GGAGCCAGCCCUGGAGGGAC 8667 84166_2_65 NLRC5 EXON - xp16:57020695-57020715 CAUGAGGAGCCAGCCCUGGA 8668 84166_2_66 NLRC5 EXON - xp16:57020696-57020716 CCAUGAGGAGCCAGCCCUGG 8669 84166_2_69 NLRC5 EXON - xp16:57020699-57020719 GGUCCAUGAGGAGCCAGCCC 8670 84166_2_72 NLRC5 EXON - xp16:57020711-57020731 GGAGGCCAACGGGGUCCAUG 8671 84166_2_78 NLRC5 EXON - xp16:57020720-57020740 UGCCGAGCUGGAGGCCAACG 8672 84166_2_80 NLRC5 EXON - xp16:57020721-57020741 UUGCCGAGCUGGAGGCCAAC 8673 84166_2_82 NLRC5 EXON - xp16:57020722-57020742 GUUGCCGAGCUGGAGGCCA 8674 84166_2_84 NLRC5 EXON - xp16:57020729-57020749 GGUUCUUGUUGCCGAGCUGG 8675 84166_2_86 NLRC5 EXON - xp16:57020732-57020752 ACAGGUUCUUGUUGCCGAGC 8676 84166_2_89 NLRC5 EXON - xp16:57020750-57020770 GCCUCACAAGACAGCUCCAC 8677 84166_2_96 NLRC5 EXON - xp16:57020779-57020799 GUUCAGCCAUUCUGGGUCUU 8678 84166_2_98 NLRC5 EXON - xp16:57020786-57020806 UCUUGGCGUUCAGCCAUUCU 8679 84166_2_99 NLRC5 EXON - xp16:57020787-57020807 AUCUUGGCGUUCAGCCAUUC 8680 84166_2_102 NLRC5 EXON - xp16:57020803-57020823 GGGGAGGAAGAACUUCAUCU 8681 84166_2_105 NLRC5 EXON - xp16:57020819-57020839 AAUCCAGGUCCGUGUUGGGG 8682 84166_2_109 NLRC5 EXON - xp16:57020822-57020842 UGGAAUCCAGGUCCGUGUUG 8683 84166_2_112 NLRC5 EXON - xp16:57020823-57020843 CUGGAAUCCAGGUCCGUGUU 8684 84166_2_114 NLRC5 EXON - xp16:57020824-57020844 CCUGGAAUCCAGGUCCGUGU 8685 84166_2_116 NLRC5 EXON - xp16:57020834-57020854 AGGUCUCGUUCCUGGAAUCC 8686 84166_2_118 NLRC5 EXON - xp16:57020842-57020862 AGGGUCCAAGGUCUCGUUCC 8687 84166_2_121 NLRC5 EXON - xp16:57020854-57020874 GACUCUCUGUUCAGGGUCCA 8688 84166_2_123 NLRC5 EXON - xp16:57020861-57020881 GCAGGAUGACUCUCUGUUCA 8689 84166_2_125 NLRC5 EXON - xp16:57020862-57020882 UGCAGGAUGACUCUCUGUUC 8690 84166_2_128 NLRC5 EXON - xp16:57020879-57020899 CAUGCAGCUUGUUGAGUUGC 8691 84166_2_131 NLRC5 EXON - xp16:57020903-57020923 ACUGCCAGGUGUCCGAACCC 8692 84166_2_134 NLRC5 EXON - xp16:57020917-57020937 ACAAUGAAUGAAAGACUGCC 8693 84166_3_2 NLRC5 EXON + xp16:57022250-57022270 UGCAGGGUUCACCAGCCAGC 8694 84166_3_5 NLRC5 EXON + xp16:57022251-57022271 GCAGGGUUCACCAGCCAGCU 8695 84166_3_10 NLRC5 EXON + xp16:57022259-57022279 CACCAGCCAGCUGGGAGCUG 8696 84166_3_12 NLRC5 EXON + xp16:57022260-57022280 ACCAGCCAGCUGGGAGCUGA 8697 84166_3_14 NLRC5 EXON + xp16:57022261-57022281 CCAGCCAGCUGGGAGCUGAG 8698 84166_3_17 NLRC5 EXON + xp16:57022293-57022313 CCUGAAUCUCAGCUCCACCA 8699 84166_3_20 NLRC5 EXON + xp16:57022298-57022318 AUCUCAGCUCCACCAUGGUG 8700 84166_3_23 NLRC5 EXON + xp16:57022303-57022323 AGCUCCACCAUGGUGAGGAC 8701 84166_3_26 NLRC5 EXON + xp16:57022309-57022329 ACCAUGGUGAGGACUGGAGU 8702 84166_3_28 NLRC5 EXON + xp16:57022310-57022330 CCAUGGUGAGGACUGGAGUU 8703 84166_3_29 NLRC5 EXON + xp16:57022311-57022331 CAUGGUGAGGACUGGAGUUG 8704 84166_3_30 NLRC5 EXON + xp16:57022312-57022332 AUGGUGAGGACUGGAGUUGG 8705 84166_3_32 NLRC5 EXON - xp16:57022244-57022264 UGGUGAACCCUGCAAGAGAG 8706 84166_3_35 NLRC5 EXON - xp16:57022245-57022265 CUGGUGAACCCCUGCAAGAGA 8707 84166_3_36 NLRC5 EXON - xp16:57022246-57022266 GCUGGUGAACCCUGCAAGAG 8708 84166_3_45 NLRC5 EXON - xp16:57022264-57022284 CCCCUCAGCUCCCAGCUGGC 8709 84166_3_47 NLRC5 EXON - xp16:57022268-57022288 UUUUCCCCUCAGCUCCCAGC 8710 84166_3_49 NLRC5 EXON - xp16:57022292-57022312 GGUGGAGCUGAGAUUCAGGU 8711 84166_3_50 NLRC5 EXON - xp16:57022296-57022316 CCAUGGUGGAGCUGAGAUUC 8712 84166_3_53 NLRC5 EXON - xp16:57022310-57022330 AACUCCAGUCCUCACCAUGG 8713 84166_3_55 NLRC5 EXON - xp16:57022313-57022333 CCCAACUCCAGUCCUCACCA 8714 84166_4_11 NLRC5 EXON + xp16:57023789-57023809 AAGCGCCCACAUCAGAGCUG 8715 84166_4_12 NLRC5 EXON + xp16:57023790-57023810 AGCGCCCACAUCAGAGCUGU 8716 84166_4_15 NLRC5 EXON + xp16:57023805-57023825 GCUGUGGGUCCUCCACCCCGC 8717 84166_4_17 NLRC5 EXON + xp16:57023831-57023851 CAGUGCAAGAAGCAGCAGCU 8718 84166_4_19 NLRC5 EXON + xp16:57023834-57023854 UGCAAGAAGCAGCAGCUAGG 8719 84166_4_20 NLRC5 EXON + xp16:57023835-57023855 GCAAGAAGCAGCAGCUAGGU 8720 84166_4_23 NLRC5 EXON + xp16:57023846-57023866 CAGCUAGGUGGGUACCAGUG 8721 84166_4_24 NLRC5 EXON + xp16:57023847-57023867 AGCUAGGUGGGUACCAGUGU 8722 84166_4_27 NLRC5 EXON + xp16:57023848-57023868 GCUAGGUGGGUACCAGUGUG 8723 84166_4_29 NLRC5 EXON - xp16:57023767-57023787 GGCCUGAAAAAGCAAAGGAA 8724 84166_4_30 NLRC5 EXON - xp16:57023768-57023788 AGGCCUGAAAAAGCAAAGGA 8725 84166_4_32 NLRC5 EXON - xp16:57023772-57023792 CUUCAGGCCUGAAAAAGCAA 8726 84166_4_36 NLRC5 EXON - xp16:57023788-57023808 AGCUCUGAUGUGGGCGCUUC 8727 84166_4_37 NLRC5 EXON - xp16:57023797-57023817 AGGACCCAGACUCUGAUGU 8728 84166_4_38 NLRC5 EXON - xp16:57023798-57023818 GAGGACCCAGACUCUGAUG 8729 84166_4_43 NLRC5 EXON - xp16:57023817-57023837 GCACUGCUUCCGGCGGGGUG 8730 84166_4_46 NLRC5 EXON - xp16:57023822-57023842 UUCUUGCACUGCUUCCGGCG 8731 84166_4_47 NLRC5 EXON - xp16:57023823-57023843 CUUCUUGCACUGCUUCCGGC 8732 84166_4_49 NLRC5 EXON - xp16:57023824-57023844 GCUUCUUGCACUGCUUCCGG 8733 84166_4_51 NLRC5 EXON - xp16:57023827-57023847 GCUGCUUCUUGCACUGCUUC 8734 84166_5_1 NLRC5 EXON + xp16:57025350-57025370 GUCCCUGCCCCUUGCAGAGU 8735 84166_5_6 NLRC5 EXON + xp16:57025376-57025396 AGAAGUACCUGCAGCUCCUG 8736 84166_5_9 NLRC5 EXON + xp16:57025400-57025420 CCUCUGCCCAGCAGCCGCUAC 8737 84166_5_11 NLRC5 EXON + xp16:57025414-57025434 CGCUACAGGAGCCAAAUCCC 8738 84166_5_12 NLRC5 EXON + xp16:57025415-57025435 GCUACAGGAGCCAAAUCCCU 8739 84166_5_14 NLRC5 EXON + xp16:57025420-57025440 AGGAGCCAAAUCCCUGGGUC 8740 84166_5_15 NLRC5 EXON + xp16:57025421-57025441 GGAGCCAAAUCCCUGGGUCA 8741 84166_5_16 NLRC5 EXON + xp16:57025443-57025463 GCAGCCCCACGCCUUCCACC 8742 84166_5_19 NLRC5 EXON + xp16:57025469-57025489 AUGUCCCUCCAAUCCUGCGC 8743 84166_5_20 NLRC5 EXON + xp16:57025470-57025490 UGUCCCUCCAAUCCUGCGCC 8744 84166_5_22 NLRC5 EXON + xp16:57025494-57025514 CACAGCAUCCUUAGACACUC 8745 84166_5_26 NLRC5 EXON + xp16:57025497-57025517 AGCAUCCUUAGACACUCCGG 8746 84166_5_27 NLRC5 EXON + xp16:57025498-57025518 GCAUCCUUAGACACUCCGGA 8747 84166_5_29 NLRC5 EXON + xp16:57025499-57025519 CAUCCUUAGACACUCCGGAG 8748 84166_5_30 NLRC5 EXON + xp16:57025500-57025520 AUCCUUAGACACUCCGGAGG 8749 84166_5_34 NLRC5 EXON + xp16:57025509-57025529 CACUCCGGAGGGGGCCAUUA 8750 84166_5_35 NLRC5 EXON + xp16:57025510-57025530 ACUCCGGAGGGGGCCAUUAU 8751 84166_5_37 NLRC5 EXON + xp16:57025511-57025531 CUCCGGAGGGGGCCAUUAUG 8752 84166_5_39 NLRC5 EXON + xp16:57025512-57025532 UCCGGAGGGGGCCAUUAUGG 8753 84166_5_40 NLRC5 EXON + xp16:57025521-57025541 GGCCAUUAUGGGGGACGUCA 8754 84166_5_43 NLRC5 EXON + xp16:57025524-57025544 CAUUAUGGGGGACGUCAAGG 8755 84166_5_45 NLRC5 EXON + xp16:57025531-57025551 GGGGACGUCAAGGUGGAAGA 8756 84166_5_48 NLRC5 EXON + xp16:57025551-57025571 UGGUGCUGACGUGAGCAUCU 8757 84166_5_50 NLRC5 EXON + xp16:57025568-57025588 UCUCGGACCUCUUCAACACC 8758 84166_5_51 NLRC5 EXON + xp16:57025569-57025589 CUCGGACCUCUUCAACACCA 8759 84166_5_53 NLRC5 EXON + xp16:57025578-57025598 CUUCAACACCAGGGUUAACA 8760 84166_5_54 NLRC5 EXON + xp16:57025579-57025599 UUCAACACCAGGGUUAACAA 8761 84166_5_58 NLRC5 EXON + xp16:57025586-57025606 CCAGGGUUAACAAGGGCCCG 8762 84166_5_59 NLRC5 EXON + xp16:57025587-57025607 CAGGGUUAACAAGGGCCCGA 8763 84166_5_63 NLRC5 EXON + xp16:57025602-57025622 CCCGAGGGUGACCGUGCUUU 8764 84166_5_65 NLRC5 EXON + xp16:57025603-57025623 CCGAGGGUGACCGUGCUUUU 8765 84166_5_66 NLRC5 EXON + xp16:57025604-57025624 CGAGGGUGACCGUGCUUUUG 8766 84166_5_68 NLRC5 EXON + xp16:57025608-57025628 GGUGACCGUGCUUUUGGGGA 8767 84166_5_69 NLRC5 EXON + xp16:57025612-57025632 ACCGUGCUUUUGGGGAAGGC 8768 84166_5_71 NLRC5 EXON + xp16:57025617-57025637 GCUUUUGGGGAAGGCUGGCA 8769 84166_5_72 NLRC5 EXON + xp16:57025618-57025638 CUUUUGGGGAAGGCUGGCAU 8770 84166_5_76 NLRC5 EXON + xp16:57025632-57025652 UGGCAUGGGCAAGACCACGC 8771 84166_5_77 NLRC5 EXON + xp16:57025640-57025660 GCAAGACCACGCUGGCCCAC 8772 84166_5_80 NLRC5 EXON + xp16:57025655-57025675 CCCACCGGCUCUGCCAGAAG 8773 84166_5_81 NLRC5 EXON + xp16:57025656-57025676 CCACCGGCUCUGCCAGAAGU 8774 84166_5_84 NLRC5 EXON + xp16:57025662-57025682 GCUCUGCCAGAAGUGGGCAG 8775 84166_5_85 NLRC5 EXON + xp16:57025663-57025683 CUCUGCCAGAAGUGGGCAGA 8776 84166_5_87 NLRC5 EXON + xp16:57025683-57025703 GGGCCAUCUGAACUGUUUCC 8777 84166_5_98 NLRC5 EXON + xp16:57025727-57025747 GCCAGCUCAACUUGAUCACCG 8778 84166_5_109 NLRC5 EXON + xp16:57025779-57025799 UCUGUACCUGAGCCCUGAAU 8779 84166_5_112 NLRC5 EXON + xp16:57025806-57025826 CGACACUGUCUUCCAGUAC 8780 84166_5_117 NLRC5 EXON + xp16:57025843-57025863 CAAGUCCUGCUGAUCUUUGA 8781 84166_5_118 NLRC5 EXON + xp16:57025844-57025864 AAGUCCUGCUGAUCUUUGAU 8782 84166_5_120 NLRC5 EXON + xp16:57025854-57025874 GAUCUUUGAUGGGCUAGAUG 8783 84166_5_124 NLRC5 EXON + xp16:57025869-57025889 AGAUGAGGCCCUCCAGCCUA 8784 84166_5_125 NLRC5 EXON + xp16:57025870-57025890 GAUGAGGCCCUCCAGCCUAU 8785 84166_5_126 NLRC5 EXON + xp16:57025879-57025899 CUCCAGCCUAUGGGUCCUGA 8786 84166_5_127 NLRC5 EXON + xp16:57025885-57025905 CCUAUGGGUCCUGAUGGCCC 8787 84166_5_129 NLRC5 EXON + xp16:57025921-57025941 CUUUUCUCCCAUCUCUGCAA 8788 84166_5_131 NLRC5 EXON + xp16:57025922-57025942 UUUUCUCCCAUCUCUGCAAU 8789 84166_5_136 NLRC5 EXON + xp16:57025995-57026015 GCCUGCCUGCCUGCCUGCAG 8790 84166_5_137 NLRC5 EXON + xp16:57026004-57026024 CCUGCCUGCAGAGGCAGCCA 8791 84166_5_139 NLRC5 EXON + xp16:57026016-57026036 GGCAGCCAUGGUCCACAUGU 8792 84166_5_140 NLRC5 EXON + xp16:57026017-57026037 GCAGCCAUGGUCCACAUGUU 8793 84166_5_142 NLRC5 EXON + xp16:57026026-57026046 GUCCACAUGUUGGGCUUUGA 8794 84166_5_143 NLRC5 EXON + xp16:57026027-57026047 UCCACAUGUUGGGCUUUGAU 8795 84166_5_145 NLRC5 EXON + xp16:57026033-57026053 UGUUGGGCUUUGAUGGGCCA 8796 84166_5_146 NLRC5 EXON + xp16:57026034-57026054 GUUGGGCUUUGAUGGGCCAC 8797 84166_5_149 NLRC5 EXON + xp16:57026037-57026057 GGGCUUUGAUGGGCCACGGG 8798 84166_5_158 NLRC5 EXON + xp16:57026078-57026098 UCUUCAGCGGCCCAGCCAUCG 8799 84166_5_159 NLRC5 EXON + xp16:57026079-57026099 CUUCAGCGCCCAGCCAUCGC 8800 84166_5_163 NLRC5 EXON + xp16:57026082-57026102 CAGCGCCCAGCCAUCGCGGG 8801 84166_5_165 NLRC5 EXON + xp16:57026083-57026103 AGCGCCCAGCCAUCGCGGGA 8802 84166_5_168 NLRC5 EXON + xp16:57026084-57026104 GCGCCCAGCCAUCGCGGGAG 8803 84166_5_169 NLRC5 EXON + xp16:57026085-57026105 CGCCCAGCCAUCGCGGGAGG 8804 84166_5_170 NLRC5 EXON + xp16:57026091-57026111 GCCAUCGCGGGAGGGGGCCC 8805 84166_5_173 NLRC5 EXON + xp16:57026094-57026114 AUCGCGGGAGGGGGCCCUGG 8806 84166_5_175 NLRC5 EXON + xp16:57026110-57026130 CUGGUGGAGUUACAGACAAA 8807 84166_5_178 NLRC5 EXON + xp16:57026133-57026153 ACGUCUCCGAAGCCUGUGUG 8808 84166_5_179 NLRC5 EXON + xp16:57026197-57026217 CUGCUUCCUGACCACGCCCC 8809 84166_5_181 NLRC5 EXON + xp16:57026208-57026228 CCACGCCCCAGGCCAGUCUG 8810 84166_5_182 NLRC5 EXON + xp16:57026247-57026267 GACUCAGCUCUAUAUGCAGA 8811 84166_5_184 NLRC5 EXON + xp16:57026269-57026289 GUGCUCGCCCUCAGCCCCCC 8812 84166_5_185 NLRC5 EXON + xp16:57026270-57026290 UGCUCGCCCUCAGCCCCCCU 8813 84166_5_187 NLRC5 EXON + xp16:57026295-57026315 CUUGCCCACCUCGUCCCUAC 8814 84166_5_191 NLRC5 EXON + xp16:57026301-57026321 CACCUCGUCCCUACUGGACC 8815 84166_5_193 NLRC5 EXON + xp16:57026302-57026322 ACCUCGUCCCUACUGGACCU 8816 84166_5_195 NLRC5 EXON + xp16:57026303-57026323 CCUCGUCCCUACUGGACCUG 8817 84166_5_197 NLRC5 EXON + xp16:57026304-57026324 CUCGUCCCUACUGGACCUGG 8818 84166_5_198 NLRC5 EXON + xp16:57026307-57026327 GUCCCUACUGGACCUGGGGG 8819 84166_5_199 NLRC5 EXON + xp16:57026310-57026330 CCUACUGGACCUGGGGGAGG 8820 84166_5_203 NLRC5 EXON + xp16:57026318-57026338 ACCUGGGGGAGGUGGCCCUG 8821 84166_5_204 NLRC5 EXON + xp16:57026319-57026339 CCUGGGGGAGGUGGCCCUGA 8822 84166_5_205 NLRC5 EXON + xp16:57026320-57026340 CUGGGGGAGGUGGCCCUGAG 8823 84166_5_208 NLRC5 EXON + xp16:57026325-57026345 GGAGGUGGCCCUGAGGGGCC 8824 84166_5_210 NLRC5 EXON + xp16:57026332-57026352 GCCCUGAGGGGCCUGGAGAC 8825 84166_5_212 NLRC5 EXON + xp16:57026333-57026353 CCCUGAGGGGCCUGGAGACA 8826 84166_5_214 NLRC5 EXON + xp16:57026337-57026357 GAGGGGCCUGGAGACAGGGA 8827 84166_5_218 NLRC5 EXON + xp16:57026383-57026403 GCUCCACCCUUGAUAGCUUU 8828 84166_5_220 NLRC5 EXON + xp16:57026384-57026404 CUCCACCCUUGAUAGCUUUU 8829 84166_5_222 NLRC5 EXON + xp16:57026385-57026405 UCCACCCUUGAUAGCUUUUG 8830 84166_5_227 NLRC5 EXON + xp16:57026425-57026445 ACUUCCUUCUGCGUCUGCAC 8831 84166_5_230 NLRC5 EXON + xp16:57026431-57026451 UUCUGCGUCUGCACAGGCCC 8832 84166_5_231 NLRC5 EXON + xp16:57026432-57026452 UCUGCGUCUGCACAGGCCCU 8833 84166_5_233 NLRC5 EXON + xp16:57026446-57026466 GGCCCUGGGCACCAGCAGAC 8834 84166_5_235 NLRC5 EXON + xp16:57026475-57026495 UUUCACCCACCUCAGCCUGC 8835 84166_5_239 NLRC5 EXON + xp16:57026502-57026522 UCUUGCUGCCCUGCACCUGA 8836 84166_5_243 NLRC5 EXON + xp16:57026514-57026534 GCACCUGAUGGCCAGCCCCA 8837 84166_5_247 NLRC5 EXON + xp16:57026561-57026581 AUGUUACCCUCCAUUCCCGC 8838 84166_5_248 NLRC5 EXON + xp16:57026562-57026582 UGUUACCCUCCAUUCCCGCU 8839 84166_5_251 NLRC5 EXON + xp16:57026570-57026590 UCCAUUCCCCGCUGGGUACAG 8840 84166_5_254 NLRC5 EXON + xp16:57026586-57026606 ACAGCGGACCAAAGCUAGAC 8841 84166_5_255 NLRC5 EXON + xp16:57026587-57026607 CAGCGGACCAAAGCUAGACU 8842 84166_5_256 NLRC5 EXON + xp16:57026616-57026636 AGACCACCUCCCCACCUUCC 8843 84166_5_258 NLRC5 EXON + xp16:57026619-57026639 CCACCUCCCCACCUUCCUGG 8844 84166_5_259 NLRC5 EXON + xp16:57026620-57026640 CACCUCCCCACCUUCCUGGC 8845 84166_5_260 NLRC5 EXON + xp16:57026625-57026645 CCCCACCUUCCUGGCGGGCC 8846 84166_5_262 NLRC5 EXON + xp16:57026661-57026681 CCGCCCCUUCCUUAGCCACC 8847 84166_5_264 NLRC5 EXON + xp16:57026667-57026687 CUUCCUUAGCCACCUGGCGC 8848 84166_5_265 NLRC5 EXON + xp16:57026668-57026688 UUCCUUAGCCACCUGGCGCA 8849 84166_5_270 NLRC5 EXON + xp16:57026676-57026696 CCACCUGGCGCAGGGCAAUG 8850 84166_5_272 NLRC5 EXON + xp16:57026685-57026705 GCAGGGCAAUGAGGACUGUG 8851 84166_5_273 NLRC5 EXON + xp16:57026686-57026706 CAGGGCAAUGAGGACUGUGU 8852 84166_5_274 NLRC5 EXON + xp16:57026697-57026717 GGACUGUGUGGGUGCCAAGC 8853 84166_5_275 NLRC5 EXON + xp16:57026712-57026732 CAAGCAGGCUGCUGUAGGC 8854 84166_5_278 NLRC5 EXON + xp16:57026727-57026747 AGUGCAGGUGUUGAAGAAGU 8855 84166_5_281 NLRC5 EXON + xp16:57026746-57026766 UUGGCCACCCGCAAGCUCAC 8856 84166_5_282 NLRC5 EXON + xp16:57026747-57026767 UGGCCACCCGCAAGCUCACA 8857 84166_5_284 NLRC5 EXON + xp16:57026754-57026774 CCGCAAGCUCACAGGGCCAAA 8858 84166_5_287 NLRC5 EXON + xp16:57026778-57026798 UGUAGAGCUGUGUCACUGUG 8859 84166_5_291 NLRC5 EXON + xp16:57026790-57026810 UCACUGUGUGGAUGAGACAC 8860 84166_5_294 NLRC5 EXON + xp16:57026802-57026822 UGAGACACAGGAGCCUGAGC 8861 84166_5_296 NLRC5 EXON + xp16:57026874-57026894 CCCACUGACCUGCACCGACC 8862 84166_5_302 NLRC5 EXON + xp16:57026903-57026923 UGACCAACAUCCUAGAGACAC 8863 84166_5_303 NLRC5 EXON + xp16:57026904-57026924 GACCAACAUCCUAGAGCACA 8864 84166_5_305 NLRC5 EXON + xp16:57026907-57026927 CAACAUCCUAGAGCACAGGG 8865 84166_5_307 NLRC5 EXON + xp16:57026922-57026942 CAGGGAGGCCCCCAUCCACC 8866 84166_5_308 NLRC5 EXON + xp16:57026932-57026952 CCCAUCCACCUGGAUUUUGA 8867 84166_5_311 NLRC5 EXON + xp16:57026943-57026963 GGAUUUUGAUGGCUGUCCCC 8868 84166_5_316 NLRC5 EXON + xp16:57026961-57026981 CCUGGAGCCCCACUGCCCUG 8869 84166_5_317 NLRC5 EXON + xp16:57026967-57026987 GCCCCACUGCCCUGAGGCUC 8870 84166_5_318 NLRC5 EXON + xp16:57026971-57026991 CACUGCCCUGAGGCUCUGGU 8871 84166_5_320 NLRC5 EXON + xp16:57026977-57026997 CCUGAGGCUCUGGUAGGCUG 8872 84166_5_321 NLRC5 EXON + xp16:57026978-57026998 CUGAGGCUCUGGUAGGCUGU 8873 84166_5_325 NLRC5 EXON + xp16:57026996-57027016 GUGGGCAGAUAGAGAAUCUC 8874 84166_5_330 NLRC5 EXON + xp16:57027009-57027029 GAAUCUCAGGUGAGUAAGAG 8875 84166_5_333 NLRC5 EXON + xp16:57027012-57027032 UCUCAGGUGAGUAAGAGUGG 8876 84166_5_334 NLRC5 EXON + xp16:57027015-57027035 CAGGUGAGUAAGAGUGGAGG 8877 84166_5_337 NLRC5 EXON - xp16:57025355-57025375 GGCCAACUCUGCAAGGGGCA 8878 84166_5_338 NLRC5 EXON - xp16:57025356-57025376 UGGCCAACUCUGCAAGGGGC 8879 84166_5_341 NLRC5 EXON - xp16:57025360-57025380 UUCUUGGCCAACCUCUGCAAG 8880 84166_5_342 NLRC5 EXON - xp16:57025361-57025381 CUUCUUGGCCAACCUCUGCAA 8881 84166_5_344 NLRC5 EXON - xp16:57025362-57025382 ACUUCUUGGCCAACCUCUGCA 8882 84166_5_346 NLRC5 EXON - xp16:57025376-57025396 CAGGAGCUGCAGGUACUUCU 8883 84166_5_347 NLRC5 EXON - xp16:57025386-57025406 CAGAGGUCCGCAGGAGCUGC 8884 84166_5_348 NLRC5 EXON - xp16:57025395-57025415 GCUGCUGGGCAGAGGUCCGC 8885 84166_5_351 NLRC5 EXON - xp16:57025403-57025423 CCUGUAGCGCUGCUGGGCAG 8886 84166_5_355 NLRC5 EXON - xp16:57025409-57025429 UUGGCUCCUGUAGCGCUGCU 8887 84166_5_356 NLRC5 EXON - xp16:57025410-57025430 UUUGGCUCCUGUAGCGCUGC 8888 84166_5_358 NLRC5 EXON - xp16:57025428-57025448 GCUGCCCUGACCCAGGGAUU 8889 84166_5_359 NLRC5 EXON - xp16:57025434-57025454 CGUGGGGCUGCCCUGACCCA 8890 84166_5_361 NLRC5 EXON - xp16:57025435-57025455 GCGUGGGGCUGCCCUGACCCC 8891 84166_5_363 NLRC5 EXON - xp16:57025450-57025470 UAGACCUGGUGGAAGGCGUG 8892 84166_5_364 NLRC5 EXON - xp16:57025451-57025471 AUAGACCUGGUGGAAGGCGU 8893 84166_5_365 NLRC5 EXON - xp16:57025452-57025472 CAUAGACCUGGUGGAAGGCG 8894 84166_5_369 NLRC5 EXON - xp16:57025457-57025477 AGGGACAUAGACCUGGUGGA 8895 84166_5_370 NLRC5 EXON - xp16:57025461-57025481 UUGGAGGGACAUAGACCUGG 8896 84166_5_373 NLRC5 EXON - xp16:57025464-57025484 GGAUUGGAGGGACAUAGACC 8897 84166_5_374 NLRC5 EXON - xp16:57025476-57025496 UGGCCCGGCGCAGGAUUGGA 8898 84166_5_376 NLRC5 EXON - xp16:57025477-57025497 GUGGCCCGGCGCAGGAUUGG 8899 84166_5_378 NLRC5 EXON - xp16:57025480-57025500 GCUGUGGCCCGGCGCAGGAU 8900 84166_5_381 NLRC5 EXON - xp16:57025485-57025505 AGGAUGCUGUGGCCCGGCGC 8901 84166_5_383 NLRC5 EXON - xp16:57025491-57025511 UGUCUAAGGAUGCUGUGGCC 8902 84166_5_384 NLRC5 EXON - xp16:57025496-57025516 CGGAGUGUCUAAGGAUGCUG 8903 84166_5_385 NLRC5 EXON - xp16:57025505-57025525 GGCCCCCUCCGGAGUGUCUUA 8904 84166_5_388 NLRC5 EXON - xp16:57025516-57025536 UCCCCCAUAAUGGCCCCCUC 8905 84166_5_392 NLRC5 EXON - xp16:57025526-57025546 CACCUUGACGUCCCCCAUAA 8906 84166_5_397 NLRC5 EXON - xp16:57025578-57025598 UGUUAACCCUGGUGUUGAAG 8907 84166_5_400 NLRC5 EXON - xp16:57025589-57025609 CCUCGGGCCCUUGUUAACCC 8908 84166_5_402 NLRC5 EXON - xp16:57025605-57025625 CCAAAAGCACGGUCACCCUC 8909 84166_5_403 NLRC5 EXON - xp16:57025606-57025626 CCCAAAAGCACGGUCACCCU 8910 84166_5_405 NLRC5 EXON - xp16:57025616-57025636 GCCAGCCUUCCCCAAAAGCA 8911 84166_5_408 NLRC5 EXON - xp16:57025649-57025669 GCAGAGCCGGUGGGCCAGCG 8912 84166_5_409 NLRC5 EXON - xp16:57025658-57025678 CCACUUCUGGCAGAGCCGGU 8913 84166_5_410 NLRC5 EXON - xp16:57025659-57025679 CCCACUUCUGGCAGAGCCGG 8914 84166_5_412 NLRC5 EXON - xp16:57025662-57025682 CUGCCCACUUCUGGCAGAGC 8915 84166_5_415 NLRC5 EXON - xp16:57025671-57025691 GAUGGCCCUCUGCCCACUUC 8916 84166_5_416 NLRC5 EXON - xp16:57025689-57025709 GGGCCUGGAAACAGUUCAGA 8917 84166_5_419 NLRC5 EXON - xp16:57025704-57025724 AUUCAAAAAGGAACAGGGCC 8918 84166_5_421 NLRC5 EXON - xp16:57025709-57025729 GCGGAAUUCAAAAAGGAACA 8919 84166_5_422 NLRC5 EXON - xp16:57025710-57025730 GGCGGAAUUCAAAAAGGAAC 8920 84166_5_426 NLRC5 EXON - xp16:57025716-57025736 UGAGCUGGCGGAAUUCAAAA 8921 84166_5_429 NLRC5 EXON - xp16:57025728-57025748 UCGUGAUCAAGUUGAGCUGG 8922 84166_5_431 NLRC5 EXON - xp16:57025731-57025751 ACCUCGUGAUCAAGUUGAGC 8923 84166_5_433 NLRC5 EXON - xp16:57025755-57025775 AAAGGAGCUCGGACGGUGUC 8924 84166_5_436 NLRC5 EXON - xp16:57025762-57025782 AGAUCAAAAAGGAGCCUCGGA 8925 84166_5_437 NLRC5 EXON - xp16:57025766-57025786 GUACAGAUCAAAAAGGAGCU 8926 84166_5_440 NLRC5 EXON - xp16:57025773-57025793 GGCUCAGGUACAGAUCAAAAA 8927 84166_5_443 NLRC5 EXON - xp16:57025788-57025808 CGUGGUCCGAUUCAGGGCUC 8928 84166_5_444 NLRC5 EXON - xp16:57025794-57025814 CAGUGUCGUGGUCCGAUUCA 8929 84166_5_445 NLRC5 EXON - xp16:57025795-57025815 ACAGUGUCGUGGUCCGAUUC 8930 84166_5_447 NLRC5 EXON - xp16:57025806-57025826 GGUACUGGAAGACAGUGUCG 8931 84166_5_451 NLRC5 EXON - xp16:57025821-57025841 CAGCGUUCUUCUCCAGGUAC 8932 84166_5_454 NLRC5 EXON - xp16:57025827-57025847 CUUGGUCAGCGUUCUUCUCC 8933 84166_5_455 NLRC5 EXON - xp16:57025845-57025865 CAUCAAAGAUCAGCAGGACU 8934 84166_5_456 NLRC5 EXON - xp16:57025851-57025871 CUAGCCCAUCAAAGAUCAGC 8935 84166_5_458 NLRC5 EXON - xp16:57025880-57025900 AUCAGGACCCAAUAGGCUGGA 8936 84166_5_459 NLRC5 EXON - xp16:57025881-57025901 CAUCAGGACCCAAUAGGCUGG 8937 84166_5_462 NLRC5 EXON - xp16:57025884-57025904 GGCCAUCAGGACCCAAUAGGC 8938 84166_5_464 NLRC5 EXON - xp16:57025888-57025908 CCUGGGCCAUCAGGACCCAU 8939 84166_5_465 NLRC5 EXON - xp16:57025897-57025917 AGGACUGGGCCUGGGCCAUC 8940 84166_5_467 NLRC5 EXON - xp16:57025905-57025925 AAAGGGUGAGGACUGGGCCU 8941 84166_5_468 NLRC5 EXON - xp16:57025906-57025926 AAAAGGGUGAGGACUGGGCC 8942 84166_5_470 NLRC5 EXON - xp16:57025911-57025931 GGGAGAAAAGGGUGAGGACU 8943 84166_5_471 NLRC5 EXON - xp16:57025912-57025932 UGGGAGAAAAGGGUGAGGAC 8944 84166_5_474 NLRC5 EXON - xp16:57025917-57025937 AGAGAUGGGAGAAAAGGGUG 8945 84166_5_477 NLRC5 EXON - xp16:57025922-57025942 AUUGCAGAGAUGGGAGAAAAA 8946 84166_5_478 NLRC5 EXON - xp16:57025923-57025943 CAUUGCAGAGAUGGGAGAAA 8947 84166_5_481 NLRC5 EXON - xp16:57025931-57025951 CUCCGUCCCAUUGCAGAGAU 8948 84166_5_483 NLRC5 EXON - xp16:57025932-57025952 CCUCCGUCCCAUUGCAGAGA 8949 84166_5_487 NLRC5 EXON - xp16:57026024-57026044 AAAGCCCAACAUGUGGACCCA 8950 84166_5_488 NLRC5 EXON - xp16:57026031-57026051 GCCCAUCAAAGCCCAACAUG 8951 84166_5_493 NLRC5 EXON - xp16:57026053-57026073 UUCACAUAUUCUUCCACCCG 8952 84166_5_497 NLRC5 EXON - xp16:57026090-57026110 GGCCCCCUCCCGCGAUGGCU 8953 84166_5_498 NLRC5 EXON - xp16:57026091-57026111 GGGCCCCCUCCCGCGAUGGC 8954 84166_5_500 NLRC5 EXON - xp16:57026095-57026115 ACCAGGGCCCCCUCCCGCGA 8955 84166_5_503 NLRC5 EXON - xp16:57026111-57026131 AUUUGUCUGUAACUCCACCA 8956 84166_5_504 NLRC5 EXON - xp16:57026112-57026132 CAUUUGUCUGUAAACUCCACC 8957 84166_5_508 NLRC5 EXON - xp16:57026142-57026162 CGGGCACCCGCACACAGGCUU 8958 84166_5_511 NLRC5 EXON - xp16:57026148-57026168 ACAGUGCGGGCACCGCACAC 8959 84166_5_512 NLRC5 EXON - xp16:57026161-57026181 CAGGCGACUUGGCACAGUGC 8960 84166_5_513 NLRC5 EXON - xp16:57026162-57026182 ACAGGCGACUUGGCACAGUG 8961 84166_5_515 NLRC5 EXON - xp16:57026172-57026192 GGAGGCAGAGACAGGCGACU 8962 84166_5_516 NLRC5 EXON - xp16:57026180-57026200 CAGAUGGUGGAGGCAGAGAC 8963 84166_5_518 NLRC5 EXON - xp16:57026190-57026210 GGUCAGGAAGCAGAUGGUGG 8964 84166_5_520 NLRC5 EXON - xp16:57026193-57026213 CGUGGUCAGGAAGCAGAUGG 8965 84166_5_522 NLRC5 EXON - xp16:57026196-57026216 GGGCGUGGUCAGGAAGCAGA 8966 84166_5_523 NLRC5 EXON - xp16:57026206-57026226 GACUGGCCUGGGGCGUGGUC 8967 84166_5_526 NLRC5 EXON - xp16:57026211-57026231 CCACAGACUGGCCUGGGGCG 8968 84166_5_527 NLRC5 EXON - xp16:57026216-57026236 GAGGGCCACAGACUGGCCUG 8969 84166_5_528 NLRC5 EXON - xp16:57026217-57026237 GGAGGGCCACAGACUGGCCU 8970 84166_5_529 NLRC5 EXON - xp16:57026218-57026238 AGGAGGGCCACAGACUGGCC 8971 84166_5_533 NLRC5 EXON - xp16:57026223-57026243 UGGGCAGGAGGGCCACAGAC 8972 84166_5_534 NLRC5 EXON - xp16:57026234-57026254 CUGAGUCAUGUUGGGCAGGA 8973 84166_5_535 NLRC5 EXON - xp16:57026235-57026255 GCUGAGUCAUGUUGGGCAGG 8974 84166_5_537 NLRC5 EXON - xp16:57026238-57026258 AGAGCUGAGUCAUGUUGGGC 8975 84166_5_540 NLRC5 EXON - xp16:57026242-57026262 AUAUAGAGCUGAGUCAUGUU 8976 84166_5_541 NLRC5 EXON - xp16:57026243-57026263 CAUAUAGAGCUGAGUCAUGU 8977 84166_5_546 NLRC5 EXON - xp16:57026279-57026299 CAAGUGCCCAGGGGGGCUGA 8978 84166_5_547 NLRC5 EXON - xp16:57026280-57026300 GCAAGUGCCCAGGGGGGCUG 8979 84166_5_550 NLRC5 EXON - xp16:57026286-57026306 AGGUGGGCAAGUGCCCAGGG 8980 84166_5_551 NLRC5 EXON - xp16:57026287-57026307 GAGGUGGGCAAGUGCCCAGG 8981 84166_5_553 NLRC5 EXON - xp16:57026288-57026308 CGAGGUGGGCAAGUGCCCAG 8982 84166_5_555 NLRC5 EXON - xp16:57026289-57026309 ACGAGGUGGGCAAGUGCCCA 8983 84166_5_556 NLRC5 EXON - xp16:57026290-57026310 GACGAGGUGGGCAAGUGCCC 8984 84166_5_559 NLRC5 EXON - xp16:57026302-57026322 AGGUCCAGGUAGGGACGAGGU 8985 84166_5_560 NLRC5 EXON - xp16:57026303-57026323 CAGGUCCAGGUAGGGACGAGG 8986 84166_5_562 NLRC5 EXON - xp16:57026306-57026326 CCCCAGGUCCAGGUAGGGACG 8987 84166_5_564 NLRC5 EXON - xp16:57026312-57026332 CACCUCCCCCAGGUCCAGUA 8988 84166_5_565 NLRC5 EXON - xp16:57026313-57026333 CCACCUCCCCCAGGUCCAGU 8989 84166_5_568 NLRC5 EXON - xp16:57026322-57026342 CCCUCAGGGCCACCUCCCCC 8990 84166_5_570 NLRC5 EXON - xp16:57026336-57026356 CCCUGUCUCCAGGCCCCUCA 8991 84166_5_571 NLRC5 EXON - xp16:57026337-57026357 UCCCUGUCUCCAGGCCCCUC 8992 84166_5_573 NLRC5 EXON - xp16:57026346-57026366 AGAUAACCUUCCCUGUCUCC 8993 84166_5_580 NLRC5 EXON - xp16:57026389-57026409 GCCCCAAAAGCUAUCAAGGG 8994 84166_5_582 NLRC5 EXON - xp16:57026392-57026412 GUGGCCCCAAAAGCUAUCAAA 8995 84166_5_583 NLRC5 EXON - xp16:57026393-57026413 AGUGGCCCCAAAAGCUAUCA 8996 84166_5_585 NLRC5 EXON - xp16:57026411-57026431 GGAAGUCAGCAGGCUGUGAG 8997 84166_5_587 NLRC5 EXON - xp16:57026421-57026441 AGACGCAGAAGGAAGUCAGC 8998 84166_5_588 NLRC5 EXON - xp16:57026432-57026452 AGGGCCUGUGCAGACGCAGA 8999 84166_5_593 NLRC5 EXON - xp16:57026451-57026471 AGCCUGUCUGCUGGUGCCCA 9000 84166_5_594 NLRC5 EXON - xp16:57026452-57026472 UAGCCUGUCUGCUGGUGCCC 9001 84166_5_596 NLRC5 EXON - xp16:57026460-57026480 UGAAAGCAUAGCCUGUCUGC 9002 84166_5_598 NLRC5 EXON - xp16:57026483-57026503 AAACUCCUGCAGGCUGAGGU 9003 84166_5_599 NLRC5 EXON - xp16:57026484-57026504 GAAACUCCUGCAGGCUGAGG 9004 84166_5_601 NLRC5 EXON - xp16:57026487-57026507 CAAGAAACUCCUGCAGGCUG 9005 84166_5_603 NLRC5 EXON - xp16:57026493-57026513 GGGCAGCAAGAAACUCCUGC 9006 84166_5_606 NLRC5 EXON - xp16:57026513-57026533 GGGGCUGGCCAUCAGGUGCA 9007 84166_5_607 NLRC5 EXON - xp16:57026514-57026534 UGGGGCUGGCCAUCAGGUGC 9008 84166_5_612 NLRC5 EXON - xp16:57026520-57026540 UCACCUUGGGGCUGGCCAUC 9009 84166_5_613 NLRC5 EXON - xp16:57026528-57026548 GUCUUUGUUCACCUUGGGGC 9010 84166_5_614 NLRC5 EXON - xp16:57026532-57026552 GUGUGUCUUUGUUCACCUUG 9011 84166_5_615 NLRC5 EXON - xp16:57026533-57026553 AGUGUGUCUUUGUUCACCUU 9012 84166_5_616 NLRC5 EXON - xp16:57026534-57026554 AAGUGUGUCUUUGUUCACCU 9013 84166_5_619 NLRC5 EXON - xp16:57026558-57026578 GGAAUGGAGGGUAACAUACU 9014 84166_5_620 NLRC5 EXON - xp16:57026559-57026579 GGGAAUGGAGGGUAACAUAC 9015 84166_5_622 NLRC5 EXON - xp16:57026570-57026590 CUGUACCCAGCGGGAAUGGA 9016 84166_5_623 NLRC5 EXON - xp16:57026571-57026591 GCUGUACCCAGCGGGAAUGG 9017 84166_5_627 NLRC5 EXON - xp16:57026574-57026594 UCCGCUGUACCCAGCGGGAA 9018 84166_5_630 NLRC5 EXON - xp16:57026579-57026599 UUUGGUCCGCUGUACCCAGGC 9019 84166_5_633 NLRC5 EXON - xp16:57026580-57026600 CUUUGGUCCGCUGUACCCAG 9020 84166_5_635 NLRC5 EXON - xp16:57026597-57026617 UGAGAGGCCCCAGUCUAGCUU 9021 84166_5_636 NLRC5 EXON - xp16:57026613-57026633 AGGUGGGGAGGUGGUCUGAG 9022 84166_5_639 NLRC5 EXON - xp16:57026622-57026642 CCGCCAGGAAGGUGGGGAGG 9023 84166_5_640 NLRC5 EXON - xp16:57026625-57026645 GGCCCGCCAGGAAGGUGGGG 9024 84166_5_641 NLRC5 EXON - xp16:57026628-57026648 CCAGGCCCCGCCAGGAAGGUG 9025 84166_5_643 NLRC5 EXON - xp16:57026629-57026649 GCCAGGCCCCGCCAGGAAGGU 9026 84166_5_645 NLRC5 EXON - xp16:57026630-57026650 UGCCAGGCCCCGCCAGGAAGG 9027 84166_5_648 NLRC5 EXON - xp16:57026633-57026653 GGAUGCCAGGCCCGCCAGGA 9028 84166_5_650 NLRC5 EXON - xp16:57026637-57026657 UGCAGGAUGCCAGGCCCGCC 9029 84166_5_652 NLRC5 EXON - xp16:57026646-57026666 GGCGGCAGGUGCAGGAUGCC 9030 84166_5_653 NLRC5 EXON - xp16:57026654-57026674 AAGGAAGGGGCGGCAGGUGC 9031 84166_5_655 NLRC5 EXON - xp16:57026660-57026680 GUGGCUAAGGAAGGGGCGGC 9032 84166_5_656 NLRC5 EXON - xp16:57026664-57026684 CCAGGUGGCUAAGGAAGGGG 9033 84166_5_657 NLRC5 EXON - xp16:57026667-57026687 GCGCCAGGUGGCUAAGGAAG 9034 84166_5_658 NLRC5 EXON - xp16:57026668-57026688 UGCGCCAGGUGGCUAAGGAA 9035 84166_5_660 NLRC5 EXON - xp16:57026669-57026689 CUGCGCCAGGUGGCUAAGGA 9036 84166_5_664 NLRC5 EXON - xp16:57026673-57026693 UGCCCUGCCGCCAGGUGGCUA 9037 84166_5_666 NLRC5 EXON - xp16:57026679-57026699 CCUCAUUGCCCUGCGCCAGG 9038 84166_5_667 NLRC5 EXON - xp16:57026682-57026702 AGUCCUAUUGCCCUGCGCC 9039 84166_5_669 NLRC5 EXON - xp16:57026714-57026734 CUGCACUACAGCAGCCUGCU 9040 84166_5_675 NLRC5 EXON - xp16:57026753-57026773 UGGCCCUGUGAGCUUGCGGG 9041 84166_5_676 NLRC5 EXON - xp16:57026756-57026776 CUUUGGCCCUGUGAGCUUGC 9042 84166_5_677 NLRC5 EXON - xp16:57026757-57026777 CCUUUGGCCCUGUGAGCUUG 9043 84166_5_680 NLRC5 EXON - xp16:57026773-57026793 UGACACAGCCUUACAACCUU 9044 84166_5_683 NLRC5 EXON - xp16:57026818-57026838 GCGGUGAGACUGGCCAGCUC 9045 84166_5_684 NLRC5 EXON - xp16:57026828-57026848 GAGGCUUUGUGCGGUGAGAC 9046 84166_5_687 NLRC5 EXON - xp16:57026837-57026857 UUGAUAGGGGAGGCUUUGUG 9047 84166_5_689 NLRC5 EXON - xp16:57026847-57026867 GGAAGGGCAGUUGAUAGGGG 9048 84166_5_691 NLRC5 EXON - xp16:57026850-57026870 UGUGGAAGGGCAGUUGAUAG 9049 84166_5_692 NLRC5 EXON - xp16:57026851-57026871 UUGUGGAAGGGCAGUUGAUA 9050 84166_5_695 NLRC5 EXON - xp16:57026852-57026872 AUUGUGGAAGGGCAGUUGAU 9051 84166_5_697 NLRC5 EXON - xp16:57026863-57026883 GUCAGUGGGAAAUUGUGGAA 9052 84166_5_698 NLRC5 EXON - xp16:57026864-57026884 GGUCAGUGGGAAAUUGUGGA 9053 84166_5_701 NLRC5 EXON - xp16:57026868-57026888 UGCAGGUCAGUGGGAAAUUG 9054 84166_5_704 NLRC5 EXON - xp16:57026877-57026897 CCAGGUCGGUGCAGGUCAGU 9055 84166_5_705 NLRC5 EXON - xp16:57026878-57026898 GCCAGGUCGGUGCAGGUCAG 9056 84166_5_709 NLRC5 EXON - xp16:57026885-57026905 CAGGGUGGCCAGGUCGGUGC 9057 84166_5_710 NLRC5 EXON - xp16:57026891-57026911 GUUGGUCAGGGUGGCCAGGU 9058 84166_5_711 NLRC5 EXON - xp16:57026895-57026915 GGAUGUUGGUCAGGGUGGCC 9059 84166_5_712 NLRC5 EXON - xp16:57026900-57026920 CUCUAGGAUGUUGGUCAGGG 9060 84166_5_713 NLRC5 EXON - xp16:57026903-57026923 GUGCUCUAGGAUGUUGGUCA 9061 84166_5_714 NLRC5 EXON - xp16:57026904-57026924 UGUGCUCUAGGAUGUUGGUC 9062 84166_5_716 NLRC5 EXON - xp16:57026909-57026929 CUCCCUGUGCUCUAGGAUGU 9063 84166_5_717 NLRC5 EXON - xp16:57026916-57026936 UGGGGGCCUCCCUGUGCUCU 9064 84166_5_719 NLRC5 EXON - xp16:57026933-57026953 AUCAAAAUCCAGGUGGAUGG 9065 84166_5_720 NLRC5 EXON - xp16:57026934-57026954 CAUCAAAAUCCAGGUGGAUG 9066 84166_5_721 NLRC5 EXON - xp16:57026935-57026955 CCAUCAAAAUCCAGGUGGAU 9067 84166_5_724 NLRC5 EXON - xp16:57026936-57026956 GCCAUCAAAAUCCAGGUGGA 9068 84166_5_726 NLRC5 EXON - xp16:57026940-57026960 GACAGCCAUCAAAAUCCAGG 9069 84166_5_728 NLRC5 EXON - xp16:57026943-57026963 GGGGACAGCCAUCAAAAUCC 9070 84166_5_729 NLRC5 EXON - xp16:57026962-57026982 UCAGGGCAGUGGGGCUCCAG 9071 84166_5_731 NLRC5 EXON - xp16:57026963-57026983 CUCAGGGCAGUGGGGCUCCA 9072 84166_5_732 NLRC5 EXON - xp16:57026964-57026984 CCUCAGGGCAGUGGGGCUCC 9073 84166_5_735 NLRC5 EXON - xp16:57026971-57026991 ACCAGAGCCUCAGGGCAGUG 9074 84166_5_736 NLRC5 EXON - xp16:57026972-57026992 UACCAGAGCCUCAGGGCAGU 9075 84166_5_738 NLRC5 EXON - xp16:57026973-57026993 CUACCAGAGCCUCAGGGCAG 9076 84166_5_740 NLRC5 EXON - xp16:57026979-57026999 CACAGCCUACCAGAGCCUCA 9077 84166_5_741 NLRC5 EXON - xp16:57026980-57027000 CCACAGCCUACCAGAGCCUC 9078 84166_6_5 NLRC5 EXON + xp16:57028061-57028081 CUUAUGGCAGCUUUAAGGC 9079 84166_6_10 NLRC5 EXON + xp16:57028069-57028089 AGCUUUAAGAGCAGGAAGUG 9080 84166_6_13 NLRC5 EXON + xp16:57028070-57028090 GCUUUAAGAGCAGGAAGUGU 9081 84166_6_14 NLRC5 EXON + xp16:57028071-57028091 CUUUAAGAGCAGGAAGUGUG 9082 84166_6_19 NLRC5 EXON + xp16:57028097-57028117 CCUUUGCAGAAGCCCUCUCC 9083 84166_6_24 NLRC5 EXON + xp16:57028113-57028133 CUCCAGGAGCUUGCCGACAA 9084 84166_6_27 NLRC5 EXON + xp16:57028114-57028134 UCCAGGAGCUUGCCGACAAU 9085 84166_6_28 NLRC5 EXON + xp16:57028115-57028135 CCAGGAGCUUGCCGACAAUG 9086 84166_6_30 NLRC5 EXON + xp16:57028118-57028138 GGAGCUUGCCGACAAUGGGG 9087 84166_6_34 NLRC5 EXON + xp16:57028131-57028151 AAUGGGGAGGCUGCAGAUGC 9088 84166_6_35 NLRC5 EXON + xp16:57028132-57028152 AUGGGGAGGCUGCAGAUGCU 9089 84166_6_36 NLRC5 EXON + xp16:57028133-57028153 UGGGGAGGCUGCAGAUGCUG 9090 84166_6_38 NLRC5 EXON + xp16:57028142-57028162 UGCAGAUGCUGGGGUGAGCC 9091 84166_6_41 NLRC5 EXON + xp16:57028148-57028168 UGCUGGGGUGAGCCAGGCCU 9092 84166_6_50 NLRC5 EXON - xp16:57028100-57028120 CCUGGAGAGGGCUUCUGCAA 9093 84166_6_52 NLRC5 EXON - xp16:57028112-57028132 UGUCGGCAAGCUCCUGGAGA 9094 84166_6_53 NLRC5 EXON - xp16:57028113-57028133 UUGUCGGCAAGCUCCUGGAG 9095 84166_6_57 NLRC5 EXON - xp16:57028118-57028138 CCCCAUUGUCGGCAAGCUCC 9096 84166_6_59 NLRC5 EXON - xp16:57028129-57028149 AUCUGCAGCCCUCCCCAUGUGU 9097 84166_7_3 NLRC5 EXON + xp16:57028287-57028307 UGCUUACUCUGUAGGUUAGC 9098 84166_7_9 NLRC5 EXON + xp16:57028308-57028328 GGAAGUAAAAUCACUGCCCG 9099 84166_7_10 NLRC5 EXON + xp16:57028322-57028342 UGCCCGAGGCAUCAGCCACC 9100 84166_7_16 NLRC5 EXON + xp16:57028363-57028383 GUCCACAGCUGAAAGAAGUC 9101 84166_7_19 NLRC5 EXON + xp16:57028378-57028398 AAGUCAGGUGAGUGAUCUCC 9102 84166_7_22 NLRC5 EXON + xp16:57028381-57028401 UCAGGUGAGUGAUCCCAGG 9103 84166_7_23 NLRC5 EXON + xp16:57028382-57028402 CAGGUGAGUGAUCCCAGGA 9104 84166_7_31 NLRC5 EXON - xp16:57028327-57028347 CACCAGGUGGCUGAUGCCUC 9105 84166_7_32 NLRC5 EXON - xp16:57028328-57028348 UCACCAGGUGGCUGAUGCCU 9106 84166_7_34 NLRC5 EXON - xp16:57028340-57028360 GAGGCAAAGCUUUCACCAGG 9107 84166_7_35 NLRC5 EXON - xp16:57028343-57028363 AGAGAGGCAAAGCUUUCACCC 9108 84166_7_39 NLRC5 EXON - xp16:57028359-57028379 UCUUUCAGCUGUGGACAGAG 9109 84166_7_42 NLRC5 EXON - xp16:57028368-57028388 CACCUGACUUCUUUCAGCUG 9110 84166_8_2 NLRC5 EXON + xp16:57029756-57029776 CUUGGUCUCCUCCGCAGUUUU 9111 84166_8_4 NLRC5 EXON + xp16:57029757-57029777 UUGGUCUCCUCCGCAGUUUUC 9112 84166_8_9 NLRC5 EXON + xp16:57029778-57029798 GGACAACCAGCCUCAGUGACC 9113 84166_8_10 NLRC5 EXON + xp16:57029781-57029801 CAACCAGCUCAGUGACCAGG 9114 84166_8_13 NLRC5 EXON + xp16:57029796-57029816 CCAGGUGGUGCUGAACAUUG 9115 84166_8_15 NLRC5 EXON + xp16:57029799-57029819 GGUGGUGCUGAACAUUGUGG 9116 84166_8_17 NLRC5 EXON + xp16:57029819-57029839 AGGUUCUCCCUCACCUACCA 9117 84166_8_21 NLRC5 EXON + xp16:57029825-57029845 UCCCUCACCUACCACGGCUC 9118 84166_8_24 NLRC5 EXON - xp16:57029758-57029778 CGAAAACUGCGAGGAGACCA 9119 84166_8_26 NLRC5 EXON - xp16:57029767-57029787 UGGUUGUCCCGAAAACUGCG 9120 84166_8_31 NLRC5 EXON - xp16:57029787-57029807 GCACCACCUGGUCACUGAGC 9121 84166_8_33 NLRC5 EXON - xp16:57029799-57029819 CCACAAUGUUCAGCACCACC 9122 84166_8_38 NLRC5 EXON - xp16:57029829-57029849 UCCGGAGCCGUGGUAGGUGA 9123 84166_8_39 NLRC5 EXON - xp16:57029830-57029850 UUCCGGAGCCGUGGUAGGUG 9124 84166_8_44 NLRC5 EXON - xp16:57029835-57029855 CAAGCUUCCGGAGCCGUGGU 9125 84166_8_45 NLRC5 EXON - xp16:57029839-57029859 UACUCAAGCUUCCGGAGCCG 9126 84166_8_46 NLRC5 EXON - xp16:57029847-57029867 AGAUCACUUACUCAAGCUUC 9127 84166_9_5 NLRC5 EXON + xp16:57030015-57030035 CGUGUCAACCCUACUCUGCU 9128 84166_9_7 NLRC5 EXON + xp16:57030020-57030040 CAACCCUACUCUGCUUGGCA 9129 84166_9_8 NLRC5 EXON + xp16:57030021-57030041 AACCCUACUCUGCUUGGCAA 9130 84166_9_9 NLRC5 EXON + xp16:57030024-57030044 CCUACUCUGCUUGGCAAGGG 9131 84166_9_12 NLRC5 EXON + xp16:57030047-57030067 CAGUCACGUGUCCUACCCGUC 9132 84166_9_13 NLRC5 EXON + xp16:57030057-57030077 UCCUACCGUCAGGAUGCUUC 9133 84166_9_14 NLRC5 EXON + xp16:57030062-57030082 CCGUCAGGAUGCUUCAGGCC 9134 84166_9_18 NLRC5 EXON + xp16:57030073-57030093 CUUCAGGCCAGGUGAGCAGA 9135 84166_9_22 NLRC5 EXON + xp16:57030078-57030098 GGCCAGGUGAGCAGGAAGGAA 9136 84166_9_24 NLRC5 EXON + xp16:57030079-57030099 GCCAGGUGAGCAGGAAGGAAA 9137 84166_9_25 NLRC5 EXON - xp16:57029977-57029997 AGGCUGCAAGAUUGUGGCAA 9138 84166_9_27 NLRC5 EXON - xp16:57029983-57030003 CUGCUCAGGCUGCAAGAUUG 9139 84166_9_29 NLRC5 EXON - xp16:57029997-57030017 CGCAGAUGCUGUUGCUGCUC 9140 84166_9_31 NLRC5 EXON - xp16:57030026-57030046 CACCCUUGCCAAGCAGAGUA 9141 84166_9_32 NLRC5 EXON - xp16:57030027-57030047 CCACCCUUGCCAAGCAGAGU 9142 84166_9_35 NLRC5 EXON - xp16:57030061-57030081 GCCUGAAGCAUCCUGACGGU 9143 84166_9_37 NLRC5 EXON - xp16:57030065-57030085 CCUGGCCUGAAGCAUCCUGA 9144 84166_9_42 NLRC5 EXON - xp16:57030083-57030103 UCCCUUUCCUUCUGCUCACC 9145 84166_10_1 NLRC5 EXON + xp16:57031385-57031405 UGGUAUCUGAUCCUGCAGGG 9146 84166_10_4 NLRC5 EXON + xp16:57031388-57031408 UAUCUGAUCCUGCAGGGAGG 9147 84166_10_11 NLRC5 EXON + xp16:57031441-57031461 AGACAACUGCAGAGCUACAA 9148 84166_10_14 NLRC5 EXON + xp16:57031456-57031476 UACAAAGGUAAGAAGCCAAG 9149 84166_10_15 NLRC5 EXON + xp16:57031459-57031479 AAAGGUAAGAAGCCAAGAGG 9150 84166_10_16 NLRC5 EXON - xp16:57031399-57031419 GAUGAGGUCCGCCUCCCUGC 9151 84166_10_18 NLRC5 EXON - xp16:57031415-57031435 GCGGGGAAAGAAGGAAGAUG 9152 84166_10_21 NLRC5 EXON - xp16:57031424-57031444 UCUCUGUGGGCGGGGAAAGA 9153 84166_10_27 NLRC5 EXON - xp16:57031432-57031452 UGCAGUUGUCUCUGUGGGCG 9154 84166_10_29 NLRC5 EXON - xp16:57031433-57031453 CUGCAGUUGUCUCUGUGGGC 9155 84166_10_31 NLRC5 EXON - xp16:57031434-57031454 UCUGCAGUUGUCUCUGUGGG 9156 84166_10_35 NLRC5 EXON - xp16:57031437-57031457 AGCUCUGCAGUUGUCUCUGU 9157 84166_10_36 NLRC5 EXON - xp16:57031438-57031458 UAGCUCUGCAGUUGUCUCUG 9158 84166_11_7 NLRC5 EXON + xp16:57033597-57033617 UGCCAGAGCUCCAGACCUGC 9159 84166_11_9 NLRC5 EXON + xp16:57033607-57033627 CCAGACCUGCAGGAAAGUGA 9160 84166_11_13 NLRC5 EXON + xp16:57033614-57033634 UGCAGGAAAGUGACGGCCAG 9161 84166_11_16 NLRC5 EXON + xp16:57033619-57033639 GAAAGUGACGGCCAGAGGAA 9162 84166_11_17 NLRC5 EXON + xp16:57033620-57033640 AAAGUGACGGCCAGAGGAAA 9163 84166_11_18 NLRC5 EXON + xp16:57033621-57033641 AAGUGACGGCCAGAGGAAAG 9164 84166_11_21 NLRC5 EXON + xp16:57033647-57033667 AGAGCAGAAGCUUGACGCUC 9165 84166_11_23 NLRC5 EXON + xp16:57033655-57033675 AGCUUGACGCUCAGGUACCU 9166 84166_11_27 NLRC5 EXON + xp16:57033658-57033678 UUGACGCUCAGGUACCUUGG 9167 84166_11_28 NLRC5 EXON + xp16:57033659-57033679 UGACGCUCAGGUACCUUGGA 9168 84166_11_34 NLRC5 EXON - xp16:57033602-57033622 UUCCUGCAGGUCUGGAGCUC 9169 84166_11_36 NLRC5 EXON - xp16:57033610-57033630 CCGUCACUUUCCUGCAGGUC 9170 84166_11_40 NLRC5 EXON - xp16:57033615-57033635 UCUGGCCGUCACUUUCCUGC 9171 84166_11_42 NLRC5 EXON - xp16:57033633-57033653 UGCUCUGAGCCCCUUUCCUC 9172 84166_12_2 NLRC5 EXON + xp16:57034167-57034187 GCUGCAGAAGUGUCAGCUCC 9173 84166_12_5 NLRC5 EXON + xp16:57034179-57034199 UCAGCUCCAGGUCCACGAUG 9174 84166_12_6 NLRC5 EXON + xp16:57034182-57034202 GCUCCAGGUCCACGAUGCGG 9175 84166_12_9 NLRC5 EXON + xp16:57034203-57034223 GGCCCUCAUAGCCCUGCUCC 9176 84166_12_10 NLRC5 EXON + xp16:57034207-57034227 CUCAUAGCCCUGCUCCAGGA 9177 84166_12_12 NLRC5 EXON + xp16:57034218-57034238 GCUCCAGGAAGGCCCUCACC 9178 84166_12_16 NLRC5 EXON + xp16:57034221-57034241 CCAGGAAGGCCCUCACCUGG 9179 84166_12_18 NLRC5 EXON + xp16:57034227-57034247 AGGCCCUCACCUGGAGGAAG 9180 84166_12_23 NLRC5 EXON + xp16:57034241-57034261 AGGAAGUGGAGUGAGUAUCA 9181 84166_12_24 NLRC5 EXON + xp16:57034242-57034262 GGAAGUGGAGUGAGUAUUCAC 9182 84166_12_27 NLRC5 EXON - xp16:57034152-57034172 GCAGCCUUGGGUAGGAGUGG 9183 84166_12_28 NLRC5 EXON - xp16:57034153-57034173 UGCAGCCUUGGGUAGGAGUG 9184 84166_12_30 NLRC5 EXON - xp16:57034154-57034174 CUGCAGCCUUGGGUAGGAGU 9185 84166_12_33 NLRC5 EXON - xp16:57034155-57034175 UCUGCAGCCUUGGGUAGGAG 9186 84166_12_36 NLRC5 EXON - xp16:57034160-57034180 ACACUUCUGCAGCCUUGGGU 9187 84166_12_38 NLRC5 EXON - xp16:57034164-57034184 GCUGACACUUCUGCAGCCUU 9188 84166_12_39 NLRC5 EXON - xp16:57034165-57034185 AGCUGACACUUCUGCAGCCU 9189 84166_12_42 NLRC5 EXON - xp16:57034188-57034208 GGGCCUCCCGCAUCGUGGACC 9190 84166_12_44 NLRC5 EXON - xp16:57034194-57034214 CUAUGAGGGCCUCCGCAUCG 9191 84166_12_47 NLRC5 EXON - xp16:57034208-57034228 UUCCUGGAGCAGGGCUAUGA 9192 84166_12_48 NLRC5 EXON - xp16:57034209-57034229 CUUCCUGGAGCAGGGCUAUG 9193 84166_12_51 NLRC5 EXON - xp16:57034217-57034237 GUGAGGGCCUUCCUGGAGCA 9194 84166_12_52 NLRC5 EXON - xp16:57034218-57034238 GGUGAGGGCCUUCCUGGAGC 9195 84166_12_55 NLRC5 EXON - xp16:57034224-57034244 CCUCCAGGUGAGGGCCUUCC 9196 84166_12_58 NLRC5 EXON - xp16:57034233-57034253 ACUCCACUUCCUCCAGGUGA 9197 84166_12_59 NLRC5 EXON - xp16:57034234-57034254 CACUCCACUUCCUCCAGGUG 9198 84166_12_62 NLRC5 EXON - xp16:57034239-57034259 AUACUCACUCCACUUCCUCC 9199 84166_13_4 NLRC5 EXON + xp16:57036085-57036105 GCCCCCCGUCUCAGCCUCUC 9200 84166_13_6 NLRC5 EXON + xp16:57036086-57036106 CCCCCCGUCUCAGCCUCUCA 9201 84166_13_9 NLRC5 EXON + xp16:57036096-57036116 CAGCCUCUCAGGGAACCAGC 9202 84166_13_11 NLRC5 EXON + xp16:57036106-57036126 GGGAACCAGCUGGAAGAUGA 9203 84166_13_12 NLRC5 EXON + xp16:57036113-57036133 AGCUGGAAGAUGAAGGCUGU 9204 84166_13_13 NLRC5 EXON + xp16:57036120-57036140 AGAUGAAGGCUGUCGGCUGA 9205 84166_13_15 NLRC5 EXON + xp16:57036126-57036146 AGGCUGUCGGCUGAUGGCAG 9206 84166_13_17 NLRC5 EXON + xp16:57036152-57036172 CAUCCCAGCUGCACAUCGCC 9207 84166_13_20 NLRC5 EXON + xp16:57036159-57036179 GCUGCACAUCGCCAGGAAGC 9208 84166_13_24 NLRC5 EXON - xp16:57036089-57036109 CCCUGAGAGGCUGAGACGGG 9209 84166_13_25 NLRC5 EXON - xp16:57036090-57036110 UCCCUGAGAGGCUGAGACGG 9210 84166_13_26 NLRC5 EXON - xp16:57036091-57036111 UUCCCUGAGAGGCUGAGACG 9211 84166_13_29 NLRC5 EXON - xp16:57036092-57036112 GUUCCCUGAGAGGCUGAGAC 9212 84166_13_30 NLRC5 EXON - xp16:57036093-57036113 GGUUCCCUGAGAGGCUGAGA 9213 84166_13_36 NLRC5 EXON - xp16:57036102-57036122 CUUCCAGCUGGUUCCCUGAG 9214 84166_13_39 NLRC5 EXON - xp16:57036114-57036134 GACAGCCUUCAUCUUCCAGC 9215 84166_13_41 NLRC5 EXON - xp16:57036158-57036178 CUUCCUGGCGAUGUGCAGCU 9216 84166_13_42 NLRC5 EXON - xp16:57036159-57036179 GCUUCCUGGCGAUGUGCAGC 9217 84166_13_45 NLRC5 EXON - xp16:57036173-57036193 GACAACUCACUCCAGCUUCC 9218 84166_14_3 NLRC5 EXON + xp16:57037186-57037206 CUCCACAGCCUCAGUAACAA 9219 84166_14_4 NLRC5 EXON + xp16:57037187-57037207 UCCACAGCCUCAGUAACAAC 9220 84166_14_5 NLRC5 EXON + xp16:57037197-57037217 CAGUAACAACGGGCUUUCUG 9221 84166_14_7 NLRC5 EXON + xp16:57037201-57037221 AACAACGGGCUUUCUGUGGC 9222 84166_14_9 NLRC5 EXON + xp16:57037202-57037222 ACAACGGGCUUUCUGUGGCC 9223 84166_14_10 NLRC5 EXON + xp16:57037203-57037223 CAACGGGCUUUCUGUGGCCG 9224 84166_14_15 NLRC5 EXON + xp16:57037220-57037240 CCGGGGUGCAUUGUGUGCUG 9225 84166_14_16 NLRC5 EXON + xp16:57037221-57037241 CGGGGUGCAUUGUGUGCUGA 9226 84166_14_20 NLRC5 EXON + xp16:57037238-57037258 UGAGGGCCGUGAGUGCGUGC 9227 84166_14_21 NLRC5 EXON + xp16:57037245-57037265 CGUGAGUGCGUGCUGGACCCC 9228 84166_14_23 NLRC5 EXON + xp16:57037262-57037282 CCCUGGCAGAGCUGCACAUC 9229 84166_14_26 NLRC5 EXON + xp16:57037265-57037285 UGGCAGAGCUGCACAUCAGG 9230 84166_14_28 NLRC5 EXON + xp16:57037266-57037286 GGCAGAGCUGCACAUCAGGU 9231 84166_14_29 NLRC5 EXON - xp16:57037177-57037197 AGGCUGUGGAGAGCAGGAGA 9232 84166_14_34 NLRC5 EXON - xp16:57037183-57037203 UUACUGAGGCUGUGGAGAGC 9233 84166_14_39 NLRC5 EXON - xp16:57037191-57037211 GCCCGUUGUUACUGAGGCUG 9234 84166_14_41 NLRC5 EXON - xp16:57037197-57037217 CAGAAAGCCCGUUGUUACUG 9235 84166_14_44 NLRC5 EXON - xp16:57037223-57037243 CCUCAGCACACAAUGCACCC 9236 84166_14_45 NLRC5 EXON - xp16:57037247-57037267 CAGGGUCCAGCACGCACUCA 9237 84166_14_46 NLRC5 EXON - xp16:57037265-57037285 CCUGAUGUGCAGCUCUGCCA 9238 84166_14_47 NLRC5 EXON - xp16:57037266-57037286 ACCUGAUGUGCAGCUCUGCC 9239 84166_15_7 NLRC5 EXON + xp16:57039795-57039815 UGUGAUCUUCAUGUUUGCCC 9240 84166_15_11 NLRC5 EXON + xp16:57039804-57039824 CAUGUUUGCCCAGGAGCCAG 9241 84166_15_17 NLRC5 EXON + xp16:57039813-57039833 CCAGGAGCCAGAGGAGCAGA 9242 84166_15_19 NLRC5 EXON + xp16:57039814-57039834 CAGGAGCCAGAGGAGCAGAA 9243 84166_15_20 NLRC5 EXON + xp16:57039815-57039835 AGGAGCCAGAGGAGCAGAAG 9244 84166_15_23 NLRC5 EXON + xp16:57039822-57039842 AGAGGAGCAGAAGGGGCCCC 9245 84166_15_25 NLRC5 EXON + xp16:57039827-57039847 AGCAGAAGGGGCCCCAGGAG 9246 84166_15_27 NLRC5 EXON + xp16:57039831-57039851 GAAGGGGCCCCAGGAGAGGU 9247 84166_15_28 NLRC5 EXON + xp16:57039832-57039852 AAGGGGCCCCAGGAGAGGUA 9248 84166_15_29 NLRC5 EXON - xp16:57039763-57039783 AGGCUGUGAAGACAAAAAGAG 9249 84166_15_30 NLRC5 EXON - xp16:57039764-57039784 CAGGCUGUGAAGACAAAAGA 9250 84166_15_32 NLRC5 EXON - xp16:57039765-57039785 GCAGGCUGUGAAGACAAAG 9251 84166_15_39 NLRC5 EXON - xp16:57039783-57039803 AGAUCACAGUUUUGUGCUGC 9252 84166_15_42 NLRC5 EXON - xp16:57039815-57039835 CUUCUGCUCCUCUGGCUCCU 9253 84166_15_43 NLRC5 EXON - xp16:57039816-57039836 CCUUCUGCUCCUCUGGCUCC 9254 84166_15_45 NLRC5 EXON - xp16:57039823-57039843 UGGGGCCCCUUCUGCUCCUC 9255 84166_15_46 NLRC5 EXON - xp16:57039841-57039861 AUCGGGCCCUACCUCUCCUG 9256 84166_15_47 NLRC5 EXON - xp16:57039842-57039862 AAUCGGGCCCUACCUCUCCU 9257 84166_15_49 NLRC5 EXON - xp16:57039843-57039863 AAAUCGGGCCCUACCUCUCC 9258 84166_16_9 NLRC5 EXON + xp16:57040690-57040710 AGCUGCCUCUGAGCUCCCGA 9259 84166_16_11 NLRC5 EXON + xp16:57040696-57040716 CUCUGAGCUCCCGAAGGAUG 9260 84166_16_12 NLRC5 EXON + xp16:57040707-57040727 CGAAGGAUGAGGUACAGGUGA 9261 84166_16_13 NLRC5 EXON - xp16:57040632-57040652 GCCCUGGAGGGACAUCACCA 9262 84166_16_14 NLRC5 EXON - xp16:57040644-57040664 UCAAGAAAUGCAGCCCUGGA 9263 84166_16_16 NLRC5 EXON - xp16:57040645-57040665 GUCAAGAAAUGCAGCCCUGG 9264 84166_16_18 NLRC5 EXON - xp16:57040648-57040668 GCUGUCAAGAAAUGCAGCCC 9265 84166_16_22 NLRC5 EXON - xp16:57040670-57040690 CAGAGGGCAUCUGGAGCAUG 9266 84166_16_24 NLRC5 EXON - xp16:57040679-57040699 GAGGCAGCUCAGAGGGCAUC 9267 84166_16_28 NLRC5 EXON - xp16:57040686-57040706 GAGCUCAGAGGCAGCUCAGA 9268 84166_16_29 NLRC5 EXON - xp16:57040687-57040707 GGAGCUCAGAGGCAGCUCAG 9269 84166_16_32 NLRC5 EXON - xp16:57040698-57040718 CUCAUCCUUCGGGAGCUCAG 9270 84166_16_35 NLRC5 EXON - xp16:57040708-57040728 AUCACUGUACCUCAUCCUUC 9271 84166_16_36 NLRC5 EXON - xp16:57040709-57040729 CAUCACUGUACCUCAUCCUU 9272 84166_17_5 NLRC5 EXON + xp16:57041476-57041496 CUGGGCAGGCUGACACAUUG 9273 84166_17_10 NLRC5 EXON + xp16:57041511-57041531 GCACCUAGAGCAGCUCUGCA 9274 84166_17_13 NLRC5 EXON + xp16:57041517-57041537 AGAGCAGCUCUGCAAGGCUC 9275 84166_17_15 NLRC5 EXON + xp16:57041518-57041538 GAGCAGCUCUGCAAGGCUCU 9276 84166_17_18 NLRC5 EXON + xp16:57041521-57041541 CAGCUCUGCAAGGCUCUGGG 9277 84166_17_19 NLRC5 EXON + xp16:57041536-57041556 CUGGGAGGAAGCUGCCACCU 9278 84166_17_22 NLRC5 EXON + xp16:57041559-57041579 UCACCUCCACCUCGAGUGAG 9279 84166_17_23 NLRC5 EXON + xp16:57041571-57041591 CGAGUGAGUGGUUUGUGUGU 9280 84166_17_24 NLRC5 EXON - xp16:57041477-57041497 ACAAUGUGUCAGCCUGCCCA 9281 84166_17_25 NLRC5 EXON - xp16:57041478-57041498 CACAAUGUGUCAGCCUGCCC 9282 84166_17_32 NLRC5 EXON - xp16:57041502-57041522 GCUCUAGGUGCUUUUCUUGG 9283 84166_17_33 NLRC5 EXON - xp16:57041505-57041525 GCUGCUCUAGGUGCUUUUCU 9284 84166_17_37 NLRC5 EXON - xp16:57041517-57041537 GAGCCUUGCAGAGCUGCUCU 9285 84166_17_41 NLRC5 EXON - xp16:57041553-57041573 CGAGGUGGAGGUGACCGAGG 9286 84166_17_42 NLRC5 EXON - xp16:57041556-57041576 ACUCGAGGUGGAGGUGACCG 9287 84166_17_44 NLRC5 EXON - xp16:57041565-57041585 AAACCACUCACUCGAGGUGG 9288 84166_17_46 NLRC5 EXON - xp16:57041568-57041588 CACAAACCACUCACUCGAGG 9289 84166_17_48 NLRC5 EXON - xp16:57041571-57041591 ACACACAAACCACUCACUCG 9290 84166_18_1 NLRC5 EXON + xp16:57041967-57041987 CUCCCCACCCCCAGCUUCUC 9291 84166_18_5 NLRC5 EXON + xp16:57041978-57041998 CAGCUUCUCAGGCAAUGCUC 9292 84166_18_6 NLRC5 EXON + xp16:57041979-57041999 AGCUUCUCAGGCAAUGCUCU 9293 84166_18_8 NLRC5 EXON + xp16:57041980-57042000 GCUUCUCAGGCAAUGCUCUG 9294 84166_18_10 NLRC5 EXON + xp16:57041981-57042001 CUUCUCAGGCAAUGCUCUGG 9295 84166_18_13 NLRC5 EXON + xp16:57041988-57042008 GGCAAUGCUCUGGGGGAUGA 9296 84166_18_14 NLRC5 EXON + xp16:57041998-57042018 UGGGGGAUGAAGGUGCAGCC 9297 84166_18_15 NLRC5 EXON + xp16:57042002-57042022 GGAUGAAGGUGCAGCCCGGC 9298 84166_18_17 NLRC5 EXON + xp16:57042018-57042038 CGGCUGGCUCAGCUGCUCCC 9299 84166_18_18 NLRC5 EXON + xp16:57042019-57042039 GGCUGGCUCAGCUGCUCCCA 9300 84166_18_21 NLRC5 EXON + xp16:57042023-57042043 GGCUCAGCUGCUCCCAGGGC 9301 84166_18_22 NLRC5 EXON + xp16:57042024-57042044 GCUCAGCUGCUCCCAGGGCU 9302 84166_18_26 NLRC5 EXON + xp16:57042059-57042079 CUUGAAGUGAGUAGCCCGCU 9303 84166_18_27 NLRC5 EXON - xp16:57041965-57041985 GAAGCUGGGGGUGGGGAGAA 9304 84166_18_28 NLRC5 EXON - xp16:57041966-57041986 AGAAGCUGGGGGUGGGGAGA 9305 84166_18_34 NLRC5 EXON - xp16:57041972-57041992 UGCCUGAGAAGCUGGGGGUG 9306 84166_18_37 NLRC5 EXON - xp16:57041973-57041993 UUGCCUGAGAAGCUGGGGGU 9307 84166_18_39 NLRC5 EXON - xp16:57041974-57041994 AUUGCCUGAGAAGCUGGGGG 9308 84166_18_41 NLRC5 EXON - xp16:57041977-57041997 AGCAUUGCCUGAGAAGCUGG 9309 84166_18_42 NLRC5 EXON - xp16:57041978-57041998 GAGCAUUGCCUGAGAAGCUG 9310 84166_18_43 NLRC5 EXON - xp16:57041979-57041999 AGAGCAUUGCCUGAGAAGCU 9311 84166_18_46 NLRC5 EXON - xp16:57041980-57042000 CAGAGCAUUGCCUGAGAAGC 9312 84166_18_53 NLRC5 EXON - xp16:57042019-57042039 UGGGAGCAGCUGAGCCAGCC 9313 84166_18_54 NLRC5 EXON - xp16:57042020-57042040 CUGGGAGCAGCUGAGCCAGC 9314 84166_18_57 NLRC5 EXON - xp16:57042038-57042058 ACUGCAGAGCUCCAGCCCU 9315 84166_18_59 NLRC5 EXON - xp16:57042039-57042059 GACUGCAGAGCUCCCAGCCC 9316 84166_18_64 NLRC5 EXON - xp16:57042061-57042081 CUAGCGGGCUACUCACUUCA 9317 84166_19_3 NLRC5 EXON + xp16:57043506-57043526 AUCUCCAGCCUCAGUGAGAA 9318 84166_19_5 NLRC5 EXON + xp16:57043517-57043537 CAGUGAGAACGGUUUGUCCC 9319 84166_19_7 NLRC5 EXON + xp16:57043529-57043549 UUUGUCCCUGGAUGCCGUGU 9320 84166_19_8 NLRC5 EXON + xp16:57043530-57043550 UUGUCCCUGGAUGCCGUGUU 9321 84166_19_11 NLRC5 EXON + xp16:57043535-57043555 CCUGGAUGCCGUGUUGGGUU 9322 84166_19_12 NLRC5 EXON + xp16:57043540-57043560 AUGCCGUGUUGGGUUUGGUU 9323 84166_19_16 NLRC5 EXON + xp16:57043561-57043581 GGUGCUUCUCCACUCUGCAG 9324 84166_19_20 NLRC5 EXON + xp16:57043574-57043594 UCUGCAGUGGCUCUUCCGCU 9325 84166_19_21 NLRC5 EXON + xp16:57043582-57043602 GGCUCUUCCGCUUGGACAUC 9326 84166_19_25 NLRC5 EXON - xp16:57043498-57043518 GAGGCUGGAGAUCACAGGGG 9327 84166_19_27 NLRC5 EXON - xp16:57043501-57043521 ACUGAGGCUGGAGAUCACAG 9328 84166_19_28 NLRC5 EXON - xp16:57043502-57043522 CACUGAGGCUGGAGAUCACCA 9329 84166_19_30 NLRC5 EXON - xp16:57043503-57043523 UCACUGAGGCUGGAGAUCAC 9330 84166_19_33 NLRC5 EXON - xp16:57043513-57043533 CAAACCGUUCUCACUGAGGC 9331 84166_19_35 NLRC5 EXON - xp16:57043517-57043537 GGGACAAACCGUUCUCACUG 9332 84166_19_37 NLRC5 EXON - xp16:57043537-57043557 CAAACCCAACACGGCAUCCA 9333 84166_19_38 NLRC5 EXON - xp16:57043538-57043558 CCAAACCCAACACGGCAUCC 9334 84166_19_41 NLRC5 EXON - xp16:57043546-57043566 GCACCGAACCAAACCCAACA 9335 84166_19_46 NLRC5 EXON - xp16:57043573-57043593 GCGGAAGAGCCCACUGCAGAG 9336 84166_19_50 NLRC5 EXON - xp16:57043592-57043612 ACGCUCACCUGAUGUCCAAG 9337 84166_20_10 NLRC5 EXON + xp16:57045454-57045474 AGCCAACACAUCCUCCUGAG 9338 84166_20_11 NLRC5 EXON + xp16:57045455-57045475 GCCAACACAUCCUCCUGAGA 9339 84166_20_13 NLRC5 EXON + xp16:57045456-57045476 CCAACACAUCCUCCUGAGAG 9340 84166_20_14 NLRC5 EXON + xp16:57045470-57045490 UGAGAGGGGACAAGACAAGC 9341 84166_20_18 NLRC5 EXON + xp16:57045475-57045495 GGGGACAAGACAAGCAGGUG 9342 84166_20_21 NLRC5 EXON + xp16:57045478-57045498 GACAAGACAAGCAGGUGAGG 9343 84166_20_23 NLRC5 EXON + xp16:57045479-57045499 ACAAGACAAGCAGGUGAGGA 9344 84166_20_25 NLRC5 EXON + xp16:57045488-57045508 GCAGGUGAGGAGGGAACGCU 9345 84166_20_26 NLRC5 EXON + xp16:57045489-57045509 CAGGUGAGGAGGGAACGCUC 9346 84166_20_30 NLRC5 EXON - xp16:57045435-57045455 UUUCAAAGCUGGAAGCAGAG 9347 84166_20_35 NLRC5 EXON - xp16:57045446-57045466 GAUGUGUUGGCUUUCAAAGC 9348 84166_20_39 NLRC5 EXON - xp16:57045459-57045479 CCCCUCUCAGGAGGAUGUGU 9349 84166_20_41 NLRC5 EXON - xp16:57045468-57045488 UUGUCUUGUCCCCUCUCAGG 9350 84166_20_44 NLRC5 EXON - xp16:57045471-57045491 UGCUUGUCUUGUCCCCUCUC 9351 84166_21_2 NLRC5 EXON + xp16:57046538-57046558 AUCCCCCUCCUAGGGAUAUG 9352 84166_21_3 NLRC5 EXON + xp16:57046539-57046559 UCCCCCUCCUAGGGAUAUGU 9353 84166_21_5 NLRC5 EXON + xp16:57046546-57046566 CCUAGGGAUAUGUGGGCCAC 9354 84166_21_9 NLRC5 EXON + xp16:57046585-57046605 CCAGCUGCAGCCAAGUUCUU 9355 84166_21_11 NLRC5 EXON + xp16:57046586-57046606 CAGCUGCAGCCAAGUUCUUA 9356 84166_21_15 NLRC5 EXON + xp16:57046610-57046630 UCCGUCAGCGCUGCAUCCCC 9357 84166_21_18 NLRC5 EXON + xp16:57046619-57046639 GCUGCAUCCCCAGGAGCCUC 9358 84166_21_19 NLRC5 EXON - xp16:57046543-57046563 GCCCACAUAUCCCUAGGAGG 9359 84166_21_21 NLRC5 EXON - xp16:57046544-57046564 GGCCCACAUAUCCCUAGGAG 9360 84166_21_22 NLRC5 EXON - xp16:57046545-57046565 UGGCCCACAUAUCCCUAGGA 9361 84166_21_24 NLRC5 EXON - xp16:57046546-57046566 GUGGCCCACAUAUCCCUAGG 9362 84166_21_28 NLRC5 EXON - xp16:57046549-57046569 CCAGUGGCCCACAUAUCCCU 9363 84166_21_30 NLRC5 EXON - xp16:57046565-57046585 GAAGUCUGGCAAAGAUCCAG 9364 84166_21_32 NLRC5 EXON - xp16:57046579-57046599 UUGGCUGCAGCUGGGAAGUC 9365 84166_21_34 NLRC5 EXON - xp16:57046587-57046607 CUAAGAACUUGGCUGCAGCU 9366 84166_21_36 NLRC5 EXON - xp16:57046588-57046608 CCUAAGAACUUGGCUGCAGC 9367 84166_21_38 NLRC5 EXON - xp16:57046598-57046618 CUGACGGAACCCUAAGAACU 9368 84166_21_41 NLRC5 EXON - xp16:57046614-57046634 UCCUGGGGAUGCAGCGCUGA 9369 84166_21_44 NLRC5 EXON - xp16:57046629-57046649 GACAGUACCAGAGGCUCCUG 9370 84166_21_46 NLRC5 EXON - xp16:57046630-57046650 GGACAGUACCAGAGGCUCCU 9371 84166_21_47 NLRC5 EXON - xp16:57046631-57046651 GGGACAGUACCAGAGGCUCC 9372 84166_21_50 NLRC5 EXON - xp16:57046638-57046658 AAGGGCUGGGACAGUACAG 9373 84166_22_5 NLRC5 EXON + xp16:57047541-57047561 CAGCCUCAGUGAGUGUCCUC 9374 84166_22_10 NLRC5 EXON + xp16:57047580-57047600 CCGCCUCUGUGCCACUCUGA 9375 84166_22_12 NLRC5 EXON + xp16:57047589-57047609 UGCCACUCUGAAGGACUGCC 9376 84166_22_14 NLRC5 EXON + xp16:57047590-57047610 GCCACUCUGAAGGACUGCCC 9377 84166_22_16 NLRC5 EXON + xp16:57047598-57047618 GAAGGACUGCCCGGGACCCC 9378 84166_22_20 NLRC5 EXON + xp16:57047618-57047638 UGGAACUGCAGUAAGUAACG 9379 84166_22_21 NLRC5 EXON - xp16:57047529-57047549 UGAGGCUGCAAAGGGGCAAU 9380 84166_22_22 NLRC5 EXON - xp16:57047530-57047550 CUGAGGCUGCAAAGGGGCAA 9381 84166_22_24 NLRC5 EXON - xp16:57047536-57047556 CACUCACUGAGGCUGCAAAG 9382 84166_22_25 NLRC5 EXON - xp16:57047537-57047557 ACACUCACUGAGGCUGCAAA 9383 84166_22_26 NLRC5 EXON - xp16:57047538-57047558 GACACUCACUGAGGCUGCAA 9384 84166_22_30 NLRC5 EXON - xp16:57047547-57047567 GCUCCAGAGGACACUCACUG 9385 84166_22_32 NLRC5 EXON - xp16:57047560-57047580 GUGAGGCUUGGGGGCUCCAG 9386 84166_22_35 NLRC5 EXON - xp16:57047569-57047589 CAGAGGCGGGUGAGGCUUGG 9387 84166_22_36 NLRC5 EXON - xp16:57047570-57047590 ACAGAGGCGGGUGAGGCUUG 9388 84166_22_38 NLRC5 EXON - xp16:57047571-57047591 CACAGAGGCGGGUGAGGCUU 9389 84166_22_40 NLRC5 EXON - xp16:57047572-57047592 GCACAGAGGCGGGUGAGGCU 9390 84166_22_43 NLRC5 EXON - xp16:57047577-57047597 GAGUGGCACAGAGGCGGGUG 9391 84166_22_45 NLRC5 EXON - xp16:57047582-57047602 CUUCAGAGGUGGCACAGAGGC 9392 84166_22_46 NLRC5 EXON - xp16:57047583-57047603 CCUUCAGAGGUGGCACAGAGG 9393 84166_22_48 NLRC5 EXON - xp16:57047586-57047606 AGUCCUUCAGAGGUGGCACAG 9394 84166_22_50 NLRC5 EXON - xp16:57047594-57047614 UCCCGGGCAGUCCUUCAGAG 9395 84166_22_54 NLRC5 EXON - xp16:57047610-57047630 ACUGCAGUUCCAGGGGUCCC 9396 84166_22_56 NLRC5 EXON - xp16:57047611-57047631 UACUGCAGUUCCAGGGGUCC 9397 84166_22_58 NLRC5 EXON - xp16:57047617-57047637 GUUACUUACUGCAGUUCCAG 9398 84166_22_59 NLRC5 EXON - xp16:57047618-57047638 CGUUACUUACUGCAGUUCCA 9399 84166_22_60 NLRC5 EXON - xp16:57047619-57047639 UCGUUACUUACUGCAGUUCC 9400 84166_23_11 NLRC5 EXON + xp16:57051549-57051569 GUUCCUGAGUGACCAGAGCC 9401 84166_23_14 NLRC5 EXON + xp16:57051561-57051581 CCAGAGCCUGGAGACUCUAC 9402 84166_23_19 NLRC5 EXON - xp16:57051520-57051540 AAUCUGUGAAACAAAGCAGG 9403 84166_23_20 NLRC5 EXON - xp16:57051523-57051543 GACAAUCUGUGAAACAAAGC 9404 84166_23_22 NLRC5 EXON - xp16:57051545-57051565 CUGGUCACUCAGGAACUCAC 9405 84166_23_25 NLRC5 EXON - xp16:57051555-57051575 UCUCCAGGCUCUGGUCACUC 9406 84166_23_27 NLRC5 EXON - xp16:57051564-57051584 CCAGUAGAGUCUCCAGGCUC 9407 84166_23_28 NLRC5 EXON - xp16:57051570-57051590 AGCAGUCCAGUAGAGUCUCC 9408 84166_23_31 NLRC5 EXON - xp16:57051595-57051615 AGGCUCAGCUGAGGGAGUUG 9409 84166_23_35 NLRC5 EXON - xp16:57051603-57051623 ACUGCAGCAGGCUCAGCUGA 9410 84166_23_36 NLRC5 EXON - xp16:57051604-57051624 UACUGCAGCAGGCUCAGCUG 9411 84166_23_40 NLRC5 EXON - xp16:57051615-57051635 AACUCUCGUCUUACUGCAGC 9412 84166_24_4 NLRC5 EXON + xp16:57054741-57054761 CCUUUUCAGGCUGAGCCAGA 9413 84166_24_6 NLRC5 EXON + xp16:57054742-57054762 CUUUUCAGGCUGAGCCAGAC 9414 84166_24_12 NLRC5 EXON + xp16:57054771-57054791 CCCGAAAAGCCCCUUCCUGC 9415 84166_24_15 NLRC5 EXON + xp16:57054797-57054817 ACACCUUAAGCCUGUGUCCA 9416 84166_24_16 NLRC5 EXON + xp16:57054798-57054818 CACCUUAAGCCUGUGUCCAC 9417 84166_24_18 NLRC5 EXON + xp16:57054807-57054827 CCUGUGUCCACGGGUUAAAAA 9418 84166_24_20 NLRC5 EXON + xp16:57054810-57054830 GUGUCCACGGGUUAAAAAAGG 9419 84166_24_21 NLRC5 EXON + xp16:57054818-57054838 GGGUUAAAAAAGGUGGAUCUC 9420 84166_24_23 NLRC5 EXON + xp16:57054821-57054841 UUAAAAAAGGUGGAUCUCAGG 9421 84166_24_24 NLRC5 EXON + xp16:57054822-57054842 UAAAAAGGUGGAUCUCAGGU 9422 84166_24_28 NLRC5 EXON + xp16:57054833-57054853 AUCUCAGGUGGGCAUUCCCCC 9423 84166_24_29 NLRC5 EXON + xp16:57054834-57054854 UCUCAGGUGGGCAUUCCCCU 9424 84166_24_30 NLRC5 EXON - xp16:57054736-57054756 CUCAGCCUGAAAAGGAAAGG 9425 84166_24_31 NLRC5 EXON - xp16:57054737-57054757 GCUCAGCCUGAAAAGGAAAG 9426 84166_24_33 NLRC5 EXON - xp16:57054738-57054758 GGCUCAGCCUGAAAAGGAAA 9427 84166_24_34 NLRC5 EXON - xp16:57054739-57054759 UGGCUCAGCCUGAAAAGGAA 9428 84166_24_38 NLRC5 EXON - xp16:57054744-57054764 CCGUCUGGCUCAGCCUGAAA 9429 84166_24_44 NLRC5 EXON - xp16:57054759-57054779 UUUUCGGGGACAGUCCCGUC 9430 84166_24_46 NLRC5 EXON - xp16:57054773-57054793 CAGCAGGAAGGGGCUUUUCG 9431 84166_24_47 NLRC5 EXON - xp16:57054774-57054794 CCAGCAGGAAGGGGCUUUUC 9432 84166_24_49 NLRC5 EXON - xp16:57054775-57054795 GCCAGCAGGAAGGGGCUUUU 9433 84166_24_53 NLRC5 EXON - xp16:57054783-57054803 AGGUGUUGGCCAGCAGGAAG 9434 84166_24_54 NLRC5 EXON - xp16:57054784-57054804 AAGGUGUUGGCCAGCAGGAA 9435 84166_24_55 NLRC5 EXON - xp16:57054785-57054805 UAAGGUGUUGGCCAGCAGGA 9436 84166_24_58 NLRC5 EXON - xp16:57054789-57054809 GGCUUAAGGUGUUGGCCAGC 9437 84166_24_61 NLRC5 EXON - xp16:57054797-57054817 UGGACACAGGCUUAAGGUGU 9438 84166_24_66 NLRC5 EXON - xp16:57054803-57054823 AACCCGUGGACACAGGCUUA 9439 84166_24_67 NLRC5 EXON - xp16:57054810-57054830 CCUUUUUAACCCGUGGACAC 9440 84166_24_68 NLRC5 EXON - xp16:57054817-57054837 AGAUCCACCUUUUUAACCCG 9441 84166_25_3 NLRC5 EXON + xp16:57055049-57055069 UUUGCACUUCAGAUCCAACG 9442 84166_25_8 NLRC5 EXON + xp16:57055052-57055072 GCACUUCAGAUCCAACGAGG 9443 84166_25_12 NLRC5 EXON + xp16:57055055-57055075 CUUCAGAUCCAACGAGGAGG 9444 84166_25_14 NLRC5 EXON + xp16:57055059-57055079 AGAUCCAACGAGGAGGAGGA 9445 84166_25_16 NLRC5 EXON + xp16:57055071-57055091 GAGGAGGAAGGCGUGUGCUG 9446 84166_25_17 NLRC5 EXON + xp16:57055072-57055092 AGGAGGAAGGCGUGUGCUGU 9447 84166_25_19 NLRC5 EXON - xp16:57055014-57055034 GACCUGGAUCAGACAGGACC 9448 84166_25_20 NLRC5 EXON - xp16:57055020-57055040 UGCAGGGACCUGGAUCAGAC 9449 84166_25_23 NLRC5 EXON - xp16:57055030-57055050 AGUUGCAUGGUGCAGGGACC 9450 84166_25_25 NLRC5 EXON - xp16:57055036-57055056 GUGCAAAGUUGCAUGGUGCA 9451 84166_25_27 NLRC5 EXON - xp16:57055037-57055057 AGUGCAAAGUUGCAUGGUGC 9452 84166_25_30 NLRC5 EXON - xp16:57055043-57055063 AUCUGAAGUGCAAAGUUGCA 9453 84166_25_33 NLRC5 EXON - xp16:57055066-57055086 CACGCCUUCCUCCUCCUCGU 9454 84166_26_1 NLRC5 EXON + xp16:57055413-57055433 CCCCUUUACCUCCGUCCAGC 9455 84166_26_4 NLRC5 EXON + xp16:57055421-57055441 CCUCCGUCCAGCAGGUUCAC 9456 84166_26_7 NLRC5 EXON + xp16:57055438-57055458 CACAGGCUGCAGCCUCAGCC 9457 84166_26_10 NLRC5 EXON + xp16:57055461-57055481 AGCACGUAGAGUCACUCUGC 9458 84166_26_13 NLRC5 EXON - xp16:57055416-57055436 CCUGCUGGACGGAGGUAAAG 9459 84166_26_15 NLRC5 EXON - xp16:57055417-57055437 ACCUGCUGGACGGAGGUAAAA 9460 84166_26_16 NLRC5 EXON - xp16:57055418-57055438 AACCUGCUGGACGGAGGUAA 9461 84166_26_19 NLRC5 EXON - xp16:57055424-57055444 CCUGUGAACCUGCUGGACGG 9462 84166_26_20 NLRC5 EXON - xp16:57055427-57055447 CAGCCUGUGAACCUGCUGGA 9463 84166_26_23 NLRC5 EXON - xp16:57055431-57055451 GCUGCAGCCUGUGAACCUGC 9464 84166_26_26 NLRC5 EXON - xp16:57055453-57055473 ACUCUACGUGCUCCUGGCUG 9465 84166_26_28 NLRC5 EXON - xp16:57055459-57055479 AGAGUGACUCUACGUGCUCC 9466 84166_26_33 NLRC5 EXON - xp16:57055507-57055527 GUUGAAUGAGGUGGAGGCUG 9467 84166_26_35 NLRC5 EXON - xp16:57055513-57055533 GAGGGAGUUGAAUGAGGUGG 9468 84166_27_3 NLRC5 EXON + xp16:57058061-57058081 CAGUCUCUCAGCAAACCUGC 9469 84166_27_4 NLRC5 EXON + xp16:57058062-57058082 AGUCUCUCAGCAAACCUGCU 9470 84166_27_6 NLRC5 EXON + xp16:57058071-57058091 GCAAACCUGCUGGGCGACAG 9471 84166_27_9 NLRC5 EXON + xp16:57058088-57058108 CAGCGGACUCAGAUGCCUUC 9472 84166_27_10 NLRC5 EXON + xp16:57058103-57058123 CCUUCUGGAAUGUCUGCCGC 9473 84166_27_12 NLRC5 EXON + xp16:57058116-57058136 CUGCCGCAGGUGCCCAUCUC 9474 84166_27_15 NLRC5 EXON + xp16:57058133-57058153 CUCCGGUUUGCUUGAGUAAG 9475 84166_27_22 NLRC5 EXON - xp16:57058052-57058072 CUGAGAGACUGUAGGGGGUA 9476 84166_27_24 NLRC5 EXON - xp16:57058057-57058077 GUUUGCUGAGAGACUGUAGG 9477 84166_27_25 NLRC5 EXON - xp16:57058058-57058078 GGUUUGCUGAGAGACUGUAG 9478 84166_27_26 NLRC5 EXON - xp16:57058059-57058079 AGGUUUGCUGAGAGACUGUA 9479 84166_27_28 NLRC5 EXON - xp16:57058060-57058080 CAGGUUUGCUGAGAGACUGU 9480 84166_27_33 NLRC5 EXON - xp16:57058079-57058099 UGAGUCCCGCUGUCGCCCAGC 9481 84166_27_36 NLRC5 EXON - xp16:57058106-57058126 CCUGCGGCAGACAUUCCAGA 9482 84166_27_39 NLRC5 EXON - xp16:57058122-57058142 AAACCGGAGAUGGGCACCUG 9483 84166_27_41 NLRC5 EXON - xp16:57058131-57058151 UACUCAAGCAAACCGGAGAU 9484 84166_27_42 NLRC5 EXON - xp16:57058132-57058152 UUACUCAAGCAAACCGGAGA 9485 84166_27_47 NLRC5 EXON - xp16:57058138-57058158 UUCCACUUACUCAAGCAAAC 9486 84166_28_6 NLRC5 EXON + xp16:57058974-57058994 GAGUCACAACAGCAUUUCUC 9487 84166_28_12 NLRC5 EXON + xp16:57058995-57059015 GGAAAGUGCCCUGUACCUGC 9488 84166_28_14 NLRC5 EXON + xp16:57059024-57059044 UGCCCUCCUGCCCACGUGUC 9489 84166_28_17 NLRC5 EXON + xp16:57059025-57059045 GCCCUCCUGCCCACGUGUCC 9490 84166_28_18 NLRC5 EXON + xp16:57059028-57059048 CUCCUGCCCACGUGUCCGGG 9491 84166_28_21 NLRC5 EXON + xp16:57059044-57059064 CGGGAGGCCUCAGUGAAGUA 9492 84166_28_24 NLRC5 EXON + xp16:57059045-57059065 GGGAGGCCUCAGUGAAGUAA 9493 84166_28_25 NLRC5 EXON + xp16:57059046-57059066 GGAGGCCUCAGUGAAGUAAG 9494 84166_28_26 NLRC5 EXON + xp16:57059053-57059073 UCAGUGAAGUAAGGGGAUGU 9495 84166_28_29 NLRC5 EXON - xp16:57058959-57058979 GACUCAGACUAGAAGGGAAA 9496 84166_28_32 NLRC5 EXON - xp16:57058965-57058985 UGUUGUGACUCAGACUAGAA 9497 84166_28_33 NLRC5 EXON - xp16:57058966-57058986 CUGUUGUGACUCAGACUAGA 9498 84166_28_42 NLRC5 EXON - xp16:57059006-57059026 CAGUGUCUCCAGCAGGUAC 9499 84166_28_43 NLRC5 EXON - xp16:57059007-57059027 GCAGUGUCUCCAGCAGGUAC 9500 84166_28_45 NLRC5 EXON - xp16:57059013-57059033 AGGAGGGCAGUGUCUCCAGGC 9501 84166_28_46 NLRC5 EXON - xp16:57059029-57059049 UCCCGGACACGUGGGCAGGA 9502 84166_28_47 NLRC5 EXON - xp16:57059030-57059050 CUCCCGGACACGUGGGCAGG 9503 84166_28_49 NLRC5 EXON - xp16:57059033-57059053 GGCCUCCCGGACACGUGGGC 9504 84166_28_53 NLRC5 EXON - xp16:57059037-57059057 CUGAGGCCUCCCGGACACGU 9505 84166_28_54 NLRC5 EXON - xp16:57059038-57059058 ACUGAGGCCUCCCGGACACG 9506 84166_28_57 NLRC5 EXON - xp16:57059046-57059066 CUUACUUCACUGAGGCCUCC 9507 84166_28_59 NLRC5 EXON - xp16:57059054-57059074 AACAUCCCCUUACUUCACUG 9508 84166_29_2 NLRC5 EXON + xp16:57059448-57059468 AGGCCCUUCUCUCUGCAGCC 9509 84166_29_3 NLRC5 EXON + xp16:57059449-57059469 GGCCCUUCUCUCUGCAGCCU 9510 84166_29_8 NLRC5 EXON + xp16:57059468-57059488 UGGGCUCUGAGCAGAGCUUC 9511 84166_29_12 NLRC5 EXON + xp16:57059487-57059507 CCGGAUUCACUUCUCCAGAG 9512 84166_29_14 NLRC5 EXON + xp16:57059493-57059513 UCACUUCUCCAGAGAGGACC 9513 84166_29_18 NLRC5 EXON + xp16:57059497-57059517 UUCUCCAGAGAGGACCAGGC 9514 84166_29_20 NLRC5 EXON + xp16:57059498-57059518 UCUCCAGAGAGGACCAGGCU 9515 84166_29_22 NLRC5 EXON + xp16:57059510-57059530 ACCAGGCUGGGAAGACACUC 9516 84166_29_24 NLRC5 EXON + xp16:57059523-57059543 GACACUCAGGUAAAUCCCUGC 9517 84166_29_25 NLRC5 EXON + xp16:57059524-57059544 ACACUCAGGUAAAUCCCUGCA 9518 84166_29_26 NLRC5 EXON - xp16:57059449-57059469 AGGCUGCAGAGAGAAGGGCC 9519 84166_29_27 NLRC5 EXON - xp16:57059454-57059474 AGCCCAGGCUGCAGAGAGAA 9520 84166_29_28 NLRC5 EXON - xp16:57059455-57059475 GAGCCCAGGCUGCAGAGAGA 9521 84166_29_34 NLRC5 EXON - xp16:57059469-57059489 GGAAGCUCUGCUCAGAGCCC 9522 84166_29_36 NLRC5 EXON - xp16:57059490-57059510 CCUCUCUGGAGAAGUGAAUC 9523 84166_29_44 NLRC5 EXON - xp16:57059504-57059524 CUUCCCAGCCCUGGUCCUCUC 9524 84166_29_47 NLRC5 EXON - xp16:57059514-57059534 ACCUGAGUGUCUUCCCAGCC 9525 84166_30_4 NLRC5 EXON + xp16:57061446-57061466 GGCUAAGUGAGUGCAGCUUC 9526 84166_30_6 NLRC5 EXON + xp16:57061464-57061484 UCCGGCCAGAGCACGUGUCC 9527 84166_30_8 NLRC5 EXON + xp16:57061468-57061488 GCCAGAGCACGUGUCCAGGC 9528 84166_30_9 NLRC5 EXON + xp16:57061475-57061495 CACGUGUCCAGGCUGGCCAC 9529 84166_30_12 NLRC5 EXON + xp16:57061501-57061521 GAGCAAGUCCCUGCAGCUGA 9530 84166_30_16 NLRC5 EXON - xp16:57061430-57061450 AGCCUGAGGGCAGAAAGCCA 9531 84166_30_17 NLRC5 EXON - xp16:57061431-57061451 UAGCCUGAGGGCAGAAAGCC 9532 84166_30_20 NLRC5 EXON - xp16:57061443-57061463 GCUGCACUCACUUAGCCUGA 9533 84166_30_21 NLRC5 EXON - xp16:57061444-57061464 AGCUGCACUCACUUAGCCUG 9534 84166_30_24 NLRC5 EXON - xp16:57061468-57061488 GCCUGGACACGUGCUCUGGC 9535 84166_30_27 NLRC5 EXON - xp16:57061472-57061492 GCCAGCCUGGACACGUGCUC 9536 84166_30_29 NLRC5 EXON - xp16:57061485-57061505 GCUCAAGCCGGUGGCCAGCC 9537 84166_30_31 NLRC5 EXON - xp16:57061494-57061514 CAGGGACUUGCUCAAGCCGG 9538 84166_30_32 NLRC5 EXON - xp16:57061497-57061517 CUGCAGGGACUUGCUCAAGC 9539 84166_30_33 NLRC5 EXON - xp16:57061512-57061532 CGUGAGCUCCGUCAGCUGCA 9540 84166_30_34 NLRC5 EXON - xp16:57061513-57061533 ACGUGAGCUCCGUCAGCUGC 9541 84166_31_2 NLRC5 EXON + xp16:57061614-57061634 CAGGCUGACCCAGUGCUGCC 9542 84166_31_3 NLRC5 EXON + xp16:57061615-57061635 AGGCUGACCCAGUGCUGCCU 9543 84166_31_5 NLRC5 EXON + xp16:57061629-57061649 CUGCCUGGGCCAGAAGCAGC 9544 84166_31_7 NLRC5 EXON + xp16:57061647-57061667 GCUGGCCAUCCUCCUGAGCU 9545 84166_31_10 NLRC5 EXON + xp16:57061650-57061670 GGCCAUCCUCCUGAGCUUGG 9546 84166_31_11 NLRC5 EXON + xp16:57061651-57061671 GCCAUCCUCCUGAGCUUGGU 9547 84166_31_12 NLRC5 EXON + xp16:57061652-57061672 CCAUCCUCCUGAGCUUGGUG 9548 84166_31_14 NLRC5 EXON + xp16:57061663-57061683 AGCUUGGUGGGGCGACCGC 9549 84166_31_15 NLRC5 EXON + xp16:57061664-57061684 GCUUGGUGGGGCGACCCGCA 9550 84166_31_17 NLRC5 EXON + xp16:57061679-57061699 CCGCAGGGCUGUUCAGCCUC 9551 84166_31_19 NLRC5 EXON - xp16:57061607-57061627 CUGGGUCAGCCUGGAGACAG 9552 84166_31_22 NLRC5 EXON - xp16:57061616-57061636 CAGGCAGCACUGGGUCAGCC 9553 84166_31_25 NLRC5 EXON - xp16:57061625-57061645 CUUCUGGCCCAGGCAGCACU 9554 84166_31_26 NLRC5 EXON - xp16:57061626-57061646 GCUUCUGGCCCAGGCAGCAC 9555 84166_31_28 NLRC5 EXON - xp16:57061635-57061655 UGGCCAGCUGCUUCUGGCCC 9556 84166_31_29 NLRC5 EXON - xp16:57061641-57061661 GGAGGAUGGCCAGCUGCUUC 9557 84166_31_30 NLRC5 EXON - xp16:57061655-57061675 CCCCACCAAGCUCAGGAGGA 9558 84166_31_31 NLRC5 EXON - xp16:57061659-57061679 GUCGCCCCACCAAGCUCAGG 9559 84166_31_33 NLRC5 EXON - xp16:57061662-57061682 CGGGUCGCCCCACCAAGCUC 9560 84166_31_36 NLRC5 EXON - xp16:57061681-57061701 CUGAGGCUGAACAGCCCUGC 9561 84166_31_37 NLRC5 EXON - xp16:57061682-57061702 CCUGAGGCUGAACAGCCCUG 9562 84166_31_40 NLRC5 EXON - xp16:57061698-57061718 AGCGGGGGAGGAGGUACCUG 9563 84166_32_2 NLRC5 EXON + xp16:57065196-57065216 CCCCUUCUGUGACAGGGUGC 9564 84166_32_6 NLRC5 EXON + xp16:57065204-57065224 GUGACAGGGUGCAGGAGCCG 9565 84166_32_7 NLRC5 EXON + xp16:57065205-57065225 UGACAGGGUGCAGGAGCCGU 9566 84166_32_9 NLRC5 EXON + xp16:57065208-57065228 CAGGGUGCAGGAGCCGUGGG 9567 84166_32_12 NLRC5 EXON + xp16:57065219-57065239 AGCCGUGGGCGGACAGAGCC 9568 84166_32_13 NLRC5 EXON + xp16:57065220-57065240 GCCGUGGGCGGACAGAGCCA 9569 84166_32_16 NLRC5 EXON + xp16:57065250-57065270 CCUGUUAGAAGCUGCGCCC 9570 84166_32_18 NLRC5 EXON + xp16:57065257-57065277 GAAGUCUGCGCCCAGGCCUC 9571 84166_32_20 NLRC5 EXON + xp16:57065276-57065296 CAGGCAGUGUCACUGAAAUC 9572 84166_32_25 NLRC5 EXON + xp16:57065293-57065313 AUCAGGUGAGUCCAGAGAGAG 9573 84166_32_26 NLRC5 EXON - xp16:57065199-57065219 CCUGCACCCUGUCACAGAAG 9574 84166_32_28 NLRC5 EXON - xp16:57065200-57065220 UCCUGCACCCUGUCACAGAA 9575 84166_32_30 NLRC5 EXON - xp16:57065201-57065221 CUCCUGCACCCUGUCACAGA 9576 84166_32_34 NLRC5 EXON - xp16:57065224-57065244 ACCCUGGCUCUGUCCGCCCA 9577 84166_32_36 NLRC5 EXON - xp16:57065240-57065260 UUCUAACAGGGAGAGAACCC 9578 84166_32_40 NLRC5 EXON - xp16:57065252-57065272 CUGGGCCGCAGACUUCUAACA 9579 84166_32_43 NLRC5 EXON - xp16:57065253-57065273 CCUGGGCCGCAGACUUCUAAC 9580 84166_32_47 NLRC5 EXON - xp16:57065270-57065290 AGUGACACUGCCUGAGGCCU 9581 84166_32_48 NLRC5 EXON - xp16:57065271-57065291 CAGUGACACUGCCUGAGGCC 9582 84166_32_50 NLRC5 EXON - xp16:57065276-57065296 GAUUUCAGUGACACUGCCUG 9583 84166_33_5 NLRC5 EXON + xp16:57066548-57066568 GCAGCAGCUCUGUGUCCAGGC 9584 84166_33_8 NLRC5 EXON + xp16:57066563-57066583 CCAGCUGGAAUUUCCUCGCC 9585 84166_33_15 NLRC5 EXON + xp16:57066584-57066604 GGAAGAGAAUCCAGAAGCUG 9586 84166_33_16 NLRC5 EXON + xp16:57066592-57066612 AUCCAGAAGCUGUGGCACUC 9587 84166_33_19 NLRC5 EXON + xp16:57066595-57066615 CAGAAGCUGUGGCACUCAGG 9588 84166_33_20 NLRC5 EXON + xp16:57066596-57066616 AGAAGCUGUGGCACUCAGGU 9589 84166_33_22 NLRC5 EXON + xp16:57066609-57066629 CUCAGGUGGGACCCAGCACC 9590 84166_33_24 NLRC5 EXON + xp16:57066610-57066630 UCAGGUGGGACCCAGCACCA 9591 84166_33_27 NLRC5 EXON - xp16:57066530-57066550 GCUGGGUCUCGGAGAUGCUG 9592 84166_33_31 NLRC5 EXON - xp16:57066541-57066561 ACAGAGCUGCUGCUGGGUCU 9593 84166_33_33 NLRC5 EXON - xp16:57066547-57066567 CUGGACACAGAGCUGCUGCU 9594 84166_33_35 NLRC5 EXON - xp16:57066548-57066568 GCUGGACACAGAGCUGCUGC 9595 84166_33_39 NLRC5 EXON - xp16:57066566-57066586 CCUGGCGAGGAAAUUCCAGC 9596 84166_33_44 NLRC5 EXON - xp16:57066579-57066599 UCUGGAUUCUCUUCCUGGCG 9597 84166_33_47 NLRC5 EXON - xp16:57066584-57066604 CAGCUUCUGGAUUCUCUUCC 9598 84166_33_48 NLRC5 EXON - xp16:57066597-57066617 CACCUGAGUGCCACAGCUUC 9599 84166_34_1 NLRC5 EXON + xp16:57067368-57067388 CUCCCUGUCUGUGUCCAGGU 9600 84166_34_4 NLRC5 EXON + xp16:57067384-57067404 AGGUUGGCUCACUGUGACCU 9601 84166_34_8 NLRC5 EXON + xp16:57067408-57067428 GCCCACCACAGCCUUCUUGU 9602 84166_34_9 NLRC5 EXON + xp16:57067409-57067429 CCCACCACAGCCUUCUUGUC 9603 84166_34_11 NLRC5 EXON + xp16:57067419-57067439 CCUUCUUGUCGGGCAGCUGA 9604 84166_34_15 NLRC5 EXON + xp16:57067433-57067453 AGCUGAUGGAGACAUGUGCC 9605 84166_34_16 NLRC5 EXON + xp16:57067448-57067468 GUGCCAGGCUGCAGCAGCUC 9606 84166_34_19 NLRC5 EXON + xp16:57067459-57067479 CAGCAGCUCAGGUCACGCGCC 9607 84166_34_21 NLRC5 EXON - xp16:57067373-57067393 AGCCAACCUGGACACAGACA 9608 84166_34_22 NLRC5 EXON - xp16:57067374-57067394 GAGCCAACCUGGACACAGAC 9609 84166_34_25 NLRC5 EXON - xp16:57067385-57067405 AAGGUCACAGUGAGCCAACC 9610 84166_34_28 NLRC5 EXON - xp16:57067404-57067424 GAAGGCUGUGGUGGGCUCCA 9611 84166_34_29 NLRC5 EXON - xp16:57067412-57067432 CCCGACAAGAAGGCUGUGGU 9612 84166_34_30 NLRC5 EXON - xp16:57067413-57067433 GCCCGACAAGAAGGCUGUGG 9613 84166_34_32 NLRC5 EXON - xp16:57067416-57067436 GCUGCCCGACAAAGAAGGCUG 9614 84166_34_33 NLRC5 EXON - xp16:57067422-57067442 CCAUCAGCUGCCCGACAAAGA 9615 84166_34_36 NLRC5 EXON - xp16:57067454-57067474 UGACCUGAGCUGCUGCAGCC 9616 84166_35_1 NLRC5 EXON + xp16:57067723-57067743 GGACCUUUUCAGCUUGUCUC 9617 84166_35_8 NLRC5 EXON + xp16:57067738-57067758 GUCUCAGGUUAACCUCUGUG 9618 84166_35_15 NLRC5 EXON + xp16:57067806-57067826 UCUCUGAGCUGAAGACAUUU 9619 84166_35_16 NLRC5 EXON - xp16:57067722-57067742 AGACAAGCUGAAAAGGUCCA 9620 84166_35_19 NLRC5 EXON - xp16:57067729-57067749 UAACCUGAGACAAGCUGAAA 9621 84166_35_22 NLRC5 EXON - xp16:57067753-57067773 UGGCAUCAUCGUCCUCACAG 9622 84166_35_24 NLRC5 EXON - xp16:57067773-57067793 GCUCUGCAGCAGCAGGGAAC 9623 84166_35_25 NLRC5 EXON - xp16:57067779-57067799 CAGGAGGCUCUGCAGCAGCA 9624 84166_35_27 NLRC5 EXON - xp16:57067780-57067800 GCAGGAGGCUCUGCAGCAGC 9625 84166_35_31 NLRC5 EXON - xp16:57067795-57067815 GCUCAGAGAGGGACAGCAGG 9626 84166_35_33 NLRC5 EXON - xp16:57067798-57067818 UCAGCUCAGAGAGGGACAGC 9627 84166_35_35 NLRC5 EXON - xp16:57067806-57067826 AAAUGUCUUCAGCUCAGAGA 9628 84166_35_37 NLRC5 EXON - xp16:57067807-57067827 GAAAUGUCUUCAGCUCAGAG 9629 84166_36_6 NLRC5 EXON + xp16:57069841-57069861 CUCCAGCUGUGUGAGCACCG 9630 84166_36_7 NLRC5 EXON + xp16:57069842-57069862 UCCAGCUGUGUGAGCACCGA 9631 84166_36_8 NLRC5 EXON + xp16:57069856-57069876 CACCGAGGGCCUCGCCCACC 9632 84166_36_9 NLRC5 EXON + xp16:57069863-57069883 GGCCUCGCCCACCUGGCUC 9633 84166_36_11 NLRC5 EXON + xp16:57069868-57069888 CGCCCACCUGGCAUCUGGUC 9634 84166_36_12 NLRC5 EXON + xp16:57069869-57069889 GCCCACCUGGCAUCUGGUCU 9635 84166_36_14 NLRC5 EXON + xp16:57069886-57069906 UCUGGGCCACUGCCACCACU 9636 84166_36_17 NLRC5 EXON + xp16:57069889-57069909 GGGCCACUGCCACCACUUGG 9637 84166_36_21 NLRC5 EXON + xp16:57069895-57069915 CUGCCACCACUUGGAGGAGC 9638 84166_36_27 NLRC5 EXON + xp16:57069912-57069932 AGCUGGAGUGAGUUGCAGAG 9639 84166_36_29 NLRC5 EXON + xp16:57069915-57069935 UGGAGUGAGUUGCAGAGUGG 9640 84166_36_30 NLRC5 EXON + xp16:57069916-57069936 GGAGUGAGUUGCAGAGUGGA 9641 84166_36_31 NLRC5 EXON - xp16:57069820-57069840 UCAGCCUGGUGGGGGUCAAA 9642 84166_36_32 NLRC5 EXON - xp16:57069821-57069841 GUCAGCCUGGUGGGGGUCAA 9643 84166_36_34 NLRC5 EXON - xp16:57069828-57069848 GCUGGAGGUCAGCCUGGUGG 9644 84166_36_35 NLRC5 EXON - xp16:57069829-57069849 AGCUGGAGGUCAGCCUGGUG 9645 84166_36_37 NLRC5 EXON - xp16:57069830-57069850 CAGCUGGAGGUCAGCCUGGU 9646 84166_36_39 NLRC5 EXON - xp16:57069831-57069851 ACAGCUGGAGGUCAGCCUGG 9647 84166_36_41 NLRC5 EXON - xp16:57069834-57069854 CACACAGCUGGAGGUCAGCC 9648 84166_36_42 NLRC5 EXON - xp16:57069843-57069863 CUCGGUGCUCACACAGCUGG 9649 84166_36_44 NLRC5 EXON - xp16:57069846-57069866 GCCCUCGGUGCUCACACAGC 9650 84166_36_46 NLRC5 EXON - xp16:57069861-57069881 UGCCAGGUGGGCGAGGCCCU 9651 84166_36_47 NLRC5 EXON - xp16:57069868-57069888 GACCAGAUGCCAGGUGGGCG 9652 84166_36_49 NLRC5 EXON - xp16:57069873-57069893 GCCCAGACCAGAUGCCAGGU 9653 84166_36_50 NLRC5 EXON - xp16:57069874-57069894 GGCCCAGACCAGAUGCCAGG 9654 84166_36_52 NLRC5 EXON - xp16:57069877-57069897 AGUGGCCCAGACCAGAUGCC 9655 84166_36_53 NLRC5 EXON - xp16:57069895-57069915 GCUCCUCCAAGUGGUGGCAG 9656 84166_36_54 NLRC5 EXON - xp16:57069901-57069921 ACUCCAGCUCCUCCAAGUGG 9657 84166_36_55 NLRC5 EXON - xp16:57069904-57069924 CUCACUCCAGCUCCUCCAAG 9658 84166_37_4 NLRC5 EXON + xp16:57070537-57070557 GUCUAACAAUCAAUUUGAUG 9659 84166_37_8 NLRC5 EXON + xp16:57070540-57070560 UAACAAUCAAUUUGAUGAGG 9660 84166_37_9 NLRC5 EXON + xp16:57070541-57070561 AACAAUCAAUUUGAUGAGGA 9661 84166_37_10 NLRC5 EXON + xp16:57070549-57070569 AUUUGAUGAGGAGGGCACCA 9662 84166_37_15 NLRC5 EXON + xp16:57070560-57070580 AGGGCACCAAGGCCGCUGAUG 9663 84166_37_16 NLRC5 EXON + xp16:57070561-57070581 GGGCACCAAGGCCGCUGAUGA 9664 84166_37_20 NLRC5 EXON + xp16:57070570-57070590 GGCCGCUGAUGAGGGCCCUUG 9665 84166_37_21 NLRC5 EXON + xp16:57070571-57070591 GCGCUGAUGAGGGCCCUUGA 9666 84166_37_24 NLRC5 EXON + xp16:57070572-57070592 CGCUGAUGAGGGCCCUUGAG 9667 84166_37_26 NLRC5 EXON + xp16:57070578-57070598 UGAGGGCCCUUGAGGGGAAA 9668 84166_37_28 NLRC5 EXON + xp16:57070590-57070610 AGGGGAAAUGGAUGCUAAAG 9669 84166_37_31 NLRC5 EXON + xp16:57070594-57070614 GAAAUGGAUGCUAAAGAGGC 9670 84166_37_33 NLRC5 EXON + xp16:57070609-57070629 GAGGCUGGAGUAAGUGAGUGA 9671 84166_37_34 NLRC5 EXON + xp16:57070612-57070632 GCUGGAGUAAAGUAGUGAUGG 9672 84166_37_38 NLRC5 EXON - xp16:57070522-57070542 UAGACAAGCUGCAGAAGACC 9673 84166_37_43 NLRC5 EXON - xp16:57070569-57070589 AAGGGCCCUCAUCAGCGCCU 9674 84166_37_48 NLRC5 EXON - xp16:57070587-57070607 UAGCAUCCAUUUCCCCUCAA 9675 84166_37_49 NLRC5 EXON - xp16:57070588-57070608 UUAGCAUCCAUUUCCCCUCA 9676 84166_38_3 NLRC5 EXON + xp16:57074611-57074631 UCUGCUGAACAGCUCCACCU 9677 84166_38_9 NLRC5 EXON + xp16:57074661-57074681 UGACCCUGCCUGCAGAGCCUC 9678 84166_38_12 NLRC5 EXON + xp16:57074676-57074696 GCCUCAGGUGAGUGACCGAG 9679 84166_38_13 NLRC5 EXON - xp16:57074582-57074602 AGGCUGGAGAAGAGGAGGCC 9680 84166_38_14 NLRC5 EXON - xp16:57074587-57074607 GACUGAGGCUGGAGAAGAGG 9681 84166_38_16 NLRC5 EXON - xp16:57074590-57074610 GGUGACUGAGGCUGGAGAAG 9682 84166_38_22 NLRC5 EXON - xp16:57074598-57074618 CAGCAGAAGGUGACUGAGGC 9683 84166_38_25 NLRC5 EXON - xp16:57074602-57074622 UGUUCAGCAGAAGGUGACUG 9684 84166_38_27 NLRC5 EXON - xp16:57074611-57074631 AGGUGGAGCUGUUCAGCAGA 9685 84166_38_30 NLRC5 EXON - xp16:57074628-57074648 GUGAGUAAGCAAGGCCAAGG 9686 84166_38_34 NLRC5 EXON - xp16:57074631-57074651 UCUGUGAGUAAGCAAGGCCA 9687 84166_38_35 NLRC5 EXON - xp16:57074637-57074657 GCUUAGUCUGUGAGUAAGCA 9688 84166_38_37 NLRC5 EXON - xp16:57074659-57074679 GGCUCUGCAGGCAGGUCAUC 9689 84166_38_38 NLRC5 EXON - xp16:57074667-57074687 UCACCUGAGGCUCUGCAGGC 9690 84166_38_39 NLRC5 EXON - xp16:57074671-57074691 UCACUCACCUGAGGCUCUGC 9691 84166_38_40 NLRC5 EXON - xp16:57074680-57074700 GCCGCUCGGUCACUCACCUG 9692 84166_39_3 NLRC5 EXON + xp16:57076805-57076825 CCUGCUUUUCCAGACUGAAC 9693 84166_39_9 NLRC5 EXON + xp16:57076816-57076836 AGACUGAACAGGAACAGUAU 9694 84166_39_10 NLRC5 EXON + xp16:57076825-57076845 AGGAACAGUAUCGGUGAUGU 9695 84166_39_12 NLRC5 EXON + xp16:57076845-57076865 CGGUUGCUGCCACCUUUCUG 9696 84166_39_15 NLRC5 EXON + xp16:57076853-57076873 GCCACCUUUCUGAGGCUCUC 9697 84166_39_16 NLRC5 EXON + xp16:57076854-57076874 CCACCUUUCUGAGGCUCUCA 9698 84166_39_22 NLRC5 EXON + xp16:57076872-57076892 CAGGGCUGCCACCAGCCUAG 9699 84166_39_24 NLRC5 EXON + xp16:57076878-57076898 UGCCACCAGCCUAGAGGAGC 9700 84166_39_30 NLRC5 EXON - xp16:57076807-57076827 CUGUUCAGUCUGGAAAAGCA 9701 84166_39_31 NLRC5 EXON - xp16:57076808-57076828 CCUGUUCAGUCUGGAAAAGC 9702 84166_39_35 NLRC5 EXON - xp16:57076817-57076837 GAUACUGUUCCUGUUCAGUC 9703 84166_39_37 NLRC5 EXON - xp16:57076857-57076877 CCCUGAGAGCCCUCAGAAAGG 9704 84166_39_38 NLRC5 EXON - xp16:57076860-57076880 CAGCCCUGAGAGCCUCAGAA 9705 84166_39_42 NLRC5 EXON - xp16:57076883-57076903 CUCCAGCUCCUCUAGGCUGG 9706 84166_39_43 NLRC5 EXON - xp16:57076886-57076906 UCACUCCAGCUCCUCUAGGC 9707 84166_39_44 NLRC5 EXON - xp16:57076890-57076910 CAACUCACUCCAGCUCCUCU 9708 84166_40_7 NLRC5 EXON + xp16:57077293-57077313 AGCUUGAGCCACAACCAGAU 9709 84166_40_9 NLRC5 EXON + xp16:57077302-57077322 CACAACCAGAUUGGAGACGC 9710 84166_40_12 NLRC5 EXON + xp16:57077332-57077352 CACUUAGCUACCAUCCUGCC 9711 84166_40_13 NLRC5 EXON + xp16:57077333-57077353 ACUUAGCUACCAUCCUGCCU 9712 84166_40_18 NLRC5 EXON + xp16:57077348-57077368 UGCCUGGGCUGCCAGAGCUC 9713 84166_40_24 NLRC5 EXON - xp16:57077290-57077310 UGGUUGUGGCUCAAGCUUGG 9714 84166_40_25 NLRC5 EXON - xp16:57077291-57077311 CUGGUUGUGGCUCAAGCUUG 9715 84166_40_28 NLRC5 EXON - xp16:57077292-57077312 UCUGGUUGUGGCUCAAGCUU 9716 84166_40_30 NLRC5 EXON - xp16:57077293-57077313 AUCUGGUUGUGGCUCAAGCU 9717 84166_40_32 NLRC5 EXON - xp16:57077304-57077324 CAGCGUCUCCAAUCUGGUUG 9718 84166_40_33 NLRC5 EXON - xp16:57077310-57077330 GGACACCAGGCGUCUCCAAUC 9719 84166_40_34 NLRC5 EXON - xp16:57077331-57077351 GCAGGAUGGUAGCUAAGUGC 9720 84166_40_36 NLRC5 EXON - xp16:57077345-57077365 CUCUGGCAGCCCAGGCAGGA 9721 84166_40_38 NLRC5 EXON - xp16:57077349-57077369 UGAGCUCUGGCAGCCCAGGC 9722 84166_40_40 NLRC5 EXON - xp16:57077353-57077373 UUCCUGAGCUCUGGCAGCCCC 9723 84166_40_41 NLRC5 EXON - xp16:57077362-57077382 CACUCUAUCUUCCUGAGCUC 9724 84166_41_2 NLRC5 EXON + xp16:57077704-57077724 CCCCCCUCCCACAGCCUCUC 9725 84166_41_5 NLRC5 EXON + xp16:57077705-57077725 CCCCCUCCCACAGCCUCUCA 9726 84166_41_7 NLRC5 EXON + xp16:57077725-57077745 GGGAAUAGCAUCAGCUCAGC 9727 84166_41_10 NLRC5 EXON + xp16:57077726-57077746 GGAAUAGCAUCAGCUCAGCC 9728 84166_41_11 NLRC5 EXON + xp16:57077727-57077747 GAAUAGCAUCAGCUCAGCCG 9729 84166_41_13 NLRC5 EXON + xp16:57077728-57077748 AAUAGCAUCAGCUCAGCCGG 9730 84166_41_15 NLRC5 EXON + xp16:57077739-57077759 CUCAGCCGGGGGAGUGCAGU 9731 84166_41_18 NLRC5 EXON + xp16:57077762-57077782 CAGAGUCUCUCGUUCUUUGC 9732 84166_41_21 NLRC5 EXON + xp16:57077769-57077789 UCUCGUUCUUUGCAGGCGCC 9733 84166_41_23 NLRC5 EXON + xp16:57077772-57077792 CGUUCUUUGCAGGCGCCUGG 9734 84166_41_29 NLRC5 EXON + xp16:57077796-57077816 GUUGAUGUGAGUGUCUGCCC 9735 84166_41_30 NLRC5 EXON + xp16:57077799-57077819 GAUGUGAGUGUCUGCCCAGG 9736 84166_41_32 NLRC5 EXON - xp16:57077707-57077727 CCUGAGAGGCUGUGGGAGGG 9737 84166_41_33 NLRC5 EXON - xp16:57077708-57077728 CCCUGAGAGGCUGUGGGAGG 9738 84166_41_35 NLRC5 EXON - xp16:57077709-57077729 UCCCUGAGAGGCUGUGGGAG 9739 84166_41_36 NLRC5 EXON - xp16:57077710-57077730 UUCCCUGAGAGGCUGUGGGA 9740 84166_41_38 NLRC5 EXON - xp16:57077711-57077731 AUUCCCUGAGAGGCUGUGGG 9741 84166_41_41 NLRC5 EXON - xp16:57077714-57077734 GCUAUUCCCUGAGAGGCUGU 9742 84166_41_43 NLRC5 EXON - xp16:57077715-57077735 UGCUAUUCCCUGAGAGGCUG 9743 84166_41_46 NLRC5 EXON - xp16:57077721-57077741 AGCUGAUGCUAUUCCCUGAG 9744 84166_41_50 NLRC5 EXON - xp16:57077747-57077767 CUCUGCCAACUGCACUCCCC 9745 84166_41_55 NLRC5 EXON - xp16:57077790-57077810 ACACUCACAUCAACUCCUCC 9746 84166_42_1 NLRC5 EXON + xp16:57077925-57077945 UUCCUCUCCCUCUUCCAGCU 9747 84166_42_6 NLRC5 EXON + xp16:57077939-57077959 CAGGCUUGGCUGCAAUGCCC 9748 84166_42_7 NLRC5 EXON + xp16:57077940-57077960 AGGCUUGGCUGCAAUGCCCU 9749 84166_42_10 NLRC5 EXON + xp16:57077941-57077961 GGCUUGGCUGCAAUGCCCUG 9750 84166_42_11 NLRC5 EXON + xp16:57077942-57077962 GCUUGGCUGCAAUGCCCUGG 9751 84166_42_14 NLRC5 EXON + xp16:57077957-57077977 CCUGGGGGAUCCCACAGCCCC 9752 84166_42_16 NLRC5 EXON + xp16:57077958-57077978 CUGGGGGAUCCCACAGCCCU 9753 84166_42_17 NLRC5 EXON + xp16:57077959-57077979 UGGGGGAUCCCACAGCCCUG 9754 84166_42_18 NLRC5 EXON + xp16:57077963-57077983 GGAUCCCACAGCCCUGGGGC 9755 84166_42_20 NLRC5 EXON + xp16:57077969-57077989 CACAGCCCUGGGGCUGGCUC 9756 84166_42_24 NLRC5 EXON + xp16:57077989-57078009 AGGAGCUGCCCCAGCACCUG 9757 84166_42_25 NLRC5 EXON + xp16:57077990-57078010 GGAGCUGCCCCAGCACCUGA 9758 84166_42_27 NLRC5 EXON + xp16:57078005-57078025 CCUGAGGGUCCUACAGUGAG 9759 84166_42_29 NLRC5 EXON - xp16:57077930-57077950 AGCCAAGCCUGGAAGAGGAG 9760 84166_42_34 NLRC5 EXON - xp16:57077935-57077955 AUUGCAGCCAAGCCUGGAAG 9761 84166_42_37 NLRC5 EXON - xp16:57077941-57077961 CAGGGCAUUGCAGCCAAGCC 9762 84166_42_40 NLRC5 EXON - xp16:57077959-57077979 CAGGGCUGUGGGAUCCCCA 9763 84166_42_41 NLRC5 EXON - xp16:57077960-57077980 CCAGGGCUGUGGGAUCCCCC 9764 84166_42_43 NLRC5 EXON - xp16:57077970-57077990 UGAGCCAGCCCCAGGGCUGU 9765 84166_42_45 NLRC5 EXON - xp16:57077971-57077991 CUGAGCCAGCCCCAGGGCUG 9766 84166_42_47 NLRC5 EXON - xp16:57077977-57077997 CAGCUCCUGAGCCAGCCCCA 9767 84166_42_48 NLRC5 EXON - xp16:57077978-57077998 GCAGCUCCUGAGCCAGCCCC 9768 84166_42_51 NLRC5 EXON - xp16:57078000-57078020 UGUAGGACCCUCAGGUGCUG 9769 84166_42_52 NLRC5 EXON - xp16:57078001-57078021 CUGUAGGACCCUCAGGUGCU 9770 84166_42_54 NLRC5 EXON - xp16:57078002-57078022 ACUGUAGGACCUCACAGGUGC 9771 84166_42_56 NLRC5 EXON - xp16:57078008-57078028 CCACUCACUGUAGGACCCUC 9772 84166_42_57 NLRC5 EXON - xp16:57078017-57078037 GGCAGGGGGCCACUCACUGU 9773 84166_43_4 NLRC5 EXON + xp16:57079046-57079066 CAGCCUACCAUUCAGCCAUC 9774 84166_43_5 NLRC5 EXON + xp16:57079047-57079067 AGCCUACCAUUCAGCCAUCU 9775 84166_43_6 NLRC5 EXON + xp16:57079053-57079073 CCAUUCAGCCAUCUGGGCCC 9776 84166_43_9 NLRC5 EXON + xp16:57079056-57079076 UUCAGCCAUCUGGGCCCAGG 9777 84166_43_10 NLRC5 EXON + xp16:57079057-57079077 UCAGCCAUCUGGGCCCAGGU 9778 84166_43_11 NLRC5 EXON + xp16:57079058-57079078 CAGCCAUCUGGGCCCAGGUG 9779 84166_43_14 NLRC5 EXON + xp16:57079070-57079090 CCCAGGUGGGGCCCUGAGCC 9780 84166_43_15 NLRC5 EXON + xp16:57079076-57079096 UGGGGCCCUGAGCCUGGCCC 9781 84166_43_17 NLRC5 EXON + xp16:57079082-57079102 CCUGAGCCUGGCCCAGGCCC 9782 84166_43_19 NLRC5 EXON + xp16:57079086-57079106 AGCCUGGCCCAGGCCCUGGA 9783 84166_43_21 NLRC5 EXON + xp16:57079100-57079120 CCUGGAUGGAUCCCCCAUU 9784 84166_43_24 NLRC5 EXON + xp16:57079111-57079131 CCCCCCAUUUUGGAAGAGAUC 9785 84166_43_27 NLRC5 EXON + xp16:57079119-57079139 UUGGAAGAGAUCAGGUAAGU 9786 84166_43_28 NLRC5 EXON + xp16:57079120-57079140 UGGAAGAGAUCAGGUAAGUA 9787 84166_43_30 NLRC5 EXON + xp16:57079121-57079141 GGAAGAGAUCAGGUAAGUAG 9788 84166_43_32 NLRC5 EXON - xp16:57079033-57079053 UAGGCUGGGGAAAAGAGGAGA 9789 84166_43_33 NLRC5 EXON - xp16:57079034-57079054 GUAGGCUGGGGAAAAGAGGAG 9790 84166_43_37 NLRC5 EXON - xp16:57079039-57079059 GAAUGGUAGGCUGGGGAAAG 9791 84166_43_40 NLRC5 EXON - xp16:57079046-57079066 GAUGGCUGAAUGGUAGGCUG 9792 84166_43_43 NLRC5 EXON - xp16:57079047-57079067 AGAUGGCUGAAUGGUAGGCU 9793 84166_43_44 NLRC5 EXON - xp16:57079048-57079068 CAGAUGGCUGAAUGGUAGGC 9794 84166_43_47 NLRC5 EXON - xp16:57079052-57079072 GGCCCAGAUGGCUGAAUGGU 9795 84166_43_48 NLRC5 EXON - xp16:57079056-57079076 CCUGGGCCCAGAUGGCUGAA 9796 84166_43_50 NLRC5 EXON - xp16:57079064-57079084 GGGCCCCACCUGGGCCCAGA 9797 84166_43_51 NLRC5 EXON - xp16:57079073-57079093 CCAGGCUCAGGGCCCCACCU 9798 84166_43_52 NLRC5 EXON - xp16:57079074-57079094 GCCAGGCUCAGGGCCCCACC 9799 84166_43_54 NLRC5 EXON - xp16:57079084-57079104 CAGGGCCUGGGCCAGGCUCA 9800 84166_43_55 NLRC5 EXON - xp16:57079085-57079105 CCAGGGCCUGGGCCAGGCUC 9801 84166_43_57 NLRC5 EXON - xp16:57079091-57079111 AUCCAUCCAGGGCCUGGGCC 9802 84166_43_58 NLRC5 EXON - xp16:57079096-57079116 GGGGGAUCCAUCCAGGGCCU 9803 84166_43_59 NLRC5 EXON - xp16:57079097-57079117 GGGGGAUCCAUCCAGGGCC 9804 84166_43_62 NLRC5 EXON - xp16:57079102-57079122 CAAAUGGGGGGAUCCAUCCA 9805 84166_43_63 NLRC5 EXON - xp16:57079103-57079123 CCAAAUGGGGGGAUCCACC 9806 84166_43_66 NLRC5 EXON - xp16:57079114-57079134 CCUGAUCUCUUCCAAAUGGG 9807 84166_43_67 NLRC5 EXON - xp16:57079115-57079135 ACCUGAUCUCUUCCAAAUGG 9808 84166_43_69 NLRC5 EXON - xp16:57079116-57079136 UACCUGAUCUCUUCCAAAUG 9809 84166_43_71 NLRC5 EXON - xp16:57079117-57079137 UUACCUGAUCUCUUCCAAAU 9810 84166_43_74 NLRC5 EXON - xp16:57079118-57079138 CUUACCUGAUCUCUUCCAAA 9811 84166_44_1 NLRC5 EXON + xp16:57079202-57079222 AUCUCCCCUACCCUGCAGCU 9812 84166_44_3 NLRC5 EXON + xp16:57079205-57079225 UCCCCUACCCUGCAGCUUGG 9813 84166_44_5 NLRC5 EXON + xp16:57079217-57079237 CAGCUUGGCGGAAAACAACC 9814 84166_44_7 NLRC5 EXON + xp16:57079221-57079241 UUGGCGGAAAACAACCUGGC 9815 84166_44_11 NLRC5 EXON + xp16:57079224-57079244 GCGGAAAAACAACCUGGCUGG 9816 84166_44_13 NLRC5 EXON + xp16:57079225-57079245 CGGAAAAACAACCUGGCUGGA 9817 84166_44_14 NLRC5 EXON + xp16:57079226-57079246 GGAAAAACAACCUGGCUGGAG 9818 84166_44_16 NLRC5 EXON + xp16:57079244-57079264 AGGGGUCCCUGCGUUUCUGUA 9819 84166_44_25 NLRC5 EXON - xp16:57079209-57079229 UCCGCCAAGCUGCAGGGUAG 9820 84166_44_27 NLRC5 EXON - xp16:57079210-57079230 UUCCGCAAGCUGCAGGGUA 9821 84166_44_29 NLRC5 EXON - xp16:57079211-57079231 UUUCCCGCCAAGCUGCAGGGU 9822 84166_44_32 NLRC5 EXON - xp16:57079215-57079235 UUGUUUUCCCGCCAAGCUGCA 9823 84166_44_33 NLRC5 EXON - xp16:57079216-57079236 GUUGUUUUCCCGCCAAGCUGC 9824 84166_44_35 NLRC5 EXON - xp16:57079238-57079258 AACGCAGGACCCCCUCCAGCC 9825 84166_44_36 NLRC5 EXON - xp16:57079253-57079273 GGAGCUCCAUACAGAAACGC 9826 84166_44_41 NLRC5 EXON - xp16:57079274-57079294 ACUCUAUCUGUCUGAGCAGC 9827 84166_44_42 NLRC5 EXON - xp16:57079275-57079295 UACUCUAUCUGUCUGAGCAG 9828 84166_45_1 NLRC5 EXON + xp16:57079527-57079547 GCCCUUCUCCAUCCCAGCC 9829 84166_45_9 NLRC5 EXON - xp16:57079548-57079568 UGUCAAUCUUACAGGAAACC 9830 84166_45_11 NLRC5 EXON - xp16:57079556-57079576 AGUCUGGUUGUCAAUCUUAC 9831 84166_45_14 NLRC5 EXON - xp16:57079572-57079592 AGGUGAGGAGCUUGGCAGUC 9832 84166_45_15 NLRC5 EXON - xp16:57079580-57079600 GAAGCUGGAGGUGAGGAGCU 9833 84166_45_16 NLRC5 EXON - xp16:57079587-57079607 AGCUCGUGAAGCUGGAGGUG 9834 84166_45_20 NLRC5 EXON - xp16:57079592-57079612 AGGGCAGCUCGUGAAGCUGG 9835 84166_45_21 NLRC5 EXON - xp16:57079595-57079615 GGCAGGGCAGCUCGUGAAGC 9836 84166_45_25 NLRC5 EXON - xp16:57079611-57079631 UGUUCUAAUGAAGCAGGGCA 9837 84166_45_26 NLRC5 EXON - xp16:57079612-57079632 GUGUUCUAAUGAAGCAGGGC 9838 84166_45_28 NLRC5 EXON - xp16:57079616-57079636 GUGAGUGUUCUAAUGAAGCA 9839 84166_45_29 NLRC5 EXON - xp16:57079617-57079637 AGUGAGUGUUCUAAUGAAGC 9840 84166_46_3 NLRC5 EXON + xp16:57081084-57081104 CCCUACCCUGCAGGCUGUCC 9841 84166_46_7 NLRC5 EXON + xp16:57081095-57081115 AGGCUGUCCCUGGAAUCUCCU 9842 84166_46_9 NLRC5 EXON + xp16:57081096-57081116 GGCUGUCCCUGGAAUCUCCUC 9843 84166_46_10 NLRC5 EXON + xp16:57081097-57081117 GCUGUCCCUGGAAUCUCCUCG 9844 84166_46_12 NLRC5 EXON + xp16:57081103-57081123 CUGGAAUCUCCUCGGGGAUG 9845 84166_46_14 NLRC5 EXON + xp16:57081118-57081138 GGAUGAGGCAGCUGCCGAGC 9846 84166_46_15 NLRC5 EXON + xp16:57081124-57081144 GGCAGCUGCCGAGCUGGCCC 9847 84166_46_17 NLRC5 EXON + xp16:57081139-57081159 GGCCCAGGUGCUGCCGCAGA 9848 84166_46_18 NLRC5 EXON + xp16:57081140-57081160 GCCCAGGUGCUGCCGCAGAU 9849 84166_46_19 NLRC5 EXON + xp16:57081144-57081164 AGGUGCUGCCGCAGAUGGGC 9850 84166_46_24 NLRC5 EXON + xp16:57081157-57081177 GAUGGGCCGGCUGAAGAGAG 9851 84166_46_29 NLRC5 EXON + xp16:57081166-57081186 GCUGAAGAGAGGUGGAGUAUG 9852 84166_46_30 NLRC5 EXON + xp16:57081167-57081187 CUGAAGAGAGUGGAGUAUGA 9853 84166_46_31 NLRC5 EXON + xp16:57081168-57081188 UGAAGAGAGGUGGAGUAUGAG 9854 84166_46_33 NLRC5 EXON + xp16:57081172-57081192 GAGAGUGGAGUAUGAGGGGC 9855 84166_46_36 NLRC5 EXON + xp16:57081173-57081193 AGAGUGGAGUAUGAGGGGCC 9856 84166_46_38 NLRC5 EXON + xp16:57081174-57081194 GAGUGGAGUAUGAGGGGCCG 9857 84166_46_40 NLRC5 EXON + xp16:57081175-57081195 AGUGGAGUAUGAGGGGCCGG 9858 84166_46_41 NLRC5 EXON + xp16:57081178-57081198 GGAGUAUGAGGGGCCGGGGG 9859 84166_46_43 NLRC5 EXON - xp16:57081086-57081106 CAGGACAGCCUGCAGGGUAG 9860 84166_46_44 NLRC5 EXON - xp16:57081087-57081107 CCAGGACAGCCUGCAGGGUA 9861 84166_46_46 NLRC5 EXON - xp16:57081088-57081108 UCCAGGACAGCCUGCAGGGU 9862 84166_46_48 NLRC5 EXON - xp16:57081092-57081112 AGAUUCCAGGACAGCCUGCA 9863 84166_46_49 NLRC5 EXON - xp16:57081093-57081113 GAGAUUCCAGGACAGCCUGC 9864 84166_46_51 NLRC5 EXON - xp16:57081105-57081125 CUCAUCCCCGAGGAGAUUCC 9865 84166_46_53 NLRC5 EXON - xp16:57081115-57081135 CGGCAGCUGCCUCAUCCCCG 9866 84166_46_57 NLRC5 EXON - xp16:57081135-57081155 CGGCAGCACCCUGGGCCAGCU 9867 84166_46_58 NLRC5 EXON - xp16:57081144-57081164 GCCCAUCUGCGGCAGCACCU 9868 84166_46_59 NLRC5 EXON - xp16:57081145-57081165 GGCCCAUCUGCGGCAGCACC 9869 84166_46_62 NLRC5 EXON - xp16:57081155-57081175 CUCUUCAGCCGGCCCAUCUG 9870 84166_46_63 NLRC5 EXON - xp16:57081166-57081186 CAUACUCCACUCUCUUCAGGC 9871 84166_47_3 NLRC5 EXON + xp16:57081508-57081528 UCACUGUCCCACUGAGAAGCC 9872 84166_47_8 NLRC5 EXON + xp16:57081532-57081552 GAAGAAUCAGAUCACAGCUU 9873 84166_47_11 NLRC5 EXON + xp16:57081533-57081553 AAGAAUCAGAUCACAGCUUU 9874 84166_47_12 NLRC5 EXON + xp16:57081534-57081554 AGAAUCAGAUCACAGCUUUG 9875 84166_47_13 NLRC5 EXON + xp16:57081535-57081555 GAAUCAGAUCACAGCUUUGG 9876 84166_47_14 NLRC5 EXON + xp16:57081540-57081560 AGAUCACAGCUUUGGGGGCC 9877 84166_47_15 NLRC5 EXON + xp16:57081547-57081567 AGCUUUGGGGGCCUGGCUCC 9878 84166_47_19 NLRC5 EXON + xp16:57081554-57081574 GGGGCCUGGCUCCUGGCUGA 9879 84166_47_21 NLRC5 EXON + xp16:57081559-57081579 CUGGCUCCUGGCUGAAGGAC 9880 84166_47_24 NLRC5 EXON + xp16:57081565-57081585 CCUGGCUGAAGGACUGGCCC 9881 84166_47_25 NLRC5 EXON + xp16:57081566-57081586 CUGGCUGAAGGACUGGCCCA 9882 84166_47_26 NLRC5 EXON + xp16:57081567-57081587 UGGCUGAAGGACUGGCCCAG 9883 84166_47_27 NLRC5 EXON + xp16:57081588-57081608 GGUCUAGCAUCCAAGUCAUC 9884 84166_47_29 NLRC5 EXON + xp16:57081597-57081617 UCCAAGUCAUCCGGUAACAG 9885 84166_47_31 NLRC5 EXON + xp16:57081605-57081625 AUCCGGUAACAGAGGCCUGC 9886 84166_47_33 NLRC5 EXON + xp16:57081606-57081626 UCCGGUAACAGAGGCCUGCA 9887 84166_47_34 NLRC5 EXON + xp16:57081607-57081627 CCGGUAACAGAGGCCUGCAG 9888 84166_47_36 NLRC5 EXON - xp16:57081509-57081529 AGGCUUCUCAGUGGACAGUG 9889 84166_47_39 NLRC5 EXON - xp16:57081518-57081538 UUCUUCUCCAGGCUUCUCAG 9890 84166_47_41 NLRC5 EXON - xp16:57081529-57081549 CUGUGAUCUGAUUCUUCUCC 9891 84166_47_43 NLRC5 EXON - xp16:57081561-57081581 CAGUCCUUCAGCCAGGAGCC 9892 84166_47_44 NLRC5 EXON - xp16:57081568-57081588 CCUGGGCCAGUCCUUCAGCC 9893 84166_47_48 NLRC5 EXON - xp16:57081585-57081605 GACUUGGAUGCUAGACCCCU 9894 84166_47_49 NLRC5 EXON - xp16:57081586-57081606 UGACUUGGAUGCUAGACCCC 9895 84166_47_52 NLRC5 EXON - xp16:57081601-57081621 GCCUCUGUUACCGGAUGACU 9896 84166_47_54 NLRC5 EXON - xp16:57081610-57081630 CCCCUGCAGGCCUCUGUUAC 9897 84166_48_2 NLRC5 EXON + xp16:57082400-57082420 UAUCUGUGCCCCACAGCCUC 9898 84166_48_4 NLRC5 EXON + xp16:57082425-57082445 UAACCCCAUUCCCUGCGACA 9899 84166_48_10 NLRC5 EXON + xp16:57082446-57082466 GGCCCAGCACCCUGAAGAGCC 9900 84166_48_11 NLRC5 EXON + xp16:57082454-57082474 ACCUGAAGAGCCAGGAGCCC 9901 84166_48_13 NLRC5 EXON + xp16:57082458-57082478 GAAGAGCCAGGAGCCCAGGC 9902 84166_48_16 NLRC5 EXON + xp16:57082488-57082508 CUUCUUUGACAACCAGCCCC 9903 84166_48_21 NLRC5 EXON + xp16:57082496-57082516 ACAACCAGCCCCAGGCCCCU 9904 84166_48_23 NLRC5 EXON + xp16:57082497-57082517 CAACCAGCCCCAGGCCCCUU 9905 84166_48_24 NLRC5 EXON + xp16:57082498-57082518 AACCAGCCCCAGGCCCCUUG 9906 84166_48_25 NLRC5 EXON + xp16:57082508-57082528 AGGCCCCUUGGGGUACUGA 9907 84166_48_29 NLRC5 EXON + xp16:57082526-57082546 GAUGGCCCCCUCAAGACCUU 9908 84166_48_35 NLRC5 EXON + xp16:57082573-57082593 AUGAUCCCACCUUUCGCCCAC 9909 84166_48_36 NLRC5 EXON + xp16:57082574-57082594 UGAUCCACUUUCGCCCACU 9910 84166_48_40 NLRC5 EXON + xp16:57082588-57082608 CCCACUGGGAUAAUUGACUC 9911 84166_48_44 NLRC5 EXON + xp16:57082603-57082623 GACUCAGGAAAGAAGAGCCU 9912 84166_48_47 NLRC5 EXON + xp16:57082607-57082627 CAGGAAAGAAGAGCCUCGGC 9913 84166_48_48 NLRC5 EXON + xp16:57082608-57082628 AGGAAAGAAGAGCCUCGGCA 9914 84166_48_50 NLRC5 EXON + xp16:57082628-57082648 GGGCCGCUCUGCACUCCACCC 9915 84166_48_53 NLRC5 EXON + xp16:57082631-57082651 CGCUCUGCACUCCACCCAGG 9916 84166_48_56 NLRC5 EXON + xp16:57082635-57082655 CUGCACUCCACCCAGGAGGA 9917 84166_48_59 NLRC5 EXON + xp16:57082663-57082683 UGUGUCCCUGCUGCAGUCCUC 9918 84166_48_61 NLRC5 EXON + xp16:57082664-57082684 GUGUCCUGCUGCAGUCCUCA 9919 84166_48_64 NLRC5 EXON + xp16:57082677-57082697 GUCCUCAGGGAGAACUUUUU 9920 84166_48_67 NLRC5 EXON + xp16:57082678-57082698 UCCUCAGGGAGAACUUUUUU 9921 84166_48_70 NLRC5 EXON + xp16:57082685-57082705 GGAGAACUUUUUUGGGAAC 9922 84166_48_72 NLRC5 EXON + xp16:57082691-57082711 CUUUUUUGGGAACCAGGAGC 9923 84166_48_73 NLRC5 EXON + xp16:57082692-57082712 UUUUUUGGGAACCAGGAGCU 9924 84166_48_77 NLRC5 EXON + xp16:57082697-57082717 UGGGAACCAGGAGCUGGGUC 9925 84166_48_83 NLRC5 EXON + xp16:57082704-57082724 CAGGAGCUGGGUCUGGACAAA 9926 84166_48_86 NLRC5 EXON + xp16:57082723-57082743 AAGGAGUACCCCUGCAUUACG 9927 84166_48_87 NLRC5 EXON + xp16:57082724-57082744 AGGAGUACCCCUGCAUUACGU 9928 84166_48_90 NLRC5 EXON + xp16:57082742-57082762 GUGGGAUAUGUGUGUGAUCAAU 9929 84166_48_93 NLRC5 EXON + xp16:57082743-57082763 UGGGAUAUGUGUGAUCAAUU 9930 84166_48_94 NLRC5 EXON + xp16:57082744-57082764 GGGAUAUGUGUGAUCAAUUG 9931 84166_48_97 NLRC5 EXON + xp16:57082764-57082784 GGGACAUGCGACACACAAUG 9932 84166_48_99 NLRC5 EXON + xp16:57082765-57082785 GGACAUGCGACACACAAUGA 9933 84166_48_100 NLRC5 EXON + xp16:57082792-57082812 AUGACAAUGCAUGACACGUA 9934 84166_48_101 NLRC5 EXON + xp16:57082802-57082822 AUGACACGUACGGUUAUAUG 9935 84166_48_103 NLRC5 EXON + xp16:57082825-57082845 CAGUGUGACCCCCUUGACAUG 9936 84166_48_106 NLRC5 EXON + xp16:57082847-57082867 GCGUUACAUGAAAGUCAGUG 9937 84166_48_108 NLRC5 EXON + xp16:57082861-57082881 UCAGUGUGGCACGUGUUCUG 9938 84166_48_110 NLRC5 EXON + xp16:57082866-57082886 GUGGCACGUGUUCUGUGGCA 9939 84166_48_111 NLRC5 EXON + xp16:57082867-57082887 UGGCACGUGUUCUGUGGCAU 9940 84166_48_112 NLRC5 EXON + xp16:57082873-57082893 GUGUUCUGUGGCAUGGGUGC 9941 84166_48_115 NLRC5 EXON + xp16:57082889-57082909 GUGCUGGCAUCCCAAGUAGC 9942 84166_48_116 NLRC5 EXON + xp16:57082904-57082924 GUAGCAGGAUACAUGAUUGU 9943 84166_48_120 NLRC5 EXON + xp16:57082941-57082961 AUGACAAAAUGUCCAUGUCAC 9944 84166_48_121 NLRC5 EXON + xp16:57082949-57082969 UGUCCAUGUCACAAGGACUCA 9945 84166_48_122 NLRC5 EXON + xp16:57082953-57082973 CAUGUCACAAGGACUCAUGGC 9946 84166_48_123 NLRC5 EXON + xp16:57082968-57082988 AUGGCUGGCCAGAUGACCUC 9947 84166_48_124 NLRC5 EXON + xp16:57082972-57082992 CUGGCCAGAUGACCUCAGGC 9948 84166_48_134 NLRC5 EXON + xp16:57083031-57083051 AUAUUUAUAGAUUGUGUGUGUA 9949 84166_48_140 NLRC5 EXON + xp16:57083046-57083066 GUGUAUGGAGCAGCUAAGUC 9950 84166_48_144 NLRC5 EXON + xp16:57083068-57083088 GAAAAGUCUUCCCGCCCGAGC 9951 84166_48_145 NLRC5 EXON + xp16:57083069-57083089 AAAAGUCUUCCGCCCGAGCU 9952 84166_48_148 NLRC5 EXON + xp16:57083072-57083092 AGUCUUCCGCCCGAGCUGGG 9953 84166_48_151 NLRC5 EXON + xp16:57083073-57083093 GUCUUCCGCCCGAGCUGGGA 9954 84166_48_152 NLRC5 EXON + xp16:57083074-57083094 UCUUCCGCCCGAGCUGGGAG 9955 84166_48_158 NLRC5 EXON + xp16:57083102-57083122 GUCCAUGCACUGACCAGUCC 9956 84166_48_159 NLRC5 EXON + xp16:57083103-57083123 UCCAUGCACUGACCAGUCCA 9957 84166_48_160 NLRC5 EXON + xp16:57083104-57083124 CCAUGCACUGACCAGUCCAG 9958 84166_48_162 NLRC5 EXON + xp16:57083111-57083131 CUGACCAGUCCAGGGGCUCA 9959 84166_48_163 NLRC5 EXON + xp16:57083112-57083132 UGACCAGUCCAGGGGCUCAA 9960 84166_48_165 NLRC5 EXON + xp16:57083117-57083137 AGUCCAGGGGCUCAAGGGCC 9961 84166_48_166 NLRC5 EXON + xp16:57083118-57083138 GUCCAGGGGCUCAAGGGCCA 9962 84166_48_168 NLRC5 EXON + xp16:57083124-57083144 GGGCUCAAGGGCCAGGGCUC 9963 84166_48_172 NLRC5 EXON + xp16:57083135-57083155 CCAGGGCUCUGGAACAAGCC 9964 84166_48_173 NLRC5 EXON + xp16:57083136-57083156 CAGGGCUCUGGAACAAGCCA 9965 84166_48_177 NLRC5 EXON + xp16:57083229-57083249 UACUUACAUACUAGCUUCCA 9966 84166_48_179 NLRC5 EXON + xp16:57083234-57083254 ACAUACUAGCUUCCAAGGAC 9967 84166_48_183 NLRC5 EXON + xp16:57083237-57083257 UACUAGCUUCCAAGGACAGG 9968 84166_48_184 NLRC5 EXON + xp16:57083240-57083260 UAGCUUCCAAGGACAGGUGG 9969 84166_48_186 NLRC5 EXON + xp16:57083244-57083264 UUCCAAGGACAGGUGGAGGU 9970 84166_48_187 NLRC5 EXON + xp16:57083245-57083265 UCCAAGGACAGGUGGAGGUA 9971 84166_48_189 NLRC5 EXON + xp16:57083254-57083274 AGGUGGAGGUAGGGCCAGCC 9972 84166_48_191 NLRC5 EXON + xp16:57083257-57083277 UGGAGGUAGGGCCAGCCUGG 9973 84166_48_194 NLRC5 EXON + xp16:57083258-57083278 GGAGGUAGGGCCAGCCUGGC 9974 84166_48_196 NLRC5 EXON + xp16:57083263-57083283 UAGGGCCAGCCUGGCGGGAG 9975 84166_48_201 NLRC5 EXON + xp16:57083289-57083309 AGCCCAGUCUGUCCUAUGUA 9976 84166_48_202 NLRC5 EXON + xp16:57083290-57083310 GCCCAGUCUGUCCUAUGUAA 9977 84166_48_203 NLRC5 EXON + xp16:57083301-57083321 CCUAUGUAAGGGACAAAAGCC 9978 84166_48_204 NLRC5 EXON + xp16:57083309-57083329 AGGGACAAAAGCCAGGUCUAA 9979 84166_48_206 NLRC5 EXON + xp16:57083315-57083335 AAAGCCAGGUCUAAUGGUAC 9980 84166_48_207 NLRC5 EXON + xp16:57083316-57083336 AAGCCAGGUCUAAUGGUACU 9981 84166_48_210 NLRC5 EXON + xp16:57083320-57083340 CAGGUCUAAUGGUACUGGGU 9982 84166_48_212 NLRC5 EXON + xp16:57083321-57083341 AGGUCUAAUGGUACUGGGUA 9983 84166_48_213 NLRC5 EXON + xp16:57083322-57083342 GGUCUAAUGGUACUGGGUAG 9984 84166_48_214 NLRC5 EXON + xp16:57083323-57083343 GUCUAAUGGUACUGGGUAGG 9985 84166_48_215 NLRC5 EXON + xp16:57083346-57083366 CACUGCCAAGACAAUAAGCU 9986 84166_48_217 NLRC5 EXON + xp16:57083353-57083373 AAGACAAUAAGCUAGGCUAC 9987 84166_48_218 NLRC5 EXON + xp16:57083354-57083374 AGACAAUAAGCUAGGCUACU 9988 84166_48_219 NLRC5 EXON + xp16:57083371-57083391 ACUGGGUCCAGCUACUACUU 9989 84166_48_222 NLRC5 EXON + xp16:57083374-57083394 GGGUCCAGCUACUACUUUGG 9990 84166_48_223 NLRC5 EXON + xp16:57083375-57083395 GGUCCAGCUACUACUUUGGU 9991 84166_48_224 NLRC5 EXON + xp16:57083382-57083402 CUACUACUUUGGUGGGAUUC 9992 84166_48_233 NLRC5 EXON + xp16:57083433-57083453 CAGUGUUCUUGUUACUUCCA 9993 84166_48_239 NLRC5 EXON + xp16:57083447-57083467 CUUCCAAGGAGAACCAAGAA 9994 84166_48_243 NLRC5 EXON + xp16:57083469-57083489 GCUCUGUCACACUCGAAGCC 9995 84166_48_244 NLRC5 EXON + xp16:57083490-57083510 GGCUUGAUCAAUAAACACAA 9996 84166_48_249 NLRC5 EXON - xp16:57082399-57082419 AGGCUGUGGGGCACAGAUAU 9997 84166_48_251 NLRC5 EXON - xp16:57082411-57082431 GGGUUAUUCCAGAGGCUGUG 9998 84166_48_252 NLRC5 EXON - xp16:57082412-57082432 GGGGUUAUUCCAGAGGCUGU 9999 84166_48_253 NLRC5 EXON - xp16:57082413-57082433 UGGGGUUAUUCCAGAGGCUG 10000 84166_48_256 NLRC5 EXON - xp16:57082419-57082439 AGGGAAUGGGGUUAUUCCAG 10001 84166_48_258 NLRC5 EXON - xp16:57082431-57082451 GGGCCAUGUCGCAGGGAAUG 10002 84166_48_259 NLRC5 EXON - xp16:57082432-57082452 UGGGCCAUGUCCGCAGGGAAU 10003 84166_48_261 NLRC5 EXON - xp16:57082433-57082453 CUGGGCCAUGUCCGCAGGGAA 10004 84166_48_264 NLRC5 EXON - xp16:57082438-57082458 AGGUGCUGGGCCAUGUCGCA 10005 84166_48_267 NLRC5 EXON - xp16:57082439-57082459 CAGGUGCUGGGCCAUGUCGC 10006 84166_48_269 NLRC5 EXON - xp16:57082451-57082471 CUCCUGGCUCUUCAGGUGCU 10007 84166_48_270 NLRC5 EXON - xp16:57082452-57082472 GCUCCUGGCUCUUCAGGUGC 10008 84166_48_272 NLRC5 EXON - xp16:57082458-57082478 GCCUGGGCUCCUGGCUCUUC 10009 84166_48_273 NLRC5 EXON - xp16:57082467-57082487 CAAAGUCCAGCCUGGGCUCC 10010 84166_48_274 NLRC5 EXON - xp16:57082474-57082494 AAGAAGGCAAAGUCCAGCCU 10011 84166_48_276 NLRC5 EXON - xp16:57082475-57082495 AAAGAAGGCAAAGUCCAGCC 10012 84166_48_278 NLRC5 EXON - xp16:57082490-57082510 CUGGGGCUGGUUGUCAAAGA 10013 84166_48_281 NLRC5 EXON - xp16:57082503-57082523 UACCCCAAGGGGCCUGGGGC 10014 84166_48_282 NLRC5 EXON - xp16:57082507-57082527 CAAGUACCCCAAGGGGCCUG 10015 84166_48_283 NLRC5 EXON - xp16:57082508-57082528 UCAAGUACCCCAAGGGGCCU 10016 84166_48_284 NLRC5 EXON - xp16:57082509-57082529 AUCAAGUACCCCAAGGGGCC 10017 84166_48_287 NLRC5 EXON - xp16:57082514-57082534 GGGCCAUCAAGUACCCCAAG 10018 84166_48_289 NLRC5 EXON - xp16:57082515-57082535 GGGGCCAUCAAGUACCCCAA 10019 84166_48_291 NLRC5 EXON - xp16:57082516-57082536 GGGGGCCAUCAAGUACCCCA 10020 84166_48_294 NLRC5 EXON - xp16:57082534-57082554 GGAUUCCAAAGGUCUUGAGG 10021 84166_48_296 NLRC5 EXON - xp16:57082535-57082555 UGGAUUCCAAAGGUCUUGAG 10022 84166_48_297 NLRC5 EXON - xp16:57082536-57082556 CUGGAUUCCAAAGGUCUUGA 10023 84166_48_300 NLRC5 EXON - xp16:57082537-57082557 GCUGGAUUCCAAAGGUCUUG 10024 84166_48_303 NLRC5 EXON - xp16:57082545-57082565 AUCACUUGGCUGGAUUCCAA 10025 84166_48_306 NLRC5 EXON - xp16:57082555-57082575 AUUUGGGUGCAUCACUUGGC 10026 84166_48_308 NLRC5 EXON - xp16:57082559-57082579 GAUCAUUUGGGUGCAUCACU 10027 84166_48_309 NLRC5 EXON - xp16:57082571-57082591 GGGCGAAAGGUGGAUCAUUU 10028 84166_48_310 NLRC5 EXON - xp16:57082572-57082592 UGGGCGAAAGGUGGAUCAUU 10029 84166_48_313 NLRC5 EXON - xp16:57082581-57082601 UUAUCCCCAGUGGGCGAAAGG 10030 84166_48_315 NLRC5 EXON - xp16:57082584-57082604 CAAUUAUCCCAGUGGGCGAA 10031 84166_48_320 NLRC5 EXON - xp16:57082591-57082611 CCUGAGUCAAUUAUCCCAGU 10032 84166_48_321 NLRC5 EXON - xp16:57082592-57082612 UCCUGAGUCAAUUAUCCCAG 10033 84166_48_324 NLRC5 EXON - xp16:57082623-57082643 GAGUGCAGAGCGCCCUGCCG 10034 84166_48_328 NLRC5 EXON - xp16:57082645-57082665 CACGUAUCCUUCCUCCUGGG 10035 84166_48_331 NLRC5 EXON - xp16:57082648-57082668 ACACACGUAUUCCUUCCUCCU 10036 84166_48_332 NLRC5 EXON - xp16:57082649-57082669 GACACACGUAUCCUUCCUCC 10037 84166_48_335 NLRC5 EXON - xp16:57082671-57082691 UUCUCCCUGAGGACUGCAGC 10038 84166_48_338 NLRC5 EXON - xp16:57082682-57082702 UCCCAAAAAAGUUCUCCCCUG 10039 84166_48_343 NLRC5 EXON - xp16:57082706-57082726 CUUUGUCCAGACCCAGCUCC 10040 84166_48_344 NLRC5 EXON - xp16:57082734-57082754 CACAUAUCCCACGUAAUGCA 10041 84166_48_346 NLRC5 EXON - xp16:57082735-57082755 ACACAUAUCCCACGUAAUGC 10042 84166_48_352 NLRC5 EXON - xp16:57082836-57082856 AUGUAACGCCACAUGUCAAG 10043 84166_48_353 NLRC5 EXON - xp16:57082837-57082857 CAUGUAACGCCACAUGUCAA 10044 84166_48_354 NLRC5 EXON - xp16:57082838-57082858 UCAUGUAACGCCACAUGUCA 10045 84166_48_360 NLRC5 EXON - xp16:57082902-57082922 AAUCAUGUAUUCCUGCUACUU 10046 84166_48_362 NLRC5 EXON - xp16:57082903-57082923 CAAUCAUGUAUCCCUGCUACU 10047 84166_48_366 NLRC5 EXON - xp16:57082955-57082975 CAGCCAUGAGUCCCUGUGACA 10048 84166_48_370 NLRC5 EXON - xp16:57082979-57082999 UGGGCCAGCCUGAGGUCAUC 10049 84166_48_372 NLRC5 EXON - xp16:57082987-57083007 UUAGAUCUUGGGCCAGCCUG 10050 84166_48_377 NLRC5 EXON - xp16:57082998-57083018 AAAUUAAUAAAUUAGAUCUU 10051 84166_48_378 NLRC5 EXON - xp16:57082999-57083019 AAAAUUAAUAAAUUAGAUCU 10052 84166_48_386 NLRC5 EXON - xp16:57083081-57083101 CUCUCCCCUCCCAGCUCGGG 10053 84166_48_389 NLRC5 EXON - xp16:57083084-57083104 ACACUCUCCCCUCCCAGCUC 10054 84166_48_390 NLRC5 EXON - xp16:57083085-57083105 GACACUCUCCCCUCCCAGCU 10055 84166_48_393 NLRC5 EXON - xp16:57083107-57083127 CCCCUGGACUGGUCAGUGCA 10056 84166_48_395 NLRC5 EXON - xp16:57083118-57083138 UGGCCCUUGAGCCCCUGGAC 10057 84166_48_397 NLRC5 EXON - xp16:57083123-57083143 AGCCCUGGCCCUUGAGCCCC 10058 84166_48_401 NLRC5 EXON - xp16:57083138-57083158 CCUGGCUUGUUCCAGAGCCC 10059 84166_48_404 NLRC5 EXON - xp16:57083156-57083176 GGACUUAAUGGCUGAGUCCCC 10060 84166_48_407 NLRC5 EXON - xp16:57083168-57083188 UGAGGCAGGAGGGGACUUAA 10061 84166_48_408 NLRC5 EXON - xp16:57083177-57083197 GCUGAGGAUUGAGGCAGGAG 10062 84166_48_410 NLRC5 EXON - xp16:57083178-57083198 GGCUGAGGAUUUGAGGCAGGA 10063 84166_48_412 NLRC5 EXON - xp16:57083179-57083199 AGGCUGAGGAUUGAGGCAGG 10064 84166_48_415 NLRC5 EXON - xp16:57083182-57083202 GGUAGGCUGAGGAUUGAGGC 10065 84166_48_419 NLRC5 EXON - xp16:57083186-57083206 GAUGGGUAGGCUGAGGAUUG 10066 84166_48_421 NLRC5 EXON - xp16:57083193-57083213 GUUUAUAGAUGGGUAGGCUG 10067 84166_48_424 NLRC5 EXON - xp16:57083199-57083219 CAUCAAGUUUAUAGAUGGGU 10068 84166_48_425 NLRC5 EXON - xp16:57083203-57083223 GAGUCAUCAAGUUUAUAGAU 10069 84166_48_426 NLRC5 EXON - xp16:57083204-57083224 GGAGUCAUCAAGUUUAUAGA 10070 84166_48_430 NLRC5 EXON - xp16:57083225-57083245 AGCUAGUAUGUAAAGUAAGGG 10071 84166_48_432 NLRC5 EXON - xp16:57083228-57083248 GGAAGCUAGUAUGUAAGUAA 10072 84166_48_434 NLRC5 EXON - xp16:57083229-57083249 UGGAAGCUAGUAUGUAAAGUA 10073 84166_48_437 NLRC5 EXON - xp16:57083249-57083269 GCCCUACCUCCACCUGUCCU 10074 84166_48_441 NLRC5 EXON - xp16:57083271-57083291 CUUCUCCACUCCCGCCAGGC 10075 84166_48_442 NLRC5 EXON - xp16:57083275-57083295 UGGGCUUCUCCACUCCCGCC 10076 84166_48_446 NLRC5 EXON - xp16:57083294-57083314 UCCCUUACAUAGGACAGACU 10077 84166_48_447 NLRC5 EXON - xp16:57083295-57083315 GUCCCUUACAAUAGGACAGAC 10078 84166_48_450 NLRC5 EXON - xp16:57083304-57083324 CCUGGCUUUGUCCCUUACAU 10079 84166_48_452 NLRC5 EXON - xp16:57083322-57083342 CUACCCAGUACCAUUAGACC 10080 84166_48_456 NLRC5 EXON - xp16:57083354-57083374 AGUAGCCUAGCUUAUUGUCU 10081 84166_48_457 NLRC5 EXON - xp16:57083381-57083401 AAUCCCACCAAAGUAGUAGC 10082 84166_48_461 NLRC5 EXON - xp16:57083415-57083435 UGGGUAACAUGUGAAGUGCA 10083 84166_48_465 NLRC5 EXON - xp16:57083434-57083454 UUGGAAGUAACAAGAACACCU 10084 84166_48_467 NLRC5 EXON - xp16:57083435-57083455 CUUGGAAGUAACAAGAACAC 10085 84166_48_474 NLRC5 EXON - xp16:57083453-57083473 GAGCCAUUCUUGGUUCUCCU 10086 84166_48_477 NLRC5 EXON - xp16:57083463-57083483 GAGUGUGACAGAGCCAUUCU 10087 84166_48_484 NLRC5 EXON - xp16:57083490-57083510 UUGUGUUUAUUGAUCAAGCC 10088 84166_48_487 NLRC5 EXON - xp16:57083520-57083540 CAUUGGAUUCACGCUAGACG 10089

Table 2: nRNA targeting domains for exemplary inhibitory molecules ID Target target area Chain Position in the genome (hg38) nRNA guide domain sequence SEQID NO: 29126_1_1 CD274 Exon 1 + xp9:5450495-5450520 CGGGCCUGGCGCAACGCUGAGCAGGC 2942 29126_1_2 CD274 Exon 1 + xp9:5450509-5450534 CGCUGAGCAGCUGGCGCGUCCCGCG 2943 29126_1_3 CD274 Exon 1 + xp9:5450535-5450560 GGCCCCAGUUCUGCGCAGCUUCCCG 2944 29126_1_4 CD274 Exon 1 + xp9:5450569-5450594 ACCAGCCGCGCUUCUGUCCGCCUGC 2945 29126_1_5 CD274 Exon 1 + xp9:5450573-5450598 GCCGCGCUUCUGUCCGCCUGCAGGU 2946 29126_1_6 CD274 Exon 1 + xp9:5450574-5450599 CCGCGCUUCUGUCCGCCUGCAGGUA 2947 29126_1_7 CD274 Exon 1 + xp9:5450592-5450617 GCAGGUAGGGAGCGUUGUUCCUCCCG 2948 29126_1_8 CD274 Exon 1 + xp9:5450593-5450618 CAGGUAGGGAGCGUUGUUCCUCCGC 2949 29126_1_9 CD274 Exon 1 - xp9:5450489-5450514 CAGCGUUGCCGCCAGGCCCGGAGGCG 2950 29126_1_10 CD274 Exon 1 - xp9:5450490-5450515 UCAGCGUUGCCGCCAGGCCCGGAGGC 2951 29126_1_11 CD274 Exon 1 - xp9:5450491-5450516 CUCAGCGUUGCCGCCAGGCCCGGAGG 2952 29126_1_12 CD274 Exon 1 - xp9:5450494-5450519 CUGCUCAGCGUUGCCGCCAGGCCCGG 2953 29126_1_13 CD274 Exon 1 - xp9:5450497-5450522 CAGCUGCUCAGCGUUGCGCCAGGCC 2954 29126_1_14 CD274 Exon 1 - xp9:5450502-5450527 CGCGCCAGCUGCUCAGCGUUGCGCC 2955 29126_1_15 CD274 Exon 1 - xp9:5450531-5450556 AAGCUGCGCAGAACUGGGGCCGCGC 2956 29126_1_16 CD274 Exon 1 - xp9:5450532-5450557 GAAGCUGCGCAGAACUGGGGCCGCG 2957 29126_1_17 CD274 Exon 1 - xp9:5450540-5450565 AGCCUCGGGAAGCUGCGCAGAACUG 2958 29126_1_18 CD274 Exon 1 - xp9:5450541-5450566 GAGCCUCGGGAAGCUGCGCAGAACU 2959 29126_1_19 CD274 Exon 1 - xp9:5450542-5450567 GGAGCCUCGGGAAGCUGCCGCAGAAC 2960 29126_1_20 CD274 Exon 1 - xp9:5450559-5450584 AGAAGCGCGGCUGGUGCGGAGCCUC 2961 29126_1_21 CD274 Exon 1 - xp9:5450560-5450585 CAGAAGCGCGGCUGGUGCGGAGCCU 2962 29126_1_22 CD274 Exon 1 - xp9:5450568-5450593 CAGGCGGACAGAAGCGCGGCUGGUG 2963 29126_1_23 CD274 Exon 1 - xp9:5450573-5450598 ACCUGCAGGCGGACAGAAGCGCGGC 2964 29126_1_24 CD274 Exon 1 - xp9:5450577-5450602 CCCUACCUGCAGGCGGACAGAAGCG 2965 29126_1_25 CD274 Exon 1 - xp9:5450589-5450614 AGGAACAACGCUCCCUACCUGCAGG 2966 29126_1_26 CD274 Exon 1 - xp9:5450592-5450617 CGGAGGAACAACGCUCCCUACCUGC 2967 29126_2_1 CD274 Exon 2 + xp9:5456091-5456116 AUAAUUAGGGCAUUCCAGAAAAGAUG 2968 29126_2_2 CD274 Exon 2 + xp9:5456124-5456149 UGCUGUCUUUAUAUUCAUGACCUAC 2969 29126_2_3 CD274 Exon 2 + xp9:5456138-5456163 UCAUGACCUACUGGCAUUUGCUGAA 2970 29126_2_4 CD274 Exon 2 - xp9:5456092-5456117 UCAUCUUUCUGGAAUGCCCUAAUUA 2971 29126_2_5 CD274 Exon 2 - xp9:5456108-5456133 AAGACAGCAAAUAUCCUCAUCUUUC 2972 29126_2_6 CD274 Exon 2 - xp9:5456147-5456172 GUCUUACCGUUCAGCAAAUGCCAGU 2973 29126_3_1 CD274 Exon 3 + xp9:5457065-5457090 UCUUUCUUUUUAGCAUUUACUGUCA 2974 29126_3_2 CD274 Exon 3 + xp9:5457074-5457099 UUAGCAUUUACUGUCACGGUUCCCA 2975 29126_3_3 CD274 Exon 3 + xp9:5457086-5457111 GUCACGGUUCCCAAGGACCUAUAUG 2976 29126_3_4 CD274 Exon 3 + xp9:5457096-5457121 CCAAGGACCUAUAUGUGGUAGAGUA 2977 29126_3_5 CD274 Exon 3 + xp9:5457149-5457174 UUCCCAGUAGAAAAACAAUUAGACC 2978 29126_3_6 CD274 Exon 3 + xp9:5457169-5457194 AGACCUGGCUGCACUAAUUGUCUAU 2979 29126_3_7 CD274 Exon 3 + xp9:5457170-5457195 GACCUGGCUGCACUAAUUGUCUAUU 2980 29126_3_8 CD274 Exon 3 + xp9:5457176-5457201 GCUGCACUAAUUGUCUAUUGGGAAA 2981 29126_3_9 CD274 Exon 3 + xp9:5457179-5457204 GCACUAAUUGUCUAUUGGGAAAUGG 2982 29126_3_10 CD274 Exon 3 + xp9:5457207-5457232 AUAAGAACAUUAUUCAAUUUGUGCA 2983 29126_3_11 CD274 Exon 3 + xp9:5457212-5457237 AACAUUAUUCAAUUUGUGCAUGGAG 2984 29126_3_12 CD274 Exon 3 + xp9:5457224-5457249 UUUGUGCAUGGAGAGGAAGACCUGA 2985 29126_3_13 CD274 Exon 3 + xp9:5457250-5457275 GGUUCAGCAUAGUAGCUACAGACAG 2986 29126_3_14 CD274 Exon 3 + xp9:5457251-5457276 GUUCAGCAUAGUAGCUACAGACGA 2987 29126_3_15 CD274 Exon 3 + xp9:5457256-5457281 GCAUAGUAGCUACAGACAGAGGGCC 2988 29126_3_16 CD274 Exon 3 + xp9:5457266-5457291 UACAGACAGAGGGCCCGGCUGUUGA 2989 29126_3_17 CD274 Exon 3 + xp9:5457281-5457306 CGGCUGUUGAAGGACCAGCUCUCCCC 2990 29126_3_18 CD274 Exon 3 + xp9:5457282-5457307 GGCUGUUGAAGGACCAGCUCUCCCU 2991 29126_3_19 CD274 Exon 3 + xp9:5457320-5457345 CUUCAGAUCACAGAAUGUGAAAUUGC 2992 29126_3_20 CD274 Exon 3 + xp9:5457327-5457352 UCACAGAUGUGAAAUUGCAGGAUGC 2993 29126_3_21 CD274 Exon 3 + xp9:5457328-5457353 CACAGAUGUGAAAUUGCAGGAUGCA 2994 29126_3_22 CD274 Exon 3 + xp9:5457329-5457354 ACAGAUGUGAAAUUGCAGGAUGCAG 2995 29126_3_23 CD274 Exon 3 + xp9:5457354-5457379 GGGUGUACCGCUGCAUGAUCAGCUA 2996 29126_3_24 CD274 Exon 3 + xp9:5457357-5457382 UGUACCGCUGCAUGAUCAGCUAUGG 2997 29126_3_25 CD274 Exon 3 + xp9:5457393-5457418 ACAAGCGAAUUACUGUGAAAGUCAA 2998 29126_3_26 CD274 Exon 3 + xp9:5457416-5457441 AAUGGUAAGAAUUAUUAUAGAUGAG 2999 29126_3_27 CD274 Exon 3 - xp9:5457065-5457090 UGACAGUAAAUGCUAAAAAGAAAGA 3000 29126_3_28 CD274 Exon 3 - xp9:5457098-5457123 CAUACUCUACCACAUAUAGGUCCUU 3001 29126_3_29 CD274 Exon 3 - xp9:5457099-5457124 CCAUACUCUACCACAUAUAGGUCCU 3002 29126_3_30 CD274 Exon 3 - xp9:5457106-5457131 AUUGCUACCAUACUCUACCACAUAU 3003 29126_3_31 CD274 Exon 3 - xp9:5457154-5457179 AGCCAGGUCUAAUUGUUUUUCUACU 3004 29126_3_32 CD274 Exon 3 - xp9:5457155-5457180 CAGCCAGGUCUAAUUGUUUUUCUAC 3005 29126_3_33 CD274 Exon 3 - xp9:5457175-5457200 UUCCCAAUAGACAAUUAGUGCAGCC 3006 29126_3_34 CD274 Exon 3 - xp9:5457247-5457272 UCUGUAGCUACUAUGCUGAACCUUC 3007 29126_3_35 CD274 Exon 3 - xp9:5457282-5457307 AGGGAGAGCUGGUCCUUCAACAGCC 3008 29126_3_36 CD274 Exon 3 - xp9:5457283-5457308 CAGGGAGAGCUGGUCCUUCAACAGC 3009 29126_3_37 CD274 Exon 3 - xp9:5457298-5457323 AAGUGCAGCAUUUCCCAGGGAGAGC 3010 29126_3_38 CD274 Exon 3 - xp9:5457306-5457331 GUGAUCUGAAGUGCAGCAUUUCCCA 3011 29126_3_39 CD274 Exon 3 - xp9:5457307-5457332 UGUGAUCUGAAGUGCAGCAUUUCCC 3012 29126_3_40 CD274 Exon 3 - xp9:5457364-5457389 GGCACCACCAUAGCUGAUCAUGCAG 3013 29126_3_41 CD274 Exon 3 - xp9:5457390-5457415 ACUUUCACAGUAAUUCGCUUGUAGU 3014 29126_4_1 CD274 Exon 4 + xp9:5462838-5462863 UACAACAAAAUCAACCAAAGAAUUU 3015 29126_4_2 CD274 Exon 4 + xp9:5462844-5462869 AAAAUCAACCAAAGAAUUUUGGUUG 3016 29126_4_3 CD274 Exon 4 + xp9:5462880-5462905 ACCUCUGAACAUGAACUGACAUGUC 3017 29126_4_4 CD274 Exon 4 + xp9:5462886-5462911 GAACAUGAACUGACAUGUCAGGCUG 3018 29126_4_5 CD274 Exon 4 + xp9:5462887-5462912 AACAUGAACUGACAUGUCAGGCUGA 3019 29126_4_6 CD274 Exon 4 + xp9:5462898-5462923 ACAUGUCAGGCUGAGGGCUACCCCA 3020 29126_4_7 CD274 Exon 4 + xp9:5462912-5462937 GGGCUACCCCAAGGCCGAAGUCAUC 3021 29126_4_8 CD274 Exon 4 + xp9:5462941-5462966 CAAGCAGUGACCAUCAAGUCCUGAG 3022 29126_4_9 CD274 Exon 4 + xp9:5462973-5462998 ACCACCACCACCAAUUCCAAGAGAG 3023 29126_4_10 CD274 Exon 4 + xp9:5463047-5463072 UAAUGAGAUUUUCUACUGCACUUUU 3024 29126_4_11 CD274 Exon 4 + xp9:5463063-5463088 UGCACUUUUAGGAGAUUAGAUCCUG 3025 29126_4_12 CD274 Exon 4 + xp9:5463084-5463109 CCUGAGGAAAACCAUACAGCUGAAU 3026 29126_4_13 CD274 Exon 4 + xp9:5463094-5463119 ACCAUACAGCUGAAUUGGUCAUCCC 3027 29126_4_14 CD274 Exon 4 - xp9:5462831-5462856 UUGGUUGAUUUUGUUGUAUGGGGCU 3028 29126_4_15 CD274 Exon 4 - xp9:5462836-5462861 AUUCUUUGGUUGAUUUUGUUGUAUG 3029 29126_4_16 CD274 Exon 4 - xp9:5462837-5462862 AAUUCUUUGGUUGAUUUUGUUGUAU 3030 29126_4_17 CD274 Exon 4 - xp9:5462838-5462863 AAAUUCUUUGGUUGAUUUUGUUGUA 3031 29126_4_18 CD274 Exon 4 - xp9:5462855-5462880 GACUGGAUCCACAACCAAAAUUCUU 3032 29126_4_19 CD274 Exon 4 - xp9:5462877-5462902 AUGUCAGUUCAUGUUCAGAGGUGAC 3033 29126_4_20 CD274 Exon 4 - xp9:5462884-5462909 GCCUGACAUGUCAGUUCAUGUUCAG 3034 29126_4_21 CD274 Exon 4 - xp9:5462921-5462946 GCUUGUCCAGAUGACUUCGGCCUUG 3035 29126_4_22 CD274 Exon 4 - xp9:5462922-5462947 UGCUUGUCCAGAUGACUUCGGCCUU 3036 29126_4_23 CD274 Exon 4 - xp9:5462923-5462948 CUGCUUGUCCAGAUGACUUCGGCCU 3037 29126_4_24 CD274 Exon 4 - xp9:5462929-5462954 UGGUCACUGCUUGUCCAGAUGACUU 3038 29126_4_25 CD274 Exon 4 - xp9:5462954-5462979 GGUGGUCUUACCACUCAGGACUUGA 3039 29126_4_26 CD274 Exon 4 - xp9:5462963-5462988 AUUGGUGGUGGUGGUCUUACCACUC 3040 29126_4_27 CD274 Exon 4 - xp9:5462977-5463002 UCCUCUCUCUUGGAAUUGGUGGUGG 3041 29126_4_28 CD274 Exon 4 - xp9:5462980-5463005 UUCUCCUCUCUCUUGGAAUUGGUGG 3042 29126_4_29 CD274 Exon 4 - xp9:5462983-5463008 AGCUUCUCCUCUCUCUUGGAAUUGG 3043 29126_4_30 CD274 Exon 4 - xp9:5462986-5463011 AAAAGCUUCUCCUCUCUCUUGGAAU 3044 29126_4_31 CD274 Exon 4 - xp9:5462992-5463017 ACAUUGAAAAGCUUCUCCUCUCUCU 3045 29126_4_32 CD274 Exon 4 - xp9:5463022-5463047 GUUGUUGUGUUGAUUCUCAGUGUGC 3046 29126_4_33 CD274 Exon 4 - xp9:5463087-5463112 CCAAUUCAGCUGUAUGGUUUUCCUC 3047 29126_4_34 CD274 Exon 4 - xp9:5463098-5463123 ACCUGGGAUGACCAAUUCAGCUGUA 3048 29126_4_35 CD274 Exon 4 - xp9:5463119-5463144 AAUGGACACAUUCAGAAUAUUACCU 3049 29126_4_36 CD274 Exon 4 - xp9:5463120-5463145 UAAUGGACACAUUCAGAAUAUUACC 3050 29126_5_1 CD274 Exon 5 + xp9:5465482-5465507 UUGUUUUGUUUUUCAGAACUACCUCCUC 3051 29126_5_2 CD274 Exon 5 + xp9:5465502-5465527 ACCUCUGGCACAUCCUCCAAAUGAA 3052 29126_5_3 CD274 Exon 5 + xp9:5465512-5465537 CAUCCUCCAAAUGAAAGGACUCACU 3053 29126_5_4 CD274 Exon 5 + xp9:5465521-5465546 AAUGAAAGGACUCACUUGGUAAUUC 3054 29126_5_5 CD274 Exon 5 + xp9:5465522-5465547 AUGAAAGGACUCACUUGGUAAUUCU 3055 29126_5_6 CD274 Exon 5 + xp9:5465543-5465568 UUCUGGGAGCCAUCUUAUUAUGCCU 3056 29126_5_7 CD274 Exon 5 + xp9:5465579-5465604 UGACAUUCAUCUUCCGUUUAAAGAAA 3057 29126_5_8 CD274 Exon 5 + xp9:5465602-5465627 AAAGGUAGUAUUUCCUUAAUUGCAG 3058 29126_5_9 CD274 Exon 5 - xp9:5465506-5465531 UCCUUUCAUUUGGAGGAUGUGCCAG 3059 29126_5_10 CD274 Exon 5 - xp9:5465518-5465543 UUACCAAGUGAGUCCCUUUCAUUUGG 3060 29126_5_11 CD274 Exon 5 - xp9:5465521-5465546 GAAUUACCAAGUGAGUCCCUUUCAUU 3061 29126_5_12 CD274 Exon 5 - xp9:5465555-5465580 AGUGCUACACCAAGGCAUAAUAAGA 3062 29126_5_13 CD274 Exon 5 - xp9:5465568-5465593 GAAGAUGAAUGUCAGUGCUACACCA 3063 29126_5_14 CD274 Exon 5 - xp9:5465595-5465620 UAAGGAAAUACUACCUUUUCUUAAA 3064 29126_6_1 CD274 Exon 6 + xp9:5466753-5466778 AUUUCUUUUUCUCAAGGGAGAAUGA 3065 29126_6_2 CD274 Exon 6 + xp9:5466769-5466794 GGAGAAUGAUGGAUGUGAAAAAAUG 3066 29126_6_3 CD274 Exon 6 + xp9:5466802-5466827 AAGAUACAAACUCAAAGAAGCAAAG 3067 29126_6_4 CD274 Exon 6 + xp9:5466818-5466843 GAAGCAAAGUGGUAAGAAUAUCAGA 3068 29126_6_5 CD274 Exon 6 + xp9:5466824-5466849 AAGUGGUAAGAAUAUCAGAAGGAAU 3069 29126_6_6 CD274 Exon 6 + xp9:5466825-5466850 AGUGGUAAGAAUAUCAGAAGGAAUU 3070 29126_6_7 CD274 Exon 6 - xp9:5466803-5466828 ACUUUGCUUCUUUGAGUUUGUAUCU 3071 29126_7_1 CD274 Exon 7 + xp9:5467823-5467848 UAUUAUCACUCUCCAGAUACACAUU 3072 29126_7_2 CD274 Exon 7 + xp9:5467826-5467851 UAUCACUCUCCAGAUACACAUUUGG 3073 29126_7_3 CD274 Exon 7 + xp9:5467845-5467870 AUUUGGAGGAGACGUAAUCCAGCAU 3074 29126_7_4 CD274 Exon 7 + xp9:5467866-5467891 GCAUUGGAACUUCUGAUCUUCAAGC 3075 29126_7_5 CD274 Exon 7 + xp9:5467867-5467892 CAUUGGAACUUCUGAUCUUCAAGCA 3076 29126_7_6 CD274 Exon 7 + xp9:5467882-5467907 UCUUCAAGCAGGGAUUCUCAACCUG 3077 29126_7_7 CD274 Exon 7 + xp9:5467888-5467913 AGCAGGGAUUCUCAACCUGUGGUUU 3078 29126_7_8 CD274 Exon 7 + xp9:5467889-5467914 GCAGGGAUUCUCAACCUGUGGUUUA 3079 29126_7_9 CD274 Exon 7 + xp9:5467890-5467915 CAGGGAUUCUCAACCUGUGGUUUAG 3080 29126_7_10 CD274 Exon 7 + xp9:5467898-5467923 CUCAACCUGUGGUUUAGGGGUUCAU 3081 29126_7_11 CD274 Exon 7 + xp9:5467899-5467924 UCAACCUGUGGUUUAGGGGUUCAUC 3082 29126_7_12 CD274 Exon 7 + xp9:5467900-5467925 CAACCUGUGGUUUAGGGGUUCAUCG 3083 29126_7_13 CD274 Exon 7 + xp9:5467917-5467942 GUUCAUCGGGGCUGAGCGUGACAAG 3084 29126_7_14 CD274 Exon 7 + xp9:5467921-5467946 AUCGGGGCUGAGCGUGACAAGAGGA 3085 29126_7_15 CD274 Exon 7 + xp9:5467926-5467951 GGCUGAGCGUGACAAGAGGAAGGAA 3086 29126_7_16 CD274 Exon 7 + xp9:5467927-5467952 GCUGAGCGUGACAAGAGGAAGGAAU 3087 29126_7_17 CD274 Exon 7 + xp9:5467934-5467959 GUGACAAGAGGAAGGAAUGGGCCCG 3088 29126_7_18 CD274 Exon 7 + xp9:5467935-5467960 UGACAAGAGGAAGGAAUGGGCCCGU 3089 29126_7_19 CD274 Exon 7 + xp9:5467942-5467967 AGGAAGGAAUGGGCCCGUGGGAUGC 3090 29126_7_20 CD274 Exon 7 + xp9:5467950-5467975 AUGGGCCCGUGGGAUGCAGGCAAUG 3091 29126_7_21 CD274 Exon 7 + xp9:5467951-5467976 UGGGCCCGUGGGAUGCAGGCAAUGU 3092 29126_7_22 CD274 Exon 7 + xp9:5467961-5467986 GGAUGCAGGCAAUGUGGGACUUAAA 3093 29126_7_23 CD274 Exon 7 + xp9:5467979-5468004 ACUUAAAAGGCCCAAGCACUGAAA 3094 29126_7_24 CD274 Exon 7 + xp9:5467986-5468011 AGGCCCAAGCACUGAAAAUGGAACC 3095 29126_7_25 CD274 Exon 7 + xp9:5467998-5468023 UGAAAAUGGAACCUGGCGAAAGCAG 3096 29126_7_26 CD274 Exon 7 + xp9:5468001-5468026 AAAUGGAACCUGGCGAAAGCAGAGG 3097 29126_7_27 CD274 Exon 7 + xp9:5468018-5468043 AGCAGAGGAGGAGAAUGAAGAAGA 3098 29126_7_28 CD274 Exon 7 + xp9:5468029-5468054 AGAAUGAAGAAAGAUGGAGUCAAAAC 3099 29126_7_29 CD274 Exon 7 + xp9:5468030-5468055 GAAUGAAGAAAGAUGGAGUCAAACA 3100 29126_7_30 CD274 Exon 7 + xp9:5468037-5468062 GAAAGAUGGAGUCAAAACAGGGAGCC 3101 29126_7_31 CD274 Exon 7 + xp9:5468040-5468065 AGAUGGAGUCAAAACAGGGAGCCUGG 3102 29126_7_32 CD274 Exon 7 + xp9:5468041-5468066 GAUGGAGUCAAAACAGGGAGCCUGGA 3103 29126_7_33 CD274 Exon 7 + xp9:5468069-5468094 AGACCUUGAUACUUUCAAAUGCCUG 3104 29126_7_34 CD274 Exon 7 + xp9:5468070-5468095 GACCUUGAUACUUUCAAAUGCCUGA 3105 29126_7_35 CD274 Exon 7 + xp9:5468071-5468096 ACCUUGAUACUUUCAAAUGCCUGAG 3106 29126_7_36 CD274 Exon 7 + xp9:5468092-5468117 UGAGGGGCUCAUCGACGCCUGUGAC 3107 29126_7_37 CD274 Exon 7 + xp9:5468093-5468118 GAGGGGCUCAUCGACGCCUGUGACA 3108 29126_7_38 CD274 Exon 7 + xp9:5468100-5468125 UCAUCGACGCCUGUGACAGGGAGAA 3109 29126_7_39 CD274 Exon 7 + xp9:5468116-5468141 CAGGGAGAAAGGAUACUUCUGAACA 3110 29126_7_40 CD274 Exon 7 + xp9:5468151-5468176 AAGCAAAUCAUCCAUUGCUCAUCCU 3111 29126_7_41 CD274 Exon 7 + xp9:5468158-5468183 UCAUCCAUUGCUCAUCCUAGGAAGA 3112 29126_7_42 CD274 Exon 7 + xp9:5468159-5468184 CAUCCAUUGCUCAUCCUAGGAAGAC 3113 29126_7_43 CD274 Exon 7 + xp9:5468180-5468205 AGACGGGUUGAGAAUCCCUAAUUUG 3114 29126_7_44 CD274 Exon 7 + xp9:5468181-5468206 GACGGGUUGAGAAUCCCUAAUUUGA 3115 29126_7_45 CD274 Exon 7 + xp9:5468260-5468285 UCUGCAUGACUGAGAGUCUCAGUGU 3116 29126_7_46 CD274 Exon 7 + xp9:5468265-5468290 AUGACUGAGAGUCUCAGUGUUGGAA 3117 29126_7_47 CD274 Exon 7 + xp9:5468266-5468291 UGACUGAGAGUCUCAGUGUUGGAAC 3118 29126_7_48 CD274 Exon 7 + xp9:5468313-5468338 UUUUCCUAUUUAUUUUGAGUCUGUG 3119 29126_7_49 CD274 Exon 7 + xp9:5468335-5468360 GUGAGGUCUUCUUGUCAUGUGAGUG 3120 29126_7_50 CD274 Exon 7 + xp9:5468438-5468463 UGAUUUGCUCACAUCUAGUAAAAACA 3121 29126_7_51 CD274 Exon 7 + xp9:5468451-5468476 UCUAGUAAAACAUGGAGUAUUUGUA 3122 29126_7_52 CD274 Exon 7 + xp9:5468458-5468483 AAACAUGGAGUAUUUGUAAGGUGCU 3123 29126_7_53 CD274 Exon 7 + xp9:5468487-5468512 CUCCUCUAUAACUACAAGUAUACAU 3124 29126_7_54 CD274 Exon 7 + xp9:5468510-5468535 AUUGGAAGCAAUAAAGAUCAAACCGU 3125 29126_7_55 CD274 Exon 7 + xp9:5468519-5468544 AUAAAGAUCAAACCGUUGGUUGCAU 3126 29126_7_56 CD274 Exon 7 + xp9:5468552-5468577 ACCUUUAUUUAACCCAUUAAUACUC 3127 29126_7_57 CD274 Exon 7 + xp9:5469037-5469062 GGAAAACCCGAGCAGUGUUGCCAAG 3128 29126_7_58 CD274 Exon 7 + xp9:5469040-5469065 AAACCCGAGCAGUGUUGCCAAGAGG 3129 29126_7_59 CD274 Exon 7 + xp9:5469047-5469072 AGCAGUGUUGCCAAGAGGAGGAAAU 3130 29126_7_60 CD274 Exon 7 + xp9:5469056-5469081 GCCAAGAGGAGGAAAUAGGCCAAUG 3131 29126_7_61 CD274 Exon 7 + xp9:5469061-5469086 GAGGAGGAAAUAGGCCAAUGUGGUC 3132 29126_7_62 CD274 Exon 7 + xp9:5469062-5469087 AGGAGGAAAUAGGCCAAUGUGGUCU 3133 29126_7_63 CD274 Exon 7 + xp9:5469066-5469091 GGAAAUAGGCCAAUGUGGUCUGGGA 3134 29126_7_64 CD274 Exon 7 + xp9:5469070-5469095 AUAGGCCAAUGUGGUCUGGGACGGU 3135 29126_7_65 CD274 Exon 7 + xp9:5469121-5469146 CAGAGUAAUUUUCAUUUACAAAAGAG 3136 29126_7_66 CD274 Exon 7 + xp9:5469125-5469150 GUAAUUUUCAUUUACAAAAGAGAGGU 3137 29126_7_67 CD274 Exon 7 + xp9:5469156-5469181 UUAAAAUAACCCUGAAAAAUAACAC 3138 29126_7_68 CD274 Exon 7 + xp9:5469233-5469258 AUCUAAUGCUUGUUUAUAUAGUGUC 3139 29126_7_69 CD274 Exon 7 + xp9:5469553-5469578 AUUUUAGUGUUUCUUAUAUAGCAGA 3140 29126_7_70 CD274 Exon 7 + xp9:5469574-5469599 CAGAUGGAAUGAAUUUGAAGUUCCC 3141 29126_7_71 CD274 Exon 7 + xp9:5469575-5469600 AGAUGGAAUGAAUUUGAAGUUCCA 3142 29126_7_72 CD274 Exon 7 + xp9:5469581-5469606 AAUGAAUUUGAAGUUCCCAGGGCUG 3143 29126_7_73 CD274 Exon 7 + xp9:5469712-5469737 CCACCAUUUGUUAAGUAUUUGCUCU 3144 29126_7_74 CD274 Exon 7 + xp9:5469723-5469748 UAAGUAUUUGCUCUAGGACAGAGUU 3145 29126_7_75 CD274 Exon 7 + xp9:5469747-5469772 UUGGAUUUGUUUAUGUUUGCUCAAA 3146 29126_7_76 CD274 Exon 7 + xp9:5469757-5469782 UUAUGUUUGCUCAAAAGGAGACCCA 3147 29126_7_77 CD274 Exon 7 + xp9:5469758-5469783 UAUGUUUGCUCAAAAGGAGACCCAU 3148 29126_7_78 CD274 Exon 7 + xp9:5469767-5469792 UCAAAAGGAGACCCAUGGGCUCUCC 3149 29126_7_79 CD274 Exon 7 + xp9:5469768-5469793 CAAAAGGAGACCCAUGGGCUCUCCA 3150 29126_7_80 CD274 Exon 7 + xp9:5469836-5469861 UAACUCUGUAUGACAGAAUCAUGUC 3151 29126_7_81 CD274 Exon 7 + xp9:5469913-5469938 UACUUGCAAAAUCACAUUUUCUUUC 3152 29126_7_82 CD274 Exon 7 + xp9:5469922-5469947 AAUCACAUUUUCUUUCUGGAAAUUC 3153 29126_7_83 CD274 Exon 7 + xp9:5470028-5470053 GUCAUCACUACACAGCCCUCCUAAG 3154 29126_7_84 CD274 Exon 7 + xp9:5470036-5470061 UACACAGCCCUCCUAAGAGGCUUCC 3155 29126_7_85 CD274 Exon 7 + xp9:5470039-5470064 ACAGCCCUCCUAAGAGGCUUCCUGG 3156 29126_7_86 CD274 Exon 7 + xp9:5470061-5470086 UGGAGGUUUCGAGAUUCAGAUGCCC 3157 29126_7_87 CD274 Exon 7 + xp9:5470062-5470087 GGAGGUUUCGAGAUUCAGAUGCCCU 3158 29126_7_88 CD274 Exon 7 + xp9:5470090-5470115 AGAUCCCAGAGUUUCCUUUCCCUCU 3159 29126_7_89 CD274 Exon 7 + xp9:5470101-5470126 UUUCCUUUCCCUCUUGGCCAUAUUC 3160 29126_7_90 CD274 Exon 7 + xp9:5470115-5470140 UGGCCAUAUUCUGGUGUCAAUGACA 3161 29126_7_91 CD274 Exon 7 + xp9:5470125-5470150 CUGGUGUCAAUGACAAGGAGUACCU 3162 29126_7_92 CD274 Exon 7 + xp9:5470143-5470168 AGUACCUUGGCUUUGCCACAUGUCA 3163 29126_7_93 CD274 Exon 7 + xp9:5470215-5470240 UGUACAUGUGCAUUUGUACAGUAAU 3164 29126_7_94 CD274 Exon 7 + xp9:5470245-5470270 UGACAGUGUUCUUUGUGUGAAUUAC 3165 29126_7_95 CD274 Exon 7 + xp9:5470257-5470282 UUGUGUGAAUUACAGGCAAGAAUUG 3166 29126_7_96 CD274 Exon 7 + xp9:5470267-5470292 UACAGGCAAGAAUUGUGGCUGAGCA 3167 29126_7_97 CD274 Exon 7 + xp9:5470314-5470339 AUUCCUAAAGUCCUAACUCCUCCUUG 3168 29126_7_98 CD274 Exon 7 + xp9:5470320-5470345 AAGUCCUAACUCCUCCUUGUGGUGU 3169 29126_7_99 CD274 Exon 7 + xp9:5470330-5470355 UCCUCCUUGUGGUGUUGGAUUUGUA 3170 29126_7_100 CD274 Exon 7 + xp9:5470368-5470393 CUUUUGUCUCAUGUUUCAUCGUAAA 3171 29126_7_101 CD274 Exon 7 + xp9:5470374-5470399 UCUCAUGUUUCAUCGUAAAUGGCAU 3172 29126_7_102 CD274 Exon 7 + xp9:5470462-5470487 AAAUAUUCUUAUUUAUUUUGUUACU 3173 29126_7_103 CD274 Exon 7 + xp9:5470530-5470555 UAAAAUGUUCAGUUUAACAUCCAG 3174 29126_7_104 CD274 Exon 7 + xp9:5470544-5470569 UAACAUCCCAGUGGAGAAAGUUACU 3175 29126_7_105 CD274 Exon 7 - xp9:5467838-5467863 AUUACGUCUCCUCCAAAUGUGUAUUC 3176 29126_7_106 CD274 Exon 7 - xp9:5467866-5467891 GCUUGAAGAUCAGAAGUUCCAAUGC 3177 29126_7_107 CD274 Exon 7 - xp9:5467906-5467931 CAGCCCCGAUGAACCCCUAAACCAC 3178 29126_7_108 CD274 Exon 7 - xp9:5467958-5467983 AAGUCCCACAUUGCCUGCAUCCCAC 3179 29126_7_109 CD274 Exon 7 - xp9:5467959-5467984 UAAGUCCCACAUUGCCUGCAUCCCA 3180 29126_7_110 CD274 Exon 7 - xp9:5467992-5468017 UCGCCAGGUUCCAUUUUCAGUGCUU 3181 29126_7_111 CD274 Exon 7 - xp9:5467993-5468018 UUCGCCAGGUUCCAUUUUCAGUGCU 3182 29126_7_112 CD274 Exon 7 - xp9:5468012-5468037 UUCAUUCUCCCUCCUCUGCUUUCGCC 3183 29126_7_113 CD274 Exon 7 - xp9:5468063-5468088 UUUGAAAGUAUCAAGGUCUCCCUCC 3184 29126_7_114 CD274 Exon 7 - xp9:5468075-5468100 GCCCCUCAGGCAUUUGAAAGUAUCA 3185 29126_7_115 CD274 Exon 7 - xp9:5468093-5468118 UGUCACAGGCGUCGAUGAGCCCCUC 3186 29126_7_116 CD274 Exon 7 - xp9:5468112-5468137 CAGAAGUAUCCUUUCUCCCCUGUCAC 3187 29126_7_117 CD274 Exon 7 - xp9:5468149-5468174 GAUGAGCAAUGGAUGAUUUGCUUGG 3188 29126_7_118 CD274 Exon 7 - xp9:5468152-5468177 UAGGAUGAGCAAUGGAUGAUUUGCU 3189 29126_7_119 CD274 Exon 7 - xp9:5468165-5468190 CAACCCGUCUUCCUAGGAUGAGCAA 3190 29126_7_120 CD274 Exon 7 - xp9:5468176-5468201 UUAGGGAUUUCUCAACCCGUCUUCCU 3191 29126_7_121 CD274 Exon 7 - xp9:5468198-5468223 UCUGCAGGAACUGACCCUCAAAUUA 3192 29126_7_122 CD274 Exon 7 - xp9:5468199-5468224 UUCUGCAGGAACUGACCCUCAAAUU 3193 29126_7_123 CD274 Exon 7 - xp9:5468218-5468243 GAGUGGAGGCAAAGGGCACUUCUGC 3194 29126_7_124 CD274 Exon 7 - xp9:5468230-5468255 AAUUGAGGCAUUGAGUGGAGGCAAA 3195 29126_7_125 CD274 Exon 7 - xp9:5468231-5468256 AAAUUGAGGCAUUGAGUGGAGGCAA 3196 29126_7_126 CD274 Exon 7 - xp9:5468237-5468262 GAAAACAAAUUGAGGCAUUGAGUGG 3197 29126_7_127 CD274 Exon 7 - xp9:5468240-5468265 GCAGAAAACAAAUUGAGGCAUUGAG 3198 29126_7_128 CD274 Exon 7 - xp9:5468250-5468275 UCUCAGUCAUGCAGAAAACAAAUUG 3199 29126_7_129 CD274 Exon 7 - xp9:5468320-5468345 AAGACCUCACAGACUCAAAAUAAAU 3200 29126_7_130 CD274 Exon 7 - xp9:5468419-5468444 AAAUCAUUAAGCAGCAAGUUUAGUU 3201 29126_7_131 CD274 Exon 7 - xp9:5468492-5468517 UUCCAAUGUAUACUUGUAGUUAUAG 3202 29126_7_132 CD274 Exon 7 - xp9:5468534-5468559 UAAAGGUGACAUCCUAUGCAACCAA 3203 29126_7_133 CD274 Exon 7 - xp9:5468556-5468581 ACCAGAGUAUUAAUGGGUUAAAAUAA 3204 29126_7_134 CD274 Exon 7 - xp9:5468567-5468592 AGAUUAGGUCAACCAGAGUAUUAAU 3205 29126_7_135 CD274 Exon 7 - xp9:5468568-5468593 AAGAUUAGGUCAACCAGAGUAUUAA 3206 29126_7_136 CD274 Exon 7 - xp9:5468587-5468612 ACACUUGAGGUCUGAGAAUAAGAUU 3207 29126_7_137 CD274 Exon 7 - xp9:5468605-5468630 CCUUGUCUAACUGCACAGACACUUG 3208 29126_7_138 CD274 Exon 7 - xp9:5468811-5468836 AUAUAGCUGUAAAUUGUAUUAUAAA 3209 29126_7_139 CD274 Exon 7 - xp9:5469060-5469085 ACCACAUUGGCCUAUUUCCUCCUCU 3210 29126_7_140 CD274 Exon 7 - xp9:5469078-5469103 UAUAUCCAACCGUCCCAGACCACAU 3211 29126_7_141 CD274 Exon 7 - xp9:5469168-5469193 AAAGGAAUUCCAGUGUUAUUUUUCA 3212 29126_7_142 CD274 Exon 7 - xp9:5469169-5469194 AAAAGGAAUUCCAGUGUUAUUUUUC 3213 29126_7_143 CD274 Exon 7 - xp9:5469191-5469216 UCAGGAAUAAAUAUAUGCUAGAAA 3214 29126_7_144 CD274 Exon 7 - xp9:5469214-5469239 UUAGAUUAUAUGGCAAAGGCAAAUC 3215 29126_7_145 CD274 Exon 7 - xp9:5469223-5469248 AAACAAGCAUUAGAUUAUAUGGCAA 3216 29126_7_146 CD274 Exon 7 - xp9:5469229-5469254 CUAUAUAAACAAGCAUUAGAUUAUA 3217 29126_7_147 CD274 Exon 7 - xp9:5469299-5469324 CCUUUCCAUACUUAAAUUUUUUUAG 3218 29126_7_148 CD274 Exon 7 - xp9:5469599-5469624 AAAGAAGGCAUGGAUCCCAGCCCU 3219 29126_7_149 CD274 Exon 7 - xp9:5469600-5469625 CAAAGAAGGCAUGGAUCCUCAGCCC 3220 29126_7_150 CD274 Exon 7 - xp9:5469614-5469639 AGAUAACUUAGAAACAAAGAAGGCA 3221 29126_7_151 CD274 Exon 7 - xp9:5469619-5469644 GGGAAAGAUAACUUAGAAACAAAGA 3222 29126_7_152 CD274 Exon 7 - xp9:5469644-5469669 CAUAUGAAAGAUAAUGAAAAGCUAU 3223 29126_7_153 CD274 Exon 7 - xp9:5469645-5469670 UCAUAUGAAAGAUAAUGAAAAGCUA 3224 29126_7_154 CD274 Exon 7 - xp9:5469674-5469699 UAUGUAGGACAUAUUUAACAUAUAC 3225 29126_7_155 CD274 Exon 7 - xp9:5469694-5469719 AUGGUGGUUGUCUAAAUGUAUAUGU 3226 29126_7_156 CD274 Exon 7 - xp9:5469715-5469740 CCUAGAGCAAAUACUUAACAAAUGG 3227 29126_7_157 CD274 Exon 7 - xp9:5469718-5469743 UGUCCUAGAGCAAAUACUUAACAAAA 3228 29126_7_158 CD274 Exon 7 - xp9:5469781-5469806 ACUCAGUGCACCCUGGAGAGCCCAU 3229 29126_7_159 CD274 Exon 7 - xp9:5469782-5469807 GACUCAGUGCACCCUGGAGAGCCCA 3230 29126_7_160 CD274 Exon 7 - xp9:5469793-5469818 AGGACUAGAUUGACUCAGUGCACCC 3231 29126_7_161 CD274 Exon 7 - xp9:5469818-5469843 AGAGUUAAUAAUAAGAUUGCUUUUU 3232 29126_7_162 CD274 Exon 7 - xp9:5469949-5469974 GUAGCUAGCAGUCAAGGUACACCUGC 3233 29126_7_163 CD274 Exon 7 - xp9:5469960-5469985 UCUGGCACAGGGUAGCUAGCAGUCA 3234 29126_7_164 CD274 Exon 7 - xp9:5469976-5470001 CAACGAAUGAGGCUUUUCUGGCACA 3235 29126_7_165 CD274 Exon 7 - xp9:5469977-5470002 ACAACGAAUGAGGCUUUUCUGGCAC 3236 29126_7_166 CD274 Exon 7 - xp9:5469983-5470008 UCAAGCACAACGAAUGAGGCUUUUC 3237 29126_7_167 CD274 Exon 7 - xp9:5469992-5470017 UUCAAGGGUUCAAGCACAACGAAUG 3238 29126_7_168 CD274 Exon 7 - xp9:5470012-5470037 AGUGAUGACAGCUGGUGGCAUUCAA 3239 29126_7_169 CD274 Exon 7 - xp9:5470013-5470038 UAGUGAUGACAGCUGGUGGCAUUCA 3240 29126_7_170 CD274 Exon 7 - xp9:5470022-5470047 AGGGCUGUGUAGGUGAUGACAGCUGG 3241 29126_7_171 CD274 Exon 7 - xp9:5470025-5470050 AGGAGGGCUGUGUAGUGAUGACAGC 3242 29126_7_172 CD274 Exon 7 - xp9:5470046-5470071 GAAACCUCCAGGAAGCCUCUUAGGA 3243 29126_7_173 CD274 Exon 7 - xp9:5470047-5470072 CGAAACCUCCAGGAAGCCUCUUAGG 3244 29126_7_174 CD274 Exon 7 - xp9:5470050-5470075 UCUCGAAACCUCCAGGAAGCCUCUU 3245 29126_7_175 CD274 Exon 7 - xp9:5470062-5470087 AGGGCAUCUGAAUCUCGAAACCUCC 3246 29126_7_176 CD274 Exon 7 - xp9:5470086-5470111 GGAAAGGAAACUCUGGGAUCUCCCA 3247 29126_7_177 CD274 Exon 7 - xp9:5470087-5470112 GGGAAAGGAAACUCUGGGAUCUCCC 3248 29126_7_178 CD274 Exon 7 - xp9:5470097-5470122 AUGGCCAAGAGGGAAAGGAAACUCU 3249 29126_7_179 CD274 Exon 7 - xp9:5470098-5470123 UAUGGCCAAGAGGGAAAGGAAAACUC 3250 29126_7_180 CD274 Exon 7 - xp9:5470107-5470132 ACACCAGAAUAUGGCCAAGAGGGAA 3251 29126_7_181 CD274 Exon 7 - xp9:5470112-5470137 CAUUGACACCAAGAAUAUGGCCAAGA 3252 29126_7_182 CD274 Exon 7 - xp9:5470113-5470138 UCAUUGACACCAGAAUAUGGCCAAG 3253 29126_7_183 CD274 Exon 7 - xp9:5470121-5470146 ACUCCUUGUCAUUGACACCAGAAUA 3254 29126_7_184 CD274 Exon 7 - xp9:5470150-5470175 UCAGCCUUGACAUGUGGCAAAGCCA 3255 29126_7_185 CD274 Exon 7 - xp9:5470161-5470186 ACACUGUUUCUUCAGCCUUGACAUG 3256 29126_7_186 CD274 Exon 7 - xp9:5470191-5470216 AAACAGAUAACACAAGGAGCUCUGU 3257 29126_7_187 CD274 Exon 7 - xp9:5470202-5470227 UGCACAUGUACAAACAGAUAACACA 3258 29126_7_188 CD274 Exon 7 - xp9:5470320-5470345 ACACCACAAGGAGGAGUUAGGACUU 3259 29126_7_189 CD274 Exon 7 - xp9:5470327-5470352 AAAUCCAACACCACAAGGAGGAGUU 3260 29126_7_190 CD274 Exon 7 - xp9:5470334-5470359 GCCUUACAAAUCCAACACCACAAGG 3261 29126_7_191 CD274 Exon 7 - xp9:5470337-5470362 AGUGCCUUACAAAUCCAACACCACA 3262 29126_7_192 CD274 Exon 7 - xp9:5470369-5470394 AUUUACGAUGAAACAUGAGACAAAAA 3263 29126_7_193 CD274 Exon 7 - xp9:5470370-5470395 CAUUUACGAUGAAACAUGAGACAAA 3264 29126_7_194 CD274 Exon 7 - xp9:5470416-5470441 AAAAGUGACAAUCAAUAUGCAGAAUU 3265 29126_7_195 CD274 Exon 7 - xp9:5470448-5470473 UAAGAAUAUUUUAUUAAAUUAAUGC 3266 29126_7_196 CD274 Exon 7 - xp9:5470497-5470522 AAAAUAAACAAGAAAAUGGACAUGC 3267 29126_7_197 CD274 Exon 7 - xp9:5470506-5470531 AUUAAACACAAAAUAAACAAGAAAAA 3268 29126_7_198 CD274 Exon 7 - xp9:5470553-5470578 AAUAUUCCAAGUAACUUUCUCCACU 3269 29126_7_199 CD274 Exon 7 - xp9:5470554-5470579 AAAUAUUCCAAGUAACUUUCUCCAC 3270 84868_7_1 HAVCR2 Exon 7 + xp5:157085921-157085946 UAUACCGUCUUGAAAUUUAAGUUA 3271 84868_7_2 HAVCR2 Exon 7 + xp5:157085939-157085964 AAGUUUAGGGACCACCUCUCUGUCAA 3272 84868_7_3 HAVCR2 Exon 7 + xp5:157085951-157085976 CACUCUCUGUCAAAGGAUCCAGCGC 3273 84868_7_4 HAVCR2 Exon 7 + xp5:157085970-157085995 CAGCGCUGGUAAUAUAGAUUGCUGA 3274 84868_7_5 HAVCR2 Exon 7 + xp5:157085992-157086017 UGAAGGCCUUUGCCUUCUUUCCACC 3275 84868_7_6 HAVCR2 Exon 7 + xp5:157086053-157086078 UUCUGUGAAAAAAUAUAGCUUCAGUU 3276 84868_7_7 HAVCR2 Exon 7 + xp5:157086073-157086098 CAGUUUGGUCCACGAAUACAGAAGU 3277 84868_7_8 HAVCR2 Exon 7 + xp5:157086115-157086140 UUUCAAGCCACAAACAAGCAAAAACU 3278 84868_7_9 HAVCR2 Exon 7 + xp5:157086154-157086179 CAAUCAAAUGCACUUCGUUUUUCCC 3279 84868_7_10 HAVCR2 Exon 7 + xp5:157086155-157086180 AAUCAAAUGCACUUCGUUUUUCCCU 3280 84868_7_11 HAVCR2 Exon 7 + xp5:157086183-157086208 AGCUCCUGCCACAUCUCAGCCCUGC 3281 84868_7_12 HAVCR2 Exon 7 + xp5:157086184-157086209 GCUCCUGCCACAUCUCAGCCCUGCA 3282 84868_7_13 HAVCR2 Exon 7 + xp5:157086198-157086223 UCAGCCCUGCAGGGCAGUCUCAUA 3283 84868_7_14 HAVCR2 Exon 7 + xp5:157086199-157086224 CAGCCCUGCAGGGCAGUCUUCAUAA 3284 84868_7_15 HAVCR2 Exon 7 + xp5:157086212-157086237 CAGUCUUCAUAAGGGAGACAAAAAGA 3285 84868_7_16 HAVCR2 Exon 7 + xp5:157086213-157086238 AGUCUUCAUAAGGGAGACAAAAGAA 3286 84868_7_17 HAVCR2 Exon 7 + xp5:157086224-157086249 GGGAGACAAAAAGAAGGGCUAUGCAC 3287 84868_7_18 HAVCR2 Exon 7 + xp5:157086237-157086262 AGGGCUAUGCACUGGCACUGACAGU 3288 84868_7_19 HAVCR2 Exon 7 + xp5:157086238-157086263 GGGCUAUGCACUGGCACUGACAGUU 3289 84868_7_20 HAVCR2 Exon 7 + xp5:157086242-157086267 UAUGCACUGGCACUGACAGUUGGGC 3290 84868_7_21 HAVCR2 Exon 7 + xp5:157086279-157086304 AAUAAGCCUAAAUCUCAACAUUCCA 3291 84868_7_22 HAVCR2 Exon 7 + xp5:157086280-157086305 AUAAGCCUAAAUCUCAACAUUCCAA 3292 84868_7_23 HAVCR2 Exon 7 + xp5:157086297-157086322 CAUUCCAAGGGAAUCUUCAAGAUCA 3293 84868_7_24 HAVCR2 Exon 7 + xp5:157086306-157086331 GGAAUCUUCAAGAUCAAGGUAGAC 3294 84868_7_25 HAVCR2 Exon 7 + xp5:157086332-157086357 GGUCCAGUCAUCUCUUAAUCUUUUA 3295 84868_7_26 HAVCR2 Exon 7 + xp5:157086639-157086664 UCCAUCUCAAAAACAAAAAACAAAA 3296 84868_7_27 HAVCR2 Exon 7 + xp5:157086640-157086665 CCAUCUCAAAAACAAAAAACAAAAA 3297 84868_7_28 HAVCR2 Exon 7 + xp5:157086667-157086692 GAUCACAGAUCUCUUUGAAAAUCAG 3298 84868_7_29 HAVCR2 Exon 7 + xp5:157086748-157086773 UUUCCCUAGUUUAUCUGAAGUUUCA 3299 84868_7_30 HAVCR2 Exon 7 + xp5:157086774-157086799 GGACAUAUGAUGUGCCCGAAUUUCC 3300 84868_7_31 HAVCR2 Exon 7 + xp5:157086857-157086882 UCUAACAUCCAUGAUUAACAGUCUC 3301 84868_7_32 HAVCR2 Exon 7 + xp5:157086858-157086883 CUAACAUCCAUGAUUAACAGUCCUCU 3302 84868_7_33 HAVCR2 Exon 7 + xp5:157086862-157086887 CAUCCAUGAUUAACAGUCUCUGGU 3303 84868_7_34 HAVCR2 Exon 7 + xp5:157086863-157086888 AUCCAUGAUUAACAGUCCUCUGGGUU 3304 84868_7_35 HAVCR2 Exon 7 + xp5:157086875-157086900 CAGUCUCUGGGUUGGGUAACUCUGU 3305 84868_7_36 HAVCR2 Exon 7 + xp5:157086889-157086914 GGUAACUCUGUUGGCUUAAAUACAG 3306 84868_7_37 HAVCR2 Exon 7 + xp5:157086920-157086945 UGACAUGCCUGUUUAAGUUCAGGUGC 3307 84868_7_38 HAVCR2 Exon 7 + xp5:157086963-157086988 CAUGUGAGUCAUUAUCUUCUGAAA 3308 84868_7_39 HAVCR2 Exon 7 + xp5:157086964-157086989 AUGUGAGUCAUUAUCUUCUGAAAAU 3309 84868_7_40 HAVCR2 Exon 7 + xp5:157086987-157087012 AUGGGAAAACCUGCUCCAUAGCAG 3310 84868_7_41 HAVCR2 Exon 7 + xp5:157087011-157087036 GUGGACAGAACCUCCAAAACCAGUC 3311 84868_7_42 HAVCR2 Exon 7 + xp5:157087064-157087089 AGACAAAACACCAAGCUCAAAAAUA 3312 84868_7_43 HAVCR2 Exon 7 + xp5:157087067-157087092 CAAAACACCAAGCUCAAAAAUAAGG 3313 84868_7_44 HAVCR2 Exon 7 + xp5:157087071-157087096 ACACCAAGCUCAAAAAUAAGGUGGU 3314 84868_7_45 HAVCR2 Exon 7 + xp5:157087079-157087104 CUCAAAAAUAAGGUGGUUGGAUCUA 3315 84868_7_46 HAVCR2 Exon 7 + xp5:157087103-157087128 AUGGCAUUGCAAAGCGACAACCCAA 3316 84868_7_47 HAVCR2 Exon 7 + xp5:157087111-157087136 GCAAAGCGACAACCCAAAGGUUGUG 3317 84868_7_48 HAVCR2 Exon 7 + xp5:157087112-157087137 CAAAGCGACAACCCAAAGGUUGUGA 3318 84868_7_49 HAVCR2 Exon 7 + xp5:157087150-157087175 CUGCUGACAUAGCAAUAAUACUCAU 3319 84868_7_50 HAVCR2 Exon 7 + xp5:157087151-157087176 UGCUGACAUAGCAAUAAUACUCAUU 3320 84868_7_51 HAVCR2 Exon 7 + xp5:157087183-157087208 UCCACUUCAUAUACGUUCUCUUCAA 3321 84868_7_52 HAVCR2 Exon 7 + xp5:157087240-157087265 UCUGCUACUGCAUUUUGCCAAUCCUG 3322 84868_7_53 HAVCR2 Exon 7 + xp5:157087241-157087266 CUGCUACUGCAUUUUGCCAAUCCUGA 3323 84868_7_54 HAVCR2 Exon 7 + xp5:157087244-157087269 CUACUGCAUUUUGCCAAUCCUGAGGG 3324 84868_7_55 HAVCR2 Exon 7 + xp5:157087245-157087270 UACUGCAUUUGCCAAUCCUGAGGGA 3325 84868_7_56 HAVCR2 Exon 7 + xp5:157087248-157087273 UGCAUUUGCCAAUCCUGAGGGAGGG 3326 84868_7_57 HAVCR2 Exon 7 + xp5:157087252-157087277 UUUGCCCAAUCCUGAGGGAGGGAGGU 3327 84868_7_58 HAVCR2 Exon 7 + xp5:157087266-157087291 GGGAGGGAGGUUGGCCAAAGAGAUG 3328 84868_7_59 HAVCR2 Exon 7 + xp5:157087272-157087297 GAGGUUGGCCAAAAGAGAUGAGGCUG 3329 84868_7_60 HAVCR2 Exon 7 + xp5:157087288-157087313 AUGAGGCUGUGGAAAUAAAGUGUUG 3330 84868_7_61 HAVCR2 Exon 7 - xp5:157085953-157085978 CAGCGCUGGAUCCUUUGACAGAGAG 3331 84868_7_62 HAVCR2 Exon 7 - xp5:157085972-157085997 CUUCAGCAAUCUAUAUUACCAGGCGC 3332 84868_7_63 HAVCR2 Exon 7 - xp5:157086001-157086026 CUGUUGCCUGGUGGAAAGAAGGCAA 3333 84868_7_64 HAVCR2 Exon 7 - xp5:157086007-157086032 CAAAUUCUGUUGCCUGGUGGAAAGA 3334 84868_7_65 HAVCR2 Exon 7 - xp5:157086015-157086040 CGGGGACACAAAAUUCUGUUGCCUGG 3335 84868_7_66 HAVCR2 Exon 7 - xp5:157086018-157086043 UGACGGGGACACAAAAUUCUGUUGCC 3336 84868_7_67 HAVCR2 Exon 7 - xp5:157086038-157086063 UUUCACAGAAGAAGAAAGCAGUGACG 3337 84868_7_68 HAVCR2 Exon 7 - xp5:157086039-157086064 UUUUCACAGAAGAAGAAAGCAGUGAC 3338 84868_7_69 HAVCR2 Exon 7 - xp5:157086040-157086065 UUUUUCCACAGAAGAAGAAGCAGUGA 3339 84868_7_70 HAVCR2 Exon 7 - xp5:157086085-157086110 UAUCUCUGACCAACUUCUGUAUUCG 3340 84868_7_71 HAVCR2 Exon 7 - xp5:157086146-157086171 CGAAGUGCAUUUGAUUGGUGUGUAU 3341 84868_7_72 HAVCR2 Exon 7 - xp5:157086156-157086181 CAGGGAAAAACGAAGUGCAUUUGAU 3342 84868_7_73 HAVCR2 Exon 7 - xp5:157086179-157086204 GGCUGAGAUGUGGCAGGAGCUCCCA 3343 84868_7_74 HAVCR2 Exon 7 - xp5:157086180-157086205 GGGCUGAGAUGUGGCAGGAGCUCCC 3344 84868_7_75 HAVCR2 Exon 7 - xp5:157086190-157086215 CUGCCCUGCAGGGCUGAGAUGUGGC 3345 84868_7_76 HAVCR2 Exon 7 - xp5:157086194-157086219 AAGACUGCCCUGCAGGGCUGAGAUG 3346 84868_7_77 HAVCR2 Exon 7 - xp5:157086205-157086230 UCUCCCUUAUGAAGACUGCCCUGCA 3347 84868_7_78 HAVCR2 Exon 7 - xp5:157086206-157086231 GUCUCCCUUAUGAAGACUGCCCUGC 3348 84868_7_79 HAVCR2 Exon 7 - xp5:157086288-157086313 AGAUUCCCCUUGGAAUGUUGAGAUUU 3349 84868_7_80 HAVCR2 Exon 7 - xp5:157086304-157086329 UCUACCUUGAUCUUGAAGAUUCCCU 3350 84868_7_81 HAVCR2 Exon 7 - xp5:157086332-157086357 UAAAAGAUUAAGAGAUGACUGGACC 3351 84868_7_82 HAVCR2 Exon 7 - xp5:157086338-157086363 GAUCCUUAAAAGAUUAAGAGAUGAC 3352 84868_7_83 HAVCR2 Exon 7 - xp5:157086698-157086723 CUUUUUUGGCACAGAAAGUCUAAAG 3353 84868_7_84 HAVCR2 Exon 7 - xp5:157086699-157086724 ACUUUUUUGGCACAGAAAGUCUAAA 3354 84868_7_85 HAVCR2 Exon 7 - xp5:157086700-157086725 AACUUUUUUGGCACAGAAAGUCUAA 3355 84868_7_86 HAVCR2 Exon 7 - xp5:157086717-157086742 UGCUGAGGUGAAAGCAUAACUUUUU 3356 84868_7_87 HAVCR2 Exon 7 - xp5:157086737-157086762 AUAAACUAGGGAAAAACUGGGUGCUG 3357 84868_7_88 HAVCR2 Exon 7 - xp5:157086745-157086770 AACUUCAGAUAAAACUAGGGAAAACU 3358 84868_7_89 HAVCR2 Exon 7 - xp5:157086746-157086771 AAACUUCAGAUAAAACUAGGGAAAAC 3359 84868_7_90 HAVCR2 Exon 7 - xp5:157086754-157086779 UGUCCAUGAAACUUCAGAUAAACUA 3360 84868_7_91 HAVCR2 Exon 7 - xp5:157086755-157086780 AUGUCCAUGAAACUUCAGAUAAACCU 3361 84868_7_92 HAVCR2 Exon 7 - xp5:157086791-157086816 GGGUCUCUGGAGCUCCAGGAAAUUC 3362 84868_7_93 HAVCR2 Exon 7 - xp5:157086792-157086817 GGGGUCUCUGGAGCUCCAGGAAAUU 3363 84868_7_94 HAVCR2 Exon 7 - xp5:157086800-157086825 CUUGACGUGGGGUCUCUGGAGCUCC 3364 84868_7_95 HAVCR2 Exon 7 - xp5:157086809-157086834 CUAGGAAUUCUUGACGUGGGGUCUC 3365 84868_7_96 HAVCR2 Exon 7 - xp5:157086816-157086841 AUAUACACUAGGAAUUCUUGACGUG 3366 84868_7_97 HAVCR2 Exon 7 - xp5:157086817-157086842 UAUAUACACUAGGAAUUCUUGACGU 3367 84868_7_98 HAVCR2 Exon 7 - xp5:157086818-157086843 UUAUAUACACUAGGAAUUCUUGACG 3368 84868_7_99 HAVCR2 Exon 7 - xp5:157086832-157086857 GCUCAAACGGGCUUUUAUAUACACU 3369 84868_7_100 HAVCR2 Exon 7 - xp5:157086849-157086874 UAAUCAUGGAUGUUAGAGCUCAAAC 3370 84868_7_101 HAVCR2 Exon 7 - xp5:157086850-157086875 UUAAUCAUGGAUGUUAGAGCUCAAA 3371 84868_7_102 HAVCR2 Exon 7 - xp5:157086868-157086893 UACCCAACCCAGAGACUGUUAAUCA 3372 84868_7_103 HAVCR2 Exon 7 - xp5:157086930-157086955 ACUGGGACCUGCACUGAACUUAAAC 3373 84868_7_104 HAVCR2 Exon 7 - xp5:157086952-157086977 UAAUGACUCACAUGGGAAUUGACU 3374 84868_7_105 HAVCR2 Exon 7 - xp5:157086953-157086978 AUAAUGACUCACAUGGGAAUUGAAC 3375 84868_7_106 HAVCR2 Exon 7 - xp5:157086964-157086989 AUUUUCAGAAGAUAAUGACUCACAU 3376 84868_7_107 HAVCR2 Exon 7 - xp5:157086965-157086990 CAUUUUCAGAAGAUAAUGACUCACA 3377 84868_7_108 HAVCR2 Exon 7 - xp5:157087006-157087031 GUUUUGGAGGUUCUGUCCCACUGCUA 3378 84868_7_109 HAVCR2 Exon 7 - xp5:157087024-157087049 AGCUGUGUCACCUGACUGGUUUUGG 3379 84868_7_110 HAVCR2 Exon 7 - xp5:157087027-157087052 AUGAGCUGUGUCACCUGACUGGUUU 3380 84868_7_111 HAVCR2 Exon 7 - xp5:157087033-157087058 GAAACUAUGAGCUGUGUGUCACCUGAC 3381 84868_7_112 HAVCR2 Exon 7 - xp5:157087077-157087102 GAUCCAACCACCUUAUUUUUGAGCU 3382 84868_7_113 HAVCR2 Exon 7 - xp5:157087126-157087151 GCAGGCAGCAACCCCUCAACCUUU 3383 84868_7_114 HAVCR2 Exon 7 - xp5:157087127-157087152 AGCAGGCAGCAACCCCUCACAACCUU 3384 84868_7_115 HAVCR2 Exon 7 - xp5:157087149-157087174 UGAGUAUUAUUGCUAUGUCAGCAGC 3385 84868_7_116 HAVCR2 Exon 7 - xp5:157087184-157087209 AUUGAAGAGAACGUAUAUGAAGUGG 3386 84868_7_117 HAVCR2 Exon 7 - xp5:157087187-157087212 ACCAUUGAAGAGACGUAUAUGAAG 3387 84868_7_118 HAVCR2 Exon 7 - xp5:157087240-157087265 CAGGAUUGGCAAAUGCAGUAGCAGA 3388 84868_7_119 HAVCR2 Exon 7 - xp5:157087241-157087266 UCAGGAUUGGCAAAUGCAGUAGCAG 3389 84868_7_120 HAVCR2 Exon 7 - xp5:157087259-157087284 UUGGCCAACCUCCCUCCUCACAGGAU 3390 84868_7_121 HAVCR2 Exon 7 - xp5:157087264-157087289 UCUCUUUGGCCAACCUCCCUCCUCUC 3391 84868_7_122 HAVCR2 Exon 7 - xp5:157087283-157087308 CUUUAUUUCCACAGCCUCAUCUCUU 3392 84868_6_1 HAVCR2 Exon 6 + xp5:157088958-157088983 UCUUUGCUAUGAGAAUACCCUAGUA 3393 84868_6_2 HAVCR2 Exon 6 + xp5:157088959-157088984 CUUUGCUAUGAGAAUACCCUAGUAA 3394 84868_6_3 HAVCR2 Exon 6 + xp5:157088960-157088985 UUUGCUAUGAGAAUACCCUAGUAAG 3395 84868_6_4 HAVCR2 Exon 6 + xp5:157088961-157088986 UUGCUAUGAGAAUACCCUAGUAAGG 3396 84868_6_5 HAVCR2 Exon 6 - xp5:157088918-157088943 AAGGUAAGAAUAAUGGAAUGGGGUU 3397 84868_6_6 HAVCR2 Exon 6 - xp5:157088919-157088944 UAAGGUAAGAAUAAUGGAAUGGGGU 3398 84868_6_7 HAVCR2 Exon 6 - xp5:157088923-157088948 AAUUUAAGGUAAGAAUAAUGGAAUG 3399 84868_6_8 HAVCR2 Exon 6 - xp5:157088924-157088949 GAAUUUAAGGUAAGAAUAAUGGAAU 3400 84868_6_9 HAVCR2 Exon 6 - xp5:157088925-157088950 AGAAUUUAAGGUAAGAAUAAUGGAA 3401 84868_6_10 HAVCR2 Exon 6 - xp5:157088930-157088955 GAUACAGAAUUUAAGGUAAGAAUAA 3402 84868_6_11 HAVCR2 Exon 6 - xp5:157088942-157088967 UAGCAAAGAGAAGAUACAGAAUUUA 3403 84868_5_1 HAVCR2 Exon 5 + xp5:157095361-157095386 GCUCCGAUGUAGAUGCCUAUUCUGA 3404 84868_5_2 HAVCR2 Exon 5 + xp5:157095388-157095413 GUUGCUCCAGAGUCCCGUAAGUCAU 3405 84868_5_3 HAVCR2 Exon 5 + xp5:157095415-157095440 GCCAAUCUAGAGUCCCGUAACUCAU 3406 84868_5_4 HAVCR2 Exon 5 + xp5:157095424-157095449 GAGUCCCGUAACUCAUUGGCCAAUG 3407 84868_5_5 HAVCR2 Exon 5 + xp5:157095437-157095462 CAUUGGCCAAUGUGGAUAUUUGCUA 3408 84868_5_6 HAVCR2 Exon 5 + xp5:157095450-157095475 GGAUAUUUGCUAUGGAAAACACAAAC 3409 84868_5_7 HAVCR2 Exon 5 - xp5:157095325-157095350 CUGGGCUGGCUCUGGCUCUUAUCUU 3410 84868_5_8 HAVCR2 Exon 5 - xp5:157095338-157095363 GCAGGGAUCUGUGCUGGGCUGGCUC 3411 84868_5_9 HAVCR2 Exon 5 - xp5:157095344-157095369 AUCGGAGCAGGGAUCUGUGCUGGGC 3412 84868_5_10 HAVCR2 Exon 5 - xp5:157095348-157095373 CUACAUCGGAGCAGGGAUCUGUGCU 3413 84868_5_11 HAVCR2 Exon 5 - xp5:157095349-157095374 UCUACAUCGGAGCAGGGAUCUGUGC 3414 84868_5_12 HAVCR2 Exon 5 - xp5:157095360-157095385 CAGAAUAGGCAUCUACAUCGGAGCA 3415 84868_5_13 HAVCR2 Exon 5 - xp5:157095361-157095386 UCAGAAUAGGCAUCUACAUCGGAGC 3416 84868_5_14 HAVCR2 Exon 5 - xp5:157095367-157095392 CAACCAUCAGAAUAGGCAUCUACAU 3417 84868_5_15 HAVCR2 Exon 5 - xp5:157095379-157095404 GGGACUCUGGAGCAACCAUCAGAAU 3418 84868_5_16 HAVCR2 Exon 5 - xp5:157095397-157095422 GAUUGGCCAAUGACUUACGGGACUC 3419 84868_5_17 HAVCR2 Exon 5 - xp5:157095404-157095429 GACUCUAGAUUGGCCAAUGACUUAC 3420 84868_5_18 HAVCR2 Exon 5 - xp5:157095405-157095430 GGACUCUAGAUUGGCCAAUGACUUA 3421 84868_5_19 HAVCR2 Exon 5 - xp5:157095419-157095444 GCCAAUGAGUUACGGGACUCUAGAU 3422 84868_5_20 HAVCR2 Exon 5 - xp5:157095431-157095456 AUAUCCACAUUGGCCAAUGAGUUAC 3423 84868_5_21 HAVCR2 Exon 5 - xp5:157095432-157095457 AAUAUCCACAUUGGCCAAUGAGUUA 3424 84868_5_22 HAVCR2 Exon 5 - xp5:157095446-157095471 GUGUUUCCAUAGCAAAUAUCCACAU 3425 84868_4_1 HAVCR2 Exon 4 + xp5:157098847-157098872 AGUUACUUACUGUUAGAUUUAUAUC 3426 84868_4_2 HAVCR2 Exon 4 + xp5:157098848-157098873 GUUACUUACUGUUAGAUUUAUAUCA 3427 84868_4_3 HAVCR2 Exon 4 + xp5:157098851-157098876 ACUUACUGUUAGAUUUAUAUCAGGG 3428 84868_4_4 HAVCR2 Exon 4 - xp5:157098884-157098909 UUUUAUAGCAGAGACACAGACACUG 3429 84868_4_5 HAVCR2 Exon 4 - xp5:157098885-157098910 AUUUUAUAGCAGAGACACAGACACU 3430 84868_4_6 HAVCR2 Exon 4 - xp5:157098886-157098911 GAUUUUAUAGCAGAGACACAGACAC 3431 84868_3_1 HAVCR2 Exon 3 + xp5:157104641-157104666 CUCCUCUGCCCCAUGCAUAGUUACC 3432 84868_3_2 HAVCR2 Exon 3 + xp5:157104642-157104667 UCCUCUGCCCCAUGCAUAGUUACCU 3433 84868_3_3 HAVCR2 Exon 3 + xp5:157104655-157104680 GCAUAGUUACCUGGGCCAUGUCCCC 3434 84868_3_4 HAVCR2 Exon 3 + xp5:157104658-157104683 UAGUUACCUGGGCCAUGUCCCCCUGG 3435 84868_3_5 HAVCR2 Exon 3 + xp5:157104671-157104696 CAUGUCCCCCUGGUGGUAAGCAUCCU 3436 84868_3_6 HAVCR2 Exon 3 + xp5:157104676-157104701 CCCCUGGUGGUAAGCAUCCUUGGAA 3437 84868_3_7 HAVCR2 Exon 3 + xp5:157104704-157104729 CUGCAGUGAAGCUCUCUGCCGAGU 3438 84868_3_8 HAVCR2 Exon 3 + xp5:157104710-157104735 UGAAGUCCUCUGCCGAGUCGGUGC 3439 84868_3_9 HAVCR2 Exon 3 + xp5:157104711-157104736 GAAGUCUCUCUGCCGAGUCGGUGCA 3440 84868_3_10 HAVCR2 Exon 3 + xp5:157104712-157104737 AAGUCUCUCUGCCGAGUCGGUGCAG 3441 84868_3_11 HAVCR2 Exon 3 + xp5:157104721-157104746 UGCCGAGUCGGUGCAGGGGUGACCU 3442 84868_3_12 HAVCR2 Exon 3 + xp5:157104744-157104769 CUUGGCUAAUGUCAGAAACAACUA 3443 84868_3_13 HAVCR2 Exon 3 - xp5:157104643-157104668 CAGGUAACUAUGCAUGGGGCAGAGG 3444 84868_3_14 HAVCR2 Exon 3 - xp5:157104646-157104671 GCCCAGGUAACUAUGCAUGGGGCAG 3445 84868_3_15 HAVCR2 Exon 3 - xp5:157104652-157104677 GACAUGGCCCAGGUAACUAUGCAUG 3446 84868_3_16 HAVCR2 Exon 3 - xp5:157104653-157104678 GGACAUGGCCCAGGUAACUAUGCAU 3447 84868_3_17 HAVCR2 Exon 3 - xp5:157104654-157104679 GGGACAUGGCCCAGGUAACUAUGCA 3448 84868_3_18 HAVCR2 Exon 3 - xp5:157104667-157104692 UGCUUACCACCAGGGGACAUGGCCC 3449 84868_3_19 HAVCR2 Exon 3 - xp5:157104673-157104698 CAAGGAUGCUUACCACCAGGGGACA 3450 84868_3_20 HAVCR2 Exon 3 - xp5:157104679-157104704 CCUUUCCAAGGAUGCUUACCACCAG 3451 84868_3_21 HAVCR2 Exon 3 - xp5:157104680-157104705 GCCUUUCCAAGGAUGCUUACCACCA 3452 84868_3_22 HAVCR2 Exon 3 - xp5:157104681-157104706 AGCCUUUCCAAGGAUGCUUACCACC 3453 84868_3_23 HAVCR2 Exon 3 - xp5:157104696-157104721 GAGAGACUUCACUGCAGCCUUUCCA 3454 84868_3_24 HAVCR2 Exon 3 - xp5:157104726-157104751 AGCCAAGGUCACCCCUGCACCGACU 3455 84868_3_25 HAVCR2 Exon 3 - xp5:157104746-157104771 CUUAUGUUGUUUCUGACAUUAGCCA 3456 84868_2_1 HAVCR2 Exon 2 + xp5:157106602-157106627 GAUGGCAUGCAAAUGUCCCACUCACC 3457 84868_2_2 HAVCR2 Exon 2 + xp5:157106621-157106646 CUCACCUGGUUUGAUGACCAACUUC 3458 84868_2_3 HAVCR2 Exon 2 + xp5:157106650-157106675 UAAAUUUUCAUCAUUCAUUAUGCC 3459 84868_2_4 HAVCR2 Exon 2 + xp5:157106651-157106676 AAAUUUUUCAUCAUUCAUUAUGCCU 3460 84868_2_5 HAVCR2 Exon 2 + xp5:157106657-157106682 UUCAUUCAUUCAUUAUGCCUGGGAUU 3461 84868_2_6 HAVCR2 Exon 2 + xp5:157106663-157106688 AUUCAUUAUGCCUGGGAUUUGGAUC 3462 84868_2_7 HAVCR2 Exon 2 + xp5:157106706-157106731 CUGUCUGCUAGAGUCACAUUCUCUA 3463 84868_2_8 HAVCR2 Exon 2 + xp5:157106711-157106736 UGCUAGAGUCACAUUCUCUAUGGUC 3464 84868_2_9 HAVCR2 Exon 2 + xp5:157106712-157106737 GCUAGAGUCACAUUCUCUAUGGUCA 3465 84868_2_10 HAVCR2 Exon 2 + xp5:157106729-157106754 UAUGGUCAGGGACACAUCUCCUUUG 3466 84868_2_11 HAVCR2 Exon 2 + xp5:157106754-157106779 CGGAAAUCCCCAUUUAGCCAGUAUC 3467 84868_2_12 HAVCR2 Exon 2 + xp5:157106818-157106843 GCACCACGUUGCCACAUUCAAACAC 3468 84868_2_13 HAVCR2 Exon 2 + xp5:157106823-157106848 ACGUUGCCACAUUCAAACACAGGAC 3469 84868_2_14 HAVCR2 Exon 2 + xp5:157106844-157106869 GGACAGGCUCCUUUGCCCCAGCAGA 3470 84868_2_15 HAVCR2 Exon 2 + xp5:157106845-157106870 GACAGGCUCCUUUGCCCCAGCAGAC 3471 84868_2_16 HAVCR2 Exon 2 + xp5:157106852-157106877 UCCUUUGCCCCAGCAGACGGGCACG 3472 84868_2_17 HAVCR2 Exon 2 + xp5:157106860-157106885 CCCAGCAGACGGGCACGAGGUUCCC 3473 84868_2_18 HAVCR2 Exon 2 + xp5:157106861-157106886 CCAGCAGACGGGCACGAGGUUCCCU 3474 84868_2_19 HAVCR2 Exon 2 + xp5:157106862-157106887 CAGCAGACGGGCACGAGGUUCCCUG 3475 84868_2_20 HAVCR2 Exon 2 + xp5:157106865-157106890 CAGACGGGCACGAGGUUCCCUGGGG 3476 84868_2_21 HAVCR2 Exon 2 + xp5:157106869-157106894 CGGGCACGAGGUUCCCUGGGGCGGC 3477 84868_2_22 HAVCR2 Exon 2 + xp5:157106870-157106895 GGGCACGAGGUUCCCUGGGGCGGCU 3478 84868_2_23 HAVCR2 Exon 2 + xp5:157106871-157106896 GGCACGAGGUUCCCUGGGGCGGCUG 3479 84868_2_24 HAVCR2 Exon 2 + xp5:157106883-157106908 CCUGGGGCGGCUGGGGUGUAGAAGC 3480 84868_2_25 HAVCR2 Exon 2 + xp5:157106884-157106909 CUGGGGCGGCUGGGGUGUAGAAAGCA 3481 84868_2_26 HAVCR2 Exon 2 + xp5:157106892-157106917 GCUGGGGUGUAGAAGCAGGGCAGAU 3482 84868_2_27 HAVCR2 Exon 2 + xp5:157106931-157106956 ACCUCCGCUCUGUAUUCCACUUCUG 3483 84868_2_28 HAVCR2 Exon 2 + xp5:157106952-157106977 UCUGAGGACCCUGCAUAGAGAGAGA 3484 84868_2_29 HAVCR2 Exon 2 - xp5:157106621-157106646 GAAGUUGGUCAAUCAAACCAGGUGAG 3485 84868_2_30 HAVCR2 Exon 2 - xp5:157106628-157106653 UUAACCUGAAGUUGGUCAUCAAACC 3486 84868_2_31 HAVCR2 Exon 2 - xp5:157106641-157106666 AAUGAUGAAAAAAUUUAACCUGAGU 3487 84868_2_32 HAVCR2 Exon 2 - xp5:157106676-157106701 UCUACUGCUGCCGGAUCCAAAUCCC 3488 84868_2_33 HAVCR2 Exon 2 - xp5:157106690-157106715 AGCAGACAGUGGGAUCUACUGCUGC 3489 84868_2_34 HAVCR2 Exon 2 - xp5:157106705-157106730 AGAGAAUGUGACUCUAGCAGACAGU 3490 84868_2_35 HAVCR2 Exon 2 - xp5:157106706-157106731 UAGAGAAUGUGACUCUAGCAGACAG 3491 84868_2_36 HAVCR2 Exon 2 - xp5:157106751-157106776 ACUGGCUAAAUGGGGAUUUCCGCAA 3492 84868_2_37 HAVCR2 Exon 2 - xp5:157106764-157106789 UGGACAUCCAGAUACUGGCUAAAUG 3493 84868_2_38 HAVCR2 Exon 2 - xp5:157106765-157106790 UUGGACAUCCAGAUACUGGCUAAAU 3494 84868_2_39 HAVCR2 Exon 2 - xp5:157106766-157106791 AUUGGACAUCCAGAUACUGGCUAAA 3495 84868_2_40 HAVCR2 Exon 2 - xp5:157106774-157106799 UGUGAAUUAUUGGACAUCCAGAAUAC 3496 84868_2_41 HAVCR2 Exon 2 - xp5:157106789-157106814 GACUGAUGAAAGGGAUGUGAAUUAU 3497 84868_2_42 HAVCR2 Exon 2 - xp5:157106803-157106828 AACGUGGUGCUCAGGACUGAUGAAA 3498 84868_2_43 HAVCR2 Exon 2 - xp5:157106804-157106829 CAACGUGGUGCUCAGGACUGAUGAA 3499 84868_2_44 HAVCR2 Exon 2 - xp5:157106816-157106841 GUUUGAAUGUGGCAACGUGGUGCUC 3500 84868_2_45 HAVCR2 Exon 2 - xp5:157106824-157106849 UGUCCUGUGUUUGAAUGUGGCAACG 3501 84868_2_46 HAVCR2 Exon 2 - xp5:157106832-157106857 AAGGAGCCUGUCCUGUGUUUGAAUG 3502 84868_2_47 HAVCR2 Exon 2 - xp5:157106856-157106881 ACCUCGUGCCCGUCUGCUGGGGCAA 3503 84868_2_48 HAVCR2 Exon 2 - xp5:157106862-157106887 CAGGGAACCUCGUGCCCGUCUGCUG 3504 84868_2_49 HAVCR2 Exon 2 - xp5:157106863-157106888 CCAGGGAACCUCGUGCCCGUCUGCU 3505 84868_2_50 HAVCR2 Exon 2 - xp5:157106864-157106889 CCCAGGGAACCUCGUGCCCGUCUGC 3506 84868_2_51 HAVCR2 Exon 2 - xp5:157106885-157106910 CUGCUUCUACACCCCAGCCGCCCCA 3507 84868_2_52 HAVCR2 Exon 2 - xp5:157106886-157106911 CCUGCUUCUACACCCCAGCCGCCCC 3508 84868_2_53 HAVCR2 Exon 2 - xp5:157106931-157106956 CAGAAGUGGAAUACAGAGCGGAGGU 3509 84868_2_54 HAVCR2 Exon 2 - xp5:157106935-157106960 UCCUCAGAAGUGGAAUACAGAGCGG 3510 84868_2_55 HAVCR2 Exon 2 - xp5:157106938-157106963 GGGUCCUCAGAAGUGGAAUACAGAG 3511 84868_2_56 HAVCR2 Exon 2 - xp5:157106950-157106975 UCUCUCUAUGCAGGGUCCUCCAGAAG 3512 84868_1_1 HAVCR2 Exon 1 + xp5:157108939-157108964 AGCAGCAGCAGCAGGACACAGUCAA 3513 84868_1_2 HAVCR2 Exon 1 + xp5:157108940-157108965 GCAGCAGCAGCAGGACACAGUCAAA 3514 84868_1_3 HAVCR2 Exon 1 + xp5:157108957-157108982 CAGUCAAAGGGAAGAUGUGAAAAACA 3515 84868_1_4 HAVCR2 Exon 1 + xp5:157108981-157109006 AUGGAGCUUGCAGAAGAAAAGUCAG 3516 84868_1_5 HAVCR2 Exon 1 + xp5:157108995-157109020 AGAAAAGUCAGAGGACACCUCUGUU 3517 84868_1_6 HAVCR2 Exon 1 + xp5:157109018-157109043 UUAGGCACAGUUUUAACUCUCCAAA 3518 84868_1_7 HAVCR2 Exon 1 + xp5:157109023-157109048 CACAGUUUUAACCUCUCCAAAUGGAC 3519 84868_1_8 HAVCR2 Exon 1 + xp5:157109024-157109049 ACAGUUUUAACCUCUCCAAAUGGACU 3520 84868_1_9 HAVCR2 Exon 1 + xp5:157109100-157109125 CCACUGAGUGCUAGCUCAGCACACC 3521 84868_1_10 HAVCR2 Exon 1 + xp5:157109101-157109126 CACUGAGUGCUAGCUCAGCACACCC 3522 84868_1_11 HAVCR2 Exon 1 + xp5:157109140-157109165 CAGUGAUUCUUAUAGUAACACUGCC 3523 84868_1_12 HAVCR2 Exon 1 + xp5:157109159-157109184 ACUGCCAGGUCUACAGUCACAUUAA 3524 84868_1_13 HAVCR2 Exon 1 - xp5:157108917-157108942 CGACGAUGAUGAUACAAGUAAGUCU 3525 84868_1_14 HAVCR2 Exon 1 - xp5:157109015-157109040 GGAGAGUUAAAAACUGUGCCUAACAG 3526 84868_1_15 HAVCR2 Exon 1 - xp5:157109041-157109066 AGUUGGAAGAAGUACCCAGUCCAUU 3527 84868_1_16 HAVCR2 Exon 1 - xp5:157109063-157109088 CUCAUGUGAUUGUGGAGUAGACGU 3528 84868_1_17 HAVCR2 Exon 1 - xp5:157109076-157109101 GGGGCGGCUACUGCUCAUGUGAUUG 3529 84868_1_18 HAVCR2 Exon 1 - xp5:157109097-157109122 GUGCUGAGCUAGCACUCAGUGGGGG 3530 84868_1_19 HAVCR2 Exon 1 - xp5:157109100-157109125 GGUGUGCUGAGCUAGCACUCAGUGG 3531 84868_1_20 HAVCR2 Exon 1 - xp5:157109101-157109126 GGGUGUGCUGAGCUAGCACUCAGUG 3532 84868_1_21 HAVCR2 Exon 1 - xp5:157109102-157109127 CGGGUGUGCUGAGCUAGCACUCAGU 3533 84868_1_22 HAVCR2 Exon 1 - xp5:157109103-157109128 CCGGGUGUGCUGAGCUAGCACUCAG 3534 84868_1_23 HAVCR2 Exon 1 - xp5:157109126-157109151 AAGAAUCACUGGCAAUCAGACACCC 3535 84868_1_24 HAVCR2 Exon 1 - xp5:157109127-157109152 UAAGAAUCACUGGCAAUCAGACACC 3536 84868_1_25 HAVCR2 Exon 1 - xp5:157109142-157109167 CUGGCAGUGUUACUAUAAGAAUCAC 3537 84868_1_26 HAVCR2 Exon 1 - xp5:157109166-157109191 GUUUCCUUUAAUGUGACUGUAGAC 3538 84868_1_27 HAVCR2 Exon 1 - xp5:157109193-157109218 UGUAGUGUGGCAUGACAGAGAACUU 3539 84868_1_28 HAVCR2 Exon 1 - xp5:157109211-157109236 GAACACUUACAGGAUGUGUGUAGGUG 3540 84868_1_29 HAVCR2 Exon 1 - xp5:157109226-157109251 ACAGGACAGACAUCAGAAACCUUAC 3541 3902_1_1 LAG3 Exon 1 + xp12:6772480-6772505 GGAAGGUGGAGGGAAGGCCGGGCAC 3542 3902_1_2 LAG3 Exon 1 + xp12:6772481-6772506 GAAGGUGGAGGGAAGGCCGGGCACA 3543 3902_1_3 LAG3 Exon 1 + xp12:6772482-6772507 AAGGUGGAGGGAAGGCCGGGCACAG 3544 3902_1_4 LAG3 Exon 1 + xp12:6772488-6772513 GAGGGAAGGCCGGGCACAGGGGUGA 3545 3902_1_5 LAG3 Exon 1 + xp12:6772508-6772533 GGUGAAGGCCCAGAGACCAGCAGAA 3546 3902_1_6 LAG3 Exon 1 + xp12:6772525-6772550 CAGCAGAACGGCAUCCCAGCCACGA 3547 3902_1_7 LAG3 Exon 1 + xp12:6772555-6772580 ACUUUGCUCUGUCUGCUCUCCGCCA 3548 3902_1_8 LAG3 Exon 1 + xp12:6772573-6772598 UCCGCCACGGCCCUGCUCUGUUCCC 3549 3902_1_9 LAG3 Exon 1 + xp12:6772574-6772599 CCGCCACGGCCCUGCUCUGUUCCCU 3550 3902_1_10 LAG3 Exon 1 + xp12:6772599-6772624 GGGACACCCCCCGCCCCCACCUCCUC 3551 3902_1_11 LAG3 Exon 1 + xp12:6772635-6772660 UCUGCCCAGCUUUCCAGCUUUCCUC 3552 3902_1_12 LAG3 Exon 1 + xp12:6772642-6772667 AGCUUUCCAGCUUUCCUCUGGAUUC 3553 3902_1_13 LAG3 Exon 1 + xp12:6772649-6772674 CAGCUUUCCUCUGGAUUCCGGCCUC 3554 3902_1_14 LAG3 Exon 1 + xp12:6772676-6772701 GUCAUCCCUCCCCACCCUCUCUCCA 3555 3902_1_15 LAG3 Exon 1 + xp12:6772687-6772712 CCACCCUCUCUCCAAGGCCCUCUCC 3556 3902_1_16 LAG3 Exon 1 + xp12:6772793-6772818 CCCCUUUCCUUUUCUGACCUCCUUU 3557 3902_1_17 LAG3 Exon 1 + xp12:6772796-6772821 CUUUCCUUUUCUGACCUCCUUUUGG 3558 3902_1_18 LAG3 Exon 1 + xp12:6772797-6772822 UUUCCUUUUCUGACCUCCUUUUGGA 3559 3902_1_19 LAG3 Exon 1 + xp12:6772820-6772845 GAGGGCUCAGCGCUGCCCAGACCAU 3560 3902_1_20 LAG3 Exon 1 + xp12:6772830-6772855 CGCUGCCCCAGACCAUAGGAGAGAUG 3561 3902_1_21 LAG3 Exon 1 + xp12:6772831-6772856 GCUGCCCAGACCAUAGGAGAGAUGU 3562 3902_1_22 LAG3 Exon 1 + xp12:6772834-6772859 GCCCAGACCAUAGGAGAGAUGUGGG 3563 3902_1_23 LAG3 Exon 1 + xp12:6772846-6772871 GGAGAGAUGUGGGAGGCUCAGUUCC 3564 3902_1_24 LAG3 Exon 1 + xp12:6772847-6772872 GAGAGAUGUGGGAGGCUCAGUUCCU 3565 3902_1_25 LAG3 Exon 1 + xp12:6772872-6772897 GGGCUUGCUGUUUCUGCAGCCGCUU 3566 3902_1_26 LAG3 Exon 1 + xp12:6772873-6772898 GGCUUGCUGUUUCUGCAGCCGCUUU 3567 3902_1_27 LAG3 Exon 1 + xp12:6772876-6772901 UUGCUGUUUCUGCAGCCGCUUUGGG 3568 3902_1_28 LAG3 Exon 1 + xp12:6772883-6772908 UUCUGCAGCCGCUUUGGGUGGCUCC 3569 3902_1_29 LAG3 Exon 1 + xp12:6772891-6772916 CCGCUUUGGGUGGCUCCAGGUAAAA 3570 3902_1_30 LAG3 Exon 1 + xp12:6772892-6772917 CGCUUUGGGUGGCUCCAGGUAAAAAC 3571 3902_1_31 LAG3 Exon 1 + xp12:6772893-6772918 GCUUUGGGUGGCUCCAGGUAAAACG 3572 3902_1_32 LAG3 Exon 1 + xp12:6772897-6772922 UGGGUGGCUCCAGGUAAAACGGGGA 3573 3902_1_33 LAG3 Exon 1 + xp12:6772900-6772925 GUGGCUCCAGGUAAAACGGGGAUGG 3574 3902_1_34 LAG3 Exon 1 + xp12:6772901-6772926 UGGCUCCAGGUAAAACGGGGAUGGC 3575 3902_1_35 LAG3 Exon 1 + xp12:6772904-6772929 CUCCAGGUAAAACGGGGAUGGCGGG 3576 3902_1_36 LAG3 Exon 1 + xp12:6772905-6772930 UCCAGGUAAAACGGGGAUGGCGGGA 3577 3902_1_37 LAG3 Exon 1 - xp12:6772500-6772525 GUCUCUGGGCCUUCACCCCUGUGCC 3578 3902_1_38 LAG3 Exon 1 - xp12:6772519-6772544 CUGGGAUGCCGUUCUGCUGGUCUCU 3579 3902_1_39 LAG3 Exon 1 - xp12:6772520-6772545 GCUGGGAUGCCGUUCUGCUGGUCUC 3580 3902_1_40 LAG3 Exon 1 - xp12:6772527-6772552 CGUCGUGGCUGGGAUGCCGUUCUGC 3581 3902_1_41 LAG3 Exon 1 - xp12:6772542-6772567 ACAGAGCAAAGUGGCCGUCGUGGCU 3582 3902_1_42 LAG3 Exon 1 - xp12:6772543-6772568 GACAGAGCAAAGUGGCCGUCGUGGC 3583 3902_1_43 LAG3 Exon 1 - xp12:6772547-6772572 AGCAGACAGAGCAAAGUGGCCGUCG 3584 3902_1_44 LAG3 Exon 1 - xp12:6772556-6772581 GUGGCGGAGAGCAGACAGCAAAG 3585 3902_1_45 LAG3 Exon 1 - xp12:6772577-6772602 CCCAGGGAACAGAGCAGGGCCGUGG 3586 3902_1_46 LAG3 Exon 1 - xp12:6772580-6772605 UGUCCCAGGGAACAGAGCAGGGCCG 3587 3902_1_47 LAG3 Exon 1 - xp12:6772586-6772611 CGGGGGUGUCCCAGGGAACAGAGCA 3588 3902_1_48 LAG3 Exon 1 - xp12:6772587-6772612 GCGGGGGUGUGCCCAGGGAACAGAGGC 3589 3902_1_49 LAG3 Exon 1 - xp12:6772598-6772623 AGGAGGUGGGGGCGGGGGUGUCCCA 3590 3902_1_50 LAG3 Exon 1 - xp12:6772599-6772624 GAGGAGGUGGGGGCGGGGGUGUCCC 3591 3902_1_51 LAG3 Exon 1 - xp12:6772608-6772633 AGGCAGCCCUGAGGAGGUGGGGGCGG 3592 3902_1_52 LAG3 Exon 1 - xp12:6772609-6772634 CAGGCAGCCCUGAGGAGGUGGGGGCG 3593 3902_1_53 LAG3 Exon 1 - xp12:6772610-6772635 UCAGGCAGCCCUGAGGAGGUGGGGGC 3594 3902_1_54 LAG3 Exon 1 - xp12:6772611-6772636 AUCAGGCAGCCUGAGGAGGUGGGGG 3595 3902_1_55 LAG3 Exon 1 - xp12:6772614-6772639 CAGAUCAGGCAGCCUGAGGAGGUGG 3596 3902_1_56 LAG3 Exon 1 - xp12:6772615-6772640 GCAGAUCAGGCAGCCUGAGGAGGUG 3597 3902_1_57 LAG3 Exon 1 - xp12:6772616-6772641 GGCAGAUCAGGCAGCCUGAGGAGGU 3598 3902_1_58 LAG3 Exon 1 - xp12:6772617-6772642 GGGCAGAUCAGGCAGCCUGAGGAGG 3599 3902_1_59 LAG3 Exon 1 - xp12:6772620-6772645 GCUGGGCAGAUCAGGCAGCCUGAGG 3600 3902_1_60 LAG3 Exon 1 - xp12:6772623-6772648 AAAGCUGGGCAGAUCAGGCAGCCUG 3601 3902_1_61 LAG3 Exon 1 - xp12:6772633-6772658 GGAAAAGCUGGAAAGCUGGGCAGAUC 3602 3902_1_62 LAG3 Exon 1 - xp12:6772642-6772667 GAAUCCAGAGGAAAAGCUGGAAAGCU 3603 3902_1_63 LAG3 Exon 1 - xp12:6772643-6772668 GGAAUCCAGAGGAAAAGCUGGAAAGC 3604 3902_1_64 LAG3 Exon 1 - xp12:6772651-6772676 CAGAGGCCGGAAUCCAGAGGAAAGC 3605 3902_1_65 LAG3 Exon 1 - xp12:6772659-6772684 GGGAUGACCAGAGGCCGGAAUCCAG 3606 3902_1_66 LAG3 Exon 1 - xp12:6772669-6772694 AGGGUGGGGAGGGAUGACCAGAGGC 3607 3902_1_67 LAG3 Exon 1 - xp12:6772673-6772698 AGAGAGGGUGGGGAGGGAUGACCAG 3608 3902_1_68 LAG3 Exon 1 - xp12:6772684-6772709 GAGGGCCUUGGAGAGAGGGUGGGGA 3609 3902_1_69 LAG3 Exon 1 - xp12:6772685-6772710 AGAGGGCCUUGGAGAGAGGGUGGGG 3610 3902_1_70 LAG3 Exon 1 - xp12:6772688-6772713 AGGAGAGGGCCUUGGAGAGAGGGUG 3611 3902_1_71 LAG3 Exon 1 - xp12:6772689-6772714 CAGGAGAGGGCCUUGGAGAGAGGGU 3612 3902_1_72 LAG3 Exon 1 - xp12:6772690-6772715 CCAGGAGAGGGCCUUGGAGAGAGGG 3613 3902_1_73 LAG3 Exon 1 - xp12:6772693-6772718 AGACCAGGAGAGGGCCUUGGAGAGA 3614 3902_1_74 LAG3 Exon 1 - xp12:6772694-6772719 GAGACCAGGAGAGGGCCUUGGAGAG 3615 3902_1_75 LAG3 Exon 1 - xp12:6772701-6772726 AAGAAGGGAGACCAGGAGAGGGCCU 3616 3902_1_76 LAG3 Exon 1 - xp12:6772707-6772732 UUCUAGAAGAAGGGAGACCAGGAGA 3617 3902_1_77 LAG3 Exon 1 - xp12:6772708-6772733 GUUCUAGAAGAAGGGAGACCAGGAG 3618 3902_1_78 LAG3 Exon 1 - xp12:6772713-6772738 AAGGGGUUCUAGAAGAAGGGAGACC 3619 3902_1_79 LAG3 Exon 1 - xp12:6772721-6772746 GGUGGAGGAAGGGGUUCUAGAAGAA 3620 3902_1_80 LAG3 Exon 1 - xp12:6772722-6772747 AGGUGGAGGAAGGGGUUCUAGAGA 3621 3902_1_81 LAG3 Exon 1 - xp12:6772735-6772760 UCUGCAGAGAGGGAGGUGGAGGAAG 3622 3902_1_82 LAG3 Exon 1 - xp12:6772736-6772761 UUCUGCAGAGAGGGAGGUGGAGGAA 3623 3902_1_83 LAG3 Exon 1 - xp12:6772737-6772762 GUUCUGCAGAGAGGGAGGUGGAGGA 3624 3902_1_84 LAG3 Exon 1 - xp12:6772741-6772766 AGAAGUUCUGCAGAGAGGGAGGUGG 3625 3902_1_85 LAG3 Exon 1 - xp12:6772744-6772769 AGGAGAAGUCUGCAGAGAGGGAGG 3626 3902_1_86 LAG3 Exon 1 - xp12:6772747-6772772 UAAAGGAGAAGUCUGCAGAGAGGG 3627 3902_1_87 LAG3 Exon 1 - xp12:6772750-6772775 GGGUAAAGGAGAAGUUCUGCAGAGA 3628 3902_1_88 LAG3 Exon 1 - xp12:6772751-6772776 GGGGUAAAGGAGAAGUUCUGCAGAG 3629 3902_1_89 LAG3 Exon 1 - xp12:6772769-6772794 GGCAGUGGUGGGGGGUGGGGGGUAA 3630 3902_1_90 LAG3 Exon 1 - xp12:6772775-6772800 AAAGGGGGCAGUGGUGGGGGGUGGG 3631 3902_1_91 LAG3 Exon 1 - xp12:6772776-6772801 GAAAGGGGGCAGUGGUGGGGGGUGG 3632 3902_1_92 LAG3 Exon 1 - xp12:6772777-6772802 GGAAAGGGGGCAGUGGUGGGGGGUG 3633 3902_1_93 LAG3 Exon 1 - xp12:6772778-6772803 AGGAAAGGGGGCAGUGGUGGGGGGU 3634 3902_1_94 LAG3 Exon 1 - xp12:6772779-6772804 AAGGAAAGGGGGCAGUGGUGGGGGG 3635 3902_1_95 LAG3 Exon 1 - xp12:6772782-6772807 GAAAAGGAAAGGGGGCAGUGGUGGG 3636 3902_1_96 LAG3 Exon 1 - xp12:6772783-6772808 AGAAAAGGAAAGGGGGCAGUGGUGG 3637 3902_1_97 LAG3 Exon 1 - xp12:6772784-6772809 CAGAAAAGGAAAGGGGGCAGUGGUG 3638 3902_1_98 LAG3 Exon 1 - xp12:6772785-6772810 UCAGAAAAGGAAAGGGGGCAGUGGU 3639 3902_1_99 LAG3 Exon 1 - xp12:6772786-6772811 GUCAGAAAAGGAAAGGGGGCAGUGG 3640 3902_1_100 LAG3 Exon 1 - xp12:6772789-6772814 GAGGUCAGAAAAGGAAAGGGGGCAG 3641 3902_1_101 LAG3 Exon 1 - xp12:6772795-6772820 CAAAAGGAGGUCAGAAAAGGAAAGG 3642 3902_1_102 LAG3 Exon 1 - xp12:6772796-6772821 CCAAAAGGAGGUCAGAAAAGGAAAG 3643 3902_1_103 LAG3 Exon 1 - xp12:6772797-6772822 UCCAAAAGGAGGUCAGAAAAGGAAA 3644 3902_1_104 LAG3 Exon 1 - xp12:6772798-6772823 CUCCAAAAGGAGGUCAGAAAAGGAA 3645 3902_1_105 LAG3 Exon 1 - xp12:6772803-6772828 GAGCCCUCCAAAAGGAGGUCAGAAA 3646 3902_1_106 LAG3 Exon 1 - xp12:6772813-6772838 GGGCAGCGCUGAGCCCUCCAAAAGG 3647 3902_1_107 LAG3 Exon 1 - xp12:6772816-6772841 UCUGGGCAGCGCUGAGCCCUCCAAA 3648 3902_1_108 LAG3 Exon 1 - xp12:6772838-6772863 GCCUCCCACAUCUCCUAUGGUCU 3649 3902_1_109 LAG3 Exon 1 - xp12:6772839-6772864 AGCCUCCCACAUCUCUCCUAUGGUC 3650 3902_1_110 LAG3 Exon 1 - xp12:6772844-6772869 AACUGAGCCUCCCACAUCUCUCCUA 3651 3902_1_111 LAG3 Exon 1 - xp12:6772872-6772897 AAGCGGCUGCAGAAACAGCAAGCCC 3652 3902_1_112 LAG3 Exon 1 - xp12:6772894-6772919 CCGUUUUACCUGGAGCCACCCAAAG 3653 3902_1_113 LAG3 Exon 1 - xp12:6772909-6772934 ACCCUCCCGCCAUCCCCGUUUUACC 3654 3902_2_1 LAG3 Exon 2 + xp12:6773182-6773207 CUCACCUAGUGAAGCCUCUCCAGCC 3655 3902_2_2 LAG3 Exon 2 + xp12:6773183-6773208 UCACCUAGUGAAGCCUCUCCAGCCA 3656 3902_2_3 LAG3 Exon 2 + xp12:6773184-6773209 CACCUAGUGAAGCCUCUCCAGCCAG 3657 3902_2_4 LAG3 Exon 2 + xp12:6773190-6773215 GUGAAGCCUCUCCAGCCAGGGGCUG 3658 3902_2_5 LAG3 Exon 2 + xp12:6773196-6773221 CCUCUCCAGCCAGGGGCUGAGGUCC 3659 3902_2_6 LAG3 Exon 2 + xp12:6773199-6773224 CUCCAGCCAGGGGCUGAGGUCCCGG 3660 3902_2_7 LAG3 Exon 2 + xp12:6773204-6773229 GCCAGGGGCUGAGGUCCCGGUGGUG 3661 3902_2_8 LAG3 Exon 2 + xp12:6773205-6773230 CCAGGGGCUGAGGUCCCGGUGGUGU 3662 3902_2_9 LAG3 Exon 2 + xp12:6773211-6773236 GCUGAGGUCCCGGUGGUGUGGGCCC 3663 3902_2_10 LAG3 Exon 2 + xp12:6773214-6773239 GAGGUCCCGGUGGUGUGGGCCCAGG 3664 3902_2_11 LAG3 Exon 2 + xp12:6773215-6773240 AGGUCCCGGUGGUGUGGGCCCAGGA 3665 3902_2_12 LAG3 Exon 2 + xp12:6773216-6773241 GGUCCCGGUGGUGUGGGCCCAGGAG 3666 3902_2_13 LAG3 Exon 2 + xp12:6773217-6773242 GUCCCGGUGGUGUGGGCCCAGGAGG 3667 3902_2_14 LAG3 Exon 2 + xp12:6773259-6773284 CCCUGCAGCCCCCACAAUCCCCCUCC 3668 3902_2_15 LAG3 Exon 2 + xp12:6773284-6773309 AGGAUCUCAGCCUUCUGCGAAGAGC 3669 3902_2_16 LAG3 Exon 2 + xp12:6773285-6773310 GGAUCUCAGCCUUCUGCGAAGAGCA 3670 3902_2_17 LAG3 Exon 2 + xp12:6773286-6773311 GAUCUCAGCCUUCUGCGAAGAGCAG 3671 3902_2_18 LAG3 Exon 2 + xp12:6773294-6773319 CCUUCUGCGAAGAGCAGGGGUCACU 3672 3902_2_19 LAG3 Exon 2 + xp12:6773312-6773337 GGUCACUUGGCAGCAUCAGCCAGAC 3673 3902_2_20 LAG3 Exon 2 + xp12:6773330-6773355 GCCAGACAGGUAUGCACCCCAAACU 3674 3902_2_21 LAG3 Exon 2 + xp12:6773331-6773356 CCAGACAGGUAUGCACCCCAAACUU 3675 3902_2_22 LAG3 Exon 2 - xp12:6773174-6773199 AGGCUUCACUAGGUGAGCAAAAGAG 3676 3902_2_23 LAG3 Exon 2 - xp12:6773189-6773214 AGCCCCUGGCUGGAGAGGCUUCACU 3677 3902_2_24 LAG3 Exon 2 - xp12:6773199-6773224 CCGGGACCUCAGCCCCUGGCUGGAG 3678 3902_2_25 LAG3 Exon 2 - xp12:6773204-6773229 CACCACCGGGACCUCAGCCCCCUGGC 3679 3902_2_26 LAG3 Exon 2 - xp12:6773208-6773233 CCCACACCACCGGGACCUCAGCCCC 3680 3902_2_27 LAG3 Exon 2 - xp12:6773222-6773247 AGCCCCCUCCUGGCCCACACCACC 3681 3902_2_28 LAG3 Exon 2 - xp12:6773223-6773248 GAGCCCCCUCCUGGGCCCCACCAC 3682 3902_2_29 LAG3 Exon 2 - xp12:6773236-6773261 GGGAGCUGGGCAGGAGCCCCCUCCU 3683 3902_2_30 LAG3 Exon 2 - xp12:6773237-6773262 GGGGAGCUGGGCAGGAGCCCCCUCC 3684 3902_2_31 LAG3 Exon 2 - xp12:6773250-6773275 UUGUGGGGCUGCAGGGGAGCUGGGC 3685 3902_2_32 LAG3 Exon 2 - xp12:6773254-6773279 GGGAUUGUGGGGCUGCAGGGGAGCU 3686 3902_2_33 LAG3 Exon 2 - xp12:6773255-6773280 GGGGAUUGUGGGGCUGCAGGGGAGC 3687 3902_2_34 LAG3 Exon 2 - xp12:6773261-6773286 CUGGAGGGGGAUUGUGGGGCUGCAG 3688 3902_2_35 LAG3 Exon 2 - xp12:6773262-6773287 CCUGGAGGGGGAUUGUGGGGCUGCA 3689 3902_2_36 LAG3 Exon 2 - xp12:6773263-6773288 UCCUGGAGGGGGAUUGUGGGGCUGC 3690 3902_2_37 LAG3 Exon 2 - xp12:6773270-6773295 GCUGAGAUCCUGGAGGGGGAUUGUG 3691 3902_2_38 LAG3 Exon 2 - xp12:6773271-6773296 GGCUGAGAUCCUGGAGGGGGAUUGU 3692 3902_2_39 LAG3 Exon 2 - xp12:6773272-6773297 AGGCUGAGAUCCUGGAGGGGGAUUG 3693 3902_2_40 LAG3 Exon 2 - xp12:6773279-6773304 UCGCAGAAGGCUGAGAUCCUGGAGG 3694 3902_2_41 LAG3 Exon 2 - xp12:6773280-6773305 UUCGCAGAAGGCUGAGAUCCUGGAG 3695 3902_2_42 LAG3 Exon 2 - xp12:6773281-6773306 CUUCGCAGAAGGCUGAGAUCCUGGA 3696 3902_2_43 LAG3 Exon 2 - xp12:6773282-6773307 UCUUCCGCAGAAGGCUGAGAUCCUGG 3697 3902_2_44 LAG3 Exon 2 - xp12:6773285-6773310 UGCUCUUCCGCAGAAGGCUGAGAUCC 3698 3902_2_45 LAG3 Exon 2 - xp12:6773297-6773322 CCAAGUGACCCCCUGCUCUUCGCAGA 3699 3902_2_46 LAG3 Exon 2 - xp12:6773334-6773359 CCCAAGUUUGGGGUGCAUACCUGUC 3700 3902_3_1 LAG3 Exon 3 + xp12:6773671-6773696 CAACUCCAUUCUCUUUCCCGCCCAG 3701 3902_3_2 LAG3 Exon 3 + xp12:6773692-6773717 CCAGUGGCCCGCCCGCUGCCGCCCC 3702 3902_3_3 LAG3 Exon 3 + xp12:6773703-6773728 CCCGCUGCCGCCCCCGGCCAUCCCC 3703 3902_3_4 LAG3 Exon 3 + xp12:6773710-6773735 CCGCCCCCGGCCAUCCCCUGGCCCC 3704 3902_3_5 LAG3 Exon 3 + xp12:6773721-6773746 CAUCCCCUGGCCCCCGGCCCUCACC 3705 3902_3_6 LAG3 Exon 3 + xp12:6773724-6773749 CCCCUGGCCCCCGGCCCCUCACCCGG 3706 3902_3_7 LAG3 Exon 3 + xp12:6773738-6773763 CCCUCACCCGGCGGCGCCCUCCUCC 3707 3902_3_8 LAG3 Exon 3 + xp12:6773739-6773764 CCUCACCCGGCGGCGCCCCUCCUCCU 3708 3902_3_9 LAG3 Exon 3 + xp12:6773740-6773765 CUCACCCGGCGGCGCCCCUCCUCCUG 3709 3902_3_10 LAG3 Exon 3 + xp12:6773741-6773766 UCACCCGGCGGCGCCCCUCCUCCUGG 3710 3902_3_11 LAG3 Exon 3 + xp12:6773747-6773772 GGCGGCCGCCCUCCUCCUGGGGGCCC 3711 3902_3_12 LAG3 Exon 3 + xp12:6773763-6773788 UGGGGGCCCAGGCCCCGCCGCUACACA 3712 3902_3_13 LAG3 Exon 3 + xp12:6773775-6773800 CCCCGCCGCUACACGGUGCUGAGCG 3713 3902_3_14 LAG3 Exon 3 + xp12:6773776-6773801 CCCGCCGCUACACGGUGCUGAGCGU 3714 3902_3_15 LAG3 Exon 3 + xp12:6773782-6773807 GCUACACGGUGCUGAGCGUGGGUCC 3715 3902_3_16 LAG3 Exon 3 + xp12:6773785-6773810 ACACGGUGCUGAGCGUGGGUCCCGG 3716 3902_3_17 LAG3 Exon 3 + xp12:6773797-6773822 GCGUGGGUCCCGGAGGCCUGCGCAG 3717 3902_3_18 LAG3 Exon 3 + xp12:6773798-6773823 CGUGGGUCCCGGAGGCCUGCGCAGGC 3718 3902_3_19 LAG3 Exon 3 + xp12:6773801-6773826 GGGUCCCGGAGGCCUGCGCAGCGGG 3719 3902_3_20 LAG3 Exon 3 + xp12:6773829-6773854 CUGCCCCUGCAGCCCCGCGUCCAGGC 3720 3902_3_21 LAG3 Exon 3 + xp12:6773839-6773864 AGCCCCGCGUCCAGCUGGAUGAGCG 3721 3902_3_22 LAG3 Exon 3 + xp12:6773843-6773868 CCGCGUCCAGCUGGAUGAGCGCGGC 3722 3902_3_23 LAG3 Exon 3 + xp12:6773851-6773876 AGCUGGAUGAGCGCGGCCGGCAGCG 3723 3902_3_24 LAG3 Exon 3 + xp12:6773852-6773877 GCUGGAUGAGCGCGGCCGGCAGGCGC 3724 3902_3_25 LAG3 Exon 3 + xp12:6773853-6773878 CUGGAUGAGCGCGGCCGGCAGCGCG 3725 3902_3_26 LAG3 Exon 3 + xp12:6773867-6773892 CCGGCAGCGCGGGGACUUCUCGCUA 3726 3902_3_27 LAG3 Exon 3 + xp12:6773882-6773907 CUUCUCCGCUAUGGCUGCGCCCAGCC 3727 3902_3_28 LAG3 Exon 3 + xp12:6773889-6773914 CUAUGGCUGCGCCCAGCCCGGCGCG 3728 3902_3_29 LAG3 Exon 3 + xp12:6773896-6773921 UGCGCCCAGCCCGGCGCGCGGACGC 3729 3902_3_30 LAG3 Exon 3 + xp12:6773913-6773938 GCGGACGCCGGCGAGUACCGCGCCG 3730 3902_3_31 LAG3 Exon 3 + xp12:6773924-6773949 CGAGUACCGCGCCGCGGUGCACCUC 3731 3902_3_32 LAG3 Exon 3 + xp12:6773925-6773950 GAGUACCGCGCCGCGGUGCACCUCA 3732 3902_3_33 LAG3 Exon 3 + xp12:6773981-6774006 GCGCCUGGGCCAGGCCUCGAGUAUG 3733 3902_3_34 LAG3 Exon 3 + xp12:6773982-6774007 CGCCUGGGCCAGGCCUCGAGUAUGU 3734 3902_3_35 LAG3 Exon 3 + xp12:6773983-6774008 GCCUGGGCCAGGCCUCGAGUAUGUG 3735 3902_3_36 LAG3 Exon 3 + xp12:6773986-6774011 UGGGCCAGGCCUCGAGUAUGUGGGG 3736 3902_3_37 LAG3 Exon 3 + xp12:6773987-6774012 GGGCCAGGCCUCGAGUAUGUGGGGC 3737 3902_3_38 LAG3 Exon 3 + xp12:6773994-6774019 GCCUCGAGUAUGUGGGGCGGGACGA 3738 3902_3_39 LAG3 Exon 3 + xp12:6773995-6774020 CCUCGAGUAUGUGGGGCGGGACGAU 3739 3902_3_40 LAG3 Exon 3 - xp12:6773679-6773704 GCGGGCCACUGGGCGGGAAAGAGAA 3740 3902_3_41 LAG3 Exon 3 - xp12:6773690-6773715 GGCGGCAGCGGGCGGGCCACUGGGC 3741 3902_3_42 LAG3 Exon 3 - xp12:6773691-6773716 GGGCGGCAGCGGGCGGGCCACUGGG 3742 3902_3_43 LAG3 Exon 3 - xp12:6773694-6773719 CGGGGGCGGCAGCGGGCGGGCCACU 3743 3902_3_44 LAG3 Exon 3 - xp12:6773695-6773720 CCGGGGGCGGCAGCGGGCGGGCCAC 3744 3902_3_45 LAG3 Exon 3 - xp12:6773702-6773727 GGGAUGGCCGGGGGCGGCAGCGGGC 3745 3902_3_46 LAG3 Exon 3 - xp12:6773703-6773728 GGGGAUGGCCGGGGGCGGCAGCGGG 3746 3902_3_47 LAG3 Exon 3 - xp12:6773706-6773731 CCAGGGGAUGGCCGGGGGCGGCAGGC 3747 3902_3_48 LAG3 Exon 3 - xp12:6773707-6773732 GCCAGGGGAUGGCCGGGGGCGGCAG 3748 3902_3_49 LAG3 Exon 3 - xp12:6773713-6773738 CCGGGGGCCAGGGGAUGGCCGGGGG 3749 3902_3_50 LAG3 Exon 3 - xp12:6773716-6773741 GGGCCGGGGGCCAGGGGAUGGCCGG 3750 3902_3_51 LAG3 Exon 3 - xp12:6773717-6773742 AGGGCCGGGGGCCAGGGGAUGGCCG 3751 3902_3_52 LAG3 Exon 3 - xp12:6773718-6773743 GAGGGCCGGGGGCCAGGGGAUGGCC 3752 3902_3_53 LAG3 Exon 3 - xp12:6773719-6773744 UGAGGGCCGGGGGCCAGGGGAUGGC 3753 3902_3_54 LAG3 Exon 3 - xp12:6773723-6773748 CGGGUGAGGGCCGGGGGCCAGGGGA 3754 3902_3_55 LAG3 Exon 3 - xp12:6773727-6773752 CCGCCGGGUGAGGGCCGGGGGCCAG 3755 3902_3_56 LAG3 Exon 3 - xp12:6773728-6773753 GCCGCCGGGUGAGGGCCGGGGGCCA 3756 3902_3_57 LAG3 Exon 3 - xp12:6773729-6773754 CGCCGCCGGGUGAGGGCCGGGGGCC 3757 3902_3_58 LAG3 Exon 3 - xp12:6773734-6773759 GAGGGCGCCGCCGGGUGAGGGCCGG 3758 3902_3_59 LAG3 Exon 3 - xp12:6773735-6773760 GGAGGGCCGCCGCCGGGUGAGGGCCG 3759 3902_3_60 LAG3 Exon 3 - xp12:6773736-6773761 AGGAGGGCCGCCGCCGGGUGAGGGCC 3760 3902_3_61 LAG3 Exon 3 - xp12:6773737-6773762 GAGGAGGGCGCCCGCCGGGUGAGGGC 3761 3902_3_62 LAG3 Exon 3 - xp12:6773741-6773766 CCAGGAGGAGGGCCGCCGCCGGGUGA 3762 3902_3_63 LAG3 Exon 3 - xp12:6773742-6773767 CCCAGGAGGAGGGCGCCGCCGGGUG 3763 3902_3_64 LAG3 Exon 3 - xp12:6773747-6773772 GGGCCCCCAGGAGGAGGGCGCCGCC 3764 3902_3_65 LAG3 Exon 3 - xp12:6773748-6773773 UGGGCCCCCAGGAGGAGGGCGCCGC 3765 3902_3_66 LAG3 Exon 3 - xp12:6773757-6773782 GGCGGGGCCUGGGCCCCCAGGAGGA 3766 3902_3_67 LAG3 Exon 3 - xp12:6773758-6773783 CGGCGGGGCCUGGGCCCCCAGGAGG 3767 3902_3_68 LAG3 Exon 3 - xp12:6773761-6773786 UAGCGGCGGGGCCUGGGCCCCCAGG 3768 3902_3_69 LAG3 Exon 3 - xp12:6773764-6773789 GUGUAGCGGCGGGGCCUGGGCCCCC 3769 3902_3_70 LAG3 Exon 3 - xp12:6773772-6773797 UCAGCACCGUGUAGCGGCGGGGCCU 3770 3902_3_71 LAG3 Exon 3 - xp12:6773773-6773798 CUCAGCACCGUGUAGCGGCGGGGCC 3771 3902_3_72 LAG3 Exon 3 - xp12:6773778-6773803 CCACGCUCAGCACCGUGUAGCGGCG 3772 3902_3_73 LAG3 Exon 3 - xp12:6773779-6773804 CCCACGCUCAGCACCGUGUAGCGGC 3773 3902_3_74 LAG3 Exon 3 - xp12:6773780-6773805 ACCCACGCUCAGCACCGUGUAGCGG 3774 3902_3_75 LAG3 Exon 3 - xp12:6773783-6773808 GGGACCCACGCUCAGCACCGUGUAG 3775 3902_3_76 LAG3 Exon 3 - xp12:6773808-6773833 GCAGCCUCCCGCUGCGCAGGCCUCC 3776 3902_3_77 LAG3 Exon 3 - xp12:6773809-6773834 GGCAGCCUCCCGCUGCGCAGGCCUC 3777 3902_3_78 LAG3 Exon 3 - xp12:6773816-6773841 CUGCAGGGGCAGCCUCCCCGCUGCGC 3778 3902_3_79 LAG3 Exon 3 - xp12:6773835-6773860 CAUCCAGCUGGACGCGGGGCUGCAG 3779 3902_3_80 LAG3 Exon 3 - xp12:6773836-6773861 UCAUCCAGCUGGACGCGGGGCUGCA 3780 3902_3_81 LAG3 Exon 3 - xp12:6773837-6773862 CUCAUCCAGCUGGACGCGGGGCUGC 3781 3902_3_82 LAG3 Exon 3 - xp12:6773844-6773869 GGCCGCGCUCAUCCAGCUGGACGCG 3782 3902_3_83 LAG3 Exon 3 - xp12:6773845-6773870 CGGCCGCGCUCAUCCAGCUGGACGC 3783 3902_3_84 LAG3 Exon 3 - xp12:6773846-6773871 CCGGCCGCGCUCAUCCAGCUGGACG 3784 3902_3_85 LAG3 Exon 3 - xp12:6773852-6773877 GCGCUGCCGGCCGCGCUCAUCCAGC 3785 3902_3_86 LAG3 Exon 3 - xp12:6773870-6773895 CCAUAGCGAGAAGUCCCCGCGCUGC 3786 3902_3_87 LAG3 Exon 3 - xp12:6773903-6773928 CUCGCCGGCGUCCGCGCGCCGGGCU 3787 3902_3_88 LAG3 Exon 3 - xp12:6773904-6773929 ACUCGCCGGCGUCCGCGCGCCGGGC 3788 3902_3_89 LAG3 Exon 3 - xp12:6773908-6773933 CGGUACUCGCCGGCGUCCGCGCGCC 3789 3902_3_90 LAG3 Exon 3 - xp12:6773909-6773934 GCGGUACUCGCCGGCGUCCGCGCGC 3790 3902_3_91 LAG3 Exon 3 - xp12:6773923-6773948 AGGUGCACCGCGGCGCGGUACUCGC 3791 3902_3_92 LAG3 Exon 3 - xp12:6773933-6773958 CGGGUCCCUGAGGUGCACCGCGGCG 3792 3902_3_93 LAG3 Exon 3 - xp12:6773938-6773963 UCCCGCGGGUCCCUGAGGUGCACCG 3793 3902_3_94 LAG3 Exon 3 - xp12:6773948-6773973 CGCCGUCCUCUCCCGCGGGUCCCUG 3794 3902_3_95 LAG3 Exon 3 - xp12:6773957-6773982 GUCUGCCUCCGCCCGUCCUCUCCCGC 3795 3902_4_1 LAG3 Exon 4 + xp12:6774585-6774610 CUUGCACAGUGACUGCCAGCCCCCC 3796 3902_4_2 LAG3 Exon 4 + xp12:6774607-6774632 CCCAGGAUCUCUCAGAGCCUCCGAC 3797 3902_4_3 LAG3 Exon 4 + xp12:6774608-6774633 CCAGGAUCUCUCAGAGCCCUCCGACU 3798 3902_4_4 LAG3 Exon 4 + xp12:6774661-6774686 CCCUGACCGCCCAGCCUCUGUGCAU 3799 3902_4_5 LAG3 Exon 4 + xp12:6774667-6774692 CCGCCCAGCCUCUGUGCAUUGGUUC 3800 3902_4_6 LAG3 Exon 4 + xp12:6774673-6774698 AGCCUCUGUGCAUUGGUUCCGGAAC 3801 3902_4_7 LAG3 Exon 4 + xp12:6774674-6774699 GCCUCUGUGCAUUGGUUCCGGAACC 3802 3902_4_8 LAG3 Exon 4 + xp12:6774675-6774700 CCUCUGUGCAUUGGUUCCGGAACCG 3803 3902_4_9 LAG3 Exon 4 + xp12:6774680-6774705 GUGCAUUGGUUCCGGAACCGGGGCC 3804 3902_4_10 LAG3 Exon 4 + xp12:6774681-6774706 UGCAUUGGUUCCGGAACCGGGGCCA 3805 3902_4_11 LAG3 Exon 4 + xp12:6774697-6774722 CCGGGGCCAGGGCCGAGUCCCUGUC 3806 3902_4_12 LAG3 Exon 4 + xp12:6774698-6774723 CGGGGCCAGGGCCGAGUCCCUGUCC 3807 3902_4_13 LAG3 Exon 4 + xp12:6774722-6774747 CGGGAGUCCCCCCAUCACCACCUUAG 3808 3902_4_14 LAG3 Exon 4 + xp12:6774758-6774783 CUCUUCCUGCCCCAAGUCAGCCCCCA 3809 3902_4_15 LAG3 Exon 4 + xp12:6774765-6774790 UGCCCCAAGUCAGCCCCAUGGACUC 3810 3902_4_16 LAG3 Exon 4 + xp12:6774766-6774791 GCCCCAAGUCAGCCCCAUGGACUCU 3811 3902_4_17 LAG3 Exon 4 + xp12:6774772-6774797 AGUCAGCCCCAUGGACUCUGGGCCC 3812 3902_4_18 LAG3 Exon 4 + xp12:6774773-6774798 GUCAGCCCCAUGGACUCUGGGCCCU 3813 3902_4_19 LAG3 Exon 4 + xp12:6774774-6774799 UCAGCCCCAUGGACUCUGGGCCCUG 3814 3902_4_20 LAG3 Exon 4 + xp12:6774798-6774823 GGGGCUGCAUCCUCACCUACAGAGA 3815 3902_4_21 LAG3 Exon 4 + xp12:6774836-6774861 UCCAUCAUGUAUAAACCUCACUGUUC 3816 3902_4_22 LAG3 Exon 4 + xp12:6774837-6774862 CCAUCAUGUAUAAACCUCACUGUUCU 3817 3902_4_23 LAG3 Exon 4 - xp12:6774587-6774612 CUGGGGGGCUGGCAGUCACUGUGCA 3818 3902_4_24 LAG3 Exon 4 - xp12:6774603-6774628 GAGGCUCUGAGAGAUCCUGGGGGGC 3819 3902_4_25 LAG3 Exon 4 - xp12:6774607-6774632 GUCGGAGGCUCUGAGAGAUCCUGGG 3820 3902_4_26 LAG3 Exon 4 - xp12:6774608-6774633 AGUCGGAGGCUCUGAGAGAUCCUGG 3821 3902_4_27 LAG3 Exon 4 - xp12:6774609-6774634 CAGUCGGAGGCUCUGAGAGAUCCUG 3822 3902_4_28 LAG3 Exon 4 - xp12:6774610-6774635 CCAGUCGGAGGCUCUGAGAGAUCCU 3823 3902_4_29 LAG3 Exon 4 - xp12:6774611-6774636 CCCAGUCGGAGGCUCUGAGAGAUCC 3824 3902_4_30 LAG3 Exon 4 - xp12:6774627-6774652 GAGCAGUUCAAAAAUGACCCAGUCGG 3825 3902_4_31 LAG3 Exon 4 - xp12:6774630-6774655 AAGGAGCAGUUCAAAAAUGACCCAGU 3826 3902_4_32 LAG3 Exon 4 - xp12:6774654-6774679 GAGGCUGGGCGGUUCAGGGCGGCUGA 3827 3902_4_33 LAG3 Exon 4 - xp12:6774661-6774686 AUGCACAGAGGCUGGGCGGUUCAGGG 3828 3902_4_34 LAG3 Exon 4 - xp12:6774664-6774689 CCAAUGCACAGAGGCUGGGCGGUCA 3829 3902_4_35 LAG3 Exon 4 - xp12:6774665-6774690 ACCAAUGCACAGAGGCUGGGCGGUC 3830 3902_4_36 LAG3 Exon 4 - xp12:6774670-6774695 CCGGAACCAAUGCACAGAGGCUGGG 3831 3902_4_37 LAG3 Exon 4 - xp12:6774673-6774698 GUUCCGGAACCAAUGCACAGAGGCU 3832 3902_4_38 LAG3 Exon 4 - xp12:6774674-6774699 GGUUCCGGAACCAAUGCACAGAGGC 3833 3902_4_39 LAG3 Exon 4 - xp12:6774678-6774703 CCCCGGUUCCGGAACCAAUGCACAG 3834 3902_4_40 LAG3 Exon 4 - xp12:6774694-6774719 AGGGACUCGGCCCUGGCCCCGGUUC 3835 3902_4_41 LAG3 Exon 4 - xp12:6774700-6774725 CCGGACAGGGACUCGGCCCUGGCCC 3836 3902_4_42 LAG3 Exon 4 - xp12:6774706-6774731 GGACUCCCGGACAGGGACUCGGCCC 3837 3902_4_43 LAG3 Exon 4 - xp12:6774712-6774737 AUGGGGGGACUCCCGGACAGGGACU 3838 3902_4_44 LAG3 Exon 4 - xp12:6774718-6774743 GUGGUGAUGGGGGGACUCCCGGACA 3839 3902_4_45 LAG3 Exon 4 - xp12:6774719-6774744 AGUGGUGAUGGGGGGACUCCCGGAC 3840 3902_4_46 LAG3 Exon 4 - xp12:6774724-6774749 CGCUAAGUGGUGAUGGGGGGACUCC 3841 3902_4_47 LAG3 Exon 4 - xp12:6774732-6774757 AAGCUUUCCGCUAAGUGGUGAUGGG 3842 3902_4_48 LAG3 Exon 4 - xp12:6774733-6774758 GAAGCUUUCCGCUAAGUGGUGAUGG 3843 3902_4_49 LAG3 Exon 4 - xp12:6774734-6774759 GGAAGCUUUCCGCUAAGUGGUGAUG 3844 3902_4_50 LAG3 Exon 4 - xp12:6774735-6774760 AGGAAGCUUUCCGCUAAGUGGUGAU 3845 3902_4_51 LAG3 Exon 4 - xp12:6774736-6774761 GAGGAAGCUUUCCGCUAAGUGGUGA 3846 3902_4_52 LAG3 Exon 4 - xp12:6774742-6774767 CAGGAAGAGGAAGCUUUCCGCUAAG 3847 3902_4_53 LAG3 Exon 4 - xp12:6774760-6774785 CAUGGGGCUGACUUGGGGCAGGAAG 3848 3902_4_54 LAG3 Exon 4 - xp12:6774766-6774791 AGAGUCCAUGGGGCUGACUUGGGGC 3849 3902_4_55 LAG3 Exon 4 - xp12:6774770-6774795 GCCCAGAGUCCAUGGGGCUGACUUG 3850 3902_4_56 LAG3 Exon 4 - xp12:6774771-6774796 GGCCCAGAGUCCAUGGGGCUGACUU 3851 3902_4_57 LAG3 Exon 4 - xp12:6774772-6774797 GGGCCCAGAGUCCAUGGGGCUGACU 3852 3902_4_58 LAG3 Exon 4 - xp12:6774781-6774806 GCAGCCCCAGGGCCCAGAGUCCAUG 3853 3902_4_59 LAG3 Exon 4 - xp12:6774782-6774807 UGCAGCCCCAGGGCCCAGAGUCCAU 3854 3902_4_60 LAG3 Exon 4 - xp12:6774783-6774808 AUGCAGCCCCAGGGCCCAGAGUCCA 3855 3902_4_61 LAG3 Exon 4 - xp12:6774797-6774822 CUCUGUAGGUGAGGAUGCAGCCCCA 3856 3902_4_62 LAG3 Exon 4 - xp12:6774798-6774823 UCUCUGUAGGUGAGGAUGCAGCCCC 3857 3902_4_63 LAG3 Exon 4 - xp12:6774811-6774836 GACGUUGAAGCCAUCUCUGUAGGUG 3858 3902_4_64 LAG3 Exon 4 - xp12:6774816-6774841 AUGGAGACGUUGAAGCCAUCUCUGU 3859 3902_4_65 LAG3 Exon 4 - xp12:6774840-6774865 CCCAGAACAGUGAGGUUAUACAUGA 3860 3902_4_66 LAG3 Exon 4 - xp12:6774853-6774878 AGUGGGGGAGUUACCCAGAACAGUG 3861 3902_5_1 LAG3 Exon 5 + xp12:6775250-6775275 UUGGGUUUUCUUUUCUCUUCAGGUC 3862 3902_5_2 LAG3 Exon 5 + xp12:6775281-6775306 CCCCAACUCCCUUGACAGUGUACGC 3863 3902_5_3 LAG3 Exon 5 + xp12:6775287-6775312 CUCCCUUGACAGUGUACGCUGGAGC 3864 3902_5_4 LAG3 Exon 5 + xp12:6775294-6775319 GACAGUGUACGCUGGAGCAGGUUCC 3865 3902_5_5 LAG3 Exon 5 + xp12:6775295-6775320 ACAGUGUACGCUGGAGCAGGUUCCA 3866 3902_5_6 LAG3 Exon 5 + xp12:6775298-6775323 GUGUACGCUGGAGCAGGUUCCAGGG 3867 3902_5_7 LAG3 Exon 5 + xp12:6775299-6775324 UGUACGCUGGAGCAGGUUCCAGGGU 3868 3902_5_8 LAG3 Exon 5 + xp12:6775300-6775325 GUACGCUGGAGCAGGUUCCAGGGUG 3869 3902_5_9 LAG3 Exon 5 + xp12:6775323-6775348 UGGGGCUGCCCUGCCGCCUGCCUGC 3870 3902_5_10 LAG3 Exon 5 + xp12:6775328-6775353 CUGCCCUGCCGCCUGCCUGCUGGUG 3871 3902_5_11 LAG3 Exon 5 + xp12:6775329-6775354 UGCCCUGCCGCCUGCCUGCUGGUGU 3872 3902_5_12 LAG3 Exon 5 + xp12:6775330-6775355 GCCCUGCCGCCUGCCUGCUGGUGUG 3873 3902_5_13 LAG3 Exon 5 + xp12:6775336-6775361 CCGCCUGCCUGCUGGUGUGGGGACC 3874 3902_5_14 LAG3 Exon 5 + xp12:6775357-6775382 GACCCGGUCUUUCCUCACUGCCAAG 3875 3902_5_15 LAG3 Exon 5 + xp12:6775368-6775393 UCCUCACUGCCAAGUGGACUCCUCCC 3876 3902_5_16 LAG3 Exon 5 + xp12:6775369-6775394 CCUCACUGCCAAGUGGACUCCUCCU 3877 3902_5_17 LAG3 Exon 5 + xp12:6775370-6775395 CUCACUGCCAAGUGGACUCCUCCUG 3878 3902_5_18 LAG3 Exon 5 + xp12:6775371-6775396 UCACUGCCAAGUGGACUCCUCCUGG 3879 3902_5_19 LAG3 Exon 5 + xp12:6775374-6775399 CUGCCAAGUGGACUCCUCCUGGGGG 3880 3902_5_20 LAG3 Exon 5 + xp12:6775388-6775413 CCUCCUGGGGGAGGCCCUGACCUCC 3881 3902_5_21 LAG3 Exon 5 + xp12:6775395-6775420 GGGGAGGCCCUGACCUCCUGGUGAC 3882 3902_5_22 LAG3 Exon 5 + xp12:6775404-6775429 CUGACCUCCUGGUGACUGGAGACAAA 3883 3902_5_23 LAG3 Exon 5 + xp12:6775427-6775452 AAUGGCGACUUUACCCUUCGACUAG 3884 3902_5_24 LAG3 Exon 5 + xp12:6775439-6775464 ACCCUUCGACUAGAGGAUGUGAGCC 3885 3902_5_25 LAG3 Exon 5 + xp12:6775445-6775470 CGACUAGAGGAUGUGAGCCAGGCCC 3886 3902_5_26 LAG3 Exon 5 + xp12:6775449-6775474 UAGAGGAUGUGAGCCAGGCCCAGGC 3887 3902_5_27 LAG3 Exon 5 + xp12:6775450-6775475 AGAGGAUGUGAGCCAGGCCCAGGCU 3888 3902_5_28 LAG3 Exon 5 + xp12:6775478-6775503 ACCUACACCUGCCAUAUCCAUCUGC 3889 3902_5_29 LAG3 Exon 5 + xp12:6775508-6775533 CAGCAGCUCAAUGCCACUGUCACAU 3890 3902_5_30 LAG3 Exon 5 + xp12:6775521-6775546 CCACUGUCACAAUUGGCAAUCAUCAC 3891 3902_5_31 LAG3 Exon 5 + xp12:6775532-6775557 UUGGCAAUCAUCACAGGUCAGCCUC 3892 3902_5_32 LAG3 Exon 5 + xp12:6775535-6775560 GCAAUCAUCACAGGUCAGCCUCAGG 3893 3902_5_33 LAG3 Exon 5 + xp12:6775536-6775561 CAAUCAUCACAGGUCAAGCCUCAGGU 3894 3902_5_34 LAG3 Exon 5 + xp12:6775541-6775566 AUCACAGGUCAGCCUCAGGUGGGAA 3895 3902_5_35 LAG3 Exon 5 - xp12:6775283-6775308 CAGCGUACACUGUCAAGGGAGUUGG 3896 3902_5_36 LAG3 Exon 5 - xp12:6775284-6775309 CCAGCGUACACUGUCAAGGGAGUUG 3897 3902_5_37 LAG3 Exon 5 - xp12:6775285-6775310 UCCAGCGUACACUGUCAAGGGAGUU 3898 3902_5_38 LAG3 Exon 5 - xp12:6775286-6775311 CUCCAGCGUACACUGUCAAGGGAGU 3899 3902_5_39 LAG3 Exon 5 - xp12:6775292-6775317 AACCUGCUCCAGCGUACACUGUCAA 3900 3902_5_40 LAG3 Exon 5 - xp12:6775293-6775318 GAACCUGCUCCAGCGUACACUGUCA 3901 3902_5_41 LAG3 Exon 5 - xp12:6775320-6775345 GGCAGGCGGCAGGGCAGCCCCACCC 3902 3902_5_42 LAG3 Exon 5 - xp12:6775334-6775359 UCCCCACACCAGCAGGCAGGCGGCA 3903 3902_5_43 LAG3 Exon 5 - xp12:6775335-6775360 GUCCCCACACCAGCAGGCAGGCGGC 3904 3902_5_44 LAG3 Exon 5 - xp12:6775339-6775364 CCGGGUCCCCACACCAGCAGGCAGG 3905 3902_5_45 LAG3 Exon 5 - xp12:6775342-6775367 AGACCGGGUCCCCACACCAGCAGGC 3906 3902_5_46 LAG3 Exon 5 - xp12:6775346-6775371 GGAAAGACCGGGUCCCCACACCAGC 3907 3902_5_47 LAG3 Exon 5 - xp12:6775362-6775387 GUCCACUUGGCAGUGAGGAAAGACC 3908 3902_5_48 LAG3 Exon 5 - xp12:6775363-6775388 AGUCCACUUGGCAGUGAGGAAAGAC 3909 3902_5_49 LAG3 Exon 5 - xp12:6775372-6775397 CCCAGGAGGAGUCCCACUUGGCAGUG 3910 3902_5_50 LAG3 Exon 5 - xp12:6775380-6775405 GGGCCUCCCCCAGGAGGAGUCCCACU 3911 3902_5_51 LAG3 Exon 5 - xp12:6775391-6775416 CCAGGAGGUCAGGGCCUCCCCCAGG 3912 3902_5_52 LAG3 Exon 5 - xp12:6775394-6775419 UCACCAGGAGGUCAGGGCCUCCCCC 3913 3902_5_53 LAG3 Exon 5 - xp12:6775405-6775430 AUUGUCUCCAGUCACCAGGAGGUCA 3914 3902_5_54 LAG3 Exon 5 - xp12:6775406-6775431 CAUUGUCUCCAGUCACCAGGAGGUC 3915 3902_5_55 LAG3 Exon 5 - xp12:6775411-6775436 GUCGCCAUUGUCUCCAGUCACCAGG 3916 3902_5_56 LAG3 Exon 5 - xp12:6775414-6775439 AAAGUCGCCAUUGUCUCCAGUCACCC 3917 3902_5_57 LAG3 Exon 5 - xp12:6775443-6775468 GCCUGGCUCACAUCCUCUAGUCGAA 3918 3902_5_58 LAG3 Exon 5 - xp12:6775444-6775469 GGCCUGGCUCACAUCCUCUAGUCGA 3919 3902_5_59 LAG3 Exon 5 - xp12:6775465-6775490 GCAGGUGUAGGUCCCAGCCUGGGCC 3920 3902_5_60 LAG3 Exon 5 - xp12:6775470-6775495 AUAUGGCAGGUGUAGGUCCCAGCCU 3921 3902_5_61 LAG3 Exon 5 - xp12:6775471-6775496 GAUAUGGCAGGUGUAGGUCCCCAGCC 3922 3902_5_62 LAG3 Exon 5 - xp12:6775482-6775507 UCCUGCAGAUGGAUAUGGCAGGUGU 3923 3902_5_63 LAG3 Exon 5 - xp12:6775488-6775513 UGCUGUUCCUGCAGAUGGAUAUGGC 3924 3902_5_64 LAG3 Exon 5 - xp12:6775492-6775517 GAGCUGCUGUUCCUGCAGAUGGAUA 3925 3902_5_65 LAG3 Exon 5 - xp12:6775498-6775523 GGCAUUGAGCUGCUGUUCCUGCAGA 3926 3902_5_66 LAG3 Exon 5 - xp12:6775524-6775549 CCUGUGAUGAUUGCCAAUGUGACAG 3927 3902_6_1 LAG3 Exon 6 + xp12:6777254-6777279 UCUUUUCAGUGACUCCCAAAUCCUU 3928 3902_6_2 LAG3 Exon 6 + xp12:6777255-6777280 CUUUUCAGUGACUCCCAAAUCCUUU 3929 3902_6_3 LAG3 Exon 6 + xp12:6777263-6777288 UGACUCCCAAAUCCUUUGGGUCACC 3930 3902_6_4 LAG3 Exon 6 + xp12:6777271-6777296 AAAUCCUUUGGGUCACCUGGAUCCC 3931 3902_6_5 LAG3 Exon 6 + xp12:6777272-6777297 AAUCCUUUGGGUCACCUGGAUCCCU 3932 3902_6_6 LAG3 Exon 6 + xp12:6777273-6777298 AUCCUUUGGGUCACCUGGAUCCCUG 3933 3902_6_7 LAG3 Exon 6 + xp12:6777289-6777314 GGAUCCCUGGGGAAGCUGCUUUGUG 3934 3902_6_8 LAG3 Exon 6 + xp12:6777305-6777330 UGCUUUGUGAGGUGACUCCAGUAUC 3935 3902_6_9 LAG3 Exon 6 + xp12:6777324-6777349 AGUAUCUGGACAAGAACGCUUUGUG 3936 3902_6_10 LAG3 Exon 6 + xp12:6777334-6777359 CAAGAACGCUUUGUGUGGAGCUCUC 3937 3902_6_11 LAG3 Exon 6 + xp12:6777351-6777376 GAGCUCUCUGGACACCCCAUCCAG 3938 3902_6_12 LAG3 Exon 6 + xp12:6777362-6777387 ACACCCCAUCCCAGAGGAGUUUCUC 3939 3902_6_13 LAG3 Exon 6 + xp12:6777369-6777394 AUCCCAGAGGAGUUUCUCAGGACCU 3940 3902_6_14 LAG3 Exon 6 + xp12:6777373-6777398 CAGAGGAGUUUCUCAGGACCUUGGC 3941 3902_6_15 LAG3 Exon 6 + xp12:6777376-6777401 AGGAGUUUCUCAGGACCUUGGCUGG 3942 3902_6_16 LAG3 Exon 6 + xp12:6777382-6777407 UUCUCAGGACCUUGGCUGGAGGCAC 3943 3902_6_17 LAG3 Exon 6 + xp12:6777385-6777410 UCAGGACCUUGGCUGGAGGCACAGG 3944 3902_6_18 LAG3 Exon 6 + xp12:6777408-6777433 GGAGGCCCAGCUCCUUUCCCAGCCU 3945 3902_6_19 LAG3 Exon 6 + xp12:6777427-6777452 CAGCCUUGGCAAUGCCAGCUGUAC 3946 3902_6_20 LAG3 Exon 6 + xp12:6777428-6777453 AGCCUUGGCAAUGCCAGCUGUACCA 3947 3902_6_21 LAG3 Exon 6 + xp12:6777429-6777454 GCCUUGGCAAUGCCAGCUGUACAG 3948 3902_6_22 LAG3 Exon 6 + xp12:6777430-6777455 CCUUGGCAAUGCCAGCUGUACCAGG 3949 3902_6_23 LAG3 Exon 6 + xp12:6777435-6777460 GCAAUGCCAGCUGUACCAGGGGGAG 3950 3902_6_24 LAG3 Exon 6 + xp12:6777443-6777468 AGCUGUACCAGGGGGAGAGGCUUCU 3951 3902_6_25 LAG3 Exon 6 + xp12:6777479-6777504 UGUACUUCACAGAGCUGUCUAGCCCC 3952 3902_6_26 LAG3 Exon 6 + xp12:6777486-6777511 CACAGAGCUGUCUAGCCCAGGUCCG 3953 3902_6_27 LAG3 Exon 6 + xp12:6777501-6777526 CCCAGGUCCGAGGCCCCAGAAUGCC 3954 3902_6_28 LAG3 Exon 6 - xp12:6777249-6777274 UUUGGGAGUCACUGAAAAGAGUAGA 3955 3902_6_29 LAG3 Exon 6 - xp12:6777271-6777296 GGGAUCCAGGUGACCCAAAGGAUUU 3956 3902_6_30 LAG3 Exon 6 - xp12:6777272-6777297 AGGGAUCCAGGUGACCCAAAGGAUU 3957 3902_6_31 LAG3 Exon 6 - xp12:6777278-6777303 UUCCCCAGGGAUCCAGGUGACCCAA 3958 3902_6_32 LAG3 Exon 6 - xp12:6777289-6777314 CACAAAGCAGCUUCCCCAGGGAUCC 3959 3902_6_33 LAG3 Exon 6 - xp12:6777296-6777321 GUCACCUCACAAAGCAGCUUCCCCA 3960 3902_6_34 LAG3 Exon 6 - xp12:6777297-6777322 AGUCACCUCACAAAGCAGCUUCCCCC 3961 3902_6_35 LAG3 Exon 6 - xp12:6777325-6777350 ACACAAAGCGUUCUUGUCCAGAUAC 3962 3902_6_36 LAG3 Exon 6 - xp12:6777368-6777393 GGUCCUGAGAAAACUCCUCUGGGAUG 3963 3902_6_37 LAG3 Exon 6 - xp12:6777369-6777394 AGGUCCUGAGAAAACUCCUCUGGGAU 3964 3902_6_38 LAG3 Exon 6 - xp12:6777370-6777395 AAGGUCCCUGAGAAAACUCCUCUGGA 3965 3902_6_39 LAG3 Exon 6 - xp12:6777374-6777399 AGCCAAGGUCCUGAGAAAACUCCUCU 3966 3902_6_40 LAG3 Exon 6 - xp12:6777375-6777400 CAGCCAAGGUCCUGAGAAACUCCUC 3967 3902_6_41 LAG3 Exon 6 - xp12:6777394-6777419 GCUGGGCCUCCUGUGCCUCCAGCCCA 3968 3902_6_42 LAG3 Exon 6 - xp12:6777416-6777441 CAUUGCCAAGGCUGGGAAAGGAGCU 3969 3902_6_43 LAG3 Exon 6 - xp12:6777417-6777442 GCAUUGCCAAGGCUGGGAAAGGAGC 3970 3902_6_44 LAG3 Exon 6 - xp12:6777423-6777448 CAGCUGGCAUUGCCAAGGCUGGGAA 3971 3902_6_45 LAG3 Exon 6 - xp12:6777428-6777453 UGGUACAGCUGGCAUUGCCAAGGCU 3972 3902_6_46 LAG3 Exon 6 - xp12:6777429-6777454 CUGGUACAGCUGGCAUUGCCAAGGC 3973 3902_6_47 LAG3 Exon 6 - xp12:6777433-6777458 CCCCCUGGUACAGCUGGCAUUGCCA 3974 3902_6_48 LAG3 Exon 6 - xp12:6777444-6777469 AAGAAGCCUCUCCCCCUGGUACAGGC 3975 3902_6_49 LAG3 Exon 6 - xp12:6777453-6777478 UGCUGCUCCAAGAAGCCUCUCCCCC 3976 3902_6_50 LAG3 Exon 6 - xp12:6777504-6777529 CCUGGCAUUCUGGGGCCUCGGACCU 3977 3902_6_51 LAG3 Exon 6 - xp12:6777505-6777530 UCCUGGCAUUCUGGGGCCUCGGACC 3978 3902_7_1 LAG3 Exon 7 + xp12:6777778-6777803 CUUUCUCCAUAGGUGCCCAACGCUC 3979 3902_7_2 LAG3 Exon 7 + xp12:6777779-6777804 UUUCUCCAUAGGUGCCCAACGCUCU 3980 3902_7_3 LAG3 Exon 7 + xp12:6777790-6777815 GUGCCCAACGCUCUGGGAGAGCCCC 3981 3902_7_4 LAG3 Exon 7 + xp12:6777805-6777830 GGAGAGCCCCAGGUGCCCUCCCAGC 3982 3902_7_5 LAG3 Exon 7 + xp12:6777832-6777857 GCCACCUCCUGCUGUUUCUCACCU 3983 3902_7_6 LAG3 Exon 7 + xp12:6777855-6777880 CUUGGUGUCCUUUCUCUGCUCCUUU 3984 3902_7_7 LAG3 Exon 7 + xp12:6777862-6777887 UCCUUUCUCUGCUCCUUUUGGUGAC 3985 3902_7_8 LAG3 Exon 7 + xp12:6777871-6777896 UGCUCCUUUUGGUGACUGGAGCCUU 3986 3902_7_9 LAG3 Exon 7 + xp12:6777884-6777909 GACUGGAGCCUUUGGCUUUCACCUU 3987 3902_7_10 LAG3 Exon 7 + xp12:6777894-6777919 UUUGGCUUUCACCUUUGGAGAAGAC 3988 3902_7_11 LAG3 Exon 7 + xp12:6777903-6777928 CACCUUUGGAGAAGACAGGUGAGCC 3989 3902_7_12 LAG3 Exon 7 + xp12:6777904-6777929 ACCUUUGGAGAAGACAGGUGAGCCA 3990 3902_7_13 LAG3 Exon 7 + xp12:6777910-6777935 GGAGAAGACAGGUGAGCCAGGGACA 3991 3902_7_14 LAG3 Exon 7 - xp12:6777775-6777800 CGUUGGGCACCUAUGGAGAAAGUAC 3992 3902_7_15 LAG3 Exon 7 - xp12:6777787-6777812 GCUCUCCCAGAGCGUUGGGCACCUA 3993 3902_7_16 LAG3 Exon 7 - xp12:6777796-6777821 GCACCUGGGGCUCUCCCAGAGCGUU 3994 3902_7_17 LAG3 Exon 7 - xp12:6777797-6777822 GGCACCUGGGGCUCUCCCAGAGCGU 3995 3902_7_18 LAG3 Exon 7 - xp12:6777814-6777839 AGGUGGCCUGCUGGGAGGGCACCUG 3996 3902_7_19 LAG3 Exon 7 - xp12:6777815-6777840 GAGGUGGCCUGCUGGGAGGGCACCU 3997 3902_7_20 LAG3 Exon 7 - xp12:6777816-6777841 GGAGGUGGCCUGCUGGGAGGGCACC 3998 3902_7_21 LAG3 Exon 7 - xp12:6777823-6777848 AACAGCAGGAGGUGGCCUGCUGGGA 3999 3902_7_22 LAG3 Exon 7 - xp12:6777824-6777849 AAACAGCAGGAGGUGGCCUGCUGGG 4000 3902_7_23 LAG3 Exon 7 - xp12:6777827-6777852 GAGAAACAGCAGGAGGUGGCCUGCU 4001 3902_7_24 LAG3 Exon 7 - xp12:6777828-6777853 UGAGAAACAGCAGGAGGUGGCCUGC 4002 3902_7_25 LAG3 Exon 7 - xp12:6777836-6777861 ACCAAGGAUGAGAAACAGCAGGAGG 4003 3902_7_26 LAG3 Exon 7 - xp12:6777839-6777864 GACACCAAGGAUGAGAAACAGCAGG 4004 3902_7_27 LAG3 Exon 7 - xp12:6777842-6777867 AAGGACACCCAAGGAUGAGAAACAGC 4005 3902_7_28 LAG3 Exon 7 - xp12:6777857-6777882 CAAAAGGAGCAGAGAAAGGACACCA 4006 3902_7_29 LAG3 Exon 7 - xp12:6777866-6777891 UCCAGUCACCAAAAGGAGCAGAGAA 4007 3902_7_30 LAG3 Exon 7 - xp12:6777878-6777903 AAAGCCAAAGGCUCCAGUCACCAAA 4008 3902_7_31 LAG3 Exon 7 - xp12:6777895-6777920 UGUCUUCUCCAAAGGUGAAAGCCAA 4009 3902_7_32 LAG3 Exon 7 - xp12:6777908-6777933 UCCCUGGCUCACCUGUCUUCUCCAA 4010 3902_8_1 LAG3 Exon 8 + xp12:6778218-6778243 UCUCUCUCUCCAUCUCUUCUCACAG 4011 3902_8_2 LAG3 Exon 8 + xp12:6778250-6778275 CAAGACGAUUUUCUGCCUUAGAGCA 4012 3902_8_3 LAG3 Exon 8 + xp12:6778251-6778276 AAGACGAUUUUCUGCCUUAGAGCAA 4013 3902_8_4 LAG3 Exon 8 + xp12:6778267-6778292 UUAGAGCAAGGGAUUCACCCCUCCGC 4014 3902_8_5 LAG3 Exon 8 + xp12:6778285-6778310 CCUCCGCAGGCUCAGAGCAAGAUAG 4015 3902_8_6 LAG3 Exon 8 + xp12:6778291-6778316 CAGGCUCAGAGCAAGAUAGAGGAGC 4016 3902_8_7 LAG3 Exon 8 + xp12:6778367-6778392 AGCCCGAGCCGGAGCAGCUCUGACC 4017 3902_8_8 LAG3 Exon 8 + xp12:6778375-6778400 CCGGAGCAGCUCUGACCUGGAGCUG 4018 3902_8_9 LAG3 Exon 8 + xp12:6778439-6778464 UCCCUGUCAGCAGCAAGCCUGAGUC 4019 3902_8_10 LAG3 Exon 8 - xp12:6778230-6778255 UCUUGGUCCGCCACUGUGAGAAGAGA 4020 3902_8_11 LAG3 Exon 8 - xp12:6778252-6778277 CUUGCUCUAAGGCAGAAAAUCGUCU 4021 3902_8_12 LAG3 Exon 8 - xp12:6778268-6778293 UGCGGAGGGUGAAUCCCUUGCUCUA 4022 3902_8_13 LAG3 Exon 8 - xp12:6778287-6778312 CUCUAUCUUGCUCUGAGCCUGCGGA 4023 3902_8_14 LAG3 Exon 8 - xp12:6778288-6778313 CCUCUAUCUUGCUCUGAGCCUGCGG 4024 3902_8_15 LAG3 Exon 8 - xp12:6778291-6778316 GCUCCUCUAUCUUGCUCUGAGCCUG 4025 3902_8_16 LAG3 Exon 8 - xp12:6778393-6778418 GAGAUCUGCUGGCUGCCUCAGCUCC 4026 3902_8_17 LAG3 Exon 8 - xp12:6778409-6778434 UUUGGACUGGGCUGCUGAGAUCUGC 4027 3902_8_18 LAG3 Exon 8 - xp12:6778426-6778451 UGCUGACAGGGAGUUUAUUUGGACU 4028 3902_8_19 LAG3 Exon 8 - xp12:6778427-6778452 CUGCUGACAGGGAGUUUAUUUGGAC 4029 3902_8_20 LAG3 Exon 8 - xp12:6778432-6778457 GCUUGCUGCUGACAGGGAGUUUAUU 4030 3902_8_21 LAG3 Exon 8 - xp12:6778443-6778468 GCCAGACUCAGGCUUGCUGCUGACA 4031 3902_8_22 LAG3 Exon 8 - xp12:6778444-6778469 AGCCAGACUCAGGCUUGCUGCUGAC 4032 5133_5_1 PDCD1 Exon 5 + xp2:241849905-241849930 UAUAAUUAUAAUAUAUAGAACCAC 4033 5133_5_2 PDCD1 Exon 5 + xp2:241849906-241849931 AUAAUUAUAAUAUAAUAGAACCACA 4034 5133_5_3 PDCD1 Exon 5 + xp2:241849910-241849935 UUAUAAUAUUAAUAGAACCACAGGGA 4035 5133_5_4 PDCD1 Exon 5 + xp2:241849911-241849936 UAUAAUAUAAUAGAACCACAGGGAA 4036 5133_5_5 PDCD1 Exon 5 + xp2:241849912-241849937 AUAAUAUAAUAGAACCACAGGGAAG 4037 5133_5_6 PDCD1 Exon 5 + xp2:241849913-241849938 UAAUAUAAUAGAACCACAGGGAAGG 4038 5133_5_7 PDCD1 Exon 5 + xp2:241849936-241849961 GGGGGAUCCCUUGUCCCCAGCCACUC 4039 5133_5_8 PDCD1 Exon 5 + xp2:241849946-241849971 UUGUCCCAGCCACUCAGGUGCCUGC 4040 5133_5_9 PDCD1 Exon 5 + xp2:241849954-241849979 GCCACUCAGGUGCCUGCUGGCCGCC 4041 5133_5_10 PDCD1 Exon 5 + xp2:241849961-241849986 AGGUGCCUGCUGGCCGCCUGGAUGC 4042 5133_5_11 PDCD1 Exon 5 + xp2:241849964-241849989 UGCCUGCUGGCCGCCUGGAUGCUGG 4043 5133_5_12 PDCD1 Exon 5 + xp2:241849976-241850001 GCCUGGAUGCUGGUGGCCCUGCCCC 4044 5133_5_13 PDCD1 Exon 5 + xp2:241849981-241850006 GAUGCUGGUGGCCCUGCCCCAGGAG 4045 5133_5_14 PDCD1 Exon 5 + xp2:241849982-241850007 AUGCUGGUGGCCCUGCCCCAGGAGU 4046 5133_5_15 PDCD1 Exon 5 + xp2:241849983-241850008 UGCUGGUGGCCCUGCCCCAGGAGUG 4047 5133_5_16 PDCD1 Exon 5 + xp2:241849984-241850009 GCUGGUGGCCCUGCCCCAGGAGUGG 4048 5133_5_17 PDCD1 Exon 5 + xp2:241849996-241850021 GCCCCAGGAGUGGGGGUGCAGUGUG 4049 5133_5_18 PDCD1 Exon 5 + xp2:241850004-241850029 AGUGGGGGUGCAGUGUGUGGAUGUG 4050 5133_5_19 PDCD1 Exon 5 + xp2:241850009-241850034 GGGUGCAGUGUGUGGAUGUGAGGAG 4051 5133_5_20 PDCD1 Exon 5 + xp2:241850014-241850039 CAGUGUGUGGAUGUGAGGAGUGGAU 4052 5133_5_21 PDCD1 Exon 5 + xp2:241850020-241850045 GUGGAUGUGAGGAGUGGAUAGGCCA 4053 5133_5_22 PDCD1 Exon 5 + xp2:241850023-241850048 GAUGUGAGGAGUGGAUAGGCCACGG 4054 5133_5_23 PDCD1 Exon 5 + xp2:241850024-241850049 AUGUGAGGAGUGGAUAGGCCACGGC 4055 5133_5_24 PDCD1 Exon 5 + xp2:241850025-241850050 UGUGAGGAGUGGAUAGGCCACGGCG 4056 5133_5_25 PDCD1 Exon 5 + xp2:241850026-241850051 GUGAGGAGUGGAUAGGCCACGGCGG 4057 5133_5_26 PDCD1 Exon 5 + xp2:241850033-241850058 GUGGAUAGGCCACGGCGGGGGUAC 4058 5133_5_27 PDCD1 Exon 5 + xp2:241850039-241850064 AGGCCACGGCGGGGGUACUAGGCCC 4059 5133_5_28 PDCD1 Exon 5 + xp2:241850040-241850065 GGCCACGGCGGGGGUACUAGGCCCC 4060 5133_5_29 PDCD1 Exon 5 + xp2:241850041-241850066 GCCACGGCGGGGGUACUACUAGGCCCCG 4061 5133_5_30 PDCD1 Exon 5 + xp2:241850042-241850067 CCACGGCGGGGGUACUAGGCCCCGG 4062 5133_5_31 PDCD1 Exon 5 + xp2:241850066-241850091 GGGGAACGCCUGUACCUUCCCACCC 4063 5133_5_32 PDCD1 Exon 5 + xp2:241850072-241850097 CGCCUGUACCUUCCCACCCAGGCCC 4064 5133_5_33 PDCD1 Exon 5 + xp2:241850075-241850100 CUGUACCUUCCCACCCAGGCCCUGG 4065 5133_5_34 PDCD1 Exon 5 + xp2:241850076-241850101 UGUACCUUCCCACCCAGGCCCUGGU 4066 5133_5_35 PDCD1 Exon 5 + xp2:241850083-241850108 UCCCACCCAGGCCCUGGUGGGAGCC 4067 5133_5_36 PDCD1 Exon 5 + xp2:241850107-241850132 CCGGCCAACCCCUUUAAAUAAUUUC 4068 5133_5_37 PDCD1 Exon 5 + xp2:241850112-241850137 CAACCCCUUUAAAUAAUUUCAGGAA 4069 5133_5_38 PDCD1 Exon 5 + xp2:241850113-241850138 AACCCCUUUAAAUAAUUUCAGGAAU 4070 5133_5_39 PDCD1 Exon 5 + xp2:241850121-241850146 UAAAUAAUUUCAGGAAUGGGUUCCA 4071 5133_5_40 PDCD1 Exon 5 + xp2:241850133-241850158 GGAAUGGGUUCCAAGGAGAGCUCCC 4072 5133_5_41 PDCD1 Exon 5 + xp2:241850134-241850159 GAAUGGGUUCCAAGGAGAGCUCCCA 4073 5133_5_42 PDCD1 Exon 5 + xp2:241850137-241850162 UGGGUUCCAAGGAGAGCUCCCAGGG 4074 5133_5_43 PDCD1 Exon 5 + xp2:241850138-241850163 GGGUUCCAAGGAGAGCUCCCAGGGU 4075 5133_5_44 PDCD1 Exon 5 + xp2:241850145-241850170 AAGGAGAGCUCCCAGGGUGGGCACA 4076 5133_5_45 PDCD1 Exon 5 + xp2:241850146-241850171 AGGAGAGCUCCCAGGGUGGGCACAU 4077 5133_5_46 PDCD1 Exon 5 + xp2:241850147-241850172 GGAGAGCUCCCAGGGUGGGCACAUG 4078 5133_5_47 PDCD1 Exon 5 + xp2:241850148-241850173 GAGAGCUCCCAGGGUGGGCACAUGG 4079 5133_5_48 PDCD1 Exon 5 + xp2:241850149-241850174 AGAGCUCCCAGGGUGGGCACAUGGG 4080 5133_5_49 PDCD1 Exon 5 + xp2:241850156-241850181 CCAGGGUGGGCACAUGGGGGGCCCU 4081 5133_5_50 PDCD1 Exon 5 + xp2:241850187-241850212 CUGCACUUCUGCCCUCCCAACACCC 4082 5133_5_51 PDCD1 Exon 5 + xp2:241850190-241850215 CACUUCUGCCCUCCCAACACCCAGG 4083 5133_5_52 PDCD1 Exon 5 + xp2:241850200-241850225 CUCCCAACACCCAGGUGGCCACAGC 4084 5133_5_53 PDCD1 Exon 5 + xp2:241850201-241850226 UCCCAACACCCAGGUGGCCACAGCU 4085 5133_5_54 PDCD1 Exon 5 + xp2:241850204-241850229 CAACACCCAGGUGGCCACAGCUGGG 4086 5133_5_55 PDCD1 Exon 5 + xp2:241850205-241850230 AACACCCAGGUGGCCACAGCUGGGA 4087 5133_5_56 PDCD1 Exon 5 + xp2:241850206-241850231 ACACCCAGGUGGCCACAGCUGGGAG 4088 5133_5_57 PDCD1 Exon 5 + xp2:241850242-241850267 AACCCCAGCCCUGCCCUCCUGACCCU 4089 5133_5_58 PDCD1 Exon 5 + xp2:241850243-241850268 ACCCCAGCCCUGCCCUCCUGACCUU 4090 5133_5_59 PDCD1 Exon 5 + xp2:241850251-241850276 CCUGCCCUCCUGACCUUGGGACCGU 4091 5133_5_60 PDCD1 Exon 5 + xp2:241850270-241850295 GACCGUAGGAUGUCCCUCUCCCGAG 4092 5133_5_61 PDCD1 Exon 5 + xp2:241850277-241850302 GGAUGUCCCUCUCCCGAGUGGUGUG 4093 5133_5_62 PDCD1 Exon 5 + xp2:241850278-241850303 GAUGUCCCUCUCCGAGUGGUGUGA 4094 5133_5_63 PDCD1 Exon 5 + xp2:241850279-241850304 AUGUCCCUCUCCGAGUGGUGUGAG 4095 5133_5_64 PDCD1 Exon 5 + xp2:241850283-241850308 CCCUUCCCGAGUGGUGUGAGGGGC 4096 5133_5_65 PDCD1 Exon 5 + xp2:241850284-241850309 CCUCUCCCGAGUGGUGUGAGGGGCU 4097 5133_5_66 PDCD1 Exon 5 + xp2:241850285-241850310 CUCUCCCGAGUGGUGUGAGGGGCUG 4098 5133_5_67 PDCD1 Exon 5 + xp2:241850288-241850313 UCCCGAGUGGUGUGAGGGGCUGGGG 4099 5133_5_68 PDCD1 Exon 5 + xp2:241850295-241850320 UGGUGUGAGGGGCUGGGGUGGAAUG 4100 5133_5_69 PDCD1 Exon 5 + xp2:241850298-241850323 UGUGAGGGGCUGGGGUGGAAUGCGG 4101 5133_5_70 PDCD1 Exon 5 + xp2:241850302-241850327 AGGGGCUGGGGUGGAAUGCGGCGGC 4102 5133_5_71 PDCD1 Exon 5 + xp2:241850305-241850330 GGCUGGGGUGGAAUGCGGCGGCAGG 4103 5133_5_72 PDCD1 Exon 5 + xp2:241850317-241850342 AUGCGGCGGCAGGAGGCCAGAGUGC 4104 5133_5_73 PDCD1 Exon 5 + xp2:241850321-241850346 GGCGGCAGGAGGCCAGAGUGCUGGC 4105 5133_5_74 PDCD1 Exon 5 + xp2:241850322-241850347 GCGGCAGGAGGCCAGAGUGCUGGCU 4106 5133_5_75 PDCD1 Exon 5 + xp2:241850331-241850356 GGCCAGAGUGCUGGCUGGGCCUGAA 4107 5133_5_76 PDCD1 Exon 5 + xp2:241850383-241850408 CUGCCUCAGCUUCCCUGCCCCACAA 4108 5133_5_77 PDCD1 Exon 5 + xp2:241850384-241850409 UGCCUCAGCUUCCCUGCCCCACAAA 4109 5133_5_78 PDCD1 Exon 5 + xp2:241850391-241850416 GCUUCCCUGCCCCACAAAGGGCCUG 4110 5133_5_79 PDCD1 Exon 5 + xp2:241850401-241850426 CCCACAAAGGGCCUGAGGUGCUGCC 4111 5133_5_80 PDCD1 Exon 5 + xp2:241850402-241850427 CCACAAAGGGCCUGAGGUGCUGCCU 4112 5133_5_81 PDCD1 Exon 5 + xp2:241850414-241850439 UGAGGUGCUGCCUGGGCAUGUGUAA 4113 5133_5_82 PDCD1 Exon 5 + xp2:241850417-241850442 GGUGCUGCCUGGGCAUGUGUAAAGG 4114 5133_5_83 PDCD1 Exon 5 + xp2:241850420-241850445 GCUGCCUGGGCAUGUGUAAAGGUGG 4115 5133_5_84 PDCD1 Exon 5 + xp2:241850421-241850446 CUGCCUGGGCAUGUGUAAAGGUGGA 4116 5133_5_85 PDCD1 Exon 5 + xp2:241850422-241850447 UGCCUGGGCAUGUGUAAAGGUGGAG 4117 5133_5_86 PDCD1 Exon 5 + xp2:241850449-241850474 GUUUCCUGCCCUGCCCACCACAGCC 4118 5133_5_87 PDCD1 Exon 5 + xp2:241850482-241850507 UUCUGACCUUCCCUGAAACUUCUCU 4119 5133_5_88 PDCD1 Exon 5 + xp2:241850490-241850515 UUCCCUGAAACUUCUCUAGGCCUGC 4120 5133_5_89 PDCD1 Exon 5 + xp2:241850491-241850516 UCCCUGAAACUUCUCUAGGCCUGCA 4121 5133_5_90 PDCD1 Exon 5 + xp2:241850507-241850532 AGGCCUGCAGGGAGCAGAUAACUCC 4122 5133_5_91 PDCD1 Exon 5 + xp2:241850508-241850533 GGCCUGCAGGGAGCAGUAACUCCU 4123 5133_5_92 PDCD1 Exon 5 + xp2:241850509-241850534 GCCUGCAGGGAGCAGUAACUCCUG 4124 5133_5_93 PDCD1 Exon 5 + xp2:241850553-241850578 UACCUCCCACUCCUGUGCCCAGUCU 4125 5133_5_94 PDCD1 Exon 5 + xp2:241850554-241850579 ACCUCCCACUCCUGUGCCCAGUCUU 4126 5133_5_95 PDCD1 Exon 5 + xp2:241850567-241850592 GUGCCCAGUCUUGGGCCCUGCGUCC 4127 5133_5_96 PDCD1 Exon 5 + xp2:241850568-241850593 UGCCCAGUCUUGGGCCCCUGCGUCCCA 4128 5133_5_97 PDCD1 Exon 5 + xp2:241850576-241850601 CUUGGGCCCUGCGUCCAGGGCGUUU 4129 5133_5_98 PDCD1 Exon 5 + xp2:241850577-241850602 UUGGGCCCUGCGUCCAGGGCGUUUC 4130 5133_5_99 PDCD1 Exon 5 + xp2:241850591-241850616 CAGGGCGUUUCGGGAUGCCACUGCC 4131 5133_5_100 PDCD1 Exon 5 + xp2:241850592-241850617 AGGGCGUUUCGGGAUGCCACUGCCA 4132 5133_5_101 PDCD1 Exon 5 + xp2:241850593-241850618 GGGCGUUUCGGGAUGCCACUGCCAG 4133 5133_5_102 PDCD1 Exon 5 + xp2:241850601-241850626 CGGGAUGCCACUGCCAGGGGCACCU 4134 5133_5_103 PDCD1 Exon 5 + xp2:241850612-241850637 UGCCAGGGGCACCUUGGCUGCUCCA 4135 5133_5_104 PDCD1 Exon 5 + xp2:241850640-241850665 CCAUCUCCAACCAGCCCCCAAGUUC 4136 5133_5_105 PDCD1 Exon 5 + xp2:241850644-241850669 CUCCAACCAGCCCCCAAGUUCAGGC 4137 5133_5_106 PDCD1 Exon 5 + xp2:241850647-241850672 CAACCAGCCCCCAAGUUCAGGCAGG 4138 5133_5_107 PDCD1 Exon 5 + xp2:241850653-241850678 GCCCCCAAGUUCAGGCAGGAGGCUC 4139 5133_5_108 PDCD1 Exon 5 + xp2:241850654-241850679 CCCCCAAGUUCAGGCAGGAGGCUCC 4140 5133_5_109 PDCD1 Exon 5 + xp2:241850655-241850680 CCCCAAGUUCAGGCAGGAGGCUCCG 4141 5133_5_110 PDCD1 Exon 5 + xp2:241850662-241850687 UUCAGGCAGGAGGCUCCGGGGCGUC 4142 5133_5_111 PDCD1 Exon 5 + xp2:241850666-241850691 GGCAGGAGGCUCCGGGGCGUCAGGC 4143 5133_5_112 PDCD1 Exon 5 + xp2:241850667-241850692 GCAGGAGGCUCCGGGGCGUCAGGCA 4144 5133_5_113 PDCD1 Exon 5 + xp2:241850673-241850698 GGCUCCGGGGCGUCAGGCAGGGCCA 4145 5133_5_114 PDCD1 Exon 5 + xp2:241850688-241850713 GGCAGGGCCACGGCGCCUUCAGCCCC 4146 5133_5_115 PDCD1 Exon 5 + xp2:241850689-241850714 GCAGGGCCACGGCGCCUUCAGCCCC 4147 5133_5_116 PDCD1 Exon 5 + xp2:241850735-241850760 GCAGCAGCAGCAGCAGCAGAGAUUC 4148 5133_5_117 PDCD1 Exon 5 + xp2:241850736-241850761 CAGCAGCAGCAGCAGCAGAGAUUCA 4149 5133_5_118 PDCD1 Exon 5 + xp2:241850742-241850767 CAGCAGCAGCAGAGAUUCAGGGAGC 4150 5133_5_119 PDCD1 Exon 5 + xp2:241850749-241850774 AGCAGAGAUUCAGGGAGCUGGACGC 4151 5133_5_120 PDCD1 Exon 5 + xp2:241850763-241850788 GAGCUGGACGCAGGCAGCUCUGUGC 4152 5133_5_121 PDCD1 Exon 5 + xp2:241850767-241850792 UGGACGCAGGCAGCUCUGUGCUGGC 4153 5133_5_122 PDCD1 Exon 5 + xp2:241850791-241850816 CAGGACCUGAAGCAGUGACUGCAUC 4154 5133_5_123 PDCD1 Exon 5 + xp2:241850804-241850829 AGUGACUGCAUCUGGCCCUCCCUGU 4155 5133_5_124 PDCD1 Exon 5 + xp2:241850805-241850830 GUGACUGCAUCUGGCCCUCCCUGUA 4156 5133_5_125 PDCD1 Exon 5 + xp2:241850806-241850831 UGACUGCAUCUGGCCCUCCCUGUAG 4157 5133_5_126 PDCD1 Exon 5 + xp2:241850810-241850835 UGCAUCUGGCCCUCCCUGUAGGGGA 4158 5133_5_127 PDCD1 Exon 5 + xp2:241850827-241850852 GUAGGGGACGGUGACACCUGCUGCC 4159 5133_5_128 PDCD1 Exon 5 + xp2:241850828-241850853 UAGGGGACGGUGACACCUGCUGCCU 4160 5133_5_129 PDCD1 Exon 5 + xp2:241850838-241850863 UGACACCCUGCUGCCUGGGCUCACUG 4161 5133_5_130 PDCD1 Exon 5 + xp2:241850839-241850864 GACACCUGCUGCCUGGGCUCACUGU 4162 5133_5_131 PDCD1 Exon 5 + xp2:241850861-241850886 UGUGGGCAUUGAGACAUGAGUCCUG 4163 5133_5_132 PDCD1 Exon 5 + xp2:241850864-241850889 GGGCAUUGAGACAUGAGUCCCUGUGG 4164 5133_5_133 PDCD1 Exon 5 + xp2:241850865-241850890 GGCAUUGAGACAUGAGUCCUGUGGU 4165 5133_5_134 PDCD1 Exon 5 + xp2:241850866-241850891 GCAUUGAGACAUGAGUCCUGUGGUG 4166 5133_5_135 PDCD1 Exon 5 + xp2:241850876-241850901 AUGAGUCCCUGUGGUGGGGCUGUGCC 4167 5133_5_136 PDCD1 Exon 5 + xp2:241850882-241850907 CCUGUGGUGGGGCUGUGCCUGGUGC 4168 5133_5_137 PDCD1 Exon 5 + xp2:241850888-241850913 GUGGGGCUGUGCCUGGUGCAGGUGC 4169 5133_5_138 PDCD1 Exon 5 + xp2:241850892-241850917 GGCUGUGCCUGGUGCAGGUGCAGGC 4170 5133_5_139 PDCD1 Exon 5 + xp2:241850900-241850925 CUGGUGCAGGUGCAGGCUGGAGCCC 4171 5133_5_140 PDCD1 Exon 5 + xp2:241850911-241850936 GCAGGCUGGAGCCCCGGUCCGCCCCC 4172 5133_5_141 PDCD1 Exon 5 + xp2:241850926-241850951 GGUCCGCCCCCAGGCAGCUCAGCCCC 4173 5133_5_142 PDCD1 Exon 5 + xp2:241850930-241850955 GCCCCCAGGCAGCUCAGCCCCUGGA 4174 5133_5_143 PDCD1 Exon 5 + xp2:241850940-241850965 AGCUCAGCCCCUGGACGGCCUGCAA 4175 5133_5_144 PDCD1 Exon 5 + xp2:241850967-241850992 GCCUGCACCCUGCCUGCUUCUCCUG 4176 5133_5_145 PDCD1 Exon 5 + xp2:241850983-241851008 CUUCUCCUGAGGAAAUGCCGCUGACC 4177 5133_5_146 PDCD1 Exon 5 + xp2:241850984-241851009 UUCUCCUGAGGAAAUGCCGCUGACCCC 4178 5133_5_147 PDCD1 Exon 5 + xp2:241850991-241851016 GAGGAAAUGCCGCUGACCCGGGCUCA 4179 5133_5_148 PDCD1 Exon 5 + xp2:241850994-241851019 GAAAUGCCGCUGACCCGGGCUCAUGG 4180 5133_5_149 PDCD1 Exon 5 + xp2:241850997-241851022 AUGCCGCUGACCCGGGCUCAUGGUGG 4181 5133_5_150 PDCD1 Exon 5 + xp2:241850998-241851023 UGCCGCUGACCCGGGCUCAUGGUGGA 4182 5133_5_151 PDCD1 Exon 5 + xp2:241851013-241851038 UCAUGGUGGAGGGUCUGCAGAACAC 4183 5133_5_152 PDCD1 Exon 5 + xp2:241851016-241851041 UGGUGGAGGGUCUGCAGAACACUGG 4184 5133_5_153 PDCD1 Exon 5 + xp2:241851022-241851047 AGGGUCUGCAGAACACUGGUGGCCA 4185 5133_5_154 PDCD1 Exon 5 + xp2:241851029-241851054 GCAGAACACUGGUGGCCAAGGAAGC 4186 5133_5_155 PDCD1 Exon 5 + xp2:241851036-241851061 ACUGGUGGCCAAGGAAGCCGGUUCAG 4187 5133_5_156 PDCD1 Exon 5 + xp2:241851037-241851062 CUGGUGGCCAAGGAAGCCGGUCAGA 4188 5133_5_157 PDCD1 Exon 5 + xp2:241851038-241851063 UGGUGGCCAAGGAAGCCGGUUCAGAG 4189 5133_5_158 PDCD1 Exon 5 + xp2:241851062-241851087 GGGGCCAAGAGCAGUGUCCAUCCUC 4190 5133_5_159 PDCD1 Exon 5 + xp2:241851071-241851096 AGCAGUGUCCAUCCUCAGGCCUCAG 4191 5133_5_160 PDCD1 Exon 5 + xp2:241851075-241851100 GUGUCCAUCCUCAGGCCUCAGUGGC 4192 5133_5_161 PDCD1 Exon 5 + xp2:241851076-241851101 UGUCCAUCCUCAGGCCUCAGUGGCU 4193 5133_5_162 PDCD1 Exon 5 + xp2:241851086-241851111 CAGGCCUCAGUGGCUGGGCACUCCG 4194 5133_5_163 PDCD1 Exon 5 + xp2:241851087-241851112 AGGCCUCAGUGGCUGGGCACUCCGA 4195 5133_5_164 PDCD1 Exon 5 + xp2:241851108-241851133 CCGAGGGCCGUCAGCUGAGCCCCUG 4196 5133_5_165 PDCD1 Exon 5 + xp2:241851109-241851134 CGAGGGCCGUCAGCUGAGCCCCUGC 4197 5133_5_166 PDCD1 Exon 5 + xp2:241851112-241851137 GGGCCGUCAGCUGAGCCCCUGCGGG 4198 5133_5_167 PDCD1 Exon 5 + xp2:241851113-241851138 GGCCGUCAGCUGAGCCCCUGCGGGC 4199 5133_5_168 PDCD1 Exon 5 + xp2:241851114-241851139 GCCGUCAGCUGAGCCCCUGCGGGCG 4200 5133_5_169 PDCD1 Exon 5 + xp2:241851115-241851140 CCGUCAGCUGAGCCCCUGCGGGCGG 4201 5133_5_170 PDCD1 Exon 5 + xp2:241851121-241851146 GCUGAGCCCCUGCGGGCGGGGGAUG 4202 5133_5_171 PDCD1 Exon 5 + xp2:241851137-241851162 CGGGGGAUGAGGUGCCCAUUCCGCU 4203 5133_5_172 PDCD1 Exon 5 + xp2:241851148-241851173 GUGCCCAUUCCGCUAGGAAAGACAA 4204 5133_5_173 PDCD1 Exon 5 + xp2:241851151-241851176 CCCAUUCCGCUAGGAAAGACAAUGG 4205 5133_5_174 PDCD1 Exon 5 + xp2:241851170-241851195 CAAUGGUGGCAUACUCCGUCUGCUC 4206 5133_5_175 PDCD1 Exon 5 + xp2:241851171-241851196 AAUGGUGGCAUACUCCGUCUGCUCA 4207 5133_5_176 PDCD1 Exon 5 + xp2:241851178-241851203 GCAUACUCCGUCUGCUCAGGGACAC 4208 5133_5_177 PDCD1 Exon 5 + xp2:241851179-241851204 CAUACUCCGUCUGCUCAGGGACACA 4209 5133_5_178 PDCD1 Exon 5 + xp2:241851184-241851209 UCCGUCUGCUCAGGGACACAGGGCA 4210 5133_5_179 PDCD1 Exon 5 + xp2:241851185-241851210 CCGUCUGCUCAGGGACACAGGGCAC 4211 5133_5_180 PDCD1 Exon 5 + xp2:241851186-241851211 CGUCUGCUCAGGGACACAGGGCACG 4212 5133_5_181 PDCD1 Exon 5 + xp2:241851187-241851212 GUCUGCUCAGGGACACAGGGCACGG 4213 5133_5_182 PDCD1 Exon 5 + xp2:241851188-241851213 UCUGCUCAGGGACACAGGGCACGGG 4214 5133_5_183 PDCD1 Exon 5 + xp2:241851194-241851219 CAGGGACACAGGGCACGGGGGGCUC 4215 5133_5_184 PDCD1 Exon 5 + xp2:241851195-241851220 AGGGACACAGGGCACGGGGGGCUCC 4216 5133_5_185 PDCD1 Exon 5 + xp2:241851196-241851221 GGGACACAGGGCACGGGGGGCUCCG 4217 5133_5_186 PDCD1 Exon 5 + xp2:241851213-241851238 GGGCUCCGGGGUCUUCUCUCGCCAC 4218 5133_5_187 PDCD1 Exon 5 + xp2:241851248-241851273 GCUCCCCAUAGUCCACAGAGAACAC 4219 5133_5_188 PDCD1 Exon 5 + xp2:241851253-241851278 CCAUAGUCCACAGAGAACACAGGCA 4220 5133_5_189 PDCD1 Exon 5 + xp2:241851259-241851284 UCCACAGAGAACACAGGCACGGCUG 4221 5133_5_190 PDCD1 Exon 5 + xp2:241851260-241851285 CCACAGAGAACACAGGCACGGCUGA 4222 5133_5_191 PDCD1 Exon 5 + xp2:241851261-241851286 CACAGAGAACACAGGCACGGCUGAG 4223 5133_5_192 PDCD1 Exon 5 + xp2:241851277-241851302 ACGGCUGAGGGGUCCUCCUUCUUUG 4224 5133_5_193 PDCD1 Exon 5 + xp2:241851284-241851309 AGGGGUCCUCCUUCUUUGAGGAGAA 4225 5133_5_194 PDCD1 Exon 5 + xp2:241851285-241851310 GGGGUCCUCCUUCUUUGAGGAAA 4226 5133_5_195 PDCD1 Exon 5 + xp2:241851290-241851315 CCUCCUUCUUUGAGGAGAAAGGGAG 4227 5133_5_196 PDCD1 Exon 5 + xp2:241851291-241851316 CUCCUUCUUUGAGGAGAAAGGGAGA 4228 5133_5_197 PDCD1 Exon 5 - xp2:241849858-241849883 GGAGUUCUGUCCUGUCUGGUGGCUG 4229 5133_5_198 PDCD1 Exon 5 - xp2:241849864-241849889 UGCUAAGGAGUUCUGUCCUGUCUGG 4230 5133_5_199 PDCD1 Exon 5 - xp2:241849867-241849892 GCAUGCUAAGGAGUUCUGUCCUGUC 4231 5133_5_200 PDCD1 Exon 5 - xp2:241849884-241849909 UAUAAUUAAAUAUGAGAGCAUGCUA 4232 5133_5_201 PDCD1 Exon 5 - xp2:241849929-241849954 UGGGACAAGGGAUCCCCCCUUCCCUG 4233 5133_5_202 PDCD1 Exon 5 - xp2:241849946-241849971 GCAGGCACCUGAGUGGCUGGGACAAA 4234 5133_5_203 PDCD1 Exon 5 - xp2:241849947-241849972 AGCAGGCACCUGAGUGGCUGGGACA 4235 5133_5_204 PDCD1 Exon 5 - xp2:241849953-241849978 GCGGCCAGCAGGCACCUGAGUGGCU 4236 5133_5_205 PDCD1 Exon 5 - xp2:241849954-241849979 GGCGGCCAGCAGGCACCUGAGUGGC 4237 5133_5_206 PDCD1 Exon 5 - xp2:241849958-241849983 UCCAGGCGGCCAGCAGGCACCUGAG 4238 5133_5_207 PDCD1 Exon 5 - xp2:241849969-241849994 GGCCACCAGCAUCCAGGCGGCCAGC 4239 5133_5_208 PDCD1 Exon 5 - xp2:241849977-241850002 UGGGGCAGGGCCACCAGCAUCCAG 4240 5133_5_209 PDCD1 Exon 5 - xp2:241849980-241850005 UCCUGGGGCAGGGCCACCAGCAUCC 4241 5133_5_210 PDCD1 Exon 5 - xp2:241849995-241850020 ACACUGCACCCCCACUCCUGGGGCA 4242 5133_5_211 PDCD1 Exon 5 - xp2:241849996-241850021 CACACUGCACCCCCACUCCUGGGGC 4243 5133_5_212 PDCD1 Exon 5 - xp2:241850000-241850025 UCCACACACUGCACCCCCACUCCUG 4244 5133_5_213 PDCD1 Exon 5 - xp2:241850001-241850026 AUCCACACACUGCACCCCCACUCCU 4245 5133_5_214 PDCD1 Exon 5 - xp2:241850002-241850027 CAUCCACACACUGCACCCCCACUCC 4246 5133_5_215 PDCD1 Exon 5 - xp2:241850045-241850070 CCCCCGGGGCCUAGUACCCCCGCCCG 4247 5133_5_216 PDCD1 Exon 5 - xp2:241850064-241850089 GUGGGAAGGUACAGGCGUUCCCCCG 4248 5133_5_217 PDCD1 Exon 5 - xp2:241850065-241850090 GGUGGGAAGGUACAGGCGUUCCCCC 4249 5133_5_218 PDCD1 Exon 5 - xp2:241850066-241850091 GGGUGGGAAGGUACAGGCGUUCCCCC 4250 5133_5_219 PDCD1 Exon 5 - xp2:241850077-241850102 CACCAGGGCCUGGGUGGGAAGGUAC 4251 5133_5_220 PDCD1 Exon 5 - xp2:241850083-241850108 GGCUCCCACCAGGGCCUGGGUGGGA 4252 5133_5_221 PDCD1 Exon 5 - xp2:241850087-241850112 GCCGGGCUCCCACCAGGGCCUGGGU 4253 5133_5_222 PDCD1 Exon 5 - xp2:241850088-241850113 GGCCGGGCUCCCACCAGGGCCUGGG 4254 5133_5_223 PDCD1 Exon 5 - xp2:241850091-241850116 GUUGGCCGGGCUCCCACCAGGGCCU 4255 5133_5_224 PDCD1 Exon 5 - xp2:241850092-241850117 GGUUGGCCGGGCUCCCACCAGGGCC 4256 5133_5_225 PDCD1 Exon 5 - xp2:241850097-241850122 AAAGGGGUUGGCCGGGCUCCCACCA 4257 5133_5_226 PDCD1 Exon 5 - xp2:241850098-241850123 UAAAGGGGUUGGCCGGGCUCCCACC 4258 5133_5_227 PDCD1 Exon 5 - xp2:241850109-241850134 CUGAAAUUAUUUAAAGGGGUUGGCC 4259 5133_5_228 PDCD1 Exon 5 - xp2:241850110-241850135 CCUGAAAUUAUUUAAAGGGGUUGGC 4260 5133_5_229 PDCD1 Exon 5 - xp2:241850114-241850139 CAUUCCUGAAAUUAUUUAAAGGGGU 4261 5133_5_230 PDCD1 Exon 5 - xp2:241850118-241850143 AACCCAUUCCUGAAAUUAUUUAAG 4262 5133_5_231 PDCD1 Exon 5 - xp2:241850119-241850144 GAACCCAUUCCUGAAAUUAUUUAAA 4263 5133_5_232 PDCD1 Exon 5 - xp2:241850120-241850145 GGAACCCAUUCCUGAAAUUAUUUAA 4264 5133_5_233 PDCD1 Exon 5 - xp2:241850146-241850171 AUGUGCCCACCCUGGGAGCUCUCCU 4265 5133_5_234 PDCD1 Exon 5 - xp2:241850158-241850183 CUAGGGCCCCCCAUGUGCCCACCCU 4266 5133_5_235 PDCD1 Exon 5 - xp2:241850159-241850184 CCUAGGGCCCCCCAUGUGCCCACCC 4267 5133_5_236 PDCD1 Exon 5 - xp2:241850180-241850205 GGGAGGGCAGAAGUGCAGGCACCUA 4268 5133_5_237 PDCD1 Exon 5 - xp2:241850181-241850206 UGGGAGGGCAGAAGUGCAGGCACCU 4269 5133_5_238 PDCD1 Exon 5 - xp2:241850189-241850214 CUGGGUGUUGGGAGGGCAGAAGUGC 4270 5133_5_239 PDCD1 Exon 5 - xp2:241850201-241850226 AGCUGUGGCCACCUGGGUGUUGGGA 4271 5133_5_240 PDCD1 Exon 5 - xp2:241850202-241850227 CAGCUGUGGCCACCUGGGUGUUGGG 4272 5133_5_241 PDCD1 Exon 5 - xp2:241850205-241850230 UCCCAGCUGUGGCCACCUGGGUGUU 4273 5133_5_242 PDCD1 Exon 5 - xp2:241850206-241850231 CUCCCAGCUGUGGCCACCUGGGUGU 4274 5133_5_243 PDCD1 Exon 5 - xp2:241850212-241850237 AGGCCCCCCCAGCUGUGGCCACCU 4275 5133_5_244 PDCD1 Exon 5 - xp2:241850213-241850238 CAGGCCCCUCCCAGCUGUGGCCACC 4276 5133_5_245 PDCD1 Exon 5 - xp2:241850221-241850246 GGUUGACUCAGGCCCCUCCCAGCUG 4277 5133_5_246 PDCD1 Exon 5 - xp2:241850237-241850262 AGGAGGGCAGGGCUGGGGUUGACUC 4278 5133_5_247 PDCD1 Exon 5 - xp2:241850247-241850272 UCCCAAGGUCAGGAGGGCAGGGCUG 4279 5133_5_248 PDCD1 Exon 5 - xp2:241850248-241850273 GUCCCAAGGUCAGGAGGGCAGGGCU 4280 5133_5_249 PDCD1 Exon 5 - xp2:241850249-241850274 GGUCCCAAGGUCAGGAGGGCAGGGC 4281 5133_5_250 PDCD1 Exon 5 - xp2:241850253-241850278 CUACGGUCCCAAGGUCAGGAGGGCA 4282 5133_5_251 PDCD1 Exon 5 - xp2:241850254-241850279 CCUACGGUCCCAAGGUUCAGGAGGGC 4283 5133_5_252 PDCD1 Exon 5 - xp2:241850258-241850283 ACAUCCUACGGUCCCAAGGUCAGGA 4284 5133_5_253 PDCD1 Exon 5 - xp2:241850259-241850284 GACAUCCUACGGUCCCAAGGUCAGG 4285 5133_5_254 PDCD1 Exon 5 - xp2:241850262-241850287 AGGGACAUCCUACGGUCCCAAGGUC 4286 5133_5_255 PDCD1 Exon 5 - xp2:241850267-241850292 GGGAGAGGGACAUCCUACGGUCCCA 4287 5133_5_256 PDCD1 Exon 5 - xp2:241850275-241850300 CACCACUCGGGAGAGGGACAUCCUA 4288 5133_5_257 PDCD1 Exon 5 - xp2:241850286-241850311 CCAGCCCCUCACACCACUCGGGAGA 4289 5133_5_258 PDCD1 Exon 5 - xp2:241850287-241850312 CCCAGCCCCUCACACCACUCGGGAG 4290 5133_5_259 PDCD1 Exon 5 - xp2:241850292-241850317 UCCACCCCAGCCCCUCACACCACUC 4291 5133_5_260 PDCD1 Exon 5 - xp2:241850293-241850318 UUCCACCCCAGCCCCUCACACCACU 4292 5133_5_261 PDCD1 Exon 5 - xp2:241850336-241850361 GGCCUUUCAGGCCCAGCCAGCACUC 4293 5133_5_262 PDCD1 Exon 5 - xp2:241850353-241850378 GGGCAGGCAGAGCUGGAGGCCUUUC 4294 5133_5_263 PDCD1 Exon 5 - xp2:241850362-241850387 GCAGUAAGCGGGCAGGCAGAGCUGG 4295 5133_5_264 PDCD1 Exon 5 - xp2:241850365-241850390 GAGGCAGUAAGCGGGCAGGCAGAGC 4296 5133_5_265 PDCD1 Exon 5 - xp2:241850374-241850399 AGGGAAGCUGAGGCAGUAAGCGGGC 4297 5133_5_266 PDCD1 Exon 5 - xp2:241850378-241850403 GGGCAGGGAAGCUGAGGCAGUAAGC 4298 5133_5_267 PDCD1 Exon 5 - xp2:241850379-241850404 GGGGCAGGGAAGCUGAGGCAGUAAG 4299 5133_5_268 PDCD1 Exon 5 - xp2:241850389-241850414 GGCCCUUUGUGGGGCAGGGAAGCUG 4300 5133_5_269 PDCD1 Exon 5 - xp2:241850398-241850423 AGCACCUCAGGCCCUUUGUGGGGCA 4301 5133_5_270 PDCD1 Exon 5 - xp2:241850399-241850424 CAGCACCUCAGGCCCUUUGUGGGGC 4302 5133_5_271 PDCD1 Exon 5 - xp2:241850403-241850428 CAGGCAGCACCUCAGGCCCUUUGUG 4303 5133_5_272 PDCD1 Exon 5 - xp2:241850404-241850429 CCAGGCAGCACCUCAGGCCCUUUGUGU 4304 5133_5_273 PDCD1 Exon 5 - xp2:241850405-241850430 CCCAGGCAGCACCUCAGGCCCUUUG 4305 5133_5_274 PDCD1 Exon 5 - xp2:241850415-241850440 UUUACACAUGCCCAGGCAGCACCUC 4306 5133_5_275 PDCD1 Exon 5 - xp2:241850427-241850452 AACCCCUCCACCUUUACACAUGCCC 4307 5133_5_276 PDCD1 Exon 5 - xp2:241850456-241850481 AGCUCCUGGCUGUGGUGGGCAGGGC 4308 5133_5_277 PDCD1 Exon 5 - xp2:241850460-241850485 GAAGAGCUCCUGGCUGUGGUGGGCA 4309 5133_5_278 PDCD1 Exon 5 - xp2:241850461-241850486 AGAAGAGCUCCUGGCUGUGGUGGGC 4310 5133_5_279 PDCD1 Exon 5 - xp2:241850465-241850490 GGUCAGAAGAGCUCCUGGCUGUGGU 4311 5133_5_280 PDCD1 Exon 5 - xp2:241850466-241850491 AGGUCAGAAGAGCUCCUGGCUGUGG 4312 5133_5_281 PDCD1 Exon 5 - xp2:241850469-241850494 GGAAGGUCAGAAGAGCUCCUGGCUG 4313 5133_5_282 PDCD1 Exon 5 - xp2:241850475-241850500 UUUCAGGGAAGGUCAGAAGAGCUCC 4314 5133_5_283 PDCD1 Exon 5 - xp2:241850491-241850516 UGCAGGCCUAGAGAAGUUUCAGGGA 4315 5133_5_284 PDCD1 Exon 5 - xp2:241850495-241850520 UCCCUGCAGGCCUAGAGAAGUUUCA 4316 5133_5_285 PDCD1 Exon 5 - xp2:241850496-241850521 CUCCCUGCAGGCCUAGAGAAGUUUC 4317 5133_5_286 PDCD1 Exon 5 - xp2:241850513-241850538 UCCCCAGGAGUUAUCUGCUCCCUGC 4318 5133_5_287 PDCD1 Exon 5 - xp2:241850533-241850558 AGGUACAUGGGGCUGGGGACUCCCC 4319 5133_5_288 PDCD1 Exon 5 - xp2:241850543-241850568 CAGGAGUGGGAGGUACAUGGGGCUG 4320 5133_5_289 PDCD1 Exon 5 - xp2:241850544-241850569 ACAGGAGUGGGAGGUACAUGGGGCU 4321 5133_5_290 PDCD1 Exon 5 - xp2:241850545-241850570 CACAGGAGUGGGAGGUACAUGGGGC 4322 5133_5_291 PDCD1 Exon 5 - xp2:241850549-241850574 UGGGCACAGGAGUGGGAGGUACAUG 4323 5133_5_292 PDCD1 Exon 5 - xp2:241850550-241850575 CUGGGCACAGGAGUGGGAGGUACAU 4324 5133_5_293 PDCD1 Exon 5 - xp2:241850551-241850576 ACUGGGCACAGGAGUGGGAGGUAC 4325 5133_5_294 PDCD1 Exon 5 - xp2:241850558-241850583 GCCCAAGACUGGGCACAGGAGUGGG 4326 5133_5_295 PDCD1 Exon 5 - xp2:241850561-241850586 AGGGCCCAAGACUGGGCACAGGAGU 4327 5133_5_296 PDCD1 Exon 5 - xp2:241850562-241850587 CAGGGCCCAAGACUGGGCACAGGAG 4328 5133_5_297 PDCD1 Exon 5 - xp2:241850567-241850592 GGACGCAGGGCCCAAGACUGGGCAC 4329 5133_5_298 PDCD1 Exon 5 - xp2:241850573-241850598 CGCCCUGGACGCAGGGCCCAAGACU 4330 5133_5_299 PDCD1 Exon 5 - xp2:241850574-241850599 ACGCCCUGGACGCAGGGCCCAAGAC 4331 5133_5_300 PDCD1 Exon 5 - xp2:241850585-241850610 GGCAUCCCGAAACGCCCUGGACGCA 4332 5133_5_301 PDCD1 Exon 5 - xp2:241850586-241850611 UGGCAUCCCGAAACGCCCUGGACGC 4333 5133_5_302 PDCD1 Exon 5 - xp2:241850593-241850618 CUGGCAGUGGCAUCCCGAAACGCCC 4334 5133_5_303 PDCD1 Exon 5 - xp2:241850611-241850636 GGAGCAGCCCAAGGUGCCCCUGGCAG 4335 5133_5_304 PDCD1 Exon 5 - xp2:241850617-241850642 GGCCUUGGAGCAGCCCAAGGUGCCCC 4336 5133_5_305 PDCD1 Exon 5 - xp2:241850626-241850651 GUUGGAGAUGGCCUUGGAGCAGCCCA 4337 5133_5_306 PDCD1 Exon 5 - xp2:241850637-241850662 CUUGGGGGCUGGUUGGAGAUGGCCU 4338 5133_5_307 PDCD1 Exon 5 - xp2:241850643-241850668 CCUGAACUUGGGGGCUGGUUGGAGA 4339 5133_5_308 PDCD1 Exon 5 - xp2:241850649-241850674 CUCCUGCCUGAACUUGGGGGCUGGU 4340 5133_5_309 PDCD1 Exon 5 - xp2:241850653-241850678 GAGCCUCCUGCCUGAACUUGGGGGC 4341 5133_5_310 PDCD1 Exon 5 - xp2:241850657-241850682 CCCGGAGCCUCCUGCCUGAACUUGG 4342 5133_5_311 PDCD1 Exon 5 - xp2:241850658-241850683 CCCCGGAGCCUCCUGCCUGAACUUG 4343 5133_5_312 PDCD1 Exon 5 - xp2:241850659-241850684 GCCCCGGAGCCUCCUGCCUGAACUU 4344 5133_5_313 PDCD1 Exon 5 - xp2:241850660-241850685 CGCCCCGGAGCCCUCCUGCCUGAACU 4345 5133_5_314 PDCD1 Exon 5 - xp2:241850680-241850705 GGCGCCGUGGCCCUGCCUGACGCCC 4346 5133_5_315 PDCD1 Exon 5 - xp2:241850698-241850723 CUGCGGCCCGGGGCUGAAGGCGCCG 4347 5133_5_316 PDCD1 Exon 5 - xp2:241850706-241850731 CGACGACGCUGCGGCCCGGGGCUGA 4348 5133_5_317 PDCD1 Exon 5 - xp2:241850713-241850738 ACGACGACGACGCUGCGGCCCG 4349 5133_5_318 PDCD1 Exon 5 - xp2:241850714-241850739 GACGACGACGACGACGCUGCGGCCC 4350 5133_5_319 PDCD1 Exon 5 - xp2:241850715-241850740 CGACGACGACGACGCUGCGGCC 4351 5133_5_320 PDCD1 Exon 5 - xp2:241850720-241850745 GACGACGACGACGACGACGACGCUG 4352 5133_5_321 PDCD1 Exon 5 - xp2:241850799-241850824 GAGGGCCAGAUGCAGUCACUGCUUC 4353 5133_5_322 PDCD1 Exon 5 - xp2:241850822-241850847 CAGGUGUCACCGUCCCCCUACAGGGA 4354 5133_5_323 PDCD1 Exon 5 - xp2:241850823-241850848 GCAGGUGUCACCGUCCCCUACAGGG 4355 5133_5_324 PDCD1 Exon 5 - xp2:241850826-241850851 GCAGCAGGUGUCACCGUCCCCUACA 4356 5133_5_325 PDCD1 Exon 5 - xp2:241850827-241850852 GGCAGCAGGUGUCACCGUCCCCUAC 4357 5133_5_326 PDCD1 Exon 5 - xp2:241850846-241850871 AAUGCCCACAGUGAGCCCAGGCAGC 4358 5133_5_327 PDCD1 Exon 5 - xp2:241850853-241850878 AUGUCUCAAUGCCCACAGUGAGCCC 4359 5133_5_328 PDCD1 Exon 5 - xp2:241850885-241850910 CCUGCACCAGGCACAGCCCCACAC 4360 5133_5_329 PDCD1 Exon 5 - xp2:241850902-241850927 CGGGGCUCCAGCCUGCACCUGCACC 4361 5133_5_330 PDCD1 Exon 5 - xp2:241850925-241850950 GGGCUGAGCUGCCUGGGGGCGACCG 4362 5133_5_331 PDCD1 Exon 5 - xp2:241850926-241850951 GGGGCUGAGCUGCCUGGGGGCGACC 4363 5133_5_332 PDCD1 Exon 5 - xp2:241850927-241850952 AGGGGCUGAGCUGCCUGGGGGCGAC 4364 5133_5_333 PDCD1 Exon 5 - xp2:241850934-241850959 GCCGUCCAGGGGCUGAGCUGCCUGG 4365 5133_5_334 PDCD1 Exon 5 - xp2:241850935-241850960 GGCCGUCCAGGGGCUGAGCUGCCUG 4366 5133_5_335 PDCD1 Exon 5 - xp2:241850936-241850961 AGGCCGUCCAGGGGCUGAGCUGCCU 4367 5133_5_336 PDCD1 Exon 5 - xp2:241850937-241850962 CAGGCCGUCCAGGGGCUGAGCUGCC 4368 5133_5_337 PDCD1 Exon 5 - xp2:241850950-241850975 GUGCAGGCCAUUGCAGGCCGUCCAG 4369 5133_5_338 PDCD1 Exon 5 - xp2:241850951-241850976 GGUGCAGGCCAUUGCAGGCCGUCCA 4370 5133_5_339 PDCD1 Exon 5 - xp2:241850952-241850977 GGGUGCAGGCCAUUGCAGGCCGUCC 4371 5133_5_340 PDCD1 Exon 5 - xp2:241850961-241850986 AAGCAGGCAGGGUGCAGGCCAUUGC 4372 5133_5_341 PDCD1 Exon 5 - xp2:241850971-241850996 UCCUCAGGAGAAGCAGGCAGGGUGC 4373 5133_5_342 PDCD1 Exon 5 - xp2:241850977-241851002 CGCAUUUCCUCAGGAGAAGCAGGCA 4374 5133_5_343 PDCD1 Exon 5 - xp2:241850978-241851003 GCGCAUUUCCUCAGGAGAAGCAGGC 4375 5133_5_344 PDCD1 Exon 5 - xp2:241850982-241851007 GUCAGCGCAUUUCCUCAGGAGAAGC 4376 5133_5_345 PDCD1 Exon 5 - xp2:241850991-241851016 UGAGCCCGGGUCAGCGCAUUUCCUC 4377 5133_5_346 PDCD1 Exon 5 - xp2:241851009-241851034 UCUGCAGACCCUCCACCAUGAGCCC 4378 5133_5_347 PDCD1 Exon 5 - xp2:241851010-241851035 UUCUGCAGACCCUCCACCAUGAGCC 4379 5133_5_348 PDCD1 Exon 5 - xp2:241851047-241851072 UCUUGGCCCCUCUGACCGGCUUCCU 4380 5133_5_349 PDCD1 Exon 5 - xp2:241851056-241851081 GGACACUGCUCUUGGCCCCUCUGAC 4381 5133_5_350 PDCD1 Exon 5 - xp2:241851069-241851094 GAGGCCUGAGGAUGGACACUGCUCU 4382 5133_5_351 PDCD1 Exon 5 - xp2:241851082-241851107 GUGCCCAGCCCACUGAGGCCUGAGGA 4383 5133_5_352 PDCD1 Exon 5 - xp2:241851086-241851111 CGGAGUGCCCAGCCCACUGAGGCCUG 4384 5133_5_353 PDCD1 Exon 5 - xp2:241851093-241851118 CGGCCCCUCGGAGUGCCCAGCCCACUG 4385 5133_5_354 PDCD1 Exon 5 - xp2:241851111-241851136 CCGCAGGGGCUCAGCUGACGGCCCU 4386 5133_5_355 PDCD1 Exon 5 - xp2:241851118-241851143 CCCCCGCCCGCAGGGGCUCAGCUGA 4387 5133_5_356 PDCD1 Exon 5 - xp2:241851130-241851155 UGGGCACCUCAUCCCCCGCCCGCAG 4388 5133_5_357 PDCD1 Exon 5 - xp2:241851131-241851156 AUGGGCACCUCAUCCCCCGCCCCGCA 4389 5133_5_358 PDCD1 Exon 5 - xp2:241851132-241851157 AAUGGGCACCUCAUCCCCCGCCCGC 4390 5133_5_359 PDCD1 Exon 5 - xp2:241851154-241851179 CCACCAUUGUCUUUCCUAGCGGAAU 4391 5133_5_360 PDCD1 Exon 5 - xp2:241851155-241851180 GCCACCAUUGUCUUUCCUAGCGGAA 4392 5133_5_361 PDCD1 Exon 5 - xp2:241851160-241851185 AGUAUGCCACCAUUGUCUUUCCUAG 4393 5133_5_362 PDCD1 Exon 5 - xp2:241851188-241851213 CCCGUGCCCUGUGUCCCUGAGCAGA 4394 5133_5_363 PDCD1 Exon 5 - xp2:241851221-241851246 GAUUUCCAGUGGCGAGAGAAGACCC 4395 5133_5_364 PDCD1 Exon 5 - xp2:241851237-241851262 GGACUAUGGGGAGCUGGAUUUCCAG 4396 5133_5_365 PDCD1 Exon 5 - xp2:241851248-241851273 GUGUUCUCUGUGGACUAUGGGGAGC 4397 5133_5_366 PDCD1 Exon 5 - xp2:241851254-241851279 GUGCCUGUGUUCUCUGUGGACUAUG 4398 5133_5_367 PDCD1 Exon 5 - xp2:241851255-241851280 CGUGCCUGUGUUCUCUGUGGACUAU 4399 5133_5_368 PDCD1 Exon 5 - xp2:241851256-241851281 CCGUGCCUGUGUUCUCUGUGGACUA 4400 5133_5_369 PDCD1 Exon 5 - xp2:241851263-241851288 CCCUCAGCCGUGCCUGUGUUCUCUG 4401 5133_5_370 PDCD1 Exon 5 - xp2:241851293-241851318 CCUCUCCCUUUCUCCUCAAAGAAGG 4402 5133_5_371 PDCD1 Exon 5 - xp2:241851296-241851321 CUCCCUCUCCCUUUCUCCUCAAAGA 4403 5133_4_1 PDCD1 Exon 4 + xp2:241851924-241851949 AUGCAGGAAAAAGAGUGAGACUCACC 4404 5133_4_2 PDCD1 Exon 4 + xp2:241851925-241851950 UGCAGGAAAAAGAGUGAGACUCACCA 4405 5133_4_3 PDCD1 Exon 4 + xp2:241851926-241851951 GCAGGAAAAAGAGUGAGACUCACCAG 4406 5133_4_4 PDCD1 Exon 4 + xp2:241851930-241851955 GAAAAGAGUGAGACUCACCAGGGGC 4407 5133_4_5 PDCD1 Exon 4 + xp2:241851934-241851959 AGAGUGAGACUCACCAGGGGCUGGC 4408 5133_4_6 PDCD1 Exon 4 + xp2:241851943-241851968 CUCACCAGGGGCUGGCCGGUGCGCC 4409 5133_4_7 PDCD1 Exon 4 + xp2:241851975-241852000 UAUUGUCCCUGCAGAGAAACACACU 4410 5133_4_8 PDCD1 Exon 4 + xp2:241851976-241852001 AUUGUCCCUGCAGAGAAACACACUU 4411 5133_4_9 PDCD1 Exon 4 + xp2:241851977-241852002 UUGUCCCUGCAGAGAAACACACUUG 4412 5133_4_10 PDCD1 Exon 4 - xp2:241851950-241851975 GGAGCCAGGCGCACCGGCCAGCCCC 4413 5133_4_11 PDCD1 Exon 4 - xp2:241851961-241851986 CAGGGACAAUAGGAGCCAGGCGCAC 4414 5133_4_12 PDCD1 Exon 4 - xp2:241851969-241851994 UUUCUCUGCAGGGACAAUAGGAGCC 4415 5133_4_13 PDCD1 Exon 4 - xp2:241851976-241852001 AAGUGUGUUUCUCUGCAGGGACAAU 4416 5133_3_1 PDCD1 Exon 3 + xp2:241852178-241852203 GGGGCUGGGAUGACGUUACCUCGUG 4417 5133_3_2 PDCD1 Exon 3 + xp2:241852183-241852208 UGGGAUGACGUUACCUCGUGCGGCC 4418 5133_3_3 PDCD1 Exon 3 + xp2:241852184-241852209 GGGAUGACGUUACCUCGUGCGGCCC 4419 5133_3_4 PDCD1 Exon 3 + xp2:241852196-241852221 CCUCGUGCGGCCCGGGAGCAGAUGA 4420 5133_3_5 PDCD1 Exon 3 + xp2:241852201-241852226 UGCGGCCCGGGAGCAGAUGACGGCC 4421 5133_3_6 PDCD1 Exon 3 + xp2:241852222-241852247 GGCCAGGACCCAGACUAGCAGCACC 4422 5133_3_7 PDCD1 Exon 3 + xp2:241852234-241852259 GACUAGCAGCACCAGGCUGCCCAGC 4423 5133_3_8 PDCD1 Exon 3 + xp2:241852258-241852283 CAGGCCGCCCACGACACCAACCACC 4424 5133_3_9 PDCD1 Exon 3 + xp2:241852259-241852284 AGGCCGCCCACGACACCAACCACCA 4425 5133_3_10 PDCD1 Exon 3 + xp2:241852264-241852289 GCCCACGACACCAACCACCAGGGUU 4426 5133_3_11 PDCD1 Exon 3 + xp2:241852270-241852295 GACACCAACCACCAGGGUUUGGAAC 4427 5133_3_12 PDCD1 Exon 3 + xp2:241852307-241852332 CUGGGUGAGGGGCUGGGGUGGGCUG 4428 5133_3_13 PDCD1 Exon 3 + xp2:241852308-241852333 UGGGUGAGGGGCUGGGGUGGGCUGU 4429 5133_3_14 PDCD1 Exon 3 + xp2:241852329-241852354 CUGUGGGCACUUCUGCCCUUCUCUC 4430 5133_3_15 PDCD1 Exon 3 + xp2:241852333-241852358 GGGCACUUCUGCCCUUCUCUCUGGA 4431 5133_3_16 PDCD1 Exon 3 + xp2:241852334-241852359 GGCACUUCUGCCCUUCUCUCUGGAA 4432 5133_3_17 PDCD1 Exon 3 - xp2:241852199-241852224 CCGUCAUCUGCUCCCGGGCCGCACG 4433 5133_3_18 PDCD1 Exon 3 - xp2:241852209-241852234 UGGGUCCCUGGCCGUCAUCUGCUCCC 4434 5133_3_19 PDCD1 Exon 3 - xp2:241852210-241852235 CUGGGUCCCUGGCCGUCAUCUGCUCC 4435 5133_3_20 PDCD1 Exon 3 - xp2:241852227-241852252 AGCCUGGUGCUGCUAGUCUGGGUCC 4436 5133_3_21 PDCD1 Exon 3 - xp2:241852233-241852258 CUGGGCAGCCUGGUGCUGCUAGUCU 4437 5133_3_22 PDCD1 Exon 3 - xp2:241852234-241852259 GCUGGGCAGCCUGGUGCUGCUAGUC 4438 5133_3_23 PDCD1 Exon 3 - xp2:241852248-241852273 GUCGUGGGCGGCCUGCUGGGCAGCC 4439 5133_3_24 PDCD1 Exon 3 - xp2:241852256-241852281 UGGUUGGUGUCGUGGGCGGCCUGCU 4440 5133_3_25 PDCD1 Exon 3 - xp2:241852257-241852282 GUGGUUGGUGUCGUGGGCGGCCUGC 4441 5133_3_26 PDCD1 Exon 3 - xp2:241852265-241852290 AAACCCUGGUGGUUGGUGUCGUGGG 4442 5133_3_27 PDCD1 Exon 3 - xp2:241852268-241852293 UCCAAACCCUGGUGGUUGGUGUCGU 4443 5133_3_28 PDCD1 Exon 3 - xp2:241852269-241852294 UUCCAAACCCUGGUGGUUGGUGUCG 4444 5133_3_29 PDCD1 Exon 3 - xp2:241852277-241852302 GGGGCCAGUUCCAAACCCUGGUGGU 4445 5133_3_30 PDCD1 Exon 3 - xp2:241852281-241852306 GGUCGGGGCCAGUUCCAAACCCUGG 4446 5133_3_31 PDCD1 Exon 3 - xp2:241852284-241852309 UCCGGUCGGGGCCAGUUCCAAACCC 4447 5133_3_32 PDCD1 Exon 3 - xp2:241852301-241852326 UGGGGUCGGGGAGUGGGUCCGGUCG 4448 5133_3_33 PDCD1 Exon 3 - xp2:241852347-241852372 CUGGUUUGUGCCCUUCCAGAGAGAA 4449 5133_3_34 PDCD1 Exon 3 - xp2:241852348-241852373 ACUGGUUUGUGCCCUUCCAGAGAGA 4450 5133_2_1 PDCD1 Exon 2 + xp2:241852618-241852643 ACCUGUCACCCUGAGCUCUGCCCGC 4451 5133_2_2 PDCD1 Exon 2 + xp2:241852640-241852665 CGCAGGCUCUCUUUGAUCUGCGCCU 4452 5133_2_3 PDCD1 Exon 2 + xp2:241852641-241852666 GCAGGCUCUCUUUGAUCUGCGCCUU 4453 5133_2_4 PDCD1 Exon 2 + xp2:241852642-241852667 CAGGCUCUCUUUGAUCUGCGCCUUG 4454 5133_2_5 PDCD1 Exon 2 + xp2:241852643-241852668 AGGCUCUCUUUGAUCUGCGCCUUGG 4455 5133_2_6 PDCD1 Exon 2 + xp2:241852648-241852673 CUCUUUGAUCUGCGCCUUGGGGGCC 4456 5133_2_7 PDCD1 Exon 2 + xp2:241852649-241852674 UCUUUGAUCUGCGCCUUGGGGGCCA 4457 5133_2_8 PDCD1 Exon 2 + xp2:241852655-241852680 AUCUGCGCCUUGGGGGCCAGGGAGA 4458 5133_2_9 PDCD1 Exon 2 + xp2:241852666-241852691 GGGGGCCAGGGAGAUGGCCCCACAG 4459 5133_2_10 PDCD1 Exon 2 + xp2:241852670-241852695 GCCAGGGAGAUGGCCCCACAGAGGU 4460 5133_2_11 PDCD1 Exon 2 + xp2:241852690-241852715 GAGGUAGGUGCCGCUGUCAUUGCGC 4461 5133_2_12 PDCD1 Exon 2 + xp2:241852691-241852716 AGGUAGGUGCCGCUGUCAUUGCGCC 4462 5133_2_13 PDCD1 Exon 2 + xp2:241852711-241852736 GCGCCGGGCCCUGACCACGCUCAUG 4463 5133_2_14 PDCD1 Exon 2 + xp2:241852727-241852752 ACGCUCAUGUGGAAGUCACGCCCGU 4464 5133_2_15 PDCD1 Exon 2 + xp2:241852728-241852753 CGCUCAUGUGGAAGUCACGCCCGUU 4465 5133_2_16 PDCD1 Exon 2 + xp2:241852744-241852769 ACGCCCGUUGGGCAGUUGUGUGACA 4466 5133_2_17 PDCD1 Exon 2 + xp2:241852750-241852775 GUUGGGCAGUUGUGUGACACGGAAG 4467 5133_2_18 PDCD1 Exon 2 + xp2:241852759-241852784 UUGUGUGACACGGAAGCGGCAGUCC 4468 5133_2_19 PDCD1 Exon 2 + xp2:241852763-241852788 GUGACACGGAAGCGGCAGUCCUGGC 4469 5133_2_20 PDCD1 Exon 2 + xp2:241852764-241852789 UGACACGGAAGCGGCAGUCCUGCC 4470 5133_2_21 PDCD1 Exon 2 + xp2:241852768-241852793 ACGGAAGCGGCAGUCCUGGCCGGGC 4471 5133_2_22 PDCD1 Exon 2 + xp2:241852774-241852799 GCGGCAGUCCUGGCCGGGCUGGCUG 4472 5133_2_23 PDCD1 Exon 2 + xp2:241852781-241852806 UCCUGGCCGGGCUGGCUGCGGUCCU 4473 5133_2_24 PDCD1 Exon 2 + xp2:241852782-241852807 CCUGGCCGGGCUGGCUGCGGUCCUC 4474 5133_2_25 PDCD1 Exon 2 + xp2:241852783-241852808 CUGGCCGGGCUGGCUGCGGUCCUCG 4475 5133_2_26 PDCD1 Exon 2 + xp2:241852787-241852812 CCGGGCUGGCUGCGGUCCUCGGGGA 4476 5133_2_27 PDCD1 Exon 2 + xp2:241852790-241852815 GGCUGGCUGCGGUCCUCGGGGAAGG 4477 5133_2_28 PDCD1 Exon 2 + xp2:241852807-241852832 GGGGAAGGCGGCCAGCUUGUCCGUC 4478 5133_2_29 PDCD1 Exon 2 + xp2:241852814-241852839 GCGGCCAGCUUGUCCGUCUGGUUGC 4479 5133_2_30 PDCD1 Exon 2 + xp2:241852815-241852840 CGGCCAGCUUGUCCGUCUGGUUGCU 4480 5133_2_31 PDCD1 Exon 2 + xp2:241852816-241852841 GGCCAGCUUGUCCGUCUGGUUGCUG 4481 5133_2_32 PDCD1 Exon 2 + xp2:241852825-241852850 GUCCGUCUGGUUGCUGGGGCUCAUG 4482 5133_2_33 PDCD1 Exon 2 + xp2:241852859-241852884 UUUAGCACGAAGCUCUCCGAUGUGU 4483 5133_2_34 PDCD1 Exon 2 + xp2:241852871-241852896 CUCUCCGAUGUGUUGGAGAAGCUGC 4484 5133_2_35 PDCD1 Exon 2 + xp2:241852877-241852902 GAUGUGUUGGAGAAGCUGCAGGUGA 4485 5133_2_36 PDCD1 Exon 2 + xp2:241852880-241852905 GUGUUGGAGAAGCUGCAGGUGAAGG 4486 5133_2_37 PDCD1 Exon 2 + xp2:241852895-241852920 CAGGUGAAGGUGGCGUUGUCCCCCUU 4487 5133_2_38 PDCD1 Exon 2 + xp2:241852909-241852934 GUUGUCCCCCUUCGGUCACCACGAGC 4488 5133_2_39 PDCD1 Exon 2 + xp2:241852910-241852935 UUGUCCCCCUUCGGUCACCACGAGCA 4489 5133_2_40 PDCD1 Exon 2 + xp2:241852914-241852939 CCCCUUCGGUCACCACGAGCAGGGC 4490 5133_2_41 PDCD1 Exon 2 + xp2:241852915-241852940 CCCUUCGGUCACCACGAGCAGGGCU 4491 5133_2_42 PDCD1 Exon 2 + xp2:241852916-241852941 CCUUCGGUCACCACGAGCAGGGCUG 4492 5133_2_43 PDCD1 Exon 2 + xp2:241852922-241852947 GUCACCACGAGCAGGGCUGGGGAGA 4493 5133_2_44 PDCD1 Exon 2 + xp2:241852925-241852950 ACCACGAGCAGGGCUGGGGAGAAGG 4494 5133_2_45 PDCD1 Exon 2 + xp2:241852926-241852951 CCACGAGCAGGGCUGGGGAGAAGGU 4495 5133_2_46 PDCD1 Exon 2 + xp2:241852927-241852952 CACGAGCAGGGCUGGGGAGAAGGUG 4496 5133_2_47 PDCD1 Exon 2 + xp2:241852928-241852953 ACGAGCAGGGCUGGGGAGAAGGUGG 4497 5133_2_48 PDCD1 Exon 2 + xp2:241852929-241852954 CGAGCAGGGCUGGGGAGAAGGUGGG 4498 5133_2_49 PDCD1 Exon 2 + xp2:241852930-241852955 GAGCAGGGCUGGGGAGAAGGUGGGG 4499 5133_2_50 PDCD1 Exon 2 + xp2:241852937-241852962 GCUGGGGAGAAGGUGGGGGGGUUCC 4500 5133_2_51 PDCD1 Exon 2 + xp2:241852938-241852963 CUGGGGAGAAGGUGGGGGGGUUCCA 4501 5133_2_52 PDCD1 Exon 2 + xp2:241852947-241852972 AGGUGGGGGGGUUCCAGGGCCUGUC 4502 5133_2_53 PDCD1 Exon 2 + xp2:241852948-241852973 GGUGGGGGGGUUCCAGGGCCUGUCU 4503 5133_2_54 PDCD1 Exon 2 + xp2:241852949-241852974 GUGGGGGGGUUCCAGGGCCUGUCUG 4504 5133_2_55 PDCD1 Exon 2 + xp2:241852963-241852988 GGGCCUGUCUGGGGAGUCUGAGAGA 4505 5133_2_56 PDCD1 Exon 2 + xp2:241852970-241852995 UCUGGGGAGUCUGAGAGAUGGAGAG 4506 5133_2_57 PDCD1 Exon 2 + xp2:241852975-241853000 GGAGUCUGAGAGAUGGAGAGAGGUG 4507 5133_2_58 PDCD1 Exon 2 - xp2:241852600-241852625 GACAGGUGCGGCCUCGGAGGCCCCG 4508 5133_2_59 PDCD1 Exon 2 - xp2:241852601-241852626 UGACAGGUGCGGCCUCGGAGGCCCC 4509 5133_2_60 PDCD1 Exon 2 - xp2:241852602-241852627 GUGACAGGUGCGGCCUCGGAGGCCC 4510 5133_2_61 PDCD1 Exon 2 - xp2:241852608-241852633 CUCAGGGUGACAGGUGCGGCCUCGG 4511 5133_2_62 PDCD1 Exon 2 - xp2:241852611-241852636 GAGCUCAGGGUGACAGGUGCGGCCU 4512 5133_2_63 PDCD1 Exon 2 - xp2:241852617-241852642 CGGGCAGAGCUCAGGGUGACAGGUG 4513 5133_2_64 PDCD1 Exon 2 - xp2:241852622-241852647 GCCUGCGGGCAGAGCUCAGGGUGAC 4514 5133_2_65 PDCD1 Exon 2 - xp2:241852629-241852654 AAAGAGAGCCUGCGGGCAGAGCUCA 4515 5133_2_66 PDCD1 Exon 2 - xp2:241852630-241852655 CAAAGAGAGCCUGCGGGCAGAGCUC 4516 5133_2_67 PDCD1 Exon 2 - xp2:241852641-241852666 AAGGCGCAGAUCAAAGAGAGCCUGC 4517 5133_2_68 PDCD1 Exon 2 - xp2:241852642-241852667 CAAGGCGCAGAUCAAAGAGAGCCUG 4518 5133_2_69 PDCD1 Exon 2 - xp2:241852665-241852690 UGUGGGGCCAUCUCCCUGGCCCCCA 4519 5133_2_70 PDCD1 Exon 2 - xp2:241852674-241852699 ACCUACCUCUGUGGGGCCAUCUCCC 4520 5133_2_71 PDCD1 Exon 2 - xp2:241852686-241852711 AAUGACAGCGGCACCUACCUCUGUG 4521 5133_2_72 PDCD1 Exon 2 - xp2:241852687-241852712 CAAUGACAGCGGCACCUACCUCUGU 4522 5133_2_73 PDCD1 Exon 2 - xp2:241852688-241852713 GCAAUGACAGCGGCACCUACCUCUG 4523 5133_2_74 PDCD1 Exon 2 - xp2:241852703-241852728 UGGUCAGGGCCCGGCCGCAAUGACAG 4524 5133_2_75 PDCD1 Exon 2 - xp2:241852717-241852742 CUUCCAAUGAGCGUGGUCAGGGCC 4525 5133_2_76 PDCD1 Exon 2 - xp2:241852722-241852747 CGUGACUUCCACAUGAGCGUGGUCA 4526 5133_2_77 PDCD1 Exon 2 - xp2:241852723-241852748 GCGUGACUUCCACAUGAGCGUGGUC 4527 5133_2_78 PDCD1 Exon 2 - xp2:241852728-241852753 AACGGGCGUGACUUCCACAUGAGCG 4528 5133_2_79 PDCD1 Exon 2 - xp2:241852750-241852775 CUUCCGGUGUCACACAACUGCCCAAC 4529 5133_2_80 PDCD1 Exon 2 - xp2:241852751-241852776 GCUUCCGUGUCACACAACUGCCCAA 4530 5133_2_81 PDCD1 Exon 2 - xp2:241852785-241852810 CCCGAGGACCGCAGCCAGCCCGGCC 4531 5133_2_82 PDCD1 Exon 2 - xp2:241852790-241852815 CCUUCCCCGAGGACCGCAGCCAGCC 4532 5133_2_83 PDCD1 Exon 2 - xp2:241852806-241852831 ACGGACAAGCUGGCCGCCUUCCCCG 4533 5133_2_84 PDCD1 Exon 2 - xp2:241852821-241852846 AGCCCCAGCAACCAGACGGACAAGC 4534 5133_2_85 PDCD1 Exon 2 - xp2:241852830-241852855 UACCGCAUGAGCCCCAGCAACCAGA 4535 5133_2_86 PDCD1 Exon 2 - xp2:241852858-241852883 CACAUCGGAGAGCUUCGUGCUAAAC 4536 5133_2_87 PDCD1 Exon 2 - xp2:241852878-241852903 UUCACCUGCAGCUUCUCCAACACAU 4537 5133_2_88 PDCD1 Exon 2 - xp2:241852917-241852942 CCAGCCCUGCUCGUGGUGACCGAAG 4538 5133_2_89 PDCD1 Exon 2 - xp2:241852918-241852943 CCCAGCCCUGCUCGUGGUGACCGAA 4539 5133_2_90 PDCD1 Exon 2 - xp2:241852919-241852944 CCCCAGCCCUGCUCGUGGUGACCGA 4540 5133_2_91 PDCD1 Exon 2 - xp2:241852929-241852954 CCCACCUUCUCCCCCAGCCCUGCUCG 4541 5133_2_92 PDCD1 Exon 2 - xp2:241852963-241852988 UCUCUCAGACUCCCCAGACAGGCCC 4542 5133_2_93 PDCD1 Exon 2 - xp2:241852969-241852994 UCUCCAUCUCUCAGACUCCCCAGAC 4543 5133_1_1 PDCD1 Exon 1 + xp2:241858750-241858775 GACCCCACCUACCUAAGAACCAUCC 4544 5133_1_2 PDCD1 Exon 1 + xp2:241858786-241858811 CCAGUUGUAGCACCGCCCAGACGAC 4545 5133_1_3 PDCD1 Exon 1 + xp2:241858791-241858816 UGUAGCACCGCCCAGACGACUGCC 4546 5133_1_4 PDCD1 Exon 1 + xp2:241858792-241858817 GUAGCACCGCCCAGACGACUGGCCA 4547 5133_1_5 PDCD1 Exon 1 + xp2:241858801-241858826 CCCAGACGACUGGCCAGGGCGCCUG 4548 5133_1_6 PDCD1 Exon 1 + xp2:241858802-241858827 CCAGACGACUGGCCAGGGCGCCUGU 4549 5133_1_7 PDCD1 Exon 1 + xp2:241858816-241858841 AGGGCGCCUGUGGGAUCUGCAUGCC 4550 5133_1_8 PDCD1 Exon 1 + xp2:241858855-241858880 CAGAGUGCCGCCUUCUCCACUGCUC 4551 5133_1_9 PDCD1 Exon 1 + xp2:241858858-241858883 AGUGCCGCCUUCUCCACUGCUCAGG 4552 5133_1_10 PDCD1 Exon 1 + xp2:241858861-241858886 GCCGCCUUCUCCACUGCUCAGGCGG 4553 5133_1_11 PDCD1 Exon 1 + xp2:241858868-241858893 UCUCCACUGCUCAGGCGGAGGUGAG 4554 5133_1_12 PDCD1 Exon 1 + xp2:241858872-241858897 CACUGCUCAGGCGGAGGUGAGCGA 4555 5133_1_13 PDCD1 Exon 1 + xp2:241858873-241858898 ACUGCUCAGGCGGAGGUGAGCGGAA 4556 5133_1_14 PDCD1 Exon 1 + xp2:241858886-241858911 AGGUGAGCGGAAGGGAAACUGUCCC 4557 5133_1_15 PDCD1 Exon 1 + xp2:241858891-241858916 AGCGGAAGGGAAACUGUCCCAGGUC 4558 5133_1_16 PDCD1 Exon 1 + xp2:241858898-241858923 GGGAAACUGUCCCCAGGUCAGGUUGA 4559 5133_1_17 PDCD1 Exon 1 + xp2:241858899-241858924 GGAAACUGUCCCCAGGUCAGGUUGAA 4560 5133_1_18 PDCD1 Exon 1 + xp2:241858902-241858927 AACUGUCCCCAGGUCAGGUUGAAGGG 4561 5133_1_19 PDCD1 Exon 1 + xp2:241858903-241858928 ACUGUCCCCAGGUCAGGUUGAAGGGA 4562 5133_1_20 PDCD1 Exon 1 - xp2:241858743-241858768 UCUUAGGUAGGUGGGGUCGGCGGUC 4563 5133_1_21 PDCD1 Exon 1 - xp2:241858748-241858773 AUGGUUCUUAGGUAGGUGGGGUCGG 4564 5133_1_22 PDCD1 Exon 1 - xp2:241858751-241858776 AGGAUGGUUCUUAGGUAGGUGGGGU 4565 5133_1_23 PDCD1 Exon 1 - xp2:241858755-241858780 GGCCAGGAUGGUUCUUAGGUAGGUG 4566 5133_1_24 PDCD1 Exon 1 - xp2:241858756-241858781 CGGCCAGGAUGGUUCUUAGGUAGGU 4567 5133_1_25 PDCD1 Exon 1 - xp2:241858757-241858782 GCGGCCAGGAUGGUUCUUAGGUAGG 4568 5133_1_26 PDCD1 Exon 1 - xp2:241858760-241858785 CUGGCGGCCAGGAUGGUUCUUAGGU 4569 5133_1_27 PDCD1 Exon 1 - xp2:241858764-241858789 UGGGCUGGCGGCCAGGAUGGUUCUU 4570 5133_1_28 PDCD1 Exon 1 - xp2:241858772-241858797 GCUACAACUGGGCUGGCGGCCAGGA 4571 5133_1_29 PDCD1 Exon 1 - xp2:241858776-241858801 CGGUGCUACAACUGGGCUGGCGGCC 4572 5133_1_30 PDCD1 Exon 1 - xp2:241858781-241858806 CUGGGCGGUGCUACAACUGGGCUGG 4573 5133_1_31 PDCD1 Exon 1 - xp2:241858784-241858809 CGUCUGGGCGGUGCUACAACUGGGC 4574 5133_1_32 PDCD1 Exon 1 - xp2:241858788-241858813 CAGUCGUCUGGGCGGUGCUACAACU 4575 5133_1_33 PDCD1 Exon 1 - xp2:241858789-241858814 CCAGUCGUCUGGGCGGUGCUACAAC 4576 5133_1_34 PDCD1 Exon 1 - xp2:241858801-241858826 CAGGCCGCCCUGGCCAGUCGUCUGGG 4577 5133_1_35 PDCD1 Exon 1 - xp2:241858804-241858829 CCACAGGCCGCCCUGGCCAGUCGUCU 4578 5133_1_36 PDCD1 Exon 1 - xp2:241858805-241858830 CCCACAGGCCGCCCUGGCCAGUCGUC 4579 5133_1_37 PDCD1 Exon 1 - xp2:241858817-241858842 AGGCAUGCAGAUCCCACAGGCGCCC 4580 5133_1_38 PDCD1 Exon 1 - xp2:241858825-241858850 GCUGCUCCAGGCAUGCAGAUCCCAC 4581 5133_1_39 PDCD1 Exon 1 - xp2:241858842-241858867 GGCGGCACUCUGGUGGGGCUGCUCC 4582 5133_1_40 PDCD1 Exon 1 - xp2:241858852-241858877 CAGUGGAGAAGGCGGCACUCUGGUG 4583 5133_1_41 PDCD1 Exon 1 - xp2:241858853-241858878 GCAGUGGAGAAGGCGGCACUCUGGU 4584 5133_1_42 PDCD1 Exon 1 - xp2:241858854-241858879 AGCAGUGGAGAAGGCGGCACUCUGG 4585 5133_1_43 PDCD1 Exon 1 - xp2:241858857-241858882 CUGAGCAGUGGAGAAGGCGGCACUC 4586 5133_1_44 PDCD1 Exon 1 - xp2:241858865-241858890 ACCUCCGCCUGAGCAGUGGAGAAGG 4587 5133_1_45 PDCD1 Exon 1 - xp2:241858868-241858893 CUCACCUCCGCCUGAGCAGUGGAGA 4588 5133_1_46 PDCD1 Exon 1 - xp2:241858874-241858899 CUUCCGCUCACCUCCCGCCUGAGCAG 4589 5781_1_1 PTPN11 Exon 1 + xp12:112418706-112418731 CGCGGAGCGCGCAGCUCACACCUGG 4590 5781_1_2 PTPN11 Exon 1 + xp12:112418712-112418737 GCGCGCAGCUCACACCUGGCGGCCG 4591 5781_1_3 PTPN11 Exon 1 + xp12:112418720-112418745 CUCACACCUGGCGGCCGCGGUUUCC 4592 5781_1_4 PTPN11 Exon 1 + xp12:112418723-112418748 ACACCUGGCGGCCGCGGUUUCCAGG 4593 5781_1_5 PTPN11 Exon 1 + xp12:112418731-112418756 CGGCCGCGGUUUCCAGGAGGAAGCA 4594 5781_1_6 PTPN11 Exon 1 + xp12:112418740-112418765 UUUCCAGGAGGAAGCAAGGAUGCUU 4595 5781_1_7 PTPN11 Exon 1 + xp12:112418753-112418778 GCAAGGAUGCUUUGGACACUGUGCG 4596 5781_1_8 PTPN11 Exon 1 + xp12:112418764-112418789 UUGGACACUGUGCGUGGCGCCUCCCG 4597 5781_1_9 PTPN11 Exon 1 + xp12:112418787-112418812 CGCGGAGCCCCCGCCGCUGCCAUUCC 4598 5781_1_10 PTPN11 Exon 1 + xp12:112418798-112418823 CGCGCUGCCAUUCCCGGCCGUCGCU 4599 5781_1_11 PTPN11 Exon 1 + xp12:112418812-112418837 CGGCCGUCGCUCGGUCCUCCGCUGA 4600 5781_1_12 PTPN11 Exon 1 + xp12:112418813-112418838 GGCCGUCGCUCGGUCCUCCGCUGAC 4601 5781_1_13 PTPN11 Exon 1 + xp12:112418820-112418845 GCUCGGUCCUCCGCUGACGGGAAGC 4602 5781_1_14 PTPN11 Exon 1 + xp12:112418927-112418952 GGCCGGGGGGCAGCUGCACAGUCUC 4603 5781_1_15 PTPN11 Exon 1 + xp12:112418928-112418953 GCCGGGGGGCAGCUGCACAGUCUCC 4604 5781_1_16 PTPN11 Exon 1 + xp12:112418937-112418962 CAGCUGCACAGUCUCCGGGAUCCCCC 4605 5781_1_17 PTPN11 Exon 1 + xp12:112418942-112418967 GCACAGUCUCCGGGAUCCCAGGCC 4606 5781_1_18 PTPN11 Exon 1 + xp12:112418945-112418970 CAGUCUCCGGGAUCCCAGGCCUGG 4607 5781_1_19 PTPN11 Exon 1 + xp12:112418946-112418971 AGUCUCCGGGAUCCCAGGCCUGGA 4608 5781_1_20 PTPN11 Exon 1 + xp12:112418947-112418972 GUCUCCGGGAUCCCAGGCCUGGAG 4609 5781_1_21 PTPN11 Exon 1 + xp12:112418948-112418973 UCUCCGGGAUCCCAGGCCUGGAGG 4610 5781_1_22 PTPN11 Exon 1 + xp12:112418949-112418974 CUCCGGGAUCCCAGGCCUGGAGGG 4611 5781_1_23 PTPN11 Exon 1 + xp12:112418960-112418985 CCAGGCCUGGAGGGGGGUCUGUGCG 4612 5781_1_24 PTPN11 Exon 1 + xp12:112418964-112418989 GCCUGGAGGGGGGUCUGUGGCCGGC 4613 5781_1_25 PTPN11 Exon 1 + xp12:112418968-112418993 GGAGGGGGGUCUGUGCGCGGCCGGC 4614 5781_1_26 PTPN11 Exon 1 + xp12:112418985-112419010 CGGCCGGCUGGCUCUGCCCCGCGUC 4615 5781_1_27 PTPN11 Exon 1 + xp12:112418995-112419020 GCUCUGCCCCGCGUCCGGUCCCGAG 4616 5781_1_28 PTPN11 Exon 1 + xp12:112418996-112419021 CUCUGCCCCGCGUCCGGUCCCCGAGC 4617 5781_1_29 PTPN11 Exon 1 + xp12:112419006-112419031 CGUCCGGUCCCGAGCGGGCCUCCCU 4618 5781_1_30 PTPN11 Exon 1 + xp12:112419007-112419032 GUCCGGUCCCGAGCGGGCCUCCCUC 4619 5781_1_31 PTPN11 Exon 1 + xp12:112419034-112419059 GCCAGCCCGAUGUGACCGAGCCCAG 4620 5781_1_32 PTPN11 Exon 1 + xp12:112419047-112419072 GACCGAGCCCAGCGGAGCCUGAGCA 4621 5781_1_33 PTPN11 Exon 1 + xp12:112419052-112419077 AGCCCAGCGGAGCCUGAGCAAGGAG 4622 5781_1_34 PTPN11 Exon 1 + xp12:112419053-112419078 GCCCAGCGGAGCCUGAGCAAGGAGC 4623 5781_1_35 PTPN11 Exon 1 + xp12:112419063-112419088 GCCUGAGCAAGGAGCGGGUCCGUCG 4624 5781_1_36 PTPN11 Exon 1 + xp12:112419069-112419094 GCAAGGAGCGGGUCCGUCGCGGAGC 4625 5781_1_37 PTPN11 Exon 1 + xp12:112419072-112419097 AGGAGCGGGUCCGUCGCGGAGCCGG 4626 5781_1_38 PTPN11 Exon 1 + xp12:112419073-112419098 GGAGCGGGUCCGUCGCGGAGCCGGA 4627 5781_1_39 PTPN11 Exon 1 + xp12:112419076-112419101 GCGGGUCCGUCGCGGAGCCGGAGGG 4628 5781_1_40 PTPN11 Exon 1 + xp12:112419077-112419102 CGGGUCCGUCGCGGAGCCGGAGGGC 4629 5781_1_41 PTPN11 Exon 1 + xp12:112419080-112419105 GUCCGUCGCGGAGCCGGAGGGCGGG 4630 5781_1_42 PTPN11 Exon 1 + xp12:112419095-112419120 GGAGGGCGGGAGGAACAUGACAUCG 4631 5781_1_43 PTPN11 Exon 1 + xp12:112419098-112419123 GGGCGGGAGGAACAUGACAUCGCGG 4632 5781_1_44 PTPN11 Exon 1 + xp12:112419103-112419128 GGAGGAACAUGACAUCGCGGAGGUG 4633 5781_1_45 PTPN11 Exon 1 + xp12:112419113-112419138 GACAUCCGCGGAGGUGAGGAGCCCCG 4634 5781_1_46 PTPN11 Exon 1 + xp12:112419114-112419139 ACAUCGCGGAGGUGAGGAGCCCCGA 4635 5781_1_47 PTPN11 Exon 1 + xp12:112419115-112419140 CAUCGCGGAGGUGAGGAGCCCCGAG 4636 5781_1_48 PTPN11 Exon 1 + xp12:112419120-112419145 CGGAGGUGAGGAGCCCCGAGGGGCC 4637 5781_1_49 PTPN11 Exon 1 - xp12:112418729-112418754 CUUCCUCCCUGGAAACCGCGGCCGCC 4638 5781_1_50 PTPN11 Exon 1 - xp12:112418737-112418762 CAUCCUUGCUUCCUCCUGGAAAACCG 4639 5781_1_51 PTPN11 Exon 1 - xp12:112418746-112418771 UGUCCAAAGCAUCCUUGCUUCCUCC 4640 5781_1_52 PTPN11 Exon 1 - xp12:112418786-112418811 GAAUGGCAGCGCGGGGGCUCCGCGG 4641 5781_1_53 PTPN11 Exon 1 - xp12:112418789-112418814 CGGGAAUGGCAGCGCGGGGGCUCCG 4642 5781_1_54 PTPN11 Exon 1 - xp12:112418797-112418822 GCGACGGCCGGGAAUGGCAGCGCGG 4643 5781_1_55 PTPN11 Exon 1 - xp12:112418798-112418823 AGCGACGGCCGGGAAUGGCAGCGCG 4644 5781_1_56 PTPN11 Exon 1 - xp12:112418799-112418824 GAGCGACGGCCGGGAAUGGCAGGCGC 4645 5781_1_57 PTPN11 Exon 1 - xp12:112418800-112418825 CGAGCGACGGCCGGGAAUGGCAGCG 4646 5781_1_58 PTPN11 Exon 1 - xp12:112418808-112418833 CGGAGGACCGAGCGACGGCCGGGAA 4647 5781_1_59 PTPN11 Exon 1 - xp12:112418813-112418838 GUCAGCGGAGGACCGAGCGACGGCC 4648 5781_1_60 PTPN11 Exon 1 - xp12:112418814-112418839 CGUCAGCGGAGGACCGAGCGACGGC 4649 5781_1_61 PTPN11 Exon 1 - xp12:112418818-112418843 UUCCCGUCACGCGGAGGACCGAGCGA 4650 5781_1_62 PTPN11 Exon 1 - xp12:112418830-112418855 CGGACUUCCUGCUUCCCGUCACGGG 4651 5781_1_63 PTPN11 Exon 1 - xp12:112418833-112418858 CGGCGGACUUCCUGCUUCCCGUCAG 4652 5781_1_64 PTPN11 Exon 1 - xp12:112418954-112418979 GACCCCCCUCCAGGCCUGGGGAUCC 4653 5781_1_65 PTPN11 Exon 1 - xp12:112418961-112418986 GCGCACAGACCCCCCUCCAGGCCUG 4654 5781_1_66 PTPN11 Exon 1 - xp12:112418962-112418987 CGCGCACAGACCCCCCUCCAGGCCU 4655 5781_1_67 PTPN11 Exon 1 - xp12:112418963-112418988 CCGCGCACAGACCCCCCUCCAGGCC 4656 5781_1_68 PTPN11 Exon 1 - xp12:112418968-112418993 GCCGGCCCGCGCACAGACCCCCCUCC 4657 5781_1_69 PTPN11 Exon 1 - xp12:112418991-112419016 GGACCGGACGCGGGGCAGAGCCAGC 4658 5781_1_70 PTPN11 Exon 1 - xp12:112419004-112419029 GGAGGCCCCGCUCGGGACCGGACGCG 4659 5781_1_71 PTPN11 Exon 1 - xp12:112419005-112419030 GGGAGGCCCCGCUCGGGACCGGACGC 4660 5781_1_72 PTPN11 Exon 1 - xp12:112419006-112419031 AGGGAGGCCCCGCUCGGGACCGGACG 4661 5781_1_73 PTPN11 Exon 1 - xp12:112419012-112419037 GGCCCGAGGGAGGCCCCGCUCGGGAC 4662 5781_1_74 PTPN11 Exon 1 - xp12:112419017-112419042 GGGCUGGCCCGAGGGAGGCCCGCUC 4663 5781_1_75 PTPN11 Exon 1 - xp12:112419018-112419043 CGGGCUGGCCCGAGGGAGGCCCGCU 4664 5781_1_76 PTPN11 Exon 1 - xp12:112419027-112419052 CGGUCACAUCGGGCUGGCCCGAGGG 4665 5781_1_77 PTPN11 Exon 1 - xp12:112419030-112419055 GCUCGGUCACAUCGGGCUGGCCCGA 4666 5781_1_78 PTPN11 Exon 1 - xp12:112419031-112419056 GGCUCGGUCACAUCGGGCUGGCCCG 4667 5781_1_79 PTPN11 Exon 1 - xp12:112419038-112419063 UCCGCUGGGCCUCGGUCACAUCGGGC 4668 5781_1_80 PTPN11 Exon 1 - xp12:112419042-112419067 AGGCUCCGCUGGGCCUCGGUCACAUC 4669 5781_1_81 PTPN11 Exon 1 - xp12:112419043-112419068 CAGGCUCCGCUGGGCCUCGGUCACAU 4670 5781_1_82 PTPN11 Exon 1 - xp12:112419052-112419077 CUCCUUGCUCAGGCUCCGCUGGGCU 4671 5781_1_83 PTPN11 Exon 1 - xp12:112419057-112419082 ACCCGCUCCUUGCUCAGGCUCCGCU 4672 5781_1_84 PTPN11 Exon 1 - xp12:112419058-112419083 GACCCGCUCCUUGCUCAGGCUCCGC 4673 5781_1_85 PTPN11 Exon 1 - xp12:112419067-112419092 UCCGCGACGGACCCGCUCCUUGCUC 4674 5781_1_86 PTPN11 Exon 1 - xp12:112419085-112419110 UUCCUCCCGCCCUCCGGCUCCGCGA 4675 5781_1_87 PTPN11 Exon 1 - xp12:112419096-112419121 GCGAUGUCAUGUUCCUCCCGCCUCUC 4676 5781_2_1 PTPN11 Exon 2 + xp12:112446251-112446276 ACUUACUUUGUCUUUCUUUUAAGA 4677 5781_2_2 PTPN11 Exon 2 + xp12:112446271-112446296 UAAGAUGGUUUCACCCAAAUAUUCAC 4678 5781_2_3 PTPN11 Exon 2 + xp12:112446276-112446301 UGGUUUCACCCAAAUAUCACUGGUG 4679 5781_2_4 PTPN11 Exon 2 + xp12:112446279-112446304 UUUCACCCAAAUAUCACUGGUGUGG 4680 5781_2_5 PTPN11 Exon 2 + xp12:112446304-112446329 AGGCAGAAAACCUACUGUUGACAAG 4681 5781_2_6 PTPN11 Exon 2 + xp12:112446313-112446338 ACCUACUGUUGACAAGAGGAGUUGA 4682 5781_2_7 PTPN11 Exon 2 + xp12:112446324-112446349 ACAAGAGGAGUUGAUGGCAGUUUUU 4683 5781_2_8 PTPN11 Exon 2 + xp12:112446329-112446354 AGGAGUUGAUGGCAGUUUUUUGGCA 4684 5781_2_9 PTPN11 Exon 2 + xp12:112446349-112446374 UGGCAAGGCCUAGUAAAAGUAACCC 4685 5781_2_10 PTPN11 Exon 2 + xp12:112446371-112446396 CCCUGGAGACUUCACACUUUCCGUU 4686 5781_2_11 PTPN11 Exon 2 + xp12:112446379-112446404 ACUUCACACUUUCCGUUAGGUAAGU 4687 5781_2_12 PTPN11 Exon 2 + xp12:112446393-112446418 GUUAGGUAAGUUGGAAUGAAAAGAG 4688 5781_2_13 PTPN11 Exon 2 - xp12:112446287-112446312 UUCUGCCUCCACACCAGUGAUAUUU 4689 5781_2_14 PTPN11 Exon 2 - xp12:112446288-112446313 UUUCUGCCUCCACACCAGUGAUAUU 4690 5781_2_15 PTPN11 Exon 2 - xp12:112446317-112446342 GCCAUCAACUCCUCUUGUCAACAGGU 4691 5781_2_16 PTPN11 Exon 2 - xp12:112446360-112446385 UGAAGUCUCCAGGGUUACUUUUACU 4692 5781_2_17 PTPN11 Exon 2 - xp12:112446374-112446399 CCUAACGGAAAGUGUGAAGUCUCCA 4693 5781_2_18 PTPN11 Exon 2 - xp12:112446375-112446400 ACCUAACGGAAAGUGUGAAGUCCC 4694 5781_2_19 PTPN11 Exon 2 - xp12:112446394-112446419 UCUCUUUUCAUUCCAACUUACCUAA 4695 5781_3_1 PTPN11 Exon 3 + xp12:112450298-112450323 UUCCAAUGGACUAUUUUAGAAAAA 4696 5781_3_2 PTPN11 Exon 3 + xp12:112450331-112450356 UCACCCAAUCAAGAUUCAGAACAC 4697 5781_3_3 PTPN11 Exon 3 + xp12:112450352-112450377 ACACUGGUGAUUACUAUGACCUGUA 4698 5781_3_4 PTPN11 Exon 3 + xp12:112450355-112450380 CUGGUGAUUACUAUGACCUGUAUGG 4699 5781_3_5 PTPN11 Exon 3 + xp12:112450356-112450381 UGGUGAUUACUAUGACCUGUAUGGA 4700 5781_3_6 PTPN11 Exon 3 + xp12:112450357-112450382 GGUGAUUACUAUGACCUGUAUGGAG 4701 5781_3_7 PTPN11 Exon 3 + xp12:112450375-112450400 UAUGGAGGGGAGAAAUUUGCCACUU 4702 5781_3_8 PTPN11 Exon 3 + xp12:112450384-112450409 GAGAAAUUUGCCACUUUGGCUGAGU 4703 5781_3_9 PTPN11 Exon 3 + xp12:112450399-112450424 UUGGCUGAGUUGGUCCCAGUAUUACA 4704 5781_3_10 PTPN11 Exon 3 + xp12:112450409-112450434 UGGUCCAGUAUUACAUGGAACAUCA 4705 5781_3_11 PTPN11 Exon 3 + xp12:112450410-112450435 GGUCCAGUAUUACAUGGAACAUCAC 4706 5781_3_12 PTPN11 Exon 3 + xp12:112450430-112450455 AUCACGGGCAAUUAAAAAGAGAAGAA 4707 5781_3_13 PTPN11 Exon 3 + xp12:112450485-112450510 GAACUGUGCAGAUCCUACCUCUGAA 4708 5781_3_14 PTPN11 Exon 3 - xp12:112450297-112450322 UUCUUCUAAAAUAGUCCAUUGGAAA 4709 5781_3_15 PTPN11 Exon 3 - xp12:112450298-112450323 UUUCUUCUAAAAUAGUCCAUUGGAA 4710 5781_3_16 PTPN11 Exon 3 - xp12:112450303-112450328 CUCCAUUUCUUCUAAAAUAGUCCAU 4711 5781_3_17 PTPN11 Exon 3 - xp12:112450337-112450362 UCACCAGUGUUCUGAAUCUUGAUGU 4712 5781_3_18 PTPN11 Exon 3 - xp12:112450338-112450363 AUCACCAGUGUUCUGAAUCUUGAUG 4713 5781_3_19 PTPN11 Exon 3 - xp12:112450374-112450399 AGUGGCAAAUUUCUCCCCUCCAUAC 4714 5781_3_20 PTPN11 Exon 3 - xp12:112450397-112450422 UAAUACUGGACCAAACUCAGCCAAAG 4715 5781_3_21 PTPN11 Exon 3 - xp12:112450416-112450441 UUGCCCGUGAUGUUCCAUGUAAUAC 4716 5781_3_22 PTPN11 Exon 3 - xp12:112450483-112450508 CAGAGGUAGGAUCUGCACAGUUCAG 4717 5781_3_23 PTPN11 Exon 3 - xp12:112450501-112450526 AAAAUGUUACUGACCUUUCAGAGGU 4718 5781_3_24 PTPN11 Exon 3 - xp12:112450505-112450530 CACUAAAAUGUUACUGACCUUUCAG 4719 5781_4_1 PTPN11 Exon 4 + xp12:112453170-112453195 UUUUUUAUUUUUUAAAAACUUUAGG 4720 5781_4_2 PTPN11 Exon 4 + xp12:112453178-112453203 UUUUUAAAAACUUUAGGUGGUUUCA 4721 5781_4_3 PTPN11 Exon 4 + xp12:112453190-112453215 UUAGGUGGUUUCAUGGACAUCUCUCUC 4722 5781_4_4 PTPN11 Exon 4 + xp12:112453191-112453216 UAGGUGGUUUCAUGGACAUCUCUCU 4723 5781_4_5 PTPN11 Exon 4 + xp12:112453223-112453248 AAGCAGAGAAAUUAUUAACUGAAA 4724 5781_4_6 PTPN11 Exon 4 + xp12:112453232-112453257 AAUUAUUAACUGAAAAAAGGAAAAACA 4725 5781_4_7 PTPN11 Exon 4 + xp12:112453268-112453293 UUGUACGAGAGAGCCAGAGCCACCC 4726 5781_4_8 PTPN11 Exon 4 + xp12:112453295-112453320 GAGAUUUUGUUCUUUCUGUGCGCAC 4727 5781_4_9 PTPN11 Exon 4 + xp12:112453307-112453332 UUUCUGUGCCGCACUGGUGAUGACAAA 4728 5781_4_10 PTPN11 Exon 4 + xp12:112453308-112453333 UUCUGUGCCGCACUGGUGAUGACAAA 4729 5781_4_11 PTPN11 Exon 4 + xp12:112453309-112453334 UCUGUGCCGCACUGGUGAUGACAAAAG 4730 5781_4_12 PTPN11 Exon 4 + xp12:112453322-112453347 GUGAUGACAAAAGGGGAGAGCAAUGA 4731 5781_4_13 PTPN11 Exon 4 + xp12:112453360-112453385 GUGACCCAUGUUAUGAUUCGCUGUC 4732 5781_4_14 PTPN11 Exon 4 + xp12:112453382-112453407 GUCAGGUAAAUCUCCAGUUGAAAAA 4733 5781_4_15 PTPN11 Exon 4 + xp12:112453383-112453408 UCAGGUAAAUCUCCAGUUGAAAAAAU 4734 5781_4_16 PTPN11 Exon 4 - xp12:112453284-112453309 AAGAACAAAAUCUCCAGGGUGGCUC 4735 5781_4_17 PTPN11 Exon 4 - xp12:112453290-112453315 CACAGAAAGAACAAAAUCUCCAGGG 4736 5781_4_18 PTPN11 Exon 4 - xp12:112453293-112453318 GCGCACAGAAAGAACAAAAUCUCCA 4737 5781_4_19 PTPN11 Exon 4 - xp12:112453294-112453319 UGCGCACAGAAAGAACAAAAUCUCC 4738 5781_4_20 PTPN11 Exon 4 - xp12:112453367-112453392 UUUACCUGACAGCGAAUCAUAACAU 4739 5781_4_21 PTPN11 Exon 4 - xp12:112453368-112453393 AUUUACCUGACAGCGAAUCAUACACA 4740 5781_5_1 PTPN11 Exon 5 + xp12:112454555-112454580 CUUGAAAGGAACUGAAAUACGACGU 4741 5781_5_2 PTPN11 Exon 5 + xp12:112454558-112454583 GAAAGGAACUGAAAUACGACGUUGG 4742 5781_5_3 PTPN11 Exon 5 + xp12:112454561-112454586 AGGAACCUGAAAUACGACGUUGGUGG 4743 5781_5_4 PTPN11 Exon 5 + xp12:112454568-112454593 GAAAUACGACGUUGGUGGAGGAGAA 4744 5781_5_5 PTPN11 Exon 5 + xp12:112454593-112454618 CGGUUUGAUUCUUUGACAGAUCUUG 4745 5781_5_6 PTPN11 Exon 5 + xp12:112454617-112454642 GUGGAACAUUAUAAGAAGAAUCCUA 4746 5781_5_7 PTPN11 Exon 5 + xp12:112454620-112454645 GAACAUUAUAAGAAGAAUCCUAUGG 4747 5781_5_8 PTPN11 Exon 5 + xp12:112454629-112454654 AAGAAGAAUCCUAUGGUGGAAACAU 4748 5781_5_9 PTPN11 Exon 5 + xp12:112454630-112454655 AGAAGAAUCCUAUGGUGGAAACAUU 4749 5781_5_10 PTPN11 Exon 5 + xp12:112454653-112454678 UUGGGUACAGUACUACAACUCAAGC 4750 5781_5_11 PTPN11 Exon 5 + xp12:112454665-112454690 CUACAACUCAAGCAGGUGAGCAGAU 4751 5781_5_12 PTPN11 Exon 5 - xp12:112454641-112454666 GUACUGUACCAAUGUUUCCACCAU 4752 5781_6_1 PTPN11 Exon 6 + xp12:112456016-112456041 CUGAGACCACAGAUAAAGUCAAACA 4753 5781_6_2 PTPN11 Exon 6 + xp12:112456023-112456048 CACAGAUAAAGUCAAACAAGGCUUU 4754 5781_6_3 PTPN11 Exon 6 + xp12:112456024-112456049 ACAGAUAAAGUCAAACAAGGCUUUU 4755 5781_6_4 PTPN11 Exon 6 + xp12:112456036-112456061 AAACAAGGCUUUUGGGAAGAAUUUG 4756 5781_6_5 PTPN11 Exon 6 - xp12:112455952-112455977 CAGCAUUUAUACGAGUCGUGUUAAG 4757 5781_6_6 PTPN11 Exon 6 - xp12:112455953-112455978 GCAGCAUUUAUACGAGUCGUGUUAA 4758 5781_6_7 PTPN11 Exon 6 - xp12:112455954-112455979 AGCAGCAUUUAUACGAGUCGUGUUA 4759 5781_6_8 PTPN11 Exon 6 - xp12:112456025-112456050 CAAAAGCCUUGUUUGACUUUAUCUG 4760 5781_7_1 PTPN11 Exon 7 + xp12:112472931-112472956 CUUUCUUUCCAGACACUACAACAAC 4761 5781_7_2 PTPN11 Exon 7 + xp12:112472961-112472986 UGCAAACUUCUCUACAGCCGAAAAG 4762 5781_7_3 PTPN11 Exon 7 + xp12:112472962-112472987 GCAAACUUCUCUACAGCCGAAAAGA 4763 5781_7_4 PTPN11 Exon 7 + xp12:112472969-112472994 UCUCUACAGCCGAAAAGAGGGUCAA 4764 5781_7_5 PTPN11 Exon 7 - xp12:112472942-112472967 UUUGCAUCCUGUUGUUGUAGUGUC 4765 5781_7_6 PTPN11 Exon 7 - xp12:112472981-112473006 GUUUUCUUGCCUUUGACCCUCUUUU 4766 5781_7_7 PTPN11 Exon 7 - xp12:112473035-112473060 AGCGGAAUAUUGAUACUUACAGGGC 4767 5781_7_8 PTPN11 Exon 7 - xp12:112473039-112473064 ACUGAGCGGAAUAUUGAUACUUACA 4768 5781_7_9 PTPN11 Exon 7 - xp12:112473040-112473065 UACUGAGCGGAAUAUUGAUACUUAC 4769 5781_8_1 PTPN11 Exon 8 + xp12:112477636-112477661 UCUUUUCUUCUAGUUGAUCUACC 4770 5781_8_2 PTPN11 Exon 8 + xp12:112477637-112477662 CUUUUUCUUCUAGUUGAUCAUACCA 4771 5781_8_3 PTPN11 Exon 8 + xp12:112477653-112477678 AUCAUACCAGGGUUGUCCUACACGA 4772 5781_8_4 PTPN11 Exon 8 + xp12:112477703-112477728 GAUUACAUCAUCAAUGCAAAUAUCAUCA 4773 5781_8_5 PTPN11 Exon 8 - xp12:112477631-112477656 GAUCAACUAGAAGAAAAAGAGACCA 4774 5781_8_6 PTPN11 Exon 8 - xp12:112477662-112477687 GGAUCACCAUCGUGUAGGACAACCC 4775 5781_8_7 PTPN11 Exon 8 - xp12:112477672-112477697 AGGCUCAUUGGGAUCACCAUCGUGU 4776 5781_8_8 PTPN11 Exon 8 - xp12:112477688-112477713 UGAUGUAAUCUGAAACAGGCUCAUU 4777 5781_8_9 PTPN11 Exon 8 - xp12:112477689-112477714 UUGAUGUAAUCUGAAACAGGCUCAU 4778 5781_8_10 PTPN11 Exon 8 - xp12:112477697-112477722 UAUUUGCAUUGAUGUAAUCUGAAC 4779 5781_9_1 PTPN11 Exon 9 + xp12:112477890-112477915 CCAAAAAGAGUUACAUUGCCACACA 4780 5781_9_2 PTPN11 Exon 9 + xp12:112477907-112477932 GCCACACAAGGCUGCCUGCAAAACA 4781 5781_9_3 PTPN11 Exon 9 + xp12:112477921-112477946 CCUGCAAAACACGGUGAAUGACUUU 4782 5781_9_4 PTPN11 Exon 9 + xp12:112477924-112477949 GCAAAACACGGUGAAUGACUUUUGG 4783 5781_9_5 PTPN11 Exon 9 + xp12:112477928-112477953 AACACGGUGAAUGACUUUUGGCGGA 4784 5781_9_6 PTPN11 Exon 9 + xp12:112477976-112478001 GUGAUUGUCAUGACAACGAAAGAAG 4785 5781_9_7 PTPN11 Exon 9 + xp12:112477983-112478008 UCAUGACAACGAAAGAAGGUGGAGAG 4786 5781_9_8 PTPN11 Exon 9 + xp12:112477988-112478013 ACAACGAAAGAAGUGGAGAGAGGAA 4787 5781_9_9 PTPN11 Exon 9 - xp12:112477846-112477871 GGUUUCAAAUUCAGGCUAGAAAUUU 4788 5781_9_10 PTPN11 Exon 9 - xp12:112477859-112477884 AAUUGUUGCACUUGGUUUCAAAUUC 4789 5781_9_11 PTPN11 Exon 9 - xp12:112477872-112477897 UUUUUGGGCUUUGAAUUGUUGCACU 4790 5781_9_12 PTPN11 Exon 9 - xp12:112477892-112477917 CUUGUGUGGCAAUGUAACUCUUUUU 4791 5781_9_13 PTPN11 Exon 9 - xp12:112477893-112477918 CCUUGUGUGGCAAUGUAACUCUUUU 4792 5781_9_14 PTPN11 Exon 9 - xp12:112477911-112477936 ACCGUGUUUUGCAGGCAGCCUUGUG 4793 5781_9_15 PTPN11 Exon 9 - xp12:112477924-112477949 CCAAAAGUCAUUCACCGUGUUUUGC 4794 5781_9_16 PTPN11 Exon 9 - xp12:112477963-112477988 CAUGACAAUCACUCGGGAGUUUUCU 4795 5781_9_17 PTPN11 Exon 9 - xp12:112477974-112477999 UCUUUCGUUGUCAUGACAAUCACUC 4796 5781_9_18 PTPN11 Exon 9 - xp12:112477975-112478000 UUCUUUCGUUGUCAUGACAAUCACU 4797 5781_10_1 PTPN11 Exon 10 + xp12:112482066-112482091 CUUCCAGAGUAAAUGUGUCAAAAUAC 4798 5781_10_2 PTPN11 Exon 10 + xp12:112482095-112482120 CUGAUGAGUAUGCCUUAAAAGAAUA 4799 5781_10_3 PTPN11 Exon 10 + xp12:112482111-112482136 AAAAGAAUAUGGCGUCAUGCGUGUU 4800 5781_10_4 PTPN11 Exon 10 + xp12:112482169-112482194 ACGCUAAGAGAACUUAAACUUUCAA 4801 5781_10_5 PTPN11 Exon 10 + xp12:112482173-112482198 UAAGAGAACUUAAACUUUCAAAGGU 4802 5781_10_6 PTPN11 Exon 10 - xp12:112482072-112482097 AGGCCAGUAUUUUGACACAUUUACUC 4803 5781_10_7 PTPN11 Exon 10 - xp12:112482097-112482122 CAUAUUCUUUUAGAGCAUACUCACUC 4804 5781_10_8 PTPN11 Exon 10 - xp12:112482158-112482183 AGUUCUCUUAGCGUAUAGUCAUGAG 4805 5781_11_1 PTPN11 Exon 11 + xp12:112486449-112486474 CUGGUUUUUCUUGGCUCUACUCCAG 4806 5781_11_2 PTPN11 Exon 11 + xp12:112486456-112486481 UUCUUGGCCUUACUCCAGGGGAAUA 4807 5781_11_3 PTPN11 Exon 11 + xp12:112486465-112486490 CUACUCCAGGGGAAUACGGAGAGAA 4808 5781_11_4 PTPN11 Exon 11 + xp12:112486470-112486495 CCAGGGGAAUACGGAGAGAACGGUC 4809 5781_11_5 PTPN11 Exon 11 + xp12:112486485-112486510 GAGAACGGUCUGGCAAUACCACUUU 4810 5781_11_6 PTPN11 Exon 11 + xp12:112486491-112486516 GGUCUGGCAAUACCACUUUCGGACC 4811 5781_11_7 PTPN11 Exon 11 + xp12:112486495-112486520 UGGCAAUACCACUUUCGGACCUGGC 4812 5781_11_8 PTPN11 Exon 11 + xp12:112486502-112486527 ACCACUUUCGGACCUGGCCGGACCA 4813 5781_11_9 PTPN11 Exon 11 + xp12:112486520-112486545 CGGACCACGGCGUGCCCAGCGACCC 4814 5781_11_10 PTPN11 Exon 11 + xp12:112486521-112486546 GGACCACGGCGUGCCCAGGCGACCCU 4815 5781_11_11 PTPN11 Exon 11 + xp12:112486522-112486547 GACCACGGCGUGCCCAGCGACCCUG 4816 5781_11_12 PTPN11 Exon 11 + xp12:112486523-112486548 ACCACGGCGUGCCCAGCGACCCUGG 4817 5781_11_13 PTPN11 Exon 11 + xp12:112486531-112486556 GUGCCCAGCGGACCCUGGGGGCGUGC 4818 5781_11_14 PTPN11 Exon 11 + xp12:112486540-112486565 GACCCUGGGGGCGUGCUGGACUUCC 4819 5781_11_15 PTPN11 Exon 11 + xp12:112486543-112486568 CCUGGGGGCGUGCUGGACUUCCUGG 4820 5781_11_16 PTPN11 Exon 11 + xp12:112486546-112486571 GGGGGCGUGCUGGACUUCCUGGAGG 4821 5781_11_17 PTPN11 Exon 11 + xp12:112486561-112486586 UUCCUGGAGGAGGUGCACCAUAAGC 4822 5781_11_18 PTPN11 Exon 11 + xp12:112486573-112486598 GUGCACCAUAAGCAGGAGAGCAUCA 4823 5781_11_19 PTPN11 Exon 11 + xp12:112486580-112486605 AUAAGCAGGAGAGCAUCAUGGAUGC 4824 5781_11_20 PTPN11 Exon 11 + xp12:112486581-112486606 UAAGCAGGAGAGCAUCAUGGAUGCA 4825 5781_11_21 PTPN11 Exon 11 + xp12:112486585-112486610 CAGGAGAGCAUCAUGGAUGCAGGGC 4826 5781_11_22 PTPN11 Exon 11 + xp12:112486591-112486616 AGCAUCAUGGAUGCAGGGCCGGUCG 4827 5781_11_23 PTPN11 Exon 11 + xp12:112486602-112486627 UGCAGGGCCGGUCGUGGUGCACUGC 4828 5781_11_24 PTPN11 Exon 11 + xp12:112486627-112486652 AGGUGACAGCUCCUGCUGCCCCUCU 4829 5781_11_25 PTPN11 Exon 11 + xp12:112486659-112486684 AGCCUGUCCCUGUCUCCUAGCGCCC 4830 5781_11_26 PTPN11 Exon 11 + xp12:112486660-112486685 GCCUGUCCCUGUCUCCUAGCGCCCA 4831 5781_11_27 PTPN11 Exon 11 + xp12:112486700-112486725 UACCCACUCCUAGCUCUUUAACUGU 4832 5781_11_28 PTPN11 Exon 11 + xp12:112486723-112486748 GUAGGAAGAAUUUAAUAUCUGUUUG 4833 5781_11_29 PTPN11 Exon 11 + xp12:112486744-112486769 UUUGAGGCAUAGAGCAACUGCAUUG 4834 5781_11_30 PTPN11 Exon 11 + xp12:112486745-112486770 UUGAGGCAUAGAGCAACUGCAUUGA 4835 5781_11_31 PTPN11 Exon 11 + xp12:112486762-112486787 UGCAUUGAGGGACAUUUUGAUCCA 4836 5781_11_32 PTPN11 Exon 11 + xp12:112486797-112486822 CUCCUAGACCCUACAGCACUGCCAU 4837 5781_11_33 PTPN11 Exon 11 + xp12:112486803-112486828 GACCCUACAGCACUGCCAUUGGCCA 4838 5781_11_34 PTPN11 Exon 11 + xp12:112486809-112486834 ACAGCACUGCCAUUGGCCAUGGCCA 4839 5781_11_35 PTPN11 Exon 11 + xp12:112486895-112486920 AGUUGUGCAUUAAAACAACUUCAUCC 4840 5781_11_36 PTPN11 Exon 11 - xp12:112486473-112486498 CCAGACCGUUCUCUCCGUAUUCCCCC 4841 5781_11_37 PTPN11 Exon 11 - xp12:112486506-112486531 GCCGUGGUCCGGCCAGGUCCGAAAG 4842 5781_11_38 PTPN11 Exon 11 - xp12:112486517-112486542 UCGCUGGGCACGCCGUGGUCCGGCC 4843 5781_11_39 PTPN11 Exon 11 - xp12:112486522-112486547 CAGGGUCGCUGGGCACGCCGUGGUC 4844 5781_11_40 PTPN11 Exon 11 - xp12:112486527-112486552 GCCCCCAGGGUCGCUGGGCACGCCG 4845 5781_11_41 PTPN11 Exon 11 - xp12:112486537-112486562 AGUCCAGCACGCCCCCAGGGUCGCU 4846 5781_11_42 PTPN11 Exon 11 - xp12:112486538-112486563 AAGUCCAGCACGCCCCCAGGGUCGC 4847 5781_11_43 PTPN11 Exon 11 - xp12:112486545-112486570 CUCCAGGAAGUCCAGCACCCCCCA 4848 5781_11_44 PTPN11 Exon 11 - xp12:112486546-112486571 CCUCCAGGAAGUCCAGCACGCCCCC 4849 5781_11_45 PTPN11 Exon 11 - xp12:112486566-112486591 CUCCUGCUUAUGGUGCACCUCCUCC 4850 5781_11_46 PTPN11 Exon 11 - xp12:112486581-112486606 UGCAUCCAUGAUGCUCUCCUGCUUA 4851 5781_11_47 PTPN11 Exon 11 - xp12:112486612-112486637 GCUGUGCACCUGCAGUGCACCACGAC 4852 5781_11_48 PTPN11 Exon 11 - xp12:112486641-112486666 ACAGGCUGUGGCCUAGAGGGGCAGC 4853 5781_11_49 PTPN11 Exon 11 - xp12:112486648-112486673 GACAGGGACAGGCUGUGGCCUAGAG 4854 5781_11_50 PTPN11 Exon 11 - xp12:112486649-112486674 AGACAGGGACAGGCUGUGGCCUAGA 4855 5781_11_51 PTPN11 Exon 11 - xp12:112486650-112486675 GAGACAGGGACAGGCUGUGGCCUAG 4856 5781_11_52 PTPN11 Exon 11 - xp12:112486658-112486683 GGCGCUAGGAGACAGGGACAGGCUG 4857 5781_11_53 PTPN11 Exon 11 - xp12:112486664-112486689 GCCCUGGGCGCUAGGAGACAGGGAC 4858 5781_11_54 PTPN11 Exon 11 - xp12:112486669-112486694 AGCAAGCCCUGGGCGCUAGGAGACA 4859 5781_11_55 PTPN11 Exon 11 - xp12:112486670-112486695 AAGCAAGCCCUGGGCGCUAGGAGAC 4860 5781_11_56 PTPN11 Exon 11 - xp12:112486677-112486702 UAGGUAAAAAGCAAGCCCUGGGCGCU 4861 5781_11_57 PTPN11 Exon 11 - xp12:112486684-112486709 GAGUGGGUAGGUAAAAAGCAAGCCCU 4862 5781_11_58 PTPN11 Exon 11 - xp12:112486685-112486710 GGAGUGGGUAGGUAAAAGCAAGCCC 4863 5781_11_59 PTPN11 Exon 11 - xp12:112486701-112486726 UACAGUUAAAAGAGCUAGGAGUGGGU 4864 5781_11_60 PTPN11 Exon 11 - xp12:112486705-112486730 UUCCUACAGGUUAAAAGAGCUAGGAGU 4865 5781_11_61 PTPN11 Exon 11 - xp12:112486706-112486731 CUUCCUACAGUUAAAAGAGCUAGGAG 4866 5781_11_62 PTPN11 Exon 11 - xp12:112486711-112486736 AAAUUCUUCCUACAGUUAAAAGAGCU 4867 5781_11_63 PTPN11 Exon 11 - xp12:112486786-112486811 GUAGGGUCUAGGAGAAAUAUGCCUU 4868 5781_11_64 PTPN11 Exon 11 - xp12:112486787-112486812 UGUAGGGUCUAGGAGAAAUAUGCCU 4869 5781_11_65 PTPN11 Exon 11 - xp12:112486802-112486827 GGCCAAUGGCAGUGCUGUAGGGUCU 4870 5781_11_66 PTPN11 Exon 11 - xp12:112486808-112486833 GGCCAUGGCCAAUGGCAGUGCUGUA 4871 5781_11_67 PTPN11 Exon 11 - xp12:112486809-112486834 UGGCCAUGGCCAAUGGCAGUGCUGU 4872 5781_11_68 PTPN11 Exon 11 - xp12:112486821-112486846 AGCAUGUUGCCAUGGCCAUGGCCAA 4873 5781_11_69 PTPN11 Exon 11 - xp12:112486828-112486853 UUAACUGAGCAUGUUGCCAUGGCCA 4874 5781_11_70 PTPN11 Exon 11 - xp12:112486834-112486859 GCUGUUUUAACUGAGCAUGUUGCCA 4875 5781_11_71 PTPN11 Exon 11 - xp12:112486890-112486915 AAGUUGUUUAAUGCACAACUUCUGG 4876 5781_11_72 PTPN11 Exon 11 - xp12:112486893-112486918 AUGAAGUUGUUUAAUGCACAACUUC 4877 5781_11_73 PTPN11 Exon 11 - xp12:112486921-112486946 AAGAAUAAGGAGAAACUGCAGAGCC 4878 5781_12_1 PTPN11 Exon 12 + xp12:112488420-112488445 CUUUUUGUCCUUCUGCCCGCAGUGC 4879 5781_12_2 PTPN11 Exon 12 + xp12:112488426-112488451 GUCCUUCUGCCCGCAGUGCUGGAAU 4880 5781_12_3 PTPN11 Exon 12 + xp12:112488430-112488455 UUCUGCCCGCAGUGCUGGAAUUGGC 4881 5781_12_4 PTPN11 Exon 12 + xp12:112488435-112488460 CCCGCAGUGCUGGAAUUGGCCGGAC 4882 5781_12_5 PTPN11 Exon 12 + xp12:112488436-112488461 CCGCAGUGCUGGAAUUGGCCGGACA 4883 5781_12_6 PTPN11 Exon 12 + xp12:112488483-112488508 UUCUUAUUGACAUCAUCAGAGAGAA 4884 5781_12_7 PTPN11 Exon 12 + xp12:112488486-112488511 UUAUUGACAUCAUCAGAGAGAAAGG 4885 5781_12_8 PTPN11 Exon 12 + xp12:112488487-112488512 UAUUGACAUCAUCAGAGAGAAAGGU 4886 5781_12_9 PTPN11 Exon 12 + xp12:112488495-112488520 UCAUCAGAGAGAAAGGUGGGUCAUC 4887 5781_12_10 PTPN11 Exon 12 + xp12:112488498-112488523 UCAGAGAGAAAGGUGGGUCAUCUGG 4888 5781_12_11 PTPN11 Exon 12 + xp12:112488499-112488524 CAGAGAGAAAGGUGGGUCAUCUGGU 4889 5781_12_12 PTPN11 Exon 12 - xp12:112488431-112488456 GGCCAAUUCCAGCACUGCGGGCAGA 4890 5781_12_13 PTPN11 Exon 12 - xp12:112488438-112488463 CCUGUCCGGCCAAUUCCAGCACUGC 4891 5781_12_14 PTPN11 Exon 12 - xp12:112488439-112488464 CCCUGUCCGGCCAAUUCCAGCACUG 4892 5781_12_15 PTPN11 Exon 12 - xp12:112488457-112488482 AUCAAUCACAAUGAACGUCCCUGUC 4893 5781_13_1 PTPN11 Exon 13 + xp12:112489037-112489062 AUUGACGUUCCCCAAAACCAUCCAGA 4894 5781_13_2 PTPN11 Exon 13 + xp12:112489042-112489067 CGUUCCCAAAACCAUCCAGAUGGUG 4895 5781_13_3 PTPN11 Exon 13 + xp12:112489051-112489076 AACCAUCCAGAUGGUGCGGUCUCAG 4896 5781_13_4 PTPN11 Exon 13 + xp12:112489056-112489081 UCCAGAUGGUGCGGUCUCAGAGGUC 4897 5781_13_5 PTPN11 Exon 13 + xp12:112489057-112489082 CCAGAUGGUGCGGUCUCAGAGGUCA 4898 5781_13_6 PTPN11 Exon 13 + xp12:112489061-112489086 AUGGUGCGGUCUCAGAGGUCAGGGA 4899 5781_13_7 PTPN11 Exon 13 + xp12:112489097-112489122 GAAGCACAGUACCGAUUUAUCUAUA 4900 5781_13_8 PTPN11 Exon 13 + xp12:112489100-112489125 GCACAGUACCGAUUUAUCUAUAUGG 4901 5781_13_9 PTPN11 Exon 13 + xp12:112489132-112489157 GCAUUAUAUUGAAACACUACAGGCGC 4902 5781_13_10 PTPN11 Exon 13 + xp12:112489148-112489173 CUACAGCGCAGGAUUGAAGAAGAGC 4903 5781_13_11 PTPN11 Exon 13 + xp12:112489161-112489186 UUGAAGAAGAGCAGGUACCAGCCUG 4904 5781_13_12 PTPN11 Exon 13 + xp12:112489162-112489187 UGAAGAAGAGCAGGUACCAGCCUGA 4905 5781_13_13 PTPN11 Exon 13 + xp12:112489166-112489191 GAAGAGCAGGUACCAGCCUGAGGGC 4906 5781_13_14 PTPN11 Exon 13 - xp12:112489017-112489042 UCAAUAUCGCAGUCAACACCUACGA 4907 5781_13_15 PTPN11 Exon 13 - xp12:112489049-112489074 GAGACCGCACCAUCUGGAUGGUUUU 4908 5781_13_16 PTPN11 Exon 13 - xp12:112489050-112489075 UGAGACCCGCACCAUCUGGAUGGUUU 4909 5781_13_17 PTPN11 Exon 13 - xp12:112489056-112489081 GACCUCUGAGACCCGCACCAUCUGGA 4910 5781_13_18 PTPN11 Exon 13 - xp12:112489060-112489085 CCCUGACCCUCUGAGACCGCACCAUC 4911 5781_13_19 PTPN11 Exon 13 - xp12:112489093-112489118 GAUAAAUCGGUACUGUGCUUCUGUC 4912 5781_13_20 PTPN11 Exon 13 - xp12:112489111-112489136 AUGCUGGACCGCCAUAUAGAUAAAU 4913 5781_13_21 PTPN11 Exon 13 - xp12:112489132-112489157 GCGCUGUAGGUUUCAAUAUAAUGC 4914 5781_14_1 PTPN11 Exon 14 + xp12:112502127-112502152 CUCUUCCAAAUUUCAGAAAAGCAAG 4915 5781_14_2 PTPN11 Exon 14 + xp12:112502132-112502157 CCAAAUUUCAGAAAAGCAAGAGGAA 4916 5781_14_3 PTPN11 Exon 14 + xp12:112502133-112502158 CAAAUUUCAGAAAAGCAAGAGGAAA 4917 5781_14_4 PTPN11 Exon 14 + xp12:112502167-112502192 UAUACAAAUAUUAAGUAUUCUCUAG 4918 5781_14_5 PTPN11 Exon 14 + xp12:112502180-112502205 AGUAUUCUCUAGCGGACCAGACGAG 4919 5781_14_6 PTPN11 Exon 14 + xp12:112502245-112502270 CCCUGUGCAGAGUAAGUAGUGCUGA 4920 5781_14_7 PTPN11 Exon 14 - xp12:112502135-112502160 CCUUUCCUCUUGCUUUUCUGAAAUU 4921 5781_14_8 PTPN11 Exon 14 - xp12:112502199-112502224 GAGAGGGCUCUGAUCUCCACUCGUC 4922 5781_14_9 PTPN11 Exon 14 - xp12:112502220-112502245 UGGCGUUGGAGUACAAGGCGGGAGA 4923 5781_14_10 PTPN11 Exon 14 - xp12:112502221-112502246 GUGGCGUUGGAGUACAAGGCGGGAG 4924 5781_14_11 PTPN11 Exon 14 - xp12:112502226-112502251 ACAGGGUGGCGUUGGAGUACAGGC 4925 5781_14_12 PTPN11 Exon 14 - xp12:112502227-112502252 CACAGGGUGGCGUUGGAGUACAAGG 4926 5781_14_13 PTPN11 Exon 14 - xp12:112502230-112502255 CUGCACAGGGUGGCGUUGGAGUAC 4927 5781_14_14 PTPN11 Exon 14 - xp12:112502239-112502264 CUACUUACUCUGCACAGGGUGGCGU 4928 5781_14_15 PTPN11 Exon 14 - xp12:112502245-112502270 UCAGCACUACUUACUCUGCACAGGG 4929 5781_14_16 PTPN11 Exon 14 - xp12:112502248-112502273 CCUUCAGCACUACUUACUCUGCACA 4930 5781_14_17 PTPN11 Exon 14 - xp12:112502249-112502274 UCCUUCAGCACUACUUACUCUGCAC 4931 5781_15_1 PTPN11 Exon 15 + xp12:112504704-112504729 GACAGUGCUAGAGUCUAUGAAAACG 4932 5781_15_2 PTPN11 Exon 15 + xp12:112504705-112504730 ACAGUGCUAGAGUCUAUGAAAACGU 4933 5781_15_3 PTPN11 Exon 15 + xp12:112504769-112504794 CCUGCCAAAACUUCAGCACAGAAAU 4934 5781_15_4 PTPN11 Exon 15 - xp12:112504693-112504718 ACUCUAGCACUGUCUUCUCUCAUUC 4935 5781_15_5 PTPN11 Exon 15 - xp12:112504736-112504761 UCUGAAACUUUUCUGCUGUUGCAUC 4936 5781_15_6 PTPN11 Exon 15 - xp12:112504772-112504797 CCUAUUUCUGUGCUGAAGUUUUGGC 4937 5781_15_7 PTPN11 Exon 15 - xp12:112504776-112504801 AAUACCUAUUUCUGUGCUGAAGUUU 4938 5781_16_1 PTPN11 Exon 16 + xp12:112505802-112505827 UCUUAACUUAUUUCUUCCCCAGAUG 4939 5781_16_2 PTPN11 Exon 16 + xp12:112505869-112505894 AGAAAGUUUAUGUGAAGACAGAAUU 4940 5781_16_3 PTPN11 Exon 16 + xp12:112505875-112505900 UUUAUGUGAAGACAGAAUUUGGAUU 4941 5781_16_4 PTPN11 Exon 16 + xp12:112505879-112505904 UGUGAAGACAGAAUUUGGAUUUGGA 4942 5781_16_5 PTPN11 Exon 16 + xp12:112505891-112505916 AUUUGGAUUUGGAAGGCUUGCAAUG 4943 5781_16_6 PTPN11 Exon 16 + xp12:112506051-112506076 AUUUUAUAGAAUUUGUUUGAAAUUG 4944 5781_16_7 PTPN11 Exon 16 + xp12:112506089-112506114 AUUGUGCCGCUGUAUUUUGCAGAUUA 4945 5781_16_8 PTPN11 Exon 16 + xp12:112506090-112506115 UUGUGCCGCUGUAUUUUGCAGAUUAU 4946 5781_16_9 PTPN11 Exon 16 + xp12:112506091-112506116 UGUGCCGCUGUAUUUUGCAGAUUAUG 4947 5781_16_10 PTPN11 Exon 16 + xp12:112506111-112506136 UUAUGGGGAUUCAAAUUCUAGUAUAU 4948 5781_16_11 PTPN11 Exon 16 + xp12:112506171-112506196 GUUUAAUUUUUUUUUUCCUCAUUGU 4949 5781_16_12 PTPN11 Exon 16 + xp12:112506172-112506197 UUUAAUUUUUUUUUUCCUCAUUGUU 4950 5781_16_13 PTPN11 Exon 16 + xp12:112506173-112506198 UUAAUUUUUUUUUUCCUCAUUGUUG 4951 5781_16_14 PTPN11 Exon 16 + xp12:112506195-112506220 UUGGGGAUGAUGAGAAGAAAUGAUU 4952 5781_16_15 PTPN11 Exon 16 + xp12:112506196-112506221 UGGGGAUGAUGAGAAGAAAUGAUUU 4953 5781_16_16 PTPN11 Exon 16 + xp12:112506263-112506288 UCAUUUACCAUCAUGUAUUCCAGUAG 4954 5781_16_17 PTPN11 Exon 16 + xp12:112506280-112506305 UCCAGUAGUGGAUAAUUCAUUUUGA 4955 5781_16_18 PTPN11 Exon 16 + xp12:112506293-112506318 AAUUCAUUUUGAUGGCUUCUAUUUU 4956 5781_16_19 PTPN11 Exon 16 + xp12:112506348-112506373 GACUGUCAGAAGUUGACCUUUGCAC 4957 5781_16_20 PTPN11 Exon 16 + xp12:112506378-112506403 UUAAAGAGUCAUAGAAAAAGAAUCA 4958 5781_16_21 PTPN11 Exon 16 + xp12:112506395-112506420 AAGAAUCAUGGAUAUUUAUGAAUUA 4959 5781_16_22 PTPN11 Exon 16 + xp12:112506402-112506427 AUGGAUAUUUAUGAAUUAAGGUAAG 4960 5781_16_23 PTPN11 Exon 16 + xp12:112506407-112506432 UAUUUAUGAAUUAAGGUAAGAGGUG 4961 5781_16_24 PTPN11 Exon 16 + xp12:112506453-112506478 UUCCAGCCCGUUGACCAAUUAUAGUU 4962 5781_16_25 PTPN11 Exon 16 + xp12:112506475-112506500 GUUCGGCUGUUGACUGAGAAGUUUG 4963 5781_16_26 PTPN11 Exon 16 + xp12:112506478-112506503 CGGCUGUUGACUGAGAAGUUUGUGG 4964 5781_16_27 PTPN11 Exon 16 + xp12:112506479-112506504 GGCUGUUGACUGAGAAGUUUGUGGU 4965 5781_16_28 PTPN11 Exon 16 + xp12:112506537-112506562 AAUAAUUGUCUUGUACUUAGAAAAA 4966 5781_16_29 PTPN11 Exon 16 + xp12:112506563-112506588 GGCGUCUAUGAAUGACCAGUGUUUU 4967 5781_16_30 PTPN11 Exon 16 + xp12:112506991-112507016 UGGUUUUUUCUAAUCAGAAGAAAGC 4968 5781_16_31 PTPN11 Exon 16 + xp12:112506992-112507017 GGUUUUUUCUAAUCAGAAGAAAGCU 4969 5781_16_32 PTPN11 Exon 16 + xp12:112506993-112507018 GUUUUUUCUAAUCAGAAGAAAGCUG 4970 5781_16_33 PTPN11 Exon 16 + xp12:112507061-112507086 GAUUCAAGAAAAGGGUGUGAAGGUAG 4971 5781_16_34 PTPN11 Exon 16 + xp12:112507074-112507099 GGUGUGAAGUAAGAGGUGCAGUUAAG 4972 5781_16_35 PTPN11 Exon 16 + xp12:112507075-112507100 GUGUGAAGUAAGAGGUGCAGUUAAGGU 4973 5781_16_36 PTPN11 Exon 16 + xp12:112507076-112507101 UGUGAAGUAGAGGUGCAGUUAAGUG 4974 5781_16_37 PTPN11 Exon 16 + xp12:112507077-112507102 GUGAAGUAGAGGUGCAGUUAAGGG 4975 5781_16_38 PTPN11 Exon 16 + xp12:112507078-112507103 UGAAGUAGAGGUGCAGUUAAGUGGG 4976 5781_16_39 PTPN11 Exon 16 + xp12:112507097-112507122 AGUGGGGGGCCACUAGUCUAACAGA 4977 5781_16_40 PTPN11 Exon 16 + xp12:112507115-112507140 UAACAGACGGUCACAACCAGUGCCA 4978 5781_16_41 PTPN11 Exon 16 + xp12:112507125-112507150 UCACAACCAGUGCCAUGGAAAACCA 4979 5781_16_42 PTPN11 Exon 16 + xp12:112507160-112507185 CAAAAGCAGAAGUUGCUAGUGACCU 4980 5781_16_43 PTPN11 Exon 16 + xp12:112507161-112507186 AAAAGCAGAAGUUGCUAGUGACCUU 4981 5781_16_44 PTPN11 Exon 16 + xp12:112507187-112507212 GGAAGCCGAAGCUGCUUACAGUAGGC 4982 5781_16_45 PTPN11 Exon 16 + xp12:112507188-112507213 GAAGCCGAAGCUGCUUACAGUAGCU 4983 5781_16_46 PTPN11 Exon 16 + xp12:112507223-112507248 GAAAGUCAGACUAAGAAAUAAAGAG 4984 5781_16_47 PTPN11 Exon 16 + xp12:112507224-112507249 AAAGUCAGACUAAGAAAUAAAGAGA 4985 5781_16_48 PTPN11 Exon 16 + xp12:112507275-112507300 UUUCUGCUAGCCCUGAGCCUAUUUU 4986 5781_16_49 PTPN11 Exon 16 + xp12:112507288-112507313 UGAGCCUAUUUUUGGAACCACU 4987 5781_16_50 PTPN11 Exon 16 + xp12:112507289-112507314 GAGCCUAUUUUUGGAACCAGCACUU 4988 5781_16_51 PTPN11 Exon 16 + xp12:112507290-112507315 AGCCUAUUUUUGGAACCAGCACUUG 4989 5781_16_52 PTPN11 Exon 16 + xp12:112507307-112507332 AGCACUUGGGGAAACUGAUCUUGUG 4990 5781_16_53 PTPN11 Exon 16 + xp12:112507311-112507336 CUUGGGGAAACUGAUCUUGUGAGGA 4991 5781_16_54 PTPN11 Exon 16 + xp12:112507322-112507347 UGAUCUUGUGAGGAUGGAUGUGUUU 4992 5781_16_55 PTPN11 Exon 16 + xp12:112507323-112507348 GAUCUUGUGAGGAUGGAUGUGUUUA 4993 5781_16_56 PTPN11 Exon 16 + xp12:112507330-112507355 UGAGGAUGGAUGUGUUUAGGGACAC 4994 5781_16_57 PTPN11 Exon 16 + xp12:112507331-112507356 GAGGAUGGAUGUGUUUAGGGACACA 4995 5781_16_58 PTPN11 Exon 16 + xp12:112507358-112507383 GCUUUUGAGAGCAGCACCACCCAC 4996 5781_16_59 PTPN11 Exon 16 + xp12:112507359-112507384 CUUUUGAGAGCAGCACCACCCCACU 4997 5781_16_60 PTPN11 Exon 16 + xp12:112507360-112507385 UUUUGAGAGCAGCACCACCCCACUG 4998 5781_16_61 PTPN11 Exon 16 + xp12:112507375-112507400 CACCCCACUGGGGCAUCCCCAGACU 4999 5781_16_62 PTPN11 Exon 16 + xp12:112507376-112507401 ACCCCACUGGGGCAUCCCCAGACUU 5000 5781_16_63 PTPN11 Exon 16 + xp12:112507404-112507429 AAACGUGACUCUUUCUUAAUGCCAC 5001 5781_16_64 PTPN11 Exon 16 + xp12:112507405-112507430 AACGUGACUCUUUCUUAAUGCCACU 5002 5781_16_65 PTPN11 Exon 16 + xp12:112507416-112507441 UUCUUAAUGCCACUGGGUUUUAGUC 5003 5781_16_66 PTPN11 Exon 16 + xp12:112507430-112507455 GGGUUUUAGUCAGGCCACAGUGAGA 5004 5781_16_67 PTPN11 Exon 16 + xp12:112507445-112507470 CACAGUGAGAAGGAACAGCCCUAAC 5005 5781_16_68 PTPN11 Exon 16 + xp12:112507457-112507482 GAACAGCCCUAACAGGCCUCCAGCC 5006 5781_16_69 PTPN11 Exon 16 + xp12:112507571-112507596 GCCUCAUAUGUUGAAUCAUCCAGUG 5007 5781_16_70 PTPN11 Exon 16 + xp12:112507595-112507620 GCGGAUAUUUCAAUGAAAAUAUUCAU 5008 5781_16_71 PTPN11 Exon 16 + xp12:112507611-112507636 AAAUAUCAUUGGUUGACUUUUGUGA 5009 5781_16_72 PTPN11 Exon 16 + xp12:112507625-112507650 GACUUUUGUGAUGGUAAUAAUGCUA 5010 5781_16_73 PTPN11 Exon 16 + xp12:112507647-112507672 CUAUGGCAUCUUUGCCAUGAAGUUG 5011 5781_16_74 PTPN11 Exon 16 + xp12:112507656-112507681 CUUUGCCAUGAAGUUGUGGCCUCCU 5012 5781_16_75 PTPN11 Exon 16 + xp12:112507672-112507697 UGGCCUCCUUGGAUUCUUCUGACUU 5013 5781_16_76 PTPN11 Exon 16 + xp12:112507683-112507708 GAUUCUUCUGACUUUGGCUUCUGAA 5014 5781_16_77 PTPN11 Exon 16 + xp12:112507687-112507712 CUUCUGACUUUGGCUUCUGAAAGGA 5015 5781_16_78 PTPN11 Exon 16 + xp12:112507704-112507729 UGAAAGGAAGGCCUAGAUCCAGCCCC 5016 5781_16_79 PTPN11 Exon 16 + xp12:112507707-112507732 AAGGAAGGCCUAGAUCCAGCCCUGG 5017 5781_16_80 PTPN11 Exon 16 + xp12:112507723-112507748 CAGCCCUGGUGGUAGUUCCUUUCUG 5018 5781_16_81 PTPN11 Exon 16 + xp12:112507747-112507772 GAGGUCUCUCAGUCCCUUGAGACUU 5019 5781_16_82 PTPN11 Exon 16 + xp12:112507748-112507773 AGGUCUCUCAGUCCCUUGAGACUUU 5020 5781_16_83 PTPN11 Exon 16 + xp12:112507749-112507774 GGUCUCUCAGUCCCUUGAGACUUUG 5021 5781_16_84 PTPN11 Exon 16 + xp12:112507757-112507782 AGUCCCUUGAGACUUUGGGGUAGUU 5022 5781_16_85 PTPN11 Exon 16 + xp12:112507843-112507868 UGAACUUUGAAUUGCUUCAGAACAC 5023 5781_16_86 PTPN11 Exon 16 + xp12:112507848-112507873 UUUGAAUUGCUUCAGAACACAGGUG 5024 5781_16_87 PTPN11 Exon 16 + xp12:112507856-112507881 GCUUCAGAACACAGGUGUGGCCUGA 5025 5781_16_88 PTPN11 Exon 16 + xp12:112507871-112507896 UGUGGCCUGAAGGUAUUCCCUUAUU 5026 5781_16_89 PTPN11 Exon 16 + xp12:112507872-112507897 GUGGCCUGAAGGUAUUCCCUUAUUA 5027 5781_16_90 PTPN11 Exon 16 + xp12:112508001-112508026 CAUCGACUCAUUCUCCAUUUUGCUU 5028 5781_16_91 PTPN11 Exon 16 + xp12:112508028-112508053 GUUUUGUCUUGACUUGACUUGACUU 5029 5781_16_92 PTPN11 Exon 16 + xp12:112508029-112508054 UUUUGUCUUGACUUGACUUGACUUU 5030 5781_16_93 PTPN11 Exon 16 + xp12:112508030-112508055 UUUGUCUUGACUUGACUUGACUUUG 5031 5781_16_94 PTPN11 Exon 16 + xp12:112508031-112508056 UUGUCUUGACUUGACUUGACUUUGG 5032 5781_16_95 PTPN11 Exon 16 + xp12:112508135-112508160 AGAUCAGUUGCUUUUAUACUCAGAA 5033 5781_16_96 PTPN11 Exon 16 + xp12:112508151-112508176 UACUCAGAAUGGAAAUACCUGAUCU 5034 5781_16_97 PTPN11 Exon 16 + xp12:112508200-112508225 GAUUUCAUUUAGAUUUCCCUCCACG 5035 5781_16_98 PTPN11 Exon 16 + xp12:112508234-112508259 AACUAUCAUGUUCUUAUGUAAAACUU 5036 5781_16_99 PTPN11 Exon 16 + xp12:112508240-112508265 CAUGUUCUUAUGUAAACCUUAGGCCA 5037 5781_16_100 PTPN11 Exon 16 + xp12:112508263-112508288 CAAGGCCAGAGUUAUCAUAGUCCCU 5038 5781_16_101 PTPN11 Exon 16 + xp12:112508272-112508297 AGUUAUCAUAGUCCCUAGGUUGCUA 5039 5781_16_102 PTPN11 Exon 16 + xp12:112508288-112508313 AGGUUGCUACGGCUUAUCAUGUGCU 5040 5781_16_103 PTPN11 Exon 16 + xp12:112508295-112508320 UACGGCUUAUCAUGUGCUUGGUAAAA 5041 5781_16_104 PTPN11 Exon 16 + xp12:112508305-112508330 CAUGUGCUUGGUAAAAAGGUGAUCGC 5042 5781_16_105 PTPN11 Exon 16 + xp12:112508336-112508361 UCAGACGAGUUUACUUUACAUGAGA 5043 5781_16_106 PTPN11 Exon 16 + xp12:112508343-112508368 AGUUUACUUUACAUGAGAUGGAAUC 5044 5781_16_107 PTPN11 Exon 16 + xp12:112508351-112508376 UUACAUGAGAUGGAAUCAGGCAGAG 5045 5781_16_108 PTPN11 Exon 16 + xp12:112508355-112508380 AUGAGAUGGAAUCAGGCAGAGAGGC 5046 5781_16_109 PTPN11 Exon 16 + xp12:112508356-112508381 UGAGAUGGAAUCAGGCAGAGAGGCU 5047 5781_16_110 PTPN11 Exon 16 + xp12:112508363-112508388 GAAUCAGGCAGAGAGGCUGGGAUGA 5048 5781_16_111 PTPN11 Exon 16 + xp12:112508376-112508401 AGGCUGGGAUGAUGGAGAAAGCUCG 5049 5781_16_112 PTPN11 Exon 16 + xp12:112508401-112508426 AGGUGAAGUUUUAAAAAAAAAGUUG 5050 5781_16_113 PTPN11 Exon 16 + xp12:112508406-112508431 AAGUUUUAAAAAAAAAGUUGUGGAA 5051 5781_16_114 PTPN11 Exon 16 + xp12:112508421-112508446 AGUUGUGGAAAGGAAAGUUCCAAAG 5052 5781_16_115 PTPN11 Exon 16 + xp12:112508424-112508449 UGUGGAAAGGAAAGUUCCAAAGAGG 5053 5781_16_116 PTPN11 Exon 16 + xp12:112508433-112508458 GAAAGUUCCAAAAGAGGUGGUUUCUG 5054 5781_16_117 PTPN11 Exon 16 + xp12:112508450-112508475 GGUUUCUGAGGAAGUCAGAGCGCCC 5055 5781_16_118 PTPN11 Exon 16 + xp12:112508451-112508476 GUUUCUGAGGAAGUCAGAGCGCCCA 5056 5781_16_119 PTPN11 Exon 16 + xp12:112508470-112508495 CGCCCAGGGCCAGAGCAGUCAGUAA 5057 5781_16_120 PTPN11 Exon 16 + xp12:112508471-112508496 GCCCAGGGCCAGAGCAGUCAGUAAU 5058 5781_16_121 PTPN11 Exon 16 + xp12:112508480-112508505 CAGAGCAGUCAGUAAUGGGUGAAUG 5059 5781_16_122 PTPN11 Exon 16 + xp12:112508488-112508513 UCAGUAAUGGGUGAAUGAGGUUGUU 5060 5781_16_123 PTPN11 Exon 16 + xp12:112508496-112508521 GGGUGAAUGAGGUUGUUUGGAAAGU 5061 5781_16_124 PTPN11 Exon 16 + xp12:112508512-112508537 UUGGAAAGUCGGUGUGACAGACACA 5062 5781_16_125 PTPN11 Exon 16 + xp12:112508530-112508555 AGACACAUGGAUGCCAUCUACUUCU 5063 5781_16_126 PTPN11 Exon 16 + xp12:112508537-112508562 UGGAUGCCAUCUACUUCUAGGUUGC 5064 5781_16_127 PTPN11 Exon 16 + xp12:112508540-112508565 AUGCCAUCUACUUCUAGGUUGCUGG 5065 5781_16_128 PTPN11 Exon 16 + xp12:112508541-112508566 UGCCAUCUACUUCUAGGUUGCUGGU 5066 5781_16_129 PTPN11 Exon 16 + xp12:112508577-112508602 AUGCACAAUAUUCCAUAGCUCACUG 5067 5781_16_130 PTPN11 Exon 16 + xp12:112508599-112508624 CUGAGGAUUUUAAAAUUAUAAGCAU 5068 5781_16_131 PTPN11 Exon 16 + xp12:112508613-112508638 AUUAUAAGCAUAGGAUUUUAUAUUU 5069 5781_16_132 PTPN11 Exon 16 + xp12:112508614-112508639 UUAUAAGCAUAGGAUUUUAUAUUUU 5070 5781_16_133 PTPN11 Exon 16 + xp12:112508615-112508640 UAUAAGCAUAGGAUUUUAUAUUUUG 5071 5781_16_134 PTPN11 Exon 16 + xp12:112508631-112508656 UAUAUUUUGGGGUGAAAGAAUUAUC 5072 5781_16_135 PTPN11 Exon 16 + xp12:112508640-112508665 GGGUGAAAGAAUUAUCUGGCACAUU 5073 5781_16_136 PTPN11 Exon 16 + xp12:112508646-112508671 AAGAAUUAUCUGGCACAUUAGGUAU 5074 5781_16_137 PTPN11 Exon 16 + xp12:112508707-112508732 AUAACUUUUUUUAAAAAAAACUAAA 5075 5781_16_138 PTPN11 Exon 16 + xp12:112508728-112508753 UAAAAGGCGCUUCAUGUCCAGGUGUG 5076 5781_16_139 PTPN11 Exon 16 + xp12:112508746-112508771 CAGUGUGUGGCCCUUCUGAAACUUA 5077 5781_16_140 PTPN11 Exon 16 + xp12:112508770-112508795 AUGGUCAUCUCUCCCACUGAACCA 5078 5781_16_141 PTPN11 Exon 16 + xp12:112508785-112508810 ACUGAAACCAAGGUCUUUUCAAAUG 5079 5781_16_142 PTPN11 Exon 16 + xp12:112508793-112508818 CAAGGUCUUUUCAAAUGUGGCUAAA 5080 5781_16_143 PTPN11 Exon 16 + xp12:112508794-112508819 AAGGUCUUUUCAAAUGUGGCUAAAU 5081 5781_16_144 PTPN11 Exon 16 + xp12:112508795-112508820 AGGUCUUUUCAAAUGUGGCUAAAUG 5082 5781_16_145 PTPN11 Exon 16 + xp12:112508801-112508826 UUUCAAAUGUGGCUAAAUGGGGAUG 5083 5781_16_146 PTPN11 Exon 16 + xp12:112508809-112508834 GUGGCUAAAUGGGGAUGAGGAGACA 5084 5781_16_147 PTPN11 Exon 16 + xp12:112508810-112508835 UGGCUAAAUGGGGAUGAGGAGACAC 5085 5781_16_148 PTPN11 Exon 16 + xp12:112508814-112508839 UAAAUGGGGAUGAGGAGACACGGGU 5086 5781_16_149 PTPN11 Exon 16 + xp12:112508824-112508849 UGAGGAGACACGGGUAGGACUUUCU 5087 5781_16_150 PTPN11 Exon 16 + xp12:112508860-112508885 CAUUCUUUAAAAGAGCCAAGUUGCUU 5088 5781_16_151 PTPN11 Exon 16 + xp12:112508861-112508886 AUUCUUUAAAAGAGCCAAGUUGCUUC 5089 5781_16_152 PTPN11 Exon 16 + xp12:112508862-112508887 UUCUUUAAAAGAGCCAAGUUGCUUCG 5090 5781_16_153 PTPN11 Exon 16 + xp12:112508873-112508898 GCCAAGUUGCUUCGGGGAAACAGCC 5091 5781_16_154 PTPN11 Exon 16 + xp12:112508880-112508905 UGCUUCGGGGAAAACAGCCAGGAAAA 5092 5781_16_155 PTPN11 Exon 16 + xp12:112508899-112508924 GGAAAAUGGUCAAGAUUAUUUUUAG 5093 5781_16_156 PTPN11 Exon 16 + xp12:112508911-112508936 AGAUUAUUUUUAGAGGUUAUUUUAU 5094 5781_16_157 PTPN11 Exon 16 + xp12:112508912-112508937 GAUUAUUUUUAGAGGUUAUUUUAUU 5095 5781_16_158 PTPN11 Exon 16 + xp12:112508913-112508938 AUUAUUUUUAGAGGUUAUUUUAUUG 5096 5781_16_159 PTPN11 Exon 16 + xp12:112508955-112508980 UAACAUCUUGAGUUAUUUUUAAUUC 5097 5781_16_160 PTPN11 Exon 16 + xp12:112508956-112508981 AACAUCUUGAGUUAUUUUUAAUUCA 5098 5781_16_161 PTPN11 Exon 16 + xp12:112508957-112508982 ACAUCUUGAGUUAUUUUUAAUUCAG 5099 5781_16_162 PTPN11 Exon 16 + xp12:112508958-112508983 CAUCUUGAGUUAUUUUUAAUUCAGG 5100 5781_16_163 PTPN11 Exon 16 + xp12:112508964-112508989 GAGUUAUUUUUAAUUCAGGGGGAUG 5101 5781_16_164 PTPN11 Exon 16 + xp12:112508969-112508994 AUUUUUAAUUCAGGGGGAUGUGGAA 5102 5781_16_165 PTPN11 Exon 16 + xp12:112509013-112509038 GUUUUGUUGUAGCUUAGUAUCCAUA 5103 5781_16_166 PTPN11 Exon 16 + xp12:112509014-112509039 UUUUGUUGUAGCUUAGUAUCCAUAA 5104 5781_16_167 PTPN11 Exon 16 + xp12:112509076-112509101 GCAGCUUUUGUUUUCUGUAUGUUGU 5105 5781_16_168 PTPN11 Exon 16 + xp12:112509077-112509102 CAGCUUUUGUUUUCUGUAUGUUGUU 5106 5781_16_169 PTPN11 Exon 16 + xp12:112509078-112509103 AGCUUUUGUUUUCUGUAUGUUGUUG 5107 5781_16_170 PTPN11 Exon 16 + xp12:112509079-112509104 GCUUUUGUUUUCUGUAUGUUGUUGG 5108 5781_16_171 PTPN11 Exon 16 + xp12:112509108-112509133 UCAACUUUCACACAUAGCAAGCACA 5109 5781_16_172 PTPN11 Exon 16 + xp12:112509124-112509149 GCAAGCACAUGGCCUCCCUGAUGUC 5110 5781_16_173 PTPN11 Exon 16 + xp12:112509138-112509163 UCCCUGAUGUCAGGAUGCCUUUGUU 5111 5781_16_174 PTPN11 Exon 16 + xp12:112509254-112509279 CUAAAAAUUUGUUCCUUUUUCACUA 5112 5781_16_175 PTPN11 Exon 16 + xp12:112509255-112509280 UAAAAAUUUGUUCCUUUUUCACUAU 5113 5781_16_176 PTPN11 Exon 16 + xp12:112509269-112509294 UUUUUCACUAUGGGCAGUUCACCACA 5114 5781_16_177 PTPN11 Exon 16 + xp12:112509290-112509315 CACAAGGCCAAAAACUAUUGAACAGU 5115 5781_16_178 PTPN11 Exon 16 + xp12:112509429-112509454 UGAUUCUUUUAUUAAUAAAAAGCUAA 5116 5781_16_179 PTPN11 Exon 16 + xp12:112509430-112509455 GAUUCUUUUAUUAAUAAAAGCUAAU 5117 5781_16_180 PTPN11 Exon 16 + xp12:112509436-112509461 UUUAUUAAUAAAAGCUAAUGGGAAA 5118 5781_16_181 PTPN11 Exon 16 + xp12:112509553-112509578 UUUAUUGAUAAAUCUAUCCUUUAAA 5119 5781_16_182 PTPN11 Exon 16 + xp12:112509566-112509591 CUAUCCUUUAAAAGGAAUACGUUUU 5120 5781_16_183 PTPN11 Exon 16 + xp12:112509744-112509769 AAUAGUUUAUGUAGAGAAACAUUAG 5121 5781_16_184 PTPN11 Exon 16 + xp12:112509775-112509800 UUAAUUGUCUCCCCACCUAUAUUUA 5122 5781_16_185 PTPN11 Exon 16 + xp12:112509776-112509801 UAAUUGUCUCCCCACCUAUAUUUAU 5123 5781_16_186 PTPN11 Exon 16 + xp12:112509847-112509872 AGUAAAAGUGUAUUUGUAAACUGUA 5124 5781_16_187 PTPN11 Exon 16 + xp12:112509848-112509873 GUAAAAGUGUAUUUGUAAAACUGUAU 5125 5781_16_188 PTPN11 Exon 16 + xp12:112509862-112509887 GUAAACUGUAUGGGAACUAAAAAAUU 5126 5781_16_189 PTPN11 Exon 16 + xp12:112509888-112509913 GGAAUAAAACCAUUUUCUUAUAUGA 5127 5781_16_190 PTPN11 Exon 16 - xp12:112505821-112505846 GGGAGAGGGUGAAAGUCCACAUCUG 5128 5781_16_191 PTPN11 Exon 16 - xp12:112505822-112505847 AGGGAGAGGGUGAAAGUCCACAUCU 5129 5781_16_192 PTPN11 Exon 16 - xp12:112505823-112505848 UAGGGAGAGGGUGAAAGUCCAUC 5130 5781_16_193 PTPN11 Exon 16 - xp12:112505840-112505865 UCUGUUCUUGAUCUUUUUAGGGAGA 5131 5781_16_194 PTPN11 Exon 16 - xp12:112505841-112505866 GUCUGUUCUUGAUCUUUUUAGGGAG 5132 5781_16_195 PTPN11 Exon 16 - xp12:112505846-112505871 CUUGCGUCUGUUCUUGAUCUUUUUA 5133 5781_16_196 PTPN11 Exon 16 - xp12:112505847-112505872 UCUUGCGUCUGUUCUUGAUCUUUUU 5134 5781_16_197 PTPN11 Exon 16 - xp12:112505929-112505954 AUGGUUUCAAAUUUUGCUUAUCAAA 5135 5781_16_198 PTPN11 Exon 16 - xp12:112505953-112505978 GAGUUAAAAUACAGGUGGUCUUUAAA 5136 5781_16_199 PTPN11 Exon 16 - xp12:112505964-112505989 CAGGUAUUGUUGAGUUAAAAUACAG 5137 5781_16_200 PTPN11 Exon 16 - xp12:112505988-112506013 CUGAGGAAAUGAGUAAUUGGGAAGC 5138 5781_16_201 PTPN11 Exon 16 - xp12:112505995-112506020 UUCUUAUCUGAGGAAAUGAGUAAUU 5139 5781_16_202 PTPN11 Exon 16 - xp12:112505996-112506021 CUUCUUAUCUGAGGAAAUGAGUAAU 5140 5781_16_203 PTPN11 Exon 16 - xp12:112506010-112506035 UGUAGAGAUGAUUUCUUCUUAUCUG 5141 5781_16_204 PTPN11 Exon 16 - xp12:112506164-112506189 GGAAAAAAAAAAUUAAACUGGUUAA 5142 5781_16_205 PTPN11 Exon 16 - xp12:112506165-112506190 AGGAAAAAAAAAAUUAAACUGGUUA 5143 5781_16_206 PTPN11 Exon 16 - xp12:112506171-112506196 ACAAUGAGGAAAAAAAAAAUUAAAAC 5144 5781_16_207 PTPN11 Exon 16 - xp12:112506190-112506215 UUUCUUCUCAUCAUCCCCAACAAUG 5145 5781_16_208 PTPN11 Exon 16 - xp12:112506245-112506270 UAAAUGAGAUUGUUCUCACUUUUCU 5146 5781_16_209 PTPN11 Exon 16 - xp12:112506273-112506298 GAAUUAUCCACUACUGGAUACAUGA 5147 5781_16_210 PTPN11 Exon 16 - xp12:112506284-112506309 GCCAUCAAAAUGAAUUAUCCACUAC 5148 5781_16_211 PTPN11 Exon 16 - xp12:112506324-112506349 CUCAGGCACUGGCUUAAUUCUCAUU 5149 5781_16_212 PTPN11 Exon 16 - xp12:112506340-112506365 GUCAACUUCUGACAGUCUCAGGCAC 5150 5781_16_213 PTPN11 Exon 16 - xp12:112506346-112506371 GCAAAGGUCAACUUCUGACAGUCUC 5151 5781_16_214 PTPN11 Exon 16 - xp12:112506367-112506392 CUAUGACUCUUUAAUGCCAGUGCAA 5152 5781_16_215 PTPN11 Exon 16 - xp12:112506458-112506483 AGCCGAACUAUAAUUGGUCAACGGC 5153 5781_16_216 PTPN11 Exon 16 - xp12:112506462-112506487 CAACAGCCGAACUAUAAUUGGUCAA 5154 5781_16_217 PTPN11 Exon 16 - xp12:112506469-112506494 UCUCAGUCAACAGCCGAACUAUAAU 5155 5781_16_218 PTPN11 Exon 16 - xp12:112506520-112506545 CAAUUAUUCAAAUGCAAAGAAAAUA 5156 5781_16_219 PTPN11 Exon 16 - xp12:112506581-112506606 UCGUUGUUUUGGCGACCAAAAACAC 5157 5781_16_220 PTPN11 Exon 16 - xp12:112506597-112506622 AACCCUAUUCAAACAGUCGUUGUUU 5158 5781_16_221 PTPN11 Exon 16 - xp12:112507028-112507053 CGAACACUGAACAAAUCAUUCAUCU 5159 5781_16_222 PTPN11 Exon 16 - xp12:112507029-112507054 CCGAACACUGAACAAAUCAUUCAUUC 5160 5781_16_223 PTPN11 Exon 16 - xp12:112507109-112507134 UGGUUGUGACCGUCUGUUAGACUAG 5161 5781_16_224 PTPN11 Exon 16 - xp12:112507134-112507159 UAAUAUCCUUGGUUUUCCAUGGCAC 5162 5781_16_225 PTPN11 Exon 16 - xp12:112507140-112507165 UUUUGCUAAUAUCCUUGGUUUUCCA 5163 5781_16_226 PTPN11 Exon 16 - xp12:112507150-112507175 CAACUUCUGCUUUUGCUAAUAUUCCU 5164 5781_16_227 PTPN11 Exon 16 - xp12:112507185-112507210 UACUGUAAGCAGCUUCGGCUUCCCA 5165 5781_16_228 PTPN11 Exon 16 - xp12:112507195-112507220 UUGUCCCAGCUACUGUAAGCAGCUU 5166 5781_16_229 PTPN11 Exon 16 - xp12:112507255-112507280 AGAAAUCAUUCAGGAAGCUUCUUGA 5167 5781_16_230 PTPN11 Exon 16 - xp12:112507269-112507294 GGCUCAGGGCUAGCAGAAAUCAUUC 5168 5781_16_231 PTPN11 Exon 16 - xp12:112507288-112507313 AGUGCUGGUUCCAAAAAAUAGGCUCA 5169 5781_16_232 PTPN11 Exon 16 - xp12:112507289-112507314 AAGUGCUGGUUCCAAAAAAUAGGCUC 5170 5781_16_233 PTPN11 Exon 16 - xp12:112507295-112507320 UUCCCCAAGGUGCUGGUUCCAAAAAAU 5171 5781_16_234 PTPN11 Exon 16 - xp12:112507308-112507333 UCACAAGAUCAGUUUCCCCAAGUGC 5172 5781_16_235 PTPN11 Exon 16 - xp12:112507377-112507402 CAAGUCUGGGGAUGCCCCAGUGGGG 5173 5781_16_236 PTPN11 Exon 16 - xp12:112507380-112507405 UCCCAAGUCUGGGGAUGCCCCAGUG 5174 5781_16_237 PTPN11 Exon 16 - xp12:112507381-112507406 UUCCCAAGUCUGGGGAUGCCCCAGU 5175 5781_16_238 PTPN11 Exon 16 - xp12:112507382-112507407 UUUCCCAAGUCUGGGGAUGCCCCAG 5176 5781_16_239 PTPN11 Exon 16 - xp12:112507394-112507419 GAAAGAGUCACGUUUCCCAAGUCUG 5177 5781_16_240 PTPN11 Exon 16 - xp12:112507395-112507420 AGAAAGAGUCACGUUUCCCAAGUCU 5178 5781_16_241 PTPN11 Exon 16 - xp12:112507396-112507421 AAGAAAGAGUCACGUUUCCCAAGUC 5179 5781_16_242 PTPN11 Exon 16 - xp12:112507428-112507453 UCACUGUGGCCUGACUAAAAACCCAG 5180 5781_16_243 PTPN11 Exon 16 - xp12:112507447-112507472 CUGUUAGGGCUGUUCCUUCUCACUG 5181 5781_16_244 PTPN11 Exon 16 - xp12:112507466-112507491 AUUCAACCCUGGCUGGAGGCCUGUUA 5182 5781_16_245 PTPN11 Exon 16 - xp12:112507467-112507492 CAUUCAACCCUGGCUGGAGGCCUGUU 5183 5781_16_246 PTPN11 Exon 16 - xp12:112507476-112507501 AAAUGAGCUCAUUCAACCUGGCUGG 5184 5781_16_247 PTPN11 Exon 16 - xp12:112507479-112507504 CAAAAAUGAGCUCAUUCAACCUGGC 5185 5781_16_248 PTPN11 Exon 16 - xp12:112507483-112507508 ACAACAAAAAUGAGCUCAUUCAACC 5186 5781_16_249 PTPN11 Exon 16 - xp12:112507513-112507538 UAGAACAUUAGCAAAUCUUACUGGU 5187 5781_16_250 PTPN11 Exon 16 - xp12:112507517-112507542 AAUGUAGAAACAUUAGCAAAUCUUAC 5188 5781_16_251 PTPN11 Exon 16 - xp12:112507550-112507575 AGGCAAAGAGGGAUGUCUUUGGAGA 5189 5781_16_252 PTPN11 Exon 16 - xp12:112507556-112507581 CAUAUGAGGCAAAGAGGGAUGUCUU 5190 5781_16_253 PTPN11 Exon 16 - xp12:112507566-112507591 GAUGAUUCAACAUAUGAGGCAAAGA 5191 5781_16_254 PTPN11 Exon 16 - xp12:112507567-112507592 GGAUGAUUCAACAUAUGAGGCAAAG 5192 5781_16_255 PTPN11 Exon 16 - xp12:112507575-112507600 UCCGCACUGGAUGAUUCAACAUAUG 5193 5781_16_256 PTPN11 Exon 16 - xp12:112507593-112507618 GAUAUUUUCAUUGAAAUAUCCGCAC 5194 5781_16_257 PTPN11 Exon 16 - xp12:112507664-112507689 AGAAUCCAAGGAGGCCACACUUCA 5195 5781_16_258 PTPN11 Exon 16 - xp12:112507678-112507703 AAGCCAAAGUCAGAAGAAUCCAAGG 5196 5781_16_259 PTPN11 Exon 16 - xp12:112507681-112507706 CAGAAGCCAAAGUCAGAAGAAUCCA 5197 5781_16_260 PTPN11 Exon 16 - xp12:112507718-112507743 AGGAACCUACCACCAGGGCUGGAUCU 5198 5781_16_261 PTPN11 Exon 16 - xp12:112507725-112507750 CUCAGAAAGGAACCUACCACCAGGGC 5199 5781_16_262 PTPN11 Exon 16 - xp12:112507729-112507754 AGACCUCAGAAAGGAACUACCACCA 5200 5781_16_263 PTPN11 Exon 16 - xp12:112507730-112507755 GAGACCUCAGAAAGGAACCUACCACC 5201 5781_16_264 PTPN11 Exon 16 - xp12:112507743-112507768 CUCAAGGGACUGAGAGACCUCAGAA 5202 5781_16_265 PTPN11 Exon 16 - xp12:112507763-112507788 CAGCCAAACUACCCCAAAGUCUCAA 5203 5781_16_266 PTPN11 Exon 16 - xp12:112507764-112507789 GCAGCCAAACUACCCCAAAGUCUCA 5204 5781_16_267 PTPN11 Exon 16 - xp12:112507791-112507816 CUGAUAUACAUUUUGUCAGUGAGAA 5205 5781_16_268 PTPN11 Exon 16 - xp12:112507819-112507844 AAGGAAUAUUGGGGGGUGGAGGUGG 5206 5781_16_269 PTPN11 Exon 16 - xp12:112507820-112507845 CAAGGAAUAUUGGGGGGUGGAGGUG 5207 5781_16_270 PTPN11 Exon 16 - xp12:112507821-112507846 UCAAGGAAUAUUGGGGGGUGGAGGU 5208 5781_16_271 PTPN11 Exon 16 - xp12:112507822-112507847 UUCAAGGAAUAUUGGGGGGUGGAGG 5209 5781_16_272 PTPN11 Exon 16 - xp12:112507825-112507850 AAGUUCAAGGAAUAUUGGGGGGUGG 5210 5781_16_273 PTPN11 Exon 16 - xp12:112507828-112507853 UCAAAGUUCAAGGAAUAUUGGGGGG 5211 5781_16_274 PTPN11 Exon 16 - xp12:112507831-112507856 AAUUCAAAGGUUCAAGGAAUAUUGGG 5212 5781_16_275 PTPN11 Exon 16 - xp12:112507832-112507857 CAAUUCAAAGGUUCAAGGAAUAUUGG 5213 5781_16_276 PTPN11 Exon 16 - xp12:112507833-112507858 GCAAUUCAAAGUUCAAGGAAUAUUG 5214 5781_16_277 PTPN11 Exon 16 - xp12:112507834-112507859 AGCAAUUCAAAGGUUCAAGGAAUAUU 5215 5781_16_278 PTPN11 Exon 16 - xp12:112507835-112507860 AAGCAAUUCAAAGUUCAAGGAAUAU 5216 5781_16_279 PTPN11 Exon 16 - xp12:112507843-112507868 GUGUUCUGAAGCAAUUCAAAGGUUCA 5217 5781_16_280 PTPN11 Exon 16 - xp12:112507879-112507904 ACUUCCCUAAUAAGGGAAUACCUUC 5218 5781_16_281 PTPN11 Exon 16 - xp12:112507891-112507916 GACAGCAGUGACACUUCCCUAAUAA 5219 5781_16_282 PTPN11 Exon 16 - xp12:112507892-112507917 AGACAGCAGUGACACUUCCCUAAUA 5220 5781_16_283 PTPN11 Exon 16 - xp12:112507948-112507973 AAGCUUCUUGCUGCAAAUACUGAAC 5221 5781_16_284 PTPN11 Exon 16 - xp12:112508018-112508043 AAGUCAAGACAAAACCAAAGCAAAA 5222 5781_16_285 PTPN11 Exon 16 - xp12:112508074-112508099 UUUGUACAUCAAACUCUUGUGUGC 5223 5781_16_286 PTPN11 Exon 16 - xp12:112508127-112508152 AUAAAAGCAACUGAUCUUAAGCAAC 5224 5781_16_287 PTPN11 Exon 16 - xp12:112508171-112508196 UCUUAUAACAAAACUAGCCAAGAUC 5225 5781_16_288 PTPN11 Exon 16 - xp12:112508219-112508244 CAUGAUAGUUUGCUGACCUCGUGGA 5226 5781_16_289 PTPN11 Exon 16 - xp12:112508220-112508245 ACAUGAUAGUUUGCUGACCUCGUGG 5227 5781_16_290 PTPN11 Exon 16 - xp12:112508223-112508248 AGAACAUGAUAGUUUGCUGACCUCG 5228 5781_16_291 PTPN11 Exon 16 - xp12:112508265-112508290 CUAGGGACUAUGAUAACUCUGGCCU 5229 5781_16_292 PTPN11 Exon 16 - xp12:112508271-112508296 AGCAACCUAGGGACUAUGAUAACUC 5230 5781_16_293 PTPN11 Exon 16 - xp12:112508287-112508312 GCACAUGAUAAGCCGUAGCAACCUA 5231 5781_16_294 PTPN11 Exon 16 - xp12:112508288-112508313 AGCACAUGAUAAGCCGUAGCAACCU 5232 5781_16_295 PTPN11 Exon 16 - xp12:112508443-112508468 CUGACUUCCUCAGAAACCACCUCUU 5233 5781_16_296 PTPN11 Exon 16 - xp12:112508475-112508500 ACCCAUUACUGACUGCUCUGGCCCU 5234 5781_16_297 PTPN11 Exon 16 - xp12:112508476-112508501 CACCCAUUACUGACUGCUCUGGCCC 5235 5781_16_298 PTPN11 Exon 16 - xp12:112508482-112508507 CUCAUUCACCCAUUACUGACUGCUC 5236 5781_16_299 PTPN11 Exon 16 - xp12:112508546-112508571 UACCCACCAGCAACCUAGAAGUAGA 5237 5781_16_300 PTPN11 Exon 16 - xp12:112508592-112508617 UAAUUUUAAAAUCCCUCAGUGAGCUA 5238 5781_16_301 PTPN11 Exon 16 - xp12:112508692-112508717 AAAAAGUUAUUAAGACUGUGAAAUU 5239 5781_16_302 PTPN11 Exon 16 - xp12:112508748-112508773 CAUAAGUUUCAGAAGGGCCACACAC 5240 5781_16_303 PTPN11 Exon 16 - xp12:112508759-112508784 GGAGAGAUGACCAUAAGUUUCAGAA 5241 5781_16_304 PTPN11 Exon 16 - xp12:112508760-112508785 GGGAGAGAUGACCAUAAGUUUCAGA 5242 5781_16_305 PTPN11 Exon 16 - xp12:112508785-112508810 CAUUUGAAAAGACCUUGGUUUCAGU 5243 5781_16_306 PTPN11 Exon 16 - xp12:112508786-112508811 ACAUUUGAAAAGACCUUGGUUUCAG 5244 5781_16_307 PTPN11 Exon 16 - xp12:112508795-112508820 CAUUUAGCCACAUUUGAAAAGACCU 5245 5781_16_308 PTPN11 Exon 16 - xp12:112508877-112508902 UCCUGGCUGUUUCCCCGAAGCAACU 5246 5781_16_309 PTPN11 Exon 16 - xp12:112508899-112508924 CUAAAAAUAAUCUUGACCAUUUUCC 5247 5781_16_310 PTPN11 Exon 16 - xp12:112509036-112509061 AUGUCUAUAGUCUAAGUUUCCCUUA 5248 5781_16_311 PTPN11 Exon 16 - xp12:112509074-112509099 AACAUACAGAAAACAAAAGCUGCAC 5249 5781_16_312 PTPN11 Exon 16 - xp12:112509139-112509164 UAACAAAGGCAUCCUGACAUCAGGG 5250 5781_16_313 PTPN11 Exon 16 - xp12:112509142-112509167 UCCUAACAAAGGCAUCCUGACAUCA 5251 5781_16_314 PTPN11 Exon 16 - xp12:112509143-112509168 AUCCUAACAAAGGCAUCCUGACAUC 5252 5781_16_315 PTPN11 Exon 16 - xp12:112509158-112509183 UAAGGGCAAAUACAGAUCCUAACAA 5253 5781_16_316 PTPN11 Exon 16 - xp12:112509180-112509205 GGAAAAAAGAUUUCAACAAAAUUAA 5254 5781_16_317 PTPN11 Exon 16 - xp12:112509181-112509206 AGGAAAAAAGAUUUCAACAAAAUUA 5255 5781_16_318 PTPN11 Exon 16 - xp12:112509206-112509231 AUUUUGGAACUUUUCAAGAGGAAGA 5256 5781_16_319 PTPN11 Exon 16 - xp12:112509213-112509238 AAACUAUAUUUUGGAACUUUUCAAG 5257 5781_16_320 PTPN11 Exon 16 - xp12:112509227-112509252 AUGAAAGAAUACAAUAAACUAUAUUU 5258 5781_16_321 PTPN11 Exon 16 - xp12:112509270-112509295 UUGUGUGAACUGCCCAUAGUGAAAAA 5259 5781_16_322 PTPN11 Exon 16 - xp12:112509377-112509402 UUAUUAAUUACAUGAUUUGAGGCUU 5260 5781_16_323 PTPN11 Exon 16 - xp12:112509383-112509408 GGCAAAUUAUUAAUUACAUGAUUUG 5261 5781_16_324 PTPN11 Exon 16 - xp12:112509409-112509434 AAUCACAAUUAGGUCAAUAAAUAAAC 5262 5781_16_325 PTPN11 Exon 16 - xp12:112509424-112509449 UUUUAUUAAUAAAAGAAUCACAAUU 5263 5781_16_326 PTPN11 Exon 16 - xp12:112509469-112509494 GUAGGUCUAGUCAUCAGCUUAAUCA 5264 5781_16_327 PTPN11 Exon 16 - xp12:112509470-112509495 UGUAGGUCUAGUCAUCAGCUUAAUC 5265 5781_16_328 PTPN11 Exon 16 - xp12:112509492-112509517 CAUAUACUGCAGGAAAAUUAAUUGU 5266 5781_16_329 PTPN11 Exon 16 - xp12:112509507-112509532 UCUGGUACAAUACUUCAUAUACUGC 5267 5781_16_330 PTPN11 Exon 16 - xp12:112509530-112509555 AAAUAUUACAUAUCUUUUAAUACUC 5268 5781_16_331 PTPN11 Exon 16 - xp12:112509573-112509598 ACAUCCUAAAACGUAUUCCUUUUAA 5269 5781_16_332 PTPN11 Exon 16 - xp12:112509683-112509708 GACUACAUAAUAUACGUGGGCAAAA 5270 5781_16_333 PTPN11 Exon 16 - xp12:112509691-112509716 UGCAAAUAGACUACAUAAUAUACGU 5271 5781_16_334 PTPN11 Exon 16 - xp12:112509692-112509717 UUGCAAAUAGACUACAUAAUAUACG 5272 5781_16_335 PTPN11 Exon 16 - xp12:112509788-112509813 GCGCUAACACCCAUAAAUAUAGGUG 5273 5781_16_336 PTPN11 Exon 16 - xp12:112509789-112509814 UGCGCUAACACCCAUAAAUAUAGGU 5274 5781_16_337 PTPN11 Exon 16 - xp12:112509790-112509815 UUGCGCUAACACCCAUAAAUAUAGG 5275 5781_16_338 PTPN11 Exon 16 - xp12:112509793-112509818 CAGUUGCGCUAACACCCAUAAAUAU 5276 5781_16_339 PTPN11 Exon 16 - xp12:112509900-112509925 CGACAAAUGCCAUCAUAUAAGAAAAA 5277

Exemplary preferred nRNA targeting domains for use in the compositions and methods of the invention are described in the tables below.

Table 3: nRNA targeting domains to human B2M ID Regulations Target Chain nRNA guide domain sequence SEQID NO: CR00438 Xp15:44711472-44711494 B2M + CACGCGUUUAAUAUAAGUGG 5492 CR00439 Xp15:44711483-44711505 B2M + UAUAAGUGGAGGCGUGCGCGC 5493 CR00440 Xp15:44711486-44711508 B2M + AAGUGGAGGCGUCGCGCUGG 5494 CR00441 Xp15:44711534-44711556 B2M + GGCCGAGAUGUCUCGCUCCCG 5495 CR00442 Xp15:44711536-44711558 B2M - GGCCACGGAGCGAGACAUCU 5496 CR00443 Xp15:44711551-44711573 B2M - CGCGAGCACAGCUAAGGCCA 5497 CR00444 Xp15:44711557-44711579 B2M - GAGUAGCGCGAGCACAGCUA 5498 CR00445 Xp15:44711591-44711613 B2M - ACUCACGCUGGAUAGCCUCC 5499 CR00446 Xp15:44711603-44711625 B2M - AGGGUAGGAGAGACUCACGC 5500 CR00447 Xp15:44715412-44715434 B2M + CUCAGGUACUCCAAAAGAUUC 5501 CR00448 Xp15:44715422-44715444 B2M - CGUGAGUAAACCUGAAUCUU 5502 CR00449 Xp15:44715507-44715529 B2M - CAGUAAGUCAACUUCAAUGU 5503 CR00450 Xp15:44715567-44715589 B2M + ACUUGUCUUUCAGCAAGGAC 5504 CR00451 Xp15:44715645-44715667 B2M - AGUCACAUGGUUCACACGGC 5505 CR00452 Xp15:44715649-44715671 B2M - ACAAAGUCACAUGGUUCACA 5506 CR00453 Xp15:44715672-44715694 B2M + CACAGCCCAAGAUAGUUAAG 5507 CR00454 Xp15:44715673-44715695 B2M + ACAGCCCAAGUAGUUAAGU 5508 CR00455 Xp15:44715677-44715699 B2M - UUACCCCCACUUAACUAUCUU 5509 CR00456 Xp15:44715678-44715700 B2M - CUUACCCCCACUUAACUAUCU 5510 CR00457 Xp15:44717599-44717621 B2M + AGGUUUGAAGAUGCCGCAUU 5511 CR00458 Xp15:44717604-44717626 B2M + UGAAGAUGCCGCAUUUGGAU 5512 CR00459 Xp15:44717612-44717634 B2M - GAAUUCAUCCAAAUCCAAAUG 5513 CR00460 Xp15:44717681-44717703 B2M + ACACUUUAUGCACAAAAUGU 5514 CR00461 Xp15:44717763-44717785 B2M - CUGCUCAGAUACAUCAAACA 5515 CR00462 Xp15:44717764-44717786 B2M + CAUGUUUGAUGUAUCUGAGC 5516 CR00463 Xp15:44717776-44717798 B2M + AUCUGAGCAGGUUGCUCCAC 5517 CR00464 Xp15:44717789-44717811 B2M + GCUCCACAGGUAGCUCUAGG 5518 CR00465 Xp15:44717805-44717827 B2M + UAGGAGGGCUGGCAACUUAG 5519 CR00466 Xp15:44717808-44717830 B2M + GAGGGCUGGCAACUUAGAGG 5520 CR00467 Xp15:44717809-44717831 B2M + AGGGCUGGCAACUUAGGU 5521 CR00468 Xp15:44717810-44717832 B2M + GGGCUGGCAACUUAGAGGUG 5522 CR00469 Xp15:44717851-44717873 B2M - UCUGACCAAAGAUGUUGAUGU 5523 CR00470 Xp15:44717939-44717961 B2M - UCUAAGCAGAGUAUGUAAAU 5524 CR00471 Xp15:44717981-44718003 B2M + AAUAUAAUUGACAGGAUUAU 5525 CR00472 Xp15:44718056-44718078 B2M + CUUAUACAUUUGAUAAAAGUA 5526 CR00473 Xp15:44718076-44718098 B2M + AGGCAUGGUUGUGGUUAAUC 5527

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00465. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00443. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00445. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR00444 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00449. In an embodiment, the targeting domain of an nRNA according to the invention comprises, for example consists of, the targeting domain of CR00442. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example, consists of the targeting domain CR00453. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR00461 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00439. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00452. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR00455. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR00463 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00467. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00466. In an embodiment, the targeting domain of an nRNA according to the invention includes, for example consists of, the targeting domain of CR00446. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00440. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00454. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00460. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00438. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain of CR00439. Such nRNA molecules and combinations thereof are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 4: Sequences of the nRNA targeting domains to the human T-cell receptor alpha (TRAC) ID Target name Chain Genomic Information nRNA guide domain sequence SEQID NO: CR000920 TRAC + Xp14:22281089-22281111 CUCAAGGUUCAGAUCAGAAG 5528 CR000921 TRAC + Xp14:22281092-22281114 AAGGUUCAGAUCAGAAGAGG 5529 CR000922 TRAC + Xp14:22281111-22281133 GAGGCUUCUCACCCCUGCAGC 5530 CR000923 TRAC + Xp14:22281112-22281134 AGGCUUCUCACCCCUGCAGCA 5531 CR000924 TRAC - Xp14:22281122-22281144 GCUCACAGGUCCCUGCUGCA 5532 CR000925 TRAC - Xp14:22281123-22281145 UGCUCACAGGUCCCUGCUGC 5533 CR000926 TRAC + Xp14:22281126-22281148 GCAGCAGGGACCUGUGAGCA 5534 CR000927 TRAC + Xp14:22281136-22281158 CCUGUGAGCAUGGCAUGCCC 5535 CR000928 TRAC - Xp14:22281136-22281158 CCAGGGCAUGCCAUGCUCAC 5536 CR000929 TRAC - Xp14:22281153-22281175 CAAGUGCCCACAGGAAGCCA 5537 CR000930 TRAC - Xp14:22281154-22281176 ACAAGUGCCCACAGGAAGCC 5538 CR000931 TRAC - Xp14:22281162-22281184 UGGAGAUCACAAGUGCCCAC 5539 CR000932 TRAC - Xp14:22281182-22281204 GCCUUCCUUACCAAGACAGG 5540 CR000933 TRAC - Xp14:22281185-22281207 UGCGCCUUCCUUACCAAGAC 5541 CR000934 TRAC + Xp14:22281432-22281454 CUUUCCCCAGAAUUUAGCA 5542 CR000935 TRAC + Xp14:22281477-22281499 ACCAGAGAUGUCUGUGCAGG 5543 CR000936 TRAC - Xp14:22281478-22281500 GCCUCCUGCACAGACAUCUC 5544 CR000937 TRAC - Xp14:22281506-22281528 AUAUGUGCAGCUCAGGGUCA 5545 CR000938 TRAC - Xp14:22281512-22281534 GGUGUCAUAUGUGCAGCUCA 5546 CR000939 TRAC - Xp14:22281513-22281535 UGGUGUCAUAUGUGCAGCUC 5547 CR000940 TRAC - Xp14:22281533-22281555 UAAAUAAUAAUCACUCUCAC 5548 CR000941 TRAC + Xp14:22281539-22281561 AGAGUGAUUAUUAUUUAUUC 5549 CR000942 TRAC + Xp14:22281560-22281582 GGUACAAGCAGCCUCCCAGGC 5550 CR000943 TRAC - Xp14:22281571-22281593 AGAAUCAUCUGCCUGCUGGG 5551 CR000944 TRAC - Xp14:22281574-22281596 ACGAGAAUCAUCUGCCUGCU 5552 CR000945 TRAC - Xp14:22281575-22281597 AACGAGAAUCAUCUGCCUGC 5553 CR000946 TRAC - Xp14:22281603-22281625 UCUGUUGCUUAUAAGCUUCU 5554 CR000947 TRAC - Xp14:22338946-22338968 GUUGGUGAGGUUGAUAAAUU 5555 CR000948 TRAC - Xp14:22338959-22338981 GCUGUAUGUGUGAGUUGGUG 5556 CR000949 TRAC + Xp14:22338963-22338985 ACCAACUCACACAUACAGCC 5557 CR000950 TRAC + Xp14:22338964-22338986 CCAACUCACACAUACAGCCA 5558 CR000951 TRAC - Xp14:22338981-22339003 AGCACAAGAAUAUAGAUCCC 5559 CR000952 TRAC + Xp14:22338992-22339014 UAUUCUUGUGCUCUCAGAGA 5560 CR000953 TRAC + Xp14:22513941-22513963 GGAAAACACACCUCUUGUCUU 5561 CR000954 TRAC + Xp14:22513946-22513968 CACACCUCUUGUCUUUGGAA 5562 CR000955 TRAC + Xp14:22513947-22513969 ACACCUCUUGUCUUUGGAAA 5563 CR000956 TRAC - Xp14:22513950-22513972 GUGCCCUUUCCAAAGACAAG 5564 CR000957 TRAC - Xp14:22547504-22547526 ACACGGCAGGGUCAGGGUUC 5565 CR000958 TRAC - Xp14:22547511-22547533 AGCUGGUACACGGCAGGGUC 5566 CR000959 TRAC - Xp14:22547516-22547538 CUCUCAGCUGGUACACGGCA 5567 CR000960 TRAC - Xp14:22547517-22547539 UCUCUCAGCUGGUACACGGC 5568 CR000961 TRAC - Xp14:22547521-22547543 AGAGUCUCUCAGCUGGUAC 5569 CR000962 TRAC - Xp14:22547528-22547550 UGGAUUUAGAGUCUCUCAGC 5570 CR000963 TRAC - Xp14:22547548-22547570 UAGGCAGACAGACUUGUCAC 5571 CR000964 TRAC - Xp14:22547567-22547589 GAGAAUCAAAAUCGGUGAAU 5572 CR000965 TRAC - Xp14:22547575-22547597 AUUUGUUUGAGAAUCAAAAU 5573 CR000966 TRAC + Xp14:22547591-22547613 AACAAAUGUGUCACAAAAGUA 5574 CR000967 TRAC + Xp14:22547635-22547657 ACAAAACUGUGCUAGACAUG 5575 CR000968 TRAC + Xp14:22547642-22547664 UGUGCUAGACAUGAGGUCUA 5576 CR000969 TRAC + Xp14:22547666-22547688 CUUCAAGAGCAACAGUGCUG 5577 CR000970 TRAC + Xp14:22547671-22547693 AGAGCAACAGUGCUGUGGCC 5578 CR000971 TRAC - Xp14:22547689-22547711 AAAGUCAGAUUUGUUGCUCC 5579 CR000972 TRAC - Xp14:22547725-22547747 UGGAAUAAUGCUGUUGUUGA 5580 CR000973 TRAC - Xp14:22547745-22547767 CUGGGGAAGAAGGUGUCUUC 5581 CR000974 TRAC - Xp14:22547762-22547784 AGCUGCCCUUACCUGGGCUG 5582 CR000975 TRAC - Xp14:22547763-22547785 AAGCUGCCCUUACCUGGGCU 5583 CR000976 TRAC - Xp14:22547764-22547786 AAAGCUGCCCUUACCUGGGC 5584 CR000977 TRAC - Xp14:22547768-22547790 CACCAAAGCUGCCCUUACCU 5585 CR000978 TRAC - Xp14:22547769-22547791 GCACCAAAGCUGCCCUUACC 5586 CR000979 TRAC + Xp14:22549633-22549655 AAGUUCCUGUGAUGUCAAGC 5587 CR000980 TRAC - Xp14:22549638-22549660 CUCGACCAGCUUGACAUCAC 5588 CR000981 TRAC - Xp14:22550558-22550580 CUGACAGGUUUUGAAAGUUU 5589 CR000982 TRAC + Xp14:22550565-22550587 UUUCAAAAACCUGUCAGUGAU 5590 CR000983 TRAC + Xp14:22550566-22550588 UUCAAAAACCUGUCAGUGAUU 5591 CR000984 TRAC - Xp14:22550573-22550595 UUCGGAACCCCAAUCACUGAC 5592 CR000985 TRAC + Xp14:22550591-22550613 CCGAAUCCUCCUCCUGAAG 5593 CR000986 TRAC - Xp14:22550591-22550613 CCACUUUCAGGAGGAGGAUU 5594 CR000987 TRAC + Xp14:22550595-22550617 AUCCUCCUCCUGAAAGUGGC 5595 CR000988 TRAC + Xp14:22550596-22550618 UCCUCCUCCUGAAAGUGGCC 5596 CR000989 TRAC - Xp14:22550597-22550619 ACCCGGCCACUUUCAGGAGG 5597 CR000990 TRAC - Xp14:22550600-22550622 UAAACCCGGCCACUUUCAGG 5598 CR000991 TRAC - Xp14:22550603-22550625 GAUUAAACCCGGCCACUUUC 5599 CR000992 TRAC - Xp14:22550614-22550636 CGUCAUGAGCAGAUUAAACC 5600 CR000993 TRAC + Xp14:22550620-22550642 UUAAUCUGCUCAUGACGCUG 5601 CR000994 TRAC + Xp14:22550626-22550648 UGCUCAUGACGCUGCGGCUG 5602 CR000995 TRAC - Xp14:22550650-22550672 UCAAGGCCCCUCACCUCAGGC 5603 CR000996 TRAC - Xp14:22551620-22551642 AGGAAGGAGCGAGGGAGCAC 5604 CR000997 TRAC - Xp14:22551628-22551650 CAAUGCAGAGGAAGGAGCGA 5605 CR000998 TRAC - Xp14:22551629-22551651 GCAAUGCAGAGGAAGGAGCG 5606 CR000999 TRAC - Xp14:22551636-22551658 AAGAGGGGCAAUGCAGAGGA 5607 CR001000 TRAC - Xp14:22551640-22551662 GGAGAAGAGGGGCAAUGCAG 5608 CR001001 TRAC - Xp14:22551653-22551675 UCUGUUUGGAGAGGGAGAAG 5609 CR001002 TRAC + Xp14:22551655-22551677 UCUUCUCCCCUCCAAACAG 5610 CR001003 TRAC + Xp14:22551656-22551678 CUUCUCCCUCUCCAAACAGA 5611 CR001004 TRAC - Xp14:22551661-22551683 GAGUUCCCCUCUGUUUGGAGA 5612 CR001005 TRAC - Xp14:22551662-22551684 AGAGUUCCCCUCUGUUUGGAG 5613 CR001006 TRAC - Xp14:22551667-22551689 GUAGGAGAGUUCCCUCUGUU 5614 CR001007 TRAC + Xp14:22551678-22551700 GAACUCUCCUACCCCCAAGG 5615 CR001008 TRAC - Xp14:22551685-22551707 GCUUUCACCUCCUUGGGGGU 5616 CR001009 TRAC - Xp14:22551689-22551711 AGCAGCUUUCACCUCCUUGG 5617 CR001010 TRAC - Xp14:22551690-22551712 UAGCAGCUUUCACCUCCUUG 5618 CR001011 TRAC - Xp14:22551691-22551713 GUAGCAGCUUUCACCUCCUU 5619 CR001012 TRAC + Xp14:22551710-22551732 CUACCACCUCUGUGCCCCCC 5620 CR001013 TRAC - Xp14:22551713-22551735 UUGCCGGGGGGGCACAGAGG 5621 CR001014 TRAC - Xp14:22551716-22551738 GCAUUGCCGGGGGGGCACAG 5622 CR001015 TRAC - Xp14:22551724-22551746 AGUUGGUGGCAUUGCCGGGG 5623

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000961. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000977. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000984. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000993. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000981. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000992. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000986. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000963. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000985. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR000966. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000990. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000978. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000991. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000983. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000960. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR001002. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR001000 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR001009. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR001011. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR001012. Such nRNA molecules and combinations thereof are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 5: nRNA targeting domains to human T-cell receptor beta (Constant domain 1 and Constant domain 2) ID Target name nRNA guide domain sequence Genomic Information SEQID NO: CR000728 TRBC1 CAGGGAAGAAGCCUGUGGCC Xp7:142791779-142791801 5624 CR000729 TRBC1 GUGGUCAGGGAAGAAGCCUG Xp7:142791784-142791806 5625 CR000730 TRBC1 CUGACCACGUGGAGCUGAGC Xp7:142791799-142791821 5626 CR000731 TRBC1 CACGGACCCGCAGCCCCUCA Xp7:142791857-142791879 5627 CR000732 TRBC1 GGUGCACAGUGGGGUCAGCA Xp7:142791839-142791861 5628 CR000733 TRBC1 GACGGGUUUGGCCCUAUCCU Xp7:142792015-142792037 5629 CR000734 TRBC1 UGGCUCAAACACAGCGACCU Xp7:142791712-142791734 5630 CR000735 TRBC1 AGGCUUCUUCCCUGACCACG Xp7:142791788-142791810 5631 CR000736 TRBC1 CAGCUCAGCUCCACGUGGUC Xp7:142791798-142791820 5632 CR000737 TRBC1 GCGCUGACGAUCUGGGUGAC Xp7:142792032-142792054 5633 CR000738 TRBC1 CUUUCCAGAGGACCUGAACA Xp7:142791680-142791702 5634 CR000739 TRBC1 UCAAACACAGCGACCUCGGG Xp7:142791708-142791730 5635 CR000740 TRBC1 UGACGGGUUUGGCCCUAUCC Xp7:142792016-142792038 5636 CR000741 TRBC1 GGCGCUGACGAUCUGGGUGA Xp7:142792033-142792055 5637 CR000742 TRBC1 CGGGUGGGAACACCUUGUUC Xp7:142791692-142791714 5638 CR000743 TRBC1 GAACAAGGUGUUCCCACCCG Xp7:142791695-142791717 5639 CR000744 TRBC1 CAAACACAGCGACCUCGGGU Xp7:142791707-142791729 5640 CR000745 TRBC1 GGCUCAAACACAGCGACCUC Xp7:142791711-142791733 5641 CR000746 TRBC1 AGCUCAGCUCCACGUGGUCA Xp7:142791797-142791819 5642 CR000747 TRBC1 GACGAUCUGGGUGACGGGUU Xp7:142792027-142792049 5643 CR000748 TRBC2 UAUCAGGCUCCUCUGCUACG Xp7:142670776-142670798 5644 CR000749 TRBC2 AUCAGGCUCCUCUGCUACGU Xp7:142670777-142670799 5645 CR000750 TRBC2 CUACGUGGGCUUUUAUUUUC Xp7:142670791-142670813 5646 CR000751 TRBC2 ACGUGGGCUUUUAUUUUCUG Xp7:142670793-142670815 5647 CR000752 TRBC2 CGUGGGCUUUUAUUUUCUGG Xp7:142670794-142670816 5648 CR000753 TRBC2 AAUAAAAGCCCACGUAGCAG Xp7:142670785-142670807 5649 CR000754 TRBC2 ACCCCAAGAUACCUUGUUAU Xp7:142670970-142670992 5650 CR000755 TRBC2 AGAUACCUUGUUAUAGGGAC Xp7:142670976-142670998 5651 CR000756 TRBC2 GACAGGAAAGAAGAUCACUC Xp7:142670993-142671015 5652 CR000757 TRBC2 UCUGGAAUGUUCUCAAACCA Xp7:142671011-142671033 5653 CR000758 TRBC2 CUGGAAUGUUCUCAAACCAU Xp7:142671012-142671034 5654 CR000759 TRBC2 UACUGGUAUCAACAAGAUCC Xp7:142671048-142671070 5655 CR000760 TRBC2 GUAUCAACAAGAUCCAGGAA Xp7:142671053-142671075 5656 CR000761 TRBC2 CACCUCAUCCACUAUUCCUA Xp7:142671081-142671103 5657 CR000762 TRBC2 GGAGUUAAUUCCACAGAGAA Xp7:142671102-142671124 5658 CR000763 TRBC2 AGUCAACAGUCUCCAGAAUA Xp7:142671139-142671161 5659 CR000764 TRBC2 AACAGUCUCCAGAAUAAGGA Xp7:142671143-142671165 5660 CR000765 TRBC2 CCCUGACCCUGGAGUCUGCC Xp7:142671175-142671197 5661 CR000766 TRBC2 UAACAAGGUAUCUUGGGGUC Xp7:142670966-142670988 5662 CR000767 TRBC2 CCCUAUAACAAGGUAUCUUG Xp7:142670971-142670993 5663 CR000768 TRBC2 UCCCUAUAACAAGGUAUCUU Xp7:142670972-142670994 5664 CR000769 TRBC2 GUCCCUAUAACAAGGUAUCU Xp7:142670973-142670995 5665 CR000770 TRBC2 UCUUUCCUGUCCCUAUAACA Xp7:142670981-142671003 5666 CR000771 TRBC2 GAUACCAGUACAUUUUGUCA Xp7:142671035-142671057 5667 CR000772 TRBC2 AUGAGGUGUAGUUCCAUUCC Xp7:142671066-142671088 5668 CR000773 TRBC2 CUCCAUAGGAAUAGUGGAUG Xp7:142671083-142671105 5669 CR000774 TRBC2 AAUUAACUCCCAUAGGAAUAG Xp7:142671089-142671111 5670 CR000775 TRBC2 CUCUGUGGAAUUAACUCCAU Xp7:142671097-142671119 5671 CR000776 TRBC2 UCUGGAGACUGUUGACUCAG Xp7:142671133-142671155 5672 CR000777 TRBC2 AAAAUGCUCCGUCCUUAUUC Xp7:142671151-142671173 5673 CR000778 TRBC2 CCUGGCAGACUCCAGGGUCA Xp7:142671175-142671197 5674 CR000779 TRBC2 GCCUGGCAGACCUCCAGGGUC Xp7:142671176-142671198 5675 CR000780 TRBC2 UGAGGGCCUGGCAGACUCCA Xp7:142671181-142671203 5676 CR000781 TRBC2 GUGAGGGCCUGGCAGACUCC Xp7:142671182-142671204 5677 CR000782 TRBC2 GAGGUACUGAGAGGUAUGUG Xp7:142671199-142671221 5678 CR000783 TRBC2 GCUGGCACAGAGGUACUGAG Xp7:142671208-142671230 5679 CR000784 TRBC2 UGUAUUCACUGCUGGCACAG Xp7:142671218-142671240 5680 CR000785 TRBC2 GAGCUGUCUGGUUCUGGUAG Xp7:142791626-142791648 5681 CR000786 TRBC2 AGAGCUGUCUGGUUCUGGUA Xp7:142791627-142791649 5682 CR000787 TRBC2 GAGAGCUGUCUGGUUCUGGU Xp7:142791628-142791650 5683 CR000788 TRBC2 CUCUGAGAGCUGUCUGGUUC Xp7:142791632-142791654 5684 CR000789 TRBC2 GGGUUGCUCUGAGAGCUGUC Xp7:142791638-142791660 5685 CR000790 TRBC2 GAAAAACGUGUUCCCACCA Xp7:142801042-142801064 5686 CR000791 TRBC2 AGGCUUCUACCCCGACCACG Xp7:142801135-142801157 5687 CR000792 TRBC2 CCGACCACGUGGAGCUGAGC Xp7:142801146-142801168 5688 CR000793 TRBC2 CACAGACCCGCAGCCCCUCA Xp7:142801204-142801226 5689 CR000794 TRBC2 UGGGUGGGAACACGUUUUUC Xp7:142801039-142801061 5690 CR000795 TRBC2 CAAACACAGCGACCUUGGGU Xp7:142801054-142801076 5691 CR000796 TRBC2 UCAAACACAGCGACCUUGGG Xp7:142801055-142801077 5692 CR000797 TRBC2 GGCUCAAACACAGCGACCUU Xp7:142801058-142801080 5693 CR000798 TRBC2 UGGCUCAAACACAGCGACCU Xp7:142801059-142801081 5694 CR000799 TRBC2 CGGGGUAGAAGCCUGUGGCC Xp7:142801126-142801148 5695 CR000800 TRBC2 GUGGUCGGGGUAGAAGCCUG Xp7:142801131-142801153 5696 CR000801 TRBC2 AGCUCAGCUCCACGUGGUCG Xp7:142801144-142801166 5697 CR000802 TRBC2 CAGCUCAGCUCCACGUGGUC Xp7:142801145-142801167 5698 CR000803 TRBC2 CCAGCUCAGCUCCACGUGGU Xp7:142801146-142801168 5699 CR000804 TRBC2 GACAGGUUUGGCCCUAUCCU Xp7:142801362-142801384 5700 CR000805 TRBC2 UGACAGGUUUGGCCCUAUCC Xp7:142801363-142801385 5701 CR000806 TRBC2 GACGAUCUGGGUGACAGGUU Xp7:142801374-142801396 5702 CR000807 TRBC2 GCGCUGACGAUCUGGGUGAC Xp7:142801379-142801401 5703 CR000808 TRBC2 CCCUGUUUUCUUUCAGACUG Xp7:142801922-142801944 5704 CR000809 TRBC2 AGGAGAGACUCACUUACCGG Xp7:142801950-142801972 5705 CR000810 TRBC2 AAAAGGAGAGACUCACUUAC Xp7:142801953-142801975 5706 CR000811 TRBC2 UCAACAGAGUCUUACCAGCA Xp7:142802092-142802114 5707 CR000812 TRBC2 CAACAGAGUCUUACCAGCAA Xp7:142802093-142802115 5708 CR000813 TRBC2 AACAGAGUCUUACCAGCAAG Xp7:142802094-142802116 5709 CR000814 TRBC2 AUCCUCUAUGAGAUCUUGCU Xp7:142802131-142802153 5710 CR000815 TRBC2 UCCUCUAUGAGAUCUUGCUA Xp7:142802132-142802154 5711 CR000816 TRBC2 CUAUGAGAUCUUGCUAGGGA Xp7:142802136-142802158 5712 CR000817 TRBC2 GGCCACCUUGUAUGCCGUGC Xp7:142802157-142802179 5713 CR000818 TRBC2 GGUCAGUGCCCUCGUGCUGA Xp7:142802178-142802200 5714 CR000819 TRBC2 UGGCAGACAGGACCCCUUGC Xp7:142802106-142802128 5715 CR000820 TRBC2 CAUAGAGGAUGGUGGCAGAC Xp7:142802118-142802140 5716 CR000821 TRBC2 CAAGAUCUCAUAGAGGAUGG Xp7:142802126-142802148 5717 CR000822 TRBC2 UAGCAAGAUCUCAUAGAGGA Xp7:142802129-142802151 5718 CR000823 TRBC2 UCCCUAGCAAGAUCUCAUAG Xp7:142802133-142802155 5719

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000823. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000798. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000810. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000800. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000815. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000812. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000813. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000816. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000807. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000811. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000791. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000809. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000817. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000819. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000814. Such nRNA molecules and combinations thereof are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 6a: Targeting domains of nRNA to human PDCD1 ID Target name nRNA guide domain sequence Genomic Information SEQID NO: CR000824 PDCD1 UCAGGCGGAGGUGAGCGGAA Xp2:241858873-241858895 5720 CR000825 PDCD1 CUCAGGCGGAGGUGAGCGGA Xp2:241858872-241858894 5721 CR000826 PDCD1 ACUGCUCAGGCGGAGGUGAG Xp2:241858868-241858890 5722 CR000827 PDCD1 GCUCACCUCCGCCUGAGCAG Xp2:241858866-241858888 5723 CR000828 PDCD1 CUUCUCCACUGCUCAGGCGG Xp2:241858861-241858883 5724 CR000829 PDCD1 CAGUGGAGAAGGCGGCACUC Xp2:241858849-241858871 5725 CR000830 PDCD1 UGGAGAAGGCGGCACUCUGG Xp2:241858846-241858868 5726 CR000831 PDCD1 GGAGAAGGCGGCACUCUGGU Xp2:241858845-241858867 5727 CR000832 PDCD1 GAGAAGGCGGCACCUCUGGUG Xp2:241858844-241858866 5728 CR000833 PDCD1 AGGCCGCCCUGGCCAGUCGUC Xp2:241858797-241858819 5729 CR000834 PDCD1 GGCGCCCUGGCCAGUCGUCU Xp2:241858796-241858818 5730 CR000835 PDCD1 GCCCUGGCCAGUCGUCUGGG Xp2:241858793-241858815 5731 CR000836 PDCD1 CACCGCCCAGACGACUGGCC Xp2:241858791-241858813 5732 CR000837 PDCD1 UGUAGCACCGCCCAGACGAC Xp2:241858786-241858808 5733 CR000838 PDCD1 CGUCUGGGCGGUGCUACAAC Xp2:241858781-241858803 5734 CR000839 PDCD1 GUCUGGGCGGUGCUACAACU Xp2:241858780-241858802 5735 CR000840 PDCD1 GGGCGGUGCUACAACUGGGC Xp2:241858776-241858798 5736 CR000841 PDCD1 CGGUGCUACAACUGGGCUGG Xp2:241858773-241858795 5737 CR000842 PDCD1 CACCUACCUAAGAACCAUCC Xp2:241858750-241858772 5738 CR000843 PDCD1 GAGAAGGUGGGGGGUUCCA Xp2:241852938-241852960 5739 CR000844 PDCD1 CGGUCACCACGAGCAGGGCU Xp2:241852915-241852937 5740 CR000845 PDCD1 UCGGUCACCACGAGCAGGGC Xp2:241852914-241852936 5741 CR000846 PDCD1 GCCCUGCUCGUGGUGACCGA Xp2:241852911-241852933 5742 CR000847 PDCD1 CCCUUCGGUCACCACGAGCA Xp2:241852910-241852932 5743 CR000848 PDCD1 CCCUGCUCGUGGUGACCGAA Xp2:241852910-241852932 5744 CR000849 PDCD1 CCCCUUCCGGUCACCACGAGC Xp2:241852909-241852931 5745 CR000850 PDCD1 CCUGCUCGUGGUGACCGAAG Xp2:241852909-241852931 5746 CR000851 PDCD1 GAAGGUGGCGUUGUCCCCUU Xp2:241852895-241852917 5747 CR000852 PDCD1 GUUGGAGAAGCUGCAGGUGA Xp2:241852877-241852899 5748 CR000853 PDCD1 CACGAAGCUCUCCGAUGUGU Xp2:241852859-241852881 5749 CR000854 PDCD1 CGGAGAGCUUCGUGCUAAAC Xp2:241852850-241852872 5750 CR000855 PDCD1 UCUGGUUGCUGGGGCUCAUG Xp2:241852825-241852847 5751 CR000856 PDCD1 GCUUGUCCGUCUGGUUGCUG Xp2:241852816-241852838 5752 CR000857 PDCD1 AGCUUGUCCGUCUGGUUGCU Xp2:241852815-241852837 5753 CR000858 PDCD1 CAGCUUGUCCGUCUGGUUGC Xp2:241852814-241852836 5754 CR000859 PDCD1 CAGCAACCAGACGGACAAGC Xp2:241852813-241852835 5755 CR000860 PDCD1 AGGCGGCCAGCUUGUCCCGUC Xp2:241852807-241852829 5756 CR000861 PDCD1 CUGGCUGCGGUCCUCGGGGA Xp2:241852787-241852809 5757 CR000862 PDCD1 CGGGCUGGCUGCGGUCCUCG Xp2:241852783-241852805 5758 CR000863 PDCD1 CCGGGCUGGCUGCGGUCCUC Xp2:241852782-241852804 5759 CR000864 PDCD1 CCCGAGGACCGCAGCCAGCC Xp2:241852782-241852804 5760 CR000865 PDCD1 GCCGGGCUGGCUGCGGUCCU Xp2:241852781-241852803 5761 CR000866 PDCD1 CGGAAGCGGCAGUCCUGGCC Xp2:241852764-241852786 5762 CR000867 PDCD1 ACGGAAGCGGCAGUCCUGGC Xp2:241852763-241852785 5763 CR000868 PDCD1 UGACACGGAAGCGGCAGUCC Xp2:241852759-241852781 5764 CR000869 PDCD1 GCAGUUGUGUGACACGGAAG Xp2:241852750-241852772 5765 CR000870 PDCD1 CGUGUCACACAACUGCCCAA Xp2:241852743-241852765 5766 CR000871 PDCD1 GUGUCACACAACUGCCCAAC Xp2:241852742-241852764 5767 CR000872 PDCD1 AUGUGGAAGUCACGCCCGUU Xp2:241852728-241852750 5768 CR000873 PDCD1 CAUGUGGAAGUCACGCCCGU Xp2:241852727-241852749 5769 CR000874 PDCD1 GCGUGACUUCCACAUGAGCG Xp2:241852720-241852742 5770 CR000875 PDCD1 ACUUCCACAUGAGCGUGGUC Xp2:241852715-241852737 5771 CR000876 PDCD1 CUUCCACAUGAGCGUGGUCA Xp2:241852714-241852736 5772 CR000877 PDCD1 GGGCCCUGACCACGCUCAUG Xp2:241852711-241852733 5773 CR000878 PDCD1 ACAUGAGCGUGGUCAGGGCC Xp2:241852709-241852731 5774 CR000879 PDCD1 AGGGCCCGGCCGCAAUGACAG Xp2:241852695-241852717 5775 CR000880 PDCD1 GGUGCCGCUGUCAUUGCGCC Xp2:241852691-241852713 5776 CR000881 PDCD1 AGGUGCCGCUGUCAUUGCGC Xp2:241852690-241852712 5777 CR000882 PDCD1 GACAGCGGCACCUACCUCUG Xp2:241852680-241852702 5778 CR000883 PDCD1 ACAGCGGCACCUACCUCUGU Xp2:241852679-241852701 5779 CR000884 PDCD1 CCAGGGAGAUGGCCCCACAG Xp2:241852666-241852688 5780 CR000885 PDCD1 GAUCUGCGCCUUGGGGGCCA Xp2:241852649-241852671 5781 CR000886 PDCD1 UGAUCUGCGCCUUGGGGGCC Xp2:241852648-241852670 5782 CR000887 PDCD1 CUCUUUGAUCUGCGCCUUGG Xp2:241852643-241852665 5783 CR000888 PDCD1 UCUCUUUGAUCUGCGCCUUG Xp2:241852642-241852664 5784 CR000889 PDCD1 CUCUCUUUGAUCUGCGCCUU Xp2:241852641-241852663 5785 CR000890 PDCD1 GCUCUCUUUGAUCUGCGCCU Xp2:241852640-241852662 5786 CR000891 PDCD1 CGCAGAUCAAAGAGAGCCUG Xp2:241852634-241852656 5787 CR000892 PDCD1 GCAGAUCAAAGAGAGCCUGC Xp2:241852633-241852655 5788 CR000893 PDCD1 AGAGCCUGCGGGCAGAGCUC Xp2:241852622-241852644 5789 CR000894 PDCD1 AGGGUUUGGAACUGGCCGGC Xp2:241852278-241852300 5790 CR000895 PDCD1 CACCAGGGUUUGGAACUGGC Xp2:241852274-241852296 5791 CR000896 PDCD1 CGGCCAGUUCCAAACCCUGG Xp2:241852273-241852295 5792 CR000897 PDCD1 CAACCACCAGGGUUUGGAAC Xp2:241852270-241852292 5793 CR000898 PDCD1 CAGUUCCAAACCCUGGUGGU Xp2:241852269-241852291 5794 CR000899 PDCD1 CGACACCAACCACCAGGGUU Xp2:241852264-241852286 5795 CR000900 PDCD1 AACCCUGGUGGUUGGUGUCG Xp2:241852261-241852283 5796 CR000901 PDCD1 ACCCUGGUGGUUGGUGUCGU Xp2:241852260-241852282 5797 CR000902 PDCD1 GCCCACGACACCAACCACCA Xp2:241852259-241852281 5798 CR000903 PDCD1 CGCCCACGACACCAACCACC Xp2:241852258-241852280 5799 CR000904 PDCD1 CUGGUGGUUGGUGUCGUGGG Xp2:241852257-241852279 5800 CR000905 PDCD1 UGGUGUCGUGGGCGGCCUGC Xp2:241852249-241852271 5801 CR000906 PDCD1 GGUGUCGUGGGCGGCCUGCU Xp2:241852248-241852270 5802 CR000907 PDCD1 GGUGCUGCUAGUCUGGGUCC Xp2:241852219-241852241 5803 CR000908 PDCD1 UCCUGGCCGUCAUCUGCUCC Xp2:241852202-241852224 5804 CR000909 PDCD1 CCCGGGAGCAGAUGACGGCC Xp2:241852201-241852223 5805 CR000910 PDCD1 CCUGGCCGUCAUCUGCUCCC Xp2:241852201-241852223 5806 CR000911 PDCD1 GACGUUACCUCGUGCGGCCC Xp2:241852184-241852206 5807 CR000912 PDCD1 UGACGUUACCUCGUGCGGCC Xp2:241852183-241852205 5808 CR000913 PDCD1 UGGGAUGACGUUACCUCGUG Xp2:241852178-241852200 5809 CR000914 PDCD1 CUGCAGGGACAAUAGGAGCC Xp2:241851961-241851983 5810 CR000915 PDCD1 ACAAUAGGAGCCAGGCGCAC Xp2:241851953-241851975 5811 CR000916 PDCD1 CAGGGGCUGGCCGGUGCGCC Xp2:241851943-241851965 5812 CR000917 PDCD1 AAAAGAGUGAGACUCACCAG Xp2:241851926-241851948 5813 CR000918 PDCD1 GAAAAGAGUGAGACUCACCA Xp2:241851925-241851947 5814 CR000919 PDCD1 GGAAAAAGAGUGAGACUCACC Xp2:241851924-241851946 5815

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000847. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000902. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000852. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000826. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000904. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000839. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000828. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000835. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000829. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR000879. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000870. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000831. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000848. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000855. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR000838. Such nRNA molecules and combinations thereof are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 6b. nRNA targeting domains to human FKBP1A ID Target Chain Target sequence position nRNA guide domain sequence SEQID NO: CR002054 FKBP1A - Xp20:1393120-1393142 CGCACGCAGGGCUGGGCGUG 6662 CR002055 FKBP1A - Xp20:1393119-1393141 GCACGCAGGGCUGGGCGUGA 6663 CR002056 FKBP1A - Xp20:1393118-1393140 CACGCAGGGCUGGGCGUGAG 6664 CR002057 FKBP1A - Xp20:1393117-1393139 ACGCAGGGCUGGGCGUGAGG 6665 CR002058 FKBP1A - Xp20:1393101-1393123 GAGGGGGCGUGCGCGUGCGC 6666 CR002059 FKBP1A - Xp20:1393088-1393110 CGUGCGCAGGCGACGCGCCG 6667 CR002060 FKBP1A - Xp20:1393081-1393103 AGGCGACGCGCCGAGGUAC 6668 CR002061 FKBP1A + Xp20:1393071-1393093 CACGGCUCUGCCUAGUACCU 6669 CR002062 FKBP1A - Xp20:1393070-1393092 CGAGGUACUACUAGGCAGAGCCG 6670 CR002063 FKBP1A - Xp20:1393057-1393079 AGAGCCGUGGAACCGCCGCC 6671 CR002064 FKBP1A + Xp20:1393053-1393075 GCGACCUGGCGGCGGUUCCA 6672 CR002065 FKBP1A - Xp20:1393047-1393069 AACCGCCGCCAGGUCGCUGU 6673 CR002066 FKBP1A + Xp20:1393045-1393067 GACCAACAGCGACCUGGCGG 6674 CR002067 FKBP1A + Xp20:1393042-1393064 GUGGACCAACAGCGACCUGG 6675 CR002068 FKBP1A + Xp20:1393039-1393061 GGCGUGGACCAACAGCGACC 6676 CR002069 FKBP1A + Xp20:1393023-1393045 GGGCGGCGCGACGGGCGGCG 6677 CR002070 FKBP1A + Xp20:1393018-1393040 CGGGCGGGCGGCGCGACGGG 6678 CR002071 FKBP1A + Xp20:1393015-1393037 GAGCGGGCGGGCGGCGCGAC 6679 CR002072 FKBP1A + Xp20:1393014-1393036 UGAGCGGGCGGGCGGCGCGA 6680 CR002073 FKBP1A + Xp20:1393006-1393028 GCGGACGCUGAGCGGGCGGG 6681 CR002074 FKBP1A + Xp20:1393003-1393025 GCGGCGGACGCUGAGCGGGC 6682 CR002075 FKBP1A + Xp20:1393002-1393024 GGCGGCGGACGCUGAGCGGG 6683 CR002076 FKBP1A + Xp20:1392999-1393021 GGCGGCGGCGGACGCUGAGC 6684 CR002077 FKBP1A + Xp20:1392998-1393020 UGGCGGCGGCGGACGCUGAG 6685 CR002078 FKBP1A - Xp20:1392995-1393017 CUCAGCGUCCGCCGCCGCCA 6686 CR002079 FKBP1A - Xp20:1392994-1393016 UCAGCGUCCGCCGCCGCCAU 6687 CR002080 FKBP1A + Xp20:1392987-1393009 CUGCACUCCCAUGGCGGCGG 6688 CR002081 FKBP1A - Xp20:1392986-1393008 CGCCGCCGCCAUGGGAGUGC 6689 CR002082 FKBP1A + Xp20:1392984-1393006 CACCUGCACUCCCAUGGCGG 6690 CR002083 FKBP1A - Xp20:1392983-1393005 CGCCGCCAUGGGAGUGCAGG 6691 CR002084 FKBP1A + Xp20:1392981-1393003 UUCCACCCUGCACUCCCAUGG 6692 CR002085 FKBP1A + Xp20:1392978-1393000 GGUUUCCACCCUGCACUCCCA 6693 CR002086 FKBP1A - Xp20:1392967-1392989 CAGGUGGAAACCAUCUCCCC 6694 CR002087 FKBP1A + Xp20:1392957-1392979 CUCACCGUCUCCUGGGGAGA 6695 CR002088 FKBP1A + Xp20:1392951-1392973 CCACUACUCACCGUCUCCUG 6696 CR002089 FKBP1A + Xp20:1392950-1392972 GCCACUACUCACCGUCUCCU 6697 CR002090 FKBP1A + Xp20:1392949-1392971 CGCCACUACUCACCGUCUCC 6698 CR002091 FKBP1A - Xp20:1392880-1392902 UGCCCGUCUCUGUCUCCUCA 6699 CR002092 FKBP1A - Xp20:1392860-1392882 GGGCGCACCUUCCCCAAGCG 6700 CR002093 FKBP1A + Xp20:1392853-1392875 GGUCUGGCCGCGCUUGGGGA 6701 CR002094 FKBP1A + Xp20:1392849-1392871 CGCAGGUCUGGCCGCGCUUG 6702 CR002095 FKBP1A + Xp20:1392848-1392870 ACGCAGGUCUGGCCGCGCUU 6703 CR002096 FKBP1A + Xp20:1392847-1392869 CACGCAGGUCUGGCCGCGCU 6704 CR002097 FKBP1A - Xp20:1392846-1392868 CAAGCGCGGCCAGACCUGCG 6705 CR002098 FKBP1A + Xp20:1392837-1392859 UGUAGUGCACCACGCAGGUC 6706 CR002099 FKBP1A + Xp20:1392832-1392854 ACCGGUGUAGUGCACCACGC 6707 CR002100 FKBP1A + Xp20:1392814-1392836 CCGCUGGGCCCCCGACUCAC 6708 CR002101 FKBP1A - Xp20:1375602-1375624 UUACAGUCCGUCUUUUUCACA 6709 CR002102 FKBP1A - Xp20:1375588-1375610 UUCACAGGGGAUGCUUGAAGA 6710 CR002103 FKBP1A - Xp20:1375566-1375588 GAAAGAAAUUUGAUUCCUCC 6711 CR002104 FKBP1A - Xp20:1375565-1375587 AAAGAAAUUUGAUUCCUCCCC 6712 CR002105 FKBP1A + Xp20:1375551-1375573 GGGCUUGUUUCUGUCCCGGG 6713 CR002106 FKBP1A + Xp20:1375548-1375570 AAAGGGCUUGUUUCUGUCCC 6714 CR002107 FKBP1A + Xp20:1375547-1375569 UAAAGGGCUUGUUUCUGUCC 6715 CR002108 FKBP1A - Xp20:1375534-1375556 AAGCCCUUUAAGUUUAUGCU 6716 CR002109 FKBP1A + Xp20:1375531-1375553 UUGCCUAGCAUAAACUUAAA 6717 CR002110 FKBP1A + Xp20:1375530-1375552 CUUGCCUAGCAUAAACUUAA 6718 CR002111 FKBP1A - Xp20:1375526-1375548 UAAGUUUAUGCUAGGCAAGC 6719 CR002112 FKBP1A - Xp20:1375523-1375545 GUUUAUGCUAGGCAAGCAGG 6720 CR002113 FKBP1A - Xp20:1375513-1375535 GGCAAGCAGGAGGUGAUCCG 6721 CR002114 FKBP1A - Xp20:1375509-1375531 AGCAGGAGGUGAUCCGAGGC 6722 CR002115 FKBP1A - Xp20:1375508-1375530 GCAGGAGGUGAUCCGAGGCU 6723 CR002116 FKBP1A - Xp20:1375501-1375523 GUGAUCCGAGGCUGGGAAGA 6724 CR002117 FKBP1A - Xp20:1375500-1375522 UGAUCCGAGGCUGGGAAGAA 6725 CR002118 FKBP1A - Xp20:1375499-1375521 GAUCCGAGGCUGGGAAGAAG 6726 CR002119 FKBP1A + Xp20:1375496-1375518 CAACCCCUUCUUCCCAGCCU 6727 CR002120 FKBP1A + Xp20:1375473-1375495 ACAAAUGAGAGAGCAUACCU 6728 CR002121 FKBP1A + Xp20:1375472-1375494 AACAAAUGAGAGAGCAUACC 6729 CR002122 FKBP1A - Xp20:1372231-1372253 GUUCUUUUCACAGAUGAGUG 6730 CR002123 FKBP1A - Xp20:1372230-1372252 UUCUUUUCACAGAUGAGUGU 6731 CR002124 FKBP1A + Xp20:1372199-1372221 AUCUGGAGAUAUAGUCAGUU 6732 CR002125 FKBP1A - Xp20:1372188-1372210 AUAUCUCCAGAUUAUGCCUA 6733 CR002126 FKBP1A + Xp20:1372182-1372204 GUGGCACCAUAGGCAUAAUC 6734 CR002127 FKBP1A - Xp20:1372179-1372201 GAUUAUGCCUAUGGUGCCAC 6735 CR002128 FKBP1A - Xp20:1372178-1372200 AUUAUGCCUAUGGUGCCACU 6736 CR002129 FKBP1A + Xp20:1372172-1372194 UGGGUGCCCAGUGGCACCAU 6737 CR002130 FKBP1A - Xp20:1372170-1372192 UAUGGUGCCACUGGGCACCC 6738 CR002131 FKBP1A + Xp20:1372163-1372185 GAUGAUGCCUGGGUGCCCAG 6739 CR002132 FKBP1A + Xp20:1372153-1372175 CAUGUGGUGGGAUGAUGCCU 6740 CR002133 FKBP1A + Xp20:1372152-1372174 GCAUGUGGUGGGAUGAUGCC 6741 CR002134 FKBP1A + Xp20:1372141-1372163 AGACGAGAGUGGCAUGUGGU 6742 CR002135 FKBP1A + Xp20:1372140-1372162 AAGACGAGAGUGGCAUGUGG 6743 CR002136 FKBP1A + Xp20:1372137-1372159 UCGAAGACGAGAGUGGCAUG 6744 CR002137 FKBP1A - Xp20:1372132-1372154 UGCCACUCUCGUCUUCGAUG 6745 CR002138 FKBP1A + Xp20:1372130-1372152 CUCCACAUCGAAGACGAGAG 6746 CR002139 FKBP1A - Xp20:1372117-1372139 CGAUGUGGAGCUUCUAAAAC 6747 CR002140 FKBP1A - Xp20:1372108-1372130 GCUUCUAAAACUGGAAUGAC 6748 CR002141 FKBP1A - Xp20:1372103-1372125 UAAAACUGGAAUGACAGGAA 6749

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002100 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002097. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR002091. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002085. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002086. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002089. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002088. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002095. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002096. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002080 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002109. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002112. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002110. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002108. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR002104. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR002115. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002116. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002087. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002107. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002113. Such nRNA molecules, including combinations thereof, are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 6c. nRNA targeting domains to human CIITA ID Target Chain position on the chromosome nRNA guide domain sequence SEQID NO: CR002939 CIITA + Xp16:10877252-10877274 GGCAUCCUUGGGGAAGCUGA 7717 CR002940 CIITA - Xp16:10877257-10877279 UCGUGCCCUCAGCUUCCCCA 7718 CR002941 CIITA + Xp16:10877259-10877281 UUGGGGAAGCUGAGGGCACG 7719 CR002942 CIITA + Xp16:10877262-10877284 GGGAAGCUGAGGGCACGAGG 7720 CR002943 CIITA + Xp16:10877263-10877285 GGAAGCUGAGGGCACGAGGA 7721 CR002944 CIITA + Xp16:10877264-10877286 GAAGCUGAGGGCACGAGGAG 7722 CR002945 CIITA + Xp16:10877278-10877300 GAGGAGGGGCUGCCAGACUC 7723 CR002946 CIITA + Xp16:10877279-10877301 AGGAGGGGCUGCCAGACUCC 7724 CR002947 CIITA - Xp16:10877290-10877312 AGGCAGCAGCUCCCGGAGUC 7725 CR002948 CIITA + Xp16:10877292-10877314 AGACUCCGGGAGCUGCUGCC 7726 CR002949 CIITA + Xp16:10877296-10877318 UCCGGGAGCUGCUGCCUGGC 7727 CR002950 CIITA + Xp16:10877297-10877319 CCGGGAGCUGCUGCCUGGCU 7728 CR002951 CIITA - Xp16:10877297-10877319 CCCAGCCAGGCAGCAGCUCC 7729 CR002952 CIITA - Xp16:10877310-10877332 AUUGUGUAGGAAUCCCAGCC 7730 CR002953 CIITA + Xp16:10877321-10877343 UUCCUACACAAUGCGUUGCC 7731 CR002954 CIITA - Xp16:10877323-10877345 AGCCAGGCAACGCAUUGUGU 7732 CR002955 CIITA + Xp16:10877337-10877359 UGCCUGGCUCCACGCCCUGC 7733 CR002956 CIITA + Xp16:10877338-10877360 GCCUGGCUCCACGCCCUGCU 7734 CR002957 CIITA - Xp16:10877339-10877361 ACCCAGCAGGGCGUGGAGCC 7735 CR002958 CIITA - Xp16:10877346-10877368 AGGUAGGACCCAGCAGGGCG 7736 CR002959 CIITA - Xp16:10877351-10877373 CUGACAGGUAGGACCCAGCA 7737 CR002960 CIITA - Xp16:10877352-10877374 UCUGACAGGUAGGACCCAGC 7738 CR002961 CIITA + Xp16:10895283-10895305 CAGCUCACAGUGUGCCACCA 7739 CR002962 CIITA + Xp16:10895289-10895311 ACAGUGUGCCACCAUGGAGU 7740 CR002963 CIITA + Xp16:10895290-10895312 CAGUGUGCCACCAUGGAGUU 7741 CR002964 CIITA + Xp16:10895291-10895313 AGUGUGCCACCAUGGAGUUG 7742 CR002965 CIITA - Xp16:10895297-10895319 UAGGGGCCCCAACUCCAUGG 7743 CR002966 CIITA - Xp16:10895300-10895322 UUCUAGGGGCCCCAACUCCA 7744 CR002967 CIITA + Xp16:10895302-10895324 AUGGAGUUGGGGCCCCUAGA 7745 CR002968 CIITA + Xp16:10895305-10895327 GAGUUGGGGCCCCUAGAAGG 7746 CR002969 CIITA + Xp16:10895313-10895335 GCCCCUAGAAGGUGGCUACC 7747 CR002970 CIITA - Xp16:10895314-10895336 UCCAGGUAGCCACCUUCUAG 7748 CR002971 CIITA - Xp16:10895315-10895337 CUCCAGGUAGCCACCUUCUA 7749 CR002972 CIITA - Xp16:10895316-10895338 GCUCCAGGUAGCCACCUUCU 7750 CR002973 CIITA - Xp16:10895331-10895353 CAUCGCUGUUAAGAAGCUCC 7751 CR002974 CIITA - Xp16:10895358-10895380 AGAAGUGGUAGAGGCACAGG 7752 CR002975 CIITA - Xp16:10895359-10895381 UAGAAGUGGUAGAGGCACAG 7753 CR002976 CIITA - Xp16:10895360-10895382 AUAGAAGUGGUAGAGGCACA 7754 CR002977 CIITA - Xp16:10895361-10895383 CAUAGAAGUGGUAGAGGCAC 7755 CR002978 CIITA - Xp16:10895367-10895389 UCUGGUCAAUAGAAGUGGUAG 7756 CR002979 CIITA + Xp16:10895370-10895392 CUACCACUUCUAUGACCAGA 7757 CR002980 CIITA - Xp16:10895373-10895395 GGUCCAUCUGGUCAUAGAAG 7758 CR002981 CIITA + Xp16:10895376-10895398 CUUCUAUGACCAGAUGGACC 7759 CR002982 CIITA + Xp16:10895380-10895402 UAUGACCAGAUGGACCUGGC 7760 CR002983 CIITA - Xp16:10895385-10895407 CUUCUCCAGCCAGGUCCAUC 7761 CR002984 CIITA - Xp16:10895394-10895416 CAAUCUCUUCUUCUCCAGCC 7762 CR002985 CIITA - Xp16:10895671-10895693 CAGUUGAUGGUGUCUGUGUC 7763 CR002986 CIITA - Xp16:10895672-10895694 GCAGUUGAUGGUGUCUGUGU 7764 CR002987 CIITA - Xp16:10895684-10895706 GCUGAACUGGUCGCAGUUGA 7765 CR002988 CIITA + Xp16:10895687-10895709 UCAACUGCGACCAGUUCAGC 7766 CR002989 CIITA - Xp16:10895697-10895719 CACACAACAGCCUGCUGAAC 7767 CR002990 CIITA + Xp16:10895703-10895725 CAGCAGGCUGUUGUGUGACA 7768 CR002991 CIITA + Xp16:10895707-10895729 AGGCUGUUGUGUGACAUGGA 7769 CR002992 CIITA + Xp16:10895723-10895745 UGGAAGGUGAUGAAGAGAC 7770 CR002993 CIITA + Xp16:10895724-10895746 GGAAGGUGAUGAAGAGACCA 7771 CR002994 CIITA + Xp16:10895727-10895749 AGGUGAUGAAGAGACAGGG 7772 CR002995 CIITA - Xp16:10895741-10895763 GAUAUUGGCAUAAGCCUCCC 7773 CR002996 CIITA - Xp16:10895756-10895778 AGGUGCUUCUCACCGAUAU 7774 CR002997 CIITA + Xp16:10898674-10898696 ACUGGACCAGUAUGUCUUCC 7775 CR002998 CIITA - Xp16:10898680-10898702 GGGAGUCCCUGGAAGACAUAC 7776 CR002999 CIITA + Xp16:10898686-10898708 UGUCUUCCAGGACUCCCAGC 7777 CR003000 CIITA + Xp16:10898689-10898711 CUUCCAGGACUCCCAGCUGG 7778 CR003001 CIITA + Xp16:10898690-10898712 UUCCAGGACUCCCAGCUGGA 7779 CR003002 CIITA - Xp16:10898692-10898714 GGCCCUCCAGCUGGGAGUCC 7780 CR003003 CIITA - Xp16:10898700-10898722 CUUGCUCAGGCCCUCCAGCU 7781 CR003004 CIITA - Xp16:10898701-10898723 CCUUGCUCAGGCCCUCCAGC 7782 CR003005 CIITA + Xp16:10898701-10898723 CCAGCUGGAGGGCCUGAGCA 7783 CR003006 CIITA - Xp16:10898713-10898735 UACUGAAAAUGUCCUUGCUC 7784 CR003007 CIITA + Xp16:10898930-10898952 AUAGGACCAGAUGAAGUGAU 7785 CR003008 CIITA - Xp16:10898936-10898958 CUCUCACCGAUCACUUCAUC 7786 CR003009 CIITA + Xp16:10898941-10898963 UGAAGUGAUCGGUGAGAGUA 7787 CR003010 CIITA + Xp16:10898960-10898982 AUGGAGAUGCCAGCAGAAGU 7788 CR003011 CIITA + Xp16:10898961-10898983 UGGAGAUGCCAGCAGAAGUU 7789 CR003012 CIITA - Xp16:10898969-10898991 CUUUUCUGCCCAACUUCUGC 7790 CR003013 CIITA - Xp16:10901514-10901536 UGCCGGAAGCUCCUCUGGGA 7791 CR003014 CIITA - Xp16:10901518-10901540 GGUCUGCCGGAAGCUCCUCU 7792 CR003015 CIITA - Xp16:10901519-10901541 AGGUCUGCCGGAAGCUCCUC 7793 CR003016 CIITA + Xp16:10901529-10901551 UUCCGGCAGACCUGAAGCAC 7794 CR003017 CIITA - Xp16:10901531-10901553 UUCCAGUGCUUCAGGUCUGC 7795 CR003018 CIITA + Xp16:10902040-10902062 GAGCCCCCCACUGUGGUGAC 7796 CR003019 CIITA - Xp16:10902043-10902065 CUGCCAGUCACCACAGUGGG 7797 CR003020 CIITA - Xp16:10902044-10902066 ACUGCCAGUCACCACAGUGG 7798 CR003021 CIITA - Xp16:10902045-10902067 GACUGCCAGUCACCACAGUG 7799 CR003022 CIITA - Xp16:10902046-10902068 AGACUGCCAGUCACCACAGU 7800 CR003023 CIITA - Xp16:10902047-10902069 GAGACUGCCAGUCACCACAG 7801 CR003024 CIITA + Xp16:10902054-10902076 GGUGACUGGCAGUCUCCUAG 7802 CR003025 CIITA + Xp16:10902055-10902077 GUGACUGGCAGUCUCCUAGU 7803 CR003026 CIITA - Xp16:10902069-10902091 AGUCGCUCACUGGUCCCACU 7804

In various aspects of the invention, the nRNA molecule may include the above guide domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002939. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002940. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002941. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002942. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002943. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002944 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002945. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002946 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002947. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002948. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002949. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002950. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002951. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002952. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002953. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002954 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002955. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002956. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002957 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002958. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002959. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002960. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002961. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002962. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002963. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002964 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002965. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002966 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002967. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002968 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002969. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002970. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR002971. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002972. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002973 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002974. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002975. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002976. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, targeting domain CR002977. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002978. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002979. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002980. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002981. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002982. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002983. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002984. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002985. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002986. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002987. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002988. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002989. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002990. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002991. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002992. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002993. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002994. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002995. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002996. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002997. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR002998 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR002999. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR003000 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003001. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003002. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003003. In an embodiment, the nRNA targeting domain of the invention comprises, for example consists of, the CR003004 targeting domain. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003005. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003006. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003007. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003008. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003009. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003010. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003011. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003012. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003013. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003014. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003015. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003016. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003017. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003018. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003019. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003020. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003021. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003022. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003023. In an embodiment, the targeting domain of the nRNA according to the invention includes, for example consists of, the targeting domain CR003024. In an embodiment, the targeting domain of the nRNA according to the invention comprises, for example consists of, the targeting domain CR003025. In an embodiment, the nRNA targeting domain of the invention includes, for example, consists of the CR003026 targeting domain. Such nRNA molecules and combinations thereof are suitable for use in, for example, CRISPR systems, methods and cells, and other aspects of the invention described herein.

Table 6d. Targeting domains to human LILRB1, an exemplary target of an NK inhibitory molecule. ID Target Region Chain position on the chromosome nRNA guide domain sequence SEQID NO: 10859_2_1 LILRB1 EXON + xp19:54630390-54630410 UAAAAAGGGGAAGUUAAGAG 10090 10859_2_2 LILRB1 EXON + xp19:54630399-54630419 GAAGUUAAGAGGGGACUAUU 10091 10859_2_23 LILRB1 EXON + xp19:54630503-54630523 CUGCCACACGCAGCUCAGCC 10092 10859_2_24 LILRB1 EXON + xp19:54630504-54630524 UGCCACACGCAGCUCAGCCU 10093 10859_2_25 LILRB1 EXON + xp19:54630507-54630527 CACACGCAGCUCAGCCUGGG 10094 10859_2_29 LILRB1 EXON + xp19:54630560-54630580 AUCUGAGUCUGCCUGCAGCA 10095 10859_2_31 LILRB1 EXON + xp19:54630566-54630586 GUCUGCCUGCAGCAUGGACC 10096 10859_2_32 LILRB1 EXON + xp19:54630567-54630587 UCUGCCUGCAGCAUGGACCU 10097 10859_2_35 LILRB1 EXON + xp19:54630589-54630609 GUCUUCCCUGAAGCAUCUCC 10098 10859_2_36 LILRB1 EXON + xp19:54630590-54630610 UCUUCCCUGAAGCAUCUCCA 10099 10859_2_39 LILRB1 EXON + xp19:54630594-54630614 CCCUGAAGCAUCCUCCAGGGC 10100 10859_2_42 LILRB1 EXON + xp19:54630597-54630617 UGAAGCAUCUCCAGGGCUGG 10101 10859_2_44 LILRB1 EXON + xp19:54630598-54630618 GAAGCAUCUCCAGGGCUGGA 10102 10859_2_45 LILRB1 EXON + xp19:54630611-54630631 GGCUGGAGGGACGACUGCCA 10103 10859_2_47 LILRB1 EXON + xp19:54630616-54630636 GAGGGACGACUGCCAUGGUA 10104 10859_2_58 LILRB1 EXON - xp19:54630436-54630456 CUUUCUUGACACUGGAUUGU 10105 10859_2_60 LILRB1 EXON - xp19:54630437-54630457 UCUUUCUUGACACUGGAUUG 10106 10859_2_62 LILRB1 EXON - xp19:54630444-54630464 GUUGACUUCUUUCUUGACAC 10107 10859_2_65 LILRB1 EXON - xp19:54630474-54630494 AAGAGAAAUGCAGGGAAAUA 10108 10859_2_67 LILRB1 EXON - xp19:54630475-54630495 GAAGAGAAAUGCAGGGAAAU 10109 10859_2_70 LILRB1 EXON - xp19:54630482-54630502 GAGCACAGAAGAGAAAUGCA 10110 10859_2_72 LILRB1 EXON - xp19:54630483-54630503 UGAGCACAGAAGAGAAAUGC 10111 10859_2_80 LILRB1 EXON - xp19:54630509-54630529 CGCCCAGGCUGAGCUGCGUG 10112 10859_2_82 LILRB1 EXON - xp19:54630524-54630544 CGCAUCUGGCUGUGCCGCCC 10113 10859_2_83 LILRB1 EXON - xp19:54630538-54630558 GCAGAGACGCAUCUCGCAUC 10114 10859_2_85 LILRB1 EXON - xp19:54630574-54630594 AAGACCCAGGUCCAUGCUGC 10115 10859_2_87 LILRB1 EXON - xp19:54630587-54630607 AGAUGCUUCAGGGAAGACCC 10116 10859_2_88 LILRB1 EXON - xp19:54630597-54630617 CCAGCCCUGGAGAUGCUUCA 10117 10859_2_90 LILRB1 EXON - xp19:54630598-54630618 UCCAGCCCUGGAGAUGCUUC 10118 10859_2_94 LILRB1 EXON - xp19:54630610-54630630 GGCAGUCGUCCCUCCAGCCCC 10119 10859_2_98 LILRB1 EXON - xp19:54630631-54630651 GUGUUGUGGGGUCCUUACCA 10120 10859_3_3 LILRB1 EXON + xp19:54631010-54631030 UCCUUAUCCUGCCAGCACCG 10121 10859_3_4 LILRB1 EXON + xp19:54631011-54631031 CUCUAUCCUGCCAGCACCGA 10122 10859_3_7 LILRB1 EXON + xp19:54631032-54631052 GGCUCAUCCAUCCACAGAGGC 10123 10859_3_8 LILRB1 EXON + xp19:54631033-54631053 GCUCAUCCAUCCACAGAGCA 10124 10859_3_10 LILRB1 EXON + xp19:54631039-54631059 CCAUCCACAGAGCAGGGCAG 10125 10859_3_12 LILRB1 EXON + xp19:54631040-54631060 CAUCCACAGAGCAGGGCAGU 10126 10859_3_15 LILRB1 EXON + xp19:54631043-54631063 CCACAGAGCAGGGCAGUGGG 10127 10859_3_17 LILRB1 EXON + xp19:54631069-54631089 CGCCAUGACCCCCAUCCUCA 10128 10859_3_18 LILRB1 EXON + xp19:54631085-54631105 CUCACGGUCCCUGAUCUGUCU 10129 10859_3_24 LILRB1 EXON + xp19:54631101-54631121 GUCUCGGUGAGAUUUGAAGA 10130 10859_3_25 LILRB1 EXON + xp19:54631104-54631124 UCGGUGAGAUUUGAAGAAGG 10131 10859_3_28 LILRB1 EXON - xp19:54631020-54631040 GAUGAGCCCUCGGUGCUGGC 10132 10859_3_30 LILRB1 EXON - xp19:54631024-54631044 GAUGGAUGAGCCCUCGGUGC 10133 10859_3_31 LILRB1 EXON - xp19:54631030-54631050 UCUGUGGAUGGAUGAGCCCU 10134 10859_3_33 LILRB1 EXON - xp19:54631042-54631062 CCACUGCCCUGCUCUGUGGA 10135 10859_3_35 LILRB1 EXON - xp19:54631046-54631066 CCUCCCACUGCCCUGCUCUG 10136 10859_3_37 LILRB1 EXON - xp19:54631074-54631094 GACCGUGAGGAUGGGGGUCA 10137 10859_3_38 LILRB1 EXON - xp19:54631080-54631100 GAUCAGGACCGUGAGGAUGG 10138 10859_3_39 LILRB1 EXON - xp19:54631081-54631101 AGAUCAGGACCGUGAGGAUG 10139 10859_3_40 LILRB1 EXON - xp19:54631082-54631102 CAGAUCAGGACCGUGAGGAU 10140 10859_3_42 LILRB1 EXON - xp19:54631083-54631103 ACAGAUCAGGACCGUGAGGA 10141 10859_3_45 LILRB1 EXON - xp19:54631087-54631107 CGAGACAGAUCAGGACCGUG 10142 10859_3_50 LILRB1 EXON - xp19:54631096-54631116 AAAUCUCACCGAGACAGAUC 10143 10859_4_3 LILRB1 EXON + xp19:54631259-54631279 CUCUCUUCCAGGGCUGAGUC 10144 10859_4_4 LILRB1 EXON + xp19:54631260-54631280 UCUCUUCCAGGGCUGAGUCU 10145 10859_4_7 LILRB1 EXON + xp19:54631267-54631287 CAGGGCUGAGUCUGGGCCCC 10146 10859_4_8 LILRB1 EXON + xp19:54631280-54631300 GGGCCCCCGGACCACGUGC 10147 10859_4_9 LILRB1 EXON + xp19:54631284-54631304 CCCCGGACCACGUGCAGGC 10148 10859_4_11 LILRB1 EXON - xp19:54631255-54631275 CAGCCCUGGAAGAGAGGUUCC 10149 10859_4_15 LILRB1 EXON - xp19:54631269-54631289 CGGGGGCCCAGACUCAGCCC 10150 10859_4_17 LILRB1 EXON - xp19:54631286-54631306 CUGCCUGCACGUGGGUCCGG 10151 10859_4_18 LILRB1 EXON - xp19:54631287-54631307 CCUGCCUGCACGUGGGUCCG 10152 10859_4_20 LILRB1 EXON - xp19:54631288-54631308 ACCUGCCUGCACGUGGGUCC 10153 10859_4_21 LILRB1 EXON - xp19:54631289-54631309 CACCUGCCUGCACGUGGGUC 10154 10859_4_24 LILRB1 EXON - xp19:54631294-54631314 AGACUCACCUGCCUGCACGU 10155 10859_4_25 LILRB1 EXON - xp19:54631295-54631315 CAGACUCACCUGCCUGCACG 10156 10859_5_5 LILRB1 EXON + xp19:54631502-54631522 ACCUCCCCAAGCCCACCCUC 10157 10859_5_6 LILRB1 EXON + xp19:54631503-54631523 CCUCCCCAAGCCCACCCUCU 10158 10859_5_8 LILRB1 EXON + xp19:54631513-54631533 CCCACCCUCUGGGCUGAACC 10159 10859_5_10 LILRB1 EXON + xp19:54631530-54631550 ACCAGGCUCUGUGAUCACCC 10160 10859_5_12 LILRB1 EXON + xp19:54631531-54631551 CCAGGCUCUGUGAUCACCCA 10161 10859_5_15 LILRB1 EXON + xp19:54631532-54631552 CAGGCUCUGUGAUCACCCAG 10162 10859_5_16 LILRB1 EXON + xp19:54631550-54631570 AGGGGAGUCCCUGUGACCCUC 10163 10859_5_19 LILRB1 EXON + xp19:54631557-54631577 UCCUGUGACCCUCAGGUGUC 10164 10859_5_20 LILRB1 EXON + xp19:54631558-54631578 CCUGUGACCCUCAGGUGUCA 10165 10859_5_22 LILRB1 EXON + xp19:54631559-54631579 CUGUGACCCUCAGGUGUCAG 10166 10859_5_24 LILRB1 EXON + xp19:54631560-54631580 UGUGACCCUCAGGUGUCAGG 10167 10859_5_25 LILRB1 EXON + xp19:54631561-54631581 GUGACCCUCAGGUGUCAGGG 10168 10859_5_28 LILRB1 EXON + xp19:54631566-54631586 CCUCAGGUGUCAGGGGGGCC 10169 10859_5_30 LILRB1 EXON + xp19:54631575-54631595 UCAGGGGGGCCAGGAGACCCC 10170 10859_5_38 LILRB1 EXON + xp19:54631613-54631633 GAGAAAAGAAAACAGCACCC 10171 10859_5_40 LILRB1 EXON + xp19:54631622-54631642 AAACAGCACCCUGGAUUACA 10172 10859_5_42 LILRB1 EXON + xp19:54631632-54631652 CUGGAUUACACGGAUCCCAC 10173 10859_5_48 LILRB1 EXON + xp19:54631647-54631667 CCCACAGGAGCUUGUGAAGA 10174 10859_5_49 LILRB1 EXON + xp19:54631648-54631668 CCACAGGAGCUUGUGAAGAA 10175 10859_5_53 LILRB1 EXON + xp19:54631676-54631696 UCCCCAUCCCAUCCAUCACC 10176 10859_5_54 LILRB1 EXON + xp19:54631677-54631697 CCCCAUCCCAUCCAUCACCU 10177 10859_5_58 LILRB1 EXON + xp19:54631687-54631707 UCCAUCACCUGGGAACACAC 10178 10859_5_59 LILRB1 EXON + xp19:54631688-54631708 CCAUCACCUGGGAACACCACA 10179 10859_5_60 LILRB1 EXON + xp19:54631691-54631711 UCACCUGGGAACACACAGGG 10180 10859_5_61 LILRB1 EXON + xp19:54631708-54631728 GGGCGGUAUCGCUGUUACUA 10181 10859_5_62 LILRB1 EXON + xp19:54631723-54631743 UACUAUGGUAGCGGACACUGC 10182 10859_5_68 LILRB1 EXON + xp19:54631749-54631769 CUCAGAGAGCAGUGACCCCCC 10183 10859_5_69 LILRB1 EXON + xp19:54631755-54631775 GAGCAGUGACCCCCUGGAGC 10184 10859_5_70 LILRB1 EXON + xp19:54631758-54631778 CAGUGACCCCCUGGAGCUGG 10185 10859_5_71 LILRB1 EXON + xp19:54631765-54631785 CCCCUGGAGCUGGUGGUGAC 10186 10859_5_75 LILRB1 EXON + xp19:54631781-54631801 UGACAGGUGAGCUGACACUC 10187 10859_5_76 LILRB1 EXON + xp19:54631782-54631802 GACAGGUGAGCUGACACUCA 10188 10859_5_77 LILRB1 EXON + xp19:54631783-54631803 ACAGGUGAGCUGACACUCAG 10189 10859_5_79 LILRB1 EXON - xp19:54631486-54631506 AGGUGCCCUGGAAGGAAAUC 10190 10859_5_82 LILRB1 EXON - xp19:54631494-54631514 GCUUGGGGAGGUGCCCUGGA 10191 10859_5_85 LILRB1 EXON - xp19:54631498-54631518 GUGGGCUUGGGGAGGUGCCC 10192 10859_5_89 LILRB1 EXON - xp19:54631506-54631526 CCCAGAGGGUGGGCUUGGGG 10193 10859_5_90 LILRB1 EXON - xp19:54631509-54631529 CAGCCCAGAGGGUGGGCUUG 10194 10859_5_92 LILRB1 EXON - xp19:54631510-54631530 UCAGCCCAGAGGGUGGGCUU 10195 10859_5_95 LILRB1 EXON - xp19:54631511-54631531 UUCAGCCCAGAGGGUGGGCU 10196 10859_5_97 LILRB1 EXON - xp19:54631516-54631536 CCUGGUUCAGCCCAGAGGGU 10197 10859_5_98 LILRB1 EXON - xp19:54631517-54631537 GCCUGGUUCAGCCCAGAGGG 10198 10859_5_100 LILRB1 EXON - xp19:54631520-54631540 AGAGCCUGGUUCAGCCCAGA 10199 10859_5_101 LILRB1 EXON - xp19:54631521-54631541 CAGAGCCUGGUUCAGCCAG 10200 10859_5_104 LILRB1 EXON - xp19:54631534-54631554 CCCUGGGUGAUCACAGAGCC 10201 10859_5_106 LILRB1 EXON - xp19:54631550-54631570 GAGGGUCACAGGACUCCCCU 10202 10859_5_107 LILRB1 EXON - xp19:54631551-54631571 UGAGGGUCACAAGGACUCCCC 10203 10859_5_109 LILRB1 EXON - xp19:54631561-54631581 CCCUGACACCCUGAGGGUCAC 10204 10859_5_111 LILRB1 EXON - xp19:54631568-54631588 CUGGCCCCCCUGACACCUGA 10205 10859_5_112 LILRB1 EXON - xp19:54631569-54631589 CCUGGCCCCCCUGACACCUG 10206 10859_5_115 LILRB1 EXON - xp19:54631587-54631607 GACGGUACUCCUGGGUCUCC 10207 10859_5_119 LILRB1 EXON - xp19:54631595-54631615 UCUAUAUAGACGGUACUCCU 10208 10859_5_120 LILRB1 EXON - xp19:54631596-54631616 CUCUAUAUAGACGGUACUCCC 10209 10859_5_125 LILRB1 EXON - xp19:54631605-54631625 UUUUCUUUUCUCUAUAUAGA 10210 10859_5_126 LILRB1 EXON - xp19:54631633-54631653 UGUGGGAUCCGUGUAAUCCA 10211 10859_5_127 LILRB1 EXON - xp19:54631634-54631654 CUGUGGGAUCCGUGUAAAUCC 10212 10859_5_131 LILRB1 EXON - xp19:54631650-54631670 CCUUCUUCACAAGCUCCUGU 10213 10859_5_132 LILRB1 EXON - xp19:54631651-54631671 CCCUUCUUCACAAGCUCCUG 10214 10859_5_135 LILRB1 EXON - xp19:54631674-54631694 UGAUGGAUGGGAUGGGGAAC 10215 10859_5_137 LILRB1 EXON - xp19:54631680-54631700 CCCAGGUGAUGGAUGGGAUG 10216 10859_5_140 LILRB1 EXON - xp19:54631681-54631701 UCCCAGGUGAUGGAUGGGAU 10217 10859_5_141 LILRB1 EXON - xp19:54631682-54631702 UUCCCAGGUGAUGGAUGGGA 10218 10859_5_144 LILRB1 EXON - xp19:54631686-54631706 UGUGUUCCCAGGUGAUGGAU 10219 10859_5_146 LILRB1 EXON - xp19:54631687-54631707 GUGUGUUCCCAGGUGAUGGA 10220 10859_5_148 LILRB1 EXON - xp19:54631691-54631711 CCCUGUGUGUUCCCAGGUGA 10221 10859_5_150 LILRB1 EXON - xp19:54631697-54631717 AUACCGCCCUGUGUGUUCCC 10222 10859_5_151 LILRB1 EXON - xp19:54631749-54631769 GGGGGUCACUGCUCUCUGAG 10223 10859_5_153 LILRB1 EXON - xp19:54631767-54631787 CUGUCACCACCAGCUCCAGG 10224 10859_5_154 LILRB1 EXON - xp19:54631768-54631788 CCUGUCACCACCAGCUCCAG 10225 10859_5_155 LILRB1 EXON - xp19:54631769-54631789 ACCUGUCACCACCAGCUCCA 10226 10859_5_157 LILRB1 EXON - xp19:54631770-54631790 CACCUGUCCACCACCAGCUCC 10227 10859_6_2 LILRB1 EXON + xp19:54631956-54631976 CUCAGCCCAGCCCAGCCCCG 10228 10859_6_6 LILRB1 EXON + xp19:54631966-54631986 CCCAGCCCCGUGGUGAACUC 10229 10859_6_8 LILRB1 EXON + xp19:54631969-54631989 AGCCCCGUGGUGAACUCAGG 10230 10859_6_10 LILRB1 EXON + xp19:54631970-54631990 GCCCCGUGGUGAACUCAGGA 10231 10859_6_12 LILRB1 EXON + xp19:54631998-54632018 AACCCUCCAGUGUGACUCAC 10232 10859_6_13 LILRB1 EXON + xp19:54632001-54632021 CCUCCAGUGUGACUCACAGG 10233 10859_6_14 LILRB1 EXON + xp19:54632011-54632031 GACUCACAGGUGGCAUUUGA 10234 10859_6_17 LILRB1 EXON + xp19:54632028-54632048 UGAUGGCUUCAUUCUGUGUA 10235 10859_6_21 LILRB1 EXON + xp19:54632032-54632052 GGCUUCAUUCUGUGUAAGGA 10236 10859_6_29 LILRB1 EXON + xp19:54632080-54632100 AACUCCCAGCCCCAUGCCCG 10237 10859_6_30 LILRB1 EXON + xp19:54632081-54632101 ACUCCCAGCCCCAUGCCCGU 10238 10859_6_32 LILRB1 EXON + xp19:54632106-54632126 GUCCCGCGCCAUCUUCUCCG 10239 10859_6_33 LILRB1 EXON + xp19:54632107-54632127 UCCCGCGCCAUCUUCUCCGU 10240 10859_6_37 LILRB1 EXON + xp19:54632129-54632149 GCCCCGUGAGCCCGAGUCGC 10241 10859_6_38 LILRB1 EXON + xp19:54632132-54632152 CCGUGAGCCCGAGUCCGCAGG 10242 10859_6_39 LILRB1 EXON + xp19:54632135-54632155 UGAGCCCGAGUCCGCAGGUGG 10243 10859_6_40 LILRB1 EXON + xp19:54632141-54632161 CGAGUCGCAGGUGGUGGUAC 10244 10859_6_44 LILRB1 EXON + xp19:54632177-54632197 ACUCGAACCUCCCUAUGAG 10245 10859_6_46 LILRB1 EXON + xp19:54632199-54632219 GUCCUUACCCAGUGAUCUCC 10246 10859_6_48 LILRB1 EXON + xp19:54632208-54632228 CAGUGAUCUCCUGGAGCUCC 10247 10859_6_49 LILRB1 EXON + xp19:54632215-54632235 CUCCUGGAGCUCCUGGUCCU 10248 10859_6_53 LILRB1 EXON - xp19:54631921-54631941 UAGGCUCCUAGGAGAGAAGG 10249 10859_6_57 LILRB1 EXON - xp19:54631924-54631944 AUGUAGGCUCCUAGGAGAGA 10250 10859_6_62 LILRB1 EXON - xp19:54631932-54631952 UGGGUUUGAUGUAGGCUCCU 10251 10859_6_65 LILRB1 EXON - xp19:54631940-54631960 UGAGAGGGUGGGUUUGAUGU 10252 10859_6_66 LILRB1 EXON - xp19:54631951-54631971 CUGGGCUGGGCUGAGAGGGU 10253 10859_6_67 LILRB1 EXON - xp19:54631952-54631972 GCUGGGCUGGGCUGAGAGGG 10254 10859_6_69 LILRB1 EXON - xp19:54631955-54631975 GGGGCUGGGCUGGGCUGAGA 10255 10859_6_70 LILRB1 EXON - xp19:54631956-54631976 CGGGGCUGGGCUGGGCUGAG 10256 10859_6_75 LILRB1 EXON - xp19:54631964-54631984 GUUCACCACGGGGCUGGGCU 10257 10859_6_76 LILRB1 EXON - xp19:54631965-54631985 AGUUCACCACGGGGCUGGGC 10258 10859_6_79 LILRB1 EXON - xp19:54631969-54631989 CCUGAGUUCACCACGGGGCU 10259 10859_6_80 LILRB1 EXON - xp19:54631970-54631990 UCCUGAGUUCACCACGGGGC 10260 10859_6_83 LILRB1 EXON - xp19:54631974-54631994 UCCCUCCUGAGUUCACCACG 10261 10859_6_84 LILRB1 EXON - xp19:54631975-54631995 UUCCCUCCUGAGUUCACAC 10262 10859_6_85 LILRB1 EXON - xp19:54631976-54631996 AUUCCCUCCUGAGUUCACCA 10263 10859_6_89 LILRB1 EXON - xp19:54632003-54632023 CACCUGUGAGUCACACUGGA 10264 10859_6_90 LILRB1 EXON - xp19:54632004-54632024 CCACCUGUGAGUCACACUGG 10265 10859_6_92 LILRB1 EXON - xp19:54632007-54632027 AUGCCACCUGUGAGUCAACAC 10266 10859_6_104 LILRB1 EXON - xp19:54632070-54632090 GCUGGGAGUUCAGGCAUUGU 10267 10859_6_105 LILRB1 EXON - xp19:54632071-54632091 GGCUGGGAGUUCAGGCAUUG 10268 10859_6_107 LILRB1 EXON - xp19:54632079-54632099 GGGCAUGGGGCUGGGAGUUC 10269 10859_6_108 LILRB1 EXON - xp19:54632087-54632107 CGACCCACGGGCAUGGGGCU 10270 10859_6_110 LILRB1 EXON - xp19:54632088-54632108 ACGACCCACGGGCAUGGGGC 10271 10859_6_113 LILRB1 EXON - xp19:54632092-54632112 CGGGACGACCCACGGGCAUG 10272 10859_6_114 LILRB1 EXON - xp19:54632093-54632113 GCGGGACGACCCACGGGCAU 10273 10859_6_116 LILRB1 EXON - xp19:54632094-54632114 CGCGGGACGACCCACGGGCA 10274 10859_6_118 LILRB1 EXON - xp19:54632099-54632119 GAUGGCGCGGGACGACCCAC 10275 10859_6_119 LILRB1 EXON - xp19:54632100-54632120 AGAUGGCGCGGGACGACCCA 10276 10859_6_121 LILRB1 EXON - xp19:54632111-54632131 GCCCACGGAGAAGAUGGCGC 10277 10859_6_123 LILRB1 EXON - xp19:54632112-54632132 GGCCCACGGAGAAGAUGGCG 10278 10859_6_125 LILRB1 EXON - xp19:54632117-54632137 CACGGGGCCCACGGAGAAGA 10279 10859_6_129 LILRB1 EXON - xp19:54632126-54632146 ACUCGGGCUCACGGGGCCCA 10280 10859_6_131 LILRB1 EXON - xp19:54632133-54632153 ACCUGCGACUCGGGCUCACG 10281 10859_6_132 LILRB1 EXON - xp19:54632134-54632154 CACCUGCGACUCGGGCUCAC 10282 10859_6_133 LILRB1 EXON - xp19:54632135-54632155 CCACCUGCGACUCGGGCUCA 10283 10859_6_136 LILRB1 EXON - xp19:54632142-54632162 UGUACCACCACCUGCGACUC 10284 10859_6_137 LILRB1 EXON - xp19:54632143-54632163 CUGUACCACCACCUGCGACU 10285 10859_6_143 LILRB1 EXON - xp19:54632191-54632211 CUGGGUAGAGACCACUCAUA 10286 10859_6_144 LILRB1 EXON - xp19:54632192-54632212 ACUGGGUAGAGACCACUCAU 10287 10859_6_148 LILRB1 EXON - xp19:54632209-54632229 AGGAGCUCCAGGAGAUCACCU 10288 10859_6_149 LILRB1 EXON - xp19:54632210-54632230 CAGGAGCUCCAGGAGAUCAC 10289 10859_6_154 LILRB1 EXON - xp19:54632220-54632240 CACCUAGGACCAGGAGCUCC 10290 10859_6_156 LILRB1 EXON - xp19:54632229-54632249 UGAAUUUCUCACCUAGGACC 10291 10859_6_159 LILRB1 EXON - xp19:54632235-54632255 AUGCUGUGAAUUUCUCACCU 10292 10859_7_7 LILRB1 EXON + xp19:54632477-54632497 CCAUCACUCUCAGUGCAGCC 10293 10859_7_8 LILRB1 EXON + xp19:54632488-54632508 AGUGCAGCCAGGUCCCUAUCG 10294 10859_7_12 LILRB1 EXON + xp19:54632497-54632517 AGGUCCUAUCGUGGCCCCUG 10295 10859_7_13 LILRB1 EXON + xp19:54632519-54632539 GAGACCCUGACUCUGCAGUG 10296 10859_7_14 LILRB1 EXON + xp19:54632531-54632551 CUGCAGUGUGGCUCUGAUGC 10297 10859_7_16 LILRB1 EXON + xp19:54632557-54632577 CAACAGAUUUGUUCUGUUA 10298 10859_7_18 LILRB1 EXON + xp19:54632561-54632581 AGAUUUGUUCUGUAUAAGGA 10299 10859_7_21 LILRB1 EXON + xp19:54632562-54632582 GAUUUGUUCUGUAUAAAGGAC 10300 10859_7_23 LILRB1 EXON + xp19:54632563-54632583 AUUUGUUCUGUAUAAGGACG 10301 10859_7_27 LILRB1 EXON + xp19:54632588-54632608 CGUGACUUCCUUCAGCUCGC 10302 10859_7_30 LILRB1 EXON + xp19:54632602-54632622 GCUCGCUGGCGCACAGCCCC 10303 10859_7_32 LILRB1 EXON + xp19:54632606-54632626 GCUGGCGCACAGCCCCAGGC 10304 10859_7_33 LILRB1 EXON + xp19:54632607-54632627 CUGGCGCACAGCCCCAGGCU 10305 10859_7_34 LILRB1 EXON + xp19:54632617-54632637 GCCCCAGGCUGGGCUCUCCC 10306 10859_7_36 LILRB1 EXON + xp19:54632632-54632652 CUCCCAGGCCAACCUUCACCC 10307 10859_7_37 LILRB1 EXON + xp19:54632633-54632653 UCCCAGGCCAACCUUCACCCCU 10308 10859_7_42 LILRB1 EXON + xp19:54632654-54632674 GGCCCUGUGAGCCGCUCCUA 10309 10859_7_43 LILRB1 EXON + xp19:54632655-54632675 GCCCUGUGAGCCGCUCCUAC 10310 10859_7_45 LILRB1 EXON + xp19:54632656-54632676 CCCUGUGAGCCGCUCCUACG 10311 10859_7_46 LILRB1 EXON + xp19:54632657-54632677 CCUGUGAGCCGCUCCUACGG 10312 10859_7_47 LILRB1 EXON + xp19:54632675-54632695 GGGGGCCAGUACAGAUGCUA 10313 10859_7_49 LILRB1 EXON + xp19:54632700-54632720 CACACAACCUCUCCUCCGAG 10314 10859_7_50 LILRB1 EXON + xp19:54632704-54632724 CAACCUCUCCUCCGAGUGGU 10315 10859_7_52 LILRB1 EXON + xp19:54632722-54632742 GUCGGCCCCCAGCGACCCCC 10316 10859_7_53 LILRB1 EXON + xp19:54632738-54632758 CCCCUGGACAUCCUGAUCGC 10317 10859_7_56 LILRB1 EXON + xp19:54632743-54632763 GGACAUCCUGAUCGCAGGUG 10318 10859_7_59 LILRB1 EXON + xp19:54632753-54632773 AUCGCAGGUGAGGAGCCCAG 10319 10859_7_60 LILRB1 EXON + xp19:54632754-54632774 UCGCAGGUGAGGAGCCCAGC 10320 10859_7_61 LILRB1 EXON - xp19:54632446-54632466 CACCUGGGAAAAGGUGGUCA 10321 10859_7_64 LILRB1 EXON - xp19:54632452-54632472 UAGAAACACCUGGGAAAAGG 10322 10859_7_65 LILRB1 EXON - xp19:54632455-54632475 UCUUAGAAAACCUGGGAAA 10323 10859_7_66 LILRB1 EXON - xp19:54632461-54632481 AUGGCUUCUUGAAAACACCU 10324 10859_7_68 LILRB1 EXON - xp19:54632462-54632482 GAUGGCUUCUUAGAAACACC 10325 10859_7_72 LILRB1 EXON - xp19:54632480-54632500 CCUGGCUGCACUGAGAGUGA 10326 10859_7_75 LILRB1 EXON - xp19:54632498-54632518 UCAGGGGCCACGAUAGGACC 10327 10859_7_76 LILRB1 EXON - xp19:54632504-54632524 GUCUCCUCAGGGGCCACGAU 10328 10859_7_78 LILRB1 EXON - xp19:54632514-54632534 CAGAGUCAGGGUCUCCUCAG 10329 10859_7_79 LILRB1 EXON - xp19:54632515-54632535 GCAGAGUCAGGGUCUCCUCA 10330 10859_7_80 LILRB1 EXON - xp19:54632516-54632536 UGCAGAGUCAGGGUCUCCUC 10331 10859_7_83 LILRB1 EXON - xp19:54632526-54632546 AGAGCCACACUGCAGAGUCA 10332 10859_7_84 LILRB1 EXON - xp19:54632527-54632547 CAGAGCCACACUGCAGAGUC 10333 10859_7_93 LILRB1 EXON - xp19:54632599-54632619 GCUGUGCCGCCAGCGAGCUGA 10334 10859_7_99 LILRB1 EXON - xp19:54632621-54632641 GCCUGGGAGAGCCCAGCCUG 10335 10859_7_100 LILRB1 EXON - xp19:54632622-54632642 GGCCUGGGAGAGCCCAGCCU 10336 10859_7_102 LILRB1 EXON - xp19:54632623-54632643 UGGCCUGGGAGAGCCCAGCC 10337 10859_7_106 LILRB1 EXON - xp19:54632637-54632657 GCCCAGGGUGAAGUUGGCCU 10338 10859_7_107 LILRB1 EXON - xp19:54632638-54632658 GGCCCAGGGUGAAGUUGGCC 10339 10859_7_110 LILRB1 EXON - xp19:54632643-54632663 CACAGGGCCCAGGGUGAAGU 10340 10859_7_112 LILRB1 EXON - xp19:54632652-54632672 GGAGCGGCUCACAGGGCCCA 10341 10859_7_113 LILRB1 EXON - xp19:54632653-54632673 AGGAGCGGCUCACAGGGCCC 10342 10859_7_115 LILRB1 EXON - xp19:54632659-54632679 CCCCGUAGGAGCGGCUCACA 10343 10859_7_116 LILRB1 EXON - xp19:54632660-54632680 CCCCCGUAGGAGCGGCUCAC 10344 10859_7_118 LILRB1 EXON - xp19:54632668-54632688 UGUACUGGCCCCCGUAGGAG 10345 10859_7_119 LILRB1 EXON - xp19:54632673-54632693 GCAUCUGUACUGGCCCCCGU 10346 10859_7_123 LILRB1 EXON - xp19:54632683-54632703 GUGCACCGUAGCAUCUGUAC 10347 10859_7_124 LILRB1 EXON - xp19:54632710-54632730 GGGCCGACCACUCGGAGGAG 10348 10859_7_126 LILRB1 EXON - xp19:54632715-54632735 GCUGGGGGCCGACCACUCGG 10349 10859_7_129 LILRB1 EXON - xp19:54632718-54632738 GUCGCUGGGGGCCGACCACU 10350 10859_7_132 LILRB1 EXON - xp19:54632730-54632750 GAUGUCCAGGGGGUCGCUGG 10351 10859_7_133 LILRB1 EXON - xp19:54632731-54632751 GGAUGUCCAGGGGGUCGCUG 10352 10859_7_135 LILRB1 EXON - xp19:54632732-54632752 AGGAUGUCCAGGGGGUCGCU 10353 10859_7_137 LILRB1 EXON - xp19:54632733-54632753 CAGGAUGUCCAGGGGGUCCGC 10354 10859_7_139 LILRB1 EXON - xp19:54632740-54632760 CUGCGAUCAGGAUGUCCAGG 10355 10859_7_140 LILRB1 EXON - xp19:54632741-54632761 CCUGCGAUCAGGAUGUCCAG 10356 10859_7_141 LILRB1 EXON - xp19:54632742-54632762 ACCUGCGAUCAGGAUGUCCA 10357 10859_7_144 LILRB1 EXON - xp19:54632743-54632763 CACCUGCGAUCAGGAUGUCC 10358 10859_7_146 LILRB1 EXON - xp19:54632752-54632772 UGGGCUCCUCACCUGCGAUC 10359 10859_8_4 LILRB1 EXON + xp19:54633022-54633042 CUAUGACAGAGUCUCCCUCU 10360 10859_8_7 LILRB1 EXON + xp19:54633031-54633051 AGUCUCCCUCUCGGUGCAGC 10361 10859_8_8 LILRB1 EXON + xp19:54633032-54633052 GUCUCCCUCUCGGUGCAGCC 10362 10859_8_9 LILRB1 EXON + xp19:54633040-54633060 CUCGGUGCAGCCGGGCCCCA 10363 10859_8_10 LILRB1 EXON + xp19:54633043-54633063 GGUGCAGCCGGGCCCCACGG 10364 10859_8_13 LILRB1 EXON + xp19:54633050-54633070 CCGGGCCCCACGGUGGCCUC 10365 10859_8_17 LILRB1 EXON + xp19:54633082-54633102 GACCCUGCUGUGUGUCAGUCAC 10366 10859_8_19 LILRB1 EXON + xp19:54633083-54633103 ACCCUGCUGUGUCAGUCACA 10367 10859_8_21 LILRB1 EXON + xp19:54633087-54633107 UGCUGUGUGUCAGUCACAGGGA 10368 10859_8_23 LILRB1 EXON + xp19:54633112-54633132 GCAAACUUUCCUUCUGACCCA 10369 10859_8_26 LILRB1 EXON + xp19:54633115-54633135 AACUUUCCUUCUGACCAAGG 10370 10859_8_28 LILRB1 EXON + xp19:54633116-54633136 ACUUUCCUUCUGACCAAGGA 10371 10859_8_30 LILRB1 EXON + xp19:54633117-54633137 CUUUCCUUCUGACCAAGGAG 10372 10859_8_31 LILRB1 EXON + xp19:54633118-54633138 UUUCCUUCUGACCAAGGAGG 10373 10859_8_35 LILRB1 EXON + xp19:54633135-54633155 AGGGGGCAGCUGAUGACCCA 10374 10859_8_36 LILRB1 EXON + xp19:54633172-54633192 GUACCAAUCUCAAAAAUACC 10375 10859_8_39 LILRB1 EXON + xp19:54633187-54633207 AUACCAGGCUGAAUUCCCCA 10376 10859_8_40 LILRB1 EXON + xp19:54633188-54633208 UACCAGGCUGAAUUCCCCAU 10377 10859_8_44 LILRB1 EXON + xp19:54633211-54633231 UCCUGUGACCUCAGCCCAUG 10378 10859_8_46 LILRB1 EXON + xp19:54633212-54633232 CCUGUGACCUCAGCCCAUGC 10379 10859_8_47 LILRB1 EXON + xp19:54633213-54633233 CUGUGACCUCAGCCCAUGCG 10380 10859_8_48 LILRB1 EXON + xp19:54633222-54633242 CAGCCCAUGCGGGGACCUAC 10381 10859_8_49 LILRB1 EXON + xp19:54633230-54633250 GCGGGGACCUACAGGUGCUA 10382 10859_8_52 LILRB1 EXON + xp19:54633280-54633300 GACUCACCCCAGUGACCCCCC 10383 10859_8_54 LILRB1 EXON + xp19:54633289-54633309 CAGUGACCCCCUGGAGCUCG 10384 10859_8_55 LILRB1 EXON + xp19:54633296-54633316 CCCCUGGAGCUCGUGGUCUC 10385 10859_8_58 LILRB1 EXON + xp19:54633299-54633319 CUGGAGCUCGUGGUCUCAGG 10386 10859_8_59 LILRB1 EXON + xp19:54633300-54633320 UGGAGCUCGUGGUCUCAGGU 10387 10859_8_61 LILRB1 EXON + xp19:54633301-54633321 GGAGCUCGUGGUCUCAGGUG 10388 10859_8_62 LILRB1 EXON + xp19:54633302-54633322 GAGCUCGUGGUCUCAGGUGG 10389 10859_8_63 LILRB1 EXON - xp19:54632998-54633018 GUCCUGGAGAGAAGAAGGAU 10390 10859_8_64 LILRB1 EXON - xp19:54632999-54633019 UGUCCUGGAGAGAAGGAAGGA 10391 10859_8_66 LILRB1 EXON - xp19:54633003-54633023 GAACUGUCCCUGGAGAGAAGA 10392 10859_8_74 LILRB1 EXON - xp19:54633014-54633034 ACUCUGUCAUAGAACUGUCC 10393 10859_8_79 LILRB1 EXON - xp19:54633039-54633059 GGGGCCCGGCUGCACCGAGA 10394 10859_8_81 LILRB1 EXON - xp19:54633040-54633060 UGGGGCCCGGCUGCACCGAG 10395 10859_8_86 LILRB1 EXON - xp19:54633053-54633073 CCUGAGGCCACCGUGGGGCC 10396 10859_8_87 LILRB1 EXON - xp19:54633058-54633078 UCUCUCCUGAGGCCACCGUG 10397 10859_8_88 LILRB1 EXON - xp19:54633059-54633079 UUCUCUCCUGAGGCCACCGU 10398 10859_8_90 LILRB1 EXON - xp19:54633060-54633080 GUUCUCUCCUGAGGCCACCG 10399 10859_8_92 LILRB1 EXON - xp19:54633069-54633089 CAGGGUCACGUUCUCUCCUG 10400 10859_8_94 LILRB1 EXON - xp19:54633087-54633107 UCCCUGUGACUGACACAGCA 10401 10859_8_95 LILRB1 EXON - xp19:54633088-54633108 AUCCCUGUGACUGACACAGC 10402 10859_8_100 LILRB1 EXON - xp19:54633124-54633144 CUGCCCCCUCCUUGGUCAGA 10403 10859_8_105 LILRB1 EXON - xp19:54633132-54633152 GUCAUCAGCUGCCCCCUCCU 10404 10859_8_109 LILRB1 EXON - xp19:54633154-54633174 ACGUUGAUCUUAGACGCCAU 10405 10859_8_110 LILRB1 EXON - xp19:54633155-54633175 UACGUUGAUCUUAGACGCCA 10406 10859_8_117 LILRB1 EXON - xp19:54633178-54633198 CAGCCUGGUAUUUUUGAGAU 10407 10859_8_119 LILRB1 EXON - xp19:54633193-54633213 GACCCAUGGGGAAUUCAGCC 10408 10859_8_120 LILRB1 EXON - xp19:54633205-54633225 CUGAGGUCACAAGGACCCAUG 10409 10859_8_123 LILRB1 EXON - xp19:54633206-54633226 GCUGAGGUCACAGGACCCAU 10410 10859_8_125 LILRB1 EXON - xp19:54633207-54633227 GGCUGAGGUCACAGGACCCA 10411 10859_8_127 LILRB1 EXON - xp19:54633215-54633235 CCCGCAUGGGCUGAGGUCAC 10412 10859_8_129 LILRB1 EXON - xp19:54633222-54633242 GUAGGUCCCCGCAUGGGCUG 10413 10859_8_131 LILRB1 EXON - xp19:54633228-54633248 GCACCUGUAGGUCCCCGCAU 10414 10859_8_132 LILRB1 EXON - xp19:54633229-54633249 AGCACCUGUAGGUCCCCCGCA 10415 10859_8_134 LILRB1 EXON - xp19:54633240-54633260 CUGUGAGCCGUAGCACCUGU 10416 10859_8_139 LILRB1 EXON - xp19:54633267-54633287 GUGAGUCAGCAGGUAGGGUU 10417 10859_8_141 LILRB1 EXON - xp19:54633272-54633292 CUGGGGUGAGUCAGCAGGUA 10418 10859_8_142 LILRB1 EXON - xp19:54633273-54633293 ACUGGGGUGAGUCAGCAGGU 10419 10859_8_144 LILRB1 EXON - xp19:54633277-54633297 GGUCACUGGGGUGAGUCAGC 10420 10859_8_146 LILRB1 EXON - xp19:54633289-54633309 CGAGCUCCAGGGGGUCACUG 10421 10859_8_147 LILRB1 EXON - xp19:54633290-54633310 ACGAGCUCCAGGGGGUCACU 10422 10859_8_149 LILRB1 EXON - xp19:54633291-54633311 CACGAGCUCCAGGGGGUCAC 10423 10859_8_151 LILRB1 EXON - xp19:54633298-54633318 CUGAGACCACGAGCUCCAGG 10424 10859_8_152 LILRB1 EXON - xp19:54633299-54633319 CCUGAGACCACGAGCUCCAG 10425 10859_8_153 LILRB1 EXON - xp19:54633300-54633320 ACCUGAGACCACGAGCUCCA 10426 10859_8_156 LILRB1 EXON - xp19:54633301-54633321 CACCUGAGACCACGAGCUCC 10427 10859_9_2 LILRB1 EXON + xp19:54633624-54633644 UUCUUUUACCCAGGACCGUC 10428 10859_9_5 LILRB1 EXON + xp19:54633625-54633645 UCUUUUACCCAGGACCGUCU 10429 10859_9_6 LILRB1 EXON + xp19:54633626-54633646 CUUUUACCCAGGACCGUCUG 10430 10859_9_7 LILRB1 EXON + xp19:54633627-54633647 UUUUACCCAGGACCGUCUGG 10431 10859_9_12 LILRB1 EXON + xp19:54633648-54633668 GGCCCCAGCUCCCCGACAAC 10432 10859_9_13 LILRB1 EXON + xp19:54633666-54633686 ACAGGCCCCACCUCCACAUC 10433 10859_9_16 LILRB1 EXON + xp19:54633679-54633699 CCACAUCUGGUGAGUCCCUG 10434 10859_9_17 LILRB1 EXON - xp19:54633620-54633640 GUCCUGGGUAAAAGAAUGAG 10435 10859_9_21 LILRB1 EXON - xp19:54633635-54633655 UGGGGCCCCCAGACGGUCCU 10436 10859_9_22 LILRB1 EXON - xp19:54633636-54633656 CUGGGGCCCCCAGACGGUCC 10437 10859_9_25 LILRB1 EXON - xp19:54633642-54633662 GGGGAGCUGGGGCCCCCAGA 10438 10859_9_26 LILRB1 EXON - xp19:54633653-54633673 GGCCUGUUGUCGGGGAGCUG 10439 10859_9_27 LILRB1 EXON - xp19:54633654-54633674 GGGCCUGUUGUCGGGGAGCU 10440 10859_9_28 LILRB1 EXON - xp19:54633655-54633675 GGGGCCUGUUGUCGGGGAGC 10441 10859_9_31 LILRB1 EXON - xp19:54633661-54633681 GGAGGUGGGGCCUGUUGUCG 10442 10859_9_34 LILRB1 EXON - xp19:54633662-54633682 UGGAGGUGGGGCCUGUUGUC 10443 10859_9_36 LILRB1 EXON - xp19:54633663-54633683 GUGGAGGUGGGGCCUGUUGU 10444 10859_9_38 LILRB1 EXON - xp19:54633674-54633694 ACUCACCAGAUGUGGAGGUG 10445 10859_9_39 LILRB1 EXON - xp19:54633675-54633695 GACUCACCAGAUGUGGAGGU 10446 10859_9_41 LILRB1 EXON - xp19:54633676-54633696 GGACUCACCAGAUGUGGAGG 10447 10859_9_43 LILRB1 EXON - xp19:54633679-54633699 CAGGGACUCACCAGAUGUGG 10448 10859_9_44 LILRB1 EXON - xp19:54633682-54633702 CCUCAGGGACUCACCAGAUG 10449 10859_10_1 LILRB1 EXON + xp19:54633951-54633971 CCUCCCCGUCCUGACCCAGC 10450 10859_10_4 LILRB1 EXON + xp19:54633959-54633979 UCCUGACCCAGCAGGCCCUG 10451 10859_10_6 LILRB1 EXON + xp19:54633981-54634001 GACCAGCCCCUCACCCCCAC 10452 10859_10_7 LILRB1 EXON + xp19:54633982-54634002 ACCAGCCCCUCACCCCCACC 10453 10859_10_9 LILRB1 EXON + xp19:54633986-54634006 GCCCCUCACCCCCACCGGGU 10454 10859_10_11 LILRB1 EXON + xp19:54633999-54634019 ACCGGGUCGGAUCCCAGAG 10455 10859_10_14 LILRB1 EXON + xp19:54634009-54634029 AUCCCCAGAGUGGUGAGUGA 10456 10859_10_15 LILRB1 EXON + xp19:54634010-54634030 UCCCCAGAGUGGUGAGUGAC 10457 10859_10_18 LILRB1 EXON + xp19:54634020-54634040 GGUGAGUGACGGGCUCUGAG 10458 10859_10_21 LILRB1 EXON + xp19:54634021-54634041 GUGAGUGACGGGCUCUGAGU 10459 10859_10_22 LILRB1 EXON + xp19:54634024-54634044 AGUGACGGGCUCUGAGUGGG 10460 10859_10_24 LILRB1 EXON + xp19:54634027-54634047 GACGGGCUCUGAGUGGGAGG 10461 10859_10_25 LILRB1 EXON + xp19:54634028-54634048 ACGGGCUCUGAGUGGGAGGU 10462 10859_10_27 LILRB1 EXON + xp19:54634032-54634052 GCUCUGAGUGGGAGGUGGGC 10463 10859_10_28 LILRB1 EXON + xp19:54634033-54634053 CUCUGAGUGGGAGGUGGGCA 10464 10859_10_29 LILRB1 EXON - xp19:54633954-54633974 CCUGCUGGGUCAGGACGGGG 10465 10859_10_30 LILRB1 EXON - xp19:54633957-54633977 GGGCCUGCUGGGUCAGGACG 10466 10859_10_32 LILRB1 EXON - xp19:54633958-54633978 AGGGCCUGCUGGGUCAGGAC 10467 10859_10_34 LILRB1 EXON - xp19:54633959-54633979 CAGGGCCUGCUGGGUCAGGA 10468 10859_10_37 LILRB1 EXON - xp19:54633963-54633983 UCCUCAGGGCCUGCUGGGUC 10469 10859_10_39 LILRB1 EXON - xp19:54633968-54633988 GCUGGUCCUCAGGGCCUGCU 10470 10859_10_40 LILRB1 EXON - xp19:54633969-54633989 GGCUGGUCCUCAGGGCCUGC 10471 10859_10_42 LILRB1 EXON - xp19:54633977-54633997 GGGUGAGGGGCUGGUCCUCCA 10472 10859_10_43 LILRB1 EXON - xp19:54633978-54633998 GGGGUGAGGGGCUGGUCCUC 10473 10859_10_45 LILRB1 EXON - xp19:54633986-54634006 ACCCGGUGGGGGUGAGGGGC 10474 10859_10_46 LILRB1 EXON - xp19:54633990-54634010 UCCGACCCGGUGGGGGUGAG 10475 10859_10_47 LILRB1 EXON - xp19:54633991-54634011 AUCCGACCCGGUGGGGGUGA 10476 10859_10_48 LILRB1 EXON - xp19:54633992-54634012 GAUCCGACCCGGUGGGGGUG 10477 10859_10_52 LILRB1 EXON - xp19:54633997-54634017 CUGGGGAUCCGACCCGGUGG 10478 10859_10_53 LILRB1 EXON - xp19:54633998-54634018 UCUGGGGAUCCGACCCGGUG 10479 10859_10_55 LILRB1 EXON - xp19:54633999-54634019 CUCUGGGGAUCCGACCCGGU 10480 10859_10_57 LILRB1 EXON - xp19:54634000-54634020 ACUCUGGGGAUCCGACCCGG 10481 10859_10_59 LILRB1 EXON - xp19:54634003-54634023 ACCACUCUGGGGAUCCGACC 10482 10859_10_60 LILRB1 EXON - xp19:54634014-54634034 GCCCGUCACUCACCACUCUG 10483 10859_10_62 LILRB1 EXON - xp19:54634015-54634035 AGCCCGUCACUCACCACUCU 10484 10859_10_64 LILRB1 EXON - xp19:54634016-54634036 GAGCCCGUCACUCACCACUC 10485 10859_10_67 LILRB1 EXON - xp19:54634060-54634080 CUUGGGUGGGGACGGAGGGC 10486 10859_11_2 LILRB1 EXON + xp19:54634623-54634643 ACAUCAUCGUGCUCAAGGUC 10487 10859_11_4 LILRB1 EXON + xp19:54634624-54634644 CAUCAUCGUGCUCAAGGUCU 10488 10859_11_6 LILRB1 EXON + xp19:54634628-54634648 AUCGUGCUCAAGGUCUGGGA 10489 10859_11_9 LILRB1 EXON + xp19:54634635-54634655 UCAAGGUCUGGGAAGGCACC 10490 10859_11_11 LILRB1 EXON + xp19:54634636-54634656 CAAGGUCUGGGAAGGCACCU 10491 10859_11_12 LILRB1 EXON + xp19:54634637-54634657 AAGGUCUGGGAAGGCACCUG 10492 10859_11_13 LILRB1 EXON + xp19:54634638-54634658 AGGUCUGGGAAGGCACCUGG 10493 10859_11_14 LILRB1 EXON + xp19:54634648-54634668 AGGCACCUGGGGGUUGUGAU 10494 10859_11_15 LILRB1 EXON + xp19:54634656-54634676 GGGGGUUGUGUGAUCGGCAUCU 10495 10859_11_16 LILRB1 EXON + xp19:54634659-54634679 GGUUGUGAUCGGCAUCUUGG 10496 10859_11_20 LILRB1 EXON + xp19:54634722-54634742 CAUCCUCCGACAUCGACGUC 10497 10859_11_21 LILRB1 EXON + xp19:54634723-54634743 AUCCUCCGACAUCGACGUCA 10498 10859_11_23 LILRB1 EXON + xp19:54634733-54634753 AUCGACGUCAGGGCAAACAC 10499 10859_11_28 LILRB1 EXON + xp19:54634749-54634769 ACACUGGACAUCGAGUGAGU 10500 10859_11_29 LILRB1 EXON + xp19:54634750-54634770 CACUGGACAUCGAGUGAGUA 10501 10859_11_32 LILRB1 EXON + xp19:54634755-54634775 GACAUCGAGUGAGUAGGGAA 10502 10859_11_35 LILRB1 EXON + xp19:54634756-54634776 ACAUCGAGUGAGUAGGGAAU 10503 10859_11_36 LILRB1 EXON + xp19:54634757-54634777 CAUCGAGUGAGUAGGGAAUG 10504 10859_11_38 LILRB1 EXON + xp19:54634758-54634778 AUCGAGUGAGUAGGGAAUGG 10505 10859_11_40 LILRB1 EXON + xp19:54634759-54634779 UCGAGUGAGUAGGGAAUGGG 10506 10859_11_43 LILRB1 EXON - xp19:54634656-54634676 AGAUGCCGAUCACAACCCCC 10507 10859_11_44 LILRB1 EXON - xp19:54634685-54634705 CUCCUCCUCCAGUAGGAUGA 10508 10859_11_45 LILRB1 EXON - xp19:54634692-54634712 CCUCCUCCUCCUCCUCCAGU 10509 10859_12_4 LILRB1 EXON + xp19:54635092-54635112 UCUUCCCCCAGCCCAGAGAA 10510 10859_12_8 LILRB1 EXON + xp19:54635114-54635134 GCUGAUUUCCAACAUCCUGC 10511 10859_12_10 LILRB1 EXON + xp19:54635115-54635135 CUGAUUUCCAACAUCCUGCA 10512 10859_12_11 LILRB1 EXON + xp19:54635116-54635136 UGAUUUCCAACAUCCUGCAG 10513 10859_12_15 LILRB1 EXON + xp19:54635122-54635142 CCAACAUCCUGCAGGGGCUG 10514 10859_12_16 LILRB1 EXON + xp19:54635123-54635143 CAACAUCCUGCAGGGGCUGU 10515 10859_12_18 LILRB1 EXON + xp19:54635124-54635144 AACAUCCUGCAGGGGCUGUG 10516 10859_12_21 LILRB1 EXON + xp19:54635144-54635164 GGGCCAGAGCCCACAGACAG 10517 10859_12_24 LILRB1 EXON + xp19:54635154-54635174 CCACAGACAGAGGCCUGCAG 10518 10859_12_25 LILRB1 EXON + xp19:54635157-54635177 CAGACAGAGGCCUGCAGUGG 10519 10859_12_30 LILRB1 EXON - xp19:54635092-54635112 UUCUCUGGGCUGGGGGAAGA 10520 10859_12_35 LILRB1 EXON - xp19:54635099-54635119 UCAGCCUUUCUCUGGGCUGG 10521 10859_12_37 LILRB1 EXON - xp19:54635100-54635120 AUCAGCCUUUCUCUGGGCUG 10522 10859_12_40 LILRB1 EXON - xp19:54635101-54635121 AAUCAGCCUUUCUCUGGGCU 10523 10859_12_42 LILRB1 EXON - xp19:54635102-54635122 AAAUCAGCCUUUCUCUGGGC 10524 10859_12_44 LILRB1 EXON - xp19:54635106-54635126 UUGGAAAAUCAGCCUUUCUCU 10525 10859_12_45 LILRB1 EXON - xp19:54635107-54635127 GUUGGAAAAUCAGCCUUUCUC 10526 10859_12_48 LILRB1 EXON - xp19:54635125-54635145 CCACAGCCCCUGCAGGAUGU 10527 10859_12_50 LILRB1 EXON - xp19:54635132-54635152 UCUGGCCCCACAGCCCCUGC 10528 10859_12_52 LILRB1 EXON - xp19:54635150-54635170 AGGCCUCUGUCUGUGGGCUC 10529 10859_12_53 LILRB1 EXON - xp19:54635156-54635176 CACUGCAGGCCUCUGUCUGU 10530 10859_12_55 LILRB1 EXON - xp19:54635157-54635177 CCACUGCAGGCCUCUGUCUG 10531 10859_12_58 LILRB1 EXON - xp19:54635170-54635190 GGCAGAAUUACCUCCACUGC 10532 10859_13_5 LILRB1 EXON + xp19:54635261-54635281 CAGCCCAGCUGCCGAUGCCC 10533 10859_13_13 LILRB1 EXON + xp19:54635285-54635305 AGAAAACCUCUGUGAGUGAG 10534 10859_13_15 LILRB1 EXON + xp19:54635291-54635311 CCUCUGUGAGUGAGAGGAAG 10535 10859_13_16 LILRB1 EXON - xp19:54635245-54635265 GCUGGACCUGGGGGAAGAAU 10536 10859_13_19 LILRB1 EXON - xp19:54635246-54635266 GGCUGGACCUGGGGGAAGAA 10537 10859_13_23 LILRB1 EXON - xp19:54635254-54635274 GGCAGCUGGGCUGGACCUGG 10538 10859_13_25 LILRB1 EXON - xp19:54635255-54635275 CGGCAGCUGGGCUGGACCUG 10539 10859_13_27 LILRB1 EXON - xp19:54635256-54635276 UCGGCAGCUGGGCUGGACCU 10540 10859_13_28 LILRB1 EXON - xp19:54635257-54635277 AUCGGCAGCUGGGCUGGACC 10541 10859_13_33 LILRB1 EXON - xp19:54635263-54635283 CUGGGCAUCGGCAGCUGGGC 10542 10859_13_37 LILRB1 EXON - xp19:54635267-54635287 CUUCCUGGGCAUCGGCAGCU 10543 10859_13_38 LILRB1 EXON - xp19:54635268-54635288 UCUUCCUGGGCAUCGGCAGC 10544 10859_13_40 LILRB1 EXON - xp19:54635275-54635295 GAGGUUUCUUCCUGGGCAU 10545 10859_13_41 LILRB1 EXON - xp19:54635281-54635301 CUCACAGAGGUUUUCUUCCU 10546 10859_13_42 LILRB1 EXON - xp19:54635282-54635302 ACUCACAGAGGUUUUCUUCC 10547 10859_13_45 LILRB1 EXON - xp19:54635294-54635314 CCUCUUCCUCUCACUCACAG 10548 10859_14_5 LILRB1 EXON + xp19:54635563-54635583 CGUGAAGCACACACAGCCUG 10549 10859_14_7 LILRB1 EXON + xp19:54635567-54635587 AAGCACACACAGCCUGAGGA 10550 10859_14_9 LILRB1 EXON + xp19:54635568-54635588 AGCACACACAGCCUGAGGAU 10551 10859_14_10 LILRB1 EXON + xp19:54635569-54635589 GCACACACAGCCUGAGGAUG 10552 10859_14_12 LILRB1 EXON + xp19:54635572-54635592 CACACAGCCUGAGGAUGGGG 10553 10859_14_15 LILRB1 EXON + xp19:54635578-54635598 GCCUGAGGAUGGGGUGGAGA 10554 10859_14_17 LILRB1 EXON + xp19:54635586-54635606 AUGGGGUGGAGAUGGACACU 10555 10859_14_18 LILRB1 EXON + xp19:54635587-54635607 UGGGGUGGAGAUGGACACUC 10556 10859_14_20 LILRB1 EXON - xp19:54635539-54635559 CAUCUGCUGGGGCAGAGCAA 10557 10859_14_21 LILRB1 EXON - xp19:54635540-54635560 GCAUCUGCUGGGGCAGAGCA 10558 10859_14_25 LILRB1 EXON - xp19:54635550-54635570 CUUCACGGCAGCAUCUGCUG 10559 10859_14_26 LILRB1 EXON - xp19:54635551-54635571 GCUUCACGGCAGCAUCUGCU 10560 10859_14_28 LILRB1 EXON - xp19:54635552-54635572 UGCUUCACGGCAGCAUCUGC 10561 10859_14_30 LILRB1 EXON - xp19:54635565-54635585 CUCAGGCUGUGUGUGCUUCA 10562 10859_14_31 LILRB1 EXON - xp19:54635582-54635602 UCCAUCUCCACCCCAUCCUC 10563 10859_15_3 LILRB1 EXON + xp19:54636498-54636518 CCCACACGAUGAAGACCCCC 10564 10859_15_5 LILRB1 EXON + xp19:54636516-54636536 CCAGGCAGUGACGUAUGCCG 10565 10859_15_8 LILRB1 EXON + xp19:54636536-54636556 AGGUGAAACACUCCAGACCU 10566 10859_15_13 LILRB1 EXON + xp19:54636546-54636566 CUCCAGACCUAGGAGAGAAA 10567 10859_15_15 LILRB1 EXON + xp19:54636571-54636591 UCUCCUCCUUCCCCACUGUC 10568 10859_15_17 LILRB1 EXON + xp19:54636572-54636592 CUCCUCCUUCCCCACUGUCU 10569 10859_15_20 LILRB1 EXON + xp19:54636573-54636593 UCCUCCUUCCCCACUGUCUG 10570 10859_15_23 LILRB1 EXON + xp19:54636582-54636602 CCCACUGUCUGGGGAAUUCC 10571 10859_15_25 LILRB1 EXON + xp19:54636591-54636611 UGGGGAAUUCCUGGACACAAA 10572 10859_15_26 LILRB1 EXON + xp19:54636600-54636620 CCUGGACACAAAAGGACAGAC 10573 10859_15_29 LILRB1 EXON + xp19:54636603-54636623 GGACACAAAAGGACAGACAGG 10574 10859_15_33 LILRB1 EXON + xp19:54636609-54636629 AAAGGACAGACAAGGCGGAAG 10575 10859_15_34 LILRB1 EXON + xp19:54636614-54636634 ACAGACAGGCGGAAGAGGAC 10576 10859_15_36 LILRB1 EXON + xp19:54636621-54636641 GGCGGAAGAGGACAGGCAGA 10577 10859_15_38 LILRB1 EXON + xp19:54636630-54636650 GGACAGGCAGAUGGACACUG 10578 10859_15_40 LILRB1 EXON - xp19:54636476-54636496 CUGCUGGAGAGAGACAGUGG 10579 10859_15_41 LILRB1 EXON - xp19:54636479-54636499 GCUCUGCUGGAGAGAGACAG 10580 10859_15_46 LILRB1 EXON - xp19:54636492-54636512 CUUCAUCGUGUGGGCUCUGC 10581 10859_15_48 LILRB1 EXON - xp19:54636501-54636521 CCUGGGGGUCUUCAUCGUGU 10582 10859_15_49 LILRB1 EXON - xp19:54636502-54636522 GCCUGGGGGUCUUCAUCGUG 10583 10859_15_51 LILRB1 EXON - xp19:54636516-54636536 CGGCAUACGUCACUGCCUGG 10584 10859_15_52 LILRB1 EXON - xp19:54636517-54636537 UCGGCAUACGUCACUGCCUG 10585 10859_15_55 LILRB1 EXON - xp19:54636518-54636538 CUCGGCAUACGUCACUGCCU 10586 10859_15_58 LILRB1 EXON - xp19:54636519-54636539 CCUCGGCAUACGUCACUGCC 10587 10859_15_60 LILRB1 EXON - xp19:54636536-54636556 AGGUCUGGAGUGUUUCACCU 10588 10859_15_63 LILRB1 EXON - xp19:54636551-54636571 GGCCAUUUCUCUCCUAGGUC 10589 10859_15_66 LILRB1 EXON - xp19:54636556-54636576 GGAGAGGCCAUUUCUCUCCU 10590 10859_15_68 LILRB1 EXON - xp19:54636572-54636592 AGACAGUGGGGAAGGAGGAG 10591 10859_15_70 LILRB1 EXON - xp19:54636577-54636597 UCCCCAGACAGUGGGGAAGG 10592 10859_15_74 LILRB1 EXON - xp19:54636580-54636600 AAUUCCCCAGACAGUGGGGA 10593 10859_15_76 LILRB1 EXON - xp19:54636584-54636604 CAGGAAUUCCCCAGACAGUG 10594 10859_15_80 LILRB1 EXON - xp19:54636585-54636605 CCAGGAAUUCCCCAGACAGU 10595 10859_15_82 LILRB1 EXON - xp19:54636586-54636606 UCCAGGAAUUCCCCAGACAG 10596 10859_15_87 LILRB1 EXON - xp19:54636603-54636623 CCUGUCUGUCCCUUUGUGUCC 10597 10859_16_3 LILRB1 EXON + xp19:54636733-54636753 UGCUGCAUCUGAAGCCCCCC 10598 10859_16_6 LILRB1 EXON + xp19:54636774-54636794 UGCACAGCUUGACCCUCAGA 10599 10859_16_7 LILRB1 EXON + xp19:54636775-54636795 GCACAGCUUGACCCUCAGAC 10600 10859_16_9 LILRB1 EXON + xp19:54636778-54636798 CAGCUUGACCCUCAGACGGG 10601 10859_16_14 LILRB1 EXON + xp19:54636802-54636822 AACUGAGCCUCCUCCAUCCC 10602 10859_16_16 LILRB1 EXON + xp19:54636806-54636826 GAGCCUCCUCCAUCCCAGGA 10603 10859_16_17 LILRB1 EXON + xp19:54636807-54636827 AGCCUCCUCCAUCCCAGGAA 10604 10859_16_18 LILRB1 EXON + xp19:54636844-54636864 GCCCAGCAUCUACGCCACUC 10605 10859_16_21 LILRB1 EXON + xp19:54636861-54636881 CUCUGGCCAUCCACUAGCCCC 10606 10859_16_22 LILRB1 EXON + xp19:54636862-54636882 UCUGGCCAUCCACUAGCCCA 10607 10859_16_25 LILRB1 EXON + xp19:54636863-54636883 CUGGCCAUCCACUAGCCAG 10608 10859_16_27 LILRB1 EXON + xp19:54636864-54636884 UGGCCAUCCACUAGCCCAGG 10609 10859_16_28 LILRB1 EXON + xp19:54636865-54636885 GGCCAUCCACUAGCCCAGGG 10610 10859_16_30 LILRB1 EXON + xp19:54636866-54636886 GCCAUCCACUAGCCCAGGGG 10611 10859_16_32 LILRB1 EXON + xp19:54636888-54636908 GACGCAGACCCCACACUCCA 10612 10859_16_35 LILRB1 EXON + xp19:54636895-54636915 ACCCCACACUCCAUGGAGUC 10613 10859_16_38 LILRB1 EXON + xp19:54636904-54636924 UCCAUGGAGUCUGGAAUGCA 10614 10859_16_40 LILRB1 EXON + xp19:54636905-54636925 CCAUGGAGUCUGGAAUGCAU 10615 10859_16_43 LILRB1 EXON + xp19:54636922-54636942 CAUGGGAGCUGCCCCCCCAG 10616 10859_16_45 LILRB1 EXON + xp19:54636932-54636952 GCCCCCCCAGUGGACACCAU 10617 10859_16_47 LILRB1 EXON + xp19:54636948-54636968 CCAUUGGACCCCACCCAGCC 10618 10859_16_50 LILRB1 EXON + xp19:54636960-54636980 ACCCAGCCUGGAUCUACCCC 10619 10859_16_54 LILRB1 EXON + xp19:54636969-54636989 GGAUCUACCCCAGGAGACUC 10620 10859_16_55 LILRB1 EXON + xp19:54636970-54636990 GAUCUACCCCAGGAGACUCU 10621 10859_16_58 LILRB1 EXON + xp19:54636980-54637000 AGGAGACUCUGGGAACUUUU 10622 10859_16_60 LILRB1 EXON + xp19:54636981-54637001 GGAGACUCUGGGAACUUUUA 10623 10859_16_61 LILRB1 EXON + xp19:54636982-54637002 GAGACUCUGGGAACUUUUAG 10624 10859_16_70 LILRB1 EXON - xp19:54636722-54636742 GAUGCAGCAGCCUGCAGCGG 10625 10859_16_72 LILRB1 EXON - xp19:54636723-54636743 AGAUGCAGCAGCCUGCAGCG 10626 10859_16_74 LILRB1 EXON - xp19:54636724-54636744 CAGAUGCAGCAGCCUGCAGC 10627 10859_16_75 LILRB1 EXON - xp19:54636725-54636745 UCAGAUGCAGCAGCCUGCAG 10628 10859_16_78 LILRB1 EXON - xp19:54636750-54636770 GGCGUAGGUCACAUCCUGGG 10629 10859_16_79 LILRB1 EXON - xp19:54636751-54636771 GGGCGUAGGUCACAUCCUGG 10630 10859_16_81 LILRB1 EXON - xp19:54636752-54636772 UGGGCGUAGGUCACAUCCUG 10631 10859_16_83 LILRB1 EXON - xp19:54636753-54636773 CUGGGCGUAGGUCACAUCCU 10632 10859_16_84 LILRB1 EXON - xp19:54636754-54636774 GCUGGGCGUAGGUCACAUCCC 10633 10859_16_87 LILRB1 EXON - xp19:54636765-54636785 CAAGCUGUGCAGCUGGGCGU 10634 10859_16_88 LILRB1 EXON - xp19:54636771-54636791 GAGGGUCAAGCUGUGCAGCU 10635 10859_16_89 LILRB1 EXON - xp19:54636772-54636792 UGAGGGUCAAGCUGUGCAGC 10636 10859_16_92 LILRB1 EXON - xp19:54636789-54636809 CUCAGUUGCCUCCCGUCUGA 10637 10859_16_93 LILRB1 EXON - xp19:54636790-54636810 GCUCAGUUGCCUCCCGUCUG 10638 10859_16_97 LILRB1 EXON - xp19:54636812-54636832 GGCCCUUCCUGGGAUGGAGG 10639 10859_16_98 LILRB1 EXON - xp19:54636815-54636835 GAGGGCCCUUCCUGGGAUGG 10640 10859_16_101 LILRB1 EXON - xp19:54636818-54636838 GGAGAGGGCCCUUCCUGGGA 10641 10859_16_104 LILRB1 EXON - xp19:54636822-54636842 AGCUGGAGAGGGCCCUUCCU 10642 10859_16_105 LILRB1 EXON - xp19:54636823-54636843 CAGCUGGAGAGGGCCCUUCC 10643 10859_16_108 LILRB1 EXON - xp19:54636833-54636853 AUGCUGGGCACAGCUGGAGA 10644 10859_16_109 LILRB1 EXON - xp19:54636834-54636854 GAUGCUGGGCACAGCUGGAG 10645 10859_16_112 LILRB1 EXON - xp19:54636839-54636859 GCGUAGAUGCUGGGCACAGC 10646 10859_16_115 LILRB1 EXON - xp19:54636848-54636868 GCCAGAGUGGCGUAGAUGCU 10647 10859_16_116 LILRB1 EXON - xp19:54636849-54636869 GGCCAGAGUGGCGUAGAUGC 10648 10859_16_118 LILRB1 EXON - xp19:54636861-54636881 GGGCUAGUGGAUGGCCAGAG 10649 10859_16_120 LILRB1 EXON - xp19:54636870-54636890 UCCCCCCCUGGGCUAGUGGA 10650 10859_16_121 LILRB1 EXON - xp19:54636874-54636894 UGCGUCCCCCCCUGGGCUAG 10651 10859_16_123 LILRB1 EXON - xp19:54636881-54636901 UGGGGUCUGCGUCCCCCCCU 10652 10859_16_124 LILRB1 EXON - xp19:54636882-54636902 GUGGGGUCUGCGCCCCCCC 10653 10859_16_127 LILRB1 EXON - xp19:54636899-54636919 UCCAGACUCCAUGGAGUGUG 10654 10859_16_128 LILRB1 EXON - xp19:54636900-54636920 UUCCAGACUCCAUGGAGUGU 10655 10859_16_129 LILRB1 EXON - xp19:54636901-54636921 AUUCCAGACUCCAUGGAGUG 10656 10859_16_132 LILRB1 EXON - xp19:54636908-54636928 CCCAUGCAUUCCAGACUCCA 10657 10859_16_135 LILRB1 EXON - xp19:54636936-54636956 UCCAAUGGUGUCCACUGGGG 10658 10859_16_136 LILRB1 EXON - xp19:54636937-54636957 GUCCAAUGGUGUCCCACUGGG 10659 10859_16_137 LILRB1 EXON - xp19:54636938-54636958 GGUCCAAUGGUGUCCACUGG 10660 10859_16_139 LILRB1 EXON - xp19:54636939-54636959 GGGUCCAAUGGUGUCCACUG 10661 10859_16_141 LILRB1 EXON - xp19:54636940-54636960 GGGGUCCCAAUGGUGUCCACU 10662 10859_16_143 LILRB1 EXON - xp19:54636941-54636961 UGGGGUCCACAUGGUGUCCAC 10663 10859_16_146 LILRB1 EXON - xp19:54636951-54636971 CCAGGCUGGGUGGGGUCCAA 10664 10859_16_147 LILRB1 EXON - xp19:54636959-54636979 GGGUAGAUCCAGGCUGGGUG 10665 10859_16_148 LILRB1 EXON - xp19:54636960-54636980 GGGGUAGAUCCAGGCUGGGU 10666 10859_16_150 LILRB1 EXON - xp19:54636961-54636981 UGGGGUAGAUCCAGGCUGGG 10667 10859_16_152 LILRB1 EXON - xp19:54636964-54636984 UCCUGGGGUAGAUCCAGGCU 10668 10859_16_153 LILRB1 EXON - xp19:54636965-54636985 CUCCUGGGGUAGAUCCAGGC 10669 10859_16_156 LILRB1 EXON - xp19:54636969-54636989 GAGUCUCCUGGGGUAGAUCC 10670 10859_16_157 LILRB1 EXON - xp19:54636979-54636999 AAAGUUCCCAGAGUCUCCUG 10671 10859_16_158 LILRB1 EXON - xp19:54636980-54637000 AAAAGUUCCCAGAGUCUCCU 10672 10859_16_159 LILRB1 EXON - xp19:54636981-54637001 UAAAAGUUCCCCAGAGUCUCC 10673

Table 6e. Exemplary Preferred Targeting Domains for nRNA Molecules Targeting CD3E Referring domain ID Chain Target sequence position (hg38) guiding domain sequence SEQID NO: CR002230 + Xp11:118304702-118304724 AGGCCUCUCUACUUCCUGUG 10677 CR002231 + Xp11:118304703-118304725 GGCCUCUCUACUUCCUGUGU 10678 CR002232 + Xp11:118304704-118304726 GCCUCUUACUUCCUGUGUG 10679 CR002233 - Xp11:118304570-118304592 GACUCUGACAAUACCUGGAG 10680 CR002234 - Xp11:118304571-118304593 GGACUCUGACAAUACCUGGA 10681 CR002235 - Xp11:118304575-118304597 AAGAGGACUCUGACAAUACC 10682 CR002236 - Xp11:118304592-118304614 UUCCUAGAGGCCAAACAAG 10683 CR002237 - Xp11:118304604-118304626 GGUCCCACAGCCUUCCUAGA 10684 CR002238 - Xp11:118304625-118304647 UGGACUGGUUGAAGAAAGCU 10685 CR002239 - Xp11:118304640-118304662 GCAGAGGCCUCCACCUGGAC 10686 CR002240 - Xp11:118304656-118304678 CUUGGAAACGUUCAAGGCAG 10687 CR002241 - Xp11:118304662-118304684 ACCUCACUUGGAAAACGUUCA 10688 CR002242 - Xp11:118304674-118304696 CCUGCGGGUUUUACCUCACU 10689 CR002243 - Xp11:118304689-118304711 AGAGAGGCCUCUGGGCCUGC 10690 CR002244 - Xp11:118304697-118304719 CAGGAAGUAGAGAGGCCUCU 10691 CR002245 - Xp11:118304705-118304727 ACCCCACACAGGAAGUAGAG 10692 CR002246 - Xp11:118304716-118304738 AGGGUUUCUGAACCCCAACAC 10693 CR002247 - Xp11:118304736-118304758 CCUGAGGCUGGGAGGGGAGG 10694 CR002248 - Xp11:118304747-118304769 UGAAGCAGGCACCUGAGGCU 10695 CR002249 - Xp11:118304748-118304770 CUGAAGCAGGCACCUGAGGC 10696 CR002250 - Xp11:118304752-118304774 UUUUCUGAAGCAGGCACCUG 10697 CR002251 + Xp11:118304889-118304911 UCCAGAAGUAGUAAGUCUGC 10698 CR002252 + Xp11:118304940-118304962 CCAUGAAAACAAAGAUGCAGU 10699 CR002253 + Xp11:118304941-118304963 CAUGAAAACAAAGAUGCAGUC 10700 CR002254 + Xp11:118304951-118304973 AGAUGCAGUCGGGCACUCAC 10701 CR002255 + Xp11:118304961-118304983 GGGCACUCACUGGAGAGUUC 10702 CR002256 + Xp11:118304962-118304984 GGCACUCACUGGAGAGUUCU 10703 CR002257 - Xp11:118304912-118304934 UUACUUUACUAAAGAUGGCGG 10704 CR002258 - Xp11:118304915-118304937 CUGUUACUUUACUAAAGAUGG 10705 CR002259 - Xp11:118304918-118304940 GGACUGUUACUUUACUAAGA 10706 CR002260 - Xp11:118304939-118304961 CGACUGCAUCUUUGUUUCAU 10707 CR002261 - Xp11:118304940-118304962 CCGACUGCAUCUUUGUUUCA 10708 CR002262 - Xp11:118304985-118305007 ACUCACCUGAUAAGAGGCAG 10709 CR002263 - Xp11:118304991-118305013 CAUCCUACUCACCUGAUAAG 10710 CR002264 + Xp11:118307269-118307291 UUUCUUAUUUAUUUUCUAGU 10711 CR002265 + Xp11:118307276-118307298 UUUAUUUUCUAGUUGGCGUU 10712 CR002266 + Xp11:118307277-118307299 UUAUUUUCUAGUUGGCGUUU 10713 CR002267 + Xp11:118307278-118307300 UAUUUUCUAGUUGGCGUUUG 10714 CR002268 + Xp11:118307279-118307301 AUUUUCUAGUUGGCGUUUGG 10715 CR002269 + Xp11:118308419-118308441 CUUUUCAGGUAAUGAAGAAAA 10716 CR002270 + Xp11:118312617-118312639 GCAUAUAAAGUCUCCAUCUC 10717 CR002271 + Xp11:118312653-118312675 UUGACAUGCCCUCAGUAUCC 10718 CR002272 + Xp11:118312669-118312691 AUCCUGGAUCUGAAAUACUA 10719 CR002273 + Xp11:118312695-118312717 CACAAUGAUAAAAAACAUAGG 10720 CR002274 + Xp11:118312703-118312725 UAAAAACAUAGGCGGUGAUG 10721 CR002275 + Xp11:118312719-118312741 GAUGAGGAUGAUAAAAAACAU 10722 CR002276 + Xp11:118312730-118312752 UAAAAACAUAGGCAGUGAUG 10723 CR002277 + Xp11:118312748-118312770 UGAGGAUCACCUGUCACUGA 10724 CR002278 + Xp11:118312763-118312785 ACUGAAGGAAUUUUCAGAAU 10725 CR002279 + Xp11:118312773-118312795 UUUUCAGAAUUGGAGCAAAG 10726 CR002280 + Xp11:118312838-118312860 GAACUUUUAUCUCUACCUGA 10727 CR002281 - Xp11:118312630-118312652 UAUUACUGUGGUUCCAGAGA 10728 CR002282 - Xp11:118312642-118312664 AGGGCAUGUCAAUAUUACUG 10729 CR002283 - Xp11:118312661-118312683 UUUCAGAUCCAGGAUACUGA 10730 CR002284 - Xp11:118312662-118312684 AUUUCAGAUCCAGGAUACUG 10731 CR002285 - Xp11:118312671-118312693 UGCCAUAGUAUUUCAGAUCC 10732 CR002286 - Xp11:118312757-118312779 CUGAAAAUUCCUUCAGUGAC 10733 CR002287 - Xp11:118312811-118312833 CUUCUGGUUUGCUUCCUCUG 10734 CR002288 - Xp11:118312812-118312834 UCUUCUGGUUUGCUUCCUCU 10735 CR002289 - Xp11:118312813-118312835 AUCUUCUGGUUUGCUUCCUC 10736 CR002290 - Xp11:118312827-118312849 AGAUAAAAGUUCGCAUCUUC 10737 CR002291 - Xp11:118312853-118312875 CUGGAUUACCUCUUGCCCUC 10738 CR002292 + Xp11:118313720-118313742 CAUGGAGAUGGAUGUGAUGU 10739 CR002293 + Xp11:118313758-118313780 UAGUGGACAUCUGCAUCACU 10740 CR002294 + Xp11:118313760-118313782 GUGGACAUCUGCAUCACUGG 10741 CR002295 + Xp11:118313774-118313796 CACUGGGGGCUUGCUGCUGC 10742 CR002296 + Xp11:118313801-118313823 CUACUGGAGCAAGAAUAGAA 10743 CR002297 + Xp11:118313807-118313829 GAGCAAGAAUAGAAAGGCCA 10744 CR002298 + Xp11:118313826-118313848 AAGGCCAAGCCUGUGACACG 10745 CR002299 + Xp11:118313831-118313853 CAAGCCUGUGACACGAGGAG 10746 CR002300 - Xp11:118313746-118313768 GAUGUCCCACUAUGACAAUUG 10747 CR002301 - Xp11:118313824-118313846 UCGUGUGUCACAGGCUUGGCCU 10748 CR002302 - Xp11:118313830-118313852 CGCUCCUCGUGUGCACAGGCU 10749 CR002303 - Xp11:118313835-118313857 GCACCCGCUCCUCGUGUCAC 10750 CR002304 + Xp11:118314442-118314464 CCGCAGGACAAAAACAAGGAG 10751 CR002305 - Xp11:118314465-118314487 UCUGGGUUGGGAACAGGUGG 10752 CR002306 - Xp11:118314468-118314490 UAGUCUGGGUUGGGAACAGG 10753 CR002307 - Xp11:118314471-118314493 UCAUAGUCUGGGUUGGGAAC 10754 CR002308 - Xp11:118314477-118314499 GUUACCUCAUAGUCUGGGUU 10755 CR002309 - Xp11:118314478-118314500 CGUUACCUCAUAGUCUGGGU 10756 CR002310 - Xp11:118314482-118314504 CCCACGUUACCUCAUAGUCU 10757 CR002311 - Xp11:118314483-118314505 UCCCACGUUACCUCAUAGUC 10758 CR002312 + Xp11:118315472-118315494 UAUUUCACCCCCAGCCCAUC 10759 CR002313 + Xp11:118315477-118315499 CACCCCCAGCCCAUCCGGAA 10760 CR002314 + Xp11:118315484-118315506 AGCCCAUCCGGAAAGGCCAG 10761 CR002315 + Xp11:118315485-118315507 GCCCAUCCGGAAAGGCCAGC 10762 CR002316 + Xp11:118315498-118315520 GGCCAGCGGGACCUGUAUUC 10763 CR002317 + Xp11:118315528-118315550 CAGAGACGCAUCUGACCCUC 10764

Table 6f. Exemplary Preferred Targeting Domains for nRNA Molecules Directly Interacting with CD3G Referring domain ID Exon Chain Target sequence position (hg38) guiding domain sequence SEQID NO: CR005349 3 - chr11:118349904-118349926 UUACACUGAUACAUCCCUCG 10765 CR005350 4 - chr11:118350673-118350695 GCAUUCUUUUACCCUCGAC 10766 CR005351 3 - chr11:118349903-118349925 UACACUGAUACAUCCCUCGA 10767 CR005352 3 - chr11:118349896-118349918 AUACAUCCCUCGAGGGUCCU 10768 CR005353 5 - chr11:118351652-118351674 UACCUGGUAGAGCUGGUCAU 10769 CR005354 3 + chr11:118349907-118349929 CGAGGGAUGUAUCAGUGUAA 10770 CR005355 4 + chr11:118350640-118350662 GGUCUACUUCAUUGCUGGAC 10771 CR005356 3 + chr11:118349890-118349912 GUAAUGCCAAGGACCCUCGA 10772 CR005357 5 - chr11:118351651-118351673 ACCUGGUAGAGCUGGUCAUU 10773 CR005358 4 + chr11:118350618-118350640 GCAUUUUCCGUCCUUGCUGUU 10774 CR005359 4 + chr11:118350635-118350657 GUUGGGGUCUACUUCAUUGC 10775 CR005360 6 - chr11:118352405-118352427 GUCAUCUUCUCGAUCCUUGA 10776 CR005361 6 - chr11:118352404-118352426 UCAUCUUCUCGAUCCUUGAG 10777 CR005362 3 + chr11:118349760-118349782 GUGUAUGACUAUCAAGAAGA 10778 CR005363 3 + chr11:118349738-118349760 UUCAGGAAACCACCUUGGUUA 10779

Table 6g. Exemplary Preferred Targeting Domains for nRNA Molecules Targeting CD3D Referring domain ID Exon Chain Target sequence position (hg38) guiding domain sequence SEQID NO: CR005334 2 + chr11:118340373-118340395 ACUUCGAUAAUGAACUUGCA 10780 CR005335 5 + chr11:118339204-118339226 AGCAUCAUCUCGAUCUCGGA 10781 CR005336 5 + chr11:118339203-118339225 GAGCAUCAUCUCGAUCUCGG 10782 CR005337 2 - chr11:118340453-118340475 GGACCUGGGAAAACGCAUCC 10783 CR005338 2 - chr11:118340467-118340489 GACAUUACAAAGACUGGACCU 10784 CR005339 2 - chr11:118340443-118340465 AAACGCAUCCUGGACCCACG 10785 CR005340 5 + chr11:118339004-118339026 GGCGAGAUCCCAAGCAAGUC 10786 CR005341 5 + chr11:118339200-118339222 ACUGAGCAUCAUCUCGAUCU 10787 CR005342 5 + chr11:118339205-118339227 GCAUCAUCUCGAUCUCGGAG 10788 CR005343 4 - chr11:118339469-118339491 CCGACACACAAGCUCUGUUG 10789 CR005344 2 + chr11:118340429-118340451 UACACCUAUAUAUUCCUCGU 10790 CR005345 2 - chr11:118340558-118340580 GAUACCUAUAGAGGAACUUG 10791 CR005346 5 + chr11:118339027-118339049 ACAACUCCCACGCCUUGCCC 10792 CR005347 2 + chr11:118340428-118340450 UUACACCUAUAUAUUCCUCG 10793 CR005348 5 - chr11:118339150-118339172 GGAACAAGUGAACCUGAGAC 10794

In aspects of the invention, an anti-TRAC nRNA that includes the CR00961 targeting domain (SEQ ID NO: 5569, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00961 #1:

AGAGUCUCUCAGCUGGUACAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7833)

sRNA CR00961 #2:

mA*mG*mA*GUCUCUCAGCUGGUACAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7834)

sRNA CR00961 #3:

mA*mG*mA*GUCUCUCAGCUGGUACAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7835)

lncRNA CR00961 #1:

crRNA: AGAGUCUCUCAGCUGGUACAGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7836)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00961 #2:

crRNA: mA*mG*mA*GUCUCUCAGCUGGUACAGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7837)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00961 #3:

crRNA: mA*mG*mA*GUCUCUCAGCUGGUACAGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7837)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-TRAC nRNA that includes the CR00984 targeting domain (SEQ ID NO: 5592, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00984 #1:

UUCGGAACCCAAUCACUGACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7838)

sRNA CR00984 #2:

mU*mU*mC*GGAACCCAAUCACUGACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7839)

sRNA CR00984 #3:

mU*mU*mC*GGAACCCAAUCACUGACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7840)

lncRNA CR00984 #1:

crRNA: UUCGGAACCCAAUCACUGACGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7841)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00984 #2:

crRNA: mU*mU*mC*GGAACCCAAUCACUGACGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7842)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00984 #3:

crRNA: mU*mU*mC*GGAACCCAAUCACUGACGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7842)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-TRBC nRNA that includes the CR00798 targeting domain (SEQ ID NO: 5694, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00798 #1:

UGGCUCAAACACAGCGACCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7843)

sRNA CR00798 #2:

mU*mG*mG*CUCAAAACACAGCGACCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7844)

sRNA CR00798 #3:

mU*mG*mG*CUCAAAACACAGCGACCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7845)

lncRNA CR00798 #1:

crRNA: UGGCUCAAACACAGCGACCUGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7846)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00798 #2:

crRNA: mU*mG*mG*CUCAAACACAGCGACCUGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7847)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00798 #3:

crRNA: mU*mG*mG*CUCAAACACAGCGACCUGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7847)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-TRBC nRNA that includes the CR00823 targeting domain (SEQ ID NO: 5719, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00823 #1:

UCCCUAGCAAGAUCUCAUAGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7848)

sRNA CR00823 #2:

mU*mC*mC*CUAGCAAGAUCUCAUAGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7849)

sRNA CR00823 #3:

mU*mC*mC*CUAGCAAGAUCUCAUAGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7850)

lncRNA CR00823 #1:

crRNA: UCCCUAGCAAGAUCUCAUAGGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7851)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00823 #2:

crRNA: mU*mC*mC*CUAGCAAGAUCUCAUAGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7852)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00823 #3:

crRNA: mU*mC*mC*CUAGCAAGAUCUCAUAGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7852)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-B2M nRNA that includes the CR00442 targeting domain (SEQ ID NO: 5496, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00442 #1:

GGCCACGGAGCGAGACAUCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7853)

sRNA CR00442 #2:

mG*mG*mC*CACGGAGCGAGACAUCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7854)

sRNA CR00442 #3:

mG*mG*mC*CACGGAGCGAGACAUCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7855)

lncRNA CR00442 #1:

crRNA: GGCCACGGAGCGAGACAUCUGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7856)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00442 #2:

crRNA: mG*mG*mC*CACGGAGCGAGACAUCUGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7857)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00442 #3:

crRNA: mG*mG*mC*CACGGAGCGAGACAUCUGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7857)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-B2M nRNA that includes the CR00444 targeting domain (SEQ ID NO: 5498, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR00444 #1:

GAGUAGCGCGAGCACAGCUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7858)

sRNA CR00444 #2:

mG*mA*mU*AGCGCGAGCACAGCUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7859)

sRNA CR00444 #3:

mG*mA*mU*AGCGCGAGCACAGCUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7860)

lncRNA CR00444 #1:

crRNA: GAGUAGCGCGAGCACAGCUAGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7861)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR00444 #2:

crRNA: mG*mA*mU*AGCGCGAGCACAGCUAGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7862)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR00444 #3:

crRNA: mG*mA*mU*AGCGCGAGCACAGCUAGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7862)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-FKBP1A nRNA that includes the CR002097 targeting domain (SEQ ID NO: 6705, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR002097 #1:

CAAGCGCGGCCAGACCUGCGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7863)

sRNA CR002097 #2:

mC*mA*mA*GCGCGGCCAGACCUGCGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7864)

sRNA CR002097 #3:

mC*mA*mA*GCGCGGCCAGACCUGCGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7865)

lncRNA CR002097 #1:

crRNA: CAAGCGCGGCCAGACCUGCGGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7866)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR002097 #2:

crRNA: mC*mA*mA*GGCCGGCCAGACCUGCGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7867)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR002097 #3:

crRNA: mC*mA*mA*GGCCGGCCAGACCUGCGGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7867)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In aspects of the invention, an anti-FKBP1A nRNA that includes the CR002100 targeting domain (SEQ ID NO: 6708, underlined below, or a modified variant thereof (also underlined)), e.g., one of the nRNA molecules described below, is used in CRISPR systems, methods , cells and other aspects and embodiments of the invention (and combinations thereof), including, in some aspects, the use of more than one nRNA molecule, for example, described in this application:

sRNA CR002100 #1:

CCGCUGGGCCCCCGACUCACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7868)

sRNA CR002100 #2:

mC*mC*mG*CUGGGCCCCCGACUCACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU*mU*mU*mU (SEQ ID NO: 7869)

sRNA CR002100 #3:

mC*mC*mG*CUGGGCCCCCGACUCACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCmU*mU*mU*U (SEQ ID NO: 7870)

lncRNA CR002100 #1:

crRNA: CCGCUGGGCCCCCGACUCACGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 7871)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660)

lncRNA CR002100 #2:

crRNA: mC*mC*mG*CUGGGCCCCCGACUCACGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7872)

tracr: mA*mA*mC*AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU*mU*mU*mU (SEQ ID NO: 10798)

lncRNA CR002100 #3:

crRNA: mC*mC*mG*CUGGGCCCCCGACUCACGUUUUAGAGCUAUGCUGUU*mU*mU*mG (SEQ ID NO: 7872)

tracr: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660).

In each of the nRNA molecules described above, "*" denotes a phosphothioate bond between adjacent nucleotides, and "mN" (where N=A, G, C or U) denotes a 2'-OMe modified nucleotide. In embodiments, any of the nRNA molecules described herein, such as those described above, are complexed to a Cas9 molecule, such as as described herein, to form a ribonucleoprotein complex (RNP). Such RNPs are particularly useful in methods, cells, and other aspects and embodiments of the invention, such as those described herein.

III. Methods for constructing nRNA

Methods for creating nRNA are described in this application, including methods for selecting, constructing and validating target sequences. Examples of guide domains are also presented in this application. The targeting domains discussed in this application may be included in the nRNAs described in this application.

Methods for selecting and validating target sequences, as well as off-target activity assays, are described, for example, in Mali el al., 2013 SCIENCE 339(6121): 823-826; Hsu et al., 2013 NAT BIOTECHNOL, 31(9):827-32; Fu et al., 2014 NAT BIOTECHNOL, doi: 10.1038/nbt.2808. PubMed PM ID: 24463574; Heigwer et al., 2014 NAT METHODS 11(2):122-3. doi: 10.1038/nmeth.2812. PubMed PMID: 24481216; Bae el al., 2014 BIOINFORMATICS PubMed PMID: 24463181; Xiao A el al., 2014 BIOINFORMATICS PubMed PMID: 24389662.

For example, the software tool can be used to optimize the selection of nRNA in a user's target sequence, eg, to minimize overall off-target activity in the genome. Off-target activity may not be cleavage. To match each possible nRNA, such as when using S. pyogenes Cas9, the tool can identify all non-target sequences (eg, NAG or NGG PAM precursors) in the entire genome that contain a number (eg, 1, 2, 3, 4, 5 , 6, 7, 8, 9, or 10) mismatched base pairs. The efficiency of cleavage on each non-target sequence can be predicted, for example, using an experimental weighting scheme. Each candidate nRNA is then scored according to its total predicted off-target cleavage; The best-scoring nRNAs are those nRNAs that are most likely to have the most target cleavage and the least off-target cleavage. Other features, such as automated reagent design for a CRISPR construct, primer selection for the Surveyor target activity assay, and primer selection for high-throughput detection and quantification of off-target cleavage using next-generation sequencing, can also be included in the tool. Candidate nRNA molecules can be evaluated using methods known or described herein.

Although software algorithms can be used to generate an initial list of potential nRNA molecules, cleavage efficiency and specificity will not necessarily reflect predicted values, and nRNA molecules usually require screening in certain cell lines, e.g. primary human cell lines, e.g. human primary immune effector cells. , such as primary human T cells, to determine, for example, cleavage efficiency, indel formation, cleavage specificity, and change in desired phenotype. Such properties can be investigated using the methods described in this application.

IV. Cas molecules

Cas9 molecules

In preferred embodiments, the Cas molecule is a Cas9 molecule. Cas9 molecules from various species can be used in the methods and compositions described in this application. While the S. pyogenes Cas9 molecule is the subject of much of this disclosure, Cas9 molecules derived from or based on the Cas9 proteins of other species listed herein may also be used. In other words, other Cas9 molecules, such as S. thermophilus, Staphylococcus aureus and/or Neisseria meningitidis Cas9 molecules, may be used in the systems, methods and compositions described herein. Additional Cas9 species include: Acidovorax avenae, Actinobacillus pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces sp., cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides sp., Blastopirellula marina, Bradyrhiz'obiumac sp. latemsporus, Campylobacter coli, Campylobacter jejuni, Campylobacter lad, Candidatus Puniceispirillum, Clostridiu cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheria, Corynebacterium matruchotii, Dinoroseobacter sliibae, Eubacterium dolichum, gamma proteobacterium, Gluconacetobacler diazotrophicus, Haemophilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicobacter cinaedi, Helicobacter mustelae, Ilyobacler polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria monocytogenes, Listeriaceae bacterium, Methylocystis sp., Methylosinus trichosporium, Mobiluncus mulieri s, Neisseria bacilliformis, Neisseria cinerea, Neisseria flavescens, Neisseria lactamica. Neisseria sp., Neisseria wadsworthii, Nitrosomonas sp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris, Rhodovulum sp., Simonsiella muelleri, Sphingomonas sp. , Tistrella mobilis, Treponema sp. or Verminephrobacter eiseniae.

A Cas9 molecule, as the term is used in this application, refers to a molecule that can interact with an nRNA molecule (e.g., the tracr domain sequence) and, together with the nRNA molecule, localize (e.g., on a target or target) to a site that includes the sequence -target and PAM sequence.

In an embodiment, the Cas9 molecule is capable of cleaving a target nucleic acid molecule, which may be referred to herein as an active Cas9 molecule. In an embodiment, the active Cas9 molecule includes one or more of the following activities: nicase activity, ie. the ability to cleave one strand, such as a non-complementary strand or complementary strand, of a nucleic acid molecule; double-stranded nuclease activity, i.e. the ability to cleave both strands of a double-stranded nucleic acid and create a double-strand break, which in an embodiment is due to the presence of two nicase activities; endonuclease activity; exonuclease activity; and helicase activity, i.e. the ability to unwind the helical structure of a double-stranded nucleic acid.

In one embodiment, the enzymatically active Cas9 molecule cleaves both DNA strands and results in a double-strand break. In one embodiment, the Cas9 molecule cleaves only one strand, such as the strand to which the nRNA hybridizes, or the strand that is complementary to the strand to which the nRNA hybridizes. In one embodiment, the active Cas9 molecule includes a cleaving activity associated with an HNH-like domain. In one embodiment, the active Cas9 molecule includes a cleaving activity associated with an N-terminal RuvC-like domain. In one embodiment, the active Cas9 molecule includes a cleaving activity associated with an HNH-like domain and a cleaving activity associated with an N-terminal RuvC-like domain. In one embodiment, the active Cas9 molecule comprises an active or cleavable HNH-like domain and an inactive or incapable of cleaving an N-terminal RuvC-like domain. In one embodiment, the active Cas9 molecule contains an inactive or incapable of cleaving an HNH-like domain and an active or capable of cleaving an N-terminal RuvC-like domain.

In an embodiment, the ability of the active Cas9 molecule to interact with and cleave the target nucleic acid is dependent on the PAM sequence. The PAM sequence is a sequence in a target nucleic acid. In an embodiment, cleavage of the target nucleic acid occurs before the PAM sequence. Active Cas9 molecules from different bacterial species can recognize different sequence motifs (eg, PAM sequences). In an embodiment, the active S. pyogenes Cas9 molecule recognizes the NGG sequence motif and directs cleavage of the target nucleic acid sequence 1-10, eg 3-5 base pairs prior to that sequence. See, for example, Mali et al., SCIENCE 2013; 339(6121):823-826. In an embodiment, the active S. thermophilus Cas9 molecule recognizes the NGGNG and NNAG AAW (W=A or T) sequence motif and directs cleavage of the target nucleic acid core sequence 1-10, eg 3-5 base pairs prior to said sequences. See, for example, Horvath et al., SCIENCE 2010; 327(5962):167-170 and Deveau et al., J BACTERIOL 2008; 190(4):1390-1400. In an embodiment, the active C. mulans Cas9 molecule recognizes the NGG or NAAR (R-A or G) sequence motif and directs cleavage of the target nucleic acid core sequence 1-10, eg 3-5 base pairs prior to that sequence. See, for example, Deveau et al., J BACTERIOL 2008; 190(4):1390-1400.

In an embodiment, the active S. aureus Cas9 molecule recognizes the NNGRR sequence motif (R=A or G) and directs cleavage of the target nucleic acid sequence 1-10, eg 3-5 base pairs prior to that sequence. See, for example, Ran F. et al., NATURE, vol. 520, 2015, pp. 186-191. In an embodiment, the active N. meningitidis Cas9 molecule recognizes the NNNNGATT sequence motif and directs cleavage of the target nucleic acid sequence 1-10, eg 3-5 base pairs prior to that sequence. See, for example, Hou et al., PNAS EARLY EDITION 2013, 1-6. The ability of a Cas9 molecule to recognize a PAM sequence can be determined, for example, using the transformation assay described in Jinek et al., SCIENCE 2012, 337:816.

Some Cas9 molecules have the ability to interact with the nRNA molecule and, together with the nRNA molecule, are directed (for example, interact or localize directionally) to the target core domain, but are unable to cleave the target nucleic acid or are unable to cleave at an effective rate. Cas9 molecules with no or no significant cleavage activity may be referred to herein as an inactive Cas9 molecule (enzymatically inactive Cas9 molecule), "dead" Cas9, or dCas9. For example, an inactive Cas9 molecule may have no cleavage activity, or have substantially less, such as less than 20%, 10%, 5%, 1%, or 0.1%, the cleavage activity of a Cas9 reference molecule as measured by the assay described herein.

Examples of natural Cas9 molecules are described in Chylinski et al., RNA Biology 2013; 10:5, 727-737. Such Cas9 molecules include Cas9 molecules of bacterial family cluster 1, bacterial family cluster 2, bacterial family cluster 3, bacterial family cluster 4, bacterial family cluster 5, bacterial family cluster 6, bacterial family cluster 7, bacterial family cluster 8, bacterial family cluster 9 , cluster 10 bacteria families, cluster 11 bacteria families, cluster 12 bacteria families, cluster 13 bacteria families, cluster 14 bacteria families, cluster 15 bacteria families, cluster 16 bacteria families, cluster 17 bacteria families, cluster 18 bacteria families, cluster 19 bacteria families , cluster 20 bacteria families, cluster 21 bacteria families, cluster 22 bacteria families, cluster 23 bacteria families, cluster 24 bacteria families, cluster 25 bacteria families, cluster 26 bacteria families, cluster 27 bacteria families, cluster 28 bacteria families, cluster 29 bacteria families , families of bacteria cluster 30, families cluster 31 bacteria, cluster 32 bacteria families, cluster 33 bacteria families, cluster 34 bacteria families, cluster 35 bacteria families, cluster 36 bacteria families, cluster 37 bacteria families, cluster 38 bacteria families, cluster 39 bacteria families, cluster 40 bacteria families, cluster 41 bacteria families, cluster 42 bacteria families, cluster 43 bacteria families, cluster 44 bacteria families, cluster 45 bacteria families, cluster 46 bacteria families, cluster 47 bacteria families, cluster 48 bacteria families. cluster 49 bacteria families, cluster 50 bacteria families, cluster 51 bacteria families, cluster 52 bacteria families, cluster 53 bacteria families, cluster 54 bacteria families, cluster 55 bacteria families, cluster 56 bacteria families, cluster 57 bacteria families, cluster 58 bacteria families, cluster 59 bacteria families, cluster 60 bacteria families, families of bacteria cluster 61, families bact cluster 62 bacterial families cluster 63 bacterial families cluster 64 bacterial families cluster 65 bacterial families cluster 66 bacterial families cluster 67 bacterial families cluster 68 bacterial families cluster 69 bacterial families cluster 70 bacterial families cluster 71 families cluster 72 bacteria, cluster 73 bacteria family, cluster 74 bacteria family, cluster 75 bacteria family, cluster 76 bacteria family, cluster 77 bacteria family, or cluster 78 bacteria family.

Examples of naturally occurring Cas9 molecules include the Cas9 molecule of the cluster 1 bacteria family. Examples include the Cas9 molecule from: S. pyogenes (e.g. strain SF370, MGAS 10270, MGAS 10750, MGAS2096, MGAS315, MGAS5005, MGAS6180, MGAS9429, NZ131 and SSI-1), S. thermophilus (e.g. strain LMD-9), S. pseudoporcinus (e.g. strain SPIN 20026), S. mutans (e.g. strain UA 159, NN2025), S. macacae (e.g. strain NCTC1 1558), S. gallolylicus (e.g. strain UCN34, ATCC BAA-2069), S. equines (e.g. strain ATCC 9812, MGCS 124), S. dysdalactiae (e.g. strain GGS 124), S. bovis (e.g. strain ATCC 700338), S. anginosus (for example; strain F021 1), S. agalactia* (for example, strain NEM316, A909), Listeria monocytogenes (for example, strain F6854), Listeria innocua (L. innocua, for example, strain Clip 11262), Enterococcus italicus (for example, strain DSM 15952) or Enterococcus faecium (eg strain 1,231,408). Additional examples of Cas9 molecules are the Neisseria meningitidis Cas9 molecule (Hou et al., PNAS Early Edition 2013, 1-6) and the S. aureus Cas9 molecule.

In an embodiment, a Cas9 molecule, such as an active Cas9 molecule or an inactive Cas9 molecule, comprises an amino acid sequence that: has 60%, 65%, 70%, 75%, 80%, 85%, 90%, 97%, 98% or 99% homology with; differs by no more than 1%, 2%, 5%, 10%, 15%, 20%, 30%, or 40% of amino acid residues when compared to; differs by at least 1, 2, 5, 10, or 20 amino acids, but not more than 100, 80, 70, 60, 50, 40, or 30 amino acids from; or identical to any sequence of the Cas9 molecule described in this application or the sequence of a natural Cas9 molecule, for example, a Cas9 molecule from the species listed in this application or described in Chylinski et al., RNA Biology 2013, 10:5, I2I-Τ,1 Hou et al. PNAS Early Edition 2013, 1-6.

In an embodiment, the Cas9 molecule includes an amino acid sequence that shares 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology with; differs by no more than 1%, 2%, 5%, 10%, 15%, 20%, 30%, or 40% of amino acid residues when compared to; differs by at least 1, 2, 5, 10, or 20 amino acids, but not more than 100, 80, 70, 60, 50, 40, or 30 amino acids from; or identical to Cas9 S. pyogenes:

(SEQ ID NO: 6611)

(SEQ ID NO: 6611)

In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes one or more positively charged amino acid (e.g., lysine, arginine, or histidine) mutations to introduce an uncharged or nonpolar amino acid, e.g., alanine, at the indicated position. In embodiments, the mutation is present in one or more positively charged amino acids in the nt-groove of Cas9. In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes a mutation at position 855 of SEQ ID NO: 6611, e.g., a mutation to an uncharged amino acid, e.g., alanine, at position 855 of SEQ ID NO: 6611. In embodiments, the Cas9 molecule contains a mutation only at position 855 of SEQ ID NO: 6611, relative to SEQ ID NO: 6611, for example, with a change to an uncharged amino acid, such as alanine. In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes a mutation at position 810, a mutation at position 1003, and/or a mutation at position 1060 of SEQ ID NO: 6611, such as an alanine substitution mutation at position 810 , position 1003, and/or position 1060 of SEQ ID NO: 6611. In embodiments, the Cas9 molecule contains a mutation only at position 810, position 1003, and position 1060 of SEQ ID NO: 6611, relative to SEQ ID NO: 6611, for example, where each mutation is substitution for an uncharged amino acid, such as alanine. In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes a mutation at position 848, a mutation at position 1003, and/or a mutation at position 1060 of SEQ ID NO: 6611, such as an alanine substitution mutation at position 848, position 1003 and/or position 1060 of SEQ ID NO: 6611. In embodiments, the Cas9 molecule contains a mutation only at position 848, position 1003, and position 1060 of SEQ ID NO: 6611, relative to SEQ ID NO: 6611, for example, where each mutation is a replacement for an uncharged amino acid, such as alanine. In embodiments, the Cas9 molecule is a Cas9 molecule as described in Slaymaker et al., Science Express, available online December 1, 2015 at Science DOI: 10.1126/science.aad5227.

In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes one or more mutations. In embodiments, the Cas9 variant includes a mutation at position 80 of SEQ ID NO: 6611, for example, includes leucine at position 80 of SEQ ID NO: 6611 (i.e., includes, for example consists of, SEQ ID NO: 6611 with the C80L mutation). In embodiments, the Cas9 variant includes a mutation at position 574 of SEQ ID NO: 6611, for example, includes glutamic acid at position 574 of SEQ ID NO: 6611 (i.e., includes, for example, consists of, SEQ ID NO: 6611 with the C574E mutation). In embodiments, the Cas9 variant includes a mutation at position 80 and a mutation at position 574 of SEQ ID NO: 6611, e.g., includes leucine at position 80 of SEQ ID NO: 6611 and glutamic acid at position 574 of SEQ ID NO: 6611 (i.e., includes , for example consists of, SEQ ID NO: 6611 with C80L mutation and C574E mutation). Without being limited by theory, it is believed that such mutations improve the properties of the Cas9 molecule in solution.

In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes one or more mutations. In embodiments, the Cas9 variant includes a mutation at position 147 of SEQ ID NO: 6611, for example, includes a tyrosine at position 147 of SEQ ID NO: 6611 (i.e., includes, for example consists of, SEQ ID NO: 6611 with the D147Y mutation). In embodiments, the Cas9 variant includes a mutation at position 411 of SEQ ID NO: 6611, for example, includes a threonine at position 411 of SEQ ID NO: 6611 (i.e., includes, for example consists of, SEQ ID NO: 6611 with the P411T mutation). In embodiments, the Cas9 variant includes a mutation at position 147 and a mutation at position 411 of SEQ ID NO: 6611, for example, includes a tyrosine at position 147 of SEQ ID NO: 6611 and a threonine at position 411 of SEQ ID NO: 6611 (i.e., includes, for example consists of, SEQ ID NO: 6611 with D147Y mutation and P411T mutation). Without being limited by theory, it is believed that such mutations increase the efficiency of the directed interaction of the Cas9 molecule, for example, in yeast.

In embodiments, the Cas9 molecule is a Cas9 variant of S. pyogenes SEQ ID NO: 6611 that includes one or more mutations. In embodiments, the Cas9 variant includes a mutation at position 1135 of SEQ ID NO: 6611, for example, includes glutamic acid at position 1135 of SEQ ID NO: 6611 (i.e., includes, for example, consists of, SEQ ID NO: 6611 with mutation D1135E). Without being limited by theory, such mutations are believed to increase the selectivity of the Cas9 molecule for the PAM NGG sequence over the PAM NAG sequence.

In embodiments, the Cas9 molecule is a variant of S. pyogenes Cas9 SEQ ID NO: 6611 that includes one or more mutations to introduce an uncharged or non-polar amino acid, such as alanine, at certain positions. In embodiments, the Cas9 molecule is a variant of S. pyogenes Cas9 SEQ ID NO: 6611 that includes a mutation at position 497, a mutation at position 661, a mutation at position 695, and/or a mutation at position 926 of SEQ ID NO: 6611, such as a substitution mutation to alanine at position 497, position 661, position 695, and/or position 926 of SEQ ID NO: 6611. In embodiments, the Cas9 molecule contains a mutation only at position 497, position 661, position 695, and position 926 of SEQ ID NO: 6611, relative to SEQ ID NO: 6611, for example, where each mutation is a replacement for an uncharged amino acid, such as alanine. Without being limited by theory, it is believed that such mutations reduce the cleavage produced by the Cas9 molecule at off-target sites.

It should be understood that mutations in the Cas9 molecule described in this application can be combined in combination and can be combined in combination with any of the fusion constructs or other modifications described in this application and the Cas9 molecule tested in the assays described in this application. application.

Various types of Cas molecules can be used to practice the invention disclosed in this application. In some embodiments, Cas molecules of Type II Cas systems are used. In other embodiments, Cas molecules of other Cas systems are used. For example, type 1 or type III Cas molecules can be used. Examples of Cas molecules (and Cas systems) are described, for example, in Haft et al., PLoS COMPUTATIONAL BIOLOGY 2005, 1(6):e60 and Makarova et al., NATURE REVIEW MICROBIOLOGY 2011, 9:467-477, the contents of which are in full incorporated into this application by reference.

In an embodiment, the Cas9 molecule includes one or more of the following activities: nicase activity; double strand cleavage activity (eg, endonuclease and/or exonuclease activity); helicase activity; or the ability, together with the nRNA molecule, to localize to the target nucleic acid.

Altered Cas9 molecules

Natural Cas9 molecules have many properties including: nicase activity, nuclease activity (eg, endonuclease and/or exonuclease activity); helicase activity; the ability to functionally bind to an nRNA molecule; and the ability to target (or localize to) a site on a nucleic acid (eg, PAM recognition and specificity). In an embodiment, Cas9 molecules may include all or part of these properties. In exemplary embodiments, Cas9 molecules have the ability to interact with an nRNA molecule and, together with the nRNA molecule, localize to a site of a nucleic acid. Other activities, such as PAM specificity, cleavage activity, or helicase activity, may vary more widely across Cas9 molecules.

Cas9 molecules with the desired properties can be obtained in many ways, for example, by modifying the original, for example natural, Cas9 molecules to obtain a modified Cas9 molecule with the desired property. For example, one or more mutations or differences from the original Cas9 molecule may be introduced. Such mutations and differences include: substitutions (eg conservative or non-essential amino acid substitutions); inserts; or deletions. In an embodiment, the Cas9 molecule may include one or more mutations or differences, such as at least 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50 mutations, but less than 200, 100, or 80 mutations compared to the reference Cas9 molecule.

In an embodiment, the mutation or mutations do not significantly affect the activity of Cas9, such as the activity of Cas9 described in this application. In an embodiment, the mutation or mutations have a significant effect on the activity of Cas9, such as the activity of Cas9 described in this application. In an embodiment, exemplary activities include one or more of PAM specificity, cleavage activity, and helicase activity. The mutation(s) may be present, for example, in: one or more RuvC-like domains, eg, an N-terminal RuvC-like domain; HNH-like domain; regions outside the RuvC-like domains and the HNH-like domain. In some embodiments, the mutation(s) is present in the N-terminal RuvC-like domain. In some embodiments, the implementation of the mutation(s) is present in the HNH-like domain. In some embodiments, mutations are present in both the N-terminal RuvC-like domain and the HNH-like domain.

Whether a particular sequence, such as a substitution, can affect one or more activities, such as targeting activity, cleaving activity, etc., can be assessed or predicted, for example, by assessing whether a mutation is conservative, or using the method described in section III. In an embodiment, a "non-essential" amino acid residue, when used in relation to a Cas9 molecule, is a residue that can be altered from the wild-type sequence of the Cas9 molecule, e.g., a naturally occurring Cas9 molecule, e.g., an active Cas9 molecule, without disturbing, or more preferably, at essentially no change in Cas9 activity (eg, cleavage activity), while a change in a "substantial" amino acid residue results in a significant loss of activity (eg, cleavage activity).

Cas9 molecules with altered PAM recognition or no PAM recognition

Natural Cas9 molecules can recognize certain PAM sequences, such as the PAM recognition sequences described above for S. pyogenes, S. thermophilus, S. mutans, S. aureus, and N. meningitidis.

In an embodiment, the Cas9 molecule has the same PAM specificity as the native Cas9 molecule. In other embodiments, the Cas9 molecule has a PAM specificity unrelated to the naturally occurring Cas9 molecule, or a PAM specificity unrelated to the naturally occurring Cas9 molecule with which it has the closest sequence homology. For example, a native Cas9 molecule can be altered, eg, to alter PAM recognition, eg, alter the PAM sequence that the Cas9 molecule recognizes to reduce off-target sites and/or increase specificity; or to eliminate the PAM recognition requirement. In an embodiment, the Cas9 molecule can be modified, for example, to increase the length of the PAM recognition sequence and/or increase the specificity of Cas9 to a high level of identity to reduce off-target sites and increase specificity. In an embodiment, the PAM sequence to be recognized is at least 4, 5, 6, 7, 8, 9, 10, or 15 amino acids long. Cas9 molecules that recognize different PAM sequences and/or have reduced off-target activity can be generated using directed evolution. Exemplary methods and systems that can be used for directed evolution of Cas9 molecules are described, for example, in Esvelt el al, Nature 2011, 472(7344): 499-503. Candidate Cas9 molecules can be evaluated, for example, using the methods described in this application.

Non-cleavage and modified cleavage Cas9 molecules

In an embodiment, the Cas9 molecule includes a cleavage property that is different from naturally occurring Cas9 molecules, eg, that is different from the naturally occurring Cas9 molecule of closest homology. For example, a Cas9 molecule may differ from naturally occurring Cas9 molecules, such as the S. pyogenes Cas9 molecule, in the following way: its ability to modulate, e.g. decrease or increase, double-strand break cleavage (endonuclease and/or exonuclease activity) may be eliminated, e.g., compared to a naturally occurring Cas9 molecule (eg, S. pyogenes Cas9 molecule); its ability to modulate, e.g. decrease or increase, the cleavage of a single strand of a nucleic acid, e.g., a non-complementary strand of a nucleic acid molecule or a complementary strand of a nucleic acid molecule (no activity), e.g. compared to a native Cas9 molecule (e.g., a Cas9 molecule of S. pyogenes) ; or the ability to cleave a nucleic acid molecule, such as a double-stranded or single-stranded nucleic acid molecule.

Active Cas9 molecules with modified cleavage

In an embodiment, an active Cas9 molecule includes one or more of the following activities: a cleaving activity associated with an N-terminal RuvC-like domain; cleavage activity associated with the HNH-like domain; a cleaving activity associated with an HNH-like; and a cleaving activity associated with an N-terminal RuvC-like domain.

In an embodiment, the Cas9 molecule is a Cas9 nickase, eg, cleaves only one strand of DNA. In an embodiment of Cas9, nikase includes a mutation at position 10 and/or a mutation at position 840 of SEQ ID NO: 6611, for example, includes a D10A and/or H840A mutation in SEQ ID NO: 6611.

Non-cleaving inactive Cas9 molecules

In an embodiment, the altered Cas9 molecule is an inactive Cas9 molecule that does not cleave the nucleic acid molecule (double-stranded or single-stranded nucleic acid molecules) or cleaves the nucleic acid molecule at a significantly lower efficiency, such as less than 20, 10, 5, 1, or 0.1 % cleavage activity of the reference Cas9 molecule, for example, when measured using the assay described in this application. The reference Cas9 molecule may be a naturally occurring, unmodified Cas9 molecule, for example, a naturally occurring Cas9 molecule, such as the Cas9 molecule of S. pyogenes, S. thermophilus, S. aureus, or N. meningitidis. In an embodiment, the Cas9 reference molecule is the naturally occurring Cas9 molecule having the closest sequence identity or homology. In an embodiment, the inactive Cas9 molecule does not have significant cleavage activity associated with the N-terminal RuvC-like domain and cleavage activity associated with the HNH-like domain.

In an embodiment, the Cas9 molecule is dCas9. Tsai et al., (2014), Nat. Biotech., 32:569-577.

A catalytically inactive Cas9 molecule can be fused to a transcriptional repressor. The inactive Cas9 fusion protein forms a complex with the nRNA and localizes to the DNA sequence defined by the nRNA guide domain, but unlike the active Cas9, it does not cleave the target DNA. Fusion of an effector domain, such as a transcriptional repression domain, with inactive Cas9 allows the recruitment of the effector to any DNA region determined by the nRNA. Site-specific targeting of a Cas9 fusion protein to the promoter region of a gene can block or interfere with polymerase binding to the promoter region, e.g., fusion of Cas9 with a transcription factor (e.g., a transcription activator) and/or binding of a transcriptional enhancer to a nucleic acid causes an increase or inhibition of transcription activation . Alternatively, a site-specific targeting interaction of the Cas9 fusion construct with a transcriptional repressor in the promoter region of the gene can be used to reduce transcriptional activation.

Transcriptional repressors or transcription repressor domains that can be fused to an inactive Cas9 molecule may include a ruppel associated box (KRAB or SKD), an mSIN3 Mad interaction domain (SID), or an ERF repressor domain (ERD).

In another embodiment, an inactive Cas9 molecule can be fused to a protein that modifies chromatin. For example, an inactive Cas9 molecule can be fused to heterochromatin protein 1 (HP1), histone lysine methyltransferase (e.g., SUV39H1, SUV39H2, G9A, ESET/SETDB1, Pr-SET7/8, SUV4-20H1, RIZ1), histone lysine demethylases (e.g. LSD1/BHC110, SpLsd1/Sw, 1/Saf110, Su(var)3-3, JMJD2A/JHDM3A, JMJD2B, JMJD2C/GASC1, JMJD2D, Rph 1, JARID1A/RBP2, JARID1B/PLU-1, JARID1C/ SMCX, JARID1D/SMCY, Lid, Jhn2, Jmj2), histone lysine deacetylases (e.g. HDAC1, HDAC2, HDAC3, HDAC8, Rpd3, Hos1, Cir6, HDAC4, HDAC5, HDAC7, HDAC9, Hda1, Cir3, SIRT1, SIRT2, Sir2, HST1, Hst2, Hst3, Hst4, HDAC11) and DNA methylases (DNMT1, DNMT2a/DMNT3b, MET1). The inactive Cas9 chromatin-modifying molecule fusion protein can be used to change the status of the chromatin to reduce the expression of the target gene.

A heterologous sequence (eg, a transcriptional repressor domain) can be fused to the N- or C-terminus of an inactive Cas9 protein. In an alternative embodiment, a heterologous sequence (eg, a transcriptional repressor domain) can be fused to the interior (ie, the portion other than the N-terminus or C-terminus) of an inactive Cas9 protein.

The ability of the Cas9 molecule/nRNA molecule complex to bind to and cleave a target nucleic acid can be assessed, for example, using the methods described in section III of this specification. The activity of a Cas9 molecule, such as active Cas9 or inactive Cas9, alone or in combination with an nRNA molecule, can also be assessed using methods known in the art, including gene expression assays and chromatin-based assays, such as chromatin immunoprecipitation (ChiP) and in vivo chromatin analysis (CiA).

Other Cas9 fusion molecules

In embodiments, a Cas9 molecule, eg, S. pyogenes Cas9, may further include one or more amino acid sequences that confer additional activity.

In some aspects, the Cas9 molecule may include one or more nuclear localization sequences (NLS), such as at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS. In some embodiments, the Cas9 molecule includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLSs at or near the N-terminus, at least 1, 2, 3, 4 , 5, 6, 7, 8, 9, 10 or more NLSs at or near the C-terminus, or a combination thereof (eg, one or more NLSs at the N-terminus and one or more NLSs at the C-terminus). Where more than one NLS is present, each may be selected independently of the others, wherein one NLS may be present in more than one copy and/or in combination with one or more other NLS present in one or more copies. In some embodiments, the NLS is assumed to be near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more amino acids along the polypeptide chains from the N- or C-terminus. As a rule, NLS consists of one or more short sequences of positively charged lysines or arginines, which are located on the surface of the protein, but other types of NLS are known. Non-limiting examples of NLSs include an NLS sequence comprising or derived from: an NLS from the SV40 large T antigen having the amino acid sequence PKKKRKV (SEQ ID NO: 6612); NLS from nucleoplasmin (e.g. double nucleoplasmin NLS with the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 6613); c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 6614) or RQRRNELKRSP (SEQ ID NO: 6615); NLS hRNPA1 M9, having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 6616); ; PQPKKKPL (SEQ ID NO: 6620) sequence from human p53; SALIKKKKKMAP sequence (SEQ ID NO: 6621) from murine c-ab1 IV; DRLRR (SEQ ID NO: 6622) and PKQKKRK (SEQ ID NO: 6623) sequences from influenza NS1 virus RKLKKKIKKL (SEQ ID NO: 6624) hepatitis virus delta antigen sequence REKKKFLKRR (SEQ ID NO: 6625) mouse Mx1 protein sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 6626) from poly(ADP-ribose) polymer zy man; and the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: 6627) of steroid hormone glucocorticoid receptors (human). Other suitable NLS sequences are known in the art (eg Sorokin, Biochemistry (Moscow) (2007) 72:13, 1439-1457; Lange J Biol Chem. (2007) 282:8, 5101-5).

In some aspects, the Cas9 molecule may include one or more amino acid sequences that provide specific recognition of the Cas9 molecule, such as a tag. In one embodiment, the label is a histidine label, eg, a histidine label, comprising at least 3, 4, 5, 6, 7, 8, 9, 10 or more histidine amino acid residues (SEQ ID NO: 10800). In embodiments, the histidine tag is a His6 tag (six histidines) (SEQ ID NO: 10795). In other embodiments, the histidine tag is a His8 tag (eight histidines). In embodiments, the histidine tag can be separated from one or more other parts of the Cas9 molecule by a linker. In embodiments, the linker is GGS. An example of such a fusion construct is the Cas9 iProt106520 molecule.

In some aspects, the Cas9 molecule may include one or more amino acid sequences that are recognized by the protease (eg, contains a protease cleavage site). In embodiments, the cleavage site is a tobacco etch virus (TEV) cleavage site, eg, includes the ENLYFQG sequence (SEQ ID NO: 7810). In some aspects, a protease cleavage site, such as a TEV cleavage site, is located between a tag, such as a His tag, such as His6 (SEQ ID NO: 10795) or His8 tag (SEQ ID NO: 10796), and the rest of the Cas9 molecule. Without being limited by theory, it is believed that such an introduction would allow the label to be used, for example, to purify the Cas9 molecule followed by cleavage, whereby the label would not interfere with the function of the Cas9 molecule.

In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal NLS and a C-terminal NLS (e.g., includes, N- to C-terminal, NLS-Cas9-NLS), e.g., where each NLS is an NLS SV40 (PKKKRKV (SEQ ID NO: 6612)). In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal NLS, a C-terminal NLS, and a C-terminal His6 tag (SEQ ID NO: 10795) (e.g., includes, N- to C -end, NLS-Cas9-NLS-His label), for example, where each NLS is an NLS SV40 (PKKKRKV (SEQ ID NO: 6612)). In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal His tag (e.g., His6 tag (SEQ ID NO: 10795)), an N-terminal NLS, and a C-terminal NLS (e.g., includes , N- to C-terminal, His label-NLS-Cas9-NLS), for example, where each NLS is an NLS SV40 (PKKKRKV (SEQ ID NO: 6612)). In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal NLS and a C-terminal His tag (e.g., His6 tag (SEQ ID NO: 10795)) (e.g., includes, N- to C-terminus, His tag-Cas9-NLS), for example, where NLS is NLS SV40 (PKKKRKV (SEQ ID NO: 6612)). In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal His tag (e.g., His6 tag (SEQ ID NO: 10795)) and a C-terminal NLS (e.g., includes, N- to C-terminus, NLS-Cas9-His label), for example, where NLS is NLS SV40 (PKKKRKV (SEQ ID NO: 6612)). In embodiments, a Cas9 molecule (e.g., a Cas9 molecule as described herein) includes an N-terminal His tag (e.g., His8 tag (SEQ ID NO: 10796)), an N-terminal cleavage domain (e.g., tobacco etch virus cleavage domain (TEV) (for example, includes the sequence ENLYFQG (SEQ ID NO: 7810))), N-terminal NLS (for example, NLS SV40; SEQ ID NO: 6612) and C-terminal NLS (for example, NLS SV40; SEQ ID NO: 6612) (eg, includes, N- to C-terminus, His tag-TEV-NLS-Cas9-NLS). In any of the above embodiments, Cas9 has the sequence of SEQ ID NO: 6611. Alternatively, in any of the above embodiments, Cas9 has the sequence of the Cas9 variant SEQ ID NO: 6611, for example, as described herein. In any of the above embodiments, the Cas9 molecule includes a linker between the His tag and another part of the molecule, such as a GGS linker. The amino acid sequences of the exemplary Cas9 molecules described above are shown below. Identifiers "iProt" correspond to those indicated in Figure 60.

iProt105026 (also listed as iProt106154, iProt106331, iProt106545 and PID426303, depending on protein preparation) (SEQ ID NO: 7821):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP KLESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKRPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

iProt106518 (SEQ ID NO: 7822):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRILYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI EEFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP KLESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKRPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

iProt106519 (SEQ ID NO: 7823):

MGSSHHHHHH HHENLYFQGS MDKKYSIGLD IGTNSVGWAV ITDEYKVPSK KFKVLGNTDR HSIKKNLIGA LLFDSGETAE ATRLKRTARR RYTRRKNRIC YLQEIFSNEM AKVDDSFFHR LEESFLVEED KKHERHPIFG NIVDEVAYHE KYPTIYHLRK KLVDSTDKAD LRLIYLALAH MIKFRGHFLI EGDLNPDNSD VDKLFIQLVQ TYNQLFEENP INASGVDAKA ILSARLSKSR RLENLIAQLP GEKKNGLFGN LIALSLGLTP NFKSNFDLAE DAKLQLSKDT YDDDLDNLLA QIGDQYADLF LAAKNLSDAI LLSDILRVNT EITKAPLSAS MIKRYDEHHQ DLTLLKALVR QQLPEKYKEI FFDQSKNGYA GYIDGGASQE EFYKFIKPIL EKMDGTEELL VKLNREDLLR KQRTFDNGSI PHQIHLGELH AILRRQEDFY PFLKDNREKI EKILTFRIPY YVGPLARGNS RFAWMTRKSE ETITPWNFEE VVDKGASAQS FIERMTNFDK NLPNEKVLPK HSLLYEYFTV YNELTKVKYV TEGMRKPAFL SGEQKKAIVD LLFKTNRKVT VKQLKEDYFK KIECFDSVEI SGVEDRFNAS LGTYHDLLKI IKDKDFLDNE ENEDILEDIV LTLTLFEDRE MIEERLKTYA HLFDDKVMKQ LKRRRYTGWG RLSRKLINGI RDKQSGKTIL DFLKSDGFAN RNFMQLIHDD SLTFKEDIQK AQVSGQGDSL HEHIANLAGS PAIKKGILQT VKVVDELVKV MGRHKPENIV IEMARENQTT QKGQKNSRER MKRIEEGIKE LGSQILKEHP VENTQLQNEK LYLYYLQNGR DMYVDQELDI NRLSDYDVDH IVPQSFLKDD SIDNKVLTRS DKNRGKSDNV PSEEVVKKMK NYWRQLLNAK LITQRKFDNL TKAERGGLSE LDKAGFIKRQ LVETRQITKH VAQILDSRMN TKYDENDKLI REVKVITLKS KLVSDFRKDF QFYKVREINN YHHAHDAYLN AVVGTALIKK YPKLESEFVY GDYKVYDVRK MIAKSEQEIG KATAKYFFYS NIMNFFKTEI TLANGEIRKR PLIETNGETG EIVWDKGRDF ATVRKVLSMP QVNIVKKTEV QTGGFSKESI LPKRNSDKLI ARKKDWDPKK YGGFDSPTVA YSVLVVAKVE KGKSKKLKSV KELLGITIME RSSFEKNPID FLEAKGYKEV KKDLIIKLPK YSLFELENGR KRMLASAGEL QKGNELALPS KYVNFLYLAS HYEKLKGSPE DNEQKQLFVE QHKHYLDEII EQISEFSKRV ILADANLDKV LSAYNKHRDK PIREQAENII HLFTLTNLGA PAAFKYFDTT IDRKRYTSTK EVLDATLIHQ SITGLYETRI DLSQLGGDGG GSPKKKRKV

iProt106520 (SEQ ID NO: 7824):

MAHHHHHHGG SPKKKRKVDK KYSIGLDIGT NSVGWAVITD EYKVPSKKFK VLGNTDRHSI KKNLIGALLF DSGETAEATR LKRTARRRYT RRKNRICYLQ EIFSNEMAKV DDSFFHRLEE SFLVEEDKKH ERHPIFGNIV DEVAYHEKYP TIYHLRKKLV DSTDKADLRL IYLALAHMIK FRGHFLIEGD LNPDNSDVDK LFIQLVQTYN QLFEENPINA SGVDAKAILS ARLSKSRRLE NLIAQLPGEK KNGLFGNLIA LSLGLTPNFK SNFDLAEDAK LQLSKDTYDD DLDNLLAQIG DQYADLFLAA KNLSDAILLS DILRVNTEIT KAPLSASMIK RYDEHHQDLT LLKALVRQQL PEKYKEIFFD QSKNGYAGYI DGGASQEEFY KFIKPILEKM DGTEELLVKL NREDLLRKQR TFDNGSIPHQ IHLGELHAIL RRQEDFYPFL KDNREKIEKI LTFRIPYYVG PLARGNSRFA WMTRKSEETI TPWNFEEVVD KGASAQSFIE RMTNFDKNLP NEKVLPKHSL LYEYFTVYNE LTKVKYVTEG MRKPAFLSGE QKKAIVDLLF KTNRKVTVKQ LKEDYFKKIE CFDSVEISGV EDRFNASLGT YHDLLKIIKD KDFLDNEENE DILEDIVLTL TLFEDREMIE ERLKTYAHLF DDKVMKQLKR RRYTGWGRLS RKLINGIRDK QSGKTILDFL KSDGFANRNF MQLIHDDSLT FKEDIQKAQV SGQGDSLHEH IANLAGSPAI KKGILQTVKV VDELVKVMGR HKPENIVIEM ARENQTTQKG QKNSRERMKR IEEGIKELGS QILKEHPVEN TQLQNEKLYL YYLQNGRDMY VDQELDINRL SDYDVDHIVP QSFLKDDSID NKVLTRSDKN RGKSDNVPSE EVVKKMKNYW RQLLNAKLIT QRKFDNLTKA ERGGLSELDK AGFIKRQLVE TRQITKHVAQ ILDSRMNTKY DENDKLIREV KVITLKSKLV SDFRKDFQFY KVREINNYHH AHDAYLNAVV GTALIKKYPK LESEFVYGDY KVYDVRKMIA KSEQEIGKAT AKYFFYSNIM NFFKTEITLA NGEIRKRPLI ETNGETGEIV WDKGRDFATV RKVLSMPQVN IVKKTEVQTG GFSKESILPK RNSDKLIARK KDWDPKKYGG FDSPTVAYSV LVVAKVEKGK SKKLKSVKEL LGITIMERSS FEKNPIDFLE AKGYKEVKKD LIIKLPKYSL FELENGRKRM LASAGELQKG NELALPSKYV NFLYLASHYE KLKGSPEDNE QKQLFVEQHK HYLDEIIEQI SEFSKRVILA DANLDKVLSA YNKHRDKPIR EQAENIIHLF TLTNLGAPAA FKYFDTTIDR KRYTSTKEVL DATLIHQSIT GLYETRIDLS QLGGDSRADP KKKRKV

iProt106521 (SEQ ID NO: 7825):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP KLESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKRPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD HHHHHH

iProt106522 (SEQ ID NO: 7826):

MAHHHHHHGG SDKKYSIGLD IGTNSVGWAV ITDEYKVPSK KFKVLGNTDR HSIKKNLIGA LLFDSGETAE ATRLKRTARR RYTRRKNRIC YLQEIFSNEM AKVDDSFFHR LEESFLVEED KKHERHPIFG NIVDEVAYHE KYPTIYHLRK KLVDSTDKAD LRLIYLALAH MIKFRGHFLI EGDLNPDNSD VDKLFIQLVQ TYNQLFEENP INASGVDAKA ILSARLSKSR RLENLIAQLP GEKKNGLFGN LIALSLGLTP NFKSNFDLAE DAKLQLSKDT YDDDLDNLLA QIGDQYADLF LAAKNLSDAI LLSDILRVNT EITKAPLSAS MIKRYDEHHQ DLTLLKALVR QQLPEKYKEI FFDQSKNGYA GYIDGGASQE EFYKFIKPIL EKMDGTEELL VKLNREDLLR KQRTFDNGSI PHQIHLGELH AILRRQEDFY PFLKDNREKI EKILTFRIPY YVGPLARGNS RFAWMTRKSE ETITPWNFEE VVDKGASAQS FIERMTNFDK NLPNEKVLPK HSLLYEYFTV YNELTKVKYV TEGMRKPAFL SGEQKKAIVD LLFKTNRKVT VKQLKEDYFK KIECFDSVEI SGVEDRFNAS LGTYHDLLKI IKDKDFLDNE ENEDILEDIV LTLTLFEDRE MIEERLKTYA HLFDDKVMKQ LKRRRYTGWG RLSRKLINGI RDKQSGKTIL DFLKSDGFAN RNFMQLIHDD SLTFKEDIQK AQVSGQGDSL HEHIANLAGS PAIKKGILQT VKVVDELVKV MGRHKPENIV IEMARENQTT QKGQKNSRER MKRIEEGIKE LGSQILKEHP VENTQLQNEK LYLYYLQNGR DMYVDQELDI NRLSDYDVDH IVPQSFLKDD SIDNKVLTRS DKNRGKSDNV PSEEVVKKMK NYWRQLLNAK LITQRKFDNL TKAERGGLSE LDKAGFIKRQ LVETRQITKH VAQILDSRMN TKYDENDKLI REVKVITLKS KLVSDFRKDF QFYKVREINN YHHAHDAYLN AVVGTALIKK YPKLESEFVY GDYKVYDVRK MIAKSEQEIG KATAKYFFYS NIMNFFKTEI TLANGEIRKR PLIETNGETG EIVWDKGRDF ATVRKVLSMP QVNIVKKTEV QTGGFSKESI LPKRNSDKLI ARKKDWDPKK YGGFDSPTVA YSVLVVAKVE KGKSKKLKSV KELLGITIME RSSFEKNPID FLEAKGYKEV KKDLIIKLPK YSLFELENGR KRMLASAGEL QKGNELALPS KYVNFLYLAS HYEKLKGSPE DNEQKQLFVE QHKHYLDEII EQISEFSKRV ILADANLDKV LSAYNKHRDK PIREQAENII HLFTLTNLGA PAAFKYFDTT IDRKRYTSTK EVLDATLIHQ SITGLYETRI DLSQLGGDSR ADPKKKRKV

iProt106658 (SEQ ID NO: 7827):

MGSSHHHHHH HHENLYFQGS MDKKYSIGLD IGTNSVGWAV ITDEYKVPSK KFKVLGNTDR HSIKKNLIGA LLFDSGETAE ATRLKRTARR RYTRRKNRIC YLQEIFSNEM AKVDDSFFHR LEESFLVEED KKHERHPIFG NIVDEVAYHE KYPTIYHLRK KLVDSTDKAD LRLIYLALAH MIKFRGHFLI EGDLNPDNSD VDKLFIQLVQ TYNQLFEENP INASGVDAKA ILSARLSKSR RLENLIAQLP GEKKNGLFGN LIALSLGLTP NFKSNFDLAE DAKLQLSKDT YDDDLDNLLA QIGDQYADLF LAAKNLSDAI LLSDILRVNT EITKAPLSAS MIKRYDEHHQ DLTLLKALVR QQLPEKYKEI FFDQSKNGYA GYIDGGASQE EFYKFIKPIL EKMDGTEELL VKLNREDLLR KQRTFDNGSI PHQIHLGELH AILRRQEDFY PFLKDNREKI EKILTFRIPY YVGPLARGNS RFAWMTRKSE ETITPWNFEE VVDKGASAQS FIERMTNFDK NLPNEKVLPK HSLLYEYFTV YNELTKVKYV TEGMRKPAFL SGEQKKAIVD LLFKTNRKVT VKQLKEDYFK KIECFDSVEI SGVEDRFNAS LGTYHDLLKI IKDKDFLDNE ENEDILEDIV LTLTLFEDRE MIEERLKTYA HLFDDKVMKQ LKRRRYTGWG RLSRKLINGI RDKQSGKTIL DFLKSDGFAN RNFMQLIHDD SLTFKEDIQK AQVSGQGDSL HEHIANLAGS PAIKKGILQT VKVVDELVKV MGRHKPENIV IEMARENQTT QKGQKNSRER MKRIEEGIKE LGSQILKEHP VENTQLQNEK LYLYYLQNGR DMYVDQELDI NRLSDYDVDH IVPQSFLKDD SIDNKVLTRS DKNRGKSDNV PSEEVVKKMK NYWRQLLNAK LITQRKFDNL TKAERGGLSE LDKAGFIKRQ LVETRQITKH VAQILDSRMN TKYDENDKLI REVKVITLKS KLVSDFRKDF QFYKVREINN YHHAHDAYLN AVVGTALIKK YPKLESEFVY GDYKVYDVRK MIAKSEQEIG KATAKYFFYS NIMNFFKTEI TLANGEIRKR PLIETNGETG EIVWDKGRDF ATVRKVLSMP QVNIVKKTEV QTGGFSKESI LPKRNSDKLI ARKKDWDPKK YGGFDSPTVA YSVLVVAKVE KGKSKKLKSV KELLGITIME RSSFEKNPID FLEAKGYKEV KKDLIIKLPK YSLFELENGR KRMLASAGEL QKGNELALPS KYVNFLYLAS HYEKLKGSPE DNEQKQLFVE QHKHYLDEII EQISEFSKRV ILADANLDKV LSAYNKHRDK PIREQAENII HLFTLTNLGA PAAFKYFDTT IDRKRYTSTK EVLDATLIHQ SITGLYETRI DLSQLGGDGG GSPKKKRKV

iProt106745 (SEQ ID NO: 7828):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNAVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP KLESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKRPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

iProt106746 (SEQ ID NO: 7829):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEALY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP ALESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKAPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

iProt106747 (SEQ ID NO: 7830):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTNFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGRL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMQLIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLADDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRQITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP ALESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKAPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

iProt106884 (SEQ ID NO: 7831):

MAPKKKRKVD KKYSIGLDIG TNSVGWAVIT DEYKVPSKKF KVLGNTDRHS IKKNLIGALL FDSGETAEAT RLKRTARRRY TRRKNRICYL QEIFSNEMAK VDDSFFHRLE ESFLVEEDKK HERHPIFGNI VDEVAYHEKY PTIYHLRKKL VDSTDKADLR LIYLALAHMI KFRGHFLIEG DLNPDNSDVD KLFIQLVQTY NQLFEENPIN ASGVDAKAIL SARLSKSRRL ENLIAQLPGE KKNGLFGNLI ALSLGLTPNF KSNFDLAEDA KLQLSKDTYD DDLDNLLAQI GDQYADLFLA AKNLSDAILL SDILRVNTEI TKAPLSASMI KRYDEHHQDL TLLKALVRQQ LPEKYKEIFF DQSKNGYAGY IDGGASQEEF YKFIKPILEK MDGTEELLVK LNREDLLRKQ RTFDNGSIPH QIHLGELHAI LRRQEDFYPF LKDNREKIEK ILTFRIPYYV GPLARGNSRF AWMTRKSEET ITPWNFEEVV DKGASAQSFI ERMTAFDKNL PNEKVLPKHS LLYEYFTVYN ELTKVKYVTE GMRKPAFLSG EQKKAIVDLL FKTNRKVTVK QLKEDYFKKI ECFDSVEISG VEDRFNASLG TYHDLLKIIK DKDFLDNEEN EDILEDIVLT LTLFEDREMI EERLKTYAHL FDDKVMKQLK RRRYTGWGAL SRKLINGIRD KQSGKTILDF LKSDGFANRN FMALIHDDSL TFKEDIQKAQ VSGQGDSLHE HIANLAGSPA IKKGILQTVK VVDELVKVMG RHKPENIVIE MARENQTTQK GQKNSRERMK RIEEGIKELG SQILKEHPVE NTQLQNEKLY LYYLQNGRDM YVDQELDINR LSDYDVDHIV PQSFLKDDSI DNKVLTRSDK NRGKSDNVPS EEVVKKMKNY WRQLLNAKLI TQRKFDNLTK AERGGLSELD KAGFIKRQLV ETRAITKHVA QILDSRMNTK YDENDKLIRE VKVITLKSKL VSDFRKDFQF YKVREINNYH HAHDAYLNAV VGTALIKKYP KLESEFVYGD YKVYDVRKMI AKSEQEIGKA TAKYFFYSNI MNFFKTEITL ANGEIRKRPL IETNGETGEI VWDKGRDFAT VRKVLSMPQV NIVKKTEVQT GGFSKESILP KRNSDKLIAR KKDWDPKKYG GFDSPTVAYS VLVVAKVEKG KSKKLKSVKE LLGITIMERS SFEKNPIDFL EAKGYKEVKK DLIIKLPKYS LFELENGRKR MLASAGELQK GNELALPSKY VNFLYLASHY EKLKGSPEDN EQKQLFVEQH KHYLDEIIEQ ISEFSKRVIL ADANLDKVLS AYNKHRDKPI REQAENIIHL FTLTNLGAPA AFKYFDTTID RKRYTSTKEV LDATLIHQSI TGLYETRIDL SQLGGDSRAD PKKKRKVHHH HHH

Nucleic acids encoding Cas9 molecules

Nucleic acids encoding Cas9 molecules, for example an active Cas9 molecule or an inactive Cas9 molecule, are provided in this application.

Exemplary nucleic acids encoding Cas9 molecules are described in Cong et al., SCIENCE 2013, 399(6121):819-823; Wang et al., CELL 2013, 153(4):910-918; Mali et al., SCIENCE 2013, 399(6121):823-826; Jinek et al., SCIENCE 2012, 337(6096):816-821.

In an embodiment, the nucleic acid encoding the Cas9 molecule may be a synthetic nucleic acid sequence. For example, a synthetic nucleic acid molecule can be chemically modified, for example, as described in section XIII. In an embodiment, the Cas9 mRNA has one or more, eg all, of the following: capped, polyadenylated, 5-methylcytidine and/or pseudouridine substitution.

Additionally or alternatively, the synthetic nucleic acid sequence may be codon-optimized, for example, at least one uncommon codon or less common codon has been replaced with a common codon. For example, a synthetic nucleic acid can direct the synthesis of an optimized messenger mRNA, eg, optimized for expression in a mammalian cell-based expression system, eg, as described herein.

Below is an exemplary codon-optimized nucleic acid sequence encoding a Cas9 S. pyogenes molecule.

atggataaaa agtacagcat cgggctggac atcggtacaa actcagtggg gtgggccgtg
attacggacg agtacaaggt accctccaaa aaatttaaag tgctgggtaa cacggacaga
cactctataa agaaaaatct tattggagcc ttgctgttcg actcaggcga gacagccgaa
gccacaaggt tgaagcggac cgccaggagg cggtatacca ggagaaagaa ccgcatatgc
tacctgcaag aaatcttcag taacgagatg gcaaaaggttg acgatagctt tttccatcgc
ctggaagaat cctttcttgt tgaggaagac aagaagcacg aacggcaccc catctttggc
aatattgtcg acgaagtggc atatcacgaa aagtacccga ctatctacca cctcaggaag
aagctggtgg actctaccga taaggcggac ctcagactta tttatttggc actcgcccac
atgattaaat ttagaggaca tttcttgatc gagggcgacc tgaacccgga caacagtgac
gtcgataagc tgttcatcca acttgtgcag acctacaatc aactgttcga agaaaaccct
ataaatgctt caggagtcga cgctaaagca atcctgtccg cgcgcctctc aaaatctaga
agacttgaga atctgattgc tcagttgccc ggggaaaaga aaaatggatt gtttggcaac
ctgatcgccc tcagtctcgg actgacccca aatttcaaaa gtaacttcga cctggccgaa
gacgctaagc tccagctgtc caaggacaca tacgatgacg acctcgacaa tctgctggcc
cagattgggg atcagtacgc cgatctcttt ttggcagcaa agaacctgtc cgacgccatc
ctgttgagcg atatcttgag agtgaacacc gaaattacta aagcacccct tagcgcatct
atgatcaagc ggtacgacga gcatcatcag gatctgaccc tgctgaaggc tcttgtgagg
caacagctcc ccgaaaaata caaggaaatc ttctttgacc agagcaaaaa cggctacgct
ggctatatag atggtggggc cagtcaggag gaattctata aattcatcaa gcccattctc
gagaaaatgg acggcacaga ggagttgctg gtcaaactta acagggagga cctgctgcgg
aagcagcgga cctttgacaa cgggtctatc ccccaccaga ttcatctggg cgaactgcac
gcaatcctga ggaggcagga ggatttttat ccttttctta aagataaccg cgagaaaata
gaaaagattc ttacattcag gatcccgtac tacgtgggac ctctcgcccg gggcaattca
cggtttgcct ggatgacaag gaagtcagag gagactatta caccttggaa cttcgaagaa
gtggtggaca agggtgcatc tgcccagtct ttcatcgagc ggatgacaaa ttttgacaag
aacctcccta atgagaaggt gctgcccaaa cattctctgc tctacgagta ctttaccgtc
tacaatgaac tgactaaagt caagtacgtc accgagggaa tgaggaagcc ggcattcctt
agtggagaac agaagaaggc gattgtagac ctgttgttca agaccaacag gaaggtgact
gtgaagcaac ttaaagaaga ctactttaag aagatcgaat gttttgacag tgtggaaatt
tcaggggttg aagaccgctt caatgcgtca ttggggactt accatgatct tctcaagatc
ataaaggaca aagacttcct ggacaacgaa gaaaatgagg atattctcga agacatcgtc
ctcaccctga ccctgttcga agacagggaa atgatagaag agcgcttgaa aacctatgcc
cacctcttcg acgataaagt tatgaagcag ctgaagcgca ggagatacac aggatgggga
agattgtcaa ggaagctgat caatggaatt agggataaac agagtggcaa gaccatactg
gattcctca aatctgatgg cttcgccaat aggaacttca tgcaactgat tcacgatgac
tctcttacct tcaaggagga cattcaaaag gctcaggtga gcgggcaggg agactccctt
catgaacaca tcgcgaattt ggcaggttcc cccgctatta aaaagggcat ccttcaaact
gtcaaggtgg tggatgaatt ggtcaaggta atgggcagac ataagccaga aaatattgtg
atcgagatgg cccgcgaaaa ccagaccaca cagaagggcc agaaaaatag tagagagcgg
atgaagagga tcgaggaggg catcaaagag ctgggatctc agattctcaa agaacaccccc
gtagaaaaca cacagctgca gaacgaaaaa ttgtacttgt actatctgca gaacggcaga
gacatgtacg tcgaccaaga acttgatatt aatagactgt ccgactatga cgtagaccat
atcgtgcccc agtccttcct gaaggacgac tccattgata acaaagtctt gacaagaagc
gacaagaaca ggggtaaaag tgataatgtg cctagcgagg aggtggtgaa aaaaatgaag
aactactggc gacagctgct taatgcaaag ctcattacac aacggaagtt cgataatctg
acgaaagcag agagaggtgg cttgtctgag ttggacaagg cagggtttat taagcggcag
ctggtggaaa ctaggcagat cacaaagcac gtggcgcaga ttttggacag ccggatgaac
acaaaatacg acgaaaatga taaactgata cgagaggtca aagttatcac gctgaaaagc
aagctggtgt ccgattttcg gaaagacttc cagttctaca aagttcgcga gattaataac
taccatcatg ctcacgatgc gtacctgaac gctgttgtcg ggaccgcctt gataaagaag
tacccaaagc tggaatccga gttcgtatac ggggattaca aagtgtacga tgtgaggaaa
atgatagcca agtccgagca ggagattgga aaggccacag ctaagtactt cttttattct
aacatcatga atttttttaa gacggaaatt accctggcca acggagagat cagaaagcgg
ccccttatag agacaaatgg tgaaacaggt gaaatcgtct gggataaggg cagggatttc
gctactgtga ggaaggtgct gagtatgcca caggtaaata tcgtgaaaaa aaccgaagta
cagaccggag gattttccaa ggaaagcatt ttgcctaaaa gaaactcaga caagctcatc
gcccgcaaga aagattggga ccctaagaaa tacgggggat ttgactcacc caccgtagcc
tattctgtgc tggtggtagc taaggtggaa aaaggaaagt ctaagaagct gaagtccgtg
aaggaactct tgggaatcac tatcatggaa agatcatcct ttgaaaagaa ccctatcgat
ttcctggagg ctaagggtta caaggaggtc aagaaagacc tcatcattaa actgccaaaa
tactctctct tcgagctgga aaatggcagg aagagaatgt tggccagcgc cggagagctg
caaaagggaa acgagcttgc tctgccctcc aaatatgtta attttctcta tctcgcttcc
cactatgaaa agctgaaagg gtctcccgaa gataacgagc agaagcagct gttcgtcgaa
cagcacaagc actatctgga tgaaataatc gaacaaataa gcgagttcag caaaagggtt
atcctggcgg atgctaattt ggacaaagta ctgtctgctt ataacaagca ccgggataag
cctattaggg aacaagccga gaatataatt cacctcttta cactcacgaa tctcggagcc
cccgccgcct tcaaatactt tgatacgact atcgaccgga aacggtatac cagtaccaaa
gaggtcctcg atgccaccct catccaccag tcaattactg gcctgtacga aacacggatc
gacctctctc aactgggcgg cgactag 60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1080
1140
1200
1260
1320
1380
1440
1500
1560
1620
1680
1740
1800
1860
1920
1980
2040
2100
2160
2220
2280
2340
2400
2460
2520
2580
2640
2700
2760
2820
2880
2940
3000
3060
3120
3180
3240
3300
3360
3420
3480
3540
3600
3660
3720
3780
3840
3900
3960
4020
4080
4107

(SEQ ID NO: 6628)

If the above Cas9 sequences are fused to a peptide or polypeptide at the C-terminus (eg, an inactive Cas9 is fused to a transcriptional repressor at the C-terminus), it is to be understood that the stop codon will be removed.

V. Chimeric antigen receptors

The invention provides nRNA molecules and CRISPR systems for use in combination with adoptive immunotherapy methods, as well as reagents such as chimeric antigen receptor (CAR) immune effector cells, e.g. T cells, or chimeric TCR-transduced immune effector cells, e.g. , T cells. The nRNA molecules and CRISPR systems of the invention can be used to produce adoptive immunotherapy cells and compositions with improved properties such as efficacy and safety. This section generally describes the CAR technology that can be used in combination with the gRNA molecules and CRISPR systems of the invention, and describes improved CAR reagents, eg, cells and compositions, and methods.

In general, aspects of the invention relate to or include an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain (e.g., an antibody or antibody fragment, TCR or TCR fragment) that binds to a tumor antigen as described herein. application, a transmembrane domain (for example, the transmembrane domain described in this application) and an intracellular signaling domain (for example, an intracellular signaling domain described in this application) (for example, an intracellular signaling domain including a costimulatory domain (for example, a costimulatory domain described in this application) application) and/or a primary signaling domain (e.g., the primary signaling domain described herein).In other aspects, the invention includes: host cells containing the above nucleic acids, and isolated proteins encoded by such nucleic acid molecules. , encoded proteins containing and their vectors, host cells, pharmaceutical compositions, and methods of administration and treatment related to the present invention are disclosed in detail in International Patent Application WO2015142675, which is incorporated by reference in its entirety.

In one aspect, the invention provides an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain (e.g., an antibody or antibody fragment, TCR or TCR fragment) that binds to a tumor-supporting antigen (e.g., a tumor-supporting antigen). , as described in this application), a transmembrane domain (for example, a transmembrane domain described in this application) and an intracellular signaling domain (for example, an intracellular signaling domain described in this application) (for example, an intracellular signaling domain including a costimulatory domain (for example, co-stimulatory domain described in this application) and/or primary signaling domain (for example, the primary signaling domain described in this application)). In some embodiments, the tumor maintaining antigen is an antigen present on a stromal cell or myeloid suppressor cell (MSC). In other aspects of the invention, polypeptides encoded by such nucleic acids and host cells containing such nucleic acids and/or polypeptides are provided.

In an alternative, aspects of the invention relate to an isolated nucleic acid encoding a chimeric T-cell receptor (TCR) comprising a TCR-alpha and/or TCR-beta variable domain with specificity for the cancer antigen described herein. See, for example, Dembic et al., Nature, 320, 232-238 (1986), Schumacher, Nat. Rev. Immunol., 2, 512-519 (2002), Kershaw et al., Nat. Rev. Immunol., 5, 928-940 (2005), Xue et al., Clin. Exp. Immunol., 139, 167-172 (2005), Rossig et al., Mol. Ther., 10, 5-18 (2004) and Murphy et al., Immunity, 22, 403-414 (2005); (Morgan et al. J. Immunol., 171, 3287-3295 (2003), Hughes et al., Hum. Gene Ther., 16, 1-16 (2005), Zhao et al., J. Immunol., 174 , 4415-4423 (2005), Roszkowski et al., Cancer Res., 65, 1570-1576 (2005) and Engels et al., Hum Gene Ther., 16, 799-810 (2005); US2009/03046557, the contents of which are hereby incorporated by reference in their entirety Such chimeric TCRs can recognize, for example, cancer antigens such as MART-1, gp-100, p53 and NY-ESO-1, MAGE A3/A6, MAGEA3, SSX2, HPV-16 E6 or HPV-16 E7 In other aspects of the invention, polypeptides encoded by such nucleic acids and host cells containing such nucleic acids and/or polypeptides are provided.

targets

The present invention provides cells, e.g., immune effector cells (e.g., T cells, NK cells), that include or have at any time included an nRNA molecule or a CRISPR system as described herein, which are also modified to include one or more CARs that direct immune effector cells to unwanted cells (eg cancer cells). This is achieved through an antigen-binding domain on CAR that is specific for an antigen associated with cancer. There are two classes of cancer-associated antigens (tumor antigens) that can be targeted by the CARs of the present invention: (1) cancer-associated antigens that are expressed on the surface of cancer cells; and (2) cancer-associated antigens, which are themselves intracellular, however, a fragment of such an antigen (peptide) is presented on the surface of cancer cells MHC (major histocompatibility complex).

In some embodiments, the tumor antigen is selected from one or more of the following: CD19; CD123; CD22; CD30; CD171; CS-1 (also called CD2 subgroup 1, CRACC, SLAMF7, CD319 and 19A24); lectin-like molecule 1 C-type (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); B cell maturation antigen, a member of the TNF receptor (BCMA) family; Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor associated glycoprotein 72 (TAG72); CD38; CD44v6; cancer embryonic antigen (CEA); epitheliocyte adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); alpha-2 subunit of the interleukin-13 receptor (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostatic stem cell antigen (PSCA); serine protease 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis antigen (Y); CD24; platelet growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen 4 (SSEA-4); CD20; folate receptor alpha; receptor tyrosine protein kinase ERBB2 (Her2/neu); mucin 1 associated with the cell surface (MUC1); epidermal growth factor receptor (EGFR); nerve cell adhesion molecule (NCAM); prostasis; prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); proteasome subunit (prosoma, macropain), beta type, 9 (LMP2); glycoprotein 100 (gp100); an oncogenic fusion protein consisting of a clustered punctate break region (BCR) and Abelson murine leukemia virus (Abl) oncogene homologue 1 (bcr-abl); tyrosinase; ephrin type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); melanoma-associated high molecular weight antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid-stimulating hormone receptor (TSHR); group 5 G-protein coupled receptor class C, member D (GPRC5D); X chromosome open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); the hexasaccharide portion of glycoceramide globoH (GloboH); breast differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cell receptor 1 (HAVCR1); beta-3 adrenoreceptor (ADRB3); pannexin 3 (PANX3); G-protein coupled receptor 20 (GPR20); lymphocyte antigen complex 6, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternative reading frame protein (TARP); Wilms tumor protein (WT1); cancer/testicular antigen 1 (NY-ESO-1); cancer/testicular antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); translocation variant of the ETS 6 gene located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); antigen family X, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); cancer-testicular melanoma antigen 1 (MAD-CT-1); cancer-testicular melanoma antigen 2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); mutant p53; protein; survivin; telomerase; prostate carcinoma tumor antigen 1 (PCTA-1 or galectin-8), T cell-recognized melanoma antigen 1 (MelanA or MART1); rat sarcoma (Ras) mutant oncogene; human telomerase reverse transcriptase (hTERT); point breaks in the translocation of the sarcoma; melanoma apoptosis inhibitor (ML-IAP); ERG (transmembrane serine protease 2 (TMPRSS2) ETS fusion gene); N-acetyl-glucosaminyl transferase V (NA17); paired box-containing protein Pax-3 (PAX3); androgen receptor; cyclin B1; a homologue of the v-myc viral oncogene of avian myelocytomatosis from neuroblastoma (MYCN); member C of the Ras homologue family (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B1 (CYP1B1); CCCTC-binding factor (zinc-finger protein)-like (BORIS or Brother of the Regulator of Imprinted Sites), T-cell-recognized squamous cell carcinoma antigen 3 (SART3); Containing paired boxing protein Pax-5 (PAX5); proacrosin-binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); anchor protein A-kinase 4 (AKAP-4); synovial sarcoma, X break point 2 (SSX2); glycation end products receptor (RAGE-1); renal common 1 (RU1); renal common 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); IgA Fc receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily member 2 (LILRA2); member f of the CD300 family of molecule-like proteins (CD300LF); a member of the A family of 12 proteins with C-type lectin domains (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocytic antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1).

The CAR described herein may include an antigen-binding domain (eg, an antibody or antibody fragment, TCR or TCR fragment) that binds to a tumor-supporting antigen (eg, a tumor-supporting antigen as described herein). In some embodiments, the tumor maintaining antigen is an antigen present on a stromal cell or myeloid suppressor cell (MSC). Stromal cells can secrete growth factors causing cell division in the microenvironment. MSC cells can inhibit T cell proliferation and activation. Without being limited by theory, in some embodiments, CAR-expressing cells destroy tumor-supporting cells, thereby indirectly inhibiting tumor growth or survival.

In embodiments, the stromal cell antigen is selected from one or more of bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP), and tenascin. In an embodiment, the FAP-specific antibody is, competes for binding to sibrotuzumab, or has the same CDR regions as sibrotuzumab. In embodiments, the MSC antigen is selected from one or more of the following: CD33, CD11b, C14, CD15, and CD66b. Thus, in some embodiments, the tumor supporting antigen is selected from one or more of bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP), or tenascin, CD33, CD11b, C14, CD15, and CD66b.

Structures of antigen-binding domains

In some embodiments, the antigen-binding domain of the encoded CAR molecule comprises an antibody, an antibody fragment, scFv, Fv, Fab, (Fab')2, a single domain antibody (SDAB), a VH or VL domain, a camelid VHH domain, or a bifunctional (e.g., bispecific) hybrid antibody. (e.g. Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)).

In some cases, scFv fragments can be obtained according to a method known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad Sci USA 85:5879-5883). ScFv molecules can be generated by linking the VH and VL regions to each other using flexible polypeptide linkers. The scFv molecules include a linker (eg, Ser-Gly linker) with an optimized length and/or amino acid composition. Linker length can greatly influence how scFv variable regions fold and interact. In fact, if a short polypeptide linker (eg, 5-10 amino acids long) is used, intrachain folding is prevented. Interchain folding is also required to bring two variable regions together to form a functional epitope binding site. For examples of linker orientation and size, see, for example, Hollinger et al. 1993 Proc Natl Acad. sci. U.S.A 90:6444-6448, US Patent Application Publications 2005/0100543, 2005/0175606, 2007/0014794, and PCT Publications WO2006/020258 and WO2007/024715, incorporated herein by reference.

The ScFv may include a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more amino acid residues between the VL and VH regions it connects. The linker sequence may include any naturally occurring amino acid. In some embodiments, the linker sequence includes the amino acids glycine and serine. In another embodiment, the linker sequence includes sets of glycine and serine repeats such as (Gly ₄ Ser)n, where n is a positive integer greater than or equal to 1 (SEQ ID NO:6629). In one embodiment, the linker may be (Gly ₄ Ser) ₄ (SEQ ID NO:6593) or (Gly ₄ Ser) ₃ (SEQ ID NO:6594). Changing the length of the linker can maintain or increase activity, providing excellent performance in activity assays.

In another aspect, the antigen binding domain is a T cell receptor ("TCR") or a fragment thereof, such as a single chain TCR (scTCR). Methods for producing such TCR receptors are known in the art. See, for example, Willemsen RA et al., Gene Therapy 7: 1369-1377 (2000); Zhang T et al., Cancer Gene Ther 11: 487-496 (2004); Aggen et al., Gene Ther. 19(4):365-74 (2012) (these references are incorporated in this application in their entirety). For example, an scTCR can be constructed that contains the Vα and Vβ genes from a T cell clone linked by a linker (eg, a flexible peptide). This approach is very convenient in the case of a cancer-associated target, which itself is intracellular, but at the same time a fragment of such an antigen (peptide) is presented on the surface of cancer cells by the MHC complex.

In some embodiments, the encoded antigen-binding domain has a KD binding affinity of 10 ^-4 M to 10 ^-8 M.

In one embodiment, the encoded CAR molecule comprises an antigen binding domain that has a KD binding affinity of 10 ^-4 M to 10 ^-8 M, such as 10 ^-5 M to 10 ^-7 M, such as 10 ^-6 M or 10 ^-7 M, in relation to the target antigen. In one embodiment, the antigen binding domain has a binding affinity that is at least five-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, or 1000-fold less than a reference antibody, e.g., an antibody described herein. In one embodiment, the encoded antigen-binding domain has at least 5-fold lower binding affinity than the reference antibody (eg, the antibody from which the antigen-binding domain is derived). In one aspect, such antibody fragments are functional in that they provide a biological response, which may include, but is not limited to, activating an immune response, inhibiting the generation of signal transduction from their target antigen, inhibiting kinase activity, and the like, as will be known to those skilled in the art. this area.

In one aspect, a CAR antigen binding domain is an antibody scFv fragment that is humanized relative to the murine scFv sequence from which it is derived.

In one aspect, a CAR antigen-binding domain of the invention (eg, scFv) is encoded by a nucleic acid molecule whose sequence has been codon-optimized for expression in a mammalian cell. In one aspect, the entire CAR construct of the invention is encoded by a nucleic acid molecule whose entire sequence has been codon-optimized for expression in a mammalian cell. Codon optimization refers to the discovery that the frequency of occurrence of synonymous codons (ie, codons that code for the same amino acid) in coding DNA differs between species. This codon degeneration allows a single polypeptide to be encoded by multiple nucleotide sequences. A variety of codon optimization techniques are known in the art and include, for example, those disclosed in at least US Pat. Nos. 5,786,464 and 6,114,148.

Antigen-binding domains (and their target antigens)

In one embodiment, an anti-CD19 antigen-binding domain is an antigen-binding portion, eg, CDR regions, of a CAR receptor, an antibody, or an antigen-binding fragment thereof, as described, for example, in PCT publication WO2012/079000; PCT publication WO2014/153270; Kochenderfer, J.N. et al., J. Immunother., 32(7), 689-702 (2009); Kochenderfer, J.N., et al., Blood, 116(20), 4099-4102 (2010); PCT publications WO2014/031687; Bejcek, Cancer Research, 55, 2346-2351, 1995; or U.S. Patent 7,446,190.

In one embodiment, the anti-mesothelin antigen-binding domain is an antigen-binding portion, eg, CDR regions, of an antibody, antigen-binding fragment, or CAR, as described in, for example, PCT publication WO2015/090230. In one embodiment, the anti-mesothelin antigen-binding domain is an antigen-binding portion, e.g., CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described, for example, in PCT Publications WO1997/025068, WO1999/028471, WO2005/014652, WO2006/099141, WO2009/045957 , WO2009/068204, WO2013/142034, WO2013/040557 or WO2013/063419. In one embodiment, the anti-mesothelin antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described in WO/2015/090230.

In one embodiment, the antigen-binding domain against CD123 is an antigen-binding portion, eg CDR regions, of an antibody, an antigen-binding fragment, or a CAR as described, for example, in PCT publication WO2014/130635. In one embodiment, an anti-CD123 antigen-binding domain is an antigen-binding portion, e.g., CDR regions, of an antibody, antigen-binding fragment, or CAR, as described in e.g. , WO2010/126066, WO2014/144622 or US2009/0252742. In one embodiment, the anti-CD123 antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described in WO/2016/028896.

Examples include CAR molecules that include an antigen binding domain or VL and VH (in the sequences below separated by a (G4S)3 linker (SEQ ID NO: 6594)):

CD123-1:

QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAAFSLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQGDSVPLTFGGGTKLEIK (SEQ ID NO: 7812);

CD123-2:

QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTRLEIK (SEQ ID NO: 7813);

CD123-3:

QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYIHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSGLRSDDPAVYYCARDMNILATVPFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK (SEQ ID NO: 7814); or

CD123-4:

QVQLQQSGAEVKKSGASVKVSCKASGYTFTDYYMHWLRQAPGQGLEWMGWINPNSGDTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK (SEQ ID NO: 7815), из WO2016/0028896.

A CAR comprising said anti-CD123 binding domain may include, for example, the amino acid sequence:

CAR123-2:

MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 7816);

CAR123-3:

MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYIHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSGLRSDDPAVYYCARDMNILATVPFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 7817);

CAR123-4:

MALPVTALLLPLALLLHAARPQVQLQQSGAEVKKSGASVKVSCKASGYTFTDYYMHWLRQAPGQGLEWMGWINPNSGDTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSVPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCK (SEQ ID NO: 7818); or

CAR123-1: malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardmnilatvpfdiwgqgtmvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaafslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqgdsvpltfgggtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 7819). In each case, the CAR may or may not necessarily include the leader sequence included in each of the above sequences (MALPVTALLLPLALLLHAARP; SEQ ID NO: 6640).

In one embodiment, the anti-EGFRvIII antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described in, for example, WO/2014/130657.

In one embodiment, the antigen-binding domain against CD22 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Haso et al., Blood, 121(7):1165-1174 (2013); Wayne et al., Clin Cancer Res 16(6):1894-1903 (2010); Kato et al., Leuk Res 37(1):83-88 (2013); Creative BioMart (creativebiomart.net): MOM-18047-S(P).

In one embodiment, the antigen-binding domain against CS-1 is the antigen-binding portion, eg, CDR regions, of elotuzumab (BMS), see, eg, Tai et al., 2008, Blood 112(4):1329-37; Tai et al., 2007, Blood. 110(5):1656-63.

In one embodiment, the antigen-binding domain against CLL-1 is the antigen-binding portion, eg CDR regions, of an antibody available from R&D, ebiosciences, Abcam, eg PE-CLL1-hu cat no. 353604 (BioLegend); and PE-CLL1 (CLEC12A) (BD) part no. 562566. In one embodiment, the anti-CLL-1 antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, antigen-binding fragment, or CAR, as described in WO/2016/014535.

In one embodiment, the anti-CD33 antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of an antibody described in e.g. ), Caron et al., Cancer Res 52(24):6761-6767 (1992) (lintuzumab, HuM195), Lapusan et al., Invest New Drugs 30(3):1121-1131 (2012) (AVE9633), Aigner et al., Leukemia 27(5): 1107-1115 (2013) (AMG330, CD33 BiTE), Dutour et al., Adv hematol 2012:683065 (2012) and Pizzitola et al., Leukemia doi:10.1038/Lue.2014.62 (2014). In one embodiment, an anti-CD33 antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described in WO/2016/014576.

In one embodiment, the antigen-binding domain against GD2 is the antigen-binding portion, such as the CDR regions, of an antibody as described, for example, in Mujoo et al., Cancer Res. 47(4):1098-1104 (1987); Cheung et al., Cancer Res 45(6):2642-2649 (1985), Cheung et al., J Clin Oncol 5(9):1430-1440 (1987), Cheung et al., J Clin Oncol 16(9 ):3053-3060 (1998), Handgretinger et al., Cancer Immunol Immunother 35(3):199-204 (1992). In some embodiments, the antigen-binding domain against GD2 is the antigen-binding portion of an antibody selected from mAbs 14.18, 14G2a, ch14.18, hu14.18, 3F8, hu3F8, 3G6, 8B6, 60C3, 10B8, ME36.1, and 8H9, see e.g. , WO2012033885, WO2013040371, WO2013192294, WO2013061273, WO2013123061, WO2013074916 and WO201385552. In some embodiments, the antigen-binding domain against GD2 is the antigen-binding portion of an antibody described in US 20100150910 or PCT WO 2011160119.

In one embodiment, the antigen-binding domain against BCMA is the antigen-binding portion, eg CDR regions, of an antibody as described in eg WO2012163805, WO200112812 and WO2003062401. In one embodiment, an anti-BCMA antigen-binding domain is an antigen-binding portion, such as the CDR regions, of an antibody, an antigen-binding fragment, or a CAR, as described in WO/2016/014565.

In one embodiment, the antigen-binding domain against the Tn antigen is the antigen-binding portion, e.g., CDR regions, of an antibody as described in, e.g., US 8,440,798, Brooks et al., PNAS 107(22):10056-10061 (2010) and Stone et al. , OncoImmunology 1(6):863-873(2012).

In one embodiment, the antigen-binding domain against PSMA is the antigen-binding portion, e.g. CDR regions, of an antibody as described in e.g. Parker et al., Protein Expr Purif 89(2):136-145 (2013), US 20110268656 (J591 ScFv) ; Frigerio et al., European J Cancer 49(9):2223-2232 (2013) (scFvD2B); WO 2006125481 (mAbs 3/A12, 3/E7 and 3/F11) and single chain antibody fragments (scFv A5 and D7).

In one embodiment, the anti-ROR1 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Hudecek et al., Clin Cancer Res 19(12):3153-3164 (2013); WO 2011159847 and US20130101607.

In one embodiment, the anti-FLT3 antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of an antibody described in e.g.

In one embodiment, the antigen-binding domain against TAG72 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Hombach et al., Gastroenterology 113(4):1163-1170 (1997); and Abcam ab691.

In one embodiment, an anti-FAP antigen-binding domain is an antigen-binding portion, e.g., CDR regions, of an antibody as described in, e.g., Ostermann et al., Clinical Cancer Research 14:4584-4592 (2008) (FAP5), US Patent Publication 2009/0304718 ; sibrotuzumab (see, for example, Hofheinz et al., Oncology Research and Treatment 26(1), 2003); and Tran et al., J Exp Med 210(6):1125-1135 (2013).

In one embodiment, the antigen-binding domain against CD38 is the antigen-binding portion, eg, CDR regions, of daratumumab (see, eg, Groen et al., Blood 116(21):1261-1262 (2010)); MOR202 (see, for example, US 8,263,746); or antibodies described in US 8,362,211.

In one embodiment, the antigen-binding domain against CD44v6 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Casucci et al., Blood 122(20):3461-3472 (2013).

In one embodiment, the antigen-binding domain against CEA is the antigen-binding portion, eg, CDR regions, of an antibody as described, for example, in Chmielewski et al., Gastoenterology 143(4):1095-1107 (2012).

In one embodiment, the anti-EPCAM antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody selected from MT110, EpCAM-CD3 bispecific Ab (see, eg, clinicaltrials.gov/ct2/show/NCT00635596); edrecolomab; 3622W94; ING 1; and adecatumumab (MT201).

In one embodiment, the antigen-binding domain against PRSS21 is the antigen-binding portion, eg CDR regions, of the antibody described in US Pat. No. 8,080,650.

In one embodiment, the antigen-binding domain against B7H3 is the antigen-binding portion, eg CDR regions, of the MGA271 antibody (Macrogenics).

In one embodiment, the antigen-binding domain against KIT is the antigen-binding portion, eg CDR regions, of an antibody as described in eg US7915391, US20120288506, and several antibodies from commercial catalogs.

In one embodiment, the anti-IL-13Ra2 antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of an antibody as described in e.g.

In one embodiment, the antigen-binding domain against CD30 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US7090843 B1 and EP0805871.

In one embodiment, the antigen-binding domain against GD3 is the antigen-binding portion, eg CDR regions, of an antibody as described in, for example, US7253263; US 8,207,308; US20120276046; EP1013761; WO2005035577; and US6437098.

In one embodiment, the antigen-binding domain against CD171 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Hong et al., J Immunother 37(2):93-104 (2014).

In one embodiment, the anti-IL-11Ra antigen-binding domain is the antigen-binding portion, eg, CDR regions, of an antibody available from Abcam (cat. no. ab55262) or Novus Biologicals (cat. no. EPR5446). In another embodiment, the anti-IL-11Ra antigen-binding domain is a peptide, see, for example, Huang et al., Cancer Res 72(1):271-281 (2012).

In one embodiment, the antigen-binding domain against PSCA is the antigen-binding portion, eg, CDR regions, of an antibody as described, for example, in Morgenroth et al., Prostate 67(10):1121-1131 (2007) (scFv 7F5); Nejatollahi et al., J of Oncology 2013(2013), article ID 839831 (scFv C5-II); and US Patent Publication 20090311181.

In one embodiment, the anti-VEGFR2 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Chinnasamy et al., J Clin Invest 120(11):3953-3968 (2010).

In one embodiment, the anti-LewisY antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of an antibody as described in e.g. Kelly et al., Cancer Biother Radiopharm 23(4):411-423 (2008) (hu3S193 Ab (scFvs)) ; Dolezal et al., Protein Engineering 16(1):47-56 (2003) (NC10 scFv).

In one embodiment, the antigen-binding domain against CD24 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Maliar et al., Gastroenterology 143(5):1375-1384 (2012).

In one embodiment, the anti-PDGFR-beta antigen-binding domain is the antigen-binding portion, eg CDR regions, of the Abcam ab32570 antibody.

In one embodiment, the anti-SSEA-4 antigen-binding domain is an antigen-binding portion, such as the CDR regions, of the MC813 antibody (Cell Signaling) or other commercial antibodies.

In one embodiment, the antigen-binding domain against CD20 is an antigen-binding portion, such as the CDR regions, of the rituximab, ofatumumab, ocrelizumab, veltuzumab, or GA101 antibodies.

In one embodiment, the antigen-binding domain against folate receptor alpha is the antigen-binding portion, eg CDR regions, of the IMGN853 antibody or of the antibody described in US20120009181; US4851332, LK26: US5952484.

In one embodiment, the anti-ERBB2 antigen-binding domain (Her2/neu) is the antigen-binding portion, eg CDRs, of the trastuzumab or pertuzumab antibodies.

In one embodiment, the anti-MUC1 antigen-binding domain is the antigen-binding portion, eg the CDR regions, of the SAR566658 antibody.

In one embodiment, the anti-EGFR antigen-binding domain is an antigen-binding portion, such as the CDR regions, of cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab antibodies.

In one embodiment, the anti-NCAM antigen-binding domain is the antigen-binding portion, eg CDR regions, of clone 2-2B of the MAB5324 antibody (EMD Millipore).

In one embodiment, the antigen-binding domain against ephrin B2 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Abengozar et al., Blood 119(19):4565-4576 (2012).

In one embodiment, the antigen-binding domain against the IGF-I receptor is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US8344112 B2; EP2322550A1; WO 2006/138315 or PCT/US2006/022995.

In one embodiment, the anti-CAIX antigen-binding domain is the antigen-binding portion, eg CDR regions, of antibody clone 303123 (R&D Systems).

In one embodiment, the antigen-binding domain against LMP2 is the antigen-binding portion, such as the CDR regions, of an antibody as described in, for example, US7,410,640 or US20050129701.

In one embodiment, the antigen-binding domain against gp100 is an antigen-binding portion, such as the CDR regions, of an HMB45 antibody, NKIbetaB, or an antibody described in WO2013165940 or US20130295007

In one embodiment, the anti-tyrosinase antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, for example, US5843674; or US19950504048.

In one embodiment, the antigen-binding domain against EphA2 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Yu et al., Mol Ther 22(1):102-111 (2014).

In one embodiment, the antigen-binding domain against GD3 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US7253263; US 8,207,308; US20120276046; EP1013761A3; 20120276046; WO2005035577; or US6437098.

In one embodiment, the anti-fucosyl GM1 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US20100297138; or WO2007/067992.

In one embodiment, the antigen-binding domain against sLe is the antigen-binding portion, e.g. CDR regions, of the G193 (anti-lewis Y) antibody, see Scott AM et al, Cancer Res 60: 3254-61 (2000), also described in Neeson et al, J Immunol May 2013 190 (Meeting Abstract Supplement) 177.10.

In one embodiment, the antigen-binding domain against GM3 is the antigen-binding portion, eg the CDR regions, of the CA 2523449 antibody (mAb 14F7).

In one embodiment, the anti-HMWMAA antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of an antibody as described in e.g. Kmiecik et al., Oncoimmunology 3(1):e27185 (2014) (PMID: 24575382) (mAb 9.2.27) ; US6528481; WO2010033866; or US 20140004124.

In one embodiment, the antigen-binding domain against O-acetyl-GD2 is the antigen-binding portion, eg CDR regions, of the 8B6 antibody.

In one embodiment, the anti-TEM1/CD248 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Marty et al., Cancer Lett 235(2):298-308 (2006); Zhao et al., J Immunol Methods 363(2):221-232 (2011).

In one embodiment, the anti-CLDN6 antigen-binding domain is the antigen-binding portion, eg CDR regions, of the IMAB027 antibody (Ganymed Pharmaceuticals), see eg clinicaltrial.gov/show/NCT02054351.

In one embodiment, the anti-TSHR antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US8,603,466; US8,501,415; or US8,309,693.

In one embodiment, the antigen-binding domain against GPRC5D is the antigen-binding portion, eg CDR regions, of the FAB6300A antibody (R&D Systems); or LS-A4180 (Lifespan Biosciences).

In one embodiment, the antigen-binding domain against CD97 is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, US6,846,911; de Groot et al., J Immunol 183(6):4127-4134 (2009); or antibodies manufactured by R&D: MAB3734.

In one embodiment, the anti-ALK antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Mino-Kenudson et al., Clin Cancer Res 16(5):1561-1571 (2010).

In one embodiment, the anti-polysialic acid antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of an antibody as described in, e.g., Nagae et al., J Biol Chem 288(47):33784-33796 (2013).

In one embodiment, the anti-PLAC1 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Ghods et al., Biotechnol Appl Biochem 2013 doi:10.1002/bab.1177.

In one embodiment, the antigen-binding domain against GloboH is the antigen-binding portion of a VK9 antibody; or an antibody as described, for example, in Kudryashov V et al, Glycoconj J.15(3):243-9 (1998), Lou et al., Proc Natl Acad Sci USA 111(7):2482-2487 (2014); MBr1: Bremer E-G et al. J Biol Chem 259:14773-14777 (1984).

In one embodiment, the anti-NY-BR-1 antigen-binding domain is the antigen-binding portion, eg, CDR regions, of an antibody as described, for example, in Jager et al., Appl Immunohistochem Mol Morphol 15(1):77-83 (2007).

In one embodiment, the antigen-binding domain against WT-1 is the antigen-binding portion, eg CDR regions, of an antibody as described in, for example, Dao et al., Sci Transl Med 5(176):176ra33 (2013); or WO2012/135854.

In one embodiment, the anti-MAGEA-A1 antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of an antibody as described in e.g. Willemsen et al., J Immunol 174(12):7853-7858 (2005) (TCR-like scFv) .

In one embodiment, the antigen-binding domain against sperm protein 17 is the antigen-binding portion, eg, CDR regions, of an antibody as described in, eg, Song et al., Target Oncol 2013 Aug 14 (PMID: 23943313); Song et al., Med Oncol 29(4):2923-2931 (2012).

In one embodiment, the antigen-binding domain against Tie 2 is the antigen-binding portion, eg CDR regions, of the AB33 antibody (Cell Signaling Technology).

In one embodiment, the antigen-binding domain against MAD-CT-2 is the antigen-binding portion, eg CDR regions, of an antibody as described in eg PMID: 2450952; US7635753.

In one embodiment, the antigen-binding domain against Fos-related antigen 1 is the antigen-binding portion, eg CDR regions, of the 12F9 antibody (Novus Biologicals).

In one embodiment, the antigen-binding domain against MelanA/MART1 is the antigen-binding portion, eg CDR regions, of an antibody described in EP2514766 A2; or US 7,749,719.

In one embodiment, the antigen-binding domain against sarcoma translocation sites is the antigen-binding portion, eg CDR regions, of an antibody as described, for example, in Luo et al, EMBO Mol. Med. 4(6):453-461 (2012).

In one embodiment, the anti-TRP-2 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Wang et al, J Exp Med. 184(6):2207-16 (1996).

In one embodiment, the anti-CYP1B1 antigen-binding domain is the antigen-binding portion, eg CDR regions, of an antibody as described in, eg, Maecker et al, Blood 102 (9): 3287-3294 (2003).

In one embodiment, the anti-RAGE-1 antigen-binding domain is the antigen-binding portion, eg CDR regions, of the MAB5328 antibody (EMD Millipore).

In one embodiment, the antigen-binding domain against human telomerase reverse transcriptase is the antigen-binding portion, such as the CDR regions, of an antibody cat. LS-B95-100 (Lifespan Biosciences)

In one embodiment, the anti-intestinal carboxylesterase antigen-binding domain is the antigen-binding portion, eg, CDR regions, of the 4F12 antibody: cat. LS-B6190-50 (Lifespan Biosciences).

In one embodiment, the anti-mut hsp70-2 antigen-binding domain is the antigen-binding portion, eg CDRs, of a Lifespan Biosciences antibody: monoclone: cat number: LS-C133261-100 (Lifespan Biosciences).

In one embodiment, the anti-CD79a antigen-binding domain is the antigen-binding portion, eg CDR regions, of an anti-CD79a antibody [HM47/A9] (ab3121) manufactured by Abcam; antibodies against CD79A #3351 manufactured by Cell Signaling Technology; or antibody HPA017748, an antibody against CD79A produced in rabbits, available from Sigma-Aldrich.

In one embodiment, the anti-CD79b antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of the anti-CD79b antibody polatuzumab vedotin described in Dornan et al., "Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc- MMAE, for the treatment of non-Hodgkin's lymphoma", Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24, or the anti-CD79b/CD3 bispecific antibody described in "4507 Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies", Abstracts of 56th ASH Annual Meeting and Exposition, San Francisco, CA December 6-9 2014.

In one embodiment, the anti-CD72 antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of the J3-109 antibody described in Myers, and Uckun, "An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia". Leuk Lymphoma. 1995 Jun; 18(1-2):119-22, or anti-CD72 (10D6.8.1, mIgG1) antibodies described in Polson et al., "Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection Cancer Res March 15, 2009 69; 2358.

In one embodiment, the anti-LAIR1 antigen-binding domain is the antigen-binding portion, eg, CDR regions, of an anti-LAIR1 antibody, ANT-301, manufactured by ProSpec; or antibodies against human CD305 (LAIR1) manufactured by BioLegend.

In one embodiment, the anti-FCAR antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of the CD89/FCAR antibody (Cat. #10414-H08H) manufactured by Sino Biological Inc.

In one embodiment, an anti-LILRA2 antigen-binding domain is an antigen-binding portion, e.g., CDRs, of an anti-LILRA2 monoclonal antibody (M17), clone 3C7, manufactured by Abnova, or a mouse anti-LILRA2 monoclonal antibody, (2D7) manufactured by Lifespan Biosciences.

In one embodiment, an anti-CD300LF antigen-binding domain is an antigen-binding portion, e.g., CDR regions, of a mouse anti-CMRF35-like molecule 1 monoclonal antibody [UP-D2 available from BioLegend] or a rat anti-CMRF35-like molecule 1 monoclonal antibody [234903] available from R&D systems.

In one embodiment, an anti-CLEC12A antigen-binding domain is an antigen-binding portion, such as the anti-bispecific T-cell activator (BiTE) CDR regions, scFv antibodies, and ADCs described in Noordhuis et al., "Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody- Drug-Conjugates and Bispecific CLL-1xCD3 BiTE Antibody", 53rd ASH Annual Meeting and Exposition, December 10-13, 2011, and MCLA-117 (Merus).

In one embodiment, the anti-BST2 antigen-binding domain (also referred to as CD317) is the antigen-binding portion, e.g., CDR regions, of a mouse anti-CD317 monoclonal antibody, [3H4] marketed by Antibodies-Online or a mouse anti-CD317 monoclonal antibody [696739] marketed by R&D Systems .

In one embodiment, the anti-EMR2 (also referred to as CD312) antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of a mouse anti-CD312 monoclonal antibody [LS-B8033] from Lifespan Biosciences or a mouse anti-CD312 monoclonal antibody [494025] from R&D Systems. .

In one embodiment, the anti-LY75 antigen-binding domain is the antigen-binding portion, e.g., the CDRs, of a mouse anti-lymphocyte antigen 75 monoclonal antibody [HD30] from EMD Millipore or a mouse anti-lymphocyte antigen 75 monoclonal antibody [A15797] from Life Technologies.

In one embodiment, the antigen-binding domain against GPC3 is the antigen-binding portion, eg CDR regions, of the hGC33 antibody described in Nakano K, Ishiguro T, Konishi H, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 2010 Nov;21(10):907-916, or MDX-1414, HN3, or YP7, all three of which are described in Feng et al., "Glypican-3 antibodies: a new therapeutic target for liver cancer". FEBS Lett. 2014 Jan 21; 588(2):377-82.

In one embodiment, an anti-FCRL5 antigen-binding domain is the antigen-binding portion, e.g., CDR regions, of an anti-FcRL5 antibody described in Elkins et al., "FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma" by Mol Cancer Ther. 2012 Oct; 11(10):2222-32. In one embodiment, an anti-FCRL5 antigen-binding domain is an antigen-binding portion, e.g. CDR regions, of an anti-FcRL5 antibody as described in e.g. 120561 or WO2014/210064.

In one embodiment, the anti-IGLL1 antigen-binding domain is the antigen-binding portion, e.g. CDR regions, of a mouse anti-IgLL1 [AT1G4] monoclonal antibody manufactured by Lifespan Biosciences, a mouse anti-IgLL1 monoclonal antibody [HSL11] manufactured by BioLegend.

In one embodiment, the antigen binding domain comprises one, two, three (e.g., all three) heavy chain CDR regions, HC CDR1, HC CDR2, and HC CDR3, from the antibody above and/or one, two, three (e.g., all three) light chain CDR regions, LC CDR1, LC CDR2 and LC CDR3, from the antibody above. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a light chain variable region of an antibody as defined above.

In another aspect, the antigen binding domain includes a humanized antibody or antibody fragment. In some aspects, a non-human antibody is humanized in which certain sequences or regions of the antibody are modified to increase similarity to an antibody naturally produced in humans, or a fragment thereof. In one aspect, the antigen binding domain is humanized.

In an embodiment, the antigen binding domain of a CAR, such as the CAR expressed by the cell of the invention, binds to CD19. CD19 is present on B cells during cell line differentiation from the pro/pre-B cell stage to the terminally differentiated plasma cell stage. In an embodiment, the antigen binding domain is a murine scFv domain that binds to human CD19, eg CTL019 antigen binding domain (eg, SEQ ID NO: 7895). In an embodiment, the antigen binding domain is a humanized antibody or antibody fragment, eg, an scFv domain derived from a mouse scFv CTL019. In an embodiment, the antigen binding domain is a human antibody or antibody fragment that binds to human CD19. Examples of scFv domains (and sequences thereof, e.g., sequences of CDR regions, VL and VH) that bind to CD19 are shown in Table 14. The scFv domain sequences shown in Table 14 include the light chain (VL) variable region and the variable region heavy chain (VH). VL and VH are linked by a linker comprising the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 6594), for example in the following orientation: VL-linker-VH.

Table 14. Antigen-binding domains that bind CD19 Antigen Name Amino acid sequence SEQID NO: CD19 muCTL019 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS 7895 CD19 huscFv1 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7883 CD19 huscFv2 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7884 CD19 huscFv3 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7885 CD19 huscFv4 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7886 CD19 huscFv5 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7887 CD19 huscFv6 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7888 CD19 huscFv7 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7889 CD19 huscFv8 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7890 CD19 huscFv9 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7891 CD19 Hu
scFv10 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7892 CD19 Hu
scFv11 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 7893 CD19 Hu scFv12 QVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIK 7894

The CDR sequences of the scFv sequences of the CD19 antigen binding domains shown in Table 14 are shown in Table 15 for the heavy chain variable domains and in Table 16 for the light chain variable domains. "ID" denotes the corresponding SEQ ID NO for each CDR.

Table 15 Heavy chain variable domain CDRs Description FW HCDR1 ID HCDR2 ID HDDR3 ID mouse CART19 GVSLPDYGVS 7899 VIWGSETTYYNSALKS 7900 HYYYGGSYAMDY 7904 humanized CART19 a VH4 GVSLPDYGVS 7899 VIWGSETTYYSSSLKS 7901 HYYYGGSYAMDY 7904 humanized CART19 b VH4 GVSLPDYGVS 7899 VIWGSETTYYQSSLKS 7902 HYYYGGSYAMDY 7904 humanized CART19 c VH4 GVSLPDYGVS 7899 VIWGSETTYYNSSLKS 7903 HYYYGGSYAMDY 7904

Table 16 Light chain variable domain CDRs Description FW LCDR1 ID LCDR2 ID LCDR3 ID mouse CART19 RASQDISKYLN 7905 HTSRLHS 7906 QQGNTLPYT 7907 humanized CART19 a VK3 RASQDISKYLN 7905 HTSRLHS 7906 QQGNTLPYT 7907 humanized CART19 b VK3 RASQDISKYLN 7905 HTSRLHS 7906 QQGNTLPYT 7907 humanized CART19 c VK3 RASQDISKYLN 7905 HTSRLHS 7906 QQGNTLPYT 7907

In an embodiment, the antigen binding domain comprises an anti-CD19 antibody or a fragment thereof, eg scFv. For example, the antigen binding domain includes the variable heavy chain and the variable light chain listed in Table 17. The linker sequence connecting the variable heavy and variable light chain can be any of the linker sequences described herein, or alternatively can be GSTSGSGKPGSGEGSTKG ( SEQ ID NO: 8167). The light chain variable region and the scFv heavy chain variable region can be, for example, in any of the following orientations: heavy chain variable region-linker-light chain variable region or light chain variable region-linker-heavy chain variable region.

Table 17 Binding domains of complementary anti-CD19 antibodies Name At VH sequence VL sequence SJ25-C1 QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDGDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFDYWGQGTTVT (SEQ ID NO: 7896) ELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFYFCQYNRYPYTSGGGTKLEIKRRS (SEQ ID NO: 7897) ScFv sequence SJ25-C1
scFv QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDGDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFDYWGQGTTVTGSTSGSGKPGSGEGSTKGELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFYFCQYNRYPYTSGGGTKLEIKRRS (SEQ ID NO: 7898)

In one embodiment, the CD19 binding domain includes one or more (e.g., all three) of light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3). ) a CD19 binding domain as described herein, such as those shown in Table 14 or 15, and/or one or more (eg, all three) of the heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2) and the complementarity determining region 3 of the heavy chain (HC CDR3) of the CD19 binding domain described in this application, for example, presented in Table 14 or 16. In one embodiment, the CD19 binding domain includes one, two or all LC CDR1 , LC CDR2 and LC CDR3 with any of the amino acid sequences as shown in Table 16, incorporated herein by reference; and one, two or all HC CDR1, HC CDR2 and HC CDR3 with any amino acid sequences as shown in Table 15.

In one embodiment, the CD19 antigen binding domain includes:

(i) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 7905, the amino acid sequence of LC CDR2 SEQ ID NO: 7906, and the amino acid sequence of LC CDR3 SEQ ID NO: 7907; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 7899, the amino acid sequence of HC CDR2 SEQ ID NO: 7900, and the amino acid sequence of HC CDR3 SEQ ID NO: 7904

(ii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 7905, the amino acid sequence of LC CDR2 SEQ ID NO: 7906, and the amino acid sequence of LC CDR3 SEQ ID NO: 7907; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 7899, the amino acid sequence of HC CDR2 SEQ ID NO: 7901, and the amino acid sequence of HC CDR3 SEQ ID NO: 7904;

(iii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 7905, the amino acid sequence of LC CDR2 SEQ ID NO: 7906, and the amino acid sequence of LC CDR3 SEQ ID NO: 7907; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 7899, the amino acid sequence of HC CDR2 SEQ ID NO: 7902, and the amino acid sequence of HC CDR3 SEQ ID NO: 7904; or

(iv) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 7905, the amino acid sequence of LC CDR2 SEQ ID NO: 7906, and the amino acid sequence of LC CDR3 SEQ ID NO: 7907; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 7899, the amino acid sequence of HC CDR2 SEQ ID NO: 7903, and the amino acid sequence of HC CDR3 SEQ ID NO: 7904.

In one embodiment, the CD19 binding domain comprises the light chain variable region described herein (eg, Table 14 or 17) and/or the heavy chain variable region described herein (eg, Table 14 or 17). In one embodiment, the CD19 binding domain is an scFv comprising the light chain and heavy chain amino acid sequences listed in Table 14 or 17. In an embodiment, the CD19 binding domain (e.g., scFv) comprises: a light chain variable region comprising the amino acid sequence having at least one, two, or three modifications (e.g., substitutions, e.g., conservative substitutions), but not more than 30, 20, or 10 modifications (e.g., substitutions, e.g. conservative substitutions) of the light chain variable region amino acid sequence shown in Table 14 or 17, or a sequence with 95-99% identity with the amino acid sequence presented in Table 14 or 17; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions, e.g., conservative substitutions), but no more than 30, 20, or 10 modifications (e.g., substitutions, substitutions) the heavy chain variable region amino acid sequence shown in Table 14 or 17, or a sequence with 95-99% identity to the amino acid sequence shown in Table 14 or 17.

In one embodiment, the CD19 binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7883; SEQ ID NO: 7884, SEQ ID NO: 7885; SEQ ID NO: 7886; SEQ ID NO: 7887; SEQ ID NO: 7888; SEQ ID NO: 7889, SEQ ID NO: 7890, SEQ ID NO: 7891, SEQ ID NO: 7892, SEQ ID NO: 7893, SEQ ID NO: 7894, SEQ ID NO: 7895 and SEQ ID NO: 7898; or an amino acid sequence having at least one, two, or three modifications (eg, substitutions, eg, conservative substitutions), but no more than 30, 20, or 10 modifications (eg, substitutions, eg, conservative substitutions) in any of the above sequences; or a sequence with 95-99% identity with any of the above sequences. In one embodiment, the CD19 binding domain is scFv and a light chain variable region comprising the amino acid sequence described herein, such as in Table 14 or 17, is fused to a heavy chain variable region comprising the amino acid sequence described herein, for example in Table 14 or 17, through a linker, for example, the linker described in this application. In one embodiment, the CD19 binding domain includes a (Gly4-Ser)n linker where n is 1, 2, 3, 4, 5, or 6, preferably 3 (SEQ ID NO: 10801). The light chain variable region and the scFv heavy chain variable region can be, for example, in any of the following orientations: heavy chain variable region-linker-light chain variable region or light chain variable region-linker-heavy chain variable region.

Any known CD19 CAR, for example, the CD19 antigen binding domain of any prior art known CD19 CAR, can be used in accordance with the present invention to construct a CAR. For example, LG-740; CD19 CAR as described in US Pat. No. 8,399,645; US Pat. No. 7,446,190; Xu et al., Leuk Lymphoma. 2013 54(2):255-260(2012); Cruz et al., Blood 122(17):2965-2973 (2013); Brentjens et al., Blood, 118(18):4817-4828 (2011); Kochenderfer et al., Blood 116(20):4099-102 (2010); Kochenderfer et al., Blood 122(25):4129-39(2013); and 16th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10. In one embodiment, the anti-CD19 antigen-binding domain is an antigen-binding portion, e.g. a fragment described, for example, in PCT publication WO2012/079000; PCT publications WO2014/153270; Kochenderfer, J.N. et al., J. Immunother. 32 (7), 689-702 (2009); Kochenderfer, J. N., et al., Blood, 116 (20), 4099-4102 (2010); PCT publications WO2014/031687; Bejcek, Cancer Research, 55, 2346-2351, 1995; or U.S. Patent 7,446,190.

In an embodiment, the antigen-binding domain of a CAR, for example the CAR expressed by the cell of the invention, binds to BCMA. BCMA was found to be predominantly expressed in mature B lymphocytes. In an embodiment, the antigen binding domain is a mouse scFv domain that binds to human BCMA. In an embodiment, the antigen binding domain is a humanized antibody or antibody fragment, such as a scFv domain, that binds human BCMA. In an embodiment, the antigen binding domain is a human antibody or antibody fragment that binds to human BCMA. Examples of scFv domains (and sequences thereof, e.g., sequences of CDR regions, VL and VH) that bind to BCMA are shown in Table 18, Table 19, Table 20, and Table 21. The scFv domain sequences shown in Table 18 and Table 19 , include the light chain variable region (VL) and the heavy chain variable region (VH). VL and VH are connected by a linker, for example in the following orientation: VH-linker-VL.

Table 18. Antigen-binding domains that bind BCMA

Also provided are the variable heavy chain amino acid sequences and the variable light chain sequences for each scFv.

Name/ description SEQID NO: Subsequence 139109 139109-ak
ScFv domain 7949 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK 139109-nt
ScFv domain 7964 GAAGTGCAATTGGTGGAATCAGGGGGAGGACTTGTGCAGCCTGGAGGATCGCTGAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCACGGGATGTCCTGGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTCGGGTATTGTGTACAGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTCACCATCAGCCGGGACAACTCCAGGAACACTCTGTACCTCCAAATGAATTCGCTGAGGCCAGAGGACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGACGTCTGGGGACAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCGGCAGCGGGGGTCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCACCCAGTCCCCGAGCTCGCTGTCCGCCTCCGTGGGAGATCGGGTCACCATCACGTGCCGCGCCAGCCAGTCGATTTCCTCCTACCTGAACTGGTACCAACAGAAGCCCGGAAAAGCCCCGAAGCTTCTCATCTACGCCGCCTCGAGCCTGCAGTCAGGAGTGCCCTCACGGTTCTCCGGCTCCGGTTCCGGTACTGATTTCACCCTGACCATTTCCTCCCTGCAACCGGAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCCCCTACACTTTCGGACAAGGCACCAAGGTCGAAATCAAG 139109-ak
vh 7979 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139109-ak
VL 7994 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIK 139103 139103-ak
ScFv domain 7939 QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISRSGENTYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARSPAHYYGGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVLTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTKLEIK 139103-nt
ScFv domain 7954 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGAAGATCGCTTAGACTGTCGTGTGCCGCCAGCGGGTTCACTTTCTCGAACTACGCGATGTCCTGGGTCCGCCAGGCACCCGGAAAGGGACTCGGTTGGGTGTCCGGCATTTCCCGGTCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTCAAGGGACAACAGCAAAAACACCCTGTACTTGCAAATGAACTCCCTGCGGGATGAAGATACAGCCGTGTACTATTGCGCCCGGTCGCCTGCCCATTACTACGGCGGAATGGACGTCTGGGGACAGGGAACCACTGTGACTGTCAGCAGCGCGTCGGGTGGCGGCGGCTCAGGGGGTCGGGCCTCCGGGGGGGGAGGGTCCGACATCGTGCTGACCCAGTCCCCGGGAACCCTGAGCCTGAGCCCGGGAGAGCGCGCGACCCTGTCATGCCGGGCATCCCAGAGCATTAGCTCCTCCTTTCTCGCCTGGTATCAGCAGAAGCCCGGACAGGCCCCGAGGCTGCTGATCTACGGCGCTAGCAGAAGGGCTACCGGAATCCCAGACCGGTTCTCCGGCTCCGGTTCCGGGACCGATTTCACCCTTACTATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCCAGCAGTACCACTCATCCCCGTCGTGGACGTTCGGACAGGGCACCAAGCTGGAGATTAAG 139103-ak
vh 7969 QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISRSGENTYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARSPAHYYGGMDVWGQGTTVTVSS 139103-ak
VL 7984 DIVLTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYCQQYHSSPSWTFGQGTKLEIK 139105 139105-ak
ScFv domain 7940 QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSVHSFLAYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK 139105-nt
ScFv domain 7955 CAAGTGCAACTCGTCGAATCCGGTGGAGGTCTGGTCCAACCTGGTAGAAGCCTGAGACTGTCGTGTGCGGCCAGCGGATTCACCTTTGATGACTATGCTATGCACTGGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTCGGGAATTAGCTGGAACTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTCCCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCGCTCAGGGCTGAGGATACCGCGCTGTACTACTGCTCCGTGCATTCCTTCCTGGCCTACTGGGGACAGGGAACTCTGGTCACCGTGTCGAGCGCCTCCGGCGGCGGGGGCTCGGGTGGACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAGACCCCGCTGAGCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCGGTCATCCCAGTCCCTTCTCCACTCCAACGGATACAACTACCTCGACTGGTACCTCCAGAAGCCGGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGAGCCTCAGGAGTGCCGGATCGGTTCAGCGGATCTGGTTCGGGAACTGATTTCACTCTGAAGATTTCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGCAGGCGCTGCAGACCCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAG 139105-ak
vh 7970 QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSVHSFLAYWGQGTLVTVSS 139105-ak
VL 7985 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK 139111 139111-ak
ScFv domain 7941 EVQLLESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFPSFGGGTKLEIK 139111-nt
ScFv domain 7956 GAAGTGCAATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTGGAGGATCACTGAGACTTTCGTGTGCGGTGTCAGGCTTCGCCCTGAGCAACCACGGCATGAGCTGGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGGGATCGTCTACTCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTCGCTTCACCATTTCCCGCGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTGCGGCCCGAGGACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGATGTCTGGGGACAGGGCACTACCGTGACCGTGTCGAGCGCCTCGGGGGGAGGAGGCTCCGGCGGTCGCGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAGACTCCACTCTCGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAAGAGCTCCCAGAGCCTGCTGAGGAACGACGGAAAGACTCCTCTGTATTGGTACCTCCAGAAGGCTGGACAGCCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGCTTCTCCGGGGTGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCGACTTCACCCTGAAAATCTCCAGGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGCAAAACATCCAGTTCCCTTCCTTCGGCGGCGGCACAAAGCTGGAGATTAAG 139111-ak
vh 7971 EVQLLESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139111-ak
VL 7986 DIVMTQTPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFPSFGGGTKLEIK 139100 139100-ak
ScFv domain 7942 QVQLVQSGAEVRKTGASVKVSCKASGYIFDNFGINWVRQAPGQGLEWMGWINPKNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDTAVYYCARGPYYYQSYMDVWGQGTMVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLNWYLQKPGQSPQLLIYLGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGTKLEIK 139100-nt
ScFv domain 7957 CAAGTCCAACTCGTCCAGTCCGGCGCAGAAGTCAGAAAAACCGGTGCTAGCGTGAAAGTGTCCTGCAAGGCCTCCGGCTACATTTTCGATAACTTCGGAATCAACTGGGTCAGACAGGCCCCGGGCCAGGGGCTGGAATGGATGGGATGGATCAACCCCAAGAACAACAACACCAACTACGCACAGAAGTTCCAGGGCCGCGTGACTATCACCGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCCTCCCTGCGGTCGGAGGACACTGCCGTGTATTACTGCGCGAGGGGCCCATACTACTACCAAAGCTACATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTCATCCGCCTCCGGTGGTGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGATATTGTGATGACCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCGGCCTCCATTTCCTGCCGGTCCTCGCAATCACTCCTGCATTCCAACGGTTACAACTACCTGAATTGGTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTATCTGGGCTCGAAGCGCGCCTCCGGGGTGCCTGACCGGTTTAGCGGATCTGGGAGCGGCACGGACTTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAGTGTACTACTGTATGCAGGCGCTGCAGACTCCGTACACATTCGGACAGGGCACCAAGCTGGAGATCAAG 139100-ak
vh 7972 QVQLVQSGAEVRKTGASVKVSCKASGYIFDNFGINWVRQAPGQGLEWMGWINPKNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDTAVYYCARGPYYYQSYMDVWGQGTMVTVSS 139100-ak
VL 7987 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLNWYLQKPGQSPQLLIYLGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGTKLEIK 139101 139101-ak
ScFv domain 7943 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYYARGPRYWGQGTLVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASTLASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRASFGQGTKVEIK 139101-nt
ScFv domain 7958 CAAGTGCAACTTCAAGAATCAGGCGGAGGACTCGTGCAGCCCGGAGGATCATTGCGGCTCTCGTGCGCCGCCTCGGGCTTCACCTTCTCGAGCGACGCCATGACCTGGGTCCGCCAGGCCCCGGGGAAGGGGCTGGAATGGGTGTCTGTGATTTCCGGCTCCGGGGGAACTACGTACTACGCCGATTCCGTGAAAGGTCGCTTCACTATCTCCCGGGACAACAGCAAGAACACCCTTTATCTGCAAATGAATTCCCTCCGCGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGGCTACTACTATGCCCGGGGTCCGAGATACTGGGGACAGGGAACCCTCGTGACCGTGTCCTCCGCGTCCGGCGGAGGAGGGTCGGGAGGGCGGGCCTCCGGCGGCGGCGGTTCGGACATCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGGGCGACAGAGTCACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGAACTGGTACCAACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCTTCGACCCTGGCATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCACTCACTTCACTCTGACCATTAACAGCCTCCAGTCCGAGGATTCAGCCACTTACTACTGTCAGCAGTCCTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTCGAGATCAAG 139101-ak
vh 7973 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYYARGPRYWGQGTLVTVSS 139101-ak
VL 7988 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASTLASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRASFGQGTKVEIK 139102 139102-ak
ScFv domain 7944 QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISAYNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGPYYYYMDVWGKGTMVTVSSASGGGGSGGRASGGGGSEIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQGTKVEIK 139102-nt
ScFv domain 7959 CAAGTCCAACTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCGGAGCGAGCGTGAAAGTGTCCTGCAAGGCTTCCGGGTACACCTTCTCCAACTACGGCATCACTTGGGTGCGCCAGGCCCCGGGACAGGGCCTGGAATGGATGGGGTGGATTTCCGCGTACAACGGCAATACGAACTACGCTCAGAAGTTCCAGGGTAGAGTGACCATGACTAGGAACACCTCCATTTCCACCGCCTACATGGAACTGTCCTCCCTGCGGAGCGAGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTACTACATGGATGTCTGGGGGAAGGGGACTATGGTCACCGTGTCATCCGCCTCGGGAGGCGGCGGATCAGGAGGACGCGCCTCTGGTGGTGGAGGATCGGAGATCGTGATGACCCAGAGCCCTCTCTCCTTGCCCGTGACTCCTGGGGAGCCCGCATCCATTTCATGCCGGAGCTCCCAGTCACTTCTCTACTCCAACGGCTATAACTACGTGGATTGGTACCTCCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGCTCGAACAGGGCCAGCGGAGTGCCTGACCGGTTCTCCGGGTCGGGAAGCGGGACCGACTTCAAGCTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACTACTGTATGCAGGGCCGCCAGTTTCCGTACTCGTTCGGACAGGGCACCAAAGTGGAAATCAAG 139102-ak
vh 7974 QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISAYNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGPYYYYMDVWGKGTMVTVSS 139102-ak
VL 7989 EIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQGTKVEIK 139104 139104-ak
ScFv domain 7945 EVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRASGIPDRFSGAGTDFTLTISSLY 139104-nt
ScFv domain 7960 GAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTGGAGGATCACTTCGCCTGTCCTGCGCCGTGTCGGGCTTTGCCCTGTCCAACCATGGAATGAGCTGGGTCCGCCGCGCGCCGGGGAAGGGCCTCGAATGGGTGTCCGGCATCGTCTACTCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCACGATTTCACGGGACAACTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTTCGGCCGGAGGATACTGCCATCTACTACTGCTCCGCCCACGGTGGCGAATCCGACGTCTGGGGCCAGGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAGGAAGCGGGGGTAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAGTCCCCCGCCACCTTGAGCGTGTCACCAGGAGAGTCCGCCACCCTGTCATGCCGCGCCAGCCAGTCCGTGTCCTCCAACCTGGCTTGGTACCAGCAGAAGCCGGGGCAGGCCCCTAGACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCCCGATAGGTTCAGCGGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTCGCTGCAAGCCGAGGACGTGGCTGTGTACTACTGTCAGCAGTACGGAAGCTCCCTGACTTTCGGTGGCGGGACCAAAGTCGAGATTAAG 139104-ak
vh 7975 EVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139104-ak
VL 7990 EIVLTQSPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRASGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSLTFGGGTKVEIK 139106 139106-ak
ScFv domain 7946 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVMTQSPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLGTKTFGASIRATGIPDRNSGSGTEFTISSGVELTISS 139106-nt
ScFv domain 7961 GAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATTGAGACTGAGCTGCGCAGTGTCGGGATTCGCCCTGAGCAACCATGGAATGTCCTGGGTCAGAAGGGCCCCTGGAAAAGGCCTCGAATGGGTGTCAGGGATCGTGTACTCCGGTTCCACTTACTACGCCGCCTCCGTGAAGGGGCGCTTCACTATCTCACGGGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTGCGGCCGGAGGATACCGCCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGACGTCTGGGGCCAGGGAACTACCGTGACCGTGTCCTCCGCGTCCGGCGGTGGAGGGAGCGGCGGCCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAGAGCCCCGCTACTCTGTCGGTGTCGCCCGGAGAAAGGGCGACCCTGTCCTGCCGGGCGTCGCAGTCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCCAGGCACCACGCCTGCTTATGTACGGTGCCTCCATTCGGGCCACCGGAATCCCGGACCGGTTCTCGGGGTCGGGGTCCGGTACCGAGTTCACACTGACCATTTCCTCGCTCGAGCCCGAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCTCATGGACGTTCGGCCAGGGGACCAAGGTCGAAATCAAG 139106-ak
vh 7976 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139106-ak
VL 7991 EIVMTQSPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASIRATGIPDRFSGSGSGTEFTLTISSLEPEDFAVYYCQQYGSSSWTFGQGTKVEIK 139107 139107-ak
ScFv domain 7947 EVQLVETGGGVVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIK 139107-nt
ScFv domain 7962 GAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTGGAGGAAGCCTGAGACTGTCATGCGCGGTGTCGGGCTTCGCCCTCTCCAACCACGGAATGTCCTGGGTCCGCCGGGCCCCTGGGAAAGGACTTGAATGGGTGTCCGGCATCGTGTACTCGGGTTCCACCTACTACGCGGCCTCAGTGAAGGGCCGGTTTACTATTAGCCGCGACAACTCCAGAAACACACTGTACCTCCAAATGAACTCGCTGCGGCCGGAAGATACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGACGTCTGGGGACAGGGCACCACTGTCACTGTGTCCAGCGCTTCCGGCGGTGGTGGAAGCGGGGGACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAGTCCCCCGGGACCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCCTGTCGGGCATCCCAGTCCGTGGGGTCTACTAACCTTGCATGGTACCAGCAGAAGCCCGGCCAGGCCCCTCGCCTGCTGATCTACGACGCGTCCAATAGAGCCACCGGCATCCCGGATCGCTTCAGCGGAGGCGGATCGGGCACCGACTTCACCCTCACCATTTCAAGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCGTCCCCACCCTGGACGTTCGGCCAGGGGACTAAGGTCGAGATCAAG 139107-ak
vh 7977 EVQLVETGGGVVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139107-ak
VL 7992 EIVLTQSPGTLSLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSPPWTFGQGTKVEIK 139108 139108-ak
ScFv domain 7948 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGDGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTLAFGQGTKVDIK 139108-nt
ScFv domain 7963 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTGGAGGATCATTGAGACTGTCATGCGCGGCCTCGGGATTCACGTTCTCCGATTACTACATGAGCTGGATTCGCCAGGCTCCGGGGAAGGGACTGGAATGGGTGTCCTACATTTCCTCATCCGGCTCCACCATCTACTACGCGGACTCCGTGAAGGGGAGATTCACCATTAGCCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACTCCCTGCGGGCTGAAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGGGATGGACGTCTGGGGACAGGGTACCACTGTGACCGTGTCGTCGGCCTCCGGCGGAGGGGGTTCGGGTGGAAGGGCCAGCGGCGGCGGAGGCAGCGACATCCAGATGACCCAGTCCCCCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCACATGCCGGGCCTCACAGTCGATCTCCTCCTACCTCAATTGGTATCAGCAGAAGCCCGGAAAGGCCCCTAAGCTTCTGATCTACGCAGCGTCCTCCCTGCAATCCGGGGTCCCATCTCGGTTCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCATCTCGAGCCTGCAGCCGGAGGACTTCGCCACTTACTACTGTCAGCAAAGCTACACCCTCGCGTTTGGCCAGGGCACCAAAGTGGACATCAAG 139108-ak
vh 7978 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGDGMDVWGQGTTVTVSS 139108-ak
VL 7993 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTLAFGQGTKVDIK 139110 139110-ak
ScFv domain 7950 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGNTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSTMVREDYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVLTQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPGQSPRRLIYEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQGTKLEIK 139110-nt
ScFv domain 7965 CAAGTGCAACTGGTGCAAAGCGGAGGAGGATTGGTCAAACCCGGAGGAAGCCTGAGACTGTCATGCGCGGCCTCTGGATTCACCTTCTCCGATTACTACATGTCATGGATCAGACAGGCCCCGGGGAAGGGCCTCGAATGGGTGTCCTACATCTCGTCCTCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCTTTACCATTTCCCGCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATTCCCTGCGGGCTGAAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCGGGAGGACTACTGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGGGTGGAGGCAGCGGTGGACGCGCCTCCGGCGGCGGCGGTTCAGACATCGTGCTGACTCAGTCGCCCCTGTCGCTGCCGGTCACCCTGGGCCAACCGGCCTCAATTAGCTGCAAGTCCTCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACTGGTTCCATCAGCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTCCAACAGGGATTCGGGGGTGCCCGACCGCTTCACTGGCTCCGGGTCCGGCACCGACTTCACCTTGAAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTATGCAGGGTACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAGATTAAG 139110-ak
vh 7980 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGNTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSTMVREDYWGQGTLVTVSS 139110-ak
VL 7995 DIVLTQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPGQSPRRLIYEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQGTKLEIK 139112 139112-ak
ScFv domain 7951 QVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIRLTQSPSPLSASVGDRVTITCQASEDINKFLNWYHQTPGKAPKLLIYDASTLQTGVPSRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGTKVEIK 139112-nt
ScFv domain 7966 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGTGGAAGCCTTAGGCTGTCGTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCATGGAATGTCCTGGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGGCATCGTGTACAGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCACTATCTCAAGAGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTGCGCCCCGAGGACACCGCCATCTACTACTGCTCCGCCCACGGAGGAGAGTCGGACGTGTGGGGCCAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGGTGGTTCGGGCGGCCGGGCCTCGGGGGGAGGAGGTTCCGACATTCGGCTGACCCAGTCCCCGTCCCCACTGTCGGCCTCCGTCGGCGACCGCGTGACCATCACTTGTCAGGCGTCCGAGGACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAAAGGCCCCCAAGCTGCTGATCTACGATGCCTCGACCCTTCAAACTGGAGTGCCTAGCCGGTTCTCCGGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTCATTGCAGCCGGAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCCCGCTCACATTCGGCGGGGGAACCAAGGTCGAGATTAAG 139112-ak
vh 7981 QVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139112-ak
VL 7996 DIRLTQSPSPLSASVGDRVTITCQASEDINKFLNWYHQTPGKAPKLLIYDASTLQTGVPSRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGTKVEIK 139113 139113-ak
ScFv domain 7952 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSETTLTQSPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCQQYNDWLPVTFGQGTKVEIK 139113-nt
ScFv domain 7967 GAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATTGCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCACGGGATGTCGTGGGTCAGACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTCGGGGATTGTGTACAGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCACTATTTCACGGGACAACAGCCGCAACACCCTCTATCTGCAAATGAACTCTCTCCGCCCGGAGGATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGACGTGTGGGGACAGGGAACCACTGTCACCGTGTCGTCCGCATCCGGTGGCGGAGGATCGGGTGGCCGGGCCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAGTCCCCTGCCACTCTGTCCGTGAGCCCGGGAGAGAGAGCCACCCTTAGCTGCCGGGCCAGCCAGAGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGGTCCCAGGCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCCGCGAGGTTCTCCGGGTCGGGTTCCGGGACCGAGTTCACCCTGACCATCTCCTCCCTCCAACCGGAGGACTTCGCGGTGTACTACTGTCAGCAGTACAACGATTGGCTGCCCGTGACATTTGGACAGGGGACGAAGGTGGAAATCAAA 139113-ak
vh 7982 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139113-ak
VL 7997 ETTLTQSPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCQQYNDWLPVTFGQGTKVEIK 139114 139114-ak
ScFv domain 7953 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPPFTFGQGTKVEIK 139114-nt
ScFv domain 7968 GAAGTGCAATTGGTGGAATCTGGTGGAGGACTTGTGCAACCTGGAGGATCACTGAGACTGTCATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCATGGGATGTCGTGGGTCCGGCGCGCCCCCGGAAAGGGTCTGGAATGGGTGTCGGGTATCGTCTACTCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTCACCATTTCCCGCGATAACTCCCGCAACACCCTGTACTTGCAAATGAACTCGCTCCGGCCTGAGGACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGACGTGTGGGGCCAGGGAACTACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGGGCTCAGGCGGACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGCTGACCCAGTCGCCTGGCACTCTCTCGCTGAGCCCCGGGGAAAGGGCAACCCTGTCCTGTCGGGCCAGCCAGTCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGGGACAGGCTCCGCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATTCCCGACCGGTTCTCCGGGTCCGGTTCCGGCACCGATTTCACCCTGACTATCTCGAGGCTGGAGCCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGTCCCCGCCGTTCACGTTCGGACAGGGAACCAAGGTCGAGATCAAG 139114-ak
vh 7983 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSS 139114-ak
VL 7998 EIVLTQSPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYCQQYAGSPPFTFGQGTKVEIK 149362 149362-ak ScFv domain 8029 QVQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSETTLTQSPAFMSATPGDKVIISCKASQDIDDAMNWYQQKPGEAPLFIIQSATSPVPGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFPLTFGQGTKLEIK 149362-nt ScFv domain 8050 CAAGTGCAGCTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCATCCGAAACTCTCTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCGTACTACTACTGGGGCTGGATTAGGCAGCCGCCCGGAAAGGGACTGGAGTGGATCGGAAGCATCTACTATTCCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGAGAGTGACCATCTCCGTGGATACCTCCAAGAACCAGTTTTCCCTGCGCCTGAGCTCCGTGACCGCCGCTGACACCGCCGTGTACTACTGTGCTCGGCATTGGCAGGAATGGCCCGATGCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGTCATCCGGGGGTGGAGGCAGCGGGGGAGGAGGGTCCGGGGGGGGAGGTTCAGAGACAACCTTGACCCAGTCACCCGCATTCATGTCCGCCACTCCGGGAGACAAGGTCATCATCTCGTGCAAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGCAGAAGCCTGGCGAAGCGCCGCTGTTCATTATCCAATCCGCAACCTCGCCCGTGCCTGGAATCCCACCGCGGTTCAGCGGCAGCGGTTTCGGAACCGACTTTTCCCTGACCATTAACAACATTGAGTCCGAGGACGCCGCCTACTACTTCTGCCTGCAACACGACAACTTCCCTCTCACGTTCGGCCAGGGAACCAAGCTGGAAATCAAG 149362-ak VH 8071 QVQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPDAFDIWGQGTMVTVSS 149362-ak VL 8092 ETTLTQSPAFMSATPGDKVIISCKASQDIDDAMNWYQQKPGEAPLFIIQSATSPVPGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFPLTFGQGTKLEIK 149363 149363-ak ScFv domain 8030 QVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARIDWDEDKFYSTSLKTRLTISKDTSDNQVVLRMTNMDPADTATYYCARSGAGGTSATAFDIWGPGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDIYNNLAWFQLKPGSAPRSLMYAANKSQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYYRFPYSFGQGTKLEIK 149363-nt ScFv domain 8051 CAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTACCCAGACCCTCACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCCGGGATGTGCGTGTCCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCTCGCTCGCATTGACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCAGGCTGACCATCAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACCAACATGGACCCAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGGCGGAACCTCCGCCACCGCCTTCGATATTTGGGGCCCGGGTACCATGGTCACCGTGTCAAGCGGAGGAGGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCGGACATTCAGATGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAGAGTGACAATCACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCGTGGTTCCAGCTGAAGCCTGGTTCCGCACCGCGGTCACTTATGTACGCCGCCAACAAGAGCCAGTCGGGAGTGCCGTCCCGGTTTTCCGGTTCGGCCTCGGGAACTGACTTCACCCTGACGATCTCCAGCCTGCAACCCGAGGATTTCGCCACCTACTACTGCCAGCACTACTACCGCTTTCCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATCAAG 149363-ak VH 8072 QVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARIDWDEDKFYSTSLKTRLTISKDTSDNQVVLRMTNMDPADTATYYCARSGAGGTSATAFDIWGPGTMVTVSS 149363-ak VL 8093 DIQMTQSPSSLSASVGDRVTITCRASQDIYNNLAWFQLKPGSAPRSLMYAANKSQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYYRFPYSFGQGTKLEIK 149364 149364-ak ScFv domain 8031 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPLSLPVTPEEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK 149364-nt ScFv domain 8052 GAAGTGCAGCTTGTCGAATCCGGGGGGGGACTGGTCAAGCCGGGCGGATCACTGAGACTGTCCTGCGCCGCGAGCGGCTTCACGTTCTCCTCCTACTCCATGAACTGGGTCCGCCAAGCCCCCGGGAAGGGACTGGAATGGGTGTCCTCTATCTCCTCGTCGTCGTCCTACATCTACTACGCCGACTCCGTGAAGGGAAGATTCACCATTTCCCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCACTCCGGGCCGAAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCGCCGTCTACGCTTTCGACATCTGGGGCCAGGGAACCACCGTGACTGTGTCGTCCGGTGGTGGTGGCTCGGGCGGAGGAGGAAGCGGCGGCGGGGGGTCCGAGATTGTGCTGACCCAGTCGCCACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAGCTGCCGGTCCAGCCAGTCCCTGCTCCACTCCAACGGATACAATTACCTCGATTGGTACCTTCAGAAGCCTGGACAAAGCCCGCAGCTGCTCATCTACTTGGGATCAAACCGCGCGTCAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGATTTCACCCTGAAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACTGTATGCAGGCGCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAGATCAAG 149364-ak VH 8073 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAFDIWGQGTTVTVSS 149364-ak VL 8094 EIVLTQSPLSLPVTPEEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK 149365 149365-ak ScFv domain 8032 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQSPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPGRFSGSNSGNMATLTISGVQAGDEADFYCQVWDSDSEHVVFGGGTKLTVL 149365-nt ScFv domain 8053 GAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCTTGTGAAGCCTGGAGGTTCGCTGAGACTGTCCTGCGCCGCCTCCGGCTTCACCTTCTCCGACTACTACATGTCCTGGATCAGACAGGCCCCGGGAAAGGGCCTGGAATGGGTGTCCTACATCTCGTCATCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGTTCACCATTTCCCGGGATAACGCGAAGAACTCGCTGTATCTGCAAATGAACTCACTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCCGCGATCTCCGCGGGGCATTTGACATCTGGGGACAGGGAACCATGGTCACAGTGTCCAGCGGAGGGGGAGGATCGGGTGGCGGAGGTTCCGGGGGTGGAGGCTCCTCCTACGTGCTGACTCAGAGCCCAAGCGTCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGGAAACAACATTGGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAGCTCCCCTGTTGGTGATCCGCGATGACTCCGTGCGGCCTAGCAAAATTCCGGGACGGTTCTCCGGCTCCAACAGCGGCAATATGGCCACTCTCACCATCTCGGGAGTGCAGGCCGGAGATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCGAGCATGTGGTGTTCGGGGGCGGAACCAAGCTGACTGTGCTC 149365-ak VH 8074 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLRGAFDIWGQGTMVTVSS 149365-ak VL 8095 SYVLTQSPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPGRFSGSNSGNMATLTISGVQAGDEADFYCQVWDSDSEHVVFGGGTKLTVL 149366 149366-ak ScFv domain 8033 QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINPSGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKERPSGIPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVL 149366-nt ScFv domain 8054 CAAGTGCAGCTGGTGCAGAGCGGGGCCGAAGTCAAGAAGCCGGGAGCCTCCGTGAAAGTGTCCTGCAAGCCTTCGGGATACACCGTGACCTCCCACTACATTCATTGGGTCCGCCGCGCCCCCGGCCAAGGACTCGAGTGGATGGGCATGATCAACCCTAGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCGTGACTATGACCTCGGATACCTCCTCCTCCACCGTCTATATGGAACTGTCCAGCCTGCGGTCCGAGGATACCGCCATGTACTACTGCGCCCGGGAAGGATCAGGCTCCGGGTGGTATTTCGACTTCTGGGGAAGAGGCACCCTCGTGACTGTGTCATCTGGGGGAGGGGGTTCCGGTGGTGGCGGATCGGGAGGAGGCGGTTCATCCTACGTGCTGACCCAGCCACCCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTACATGTAGCGGCGACGGCCTCTCCAAGAAATACGTGTCGTGGTACCAGCAGAAGGCCGGACAGAGCCCGGTGGTGCTGATCTCAAGAGATAAGGAGCGGCCTAGCGGAATCCCGGACAGGTTCTCGGGTTCCAACTCCGCGGACACTGCTACTCTGACCATCTCGGGGACCCAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACGACACTACTGTCGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTT 149366-ak VH 8075 QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINPSGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWYFDFWGRGTLVTVSS 149366-ak VL 8096 SYVLTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKERPSGIPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVL 149367 149367-ak ScFv domain 8034 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDRVIITCRASQGIRNWLAWYQQKPGKAPNLLIYAASNLQSGVPSRFSGSGSGADFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK 149367-nt ScFv domain 8055 CAAGTGCAGCTTCAGGAGAGCGGCCCGGGACTCGTGAAGCCGTCCCAGACCCTGTCCCTGACTTGCACCGTGTCGGGAGGAAGCATCTCGAGCGGAGGCTACTATTGGTCGTGGATTCGGCAGCACCCTGGAAAGGGCCTGGAATGGATCGGCTACATCTACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCAGAGTGACAATCTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCTTCCGTGACTGCGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGCCGCCCGGCTGAGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCGTGTCCTCCGGCGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGGTCCGACATCGTCATGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTCGGGGACAGAGTGATCATCACCTGTCGGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGTATCAGCAGAAGCCCGGAAAGGCCCCCAACCTGTTGATCTACGCCGCCTCAAACCTCCAATCCGGGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTTCACTCTGACCATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCCAAAAGTACAACTCCGCACCTTTTACTTTCGGACCGGGGACCAAAGTGGACATTAAG 149367-ak VH 8076 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARLRGAFDIWGQGTMVTVSS 149367-ak VL 8097 DIVMTQSPSSVSASVGDRVIITCRASQGIRNWLAWYQQKPGKAPNLLIYAASNLQSGVPSRFSGSGSGADFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK 149368 149368-ak ScFv domain 8035 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLRWDVGLLRSAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVLYGKNNRPSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTKVTVL 149368-nt ScFv domain 8056 CAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCGGGAGCTCTGTGAAAGTGTCCTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTACGCCATCTCCTGGGTCCGCCAAGCACCGGGTCAAGGCCTGGAGTGGATGGGGGGAATTATCCCTATCTTCGGCACTGCCAACTACGCCCAGAAGTTCCAGGGACGCGTGACCATTACCGCGGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGCTTGCGCTCGGAAGATACCGCCGTGTACTACTGCGCCCGGAGGGGTGGATACCAGCTGCTGAGATGGGACGTGGGCCTCCTGCGGTCGGCGTTCGACATCTGGGGCCAGGGCACTATGGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGGCGGATCAGGGGGAGGCGGTTCCAGCTACGTGCTTACTCAACCCCCTTCGGTGTCCGTGGCCCCGGGACAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCAAGAGCGTGCATTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTGCTGGTGCTCTACGGGAAGAACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACGCTCCGGTACAACCGCTTCACTGACTATCACCGGGGCCCAGGCAGAGGATGAAGCGGACTACTACTGTTCCTCCCGGGATTCATCCGGCGACCACCTCCGGGTGTTCGGAACCGGAACGAAGGTCACCGTGCTG 149368-ak VH 8077 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLRWDVGLLRSAFDIWGQGTMVTVSS 149368-ak VL 8098 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVLYGKNNRPSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTKVTVL 149369 149369-ak ScFv domain 8036 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEGLFLYWFDPWGQGTLVTVSSGGDGSGGGGSGGGGSSSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNRPSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHHLLFGTGTKVTVL 149369-nt ScFv domain 8057 GAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCATCCCAGACCCTGTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTCATCGAACTCCGCCGCCTGGAACTGGATTCGGCAGAGCCCGTCCCGCGGACTGGAGTGGCTTGGAAGGACCTACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGAAGTCCCGCATTATCATTAACCCTGATACCTCCAAGAATCAGTTCTCCCTCCAACTGAAATCCGTCACCCCCGAGGACACAGCAGTGTATTACTGCGCACGGAGCAGCCCCGAAGGACTGTTCCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTGTGACCGTGTCGAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGCGGATCATCATCCGAACTGACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACAAACCATCCGCATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTTGGTACCAGCAGAAGCCGGGCCAAGCCCCTGTGTTGGTCATCTACGGGACCAACAACAGACCTTCCGGCATCCCCGACCGGTTCAGCGCTTCGTCCTCCGGCAACACTGCCAGCCTGACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACTGCAACAGCAGAGACTCCTCGGGTCATCACCTCTTGTTCGGAACTGGAACCAAGGTCACCGTGCTG 149369-ak VH 8078 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEGLFLYWFDPWGQGTLVTVSS 149369-AK VL 8099 SSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNRPSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHHLLFGTGTKVTVL BCMA_EBB-C1978-A4 BCMA_EBB-C1978-A4 -ac
ScFv domain 8037 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQPPRLLISGASTRATGIPDRFGGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFNGSSLFTFGQGTRLEIK BCMA_EBB-C1978-A4 -nt
ScFv domain 8058 GAAGTGCAGCTCGTGGAGTCAGGAGGCGGCCTGGTCCAGCCGGGAGGGTCCCTTAGACTGTCATGCGCCGCAAGCGGATTCACTTTCTCCTCCTATGCCATGAGCTGGGTCCGCCAAGCCCCCGGAAAGGGACTGGAATGGGTGTCCGCCATCTCGGGGTCTGGAGGCTCAACTTACTACGCTGACTCCGTGAAGGGACGGTTCACCATTAGCCGCGACAACTCCAAGAACACCCTCTACCTCCAAATGAACTCCCTGCGGGCCGAGGATACCGCCGTCTACTACTGCGCCAAAGTGGAAGGTTCAGGATCGCTGGACTACTGGGGACAGGGTACTCTCGTGACCGTGTCATCGGGCGGAGGAGGTTCCGGCGGTGGCGGCTCCGGCGGCGGAGGGTCGGAGATCGTGATGACCCAGAGCCCTGGTACTCTGAGCCTTTCGCCGGGAGAAAGGGCCACCCTGTCCTGCCGCGCTTCCCAATCCGTGTCCTCCGCGTACTTGGCGTGGTACCAGCAGAAGCCGGGACAGCCCCCTCGGCTGCTGATCAGCGGGGCCAGCACCCGGGCAACCGGAATCCCAGACAGATTCGGGGGTTCCGGCAGCGGCACAGATTTCACCCTGACTATTTCGAGGTTGGAGCCCGAGGACTTTGCGGTGTATTACTGTCAGCACTACGGGTCGTCCTTTAATGGCTCCAGCCTGTTCACGTTCGGACAGGGGACCCGCCTGGAAATCAAG BCMA_EBB-C1978-A4 -ac
vh 8079 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLDYWGQGTLVTVSS BCMA_EBB-C1978-A4 -ac
VL 8100 EIVMTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQPPRLLISGASTRATGIPDRFGGSGSGTDFTLTISRLEPEDFAVYCQHYGSSFNGSSLFTFGQGTRLEIK BCMA_EBB-C1978-G1 BCMA_EBB-C1978-G1 -ac
ScFv domain 8038 EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWVSGISDSGVSTYYADSAKGRFTISRDNSKNTLFLQMSSLRDEDTAVYYCVTRAGSEASDIWGQGTMVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGTKLEIK BCMA_EBB-C1978-G1 -nt
ScFv domain 8059 GAAGTGCAACTGGTGGAAACCGGTGGCGGCCTGGTGCAGCCTGGAGGATCATTGAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTACCCCATGTCCTGGGTCAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGGGATCTCGGACTCCGGTGTCAGCACTTACTACGCCGACTCCGCCAAGGGACGCTTCACCATTTCCCGGGACAACTCGAAGAACACCCTGTTCCTCCAAATGAGCTCCCTCCGGGACGAGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGAGGCGTCTGACATTTGGGGACAGGGCACTATGGTCACCGTGTCGTCCGGCGGAGGGGGCTCGGGAGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACCCAATCCCCGGCCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCCTGTCGCGCGAGCCAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCTCCGAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATCCCCGACCGCTTTTCGGGGTCCGGCTCAGGAACCGATTTCACCCTGACAATCTCACGGCTGGAGCCAGAGGATTTCGCCATCTATTACTGCCAGCAGTTCGGTACTTCCTCCGGCCTGACTTTCGGAGGCGGCACGAAGCTCGAAATCAAG BCMA_EBB-C1978-G1 -ac
vh 8080 EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWVSGISDSGVSTYYADSAKGRFTISRDNSKNTLFLQMSSLRDEDTAVYYCVTRAGSEASDIWGQGTMVTVSS BCMA_EBB-C1978-G1 -ac
VL 8101 EIVLTQSPATLSLSPGERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYCQQFGTSSGLTFGGGTKLEIK BCMA_EBB-C1979-C1 BCMA_EBB-C1979-C1 -ak
ScFv domain 8039 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIYYCARATYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTRLEIK BCMA_EBB-C1979-C1 -NT
ScFv domain 8060 CAAGTGCAGCTCGTGGAATCGGGTGGCGGACTGGTGCAGCCGGGGGGCTCACTTAGACTGTCCTGCGCGGCCAGCGGATTCACTTTCTCCTCCTACGCCATGTCCTGGGTCAGACAGGCCCCTGGAAAGGGCCTGGAATGGGTGTCCGCAATCAGCGGCAGCGGCGGCTCGACCTATTACGCGGATTCAGTGAAGGGCAGATTCACCATTTCCCGGGACAACGCCAAGAACTCCTTGTACCTTCAAATGAACTCCCTCCGCGCGGAAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAGGGAACTGCGCTACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCACCGTGTCCAGCGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGGTCGGAGATCGTGATGACCCAGTCCCCCGGCACTGTGTCGCTGTCCCCCGGCGAACGGGCCACCCTGTCATGTCGGGCCAGCCAGTCAGTGTCGTCAAGCTTCCTCGCCTGGTACCAGCAGAAACCGGGACAAGCTCCCCGCCTGCTGATCTACGGAGCCAGCAGCCGGGCCACCGGTATTCCTGACCGGTTCTCCGGTTCGGGGTCCGGGACCGACTTTACTCTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATTACTGCCAGCAGTACCACTCCTCCCCGTCCTGGACGTTCGGACAGGGCACAAGGCTGGAGATTAAG BCMA_EBB-C1979-C1 -ac
vh 8081 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIYYCARATYKRELRYYYGMDVWGQGTMVTVSS BCMA_EBB-C1979-C1 -ac
VL 8102 EIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYCQQYHSSPSWTFGQGTRLEIK BCMA_EBB-C1978-C7 BCMA_EBB-C1978-C7 -ac
ScFv domain 8040 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNTLKAEDTAVYYCARATYKRELRYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTKVEIK BCMA_EBB-C1978-C7 -nt
ScFv domain 8061 GAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCGGAGGAAGCCTCAGGCTGTCCTGCGCCGCGTCCGGCTTCACCTTCTCCTCGTACGCCATGTCCTGGGTCCGCCAGGCCCCCGGAAAGGGCCTGGAATGGGTGTCCGCCATCTCTGGAAGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGTTCACAATCTCCCGCGATAATTCGAAGAACACTCTGTACCTTCAAATGAACACCCTGAAGGCCGAGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAGAGAGCTCCGGTACTACTACGGAATGGACGTCTGGGGCCAGGGAACTACTGTGACCGTGTCCTCGGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGTTCCGAGATTGTGCTGACCCAGTCACCTTCAACTCTGTCGCTGTCCCCGGGAGAGAGCGCTACTCTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCCTCGCCTGGTATCAGCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCAAGCAACAGAGCGACCGGAATTCCTGACCGCTTCTCGGGGAGCGGTTCAGGCACCGACTTCACCCTGACTATCCGGCGCCTGGAACCCGAAGATTTCGCCGTGTATTACTGTCAACAGTACCACTCCTCGCCGTCCTGGACCTTTGGCCAAGGAACCAAAGTGGAAATCAAG BCMA_EBB-C1978-C7 -ac
vh 8082 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNTLKAEDTAVYYCARATYKRELRYYYGMDVWGQGTTVTVSS BCMA_EBB-C1978-C7 -ac
VL 8103 EIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYCQQYHSSPSWTFGQGTKVEIK BCMA_EBB-C1978-D10 BCMA_EBB-C1978-D10-ak
ScFv domain 8041 EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVGKAVPDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQTPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYSFGQGTRLEIK BCMA_EBB-C1978-D10-NT
ScFv domain 8062 GAAGTGCAGCTCGTGGAAACTGGAGGTGGACTCGTGCAGCCTGGACGGTCGCTGCGGCTGAGCTGCGCTGCATCCGGCTTCACCTTCGACGATTATGCCATGCACTGGGTCAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGGTATCAGCTGGAATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGTTCACCATTTCCCGCGACAACGCCAAGAACTCCCTGTACTTGCAAATGAACAGCCTCCGGGATGAGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGTGCCCGACGTCTGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGGCGGGGGTGGATCGGGCGGTGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAGACCCCCTCGTCCCTGTCCGCCTCGGTCGGCGACCGCGTGACTATCACATGTAGAGCCTCGCAGAGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGAAGGCCCCGAAGCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCGAGCCGGTTTTCCGGGTCCGGCTCCGGCACCGACTTCACGCTGACCATTTCTTCCCTGCAACCCGAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCCCTTACTCCTTCGGCCAAGGAACCAGGCTGGAAATCAAG BCMA_EBB-C1978-D10-ac
vh 8083 EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVGKAVPDVWGQGTTVTVSS BCMA_EBB-C1978-D10-ac
VL 8104 DIVMTQTPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYSFGQGTRLEIK BCMA_EBB-C1979-C12 BCMA_EBB-C1979-C12-ak
ScFv domain 8042 EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPGKGLEWVASINWKGNSLAYGDSVKGRFAISRDNAKNTVFLQMNSLRTEDTAVYYCASHQGVAYYNYAMDVWGRGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRATQSIGSSFLAWYQQRPGQAPRLLIYGASQRATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKVEIK BCMA_EBB-C1979-C12-NT
ScFv domain 8063 GAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCGGAAGGTCCCTGCGGCTCTCCTGCACTGCGTCTGGCTTCACCTTCGACGACTACGCGATGCACTGGGTCAGACAGCGCCCGGGAAAGGGCCTGGAATGGGTCGCCTCAATCAACTGGAAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCTTCGCCATTTCGCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCCCTGCGGACCGAGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGCATACTATAACTACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGTCCTCCGGGGGCGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAAATCGTGCTGACTCAGAGCCCGGGAACTCTTTCACTGTCCCCGGGAGAACGGGCCACTCTCTCGTGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCCTGGTACCAGCAGAGGCCAGGACAGGCGCCCCGCCTGCTGATCTACGGTGCTTCCCAACGCGCCACTGGCATTCCTGACCGGTTCAGCGGCAGAGGGTCGGGAACCGATTTCACACTGACCATTTCCCGGGTGGAGCCCGAAGATTCGGCAGTCTACTACTGTCAGCATTACGAGTCCTCCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAGATCAAG BCMA_EBB-C1979-C12-ac
vh 8084 EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPGKGLEWVASINWKGNSLAYGDSVKGRFAISRDNAKNTVFLQMNSLRTEDTAVYYCASHQGVAYYNYAMDVWGRGTLVTVSS BCMA_EBB-C1979-C12-ac
VL 8105 EIVLTQSPGTLSLSPGERATLSCRATQSIGSSFLAWYQQRPGQAPRLLIYGASQRATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKVEIK BCMA_EBB-C1980-G4 BCMA_EBB-C1980-G4-ac
ScFv domain 8043 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVVRDGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKVDIK BCMA_EBB-C1980-G4-NT
ScFv domain 8064 GAGGTGCAGTTGGTCGAAAGCGGGGGCGGGCTTGTGCAGCCTGGCGGATCACTGCGGCTGTCCTGCGCGGCATCAGGCTTCACGTTTTCTTCCTACGCCATGTCCTGGGTGCGCCAGGCCCCTGGAAAGGGACTGGAATGGGTGTCCGCGATTTCGGGGTCCGGCGGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCTTCACTATCTCGCGGGACAACTCCAAGAACACCCTCTACCTCCAAATGAATAGCCTGCGGGCCGAGGATACCGCCGTCTACTATTGCGCTAAGGTCGTGCGCGACGGAATGGACGTGTGGGGACAGGGTACCACCGTGACAGTGTCCTCGGGGGGAGGCGGTAGCGGCGGAGGAGGAAGCGGTGGTGGAGGTTCCGAGATTGTGCTGACTCAATCACCCGCGACCCTGAGCCTGTCCCCCGGCGAAAGGGCCACTCTGTCCTGTCGGGCCAGCCAATCAGTCTCCTCCTCGTACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGCTCCGAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATCCCGGATAGGTTCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTCCCGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCCCGCCTAGATTCACTTTCGGCCCCGGCACCAAAGTGGACATCAAG BCMA_EBB-C1980-G4-ac
vh 8085 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVVRDGMDVWGQGTTVTVSS BCMA_EBB-C1980-G4-ak
VL 8106 EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKVDIK BCMA_EBB-C1980-D2 BCMA_EBB-C1980-D2-ac
ScFv domain 8044 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRLEIK BCMA_EBB-C1980-D2-nt
ScFv domain 8065 GAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGGGGGGATCGCTCAGACTGTCCTGTGCGGCGTCAGGCTTCACCTTCTCGAGCTACGCCATGTCATGGGTCAGACAGGCCCCTGGAAAGGGTCTGGAATGGGTGTCCGCCATTTCCGGGAGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCTTCACCATTTCCCGGGACAACTCCAAGAACACTCTCTATCTGCAAATGAACTCCCTCCGCGCTGAGGACACTGCCGTGTACTACTGCGCCAAAATCCCTCAGACCGGCACCTTCGACTACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCGGAGGTTCGGGGGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACCCAGTCACCCGGCACTTTGTCCCTGTCGCCTGGAGAAAGGGCCACCCTTTCCTGCCGGGCATCCCAATCCGTGTCCTCCTCGTACCTGGCCTGGTACCAGCAGAGGCCCGGACAGGCCCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGCGACCGGTATCCCGGACCGGTTTTCGGGCTCGGGCTCAGGAACTGACTTCACCCTCACCATCTCCCGCCTGGAACCCGAAGATTTCGCTGTGTATTACTGCCAGCACTACGGCAGCTCCCCGTCCTGGACGTTCGGCCAGGGAACTCGGCTGGAGATCAAG BCMA_EBB-C1980-D2-ac
vh 8086 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFDYWGQGTLVTVSS BCMA_EBB-C1980-D2-ac
VL 8107 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYCQHYGSPSWTFGQGTRLEIK BCMA_EBB-C1978-A10 BCMA_EBB-C1978-A10-ak
ScFv domain 8045 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVYYCARANYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLLISGASSRATGVPDRFSGSGSGTDFTLAISRLEPEDSAVYYCQHYDSSPSWTFGQGTKVEIK BCMA_EBB-C1978-A10-nt
ScFv domain 8066 GAAGTGCAACTGGTGGAAACCGGTGGAGGACTCGTGCAGCCTGGCGGCAGCCTCCGGCTGAGCTGCGCCGCTTCGGGATTCACCTTTTCCTCCTACGCGATGTCTTGGGTCAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGCCATCTCCGGCTCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGTTCACCATGTCGCGCGAGAATGACAAGAACTCCGTGTTCCTGCAAATGAACTCCCTGAGGGTGGAGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAGAGAGCTGCGGTACTACTACGGAATGGACGTCTGGGGACAGGGAACTATGGTGACCGTGTCATCCGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGGTTCAGAAATTGTCATGACCCAGTCCCCGGGAACTCTTTCCCTCTCCCCCGGGGAATCCGCGACTTTGTCCTGCCGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCGCATGGTACCAGCATAAGCCAGGCCAAGCCCCTTCCCTGCTGATTTCCGGGGCTAGCAGCCGCGCCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTACCGATTTCACCCTGGCAATCTCGCGGCTGGAACCGGAGGATTCGGCCGTGTACTACTGCCAGCACTATGACTCATCCCCCTCCTGGACATTCGGACAGGGCACCAAGGTCGAGATCAAG BCMA_EBB-C1978-A10-ak
vh 8087 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVYYCARANYKRELRYYYGMDVWGQGTMVTVSS BCMA_EBB-C1978-A10-ak
VL 8108 EIVMTQSPGTLSLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLLISGASSRATGVPDRFSGSGSGTDFTLAISRLEPEDSAVYCQHYDSSPSWTFGQGTKVEIK BCMA_EBB-C1978-D4 BCMA_EBB-C1978-D4-ac
ScFv domain 8046 EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALVGATGAFDIWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGASNWATGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK BCMA_EBB-C1978-D4-NT
ScFv domain 8067 GAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAGGGGGCTCCCTGAGGCTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTACGCCATGTCGTGGGTCCGCCAAGCCCCTGGAAAAGGCCTGGAATGGGTGTCCGCGATTTCCGGGAGCGGAGGTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCTTTACCATCTCCCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCGCTGAGAGCCGAGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCGGCGCGACTGGGGCATTCGACATCTGGGGACAGGGAACTCTTGTGACCGTGTCGAGCGGAGGCGGCGGCTCCGGCGGAGGAGGGAGCGGGGGCGGTGGTTCCGAAATCGTGTTGACTCAGTCCCCGGGAACCCTGAGCTTGTCACCCGGGGAGCGGGCCACTCTCTCCTGTCGCGCCTCCCAATCGCTCTCATCCAATTTCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCCCCGGGCCTGCTCATCTACGGCGCTTCAAACTGGGCAACGGGAACCCCTGATCGGTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCTGACCATCACCAGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACTACGGCACCTCCCCCATGTACACATTCGGACAGGGTACCAAGGTCGAGATTAAG BCMA_EBB-C1978-D4-ak
vh 8088 EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALVGATGAFDIWGQGTLVTVSS BCMA_EBB-C1978-D4-ak
VL 8109 EIVLTQSPGTLSLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGASNWATGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK BCMA_EBB-C1980-A2 BCMA_EBB-C1980-A2-ac
ScFv domain 8047 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDPWGQGTLVTVSSGGGGSGGGGSGGGGSDIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIK BCMA_EBB-C1980-A2-NT
ScFv domain 8068 GAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCGGGGGATCACTGCGCCTGTCCTGTGCCGCGTCCGGTTTCACTTTCTCCTCGTACGCCATGTCGTGGGTCAGACAGGCACCGGGAAAGGGACTGGAATGGGTGTCAGCCATTTCGGGTTCGGGGGGCAGCACCTACTACGCTGACTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAACTCCAAGAACACCTTGTACCTCCAAATGAACTCCCTGCGGGCCGAAGATACCGCCGTGTATTACTGCGTGCTGTGGTTCGGAGAGGGATTCGACCCGTGGGGACAAGGAACACTCGTGACTGTGTCATCCGGCGGAGGCGGCAGCGGTGGCGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTTGACCCAGTCCCCTCTGAGCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCGGTCGAGCCAGTCCCTCCTGCACTCCAATGGGTACAACTACCTCGATTGGTATCTGCAAAAGCCGGGCCAGAGCCCCCAGCTGCTGATCTACCTTGGGTCAAACCGCGCTTCCGGGGTGCCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTACCCTGAAAATCTCGAGGGTGGAGGCCGAGGACGTCGGAGTGTACTACTGCATGCAGGCGCTCCAGACTCCCCTGACCTTCGGAGGAGGAACGAAGGTCGACATCAAGA BCMA_EBB-C1980-A2-ac
vh 8089 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDPWGQGTLVTVSS BCMA_EBB-C1980-A2-ac
VL 8110 DIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIK BCMA_EBB-C1981-C3 BCMA_EBB-C1981-C3-ac
ScFv domain 8048 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGYYRDYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTKLEIK BCMA_EBB-C1981-C3-NT
ScFv domain 8069 CAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCGGGGGCTCCCTGAGACTTTCCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTATGCTATGTCCTGGGTGCGCCAGGCCCCGGGAAAGGGACTGGAATGGGTGTCCGCAATCAGCGGTAGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTCGCTTCACTATTTCCCGGGACAACTCCAAGAATACCCTGTACCTCCAAATGAACAGCCTCAGGGCCGAGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAGCTCCGGTTACTACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCACCGTGACCGTGTCAAGCGGCGGAGGCGGTTCAGGAGGGGGAGGCTCCGGCGGTGGAGGGTCCGAAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCGTTGTCCCCGGGGGAGCGCGCTACCCTGTCGTGTCGGGCGTCGCAGTCCGTGTCGAGCTCCTACCTCGCGTGGTACCAGCAGAAGCCCGGACAGGCCCCTAGACTTCTGATCTACGGCACTTCTTCACGCGCCACCGGGATCAGCGACAGGTTCAGCGGCTCCGGCTCCGGGACCGACTTCACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCGCCGTGTATTACTGCCAACACTACGGAAACTCGCCGCCAAAGTTCACGTTCGGACCCGGAACCAAGCTGGAAATCAAG BCMA_EBB-C1981-C3-ac
vh 8090 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGYYRDYYGMDVWGQGTTVTVSS BCMA_EBB-C1981-C3-ak
VL 8111 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYCQHYGNSPPKFTFGPGTKLEIK BCMA_EBB-C1978-G4 BCMA_EBB-C1978-G4-ak
ScFv domain 8049 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYLGAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPRLTFGGGTKVDIK BCMA_EBB-C1978-G4-NT
ScFv domain 8070 GAAGTCCAACTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCGGAGGCAGCCTTCGGCTGTCGTGCGCCGCCTCCGGGTTCACGTTCTCATCCTACGCGATGTCGTGGGTCAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGCCATTAGCGGCTCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGTTCACTATCTCCCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCTCTGCGGGCCGAGGATACCGCGGTGTACTATTGCGCCAAGATGGGTTGGTCCAGCGGATACTTGGGAGCCTTCGACATTTGGGGACAGGGCACTACTGTGACCGTGTCCTCCGGGGGTGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAAATCGTGTTGACCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGCTACACTGTCATGTAGAGCGTCCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGTACCAGCAGAAGCCGGGACAGGCACCCCGCCTGCTCATCTACGGAGCCAGCGGCCGGGCGACCGGCATCCCTGACCGCTTCTCCGGTTCCGGCTCGGGCACCGACTTTACTCTGACCATTAGCAGGCTTGAGCCCGAGGATTTTGCCGTGTACTACTGCCAACACTACGGGGGGAGCCCTCGCCTGACCTTCGGAGGCGGAACTAAGGTCGATATCAAAA BCMA_EBB-C1978-G4-ak
vh 8091 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYLGAFDIWGQGTTVTVSS BCMA_EBB-C1978-G4-ac
VL 8112 EIVLTQSPGTLSLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYCQHYGGSPRLTTFGGGTKVDIK

In embodiments, additional exemplary BCMA CAR constructs are derived using the VH and VL sequences from PCT Publication WO2012/0163805 (the contents of which are hereby incorporated by reference in their entirety). In embodiments, additional exemplary BCMA CAR constructs are derived using the VH and VL sequences from PCT Publication WO2016/014565 (the contents of which are hereby incorporated by reference in their entirety). In embodiments, additional exemplary BCMA CAR constructs are derived using the VH and VL sequences from PCT Publication WO2014/122144 (the contents of which are hereby incorporated by reference in their entirety). In embodiments, additional exemplary BCMA CAR constructs are generated using CAR molecules and/or VH and VL sequences from PCT Publication WO2016/014789 (the contents of which are hereby incorporated by reference in their entirety). In embodiments, additional exemplary BCMA CAR constructs are generated using CAR molecules and/or VH and VL sequences from PCT Publication WO2014/089335 (the contents of which are hereby incorporated by reference in their entirety). In embodiments, additional exemplary BCMA CAR constructs are generated using CAR molecules and/or VH and VL sequences from PCT Publication WO2014/140248 (the contents of which are hereby incorporated by reference in their entirety).

In embodiments, additional exemplary BCMA CAR constructs can also be generated using the VH and VL sequences shown in Table 19. Amino acid sequences of exemplary scFv domains, including VH and VL domains and a linker sequence, and full-length CARs are also shown in Table 19.

Table 19 Sequences of Additional Exemplary BCMA Binding Domains Name Subsequence SEQID NO: A7D12.2 VH QIQLVQSGPDLKKPGETVKLSCKASGYTFFTNFGMNWVKQAPGKGFKWMAWINTYTGESYFADDFKGRFAFSVETSATTAYLQINNLKTEDTATYFCARGEIYYGYDGGFAYWGQGTLVTVSA 8155 A7D12.2L DVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKLLIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLDIK 8159 A7D12.2
scFv domain QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGESYFADDFKGRFAFSVETSATTAYLQINNLKTEDTATYFCARGEIYYGYDGGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKLLIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLDIK 8163 C11D5.3 VH QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVTVSS 8156 C11D5.3 VL DIVLTQSPASLAMSLGKRATISCRASESVSVIGAHLIHWYQQKPGQPPKLLIYLASNLETGVPARFSGSGSGTDFTLTIDPVEEDDVAIYSCLQSRIFPRTFGGGTKLEIK 8160 C11D5.3
scFv domain QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVTVSS 8164 C12A3.2 VH QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGVPIYADDFKGRFAFSVETSASTAYLVINNLKDEDTASYFCSNDYLYSLDFWGQGTALTVSS 8157 C12A3.2 VL DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 8161 C12A3.2
scFv domain QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGVPIYADDFKGRFAFSVETSASTAYLVINNLKDEDTASYFCSNDYLYSLDFWGQGTALTVSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 8165 C13F12.1 VH QIQLVQSGPELKKPGETVKISCKASGYTFTHYSMNWVKQAPGKGLKWMGRINTETGEPLYADDFKGRFAFSLETSASTAYLVINNLKNEDTATFFCSNDYLYSCDYWGQGTTLTVSS 8158 C13F12.1 VL DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 8162 C13F12.1
scFv domain QIQLVQSGPELKKPGETVKISCKASGYTFTHYSMNWVKQAPGKGLKWMGRINTETGEPLYADDFKGRFAFSLETSASTAYLVINNLKNEDTATFFCSNDYLYSCDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 8166

The sequences of the human CDR sequences of the scFv domains are shown in Table 20 for the heavy chain variable domains and in Table 21 for the light chain variable domains. "ID" denotes the corresponding SEQ ID NO for each CDR. CDR regions are shown according to the Kabat definition, while CDR regions according to another rule, such as Chothia or the combined Kabat/Chothia definitions, can be easily inferred from the VH and VL sequences above.

Table 20: Heavy chain variable domain CDRs according to Kabat's numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD) Candidate HCDR1 ID HCDR2 ID HDDR3 ID 139109 NHGMS 8294 GIVYSGSTYYAASVKG 8334 HGGESDV 8374 139103 NYAMS 8284 GISRSGENTYYADSVKG 8324 SPAHYYGGMDV 8364 139105 DYAMH 8285 GISWNSGSIGYADSVKG 8325 HSFLAY 8365 139111 NHGMS 8286 GIVYSGSTYYAASVKG 8326 HGGESDV 8366 139100 NFGIN 8287 WINPKNNNTNYAQKFQG 8327 GPYYYQSYMDV 8367 139101 SDAMT 8288 VISGSGGTTYYADSVKG 8328 LDSSGYYYARGPRY 8368 139102 NYGIT 8289 WISAYNGNTNYAQKFQG 8329 GPYYYYMDV 8369 139104 NHGMS 8290 GIVYSGSTYYAASVKG 8330 HGGESDV 8370 139106 NHGMS 8291 GIVYSGSTYYAASVKG 8331 HGGESDV 8371 139107 NHGMS 8292 GIVYSGSTYYAASVKG 8332 HGGESDV 8372 139108 DYYMS 8293 YISSGSTIYYADSVKG 8333 ESGDGMDV 8373 139110 DYYMS 8295 YISSSGNTIYYADSVKG 8335 STMVREDY 8375 139112 NHGMS 8296 GIVYSGSTYYAASVKG 8336 HGGESDV 8376 139113 NHGMS 8297 GIVYSGSTYYAASVKG 8337 HGGESDV 8377 139114 NHGMS 8298 GIVYSGSTYYAASVKG 8338 HGGESDV 8378 149362 SSYYYWG 8299 SIYYSGSAYYNPSLKS 8339 HWQEWPDAFDI 8379 149363 TSGMCVS 8300 RIDWDEDKFYSTSLKT 8340 SGAGGTSATAFDI 8380 149364 SYSMN 8301 SISSSSSYIYYADSVKG 8341 TIAAVYAFDI 8381 149365 DYYMS 8302 YISSGSTIYYADSVKG 8342 DLRGAFDI 8382 149366 SHYIH 8303 MINPSGGVTAYSQTLQG 8343 EGSGSGWYFDF 8383 149367 SGGYYWS 8304 YIYYSGSTYYNPSLKS 8344 AGIAARLRGAFDI 8384 149368 SYAIS 8305 GIIPIFGTANYAQKFQG 8345 RGGYQLLRWDVGLLRSAFDI 8385 149369 SNSAAWN 8306 RTYYRSKWYSFYAISLKS 8346 SSPEGLFLYWFDP 8386 BCMA_EBB-C1978-A4 SYAMS 8307 AISGSGGSTYYADSVKG 8347 VEGSGSLDY 8387 BCMA_EBB-C1978-G1 RYPMS 8308 GISDSGVSTYYADSAKG 8348 RAGSEASDI 8388 BCMA_EBB-C1979-C1 SYAMS 8309 AISGSGGSTYYADSVKG 8349 ATYKRELRYYYGMDV 8389 BCMA_EBB-C1978-C7 SYAMS 8310 AISGSGGSTYYADSVKG 8350 ATYKRELRYYYGMDV 8390 BCMA_EBB-C1978-D10 DYAMH 8311 GISWNSGSIGYADSVKG 8351 VGKAVPDV 8391 BCMA_EBB-C1979-C12 DYAMH 8312 SINWKGNSLAYGDSVKG 8352 HQGVAYYNYAMDV 8392 BCMA_EBB-C1980-G4 SYAMS 8313 AISGSGGSTYYADSVKG 8353 VVRDGMDV 8393 BCMA_EBB-C1980-D2 SYAMS 8314 AISGSGGSTYYADSVKG 8354 IPQTGTFDY 8394 BCMA_EBB-C1978-A10 SYAMS 8315 AISGSGGSTYYADSVKG 8355 ANYKRELRYYYGMDV 8395 BCMA_EBB-C1978-D4 SYAMS 8316 AISGSGGSTYYADSVKG 8356 ALVGATGAFDI 8396 BCMA_EBB-C1980-A2 SYAMS 8317 AISGSGGSTYYADSVKG 8357 WFGEGFDP 8397 BCMA_EBB-C1981-C3 SYAMS 8318 AISGSGGSTYYADSVKG 8358 VGYDSSGYYRDYYGMDV 8398 BCMA_EBB-C1978-G4 SYAMS 8319 AISGSGGSTYYADSVKG 8359 MGWSSGYLGAFDI 8399 A7D12.2 NFGMN 8320 WINTYTGESYFADDFKG 8360 GEIYYGYDGGFAY 8400 C11D5.3 DYSIN 8321 WINTETREPAYAYDFRG 8361 DYSYAMDY 8401 C12A3.2 HYSMN 8322 RINTESGVPIYADDFKG 8362 DYLYSLDF 8402 C13F12.1 HYSMN 8323 RINTEGEPLYADDFKG 8363 DYLYSCDY 8403

Table 21: Light chain variable domain CDRs according to Kabat's numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD) Candidate LCDR1 ID LCDR2 ID LCDR3 ID 139109 RASQSISSYLN 8414 AASSLQS 8454 QQSYSTPYT 8494 139103 RASQSISSSFLA 8404 GASRRAT 8444 QQYHSSPSWT 8484 139105 RSSQSLLHSNGYNYLD 8405 LGSNRAS 8445 MQALQTPYT 8485 139111 KSSQSLLRNDGKTPLY 8406 EVSNRFS 8446 MQNIQFPS 8486 139100 RSSQSLLHSNGYNYLN 8407 LGSKRAS 8447 MQALQTPYT 8487 139101 RASQSISSYLN 8408 GASTLAS 8448 QQSYKRAS 8488 139102 RSSQSLLYSNGYNYVD 8409 LGSNRAS 8449 MQGRQFPYS 8489 139104 RASQSVSSNLA 8410 GASTRAS 8450 QQYGSSLT 8490 139106 RASQSVSSKLA 8411 GASIRAT 8451 QQYGSSSWT 8491 139107 RASQSVGSTNLA 8412 DASNRAT 8452 QQYGSPPWT 8492 139108 RASQSISSYLN 8413 AASSLQS 8453 QQSYTLA 8493 139110 KSSELVHNSGKTYLN 8415 EVSNRDS 8455 MQGTHWPGT 8495 139112 QASEDINKFLN 8416 DASTLQT 8456 QQYESLPLT 8496 139113 RASQSVGSNLA 8417 GASTRAT 8457 QQYNDWLPVT 8497 139114 RASQSIGSSSLA 8418 GASSRAS 8458 QQYAGSPPPFT 8498 149362 KASQDIDDAMN 8419 SATSPVP 8459 LQHDNFPLT 8499 149363 RASQDIYNNLA 8420 AANKSQS 8460 QHYYRFPYS 8500 149364 RSSQSLLHSNGYNYLD 8421 LGSNRAS 8461 MQALQTPYT 8501 149365 GGNNGTKSVH 8422 DDSVRPS 8462 QVWDSDSEHVV 8502 149366 SGDGLSKKYVS 8423 RDKERPS 8463 QAWDDDTTVV 8503 149367 RASQGIRNWLA 8424 AASNLQS 8464 QKYNSAPFT 8504 149368 GGNNIGSKSVH 8425 GKNNRPS 8465 SSRDSSGDHLRV 8505 149369 QGDSLGNYYAT 8426 GTNNRPS 8466 NSRDSSGHHL 8506 BCMA_EBB-C1978-A4 RASQSVSSAYLA 8427 GASTRAT 8467 QHYGSSFNGSSLFT 8507 BCMA_EBB-C1978-G1 RASQSVSNSLA 8428 DASSRAT 8468 QQFGTSSGLT 8508 BCMA_EBB-C1979-C1 RASQSVSSSFLA 8429 GASSRAT 8469 QQYHSSPSWT 8509 BCMA_EBB-C1978-C7 RASQSVSTTFLA 8430 GSSNRAT 8470 QQYHSSPSWT 8510 BCMA_EBB-C1978-D10 RASQSISSYLN 8431 AASSLQS 8471 QQSYSTPYS 8511 BCMA_EBB-C1979-C12 RATQSIGSSFLA 8432 GASQRAT 8472 QHYESSPSWT 8512 BCMA_EBB-C1980-G4 RASQSVSSSYLA 8433 GASSRAT 8473 QQYGSPPRFT 8513 BCMA_EBB-C1980-D2 RASQSVSSSYLA 8434 GASSRAT 8474 QHYGSSPSWT 8514 BCMA_EBB-C1978-A10 RASQRVASNYLA 8435 GASSRAT 8475 QHYDSSPSWT 8515 BCMA_EBB-C1978-D4 RASQSLSSNFLA 8436 GASNWAT 8476 QYYGTSPMYT 8516 BCMA_EBB-C1980-A2 RSSQSLLHSNGYNYLD 8437 LGSNRAS 8477 MQALQTPLT 8517 BCMA_EBB-C1981-C3 RASQSVSSSYLA 8438 GTSSRAT 8478 QHYGNSPPKFT 8518 BCMA_EBB-C1978-G4 RASQSVASSFL 8439 GASGRAT 8479 QHYGGSPRLT 8519 A7D12.2 RASQDVNTAVS 8440 SASYRYT 8480 QQHYSTPWT 8520 C11D5.3 RASESVSVIGAHLIH 8441 LASNLET 8481 LQSRIFPRT 8521 C12A3.2 RASESVTILGSHLIY 8442 LASNVQT 8482 LQSRTIPRT 8522 C13F12.1 RASESVTILGSHLIY 8443 LASNVQT 8483 LQSRTIPRT 8523

In one embodiment, the BCMA binding domain includes one or more (e.g., all three) of light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3). ) a BCMA binding domain as described herein, such as those shown in Table 18, 19, or 21, and/or one or more (e.g., all three) of the Heavy Chain Complementarity Determining Region 1 (HC CDR1) Complementarity Determining Region 2 heavy chain (HC CDR2) and complementarity determining region 3 of the heavy chain (HC CDR3) of the BCMA binding domain described in this application, for example, presented in Table 18, 19 or 20. In one embodiment, the BCMA binding domain includes one, two or all LC CDR1, LC CDR2 and LC CDR3 with any amino acid sequence as shown in Table 18, incorporated herein by reference; and one, two or all HC CDR1, HC CDR2 and HC CDR3 with any amino acid sequence as shown in Table 18.

In one embodiment, the BCMA antigen binding domain includes:

(i) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8414, the amino acid sequence of LC CDR2 SEQ ID NO: 8454, and the amino acid sequence of LC CDR3 SEQ ID NO: 8494; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8294, the amino acid sequence of HC CDR2 SEQ ID NO: 8334, and the amino acid sequence of HC CDR3 SEQ ID NO: 8374

(ii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8404, the amino acid sequence of LC CDR2 SEQ ID NO: 8444, and the amino acid sequence of LC CDR3 SEQ ID NO: 8484; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8284, the amino acid sequence of HC CDR2 SEQ ID NO: 8324, and the amino acid sequence of HC CDR3 SEQ ID NO: 8364

(iii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8405, the amino acid sequence of LC CDR2 SEQ ID NO: 8445, and the amino acid sequence of LC CDR3 SEQ ID NO: 8485; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8285, the amino acid sequence of HC CDR2 SEQ ID NO: 8325, and the amino acid sequence of HC CDR3 SEQ ID NO: 8365

(iv) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8406, the amino acid sequence of LC CDR2 SEQ ID NO: 8446, and the amino acid sequence of LC CDR3 SEQ ID NO: 8486; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8286, the amino acid sequence of HC CDR2 SEQ ID NO: 8326, and the amino acid sequence of HC CDR3 SEQ ID NO: 8366

(v) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8407, the amino acid sequence of LC CDR2 SEQ ID NO: 8447, and the amino acid sequence of LC CDR3 SEQ ID NO: 8487; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8287, the amino acid sequence of HC CDR2 SEQ ID NO: 8327, and the amino acid sequence of HC CDR3 SEQ ID NO: 8367

(vi) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8408, the amino acid sequence of LC CDR2 SEQ ID NO: 8448, and the amino acid sequence of LC CDR3 SEQ ID NO: 8488; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8288, the amino acid sequence of HC CDR2 SEQ ID NO: 8328, and the amino acid sequence of HC CDR3 SEQ ID NO: 8368

(vii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8409, the amino acid sequence of LC CDR2 SEQ ID NO: 8449, and the amino acid sequence of LC CDR3 SEQ ID NO: 8489; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8289, the amino acid sequence of HC CDR2 SEQ ID NO: 8329, and the amino acid sequence of HC CDR3 SEQ ID NO: 8369

(viii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8410, the amino acid sequence of LC CDR2 SEQ ID NO: 8450, and the amino acid sequence of LC CDR3 SEQ ID NO: 8490; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8290, the amino acid sequence of HC CDR2 SEQ ID NO: 8330, and the amino acid sequence of HC CDR3 SEQ ID NO: 8370

(ix) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8411, the amino acid sequence of LC CDR2 SEQ ID NO: 8451, and the amino acid sequence of LC CDR3 SEQ ID NO: 8491; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8291, the amino acid sequence of HC CDR2 SEQ ID NO: 8331, and the amino acid sequence of HC CDR3 SEQ ID NO: 8371

(x) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8412, the amino acid sequence of LC CDR2 SEQ ID NO: 8452, and the amino acid sequence of LC CDR3 SEQ ID NO: 8492; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8292, the amino acid sequence of HC CDR2 SEQ ID NO: 8332, and the amino acid sequence of HC CDR3 SEQ ID NO: 8372

(xi) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8413, the amino acid sequence of LC CDR2 SEQ ID NO: 8453, and the amino acid sequence of LC CDR3 SEQ ID NO: 8493; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8293, the amino acid sequence of HC CDR2 SEQ ID NO: 8333, and the amino acid sequence of HC CDR3 SEQ ID NO: 8373

(xii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8415, the amino acid sequence of LC CDR2 SEQ ID NO: 8455, and the amino acid sequence of LC CDR3 SEQ ID NO: 8495; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8295, the amino acid sequence of HC CDR2 SEQ ID NO: 8335, and the amino acid sequence of HC CDR3 SEQ ID NO: 8375

(xiii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8416, the amino acid sequence of LC CDR2 SEQ ID NO: 8456, and the amino acid sequence of LC CDR3 SEQ ID NO: 8496; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8296, the amino acid sequence of HC CDR2 SEQ ID NO: 8336, and the amino acid sequence of HC CDR3 SEQ ID NO: 8376

(xiv) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8417, the amino acid sequence of LC CDR2 SEQ ID NO: 8457, and the amino acid sequence of LC CDR3 SEQ ID NO: 8497; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8297, the amino acid sequence of HC CDR2 SEQ ID NO: 8337, and the amino acid sequence of HC CDR3 SEQ ID NO: 8377

(xv) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8418, the amino acid sequence of LC CDR2 SEQ ID NO: 8458, and the amino acid sequence of LC CDR3 SEQ ID NO: 8498; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8298, the amino acid sequence of HC CDR2 SEQ ID NO: 8338, and the amino acid sequence of HC CDR3 SEQ ID NO: 8378

(xvi) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8419, the amino acid sequence of LC CDR2 SEQ ID NO: 8459, and the amino acid sequence of LC CDR3 SEQ ID NO: 8499; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8299, the amino acid sequence of HC CDR2 SEQ ID NO: 8339, and the amino acid sequence of HC CDR3 SEQ ID NO: 8379

(xvii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8420, the amino acid sequence of LC CDR2 SEQ ID NO: 8460, and the amino acid sequence of LC CDR3 SEQ ID NO: 8500; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8300, the amino acid sequence of HC CDR2 SEQ ID NO: 8340, and the amino acid sequence of HC CDR3 SEQ ID NO: 8380

(xviii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8421, the amino acid sequence of LC CDR2 SEQ ID NO: 8461, and the amino acid sequence of LC CDR3 SEQ ID NO: 8501; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8301, the amino acid sequence of HC CDR2 SEQ ID NO: 8341, and the amino acid sequence of HC CDR3 SEQ ID NO: 8381

(xix) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8422, the amino acid sequence of LC CDR2 SEQ ID NO: 8462, and the amino acid sequence of LC CDR3 SEQ ID NO: 8502; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8302, the amino acid sequence of HC CDR2 SEQ ID NO: 8342, and the amino acid sequence of HC CDR3 SEQ ID NO: 8382

(xx) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8423, the amino acid sequence of LC CDR2 SEQ ID NO: 8463, and the amino acid sequence of LC CDR3 SEQ ID NO: 8503; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8303, the amino acid sequence of HC CDR2 SEQ ID NO: 8343, and the amino acid sequence of HC CDR3 SEQ ID NO: 8383

(xxi) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8424, the amino acid sequence of LC CDR2 SEQ ID NO: 8464, and the amino acid sequence of LC CDR3 SEQ ID NO: 8504; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8304, the amino acid sequence of HC CDR2 SEQ ID NO: 8344, and the amino acid sequence of HC CDR3 SEQ ID NO: 8384

(xxii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8425, the amino acid sequence of LC CDR2 SEQ ID NO: 8465, and the amino acid sequence of LC CDR3 SEQ ID NO: 8505; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8305, the amino acid sequence of HC CDR2 SEQ ID NO: 8345, and the amino acid sequence of HC CDR3 SEQ ID NO: 8385, or

(xxiii) (a) the amino acid sequence of LC CDR1 SEQ ID NO: 8426, the amino acid sequence of LC CDR2 SEQ ID NO: 8466, and the amino acid sequence of LC CDR3 SEQ ID NO: 8506; and

(b) the amino acid sequence of HC CDR1 SEQ ID NO: 8306, the amino acid sequence of HC CDR2 SEQ ID NO: 8346, and the amino acid sequence of HC CDR3 SEQ ID NO: 8386.

In one embodiment, the BCMA binding domain comprises a light chain variable region as described herein (eg, Table 18 or 19) and/or a heavy chain variable region as described herein (eg, Table 18 or 19). In one embodiment, the BCMA binding domain is an scFv comprising the light chain and heavy chain of the amino acid sequence listed in Table 18 or 19. In an embodiment, the BCMA binding domain (e.g., scFv) includes: a light chain variable region comprising the amino acid sequence, having at least one, two, or three modifications (e.g., substitutions, e.g., conservative substitutions), but not more than 30, 20, or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of the light chain variable region amino acid sequence shown in Table 18 or 19, or sequences with 95-99% identity with the amino acid sequence shown in Table 18 or 19; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions, e.g., conservative substitutions), but no more than 30, 20, or 10 modifications (e.g., substitutions, substitutions) the heavy chain variable region amino acid sequence shown in Table 18 or 19, or a sequence with 95-99% identity to the amino acid sequence shown in Table 18 or 19.

In one embodiment, the BCMA binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7949; SEQ ID NO: 7939, SEQ ID NO: 7940; SEQ ID NO: 7941; SEQ ID NO: 7942; SEQ ID NO: 7943; SEQ ID NO: 7944, SEQ ID NO: 7945, SEQ ID NO: 7946, SEQ ID NO: 7947, SEQ ID NO: 7948, SEQ ID NO: 7950, SEQ ID NO: 7951, SEQ ID NO: 7952, SEQ ID NO: 7953, SEQ ID NO: 8029, SEQ ID NO: 8030, SEQ ID NO: 8031, SEQ ID NO: 8032, SEQ ID NO: 8033, SEQ ID NO: 8034, SEQ ID NO: 8035, SEQ ID NO: 8036, SEQ ID NO: 8037, SEQ ID NO: 8038, SEQ ID NO: 8039, SEQ ID NO: 8040, SEQ ID NO: 8041, SEQ ID NO: 8042, SEQ ID NO: 8043, SEQ ID NO: 8044, SEQ ID NO: 8045, SEQ ID NO: 8046, SEQ ID NO: 8047, SEQ ID NO: 8048, SEQ ID NO: 8049, SEQ ID NO: 8163, SEQ ID NO: 8164, SEQ ID NO: 8165 and SEQ ID NO: 8166; or an amino acid sequence having at least one, two or three modifications (eg substitutions, eg conservative substitutions), but no more than 30, 20 or 10 modifications (eg substitutions, eg conservative substitutions) in any of the above sequences; or a sequence with 95-99% identity with any of the above sequences. In one embodiment, the BCMA binding domain is scFv and a light chain variable region comprising the amino acid sequence described herein, such as in Table 18 or 19, is fused to a heavy chain variable region comprising the amino acid sequence described herein, for example in Table 18 or 19, through a linker, for example, the linker described in this application. In one embodiment, the BCMA binding domain comprises a (Gly4-Ser)n linker where n is 1, 2, 3, 4, 5, or 6, preferably 3 (SEQ ID NO: 10801). The light chain variable region and the scFv heavy chain variable region can be, for example, in any of the following orientations: heavy chain variable region-linker-light chain variable region or light chain variable region-linker-heavy chain variable region.

Any known BCMA CAR, for example, the BMCA antigen binding domain of any prior art known BCMA CAR, can be used in accordance with the present invention. For example, BCMA CAR, described in this application.

Exemplary CAR molecules

In one aspect, a CAR, eg, a CAR expressed by a cell of the invention, comprises a CAR molecule comprising an antigen-binding domain that binds to a B-cell antigen, eg, as described herein, such as CD19 or BCMA.

In one embodiment, a CAR comprises a CAR molecule comprising a CD19 antigen binding domain (e.g., a murine, human, or humanized antibody or antibody fragment that specifically binds to CD19), a transmembrane domain, and an intracellular signaling domain (e.g., an intracellular signaling domain including a costimulatory domain and/or primary signaling domain).

Exemplary CAR molecules described herein are shown in Table 22. The CAR molecules in Table 22 include a CD19 antigen binding domain, e.g., the amino acid sequence of any CD19 antigen binding domain shown in Table 14.

Table 22 Exemplary CD19 CAR Molecules Antigen Name Amino acid sequence SEQID NO: CD19 CTL019 MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7920 CD19 CAR 1 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7908 CD19 CAR 2 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7909 CD19 CAR 3 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7910 CD19 CAR 4 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7911 CD19 CAR 5 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7912 CD19 CAR 6 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7913 CD19 CAR 7 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7914 CD19 CAR 8 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7915 CD19 CAR 9 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7916 CD19 CAR 10 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7917 CD19 CAR 11 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7918 CD19 CAR 12 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 7919

In one embodiment, the CAR molecule includes (eg, consists of) the amino acid sequence shown in Table 22 or Table 3 of International Application WO2014/153270 filed March 15, 2014; included in this application by reference. In one embodiment, the CAR molecule comprises (e.g., consists of) the amino acid sequence of SEQ ID NO: 7908, SEQ ID NO: 7909, SEQ ID NO: 7910, SEQ ID NO: 7911, SEQ ID NO: 7912, SEQ ID NO: 7913 , SEQ ID NO: 7914, SEQ ID NO: 7915, SEQ ID NO: 7916, SEQ ID NO: 7917, SEQ ID NO: 7918, SEQ ID NO: 7919, or SEQ ID NO: 7920; or an amino acid sequence having at least one, two, three, four, five, 10, 15, 20, or 30 modifications (e.g., substitutions, e.g. conservative substitutions), but no more than 60, 50, or 40 modifications (e.g., substitutions , for example, conservative substitutions) of the amino acid sequence of SEQ ID NO: 7908, SEQ ID NO: 7909, SEQ ID NO: 7910, SEQ ID NO: 7911, SEQ ID NO: 7912, SEQ ID NO: 7913, SEQ ID NO: 7914, SEQ ID NO: 7915, SEQ ID NO: 7916, SEQ ID NO: 7917, SEQ ID NO: 7918, SEQ ID NO: 7919 or SEQ ID NO: 7920; or an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence of SEQ ID NO: 7908, SEQ ID NO: 7909, SEQ ID NO: 7910, SEQ ID NO : 7911, SEQ ID NO: 7912, SEQ ID NO: 7913, SEQ ID NO: 7914, SEQ ID NO: 7915, SEQ ID NO: 7916, SEQ ID NO: 7917, SEQ ID NO: 7918, SEQ ID NO: 7919 or SEQ ID NO: 7920.

In one aspect, a CAR, e.g., a CAR expressed by a cell of the invention, comprises a CAR molecule comprising an antigen-binding domain that binds to BCMA, e.g., includes a BCMA antigen-binding domain (e.g., a mouse, human, or humanized antibody or antibody fragment that specifically with BCMA, eg human BCMA), a transmembrane domain, and an intracellular signaling domain (eg, an intracellular signaling domain including a costimulatory domain and/or a primary signaling domain).

Exemplary CAR molecules described in this application are presented in Table 23 or Table 1 of WO2016/014565, or are as further described in this application. The CAR molecules in Table 23 include a BCMA antigen binding domain, for example, the amino acid sequence of any BCMA antigen binding domain shown in Table 18 or 19.

Table 23 Exemplary BCMA CAR molecules. Sequences are presented with a leader sequence. Name/ description SEQID NO: Subsequence 139109 139109-ak
Full size CAR 8559 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139109-nt
Full size CAR 8574 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGGTGGAATCAGGGGGAGGACTTGTGCAGCCTGGAGGATCGCTGAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCACGGGATGTCCTGGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTCGGGTATTGTGTACAGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTCACCATCAGCCGGGACAACTCCAGGAACACTCTGTACCTCCAAATGAATTCGCTGAGGCCAGAGGACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGACGTCTGGGGACAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCGGCAGCGGGGGTCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCACCCAGTCCCCGAGCTCGCTGTCCGCCTCCGTGGGAGATCGGGTCACCATCACGTGCCGCGCCAGCCAGTCGATTTCCTCCTACCTGAACTGGTACCAACAGAAGCCCGGAAAAGCCCCGAAGCTTCTCATCTACGCCGCCTCGAGCCTGCAGTCAGGAGTGCCCTCACGGTTCTCCGGCTCCGGTTCCGGTACTGATTTCACCCTGACCATTTCCTCCCTGCAACCGGAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCCCCTACACTTTCGGACAAGGCACCAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGA AGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139103 139103-ak
Full size CAR 8549 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISRSGENTYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARSPAHYYGGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVLTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139103-nt
Full size CAR 8564 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGAAGATCGCTTAGACTGTCGTGTGCCGCCAGCGGGTTCACTTTCTCGAACTACGCGATGTCCTGGGTCCGCCAGGCACCCGGAAAGGGACTCGGTTGGGTGTCCGGCATTTCCCGGTCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTCAAGGGACAACAGCAAAAACACCCTGTACTTGCAAATGAACTCCCTGCGGGATGAAGATACAGCCGTGTACTATTGCGCCCGGTCGCCTGCCCATTACTACGGCGGAATGGACGTCTGGGGACAGGGAACCACTGTGACTGTCAGCAGCGCGTCGGGTGGCGGCGGCTCAGGGGGTCGGGCCTCCGGGGGGGGAGGGTCCGACATCGTGCTGACCCAGTCCCCGGGAACCCTGAGCCTGAGCCCGGGAGAGCGCGCGACCCTGTCATGCCGGGCATCCCAGAGCATTAGCTCCTCCTTTCTCGCCTGGTATCAGCAGAAGCCCGGACAGGCCCCGAGGCTGCTGATCTACGGCGCTAGCAGAAGGGCTACCGGAATCCCAGACCGGTTCTCCGGCTCCGGTTCCGGGACCGATTTCACCCTTACTATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCCAGCAGTACCACTCATCCCCGTCGTGGACGTTCGGACAGGGCACCAAGCTGGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139105 139105-ak
Full size CAR 8550 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSVHSFLAYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139105-nt
Full size CAR 8565 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTCGTCGAATCCGGTGGAGGTCTGGTCCAACCTGGTAGAAGCCTGAGACTGTCGTGTGCGGCCAGCGGATTCACCTTTGATGACTATGCTATGCACTGGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTCGGGAATTAGCTGGAACTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTCCCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCGCTCAGGGCTGAGGATACCGCGCTGTACTACTGCTCCGTGCATTCCTTCCTGGCCTACTGGGGACAGGGAACTCTGGTCACCGTGTCGAGCGCCTCCGGCGGCGGGGGCTCGGGTGGACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAGACCCCGCTGAGCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCGGTCATCCCAGTCCCTTCTCCACTCCAACGGATACAACTACCTCGACTGGTACCTCCAGAAGCCGGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGAGCCTCAGGAGTGCCGGATCGGTTCAGCGGATCTGGTTCGGGAACTGATTTCACTCTGAAGATTTCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGCAGGCGCTGCAGACCCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACT GTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139111 139111-ak
Full size CAR 8551 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFPSFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139111-nt
Full size CAR 8566 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTGGAGGATCACTGAGACTTTCGTGTGCGGTGTCAGGCTTCGCCCTGAGCAACCACGGCATGAGCTGGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGGGATCGTCTACTCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTCGCTTCACCATTTCCCGCGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTGCGGCCCGAGGACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGATGTCTGGGGACAGGGCACTACCGTGACCGTGTCGAGCGCCTCGGGGGGAGGAGGCTCCGGCGGTCGCGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAGACTCCACTCTCGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAAGAGCTCCCAGAGCCTGCTGAGGAACGACGGAAAGACTCCTCTGTATTGGTACCTCCAGAAGGCTGGACAGCCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGCTTCTCCGGGGTGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCGACTTCACCCTGAAAATCTCCAGGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGCAAAACATCCAGTTCCCTTCCTTCGGCGGCGGCACAAAGCTGGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTA AGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139100 139100-ak
Full size CAR 8552 MALPVTALLLPLALLLHAARPQVQLVQSGAEVRKTGASVKVSCKASGYIFDNFGINWVRQAPGQGLEWMGWINPKNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDTAVYYCARGPYYYQSYMDVWGQGTMVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLNWYLQKPGQSPQLLIYLGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139100-nt
Full size CAR 8567 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTCCAACTCGTCCAGTCCGGCGCAGAAGTCAGAAAAACCGGTGCTAGCGTGAAAGTGTCCTGCAAGGCCTCCGGCTACATTTTCGATAACTTCGGAATCAACTGGGTCAGACAGGCCCCGGGCCAGGGGCTGGAATGGATGGGATGGATCAACCCCAAGAACAACAACACCAACTACGCACAGAAGTTCCAGGGCCGCGTGACTATCACCGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCCTCCCTGCGGTCGGAGGACACTGCCGTGTATTACTGCGCGAGGGGCCCATACTACTACCAAAGCTACATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTCATCCGCCTCCGGTGGTGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGATATTGTGATGACCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCGGCCTCCATTTCCTGCCGGTCCTCGCAATCACTCCTGCATTCCAACGGTTACAACTACCTGAATTGGTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTATCTGGGCTCGAAGCGCGCCTCCGGGGTGCCTGACCGGTTTAGCGGATCTGGGAGCGGCACGGACTTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAGTGTACTACTGTATGCAGGCGCTGCAGACTCCGTACACATTCGGACAGGGCACCAAGCTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCG TGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139101 139101-ak
Full size CAR 8553 MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYYARGPRYWGQGTLVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASTLASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRASFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139101-nt
Full size CAR 8568 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTTCAAGAATCAGGCGGAGGACTCGTGCAGCCCGGAGGATCATTGCGGCTCTCGTGCGCCGCCTCGGGCTTCACCTTCTCGAGCGACGCCATGACCTGGGTCCGCCAGGCCCCGGGGAAGGGGCTGGAATGGGTGTCTGTGATTTCCGGCTCCGGGGGAACTACGTACTACGCCGATTCCGTGAAAGGTCGCTTCACTATCTCCCGGGACAACAGCAAGAACACCCTTTATCTGCAAATGAATTCCCTCCGCGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGGCTACTACTATGCCCGGGGTCCGAGATACTGGGGACAGGGAACCCTCGTGACCGTGTCCTCCGCGTCCGGCGGAGGAGGGTCGGGAGGGCGGGCCTCCGGCGGCGGCGGTTCGGACATCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGGGCGACAGAGTCACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGAACTGGTACCAACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCTTCGACCCTGGCATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCACTCACTTCACTCTGACCATTAACAGCCTCCAGTCCGAGGATTCAGCCACTTACTACTGTCAGCAGTCCTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139102 139102-ak
Full size CAR 8554 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISAYNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGPYYYYMDVWGKGTMVTVSSASGGGGSGGRASGGGGSEIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139102-nt
Full size CAR 8569 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTCCAACTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCGGAGCGAGCGTGAAAGTGTCCTGCAAGGCTTCCGGGTACACCTTCTCCAACTACGGCATCACTTGGGTGCGCCAGGCCCCGGGACAGGGCCTGGAATGGATGGGGTGGATTTCCGCGTACAACGGCAATACGAACTACGCTCAGAAGTTCCAGGGTAGAGTGACCATGACTAGGAACACCTCCATTTCCACCGCCTACATGGAACTGTCCTCCCTGCGGAGCGAGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTACTACATGGATGTCTGGGGGAAGGGGACTATGGTCACCGTGTCATCCGCCTCGGGAGGCGGCGGATCAGGAGGACGCGCCTCTGGTGGTGGAGGATCGGAGATCGTGATGACCCAGAGCCCTCTCTCCTTGCCCGTGACTCCTGGGGAGCCCGCATCCATTTCATGCCGGAGCTCCCAGTCACTTCTCTACTCCAACGGCTATAACTACGTGGATTGGTACCTCCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGCTCGAACAGGGCCAGCGGAGTGCCTGACCGGTTCTCCGGGTCGGGAAGCGGGACCGACTTCAAGCTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACTACTGTATGCAGGGCCGCCAGTTTCCGTACTCGTTCGGACAGGGCACCAAAGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCA CTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139104 139104-ak
Full size CAR 8555 MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRASGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139104-nt
Full size CAR 8570 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTGGAGGATCACTTCGCCTGTCCTGCGCCGTGTCGGGCTTTGCCCTGTCCAACCATGGAATGAGCTGGGTCCGCCGCGCGCCGGGGAAGGGCCTCGAATGGGTGTCCGGCATCGTCTACTCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCACGATTTCACGGGACAACTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTTCGGCCGGAGGATACTGCCATCTACTACTGCTCCGCCCACGGTGGCGAATCCGACGTCTGGGGCCAGGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAGGAAGCGGGGGTAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAGTCCCCCGCCACCTTGAGCGTGTCACCAGGAGAGTCCGCCACCCTGTCATGCCGCGCCAGCCAGTCCGTGTCCTCCAACCTGGCTTGGTACCAGCAGAAGCCGGGGCAGGCCCCTAGACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCCCGATAGGTTCAGCGGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTCGCTGCAAGCCGAGGACGTGGCTGTGTACTACTGTCAGCAGTACGGAAGCTCCCTGACTTTCGGTGGCGGGACCAAAGTCGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGA AGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139106 139106-ak
Full size CAR 8556 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVMTQSPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASIRATGIPDRFSGSGSGTEFTLTISSLEPEDFAVYYCQQYGSSSWTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139106-nt
Full size CAR 8571 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATTGAGACTGAGCTGCGCAGTGTCGGGATTCGCCCTGAGCAACCATGGAATGTCCTGGGTCAGAAGGGCCCCTGGAAAAGGCCTCGAATGGGTGTCAGGGATCGTGTACTCCGGTTCCACTTACTACGCCGCCTCCGTGAAGGGGCGCTTCACTATCTCACGGGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTGCGGCCGGAGGATACCGCCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGACGTCTGGGGCCAGGGAACTACCGTGACCGTGTCCTCCGCGTCCGGCGGTGGAGGGAGCGGCGGCCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAGAGCCCCGCTACTCTGTCGGTGTCGCCCGGAGAAAGGGCGACCCTGTCCTGCCGGGCGTCGCAGTCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCCAGGCACCACGCCTGCTTATGTACGGTGCCTCCATTCGGGCCACCGGAATCCCGGACCGGTTCTCGGGGTCGGGGTCCGGTACCGAGTTCACACTGACCATTTCCTCGCTCGAGCCCGAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCTCATGGACGTTCGGCCAGGGGACCAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGA AGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139107 139107-ak
Full size CAR 8557 MALPVTALLLPLALLLHAARPEVQLVETGGGVVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139107-nt
Full size CAR 8572 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTGGAGGAAGCCTGAGACTGTCATGCGCGGTGTCGGGCTTCGCCCTCTCCAACCACGGAATGTCCTGGGTCCGCCGGGCCCCTGGGAAAGGACTTGAATGGGTGTCCGGCATCGTGTACTCGGGTTCCACCTACTACGCGGCCTCAGTGAAGGGCCGGTTTACTATTAGCCGCGACAACTCCAGAAACACACTGTACCTCCAAATGAACTCGCTGCGGCCGGAAGATACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGACGTCTGGGGACAGGGCACCACTGTCACTGTGTCCAGCGCTTCCGGCGGTGGTGGAAGCGGGGGACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAGTCCCCCGGGACCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCCTGTCGGGCATCCCAGTCCGTGGGGTCTACTAACCTTGCATGGTACCAGCAGAAGCCCGGCCAGGCCCCTCGCCTGCTGATCTACGACGCGTCCAATAGAGCCACCGGCATCCCGGATCGCTTCAGCGGAGGCGGATCGGGCACCGACTTCACCCTCACCATTTCAAGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCGTCCCCACCCTGGACGTTCGGCCAGGGGACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCG GTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139108 139108-ak
Full size CAR 8558 MALPVTALLLPLALLLHAARPQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGDGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTLAFGQGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139108-nt
Full size CAR 8573 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTGGAGGATCATTGAGACTGTCATGCGCGGCCTCGGGATTCACGTTCTCCGATTACTACATGAGCTGGATTCGCCAGGCTCCGGGGAAGGGACTGGAATGGGTGTCCTACATTTCCTCATCCGGCTCCACCATCTACTACGCGGACTCCGTGAAGGGGAGATTCACCATTAGCCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACTCCCTGCGGGCTGAAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGGGATGGACGTCTGGGGACAGGGTACCACTGTGACCGTGTCGTCGGCCTCCGGCGGAGGGGGTTCGGGTGGAAGGGCCAGCGGCGGCGGAGGCAGCGACATCCAGATGACCCAGTCCCCCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCACATGCCGGGCCTCACAGTCGATCTCCTCCTACCTCAATTGGTATCAGCAGAAGCCCGGAAAGGCCCCTAAGCTTCTGATCTACGCAGCGTCCTCCCTGCAATCCGGGGTCCCATCTCGGTTCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCATCTCGAGCCTGCAGCCGGAGGACTTCGCCACTTACTACTGTCAGCAAAGCTACACCCTCGCGTTTGGCCAGGGCACCAAAGTGGACATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGA AGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139110 139110-ak
Full size CAR 8560 MALPVTALLLPLALLLHAARPQVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGNTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSTMVREDYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVLTQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPGQSPRRLIYEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139110-nt
Full size CAR 8575 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTGGTGCAAAGCGGAGGAGGATTGGTCAAACCCGGAGGAAGCCTGAGACTGTCATGCGCGGCCTCTGGATTCACCTTCTCCGATTACTACATGTCATGGATCAGACAGGCCCCGGGGAAGGGCCTCGAATGGGTGTCCTACATCTCGTCCTCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCTTTACCATTTCCCGCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATTCCCTGCGGGCTGAAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCGGGAGGACTACTGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGGGTGGAGGCAGCGGTGGACGCGCCTCCGGCGGCGGCGGTTCAGACATCGTGCTGACTCAGTCGCCCCTGTCGCTGCCGGTCACCCTGGGCCAACCGGCCTCAATTAGCTGCAAGTCCTCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACTGGTTCCATCAGCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTCCAACAGGGATTCGGGGGTGCCCGACCGCTTCACTGGCTCCGGGTCCGGCACCGACTTCACCTTGAAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTATGCAGGGTACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139112 139112-ak
Full size CAR 8561 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIRLTQSPSPLSASVGDRVTITCQASEDINKFLNWYHQTPGKAPKLLIYDASTLQTGVPSRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139112-nt
Full size CAR 8576 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGTGGAAGCCTTAGGCTGTCGTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCATGGAATGTCCTGGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGGCATCGTGTACAGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCACTATCTCAAGAGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTGCGCCCCGAGGACACCGCCATCTACTACTGCTCCGCCCACGGAGGAGAGTCGGACGTGTGGGGCCAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGGTGGTTCGGGCGGCCGGGCCTCGGGGGGAGGAGGTTCCGACATTCGGCTGACCCAGTCCCCGTCCCCACTGTCGGCCTCCGTCGGCGACCGCGTGACCATCACTTGTCAGGCGTCCGAGGACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAAAGGCCCCCAAGCTGCTGATCTACGATGCCTCGACCCTTCAAACTGGAGTGCCTAGCCGGTTCTCCGGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTCATTGCAGCCGGAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCCCGCTCACATTCGGCGGGGGAACCAAGGTCGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGA AGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139113 139113-ak
Full size CAR 8562 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSETTLTQSPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCQQYNDWLPVTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139113-nt
Full size CAR 8577 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATTGCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCACGGGATGTCGTGGGTCAGACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTCGGGGATTGTGTACAGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCACTATTTCACGGGACAACAGCCGCAACACCCTCTATCTGCAAATGAACTCTCTCCGCCCGGAGGATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGACGTGTGGGGACAGGGAACCACTGTCACCGTGTCGTCCGCATCCGGTGGCGGAGGATCGGGTGGCCGGGCCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAGTCCCCTGCCACTCTGTCCGTGAGCCCGGGAGAGAGAGCCACCCTTAGCTGCCGGGCCAGCCAGAGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGGTCCCAGGCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCCGCGAGGTTCTCCGGGTCGGGTTCCGGGACCGAGTTCACCCTGACCATCTCCTCCCTCCAACCGGAGGACTTCGCGGTGTACTACTGTCAGCAGTACAACGATTGGCTGCCCGTGACATTTGGACAGGGGACGAAGGTGGAAATCAAAACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTC GGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 139114 139114-ak
Full size CAR 8563 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGASSRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPPFTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 139114-nt
Full size CAR 8578 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAATTGGTGGAATCTGGTGGAGGACTTGTGCAACCTGGAGGATCACTGAGACTGTCATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCATGGGATGTCGTGGGTCCGGCGCGCCCCCGGAAAGGGTCTGGAATGGGTGTCGGGTATCGTCTACTCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTCACCATTTCCCGCGATAACTCCCGCAACACCCTGTACTTGCAAATGAACTCGCTCCGGCCTGAGGACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGACGTGTGGGGCCAGGGAACTACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGGGCTCAGGCGGACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGCTGACCCAGTCGCCTGGCACTCTCTCGCTGAGCCCCGGGGAAAGGGCAACCCTGTCCTGTCGGGCCAGCCAGTCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGGGACAGGCTCCGCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATTCCCGACCGGTTCTCCGGGTCCGGTTCCGGCACCGATTTCACCCTGACTATCTCGAGGCTGGAGCCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGTCCCCGCCGTTCACGTTCGGACAGGGAACCAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCG GTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149362 149362-AK Full size CAR 8579 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSETTLTQSPAFMSATPGDKVIISCKASQDIDDAMNWYQQKPGEAPLFIIQSATSPVPGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFPLTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149362-nt
Full size CAR 8601 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCATCCGAAACTCTCTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCGTACTACTACTGGGGCTGGATTAGGCAGCCGCCCGGAAAGGGACTGGAGTGGATCGGAAGCATCTACTATTCCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGAGAGTGACCATCTCCGTGGATACCTCCAAGAACCAGTTTTCCCTGCGCCTGAGCTCCGTGACCGCCGCTGACACCGCCGTGTACTACTGTGCTCGGCATTGGCAGGAATGGCCCGATGCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGTCATCCGGGGGTGGAGGCAGCGGGGGAGGAGGGTCCGGGGGGGGAGGTTCAGAGACAACCTTGACCCAGTCACCCGCATTCATGTCCGCCACTCCGGGAGACAAGGTCATCATCTCGTGCAAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGCAGAAGCCTGGCGAAGCGCCGCTGTTCATTATCCAATCCGCAACCTCGCCCGTGCCTGGAATCCCACCGCGGTTCAGCGGCAGCGGTTTCGGAACCGACTTTTCCCTGACCATTAACAACATTGAGTCCGAGGACGCCGCCTACTACTTCTGCCTGCAACACGACAACTTCCCTCTCACGTTCGGCCAGGGAACCAAGCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTA AGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149363 149363-AK Full size CAR 8580 MALPVTALLLPLALLLHAARPQVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARIDWDEDKFYSTSLKTRLTISKDTSDNQVVLRMTNMDPADTATYYCARSGAGGTSATAFDIWGPGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDIYNNLAWFQLKPGSAPRSLMYAANKSQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYYRFPYSFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149363-nt
Full size CAR 8602 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTACCCAGACCCTCACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCCGGGATGTGCGTGTCCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCTCGCTCGCATTGACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCAGGCTGACCATCAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACCAACATGGACCCAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGGCGGAACCTCCGCCACCGCCTTCGATATTTGGGGCCCGGGTACCATGGTCACCGTGTCAAGCGGAGGAGGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCGGACATTCAGATGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAGAGTGACAATCACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCGTGGTTCCAGCTGAAGCCTGGTTCCGCACCGCGGTCACTTATGTACGCCGCCAACAAGAGCCAGTCGGGAGTGCCGTCCCGGTTTTCCGGTTCGGCCTCGGGAACTGACTTCACCCTGACGATCTCCAGCCTGCAACCCGAGGATTTCGCCACCTACTACTGCCAGCACTACTACCGCTTTCCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTT ACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149364 149364-AK Full size CAR 8581 MALPVTALLLPLALLLHAARPEVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPLSLPVTPEEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149364-nt
Full size CAR 8603 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTTGTCGAATCCGGGGGGGGACTGGTCAAGCCGGGCGGATCACTGAGACTGTCCTGCGCCGCGAGCGGCTTCACGTTCTCCTCCTACTCCATGAACTGGGTCCGCCAAGCCCCCGGGAAGGGACTGGAATGGGTGTCCTCTATCTCCTCGTCGTCGTCCTACATCTACTACGCCGACTCCGTGAAGGGAAGATTCACCATTTCCCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCACTCCGGGCCGAAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCGCCGTCTACGCTTTCGACATCTGGGGCCAGGGAACCACCGTGACTGTGTCGTCCGGTGGTGGTGGCTCGGGCGGAGGAGGAAGCGGCGGCGGGGGGTCCGAGATTGTGCTGACCCAGTCGCCACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAGCTGCCGGTCCAGCCAGTCCCTGCTCCACTCCAACGGATACAATTACCTCGATTGGTACCTTCAGAAGCCTGGACAAAGCCCGCAGCTGCTCATCTACTTGGGATCAAACCGCGCGTCAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGATTTCACCCTGAAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACTGTATGCAGGCGCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149365 149365-AK Full size CAR 8582 MALPVTALLLPLALLLHAARPEVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQSPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPGRFSGSNSGNMATLTISGVQAGDEADFYCQVWDSDSEHVVFGGGTKLTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149365-nt
Full size CAR 8604 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCTTGTGAAGCCTGGAGGTTCGCTGAGACTGTCCTGCGCCGCCTCCGGCTTCACCTTCTCCGACTACTACATGTCCTGGATCAGACAGGCCCCGGGAAAGGGCCTGGAATGGGTGTCCTACATCTCGTCATCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGTTCACCATTTCCCGGGATAACGCGAAGAACTCGCTGTATCTGCAAATGAACTCACTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCCGCGATCTCCGCGGGGCATTTGACATCTGGGGACAGGGAACCATGGTCACAGTGTCCAGCGGAGGGGGAGGATCGGGTGGCGGAGGTTCCGGGGGTGGAGGCTCCTCCTACGTGCTGACTCAGAGCCCAAGCGTCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGGAAACAACATTGGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAGCTCCCCTGTTGGTGATCCGCGATGACTCCGTGCGGCCTAGCAAAATTCCGGGACGGTTCTCCGGCTCCAACAGCGGCAATATGGCCACTCTCACCATCTCGGGAGTGCAGGCCGGAGATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCGAGCATGTGGTGTTCGGGGGCGGAACCAAGCTGACTGTGCTCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTC GGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149366 149366-AK Full size CAR 8583 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINPSGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKERPSGIPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149366-nt
Full size CAR 8605 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTGGTGCAGAGCGGGGCCGAAGTCAAGAAGCCGGGAGCCTCCGTGAAAGTGTCCTGCAAGCCTTCGGGATACACCGTGACCTCCCACTACATTCATTGGGTCCGCCGCGCCCCCGGCCAAGGACTCGAGTGGATGGGCATGATCAACCCTAGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCGTGACTATGACCTCGGATACCTCCTCCTCCACCGTCTATATGGAACTGTCCAGCCTGCGGTCCGAGGATACCGCCATGTACTACTGCGCCCGGGAAGGATCAGGCTCCGGGTGGTATTTCGACTTCTGGGGAAGAGGCACCCTCGTGACTGTGTCATCTGGGGGAGGGGGTTCCGGTGGTGGCGGATCGGGAGGAGGCGGTTCATCCTACGTGCTGACCCAGCCACCCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTACATGTAGCGGCGACGGCCTCTCCAAGAAATACGTGTCGTGGTACCAGCAGAAGGCCGGACAGAGCCCGGTGGTGCTGATCTCAAGAGATAAGGAGCGGCCTAGCGGAATCCCGGACAGGTTCTCGGGTTCCAACTCCGCGGACACTGCTACTCTGACCATCTCGGGGACCCAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACGACACTACTGTCGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTTACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCG GTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149367 149367-AK Full size CAR 8584 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDRVIITCRASQGIRNWLAWYQQKPGKAPNLLIYAASNLQSGVPSRFSGSGSGADFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149367-nt
Full size CAR 8606 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTTCAGGAGAGCGGCCCGGGACTCGTGAAGCCGTCCCAGACCCTGTCCCTGACTTGCACCGTGTCGGGAGGAAGCATCTCGAGCGGAGGCTACTATTGGTCGTGGATTCGGCAGCACCCTGGAAAGGGCCTGGAATGGATCGGCTACATCTACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCAGAGTGACAATCTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCTTCCGTGACTGCGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGCCGCCCGGCTGAGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCGTGTCCTCCGGCGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGGTCCGACATCGTCATGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTCGGGGACAGAGTGATCATCACCTGTCGGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGTATCAGCAGAAGCCCGGAAAGGCCCCCAACCTGTTGATCTACGCCGCCTCAAACCTCCAATCCGGGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTTCACTCTGACCATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCCAAAAGTACAACTCCGCACCTTTTACTTTCGGACCGGGGACCAAAGTGGACATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTT ACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149368 149368-AK Full size CAR 8585 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLRWDVGLLRSAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVLYGKNNRPSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTKVTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149368-nt
Full size CAR 8607 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCGGGAGCTCTGTGAAAGTGTCCTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTACGCCATCTCCTGGGTCCGCCAAGCACCGGGTCAAGGCCTGGAGTGGATGGGGGGAATTATCCCTATCTTCGGCACTGCCAACTACGCCCAGAAGTTCCAGGGACGCGTGACCATTACCGCGGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGCTTGCGCTCGGAAGATACCGCCGTGTACTACTGCGCCCGGAGGGGTGGATACCAGCTGCTGAGATGGGACGTGGGCCTCCTGCGGTCGGCGTTCGACATCTGGGGCCAGGGCACTATGGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGGCGGATCAGGGGGAGGCGGTTCCAGCTACGTGCTTACTCAACCCCCTTCGGTGTCCGTGGCCCCGGGACAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCAAGAGCGTGCATTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTGCTGGTGCTCTACGGGAAGAACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACGCTCCGGTACAACCGCTTCACTGACTATCACCGGGGCCCAGGCAGAGGATGAAGCGGACTACTACTGTTCCTCCCGGGATTCATCCGGCGACCACCTCCGGGTGTTCGGAACCGGAACGAAGGTCACCGTGCTGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGC TGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 149369 149369-AK Full size CAR 8586 MALPVTALLLPLALLLHAARPEVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEGLFLYWFDPWGQGTLVTVSSGGDGSGGGGSGGGGSSSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNRPSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHHLLFGTGTKVTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 149369-nt
Full size CAR 8608 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCATCCCAGACCCTGTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTCATCGAACTCCGCCGCCTGGAACTGGATTCGGCAGAGCCCGTCCCGCGGACTGGAGTGGCTTGGAAGGACCTACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGAAGTCCCGCATTATCATTAACCCTGATACCTCCAAGAATCAGTTCTCCCTCCAACTGAAATCCGTCACCCCCGAGGACACAGCAGTGTATTACTGCGCACGGAGCAGCCCCGAAGGACTGTTCCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTGTGACCGTGTCGAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGCGGATCATCATCCGAACTGACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACAAACCATCCGCATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTTGGTACCAGCAGAAGCCGGGCCAAGCCCCTGTGTTGGTCATCTACGGGACCAACAACAGACCTTCCGGCATCCCCGACCGGTTCAGCGCTTCGTCCTCCGGCAACACTGCCAGCCTGACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACTGCAACAGCAGAGACTCCTCGGGTCATCACCTCTTGTTCGGAACTGGAACCAAGGTCACCGTGCTGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGA TCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-A4 BCMA_EBB-C1978-A4 -ak
Full size CAR 8587 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQPPRLLISGASTRATGIPDRFGGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFNGSSLFTFGQGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-A4 -NT
Full size CAR 8609 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTCGTGGAGTCAGGAGGCGGCCTGGTCCAGCCGGGAGGGTCCCTTAGACTGTCATGCGCCGCAAGCGGATTCACTTTCTCCTCCTATGCCATGAGCTGGGTCCGCCAAGCCCCCGGAAAGGGACTGGAATGGGTGTCCGCCATCTCGGGGTCTGGAGGCTCAACTTACTACGCTGACTCCGTGAAGGGACGGTTCACCATTAGCCGCGACAACTCCAAGAACACCCTCTACCTCCAAATGAACTCCCTGCGGGCCGAGGATACCGCCGTCTACTACTGCGCCAAAGTGGAAGGTTCAGGATCGCTGGACTACTGGGGACAGGGTACTCTCGTGACCGTGTCATCGGGCGGAGGAGGTTCCGGCGGTGGCGGCTCCGGCGGCGGAGGGTCGGAGATCGTGATGACCCAGAGCCCTGGTACTCTGAGCCTTTCGCCGGGAGAAAGGGCCACCCTGTCCTGCCGCGCTTCCCAATCCGTGTCCTCCGCGTACTTGGCGTGGTACCAGCAGAAGCCGGGACAGCCCCCTCGGCTGCTGATCAGCGGGGCCAGCACCCGGGCAACCGGAATCCCAGACAGATTCGGGGGTTCCGGCAGCGGCACAGATTTCACCCTGACTATTTCGAGGTTGGAGCCCGAGGACTTTGCGGTGTATTACTGTCAGCACTACGGGTCGTCCTTTAATGGCTCCAGCCTGTTCACGTTCGGACAGGGGACCCGCCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-G1 BCMA_EBB-C1978-G1 -ac
Full size CAR 8588 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWVSGISDSGVSTYYADSAKGRFTISRDNSKNTLFLQMSSLRDEDTAVYYCVTRAGSEASDIWGQGTMVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-G1 -NT
Full size CAR 8610 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAACTGGTGGAAACCGGTGGCGGCCTGGTGCAGCCTGGAGGATCATTGAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTACCCCATGTCCTGGGTCAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGGGATCTCGGACTCCGGTGTCAGCACTTACTACGCCGACTCCGCCAAGGGACGCTTCACCATTTCCCGGGACAACTCGAAGAACACCCTGTTCCTCCAAATGAGCTCCCTCCGGGACGAGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGAGGCGTCTGACATTTGGGGACAGGGCACTATGGTCACCGTGTCGTCCGGCGGAGGGGGCTCGGGAGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACCCAATCCCCGGCCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCCTGTCGCGCGAGCCAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCTCCGAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATCCCCGACCGCTTTTCGGGGTCCGGCTCAGGAACCGATTTCACCCTGACAATCTCACGGCTGGAGCCAGAGGATTTCGCCATCTATTACTGCCAGCAGTTCGGTACTTCCTCCGGCCTGACTTTCGGAGGCGGCACGAAGCTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCG GTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1979-C1 BCMA_EBB-C1979-C1 -ak
Full size CAR 8589 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIYYCARATYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1979-C1 -NT
Full size CAR 8611 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTCGTGGAATCGGGTGGCGGACTGGTGCAGCCGGGGGGCTCACTTAGACTGTCCTGCGCGGCCAGCGGATTCACTTTCTCCTCCTACGCCATGTCCTGGGTCAGACAGGCCCCTGGAAAGGGCCTGGAATGGGTGTCCGCAATCAGCGGCAGCGGCGGCTCGACCTATTACGCGGATTCAGTGAAGGGCAGATTCACCATTTCCCGGGACAACGCCAAGAACTCCTTGTACCTTCAAATGAACTCCCTCCGCGCGGAAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAGGGAACTGCGCTACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCACCGTGTCCAGCGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGGTCGGAGATCGTGATGACCCAGTCCCCCGGCACTGTGTCGCTGTCCCCCGGCGAACGGGCCACCCTGTCATGTCGGGCCAGCCAGTCAGTGTCGTCAAGCTTCCTCGCCTGGTACCAGCAGAAACCGGGACAAGCTCCCCGCCTGCTGATCTACGGAGCCAGCAGCCGGGCCACCGGTATTCCTGACCGGTTCTCCGGTTCGGGGTCCGGGACCGACTTTACTCTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATTACTGCCAGCAGTACCACTCCTCCCCGTCCTGGACGTTCGGACAGGGCACAAGGCTGGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGA TCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-C7 BCMA_EBB-C1978-C7 -ac
Full size CAR 8590 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNTLKAEDTAVYYCARATYKRELRYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-C7 -NT
Full size CAR 8612 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCGGAGGAAGCCTCAGGCTGTCCTGCGCCGCGTCCGGCTTCACCTTCTCCTCGTACGCCATGTCCTGGGTCCGCCAGGCCCCCGGAAAGGGCCTGGAATGGGTGTCCGCCATCTCTGGAAGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGTTCACAATCTCCCGCGATAATTCGAAGAACACTCTGTACCTTCAAATGAACACCCTGAAGGCCGAGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAGAGAGCTCCGGTACTACTACGGAATGGACGTCTGGGGCCAGGGAACTACTGTGACCGTGTCCTCGGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGTTCCGAGATTGTGCTGACCCAGTCACCTTCAACTCTGTCGCTGTCCCCGGGAGAGAGCGCTACTCTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCCTCGCCTGGTATCAGCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCAAGCAACAGAGCGACCGGAATTCCTGACCGCTTCTCGGGGAGCGGTTCAGGCACCGACTTCACCCTGACTATCCGGCGCCTGGAACCCGAAGATTTCGCCGTGTATTACTGTCAACAGTACCACTCCTCGCCGTCCTGGACCTTTGGCCAAGGAACCAAAGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGA TCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-D10 BCMA_EBB-C1978-D10 -ak
Full size CAR 8591 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVGKAVPDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQTPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYSFGQGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-D10 -NT
Full size CAR 8613 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTCGTGGAAACTGGAGGTGGACTCGTGCAGCCTGGACGGTCGCTGCGGCTGAGCTGCGCTGCATCCGGCTTCACCTTCGACGATTATGCCATGCACTGGGTCAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGGTATCAGCTGGAATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGTTCACCATTTCCCGCGACAACGCCAAGAACTCCCTGTACTTGCAAATGAACAGCCTCCGGGATGAGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGTGCCCGACGTCTGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGGCGGGGGTGGATCGGGCGGTGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAGACCCCCTCGTCCCTGTCCGCCTCGGTCGGCGACCGCGTGACTATCACATGTAGAGCCTCGCAGAGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGAAGGCCCCGAAGCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCGAGCCGGTTTTCCGGGTCCGGCTCCGGCACCGACTTCACGCTGACCATTTCTTCCCTGCAACCCGAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCCCTTACTCCTTCGGCCAAGGAACCAGGCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGA AGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1979-C12 BCMA_EBB-C1979-C12 -ac
Full size CAR 8592 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPGKGLEWVASINWKGNSLAYGDSVKGRFAISRDNAKNTVFLQMNSLRTEDTAVYYCASHQGVAYYNYAMDVWGRGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRATQSIGSSFLAWYQQRPGQAPRLLIYGASQRATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1979-C12 -nt
Full size CAR 8614 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCGGAAGGTCCCTGCGGCTCTCCTGCACTGCGTCTGGCTTCACCTTCGACGACTACGCGATGCACTGGGTCAGACAGCGCCCGGGAAAGGGCCTGGAATGGGTCGCCTCAATCAACTGGAAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCTTCGCCATTTCGCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCCCTGCGGACCGAGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGCATACTATAACTACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGTCCTCCGGGGGCGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAAATCGTGCTGACTCAGAGCCCGGGAACTCTTTCACTGTCCCCGGGAGAACGGGCCACTCTCTCGTGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCCTGGTACCAGCAGAGGCCAGGACAGGCGCCCCGCCTGCTGATCTACGGTGCTTCCCAACGCGCCACTGGCATTCCTGACCGGTTCAGCGGCAGAGGGTCGGGAACCGATTTCACACTGACCATTTCCCGGGTGGAGCCCGAAGATTCGGCAGTCTACTACTGTCAGCATTACGAGTCCTCCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1980-G4 BCMA_EBB-C1980-G4-ac
Full size CAR 8593 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVVRDGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1980-G4 -NT
Full size CAR 8615 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAGGTGCAGTTGGTCGAAAGCGGGGGCGGGCTTGTGCAGCCTGGCGGATCACTGCGGCTGTCCTGCGCGGCATCAGGCTTCACGTTTTCTTCCTACGCCATGTCCTGGGTGCGCCAGGCCCCTGGAAAGGGACTGGAATGGGTGTCCGCGATTTCGGGGTCCGGCGGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCTTCACTATCTCGCGGGACAACTCCAAGAACACCCTCTACCTCCAAATGAATAGCCTGCGGGCCGAGGATACCGCCGTCTACTATTGCGCTAAGGTCGTGCGCGACGGAATGGACGTGTGGGGACAGGGTACCACCGTGACAGTGTCCTCGGGGGGAGGCGGTAGCGGCGGAGGAGGAAGCGGTGGTGGAGGTTCCGAGATTGTGCTGACTCAATCACCCGCGACCCTGAGCCTGTCCCCCGGCGAAAGGGCCACTCTGTCCTGTCGGGCCAGCCAATCAGTCTCCTCCTCGTACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGCTCCGAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATCCCGGATAGGTTCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTCCCGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCCCGCCTAGATTCACTTTCGGCCCCGGCACCAAAGTGGACATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCG GTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1980-D2 BCMA_EBB-C1980-D2-ac
Full size CAR 8594 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1980-D2 -NT
Full size CAR 8616 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGGGGGGATCGCTCAGACTGTCCTGTGCGGCGTCAGGCTTCACCTTCTCGAGCTACGCCATGTCATGGGTCAGACAGGCCCCTGGAAAGGGTCTGGAATGGGTGTCCGCCATTTCCGGGAGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCTTCACCATTTCCCGGGACAACTCCAAGAACACTCTCTATCTGCAAATGAACTCCCTCCGCGCTGAGGACACTGCCGTGTACTACTGCGCCAAAATCCCTCAGACCGGCACCTTCGACTACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCGGAGGTTCGGGGGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACCCAGTCACCCGGCACTTTGTCCCTGTCGCCTGGAGAAAGGGCCACCCTTTCCTGCCGGGCATCCCAATCCGTGTCCTCCTCGTACCTGGCCTGGTACCAGCAGAGGCCCGGACAGGCCCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGCGACCGGTATCCCGGACCGGTTTTCGGGCTCGGGCTCAGGAACTGACTTCACCCTCACCATCTCCCGCCTGGAACCCGAAGATTTCGCTGTGTATTACTGCCAGCACTACGGCAGCTCCCCGTCCTGGACGTTCGGCCAGGGAACTCGGCTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGC GCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-A10 BCMA_EBB-C1978-A10-ac
Full size CAR 8595 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVYYCARANYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLLISGASSRATGVPDRFSGSGSGTDFTLAISRLEPEDSAVYYCQHYDSSPSWTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-A10 -NT
Full size CAR 8617 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAACTGGTGGAAACCGGTGGAGGACTCGTGCAGCCTGGCGGCAGCCTCCGGCTGAGCTGCGCCGCTTCGGGATTCACCTTTTCCTCCTACGCGATGTCTTGGGTCAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGCCATCTCCGGCTCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGTTCACCATGTCGCGCGAGAATGACAAGAACTCCGTGTTCCTGCAAATGAACTCCCTGAGGGTGGAGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAGAGAGCTGCGGTACTACTACGGAATGGACGTCTGGGGACAGGGAACTATGGTGACCGTGTCATCCGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGGTTCAGAAATTGTCATGACCCAGTCCCCGGGAACTCTTTCCCTCTCCCCCGGGGAATCCGCGACTTTGTCCTGCCGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCGCATGGTACCAGCATAAGCCAGGCCAAGCCCCTTCCCTGCTGATTTCCGGGGCTAGCAGCCGCGCCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTACCGATTTCACCCTGGCAATCTCGCGGCTGGAACCGGAGGATTCGGCCGTGTACTACTGCCAGCACTATGACTCATCCCCCTCCTGGACATTCGGACAGGGCACCAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGA TCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-D4 BCMA_EBB-C1978-D4-ac
Full size CAR 8596 MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALVGATGAFDIWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGASNWATGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-D4 -NT
Full size CAR 8618 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAGGGGGCTCCCTGAGGCTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTACGCCATGTCGTGGGTCCGCCAAGCCCCTGGAAAAGGCCTGGAATGGGTGTCCGCGATTTCCGGGAGCGGAGGTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCTTTACCATCTCCCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCGCTGAGAGCCGAGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCGGCGCGACTGGGGCATTCGACATCTGGGGACAGGGAACTCTTGTGACCGTGTCGAGCGGAGGCGGCGGCTCCGGCGGAGGAGGGAGCGGGGGCGGTGGTTCCGAAATCGTGTTGACTCAGTCCCCGGGAACCCTGAGCTTGTCACCCGGGGAGCGGGCCACTCTCTCCTGTCGCGCCTCCCAATCGCTCTCATCCAATTTCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCCCCGGGCCTGCTCATCTACGGCGCTTCAAACTGGGCAACGGGAACCCCTGATCGGTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCTGACCATCACCAGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACTACGGCACCTCCCCCATGTACACATTCGGACAGGGTACCAAGGTCGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACT GTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1980-A2 BCMA_EBB-C1980-A2-ac
Full size CAR 8597 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDPWGQGTLVTVSSGGGGSGGGGSGGGGSDIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1980-A2 -NT
Full size CAR 8619 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCGGGGGATCACTGCGCCTGTCCTGTGCCGCGTCCGGTTTCACTTTCTCCTCGTACGCCATGTCGTGGGTCAGACAGGCACCGGGAAAGGGACTGGAATGGGTGTCAGCCATTTCGGGTTCGGGGGGCAGCACCTACTACGCTGACTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAACTCCAAGAACACCTTGTACCTCCAAATGAACTCCCTGCGGGCCGAAGATACCGCCGTGTATTACTGCGTGCTGTGGTTCGGAGAGGGATTCGACCCGTGGGGACAAGGAACACTCGTGACTGTGTCATCCGGCGGAGGCGGCAGCGGTGGCGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTTGACCCAGTCCCCTCTGAGCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCGGTCGAGCCAGTCCCTCCTGCACTCCAATGGGTACAACTACCTCGATTGGTATCTGCAAAAGCCGGGCCAGAGCCCCCAGCTGCTGATCTACCTTGGGTCAAACCGCGCTTCCGGGGTGCCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTACCCTGAAAATCTCGAGGGTGGAGGCCGAGGACGTCGGAGTGTACTACTGCATGCAGGCGCTCCAGACTCCCCTGACCTTCGGAGGAGGAACGAAGGTCGACATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACT GTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1981-C3 BCMA_EBB-C1981-C3-ac
Full size CAR 8598 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGYYRDYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1981-C3 -NT
Full size CAR 8620 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCCAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCGGGGGCTCCCTGAGACTTTCCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTATGCTATGTCCTGGGTGCGCCAGGCCCCGGGAAAGGGACTGGAATGGGTGTCCGCAATCAGCGGTAGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTCGCTTCACTATTTCCCGGGACAACTCCAAGAATACCCTGTACCTCCAAATGAACAGCCTCAGGGCCGAGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAGCTCCGGTTACTACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCACCGTGACCGTGTCAAGCGGCGGAGGCGGTTCAGGAGGGGGAGGCTCCGGCGGTGGAGGGTCCGAAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCGTTGTCCCCGGGGGAGCGCGCTACCCTGTCGTGTCGGGCGTCGCAGTCCGTGTCGAGCTCCTACCTCGCGTGGTACCAGCAGAAGCCCGGACAGGCCCCTAGACTTCTGATCTACGGCACTTCTTCACGCGCCACCGGGATCAGCGACAGGTTCAGCGGCTCCGGCTCCGGGACCGACTTCACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCGCCGTGTATTACTGCCAACACTACGGAAACTCGCCGCCAAAGTTCACGTTCGGACCCGGAACCAAGCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTT CACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG BCMA_EBB-C1978-G4 BCMA_EBB-C1978-G4-ac
Full size CAR 8599 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYLGAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPRLTFGGGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR BCMA_EBB-C1978-G4 -NT
Full size CAR 8621 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAAGTCCAACTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCGGAGGCAGCCTTCGGCTGTCGTGCGCCGCCTCCGGGTTCACGTTCTCATCCTACGCGATGTCGTGGGTCAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGCCATTAGCGGCTCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGTTCACTATCTCCCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCTCTGCGGGCCGAGGATACCGCGGTGTACTATTGCGCCAAGATGGGTTGGTCCAGCGGATACTTGGGAGCCTTCGACATTTGGGGACAGGGCACTACTGTGACCGTGTCCTCCGGGGGTGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAAATCGTGTTGACCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGCTACACTGTCATGTAGAGCGTCCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGTACCAGCAGAAGCCGGGACAGGCACCCCGCCTGCTCATCTACGGAGCCAGCGGCCGGGCGACCGGCATCCCTGACCGCTTCTCCGGTTCCGGCTCGGGCACCGACTTTACTCTGACCATTAGCAGGCTTGAGCCCGAGGATTTTGCCGTGTACTACTGCCAACACTACGGGGGGAGCCCTCGCCTGACCTTCGGAGGCGGAACTAAGGTCGATATCAAAACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTC TTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG

In one embodiment, the CAR molecule includes (eg, consists of) the amino acid sequence shown in Table 23 or Table 1 of WO2016/014565, or as further described herein. In one embodiment, the CAR molecule comprises (e.g., consists of) the amino acid sequence SEQ ID NO: 8549, SEQ ID NO: 8550, SEQ ID NO: 8551, SEQ ID NO: 8552, SEQ ID NO: 8553, SEQ ID NO: 8554 , SEQ ID NO: 8555, SEQ ID NO: 8556, SEQ ID NO: 8557, SEQ ID NO: 8558, SEQ ID NO: 8559, SEQ ID NO: 8560, SEQ ID NO: 8561, SEQ ID NO: 8562, SEQ ID NO: 8563, SEQ ID NO: 8579, SEQ ID NO: 8580, SEQ ID NO: 8581, SEQ ID NO: 8582, SEQ ID NO: 8583, SEQ ID NO: 8584, SEQ ID NO: 8585, SEQ ID NO : 8586, SEQ ID NO: 8587, SEQ ID NO: 8588, SEQ ID NO: 8589, SEQ ID NO: 8590, SEQ ID NO: 8591, SEQ ID NO: 8592, SEQ ID NO: 8593, SEQ ID NO: 8594 , SEQ ID NO: 8595, SEQ ID NO: 8596, SEQ ID NO: 8597, SEQ ID NO: 8598 or SEQ ID NO: 8599; or an amino acid sequence having at least one, two, three, four, five, 10, 15, 20, or 30 modifications (e.g., substitutions, e.g. conservative substitutions), but no more than 60, 50, or 40 modifications (e.g., substitutions , for example, conservative substitutions) of the amino acid sequence of SEQ ID NO: 8549, SEQ ID NO: 8550, SEQ ID NO: 8551, SEQ ID NO: 8552, SEQ ID NO: 8553, SEQ ID NO: 8554, SEQ ID NO: 8555, SEQ ID NO: 8556, SEQ ID NO: 8557, SEQ ID NO: 8558, SEQ ID NO: 8559, SEQ ID NO: 8560, SEQ ID NO: 8561, SEQ ID NO: 8562, SEQ ID NO: 8563, SEQ ID NO: 8579, SEQ ID NO: 8580, SEQ ID NO: 8581, SEQ ID NO: 8582, SEQ ID NO: 8583, SEQ ID NO: 8584, SEQ ID NO: 8585, SEQ ID NO: 8586, SEQ ID NO: 8587, SEQ ID NO: 8588, SEQ ID NO: 8589, SEQ ID NO: 8590, SEQ ID NO: 8591, SEQ ID NO: 8592, SEQ ID NO: 8593, SEQ ID NO: 8594, SEQ ID NO: 8595, SEQ ID NO: 8596, SEQ ID NO: 8597, SEQ ID NO: 8598 or SEQ ID NO: 8599; or an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence of SEQ ID NO: 8549, SEQ ID NO: 8550, SEQ ID NO: 8551, SEQ ID NO : 8552, SEQ ID NO: 8553, SEQ ID NO: 8554, SEQ ID NO: 8555, SEQ ID NO: 8556, SEQ ID NO: 8557, SEQ ID NO: 8558, SEQ ID NO: 8559, SEQ ID NO: 8560 , SEQ ID NO: 8561, SEQ ID NO: 8562, SEQ ID NO: 8563, SEQ ID NO: 8579, SEQ ID NO: 8580, SEQ ID NO: 8581, SEQ ID NO: 8582, SEQ ID NO: 8583, SEQ ID NO: 8584, SEQ ID NO: 8585, SEQ ID NO: 8586, SEQ ID NO: 8587, SEQ ID NO: 8588, SEQ ID NO: 8589, SEQ ID NO: 8590, SEQ ID NO: 8591, SEQ ID NO : 8592, SEQ ID NO: 8593, SEQ ID NO: 8594, SEQ ID NO: 8595, SEQ ID NO: 8596, SEQ ID NO: 8597, SEQ ID NO: 8598 or SEQ ID NO: 8599.

Transmembrane domains

With respect to the transmembrane domain, in various embodiments, a CAR can be engineered to include a transmembrane domain that is attached to the extracellular domain of the CAR. The transmembrane domain may include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acids associated with the extracellular region of the protein from which the transmembrane protein was derived (e.g., 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10 to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (for example, 1, 2, 3, 4, 5, 6, 7, 8 , 9, 10 to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is a domain that is associated with one of the other CAR domains, for example, in one embodiment, the transmembrane domain can be derived from the same protein from which the signaling domain, costimulatory domain, or hinge domain is derived. In another aspect, the transmembrane domain is not derived from the same protein that any other CAR domain is derived from. In some cases, the transmembrane domain may be selected or modified by amino acid substitution to avoid binding such domains to transmembrane domains of the same or different surface membrane proteins, for example, to minimize interactions with other members of the receptor complex. In one aspect, the transmembrane domain is capable of homodimerizing with another CAR on the cell surface of a CAR-expressing cell. In another aspect, the amino acid sequence of the transmembrane domain may be modified or substituted to minimize interactions with the binding domains of a native binding partner present in the same CAR-expressing cell.

The transmembrane domain can be obtained from a natural or recombinant source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one aspect, the transmembrane domain is capable of signaling to the intracellular domain(s) each time a CAR binds to a target. A transmembrane domain for a particular use in the present invention may include at least the transmembrane region(s), e.g. T cell receptor alpha, beta or zeta chain, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9 , CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In some embodiments, the transmembrane domain may include at least the transmembrane region(s), e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6 , VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226 ), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKG2D, NKG2C.

In some cases, the transmembrane domain may be attached to the extracellular region of the CAR, such as the antigen-binding domain of the CAR, via a hinge region, such as a hinge region from a human protein. For example, in one embodiment, the hinge can be a human Ig (immunoglobulin) hinge (e.g., IgG4 hinge, IgD hinge), a GS linker (e.g., a GS linker described herein), a KIR2DS2 hinge, or a CD8a hinge. . In one embodiment, the hinge region or spacer comprises (eg, consists of) the amino acid sequence of SEQ ID NO:6642. In one aspect, the transmembrane domain includes (for example, consists of) the transmembrane domain of SEQ ID NO: 6644.

In some embodiments, the encoded transmembrane domain comprises an amino acid sequence of a CD8 transmembrane domain having at least one, two, or three modifications, but no more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 6644, or a sequence with 95-99% identity with the amino acid sequence of SEQ ID NO: 6644. In one embodiment, the encoded transmembrane domain comprises the sequence of SEQ ID NO: 6644.

In other embodiments, the nucleic acid molecule encoding the CAR comprises the nucleotide sequence of the CD8 transmembrane domain, for example, comprising the sequence of SEQ ID NO: 6645 or a sequence with 95-99% identity.

In some embodiments, the encoded antigen-binding domain is linked to the transmembrane domain by a hinge region. In one embodiment, the encoded hinge region includes the amino acid sequence of the CD8 hinge region, for example, SEQ ID NO: 6642; or an IgG4 hinge amino acid sequence, e.g., SEQ ID NO: 6630, or a sequence with 95-99% identity to SEQ ID NO: 6642 or 6630. In other embodiments, the nucleic acid sequence encoding the hinge region comprises the sequence of SEQ ID NO: 6643 or SEQ ID NO: 6631 corresponding to the CD8 hinge or IgG4 hinge, respectively, or a sequence with 95-99% identity to SEQ ID NO: 6643 or 6631.

In one aspect, the hinge region or spacer includes an IgG4 hinge region. Например, в одном варианте осуществления шарнирная область или спейсер включает шарнирную область с аминокислотной последовательностью ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM (SEQ ID NO:6630). В некоторых вариантах осуществления шарнирная область или спейсер включает шарнирную область, кодируемую нуклеотидной последовательностью GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG (SEQ ID NO:6631).

In one aspect, the hinge region or spacer includes an IgD hinge region. Например, в одном варианте осуществления шарнирная область или спейсер включает шарнирную область с аминокислотной последовательностью RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDH (SEQ ID NO:6632). В некоторых вариантах осуществления шарнирная область или спейсер включает шарнирную область, кодируемую нуклеотидной последовательностью AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACAGCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAAGAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATACCCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAGGATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACATGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAGAGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGCTTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTACCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCCCAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT (SEQ ID NO:663 3).

In one aspect, the transmembrane domain may be recombinant, in which case it will include predominantly hydrophobic residues such as leucine and valine. In one aspect, a triplet of phenylalanine, tryptophan and valine may be present at each end of the recombinant transmembrane domain.

Optionally, a short oligo- or polypeptide linker, 2 to 10 amino acids in length, may form a link between the transmembrane domain and the cytoplasmic region of the CAR. The glycine-serine doublet provides the most suitable linker. For example, in one aspect, the linker includes the amino acid sequence GGGGSGGGGS (SEQ ID NO:6634). In some embodiments, the linker is encoded by the nucleotide sequence GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC (SEQ ID NO:6635).

In one aspect, the hinge region or spacer includes a KIR2DS2 hinge region.

Signaling domains

In embodiments of the invention that include an intracellular signaling domain, such a domain may comprise, for example, one or more of a primary signaling domain and/or a costimulatory signaling domain. In some embodiments, the implementation of the intracellular signaling domain includes a sequence encoding the primary signaling domain. In some embodiments, the intracellular signaling domain includes a costimulatory signaling domain. In some embodiments, the intracellular signaling domain includes a primary signaling domain and a costimulatory signaling domain.

The intracellular signal sequences in the cytoplasmic portion of the CAR according to the invention may be linked to each other in a random or specific order. Optionally, a short oligo or polypeptide linker, eg 2 to 10 amino acids long (eg 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids), can form a link between intracellular signal sequences. In one embodiment, a glycine-serine doublet may be used as a suitable linker. In one embodiment, one amino acid, eg alanine, glycine, may be used as a suitable linker.

In one aspect, an intracellular signaling domain is constructed to include two or more, eg 2, 3, 4, 5 or more co-stimulatory signaling domains. In an embodiment, two or more, eg 2, 3, 4, 5 or more costimulatory signaling domains are separated by a linker molecule, eg the linker molecule described herein. In one embodiment, the intracellular signaling domain includes two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue.

Primary signaling domains

The primary signaling domain regulates the primary activation of the TCR complex in either a stimulatory or an inhibitory manner. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs, which are known as immunoreceptor tyrosine activating motifs or ITAMs.

Examples of ITAM-containing primary intracellular signaling domains that are of particular use in the invention include signaling domains from CD3 zeta, FcR generic gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc epsilon R1b), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10 and DAP12. In one embodiment, the CAR of the invention includes an intracellular signaling domain, such as the primary signaling domain of CD3-zeta.

In one embodiment, the encoded primary signaling domain includes a functional CD3 zeta signaling domain. The encoded primary signaling domain of CD3 zeta may include an amino acid sequence having at least one, two, or three modifications, but no more than 20, 10, or 5 amino acid sequence modifications of SEQ ID NO: 6648 or SEQ ID NO: 6650, or sequences from 95- 99% identity with the amino acid sequence of SEQ ID NO: 6648 or SEQ ID NO: 6650. In some embodiments, the encoded primary signaling domain comprises the sequence of SEQ ID NO: 6648 or SEQ ID NO: 6650. In other embodiments, the nucleic acid sequence encoding the primary the signal domain includes the sequence SEQ ID NO: 6649 or SEQ ID NO: 6651, or a sequence with 95-99% identity with it.

Costimulatory signaling domains

In some embodiments, the encoded intracellular signaling domain includes a costimulatory signaling domain. For example, an intracellular signaling domain may include a primary signaling domain and a costimulatory signaling domain. In some embodiments, the encoded co-stimulatory signaling domain comprises a functional signaling domain of a protein selected from one or more of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 ( LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds to CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19 , CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile) , CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, NKp44, NKp30, NKp46 or NKG2D.

In certain embodiments, the encoded co-stimulatory signaling domain comprises an amino acid sequence having at least one, two, or three modifications, but no more than 20, 10, or 5 amino acid sequence modifications of SEQ ID NO: 6646 or SEQ ID NO: 6636, or a sequence with 95 -99% identity with the amino acid sequence of SEQ ID NO: 6646 or SEQ ID NO: 6636. In one embodiment, the encoded costimulatory signaling domain comprises the sequence of SEQ ID NO: 6646 or SEQ ID NO: 6636. In other embodiments, a nucleic acid sequence encoding costimulatory signaling domain includes the sequence SEQ ID NO: 6647 or SEQ ID NO: 6637 or a sequence with 95-99% identity with it.

In other embodiments, the encoded intracellular domain comprises the sequence of SEQ ID NO: 6646 or SEQ ID NO: 6636 and the sequence of SEQ ID NO: 6648 or SEQ ID NO: 6650, wherein the sequences comprising the intracellular signaling domain are expressed in the same reading frame and as one polypeptide chain.

In some embodiments, the nucleic acid sequence encoding the intracellular signal domain comprises SEQ ID NO: 6647 or SEQ ID NO: 6637 or a sequence with 95-99% identity thereto and SEQ ID NO: 6649 or SEQ ID NO: 6651 or a sequence with 95-99% identity with it.

In some embodiments, the nucleic acid molecule further encodes a leader sequence. In one embodiment, the leader sequence includes SEQ ID NO: 6640.

In one aspect, an intracellular signaling domain is constructed to include a CD3-zeta signaling domain and a CD28 signaling domain. In one aspect, the intracellular signaling domain is constructed to include the CD3-zeta signaling domain and the 4-1BB signaling domain. In one aspect, the 4-1BB signaling domain is the signal domain of SEQ ID NO: 6646. In one aspect, the CD3 zeta signal domain is the signal domain of SEQ ID NO: 6648.

In one aspect, the intracellular signaling domain is constructed to include the CD3-zeta signaling domain and the CD27 signaling domain. In one aspect, the CD27 signaling domain includes the amino acid sequence QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP (SEQ ID NO: 6636). In one aspect, the CD27 signaling domain is encoded by the nucleic acid sequence AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGACTTCGCAGCCTATCGCTCC (SEQ ID NO: 6637).

Vectors

In another aspect, the invention relates to a vector comprising a nucleic acid sequence encoding a CAR described in this application. In one embodiment, the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector. In one embodiment, the vector is a lentiviral vector. These vectors, or portions thereof, may, inter alia, be used to generate template nucleic acids as described herein for use with CRISPR systems as described herein. Alternatively, vectors can be used to deliver the nucleic acid directly to a cell, eg an immune effector cell, eg a T cell, eg an allogeneic T cell, independent of the CRISPR system.

The present invention also provides vectors into which the DNA of the present invention is inserted. Vectors derived from retroviruses, such as lentivirus, are suitable tools for long-term gene transfer because they allow for long-term, stable integration of the transgene and its propagation in daughter cells. Lentiviral vectors have an additional advantage over vectors derived from oncoretroviruses such as murine leukemia virus in that they can transduce non-proliferating cells such as hepatocytes. They also have the additional advantage of low immunogenicity. The retroviral vector may also be, for example, a gammaretroviral vector. The gammaretrovirus vector may include, for example, a promoter, a packaging signal (ψ), a primer binding site (PBS), one or more (eg, two) long terminal repeats (LTRs), and a transgene of interest, for example, a gene encoding CAR. The gammaretrovirus vector may not contain viral structural genes such as gag, pol and env. Exemplary gamma-retroviral vectors include murine leukemia virus (MLV), splenic foci virus (SFFV), and myeloproliferative sarcoma virus (MPSV), as well as vectors derived therefrom. Other gammaretroviral vectors are described, for example, in Tobias Maetzig et al., "Gammaretroviral Vectors: Biology, Technology and Application" Viruses. Jun 2011; 3(6): 677-713.

In another embodiment, the vector comprising the nucleic acid encoding the desired CAR of the invention is an adenoviral vector (A5/35). In another embodiment, expression of CAR-encoding nucleic acids can be achieved using transposons such as sleeping beauty, crisper, CAS9, and zinc finger nucleases. See June et al below. 2009 Nature Reviews Immunology 9.10: 704-716, incorporated herein by reference.

The nucleic acid can be cloned into various types of vectors. For example, the nucleic acid can be cloned into a vector, including, but not limited to, a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe vectors, and sequencing vectors.

This application discloses methods for producing in vitro transcribed CAR RNA. The present invention also includes an RNA coding construct for a CAR that can be directly transfected into a cell. A method for generating mRNA for use in transfection may include in vitro transcription (IVT) of a template with specially designed primers and subsequent addition of polyA to produce a construct containing 3' and 5' untranslated sequences ("UTRs"), a 5' cap, and/or an internal region. ribosome landing (IRES), expressed nucleic acid and polyA tail, typically 50-2000 bases long (SEQ ID NO: 6638). RNA thus obtained can efficiently transfect various cell types. In one aspect, the matrix includes CAR sequences.

Non-viral delivery methods

In some aspects, non-viral methods can be used to deliver a nucleic acid encoding a CAR described herein to a cell or tissue, or to a subject.

In some embodiments, the non-viral method includes the use of a transposon (also referred to as a transposable element). In some embodiments, a transposon is a DNA fragment that can be inserted into a region of the genome, such as a DNA fragment that is capable of self-replication and inserting a copy of itself into the genome, or a DNA fragment that can be cut from a longer nucleic acid and inserted into another region of the genome. For example, a transposon includes a DNA sequence consisting of inverted repeats of flanking genes for transposition.

In some embodiments, cells, e.g., T or NK cells, are created that express the CAR described herein by a combination of gene insertion with STBS and genetic editing with a nuclease (e.g., zinc finger nucleases (ZFN)), like effector transcription activators. nucleases (TALEN), the CRISPR/Cas system, or engineered meganuclease, reshaped targeting homing endonuclease).

In some embodiments, the cells of the invention, e.g., T or NK cells, e.g., allogeneic T cells, e.g., those described herein (e.g., which express the CAR described herein), are generated by contacting the cells with: (a ) a composition comprising one or more nRNA molecules, for example, as described in this application, and one or more Cas molecules, for example, a Cas9 molecule, for example, as described in this application, and (b) a nucleic acid comprising a sequence encoding CAR , for example, as described herein (such as a template nucleic acid molecule as described herein). Without being limited by theory, said composition (a) above will cause a break to form at or near the genomic DNA that is the target of the targeting domain of the nRNA molecule(s), and the nucleic acid (b) will be incorporated, for example, partially or completely, into the genome at or near said gap, resulting in expression of the encoded CAR molecule upon integration. In embodiments, CAR expression will be regulated by promoters or other regulatory elements endogenous to the genome (eg, a promoter that regulates expression from the gene into which the nucleic acid (b) has been inserted). In other embodiments, the nucleic acid (b) further comprises a promoter and/or other regulatory elements, e.g., as described herein, e.g., an EF1-alpha promoter operably linked to a CAR coding sequence such that upon integration, such a promoter and /or other regulatory elements will regulate the expression of CAR. Additional features of the invention that relate to the use of CRISPR/Cas9 systems, e.g., as described herein, to direct incorporation of a CAR-encoding nucleic acid sequence, e.g., as described herein, are described later in this specification, e.g., in the section which refers to gene insertion and homologous recombination. In embodiments, the composition according to a) above is a composition comprising RNPs comprising one or more nRNA molecules. In embodiments, RNPs comprising nRNAs that interact specifically with unique target sequences are introduced into the cell simultaneously, for example, as a mixture of RNPs comprising one or more nRNAs. In embodiments, RNPs comprising nRNAs that interact in a targeted manner with unique target sequences are introduced sequentially into the cell.

In some embodiments, the use of a non-viral delivery method allows reprogramming of cells, such as T or NK cells, and direct infusion of cells into a subject. The advantages of non-viral vectors include, but are not limited to, ease and relatively low cost of producing sufficient quantities to meet the needs of patient populations, storage stability, and lack of immunogenicity.

Inhibitory domains

In an embodiment, the vector includes a nucleic acid sequence that encodes a CAR, such as the CAR described in this application, and a nucleic acid sequence that encodes an inhibitory molecule, including: inhKIR cytoplasmic domain; a transmembrane domain, eg, a KIR transmembrane domain; and an inhibitory cytoplasmic domain, eg, an ITIM domain, eg, an inhKIR ITIM domain. In an embodiment, the inhibitory molecule is a native inhKIR or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, or 99% homology to c, or which differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 residues from natural inhKIR.

In an embodiment, the nucleic acid sequence that encodes an inhibitory molecule includes: a cytoplasmic domain of the SLAM family; a transmembrane domain, for example, a transmembrane domain of the SLAM family; and an inhibitory cytoplasmic domain, eg, a SLAM family domain, eg, an ITIM domain of the SLAM family. In an embodiment, the inhibitory molecule is a natural member of the SLAM family, or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, or 99% homology with, or which differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 residues from a natural member of the SLAM family.

In one embodiment, the vector is an in vitro transcribable vector, such as a vector that transcribes the RNA of the nucleic acid molecule described in this application. In one embodiment, the nucleic acid sequence in the vector further includes a poly(A) tail, such as a polyA tail. In one embodiment, the nucleic acid sequence in the vector further comprises a 3'UTR, eg the 3'UTRs described herein, eg including at least one 3'UTR repeat derived from human beta globulin. In one embodiment, the nucleic acid sequence in the vector further includes a promoter, such as the T2A promoter.

promoters

In one embodiment, the vector further includes a promoter. In some embodiments, the promoter is selected from the EF-1 promoter, the CMV IE gene promoter, the EF-1α promoter, the ubiquitin C promoter, or the phosphoglycerate kinase (PGK) promoter. In one embodiment, the promoter is the EF-1 promoter. In one embodiment, the EF-1 promoter includes the sequence of SEQ ID NO: 6639.

Host cells for CAR expression

As noted above, in some aspects, the invention relates to a cell, for example, an immune effector cell (for example, a population of cells, for example, a population of immune effector cells), comprising a nucleic acid molecule, a CAR polypeptide molecule, or a vector, as described in this application.

In some aspects of the present description, immune effector cells, such as T cells, can be obtained from a unit of blood taken from a subject using any number of methods known to the specialist, such as separation in Ficoll™. In one preferred aspect, cells from human circulating blood are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In one aspect, cells harvested by apheresis can be washed to remove a plasma fraction and optionally placed in a suitable buffer or medium for subsequent processing steps. In one embodiment, cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the wash solution is calcium-free and may be magnesium-free or free of many, if not all, divalent cations.

The initial stages of activation in the absence of calcium can lead to increased activation. As will be known to those of ordinary skill in the art, the washing step can be performed by known methods, for example, using a semi-automatic "flow through" centrifuge (for example, Cobe 2991 cell processor, Baxter CytoMate or Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells can be resuspended in various biocompatible buffers such as, for example, Ca-free, Mg-free PBS, PlasmaLyte A, or other saline with or without buffer. Alternatively, unwanted components of the apheresis sample can be removed and the cells directly resuspended in culture media.

It is known that culture media comprising 5% or less, e.g. 2%, human AB serum and known culture media conditions and compositions, e.g., those described in Smith et al., "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement" Clinical & Translational Immunology (2015) 4, e31; doi:10.1038/cti.2014.31.

In one aspect, T cells are isolated from peripheral blood lymphocytes by erythrocyte lysis and monocyte reduction, such as by PERCOLL™ gradient centrifugation or countercurrent elutriation centrifugation.

The methods described herein may include, for example, selecting a specific subset of immune effector cells, for example, T cells that are regulatory T cell depleted, CD25+ depleted cells, using, for example, a negative selection method, for example, as described in this application. Preferably, the regulatory T cell depleted population contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells.

In one embodiment, regulatory T cells, eg CD25+ T cells, are removed from the population using an anti-CD25 antibody or fragment thereof, or a CD25 binding ligand, IL-2. In one embodiment, the CD25 antibody, or fragment thereof, or CD25 binding ligand, is conjugated to a substrate, eg a bead, or otherwise applied to a substrate, eg a bead. In one embodiment, the CD25 antibody, or fragment thereof, is conjugated to a substrate as described herein.

In one embodiment, regulatory T cells, eg CD25+ T cells, are removed from the population using Miltenyi™ CD25 Removal Reagent. In one embodiment, the ratio of cells to CD25 removal reagent is 1e7 cells per 20 µl, or 1e7 cells per 15 µl, or 1e7 cells per 10 µl, or 1e7 cells per 5 µl, or 1e7 cells per 2.5 µl, or 1e7 cells for 1.25 µl. In one embodiment, for example, a CD25+ depletion greater than 500 million cells/ml is used to remove regulatory T cells, for example. In another aspect, the cell concentration used is 600, 700, 800 or 900 million cells/ml.

In one embodiment, the population of immune effector cells subjected to depletion includes approximately 6×10 ⁹ CD25+ T cells. In other aspects, the immune effector cell population to be depleted comprises from about 1×10 ⁹ to 1×10 ¹⁰ CD25+ T cells and any integer value in between. In one embodiment, the resulting regulatory T cell depleted population contains 2×10 ⁹ regulatory T cells, e.g., CD25+ cells, or less (e.g., 1×10 ⁹ , 5×10 ⁸ , 1×10 ⁸ , 5×10 ⁷ , 1×10 ⁷ CD25+ cells or less).

In one embodiment, regulatory T cells, eg, CD25+ cells, are removed from the population using the CliniMACS system with a set of cell depletion tubes, such as, for example, a 162-01 tube. In one embodiment, the CliniMACS system operates with a lean mode setting such as, for example, DEPLETION2.1.

Without wishing to be bound by a particular theory, reducing the level of negative immune cell regulators (e.g., reducing unwanted immune cells, e.g., T _REG cells) in a subject prior to apheresis or during the production of a CAR-expressing cell product may reduce the subject's risk of relapse. For example, methods for depleting T _REG cells are known in the art. Methods for reducing the number of T _REG cells include, but are not limited to, cyclophosphamide, an anti-GITR antibody (an anti-GITR antibody described herein), CD25 depletion, and combinations thereof.

In some embodiments, the production methods include reducing (eg, depleting) T _REG cells prior to producing a CAR-expressing cell. For example, manufacturing methods include contacting a sample, such as an apheresis sample, with an anti-GITR antibody and/or an anti-CD25 antibody (or fragment or CD25 binding ligand thereof), e.g., to deplete T _REG cells prior to production of a CAR-expressing cell (e.g. cellular, NK cellular) product.

In an embodiment, the subject is pre-treated with one or more therapies that decrease the T _REG of the cell prior to harvesting the cells for production of a CAR-expressing cell product, thereby reducing the subject's risk of relapse when treated with a CAR-expressing cell. In an embodiment, methods for reducing T _REG cells include, but are not limited to, administering to the subject one or more of cyclophosphamide, an anti-GITR antibody, CD25 depletion, or a combination thereof. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof may be done before, during, or after infusion of the CAR-expressing cell product.

In an embodiment, the subject is pre-treated with cyclophosphamide prior to harvesting cells to produce a CAR-expressing cell product, thereby reducing the subject's risk of relapse when treated with a CAR-expressing cell. In an embodiment, the subject is pre-treated with an anti-GITR antibody prior to harvesting cells to produce a CAR-expressing cell product, thereby reducing the subject's risk of relapse when treated with a CAR-expressing cell.

In one embodiment, the population of cells to be removed are neither regulatory T cells nor tumor cells, but cells that otherwise interfere with the proliferation and/or function of CART cells, e.g., cells expressing CD14, CD11b, CD33, CD15, or other markers expressed by potentially immunoinhibitory cells. In one embodiment, such cells are intended to be removed at the same time as regulatory T cells and/or tumor cells, or after said depletion, or in a different order.

The methods described in this application may include more than one stage of selection, for example, more than one stage of depletion. Enrichment of a population of T cells using negative selection can be performed, for example, using a combination of antibodies directed against surface markers unique to cells subjected to negative selection. One method is cell sorting and/or selection using negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies directed against cell surface markers present on the negatively selected cells. For example, to enrich CD4+ cells using negative selection, a mixture of monoclonal antibodies may include antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8.

The methods described herein may further include removing from a population of cells that express a tumor antigen, e.g., a tumor antigen that does not include CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, to obtain thus, a regulatory T cell depleted population, eg CD25+ depleted, and tumor antigen depleted cells that are suitable for expression of a CAR, eg the CAR described herein. In one embodiment, tumor antigen-expressing cells are removed at the same time as regulatory T cells, such as CD25+ cells. For example, an anti-CD25 antibody or fragment thereof and an antibody against a tumor antigen or fragment thereof may be attached to the same substrate, such as a bead that can be used to remove cells, or an anti-CD25 antibody or fragment thereof, or an antibody against tumor antigen or a fragment thereof. can be attached to individual beads, a mixture of which can be used to remove cells. In other embodiments, the removal of regulatory T cells, such as CD25+ cells, and the removal of tumor antigen expressing cells are sequential and may occur, for example, in any order.

Also provided are methods that include removing from a population of cells that express a checkpoint inhibitor, such as the checkpoint inhibitor described herein, for example, one or more of PD-1+ cells, LAG3+ cells, and TIM3+ cells, thereby obtaining thus, a regulatory T cell depleted population, eg CD25+ depleted cells, and checkpoint inhibitor depleted cells, eg PD-1+, LAG3+ and/or TIM3+ depleted cells. Exemplary checkpoint inhibitors include B7-H1, B7-1, CD160, P1H, 2B4, PD-1, TIM3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, TIGIT, CTLA- 4, BTLA and LAIR1. In one embodiment, cells expressing the checkpoint inhibitor are removed at the same time as regulatory T cells, eg, CD25+ cells. For example, an anti-CD25 antibody or fragment thereof and an anti-checkpoint inhibitor antibody or fragment thereof may be attached to a single bead which may be used to remove cells, or an anti-CD25 antibody or fragment thereof and an anti-checkpoint inhibitor antibody or fragment thereof may be attached. to individual granules, the mixture of which can be used to remove cells. In other embodiments, the removal of regulatory T cells, such as CD25+ cells, and the removal of cells expressing the checkpoint inhibitor are sequential and may occur, for example, in any order.

The methods described in this application may include the step of positive selection. For example, T cells can be isolated by incubating with anti-CD3/anti-CD28 antibody conjugated beads (e.g., 3×28) such as DYNABEADS® M-450 CD3/CD28 T for a period of time sufficient to positively select for the desired T cells. In one embodiment, the time period is approximately 30 minutes. In another embodiment, the time period varies from 30 minutes to 36 hours or longer, including all integer values between the specified values. In another embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time period is 10-24 hours, such as 24 hours. Longer incubation times can be used to isolate T cells in any situation where few T cells are present compared to other cell types, such as when isolating tumor infiltrating lymphocytes (TILs) from tumor tissue or in immunocompromised individuals. In addition, the use of longer incubation times may increase the efficiency of CD8+ T cell uptake. Thus, by simply decreasing or increasing the time, T cells can bind to CD3/CD28 beads, and/or by increasing or decreasing the ratio of beads to T cells (as described later in this application), T cell subsets can be selectively selected for or against when laying the culture or at other points in time during the process. In addition, by increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, T cell subpopulations can be selectively selected for or against at culture inception or at other desired time points.

In one embodiment, a population of T cells that express one or more of IFN-γ, TNFα, IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10, IL- 13, granzyme B and perforin, or other suitable molecules such as other cytokines. Methods for screening for cell expression can be determined, for example, using the methods described in PCT publication WO 2013/126712.

To isolate the desired population of cells using positive or negative selection, the concentration of cells and the surface (eg, particles such as beads) can be different. In some aspects, it may be desirable to significantly reduce the volume in which the beads and cells are mixed with each other (eg, increase the concentration of cells) to ensure maximum contact of cells and beads. For example, in one aspect, a concentration of 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, or 5 billion/ml is used. In one aspect, a concentration of 1 billion cells/ml is used. In yet another aspect, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells/mL is used. In other aspects, concentrations of 125 or 150 million cells/ml may be used.

The use of high concentrations can result in increased cell yield, cell activation and cell proliferation. In addition, the use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples that contain many tumor cells (eg, leukemic blood, tumor tissue etc.). Such cell populations may be of therapeutic value and may be obtained. For example, the use of a high concentration of cells provides a more efficient selection of CD8+ T cells, which usually have a weaker expression of CD28.

In a related aspect, it may be necessary to use lower concentrations of cells. By greatly diluting the mixture of T cells and the surface (eg, particles such as beads), interactions between particles and cells are minimized. This allows the selection of cells that express a large amount of the desired antigens that bind to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells at low concentrations. In one aspect, the concentration of cells used is 5×10 ⁶ /ml. In other aspects, the concentration used can be from about 1×10 ⁵ /ml to 1×10 ⁶ /ml, including any intermediate integer value.

In other aspects, the cells may be incubated on a shaker for varying periods of time at variable speeds, at 2-10°C, or at room temperature.

T cells for stimulation can also be frozen after the washing step. Without being limited by theory, freezing followed by a thawing step results in a more uniform product by removing granulocytes and, to some extent, monocytes in the cell population. After a washing step in which plasma and platelets are removed, the cells can be suspended in a freezing solution. Although many solutions and freezing parameters are known in the art and will be used in this context, one method involves the use of PBS containing 20% DMSO and 8% human serum albumin, or culture medium containing 10% dextran 40 and 5% dextrose, 20% human serum albumin and 7.5% DMSO, or 31.25% PlasmaLyte-A, 31.25% dextrose 5%, 0.45% NaCl, 10% dextran 40 and 5% dextrose, 20% human serum albumin and 7.5% DMSO or other suitable cell freezing media, eg Hespan and PlasmaLyte A, after which the cells are frozen at -80° C. at 1° per minute and stored in the vapor phase in a liquid nitrogen storage tank. Other methods of controlled freezing may be used, as well as uncontrolled freezing directly at -20°C or in liquid nitrogen.

In some aspects, cryopreserved cells are thawed and washed as described herein and left for one hour at room temperature prior to activation using the methods of the present invention.

It is also within the scope of the invention to collect blood or apheresis product samples from a subject some time before expanded cells may be needed, as described herein. Thus, a source of proliferating cells can be harvested at any time, desired cells such as T cells isolated, and frozen for later use in immune effector cell therapy for any disease or condition for which immune effector cell therapy, such as as described in this application. In one aspect, a blood sample or apheresis is taken from a generally healthy subject. In some aspects, a blood sample or apheresis is taken from a generally healthy subject who is at risk of developing a disease but who has not yet developed a disease, and the cells of interest are isolated and frozen for later use. In some aspects, T cells can be expanded, frozen, and used at a later time. In some aspects, samples are collected from the patient shortly after the diagnosis of a particular disease, as described in this application, but before any therapy. In a further aspect, cells are isolated from a blood sample or apheresis of a subject prior to administration of any number of appropriate therapies, including, but not limited to, treatment with agents such as natalizumab, efalizumab, antivirals, chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate , mycophenolate and FK506, antibodies or other immunoablative agents such as Campas, CD3 antibodies, cytoxan, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and radiation.

In another aspect of the present invention, T cells are obtained from the patient immediately after treatment, after which the subject remains functional T cells. In this regard, it has been found that after some antitumor therapies, in particular, treatment with drugs that damage the immune system, shortly after treatment, during the period when patients usually recover from treatment, the quality of the obtained T cells can be optimal or improved according to their ability to reproduce ex vivo. Similarly, after ex vivo manipulation using the methods described in this application, these cells may be in a preferred state for improved engraftment and reproduction in vivo. Thus, it is within the scope of the present invention to harvest blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. In addition, in some aspects, mobilization regimens (e.g., GM-CSF-induced mobilization) and conditioning can be used to create conditions in a subject that promote repopulation, recycling, regeneration, and/or expansion of specific cell types, especially for a certain time after therapy. . Exemplary cell types include T cells, B cells, dendritic cells, and other cells of the immune system.

In one embodiment, immune effector cells expressing a CAR molecule, such as the CAR molecule described herein, are obtained from a subject who has received a low immunostimulatory dose of an mTOR inhibitor. In one embodiment, a population of immune effector cells, e.g., T cells modified to express CAR, is harvested after sufficient time or after sufficient administration of a low, immunostimulatory dose of an mTOR inhibitor, resulting in a PD1 level of negative immune effector cells, e.g., T cells, or the ratio of PD1-negative immune effector cells, eg T cells/PD1-positive immune effector cells, eg T cells from the subject or harvested from the subject, were at least temporarily increased.

In other embodiments, a population of immune effector cells, e.g., T cells, that have been or will be modified to express CAR, can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1-negative immune effector cells, e.g., T cells. , or increases the ratio of PD1 negative immune effector cells, eg T cells/PD1 positive immune effector cells, eg T cells.

In one embodiment, the T cell population is diaglycerol kinase (DGK) deficient. DGK-deficient cells include cells that do not express DGK RNA or protein, or have reduced or inhibited DGK activity. DGK-deficient cells can be obtained by genetic methods, for example, by introducing RNA interference agents, such as siRNA, shRNA, miRNA, to reduce or prevent the expression of DGK. Alternatively, DGK-deficient cells can be obtained by treatment with the DGK inhibitors described herein.

In one embodiment, the T cell population is Ikaros deficient. Ikaros-deficient cells refer to cells that do not express Ikaros RNA or protein, or have reduced or inhibited Ikaros activity. Ikaros-deficient cells can be obtained by genetic methods, for example, by introducing RNA interfering agents, such as siRNA, shRNA, miRNA, to reduce or prevent the expression of Ikaros. Alternatively, Ikaros-deficient cells can be obtained by treatment with Ikaros inhibitors, such as lenalidomide.

In embodiments, the T cell population is DGK-deficient and Ikaros-deficient, eg, does not express DGK and Ikaros, or has reduced or inhibited DGK and Ikaros activity. Such DGK and Ikaros-deficient cells can be obtained using any of the methods described in this application.

In an embodiment, the NK cells are from a subject. In another embodiment, the NK cells are an NK cell line, such as the NK-92 cell line (Conkwest).

In some aspects, the cells of the invention (e.g., immune effector cells of the invention, e.g., CAR-expressing cells of the invention) are induced pluripotent stem cells ("iPSCs") or embryonic stem cells (ESCs), or are T cells derived from (e.g., , differentiated from) the specified iPSC and/or ESC. iPSC cells can be obtained, for example, using methods known in the art, from peripheral blood T-lymphocytes, for example, peripheral blood T-lymphocytes isolated from a healthy donor. Also, such cells can be differentiated into T cells using methods known in the art. See, for example, Themeli M. et al., Nat. Biotechnol., 31, pp. 928-933 (2013); doi:10.1038/nbt.2678; WO2014/165707, the contents of which are hereby incorporated by reference in their entirety.

Additional expressed agents

In another embodiment, the CAR-expressing immune effector cell described herein may also express another agent, such as an agent that increases the activity of the CAR-expressing cell. For example, in one embodiment, the agent may be an agent that inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1 , CD160, 2B4 and TGF beta, for example, as described in this application. In one embodiment, an agent that inhibits an inhibitory molecule includes a first polypeptide, such as an inhibitory molecule, associated with a second polypeptide that transmits a positive signal to the cell, such as an intracellular signaling domain as described herein. In one embodiment, the agent comprises a first polypeptide, e.g., an inhibitory molecule such as PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5) , LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of them, and a second polypeptide that is an intracellular signaling domain described in this application (for example, including a costimulatory domain (for example, 41BB , CD27, or CD28, e.g., as described herein), and/or a primary signaling domain (e.g., the CD3 zeta signaling domain described herein).In one embodiment, the agent comprises a first PD-1 polypeptide or fragment thereof and a second an intracellular signaling domain polypeptide described herein (e.g., the CD28, CD27, OX40, or 4-IBB signaling domain described herein and/or the CD3 zeta signaling domain described herein).In embodiments, the agent comprises a first polypeptide e of the extracellular domain of an inhibitory molecule; and the second polypeptide of the intracellular signaling domain of the costimulatory molecule described herein or the primary signaling molecule described herein. Such molecules, in which an inhibitory molecule (eg, the domain of the inhibitory molecule) is linked to a molecule that transmits a positive signal (eg, the domain of a co-stimulatory molecule or a primary signaling molecule), are further described, for example, in WO2013/019615.

In one embodiment, the CAR-expressing immune effector cell described herein may further comprise a second CAR, e.g., a second CAR that includes a different antigen-binding domain, e.g., to the same target (e.g., the target described above) or a different target. . In one embodiment, the second CAR includes an antigen-binding domain to a target expressed on the same type of cancer cell as the target of the first CAR. In one embodiment, a CAR-expressing immune effector cell includes a first CAR that interacts in a targeted manner with a first antigen and includes an intracellular signaling domain having a co-stimulatory signaling domain but not a primary signaling domain, and a second CAR that interacts in a targeted manner with a second, different, antigen, and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain.

Without being limited by theory, the presence of a co-stimulatory signaling domain, e.g., 4-1BB, CD28, CD27, or OX-40, in the first CAR and a primary signaling domain, e.g., CD3 zeta, in the second CAR may limit CAR activity towards cells in which both targets are expressed. In one embodiment, a CAR-expressing immune effector cell includes a first CAR that includes an antigen-binding domain that targets, for example, the target described above, a transmembrane domain, and a costimulatory domain, and a second CAR that targets an antigen that is different from the antigen. , which is the target of the first CAR (for example, an antigen expressed on a cancer cell of the same type as the first target), and includes an antigen-binding domain, a transmembrane domain, and a primary signaling domain. In another embodiment, the CAR-expressing immune effector cell includes a first CAR that includes an antigen-binding domain that interacts specifically with, for example, the target described above, a transmembrane domain, and a primary signaling domain, and a second CAR that interacts specifically with an antigen other than an antigen that is the target of the first CAR (eg, an antigen expressed on a cancer cell of the same type as the first target), and includes an antigen-binding domain to the antigen, a transmembrane domain, and a costimulatory signaling domain.

In one embodiment, the CAR-expressing immune effector cell comprises a CAR as described herein, eg, a CAR to the target described above, and an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen-binding domain that binds an antigen present on normal cells but not present on cancer cells, eg, normal cells that also express the target. In one embodiment, the inhibitory CAR includes an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of an inhibitory CAR may be the intracellular domain of PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA , BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta.

In one embodiment, the immune effector cell (e.g., T cell, NK cell) comprises a first CAR comprising an antigen-binding domain that binds to a tumor antigen as described herein and a second CAR comprising a PD-1 extracellular domain or fragment thereof.

In one embodiment, the cell further comprises an inhibitory molecule as described above.

In one embodiment, the second CAR in the cell is an inhibitory CAR, where the inhibitory CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. The inhibitory molecule may be selected from one or more of: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGF-beta, CEACAM-1 , CEACAM-3 and CEACAM-5. In one embodiment, the second CAR molecule includes the extracellular domain of PD-1 or a fragment thereof.

In embodiments, the second CAR molecule in the cell further comprises an intracellular signaling domain, including a primary signaling domain and/or an intracellular signaling domain.

In other embodiments, the intracellular signaling domain in the cell includes a primary signaling domain, including a functional CD3 zeta domain, and a co-stimulatory signaling domain, including a functional 4-1BB domain.

In one embodiment, the second CAR molecule in the cell comprises the amino acid sequence of SEQ ID NO: 6654.

In certain embodiments, the antigen-binding domain of the first CAR molecule includes scFv and the antigen-binding domain of the second CAR molecule does not include scFv. For example, the antigen-binding domain of the first CAR molecule includes scFv, and the antigen-binding domain of the second CAR molecule includes the camelid VHH domain.

In other aspects and embodiments, a cell of the invention, such as a cell modified to express a CAR, is also modified to express a safety molecule, such as a molecule (or set of molecules) that mediates cell depletion, such as CAR T cells, if desired ( for example, after the T cells have performed an antitumor function or if the T cells cause life-threatening side effects). In one exemplary aspect, a security molecule is a molecule that does not affect cell function, but that can be targeted by another agent, such as an antibody or an ADC molecule, that interacts directionally with said molecule. One exemplary embodiment of such a molecule is a truncated receptor, such as a receptor that includes the extracellular domain and transmembrane domain of the receptor, but does not contain, or does not contain a significant portion of, the intracellular domain of the receptor. An example is a truncated EGFR receptor, for example as described in WO02011/056894. Without being limited by theory, targeting an anti-EGFR antibody, such as cetuximab, with said truncated EGFR receptor will deplete cells expressing the truncated EGFR receptor. A second example is an iCasp9 switch polypeptide, e.g., a polypeptide having a dimerization domain, an optional linker, and a caspase domain oriented such that when expressed in the presence of the dimerization compound in a mammalian host cell, the iCasp9 polypeptide homodimerizes, resulting in apoptosis of the host cell. In embodiments, the dimerization domain is an FKBP-based dimerization domain, e.g., the sequence contains a mutation (F37V) that provides a complementary suitable cavity for AP1903 and AP1903 structurally related ligands (such as AP20187), which molecules can act as a dimerization compound. Such iCasp9 switch polypeptides (and corresponding dimerization compounds) are described, for example, in WO97/31899, US2101/286980, WO02014/164348, WO2013/040371, US2013/071414, WO2014/255360 and N Engl J Med. 2011 Nov 3;365(18):1673-83. A third example of such a molecule is one that is targeted by an anti-CD20 antibody, where, for example, administration of an anti-CD20 antibody (eg, rituximab) causes depletion of said cells. Examples of molecules targeted by an anti-CD20 antibody include CD20 and truncated variants thereof (eg, molecules containing an extracellular domain recognized by an anti-CD20 antibody, a transmembrane domain and not containing at least a portion of an intracellular domain).

In other aspects and embodiments, a cell of the invention, for example, a cell modified to express a CAR, is also modified to express an NK inhibitory molecule. As used herein, the term "NK inhibitory molecule" refers to a molecule that inhibits function, eg, cytolytic function, of NK cells. Without being limited by theory, it is believed that a cell, for example a cell according to the invention, in which the expression of one or more MHC class I molecules is reduced or eliminated (for example, in which the expression of B2M, NLRC5 and/or CIITA is reduced or eliminated, for example, by introducing a CRISPR system targeting B2M, NLRC5 and/or CIITA, as described in this application, in the specified cell) can be recognized by NK cells as foreign and undergo cytolysis. Thus, expression of one or more NK inhibitory molecules on said cell protects it from destruction by NK cells. In one aspect, the NK inhibitory molecule is a ligand for an NK inhibitory receptor. Non-limiting examples of NK inhibitory receptors include NK cell surface receptors that have or associate with an immunoreceptor tyrosine inhibitory motif (ITIM). Non-limiting examples of such receptors include 2B4 (also known as CD244); NK cell receptor protein 1 (NKR-P1) family member (eg NKR-P1A, NKR-P1B, NKR-P1C, NKR-P1D, NKR-P1E and NKR-P1F, eg NKR-P1B and NKR-P1D); a member of the cancer embryonic antigen related cell adhesion molecules (CEACAM) family (eg, CEACAM1); members of the sialic acid-binding immunoglobulin-like lectins (SIGLEC) family (eg, SIGLEC7 and SIGLEC9); leukocyte immunoglobulin-like receptor 1 (LAIR1); glycoprotein 49 B1 (gp49B1) or its homologue; CD81; and a member of the signal-regulatory protein (SIRP) family. In embodiments, the NK inhibitory molecule is not an MHC class I molecule. Non-limiting examples of NK inhibitory molecules include ligands for the above receptors, e.g., CD48, a member of the C-type lectin family of proteins (e.g., CLR-B (also known as OCIL) , CLR-F and CLR-G (also known as OCILrP2)), CEACAM1, a sialic acid displaying polypeptide, and alpha-V beta-3 integrin. In embodiments, the NK inhibitory molecule is a fragment of a natural molecule, e.g., includes the extracellular domain and the transmembrane domain of the NK inhibitory molecule, but does not contain, or does not contain a portion of the intracellular domain (e.g., does not contain an intracellular ITIM or inhibitory domain). In other embodiments, the NK inhibitory molecule is an HLA-G molecule. HLA-G has been shown to block or reduce the function of the immune system, such as NK cells. Carosella et al., Advances in Immunol., vol. 127, pp. 33-144, 2015; Torikai H. et al., Blood., vol. 122(8), pp. 1341-1349, 2013. Without being limited by theory, the presence of HLA-G on the surface of a CAR-expressing cell, e.g., an allogeneic CAR-expressing cell, e.g., as described herein, e.g. TCR, (B2M or NLRC5) and/or CIITA, for example, as described in this application, can protect the cell from attack by NK cells. In embodiments, the NK inhibitory molecule is an HLA-G isoform that does not require B2M, eg HLA-G2, HLA-G3, HLA-G4. Such embodiments that are preferred with a cell of the invention, eg, as described herein, include an agent or system (eg, a CRISPR/Cas system, eg, as described herein) that inhibits B2M function and/or expression. Alternatively, in other embodiments in which the cell of the invention, e.g., as described herein, includes (or has at any time included) an agent or system (e.g., a CRISPR/Cas system, e.g., as described herein) ) that inhibits B2M function and/or expression (i.e., a cell in which B2M function and/or expression has been reduced or abolished, e.g. as described herein), the NK inhibitory molecule may be an HLA-G molecule that is naturally forms a complex with B2M, provided that the NK inhibitory molecule includes a fusion protein with the B2M molecule. Such fusion structures and methods for their preparation are known in the art. See, for example, Favier B, HoWangYin K-Y, Wu J, Caumartin J, Daouya M, et al. (2011) Tolerogenic Function of Dimeric Forms of HLA-G Recombinant Proteins: A Comparative Study In Vivo. PLoS ONE 6(7): e21011. doi:10.1371/journal.pone.0021011. In such embodiments, to the extent that the gene encoding the HLA-G:B2M fusion molecule contains a B2M coding sequence that contains the target sequence of a B2M-targeted nRNA molecule, the sequence of said nucleic acid may be altered to reduce or eliminate binding the nRNA to the nucleic acid encoding the HLA-G:B2M fusion molecule, whereby the expression and/or function of the HLA-G:B2M fusion molecule is not reduced or abolished. In embodiments, the HLA-G:B2M fusion molecule may further comprise a transmembrane domain or sequence suitable for anchoring a membrane anchor molecule (such as a GPI anchor). An exemplary HLA-G:B2M fusion molecule (eg, HLA-G1:B2M fusion molecule) is shown below (linker (G4S)3 (SEQ ID NO: 6594) highlighted in grey). The linker may or may not be present and, in the alternative, may include any peptide linker, for example, as described in this application. This particular construct has the format B2M-linker ((G4S)3)-HLA-G:

SEQ ID NO: 10674

An exemplary codon-optimized nucleic acid sequence encoding the above HLA-G:B2M fusion molecule is shown below:

GCC ACC ATG AGC AGA TCT GTG GCC CTG GCT GTG CTG GCC CTG CTG TCT CTG TCT GGC CTG GAA GCC ATC CAG CGG ACC CCC AAG ATC CAG GTG TAC AGC AGA CAC CCC GCC GAA AAC GGC AAG AGC AAC TTC CTG AAC TGC TAC GTG TCC GGC TTC CAC CCC AGC GAC ATC GAG GTG GAC CTG CTG AAG AAC GGC GAG CGG ATC GAA AAG GTG GAA CAT AGC GAC CTG AGC TTC AGC AAG GAC TGG TCC TTC TAC CTG CTG TAC TAC ACC GAG TTC ACC CCC ACC GAA AAG GAC GAG TAC GCC TGC AGA GTG AAC CAC GTG ACC CTG AGC CAG CCC AAG ATC GTG AAG TGG GAC CGG GAT ATG GGC GGA GGC GGA TCC GGC GGC GGA GGA TCA GGG GGG GGA GGG TCC GGA TCC CAC AGC ATG CGG TAC TTC TCT GCC GCC GTG TCC AGA CCT GGA AGA GGC GAG CCC CGG TTT ATC GCC ATG GGC TAC GTG GAC GAC ACC CAG TTC GTC AGA TTC GAC AGC GAC AGC GCC TGC CCC CGG ATG GAA CCT AGA GCA CCT TGG GTG GAA CAG GAA GGC CCC GAG TAC TGG GAG GAA GAG ACA CGG AAC ACC AAG GCC CAC GCC CAG ACC GAC AGA ATG AAC CTG CAG ACC CTG CGG GGC TAC TAC AAC CAG AGC GAG GCC AGC AGC CAC ACC CTG CAG TGG ATG ATC GGC TGC GAT CTG GGC AGC GAC GGC AGA CTG CTG AGA GGT TAC GAACAG TAC GCC TAC GAC GGC AAG GAC TAC CTG GCC CTG AAC GAG GAC CTG CGG TCT TGG ACA GCC GCC GAT ACA GCC GCC CAG ATC AGC AAG AGA AAG TGC GAG GCC GCC AAC GTG GCC GAG CAG AGA AGG GCT TAC CTG GAA GGC ACC TGT GTG GAA TGG CTG CAT AGA TAC CTG GAA AAC GGC AAA GAG ATG CTG CAG CGG GCC GAC CCC CCT AAG ACA CAC GTG ACA CAC CAC CCC GTG TTC GAC TAC GAG GCC ACC CTG AGA TGT TGG GCC CTG GGC TTC TAT CCT GCC GAG ATC ATC CTG ACC TGG CAG AGG GAT GGC GAG GAC CAG ACC CAG GAC GTG GAA CTG GTG GAA ACC AGA CCT GCC GGC GAC GGC ACC TTC CAG AAA TGG GCT GCT GTG GTG GTG CCC AGC GGC GAA GAA CAG AGA TAC ACC TGT CAC GTG CAG CAC GAG GGC CTG CCC GAA CCC CTG ATG CTG AGA TGG AAG CAG AGC AGC CTG CCC ACC ATC CCC ATC ATG GGA ATC GTG GCC GGA CTG GTG GTG CTG GCC GCT GTC GTG ACA GGC GCT GCA GTG GCC GCC GTG CTG TGG CGG AAG AAG TCC AGC GAC TAA

SEQ ID NO: 10675

Another exemplary HLA-G molecule that can be combined with or without the B2M sequence is shown below (optional leader sequence highlighted in grey):

SEQ ID NO: 10676

In other embodiments, where the NK inhibitory molecule requires B2M and it is desired to reduce or eliminate the expression of one or more HLA class I molecules, a CRISPR/Cas system (e.g., as described herein) that includes an nRNA that includes a guide domain may be used. , which is complementary to an NLRC5 target sequence (human NLRC5: Entrez 84166; UniProt Q86WI3) or its regulatory elements, e.g. nucleotides of such a targeting domain, listed in Table 1, to NLRC5; for example, an nRNA comprising a targeting domain including any of SEQ ID NO: 8622 - SEQ ID NO: 10089 or a fragment thereof (for example, a fragment of 3'20 nucleotides)). Without being limited by theory, it is believed that reduced or abolished expression and/or function of NLRC5 will reduce or abolish the expression and/or function of one or more MHC class I molecules, even in the presence of B2M. See, for example, Downs, I., Vijayan, S., Sidiq, T. and Kobayashi, K. S. (2016), CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression. BioFactors, 42: 349-357. doi:10.1002/biof.1285.

In other embodiments, the NK inhibitory molecule is a membrane bound isoform of HLA-G, such as HLA-G1, HLA-G2, HLA-G3 and/or HLA-G4. In other embodiments, the NK inhibitory molecule is a soluble HLA-G isoform, eg, sHLA-G1 (released), HLA-G5, HLA-G6, and/or HLA-G7. In embodiments, the NK inhibitory molecule is selected from one or more of HLA-G2, HLA-G3, and HLA-G4. In an embodiment, the NK inhibitory molecule is HLA-G2.

In other embodiments, the NK inhibitory molecule is an HLA-E molecule. HLA-E has been shown to block or reduce NK cell function against HLA class I-negative cells. Torikai H. et al., Blood, vol. 122(8), pp. 1341-1349, 2013. Without being limited by theory, the presence of HLA-E on the surface of a CAR-expressing cell, e.g., an allogeneic CAR-expressing cell, e.g., as described herein, e.g. TCR (B2M or NLRC5) and/or CIITA, for example, as described in this application, can protect the cell from attack by NK cells. In an embodiment, the NK inhibitory molecule is an HLA-G molecule and an HLA-E molecule.

In embodiments in which a cell of the invention, e.g. a CAR expressing cell of the invention, e.g. as described herein, is modified to express an NK inhibitory molecule, wherein the cell may be further modified to reduce or eliminate expression and/or the functions of one or more ligands or binding partners of said NK inhibitory molecule (referred to herein as a "target NK inhibitory molecule"). Without being limited by theory, it is believed that reducing or eliminating expression and/or function, e.g. surface expression, of a target NK inhibitory molecule will reduce or prevent inhibition of a cell of interest, e.g., a CAR expressing cell of the invention, e.g., as described herein. application, as a result of the expression of the NK-inhibiting molecule, thus improving the function of the cells according to the invention, for example, CAR-expressing cells according to the invention, for example, as described in this application. In other embodiments, the inhibitory effects of a NK inhibitory molecule can be reduced or abolished in a cell of interest, e.g., a CAR-expressing cell of the invention, e.g., as described herein, by expression of a dominant negative mutant or fragment of an NK-target. an inhibitory molecule, e.g., a target NK inhibitory molecule that has a modified or removed (partially or completely) intracellular inhibitory domain (e.g., one or more ITIM domains) such that no inhibitory signal is transmitted upon binding of the NK inhibitory molecule. In embodiments where the NK inhibitory molecule is an HLA-G molecule, for example as described herein, the target of the NK inhibitory molecule is LILRB1 (eg, human LILRB1: Entrez: 10859, UniProt Q8NHL6). In embodiments, the reduction or elimination of expression and/or function of a target NK inhibitory molecule, eg, LILRB1, is accomplished by introducing a nucleotide inhibitor of the target NK inhibitory molecule (eg, a shRNA or siRNA molecule to LILRB1). In other embodiments, reduction or elimination of expression and/or function of a target NK inhibitory molecule, e.g., LILRB1, is accomplished by introducing a gene editing system, e.g., a CRISPR/Cas gene editing system, e.g., as described herein, that recognizes the target sequence. in a gene or its regulatory elements of a target NK inhibitory molecule (eg, recognizes a target sequence in the LILRB1 gene or its regulatory elements), whereby the expression and/or function of the target NK inhibitory molecule, such as LILRB1, is reduced or abolished. In embodiments where the target of the NK inhibitory molecule is LILRB1, the gene editing system is a CRISPR/Cas system, e.g. , containing a fragment, for example, a fragment of 20 nucleotides, for example 3' 20 nucleotides, of the directing domain indicated in Table 6d).

In embodiments and aspects, the invention relates to a cell, e.g., an immune effector cell (or a population of said cells), containing a nucleic acid encoding an NK inhibitory molecule, e.g. such that the NK inhibitory molecule is expressed in said cell, e.g. an acid encoding an NK inhibitory molecule operably linked to a promoter active in the cell. In embodiments, the nucleic acid molecule encoding the NK inhibitory molecule contains an additional sequence encoding a CAR. In embodiments, a nucleic acid sequence encoding an NK inhibitory molecule and a nucleic acid sequence encoding a CAR are operably linked to separate promoters as described herein. In other embodiments, an NK inhibitory molecule, a nucleic acid sequence encoding an NK inhibitory molecule, and a nucleic acid sequence encoding a CAR are expressed from the same promoter, optionally with a sequence encoding a cleavable peptide (e.g., a 2A peptide) located between the sequences encoding two molecules.

A cell of the invention, for example cells modified to express CAR, may be modified to express more than one of the additional molecules described above. In embodiments, the cell is modified to express a CAR, for example, as described herein, an iCasp9 switch polypeptide and an NK inhibitory molecule.

In embodiments and aspects, a cell of the invention, e.g., an immune effector cell (or a population of said cells), e.g., a CAR expressing cell as described herein, has reduced or abolished expression of a protein comprising a target antigen of a CAR molecule (e.g. , the target antigen described in this application). Such reduced or abolished expression of a protein containing the target antigen of the CAR molecule can be obtained, for example, by introducing a mutation (for example, an indel) into the sequence of the gene encoding the specified protein, including the target antigen (or its regulatory elements), using the system gene editing, for example, a CRISPR gene editing system (for example, including an nRNA molecule complementary to a target sequence in the specified gene), for example, described in this application. Without being limited by theory, reduced or abolished expression of a protein comprising a target antigen of a CAR molecule may protect said CAR-expressing cells from cognate recognition and/or attack. In embodiments, expression of said protein comprising a CAR target antigen is reduced or abolished compared to expression of said protein comprising a CAR target antigen in a resting cell, such as a resting T cell. In other embodiments, expression of said protein comprising a CAR target antigen is reduced or abolished compared to expression of said protein comprising a CAR target antigen in an activated cell, e.g., an activated T cell, e.g., a T cell activated stimulation of CD3 and/or CD28, or signaling activation of the CAR molecule.

Separate CAR

In some embodiments, a separate CAR is used in the CAR-expressing cell. The split CAR method is described in more detail in WO2014/055442 and WO2014/055657. Briefly, a separate CAR system includes a cell expressing a first CAR having a first antigen-binding domain and a costimulatory domain (e.g., 41BB), while the cell also expresses a second CAR having a second antigen-binding domain and an intracellular signaling domain (e.g., CD3 zeta). When the cell is exposed to the first antigen, the co-stimulatory domain is activated and the cell proliferates. When a cell is exposed to a second antigen, an intracellular signaling domain is activated and cytolytic activity begins to appear. Thus, a CAR-expressing cell is fully activated only in the presence of both antigens.

Multiple expression of CAR

In one aspect, the CAR-expressing cell described herein may further comprise a second CAR, e.g., a second CAR that includes a different antigen-binding domain, e.g., to the same target or a different target (e.g., a target other than a cancer-associated antigen described in this application, or other cancer-associated antigen described in this application). In one embodiment, the second CAR comprises an antigen-binding domain to a target expressed by the same type of cancer cell as the cancer-associated antigen. In one embodiment, a CAR-expressing cell includes a first CAR that is targeted to interact with a first antigen and includes an intracellular signaling domain having a co-stimulatory signaling domain but not a primary signaling domain, and a second CAR that is targeted to interact with a second, different antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. Without being limited by theory, the presence of a co-stimulatory signaling domain, such as 4-1BB, CD28, CD27, or OX-40, on the first CAR and a primary signaling domain, such as CD3 zeta, on the second CAR can limit CAR activity to cells expressing both targets. In one embodiment, a CAR-expressing cell includes a first cancer-associated CAR antigen that includes an antigen-binding domain that binds a target antigen described herein, a transmembrane domain, and a co-stimulatory domain, and a second CAR that interacts in a targeted manner with another target antigen. (eg, an antigen expressed on a cancer cell of the same type as the first target antigen) and includes an antigen-binding domain, a transmembrane domain, and a primary signaling domain. In another embodiment, a CAR-expressing cell includes a first CAR that includes an antigen-binding domain that binds a target antigen described herein, a transmembrane domain, and a primary signaling domain, and a second CAR that interacts directedly with an antigen that is different from the first antigen- target (eg, an antigen expressed on a cancer cell of the same type as the first target antigen), and includes an antigen-binding domain to the antigen, a transmembrane domain, and a costimulatory signaling domain.

In some embodiments, the invention includes first and second CARs, wherein the antigen-binding domain of one of said first CAR and said second CAR does not include a variable light domain and a variable heavy domain. In some embodiments, the antigen-binding domain of one of said first CAR and said second CAR is scFv and the other is not scFv. In some embodiments, the antigen binding domain of one of said first CAR and said second CAR comprises a single VH domain, for example, a single camelid, shark, or lamprey VH domain, or a single VH domain derived from a mouse or human sequence. In some embodiments, the antigen-binding domain of one of said first CAR and said second CAR comprises a nanobody. In some embodiments, the antigen-binding domain of one of said first CAR and said second CAR comprises a camelid VHH domain.

Telomerase expression

Without being limited to any particular theory, in some embodiments, the therapeutic T cell persists transiently in the patient due to shortened telomeres in the T cell; thus, transfection with the telomerase genome can lengthen T cell telomeres and improve T cell persistence in a patient. See Carl June, "Adoptive T cell therapy for cancer in the clinic", Journal of Clinical Investigation, 117:1466-1476 (2007). Thus, in an embodiment, an immune effector cell, eg a T cell, ectopically expresses a telomerase subunit, eg a telomerase catalytic subunit, eg TERT, eg hTERT. In some aspects, the present disclosure provides a method for producing a CAR-expressing cell, comprising contacting the cell with a nucleic acid encoding a telomerase subunit, eg, a telomerase catalytic subunit, eg, TERT, eg, hTERT. The cell may contact the nucleic acid before, simultaneously with, or after contact with the CAR-encoding construct.

In embodiments in which the cell is modified to express more than one molecule, the sequence encoding each of said molecules (e.g., the sequence encoding a CAR and the sequence encoding an NK inhibitory molecule) may be located on the same nucleic acid molecule. acids, eg on the same plasmid or vector, eg a viral vector, eg a lentiviral vector. In an embodiment, (i) a sequence encoding a CAR as described herein and (ii) a sequence encoding an NK inhibitory molecule as described herein may be present on the same nucleic acid, eg a vector. Corresponding proteins can be generated, for example, by separate promoters or by a bicistronic transcription product (which may result in the production of two proteins by cleavage of one translation product or by translation of two separate protein products). In an embodiment, the sequence encoding the cleavable peptide, for example the P2A, T2A or F2A sequence, is located between (i) and (ii). In an embodiment, the sequence encoding the IRES, eg, the EMCV or EV71 IRES, is located between (i) and (ii). In these embodiments, (i) and (ii) are transcribed as a single RNA. In other aspects, each molecule may be expressed from different promoters. In an embodiment, the first promoter is operably linked to (i) and the second promoter is operably linked to (ii), with (i) and (ii) being transcribed as separate mRNAs.

In the alternative, a sequence encoding more than one molecule may be located on different nucleic acid molecules, eg different plasmids or vectors, eg a viral vector, eg a lentiviral vector. For example, (i) a sequence encoding a CAR as described herein may be present on a first nucleic acid, such as a first vector, and (ii) a sequence encoding an NK inhibitory molecule may be present on a second nucleic acid, such as a second vector.

Table 7. Exemplary sequences of various CAR components (aa - amino acids, nc - nucleic acids that encode the corresponding protein), SEQID NO Description Subsequence Resp. huCD19 6639 EF-1 promoter CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGG TTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTTCCATTTCAGGTGTCGTGA 100 6640 Leader (ak) MALPVTALLLPLALLLHAARP thirteen 6641 Leader (nk) ATGGCCCTGCCTGTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCATGCCGCTAGACCC 54 10802 Leader (nk) ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCC 6642 Hinge CD 8 (AK) TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD fourteen 6643 Hinge CD8 (NK) ACCAGACGCCAGCGCCGCGACCACCAACACCGGCCCACCATCGCGTCGCAGCCCCTGTCCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT 55 6630 Hinge Ig4 (AK) ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM 102 6631 Hinge Ig4 (nk) GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG 103 6632 Hinge IgD (ak) RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDH 47 6633 Hinge IgD (nc) AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACAGCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAAGAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATACCCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAGGATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACATGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAGAGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGCTTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTACCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCCCAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT 48 6634 GS hinge/linker (AK) GGGGSGGGGS 49 6635 GS joint/linker (NK) GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC fifty 6644 CD8TM (AK) IYIWAPLAGTCGVLLLSLVITLYC fifteen 6645 CD8 TM (nk) ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC 56 10803 CD8 TM (nk) ATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGT 6646 Intracellular domain 4-1BB (aa) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL sixteen 6647 Intracellular domain 4-1BB (nk) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG 60 10804 4-1BB intracellular domain (nc) aagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactg 6636 CD27 (ak) QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP 51 6637 CD27 (nc) AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGACTTCGCAGCCTATCGCTCC 52 6648 CD3-zeta (ak) RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 17 6649 CD3-zeta (nc) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC 101 10805 CD3-zeta (nc) CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 6650 CD3-zeta (ak) RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 43 6651 CD3-zeta (nc) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAG
AACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTT
TGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGA
AGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGG
AGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGC
ACGATGGCCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGC
CCTTCACATGCAGGCCCTGCCCCCTCGC 44 6629 linker GGGGS eighteen 6635 linker GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC fifty 6652 Extracellular domain of PD-1 (aa) Pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqtlv 6653 Extracellular domain of PD-1 (nk) Cccggatggtttctggactctccggatcgcccgtggaatcccccaaccttctcaccggcactcttggttgtgactgagggcgataatgcgaccttcacgtgctcgttctccaacacctccgaatcattcgtgctgaactggtaccgcatgagcccgtcaaaccagaccgacaagctcgccgcgtttccggaagatcggtcgcaaccgggacaggattgtcggttccgcgtgactcaactgccgaatggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccgggacctacctgtgcggagccatctcgctggcgcctaaggcccaaatcaaagagagcttgagggccgaactgagagtgaccgagcgcagagctgaggtgccaactgcacatccatccccatcgcctcggcctgcggggcagtttcagaccctggtc 6654 PD-1 CAR (ak) with signal sequence. Malpvtalllplalllhaarppgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqtlvtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr 6655 PD-1 CAR (nk) Atggccctccctgtcactgccctgcttctccccctcgcactcctgctccacgccgctagaccacccggatggtttctggactctccggatcgcccgtggaatcccccaaccttctcaccggcactcttggttgtgactgagggcgataatgcgaccttcacgtgctcgttctccaacacctccgaatcattcgtgctgaactggtaccgcatgagcccgtcaaaccagaccgacaagctcgccgcgtttccggaagatcggtcgcaaccgggacaggattgtcggttccgcgtgactcaactgccgaatggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccgggacctacctgtgcggagccatctcgctggcgcctaaggcccaaatcaaagagagcttgagggccgaactgagagtgaccgagcgcagagctgaggtgccaactgcacatccatccccatcgcctcggcctgcggggcagtttcagaccctggtcacgaccactccggcgccgcgcccaccgactccggccccaactatcgcgagccagcccctgtcgctgaggccggaagcatgccgccctgccgccggaggtgctgtgcatacccggggattggacttcgcatgcgacatctacatttgggctcctctcgccggaacttgtggcgtgctccttctgtccctggtcatcaccctgtactgcaagcggggtcggaaaaagcttctgtacattttcaagcagcccttcatgaggcccgtgcaaaccacccaggaggaggacggttgctcctgccggttccccgaagaggaagaaggaggttgcgagctgcgcgtgaagttctcccggagcgccgacgcccccgcctataagcagggccagaaccagctgtacaacgaactgaacctgggacggcgggaagagtacgatgtgctggacaagcggcgcggccgggaccccgaaatgggcgggaagcctagaagaa agaaccctcaggaaggcctgtataacgagctgcagaaggacaagatggccgaggcctactccgaaattgggatgaagggagagcggcggaggggaaaggggcacgacggcctgtaccaaggactgtccaccgccaccaaggacacatacgatgccctgcacatgcaggcccttccccctcgc 6592 linker (Gly-Gly-Gly-Ser)n, where n=1-10 105 6593 linker (Gly4 Ser)4 106 6594 linker (Gly4 Ser)3 107 6595 linker (Gly3Ser) 108 6656 PD1 CAR (ac) Pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqtlvtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr

VI. Cells

In another aspect of the invention, cells are provided that include or have ever included an nRNA molecule, such as one or more nRNA molecules, as described herein, or a CRISPR system, as described herein. In an embodiment, the cell has been altered, e.g., the target sequence of the nRNA molecule has been altered, e.g. to create an indel, by introducing an nRNA molecule as described herein (or a nucleic acid encoding said nRNA molecule), or a system CRISPR (or a nucleic acid encoding one or more components of said CRISPR system) as described herein, eg modified in the manner described herein. In an embodiment, the change results in reduced or no expression of a functional product (eg, wild type) of a gene comprising the target site.

In one aspect, the cell is an animal cell. In embodiments, the cell is a mammalian, primate, or human cell. In embodiments, the cell is a human cell. In embodiments, the cell is an immune effector cell (eg, a population of immune effector cells), eg, a T cell or an NK cell. In embodiments, the T cell (eg, a population of T cells) is or includes a CD4+ T cell, a CD8+ T cell, or a combination thereof. In embodiments, the cell is autologous. In embodiments, the cell is allogeneic.

In a preferred embodiment, the cell (e.g., a population of cells) has been or will be modified to express a chimeric antigen receptor (CAR), e.g., CAR, as described in section V. In embodiments, the cell is modified to express a BCMA CAR, e.g., as described herein. application. In embodiments, the CAR-modified cell is allogeneic. In embodiments, the CAR-modified cell is autologous.

In another aspect of the invention, cells such as those described above are provided, which include, have ever included or will include a second nRNA molecule as described herein, for example, a second nRNA molecule with a guide domain different from the guide domain from the first nRNA molecule. In embodiments, the two nRNA molecules are complementary to target sites in the same gene, eg, complementary to two target sites in the gene of the same allogeneic T cell target, eg, include two target sites in the TRAC gene. Such cells may include large, such as 20-60, 20-70, 20-80, 20-90, 20-100 or greater than 1000, greater than 2000, greater than 3000, greater than 4000, greater than 5000, greater than 6000 base pairs, fragment to be deleted DNA located between the target sites of two molecules of nRNA, as described in this application in section VIII. Alternatively, two nRNAs directed to target sequences in the same gene may not result in the deletion of a fragment, but may instead, for example, create an indel at or near each of the target sites. In other embodiments, two or more nRNA molecules are complementary to target sites in two different genes whose products bind to form a molecular complex. An example of such an embodiment is a first nRNA molecule targeting TRAC and a second nRNA molecule targeting TRBC1 (where TCR-alpha constant strand and TCR-beta constant strand 1 are TCR components on the cell surface). Without being limited by theory, the introduction of CRISPR systems that target two or more target sequences in the same gene or target two or more genes of the same molecular complex (for example, targeting TRAC and TRBC1) can result in to further reduce or eliminate the expression of the target gene product compared to the introduction of a CRISPR system that targets only one target sequence of the target gene.

It should be understood that in any of the aspects and embodiments of the invention in which the targets are two or more target sites in different genes (or different molecular complexes, for example, when targeting TCR and B2M), for any possible target genes ( or molecular complexes), two or more nRNAs can be applied to one or more of these different genes or different molecular complexes. For example, in embodiments and aspects in which TCR expression and B2M expression are reduced or abolished, reduced or abolished TCR expression can be achieved with, for example, one TRAC-targeting nRNA, more than one TRAC-targeting nRNA molecule. , or one nRNA molecule targeting TRAC and a second nRNA targeting another TCR component, eg TRBC1; while at the same time, or alternatively, B2M targeting can be achieved with, for example, one B2M targeting nRNA molecule or two or more B2M targeting nRNA molecules.

In other embodiments, two or more, for example two, nRNA molecules are complementary to target sites in different genes. Such cells may include changes, such as indels, at or near each target site, resulting in the expression of a functional product of more than one gene is reduced or eliminated. As discussed above, in such embodiments, more than one nRNA molecule can be used to target each of the different genes.

In embodiments, the cell includes, has included or will include a first nRNA molecule comprising a guide domain complementary to the target sequence of the allogeneic T cell target (e.g., the guide domain described in Tables 1, 3, 4, or 5) and a second nRNA molecule, comprising a targeting domain complementary to the target sequence of an inhibitory molecule or a downstream signaling effector via an inhibitory molecule (eg, includes a targeting domain as described in Table 2 or Table 6). In embodiments, the inhibitory molecule or downstream signaling effector through the inhibitory molecule is CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF -beta or PTPN11.

In embodiments, the cell includes, has included or will include a first nRNA molecule comprising a guide domain complementary to the TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E or CD3G target sequences and a second nRNA molecule comprising a guide domain complementary to the B2M target sequence , NLRC5, HLA-A, HLA-B or HLA-C.

In embodiments, a cell of the invention includes, has included or will include a first nRNA molecule comprising a guide domain complementary to a TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E, or CD3G target sequence; a second nRNA molecule comprising a guide domain complementary to a B2M, NLRC5, HLA-A, HLA-B, or HLA-C target sequence; and a third nRNA molecule comprising a guide domain complementary to the CIITA target sequence. Without being limited by theory, it is believed that the reduction or elimination of the expression of a MHC class I molecule, for example, using the method described in this application, using nRNA to B2M or nRNA to NLRC5, can cause an increase in the expression of one or more MHC class I molecules in a modified cell. II. Under such circumstances, in order to create, for example, an allogeneic cell (for example, an allogeneic T cell, for example, a CAR-expressing allogeneic T cell described in this application) capable of eliminating the host anti-graft reaction, it may be useful to reduce or eliminate the expression of one or more MHC class II molecules (in addition to one or more MHC class I molecules), for example, in the manner described in this application using CIITA nRNA. In one embodiment, a cell, e.g., a CAR-expressing cell, e.g., as described herein, includes, has included or will include a first nRNA to TRAC, e.g., as described herein, a second nRNA to B2M, e.g., as described in the present application, and a third nRNA to CIITA, for example, as described in this application. In one embodiment, a cell, e.g., a CAR-expressing cell, e.g., as described herein, includes, has included or will include a first anti-TRAC nRNA, e.g., as described herein, a second anti-NLRC5 nRNA, e.g., as described in the present application, and a third nRNA to CIITA, for example, as described in this application.

Embodiments of the invention provide a cell, e.g., a CAR-expressing cell, e.g., as described herein, that includes one or more modifications (e.g., nucleotide insertions or deletions) in an endogenous gene encoding a TCR component, e.g., TRAC or TRBC ( e.g. TRBC1 or TRBC2); one or more modifications (eg, nucleotide insertions or deletions) in the endogenous B2M gene; and/or one or more modifications (eg, nucleotide insertions or deletions) in the endogenous CIITA gene. In embodiments, said modifications reduce or eliminate the expression of said gene. Embodiments of the invention provide a cell, e.g., a CAR-expressing cell, e.g., as described herein, that is TCR- (e.g., has a TCR expression level greater than 50%, 60%, 70%, 80%, 90% , 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using an anti-CD3 antibody), B2M- (e.g., has a B2M expression level and/or one or more MHC class I proteins greater than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using an anti-B2M antibody) and/or CIITA- (e.g., has an expression level of CIITA and/or MHC class II protein greater than 50%, 60%, 70%, 80% , 90%, 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using an anti-CIITA antibody) . In an embodiment, the cell is modified to express a CAR molecule, for example, as described herein. In embodiments, the implementation of the CAR is CD19 CAR, for example, as described in this application. In other embodiments, the implementation of the CAR is BCMA CAR, for example, as described in this application. In other embodiments, the implementation of the CAR is CD123 CAR, for example, as described in this application.

Embodiments of the invention provide a cell, e.g., a CAR-expressing cell, e.g., as described herein, that includes one or more modifications (e.g., nucleotide insertions or deletions) in an endogenous gene encoding a TCR component, e.g., TRAC or TRBC ( e.g. TRBC1 or TRBC2); one or more modifications (eg, nucleotide insertions or deletions) in the endogenous NLRC5 gene; and/or one or more modifications (eg, nucleotide insertions or deletions) in the endogenous CIITA gene. In embodiments, said modifications reduce or abolish the expression of said gene. Embodiments of the invention provide a cell, e.g., a CAR-expressing cell, e.g., as described herein, that is TCR- (e.g., has a TCR expression level greater than 50%, 60%, 70%, 80%, 90% , 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using anti-CD3 antibody), NLRC5- (e.g., has NLRC5 expression level and/or one or more MHC class I proteins greater than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using an anti-NLRC5 antibody) and/or CIITA- (e.g., has an expression level of CIITA and/or MHC class II protein greater than 50%, 60%, 70%, 80% , 90%, 95%, 96%, 97%, 98%, or 99% lower than in an unmodified cell of the same type as detected by FACS, e.g., FACS using an antibody against CITA). In an embodiment, the cell is modified to express a CAR molecule, for example, as described herein. In embodiments, the implementation of the CAR is CD19 CAR, for example, as described in this application. In other embodiments, the implementation of the CAR is BCMA CAR, for example, as described in this application. In other embodiments, the implementation of the CAR is CD123 CAR, for example, as described in this application.

In embodiments, the cell includes, has included or will include a first nRNA molecule that includes a guide domain complementary to the TRAC, TRBC1, TRBC2, CD247, CD3D, CD3E or CD3G target sequences and a second nRNA molecule that includes a guide domain complementary to the target sequence NR3C1, DCK, CD52, or FKBP1A.

In embodiments, the cell includes, has included or will include a first nRNA molecule and a second nRNA molecule, where: (1) the first nRNA molecule includes a targeting domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (2) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (3) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (4) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (5) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (6) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (7) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (8) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (9) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (10) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (11) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (12) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (13) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (14) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (15) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (16) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (17) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (18) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (19) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (20) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (21) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (22) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (23) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (24) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (25) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (26) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (27) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (28) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (29) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (30) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (31) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (32) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (33) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (34) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (35) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (36) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (37) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (38) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (39) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (40) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (41) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (42) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (43) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (44) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (45) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (46) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (47) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (48) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (49) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 83 and SEQ ID NO: 5492 - SEQ ID NO: 5527; (50) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 969 - SEQ ID NO: 1345; (51) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1346 - SEQ ID NO: 1698; (52) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 1699 - SEQ ID NO: 2068; (53) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2069 - SEQ ID NO: 2941; (54) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5278 - SEQ ID NO: 5491; (55) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6227 - SEQ ID NO: 6324; (55) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 6325 - SEQ ID NO: 6583; (56) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (57) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (58) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (59) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (60) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (61) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (62) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (63) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (64) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (65) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (66) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (67) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (68) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (69) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (70) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (71) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (72) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (73) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (74) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (75) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 84 - SEQ ID NO: 392, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (76) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (77) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (78) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (79) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (80) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 393 - SEQ ID NO: 532, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (81) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (82) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (83) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (85) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; (86) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 533 - SEQ ID NO: 839, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277; (87) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 2942 - SEQ ID NO: 3270; (88) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3271 - SEQ ID NO: 3541; (89) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 3542 - SEQ ID NO: 4032; (90) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4033 - SEQ ID NO: 4589 and SEQ ID NO: 5720 - SEQ ID NO: 5815; or (91) the first nRNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 840 - SEQ ID NO: 968, and the second guide RNA molecule includes a guide domain selected from the group consisting of SEQ ID NO: 4590 - SEQ ID NO: 5277.

In an embodiment, the cell includes, has included or will include a first nRNA molecule comprising a targeting domain, including, for example, consisting of, SEQ ID NO: 5569 or 5586, and a second nRNA molecule, including a targeting domain, including, for example, consisting of, SEQ ID NO: : 5775. Said cell preferably includes a change in TRAC and in PDCD1 such that expression of functional TCR and expression of functional PD-1 is reduced or abolished. In an embodiment, the cell is an immune effector cell, such as a T cell or an NK cell. In an embodiment, the cell is allogeneic. In an embodiment, the cell is autologous. In an embodiment, the cell is or will be further modified to express CAR as described herein.

In embodiments of the invention, the cell of the invention includes, has included or will include a first nRNA molecule comprising a guide domain complementary to the target sequence of a T-cell receptor component (eg, TRAC); a second nRNA molecule comprising a guide domain complementary to the B2M target sequence; and a third nRNA molecule comprising a guide domain complementary to the CIITA target sequence. Said cell preferably comprises a modification at or near the target sequence of said first nRNA, said second nRNA and said third nRNA molecule such that functional TCR expression, functional B2M expression and functional CIITA expression are reduced or abolished. In an embodiment, the cell is an immune effector cell, such as a T cell or an NK cell. In an embodiment, the cell is allogeneic. In an embodiment, the cell is autologous. In an embodiment, the cell is or will be further modified to express CAR as described herein.

In an aspect, a cell according to the invention includes (for example, a population of cells according to the invention includes one or more cells that include):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) A nucleic acid sequence encoding an NK inhibitory molecule, eg as described herein, eg a nucleic acid encoding an HLA-G or HLA-G:B2M fusion molecule as described herein;

(c) an indel at or near the sequence of a gene encoding a TCR component (e.g., TRAC, TRBC1, or TRBC2, e.g., TRAC) or its regulatory elements, e.g., an indel at or near a target nRNA sequence comprising a guide domain to the component TCR (for example, TRAC, TRBC1 or TRBC2, for example, TRAC), for example, including the directing domain listed in Table 1, Table 4 or Table 5;

(d) an indel at or near the sequence of a B2M-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a B2M guide domain, e.g., a guide domain listed in Table 1 or Table 3 ;

(e) Optionally, an indel at or near the sequence of the CIITA-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a CIITA targeting domain, e.g., including the targeting domain listed in Table 1 or Table 6c; and

(f) Optionally, an indel at or near the sequence of the gene encoding LILRB1 or its regulatory elements, for example, an indel at or near the target sequence of the nRNA, including the directing domain to LILRB1, for example, including the directing domain is listed in Table 6d;

Wherein the cell (or population of cells includes one or more cells that) expresses a CAR and an NK inhibitory molecule, and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1, or TRBC2, for example, TRAC), ii) B2M, iii) CIITA and/or iv) LILRB1. In embodiments, the indels are

In an aspect, a cell according to the invention includes (for example, a population of cells according to the invention includes one or more cells that include):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) A nucleic acid sequence encoding an NK inhibitory molecule, for example, as described in this application, for example, a nucleic acid encoding HLA-G, as described in this application;

(c) an indel at or near the sequence of a gene encoding a TCR component (e.g., TRAC, TRBC1, or TRBC2, e.g., TRAC) or its regulatory elements, e.g., an indel at or near a target nRNA sequence comprising a guide domain to the component TCR (for example, TRAC, TRBC1 or TRBC2, for example, TRAC), for example, including the directing domain listed in Table 1, Table 4 or Table 5;

(d) an indel at or near the sequence of the gene encoding NLRC5 or its regulatory elements, for example, an indel at or near the target sequence of the nRNA, including the targeting domain to NLRC5, for example, including the targeting domain listed in Table 1;

(e) Optionally, an indel at or near the sequence of the CIITA-encoding gene or its regulatory elements, e.g., an indel at or near an nRNA target sequence comprising a CIITA targeting domain, e.g., including the targeting domain listed in Table 1 or Table 6c; and

(f) Optionally, an indel at or near the sequence of the gene encoding LILRB1 or its regulatory elements, for example, an indel at or near the target sequence of an nRNA comprising a LILRB1 targeting domain, such as including the targeting domain listed in Table 6d;

Wherein the cell (or population of cells includes one or more cells that) expresses a CAR and an NK inhibitory molecule, and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1, or TRBC2, for example, TRAC), ii) B2M, iii) NLRC5 and/or iv) LILRB1.

In an aspect, a cell of the invention includes (for example, the population of cells of the invention includes one or more cells that include):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) an indel at or near the sequence of a gene encoding a TCR component (e.g., TRAC, TRBC1 or TRBC2, e.g., TRAC) or its regulatory elements, e.g., an indel at or near a target nRNA sequence comprising a guide domain to the component TCR (for example, TRAC, TRBC1 or TRBC2, for example, TRAC), for example, including the directing domain listed in Table 1, Table 4 or Table 5; and

(c) an indel at or near the sequence of a gene encoding FKBP1A or its regulatory elements, e.g. an indel at or near an nRNA target sequence comprising a FKBP1A guide domain, e.g. including the guide domain listed in Table 1 or Table 6b ;

Wherein the cell (or population of cells includes one or more cells that) expresses a CAR and exhibits reduced or abolished expression and/or function of one or more of: i) a TCR component (e.g., TRAC, TRBC1 or TRBC2, e.g., TRAC), and /or ii) FKBP12. Such cells (or a population of cells including said cells) are particularly useful, for example, in methods of treatment that involve the administration of an immunosuppressant (eg, cyclosporine, rapamycin, or rapalogue, or an mTor inhibitor, eg, RAD001).

In an aspect, a cell according to the invention includes (for example, a population of cells according to the invention includes one or more cells that include):

(a) A nucleic acid sequence encoding a CAR, for example, as described in this application;

(b) A nucleic acid sequence encoding a rapamycin-resistant mTor, eg as described herein, eg a nucleic acid sequence encoding an mTor comprising an S2035 mutation, eg an S2035I mutation; and;

(c) an indel at or near the sequence of a gene encoding a TCR component (e.g., TRAC, TRBC1, or TRBC2, e.g., TRAC) or its regulatory elements, e.g., an indel at or near a target nRNA sequence comprising a guide domain to the component TCR (for example, TRAC, TRBC1 or TRBC2, for example, TRAC), for example, including the directing domain listed in Table 1, Table 4 or Table 5;

Wherein the cell (or cell population includes one or more cells that) expresses CAR and rapamycin-resistant mTor and exhibits reduced or abolished expression and/or function of a TCR component (e.g., TRAC, TRBC1 or TRBC2, e.g., TRAC). Such cells (or a population of cells including said cells) are particularly useful, for example, in methods of treatment that involve the administration of an immunosuppressant (eg, cyclosporine, rapamycin, or rapalogue, or an mTor inhibitor, eg, RAD001).

In any of the above embodiments and aspects, the cell includes one or more CRISPR systems, for example, as described in this application, including the specified nRNA molecule(s). In embodiments, the cell includes one or more ribonucleoprotein (RNP) complexes, each of which includes a Cas9 molecule, eg, as described herein, and an nRNA molecule comprising said targeting domain, eg, as described herein. In embodiments, including any of the methods described herein, in which nRNAs are applied to more than one target sequence, the nRNAs (and CRISPR systems including said nRNAs) can be introduced into the cell at the same time. In other embodiments, including any of the methods described herein that apply nRNAs to more than one target sequence, the nRNAs (and CRISPR systems including said nRNAs) can be introduced sequentially into the cell.

In an aspect including any of the above embodiments or aspects, the cell population comprises at least 20%, such as at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of cells that include an indel at or near each of the target sequences targeted by each of the nRNA molecules. Said population can be obtained, for example, by using highly efficient nRNA molecules (eg, nRNA molecules that induce indel formation in >85% of said cells that come into contact with said nRNA molecule) or by enriching the population with the desired cell, such as by selecting a population desired cells, for example, using affinity chromatography or cell sorting.

VII. Matrix nucleic acids (for the introduction of nucleic acids)

The term "template nucleic acid" or "donor template" as used herein refers to a nucleic acid that is intended to be introduced at or near a target sequence that has been modified, eg cleaved, by the CRISPR system of the present invention. In an embodiment, the nucleic acid sequence at or near the target sequence is modified to introduce part or all of the template nucleic acid sequence, typically at or near the cleavage site(s). In an embodiment, the template nucleic acid is single stranded. In an alternative embodiment, the template nucleic acid is double stranded. In an embodiment, the template nucleic acid is DNA, eg, double-stranded DNA. In an alternative embodiment, the template nucleic acid is single stranded DNA.

In embodiments, the template nucleic acid comprises a sequence encoding a chimeric antigen receptor (CAR), e.g., CAR, as described in section V above.

In an embodiment, the template nucleic acid changes the structure of the target position by participating in a homology-directed repair event. In an embodiment, the template nucleic acid alters the sequence of the target position. In an embodiment, the template nucleic acid results in the incorporation of a modified or non-natural base into the target nucleic acid.

Mutations in a gene or pathway described in this application can be corrected using one of the approaches discussed in this application. In an embodiment, a mutation in a gene or pathway described herein is corrected by homology-directed repair (HDR) using a template nucleic acid. In an embodiment, a mutation in a gene or pathway described herein is corrected by homologous recombination (HR) using a template nucleic acid. In an embodiment, a mutation in a gene or pathway described herein is corrected by non-homologous end joining (NHEJ) repair using a template nucleic acid. In other embodiments, a nucleic acid encoding molecules of interest may be inserted at or near the site modified by the CRISPR system of the present invention. In an embodiment, the inserted nucleic acid encodes a chimeric antigen receptor as described herein. In embodiments, the template nucleic acid comprises regulatory elements, e.g., one or more promoters and/or enhancers, operably linked to a nucleic acid sequence encoding a molecule of interest, e.g., a chimeric antigen receptor, e.g., as described herein.

HDR repair and matrix nucleic acids

As described herein, nuclease-induced homology-directed repair (HDR) can be used to modify a target sequence and correct (eg, repair or edit) a mutation in the genome. Without being limited by theory, the change in the target sequence is believed to occur by homology-directed repair (HDR) with the donor template or template nucleic acid. For example, the donor template or template nucleic acid provides for a change in the target sequence. It is assumed that the donor plasmid can be used as a template for homologous recombination. It is also contemplated that a single-stranded donor template can be used as a template for modifying the target sequence by alternative methods of homology-guided repair (eg, single-strand annealing) between the target sequence and the donor template. The change in the target sequence caused by the donor template is dependent on cleavage by the Cas9 molecule. Cas9-induced cleavage may include a double-strand break or two single-strand breaks.

In an embodiment, the mutation may be corrected with one double strand break or two single strand breaks. In an embodiment, the mutation can be corrected by: (1) one double strand break, (2) two single strand breaks, (3) two double strand breaks, where the break occurs on each side of the target sequence, (4) one double strand break and two single strand breaks, where a double strand break and two single strand breaks are generated on each side of the target sequence, or (5) four single strand breaks where a pair of single strand breaks are generated on each side of the target sequence.

Double-strand break-mediated correction

In an embodiment, double strand cleavage is performed by a Cas9 molecule having a cleaving activity that is associated with an HNH-like domain and a cleaving activity that is associated with a RuvC-like domain, e.g., an N-terminal RuvC-like domain, e.g., wild-type Cas9. Such embodiments require only one nRNA.

Single-strand break-mediated correction

In other embodiments, two nicks or nicks are generated by a Cas9 molecule having nicase activity, such as cleaving activity associated with an HNH-like domain or cleaving activity associated with an N-terminal RuvC-like domain. Such embodiments require the presence of two nRNAs, one to introduce each single strand break. In an embodiment, the Cas9 molecule having nicase activity cleaves the strand to which the nRNA hybridizes, but not the strand that is complementary to the strand to which the nRNA hybridizes. In an embodiment, the Cas9 molecule with nicase activity does not cleave the strand to which the nRNA hybridizes, but cleaves the strand that is complementary to the strand to which the nRNA hybridizes.

In an embodiment, the nickase has HNH activity, eg the Cas9 molecule has inactivated RuvC activity, eg the Cas9 molecule has a mutation at the D10 position, eg the D10A mutation. D10A inactivates RuvC; therefore Cas9 nickase has (only) HNH activity and cuts the strand to which the nRNA hybridizes (eg, the complementary strand that does not contain NGG PAM). In other embodiments, a Cas9 molecule having an H840 mutation, such as H840A, can be used as a nickase. H840A inactivates HNH; therefore Cas9 nickase has (only) RuvC activity and cuts on a non-complementary strand (eg, a strand that contains NGG PAM and is sequence identical to the nRNA).

In an embodiment in which a nickase and two nRNAs are used to introduce two single-stranded nicks, one nick is located on the + strand and one nick is located on the - strand of the target nucleic acid. PAM motifs are directed outward. The nRNA molecules can be chosen such that the nRNAs are separated by approximately 0-50, 0-100, or 0-200 nucleotides. In an embodiment, there is no overlap between the target sequence that is complementary to the guide domains of the two nRNAs. In an embodiment, the nRNAs do not overlap and are separated by at least 50, 100, or 200 nucleotides. In an embodiment, the use of two nRNAs may increase specificity, for example by reducing off-target binding (Ran el cil., CELL 2013).

In an embodiment, one nickname may be used to induce HDR. The present application contemplates that one nickname may be used to increase the HDR, HR or NHEJ ratio in a given split region.

Introduction of a double-strand break or a single-strand break relative to the target position

A double-strand break or a single-strand break in one of the strands must be close enough to the target position for adjustment to occur. In an embodiment, the distance does not exceed 50, 100, 200, 300, 350, or 400 nucleotides. Without being limited by theory, it is believed that the gap must be located close enough to the target position that the gap is in the region that undergoes exonuclease-mediated removal upon terminal cleavage. If the distance between the target position and the break is too large, the mutation may not be included in the terminal cleavage and therefore may not be repaired since the donor sequence can only be used to correct the sequence in the region of the terminal cleavage.

In an embodiment in which the nRNA (monomolecular (or chimeric) or modular nRNA) and Cas9 nuclease cause a double strand break to induce HDR- or HR-mediated correction, the cleavage site is located within 0-200 bp (e.g., 0 to 175 bp). , 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25-200, 25-175, 25-150, 25-125, 25-100 , 25-75, 25-50, 50-200, 50-175, 50-150, 50-125, 50-100, 50-75, 75-200, 75-175, 75-150, 75 to 125, 75-100 bp) from the target position. In an embodiment, the cleavage site is located within 0-100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25-100, 25-75, 25-50, 50-100, 50-75, or 75-100 bp) from the target position.

In an embodiment in which two nRNAs (independently, monomolecular (or chimeric) or modular nRNAs) complexed with Cas9 nicases induce two single-strand breaks to induce HDR-mediated correction, the closer nick is located within 0-200 bp. (for example, 0 to 175, 0 to 150, 0 to 125, 0 to 100, 0 to 75, 0 to 50, 0 to 25, 25-200, 25-175, 25-150, 25-125, 25-100, 25-75, 25-50, 50-200, 50-175, 50-150, 50-125, 50-100, 50-75, 75-200, 75-175, 75- 150, 75-125, 75-100 bp) from the target position, and ideally the two nicks will be within 25-55 bp of each other (e.g. 25-50, 25-45, 25-40, 25- 35, 25-30, 30-55, 30-50, 30-45, 30-40, 30-35, 35-55, 35-50, 35-45, 35-40, 40-55, 40-50, 40-45 bp and no more than 100 bp apart (for example, no more than 90, 80, 70, 60, 50, 40, 30, 20, 10 or 5 bp apart)). In an embodiment, the cleavage site is located within 0-100 bp (e.g., 0 to 75, 0 to 50, 0 to 25, 25-100, 25-75, 25-50, 50-100, 50-75, or 75-100 bp) from the target position.

In one embodiment, two nRNAs, eg, independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double-strand break on either side of the target position. In a further embodiment, three nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double-strand break (i.e., one nRNA forms a complex with the Cas9 nuclease) and two single-strand breaks or pairwise single-strand breaks (i.e. two nRNAs complex with Cas9 nycases) on either side of the target position (e.g., the first nRNA is used to target to the left (i.e., 5') of the target position, and the second nRNA is used to target to the right (i.e., .3') from the target position). In another embodiment, four nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of making two pairs of single-strand breaks (i.e., two pairs of two nRNAs form complexes with Cas9 nicases) on either side of the target position ( for example, the first nRNA is used to target to the left (ie, 5') of the target position, and the second nRNA is used to target to the right (ie, 3') of the target position). The double-strand break(s), or the closest of two single-strand nicks in a pair, will ideally be located within 0-500 bp of the target position (e.g. no greater than 450, 400, 350, 300, 250, 200, 150, l00, 50 or 25 mon from the target position). When using nikaz, two nicknames in a pair are located within 25-55 bp from each other (for example, within 25-50, 25-45, 25-40, 25-35, 25-30, 50-55, 45-55 , 40-55, 35-55, 30-55, 30-50, 35-50, 40-50, 45-50, 35-45 or 40-45 bp) and no more than 100 bp from each other (for example, no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 mon).

In one embodiment, two nRNAs, eg, independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double-strand break on either side of the target position. In a further embodiment, three nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double strand break (i.e., the nRNAs are complexed with Cas9 nuclease) and two single strand breaks or paired single strand breaks (i.e., two nRNAs complex with Cas9 nycases) on two target sequences (e.g., the first nRNA is used to target to the left (i.e., 5') of the target sequence, and the second nRNA is used to target to the right (i.e., 3' ) from the target sequence of the insertion site In another embodiment, four nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of creating two pairs of single-strand breaks (i.e., two pairs of two nRNAs form complexes with Cas9 ncases) on both sides of the insertion site (e.g., the first nRNA is used to target to the left (i.e., 5') of the target sequence described in this application , and the second nRNA is used for targeting on the right (i.e. 3') from the target sequence described in this application). The double-strand break(s), or the closest of two single-strand nicks in a pair, will ideally be within 0-500 bp of the target position (e.g. no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 mon from the target position). When using nikaz, two nicknames in a pair are located within 25-55 bp from each other (for example, within 25-50, 25-45, 25-40, 25-35, 25-30, 50-55, 45-55 , 40-55, 35-55, 30-55, 30-50, 35-50, 40-50, 45-50, 35-45 or 40-45 bp) and no more than 100 bp from each other (for example, no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 mon).

Homology arm length

The homology arm should extend at least to the region where terminal cleavage can occur, for example, so that the overhanging single stranded end formed during cleavage can find a complementary region in the donor template. The overall length could be limited by parameters such as plasmid size or virus packaging restrictions. In an embodiment, the homology arm does not extend to elements containing repeats, eg ALU repeats, LINE repeats. The matrix may have two homology arms of the same or different lengths.

An exemplary homology arm length is at least 25, 50, 100, 250, 500, 750, or 1000 nucleotides.

A target position, as used herein, refers to a site on a target nucleic acid (eg, chromosome) that undergoes modification in a Cas9 molecule dependent process. For example, the target position can be modified by Cas9 cleavage of the target nucleic acid and by modification directed by the template nucleic acid, such as a correction, of the target position. In an embodiment, the target position may be a region between two nucleotides, such as adjacent nucleotides, on the target nucleic acid into which one or more nucleotides are inserted. The target position may include one or more nucleotides that are altered, eg corrected, by the template nucleic acid. In an embodiment, the target position within the target sequence (eg, the sequence to which the nRNA binds). In an embodiment, the target position is before or after the target sequence (eg, the sequence to which the nRNA binds).

Typically, the template sequence undergoes cleavage mediated or catalyzed by recombination with the target sequence. In an embodiment, the template nucleic acid includes a sequence that corresponds to a site on the target sequence that is cleaved by a Cas9-mediated cleavage event. In an embodiment, the template nucleic acid comprises a sequence that corresponds to a first site on the target sequence that is cleaved by the first Cas9-mediated cleavage event and a second site on the target sequence that is cleaved by the second Cas9-mediated cleavage event.

In an embodiment, the template nucleic acid may include a sequence that results in a change in the coding sequence of the translated sequence, for example, a sequence that results in the substitution of one amino acid for another in the protein product, for example, by transforming a mutant allele into a wild-type allele, by transforming the allele wild-type into a mutant allele, and/or as a result of the introduction of a stop codon, insertion of an amino acid residue, deletion of an amino acid residue, or nonsense mutation.

In other embodiments, the template nucleic acid may include a sequence that results in a change in a non-coding sequence, such as a change in an exon or 5' or 3' non-translated or non-transcribed regions. Such changes include changing the regulatory element, eg promoter, enhancer, and changing the cis-acting or trans-acting regulatory element.

The template nucleic acid may include a sequence that, when integrated, results in:

decrease in the activity of the element of positive regulation;

increasing the activity of the element of positive regulation;

decrease in the activity of the element of negative regulation;

increasing the activity of the element of negative regulation;

decrease in gene expression;

increased gene expression;

increasing resistance to disorder or disease;

increase resistance to virus penetration;

correcting a mutation or change in an undesirable amino acid residue;

conferring, enhancing, eliminating, or reducing a biological property of a gene product, such as increasing the enzymatic activity of an enzyme or increasing the ability of the gene product to interact with another molecule.

The template nucleic acid may include a sequence that results in:

sequence change of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides of the target sequence.

In an embodiment, the template nucleic acid has a length of 20+/-10, 30+/-10, 40+/-10, 50+/-10, 60+/-10, 70+/-10, 80+/-10, 90+/-10, 100+/-10, 110+/-10, 120+/-10, 130+/-10, 140+/-10, 150+/-10, 160+/-10, 170+ /-10, 180+/-10, 190+/-10, 200+/-10, 210+/-10, 220+/-10, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-2000, 2000-3000 or more than 3000 nucleotides.

The template nucleic acid includes the following components:

[5' homology arm]-[insert sequence]-[3' homology arm].

Homology arms allow for recombination into the chromosome, which can cause an undesired element, such as a mutation or signature, to be replaced by a replacement sequence. In an embodiment, the homology arms flank the outermost cleavage sites.

In an embodiment, the 3' end of the 5' arm of the homology is adjacent to the 5' end of the replacement sequence. In an embodiment, the 5' homology arm may extend at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500 or 2000 nucleotides 5' from the 5' end of the replacement sequence.

In an embodiment, the 5' end of the 3' homology arm is adjacent to the 3' end of the replacement sequence. In an embodiment, the 3' homology arm may extend at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500 or 2000 nucleotides 3' from the 3' end of the replacement sequence.

The present application contemplates that one or both of the homology arms may be truncated to prevent the inclusion of some sequence elements containing repeats, eg Alu repeats, LINE elements. For example, the 5' homology arm can be shortened to prevent inclusion of a sequence element containing repeats. In other embodiments, the 3' homology arm may be shortened to prevent inclusion of a sequence element containing repeats. In some embodiments, the 5' and 3' homology arms may be truncated to prevent the inclusion of some sequence elements containing repeats.

The present application contemplates that mutation correcting template nucleic acids can be designed for use as a single stranded oligonucleotide (ssODN). In the case of ssODN, the 5' and 3' homology arms can be up to about 200 base pairs (bp) long, eg at least 25, 50, 75, 100, 125, 150, 175 or 200 bp long. Longer homology arms are also being considered for ssODN as oligonucleotide synthesis continues to improve.

In one aspect, the insert sequence includes a nucleic acid sequence that encodes a chimeric antigen receptor, for example, as described herein. In one embodiment, the insert sequence further comprises a promoter operably linked to a nucleic acid sequence encoding a chimeric antigen receptor, for example, the EF-1 alpha promoter. In one aspect, the insert sequence includes a vector encoding a chimeric antigen receptor, for example, as described in this application, or part of it.

NHEJ methods for gene targeting

As described herein, nuclease-induced non-homologous end joining (NHEJ) can be used to generate gene-specific knockouts. Nuclease-induced NHEJ can also be used to eliminate (eg, delete) a sequence in a gene of interest.

Without being limited by theory, in an embodiment, the genomic changes associated with the methods described herein are believed to be based on the nuclease-induced NHEJ and the error-prone nature of the NHEJ repair pathway. NHEJ eliminates a double-strand break in DNA when two ends are joined; however, usually the original sequence is only restored if two compatible ends, exactly the same as those formed by a double-strand break, are perfectly ligated. The DNA ends of a double-strand break are often attacked by enzymes, resulting in the addition or removal of nucleotides, on one or both strands, before the ends are rejoined. This results in the presence of an insertion and/or deletion (indel) mutation in the DNA sequence at the NHEJ repair site. Two-thirds of these mutations can cause a change in the reading frame and therefore give rise to a non-functional protein. In addition, mutations that retain the reading frame, but which involve the insertion or deletion of a significant portion of the sequence, can disrupt the functionality of the protein. This is locus dependent, as mutations in critical functional domains are more likely to be less tolerated than mutations in non-essential regions of the protein.

The indel mutations that NHEJ creates are inherently unpredictable; however, some indel sequences are favored at a particular break site and present with increased frequency in the population. The length of deletions can vary considerably, usually in the range of 1-50 bp, but they can easily reach more than 100-200 bp. Insertions are usually shorter and often include short sequence duplications immediately surrounding the break site. However, large inserts can be made, and in such cases the inserted sequence is often found in other regions of the genome or in plasmid DNA present in cells.

Because NHEJ is a mutagenic process, it can also be used to remove small sequence motifs, provided that no specific final sequence is required. If a strand break is directed near a short target sequence, deletion mutations caused by NHEJ repair often span and therefore remove unwanted nucleotides. To remove larger DNA segments, the introduction of two double-strand breaks, one on each side of the sequence, can result in NHEJ between the ends, removing the entire intermediate sequence. Both of these methods can be used to remove specific DNA sequences; however, the error proneness of NHEJ can still produce indel mutations at the repair site.

Both double chain cleaving Cas9 molecules and single chain Cas9 molecules, or nikases, can be used in the methods and compositions described herein to create NHEJ-mediated indels. NHEJ-mediated indels directed to a gene, eg a coding region, eg an early coding region of a gene of interest, can be used to knock out (ie eliminate expression) the gene of interest. For example, the early coding region of a gene of interest includes a sequence immediately after the transcription start site, in the first exon of the coding sequence, or within 500 bp of the transcription start site (e.g., less than 500, 450, 400, 350, 300, 250, 200, 150 , 100 or 50 mon).

Location of double-strand or single-strand breaks relative to the target position

In an embodiment in which the nRNA and Cas9 nuclease create a double-strand break to induce the formation of NHEJ-mediated indels, the nRNA, e.g., a monomolecular (or chimeric) or modular nRNA molecule, is capable of introducing a single double-strand break in close proximity to the nucleotide at the target position . In an embodiment, the cleavage site is located within 0-500 bp of the target position (e.g., less than 500, 400, 300, 200, 100, 50, 40, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mon from the target position).

In an embodiment in which two nRNAs complexed with Cas9 nicases create two nicks to induce the formation of NHEJ-mediated indels, the two nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing two nicks, providing NHEJ repair of the nucleotide at the target position. In an embodiment, the nRNAs are capable of introducing cuts at the same position, or within a few nucleotides of each other, on different strands, essentially mimicking a double strand break. In an embodiment, the closest nick is located within 0-30 bp from the target position (e.g., less than 30, 25, 20, 1, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 bp from the target position). -target), and two nicknames are located within 25-55 bp from each other (for example, within 25-50, 25-45, 25-40, 25-35, 25-30, 50-55, 45-55, 40-55, 35-55, 30-55, 30-50, 35-50, 40-50, 45-50, 35-45, or 40-45 bp) and no more than 100 bp apart (for example, no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 mon). In an embodiment, the nRNAs are capable of introducing a single strand break on either side of the nucleotide at the target position.

Both double strand cleaving Cas9 molecules and single strand Cas9 molecules, or nickases, can be used in the methods and compositions described herein to create breaks on both sides at the target position. Double-stranded or double-stranded breaks can be created on both sides at the target position to remove the nucleic acid sequence between two cuts (eg, the area between two breaks is removed). In one embodiment, two nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double-strand break on both sides at the target position (e.g., the first nRNA is used for targeting to the left (i.e., 5') of mutation in a gene or pathway described herein and a second nRNA is used to target to the right (ie 3') of a mutation in a gene or pathway described herein). In a further embodiment, three nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of introducing a double-strand break (i.e., the nRNA forms a complex with Cas9 nuclease) and two single-strand breaks or paired single-strand breaks (i.e., two nRNA forms a complex with Cas9 nicases) on both sides of the target position (for example, the first nRNA is used to target to the left (i.e. 5') of the mutation in the gene or pathway described in this application, and the second nRNA is used to target exposure to the right (i.e. 3') of a mutation in a gene or pathway described in this application). In another embodiment, four nRNAs, e.g., independently, monomolecular (or chimeric) or modular nRNAs, are capable of making two pairs of single-strand breaks (i.e., two pairs of two nRNAs form complexes with Cas9 nicases) on either side of the target position ( for example, the first nRNA is used to target to the left (i.e., 5') of a mutation in a gene or pathway described herein, and the second nRNA is used to target to the right (i.e., 3') of a mutation in a gene or the way described in this application). The double-strand break(s) or the closest of two single-strand nicks in a pair will ideally be within 0-500 bp of the target position (e.g. no more than 450, 400, 350, 300, 250, 200, 150, 100, 50 or 25 mon from the target position). In the case of using nikaz, two nick pairs are located within 25-55 bp from each other (for example, within 25-50, 25-45, 25-40, 25-35, 25-30, 50-55, 45- 55, 40-55, 35-55, 30-55, 30-50, 35-50, 40-50, 45-50, 35-45 or 40-45 bp) and no more than 100 bp apart (for example , no more than 90, 80, 70, 60, 50, 40, 30, 20 or 10 mon).

VIII. Systems containing more than one nRNA molecule

Without wishing to be bound by theory, it has surprisingly been shown herein that targeting two target sequences (e.g., two nRNA/Cas9 molecule complexes, each causing a single or double strand break at or near their respective target sequence), located in close proximity to a contiguous nucleic acid causes deletion (e.g., deletion) of the nucleic acid sequence (or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% of the nucleic acid sequence ) located between two target sequences. In some aspects of the present description, the use of two or more nRNA molecules that contain targeting domains directed to target sequences in close proximity to a continuous nucleic acid, for example, a chromosome, for example, a gene or a gene locus, including its introns, exons and regulatory elements, is proposed. . Application can be carried out, for example, by introducing two or more molecules of nRNA together with one or more molecules of Cas9 (or a nucleic acid encoding two or more molecules of nRNA and/or one or more molecules of Cas9) into the cell.

In some aspects, the target sequences of two or more nRNA molecules are spaced apart by at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300 , 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, or 70,000 nucleotides apart on a continuous nucleic acid, but not more than 10,000 nucleotides apart on a continuous nucleic acid. In an embodiment, the target sequences are spaced approximately 4000 nucleotides apart. In an embodiment, the target sequences are spaced approximately 6000 nucleotides apart.

In some aspects, each of a plurality of nRNA molecules targets target sequences in the same gene or locus. In another aspect, each of the plurality of nRNA molecules targets target sequences in 2 or more different genes.

In some aspects of the invention, compositions and cells are provided comprising a plurality, such as 2 or more, such as 2, of the nRNA molecules of the invention, wherein the plurality of nRNA molecules target sequences at intervals of less than 10,000, less than 9,000, less than 8,000, less than 7,000, less than 6000, less than 5000, less than 4000, less than 3000, less than 2000, less than 1000, less than 900, less than 800, less than 700, less than 600, less than 500, less than 400, less than 300, less than 200, less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, or less than 30 nucleotides apart. In an embodiment, the target sequences are on the same strand of a double-stranded nucleic acid. In an embodiment, the target sequences are on different strands of a double-stranded nucleic acid.

In one embodiment, the invention provides a method for excising (e.g., removing) a nucleic acid located between two nRNA binding sites spaced less than 10,000, less than 9,000, less than 8,000, less than 7,000, less than 6,000, less than 5,000, less than 4,000, less than 3,000, less than 2000, less than 1000, less than 900, less than 800, less than 700, less than 600, less than 500, less than 400, less than 300, less than 200, less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40 or less than 30 nucleotides apart on the same or different strands of a double-stranded nucleic acid. In an embodiment, the method provides for a deletion greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91% , greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99% or 100% of the nucleotides located between the PAM sites associated with each nRNA binding site. In embodiments, the deletion further includes one or more nucleotides at one or more PAM sites associated with each nRNA binding site. In embodiments, the deletion also includes one or more nucleotides outside of the region between the PAM sites associated with each nRNA binding site.

In one aspect, two or more nRNA molecules include targeting domains that interact directedly with target sequences adjacent to a gene regulatory element, such as a promoter binding site, enhancer region, or repressor region, wherein excision of the intermediate sequence (or part of the intermediate sequence) causes an - or downregulation of a gene of interest.

In one embodiment, two or more nRNA molecules are selected from the nRNA molecules in Table 1. In aspects, two or more nRNA molecules contain targeting domains that are complementary to sequences in the same gene. In aspects, two or more nRNA molecules contain targeting domains that are complementary to different gene sequences. In one embodiment, two or more nRNA molecules are selected from the nRNA molecules in Table 2. In aspects, two or more nRNA molecules contain targeting domains that are complementary to sequences in the same gene. In aspects, two or more nRNA molecules contain targeting domains that are complementary to different gene sequences. In one embodiment, two or more nRNA molecules are selected from the nRNA molecules in Table 3. In one embodiment, two or more nRNA molecules are selected from the nRNA molecules in Table 4. In one embodiment, two or more nRNA molecules are selected from the rRNA molecules in Table 5 In one embodiment, two or more nRNA molecules are selected from the nRNA molecules in Table 6. In one embodiment, the first and second nRNA molecules are selected from Tables 1-6 and selected from different tables, for example, and include targeting domains that are complementary to sequences of different genes. In embodiments, such two or more nRNA molecules can additionally be combined with one or more additional nRNA molecules that are complementary to the target domain of another gene, as described herein.

As described herein, it is contemplated to provide a cell (or population of cells), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which expression of TRAC, B2M, and CIITA is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 33 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of, the sequence: [guide domain]-SEQ ID NO: 7811. In embodiments, one or more nRNA molecules, for example, all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, eg 3, 3' and/or 5' phosphothioate bonds, and/or one or more, eg 3, 3' and/or 5' 2'-OMe modifications. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or population of cells, eg, as described herein) as RNP, eg, by electroporation. In embodiments, an RNP comprising each nRNA molecule is mixed with cells and administered simultaneously, eg, in a single electroporation step. In other embodiments, RNPs may be administered sequentially. In cases where reduction or elimination of B2M and CIITA expression in a cell is envisaged (as in the present application), in embodiments, cells can be further modified to express an NK inhibitory molecule, for example, as described in this application, for example, an HLA- G:B2M described in this application.

Table 33: Examples of preferred first, second, and third nRNA targeting domains that can be used in combination to reduce or eliminate TRAC, B2M, and CIITA expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively A1 SEQ ID NO: 5569 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A37 SEQ ID NO: 5592 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A2 SEQ ID NO: 5569 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A38 SEQ ID NO: 5592 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A3 SEQ ID NO: 5569 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A39 SEQ ID NO: 5592 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A4 SEQ ID NO: 5569 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A40 SEQ ID NO: 5592 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A5 SEQ ID NO: 5569 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A41 SEQ ID NO: 5592 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A6 SEQ ID NO: 5569 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A42 SEQ ID NO: 5592 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A7 SEQ ID NO: 5569 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A43 SEQ ID NO: 5592 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A8 SEQ ID NO: 5569 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A44 SEQ ID NO: 5592 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A9 SEQ ID NO: 5569 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A45 SEQ ID NO: 5592 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A10 SEQ ID NO: 5569 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A46 SEQ ID NO: 5592 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A11 SEQ ID NO: 5569 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A47 SEQ ID NO: 5592 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A12 SEQ ID NO: 5569 and SEQ ID NO: 7785 and SEQ ID NO: 5509 A48 SEQ ID NO: 5592 and SEQ ID NO: 7785 and SEQ ID NO: 5509 A13 SEQ ID NO: 5586 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A49 SEQ ID NO: 5599 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A14 SEQ ID NO: 5586 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A50 SEQ ID NO: 5599 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A15 SEQ ID NO: 5586 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A51 SEQ ID NO: 5599 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A16 SEQ ID NO: 5586 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A52 SEQ ID NO: 5599 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A17 SEQ ID NO: 5586 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A53 SEQ ID NO: 5599 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A18 SEQ ID NO: 5586 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A54 SEQ ID NO: 5599 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A19 SEQ ID NO: 5586 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A55 SEQ ID NO: 5599 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A20 SEQ ID NO: 5586 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A56 SEQ ID NO: 5599 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A21 SEQ ID NO: 5586 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A57 SEQ ID NO: 5599 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A22 SEQ ID NO: 5586 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A58 SEQ ID NO: 5599 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A23 SEQ ID NO: 5586 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A59 SEQ ID NO: 5599 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A24 SEQ ID NO: 5586 and SEQ ID NO: 7785 and SEQ ID NO: 5509 A60 SEQ ID NO: 5599 and SEQ ID NO: 7785 and SEQ ID NO: 5509 A25 SEQ ID NO: 5587 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A61 SEQ ID NO: 5600 and SEQ ID NO: 7769 and SEQ ID NO: 5496 A26 SEQ ID NO: 5587 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A62 SEQ ID NO: 5600 and SEQ ID NO: 7771 and SEQ ID NO: 5496 A27 SEQ ID NO: 5587 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A63 SEQ ID NO: 5600 and SEQ ID NO: 7739 and SEQ ID NO: 5496 A28 SEQ ID NO: 5587 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A64 SEQ ID NO: 5600 and SEQ ID NO: 7785 and SEQ ID NO: 5496 A29 SEQ ID NO: 5587 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A65 SEQ ID NO: 5600 and SEQ ID NO: 7769 and SEQ ID NO: 5498 A30 SEQ ID NO: 5587 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A66 SEQ ID NO: 5600 and SEQ ID NO: 7771 and SEQ ID NO: 5498 A31 SEQ ID NO: 5587 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A67 SEQ ID NO: 5600 and SEQ ID NO: 7739 and SEQ ID NO: 5498 A32 SEQ ID NO: 5587 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A68 SEQ ID NO: 5600 and SEQ ID NO: 7785 and SEQ ID NO: 5498 A33 SEQ ID NO: 5587 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A69 SEQ ID NO: 5600 and SEQ ID NO: 7769 and SEQ ID NO: 5509 A34 SEQ ID NO: 5587 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A70 SEQ ID NO: 5600 and SEQ ID NO: 7771 and SEQ ID NO: 5509 A35 SEQ ID NO: 5587 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A71 SEQ ID NO: 5600 and SEQ ID NO: 7739 and SEQ ID NO: 5509 A36 SEQ ID NO: 5587 and SEQ ID NO: 7785 and SEQ ID NO: 5509 A72 SEQ ID NO: 5600 and SEQ ID NO: 7785 and SEQ ID NO: 5509

Particularly preferred combinations include A1-A4 combination, A5-A8 combination, A37-A40 combination or A41-A44 combination.

As described herein, it is contemplated to provide a cell (or population of cells), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which the expression of CD3E, B2M, and CIITA is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 34 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example consisting of, the sequence: [guide domain]-SEQ ID NO: 7811.

In embodiments, one or more nRNA molecules, for example all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, for example 3, 3' and/or 5' phosphothioate bonds, and/or one or more, for example 3, 3' and/or 5' 2'-OMe modification. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or population of cells, eg, as described herein) as RNP, eg, by electroporation. In embodiments, an RNP comprising each nRNA molecule is mixed with cells and administered simultaneously, for example, in a single electroporation step. In other embodiments, RNPs may be administered sequentially. In cases where reduction or elimination of B2M and CIITA expression in a cell is envisaged (as in the present application), in embodiments, cells can be further modified to express an NK inhibitory molecule, for example, as described in this application, for example, an HLA- G:B2M described in this application.

Table 34: Examples of preferred first, second and third nRNA targeting domains that can be used in combination to reduce or eliminate CD3E, B2M and CIITA expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively B1 SEQ ID NO: 10729 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B49 SEQ ID NO: 10701 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B2 SEQ ID NO: 10729 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B50 SEQ ID NO: 10701 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B3 SEQ ID NO: 10729 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B51 SEQ ID NO: 10701 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B4 SEQ ID NO: 10729 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B52 SEQ ID NO: 10701 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B5 SEQ ID NO: 10729 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B53 SEQ ID NO: 10701 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B6 SEQ ID NO: 10729 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B54 SEQ ID NO: 10701 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B7 SEQ ID NO: 10729 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B55 SEQ ID NO: 10701 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B8 SEQ ID NO: 10729 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B56 SEQ ID NO: 10701 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B9 SEQ ID NO: 10729 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B57 SEQ ID NO: 10701 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B10 SEQ ID NO: 10729 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B58 SEQ ID NO: 10701 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B11 SEQ ID NO: 10729 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B59 SEQ ID NO: 10701 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B12 SEQ ID NO: 10729 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B60 SEQ ID NO: 10701 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B13 SEQ ID NO: 10719 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B61 SEQ ID NO: 10700 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B14 SEQ ID NO: 10719 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B62 SEQ ID NO: 10700 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B15 SEQ ID NO: 10719 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B63 SEQ ID NO: 10700 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B16 SEQ ID NO: 10719 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B64 SEQ ID NO: 10700 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B17 SEQ ID NO: 10719 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B65 SEQ ID NO: 10700 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B18 SEQ ID NO: 10719 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B66 SEQ ID NO: 10700 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B19 SEQ ID NO: 10719 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B67 SEQ ID NO: 10700 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B20 SEQ ID NO: 10719 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B68 SEQ ID NO: 10700 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B21 SEQ ID NO: 10719 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B69 SEQ ID NO: 10700 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B22 SEQ ID NO: 10719 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B70 SEQ ID NO: 10700 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B23 SEQ ID NO: 10719 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B71 SEQ ID NO: 10700 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B24 SEQ ID NO: 10719 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B72 SEQ ID NO: 10700 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B25 SEQ ID NO: 10764 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B73 SEQ ID NO: 10722 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B26 SEQ ID NO: 10764 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B74 SEQ ID NO: 10722 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B27 SEQ ID NO: 10764 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B75 SEQ ID NO: 10722 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B28 SEQ ID NO: 10764 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B76 SEQ ID NO: 10722 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B29 SEQ ID NO: 10764 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B77 SEQ ID NO: 10722 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B30 SEQ ID NO: 10764 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B78 SEQ ID NO: 10722 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B31 SEQ ID NO: 10764 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B79 SEQ ID NO: 10722 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B32 SEQ ID NO: 10764 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B80 SEQ ID NO: 10722 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B33 SEQ ID NO: 10764 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B81 SEQ ID NO: 10722 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B34 SEQ ID NO: 10764 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B82 SEQ ID NO: 10722 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B35 SEQ ID NO: 10764 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B83 SEQ ID NO: 10722 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B36 SEQ ID NO: 10764 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B84 SEQ ID NO: 10722 and SEQ ID NO: 7785 and SEQ ID NO: 5509 B37 SEQ ID NO: 10689 and SEQ ID NO: 7769 and SEQ ID NO: 5496 B38 SEQ ID NO: 10689 and SEQ ID NO: 7771 and SEQ ID NO: 5496 B39 SEQ ID NO: 10689 and SEQ ID NO: 7739 and SEQ ID NO: 5496 B40 SEQ ID NO: 10689 and SEQ ID NO: 7785 and SEQ ID NO: 5496 B41 SEQ ID NO: 10689 and SEQ ID NO: 7769 and SEQ ID NO: 5498 B42 SEQ ID NO: 10689 and SEQ ID NO: 7771 and SEQ ID NO: 5498 B43 SEQ ID NO: 10689 and SEQ ID NO: 7739 and SEQ ID NO: 5498 B44 SEQ ID NO: 10689 and SEQ ID NO: 7785 and SEQ ID NO: 5498 B45 SEQ ID NO: 10689 and SEQ ID NO: 7769 and SEQ ID NO: 5509 B46 SEQ ID NO: 10689 and SEQ ID NO: 7771 and SEQ ID NO: 5509 B47 SEQ ID NO: 10689 and SEQ ID NO: 7739 and SEQ ID NO: 5509 B48 SEQ ID NO: 10689 and SEQ ID NO: 7785 and SEQ ID NO: 5509

As described herein, it is contemplated to provide a cell (or cell population), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which expression of TRBC, B2M, and CIITA is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 38 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of, the sequence: [guide domain]-SEQ ID NO: 7811. In embodiments, one or more nRNA molecules, for example, all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, eg 3, 3' and/or 5' phosphothioate bonds, and/or one or more, eg 3, 3' and/or 5' 2'-OMe modifications. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or population of cells, eg, as described herein) as RNP, eg, by electroporation. In embodiments, an RNP comprising each nRNA molecule is mixed with cells and administered simultaneously, for example, in a single electroporation step. In other embodiments, RNPs may be administered sequentially. In cases where reduction or elimination of B2M and CIITA expression in a cell is envisaged (as in the present application), in embodiments, cells can be further modified to express an NK inhibitory molecule, for example, as described in this application, for example, an HLA- G:B2M described in this application.

Table 38: Examples of preferred first, second, and third nRNA targeting domains that can be used in combination to reduce or eliminate TRBC, B2M, and CIITA expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, second nRNA and third nRNA, respectively F1 SEQ ID NO: 5719 and SEQ ID NO: 5496 and SEQ ID NO: 7769 F33 SEQ ID NO: 5706 and SEQ ID NO: 5499 and SEQ ID NO: 7769 F2 SEQ ID NO: 5719 and SEQ ID NO: 5496 and SEQ ID NO: 7771 F34 SEQ ID NO: 5706 and SEQ ID NO: 5499 and SEQ ID NO: 7771 F3 SEQ ID NO: 5719 and SEQ ID NO: 5496 and SEQ ID NO: 7739 F35 SEQ ID NO: 5706 and SEQ ID NO: 5499 and SEQ ID NO: 7739 F4 SEQ ID NO: 5719 and SEQ ID NO: 5496 and SEQ ID NO: 7785 F36 SEQ ID NO: 5706 and SEQ ID NO: 5499 and SEQ ID NO: 7785 F5 SEQ ID NO: 5719 and SEQ ID NO: 5498 and SEQ ID NO: 7769 F37 SEQ ID NO: 5696 and SEQ ID NO: 5496 and SEQ ID NO: 7769 F6 SEQ ID NO: 5719 and SEQ ID NO: 5498 and SEQ ID NO: 7771 F38 SEQ ID NO: 5696 and SEQ ID NO: 5496 and SEQ ID NO: 7771 F7 SEQ ID NO: 5719 and SEQ ID NO: 5498 and SEQ ID NO: 7739 F39 SEQ ID NO: 5696 and SEQ ID NO: 5496 and SEQ ID NO: 7739 F8 SEQ ID NO: 5719 and SEQ ID NO: 5498 and SEQ ID NO: 7785 F40 SEQ ID NO: 5696 and SEQ ID NO: 5496 and SEQ ID NO: 7785 F9 SEQ ID NO: 5719 and SEQ ID NO: 5499 and SEQ ID NO: 7769 F41 SEQ ID NO: 5696 and SEQ ID NO: 5498 and SEQ ID NO: 7769 F10 SEQ ID NO: 5719 and SEQ ID NO: 5499 and SEQ ID NO: 7771 F42 SEQ ID NO: 5696 and SEQ ID NO: 5498 and SEQ ID NO: 7771 F11 SEQ ID NO: 5719 and SEQ ID NO: 5499 and SEQ ID NO: 7739 F43 SEQ ID NO: 5696 and SEQ ID NO: 5498 and SEQ ID NO: 7739 F12 SEQ ID NO: 5719 and SEQ ID NO: 5499 and SEQ ID NO: 7785 F44 SEQ ID NO: 5696 and SEQ ID NO: 5498 and SEQ ID NO: 7785 F13 SEQ ID NO: 5694 and SEQ ID NO: 5496 and SEQ ID NO: 7769 F45 SEQ ID NO: 5696 and SEQ ID NO: 5499 and SEQ ID NO: 7769 F14 SEQ ID NO: 5694 and SEQ ID NO: 5496 and SEQ ID NO: 7771 F46 SEQ ID NO: 5696 and SEQ ID NO: 5499 and SEQ ID NO: 7771 F15 SEQ ID NO: 5694 and SEQ ID NO: 5496 and SEQ ID NO: 7739 F47 SEQ ID NO: 5696 and SEQ ID NO: 5499 and SEQ ID NO: 7739 F16 SEQ ID NO: 5694 and SEQ ID NO: 5496 and SEQ ID NO: 7785 F48 SEQ ID NO: 5696 and SEQ ID NO: 5499 and SEQ ID NO: 7785 F17 SEQ ID NO: 5694 and SEQ ID NO: 5498 and SEQ ID NO: 7769 F49 SEQ ID NO: 5711 and SEQ ID NO: 5496 and SEQ ID NO: 7769 F18 SEQ ID NO: 5694 and SEQ ID NO: 5498 and SEQ ID NO: 7771 F50 SEQ ID NO: 5711 and SEQ ID NO: 5496 and SEQ ID NO: 7771 F19 SEQ ID NO: 5694 and SEQ ID NO: 5498 and SEQ ID NO: 7739 F51 SEQ ID NO: 5711 and SEQ ID NO: 5496 and SEQ ID NO: 7739 F20 SEQ ID NO: 5694 and SEQ ID NO: 5498 and SEQ ID NO: 7785 F52 SEQ ID NO: 5711 and SEQ ID NO: 5496 and SEQ ID NO: 7785 F21 SEQ ID NO: 5694 and SEQ ID NO: 5499 and SEQ ID NO: 7769 F53 SEQ ID NO: 5711 and SEQ ID NO: 5498 and SEQ ID NO: 7769 F22 SEQ ID NO: 5694 and SEQ ID NO: 5499 and SEQ ID NO: 7771 F54 SEQ ID NO: 5711 and SEQ ID NO: 5498 and SEQ ID NO: 7771 F23 SEQ ID NO: 5694 and SEQ ID NO: 5499 and SEQ ID NO: 7739 F55 SEQ ID NO: 5711 and SEQ ID NO: 5498 and SEQ ID NO: 7739 F24 SEQ ID NO: 5694 and SEQ ID NO: 5499 and SEQ ID NO: 7785 F56 SEQ ID NO: 5711 and SEQ ID NO: 5498 and SEQ ID NO: 7785 F25 SEQ ID NO: 5706 and SEQ ID NO: 5496 and SEQ ID NO: 7769 F57 SEQ ID NO: 5711 and SEQ ID NO: 5499 and SEQ ID NO: 7769 F26 SEQ ID NO: 5706 and SEQ ID NO: 5496 and SEQ ID NO: 7771 F58 SEQ ID NO: 5711 and SEQ ID NO: 5499 and SEQ ID NO: 7771 F27 SEQ ID NO: 5706 and SEQ ID NO: 5496 and SEQ ID NO: 7739 F59 SEQ ID NO: 5711 and SEQ ID NO: 5499 and SEQ ID NO: 7739 F28 SEQ ID NO: 5706 and SEQ ID NO: 5496 and SEQ ID NO: 7785 F60 SEQ ID NO: 5711 and SEQ ID NO: 5499 and SEQ ID NO: 7785 F29 SEQ ID NO: 5706 and SEQ ID NO: 5498 and SEQ ID NO: 7769 F30 SEQ ID NO: 5706 and SEQ ID NO: 5498 and SEQ ID NO: 7771 F31 SEQ ID NO: 5706 and SEQ ID NO: 5498 and SEQ ID NO: 7739 F32 SEQ ID NO: 5706 and SEQ ID NO: 5498 and SEQ ID NO: 7785

Most preferred combinations include F1-F4 combination, F5-F8 combination, F13-F16 combination or F17-F20 combination.

As described herein, it is contemplated to provide a cell (or population of cells), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which the expression of CD3E and FKBP1A is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 35 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of, the sequence: [guide domain]-SEQ ID NO: 7811. In embodiments, one or more nRNA molecules, for example, all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, eg 3, 3' and/or 5' phosphothioate bonds, and/or one or more, eg 3, 3' and/or 5' 2'-OMe modifications. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or cell population) as RNP, eg, by electroporation. In embodiments, an RNP comprising each nRNA molecule is mixed with cells and administered simultaneously, for example, in a single electroporation step. In other embodiments, RNPs may be administered sequentially.

Table 35: Examples of preferred first, second and (optionally) third nRNA targeting domains that can be used in combination to reduce or eliminate CD3E and FKBP1A expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively C1 SEQ ID NO: 10729 and SEQ ID NO: 6693 C25 SEQ ID NO: 10701 and SEQ ID NO: 6693 C2 SEQ ID NO: 10729 and SEQ ID NO: 6705 C26 SEQ ID NO: 10701 and SEQ ID NO: 6705 C3 SEQ ID NO: 10729 and SEQ ID NO: 6694 C27 SEQ ID NO: 10701 and SEQ ID NO: 6694 C4 SEQ ID NO: 10729 and SEQ ID NO: 6708 C28 SEQ ID NO: 10701 and SEQ ID NO: 6708 C5 SEQ ID NO: 10729 and SEQ ID NO: 6699 C29 SEQ ID NO: 10701 and SEQ ID NO: 6699 C6 SEQ ID NO: 10729 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C30 SEQ ID NO: 10701 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C7 SEQ ID NO: 10719 and SEQ ID NO: 6693 C31 SEQ ID NO: 10700 and SEQ ID NO: 6693 C8 SEQ ID NO: 10719 and SEQ ID NO: 6705 C32 SEQ ID NO: 10700 and SEQ ID NO: 6705 C9 SEQ ID NO: 10719 and SEQ ID NO: 6694 C33 SEQ ID NO: 10700 and SEQ ID NO: 6694 C10 SEQ ID NO: 10719 and SEQ ID NO: 6708 C34 SEQ ID NO: 10700 and SEQ ID NO: 6708 C11 SEQ ID NO: 10719 and SEQ ID NO: 6699 C35 SEQ ID NO: 10700 and SEQ ID NO: 6699 C12 SEQ ID NO: 10719 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C36 SEQ ID NO: 10700 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C13 SEQ ID NO: 10764 and SEQ ID NO: 6693 C37 SEQ ID NO: 10722 and SEQ ID NO: 6693 C14 SEQ ID NO: 10764 and SEQ ID NO: 6705 C38 SEQ ID NO: 10722 and SEQ ID NO: 6705 C15 SEQ ID NO: 10764 and SEQ ID NO: 6694 C39 SEQ ID NO: 10722 and SEQ ID NO: 6694 C16 SEQ ID NO: 10764 and SEQ ID NO: 6708 C40 SEQ ID NO: 10722 and SEQ ID NO: 6708 C17 SEQ ID NO: 10764 and SEQ ID NO: 6699 C41 SEQ ID NO: 10722 and SEQ ID NO: 6699 C18 SEQ ID NO: 10764 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C42 SEQ ID NO: 10722 and SEQ ID NO: 6705 and SEQ ID NO: 6694 C19 SEQ ID NO: 10689 and SEQ ID NO: 6693 C20 SEQ ID NO: 10689 and SEQ ID NO: 6705 C21 SEQ ID NO: 10689 and SEQ ID NO: 6694 C22 SEQ ID NO: 10689 and SEQ ID NO: 6708 C23 SEQ ID NO: 10689 and SEQ ID NO: 6699 C24 SEQ ID NO: 10689 and SEQ ID NO: 6705 and SEQ ID NO: 6694

As described herein, it is contemplated to provide a cell (or population of cells), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which expression of TRAC and FKBP1A is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 36 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of, the sequence: [guide domain]-SEQ ID NO: 7811. In embodiments, one or more nRNA molecules, for example, all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, eg 3, 3' and/or 5' phosphothioate bonds, and/or one or more, eg 3, 3' and/or 5' 2'-OMe modifications. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or population of cells, eg, as described herein) as RNP, eg, by electroporation. In embodiments, an RNP comprising each nRNA molecule is mixed with cells and administered simultaneously, for example, in a single electroporation step. In other embodiments, RNPs may be administered sequentially.

Table 36: Examples of preferred first, second and (optionally) third nRNA targeting domains that can be used in combination to reduce or eliminate TRAC and FKBP1A expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively D1 SEQ ID NO: 5569 and SEQ ID NO: 6693 D19 SEQ ID NO: 5592 and SEQ ID NO: 6693 D2 SEQ ID NO: 5569 and SEQ ID NO: 6705 D20 SEQ ID NO: 5592 and SEQ ID NO: 6705 D3 SEQ ID NO: 5569 and SEQ ID NO: 6694 D21 SEQ ID NO: 5592 and SEQ ID NO: 6694 D4 SEQ ID NO: 5569 and SEQ ID NO: 6708 D22 SEQ ID NO: 5592 and SEQ ID NO: 6708 D5 SEQ ID NO: 5569 and SEQ ID NO: 6699 D23 SEQ ID NO: 5592 and SEQ ID NO: 6699 D6 SEQ ID NO: 5569 and SEQ ID NO: 6705 and SEQ ID NO: 6694 D24 SEQ ID NO: 5592 and SEQ ID NO: 6705 and SEQ ID NO: 6694 D7 SEQ ID NO: 5586 and SEQ ID NO: 6693 D25 SEQ ID NO: 5599 and SEQ ID NO: 6693 D8 SEQ ID NO: 5586 and SEQ ID NO: 6705 D26 SEQ ID NO: 5599 and SEQ ID NO: 6705 D9 SEQ ID NO: 5586 and SEQ ID NO: 6694 D27 SEQ ID NO: 5599 and SEQ ID NO: 6694 D10 SEQ ID NO: 5586 and SEQ ID NO: 6708 D28 SEQ ID NO: 5599 and SEQ ID NO: 6708 D11 SEQ ID NO: 5586 and SEQ ID NO: 6699 D29 SEQ ID NO: 5599 and SEQ ID NO: 6699 D12 SEQ ID NO: 5586 and SEQ ID NO: 6705 and SEQ ID NO: 6694 D30 SEQ ID NO: 5599 and SEQ ID NO: 6705 and SEQ ID NO: 6694 D13 SEQ ID NO: 5587 and SEQ ID NO: 6693 D31 SEQ ID NO: 5600 and SEQ ID NO: 6693 D14 SEQ ID NO: 5587 and SEQ ID NO: 6705 D32 SEQ ID NO: 5600 and SEQ ID NO: 6705 D15 SEQ ID NO: 5587 and SEQ ID NO: 6694 D33 SEQ ID NO: 5600 and SEQ ID NO: 6694 D16 SEQ ID NO: 5587 and SEQ ID NO: 6708 D34 SEQ ID NO: 5600 and SEQ ID NO: 6708 D17 SEQ ID NO: 5587 and SEQ ID NO: 6699 D35 SEQ ID NO: 5600 and SEQ ID NO: 6699 D18 SEQ ID NO: 5587 and SEQ ID NO: 6705 and SEQ ID NO: 6694 D36 SEQ ID NO: 5600 and SEQ ID NO: 6705 and SEQ ID NO: 6694

The most preferred combinations include the D2 combination, the D4 combination, the D20 combination, or the D22 combination.

As described herein, it is contemplated to provide a cell (or cell population), e.g., an immune effector cell, e.g., a CAR-expressing immune effector cell, e.g., as described herein, in which expression of TRBC and FKBP1A is reduced or abolished. While it is contemplated that nRNAs comprising any of the targeting domains disclosed herein for each of these targets may be used in combination, the most preferred targeting domain sequences to be used, for example in combination, are shown in Table 37 below. In embodiments, each of the nRNA molecules is presented in a double guide RNA format and includes a crRNA including, for example consisting of, the sequence of [guide domain]-SEQ ID NO: 6607, and tracr, including, for example consisting of, the sequence of SEQ ID NO: 6660 In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of the sequence: [guide domain]-SEQ ID NO: 6601. In other embodiments, each of the nRNA molecules is presented in a single guide RNA format, including, for example, consisting of, the sequence: [guide domain]-SEQ ID NO: 7811. In embodiments, one or more nRNA molecules, for example, all nRNA molecules, further include one or more modifications described in this application, for example, include one or more, eg 3, 3' and/or 5' phosphothioate bonds, and/or one or more, eg 3, 3' and/or 5' 2'-OMe modifications. In embodiments, each of the nRNA molecules is complexed to a Cas9 molecule (eg, as described herein) and delivered to a cell (or cell population) as RNP, eg, by electroporation. In embodiments, RNPs including each nRNA molecule are mixed with cells and administered simultaneously, for example, in a single electroporation step. In other embodiments, RNPs may be administered sequentially.

Table 37: Examples of preferred first, second and (optionally) third nRNA targeting domains that can be used in combination to reduce or eliminate TRBC and FKBP1A expression in a cell (as described herein). Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively Combination number SEQ ID NOs: guide domains of the first nRNA, the second nRNA, and optionally the third nRNA, respectively E1 SEQ ID NO: 5719 and SEQ ID NO: 6693 E19 SEQ ID NO: 5696 and SEQ ID NO: 6693 E2 SEQ ID NO: 5719 and SEQ ID NO: 6705 E20 SEQ ID NO: 5696 and SEQ ID NO: 6705 E3 SEQ ID NO: 5719 and SEQ ID NO: 6694 E21 SEQ ID NO: 5696 and SEQ ID NO: 6694 E4 SEQ ID NO: 5719 and SEQ ID NO: 6708 E22 SEQ ID NO: 5696 and SEQ ID NO: 6708 E5 SEQ ID NO: 5719 and SEQ ID NO: 6699 E23 SEQ ID NO: 5696 and SEQ ID NO: 6699 E6 SEQ ID NO: 5719 and SEQ ID NO: 6705 and SEQ ID NO: 6694 E24 SEQ ID NO: 5696 and SEQ ID NO: 6705 and SEQ ID NO: 6694 E7 SEQ ID NO: 5694 and SEQ ID NO: 6693 E25 SEQ ID NO: 5711 and SEQ ID NO: 6693 E8 SEQ ID NO: 5694 and SEQ ID NO: 6705 E26 SEQ ID NO: 5711 and SEQ ID NO: 6705 E9 SEQ ID NO: 5694 and SEQ ID NO: 6694 E27 SEQ ID NO: 5711 and SEQ ID NO: 6694 E10 SEQ ID NO: 5694 and SEQ ID NO: 6708 E28 SEQ ID NO: 5711 and SEQ ID NO: 6708 E11 SEQ ID NO: 5694 and SEQ ID NO: 6699 E29 SEQ ID NO: 5711 and SEQ ID NO: 6699 E12 SEQ ID NO: 5694 and SEQ ID NO: 6705 and SEQ ID NO: 6694 E30 SEQ ID NO: 5711 and SEQ ID NO: 6705 and SEQ ID NO: 6694 E13 SEQ ID NO: 5706 and SEQ ID NO: 6693 E14 SEQ ID NO: 5706 and SEQ ID NO: 6705 E15 SEQ ID NO: 5706 and SEQ ID NO: 6694 E16 SEQ ID NO: 5706 and SEQ ID NO: 6708 E17 SEQ ID NO: 5706 and SEQ ID NO: 6699 E18 SEQ ID NO: 5706 and SEQ ID NO: 6705 and SEQ ID NO: 6694

Most preferred combinations include combination E2, combination E4, combination E8 or combination E10.

Without being limited by theory, it has also been unexpectedly shown in this application that targeting two or more target sequences located in different genes can cause mutations (for example, insertions or deletions of one or more nucleic acid residues) in each of the targeted sites, which leads to a decrease or elimination of the expression of two or more proteins in the cell. This application describes combinations of nRNA that target two or more different genes of interest.

As described herein, in the case of using more than one nRNA molecule (or a CRISPR system including more than one nRNA molecule, for example, a CRISPR system including a first nRNA molecule, and a CRISPR system including a second nRNA molecule, for example, where each molecule The nRNA is complexed to a Cas molecule, e.g. a Cas9 molecule, e.g. as described herein), more than one nRNA molecule may be introduced into a cell at the same time, e.g., in one injection step, e.g., in one electroporation step. Alternatively, more than one nRNA molecule (or CRISPR systems including said nRNA molecules) may be introduced into the cell in more than one step, eg, more than one electroporation. In the case of multiple administration steps, the steps may be separated by a period of several hours, days, or weeks, such as a period of 1 hour, 2 hours, 5 hours, 10 hours, 15 hours, 20 hours, 24 hours, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more.

IX. nRNA properties

The present application has also surprisingly shown that nRNA molecules and CRISPR systems comprising said nRNA molecules produce similar or identical indel profiles in different cell types using different delivery methods and using different crRNA/tracr components. Without being limited by theory, it is believed that some indel profiles may be preferred over others. For example, indels that predominantly include insertions and/or deletions that result in "frameshift mutations" (e.g., insertions or deletions of 1 or 2 base pairs, or any insertion or deletion where n/3 is not an integer ( where n=number of nucleotides in the insertion or deletion)) may be effective in reducing or eliminating the expression of a functional protein. Similarly, indels that predominantly include "large deletions" (deletions greater than 10, 11, 12, 13, 14, 15, 20, 25, or 30 nucleotides) can also be effective, for example, in removing important regulatory sequences such as promoter binding sites, which can also improve functional protein expression. Although the indel profiles produced using this nRNA/CRISPR system have surprisingly been found to be consistently reproducible in different cell types as described herein, not every single indel structure will necessarily be produced in a given cell when the nRNA/CRISPR system is introduced.

Thus, the invention provides nRNA molecules that create a preferred indel profile or structure, for example, that have indel profiles or structures predominantly consisting of frameshift mutation(s) and/or large deletions. Such nRNA molecules can be selected by evaluating the profile or structure of the indels generated by a candidate nRNA molecule in a test cell (eg, a HEK293 cell or a cell of interest, eg, a T cell) using NGS, as described herein. As shown in the Examples, nRNA molecules have been found which, when introduced into the desired population of cells, result in a population of cells comprising a significant percentage of cells containing a frameshift mutation in the target gene. In some cases, the percent frameshift mutation is up to 75%, 80%, 85%, 90%, or more. Thus, the invention provides cell populations that include at least about 40% cells (e.g., at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least at least about 99%) containing a frameshift mutation, for example, as described herein, at or near the target site of the nRNA molecule described herein. The invention also provides cell populations that include at least about 50% cells (e.g., at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%) containing a frameshift mutation, for example, as described in this application, at or near the target site of the nRNA molecule described in this application.

Thus, the invention provides methods for selecting nRNA molecules for use in therapeutic methods according to the invention, including: 1) obtaining a plurality of nRNA molecules to a target of interest, 2) evaluating the profile or structure of indels created using said nRNA molecules, 3) selecting a molecule an nRNA that forms an indel profile or structure consisting predominantly of frameshift mutations, large deletions, or a combination thereof, and 4) using said selected nRNAs in the methods of the invention.

The invention also provides cell alteration methods and altered cells wherein a particular indel profile is consistently produced by a given nRNA/CRISPR system in that cell type. Indel profiles comprising the top 5 most frequently occurring indels observed with the nRNA/CRISPR systems described herein are disclosed, for example, in the Examples. As shown in the examples, cell populations were created in which a significant percentage of cells included one of the top 5 indels (e.g., cell populations in which one of the top 5 indels was present in more than 30%, more than 40%, more than 50 %, greater than 60% or more of the cells in the population.Thus, the invention provides cells, for example, immune effector cells, for example, CAR-expressing immune effector cells (as described in this application), which include any indel of the top 5 indels observed with a given nRNA/CRISPR system.Furthermore, the invention provides populations of cells, e.g., immune effector cells, e.g. include a high percentage of cells comprising one of the top 5 indels described herein for a given nRNA/CRISPR system. cent" refers to at least about 50% (e.g., at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%) of cells in a population that includes one of Top 5 indels described in this application for this nRNA/CRISPR system. In other embodiments, the cell population comprises at least about 25% (for example, from about 25% to about 60%, for example, from about 25% to about 50%, for example, from about 25% to about 40%, for example, from about 25% to about 35%) of cells that contain one of the top 5 indels described herein for a given nRNA/CRISPR system. In embodiments, the top 5 indels for a given nRNA/CRISPR system that targets TRAC are shown in Figure 34A, Figure 34B, and Figure 49. In embodiments, the top 5 indels for a given nRNA/CRISPR system that target B2M are shown in Figure 36 and Figure 48. In embodiments, the top 5 indels for a given nRNA/CRISPR system that targeted CIITA are shown in Figure 38, Figure 41, Figure 44, and Figure 50. In embodiments, the top 5 indels for a given nRNA system /CRISPR, which specifically interacts with FKBP1A, are shown in Figure 53.

It has also been found that some nRNA molecules do not create indels in non-target sequences in the genome of a given type of target cell, or create indels outside target sites at a very low frequency (e.g., <5% of cells in a population) compared to the frequency of indels created in target site. Thus, the invention provides nRNA molecules and CRISPR systems that do not exhibit the formation of off-target indels in a given type of target cell, or that create off-target indels at a frequency of <5%. In embodiments of the invention, nRNA molecules and CRISPR systems are provided that do not exhibit off-target indel creation in a given type of target cell. Thus, the invention also provides a cell, e.g. a population of cells, e.g. immune effector cells, e.g. CAR-expressing immune effector cells, e.g. as described herein (e.g., a frameshifted indel or any of the top 5 indels produced by this nRNA/CRISPR system, e.g., as described herein), but does not include an indel anywhere outside the target of the nRNA molecule. In other embodiments, the invention also provides a population of cells, e.g., immune effector cells, e.g., CAR-expressing immune effector cells, e.g., as described herein, which include >50% of cells that contain an indel at or near the target site. an nRNA molecule as described herein (e.g., a frameshifted indel or any of the top 5 indels generated by a given nRNA/CRISPR system, e.g., as described herein), but which comprise less than 5%, e.g., less than 4%, less than 3%, less than 2%, or less than 1% of cells that include an indel at any site outside the target of the nRNA molecule.

X. Shipping/Design

The components, for example the Cas9 molecule and/or the nRNA molecule, may be delivered, formulated into a dosage form, or administered in various forms. As a non-limiting example, an nRNA molecule and a Cas9 molecule can be included in one or more compositions, directly delivered, or introduced into a cell in which a genome editing event is to be performed. Alternatively, a nucleic acid encoding one or more components, such as a Cas9 molecule and/or an nRNA molecule, can be included in one or more compositions, delivered, or administered. In one aspect, the nRNA molecule is in the form of DNA encoding the nRNA molecule and the Cas9 molecule is in the form of DNA encoding the Cas9 molecule. In one embodiment, the nRNA molecule and the Cas9 molecule are encoded by separate nucleic acid molecules. In one embodiment, the nRNA molecule and the Cas9 molecule are encoded by the same nucleic acid molecule. In one aspect, the nRNA molecule is in the form of RNA and the Cas9 molecule is in the form of DNA encoding the Cas9 molecule. In one embodiment, the nRNA molecule contains one or more modifications, for example, as described in this application. In one aspect, the nRNA molecule is in the form of an RNA and the Cas9 molecule is in the form of an mRNA encoding a Cas9 molecule. In one aspect, the nRNA molecule is in the form of RNA and the Cas9 molecule is in the form of a protein. In one embodiment, the nRNA and the Cas9 molecule are presented as a ribonucleoprotein complex (RNP). In one aspect, the nRNA molecule is in the form of DNA encoding the nRNA molecule and the Cas9 molecule is in the form of a protein.

Delivery can be accomplished, for example, by electroporation (eg, as known in the art) or other method that renders the cell membrane permeable to nucleic acid molecules and/or polypeptides. Additional methods for membrane permeabilization are known in the art and include, for example, cell compression (for example, as described in WO2015/023982 and WO2013/059343, the contents of which are hereby incorporated by reference in their entirety), nanoneedles (for example, as described in Chiappini et al. ., Nat. Mat., 14; 532-39 or US2014/0295558, the contents of which are hereby incorporated by reference in their entirety) and nanostraws (e.g., as described in Xie, ACS Nano, 7(5); 4351-58, the contents of which are incorporated herein by reference in their entirety).

In the case where the component is delivered encoded in DNA, the DNA typically includes a region of regulation, such as containing a promoter, to effect expression. Suitable promoters for Cas9 molecular sequences include CMV, EF-1 alpha, MSCV, PGK, CAG promoters. Suitable promoters for nRNA include the H1, EF-1a and U6 promoters. Promoters with similar or different activities can be selected to direct the expression of the components. Sequences encoding the Cas9 molecule may contain a nuclear localization signal (NLS), such as NLS SV40. In one embodiment, a promoter for a Cas9 molecule or an nRNA molecule can be, independently, inducible, tissue-specific, or cell-specific.

Delivery of a Cas9 molecule and/or an nRNA molecule via DNA

DNA encoding Cas9 molecules and/or nRNA molecules can be administered to subjects or delivered to cells using methods known in the art or described herein. For example, Cas9 encoding and/or gRNA encoding DNA can be delivered, for example, using vectors (eg, viral or non-viral vectors), non-vector based methods (eg, using naked DNA or DNA complexes), or a combination thereof.

In some embodiments, Cas9 and/or nRNA encoding DNA is delivered by a vector (eg, viral vector/virus, plasmid, minicircle, or nanoplasmid).

The vector may include a sequence that encodes a Cas9 molecule and/or an nRNA molecule. The vector may also include a sequence encoding a signal peptide (eg, for nuclear localization, nucleolar localization, mitochondrial localization) fused to, for example, the sequence of a Cas9 molecule. For example, the vector may include one or more nuclear localization sequences (eg, from SV40) fused to a sequence encoding a Cas9 molecule.

One or more regulatory elements may be included in the vectors, for example, a promoter, an enhancer, an intron, a polyadenylation signal, a Kozak consensus sequence, an internal ribosome entry site (IRES), a 2A sequence, and a splicing acceptor or donor. In some embodiments, the promoter is recognized by RNA polymerase II (eg, the CMV promoter). In other embodiments, the promoter is recognized by RNA polymerase III (eg, the U6 promoter). In some embodiments, the promoter is a regulated promoter (eg, an inducible promoter). In other embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is a tissue-specific promoter. In some embodiments, the promoter is a viral promoter. In other embodiments, the promoter is a non-viral promoter.

In some embodiments, the delivery vector or vehicle is a minicircle. In some embodiments, the delivery vector or carrier is a nanoplasmid.

In some embodiments, the delivery vector or carrier is a viral vector (eg, for generating recombinant viruses). In some embodiments, the virus is a DNA virus (eg, dsDNA or ssDNA virus). In other embodiments, the virus is an RNA virus (eg, an ssRNA virus).

Exemplary viral vectors/viruses include, for example, retroviruses, lentiviruses, adenovirus, adeno-associated virus (AAV), vaccinia viruses, poxviruses, and herpes simplex viruses. Viral vector technology is known in the art and is described, for example, in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY, and other virology and molecular biology textbooks.

In some embodiments, the virus infects dividing cells. In other embodiments, the virus infects non-dividing cells. In some embodiments, the virus infects dividing and non-dividing cells. In some embodiments, the implementation of the virus can be integrated into the genome of the host. In some embodiments, the implementation of the virus is engineered with reduced immunity, for example, in humans. In some embodiments, the virus is replication competent. In other embodiments, the virus is replication defective, for example, one or more coding regions of genes required for additional rounds of virion replication and/or virus packaging have been replaced with other genes or deleted. In some embodiments, the implementation of the virus causes transient expression of the Cas9 molecule and/or the nRNA molecule. In other embodiments, the virus induces long-term, e.g., for at least 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 1 year, 2 years, or persistent expression of the Cas9 molecule and/or the nRNA. The ability of viruses to pack can vary, for example, from at least about 4 tons to at least about 30 tons, for example, at least about 5 tons, 10 tons, 15 tons, 20 tons, 25 tons, 30 tons, 35 tons , 40 tons, 45 tons or 50 tons.

In some embodiments, the implementation of Cas9 - and/or nRNA-coding DNA is delivered using a recombinant retrovirus. In some embodiments, the retrovirus (eg, Moloney murine leukemia virus) includes a reverse transcriptase, eg, which allows integration into the host genome. In some embodiments, the retrovirus is replication competent. In other embodiments, the retrovirus is replication defective, eg, one or more coding regions of genes required for additional rounds of virion replication and/or virus packaging have been replaced by other genes or deleted.

In some embodiments, Cas9 and/or nRNA encoding DNA is delivered with a recombinant lentivirus. For example, a lentivirus is replication defective, eg, lacking one or more of the genes required for virus replication.

In some embodiments, Cas9 and/or nRNA encoding DNA is delivered using a recombinant adenovirus. In some embodiments, the implementation of the adenovirus is engineered with reduced immunity in humans.

In some embodiments, the implementation of Cas9 - and/or nRNA-coding DNA is delivered using recombinant AAV. In some embodiments, the implementation of the AAV may include its genome in the genome of the host cell, for example, target cells, as described in this application. In some embodiments, the AAV is a self-complementary adeno-associated virus (scAAV), such as scAAV, that contains both strands that anneal to each other to form double-stranded DNA. Serotypes of AAV that can be used in the disclosed methods include, for example, AAV1, AAV2 modified by AAV2 (e.g., with modifications Y444F, Y500F, Y730F, and/or S662V), AAV3, modified by AAV3 (e.g., with modifications Y705F, Y731F, and/ or T492V), AAV4, AAV5, AAV6, modified AAV6 (for example, with modifications S663V and/or T492V), AAV8, AAV 8.2, AAV9, AAVrh10, and pseudotyped AAVs such as AAV2/8, AAV2/5 and AAV2/6 , can also be used in the disclosed methods.

In some embodiments, the implementation of Cas9 - and/or nRNA-coding DNA is delivered using a hybrid virus, for example, a hybrid of one or more of the viruses described in this application.

The packaging cell is used to form a viral particle that is capable of infecting a host cell or a target cell. Such a cell includes a 293 cell that can package an adenovirus and a ψ2 cell or a PA317 cell that can package a retrovirus. The viral vector used in gene therapy is usually produced by a producer cell line that packages the nucleic acid vector into a viral particle. The vector typically contains the minimum viral sequences required for packaging and subsequent integration into a host or target cell (as appropriate), with other viral sequences replaced by an expression cassette encoding the protein to be expressed. For example, an AAV vector used in gene therapy typically contains only inverted terminal repeat (ITR) sequences from the AAV genome that are required for gene packaging and expression in a host or target cell. The missing viral functions are provided upon delivery by the packaging cell line. The viral DNA is then packaged into a cell line that contains a helper plasmid encoding other AAV genes, namely rep and cap, but lacking the ITR sequence. The cell line is also infected with adenovirus as a helper. The helper virus causes replication of the AAV vector and expression of the AAV genes from the helper plasmid. The helper plasmid is not packaged in significant quantities due to the lack of ITR sequences. Adenovirus contamination can be reduced, for example, by heat treatment, to which adenovirus is more sensitive than AAV.

In an embodiment, the viral vector has the ability to recognize a cell type and/or tissue type. For example, the viral vector may be pseudotyped with a different/alternative viral envelope glycoprotein; engineered with a cell type specific receptor (eg, genetic modification of viral envelope glycoproteins to include specific ligands such as a peptide ligand, single chain antibody, growth factor); and/or designed with a dual specificity molecular bridge, one end of which recognizes a viral glycoprotein and the other end recognizes a molecule on the surface of the target cell (eg, receptor ligand, monoclonal antibody, avidin-biotin and chemical conjugation).

In one embodiment, the viral vector provides specificity for a particular cell type. For example, a tissue-specific promoter can be designed to limit the expression of the transgene (Cas 9 and nRNA) only in the target cell. Vector specificity can also be mediated by miRNA-dependent control of transgene expression. In one embodiment, the viral vector has increased efficiency in fusing the viral vector and the target cell membrane. For example, a fusion protein, such as fused hemagglutin (HA), can be included to increase uptake of the virus by the cells. In one embodiment, the viral vector has nuclear localization capability. For example, a virus that requires cell wall destruction (during cell division) and therefore will not infect a non-dividing cell can be modified to include a nuclear localization peptide in the virus matrix protein, thus allowing transduction of non-proliferating cells.

In some embodiments, DNA encoding Cas9 and/or nRNA is delivered using a non-vector method (eg, using naked DNA or DNA complexes). For example, DNA can be delivered using, for example, organo-modified silica or silicate (Ormosil), electroporation, gene gun, sonoporation, magnetofection, lipid-mediated transfection, dendrimers, inorganic nanoparticles, calcium phosphate, or combinations thereof.

In some embodiments, DNA encoding Cas9 and/or nRNA is delivered using a combination of a vector and a non-vector method. For example, a virosome contains a liposome in combination with an inactivated virus (eg, HIV or influenza virus), which may allow for more efficient gene transfer, eg, into a cell of the airway epithelium, compared to the viral or liposomal method alone.

In one embodiment, the delivery vehicle is a non-viral vector. In one embodiment, the non-viral vector is an inorganic nanoparticle (eg, associated with a payload on the surface of the nanoparticle). Examples of inorganic nanoparticles include, for example, magnetic nanoparticles (eg Fe lvln0 ₂ ) or silicon dioxide. The outer surface of the nanoparticle can be conjugated to a positively charged polymer (eg, polyethyleneimine, polylysine, polyserine) to allow binding (eg, conjugation or capture) of the payload. In one embodiment, the non-viral vector is an organic nanoparticle (eg, enclosing a payload within a nanoparticle). Exemplary organic nanoparticles include, for example, SNALP liposomes, which contain cationic lipids along with neutral accessory lipids that are coated with polyethylene glycol (PEG) and a lipid-coated protamine-nucleic acid complex.

Exemplary lipids and/or polymers for transferring CRISPR systems or nucleic acids, for example, vectors encoding CRISPR systems or components thereof, include, for example, those described in WO2011/076807, WO2014/136086, WO2005/060697, WO2014/140211, WO2012/031046, WO2013/103467, WO2013/006825, WO2012/006378, WO2015/095340 and WO2015/095346, the contents of which are incorporated by reference in their entirety. In one embodiment, the carrier has targeting modifications to increase uptake of nanoparticles and liposomes by target cells, such as cell-specific antigens, monoclonal antibodies, single chain antibodies, aptamers, polymers, sugars, and cell-penetrating peptides. In one embodiment, fusogenic and endosome destabilizing peptides/polymers are used in the vehicle. In one embodiment, the carrier undergoes an acid-induced conformational change (eg, to accelerate endosomal load release). In one embodiment, a stimulus-cleavable polymer is used, for example, for release in a cellular compartment. For example, disulfide cationic polymers that are cleavable in a reducing cellular environment can be used.

In one embodiment, the delivery vehicle is a biological non-viral delivery vehicle. In one embodiment, the carrier is an attenuated bacterium (e.g., naturally occurring or engineered to be invasive but attenuated to prevent pathogenesis and to express the transgene (e.g., Listeria monocytogens, some strains of Salmonella, Bifidobacterium longum, and modified Escherichia coli), bacteria having nutritional and tissue-specific tropism for specific target tissues, bacteria with modified surface proteins to alter target tissue specificity). In one embodiment, the carrier is a genetically modified bacteriophage (eg, recombinant phages with high packaging capacity, less immunogenic, containing mammalian sequences to support the plasmid, and including specific ligands). In one embodiment, the carrier is a mammalian virus-like particle. For example, modified viral particles can be obtained (eg, by purifying "blank" particles, followed by assembly of the virus ex vivo with the desired load). The carrier can also be designed to include targeting ligands to alter tissue specificity. In one embodiment, the carrier is a biological liposome. For example, a biological liposome is a phospholipid-based particle derived from human cells (e.g., erythrocyte shadows, which are erythrocyte membranes in the form of spherical structures, obtained from a subject (e.g., tissue targeting can be performed by attaching various tissue or cell-specific ligands ) or secretory exosomes, subject-derived (i.e., patient) membrane-bound nanovesicles (30-100 nm) of endocytic origin (eg, can be obtained from various cell types and can therefore be taken up by cells without the need for targeting ligands).

In one embodiment, one or more nucleic acid molecules (eg, DNA molecules) other than the components of the Cas system, eg, a component of the Cas9 molecule and/or a component of the nRNA molecule described herein, are delivered. In one embodiment, the nucleic acid molecule is delivered simultaneously with the delivery of one or more components of the Cas system. In one embodiment, the nucleic acid molecule is delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks or 4 weeks) delivery of one or more components of the Cas9 system. In one embodiment, the nucleic acid molecule is delivered in a different manner than one or more components of the Cas9 system, for example, a component of the Cas9 molecule and/or a component of the nRNA molecule. The nucleic acid molecule can be delivered by any of the delivery methods described in this application. For example, a nucleic acid molecule can be delivered by a viral vector, such as an integration-deficient lentivirus, and a component of the Cas9 molecule and/or a component of the gRNA molecule can be delivered by electroporation, such as such that nucleic acid-mediated toxicity (e.g. , DNA) could be reduced. In one embodiment, the nucleic acid molecule encodes a therapeutic protein, for example, the protein described in this application. In one embodiment, the nucleic acid molecule encodes an RNA molecule, such as the RNA molecule described in this application.

Delivery of RNA encoding the Cas9 molecule

RNA encoding Cas9 molecules (e.g., active Cas9 molecules, inactive Cas9 molecules, or inactive Cas9 fusion proteins) and/or nRNA molecules can be delivered to cells, for example, target cells described in this application, using known or described in the present application methods. For example, Cas9-coding and/or gRNA-coding RNA can be delivered, for example, by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, or a combination thereof.

Delivery of the Cas9 molecule as a protein

Cas9 molecules (eg, active Cas9 molecules, inactive Cas9 molecules, or inactive Cas9 fusion proteins) can be delivered to cells using methods known or described herein. For example, Cas9 protein molecules can be delivered, for example, by microinjection, electroporation, lipid-mediated transfection, peptide-mediated delivery, cell compression or abrasion (eg, nanoneedles), or combinations thereof. Delivery may be accompanied by the introduction of DNA encoding nRNA or nRNA.

In an embodiment, the Cas9 molecule, eg, as described herein, is delivered as a protein, and the nRNA molecule is delivered in one or more RNAs (eg, lncRNA or sRNA, as described herein). In embodiments, the Cas9 protein is complexed with an nRNA molecule prior to delivery to the cell, eg, as described herein, as a ribonucleoprotein complex ("RNP"). In embodiments, the implementation of the RNP can be delivered to cells, for example, described in this application, using any known method, such as electroporation. As described herein, and without being limited by theory, it may be preferable to use an nRNA molecule and a Cas9 molecule that result in a high % editing of the target sequence (e.g., >85%, >90%, >95%, >98% or > 99%) in a target cell, such as described in this application, even if the concentration of RNP delivered to the cell is reduced. Again, without being limited by theory, delivery of a reduced or low concentration of RNP comprising an nRNA molecule that results in a high % editing of the target sequence in the target cell (including at low concentration of RNP) may be beneficial as this may reduce the frequency and the number of edit events outside the target. In one aspect, when it is desired to use a low or reduced concentration of RNP, the following procedure may be used to generate the RNP:

1. Getting the Cas9 molecule and tracr in solution at a high concentration (eg, a concentration above the final concentration of RNP delivered to the cell) and balancing the two components;

2. Obtaining a crRNA molecule and balancing the components (with obtaining a solution of RNP with a high concentration);

3. Dilution of the RNP solution to the required concentration;

4. Delivery of the specified RNP in the specified required concentration to the target cells, for example, using electroporation.

The above procedure can be modified for use with ssRNA molecules by omitting step 2 above and, in step 1, getting the Cas9 molecule and the ssRNA molecule in solution at high concentration, followed by balancing the components. In embodiments, the Cas9 molecule and each component of the nRNA are provided in solution in a 1:2 ratio (Cas9:nRNA), such as a 1:2 molar ratio of the Cas9 :nRNA molecule. When using a lncRNA molecule, the ratio, for example the molar ratio, is 1:2:2 (Cas9:tracr:crRNA). In embodiments, the RNP is formed at a concentration of 20 μM or higher, for example, at a concentration of from about 20 μM to about 50 μM. In embodiments, the RNP is formed at a concentration of 10 μM or higher, for example, at a concentration of from about 10 μM to about 30 μM. In embodiments, RNP is diluted to a final concentration of 10 μM or less (e.g., a concentration of about 0.01 μM to about 10 μM) in a solution containing a target cell (e.g., as described herein) for delivery to said target cell. . In embodiments, RNP is diluted to a final concentration of 3 μM or less (e.g., a concentration of about 0.01 μM to about 3 μM) in a solution containing a target cell (e.g., as described herein) for delivery to said target cell. . In embodiments, RNP is diluted to a final concentration of 1 μM or less (e.g., a concentration of about 0.01 μM to about 1 μM) in a solution containing a target cell (e.g., as described herein) for delivery to said target cell. . In embodiments, RNP is diluted to a final concentration of 0.3 μM or less (e.g., a concentration of about 0.01 μM to about 0.3 μM) in a solution containing a target cell (e.g., as described herein) for delivery to specified target cell. In embodiments, RNP is provided at a final concentration of approximately 3 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 1 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 0.3 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 0.1 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 0.05 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 0.03 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell. In embodiments, RNP is provided at a final concentration of approximately 0.01 μM in a solution containing a target cell (eg, as described herein) for delivery to said target cell.

Bimodal or differentiated component delivery

Separate delivery of components of the Cas system, for example, a component of the Cas9 molecule and a component of the nRNA molecule, and more specifically, delivery of the components in different ways, can increase efficiency, for example, by increasing tissue specificity and safety.

In an embodiment, the Cas9 molecule and the nRNA molecule are delivered in different ways, or as sometimes stated herein, in differentiated ways. Different or differentiated methods, as used herein, refer to delivery methods that confer different pharmacodynamic or pharmacokinetic properties on the respective component molecule, for example, a Cas9 molecule, an nRNA molecule, or a messenger nucleic acid. For example, delivery methods may result in different tissue distributions, different half-lives, or different temporal distributions, eg, in a selected compartment, tissue, or organ.

Some delivery methods, such as delivery with a nucleic acid vector that persists in the cell or progeny of the cell, such as by autonomous replication or insertion into the cellular nucleic acid, result in more stable expression and long-term presence of the component.

XI. Methods of treatment

The Cas systems, eg one or more nRNA molecules and one or more Cas molecules (eg Cas9 molecules) described herein, can be used to treat a disease in a mammal, eg a human. The terms "treat", "treated" and "treatment" include the introduction of Cas systems, for example one or more molecules of nRNA and one or more molecules of Cas9, into cells to prevent or delay the onset of symptoms, complications or biochemical signs of the disease, reduce the severity of symptoms or stopping or slowing down the further progression of the disease, condition or disorder. Treatment may be prophylactic (to prevent or delay the onset of the disease, or to prevent the onset of its clinical or subclinical symptoms) or therapeutic suppression or reduction in the severity of symptoms after the onset of the disease. Treatment can be measured by the therapeutic parameters described in this application. The "treatment" methods of the present invention also include administering to a subject cells altered by the introduction of the Cas system (e.g., one or more nRNA molecules and one or more Cas molecules) into said cells to cure, reduce the severity, or alleviate one or more symptoms. disease or condition, to prolong the health or survival of the subject beyond that expected in the absence of such treatment. For example, "treatment" includes alleviating a symptom of a disease in a subject by at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16% , 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85 %, 90%, 95% or more.

Methods of treatment/combination therapy

In another aspect of the present invention, there is provided a method comprising administering a cell of the invention, for example, a cell that includes or has ever included an nRNA molecule as described herein, to a subject. In embodiments, the cell has been modified by the introduction of an nRNA molecule such that a gene comprising a sequence complementary to the targeting domain of the nRNA molecule has been altered such that expression of the functional product of the gene has been reduced or abolished compared to an unmodified cell. In embodiments, the cell is further modified to express CAR, for example, as described herein. In embodiments, the cell is an immune effector cell, such as an NK cell or a T cell. In embodiments, the cell is allogeneic. In embodiments, the cell is autologous.

In another aspect, the present invention provides a method comprising administering an nRNA molecule, e.g., an nRNA molecule described herein, or a cell comprising or has ever included an nRNA molecule, e.g., an nRNA molecule described herein, to a subject in need thereof. In one embodiment, the subject has a disorder described in this application, for example, the subject has cancer, for example, the subject has a cancer that expresses the target antigen described in this application. In one embodiment, the subject is a human.

In another aspect, the invention relates to a method of treating a subject having a disease associated with the expression of an antigen associated with cancer, as described in this application, comprising administering to the subject an effective amount of an nRNA molecule, for example, an nRNA molecule described in this application, or a cell comprising or ever included an nRNA molecule, for example, the nRNA molecule described in this application.

In yet another aspect of the invention, a method of treating a subject having a disease associated with the expression of a tumor antigen (e.g., an antigen described herein) is provided, comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells), comprising or ever including an nRNA molecule, for example, an nRNA molecule described in this application, additionally including a CAR molecule, where the CAR molecule includes an antigen-binding domain, a transmembrane domain and an intracellular domain, while the specified intracellular domain includes a co-stimulatory domain and/or a primary signaling a domain where said antigen-binding domain binds to a disease-associated tumor antigen, such as a tumor antigen, as described herein.

In a related aspect of the invention, a method of treating a subject having a disease associated with the expression of a tumor antigen is provided. The method comprises administering to a subject an effective amount of an nRNA molecule, such as an nRNA molecule as described herein, or a cell that includes or has ever included an nRNA molecule, such as an nRNA molecule as described herein, in combination with an agent that increases the efficiency of the cell. , where:

an agent that increases the effectiveness of an immune cell is selected from one or more of the following:

a protein phosphatase inhibitor;

kinase inhibitor;

cytokine;

an immune inhibitory molecule inhibitor; or

an agent that reduces the level or activity of a T _REG cell.

In another aspect of the invention, a composition is provided comprising an immune effector cell (e.g., a population of immune effector cells) comprising or at any time including an nRNA molecule, e.g., an nRNA molecule described herein, for use in the treatment of a subject having a disease associated with expression of a tumor antigen, for example, a violation, as described in this application.

In some embodiments of any of the above methods or uses, a cell comprising or at any time including an nRNA described herein has been altered such that the expression of a functional gene product comprising a target sequence complementary to the nRNA guide domain has been reduced or eliminated. . In an embodiment, the expression of a functional gene product comprising a target sequence complementary to the nRNA guide domain has been abolished. In embodiments, the cell further expresses a CAR, for example, as described herein. In embodiments, the cell is allogeneic. In embodiments, the cell is autologous.

In some embodiments of any of the above methods or uses, the disease associated with the tumor antigen, e.g., the tumor antigen described herein, is selected from a proliferative disease, such as cancer or malignancy, or a precancerous condition, such as myelodysplasia, myelodysplastic syndrome, or preleukemia, or is a non-cancer indication associated with the expression of the tumor antigen described in this application. In one embodiment, the disease is a cancer described in this application, for example, a cancer described in this application as associated with the target described in this application. In one embodiment, the disease is hemoblastosis. In one embodiment, the hemoblastosis is leukemia. In one embodiment, the cancer is selected from the group consisting of one or more acute leukemias, including, without limitation, B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), acute lymphoid leukemia ( ALL); one or more chronic leukemias, including, without limitation, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic or hematologic conditions including, but not limited to, B-cell prolymphocytic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT -lymphoma, mantle cell lymphoma, marginal cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, Waldenström's macroglobulinemia and preleukemia, which are a group of diverse hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and a disease associated with the expression of the tumor antigen described in this application, which includes, without limitation, atypical and/or non-classical forms of cancer, malignant neoplasms, precancerous conditions or proliferative diseases characterized by the expression of a tumor antigen, as described in this application; and any combination of them. In another embodiment, the disease associated with the tumor antigen described in this application is a solid tumor.

In some embodiments, the methods or uses are carried out in combination with an agent that increases the efficacy of an immune effector cell, such as an agent as described herein.

In any of the above methods or uses, the disease associated with tumor antigen expression is selected from the group consisting of proliferative disease, precancerous condition, cancer, and a non-cancer indication associated with tumor antigen expression.

The cancer may be a hemoblastosis, for example, selected from one or more of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T -ALL), chronic myelogenous leukemia (CML), B-cell prolymphocytic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small or large follicular cell lymphoma, malignant lymphoproliferative conditions, MALT - lymphoma, mantle cell lymphoma, marginal zone cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, Waldenström's macroglobulinemia and preleukemia.

The cancer may also be selected from colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung carcinoma, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's disease lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer, childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis carcinoma, neoplasia of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal canal tumors, brainstem gliomas, adenomas pituitary tumors, Kaposi's sarcoma, epidermoid cancer, squamous cell carcinoma, T-cell lymphoma, environmental cancers, combinations of said cancers, and metastatic lesions of said cancers.

In some embodiments of the methods or uses described herein, the cell is administered in combination with an agent that enhances the efficacy of an immune effector cell, for example, one or more of a protein phosphatase inhibitor, a kinase inhibitor, a cytokine, an immune inhibitory molecule inhibitor; or an agent that reduces the level or activity of a T _REG cell.

In some embodiments of the methods or uses described herein, the protein phosphatase inhibitor is an SHP-1 inhibitor and/or an SHP-2 inhibitor.

In other embodiments of the methods or uses described herein, the kinase inhibitor is selected from one or more of a CDK4 inhibitor, a CDK4/6 inhibitor (e.g., palbociclib), a BTK inhibitor (e.g., ibrutinib or RN-486), an mTor inhibitor (e.g. , rapamycin or everolimus (RAD001)), an MNK inhibitor, or a dual P13K/mTOR inhibitor. In one embodiment, the BTK inhibitor does not reduce or inhibits the kinase activity of interleukin-2-inducible kinase (ITK).

In other embodiments of the methods or uses described herein, the agent that reduces the level or activity of T _REG cells is selected from cyclophosphamide, an anti-GITR antibody, CD25 depletion, or a combination thereof.

In other embodiments, an agent that inhibits an inhibitory molecule includes a first polypeptide comprising the inhibitory molecule or a fragment thereof and a second polypeptide that positively signals the cell, and wherein the first and second polypeptides are expressed on CAR-containing immune cells, where: (i ) the first polypeptide comprises PD-1, PD-L1, CTLA-4, TIM-3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGF-beta, CEACAM-1, CEACAM-3 and CEACAM-5, or their fragment; and/or (ii) the second polypeptide comprises an intracellular signaling domain, including a primary signaling domain and/or a costimulatory signaling domain. In one embodiment, the primary signaling domain includes a functional CD3-zeta domain; and/or the costimulatory signaling domain includes a functional domain of a protein selected from 41BB, CD27 and CD28.

In other embodiments, the cytokine is selected from IL-7; IL-15; compositions comprising an interleukin-15 (IL-15) polypeptide, an interleukin-15 alpha receptor (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide, eg hetIL-15; IL-18; IL-21 or a combination thereof. Exemplary hetIL-15 are heterodimeric non-covalent complexes of IL-15 and IL-15Ra (Admune Therapeutics, LLC). Such hetIL-15s are described, for example, in U.S. 8,124,084 U.S. 2012/0177598, U.S. 2009/0082299, U.S. 2012/0141413 and U.S. 2011/0081311 included in this application by reference. For example, hetIL-15 is described in U.S. 8,124,084 U.S. 2012/0177598, U.S. 2009/0082299, U.S. 2012/0141413 and U.S. 2011/0081311 included in this application by reference. Other exemplary embodiments of hetIL-15 are covalent complexes of an IL-15 polypeptide and an IL-15R polypeptide (eg, IL-15Ra).

In other embodiments, the implementation of the cell and the second, for example any combination therapy disclosed in this application (for example, an agent that increases the efficiency of the cells), enter essentially simultaneously or sequentially.

In other embodiments, the cell is administered in combination with a molecule that specifically interacts with GITR and/or modulates GITR function. In some embodiments, a molecule that targets GITR and/or modulates GITR function is administered prior to a CAR-expressing cell or cell population, or prior to apheresis.

In one embodiment, a lymphocyte infusion, eg an allogeneic lymphocyte infusion, is used in the treatment of cancer, where the lymphocyte infusion comprises at least one cell, eg a CAR expressing cell, of the present invention. In one embodiment, autologous lymphocyte infusion is used in the treatment of cancer, where the autologous lymphocyte infusion comprises at least one cell, eg, a CAR-expressing cell as described herein.

In one embodiment, the cell is a T cell and the T cell is diaglycerol kinase (DGK) deficient. In one embodiment, the cell is a T cell and the T cell is Ikaros deficient. In one embodiment, the cell is a T cell and the T cell is DGK and Ikaros deficient.

In one embodiment, the method comprises administering a cell of the invention as described herein in combination with an agent that increases cell activity, wherein the agent is a cytokine, eg IL-7; IL-15; a composition comprising an interleukin-15 (IL-15) polypeptide, an interleukin-15 alpha receptor (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide, such as hetIL-15; IL-18; IL-21; or a combination of them. The cytokine can be delivered in combination, for example simultaneously or shortly after, with the administration of the cell. Alternatively, the cytokine can be delivered over a long period of time after cell administration, for example after evaluating the subject's response to the cell. In one embodiment, the cytokine is administered to the subject simultaneously (e.g., administered on the same day) with or shortly after administration (e.g., administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration) cells or populations of cells according to any one of paragraphs. 61-80. In other embodiments, the cytokine is administered to the subject over an extended period of time (e.g., at least 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks or more) after administration of the cell or cell population according to any one of paragraphs. 61-80 or after evaluating the subject's response to the cell.

In other embodiments, cells of the invention that are further modified to express a CAR are administered in combination with an agent that alleviates one or more side effects associated with the administration of a cell expressing a CAR molecule. Side effects associated with the CAR-expressing cell can be selected from cytokine release syndrome (CRS) or hemophagocytic lymphohistiocytosis (HLH).

In embodiments of any of the above methods or uses, cells expressing a CAR molecule are administered in combination with an agent that treats a disease associated with tumor antigen expression, such as any of the second or third therapy disclosed herein. Additional exemplary combinations include one or more of the following.

In another embodiment, the cell, eg, as described herein, may be administered in combination with another agent, eg, a kinase inhibitor and/or checkpoint inhibitor, as described herein. In an embodiment, the cell according to the invention may additionally express another agent, for example, an agent that increases the activity of the cell.

For example, in one embodiment, an agent that increases cell activity may be an agent that inhibits an inhibitory molecule.

In one embodiment, the agent that inhibits the inhibitory molecule is an inhibitory nucleic acid, dsRNA, siRNA, or shRNA.

In another embodiment, an agent that inhibits an inhibitory molecule, for example, is a molecule described in this application, for example, an agent that includes a first polypeptide, for example, an inhibitory molecule associated with a second polypeptide, which transmits a positive signal to the cell, for example, an intracellular signaling domain described in this application. In one embodiment, the agent includes a first polypeptide, for example, an inhibitory molecule or fragment thereof (for example, at least part of the extracellular domain of any of them), and a second polypeptide, which is an intracellular signaling domain described in this application (for example, including a costimulatory domain (e.g., 41BB, CD27, or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., the CD3-zeta signaling domain described herein) In one embodiment, the agent comprises a first PD-1 polypeptide or a fragment thereof (for example, at least part of the extracellular domain of PD-1) and a second polypeptide of the intracellular signaling domain described in this application (for example, the CD28 signaling domain described in this application and/or the CD3-zeta signaling domain described in this application). application).

In one embodiment, a cell of the present invention, eg a T cell or an NK cell, is administered to a subject who has previously undergone a stem cell transplant, eg an autologous stem cell transplant.

In one embodiment, a cell of the present invention, such as a T cell or NK cell, is administered to a subject who has previously received a dose of melphalan.

In one embodiment, the cell according to the invention is administered in combination with an agent that increases the efficiency of the cell, for example, the agent described in this application.

In one embodiment, the cells of the invention are administered in combination with a low, immunostimulatory dose of an mTor inhibitor. Without being bound by theory, it is believed that treatment with a low, immunostimulatory dose (e.g., a dose that is insufficient to completely suppress the immune system, but sufficient to improve immune function) is associated with a decrease in PD-1 positive T cells or an increase in PD-1 negative cells. . PD-1 positive T cells, but not PD-1 negative T cells, can be depleted when bound to cells that express a PD-1 ligand, such as PD-L1 or PD-L2. In an embodiment, this approach can be used to optimize the performance of the cells described herein in a subject. Without being limited by theory, it is believed that in an embodiment, the efficacy of endogenous, unmodified immune effector cells, eg, T cells or NK cells, is increased. Without being limited by theory, it is believed that in an embodiment, the efficiency of CAR-expressing cells is increased. In other embodiments, cells, e.g., T cells or NK cells, that include or will be modified to include an nRNA molecule according to the invention, can be treated ex vivo by contact with some mTor inhibitor, resulting in an increase in the number of PD-1-negative immune effector cells, eg T cells, or an increase in the ratio of PD-1 negative immune effector cells, eg T cells/PD-1 positive immune effector cells, eg T cells.

In an embodiment, administration of a low, immunostimulatory dose of an mTor inhibitor, eg, an allosteric inhibitor, eg RAD001, or a catalytic inhibitor, is started prior to administration of the CAR expressing cell described herein, eg, T cells or NK cells. In an embodiment, the cells are administered after a sufficient time or sufficient dose of the mTor inhibitor is administered, resulting in a level of PD-1 negative immune effector cells, such as T cells or NK cells, or a ratio of PD-1 negative immune effector cells, such as T cells/ PD-1 positive immune effector cells, eg T cells, were at least temporarily increased.

In an embodiment, the cell, e.g., a T cell or NK cell, to be modified to include an nRNA according to the invention is harvested after sufficient time or after sufficient administration of a low, immunostimulatory dose of an mTor inhibitor, resulting in a level of PD-1 negative immune effector cells, e.g. T cells, or the ratio of PD-1 negative immune effector cells, eg T cells/PD-1 positive immune effector cells, eg T cells, in the subject or derived from the subject was, at least temporarily, increased.

In one embodiment, the cell according to the invention is administered in combination with an agent that alleviates one or more side effects associated with the introduction of the cell, for example, the agent described in this application.

In one embodiment, the cell is administered in combination with an agent that treats a disease associated with an antigen associated with cancer, as described in this application, for example, an agent described in this application.

In one embodiment, the cell is administered at a dose and/or according to the administration scheme described in this application.

In one embodiment, a subject (e.g., a human) receives an initial administration of cells according to the invention and one or more subsequent administrations of cells according to the invention, where one or more subsequent administrations occur in less than 15 days, for example, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2 days after previous administration. In one embodiment, a subject (eg, a human) is given more than one administration of the cells of the invention per week, eg, 2, 3, or 4 administrations of cells comprising a CAR molecule per week. In one embodiment, the subject (for example, a human) receives more than one injection of cells according to the invention per week (for example, 2, 3 or 4 injections per week) (also referred to in this application as a course), followed by a week without the introduction of cells according to the invention, and then the subject is given one or more additional administrations of the cells of the invention (eg, more than one administration of the cells of the invention per week). In another embodiment, a subject (eg, a human) receives more than one course of cells according to the invention, with the time between each course being less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one embodiment, cells according to the invention are administered every other day, with 3 injections per week. In one embodiment, cells according to the invention are administered for at least two, three, four, five, six, seven, eight or more weeks.

In one embodiment, the cells of the invention are administered as a first line therapy for a disease, such as cancer, such as the cancer described herein. In another embodiment, the cells of the invention are administered as second, third, fourth line therapy for a disease, eg cancer, eg the cancer described herein.

In one embodiment, a population of cells described in this application is administered.

In another aspect, the invention relates to an isolated nucleic acid molecule encoding an nRNA according to the invention, an nRNA molecule according to the invention, and cells comprising or at any time including an nRNA according to the invention for use as a drug. In embodiments, a cell that contains or has ever included an nRNA of the invention is or will be modified such that the expression of a functional gene product comprising a sequence complementary to the nRNA guide domain is reduced or eliminated.

In another aspect, the invention relates to an isolated nucleic acid molecule encoding an nRNA according to the invention, an nRNA molecule according to the invention, and a cell comprising or at any time including an nRNA according to the invention, for use in the treatment of a disease characterized by the expression of a cancer-associated antigen as described herein. application. In embodiments, a cell that contains or has ever included an nRNA of the invention is or will be modified such that the expression of a functional gene product comprising a sequence complementary to the nRNA guide domain is reduced or eliminated.

In another aspect, the invention relates to an isolated nucleic acid molecule encoding an nRNA according to the invention, an nRNA molecule according to the invention, and a cell comprising or at any time including an nRNA according to the invention, for use as a drug in combination with a cytokine, for example, IL-7; IL-15; a composition comprising an interleukin-15 (IL-15) polypeptide, an interleukin-15 alpha receptor (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide, eg hetIL-15; IL-18; and/or IL-21; and/or combinations thereof, as described in this application. In another aspect, the invention relates to a cytokine described in this application for use as a drug in combination with a cell described in this application. In embodiments, a cell that contains or has ever included an nRNA of the invention is or will be modified such that the expression of a functional gene product comprising a sequence complementary to the nRNA guide domain is reduced or eliminated.

In another aspect, the invention relates to an isolated nucleic acid molecule encoding an nRNA according to the invention, an nRNA molecule according to the invention, and a cell comprising or at any time including an nRNA according to the invention for use as a drug in combination with a kinase inhibitor and/or a checkpoint inhibitor. as described in this application. In another aspect, the invention relates to a kinase inhibitor and/or checkpoint inhibitor described in this application, for use as a drug in combination with a cell that includes or has ever included an nRNA according to the invention.

In another aspect of the invention, a composition comprising a cell of the invention is provided for use in the treatment of a subject having a disease associated with the expression of a tumor-supporting antigen, eg, a disorder as described herein.

In any of the above methods or uses, the disease associated with the expression of a tumor-supporting antigen is selected from the group consisting of a proliferative disease, a precancerous condition, cancer, and a non-cancer indication associated with the expression of a tumor-supporting antigen. In an embodiment, the disease associated with the tumor-supporting antigen described herein is a solid tumor.

In one embodiment of the methods or uses described herein, the cell of the invention is administered in combination with another agent. In one embodiment, the agent may be a kinase inhibitor, eg, a CDK4/6 inhibitor, a BTK inhibitor, an mTor inhibitor, an MNK inhibitor, or a dual PI3K/mTOR inhibitor, and combinations thereof. In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor as described herein, e.g., a CD4/6 inhibitor, such as, e.g., 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine -1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (also called palbociclib or PD0332991). In one embodiment, the kinase inhibitor is a BTK inhibitor, such as a BTK inhibitor as described herein, such as, for example, ibrutinib. In one embodiment, the kinase inhibitor is an mTor inhibitor, eg, an mTor inhibitor as described herein, such as, eg, rapamycin, a rapamycin analog, OSI-027. The mTor inhibitor may be, for example, an mTORC1 inhibitor and/or an mTORC2 inhibitor, such as an mTORC1 inhibitor and/or an mTORC2 inhibitor as described herein. In one embodiment, the kinase inhibitor is an MNK inhibitor, such as an MNK inhibitor as described herein, such as, for example, 4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine. The MNK inhibitor may be, for example, an inhibitor of MNK1a, MNK1b, MNK2a and/or MNK2b. A dual PI3K/mTOR inhibitor can be, for example, PF-04695102.

In one embodiment of the methods or uses described herein, the kinase inhibitor is a CDK4 inhibitor selected from: aloisin A; flavopyridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran- 4-one hydrochloride (P276-00); )phenyl]-1H-benzimidazol-2-amine (RAF265), indiesulam (E7070), roscovitine (CYC202), palbociclib (PD0332991), dinacyclib (SCH727965), N-[5-[[(5-tert-butyloxazole-2 -yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032);4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d ][2]benzazepin-2-yl]amino]-benzoic acid (MLN8054);5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N -ethyl-4-methyl-3-pyridinemethanamine (AG-024322);4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide (AT7519);4- [2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438), and XL281 (BMS908662).

In one embodiment of the methods or uses described herein, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), wherein palbociclib is administered at a dose of approximately 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg . -21 days of a 28 day course or daily for 7-12 days of a 21 day course. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more courses of palbociclib are administered.

In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In one embodiment, the BTK inhibitor does not reduce or inhibits the kinase activity of interleukin-2-inducible kinase (ITK) and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13.

In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor, such as ibrutinib (PCI-32765), wherein ibrutinib is administered at a dose of approximately 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g. 250 mg, 420 mg, or 560 mg) daily for a period of time, such as daily at for a 21-day course or daily for a 28-day course. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more courses of ibrutinib are administered.

In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor that does not inhibit ITK kinase activity, such as RN-486, wherein RN-486 is administered at a dose of approximately 100 mg, 110 mg, 120 mg 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg (for example, 150 mg, 200 mg, or 250 mg) daily, for some period of time, for example, daily for a 28-day course. In one embodiment, 1, 2, 3, 4, 5, 6, 7 or more courses of RN-486 are administered.

In one embodiment of the methods or uses described herein, the kinase inhibitor is an mTor inhibitor selected from temsirolimus; ridaforolimus (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E, 28Z,30S,32S,35R)- 1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3. 1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimoda; (5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidine-7(8H)- she (PF04691502); and N2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl- L-α-aspartyl-L-serine (SEQ ID NO: 6659), internal salt (SF1126); and XL765.

In one embodiment of the methods or uses described herein, the kinase inhibitor is an mTor inhibitor, such as rapamycin, wherein the rapamycin is administered at a dose of approximately 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg , 10 mg (eg 6 mg) daily for a period of time, eg daily for a 21 day course or daily for a 28 day course. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more courses of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTor inhibitor, such as everolimus, wherein everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (eg 10 mg) daily for a period of time, eg daily for a 28 day course. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more courses of everolimus are administered.

In one embodiment of the methods or uses described herein, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo[3,4-d]pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine.

In one embodiment of the methods or uses described herein, the kinase inhibitor is a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTor selected from 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]- 6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502); N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl )phenyl]urea (PF-05212384, PKI-587); 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl] phenyl}propanenitrile (BEZ-235); apitolizib (GDC-0980, RG7422); 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458); 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinoline-2 (3H)-one maleic acid (NVP-BGT226); 3-[4-(4-morpholinylpyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol (PI-103); 5-(9-isopropyl-8- methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (VS-5584, SB2343); and N-[2-[(3,5-dimethoxyphenyl)amino]quinoxalin-3-yl]- 4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide (XL765).

In one embodiment of the methods or uses described herein, the CAR-expressing immune effector cell described herein is administered to a subject in combination with a protein tyrosine phosphatase inhibitor, e.g., a protein tyrosine phosphatase inhibitor described herein. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-1 inhibitor, such as an SHP-1 inhibitor described herein, such as, for example, sodium stibogluconate. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-2 inhibitor.

In one embodiment of the methods or uses described herein, the cell of the invention is administered in combination with another agent, and the agent is a cytokine. The cytokine may be, for example, IL-7; IL-15; a composition comprising an interleukin-15 (IL-15) polypeptide, an interleukin-15 alpha receptor (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide, eg hetIL-15; IL-18; IL-21; or a combination of them. In another embodiment, the cell of the invention is administered in combination with a checkpoint inhibitor, such as the checkpoint inhibitor described herein. For example, in one embodiment, the checkpoint inhibitor inhibits an inhibitory molecule selected from PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF-beta.

In one aspect of the invention, a method is provided for treating a subject, e.g., a subject having the condition described herein, using an allogeneic cell, e.g., an allogeneic immune effector cell, e.g. invention. In embodiments, the cell has been altered such that the expression of a functional gene product comprising a target sequence complementary to the nRNA guide domain is reduced or abolished.

In one aspect of the invention, a method of treatment is provided, comprising:

(a) obtaining a population of cells from an allogeneic donor;

(b) introducing into cells a CRISPR system (eg, the S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule);

(c) optionally, selecting those cells in which the expression of a product (eg, a functional product) of a gene comprising a target sequence complementary to the guide domain of the first nRNA is reduced or abolished;

(d) transducing cells with a nucleic acid encoding a CAR as described herein; and

(e) administering the cells to a patient in need, for example, a patient who has a disease associated with the expression of an antigen recognized by CAR.

In embodiments, the first nRNA molecule includes a targeting domain that is complementary to an allogeneic T cell target, e.g., a TCR component, e.g., a first nRNA molecule that includes a targeting domain that is complementary to a target sequence in a gene selected from CD247, CD3D, CD3E, CD3G, TRAC , TRBC1 and TRBC2. In embodiments, the first nRNA to CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, or TRBC2 is the first nRNA to include the targeting domain listed in Table 1, Table 4, or Table 5. In embodiments, step (c) includes selecting cells that are negative for TCR expression. In embodiments, the method further comprises administering to the patient an agent that selectively inhibits or depletes NK cells, such as an antibody or antigen-binding fragment to an antigen specific to NK cells, eg, that is not expressed on T cells.

In embodiments, the method further comprises introducing into cells a second nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule), for example, introducing into cells a CRISPR system (for example, the Cas9 CRISPR system of S. pyogenes) comprising a second nRNA molecule according to the invention ( or a nucleic acid encoding said nRNA molecule). In embodiments, the second nRNA molecule includes a targeting domain that is complementary to an allogeneic T cell target, e.g., a second nRNA molecule that includes a targeting domain that is complementary to a target sequence in a gene selected from B2M, HLA-A, HLA-B, and HLA-C. In embodiments, the second nRNA to B2M, HLA-A, HLA-B, or HLA-C is a second nRNA comprising a targeting domain from Table 1 or Table 3. In embodiments, step (c) optionally includes selecting cells in which the expression of the product ( for example, a functional product) of a gene comprising a target sequence complementary to the first nRNA guide domain, and in which the expression of a gene product (e.g., a functional product) comprising a target sequence complementary to the guide domain of the second nRNA is reduced or eliminated. In embodiments, step (c) includes selecting cells that are negative for TCR expression and/or negative for B2M or HLA expression. In embodiments, the method further comprises administering to the patient an agent that selectively inhibits or depletes NK cells, eg, an antibody or antigen-binding fragment to an NK cell-specific antigen, eg, that is not expressed on T cells.

In embodiments, the method further comprises introducing into cells a third nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule), for example, introducing into cells a CRISPR system (for example, the Cas9 CRISPR system of S. pyogenes) comprising a second nRNA molecule according to the invention ( or a nucleic acid encoding said nRNA molecule). In embodiments, the third nRNA molecule includes a targeting domain complementary to a target sequence in the gene of the inhibitory molecule or a downstream signaling effector through the inhibitory molecule, e.g. , PDCD1, PD-L2, CTLA4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113) , B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF-beta and PTPN11. In embodiments, the third nRNA includes a targeting domain for CD274, HAVCR2, LAG3, PDCD1, or PTPN11 selected from the targeting domains in Table 2 or Table 6. In embodiments, step (c) optionally includes selecting cells in which expression of a product (e.g., a functional product) of a gene comprising a target sequence complementary to the guide domain of the first nRNA, in which the expression of the product (for example, a functional product) of a gene comprising a target sequence complementary to the guide domain of the second nRNA, and / or in which the expression of the product (for example, a functional product ) of a gene containing a target sequence complementary to the third nRNA guide domain is reduced or eliminated. In embodiments, step (c) includes selecting cells that are negative for TCR expression, negative for B2M or HLA expression, and/or negative for expression of an inhibitory target molecule or downstream signaling effector via an inhibitory molecule. In embodiments, the method further comprises administering to the patient an agent that selectively inhibits or depletes NK cells, eg, an antibody or antigen-binding fragment to an NK cell-specific antigen, eg, that is not expressed on T cells. In other embodiments, the implementation of the third nRNA includes a guide domain complementary to the target sequence in the gene selected from CIITA, RFXANK, RFX5, RFXAP, for example, as described in this application. In embodiments, the third nRNA includes a guide domain complementary to a target sequence in the CIITA gene, eg as described herein, eg in Table 6c.

In any of the above aspects and embodiments, the CAR is a CAR as described herein. In any of the above aspects and embodiments, the CAR is a BCMA CAR, e.g., the BCMA CAR described herein, for example, includes or is engineered to express a CAR comprising SEQ ID NO: 8559. In aspects, a nucleic acid encoding a CAR is introduced into a cell by transduction with a viral vector, such as a lentiviral vector. In other aspects, a nucleic acid encoding a CAR is introduced as DNA that is inserted into the genome of a host cell at or near the site modified by one of the CRISPR systems introduced into said cells.

In one aspect of the invention, a method of treatment is provided, comprising:

(a) obtaining a population of cells, for example, immune effector cells, for example, T cells or NK cells, for example, as described in this application (for example, a population of these cells from an allogeneic donor);

(b) introducing into the cell population a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, TRBC2, eg TRAC target sequences, TRBC1 or TRBC2, eg TRAC target sequences, eg as described herein;

(c) introducing into the cell population a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to the target sequence in B2M, for example, as described in this application;

(d) optionally, selecting cells in which the expression of a functional TCR is reduced or abolished;

(e) transduction of a population of cells with a nucleic acid encoding a CAR, for example, as described in this application, for example, BCMA CAR, as described in this application; and

(f) administering the cell population to a patient in need thereof, eg a patient who has a disease associated with expression of an antigen recognized by CAR.

In one embodiment, the method further comprises the step of (g) introducing into said population of cells a CRISPR system (e.g., S. pyogenes Cas9 CRISPR system) comprising a third nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain, complementary to a target sequence in CIITA, RFXANK, RFX5 or RFXAP, eg complementary to a target sequence in CIITA, eg as described herein.

In one aspect of the invention, a method of treatment is provided, comprising:

(a) obtaining a population of cells, for example, immune effector cells, for example, T cells or NK cells, for example, as described in this application, (for example, a population of these cells from an allogeneic donor);

(b) introducing into the cell population a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, TRBC2, eg TRAC target sequences, TRBC1 or TRBC2, eg TRAC target sequences, eg as described herein;

(c) introducing into the cell population a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in NLRC5, for example, as described in this application;

(d) optionally, selecting cells in which the expression of a functional TCR is reduced or abolished;

(e) transduction of a population of cells with a nucleic acid encoding a CAR, for example, as described in this application, for example, BCMA CAR, as described in this application; and

(f) administering the cell population to a patient in need thereof, eg a patient who has a disease associated with expression of an antigen recognized by CAR.

In one embodiment, the method further comprises the step of (g) introducing into said population of cells a CRISPR system (e.g., S. pyogenes Cas9 CRISPR system) comprising a third nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain, complementary to a target sequence in CIITA, RFXANK, RFX5 or RFXAP, eg complementary to a target sequence in CIITA, eg as described herein.

In one aspect of the invention, a method of treatment is provided, comprising:

(a) obtaining a population of cells, such as immune effector cells (eg, NK or T cells), from an allogeneic or autologous donor;

(b) introducing into cells a CRISPR system (eg, the S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule);

(c) optionally, selecting cells in which the expression of a product (eg, a functional product) of a gene comprising a target sequence complementary to the guide domain of the first nRNA is reduced or abolished;

(d) transducing cells with a nucleic acid encoding a CAR as described herein; and

(e) administering the cells to a patient in need, for example, a patient who has a disease associated with the expression of an antigen recognized by CAR.

In embodiments, the first nRNA molecule includes a guide domain complementary to a target sequence in the gene of the inhibitory molecule or a downstream signaling effector through the inhibitory molecule, e.g., the first nRNA molecule includes a guide domain complementary to the target sequence in a gene selected from CD274, HAVCR2, LAG3 , PDCD1, PD-L2, CTLA4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113) , B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF-beta and PTPN11. In embodiments, the first nRNA includes a targeting domain for CD274, HAVCR2, LAG3, PDCD1, or PTPN11 selected from the targeting domains in Table 2 or Table 6. In embodiments, step (c) optionally includes selecting cells in which expression of a product (e.g., a functional product) of a gene comprising a target sequence complementary to the guide domain of the first nRNA is reduced or eliminated.

In embodiments, the method further comprises introducing into the cells at least a second nRNA molecule (eg, 2 or more nRNA molecules) according to the invention (or a nucleic acid encoding said nRNA molecule(s)). In embodiments, each additional nRNA molecule(s), e.g., the second nRNA molecule, includes a targeting domain that is complementary to a target sequence in the inhibitory molecule gene or a downstream signaling effector through the inhibitory molecule, e.g., complementary to a target sequence in a gene selected from CD274, HAVCR2, LAG3, PDCD1, PD-L2, CTLA4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD113), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD107), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine and TGF-beta and PTPN11. In embodiments, the third nRNA includes a targeting domain for CD274, HAVCR2, LAG3, PDCD1, or PTPN11 selected from the targeting domains in Table 2 or Table 6. In embodiments, each additional nRNA molecule includes a targeting domain that is complementary to a sequence in the gene of another inhibitory molecule or downstream signaling effector through an inhibitory molecule. In embodiments, step (c) optionally includes selecting cells in which expression of a product (e.g., functional product) of a gene comprising a target sequence complementary to the first nRNA guide domain, in which expression of a product (e.g., functional product) of a gene comprising a sequence of - a target complementary to the targeting domain of the second nRNA, and/or in which the expression of a product (eg, a functional product) of a gene comprising a target sequence complementary to the targeting domain of a third or more nRNAs (if any) is reduced or eliminated.

In one aspect of the invention, a method is provided for treating a subject, e.g., a subject having the condition described herein, using an allogeneic cell, e.g., an allogeneic immune effector cell, e.g. directed to the TCR component, and an nRNA molecule directed to the target of the immunosuppressant. In embodiments, the cell has been altered such that expression of a functional TCR and expression of a functional immunosuppressant target has been reduced or abolished.

In one aspect of the invention, a method of treatment is provided, comprising:

(a) obtaining a population of cells from an allogeneic donor;

(b) introducing into cells a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a first nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in CD247, CD3D, CD3E , CD3G, TRAC, TRBC1, TRBC2;

(c) introducing into cells a CRISPR system (e.g. S. pyogenes CRISPR Cas9 system) comprising a second nRNA molecule according to the invention (or a nucleic acid encoding said nRNA molecule) comprising a targeting domain complementary to a target sequence in DCK, CD52, FKBP1A or NR3C1;

(d) optionally, selecting cells in which expression of a functional TCR, expression of a functional target of an immunosuppressant, or expression of a functional TCR and a functional target of an immunosuppressant is reduced or abolished;

(e) transduction of cells with nucleic acid encoding CAR, as described in this application; and

(f) administering the cells to a patient in need thereof, for example, a patient who has a disease associated with the expression of an antigen recognized by CAR; and

(g) administering to the patient an immunosuppressant that binds to the target of the immunosuppressant, which is the target of the nRNA (c).

In embodiments, the first nRNA to CD247, CD3D, CD3E, CD3G, TRAC, TRBC1, or TRBC2 is the first nRNA to include the targeting domain listed in Table 1, Table 4, or Table 5. In embodiments, the second nRNA to DCK, CD52, FKBP1A, or NR3C1 is the second nRNA molecule that includes the targeting domain listed in Table 1. In embodiments, the first nRNA interacts directedly with TRAC, TRBC1, or TRBC2. In embodiments, the second nRNA interacts specifically with DCK and the immunosuppressant (g) is a nucleoside analog drug such as cytarabine (cytosine arabinoside) or gemcitabine. In an embodiment, the second nRNA interacts specifically with NR3C1 (the gene encoding the glucocorticoid receptor (GR)), and the immunosuppressant is a corticosteroid such as dexamethasone. In an embodiment, the second nRNA targets CD52 and the immunosuppressant is an anti-CD52 antibody or antigen-binding fragment thereof, such as alemtuzumab (Campas®). In an embodiment, the second nRNA interacts specifically with FKBP1A and the immunosuppressant is FK506 (or a FKBP12 binding fragment or equivalent), cyclosporine, rapamycin, or rapalogue, or an mTor inhibitor such as RAD001.

In any of the embodiments and aspects of the invention, including any of the above aspects and embodiments, the population of cells can be enriched, for example, during production, with a certain subgroup or subpopulation, for example, T cells, for example, stem cell-like T- memory cells.

In another aspect, a method is provided for treating a subject, eg, reducing or lessening the severity of a hyperproliferative condition or disorder (eg, cancer), eg, a solid tumor, soft tissue tumor, or metastatic lesion, in a subject. As used herein, the term "cancer" is intended to include all types of malignant tumors or oncogenic processes, metastatic tissues, or malignant cells, tissues, or organs, regardless of histopathological type or stage of invasiveness. Examples of solid tumors include malignant tumors, such as sarcomas, adenocarcinomas, and carcinomas of various organ systems, such as those affecting the liver, lung, breast, lymphoid tissue, gastrointestinal (eg, colon), genitourinary system (eg, kidney, urothelial cells ), prostate, and pharynx. Adenocarcinomas include malignancies such as most colon cancers, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung carcinoma, small intestine cancer, and cancer of the esophagus. In one embodiment, the cancer is melanoma, eg, advanced stage melanoma. Metastatic lesions of the above forms of cancer can also be treated or prevented using the methods and compositions of the invention. Examples of other forms of cancer that can be treated include bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer. , uterine cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, cancer urethra, penile cancer, chronic or acute leukemia, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, cancer of the kidney or ureters, carcinoma of the renal pelvis , neoplasia of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, tumor of the spinal canal , glioma of the brain, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell carcinoma, T-cell lymphoma, forms of cancer caused by environmental factors, including those caused by asbestos, combinations of these cancers and metastatic lesions of these cancers. Treatment of metastatic cancer, for example, metastatic cancer that expresses PD-L1 (Iwai et al., 2005, Int. Immunol. 17: 133-144), can be carried out using the antibody molecules described in this application.

Examples of cancers whose growth can be inhibited include cancers that typically respond to immunotherapy. Non-limiting examples of cancers for treatment include melanoma (eg, metastatic malignant melanoma), kidney cancer (eg, clear cell carcinoma), prostate cancer (eg, hormone refractory adenocarcinoma of the prostate), breast cancer, colon cancer, and lung cancer (eg, non-small cell lung cancer). In addition, refractory or recurrent cancers can be treated using the molecules described in this application.

In one aspect, the invention relates to a method for treating cancer in a subject. In one aspect, the cancer associated with expression of a cancer-associated antigen as described herein is hemoblastosis. In one aspect, the hemoblastosis is leukemia or lymphoma. In one aspect, cancer associated with the expression of a cancer-associated antigen as described herein includes cancers and malignancies, including, but not limited to, for example, one or more acute leukemias, including but not limited to, for example, B -cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), acute lymphoid leukemia (ALL); one or more chronic leukemias, including, without limitation, for example, chronic myelogenous leukemia (CML), chronic lymphoid leukemia (CLL). Additional cancers or hematologic conditions associated with the expression of a cancer-associated antigen as described herein include, but are not limited to, e.g. , follicular lymphoma, hairy cell leukemia, small or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, Waldenström's macroglobulinemia and preleukemia, which are a group of diverse hematological conditions united by inefficient production (or dysplasia) of myeloid blood cells, and the like. In addition, a disease associated with the expression of a cancer-associated antigen as described herein includes, but is not limited to, for example, atypical and/or non-classical cancers, malignancies, precancerous conditions, or proliferative diseases associated with the expression of a cancer-associated antigen. antigen, as described in this application.

In some embodiments, the cancer that can be treated is multiple myeloma. Typically, myeloma cells are considered negative for the expression of a cancer-associated antigen as described herein by flow cytometry. Thus, in some embodiments, the cell is further modified to express a CAR as described herein, for example, the CD19 CAR or BCMA CAR as described herein can be used to target myeloma cells. In some embodiments, the CARs in the therapy of the present invention may be used in combination with one or more additional therapies, such as lenalidomide therapy.

In various aspects, the immune effector cells (e.g., T cells, NK cells) of the invention administered to a patient, or progeny thereof, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty one months, twenty two months, twenty three months, two years, three years , four years or five years after the introduction of T cells or NK cells to the patient.

The invention also includes a type of cell therapy where immune effector cells (e.g., T cells, NK cells) are further modified, e.g., with in vitro transcribed RNA, to transiently express a chimeric antigen receptor (CAR), and a CAR T cell or NK cell is administered to a person in need of this recipient. The injected cell is capable of destroying tumor cells in the recipient. Thus, in various aspects, immune effector cells (eg, T cells, NK cells) administered to a patient are present for less than one month, such as three weeks, two weeks, one week, after the administration of the T cell or NK cells to the patient.

Without being limited to any particular theory, the antitumor immune response elicited by CAR-modified immune effector cells (eg, T cells, NK cells) may be an active or passive immune response, or alternatively may be elicited by a direct or indirect immune response. In one aspect, CAR-transduced immune effector cells (e.g., T cells, NK cells) exhibit secretion of specific pro-inflammatory cytokines and potent cytolytic activity in response to human cancer cells expressing a cancer-associated antigen as described herein, antagonize inhibition of the soluble associated antigen. with a cancer antigen as described herein mediate non-specific cytolysis and mediate regression of an established human tumor. For example, antigen-free tumor cells in a heterogeneous region of a tumor expressing a cancer-associated antigen as described herein may be susceptible to mediated destruction by redirected anti-cancer-associated antigen as described herein by immune effector cells (e.g., T cells, NK cells) that have previously reacted against neighboring antigen-positive cancer cells.

Ex vivo techniques are known in the art and are described in more detail below. Briefly, cells are isolated from a mammal (eg, human) and genetically modified (ie, transduced or transfected in vitro) with an nRNA molecule of the invention and optionally with a CAR expressing vector disclosed herein. The modified cell can be administered to a mammalian recipient to obtain a therapeutic effect. The mammalian recipient may be a human and the cell may be autologous to the recipient. In the alternative, the cells may be allogeneic to the recipient.

A technique for ex vivo expression of hematopoietic stem and progenitor cells is described in US Pat. No. 5,199,942, incorporated herein by reference, and can be applied to the cells of the present invention. Other suitable methods are known in the art, so the present invention is not limited to any particular method for expressing cells ex vivo. Briefly, ex vivo culture and expansion of immune effector cells (eg, T cells, NK cells) involves: (1) harvesting mammalian CD34+ hematopoietic stem and progenitor cells from peripheral blood samples or bone marrow explant; and (2) expansion of such cells ex vivo. In addition to the cell growth factors described in US Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 and c-kit ligand can be used to culture and expand cells.

Ex vivo propagation techniques for immune effector cells, eg T cells, are described, for example, in WO2015/142675, the contents of which are hereby incorporated by reference in their entirety. Such techniques can be used in combination with the methods described in this application.

In addition to the use of a cellular vaccine for ex vivo immunization, the present invention also provides in vivo immunization compositions and methods for inducing an immune response directed against an antigen in a patient.

Generally, cells activated and propagated as described herein can be used in the treatment and prevention of diseases that occur in immunocompromised individuals. In particular, the CAR-modified immune effector cells (eg, T cells, NK cells) of the invention are useful in the treatment of diseases, disorders, and conditions associated with the expression of a cancer-associated antigen, as described herein. In some aspects, the cells of the invention are used in the treatment of patients at risk of developing diseases, disorders, and conditions associated with the expression of a cancer-associated antigen, as described herein. Thus, the present invention provides methods for treating or preventing diseases, disorders, and conditions associated with expression of a cancer-associated antigen as described herein, comprising administering to a subject in need thereof a therapeutically effective amount of a CAR-modified immune effector cell (e.g., T cells, NK cells) according to the invention.

In one aspect, the cells of the invention, including cells further modified to express CAR, may be used to treat a proliferative disease such as cancer or malignancy, or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or preleukemia. In addition, a disease associated with the expression of a cancer-associated antigen as described herein includes, but is not limited to, for example, atypical and/or non-classical cancers, malignancies, precancerous conditions, or proliferative diseases with expression of a cancer-associated antigen, as described in this application. Non-cancer indications associated with the expression of a cancer-associated antigen as described herein include, but are not limited to, for example, autoimmune disease (eg, lupus), inflammatory disorders (allergy and asthma), and transplantation.

The cells (eg, T cells, NK cells) of the present invention may be administered alone or as a pharmaceutical composition in combination with diluents and/or other components such as IL-2, or with other cytokines or cell populations.

Hemoblastosis

Hematologic cancers are types of cancers such as leukemia, lymphoma, and malignant lymphoproliferative conditions that affect the blood, bone marrow, and lymphatic system.

Leukemia can be divided into acute leukemia and chronic leukemia. Acute leukemia can also be subdivided into acute myelogenous leukemia (AML) and acute lymphoid leukemia (ALL). Chronic leukemia includes chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Other associated conditions include myelodysplastic syndromes (MDS, formerly known as "preleukemia"), which are a diverse group of hematological conditions associated with inefficient production (or dysplasia) of myeloid blood cells and the risk of transformation into AML.

Lymphoma is a group of blood cell tumors that develop from lymphocytes. Examples of lymphomas include Hodgkin's lymphoma and non-Hodgkin's lymphoma.

The present invention also provides methods for inhibiting the proliferation or reduction of a population of cells expressing a cancer associated antigen as described herein, comprising contacting a population of cells comprising a cell expressing a cancer associated antigen as described herein with a cell of the invention ( eg, NK cell or T cell) further modified to express a CAR that binds to a cell expressing a cancer-associated antigen as described herein. In a certain aspect of the present invention, methods are provided for inhibiting the proliferation or reducing the population of cancer cells expressing a cancer-associated antigen as described herein, comprising contacting a population of cancer cells expressing a cancer-associated antigen as described herein with a T cell or NK a cell of the invention further modified to express a CAR that binds to a cell expressing a cancer-associated antigen as described herein. In one aspect of the present invention, methods are provided for inhibiting the proliferation or reducing the population of cancer cells expressing a cancer-associated antigen as described herein, comprising contacting a population of cancer cells expressing a cancer-associated antigen as described herein with a T cell or NK a cell of the invention further modified to express a CAR that binds to a cell expressing a cancer-associated antigen as described herein. In some aspects, the T cell or NK cell of the invention reduces the number, number, or percentage of cells and/or cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject, or in an animal model, with myeloid leukemia or other cancer associated with cells expressing cancer associated antigen, as described in this application, compared with a negative control. In one aspect, the subject is a human.

The present invention also provides methods for the prevention, treatment and/or control of a disease associated with cells expressing a cancer-associated antigen as described herein (e.g., hemoblastosis or atypical cancer characterized by the expression of a cancer-associated antigen as described herein). ), comprising administering to a subject in need a T cell or NK cell of the invention, comprising cells further modified to express a CAR that binds to a cell expressing a cancer-associated antigen as described herein. In one aspect, the subject is a human. Non-limiting examples of disorders associated with cells expressing a cancer-associated antigen as described herein include autoimmune disorders (such as lupus), inflammatory disorders (such as allergies and asthma), and cancers (such as hematological malignancies or atypical cancers, characterized by the expression of a cancer-associated antigen as described herein).

The present invention also provides methods for the prevention, treatment and/or control of a disease associated with cells expressing a cancer associated antigen as described herein, comprising administering to a subject in need a T cell or NK cell of the invention comprising cells further modified to express A CAR that binds to a cell expressing a cancer-associated antigen as described herein. In one aspect, the subject is a human.

The present invention provides methods for preventing the recurrence of cancer associated with cells expressing a cancer-associated antigen as described herein, comprising administering to a subject in need thereof a T cell or NK cell of the invention comprising cells further modified to express a CAR that binds with a cell expressing a cancer-associated antigen as described herein. In one aspect, the methods include administering the cell in combination with an effective amount of another therapy.

Pharmaceutical compositions and treatment

Pharmaceutical compositions according to the present invention may include a cell, for example a plurality of cells, as described in this application, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers such as neutral saline, phosphate buffered saline, and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (eg aluminum hydroxide); and preservatives. Compositions according to the present invention, in one aspect, are made for intravenous administration.

Pharmaceutical compositions according to the present invention may be administered in a manner that is appropriate for the disease that is intended to be treated (or prevented). The amount and frequency of administration will be determined by such factors as the condition of the patient and the type and severity of the patient's disease, although appropriate doses may be determined in clinical trials.

In one embodiment, the pharmaceutical composition is substantially free, e.g., does not contain any detectable levels of a contaminant, e.g., selected from the group consisting of endotoxin, mycoplasma, replication competent lentivirus (RCL), p24, VSV-G nucleic acid, gag HIV, anti-CD3/anti-CD28 antibody-coated residual beads, mouse antibodies, mixed human serum, bovine serum albumin, bovine serum, culture media components, vector packaging cell or plasmid components, bacteria and fungi. In one embodiment, the bacterium is at least one bacterium selected from the group consisting of Alcaligenes faecalis, Candida albicans, Escherichia coli, Haemophilus influenza, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia, and Group A Streptococcus pyogenes.

Where an "immunologically effective amount", "antineoplastic effective amount", "tumor-inhibiting effective amount", or "therapeutic amount" is indicated, the exact amount of the compositions of the present invention to be administered may be determined by the physician taking into account individual differences in age. , weight, tumor size, degree of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising immune effector cells (eg T cells, NK cells) described herein can be administered at a dose of 10 ⁴ -10 ⁹ cells/kg body weight, in some cases 10 ⁵ -10 ⁶ cells/kg body weight, including all integer values in the indicated ranges. T cell compositions can also be administered multiple times at such doses. Cells can be administered using infusion techniques that are well known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

In some aspects, it may be desirable to administer activated immune effector cells (e.g., T cells, NK cells) to a subject, and then rebleed (or perform apheresis), activate immune effector cells (e.g., T cells, NK cells) in the resulting sample according to the present of the invention and re-administer such activated and expanded immune effector cells (eg, T cells, NK cells) to the patient. This process can be repeated multiple times every few weeks. In some aspects, immune effector cells (eg, T cells, NK cells) can be activated from collected blood samples from 10 cm ³ to 400 cm ³ . In some aspects, immune effector cells (eg, T cells, NK cells) are activated from the collected blood samples 20 cm ³ , 30 cm ³ , 40 cm ³ , 50 cm ³ , 60 cm ³ , 70 cm ³ , 80 cm ³ , 90 cm ³ or 100 cm ³ .

Administration of the subject compositions may be by any convenient means, including aerosol inhalation, injection, ingestion, transfusion, implantation, or transplantation. The compositions described herein may be administered to a patient transarterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (IV) injection, or intraperitoneally. In one aspect, the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In one aspect, the T cell compositions of the present invention are administered by intravenous injection. Immune effector cell compositions (eg, T cells, NK cells) can be administered directly to a tumor, lymph node, or site of infection.

In a certain exemplary aspect, subjects may be subjected to leukapheresis, in which leukocytes are harvested, enriched or depleted ex vivo in order to select and/or isolate cells of interest, such as T cells. Such T cell isolates can be propagated by methods known in the art and processed as described in this application, resulting in T cells according to the invention. Subjects in need may subsequently receive standard treatment with high-dose chemotherapy, followed by peripheral blood stem cell transplantation. In some aspects, after or in parallel with transplantation, subjects receive an infusion of expanded T cells according to the present invention. In an additional aspect, the expanded cells are administered before or after surgery.

The dose in the above treatment to be administered to a patient will vary depending on the exact nature of the condition being treated and the recipient of the treatment. Determination of doses for administration to a human can be performed according to accepted practice in this field. The dose of Campas, for example, will typically be from 1 to about 100 mg for an adult patient, usually administered daily over a period of 1 to 30 days. The preferred daily dose is 1-10 mg per day, although in some cases higher doses up to 40 mg per day may be used (described in US patent 6,120,766).

In one aspect, CAR-expressing cells of the present invention are generated using lentiviral vectors, such as lentivirus. Cells, such as CART cells, obtained in this way will have a stable expression of CAR.

In one aspect, CAR-expressing cells, such as CART cells, are obtained using a viral vector, such as a gammaretroviral vector, for example, the gammaretroviral vector described in this application. CART cells obtained using such vectors can have stable CAR expression.

In one aspect, CART cells transiently express CAR vectors 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days after transduction. Transient expression of CAR receptors can be obtained by delivery of a CAR RNA vector. In one aspect, the CAR RNA is transduced into a T cell by electroporation.

A potential problem that may occur in patients treated with transiently expressing CAR receptor immune effector cells (eg, T cells, NK cells) (especially with mouse scFv CART cells) is anaphylaxis after multiple treatments.

Without being limited by theory, it is believed that such an anaphylactic reaction may be caused by the development of a humoral response in the patient against CAR, ie. anti-CAR antibodies having an anti-IgE isotype. A patient's antibody-producing cells are considered to undergo a class switch from the IgG isotype (which does not cause anaphylaxis) to the IgE isotype if there is a gap of ten to fourteen days in contact with the antigen.

If a patient is at high risk of developing an anti-CAR antibody response during a course of transient CAR therapy (such as that obtained from RNA transduction), the intervals between CART infusions should not exceed ten to fourteen days.

Methods for obtaining modified CAR-expressing cells

In another aspect, the invention relates to a method for obtaining a cell (for example, an immune effector cell or a population of such cells), including the introduction (for example, transduction) into a cell, for example, a T cell or NK cell, described in this application, a vector comprising a nucleic acid encoding CAR, for example, the CAR described in this application; or a nucleic acid encoding a CAR molecule, such as the CAR described in this application.

The cell in the methods is an immune effector cell (eg, a T cell or an NK cell, or a combination thereof). In some embodiments, the cell in the methods is diaglycerol kinase (DGK) and/or Ikaros deficient.

In some embodiments, introducing a nucleic acid molecule encoding a CAR comprises transducing a vector comprising a nucleic acid molecule encoding a CAR, or transfecting a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule is an in vitro transcribed RNA.

In some embodiments, the method further comprises:

obtaining a population of immune effector cells (eg, T cells or NK cells); and

removal of regulatory T cells from the population to obtain a population of cells depleted in regulatory T cells;

where steps a) and b) are performed prior to the introduction of a nucleic acid encoding a CAR and/or a CRISPR system into the population.

In embodiments of the methods, regulatory T cells include CD25+ T cells that are removed from a population of cells with an anti-CD25 antibody or fragment thereof. The anti-CD25 antibody, or fragment thereof, may be conjugated to a substrate, such as a bead.

In other embodiments, the cell population depleted in regulatory T cells obtained in step (b) contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells.

In other embodiments, the method further comprises removing from a population of cells that express a tumor antigen that does not include CD25 to obtain a population of cells depleted in regulatory T cells and tumor antigen prior to introducing a CAR-encoding nucleic acid into the population. The tumor antigen may be selected from CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, or combinations thereof.

In other embodiments, the method further comprises removing from the population of cells that express the checkpoint inhibitor to obtain a population of cells depleted of regulatory T cells and an inhibitory molecule prior to introducing a nucleic acid encoding a CAR or a CRISPR system into the population. The checkpoint inhibitor can be selected from PD-1, LAG-3, TIM3, B7-H1, CD160, P1H, 2B4, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), TIGIT, CTLA- 4, BTLA and LAIR1.

Other embodiments disclosed in this application cover the generation of a population of immune effector cells. The resulting population of immune effector cells can be selected based on the expression of one or more of CD3, CD28, CD4, CD8, CD45RA and/or CD45RO. In some embodiments, the immune effector cell population obtained is CD3+ and/or CD28+.

In some embodiments, the method further comprises expanding the cell population after the introduction of a nucleic acid molecule encoding a CAR.

In embodiments, the cell population is expanded for 8 days or less.

In some embodiments, a population of cells is expanded in culture for 5 days, whereby the resulting cells are more active than the same cells expanded in culture for 9 days under the same culture conditions.

In other embodiments, a cell population is expanded in culture for 5 days and exhibits at least a one, two-fold, three-fold, or four-fold increase in cell doublings upon antigen challenge compared to the same cells expanded in culture for 9 days under the same culture conditions. .

In other embodiments, a population of cells is expanded in culture for 5 days, wherein the resulting cells exhibit higher levels of pro-inflammatory IFN-γ and/or GM-CSF compared to the same cells expanded in culture for 9 days under the same conditions. cultivation.

In other embodiments, the cell population is expanded by culturing the cells in the presence of an agent that stimulates a CD3/TCR complex-associated signal and/or a ligand that stimulates a co-stimulatory molecule on the cell surface. The agent may be a bead conjugated to an anti-CD3 antibody or fragment thereof and/or an anti-CD28 antibody or fragment thereof.

In other embodiments, the cell population is expanded in suitable media that include one or more interleukins that result in at least a 200-fold, 250-fold, 300-fold, or 350-fold increase in cells over a 14-day expansion period as measured using flow cytometry.

In other embodiments, the cell population is expanded in the presence of IL-15 and/or IL-7.

In some embodiments, the method further comprises cryopreserving the cell population after a suitable expansion period.

In other embodiments, the production method disclosed herein further comprises contacting a population of immune effector cells with a nucleic acid encoding a telomerase subunit, such as hTERT. The nucleic acid encoding the telomerase subunit may be DNA.

The present invention also provides a method for obtaining a population of RNA-modified cells, for example, the cells described in this application, for example, immune effector cells (eg, T cells, NK cells), transiently expressing exogenous RNA. The method includes introducing in vitro transcribed RNA or synthetic RNA into a cell, where the RNA includes a nucleic acid encoding a CAR molecule described in this application.

In another aspect, the invention relates to a method of providing antitumor immunity in a subject, comprising administering to the subject an effective amount of a cell comprising a CAR molecule, for example, a cell expressing the CAR molecule described in this application. In one embodiment, the cell is an autologous T cell or NK cell. In one embodiment, the cell is an allogeneic T cell or NK cell. In one embodiment, the subject is a human.

In one aspect, the invention includes a population of autologous cells that are transfected or transduced with a vector comprising a nucleic acid molecule encoding a CAR molecule, for example, as described in this application. In one embodiment, the vector is a retroviral vector. In one embodiment, the vector is a self-inactivating lentiviral vector, as described elsewhere in this specification. In one embodiment, the vector is delivered (for example, by transfection or electroporation) into a cell, for example, a T cell or an NK cell, where the vector includes a nucleic acid molecule encoding a CAR of the present invention, as described in this application, which is transcribed as an mRNA molecule, while the CAR receptors according to the present invention are translated from the RNA molecule and expressed on the cell surface.

In another aspect, the present invention provides a population of CAR-expressing cells, eg, CAR-expressing immune effector cells (eg, T cells or NK cells). In some embodiments, the population of CAR-expressing cells includes a mixture of cells expressing various CAR receptors. For example, in one embodiment, the population of CAR-expressing immune effector cells (e.g., T cells or NK cells) may include a first cell expressing a CAR having an antigen-binding domain that binds to a first tumor antigen, as described herein, and a second cell expressing a CAR having a different antigen-binding domain that binds to a second tumor antigen as described herein. As another example, a population of CAR-expressing cells may include a first cell expressing a CAR that includes an antigen-binding domain that binds to a tumor antigen as described herein, and a second cell expressing a CAR that includes an antigen-binding domain to a target that is different from a tumor antigen, as described in this application. In one embodiment, the population of CAR-expressing cells includes, for example, a first cell expressing a CAR that includes a primary intracellular signaling domain and a second cell expressing a CAR that includes a secondary signaling domain, such as a costimulatory signaling domain.

In another aspect of the present invention, a population of cells is provided, wherein at least one cell in the population expresses a CAR having an antigen-binding domain that binds to a tumor antigen as described herein, and a second cell expressing another agent, e.g., an agent that increases activity of a CAR-expressing cell. For example, in one embodiment, the agent may be an agent that inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g. CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1 , CD160, 2B4 and TGF-beta. In one embodiment, an agent that inhibits an inhibitory molecule, for example, is a molecule described in this application, for example, an agent that includes a first polypeptide, for example, an inhibitory molecule associated with a second polypeptide, which transmits a positive signal to the cell, for example, intracellular signaling domain described in this application. In one embodiment, the agent comprises a first polypeptide, e.g., an inhibitory molecule such as PD-1, LAG-3, CTLA-4, CD160, BTLA, LAIR1, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and /or CEACAM-5), 2B4 and TIGIT or a fragment of any of them, and a second polypeptide that is an intracellular signaling domain described in this application (for example, including a co-stimulatory domain (for example, 41BB, CD27 or CD28, for example, as described in herein) and/or a primary signaling domain (e.g., the CD3-zeta signaling domain described herein).In one embodiment, the agent comprises a first PD-1 polypeptide or fragment thereof and a second intracellular signaling domain polypeptide described herein. (for example, the CD28, CD27, OX40 or 4-IBB signaling domain described herein and/or the CD3-zeta signaling domain described herein).

In one embodiment, a nucleic acid molecule encoding a CAR molecule of the present invention, for example as described herein, is expressed as an mRNA molecule. In one embodiment, cells expressing a genetically modified CAR of the present invention, e.g., immune effector cells (e.g., T cells, NK cells), can be obtained by transfection or electroporation of an RNA molecule encoding the desired CAR receptors (e.g., without the vector sequence ), in a cell. In one embodiment, the CAR molecule of the present invention is translated from an RNA molecule when incorporated and expressed on the surface of a recombinant cell.

A method for producing mRNA for use in transfection involves in vitro transcription (IVT) of the template using specially designed primers, followed by polyA attachment and generation of a construct containing 3' and 5' untranslated sequences ("UTRs") (e.g., 3' and/or 5' UTR as described herein), a 5' cap (for example, a 5' cap as described herein) and/or an internal ribosome entry site (IRES) (for example, an IRES as described herein), an expressed nucleic acid, and polyA tail, typically 50-2000 bases long (SEQ ID NO: 6638). The RNA obtained in this way can effectively transfect various cell types. In one embodiment, the template includes CAR sequences. In an embodiment, the CAR RNA vector is transduced into a cell, such as a T cell or NK cell, by electroporation.

XII. Production methods

Provided herein are methods for producing cells, eg, T cells, eg, allogeneic T cells, eg, CAR-modified cells modified, or intended to be modified, with the nRNA molecules described herein.

Introduction of CRISPR systems

The invention includes cells, such as immune effector cells, such as allogeneic or autologous cells, which include or have ever included one or more molecules of nRNA, as described in this application. The CRISPR systems described in this application may be introduced into cells by any of the methods described in this application. Cells can also be modified to express CARs as described herein.

In one aspect of the description, a method for producing a cell is provided, comprising:

a) introducing an nRNA molecule or a nucleic acid encoding said nRNA molecule, as described herein, into said cell;

b) introducing a Cas9 molecule as described herein or a nucleic acid encoding said Cas9 molecule into said cell;

c) introducing a nucleic acid encoding a CAR into said cell; and

d) reproduction and activation of cells.

In embodiments, administration of a) and b) takes place before steps c) and d). In embodiments, administration of c) takes place before administration of a) and b). In embodiments, the administration of c) and the propagation and activations of d) take place before the administration of a) and b). In embodiments, the method further comprises e) selecting cells that are CAR-expressing. In embodiments, the method further comprises f) selecting cells that lack or have reduced expression of the gene targeted by the nRNA molecule of step a). For example, if the nRNA molecule includes a targeting domain that is complementary to a target sequence in the TRAC gene (for example, includes a targeting domain that includes any of SEQ ID NO: 5816 - SEQ ID NO: 5965 or SEQ ID NO: 5528 - SEQ ID NO: 5623) , after the introduction of a) and b), cells that do not have TCR expression (for example, detectable, for example, using an anti-CD3 antibody) can be sorted for subsequent use in production methods, as described in this application, or for subsequent use in the therapeutic methods described in this application. Such sorting can be performed by methods known in the art, such as cell sorting or mechanical separation (eg, magnetic bead-bound anti-CD3 antibody separation to remove cells that still express CD3/TCR).

Reproduction and activation of cells

Immune effector cells, such as T cells, can be activated and propagated, usually using the methods described, for example, in US patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and in US Patent Application Publication 20060121005, each of which is incorporated by reference in its entirety.

In general, a population of immune effector cells, such as those depleted in regulatory T cells, can be expanded upon contact with a surface bound to an agent that stimulates the CD3/TCR complex-associated signal and a ligand that stimulates a co-stimulatory molecule on the T surface. -cells. In particular, a population of T cells can be stimulated as described herein, for example, by contact with an anti-CD3 antibody or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (for example, bryostatin) in combination with a calcium ionophore. To costimulate a helper molecule on the surface of T cells, a ligand is used that binds the helper molecule. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under conditions suitable to promote T cell proliferation. To stimulate the proliferation of CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody can be used. Examples of anti-CD28 antibodies include 9.3, B-T3, XR-CD28 (Diaclone, Besancon, France) and can be used as other methods well known in the art (Berg et al., Transplant Proc. 30(8):3975- 3977, 1998; Haanen et al., J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999).

In embodiments in which cells have reduced levels of, or no, expression or levels of a TCR component, activation may be accomplished by means other than interaction with CD3. In cells that also express CAR, activation can be accomplished by contacting said cells with an antigen bound by the CAR antigen-binding domain, or a CAR-binding fragment thereof. Such an antigen or fragment thereof may be present, for example, in the form of an antibody scaffold, a cell (e.g., an antigen-presenting cell, e.g., a cell that normally expresses said antigen, or a cell that has been engineered to express said antigen on its cell surface), or a solid a carrier such as a bead or membrane.

In some aspects, the primary stimulatory signal and the co-stimulatory signal for the T cell may be provided using different protocols. For example, the means providing each signal may be present in solution or may be associated with the surface. When bound to a surface, the agents may be bound to a single surface (ie, in a "cis" configuration) or to separate surfaces (ie, in a "trans" configuration). Alternatively, one agent may be associated with the surface and the other agent may be present in solution. In one aspect, the agent providing the cosimulator signal is associated with the cell surface and the agent providing the primary activation signal is present in solution or associated with the surface. In some aspects, both agents may be present in solution. In one aspect, the agents may be in soluble form and then bound to a surface, such as a cell expressing Fc receptors, or an antibody or other binding agent that will bind to the agents. In this regard, see, for example, US Patent Application Publications 20040101519 and 20060034810 which describe artificial antigen presenting cells (iAPCs) that are considered for use in T cell activation and expansion in the present invention.

In one aspect, the two agents are immobilized on the beads, e.g. on one bead, ie. "cis", or on separate granules, ie. "trance". By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof, and the agent providing a co-stimulatory signal is an anti-CD28 antibody or an antigen-binding fragment thereof; and both agents are simultaneously immobilized on the same bead in equivalent molecular amounts. In one aspect, a 1:1 ratio of each antibody coupled to CD4+ T cell expansion and T cell growth beads is used. In some aspects of the present invention, a ratio of bead-bound CD3:CD28 antibodies is used such that an increase in T cell expansion is observed compared to that observed using a 1:1 ratio. In one particular aspect, there is an increase from about 1 to about 3 times compared to the reproduction observed when using a ratio of 1:1. In one aspect, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 1:100, including all integer values in between. In one aspect, more anti-CD28 antibody is bound to the particles than anti-CD3 antibody, i. the CD3:CD28 ratio is less than one. In some aspects, the ratio of anti-CD28 antibody to bead-bound anti-CD3 antibody is greater than 2:1. In one specific aspect, a 1:100 ratio of CD3:CD28 antibodies associated with beads is used. In one aspect, a 1:75 ratio of CD3:CD28 antibodies associated with beads is used. In another aspect, a 1:50 ratio of CD3:CD28 antibodies associated with beads is used. In one aspect, a 1:30 ratio of CD3:CD28 antibodies associated with beads is used. In one preferred aspect, a 1:10 ratio of CD3:CD28 antibodies associated with beads is used. In one aspect, a 1:3 ratio of CD3:CD28 antibodies associated with beads is used. In yet another aspect, a 3:1 ratio of CD3:CD28 antibodies associated with beads is used.

Particle-to-cell ratios from 1:500 to 500:1, including any integer values in between, can be used to stimulate T cells or other target cells. As will be appreciated by one of ordinary skill in the art, the ratio of particles to cells may depend on the size of the particles compared to the target cell. For example, small granules may bind only a few cells, while large granules may bind many cells. In some aspects, the ratio of cells to particles ranges from 1:100 to 100:1, including any intermediate integer values, and in other aspects, a ratio that includes from 1:9 to 9:1, including any intermediate integer values, can also be used to stimulation of T cells. The ratio of anti-CD3 and anti-CD28 bound particles to T cells that results in T cell stimulation can be varied as above, however some preferred values include 1:100, 1:50, 1:40, 1: 30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1 and 15:1, with one preferred particle to T cell ratio being at least 1 :one. In one aspect, a particle to cell ratio of 1:1 or less is used. In one particular aspect, the preferred ratio of particles to cells is 1:5. In other aspects, the ratio of particles to cells may vary depending on the day of stimulation. For example, in one aspect, the ratio of particles to cells is from 1:1 to 10:1 on the first day, and additional particles are added to the cells daily or every two days, for 10 days, with final ratios from 1:1 to 1: 10 (depending on the number of cells on the day of addition). In one specific aspect, the ratio of particles to cells is 1:1 on the first day of stimulation and goes up to 1:5 on the third and fifth days of stimulation. In one aspect, the particles are added daily or every two days, to a final ratio of 1:1 on the first day and 1:5 on the third and fifth days of stimulation. In one aspect, the ratio of particles to cells is 2:1 on the first day of stimulation and goes up to 1:10 on the third and fifth days of stimulation. In one aspect, the particles are added daily or every other day, to a final ratio of 1:1 on the first day and 1:10 on the third and fifth days of stimulation. One skilled in the art will recognize that many other ratios may be suitable for use in the present invention. In particular, the ratios will vary depending on particle size as well as cell size and type. In one aspect, the most typical ratios for use are in the region of 1:1, 2:1 and 3:1 on the first day.

In other aspects, cells, such as T cells, are combined with agent-coated beads, then the beads and cells are separated, after which the cells are cultured. In an alternative aspect, prior to culturing, the drug-coated beads and cells are not separated but cultured together. In another aspect, the beads and cells are first concentrated by the application of a force, such as a magnetic force, which results in increased binding of cell surface markers, thus causing stimulation of the cells.

As an example, cell surface proteins can be coupled by contacting paramagnetic beads to which anti-CD3 and anti-CD28 antibodies (3x28 beads) are attached to T cells. In one aspect, cells (eg, 10 ⁴ -10 ⁹ T cells) and beads (eg, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads in a 1:1 ratio) are pooled in a buffer, such as PBS (without divalent cations, such as calcium and magnesium). Again, those of ordinary skill in the art will be able to determine any concentration of cells that can be used. For example, the target cell may be very rare in the sample and make up only 0.01% of the sample, or the entire sample (ie 100%) may be the target cell of interest. Thus, any number of cells is included within the scope of the present invention. In some aspects, it may be necessary to significantly reduce the volume in which particles and cells are mixed together (ie, increase the concentration of cells) to ensure maximum cell-particle contact. For example, in one aspect, concentrations of approximately 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, 5 billion/ml, or 2 billion cells/ml are used. In one aspect, more than 100 million cells/ml are used. In another aspect, a cell concentration of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In another aspect, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells/ml is used. In other aspects, concentrations of 125 or 150 million cells/ml may be used. The use of high concentrations can result in increased cell yield, cell activation and cell proliferation. In addition, the use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells. Such cell populations may be of therapeutic value, and may be obtained in some aspects. For example, the use of a high concentration of cells allows more efficient selection of CD8+ T cells, which typically have weaker expression of CD28.

In one embodiment, the cells according to the invention, for example, cells that include or have ever included or will include an nRNA molecule as described in this application, for example, these cells transduced with a nucleic acid encoding a CAR, for example, the CAR described in this application application, propagated, for example, by the method described in this application. In one embodiment, the cells are expanded in culture over a period ranging from several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., , 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days). In one embodiment, the cells are propagated within 4-9 days. In one embodiment, the cells are propagated for 8 days or less, such as 7, 6 or 5 days. In one embodiment, the cells are propagated in culture for 5 days, the resulting cells being more active than the same cells propagated in culture for 9 days under the same culture conditions. Activity can be determined, for example, by various functions of T cells, for example, proliferation, killing of target cells, cytokine production, activation, migration, or combinations thereof. In one embodiment, cells that are expanded for 5 days show an increase of at least one, two, three, or four times the number of cell doublings when challenged with antigen compared to the same cells expanded in culture for 9 days at the same cultivation conditions. In one embodiment, cells are expanded in culture for 5 days, whereby the resulting cells show higher production of pro-inflammatory cytokines, e.g., levels of IFN-γ and/or GM-CSF, compared to the same cells expanded in culture for 9 days. days under the same cultivation conditions. In one embodiment, cells expanded for 5 days show an increase of at least one, two, three, four, five, ten times or more, in pg/ml, the production of pro-inflammatory cytokines, for example, levels of IFN-γ and/ or GM-CSF compared to the same cells expanded in culture for 9 days under the same culture conditions.

Several cycles of stimulation may also be required, with the T cell culture time being 60 days or more. Suitable conditions for culturing T cells include suitable media (e.g., minimal culture media or RPMI 1640 or X-vivo 15 (Lonza) media) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ and TNF- α or any other cell growth supplements known to those skilled in the art. Other cell growth additives include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media may include RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12, X-Vivo 15 and X-Vivo 20, Optimizer, supplemented with amino acids, sodium pyruvate and vitamins, serum-free or supplemented with an appropriate amount of serum (or plasma) or a certain set of hormones, and/or an amount of cytokine(s) sufficient for the growth and reproduction of T-cells. Antibiotics, such as penicillin and streptomycin, are included only in experimental cultures, not in cell cultures to be administered to a subject. Target cells are maintained under conditions necessary to support growth, eg at a suitable temperature (eg 37° C.) and in an atmosphere (eg air plus 5% CO ₂ ).

In one embodiment, cells are expanded in suitable media (e.g., media described herein) that include one or more interleukins, resulting in at least 200-fold (e.g., 200-fold, 250-fold, 300-fold , 350-fold) increase in cells over a 14-day propagation period, for example, when measured using the method described in this application, such as flow cytometry. In one embodiment, cells are propagated in the presence of IL-15 and/or IL-7 (eg, IL-15 and IL-7).

In embodiments, the methods described herein, methods for producing cells of the invention, e.g., cells that include or have ever included or will include an nRNA molecule as described herein, for example, said cells expressing CAR, involve the removal of regulatory T cells, eg CD25+ T cells, from a population of cells, eg using an anti-CD25 antibody or fragment thereof, or a CD25 binding ligand, IL-2. Methods for removing regulatory T cells, such as CD25+ T cells, from a population of cells are described in this application. In embodiments, the methods, e.g., manufacturing methods, further comprise contacting a cell population (e.g., a cell population depleted in regulatory T cells, such as CD25+ T cells; or a cell population that has previously been contacted with an anti-CD25 antibody, fragment, or CD25 binding ligand) with IL-15 and/or IL-7. For example, a cell population (eg, that has previously been exposed to an anti-CD25 antibody, fragment thereof, or CD25 binding ligand) is expanded in the presence of IL-15 and/or IL-7.

In some embodiments, cells according to the invention, for example, cells that include or have ever included or will include an nRNA molecule, as described in this application, for example, these cells expressing a CAR, as described in this application, are contacted with a composition, comprising an interleukin-15 (IL-15) polypeptide, an interleukin-15 alpha (IL-15Ra) receptor polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide, e.g. hetIL-15, during the production of a CAR-expressing cell, e.g., ex vivo. In embodiments, a cell described herein is contacted with a composition comprising an IL-15 polypeptide during cell production, eg ex vivo. In embodiments, a cell described herein is contacted with a composition comprising a combination of an IL-15 polypeptide and an IL-15Ra polypeptide during the production of a CAR-expressing cell, eg ex vivo. In embodiments, a cell described herein is contacted with a composition comprising hetIL-15 during the production of a CAR-expressing cell, eg ex vivo.

In one embodiment, cells according to the invention, for example, cells that include or have ever included or will include an nRNA molecule, as described in this application, for example, these cells expressing a CAR, as described in this application, are contacted with a composition, including hetIL-15 during ex vivo propagation. In an embodiment, a cell described herein is contacted with a composition comprising an IL-15 polypeptide during ex vivo propagation. In an embodiment, the CAR-expressing cell described herein is contacted with a composition comprising an IL-15 polypeptide and an IL-15Ra polypeptide during ex vivo propagation. In one embodiment, the contact results in the survival and proliferation of a subpopulation of lymphocytes, such as CD8+ T cells.

T cells that have been exposed to different periods of stimulation may show different characteristics. For example, typical blood mononuclear cell products or apheresis peripheral blood products contain a population of helper T cells (TH, CD4+) that is larger than a population of cytotoxic or suppressor T cells (TC, CD8+). Ex vivo expansion of T cells by stimulation of CD3 and CD28 receptors results in a T cell population that is predominantly TH cells up to about 8-9 days, while after about 8-9 days the T cell population is increasingly population of TC cells. Thus, depending on the goal of treatment, it may be preferable to administer to the subject a T cell population comprising predominantly TH cells. Similarly, if an antigen-specific subset of TC cells has been isolated, it may be beneficial to expand that subset to a greater extent.

Moreover, in addition to CD4 and CD8 markers, other phenotypic markers differ significantly, but more reproducibly during the process of cell expansion. Thus, this reproducibility provides the ability to prepare an activated T-cell product for specific purposes.

Once a cell of the invention has been modified to express the CAR described herein, various assays can be used to evaluate the activity of the molecule, such as, but not limited to, the ability to expand T cells following antigen challenge, maintaining T cell expansion in the absence of repetitive stimulation and antitumor activities in appropriate in vitro and animal models. Assays for evaluating the impact of car receptors according to the present invention are described in more detail below.

Western blot analysis of CAR expression in primary T cells can be used to detect the presence of monomers and dimers. See, for example, Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Very briefly, T cells (a 1:1 mixture of CD4+ and CD8+ T cells) expressing CAR receptors are expanded in vitro for more than 10 days, followed by lysis and SDS-PAGE under reducing conditions. CARs containing the full-length TCR-ζ cytoplasmic domain and the endogenous TCR-ζ chain are detected by Western blot using an anti-TCR-ζ chain antibody. The same T cell subsets are used for SDS-PAGE analysis under non-reducing conditions to be able to evaluate covalent dimer formation.

In vitro expansion of CAR+ T cells following antigen challenge can be measured by flow cytometry. For example, a mixture of CD4+ and CD8+ T cells are stimulated with αCD3/αCD28 and APC cells, followed by transduction with lentiviral vectors expressing GFP under the control of promoters for analysis. Exemplary promoters include the CMV IE, EF-1α, ubiquitin C, or phosphoglycerokinase (PGK) gene promoters. GFP fluorescence was assessed on day 6 of culture in a subpopulation of CD4+ and/or CD8+ T cells by flow cytometry. See, for example, Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Alternatively, a mixture of CD4+ and CD8+ T cells are stimulated with αCD3/αCD28-coated magnetic beads on day 0 and CAR transduced on day 1 using a bicistronic lentiviral vector expressing CAR together with eGFP using a 2A ribosome skipping sequence. Cultures are restimulated with any cancer-associated antigen as described herein+K562 cells (K562 expressing cancer-associated antigen as described herein), K562 wild-type (wild-type K562) cells, or K562 cells expressing hCD32 and 4-1BBL in the presence of anti-CD3 and anti-CD28 antibody (K562-BBL-3/28) after washing. Exogenous IL-2 is added to the cultures every other day at 100 IU/ml. GFP+ T cells are counted by flow cytometry using bead-based counting. See, for example, Milone et al., Molecular Therapy 17(8):1453-1464 (2009).

Long-term expansion of CAR+ T cells in the absence of restimulation can also be measured. See, for example, Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Briefly, mean T cell volume (f1) is measured on day 8 of culture using a Coulter Multisizer III particle counter, Nexcelom Cellometer Vision, or Millipore Scepter after stimulation with αCD3/αCD28-coated magnetic beads on day 0 and transduction with the indicated CAR on day 1.

Animal models can also be used to measure CART activity. For example, a xenograft model using CAR+ T cells specific for the human cancer-associated antigen described herein can be used to treat primary human pre-B cell ALL in immunodeficient mice. See, for example, Milone et al., Molecular Therapy 17 (8): 1453-1464 (2009). Very briefly, after developing ALL, mice were randomized into treatment groups. Various amounts of cancer-associated antigen-specific CAR-modified T cells were co-administered in a 1:1 ratio to B-ALL-bearing NOD-SCID-γ ^-/- mice. The copy number of the cancer-associated antigen-specific CAR vector in mouse spleen DNA was assessed at various times after T-cell injection. Animals were assessed for leukemia at weekly intervals. The number of peripheral blood B-ALL blast cells + per cancer-associated antigen as described herein was measured in mice treated with the cancer-associated antigen described herein, -ζ CAR ⁺ T cells or control transduced T- cells. Survival curves for groups were compared using a log-rank test. In addition, it is also possible to analyze the absolute counts of CD4+ and CD8+ peripheral blood cells 4 weeks after T cell administration in NOD-SCID-γ ^-/- mice. Mice are injected with leukemia cells and 3 weeks later are injected with T cells modified to express CAR with a bicistronic lentiviral vector that encodes an eGFP-coupled CAR. T cells are normalized to 45-50% of the injected GFP+ T cells by mixing with control transduced cells prior to injection and confirmed by flow cytometry. Animals are evaluated for leukemia at 1 week intervals. Survival curves for groups of CAR+ T cells are compared using a log-rank test.

A dose-dependent response to CAR treatment can be assessed. See, for example, Milone et al., Molecular Therapy 17(8):1453-1464 (2009). For example, peripheral blood is obtained 35-70 days after the onset of leukemia in mice treated on day 21 with CAR T cells, an equivalent number of control transduced T cells, or no T cells. Mice from each group were randomly bled to determine the number of ALL peripheral blood blast cells + cancer-associated antigen as described in this application, and then sacrificed on days 35 and 49. The remaining animals were evaluated on days 57 and 70.

Assessment of cell proliferation and cytokine production has been described previously, for example, in Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Briefly, the assessment of CAR-mediated proliferation is performed in microtiter plates by mixing washed T cells with K562 cells expressing the cancer associated antigen described in this application (K19) or CD32 and CD137 (KT32-BBL) at a final ratio of T cells :K562 2:1. K562 cells are irradiated with gamma radiation prior to use. Anti-CD3 (clone OKT3) and anti-CD28 (clone 9.3) monoclonal antibodies are added to the cultures, with KT32-BBL cells serving as a positive control to stimulate T cell proliferation as these signals support the long-term expansion of CD8+ T cells ex vivo. T cells are counted in cultures using CountBright™ fluorescent beads (Invitrogen, Carlsbad, CA) and flow cytometry as described by the manufacturer. CAR+ T cells are identified by GFP expression using T cells that carry lentiviral vectors expressing the eGFP-2A associated CAR. In the case of CAR+ T cells not expressing GFP, CAR+ T cells are detected using a biotinylated recombinant cancer-associated antigen as described herein in the form of a protein and a secondary avidin-PE conjugate. The expression of CD4+ and CD8+ on T cells is also simultaneously detected using specific monoclonal antibodies (BD Biosciences). Cytokine measurements are performed on supernatants harvested 24 hours after restimulation using the TH1/TH2 Cytometric Bead Array (BD Biosciences, San Diego, CA) according to the manufacturer's instructions. Fluorescence is assessed using a FACScalibur flow cytometer and the data is analyzed according to the manufacturer's instructions.

Cytotoxicity can be assessed using a standard ⁵¹ Cr release assay. See, for example, Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Briefly, target cells (K562 lines and primary ALL pro-B cells) are loaded with ⁵¹ Cr (as NaCrO ₄ , New England Nuclear, Boston, MA) at 37°C for 2 hours with frequent agitation, washed twice in complete RPMI and placed in microtiter plates. Effector T cells are mixed with target cells in complete RPMI wells at various ratios of effector cells:target cells (E:T). Also prepare additional wells containing only medium (spontaneous release, SR) or 1% solution of detergent Triton X-100 (total release, TR). After 4 hours of incubation at 37°C, the supernatant is taken from each well. The ⁵¹ Cr released is then measured with a gamma counter (Packard Instrument Co., Waltham, MA). Each condition is performed at least in triplicate and percent lysis is calculated by the formula: % lysis=(ER-SR)/(TR-SR) where ER is the average ⁵¹ Cr released for each experimental condition.

Imaging technologies can be used to evaluate the specific migration and proliferation of CARs in tumor-bearing animal models. Such assays have been described, for example, in Barrett et al., Human Gene Therapy 22:1575-1586 (2011). Briefly, NOD/SCID/γc ^−/− (NSG) mice are injected with Nalm-6 cells iv, followed by T cells 7 days later, 4 hours after electroporation with CAR constructs. T cells are stably transfected with a lentiviral construct to express firefly luciferase, and bioluminescence is imaged in mice. Alternatively, the therapeutic efficacy and specificity of a single injection of CAR+ T cells in the Nalm-6 xenograft model can be measured as follows: NSG mice are injected with Nalm-6 transduced to stably express firefly luciferase followed by a single injection of T- cells electroporated with CAR according to the present invention. Animals are visualized at various time points after injection. For example, firefly luciferase phosphor photon density heatmaps can be obtained from representative mice on day 5 (2 days before treatment) and day 8 (24 hours after CAR+ PBL).

Other assays, including those described in the Examples section of this application, as well as those known in the art, can also be used to evaluate the cells and cells expressing the CARs described in this application.

Choice of delivery time

In an embodiment, one or more nucleic acid molecules (eg, DNA molecules) are delivered that are different from the components of the Cas system, for example, a component of the Cas9 molecule and/or a component of the nRNA molecule described in this application. In an embodiment, the delivery of the nucleic acid molecule occurs simultaneously with the delivery of one or more components of the Cas system. In an embodiment, the nucleic acid molecule is delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks or 4 weeks) delivery of one or more components of the Cas system.

In an embodiment, the nucleic acid molecule is delivered using a different method than one or more components of the Cas system, for example, a component of the Cas9 molecule and/or a component of the nRNA molecule. The nucleic acid molecule can be delivered using any of the delivery methods described in this application. For example, a nucleic acid molecule can be delivered by a viral vector, such as an integration-deficient lentivirus, and a component of the Cas9 molecule and/or a component of the gRNA molecule can be delivered by electroporation, such as such that nucleic acid-induced toxicity (e.g. , DNA) can be reduced. In an embodiment, the nucleic acid molecule encodes a therapeutic protein, for example, the protein described in this application. In an embodiment, the nucleic acid molecule encodes an RNA molecule, such as the RNA molecule described in this application.

Bimodal or differential component delivery

Separate delivery of components of the Cas system, such as a component of the Cas9 molecule and a component of the nRNA molecule, and more specifically, delivery of the components in different ways, can increase efficiency, for example, by increasing tissue specificity and safety. In an embodiment, the Cas9 molecule and the nRNA molecule are delivered in different ways, or as sometimes stated herein, in differential ways. Different or differential methods, as used herein, refer to delivery methods that impart different pharmacodynamic or pharmacokinetic properties to the respective component molecule, e.g., Cas9 molecule, nRNA molecule, template nucleic acid, or payload. For example, delivery methods may result in different tissue distribution, different half-life, or different temporal distribution, eg, in a selected compartment, tissue, or organ.

Some delivery methods, such as delivery with a nucleic acid vector that persists in the cell or in the progeny of the cell, such as by autonomous replication or insertion into the cellular nucleic acid, result in more consistent expression and presence of the component. Examples include viral, eg using adeno-associated virus or lentivirus, delivery.

By way of example, components such as a Cas9 molecule and an nRNA molecule can be delivered by methods that differ in the resulting half-life or persistence of the delivered component in the body or in a particular compartment, tissue, or organ. In an embodiment, the nRNA molecule can be delivered by such methods. A component of the Cas9 molecule can be delivered in a manner that results in less persistence or less exposure in the body or in a particular compartment or tissue or organ.

More broadly, in an embodiment, the first delivery method is used to deliver the first component and the second delivery method is used to deliver the second component. The first delivery method confers the first pharmacodynamic or pharmacokinetic property. The first pharmacodynamic property may be, for example, the distribution, persistence, or exposure of a component, or a nucleic acid that encodes a component, in a body, compartment, tissue, or organ. The second delivery method confers a second pharmacodynamic or pharmacokinetic property. The second pharmacodynamic property may be, for example, the distribution, persistence or exposure of the component, or the nucleic acid that encodes the component, in the body, compartment, tissue or organ.

In an embodiment, the first pharmacodynamic or pharmacokinetic property, such as distribution, persistence or exposure, is more limited than the second pharmacodynamic or pharmacokinetic property.

In an embodiment, the first delivery method is selected to optimize, eg, minimize, a pharmacodynamic or pharmacokinetic property, eg, distribution, persistence, or exposure.

In an embodiment, the second delivery method is selected to optimize, eg, maximize, a pharmacodynamic or pharmacokinetic property, eg, distribution, persistence, or exposure.

In an embodiment, the first delivery method involves the use of a relatively persistent element, such as a nucleic acid, such as a plasmid, or a viral vector, such as an AAV or a lentivirus. Since such vectors are relatively persistent, the product transcribed from them will be relatively persistent.

In an embodiment, the second delivery method includes a relatively transient element, such as RNA or protein.

In an embodiment, the first component comprises an nRNA and the delivery method is relatively persistent, eg the nRNA is transcribed from a plasmid or a viral vector, eg AAV or lentivirus. Transcription of such genes would not be physiologically relevant, since these genes do not code for a protein product, and nRNA is not capable of acting in isolation. The second component, the Cas9 molecule, is delivered transiently, eg as mRNA or protein, which ensures that the complete Cas9 molecule/nRNA molecule complex is present and only active for a short time.

In addition, the components can be delivered in different molecular form or using different delivery vectors that complement each other to increase tissue specificity and safety.

The use of differential delivery methods can improve potency, safety and efficacy. For example, the possibility of possible off-target modification can be reduced. Delivery of immunogenic components, such as Cas9 molecules, by less persistent means can reduce immunogenicity because bacterially derived Cas enzyme peptides are exposed on the cell surface to MHC molecules. A two-component delivery system can reduce such drawbacks.

Differential delivery methods can be used to deliver components to different but overlapping target regions. The formation of the active complex is minimized outside the region of overlap of the target regions. Thus, in an embodiment, the first component, eg the nRNA molecule, is delivered by the first delivery method that results in the first spatial, eg tissue, distribution. The second component, eg the Cas9 molecule, is delivered by a second delivery method which results in a second spatial, eg tissue, distribution. In an embodiment, the first method includes a first element selected from a liposome, a nanoparticle, such as a polymeric nanoparticle, and a nucleic acid, such as a viral vector. The second method includes the second element selected from the group. In an embodiment, the first delivery method includes a first targeting element, such as a cell-specific receptor or antibody, and the second delivery method does not include such an element. In an embodiment, the second delivery method includes a second targeting element, such as a second cell-specific receptor or a second antibody.

By delivering the Cas9 molecule in a viral delivery vector, liposome, or polymeric nanoparticle, there is the potential for delivery and therapeutic activity in multiple tissues, while exposure to only one tissue may be required. A two-component delivery system can solve this problem and increase tissue specificity. If the nRNA molecule and the Cas9 molecule are packaged in separate delivery vehicles, with different but overlapping tissue tropisms, a fully functional complex is formed only in the tissue that is targeted by both vectors.

In one aspect, delivery is ex vivo.

XIII. Modified nucleosides, nucleotides and nucleic acids

Modified nucleosides and modified nucleotides may be present in nucleic acids, for example, in particular nRNA, but also other forms of RNA, such as mRNA, RNAi or miRNA. As described in this application, "nucleoside" is defined as a compound containing a five-carbon sugar molecule (pentose or ribose) or its derivative, and an organic base, purine or pyrimidine, or their derivative. As described herein, a "nucleotide" is defined as a nucleoside further comprising a phosphate group.

Modified nucleosides and nucleotides may include one or more of the following:

(i) altering, for example replacing, one or both of the non-binding phosphate oxygens and/or one or more binding phosphate oxygens in the phosphodiester backbone;

(ii) changing, eg replacing, the ribose sugar element, eg 2'-hydroxyl, on the ribose sugar;

(iii) complete replacement of the "dephospho" phosphate group with linkers;

(iv) modification or replacement of a natural nucleobase, including a non-canonical nucleobase;

(v) replacement or modification of the ribose phosphate backbone;

(vi) modifying the 3' end or 5' end of the oligonucleotide, for example removing, modifying, or replacing a terminal phosphate group, or linking a group, cap, or linker; and

(vii) modification or replacement of sugar.

The modifications listed above can be combined to produce modified nucleosides and nucleotides that may have two, three, four or more modifications. For example, a modified nucleoside or nucleotide may have a modified sugar and a modified nucleobase. In an embodiment, each base of the nRNA is modified, eg all bases have a modified phosphate group, eg all are phosphothioate groups. In an embodiment, all or substantially all of the phosphate groups of the monomolecular or modular gRNA molecule are replaced by phosphothioate groups.

In an embodiment, modified nucleotides, eg, nucleotides having modifications as described herein, may be included in a nucleic acid, eg, a "modified nucleic acid". In some embodiments, the modified nucleic acids include one, two, three or more modified nucleotides. In some embodiments, at least 5% (e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%) of the provisions in a modified nucleic acid are modified nucleotides.

Unmodified nucleic acids may be subject to degradation, for example, by cellular nucleases. For example, nucleases can hydrolyze the phosphodiester bonds of a nucleic acid. Thus, in one aspect, the modified nucleic acids described in this application may contain one or more modified nucleosides or nucleotides, for example, to introduce resistance to nucleases.

In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein may exhibit a reduced innate immune response when administered to a population of cells in vivo and ex vivo. The term "innate immune response" includes a cellular response to exogenous nucleic acids, including single-stranded nucleic acids, usually of viral or bacterial origin, which includes the induction of the expression and release of cytokines, especially interferons, and cell death. In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein can disrupt the binding of the major groove partner to the nucleic acid. In some embodiments, the modified nucleosides, modified nucleotides, and modified nucleic acids described herein may exhibit a reduced innate immune response when administered to a population of cells in vivo and ex vivo, as well as disrupt the binding of the major groove interacting partner to the nucleic acid. .

Definitions of chemical groups

As used herein, "alkyl" refers to a saturated hydrocarbon group that is straight or branched. Examples of alkyl groups include methyl (Me), ethyl (Et), propyl (for example, n-propyl and isopropyl), butyl (for example, n-butyl, isobutyl, t-butyl), pentyl (for example, n-pentyl, isopentyl, neopentyl), etc. The alkyl group may contain 1 to about 20, 2 to about 20, 1 to about 12, 1 to about 8, 1 to about 6, 1 to about 4, or 1 to about 3 carbon atoms.

As used herein, "aryl" refers to monocyclic or polycyclic (eg, containing 2, 3, or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, the implementation of the aryl groups contain from 6 to about 20 carbon atoms.

As used herein, "alkenyl" refers to an aliphatic group containing at least one double bond. As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms and characterized by the presence of one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl.

As used herein, "arylalkyl" or "aralkyl" refers to an alkyl group in which an alkyl hydrogen atom has been replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl and trityl groups.

As used herein, "cycloalkyl" refers to cyclic, bicyclic, tricyclic or polycyclic non-aromatic hydrocarbon groups containing 3-12 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.

As used herein, "heterocyclyl" refers to a monovalent radical of a heterocyclic ring system. Representative heterocyclyls include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, and morpholinyl.

As used herein, "heteroaryl" refers to a monovalent radical of a heteroaromatic ring system. Examples of heteroaryl groups include, but are not limited to, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, indolyl, thiophenyl pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphtharidinyl, quinolyl, and pteridinyl.

Modifications of the phosphate skeleton

Phosphate group

In some embodiments, the implementation of the phosphate group of the modified nucleotide can be modified by replacing one or more oxygens with another substituent. In addition, a modified nucleotide, such as a modified nucleotide present in a modified nucleic acid, may include the complete replacement of an unmodified phosphate group with a modified phosphate, as described herein. In some embodiments, the modification of the phosphate backbone may include changes that result in either an uncharged linker or a charged linker with a non-symmetrical charge distribution.

Examples of modified phosphate groups include phosphothioate, phosphoselenates, boranophosphates, boranophosphate esters, hydrophosphonates, phosphoamidates, alkyl or arylphosphonates, and phosphotriesters. In some embodiments, one of the non-bridging phosphate oxygen atoms in the phosphate backbone group may be replaced by any of the following groups: sulfur (S), selenium (Se), BR ₃ (where R may be, for example, hydrogen, alkyl, or aryl), C (eg, an alkyl group, an aryl group, and the like), H, NR ₂ (where R may be, for example, hydrogen, alkyl or aryl), or OR (where R may be, for example, alkyl or aryl). The phosphorus atom in the unmodified phosphate group is achiral. However, replacing one of the non-bridging oxygens with one of the above atoms or groups of atoms can make the phosphorus atom chiral; this means that the phosphorus atom in the phosphate group thus modified is a stereogenic center. The stereogenic phosphorus atom may have an "R" configuration (here Rp) or an "S" configuration (here Sp).

In phosphodithioates, both non-bridging oxygens are replaced by sulfur. The phosphorus center in phosphodithioates is achiral, which excludes the formation of oligoribonucleotide diastereomers. In some embodiments, modifications to one or both of the non-bridging oxygens may also include replacing the non-bridging oxygens with a group independently selected from S, Se, B, C, H, N, and OR (R may be, for example, alkyl or aryl).

The phosphate linker can also be modified by replacing the bridging oxygen (ie, the oxygen that binds the phosphate to the nucleoside) with nitrogen (bridged phosphoamidates), sulfur (bridged phosphothioates), and carbon (bridged methylenephosphonates). The replacement can be made on one of the connecting oxygens or on both connecting oxygens.

Phosphate group replacement

The phosphate group can be replaced with phosphorus-free connectors. In some embodiments, the charged phosphate group may be replaced with a neutral group.

Examples of groups that can replace the phosphate group may include, but are not limited to, methylphosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formaacetal, oxime, methyleneimino, methylenemethylimino , methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.

Replacing the ribophosphate backbone

Scaffolds can also be designed that can mimic nucleic acids in which the phosphate linker and ribose sugar are replaced by nuclease-resistant nucleoside or nucleotide analogs. In some embodiments, the nucleobases may be linked by a surrogate backbone. Examples may include, but are not limited to, morpholino, cyclobutyl, pyrrolidine, and peptiducleic acid (PNA)-based nucleoside analogues.

Sugar modifications

Modified nucleosides and modified nucleotides may include one or more sugar group modifications. For example, the 2'-hydroxyl group (OH) may be modified or replaced with a number of different "oxy" or "deoxy" substituents. In some embodiments, modifications to the 2'-hydroxyl group may increase the stability of the nucleic acid, since the hydroxyl cannot be deprotonated to form the 2'-alkoxide ion. The 2'-alkoxide can catalyze degradation by intramolecular nucleophilic attack on the linker phosphorus atom.

Examples of modifications to the "oxy"-2'-hydroxyl group may include alkoxy or aryloxy (OR, where "R" may be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar); polyethylene glycols (PEG), O(CH ₂ CH ₂ O) _n CH ₂ CH ₂ OR, where R can be, for example, H or optionally substituted alkyl, and n can be an integer from 0 to 20 (for example, from 0 to 4 , 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8 , 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20). In some embodiments, the modification of the "oxy"-2'-hydroxyl group may include "locked" nucleic acids (LNA), in which the 2'-hydroxyl can be connected, for example through a C _1-6 alkylene or C _1-6 heteroalkylene bridge, c 4' carbon of the same ribose sugar, where exemplary bridges may include methylene, propylene, ether or amino bridges; O-amino (where amino can be, for example, NH ₂ ; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino) and aminoalkoxy, O(CH ₂ ) _n -amino (where amino can be, for example , NH ₂ ; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino). In some embodiments, the modification of the "oxy"-2'-hydroxyl group may include a methoxyethyl group (MOE) (OCH ₂ CH ₂ OCH ₃ , eg, a PEG derivative).

"Deoxy" modifications may include hydrogen (ie, deoxyribose sugars, eg, at the overhangs of partial dsRNA); halogen (eg bromine, chlorine, fluorine or iodine); amino (where amino may be, for example, NH ₂ ; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid); NH(CH ₂ CH ₂ NH) _n CH ₂ CH ₂ -amino (where amino can be, for example, as described in this application), -NHC(O)R (where R can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), cyano; mercapto; alkyl-thio-alkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl, and alkynyl, which may optionally be substituted, for example, with an amino group as described herein.

The sugar group may also contain one or more carbons that have the opposite stereochemical configuration than the corresponding carbon in the ribose. Thus, the modified nucleic acid may include nucleotides containing, for example, arabinose as a sugar. A nucleotide "monomer" may have an alpha bond at the γ position of the sugar, such as alpha nucleosides. Modified nucleic acids may also include "abasic" sugars that do not have a nucleobase at C-. Such abasic sugars may also be further modified at one or more of their constituent sugar atoms. Modified nucleic acids may also include one or more sugars that are in L-form, such as L-nucleosides.

Typically, RNA includes a ribose sugar group, which is a 5-membered ring containing oxygen. Exemplary modified nucleosides and modified nucleotides may include, without limitation, replacement of the oxygen in the ribose (eg, sulfur (S), selenium (Se), or alkylene, such as, for example, methylene or ethylene); addition of a double bond (for example, to replace ribose with cyclopentenyl or cyclohexenyl); reduction of the ribose ring (eg, to form a 4-membered cyclobutane or oxetane ring); an increase in the ribose ring (for example, to form a 6- or 7-membered ring containing an additional carbon atom or heteroatom, such as, for example, anhydrohexite, altrite, mannitol, cyclohexanyl, cyclohexenyl and morpholino, which also has a phosphoamidate skeleton). In some embodiments, modified nucleotides may include multicyclic forms (e.g., tricyclo; and "unlocked" forms such as glycol nucleic acid (GNA) (e.g., R-GNA or S-GNA where the ribose is replaced by glycol units attached to phosphodiester bonds), threose-nucleic acid (THNA, where the ribose is replaced by a-L-threofuranosyl-(3'-→2')).

Nucleobase modifications

The modified nucleosides and modified nucleotides described herein that may be included in a modified nucleic acid may include a modified nucleobase. Examples of nucleobases include, but are not limited to, adenine (A), guanine (G), cytosine (C), and uracil (U). Such nucleobases can be modified or completely replaced to provide modified nucleosides and modified nucleotides that can be incorporated into the modified nucleic acids. The nucleobase of a nucleotide can be independently selected from a purine, a pyrimidine, a purine analog, or a pyrimidine. In some embodiments, the implementation of the nucleobase may include, for example, natural and synthetic derivatives of the base.

Uracil

In some embodiments, the modified nucleobase is a modified uracil. Exemplary uracil-modified nucleobases and nucleosides include, but are not limited to, pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio- uridine (s2U), 4-thio-uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho ⁵ U), 5-aminoallyl-uridine, 5-halogen-uridine (for example , 5-iodine-uridine or 5-bromo-uridine), 3-methyl-uridine (m ³ U), 5-methoxy-uridine (mo ⁵ U), uridine-5-hydroxyacetic acid (cmo ⁵ U), methyl ester uridine-5-hydroxyacetic acid (mcmo ⁵ U), 5-carboxymethyl-uridine (cm ⁵ U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm ⁵ U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm ⁵ U), 5-methoxycarbonylmethyl-uridine (mcm ⁵ U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm ⁵ s ² U), 5-aminomethyl-2-thio-uridine (nm ⁵ s ² U), 5- methylaminomethyl-uridine (mnm ⁵ U), 5-methylaminomethyl-2-thio-uridine (mnm ⁵ s ² U), 5-methylaminomethyl-2-seleno-uridine (mnm ⁵ se ² U), 5-carbamoylmethyl-uridine (ncm ⁵ U), 5-carb hydroxymethylaminomethyl-uridine (cmnm ⁵ U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm ⁵ s ² U), 5-propionyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (xcm ⁵ U), 1 -taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine (Trn ⁵ s ² U), l-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m ⁵ U, i.e. having a nucleobase deoxythymine), 1-methyl-pseudouridine (m ¹ ψ), 5-methyl-2-thio-uridine (m ⁵ s ² U), 1-methyl-4-thio-pseudouridine (m ¹ s ⁴ ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m ³ ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1 -deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m ⁵ D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy -4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp ³ U), 1-methyl -3-(3-amino-3-carboxypropyl) pseudouridine, 5-(isopentenylaminomethyl) uridine (inm ⁵ U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm ⁵ s ² U), a-thio-uridine , 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m ⁵ Um), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O- methyl uridine (s ² Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm ⁵ Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm ⁵ Um), 5-carboxymethylamino methyl-2'-O-methyl-uridine (cmnm ⁵ Um), 3,2'-O-dimethyl-uridine (m ³ Um), 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm ⁵ Um ), 1-thio-uridine, deoxythymidine, 2'F-ara-uridine, 2'F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl)uridine, 5-[3-(1- E-propenylamino)uridine, pyrazolo[3,4-d]pyrimidines, xanthine and hypoxanthine.

Cytosine

In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include, but are not limited to, 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m ³ C), N4-acetyl-cytidine (act), 5-formyl- cytidines (f ⁵ C), N4-methyl-cytidine (m ⁴ C), 5-methyl-cytidine (m ⁵ C), 5-halogen-cytidine (e.g. 5-iodine-cytidine), 5-hydroxymethyl-cytidine ( hm ⁵ C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s ² C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio- 1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2- thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-ethoxy-1-methyl-pseudoisocytidine, lyzidine (k ² C), a -thio-cytidine, 2'-O-methyl-cytidine (Cm), 5,2'-O-dimethyl-cytidine (m ⁵ Cm), N4-acetyl-2'-O-methyl-cytidine (ac ⁴ Cm) , N4,2'-O-dimethyl-cytidine (m ⁴ Cm), 5-formyl-2'-O-methyl-cytidine (f ⁵ Cm), N4 ,N4,2'-O-trimethyl-cytidine (m ⁴ ₂ Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine and 2'-OH-ara-cytidine.

adenine

In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include, without limitation, 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6 -halogen-purine (e.g. 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza- 2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine ( m ¹ A), 2-methyl-adenine (m ² A), N6-methyl-adenosine (m ⁶ A), 2-methylthio-N6-methyl-adenosine (ms ² m ⁶ A), N6-isopentenyl-adenosine ( i ⁶ A), 2-methylthio-N6-isopentenyl-adenosine (ms ² i ⁶ A), N6-(cis-hydroxyisopentenyl)adenosine (io ⁶ A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms ² io ⁶ A), N6-glycinylcarbamoyl-adenosine (g ⁶ A), N6-threonylcarbamoyl-adenosine (t ⁶ A), N6-methyl-N6-threonylcarbamoyl-adenosine (m ⁶ t ⁶ A), 2-methylthio-N6 -threonylcarbamoyl-adenosine (ms ² g ⁶ A), N6,N6-dimethyl-adenosine (m ⁶ ₂ A), N6-hydroxynorvalylcarbamoyl-adenosine (hn ⁶ A), 2- methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms ² hn ⁶ A), N6-acetyl-adenosine (ac ⁶ A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, a-thio-adenosine, 2'-O-methyl-adenosine (Am), N6,2'-O-dimethyl-adenosine (m ⁵ Am), N6-methyl-2'-deoxyadenosine, N6,N6,2'-O-trimethyl-adenosine ( m ⁶ ₂ Am), 1,2'-O-dimethyl-adenosine (m ¹ Am), 2'-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1- thio-adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine and N6-(19-amino-pentaoxanonadecyl)-adenosine.

Guanine

In some embodiments, the modified nucleobase is a modified guanine. Exemplary guanine-modified nucleobases and nucleosides include, without limitation, inosine (I), 1-methyl-inosine (m ¹ I), viosin (imG), methylviosin (mimG), 4-demethyl-viosine (imG-14) , isoviosin (imG2), vibutosin (yW), peroxyvibutosin (o ₂ yW), hydroxyvibutosin (OHyW), unmodified hydroxyvibutosin (OHyW*), 7-deaza-guanosine, queuosin (Q), epoxyqueuosin (OQ), galactosyl-queuosin ( galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanosine (preQ ₀ ), 7-aminomethyl-7-deaza-guanosine (preQi), archeosin (G ⁺ ), 7-deaza-8-aza -guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m ⁷ G), 6-thio-7- methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m ¹ G), N2-methyl-guanosine (m ² G), N2,N2-dimethyl-guanosine (m ² ₂ G ), N2,7-dimethyl-guanosine (m _2,7G ), N2,N2,7-dimethyl-guanosine (m ^2,2,7G ), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, a-thio-guanosine in, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl-guanosine (m ³ / ₄ m), N2, N2-dimethyl-2'-O-methyl-guanosine (m ² ₂ Gm), 1-methyl-2'-O-methyl-guanosine (m ¹ Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m ² .7Gm), 2'-O-methyl -inosine (Im), 1,2'-O-dimethyl-inosine (m ¹ Im), 0 ⁶ -phenyl-2'-deoxyinosine, 2'-O-ribosylguanosine (phosphate) (Gr(p)), 1- thio-guanosine, 0 ⁶ -methyl-guanosine, 0 ⁶ -methyl-2'-deoxyguanosine, 2'-F-ara-guanosine and 2'-F-guanosine.

Modified nRNA

In some embodiments, the modified nucleic acids may be modified nRNAs. In some embodiments, the implementation of the nRNA can be modified at the 3'-end. In this embodiment, the nRNAs can be modified at the 3' U ribose. For example, the two terminal hydroxyl groups of a U ribose can be oxidized to aldehyde groups, with concomitant ring opening of the ribose, to produce a modified nucleoside, where U can be an unmodified or modified uridine.

In another embodiment, the 3'-terminal U may be modified with a 2'3' cyclic phosphate, where U may be unmodified or modified with uridine. In some embodiments, the implementation of the nRNA molecules may contain 3'-nucleotides that can be stabilized against degradation, for example, by including one or more of the modified nucleotides described in this application. In this embodiment, for example, the uridines may be replaced by modified uridines, such as 5-(2-amino)propyl-uridine and 5-bromo-uridine, or any of the modified uridines described herein; adenosines and guanosines can be replaced by modified adenosines and guanosines, for example with modifications in the 8 position, for example, 8-bromo-guanosine or any of the modified adenosines or guanosines described in this application. In some embodiments, deaza nucleotides, such as 7-deaza-adenosine, may be included in the nRNA. In some embodiments, O- and N-alkylated nucleotides, such as N6-methyl-adenosine, may be included in the nRNA. In some embodiments, sugar-modified ribonucleotides may be included, e.g., in which the 2'OH group is replaced with a group selected from H, -OR, -R (wherein R can be, e.g., methyl, alkyl, cycloalkyl, aryl, aralkyl , heteroaryl or sugar), halogen, -SH, -SR (where R can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), amino (where amino can be, for example, NH2; alkylamino, dialkylamino, heterocyclyl , arylamino, diarylamino, heteroarylamino, diheteroarylamino or amino acid); or cyano (-CN). In some embodiments, the implementation of the phosphate backbone can be modified, as described in this application, for example, phosphothioate group. In some embodiments, each nucleotide in the terminal overhang of the nRNA can independently be a modified or unmodified nucleotide, including, but not limited to, a 2'-sugar-modified such as, 2-F-2'-O-methyl, thymidine (T) , 2'-O-methoxyethyl-5-methyluridine (Teo), 2'-O-methoxyethyladenosine (Aeo), 2'-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof.

In an embodiment, one or more or all of the nucleotides in a single-stranded overhang of an RNA molecule, such as an nRNA molecule, are deoxynucleotides.

Candidate Cas molecules, eg, Cas9 molecules, candidate nRNA molecules, candidate Cas9 molecule/nRNA molecule complexes, and candidate CRISPR systems, can be evaluated using methods known or described herein. For example, exemplary methods for assessing the endonuclease activity of a Cas9 molecule are described, for example, in Jinek et al., SCIENCE 2012; 337(6096):8 16-821.

EXAMPLES

Example 1: Analyzes

Guide selection

Initial guide selection was performed in silico using the reference human genome and user-defined genomic regions of interest (eg, gene, exon of a gene, non-coding regulatory region, etc.) to identify PAMs in regions of interest. For each identified PAM, analyzes were performed and statistics presented. The nRNA molecules were then selected and ranked based on a number of criteria known in the art. After that, the nRNA molecules were investigated, as described in this application, for the efficiency of cleavage and formation of indels, as described in this application.

Throughout the Examples, in the experiments below, either ssRNA molecules or lncRNA molecules were used. Unless otherwise noted, the lncRNA format was used in experiments referring to the CRxxxxx identifier for the guide domain. Unless otherwise noted, where lncRNA molecules have been used, nRNA includes the following:

crRNA: [guide domain]-[SEQ ID NO: 6607]

tracr (trRNA): SEQ ID NO: 6660.

Unless otherwise noted, the following sequence was used in experiments that used the sRNA molecule:

[directing domain]-[SEQ ID NO: 6601]-UUUU

Transfection of HEK-293_Cas9GFP cells for primary screening guide

Transfection of Cas9GFP-expressing HEK293 (HEK-293_Cas9GFP) cells was used for primary screening for target-specific crRNAs. In this example, target-specific crRNAs were designed and selected for primary screening using certain criteria, including off-target detection in silico, for example, as described in this application. Selected crRNAs were chemically synthesized and delivered in a 96-well format. HEK-293-Cas9GFP cells were transfected with target crRNAs comprising the flagpole region of SEQ ID NO: 6607 in a 1:1 ratio with stock trRNA SEQ ID NO: 6660. Transfection was performed using lipofection technology according to the manufacturer's protocol (DharmaFECT Duo, GE LifeSciences; or RNAiMax , Life Technologies). Transfected cells were lysed 24 hours after lipofection and editing (eg, digestion) was detected in the lysates by T7E1 analysis and/or next generation sequencing (NGS; below).

T7E1 analysis

The T7E1 assay was used to detect mutational events in genomic DNA such as insertions, deletions and substitutions created by non-homologous end joining (NHEJ) after DNA cleavage by Cas9 (see Cho et al., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease Nature Biotechnology 2013; 31, 230-232).

Regions of genomic DNA that were targets for CRISPR/Cas9 digestion were amplified by PCR, denatured at 95°C for 10 minutes, and then annealed again while lowering the temperature from 95°C to 25°C at a rate of 0.5°C per second. If mutations were present in the amplified region, the DNA was combined to form heteroduplexes. The annealed heteroduplexes were then digested with T7E1 (New England Biolabs) at 37° C. for 1 hour. The T7E1 endonuclease recognizes non-complementary DNA bases, heteroduplexes, and double-stranded DNA with nicks and creates a double-strand break in these regions. The obtained DNA fragments were analyzed using the Fragment Analyzer system and quantified to determine the cleavage efficiency.

Next generation sequencing (NGS) and analysis for target cleavage efficiency and indel formation

To determine the efficiency of editing (eg, cleavage) of a target position in the genome, deep sequencing was used to determine the presence of insertions and deletions introduced at non-homologous end joins.

PCR primers were first matched to the region around the target site and the genomic region of interest was amplified by PCR. Additional PCRs were performed according to the manufacturer's (Illumina) protocols to introduce the necessary chemistry for sequencing. The amplicons were then sequenced on an Illumina MiSeq instrument. Reads were aligned with the reference human genome (eg, hg38) after excluding reads that had low scores. Based on the resulting files containing reads mapped to the reference genome (BAM files), the reads that overlapped with the target region of interest were selected and the number of wild-type reads versus the number of reads that contained an insertion or deletion was calculated. Edit percentage was then defined as the total number of reads with insertions or deletions relative to the total number of reads including the wild type. To determine the profile of insertions and/or deletions that resulted from editing, aligned reads with indels were selected and summed for the number of reads with a given indel. This information was then displayed as a list and also visualized in the form of histograms that represent the frequency of each indel.

Obtaining RNP

The addition of crRNA and trRNA (in the case of lncRNA) or chimeric nRNA (in the case of ssRNA) to the Cas9 protein results in the formation of an active Cas9 ribonucleoprotein complex (RNP), which mediates binding to the crRNA target region and specific cleavage of the target genomic DNA. This complex was generated by introducing trRNA and crRNA into Cas9, which is believed to induce a conformational change in Cas9, allowing it to bind and cleave dsDNA.

crRNA and trRNA were separately denatured at 95°C for 2 minutes and left to cool to room temperature. Cas9 protein (10 mg/ml) was added to 5× CCE buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl ₂ , 1 mM DTT, 5% glycerol) to which trRNA and crRNA were added (in separate reactions) and incubated at 37°C for 10 minutes to obtain an active RNP complex. The complex was delivered by electroporation and other methods to various cells, including HEK-293 and CD3+ T cells.

RNP delivery to T cells

The CD3+ T cells consisted of various T cell populations, including CD4+ helper T cells and CD8+ cytotoxic T cells. These cells can be isolated from whole blood or from leukopheresis samples. T cells can be modified to specifically interact with cancer cells and reduce immunogenicity by modifying the patient's T cells using Cas9 mediated editing. This example describes the basic method used to deliver a Cas9 RNP, eg a B2M-targeting Cas9 RNP, to T cells. Only the guide crRNA in the RNP needs to be changed to adapt this technique to a different T cell target (eg, any of those presented in this application).

First, T cells were enriched from leukopak using a commercial kit (eg EasySep™ human T cell isolation kit, Stem Cell Technology). Enriched T cells were aliquoted and frozen (at 10×10 ⁶ /vial) for later use. The vials were then thawed as needed and activated by adding a 3:1 ratio of CD3/CD28 beads (Dynabeads, Life Technologies) or using ImmunoCult Human CD3/CD28 T cell activator (Stem Cell Technologies) in T cell media (RPMI 1640 , FBS, L-glutamine, non-essential amino acids, sodium pyruvate, HEPES buffer, 2-mercaptoethanol, and optionally IL2). RNP complexes were prepared as described herein and added to ~50,000-100,000 CD3+ T cells resuspended in P3 buffer and nucleated using the Amaxa EO-115 nucleofection program. T cell media was added to cells immediately after nucleofection and cultured for 24 h or longer.

Example 2: Editing B2M

Editing results using B2M-targeted nRNAs in HEK-293 cells stably expressing Cas9

The results of the NGS analysis on the efficiency of cleavage of nRNAs targeting B2M are shown in Table 9 and Figure 1. These results demonstrate that many guide RNA molecules are able to mediate highly efficient editing of the B2M locus. The top nRNA molecules, as measured by % edit in HEK cells (followed by % edit in CD34+ cells) are shown in Figure 14 along with the results of: 1) % edit in CD34+ cells as measured by NGS, and 2) % loss of B2M as measured by c using flow cytometry in CD3+ T cells). As shown in Figure 14, three lncRNA molecules, eg, lncRNA molecules that include the targeting domain CR00442, CR00444, and CR00455, showed greater than 40% editing in CD3+ T cells as measured by flow cytometry.

Table 9: B2M editing by lncRNA-CRISPR systems in HEK-293 Cas9GFP as determined by NGS. nRNA was assessed by % editing in HEK cells. % HEK Edit (NGS) nRNA code Target name The average Art. off CR00465 B2M 89.7 1.7 CR00443 B2M 82.9 3.2 CR00445 B2M 80.9 8.4 CR00444 B2M 80.4 5.8 CR00449 B2M 79.3 5.1 CR00442 B2M 77.7 2.1 CR00453 B2M 74.3 3.6 CR00461 B2M 73.6 5.2 CR00439 B2M 71.8 12.5 CR00452 B2M 71.7 10.6 CR00455 B2M 70.4 11.1 CR00463 B2M 70.2 6.7 CR00467 B2M 69.6 12.5 CR00466 B2M 67.6 11.4 CR00446 B2M 64.4 6.0 CR00440 B2M 62.6 9.1 CR00472 B2M 57.5 4.0 CR00459 B2M 55.8 19.8 CR00468 B2M 54.8 11.9 CR00469 B2M 52.6 13.6 CR00450 B2M 51.6 4.5 CR00456 B2M 50.3 9.6 CR00454 B2M 49.2 16.8 CR00464 B2M 47.3 8.2 CR00460 B2M 45.1 9.8 CR00457 B2M 43.6 11.5 CR00451 B2M 39.8 8.0 CR00462 B2M 34.6 9.5 CR00470 B2M 31.3 7.0 CR00447 B2M 31.2 7.0 CR00458 B2M 20.6 9.0 CR00471 B2M 17.1 4.7 CR00473 B2M 15.6 2.1 CR000129 B2M NA NA CR000131 B2M NA NA CR00438 B2M NA NA

Flow cytometric analysis of B2M expression

The flow assay was designed to monitor editing performance after RNP acquisition and delivery. Beta-2-microglobin (B2M) is an essential component of the MHC class I complex (HLA type 1), which is present on the surface of all nucleated cells. Class I MHC presents endogenous (eg, self and non-self) peptides to the immune system. Series of crRNAs targeting B2M were tested by flow cytometric analysis to detect B2M expression. As a result of this primary screening, crRNAs were determined that showed stable editing in the range of 5-25%.

Cells in suspension were labeled with APC with anti-human B2M conjugate (BioLegend, cat. no. 316312), PE with anti-human HLA-A, B, C conjugate (BioLegend, cat. no. 311405) and propidium iodide (0.5 mg/ml, diluted 1/1000). Appropriate controls were prepared (eg, isotype-APC, isotype-PE, PE-anti-HLA alone, APC-anti-B2M alone). The samples were then analyzed on a flow cytometer. In this example, loss of B2M expression as assessed by surface marker staining was indicative of Cas9-mediated editing (eg, cleavage). The results are presented in Figure 14.

Example 3 Editing TCR and/or PD-1 in T cells, including CART cells

Table 10 lists the nRNA guide domains for editing the TCR-alpha and PD-1 genes. The nRNA molecules were prepared as described below as sRNAs comprising, from 5' to 3', the indicated targeting domain SEQ ID NO: 6601-(U) ₇ .

Table 10: nRNA targeting domains to TCR-alpha and PD-1 Designation nRNA guide domain SEQID NO: TRAC-1
(CR000960) UCUCUCAGCUGGUACACGGC 5568 TRAC-2
(CR000964) GAGAAUCAAAAUCGGUGAAU 5572 TRAC-3
(CR000966) AACAAAUGUGUCACAAAAGUA 5574 TRAC-5
(CR000971) AAAGUCAGAUUUGUUGCUCC 5579 TRAC-6
(CR000973) CUGGGGAAGAAGGUGUCUUC 5581 TRAC-7
(CR000980) CUCGACCAGCUUGACAUCAC 5588 TRAC-8
(CR000979) AAGUUCCUGUGAUGUCAAGC 5587 TRAC-9
(CR000984) UUCGGAACCCCAAUCACUGAC 5592 TRAC-10
(CR000991) GAUUAAACCCGGCCACUUUC 5599 PD1-1
(CR000837) UGUAGCACCGCCCAGACGAC 5733 PD1-2
(3'-20 nt 5133_1_37) UGCAGAUCCCACAGGCGCCC 6657 PD1-3
(CR000868) UGACACGGAAGCGGCAGUCC 5764 PD1-4
(CR000853) CACGAAGCUCUCCGAUGUGU 5749 PD1-5
(CR000881) AGGUGCCGCUGUCAUUGCGC 5777 PD1-6 AGGGCCCGGCCGCAAUGACAG 5775 PD1-7
(CR000859) CAGCAACCAGACGGACAAGC 5755 PD1-8
(CR000850) CCUGCUCGUGGUGACCGAAG 5746

Forward and reverse DNA oligonucleotides encoding the nRNA molecules comprising the targeting domains indicated in Table 10 above were cloned into the lentiviral vector after the U6 promoter. Briefly, using standard techniques, the vector was digested with BBSI for 1 hour at 37°C. The vector was purified using a PCR purification kit (Qiagen). Forward and reverse DNA nRNA oligonucleotides were synthesized in IDT (Integrated DNA Technologies) with the addition of a BBSI overhang (ACCG 5' forward oligo and AAAC 5' reverse strand). Olegs were annealed using IDT duplex buffer by heating to 95°C and cooling to room temperature. The annealed ligations were then ligated to the digested and purified vector using the NEB Rapid Ligation Kit. The vector also contains a nucleic acid encoding Cas9 and an mCherry reporter (mCherry is expressed using a T2A sequence after CAS9) after the EF1-alpha promoter. Lentivirus was packaged using a packaging system (Celecta catalog number CPCP-K2A). Virus was concentrated 200× for CRISPR viral production. In a 96-well flat-bottomed plate, Jurkat 1E5 cells were seeded in 100 μl of RPMI medium with 10% FBS. 50 µl of concentrated virus was added directly to each well. Then, 24 hours after adding the virus, 100 μl of medium was added to the cells. Cells were cultured with passaging every 3 days, adding new medium to maintain cells at a density of 0.5e6 cells/ml. TCR expression was measured 7 days after viral transduction. TCR was detected using APC-conjugated anti-CD3 epsilon clone OKT3 from eBioscience (catalog number 17-0037-42). 1E5 cells were incubated with 2 μl of antibody for 20 minutes, analyzed by flow cytometry (BD Fortessa). Data were analyzed using the Flow Jo software. mCherry positive cells were sorted first to detect CRISPR/Cas9 positive cells. This population was examined for loss of TCR. The results are shown in Figure 2. These results demonstrate that TCR-alpha targeting nRNAs are able to cause loss of TCR surface expression in Jurkat cells.

Generation of primary TCR-T cells using anti-TCR-alpha nRNA

The methodology described above was used to assess TCR editing and loss in primary T cells, with the following modifications. Primary 1E5 T cells were activated on Day 0 using 3:1 anti-CD3/CD28 Dynabeads beads in 10 µl of T cell medium in 96-well flat-bottomed plates. On Day 1, 50 μl of lentivirus encoding nRNA and Cas9/mCherry (as described above) was added. T cells were cultured for 12 days with the addition of new medium every 2 days to maintain a concentration of 5E5 cells/ml. TCR loss was measured as described above on day 6 and day 12 after lentivirus administration. The results are shown in Figure 3. These results demonstrate that TCR-alpha targeting nRNAs are capable of causing loss of TCR surface expression in primary T cells.

Generation of primary PD1-T cells using anti-PDCD1 nRNAs

PD-1 locus editing and loss of PD-1 expression was assessed as described above using lentiviral vectors encoding the anti-PD-1 nRNA molecules listed in Table 10. Experiments were performed as described above to evaluate TCR knockout in primary T cells. , except that cells were restimulated with 3:1 anti-CD3/CD28 Dynabeads beads in culture on Day 5 to increase PD-1 expression, allowing for better protein detection. The results are shown in Figure 4. These results demonstrate that the nRNA molecules of the invention directed against PD-1 (PDCD1) result in a highly efficient loss of PD-1 expression in primary T cells.

PD-1 or TCR editing in primary T cells using RNP

Editing of TCR or PD-1 in primary T cells was tested using ribonucleoprotein (RNP) Cas9/nRNA complexes. RNP was obtained by mixing 20 µg of CAS9 (PNA bio) and 20 µg of chemically synthesized sRNA (TriLink biotech) incorporating the TRAC-8 or PD1-6 guide domain and incubating for 15 minutes at room temperature. T cells were isolated from Leukopak PBMCs using a Pan T cell isolation kit (Miltenyi), then activated 3:1 with Dynabeads CD3/CD28 beads (Invtrogen). 48 hours after activation, 2E5 T cells (without removing beads) were centrifuged at 300 g for 6 minutes and resuspended in 20 μl of Optimem, RNP complex was added and mixed. The cells were then transferred to a 1 mm electroporation cuvette (BTX) and pulsed using a BTX ECM 830 instrument at 250 V for 500 μs and 1 pulse. The cells were again placed in their T cell medium and cultured for 5 days prior to assays. Figure 5 shows histograms of TCR or PD-1 expression as detected by flow cytometry after 7 days of culture. These results indicate that TCR-alpha and PD-1 targeting nRNAs are effective in generating TCR-negative or PD-1-negative T cells when administered as RNP.

TCR-negative CAR T cells

The ability of nRNA molecules targeting the TRAC locus to edit and result in a TCR-negative phenotype of T cells modified to express the chimeric antigen receptor (CAR) was determined. On Day 0, primary T cells were activated with 3:1 Dynabeads CD3/CD28 beads at 5E5 cells/ml in T cell medium. On Day 1, T cells were modified to express the CD19 CAR using lentiviral particles. T cells were modified to express CD19 CAR using lentiviral particles (lentivirus as described in WO2012/079000) at a MOI of 5−. On Day 2, T cells were electroporated with RNP comprising the Cas9 protein and an nRNA molecule comprising the TRAC-1 or TRAC-8 targeting domain. Then, on Day 4, new medium was added to the T cells every 2 days to maintain a concentration of 5E5 cells/ml. On day 11 of T cell culture, T cells were counted and CD3 microspheres manufactured by Miltenyi biotech were added according to the manufacturer's protocol. An LD magnetic column (Miltenyi) was used for positive selection. As shown in Figure 6, T cell populations that were ~40-50% TCR negative could be enriched to give an isolated population of TCR negative CART cells with greater than 98% purity.

Activity of TCR-negative CART cells

T cells were cultured under standard culture conditions with the following modifications. On day 2, T cells were electroporated with RNP containing an mRNA targeting TCR-alpha (TRAC-1 or TRAC-8) as described in "Editing PD-1 or TCR in Primary T Cells Using RNP" above. or transduced with a lentivirus encoding said nRNA and Cas9/mCherry as described in "Production of Primary TCR-T Cells Using Anti-PDCD1-Targeted nRNAs", above. On day 11, the TCR cell purification described in "TCR-CAR T- isolated TCR-negative cells were co-cultured with luciferase-expressing CD19+ NALM6 (B-ALL cell) or CD19-K562 (CML cell) cells, and the ability of TCR-CART cells to specifically kill CD19+ cells was evaluated. The results are shown in Figure 7 (% cell lysis) and demonstrate that TCR-negative CD19 CART cells containing TCR-targeted nRNAs (as a result of lentiviral or RNP transfection) are capable of specific killing of CD19+ cells.

Example 4: B2M excision using two molecules of nRNA

To test the ability of two nRNA molecules that bind to the same gene to remove a large segment of the target gene, cells were exposed to two nRNA molecules. CR00442 was used in each experiment in addition to a second nRNA molecule putatively binding to a target site located about 10 to about 6000 base pairs from the CR00442 binding site. Figure 8 shows the size of the excised product inferred from the number of base pairs between the two target sites of the nRNA molecules. Experiments were performed as above using crRNA molecules comprising the targeting domains of the indicated nRNA molecule (eg, CR00442) and trRNA transfected into HEK293 cells modified to stably express Cas9. Cell lysates were collected after 24 hours and subjected to PCR. Figures 9-11 show the results of these experiments. As shown in Figure 9, CR00442 paired with CR00438, CR00439, CR00440, CR00445, or CR00446 showed DNA fragments corresponding to the expected cut product ranging from 40-65 bp. Pairs of nRNA molecules that were expected to give cut products smaller than 20 base pairs did not give a detectable cut product as measured by PCR. As shown in Figures 10 and 11, when the expected cut size is approximately 4000 base pairs (Figure 10) or approximately 6000 base pairs (Figure 11), many guide pairs give the expected cut with >10% editing. These results demonstrate the feasibility of excising large portions of DNA from a gene or host genome using two molecules of nRNA and offer an alternative method for deactivating a gene or gene product.

Example 5 TRAC Editing in HEK and Primary Human CD3+ Cells

Editing of CRISPR systems containing lncRNA molecules including targeting domains to TRAC sequences was tested in editing in HEK cells (nRNA delivered to cells stably expressing Cas9) and in primary CD3+ T cells (nRNA/Cas9 RNP delivered by electroporation) according to the methods described in this application. Also, using flow cytometry investigated the surface expression of TCR after editing. Briefly, edited CD3+ cells were stained with antibodies against CD3 (OKT3, eBioscience) and/or TCR-alpha/beta (IP26#, Biolegend) on day 3-5 post-electroporation. Expression of CD3 or TCR-alpha/beta in live cells (identified by exclusion of propidium iodide) compared to unedited controls was used to determine the frequency of RNP editing.

The results are presented in Table 11. All mean % edits are measured by NGS and are based on at least 3 experiments. The nRNA molecules are ranked by % editing in HEK cells. Figure 12 shows the best anti-TRAC nRNA molecules as measured by % edit in HEK cells, along with flow cytometric data showing % edit in primary human CD3+ T cells as measured by loss of TCR surface expression.

Indels formed after editing in CD3+ T cells were also investigated. Table 11 shows the % of cells edited containing a frameshift mutation ("average % CPC edit"). Since the TRAC locus produces an expressed protein, it is possible that 3 bp deletions or insertions may not cause disruption and degradation of TRAC. At the same time, frameshift mutations (in/de 1-2 bp) can lead to sequence out of reading frame after editing and, probably, lead to nonsense-mediated degradation. It should be noted that there are often significant differences in % edit in HEK cells and CD3+ T cells, i.e. % edit in T cells is generally less than that observed in HEK cells. These differences were reproduced in many samples, including Jurkat cells and various donor sources of primary T cells (not shown). Without being limited by theory, one explanation may be that the TCR locus undergoes rearrangement in T cells and Jurkat cells, but not in HEK cells. Indeed, NGS sequencing was often unsuccessful or of poor quality in the case of T cells or Jurkat cells, regardless of donor, primers used, or the number of days after editing in which cells were collected for analysis (not shown). Thus, a more reliable measurement of % editing in primary T cells can be made by protein level knockout (eg, loss of TCR by flow cytometry).

Table 11 CD3+ (NGS) HEK (NGS) nRNA designation Target average total edit % SD average editing with CPC (%) SD2 average edit % SD CR000961 TRAC 3.4 0.9 3.1 0.7 87.9 2.8 CR000924 TRAC 37.4 6.1 30.9 5.5 87.3 2.9 CR000948 TRAC 20.3 4.5 18.4 6.1 84.5 5.6 CR000931 TRAC 37.7 11.4 34.9 9.3 83.6 7.6 CR000929 TRAC 40.3 6.3 36.1 4.8 81.6 0.7 CR000977 TRAC 44.2 4.5 35.7 4.4 80.6 4.8 CR000944 TRAC 4.3 4.5 4.3 4.6 77.6 8.5 CR000984 TRAC 52.1 4.6 42.1 4.2 77.0 5.3 CR000933 TRAC 30.6 12.5 25.2 8.3 74.8 8.6 CR000926 TRAC 22.5 9.2 19.9 6.9 73.0 4.5 CR000943 TRAC 18.1 13.9 14.5 11.3 72.4 9.2 CR000959 TRAC 2.4 0.4 2.1 0.2 71.9 4.1 CR000993 TRAC 24.1 5.7 17.8 3.9 71.0 5.3 CR000947 TRAC 7.2 3.3 6.5 2.8 70.7 9.5 CR000981 TRAC 37.6 10.0 25.1 3.5 70.0 11.6 CR000992 TRAC 33.7 12.0 29.1 12.0 69.2 12.4 CR001002 TRAC 21.8 3.7 19.7 4.8 69.1 5.2 CR001000 TRAC 26.2 9.5 22.7 7.6 68.9 7.4 CR000927 TRAC 23.8 4.5 22.6 4.1 68.7 7.2 CR000986 TRAC 36.4 5.1 14.8 3.0 68.6 14.9 CR000963 TRAC 32.5 7.1 25.3 6.3 68.4 5.4 CR000985 TRAC 17.7 5.4 16.3 4.4 68.1 10.0 CR000923 TRAC 37.3 6.5 32.7 4.6 67.4 3.3 CR000953 TRAC 17.7 2.1 14.4 1.1 66.0 12.8 CR000946 TRAC 9.8 2.9 9.2 2.3 65.9 10.1 CR000932 TRAC 9.9 3.3 7.9 4.1 65.7 7.8 CR001009 TRAC 27.3 9.4 22.8 7.8 65.3 10.6 CR000966 TRAC 22.0 2.9 21.0 2.6 65.2 2.7 CR001011 TRAC 13.2 1.2 10.8 1.8 64.8 13.5 CR001012 TRAC 31.5 14.2 22.9 12.0 64.5 1.4 CR000990 TRAC 36.1 7.0 25.3 5.9 63.7 8.9 CR000951 TRAC 6.7 3.0 6.0 3.5 63.5 16.5 CR001001 TRAC 14.4 0.2 10.9 0.4 61.8 8.0 CR000978 TRAC 24.7 5.1 20.8 4.4 60.7 2.3 CR000934 TRAC 4.4 3.0 4.1 2.6 60.6 4.6 CR000950 TRAC 7.5 0.8 5.4 0.4 60.4 9.2 CR000920 TRAC 12.8 1.9 10.5 0.4 60.2 12.9 CR000991 TRAC 51.2 8.1 45.4 6.9 60.1 6.4 CR000956 TRAC 2.2 0.5 1.9 0.0 59.9 10.5 CR000983 TRAC 26.6 2.0 18.2 0.7 59.8 1.8 CR000936 TRAC N/A N/A N/A N/A 59.7 12.9 CR000960 TRAC 1.2 0.1 1.2 0.2 59.4 6.5 CR001007 TRAC 22.0 4.4 19.0 3.2 58.4 13.9 CR000921 TRAC 12.7 2.0 11.3 1.1 58.3 9.1 CR000952 TRAC 5.8 1.7 5.6 1.8 57.9 7.9 CR000925 TRAC 19.1 4.3 12.3 5.1 56.9 6.1 CR001006 TRAC 13.6 4.3 10.4 3.2 56.8 14.3 CR000942 TRAC 9.8 6.4 9.8 6.3 56.8 1.6 CR000938 TRAC 13.9 0.3 12.5 2.2 55.0 7.1 CR000940 TRAC 22.1 4.7 14.4 4.1 55.0 10.4 CR000989 TRAC 28.2 12.5 18.2 7.6 54.5 1.1 CR000928 TRAC 18.1 1.8 14.6 0.4 54.2 22.1 CR000935 TRAC N/A N/A N/A N/A 54.2 8.2 CR001003 TRAC 13.6 4.6 10.1 4.3 53.5 9.5 CR001014 TRAC 27.3 6.8 24.3 5.9 52.7 4.3 CR000996 TRAC 11.1 0.7 8.6 0.2 52.3 7.3 CR000967 TRAC 31.1 6.3 27.3 3.8 51.9 2.7 CR000968 TRAC 26.1 4.1 24.1 4.2 51.6 10.5 CR000964 TRAC 27.0 7.9 23.5 8.9 51.2 8.9 CR000937 TRAC 15.8 3.4 10.8 2.0 50.9 6.6 CR001005 TRAC 13.9 2.4 13.0 2.4 50.5 12.9 CR001010 TRAC 21.2 4.4 18.6 3.2 48.3 7.0 CR000982 TRAC 28.5 8.9 23.2 7.3 48.1 9.5 CR001004 TRAC 6.7 2.8 6.4 2.5 47.2 15.3 CR000994 TRAC 21.5 2.7 10.8 0.6 46.9 3.4 CR000988 TRAC 22.3 4.7 17.4 3.5 41.9 5.4 CR000973 TRAC 16.2 1.0 12.4 1.1 39.7 16.1 CR000987 TRAC 20.6 1.8 18.2 2.2 39.6 4.0 CR000922 TRAC 6.4 4.5 5.0 3.4 37.8 7.6 CR001015 TRAC 21.8 0.2 20.4 0.0 35.9 17.5 CR000969 TRAC 24.8 6.0 20.9 4.4 34.0 4.9 CR000941 TRAC 9.6 4.5 7.6 4.1 33.4 3.9 CR000945 TRAC 2.3 1.1 2.2 1.1 32.3 7.2 CR000949 TRAC 2.5 2.0 2.5 1.9 30.2 6.2 CR001013 TRAC 19.6 11.5 17.6 10.0 29.7 5.3 CR000939 TRAC 13.5 3.1 12.1 2.2 27.7 5.2 CR000995 TRAC 1.9 1.8 2.5 1.2 23.2 6.3 CR000954 TRAC 2.7 0.4 2.6 0.3 22.3 6.7 CR000962 TRAC 10.4 1.3 8.6 1.2 21.3 5.0 CR000958 TRAC 1.0 0.3 1.0 0.3 20.4 4.4 CR000972 TRAC 6.9 2.5 6.4 2.3 16.2 4.9 CR001008 TRAC 5.1 1.1 4.5 0.9 13.6 1.7 CR000970 TRAC 10.9 2.3 9.3 2.8 13.4 4.7 CR000999 TRAC 12.0 2.4 11.4 2.1 13.1 17.9 CR000930 TRAC 9.9 0.6 7.1 3.2 12.2 1.6 CR000997 TRAC 6.7 0.8 6.4 0.8 11.6 4.7 CR000955 TRAC 2.7 0.7 2.7 0.7 10.0 1.5 CR000975 TRAC 3.8 2.0 3.1 1.4 8.0 0.8 CR000998 TRAC 2.4 0.6 2.2 0.8 4.3 1.3 CR000974 TRAC 1.9 0.5 1.8 0.6 3.3 0.8 CR000971 TRAC 3.0 1.0 2.4 0.5 3.1 0.6 CR000979 TRAC 2.2 1.0 2.2 1.0 3.0 0.4 CR000976 TRAC 1.8 0.6 1.7 0.6 2.8 0.1 CR000957 TRAC 1.3 0.0 1.3 0.0 1.6 0.4 CR000965 TRAC 1.0 0.1 1.0 0.1 1.4 0.1 CR000980 TRAC 33.0 5.0 26.1 3.7 N/A N/A

Editing in primary human T cells using systems including nRNA targeting TRAC was then tested in primary human CD3+ T cells from 3 different donors. As shown in Figure 15, % edit (as determined by TCR loss by flow cytometry) was uniform across all donors. These data demonstrated that certain nRNA molecules in combination with Cas9 were able to create indels in the alpha subunit of the TCR, resulting in loss of TCR expression on the surface of T cells. Editing efficiency does not depend on the donor, which ensures the wide applicability of this approach.

Example 6 Editing TRBC1 and TRBC2 in HEK cells

Editing of CRISPR systems containing lncRNA molecules including targeting domains to TRBC1 and TRBC2 sequences was tested in editing in HEK cells (nRNA delivered to cells stably expressing Cas9) and CD3+ T cells (nRNA and Cas9 delivered as RNP) according to the methods described in this application. The results are presented in Table 12. All mean % edits are measured by NGS and are based on at least 3 experiments. Figure 13 shows the best anti-TRBC1 and TRBC2 nRNA molecules as measured by % edit in HEK cells, along with flow cytometry data showing % edit in primary human CD3+ T cells, as measured by loss of TCR surface expression.

Table 12 nRNA number Target Coding or non-coding target region HEK (NGS) average total edit % SD CR000789 TRBC2 non-coding 62% 3% CR000780 TRBC2 non-coding 60% nine% CR000734 TRBC1 non-coding 59% 6% CR000761 TRBC2 non-coding 57% 2% CR000776 TRBC2 non-coding 54% nine% CR000786 TRBC2 non-coding 53% 7% CR000785 TRBC2 non-coding 52% 4% CR000737 TRBC1 non-coding 52% 5% CR000775 TRBC2 non-coding 51% 5% CR000783 TRBC2 non-coding 51% 5% CR000823 TRBC2 Coding 51% 6% CR000756 TRBC2 non-coding 45% 2% CR000798 TRBC2 non-coding 44% 2% CR000735 TRBC1 non-coding 44% 7% CR000731 TRBC1 non-coding 44% 5% CR000729 TRBC1 non-coding 43% 4% CR000774 TRBC2 non-coding 43% 5% CR000810 TRBC2 Coding 42% nine% CR000800 TRBC2 Coding 41% thirteen% CR000784 TRBC2 non-coding 40% 3% CR000762 TRBC2 non-coding 40% 5% CR000782 TRBC2 non-coding 40% 4% CR000815 TRBC2 Coding 39% nine% CR000748 TRBC2 non-coding 39% 3% CR000760 TRBC2 non-coding 38% 3% CR000781 TRBC2 non-coding 37% 4% CR000812 TRBC2 Coding 37% 7% CR000732 TRBC1 non-coding 36% 5% CR000788 TRBC2 Coding 36% 7% CR000752 TRBC2 non-coding 36% thirteen% CR000745 TRBC1 non-coding 34% 4% CR000759 TRBC2 non-coding 33% 7% CR000813 TRBC2 Coding 32% 4% CR000770 TRBC2 non-coding 32% 7% CR000738 TRBC1 Coding 31% 5% CR000816 TRBC2 Coding 31% eight% CR000744 TRBC1 non-coding 31% 2% CR000807 TRBC2 Coding 31% 4% CR000811 TRBC2 Coding thirty% 7% CR000766 TRBC2 non-coding thirty% 2% CR000787 TRBC2 non-coding thirty% one% CR000751 TRBC2 non-coding thirty% 6% CR000730 TRBC1 non-coding 29% 3% CR000739 TRBC1 non-coding 28% 6% CR000768 TRBC2 non-coding 28% 2% CR000771 TRBC2 non-coding 27% 4% CR000763 TRBC2 non-coding 26% 4% CR000754 TRBC2 non-coding 26% 7% CR000755 TRBC2 non-coding 24% 4% CR000769 TRBC2 non-coding 24% one% CR000777 TRBC2 non-coding 23% one% CR000764 TRBC2 non-coding 23% 6% CR000749 TRBC2 non-coding 23% 5% CR000767 TRBC2 non-coding 23% 5% CR000791 TRBC2 non-coding 23% 4% CR000809 TRBC2 Coding 22% eight% CR000773 TRBC2 non-coding 22% 7% CR000817 TRBC2 Coding 21% 6% CR000746 TRBC1 non-coding 21% 4% CR000753 TRBC2 non-coding 21% one% CR000757 TRBC2 non-coding 21% one% CR000793 TRBC2 non-coding 21% 4% CR000743 TRBC1 non-coding 20% 4% CR000741 TRBC1 non-coding 20% 2% CR000819 TRBC2 20% 3% CR000740 TRBC1 non-coding nineteen% 2% CR000814 TRBC2 Coding nineteen% 7% CR000728 TRBC1 non-coding sixteen% 6% CR000742 TRBC1 non-coding fourteen% 3% CR000733 TRBC1 non-coding ten% 4% CR000747 TRBC1 non-coding eight% one% CR000736 TRBC1 non-coding eight% one%

These data demonstrated that certain nRNA molecules in combination with Cas9 were able to create indels in the TCR beta subunit, resulting in loss of TCR expression on the surface of T cells.

Example 7: PDCD1 Editing in HEK Cells and Primary Human CD3+ T Cells

Editing of CRISPR systems containing lncRNA molecules including guide domains to PDCD1 sequences was tested by editing in HEK cells (nRNA delivered to cells stably expressing Cas9) and CD3+ T cells (nRNA and Cas9 delivered as RNP) according to the methods described in this application.

The results of editing in HEK cells are shown in Table 13. All mean % edits are measured by NGS and are based on at least 3 experiments. Figure 16 shows the best anti-PDCD1 nRNA molecules as measured by % editing in HEK cells. Figure 16 also shows the % of cells with loss of PD-1 expression as measured by flow cytometry using an anti-PD-1 antibody (ceBioJ105, eBioscience). Briefly, primary human CD3+ T cells were activated using the StemCell ImmunoCult starting on day 0. RNPs containing the indicated lncRNA were electroporated into cells on day 3 (Neon; 1600 V, 10 ms, 3 pulses). Two days after transfection (day 5), cells were stimulated with anti-CD3/CD28 Dynabeads beads (cell:bead ratio 1:3). PD-1 expression was assessed on day 10.

Table 13 % HEK Edit (NGS) nRNA number Target name The average St off CR000847 PDCD1 77% one% CR000902 PDCD1 72% eight% CR000852 PDCD1 72% 5% CR000826 PDCD1 70% 7% CR000904 PDCD1 70% 2% CR000839 PDCD1 69% ten% CR000828 PDCD1 69% 4% CR000835 PDCD1 69% 6% CR000829 PDCD1 68% 6% CR000879 PDCD1 68% eight% CR000870 PDCD1 66% eight% CR000831 PDCD1 66% thirteen% CR000848 PDCD1 65% 4% CR000855 PDCD1 61% 21% CR000838 PDCD1 61% 12% CR000840 PDCD1 59% 5% CR000884 PDCD1 59% 7% CR000830 PDCD1 57% 12% CR000871 PDCD1 57% eight% CR000850 PDCD1 55% nine% CR000869 PDCD1 55% 6% CR000903 PDCD1 54% eight% CR000824 PDCD1 54% 7% CR000882 PDCD1 fifty% eleven% CR000918 PDCD1 fifty% nine% CR000895 PDCD1 49% ten% CR000832 PDCD1 49% eight% CR000874 PDCD1 47% 5% CR000868 PDCD1 47% 7% CR000846 PDCD1 46% 6% CR000887 PDCD1 46% 6% CR000825 PDCD1 46% 6% CR000892 PDCD1 45% eleven% CR000917 PDCD1 43% nine% CR000896 PDCD1 42% 7% CR000919 PDCD1 42% eight% CR000863 PDCD1 40% nine% CR000842 PDCD1 40% fifteen% CR000827 PDCD1 39% eleven% CR000837 PDCD1 36% eight% CR000915 PDCD1 35% ten% CR000833 PDCD1 34% 5% CR000853 PDCD1 33% 4% CR000891 PDCD1 29% eleven% CR000849 PDCD1 29% 7% CR000897 PDCD1 26% 2% CR000872 PDCD1 26% 5% CR000844 PDCD1 25% 3% CR000854 PDCD1 24% 6% CR000867 PDCD1 24% 4% CR000856 PDCD1 23% 4% CR000845 PDCD1 21% 6% CR000881 PDCD1 21% 3% CR000894 PDCD1 nineteen% 3% CR000834 PDCD1 nineteen% 7% CR000841 PDCD1 nineteen% one% CR000858 PDCD1 sixteen% 2% CR000859 PDCD1 12% 3% CR000898 PDCD1 eleven% 3% CR000880 PDCD1 ten% 2% CR000893 PDCD1 ten% one% CR000885 PDCD1 ten% one% CR000883 PDCD1 nine% one% CR000843 PDCD1 eight% 2% CR000864 PDCD1 7% one% CR000875 PDCD1 6% 2% CR000899 PDCD1 5% 3% CR000890 PDCD1 5% 2% CR000914 PDCD1 5% one% CR000836 PDCD1 5% one% CR000916 PDCD1 5% one% CR000877 PDCD1 5% one% CR000888 PDCD1 4% one% CR000866 PDCD1 4% one% CR000851 PDCD1 4% 0% CR000865 PDCD1 4% one% CR000889 PDCD1 3% 0% CR000876 PDCD1 3% 0% CR000886 PDCD1 2% 0% CR000857 PDCD1 one% 0% CR000878 PDCD1 one% 0% CR000860 PDCD1 NA NA CR000861 PDCD1 NA NA CR000862 PDCD1 NA NA CR000873 PDCD1 NA NA CR000900 PDCD1 NA NA CR000901 PDCD1 NA NA CR000905 PDCD1 NA NA CR000906 PDCD1 NA NA CR000907 PDCD1 NA NA CR000908 PDCD1 NA NA CR000909 PDCD1 NA NA CR000910 PDCD1 NA NA CR000911 PDCD1 NA NA CR000912 PDCD1 NA NA CR000913 PDCD1 NA NA

Subsequently, editing of PDCD1 by exposure to RNPs comprising lncRNA molecules that include a guide domain with the indicated CRxxxx number was examined in primary human CD3+ T cells as measured by NGS, and loss of surface expression of PD-1 was examined by flow cytometry as described in this application. The results are shown in Figure 18. Several nRNA molecules showed good editing and loss of PD-1. These guides were then tested in CD3+ T cells from three different donors. The data are presented in Figure 19. As shown, nRNAs comprising the targeting domain CR00852, CR00828, CR00870, CR00848, CR00855 and CR00838 showed more than 50% editing in at least 2 donors.

Example 8: Simultaneous and Sequential Knockout of TRAC and B2M in Primary Human CD3+ T Cells

Primary human CD3+ T cells were activated and electroporated with RNP containing anti-B2M (CR000442) and/or TRAC (CR000984) nRNA. Briefly, B2M and/or TRAC targeting RNPs were electroporated into CD3+ T cells in the following ways: B2M RNP only; only TRAC RNP; B2M RNP+TRAC RNP; 0.5x B2M RNP+0.5x TRAC RNP; 0.5x B2M RNP+1x TRAC RNP; 1x B2M RNP+0.5x TRAC RNP; without RNP. This made it possible to determine the effect of different amounts of RNP (1 or 2 targets) on cell viability and the efficiency of target gene editing. Cells were examined by flow cytometry for TCR expression and for B2M expression. The results are shown in Figure 17A-17D. These results indicated that RNPs targeting two separate targets could be simultaneously delivered to CD3+ T cells by electroporation without adversely affecting viability or reducing the editing efficiency of any guide. In addition, high percentages of CD3+ T cells were successfully edited for both targets to produce a CD3-B2M population.

Then, the effect of editing two targets, B2M and TRAC, was evaluated with simultaneous or sequential introduction of RNPs containing lncRNA molecules to B2M and TRAC. For this experiment, RNPs were generated as described above using lncRNA containing the CR000442 targeting domain to target B2M and using lncRNA containing the CR000984 targeting domain to target TRAC. Briefly, CD3+ T cells were thawed, activated for 3 days (Immunocult CD3/CD28 T cell activator manufactured by StemCell Technologies). On day 3 and day 4 (successively) or day 3 (simultaneously), cells were electroporated with the introduction of RNP complexes and stored until day 5 after delivery (Day 9), when B2M and/or TCR expression was assessed by FACS (then by NGS after cell lysis). T cells were maintained in the presence of an activating reagent throughout electroporation and post-electroporation processing. B2M and TCR expression was assessed by FACS (using anti-B2M antibody clone 2M2 or anti-CD3 antibody clone OKT3 at a 1:200 dilution). The cells were then lysed and the editing of the target loci was assessed by NGS. The results are presented in Figures 25 and 26. These results indicate that both sequential and simultaneous targeting of B2M and TRAC results in a similar double knockout rate.

Example 9: Editing FKBP1A

Editing of FKBP1A using lncRNAs directed to the FKBP1A gene was investigated in HEK293 cells modified to express Cas9 as described above. Data including % edit and % frameshift edit (CPC) are presented in Figure 21, Figure 22 and Figure 23. Based on these results, the top 15 nRNA molecules with the highest percentage of CPC edit were identified. These nRNA molecules, including their targeting domains, are shown in Figure 23. Editing of FKBP1A in CD3+ T cells was then examined using RNPs containing double guides including the targeting domain for FKBP1A. Cells, RNP and all methods were prepared and performed as described above. The results are presented in Figure 24.

To follow up on previous experiments, nRNAs containing the guide domains of the most efficient editing nRNAs were again tested in primary human T cells. Figure 52 shows genomic editing of the FKBP1A locus by electroporation of primary human T cells using RNPs containing the indicated FKBP1A-targeted nRNAs in lncRNA format (as described above). The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown. The results demonstrate a subpopulation of nRNAs that are capable of high editing efficiency (>80%) with a high percentage of frameshift editing (>65%). Figure 53 shows the top 5 most commonly observed sequence changes (indels) for each FKBP1A directed nRNA used to edit primary human T cells.

Example 10: Editing CIITA

Editing of CIITA using lncRNA targeting the CIITA gene was tested in HEK293 cells modified to express Cas9 as described in Example 1 above. .

Table 24. % Edit (N=3) and % Frameshift Edit (FFR) as measured by NGS in HEK293 cells stably expressing Cas9 using lncRNAs that include a CIITA guide domain as indicated. The nRNA molecules in the Table are ranked by % edit. HEK293_Cas9 cells Number Target Avg. % edit Stoff % edit Avg. % CPC Stotk % SRS Rank CR002993 CIITA 60.16 6.68 48.86 4.24 one CR002991 CIITA 59.11 9.04 51.40 8.37 2 CR002995 CIITA 52.74 11.49 43.64 9.45 3 CR002948 CIITA 52.71 7.63 48.08 6.93 4 CR002980 CIITA 50.30 13.62 42.41 11.48 5 CR002961 CIITA 50.29 6.60 38.41 4.64 6 CR003001 CIITA 47.64 11.32 43.30 10.38 7 CR002992 CIITA 46.54 12.64 31.23 7.79 eight CR002971 CIITA 45.94 13.74 33.61 9.92 nine CR002976 CIITA 45.36 14.84 37.66 12.71 ten CR002967 CIITA 44.47 21.39 38.77 18.85 eleven CR003007 CIITA 43.64 12.08 32.22 8.81 12 CR002953 CIITA 43.60 11.37 34.95 9.42 thirteen CR002994 CIITA 42.35 8.53 31.32 5.55 fourteen CR002965 CIITA 41.85 16.72 29.63 10.99 fifteen CR002972 CIITA 41.06 12.07 28.56 9.07 sixteen CR003011 CIITA 38.96 19.22 22.19 10.64 17 CR002978 CIITA 38.34 18.04 34.11 16.14 eighteen CR003013 CIITA 37.75 11.18 29.94 8.82 nineteen CR002962 CIITA 37.71 10.14 26.10 7.04 20 CR002966 CIITA 37.12 18.00 31.49 15.77 21 CR002981 CIITA 36.28 15.11 29.98 12.29 22 CR002983 CIITA 35.90 10.82 33.83 10.53 23 CR002970 CIITA 35.40 15.32 25.50 10.63 24 CR002943 CIITA 35.24 3.38 26.47 2.47 25 CR002990 CIITA 35.19 11.07 24.08 7.77 26 CR003003 CIITA 35.07 16.21 27.91 12.76 27 CR002941 CIITA 34.89 4.47 21.77 3.02 28 CR002956 CIITA 34.30 9.28 29.66 8.14 29 CR002944 CIITA 34.04 2.10 22.26 1.09 thirty CR002945 CIITA 33.37 9.71 17.29 4.42 31 CR002985 CIITA 32.99 11.62 29.52 10.46 32 CR002940 CIITA 32.80 8.06 22.25 6.09 33 CR002958 CIITA 32.78 8.06 22.49 4.77 34 CR003009 CIITA 32.69 14.75 25.62 11.60 35 CR003014 CIITA 32.51 14.39 26.93 11.72 36 CR002963 CIITA 32.48 13.28 26.80 11.02 37 CR002946 CIITA 31.12 11.15 14.20 4.24 38 CR002959 CIITA 30.79 8.79 29.78 8.64 39 CR002973 CIITA 30.60 11.08 23.55 8.17 40 CR003021 CIITA 29.94 10.67 26.88 9.37 41 CR003026 CIITA 29.63 6.59 20.05 4.52 42 CR002968 CIITA 29.53 17.36 22.22 12.73 43 CR003023 CIITA 29.38 7.13 16.83 3.71 44 CR002979 CIITA 28.91 13.80 23.07 10.56 45 CR003018 CIITA 27.72 9.36 26.54 9.18 46 CR002987 CIITA 27.56 11.04 24.06 9.81 47 CR003015 CIITA 27.40 7.88 24.05 6.97 48 CR002989 CIITA 27.38 13.31 8.45 4.26 49 CR002964 CIITA 26.56 11.21 19.56 7.74 fifty CR003010 CIITA 25.45 10.54 14.37 5.52 51 CR002988 CIITA 25.29 13.48 11.35 5.56 52 CR002951 CIITA 25.09 6.28 16.13 3.91 53 CR003025 CIITA 24.52 6.66 19.21 4.70 54 CR002996 CIITA 23.91 7.13 17.83 5.34 55 CR003022 CIITA 23.73 11.35 17.96 8.69 56 CR003020 CIITA 23.67 9.57 16.44 6.58 57 CR002999 CIITA 23.50 12.38 18.58 9.69 58 CR002939 CIITA 22.02 5.58 17.27 4.64 59 CR003017 CIITA 21.90 4.21 15.22 2.47 60 CR003005 CIITA 21.11 6.97 18.08 5.97 61 CR002969 CIITA 20.82 14.36 14.85 9.88 62 CR003024 CIITA 20.40 6.26 16.33 4.88 63 CR003006 CIITA 19.46 9.28 14.66 6.72 64 CR002954 CIITA 19.43 7.05 6.28 2.27 65 CR003004 CIITA 19.43 7.68 15.63 6.01 66 CR002975 CIITA 19.31 3.56 15.82 2.58 67 CR002977 CIITA 19.11 9.48 12.99 6.31 68 CR003016 CIITA 17.86 4.27 13.55 3.56 69 CR002942 CIITA 17.14 1.59 8.91 0.97 70 CR002950 CIITA 16.64 4.84 8.65 2.46 71 CR002947 CIITA 15.86 4.03 8.10 2.13 72 CR003008 CIITA 15.30 10.49 10.91 7.58 73 CR003000 CIITA 12.83 7.31 10.53 5.76 74 CR003002 CIITA 11.85 4.06 9.78 3.32 75 CR003019 CIITA 11.80 2.88 9.74 2.19 76 CR003012 CIITA 10.67 6.52 7.51 4.18 77 CR002960 CIITA 10.56 3.88 6.96 2.14 78 CR002982 CIITA 10.45 4.28 9.05 3.66 79 CR002952 CIITA 10.37 4.96 8.22 4.17 80 CR002974 CIITA 8.99 2.67 6.92 1.79 81 CR002955 CIITA 7.88 3.56 5.04 2.25 82 CR002998 CIITA 4.95 6.44 4.84 6.27 83 CR002957 CIITA 3.73 0.70 3.15 0.48 84 CR002949 CIITA 2.39 0.64 1.83 0.32 85 CR002984 CIITA 2.33 0.18 2.19 0.17 86 CR002986 CIITA 1.77 0.51 1.48 0.27 87 CR002997 CIITA N/A N/A N/A N/A 88

The editing of CIITA nRNA molecules with the highest % editing in CD3+ primary human T cells was then assessed as described in Example 1. The results are shown in Table 32.

Table 32. % Edit and % Frameshift Edit (measured by NGS) with CIITA-targeted lncRNA molecules delivered as RNPs to CD3+ T cells CD3+ NGS Referring domain number % edit ST.off. % edit % editing with CPC Edit Std Disabled CR002948 41.6 2.3 33.6 1.7 CR003001 36.3 1.8 32.0 1.3 CR002991 33.9 3.4 29.2 3.3 CR002993 33.8 2.6 27.2 1.7 CR003007 31.6 1.6 28.8 1.7 CR002961 30.3 2.0 24.7 1.2 CR002965 29.0 3.9 24.4 3.2 CR002967 28.0 0.7 25.6 0.5 CR002972 26.6 1.1 20.9 1.9 CR002994 22.0 2.7 18.1 2.3 CR002992 16.0 1.6 11.6 0.8 CR003013 11.5 0.9 9.0 0.6 CR002971 7.2 0.7 5.4 0.4 CR002980 6.1 0.5 3.6 0.6 CR003011 5.2 0.6 4.9 0.6 CR002953 5.1 0.7 4.8 0.7 CR002978 4.7 0.7 2.7 0.2 CR002976 4.0 0.3 3.6 0.3 CR002962 3.4 0.4 2.9 0.4 CR002995 3.1 0.2 2.5 0.4

The editing and loss of expression of the class II MHC molecule in response to a subpopulation of anti-CIITA gRNA molecules was then evaluated in primary human T cells. Briefly, primary human T cells were obtained in culture and activated using CD3/CD28 bead stimulation (DynaBeads Invitrogen cat. no. 111.41D) at a bead to cell ratio of 3:1. On day 2, an RNP consisting of S. pyogenes Cas9 pre-complexed with lncRNA molecules (using the crRNA and tracr sequences described above) comprising the targeting domains was electroporated into T cells using a Neon electroporator, with three different RNP concentrations (0.3 μM, 1.0 μM and 3.0 μM; diluted after RNP formation). On Day 5 and Day 7, % edit was assessed by loss of HLA-DR expression as assessed by flow cytometry. The results obtained on Day 5 and Day 7 were comparable. % editing in T cells (eg, % of cells that are CD3+ and HLA-DR-) on day 5 is shown in Figure 37. As shown, at the highest concentration tested, each RNP that included lncRNA molecules CR02991, CR02993, and CR03007 , resulted in >50% editing as measured by loss of HLA-DR surface staining. As shown below, the lack of editing observed in the case of CR002961 nRNA was due to an error in the experimental procedure. When the experiment was repeated (data shown in Figure 39), RNP including nRNA CR002961 resulted in dose-dependent levels of reduction in HLA-DR expression.

The experiments described above were repeated with a different set of anti-CIITA nRNA molecules. Figure 38 shows the results of this experiment with genomic editing of the CIITA locus by electroporation of primary human T cells using RNP containing the specified nRNA targeting the CIITA locus. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown (% frameshift edits). The top 5 most frequently observed sequence changes are shown in detail in the bottom panel. These data indicate that CIITA targeting nRNAs are capable of >90% editing with 74% frameshift editing in primary human T cells.

The experiment was again carried out using a third set of CIITA targeting nRNAs at various RNP concentrations. Figure 39 shows the % post-electroporation Day 3 edit in primary human T cells exposed to RNPs that include the indicated anti-CIITA lncRNA (number denotes targeting domain identifier CR00xxxx) at the indicated concentration, as measured by flow cytometry using an anti-HLA reagent. -DR. The % edit represents cell surface expression of HLA-DR in cells electroporated with CIITA guide compared to expression in cells electroporated without guide RNA. As stated above, the activity of CR002961 nRNA was confirmed in this experiment. Figure 40 indicates the frequency of insertions or deletions (% indels) and shows the percentage of such edits that result in a frameshift of the coding sequence (% frameshift edit). These data indicate that another set of CIITA-targeting nRNAs have been identified that are capable of >85% editing at 87% frameshift editing (CR002967) in primary human T cells. Figure 41 shows the top 5 most frequently observed sequence changes for each CIITA-targeted nRNA used to edit primary human T cells.

The experiment was again performed using a different set of nRNAs targeting CIITA and compared with the most effective nRNAs (CR0002967) from the previous experiment. Figure 42 shows the results of % editing on Day 3 after electroporation of primary human T cells using RNPs that include the indicated lncRNA to CIITA (the number indicates the targeting domain identifier CR00xxxx) at the indicated concentration, as measured by flow cytometry using an anti-HLA reagent. -DR. Figure 42 shows the frequency of insertions or deletions (% indels), and the percentage of their edits that result in a frameshift of the coding sequence (% frameshift edits), when the indicated nRNAs are used. Figure 44 shows the top 5 most commonly observed sequence changes (indels) for each of these CIITA-targeted nRNAs in primary human T cells. These data confirm the high editing/frameshift/loss of HLA-DR for RNPs including lncRNA CR002967, and additionally identify other CIITA-targeted nRNAs that result in high editing (>90%) and high frequency of frameshift mutations (> 80%) in primary human T cells.

Example 11: Editing TCR (TRAC) and B2M in BCMA CAR T Cells

Table 25: Reagents used for flow cytometry Name Catalog number company Designation Clone R-PE streptavidin 016-110-084 Jackson Immuno Research SAPE Streptavidin AFC-eFluor780 47-43-17-82 eBiosciences SA-APC-e780 APC-conjugate against B2-human microglobulin 316312 Biolegend B2M-APC PerCP-Cyanine5.5 anti-human CD3 conjugate 45-0037-42 eBiosciences CD3 PerCPcy5.5 OKT3 APC conjugate against human CD8a 17-0087-42 eBiosciences CD8APC SK1 Alexafluor700 anti-human CD8a conjugate 300920 Biolegend CD8Af700 efluor 450 anti-human HLA-DR conjugate 48-9956-42 eBiosciences HLA-DR V450 LN3 efluor 450 anti-human CD8a conjugate 48-0086-42 eBiosciences CD8 V450 OKT8 efluor 450 human anti-CD4 conjugate 48-0047-42 eBiosciences CD4 V450 SK3 eFlour780 Fixable Stain for Live Cell Detection 65-0865-14 eBiosciences L/D e780

Table 26: Components of T cell media Component Invitrogen part number Concentration RPMI 1640 22400-089 FBS 16140 10% final L-glutamine 25030-081 200 mm (100× stock) Non-essential amino acids 11140-050 10 mM (100× stock) sodium pyruvate 11360-070 100 mm (100× stock) HEPES buffer 15630-080 1 M (100× stock) 2-mercaptoethanol 21985-023 55 mm (1000× stock)

Editing of allogeneic T cell targets in T cells modified to express BCMA CART and function of the edited cells were assessed. T cells, including TCR-B2M-/BCMA CAR+ T cells used in these experiments, were obtained as schematically described in Figure 27. Briefly, PBMCs were isolated from human blood using the Ficoll centrifugation method. Total T cells were isolated from PBMCs (Hemacare) using a Pan T cell isolation kit (Miltenyi Biotec 130-096-535) for human T cell isolation. These cells were aliquoted, frozen using CRYOSTOR CS10 medium (Biolife Solution 210102) and stored in liquid nitrogen. These frozen cell aliquots were then thawed in a 37°C water bath for 20 seconds, transferred to a 50 ml conical tube with 10 ml of prewarmed T cell medium, and centrifuged at 300 rpm for 5-10 minutes at 24°C. to remove the freezing medium, and resuspend in prewarmed T-cell medium. The cells were then transferred to a 24-well plate and activated by adding CD3/CD28 beads (DynaBeads Invitrogen cat. no. 111.41D) at a bead to cell ratio of 3:1. On Day 1 after activation, a lentivirus comprising the BCMA-13 CAR coding sequence (139112 from Table 23 above) was transduced into these cells at a MOI of 5. UTD (non-transduced cells) were not treated with virus. On Day 4 after activation, 250,000 cells per condition, BCMA CAR-13 or non-transduced T cells, were electroporated with RNP using BTX (settings: 1000 V/0.6 ms/1 pulse) with or without guide RNA as indicated. To obtain RNP, lncRNA molecules including tracr RNA and anti-TRAC and B2M crRNA were heated together at 95°C for 2 minutes and gradually cooled to room temperature, after which they were incubated with Cas9 protein and 5× CCE buffer for 10 minutes at 37°C. In the case of TRAC editing, the targeting domain CR000985 (sequence: CCGAAUCCUCCUCCUGAAAG (SEQ ID NO: 5593)) was used, and in the case of B2M editing, the targeting domain CR000442 was used (sequence: GGCCACGGAGCGAGACAUCU (SEQ ID NO: 5496)). In each case, lncRNA was used with the crRNA sequence: [guide domain]-GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 6607), and the tracr sequence: AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID NO: 6660). After electroporation, the cells were again placed in 0.5 ml of T-cell medium in a 24-well plate. Two days after electroporation, cells were collected every other day, maintaining a cell density of 0.5 million/ml. Five days after electroporation, 100,000 cells were examined by flow cytometry (BD Fortessa) using the FlowJo software. 100,000 cells were aliquoted into each well of a 96 well round bottom plate. Cells were taken from each sample, pipetted to separate from the beads, the beads were removed with a 96-well plate magnet and centrifuged with 100 µl of FACS buffer (MACS Miltenyi buffer, part number 130-092-987, with 0.5% BSA (Miltenyi, catalog number 130-091-376)) to wash the cells. Cells were then incubated with various antibodies diluted in 100 µl of FACS buffer for 30 minutes on ice. The cells were then washed twice with 200 μl of FACS buffer. The cells were then resuspended in 150 μl of FACS buffer and analyzed on a Fortessa flow cytometer (Becton Dickenson) equipped with 5 lasers. TCR expression was detected using the PercpCy5.5 anti-CD3 conjugate (eBiosciences 45-0037-42) and B2M expression was detected using the anti-B2M APC conjugate (Biolegend 316312). CAR expression on the cell surface was assessed by staining with biotinylated L protein followed by the addition of streptavidin-PE (Jackson Immuno Research 016-110-084). T cells were detected by staining for CD4 using the V450 anti-CD4 conjugate (Ebiosciences 48-0047-42) or CD8 using the alexa700 anti-CD8 conjugate (Biolegend 300920). Expression of TCR (using the anti-CD3 PercpCy5.5 conjugate) and B2M (using the anti-B2M APC conjugate) is shown in Figure 28. T cells transduced with BCMA CAR BCMA-13 are labeled "CAR". Non-transduced cells are designated "UTD". Cells electroporated with Cas9 but without guide RNA are referred to as "no nRNA". Staining for CD4 using the V450 anti-CD4 conjugate is shown in the bottom panels of FIG. 28 to confirm that the loss of CD3 staining is due to loss of TCR and not loss of T cells. These results demonstrate that simultaneous administration of B2M and TRAC CRISPR systems can be used to generate a high yield population of T cells that do not express TCR and B2M, with 72% of T cells in the CAR transduced group showing negative staining for TCR and to B2M. Then, TRAC and B2M editing was evaluated in the CAR+ subset of cells evaluated in FIG. 28. The results are shown in Figure 29. Briefly, the cells shown in Figure 28 were analyzed by sorting CAR+ cells (stained with biotinylated L protein and then streptavidin-PE), in the left panel, or without CAR sorting (total T-lymphocytes ; right panel). Editing levels in the CAR+ and total T cell populations are similar, indicating that CAR expression had no effect on editing efficiency.

The cells shown in Figure 28 were then examined for CAR expression by PE channel analysis. As shown in Figure 30, the percentage of CAR positive cells was similar in cells with guide RNA (TRAC and B2M) and in cells lacking guide RNA (no nRNA), indicating that TCR and B2M editing had no effect on expression. CAR. UTD stands for non-transduced cells. CAR refers to cells that have been transduced with BCMA CAR.

The ability of T cells to proliferate in response to BCMA (target antigen of the CAR molecule) was then evaluated. Briefly, cells were obtained as described above, thawed and co-cultured with target cells expressing BCMA (KMS11 (high expression), RPMI8226 (low expression)) or not expressing BCMA (Nalm6). T cells transduced with CAR BCMA-13 are designated "BCMA CAR". Non-transduced cells are designated "UTD". Cells electroporated with Cas9 but lacking guide RNA are labeled "no nRNA". Cells electroporated with RNP containing B2M and TCR guides are designated "B2M+TCR". 25,000 irradiated target tumor cells were co-cultured with T cells at a ratio of 1:1 for 4 days, followed by analysis by flow cytometry. The number of T cells (stained with V450-anti-CD4 and alexa700-anti-CD8) was determined by the number of CD4+ and CD8+ cells relative to 3000 enumeration beads (Life technology, catalog number C36950). As shown in Figure 31, both populations of cells transduced with CAR BCMA lentivirus showed proliferation in response to both types of BCMA-expressing cells, with the population of cells with RNPs containing B2M and TRAC-targeted nRNA molecules showing a higher number of T cells through 4 days of co-cultivation. As shown in Figure 32, when CAR+ CD4+ and/or CD8+ T cell proliferation was evaluated separately, the results were similar, with CAR+ T cells (sorted by biotinylated L protein staining followed by streptavidin-APC-efluor780 staining) proliferating in response to both type of BCMA-expressing cells. The foregoing written description is considered sufficient to enable a person skilled in the art to put the invention into practice.

Example 12 Analysis of the effect of RNP concentration and indel profiles using RNP complexes directed against TCR or B2M and generation of CIITA-/B2M-/TCR-CAR T cells

Methods

PBMCs were isolated from human blood (Hemacare) using the Ficoll centrifugation method. Total T cells were isolated from these PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec 130-096-535) for human T cell isolation. These cells were aliquoted and frozen. These frozen cell aliquots were then thawed and activated using CD3/CD28 beads (DynaBeads Invitrogen, cat. no. 111.41D) at a bead to cell ratio of 3:1. On day 2 or day 3 after bead activation, 200,000 cells were taken from the culture for electroporation. The RNP complex used to edit the T cell genome was generated using a 1:2 molar ratio of Cas9 protein to RNA (crRNA and tracRNA). 100 μm crRNA and 100 μm tracrRNA were denatured separately at 95°C for 2 minutes and cooled to room temperature. In a final volume of 5 µl, 1.4 µl of Cas9 protein at a concentration of 5.9 µg/µl (NLS-Cas9-NLS) was mixed with 1.6 µl of Cas9 buffer (20 mM Tris, pH 8.0; 200 mM KCl, 10 mM MgCl ₂ ) and mixed with 1 μl of 100 μM tracrRNA at room temperature. Then 1 µl of 100 µM crRNA was added, mixed and incubated for 10 min at 37°C. If more than one RNP was added during the electroporation step, each RNP with crRNA targeting a particular gene was collected separately using the above method, and then combined together with the addition of Cas9 buffer, obtaining different final RNP concentrations for different conditions. Details on the amounts of RNPs for "triple editing", that is, the simultaneous addition of 3 RNPs targeting different genes, are shown in the figures. The harvested RNPs were then mixed with 200,000 cells in 10 µl Buffer T (from the 10 µl Neon Transfection System kit). Electroporation was performed with a Neon electroporator using the Neon® Transfection System 10 µl (MPK1096) at 1600 V, 10 ms, 3 pulses. In the case of CIITA, editing was quantified by measuring the loss of HLA-DR expression on the cell surface by flow cytometry 3 days after electroporation. Cells were stained with anti-CD3 conjugate (PerCP-Cy5.5), V450 anti-HLA-DR conjugate and e780 live/dead cell dye (APC-Cy7) and analyzed by flow cytometry. TRAC editing was quantified by measuring the loss of CD3 epsilon surface expression by flow cytometry 3 days after electroporation using an anti-CD3 antibody (PerCP-Cy5.5). B2M editing was measured by loss of cell surface expression using flow cytometry 4 days after electroporation using anti-B2M APC antibody (Biolegend 316312). To assess the frequency of editing and sequence changes resulting from gene editing in the above T cells, genomic DNA was isolated and subjected to sequencing. Briefly, frozen cell pellets were thawed and processed using the DNeasy Blood & Tissue Kit (Qiagen, 69506) for genomic DNA isolation. The eluted DNA was used for PCR using the Titanium Taq PCR kit (Clontech Laboratories, 639211) and the primers in Table 27.

Table 27: PCR primer sequences. Target Direct primer SEQID NO: reverse primer SEQID NO: B2M GCACGCGTTTAATATAAGTGGAGG 10819 GACCCTCCCGTCGCC 10832 FKBP12 CCTCATCTGTGTCAGCGGGCAT 10820 CGAGGTACTAGGCAGAGCCGTGG 10833 TRAC (guides CR000961, CR000978) CATCACGAGCAGCTGGTTTC 10821 GGACTGCCAGACAAGGCTC 10834 TRAC (guides CR000979) GAGCCGAGGTATCGGTCCTG 10822 ATTCAGGAGAGACCCCACCC 10835 TRAC guides (CR000984, CR000991, CR000992, CR000993) TGTTTGTAAGGGGATATGCACAGA 10823 GTTTCAGGCCATTATTATTGCACA 10836 CIITA (guides CR002961, CR002967) TGTTGTAGGTGTCAATTTTCTGCC 10824 AATTTCCCCTGATTGCCGTCTCTA 10837 CIITA (guide CR002991) CCCTCTTTCCAGAAATTTCCTTCTTC 10825 GACTGACGTGGCTCATGATGAAT 10838 CIITA (guide CR003007) AATAGAGACTCACCTTGGGCTTTC 10826 GTACATTTTAAGGCTCCTGTTGGC 10839 CIITA (guide CR003001) GCCTTCAGTTAGACCTTGTTGATT 10827 GAGTCTCTATTGTACCCACCTTGG 10840 CIITA (guide CR002994) TCCTTCTTCATCCAAGGGACTTTTT 10828 CCCTTGCAATGATTTCTGTGGG 10841 CIITA (guide CR002992, CR002993) TTCTTCATCCCAAGGGACTTTTCCT 10829 GACTGACGTGGCTCATGATGAAT 10842 CIITA (guide CR002961, CR002967, CR002965) TGTTGTAGGTGTCAATTTTCTGCC 10830 AATTTCCCCTGATTGCCGTCTCTA 10843 CIITA (guide CR002972, CR002980, CR002976) TGTAGGTGTCAATTTTCTGCCTCT 10831 GAATTTCCCCTGATTGCCGTCT 10844

The PCR product was purified using the QIAquick PCR Purification Kit (Qiagen, 28104). The purified PCR product was then used for T7E1 analysis to detect non-complementary base pairs and confirm gene editing. PCR amplicons were subjected to standard Nextera NGS library preparation (Illumina) and sequenced with paired-end reads on an Illumina MiSeq sequencer. The sequencing reads were aligned with the reference genome and variants identified.

results

First, TRAC-targeting nRNAs were evaluated by their effect on cell surface TCR expression at different concentrations of Cas9 (RNP). Human primary T cells were electroporated on day 3 after activation with RNP CD3/CD28 beads at the indicated concentrations (µM) containing the respective nRNAs in double guide format. Additional guide numbers denote the identifier CRxxxxx of the nRNA guide domain. Loss of TCR expression was assessed by staining with anti-CD3 antibody and by flow cytometric analysis 3 days after electroporation (CD3 knockout T cells (%)). Figure 33A shows the loss of CD3 staining upon electroporation of RNP complexes containing guides CR000961 (961), CR000978 (978), CR000984 (984), CR000992 (992), CR000985 (985), and CR000960 (nRNA1) and CR000979 (nRNA8). These data indicate that almost maximal editing (indicated by loss of CD3 staining) was achieved for RNP complexes with CR000961 and CR000984-containing nRNAs at RNP concentrations between 0.2 and 0.3 μM. Other nRNAs achieved maximum editing at 1 μM concentrations. Figure 33B shows the loss of CD3 staining upon electroporation of RNP complexes containing guides CR000991 (991), CR000992 (992), CR000993 (993) and CR000978 (978). 991 and 992 overlap almost completely. In this case, again, for RNPs containing nRNA 991, 992, and 993, maximum editing was observed at RNP concentrations of 0.3 μM, while % editing of nRNA 978 continued to increase to 1.1 μM. As shown in Figure 33C, electroporation of T cells using nRNA directed to the TRAC locus results in a high level of indel formation at the target sites (up to 97% edit) and a high level of frameshift mutations that are expected to result in loss of protein expression (up to 78%). Mutations (indels) at each target locus were then assessed using next generation sequencing. Figure 34A and Figure 34B show the top 5 most frequently observed sequence changes for each TRAC-targeted lncRNA used to edit primary human T cells. Figures A and B represent the result of 2 independently conducted electroporation experiments. Data are the average of triplicate PCR products. These data show consistent editing profiles across many experiments using the same nRNA and RNP format, with the same delivery method.

Then similar experiments were carried out with nRNA (double guide format) targeting B2M. First, the effect of RNP concentration was evaluated. Human primary T cells were electroporated on day 2 post-activation with CD3/CD28 RNP beads at the indicated concentrations containing the appropriate nRNAs. The guide numbers denote the identifier CR00xxx of the referencing domain. Loss of B2M expression was assessed by staining with anti-B2M antibody and by flow cytometry analysis 4 days after electroporation (B2M-negative cells). The results are presented in Figure 35 and demonstrate that >85% editing (in B2M loss of surface expression assay) was achieved with nRNA 442 at 0.2 μM, and at a slightly higher RNP concentration (0.4 μM) with nRNA 442 and 455. As shown in Figure 36, RNPs including CR000444 and CR000455 nRNAs result in high level editing and high level frameshift editing in primary human T cells. The top ten indels obtained from each nRNA are shown in the bottom panel. Data are the average of triplicate PCR products.

Then, simultaneous editing of TCR, B2M and CIITA was performed on CART cells and the function of such CART cells was evaluated. Figure 45 shows the schematic protocol that was used in these experiments to generate primary human T cells edited at the B2M, TRAC and CIITA loci (triple edited cells). Figure 46 shows the % loss of expression on the cell surface of CD3 epsilon, B2M and HLA-DR, respectively, according to flow cytometry (as editing indicators for TRAC, B2M and CIITA, respectively). As expected, cells after electroporation of only one nRNA showed the loss of only the expected protein. In cells treated with 3 RNPs, each containing a specific target nRNA, cells in each population showed more than 80% loss of each of the target proteins, as well as >80% loss of B2M and TRAC, except for the lowest concentration of CIITA-targeted nRNA (triple 4), resulting in a lower loss of HLA-DR than delivering higher concentrations of this RNP to cells. Figure 47 shows genomic editing of the B2M, TRAC, and CIITA loci by simultaneous electroporation of primary human T cells with 3 RNP complexes containing gRNAs targeting the B2M, TRAC, and CIITA loci. The frequency of insertions or deletions (% indels) is indicated, and the percentage of such edits that result in a frameshift of the coding sequence is shown in parentheses. Figure 48, Figure 49 and Figure 50 show the top 10 most commonly observed sequence changes at the B2M locus (in response to nRNA including CR000442), the TRAC locus (in response to nRNA including CR000961), and at the CIITA locus (in response to nRNA , including CR002991), respectively, in primary human T-cells within the framework of simultaneous editing of 3 loci (triple editing) with different concentrations of each RNP, as shown schematically in Figure 45. These data indicate that the effective gRNA molecules used in this case, induce knockout of TRAC, CIITA, and B2M in primary human T cells with high efficiency, and result in T cells with reduced graft-versus-host ability (due to TCR loss) and reduced host-versus-graft ability (due to loss of TCR). B2M and CIITA), which represents an important step towards obtaining an allogeneic, ready for mass application, T-cell product.

Then the influence of the format of the nRNA molecule was evaluated. Anti-TRAC targeting RNA (incorporating CR000961 targeting domain; upper panel) or B2M (incorporating CR00442 targeting domain; lower panel) was synthesized in single-guide or double-guide format, with or without the indicated chemical modifications (PS (3 nt per 5' and per 3 '-terminus are phosphothioate) or OMePS (3 nt at 5' and at 3'-end are 2'-OMe and phosphothioate); in the case of double guide RNA, modifications included crRNA and tracr RNA). RNP was electroporated into human primary T cells at the indicated concentrations. Figure 51 shows the results of these experiments: editing efficiency was assessed by analyzing cell surface CD3 epsilon staining in the case of TRAC editing (top) and B2M protein in the case of B2M editing (bottom) by flow cytometry. As shown in Figure 51, all formats were able to provide high-efficiency editing at a RNP concentration of 1 μM, however, the ssRNA format was able to maintain high-efficiency editing at lower concentrations than lncRNA formats (down to 0.04 μM for nRNAs including the CR000961 guide domain, and up to 0.1 μM for nRNAs containing the CR000442 guide domain). In the case of TRAC-targeted nRNA, the chemical modification had no effect on editing efficiency at the RNP concentrations tested. In the case of the B2M-targeted nRNA, the chemical modification of the sRNA affected the editing efficiency at the lowest concentration tested, with the PS-modified sRNA having the highest editing efficiency at an RNP concentration of 0.04 µM.

Example 13 Immunosuppression resistance of T cells after FKBP1A genomic editing and functional evaluation of TCR-/FKBP12-CART cells

Without being limited by theory, as described in this application, it is believed that another strategy for creating ready-to-use ("universal") CART cells is to reduce or eliminate TCR expression (for example, to reduce or suppress graft versus host reaction), as well as reduction or elimination of the expression of the target of an immunosuppressant (for example, an mTor inhibitor). Subsequent treatment of the patient with such genomically edited CART cells in combination with said immunosuppressant inhibits the host's immune response (eg, inhibition of host anti-graft responses) without inhibiting the function of the CART cell (eg, antitumor function of the CART cell). For this purpose, the function of T-cells edited to TCR- and FKBP12- was studied, including in the presence of the mTor inhibitor RAD001.

Methods:

After thawing, isolated human T cells were activated with CD3/CD28 beads for 3 days at a bead to cell ratio of 3:1. Cells were then electroporated with RNP containing double guide RNA molecules (as indicated as described above in these examples) and Cas9 protein using a Neon instrument with a 100 µl nozzle set. RNP complexes were prepared as follows. crRNA and trRNA (10 μl each in 100 μl) were heated in separate tubes to 95 degrees Celsius for two minutes and then cooled for 5 minutes at room temperature. Cas9 protein (1.5 mg/ml), 20 μM trRNA and 20 μM crRNA and 17 μl of buffer (20 mM Tris, pH 8.0, 200 nM KCl, 10 mM MgCl ₂ ) were combined in a total volume of 50 μl and incubated at 37 degrees for 10 minutes. RNP was then mixed with 100 μl of cells at a cell density of 2 million cells per ml of buffer T (Invitrogen; cat. no. MPK1096). 100 μl of RNP-mixed cells were transferred to a Neon pipette tip and electroporated at 1600 V, 10 ms, 3 pulses. The final RNP concentration was 3.3 μM, as was the Cas9 protein.

After electroporation, the cells were transferred to a 6-well plate with 2 ml of beaded T cell medium at a bead to cell ratio of 3:1. New medium was added every two days. On day 4 after electroporation, the cells were separated from the beads and seeded again at a density of 0.5 million per well in a 96-well plate with 100 μl of medium, after which new beads were added at a ratio of beads to cells of 1:1 for 2 hours. To determine the functional effects of FKBP1A editing, cells were treated with or without 2.5 nM RAD001 (as indicated) for 3 hours. S6 phosphorylation was detected by flow cytometry and used as an indicator of RAD001 immunosuppression. To obtain flow cytometry samples, cells were centrifuged and washed with FACS buffer (MACS working buffer + 0.5% sBSA), stained with dead/live cell dye (Zombie violet fixable viability kit, Biolegend, cat. no. 423114) for 10 minutes. Cells were then washed with FACS buffer and fixed overnight with Cytofix/Cytoperm solution (Becton Dickenson, cat. no. 554714). The cells were then washed twice with PBS and permeabilized with a Cytofix/Cytoperm solution (Becton Dickenson, catalog number 554714) for 20 minutes. The cells were then washed twice with PBS and incubated with PE-conjugated anti-phospho-S6 antibody (rabbit mAb to phospho-S6 ribosomal protein Ser240/244 (D68F8), Cell Signaling Technologies, catalog number 14236) for 1 hour at 4 degrees. The cells were then washed twice with PBS and examined by flow cytometry on a Becton Dickenson LSR Fortessa using the FloJo-V10 software.

Figure 54 shows the results of S6 phosphorylation in the presence or absence of the mTor inhibitor RAD001 after exposure to anti-FKBP1A nRNA. T cells were edited with RNP complexes containing guide sequences directed to FKBP1A (CR002086, CR002097, CR002122; indicated as 2086, 2097 and 2112, respectively) or negative controls: 442 (irrelevant guide CR00442 targeting B2M); Cas9 (only one Cas9 without trRNA or crRNA); trRNA (tracer RNA, but without crRNA or Cas9 protein); Cas9+trRNA (Cas9 and tracer RNA, but without crRNA); EP (electroporation-only cells); without EP (cells without electroporation). After electroporation, cells were treated with 2.5 nM RAD001 (upper panel) or left untreated (lower panel) and the effect on inhibition of the mTOR pathway was assessed in the analysis of S6 phosphorylation (pS6) by flow cytometry. The y-axis indicates forward scatter (FSC) and the x-axis indicates the pS6 level. Positive staining for pS6 (shown in the gating spectrogram) was determined by gating above the level of fluorescence observed in the isotype antibody stained control (not shown). Quantification of S6 phosphorylation based on flow cytometry data is shown in the graph in the bottom panel. These data demonstrate that FKBP1A editing (and loss of the FKBP12 protein subsequence) renders primary T cells resistant to the inhibitory action of RAD001 rapalogue.

Then, CART cells that are TCR-negative and FKBP12-negative were obtained and their function was evaluated. Briefly, PBMCs were isolated from human blood using the Ficoll centrifugation method. Total T cells were isolated from these PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec 130-096-535) for human T cell isolation. These cells were aliquoted and frozen. These frozen cell aliquots were then thawed and activated using CD3/CD28 beads (DynaBeads Invitrogen, cat. no. 111.41D) at a bead to cell ratio of 3:1. On Day 1 after activation, CAR BCMA-10 or CAR-CD19 (CTL019) virus was used to transduce these cells with an MOI of 5. UTD (non-transduced cells) were not treated with virus. On Day 4 post-activation, CAR BCMA-10 or CAR-CD19 or non-transduced T cells were electroporated with RNP with or without guide RNA (no gRNA) as indicated using a Neon electroporator. RNPs were obtained as described above. For TRAC editing, CR000961 was used (designated as 961) alone or with guides directed to FKBP1A as indicated. CR0002097 (designated 2097) or CR002097 and CR002086 together (designated 2097+2086) were used to edit FKBP1A. The RNP complex (or RNP complexes) was then mixed with 100 μl of cells at a cell density of 2 million cells per ml of buffer T (Invitrogen; cat. no. MPK1096). 100 μl of RNP-mixed cells were transferred to a Neon pipette tip and electroporated at 1600 V, 10 ms, 3 pulses. The final RNP concentration was 3.3 μM, as was the Cas9 protein. After electroporation, the cells were transferred to a 6-well plate with 2 ml of beaded T cell medium at a bead to cell ratio of 3:1. New medium was added every two days. Five days after electroporation, 500,000 cells (for phospho-S6 staining) or 50,000 cells for cell surface marker staining (eg, CD3) were collected from the culture and analyzed by flow cytometry (BD Fortessa) using the FlowJo software. TCR expression was detected using the PercpCy5.5 anti-CD3 conjugate (eBiosciences 45-0037-42). CAR expression on the cell surface was assessed by biotinylated L protein staining followed by streptavidin-PE binding (Jackson Immuno Research 016-110-084). T cells were detected by staining for CD4 using the V450 anti-CD4 conjugate (eBiosciences 48-0047-42) or for CD8 using the anti-CD8 APC conjugate (eBiosciences 17-0087-42).

To determine the functional effects of FKBP1A editing, on day 4 after electroporation, cells were separated from the beads and replated at a density of 0.5 million per well in a 96-well plate with 100 μl of T-cell medium, and new beads were added at the ratio of beads to cells 1:1 for 2 hours. Cells were then treated with or without 2.5 nM RAD001 (as indicated) for 3 hours. Phosphorylation of S6 was detected by flow cytometry. To prepare samples for flow cytometry, cells were centrifuged and washed with FACS buffer (MACS working buffer + 0.5% sBSA), stained with dead/live cell stain (Zombie violet fixable viability kit, Biolegend, cat. no. 423114) for 10 minutes. Cells were then washed with FACS buffer and fixed overnight with Cytofix/Cytoperm solution (Becton Dickenson, cat. no. 554714). The cells were then washed twice with PBS and permeabilized with a Cytofix/Cytoperm solution (Becton Dickenson, catalog number 554714) for 20 minutes. The cells were then washed twice with PBS and incubated with PE-conjugated anti-phospho-S6 antibody (rabbit mAb to phospho-S6 ribosomal protein Ser240/244 (D68F8), Cell Signaling Technologies, catalog number 14236) for 1 hour at 4 degrees. The cells were then washed twice with PBS and examined by flow cytometry on a Becton Dickenson LSR Fortessa using the FloJo-V10 software.

To test for cytokine release from edited CART cells, effector cells (edited/unedited CART or non-transduced cells) were thawed in medium (RPMI, 5% FCS, 10 mM Hepes, 1x penicillin/streptomycin, 1x glutamine) on the day of analysis and counted on Cellometer (Nexelcom). These cells were then co-cultured with 30,000 target cells expressing BCMA (KMS11, RPMI8226) or cells expressing CD19 (Nalm6) at an effector:target ratio of 1:1. After 20 hours, 100 μl of the coculture supernatant was collected. These supernatants were then used to measure the cytokines IL-2 and IFN-gamma released using the Proinflammatory Panel 1 system, Meso Scale Discovery, catalog number N05049A-1, according to the manufacturer's protocol.

To measure the cytolytic capacity of effector cells (edited/unedited CART or non-transduced cells), cells were thawed in medium (RPMI, 5% FCS, 10 mM Hepes, 1x penicillin/streptomycin, 1x glutamine) on the day of analysis and counted on a Cellometer (Nexelcom) . These cells were then co-cultured for 20 hours with 30,000 target cells stably expressing the luciferase reporter gene and expressing BCMA (KMS11, RPMI8226) or cells expressing CD19 (Nalm6) at an effector:target ratio of 1:1 in black 96- clear bottom assay well plate (Costar, cat. no. 3904). The luciferase signal was measured using Bright-Glo substrate (Promega, part number E263B) on a Perkin Elmer EnVision High Performance Plate Spectrophotometer. Cell killing was determined based on the decrease in luciferase signal and was calculated as follows:

Target cell killing (%)=100-(sample luminescence/average maximum luminescence)*100

For T cell proliferation assay, the cells obtained above were thawed and co-cultured with target cells expressing BCMA (KMS11, RPMI8226) or cells expressing CD19 (Nalm6). Irradiated target tumor cells were co-cultured with edited or unedited CART cells at a 1:1 effector to target ratio for 4 days, followed by sample staining for CD4, CD8 and CAR as described above, analysis by Becton Dickenson LSR flow cytometry. Fortessa and processed using the FloJo-V10 software. The number of T cells (stained with V450-anti-CD4 and APC-conjugate against CD8) was determined by the number of CD4+ and CD8+ cells relative to 3000 counting beads (Life technology, catalog number C36950). The number of CAR+ T cells was determined by gating a population of CAR+ cells (stained with biotinylated L protein followed by streptavidin-PE binding).

Results:

The production of cytokines by CART cells in response to contact with the antigen was determined. Gene editing was performed in CART cells using guide CR000961 to target the TRAC locus and/or guides CR002097 and CR002086 to target the FKBP1A locus (designated cr961, 2097 and 2086, respectively). Figures 55A and 55B show interferon gamma release and IL-2 release, respectively, from edited/unedited CART cells. These data indicate that the loss of FKBP12 and/or TCR as a result of gene editing does not impair cytokine production in activated CART cells. Figure 56 shows the killing of antigen positive cancer cell lines with edited and unedited CART cells. These data indicate that the loss of FKBP12 and/or TCR as a result of gene editing does not impair the ability of CART cells to kill target cells. Figure 57 shows the proliferation of edited and unedited CART cells in response to antigen contact. These data indicate that the loss of FKBP12 as a result of gene editing does not impair the ability of CART cells to proliferate compared to non-guided cells. Finally, edited CART cells were tested for their resistance to rapalogue-induced RAD001 immunosuppression. The results are shown in Figure 58. These data indicate that FKBP1A editing (and loss of the FKBP12 protein subsequence) renders CART cells resistant to the inhibitory action of RAD001 rapalogue.

Example 14 Expression of HLA-G:B2M Fusion Protein

Without being limited by theory, it is believed that a cell made by TCR-/B2M-/CIITA- can be recognized as foreign by NK cells and subjected to targeted destruction. Thus, in other cases, an unmodified TCR-/B2M-/CIITA allogeneic CART cell may be at risk of attack when administered to, for example, a cancer patient. Again, without being limited by theory, it is believed that the expression of HLA-G on these cells should suppress any activity of the NK cell against such a cell. Because some forms of HLA-G require B2M, expression of the HLA-G:B2M fusion molecule was examined for cells in which B2M expression is reduced or abolished.

The HLA-G/B2M fusion protein was synthesized as follows. Amino acid sequences of β2 microglobulin and HLA-G were obtained from databases. The HLA-G1 isoform of HLA-G is known to complex with B2M on the cell surface. To restore such a complex, for example in a B2M cell, the N-terminal microglobulin β2 fusion polypeptide was fused to HLA-G1. In addition, B2M is linked to HLA-G1 via a glycine/serine (G4S)n linker (SEQ ID NO: 6629). The amino acid sequence was designed in the following order to obtain a fusion protein: the sequence B2M-(G4S)3-HLA-G1 ("(G4S)3" disclosed as SEQ ID NO: 6594). The nucleotide sequence of the fusion protein was codon optimized using the GeneArt® GeneOptimizer® process (Thermo Fisher Scientific Inc) for expression in mammalian cells. Optimized DNA was synthesized in Genescript. The synthesized DNA was amplified by PCR (NEB, Q5® Hot Start High Fidelity DNA Polymerase, Cat. No. M0493L) and subcloned into the pELPS vector using the Gibson Assembly Kit (NEB, Cat. No.: E2611L). The subclone sequence was further confirmed by Genewiz sequencing.

HLA-G-B2M virus or HLA-G virus were generated using LentiX-293T cells. Cells were transfected with HLA-G-B2M or HLA-G lentiviral DNA plasmid along with packaging plasmid DNA (pRSV.REV (Rev expression plasmid), pMDLg/p.RRE (Gag/Pol expression plasmid), pVSV-G (glycoprotein expression plasmid VSV)) when using Lipofectamine 2000 (Invitrogen). Media was replaced 12 hours after transfection. New media were added to the cells and supernatants were collected 30 hours after media change. Using a LentiX concentrator, the virus was concentrated and aliquoted, which were then frozen. The virus was titrated using supT1 cells. Serial dilution of the virus-containing supernatant was incubated with 20,000 SupT1 cells for 3 days. New media were added 24 hours after transduction. Cells were harvested and washed with FACS buffer, incubated with PE-conjugated HLA-G antibody. (Biolegend 335906) and examined cells using BD Fortessa and FlowJo software.

Figure 59 shows the results of transduction of SupT1 cells with a nucleic acid encoding the HLA-G:B2M fusion protein described above. The HLA-G/B2M fusion protein was introduced into SupT1 cells by lentiviral transduction. HLA-G expression on the cell surface was detected by flow cytometry. The light gray histogram indicates background fluorescence in the PE channel in non-transduced cells. The dark gray histogram shows fluorescence in the PE channel from cells transduced with HLA-G/B2M. This indicates successful expression and surface localization of the HLA-G:B2M fusion protein on T cells.

Example 15: Editing CD3-epsilon (CD3E) in HEK-293(Cas9) cells

lncRNA molecules comprising this targeting domain were chemically synthesized and edited in HEK-293 cells by NGS as described in Example 1. The results of the editing experiments are shown in Table 28. This Example shows that CD3E targeting nRNA molecules able to edit the target locus when delivered as RNP at a frequency of 3% to more than 75%. A few nRNA molecules could edit more than 50% of the cells, including generating a frameshift mutation in more than 50% of the cells.

Table 28: % edit and % frameshift edit using anti-CD3E lncRNA in HEK-293(Cas9) cells Referring domain number Wed % edit (any indel) Art. off % edit Wed % frame shift Art. off frameshift CR002275 76.01 5.72 15.70 0.95 CR002282 67.86 4.87 49.37 3.04 CR002272 64.58 4.15 46.13 2.53 CR002317 64.37 8.01 52.67 7.38 CR002242 62.63 14.18 60.27 13.41 CR002254 60.61 11.17 57.40 10.85 CR002253 60.56 12.93 57.47 12.22 CR002238 59.48 9.56 47.73 8.60 CR002316 58.02 6.94 33.73 1.04 CR002244 57.67 8.32 55.70 7.45 CR002273 56.67 14.54 41.70 12.21 CR002269 55.71 9.82 39.57 6.98 CR002234 53.46 5.59 48.40 4.19 CR002306 52.44 2.86 39.37 2.12 CR002294 50.53 2.60 43.10 2.51 CR002239 49.40 10.43 41.43 9.15 CR002263 49.02 10.60 46.10 9.98 CR002257 48.84 4.53 27.40 1.85 CR002312 48.83 5.89 41.00 6.08 CR002292 48.53 2.67 26.27 0.91 CR002262 46.30 9.31 40.53 7.39 CR002248 44.72 11.44 29.47 7.17 CR002243 43.63 5.20 42.90 5.22 CR002276 43.24 8.71 24.47 5.10 CR002286 42.49 12.84 34.50 8.76 CR002313 42.09 16.14 32.37 11.91 CR002280 41.57 6.24 35.23 4.77 CR002305 41.32 4.80 29.00 2.55 CR002293 40.95 13.91 33.93 10.96 CR002250 40.13 8.00 29.93 5.62 CR002274 39.19 4.25 21.20 4.16 CR002270 39.10 9.71 20.90 4.78 CR002287 38.67 4.82 31.63 3.42 CR002237 38.48 8.58 33.90 7.32 CR002233 37.97 16.11 30.65 13.22 CR002240 37.60 8.12 27.67 5.78 CR002268 37.55 6.09 33.63 5.30 CR002309 36.78 11.88 25.40 6.76 CR002235 35.81 13.86 31.33 11.72 CR002304 35.42 4.37 31.63 3.45 CR002258 34.45 3.18 28.67 2.30 CR002266 34.31 8.23 28.87 7.65 CR002308 33.64 6.64 25.73 6.48 CR002281 33.35 4.23 26.00 4.04 CR002310 31.16 12.69 20.73 8.20 CR002256 31.04 5.30 27.83 4.20 CR002271 30.93 10.56 21.93 7.31 CR002288 30.39 6.64 20.43 4.56 CR002236 29.27 12.38 25.90 10.78 CR002289 29.10 7.53 20.63 4.28 CR002307 29.04 5.90 22.00 4.74 CR002284 29.02 7.03 24.33 6.11 CR002279 28.69 2.73 27.30 2.63 CR002291 28.24 5.73 24.50 4.72 CR002241 27.78 8.43 24.37 7.27 CR002277 27.37 6.06 20.43 3.67 CR002260 26.89 7.90 21.93 5.79 CR002245 26.47 5.52 22.97 4.95 CR002303 26.17 6.27 22.43 5.61 CR002267 26.14 6.26 23.83 5.66 CR002249 25.67 12.15 15.37 7.09 CR002299 25.37 3.62 15.03 3.63 CR002283 24.47 6.84 19.07 5.75 CR002297 24.19 3.09 13.80 1.90 CR002252 22.37 4.23 12.57 1.43 CR002290 21.69 7.77 16.60 5.82 CR002285 21.07 10.10 15.70 7.20 CR002298 20.74 6.51 19.13 6.60 CR002230 20.64 10.21 20.10 10.02 CR002232 20.62 5.79 20.30 5.63 CR002311 20.48 3.46 12.73 1.10 CR002300 19.46 11.73 15.07 9.41 CR002259 19.23 6.38 15.27 5.03 CR002296 18.26 2.92 17.33 2.61 CR002261 17.11 3.65 15.50 3.08 CR002251 16.52 2.59 13.03 2.44 CR002302 14.54 3.42 12.93 3.02 CR002231 13.83 4.08 12.37 3.70 CR002295 13.11 9.91 5.20 3.90 CR002246 12.89 5.72 12.07 5.35 CR002265 12.38 4.56 10.20 3.46 CR002278 11.66 4.48 7.47 3.23 CR002301 10.91 1.00 4.70 0.26 CR002255 7.38 2.00 6.43 1.85 CR002315 5.97 0.49 5.63 0.47 CR002264 5.96 1.05 5.57 0.83 CR002247 3.92 1.09 3.43 0.96 CR002314 3.43 0.99 3.40 0.95

Example 16: Estimating Cas9 Variants

Assessment in CD34+ hematopoietic stem cells

14 purified Streptococcus pyogenes (SPyCas9) Cas9 proteins were evaluated to measure their effectiveness in inducing beta-2-microglobulin (B2M) gene knockout in primary human hematopoietic stem cells (HSCs). These proteins were divided into 3 groups: the first group consisted of SPyCas9 variants with improved selectivity (Slaymaker et al. 2015, Science 351: 84 (e1.0, e1.1 and K855A); Kleinstiver et al. 2016, Nature 529: 490 ( HF)). The second group consisted of wild-type SPyCas9 with varying amounts and/or positions of the SV40 nuclear localization signal (NLS) and 6x histidine tag (His6) (SEQ ID NO: 10795) or 8x histidine tag (His8) (SEQ ID NO: 10796 ), with or without a TEV cleavage site and SPyCas9 protein with two cysteine substitutions (C80L, C574E), which have been reported to stabilize Cas9 for structural studies (Nishimasu et al. 2014, Cell 156:935). The third group consisted of the same recombinant SPyCas9 obtained by other methods (Fig. 60). B2M knockout was determined using FACS and next generation sequencing (NGS).

Methods

materials

1. Neon electroporator (Invitrogen, MPK5000)

2. Neon electroporation kit (Invitrogen, MPK1025)

3. crRNA (guiding domain CR00441 (SEQ ID NO: 5495) fused to SEQ ID NO: 6607)

4. tracrRNA (SEQ ID NO: 6660)

5. Cas9 storage buffer: 20 mM Tris-Cl, pH 8.0, 200 mM KCl, 10 mM MgCl ₂

6. Bone marrow CD34+ HSCs (Lonza, 2M-101C)

7. Cell culture media (Stemcell Technologies, StemSpam SFEM II and StemSpam CC-100)

8. FACS wash buffer: 2% FCS in PBS

9. FACS blocking buffer: per ml PBS add 0.5 µg mouse IgG, 150 µg Fc block, 20 µl FCS

10. Chelex Suspension: 10% Chelex 100 (bioRad, cat. no. 142-1253) in H ₂ O

11. Anti-B2M antibody: Biolegend, cat. no. 316304

Process

Cells are thawed and grown according to Lonza's recommendations, with medium added every 2-3 days. On day 5, cells are centrifuged at 200×g for 15 min, washed once with PBS, cells are resuspended with T-buffer from the NEON kit at a density of 2×10 ⁴ /μl, placed on ice. The Cas 9 protein is diluted in Cas9 storage buffer at a concentration of 5 mg/ml. Reduce cRNA and tracrRNA to 100 μM in H ₂ O. Ribonucleoprotein (RNP) complex is prepared by mixing 0.8 μl of each CAS 9 protein, crRNA and tracrRNA with 0.6 μl of Cas9 storage buffer, incubated at room temperature for 10 min . Mix 7 µl of HSCs with the RNP complex for two minutes and transfer all 10 µl to a Neon pipette tip, electroporate at 1700 V, 20 ms and 1 pulse. After electroporation, the cells are immediately transferred to a well of a 24-well plate containing 1 ml of medium previously equilibrated at 37° C., 5% CO ₂ . Cells are harvested 72 hours after electroporation for FACS and NGS analysis.

FACS: 250 µl of cells are taken from each well of a 24-well plate, transferred to the wells of a 96-well U-bottomed plate, and the cells are pelleted. Wash once with PBS with 2% FCS (fetal calf serum). 50 µl of FACS blocking buffer was added to the cells and incubated on ice for 10 minutes, 1 µl of FITC-labeled anti-B2M antibody was added and incubated for 30 minutes. Wash once with 150 µl of FACS wash buffer, then another time with 200 µl of FACS wash buffer. Cells were resuspended in 200 µl of FACS buffer for FACS analysis.

Sample preparation for NGS: 250 µl of the cell suspension is transferred from each well of a 24-well plate into a 1.5 ml Eppendorf tube, 1 ml of PBS is added and the cells are pelleted. 100 µl of Chelex suspension is added, incubated at 99°C for 8 minutes, vortexed for 10 seconds, then incubated at 99°C for 8 minutes and vortexed for 10 seconds. The resin is precipitated by centrifugation at 10,000×g for 3 minutes and the supernatant lysate is used for PCR. Remove 4 µl of lysate and carry out a PCR reaction with b2m primers (b2mg67F: CAGACAGCAAACTCACCCAGT (SEQ ID NO: 10807), b2mg67R: CTGACGCTTATCGACGCCCT (SEQ ID NO: 10808)) using the Titanium kit (Clonetech, cat. no. 639208) according to the manufacturer's instructions . Use the following PCR conditions: 5 minutes at 98°C 1 cycle; 15 seconds at 95°C, 15 seconds at 62°C and 1 minute at 72°C 30 cycles; and at the end of 3 minutes at 72°C 1 cycle. The PCR product was used for NGS.

Statistics: The percentage of B2M knockout cells according to FACS and the percentage of indels according to NGS are used to evaluate the efficiency of CAS 9 cleavage. The experiment was designed with Cas9 as a fixed effect. Each experiment was nested by donor as nested random influences. Thus, a mixed linear model was used for the analysis of FACS and NGS data.

results

To normalize experimental and inter-donor variation, the relative activity of each protein was compared to iProt105026, the original design with two SV40 NLSs flanking wild-type SPYCas9, and a His6 tag (SEQ ID NO: 10795) at the C-terminus of the protein (Fig. 60). Статистический анализ показал, что по сравнению с референсным белком Cas9 iProt105026, iProt106331, iProt106518, iProt106520 и iProt106521 не отличались существенно при нокауте B2M в HSCs, тогда как другие протестированные варианты (PID426303, iProt106519, iProt106522, iProt106545, iProt106658, iProt106745, iProt106746, iProt106747 , iProt106884) were significantly different from the reference iProt105026 when knocking out B2M in HSCs. It was found that the movement of the His6 tag (SEQ ID NO: 10795) from the C-terminus to the N-terminus (iProt106520) did not affect the activity of the protein (Fig. 60). One of the NLSs was only sufficient to maintain activity when placed at the C-terminus of the protein (iProt106521 vs. iProt106522, Fig. 60). Proteins purified in process 1 had a higher knockout efficiency than in processes 2 and 3 (iProt106331 versus iProt106545 and PID426303, Fig. 60). In general, the selectivity-enhanced variants of SPyCas9 did not have the same activity as wild-type SPYCas9 (iProt106745, iProt106746 and iProt106747, Fig. 60). Notably, iProt106884 did not cleave the target site. This is consistent with the report by Kleinstiver et al. that this variant did not cleave up to 20% of the confirmed target sites in mammalian cells (Kleinstiver et al., 2016, Nature 529: 490). Finally, the Cas9 variant with two cysteine substitutions (iProt106518) retained high levels of enzymatic activity (Fig. 60).

Score in T cells

Methods

Various S. pyogenes Cas9 variants shown in Table 29 were used in these experiments. The structures are also shown in Figure 60.

Table 29: Cas9 variants (NLS=SV40 NLS; Cas9=Cas9 S. pyogenes wild-type, where any mutations are in parentheses; Cas9e1.1 (described in Slaymaker et al. 2015, Science 351:84); GGS=glycine- glycine-serine). iprot CAS9
(His6 disclosed as SEQ ID NO: 10795) The size
(Daltons) Conc. (µg/ml) Molar conc. [µM] 106520 His6-GGS-NLS-CAS9-NLS 161696.22 6.2 38.34 106518 NLS-CAS9(C80L, C574E)-NLS-His6 161531.04 6.5 40.24 106521 NLS-CAS9-His6 160629.9 6 37.12 106745 NLS-CAS9(K855A)-NLS-His6 161437.94 5.9 36.55 106747 NLS-CAS9e1.1-NLS-His6 161295.74 6.5 40.3 106154 (also listed as 105026) NLS-CAS9-NLS-His6 161495.04 5.9 36.54

PBMCs were isolated from human blood (obtained from Hemacare/ALL Cells) using the Ficoll centrifugation method (GE Healthcare, catalog number 17-1440-03). Total T cells were isolated from these PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec 130-096-535) for human T cell isolation. These cells were aliquoted, frozen using CRYOSTOR CS10 medium (Biolife Solution 210102) and stored in liquid nitrogen. These frozen cell aliquots were then thawed in a 37°C water bath for 20 sec, transferred to a 50 ml conical tube in 10 ml of prewarmed T cell medium, and centrifuged at 300 rpm for 5-10 minutes at 24 degrees Celsius to remove the freezing medium and resuspend with prewarmed T-cell medium. They were then activated using CD3/CD28 beads (DynaBeads Invitrogen, cat. no. 111.41D) at a bead to cell ratio of 3:1, maintaining a cell concentration of 0.5 million/mL, and activated using CD3/CD28 beads ( DynaBeads Invitrogen, cat number 111.41D) at a bead to cell ratio of 3:1 and a cell concentration of 0.5 million/mL.

On Day 3 after bead activation, 200,000 cells were used for electroporation. The RNP complex used to edit the T cell genome was generated using a 1:2 molar ratio of Cas9 protein to RNA (crRNA and tracRNA). 100 μM crRNA ([guide domain]-[SEQ ID NO: 6607]) and 100 μM tracrRNA (SEQ ID NO: 6660) were denatured separately at 95° C. for 2 minutes and cooled to room temperature. In a final volume of 5 µl, 1.4 µl of Cas9 protein at a concentration of 5.9 µg/µl was mixed with 1.6 µl of reaction buffer (20 mM Tris, pH 8.0; 200 mM KCl, 10 mM MgCl ₂ ) and mixed with 1 µl of 100 µM tracrRNA at room temperature. Then 1 µl of 100 µM crRNA was added, mixed and incubated for 10 min at 37°C. The guiding domain for B2M was CR000442 and for TRAC it was CR000961. These RNPs at higher concentrations were used to obtain serial dilution samples of RNPs. These RNP dilutions were then used to mix 200,000 cells in 10 µl of Buffer T (Neon Transfection System 10 µl kit). Electroporation was performed on a Neon electroporator using the Neon® Transfection System 10 µl kit (MPK1096) at 1600 V, 10 ms, 3 pulses. Cells were cultured in T cell medium without antibiotics. Cells were taken from each sample, pipetted to separate them from the beads, the beads were removed using a magnetic 96-well plate, and centrifuged with 100 µl of FACS buffer (Miltenyi MACS buffer, part number 130-092-987 with 0.5% BSA ( Miltenyi, part number 130-091-376)) for cell washing. The cells were then incubated with various antibodies diluted in 100 µl of FACS buffer for 30 minutes on ice. The cells were then washed twice with 200 μl of FACS buffer. The cells were then resuspended in 150 µl of FACS buffer and sorted on a BD Fortessa equipped with 5 lasers. TCR expression was detected using the PercpCy5.5 anti-CD3 conjugate (eBiosciences 45-0037-42) and B2M expression was detected using the anti-B2M APC conjugate (Biolegend 316312). Flow cytometry data were processed using the FlowJo software.

results

Obtaining low concentrations of RNP and editing with the highest efficiency was successful in cases where the RNP was received at a high concentration, and then diluted to the desired concentration. 6 different Cas9 proteins were tested for editing efficiency using the B2M guide CR00442 in primary T cells. Editing efficiency was measured using cell surface B2M protein detection by flow cytometry, with results shown in Figure 61 (Y-axis; % B2M edit), 3 days after RNP electroporation at indicated RNP concentrations (X-axis). The various Cas9 proteins tested are designated by their respective identification numbers "iprot" (see Figure 60 and Table). The results are shown in Figure 61. These data indicate that all of these Cas9 variants are active, however Cas9 proteins 106521, 106518 and 106154 (also listed as 105026) show higher activity in T cells, as evidenced by their higher activity at lower RNP concentrations. Then, two different Cas9 proteins, 106884 or 106154 (also listed as 105026), as indicated, were tested for editing efficiency using the B2M targeted guide CR00442 (Figure 62, left panel) or the TRAC targeted guide CR000961 (Figure 62, right panel) using different RNP concentrations as indicated on the x-axis. Editing efficiency (% edit) was measured by flow cytometry when measuring the loss of expression on the cell surface of B2M (Figure 62, left panel) or TCR when using the anti-CD3 antibody epsilon (Figure 62, right panel).

Example 17: Evaluation of off-target activity

T cell culture and CRISPR/Cas9 genome editing

Peripheral blood mononuclear cells (PBMCs) were isolated from human blood (HemaCare, cat. no. PB000) using standard Ficoll density gradient centrifugation methods. Total T cells were isolated from PBMCs using the Pan T Cell Isolation Kit (Miltenyi Biotec, cat. no. 130-096-535) according to the manufacturer's recommendations and stored at -80°C. T cells were thawed and activated using Dynabeads Human T-Activator CD3/CD28 T cell expansion and activation beads (Thermo Fisher Scientific, cat. no. 11131D) at a bead to cell ratio of 3:1 as recommended by the manufacturer. T cells were cultured in complete T cell medium without antibiotics (RPMI 1640 with L-glutamine, Lonza, cat. no. 12-702F; 10% FBS, GE HyClone, cat. no. SH30071; 200 mM L-glutamine, GE HyClone, cat SH30034.01, 10 mM non-essential amino acids, GE HyClone, cat 13-114E, 100 mM sodium pyruvate, Invitrogen, cat 11360-070, 1 M HEPES buffer, GE HyClone, 17-737E, and 55 mM 2-mercaptoethanol, Invitrogen, 21985-023) at 37° C., 5% CO ₂ for 3 days prior to genome editing.

The RNP complex used to edit the T cell genome was obtained using a molar ratio of Cas9 protein to nRNA (crRNA and tracRNA) of 1:2. Chemically synthesized crRNA at a concentration of 100 μM ([guide domain]-[SEQ ID NO: 6607]) and tracr (SEQ ID NO: 6660) at a concentration of 100 μM were denatured separately at 95°C for 2 minutes and cooled to room temperature. In a final volume of 5 μl buffer (20 mM Tris, pH 8.0; 200 mM KCl, 10 mM MgCl ₂ ), Cas9 protein (NLS-Cas9-NLS-His6 ("His6", disclosed as SEQ ID NO: 10795); iPROT105026; NLS=SV40 NLS; Cas9=S.py Cas9 dt) were first mixed with tracrRNA at room temperature and then mixed with crRNA and incubated for 5 minutes at 37°C. The final concentrations of Cas9 protein, tracrRNA and crRNA used were 10 μM, 20 μM and 20 μM, respectively. Bead-activated T cells were harvested by centrifugation and resuspended in T buffer from the Neon electroporation kit (Invitrogen; cat. no. MPK1096) at a cell density of 20 x 10 ⁶ /ml. 5 μl of RNP was mixed with 10 μl of T cells by gentle pipetting and incubated at room temperature for 5 minutes. The mixture of T cells with RNP was transferred to a 10 μl Neon electroporation head. Electroporation was performed using a Neon transfection system (Invitrogen; MPK5000S) using the following conditions: 3 pulses of 1600 V/10 milliseconds. 10 μl electroporation reactions were performed in duplicate. The electroporated T cells were then immediately transferred to 200 μl of prewarmed complete T cell medium without antibiotics in a 96-well plate and incubated at 37° C., 5% CO ₂ for 2 days. T cells were then diluted 1:1 using complete T cell medium without antibiotics, transferred to a 24-well plate, and cultured for another 4-7 days at 37° C., 5% CO ₂ . In parallel, activated T cells without RNP treatment were also cultured as untreated controls. T cells were then collected by centrifugation and genomic DNA was isolated from 1-2 million cells using the DNeasy Blood & Tissue Kit (Qiagen, cat. no. 69506) according to the manufacturer's recommendations. Genome editing was performed on nRNAs containing the CR00442, CR00444, CR000961, and CR000984 guide domain sequences, resulting in two processed and one unprocessed replicate for each nRNA.

Identification of potential non-targeted gRNA loci in silico

Potential non-target loci for the CR00442, CR00444, CR000961, and CR000984 gRNAs were determined by aligning the 20-nt nRNA protospacer sequence with a human genome reference sequence (GRCh38 assembly) using the BFAST sequence alignment tool (version 0.6.4f, Homer et al, 2009 PLoS One, 2009). , 4(11), e7767, PMID: 19907642) using standard parameters allowing up to 5 non-complementary nucleotides. Loci identified were filtered to contain only those regions that were 5' adjacent to the canonical Cas9 5'-NGG-3' PAM sequence (ie 5' non-target locus-PAM-3'). Using the BEDTools script (version 2.11.2, Quinlan and Hall, Bioinformatics, 2010 26(6):841-2, PMID: 20110278), regions with 5 non-complementary nucleotides were further filtered when compared to RefSeq gene annotations (Pruitt et al, Nucleic Acids Res., 2014 42(Database issue):D756-63, PMID: 24259432) to contain only loci annotated as exons. The numbers of potential non-target loci determined for each nRNA are shown in Table 30.

Table 30 Shows the in silico numbers of non-target loci identified for CR00442, CR00444, CR000961, and CR00098 mRNAs with 0, 1, 2, 3, and 4 non-complementary nucleotides and 5 non-complementary nucleotides in RefSeq exons. Number of non-targets with N non-complementary nucleotides Gene nRNA name 0 one 2 3 4 5 RefSeq exons Total B2M CR00442 0 0 0 7 72 71 150 CR00444 0 0 0 2 24 33 59 TRAC CR000961 0 0 2 23 224 63 312 CR000984 0 0 0 3 40 fifteen 58

Selection of PCR primers for targeted amplification of potential non-target sites

PCR amplicons directed at potential non-target loci (and target loci) identified for CR00442, CR00444, CR000961 and CR00098 nRNAs were selected using Primer3 (version 2.3.6, Untergasser et al, Nucleic Acids Res., 2012 40(15 ):e115, PMID: 22730293) using the default parameters set to obtain an amplicon size of approximately 160-300 bp with the nRNA protospacer sequence located in the center of the amplicon. The resulting PCR primer pairs and amplicon sequences were checked for uniqueness using BLAST sequence search (version 2.2.19, Altschul et al, J Mol Biol., 1990, 215(3):403-10, PMID: 2231712) when compared with reference sequence of the human genome (assembly GRCh38). Primer pairs giving rise to more than one amplicon sequence were excluded and reselected. Table 31 shows the number of successfully matched primer pairs for each nRNA.

Obtain, Quantify, and Sequence the Illumina Sequencing Library

Genomic DNA from RNP-treated (2 reps per nRNA) and untreated (1 rep per nRNA) T cell samples were quantitated using the Quant-iT PicoGreen dsDNA kit (Thermo Fisher, cat. no. P7581) using the manufacturer's recommendations. Illumina sequencing libraries targeting individual non-target loci (and target locus) were generated for each sample using two sequential PCR reactions. In the first PCR, the target locus was amplified using target-specific PCR primers (selected above) to which universal sequences compatible with Illumina sequencing were attached. In the second PCR, additional sequences compatible with Illumina sequencing, including sample barcodes, were added to the first PCR amplicon to allow multiplexing during sequencing. PCR 1 was performed in a final volume of 10 μl, with each reaction containing 6 ng of nDNA (equivalent to approximately 1000 cells), a pair of PCR 1 primers (Integrated DNA Technologies) at a final concentration of 0.25 μM, and 1× Q5 Hot Start Master final concentration Mix (New England BioLabs, cat. no. 102500-140). For PCR 1, the left primers at 5' were spliced (i.e., 5' tail-target-specific left primer-3') with the sequence 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 10810) and the right primers were spliced 5' ( i.e. 5'-tail-target-specific right primer-3') with the sequence 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 10811). PCR 1 was performed on a cycler using the following cycling conditions: 1 cycle 98°C for 1 minute; 25 cycles 98°C for 10 seconds, 63°C for 20 seconds and 72°C for 30 seconds; 1 cycle at 72°C for 2 minutes. PCR 1 was then diluted 1:100 in nuclease-free water (Ambion, cat. no. AM9932) and used as input to PCR 2. PCR 2 was run in a final volume of 10 µl, with each reaction containing 2 µl of diluted PCR 1 product, a couple primers (Integrated DNA Technologies) for PCR 2 at a final concentration of 0.5 μM and 1× the final concentration of Q5 Hot Start Master Mix (New England BioLabs, cat. no. 102500-140). In PCR 2, the left primer sequence was used: 5'-AATGATACGGCGACCACCGAGATCTACACNNNNNNNNTCGTCGGCAGCGTC-3' (SEQ ID NO: 10812), and the right primer sequence: 5'-CAAGCAGAAGACGGCATACGAGATNNNNNNNNNGTCTCGTGGGCTCGG-3' (SEQ ID NO: 10813), where NNNNNN denote nucleotide barcodes -sequences used for sample multiplexing as part of the standard Illumina sequencing process. PCR 2 was performed on a cycler using the following cycling conditions: 1 cycle 72°C for 3 minutes; 1 cycle 98°C for 2 minutes; 15 cycles of 98°C for 10 seconds, 63°C for 30 seconds and 72°C for 2 minutes. PCR 2 amplicons, now complete Illumina sequencing libraries, were purified using Agencourt AMPure XP beads (Beckman Coulter, cat. no. A63882) according to the manufacturer's recommendations. Purified Illumina sequencing libraries were then quantitated using standard qPCR quantitation methods using Power SYBR Green PCR premix (Life Technologies, cat. no. 4367660) and primers specific to the ends of the Illumina sequencing library (forward primer sequence 5'-CAAGCAGAAGACGGCATACGA -3' (SEQ ID NO: 10814) and the reverse primer sequence 5'-AATGATACGGCGACCACCGAGA-3' (SEQ ID NO: 10815)). Illumina sequencing libraries were then pooled into equimolar pools and subjected to Illumina sequencing on a MiSeq instrument (Illumina, p/n SY-410-1003) with 300 bp paired-end reads using a MiSeq v3 reagent kit (Illumina, p/n MS- 102-3003) as recommended by the manufacturer. A minimum of 1000-fold sequence coverage was obtained for each locus. PCR, purification, pooling and sequencing of treated and untreated samples were performed separately to avoid any possibility of cross-contamination between treated and untreated samples or PCR of amplicons derived from them.

Quality control and variant analysis of Illumina sequencing data

Using the default settings, the Illumina MiSeq assay program (MiSeq reporter, version 2.6.2, Illumina) was used to generate amplicon-specific FASTQ sequencing data files (Cock et al, Nucleic Acids Res. 2010, 38(6):1767-71, PMID: 20015970). The FASTQ files were then processed using a proprietary variant analysis process consisting of a set of publicly available software packages bundled using a standard Perl scripting shell. The workflow used was divided into five stages.

Stage 1, quality control of PCR primers, target and non-target sequences: For target and non-target sites, the 20 nucleotide protospacer gRNA plus PAM sequence and target-specific PCR primer sequences (left and right without additional Illumina sequences) were aligned with the human genome reference sequence (GRCh38 assembly). ) using BLAST search (version 2.2.29+, Altschul et al, J Mol Biol., 1990, 215(3):403-10, PMID: 2231712). Target and non-target sites with multiple positions in the genome were labeled.

Stage 2, Sequencer File Deployment: The generated Illumina FASTQ.GZ sequencer files were expanded into FASTQ files using the gzip script (version 1.3.12) and the number of reads per file was calculated. Files without reads were excluded from subsequent analysis.

Step 3, alignment and quality fit of sequence reads: The sequencing reads in FASTQ files were aligned to the human genome reference sequence (GRCh38 assembly) using the BWA-MEM alignment tool (version 0.7.4-r385, Li and Durbin, Bioinformatics, 2009, 25( 14):1754-60, PMID: 19451168) using a 'hard cut' to truncate the 3' ends of Illumina sequence reads and low quality bases. The resulting aligned reads, in BAM file format (Li et al, Bioinformatics, 2009 25(16):2078-9, PMID: 19505943) were converted to FASTQ files using the SAMtools script (version 0.1.19-44428cd, Li et al, Bioinformatics, 2009 25(16):2078-9, PMID: 19505943). The FASTQ files were then aligned again to the human reference sequence (GRCh38 assembly) using the BWA-MEM alignment tool, this time without the 'hard cut'.

Stage 4, variant analysis (ONP and INDELS): BAM files of aligned reads were processed using the VarDict variant detection program (version 1.0 'with Cas9 included', modified by ZhangWu Lia, Lai et al, Nucleic Acids Res., 2016, 44( 11):e108, PMID: 27060149) with an allelic frequency detection limit set to ≥0.0001 to identify variants (SNPs and INDELS). The VarDict variant detection program with Cas9 inclusion is based on a publicly available package, but is able to move ambiguous detectable variants generated due to repetitive sequences in the event variant alignment region to a potential Cas9 nuclease cleavage site in the nRNA protospacer sequence located 3 bases 5' from PAM sequences. The SAMtools script was used to calculate read coverage per sample amplicon to determine if target and non-target sites were covered with 1000-fold sequence coverage. Regions with <1000-fold sequence coverage were marked and additional sequencing data was generated.

Step 5, dbSNP filtering and treated/untreated differential analysis: Identified variants were filtered for the presence of known variants (SNPs and INDELS) found in the dbSNP database (assembly 142, Shery et al., Nucleic Acids Res. 2001, 29(1): 308-11, PMID: 11125122). Variants in treated samples were further filtered to exclude: 1) variants identified in untreated controls; 2) variants with a 2:1 VarDict strand bias (where the number of forward and reverse reads matching the reference sequence is balanced, but unbalanced by the definition of the non-reference variant); 3) variants located outside the 100 bp window around the potential Cas9 cleavage site; 4) single nucleotide variants within a 100 bp window around the potential Cas9 cleavage site. Finally, only sites with a combined INDELS frequency of >2% (editing in more than 20 cells) within a 100 bp window of a potential Cas9 cleavage site were considered. Potential active editing sites were further examined at the level of read alignment using the Integrative Genome Viewer (IGV version 2.3, Robinson et al., Nat Biotechnol. 2011, 9(1):24-6, PMID: 21221095), which allows visual control read alignment when compared to a reference genomic sequence. Sites identified with potential off-target activity were reworked with a complete replicate of the laboratory process (starting with PCR) and data analysis.

Results of the analysis of targeted and non-targeted activity

All of the target sites for the CR00442, CR00444, CR000961 and CR000984 mRNA showed stable editing at the putative Cas9 cleavage site in both processed biological replicates with a mean variant frequency of 96%, 84%, 81% and 98%, respectively. No editing was observed in any of the untreated controls. Table 31 shows the number of non-target sites that were identified and analyzed. Either PCR primers could not be selected for the unanalyzed regions, or their PCR amplification was unsuccessful, therefore, their study is currently ongoing.

nRNA CR00442: The target site for nRNA CR00442 showed stable editing for the putative Cas9 cleavage site in both processed biological replicates with an average INDEL frequency of 96%. No editing was observed in the raw control sample. Table 31 shows the number of non-target sites analyzed. Either PCR primers could not be selected for the unanalyzed regions, or their PCR amplification was unsuccessful, therefore, their study is currently ongoing. Analysis of potential non-target sites revealed two weak non-target sites for CR00442 nRNA with mean INDE frequencies of 3.7% and 4.4% in a 100 bp window around the putative Cas9 cleavage site. One region contains 3 non-complementary nucleotides relative to the target sequence of the protospacer nRNA (5'-GGCaACaGAGCGAGACAaCT-PAM-3', PAM=GGG (SEQ ID NO: 10816)) and is located in intron 1 of the zinc finger protein 440 (ZNF440) gene on chromosome 19 at position 11,815,253-11,815,275 bp, approximately 0.9 kb from exon 1. The second region also contains 3 non-complementary nucleotides relative to the target sequence of the protospacer gRNA (5'-GGCgACaGAaCGAGACATCT-PAM-3', PAM=CGG (SEQ ID NO: 10817)) and is located in intron 9 of the oncogene-like epitheliocyte-transforming sequence 2 (ECT2L) gene on chromosome 6 at position 138,856,234-138,856,256 bp, approximately 2 kb from exon 9. Visual examination of both regions showed typical INDELS profiles surrounding putative Cas9 cleavage sites typical of DNA repair by joining non-homologous ends of Cas9-mediated double-strand breaks. Re-amplification and sequencing of both regions gave similar results. While it is unclear whether editing at any identified site has an adverse effect on gene expression or cell viability, further research is needed.

nRNA CR00444: The target site for nRNA CR00444 showed stable editing at the putative Cas9 cleavage site in both processed biological replicates with an average INDEL frequency of 84%. No editing was observed in the untreated control. Table 31 shows the number of successfully analyzed non-target sites. Either PCR primers could not be selected for the unanalyzed regions, or their PCR amplification was unsuccessful, therefore, their study is currently ongoing. To date, no significant off-target activity has been observed at the unanalyzed sites for nRNA CR00444. However, as shown in Table 31, there remain two regions that have not yet been analyzed, one of which contains 4 non-complementary bases and is located in the intergenic region, and the other contains 5 non-complementary bases and is located in exon 4 of the non-coding gene pseudogene 46 dynamin 1 (DNM1P46 ). Due to the high number of non-complementary bases in these regions, it is suggested that these regions will probably not show significant editing, however further research is required to confirm this assumption.

nRNA CR000961: The target site for nRNA CR000961 showed stable editing at the putative Cas9 cleavage site in both processed biological replicates with an average INDEL frequency of 81%. No editing was observed in the untreated control. Table 31 shows the number of successfully analyzed non-target sites. Either PCR primers could not be selected for the unanalyzed regions, or their PCR amplification was unsuccessful, therefore, their study is currently ongoing. Analysis of potential non-target sites revealed one weak non-target site for CR000961 nRNA with an average INDEl frequency of 5.5% in a 100 bp window around the putative Cas9 cleavage site. The region contains 3 non-complementary bases compared to the protospacer sequence of the mRNA (5'-AaAGTCaCaCAGCTGGTACA-PAM-3', PAM=TGG (SEQ ID NO: 10818)) and is located in intron 12 of the doublecortin domain containing protein 1 (DCDC1) gene, on the chromosome 11 at position 31,102,920-31,102,942 bp, approximately 0.6 kb from exon 13. Visual analysis of the site showed typical profiles of INDELS surrounding putative Cas9 cleavage sites typical of DNA repair by joining the non-homologous ends of Cas9-mediated double-strand breaks. Re-amplification and sequencing of both regions gave similar results. It is not yet clear whether editing at any identified site has an adverse effect on gene expression or cell viability, so further research is needed.

nRNA CR000984: The target site for nRNA CR000984 showed stable editing at the putative Cas9 cleavage site in both processed biological replicates with an average INDEL frequency of 98%. No editing was observed in the untreated control. Table 31 shows the number of successfully analyzed non-target sites. Either PCR primers could not be selected for the unanalyzed regions, or their PCR amplification was unsuccessful, therefore, their study is currently ongoing. The analysis of off-target sites did not reveal significant off-target activity for nRNA CR000984 in the studied sites. However, as shown in Table 31, there remains one more area that has not yet been analyzed. The region contains 5 non-complementary bases and is located in the exon of an unexplored long non-coding RNA (LOC440896). Due to the high number of non-complementary bases in these regions, it is assumed that this region will probably not show significant editing, however, additional research is required to confirm this assumption.

Table 31 Shows the total number of potential non-target sites, the number of successfully analyzed non-target sites, and the number of active non-target sites identified for nRNA CR00442, CR00444, CR000961 and CR000984. Gene nRNA guide domain name Total number of non-target sites Number of non-target sites analyzed Number of active non-target sites identified B2M CR00442 150 147 (98%) 2 CR00444 59 57 (97%) 0 TRAC CR000961 312 306 (98%) one CR000984 58 57 (98%) 0

GUIDE-Seq Hit Check Results

Potential off-target loci identified using the GUIDE-seq method (Tsai et al., Nat Biotechnol. 2015, 33(2):187-97, PMID: 25513782) were analyzed in RNP-treated and untreated T cells using the same methods. described for in silico identified areas. GUIDE-seq identified 2 potential sites for CR00442 nRNA, 1 potential site for CR00444, and 1 potential site for CR000984 nRNA. No active sites were identified for nRNA CR000961. Targeted sequencing analysis of all potential GUIDE-seq regions did not reveal any significant activity in the RNP-treated T cells tested.

Assessing Off-Target Editing with Insertion Analysis

Oligonucleotide insertion assay (see, e.g., Tsai et al., Nature Biotechnology, 33, 187-197, 2015) was used to identify potential non-target genomic regions cleaved by Cas9 directed against B2M TRAC, TRBC2, PDCD1, CIITA and FKBP1A . A total of 34 guide RNAs (double guide RNAs containing the specified guide domain, modified or unmodified as indicated) targeting B2M (5), TRAC (9), TRBC2 (2), PDCD1 (8), FKBP1A (5 ) or CIITA (5) were screened in the Cas9 expressing HEK293 cells described in Example 1 above, the results are shown in Figure 63 and Figure 64. The analysis revealed highly efficient editing in putative target sequences. No off-target editing was observed for the B2M-targeted nRNA containing the CR00444 targeting domain or the CR00441 targeting domain, with only one inefficient off-target editing found when using the B2M-targeted nRNA containing the CR00442 targeting domain. The results show that for TRAC targeting nRNAs, including the targeting domain CR00961, CR00978, CR00984, CR00991 and CR00992, each resulted in highly efficient editing of the target sequence without editing anywhere off the target. In addition, no off-target editing was found for the PDCD1-targeted nRNA containing the CR00902 targeting domain. For rRNA molecules that showed potential off-target editing in this assay, deep sequencing will be used to determine if the potential sites are valid off-target sites cleaved by Cas9. In addition, any potential off-target editing will be evaluated for presence and frequency in T cells.

Example 18 Editing CD3 delta and CD3 gamma in primary human CD3+ cells

Editing of CRISPR systems containing lncRNA molecules including guide domains to CD3-delta and CD3-gamma sequences were tested for editing in primary CD3+ T cells (nRNA/Cas9 RNP delivered by electroporation) according to the methods described in this application. Surface CD3 expression after editing was analyzed by flow cytometry. Briefly, edited CD3+ cells were stained with anti-CD3 antibodies (OKT3, BioLegend) on day 7 after electroporation. Live cell CD3 expression (identified using 7AAD exclusion) compared to unedited controls was used to determine the frequency of RNP editing. The results are shown in Figure 65 and Figure 66 which include flow cytometric data showing % edit in primary human CD3+ T cells as measured by loss of CD3 surface expression. Notably, lncRNA containing the CR005334 targeting domain provided 98% loss of CD3.

The scope of the present invention is not to be limited by the exemplary constructions, as the exemplary embodiments are intended to illustrate only some aspects of the invention, and any constructions that are functionally equivalent are included within the scope of the present invention. Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description and are within the scope of the appended claims.

It should be understood that the application of the principles of the present invention to a particular problem or situation will be within the capabilities of the average person skilled in the art in accordance with the principles contained herein.

Any and all publications referenced in the description are expressly incorporated herein by reference.

The present application is filed with a sequence listing. To the extent that there is any discrepancy between the list of sequences and any sequence specified in the description, the sequence indicated in the present description should be considered the correct sequence. Unless otherwise noted, all genomic positions correspond to hg38.

--->

SEQUENCE LIST

<110> NOVARTIS AG

INTELLIA THERAPEUTICS, INC.

<120> COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY

<130> PAT057135-WO-PCT

<140> PCT/IB2016/057318

<141> 2016-12-02

<150> 62/394.290

<151> 2016-09-14

<150> 62/316.784

<151> 2016-04-01

<150> 62/263.169

<151> 2015-10-04

<160> 11159

<170>PatentIn version 3.5

<210> 1

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1

uggcugggca cgcguuuaau auaag 25

<210> 2

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2

cugggcacgc guuuaauaua agugg 25

<210> 3

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3

uuuaauauaa guggaggcgu cgcgc 25

<210> 4

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4

aauauaagug gaggcgucgc gcugg 25

<210> 5

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5

auauaagugg aggcgucgcg cuggc 25

<210> 6

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6

gggcauuccu gaagcugaca gcauu 25

<210> 7

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7

ggcauuccug aagcugacag cauuc 25

<210> 8

<211> 25

<212> RNA

<213> Homo sapiens

<400> 8

auucgggccg agaugucucg cuccg 25

<210> 9

<211> 25

<212> RNA

<213> Homo sapiens

<400> 9

cugugcucgc gcuacucucu cuuuc 25

<210> 10

<211> 25

<212> RNA

<213> Homo sapiens

<400> 10

cucgcgcuac ucucucuuuc uggcc 25

<210> 11

<211> 25

<212> RNA

<213> Homo sapiens

<400> 11

gcgcuacucu cucuuucugg ccugg 25

<210> 12

<211> 25

<212> RNA

<213> Homo sapiens

<400> 12

auauuaaacg cgugcccagc caauc 25

<210> 13

<211> 25

<212> RNA

<213> Homo sapiens

<400> 13

ucucggcccg aaugcuguca gcuuc 25

<210> 14

<211> 25

<212> RNA

<213> Homo sapiens

<400> 14

gcuaaggcca cggagcgaga caucu 25

<210> 15

<211> 25

<212> RNA

<213> Homo sapiens

<400> 15

aguagcgcga gcacagcuaa ggcca 25

<210> 16

<211> 25

<212> RNA

<213> Homo sapiens

<400> 16

agagagagua gcgcgagcac agcua 25

<210> 17

<211> 25

<212> RNA

<213> Homo sapiens

<400> 17

gagagacuca cgcuggauag ccucc 25

<210> 18

<211> 25

<212> RNA

<213> Homo sapiens

<400> 18

gcgggagggu aggagagacu cacgc 25

<210> 19

<211> 25

<212> RNA

<213> Homo sapiens

<400> 19

uauuccucag guacuccaaa gauuc 25

<210> 20

<211> 25

<212> RNA

<213> Homo sapiens

<400> 20

uuuuacucacg ucauccagca gagaa 25

<210> 21

<211> 25

<212> RNA

<213> Homo sapiens

<400> 21

caaauuuccu gaauugcuau guguc 25

<210> 22

<211> 25

<212> RNA

<213> Homo sapiens

<400> 22

aaauuuccug aauugcuaug ugucu 25

<210> 23

<211> 25

<212> RNA

<213> Homo sapiens

<400> 23

acauugaagu ugacuuacug aagaa 25

<210> 24

<211> 25

<212> RNA

<213> Homo sapiens

<400> 24

aagaauggag agagaauuga aaaag 25

<210> 25

<211> 25

<212> RNA

<213> Homo sapiens

<400> 25

gagcauucag acuugucuuu cagca 25

<210> 26

<211> 25

<212> RNA

<213> Homo sapiens

<400> 26

uucagacuug ucuuucagca aggac 25

<210> 27

<211> 25

<212> RNA

<213> Homo sapiens

<400> 27

uuugucacag cccaagauag uuaag 25

<210> 28

<211> 25

<212> RNA

<213> Homo sapiens

<400> 28

uugucacagc ccaagauagu uaagu 25

<210> 29

<211> 25

<212> RNA

<213> Homo sapiens

<400> 29

ugucacagcc caagauaguu aagug 25

<210> 30

<211> 25

<212> RNA

<213> Homo sapiens

<400> 30

aucuuuggag uaccugga auauc 25

<210> 31

<211> 25

<212> RNA

<213> Homo sapiens

<400> 31

aaucuuugga guaccugagg aauau 25

<210> 32

<211> 25

<212> RNA

<213> Homo sapiens

<400> 32

uaaaccugaa ucuuuggagu accug 25

<210> 33

<211> 25

<212> RNA

<213> Homo sapiens

<400> 33

gaugacguga guaaaccuga aucuu 25

<210> 34

<211> 25

<212> RNA

<213> Homo sapiens

<400> 34

ggaaauuuga cuuuccauuc ucugc 25

<210> 35

<211> 25

<212> RNA

<213> Homo sapiens

<400> 35

augaaaccca gacacauagc aauuc 25

<210> 36

<211> 25

<212> RNA

<213> Homo sapiens

<400> 36

ucaguaaguc aacuucaaug ucgga 25

<210> 37

<211> 25

<212> RNA

<213> Homo sapiens

<400> 37

uucuucagua agucaacuuc aaugu 25

<210> 38

<211> 25

<212> RNA

<213> Homo sapiens

<400> 38

caggcauacu caucuuuuuc agugg 25

<210> 39

<211> 25

<212> RNA

<213> Homo sapiens

<400> 39

gcaggcauac ucaucuuuuu cagug 25

<210> 40

<211> 25

<212> RNA

<213> Homo sapiens

<400> 40

ggcaggcaua cucaucuuuu ucagu 25

<210> 41

<211> 25

<212> RNA

<213> Homo sapiens

<400> 41

cggcaggcau acucaucuuu uucag 25

<210> 42

<211> 25

<212> RNA

<213> Homo sapiens

<400> 42

gacaaaguca caugguucac acggc 25

<210> 43

<211> 25

<212> RNA

<213> Homo sapiens

<400> 43

cugugacaaa gucacauggu ucaca 25

<210> 44

<211> 25

<212> RNA

<213> Homo sapiens

<400> 44

uaucuugggc ugugacaaag ucaca 25

<210> 45

<211> 25

<212> RNA

<213> Homo sapiens

<400> 45

aagacuuacc ccacuuaacu aucuu 25

<210> 46

<211> 25

<212> RNA

<213> Homo sapiens

<400> 46

uaagacuuac cccacuuaac uaucu 25

<210> 47

<211> 25

<212> RNA

<213> Homo sapiens

<400> 47

agaucgagac auguaagcag cauca 25

<210> 48

<211> 25

<212> RNA

<213> Homo sapiens

<400> 48

ucgagacaug uaagcagcau caugg 25

<210> 49

<211> 25

<212> RNA

<213> Homo sapiens

<400> 49

augucucgau cuaugaaaaa gacag 25

<210> 50

<211> 25

<212> RNA

<213> Homo sapiens

<400> 50

uuuucagguu ugaagaugcc gcauu 25

<210> 51

<211> 25

<212> RNA

<213> Homo sapiens

<400> 51

agguuugaag augccgcauu uggau 25

<210> 52

<211> 25

<212> RNA

<213> Homo sapiens

<400> 52

cacuuacacu uuaugcacaa aaugu 25

<210> 53

<211> 25

<212> RNA

<213> Homo sapiens

<400> 53

acuuacacuu uaugcacaaa augua 25

<210> 54

<211> 25

<212> RNA

<213> Homo sapiens

<400> 54

auguaggguu uaauaaugu uaaca 25

<210> 55

<211> 25

<212> RNA

<213> Homo sapiens

<400> 55

gucuccaugu uugauguauc ugagc 25

<210> 56

<211> 25

<212> RNA

<213> Homo sapiens

<400> 56

gauguaucug agcagguugc uccac 25

<210> 57

<211> 25

<212> RNA

<213> Homo sapiens

<400> 57

agcagguugc uccacaggua gcucu 25

<210> 58

<211> 25

<212> RNA

<213> Homo sapiens

<400> 58

agguugcucc acagguagcu cuagg 25

<210> 59

<211> 25

<212> RNA

<213> Homo sapiens

<400> 59

gguugcucca cagguagcuc uagga 25

<210> 60

<211> 25

<212> RNA

<213> Homo sapiens

<400> 60

gcuccacagg uagcucuagg aggc 25

<210> 61

<211> 25

<212> RNA

<213> Homo sapiens

<400> 61

agcucuagga gggcuggcaa cuuag 25

<210> 62

<211> 25

<212> RNA

<213> Homo sapiens

<400> 62

ucuaggaggg cuggcaacuu agagg 25

<210> 63

<211> 25

<212> RNA

<213> Homo sapiens

<400> 63

cuaggagggc uggcaacuua gaggu 25

<210> 64

<211> 25

<212> RNA

<213> Homo sapiens

<400> 64

uaggagggcu ggcaacuuag aggug 25

<210> 65

<211> 25

<212> RNA

<213> Homo sapiens

<400> 65

auucucuuau ccaacaucaa caucu 25

<210> 66

<211> 25

<212> RNA

<213> Homo sapiens

<400> 66

caauuuacau acucugcuua gaauu 25

<210> 67

<211> 25

<212> RNA

<213> Homo sapiens

<400> 67

aauuuacaua cucugcuuag aauuu 25

<210> 68

<211> 25

<212> RNA

<213> Homo sapiens

<400> 68

auuuacauac ucugcuuaga auuug 25

<210> 69

<211> 25

<212> RNA

<213> Homo sapiens

<400> 69

uuuacauacu cugcuuagaa uuugg 25

<210> 70

<211> 25

<212> RNA

<213> Homo sapiens

<400> 70

gggaaaauuu agaaauauaa uugac 25

<210> 71

<211> 25

<212> RNA

<213> Homo sapiens

<400> 71

uuagaaauau aauugacagg auuau 25

<210> 72

<211> 25

<212> RNA

<213> Homo sapiens

<400> 72

uacuucuuau acauuugaua aagua 25

<210> 73

<211> 25

<212> RNA

<213> Homo sapiens

<400> 73

cuuauacauu ugauaaagua aggca 25

<210> 74

<211> 25

<212> RNA

<213> Homo sapiens

<400> 74

cauuugauaa aguaaggcau gguug 25

<210> 75

<211> 25

<212> RNA

<213> Homo sapiens

<400> 75

aaguaaggca ugguuguggu uaauc 25

<210> 76

<211> 25

<212> RNA

<213> Homo sapiens

<400> 76

cuucaaaccu gaaaagaaaa gaaaa 25

<210> 77

<211> 25

<212> RNA

<213> Homo sapiens

<400> 77

auuuggaauu cauccaaucc aaaug 25

<210> 78

<211> 25

<212> RNA

<213> Homo sapiens

<400> 78

uauuaaaaag caagcaagca gaauu 25

<210> 79

<211> 25

<212> RNA

<213> Homo sapiens

<400> 79

gcaaccugcu cagauacauc aaaca 25

<210> 80

<211> 25

<212> RNA

<213> Homo sapiens

<400> 80

uugccagccc uccuagagcu accug 25

<210> 81

<211> 25

<212> RNA

<213> Homo sapiens

<400> 81

ucaaaucuga ccaagauguu gaugu 25

<210> 82

<211> 25

<212> RNA

<213> Homo sapiens

<400> 82

caaauucuaa gcagaguaug uaaau 25

<210> 83

<211> 25

<212> RNA

<213> Homo sapiens

<400> 83

caaguuuuau gauuuauuua acuug 25

<210> 84

<211> 25

<212> RNA

<213> Homo sapiens

<400> 84

cacugaagca uuuauuaugc aaaau 25

<210> 85

<211> 25

<212> RNA

<213> Homo sapiens

<400> 85

gaagcauuua uuaugcaaaa uagga 25

<210> 86

<211> 25

<212> RNA

<213> Homo sapiens

<400> 86

cagaguagag agcguuuucc aucca 25

<210> 87

<211> 25

<212> RNA

<213> Homo sapiens

<400> 87

acgcagcagu auccuaguac auuga 25

<210> 88

<211> 25

<212> RNA

<213> Homo sapiens

<400> 88

cgcagcagua uccuaguaca uugac 25

<210> 89

<211> 25

<212> RNA

<213> Homo sapiens

<400> 89

uuuuuccugu ccugcacug uccgc 25

<210> 90

<211> 25

<212> RNA

<213> Homo sapiens

<400> 90

uuuuccuguc cugccacugu ccgcu 25

<210> 91

<211> 25

<212> RNA

<213> Homo sapiens

<400> 91

cugccacugu ccgcugggca guuau 25

<210> 92

<211> 25

<212> RNA

<213> Homo sapiens

<400> 92

cugggcaguu auagguccca ugugu 25

<210> 93

<211> 25

<212> RNA

<213> Homo sapiens

<400> 93

ugggcaguua uaggucccau guguu 25

<210> 94

<211> 25

<212> RNA

<213> Homo sapiens

<400> 94

gucccaugug uugggucuuc cugcg 25

<210> 95

<211> 25

<212> RNA

<213> Homo sapiens

<400> 95

ucgcugaaag cgugaaguga aucaa 25

<210> 96

<211> 25

<212> RNA

<213> Homo sapiens

<400> 96

augccacuuu gugcacagcu cauca 25

<210> 97

<211> 25

<212> RNA

<213> Homo sapiens

<400> 97

caucaagguc agucuguuca ucuuc 25

<210> 98

<211> 25

<212> RNA

<213> Homo sapiens

<400> 98

uucaucuucu ggccccugua gcaca 25

<210> 99

<211> 25

<212> RNA

<213> Homo sapiens

<400> 99

cccuguagca caugguacag uucaa 25

<210> 100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 100

uagcacaugg uacaguucaa uggug 25

<210> 101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 101

gguacaguuc aaugggcgg cacag 25

<210> 102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 102

uucaauggug cggcacagag gccug 25

<210> 103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 103

auggugcggc acagaggccu gaggc 25

<210> 104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 104

uggugcggca cagaggccug aggca 25

<210> 105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 105

ugcggcacag aggccugagg caggg 25

<210> 106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 106

gcagggaggc ucccgcugcc cucgc 25

<210> 107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 107

aggcuccgc ugccccgca ggccc 25

<210> 108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 108

accuucccau gccccugcag cuccc 25

<210> 109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 109

gccccugcag cucccugguu gcacc 25

<210> 110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 110

gcagcucccu gguugcaccu ggccu 25

<210> 111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 111

gcuccuuucc aucugccccu cugcc 25

<210> 112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 112

ugccccucug ccggccuc ucacc 25

<210> 113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 113

gccccucugc ccggcccucu cacca 25

<210> 114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 114

ccucugcccg gcccucucac caggg 25

<210> 115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 115

gcccucucac cagggaggca caaca 25

<210> 116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 116

cauggcccag uacaguuacc uugaa 25

<210> 117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 117

ggcccaguac aguuaccuug aaagg 25

<210> 118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 118

guacaguuac cuugaaagga gguga 25

<210> 119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 119

ugacaacaga agccaaauuu acagc 25

<210> 120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 120

ucagacacag agugauacag acauu 25

<210> 121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 121

cagacacaga gugauacaga cauua 25

<210> 122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 122

caugugcuag caucugcgcu uucuc 25

<210> 123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 123

augugcuagc aucugcgcuu ucucu 25

<210> 124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 124

ugugcuagca ucugcgcuuu cucug 25

<210> 125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 125

acagacucaa caacucagcu gugag 25

<210> 126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 126

gugagaggca gugcgcccgc cuccc 25

<210> 127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 127

ugagaggcag ugcgcccgcc uccca 25

<210> 128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 128

gugcgcccgc cucccaggga gaacg 25

<210> 129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 129

cucccaggga gaacgaggaa ccgcc 25

<210> 130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 130

ggagaacgag gaaccgccag gagac 25

<210> 131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 131

caggagacag gucuaccugc accac 25

<210> 132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 132

ucuaccugca ccaccggcaa accag 25

<210> 133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 133

cuaccugcac caccggcaaa ccaga 25

<210> 134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 134

caccaccggc aaaccagagg gcca 25

<210> 135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 135

ccggcaaacc aggggccca aggcc 25

<210> 136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 136

cggcaaacca gagggcccaa ggcca 25

<210> 137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 137

ggcccaaggc cagggccgua agccc 25

<210> 138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 138

gcccaaggcc agggccguaa gcccu 25

<210> 139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 139

gggaguacac ucccuuaaag agugc 25

<210> 140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 140

ggaguacacu cccuuaaaga gugca 25

<210> 141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 141

ugcagggaca acagucugug uguga 25

<210> 142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 142

ggacaacagu cuguguguga agguu 25

<210> 143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 143

uauaaccaaa gcauccugua cauaa 25

<210> 144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 144

auaaccaaag cauccuguac auaaa 25

<210> 145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 145

uaaccaaagc auccuguaca uaaag 25

<210> 146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 146

cuguacauaa aggggaauac uucag 25

<210> 147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 147

acuucagugg cugagaagag ugaac 25

<210> 148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 148

cuucaguggc ugagaagagu gaacc 25

<210> 149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 149

augcuucauc cugugucuca uaauc 25

<210> 150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 150

ugcuucaucc ugugucucau aaucu 25

<210> 151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 151

ugugucucau aucugggcg ucugc 25

<210> 152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 152

cucauaaucu gggcgucugc agguc 25

<210> 153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 153

ggcgucugca ggucuggccu uugag 25

<210> 154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 154

cuggccuuug agggugaaa ucccc 25

<210> 155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 155

uggugaaauc cccuggcugu uagcg 25

<210> 156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 156

ggugaaaucc ccuggcuguu agcga 25

<210> 157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 157

gugaaauccc cuggcuguua gcgag 25

<210> 158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 158

ugaaaucccc uggcuguuag cgagg 25

<210> 159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 159

auccccggc uguuagcgag ggggc 25

<210> 160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 160

ucccggcu guuagcgagg gggca 25

<210> 161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 161

gcgaggggggc agggccugca uguga 25

<210> 162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 162

cgaggggggca gggccugcau gugaa 25

<210> 163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 163

agggccugca ugugaagggc gucgu 25

<210> 164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 164

augugaaggg cgucguaggu guccu 25

<210> 165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 165

ugaggggcgu cguagguguc cuugg 25

<210> 166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 166

guccuuggug gcuguacuga gaccc 25

<210> 167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 167

uuuuuucuac uguuuuaauu uauac 25

<210> 168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 168

gucauuacag ggcacaggcc augga 25

<210> 169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 169

cugcgucauu acagggcaca ggcca 25

<210> 170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 170

auacugcugc gucauuacag ggcac 25

<210> 171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 171

acuaggauac ugcugcguca uuaca 25

<210> 172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 172

uacuaggaua cugcugcguc auuac 25

<210> 173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 173

gacaggaaaa accccgucaau guacu 25

<210> 174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 174

acugcccagc ggacaguggc aggac 25

<210> 175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 175

cuauaacugc ccagcggaca guggc 25

<210> 176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 176

ggaccuauaa cugcccagcg gacag 25

<210> 177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 177

acacauggga ccuauaacug cccag 25

<210> 178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 178

ggccucgcag gaagacccaa cacau 25

<210> 179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 179

aggccucgca ggaagaccca acaca 25

<210> 180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 180

aaaaucaucu uugugaaggc cucgc 25

<210> 181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 181

gcgaaugaca aaaucaucuu uguga 25

<210> 182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 182

gaauaaagug cugcggagca agagg 25

<210> 183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 183

ugugaauaaa gugcugcgga gcaag 25

<210> 184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 184

guuacacagu gugaauaaag ugcug 25

<210> 185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 185

ugcacaaagu ggcauaaaaa acaug 25

<210> 186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 186

ugaccuugau gagcugugca caaag 25

<210> 187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 187

cauugaacug uaccaugugc uacag 25

<210> 188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 188

ccauugaacu guaccaugug cuaca 25

<210> 189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 189

accauugaac uguaccaaugu gcuac 25

<210> 190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 190

agggcagcgg gagccucccu gccuc 25

<210> 191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 191

gucagccagg gccugcgagg gcagc 25

<210> 192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 192

ggucagccag ggcugcgag ggcag 25

<210> 193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 193

ggggggguc agccaggggcc ugcga 25

<210> 194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 194

aggggagggu cagccaggggc cugcg 25

<210> 195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 195

ugggcggggca ggggaggguc agcca 25

<210> 196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 196

gugggcgggc aggggagggu cagcc 25

<210> 197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 197

caugggaagg ugggcggggca gggga 25

<210> 198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 198

gcaugggaag gugggcgggc agggg 25

<210> 199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 199

ggggcauggg aaggugggcg ggcag 25

<210> 200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 200

aggggcaugg gaaggugggc gggca 25

<210> 201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 201

caggggcaug ggaagguggg cgggc 25

<210> 202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 202

gcugcagggg caugggaagg ugggc 25

<210> 203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 203

agcugcaggg gcaugggaag guggg 25

<210> 204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 204

gggagcugca ggggcauggg aaggu 25

<210> 205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 205

agggagcugc aggggcaugg gaagg 25

<210> 206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 206

accagggagc ugcaggggca uggga 25

<210> 207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 207

ugcaaccagg gagcugcagg ggcau 25

<210> 208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 208

gugcaaccag ggagcugcag gggca 25

<210> 209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 209

gccaggugca accagggagc ugcag 25

<210> 210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 210

ggccaggugc aaccagggag cugca 25

<210> 211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 211

aggccaggug caaccaggga gcugc 25

<210> 212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 212

aaggaccua ggccaggugc aacca 25

<210> 213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 213

aaaggagccu aggccaggug caacc 25

<210> 214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 214

gggcagaugg aaaggagccu aggcc 25

<210> 215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 215

cagaggggca guggaaagg agccu 25

<210> 216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 216

gggccgggca gaggggcaga uggaa 25

<210> 217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 217

ugaggggcc gggcagaggg gcaga 25

<210> 218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 218

ucccgguga gagggccggg cagag 25

<210> 219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 219

cucccuggug aggggccgg gcaga 25

<210> 220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 220

ccucccuggu gagaggggccg ggcag 25

<210> 221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 221

guugugccuc ccuggugaga gggcc 25

<210> 222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 222

uguugugccu cccuggugag agggc 25

<210> 223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 223

gccauguugu gccucccugg ugaga 25

<210> 224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 224

ggccauguug ugccucccug gugag 25

<210> 225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 225

uguacugggc cauguugugc cuccc 25

<210> 226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 226

caccuccuuu caagguaacu guacu 25

<210> 227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 227

ucaccuccuu ucaagguaac uguac 25

<210> 228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 228

cuguugucac cuucaccucc uuuca 25

<210> 229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 229

aguggcuuca cuccugcugu aaauu 25

<210> 230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 230

augucuguau cacucugugu cugag 25

<210> 231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 231

cgguuccucg uucuccgggaggc 25

<210> 232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 232

gcgguuccuc guucucccug ggagg 25

<210> 233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 233

cuggcgguuc cucguucucc cuggg 25

<210> 234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 234

cuccuggcgg uuccucguuc ucccu 25

<210> 235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 235

ucuccggcg guuccucguu cuccc 25

<210> 236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 236

uggugcaggu agaccugucu ccugg 25

<210> 237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 237

cgguggugca gguagaccug ucucc 25

<210> 238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 238

gggcccucug guuugccggu ggugc 25

<210> 239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 239

ggccuugggc ccucugguuu gccgg 25

<210> 240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 240

ccuggccuug ggccucugg uuugc 25

<210> 241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 241

cuuacggccc uggccuuggg cccuc 25

<210> 242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 242

ucccagggcu uacggccug gccuu 25

<210> 243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 243

cucccagggc uuacggcccu ggccu 25

<210> 244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 244

aguguacucc cagggcuuac ggccc 25

<210> 245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 245

uaagggagug uacucccagg gcuua 25

<210> 246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 246

cacucuuuaa gggaguguac uccca 25

<210> 247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 247

gcacucuuua agggagugua cuccc 25

<210> 248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 248

agacuguugu cccugcacuc uuuaa 25

<210> 249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 249

cagacuguug ucccugcacu cuuua 25

<210> 250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 250

auuccccuuu auguacagga ugcuu 25

<210> 251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 251

cacugaagua uuccccuuua uguac 25

<210> 252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 252

gacacaggau gaagcauuua caacc 25

<210> 253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 253

ugcagacgcc cagauuauga gacac 25

<210> 254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 254

acagccaggg gauuucacca cucaa 25

<210> 255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 255

gcccugcccc cucgcuaaca gccag 25

<210> 256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 256

ggccugccc ccucgcuaac agcca 25

<210> 257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 257

aggccugcc cccucgcuaa cagcc 25

<210> 258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 258

gacaccuacg acgcccuuca caugc 25

<210> 259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 259

cgccaggguc ucaguacagc cacca 25

<210> 260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 260

ugaagggacg ccggcagcuc cuacc 25

<210> 261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 261

gacgccggca gcuccuaccu gguaa 25

<210> 262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 262

aaggccaucg ugccccuugc cccuc 25

<210> 263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 263

aucgugcccc uugccccucc ggcgc 25

<210> 264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 264

ccuugccccu ccggcgcugg uuguu 25

<210> 265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 265

cuugccccuc cggcgcuggu uguuu 25

<210> 266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 266

auggccuuua ccagguagga gcugc 25

<210> 267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 267

aggggcacga uggccuuuac caggu 25

<210> 268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 268

ggcaaggggc acgauggccu uuacc 25

<210> 269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 269

agcgccggag gggcaagggg cacga 25

<210> 270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 270

aaacaaccag cgccggaggg gcaag 25

<210> 271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 271

caaacaacca gcgccgggagg ggcaa 25

<210> 272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 272

ccaaacaacc agcgccggag gggca 25

<210> 273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 273

cacucccaaa caaccagcgc cggag 25

<210> 274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 274

ucacucccaa acaaccagcg ccgga 25

<210> 275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 275

uucacuccca aacaaccagc gccgg 25

<210> 276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 276

cauuucacuc ccaaacaacc agcgc 25

<210> 277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 277

ucgccuuuca ucccaaucuc acugu 25

<210> 278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 278

uaucuuucug caguuccugc agaag 25

<210> 279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 279

aucuuucugc aguuccugca gaaga 25

<210> 280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 280

ucugcaguuc cugcagaaga gggcg 25

<210> 281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 281

uacagugaga uugggaugaa aggcg 25

<210> 282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 282

aggccuacag ugagauuggg augaa 25

<210> 283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 283

gauggcggag gccuacagug agauu 25

<210> 284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 284

agauggcgga ggccuacagu gagau 25

<210> 285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 285

gaacugcaga aagauaagau ggcgg 25

<210> 286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 286

caggaacugc agaaagauaa gaugg 25

<210> 287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 287

cugcaggaac ugcagaaaga uaaga 25

<210> 288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 288

gaggucuccu cuacucacau uguac 25

<210> 289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 289

uacucacauu guacaggccu uccug 25

<210> 290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 290

acucacauug uacaggccuu ccuga 25

<210> 291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 291

uccugagggu ucuuccuucu cugcu 25

<210> 292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 292

cuuccuucuc ugcuaggaaa gacaa 25

<210> 293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 293

uuccuucucu gcuaggaaag acaac 25

<210> 294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 294

aggaaggccu guacaaugug aguag 25

<210> 295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 295

agcagagaag gaagaacccu cagga 25

<210> 296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 296

uccuagcaga gaaggaagaa cccuc 25

<210> 297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 297

uucccguugu cuuuccuagc agaga 25

<210> 298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 298

cacaggaagg uagaggaac ccuac 25

<210> 299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 299

ccccuaccgg cuuucccccc aucuc 25

<210> 300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 300

cccuaccggc uuuccccca ucuca 25

<210> 301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 301

cggcuuuccc cccaucucag ggucc 25

<210> 302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 302

ccugagaugg ggggaaagcc gguag 25

<210> 303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 303

cccugagaug gggggaaagc cggua 25

<210> 304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 304

acccugagau ggggggaaag ccggu 25

<210> 305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 305

cgggacccug agaugggggg aaagc 25

<210> 306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 306

gacguggccg ggacccugag auggg 25

<210> 307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 307

agacguggcc gggacccuga gaugg 25

<210> 308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 308

gagacguggc cgggacccug agaug 25

<210> 309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 309

agagacgugg ccgggacccu gagau 25

<210> 310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 310

aagagacgug gccgggaccc ugaga 25

<210> 311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 311

gauguuuugg acaagagacg uggcc 25

<210> 312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 312

cgauguuuug gacaagagac guggc 25

<210> 313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 313

aguacgaugu uuuggacaag agacg 25

<210> 314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 314

ggacgaagag aggaguacga uguuu 25

<210> 315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 315

uaggagcuca aucuaggacg aagag 25

<210> 316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 316

cuuaucuguu auaggagcuc aaucu 25

<210> 317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 317

gcgaggcuga cuuacguuau agagc 25

<210> 318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 318

cugacuuacg uuauagagcu gguuc 25

<210> 319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 319

guuauagagc ugguucuggc ccugc 25

<210> 320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 320

agcugguucu ggcccugcug guacg 25

<210> 321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 321

gcugguucug gcccugcugg uacgc 25

<210> 322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 322

cugguucugg cccugcuggu acgcg 25

<210> 323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 323

ugguucuggc ccugcuggua cgcgg 25

<210> 324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 324

gcgcagacgc ccccgcguac cagca 25

<210> 325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 325

agcgcagacg cccccgcgua ccagc 25

<210> 326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 326

uuugcuuucu guguugcagu ucagc 25

<210> 327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 327

cccaguggua cccaccuuca cucuc 25

<210> 328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 328

guacccaccu ucacucucag gaaca 25

<210> 329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 329

agugagaaug acaccauaga ugaag 25

<210> 330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 330

auagaugaag aggauuccau ccagc 25

<210> 331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 331

auuccaucca gcagguagca gaguu 25

<210> 332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 332

uuccauccag cagguagcag aguuu 25

<210> 333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 333

cagguagcag aguuugggau ccagc 25

<210> 334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 334

gugccucugu gccaagagau aaagc 25

<210> 335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 335

aagggggua ccacugggcu uuggg 25

<210> 336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 336

gugaaggugg guaccacugg gcuuu 25

<210> 337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 337

agugaaggug gguaccacug ggcuu 25

<210> 338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 338

ccugagagug aaggugggua ccacu 25

<210> 339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 339

uccugagagu gaaggugggu accac 25

<210> 340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 340

cugccuuguu ccugagagug aaggu 25

<210> 341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 341

acugccuugu uccugagagu gaagg 25

<210> 342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 342

cucacugccu uguuccugag aguga 25

<210> 343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 343

ugcuggaugg aauccucuuc aucua 25

<210> 344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 344

aucccaaacu cugcuaccug cugga 25

<210> 345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 345

cuggauccca aacucugcua ccugc 25

<210> 346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 346

acagaggcac agagcuuugg ccugc 25

<210> 347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 347

cucuuggcac agaggcacag agcuu 25

<210> 348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 348

ugaccagcuu uaucucuugg cacag 25

<210> 349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 349

ucgacacguc ggcccuaccu guaau 25

<210> 350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 350

accuguaauc ggcaacugug ccugc 25

<210> 351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 351

guaaucggca acugugccug cagga 25

<210> 352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 352

ggcaacugug ccugcaggau ggccg 25

<210> 353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 353

ucaucuuguc cuuucccuca gaaag 25

<210> 354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 354

cuuguccuuu cccucagaaa gaggc 25

<210> 355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 355

uuguccuuuc ccucagaaag aggcu 25

<210> 356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 356

uccuuucccu cagaaagagg cuggg 25

<210> 357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 357

cccucagaaa gaggcuggga ggcag 25

<210> 358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 358

gaaagaggcu gggaggcaga ggcug 25

<210> 359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 359

ggcugggagg cagaggcuga ggcag 25

<210> 360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 360

ugggaggcag aggcugaggc agcgg 25

<210> 361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 361

aggcagaggc ugaggcagcg guggc 25

<210> 362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 362

ggcagaggcu gaggcagcgg uggcc 25

<210> 363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 363

gaggcugagg cagcgguggc cggga 25

<210> 364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 364

ugaggcagcg guggccggga cgguu 25

<210> 365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 365

cgguggccgg gacgguuagg agaaa 25

<210> 366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 366

cgguuaggag aaaaggaguc ucugc 25

<210> 367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 367

gguuuuauuc ugcagcuacc ucccc 25

<210> 368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 368

auucugcagc uaccucccca ggaag 25

<210> 369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 369

cugcagcuac cucccgga agugg 25

<210> 370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 370

uaccucccca ggaaguggag gacug 25

<210> 371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 371

accuccccag gaagugggagg acugu 25

<210> 372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 372

ccuccccagg aaguggagga cugug 25

<210> 373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 373

ggccuuugag aaagcaccug ccgac 25

<210> 374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 374

gccuuugaga aagcaccugc cgaca 25

<210> 375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 375

cagguagggc cgacgugucg acggc 25

<210> 376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 376

auuacaggua gggccgacgu gucga 25

<210> 377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 377

caggcacagu ugccgauuac aggua 25

<210> 378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 378

gcaggcacag uugccgauua caggu 25

<210> 379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 379

uccugcaggc acaguugccg auuac 25

<210> 380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 380

gcgcuuuuca ccgcggccau ccugc 25

<210> 381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 381

augaagugga aggcgcuuuu caccg 25

<210> 382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 382

gagggaaagg acaagaugaa gugga 25

<210> 383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 383

uucugaggga aaggacaaga ugaag 25

<210> 384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 384

gccucccagc cucuuucuga gggaa 25

<210> 385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 385

ccucugccuc ccagccucuu ucuga 25

<210> 386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 386

gccucugccu cccagccucu uucug 25

<210> 387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 387

gagacuccuu uucuccuaac cgucc 25

<210> 388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 388

ccccacaguc cuccacuucc ugggg 25

<210> 389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 389

aggccccaca guccuccacu uccug 25

<210> 390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 390

aaggccccac aguccuccac uuccu 25

<210> 391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 391

aaaggcccca caguccucca cuucc 25

<210> 392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 392

gcccugucgg caggugcuuu cucaa 25

<210> 393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 393

agcccaggca ccugcugagu gaaag 25

<210> 394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 394

gcugagugaa agaggauaua uuuau 25

<210> 395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 395

ggauauauuu auuggcugag caaga 25

<210> 396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 396

gauauauuua uuggcugagc aagaa 25

<210> 397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 397

uauuuauugg cugagcaaga aggga 25

<210> 398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 398

gcugagcaag aagggaaggu acagu 25

<210> 399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 399

caagaaggga agguacaguu gguaa 25

<210> 400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 400

gcugcuucua gaagccacca gucuc 25

<210> 401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 401

cuuguuccga gcccaguuuc cucca 25

<210> 402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 402

guuccgagcc caguuuccuc caagg 25

<210> 403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 403

gcuguacuga gcaucauci gaucu 25

<210> 404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 404

guacugagca ucaucucgau cucgg 25

<210> 405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 405

uacugagcau caucucgauc ucgga 25

<210> 406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 406

acugagcauc aucucgaucu cggag 25

<210> 407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 407

aucucgaucu cggaggggcu aagag 25

<210> 408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 408

ggggcuaaga gaggagaaga gaaaa 25

<210> 409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 409

acucagcagg ugccuggcu ucua 25

<210> 410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 410

auccucuuuc acucagcagg ugccu 25

<210> 411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 411

uauccucuuu cacucagcag gugcc 25

<210> 412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 412

auaaauauau ccucuuucac ucagc 25

<210> 413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 413

ucggaacaag ugaaccugag acugg 25

<210> 414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 414

ggcucgaac aagugaaccu gagac 25

<210> 415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 415

cagccaccuu ggaggaaacu gggcu 25

<210> 416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 416

caguacagcc accuuggagg aaacu 25

<210> 417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 417

ucaguacagc caccuuggag gaaac 25

<210> 418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 418

augaugcuca guacagccac cuugg 25

<210> 419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 419

gagaugaugc ucaguacagc caccu 25

<210> 420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 420

ccccucaacg cucaccuau agacc 25

<210> 421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 421

ucauuccuca acagagcuug ugugu 25

<210> 422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 422

uaucagguga gcguugaggg gaagg 25

<210> 423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 423

gucuaucagg ugagcguuga gggga 25

<210> 424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 424

ccaggucuau caggugagcg uugag 25

<210> 425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 425

accaggucuua ucaggugagc guuga 25

<210> 426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 426

gaccaggucu aucaggugag cguug 25

<210> 427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 427

cuguugagga augaccaggu cuauc 25

<210> 428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 428

acacaagcuc uguugaggaa ugacc 25

<210> 429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 429

agcugccgac acacaagcuc uguug 25

<210> 430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 430

agcaaagcag aagacuccca aagca 25

<210> 431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 431

aagacuccca aagcaaggag cagag 25

<210> 432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 432

acaucaguga caaugaugcc agcca 25

<210> 433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 433

ucagugacaa ugaugccagc cacgg 25

<210> 434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 434

ugacaaugau gccagccacg guggc 25

<210> 435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 435

ggcuggaucc agcuccacac agcuc 25

<210> 436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 436

agcuccacac agcucuggca cacug 25

<210> 437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 437

gcuccacaca gcucuggcac acugu 25

<210> 438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 438

cuccacaca cugug 25

<210> 439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 439

uccacacagc ucuggcacac ugugg 25

<210> 440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 440

cacagcucug gcacacugug gggga 25

<210> 441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 441

acagcucugg cacacugugg gggaa 25

<210> 442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 442

gcucuggcac acuguggggg aaggg 25

<210> 443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 443

cacacugugg gggaagggag gagag 25

<210> 444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 444

gacuggaagg cugucugggg guuag 25

<210> 445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 445

gacaugagac uggaaggcug ucugg 25

<210> 446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 446

ggacaugaga cuggaaggcu gucug 25

<210> 447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 447

uggacaugag acuggaaggc ugucu 25

<210> 448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 448

cuggacauga gacuggaagg cuguc 25

<210> 449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 449

cugcuuugcu ggacaugaga cugga 25

<210> 450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 450

ucuucugcuu ugcuggacau gagac 25

<210> 451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 451

uugcuuuggg agucuucugc uuugc 25

<210> 452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 452

ucauugccac ucugcuccuu gcuuu 25

<210> 453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 453

gucauugcca cucugcuccu ugcuu 25

<210> 454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 454

uggagcugga uccagccacc guggc 25

<210> 455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 455

uguguggagc uggauccagc caccg 25

<210> 456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 456

acagugugcc agagcugugu ggagc 25

<210> 457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 457

ucccccacag ugugccagag cugug 25

<210> 458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 458

cacguacuuc gauaaugaac uugca 25

<210> 459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 459

ucccauuaca ccuauauauuu cccg 25

<210> 460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 460

cccauuacac cuauauauuc cucgu 25

<210> 461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 461

acaccuauau auuccucgug ggucc 25

<210> 462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 462

ucggggucc aggaugcguu uuccc 25

<210> 463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 463

accguucccu cuacccaugu gaugc 25

<210> 464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 464

acacucuguc cucaaguucc ucauau 25

<210> 465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 465

ucaaguuccu cuauagguau cuuga 25

<210> 466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 466

caaguuccuc uauagguauc uugaa 25

<210> 467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 467

aaguuccucu auagguaucu ugaag 25

<210> 468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 468

uagguaucuu gaaggggcuc acuaa 25

<210> 469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 469

agguaucuug aaggggcuca cuaaa 25

<210> 470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 470

gguaucuuga aggggcucac uaaag 25

<210> 471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 471

gaaguacgug cuuccugaac ccuuu 25

<210> 472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 472

cgaaguacgu gcuuccugaa cccuu 25

<210> 473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 473

agguguaaug ggacagaauau auaca 25

<210> 474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 474

cccacgagga auauauaggu guaau 25

<210> 475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 475

acccacgagg aauauauagg uguaa 25

<210> 476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 476

cauccuggac ccacgaggaa uauau 25

<210> 477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 477

ugggaaaacg cauccuggac ccacg 25

<210> 478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 478

agacuggacc ugggaaaacg caucc 25

<210> 479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 479

ucucagacau uacaagacug gaccu 25

<210> 480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 480

cucucagaca uuacaagacu ggacc 25

<210> 481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 481

acacugcucu cagacauuac aagac 25

<210> 482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 482

gcaucacaug gguagaggga acggu 25

<210> 483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 483

agcaucacau ggguagaggg aacgg 25

<210> 484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 484

accagcauca cauggguaga gggaa 25

<210> 485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 485

gcaauaccag caucacaugg guaga 25

<210> 486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 486

ugcaauacca gcaucacaug gguag 25

<210> 487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 487

gugaauugca auaccagcau cacau 25

<210> 488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 488

ugugaauugc aauaccagca ucaca 25

<210> 489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 489

uucaagauac cuauagagga acuug 25

<210> 490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 490

gugagccccu ucaagauacc uauag 25

<210> 491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 491

uggaguagcc uuaccuugcg agaga 25

<210> 492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 492

ggaguagccu uaccuugcga gagaa 25

<210> 493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 493

uugcgagaga aggguagcca guacc 25

<210> 494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 494

aaacgugcua uguuccaucu cccag 25

<210> 495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 495

cggaacucau ccaguagaua aagcc 25

<210> 496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 496

aagccagguc accgaacuau cagcc 25

<210> 497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 497

agccagguca ccgaacuauc agccu 25

<210> 498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 498

agcugcccuc cccuagcuga cucac 25

<210> 499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 499

ccuccccuag cugacucaca gguac 25

<210> 500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 500

uagcugacuc acagguaccg gaaag 25

<210> 501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 501

cucacaggua ccggaaagag gagag 25

<210> 502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 502

ucacagguac cggaaagagg agagu 25

<210> 503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 503

cacagguacc ggaaagga gagug 25

<210> 504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 504

acagguaccg gaaagaggag agugg 25

<210> 505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 505

gguaccggaa aggagagu ggggg 25

<210> 506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 506

cugcuucucu gcuuucugcc guuga 25

<210> 507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 507

cuucucugcu uucugccguu gaugg 25

<210> 508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 508

uucucugcuu ucugccguug auggu 25

<210> 509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 509

aagguaaggc uacuccaggu gggug 25

<210> 510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 510

caagguaagg cuacuccagg ugggu 25

<210> 511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 511

gcaagguaag gcuacuccag guggg 25

<210> 512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 512

cucgcaaggu aaggcuacuc caggu 25

<210> 513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 513

ucucgcaagg uaaggcuacu ccagg 25

<210> 514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 514

uucucucgca agguaaggcu acucc 25

<210> 515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 515

cuggcuaccc uucucucgca aggua 25

<210> 516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 516

ugguacuggc uacccuucuc ucgca 25

<210> 517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 517

agcacguuuc ucucuggccu gguac 25

<210> 518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 518

gaacauagca cguuucucuc uggcc 25

<210> 519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 519

agauggaaca uagcacguuu cucuc 25

<210> 520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 520

cuacuggaug aguuccgcug ggaga 25

<210> 521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 521

cuuuaucuac uggaugaguu ccgcu 25

<210> 522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 522

gcuuuaucua cuggaugagu uccgc 25

<210> 523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 523

aguucgguga ccuggcuuua ucuac 25

<210> 524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 524

cacccaggcu gauaguucgg ugacc 25

<210> 525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 525

gcagcucuca cccaggcuga uaguu 25

<210> 526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 526

agcuagggga gggcagcucu caccc 25

<210> 527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 527

cgguaccugu gagucagcua gggga 25

<210> 528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 528

ccgguaccug ugagucagcu agggg 25

<210> 529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 529

uuuccgguac cugugaguca gcuag 25

<210> 530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 530

cuuuccggua ccugugaguc agcua 25

<210> 531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 531

ucuuuccggu accugugagu cagcu 25

<210> 532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 532

aguuccuccc ccacucuccu cuuuc 25

<210> 533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 533

cagguauugu cagaguccuc uuguu 25

<210> 534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 534

ucagaguccu cuuguuuggc cuucu 25

<210> 535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 535

aguccucuug uuuggccuuc uagga 25

<210> 536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 536

cuuguuuggc cuucuaggaa ggcug 25

<210> 537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 537

uuguuuggcc uucuaggaag gcugu 25

<210> 538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 538

ggacccagcu uucuucaacc agucc 25

<210> 539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 539

cccagcuuuc uucaaccagu ccagg 25

<210> 540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 540

agcuuucuuc aaccagucca ggugg 25

<210> 541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 541

ccucugccuu gaacguuucc aagug 25

<210> 542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 542

cguuuccaag ugagguaaaa cccgc 25

<210> 543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 543

agugagguaa aacccgcagg cccag 25

<210> 544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 544

cccagaggcc ucucuacuuc cugug 25

<210> 545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 545

ccagaggccu cucuacuucc ugugu 25

<210> 546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 546

cagaggccuc ucuacuuccu gugug 25

<210> 547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 547

gaaacccucc uccccucca gccuc 25

<210> 548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 548

agccucaggu gccugcuuca gaaaa 25

<210> 549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 549

aagaggacuc ugacaauacc uggag 25

<210> 550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 550

cugaggacu cugacaauac cugga 25

<210> 551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 551

acaagaggac ucugacaaua ccugg 25

<210> 552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 552

caaacaagag gacucugaca auacc 25

<210> 553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 553

cagccuuccu agaaggccaa acaag 25

<210> 554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 554

agcugggucc cacagccuuc cuaga 25

<210> 555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 555

ccaccuggac ugguugaaga aagcu 25

<210> 556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 556

uccacugga cugguugaag aaagc 25

<210> 557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 557

ucaaggcaga ggccuccacc uggac 25

<210> 558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 558

aacguucaag gcagaggccu ccacc 25

<210> 559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 559

ccucacuugg aaacguucaa ggcag 25

<210> 560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 560

guuuuaccuc acuuggaaac guuca 25

<210> 561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 561

cugggccugc ggguuuuacc ucacu 25

<210> 562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 562

gaaguagaga ggccucuggg ccugc 25

<210> 563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 563

ggaaguagag aggccucugg gccug 25

<210> 564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 564

ccacacagga aguagagga ccucu 25

<210> 565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 565

cccacacagg aaguagagag gccuc 25

<210> 566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 566

ucugaacccc acacaggaag uagag 25

<210> 567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 567

ggaggagggu uucugaaccc cacac 25

<210> 568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 568

ggcaccugag gcugggagg gagga 25

<210> 569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 569

aggcaccuga ggcugggagg ggagg 25

<210> 570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 570

agcaggcacc ugaggcuggg agggg 25

<210> 571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 571

ugaagcaggc accugaggcu gggag 25

<210> 572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 572

cugaagcagg caccugaggc uggga 25

<210> 573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 573

ucugaagcag gcaccugagg cuggg 25

<210> 574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 574

uuuucugaag caggcaccug aggcu 25

<210> 575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 575

auuuucugaa gcaggcaccu gaggc 25

<210> 576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 576

caccauuuuc ugaagcaggc accug 25

<210> 577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 577

agagagacuc accauuuucu gaagc 25

<210> 578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 578

uuuuuuccag aaguaguaag ucugc 25

<210> 579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 579

cagucccaug aaacaaagau gcagu 25

<210> 580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 580

agucccauga aacaaagaug caguc 25

<210> 581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 581

aacaaagaug cagucggggca cucac 25

<210> 582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 582

cagucgggca cucacuggag aguuc 25

<210> 583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 583

agucgggcac ucacuggaga guucu 25

<210> 584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 584

gaguucuggg ccucugccuc uuauc 25

<210> 585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 585

ggccucugcc ucuuaucagg ugagu 25

<210> 586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 586

ucugccucuu aucaggugag uagga 25

<210> 587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 587

cucuuaucag gugaguagga uggag 25

<210> 588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 588

aucaggugag uaggauggag uggaa 25

<210> 589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 589

ucaggugagu aggauggagu ggaaa 25

<210> 590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 590

cggaggccag cagacuuacu acuuc 25

<210> 591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 591

gacuguuacu uuacuaagau ggcgg 25

<210> 592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 592

ugggacuguu acuuuacuaa gaugg 25

<210> 593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 593

ucaugggacu guuacuuuac uaaga 25

<210> 594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 594

gugcccgacu gcaucuuugu uucau 25

<210> 595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 595

agugccgac ugcaucuuug uuuca 25

<210> 596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 596

auccuacuca ccugauaaga ggcag 25

<210> 597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 597

cacuccaucc uacucaccug auaag 25

<210> 598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 598

uuuuuuuucu uauuuauuuu cuagu 25

<210> 599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 599

ucuuauuuau uuucuaguug gcguu 25

<210> 600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 600

cuuauuuuu uucuaguugg cguuu 25

<210> 601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 601

uuauuuuuu ucuaguuggc guuug 25

<210> 602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 602

uauuuauuuu cuaguuggcg uuugg 25

<210> 603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 603

uucuaguugg cguuugggg caaga 25

<210> 604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 604

guuuccuuuu cagguaauga agaaa 25

<210> 605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 605

uuuccuuuuc agguaaugaa gaaau 25

<210> 606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 606

uuacccauuu cuucauuacc ugaaa 25

<210> 607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 607

gcuguuuccu uuuuucauuuucagg 25

<210> 608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 608

guauuacaca gacacgugag uuuau 25

<210> 609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 609

uguaauacca ccugaaaaug aaaaa 25

<210> 610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 610

ccccagcaua uaaagucucc aucuc 25

<210> 611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 611

uaauauugac augcccucag uaucc 25

<210> 612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 612

ucaguauccu ggaucugaaa uacua 25

<210> 613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 613

uauggcaaca caaugauaaa aacau 25

<210> 614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 614

ggcaacacaa ugauaaaaac auagg 25

<210> 615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 615

aaugauaaaa acauaggcgg ugaug 25

<210> 616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 616

gcggugauga ggaugauaaa aacau 25

<210> 617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 617

gaugauaaaa acauaggcag ugaug 25

<210> 618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 618

agugaugagg aucaccuguc acuga 25

<210> 619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 619

cugucacuga aggaauuuuc agaau 25

<210> 620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 620

aggaauuuuc agaauuggag caaag 25

<210> 621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 621

gugguuauua ugucugcuac cccag 25

<210> 622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 622

agaugcgaac uuuuaucucu accug 25

<210> 623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 623

gaugcgaacu uuuaucucua ccuga 25

<210> 624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 624

acuuuuaucu cuaccugagg gcaag 25

<210> 625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 625

ucuaccugag ggcaagaggu aaucc 25

<210> 626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 626

aagagguaau ccaggucucc agaac 25

<210> 627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 627

uaugcugggg agaaagaagg gaaau 25

<210> 628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 628

gacuuuauau gcuggggaga aagaa 25

<210> 629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 629

agacuuuaua ugcuggggag aaaga 25

<210> 630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 630

ccagagaugg agacuuuaua ugcug 25

<210> 631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 631

uccagagaug gagacuuuau augcu 25

<210> 632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 632

uuccagagau ggagacuuua uaugc 25

<210> 633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 633

gucaauauua cugugguucc agaga 25

<210> 634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 634

uacugagggc augucaauau uacug 25

<210> 635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 635

uaguauuuca gauccaggau acuga 25

<210> 636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 636

auaguauuuc agauccagga uacug 25

<210> 637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 637

uguguugcca uaguauuuca gaucc 25

<210> 638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 638

caauucugaa aauuccuuca gugac 25

<210> 639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 639

cgcaucuucu gguuugcuuc cucug 25

<210> 640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 640

ucgcaucuuc ugguuugcuu ccucu 25

<210> 641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 641

uucgcaucuu cugguuugcu ucuc 25

<210> 642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 642

gguagagaua aaaguucgca ucuuc 25

<210> 643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 643

gagaccuga uuaccucuug cccuc 25

<210> 644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 644

ccccccacag ugugugagaa cugca 25

<210> 645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 645

acagugugug agaacugcau ggaga 25

<210> 646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 646

aacugcaugg agauggaugu gaugu 25

<210> 647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 647

ugcauggaga uggaugugau gucgg 25

<210> 648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 648

augucggugg ccacaauugu cauag 25

<210> 649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 649

uugucauagu ggacaucugc aucac 25

<210> 650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 650

ugucauagug gacaucugca ucacu 25

<210> 651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 651

gucauagugg acaucugcau cacug 25

<210> 652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 652

ucauagugga caucugcauc acugg 25

<210> 653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 653

ugcaucacug ggggcuugcu gcugc 25

<210> 654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 654

gggcuugcug cugcugguuu acuac 25

<210> 655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 655

guuuacuacu ggagcaagaa uagaa 25

<210> 656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 656

uacuggagca agaauagaaa ggcca 25

<210> 657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 657

aggccaaggc caagccugug acacg 25

<210> 658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 658

aaggccaagc cugugacacg aggag 25

<210> 659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 659

aggccaagcc ugugacacga ggagc 25

<210> 660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 660

agccugugac acgaggagcg ggugc 25

<210> 661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 661

cugugacacg aggagcgggu gcugg 25

<210> 662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 662

gacacgagga gcgggugcug gcggc 25

<210> 663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 663

aggagcgggu gcuggcggca ggcaa 25

<210> 664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 664

ggagcggggug cuggcggcag gcaaa 25

<210> 665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 665

gagcggggc uggcggcagg caaag 25

<210> 666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 666

ggugcuggcg gcaggcaaag gggua 25

<210> 667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 667

ggcggcaggc aaagggguaa ggcug 25

<210> 668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 668

acacuguggggggggggggggag 25

<210> 669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 669

cucacacacu guggggggug gggug 25

<210> 670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 670

ucucacacac uggggggggu ggggu 25

<210> 671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 671

uucucacaca cugugggggg ugggg 25

<210> 672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 672

caguucucac acacugugggg gggug 25

<210> 673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 673

gcaguucuca cacacugugg ggggu 25

<210> 674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 674

ugcaguucuc acacacugug ggggg 25

<210> 675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 675

ccaugcaguu cucacacacu guggg 25

<210> 676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 676

uccaugcagu ucucacacac ugugg 25

<210> 677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 677

cuccaugcag uucucacaca cugug 25

<210> 678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 678

ucuccaugca guucucacac acugu 25

<210> 679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 679

aucuccaugc aguucucaca cacug 25

<210> 680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 680

augcagaugu ccacuauugac aauug 25

<210> 681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 681

gcuccucgug ucacaggcuu ggccu 25

<210> 682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 682

gcacccgcuc cucgugucac aggcu 25

<210> 683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 683

cgccagcacc cgcuccucgu gucac 25

<210> 684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 684

ccuccuuccu ccgcaggaca aaaca 25

<210> 685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 685

uuccuccgca ggacaaaaca aggag 25

<210> 686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 686

ccaccuguuc ccaacccaga cuaug 25

<210> 687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 687

ucccaaccca gacuaugagg uaacg 25

<210> 688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 688

cccaacccag acuuaugaggu aacgu 25

<210> 689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 689

acuaugaggu aacgugggau agaaa 25

<210> 690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 690

cuaugaggua acgugggaua gaaau 25

<210> 691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 691

uuguuuuguc cugcggagga aggag 25

<210> 692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 692

cuuguuuugu ccugcgggagg aagga 25

<210> 693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 693

ccuuguuuug uccugcggag gaagg 25

<210> 694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 694

ucuccuuguu uuguccugcg gagga 25

<210> 695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 695

ggccucuccu uguuuugucc ugcgg 25

<210> 696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 696

gguggccucu ccuuguuuug uccug 25

<210> 697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 697

cauagucugg guugggaaca ggugg 25

<210> 698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 698

ccucauaguc uggguuggga acagg 25

<210> 699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 699

uuaccucaua gucuggguug ggaac 25

<210> 700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 700

cccacguuac cucauagucu ggguu 25

<210> 701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 701

ucccacguua ccucauaguc ugggu 25

<210> 702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 702

ucuauccac guuaccucau agucu 25

<210> 703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 703

uucuauccca cguuaccuca uaguc 25

<210> 704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 704

cucucuauuu cacccccagc ccauc 25

<210> 705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 705

uauuucaccc cggcccauc cggaa 25

<210> 706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 706

cccggccc auccggaaag gccag 25

<210> 707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 707

ccccagccca uccggaaagg ccagc 25

<210> 708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 708

ggaaaggcca gcgggaccug uauuc 25

<210> 709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 709

ugaaucatag acgcaucuga cccuc 25

<210> 710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 710

cccuggag aacacugccu cccgc 25

<210> 711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 711

ggagaacacu gccucccgcu ggccc 25

<210> 712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 712

agucccccug cgacucccug uuucc 25

<210> 713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 713

gucccccugc gacucccugu uuccu 25

<210> 714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 714

gacucccugu uuccugggcu agucu 25

<210> 715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 715

gagagagaau cguuccucag ccuca 25

<210> 716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 716

gcucccuccu cccugccuuc ucugc 25

<210> 717

<211> 25

<212> RNA

<213> Homo sapiens

<400> 717

ucaucaguag ucacacccuc acagc 25

<210> 718

<211> 25

<212> RNA

<213> Homo sapiens

<400> 718

cucacagcug gccugcccuc uugcc 25

<210> 719

<211> 25

<212> RNA

<213> Homo sapiens

<400> 719

uuugugcuau ucacucccuu cccuu 25

<210> 720

<211> 25

<212> RNA

<213> Homo sapiens

<400> 720

cgccgucccc uuuugcagcc cucuc 25

<210> 721

<211> 25

<212> RNA

<213> Homo sapiens

<400> 721

gccgcccccu uuugcagccc ucucu 25

<210> 722

<211> 25

<212> RNA

<213> Homo sapiens

<400> 722

ccgcccccuu uugcagcccu cucug 25

<210> 723

<211> 25

<212> RNA

<213> Homo sapiens

<400> 723

ccccuuuugc agcccucucu gggga 25

<210> 724

<211> 25

<212> RNA

<213> Homo sapiens

<400> 724

uuugcagccc ucucugggga uggac 25

<210> 725

<211> 25

<212> RNA

<213> Homo sapiens

<400> 725

uugcagcccu cucuggggau ggacu 25

<210> 726

<211> 25

<212> RNA

<213> Homo sapiens

<400> 726

ggauggacug gguaaauguu gacag 25

<210> 727

<211> 25

<212> RNA

<213> Homo sapiens

<400> 727

gaggcccuc cccguucaca gaucc 25

<210> 728

<211> 25

<212> RNA

<213> Homo sapiens

<400> 728

acucccucca cccccccucc acugu 25

<210> 729

<211> 25

<212> RNA

<213> Homo sapiens

<400> 729

ccaccccccc uccacuguag gccac 25

<210> 730

<211> 25

<212> RNA

<213> Homo sapiens

<400> 730

ccccccucca cuguaggcca cugga 25

<210> 731

<211> 25

<212> RNA

<213> Homo sapiens

<400> 731

gagagagaaa aaaauaaacu guauu 25

<210> 732

<211> 25

<212> RNA

<213> Homo sapiens

<400> 732

augggcuggg ggugaaauag agagg 25

<210> 733

<211> 25

<212> RNA

<213> Homo sapiens

<400> 733

gaugggcugg gggugaaaua gagag 25

<210> 734

<211> 25

<212> RNA

<213> Homo sapiens

<400> 734

ggaugggcug ggggugaaau agaga 25

<210> 735

<211> 25

<212> RNA

<213> Homo sapiens

<400> 735

cggaugggcu gggggugaaa uagag 25

<210> 736

<211> 25

<212> RNA

<213> Homo sapiens

<400> 736

ccgcuggccu uuccggaugg gcugg 25

<210> 737

<211> 25

<212> RNA

<213> Homo sapiens

<400> 737

cccgcuggcc uuuccggaug ggcug 25

<210> 738

<211> 25

<212> RNA

<213> Homo sapiens

<400> 738

ucccgcuggc cuuuccggau gggcu 25

<210> 739

<211> 25

<212> RNA

<213> Homo sapiens

<400> 739

guccicgcugg ccuuuccggga ugggc 25

<210> 740

<211> 25

<212> RNA

<213> Homo sapiens

<400> 740

acaggucccg cuggccuuuc cggau 25

<210> 741

<211> 25

<212> RNA

<213> Homo sapiens

<400> 741

uacagguccc gcuggccuuu ccgga 25

<210> 742

<211> 25

<212> RNA

<213> Homo sapiens

<400> 742

agaauacagg ucccgcuggc cuuuc 25

<210> 743

<211> 25

<212> RNA

<213> Homo sapiens

<400> 743

auucaggcca gaauacaggu cccgc 25

<210> 744

<211> 25

<212> RNA

<213> Homo sapiens

<400> 744

gcgucucuga uucaggccag aauac 25

<210> 745

<211> 25

<212> RNA

<213> Homo sapiens

<400> 745

agagggucag augcgucucu gauuc 25

<210> 746

<211> 25

<212> RNA

<213> Homo sapiens

<400> 746

ccagcgggag gcaguguucu ccaga 25

<210> 747

<211> 25

<212> RNA

<213> Homo sapiens

<400> 747

gccagcggga ggcaguguuc uccag 25

<210> 748

<211> 25

<212> RNA

<213> Homo sapiens

<400> 748

uggagaggag accugggcca gcggg 25

<210> 749

<211> 25

<212> RNA

<213> Homo sapiens

<400> 749

gacuggagag gagaccuggg ccagc 25

<210> 750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 750

ggacuggaga ggagaccugg gccag 25

<210> 751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 751

cgcaggggga cuggagagga gaccu 25

<210> 752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 752

ucgcagggggg acuggagagg agacc 25

<210> 753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 753

acagggaguc gcagggggac uggag 25

<210> 754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 754

aggaaacagg gagucgcagg gggac 25

<210> 755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 755

agccggaa acagggaguc gcagg 25

<210> 756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 756

uagccgga aacaggggagu cgcag 25

<210> 757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 757

cuagcccagg aaacagggag ucgca 25

<210> 758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 758

acuagcccag gaaacaggga gucgc 25

<210> 759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 759

ggguccaaga cuagcccagg aaaca 25

<210> 760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 760

gggguccaag acuagcccag gaaac 25

<210> 761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 761

cucucguggg guccaagacu agcc 25

<210> 762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 762

ggcugaggaa cgauucucuc ucgug 25

<210> 763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 763

aggcugga acgauucucu cucgu 25

<210> 764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 764

gaggcugagg aacgauucuc ucucg 25

<210> 765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 765

ucccgcggag uucaccauga ggcug 25

<210> 766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 766

ccgaccuccc gcggaguuca ccaug 25

<210> 767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 767

gaggaagcag caauauuuua ggacu 25

<210> 768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 768

aggaagca gcaauauuuu aggac 25

<210> 769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 769

aaggaagagg aagcagcaau auuuu 25

<210> 770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 770

acuacugaug augcuucaaa ggaag 25

<210> 771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 771

ggugugacua cugaugaugc uucaa 25

<210> 772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 772

uggcaagagg gcaggccagc uguga 25

<210> 773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 773

cuggcaagg ggcaggccag cugug 25

<210> 774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 774

caaauaaaua uccggcaag aggc 25

<210> 775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 775

agcacaaaua aauauccugg caaga 25

<210> 776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 776

uagcacaaau aaauauccug gcaag 25

<210> 777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 777

gagugaauag cacaaauaaa uaucc 25

<210> 778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 778

acggagaagu uacauccaaa gggaa 25

<210> 779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 779

aacggagaag uuacauccaa aggga 25

<210> 780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 780

acugaacgga gaaguuacau ccaaa 25

<210> 781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 781

aacugaacgg agaaguuaca uccaa 25

<210> 782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 782

caugcaagaa aaggagggaa cugaa 25

<210> 783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 783

ggacaacuua caugcaagaa aagga 25

<210> 784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 784

gggacaacuu acaugcaaga aaagg 25

<210> 785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 785

ugggggacaa cuuacaugca agaaa 25

<210> 786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 786

aaguagaugg aauacuuugg gaugg 25

<210> 787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 787

aaaguagaug gaauacuuug ggaug 25

<210> 788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 788

aaaaguagau ggaauacuuu gggau 25

<210> 789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 789

gaaaaguaga uggaauacuu uggga 25

<210> 790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 790

gauagaaaag uagauggaau acuuu 25

<210> 791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 791

cgauagaaaa guagauggaa uacuu 25

<210> 792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 792

aaggggacgg cgauagaaaa guaga 25

<210> 793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 793

ccccagagag ggcugcaaaa gggga 25

<210> 794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 794

ccauccccag agaggggcugc aaaag 25

<210> 795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 795

uccaucccca gagaggggcug caaaa 25

<210> 796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 796

guccaucccc agagaggggcu gcaaa 25

<210> 797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 797

cauuuaccca guccaucccc agaga 25

<210> 798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 798

acauuuaccc aguccauccc cagag 25

<210> 799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 799

agggccagga ucugugaacg gggca 25

<210> 800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 800

caggggccagg aucugugaac ggggc 25

<210> 801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 801

ggcucagggc caggaucugu gaacg 25

<210> 802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 802

uggcucaggg ccaggaucug ugaac 25

<210> 803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 803

cuggcucagg gccaggaucu gugaa 25

<210> 804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 804

aggagcacag ggcuggcuca gggcc 25

<210> 805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 805

gagggaggag cacagggcug gcuca 25

<210> 806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 806

ggaggggga ggacagggcu ggcuc 25

<210> 807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 807

guuggggagggaggagcac agggc 25

<210> 808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 808

gaguguuggg ggagggagga gcaca 25

<210> 809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 809

ggaguguugg gggagggagg agcac 25

<210> 810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 810

guuggaggg aguguugggg gaggg 25

<210> 811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 811

gggguuggua gggaguguug gggga 25

<210> 812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 812

ggggguuggu agggaguguu ggggg 25

<210> 813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 813

uuaggggguu gguagggagu guugg 25

<210> 814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 814

auuagggggu ugguagggag uguug 25

<210> 815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 815

gauuaggggg uugguaggga guguu 25

<210> 816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 816

ggauuagggg guugguagggg agugu 25

<210> 817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 817

ggaguagggg auuagggggu uggua 25

<210> 818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 818

gggaguagggg gauuaggggg uuggu 25

<210> 819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 819

uggagggagu aggggauuag ggggu 25

<210> 820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 820

gggguggagg gaguagggga uuagg 25

<210> 821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 821

gggggggag ggaguagggg auuag 25

<210> 822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 822

ggggggggga gggaguagggg gauua 25

<210> 823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 823

ggggggggg agggaguagg ggauu 25

<210> 824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 824

aguggagggg ggguggaggg aguag 25

<210> 825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 825

cagguggaggg ggggugggagg gagua 25

<210> 826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 826

acaguggagg ggggguggag ggagu 25

<210> 827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 827

uggccuacag uggagggggg gugga 25

<210> 828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 828

guggccuaca guggaggggg ggugg 25

<210> 829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 829

ccaguggccu acagguggagg ggggg 25

<210> 830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 830

cauccagugg ccuacagugg agggg 25

<210> 831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 831

ccauccagug gccuacagug gaggg 25

<210> 832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 832

accauccagu ggccuacagu ggagg 25

<210> 833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 833

gaccauccag uggccuacag uggag 25

<210> 834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 834

ugaccaucca guggccuaca gugga 25

<210> 835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 835

augaccaucc aguggccuac agugg 25

<210> 836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 836

caaaugacca uccaguggcc uacag 25

<210> 837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 837

uacggagaug caaaugacca uccag 25

<210> 838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 838

ucagcugagg agcagagcac auuua 25

<210> 839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 839

aguuuauuuu uuucucucuc agcug 25

<210> 840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 840

aggcuggcug gcuggcuggc ugcua 25

<210> 841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 841

ggcuggcugg cuggcuggcu gcuaa 25

<210> 842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 842

gcuaagggcu gcuccacgcu uuugc 25

<210> 843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 843

aagggcugcu ccacgcuuuu gccgg 25

<210> 844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 844

uuuugccgga ggacagagac ugaca 25

<210> 845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 845

cggaggacag agacugacau ggaac 25

<210> 846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 846

ggaggacaga gacugacaug gaaca 25

<210> 847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 847

gaggacagag acugacaugg aacag 25

<210> 848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 848

acagagacug acauggaaca gggga 25

<210> 849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 849

cagagacuga cuggaacag gggaa 25

<210> 850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 850

acugacaugg aacaggggaa gggcc 25

<210> 851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 851

gggaagggcc uggcuguccu caucc 25

<210> 852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 852

ucauccuggc uaucauucuu cuuca 25

<210> 853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 853

cuggcuauca uucuucuuca aggua 25

<210> 854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 854

uggcuaucaau ucuucuucaa gguaa 25

<210> 855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 855

uucuucuuca agguaagggc cuacu 25

<210> 856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 856

ucuucuucaa gguaagggcc uacua 25

<210> 857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 857

cuucuucaag guaagggccu acuag 25

<210> 858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 858

ucaagguaag ggccuacuag ggguc 25

<210> 859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 859

ucacuggcuc cacccaucac uguug 25

<210> 860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 860

aucacuggcu ccacccauca cuguu 25

<210> 861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 861

gaucacuggc uccacccauc acugu 25

<210> 862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 862

gucggucgga cacgucgucg aucac 25

<210> 863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 863

cagucucugu ccuccggcaa aagcg 25

<210> 864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 864

cuguuccaug ucagucucug ucuc 25

<210> 865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 865

augauagcc aggaugagga cagcc 25

<210> 866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 866

uugaagaaga augauagcca ggaug 25

<210> 867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 867

cuuaccuuga agaagaauga uagcc 25

<210> 868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 868

cucucuucug ucuuuacagg uacuu 25

<210> 869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 869

cagguacuuu ggcccaguca aucaa 25

<210> 870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 870

uacuuuggcc cagucaauca aaggu 25

<210> 871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 871

cccagucaau caaagguagg agaaa 25

<210> 872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 872

ccauuucucc uaccuuugau ugacu 25

<210> 873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 873

gccauuucuc cuaccuuuga uugac 25

<210> 874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 874

gcuuuucuca uuucaggaaa ccacu 25

<210> 875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 875

cucauuucag gaaaccacuu gguua 25

<210> 876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 876

uuaaggugua ugacuaucaa gaaga 25

<210> 877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 877

guguaugacu aucaagaaga ugguu 25

<210> 878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 878

ugaugcagaa gccaaaaaua ucaca 25

<210> 879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 879

ccaaaaauau cacaugguuu aaaga 25

<210> 880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 880

caaaaauauuc acaugguuua aagau 25

<210> 881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 881

caugguuuaa agaugggaag augau 25

<210> 882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 882

cuuccuaacu gaagauaaaa aaaaa 25

<210> 883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 883

acugaagaua aaaaaaaaug gaauc 25

<210> 884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 884

cugaagauaa aaaaaaaugg aaucu 25

<210> 885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 885

aaauggaauc ugggaaguaa ugcca 25

<210> 886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 886

ugggaaguaa ugccaaggac ccucg 25

<210> 887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 887

gggaaguaau gccaaggacc cucga 25

<210> 888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 888

acccucgagg gauguaucag uguaa 25

<210> 889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 889

uauuacagaa guauguaauc cccuu 25

<210> 890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 890

ugguuuccug aaaugagaaa agccg 25

<210> 891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 891

uugauaguca uacaccuuaa ccaag 25

<210> 892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 892

ccaucuuuaa accaugugau auuuu 25

<210> 893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 893

auuccauuuu uuuuuaucuu caguu 25

<210> 894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 894

cacugauaca ucccucgagg guccu 25

<210> 895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 895

uccuuuacac ugauacaucc cucga 25

<210> 896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 896

auccuuuaca cugauacauc ccucg 25

<210> 897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 897

acauacuucu guaauacacu uggag 25

<210> 898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 898

ggauuacaua cuucuguaau acacu 25

<210> 899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 899

uugaacuaaa ugcagccacc auauc 25

<210> 900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 900

ucgucagcau uuucguccuu gcugu 25

<210> 901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 901

cgucagcauu uucguccuug cuguu 25

<210> 902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 902

gucagcauuu ucguccuugc uguug 25

<210> 903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 903

uugcuguugg ggucuacuuc auugc 25

<210> 904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 904

guuggggucu acuucauugc uggac 25

<210> 905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 905

gggucuacuu cauugcugga cagga 25

<210> 906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 906

gacaggaugg aguucgccag ucgag 25

<210> 907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 907

gcaguucuga cacacuguag ggaaa 25

<210> 908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 908

uucaugcag uucugacaca cugua 25

<210> 909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 909

guucaugca guucugacac acugu 25

<210> 910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 910

ucagcaaaga gaaagccaga uaugg 25

<210> 911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 911

auuucagcaa agagaaagcc agaua 25

<210> 912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 912

agcaaugaag uagaccccaa cagca 25

<210> 913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 913

uaagagcauu cuuuuaccuc ucgac 25

<210> 914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 914

cuguugccca augaccagcu cuacc 25

<210> 915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 915

gccaaugac cagcucuacc aggua 25

<210> 916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 916

cccaaugacc agcucuacca gguaa 25

<210> 917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 917

ccaaugacca gcucuaccag guaag 25

<210> 918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 918

cccuuaccug guagagcugg ucauu 25

<210> 919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 919

ccccuuaccu gguagagcug gucau 25

<210> 920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 920

ucuucauccc cuuaccuggu agagc 25

<210> 921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 921

cucuuuuauu cuucaucccc uuacc 25

<210> 922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 922

cugugcuguc cuuuccagcc ccuca 25

<210> 923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 923

aagaugacca guacagccac cuuca 25

<210> 924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 924

cagccaccuu caaggaaacc aguug 25

<210> 925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 925

cccaccuucaa ggaaaccagu ugagg 25

<210> 926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 926

aaccaguuga ggaggaauug aacuc 25

<210> 927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 927

aggaauugaa cucaggacuc agagu 25

<210> 928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 928

aauugaacuc aggacucaga guagg 25

<210> 929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 929

auugaacuca ggacucagag uaggu 25

<210> 930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 930

cuucucgauc cuugaggggc uggaa 25

<210> 931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 931

gucaucuucu cgauccuuga ggggc 25

<210> 932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 932

acuggucauc uucucgaucc uugag 25

<210> 933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 933

uacuggucau cuucucgauc cuuga 25

<210> 934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 934

guacugguca ucuucucgau ccuug 25

<210> 935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 935

cugguuuccu ugaagguggc uguac 25

<210> 936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 936

ccuccucaac ugguuuccuu gaagg 25

<210> 937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 937

auuccuccuc aacugguuuc cuuga 25

<210> 938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 938

guccugaguu caauuccucc ucaac 25

<210> 939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 939

auugcaauuu uucuuuuuuc agucc 25

<210> 940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 940

uucccagaau caaagcaaug cauuu 25

<210> 941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 941

acuuucagcc cuaaaucuag acuca 25

<210> 942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 942

acucaagguu cccagagaug acaaa 25

<210> 943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 943

cccagagaug acaaauggag aagaa 25

<210> 944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 944

agaagaaagg ccaucagagc aaauu 25

<210> 945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 945

gaagaaaggc caucagagca aauuu 25

<210> 946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 946

aagaaaggcc aucagagcaa auuug 25

<210> 947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 947

agaaaggcca ucagagcaaa uuugg 25

<210> 948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 948

acuguguuuc agaagcgcca ccuau 25

<210> 949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 949

cuguguuuca gaagcgccac cuauu 25

<210> 950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 950

uguguuucag aagcgccacc uauug 25

<210> 951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 951

aaaaugaaaa gaucaaauaa ccccc 25

<210> 952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 952

gggaacugaa uaggaggaga acacc 25

<210> 953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 953

gcuuugauuc ugggaacuga auagg 25

<210> 954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 954

auugcuuuga uucugggaac ugaau 25

<210> 955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 955

uuccaaaaug cauugcuuug auucu 25

<210> 956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 956

uuuccaaaau gcauugcuuu gauuc 25

<210> 957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 957

auuuagggcu gaaagucucu cugcu 25

<210> 958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 958

ucugggaacc uugagucuag auuua 25

<210> 959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 959

cucugggaac cuugagucua gauuu 25

<210> 960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 960

ccuuucuucu ccauuuguca ucucu 25

<210> 961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 961

gccuuucuuc uccauuuguc aucuc 25

<210> 962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 962

ugagaaaccc ccaaauuugc ucuga 25

<210> 963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 963

uucuuuuaca auuuucccca auagg 25

<210> 964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 964

uuuuucuuuu acaauuuucc ccaau 25

<210> 965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 965

acaaaaaauu auauucaaau ccagg 25

<210> 966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 966

cacaaaaaau uauauucaaa uccag 25

<210> 967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 967

acacaaaaaa uuauauucaa aucca 25

<210> 968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 968

aacacaaaaa auuauauuca aaucc 25

<210> 969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 969

ccagagaagc caaucagugu cgucg 25

<210> 970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 970

uguucuaaag cccgcacgca cccac 25

<210> 971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 971

guucuaaagc ccgcacgcac ccacc 25

<210> 972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 972

ggacucagau ucuccccaga cgccg 25

<210> 973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 973

ucagauucuc cccagacgcc gagga 25

<210> 974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 974

ccccagacgc cgaggauggc cguca 25

<210> 975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 975

ccccgaaccc uccuccugcu acucu 25

<210> 976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 976

cccgaacccu ccuccucua cucuc 25

<210> 977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 977

ccgaacccuc cuccugcuac ucucg 25

<210> 978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 978

cgaacccucc uccugcuacu cucgg 25

<210> 979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 979

cuccuccuc uacucucgggg ggccc 25

<210> 980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 980

gggggcccug gcccugaccc agacc 25

<210> 981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 981

ggggccgggg cccuaccca gaccu 25

<210> 982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 982

gcccggccc ugaccagac cuggg 25

<210> 983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 983

cccuggcccu gacccagacc ugggc 25

<210> 984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 984

ugacccagac cugggcgggu gagug 25

<210> 985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 985

gacccagacc ugggcgggg agugc 25

<210> 986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 986

acccagaccu gggcggguga gugcg 25

<210> 987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 987

agaccugggc gggugagugc ggggu 25

<210> 988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 988

gaccugggcg ggugagugcg ggguc 25

<210> 989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 989

cugggcgggu gagugcgggg ucggg 25

<210> 990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 990

ugggcgggg agugcgggggu cggga 25

<210> 991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 991

cuucucugga aacccgacac ccaau 25

<210> 992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 992

gcuucucugg aaacccgaca cccaa 25

<210> 993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 993

ccgcgacgac acugauuggc uucuc 25

<210> 994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 994

gaacagcgac cgcgacgaca cugau 25

<210> 995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 995

aaucuguguc ccggugggug cgugc 25

<210> 996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 996

gaauucugagu cccggugggu gcgug 25

<210> 997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 997

gucuggggag aaucugaguc ccggu 25

<210> 998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 998

cgucugggga gaaucugagu cccgg 25

<210> 999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 999

cggcgucugg ggagaaucug agucc 25

<210> 1000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1000

ccaugacggc cauccucggc gucug 25

<210> 1001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1001

gccaugacgg ccauccucgg cgucu 25

<210> 1002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1002

cgccaugacg gccauccucg gcguc 25

<210> 1003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1003

uucggggcgc caugacggcc auccu 25

<210> 1004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1004

aggaggaggg uucggggcgc cauga 25

<210> 1005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1005

ccgagaguag caggaggagg guucg 25

<210> 1006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1006

cccgagagua gcaggaggag gguuc 25

<210> 1007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1007

ccccgagagu agcaggagga ggguu 25

<210> 1008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1008

agggccccg agaguagcag gagga 25

<210> 1009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1009

cagggcccc gagaguagca ggagg 25

<210> 1010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1010

ggccagggcc cccgagagua gcagg 25

<210> 1011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1011

cagggccagg gcccccgaga guagc 25

<210> 1012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1012

cccgcccagg ucgggucag ggcca 25

<210> 1013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1013

acccgcccag gucuggguca gggcc 25

<210> 1014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1014

cacucacccg cccaggucug gguca 25

<210> 1015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1015

gcacucaccc gcccaggucu ggguc 25

<210> 1016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1016

accccgcacu cacccgccca ggucu 25

<210> 1017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1017

gaccccgcac ucacccgcc agguc 25

<210> 1018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1018

cucccgaccc cgcacucacc cgccc 25

<210> 1019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1019

cucgccccca ggcucccacu ccaug 25

<210> 1020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1020

gagguauuuc uucacauccg ugucc 25

<210> 1021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1021

auuucuucac auccgugucc cggcc 25

<210> 1022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1022

ucacauccgu gucccggccc ggccg 25

<210> 1023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1023

cacauccgug ucccggccg gccgc 25

<210> 1024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1024

acauccgugu ccggcccgg ccgcg 25

<210> 1025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1025

cgcggggagc cccgcuucau cgccg 25

<210> 1026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1026

gcggggagcc ccgcuucauc gccgu 25

<210> 1027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1027

ccccgcuuca ucgccguggg cuacg 25

<210> 1028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1028

cuacguggac gacacgcagu ucgug 25

<210> 1029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1029

guucgacagc gacgccgcga gccag 25

<210> 1030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1030

gacagcgacg ccgcgagcca gagga 25

<210> 1031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1031

cgccgcgagc cagaggaugg agccg 25

<210> 1032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1032

gccgcgagcc agaggaugga gccgc 25

<210> 1033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1033

ccagaggaug gagccgcggg cgccg 25

<210> 1034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1034

gagccgcggg cgccguggau agagc 25

<210> 1035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1035

ccgcgggcgc cguggauaga gcagg 25

<210> 1036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1036

cgcgggcgcc guggauagag cagga 25

<210> 1037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1037

gcgggcgccg uggauagagc aggag 25

<210> 1038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1038

gcgccgugga uagagcagga ggggc 25

<210> 1039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1039

gauagagcag gaggggccgg aguau 25

<210> 1040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1040

auagagcagg aggggccgga guauu 25

<210> 1041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1041

caggaggggc cggaguauug ggacc 25

<210> 1042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1042

gccggaguau ugggaccagg agaca 25

<210> 1043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1043

ugggaccagg agacacggaa uguga 25

<210> 1044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1044

aaggcccagu cacagacuga ccgag 25

<210> 1045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1045

cagucacaga cugaccgagu ggacc 25

<210> 1046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1046

agucacagac ugaccgagug gaccu 25

<210> 1047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1047

gucacagacu gaccgagugg accug 25

<210> 1048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1048

accgagga ccggggacc cugcg 25

<210> 1049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1049

cugcgcggcu acuacacca gagcg 25

<210> 1050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1050

gcggcuacua caaccagagc gaggc 25

<210> 1051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1051

ccagagcgag gccggugagu gaccc 25

<210> 1052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1052

agcgaggccg gugagugacc ccggc 25

<210> 1053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1053

gcgaggccgg ugagugaccc cggcc 25

<210> 1054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1054

cgaggccggu gagugacccc ggccg 25

<210> 1055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1055

gaggccggug agugaccccg gccgg 25

<210> 1056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1056

ggagggggag ccuggggggcg agcag 25

<210> 1057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1057

aauaccucau ggagugggag ccugg 25

<210> 1058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1058

aaauaccuca uggaguggga gccug 25

<210> 1059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1059

gaaauaccuc aggaguggg agccu 25

<210> 1060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1060

agaaauaccu cauggagugg gagcc 25

<210> 1061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1061

gaugugaaga aauaccucau ggagu 25

<210> 1062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1062

ggaugugaag aaauaccuca uggag 25

<210> 1063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1063

gacacggaug ugaagaaaua ccuca 25

<210> 1064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1064

ggcuccccgc ggccggggccgggaca 25

<210> 1065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1065

aagcggggcu ccccgcggcc gggcc 25

<210> 1066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1066

gaagcggggc uccccgcggc cgggc 25

<210> 1067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1067

cgaugaagcg gggcuccccg cggcc 25

<210> 1068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1068

gcgaugaagc ggggcucccc gcggc 25

<210> 1069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1069

cacggcgaug aagcggggcu ccccg 25

<210> 1070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1070

ccacguagcc cacggcgaug aagcg 25

<210> 1071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1071

uccacguagc ccacggcgau gaagc 25

<210> 1072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1072

guccacguag cccacggcga ugaag 25

<210> 1073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1073

aacugcgugu cguccacgua gccca 25

<210> 1074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1074

gcccgcggcu ccauccucug gcucg 25

<210> 1075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1075

ccacggcgcc cgcggcucca uccuc 25

<210> 1076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1076

ccuccugcuc uauccacggc gcccg 25

<210> 1077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1077

accuccggccc cuccugcucu aucca 25

<210> 1078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1078

uccgugucuc cuggucccaa uacuc 25

<210> 1079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1079

cugggccuuc acauuccgug ucucc 25

<210> 1080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1080

agguccacuc ggucagucug ugacu 25

<210> 1081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1081

cagguccacu cggucagucu gugac 25

<210> 1082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1082

gccgcgcagg guccccaggu ccacu 25

<210> 1083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1083

guuguaguag ccgcgcaggg ucccc 25

<210> 1084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1084

ucgcucuggu uguaguagcc gcgca 25

<210> 1085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1085

cucgcucugg uuguaguagc cgcgc 25

<210> 1086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1086

ccggggucac ucaccggccu cgcuc 25

<210> 1087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1087

ugcgccccg gccggggguca cucac 25

<210> 1088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1088

guucucacac cauccagaua augua 25

<210> 1089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1089

aucgauaa uguauggcug cgacg 25

<210> 1090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1090

uccagauaau guauggcugc gacgu 25

<210> 1091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1091

ccagauaaug uauggcugcg acgug 25

<210> 1092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1092

auaauguaug gcugcgacgu ggggu 25

<210> 1093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1093

uguauggcug cgacgugggg ucgga 25

<210> 1094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1094

guauggcugc gacguggggu cggac 25

<210> 1095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1095

uggggucgga cgggcgcuuc cuccg 25

<210> 1096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1096

ggggucggac ggggcgcuucc uccgc 25

<210> 1097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1097

ggacgggcgc uuccuccgcg gguac 25

<210> 1098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1098

gggcgcuucc uccgcgggua ccggc 25

<210> 1099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1099

gcggguaccg gcaggacgcc uacga 25

<210> 1100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1100

uaccggcagg acgccuacga cggca 25

<210> 1101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1101

ggcaaggauu acaucgcccu gaacg 25

<210> 1102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1102

cgcccugaac gaggaccugc gcucu 25

<210> 1103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1103

aacgaggacc ugcgcucuug gaccg 25

<210> 1104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1104

gaggaccugc gcucuuggac cgcgg 25

<210> 1105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1105

cugcgcucuu ggaccgcggc ggaca 25

<210> 1106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1106

cgcucuugga ccgcggcgga caugg 25

<210> 1107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1107

ggcggcucag aucaccaagc gcaag 25

<210> 1108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1108

gcggcucaga ucaccaagcg caagu 25

<210> 1109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1109

gcucagauca ccaagcgcaa guggg 25

<210> 1110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1110

cagaucacca agcgcaagug ggagg 25

<210> 1111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1111

aagcgcaagu gggaggcggc ccaug 25

<210> 1112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1112

cgcaagggg aggcggccca ugagg 25

<210> 1113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1113

gaggcggagc aguugagagc cuacc 25

<210> 1114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1114

cggagcaguu gagagccuac cugga 25

<210> 1115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1115

agagccuacc uggauggcac gugcg 25

<210> 1116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1116

cuaccuggau ggcacgugcg uggag 25

<210> 1117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1117

ugcguggagu ggcuccgcag auacc 25

<210> 1118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1118

aguggcuccg cagauaccug gagaa 25

<210> 1119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1119

guggcuccgc agauaccugg agaac 25

<210> 1120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1120

cuccgcagau accuggagaa cggga 25

<210> 1121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1121

aacgggaagg agacgcugca gcgca 25

<210> 1122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1122

acgggaagga gacgcugcag cgcac 25

<210> 1123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1123

ggagacgcug cagcgcacgg guacc 25

<210> 1124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1124

gagacgcugc agcgcacggg uacca 25

<210> 1125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1125

agacgcugca gcgcacgggu accag 25

<210> 1126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1126

ugcagcgcac ggguaccagg ggcca 25

<210> 1127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1127

gcagcgcacg gguaccaggg gccac 25

<210> 1128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1128

cagcgcacgg guaccagggg ccacg 25

<210> 1129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1129

gugugagaac cuggccccga ccccg 25

<210> 1130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1130

acauuaucug gaugguguga gaacc 25

<210> 1131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1131

acgucgcagc cauacauuau cugga 25

<210> 1132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1132

ccccacgucg cagccauaca uuauc 25

<210> 1133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1133

guaggcgucc ugccgguacc cgcgg 25

<210> 1134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1134

gucguaggcg uccugccggu acccg 25

<210> 1135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1135

auccuugccg ucguaggcgu ccugc 25

<210> 1136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1136

agggcgaugu aauccuugcc gucgu 25

<210> 1137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1137

guccaagagc gcagguccuc guuca 25

<210> 1138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1138

gguccaagag cgcagguccu cguuc 25

<210> 1139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1139

cauguccgcc gcgguccaag agcgc 25

<210> 1140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1140

gugaucugag ccgccauguc cgccg 25

<210> 1141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1141

ucaugggccg ccucccacuu gcgcu 25

<210> 1142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1142

uaggcucuca acugcuccgc cucau 25

<210> 1143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1143

guaggcucuc aacugcuccg ccuca 25

<210> 1144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1144

cacuccacgc acgugccauc caggu 25

<210> 1145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1145

gagccacucc acgcacgugc caucc 25

<210> 1146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1146

cuccuuccg uucuccaggu aucug 25

<210> 1147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1147

cugcagcguc uccuucccgu ucucc 25

<210> 1148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1148

acccaccacc ccaucucuga ccaug 25

<210> 1149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1149

caucucugac caugaggcca cccug 25

<210> 1150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1150

ugaccaugag gccaccuga ggugc 25

<210> 1151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1151

gaccaugagg ccacccuag gugcu 25

<210> 1152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1152

gaggccaccc ugaggugcug ggccc 25

<210> 1153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1153

aggccacccu gaggugcugg gcccu 25

<210> 1154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1154

ugcgggccc ugggcuucua cccug 25

<210> 1155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1155

cuacccugcg gagaucacac ugacc 25

<210> 1156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1156

ugcggagauc acacugaccu ggcag 25

<210> 1157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1157

gcggagauca cacugaccug gcagc 25

<210> 1158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1158

agaucacacu gaccuggcag cggga 25

<210> 1159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1159

gaucacacug accuggcagc gggau 25

<210> 1160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1160

aucacacuga ccuggcagcg ggaug 25

<210> 1161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1161

acacugaccu ggcagcggga ugggg 25

<210> 1162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1162

cagcgggaug gggaggacca gaccc 25

<210> 1163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1163

gauggggagg accagaccca ggaca 25

<210> 1164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1164

gaccagaccc aggacacgga gcucg 25

<210> 1165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1165

ccaggacacg gagcucgugg agacc 25

<210> 1166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1166

cggagcucgu ggagaccagg ccugc 25

<210> 1167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1167

ggagcucgug gagaccaggc cugca 25

<210> 1168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1168

gagcucgugg agaccaggcc ugcag 25

<210> 1169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1169

ucguggagac caggccugca gggga 25

<210> 1170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1170

ugcaggggau ggaaccuucc agaag 25

<210> 1171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1171

gcaggggaug gaaccuucca gaagu 25

<210> 1172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1172

ggggauggaa ccuuccagaa guggg 25

<210> 1173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1173

ggaaccuucc agaagugggc ggcug 25

<210> 1174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1174

accuuccaga agugggcggc ugugg 25

<210> 1175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1175

agugggcggc ugggggug ccuuc 25

<210> 1176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1176

gcggcugugg uggugccuuc uggag 25

<210> 1177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1177

agauacaccu gccaugugca gcaug 25

<210> 1178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1178

gauacaccug ccaugugcag cauga 25

<210> 1179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1179

ucugcccaag ccccucaccc ugaga 25

<210> 1180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1180

cugcccaagc cccucacccu gagau 25

<210> 1181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1181

ugcccaagcc ccucacccug agaug 25

<210> 1182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1182

aagccccuca cccugagaug gggua 25

<210> 1183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1183

ccccucaccc ugagaugggg uaagg 25

<210> 1184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1184

cccucacccu gagauggggu aagga 25

<210> 1185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1185

cccugagaug ggguaaggag ggaga 25

<210> 1186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1186

ccugaugg gguaaggagg gagau 25

<210> 1187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1187

cugagauggg guaaggaggg agaug 25

<210> 1188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1188

ugagaugggg uaaggaggga gaugg 25

<210> 1189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1189

cauauguguc uugggggggu cugac 25

<210> 1190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1190

ucauaugugu cuuggggggg ucuga 25

<210> 1191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1191

guggggguc auaugugugucu ugggg 25

<210> 1192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1192

gggggggu cauauguguc uuggg 25

<210> 1193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1193

ggggggggg ucauaugugu cuugg 25

<210> 1194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1194

gggggggg gucauaugug ucuug 25

<210> 1195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1195

uggggggug ggucauaugu gucuu 25

<210> 1196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1196

agggguggu gggucauaug ugucu 25

<210> 1197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1197

gccucauggu cagagauggg guggu 25

<210> 1198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1198

ggccucaugg ucagagaugg ggugg 25

<210> 1199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1199

gguggccuca uggucagaga ugggg 25

<210> 1200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1200

caggggcc ucauggucag agaug 25

<210> 1201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1201

ucaggguggc cucaugguca gagau 25

<210> 1202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1202

cucagggggg ccucaugguc agaga 25

<210> 1203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1203

ggccgcac cucagggugg ccuca 25

<210> 1204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1204

aagcccaggg cccagcaccu caggg 25

<210> 1205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1205

uagaagccca gggcccagca ccuca 25

<210> 1206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1206

guagaagccc agggcccagc accuc 25

<210> 1207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1207

gugaucuccg caggguagaa gcca 25

<210> 1208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1208

ugugaucucc gcaggguaga agccc 25

<210> 1209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1209

cugccagguc agugugaucu ccgca 25

<210> 1210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1210

gcugccaggu cagugugauc uccgc 25

<210> 1211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1211

gucgguccu ccccaucccg cugcc 25

<210> 1212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1212

cuccacgagc uccguguccu ggguc 25

<210> 1213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1213

cuggucucca cgagcuccgu gucci 25

<210> 1214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1214

ccuggucucc acgagcuccg ugucc 25

<210> 1215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1215

uggaagguuc cauccccuc aggcc 25

<210> 1216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1216

acuucuggaa gguuccaucc ccuc 25

<210> 1217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1217

accccacag ccgcccacuu cugga 25

<210> 1218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1218

aggcaccacc acagccgccc acuuc 25

<210> 1219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1219

agguguaucu cugcuccucu ccaga 25

<210> 1220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1220

ggcagacccu caugcugcac auggc 25

<210> 1221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1221

cuugggcaga cccucaugcu gcaca 25

<210> 1222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1222

uaccccaucu caggggugagg ggcuu 25

<210> 1223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1223

uuaccccauc ucagggugag gggcu 25

<210> 1224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1224

ccuccuuacc ccaucucagg gugag 25

<210> 1225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1225

cccuccuuac cccaucucag gguga 25

<210> 1226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1226

ucccuccuua ccccaucuca gggug 25

<210> 1227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1227

ccaucucccu ccuuacccca ucuca 25

<210> 1228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1228

cccaucuccc uccuuacccc aucuc 25

<210> 1229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1229

ucuucccagc ccaccauccc caucg 25

<210> 1230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1230

cuucccagcc caccaucccc aucgu 25

<210> 1231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1231

ccauccccau cgugggcauc auugc 25

<210> 1232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1232

cccaucgugg gcaucauugc uggcc 25

<210> 1233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1233

gcaucauugc uggccugguu cuccu 25

<210> 1234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1234

ugguucuccu uggagcugug aucac 25

<210> 1235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1235

cuuggagcug ugaucacugg agcug 25

<210> 1236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1236

uggagcugug gucgcugccg ugaug 25

<210> 1237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1237

agcuggguc gcugccguga ugugg 25

<210> 1238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1238

ugggucgcu gccgugaugu ggagg 25

<210> 1239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1239

ccgugaugug gaggaggaag agcuc 25

<210> 1240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1240

ugauguggag gaggaagagc ucagg 25

<210> 1241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1241

ggaggaggaa gagcucaggu ggaga 25

<210> 1242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1242

gaggaggaag agcucaggug gagaa 25

<210> 1243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1243

aggaggaaga gcucaggugg agaag 25

<210> 1244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1244

aagagcucag guggagaagg gguga 25

<210> 1245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1245

agagcucagg uggagaaggg gugaa 25

<210> 1246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1246

gcucaggugg agaaggggug aaggg 25

<210> 1247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1247

cucaggugga gaagggguga agggu 25

<210> 1248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1248

ucagguggag aaggggugaa gggug 25

<210> 1249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1249

gcucugggaa aagaggggaa gguga 25

<210> 1250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1250

agcucuggga aaagaggggga aggug 25

<210> 1251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1251

aagacagcuc ugggaaaaga gggga 25

<210> 1252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1252

ugggaagaca gcucugggaa aagag 25

<210> 1253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1253

cugggaagac agcucuggga aaaga 25

<210> 1254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1254

gcugggaaga cagcucuggg aaaag 25

<210> 1255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1255

gauggggggc ugggaagaca gcucu 25

<210> 1256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1256

ggaugggggg cugggaagac agcuc 25

<210> 1257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1257

augccacga ugggauggu gggcu 25

<210> 1258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1258

gaugcccacg auggggaugg ugggc 25

<210> 1259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1259

caaugaugcc cacgaugggg auggu 25

<210> 1260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1260

gcaaugaugc ccacgauggg gaugg 25

<210> 1261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1261

ccagcaauga ugccacgau gggga 25

<210> 1262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1262

caggccagca augaugccca cgaug 25

<210> 1263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1263

ccaggccagc aaugaugccc acgau 25

<210> 1264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1264

accagggccag caaugaugcc cacga 25

<210> 1265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1265

agugaucaca gcuccaagga gaacc 25

<210> 1266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1266

cacagcucca gugaucacag cucca 25

<210> 1267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1267

ccugagcucu uccuccucca cauca 25

<210> 1268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1268

gacauuuucu ucucacagau agaaa 25

<210> 1269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1269

auuuucuucu cacagauaga aaagg 25

<210> 1270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1270

uuuucuucuc acagauagaa aagga 25

<210> 1271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1271

gauagaaaag gagggaguua cacuc 25

<210> 1272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1272

acacucaggc ugcaaguaag uauga 25

<210> 1273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1273

cucaggcugc aaguaaguau gaagg 25

<210> 1274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1274

ucuaccccag gcagugacag ugccc 25

<210> 1275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1275

cuaccccagg cagugacagu gccca 25

<210> 1276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1276

cugauguguc ccucacagcu uguaa 25

<210> 1277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1277

cucacagcuu guaaagguga gagcu 25

<210> 1278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1278

acagcuugua aaggugagag cuugg 25

<210> 1279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1279

gagccgggg cacugucacu gccug 25

<210> 1280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1280

agagcccugg gcacugucac ugccu 25

<210> 1281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1281

cagagcccug ggcacuguca cugcc 25

<210> 1282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1282

gcugugaggg acacaucaga gcccu 25

<210> 1283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1283

agcugugagg gacacaucag agccc 25

<210> 1284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1284

aagcucucac cuuuacaagc uguga 25

<210> 1285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1285

caagcucuca ccuuuacaag cugug 25

<210> 1286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1286

uauaguguga gacagcugcc uugug 25

<210> 1287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1287

auagugugag acagcugccu ugugu 25

<210> 1288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1288

gacagcugcc uugugggga cugag 25

<210> 1289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1289

aagaacccug acuuuguuuc ugcaa 25

<210> 1290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1290

caccugcaug ugucuguguu cgugu 25

<210> 1291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1291

ucuguguucg uguaggcaua augug 25

<210> 1292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1292

guguucgugu aggcauaaug ugagg 25

<210> 1293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1293

uucguguagg cauaauguga ggagg 25

<210> 1294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1294

ucguguaggc auaaugugag gaggu 25

<210> 1295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1295

cguguaggca uaaugugagg aggug 25

<210> 1296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1296

cccaaucauc uuuccuguuc cagag 25

<210> 1297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1297

aaucaucuuu ccuguuccag agagg 25

<210> 1298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1298

aucaucuuuc cuguuccaga gaggu 25

<210> 1299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1299

ucaucuuucc uguuccagag aggug 25

<210> 1300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1300

uuccuguucc agagaggugg ggcug 25

<210> 1301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1301

ugucuccauc ucugucucaa cuuca 25

<210> 1302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1302

uacuuucuca aauucuugcc augag 25

<210> 1303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1303

caugagaggu ugaugaguua auuaa 25

<210> 1304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1304

ccuaaaauuu gagagacaaa auaaa 25

<210> 1305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1305

aacucuugcc ucucaguccc acaca 25

<210> 1306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1306

uucuucaagu cacaaaggga agggc 25

<210> 1307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1307

aggguucuuc aagucacaaa gggaa 25

<210> 1308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1308

caggguucuu caagucacaa aggga 25

<210> 1309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1309

aagucagggu ucuucaaguc acaaa 25

<210> 1310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1310

aaagucaggg uucuucaagu cacaa 25

<210> 1311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1311

aggugccuuu gcagaaacaa aguca 25

<210> 1312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1312

caggugccuu ugcagaaaca aaguc 25

<210> 1313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1313

ugccuacacg aacacagaca caugc 25

<210> 1314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1314

ggucauggg gacaugggggg ugggg 25

<210> 1315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1315

gagggucaug guggacaugg gggug 25

<210> 1316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1316

agagggucau gguggacaug ggggu 25

<210> 1317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1317

aagaggguca ugguggacau ggggg 25

<210> 1318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1318

gggaagggg ucauggggga caugg 25

<210> 1319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1319

ugggaagagg gucaugggg acaug 25

<210> 1320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1320

gugggaagag ggucauggug gacau 25

<210> 1321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1321

cgugggaaga gggucauggu ggaca 25

<210> 1322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1322

ggucagcgug ggaagagggu caugg 25

<210> 1323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1323

acaggucagc gugggaagag gguca 25

<210> 1324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1324

gggagcacag gucagcgugg gaaga 25

<210> 1325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1325

agggagcaca ggucagcgug ggaag 25

<210> 1326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1326

uuggggaggg agcacagguc agcgu 25

<210> 1327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1327

auuggggagg gagcacaggu cagcg 25

<210> 1328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1328

ggaaagauga uuggggaggg agcac 25

<210> 1329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1329

cuggaacagg aaagaugauu gggga 25

<210> 1330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1330

ucuggaacag gaaagaugau ugggg 25

<210> 1331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1331

cucucuggaa caggaaagau gauug 25

<210> 1332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1332

ccucucugga acaggaaaga ugauu 25

<210> 1333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1333

accucucugg aacaggaaag augau 25

<210> 1334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1334

caccucagcc ccaccucucu ggaac 25

<210> 1335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1335

uggagaccc ucagccccac cucuc 25

<210> 1336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1336

gugcaccaug aaguugagac agaga 25

<210> 1337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1337

acuaagguuc uaauuuuaau aggga 25

<210> 1338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1338

uuauacuaag guucuaauuu uaaua 25

<210> 1339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1339

uuuuaacuaa gguucuaauu uuaau 25

<210> 1340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1340

aauuugagaa aguaaauuua uacua 25

<210> 1341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1341

cuuuaauuaa cucaucaacc ucuca 25

<210> 1342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1342

ccauuuauuu ugucucucaa auuuu 25

<210> 1343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1343

gcacaagaaa cacguggacu cugga 25

<210> 1344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1344

aucagcacaa gaaacacgug gacuc 25

<210> 1345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1345

gcaacaaauc agcacaagaa acacg 25

<210> 1346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1346

cucagcacag cgaacaugca gauuc 25

<210> 1347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1347

gcacagcgaa caugcagauu cugga 25

<210> 1348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1348

aacaugcaga uucuggaagg uucuc 25

<210> 1349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1349

gucuuuauuu gcucucucaa auucc 25

<210> 1350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1350

uuauauucag auucuuauuu ucagu 25

<210> 1351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1351

uauauucaga uucuuauuuu cagua 25

<210> 1352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1352

agugcacgua aaguugagac agaga 25

<210> 1353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1353

auggagacau cgccccac cucuc 25

<210> 1354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1354

accucucugg aacaagaaag augac 25

<210> 1355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1355

ccucucugga acaagaaaga ugacu 25

<210> 1356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1356

cucucuggaa caagaaagau gacug 25

<210> 1357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1357

ucuggaacaa gaaagaugac ugggg 25

<210> 1358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1358

agaaagauga cuggggagga aacac 25

<210> 1359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1359

acuggggagg aaacacaggu cagca 25

<210> 1360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1360

cuggggagga aacacagguc agcau 25

<210> 1361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1361

aggaaacaca ggucagcaug ggaac 25

<210> 1362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1362

ggaaacacag gucagcaugg gaaca 25

<210> 1363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1363

gaaacacagg ucagcauggg aacag 25

<210> 1364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1364

gucagcaugg gaacaggggu cacag 25

<210> 1365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1365

gggaacaggg gucacaggugg acaca 25

<210> 1366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1366

ggaacagggg ucacagugga cacaa 25

<210> 1367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1367

acagggguca cagguggacac aaggg 25

<210> 1368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1368

caggggucac aguggacaca agggu 25

<210> 1369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1369

cuccaccucc ucacauuaug cuaac 25

<210> 1370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1370

uccaccuccu cacauuaugc uaaca 25

<210> 1371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1371

ugcuaacagg gacgcagaca cauuc 25

<210> 1372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1372

gugccuuugc agaaagagau gccag 25

<210> 1373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1373

augccagagg cucuugaagu cacaa 25

<210> 1374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1374

ugccagaggc ucuugaaguc acaaa 25

<210> 1375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1375

gccagaggcu cuugaaguca caaag 25

<210> 1376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1376

agaggcucuu gaagucacaa agggg 25

<210> 1377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1377

cagucccuca caagacagcu gucuc 25

<210> 1378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1378

uggauuaauu aaauaaguca auucc 25

<210> 1379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1379

ucaaauauuu gcuaugagag guuga 25

<210> 1380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1380

uguuuucuca aauauuugcu augag 25

<210> 1381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1381

cuuucuuguu ccagagaggu ggggc 25

<210> 1382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1382

ucaucuuucu uguuccagag aggug 25

<210> 1383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1383

gucaucuuuc uuguuccaga gaggu 25

<210> 1384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1384

agucaucuuu cuuguuccag agagg 25

<210> 1385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1385

cccagucauc uuucuuguuc cagag 25

<210> 1386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1386

ucccuguuag cauaauguga ggagg 25

<210> 1387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1387

gcgucccugu uagcauaaug ugagg 25

<210> 1388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1388

ucugcgccc uguuagcaua augug 25

<210> 1389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1389

gagccucugg caucucuuuc ugcaa 25

<210> 1390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1390

uccccuuugu gacuucaaga gccuc 25

<210> 1391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1391

gcugucuugu gagggacuga gaugc 25

<210> 1392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1392

guagccugag acagcugucu uguga 25

<210> 1393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1393

uguagccuga gacagcuguc uugug 25

<210> 1394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1394

agcugugaga gacacaucag agccc 25

<210> 1395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1395

gcugugagag acacaucaga gcccu 25

<210> 1396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1396

cagagcccug ggcacugucg cugcc 25

<210> 1397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1397

ucgcugccug gaguagaaca aaaac 25

<210> 1398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1398

acagcuugaa aaggugagau ucuug 25

<210> 1399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1399

cacagcuuga aaaggugaga uucuu 25

<210> 1400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1400

ucacagcuug aaaaggugag auucu 25

<210> 1401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1401

cugauguguc ucucacagcu ugaaa 25

<210> 1402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1402

cuacuccagg cagcgacagu gccca 25

<210> 1403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1403

ucuacuccag gcagcgacag ugccc 25

<210> 1404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1404

gaguagcucc cuccuuuucc accug 25

<210> 1405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1405

aguagcuccc uccuuuucca ccugu 25

<210> 1406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1406

cguguaagug gugggggggg gagug 25

<210> 1407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1407

caggcugcgu guaaguggug ggggu 25

<210> 1408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1408

ucaggcugcg uguaaguggu ggggg 25

<210> 1409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1409

cucucaggcu gcguguaagu ggugg 25

<210> 1410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1410

acucucaggc ugcguguaag uggug 25

<210> 1411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1411

uacucucagg cugcguguaa guggu 25

<210> 1412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1412

cuacucucag gcugcgugua agugg 25

<210> 1413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1413

gagcuacucu caggcugcgu guaag 25

<210> 1414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1414

gguggaaaag ggggagcua cucuc 25

<210> 1415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1415

uuuucuuccc acagguggaa aagga 25

<210> 1416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1416

auuuucuucc cacaggugga aaagg 25

<210> 1417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1417

gacauuuucu ucccacaggu ggaaa 25

<210> 1418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1418

ucacaggaca uuuucuuccc acagg 25

<210> 1419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1419

cacagcuccg augaccacaa cugcu 25

<210> 1420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1420

gaugaccaca acugcuagga cagcc 25

<210> 1421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1421

gccaggccag caacaaugcc cacga 25

<210> 1422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1422

ccaggccagc aacaugccc acgau 25

<210> 1423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1423

caggccagca acaaugccca cgaug 25

<210> 1424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1424

ccagcaacaa ugcccacgau gggga 25

<210> 1425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1425

gcaacaugc cccgauggg gacgg 25

<210> 1426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1426

aaugccccg auggggacgg uggac 25

<210> 1427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1427

augccacga uggggacggu ggacu 25

<210> 1428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1428

cgauggggac gguggacugg gaaga 25

<210> 1429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1429

ggacggugga cugggaagac ggcuc 25

<210> 1430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1430

gacgguggac ugggaagacg gcucu 25

<210> 1431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1431

uggacuggga agacggcucu gggaa 25

<210> 1432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1432

acugggaaga cggcucuggg aaagg 25

<210> 1433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1433

cugggaagac ggcucuggga aagga 25

<210> 1434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1434

ugggaagacg gcucugggaa aggag 25

<210> 1435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1435

ggcucuggga aaggaggggga agaug 25

<210> 1436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1436

gcucugggaa aggaggggaa gauga 25

<210> 1437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1437

ucagguaggg aaggggugag gggug 25

<210> 1438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1438

uucagguagg gaagggguga ggggu 25

<210> 1439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1439

guucagguag ggaaggggug agggg 25

<210> 1440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1440

agaguucagg uagggaaggg gugag 25

<210> 1441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1441

aagaguucag guagggaagg gguga 25

<210> 1442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1442

gaagaguuca gguagggaag gggug 25

<210> 1443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1443

aggaggaaga guucagguag ggaag 25

<210> 1444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1444

uaggaggaag aguucaggua gggaa 25

<210> 1445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1445

guaggaggaa gaguucaggu aggga 25

<210> 1446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1446

auguguagga ggaagaguuc aggua 25

<210> 1447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1447

gauguguagg aggaagaguu caggu 25

<210> 1448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1448

cugugaugug uaggaggaag aguuc 25

<210> 1449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1449

ugggucgcu gcugugaugu guagg 25

<210> 1450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1450

agcuggguc gcugcuguga ugugu 25

<210> 1451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1451

cuagcaguug uggucaucgg agcug 25

<210> 1452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1452

uggcugucu agcaguugug gucau 25

<210> 1453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1453

gcuggccugg cuguccuagc aguug 25

<210> 1454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1454

cccaucgugg gcauuguugc uggcc 25

<210> 1455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1455

ccgccccau cgugggcauu guugc 25

<210> 1456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1456

cuucccaguc caccgucccc aucgu 25

<210> 1457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1457

ucuucccagu ccaccgccc caucg 25

<210> 1458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1458

cucauccccc uccuuacccc aucuc 25

<210> 1459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1459

ucaucccccu ccuuacccca ucuca 25

<210> 1460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1460

ccccuccuua ccccaucuca gggug 25

<210> 1461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1461

cccuccuuac cccaucucag gguga 25

<210> 1462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1462

ccuccuuacc ccaucucagg gugag 25

<210> 1463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1463

uaccccaucu caggggugagg ggcuu 25

<210> 1464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1464

cuucggcagc cccucaugcu guaca 25

<210> 1465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1465

auguguaucu cugcucuucu ccaga 25

<210> 1466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1466

aggcaccacc acagcugccc acuuc 25

<210> 1467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1467

accccacag cugcccacuu cugga 25

<210> 1468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1468

acuucuggaa gguucuaucu ccugc 25

<210> 1469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1469

uggaagguuc uaucuccugc ugguc 25

<210> 1470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1470

cuccacaagc ucaguguccu gaguu 25

<210> 1471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1471

guuugguccu cgccaucccg cugcc 25

<210> 1472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1472

gcugccaggu cagugugauc uccgc 25

<210> 1473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1473

cugccagguc agugugaucu ccgca 25

<210> 1474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1474

ugugaucucc gcaggguaga aaccc 25

<210> 1475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1475

gugaucuccg caggguagaa accca 25

<210> 1476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1476

guagaaaccc agggcccagc accuc 25

<210> 1477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1477

uagaaaccca gggcccagca ccuca 25

<210> 1478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1478

aaacccaggg cccagcaccu caggg 25

<210> 1479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1479

ggccgcac cucagggugg ccuca 25

<210> 1480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1480

cucagggggg ccucaugguc agaga 25

<210> 1481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1481

ucaggguggc cucaugguca gagau 25

<210> 1482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1482

caggggcc ucauggucag agaug 25

<210> 1483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1483

gguggccuca uggucagaga ugggg 25

<210> 1484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1484

ggccucaugg ucagagaugg ggugg 25

<210> 1485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1485

gccucauggu cagagauggg guggu 25

<210> 1486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1486

uggggggug ggucacgugu gucuu 25

<210> 1487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1487

gggggggg gucacgugug ucuuu 25

<210> 1488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1488

ggggggggg ucacgugugu cuuug 25

<210> 1489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1489

ggugggggu cacguguguc uuugg 25

<210> 1490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1490

guggggguc acgugugucu uuggg 25

<210> 1491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1491

ucacgugugu cuuugggggg ucuga 25

<210> 1492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1492

cacguguguc uuugggggggu cugau 25

<210> 1493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1493

gagauggggu aaggaggggg augag 25

<210> 1494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1494

ugagaugggg uaaggagggg gauga 25

<210> 1495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1495

cugagauggg guaaggaggg ggaug 25

<210> 1496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1496

cucacccuga gaugggguaa ggagg 25

<210> 1497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1497

ccucacccug agauggggua aggag 25

<210> 1498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1498

cccucacccu gagauggggu aagga 25

<210> 1499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1499

ccccucaccc ugagaugggg uaagg 25

<210> 1500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1500

aagccccuca cccugagaug gggua 25

<210> 1501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1501

ugccgaagcc ccucacccug agaug 25

<210> 1502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1502

cugccgaagc cccucacccu gagau 25

<210> 1503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1503

gcugccgaag ccccucaccc ugaga 25

<210> 1504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1504

auacacaugc cauguacagc augag 25

<210> 1505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1505

gauacacaug ccauguacag cauga 25

<210> 1506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1506

agauacacau gccauguaca gcaug 25

<210> 1507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1507

aguggggcagc ugggggug ccuuc 25

<210> 1508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1508

accuuccaga agugggcagc ugugg 25

<210> 1509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1509

agaaccuucc agaagugggc agcug 25

<210> 1510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1510

gcaggagaua gaaccuucca gaagu 25

<210> 1511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1511

agcaggagau agaaccuucc agaag 25

<210> 1512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1512

cugagcuugu ggagaccaga ccagc 25

<210> 1513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1513

gaccaaacuc aggacacuga gcuug 25

<210> 1514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1514

cagcgggaug gcgaggacca aacuc 25

<210> 1515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1515

acacugaccu ggcagcggga uggcg 25

<210> 1516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1516

agaucacacu gaccuggcag cggga 25

<210> 1517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1517

gcggagauca cacugaccug gcagc 25

<210> 1518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1518

ugcggagauc acacugaccu ggcag 25

<210> 1519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1519

cuacccugcg gagaucacac ugacc 25

<210> 1520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1520

ugcgggccc uggguuucua cccug 25

<210> 1521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1521

aggccacccu gaggugcugg gcccu 25

<210> 1522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1522

gaggccaccc ugaggugcug ggccc 25

<210> 1523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1523

gaccaugagg ccacccuag gugcu 25

<210> 1524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1524

ugaccaugag gccaccuga ggugc 25

<210> 1525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1525

caucucugac caugaggcca cccug 25

<210> 1526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1526

acccaccacc ccaucucuga ccaug 25

<210> 1527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1527

cuccagcuug uccuucccgu ucucc 25

<210> 1528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1528

guccuucccg uucuccaggu aucug 25

<210> 1529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1529

gagccacucc acgcacucgc ccucc 25

<210> 1530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1530

cacuccacgc acucgcccuc caggu 25

<210> 1531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1531

guaggcucuc cgcugcuccg ccuca 25

<210> 1532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1532

uaggcuccc gcugcuccgc cucac 25

<210> 1533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1533

cucacgggcc gccucccacu ugcgc 25

<210> 1534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1534

ucacggggccg ccucccacuu gcgcu 25

<210> 1535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1535

ugggugaucu gagccgccgu guccg 25

<210> 1536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1536

gugaucugag ccgccguguc cgcgg 25

<210> 1537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1537

ugagccgccg uguccgcggc ggucc 25

<210> 1538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1538

cguguccgcg gcgguccagg agcgc 25

<210> 1539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1539

gguccaggag cgcagguccu cguuc 25

<210> 1540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1540

guccaggagc gcagguccuc guuca 25

<210> 1541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1541

agggcgaugu aauccuugcc gucgu 25

<210> 1542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1542

guaauccuug ccgucguagg cguac 25

<210> 1543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1543

gucguaggcg uacuggucau gcccg 25

<210> 1544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1544

guaggcguac uggucaugcc cgcgg 25

<210> 1545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1545

ggcguaacugg ucaugcccgc ggagg 25

<210> 1546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1546

caugcccgcg gaggaggcgc ccguc 25

<210> 1547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1547

ccccacgucg cagccguaca ugcuc 25

<210> 1548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1548

cacgucgcag ccguacaugc ucugg 25

<210> 1549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1549

acgucgcagc cguacaugcu cugga 25

<210> 1550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1550

gagcgcgcug guaccagggg cagug 25

<210> 1551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1551

ggagcgcgcu gguaccaggg gcagu 25

<210> 1552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1552

uggagcgcgc ugguaccagg ggcag 25

<210> 1553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1553

acaagcugga gcgcgcuggu accag 25

<210> 1554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1554

gacaagcugg agcgcgcugg uacca 25

<210> 1555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1555

ggacaagcug gagcgcgcug guacc 25

<210> 1556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1556

acgggaagga caagcuggag cgcgc 25

<210> 1557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1557

uaccuggaga acgggaagga caagc 25

<210> 1558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1558

cuccgcagau accuggagaa cggga 25

<210> 1559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1559

guggcuccgc agauaccugg agaac 25

<210> 1560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1560

aguggcuccg cagauaccug gagaa 25

<210> 1561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1561

ugcguggagu ggcuccgcag auacc 25

<210> 1562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1562

cuaccuggag ggcgagugcg uggag 25

<210> 1563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1563

agagccuacc uggagggcga gugcg 25

<210> 1564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1564

cggagcagcg gagagccuac cugga 25

<210> 1565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1565

gcggagcagc ggagagccua ccugg 25

<210> 1566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1566

gaggcggagc agcggagagc cuacc 25

<210> 1567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1567

ggaggcggcc cgugaggcgg agcag 25

<210> 1568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1568

cgcaagggg aggcggcccg ugagg 25

<210> 1569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1569

cagcgcaagu gggaggcggc ccgug 25

<210> 1570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1570

cagaucaccc agcgcaagug ggagg 25

<210> 1571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1571

gcucagauca cccagcgcaa guggg 25

<210> 1572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1572

gcggcucaga ucacccagcg caagu 25

<210> 1573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1573

ggcggcucag aucacccagc gcaag 25

<210> 1574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1574

cgcuccugga ccgccgcgga cacgg 25

<210> 1575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1575

cugcgcuccu ggaccgccgc ggaca 25

<210> 1576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1576

gaggaccugc gcuccuggac cgccg 25

<210> 1577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1577

cgcccugaac gaggaccugc gcucc 25

<210> 1578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1578

ggcaaggauu acaucgcccu gaacg 25

<210> 1579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1579

caugaccagu acgccuacga cggca 25

<210> 1580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1580

gcgggcauga ccaguacgcc uacga 25

<210> 1581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1581

ggggccggac ggggcgccucc uccgc 25

<210> 1582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1582

uggggccgga cgggcgccuc cuccg 25

<210> 1583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1583

guacggcugc gacguggggc cggac 25

<210> 1584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1584

uguacggcug cgacgugggg ccgga 25

<210> 1585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1585

agcauguacg gcugcgacgu ggggc 25

<210> 1586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1586

ccagagcaug uacggcugcg acgug 25

<210> 1587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1587

uccagagcau guacggcugc gacgu 25

<210> 1588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1588

cuccagagca uguacggcug cgacg 25

<210> 1589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1589

ccucucacac ccuccagagc augua 25

<210> 1590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1590

ugcgccccgg gccggggguca cucac 25

<210> 1591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1591

ccggggucac ucaccggccu cgcuc 25

<210> 1592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1592

cucgcucugg uuguaguagc cgcgc 25

<210> 1593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1593

guuguaguag ccgcgcaggu uccgc 25

<210> 1594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1594

gccgcgcagg uuccgcaggc ucucu 25

<210> 1595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1595

caggcucucu cggucagucu gugcc 25

<210> 1596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1596

aggcucucuc ggucagucug ugccu 25

<210> 1597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1597

cugggccuug uagaucugug uguuc 25

<210> 1598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1598

ucuguguguu ccggucccaa uacuc 25

<210> 1599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1599

accuccggccc cuccugcucu aucca 25

<210> 1600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1600

ccuccugcuc uauccacggc gcccg 25

<210> 1601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1601

uccacggcgc ccgcggcucc ucucu 25

<210> 1602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1602

gcccgcggcu ccucucucgg acucg 25

<210> 1603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1603

ggcgucgcug ucgaaccuca cgaac 25

<210> 1604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1604

gcgucgcugu cgaaccucac gaacu 25

<210> 1605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1605

guccacguag cccacugaga ugaag 25

<210> 1606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1606

uccacguagc ccacugagau gaagc 25

<210> 1607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1607

ccacguagcc cacugagaug aagcg 25

<210> 1608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1608

cacugagaug aagcggggcu ccccg 25

<210> 1609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1609

gagaugaagc ggggcucccc gcggc 25

<210> 1610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1610

agaugaagcg gggcuccccg cggcc 25

<210> 1611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1611

gaagcggggc uccccgcggc cgggc 25

<210> 1612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1612

aagcggggcu ccccgcggcc gggcc 25

<210> 1613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1613

ggcuccccgc ggccggggccgggaca 25

<210> 1614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1614

uccccgcggc cgggccggga cacgg 25

<210> 1615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1615

gacacgggagg uguagaaaua ccuca 25

<210> 1616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1616

ggagguguag aaauaccuca uggag 25

<210> 1617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1617

gagguguaga aauaccucau ggagu 25

<210> 1618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1618

agaaauaccu cauggagugg gagcc 25

<210> 1619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1619

gaaauaccuc aggaguggg agccu 25

<210> 1620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1620

aaauaccuca uggaguggga gccug 25

<210> 1621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1621

aauaccucau ggagugggag ccugg 25

<210> 1622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1622

cucauggagu gggagccugg gggug 25

<210> 1623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1623

aggaggggg agccugggggg ugagg 25

<210> 1624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1624

uggagggga gccugggggu gagga 25

<210> 1625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1625

ggaggggag ccugggggg aggag 25

<210> 1626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1626

gaggccggug agugaccccg gcccg 25

<210> 1627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1627

cgaggccggu gagugacccc ggccc 25

<210> 1628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1628

gcgaggccgg ugagugaccc cggcc 25

<210> 1629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1629

ccagagcgag gccggugagu gaccc 25

<210> 1630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1630

gcggcuacua caaccagagc gaggc 25

<210> 1631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1631

cugcgcggcu acuacacca gagcg 25

<210> 1632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1632

accgagagag ccugcggaac cugcg 25

<210> 1633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1633

ggcacagacu gaccgagaga gccug 25

<210> 1634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1634

cggaacacac agaucuacaa ggccc 25

<210> 1635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1635

ugggaccgga acacacagau cuaca 25

<210> 1636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1636

gcaggagggg ccggaguauu gggac 25

<210> 1637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1637

auagagcagg aggggccgga guauu 25

<210> 1638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1638

gauagagcag gaggggccgg aguau 25

<210> 1639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1639

gcgccgugga uagagcagga ggggc 25

<210> 1640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1640

gcgggcgccg uggauagagc aggag 25

<210> 1641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1641

cgcgggcgcc guggauagag cagga 25

<210> 1642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1642

ccgcgggcgc cguggauaga gcagg 25

<210> 1643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1643

gagccgcggg cgccguggau agagc 25

<210> 1644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1644

uccgagagag gagccgcggg cgccg 25

<210> 1645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1645

gccgcgaguc cgagagagga gccgc 25

<210> 1646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1646

cgccgcgagu ccgagagagg agccg 25

<210> 1647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1647

gacagcgacg ccgcgagucc gagag 25

<210> 1648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1648

cuacguggac gacacccagu ucgug 25

<210> 1649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1649

ccccgcuuca ucucaguggg cuacg 25

<210> 1650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1650

gcggggagcc ccgcuucauc ucagu 25

<210> 1651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1651

cgcggggagc cccgcuucau cucag 25

<210> 1652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1652

accuccgugu ccggcccgg ccgcg 25

<210> 1653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1653

caccuccgug ucccggcccg gccgc 25

<210> 1654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1654

acaccuccgu gucccggccc ggccg 25

<210> 1655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1655

auuucuacac cuccgugucc cggcc 25

<210> 1656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1656

gagguauuuc uacaccuccg ugucc 25

<210> 1657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1657

cucaccccca ggcucccacu ccaug 25

<210> 1658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1658

cauuucccuc ccgacccgca cucac 25

<210> 1659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1659

ccucccgacc cgcacucacc ggccc 25

<210> 1660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1660

gacccgcacu caccggccca ggucu 25

<210> 1661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1661

gcacucaccg gcccaggucu cgguc 25

<210> 1662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1662

cacucaccgg cccaggucuc gguca 25

<210> 1663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1663

accggcccag gucuccgguca gggcc 25

<210> 1664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1664

ccggcccagg ucucggucag ggcca 25

<210> 1665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1665

cagggccagg gccgccgaga gcagc 25

<210> 1666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1666

ggccagggcc gccgagagca gcagg 25

<210> 1667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1667

agggccgccg agagcagcag gagga 25

<210> 1668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1668

cgccgagagc agcaggagga cgguu 25

<210> 1669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1669

gccgagagca gcaggaggac gguuc 25

<210> 1670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1670

cggagagcag caggaggacg guucg 25

<210> 1671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1671

guucggggcg ccaugaccag caucu 25

<210> 1672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1672

gccaugacca gcaucucggc gucug 25

<210> 1673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1673

ucggcgucug aggagacucu gaguc 25

<210> 1674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1674

cggcgucuga ggagacucug agucc 25

<210> 1675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1675

cgucugga gacucugagu cgggg 25

<210> 1676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1676

gucugaggag acucugaguc cgggu 25

<210> 1677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1677

gagacucuga guccggggugg gugcg 25

<210> 1678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1678

agacucugag uccgggggg ugcgu 25

<210> 1679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1679

gacucugagu ccggggggu gcgug 25

<210> 1680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1680

ggugggugcg uggggacuuu agaac 25

<210> 1681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1681

gugggugcgu ggggacuuua gaacu 25

<210> 1682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1682

cguggggacu uuagaacugg gaccg 25

<210> 1683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1683

gaacugggac cgcggcgacg cugau 25

<210> 1684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1684

cugggccggu gagugcgggu cggga 25

<210> 1685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1685

ccugggccgg ugagugcgggg ucggg 25

<210> 1686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1686

agaccugggc cggugagugc ggguc 25

<210> 1687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1687

gagaccuggg ccggugagug cgggu 25

<210> 1688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1688

gaccgagacc ugggccggug agugc 25

<210> 1689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1689

ugaccgagac cugggccggu gagug 25

<210> 1690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1690

cccggcccu gaccgagacc ugggc 25

<210> 1691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1691

gcggccgggg cccugaccga gaccu 25

<210> 1692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1692

ggcggccug gcccugaccg agacc 25

<210> 1693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1693

guccuccugc ugcucucggc ggccc 25

<210> 1694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1694

cgaaccgucc uccugcugcu cucgg 25

<210> 1695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1695

ccccgaaccg uccuccugcu gcucu 25

<210> 1696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1696

uccucagacg ccgagaugcu gguca 25

<210> 1697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1697

agagucuccu cagacgccga gaugc 25

<210> 1698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1698

guucuaaagu ccccacgcac ccacc 25

<210> 1699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1699

cucagcacag cgaacaugca aauuc 25

<210> 1700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1700

gcacagcgaa caugcaaauu cugga 25

<210> 1701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1701

aacaugcaaa uucuggaagg uucuc 25

<210> 1702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1702

gucuuuauuu gcucucucaa cuucu 25

<210> 1703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1703

uauuugagaa cacaaauuua uauuc 25

<210> 1704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1704

uuauauucag guucuuaacu ucauu 25

<210> 1705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1705

uauauucagg uucuuaacuu cauua 25

<210> 1706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1706

gugcaccaug aauuugagac agaga 25

<210> 1707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1707

aggagacau ccagccccac cucuc 25

<210> 1708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1708

acauccagcc ccaccucucu ggaac 25

<210> 1709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1709

accucucugg aacaggaaag augau 25

<210> 1710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1710

ccucucugga acaggaaaga ugauc 25

<210> 1711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1711

cucucuggaa caggaaagau gaucg 25

<210> 1712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1712

ucuggaacag gaaagaugau cgggg 25

<210> 1713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1713

cuggaacagg aaagaugauc gggga 25

<210> 1714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1714

ggaaagauga ucggggaggg aacac 25

<210> 1715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1715

aucggggagg gaacacaggu cagug 25

<210> 1716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1716

ucggggaggg aacacagguc agugu 25

<210> 1717

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1717

cggggaggga acacagguca gugug 25

<210> 1718

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1718

agggaacaca ggucagugug gggac 25

<210> 1719

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1719

gggaacacag gucagugugg ggaca 25

<210> 1720

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1720

ggaacacagg ucaguguggg gacag 25

<210> 1721

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1721

caggucagug uggggacagg gguca 25

<210> 1722

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1722

gucagugugg ggacaggggu cacgg 25

<210> 1723

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1723

guggggacag gggucacggu ggaca 25

<210> 1724

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1724

ugggacagg ggucacggug gacac 25

<210> 1725

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1725

ggggacaggg gucacgggg acacg 25

<210> 1726

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1726

gggacagggg ucacggugga cacgg 25

<210> 1727

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1727

acagggguca cgguggacac ggggg 25

<210> 1728

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1728

caggggucac gguggacacg ggggu 25

<210> 1729

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1729

cuccaccucc ucacauuaug cuaac 25

<210> 1730

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1730

ugcuaacagg aacgcagaca cauuc 25

<210> 1731

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1731

gugccuuugc agaaagagau gccag 25

<210> 1732

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1732

augccagagg cucuugaagu cacaa 25

<210> 1733

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1733

agaggcucuu gaagucacaa aggag 25

<210> 1734

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1734

gaaauccugc aucucagucc cacac 25

<210> 1735

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1735

ucagucccac acaggcagcu gucuc 25

<210> 1736

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1736

ucaaauauuu gcuaugaagc guuga 25

<210> 1737

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1737

ugucuccauc ucugucucaa auuca 25

<210> 1738

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1738

cuuuccuguu ccagagaggu ggggc 25

<210> 1739

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1739

ucaucuuucc uguuccagag aggug 25

<210> 1740

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1740

aucaucuuuc cuguuccaga gaggu 25

<210> 1741

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1741

gaucaucuuu ccuguuccag agagg 25

<210> 1742

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1742

cccgaucauc uuuccuguuc cagag 25

<210> 1743

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1743

uuccuguuag cauaauguga ggagg 25

<210> 1744

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1744

gcguuccugu uagcauaaug ugagg 25

<210> 1745

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1745

ucugcguucc uguuagcaua augug 25

<210> 1746

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1746

gagccucugg caucucuuuc ugcaa 25

<210> 1747

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1747

ucuccuuugu gacuucaaga gccuc 25

<210> 1748

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1748

agcugccugu gugggacuga gaugc 25

<210> 1749

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1749

uguagccuga gacagcugcc ugugu 25

<210> 1750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1750

cuguagccug agacagcugc cugug 25

<210> 1751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1751

agugaugaga gacucaucag agccc 25

<210> 1752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1752

gugaugagag acucaucaga gcccu 25

<210> 1753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1753

cagagcccug ggcacuguug cugcc 25

<210> 1754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1754

agagcccugg gcacuguugc ugccu 25

<210> 1755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1755

gagccgggg cacuguugcu gccug 25

<210> 1756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1756

aaggugagau ucggggagc ugaag 25

<210> 1757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1757

caucacuugu aaaggugaga uucug 25

<210> 1758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1758

ucaucacuug uaaaggugag auucu 25

<210> 1759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1759

cucaucacuu guaaagguga gauuc 25

<210> 1760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1760

cugaugaguc ucucaucacu uguaa 25

<210> 1761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1761

cuaccccagg cagcaacagu gccca 25

<210> 1762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1762

ucuaccccag gcagcaacag ugccc 25

<210> 1763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1763

gagcagcucc cuccuuuucc accug 25

<210> 1764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1764

agcagcuccc uccuuuucca ccugu 25

<210> 1765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1765

cguguaagug auggcggcgg gcgug 25

<210> 1766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1766

caggcugcgu guaagugaug gcggc 25

<210> 1767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1767

ucaggcugcg uguaagugau ggcgg 25

<210> 1768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1768

cucucaggcu gcguguaagu gaugg 25

<210> 1769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1769

cugcucucag gcugcgugua aguga 25

<210> 1770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1770

gguggaaaag ggggagcug cucuc 25

<210> 1771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1771

uuuucuuccc acagguggaa aagga 25

<210> 1772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1772

auuuucuucc cacaggugga aaagg 25

<210> 1773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1773

ggcauuuucu ucccacaggu ggaaa 25

<210> 1774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1774

ucauagggca uuuucuuccc acagg 25

<210> 1775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1775

gagcucuucc uccuacacau cauag 25

<210> 1776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1776

caucauagcg gugaccacag cucca 25

<210> 1777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1777

ggugaccaca gcuccaagga cagcu 25

<210> 1778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1778

agcuccaagg acagcuagga caacc 25

<210> 1779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1779

gacagcuagg acaaccagga cagcc 25

<210> 1780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1780

gccaggccag caacgaugcc cauga 25

<210> 1781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1781

ccaggccagc aacgaugccc augau 25

<210> 1782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1782

caggccagca acgaugccca ugaug 25

<210> 1783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1783

ccagcaacga ugcccaugau gggga 25

<210> 1784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1784

gcaacgaugc ccaugauggg gaugg 25

<210> 1785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1785

caacgaugcc caugaugggg auggu 25

<210> 1786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1786

gaugcccaug augggaugg ugggc 25

<210> 1787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1787

augcccauga ugggauggu gggcu 25

<210> 1788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1788

ugaggggau ggugggcugg gaaga 25

<210> 1789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1789

ggaugggggg cugggaagau ggcuc 25

<210> 1790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1790

gauggggggc ugggaagaug gcucu 25

<210> 1791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1791

ugggcuggga agauggcucu gggaa 25

<210> 1792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1792

gcugggaaga uggcucuggg aaagg 25

<210> 1793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1793

aagauggcuc ugggaaagga ggaga 25

<210> 1794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1794

ggcucuggga aaggaggaga aggug 25

<210> 1795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1795

gcucugggaa aggaggagaa gguga 25

<210> 1796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1796

ucagguaggg aaggggugaa gagcg 25

<210> 1797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1797

cucagguagg gaagggguga agagc 25

<210> 1798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1798

gcucagguag ggaaggggug aagag 25

<210> 1799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1799

aggaggaaga gcucagguag ggaag 25

<210> 1800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1800

uaggaggaag agcucaggua gggaa 25

<210> 1801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1801

guaggaggaa gagcucaggu aggga 25

<210> 1802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1802

auguguagga ggaaagcuc aggua 25

<210> 1803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1803

gauguguagg aggaaagcu caggu 25

<210> 1804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1804

cuaugaugug uaggaggaag agcuc 25

<210> 1805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1805

ugggucacc gcuaugaugu guagg 25

<210> 1806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1806

agcuggguc accgcuauga ugugu 25

<210> 1807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1807

guuguccuag cuguccuugg agcug 25

<210> 1808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1808

cuguccuggu uguccuagcu guccu 25

<210> 1809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1809

ggcaucguug cuggccuggc ugucc 25

<210> 1810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1810

cccaucaugg gcaucguugc uggcc 25

<210> 1811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1811

ccauccccau caugggcauc guugc 25

<210> 1812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1812

cuucccagcc caccaucccc aucau 25

<210> 1813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1813

ucuucccagc ccaccauccc cauca 25

<210> 1814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1814

cccauucccc uccuuacccc agcuc 25

<210> 1815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1815

ccauuccccu ccuuacccca gcuca 25

<210> 1816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1816

ccccuccuua ccccagcuca gggug 25

<210> 1817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1817

cccuccuuac cccagcucag gguga 25

<210> 1818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1818

ccuccuuacc ccagcucagg gugag 25

<210> 1819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1819

cucuugcagc cccucgugcu gcaua 25

<210> 1820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1820

acguguaucu cugcucuugu ccaga 25

<210> 1821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1821

aggcaccacc acagcugccc acuuc 25

<210> 1822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1822

accccacag cugcccacuu cugga 25

<210> 1823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1823

acuucuggaa gguuccaucu ccugc 25

<210> 1824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1824

uggaagguuc caucuccugc uggcc 25

<210> 1825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1825

ccugcuggcc uggucuccac aagcu 25

<210> 1826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1826

ccuggucucc acaagcucgg ugucc 25

<210> 1827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1827

cuggucucca caagcucgu guccu 25

<210> 1828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1828

cuccacaagc ucgguguccu ggguc 25

<210> 1829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1829

gucgguccu ccccaucccg cugcc 25

<210> 1830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1830

gcugccaggu cagugugauc uccgc 25

<210> 1831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1831

cugccagguc agugugaucu ccgca 25

<210> 1832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1832

ugugaucucc gcaggguaga agccc 25

<210> 1833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1833

gugaucuccg caggguagaa gcca 25

<210> 1834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1834

guagaagccc agggcccagc accuc 25

<210> 1835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1835

uagaagccca gggcccagca ccuca 25

<210> 1836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1836

aagcccaggg cccagcaccu caggg 25

<210> 1837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1837

ggccgcac cucagggugg ccuca 25

<210> 1838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1838

ccucagggug gccucauggu cagag 25

<210> 1839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1839

cucagggggg ccucaugguc agaga 25

<210> 1840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1840

ucaggguggc cucaugguca gagag 25

<210> 1841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1841

caggggcc ucauggucag agagg 25

<210> 1842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1842

gguggccuca uggucagaga ggggg 25

<210> 1843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1843

ggccucaugg ucagagagggg ggugg 25

<210> 1844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1844

gccucauggu cagagagggg guggu 25

<210> 1845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1845

gggggggug ggucacgugu gucuu 25

<210> 1846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1846

gggggggg gucacgugug ucuuu 25

<210> 1847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1847

ggggggggg ucacgugugu cuuug 25

<210> 1848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1848

ggugggggu cacguguguc uuugg 25

<210> 1849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1849

ucacgugugu cuuugggggu ucuga 25

<210> 1850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1850

cacguguguc uuuggggguu cugac 25

<210> 1851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1851

gagcuggggu aaggaggggga auggg 25

<210> 1852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1852

ugagcugggg uaaggagggg aaugg 25

<210> 1853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1853

cugaggcuggg guaaggaggg gaaug 25

<210> 1854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1854

ccugagcugg gguaaggagg ggaau 25

<210> 1855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1855

cccuagcug ggguaaggag gggaa 25

<210> 1856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1856

ccucacccug agcuggggua aggag 25

<210> 1857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1857

cccucacccu gagcuggggu aagga 25

<210> 1858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1858

ccccucaccc ugagcugggg uaagg 25

<210> 1859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1859

gagcccccuca cccugagcug gggua 25

<210> 1860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1860

ugcaagagcc ccucacccug agcug 25

<210> 1861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1861

cugcaagagc cccucacccu gagcu 25

<210> 1862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1862

gcugcaagag ccccucaccc ugagc 25

<210> 1863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1863

auacacgugc cauaugcagc acgag 25

<210> 1864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1864

gauacacgug ccauaugcag cacga 25

<210> 1865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1865

agauacacgu gccauaugca gcacg 25

<210> 1866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1866

aguggggcagc ugggggug ccuuc 25

<210> 1867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1867

accuuccaga agugggcagc ugugg 25

<210> 1868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1868

ggaaccuucc agaagugggc agcug 25

<210> 1869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1869

gcaggagaug gaaccuucca gaagu 25

<210> 1870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1870

agcaggagau ggaaccuucc agaag 25

<210> 1871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1871

uugggagac caggccagca ggaga 25

<210> 1872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1872

ccgagcuugu ggagaccagg ccagc 25

<210> 1873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1873

ccaggacacc gagcuugugg agacc 25

<210> 1874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1874

gaccagaccc aggacaccga gcuug 25

<210> 1875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1875

cagcgggaug gggaggacca gaccc 25

<210> 1876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1876

acacugaccu ggcagcggga ugggg 25

<210> 1877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1877

aucacacuga ccuggcagcg ggaug 25

<210> 1878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1878

gaucacacug accuggcagc gggau 25

<210> 1879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1879

agaucacacu gaccuggcag cggga 25

<210> 1880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1880

gcggagauca cacugaccug gcagc 25

<210> 1881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1881

ugcggagauc acacugaccu ggcag 25

<210> 1882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1882

cuacccugcg gagaucacac ugacc 25

<210> 1883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1883

ugcgggccc ugggcuucua cccug 25

<210> 1884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1884

aggccacccu gaggugcugg gcccu 25

<210> 1885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1885

gaggccaccc ugaggugcug ggccc 25

<210> 1886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1886

gaccaugagg ccacccuag gugcu 25

<210> 1887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1887

ugaccaugag gccaccuga ggugc 25

<210> 1888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1888

ccucucugac caugaggcca cccug 25

<210> 1889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1889

acccaccacc cccucucuga ccaug 25

<210> 1890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1890

cugcagcguc uccuucccgu ucucc 25

<210> 1891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1891

cuccuuccg uucuccaggu aucug 25

<210> 1892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1892

gagccacucc acgcacgugc ccucc 25

<210> 1893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1893

cacuccacgc acgugcccuc caggu 25

<210> 1894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1894

guaggcucuc agcugcuccg ccgca 25

<210> 1895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1895

uaggcucuca gcugcuccgc cgcac 25

<210> 1896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1896

cgcacgggcc gccuccaacu ugcgc 25

<210> 1897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1897

gcacggggccg ccuccaacuu gcgcu 25

<210> 1898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1898

aacuugcgcu gggugaucug agccg 25

<210> 1899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1899

ugggugaucu gagccgcggu guccg 25

<210> 1900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1900

gugaucugag ccgcgguguc cgcgg 25

<210> 1901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1901

ugagccgcgg uguccgcggc ggucc 25

<210> 1902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1902

gguguccgcg gcgguccagg agcgc 25

<210> 1903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1903

gguccaggag cgcagguccu cguuc 25

<210> 1904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1904

guccaggagc gcagguccuc guuca 25

<210> 1905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1905

agggcgaugu aauccuugcc gucgu 25

<210> 1906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1906

gcgauguaau ccuugccguc guagg 25

<210> 1907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1907

guaauccuug ccgucguagg cggac 25

<210> 1908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1908

gucguaggcg gacuggucau acccg 25

<210> 1909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1909

guaggcggac uggucauacc cgcgg 25

<210> 1910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1910

ggcggacugg ucauacccgc ggagg 25

<210> 1911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1911

ucauacccgc ggaggaggcg cccgu 25

<210> 1912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1912

cauacccgcg gaggaggcgc ccguc 25

<210> 1913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1913

gcggaggagg cgcccgucgg gcccc 25

<210> 1914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1914

ccccaggucg cagccagaca uccuc 25

<210> 1915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1915

caggucgcag ccagacaucc ucugg 25

<210> 1916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1916

aggucgcagc cagacauccu cugga 25

<210> 1917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1917

acauccucug gaggguguga gaccc 25

<210> 1918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1918

gugugagacc cuggccccgc ccccg 25

<210> 1919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1919

cagcgcgcag guaccagggg cagug 25

<210> 1920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1920

gcagcgcgca gguaccaggg gcagu 25

<210> 1921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1921

ugcagcgcgc agguaccagg ggcag 25

<210> 1922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1922

agacgcugca gcgcgcaggu accag 25

<210> 1923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1923

gagacgcugc agcgcgcagg uacca 25

<210> 1924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1924

ggagacgcug cagcgcgcag guacc 25

<210> 1925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1925

acgggaagga gacgcugcag cgcgc 25

<210> 1926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1926

cuccgcagau accuggagaa cggga 25

<210> 1927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1927

guggcuccgc agauaccugg agaac 25

<210> 1928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1928

aguggcuccg cagauaccug gagaa 25

<210> 1929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1929

ugcguggagu ggcuccgcag auacc 25

<210> 1930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1930

cuaccuggag ggcacgugcg uggag 25

<210> 1931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1931

agagccuacc uggagggcac gugcg 25

<210> 1932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1932

cggagcagcu gagagccuac cugga 25

<210> 1933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1933

gcggagcagc ugagagccua ccugg 25

<210> 1934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1934

gcggcggagc agcugagagc cuacc 25

<210> 1935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1935

cgcaaguugg aggcggcccg ugcgg 25

<210> 1936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1936

cagcgcaagu uggaggcggc ccgug 25

<210> 1937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1937

cagaucaccc agcgcaaguu ggagg 25

<210> 1938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1938

gcucagauca cccagcgcaa guugg 25

<210> 1939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1939

gcggcucaga ucacccagcg caagu 25

<210> 1940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1940

cgcuccugga ccgccgcgga caccg 25

<210> 1941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1941

gaggaccugc gcuccuggac cgccg 25

<210> 1942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1942

cgcccugaac gaggaccugc gcucc 25

<210> 1943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1943

ggcaaggauu acaucgcccu gaacg 25

<210> 1944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1944

uaugaccagu ccgccuacga cggca 25

<210> 1945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1945

gcggguauga ccaguccgcc uacga 25

<210> 1946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1946

ggggcccgac gggcgccucc uccgc 25

<210> 1947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1947

uggggcccga cgggcgccuc cuccg 25

<210> 1948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1948

gucuggcugc gaccuggggc ccgac 25

<210> 1949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1949

ugucuggcug cgaccugggg cccga 25

<210> 1950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1950

ccagaggaug ucuggcugcg accug 25

<210> 1951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1951

uccagaggau gucuggcugc gaccu 25

<210> 1952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1952

cuccagagga ugucuggcug cgacc 25

<210> 1953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1953

ggucucacac ccuccagagg auguc 25

<210> 1954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1954

ggggccagggg ucucacaccc uccag 25

<210> 1955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1955

ccggggucac ucaccguccu cgcuc 25

<210> 1956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1956

cucgcucugg uuguaguagc cgcgc 25

<210> 1957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1957

guuguaguag ccgcgcaggu uccgc 25

<210> 1958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1958

gccgcgcagg uuccgcaggc ucacu 25

<210> 1959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1959

caggcucacu cggucagccu gugcc 25

<210> 1960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1960

cuggcgcuug uacuucugug ucucc 25

<210> 1961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1961

ucugugucuc ccggucccaa uacuc 25

<210> 1962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1962

accuccggccc cuccugcucc accca 25

<210> 1963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1963

ccuccugcuc cacccacggc gcccg 25

<210> 1964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1964

cccacggcgc ccgcggcucc ccucu 25

<210> 1965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1965

gcccgcggcu ccccucucgg acucg 25

<210> 1966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1966

guccacguag cccacugaga ugaag 25

<210> 1967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1967

uccacguagc ccacugagau gaagc 25

<210> 1968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1968

ccacguagcc cacugagaug aagcg 25

<210> 1969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1969

cacugagaug aagcggggcu cuccg 25

<210> 1970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1970

gagaugaagc ggggcucucc gcggc 25

<210> 1971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1971

agaugaagcg gggcucuccg cggcc 25

<210> 1972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1972

gaagcggggc ucuccgcggc cgggc 25

<210> 1973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1973

aagcggggcu cuccgcggcc gggcc 25

<210> 1974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1974

ggcucuccgc ggccggggccg ggaca 25

<210> 1975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1975

ucuccgcggc cgggccggga cacgg 25

<210> 1976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1976

gacacggcgg ugucgaaaua ccuca 25

<210> 1977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1977

ggcggugucg aaauaccuca uggag 25

<210> 1978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1978

gcggugucga aauaccucau ggagu 25

<210> 1979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1979

cgaaauaccu cauggagugg gagcc 25

<210> 1980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1980

gaaauaccuc aggaguggg agccu 25

<210> 1981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1981

aaauaccuca uggaguggga gccug 25

<210> 1982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1982

aauaccucau ggagugggag ccugg 25

<210> 1983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1983

cucauggagu gggagccugg gggcg 25

<210> 1984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1984

auggagggg agccugggggg cgagg 25

<210> 1985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1985

uggaguggga gccuggggggc gagga 25

<210> 1986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1986

ggagggggag ccuggggggcg aggag 25

<210> 1987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1987

gaggacggug agugaccccg gcccg 25

<210> 1988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1988

cgaggacggu gagugacccc ggccc 25

<210> 1989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1989

gcgaggacgg ugagugaccc cggcc 25

<210> 1990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1990

ccagagcgag gacggugagu gaccc 25

<210> 1991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1991

gcggcuacua caaccagagc gagga 25

<210> 1992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1992

cugcgcggcu acuacacca gagcg 25

<210> 1993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1993

accgagugag ccugcggaac cugcg 25

<210> 1994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1994

ggcacaggcu gaccgaguga gccug 25

<210> 1995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1995

acacagaagu acaagcgcca ggcac 25

<210> 1996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1996

cgggagacac agaaguacaa gcgcc 25

<210> 1997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1997

caggaggggc cggaguauug ggacc 25

<210> 1998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1998

gcaggagggg ccggaguauu gggac 25

<210> 1999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 1999

guggagcagg aggggccgga guauu 25

<210> 2000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2000

gguggagcag gaggggccgg aguau 25

<210> 2001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2001

gcgccguggg uggagcagga ggggc 25

<210> 2002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2002

gcgggcgccg uggguggagc aggag 25

<210> 2003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2003

cgcgggcgcc guggguggag cagga 25

<210> 2004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2004

ccgcgggcgc cgugggugga gcagg 25

<210> 2005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2005

gagccgcggg cgccgugggu ggagc 25

<210> 2006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2006

aggggagc cgcgggcgcc guggg 25

<210> 2007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2007

ccgagagggg agccgcggggc gccgu 25

<210> 2008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2008

uccgagggg gagccgcggg cgccg 25

<210> 2009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2009

gccgcgaguc cgagagggga gccgc 25

<210> 2010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2010

cgccgcgagu ccgagagggg agccg 25

<210> 2011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2011

gacagcgacg ccgcgagucc gagag 25

<210> 2012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2012

cgacagcgac gccgcgaguc cgaga 25

<210> 2013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2013

ucgacagcga cgccgcgagu ccgag 25

<210> 2014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2014

cuacguggac gacacgcagu ucgug 25

<210> 2015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2015

ccccgcuuca ucucaguggg cuacg 25

<210> 2016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2016

gcggagagcc ccgcuucauc ucagu 25

<210> 2017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2017

cgcggagagc cccgcuucau cucag 25

<210> 2018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2018

acaccgccgu gucccggccc ggccg 25

<210> 2019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2019

auuucgacac cgccgugucc cggcc 25

<210> 2020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2020

gagguauuuc gacaccgccg ugucc 25

<210> 2021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2021

cucgccccca ggcucccacu ccaug 25

<210> 2022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2022

gcuucccucc caaccccgca cucac 25

<210> 2023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2023

cucccaaccc cgcacucaca ggccc 25

<210> 2024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2024

accccgcacu cacaggccca ggucu 25

<210> 2025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2025

gcacucacag gcccaggucu cgguc 25

<210> 2026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2026

cacucacagg cccaggucuc gguca 25

<210> 2027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2027

acaggcccag gucucgguca gggcc 25

<210> 2028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2028

cagggccagg ccucccgaga gcagc 25

<210> 2029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2029

ggccaggccu ccggagagca gcagg 25

<210> 2030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2030

caggccuccc gagagcagca ggagg 25

<210> 2031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2031

aggccucccg aggcagcag gagga 25

<210> 2032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2032

ucccgagagc agcaggagga gggcu 25

<210> 2033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2033

cccgagagca gcaggaggag ggcuc 25

<210> 2034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2034

ccgaggcag caggaggagg gcucg 25

<210> 2035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2035

gcucggggcg ccaugacccg caucu 25

<210> 2036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2036

gcgccaugac ccgcaucucg gccuc 25

<210> 2037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2037

cgccaugacc cgcaucucgg ccucu 25

<210> 2038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2038

gccaugaccc gcaucucggc cucug 25

<210> 2039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2039

ucggccucug gggagaaugu gaguc 25

<210> 2040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2040

cggccucugg ggagaaugug agucc 25

<210> 2041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2041

ccucugggga gaaugugagu ccggg 25

<210> 2042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2042

cucuggggag aaugugaguc cgggu 25

<210> 2043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2043

gagaauguga guccgggugg gugac 25

<210> 2044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2044

agaaugugag uccgggggg ugacu 25

<210> 2045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2045

gaaugugagu ccggggggu gacug 25

<210> 2046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2046

ggugggugac uggggacuuu agaac 25

<210> 2047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2047

gugggugacu ggggacuuua gaacc 25

<210> 2048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2048

acuggggacu uuagaaccgg gacug 25

<210> 2049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2049

gaaccgggac ugcggagacg cugau 25

<210> 2050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2050

ugggccugug agucgggggu uggga 25

<210> 2051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2051

cugggccugu gagugcgggg uuggg 25

<210> 2052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2052

gaccugggcc ugugagugcg ggguu 25

<210> 2053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2053

agaccugggc cugugagugc ggggu 25

<210> 2054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2054

accgagaccu gggccuguga gugcg 25

<210> 2055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2055

gaccgagacc ugggccugug agugc 25

<210> 2056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2056

ugaccgagac cugggccugu gagug 25

<210> 2057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2057

ggaggccugg cccugaccga gaccu 25

<210> 2058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2058

gggaggccug gcccugaccg agacc 25

<210> 2059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2059

cuccuccugc ugcucucggg aggcc 25

<210> 2060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2060

gagcccuccu ccugcugcuc ucggg 25

<210> 2061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2061

cccgagcccu ccuccugcug cucuc 25

<210> 2062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2062

ccccgagccc uccuccugcu gcucu 25

<210> 2063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2063

uccccagagg ccgagaugcg gguca 25

<210> 2064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2064

acauucuccc cagaggccga gaugc 25

<210> 2065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2065

cacauucucc ccagaggccg agaug 25

<210> 2066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2066

ccacccggac ucacauucuc cccag 25

<210> 2067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2067

guucuaaagu ccccagucac ccacc 25

<210> 2068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2068

aagccaauca gcgucuccgc agucc 25

<210> 2069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2069

uuuuauuaug auguuucucc auauu 25

<210> 2070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2070

ucuccauauu uggcauugcu guaaa 25

<210> 2071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2071

aaauggcuaa cauuuacugc caauu 25

<210> 2072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2072

uuacugccaa uucgguacaa August 25

<210> 2073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2073

gccaauucgg uacaaaugug ugguu 25

<210> 2074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2074

aauaaaaguu aaacauuucc acaca 25

<210> 2075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2075

uuuacagucu gacauuucac ugcgu 25

<210> 2076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2076

aaaacuacaa cuuuuauuuu uaaac 25

<210> 2077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2077

acuuuuauuu uuaaacagga gucac 25

<210> 2078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2078

uauauguagu uaagcaaguu auuug 25

<210> 2079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2079

auguaguuaa gcaaguuauuu ugagg 25

<210> 2080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2080

uguaguuaag caaguuauuu gagga 25

<210> 2081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2081

agaagcaaau ccuuuccuga aaacc 25

<210> 2082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2082

uuccugaaaa cgggucacu aaucc 25

<210> 2083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2083

uccugaaaac cuggucacua auccu 25

<210> 2084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2084

ugaaaaccug gucacuaauc cuggg 25

<210> 2085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2085

ccuggucacu aauccugggu ggacc 25

<210> 2086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2086

uggaccaggu ugcuugaaaa uaguc 25

<210> 2087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2087

ggaccagguu gcuugaaaau agucu 25

<210> 2088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2088

ugggaaauua cgaaacucca cccaa 25

<210> 2089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2089

gggaaauuac gaaacuccac ccaaa 25

<210> 2090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2090

aacacauuca ccuacagcua caguc 25

<210> 2091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2091

acacauucac cuacagcuac aguca 25

<210> 2092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2092

acagucaggg agugaccagc caaga 25

<210> 2093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2093

ccagccaaga uggaaaucuc acuga 25

<210> 2094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2094

auggaaaucu cacugaaggc uacca 25

<210> 2095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2095

aucucacuga aggcuaccau gguuc 25

<210> 2096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2096

uuguauauaca auauuuuuca uucca 25

<210> 2097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2097

uucauuccau ggugauguag uuuuc 25

<210> 2098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2098

ucauuccaug gugauguagu uuuca 25

<210> 2099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2099

ugauguaguu uucaggguuu uuaaa 25

<210> 2100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2100

gauguaguuu ucaggguuuu uaaaa 25

<210> 2101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2101

aaagggaacu aaaauuauga gacuu 25

<210> 2102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2102

uaaaauuaug agacuuaggu gaaac 25

<210> 2103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2103

auugcucccu gccucugaau ucuga 25

<210> 2104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2104

uugcuccug ccucugaauu cugaa 25

<210> 2105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2105

cugccucuga auucugaagg gagcg 25

<210> 2106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2106

cugaagggag cguggcuuuc cuuca 25

<210> 2107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2107

acacaaauca uguuaguuuu ccuuu 25

<210> 2108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2108

cacaaaucau guuaguuuuc cuuuu 25

<210> 2109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2109

acaaaucaug uuaguuuucc uuuug 25

<210> 2110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2110

aaucauguua guuuuccuuu ugggg 25

<210> 2111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2111

guuaguuuuc cuuuuggggu ggcca 25

<210> 2112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2112

ggccaagguu uccucccaua guuuu 25

<210> 2113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2113

guuuccuccc auaguuuuag gcauu 25

<210> 2114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2114

ccuacaaaca cuaaaaauac uuuuc 25

<210> 2115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2115

gaaguuacua caaacuucaa caguu 25

<210> 2116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2116

aaguuacuac aaacuucaac aguuu 25

<210> 2117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2117

uucuacaaac uucaacaguu ugggu 25

<210> 2118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2118

acuacaaacu ucaacaguuu ggguu 25

<210> 2119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2119

caaacuucaa caguuugggu uggga 25

<210> 2120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2120

ugggauggcc agauaacaca uacau 25

<210> 2121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2121

uuucuuuucc cccacguauc cuaaa 25

<210> 2122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2122

uucuuuuccc ccacguaucc uaaaa 25

<210> 2123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2123

ucuauuuuuu gagcgccaag auugu 25

<210> 2124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2124

cuauuuuuug agcgccaaga uuguu 25

<210> 2125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2125

agauuaaugu gugagaugug cuuuc 25

<210> 2126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2126

guuuuaacca cauaacauuc uauaa 25

<210> 2127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2127

auaagaauau ucaagcaguu uucuu 25

<210> 2128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2128

cuuaggcacc aaaaauuuau ccagc 25

<210> 2129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2129

uuaggcacca aaaauuuauc cagcc 25

<210> 2130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2130

aacaaaaaca uguccucauu uuauu 25

<210> 2131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2131

uuauuuggaa auaaacucuu guugu 25

<210> 2132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2132

aauaaacucu uguuguagga uagaa 25

<210> 2133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2133

ggauagaaag gaauuagugu auuau 25

<210> 2134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2134

agauucugca cuauuuacau auugc 25

<210> 2135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2135

gaagcuucug uugucauuca acugc 25

<210> 2136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2136

aagcuucugu ugucauucaa cugcu 25

<210> 2137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2137

agcuucuguu gucauucaac ugcug 25

<210> 2138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2138

gcuucuguug ucauucaacu gcugg 25

<210> 2139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2139

uucaacugcu ggggg 25

<210> 2140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2140

cuguugucau ucaacugcug gggga 25

<210> 2141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2141

uaugugaaag uaacccgcua uuaga 25

<210> 2142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2142

aacccgcuau uagauggugc cuuua 25

<210> 2143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2143

uacauacuuu acauacuuua gugca 25

<210> 2144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2144

acauacuuua cauacuuuag ugcaa 25

<210> 2145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2145

cauacuuuac auacuuuagu gcaag 25

<210> 2146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2146

aaaccugcgc ugacagacuc acugu 25

<210> 2147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2147

ugacagacuc acuguuggaa ugaga 25

<210> 2148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2148

gacagacuca cuguuggaau gagaa 25

<210> 2149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2149

agacucacug uuggaugag aaggg 25

<210> 2150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2150

guuggauga gaaggguggu cagaa 25

<210> 2151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2151

uuggaugag aagggugguc agaau 25

<210> 2152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2152

gaaugagaag gguggucaga aggg 25

<210> 2153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2153

gaaggguggu cagaauggga ggcag 25

<210> 2154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2154

aggauaacuu ccucuguaau cucac 25

<210> 2155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2155

ggauaacuuc cucuguaauc ucacu 25

<210> 2156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2156

agccucagca accuucacug cacac 25

<210> 2157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2157

cccucuuccc cuagagcaaa cuguu 25

<210> 2158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2158

ugcauguaca aacuauaaau cauau 25

<210> 2159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2159

ucaguuuucu auuacacaaa uaauu 25

<210> 2160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2160

ccuugaauag aaaucaaauu ucuug 25

<210> 2161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2161

guuaaguuuu gaguuuacag aaagu 25

<210> 2162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2162

guuuugaguu uacagaaagu uggua 25

<210> 2163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2163

gaaaguuggu aaggugcaca cagaa 25

<210> 2164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2164

aaaguuggua aggugcacac agaaa 25

<210> 2165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2165

aauuuucaac agugaagaaa uucac 25

<210> 2166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2166

uucacaggac uuguguuaaa cucua 25

<210> 2167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2167

uguguuaaac ucuauggcac acauu 25

<210> 2168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2168

guguuaaacu cuauggcaca cauua 25

<210> 2169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2169

uuagggaugu guaguuuuac aaaca 25

<210> 2170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2170

aguagcugag cuuuccugua ccauc 25

<210> 2171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2171

guaccaucag gaaagauuaa ccaau 25

<210> 2172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2172

gaaagauuaa ccaauggug acaga 25

<210> 2173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2173

aaagauuaac caauugguga cagau 25

<210> 2174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2174

uuggugacag augggaaugu gaaaa 25

<210> 2175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2175

uggugacaga ugggaaugug aaaau 25

<210> 2176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2176

uuugccauau uuagagauuua guuuu 25

<210> 2177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2177

uugccauauu agagauuuag uuuuu 25

<210> 2178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2178

uaguuuuugg guaaaguuua gugag 25

<210> 2179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2179

aaaagucucu cagcuguguu acagc 25

<210> 2180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2180

cucagcugug uuacagcugg uuauc 25

<210> 2181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2181

aagaaguuau acaaacuacu ucaaa 25

<210> 2182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2182

cuugccaauau agccauugca aaaau 25

<210> 2183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2183

uugccauaua gccauugcaa aaaua 25

<210> 2184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2184

auagccauug caaaaauagg gcguu 25

<210> 2185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2185

caaaaauagg gcguuaggua cagac 25

<210> 2186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2186

aaaaauaggg cguuagguac agaca 25

<210> 2187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2187

ggcguuaggu acagacaggg ccucu 25

<210> 2188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2188

aaccaucauc cacaguuuac ccagc 25

<210> 2189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2189

auccacaguu uacccagcag gucac 25

<210> 2190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2190

aguuuaccca gcaggucacu ggacu 25

<210> 2191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2191

cuggacuagg ugcucuauac caguu 25

<210> 2192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2192

uuuuuuuuuu uuuugacaag aauac 25

<210> 2193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2193

uacuggagau uugagucaau uuuug 25

<210> 2194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2194

ggucuucuga uagcuaagug ccauc 25

<210> 2195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2195

gauugauuaa uguuuagagu uuauu 25

<210> 2196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2196

auugauuaau guuuagaguu uauuu 25

<210> 2197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2197

agcaagcgua guucacuaaa uauaa 25

<210> 2198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2198

aaaaccagac aguaauagcu auaaa 25

<210> 2199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2199

25

<210> 2200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2200

aucaaaaaug cuauccuaac uauac 25

<210> 2201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2201

ucaaaaaugc uauccuaacu auaca 25

<210> 2202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2202

caaaaaugcu auccuaacua uacag 25

<210> 2203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2203

aaaaaugcua uccuaacuau acagg 25

<210> 2204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2204

aaaaugcuau ccuaacuaua caggg 25

<210> 2205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2205

aaaugcuauc cuaacuauac agggg 25

<210> 2206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2206

aaugcuaucc uaacuauaca ggggg 25

<210> 2207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2207

aagagaaagu ucaucacaca gacuu 25

<210> 2208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2208

agagaaaguu caucacacag acuuu 25

<210> 2209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2209

aguucaucac acagacuuug ggcac 25

<210> 2210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2210

ucaucacaca gacuuugggc acugg 25

<210> 2211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2211

cacagacuuu gggcacuggu gguuu 25

<210> 2212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2212

uuuaggugcc auccuucuuu gacug 25

<210> 2213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2213

cuguggagau uacguccaca uauua 25

<210> 2214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2214

uccacauauu aagguuucua auuuc 25

<210> 2215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2215

ccacauauua agguuucuaa uuucu 25

<210> 2216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2216

cucaacugcu ucuguugcca agucu 25

<210> 2217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2217

aaaaauaaaa caacaaaacc ucuac 25

<210> 2218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2218

aaagcuauua auucgacuuu cuuua 25

<210> 2219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2219

uucuuuaagg caaccauucu uauua 25

<210> 2220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2220

uuuugauauu uccauuugaa uauuu 25

<210> 2221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2221

ccauuugaau auuuugguau cugau 25

<210> 2222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2222

uuggugauga uuucagcuaa caucu 25

<210> 2223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2223

uggugaugau uucagcuaac aucuc 25

<210> 2224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2224

ggugaugauu ucagcuaaca ucucg 25

<210> 2225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2225

aacauucucgg ggaauucaau acuca 25

<210> 2226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2226

acucaugguc uuauccaaaa auguu 25

<210> 2227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2227

caaaaauguu uggaagcaau aguua 25

<210> 2228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2228

uuucaaccac cugcaagaga agaua 25

<210> 2229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2229

uagccauuua cagcaaugcc aaaua 25

<210> 2230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2230

accaaaccac acauuuguac cgaau 25

<210> 2231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2231

auuuuuucauuuuuuuugc uguuc 25

<210> 2232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2232

aaaugucaga cuguaaaacc uugug 25

<210> 2233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2233

ggacaaaucu auauuauacu gugua 25

<210> 2234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2234

uuuguauauu aaaugcuaua uaaug 25

<210> 2235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2235

uuuuguauau uaaaugcuau auaau 25

<210> 2236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2236

auuuuguaua uuaaaugcua uauaa 25

<210> 2237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2237

ugaaaggauu uuauuuucug augaa 25

<210> 2238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2238

ugcuucucuc uagaaaaugu cugaa 25

<210> 2239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2239

ggauuuguga ccagguuuuc aggaa 25

<210> 2240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2240

acccaggauu agugaccagg uuuuc 25

<210> 2241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2241

ccugguccac ccaggauuag ugacc 25

<210> 2242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2242

uauuuucaag caaccugguc caccc 25

<210> 2243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2243

uuucccagac uauuuucaag caacc 25

<210> 2244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2244

aggaggacac uuuaaacccu uuggg 25

<210> 2245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2245

guaaggaga cacuuuaaac ccuuu 25

<210> 2246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2246

uguaaggagg acacuuuaaa cccuu 25

<210> 2247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2247

ucagaaggga aauaaaagug uaagg 25

<210> 2248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2248

gugucagaag ggaaauaaaa gugua 25

<210> 2249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2249

acacacagac guuuuagugu cagaa 25

<210> 2250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2250

cacacacaga cguuuuagug ucaga 25

<210> 2251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2251

cuggucacuc ccugacugua gcugu 25

<210> 2252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2252

ccuucaguga gauuuccauc uuggc 25

<210> 2253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2253

guagccuuca gugagauuuc caucu 25

<210> 2254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2254

uugaucuguc aaacuuccag aacca 25

<210> 2255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2255

aaaaacccug aaaacuacau cacca 25

<210> 2256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2256

acgcucccuu cagaauucag aggca 25

<210> 2257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2257

cacgcucccu ucagaauuca gaggc 25

<210> 2258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2258

aagccacgcu cccuucagaa uucag 25

<210> 2259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2259

gggaugagcu cugggcaugc cauga 25

<210> 2260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2260

ggauaauuag caugggauga gcucu 25

<210> 2261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2261

uggauaauua gcaugggaug agcuc 25

<210> 2262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2262

cuaugaagug cuggauaauu agcau 25

<210> 2263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2263

ucuaugaagu gcuggauaau uagca 25

<210> 2264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2264

aacaugauuu gugucuauga agugc 25

<210> 2265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2265

gggaggaaac cuuggccacc ccaaa 25

<210> 2266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2266

ugccuaaaac uaugggagga aaccu 25

<210> 2267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2267

auauccaaau gccuaaaacu aggg 25

<210> 2268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2268

uauauaucca aaugccuaaa acuau 25

<210> 2269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2269

auauauaucc aaaugccuaa aacua 25

<210> 2270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2270

aggcacuuag gacauaacac uuuug 25

<210> 2271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2271

gaggcacuua ggacauaaca cuuuu 25

<210> 2272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2272

ugaggcacuu aggacauaac acuuu 25

<210> 2273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2273

cuauacaagc agaacugagg cacuu 25

<210> 2274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2274

gugggauacu auacaagcag aacug 25

<210> 2275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2275

uuuuuagugu uuguagguau ucugu 25

<210> 2276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2276

auuuuuagug uuuguaggua uucug 25

<210> 2277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2277

ccugaaaagu auuuuuagug uuugu 25

<210> 2278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2278

aguuuguagu aacuucagug agagu 25

<210> 2279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2279

auuuauuucc uauguaugug uuauc 25

<210> 2280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2280

aauuguggau uuaagugcua uaugg 25

<210> 2281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2281

uuuaauugug gauuuaagug cuaua 25

<210> 2282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2282

aagucaucuu aauuauguuu aauug 25

<210> 2283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2283

agcugugccc uuuuaggaua cgugg 25

<210> 2284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2284

aagcugugcc cuuuuaggau acgug 25

<210> 2285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2285

gaagcugugc ccuuuuagga uacgu 25

<210> 2286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2286

agaagcugug cccuuuuagg auacg 25

<210> 2287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2287

augggaaaag aagcugugcc cuuuu 25

<210> 2288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2288

aacuauagga ggcuuuucau uaaau 25

<210> 2289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2289

caacuauagg aggcuuuuca uuaaa 25

<210> 2290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2290

acugaugcuc aucgacaacu auagg 25

<210> 2291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2291

ucaacugaug cucaucgaca acuau 25

<210> 2292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2292

aaucugauuu ucaucccaac aaucu 25

<210> 2293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2293

uaucauuccu uuauagaaug uuaug 25

<210> 2294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2294

uguguaaccc ggcuggauaa auuuu 25

<210> 2295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2295

auuuuaagau gguguguaac ccggc 25

<210> 2296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2296

uaauauuuua agauggugug uaacc 25

<210> 2297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2297

uaaaagggaa uguaauauuu uaaga 25

<210> 2298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2298

uuugcuuuuu gaaugcucuc uaaaa 25

<210> 2299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2299

auuugcuuuu ugaaugcucu cuaaa 25

<210> 2300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2300

auguuauuug uuauuuucag uauuu 25

<210> 2301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2301

caagaguuua uuuccaaaua aaaug 25

<210> 2302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2302

auauguaaau agugcagaau cucau 25

<210> 2303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2303

agaaguuugg cauaguuug cauag 25

<210> 2304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2304

aaugacaaca gaagcuucag aaguu 25

<210> 2305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2305

auccuuaaag gcaccaucua auagc 25

<210> 2306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2306

cauccuuaaa ggcaccaucu aauag 25

<210> 2307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2307

aggaaggugg ugcuuacauc cuuaa 25

<210> 2308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2308

aguauguaaa caggagacag gaagg 25

<210> 2309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2309

uaaaguaugu aaacaggaga cagga 25

<210> 2310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2310

uauguaaagu auguaaacag gagac 25

<210> 2311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2311

acuaaaguau guaaaguaug uaaac 25

<210> 2312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2312

auuccaacag ugagucuguc agcgc 25

<210> 2313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2313

aggcucugac ccagugagau uacag 25

<210> 2314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2314

guccugugug cagugaaggu ugcug 25

<210> 2315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2315

uggagacugg uccugugugc aguga 25

<210> 2316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2316

ucuagggggaa gagggagaug gagac 25

<210> 2317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2317

aguuugcucu aggggaagag ggaga 25

<210> 2318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2318

ccaaacaguu ugcucuaggg gaaga 25

<210> 2319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2319

accaaacagu uugcucuagg ggaag 25

<210> 2320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2320

ucagaaacca aacaguuugc ucuag 25

<210> 2321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2321

cucagaaacc aaacaguuug cucua 25

<210> 2322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2322

ucucagaaac caaacaguuu gcucu 25

<210> 2323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2323

guacaugcau ucauacaggc agcga 25

<210> 2324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2324

uuauaguuug uacaugcauu cauac 25

<210> 2325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2325

uuuguagggg ucaaagaaau gcuga 25

<210> 2326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2326

augacauguu auauauuuuu uguag 25

<210> 2327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2327

caugacaugu uauauauuuu uugua 25

<210> 2328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2328

ucaugacaug uuauauauuu uuugu 25

<210> 2329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2329

ccauaacacu aaucugggaa gggaa 25

<210> 2330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2330

accauaacac uaaucuggga aggga 25

<210> 2331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2331

uauaaccaua acacuaaucu gggaa 25

<210> 2332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2332

guauaaccau aacacuaauc ggga 25

<210> 2333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2333

uauaguauaa ccauaacacu aaucu 25

<210> 2334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2334

auauaguaua accauaacac uaauc 25

<210> 2335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2335

aacugaaaau cuaauauuaa aaaua 25

<210> 2336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2336

caagaaauuu gauuucuauu caagg 25

<210> 2337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2337

ccacaagaaa uuugauuucu auuca 25

<210> 2338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2338

auugguuaau cuuuccugau gguac 25

<210> 2339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2339

ucaccaauug guuaaucuuu ccuga 25

<210> 2340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2340

uuucacauuc ccaucuguca ccaau 25

<210> 2341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2341

aacuaaaucu cuaauauggc aaaaa 25

<210> 2342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2342

uuacccaaaa acuaaaucuc uaaua 25

<210> 2343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2343

aaagcuggua aacuauuugu cuuuc 25

<210> 2344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2344

ugcaauggcu auauggcaag aaagc 25

<210> 2345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2345

acgcccuauu uuugcaaugg cuaua 25

<210> 2346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2346

uguaccuaac gcccuauuuu ugcaa 25

<210> 2347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2347

acuaauuuaa aaaauaacua ccaag 25

<210> 2348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2348

gaccugcugg guaaacugug gauga 25

<210> 2349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2349

guccagugac cugcugggua aacug 25

<210> 2350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2350

agagcaccua guccagugac cugcu 25

<210> 2351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2351

uagagcaccu aguccaguga ccugc 25

<210> 2352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2352

gguugugcaa auuaacaguc cuaac 25

<210> 2353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2353

uaucugcuuc aguggagaau uauau 25

<210> 2354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2354

cauauuuugu auauaucugc uucag 25

<210> 2355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2355

aaauggguug gugcuucuaa ccuga 25

<210> 2356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2356

aucaaucauc ugugugaaaa ugggu 25

<210> 2357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2357

auuaaucaau caucugugug aaaau 25

<210> 2358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2358

cauuaaucaa ucaucugugugaaaa 25

<210> 2359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2359

aaguuauugu acagcuguuu aagau 25

<210> 2360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2360

caaguuauug uacagcuguu uaaga 25

<210> 2361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2361

ugugccuuuu auagcuauua cuguc 25

<210> 2362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2362

aaguuuacaa guguauauca gaaaa 25

<210> 2363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2363

aaaguuuaca aguguauauc agaaa 25

<210> 2364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2364

uaggauagca uuuuugauuu augca 25

<210> 2365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2365

ugguguaucc ccccccugua uaguu 25

<210> 2366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2366

ggaugaaauu uucuagacuu ucugu 25

<210> 2367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2367

cuucauacuu uuuuucacag uuggc 25

<210> 2368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2368

uucucuucau acuuuuuuuc acagu 25

<210> 2369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2369

cguaaucucc acagucaaag aagga 25

<210> 2370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2370

uggacguaau cuccacaguc aaaga 25

<210> 2371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2371

cccagaaauu agaaaccuua auaug 25

<210> 2372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2372

cacuuuucag ugagggaga guaga 25

<210> 2373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2373

ugagucguca ucacuuuuca gugau 25

<210> 2374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2374

uugagucguc aucacuuuuc aguga 25

<210> 2375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2375

augugguuua uagaggggcca agacu 25

<210> 2376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2376

auacgcacua caugugguuu auaga 25

<210> 2377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2377

aauacgcacu acaugugguu uauag 25

<210> 2378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2378

uuuuguuuua aauacgcacu acaug 25

<210> 2379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2379

uauaaacuau caguuugucc uguag 25

<210> 2380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2380

ucaaaaguga cugccuuaau aagaa 25

<210> 2381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2381

ccaaucagau accaaaauau ucaaa 25

<210> 2382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2382

cuuaacuauu gcuuccaaac auuuu 25

<210> 2383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2383

ucauuaccau aucuucucuu gcagg 25

<210> 2384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2384

caguugauaa aaccgcugcc aguuc 25

<210> 2385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2385

ugauaaaacc gcugccaguu cuggc 25

<210> 2386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2386

cuggaguuuc cuucccucuu gacaa 25

<210> 2387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2387

auggcuuuuc cuagcucuuu gaugu 25

<210> 2388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2388

cauucuaauu ucaucaaaua gcucu 25

<210> 2389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2389

gcucuuggcu cuucagaccg uccuu 25

<210> 2390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2390

cuucagaccg uccuuaggaa cuaaa 25

<210> 2391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2391

cgguuuuauc aacugacaaa acucu 25

<210> 2392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2392

aggaaacucc agccagaacu ggcag 25

<210> 2393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2393

gagggaagga aacuccagcc agaac 25

<210> 2394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2394

uaggaaaagc cauugucaag aggga 25

<210> 2395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2395

gagcuaggaa aagccauugu caaga 25

<210> 2396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2396

agagcuagga aaagccauug ucaag 25

<210> 2397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2397

uuagaaugac cuacaucaaa gagcu 25

<210> 2398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2398

aucuuaaccu uuuaguuccu aagga 25

<210> 2399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2399

cuucaucuua accuuuuagu uccua 25

<210> 2400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2400

uaaacaagua aaguuguuag uaucc 25

<210> 2401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2401

auccaggcac ugaauuauac cuuca 25

<210> 2402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2402

acuucuuuaa caaguguacc gcuac 25

<210> 2403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2403

aaacgucucu agcaaugauc uuuau 25

<210> 2404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2404

aacgucucua gcaaugaucu uuauc 25

<210> 2405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2405

aaaacauuaa gaugaaugug cgcuu 25

<210> 2406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2406

gcaacaucca uagcuuacag uuauu 25

<210> 2407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2407

gcaacuauga aaccacaguu acuaa 25

<210> 2408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2408

aaauguacuu auuuguauau gaaag 25

<210> 2409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2409

auugauaugu aauuuuuacu ugaaa 25

<210> 2410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2410

uguaauuuuu acuugaaaug gccua 25

<210> 2411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2411

aauaguaauu aagcacaccu uuucu 25

<210> 2412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2412

uuucucauac augcuaauac ucauu 25

<210> 2413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2413

aauuuuuaac caaauaacag uguag 25

<210> 2414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2414

augucuuccc augucaaag aucaa 25

<210> 2415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2415

cuucccauga ucaaagauca aagga 25

<210> 2416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2416

ccaugaucaa agaucaaagg aagga 25

<210> 2417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2417

ccauaccuau uugucuuauu aaucu 25

<210> 2418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2418

cauucauaaa aaucaucuga cuagu 25

<210> 2419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2419

gacuaguagg aaauaauagu agacu 25

<210> 2420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2420

uuauauaaa uuaaccuuug uuucu 25

<210> 2421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2421

cuucauauuu caugcuuuug acaua 25

<210> 2422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2422

uucaugcuuu ugacauaagg ugaaa 25

<210> 2423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2423

uaccaaccug aagagagaag cagua 25

<210> 2424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2424

gauaccua gccuguguaa cucag 25

<210> 2425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2425

ggaaacauac agcauguguu uacau 25

<210> 2426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2426

auguguuuac auggucgua caugc 25

<210> 2427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2427

uguguuuaca uuggucguac augca 25

<210> 2428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2428

ucucugccug ugaaagauaa auagc 25

<210> 2429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2429

cucugccugu gaaagauaaa uagca 25

<210> 2430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2430

uuguuuuuuuuuuuuuuuuuuuuuu 25

<210> 2431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2431

uaccaugaag guauaauuca gugcc 25

<210> 2432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2432

aucauagcuu ugauugauac cauga 25

<210> 2433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2433

uagagacguu uaauguuacc uguag 25

<210> 2434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2434

agaaguauua auaauauuuc aguca 25

<210> 2435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2435

ucaacaaaaa guuauuuuau guuaa 25

<210> 2436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2436

auaguugcca aauaacugua agcua 25

<210> 2437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2437

aaagucuuaa uuccauuagu aacug 25

<210> 2438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2438

ugaacuaguu gguauuauaa accuu 25

<210> 2439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2439

aaauuuuaaa gcucuaugaa cuagu 25

<210> 2440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2440

ugucagagau ucauuaucua gaaaa 25

<210> 2441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2441

ggauugguua acauagcaug ggagc 25

<210> 2442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2442

uauuggggau ugguuaacau agcau 25

<210> 2443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2443

cuauugggga uugguuaaca uagca 25

<210> 2444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2444

gggugcuua auuacuauug gggau 25

<210> 2445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2445

gaaaaggugu gcuuaauuac uauug 25

<210> 2446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2446

agaaaaggug ugcuuaauua cuauu 25

<210> 2447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2447

uagaaaaggu gugcuuaauu acuau 25

<210> 2448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2448

gggagaaaaa ggcgcauccu agaaa 25

<210> 2449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2449

auguaugaga aauuauggga gaaaa 25

<210> 2450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2450

aguauuagca uguaugagaa auuau 25

<210> 2451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2451

gaguauuagc auguaugaga aauua 25

<210> 2452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2452

ugauuuuguc cacuacacug uuauu 25

<210> 2453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2453

uuugaucuuu gaucauggga agaca 25

<210> 2454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2454

cuuccuuccu uugaucuuug aucau 25

<210> 2455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2455

ccuuccuucc uuugaucuuu gauca 25

<210> 2456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2456

aacagagagg uauaugagcu gcaua 25

<210> 2457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2457

aaacagagag guauaugagc ugcau 25

<210> 2458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2458

acaaauaggu auggcagaaa cagag 25

<210> 2459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2459

ccaagauuaa uaagacaaau aggua 25

<210> 2460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2460

ugacaccaag auuaauaaga caaau 25

<210> 2461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2461

uuuuuaugaa uguaaaauau uagaa 25

<210> 2462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2462

augaaauaug aaggccuaga aacaa 25

<210> 2463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2463

cuuaugucaa aagcaugaaa uauga 25

<210> 2464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2464

aaccuuacug cuucucucuu caggu 25

<210> 2465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2465

ugaaaaccuu acugcuucuc ucuuc 25

<210> 2466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2466

guuuccucug aguuacacag gcuuc 25

<210> 2467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2467

gcuguauguu uccucugagu uacac 25

<210> 2468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2468

caacuuacuc auuaauaauc agauc 25

<210> 2469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2469

aucagauca ggagcaaaac acagc 25

<210> 2470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2470

agagcaaaug ccauaagaaa caucc 25

<210> 2471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2471

aagaaacauc caggaguacu gcagu 25

<210> 2472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2472

agaaacaucc aggaguaacug cagua 25

<210> 2473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2473

ccaggaguac ugcaguaggg ucauu 25

<210> 2474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2474

cugcaguagg gucauuuggu caucc 25

<210> 2475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2475

cugaaaccug aauuaagaga aauaa 25

<210> 2476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2476

guuucuuaug gcauuugcuc ugggg 25

<210> 2477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2477

gauguuucuu aggcauuug cucug 25

<210> 2478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2478

ggauguuucu uauggcauuu gcucu 25

<210> 2479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2479

uggauguuuc uuauggcauu ugcuc 25

<210> 2480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2480

cugcaguacu ccuggauguu ucuua 25

<210> 2481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2481

ccaaaugacc cuacugcagu acucc 25

<210> 2482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2482

aauucagguu ucaggaacuu acacc 25

<210> 2483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2483

cuuuauuucu cuuaauucag guuuc 25

<210> 2484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2484

gcucuuuuau guuuugcauc uuacc 25

<210> 2485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2485

uagucaugau ccuccaaguu gaguc 25

<210> 2486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2486

uaucauaucc ugcauauaac acuuc 25

<210> 2487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2487

uucaauaacc uccaacagug acacc 25

<210> 2488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2488

ucauaaccu ccaacaguga cacca 25

<210> 2489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2489

uaaccuccaa cagugacacc agggu 25

<210> 2490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2490

aaccuccaac agugacacca gggua 25

<210> 2491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2491

accuccaaca gugacaccag gguag 25

<210> 2492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2492

gugacaccag gguaggggug aguug 25

<210> 2493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2493

uaggggugag uugugguaac guugc 25

<210> 2494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2494

uugcaggaac uauuguuuug uuacc 25

<210> 2495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2495

auuguuuugu uaccaggauu uucag 25

<210> 2496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2496

gagguuucuu gugagacucc uguag 25

<210> 2497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2497

auuuuuuucu uuguuuuucg agcug 25

<210> 2498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2498

uuuuuuucuu uguuuuucga gcugu 25

<210> 2499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2499

cagugaaaug ggcaaaggca auacc 25

<210> 2500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2500

gugauugcag cagugaaaug ggcaa 25

<210> 2501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2501

cggcaaguga uugcagcagu gaaau 25

<210> 2502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2502

gcggcaagug auugcagcag ugaaa 25

<210> 2503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2503

gacuacgcuc aacauguuag gaggg 25

<210> 2504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2504

caugacuacg cucaacaugu uagga 25

<210> 2505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2505

ucaugacuac gcucaacaug uuagg 25

<210> 2506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2506

ggaucaugac uacgcucaac auguu 25

<210> 2507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2507

uagcucuguu ccagacucaa cuugg 25

<210> 2508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2508

ugauagcucu guuccagacu caacu 25

<210> 2509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2509

uuuugaacc ugaaguguua uaugc 25

<210> 2510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2510

accccuaccc ugggugucacu guugg 25

<210> 2511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2511

cucugguguc acugu 25

<210> 2512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2512

acguuaccac aacucacccc uaccc 25

<210> 2513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2513

ucucacaaga aaccucugaa aaucc 25

<210> 2514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2514

uaaaaggaau ucagcaggcc acuac 25

<210> 2515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2515

aagaaaaaaa uaaaaggaau ucagc 25

<210> 2516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2516

cucgaaaaac aaagaaaaaa auaaa 25

<210> 2517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2517

cuuucagaua uuuauauuac cuucc 25

<210> 2518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2518

uccagccuga agacauuuuc gauag 25

<210> 2519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2519

gaagacauuu ucgauagcgg caugc 25

<210> 2520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2520

aagacauuuu cgauagcggc augcu 25

<210> 2521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2521

gaugcaauca uuccuuccag cacau 25

<210> 2522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2522

acauagguaa uugugcuguc cuaua 25

<210> 2523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2523

auugugcugu ccuuaugga auaaa 25

<210> 2524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2524

gucuucaggc uggaaugaac cugga 25

<210> 2525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2525

aaaugucuuc aggcuggaau gaacc 25

<210> 2526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2526

gccgcuaucg aaaaugucuu caggc 25

<210> 2527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2527

gcaugccgcu aucgaaaaug ucuuc 25

<210> 2528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2528

acagcacaau uaccuaugug cugga 25

<210> 2529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2529

uaggacagca caauuaccua ugugc 25

<210> 2530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2530

uccugaagcu ucaucaagc acacc 25

<210> 2531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2531

ucaucagagc acaccaggca gaguu 25

<210> 2532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2532

caucagagca caccaggcag aguuu 25

<210> 2533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2533

caggcacac caggcagagu uuggg 25

<210> 2534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2534

agcacaccag gcagaguuug ggagg 25

<210> 2535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2535

ggagggguc cuguuguugc uguug 25

<210> 2536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2536

gguccuguug uugcuguuga ggagc 25

<210> 2537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2537

cuguuguugc uguugaggag cugga 25

<210> 2538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2538

uuguugcugu ugaggagcug gaugg 25

<210> 2539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2539

agcuggaugg aggagcuu acauc 25

<210> 2540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2540

ggagagcuua caucuggucu caugc 25

<210> 2541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2541

gagagcuuac aucggucuc augcu 25

<210> 2542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2542

agagcuuaca ucuggucuca ugcug 25

<210> 2543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2543

ucuggucuca ugcuggggcu aaaga 25

<210> 2544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2544

cuggucucau gcuggggcua aagaa 25

<210> 2545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2545

uggucucaug cuggggcuaa agaag 25

<210> 2546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2546

aaguuuucuu caaaagagca gugga 25

<210> 2547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2547

uguaaaguuu ucuucaaaag agcag 25

<210> 2548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2548

gaugucauua uggagucuua acuug 25

<210> 2549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2549

cugaugaagc uucaggaugu cauua 25

<210> 2550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2550

gccuggugug cucugaugaa gcuuc 25

<210> 2551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2551

acaggaccac cucccaaacu cugcc 25

<210> 2552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2552

cauccagcuc cucaacagca acaac 25

<210> 2553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2553

agccauuaga aaaaacuguu cgacc 25

<210> 2554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2554

gccauuagaa aaaacuguuc gacca 25

<210> 2555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2555

agucaaguug ucaucuccag auccu 25

<210> 2556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2556

gauccuuggc accuauucca auuuu 25

<210> 2557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2557

caccuauucc aauuuucgga accaa 25

<210> 2558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2558

accuauucca auuuucggaa ccaac 25

<210> 2559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2559

uccaauuuuc ggaaccaacg ggaau 25

<210> 2560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2560

aauuuucgga accaacggga auugg 25

<210> 2561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2561

gaauuggugg augacauua aaaau 25

<210> 2562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2562

aggcuucuga uccugcuguu gagaa 25

<210> 2563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2563

ggcuucugau ccugcuguug agaaa 25

<210> 2564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2564

aagggaugcu guauucaugu cauag 25

<210> 2565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2565

ucauaguggu acaucugucc uccag 25

<210> 2566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2566

gagguacuca caccaugaac agaaa 25

<210> 2567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2567

uuuuauuacc aauuauauuu gcucc 25

<210> 2568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2568

ccaguuucuc uugcuuaauu acccc 25

<210> 2569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2569

caguuucucu ugcuuaauua cccca 25

<210> 2570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2570

aguuucucuu gcuuaauuac cccag 25

<210> 2571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2571

gaaaucuucu uuuucuguuu ucacu 25

<210> 2572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2572

aaaucuucuu uuucuguuuu cacuu 25

<210> 2573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2573

aaucuucuuuuucuguuuuc acuug 25

<210> 2574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2574

uucacuuggg gcaguguuac auuac 25

<210> 2575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2575

ucacuugggg caguguuaca uuacu 25

<210> 2576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2576

cacuuggggc aguguuacau uacug 25

<210> 2577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2577

accagaucuc cauuauccuu aauuu 25

<210> 2578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2578

ccagaucucc auuauccuua auuuu 25

<210> 2579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2579

uauccuuaau uuuggguuua guguc 25

<210> 2580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2580

uggguuuagu guccgguaaa augag 25

<210> 2581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2581

guccucauuc gaguuuccuu ccaaa 25

<210> 2582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2582

ggaaugaauc gucuucuccc gccag 25

<210> 2583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2583

aagcaaacag uuuucaucua ucaac 25

<210> 2584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2584

caucuaucaa caggucugau cucca 25

<210> 2585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2585

aaggacucuc auucgucucu uuacc 25

<210> 2586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2586

aggacucuca uucgucucuu uaccu 25

<210> 2587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2587

ggacucucau ucgucucuuu accug 25

<210> 2588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2588

aacuccaaau ccugcaaaau gucaa 25

<210> 2589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2589

auccugcaaa augucaaagg ugcuu 25

<210> 2590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2590

aaaaugucaa aggugcuuug gucug 25

<210> 2591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2591

guauacaauu ucacauugcc accgu 25

<210> 2592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2592

cacauugcca ccguuggugc caguc 25

<210> 2593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2593

cugaagauac aucagaguga guuuu 25

<210> 2594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2594

ugaguuuuug gaaacuccuu cucug 25

<210> 2595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2595

gaguuuuugg aaacuccuuc ucugu 25

<210> 2596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2596

aguuuuugga aacuccuucu cugug 25

<210> 2597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2597

guuuuuggaa acuccuucuc ugugg 25

<210> 2598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2598

ucuguggggg cagcagacac agcag 25

<210> 2599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2599

gacacagcag uggaugcuga acucu 25

<210> 2600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2600

acacagcagu ggaugcugaa cucuu 25

<210> 2601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2601

cacagcagug gaugcugaac ucuug 25

<210> 2602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2602

uggaugcuga acucuugggg uucuc 25

<210> 2603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2603

gaacucuugg gguucucugg aacac 25

<210> 2604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2604

cucuggaaca cuggucgacc uauug 25

<210> 2605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2605

aaaagcuuua agucuguuuc ccccg 25

<210> 2606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2606

cuuuaagucu guuucccccg aggaa 25

<210> 2607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2607

uguuuccccc gaggaaaggc ugauu 25

<210> 2608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2608

aggaaaggcu gauuuggccc ugcug 25

<210> 2609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2609

ggaaaggcug auuuggcccu gcugu 25

<210> 2610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2610

gauuuggccc ugcuggggga auccc 25

<210> 2611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2611

agucccauug agagugaaac ugcuu 25

<210> 2612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2612

agagugaaac ugcuuuggac agauc 25

<210> 2613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2613

gcugcgcauu gcuuacugag ccuuu 25

<210> 2614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2614

aaaucaacca aaagucuucg cugcu 25

<210> 2615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2615

ucugauugag aagcgacagc cagug 25

<210> 2616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2616

cugauugaga agcgacagcc aguga 25

<210> 2617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2617

aaccuucaca guagcuccuc cucuu 25

<210> 2618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2618

accuucacag uagcuccucc ucuua 25

<210> 2619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2619

ccccucuccu gagcaagcac acugc 25

<210> 2620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2620

cccucuccug agcaagcaca cugcu 25

<210> 2621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2621

ccucuccuga gcaagcacac ugcug 25

<210> 2622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2622

cacugcuggg guuuucuucu cuacc 25

<210> 2623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2623

ucucuaccag gaguuaauga uucuu 25

<210> 2624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2624

ucaacuacaa aacaaaaaac aaaaa 25

<210> 2625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2625

aaaac 25

<210> 2626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2626

aacaguuuuu ucuaauggcu auuca 25

<210> 2627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2627

ucccuggucg aacaguuuuu ucuaa 25

<210> 2628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2628

cuucucuggg gacucugaac uuccc 25

<210> 2629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2629

uggagaugac aacuugacuu cucug 25

<210> 2630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2630

cuggagauga caacuugacu ucucu 25

<210> 2631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2631

ucggagaug acaacuugac uucuc 25

<210> 2632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2632

aaaauuggaa uaggugccaa ggauc 25

<210> 2633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2633

guuccgaaaa uuggaauagg ugcca 25

<210> 2634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2634

ucccguuggu uccgaaaauu ggaau 25

<210> 2635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2635

accaauuccc guugguuccg aaaau 25

<210> 2636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2636

uuaaugucuau uccaccaauu cccgu 25

<210> 2637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2637

aauacagcau cccuuucuca acagc 25

<210> 2638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2638

cuguucaugg ugugaguacc ucugg 25

<210> 2639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2639

uuucuguuca uggugugagu accuc 25

<210> 2640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2640

auaaaauguc ugccauuucu guuca 25

<210> 2641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2641

caagcuuucc uggagcaaau auaau 25

<210> 2642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2642

caguuuacug ucaggcaagc uuucc 25

<210> 2643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2643

gagaaacugg gcacaguuua cuguc 25

<210> 2644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2644

cugggguaau uaagcaagag aaacu 25

<210> 2645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2645

ccugggguaa uuaagcaaga gaaac 25

<210> 2646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2646

gauuucaucg aacucugcac cccug 25

<210> 2647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2647

agauuucauc gaacucugca ccccu 25

<210> 2648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2648

aagauuucau cgaacucugc acccc 25

<210> 2649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2649

cccaaaauua aggauaaugg agauc 25

<210> 2650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2650

acacuaacc caaaauuaag gauaa 25

<210> 2651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2651

uuaccggaca cuaaacccaa aauua 25

<210> 2652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2652

gaggacugca agccucucau uuuac 25

<210> 2653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2653

uuccuuuugg aaggaaacuc gaaug 25

<210> 2654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2654

gagaagacga uucauuccuu uugga 25

<210> 2655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2655

gcggggagaag acgauucauu ccuuu 25

<210> 2656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2656

aaaacuguuu gcuuucuccu cuggc 25

<210> 2657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2657

gaaaacuguu ugcuuucucc ucugg 25

<210> 2658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2658

gaugaaaacu guuugcuuuc uccuc 25

<210> 2659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2659

agguaaagag acgaaugaga guccu 25

<210> 2660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2660

auuuggaguu uucuucuggg ucccc 25

<210> 2661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2661

uuugcaggau uuggaguuuu cuucu 25

<210> 2662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2662

uuuugcagga uuuggaguuu ucuuc 25

<210> 2663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2663

agcaccuuug acauuuugca ggauu 25

<210> 2664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2664

gaccaaagca ccuuugacau uuugc 25

<210> 2665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2665

ugaagggcca gacuggcacc aacgg 25

<210> 2666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2666

auuugaaggg ccagacuggc accaa 25

<210> 2667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2667

aacagcaaca uuugaagggc cagac 25

<210> 2668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2668

uaucuucaga acagcaacau uugaa 25

<210> 2669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2669

guaucuucag aacagcaaca uuuga 25

<210> 2670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2670

gcugugucug cugcccccac agaga 25

<210> 2671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2671

ggaagaaagc auugcaaacc ucaau 25

<210> 2672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2672

ucgggggaaa cagacuuaaa gcuuu 25

<210> 2673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2673

cagggccaaa ucagccuuuc cucgg 25

<210> 2674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2674

gcagggccaa aucagccuuu ccucg 25

<210> 2675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2675

agcaggggcca aaucagccuu ucuc 25

<210> 2676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2676

cagcagggcc aaaucagccu uuccu 25

<210> 2677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2677

gaaaugaccu gggauuccca cagca 25

<210> 2678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2678

ggaaaugacc ugggauuccc acagc 25

<210> 2679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2679

aaacaaaagu gaugggaaau gaccu 25

<210> 2680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2680

gaaacaaaag ugagggaaa ugacc 25

<210> 2681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2681

ugggaggac agaaacaaaa gugau 25

<210> 2682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2682

augggagaga cagaaacaaa aguga 25

<210> 2683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2683

uuucacucuc aaugggacug uauau 25

<210> 2684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2684

guuucacucu caaugggacu guaua 25

<210> 2685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2685

uguccaaagc aguuucacuc ucaau 25

<210> 2686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2686

cuguccaaag caguuucacu cucaa 25

<210> 2687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2687

gaagacuuuu gguugauuuu ccaaa 25

<210> 2688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2688

ucagacucca agcagcgaag acuuu 25

<210> 2689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2689

aagguuucug cgucuucacc cucac 25

<210> 2690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2690

acccuaagag gaggagcuac uguga 25

<210> 2691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2691

uggacuucua uaaaacccua agagg 25

<210> 2692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2692

ugauggacuu cuauaaaacc cuaag 25

<210> 2693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2693

cuugcucagg agaggggaga uguga 25

<210> 2694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2694

ccagcagugu gcuugcucag gagag 25

<210> 2695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2695

cccagcagug ugcuugcuca ggaga 25

<210> 2696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2696

ccccagcagu gugcuugcuc aggag 25

<210> 2697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2697

gaaaacccca gcagugugcu ugcuc 25

<210> 2698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2698

uggacuccaa agaaucauua acucc 25

<210> 2699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2699

uuguuuugua guugauauuc acuga 25

<210> 2700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2700

ccccccccgc cucgcuucuu accuc 25

<210> 2701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2701

ccgccucgcu ucuuaccucu ggcag 25

<210> 2702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2702

aaacaacuua gcuugugaac gcaga 25

<210> 2703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2703

cuuagcuugu gaacgcagaa ggagc 25

<210> 2704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2704

agcuugugaa cgcagaagga gcagg 25

<210> 2705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2705

gcuugugaac gcagaaggag cagga 25

<210> 2706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2706

aaauauauuuuuuuuuucua aaaaa 25

<210> 2707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2707

aaguaaacag cgccccuuu cucca 25

<210> 2708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2708

aguaaacagc cgccccuuuc uccau 25

<210> 2709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2709

aaacagccgc cccuuucucc auggg 25

<210> 2710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2710

aacagccgcc ccuuucucca ugggu 25

<210> 2711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2711

acagccgccc cuuuucuccau gggug 25

<210> 2712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2712

cagccgcccc uuucuccaug ggugg 25

<210> 2713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2713

agccgccccu uucuccaugg guggg 25

<210> 2714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2714

gacaagccag cccuccgcc cgcgc 25

<210> 2715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2715

acaagccagc ccuccgcccc gcgcc 25

<210> 2716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2716

gcccuccgcc ccgcgccgggg cuccg 25

<210> 2717

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2717

cccuccgccc cgcgccggggc uccgc 25

<210> 2718

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2718

gccccgcgcc gggcuccgcg ggucg 25

<210> 2719

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2719

cgccgggcuc cgcgggucga gguuc 25

<210> 2720

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2720

gccgggcucc gcgggucgag guucc 25

<210> 2721

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2721

gguuccgggc gcgcgugccc cgucc 25

<210> 2722

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2722

ugccccgucc cggucccagc ugcuu 25

<210> 2723

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2723

ccggucccag cugcuucggc cgcuc 25

<210> 2724

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2724

ccagcugcuu cggccgcucc ggcug 25

<210> 2725

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2725

uuccaccac agaauccguc cccga 25

<210> 2726

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2726

uccaccaca gaauccgucc ccgac 25

<210> 2727

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2727

cccacagaau ccguccccga cgggc 25

<210> 2728

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2728

acagaauccg uccccgacgg gcagg 25

<210> 2729

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2729

cguccccgac gggcaggcgg ugacu 25

<210> 2730

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2730

guccccgacg ggcaggcggu gacuc 25

<210> 2731

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2731

ccgucacaga cacgagcucg caaaa 25

<210> 2732

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2732

ucacagacac gagcucgcaa aaugg 25

<210> 2733

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2733

cagacacgag cucgcaaaau ggagg 25

<210> 2734

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2734

acacgagcuc gcaaaaugga ggagg 25

<210> 2735

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2735

cgagcucgca aaauggagga ggcgg 25

<210> 2736

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2736

gcucgcaaaa uggaggaggc ggcgg 25

<210> 2737

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2737

cgcaaaaugg aggaggcggc ggcgg 25

<210> 2738

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2738

gcaaaaugga ggaggcggcg gcgga 25

<210> 2739

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2739

aggcggcggc ggagggaaga gagcg 25

<210> 2740

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2740

agggaagaga gcgcggacac gcgaa 25

<210> 2741

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2741

gggaagagag cgcggacacg cgaaa 25

<210> 2742

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2742

agcgcggaca cgcgaaaggg cagcc 25

<210> 2743

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2743

ggacacgcga aagggcagcc cggcc 25

<210> 2744

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2744

gacacgcgaa agggcagccc ggccu 25

<210> 2745

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2745

gggcagccg gccugggcga gcgag 25

<210> 2746

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2746

ggcagcccgg ccugggcgag cgagc 25

<210> 2747

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2747

gccugggcga gcgagcggga ccgag 25

<210> 2748

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2748

ccugggcgag cgagcgggac cgagc 25

<210> 2749

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2749

cugggcgagc gagcgggacc gagcg 25

<210> 2750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2750

cgagcgagcg ggaccgagcg gggag 25

<210> 2751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2751

gagcgagcgg gaccgagcgg ggagc 25

<210> 2752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2752

cgagcggggac cgagcgggga gcggg 25

<210> 2753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2753

gcgggaccga gcggggagcg ggugg 25

<210> 2754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2754

ggaccgagcg gggagcgggu ggagg 25

<210> 2755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2755

cggggagcgg guggaggcgg cgcca 25

<210> 2756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2756

cagagguaag aagcgaggcg ggagg 25

<210> 2757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2757

ccagagguaa gaagcgaggc gggag 25

<210> 2758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2758

gccagaggua agaagcgagg cggga 25

<210> 2759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2759

ugccagaggu aagaagcgag gcggg 25

<210> 2760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2760

cucugccaga gguaagaagc gaggc 25

<210> 2761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2761

ccucugccag agguaagaag cgagg 25

<210> 2762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2762

gcuccucugc cagagguaag aagcg 25

<210> 2763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2763

ggcgggcgag cggcuccucu gccag 25

<210> 2764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2764

ggaacugcgg acgguggcgg gcgag 25

<210> 2765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2765

ugcggcggga acugcggacg guggc 25

<210> 2766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2766

cugcggcgg aacugcggac ggugg 25

<210> 2767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2767

cggcugcggc gggaacugcg gacgg 25

<210> 2768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2768

ucucggcugc ggcgggaacu gcgga 25

<210> 2769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2769

uuuaucucgg cugcggcgg aacug 25

<210> 2770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2770

cuaaguuguu uaucuccggcu gcggc 25

<210> 2771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2771

gcuaaguugu uuaucuccggc ugcgg 25

<210> 2772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2772

caagcuaagu uguuuaucuc ggcug 25

<210> 2773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2773

cguucacaag cuaaguuguu uaucu 25

<210> 2774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2774

cuccccccac ccauggagaa agggg 25

<210> 2775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2775

gcucuccccc cacccaugga gaaag 25

<210> 2776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2776

ggcucucccc ccacccaugg agaaa 25

<210> 2777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2777

gggcucuccc cccacccaug gagaa 25

<210> 2778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2778

uaaauagggg cucucccccc accca 25

<210> 2779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2779

ggcaauggga gacuuucuua aauag 25

<210> 2780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2780

gggcaauggg agacuuucuu aaaua 25

<210> 2781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2781

ugggcaaugg gagacuuucu uaaau 25

<210> 2782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2782

agggcuggcu ugucagcugg gcaau 25

<210> 2783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2783

gagggcuggc uugucagcug ggcaa 25

<210> 2784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2784

ggggcgggagg gcuggcuugu cagcu 25

<210> 2785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2785

cggggcggag ggcuggcuug ucagc 25

<210> 2786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2786

cggagccgg cgcggggcgg aggc 25

<210> 2787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2787

ccggcggagc ccggcgcggg gcgga 25

<210> 2788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2788

acccgcggag cccggcgcgg ggcgg 25

<210> 2789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2789

ucgacccgcg gagcccggcg cgggg 25

<210> 2790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2790

accucgaccc gcggagcccg gcgcg 25

<210> 2791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2791

aaccucgacc cgcggagccc ggcgc 25

<210> 2792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2792

gaaccucgac ccgcggagcc cggcg 25

<210> 2793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2793

gcccggaacc ucgaccgcg gagcc 25

<210> 2794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2794

cacgcgcgcc cggaaccucg acccg 25

<210> 2795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2795

gggaccggga cggggcacgc gcgcc 25

<210> 2796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2796

ggccgaagca gcugggaccg ggacg 25

<210> 2797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2797

cggccgaagc agcugggacc gggac 25

<210> 2798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2798

gcggccgaag cagcugggac cggga 25

<210> 2799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2799

cggagcggcc gaagcagcug ggacc 25

<210> 2800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2800

ccggagcggc cgaagcagcu gggac 25

<210> 2801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2801

cgcagccgga gcggccgaag cagcu 25

<210> 2802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2802

ccgcagccgg agcggccgaa gcagc 25

<210> 2803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2803

guggaaggag acgccgcagc cggag 25

<210> 2804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2804

uggggugga aggagacgcc gcagc 25

<210> 2805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2805

gucggggacg gauucugugg gugga 25

<210> 2806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2806

gcccgucggg gacggauucu guggg 25

<210> 2807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2807

ccugcccguc ggggacggau ucugu 25

<210> 2808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2808

gccugcccgu cggggacggga uucug 25

<210> 2809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2809

cgagucaccg ccugcccguc gggga 25

<210> 2810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2810

agcccgaguc accgccugcc cgucg 25

<210> 2811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2811

gagcccgagu caccgccugc ccguc 25

<210> 2812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2812

ggagcccgag ucaccgccug cccgu 25

<210> 2813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2813

cauuuugcga gcucgugucu gugac 25

<210> 2814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2814

ccauuuugcg agcucguguc uguga 25

<210> 2815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2815

ucggucccgc ucgcucccc aggcc 25

<210> 2816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2816

cucggucccg cucgcucgcc caggc 25

<210> 2817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2817

cccgcucggu cccgcucgcu cgccc 25

<210> 2818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2818

gcgccgccuc cacccgcucc ccgcu 25

<210> 2819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2819

agcggggguc ggcgcauacg uacuu 25

<210> 2820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2820

gcgggggucg gcgcauacgu acuuu 25

<210> 2821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2821

ggucggcgca uacguacuuu gggcc 25

<210> 2822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2822

gucggcgcau acguacuuug ggccc 25

<210> 2823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2823

ucggcgcaua cguacuuugg gcccg 25

<210> 2824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2824

cggcgcauac guacuuuggg cccgg 25

<210> 2825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2825

ggcgcauacg uacuuugggc ccggg 25

<210> 2826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2826

uuugggccg gggggagucg cgugc 25

<210> 2827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2827

ggcccgggggg gagucgcgug ccggc 25

<210> 2828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2828

gcaggucccc caccaccgca ucauc 25

<210> 2829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2829

cagguccccc accaccgcau caucu 25

<210> 2830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2830

gucccccacc accgcaucau cuggg 25

<210> 2831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2831

cccaccaccg caucaucugg gcggc 25

<210> 2832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2832

ccaccaccgc aucaucuggg cggcc 25

<210> 2833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2833

agcugccgcc gccgcgcucu cgcac 25

<210> 2834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2834

gcugccgccg ccgcgcucuc gcacu 25

<210> 2835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2835

gaccugccgg cacgcgacuc ccccc 25

<210> 2836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2836

ggaccugccg gcacgcgacu ccccc 25

<210> 2837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2837

gaugaugcgg uggggggga ccugc 25

<210> 2838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2838

ggccgcccag augaugcggu ggugg 25

<210> 2839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2839

cggccgccca gaugaugcgg uggug 25

<210> 2840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2840

ccggccgccc agaugaugcg guggu 25

<210> 2841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2841

cccggccgcc cagaugaugc ggugg 25

<210> 2842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2842

agacccggcc gcccagauga ugcgg 25

<210> 2843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2843

ugaagaccg gccgcccaga ugaug 25

<210> 2844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2844

agcgcggcgg cggcagcuga agacc 25

<210> 2845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2845

cucucccagu gcgagagcgc ggcgg 25

<210> 2846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2846

cuucucuccc agugcgagag cgcgg 25

<210> 2847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2847

caacuucucu cccagugcga gagcg 25

<210> 2848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2848

gaagcaaagu cuucuuuguu cuuug 25

<210> 2849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2849

aaagucuucu uuguucuuug aggaa 25

<210> 2850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2850

ucuuuguucu uugaggaaag gagcc 25

<210> 2851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2851

aggcagauga aaauuccugu uauua 25

<210> 2852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2852

guuauuaagg uacaacuaaa gcccg 25

<210> 2853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2853

auuaagguac aacuaaagcc cgagg 25

<210> 2854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2854

uuaagguaca acuaaagccc gagga 25

<210> 2855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2855

gguacaacua aagcccgagg agggu 25

<210> 2856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2856

guuccucccc auucucgcac agaga 25

<210> 2857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2857

aagugcuuau caaaguuaau aucug 25

<210> 2858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2858

ccucugcagc agucgucaca gaagc 25

<210> 2859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2859

ucgucacaga agcuggcccc uuucc 25

<210> 2860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2860

cgucacagaa gcuggccccu uuccu 25

<210> 2861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2861

uuucagauca gaagauccug ucucu 25

<210> 2862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2862

uucagaucag aagauccugu cucuc 25

<210> 2863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2863

cucucgggua uaacuuuuuu uuuuu 25

<210> 2864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2864

agaaauacag ugacucuccu aauua 25

<210> 2865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2865

ccacugauuc agcagauauu ccccc 25

<210> 2866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2866

agauauuccc ccaggcagau ccuaa 25

<210> 2867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2867

agauccuaau ggaaaccaac augug 25

<210> 2868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2868

gaaaccaaca ugugaggucu gaugc 25

<210> 2869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2869

aaaccaacau gugaggucug augcu 25

<210> 2870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2870

gcugggaauu uuaucaugcu caaca 25

<210> 2871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2871

cccacucaug ccccagugcu uccgu 25

<210> 2872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2872

uuccguugga cacaugcgca uuuua 25

<210> 2873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2873

acacaugcgc auuuuacggu ccugc 25

<210> 2874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2874

cacaugcgca uuuuacgguc cugca 25

<210> 2875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2875

ggcuugaaag auuucugacc uucua 25

<210> 2876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2876

ucugaccuuc uaagguccag ugauu 25

<210> 2877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2877

agaagaggaa gagguaccuu uugaa 25

<210> 2878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2878

gaagaggaag agguaccuuu ugaau 25

<210> 2879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2879

aagaggaaga gguaccuuuu gaaug 25

<210> 2880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2880

cccuuacaua accugaccac acaau 25

<210> 2881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2881

uuacauaacc ugaccacaca auagg 25

<210> 2882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2882

cuuugcuuca uuaaaguguc ugaga 25

<210> 2883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2883

uuaauaacag gaauuuucau cugcc 25

<210> 2884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2884

cgggcuuuag uuguaccuua auaac 25

<210> 2885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2885

acaaaaugca gcuccuaccc uccuc 25

<210> 2886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2886

aacaaaaugc agcuccuacc cuccu 25

<210> 2887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2887

gugccuucuc ugugcgagaa ugggg 25

<210> 2888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2888

ugagugccuu cucugugcga gaaug 25

<210> 2889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2889

augagugccu ucucugugcg agaau 25

<210> 2890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2890

aaugagugcc uucucugugc gagaa 25

<210> 2891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2891

cuucugugac gacugcugca gaggc 25

<210> 2892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2892

ccagcuucug ugacgacugc ugcag 25

<210> 2893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2893

ucucagagca guuagcccag gaaag 25

<210> 2894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2894

cucucagagc aguuagccca ggaaa 25

<210> 2895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2895

gcucucagag caguuagccc aggaa 25

<210> 2896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2896

cuggugcucu cagagcaguu agccc 25

<210> 2897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2897

gucauaucua agucagauuu cauuc 25

<210> 2898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2898

uguguagcug gcuucuucug aaaaa 25

<210> 2899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2899

auuuguucau caagaguuguguagc 25

<210> 2900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2900

aaauucucug guuugugcuc aucgu 25

<210> 2901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2901

aauuuucuuc acuucugaaa uucuc 25

<210> 2902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2902

aaaaaaaaag uuauacccga gagac 25

<210> 2903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2903

cugaacuagg aaauucacca uaauu 25

<210> 2904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2904

ugaaucagug gcucugagcu gaacu 25

<210> 2905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2905

ccgggggaa uaucugcuga aucag 25

<210> 2906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2906

uugguuucca uuaggaucug ccugg 25

<210> 2907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2907

guugguuucc auuaggaucu gccug 25

<210> 2908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2908

uguugguuuc cauuaggauc ugccu 25

<210> 2909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2909

auguugguuu ccauuaggau cugcc 25

<210> 2910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2910

cagaccucac auguugguuu ccauu 25

<210> 2911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2911

auucccagca ucagaccuca caugu 25

<210> 2912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2912

aaaagggaaa guggugaagg caggg 25

<210> 2913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2913

gaaaaaaggg aaagugguga aggca 25

<210> 2914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2914

agaaaaaagg gaaagggug aaggc 25

<210> 2915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2915

gagaagaaaa aagggaaagu gguga 25

<210> 2916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2916

ggguaagaga agaaaaaagg gaaag 25

<210> 2917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2917

agaaagggg uaagagaaga aaaaa 25

<210> 2918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2918

cagaaagagg guaagagaag aaaaa 25

<210> 2919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2919

ugggaagga auagaaacag aaaga 25

<210> 2920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2920

guggggaagg aauagaaaca gaaag 25

<210> 2921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2921

ggaagcacug gggcaugagu gggga 25

<210> 2922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2922

caacggaagc acuggggcau gagug 25

<210> 2923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2923

ccaacggaag cacuggggca ugagu 25

<210> 2924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2924

uccaacggaa gcacuggggc augag 25

<210> 2925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2925

gcgcaugugu ccaacggaag cacug 25

<210> 2926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2926

ugcgcaugug uccaacggaa gcacu 25

<210> 2927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2927

augcgcaugu guccaacgga agcac 25

<210> 2928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2928

gaccguaaaa ugcgcaugug uccaa 25

<210> 2929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2929

aggucagaaa ucuuucaagc ccugc 25

<210> 2930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2930

ugauaccaaa ucacuggacc uuaga 25

<210> 2931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2931

cuuagaucuu cugauaccaa aucac 25

<210> 2932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2932

cacgcuucuu uaaauggcag agaga 25

<210> 2933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2933

ggaaauugca acacgcuucu uuaaa 25

<210> 2934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2934

aggcgaauca cuuucacuuc ugcug 25

<210> 2935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2935

gaggcgaauc acuuucacuu cugcu 25

<210> 2936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2936

agaggcgaau cacuuucacu ucugc 25

<210> 2937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2937

acacggaaug cagacauuug aguag 25

<210> 2938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2938

aggguuugcu uucaccccau ucaaa 25

<210> 2939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2939

ccuauugugu ggucagguua uguaa 25

<210> 2940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2940

uccuauugug uggucagguu augua 25

<210> 2941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2941

uuucauuucc uccuauugug ugguc 25

<210> 2942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2942

cgggccuggc gcaacgcuga gcagc 25

<210> 2943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2943

cgcugagcag cuggcgcguc ccgcg 25

<210> 2944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2944

ggccccaguu cugcgcagcu ucccg 25

<210> 2945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2945

accagccgcg cuucuguccg ccugc 25

<210> 2946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2946

gccgcgcuuc uguccgccug caggu 25

<210> 2947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2947

ccgcgcuucu guccgccugc aggua 25

<210> 2948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2948

gcagguaggg agcguuguuc cuccg 25

<210> 2949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2949

cagguaggga gcguuguucc uccgc 25

<210> 2950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2950

cagcguugcg ccaggccgg aggcg 25

<210> 2951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2951

ucagcguugc gccaggcccg gaggc 25

<210> 2952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2952

cucagcguug cgccaggccc ggagg 25

<210> 2953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2953

cugcucagcg uugcgccagg cccgg 25

<210> 2954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2954

cagcugcuca gcguugcgcc aggcc 25

<210> 2955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2955

cgcgccagcu gcucagcguu gcgcc 25

<210> 2956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2956

aagcugcgca gaacuggggc cgcgc 25

<210> 2957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2957

gaagcugcgc agaacugggg ccgcg 25

<210> 2958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2958

agccucggga agcugcgcag aacug 25

<210> 2959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2959

gagccucggg aagcugcgca gaacu 25

<210> 2960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2960

ggagccucgg gaagcugcgc agaac 25

<210> 2961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2961

agaagcgcgg cuggugcggga gccuc 25

<210> 2962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2962

cagaagcgcg gcuggugcgg agccu 25

<210> 2963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2963

caggcggaca gaagcgcggc uggug 25

<210> 2964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2964

accugcaggc ggacagaagc gcggc 25

<210> 2965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2965

cccuaccugc aggcggacag aagcg 25

<210> 2966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2966

aggaacaacg cucccuaccu gcagg 25

<210> 2967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2967

cggaggaaca acgcucccua ccugc 25

<210> 2968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2968

auaauuaggg cauuccagaa agaug 25

<210> 2969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2969

ugcugucuuu auauucauga ccuac 25

<210> 2970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2970

ucaugaccua cuggcauuug cugaa 25

<210> 2971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2971

ucaucuuucu ggaaugcccu aauua 25

<210> 2972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2972

aagacagcaa auauccucau cuuuc 25

<210> 2973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2973

gucuuaccgu ucagcaaaug ccagu 25

<210> 2974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2974

ucuuucuuuu uagcauuuac uguca 25

<210> 2975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2975

uuagcauuua cugucacggu uccca 25

<210> 2976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2976

gucacgguuc ccaaggaccu auaug 25

<210> 2977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2977

ccaaggaccu auauguggua gagua 25

<210> 2978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2978

uucccaguag aaaaacaauu agacc 25

<210> 2979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2979

agaccuggcu gcacuaauug ucuau 25

<210> 2980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2980

gaccuggcug cacuaauugu cuauu 25

<210> 2981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2981

gcugcacuaa uugucuauug ggaaa 25

<210> 2982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2982

gcacuaauug ucuauuggga aaugg 25

<210> 2983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2983

auaagaacau uauucaauuu gugca 25

<210> 2984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2984

aacauuauuc aauuugugca uggag 25

<210> 2985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2985

uuugugcaug gagaggaaga ccuga 25

<210> 2986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2986

gguucagcau aguagcuaca gacag 25

<210> 2987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2987

guucagcaua guagcuacag acaga 25

<210> 2988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2988

gcauaguagc uacagacaga gggcc 25

<210> 2989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2989

uacagacaga gggcccggcu guuga 25

<210> 2990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2990

cggcuguuga aggaccagcu cuccc 25

<210> 2991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2991

ggcuguugaa ggaccagcuc ucccu 25

<210> 2992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2992

cuucagauca cagaugugaa auugc 25

<210> 2993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2993

ucacagaugu gaaauugcag gaugc 25

<210> 2994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2994

cacagaugug aaauugcagg augca 25

<210> 2995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2995

acagauguga aauugcagga ugcag 25

<210> 2996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2996

ggguguaccg cugcaugauc agcua 25

<210> 2997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2997

uguaccgcug caugaucagc uaugg 25

<210> 2998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2998

acaagcgaau uacugugaaa gucaa 25

<210> 2999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 2999

aaugguaaga auuauuauag augag 25

<210> 3000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3000

ugacaguaaa ugcuaaaaag aaaga 25

<210> 3001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3001

cauacucuac cacauauagg uccuu 25

<210> 3002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3002

ccaauacucua ccacauaauag guccu 25

<210> 3003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3003

auugcuacca uacucuacca cauau 25

<210> 3004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3004

agccaggucu aauuguuuuu cuacu 25

<210> 3005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3005

cagccagguc uaauuguuuu ucuac 25

<210> 3006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3006

uucccaauag acaauuagug cagcc 25

<210> 3007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3007

ucuguagcua cuaugcugaa ccuuc 25

<210> 3008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3008

agggagagcu gguccuucaa cagcc 25

<210> 3009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3009

cagggaggc ugguccuuca acagc 25

<210> 3010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3010

aagugcagca uuucccaggg agagc 25

<210> 3011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3011

gugaucugaa gugcagcauu uccca 25

<210> 3012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3012

ugugaucuga agugcagcau uuccc 25

<210> 3013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3013

ggcaccacca uagcugauca ugcag 25

<210> 3014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3014

acuuucacag uaauucgcuu guagu 25

<210> 3015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3015

uacaacaaaa ucaaccaaag aauuu 25

<210> 3016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3016

aaaaucaacc aaagaauuuu gguug 25

<210> 3017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3017

accucugaac augaacugac auguc 25

<210> 3018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3018

gaacauguac ugacauguca ggcug 25

<210> 3019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3019

aacaugaacu gacaugucag gcuga 25

<210> 3020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3020

acaugucagg cugaggggcua cccca 25

<210> 3021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3021

gggcuacccc aaggccgaag ucauc 25

<210> 3022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3022

caagcaguga ccaaucaaguc cugag 25

<210> 3023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3023

accaccacca ccaauuccaa gagag 25

<210> 3024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3024

uaaugagauu uucuacugca cuuuu 25

<210> 3025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3025

ugcacuuuua ggagauuaga uccug 25

<210> 3026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3026

ccugaggaaa accauacagc ugaau 25

<210> 3027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3027

accauacagc ugaauugguc auccc 25

<210> 3028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3028

uugguugauu uuguuguaug gggcu 25

<210> 3029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3029

auucuuuggu ugauuuuguu guaug 25

<210> 3030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3030

aauucuuugg uugauuuugu uguau 25

<210> 3031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3031

aaauucuuug guugauuuug uugua 25

<210> 3032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3032

gacuggaucc acaaccaaaa uucuu 25

<210> 3033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3033

augucaguuc auguucagag gugac 25

<210> 3034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3034

gccugacaug ucaguucaug uucag 25

<210> 3035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3035

gcuuguccag augacuucgg ccuug 25

<210> 3036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3036

ugcuugucca gaugacuucg gccuu 25

<210> 3037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3037

cugcuugucc agaugacuuc ggccu 25

<210> 3038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3038

uggucacugc uuguccagau gacuu 25

<210> 3039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3039

gguggucuua ccacucagga cuuga 25

<210> 3040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3040

auggggug guggucuuac cacuc 25

<210> 3041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3041

uccucucucu uggaauuggu ggugg 25

<210> 3042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3042

uucuccucuc ucuuggaauu ggugg 25

<210> 3043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3043

agcuucuccu cucucuugga auugg 25

<210> 3044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3044

aaaagcuucu ccucucucuu ggaau 25

<210> 3045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3045

acauugaaaa gcuucuccuc ucucu 25

<210> 3046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3046

guuguugugu ugauucucag ugugc 25

<210> 3047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3047

ccaauucagc uguaugguuu ucuc 25

<210> 3048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3048

accugggaug accaauucag cugua 25

<210> 3049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3049

aauggacaca uucagaauau uaccu 25

<210> 3050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3050

uaauggacac auucagaaua uuacc 25

<210> 3051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3051

uuguuuuguu uuucagaacu accuc 25

<210> 3052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3052

accucuggca cauccuccaa augaa 25

<210> 3053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3053

cauccuccaa augaaaggac ucacu 25

<210> 3054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3054

aaugaaagga cucacuuggu aauuc 25

<210> 3055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3055

augaaaggac ucacuuggua auucu 25

<210> 3056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3056

uucugggagc caucuuauua ugccu 25

<210> 3057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3057

ugacauucau cuuccguuua agaaa 25

<210> 3058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3058

aaagguagua uuuccuuaau ugcag 25

<210> 3059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3059

uccuuucauu uggaggaugu gccag 25

<210> 3060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3060

uuaccaagug aguccuuuca uuugg 25

<210> 3061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3061

gaauuaccaa gugaguccuu ucauu 25

<210> 3062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3062

agugcuacac caaggcauaa uaaga 25

<210> 3063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3063

gaagaugaau gucagugcua cacca 25

<210> 3064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3064

uaaggaaaua cuaccuuuuc uuaaa 25

<210> 3065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3065

auuucuuuuu cucaagggag aauga 25

<210> 3066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3066

ggagaaugau ggaugugaaa aaaug 25

<210> 3067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3067

aagauacaaa cucaaagaag caaag 25

<210> 3068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3068

gaagcaaagu gguaagaaua ucaga 25

<210> 3069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3069

aagugguaag aauauucagaa ggaau 25

<210> 3070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3070

agugguaaga auaucagaag gaauu 25

<210> 3071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3071

acuuugcuuc uuugaguuug uaucu 25

<210> 3072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3072

uauuaucacu cuccagauac acauu 25

<210> 3073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3073

uaucacucuc cagauacaca uuugg 25

<210> 3074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3074

auuuggagga gacguaaucc agcau 25

<210> 3075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3075

gcauuggaac uucugaucuu caagc 25

<210> 3076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3076

cauuggaacu ucugaucuuc aagca 25

<210> 3077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3077

ucuucaagca gggauucuca accug 25

<210> 3078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3078

agcagggauu cucaaccugu gguuu 25

<210> 3079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3079

gcagggauuc ucaaccugug guuua 25

<210> 3080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3080

cagggauucu caaccugugg uuuag 25

<210> 3081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3081

cucaaccugu gguuuagggg uucau 25

<210> 3082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3082

ucaaccugug guuuaggggu ucauc 25

<210> 3083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3083

caaccugugg uuuagggguu caucg 25

<210> 3084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3084

guucaucggg gcugagcgug acaag 25

<210> 3085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3085

aucggggcug agcgugacaa gagga 25

<210> 3086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3086

ggcugagcgu gacaagagga aggaa 25

<210> 3087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3087

gcugagcgug acaagaggaa ggaau 25

<210> 3088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3088

gugacaagag gaaggaaugg gcccg 25

<210> 3089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3089

ugacaagagg aaggaauggg cccgu 25

<210> 3090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3090

aggaaggaau gggcccgugg gaugc 25

<210> 3091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3091

augggcccgu gggaugcagg caaug 25

<210> 3092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3092

ugggccgggggaugcaggc aaugu 25

<210> 3093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3093

ggaugcaggc aaugugggac uuaaa 25

<210> 3094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3094

acuuaaaagg cccaagcacu gaaaa 25

<210> 3095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3095

aggcccaagc acugaaaaug gaacc 25

<210> 3096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3096

ugaaaaugga accuggcgaa agcag 25

<210> 3097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3097

aauggaacc uggcgaaagc agagg 25

<210> 3098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3098

agcagaggag gagaaugaag aaaga 25

<210> 3099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3099

agaaugaaga aagauggagu caaac 25

<210> 3100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3100

gaaugaagaa agauggaguc aaaca 25

<210> 3101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3101

gaaagaugga gucaaacagg gagcc 25

<210> 3102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3102

agauggaguc aaacagggag ccugg 25

<210> 3103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3103

guggaguca aacagggagc cugga 25

<210> 3104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3104

agaccuugau acuuucaaau gccug 25

<210> 3105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3105

gaccuugaua cuuucaaaug ccuga 25

<210> 3106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3106

accuugauac uuucaaaugc cugag 25

<210> 3107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3107

ugaggggcuc aucgacgccu gugac 25

<210> 3108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3108

gaggggcuca ucgacgccug ugaca 25

<210> 3109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3109

ucaucgacgc cugugacagg gagaa 25

<210> 3110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3110

cagggagaaa ggauacuucu gaaca 25

<210> 3111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3111

aagcaaauca uccauugcuc auccu 25

<210> 3112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3112

ucauccauug cucauccuag gaaga 25

<210> 3113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3113

cauccauugc ucauccuagg aagac 25

<210> 3114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3114

agaacggguug agaaucccua auuug 25

<210> 3115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3115

gacggguuga gaaucccuaa uuuga 25

<210> 3116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3116

ucugcaugac ugagagucuc agugu 25

<210> 3117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3117

augacugaga gucucagugu uggaa 25

<210> 3118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3118

ugacugagag ucucaguguu ggaac 25

<210> 3119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3119

uuuuccuauu uauuuugagu cugug 25

<210> 3120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3120

gugaggucuu cuugucaugu gagug 25

<210> 3121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3121

ugauuugcuc acaucuagua aaaca 25

<210> 3122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3122

ucuaguaaaa cauggaguau uugua 25

<210> 3123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3123

aaacauggag uauuuguaag gugcu 25

<210> 3124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3124

cuccuuaua acuacaagua uacau 25

<210> 3125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3125

auuggaagca uaaagaucaa accgu 25

<210> 3126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3126

auaaagauca aaccguuggu ugcau 25

<210> 3127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3127

accuuuauuu aacccauuaa uacuc 25

<210> 3128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3128

ggaaaacccg agcaguguug ccaag 25

<210> 3129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3129

aaacccgagc aguguugcca agagg 25

<210> 3130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3130

agcaguguug ccaagaggag gaaau 25

<210> 3131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3131

gccaagagga ggaaauaggc caaug 25

<210> 3132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3132

gaggaggaaa uaggccaaug ugguc 25

<210> 3133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3133

aggaggaaau aggccaaugu ggucu 25

<210> 3134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3134

ggaaauaggc caauggguc uggga 25

<210> 3135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3135

auaggccaau guggucuggg acggu 25

<210> 3136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3136

cagaguaauu uucauuuaca aagag 25

<210> 3137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3137

guaauuuuca uuuacaaaga gaggu 25

<210> 3138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3138

uuaaaauaac ccugaaaaau aacac 25

<210> 3139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3139

aucuaaugcu uguuuauaua guguc 25

<210> 3140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3140

auuuuagugu uucuuauaua gcaga 25

<210> 3141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3141

cagauggaau gaauuugaag uuccc 25

<210> 3142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3142

agauggaaug aauuugaagu uccca 25

<210> 3143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3143

aaugaauuug aaguucccag ggcug 25

<210> 3144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3144

ccaccauuug uuaaguauuu gcucu 25

<210> 3145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3145

uaaguauuug cucuaggaca gaguu 25

<210> 3146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3146

uuggauuugu uuauguuugc ucaaa 25

<210> 3147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3147

uuauguuugc ucaaaaggag accca 25

<210> 3148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3148

uauguuugcu caaaaggaga cccau 25

<210> 3149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3149

ucaaaaggag acccaugggc ucucc 25

<210> 3150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3150

caaaaggaga cccaugggcu cucca 25

<210> 3151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3151

uaacucugua ugacagaauc auguc 25

<210> 3152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3152

uacuugcaaa aucacauuuu cuuuc 25

<210> 3153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3153

aauucacauuu ucuuucugga aauuc 25

<210> 3154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3154

gucaucacua cacagcccuc cuaag 25

<210> 3155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3155

uacacagccc uccuaagagg cuucc 25

<210> 3156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3156

acagcccucc uaagaggcuu ccugg 25

<210> 3157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3157

uggagguuuc gagauucaga ugccc 25

<210> 3158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3158

ggagguuucg agauucagau gcccu 25

<210> 3159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3159

agaucccaga guuuccuuuc ccucu 25

<210> 3160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3160

uuuccuuucc cucuuggcca uauuc 25

<210> 3161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3161

uggccauauu cuggugucaa ugaca 25

<210> 3162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3162

cuggugucaa ugacaaggag uaccu 25

<210> 3163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3163

aguaccuugg cuuugccaca uguca 25

<210> 3164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3164

uguacaugug cauuuguaca guaau 25

<210> 3165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3165

ugacaguguu cuuuguguga auuac 25

<210> 3166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3166

uugugugaau uacaggcaag aauug 25

<210> 3167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3167

uacaggcaag aauuguggcu gagca 25

<210> 3168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3168

auuccuaagu ccuaacuccu ccuug 25

<210> 3169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3169

aaguccuaac uccuccuugu ggugu 25

<210> 3170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3170

uccuccuugu gguguuggau uugua 25

<210> 3171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3171

cuuuugucuc auguuucauc guaaa 25

<210> 3172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3172

ucucauguuu caucguaaau ggcau 25

<210> 3173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3173

aaauauucuu auuuauuuug uuacu 25

<210> 3174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3174

uaaaauguuc aguuuaacau cccag 25

<210> 3175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3175

uuacucca guggagaaag uuacu 25

<210> 3176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3176

auuacgucuc cuccaaaugu guauc 25

<210> 3177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3177

gcuugaagau cagaaguucc aaugc 25

<210> 3178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3178

cagccccgau gaaccccuaa accac 25

<210> 3179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3179

aagucccaca uugccugcau cccac 25

<210> 3180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3180

uaagucccac auugccugca uccca 25

<210> 3181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3181

ucgccagguu ccauuuucag ugcuu 25

<210> 3182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3182

uucgccaggu uccauuuuca gugcu 25

<210> 3183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3183

uucauucucc uccucugcuu ucgcc 25

<210> 3184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3184

uuugaaagua ucaaggucuc ccucc 25

<210> 3185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3185

gccccucagg cauuugaaag uauca 25

<210> 3186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3186

ugucacaggc gucgaugagc cccuc 25

<210> 3187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3187

cagaaguauc cuuucucccu gucac 25

<210> 3188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3188

gaugagcaau ggaugauuug cuugg 25

<210> 3189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3189

uaggaugagc aauggaugau uugcu 25

<210> 3190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3190

caacccgucu uccuaggaug agcaa 25

<210> 3191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3191

uuagggauuc ucaacccguc uuccu 25

<210> 3192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3192

ucugcaggaa cugacccuca aauua 25

<210> 3193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3193

uucugcagga acugacccuc aaauu 25

<210> 3194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3194

gaguggaggc aaagggcacu ucugc 25

<210> 3195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3195

aauugaggca uugagguggag gcaaa 25

<210> 3196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3196

aaauugaggc auugagga ggcaa 25

<210> 3197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3197

gaaaacaaau ugaggcauug agugg 25

<210> 3198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3198

gcagaaaaca aauugaggca uugag 25

<210> 3199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3199

ucucagucau gcagaaaaca aauug 25

<210> 3200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3200

aagaccucac agacucaaaa uaaau 25

<210> 3201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3201

aaaucauuaa gcagcaaguu uaguu 25

<210> 3202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3202

uuccaaugua uacuuguagu uauag 25

<210> 3203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3203

uaaaggugac auccuaugca accaa 25

<210> 3204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3204

accagaguau uaauggguua aauaa 25

<210> 3205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3205

agauuagguc aaccagagua uuaau 25

<210> 3206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3206

aagauuaggu caaccagagu auuaa 25

<210> 3207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3207

acacuugagg ucugagaaua agauu 25

<210> 3208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3208

ccuugucuuaa cugcacagac acuug 25

<210> 3209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3209

auauagcugu aaauuguauu auaaa 25

<210> 3210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3210

accacauugg ccuauuuccu ccucu 25

<210> 3211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3211

uauauccaac cguccagac cacau 25

<210> 3212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3212

aaaggaauuc caguguuauu uuuca 25

<210> 3213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3213

aaaaggaauu ccaguguuau uuuuc 25

<210> 3214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3214

ucaggaauaa auauaaugcu agaaa 25

<210> 3215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3215

uuagauuaua uggcaaaggc aaauc 25

<210> 3216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3216

aaacaagcau uagauuauau ggcaa 25

<210> 3217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3217

cuauauaaac aagcauuaga uuaua 25

<210> 3218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3218

ccuuuccaua cuuaaauuuu uuuag 25

<210> 3219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3219

aaagaaggca uggauccuca gcccu 25

<210> 3220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3220

caaagaaggc auggauccuc agccc 25

<210> 3221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3221

agauaacuua gaaacaaaga aggca 25

<210> 3222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3222

gggaaagaua acuuagaaac aaaga 25

<210> 3223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3223

cauaugaaag auaaugaaaa gcuau 25

<210> 3224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3224

ucauauugaaa gauaaugaaa agcua 25

<210> 3225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3225

uauguaggac auauuuaaca uauac 25

<210> 3226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3226

auggugguug ucuaaaugua uaugu 25

<210> 3227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3227

ccuagagcaa auacuuaaca aaugg 25

<210> 3228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3228

uguccuagag caaauacuua acaaa 25

<210> 3229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3229

acucaguca cccuggagag cccau 25

<210> 3230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3230

gacucaguc acccuggaga gccca 25

<210> 3231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3231

aggacuagau ugacucagug caccc 25

<210> 3232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3232

agaguuaaua auaagauugc uuuuu 25

<210> 3233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3233

guagcuagca gucaagguac acugc 25

<210> 3234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3234

ucuggcacag gguagcuagc aguca 25

<210> 3235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3235

caacgaauga ggcuuuucug gcaca 25

<210> 3236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3236

acaacgaaug aggcuuuucu ggcac 25

<210> 3237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3237

ucaagcacaa cgaaugaggc uuuuc 25

<210> 3238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3238

uucaaggguu caagcacaac gaaug 25

<210> 3239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3239

agugaugaca gcugguggca uucaa 25

<210> 3240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3240

uugugaugac agcugguggc auuca 25

<210> 3241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3241

agggcugugu agugaugaca gcugg 25

<210> 3242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3242

aggagggcug uguagugaug acagc 25

<210> 3243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3243

gaaaccucca ggaagccucu uagga 25

<210> 3244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3244

cgaaaccucc aggaagccuc uuagg 25

<210> 3245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3245

ucucgaaacc uccaggaagc cucuu 25

<210> 3246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3246

agggcaucug aaucucgaaa ccucc 25

<210> 3247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3247

ggaaaggaaa cucugggauc uccca 25

<210> 3248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3248

gggaaaggaa acucugggau cuccc 25

<210> 3249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3249

auggccaaga gggaaaggaa acucu 25

<210> 3250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3250

uauggccaag agggaaagga aacuc 25

<210> 3251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3251

acaccagaau aggccaaga gggaa 25

<210> 3252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3252

cauugacacc agaauauggc caaga 25

<210> 3253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3253

ucauugacac cagaauuugg ccaag 25

<210> 3254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3254

acuccuuguc auugacacca gaaua 25

<210> 3255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3255

ucagccuuga cauguggcaa agcca 25

<210> 3256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3256

acacuguuuc uucagccuug acaug 25

<210> 3257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3257

aaacagauaa cacaaggagc ucugu 25

<210> 3258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3258

ugcacaugua caaacagaua acaca 25

<210> 3259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3259

acaccacaag gaggaguuag gacuu 25

<210> 3260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3260

aaauccaaca ccacaaggag gaguu 25

<210> 3261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3261

gccuuacaaa uccaacacca caagg 25

<210> 3262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3262

agugccuuac aaauccaaca ccaca 25

<210> 3263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3263

auuuacgaug aaacaugaga caaaa 25

<210> 3264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3264

cauuuacgau gaaacaugag acaaa 25

<210> 3265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3265

aaaagugaca aucaaaugca gaauu 25

<210> 3266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3266

uaagaauauu uuauuaaauu aaugc 25

<210> 3267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3267

aaaauaaaca agaaaaugga caugc 25

<210> 3268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3268

auuaaacaca aaauaaacaa gaaaa 25

<210> 3269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3269

aauauuccaa guaacuuucu ccacu 25

<210> 3270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3270

aaauauucca aguaacuuuc uccac 25

<210> 3271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3271

uauaccgucu ugaaauuuaa guuua 25

<210> 3272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3272

aaguuuaggg accacucucu gucaa 25

<210> 3273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3273

cacucucugu caaaggaucc agcgc 25

<210> 3274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3274

cagcgcuggu aauauagauu gcuga 25

<210> 3275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3275

ugaaggccuu ugccuucuuu ccacc 25

<210> 3276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3276

uucugugaaa aauauagcuu caguu 25

<210> 3277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3277

caguuugguc cacgaauaca gaagu 25

<210> 3278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3278

uuucaagcac acaacaagca aaacu 25

<210> 3279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3279

caaucaaaug cacuucguuu uuccc 25

<210> 3280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3280

aaucaaaugc acuucguuuu ucccu 25

<210> 3281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3281

agcuccugcc acaucucagc ccugc 25

<210> 3282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3282

gcuccugcca caucucagcc cugca 25

<210> 3283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3283

ucagcccuc agggcagucu ucaua 25

<210> 3284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3284

cagcccuca gggcagucuu cauaa 25

<210> 3285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3285

cagucuucau aagggagaca aaaga 25

<210> 3286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3286

agucuucaua agggagacaa aagaa 25

<210> 3287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3287

gggagacaaa agaagggcua ugcac 25

<210> 3288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3288

agggcuaugc acuggcacug acagu 25

<210> 3289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3289

gggcuaugca cuggcacuga caguu 25

<210> 3290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3290

uaugcacugg cacugacagu ugggc 25

<210> 3291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3291

aauaagccua aaucucaaca uucca 25

<210> 3292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3292

auaagccuaa aucucaacau uccaa 25

<210> 3293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3293

cauuccaagg gaaucuucaa gauca 25

<210> 3294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3294

ggaaucuuca agaucaaggu agacc 25

<210> 3295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3295

gguccaguca ucucuuaauc uuuua 25

<210> 3296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3296

uccaucucaaaaaaaaaaa caaaa 25

<210> 3297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3297

ccaucucaaa aaaaaaaac aaaaa 25

<210> 3298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3298

gaucacagau cucuuugaaa aucag 25

<210> 3299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3299

uuucccuagu uuaucugaag uuuca 25

<210> 3300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3300

ggacauuga ugugcccgaa uuucc 25

<210> 3301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3301

ucuaacaucc augauuaaca gucuc 25

<210> 3302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3302

cuaacaucca ugauuaacag ucucu 25

<210> 3303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3303

cauccaugau uaacagucuc ugggu 25

<210> 3304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3304

auccaugauu aacagucucu ggguu 25

<210> 3305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3305

cagucucugg guuggguaac ucugu 25

<210> 3306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3306

gguaacucug uuggcuuaaa uacag 25

<210> 3307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3307

ugacaugccu guuuaaguuc agugc 25

<210> 3308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3308

caugugaguc auuaucuucu gaaaa 25

<210> 3309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3309

augugaguca uuaucuucug aaaau 25

<210> 3310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3310

augggaaaac ucugcuccau agcag 25

<210> 3311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3311

guggacagaa ccuccaaaac caguc 25

<210> 3312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3312

agacaaaaca ccaagcucaa aaaua 25

<210> 3313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3313

caaaacacca agcucaaaaa uaagg 25

<210> 3314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3314

acaccaagcu caaaaauaag guggu 25

<210> 3315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3315

cucaaaaaua aggugguugg aucua 25

<210> 3316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3316

auggcauugc aaagcgacaa cccaa 25

<210> 3317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3317

gcaaagcgac aacccaaagg uugug 25

<210> 3318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3318

caaagcgaca acccaaaggu uguga 25

<210> 3319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3319

cugcugacau agcaauaaua cucau 25

<210> 3320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3320

ugcugacaua gcaauaauac ucauu 25

<210> 3321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3321

uccacuucau auacguucuc uucaa 25

<210> 3322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3322

ucugcuacug cauuugccaa uccug 25

<210> 3323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3323

cugcuacugc auuugccaau ccuga 25

<210> 3324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3324

cuacugcauu ugccaauccu gaggg 25

<210> 3325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3325

uacugcauuu gccaauccug aggga 25

<210> 3326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3326

ugcauuugcc aauccugagg gaggg 25

<210> 3327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3327

uuugccaauc cugagggagg gaggu 25

<210> 3328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3328

gggagggagg uuggccaaag agaug 25

<210> 3329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3329

gagguuggcc aaagagauga ggcug 25

<210> 3330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3330

augaggcugu ggaaauaaag uguug 25

<210> 3331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3331

cagcgcugga uccuuugaca gagag 25

<210> 3332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3332

cuucagcaau cuauauuacc agcgc 25

<210> 3333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3333

cuguugccug guggaaagaa ggcaa 25

<210> 3334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3334

caaauucugu ugccuggugg aaaga 25

<210> 3335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3335

cggggacaca aauucuguug ccugg 25

<210> 3336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3336

ugacggggac acaaauucug uugcc 25

<210> 3337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3337

uuucacagaa gaagaagcag ugacg 25

<210> 3338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3338

uuuucacaga agaagaagca gugac 25

<210> 3339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3339

uuuuucacag aagaagaagc aguga 25

<210> 3340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3340

uaucucugac caacuucugu auucg 25

<210> 3341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3341

cgaagugcau uugauuggug uguau 25

<210> 3342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3342

cagggaaaaa cgaagugcau uugau 25

<210> 3343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3343

ggcugagaug uggcaggagc uccca 25

<210> 3344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3344

gggcugagau guggcaggag cuccc 25

<210> 3345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3345

cugcccugca gggcugagau guggc 25

<210> 3346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3346

aagacugccc ugcagggcug agaug 25

<210> 3347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3347

ucucccuuau gaagacugcc cugca 25

<210> 3348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3348

gucucccuua ugaagacugc ccugc 25

<210> 3349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3349

agauucccuu ggaauguuga gauuu 25

<210> 3350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3350

ucuaccuuga ucuugaagau ucccu 25

<210> 3351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3351

uaaaagauua agagaugacu ggacc 25

<210> 3352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3352

augac 25

<210> 3353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3353

cuuuuuuggc acagaaaguc uaaag 25

<210> 3354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3354

acuuuuuugg cacagaaagu cuaaa 25

<210> 3355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3355

aacuuuuuug gcacagaaag ucuaa 25

<210> 3356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3356

ugcugaggug aaagcauaac uuuuu 25

<210> 3357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3357

auaaacuagg gaaaacuggg ugcug 25

<210> 3358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3358

aacuucagau aaacuaggga aaacu 25

<210> 3359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3359

aaacuucaga uaaacuaggg aaaac 25

<210> 3360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3360

uguccauga acuucagaua aacua 25

<210> 3361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3361

auguccauga aacuucagau aaacu 25

<210> 3362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3362

ggggucucugg agcuccagga aauuc 25

<210> 3363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3363

ggggucucug gagcuccagg aaauu 25

<210> 3364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3364

cuugacgugg ggucucuggga gcucc 25

<210> 3365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3365

cuaggaauuc uugacguggg gucuc 25

<210> 3366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3366

auauacacua ggaauucuug acgug 25

<210> 3367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3367

uauauacacu aggaauucuu gacgu 25

<210> 3368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3368

uuauauacac uaggaauucu ugacg 25

<210> 3369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3369

gcucaaacgg gcuuuuauau acacu 25

<210> 3370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3370

uaaucaugga uguuagagcu caaac 25

<210> 3371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3371

uuaaucaugg auguuagagc ucaaa 25

<210> 3372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3372

uacccaaccc agagacuguu aauca 25

<210> 3373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3373

acugggaccu gcacugaacu uaaac 25

<210> 3374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3374

uaaugacuca caugggaauu gaacu 25

<210> 3375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3375

auaaugacuc acaugggaau ugaac 25

<210> 3376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3376

auuuucagaa gauaaugacu cacau 25

<210> 3377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3377

cauuuucaga agauaaugac ucaca 25

<210> 3378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3378

guuuuggagg uucuguccac ugcua 25

<210> 3379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3379

agcuguguca ccugacuggu uuugg 25

<210> 3380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3380

augagcugug ucaccugacu gguuu 25

<210> 3381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3381

gaaacuauga gcuguguucac cugac 25

<210> 3382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3382

gauccaacca ccuuauuuuu gagcu 25

<210> 3383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3383

gcaggcagca acccucacaa ccuuu 25

<210> 3384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3384

agcaggcagc aacccucaca accuu 25

<210> 3385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3385

ugaguauuau ugcuauguca gcagc 25

<210> 3386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3386

auugaagaga acguauauga agugg 25

<210> 3387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3387

accauugaag agaacguaua ugaag 25

<210> 3388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3388

caggauuggc aaaugcagua gcaga 25

<210> 3389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3389

ucaggauugg caaaugcagu agcag 25

<210> 3390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3390

uuggccaacc ucccucccuc aggau 25

<210> 3391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3391

ucucuuuggc caaccucccu cccuc 25

<210> 3392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3392

cuuuauuucc acagccucau cucuu 25

<210> 3393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3393

ucuuugcuau gagaauaccc uagua 25

<210> 3394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3394

cuuugcuaug agaauacccu aguaa 25

<210> 3395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3395

uuugcuauga gaauacccua guaag 25

<210> 3396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3396

uugcuaugag aauacccuag uaagg 25

<210> 3397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3397

aagguaagaa uauggaaug ggguu 25

<210> 3398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3398

uaagguaaga auaauggaau ggggu 25

<210> 3399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3399

aauuuaaggu aagaauaaug gaaug 25

<210> 3400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3400

gaauuuaagg uaagaauaau ggaau 25

<210> 3401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3401

agaauuuaag guaagaauaa uggaa 25

<210> 3402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3402

gauacagaau uuaagguaag aauaa 25

<210> 3403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3403

uagcaaagag aagauacaga auuua 25

<210> 3404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3404

gcuccgaugu agaugccuau ucuga 25

<210> 3405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3405

guugcuccag agucccguaa gucau 25

<210> 3406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3406

gccaaucuag agucccguaa cucau 25

<210> 3407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3407

gagucccgua acucauuggc caaug 25

<210> 3408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3408

cauuggccaa uguggauauu ugcua 25

<210> 3409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3409

ggauauuugc uuggaaaca caaac 25

<210> 3410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3410

cugggcuggc ucuggcucuu aucuu 25

<210> 3411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3411

gcagggaucu gugcugggcu ggcuc 25

<210> 3412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3412

aucggagcag ggaucugugc ugggc 25

<210> 3413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3413

cuacaucgga gcagggaucu gugcu 25

<210> 3414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3414

ucuacaucgg agcagggauc ugugc 25

<210> 3415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3415

cagaauaggc aucuacaucg gagca 25

<210> 3416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3416

ucagaauagg caucuacauc ggagc 25

<210> 3417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3417

caaccaucag aauaggcauc uacau 25

<210> 3418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3418

gggacucugg agcaaccauc agaau 25

<210> 3419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3419

gauggccaa ugacuuacgg gacuc 25

<210> 3420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3420

gacucuagau uggccaauga cuuac 25

<210> 3421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3421

ggacucuaga uuggccaaug acuua 25

<210> 3422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3422

gccaaugagu uacgggacuc uagau 25

<210> 3423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3423

auauccacau uggccaauga guuac 25

<210> 3424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3424

aauauccaca uuggccaaug aguua 25

<210> 3425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3425

guguuuccau agcaaauauuc cacau 25

<210> 3426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3426

aguuacuuac uguuagauuu auauc 25

<210> 3427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3427

guuacuuacu guuagauuua uauca 25

<210> 3428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3428

acuuacuguu agauuuauau caggg 25

<210> 3429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3429

uuuuauagca gagacacaga cacug 25

<210> 3430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3430

auuuuauagc agagacacag acacu 25

<210> 3431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3431

gauuuuauag cagagacaca gacac 25

<210> 3432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3432

cuccucugcc ccaugcauag uuacc 25

<210> 3433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3433

Uccucugccc Caugcauagu Uaccu 25

<210> 3434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3434

gcauaguuac cugggccaug ucccc 25

<210> 3435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3435

uaguuaccug ggccaugucc ccugg 25

<210> 3436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3436

cauguccccu ggugguaagc auccu 25

<210> 3437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3437

ccccgggg uaagcauccu uggaa 25

<210> 3438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3438

cugcagugaa gucucucugc cgagu 25

<210> 3439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3439

ugaagucucu cugccgaguc ggugc 25

<210> 3440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3440

gaagucucuc ugccgagucg gugca 25

<210> 3441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3441

aagucucucu gccgagucgg ugcag 25

<210> 3442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3442

ugccgagucg gugcaggggu gaccu 25

<210> 3443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3443

cuuggcuaau gucagaaaca acaua 25

<210> 3444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3444

cagguaacua ugcauggggc agagg 25

<210> 3445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3445

gccagguaa cuaugcaugg ggcag 25

<210> 3446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3446

gacauggccc agguaacuau gcaug 25

<210> 3447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3447

ggacauggcc cagguaacua ugcau 25

<210> 3448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3448

gggacauggc cggguaacu augca 25

<210> 3449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3449

ugcuuaccac caggggacau ggccc 25

<210> 3450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3450

caaggaugcu uaccaccagg ggaca 25

<210> 3451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3451

ccuuuccaag gaugcuuacc accag 25

<210> 3452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3452

gccuuuccaa ggaugcuuac cacca 25

<210> 3453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3453

agccuuucca aggaugcuua ccacc 25

<210> 3454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3454

gagagacuuc acugcagccu uucca 25

<210> 3455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3455

agccaagguc accccugcac cgacu 25

<210> 3456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3456

cuuauguugu uucugacauu agcca 25

<210> 3457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3457

gauggcaugc aaauguccac ucacc 25

<210> 3458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3458

cucaccuggu uugaugacca acuuc 25

<210> 3459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3459

uaaauuuuuc aucauucauu augcc 25

<210> 3460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3460

aaauuuuuca ucauucauua ugccu 25

<210> 3461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3461

uucauucauuc auuaugccug ggauu 25

<210> 3462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3462

auucauuaug ccugggauuu ggauc 25

<210> 3463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3463

cugucugcua gagucacauu cucua 25

<210> 3464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3464

ugcuagaguc acauucucua ugguc 25

<210> 3465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3465

gcuagaguca cauucucuau gguca 25

<210> 3466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3466

uauggucagg gacacaucuc cuuug 25

<210> 3467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3467

cggaaauccc cauuuagcca guauc 25

<210> 3468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3468

gcaccacguu gccacauuca aacac 25

<210> 3469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3469

acguugccac auucaaacac aggac 25

<210> 3470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3470

ggacaggcuc cuuugcccca gcaga 25

<210> 3471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3471

gacaggcucc uuugccccag cagac 25

<210> 3472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3472

uccuuugccc cagcagacgg gcacg 25

<210> 3473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3473

cccagcagac gggcacgagg uuccc 25

<210> 3474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3474

ccagcagacg ggcacgaggu ucccu 25

<210> 3475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3475

cagcagacgg gcacgagguu cccug 25

<210> 3476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3476

cagacgggca cgagguuccc ugggg 25

<210> 3477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3477

cgggcacgag guucccuggg gcggc 25

<210> 3478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3478

gggcacgagg uucccugggg cggcu 25

<210> 3479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3479

ggcacgaggu ucccuggggc ggcug 25

<210> 3480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3480

ccggggcgg cuggggugua gaagc 25

<210> 3481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3481

cuggggcggc uggggguguag aagca 25

<210> 3482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3482

gcuggggugu agaagcaggg cagau 25

<210> 3483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3483

accuccgcuc uguauuccac uucug 25

<210> 3484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3484

ucugaggac cugcauagag agaga 25

<210> 3485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3485

gaaguugguc aucaaaccag gugag 25

<210> 3486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3486

uuaaccugaa guuggucauc aaacc 25

<210> 3487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3487

aaugaugaaa aauuuaaccu gaagu 25

<210> 3488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3488

ucucugcug ccggauccaa auccc 25

<210> 3489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3489

agcagacagu gggaucuacu gcugc 25

<210> 3490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3490

agagaaugug acucuagcag acagu 25

<210> 3491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3491

uagagaaugu gacucuagca gacag 25

<210> 3492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3492

acuggcuaaa uggggauuuc cgcaa 25

<210> 3493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3493

uggacaucca gauacuggcu aaaug 25

<210> 3494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3494

uuggacaucc agauacuggc uaaau 25

<210> 3495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3495

auuggacauc cagauacugg cuaaa 25

<210> 3496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3496

ugugaauuau uggacaucca gauac 25

<210> 3497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3497

gacugauga agggauguga auuau 25

<210> 3498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3498

aacguggugc ucaggacuga ugaaa 25

<210> 3499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3499

caacguggug cucaggacug augaa 25

<210> 3500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3500

guuugaaugu ggcaacgugg ugcuc 25

<210> 3501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3501

uguccugugu uugaaugugg caacg 25

<210> 3502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3502

aaggagccug uccuguguuu gaaug 25

<210> 3503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3503

accucgugcc cgucugcugg ggcaa 25

<210> 3504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3504

cagggaaccu cgugcccguc ugcug 25

<210> 3505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3505

ccagggaacc ucgugcccgu cugcu 25

<210> 3506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3506

cccagggaac cucgugcccg ucugc 25

<210> 3507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3507

cugcuucuac accccagccg cccca 25

<210> 3508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3508

ccugcuucua caccccagcc gcccc 25

<210> 3509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3509

cagaagugga auacagagcg gaggu 25

<210> 3510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3510

uccucagaag uggaauacag agcgg 25

<210> 3511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3511

ggguccucag aaguggaaua cagag 25

<210> 3512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3512

ucucucuaug caggguccuc agaag 25

<210> 3513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3513

agcagcagca gcaggacaca gucaa 25

<210> 3514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3514

gcagcagcag caggacacag ucaaa 25

<210> 3515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3515

cagucaaagg gaagauguga aaaca 25

<210> 3516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3516

auggagcuug cagaagaaaa gucag 25

<210> 3517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3517

agaaaaguca gaggacaccu cuguu 25

<210> 3518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3518

uuaggcacag uuuuaacucu ccaaa 25

<210> 3519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3519

cacaguuuua acucuccaaa uggac 25

<210> 3520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3520

acaguuuuaa cucuccaaau ggacu 25

<210> 3521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3521

ccacugagug cuagcucagc acacc 25

<210> 3522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3522

cacugagugc uagcucagca caccc 25

<210> 3523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3523

cagugauucu uauaguaaca cugcc 25

<210> 3524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3524

acugccaggu cuacagucac auuaa 25

<210> 3525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3525

cgacgaugau gauacaagua agucu 25

<210> 3526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3526

ggagaguuaa aacugugccu aacag 25

<210> 3527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3527

aguuggaaga aguacccagu ccauu 25

<210> 3528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3528

cucaugugau uguggaguag acagu 25

<210> 3529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3529

ggggcggcua cugcucaugu gauug 25

<210> 3530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3530

gugcugagcu agcacucagu ggggg 25

<210> 3531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3531

ggugugcuga gcuagcacuc agugg 25

<210> 3532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3532

gggugugcug agcuagcacu cagug 25

<210> 3533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3533

cgggugugcu gagcuagcac ucagu 25

<210> 3534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3534

ccgggugugc ugagcuagca cucag 25

<210> 3535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3535

aagaaucacu ggcaaucaga caccc 25

<210> 3536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3536

uaagaaucac uggcaaucag acacc 25

<210> 3537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3537

cuggcagugu uacuauaaga aucac 25

<210> 3538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3538

guuuccuuua augugacugu agacc 25

<210> 3539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3539

uguagugugg caugacagag aacuu 25

<210> 3540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3540

gaacacuuac aggaugugug uagug 25

<210> 3541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3541

acaggacaga caucagaaca cuuac 25

<210> 3542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3542

ggaaggggga gggaaggccg ggcac 25

<210> 3543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3543

gaaggggag ggaaggccgg gcaca 25

<210> 3544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3544

aaggugggagg gaaggccggg cacag 25

<210> 3545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3545

gagggaaggc cgggcacagg gguga 25

<210> 3546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3546

ggugaaggcc cagagaccag cagaa 25

<210> 3547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3547

cagcagaacg gcaucccagc cacga 25

<210> 3548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3548

acuuugcucu gucugcucuc cgcca 25

<210> 3549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3549

uccgcacgg cccugcucug uuccc 25

<210> 3550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3550

ccgccacggc ccugcucugu ucccu 25

<210> 3551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3551

gggacacccc cgcccccacc uccuc 25

<210> 3552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3552

ucugcccagc uuuccagcuu uccuc 25

<210> 3553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3553

agcuuuccag cuuuccucug gauuc 25

<210> 3554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3554

cagcuuuccu cuggauuccg gccuc 25

<210> 3555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3555

gucaucccuc cccacccucu cucca 25

<210> 3556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3556

ccacccucuc uccaaggccc ucucc 25

<210> 3557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3557

ccccuuuccu uuucugaccu ccuuu 25

<210> 3558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3558

cuuuccuuuu cugaccuccu uuugg 25

<210> 3559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3559

uuuccuuuuc ugaccuccuu uugga 25

<210> 3560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3560

gagggcucag cgcugcccag accau 25

<210> 3561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3561

cgcugcccag accauaggag agaug 25

<210> 3562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3562

gcugcccaga ccauaggaga gaugu 25

<210> 3563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3563

gcccagacca uaggagagau guggg 25

<210> 3564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3564

ggagagaugu gggaggcuca guucc 25

<210> 3565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3565

gagagaugug ggaggcucag uuccu 25

<210> 3566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3566

gggcuugcug uuucugcagc cgcuu 25

<210> 3567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3567

ggcuugcugu uucugcagcc gcuuu 25

<210> 3568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3568

uugcuguuuc ugcagccgcu uuggg 25

<210> 3569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3569

uucugcagcc gcuuugggug gcucc 25

<210> 3570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3570

ccgcuuuggg uggcuccagg uaaaa 25

<210> 3571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3571

cgcuuugggu ggcuccaggu aaaac 25

<210> 3572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3572

gcuuugggg gcuccaggua aaacg 25

<210> 3573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3573

uggguggcuc cagguaaaac gggga 25

<210> 3574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3574

guggcuccag guaaaacgggg gaugg 25

<210> 3575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3575

uggcuccagg uaaaacgggg auggc 25

<210> 3576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3576

cuccagguaa aacggggaug gcggg 25

<210> 3577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3577

uccagguaaa acggggaugg cggga 25

<210> 3578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3578

gucucugggc cuucaccccu gugcc 25

<210> 3579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3579

cugggaugcc guucugcugg ucucu 25

<210> 3580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3580

gcugggaugc cguucugcug gucuc 25

<210> 3581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3581

cgucguggcu gggaugccgu ucugc 25

<210> 3582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3582

acagagcaaa guggccgucg uggcu 25

<210> 3583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3583

gacagagcaa aguggccguc guggc 25

<210> 3584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3584

agcagacaga gcaaaguggc cgucg 25

<210> 3585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3585

guggcggaga gcagacagag caaag 25

<210> 3586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3586

cccagggaac aggcaggggc cgugg 25

<210> 3587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3587

ugucccaggg aacagagcag ggccg 25

<210> 3588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3588

cggggguguc ccagggaaca gagca 25

<210> 3589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3589

gcgggggugu cccagggaac agagc 25

<210> 3590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3590

aggaggggg ggcgggggg uccca 25

<210> 3591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3591

gaggaggugg gggcgggggu gucci 25

<210> 3592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3592

aggcagccug aggaggggg ggcgg 25

<210> 3593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3593

caggcagccu gaggaggugg gggcg 25

<210> 3594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3594

ucaggcagcc ugagggaggug ggggc 25

<210> 3595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3595

aucaggcagc cugaggaggu ggggg 25

<210> 3596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3596

cagaucaggc agccuggga ggugg 25

<210> 3597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3597

gcagaucagg cagccugagg aggug 25

<210> 3598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3598

ggcagaucag gcagccugag gaggu 25

<210> 3599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3599

gggcagauca ggcagccuga ggagg 25

<210> 3600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3600

gcugggcaga ucaggcagcc ugagg 25

<210> 3601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3601

aaagcugggc agaucaggca gccug 25

<210> 3602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3602

ggaaagcugg aaagcugggc agauc 25

<210> 3603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3603

gaauccagag gaaagcugga aagcu 25

<210> 3604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3604

ggaauccaga ggaaagcugg aaagc 25

<210> 3605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3605

cagaggccgg aauccagagg aaagc 25

<210> 3606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3606

gggaugacca gaggccggaa uccag 25

<210> 3607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3607

agggugggga gggaugacca gaggc 25

<210> 3608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3608

agagaggggug gggagggaug accag 25

<210> 3609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3609

gagggccuug gagagagggu gggga 25

<210> 3610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3610

agaggggccuu ggagagggg ugggg 25

<210> 3611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3611

aggagaggggc cuuggagaga gggug 25

<210> 3612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3612

caggagagggg ccuuggagag agggu 25

<210> 3613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3613

ccaggagagg gccuuggaga gaggg 25

<210> 3614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3614

agaccaggag agggccuugg agaga 25

<210> 3615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3615

gagaccagga gagggccuug gagag 25

<210> 3616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3616

aagaagggag accaggagag ggccu 25

<210> 3617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3617

uucuagaaga agggagacca ggaga 25

<210> 3618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3618

guucuagaag aagggagacc aggag 25

<210> 3619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3619

aagggguucu agaagaaggg agacc 25

<210> 3620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3620

gguggaggaa ggggguucuag aagaa 25

<210> 3621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3621

agguggagga agggguucua gaaga 25

<210> 3622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3622

ucugcagaga gggaggugga ggaag 25

<210> 3623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3623

uucugcagag agggaggugg aggaa 25

<210> 3624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3624

guucugcaga gagggaggug gagga 25

<210> 3625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3625

agaaguucug cagagaggga ggugg 25

<210> 3626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3626

aggagaaguu cugcagagag ggagg 25

<210> 3627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3627

uaaaggagaa guucugcaga gaggg 25

<210> 3628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3628

ggguaaagga gaaguucugc agaga 25

<210> 3629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3629

gggguaaagg agaaguucug cagag 25

<210> 3630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3630

ggcagggug ggggggggg gguaa 25

<210> 3631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3631

aaaggggggca guggggggg guggg 25

<210> 3632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3632

gaaaggggggc aguggugggg ggugg 25

<210> 3633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3633

ggaaaggggg caggugggggg gggug 25

<210> 3634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3634

aggaaagggg gcagugggg ggggu 25

<210> 3635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3635

aaggaaaggg ggcaguggug ggggg 25

<210> 3636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3636

gaaaaggaaa gggggcagug guggg 25

<210> 3637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3637

agaaaaggaa agggggcagu ggugg 25

<210> 3638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3638

cagaaaagga aagggggcag uggug 25

<210> 3639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3639

ucagaaaagg aaagggggca guggu 25

<210> 3640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3640

gucagaaaag gaaagggggc agugg 25

<210> 3641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3641

gaggucagaa aaggaaaggg ggcag 25

<210> 3642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3642

caaaaggagg ucagaaaagg aaagg 25

<210> 3643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3643

ccaaaaggag gucagaaaag gaaag 25

<210> 3644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3644

uccaaaagga ggucagaaaa ggaaa 25

<210> 3645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3645

cuccaaaagg aggucagaaa aggaa 25

<210> 3646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3646

gagcccucca aaaggagguc agaaa 25

<210> 3647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3647

gggcagcgcu gagcccucca aaagg 25

<210> 3648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3648

ucugggcagc gcugagcccu ccaaa 25

<210> 3649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3649

gccucccaca ucucuccuau ggucu 25

<210> 3650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3650

agccucccac aucucuccua ugguc 25

<210> 3651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3651

aacugagccu cccacaucuc uccua 25

<210> 3652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3652

aagcggcugc agaaacagca agccc 25

<210> 3653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3653

ccguuuuacc uggagccacc caaag 25

<210> 3654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3654

accccccgc cauccccguu uuacc 25

<210> 3655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3655

cucaccuagu gaagccucuc cagcc 25

<210> 3656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3656

ucaccuagug aagccucucc agcca 25

<210> 3657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3657

caccuaguga agccucucca gccag 25

<210> 3658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3658

gugaagccuc uccagccagg ggcug 25

<210> 3659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3659

ccucuccagc caggggcuga ggucc 25

<210> 3660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3660

cuccagccag gggcugaggu cccgg 25

<210> 3661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3661

gccaggggcu gaggucccgg uggug 25

<210> 3662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3662

ccaggggcug aggucccggu ggugu 25

<210> 3663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3663

gcugaggugcc cgguggugug ggccc 25

<210> 3664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3664

gaggucccgg ugguguggggc ccagg 25

<210> 3665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3665

aggucccggu ggugugggcc cagga 25

<210> 3666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3666

ggucccggug gugugggcc aggag 25

<210> 3667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3667

gucccggugg ugugggccca ggagg 25

<210> 3668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3668

cccugcagcc ccacaauccc ccucc 25

<210> 3669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3669

aggaucucag ccuucugcga agagc 25

<210> 3670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3670

ggaucucagc cuucugcgaa gagca 25

<210> 3671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3671

gaucucagcc uucugcgaag agcag 25

<210> 3672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3672

ccuucugcga aggcagggg ucacu 25

<210> 3673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3673

ggucacuugg cagcaucagc cagac 25

<210> 3674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3674

gccagacagg uaugcacccc aaacu 25

<210> 3675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3675

ccagacaggu augcacccca aacuu 25

<210> 3676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3676

aggcuucacu aggugagcaa aagag 25

<210> 3677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3677

agccccuggc uggagaggcu ucacu 25

<210> 3678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3678

ccgggaccuc agccccuggc uggag 25

<210> 3679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3679

caccaccggg accucagccc cuggc 25

<210> 3680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3680

cccacaccac cgggaccuca gcccc 25

<210> 3681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3681

agcccccucc ugggcccaca ccacc 25

<210> 3682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3682

gagcccccuc cugggcccac accac 25

<210> 3683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3683

gggagcuggg caggagcccc cuccu 25

<210> 3684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3684

ggggagcugg gcaggagccc ccucc 25

<210> 3685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3685

uugggggcu gcaggggagc ugggc 25

<210> 3686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3686

gggauugugg ggcugcaggg gagcu 25

<210> 3687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3687

ggggauugug gggcugcagg ggagc 25

<210> 3688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3688

cuggaggggg auuguggggc ugcag 25

<210> 3689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3689

ccuggagggg gauugugggg cugca 25

<210> 3690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3690

uccggaggg ggauuguggg gcugc 25

<210> 3691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3691

gcugagaucc uggaggggga uugug 25

<210> 3692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3692

ggcugagauc cuggaggggg auugu 25

<210> 3693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3693

aggcugagau ccuggagggg gauug 25

<210> 3694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3694

ucgcagaagg cugagauccu ggagg 25

<210> 3695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3695

uucgcagaag gcugagaucc uggag 25

<210> 3696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3696

cuucgcagaa ggcugagauc cugga 25

<210> 3697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3697

ucuucgcaga aggcugagau ccugg 25

<210> 3698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3698

ugcucuucgc agaaggcuga gaucc 25

<210> 3699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3699

ccaagugacc ccugcucuuc gcaga 25

<210> 3700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3700

cccaaguuug gggugcauac cuguc 25

<210> 3701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3701

caacuccauu cucuuucccg cccag 25

<210> 3702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3702

ccaguggcc gccgcugcc gcccc 25

<210> 3703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3703

cccgcugccg cccccggcca ucccc 25

<210> 3704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3704

ccgccccgg ccauccccug gcccc 25

<210> 3705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3705

caucccgggg ccccggccc ucacc 25

<210> 3706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3706

ccggggccc ccggcccuca cccgg 25

<210> 3707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3707

cccucacccg gcggcgcccu ccucc 25

<210> 3708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3708

ccucacccgg cggcgcccuc cuccu 25

<210> 3709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3709

cucacccggc ggcgcccucc uccug 25

<210> 3710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3710

ucacccggcg gcgcccuccu ccugg 25

<210> 3711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3711

ggcggcgccc uccuccugggg ggccc 25

<210> 3712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3712

uggggggcca ggccccgccg cuaca 25

<210> 3713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3713

ccccgccgcu acacggugcu gagcg 25

<210> 3714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3714

cccgccgcua cacggugcug agcgu 25

<210> 3715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3715

gcuacacggu gcugagcgug ggucc 25

<210> 3716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3716

acacggugcu gagcgugggu cccgg 25

<210> 3717

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3717

gcgugggucc cggaggccug cgcag 25

<210> 3718

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3718

cgugggccc ggaggccugc gcagc 25

<210> 3719

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3719

gggucccgga ggccugcgca gcggg 25

<210> 3720

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3720

cugccccugc agccccgcgu ccagc 25

<210> 3721

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3721

agccccgcgu ccagcuggau gagcg 25

<210> 3722

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3722

ccgcguccag cuggaugagc gcggc 25

<210> 3723

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3723

agcuggauga gcgcggccgg cagcg 25

<210> 3724

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3724

gcuggaugag cgcggccggc agcgc 25

<210> 3725

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3725

cuggaugagc gcggccggca gcgcg 25

<210> 3726

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3726

ccggcagcgc ggggacuucu cgcua 25

<210> 3727

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3727

cuucucgcua uggcugcgcc cagcc 25

<210> 3728

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3728

cuauggcugc gccgccg gcgcg 25

<210> 3729

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3729

ugcgcccagc ccggcgcgcg gacgc 25

<210> 3730

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3730

gcggacgccg gcgaguaccg cgccg 25

<210> 3731

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3731

cgaguaccgc gccgcggugc accuc 25

<210> 3732

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3732

gaguaccgcg ccgcggugca ccuca 25

<210> 3733

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3733

gcgccugggc caggccucga guaug 25

<210> 3734

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3734

cgccugggcc aggccucgag uaugu 25

<210> 3735

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3735

gccugggcca ggccucgagu August 25

<210> 3736

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3736

ugggccaggc cucgaguauggggg 25

<210> 3737

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3737

gggccaggcc ucgaguaugu ggggc 25

<210> 3738

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3738

gccucgagua uguggggcgg gacga 25

<210> 3739

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3739

ccucgaguau guggggcggg acgau 25

<210> 3740

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3740

gcggggccacu gggcgggaaa gagaa 25

<210> 3741

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3741

ggcggcagcg ggcggggccac ugggc 25

<210> 3742

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3742

gggcggcagc gggcggggcca cuggg 25

<210> 3743

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3743

cggggcggc agcggggcggg ccacu 25

<210> 3744

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3744

ccggggggcgg cagcggggcgg gccac 25

<210> 3745

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3745

gggauggccg ggggcggcag cgggc 25

<210> 3746

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3746

ggggauggcc gggggcggca gcggg 25

<210> 3747

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3747

ccaggggaug gccgggggcg gcagc 25

<210> 3748

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3748

gccaggggau ggccgggggc ggcag 25

<210> 3749

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3749

ccggggggcca ggggauggcc ggggg 25

<210> 3750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3750

gggccgggggg ccaggggaug gccgg 25

<210> 3751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3751

agggccgggg gccaggggau ggccg 25

<210> 3752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3752

ggggccggggggggggga uggcc 25

<210> 3753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3753

ugaggggccgg gggccagggg auggc 25

<210> 3754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3754

ccggggggcca gggga 25

<210> 3755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3755

ccgccggggug agggccgggg gccag 25

<210> 3756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3756

gccgccgggu ggggccgggg ggcca 25

<210> 3757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3757

cgccgccggg ugaggggccgg gggcc 25

<210> 3758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3758

gagggcgccg ccgggugagg gccgg 25

<210> 3759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3759

ggagggcgcc gccgggugag ggccg 25

<210> 3760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3760

aggagggcgc cgccggguga gggcc 25

<210> 3761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3761

gaggagggcg ccgccggggug agggc 25

<210> 3762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3762

cggagaggag ggcgccgccg gguga 25

<210> 3763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3763

cccaggagga gggcgccgcc gggug 25

<210> 3764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3764

gggcccccag gaggagggcg ccgcc 25

<210> 3765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3765

ugggcccca ggaggagggc gccgc 25

<210> 3766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3766

ggcggggccu gggcccccag gagga 25

<210> 3767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3767

cggcggggcc ugggccccca ggagg 25

<210> 3768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3768

uagcggcgg gccugggccc ccagg 25

<210> 3769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3769

guguagcggc ggggcgggg ccccc 25

<210> 3770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3770

ucagcaccgu guagcggcgg ggccu 25

<210> 3771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3771

cucagcaccg uguagcggcg gggcc 25

<210> 3772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3772

ccacgcucag caccguguag cggcg 25

<210> 3773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3773

cccacgcuca gcaccgugua gcggc 25

<210> 3774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3774

acccacgcuc agcaccgugu agcgg 25

<210> 3775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3775

gggacccg cucagcaccg uguag 25

<210> 3776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3776

gcagcccccc gcugcgcagg ccucc 25

<210> 3777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3777

ggcagccucc cgcugcgcag gccuc 25

<210> 3778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3778

cugcaggggc agccucccgc ugcgc 25

<210> 3779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3779

cauccagcug gacgcggggc ugcag 25

<210> 3780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3780

ucauccagcu ggacgcgggg cugca 25

<210> 3781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3781

cucauccagc uggacgcggg gcugc 25

<210> 3782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3782

ggccgcgcuc auccagcugg acgcg 25

<210> 3783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3783

cggccgcgcu cauccagcug gacgc 25

<210> 3784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3784

ccggccgcgc ucauccagcu ggacg 25

<210> 3785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3785

gcgcugccgg ccgcgcucau ccagc 25

<210> 3786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3786

ccauagcgag aagucccccgc gcugc 25

<210> 3787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3787

cucgccggcg uccgcgcgcc gggcu 25

<210> 3788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3788

acucgccggc guccgcgcgc cgggc 25

<210> 3789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3789

cgguaacucgc cggcguccgc gcgcc 25

<210> 3790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3790

gcgguacucg ccggcguccg cgcgc 25

<210> 3791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3791

aggugcaccg cggcgcggua cucgc 25

<210> 3792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3792

cgggucccug aggugcaccg cggcg 25

<210> 3793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3793

ucccgcgggu cccugaggug caccg 25

<210> 3794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3794

cgccguccuc ucccgcgggu cccug 25

<210> 3795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3795

gucugccucc gccguccucu cccgc 25

<210> 3796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3796

cuugcacagu gacugccagc ccccc 25

<210> 3797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3797

cccaggaucu cucagagccu cgac 25

<210> 3798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3798

ccaggaucuc ucagagccuc cgacu 25

<210> 3799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3799

cccugaccgc ccagccucug ugcau 25

<210> 3800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3800

ccgcccagcc ucugugcauu gguuc 25

<210> 3801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3801

agccucugug cauugguucc ggaac 25

<210> 3802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3802

gccucugugc auugguuccg gaacc 25

<210> 3803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3803

ccucugugca uugguuccgg aaccg 25

<210> 3804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3804

gugcauuggu uccggaaccg gggcc 25

<210> 3805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3805

ugcauugguu ccggaaccgg ggcca 25

<210> 3806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3806

ccggggccag ggccgagucc cuguc 25

<210> 3807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3807

cggggccagg gccgaguccc ugucc 25

<210> 3808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3808

cgggaguccc cccaucacca cuuag 25

<210> 3809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3809

cucuuccugc cccaagucag cccca 25

<210> 3810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3810

ugccccaagu cagccccaug gacuc 25

<210> 3811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3811

gccccaaguc agccccaugg acucu 25

<210> 3812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3812

agucagcccc auggacucug ggcc 25

<210> 3813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3813

gucagcccca uggacucugg gcccu 25

<210> 3814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3814

ucagccccau ggacucuggg cccug 25

<210> 3815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3815

ggggcugcau ccucaccuac agaga 25

<210> 3816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3816

uccaucaugu auaaccucac uguuc 25

<210> 3817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3817

ccaucaugua uaaccucacu guucu 25

<210> 3818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3818

cuggggggcu ggcagucacu gugca 25

<210> 3819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3819

gaggcucuga gagauccugg ggggc 25

<210> 3820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3820

gucggaggcu cugagagauc cuggg 25

<210> 3821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3821

agucggaggc ucugagagau ccugg 25

<210> 3822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3822

cagucggagg cucugagaga uccug 25

<210> 3823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3823

ccagucggag gcucugagag auccu 25

<210> 3824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3824

cccagucgga ggcucugaga gaucc 25

<210> 3825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3825

gagcaguuca aaaugaccca gucgg 25

<210> 3826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3826

aaggagcagu ucaaaaugac ccagu 25

<210> 3827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3827

gaggcugggc ggucagggcg gcuga 25

<210> 3828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3828

augcacagag gcugggcggu caggg 25

<210> 3829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3829

ccaaugcaca gaggcugggc gguca 25

<210> 3830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3830

accaaugcac agaggcuggg cgguc 25

<210> 3831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3831

ccggaaccaa ugcacagagg cuggg 25

<210> 3832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3832

guuccggaac caaugcacag aggcu 25

<210> 3833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3833

gguuccggaa ccaaugcaca gaggc 25

<210> 3834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3834

ccccgguucc ggaaccaaug cacag 25

<210> 3835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3835

agggacucgg cccuggcccc gguuc 25

<210> 3836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3836

ccggacaggg acucggcccu ggccc 25

<210> 3837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3837

ggacucccgg acagggacuc ggccc 25

<210> 3838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3838

auggggggac ucccggacag ggacu 25

<210> 3839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3839

guggugagg ggggacuccc ggaca 25

<210> 3840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3840

agggugaug gggggacucc cggac 25

<210> 3841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3841

cgcuaagugg ugagggggg acucc 25

<210> 3842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3842

aagcuuuccg cuaaguggug auggg 25

<210> 3843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3843

gaagcuuucc gcuaaguggu gaugg 25

<210> 3844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3844

ggaagcuuuc cgcuaagugg ugaug 25

<210> 3845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3845

aggaagcuuu ccgcuaagug gugau 25

<210> 3846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3846

gaggaagcuu uccgcuaagu gguga 25

<210> 3847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3847

caggaagagg aagcuuuccg cuaag 25

<210> 3848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3848

cauggggcug acuuggggca ggaag 25

<210> 3849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3849

agaguccaug gggcugacuu ggggc 25

<210> 3850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3850

gccagaguc cauggggcug acuug 25

<210> 3851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3851

ggccgagu ccauggggcu gacuu 25

<210> 3852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3852

gggccgag uccauggggc ugacu 25

<210> 3853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3853

gcagccccag ggcccagagu ccaug 25

<210> 3854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3854

ugcagcccca gggccgag uccau 25

<210> 3855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3855

augcagcccc agggcccaga gucca 25

<210> 3856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3856

cucuguaggu gaggaugcag cccca 25

<210> 3857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3857

ucucuguagg ugaggaugca gcccc 25

<210> 3858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3858

gacguugaag ccaucucugu aggug 25

<210> 3859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3859

auggagacgu ugaagccauc ucugu 25

<210> 3860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3860

cccagaacag ugagguuaua cauga 25

<210> 3861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3861

agugggggag uuacccagaa cagug 25

<210> 3862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3862

uuggguuuuc uuuucucuuc agguc 25

<210> 3863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3863

ccccaacucc cuugacagug uacgc 25

<210> 3864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3864

cucccuugac aguguacgcu ggagc 25

<210> 3865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3865

gacaguguac gcuggagcag guucc 25

<210> 3866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3866

acaguguacg cuggagcagg uucca 25

<210> 3867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3867

guguacgcug gagcagguuc caggg 25

<210> 3868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3868

uguacgcugg agcagguucc agggu 25

<210> 3869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3869

guacgcugga gcagguucca gggug 25

<210> 3870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3870

uggggcugcc cugccgccug ccugc 25

<210> 3871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3871

cugcccugcc gccugccugc uggug 25

<210> 3872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3872

ugccugccg ccugccugcu ggugu 25

<210> 3873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3873

gccugccgc cugccugcug gugug 25

<210> 3874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3874

ccgccugccu gcuggugugg ggacc 25

<210> 3875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3875

gacccggucu uuccucacug ccaag 25

<210> 3876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3876

uccucacugc caaguggacu ccucc 25

<210> 3877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3877

ccucacugcc aaguggacuc cuccu 25

<210> 3878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3878

cucacugcca aguggacucc uccug 25

<210> 3879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3879

ucacugccaa guggacuccu ccugg 25

<210> 3880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3880

cugccaagug gacuccuccu ggggg 25

<210> 3881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3881

ccuccugggg gaggcccuga ccucc 25

<210> 3882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3882

ggggaggccc ugaccuccug gugac 25

<210> 3883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3883

cugaccuccu ggugacugga gacaa 25

<210> 3884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3884

aauggcgacu uuacccuucg acuag 25

<210> 3885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3885

acccuucgac uagaggaugu gagcc 25

<210> 3886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3886

cgacuagagg augugagcca ggcc 25

<210> 3887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3887

uagaggaugu gagccaggcc caggc 25

<210> 3888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3888

aggaugug agccaggccc aggcu 25

<210> 3889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3889

accuacaccu gccaauaucca ucugc 25

<210> 3890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3890

cagcagcuca augccacugu cacau 25

<210> 3891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3891

ccacugucac auuggcaauc aucac 25

<210> 3892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3892

uuggcaauca ucacagguca gccuc 25

<210> 3893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3893

gcaaucauca caggucagcc ucagg 25

<210> 3894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3894

caaucaucac aggucagccu caggu 25

<210> 3895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3895

aucacagguc agccucaggu gggaa 25

<210> 3896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3896

cagcguaacac ugucaaggga guugg 25

<210> 3897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3897

ccagcguaca cugucaaggg aguug 25

<210> 3898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3898

uccagcguac acugucaagg gaguu 25

<210> 3899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3899

cuccagcgua cacugucaag ggagu 25

<210> 3900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3900

aaccugcucc agcguacacu gucaa 25

<210> 3901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3901

gaaccugcuc cagcguacac uguca 25

<210> 3902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3902

ggcaggcggc agggcagcc caccc 25

<210> 3903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3903

ucccacacc agcaggcagg cggca 25

<210> 3904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3904

guccccacac cagcaggcag gcggc 25

<210> 3905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3905

ccgggucccc acaccagcag gcagg 25

<210> 3906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3906

agaccggguc cccacaccag caggc 25

<210> 3907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3907

ggaaagaccg gguccccaca cgc 25

<210> 3908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3908

guccacuugg cagugaggaa agacc 25

<210> 3909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3909

aguccacuug gcagugagga aagac 25

<210> 3910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3910

cccaggagga guccacuugg cagug 25

<210> 3911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3911

gggccuccccc caggaggagu ccacu 25

<210> 3912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3912

ccaggagguc agggcccccc ccagg 25

<210> 3913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3913

ucaccaggag gucaggggccu ccccc 25

<210> 3914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3914

auugucucca gucaccagga gguca 25

<210> 3915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3915

cauugucucc agucaccagg agguc 25

<210> 3916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3916

gucgccauug ucuccaguca ccagg 25

<210> 3917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3917

aaagucgcca uugucuccag ucacc 25

<210> 3918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3918

gccuggcuca cauccucuag ucgaa 25

<210> 3919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3919

ggccuggcuc acauccucua gucga 25

<210> 3920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3920

gcagguguag guccigccu gggcc 25

<210> 3921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3921

auauggcagg uguagguccc agccu 25

<210> 3922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3922

gauauggcag guguaggucc cagcc 25

<210> 3923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3923

uccugcagau ggauauggca ggugu 25

<210> 3924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3924

ugcuguuccu gcagauggau auggc 25

<210> 3925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3925

gagcugcugu uccugcagau ggaua 25

<210> 3926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3926

ggcauugagc ugcuguuccu gcaga 25

<210> 3927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3927

ccugugauga uugccaaugu gacag 25

<210> 3928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3928

ucuuuucagu gacucccaaa uccuu 25

<210> 3929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3929

cuuuucagug acucccaaau ccuuu 25

<210> 3930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3930

ugacucccaa auccuuuggg ucacc 25

<210> 3931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3931

aaauccuuug ggucaccugg auccc 25

<210> 3932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3932

aauccuuugg gucaccugga ucccu 25

<210> 3933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3933

auccuuuggg ucaccuggau cccug 25

<210> 3934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3934

ggaucccugg ggaagcugcu uugug 25

<210> 3935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3935

ugcuuuguga ggugacucca guauc 25

<210> 3936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3936

aguaucugga caagaacgcu uugug 25

<210> 3937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3937

caagaacgcu uuguguggag cucuc 25

<210> 3938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3938

gagcucucug gacaccccau cccag 25

<210> 3939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3939

acaccccauc ccagaggagu uucuc 25

<210> 3940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3940

aucccagagg aguuucucag gaccu 25

<210> 3941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3941

cagaggaguu ucucaggacc uuggc 25

<210> 3942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3942

aggaguuucu caggaccuug gcugg 25

<210> 3943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3943

uucucaggac cuuggcugga ggcac 25

<210> 3944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3944

ucaggaccuu ggcuggaggc acagg 25

<210> 3945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3945

ggaggcccag cuccuuuccc agccu 25

<210> 3946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3946

cagccuuggc aaugccagcu guacc 25

<210> 3947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3947

agccuuggca augccagcug uacca 25

<210> 3948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3948

gccuuggcaa ugccagcugu accag 25

<210> 3949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3949

ccuuggcaau gccagcugua ccagg 25

<210> 3950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3950

gcaaugccag cuguaccagg gggag 25

<210> 3951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3951

agcuguacca gggggagagg cuucu 25

<210> 3952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3952

uguacuucac agagcugucu agccc 25

<210> 3953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3953

cacagagcug ucuagcccag guccg 25

<210> 3954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3954

cccagguccg aggccccaga augcc 25

<210> 3955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3955

uuugggaguc acugaaaaga guaga 25

<210> 3956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3956

gggauccagg ugacccaaag gauuu 25

<210> 3957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3957

agggauccag gugacccaaa ggauu 25

<210> 3958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3958

uuccccaggg auccagguga cccaa 25

<210> 3959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3959

cacaaagcag cuuccccagg gaucc 25

<210> 3960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3960

gucaccucac aaagcagcuu cccca 25

<210> 3961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3961

agucaccuca caaagcagcu ucccc 25

<210> 3962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3962

acacaaagcg uucuugucca gauac 25

<210> 3963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3963

gguccugaga aacuccucug ggaug 25

<210> 3964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3964

agguccugag aaacuccucu gggau 25

<210> 3965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3965

aagguccuga gaaacuccuc uggga 25

<210> 3966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3966

agccaagguc cugagaaacu ccucu 25

<210> 3967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3967

cagccaaggu ccugagaaac uccuc 25

<210> 3968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3968

gcugggccuc cugugccucc agcca 25

<210> 3969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3969

cauugccaag gcugggaaag gagcu 25

<210> 3970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3970

gcauugccaa ggcugggaaa ggagc 25

<210> 3971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3971

cagcuggcau ugccaaggcu gggaa 25

<210> 3972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3972

ugguacagcu ggcauugcca aggcu 25

<210> 3973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3973

cugguaacagc uggcauugcc aaggc 25

<210> 3974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3974

cccccuggua cagcuggcau ugcca 25

<210> 3975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3975

aagaagccuc ucccccuggu acagc 25

<210> 3976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3976

ugcugcucca agaagccucu ccccc 25

<210> 3977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3977

ccuggcauuc uggggccucg gaccu 25

<210> 3978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3978

uccggcauu cuggggccuc ggacc 25

<210> 3979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3979

cuuucuccau aggugcccaa cgcuc 25

<210> 3980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3980

uuucuccaua ggugcccaac gcucu 25

<210> 3981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3981

gugcccaacg cucugggaga gcccc 25

<210> 3982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3982

ggagagcccc ggugcccuc ccagc 25

<210> 3983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3983

gccaccuccu gcuguuucuc auccu 25

<210> 3984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3984

cuugggucc uuucucugcu ccuuu 25

<210> 3985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3985

uccuuucucu gcuccuuuug gugac 25

<210> 3986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3986

ugcuccuuuu ggugacugga gccuu 25

<210> 3987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3987

gacuggagcc uuuggcuuuc accuu 25

<210> 3988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3988

uuuggcuuuc accuuuggag aagac 25

<210> 3989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3989

caccuuugga gaagacaggu gagcc 25

<210> 3990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3990

accuuuggag aagacaggug agcca 25

<210> 3991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3991

ggagaagaca ggugagccag ggaca 25

<210> 3992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3992

cguugggcac cuauggagaa aguac 25

<210> 3993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3993

gcucucccag agcguugggc accua 25

<210> 3994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3994

gcaccugggg cucucccaga gcguu 25

<210> 3995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3995

ggcaccuggg gcucucccag agcgu 25

<210> 3996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3996

agguggccug cugggagggc accug 25

<210> 3997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3997

gagguggccu gcugggagg caccu 25

<210> 3998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3998

ggagguggcc ugcugggagg gcacc 25

<210> 3999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 3999

aacagcagga gguggccugc uggga 25

<210> 4000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4000

aaacagcagg agguggccug cuggg 25

<210> 4001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4001

gagaaacagc aggagguggc cugcu 25

<210> 4002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4002

ugagaaacag caggaggugg ccugc 25

<210> 4003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4003

accaaggaug agaaacagca ggagg 25

<210> 4004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4004

gacaccaagg augagaaaca gcagg 25

<210> 4005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4005

aaggacacca aggaugagaa acagc 25

<210> 4006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4006

caaaaggagc agagaaagga cacca 25

<210> 4007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4007

uccagucacc aaaaggagca gagaa 25

<210> 4008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4008

aaagccaaag gcuccaguca ccaaa 25

<210> 4009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4009

ugucuucucc aaaggugaaa gccaa 25

<210> 4010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4010

ucccuggcuc accugucuuc uccaa 25

<210> 4011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4011

ucucucucuc caucucuucu cacag 25

<210> 4012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4012

caagacgauu uucugccuua gagca 25

<210> 4013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4013

aagacgauuu ucugccuuag agcaa 25

<210> 4014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4014

uuagagcaag ggauucaccc uccgc 25

<210> 4015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4015

ccuccgcagg cucagagcaa gauag 25

<210> 4016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4016

caggcucaga gcaagauaga ggagc 25

<210> 4017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4017

agcccgagcc ggagcagcuc ugacc 25

<210> 4018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4018

ccggagcagc ucugaccugg agcug 25

<210> 4019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4019

ucccugucag cagcaagccu gaguc 25

<210> 4020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4020

ucuuggucgc cacugugaga agaga 25

<210> 4021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4021

cuugcucuaa ggcagaaaau cgucu 25

<210> 4022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4022

ugcggagggu gaaucccuug cucua 25

<210> 4023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4023

cucuaucuug cucugagccu gcgga 25

<210> 4024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4024

ccucuaucuu gcucugagcc ugcgg 25

<210> 4025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4025

gcuccucuau cuugcucuga gccug 25

<210> 4026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4026

gagaucugcu ggcugccuca gcucc 25

<210> 4027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4027

uuuggacugg gcugcugaga ucugc 25

<210> 4028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4028

ugcugacagg gaguuuauuu ggacu 25

<210> 4029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4029

cugcugacag ggaguuuuuu uggac 25

<210> 4030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4030

gcuugcugcu gacagggagu uuauu 25

<210> 4031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4031

gccagacuca ggcuugcugc ugaca 25

<210> 4032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4032

agccagacuc aggcuugcug cugac 25

<210> 4033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4033

uauaauuaua auauaauaga accac 25

<210> 4034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4034

auaauuauaa uauaauagaa ccaca 25

<210> 4035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4035

uuauaauaua auagaaccac aggga 25

<210> 4036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4036

uauaauauaa uagaaccaca gggaa 25

<210> 4037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4037

auaauauaau agaaccacag ggaag 25

<210> 4038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4038

uaauauuaaua gaaccacagg gaagg 25

<210> 4039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4039

gggggauccc uugucccagc cacuc 25

<210> 4040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4040

uugucccagc cacucaggug ccugc 25

<210> 4041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4041

gccacucagg ugccugcugg ccgcc 25

<210> 4042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4042

aggugccugc uggccgccug gaugc 25

<210> 4043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4043

ugccugcugg ccgccuggau gcugg 25

<210> 4044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4044

gccuggaugc ugguggcccu gcccc 25

<210> 4045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4045

gaugcuggug gcccugcccc aggag 25

<210> 4046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4046

augcuggugg cccugcccca ggagu 25

<210> 4047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4047

ugcugguggc ccugccccag gagug 25

<210> 4048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4048

gcuggggcc cugccccagg agugg 25

<210> 4049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4049

gccccaggag uggggggca gugug 25

<210> 4050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4050

aggggggg cagugugugg augug 25

<210> 4051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4051

gggugcagug uguggaugug aggag 25

<210> 4052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4052

cagugugugg augugaggag uggau 25

<210> 4053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4053

guggauguga ggaguggaua ggcca 25

<210> 4054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4054

gaugugagga guggauaggc cacgg 25

<210> 4055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4055

augugaggag uggauaggcc acggc 25

<210> 4056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4056

ugugaggagu ggauaggcca cggcg 25

<210> 4057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4057

gugaggagug gauaggccac ggcgg 25

<210> 4058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4058

guggauaggc cacggcgggg guacu 25

<210> 4059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4059

aggccacggc ggggguacua ggccc 25

<210> 4060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4060

ggccacggcg gggguacuag gcccc 25

<210> 4061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4061

gccacggcgg ggguacuagg ccccg 25

<210> 4062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4062

cccggcggggguacuaggc cccgg 25

<210> 4063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4063

ggggaacgcc uguaccuucc caccc 25

<210> 4064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4064

cgccuguacc uucccaccca ggccc 25

<210> 4065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4065

cuguaccuuc ccacccaggc ccugg 25

<210> 4066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4066

uguaccuucc cacccaggcc cuggu 25

<210> 4067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4067

ucccacccag gcccuggugg gagcc 25

<210> 4068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4068

ccggccaacc ccuuuuaaaua auuuc 25

<210> 4069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4069

caaccccuuu aaauaauuuc aggaa 25

<210> 4070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4070

aaccccuuua aauaauuuca ggaau 25

<210> 4071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4071

uaaauaauuu caggaauggg uucca 25

<210> 4072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4072

ggaauggguu ccaaggagag cuccc 25

<210> 4073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4073

gaauggguuc caaggagagc uccca 25

<210> 4074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4074

uggguuccaa ggagagcucc caggg 25

<210> 4075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4075

ggguuccaag gagagcuccc agggu 25

<210> 4076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4076

aaggaggcu cccagggugg gcaca 25

<210> 4077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4077

aggagagcuc ccagggggg cacau 25

<210> 4078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4078

ggagagcucc cagggggggc acaug 25

<210> 4079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4079

gagagcuccc aggggggca caugg 25

<210> 4080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4080

aggcucca ggggggcac auggg 25

<210> 4081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4081

ccagggggg cacauggggg gcccu 25

<210> 4082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4082

cugcacuucu gcccucccaa caccc 25

<210> 4083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4083

cacuucugcc cucccaacac ccagg 25

<210> 4084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4084

cucccaacac ccagguggcc acagc 25

<210> 4085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4085

ucccaacacc cagguggcca cagcu 25

<210> 4086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4086

caacacccag guggccacag cuggg 25

<210> 4087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4087

aacacccagg uggccacagc uggga 25

<210> 4088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4088

acacccaggu ggccacagcu gggag 25

<210> 4089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4089

aaccccagcc cugcccuccu gaccu 25

<210> 4090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4090

accccagccc ugcccuccug accuu 25

<210> 4091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4091

ccugcccucc ugaccuuggg accgu 25

<210> 4092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4092

gaccguagga ugucccucuc ccgag 25

<210> 4093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4093

ggaugucccu cucccgagug gugug 25

<210> 4094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4094

gaugucccuc ucccgagugg uguga 25

<210> 4095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4095

augucccucu cccgaguggu gugag 25

<210> 4096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4096

cccucucccg aggguguga ggggc 25

<210> 4097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4097

ccucucccga guggugugag gggcu 25

<210> 4098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4098

cuccccgag uggugugagg ggcug 25

<210> 4099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4099

ucccgaggg ugugaggggc ugggg 25

<210> 4100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4100

uggugugagg ggcuggggug gaaug 25

<210> 4101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4101

ugugaggggc ugggguggaa ugcgg 25

<210> 4102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4102

aggggcuggg guggaaugcg gcggc 25

<210> 4103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4103

ggcggggug gaaugcggcg gcagg 25

<210> 4104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4104

augcggcggc aggaggccag agugc 25

<210> 4105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4105

ggcggcagga ggccagagug cuggc 25

<210> 4106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4106

gcggcaggag gccagagugc uggcu 25

<210> 4107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4107

ggccagagug cuggcugggc cugaa 25

<210> 4108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4108

cugccucagc uucccugccc cacaa 25

<210> 4109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4109

ugccucagcu ucccugcccc acaaa 25

<210> 4110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4110

gcuucccugc cccacaaagg gccug 25

<210> 4111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4111

cccacaaagg gccugaggug cugcc 25

<210> 4112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4112

ccacaaaggg ccugaggugc ugccu 25

<210> 4113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4113

ugaggugcug ccugggcaug uguaa 25

<210> 4114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4114

ggugcugccu gggcaugugu aaagg 25

<210> 4115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4115

gcugcgggg cauguguaaa ggugg 25

<210> 4116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4116

cugccugggc auguguaaag gugga 25

<210> 4117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4117

ugggggca uguguaaagg uggag 25

<210> 4118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4118

guuuccugcc cugcccacca cagcc 25

<210> 4119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4119

uucugaccuu cccugaaacu ucucu 25

<210> 4120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4120

uucccugaaa cuucucuagg ccugc 25

<210> 4121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4121

ucccugaaac uucucuaggc cugca 25

<210> 4122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4122

aggccugcag ggagcagaua acucc 25

<210> 4123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4123

ggccugcagg gagcagauaa cuccu 25

<210> 4124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4124

gccugcaggg agcagauaac uccug 25

<210> 4125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4125

uaccucccac uccugugccc agucu 25

<210> 4126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4126

accucccacu ccugugccca gucuu 25

<210> 4127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4127

gugcccaguc uugggcccug cgucc 25

<210> 4128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4128

ugccagucu ugggccugc gucca 25

<210> 4129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4129

cuugggcccu gcguccaggg cguuu 25

<210> 4130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4130

uugggccug cguccagggc guuuc 25

<210> 4131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4131

cagggcguuu cgggaugcca cugcc 25

<210> 4132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4132

agggcguuuc gggaugccac ugcca 25

<210> 4133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4133

gggcguuucg ggaugccacu gccag 25

<210> 4134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4134

cgggaugcca cugccagggg caccu 25

<210> 4135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4135

ugccaggggc accuuggcug cucca 25

<210> 4136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4136

ccaucuccaa ccagcccca aguuc 25

<210> 4137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4137

cuccaaccag cccccaaguu caggc 25

<210> 4138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4138

caaccagccc ccaaguucag gcagg 25

<210> 4139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4139

gcccccaagu ucaggcagga ggcuc 25

<210> 4140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4140

cccccaaguu caggcaggag gcucc 25

<210> 4141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4141

ccccaaguuc aggcaggagg cuccg 25

<210> 4142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4142

uucaggcagg aggcuccgggg gcguc 25

<210> 4143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4143

ggcaggaggc uccggggcgu caggc 25

<210> 4144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4144

gcaggaggcu ccggggcguc aggca 25

<210> 4145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4145

ggcuccgggg cgucaggcag ggcca 25

<210> 4146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4146

ggcaggggcca cggcgccuuc agccc 25

<210> 4147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4147

gcagggccac ggcgccuuca gcccc 25

<210> 4148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4148

gcagcagcag cagcagcaga gauuc 25

<210> 4149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4149

cagcagcagc agcagcagag auuca 25

<210> 4150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4150

cagcagcagc agagauucag ggagc 25

<210> 4151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4151

agcagagauu cagggagcug gacgc 25

<210> 4152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4152

gagcuggacg caggcagcuc ugugc 25

<210> 4153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4153

uggacgcagg cagcucugug cuggc 25

<210> 4154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4154

caggaccuga agcagugacu gcauc 25

<210> 4155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4155

agugacugca ucuggccuc ccugu 25

<210> 4156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4156

gugacugcau cuggcccucc cugua 25

<210> 4157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4157

ugacugcauc uggccccc uguag 25

<210> 4158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4158

ugcaucuggc ccucccugua gggga 25

<210> 4159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4159

guaggggacg gugacaccug cugcc 25

<210> 4160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4160

uaggggacgg ugacaccugc ugccu 25

<210> 4161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4161

ugacaccugc ugccugggcu cacug 25

<210> 4162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4162

gacaccugcu gccugggcuc acugu 25

<210> 4163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4163

ugugggcauu gagacaugag uccug 25

<210> 4164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4164

gggcauugag acaugagucc ugugg 25

<210> 4165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4165

ggcauugaga caugaguccu guggu 25

<210> 4166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4166

gcauugagac augaguccug uggug 25

<210> 4167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4167

augaguccug uggggggcu gugcc 25

<210> 4168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4168

ccuguggugg ggcugugccu ggugc 25

<210> 4169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4169

guggggcugu gccuggugca ggugc 25

<210> 4170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4170

ggcugugccu ggugcaggug caggc 25

<210> 4171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4171

cuggugcagg ugcaggcugg agccc 25

<210> 4172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4172

gcaggcugga gccccggucg ccccc 25

<210> 4173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4173

ggucgccccc aggcagcuca gcccc 25

<210> 4174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4174

gcccccaggc agcucagccc cugga 25

<210> 4175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4175

agcucagccc cuggacggcc ugcaa 25

<210> 4176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4176

gccugcaccc ugccugcuuc uccug 25

<210> 4177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4177

cuucuccuga ggaaaugcgc ugacc 25

<210> 4178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4178

uucuccugag gaaaugcgcu gaccc 25

<210> 4179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4179

gaggaaaugc gcugacccgg gcuca 25

<210> 4180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4180

gaaaugcgcu gaccggggcu caugg 25

<210> 4181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4181

augcgcugac ccgggcucau ggugg 25

<210> 4182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4182

ugcgcugacc cgggcucaug gugga 25

<210> 4183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4183

ucaugggga gggucugcag aacac 25

<210> 4184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4184

uggggaggg ucugcagaac acugg 25

<210> 4185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4185

agggucugca gaacacuggu ggcca 25

<210> 4186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4186

gcagaacacu gguggccaag gaagc 25

<210> 4187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4187

acgguggcc aaggaagccg gucag 25

<210> 4188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4188

cugguggcca aggaagccgg ucaga 25

<210> 4189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4189

uggggccaa ggaagccggu cagag 25

<210> 4190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4190

ggggccaaga gcagugucca uccuc 25

<210> 4191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4191

agcagugucc auccucaggc cucag 25

<210> 4192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4192

guguccaucc ucaggccuca guggc 25

<210> 4193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4193

uguccauccu caggccucag uggcu 25

<210> 4194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4194

caggccucag uggcugggca cuccg 25

<210> 4195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4195

aggccucagu ggcugggcac uccga 25

<210> 4196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4196

ccgaggggccg ucagcugagc cccug 25

<210> 4197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4197

cgagggccgu cagcugagcc ccugc 25

<210> 4198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4198

gggccgucag cugagccccu gcggg 25

<210> 4199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4199

ggccgucagc ugagccccug cgggc 25

<210> 4200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4200

gccgucagcu gagccccugc gggcg 25

<210> 4201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4201

ccgucagcug agccccugcg ggcgg 25

<210> 4202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4202

gcugagcccc ugcgggcggg ggaug 25

<210> 4203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4203

cgggggauga ggugcccauu ccgcu 25

<210> 4204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4204

gugcccauuc cgcuaggaaa gacaa 25

<210> 4205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4205

cccauuccgc uaggaaagac aaugg 25

<210> 4206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4206

caaugguggc auacuccguc ugcuc 25

<210> 4207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4207

aaugguggca uacuccgucu gcuca 25

<210> 4208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4208

gcauacuccig ucugcucagg gacac 25

<210> 4209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4209

cauacuccgu cugcucaggg acaca 25

<210> 4210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4210

uccgucugcu cagggacaca gggca 25

<210> 4211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4211

ccgucugcuc agggacacag ggcac 25

<210> 4212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4212

cgucugcuca gggacacagg gcacg 25

<210> 4213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4213

gucugcucag ggacacaggg cacgg 25

<210> 4214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4214

ucugcucagg gacacaggggc acggg 25

<210> 4215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4215

cagggacaca gggcacgggg ggcuc 25

<210> 4216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4216

agggacacag ggcacggggg gcucc 25

<210> 4217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4217

gggacacagg gcacgggggg cuccg 25

<210> 4218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4218

gggcuccggg gucuucucuc gccac 25

<210> 4219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4219

gcuccccaua guccacagag aacac 25

<210> 4220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4220

ccauagucca cagagaacac aggca 25

<210> 4221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4221

uccacagaga acacaggcac ggcug 25

<210> 4222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4222

ccacagagaa cacaggcacg gcuga 25

<210> 4223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4223

cacagagaac acaggcacgg cugag 25

<210> 4224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4224

acggcugagg gguccuccuu cuuug 25

<210> 4225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4225

agggguccuc cuucuuugag gagaa 25

<210> 4226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4226

gggguccucc uucuuugagg agaaa 25

<210> 4227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4227

ccuccuucuu ugaggagaaa gggag 25

<210> 4228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4228

cuccuucuuu gaggagaaag ggaga 25

<210> 4229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4229

ggaguucugu ccugucuggu ggcug 25

<210> 4230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4230

ugcuaaggag uucuguccug ucugg 25

<210> 4231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4231

gcaugcuaag gaguucuguc cuguc 25

<210> 4232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4232

uauaauuaaa uaugagagca ugcua 25

<210> 4233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4233

ugggacaagg gaucccccuu cccug 25

<210> 4234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4234

gcaggcaccu gaguggcugg gacaa 25

<210> 4235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4235

agcaggcacc ugagguggcug ggaca 25

<210> 4236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4236

gcggccagca ggcaccugag uggcu 25

<210> 4237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4237

ggcggccagc aggcaccuga guggc 25

<210> 4238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4238

uccaggcggc cagcaggcac cugag 25

<210> 4239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4239

ggccaccagc auccaggcgg ccagc 25

<210> 4240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4240

uggggcagggg ccaccagcau ccagg 25

<210> 4241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4241

uccggggca gggccaccag caucc 25

<210> 4242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4242

acacugcacc cccacuccug gggca 25

<210> 4243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4243

cacacugcac ccccacuccu ggggc 25

<210> 4244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4244

uccacacacu gcacccccac uccug 25

<210> 4245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4245

auccacacac ugcaccccca cuccu 25

<210> 4246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4246

cauccacaca cugcaccccc acucc 25

<210> 4247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4247

cccccggggc cuaguacccc cgccg 25

<210> 4248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4248

gugggaaggu acaggcguuc ccccg 25

<210> 4249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4249

ggugggaagg uacaggcguu ccccc 25

<210> 4250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4250

ggggggaag guacaggcgu ucccc 25

<210> 4251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4251

caccagggcc ugggugggaa gguac 25

<210> 4252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4252

ggcucccacc aggggcgggg ggga 25

<210> 4253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4253

gccgggcucc caccagggcc ugggu 25

<210> 4254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4254

ggccgggcuc ccaccaggggc cuggg 25

<210> 4255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4255

guuggccggg cucccaccag ggccu 25

<210> 4256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4256

gguuggccgg gcucccacca gggcc 25

<210> 4257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4257

aaagggguug gcggggcucc cacca 25

<210> 4258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4258

uaaagggguu ggccggggcuc ccacc 25

<210> 4259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4259

cugaaauuau uuaaaggggu uggcc 25

<210> 4260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4260

ccugaaauua uuuaaagggg uuggc 25

<210> 4261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4261

cauuccugaa auuauuuaaa ggggu 25

<210> 4262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4262

aacccauucc ugaaauuauu uaaag 25

<210> 4263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4263

gaacccauuc cugaaauuau uuaaa 25

<210> 4264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4264

ggaacccauu ccugaaauua uuuaa 25

<210> 4265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4265

augugcccac ccugggagcu cuccu 25

<210> 4266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4266

cuagggcccc ccaugugccc acccu 25

<210> 4267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4267

ccuagggccc cccaugugcc caccc 25

<210> 4268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4268

gggagggcag aagugcaggc accua 25

<210> 4269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4269

ugggaggca gaagugcagg caccu 25

<210> 4270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4270

cuggguguug ggagggcaga agugc 25

<210> 4271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4271

agcuggggcc accugggugu uggga 25

<210> 4272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4272

cagcuggggc caccugggug uuggg 25

<210> 4273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4273

ucccagcugu ggccaccugg guguu 25

<210> 4274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4274

cucccagcug uggccaccug ggugu 25

<210> 4275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4275

aggccccc cagcuguggc caccu 25

<210> 4276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4276

caggccccuc ccagcuggugg ccacc 25

<210> 4277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4277

gguugacuca ggcccccccc agcug 25

<210> 4278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4278

aggagggcag ggcugggguu gacuc 25

<210> 4279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4279

ucccaagguc aggagggcag ggcug 25

<210> 4280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4280

gucccaaggu caggagggca gggcu 25

<210> 4281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4281

ggucccaagg ucagggggc agggc 25

<210> 4282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4282

cuacgguccc aaggucagga gggca 25

<210> 4283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4283

ccuacgggucc caaggucagg agggc 25

<210> 4284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4284

acauccuacg gucccaaggu cagga 25

<210> 4285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4285

gacauccuac ggucccaagg ucagg 25

<210> 4286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4286

agggacaucc uacgguccca agguc 25

<210> 4287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4287

gggagaggga cauccuacgg uccca 25

<210> 4288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4288

caccacucgg gagagggaca uccua 25

<210> 4289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4289

ccagccccuc acaccacucg ggaga 25

<210> 4290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4290

cccagccccu cacaccacuc gggag 25

<210> 4291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4291

uccaccccag ccccucacac cacuc 25

<210> 4292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4292

uuccacccca gccccucaca ccacu 25

<210> 4293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4293

ggccuuucag gcccagccag cacuc 25

<210> 4294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4294

gggcaggcag agcuggaggc cuuuc 25

<210> 4295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4295

gcaguaagcg ggcaggcaga gcugg 25

<210> 4296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4296

gaggcaguaa gcgggcaggc agagc 25

<210> 4297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4297

agggaagcug aggcaguaag cgggc 25

<210> 4298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4298

gggcagggaa gcugaggcag uaagc 25

<210> 4299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4299

ggggcaggga agcugaggca guaag 25

<210> 4300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4300

ggcccuuugu ggggcaggga agcug 25

<210> 4301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4301

agcaccucag gcccuuugug gggca 25

<210> 4302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4302

cagcaccuca ggcccuuugu ggggc 25

<210> 4303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4303

caggcagcac cucaggcccu uugug 25

<210> 4304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4304

ccaggcagca ccucaggccc uuugu 25

<210> 4305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4305

cccaggcagc accucaggcc cuuug 25

<210> 4306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4306

uuuacacaug cccaggcagc accuc 25

<210> 4307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4307

aaccccucca ccuuuacaca ugccc 25

<210> 4308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4308

agcuccuggc uguggugggc agggc 25

<210> 4309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4309

gaagagcucc uggcuguggu gggca 25

<210> 4310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4310

agaagagcuc cuggcuggugg ugggc 25

<210> 4311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4311

ggucagaaga gcuccuggcu guggu 25

<210> 4312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4312

aggucagaag agcuccuggc ugugg 25

<210> 4313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4313

ggaaggucag aagagcuccu ggcug 25

<210> 4314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4314

uuucagggaa ggucagaaga gcucc 25

<210> 4315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4315

ugcaggccua gagaaguuuc aggga 25

<210> 4316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4316

ucccugcagg ccuagagaag uuuca 25

<210> 4317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4317

cucccugcag gccuagagaa guuuc 25

<210> 4318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4318

uccccaggag uuaucugcuc ccugc 25

<210> 4319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4319

agguacaugg ggcuggggac ucccc 25

<210> 4320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4320

caggagugggg agguacaugg ggcug 25

<210> 4321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4321

acaggagugg gagguacaug gggcu 25

<210> 4322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4322

cacaggagug ggagguacau ggggc 25

<210> 4323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4323

ugggcacagg agugggaggu acaug 25

<210> 4324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4324

cugggcacag gagugggagg uacau 25

<210> 4325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4325

acugggcaca ggagugggag guaca 25

<210> 4326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4326

gcccaagacu gggcacagga guggg 25

<210> 4327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4327

agggcccaag acugggcaca ggagu 25

<210> 4328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4328

cagggcccaa gacugggcac aggag 25

<210> 4329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4329

ggacgcaggg cccaagacug ggcac 25

<210> 4330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4330

cgcccggac gcagggccca agacu 25

<210> 4331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4331

acgccgga cgcaggggcc aagac 25

<210> 4332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4332

ggcaucccga aacgcccugg acgca 25

<210> 4333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4333

uggcaucccg aaacgcccug gacgc 25

<210> 4334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4334

cuggcagugg caucccgaaa cgccc 25

<210> 4335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4335

ggagcagcca aggugccccu ggcag 25

<210> 4336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4336

ggccuuggag cagccaaggu gcccc 25

<210> 4337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4337

guuggagaug gccuuggagc agcca 25

<210> 4338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4338

cuugggggcu gguuggagau ggccu 25

<210> 4339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4339

ccugaacuug ggggcugguu ggaga 25

<210> 4340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4340

cuccugccug aacuugggggg cuggu 25

<210> 4341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4341

gagccuccug ccugaacuug ggggc 25

<210> 4342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4342

cccggagccu ccugccugaa cuugg 25

<210> 4343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4343

ccccggagcc uccugccuga acuug 25

<210> 4344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4344

gccccggagc cuccugccug aacuu 25

<210> 4345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4345

cgccccggag ccuccugccu gaacu 25

<210> 4346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4346

ggcgccgugg cccugccuga cgccc 25

<210> 4347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4347

cugcggccg gggcugaagg cgccg 25

<210> 4348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4348

cgacgacgcu gcggcccggg gcuga 25

<210> 4349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4349

acgacgacga cgacgcugcg gcccg 25

<210> 4350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4350

gacgacgacg acgacgcugc ggccc 25

<210> 4351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4351

cgacgacgac gacgacgcug cggcc 25

<210> 4352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4352

acgacgacg acgacgacga cgcug 25

<210> 4353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4353

gagggccaga ugcagucacu gcuuc 25

<210> 4354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4354

caggugucac cgucciccuac aggga 25

<210> 4355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4355

gcagguguca ccguccccua caggg 25

<210> 4356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4356

gcagcaggug ucaccguccc cuaca 25

<210> 4357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4357

ggcagcaggu gucaccgucc ccuac 25

<210> 4358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4358

aaugcccaca gugagcccag gcagc 25

<210> 4359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4359

augucucaau gcccacagug agccc 25

<210> 4360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4360

ccugcaccag gcacagcccc accac 25

<210> 4361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4361

cggggcucca gccugcaccu gcacc 25

<210> 4362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4362

gggcugagcu gccuggggggc gaccg 25

<210> 4363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4363

ggggcugagc ugccuggggg cgacc 25

<210> 4364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4364

aggggcugag cugccugggg gcgac 25

<210> 4365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4365

gccguccagg ggcugagcug ccugg 25

<210> 4366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4366

ggccguccag gggcugagcu gccug 25

<210> 4367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4367

aggccgucca ggggcugagc ugccu 25

<210> 4368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4368

caggccgucc aggggcugag cugcc 25

<210> 4369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4369

gugcaggcca uugcaggccg uccag 25

<210> 4370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4370

ggugcaggcc auugcaggcc gucca 25

<210> 4371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4371

gggugcaggc cauugcaggc cgucc 25

<210> 4372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4372

aagcaggcag ggugcaggcc auugc 25

<210> 4373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4373

uccucaggag aagcaggcag ggugc 25

<210> 4374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4374

cgcauuuccu caggagaagc aggca 25

<210> 4375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4375

gcgcauuucc ucaggagaag caggc 25

<210> 4376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4376

gucagcgcau uuccucagga gaagc 25

<210> 4377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4377

ugagcccggg ucagcgcauu uccuc 25

<210> 4378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4378

ucugcagacc cuccaccaug agcc 25

<210> 4379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4379

uucugcagac ccuccaccau gagcc 25

<210> 4380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4380

ucuuggcccc ucugaccggc uuccu 25

<210> 4381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4381

ggacacugcu cuuggccccu cugac 25

<210> 4382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4382

gaggccugag gauggacacu gcucu 25

<210> 4383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4383

gugcccagcc acugaggccu gagga 25

<210> 4384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4384

cggagugccc agccacugag gccug 25

<210> 4385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4385

cggcccucgg agugcccagc cacug 25

<210> 4386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4386

ccgcaggggc ucagcugacg gcccu 25

<210> 4387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4387

cccccgccg caggggcuca gcuga 25

<210> 4388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4388

ugggcaccuc aucccccgcc cgcag 25

<210> 4389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4389

augggcaccu caucccccgc ccgca 25

<210> 4390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4390

aaugggcacc ucaucccccg cccgc 25

<210> 4391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4391

ccaccauugu cuuuccuagc ggaau 25

<210> 4392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4392

gccaccauug ucuuuccuag cggaa 25

<210> 4393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4393

aguaugccac cauugucuuu ccuag 25

<210> 4394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4394

ccggugcccu gugucccuga gcaga 25

<210> 4395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4395

gauuuccagu ggcgagagaa gaccc 25

<210> 4396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4396

ggacuauggg gagcuggauu uccag 25

<210> 4397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4397

guguucucug uggacuaugg ggagc 25

<210> 4398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4398

gugccugugu ucucugugga cuaug 25

<210> 4399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4399

cgugccugug uucucugugg acuau 25

<210> 4400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4400

ccgugccugu guucucugug gacua 25

<210> 4401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4401

cccucagccg ugccuguguu cucug 25

<210> 4402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4402

cucuccccuu ucuccucaaa gaagg 25

<210> 4403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4403

cucccuccc cuuucuccuc aaaga 25

<210> 4404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4404

augcaggaaa aggugagac ucacc 25

<210> 4405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4405

ugcaggaaaa gagugagacu cacca 25

<210> 4406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4406

gcaggaaaag agugagacuc accag 25

<210> 4407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4407

gaaaagagug agacucacca ggggc 25

<210> 4408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4408

agagugagac ucaccagggg cuggc 25

<210> 4409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4409

cucaccaggg gcuggccggu gcgcc 25

<210> 4410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4410

uauugucccu gcagagaaac acacu 25

<210> 4411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4411

auugucccug cagagaaaca cacuu 25

<210> 4412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4412

uugucccugc agagaaacac acuug 25

<210> 4413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4413

ggagccaggc gcaccggcca gcccc 25

<210> 4414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4414

cagggacaau aggagccagg cgcac 25

<210> 4415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4415

uuucucugca gggacaauag gagcc 25

<210> 4416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4416

aaguguguuu cucugcagg acaau 25

<210> 4417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4417

ggggcuggga ugacguuacc ucgug 25

<210> 4418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4418

ugggaugacg uuaccucgug cggcc 25

<210> 4419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4419

gggaugacgu uaccucgugc ggccc 25

<210> 4420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4420

ccucgugcgg ccggggagca gauga 25

<210> 4421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4421

ugcggccgg gagcagauga cggcc 25

<210> 4422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4422

ggccaggacc cagacuagca gcacc 25

<210> 4423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4423

gacuagcagc accaggcugc ccagc 25

<210> 4424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4424

caggccgccc acgacaccaa ccacc 25

<210> 4425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4425

aggccgccca cgacaccaac cacca 25

<210> 4426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4426

gccacgaca ccaaccacca ggguu 25

<210> 4427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4427

gacaccaacc accaggguuu ggaac 25

<210> 4428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4428

cugggugagg ggcuggggug ggcug 25

<210> 4429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4429

ugggugagggg gcuggggugg gcugu 25

<210> 4430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4430

cugugggcac uucugcccuu cucuc 25

<210> 4431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4431

gggcacuucu gcccuucucu cugga 25

<210> 4432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4432

ggcacuucug cccuucucuc uggaa 25

<210> 4433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4433

ccgucaucug cucccggggcc gcacg 25

<210> 4434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4434

uggguccugg ccgucaucug cuccc 25

<210> 4435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4435

cuggguccug gccgucaucu gcucc 25

<210> 4436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4436

agccuggugc ugcuagucug ggucc 25

<210> 4437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4437

cugggcagcc uggugcugcu agucu 25

<210> 4438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4438

gcugggcagc cuggugcugc uaguc 25

<210> 4439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4439

gucgugggcg gccugcuggg cagcc 25

<210> 4440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4440

ugguuggugu cgugggcggc cugcu 25

<210> 4441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4441

gugguggug ucgugggcgg ccugc 25

<210> 4442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4442

aaacccuggu gguuggguc guggg 25

<210> 4443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4443

uccaaacccu ggugguuggu gucgu 25

<210> 4444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4444

uuccaaaccc uggugguugg ugucg 25

<210> 4445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4445

ggggccaguu ccaaacccug guggu 25

<210> 4446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4446

ggucggggcc aguuccaaac ccugg 25

<210> 4447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4447

uccggucggg gccaguucca aaccc 25

<210> 4448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4448

uggggucgggg gaggggucc ggucg 25

<210> 4449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4449

cugguuugug cccuuccaga gagaa 25

<210> 4450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4450

acugguuugu gcccuuccag agaga 25

<210> 4451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4451

accugucacc cugagcucug cccgc 25

<210> 4452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4452

cgcaggcucu cuuugaucug cgccu 25

<210> 4453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4453

gcaggcucuc uuugaucugc gccuu 25

<210> 4454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4454

caggcucucu uugaucugcg ccuug 25

<210> 4455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4455

aggcucucuu ugaucugcgc cuugg 25

<210> 4456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4456

cucuuugauc ugcgccuugg gggcc 25

<210> 4457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4457

ucuuugaucu gcgccuuggg ggcca 25

<210> 4458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4458

aucugcgccu uggggggccag ggaga 25

<210> 4459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4459

gggggccagg gagauggccc cacag 25

<210> 4460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4460

gccagggaga uggccccaca gaggu 25

<210> 4461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4461

gagguaggug ccgcugucau ugcgc 25

<210> 4462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4462

agguaggugc cgcugucauu gcgcc 25

<210> 4463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4463

gcgccgggcc cugaccacgc ucaug 25

<210> 4464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4464

acgcucaugu ggaagucacg cccgu 25

<210> 4465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4465

cgcucaugug gaagucacgc ccguu 25

<210> 4466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4466

acgcccguug ggcaguugug ugaca 25

<210> 4467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4467

guugggcagu ugugugacac ggaag 25

<210> 4468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4468

uugugugaca cggaagcggc agucc 25

<210> 4469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4469

gugacacgga agcggcaguc cuggc 25

<210> 4470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4470

ugacacggaa gcggcagucc uggcc 25

<210> 4471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4471

acggaagcgg caguccuggc cgggc 25

<210> 4472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4472

gcggcagucc uggccggggcu ggcug 25

<210> 4473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4473

uccggccgg gcuggcugcg guccu 25

<210> 4474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4474

ccuggccgggg cuggcugcgg uccuc 25

<210> 4475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4475

cuggccgggc uggcugcggu ccucg 25

<210> 4476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4476

ccgggcuggc ugcgguccuc gggga 25

<210> 4477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4477

ggcuggcugc gguccucgggg gaagg 25

<210> 4478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4478

ggggaaggcg gccagcuugu ccguc 25

<210> 4479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4479

gcggccagcu uguccgucug guugc 25

<210> 4480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4480

cggccagcuu guccgucugg uugcu 25

<210> 4481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4481

ggccagcuug uccgucuggu ugcug 25

<210> 4482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4482

guccgucugg uugcuggggc ucaug 25

<210> 4483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4483

uuuagcacga agcucuccga ugugu 25

<210> 4484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4484

cucuccgaug uguuggagaa gcugc 25

<210> 4485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4485

gauguguugg agaagcugca gguga 25

<210> 4486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4486

guguuggaga agcugcaggu gaagg 25

<210> 4487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4487

caggugaagg uggcguuguc cccuu 25

<210> 4488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4488

guuguccccu ucggucacca cgagc 25

<210> 4489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4489

uuguccccuu cggucaccac gagca 25

<210> 4490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4490

ccccuucggu caccacgagc agggc 25

<210> 4491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4491

cccuucgguc accacgagca gggcu 25

<210> 4492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4492

ccuucgguca ccacgagcag ggcug 25

<210> 4493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4493

gucaccacga gcagggcugg ggaga 25

<210> 4494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4494

accacgagca gggcugggga gaagg 25

<210> 4495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4495

ccacgagcag ggcuggggag aaggu 25

<210> 4496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4496

cacgagcagg gcuggggaga aggug 25

<210> 4497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4497

acgagcaggg cuggggagaa ggugg 25

<210> 4498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4498

cgagcagggc uggggagaag guggg 25

<210> 4499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4499

ggggggcu ggggagaagg ugggg 25

<210> 4500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4500

gcuggggaga aggugggggg guucc 25

<210> 4501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4501

cuggggagaa ggugggggg uucca 25

<210> 4502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4502

aggugggggg guuccaggggc cuguc 25

<210> 4503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4503

ggugggggggg uuccaggggcc ugucu 25

<210> 4504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4504

gugggggggu uccaggggccu gucug 25

<210> 4505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4505

gggccugucu ggggagucug agaga 25

<210> 4506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4506

ucuggggagu cugagagaug gagag 25

<210> 4507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4507

ggagucugag agauggagag aggug 25

<210> 4508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4508

gacaggugcg gcccgggagg ccccg 25

<210> 4509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4509

ugacaggugc ggccucggag gcccc 25

<210> 4510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4510

gugacaggug cggccucgga ggccc 25

<210> 4511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4511

cucagggguga caggugcggc cucgg 25

<210> 4512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4512

gagcucaggg ugacaggugc ggccu 25

<210> 4513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4513

cgggcagagc ucagggugac aggug 25

<210> 4514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4514

gccugcgggc agagcucagg gugac 25

<210> 4515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4515

aaagagcc ugcgggcaga gcuca 25

<210> 4516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4516

caaagagagc cugcggggcag agcuc 25

<210> 4517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4517

aaggcgcaga ucaaagagag ccugc 25

<210> 4518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4518

caaggcgcag aucaaagaga gccug 25

<210> 4519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4519

ugggggcca ucucccuggc cccca 25

<210> 4520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4520

accuaccucu guggggccau cuccc 25

<210> 4521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4521

augacagcg gcaccuaccu cugug 25

<210> 4522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4522

caaugacagc ggcaccuacc ucugu 25

<210> 4523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4523

gcaaugacag cggcaccuac cucug 25

<210> 4524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4524

uggucagggc ccggcgcaau gacag 25

<210> 4525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4525

cuuccacaug agcgugguca gggcc 25

<210> 4526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4526

cgugacuucc acaugagcgu gguca 25

<210> 4527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4527

gcgugacuuc cacaugagcg ugguc 25

<210> 4528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4528

aacggggcgug acuuccacaau gagcg 25

<210> 4529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4529

cuuccguguc acacaacugc ccaac 25

<210> 4530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4530

gcuuccgugu cacacaacug cccaa 25

<210> 4531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4531

cccgaggacc gcagccagcc cggcc 25

<210> 4532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4532

ccuuccccga ggaccgcagc cagcc 25

<210> 4533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4533

acggacaagc uggccgccuu ccccg 25

<210> 4534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4534

agccccagca accagacggga caagc 25

<210> 4535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4535

uaccgcauga gccccagcaa ccaga 25

<210> 4536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4536

cacaucggag agcuucgugc uaaac 25

<210> 4537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4537

uucaccuca gcuucuccaa cacau 25

<210> 4538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4538

ccagcccuc ucguggugac cgaag 25

<210> 4539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4539

ccgccug cucgugguga ccgaa 25

<210> 4540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4540

ccccagcccu gcucguggug accga 25

<210> 4541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4541

cccaccuucu cccgcccu gcucg 25

<210> 4542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4542

ucucucagac uccccagaca ggccc 25

<210> 4543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4543

ucuccaucuc ucagacuccc cagac 25

<210> 4544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4544

gaccccaccu accuaagaac caucc 25

<210> 4545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4545

ccaguuguag caccgcccag acgac 25

<210> 4546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4546

uguagcaccg ccgacgac uggcc 25

<210> 4547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4547

guagcaccgc ccagacgacu ggcca 25

<210> 4548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4548

cccagacgac uggccagggc gccug 25

<210> 4549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4549

ccagacgacu ggccaggggcg ccugu 25

<210> 4550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4550

agggcgccug ugggaucugc augcc 25

<210> 4551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4551

cagagugccg ccuucuccac ugcuc 25

<210> 4552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4552

agugccgccu ucuccacugc ucagg 25

<210> 4553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4553

gccgccuucu ccacugcuca ggcgg 25

<210> 4554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4554

ucuccacugc ucaggcggag gugag 25

<210> 4555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4555

cacugcucag gcggagguga gcgga 25

<210> 4556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4556

acugcucagg cggaggugag cggaa 25

<210> 4557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4557

aggugagcgg aagggaaacu guccc 25

<210> 4558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4558

agcggaaggg aaacuguccc agguc 25

<210> 4559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4559

gggaaacugu cccaggucag guuga 25

<210> 4560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4560

ggaaacuguc ccaggucagg uugaa 25

<210> 4561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4561

aacuguccca ggucagguug aaggg 25

<210> 4562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4562

acugucccag gucagguuga aggga 25

<210> 4563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4563

ucuuagguag guggggucgg cgguc 25

<210> 4564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4564

augguucuua gguagguggg gucgg 25

<210> 4565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4565

aggaugguuc uuagguaggu ggggu 25

<210> 4566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4566

ggccaggaug guucuuaggu aggug 25

<210> 4567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4567

cggccaggau gguucuuagg uaggu 25

<210> 4568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4568

gcggccagga ugguucuuag guagg 25

<210> 4569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4569

cuggcggcca ggaugguucu uaggu 25

<210> 4570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4570

ugggcuggcg gccaggaugg uucuu 25

<210> 4571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4571

gcuacaacug ggcuggcggc cagga 25

<210> 4572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4572

cggugcuaca acugggcugg cggcc 25

<210> 4573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4573

cugggcggug cuacaacugg gcugg 25

<210> 4574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4574

cgucgggcg gugcuacaac ugggc 25

<210> 4575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4575

cagucgucug ggcggugcua caacu 25

<210> 4576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4576

ccagucgucu gggcggugcu acaac 25

<210> 4577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4577

caggcgcccu ggccagucgu cuggg 25

<210> 4578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4578

ccacaggcgc ccuggccagu cgucu 25

<210> 4579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4579

cccacaggcg cccuggccag ucguc 25

<210> 4580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4580

aggcaugcag aucccacagg cgccc 25

<210> 4581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4581

gcugcuccag gcaugcagau cccac 25

<210> 4582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4582

ggcggcacuc uggggggcu gcucc 25

<210> 4583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4583

caguggagaa ggcggcacuc uggug 25

<210> 4584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4584

gcagggaga aggcggcacu cuggu 25

<210> 4585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4585

agcaguggag aaggcggcac ucugg 25

<210> 4586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4586

cugagcagug gagaaggcgg cacuc 25

<210> 4587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4587

accuccgccu gagcagugga gaagg 25

<210> 4588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4588

cucaccuccg ccugagcagu ggaga 25

<210> 4589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4589

cuuccgcuca ccuccgccug agcag 25

<210> 4590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4590

cgcggagcgc gcagcucaca ccugg 25

<210> 4591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4591

gcgcgcagcu cacaccuggc ggccg 25

<210> 4592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4592

cucacaccug gcggccgcgg uuucc 25

<210> 4593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4593

acaccuggcg gccgcgguuu ccagg 25

<210> 4594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4594

cggccgcggu uuccaggagg aagca 25

<210> 4595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4595

uuuccaggag gaagcaagga ugcuu 25

<210> 4596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4596

gcaaggaugc uuuggacacu gugcg 25

<210> 4597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4597

uuggacacug ugcguggcgc cuccg 25

<210> 4598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4598

cgcggagccc cgcgcugcc auucc 25

<210> 4599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4599

cgcgcugcca uucccggccg ucgcu 25

<210> 4600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4600

cggccgucgc ucgguccucc gcuga 25

<210> 4601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4601

ggccgucgcu cgguccuccg cugac 25

<210> 4602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4602

gcucgguccu ccgcugacgg gaagc 25

<210> 4603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4603

ggccgggggg cagcugcaca gucuc 25

<210> 4604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4604

gccggggggc agcugcacag ucucc 25

<210> 4605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4605

cagcugcaca gucuccggga ucccc 25

<210> 4606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4606

gcacagucuc cgggauccc aggcc 25

<210> 4607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4607

cagucuccgg gauccccagg ccugg 25

<210> 4608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4608

agucuccggg auccccaggc cugga 25

<210> 4609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4609

gucuccggga ucccaggcc uggag 25

<210> 4610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4610

ucuccgggau ccccaggccu ggagg 25

<210> 4611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4611

cuccgggauc cccaggccug gaggg 25

<210> 4612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4612

ccaggccugg aggggggucu gugcg 25

<210> 4613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4613

gccuggaggg gggucugugc gcggc 25

<210> 4614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4614

ggaggggggu cugugcgcgg ccggc 25

<210> 4615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4615

cggccggcug gcucugcccc gcguc 25

<210> 4616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4616

gcucugcccc gcguccgguc ccgag 25

<210> 4617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4617

cucugccccg cguccggucc cgagc 25

<210> 4618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4618

cguccgggucc cgagcggggcc ucccu 25

<210> 4619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4619

guccgguccc gagcggggccu cccuc 25

<210> 4620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4620

gccagccga ugugaccgag cccag 25

<210> 4621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4621

gaccgagccc agcggagccu gagca 25

<210> 4622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4622

agcccagcgg agccuagca aggag 25

<210> 4623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4623

gcccagcgga gccugagcaa ggagc 25

<210> 4624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4624

gccugagcaa ggagcggguc cgucg 25

<210> 4625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4625

gcaaggagcg gguccgucgc ggagc 25

<210> 4626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4626

aggagcgggu ccgucgcgga gccgg 25

<210> 4627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4627

ggagcggguc cgucgcggag ccgga 25

<210> 4628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4628

gcggguccgu cgcggagccg gaggg 25

<210> 4629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4629

cggguccguc gcggagccgg aggc 25

<210> 4630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4630

guccgucgcg gagccgggagg gcggg 25

<210> 4631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4631

ggagggcgggg aggaacauga caucg 25

<210> 4632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4632

gggcgggagg aacaugacau cgcgg 25

<210> 4633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4633

ggaggaacau gacaucgcgg aggug 25

<210> 4634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4634

gacaucgcgg aggugaggag ccccg 25

<210> 4635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4635

acaucgcgga ggugaggagc cccga 25

<210> 4636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4636

caucgcggag gugaggagcc ccgag 25

<210> 4637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4637

cggaggugag gagccccgag gggcc 25

<210> 4638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4638

cuuccuccug gaaaccgcgg ccgcc 25

<210> 4639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4639

cauccuugcu uccucuggga aaccg 25

<210> 4640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4640

uguccaaagc auccuugcuu ccucc 25

<210> 4641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4641

gaauggcagc gcgggggcuc cgcgg 25

<210> 4642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4642

cgggaauggc agcgcggggg cuccg 25

<210> 4643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4643

gcgacggccg ggaauggcag cgcgg 25

<210> 4644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4644

agcgacggcc gggaauggca gcgcg 25

<210> 4645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4645

gagcgacggc cgggaauggc agcgc 25

<210> 4646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4646

cgagcgacgg ccgggaaugg cagcg 25

<210> 4647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4647

cggaggaccg agcgacggcc gggaa 25

<210> 4648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4648

gucagcggag gaccgagcga cggcc 25

<210> 4649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4649

cgucagcgga ggaccgagcg acggc 25

<210> 4650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4650

uucccgucag cggaggaccg agcga 25

<210> 4651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4651

cggacuuccu gcuucccguc agcgg 25

<210> 4652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4652

cggcggacuu ccugcuuccc gucag 25

<210> 4653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4653

gaccccccuc caggccuggg gaucc 25

<210> 4654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4654

gcgcacagac cccccuccag gccug 25

<210> 4655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4655

cgcgcacaga ccccccucca ggccu 25

<210> 4656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4656

ccgcgcacag acccccccc aggcc 25

<210> 4657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4657

gccggccgcg cacagacccc ccucc 25

<210> 4658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4658

ggaccggacg cggggcagag ccagc 25

<210> 4659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4659

ggaggcccgc ucgggaccgg acgcg 25

<210> 4660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4660

gggaggccg cucgggaccg gacgc 25

<210> 4661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4661

agggaggccc gcucgggacc ggacg 25

<210> 4662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4662

ggcccgggg aggcccgcuc gggac 25

<210> 4663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4663

gggcuggccc gagggaggcc cgcuc 25

<210> 4664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4664

cgggcuggcc cgagggaggc cgcu 25

<210> 4665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4665

cggucacauc gggcuggcc gaggg 25

<210> 4666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4666

gcucggucac aucgggcugg cccga 25

<210> 4667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4667

ggcucgguca caucggggcug gcccg 25

<210> 4668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4668

uccgcugggc ucggucacau cgggc 25

<210> 4669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4669

aggcuccgcu gggcucgguc acauc 25

<210> 4670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4670

caggcuccgc ugggcucggu cacau 25

<210> 4671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4671

cuccuugcuc aggcuccgcu gggcu 25

<210> 4672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4672

acccgcuccu ugcucaggcu ccgcu 25

<210> 4673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4673

gacccgcucc uugcucaggc uccgc 25

<210> 4674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4674

uccgcgacgg acccgcuccu ugcuc 25

<210> 4675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4675

uucccccgc ccuccggcuc cgcga 25

<210> 4676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4676

gcgaugucau guuccuccg cccuc 25

<210> 4677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4677

acuuacuuug ucuuucuuuu uaaga 25

<210> 4678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4678

uaagaugguu ucacccaaau aucac 25

<210> 4679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4679

ugguuucacc caaauauucac uggug 25

<210> 4680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4680

uuucacccaa auaucacugg ugugg 25

<210> 4681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4681

aggcagaaaa ccuacuguug acaag 25

<210> 4682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4682

accuacuguu gacaagagga guuga 25

<210> 4683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4683

acaagaggag uugauggcag uuuuu 25

<210> 4684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4684

aggaguugau ggcaguuuuu uggca 25

<210> 4685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4685

uggcaaggcc uaguaaaagu aaccc 25

<210> 4686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4686

cccuggagac uucacacuuu ccguu 25

<210> 4687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4687

acuucacacu uuccguuagg uaagu 25

<210> 4688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4688

guuagguaag uuggaaugaa aagag 25

<210> 4689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4689

uucugccucc acaccaguga uauuu 25

<210> 4690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4690

uuucugccuc cacaccagug auauu 25

<210> 4691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4691

gccaucaacu ccucuuguca acagu 25

<210> 4692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4692

ugaagucucc aggguuacuu uuacu 25

<210> 4693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4693

ccuaacggaa aguguugaagu cucca 25

<210> 4694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4694

accuaacgga aagugugaag ucucc 25

<210> 4695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4695

uucucuuuuca uuccaacuua ccuaa 25

<210> 4696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4696

uuccaaugga cuauuuuaga agaaa 25

<210> 4697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4697

ucacccacau caagauucag aacac 25

<210> 4698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4698

acacugguga uuacuaugac cugua 25

<210> 4699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4699

cuggugauua cuaugaccug uaugg 25

<210> 4700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4700

uggugauuac uaugaccugu ugga 25

<210> 4701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4701

ggugauuacu augaccugua uggag 25

<210> 4702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4702

uuggagggg agaaauuugc cacuu 25

<210> 4703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4703

gagaaauuug ccacuuuggc ugagu 25

<210> 4704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4704

uuggcugagu ugguccagua uuaca 25

<210> 4705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4705

ugguccagua uuacauggaa cauca 25

<210> 4706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4706

gguccaguau uacauggaac aucac 25

<210> 4707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4707

aucacgggca auuaaaagag aagaa 25

<210> 4708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4708

gaacugugca gauccuaccu cugaa 25

<210> 4709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4709

uucuucuaaa auaguccauu ggaaa 25

<210> 4710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4710

uuucuucuaa aauaguccau uggaa 25

<210> 4711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4711

cuccauuucu ucuaaaauag uccau 25

<210> 4712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4712

ucaccagugu ucugaaucuu gaugu 25

<210> 4713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4713

aucaccagug uucugaaucu ugaug 25

<210> 4714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4714

aguggcaaau uucuccccuc cauac 25

<210> 4715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4715

uaauacugga ccaacucagc caaag 25

<210> 4716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4716

uugcccguga uguuccaugu aauac 25

<210> 4717

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4717

cagagguagg aucugcacag uucag 25

<210> 4718

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4718

aaaauguuac ugaccuuuca gaggu 25

<210> 4719

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4719

cacuaaaaug uuacugaccu uucag 25

<210> 4720

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4720

uuuuuuuuu uuuuaaaacu uuagg 25

<210> 4721

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4721

uuuuuaaaaa cuuuaggugg uuuca 25

<210> 4722

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4722

uuaggugguu ucauggacau cucuc 25

<210> 4723

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4723

uaggugguuu cauggacauc ucucu 25

<210> 4724

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4724

aagcagagaa auuauuaacu gaaaa 25

<210> 4725

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4725

aauuauuaac ugaaaaagga aaaca 25

<210> 4726

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4726

uuguacgaga gagccagagc caccc 25

<210> 4727

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4727

gagauuuugu ucuuucugug cgcac 25

<210> 4728

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4728

uuucugugcg cacuggugau gacaa 25

<210> 4729

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4729

uucugugcgc acuggugaug acaaa 25

<210> 4730

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4730

ucugugcgca cuggugauga caaag 25

<210> 4731

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4731

gugaugacaa aggggagagc aauga 25

<210> 4732

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4732

gugacccaug uuaugauucg cuguc 25

<210> 4733

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4733

gucagguaaa ucuccaguug aaaaa 25

<210> 4734

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4734

ucagguaaau cuccaguuga aaaau 25

<210> 4735

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4735

aagaacaaaa ucuccagggu ggcuc 25

<210> 4736

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4736

cacagaaaga acaaaaucuc caggg 25

<210> 4737

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4737

gcgcacagaa agaacaaaau cucca 25

<210> 4738

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4738

ugcgcacaga aagaacaaaa ucucc 25

<210> 4739

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4739

uuuaccugac agcgaaucau aacau 25

<210> 4740

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4740

auuuaccuga cagcgaauca uaaca 25

<210> 4741

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4741

cuugaaagga acugaaauac gacgu 25

<210> 4742

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4742

gaaaggaacu gaaauacgac guugg 25

<210> 4743

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4743

aggaacugaa auacgacguu ggugg 25

<210> 4744

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4744

gaaauacgac guuggggag gagaa 25

<210> 4745

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4745

cgguuugauu cuuugacaga ucuug 25

<210> 4746

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4746

guggaacauu auaagaagaa uccua 25

<210> 4747

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4747

gaacauuaua agaagaaucc uaugg 25

<210> 4748

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4748

aagaagaauc cuauggugga aacau 25

<210> 4749

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4749

agaagaaucc uaugguggaa acauu 25

<210> 4750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4750

uuggguacag uacuacaacu caagc 25

<210> 4751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4751

cuacaacuca agcaggugag cagau 25

<210> 4752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4752

guacuguacc caauguuucc accau 25

<210> 4753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4753

cugagaccac agauaaaguc aaaca 25

<210> 4754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4754

cacagauaaa gucaaacaag gcuuu 25

<210> 4755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4755

acagauaaag ucaaacaagg cuuuu 25

<210> 4756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4756

aaacaaggcu uuugggaaga auuug 25

<210> 4757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4757

cagcauuuau acgagucgug uuaag 25

<210> 4758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4758

gcagcauuua uacgagucgu guuaa 25

<210> 4759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4759

agcagcauuu auacgagucg uguua 25

<210> 4760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4760

caaaagccuu guuugacuuu aucug 25

<210> 4761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4761

cuuucuuucc agacacuaca acaac 25

<210> 4762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4762

ugcaaacuuc ucuacagccg aaaag 25

<210> 4763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4763

gcaaacuucu cuacagccga aaaga 25

<210> 4764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4764

ucucuacagc cgaaaagagg gucaa 25

<210> 4765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4765

uuugcacucc uguuguugua guguc 25

<210> 4766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4766

guuuucuugc cuuugacccu cuuuu 25

<210> 4767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4767

agcggaauau ugauacuuac agggc 25

<210> 4768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4768

acugagcgga auauugauac uuaca 25

<210> 4769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4769

uacugagcgg aauauugaua cuuac 25

<210> 4770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4770

ucuuuuucuu cuaguugauc auacc 25

<210> 4771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4771

cuuuuucuuc uaguugauca uacca 25

<210> 4772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4772

aucauaccag gguuguccua cacga 25

<210> 4773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4773

gauuacauca augcaaauau cauca 25

<210> 4774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4774

gaucaacuag aagaaaaaga gacca 25

<210> 4775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4775

ggaucaccau cguguaggac aaccc 25

<210> 4776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4776

aggcucauugggaucaccau cgugu 25

<210> 4777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4777

ugauguaauc ugaaacaggc ucauu 25

<210> 4778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4778

uugauguaau cugaaacagg cucau 25

<210> 4779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4779

uauuugcauu gauguaaucu gaaac 25

<210> 4780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4780

ccaaaaagag uuacauugcc acaca 25

<210> 4781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4781

gccacacaag gcugccugca aaaca 25

<210> 4782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4782

ccugcaaaac acggugaaug acuuu 25

<210> 4783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4783

gcaaaacacg gugaaugacu uuugg 25

<210> 4784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4784

aacacgguga augacuuuug gcgga 25

<210> 4785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4785

gugauuguca ugacaacgaa agaag 25

<210> 4786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4786

ucaugacaac gaaagaagug gagag 25

<210> 4787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4787

acaacgaaag aaguggagag aggaa 25

<210> 4788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4788

gguuucaaau ucaggcuaga aauuu 25

<210> 4789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4789

aauuguugca cuugguuuca aauuc 25

<210> 4790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4790

uuuuugggcu uugaauuguu gcacu 25

<210> 4791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4791

cuuguguggc aauguaacuc uuuuu 25

<210> 4792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4792

ccuugugugg caauguaacu cuuuu 25

<210> 4793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4793

accguguuuu gcaggcagcc uugug 25

<210> 4794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4794

ccaaaaguca uucaccgugu uuugc 25

<210> 4795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4795

caugacaauc acucgggagu uuucu 25

<210> 4796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4796

ucuuucguug ucaugacaau cacuc 25

<210> 4797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4797

uucuuucguu gucaugacaa ucacu 25

<210> 4798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4798

cuuccagagu aaauguguca aauac 25

<210> 4799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4799

cugaugagua ugcucuaaaa gaaua 25

<210> 4800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4800

aaaagaauau ggcgucaugc guguu 25

<210> 4801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4801

acgcuaagag aacuuaaacu uucaa 25

<210> 4802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4802

uaaagaacu uaaacuuuca aaggu 25

<210> 4803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4803

aggccaguau uugacacauu uacuc 25

<210> 4804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4804

cauauucuuu uagagcauac ucauc 25

<210> 4805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4805

aguucucuua gcguauaguc augag 25

<210> 4806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4806

cugguuuuuc uuggcucuac uccag 25

<210> 4807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4807

uucuuggcuc uacuccaggg gaaua 25

<210> 4808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4808

cuacuccagg ggaauacgga gagaa 25

<210> 4809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4809

cggggaau acggagagaa cgguc 25

<210> 4810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4810

gagaacgguc uggcaauacc acuuu 25

<210> 4811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4811

ggucuggcaa uaccacuuuc ggacc 25

<210> 4812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4812

uggcaauacc acuuucggac cuggc 25

<210> 4813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4813

accuuucg gaccuggccg gacca 25

<210> 4814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4814

cggaccacgg cgugcccagc gaccc 25

<210> 4815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4815

ggaccacggc gugcccagcg acccu 25

<210> 4816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4816

gaccacggcg ugcccagcga cccug 25

<210> 4817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4817

accacggcgu gccagcgac ccugg 25

<210> 4818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4818

gugcccagcg acccuggggg cgugc 25

<210> 4819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4819

gacccugggg gcgugcugga cuucc 25

<210> 4820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4820

ccugggggcg ugcuggacuu ccugg 25

<210> 4821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4821

gggggcgugc uggacuuccu ggagg 25

<210> 4822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4822

uuccuggagg aggugcacca uaagc 25

<210> 4823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4823

gugcaccaua agcaggagag cauca 25

<210> 4824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4824

auaagcagga gagcaucaug gaugc 25

<210> 4825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4825

uaagcaggag agcaucaugg augca 25

<210> 4826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4826

caggagagca ucauggaugc agggc 25

<210> 4827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4827

agcaucaugg augcaggggcc ggucg 25

<210> 4828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4828

ugcagggccg gucguggugc acugc 25

<210> 4829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4829

aggugacagc uccugcugcc ccucu 25

<210> 4830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4830

agccuguccc ugucuccuag cgccc 25

<210> 4831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4831

gccugucccu gucuccuagc gccca 25

<210> 4832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4832

uacccacucc uagcucuuua acugu 25

<210> 4833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4833

guaggaagaa uuuaauaucu guuug 25

<210> 4834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4834

uuugaggcau agagcaacug cauug 25

<210> 4835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4835

uugaggcaua gagcaacugc auuga 25

<210> 4836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4836

ugcauugagg gacauuuuga uccca 25

<210> 4837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4837

cuccuagacc cuacagcacu gccau 25

<210> 4838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4838

gacccuacag cacugccauu ggcca 25

<210> 4839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4839

acagcacugc cauuggccau ggcca 25

<210> 4840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4840

aguugugcau uaaacaacuu caucc 25

<210> 4841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4841

ccagaccguu cucuccguau ucccc 25

<210> 4842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4842

gccguggucc ggccaggucc gaaag 25

<210> 4843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4843

ucgcugggca cgccgugguc cggcc 25

<210> 4844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4844

cagggucgcu gggcacgccg ugguc 25

<210> 4845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4845

gcccccaggg ucgcugggca cgccg 25

<210> 4846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4846

aguccagcac gcccccaggg ucgcu 25

<210> 4847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4847

aaguccagca cgcccccagg gucgc 25

<210> 4848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4848

cuccaggaag uccagcacgc cccca 25

<210> 4849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4849

ccucggaa guccagcacg ccccc 25

<210> 4850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4850

cuccucuua uggugcaccu ccucc 25

<210> 4851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4851

ugcauccaug augcucuccu gcuua 25

<210> 4852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4852

gcugucaccu gcagugcacc acgac 25

<210> 4853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4853

acaggcugg gccuagaggg gcagc 25

<210> 4854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4854

gacagggaca ggcugggcc uagag 25

<210> 4855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4855

agacagggac aggcuguggc cuaga 25

<210> 4856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4856

gagacaggga caggcugugg ccuag 25

<210> 4857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4857

ggcgcuagga gacagggaca ggcug 25

<210> 4858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4858

gcccugggcg cuaggagaca gggac 25

<210> 4859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4859

agcaagcccu gggcgcuagg agaca 25

<210> 4860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4860

aagcaagccc ugggcgcuag gagac 25

<210> 4861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4861

uagguaaaag caagcccugg gcgcu 25

<210> 4862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4862

gaggggguag guaaaagcaa gcccu 25

<210> 4863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4863

ggaggggua gguaaaagca agccc 25

<210> 4864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4864

uacaguuaaa gagcuaggag ugggu 25

<210> 4865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4865

uuccuacagu uaaagagcua ggagu 25

<210> 4866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4866

cuuccuacag uuaaaagcu aggag 25

<210> 4867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4867

aaauucuucc uacaguuaaa gagcu 25

<210> 4868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4868

guagggucua ggagaaauau gccuu 25

<210> 4869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4869

uguagggucu aggagaaaua ugccu 25

<210> 4870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4870

ggccaauggc agugcuguag ggucu 25

<210> 4871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4871

ggccauggcc aauggcagug cugua 25

<210> 4872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4872

uggccauggc caauggcagu gcugu 25

<210> 4873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4873

agcauguugc cauggccaug gccaa 25

<210> 4874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4874

uuaacugagc auguugccau ggcca 25

<210> 4875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4875

gcuguuuuaa cugagcaugu ugcca 25

<210> 4876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4876

aaguuguuua augcacaacu ucugg 25

<210> 4877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4877

augaaguugu uuaaugcaca acuuc 25

<210> 4878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4878

aagaauaagg agaaacugca gagcc 25

<210> 4879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4879

cuuuuugucc uucugcccgc agugc 25

<210> 4880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4880

guccuucugc ccgcagugcu ggaau 25

<210> 4881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4881

uucugcccgc agugcuggaa uuggc 25

<210> 4882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4882

ccgcagugc uggaauuggc cggac 25

<210> 4883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4883

ccgcagugcu ggaauuggcc ggaca 25

<210> 4884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4884

uucuuauuga caucaucaga gagaa 25

<210> 4885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4885

uuauugacau caucagagag aaagg 25

<210> 4886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4886

uauugacauc aucagagaga aaggu 25

<210> 4887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4887

ucaucagaga gaaaggugggg ucauc 25

<210> 4888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4888

ucagagagaa agguggguca ucugg 25

<210> 4889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4889

cagagagaaa ggugggucau cuggu 25

<210> 4890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4890

ggccaauucc agcacugcgg gcaga 25

<210> 4891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4891

ccuguccggc caauuccagc acugc 25

<210> 4892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4892

cccuguccgg ccaauuccag cacug 25

<210> 4893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4893

aucaaucaca augaacgucc cuguc 25

<210> 4894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4894

auugacguuc ccaaaaccau ccaga 25

<210> 4895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4895

cguucccaaa accauccaga uggug 25

<210> 4896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4896

aaccauccag auggugcggu cucag 25

<210> 4897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4897

uccagauggu gcggucucag agguc 25

<210> 4898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4898

ccagauggug cggucucaga gguca 25

<210> 4899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4899

auggugcggu cucagagguc aggga 25

<210> 4900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4900

gaagcacagu accgauuuau cuaua 25

<210> 4901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4901

gcacaguacc gauuuaucua uaugg 25

<210> 4902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4902

gcauuauauu gaaacacuac agcgc 25

<210> 4903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4903

cuacagcgca ggauugaaga agagc 25

<210> 4904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4904

uugaagaaga gcagguacca gccug 25

<210> 4905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4905

ugaagaagag cagguaccag ccuga 25

<210> 4906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4906

gaagagcagg uaccagccug agggc 25

<210> 4907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4907

ucaauauucgc agucaacacc uacga 25

<210> 4908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4908

gagaccgcac caucuggaug guuuu 25

<210> 4909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4909

ugagaccgca ccaucuggau gguuu 25

<210> 4910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4910

gaccucugag accgcaccau cugga 25

<210> 4911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4911

cccugaccuc ugagaccgca ccauc 25

<210> 4912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4912

gauaaaucgg uacugugcuu cuguc 25

<210> 4913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4913

augcuggacc gccauauaga uaaau 25

<210> 4914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4914

gcgcuguagu guuucaauau aaugc 25

<210> 4915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4915

cucuuccaaa uuucagaaaa gcaag 25

<210> 4916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4916

ccaaauuuca gaaaagcaag aggaa 25

<210> 4917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4917

caaauuucag aaaagcaaga ggaaa 25

<210> 4918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4918

uauacaaaua uuaaguauuc ucuag 25

<210> 4919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4919

aguauucucu agcggaccag acgag 25

<210> 4920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4920

cccugugcag aguaaguagu gcuga 25

<210> 4921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4921

ccuuuccucu ugcuuuucug aaauu 25

<210> 4922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4922

gaggggcuc ugaucuccac ucguc 25

<210> 4923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4923

uggcguugga guacaaggcg ggaga 25

<210> 4924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4924

guggcguugg aguacaaggc gggag 25

<210> 4925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4925

acaggguggc guuggaguac aaggc 25

<210> 4926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4926

cacagggugg cguuggagua caagg 25

<210> 4927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4927

cugcacagggg uggcguugga guaca 25

<210> 4928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4928

cuacuuacuc ugcacagggu ggcgu 25

<210> 4929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4929

ucagcacuac uuacucugca caggg 25

<210> 4930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4930

ccuucagcac uacuuacucu gcaca 25

<210> 4931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4931

uccuucagca cuacuuacuc ugcac 25

<210> 4932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4932

gacagugcua gagucuauga aaacg 25

<210> 4933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4933

acagugcuag agucuaugaa aacgu 25

<210> 4934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4934

ccugccaaaa cuucagcaca gaaau 25

<210> 4935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4935

acucuagcac ugucuucucu cauuc 25

<210> 4936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4936

ucugaaacuu uucugcuguu gcauc 25

<210> 4937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4937

ccuauuucug ugcugaaguu uuggc 25

<210> 4938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4938

aauaccuauu ucugugcuga aguuu 25

<210> 4939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4939

ucuuaacuua uuucuucccc agaug 25

<210> 4940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4940

agaaaguuua ugugaagaca gaauu 25

<210> 4941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4941

uuuaugugaa gacagaauuu ggauu 25

<210> 4942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4942

ugugaagaca gaauuuggau uugga 25

<210> 4943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4943

auuuggauuu ggaaggcuug caaug 25

<210> 4944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4944

auuuuauaga auuuguuuga aauug 25

<210> 4945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4945

auugugcgcu guauuuugca gauua 25

<210> 4946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4946

uugugcgcug uauuuugcag auuau 25

<210> 4947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4947

ugugcgcugu auuuugcaga uuaug 25

<210> 4948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4948

uuauggggau ucaaauucua guaau 25

<210> 4949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4949

guuuaauuuu uuuuuuccuc auugu 25

<210> 4950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4950

uuuauuuuu uuuuuccuca uuguu 25

<210> 4951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4951

uuaauuuuuu uuuuccucau uguug 25

<210> 4952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4952

uugggauga ugagaagaaa ugauu 25

<210> 4953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4953

ugggaugau gagaagaaau gauuu 25

<210> 4954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4954

ucauuuacca ucauguaucc aguag 25

<210> 4955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4955

uccaguagug gauaauucau uuuga 25

<210> 4956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4956

aauucauuuu gauggcuucu auuuu 25

<210> 4957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4957

gacugucaga aguugaccuu ugcac 25

<210> 4958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4958

uuaaagaguc auagaaaaag aauca 25

<210> 4959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4959

aagaaucaug gauauuuaug aauua 25

<210> 4960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4960

auggauauuu augaauuaag guaag 25

<210> 4961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4961

uauuuaugaa uuaagguaag aggug 25

<210> 4962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4962

uuccagccgu ugaccaauua uaguu 25

<210> 4963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4963

guucggcugu ugacugagaa guuug 25

<210> 4964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4964

cggcuguuga cugagaaguu ugugg 25

<210> 4965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4965

ggcuguugac ugagaaguuu guggu 25

<210> 4966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4966

aauaauuguc uuguacuuag aaaaa 25

<210> 4967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4967

ggcgucuaug aaugaccagu guuuu 25

<210> 4968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4968

ugguuuuuuc uaaucagaag aaagc 25

<210> 4969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4969

gguuuuuucu aaucagaaga aagcu 25

<210> 4970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4970

guuuuuucua aucagaagaa agcug 25

<210> 4971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4971

gauucaagaa aaggguguga aguag 25

<210> 4972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4972

ggugugaagu agaggugcag uuaag 25

<210> 4973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4973

gugugaagua gaggugcagu uaagu 25

<210> 4974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4974

ugugaaguag aggugcaguu aagug 25

<210> 4975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4975

gugaaguaga ggugcaguua agugg 25

<210> 4976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4976

ugaaguagag gugcaguuaa guggg 25

<210> 4977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4977

aguggggggc cacuagucua acaga 25

<210> 4978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4978

uaacagacgg ucacaaccag ugcca 25

<210> 4979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4979

ucacaaccag ugccauggaa aacca 25

<210> 4980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4980

caaaagcaga aguugcuagu gaccu 25

<210> 4981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4981

aaaagcagaa guugcuagug accuu 25

<210> 4982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4982

ggaagccgaa gcugcuuaca guagc 25

<210> 4983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4983

gaagccgaag cugcuuacag uagcu 25

<210> 4984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4984

gaaagucaga cuaagaaaua aagag 25

<210> 4985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4985

aaagucagac uaagaaauaa agaga 25

<210> 4986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4986

uuucugcuag cccuagccu auuuu 25

<210> 4987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4987

ugagccuauu uuuggaacca gcacu 25

<210> 4988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4988

gagccuauuu uuggaaccag cacuu 25

<210> 4989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4989

agccuauuuu uggaaccagc acuug 25

<210> 4990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4990

agcacuuggg gaaacugauc uugug 25

<210> 4991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4991

cuuggggaaa cugaucuugu gagga 25

<210> 4992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4992

ugaucuugug aggauggaug uguuu 25

<210> 4993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4993

gaucuuguga ggauggaugu guuua 25

<210> 4994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4994

ugaggaugga uguguuuagg gacac 25

<210> 4995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4995

gaggauggau guguuuaggg acaca 25

<210> 4996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4996

gcuuuugaga gcagcaccac cccac 25

<210> 4997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4997

cuuuugagag cagcaccacc ccacu 25

<210> 4998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4998

uuuugagagc agcaccaccc cacug 25

<210> 4999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 4999

caccccacug gggcaucccc agacu 25

<210> 5000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5000

accccacgg ggcaucccca gacuu 25

<210> 5001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5001

aaacgugacu cuuucuuaau gccac 25

<210> 5002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5002

aacgugacuc uuucuuaaug ccacu 25

<210> 5003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5003

uucuuaaugc cacuggguuu uaguc 25

<210> 5004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5004

ggguuuuagu caggccacag ugaga 25

<210> 5005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5005

cacagugaga aggaacagcc cuaac 25

<210> 5006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5006

gaacagcccu aacagggccuc cagcc 25

<210> 5007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5007

gccucauauug uugaaucauc cagug 25

<210> 5008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5008

gcggauauuu caaugaaaau aucau 25

<210> 5009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5009

aaauauucauu gguugacuuu uguga 25

<210> 5010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5010

gacuuuugug augguaauaa ugcua 25

<210> 5011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5011

cuauggcauc uuugccauga aguug 25

<210> 5012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5012

cuuugccaug aaguuguggc cuccu 25

<210> 5013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5013

uggccuccuu ggauucuucu gacuu 25

<210> 5014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5014

gauucuucug acuuuggcuu cugaa 25

<210> 5015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5015

cuucugacuu uggcuucuga aagga 25

<210> 5016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5016

ugaaaggaag gccuagaucc agccc 25

<210> 5017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5017

aaggaaggcc uagauccagc ccugg 25

<210> 5018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5018

cagcccuggu gguaguuccu uucug 25

<210> 5019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5019

gaggucucuc agucccuuga gacuu 25

<210> 5020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5020

aggucucuca gucccuugag acuuu 25

<210> 5021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5021

ggucucucag ucccuugaga cuuug 25

<210> 5022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5022

agucccuuga gacuuugggg uaguu 25

<210> 5023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5023

ugaacuuga auugcuucag aacac 25

<210> 5024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5024

uuugaauugc uucagaacac aggug 25

<210> 5025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5025

gcuucagaac acaggugugg ccuga 25

<210> 5026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5026

ugggccuga agguauuccc uuauu 25

<210> 5027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5027

guggccugaa gguauucccu uauua 25

<210> 5028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5028

caucgacuca uucuccauuu ugcuu 25

<210> 5029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5029

guuuugucuu gacuugacuu gacuu 25

<210> 5030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5030

uuuugucuug acuugacuug acuuu 25

<210> 5031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5031

uuugucuuga cuugacuuga cuuug 25

<210> 5032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5032

uugucuugac uugacuugac uuugg 25

<210> 5033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5033

agaucaguug cuuuuauacu cagaa 25

<210> 5034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5034

uacucagaau ggaaauaccu gaucu 25

<210> 5035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5035

gauuucauuu agauuucccu ccacg 25

<210> 5036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5036

aacuaucaug uucuuaugua aacuu 25

<210> 5037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5037

cauguucuua uguaaacuua ggcca 25

<210> 5038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5038

caaggccaga guuaucauag ucccu 25

<210> 5039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5039

aguuaucaua gucccuaggu ugcua 25

<210> 5040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5040

agguugcuac ggcuuaucau gugcu 25

<210> 5041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5041

uacggcuuau caugugcuug guaaa 25

<210> 5042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5042

caugugcuug guaaaaggug aucgc 25

<210> 5043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5043

ucagacgagu uuacuuuaca ugaga 25

<210> 5044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5044

aguuuacuuu acaugagaug gaauc 25

<210> 5045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5045

uuacaugaga uggaaucagg cagag 25

<210> 5046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5046

augagaugga aucaggcaga gaggc 25

<210> 5047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5047

ugagauggaa ucaggcagag aggcu 25

<210> 5048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5048

gaaucaggca gagaggcugg gauga 25

<210> 5049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5049

aggcugggau gauggagaaa gcucg 25

<210> 5050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5050

aggugaaguu uuaaaaaaaa aguug 25

<210> 5051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5051

aaguuuuaaa aaaaaaguug uggaa 25

<210> 5052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5052

aguuguggaa aggaaaguuc caaag 25

<210> 5053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5053

uguggaaagg aaaguuccaa agagg 25

<210> 5054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5054

gaaaguucca aagagguggu uucug 25

<210> 5055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5055

gguuucugag gaagucagag cgccc 25

<210> 5056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5056

guuucugagg aagucagagc gccca 25

<210> 5057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5057

cgccggggc cagagcaguc aguaa 25

<210> 5058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5058

gccggggcc agagcaguca guaau 25

<210> 5059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5059

cagagcaguc aguaaugggu gaaug 25

<210> 5060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5060

ucaguaaugg gugaaugagg uuguu 25

<210> 5061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5061

gggugaauga gguuguuugg aaagu 25

<210> 5062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5062

uuggaaaguc ggugugacag acaca 25

<210> 5063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5063

agacacaugg augccaucua cuucu 25

<210> 5064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5064

uggaugccau cuacuucuag guugc 25

<210> 5065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5065

augccaucua cuucuagguu gcugg 25

<210> 5066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5066

ugccaucuac uucuagguug cuggu 25

<210> 5067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5067

augcacaaua uuccaauagcu cacug 25

<210> 5068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5068

cugaggauuu uaaaauuaua agcau 25

<210> 5069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5069

auuauaagca uaggauuuua uauuu 25

<210> 5070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5070

uuauaagcau aggauuuuau auuuu 25

<210> 5071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5071

uauaagcaua ggauuuuaua uuuug 25

<210> 5072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5072

uauauuuugg ggugaaagaa uuauc 25

<210> 5073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5073

gggugaaaga auuaucuggc acauu 25

<210> 5074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5074

aagaauuauc uggcacauua gguau 25

<210> 5075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5075

auaacuuuuu uuaaaaaaaa cuaaa 25

<210> 5076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5076

uaaaaggcgc uucaugucca gugug 25

<210> 5077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5077

cagugugugg cccuucugaa acuua 25

<210> 5078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5078

auggucaucu cucccacuga aacca 25

<210> 5079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5079

acugaaacca aggucuuuuc aaaug 25

<210> 5080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5080

caaggucuuu ucaaaugugg cuaaa 25

<210> 5081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5081

aaggucuuuu caaauguggc uaaau 25

<210> 5082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5082

aggucuuuuc aaauguggcu aaaug 25

<210> 5083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5083

uuucaaaugu ggcuaaaugg ggaug 25

<210> 5084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5084

guggcuaaau ggggaugagg agaca 25

<210> 5085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5085

uggcuaaaug gggaugagga gacac 25

<210> 5086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5086

uaaaugggga ugaggagaca cgggu 25

<210> 5087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5087

ugaggagaca cggguaggac uuucu 25

<210> 5088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5088

cauucuuuaa agagccaagu ugcuu 25

<210> 5089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5089

auucuuuaaa gagccaaguu gcuuc 25

<210> 5090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5090

uucuuuaaag agccaaguug cuucg 25

<210> 5091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5091

gccaaguugc uucggggaaa cagcc 25

<210> 5092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5092

ugcuucgggg aaacagccag gaaaa 25

<210> 5093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5093

ggaaaauggu caagauuauu uuuag 25

<210> 5094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5094

agauuauuuuuuuuuuuuuuuuu 25

<210> 5095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5095

gauuauuuuu agagguuuuu uuauu 25

<210> 5096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5096

auuauuuuua gagguuauuu uauug 25

<210> 5097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5097

uaacaucuug aguuauuuuu aauuc 25

<210> 5098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5098

aacaucuuga guuauuuuua auuca 25

<210> 5099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5099

acaucuugag uuauuuuuaa uucag 25

<210> 5100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5100

caucuugagu uauuuuuaauucagg 25

<210> 5101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5101

gaguuauuuu uaauucaggg ggaug 25

<210> 5102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5102

auuuuuaauu cagggggaug uggaa 25

<210> 5103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5103

guuuuguugu agcuuaguau ccaua 25

<210> 5104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5104

uuuuguugua gcuuaguauc cauaa 25

<210> 5105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5105

gcagcuuuug uuuucuguau guugu 25

<210> 5106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5106

cagcuuuugu uuucuguaug uuguu 25

<210> 5107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5107

agcuuuuguuuucuguauguuguug 25

<210> 5108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5108

gcuuuuguuu ucuguauguu guugg 25

<210> 5109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5109

ucaacuuuca cacauagcaa gcaca 25

<210> 5110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5110

gcaagcacau ggccucccug auguc 25

<210> 5111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5111

ucccuaugu caggaugccu uuguu 25

<210> 5112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5112

cuaaaaauuu guuccuuuuu cacua 25

<210> 5113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5113

uaaaaauuug uuccuuuuuc acuau 25

<210> 5114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5114

uuuuucacua ugggcaguuc acaca 25

<210> 5115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5115

cacaaggcaa aaacuauuga acagu 25

<210> 5116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5116

ugauucuuuu auuaauaaaa gcuaa 25

<210> 5117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5117

gauucuuuua uuaauaaaag cuaau 25

<210> 5118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5118

uuuauuuaaua aaagcuaaug ggaaa 25

<210> 5119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5119

uuuuugaua aucuauccu uuaaa 25

<210> 5120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5120

cuauccuuua aaaggaauac guuuu 25

<210> 5121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5121

aauaguuuau guagagaaac auuag 25

<210> 5122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5122

uuaauugucu ccccaccuau auuua 25

<210> 5123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5123

uaauugucuc cccaccuaua uuuau 25

<210> 5124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5124

aguaaaagug uauuuguaaa cugua 25

<210> 5125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5125

guaaaagugu auuuguaaac uguau 25

<210> 5126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5126

guaaacugua ugggaacuaa aaauu 25

<210> 5127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5127

ggaauaaaac cauuuucuua uauga 25

<210> 5128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5128

gggagagggu gaaaguccac aucug 25

<210> 5129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5129

agggagggg ugaaagucca caucu 25

<210> 5130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5130

uagggagagg gugaaagucc acauc 25

<210> 5131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5131

ucuguucuug aucuuuuuag ggaga 25

<210> 5132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5132

gucuguucuu gaucuuuuua gggag 25

<210> 5133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5133

cuugcgucug uucuugaucu uuuua 25

<210> 5134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5134

ucuugcgucu guucuugauc uuuuu 25

<210> 5135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5135

augguuucaa auuuugcuua ucaaa 25

<210> 5136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5136

gaguuaaaau acaguggucu uuaaa 25

<210> 5137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5137

cagguauugu ugaguuaaaa uacag 25

<210> 5138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5138

cugaggaaau gaguaauugg gaagc 25

<210> 5139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5139

uucuuaucug aggaaaugag uaauu 25

<210> 5140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5140

cuucuuaucu gaggaaauga guaau 25

<210> 5141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5141

uguagagaug auuucuucuu aucug 25

<210> 5142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5142

ggaaaaaaaa aauuaaacug guuaa 25

<210> 5143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5143

aggaaaaaaa aaauuaaacu gguua 25

<210> 5144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5144

acaaugagga aaaaaaaaau uaaac 25

<210> 5145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5145

uuucuucuca ucauccccaa caaug 25

<210> 5146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5146

uaaugagau uguucucacu uuucu 25

<210> 5147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5147

gaauuaucca cuacuggaua cauga 25

<210> 5148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5148

gccaucaaaa ugaauuaucc acuac 25

<210> 5149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5149

cucaggcacu ggcuuaauuc ucauu 25

<210> 5150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5150

gucaacuucu gacagucuca ggcac 25

<210> 5151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5151

gcaaagguca acuucugaca gucuc 25

<210> 5152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5152

cuaugacucu uuaaugccag ugcaa 25

<210> 5153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5153

agccgaacua uaauugguca acggc 25

<210> 5154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5154

caacagccga acuauaauug gucaa 25

<210> 5155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5155

ucucagucaa cagccgaacu auaau 25

<210> 5156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5156

caauuauuca aaugcaaaga aaaua 25

<210> 5157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5157

ucguuguuuu ggcgaccaaa aacac 25

<210> 5158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5158

aacccuauuc aaacagucgu uguuu 25

<210> 5159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5159

cgaacacuga acaaaucauu caucu 25

<210> 5160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5160

ccgaacacug aacaaaucau ucauc 25

<210> 5161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5161

ugguugugac cgucuguuag acuag 25

<210> 5162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5162

uauauuccuu gguuuuccau ggcac 25

<210> 5163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5163

uuuugcuaau auccuugguu uucca 25

<210> 5164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5164

caacuucugc uuuugcuaau auccu 25

<210> 5165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5165

uacuguaagc agcuucggcu uccca 25

<210> 5166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5166

uugucccagc uacuguaagc agcuu 25

<210> 5167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5167

agaaaucauu caggaagcuu cuuga 25

<210> 5168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5168

ggcucagggc uagcagaaau cauuc 25

<210> 5169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5169

agugcugguu ccaaaaauag gcuca 25

<210> 5170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5170

aagugcuggu uccaaaaaua ggcuc 25

<210> 5171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5171

uuccccaagu gcugguucca aaaau 25

<210> 5172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5172

ucacaagauc aguuucccca agugc 25

<210> 5173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5173

caagucugggg gaugccccag ugggg 25

<210> 5174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5174

ucccaagucu ggggaugccc cagug 25

<210> 5175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5175

uucccaaguc ugggaugcc ccagu 25

<210> 5176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5176

uuucccaagu cuggggaugc cccag 25

<210> 5177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5177

gaaagaguca cguuucccaa gucug 25

<210> 5178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5178

agaaagaguc acguuuccca agucu 25

<210> 5179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5179

aagaaagagu cacguuuccc aaguc 25

<210> 5180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5180

ucacuguggc cugacuaaaa cccag 25

<210> 5181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5181

cuguuagggc uguuccuucu cacug 25

<210> 5182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5182

auucaaccug gcuggaggcc uguua 25

<210> 5183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5183

cauucaaccu ggcuggaggc cuguu 25

<210> 5184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5184

aaugagcuc auucaaccug gcugg 25

<210> 5185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5185

caaaaaugag cucauucaac cuggc 25

<210> 5186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5186

acaacaaaaa ugagcucauu caacc 25

<210> 5187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5187

uagaacauua gcaaaucuua cuggu 25

<210> 5188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5188

aauguagaac auuagcaaau cuuac 25

<210> 5189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5189

aggcaaagag ggaugucuuu ggaga 25

<210> 5190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5190

cauaugaggc aaagagggau gucuu 25

<210> 5191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5191

gaugauucaa cauaugaggc aaaga 25

<210> 5192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5192

ggaugauuca acauaugagg caaag 25

<210> 5193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5193

uccgcacugg augauucaac auaug 25

<210> 5194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5194

gauauuuuca uugaaauuuc cgcac 25

<210> 5195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5195

agaauccaag gaggccacaa cuuca 25

<210> 5196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5196

aagccaaagu cagaagaauc caagg 25

<210> 5197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5197

cagaagccaa agucagaaga aucca 25

<210> 5198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5198

aggaacuacc accagggcug gaucu 25

<210> 5199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5199

cucagaaagg aacuaccacc agggc 25

<210> 5200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5200

agaccucaga aaggaacuac cacca 25

<210> 5201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5201

gagaccucag aaaggaacua ccacc 25

<210> 5202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5202

cucaagggac ugagagaccu cagaa 25

<210> 5203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5203

cagccaaacu accccaaagu cucaa 25

<210> 5204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5204

gcagccaaac uaccccaaag ucuca 25

<210> 5205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5205

cugauauaca uuuugucagu gagaa 25

<210> 5206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5206

aaggaauauu ggggggugga ggugg 25

<210> 5207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5207

caaggaauau uggggggugg aggug 25

<210> 5208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5208

ucaaggaaua uuggggggug gaggu 25

<210> 5209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5209

uucaaggaau auuggggggu ggagg 25

<210> 5210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5210

aaguucaagg aauauugggg ggugg 25

<210> 5211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5211

ucaaaguuca aggaauauug ggggg 25

<210> 5212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5212

aauucaaagu ucaaggaaua uuggg 25

<210> 5213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5213

caauucaaag uucaaggaau auugg 25

<210> 5214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5214

gcaauucaaa guucaaggaa uauug 25

<210> 5215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5215

agcaauucaa aguucaagga auauu 25

<210> 5216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5216

aagcaauuca aaguucaagg aauau 25

<210> 5217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5217

guguucugaa gcaauucaaa guuca 25

<210> 5218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5218

acuucccuaa uaagggaaua ccuuc 25

<210> 5219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5219

gacagcagug acacuucccu aauaa 25

<210> 5220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5220

agacagcagu gacacuuccc uaaua 25

<210> 5221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5221

aagcuucuug cugcaaauac ugaac 25

<210> 5222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5222

aagucaagac aaaaccaaag caaaa 25

<210> 5223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5223

uuuguacaau caaacucuug ugugc 25

<210> 5224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5224

auaaaagcaa cugaucuuaa gcaac 25

<210> 5225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5225

ucuuauaaca aaacuagcca agauc 25

<210> 5226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5226

caugauaguu ugcugaccuc gugga 25

<210> 5227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5227

acaugauagu uugcugaccu cgugg 25

<210> 5228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5228

agaacaugau aguuugcuga ccucg 25

<210> 5229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5229

cuaggacua ugauaacucu ggccu 25

<210> 5230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5230

agcaaccuag ggacuaugau aacuc 25

<210> 5231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5231

gcacaugaua agccguagca accua 25

<210> 5232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5232

agcacaugau aagccguagc aaccu 25

<210> 5233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5233

cugacuuccu cagaaaccac cucuu 25

<210> 5234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5234

acccauuacu gacugcucug gcccu 25

<210> 5235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5235

cacccauuac ugacugcucu ggccc 25

<210> 5236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5236

cucauucacc cauuacugac ugcuc 25

<210> 5237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5237

uacccaccag caaccuagaa guaga 25

<210> 5238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5238

uaauuuuaaa auccucagug agcua 25

<210> 5239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5239

aaaaaguuau uaagacugug aaauu 25

<210> 5240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5240

cauaaguuuc agaagggcca cacac 25

<210> 5241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5241

ggagagauga ccauaaguuu cagaa 25

<210> 5242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5242

gggagagaug accauaaguu ucaga 25

<210> 5243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5243

cauuugaaaa gaccuugguu ucagu 25

<210> 5244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5244

acauuugaaa agaccuuggu uucag 25

<210> 5245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5245

cauuuagcca cauuugaaaa gaccu 25

<210> 5246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5246

uccggcugu uuccccgaag caacu 25

<210> 5247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5247

cuaaaaauaa ucuugaccau uuucc 25

<210> 5248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5248

augucuauag ucuaaguuuc ccuua 25

<210> 5249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5249

aacauacaga aaacaaaagc ugcac 25

<210> 5250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5250

uaacaaaggc auccuacau caggg 25

<210> 5251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5251

uccuaacaaa ggcauccuga cauca 25

<210> 5252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5252

auccuaacaa aggcauccug acauc 25

<210> 5253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5253

uaagggcaaa uacagauccu aacaa 25

<210> 5254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5254

ggaaaaaaga uuucaacaaa auuaa 25

<210> 5255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5255

aggaaaaaag auuucaacaa aauua 25

<210> 5256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5256

auuuuggaac uuuucaagag gaaga 25

<210> 5257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5257

aaacuauauuuuuggaacuuuucaag 25

<210> 5258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5258

augaaagaua caauaaacua uauuu 25

<210> 5259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5259

uugugugaac ugcccauagu gaaaa 25

<210> 5260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5260

uuauuaauua caugauuuga ggcuu 25

<210> 5261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5261

ggcaaauuau uaauuacaug auuug 25

<210> 5262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5262

aaucacaauu aggucauaaa uaaac 25

<210> 5263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5263

uuuuauuaau aaaagaauca caauu 25

<210> 5264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5264

guaggucuag ucaucagcuu aauca 25

<210> 5265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5265

uguaggucua gucaucagcu uaauc 25

<210> 5266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5266

cauauacugc aggaaaauua auugu 25

<210> 5267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5267

ucugguacaa uacuucauau acugc 25

<210> 5268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5268

aaauauuaca uaucuuuuaa uacuc 25

<210> 5269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5269

acauccuaaa acguauuccu uuuaa 25

<210> 5270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5270

gacuacauaa uauacguggg caaaa 25

<210> 5271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5271

ugcaaauaga cuacauaaua uacgu 25

<210> 5272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5272

uugcaaauag acuacauaau auacg 25

<210> 5273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5273

gcgcuaacac ccauaaauau aggug 25

<210> 5274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5274

ugcgcuaaca cccauaaaua uaggu 25

<210> 5275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5275

uugcgcuaac acccauaaau auagg 25

<210> 5276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5276

caguugcgcu aacacccaua aauau 25

<210> 5277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5277

cgacaaaugc caucauauaa gaaaa 25

<210> 5278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5278

cccggccuuc acgugaccug gcgug 25

<210> 5279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5279

ugaccuggcg ugcggagcgc gcacg 25

<210> 5280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5280

gaccuggcgu gcggagcgcg cacgc 25

<210> 5281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5281

ggagcgcgca cgcgggaacc cgcgc 25

<210> 5282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5282

gcgcgcacgc gggaacccgc gcugg 25

<210> 5283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5283

cgcacgcggg aacccgcgcu ggagg 25

<210> 5284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5284

gcacgcggga acccgcgcug gaggc 25

<210> 5285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5285

cgggaacccg cgcuggaggc gggcg 25

<210> 5286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5286

gggaacccgc gcuggaggcg ggcga 25

<210> 5287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5287

ccgcgcugga ggcggggcgag ggccg 25

<210> 5288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5288

cgcgcuggag gcgggcgagg gccga 25

<210> 5289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5289

gcgcuggagg cgggcgaggg ccgag 25

<210> 5290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5290

ggcgggcgag ggccgagggg cagcu 25

<210> 5291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5291

gcgggcgagg gccgaggggc agcua 25

<210> 5292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5292

agggccgagg ggcagcuagg gagcg 25

<210> 5293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5293

aggggcagcu agggagcgcg gcuug 25

<210> 5294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5294

ggcagcuagg gagcgcggcu ugagg 25

<210> 5295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5295

gcagcuaggg agcgcggcuu gagga 25

<210> 5296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5296

gcuagggagc gcggcuugag gaggg 25

<210> 5297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5297

cuagggagcg cggcuugagg agggc 25

<210> 5298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5298

uagggagcgc ggcuugagga gggcg 25

<210> 5299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5299

cuugaggagg gcggggccgc cccgc 25

<210> 5300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5300

gccaaaguca aaccccgaca cccgc 25

<210> 5301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5301

aaagucaaac cccgacaccc gccgg 25

<210> 5302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5302

aagucaaacc ccgacacccg ccggc 25

<210> 5303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5303

caaaccccga cacccgccgg cgggc 25

<210> 5304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5304

gggccgguga gcucacuagc ugacc 25

<210> 5305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5305

cggugagcuc acuagcugac ccggc 25

<210> 5306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5306

agcucacuag cugacccggc agguc 25

<210> 5307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5307

cuagcugacc cggcagguca ggauc 25

<210> 5308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5308

cccggcaggu caggaucugg cuuag 25

<210> 5309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5309

ccgcgagcuc cagugcgcgc acccg 25

<210> 5310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5310

guggccgccu ccgcccuc uuugc 25

<210> 5311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5311

ccagcccucu uugccggacg agcuc 25

<210> 5312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5312

cagcccucuu ugccggacga gcucu 25

<210> 5313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5313

cgagcucugg gccgccacaa gacua 25

<210> 5314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5314

ucugggccgc cacaagacua aggaa 25

<210> 5315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5315

ugcccgucuu ucucagccag cucug 25

<210> 5316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5316

gcccgucuuu cucagccagc ucuga 25

<210> 5317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5317

cccgucuuuc ucagccagcu cugag 25

<210> 5318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5318

cccgcaucaa gaaaaucucc aucga 25

<210> 5319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5319

ccgcaucaag aaaaucucca ucgaa 25

<210> 5320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5320

agaaaaucuc caucgaaggg aacau 25

<210> 5321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5321

aucuccaucg aagggaacau cggua 25

<210> 5322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5322

gaagggaaca ucgguaagga gccuc 25

<210> 5323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5323

caucgguaag gagccuccgg aaaug 25

<210> 5324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5324

aucgguaagg agccuccgga aaugu 25

<210> 5325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5325

cgcacgccag gucacgugaa ggccg 25

<210> 5326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5326

ccgcacgcca ggucacguga aggcc 25

<210> 5327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5327

uccgcacgcc aggucacgug aaggc 25

<210> 5328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5328

gcgcuccgca cgccagguca cguga 25

<210> 5329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5329

uucccgcgug cgcgcuccgc acgcc 25

<210> 5330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5330

cucggccuc gcccgccucc agcgc 25

<210> 5331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5331

ccucggcccu cgcccgccuc cagcg 25

<210> 5332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5332

caagccgcgc ucccuagcug ccccu 25

<210> 5333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5333

ugaggacacu gggggccug cgggg 25

<210> 5334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5334

agcugaggac acuggcggggc cugcg 25

<210> 5335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5335

cagcugga cacuggcggg ccugc 25

<210> 5336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5336

gcagcugagg acacuggcgg gccug 25

<210> 5337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5337

cgcggaggca gcugaggaca cuggc 25

<210> 5338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5338

gcgcgggaggc agcugaggac acugg 25

<210> 5339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5339

ggcgcgcgga ggcagcugag gacac 25

<210> 5340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5340

ugacuuuggc gcgcgggaggc agcug 25

<210> 5341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5341

gucgggguuu gacuuuggcg cgcgg 25

<210> 5342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5342

ggugucgggg uuugacuuug gcgcg 25

<210> 5343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5343

gccggcgggu gucgggguuu gacuu 25

<210> 5344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5344

cucaccggcc cgccggcggg ugucg 25

<210> 5345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5345

gcucaccggc ccgccggcgg guguc 25

<210> 5346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5346

agcucaccgg cccgccggcg ggugu 25

<210> 5347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5347

cuagugagcu caccggcccg ccggc 25

<210> 5348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5348

gcuagugagc ucaccggccc gccgg 25

<210> 5349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5349

ucagcuagug agcucaccgg cccgc 25

<210> 5350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5350

cugccggguc agcuagugag cucac 25

<210> 5351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5351

ccgcuaagcc agauccugac cugcc 25

<210> 5352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5352

gccgcuaagc cagauccuga ccugc 25

<210> 5353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5353

ccacggggc gcgcacugga gcucg 25

<210> 5354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5354

gggaggcggc cacgggugcg cgcac 25

<210> 5355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5355

gcaaagggg cugggaggcg gccac 25

<210> 5356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5356

ggcaaagagg gcugggaggc ggcca 25

<210> 5357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5357

ucguccggca aaggggcug ggagg 25

<210> 5358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5358

agcucguccg gcaaagaggg cuggg 25

<210> 5359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5359

cagagcucgu ccggcaaaga gggcu 25

<210> 5360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5360

ccagagcucg uccggcaaag agggc 25

<210> 5361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5361

cggccgag cucguccggc aaaga 25

<210> 5362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5362

gcggcccaga gcucguccgg caaag 25

<210> 5363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5363

gucuuguggc ggccgagc ucguc 25

<210> 5364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5364

ggguggccau uccuuagucu ugugg 25

<210> 5365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5365

gcgggguggc cauuccuuag ucuug 25

<210> 5366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5366

gacggggcagc uucucuuggg cgggg 25

<210> 5367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5367

aaagacgggc agcuucucuu gggcg 25

<210> 5368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5368

gaaagacggg cagcuucucu ugggc 25

<210> 5369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5369

agaaagacgg gcagcuucuc uuggg 25

<210> 5370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5370

cugagaaaga cgggcagcuu cucuu 25

<210> 5371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5371

gcugagaaag acgggcagcu ucucu 25

<210> 5372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5372

ccccucagag cuggcugaga aagac 25

<210> 5373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5373

uccccucaga gcuggcugag aaaga 25

<210> 5374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5374

uucuugaugc ggguccccuc agagc 25

<210> 5375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5375

ccuucgaugg agauuuucuu gaugc 25

<210> 5376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5376

cccuucgaug gagauuuucu ugaug 25

<210> 5377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5377

ggcuccuuac cgauguuccc uucga 25

<210> 5378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5378

uuuuaucuuuu ccucacaaca gcugc 25

<210> 5379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5379

uuuaucuuuc cucacaacag cugca 25

<210> 5380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5380

uauccuuaaa caauugugug aagau 25

<210> 5381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5381

auccuuaaac aauuguguga agauu 25

<210> 5382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5382

aaacaauugu gugaagauug ggaag 25

<210> 5383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5383

agugguuccu gaaccuguug ccaga 25

<210> 5384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5384

guucaaagua cucaagauga auuug 25

<210> 5385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5385

uguugacuuc ccugcagcug uugug 25

<210> 5386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5386

uucccaaucu ucacacaauu guuua 25

<210> 5387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5387

cauugcacca ucuggcaaca gguuc 25

<210> 5388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5388

uuugaacauu gcaccaucug gcaac 25

<210> 5389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5389

ugaguacuuu gaacauugca ccauc 25

<210> 5390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5390

aggaacuuac aaugucucag aaaaa 25

<210> 5391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5391

aacuuacaau gucucagaaa aaugg 25

<210> 5392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5392

acuuacaaug ucucagaaaa auggu 25

<210> 5393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5393

gaugauguau gagaaaccug aacga 25

<210> 5394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5394

uaaagcuca gcuugccucu cugaa 25

<210> 5395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5395

uuuugaacga ucuguguaua gugac 25

<210> 5396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5396

guguauagug acagguaugu auaaa 25

<210> 5397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5397

cagguaugua uaaauggcuu guacg 25

<210> 5398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5398

uuuggaaggu aaaagaccau cguuc 25

<210> 5399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5399

cgacugagac aggcauaugu uugga 25

<210> 5400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5400

uauucgacug agacaggcau auguu 25

<210> 5401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5401

agcugagcuc uuauucgacu gagac 25

<210> 5402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5402

gcaucuuuga gcuugccauu cagag 25

<210> 5403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5403

acacagaucg uucaaaaaau aauac 25

<210> 5404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5404

aucugaaugc augaaugaga cagag 25

<210> 5405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5405

gacagagugg acaauuuauc aagac 25

<210> 5406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5406

gacaauuuau caagacuggc augac 25

<210> 5407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5407

ggcaugacug gaugaauaac caauu 25

<210> 5408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5408

aaccaauuug gccaaagccu ugaau 25

<210> 5409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5409

aauuuggcca aagccuugaa uugga 25

<210> 5410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5410

aucauuuauc uucaagccac uccag 25

<210> 5411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5411

auccaauuca aggcuuuggc caaau 25

<210> 5412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5412

aaugauucca uccaauucaa ggcuu 25

<210> 5413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5413

aagauaaaug auuccaucca auuca 25

<210> 5414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5414

uuuuuuugg guuuuaccuc uggag 25

<210> 5415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5415

acacauuuuu auggguuuu accuc 25

<210> 5416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5416

gacaugcuua cauagaauau auuua 25

<210> 5417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5417

acaugcuuac auagaauaua uuuac 25

<210> 5418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5418

caugcuuaca uagaauauau uuacg 25

<210> 5419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5419

auuuacgggg aagaaaugaa gagca 25

<210> 5420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5420

gaagcuucau uauaaacaug aaagc 25

<210> 5421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5421

uaaacaugaa agcuggcucc ugcau 25

<210> 5422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5422

augucuaaaa gcaaguaaua agaga 25

<210> 5423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5423

aaugaagcuu cucuuaaauau ucaag 25

<210> 5424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5424

uaagucuuac uucagugucc uaugc 25

<210> 5425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5425

agaaccaacu ucgauuaucu ucaag 25

<210> 5426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5426

cuucaagagg ugccuaucuu aacac 25

<210> 5427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5427

gacuuuaaag acaaauuuga aaguc 25

<210> 5428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5428

gacaaauauug aaagucuggu ugaaa 25

<210> 5429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5429

ggcaccucuu gaagauaauc gaagu 25

<210> 5430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5430

cuucauuaac auccaguguu aagau 25

<210> 5431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5431

acuuugugau cuugcugaag acuac 25

<210> 5432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5432

uugcugaaga cuacagggcag ccaaa 25

<210> 5433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5433

caaguuuuua aucguuuuug uuuua 25

<210> 5434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5434

uccucagcag guuggcuuuu uuccc 25

<210> 5435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5435

uuuucccugg ugccucucac uucgu 25

<210> 5436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5436

gaaagcuuua auguuacaua guaaa 25

<210> 5437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5437

aguguaccua uuaaaaguug caaag 25

<210> 5438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5438

auuaaaaguu gcaaagugga auuaa 25

<210> 5439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5439

uggaauuaaa ggaaucccua gaaua 25

<210> 5440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5440

gccucagucu gcuuucucua cuguc 25

<210> 5441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5441

gcuuucucua cugucuggau uaauu 25

<210> 5442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5442

cugaaagcau uauuuuuugu ugaau 25

<210> 5443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5443

uaggaaauaa aauuaaugaa gacag 25

<210> 5444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5444

ugugaauauu uguaaaaaua augaa 25

<210> 5445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5445

auuuucuuuc uaguuuguuu aguua 25

<210> 5446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5446

agaaaauuuu auguauuuua aaaua 25

<210> 5447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5447

gaaaauuuua uguauuuuaa aauaa 25

<210> 5448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5448

aaaauuuuau guauuuuaaa auaag 25

<210> 5449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5449

uuucuuucca agucauuuuu guuuu 25

<210> 5450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5450

uucuuauuca aagaugauaa uuuag 25

<210> 5451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5451

aguccagacg cacugaucuu ugcaa 25

<210> 5452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5452

ugcauuuuuu uaguuuguuu uuguu 25

<210> 5453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5453

uaaguauaaa ccuuaugaac uacag 25

<210> 5454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5454

cuuuuaaaua aauuaugaau auuaa 25

<210> 5455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5455

uaaauuacuu ugauuccauu uuaag 25

<210> 5456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5456

ucaugacuca aaaguugucu cagug 25

<210> 5457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5457

ugacucaaaa guugucucag ugugg 25

<210> 5458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5458

cucaaaaacu cuuugaccug aggaa 25

<210> 5459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5459

aaguacucaa aaacucuuug accug 25

<210> 5460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5460

caaagcugaa guaucuggaa ccauu 25

<210> 5461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5461

cgaagauaca caaagcugaa guauc 25

<210> 5462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5462

uuaaaacaaa aacgauuaaa aacuu 25

<210> 5463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5463

cuuaaaacaa aaacgauuaa aaacu 25

<210> 5464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5464

uuuuuuuuuu guuuucuuuu cuuuc 25

<210> 5465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5465

gucaccaacg aagugagagg cacca 25

<210> 5466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5466

ggucaccaac gaagugagag gcacc 25

<210> 5467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5467

agaaacuggu caccaacgaa gugag 25

<210> 5468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5468

cauuaaagcu uucaguuuaa gaaac 25

<210> 5469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5469

uuuuaauagg uacacuaauu uacac 25

<210> 5470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5470

uuaauuccac uuugcaacuu uuaau 25

<210> 5471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5471

auaaaacuuc agaauccuua uucua 25

<210> 5472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5472

aauaaaacuu cagaauccuu auucu 25

<210> 5473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5473

cagacugagg caggaaguaa gaggu 25

<210> 5474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5474

gcagacugag gcaggaagua agagg 25

<210> 5475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5475

aaagcagacu gaggcaggaa guaag 25

<210> 5476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5476

gacaguagag aaagcagacu gaggc 25

<210> 5477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5477

uccagacagu agagaaagca gacug 25

<210> 5478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5478

aaauguguga cuuuaacuuu auagc 25

<210> 5479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5479

cuuucaaca aaaaauaaug cuuuc 25

<210> 5480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5480

uaguuaagug ugucucauua auuaa 25

<210> 5481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5481

uuauuuuuac aaauauucac auaga 25

<210> 5482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5482

cguaaaaugg aaagguuuaa uacac 25

<210> 5483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5483

aaauuuucua aaacguaaaa uggaa 25

<210> 5484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5484

acauaaaauu uucuaaaacg uaaaa 25

<210> 5485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5485

uaagaaacca aaaacaaaaa ugacu 25

<210> 5486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5486

uuugcaaaga ucagugcguc uggac 25

<210> 5487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5487

ucuccuuugc aaagaucagu gcguc 25

<210> 5488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5488

uacguauaau gagacaguuu augua 25

<210> 5489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5489

gaguguagcu ccacuguagu ucaua 25

<210> 5490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5490

cacugaaaua ugucuccacu uaaaa 25

<210> 5491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5491

uuuaaaaguc auuauacauu uuuaa 25

<210> 5492

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5492

cacgcguuua auauaagugg 20

<210> 5493

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5493

uauaagugga ggcgucgcgc 20

<210> 5494

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5494

aagugggaggc gucgcgcugg 20

<210> 5495

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5495

ggccgagaug ucucgcuccg 20

<210> 5496

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5496

ggccacggag cgagacaucu 20

<210> 5497

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5497

cgcgagcaca gcuaaggcca 20

<210> 5498

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5498

gaguagcgcg agcacagcua 20

<210> 5499

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5499

acucacgcug gauagccucc 20

<210> 5500

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5500

aggguaggagagacucacgc 20

<210> 5501

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5501

cucagguacu ccaaagauuc 20

<210> 5502

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5502

cgugaguaaa ccugaaucuu 20

<210> 5503

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5503

caguaaguca acuucaaugu 20

<210> 5504

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5504

acuugucuuu cagcaaggac 20

<210> 5505

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5505

agucacaugg uucacacggc 20

<210> 5506

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5506

acaaagucac augguucaca 20

<210> 5507

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5507

cacagcccaa gauaguuaag 20

<210> 5508

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5508

acagcccaag auaguuaagu 20

<210> 5509

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5509

uuaccccacu uaacuaucuu 20

<210> 5510

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5510

cuuaccccac uuaacuaucu 20

<210> 5511

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5511

agguuugaag augccgcauu 20

<210> 5512

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5512

ugaagaugcc gcauuuggau 20

<210> 5513

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5513

gaauucaucc aauccaaaug 20

<210> 5514

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5514

acacuuuaug cacaaaaugu 20

<210> 5515

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5515

cugcucagau acaucaaaca 20

<210> 5516

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5516

cauguuugau guaucugagc 20

<210> 5517

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5517

aucugagcag guugcuccac 20

<210> 5518

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5518

gcuccacagg uagcucuagg 20

<210> 5519

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5519

uaggagggcu ggcaacuuag 20

<210> 5520

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5520

gagggcuggc aacuuagagg 20

<210> 5521

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5521

agggcuggca acuuagaggu 20

<210> 5522

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5522

gggcuggcaa cuuagaggug 20

<210> 5523

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5523

ucugaccaag auguugaugu 20

<210> 5524

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5524

ucuaagcaga guauguaaau 20

<210> 5525

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5525

aauauaauug acaggauuau 20

<210> 5526

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5526

cuuauacauu ugauaaagua 20

<210> 5527

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5527

aggcaugguu gugguuaauc 20

<210> 5528

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5528

cucaagguuc agaucagaag 20

<210> 5529

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5529

aagguucaga ucagaagagg 20

<210> 5530

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5530

gaggcuucuc acccugcagc 20

<210> 5531

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5531

aggcuucuca cccugcagca 20

<210> 5532

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5532

gcucacaggu cccugcugca 20

<210> 5533

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5533

ugcucacagg ucccugcugc 20

<210> 5534

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5534

gcagcaggga ccugugagca 20

<210> 5535

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5535

ccugugagca uggcaugccc 20

<210> 5536

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5536

ccagggcaug ccaugcucac 20

<210> 5537

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5537

caagugccca caggaagcca 20

<210> 5538

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5538

acaggaagcc 20

<210> 5539

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5539

uggagaucac aagugcccac 20

<210> 5540

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5540

gccuuccuua ccaagacagg 20

<210> 5541

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5541

ugcgccuucc uuaccaagac 20

<210> 5542

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5542

cuuucccaca gaauuuagca 20

<210> 5543

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5543

accagagaug ucugugcagg 20

<210> 5544

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5544

gccuccugca cagacaucuc 20

<210> 5545

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5545

auaugugcag cucaggguca 20

<210> 5546

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5546

ggugucauau gugcagcuca 20

<210> 5547

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5547

uggugucaua ugugcagcuc 20

<210> 5548

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5548

uaaauaauaa ucacucucac 20

<210> 5549

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5549

agagugauua uuauuuuuc 20

<210> 5550

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5550

gguacaagca gccucccagc 20

<210> 5551

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5551

agaaucaucu gccugcuggg 20

<210> 5552

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5552

acgagaauca ucugccugcu 20

<210> 5553

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5553

aacgagaauc aucugccugc 20

<210> 5554

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5554

ucuguugcuu auaagcuucu 20

<210> 5555

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5555

guggugagg uugauaaauu 20

<210> 5556

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5556

gcuguaugug ugaguuggug 20

<210> 5557

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5557

accaacucacacauacagcc 20

<210> 5558

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5558

ccaacucaca cauacagcca 20

<210> 5559

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5559

agcacaagaa uauagauccc 20

<210> 5560

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5560

uauucuugug cucucagaga 20

<210> 5561

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5561

ggaaacacac cucuugucuu 20

<210> 5562

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5562

cacaccucuu gucuuuggaa 20

<210> 5563

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5563

acaccucuug ucuuuggaaa 20

<210> 5564

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5564

gugcccuuuc caaagacaag 20

<210> 5565

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5565

acacggcagg gucaggguuc 20

<210> 5566

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5566

agcugguaca cggcaggguc 20

<210> 5567

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5567

cucucagcug guacacggca 20

<210> 5568

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5568

ucucucagcu gguaacacggc 20

<210> 5569

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5569

agagucucuc agcugguaca 20

<210> 5570

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5570

uggauuuaga gucucucagc 20

<210> 5571

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5571

uaggcagaca gacuugucac 20

<210> 5572

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5572

gagaaucaaa aucggugaau 20

<210> 5573

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5573

auuuguuuga gaaucaaaau 20

<210> 5574

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5574

aacaaaugug ucacaaagua 20

<210> 5575

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5575

acaaaacugu gcuagacaug 20

<210> 5576

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5576

ugugcuagac ugugcuagac 20

<210> 5577

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5577

cuucaagagc aacagugcug 20

<210> 5578

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5578

agagcaacag ugcugggcc 20

<210> 5579

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5579

aaagucagau uuguugcucc 20

<210> 5580

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5580

uggaauaaug cuguuguuga 20

<210> 5581

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5581

cuggggaaga aggugucuuc 20

<210> 5582

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5582

accuggccuu accuggcug 20

<210> 5583

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5583

aagcugcccu uaccugggcu 20

<210> 5584

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5584

aaagcugccc uuaccugggc 20

<210> 5585

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5585

caccaaagcu gcccuuaccu 20

<210> 5586

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5586

gcaccaaagc ugcccuuacc 20

<210> 5587

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5587

aaguuccugu gaugucaagc 20

<210> 5588

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5588

cucgaccagc uugacaucac 20

<210> 5589

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5589

cugacagguu uugaaaguuu 20

<210> 5590

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5590

uuucaaaacc ugucagugau 20

<210> 5591

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5591

uucaaaaccu gucagugauu 20

<210> 5592

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5592

uucggaaccc aaucacugac 20

<210> 5593

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5593

ccgaauccuc cuccugaaag 20

<210> 5594

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5594

ccacuuucag gaggaggauu 20

<210> 5595

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5595

auccuccucc ugaaaguggc 20

<210> 5596

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5596

uccuccuccu gaaaguggcc 20

<210> 5597

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5597

acccggccac uuucaggagg 20

<210> 5598

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5598

uaaacccggc cacuuucagg 20

<210> 5599

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5599

gauuaaaccc ggccacuuuc 20

<210> 5600

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5600

cgucaugagc agauuaaacc 20

<210> 5601

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5601

uuaaucugcu caugacgcug 20

<210> 5602

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5602

ugcucaugac gcugcggcug 20

<210> 5603

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5603

ucaaggcccc ucaccucagc 20

<210> 5604

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5604

aggaaggagc gagggagcac 20

<210> 5605

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5605

caaugcagag gaaggagcga 20

<210> 5606

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5606

gcaaugcaga ggaaggagcg 20

<210> 5607

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5607

aagaggggca augcagagga 20

<210> 5608

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5608

ggagaagagg ggcaaugcag 20

<210> 5609

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5609

ucuguuugga gagggagaag 20

<210> 5610

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5610

ucuucucccu cuccaaacag 20

<210> 5611

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5611

cuucucccuc uccaaacaga 20

<210> 5612

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5612

gaguucccuc uguuuggaga 20

<210> 5613

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5613

agaguucccu cuguuuggag 20

<210> 5614

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5614

guaggagagu ucccucuguu 20

<210> 5615

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5615

gaacucuccu acccccaagg 20

<210> 5616

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5616

gcuuucaccu ccuugggggu 20

<210> 5617

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5617

agcagcuuuc accuccuugg 20

<210> 5618

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5618

uagcagcuuu caccuccuug 20

<210> 5619

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5619

guagcagcuu ucaccuccuu 20

<210> 5620

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5620

cuaccaccuc ugugcccccc 20

<210> 5621

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5621

uugccgggggg ggcacagagg 20

<210> 5622

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5622

gcauugccgg gggggcacag 20

<210> 5623

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5623

aguggggc auugccgggg 20

<210> 5624

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5624

cagggaagaa gccuguggcc 20

<210> 5625

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5625

guggucaggg aagaagccug 20

<210> 5626

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5626

cugaccacgu ggagcugagc 20

<210> 5627

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5627

cacggacccg cagccccuca 20

<210> 5628

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5628

ggugcacagu ggggucagca 20

<210> 5629

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5629

gacggguuug gcccuauccu 20

<210> 5630

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5630

uggcucaaac acagcgaccu 20

<210> 5631

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5631

aggcuucuuc cuguccacg 20

<210> 5632

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5632

cagcucagcu ccacgugguc 20

<210> 5633

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5633

gcgcugacga ucgggugac 20

<210> 5634

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5634

cuuuccagag gaccugaaca 20

<210> 5635

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5635

ucaaacacag cgaccucggg 20

<210> 5636

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5636

ugacggguuu ggcccuaucc 20

<210> 5637

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5637

ggcgcugacg aucggguga 20

<210> 5638

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5638

cggggggaa caccuuguuc 20

<210> 5639

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5639

gaacaaggug uucccacccg 20

<210> 5640

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5640

caaacacagc gaccucgggu 20

<210> 5641

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5641

ggcucaaaca cagcgaccuc 20

<210> 5642

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5642

agcucagcuc cacgugguca 20

<210> 5643

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5643

gacgaucugg gugacggguu 20

<210> 5644

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5644

uaucaggcuc cucugcuacg 20

<210> 5645

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5645

aucaggcucc ucugcuacgu 20

<210> 5646

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5646

cuacgugggc uuuuauuuuc 20

<210> 5647

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5647

acgugggcuu uuauuuucug 20

<210> 5648

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5648

cgugggcuuu uauuuucugg 20

<210> 5649

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5649

aauaaaagcc cacguagcag 20

<210> 5650

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5650

accccaagau accuuguuau 20

<210> 5651

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5651

agauaccuug uuauagggac 20

<210> 5652

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5652

gacaggaaag aagaucacuc 20

<210> 5653

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5653

ucuggaaugu ucucaaacca 20

<210> 5654

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5654

cuggaauguu cucaaaccau 20

<210> 5655

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5655

uacugguauc aacaagaucc 20

<210> 5656

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5656

guaucaacaa gaucggaa 20

<210> 5657

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5657

caccucaucc acuauuccua 20

<210> 5658

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5658

ggaguuaauu ccacagagaa 20

<210> 5659

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5659

agucaacagu cuccagaaua 20

<210> 5660

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5660

aacagucucc agaauaagga 20

<210> 5661

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5661

cccugacccu ggagucugcc 20

<210> 5662

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5662

uaacaaggua ucuugggguc 20

<210> 5663

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5663

cccuauaaca agguaaucuug 20

<210> 5664

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5664

ucccuauaac aagguaucuu 20

<210> 5665

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5665

gucccuauaa caagguaucu 20

<210> 5666

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5666

ucuuuccugu cccuauuaaca 20

<210> 5667

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5667

gauaccagua cauuuuguca 20

<210> 5668

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5668

augaggugua guuccauucc 20

<210> 5669

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5669

cuccauagga auaguggaug 20

<210> 5670

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5670

aauuaacucc auaggaauag 20

<210> 5671

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5671

cucuguggaa uuaacuccau 20

<210> 5672

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5672

ucggagacu guugacucag 20

<210> 5673

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5673

aaaaugcucc guccuuauuc 20

<210> 5674

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5674

ccuggcagac uccaggguca 20

<210> 5675

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5675

gccggcaga cuccaggguc 20

<210> 5676

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5676

ugagggccug gcagacucca 20

<210> 5677

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5677

gugagggccu ggcagacucc 20

<210> 5678

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5678

gagguaacuga gagguaugug 20

<210> 5679

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5679

gcuggcacag agguacugag 20

<210> 5680

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5680

uguauucacu gcuggcacag 20

<210> 5681

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5681

gagcugucug guucugguag 20

<210> 5682

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5682

agagcugucu gguucuggua 20

<210> 5683

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5683

gagagcuguc ugguucuggu 20

<210> 5684

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5684

cucugagagc ugucugguuc 20

<210> 5685

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5685

ggguugcucu gagagcuguc 20

<210> 5686

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5686

gaaaaacgug uucccaccca 20

<210> 5687

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5687

aggcuucuac cccgaccacg 20

<210> 5688

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5688

ccgaccacgu ggagcugagc 20

<210> 5689

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5689

cacagacccg cagccccuca 20

<210> 5690

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5690

uggggggaa cacguuuuuc 20

<210> 5691

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5691

caaacacagc gaccuugggu 20

<210> 5692

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5692

ucaaacacag cgaccuuggg 20

<210> 5693

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5693

ggcucaaaca cagcgaccuu 20

<210> 5694

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5694

uggcucaaac acagcgaccu 20

<210> 5695

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5695

cgggguagaa gccuguggcc 20

<210> 5696

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5696

guggucgggg uagaagccug 20

<210> 5697

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5697

agcucagcuc cacguggucg 20

<210> 5698

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5698

cagcucagcu ccacgugguc 20

<210> 5699

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5699

ccagcucagc uccacguggu 20

<210> 5700

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5700

gacagguuug gcccuauccu 20

<210> 5701

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5701

ugacagguuu ggcccuaucc 20

<210> 5702

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5702

gacgaucugg gugacagguu 20

<210> 5703

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5703

gcgcugacga ucgggugac 20

<210> 5704

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5704

cccuguuuuc uuucagacug 20

<210> 5705

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5705

aggagagacu cacuuaccgg 20

<210> 5706

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5706

aaaaggagag acucacuuac 20

<210> 5707

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5707

ucaacagagu cuuaccagca 20

<210> 5708

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5708

caacagaguc uuaccagcaa 20

<210> 5709

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5709

aacagagucu uaccagcaag 20

<210> 5710

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5710

auccucuaug agaucuugcu 20

<210> 5711

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5711

uccucuuga gaucuugcua 20

<210> 5712

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5712

cuaugagauc uugcuaggga 20

<210> 5713

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5713

ggccaccuug uaugccgugc 20

<210> 5714

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5714

ggucagugcc cucgugcuga 20

<210> 5715

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5715

uggcagacag gaccccuugc 20

<210> 5716

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5716

cauagaggau gguggcagac 20

<210> 5717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5717

caagaucuca uagaggaugg 20

<210> 5718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5718

uagcaagauc ucauagagga 20

<210> 5719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5719

ucccuagcaa gaucucauag 20

<210> 5720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5720

ucaggcggaggugagcggaa 20

<210> 5721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5721

cucaggcgga ggugagcgga 20

<210> 5722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5722

acugcucagg cggaggugag 20

<210> 5723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5723

gcucaccucc gccugagcag 20

<210> 5724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5724

cuucuccacu gcucaggcgg 20

<210> 5725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5725

caguggagaa ggcggcacuc 20

<210> 5726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5726

uggagaaggc ggcacucugg 20

<210> 5727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5727

ggagaaggcg gcacucuggu 20

<210> 5728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5728

gagaaggcgg cacucuggug 20

<210> 5729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5729

aggcgcccug gccagucguc 20

<210> 5730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5730

ggcgccggugg ccagucgucu 20

<210> 5731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5731

gcccggcca gucgucuggg 20

<210> 5732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5732

caccgcccag acgacuggcc 20

<210> 5733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5733

uguagcaccg ccagacgac 20

<210> 5734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5734

cgucgggcg gugcuacaac 20

<210> 5735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5735

gucugggcgg ugcuacaacu 20

<210> 5736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5736

gggcggugcu acaacugggc 20

<210> 5737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5737

cggugcuaca acugggcugg 20

<210> 5738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5738

caccuaccua agaaccaucc 20

<210> 5739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5739

gagaaggugg ggggguucca 20

<210> 5740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5740

cggucaccac gaggcaggcu 20

<210> 5741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5741

ucggucacca cgaggcagggc 20

<210> 5742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5742

gccugcucg uggugaccga 20

<210> 5743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5743

cccuucgguc accacgagca 20

<210> 5744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5744

cccugcucgu ggugaccgaa 20

<210> 5745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5745

ccccuucggu caccacgagc 20

<210> 5746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5746

ccugcucgug gugaccgaag 20

<210> 5747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5747

gaagguggcg uuguccccuu 20

<210> 5748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5748

guggagaag cugcagguga 20

<210> 5749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5749

cacgaagcuc uccgaugugugu 20

<210> 5750

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5750

cggagagcuu cgugcuaaac 20

<210> 5751

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5751

ucugguugcu ggggcucaug 20

<210> 5752

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5752

gcuuguccgu cugguugcug 20

<210> 5753

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5753

agcuuguccg ucugguugcu 20

<210> 5754

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5754

cagcuugucc gucugguugc 20

<210> 5755

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5755

cagcaaccag acggaccaagc 20

<210> 5756

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5756

aggcggccag cuuguccguc 20

<210> 5757

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5757

cuggcugcgg uccucgggga 20

<210> 5758

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5758

cgggcuggcu gcgguccucg 20

<210> 5759

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5759

ccgggcuggc ugcgguccuc 20

<210> 5760

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5760

cccgaggacc gcagccagcc 20

<210> 5761

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5761

gccgggcugg cugcgguccu 20

<210> 5762

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5762

cggaagcggc aguccuggcc 20

<210> 5763

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5763

acggaagcgg caguccuggc 20

<210> 5764

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5764

ugacacggaa gcggcagucc 20

<210> 5765

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5765

gcaguugugu gacacggaag 20

<210> 5766

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5766

cgugucacac aacugcccaa 20

<210> 5767

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5767

gugucacaca acugcccaac 20

<210> 5768

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5768

auguggaagu cacgcccguu 20

<210> 5769

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5769

cauguggaag ucacgcccgu 20

<210> 5770

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5770

gcgugacuuc cacaugagcg 20

<210> 5771

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5771

acuuccacau gagcgugguc 20

<210> 5772

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5772

cuuccacaug agcgugguca 20

<210> 5773

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5773

gggcccuac cacgcucaug 20

<210> 5774

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5774

acaugagcgu ggucagggcc 20

<210> 5775

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5775

agggcccggc gcaaugacag 20

<210> 5776

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5776

ggugccgcug ucauugcgcc 20

<210> 5777

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5777

aggugccgcu gucauugcgc 20

<210> 5778

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5778

gacagcggca ccuaccucug 20

<210> 5779

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5779

acagcggcac cuaccucugu 20

<210> 5780

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5780

ccaggggau ggccccacag 20

<210> 5781

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5781

gaucugcgcc uuggggggcca 20

<210> 5782

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5782

ugaucugcgc cuugggggcc 20

<210> 5783

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5783

cucuuugauc ugcgccuugg 20

<210> 5784

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5784

ucucuuugau cugcgccuug 20

<210> 5785

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5785

cucucuuuga ucugcgccuu 20

<210> 5786

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5786

gcucucuuug aucugcgccu 20

<210> 5787

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5787

cgcagaucaa agagagccug 20

<210> 5788

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5788

gcagaucaaa gagagccugc 20

<210> 5789

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5789

agagccugcg ggcagagcuc 20

<210> 5790

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5790

aggguuugga accuggccggc 20

<210> 5791

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5791

caccaggguu uggaacuggc 20

<210> 5792

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5792

cggccaguuc caaacccugg 20

<210> 5793

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5793

caaccaccag gguuuggaac 20

<210> 5794

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5794

caguuccaaa ccggugggu 20

<210> 5795

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5795

cgacaccaac caccaggguu 20

<210> 5796

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5796

aacccggug guuggugucg 20

<210> 5797

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5797

acccuggugg uugggucgu 20

<210> 5798

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5798

gccacgaca ccaaccacca 20

<210> 5799

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5799

cgccccgac accacacc 20

<210> 5800

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5800

cuggugguug gugucguggg 20

<210> 5801

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5801

uggugucgug ggcggccugc 20

<210> 5802

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5802

ggugucgugg gcggccugcu 20

<210> 5803

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5803

ggugcugcua gucgggucc 20

<210> 5804

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5804

uccuggccgu caucugcucc 20

<210> 5805

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5805

ccggggagca gaugacggcc 20

<210> 5806

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5806

ccuggccguc aucugcuccc 20

<210> 5807

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5807

gacguuaccu cgugcggccc 20

<210> 5808

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5808

ugacguuacc ucgugcggcc 20

<210> 5809

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5809

ugggaugacg uuaccucgug 20

<210> 5810

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5810

cugcagggac aauaggagcc 20

<210> 5811

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5811

acaauaggag ccaggcgcac 20

<210> 5812

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5812

caggggcugg ccggugcgcc 20

<210> 5813

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5813

aaaagaguga gacucaccag 20

<210> 5814

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5814

gaaaagagug agacucacca 20

<210> 5815

<211> 20

<212> RNA

<213> Homo sapiens

<400> 5815

ggaaaagagu gagacucacc 20

<210> 5816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5816

ucucaaacaa augugucaca aagua 25

<210> 5817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5817

cacagacaaa acugugcuag acaug 25

<210> 5818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5818

aaaacugugc uagacaugag gucua 25

<210> 5819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5819

aggacuuca agagcaacag ugcug 25

<210> 5820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5820

cuucaagagc aacagugcug uggcc 25

<210> 5821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5821

cugggcuggg gaagaaggug ucuuc 25

<210> 5822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5822

ucuucuggaa uaaugcuguu guuga 25

<210> 5823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5823

caugcaaagu cagauuuguu gcucc 25

<210> 5824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5824

gacacauuug uuugagaauc aaaau 25

<210> 5825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5825

uguuugagaa ucaaaaucgg ugaau 25

<210> 5826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5826

gugaauaggc agacagacuu gucac 25

<210> 5827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5827

gucacuggau uuagagucuc ucagc 25

<210> 5828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5828

gauuuagagu cucucagcug guaca 25

<210> 5829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5829

uagagucucu cagcugguac acggc 25

<210> 5830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5830

agagucucuc agcugguaca cggca 25

<210> 5831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5831

cucucagcug guacacggca ggguc 25

<210> 5832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5832

ucucagcugg uacacggcag gguca 25

<210> 5833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5833

cugguaacacg gcagggucag gguuc 25

<210> 5834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5834

gcagggucag gguucuggau aucug 25

<210> 5835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5835

cagggucagg guucuggaua ucugu 25

<210> 5836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5836

ggguucugga uaucuguggg acaag 25

<210> 5837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5837

uggauauucug ugggacaaga ggauc 25

<210> 5838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5838

ggauaucugu gggacaagag gauca 25

<210> 5839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5839

ucugugggac aagaggauca ggguu 25

<210> 5840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5840

uuagaaaguu ccugugaugu caagc 25

<210> 5841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5841

agcuggucga gaaaagcuuu gaaac 25

<210> 5842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5842

agaaaagcuu ugaaacaggu aagac 25

<210> 5843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5843

gaaaagcuuu gaaacaggua agaca 25

<210> 5844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5844

aaaagcuuug aaacagguaa gacag 25

<210> 5845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5845

aaacagguaa gacagggguc uagcc 25

<210> 5846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5846

aacagguaag acaggggucu agccu 25

<210> 5847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5847

cuuuucucga ccagcuugac aucac 25

<210> 5848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5848

cuugacauca caggaacuuu cuaaa 25

<210> 5849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5849

uaaacuuuca aaaccuguca gugau 25

<210> 5850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5850

aaacuuucaa aaccugucag ugauu 25

<210> 5851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5851

ggguuccgaa uccuccuccu gaaag 25

<210> 5852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5852

uccgaauccu ccuccugaaa guggc 25

<210> 5853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5853

ccgaauccuc cuccugaaag uggcc 25

<210> 5854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5854

cggguuuaau cugcucauga cgcug 25

<210> 5855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5855

uaaucugcuc augacgcugc ggcug 25

<210> 5856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5856

ugacgcugcg gcugggucc agcug 25

<210> 5857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5857

cugcggcugu gguccagcug aggug 25

<210> 5858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5858

ugcggcugug guccagcuga gguga 25

<210> 5859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5859

gcggcugugg uccagcugag gugag 25

<210> 5860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5860

cagcugaggu gaggggccuu gaagc 25

<210> 5861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5861

agcugaggug aggggccuug aagcu 25

<210> 5862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5862

cagcuucaag gccccucacc ucagc 25

<210> 5863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5863

cgcagcguca ugagcagauu aaacc 25

<210> 5864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5864

gagcagauua aacccggcca cuuuc 25

<210> 5865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5865

cagauuaaac ccggccacuuucagg 25

<210> 5866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5866

auuaaacccg gccacuuuca ggagg 25

<210> 5867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5867

cccggccacu uucagggagga ggauu 25

<210> 5868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5868

gaggauucgg aacccaauca cugac 25

<210> 5869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5869

aaucacugac agguuuugaa aguuu 25

<210> 5870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5870

uuagguucgu aucuguaaaa ccaag 25

<210> 5871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5871

uaucuguaaa accaagaggc cacag 25

<210> 5872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5872

gccccucuuc ucccucucca aacag 25

<210> 5873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5873

ccccucuucu cccucuccaa acaga 25

<210> 5874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5874

aacagaggga acucuccuac cccca 25

<210> 5875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5875

agagggaacu cucciuacccc caagg 25

<210> 5876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5876

agcugcuacc accucugugc ccccc 25

<210> 5877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5877

gugcccccccc ggcaaugcca ccaac 25

<210> 5878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5878

gcugcuuguc acugccugac auuca 25

<210> 5879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5879

ugucacugcc ugacauucac ggcag 25

<210> 5880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5880

cugccugaca uucacggcag aggca 25

<210> 5881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5881

gaggcaaggc ugcugcagcc ucccc 25

<210> 5882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5882

acugccuccg ccaucccaca gauga 25

<210> 5883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5883

caucccacag augauggauc uucag 25

<210> 5884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5884

aucccacaga ugauggaucu ucagu 25

<210> 5885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5885

augauggauc uucagugggu ucucu 25

<210> 5886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5886

ugaggaucu ucaguggguu cucuu 25

<210> 5887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5887

ucuucagugg guucucuugg gcucu 25

<210> 5888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5888

gcucuagguc cugcagaaug uugug 25

<210> 5889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5889

cucuaggucc ugcagaaugu uguga 25

<210> 5890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5890

ucuagguccu gcagaauguu gugag 25

<210> 5891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5891

acauaguauu cuucuucuca agacg 25

<210> 5892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5892

cauaguauuc uucuucucaa gacgu 25

<210> 5893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5893

auaguauucu ucuucucaag acgug 25

<210> 5894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5894

uaguauucuu cuucucaaga cgugg 25

<210> 5895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5895

aguauucuuc uucucaagac guggg 25

<210> 5896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5896

guggggggaa auuaucucau uaucg 25

<210> 5897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5897

ucgaggcccu gcuaugcugu guauc 25

<210> 5898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5898

cgaggcccug cuaugcugug uaucu 25

<210> 5899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5899

ugccgaugcc uucauuaaaa ugauu 25

<210> 5900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5900

agcagagacu gugccucugu uugac 25

<210> 5901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5901

gcagagacug ugccucuguu ugacu 25

<210> 5902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5902

gacugugccu cuguuugacu ggguu 25

<210> 5903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5903

gugccucugu uugacugggu uuggu 25

<210> 5904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5904

accucuacca aacccaguca aacag 25

<210> 5905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5905

cugcucuucc aaaucauuuu aauga 25

<210> 5906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5906

uuccaaauca uuuuaaugaa ggcau 25

<210> 5907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5907

ucauuuuaau gaaggcaucg gcagc 25

<210> 5908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5908

aacacgccca gauacacagc auagc 25

<210> 5909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5909

acacgcccag auacacagca uagca 25

<210> 5910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5910

aaauaaaccc cucacaacau ucugc 25

<210> 5911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5911

gaaccacug aagauccauc aucug 25

<210> 5912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5912

aacccacuga agauccauca ucugu 25

<210> 5913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5913

cacugaagau ccaucaucug ggga 25

<210> 5914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5914

ugaagaucca ucaucugugg gaugg 25

<210> 5915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5915

agauccauca ucugugggau ggcgg 25

<210> 5916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5916

ucugugggau ggcgggaggca gucuc 25

<210> 5917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5917

cugggggaug gcgggaggcag ucucu 25

<210> 5918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5918

uggggaugg cggaggcagu cucug 25

<210> 5919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5919

auggcgggagg cagucucugg ggagc 25

<210> 5920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5920

gcggaggcag ucucugggga gcagg 25

<210> 5921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5921

cggaggcagu cucuggggag cagga 25

<210> 5922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5922

ggagcaggag ggaaugugca cagcc 25

<210> 5923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5923

gagcaggagg gaaugugcac agcca 25

<210> 5924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5924

agcaggaggg aaugugcaca gccag 25

<210> 5925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5925

aggagggaau gugcacagcc agggg 25

<210> 5926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5926

cagccuugcc ucugccguga auguc 25

<210> 5927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5927

ugucaggcag ugacaagcag caaua 25

<210> 5928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5928

gucaggcagu gacaagcagc aauaa 25

<210> 5929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5929

gugacaagca gcaauaaggg aacag 25

<210> 5930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5930

ugacaagcag caauaaggga acaga 25

<210> 5931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5931

gacaagcagc aauaagggaa cagag 25

<210> 5932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5932

acaagcagca auaagggaac agagg 25

<210> 5933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5933

agcagcaaua agggaacaga ggggg 25

<210> 5934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5934

gaacagagggg gguggcagca guguu 25

<210> 5935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5935

ucuucagcaa ucuuaaucau aaauu 25

<210> 5936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5936

cuucagcaau cuuaaucaua aauuc 25

<210> 5937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5937

agcaaucuua aucauaaauu cgggu 25

<210> 5938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5938

aucauaaauu cggguaggau ccagu 25

<210> 5939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5939

auaaauucgg guaggaucca guugg 25

<210> 5940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5940

gguaggaucc aguuggggc auugc 25

<210> 5941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5941

guaggaucca guugguggca uugcc 25

<210> 5942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5942

uggauccag uugguggcau ugccg 25

<210> 5943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5943

aggauccagu uggggcauu gccgg 25

<210> 5944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5944

ggauccaguu gguggcauug ccggg 25

<210> 5945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5945

gauccaguug guggcauugc cgggg 25

<210> 5946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5946

uggggcauu gccggggggg cacag 25

<210> 5947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5947

uggcauugcc gggggggcac agagg 25

<210> 5948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5948

gaggugguag cagcuuucac cuccu 25

<210> 5949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5949

aggugguagc agcuuucacc uccuu 25

<210> 5950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5950

ggugguagca gcuuucaccu ccuug 25

<210> 5951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5951

gugguagcag cuuucaccuc cuugg 25

<210> 5952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5952

uagcagcuuu caccuccuug ggggu 25

<210> 5953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5953

uggggguagg agaguucccu cuguu 25

<210> 5954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5954

guaggagagu ucccucuguu uggag 25

<210> 5955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5955

uaggagaguu cccucuguuu ggaga 25

<210> 5956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5956

uucccucugu uuggagggg agaag 25

<210> 5957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5957

ucccucuguu uggagaggga gaaga 25

<210> 5958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5958

cccucuguuu ggagagggag aagag 25

<210> 5959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5959

gagagggaga agaggggcaa ugcag 25

<210> 5960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5960

gggagaagag gggcaaugca gagga 25

<210> 5961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5961

gaggggcaau gcagaggaag gagcg 25

<210> 5962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5962

aggggcaaug cagaggaagg agcga 25

<210> 5963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5963

ugcaggaa ggagcgagg agcac 25

<210> 5964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5964

aggcugucuu acaaucuugc agauc 25

<210> 5965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5965

cuuacaaucu ugcagaucug gaaug 25

<210> 5966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5966

cuucccuuuc cagaggaccu gaaca 25

<210> 5967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5967

gaccugaaca agguguuccc acccg 25

<210> 5968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5968

gaagcagaga ucucccacac ccaaa 25

<210> 5969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5969

aucucccaca cccaaaaggc cacac 25

<210> 5970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5970

acccaaaagg ccacacuggu gugcc 25

<210> 5971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5971

aggccacacu ggugugccug gccac 25

<210> 5972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5972

gccacaggcu ucuuccccga ccacg 25

<210> 5973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5973

cuuccccgac cacguggagc ugagc 25

<210> 5974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5974

ccccgaccac guggagcuga gcugg 25

<210> 5975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5975

cccgaccacg uggagcugag cuggu 25

<210> 5976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5976

acguggagcu gagcuggugg gugaa 25

<210> 5977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5977

cguggagcug agcugguggg ugaau 25

<210> 5978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5978

gagcugagcu ggugggugaa uggga 25

<210> 5979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5979

cugagcuggu gggugaaugg gaagg 25

<210> 5980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5980

gggugaaugg gaaggaggug cacag 25

<210> 5981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5981

ggugaauggg aaggaggugc acagu 25

<210> 5982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5982

gugaauggga aggaggugca cagug 25

<210> 5983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5983

gucagcacag acccgcagcc ccuca 25

<210> 5984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5984

cagauacugc cugagcagcc gccug 25

<210> 5985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5985

agauacugcc ugagcagccg ccuga 25

<210> 5986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5986

ugccugagca gccgccugag ggucu 25

<210> 5987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5987

cgccugagg gucucggcca ccuuc 25

<210> 5988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5988

acuuccgcug ucaaguccag uucua 25

<210> 5989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5989

cuuccgcugu caaguccagu ucuac 25

<210> 5990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5990

ugucaagucc aguucuacgg gcucu 25

<210> 5991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5991

cuacgggcuc ucggagaaug acgag 25

<210> 5992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5992

cucucggaga augacgagug gaccc 25

<210> 5993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5993

ggagaaugac gaguggaccc aggau 25

<210> 5994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5994

gagaaugacg aguggaccca ggaua 25

<210> 5995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5995

cccgucaccc agaucgucag cgccg 25

<210> 5996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5996

cacccagauc gucagcgccg aggcc 25

<210> 5997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5997

acccagaucg ucagcgccga ggccu 25

<210> 5998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5998

cccagaucgu cagcgccgag gccug 25

<210> 5999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 5999

ucagcgccga ggccuggggu agagc 25

<210> 6000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6000

cgaggccugg gguagagcag gugag 25

<210> 6001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6001

gaggcgggg guagagcagg ugagu 25

<210> 6002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6002

aggccugggg uagagcaggu gagug 25

<210> 6003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6003

ugggguagag caggugagug gggcc 25

<210> 6004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6004

gggguagagc aggugaggugg ggccu 25

<210> 6005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6005

ggguagagca ggugagguggg gccug 25

<210> 6006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6006

aggccccacu caccugcucu acccc 25

<210> 6007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6007

cacucaccug cucuacccca ggccu 25

<210> 6008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6008

accccaggcc ucggcgcuga cgauc 25

<210> 6009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6009

ccccaggccu cggcgcugac gaucu 25

<210> 6010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6010

gccucggcgc ugacgaucug gguga 25

<210> 6011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6011

ccucggcgcu gacgaucugg gugac 25

<210> 6012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6012

gcgcugacga ucgggugac ggguu 25

<210> 6013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6013

cugggugacg gguuuggccc uaucc 25

<210> 6014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6014

ugggugacgg guuuggcccu auccu 25

<210> 6015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6015

gucauucucc gagagcccgu agaac 25

<210> 6016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6016

gagcccguag aacuggacuu gacag 25

<210> 6017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6017

guagaacugg acuugacagc ggaag 25

<210> 6018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6018

cuggacuuga cagcggaagu gguug 25

<210> 6019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6019

uggacuugac agcggaagug guugc 25

<210> 6020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6020

ggacuugaca gcggaagugg uugcg 25

<210> 6021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6021

gacuugacag cggaaguggu ugcgg 25

<210> 6022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6022

aagugguugc ggggguucug ccaga 25

<210> 6023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6023

ugguugcggg gguucugcca gaagg 25

<210> 6024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6024

cugccagaag guggccgaga cccuc 25

<210> 6025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6025

ccagaaggug gccgagaccc ucagg 25

<210> 6026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6026

ggccgagacc cucaggcggc ugcuc 25

<210> 6027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6027

cucaggcggc ugcucaggca guauc 25

<210> 6028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6028

gcucaggcag uaucuggagu cauug 25

<210> 6029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6029

cucaggcagu aucuggaguc auuga 25

<210> 6030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6030

aggcaguauc uggagucauu gaggg 25

<210> 6031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6031

ggcaguaucu ggagucauug agggc 25

<210> 6032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6032

gucauugagg gcgggcugcu ccuug 25

<210> 6033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6033

ucauugaggg cgggcugcuc cuuga 25

<210> 6034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6034

cauugagggc gggcugcucc uugag 25

<210> 6035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6035

ggcggggcug cuccuugagg ggcug 25

<210> 6036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6036

ggcgggcugc uccuugaggg gcugc 25

<210> 6037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6037

auucacccac cagcucagcu ccacg 25

<210> 6038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6038

acccaccagc ucagcuccac guggu 25

<210> 6039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6039

cccaccagcu cagcuccacg ugguc 25

<210> 6040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6040

ccaccagcuc agcuccacgu ggucg 25

<210> 6041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6041

uccacguggu cggggaagaa gccug 25

<210> 6042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6042

guggucgggg aagaagccug uggcc 25

<210> 6043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6043

aagccugugg ccaggcacac cagug 25

<210> 6044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6044

ggccaggcac accagugugg ccuuu 25

<210> 6045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6045

gccaggcaca ccaguguggc cuuuu 25

<210> 6046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6046

gcacaccagu guggccuuuu gggug 25

<210> 6047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6047

cacaccagug uggccuuuug ggugu 25

<210> 6048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6048

gggugggga gaucucugcu ucuga 25

<210> 6049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6049

ucugauggcu caaacacagc gaccu 25

<210> 6050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6050

cugauggcuc aaacacagcg accuc 25

<210> 6051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6051

auggcucaaa cacagcgacc ucggg 25

<210> 6052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6052

uggcucaaac acagcgaccu cgggu 25

<210> 6053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6053

gaccucgggu gggaacaccu uguuc 25

<210> 6054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6054

gugggaacac cuuguucagg uccuc 25

<210> 6055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6055

aacaccuugu ucagguccuc uggaa 25

<210> 6056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6056

acaccuuguu cagguccucu ggaaa 25

<210> 6057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6057

uguucagguc cucuggaaag ggaag 25

<210> 6058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6058

guucaggucc ucuggaaagg gaaga 25

<210> 6059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6059

uucagguccu cuggaaaggg aagag 25

<210> 6060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6060

uuucuuucag acuguggcuu uaccu 25

<210> 6061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6061

uucuuucaga cuguggcuuu accuc 25

<210> 6062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6062

guaaagccac agucugaaag aaagc 25

<210> 6063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6063

uaaagccaca gucugaaaga aagca 25

<210> 6064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6064

cggugccaac aguguccuac cagca 25

<210> 6065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6065

cgugccaaca gugccuacc agcaa 25

<210> 6066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6066

gugccaacag uguccuacca gcaag 25

<210> 6067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6067

ccaccauccu cuaugagauc cugcu 25

<210> 6068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6068

caccauccuc uugagaucc ugcua 25

<210> 6069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6069

auccucuaug agauccugcu aggga 25

<210> 6070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6070

gggaaggcca cccuguaugc ugugc 25

<210> 6071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6071

gugcugguca gcgcccuugu guuga 25

<210> 6072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6072

gucagcgccc uuguguugau ggcca 25

<210> 6073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6073

ccuuguguug aggccaugg uaagc 25

<210> 6074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6074

uguguugaug gccaugguaa gcagg 25

<210> 6075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6075

guguugaugg ccaugguaag cagga 25

<210> 6076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6076

ugaggccau gguaagcagg agggc 25

<210> 6077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6077

ggccauggua agcaggaggg cagga 25

<210> 6078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6078

gccaugguaa gcaggagggc aggau 25

<210> 6079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6079

ccaugguaag caggagggca ggaug 25

<210> 6080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6080

ccccauccug cccuccugcu uacca 25

<210> 6081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6081

ccugcuuacc aggccauca acaca 25

<210> 6082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6082

cugcuuacca uggccaucaa cacaa 25

<210> 6083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6083

aagggcgcug accagcacag cauac 25

<210> 6084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6084

agggcgcuga ccagcacagc auaca 25

<210> 6085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6085

gcgcugacca gcacagcaua caggg 25

<210> 6086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6086

agcauacagg guggccuucc cuagc 25

<210> 6087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6087

ggccuucccu agcaggaucu cauag 25

<210> 6088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6088

uucccuagca ggaucucaua gagga 25

<210> 6089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6089

ccuagcagga ucucauagag gaugg 25

<210> 6090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6090

gaucucauag aggauggugg cagac 25

<210> 6091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6091

gaugguggca gacaggaccc cuugc 25

<210> 6092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6092

guggcagaca ggaccccuug cuggu 25

<210> 6093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6093

ggaccccuug cugguaggac acugu 25

<210> 6094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6094

ccuugcuggu aggacacugu uggca 25

<210> 6095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6095

ugcugguagg acacuguugg cacgg 25

<210> 6096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6096

gcaggucaag agaaaggauu ucuga 25

<210> 6097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6097

gagaaaggau uucugaaggc agccc 25

<210> 6098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6098

gaccugaaaa acguguuccc acccg 25

<210> 6099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6099

gaagcagaga ucucccacac ccaaa 25

<210> 6100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6100

aucucccaca cccaaaaggc cacac 25

<210> 6101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6101

acccaaaagg ccacacuggu augcc 25

<210> 6102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6102

aggccacacu gguaugccug gccac 25

<210> 6103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6103

gccacaggcu ucuaccccga ccacg 25

<210> 6104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6104

caccccgac cacguggagc ugagc 25

<210> 6105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6105

ccccgaccac guggagcuga gcugg 25

<210> 6106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6106

cccgaccacg uggagcugag cuggu 25

<210> 6107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6107

acguggagcu gagcuggugg gugaa 25

<210> 6108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6108

cguggagcug agcugguggg ugaau 25

<210> 6109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6109

gagcugagcu ggugggugaa uggga 25

<210> 6110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6110

cugagcuggu gggugaaugg gaagg 25

<210> 6111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6111

gggugaaugg gaaggaggug cacag 25

<210> 6112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6112

ggugaauggg aaggaggugc acagu 25

<210> 6113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6113

gugaauggga aggaggugca cagug 25

<210> 6114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6114

gucagcacag acccgcagcc ccuca 25

<210> 6115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6115

cagauacugc cugagcagcc gccug 25

<210> 6116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6116

agauacugcc ugagcagccg ccuga 25

<210> 6117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6117

ugccugagca gccgccugag ggucu 25

<210> 6118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6118

cgccugagg gucucggcca ccuuc 25

<210> 6119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6119

acuuccgcug ucaaguccag uucua 25

<210> 6120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6120

cuuccgcugu caaguccagu ucuac 25

<210> 6121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6121

ugucaagucc aguucuacgg gcucu 25

<210> 6122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6122

cuacgggcuc ucggagaaug acgag 25

<210> 6123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6123

cucucggaga augacgagug gaccc 25

<210> 6124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6124

ggagaaugac gaguggaccc aggau 25

<210> 6125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6125

gagaaugacg aguggaccca ggaua 25

<210> 6126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6126

cccgucaccc agaucgucag cgccg 25

<210> 6127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6127

cacccagauc gucagcgccg aggcc 25

<210> 6128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6128

acccagaucg ucagcgccga ggccu 25

<210> 6129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6129

cccagaucgu cagcgccgag gccug 25

<210> 6130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6130

ucagcgccga ggccuggggu agagc 25

<210> 6131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6131

cgaggccugg gguagagcag gugag 25

<210> 6132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6132

gaggccuggg guagagcagg ugagu 25

<210> 6133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6133

aggccugggg uagagcaggu gagug 25

<210> 6134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6134

ugggguagag caggugagug gggcc 25

<210> 6135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6135

gggguagagc aggugaggugg ggccu 25

<210> 6136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6136

ggguagagca ggugaggugg gccug 25

<210> 6137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6137

aggccccacu caccugcucu acccc 25

<210> 6138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6138

cacucaccug cucuacccca ggccu 25

<210> 6139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6139

accccaggcc ucggcgcuga cgauc 25

<210> 6140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6140

ccccaggccu cggcgcugac gaucu 25

<210> 6141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6141

gccucggcgc ugacgaucug gguga 25

<210> 6142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6142

ccucggcgcu gacgaucugg gugac 25

<210> 6143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6143

gcgcugacga ucgggugac ggguu 25

<210> 6144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6144

cugggugacg gguuuggccc uaucc 25

<210> 6145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6145

ugggugacgg guuuggcccu auccu 25

<210> 6146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6146

gucauucucc gagagcccgu agaac 25

<210> 6147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6147

gagcccguag aacuggacuu gacag 25

<210> 6148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6148

guagaacugg acuugacagc ggaag 25

<210> 6149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6149

cuggacuuga cagcggaagu gguug 25

<210> 6150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6150

uggacuugac agcggaagug guugc 25

<210> 6151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6151

ggacuugaca gcggaagugg uugcg 25

<210> 6152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6152

gacuugacag cggaaguggu ugcgg 25

<210> 6153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6153

aagugguugc ggggguucug ccaga 25

<210> 6154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6154

ugguugcggg gguucugcca gaagg 25

<210> 6155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6155

cugccagaag guggccgaga cccuc 25

<210> 6156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6156

ccagaaggug gccgagaccc ucagg 25

<210> 6157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6157

ggccgagacc cucaggcggc ugcuc 25

<210> 6158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6158

cucaggcggc ugcucaggca guauc 25

<210> 6159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6159

gcucaggcag uaucuggagu cauug 25

<210> 6160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6160

cucaggcagu aucuggaguc auuga 25

<210> 6161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6161

aggcaguauc uggagucauu gaggg 25

<210> 6162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6162

ggcaguaucu ggagucauug agggc 25

<210> 6163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6163

gucauugagg gcgggcugcu ccuug 25

<210> 6164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6164

ucauugaggg cgggcugcuc cuuga 25

<210> 6165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6165

cauugagggc gggcugcucc uugag 25

<210> 6166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6166

ggcggggcug cuccuugagg ggcug 25

<210> 6167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6167

ggcgggcugc uccuugaggg gcugc 25

<210> 6168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6168

auucacccac cagcucagcu ccacg 25

<210> 6169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6169

acccaccagc ucagcuccac guggu 25

<210> 6170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6170

cccaccagcu cagcuccacg ugguc 25

<210> 6171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6171

ccaccagcuc agcuccacgu ggucg 25

<210> 6172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6172

uccacguggu cgggguagaa gccug 25

<210> 6173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6173

guggucgggg uagaagccug uggcc 25

<210> 6174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6174

aagccugugg ccaggcauac cagug 25

<210> 6175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6175

ggccaggcau accagugugg ccuuu 25

<210> 6176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6176

gccaggcaua ccaguguggc cuuuu 25

<210> 6177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6177

gcauaccagu guggccuuuu gggug 25

<210> 6178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6178

cauaccagug uggccuuuug ggugu 25

<210> 6179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6179

gggugggga gaucucugcu ucuga 25

<210> 6180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6180

ucugauggcu caaacacagc gaccu 25

<210> 6181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6181

cugauggcuc aaacacagcg accuc 25

<210> 6182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6182

auggcucaaa cacagcgacc ucggg 25

<210> 6183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6183

uggcucaaac acagcgaccu cgggu 25

<210> 6184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6184

gaccucgggu gggaacacgu uuuuc 25

<210> 6185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6185

gugggaacac guuuuucagg uccuc 25

<210> 6186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6186

aacacguuuu ucagguccuc uggaa 25

<210> 6187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6187

acacguuuuu cagguccucu ggaaa 25

<210> 6188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6188

uuuucagguc cucuggaaag ggaag 25

<210> 6189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6189

gguccucugg aaagggaaga gguaa 25

<210> 6190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6190

guccicugga aagggaagag guaau 25

<210> 6191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6191

uccuggaa agggaagagg uaaug 25

<210> 6192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6192

uucuuucaga cuguggcuuc accuc 25

<210> 6193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6193

gugaagccac agucugaaag aaaac 25

<210> 6194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6194

ugaagccaca gucugaaaga aaaca 25

<210> 6195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6195

gaagccacag ucugaaagaa aacag 25

<210> 6196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6196

ucuugucaac agagucuuac cagca 25

<210> 6197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6197

cuugucaaca gagucuuacc agcaa 25

<210> 6198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6198

uugucaacag agucuuacca gcaag 25

<210> 6199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6199

ccaccauccu cuaugagauc uugcu 25

<210> 6200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6200

caccauccuc uugagaucu ugcua 25

<210> 6201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6201

auccucuaug agaucuugcu aggga 25

<210> 6202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6202

gggaaggcca ccuuguaugc cgugc 25

<210> 6203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6203

gugcugguca gugcccucgu gcuga 25

<210> 6204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6204

gucagugccc ucgugcugau ggcca 25

<210> 6205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6205

ugcccuggug cugaggcca uggua 25

<210> 6206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6206

ccucgugcug aggccaugg uaagg 25

<210> 6207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6207

cgugcugaug gccaugguaa ggagg 25

<210> 6208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6208

gugcugaugg ccaugguaag gagga 25

<210> 6209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6209

cugaggcca ugguaaggag gaggg 25

<210> 6210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6210

ugaggccau gguaaggagg agggu 25

<210> 6211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6211

gccaugguaa ggaggagggu gggau 25

<210> 6212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6212

ccaugguaag gaggagggug ggaua 25

<210> 6213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6213

cccuauccca cccuccuccu uacca 25

<210> 6214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6214

ccuccuuacc aggccauca gcacg 25

<210> 6215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6215

cuccuuacca uggccaucag cacga 25

<210> 6216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6216

aucagcacga gggcacugac cagca 25

<210> 6217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6217

agggcacuga ccagcacggc auaca 25

<210> 6218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6218

gcacugacca gcacggcaua caagg 25

<210> 6219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6219

ggccuucccu agcaagaucu cauag 25

<210> 6220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6220

uucccuagca agaucucaua gagga 25

<210> 6221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6221

ccuagcaaga ucucauagag gaugg 25

<210> 6222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6222

gaucucauag aggauggugg cagac 25

<210> 6223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6223

gaugguggca gacaggaccc cuugc 25

<210> 6224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6224

uucucucuuc cacaggucaa gagaa 25

<210> 6225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6225

cacaggucaa gagaaaggau uccag 25

<210> 6226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6226

cucuggaac cuuucucuug accug 25

<210> 6227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6227

uuccuccuac ucaccaucag ccucc 25

<210> 6228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6228

cuacucacca ucagccuccu gguua 25

<210> 6229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6229

accaucagcc uccugguuau gguac 25

<210> 6230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6230

uuaugguaca gguaaagca acgcc 25

<210> 6231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6231

cguugcucuu accuguacca uaacc 25

<210> 6232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6232

ugcucuuacc uguaccauaa ccagg 25

<210> 6233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6233

accuguacca uaaccaggag gcuga 25

<210> 6234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6234

cauaaccagg aggcugaugg ugagu 25

<210> 6235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6235

aaccaggagg cugagguga guagg 25

<210> 6236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6236

gaggcugaug gugaguagga ggaag 25

<210> 6237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6237

aggaggaaga ggaagcgcuu cauuu 25

<210> 6238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6238

ggaagaggaa gcgcuucauu uuggu 25

<210> 6239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6239

gcgcuucauu uugguaggau cuucg 25

<210> 6240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6240

uuugguagga ucuucguggc ugucu 25

<210> 6241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6241

guggcugucu ugguagcagc uuuuu 25

<210> 6242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6242

ugguagcagc uuuuuaggug aucuc 25

<210> 6243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6243

gguagcagcu uuuuagguga ucuca 25

<210> 6244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6244

cuuuuuaggu gaucucaggg cuguc 25

<210> 6245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6245

uuuaggugau cucagggcug ucugg 25

<210> 6246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6246

cucaggggcug ucuggaggcu ucuuu 25

<210> 6247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6247

cuuuugguuu agcugcuuuu gaacc 25

<210> 6248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6248

uugguuuagc ugcuuuugaa ccagg 25

<210> 6249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6249

uagcugcuuu ugaaccagga ggcag 25

<210> 6250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6250

cugcuuuuga accaggaggc agagg 25

<210> 6251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6251

cuuuugaacc aggaggcaga ggagg 25

<210> 6252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6252

cacuucuccu ccuacagaua caaac 25

<210> 6253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6253

uccuacagau acaaacugga cucuc 25

<210> 6254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6254

gccccucagc auccagcaac auaag 25

<210> 6255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6255

ccucagcauc cagcaacaua agcgg 25

<210> 6256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6256

agcgggaggca uuuuccuuuu cuucg 25

<210> 6257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6257

uaauccaccu cuucugcuuc aguug 25

<210> 6258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6258

cucgcaagag aauccccucc aucuu 25

<210> 6259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6259

ucgcaagaga auccccucca ucuuu 25

<210> 6260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6260

caagagaauc cccuccaucu uuggg 25

<210> 6261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6261

aagagaaucc ccuccaucuu uggga 25

<210> 6262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6262

agagaauccc cuccaucuuu gggag 25

<210> 6263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6263

ggagggguug augccagaca ucacc 25

<210> 6264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6264

acaucaccag guuguagaag uugac 25

<210> 6265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6265

uuguagaagu ugacaggcag ugcca 25

<210> 6266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6266

uguagaaguu gacaggcagu gccau 25

<210> 6267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6267

guagaaguug acaggcagug ccaug 25

<210> 6268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6268

uagaaguuga caggcagugc caugg 25

<210> 6269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6269

gugccauggg ggcaacagcc aaaau 25

<210> 6270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6270

ugccaugggg gcaacagcca aaaua 25

<210> 6271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6271

gccauggggg caacagccaa aauag 25

<210> 6272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6272

ccaugggggc aacagccaaa auagg 25

<210> 6273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6273

caugggggca acagccaaaa uaggg 25

<210> 6274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6274

agccaaaaua gggggguaau gaugu 25

<210> 6275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6275

gccaaaauag ggggguaaug augua 25

<210> 6276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6276

ccaaaauagg gggguaauga uguag 25

<210> 6277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6277

auguaggggc caagcagugc ccagc 25

<210> 6278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6278

uguaggggcc aagcagugcc cagcu 25

<210> 6279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6279

guaggggcca agcagugccc agcug 25

<210> 6280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6280

uaggggccaa gcagugccca gcugg 25

<210> 6281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6281

aauaaaguua cccuuguacu ugcag 25

<210> 6282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6282

auaaaguuac ccuuguacuu gcagu 25

<210> 6283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6283

uaaaguuacc cuuguacuug cagug 25

<210> 6284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6284

uguacuugca gugggguccu gcuug 25

<210> 6285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6285

gcagggggu ccugcuugug guuac 25

<210> 6286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6286

guagggaugu ccaguaacca caagc 25

<210> 6287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6287

caagcaggac cccacugcaa guaca 25

<210> 6288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6288

aagcaggacc cacugcaag uacaa 25

<210> 6289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6289

aaggguaacu uuauugaccc ccagc 25

<210> 6290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6290

aggguaacuu uauugacccc cagcu 25

<210> 6291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6291

uauugacccc cagcugggca cugcu 25

<210> 6292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6292

ccccuacauc auuacccccc uauuu 25

<210> 6293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6293

cccccuauuu uggcuguugc cccca 25

<210> 6294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6294

gcacugccug ucaacuucua caacc 25

<210> 6295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6295

ucaacuucua caaccuggug auguc 25

<210> 6296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6296

gucuggcauc aaccccccc aaaga 25

<210> 6297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6297

uggcaucaac cccucccaaa gaugg 25

<210> 6298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6298

ggcaucaacc ccucccaaag augga 25

<210> 6299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6299

gcaucaaccc cucccaaaga uggag 25

<210> 6300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6300

aggagggga uucucuugcg aguga 25

<210> 6301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6301

gaggggauuc ucuugcgagu gaugg 25

<210> 6302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6302

ugcgagugau gguggcagcu guuuc 25

<210> 6303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6303

gcgagugaug guggcagcug uuuca 25

<210> 6304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6304

cgagugaugg uggcagcugu uucag 25

<210> 6305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6305

gagugauggu ggcagcuguu ucagg 25

<210> 6306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6306

uggggcagc uguuucaggg ggcac 25

<210> 6307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6307

gguggcagcu guuucagggg gcaca 25

<210> 6308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6308

agcuguuuca ggggcacag ggcua 25

<210> 6309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6309

cgugucaccu caacugaagc agaag 25

<210> 6310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6310

gucaccucaa cugaagcaga agagg 25

<210> 6311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6311

caacugaagc agaagaggug gauua 25

<210> 6312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6312

aagcagaaga gguggauuau ggcau 25

<210> 6313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6313

gauuauggca uuggccga agaaa 25

<210> 6314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6314

aggaaaaugc cuccgcuuau guugc 25

<210> 6315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6315

ccuccgcuua uguugcugga ugcug 25

<210> 6316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6316

cuccgcuuau guugcuggau gcuga 25

<210> 6317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6317

uccgcuuaug uugcuggaug cugag 25

<210> 6318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6318

auguugcugg augcugaggg gcugc 25

<210> 6319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6319

gcuggaugcu gaggggcugc ugguu 25

<210> 6320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6320

gaugcugagg ggcugcuggu uuggc 25

<210> 6321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6321

uccugagagu ccaguuugua ucugu 25

<210> 6322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6322

ugagagucca guuuguaucu guagg 25

<210> 6323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6323

caguuuguau cuguaggagg agaag 25

<210> 6324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6324

aguuuguauc uguaggagga gaagu 25

<210> 6325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6325

cgcgcgccgu guggggcgcg cacgc 25

<210> 6326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6326

gcgcgccgug uggggcgcgc acgca 25

<210> 6327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6327

gccgugggg gcgcgcacgc agggc 25

<210> 6328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6328

ccgugggggg cgcgcacgca gggcu 25

<210> 6329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6329

gggcgcgcac gcagggcugg gcgug 25

<210> 6330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6330

ggcgcgcacg cagggcuggg cguga 25

<210> 6331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6331

gcgcgcacgc agggcugggc gugag 25

<210> 6332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6332

cgcgcacgca gggcugggcg ugagg 25

<210> 6333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6333

ggcgugagggg ggcgugcgcg ugcgc 25

<210> 6334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6334

gugcgcggc gcaggcgacg cgccg 25

<210> 6335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6335

ugcgcaggcg acgcgccgag guacu 25

<210> 6336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6336

cgcgccgagg uacuaggcag agccg 25

<210> 6337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6337

uaggcagagc cguggaaccg ccgcc 25

<210> 6338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6338

cguggaaccg ccgccagguc gcugu 25

<210> 6339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6339

gcccgcucag cgccgccgc cgcca 25

<210> 6340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6340

cccgcucagc guccgccgcc gccau 25

<210> 6341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6341

gcguccgccg ccgccauggg agugc 25

<210> 6342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6342

uccgccgccg ccaugggagu gcagg 25

<210> 6343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6343

gagugcaggu ggaaaccauc ucccc 25

<210> 6344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6344

agguggaaac caucucccca ggaga 25

<210> 6345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6345

caucucccca ggagacggug aguag 25

<210> 6346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6346

ccaggagacg gugaguagug gcgcg 25

<210> 6347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6347

ggagacggug aguaguggcg cgcgg 25

<210> 6348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6348

ccgcgcgcca cuacucaccg ucucc 25

<210> 6349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6349

cgcgcgccac uacucaccgu cuccu 25

<210> 6350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6350

gcgcgccacu acucaccguc uccug 25

<210> 6351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6351

cacuacucac cgucuccugggg ggaga 25

<210> 6352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6352

gagaugguuu ccaccugcac uccca 25

<210> 6353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6353

augguuucca ccugcacucc caugg 25

<210> 6354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6354

guuuccaccu gcacucccau ggcgg 25

<210> 6355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6355

uccaccugca cucccauggc ggcgg 25

<210> 6356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6356

ucccauggcg gcggcggacg cugag 25

<210> 6357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6357

cccauggcgg cggcggacgc ugagc 25

<210> 6358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6358

auggcggcgg cggacgcuga gcggg 25

<210> 6359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6359

uggcggcggc ggacgcugag cgggc 25

<210> 6360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6360

cggcggcgga cgcugagcgg gcggg 25

<210> 6361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6361

gacgcugagc gggcgggcgg cgcga 25

<210> 6362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6362

acgcugagcg ggcggggcggc gcgac 25

<210> 6363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6363

cugagcgggc gggcggcgcg acggg 25

<210> 6364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6364

cgggcgggcg gcgcgacggg cggcg 25

<210> 6365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6365

cgggcggcgu ggaccaacag cgacc 25

<210> 6366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6366

gcggcgugga ccaacagcga ccugg 25

<210> 6367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6367

gcguggacca acagcgaccu ggcgg 25

<210> 6368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6368

caacagcgac cuggcggcgg uucca 25

<210> 6369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6369

gguuccacgg cucugccuag uaccu 25

<210> 6370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6370

cccagccug cgugcgcgcc ccaca 25

<210> 6371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6371

ccucagggcg caccuucccc aagcg 25

<210> 6372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6372

uuccccaagc gcggccagac cugcg 25

<210> 6373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6373

gccagaccug cguggugcac uacac 25

<210> 6374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6374

ugcguggugc acuacaccgg ugagu 25

<210> 6375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6375

gcguggugca cuacaccggu gaguc 25

<210> 6376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6376

cguggugcac uacaccggug agucg 25

<210> 6377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6377

guggugcacu acaccgguga gucgg 25

<210> 6378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6378

cuacaccggu gagucgggggg cccag 25

<210> 6379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6379

uacaccggug agucgggggc ccagc 25

<210> 6380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6380

acaccgguga gucgggggcc cagcg 25

<210> 6381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6381

ccggugaguc gggggcccag cgggg 25

<210> 6382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6382

gacucaccgg uguagugcac cacgc 25

<210> 6383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6383

accgguguag ugcaccacgc agguc 25

<210> 6384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6384

ugcaccacgc aggucuggcc gcgcu 25

<210> 6385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6385

gcaccacgca ggucuggccg cgcuu 25

<210> 6386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6386

caccacgcag gucuggccgc gcuug 25

<210> 6387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6387

acgcaggucu ggccgcgcuu gggga 25

<210> 6388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6388

ccgcgcuugg ggaaggugcg cccug 25

<210> 6389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6389

aaggugcgcc cugaggagac agaga 25

<210> 6390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6390

aggugcgccc ugaggagaca gagac 25

<210> 6391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6391

ucuuuuucac agggaugcuu gaaga 25

<210> 6392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6392

agauggaaag aaauuugauu ccucc 25

<210> 6393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6393

gauggaaaga aauuugauuc cuccc 25

<210> 6394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6394

gaaacaagcc cuuuaaguuu augcu 25

<210> 6395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6395

cccuuuaagu uuaugcuagg caagc 25

<210> 6396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6396

uuuaaguuua ugcuaggcaa gcagg 25

<210> 6397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6397

ugcuaggcaa gcaggaggug auccg 25

<210> 6398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6398

aggcaagcag gaggugaucc gaggc 25

<210> 6399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6399

ggcaagcagg aggugauccg aggcu 25

<210> 6400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6400

aggaggugau ccgaggcugg gaaga 25

<210> 6401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6401

ggaggugauc cgaggcuggg aagaa 25

<210> 6402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6402

gaggugaucc gaggcuggga agaag 25

<210> 6403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6403

cgaggcuggg aagaaggggu ugccc 25

<210> 6404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6404

aacaaaacaa augagagagc auacc 25

<210> 6405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6405

acaaaacaaa ugagagagca uaccu 25

<210> 6406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6406

cugggcaacc ccuucuuccc agccu 25

<210> 6407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6407

uccuugcuugc cuagcauaaa cuuaa 25

<210> 6408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6408

ccugcuugcc uagcauaaac uuaaa 25

<210> 6409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6409

aaacuuaaag ggcuuguuuc ugucc 25

<210> 6410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6410

aacuuaaagg gcuuguuucu guccc 25

<210> 6411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6411

uuaaagggcu uguuucuguc ccggg 25

<210> 6412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6412

uccuuguucu uuucacagau gagug 25

<210> 6413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6413

ccuuguucuu uucacagaug agugu 25

<210> 6414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6414

ugacuauauuc uccagauuau gccua 25

<210> 6415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6415

cuccagauua ugccuauggu gccac 25

<210> 6416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6416

uccagauuau gccuauggug ccacu 25

<210> 6417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6417

augccuaugg ugccacugg caccc 25

<210> 6418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6418

ccacaugcca cucucgucuu cgaug 25

<210> 6419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6419

gucuucgaug uggagcuucu aaaac 25

<210> 6420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6420

guggagcuuc uaaaacugga augac 25

<210> 6421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6421

gcuucuaaaa cuggaaugac aggaa 25

<210> 6422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6422

gccuccuccc uuagcucccu guucu 25

<210> 6423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6423

ccuccucccu uagcucccug uucuu 25

<210> 6424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6424

ucccuuagcu cccuguucuu gggua 25

<210> 6425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6425

agcucccugu ucuuggguaa ggaaa 25

<210> 6426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6426

cuuggguaag gaaauggaau acuga 25

<210> 6427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6427

uuggguaagg aaauggaaua cugaa 25

<210> 6428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6428

guauuccauu uccuuaccca agaac 25

<210> 6429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6429

uauuccauuu ccuuacccaa gaaca 25

<210> 6430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6430

uuccuuaccc aagaacaggg agcua 25

<210> 6431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6431

uccuuaccca agaacaggga gcuaa 25

<210> 6432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6432

uuacccaaga acagggagcu aaggg 25

<210> 6433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6433

cccaagaaca gggagcuaag ggagg 25

<210> 6434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6434

agaagcucca caucgaagac gagag 25

<210> 6435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6435

ccacaucgaa gacgagagug gcaug 25

<210> 6436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6436

caucgaagac gagaguggca ugugg 25

<210> 6437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6437

aucgaagacg agguggcau guggu 25

<210> 6438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6438

gaguggcaug ugggggaug augcc 25

<210> 6439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6439

aguggcaugu ggugggauga ugccu 25

<210> 6440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6440

gggggauga ugccugggug ccag 25

<210> 6441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6441

augccugggu gccaguggc accau 25

<210> 6442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6442

gcccaguggc accauaggca uaauc 25

<210> 6443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6443

gcauaaucug gagauauagu caguu 25

<210> 6444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6444

cccacacuca ucugugaaaa gaaca 25

<210> 6445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6445

uuuucugucc ccaacagauc ugcca 25

<210> 6446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6446

ucugucccca acagaucugc caugg 25

<210> 6447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6447

cuguccccaa cagaucugcc augga 25

<210> 6448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6448

ccaacagauc ugccauggag ggauc 25

<210> 6449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6449

ccagacaugu gcacaugaau ccaua 25

<210> 6450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6450

uauucauuuu auuuuguuuu cauuu 25

<210> 6451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6451

auucauuuua uuuuguuuuc auuuu 25

<210> 6452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6452

uucauuuuau uuuguuuuca uuuug 25

<210> 6453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6453

gggugaagau ucaguuucag ucuuu 25

<210> 6454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6454

gauucaguuu cagucuuuug gauau 25

<210> 6455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6455

ggauauaggu uuccaauuaa guaca 25

<210> 6456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6456

cauggucaag uauuaacagc acaag 25

<210> 6457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6457

gucaaguauu aacagcacaa guggu 25

<210> 6458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6458

acaaguggua gguuaacauu agaau 25

<210> 6459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6459

gguagguuaa cauuagaaua ggaau 25

<210> 6460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6460

uuaacauuag aauaggaauu ggugu 25

<210> 6461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6461

uaacauuaga auaggaauug guguu 25

<210> 6462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6462

aacauuagaa uaggaauugg uguug 25

<210> 6463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6463

acauuagaau aggaauuggu guugg 25

<210> 6464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6464

cauuagaaua ggaauuggug uuggg 25

<210> 6465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6465

auuagaauag gaauuggugu ugggg 25

<210> 6466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6466

uuagaauagg aauugguguu ggggg 25

<210> 6467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6467

uagaauagga auugguguug ggggg 25

<210> 6468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6468

agaauaggaa uugguguugg ggggg 25

<210> 6469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6469

gcaagaauau uuuauuuuaa uuuuu 25

<210> 6470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6470

gcgcugcaaa gccaauagcag auuug 25

<210> 6471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6471

ccauagcaga uuugaggcgc uguug 25

<210> 6472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6472

uacucuccaa guugagagau gucuu 25

<210> 6473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6473

acucuccaag uugagagaug ucuuu 25

<210> 6474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6474

aaauuaaaag cccuaccuaa aacug 25

<210> 6475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6475

uuaaaagccc uaccuaaaac ugagg 25

<210> 6476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6476

uaaaagcccu accuaaaacu gaggu 25

<210> 6477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6477

aaaagcccua ccuaaaacug aggug 25

<210> 6478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6478

gcccuaccua aaacugaggu gggga 25

<210> 6479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6479

cccuaccuaa aacugaggug gggau 25

<210> 6480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6480

ccuaccuaa acugaggugg ggaug 25

<210> 6481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6481

aaguagauca uguucacugc aaugc 25

<210> 6482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6482

uguucacugc aaugcuggac acuac 25

<210> 6483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6483

gcuggacacu acagguaucu gucci 25

<210> 6484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6484

cuggacacua cagguaucug ucccu 25

<210> 6485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6485

uacagguauc ugucccuggg ccagc 25

<210> 6486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6486

acagguaucu guccigggc cagca 25

<210> 6487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6487

gcagggaccu cugaagccuu cuuug 25

<210> 6488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6488

guggccuuuu uuuuuuuuca uccug 25

<210> 6489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6489

uuuuuucauc cugugguuuu ucuaa 25

<210> 6490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6490

ccugugguuu uucuaaugga cuuuc 25

<210> 6491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6491

aacuuuaauu gacaguuuca auuga 25

<210> 6492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6492

gaauguucuc uuaagaaaau gaugc 25

<210> 6493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6493

ucagcaucuc cuguuuuuug augcu 25

<210> 6494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6494

gcucccucug cugaucucag uuucc 25

<210> 6495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6495

cccuuugcug uccuguguag ugauu 25

<210> 6496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6496

uuauugcaau aaaagugcuu uaugc 25

<210> 6497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6497

gccggcuuuu cucagcucug uguca 25

<210> 6498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6498

ggcuuuucuc agcucugugu caugg 25

<210> 6499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6499

gcucuguguc aggugguua uuuuc 25

<210> 6500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6500

auuuucaggu gccccccug ccauu 25

<210> 6501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6501

accaugacac agagcugaga aaagc 25

<210> 6502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6502

aauaauaaaa cuugagacuc auaaa 25

<210> 6503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6503

aaaacuugag acucauaaau ggugc 25

<210> 6504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6504

aaacuugaga cucauaaaug gugcu 25

<210> 6505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6505

aacuugagac ucauaaaugg ugcug 25

<210> 6506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6506

acuugagacu cauaaauggu gcugg 25

<210> 6507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6507

gagacucaua aauggugcug gggga 25

<210> 6508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6508

agacucauaa auggugcugg gggaa 25

<210> 6509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6509

acgauuucuc accaaaucac uacac 25

<210> 6510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6510

accaaaucac uacacaggac agcaa 25

<210> 6511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6511

ccaaaucacu acacaggaca gcaaa 25

<210> 6512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6512

caaaucacua cacaggacag caaag 25

<210> 6513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6513

uacacaggac agcaaagggg ugaga 25

<210> 6514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6514

acacaggaca gcaaaggggu gagaa 25

<210> 6515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6515

cacaggacag caaaaggggug agaag 25

<210> 6516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6516

acagcaaagg ggugagaagg ggcug 25

<210> 6517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6517

cagcaaaggg gugagaaggg gcuga 25

<210> 6518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6518

caaaaggggug agaaggggcu gaggg 25

<210> 6519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6519

agaaggggcu gaggggaggaa aagcc 25

<210> 6520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6520

aaagccagga aacugagauc agcag 25

<210> 6521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6521

aagccaggaa acugagauca gcaga 25

<210> 6522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6522

cagagggagc caagcaucaa aaaac 25

<210> 6523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6523

caucauuuuc uuaagagaac auuca 25

<210> 6524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6524

gagaacauuc aaggauuugu cauga 25

<210> 6525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6525

acauucaagg auuugucaug auggc 25

<210> 6526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6526

cauucaagga uuugucauga uggcu 25

<210> 6527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6527

uuugucauga uggcuggcu uucac 25

<210> 6528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6528

uugucaugau ggcugggcuu ucacu 25

<210> 6529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6529

cugucaauua aaguucuuaa gauuu 25

<210> 6530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6530

auuaaaguuc uuaagauuua ggaag 25

<210> 6531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6531

aaaguucuua agauuuagga agugg 25

<210> 6532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6532

uuagauuua ggaaguggug gagcu 25

<210> 6533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6533

ccugaaaguc cauuagaaaa accac 25

<210> 6534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6534

aaaaccacag gaugaaaaaa aaaaa 25

<210> 6535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6535

ugaaaaaaaa aaaaggccac aaaga 25

<210> 6536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6536

aaaaaggcca caaagaaggc uucag 25

<210> 6537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6537

caaagaaggc uucagagguc ccugc 25

<210> 6538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6538

aggcuucaga ggucccugcu ggcc 25

<210> 6539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6539

ggcuucagag gucccugcug gccca 25

<210> 6540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6540

ugcagugaac augaucuacu uucaa 25

<210> 6541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6541

gaacauugauc uacuuucaaa ggcag 25

<210> 6542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6542

aacaucaucu acuuucaaag gcaga 25

<210> 6543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6543

ucuacuuuca aaggcagagg guuua 25

<210> 6544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6544

cuacuuucaa aggcagaggg uuuaa 25

<210> 6545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6545

uacuuucaaa ggcagagggu uuaag 25

<210> 6546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6546

uuucaaaggc agaggguuua agggg 25

<210> 6547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6547

uucaaaggca gaggguuuaa gggga 25

<210> 6548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6548

aaaggcagag gguuuaaggg gaggg 25

<210> 6549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6549

aaggcagagg guuuaagggg agggu 25

<210> 6550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6550

gcagaggguu uaaggggagg guggg 25

<210> 6551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6551

cagaggguuu aaggggaggg ugggu 25

<210> 6552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6552

gguuuaaggg gagggugggu gggaa 25

<210> 6553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6553

uuaaggggag ggugggugg aaugg 25

<210> 6554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6554

aggggagggu gggugggaau ggugg 25

<210> 6555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6555

gggggggg gaauggggga ggcaa 25

<210> 6556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6556

cucuccccau ccccaccuca guuuu 25

<210> 6557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6557

ccccaucccc accucaguuu uaggu 25

<210> 6558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6558

cccaucccca ccucaguuuu aggua 25

<210> 6559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6559

uuuaacccaa agacaucucu caacu 25

<210> 6560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6560

ccucaacagc gccucaaauc ugcua 25

<210> 6561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6561

guuaauacuu gaccauguac uuaau 25

<210> 6562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6562

aaaaaaaau aaaaugaaua acuug 25

<210> 6563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6563

aauaaaauga auaacuugag guuua 25

<210> 6564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6564

acuugagguu uauggcauau aguuu 25

<210> 6565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6565

uauaguuuag guaaacacac auacg 25

<210> 6566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6566

uagguaaaca cacauacgag gagaa 25

<210> 6567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6567

agguaaacac acauacgagg agaaa 25

<210> 6568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6568

gguaaacaca cauacgagga gaaag 25

<210> 6569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6569

cacacauacg aggagaaagg ggaag 25

<210> 6570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6570

gaggagaaag gggaagagga aacag 25

<210> 6571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6571

aaaggggaag aggaaacaga ggugu 25

<210> 6572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6572

gcugagugac agaacacauu caguc 25

<210> 6573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6573

cugagugaca gaacacauuc aguca 25

<210> 6574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6574

agucaggca gaugucuaua caaag 25

<210> 6575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6575

gggcagaugu cuauacaaag uggag 25

<210> 6576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6576

ucuauacaaa guggagugga acauc 25

<210> 6577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6577

guggaacauc aggaaaagcu ccaua 25

<210> 6578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6578

ccauauggau ucaugucac auguc 25

<210> 6579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6579

uuggauuca ugugcacaug ucugg 25

<210> 6580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6580

ugucuggagg caccagaucc cucca 25

<210> 6581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6581

ccagaucccu ccauggcaga ucugu 25

<210> 6582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6582

cagaucccuc cauggcagau cuguu 25

<210> 6583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6583

agaucccucc auggcagauc uguug 25

<210> 6584

<211> 12

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6584

guuuuagagc ua 12

<210> 6585

<211> 12

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6585

guuuaagagc ua 12

<210> 6586

<211> 5

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6586

ugcug 5

<210> 6587

<211> 5

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6587

uuuug 5

<210> 6588

<211> 4

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6588

gaaa 4

<210> 6589

<211> 60

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6589

uagcaaguua aaauaaggcu aguccguuau caacuugaaa aaguggcacc gagucggugc 60

<210> 6590

<211> 60

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6590

uagcaaguuu aaauaaggcu aguccguuau caacuugaaa aaguggcacc gagucggugc 60

<210> 6591

<211> 5

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6591

cagca 5

<210> 6592

<211> 40

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(40)

<223> /note="This sequence may include 1-10 'Gly-Gly-Gly-Ser'

repeating units"

<400> 6592

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

20 25 30

Gly Gly Gly Ser Gly Gly Gly Ser

35 40

<210> 6593

<211> 20

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6593

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

1 5 10 15

Gly Gly Gly Ser

20

<210> 6594

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6594

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10 15

<210> 6595

<211> 4

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6595

Gly Gly Gly Ser

one

<210> 6596

<211> 5000

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(5000)

<223> /note="This sequence can include 50-5000 nucleotides"

<400> 6596

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

1020

1080

1140

1200

1260

1320

1380

1440

1500

1560

1620

1680

1740

1800

1860

1920

1980

2040

2100

2160

2220

2280

2340

2400

2460

2520

2580

2640

2700

2760

2820

2880

2940

3000

3060

3120

3180

3240

3300

3360

3420

3480

3540

3600

3660

3720

3780

3840

3900

3960

4020

4080

4140

4200

4260

4320

4380

4440

4500

4560

4620

4680

4740

4800

4860

4920

4980

aaaaaaaaaaaaaaaaaaaa 5000

<210> 6597

<211> 13

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6597

uagcaaguua aaa 13

<210> 6598

<211> 13

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6598

uagcaaguuu aaa 13

<210> 6599

<211> 47

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6599

uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag ucggugc 47

<210> 6600

<211> 51

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6600

u 51

<210> 6601

<211> 76

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6601

guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60

ggcaccgagu cggugc 76

<210> 6602

<211> 76

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6602

guuuaagagc uagaaauagc aaguuuaaau aaggcuaguc cguuaucaac uugaaaaagu 60

ggcaccgagu cggugc 76

<210> 6603

<211> 86

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6603

guuuuagagc uaugcuggaa acagcauagc aaguuaaaau aaggcuaguc cguuaucaac 60

uugaaaaagu ggcaccgagu cggugc 86

<210> 6604

<211> 86

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6604

guuuaagagc uaugcuggaa acagcauagc aaguuuaaau aaggcuaguc cguuaucaac 60

uugaaaaagu ggcaccgagu cggugc 86

<210> 6605

<211> 17

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6605

guuuuagagc uaugcug 17

<210> 6606

<211> 17

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6606

guuuaagagc uaugcug 17

<210> 6607

<211> 22

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6607

guuuuagagc uaugcuguuu ug 22

<210> 6608

<211> 22

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6608

guuuaagagc uaugcuguuu ug 22

<210> 6609

<211> 65

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6609

cagcauagca aguuaaaaua aggcuagucc guuaucaacu ugaaaaagug gcaccgaguc 60

ggugc 65

<210> 6610

<211> 65

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6610

cagcauagca aguuuaaaua aggcuagucc guuaucaacu ugaaaaagug gcaccgaguc 60

ggugc 65

<210> 6611

<211> 1368

<212> Protein

<213> Streptococcus pyogenes

<400> 6611

Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val

1 5 10 15

Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe

20 25 30

Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile

35 40 45

Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu

50 55 60

Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys

65 70 75 80

Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser

85 90 95

Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys

100 105 110

His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr

115 120 125

His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp

130 135 140

Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His

145 150 155 160

Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro

165 170 175

Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr

180 185 190

Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala

195 200 205

Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn

210 215 220

Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn

225 230 235 240

Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe

245 250 255

Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp

260 265 270

Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp

275 280 285

Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp

290 295 300

Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser

305 310 315 320

Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys

325 330 335

Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe

340 345 350

Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser

355 360 365

Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp

370 375 380

Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg

385 390 395 400

Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu

405 410 415

Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe

420 425 430

Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile

435 440 445

Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp

450 455 460

Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu

465 470 475 480

Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr

485 490 495

Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser

500 505 510

Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys

515 520 525

Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln

530 535 540

Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr

545 550 555 560

Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp

565 570 575

Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly

580 585 590

Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp

595 600 605

Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr

610 615 620

Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala

625 630 635 640

His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr

645 650 655

Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp

660 665 670

Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe

675 680 685

Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe

690 695 700

Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu

705 710 715 720

His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly

725 730 735

Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly

740 745 750

Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln

755 760 765

Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile

770 775 780

Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro

785 790 795 800

Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu

805 810 815

Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg

820 825 830

Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys

835 840 845

Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg

850 855 860

Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys

865 870 875 880

Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys

885 890 895

Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp

900 905 910

Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr

915 920 925

Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp

930 935 940

Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser

945 950 955 960

Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg

965 970 975

Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val

980 985 990

Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe

995 1000 1005

Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala

1010 1015 1020

Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe

1025 1030 1035

Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala

1040 1045 1050

Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu

1055 1060 1065

Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val

1070 1075 1080

Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr

1085 1090 1095

Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys

1100 1105 1110

Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro

1115 1120 1125

Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val

1130 1135 1140

Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys

1145 1150 1155

Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser

1160 1165 1170

Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys

1175 1180 1185

Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu

1190 1195 1200

Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly

1205 1210 1215

Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val

1220 1225 1230

Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser

1235 1240 1245

Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys

1250 1255 1260

His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys

1265 1270 1275

Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala

1280 1285 1290

Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn

1295 1300 1305

Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala

1310 1315 1320

Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser

1325 1330 1335

Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr

1340 1345 1350

Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp

1355 1360 1365

<210> 6612

<211> 7

<212> Protein

<213> Monkey Virus 40

<400> 6612

Pro Lys Lys Lys Arg Lys Val

fifteen

<210> 6613

<211> 16

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

nucleoplasmin double NLS sequence"

<400> 6613

Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys

1 5 10 15

<210> 6614

<211> 9

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

NLS sequence C-myc"

<400> 6614

Pro Ala Ala Lys Arg Val Lys Leu Asp

fifteen

<210> 6615

<211> 11

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

NLS sequence C-myc"

<400> 6615

Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Pro

1 5 10

<210> 6616

<211> 38

<212> Protein

<213> Homo sapiens

<400> 6616

Asn Gln Ser Ser Asn Phe Gly Pro Met Lys Gly Gly Asn Phe Gly Gly

1 5 10 15

Arg Ser Ser Gly Pro Tyr Gly Gly Gly Gly Gln Tyr Phe Ala Lys Pro

20 25 30

Arg Asn Gln Gly Gly Tyr

35

<210> 6617

<211> 42

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

IBB domain sequence from importin-alpha"

<400> 6617

Arg Met Arg Ile Glx Phe Lys Asn Lys Gly Lys Asp Thr Ala Glu Leu

1 5 10 15

Arg Arg Arg Arg Val Glu Val Ser Val Glu Leu Arg Lys Ala Lys Lys

20 25 30

Asp Glu Gln Ile Leu Lys Arg Arg Asn Val

35 40

<210> 6618

<211> 8

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

myoma protein T sequence"

<400> 6618

Val Ser Arg Lys Arg Pro Arg Pro

fifteen

<210> 6619

<211> 8

<212> Protein

<213> Unknown

<220>

<221> source

<223> /note="Description of unknown:

myoma protein T sequence"

<400> 6619

Pro Pro Lys Lys Ala Arg Glu Asp

fifteen

<210> 6620

<211> 8

<212> Protein

<213> Homo sapiens

<400> 6620

Pro Gln Pro Lys Lys Lys Pro Leu

fifteen

<210> 6621

<211> 12

<212> Protein

<213> Mus musculus

<400> 6621

Ser Ala Leu Ile Lys Lys Lys Lys Lys Met Ala Pro

1 5 10

<210> 6622

<211> 5

<212> Protein

<213> Influenza virus

<400> 6622

Asp Arg Leu Arg Arg

fifteen

<210> 6623

<211> 7

<212> Protein

<213> Influenza virus

<400> 6623

Pro Lys Gln Lys Lys Arg Lys

fifteen

<210> 6624

<211> 10

<212> Protein

<213> Delta hepatitis virus

<400> 6624

Arg Lys Leu Lys Lys Lys Ile Lys Lys Leu

1 5 10

<210> 6625

<211> 10

<212> Protein

<213> Mus musculus

<400> 6625

Arg Glu Lys Lys Lys Phe Leu Lys Arg Arg

1 5 10

<210> 6626

<211> 20

<212> Protein

<213> Homo sapiens

<400> 6626

Lys Arg Lys Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala Lys Lys

1 5 10 15

Lys Ser Lys Lys

20

<210> 6627

<211> 17

<212> Protein

<213> Homo sapiens

<400> 6627

Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys

1 5 10 15

Lys

<210> 6628

<211> 4107

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6628

atggataaaa agtacagcat cgggctggac atcggtacaa actcagtggg gtgggccgtg 60

attacggacg agtacaaggt accctccaaa aaatttaaag tgctgggtaa cacggacaga 120

cactctataa agaaaaatct tattggagcc ttgctgttcg actcaggcga gacagccgaa 180

gccacaaggt tgaagcggac cgccaggagg cggtatacca ggagaaagaa ccgcatatgc 240

tacctgcaag aaatcttcag taacgagatg gcaaaaggttg acgatagctt tttccatcgc 300

ctggaagaat cctttcttgt tgaggaagac aagaagcacg aacggcaccc catctttggc 360

aatattgtcg acgaagtggc atatcacgaa aagtacccga ctatctacca cctcaggaag 420

aagctggtgg actctaccga taaggcggac ctcagactta tttatttggc actcgcccac 480

atgattaaat ttagaggaca tttcttgatc gagggcgacc tgaacccgga caacagtgac 540

gtcgataagc tgttcatcca acttgtgcag acctacaatc aactgttcga agaaaaccct 600

ataaatgctt caggagtcga cgctaaagca atcctgtccg cgcgcctctc aaaatctaga 660

agacttgaga atctgattgc tcagttgccc ggggaaaaga aaaatggatt gtttggcaac 720

ctgatcgccc tcagtctcgg actgacccca aatttcaaaa gtaacttcga cctggccgaa 780

gacgctaagc tccagctgtc caaggacaca tacgatgacg acctcgacaa tctgctggcc 840

cagattgggg atcagtacgc cgatctcttt ttggcagcaa agaacctgtc cgacgccatc 900

ctgttgagcg atatcttgag agtgaacacc gaaattacta aagcacccct tagcgcatct 960

atgatcaagc ggtacgacga gcatcatcag gatctgaccc tgctgaaggc tcttgtgagg 1020

caacagctcc ccgaaaaata caaggaaatc ttctttgacc agagcaaaaa cggctacgct 1080

ggctatatag atggtggggc cagtcaggag gaattctata aattcatcaa gcccattctc 1140

gagaaaatgg acggcacaga ggagttgctg gtcaaactta acagggagga cctgctgcgg 1200

aagcagcgga cctttgacaa cgggtctatc ccccaccaga ttcatctggg cgaactgcac 1260

gcaatcctga ggaggcagga ggatttttat ccttttctta aagataaccg cgagaaaata 1320

gaaaagattc ttacattcag gatcccgtac tacgtgggac ctctcgcccg gggcaattca 1380

cggtttgcct ggatgacaag gaagtcagag gagactatta caccttggaa cttcgaagaa 1440

gtggtggaca agggtgcatc tgcccagtct ttcatcgagc ggatgacaaa ttttgacaag 1500

aacctcccta atgagaaggt gctgcccaaa cattctctgc tctacgagta ctttaccgtc 1560

tacaatgaac tgactaaagt caagtacgtc accgagggaa tgaggaagcc ggcattcctt 1620

agtggagaac agaagaaggc gattgtagac ctgttgttca agaccaacag gaaggtgact 1680

gtgaagcaac ttaaagaaga ctactttaag aagatcgaat gttttgacag tgtggaaatt 1740

tcaggggttg aagaccgctt caatgcgtca ttggggactt accatgatct tctcaagatc 1800

ataaaggaca aagacttcct ggacaacgaa gaaaatgagg atattctcga agacatcgtc 1860

ctcaccctga ccctgttcga agacagggaa atgatagaag agcgcttgaa aacctatgcc 1920

cacctcttcg acgataaagt tatgaagcag ctgaagcgca ggagatacac aggatgggga 1980

agattgtcaa ggaagctgat caatggaatt agggataaac agagtggcaa gaccatactg 2040

gattcctca aatctgatgg cttcgccaat aggaacttca tgcaactgat tcacgatgac 2100

tctcttacct tcaaggagga cattcaaaag gctcaggtga gcgggcaggg agactccctt 2160

catgaacaca tcgcgaattt ggcaggttcc cccgctatta aaaagggcat ccttcaaact 2220

gtcaaggtgg tggatgaatt ggtcaaggta atgggcagac ataagccaga aaatattgtg 2280

atcgagatgg cccgcgaaaa ccagaccaca cagaagggcc agaaaaatag tagagagcgg 2340

atgaagagga tcgaggaggg catcaaagag ctgggatctc agattctcaa agaacacccc 2400

gtagaaaaca cacagctgca gaacgaaaaa ttgtacttgt actatctgca gaacggcaga 2460

gacatgtacg tcgaccaaga acttgatatt aatagactgt ccgactatga cgtagaccat 2520

atcgtgcccc agtccttcct gaaggacgac tccattgata acaaagtctt gacaagaagc 2580

gacaagaaca ggggtaaaag tgataatgtg cctagcgagg aggtggtgaa aaaaatgaag 2640

aactactggc gacagctgct taatgcaaag ctcattacac aacggaagtt cgataatctg 2700

acgaaagcag agagaggtgg cttgtctgag ttggacaagg cagggtttat taagcggcag 2760

ctggtggaaa ctaggcagat cacaaagcac gtggcgcaga ttttggacag ccggatgaac 2820

acaaaatacg acgaaaatga taaactgata cgagaggtca aagttatcac gctgaaaagc 2880

aagctggtgt ccgattttcg gaaagacttc cagttctaca aagttcgcga gattaataac 2940

taccatcatg ctcacgatgc gtacctgaac gctgttgtcg ggaccgcctt gataaagaag 3000

3060

atgatagcca agtccgagca ggagattgga aaggccacag ctaagtactt cttttattct 3120

aacatcatga atttttttaa gacggaaatt accctggcca acggagagat cagaaagcgg 3180

3240

gctactgtga ggaaggtgct gagtatgcca caggtaaata tcgtgaaaaa aaccgaagta 3300

3360

gcccgcaaga aagattggga ccctaagaaa tacgggggat ttgactcacc caccgtagcc 3420

tattctgtgc tggtggtagc taaggtggaa aaaggaaagt ctaagaagct gaagtccgtg 3480

aaggaactct tgggaatcac tatcatggaa agatcatcct ttgaaaagaa ccctatcgat 3540

ttcctggagg ctaagggtta caaggaggtc aagaaagacc tcatcattaa actgccaaaa 3600

3660

caaaagggaa acgagcttgc tctgccctcc aaatatgtta attttctcta tctcgcttcc 3720

cactatgaaa agctgaaagg gtctcccgaa gataacgagc agaagcagct gttcgtcgaa 3780

cagcacaagc actatctgga tgaaataatc gaacaaataa gcgagttcag caaaagggtt 3840

atcctggcgg atgctaattt ggacaaagta ctgtctgctt ataacaagca ccgggataag 3900

cctattaggg aacaagccga gaatataatt cacctcttta cactcacgaa tctcggagcc 3960

cccgccgcct tcaaatactt tgatacgact atcgaccgga aacggtatac cagtaccaaa 4020

gaggtcctcg atgccaccct catccaccag tcaattactg gcctgtacga aacacggatc 4080

gacctctctc aactgggcgg cgactag 4107

<210> 6629

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6629

Gly Gly Gly Gly Ser

fifteen

<210> 6630

<211> 230

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6630

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe

1 5 10 15

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

35 40 45

Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val

50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser

65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser

100 105 110

Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

115 120 125

Gln Val Tyr Thr Leu Pro Ser Gln Glu Glu Met Thr Lys Asn Gln

130 135 140

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu

180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser

195 200 205

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

210 215 220

Leu Ser Leu Gly Lys Met

225 230

<210> 6631

<211> 690

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6631

gagagcaagt acggccctcc ctgcccccct tgccctgccc ccgagttcct gggcggaccc 60

agcgtgttcc tgttcccccc caagcccaag gacaccctga tgatcagccg gacccccgag 120

gtgacctgtg tggtggtgga cgtgtcccag gaggaccccg aggtccagtt caactggtac 180

gtggacggcg tggaggtgca caacgccaag accaagcccc gggaggagca gttcaatagc 240

acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg actggctgaa cggcaaggaa 300

tacaagtgta aggtgtccaa caagggcctg cccagcagca tcgagaaaac catcagcaag 360

gccaagggcc agcctcggga gccccaggtg tacaccctgc cccctagcca agaggagatg 420

accaagaacc aggtgtccct gacctgcctg gtgaagggct tctaccccag cgacatcgcc 480

gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 540

gacagcgacg gcagcttctt cctgtacagc cggctgaccg tggacaagag ccggtggcag 600

gagggcaacg tctttagctg ctccgtgatg cacgaggccc tgcacaacca ctacacccag 660

aagagcctga gcctgtccct gggcaagatg 690

<210> 6632

<211> 282

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6632

Arg Trp Pro Glu Ser Pro Lys Ala Gln Ala Ser Ser Val Pro Thr Ala

1 5 10 15

Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala

20 25 30

Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu Lys

35 40 45

Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro

50 55 60

Ser His Thr Gln Pro Leu Gly Val Tyr Leu Leu Thr Pro Ala Val Gln

65 70 75 80

Asp Leu Trp Leu Arg Asp Lys Ala Thr Phe Thr Cys Phe Val Val Gly

85 90 95

Ser Asp Leu Lys Asp Ala His Leu Thr Trp Glu Val Ala Gly Lys Val

100 105 110

Pro Thr Gly Gly Val Glu Glu Gly Leu Leu Glu Arg His Ser Asn Gly

115 120 125

Ser Gln Ser Gln His Ser Arg Leu Thr Leu Pro Arg Ser Leu Trp Asn

130 135 140

Ala Gly Thr Ser Val Thr Cys Thr Leu Asn His Pro Ser Leu Pro Pro

145 150 155 160

Gln Arg Leu Met Ala Leu Arg Glu Pro Ala Ala Gln Ala Pro Val Lys

165 170 175

Leu Ser Leu Asn Leu Leu Ala Ser Ser Asp Pro Pro Glu Ala Ala Ser

180 185 190

Trp Leu Leu Cys Glu Val Ser Gly Phe Ser Pro Pro Asn Ile Leu Leu

195 200 205

Met Trp Leu Glu Asp Gln Arg Glu Val Asn Thr Ser Gly Phe Ala Pro

210 215 220

Ala Arg Pro Pro Pro Gln Pro Gly Ser Thr Thr Phe Trp Ala Trp Ser

225 230 235 240

Val Leu Arg Val Pro Ala Pro Pro Ser Pro Gln Pro Ala Thr Tyr Thr

245 250 255

Cys Val Val Ser His Glu Asp Ser Arg Thr Leu Leu Asn Ala Ser Arg

260 265 270

Ser Leu Glu Val Ser Tyr Val Thr Asp His

275 280

<210> 6633

<211> 847

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6633

aggtggcccg aaagtcccaa ggcccaggca tctagtgttc ctactgcaca gccccaggca 60

gaaggcagcc tagccaaagc tactactgca cctgcacta cgcgcaatac tggccgtggc 120

ggggaggaga agaaaaagga gaaagagaaa gaagaacagg aagagaggga gaccaagacc 180

cctgaatgtc catcccatac ccagccgctg ggcgtctatc tcttgactcc cgcagtacag 240

gacttgtggc ttagagataa ggccaccttt acatgtttcg tcgtgggctc tgacctgaag 300

gatgcccatt tgacttggga ggttgccgga aaggtaccca cagggggggt tgaggaaggg 360

ttgctggagc gccattccaa tggctctcag agccagcact caagactcac ccttccgaga 420

tccctgtgga acgccgggac ctctgtcaca tgtactctaa atcatcctag cctgccccca 480

cagcgtctga tggcccttag agagccagcc gcccaggcac cagttaagct tagcctgaat 540

ctgctcgcca gtagtgatcc cccagaggcc gccagctggc tcttatgcga agtgtccggc 600

tttagcccgc ccaacatctt gctcatgtgg ctggaggacc agcgagaagt gaacaccagc 660

ggcttcgctc cagcccggcc cccaccccag ccgggttcta ccacattctg ggcctggagt 720

gtcttaaggg tcccagcacc acctagcccc cagccagcca catacacctg tgttgtgtcc 780

catgaagata gcaggaccct gctaaatgct tctaggagtc tggaggtttc ctacgtgact 840

gaccatt 847

<210> 6634

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6634

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10

<210> 6635

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6635

ggtggcggag gttctgggagg tggaggttcc 30

<210> 6636

<211> 48

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6636

Gln Arg Arg Lys Tyr Arg Ser Asn Lys Gly Glu Ser Pro Val Glu Pro

1 5 10 15

Ala Glu Pro Cys Arg Tyr Ser Cys Pro Arg Glu Glu Glu Gly Ser Thr

20 25 30

Ile Pro Ile Gln Glu Asp Tyr Arg Lys Pro Glu Pro Ala Cys Ser Pro

35 40 45

<210> 6637

<211> 123

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6637

aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60

gggccccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120

tcc 123

<210> 6638

<211> 2000

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(2000)

<223> /note="This sequence may include 50-2000 nucleotides"

<400> 6638

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

1020

1080

1140

1200

1260

1320

1380

1440

1500

1560

1620

1680

1740

1800

1860

1920

1980

aaaaaaaaaaaaaaaaaaaa 2000

<210> 6639

<211> 1184

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6639

cgtgaggctc cggtgcccgt cagtgggcag agcgcacatc gcccacagtc cccgagaagt 60

tggggggagg ggtcggcaat tgaaccggtg cctagagaag gtggcgcggg gtaaactggg 120

180

gtgcagtagt cgccgtgaac gttctttttc gcaacgggtt tgccgccaga acacaggtaa 240

gtgccgtgtg tggttcccgc gggcctggcc tctttacgggg ttatggccct tgcgtgcctt 300

gaattacttc cacctggctg cagtacgtga ttcttgatcc cgagcttcgg gttggaagtg 360

ggtgggagag ttcgaggcct tgcgcttaag gagccccttc gcctcgtgct tgagttgagg 420

cctggcctgg gcgctggggc cgccgcgtgc gaatctggtg gcaccttcgc gcctgtctcg 480

ctgctttcga taagtctcta gccatttaaa atttttgatg acctgctgcg acgctttttt 540

tctggcaaga tagtcttgta aatgcgggcc aagatctgca cactggtatt tcggtttttg 600

gggccgcggg cggcgacggg gcccgtgcgt cccagcgcac atgttcggcg aggcggggcc 660

tgcgagcgcg gccaccgaga atcggacggg ggtagtctca agctggccgg cctgctctgg 720

tgcctggcct cgcgccgccg tgtatcgccc cgccctgggc ggcaaggctg gcccggtcgg 780

caccagttgc gtgagcggaa agatggccgc ttcccggccc tgctgcaggg agctcaaaat 840

ggaggacgcg gcgctcggga gagcgggcgg gtgagtcacc cacacaaagg aaaagggcct 900

ttccgtcctc agccgtcgct tcatgtgact ccacggagta ccgggcgccg tccaggcacc 960

tcgattagtt ctcgagcttt tggagtacgt cgtctttagg ttggggggag gggttttatg 1020

cgatggagtt tccccacact gagtgggtgg agactgaagt taggccagct tggcacttga 1080

tgtaattctc cttggaattt gccctttttg agtttggatc ttggttcatt ctcaagcctc 1140

gtga 1184

<210> 6640

<211> 21

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6640

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro

20

<210> 6641

<211> 63

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6641

atggccctgc ctgtgacagc cctgctgctg ccctctggctc tgctgctgca tgccgctaga 60

ccc 63

<210> 6642

<211> 45

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6642

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala

1 5 10 15

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly

20 25 30

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp

35 40 45

<210> 6643

<211> 135

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6643

accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60

tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120

gacttcgcct gtgat 135

<210> 6644

<211> 24

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6644

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu

1 5 10 15

Ser Leu Val Ile Thr Leu Tyr Cys

20

<210> 6645

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6645

atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc 60

accctttact gc 72

<210> 6646

<211> 42

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6646

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

1 5 10 15

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

20 25 30

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu

35 40

<210> 6647

<211> 126

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6647

aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60

actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120

gaactg 126

<210> 6648

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6648

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly

1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr

20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys

35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys

50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg

65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala

85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

100 105 110

<210> 6649

<211> 336

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6649

agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60

120

cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180

gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240

cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300

tacgacgccc ttcacatgca ggccctgccc cctcgc 336

<210> 6650

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6650

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly

1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr

20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys

35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys

50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg

65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala

85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

100 105 110

<210> 6651

<211> 336

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6651

agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60

120

cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180

gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240

cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300

tacgacgccc ttcacatgca ggccctgccc cctcgc 336

<210> 6652

<211> 150

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6652

Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr

1 5 10 15

Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe

20 25 30

Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr

35 40 45

Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu

50 55 60

Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu

65 70 75 80

Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn

85 90 95

Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala

100 105 110

Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg

115 120 125

Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly

130 135 140

Gln Phe Gln Thr Leu Val

145 150

<210> 6653

<211> 450

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6653

cccggatggt ttctggactc tccggatcgc ccgtggaatc ccccaacctt ctcaccggca 60

ctcttggttg tgactgaggg cgataatgcg accttcacgt gctcgttctc caacacctcc 120

gaatcattcg tgctgaactg gtaccgcatg agcccgtcaa accagaccga caagctcgcc 180

gcgtttccgg aagatcggtc gcaaccggga caggattgtc ggttccgcgt gactcaactg 240

ccgaatggca gagacttcca catgagcgtg gtccgcgcta ggcgaaacga ctccgggacc 300

tacctgtgcg gagccatctc gctggcgcct aaggcccaaa tcaaagagag cttgagggcc 360

gaactgagag tgaccgagcg cagagctgag gtgccaactg cacatccatc cccatcgcct 420

cggcctgcgg ggcagtttca gaccctggtc 450

<210> 6654

<211> 394

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6654

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro

20 25 30

Trp Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly

35 40 45

Asp Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe

50 55 60

Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu

65 70 75 80

Ala Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe

85 90 95

Arg Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val

100 105 110

Arg Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser

115 120 125

Leu Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg

130 135 140

Val Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser

145 150 155 160

Pro Arg Pro Ala Gly Gln Phe Gln Thr Leu Val Thr Thr Thr Pro Ala

165 170 175

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

180 185 190

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

195 200 205

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

210 215 220

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

225 230 235 240

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

245 250 255

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

260 265 270

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

275 280 285

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

290 295 300

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

305 310 315 320

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

325 330 335

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

340 345 350

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

355 360 365

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

370 375 380

Ala Leu His Met Gln Ala Leu Pro Pro Arg

385 390

<210> 6655

<211> 1182

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 6655

atggccctcc ctgtcactgc cctgcttctc cccctcgcac tcctgctcca cgccgctaga 60

ccacccggat ggtttctgga ctctccggat cgcccgtgga atcccccaac cttctcaccg 120

gcactcttgg ttgtgactga gggcgataat gcgaccttca cgtgctcgtt ctccaacacc 180

tccgaatcat tcgtgctgaa ctggtaccgc atgagcccgt caaaccagac cgacaagctc 240

gccgcgtttc cggaagatcg gtcgcaaccg ggacaggatt gtcggttccg cgtgactcaa 300

ctgccgaatg gcagagactt ccacatgagc gtggtccgcg ctaggcgaaa cgactccggg 360

acctacctgt gcggagccat ctcgctggcg cctaaggccc aaatcaaaga gagcttgagg 420

gccgaactga gagtgaccga gcgcagagct gaggtgccaa ctgcacatcc atccccatcg 480

cctcggcctg cggggcagtt tcagaccctg gtcacgacca ctccggcgcc gcgcccaccg 540

actccggccc caactatcgc gagccagccc ctgtcgctga ggccggaagc atgccgccct 600

gccgccggag gtgctgtgca tacccgggga ttggacttcg catgcgacat ctacatttgg 660

gctcctctcg ccggaacttg tggcgtgctc cttctgtccc tggtcatcac cctgtactgc 720

aagcggggtc ggaaaaagct tctgtacatt ttcaagcagc ccttcatgag gcccgtgcaa 780

accacccagg aggaggacgg ttgctcctgc cggttccccg aagaggaaga aggaggttgc 840

gagctgcgcg tgaagttctc ccggagcgcc gacgcccccg cctataagca gggccagaac 900

cagctgtaca acgaactgaa cctgggacgg cgggaagagt acgatgtgct ggacaagcgg 960

cgcggccggg accccgaaat gggcgggaag cctagaagaa agaaccctca ggaaggcctg 1020

tataacgagc tgcagaagga caagatggcc gaggcctact ccgaaattgg gatgaaggga 1080

gagcggcgga ggggaaaggg gcacgacggc ctgtaccaag gactgtccac cgccaccaag 1140

gacacatacg atgccctgca catgcaggcc cttccccctc gc 1182

<210> 6656

<211> 373

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 6656

Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr

1 5 10 15

Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe

20 25 30

Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr

35 40 45

Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu

50 55 60

Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu

65 70 75 80

Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn

85 90 95

Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala

100 105 110

Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg

115 120 125

Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly

130 135 140

Gln Phe Gln Thr Leu Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

145 150 155 160

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

165 170 175

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

180 185 190

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

195 200 205

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

210 215 220

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

225 230 235 240

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

245 250 255

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

260 265 270

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

275 280 285

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

290 295 300

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

305 310 315 320

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

325 330 335

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

340 345 350

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

355 360 365

Ala Leu Pro Pro Arg

370

<210> 6657

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6657

ugcagauccc acaggcgccc 20

<210> 6658

<400> 6658

000

<210> 6659

<211> 4

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 6659

Arg Gly Asp Ser

one

<210> 6660

<211> 74

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6660

aacagcauag caaguuaaaa uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag 60

ucggugcuuuuuuu 74

<210> 6661

<211> 74

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 6661

aacagcauag caaguuuaaa uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag 60

ucggugcuuuuuuu 74

<210> 6662

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6662

cgcacgcagg gcugggcgug 20

<210> 6663

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6663

gcacgcaggg cugggcguga 20

<210> 6664

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6664

cacgcagggc ugggcgugag 20

<210> 6665

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6665

acgcagggcu gggcgugagg 20

<210> 6666

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6666

gagggggcgu gcgcgugcgc 20

<210> 6667

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6667

cgugcgcagg cgacgcgccg 20

<210> 6668

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6668

aggcgacgcg ccgagguacu 20

<210> 6669

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6669

cacggcucug ccuaguaccu 20

<210> 6670

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6670

cgagguacua ggcagagccg 20

<210> 6671

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6671

agagccgugg aaccgccgcc 20

<210> 6672

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6672

gcgaccuggc ggcgguucca 20

<210> 6673

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6673

aaccgccgcc aggucgcugu 20

<210> 6674

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6674

gaccaacagc gaccuggcgg 20

<210> 6675

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6675

guggaccaac agcgaccugg 20

<210> 6676

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6676

ggcguggacc aacagcgacc 20

<210> 6677

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6677

ggggcggcgcg acggggcggcg 20

<210> 6678

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6678

cgggcgggcg gcgcgacggg 20

<210> 6679

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6679

gagcgggcgg gcggcgcgac 20

<210> 6680

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6680

ugagcgggcg ggcggcgcga 20

<210> 6681

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6681

gcggacgcug agcgggcggg 20

<210> 6682

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6682

gcggcggacg cugagcgggc 20

<210> 6683

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6683

ggcggcggac gcugagcggg 20

<210> 6684

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6684

ggcggcggcg gacgcugagc 20

<210> 6685

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6685

uggcggcggc ggacgcugag 20

<210> 6686

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6686

cucagcgucc gccgccgcca 20

<210> 6687

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6687

ucagcguccg ccgccgccau 20

<210> 6688

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6688

cugcacuccc auggcggcgg 20

<210> 6689

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6689

cgccgccgcc agggagugc 20

<210> 6690

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6690

caccugcacu cccauggcgg 20

<210> 6691

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6691

cgccgccaugggagugcagg 20

<210> 6692

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6692

uuccaccuc acucccaugg 20

<210> 6693

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6693

gguuuccacc ugcacucca 20

<210> 6694

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6694

cagguggaaa ccaucucccc 20

<210> 6695

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6695

cucaccgucu ccuggggaga 20

<210> 6696

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6696

ccacuacuca ccgucuccug 20

<210> 6697

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6697

gccacuacuc accgucuccu 20

<210> 6698

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6698

cgccacuacu caccgucucc 20

<210> 6699

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6699

ugcccgucuc ugucuccuca 20

<210> 6700

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6700

gggcgcaccu uccccaagcg 20

<210> 6701

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6701

ggucuggccg cgcuugggga 20

<210> 6702

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6702

cgcaggucug gccgcgcuug 20

<210> 6703

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6703

acgcaggucu ggccgcgcuu 20

<210> 6704

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6704

cacgcagguc uggccgcgcu 20

<210> 6705

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6705

caagcgcggc cagaccugcg 20

<210> 6706

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6706

uguagugcac cacgcagguc 20

<210> 6707

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6707

accgguguag ugcaccacgc 20

<210> 6708

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6708

ccgcugggcc ccgacucac 20

<210> 6709

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6709

uuacagucgu cuuuuucaca 20

<210> 6710

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6710

uucacagga ugcuugaaga 20

<210> 6711

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6711

gaaagaaauu ugauuccucc 20

<210> 6712

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6712

aaagaaauuu gauuccuccc 20

<210> 6713

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6713

gggcuuguuu cugucccggg 20

<210> 6714

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6714

aaagggcuug uuucuguccc 20

<210> 6715

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6715

uaaagggcuu guuucugucc 20

<210> 6716

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6716

aagcccuuua aguuuaugcu 20

<210> 6717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6717

uugccuagca uaaacuuaaa 20

<210> 6718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6718

cuugccuagc auaaacuuaa 20

<210> 6719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6719

uaaguuuaug cuaggcaagc 20

<210> 6720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6720

guuuaugcua ggcaagcagg 20

<210> 6721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6721

ggcaagcagg aggugauccg 20

<210> 6722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6722

agcaggaggu gauccgaggc 20

<210> 6723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6723

gcaggaggug auccgaggcu 20

<210> 6724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6724

gugauccgag gcugggaaga 20

<210> 6725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6725

ugauccgagg cugggagaa 20

<210> 6726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6726

gauccgaggc ugggaagaag 20

<210> 6727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6727

caaccccuuc uucccagccu 20

<210> 6728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6728

acaaugaga gagcauaccu 20

<210> 6729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6729

aacaaugag agagcauacc 20

<210> 6730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6730

guucuuuuca cagaugagug 20

<210> 6731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6731

uucuuuucac agaugagugu 20

<210> 6732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6732

aucuggagau auagucaguu 20

<210> 6733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6733

auaucuccag auuaugccua 20

<210> 6734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6734

guggcaccaau aggcauaauc 20

<210> 6735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6735

gauuaugccu aggugccac 20

<210> 6736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6736

auuaugccua uggugccacu 20

<210> 6737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6737

gugggccca guggcaccau 20

<210> 6738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6738

uugggcca cugggcaccc 20

<210> 6739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6739

gaugaugccu gggugcccag 20

<210> 6740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6740

cauguggugg gaugaugccu 20

<210> 6741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6741

gcauggggggaugaugcc 20

<210> 6742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6742

agacgagagu ggcauguggu 20

<210> 6743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6743

aagacgagag uggcaugugg 20

<210> 6744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6744

ucgaagacga gaguggcaug 20

<210> 6745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6745

ugccacucuc gucuucgaug 20

<210> 6746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6746

cuccacaucg aagacgagag 20

<210> 6747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6747

cgauguggag cuucuaaaac 20

<210> 6748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6748

gcuucuaaaa cuggaaugac 20

<210> 6749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 6749

uaaaacugga augacaggaa 20

<210> 6750

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6750

gugaugaggc ugugugcuuc ugagc 25

<210> 6751

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6751

ugaugaggcu gugugcuucu gagcu 25

<210> 6752

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6752

gugugcuucu gagcugggca uccga 25

<210> 6753

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6753

ugagcugggc auccgaaggc auccu 25

<210> 6754

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6754

gagcuggca uccgaaggca uccuu 25

<210> 6755

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6755

agcugggcau ccgaaggcau ccuug 25

<210> 6756

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6756

uccgaaggca uccuugggga agcug 25

<210> 6757

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6757

ccgaaggcau ccuuggggaa gcuga 25

<210> 6758

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6758

cauccuuggg gaagcugagg gcacg 25

<210> 6759

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6759

ccuuggggaa gcuggggca cgagg 25

<210> 6760

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6760

cuuggggaag cuggggcac gagga 25

<210> 6761

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6761

uuggggaagc ugagggcacg aggag 25

<210> 6762

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6762

ggcacgagga ggggcugcca gacuc 25

<210> 6763

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6763

gcacgaggag gggcugccag acucc 25

<210> 6764

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6764

cugccagacu cggggagcug cugcc 25

<210> 6765

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6765

cagacuccgg gagcugcugc cuggc 25

<210> 6766

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6766

agacuccgggg agcugcugcc uggcu 25

<210> 6767

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6767

ugggauuccu acacaaugcg uugcc 25

<210> 6768

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6768

ugcguugccu ggcuccacgc ccugc 25

<210> 6769

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6769

gcguugccug gcuccacgcc cugcu 25

<210> 6770

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6770

cuggguccua ccugucatag cccca 25

<210> 6771

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6771

uaccugucag agccccaagg uaaaa 25

<210> 6772

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6772

ugucagagcc ccaagguaaa aaggc 25

<210> 6773

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6773

gucagagccc caagguaaaa aggcc 25

<210> 6774

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6774

ggaguaguga uaccagucac caguu 25

<210> 6775

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6775

cggaguugug auaccaguca ccagu 25

<210> 6776

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6776

cccucagcuu ccccaaggau gccuu 25

<210> 6777

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6777

ccuccucgug cccucagcuu cccca 25

<210> 6778

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6778

cagccaggca gcagcucccg gaguc 25

<210> 6779

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6779

ggaaucccag ccaggcagca gcucc 25

<210> 6780

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6780

aacgcauuguguaggaaucc cagcc 25

<210> 6781

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6781

cguggagcca ggcaacgcau ugugu 25

<210> 6782

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6782

guaggaccca gcagggcgug gagcc 25

<210> 6783

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6783

cugacaggua ggacccagca gggcg 25

<210> 6784

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6784

gggcucugac agguaggacc cagca 25

<210> 6785

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6785

ggggcucuga cagguaggac ccagc 25

<210> 6786

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6786

uuuuuaccuu ggggcucuga caggu 25

<210> 6787

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6787

ggccuuuuua ccuuggggcu cugac 25

<210> 6788

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6788

ccaggcagcu cacagugugc cacca 25

<210> 6789

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6789

agcucacagu gugccaccau ggagu 25

<210> 6790

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6790

gcucacagug ugccaccaug gaguu 25

<210> 6791

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6791

cucacagugu gccaccaugg aguug 25

<210> 6792

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6792

ccaccaugga guuggggcc cuaga 25

<210> 6793

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6793

ccauggaguu ggggccccua gaagg 25

<210> 6794

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6794

uuggggcccc uagaaggugg cuacc 25

<210> 6795

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6795

ugccucuacc acuucuauga ccaga 25

<210> 6796

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6796

uaccacuucu augaccagau ggacc 25

<210> 6797

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6797

acuucuauga ccagauggac cuggc 25

<210> 6798

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6798

gagaagaaga gauugagcuc uacuc 25

<210> 6799

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6799

aagaagagau ugagcucuac ucagg 25

<210> 6800

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6800

agaagagauu gagcucuacu caggu 25

<210> 6801

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6801

cuacucaggu gggcccuccu cccuc 25

<210> 6802

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6802

guggcacacu gugagcugcc uggga 25

<210> 6803

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6803

gguggcacac ugugagcugc cuggg 25

<210> 6804

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6804

caugguggca cacugugagc ugccu 25

<210> 6805

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6805

ccauggggc acacugugag cugcc 25

<210> 6806

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6806

ccuucuaggg gccccaacuc caugg 25

<210> 6807

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6807

ccaccuucua ggggccccaa cucca 25

<210> 6808

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6808

gaagcuccag guagccaccu ucuag 25

<210> 6809

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6809

agaagcucca gguagccacc uucua 25

<210> 6810

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6810

aagaagcucc agguagccac cuucu 25

<210> 6811

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6811

gucagcaucg cuguuaagaa gcucc 25

<210> 6812

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6812

gucauagaag ugguagaggc acagg 25

<210> 6813

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6813

ggucauagaa gugguagagg cacag 25

<210> 6814

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6814

uggucauaga agugguagag gcaca 25

<210> 6815

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6815

cuggucauag aagugguaga ggcac 25

<210> 6816

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6816

guccaucugg ucauagaagu gguag 25

<210> 6817

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6817

agccaggucc aucuggucau agaag 25

<210> 6818

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6818

cucuucuucu ccagccaggu ccauc 25

<210> 6819

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6819

gagcucaauc ucuucuucuc cagcc 25

<210> 6820

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6820

caccaucaac ugcgaccagu ucagc 25

<210> 6821

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6821

caguucagca ggcuguugug ugaca 25

<210> 6822

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6822

ucagcaggcu guugugugac augga 25

<210> 6823

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6823

ugacauggaa ggugaugaag agacc 25

<210> 6824

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6824

gacauggaag gugaugaaga gacca 25

<210> 6825

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6825

auggaaggug augaagagac caggg 25

<210> 6826

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6826

agaccaggga ggcuuaugcc aauau 25

<210> 6827

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6827

agggaggcuu augccaauau cggug 25

<210> 6828

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6828

gaugggugucu gugucggguu cuggg 25

<210> 6829

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6829

guugaggug ucugugucgg guucu 25

<210> 6830

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6830

aguugauggu gucugugucg gguuc 25

<210> 6831

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6831

ggucgcaguu gaugggugucu guguc 25

<210> 6832

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6832

uggucgcagu ugauggguc uggugu 25

<210> 6833

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6833

agccugcuga acuggucgca guuga 25

<210> 6834

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6834

caugucacac aacagccugc ugaac 25

<210> 6835

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6835

ucaccgauau uggcauaagc cuccc 25

<210> 6836

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6836

ggcucaggug cuuccucacc gauau 25

<210> 6837

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6837

cuuuuccuug ucugggcagc ggaac 25

<210> 6838

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6838

gcggaacugg accaguaugu cuucc 25

<210> 6839

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6839

caguaugucu uccaggacuc ccagc 25

<210> 6840

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6840

uaugucuucc aggacuccca gcugg 25

<210> 6841

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6841

augucuucca ggacucccag cugga 25

<210> 6842

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6842

gacucccagc uggagggccu gagca 25

<210> 6843

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6843

agcaaggaca uuuucaguaa guuug 25

<210> 6844

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6844

aaggacauuu ucaguaaguu ugugg 25

<210> 6845

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6845

aggacauuuu caguaaguuu guggu 25

<210> 6846

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6846

acauuuucag uaaguuugug guggg 25

<210> 6847

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6847

cauuuucagu aaguuugugg ugggu 25

<210> 6848

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6848

cugguccagu uccgcugccc agaca 25

<210> 6849

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6849

cagcugggag uccuggaaga cauac 25

<210> 6850

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6850

gcucaggccc uccagcuggg agucc 25

<210> 6851

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6851

auguccuugc ucaggccuc cagcu 25

<210> 6852

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6852

aauguccuug cucaggcccu ccagc 25

<210> 6853

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6853

aaacuuacug aaaauguccu ugcuc 25

<210> 6854

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6854

ugguuuuucu caaaaguagag cacau 25

<210> 6855

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6855

agcacauagg accagaugaa gugau 25

<210> 6856

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6856

ccagaugaag ugaucgguga gagua 25

<210> 6857

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6857

agaguugga gaugccagca gaagu 25

<210> 6858

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6858

gaguauggag augccagcag aaguu 25

<210> 6859

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6859

ccauacucuc accgaucacu ucauc 25

<210> 6860

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6860

ucugacuuuu cugcccaacu ucugc 25

<210> 6861

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6861

cauguuuucu cugcagccuu cccag 25

<210> 6862

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6862

ucugcagccu uccgagga gcuuc 25

<210> 6863

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6863

ggagcuuccg gcagaccuga agcac 25

<210> 6864

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6864

cggcagaccu gaagcacugg aagcc 25

<210> 6865

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6865

cugaagcacu ggaagccagg ugugc 25

<210> 6866

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6866

ugaagcacug gaagccaggu gugca 25

<210> 6867

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6867

gcacuggaag ccaggugugc agggc 25

<210> 6868

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6868

cuggaagcca ggugugcagg gcagg 25

<210> 6869

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6869

uggaagccag gugugcaggg caggu 25

<210> 6870

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6870

aggucugccg gaagcuccuc uggga 25

<210> 6871

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6871

cuucaggucu gccggaagcu ccucu 25

<210> 6872

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6872

gcuucagguc ugcgggaagc uccuc 25

<210> 6873

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6873

cuggcuucca gugcuucagg ucugc 25

<210> 6874

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6874

cugcacaccu ggcuuccagu gcuuc 25

<210> 6875

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6875

uuccucacag cugagcccc cacug 25

<210> 6876

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6876

cagcugagcc ccccacugug gugac 25

<210> 6877

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6877

acuggguga cuggcagucu ccuag 25

<210> 6878

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6878

cugggugac uggcagucuc cuagu 25

<210> 6879

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6879

cugccacugc cugcgcuguu caacc 25

<210> 6880

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6880

cgcuguucaa ccaggagcca gccuc 25

<210> 6881

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6881

gagccagccu ccggccagau gcgcc 25

<210> 6882

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6882

aaaccgacca gauucccagu auguu 25

<210> 6883

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6883

aaccgaccag auucccagua uguua 25

<210> 6884

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6884

accgaccaga uucccaguau guuag 25

<210> 6885

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6885

ccgaccagau ucccaguaug uuagg 25

<210> 6886

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6886

cagauuccca guauguuagg gggcu 25

<210> 6887

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6887

guggggggcu cagcugugag gaagu 25

<210> 6888

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6888

aguggggggc ucagcuguga ggaag 25

<210> 6889

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6889

caccacagug gggggcucag cugug 25

<210> 6890

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6890

gggacugcc agucaccaca guggg 25

<210> 6891

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6891

aggagacugc cagucaccac agugg 25

<210> 6892

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6892

uuggagacug ccagucacca cagug 25

<210> 6893

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6893

cuaggagacu gccagucacc acagu 25

<210> 6894

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6894

acuggagac ugccagucac cacag 25

<210> 6895

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6895

ggagcagucg cucacugguc ccacu 25

<210> 6896

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6896

agggcagggu ggagcagucg cucac 25

<210> 6897

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6897

gcaggcagg gcaggcaggg caggg 25

<210> 6898

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6898

agcgcaggca guggcaggca gggca 25

<210> 6899

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6899

cagcgcaggc aguggcaggc agggc 25

<210> 6900

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6900

ugaacagcgc aggcaguggc aggca 25

<210> 6901

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6901

uugaacagcg caggcagugg caggc 25

<210> 6902

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6902

cugguugaac agcgcaggca guggc 25

<210> 6903

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6903

gcuccugguu gaacagcgca ggcag 25

<210> 6904

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6904

aggcuggcuc cugguugaac agcgc 25

<210> 6905

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6905

gcgcaucugg cgggaggcug gcucc 25

<210> 6906

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6906

ucuccaggcg caucuggccg gaggc 25

<210> 6907

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6907

guuuucucca ggcgcaucug gccgg 25

<210> 6908

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6908

ucgguuuucu ccaggcgcau cuggc 25

<210> 6909

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6909

cuggucgguu uucuccaggc gcauc 25

<210> 6910

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6910

acugggaauc uggucgguuu ucucc 25

<210> 6911

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6911

cccccuaaca uacugggaau cuggu 25

<210> 6912

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6912

caagcccccu aacauacugg gaauc 25

<210> 6913

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6913

ucguugagcu gccugaaucu cccug 25

<210> 6914

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6914

cguugagcug ccugaaucuc ccuga 25

<210> 6915

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6915

uccccaccau cuccacucug cccca 25

<210> 6916

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6916

ccccaccauc uccacucugc cccau 25

<210> 6917

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6917

caucuccacu cugccccaug ggcuc 25

<210> 6918

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6918

ccccaugggc ucuggcaaau cucug 25

<210> 6919

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6919

augggcucug gcaaaucucugaggc 25

<210> 6920

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6920

ucuggcaaau cucugaggcu ggaac 25

<210> 6921

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6921

cuggcaaauc ucugaggcug gaaca 25

<210> 6922

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6922

uggcaaaucu cugaggcugg aacag 25

<210> 6923

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6923

gggucuccag uauauucauc uacca 25

<210> 6924

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6924

guauauucau cuaccauggu gagug 25

<210> 6925

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6925

uauauucauc uaccauggug agugc 25

<210> 6926

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6926

auauucaucu accaugguga gugcg 25

<210> 6927

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6927

caucuaccau ggugagugcg gggcc 25

<210> 6928

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6928

uggagaaagg cacugcaaga gacaa 25

<210> 6929

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6929

ggcagcucaa cgaggaacug gagaa 25

<210> 6930

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6930

agauucaggc agcucaacga ggaac 25

<210> 6931

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6931

ucagggagau ucaggcagcu caacg 25

<210> 6932

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6932

cuggagggu cccucaggga gauuc 25

<210> 6933

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6933

ggggacaaac uggauggguc ccuca 25

<210> 6934

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6934

ugggacaaa cuggaugggu cccuc 25

<210> 6935

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6935

uggagauggu ggggacaac uggau 25

<210> 6936

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6936

guggagaugg uggggacaaa cugga 25

<210> 6937

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6937

cagaguggag augguggga caaac 25

<210> 6938

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6938

cccauggggc agguggaga uggug 25

<210> 6939

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6939

gcccaugggg cagaguggag auggu 25

<210> 6940

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6940

agcccauggg gcagagugga gaugg 25

<210> 6941

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6941

cagagcccau ggggcagagu ggaga 25

<210> 6942

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6942

auuugccaga gcccaugggg cagag 25

<210> 6943

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6943

ccucagagau uugccagagc ccaug 25

<210> 6944

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6944

gccucagaga uuugccagag cccau 25

<210> 6945

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6945

agccucagag auuugccaga gccca 25

<210> 6946

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6946

cacucaccau gguagaugaa uauac 25

<210> 6947

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6947

acccccaaug uaggugaggu gcccc 25

<210> 6948

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6948

aggccagcca aguacccccu cccag 25

<210> 6949

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6949

ccccucccag uggauucacu gucca 25

<210> 6950

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6950

ccacggccuc ccaacauucuc cagac 25

<210> 6951

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6951

gccucccaac aucuccagac cggcc 25

<210> 6952

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6952

cccugaccuc ccgagcaaac augac 25

<210> 6953

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6953

accucccgag caaacaugac aggua 25

<210> 6954

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6954

gcaaacauga cagguaagga cccuu 25

<210> 6955

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6955

caaacaugac agguaaggac ccuua 25

<210> 6956

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6956

uggggcaccu caccuacauu ggggg 25

<210> 6957

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6957

gccuggggca ccucaccuac auugg 25

<210> 6958

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6958

ggccggggc accucaccua cauug 25

<210> 6959

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6959

uggccgggg caccucaccu acauu 25

<210> 6960

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6960

cuggcgggg gcaccucacc uacau 25

<210> 6961

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6961

ugggagggggg uacuuggcug gccug 25

<210> 6962

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6962

cugggagggg guacuuggcu ggccu 25

<210> 6963

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6963

acugggaggg gguacuuggc uggcc 25

<210> 6964

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6964

aauccacugg gaggggguac uuggc 25

<210> 6965

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6965

agugaaucca cugggagggg guacu 25

<210> 6966

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6966

cguggacagu gaauccacug ggagg 25

<210> 6967

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6967

ccguggacag ugaauccacu gggag 25

<210> 6968

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6968

gccguggaca gugaauccac uggga 25

<210> 6969

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6969

ggccguggac agugaaucca cuggg 25

<210> 6970

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6970

ggaggccgug gacagugaau ccacu 25

<210> 6971

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6971

gggaggccgu ggacagugaa uccac 25

<210> 6972

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6972

ccggucggga gauguuggga ggccg 25

<210> 6973

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6973

gccuggccgg ucggagaug uuggg 25

<210> 6974

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6974

ggagccuggc cggucuggag auguu 25

<210> 6975

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6975

uggagccugg ccggucuggga gaugu 25

<210> 6976

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6976

aggggcuggu ggagccuggc cgguc 25

<210> 6977

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6977

agcgaagggg cugguggagc cuggc 25

<210> 6978

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6978

aggagcgaa ggggcuggug gagcc 25

<210> 6979

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6979

cuggcugaug gagcgaaggg gcugg 25

<210> 6980

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6980

agguggcug aggagcgaa ggggc 25

<210> 6981

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6981

guccagucug gcugauggag cgaag 25

<210> 6982

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6982

cguccagucu ggcugaugga gcgaa 25

<210> 6983

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6983

ccguccaguc uggcugaugg agcga 25

<210> 6984

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6984

cguacgaccc guccagucug gcuga 25

<210> 6985

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6985

ccaaguccgu acgacccguc caguc 25

<210> 6986

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6986

ggguccuuac cugucauguu ugcuc 25

<210> 6987

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6987

aggguccuua ccugucaugu uugcu 25

<210> 6988

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6988

cacaagacgu ccccccca augcc 25

<210> 6989

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6989

cgcccccc ccaaugcccg gcagc 25

<210> 6990

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6990

cccacccaau gcccggcagc uggag 25

<210> 6991

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6991

agaggucucc aacaagcuuc caaaa 25

<210> 6992

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6992

ucuccaacaa gcuuccaaaa uggcc 25

<210> 6993

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6993

uuccaaaaug gccggugag ugaug 25

<210> 6994

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6994

uccaaaaugg ccggugagu gaugc 25

<210> 6995

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6995

ucuugugcuc uggagaugga gaagc 25

<210> 6996

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6996

uggggacgu cuugugcucu ggaga 25

<210> 6997

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6997

auuggguggg ggacgucuug ugcuc 25

<210> 6998

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6998

ucuccagcug ccggggcauug ggugg 25

<210> 6999

<211> 25

<212> RNA

<213> Homo sapiens

<400> 6999

cucuccagcu gccgggcauu gggug 25

<210> 7000

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7000

ccucuccagc ugccggggcau ugggu 25

<210> 7001

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7001

accucuccag cugccggggca uuggg 25

<210> 7002

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7002

gagaccucuc cagcugccgg gcauu 25

<210> 7003

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7003

ggagaccucu ccagcugccg ggcau 25

<210> 7004

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7004

cuuguuggag accucuccag cugcc 25

<210> 7005

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7005

gcuuguugga gaccucucca gcugc 25

<210> 7006

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7006

ucaccaggcc auuuuggaag cuugu 25

<210> 7007

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7007

ucccgcauca cucaccaggc cauuu 25

<210> 7008

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7008

acgccccugg ccuuugcaga gccgg 25

<210> 7009

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7009

guggagcagu ucuaccgcuc acugc 25

<210> 7010

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7010

ucuaccgcuc acugcaggac acgua 25

<210> 7011

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7011

aggacacgua uggugccgag cccgc 25

<210> 7012

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7012

acguauggug ccgagcccgc aggcc 25

<210> 7013

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7013

auggugccga gcccgcaggc cggga 25

<210> 7014

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7014

agccuggagc gggaacuggc caccc 25

<210> 7015

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7015

ggagcgggaa cuggccaccc cggac 25

<210> 7016

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7016

gagcgggaac uggccacccc ggacu 25

<210> 7017

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7017

acuggccacc ccggacugg cagaa 25

<210> 7018

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7018

accccggacu gggcagaacg gcagc 25

<210> 7019

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7019

acggggcaga acggcagcug gccca 25

<210> 7020

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7020

gggcagaacg gcagcuggcc caagg 25

<210> 7021

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7021

gaacggcagc uggcccaagg aggcc 25

<210> 7022

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7022

cagcuggcc aaggaggccu ggcug 25

<210> 7023

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7023

caaggaggcc uggcugaggu gcugu 25

<210> 7024

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7024

cuggcugagg ugcuguuggc ugcca 25

<210> 7025

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7025

ggugcuguug gcugccaagg agcac 25

<210> 7026

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7026

gcuguuggcu gccaaggagc accgg 25

<210> 7027

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7027

cgugagacac gagugauugc ugugc 25

<210> 7028

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7028

gugagacacg agugauugcu gugcu 25

<210> 7029

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7029

gagugauugc ugugcugggc aaagc 25

<210> 7030

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7030

auugcugugc uggcaaagc ugguc 25

<210> 7031

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7031

uugcugugcu gggcaaagcu gguca 25

<210> 7032

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7032

caaagcuggu cagggcaaga gcuau 25

<210> 7033

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7033

aaagcugguc agggcaagag cuauu 25

<210> 7034

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7034

cuggucaggg caagagcuau ugggc 25

<210> 7035

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7035

uggucagggc aagagcuauu gggcu 25

<210> 7036

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7036

ggucagggca agagcuauug ggcug 25

<210> 7037

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7037

gagcuauugg gcuggggcag ugagc 25

<210> 7038

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7038

agcuauuggg cuggggcagu gagcc 25

<210> 7039

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7039

uugggcuggg gcagugagcc gggcc 25

<210> 7040

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7040

ugggcugggg cagugagccg ggccu 25

<210> 7041

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7041

gggcagugag ccggggccugg gcuug 25

<210> 7042

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7042

agugagccgg gccugggcuu guggc 25

<210> 7043

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7043

guccccugcc auugcuugaa ccguc 25

<210> 7044

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7044

ucccugcca uugcuugaac cgucc 25

<210> 7045

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7045

ccccugccau ugcuugaacc guccg 25

<210> 7046

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7046

cccugccauu gcuugaaccg uccgg 25

<210> 7047

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7047

gcuugaaccg uccgggggau gccua 25

<210> 7048

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7048

cguccggggg augccuaugg ccugc 25

<210> 7049

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7049

ggccugcagg aucugcucuu cuccc 25

<210> 7050

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7050

gccugcagga ucugcucuuc ucccu 25

<210> 7051

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7051

uucucccugg gcccacagcc acucg 25

<210> 7052

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7052

ucccugggcc cacagccacu cgugg 25

<210> 7053

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7053

ccacagccac ucguggcggc cgaug 25

<210> 7054

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7054

cugaccgcgu ucugcucauc cuaga 25

<210> 7055

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7055

guucugcuca uccuagacgg cuucg 25

<210> 7056

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7056

cucauccuag acggcuucga ggagc 25

<210> 7057

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7057

gcuucgagga gcuggaagcg caaga 25

<210> 7058

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7058

aagauggcuu ccugcacagc acgug 25

<210> 7059

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7059

ggcuuccugc acagcacgug cggac 25

<210> 7060

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7060

cugcacagca cgugcggacc ggcac 25

<210> 7061

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7061

cacagcacgu gcggaccggc accgg 25

<210> 7062

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7062

ggcaccggcg gagcccugcu cccuc 25

<210> 7063

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7063

gcaccggcgg agccugcuc ccucc 25

<210> 7064

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7064

caccggcgga gcccugcucc cuccg 25

<210> 7065

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7065

accggcggag ccgcuccc uccgg 25

<210> 7066

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7066

gagcccugcu cccuccgggg gcugc 25

<210> 7067

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7067

ccugcucccu ccgggggcug cuggc 25

<210> 7068

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7068

gccuuuucca gaagaagcug cuccg 25

<210> 7069

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7069

agguugcacc cuccuccuca cagcc 25

<210> 7070

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7070

cacccuccuc cucacagccc ggccc 25

<210> 7071

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7071

acccuccucc ucacagcccg gcccc 25

<210> 7072

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7072

cccucccu cacagcccgg cccg 25

<210> 7073

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7073

cucacagccc ggccccgggg ccgcc 25

<210> 7074

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7074

ggccgccugg uccagagccu gagca 25

<210> 7075

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7075

aggccgacgc ccuauuugag cuguc 25

<210> 7076

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7076

cuauuugagc uguccggcuu cucca 25

<210> 7077

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7077

gagcuguccg gcuucuccau ggagc 25

<210> 7078

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7078

uccggcuucu ccauggagca ggccc 25

<210> 7079

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7079

acgugaugcg cuacuuugag agcuc 25

<210> 7080

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7080

cgugaugcgc uacuuugaga gcuca 25

<210> 7081

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7081

ccaagacaga gcccugacgc uccuc 25

<210> 7082

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7082

caagacagag cccugacgcu ccucc 25

<210> 7083

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7083

cagagcccug acgcuccucc gggac 25

<210> 7084

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7084

ucacagccac agcccuacuu ugugc 25

<210> 7085

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7085

cacagccaca gcccuacuuu gugcc 25

<210> 7086

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7086

ugccgggcag ugugccagcu cucag 25

<210> 7087

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7087

gugugccagc ucucagaggc ccugc 25

<210> 7088

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7088

agcucucaga ggccugcug gagcu 25

<210> 7089

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7089

gcucucagag gcccugcugg agcuu 25

<210> 7090

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7090

cucucagagg cccugcugga gcuug 25

<210> 7091

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7091

ucagaggccc ugcuggagcu ugggg 25

<210> 7092

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7092

gacgccaagc ugcccuccac gcuca 25

<210> 7093

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7093

acgccaagcu gcccuccacg cucac 25

<210> 7094

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7094

ccuccacgcu cacgggacuc uaugu 25

<210> 7095

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7095

cucacgggac ucuaugucgg ccugc 25

<210> 7096

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7096

ucacgggacu cuaugucggc cugcu 25

<210> 7097

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7097

gccgugcagc ccucgacagc ccccc 25

<210> 7098

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7098

ccgugcagcc cucgacagcc ccccc 25

<210> 7099

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7099

cgugcagccc ucgacagccc cccg 25

<210> 7100

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7100

gcccucgaca gccccccgg ggccc 25

<210> 7101

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7101

agccccccggggcccggc agagc 25

<210> 7102

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7102

ggggcgggg cagagcuggc caagc 25

<210> 7103

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7103

ccuggcagag cuggccaagc uggcc 25

<210> 7104

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7104

cuggcagagc uggccaagcu ggccu 25

<210> 7105

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7105

gagcuggcca agcuggccug ggagc 25

<210> 7106

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7106

agcuggccaa gcuggccugg gagcu 25

<210> 7107

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7107

ggccgcagac aucaaaguac ccuac 25

<210> 7108

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7108

cgcagacauc aaaguacccu acagg 25

<210> 7109

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7109

ggaccaguuc ccauccgcag acgug 25

<210> 7110

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7110

guucccaucc gcagacguga ggacc 25

<210> 7111

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7111

uucccauccg cagacgugag gaccu 25

<210> 7112

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7112

uccgcagacg ugaggaccug ggcga 25

<210> 7113

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7113

acgugaggac cugggcgaug gccaa 25

<210> 7114

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7114

caaaggcuua guccaacacc caccg 25

<210> 7115

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7115

aaaggcuuag uccaacaccc accgc 25

<210> 7116

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7116

ccaccgcggg ccgcagaguc cgagc 25

<210> 7117

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7117

cccagcuucc uccugcaaug cuucc 25

<210> 7118

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7118

ccagcuuccu ccugcaaugc uuccu 25

<210> 7119

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7119

cagcuuccuc cugcaaugcu uccug 25

<210> 7120

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7120

agcuuccucc ugcaaugcuu ccugg 25

<210> 7121

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7121

ccugcaaugc uuccugggggg cccug 25

<210> 7122

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7122

caaugcuucc uggggggcccu guggc 25

<210> 7123

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7123

uggggcccu guggcuggcu cugag 25

<210> 7124

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7124

uggcuggcuc ugagguggcga aauca 25

<210> 7125

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7125

gcucugagug gcgaaaucaa ggaca 25

<210> 7126

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7126

cccgcaguac cuagcauuga cccca 25

<210> 7127

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7127

ccuagcauug accccaagga agaag 25

<210> 7128

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7128

aaggaagaag aggcccuaug acaac 25

<210> 7129

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7129

aagaagaggc ccuaugacaa cuggc 25

<210> 7130

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7130

aagaggcccu augacaacug gcugg 25

<210> 7131

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7131

agaggcccua ugacaacugg cugga 25

<210> 7132

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7132

uggcuggagg gcgugccacg cuuuc 25

<210> 7133

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7133

uggagggcgu gccacgcuuu cuggc 25

<210> 7134

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7134

ggagggcgug ccacgcuuuc uggcu 25

<210> 7135

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7135

aucuuccagc cucccgcccg cugcc 25

<210> 7136

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7136

uccuuccagcc ucccgcccgc ugccu 25

<210> 7137

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7137

ccgcccgcug ccugggagcc cuacu 25

<210> 7138

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7138

cgcccgcugc cugggagccc uacuc 25

<210> 7139

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7139

ugccugggag cccuacucgg gccau 25

<210> 7140

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7140

cugggagccc uacucggggcc aucgg 25

<210> 7141

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7141

cuacucgggc caucggcggc ugccu 25

<210> 7142

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7142

cucgggccau cggcggcugc cucgg 25

<210> 7143

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7143

gccaucggcg gcugccucgg uggac 25

<210> 7144

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7144

gcugccucgg uggacaggaa gcaga 25

<210> 7145

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7145

ggacaggaag cagaaggugc uugcg 25

<210> 7146

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7146

gaaggugcuu gcgagguacc ugaag 25

<210> 7147

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7147

gcgagguacc ugaagcggcu gcagc 25

<210> 7148

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7148

cgagguaccu gaagcggcug cagcc 25

<210> 7149

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7149

gagguaccug aagcggcugc agccg 25

<210> 7150

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7150

gaagcggcug cagccggggga cacug 25

<210> 7151

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7151

aagcggcugc agccggggac acugc 25

<210> 7152

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7152

gcugcagccg gggacacugc gggcg 25

<210> 7153

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7153

gggacacugc gggcgcggca gcugc 25

<210> 7154

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7154

cuggagcugc ugcacugcgc ccacg 25

<210> 7155

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7155

cugcugcacu gcgccccga ggccg 25

<210> 7156

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7156

cugcacugcg cccacgaggc cgagg 25

<210> 7157

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7157

acugcgccca cgaggccgag gaggc 25

<210> 7158

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7158

ccacgaggcc gaggaggcug gaauu 25

<210> 7159

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7159

gaggaggcug gaauuuggca gcacg 25

<210> 7160

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7160

gcuggaauuu ggcagcacgu gguac 25

<210> 7161

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7161

ggcagcacgu gguacaggag cuccc 25

<210> 7162

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7162

gagcuccccg gccgccucuc uuuuc 25

<210> 7163

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7163

agcuccccgg ccgccucucu uuucu 25

<210> 7164

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7164

cucacgccuc cugaugcaca uguac 25

<210> 7165

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7165

ucacgccucc ugaugcacau guacu 25

<210> 7166

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7166

ccuccugaug cacauguacu gggca 25

<210> 7167

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7167

gaugcacaug uacugggcaa ggccu 25

<210> 7168

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7168

gcacauguac ugggcaaggc cuugg 25

<210> 7169

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7169

cauguacugg gcaaggccuu ggagg 25

<210> 7170

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7170

guacugggca aggccuugga ggcgg 25

<210> 7171

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7171

uacugggcaa ggccuuggag gcggc 25

<210> 7172

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7172

gaggcggcgg gccaagacuu cuccc 25

<210> 7173

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7173

acuucucccu ggaccuccgc agcac 25

<210> 7174

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7174

uccgcagcac uggcauuugc cccuc 25

<210> 7175

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7175

agcacuggca uuugccccuc uggau 25

<210> 7176

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7176

gcacuggcau uugccccucu ggauu 25

<210> 7177

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7177

cacuggcauu ugccccucug gauug 25

<210> 7178

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7178

ugccccucug gauggggag cccg 25

<210> 7179

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7179

gccccucugg auggggagc cucgu 25

<210> 7180

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7180

gggacucagc ugugucaccc guuuc 25

<210> 7181

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7181

acucagcugu gucacccguu ucagg 25

<210> 7182

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7182

cucagcugug ucacccguuu caggu 25

<210> 7183

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7183

ucagcugugu cacccguuuc aggug 25

<210> 7184

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7184

ugugucaccc guuucaggug gggug 25

<210> 7185

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7185

gugucacccg uuucaggugg gguga 25

<210> 7186

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7186

ugucacccgu uucaggggg gugag 25

<210> 7187

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7187

cccguuucag guggggugag gggcu 25

<210> 7188

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7188

ccguuucagg uggggugagg ggcuu 25

<210> 7189

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7189

cguuucaggu ggggugaggg gcuug 25

<210> 7190

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7190

gcuccaccgg cucugcaaag gccag 25

<210> 7191

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7191

ugcuccaccg gcucugcaaa ggcca 25

<210> 7192

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7192

cugcuccacc ggcucugcaa aggcc 25

<210> 7193

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7193

uagaacugcu ccaccggcuc ugcaa 25

<210> 7194

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7194

gcagugagcg guagaacugc uccac 25

<210> 7195

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7195

ggcaccauac guguccugca gugag 25

<210> 7196

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7196

aggaugccau ccgggccugc gggcu 25

<210> 7197

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7197

ggucuaggau gccauccggg ccugc 25

<210> 7198

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7198

aggucuagga ugccauccgg gccug 25

<210> 7199

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7199

uagguggagg ucuagggaugc caucc 25

<210> 7200

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7200

cuagguggag gucuaggaug ccauc 25

<210> 7201

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7201

ccggacgugg ucuaggugga ggucu 25

<210> 7202

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7202

agcugccguu cugcccaguc cgggg 25

<210> 7203

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7203

gccagcugcc guucugccca gccg 25

<210> 7204

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7204

ggccagcugc cguucugcc agucc 25

<210> 7205

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7205

gggccagcug ccguucugcc caguc 25

<210> 7206

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7206

aacagcaccu cagccaggcc uccuu 25

<210> 7207

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7207

caacagcacc ucagccaggc cuccu 25

<210> 7208

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7208

cuuggcagcc aacagcaccu cagcc 25

<210> 7209

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7209

gucucacgcg gccgccggug cuccu 25

<210> 7210

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7210

aaucacucgu gucucacgcg gccgc 25

<210> 7211

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7211

gcacagcaau cacucguguc ucacg 25

<210> 7212

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7212

gggaagccgg ccacaagccc aggcc 25

<210> 7213

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7213

uacuggggaa gccggccaca agccc 25

<210> 7214

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7214

gaagacaaag ucguacuggg gaagc 25

<210> 7215

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7215

ggacagagaa gacaaagucg uacug 25

<210> 7216

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7216

gggacagaga agacaaaguc guacu 25

<210> 7217

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7217

ggggacagag aagacaaagu cguac 25

<210> 7218

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7218

ccccggacgg uucaagcaau ggcag 25

<210> 7219

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7219

cccccggacg guucaagcaa uggca 25

<210> 7220

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7220

ucccccggac gguucaagca auggc 25

<210> 7221

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7221

ggcauccccc ggacgguuca agcaa 25

<210> 7222

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7222

cugcaggcca uaggcauccc cggga 25

<210> 7223

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7223

gauccucag gccauaggca ucccc 25

<210> 7224

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7224

gagaagagca gauccugcag gccau 25

<210> 7225

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7225

gcccagggag aagagcagau ccugc 25

<210> 7226

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7226

gccgccacga guggcugugg gccca 25

<210> 7227

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7227

ggccgccacg aguggcugug ggccc 25

<210> 7228

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7228

cucaucggcc gccacgagug gcugu 25

<210> 7229

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7229

ccucaucggc cgccacgagu ggcug 25

<210> 7230

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7230

ugaaaaccuc aucggccgcc acgag 25

<210> 7231

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7231

uucaagaugu ggcugaaaac cucau 25

<210> 7232

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7232

aacgcgguca ggucucuuca agaug 25

<210> 7233

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7233

cgucuaggau gagcagaacg cgguc 25

<210> 7234

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7234

gaagccgucu aggaugagca gaacg 25

<210> 7235

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7235

cgcuuccagc uccucgaagc cgucu 25

<210> 7236

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7236

cggugccggu ccgcacgugc ugugc 25

<210> 7237

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7237

ggagggagca ggcuccgcc ggugc 25

<210> 7238

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7238

gccccgggggggagcagggc uccgc 25

<210> 7239

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7239

cggccagcag cccccgggagg gagca 25

<210> 7240

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7240

ccggccagca gcccccggag ggagc 25

<210> 7241

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7241

aaaaggccgg cggcagccc cggga 25

<210> 7242

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7242

gaaaaggccg gccagcagcc cccgg 25

<210> 7243

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7243

cuggaaaagg ccggccagca gcccc 25

<210> 7244

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7244

cggagcagcu ucuucuggaa aaggc 25

<210> 7245

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7245

accucggagc agcuucuucu ggaaa 25

<210> 7246

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7246

ggugcaaccu cggagcagcu ucuuc 25

<210> 7247

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7247

ggcugugagg aggagggugc aaccu 25

<210> 7248

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7248

ccccggggcc gggcugugag gagga 25

<210> 7249

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7249

gccccggggc cgggcuguga ggagg 25

<210> 7250

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7250

gcggccccgg ggccggggcug ugagg 25

<210> 7251

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7251

caggcggcc cggggccggg cugug 25

<210> 7252

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7252

cucuggacca ggcggccccg ggcc 25

<210> 7253

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7253

gcucuggacc aggcggcccc ggggc 25

<210> 7254

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7254

ucaggcucug gaccaggcgg ccccg 25

<210> 7255

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7255

cucaggcucu ggaccaggcg gcccc 25

<210> 7256

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7256

gcucaggcuc uggaccaggc ggccc 25

<210> 7257

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7257

ggccuugcuc aggcucugga ccagg 25

<210> 7258

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7258

gucggccuug cucaggcucu ggacc 25

<210> 7259

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7259

uagggcgucg gccuugcuca ggcuc 25

<210> 7260

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7260

cucaaauagg gcgucggccu ugcuc 25

<210> 7261

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7261

aagccggaca gcucaaauag ggcgu 25

<210> 7262

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7262

auggagaagc cggacagcuc aaaua 25

<210> 7263

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7263

cauggagaag ccggacagcu caaau 25

<210> 7264

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7264

gccugggccu gcuccaugga gaagc 25

<210> 7265

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7265

aucacguaug ccugggccug cucca 25

<210> 7266

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7266

ucaaaguagc gcaucacgua ugccu 25

<210> 7267

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7267

cucaaaguag cgcaucacgu augcc 25

<210> 7268

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7268

ccggagggc gucaggggcuc ugucu 25

<210> 7269

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7269

aguggccggu ccgggaggag cguca 25

<210> 7270

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7270

aaguggccgg ucccggagga gcguc 25

<210> 7271

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7271

acugagaaga aguggccggu cccgg 25

<210> 7272

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7272

gugacugaga agaaguggcc ggucc 25

<210> 7273

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7273

guggcuguga cugagaagaa guggc 25

<210> 7274

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7274

ggcugggcu gugacugaga agaag 25

<210> 7275

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7275

cacugcccgg cacaaaguag ggcug 25

<210> 7276

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7276

cuggcacacu gcccggcaca aagua 25

<210> 7277

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7277

gcuggcacac ugcccggcac aaagu 25

<210> 7278

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7278

ggccucugag agcuggcaca cugcc 25

<210> 7279

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7279

aagcuccagc agggccucug agagc 25

<210> 7280

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7280

uuggcguccu ccccaagcuc cagca 25

<210> 7281

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7281

cuuggcgucc ucccaagcu ccagc 25

<210> 7282

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7282

agucccguga gcguggaggg cagcu 25

<210> 7283

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7283

cgacauagag ucccgugagc gugga 25

<210> 7284

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7284

ccgacauaga guccigugag cgugg 25

<210> 7285

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7285

aggccgacau aggucccgu gagcg 25

<210> 7286

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7286

gcugucgagg gcugcacggc ccagc 25

<210> 7287

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7287

cccgggggggg cugucgagg cugca 25

<210> 7288

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7288

gccagggccc cggggggcu gucga 25

<210> 7289

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7289

ugccagggcc ccgggggggc ugucg 25

<210> 7290

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7290

ggccagcucu gccagggccc cgggg 25

<210> 7291

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7291

uggccagcuc ugccagggcc ccggg 25

<210> 7292

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7292

uuggccagcu cugccagggc cccgg 25

<210> 7293

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7293

cuuggccagc ucugccaggg ccccg 25

<210> 7294

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7294

gcuuggccag cucugccagg gcccc 25

<210> 7295

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7295

agcuuggcca gcucugccag ggccc 25

<210> 7296

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7296

caggccagcu uggccagcuc ugcca 25

<210> 7297

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7297

ccaggccagc uuggccagcu cugcc 25

<210> 7298

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7298

cugcggccca gcucccaggc cagcu 25

<210> 7299

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7299

cuuugauguc ugcggcccag cuccc 25

<210> 7300

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7300

cuccuguagg guacuuugau gucug 25

<210> 7301

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7301

gcggauggga acugguccuc cugua 25

<210> 7302

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7302

ugcggauggg aacugguccu ccugu 25

<210> 7303

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7303

gguccucacg ucugcggaug ggaac 25

<210> 7304

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7304

cgcccagguc cucacgucug cggau 25

<210> 7305

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7305

ucgcccaggu ccucacgucu gcgga 25

<210> 7306

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7306

gccaucgccc agguccucac gucug 25

<210> 7307

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7307

uggacuaagc cuuuggccaau cgcc 25

<210> 7308

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7308

cgcgggggu guuggacuaa gccuu 25

<210> 7309

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7309

ggacucugcg gcccgcggug ggugu 25

<210> 7310

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7310

cagcucggac ucugcggccc gcggu 25

<210> 7311

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7311

ccagcucgga cucugcggcc cgcgg 25

<210> 7312

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7312

aggccagcuc ggacucugcg gcccg 25

<210> 7313

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7313

cuggggaagg cagcucgga cucug 25

<210> 7314

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7314

aggaggaagc uggggaaggc cagcu 25

<210> 7315

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7315

aagcauugca ggaggaagcu gggga 25

<210> 7316

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7316

caggaagcau ugcaggagga agcug 25

<210> 7317

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7317

cggaagca uugcaggagg aagcu 25

<210> 7318

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7318

ccggaagc auugcaggag gaagc 25

<210> 7319

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7319

cagggcccc aggaagcauu gcagg 25

<210> 7320

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7320

ccacaggggcc ccggaagc auugc 25

<210> 7321

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7321

acucagagcc agccacaggcccccc 25

<210> 7322

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7322

auuucgccac ucagagccag ccaca 25

<210> 7323

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7323

gauuucgcca cucagagcca gccac 25

<210> 7324

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7324

ccuugggguc aaugcuaggu acugc 25

<210> 7325

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7325

uccuuggggu caaugcuagg uacug 25

<210> 7326

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7326

ccucuucuuc cuugggguca augcu 25

<210> 7327

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7327

uugucauagg gccucuucuu ccuug 25

<210> 7328

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7328

guugucauag ggccucuucu uccuu 25

<210> 7329

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7329

aguugucaua gggccucuuc uuccu 25

<210> 7330

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7330

gcacgcccuc cagccaguug ucaua 25

<210> 7331

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7331

ggcacgcccu ccagccaguu gucau 25

<210> 7332

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7332

ggaagaucag cccagccaga aagcg 25

<210> 7333

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7333

ggcucccagg cagcggggcgg gaggc 25

<210> 7334

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7334

guagggcucc caggcagcgg gcggg 25

<210> 7335

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7335

cgaguagggc ucccaggcag cgggc 25

<210> 7336

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7336

ccgaguaggg cucccaggca gcggg 25

<210> 7337

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7337

ggcccgagua gggcucccag gcagc 25

<210> 7338

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7338

uggcccgagu agggcuccca ggcag 25

<210> 7339

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7339

cgccgauggc ccgaguaggg cuccc 25

<210> 7340

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7340

gaggcagccg ccgauggccc gagua 25

<210> 7341

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7341

cgaggcagcc gccgauggcc cgagu 25

<210> 7342

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7342

uccuguccac cgaggcagcc gccga 25

<210> 7343

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7343

agcaccuucu gcuuccuguc caccg 25

<210> 7344

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7344

cagugucccc ggcugcagcc gcuuc 25

<210> 7345

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7345

gcagcugccg cgcccgcagu guccc 25

<210> 7346

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7346

caaauuccag ccuccucggc cucgu 25

<210> 7347

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7347

ccaaauucca gccuccucgg cccg 25

<210> 7348

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7348

acgugcugcc aaauuccagc cuccu 25

<210> 7349

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7349

ggugcccaga aaagagaggc ggccg 25

<210> 7350

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7350

gggugcccag aaaagagagg cggcc 25

<210> 7351

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7351

cgggugccca gaaaagagag gcggc 25

<210> 7352

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7352

gaggcggggug ccagaaaag agagg 25

<210> 7353

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7353

cgugaggcgg gugcccagaa aagag 25

<210> 7354

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7354

acaugugcau caggaggcgu gaggc 25

<210> 7355

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7355

uacaugugca ucaggaggcg ugagg 25

<210> 7356

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7356

caguacaugu gcaucaggag gcgug 25

<210> 7357

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7357

ccuugcccag uacaugugca ucagg 25

<210> 7358

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7358

aggccuugcc caguacaugu gcauc 25

<210> 7359

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7359

gagaagucuu ggcccgccgc cucca 25

<210> 7360

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7360

gcugcgggagg uccagggaga agucu 25

<210> 7361

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7361

caaaugccag ugcugcggag gucca 25

<210> 7362

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7362

gcaaaugcca gugcugcggga ggucc 25

<210> 7363

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7363

agaggggcaa augccagugc ugcgg 25

<210> 7364

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7364

uccagagggg caaaugccag ugcug 25

<210> 7365

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7365

ucccgagg cuccccaauc cagag 25

<210> 7366

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7366

guccacgag gcuccccaau ccaga 25

<210> 7367

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7367

agucccacga ggcuccccaa uccag 25

<210> 7368

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7368

acgggugaca cagcugaguc ccacg 25

<210> 7369

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7369

ccaagccccu caccccaccu gaaac 25

<210> 7370

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7370

cccaagcccc ucaccccacc ugaaa 25

<210> 7371

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7371

gcugcccuuc cauuaagguc uagcc 25

<210> 7372

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7372

uaaggucuag ccuggucacc gugcc 25

<210> 7373

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7373

aaggucuagc cuggucaccg ugccu 25

<210> 7374

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7374

agccugguca ccgugccugg gucug 25

<210> 7375

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7375

ccugggucug aggcccccc uccac 25

<210> 7376

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7376

cugggucuga ggcccucccu ccaca 25

<210> 7377

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7377

cuccacaggg cugccuugag cgaca 25

<210> 7378

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7378

cacagggcug ccuugagcga cacgg 25

<210> 7379

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7379

ugccuugagc gacacggugg cgcug 25

<210> 7380

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7380

gccuugagcg acacgguggc gcugu 25

<210> 7381

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7381

cgcuggggga gucccugcag cagca 25

<210> 7382

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7382

gcugggggag ucccugcagc agcau 25

<210> 7383

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7383

cuggggagu cccugcagca gcaug 25

<210> 7384

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7384

cagcaugggg agaccaagcu acuuc 25

<210> 7385

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7385

gagaccaagc uacuucaggc agcag 25

<210> 7386

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7386

gagccuuuca aagccaaguc ccuga 25

<210> 7387

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7387

uucaagcca agucccugaa ggaug 25

<210> 7388

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7388

aagucccuga aggaugugga agacc 25

<210> 7389

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7389

agucccugaa ggauguggaa gaccu 25

<210> 7390

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7390

ccugggaaag cuugugcaga cucag 25

<210> 7391

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7391

aagcuugugc agucucagag gugag 25

<210> 7392

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7392

ugugcagacu cagaggugag aggag 25

<210> 7393

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7393

gcagacucag aggugagagg agagg 25

<210> 7394

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7394

acucagaggu gagaggagag gcgga 25

<210> 7395

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7395

gugaccaggc uagaccuuaa uggaa 25

<210> 7396

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7396

ggugaccagg cuagaccuua ugga 25

<210> 7397

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7397

gcacggugac caggcuagac cuuaa 25

<210> 7398

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7398

ggccucagac ccaggcacgg ugacc 25

<210> 7399

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7399

ggagggaggg ccucagaccc aggca 25

<210> 7400

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7400

ccuguggagg gagggccuca gaccc 25

<210> 7401

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7401

cgcucaaggc agcccugugg aggga 25

<210> 7402

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7402

ucgcucaagg cagcccugug gaggg 25

<210> 7403

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7403

gugucgcuca aggcagcccu gugga 25

<210> 7404

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7404

cgugucgcuc aaggcagccc ugugg 25

<210> 7405

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7405

caccgugucg cucaaggcag cccug 25

<210> 7406

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7406

ucccacagcg ccaccguguc gcuca 25

<210> 7407

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7407

agcuuggucu ccccaugcug cugca 25

<210> 7408

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7408

uagcuugguc ucccaugcu gcugc 25

<210> 7409

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7409

uucuccucug cugccugaag uagcu 25

<210> 7410

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7410

agggacuugg cuuugaaagg cucga 25

<210> 7411

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7411

cauccuucag ggacuuggcu uugaa 25

<210> 7412

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7412

aggucuucca cauccuucag ggacu 25

<210> 7413

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7413

uuucccaggu cuuccacauc cuuca 25

<210> 7414

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7414

cuuucccagg ucuuccacau ccuuc 25

<210> 7415

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7415

ccucugaguc ugcacaagcu uuccc 25

<210> 7416

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7416

guucucucca ggacgagaag uuccu 25

<210> 7417

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7417

cgagaaguuc cucggaagac acagc 25

<210> 7418

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7418

gagaaguucc ucggaagaca cagcu 25

<210> 7419

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7419

agaaguuccu cggaagacac agcug 25

<210> 7420

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7420

cacagcuggg gagcucccug cuguu 25

<210> 7421

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7421

acagcugggg agcucccuc uguuc 25

<210> 7422

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7422

ccugcuguuc gggaccuaaa gaaac 25

<210> 7423

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7423

aagaaacugg aguuugcgua agcaa 25

<210> 7424

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7424

agaaacugga guuugcguaa gcaaa 25

<210> 7425

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7425

gaaacuggag uuugcguaag caaag 25

<210> 7426

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7426

acuggaguuu gcguaagcaa agggg 25

<210> 7427

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7427

aggaacuucu cguccuggag agaac 25

<210> 7428

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7428

gugucuuccg aggaacuucu cgucc 25

<210> 7429

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7429

gggagcuccc cagcuguguc uuccg 25

<210> 7430

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7430

caguuucuuu aggucccgaa cagca 25

<210> 7431

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7431

ccaguuucuu uaggucccga acagc 25

<210> 7432

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7432

ugcuuacgca aacuccaguu ucuuu 25

<210> 7433

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7433

ugccuccuag gcugggcccu gucuc 25

<210> 7434

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7434

aggcugggcc cugucucagg ccccc 25

<210> 7435

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7435

ucaggcccc aggcuuuccc caaac 25

<210> 7436

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7436

cccccaggcu uuccccaaac uggug 25

<210> 7437

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7437

uuccccaaac uggugcggau ccuca 25

<210> 7438

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7438

acggccuuuu ccucccugca gcauc 25

<210> 7439

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7439

cagcaucugg agugaguaua gacuc 25

<210> 7440

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7440

agcaucuga gugaguauag acucu 25

<210> 7441

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7441

ggcccagccu aggaggcaaa gagca 25

<210> 7442

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7442

ggccugagac agggcccagc cuagg 25

<210> 7443

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7443

gggggccuga gacaggggcc agccu 25

<210> 7444

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7444

ggggaaagcc uggggggcug agaca 25

<210> 7445

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7445

ugggaaagc cuggggggccu gagac 25

<210> 7446

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7446

ccgcaccagu uuggggaaag ccugg 25

<210> 7447

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7447

uccgcaccag uuuggggaaa gccug 25

<210> 7448

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7448

auccgcacca guuuggggaa agccu 25

<210> 7449

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7449

gauccgcacc aguuugggga aagcc 25

<210> 7450

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7450

ggccgugagg auccgcacca guuug 25

<210> 7451

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7451

aggccgugag gauccgcacc aguuu 25

<210> 7452

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7452

aaggccguga ggauccgcac caguu 25

<210> 7453

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7453

augcugcagg gaggaaaagg ccgug 25

<210> 7454

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7454

cacuccagau gcugcaggga ggaaa 25

<210> 7455

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7455

uauacucacu ccagaugcug caggg 25

<210> 7456

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7456

gucuauacuc acuccagaug cugca 25

<210> 7457

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7457

agucuauacu cacuccagau gcugc 25

<210> 7458

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7458

uggaugcgcu gagugagaac aagau 25

<210> 7459

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7459

ggaugcgcug agugagaaca agauc 25

<210> 7460

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7460

gaugcgcuga gugagaacaa gaucg 25

<210> 7461

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7461

cugagugaga acaagaucgg ggacg 25

<210> 7462

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7462

ugagugagaa caagaucggg gacga 25

<210> 7463

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7463

gccaccuucc cccagcugaa guccu 25

<210> 7464

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7464

cuuggaaacc cucaagugag ugagc 25

<210> 7465

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7465

uuggaaaccc ucaagugagu gagcu 25

<210> 7466

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7466

cauccaggcu gcagguggaa ucaga 25

<210> 7467

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7467

ucacucagcg cauccaggcu gcagg 25

<210> 7468

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7468

uucucacuca gcgcauccag gcugc 25

<210> 7469

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7469

gaucuuguuc ucacucagcg caucc 25

<210> 7470

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7470

uccaaggacu ucagcugggg gaagg 25

<210> 7471

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7471

guuuccaagg acuucagcug gggga 25

<210> 7472

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7472

gaggguuucc aaggacuuca gcugg 25

<210> 7473

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7473

ugaggguuuc caaggacuuc agcug 25

<210> 7474

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7474

uugaggguuu ccaaggacuu cagcu 25

<210> 7475

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7475

cuugaggguu uccaaggacu ucagc 25

<210> 7476

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7476

cagcucacuc acuugagggu uucca 25

<210> 7477

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7477

cugucccaga acaacaucac ugacc 25

<210> 7478

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7478

ugucccagaa caacaucacu gaccu 25

<210> 7479

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7479

gaccugggug ccuacaaacu cgccg 25

<210> 7480

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7480

gccuucgcuc gcugcauccc ugcuc 25

<210> 7481

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7481

gcucgcugca ucccugcuca ggcua 25

<210> 7482

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7482

gcaucccugc ucaggcuaag gugag 25

<210> 7483

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7483

caucccugcu caggcuaagg ugagu 25

<210> 7484

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7484

aucccugcuc aggcuaaggu gagug 25

<210> 7485

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7485

gcucaggcua aggugaggugg ggccc 25

<210> 7486

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7486

gggacagacu gcggggacac aguga 25

<210> 7487

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7487

uggacagac ugcggggaca cagug 25

<210> 7488

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7488

ugauguuguu cugggacaga cugcg 25

<210> 7489

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7489

gugauguugu ucugggacag acugc 25

<210> 7490

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7490

agugauguug uucugggaca gacug 25

<210> 7491

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7491

gcacccaggu cagugauguu guucu 25

<210> 7492

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7492

ggcacccagg ucagugaugu uguuc 25

<210> 7493

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7493

ggccucggcg aguuuguagg caccc 25

<210> 7494

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7494

gaaggcaggg ccucggcgag uuugu 25

<210> 7495

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7495

gaugcagcga gcgaaggcag ggccu 25

<210> 7496

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7496

agcagggaug cagcgagcga aggca 25

<210> 7497

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7497

gagcagggau gcagcgagcg aaggc 25

<210> 7498

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7498

gccugagcag ggaugcagcg agcga 25

<210> 7499

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7499

ggccccacuc accuuagccu gagca 25

<210> 7500

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7500

gggccccacu caccuuagcc ugagc 25

<210> 7501

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7501

uuguacaaua acugcaucug cgacg 25

<210> 7502

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7502

uguacaauaa cugcaucugc gacgu 25

<210> 7503

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7503

aucugcgacg ugggagccga gagcu 25

<210> 7504

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7504

gccgagagcu uggcucgugu gcuuc 25

<210> 7505

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7505

agcuuggcuc gugugcuucc ggaca 25

<210> 7506

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7506

ugugcuuccg gacauggugu cccuc 25

<210> 7507

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7507

gugcuuccgg acauggguc ccucc 25

<210> 7508

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7508

ccggacaugg ugucccuccg gguga 25

<210> 7509

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7509

gucccuccgg gugauggagu gagug 25

<210> 7510

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7510

ucccuccgggg ugaggagug agugu 25

<210> 7511

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7511

gggugaugga gugagugugg gaguc 25

<210> 7512

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7512

ggugauggag ugaguggugg agucu 25

<210> 7513

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7513

uuauuguaca agcugucgga aacag 25

<210> 7514

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7514

cagaugcagu uauuguacaa gcugu 25

<210> 7515

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7515

uccggaagca cacgagccaa gcucu 25

<210> 7516

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7516

ccaucacccg gagggacacc auguc 25

<210> 7517

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7517

ucccacacac acuccaucac ccgga 25

<210> 7518

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7518

cucccacacu cacuccauca cccgg 25

<210> 7519

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7519

agacuccac acucacucca ucacc 25

<210> 7520

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7520

gccagcgucc aguacaacaa guuca 25

<210> 7521

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7521

uccaguacaa caaguucacg gcugc 25

<210> 7522

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7522

ccaguacaac aaguucacgg cugcc 25

<210> 7523

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7523

caguacaaca aguucacggc ugccg 25

<210> 7524

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7524

ggcccagcag cucgcugcca gccuu 25

<210> 7525

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7525

ccagcagcuc gcugccagcc uucgg 25

<210> 7526

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7526

gccagccuuc ggaggugucc ucaug 25

<210> 7527

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7527

cggagguguc cucaugugga gacgc 25

<210> 7528

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7528

cauguggaga cgcuggcgua agucc 25

<210> 7529

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7529

acgcuggcgu aaguccaggc aaccc 25

<210> 7530

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7530

gccgugaacu uguuguacug gacgc 25

<210> 7531

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7531

cccggcagcc gugaacuuguuguac 25

<210> 7532

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7532

aggcuggcag cgagcugcug ggccc 25

<210> 7533

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7533

cuccgaaggc uggcagcgag cugcu 25

<210> 7534

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7534

ccuccgaagg cuggcagcga gcugc 25

<210> 7535

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7535

uccacaugag gacaccuccg aaggc 25

<210> 7536

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7536

cgucuccaca ugaggacacc uccga 25

<210> 7537

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7537

ggacuuacgc cagcgucucc acaug 25

<210> 7538

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7538

acgcccacca ucccauucag ugucc 25

<210> 7539

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7539

aguguccagg aacaccugca acaac 25

<210> 7540

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7540

ggaacaccug caacaacagg auuca 25

<210> 7541

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7541

gccugagaug aucccagcug ugcuc 25

<210> 7542

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7542

agaugauccc agcugugcuc uggac 25

<210> 7543

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7543

gaugauccca gcugugcucu ggaca 25

<210> 7544

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7544

cagcugugcu cuggacaggg uaacc 25

<210> 7545

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7545

agcugugcuc uggacagggu aacca 25

<210> 7546

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7546

ugugcucugg acaggguaac caggg 25

<210> 7547

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7547

gugcucugga caggguaacc agggu 25

<210> 7548

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7548

cuggacaggg uaaccagggu gggcu 25

<210> 7549

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7549

uggacagggu aaccaggggug ggcuu 25

<210> 7550

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7550

gcguccacau ccugcaaggg gggau 25

<210> 7551

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7551

ggcguccaca uccugcaagg gggga 25

<210> 7552

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7552

ggugggcguc cacauccugc aaggg 25

<210> 7553

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7553

uggggggcgu ccacauccug caagg 25

<210> 7554

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7554

aggugggcg uccacauccu gcaag 25

<210> 7555

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7555

gauggggggc guccacaucc ugcaa 25

<210> 7556

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7556

ggaugggggg cguccacauc cugca 25

<210> 7557

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7557

guuccggac acugaauggg auggu 25

<210> 7558

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7558

uguuccugga cacugaaugg gaugg 25

<210> 7559

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7559

agguguuccu ggacacugaa uggga 25

<210> 7560

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7560

uugcaggugu uccuggacac ugaau 25

<210> 7561

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7561

guugcaggug uuccuggaca cugaa 25

<210> 7562

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7562

ugaauccugu uguugcaggu guucc 25

<210> 7563

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7563

gcugauccgu gaauccuguu guugc 25

<210> 7564

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7564

ucgagcac agcugggauc aucuc 25

<210> 7565

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7565

ugguuacccu guccagagca cagcu 25

<210> 7566

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7566

cugguuaccc uguccagagc acagc 25

<210> 7567

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7567

uccuccgcu acagcauguu cucug 25

<210> 7568

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7568

uguucucuga ggacacuaac cacgc 25

<210> 7569

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7569

acacuaacca cgcuggaccu ugaac 25

<210> 7570

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7570

cacuaaccac gcuggaccuu gaacu 25

<210> 7571

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7571

cgcuggaccu ugaacugggu acuug 25

<210> 7572

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7572

guacuugugg acacagcucu ucucc 25

<210> 7573

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7573

cuguauccca ugagccucag caucc 25

<210> 7574

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7574

ccaugagccu cagcauccug gcacc 25

<210> 7575

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7575

cagcauccug gcacccggcc ccuc 25

<210> 7576

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7576

ccuggcaccc ggccccugcu gguuc 25

<210> 7577

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7577

cuggcaccg gccccugcug guuca 25

<210> 7578

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7578

cacccggccc cugcugguuc agggu 25

<210> 7579

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7579

ugcugguuca ggguuggccc cugcc 25

<210> 7580

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7580

uucaggguug gccccugccc ggcug 25

<210> 7581

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7581

cacaucuugc ucugcugaca gacac 25

<210> 7582

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7582

cuugcucugc ugacagacac aggcc 25

<210> 7583

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7583

ugcugacaga cacaggcccg gcucc 25

<210> 7584

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7584

gcuccaggcu ccuuuagcgc ccagu 25

<210> 7585

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7585

cuccaggcuc cuuuagcgcc caguu 25

<210> 7586

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7586

caggcuccuu uagcgcccag uuggg 25

<210> 7587

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7587

uuuagcgcc aguugggugg augcc 25

<210> 7588

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7588

agcgcccagu uggguggaug ccugg 25

<210> 7589

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7589

uuggguggau gccugguggc agcug 25

<210> 7590

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7590

gccugguggc agcugcgguc caccc 25

<210> 7591

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7591

agcugcgguc cacccaggag ccccg 25

<210> 7592

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7592

ccaggagccc cgaggccuuc ucuga 25

<210> 7593

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7593

ccgaggccuu cucugaagga cauug 25

<210> 7594

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7594

cucugaagga cauugcggac agcca 25

<210> 7595

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7595

aaggacauug cggacagcca cggcc 25

<210> 7596

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7596

uugcggacag ccacggccag gccag 25

<210> 7597

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7597

ugcggacagc cacggccagg ccaga 25

<210> 7598

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7598

acggccaggc cagagggagu gacag 25

<210> 7599

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7599

agaggcagcc ccauucugcc ugccc 25

<210> 7600

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7600

cugccugccc aggccccugc caccc 25

<210> 7601

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7601

ugccugccca ggccccugcc acccu 25

<210> 7602

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7602

gccugcccag gccccugcca cccug 25

<210> 7603

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7603

cugcucuccg accagacacc uugac 25

<210> 7604

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7604

ugcucuccga ccagacaccu ugaca 25

<210> 7605

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7605

gaccagacac cuugacaggg cacac 25

<210> 7606

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7606

accagacacc uugacagggc accacc 25

<210> 7607

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7607

acaccgggca cucagaagac acuga 25

<210> 7608

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7608

caccgggcac ucagaagaca cugau 25

<210> 7609

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7609

gccugcuaau uccccagauu gcaac 25

<210> 7610

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7610

gcuaauuccc cagauugcaa caggc 25

<210> 7611

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7611

cuaauucccc agauugcaac aggcu 25

<210> 7612

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7612

cagauugcaa caggcugggc uucag 25

<210> 7613

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7613

cuucaguggc agcugcuuuu gucua 25

<210> 7614

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7614

uucaguggca gcugcuuuug ucuau 25

<210> 7615

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7615

augggacuca augcacugac auugu 25

<210> 7616

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7616

gacauuguug gccaaagcca aagcu 25

<210> 7617

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7617

uguuggccaa agccaaagcu aggcc 25

<210> 7618

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7618

cuggccagau gcaccagccc uuagc 25

<210> 7619

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7619

uggccagaug caccagcccu uagca 25

<210> 7620

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7620

cagcccuuag cagggaaaca gcuaa 25

<210> 7621

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7621

agcccuuagc agggaaacag cuaau 25

<210> 7622

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7622

agggaaacag cuaaugggac acuaa 25

<210> 7623

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7623

gggaaacagc uaaugggaca cuaau 25

<210> 7624

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7624

ggaaacagcu aaugggacac uaaug 25

<210> 7625

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7625

aacagcuaau gggacacuaa ugggg 25

<210> 7626

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7626

aaugggacac uaauggggcg gugag 25

<210> 7627

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7627

augggacacu aauggggcgg ugaga 25

<210> 7628

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7628

uggacacua auggggcggu gagag 25

<210> 7629

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7629

auggggcggu gagaggggaa cagac 25

<210> 7630

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7630

auuauaaaug ucucuuuaau gucac 25

<210> 7631

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7631

uuuaauguca caggc 25

<210> 7632

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7632

ucucuuuaau gucacaggca ggucc 25

<210> 7633

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7633

cucuuuaaug ucacaggcag gucca 25

<210> 7634

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7634

uugaguucau acccuguuac cauuu 25

<210> 7635

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7635

ugaguucaua cccuguuacc auuuu 25

<210> 7636

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7636

gaguucauac ccuguuacca uuuug 25

<210> 7637

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7637

agaacaugcu guagcgggag gagcc 25

<210> 7638

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7638

uccucagaga acaugcugua gcggg 25

<210> 7639

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7639

guguccucag agaacaugcu guagc 25

<210> 7640

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7640

aguguccuca gagaacaugc uguag 25

<210> 7641

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7641

caaguaccca guucaagguc cagcg 25

<210> 7642

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7642

gcugugucca caaguaccca guuca 25

<210> 7643

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7643

augcugaggc ucaugggaua cagcc 25

<210> 7644

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7644

cgggugccag gaugcugagg cucau 25

<210> 7645

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7645

ccggggcca ggaugcugag gcuca 25

<210> 7646

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7646

gcaggggccg ggugccagga ugcug 25

<210> 7647

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7647

ccugaaccag caggggccgg gugcc 25

<210> 7648

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7648

ggccaacccu gaaccagcag gggcc 25

<210> 7649

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7649

gggccaaccc ugaaccagca ggggc 25

<210> 7650

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7650

gcaggggcca acccugaacc agcag 25

<210> 7651

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7651

ggcaggggcc aacccugaac cagca 25

<210> 7652

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7652

gggcaggggc caacccugaa ccagc 25

<210> 7653

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7653

ugugguucau uccgcagccg ggcag 25

<210> 7654

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7654

augugguuca uuccgcagcc gggca 25

<210> 7655

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7655

gaugugguuc auuccgcagc cgggc 25

<210> 7656

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7656

gcaagaugug guucauuccg cagcc 25

<210> 7657

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7657

agcaagaugu gguucauucc gcagc 25

<210> 7658

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7658

cugugucugu cagcagagca agaug 25

<210> 7659

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7659

cugggcgcua aaggagccug gagcc 25

<210> 7660

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7660

acugggcgcu aaaggagccu ggagc 25

<210> 7661

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7661

cacccaacug ggcgcuaaag gagcc 25

<210> 7662

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7662

aggcauccac ccaacugggc gcuaa 25

<210> 7663

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7663

gcugccacca ggcauccacc caacu 25

<210> 7664

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7664

agcugccacc agcuuccac ccaac 25

<210> 7665

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7665

uccgggugg accgcagcug ccacc 25

<210> 7666

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7666

cagagaaggc cucggggcuc cuggg 25

<210> 7667

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7667

cuucagagaa ggccucgggg cuccu 25

<210> 7668

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7668

ccuucagaga aggccucgggg gcucc 25

<210> 7669

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7669

gcaauguccu ucagagaagg ccucg 25

<210> 7670

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7670

cgcaaugucc uucagagaag gccuc 25

<210> 7671

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7671

ccgcaauguc cuucagagaa ggccu 25

<210> 7672

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7672

ggcuguccgc aauguccuuc agaga 25

<210> 7673

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7673

ucugucacuc ccucuggccu ggccg 25

<210> 7674

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7674

gcugccucug ucacucccuc uggcc 25

<210> 7675

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7675

aggggcugc cucugucacu cccuc 25

<210> 7676

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7676

ggcaggggcc ugggcaggca gaaug 25

<210> 7677

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7677

uggcaggggc cugggcaggc agaau 25

<210> 7678

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7678

guggcagggg ccugggcagg cagaa 25

<210> 7679

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7679

ucccagggu ggcaggggcc ugggc 25

<210> 7680

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7680

uuucucccca ggguggcagg ggccu 25

<210> 7681

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7681

cuuucucccc aggguggcag gggcc 25

<210> 7682

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7682

uuguacuuuc uccccagggu ggcag 25

<210> 7683

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7683

cuuguacuuu cucccgggg uggca 25

<210> 7684

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7684

ucuuguacuu ucuccccagg guggc 25

<210> 7685

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7685

uuuuucuugu acuuucuccc caggg 25

<210> 7686

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7686

uuuuuuuucu uguacuuucu cccca 25

<210> 7687

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7687

uuuuuuuuuc uuguacuuuuc uccc 25

<210> 7688

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7688

caaggugucu ggucggagag caggg 25

<210> 7689

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7689

ugucaaggug ucuggucgga gagca 25

<210> 7690

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7690

cugucaaggu gucuggucgg agagc 25

<210> 7691

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7691

ggugugcccu gucaaggugu cuggu 25

<210> 7692

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7692

gccggugug cccugucaag guguc 25

<210> 7693

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7693

ucugagugcc cggugugccc uguca 25

<210> 7694

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7694

ugcccaucag ugucuucuga gugcc 25

<210> 7695

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7695

gcaaucuggg gaauuagcag gcugg 25

<210> 7696

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7696

ugcaaucugg ggaauuagca ggcug 25

<210> 7697

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7697

uugcaaucug gggaauuagc aggcu 25

<210> 7698

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7698

guugcaaucu ggggaauuag caggc 25

<210> 7699

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7699

gccuguugca aucuggggaa uuagc 25

<210> 7700

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7700

cugaagccca gccuguugca aucug 25

<210> 7701

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7701

acugaagccc agccuguugc aaucu 25

<210> 7702

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7702

cacugaagcc cagccuguug caauc 25

<210> 7703

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7703

aucuggccag gccuagcuuu ggcuu 25

<210> 7704

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7704

uggugcaucu ggccaggccu agcuu 25

<210> 7705

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7705

cugcuaaggg cuggugcauc uggcc 25

<210> 7706

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7706

uuucccugcu aagggcuggu gcauc 25

<210> 7707

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7707

cauuagcugu uucccugcua agggc 25

<210> 7708

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7708

guccauuag cuguuucccu gcuaa 25

<210> 7709

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7709

ugucccauua gcuguuuccc ugcua 25

<210> 7710

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7710

uuuauaaugu agugaaaaaa gacac 25

<210> 7711

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7711

gguaacaggg uaugaacuca aaccc 25

<210> 7712

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7712

guggggguac cccaaaaugg uaaca 25

<210> 7713

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7713

cguggggua ccccaaaaug guaac 25

<210> 7714

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7714

uuggucucgu guggguaccc caaaa 25

<210> 7715

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7715

aauguauaau cuauuggucu cgugu 25

<210> 7716

<211> 25

<212> RNA

<213> Homo sapiens

<400> 7716

caauguauaa ucuauugguc ucgug 25

<210> 7717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7717

ggcauccuug gggaagcuga 20

<210> 7718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7718

ucgugcccuc agcuucccca 20

<210> 7719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7719

uuggggaagc ugagggcacg 20

<210> 7720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7720

gggaagcuga gggcacgagg 20

<210> 7721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7721

ggaagcugag ggcacgagga 20

<210> 7722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7722

gaagcugagg gcacgaggag 20

<210> 7723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7723

gaggaggggc ugccagacuc 20

<210> 7724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7724

aggaggggcu gccagacucc 20

<210> 7725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7725

aggcagcagc ucccggaguc 20

<210> 7726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7726

agcuccgggg agcugcugcc 20

<210> 7727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7727

uccgggagcu gcugccuggc 20

<210> 7728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7728

cggggagcug cugccuggcu 20

<210> 7729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7729

cccagccagg cagcagcucc 20

<210> 7730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7730

auuguguagg aauccagcc 20

<210> 7731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7731

uuccuacaca augcguugcc 20

<210> 7732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7732

agccaggcaa cgcauugugugu 20

<210> 7733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7733

ugccuggcuc cacgcccugc 20

<210> 7734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7734

gccuggcucc acgcccugcu 20

<210> 7735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7735

acccagcagg gcguggagcc 20

<210> 7736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7736

agguaggacc cagcaggggcg 20

<210> 7737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7737

cugacaggua ggacccagca 20

<210> 7738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7738

ucugacaggu aggacccagc 20

<210> 7739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7739

cagcucacag ugugccacca 20

<210> 7740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7740

acagugugcc accauggagu 20

<210> 7741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7741

cagugugcca ccauggaguu 20

<210> 7742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7742

agugugccac cauggaguug 20

<210> 7743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7743

uaggggcccc aacuccaugg 20

<210> 7744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7744

uucuaggggc cccaacucca 20

<210> 7745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7745

auggaguugg ggccccuaga 20

<210> 7746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7746

gaguuggggc cccuagaagg 20

<210> 7747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7747

gccccuagaa gguggcuacc 20

<210> 7748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7748

uccagguagc caccuucuag 20

<210> 7749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7749

cuccagguag ccaccuucua 20

<210> 7750

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7750

gcuccaggua gccaccuucu 20

<210> 7751

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7751

caucgcuguu aagaagcucc 20

<210> 7752

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7752

agaaguggua gaggcacagg 20

<210> 7753

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7753

uagaaguggu agaggcacag 20

<210> 7754

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7754

auagaagugg uagaggcaca 20

<210> 7755

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7755

cauagaagug guagaggcac 20

<210> 7756

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7756

ucuggucaua gaagugguag 20

<210> 7757

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7757

cuaccacuuc uaugaccaga 20

<210> 7758

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7758

gguccaucug gucauagaag 20

<210> 7759

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7759

cuucuaugac cagauggacc 20

<210> 7760

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7760

uaugaccaga uggaccuggc 20

<210> 7761

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7761

cuucuccagc cagguccauc 20

<210> 7762

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7762

caaucucuuc uucuccagcc 20

<210> 7763

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7763

caguugaugg ugucuguguc 20

<210> 7764

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7764

gcaguugauggugucugugugu 20

<210> 7765

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7765

gcugaacugg ucgcaguuga 20

<210> 7766

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7766

ucaacugcga ccaguucagc 20

<210> 7767

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7767

cacacaacag ccugcugaac 20

<210> 7768

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7768

cagcaggcug uugugugaca 20

<210> 7769

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7769

aggcuguugugugacaugga 20

<210> 7770

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7770

uggaagguga ugaagagacc 20

<210> 7771

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7771

ggaaggugau gaagagacca 20

<210> 7772

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7772

aggugaugaa gagaccaggg 20

<210> 7773

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7773

gauauuggca uaagccuccc 20

<210> 7774

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7774

aggugcuucc ucaccgauau 20

<210> 7775

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7775

acuggaccag uaugucuucc 20

<210> 7776

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7776

gggaguccug gaagacauac 20

<210> 7777

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7777

ugucuuccag gacucccagc 20

<210> 7778

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7778

cuuccaggac ucccagcugg 20

<210> 7779

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7779

uuccaggacu cccagcugga 20

<210> 7780

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7780

ggcccuccag cugggagucc 20

<210> 7781

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7781

cuugcucagg cccuccagcu 20

<210> 7782

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7782

ccuugcucag gcccuccagc 20

<210> 7783

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7783

ccagcuggag ggccugagca 20

<210> 7784

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7784

uacugaaaau guccuugcuc 20

<210> 7785

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7785

auaggaccag augaagugau 20

<210> 7786

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7786

cucucaccga ucacuucauc 20

<210> 7787

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7787

ugaagugauc ggugagagua 20

<210> 7788

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7788

aggagaugc cagcagaagu 20

<210> 7789

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7789

uggagaugcc agcagaaguu 20

<210> 7790

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7790

cuuuucugcc caacuucugc 20

<210> 7791

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7791

ugcgggaagc uccuggga 20

<210> 7792

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7792

ggucugccgg aagcuccucu 20

<210> 7793

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7793

aggucugccggaagcuccuc 20

<210> 7794

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7794

uuccggcaga ccugaagcac 20

<210> 7795

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7795

uuccagugcu ucaggucugc 20

<210> 7796

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7796

gagcccccca cuguggugac 20

<210> 7797

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7797

cugccaguca ccacaguggg 20

<210> 7798

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7798

accacagugg 20

<210> 7799

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7799

gacugccagu caccacagug 20

<210> 7800

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7800

agacugccag ucaccacagu 20

<210> 7801

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7801

gagacugcca gucaccacag 20

<210> 7802

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7802

ggugacuggc agucuccuag 20

<210> 7803

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7803

gugacuggca gucucuagu 20

<210> 7804

<211> 20

<212> RNA

<213> Homo sapiens

<400> 7804

agucgcucac uggucccacu 20

<210> 7805

<400> 7805

000

<210> 7806

<211> 16

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7806

guuuuagagc uaugcu 16

<210> 7807

<211> 90

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7807

guuuaagagc uaugcuggaa acagcauagc aaguuuaaau aaggcuaguc cguuaucaac 60

uugaaaaagu ggcaccgagu cggugcuuuu 90

<210> 7808

<211> 67

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7808

agcauagcaa guuaaaauaa ggcuaguccg uuaucaacuu gaaaaagugg caccgagucg 60

67

<210> 7809

<211> 85

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7809

guuggaacca uucaaaacag cauagcaagu uaaaauaagg cuaguccguu aucaacuuga 60

aaaaguggca ccgagucggu gcuuu 85

<210> 7810

<211> 7

<212> Protein

<213> Tobacco etch virus

<400> 7810

Glu Asn Leu Tyr Phe Gln Gly

fifteen

<210> 7811

<211> 80

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7811

guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60

ggcaccgagu cggugcuuuu 80

<210> 7812

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7812

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr

20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro Phe Asp Ile Trp Gly

100 105 110

Gly Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro

130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg

145 150 155 160

Ala Ser Gln Ser Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Phe Ser Leu Gln Ser

180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

195 200 205

Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys

210 215 220

Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 7813

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7813

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr

20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro Phe Asp Ile Trp Gly

100 105 110

Gly Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro

130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg

145 150 155 160

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser

180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

195 200 205

Leu Thr Val Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys

210 215 220

Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu

225 230 235 240

Glu Ile Lys

<210> 7814

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7814

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Gly Tyr

20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Gly Leu Arg Ser Asp Asp Pro Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro Phe Asp Ile Trp Gly

100 105 110

Gly Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro

130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg

145 150 155 160

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser

180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

195 200 205

Leu Thr Val Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys

210 215 220

Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val

225 230 235 240

Glu Ile Lys

<210> 7815

<211> 245

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7815

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Ser Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

20 25 30

Tyr Met His Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro Phe Asp Ile Trp Gly

100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln

130 135 140

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr

145 150 155 160

Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln

165 170 175

Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu

180 185 190

Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp

195 200 205

Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr

210 215 220

Tyr Cys Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly Gly Gly Thr

225 230 235 240

Lys Val Glu Ile Lys

245

<210> 7816

<211> 487

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7816

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser

85 90 95

Ile Ser Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro

115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly

130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln

145 150 155 160

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val

165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp

180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala

195 200 205

Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser

210 215 220

Gly Thr Asp Phe Thr Leu Thr Val Asn Ser Leu Gln Pro Glu Asp Phe

225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly

245 250 255

Gly Gly Thr Arg Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro

260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro

275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys

305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly

325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val

340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu

355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370 375 380

Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn

385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg

405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly

420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu

435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu

450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His

465 470 475 480

Met Gln Ala Leu Pro Pro Arg

485

<210> 7817

<211> 487

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7817

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Ile Phe Thr Gly Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser

85 90 95

Ile Ser Thr Ala Tyr Met Glu Leu Ser Gly Leu Arg Ser Asp Asp Pro

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro

115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly

130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln

145 150 155 160

Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val

165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp

180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala

195 200 205

Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser

210 215 220

Gly Thr Asp Phe Thr Leu Thr Val Asn Ser Leu Gln Pro Glu Asp Phe

225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly

245 250 255

Gly Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro

260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro

275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys

305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly

325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val

340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu

355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370 375 380

Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn

385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg

405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly

420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu

435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu

450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His

465 470 475 480

Met Gln Ala Leu Pro Pro Arg

485

<210> 7818

<211> 336

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7818

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Ser Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Thr Phe Thr Asp Tyr Tyr Met His Trp Leu Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser

85 90 95

Ile Ser Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro

115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp

145 150 155 160

Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp

165 170 175

Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu

180 185 190

Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr

195 200 205

Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser

210 215 220

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu

225 230 235 240

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Val Pro Leu Thr

245 250 255

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro

260 265 270

Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu

275 280 285

Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg

290 295 300

Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly

305 310 315 320

Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys

325 330 335

<210> 7819

<211> 487

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7819

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser

85 90 95

Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Met Asn Ile Leu Ala Thr Val Pro

115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly

130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln

145 150 155 160

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val

165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Tyr Leu Asn Trp

180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala

195 200 205

Phe Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser

210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe

225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Val Pro Leu Thr Phe Gly

245 250 255

Gly Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro

260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro

275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys

305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly

325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val

340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu

355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370 375 380

Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn

385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg

405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly

420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu

435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu

450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His

465 470 475 480

Met Gln Ala Leu Pro Pro Arg

485

<210> 7820

<211> 67

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7820

aacagcauag caaguuaaaa uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag 60

ucggugc 67

<210> 7821

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7821

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7822

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7822

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Leu Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Glu Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7823

<211> 1399

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7823

Met Gly Ser Ser His His His His His His His His Glu Asn Leu Tyr

1 5 10 15

Phe Gln Gly Ser Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly

20 25 30

Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro

35 40 45

Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys

50 55 60

Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu

65 70 75 80

Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys

85 90 95

Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys

100 105 110

Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu

115 120 125

Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp

130 135 140

Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys

145 150 155 160

Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu

165 170 175

Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly

180 185 190

Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu

195 200 205

Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser

210 215 220

Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg

225 230 235 240

Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly

245 250 255

Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe

260 265 270

Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys

275 280 285

Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp

290 295 300

Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile

305 310 315 320

Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro

325 330 335

Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu

340 345 350

Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys

355 360 365

Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp

370 375 380

Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu

385 390 395 400

Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu

405 410 415

Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His

420 425 430

Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp

435 440 445

Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu

450 455 460

Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser

465 470 475 480

Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp

485 490 495

Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile

500 505 510

Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu

515 520 525

Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu

530 535 540

Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu

545 550 555 560

Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn

565 570 575

Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile

580 585 590

Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn

595 600 605

Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys

610 615 620

Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val

625 630 635 640

Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu

645 650 655

Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys

660 665 670

Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn

675 680 685

Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys

690 695 700

Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp

705 710 715 720

Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln

725 730 735

Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala

740 745 750

Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val

755 760 765

Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala

770 775 780

Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg

785 790 795 800

Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu

805 810 815

Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr

820 825 830

Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu

835 840 845

Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln

850 855 860

Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser

865 870 875 880

Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val

885 890 895

Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile

900 905 910

Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu

915 920 925

Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr

930 935 940

Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn

945 950 955 960

Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile

965 970 975

Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe

980 985 990

Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr

995 1000 1005

Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys

1010 1015 1020

Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val

1025 1030 1035

Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr

1040 1045 1050

Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr

1055 1060 1065

Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile

1070 1075 1080

Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg

1085 1090 1095

Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn

1100 1105 1110

Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu

1115 1120 1125

Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys

1130 1135 1140

Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr

1145 1150 1155

Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys

1160 1165 1170

Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile

1175 1180 1185

Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu

1190 1195 1200

Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu

1205 1210 1215

Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met

1220 1225 1230

Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu

1235 1240 1245

Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu

1250 1255 1260

Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe

1265 1270 1275

Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile

1280 1285 1290

Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp

1295 1300 1305

Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg

1310 1315 1320

Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu

1325 1330 1335

Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg

1340 1345 1350

Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile

1355 1360 1365

His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser

1370 1375 1380

Gln Leu Gly Gly Asp Gly Gly Gly Ser Pro Lys Lys Lys Arg Lys

1385 1390 1395

Val

<210> 7824

<211> 1396

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7824

Met Ala His His His His His His Gly Gly Ser Pro Lys Lys Lys Arg

1 5 10 15

Lys Val Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser

20 25 30

Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys

35 40 45

Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu

50 55 60

Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg

65 70 75 80

Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile

85 90 95

Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp

100 105 110

Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys

115 120 125

Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala

130 135 140

Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val

145 150 155 160

Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala

165 170 175

His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn

180 185 190

Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr

195 200 205

Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp

210 215 220

Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu

225 230 235 240

Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly

245 250 255

Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn

260 265 270

Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr

275 280 285

Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala

290 295 300

Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser

305 310 315 320

Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala

325 330 335

Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu

340 345 350

Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe

355 360 365

Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala

370 375 380

Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met

385 390 395 400

Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu

405 410 415

Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His

420 425 430

Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro

435 440 445

Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg

450 455 460

Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala

465 470 475 480

Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu

485 490 495

Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met

500 505 510

Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His

515 520 525

Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val

530 535 540

Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu

545 550 555 560

Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val

565 570 575

Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe

580 585 590

Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu

595 600 605

Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu

610 615 620

Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu

625 630 635 640

Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr

645 650 655

Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg

660 665 670

Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg

675 680 685

Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly

690 695 700

Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr

705 710 715 720

Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser

725 730 735

Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys

740 745 750

Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met

755 760 765

Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn

770 775 780

Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg

785 790 795 800

Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His

805 810 815

Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr

820 825 830

Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn

835 840 845

Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu

850 855 860

Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn

865 870 875 880

Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met

885 890 895

Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg

900 905 910

Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu

915 920 925

Asp Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile

930 935 940

Thr Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr

945 950 955 960

Asp Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys

965 970 975

Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val

980 985 990

Arg Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala

995 1000 1005

Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser

1010 1015 1020

Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met

1025 1030 1035

Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr

1040 1045 1050

Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr

1055 1060 1065

Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn

1070 1075 1080

Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala

1085 1090 1095

Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys

1100 1105 1110

Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu

1115 1120 1125

Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp

1130 1135 1140

Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr

1145 1150 1155

Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys

1160 1165 1170

Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg

1175 1180 1185

Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly

1190 1195 1200

Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr

1205 1210 1215

Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser

1220 1225 1230

Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys

1235 1240 1245

Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys

1250 1255 1260

Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln

1265 1270 1275

His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe

1280 1285 1290

Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu

1295 1300 1305

Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala

1310 1315 1320

Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro

1325 1330 1335

Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr

1340 1345 1350

Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser

1355 1360 1365

Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly

1370 1375 1380

Gly Asp Ser Arg Ala Asp Pro Lys Lys Lys Arg Lys Val

1385 1390 1395

<210> 7825

<211> 1386

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7825

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp His His His

1370 1375 1380

His His His

1385

<210> 7826

<211> 1389

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7826

Met Ala His His His His His His Gly Gly Ser Asp Lys Lys Tyr Ser

1 5 10 15

Ile Gly Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr

20 25 30

Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr

35 40 45

Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp

50 55 60

Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg

65 70 75 80

Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe

85 90 95

Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu

100 105 110

Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile

115 120 125

Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr

130 135 140

Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp

145 150 155 160

Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly

165 170 175

His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp

180 185 190

Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu

195 200 205

Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala

210 215 220

Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro

225 230 235 240

Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu

245 250 255

Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala

260 265 270

Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu

275 280 285

Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys

290 295 300

Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr

305 310 315 320

Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp

325 330 335

Glu His His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln

340 345 350

Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly

355 360 365

Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys

370 375 380

Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu

385 390 395 400

Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp

405 410 415

Asn Gly Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile

420 425 430

Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu

435 440 445

Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro

450 455 460

Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu

465 470 475 480

Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala

485 490 495

Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu

500 505 510

Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe

515 520 525

Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met

530 535 540

Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp

545 550 555 560

Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu

565 570 575

Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly

580 585 590

Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu

595 600 605

Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp

610 615 620

Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu

625 630 635 640

Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys

645 650 655

Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu

660 665 670

Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr

675 680 685

Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met

690 695 700

Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys

705 710 715 720

Ala Gln Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn

725 730 735

Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys

740 745 750

Val Val Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn

755 760 765

Ile Val Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln

770 775 780

Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu

785 790 795 800

Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu

805 810 815

Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met

820 825 830

Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val

835 840 845

Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn

850 855 860

Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val

865 870 875 880

Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu

885 890 895

Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys

900 905 910

Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys

915 920 925

Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile

930 935 940

Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile

945 950 955 960

Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe

965 970 975

Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His

980 985 990

His Ala His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile

995 1000 1005

Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr

1010 1015 1020

Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu

1025 1030 1035

Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met

1040 1045 1050

Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg

1055 1060 1065

Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val

1070 1075 1080

Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser

1085 1090 1095

Met Pro Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly

1100 1105 1110

Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys

1115 1120 1125

Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly

1130 1135 1140

Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys

1145 1150 1155

Val Glu Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu

1160 1165 1170

Leu Gly Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro

1175 1180 1185

Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp

1190 1195 1200

Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn

1205 1210 1215

Gly Arg Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly

1220 1225 1230

Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu

1235 1240 1245

Ala Ser His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu

1250 1255 1260

Gln Lys Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu

1265 1270 1275

Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala

1280 1285 1290

Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg

1295 1300 1305

Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe

1310 1315 1320

Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp

1325 1330 1335

Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu

1340 1345 1350

Asp Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr

1355 1360 1365

Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro

1370 1375 1380

Lys Lys Lys Arg Lys Val

1385

<210> 7827

<211> 1399

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7827

Met Gly Ser Ser His His His His His His His His Glu Asn Leu Tyr

1 5 10 15

Phe Gln Gly Ser Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly

20 25 30

Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro

35 40 45

Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys

50 55 60

Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu

65 70 75 80

Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys

85 90 95

Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys

100 105 110

Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu

115 120 125

Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp

130 135 140

Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys

145 150 155 160

Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu

165 170 175

Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly

180 185 190

Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu

195 200 205

Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser

210 215 220

Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg

225 230 235 240

Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly

245 250 255

Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe

260 265 270

Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys

275 280 285

Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp

290 295 300

Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile

305 310 315 320

Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro

325 330 335

Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu

340 345 350

Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys

355 360 365

Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp

370 375 380

Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu

385 390 395 400

Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu

405 410 415

Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His

420 425 430

Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp

435 440 445

Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu

450 455 460

Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser

465 470 475 480

Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp

485 490 495

Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile

500 505 510

Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu

515 520 525

Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu

530 535 540

Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu

545 550 555 560

Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn

565 570 575

Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile

580 585 590

Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn

595 600 605

Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys

610 615 620

Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val

625 630 635 640

Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu

645 650 655

Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys

660 665 670

Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn

675 680 685

Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys

690 695 700

Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp

705 710 715 720

Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln

725 730 735

Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala

740 745 750

Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val

755 760 765

Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala

770 775 780

Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg

785 790 795 800

Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu

805 810 815

Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr

820 825 830

Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu

835 840 845

Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln

850 855 860

Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser

865 870 875 880

Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val

885 890 895

Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile

900 905 910

Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu

915 920 925

Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr

930 935 940

Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn

945 950 955 960

Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile

965 970 975

Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe

980 985 990

Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr

995 1000 1005

Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys

1010 1015 1020

Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val

1025 1030 1035

Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr

1040 1045 1050

Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr

1055 1060 1065

Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile

1070 1075 1080

Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg

1085 1090 1095

Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn

1100 1105 1110

Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu

1115 1120 1125

Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys

1130 1135 1140

Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr

1145 1150 1155

Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys

1160 1165 1170

Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile

1175 1180 1185

Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu

1190 1195 1200

Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu

1205 1210 1215

Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met

1220 1225 1230

Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu

1235 1240 1245

Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu

1250 1255 1260

Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe

1265 1270 1275

Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile

1280 1285 1290

Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp

1295 1300 1305

Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys Pro Ile Arg

1310 1315 1320

Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu Thr Asn Leu

1325 1330 1335

Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg

1340 1345 1350

Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala Thr Leu Ile

1355 1360 1365

His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser

1370 1375 1380

Gln Leu Gly Gly Asp Gly Gly Gly Ser Pro Lys Lys Lys Arg Lys

1385 1390 1395

Val

<210> 7828

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7828

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Ala Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7829

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7829

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Ala Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Ala Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Ala

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7830

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7830

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Ala Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Ala Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Ala

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7831

<211> 1393

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7831

Met Ala Pro Lys Lys Lys Arg Lys Val Asp Lys Lys Tyr Ser Ile Gly

1 5 10 15

Leu Asp Ile Gly Thr Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu

20 25 30

Tyr Lys Val Pro Ser Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg

35 40 45

His Ser Ile Lys Lys Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly

50 55 60

Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr

65 70 75 80

Thr Arg Arg Lys Asn Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn

85 90 95

Glu Met Ala Lys Val Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser

100 105 110

Phe Leu Val Glu Glu Asp Lys Lys His Glu Arg His Pro Ile Phe Gly

115 120 125

Asn Ile Val Asp Glu Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr

130 135 140

His Leu Arg Lys Lys Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg

145 150 155 160

Leu Ile Tyr Leu Ala Leu Ala His Met Ile Lys Phe Arg Gly His Phe

165 170 175

Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu

180 185 190

Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro

195 200 205

Ile Asn Ala Ser Gly Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu

210 215 220

Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu

225 230 235 240

Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu

245 250 255

Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu

260 265 270

Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala

275 280 285

Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu

290 295 300

Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile

305 310 315 320

Thr Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His

325 330 335

His Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro

340 345 350

Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala

355 360 365

Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile

370 375 380

Lys Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Glu Leu Leu Val Lys

385 390 395 400

Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly

405 410 415

Ser Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg

420 425 430

Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile

435 440 445

Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala

450 455 460

Arg Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr

465 470 475 480

Ile Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala

485 490 495

Gln Ser Phe Ile Glu Arg Met Thr Ala Phe Asp Lys Asn Leu Pro Asn

500 505 510

Glu Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val

515 520 525

Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys

530 535 540

Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu

545 550 555 560

Phe Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr

565 570 575

Phe Lys Lys Ile Glu Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu

580 585 590

Asp Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile

595 600 605

Ile Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu

610 615 620

Glu Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile

625 630 635 640

Glu Glu Arg Leu Lys Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met

645 650 655

Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp Gly Ala Leu Ser Arg

660 665 670

Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu

675 680 685

Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg Asn Phe Met Ala Leu

690 695 700

Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln

705 710 715 720

Val Ser Gly Gln Gly Asp Ser Leu His Glu His Ile Ala Asn Leu Ala

725 730 735

Gly Ser Pro Ala Ile Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val

740 745 750

Asp Glu Leu Val Lys Val Met Gly Arg His Lys Pro Glu Asn Ile Val

755 760 765

Ile Glu Met Ala Arg Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn

770 775 780

Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly

785 790 795 800

Ser Gln Ile Leu Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn

805 810 815

Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val

820 825 830

Asp Gln Glu Leu Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His

835 840 845

Ile Val Pro Gln Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val

850 855 860

Leu Thr Arg Ser Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser

865 870 875 880

Glu Glu Val Val Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn

885 890 895

Ala Lys Leu Ile Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu

900 905 910

Arg Gly Gly Leu Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln

915 920 925

Leu Val Glu Thr Arg Ala Ile Thr Lys His Val Ala Gln Ile Leu Asp

930 935 940

Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu

945 950 955 960

Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys

965 970 975

Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His His Ala

980 985 990

His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys

995 1000 1005

Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val

1010 1015 1020

Tyr Asp Val Arg Lys Met Ile Ala Lys Ser Glu Gln Glu Ile Gly

1025 1030 1035

Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe

1040 1045 1050

Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile Arg Lys Arg

1055 1060 1065

Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp

1070 1075 1080

Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro

1085 1090 1095

Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe

1100 1105 1110

Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile

1115 1120 1125

Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp

1130 1135 1140

Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu

1145 1150 1155

Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly

1160 1165 1170

Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp

1175 1180 1185

Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile

1190 1195 1200

Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg

1205 1210 1215

Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu

1220 1225 1230

Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser

1235 1240 1245

His Tyr Glu Lys Leu Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys

1250 1255 1260

Gln Leu Phe Val Glu Gln His Lys His Tyr Leu Asp Glu Ile Ile

1265 1270 1275

Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile Leu Ala Asp Ala

1280 1285 1290

Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His Arg Asp Lys

1295 1300 1305

Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe Thr Leu

1310 1315 1320

Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr Thr

1325 1330 1335

Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala

1340 1345 1350

Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile

1355 1360 1365

Asp Leu Ser Gln Leu Gly Gly Asp Ser Arg Ala Asp Pro Lys Lys

1370 1375 1380

Lys Arg Lys Val His His His His His His His

1385 1390

<210> 7832

<400> 7832

000

<210> 7833

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7833

agagucucuc agcugguaca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7834

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7834

agagucucuc agcugguaca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7835

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7835

agagucucuc agcugguaca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7836

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7836

agagucucuc agcugguaca guuuuagagc uaugcuguuu ug 42

<210> 7837

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7837

agagucucuc agcugguaca guuuuagagc uaugcuguuu ug 42

<210> 7838

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7838

uucggaaccc aaucacugac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7839

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7839

uucggaaccc aaucacugac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7840

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7840

uucggaaccc aaucacugac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7841

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7841

uucggaaccc aaucacugac guuuuagagc uaugcuguuu ug 42

<210> 7842

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7842

uucggaaccc aaucacugac guuuuagagc uaugcuguuu ug 42

<210> 7843

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7843

uggcucaaac acagcgaccu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7844

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7844

uggcucaaac acagcgaccu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7845

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7845

uggcucaaac acagcgaccu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7846

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7846

uggcucaaac acagcgaccu guuuuagagc uaugcuguuu ug 42

<210> 7847

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7847

uggcucaaac acagcgaccu guuuuagagc uaugcuguuu ug 42

<210> 7848

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7848

ucccuagcaa gaucucauag guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7849

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7849

ucccuagcaa gaucucauag guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7850

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7850

ucccuagcaa gaucucauag guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7851

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7851

ucccuagcaa gaucucauag guuuuagagc uaugcuguuu ug 42

<210> 7852

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7852

ucccuagcaa gaucucauag guuuuagagc uaugcuguuu ug 42

<210> 7853

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7853

ggccacggag cgagacaucu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7854

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7854

ggccacggag cgagacaucu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7855

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7855

ggccacggag cgagacaucu guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7856

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7856

ggccacggag cgagacaucu guuuuuagagc uaugcuguuu ug 42

<210> 7857

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7857

ggccacggag cgagacaucu guuuuuagagc uaugcuguuu ug 42

<210> 7858

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7858

gaguagcgcg agcacagcua guuuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7859

<211> 99

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7859

gauagcgcga gcacagcuag uuuuagagcu agaaauagca aguuaaaaua aggcuagucc 60

guuaucaacu ugaaaaagug gcaccgaguc ggugcuuuu 99

<210> 7860

<211> 99

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7860

gauagcgcga gcacagcuag uuuuagagcu agaaauagca aguuaaaaua aggcuagucc 60

guuaucaacu ugaaaaagug gcaccgaguc ggugcuuuu 99

<210> 7861

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7861

gaguagcgcg agcacagcua guuuuagagc uaugcuguuu ug 42

<210> 7862

<211> 41

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7862

gauagcgcga gcacagcuag uuuuagagcu augcuguuuu g 41

<210> 7863

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7863

caagcgcggc cagaccugcg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7864

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7864

caagcgcggc cagaccugcg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7865

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7865

caagcgcggc cagaccugcg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7866

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7866

caagcgcggc cagaccugcg guuuuagagc uaugcuguuu ug 42

<210> 7867

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7867

caagcgcggc cagaccugcg guuuuagagc uaugcuguuu ug 42

<210> 7868

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7868

ccgcugggcc cccgacucac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7869

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7869

ccgcugggcc cccgacucac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7870

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7870

ccgcugggcc cccgacucac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 7871

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7871

ccgcugggcc cccgacucac guuuuagagc uaugcuguuu ug 42

<210> 7872

<211> 42

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 7872

ccgcugggcc cccgacucac guuuuagagc uaugcuguuu ug 42

<210> 7873

<400> 7873

000

<210> 7874

<400> 7874

000

<210> 7875

<400> 7875

000

<210> 7876

<400> 7876

000

<210> 7877

<400> 7877

000

<210> 7878

<400> 7878

000

<210> 7879

<400> 7879

000

<210> 7880

<400> 7880

000

<210> 7881

<400> 7881

000

<210> 7882

<400> 7882

000

<210> 7883

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7883

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu

115 120 125

Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys

130 135 140

Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg

145 150 155 160

Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser

165 170 175

Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys Ser Arg Val Thr Ile Ser

180 185 190

Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr

195 200 205

Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly

210 215 220

Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val

225 230 235 240

Ser Ser

<210> 7884

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7884

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu

115 120 125

Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys

130 135 140

Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg

145 150 155 160

Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser

165 170 175

Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys Ser Arg Val Thr Ile Ser

180 185 190

Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr

195 200 205

Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly

210 215 220

Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val

225 230 235 240

Ser Ser

<210> 7885

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7885

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala

130 135 140

Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala

145 150 155 160

Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly

165 170 175

Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly

180 185 190

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu

195 200 205

Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln

210 215 220

Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu

225 230 235 240

Ile Lys

<210> 7886

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7886

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala

130 135 140

Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala

145 150 155 160

Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly

165 170 175

Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly

180 185 190

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu

195 200 205

Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln

210 215 220

Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu

225 230 235 240

Ile Lys

<210> 7887

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7887

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

115 120 125

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

130 135 140

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

145 150 155 160

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

165 170 175

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys Ser

180 185 190

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

195 200 205

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

210 215 220

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

225 230 235 240

Thr Leu Val Thr Val Ser Ser

245

<210> 7888

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7888

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

115 120 125

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

130 135 140

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

145 150 155 160

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

165 170 175

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys Ser

180 185 190

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

195 200 205

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

210 215 220

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

225 230 235 240

Thr Leu Val Thr Val Ser Ser

245

<210> 7889

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7889

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met

130 135 140

Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

145 150 155 160

Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser

180 185 190

Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala

210 215 220

Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln

225 230 235 240

Gly Thr Lys Leu Glu Ile Lys

245

<210> 7890

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7890

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met

130 135 140

Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

145 150 155 160

Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser

180 185 190

Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala

210 215 220

Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln

225 230 235 240

Gly Thr Lys Leu Glu Ile Lys

245

<210> 7891

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7891

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

115 120 125

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

130 135 140

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

145 150 155 160

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

165 170 175

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys Ser

180 185 190

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

195 200 205

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

210 215 220

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

225 230 235 240

Thr Leu Val Thr Val Ser Ser

245

<210> 7892

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7892

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met

130 135 140

Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

145 150 155 160

Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser

180 185 190

Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala

210 215 220

Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln

225 230 235 240

Gly Thr Lys Leu Glu Ile Lys

245

<210> 7893

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7893

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Glyn Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu

115 120 125

Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys

130 135 140

Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg

145 150 155 160

Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser

165 170 175

Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys Ser Arg Val Thr Ile Ser

180 185 190

Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr

195 200 205

Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly

210 215 220

Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val

225 230 235 240

Ser Ser

<210> 7894

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7894

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr

20 25 30

Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35 40 45

Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys

50 55 60

Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu

65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala

130 135 140

Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala

145 150 155 160

Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly

165 170 175

Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly

180 185 190

Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu

195 200 205

Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln

210 215 220

Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu

225 230 235 240

Ile Lys

<210> 7895

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7895

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile

35 40 45

Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln

65 70 75 80

Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser

100 105 110

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu

115 120 125

Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys

130 135 140

Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg

145 150 155 160

Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser

165 170 175

Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile

180 185 190

Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln

195 200 205

Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly

210 215 220

Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val

225 230 235 240

Ser Ser

<210> 7896

<211> 119

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7896

Gln Val Gln Leu Leu Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ser

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr

20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile

35 40 45

Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe

50 55 60

Lys Gly Gln Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Ser Cys

85 90 95

Ala Arg Lys Thr Ile Ser Ser Val Val Asp Phe Tyr Phe Asp Tyr Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr

115

<210> 7897

<211> 111

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7897

Glu Leu Val Leu Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Gly

1 5 10 15

Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile

35 40 45

Tyr Ser Ala Thr Tyr Arg Asn Ser Gly Val Pro Asp Arg Phe Thr Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser

65 70 75 80

Lys Asp Leu Ala Asp Tyr Phe Tyr Phe Cys Gln Tyr Asn Arg Tyr Pro

85 90 95

Tyr Thr Ser Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Arg Ser

100 105 110

<210> 7898

<211> 248

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7898

Gln Val Gln Leu Leu Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ser

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr

20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile

35 40 45

Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe

50 55 60

Lys Gly Gln Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Gln Leu Ser Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Ser Cys

85 90 95

Ala Arg Lys Thr Ile Ser Ser Val Val Asp Phe Tyr Phe Asp Tyr Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro

115 120 125

Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Leu Val Leu Thr Gln Ser

130 135 140

Pro Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys

145 150 155 160

Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys

165 170 175

Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Ser Ala Thr Tyr Arg Asn

180 185 190

Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe

195 200 205

Thr Leu Thr Ile Thr Asn Val Gln Ser Lys Asp Leu Ala Asp Tyr Phe

210 215 220

Tyr Phe Cys Gln Tyr Asn Arg Tyr Pro Tyr Thr Ser Gly Gly Gly Thr

225 230 235 240

Lys Leu Glu Ile Lys Arg Arg Ser

245

<210> 7899

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7899

Gly Val Ser Leu Pro Asp Tyr Gly Val Ser

1 5 10

<210> 7900

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7900

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser

1 5 10 15

<210> 7901

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7901

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys Ser

1 5 10 15

<210> 7902

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7902

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys Ser

1 5 10 15

<210> 7903

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7903

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys Ser

1 5 10 15

<210> 7904

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7904

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr

1 5 10

<210> 7905

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7905

Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn

1 5 10

<210> 7906

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7906

His Thr Ser Arg Leu His Ser

fifteen

<210> 7907

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 7907

Gln Gln Gly Asn Thr Leu Pro Tyr Thr

fifteen

<210> 7908

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7908

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

130 135 140

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

145 150 155 160

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

165 170 175

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

180 185 190

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser Ser Ser Leu Lys Ser

195 200 205

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

210 215 220

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

225 230 235 240

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

245 250 255

Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7909

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7909

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

130 135 140

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

145 150 155 160

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

165 170 175

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

180 185 190

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys Ser

195 200 205

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

210 215 220

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

225 230 235 240

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

245 250 255

Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7910

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7910

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val

35 40 45

Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys

50 55 60

Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr

65 70 75 80

Ser Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys

85 90 95

Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala

100 105 110

Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met

115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met

145 150 155 160

Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

165 170 175

Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr

180 185 190

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser

195 200 205

Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

210 215 220

Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala

225 230 235 240

Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln

245 250 255

Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7911

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7911

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val

35 40 45

Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys

50 55 60

Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr

65 70 75 80

Gln Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys

85 90 95

Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala

100 105 110

Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met

115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met

145 150 155 160

Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

165 170 175

Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr

180 185 190

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr His Thr Ser

195 200 205

Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

210 215 220

Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala

225 230 235 240

Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln

245 250 255

Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7912

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7912

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val

145 150 155 160

Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser

165 170 175

Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly

180 185 190

Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Ser

195 200 205

Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn

210 215 220

Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val

225 230 235 240

Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp

245 250 255

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7913

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7913

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val

145 150 155 160

Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser

165 170 175

Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly

180 185 190

Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln

195 200 205

Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn

210 215 220

Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val

225 230 235 240

Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp

245 250 255

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7914

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7914

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val

35 40 45

Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys

50 55 60

Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr

65 70 75 80

Ser Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys

85 90 95

Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala

100 105 110

Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met

115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

145 150 155 160

Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro

165 170 175

Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys

180 185 190

Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

195 200 205

Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln

225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro

245 250 255

Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7915

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7915

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val

35 40 45

Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys

50 55 60

Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr

65 70 75 80

Gln Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys

85 90 95

Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala

100 105 110

Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met

115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

145 150 155 160

Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro

165 170 175

Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys

180 185 190

Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

195 200 205

Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln

225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro

245 250 255

Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7916

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7916

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val

145 150 155 160

Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser

165 170 175

Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly

180 185 190

Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn

195 200 205

Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn

210 215 220

Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val

225 230 235 240

Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp

245 250 255

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7917

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7917

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val

145 150 155 160

Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser

165 170 175

Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly

180 185 190

Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn

195 200 205

Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn

210 215 220

Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val

225 230 235 240

Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp

245 250 255

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7918

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7918

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val

35 40 45

Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys

50 55 60

Gly Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr

65 70 75 80

Asn Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys

85 90 95

Asn Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala

100 105 110

Val Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met

115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

145 150 155 160

Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro

165 170 175

Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys

180 185 190

Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

195 200 205

Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln

225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro

245 250 255

Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 7919

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7919

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu

20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro

65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile

85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln

130 135 140

Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr

145 150 155 160

Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

165 170 175

Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly

180 185 190

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ser Leu Lys Ser

195 200 205

Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys

210 215 220

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys

225 230 235 240

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

245 250 255

Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7920

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7920

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu

20 25 30

Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln

35 40 45

Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr

50 55 60

Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro

65 70 75 80

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile

85 90 95

Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly

100 105 110

Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu

130 135 140

Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser

145 150 155 160

Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly

165 170 175

Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly

180 185 190

Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser

195 200 205

Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys

210 215 220

Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys

225 230 235 240

His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly

245 250 255

Thr Ser Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 7921

<400> 7921

000

<210> 7922

<400> 7922

000

<210> 7923

<400> 7923

000

<210> 7924

<400> 7924

000

<210> 7925

<400> 7925

000

<210> 7926

<400> 7926

000

<210> 7927

<400> 7927

000

<210> 7928

<400> 7928

000

<210> 7929

<400> 7929

000

<210> 7930

<400> 7930

000

<210> 7931

<400> 7931

000

<210> 7932

<400> 7932

000

<210> 7933

<400> 7933

000

<210> 7934

<400> 7934

000

<210> 7935

<400> 7935

000

<210> 7936

<400> 7936

000

<210> 7937

<400> 7937

000

<210> 7938

<400> 7938

000

<210> 7939

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7939

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gly Trp Val

35 40 45

Ser Gly Ile Ser Arg Ser Gly Glu Asn Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Pro Ala His Tyr Tyr Gly Gly Met Asp Val Trp Gly Gln

100 105 110

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser

130 135 140

Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

145 150 155 160

Arg Ala Ser Gln Ser Ile Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln

165 170 175

Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Arg Arg

180 185 190

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp

195 200 205

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala Val Tyr

210 215 220

Tyr Cys Gln Gln Tyr His Ser Ser Pro Ser Trp Thr Phe Gly Gln Gly

225 230 235 240

Thr Lys Leu Glu Ile Lys

245

<210> 7940

<211> 244

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7940

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Glu Trp Val

35 40 45

Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ser Val His Ser Phe Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro

130 135 140

Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser

145 150 155 160

Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys

165 170 175

Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala

180 185 190

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

195 200 205

Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr

210 215 220

Cys Met Gln Ala Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys

225 230 235 240

Val Glu Ile Lys

<210> 7941

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7941

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser

130 135 140

Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser

145 150 155 160

Leu Leu Arg Asn Asp Gly Lys Thr Pro Leu Tyr Trp Tyr Leu Gln Lys

165 170 175

Ala Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe

180 185 190

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

195 200 205

Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ala Tyr Tyr

210 215 220

Cys Met Gln Asn Ile Gln Phe Pro Ser Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 7942

<211> 249

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7942

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Arg Lys Thr Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Asp Asn Phe

20 25 30

Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Lys Asn Asn Asn Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr

65 70 75 80

Met Glu Val Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Pro Tyr Tyr Tyr Gln Ser Tyr Met Asp Val Trp Gly Gln

100 105 110

Gly Thr Met Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr

130 135 140

Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys

145 150 155 160

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asn

165 170 175

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu

180 185 190

Gly Ser Lys Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

195 200 205

Ser Gly Thr Asp Phe Thr Leu His Ile Thr Arg Val Gly Ala Glu Asp

210 215 220

Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Tyr Thr Phe

225 230 235 240

Gly Gln Gly Thr Lys Leu Glu Ile Lys

245

<210> 7943

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7943

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp

20 25 30

Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Val Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Leu Asp Ser Ser Gly Tyr Tyr Tyr Ala Arg Gly Pro Arg Tyr

100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu

130 135 140

Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr

145 150 155 160

Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser

180 185 190

Thr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr His Phe Thr Leu Thr Ile Asn Ser Leu Gln Ser Glu Asp Ser Ala

210 215 220

Thr Tyr Tyr Cys Gln Gln Ser Tyr Lys Arg Ala Ser Phe Gly Gln Gly

225 230 235 240

Thr Lys Val Glu Ile Lys

245

<210> 7944

<211> 247

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7944

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asn Tyr

20 25 30

Gly Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Pro Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr

100 105 110

Met Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg

115 120 125

Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Leu

130 135 140

Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser

145 150 155 160

Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn Tyr Val Asp Trp Tyr

165 170 175

Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser

180 185 190

Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Phe Lys Leu Gln Ile Ser Arg Val Glu Ala Glu Asp Val Gly

210 215 220

Ile Tyr Tyr Cys Met Gln Gly Arg Gln Phe Pro Tyr Ser Phe Gly Gln

225 230 235 240

Gly Thr Lys Val Glu Ile Lys

245

<210> 7945

<211> 238

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7945

Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser

130 135 140

Val Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

165 170 175

Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Asp

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

195 200 205

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly

210 215 220

Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

225 230 235

<210> 7946

<211> 239

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7946

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser

130 135 140

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Val Ser Ser Lys Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

165 170 175

Arg Leu Leu Met Tyr Gly Ala Ser Ile Arg Ala Thr Gly Ile Pro Asp

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser

195 200 205

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly

210 215 220

Ser Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

225 230 235

<210> 7947

<211> 241

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7947

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Val Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser

130 135 140

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Val Gly Ser Thr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala

165 170 175

Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro

180 185 190

Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile

195 200 205

Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr

210 215 220

Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile

225 230 235 240

Lys

<210> 7948

<211> 239

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7948

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Glu Ser Gly Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala

115 120 125

Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser

130 135 140

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser

145 150 155 160

Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys

165 170 175

Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val

180 185 190

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr

195 200 205

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln

210 215 220

Ser Tyr Thr Leu Ala Phe Gly Gln Gly Thr Lys Val Asp Ile Lys

225 230 235

<210> 7949

<211> 239

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7949

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser

130 135 140

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser

145 150 155 160

Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro

165 170 175

Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

195 200 205

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr

210 215 220

Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

225 230 235

<210> 7950

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7950

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Asn Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Met Val Arg Glu Asp Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala

115 120 125

Ser Gly Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Leu Ser

130 135 140

Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser

145 150 155 160

Glu Ser Leu Val His Asn Ser Gly Lys Thr Tyr Leu Asn Trp Phe His

165 170 175

Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Glu Val Ser Asn

180 185 190

Arg Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr

195 200 205

Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val

210 215 220

Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Gly Thr Phe Gly Gln Gly

225 230 235 240

Thr Lys Leu Glu Ile Lys

245

<210> 7951

<211> 239

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7951

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Arg Leu Thr Gln Ser Pro Ser Pro Leu Ser

130 135 140

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asp

145 150 155 160

Ile Asn Lys Phe Leu Asn Trp Tyr His Gln Thr Pro Gly Lys Ala Pro

165 170 175

Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln Thr Gly Val Pro Ser

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn

195 200 205

Ser Leu Gln Pro Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Glu

210 215 220

Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

225 230 235

<210> 7952

<211> 240

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7952

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Glu Thr Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser

130 135 140

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Val Gly Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Gly Pro

165 170 175

Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser

195 200 205

Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn

210 215 220

Asp Trp Leu Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

225 230 235 240

<210> 7953

<211> 241

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7953

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly

115 120 125

Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser

130 135 140

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Ile Gly Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala

165 170 175

Pro Arg Leu Leu Met Tyr Gly Ala Ser Ser Arg Ala Ser Gly Ile Pro

180 185 190

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile

195 200 205

Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr

210 215 220

Ala Gly Ser Pro Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile

225 230 235 240

Lys

<210> 7954

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7954

caagtgcaac tcgtggaatc tggtggagga ctcgtgcaac ccggaagatc gcttagactg 60

tcgtgtgccg ccagcgggtt cactttctcg aactacgcga tgtcctgggt ccgccaggca 120

ccgggaaagg gactcggttg ggtgtccggc atttcccggt ccggcgaaaa tacctactac 180

gccgactccg tgaagggccg cttcaccatc tcaagggaca acagcaaaaa caccctgtac 240

ttgcaaatga actccctgcg ggatgaagat acagccgtgt actattgcgc ccggtcgcct 300

gcccattact acggcggaat ggacgtctgg ggacagggaa ccactgtgac tgtcagcagc 360

gcgtcgggtg gcggcggctc agggggtcgg gcctccgggg ggggagggtc cgacatcgtg 420

ctgacccagt ccccgggaac cctgagcctg agcccgggag agcgcgcgac cctgtcatgc 480

cgggcatccc agagcattag ctcctccttt ctcgcctggt atcagcagaa gcccggacag 540

gccccgaggc tgctgatcta cggcgctagc agaagggcta cgggaatccc agaccggttc 600

tccggctccg gttccgggac cgatttcacc cttactatct cgcgcctgga acctgaggac 660

tccgccgtct actactgcca gcagtaccac tcatccccgt cgtggacgtt cggacagggc 720

accaagctgg agattaag 738

<210> 7955

<211> 732

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7955

caagtgcaac tcgtcgaatc cggtggaggt ctggtccaac ctggtagaag cctgagactg 60

tcgtgtgcgg ccagcggatt cacctttgat gactatgcta tgcactggggt gcggcaggcc 120

cgggaaagg gcctggaatg ggtgtcggga attagctgga actccgggtc cattggctac 180

gccgactccg tgaagggccg cttcaccatc tcccgcgaca acgcaaagaa ctccctgtac 240

ttgcaaatga actcgctcag ggctgaggat accgcgctgt actactgctc cgtgcattcc 300

ttcctggcct actggggaca gggaactctg gtcaccgtgt cgagcgcctc cggcggcggg 360

ggctcgggtg gacgggcctc gggcggaggg gggtccgaca tcgtgatgac ccagaccccg 420

ctgagcttgc ccgtgactcc cggagagcct gcatccatct cctgccggtc atcccagtcc 480

cttctccact ccaacggata caactacctc gactggtacc tccagaagcc gggacagagc 540

cctcagcttc tgatctacct ggggtcaaat agagcctcag gagtgccgga tcggttcagc 600

ggatctggtt cgggaactga tttcactctg aagatttccc gcgtggaagc cgaggacgtg 660

ggcgtctact actgtatgca ggcgctgcag accccctata ccttcggcca agggacgaaa 720

gtggagatca ag 732

<210> 7956

<211> 729

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7956

60

tcgtgtgcgg tgtcaggctt cgccctgagc aaccacggca tgagctgggt gcggagagcc 120

ccggggaagg gtctggaatg ggtgtccggg atcgtctact ccggttcaac ttactacgcc 180

gcaagcgtga agggtcgctt caccatttcc cgcgataact cccggaacac cctgtacctc 240

caaatgaact ccctgcggcc cgaggacacc gccatctact actgttccgc gcatggagga 300

gagtccgatg tctggggaca gggcactacc gtgaccgtgt cgagcgcctc ggggggagga 360

ggctccggcg gtcgcgcctc cggggggggt ggcagcgaca ttgtgatgac gcagactcca 420

ctctcgctgt ccgtgacccc gggacagccc gcgtccatct cgtgcaagag ctcccagagc 480

ctgctgagga acgacggaaa gactcctctg tattggtacc tccagaaggc tggacagccc 540

ccgcaactgc tcatctacga agtgtcaaat cgcttctccg gggtgccgga tcggttttcc 600

ggctcgggat cgggcaccga cttcaccctg aaaatctcca gggtcgaggc cgaggacgtg 660

ggagcctact actgcatgca aaacatccag ttcccttcct tcggcggcgg cacaaagctg 720

gagattaag 729

<210> 7957

<211> 747

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7957

caagtccaac tcgtccagtc cggcgcagaa gtcagaaaaa ccggtgctag cgtgaaagtg 60

tcctgcaagg cctccggcta cattttcgat aacttcggaa tcaactgggt cagacaggcc 120

ccggggccagg ggctggaatg gatgggatgg atcaacccca agaacaacaa caccaactac 180

gcacagaagt tccagggccg cgtgactatc accgccgatg aatcgaccaa taccgcctac 240

atggaggtgt cctccctgcg gtcggaggac actgccgtgt attactgcgc gaggggccca 300

tactactacc aaagctacat ggacgtctgg ggacagggaa ccatggtgac cgtgtcatcc 360

gcctccggtg gtggaggctc cggggggcgg gcttcaggag gcggaggaag cgatattgtg 420

atgacccaga ctccgcttag cctgcccgtg actcctggag aaccggcctc catttcctgc 480

cggtcctcgc aatcactcct gcattccaac ggttacaact acctgaattg gtacctccag 540

aagcctggcc agtcgcccca gttgctgatc tatctgggct cgaagcgcgc ctccggggtg 600

cctgaccggt ttagcggatc tgggagcggc acggacttca ctctccacat cacccgcgtg 660

ggagcggagg acgtgggagt gtactactgt atgcaggcgc tgcagactcc gtacacattc 720

ggacagggca ccaagctggga gatcaag 747

<210> 7958

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7958

caagtgcaac ttcaagaatc aggcggagga ctcgtgcagc ccggaggatc attgcggctc 60

tcgtgcgccg cctcgggctt caccttctcg agcgacgcca tgacctgggt ccgccaggcc 120

ccgggggaagg ggctggaatg ggtgtctgtg atttccggct ccgggggaac tacgtactac 180

gccgattccg tgaaaggtcg cttcactatc tcccgggaca acagcaagaa caccctttat 240

ctgcaaatga attccctccg cgccgaggac accgccgtgt actactgcgc caagctggac 300

tcctcgggct actactatgc ccggggtccg agatactggg gacagggaac cctcgtgacc 360

gtgtcctccg cgtccggcgg aggagggtcg ggagggcggg cctccggcgg cggcggttcg 420

gacatccagc tgacccagtc cccatcctca ctgagcgcaa gcgtgggcga cagagtcacc 480

attacatgca gggcgtccca gagcatcagc tcctacctga actggtacca acagaagcct 540

ggaaaggctc ctaagctgtt gatctacggg gcttcgaccc tggcatccgg ggtgcccgcg 600

aggtttagcg gaagcggtag cggcactcac ttcactctga ccattaacag cctccagtcc 660

gaggattcag ccacttacta ctgtcagcag tcctacaagc gggccagctt cggacagggc 720

actaaggtcg agatcaag 738

<210> 7959

<211> 741

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7959

caagtccaac tggtccagag cggtgcagaa gtgaagaagc ccggagcgag cgtgaaagtg 60

tcctgcaagg cttccgggta caccttctcc aactacggca tcacttgggt gcgccaggcc 120

ccgggacagg gcctggaatg gatggggtgg atttccgcgt acaacggcaa tacgaactac 180

gctcagaagt tccagggtag agtgaccatg actaggaaca cctccatttc caccgcctac 240

atggaactgt cctccctgcg gagcgaggac accgccgtgt actattgcgc ccggggacca 300

tactactact acatggatgt ctgggggaag gggactatgg tcaccgtgtc atccgcctcg 360

ggaggcggcg gatcaggagg acgcgcctct ggtggtggag gatcggagat cgtgatgacc 420

cagagccctc tctccttgcc cgtgactcct ggggagcccg catccatttc atgccggagc 480

tcccagtcac ttctctactc caacggctat aactacgtgg attggtacct ccaaaagccg 540

ggccagagcc cgcagctgct gatctacctg ggctcgaaca gggccagcgg agtgcctgac 600

cggttctccg ggtcgggaag cgggaccgac ttcaagctgc aaatctcgag agtggaggcc 660

gaggacgtgg gaatctacta ctgtatgcag ggccgccagt ttccgtactc gttcggacag 720

ggcaccaaag tggaaatcaa g 741

<210> 7960

<211> 714

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7960

gaagtgcaat tgctcgaaac tggaggaggt ctggtgcaac ctggaggatc acttcgcctg 60

tcctgcgccg tgtcgggctt tgccctgtcc aaccatggaa tgagctgggt ccgccgcgcg

ccgggggaagg gcctcgaatg ggtgtccggc atcgtctact ccggctccac ctactacgcc 180

gcgtccgtga agggccggtt cacgatttca cgggacaact cgcggaacac cctgtacctc 240

caaatgaatt cccttcggcc ggaggatact gccatctact actgctccgc ccacggtggc 300

gaatccgacg tctggggcca gggaaccacc gtgaccgtgt ccagcgcgtc cgggggagga 360

ggaagcgggg gtagagcatc gggtggaggc ggatcagaga tcgtgctgac ccagtccccc 420

gccaccttga gcgtgtcacc aggagagtcc gccaccctgt catgccgcgc cagccagtcc 480

gtgtcctcca acctggcttg gtaccagcag aagccggggc aggcccctag actcctgatc 540

tatgggcgt cgacccgggc atctggaatt cccgataggt tcagcggatc gggctcgggc 600

actgacttca ctctgaccat ctcctcgctg caagccgagg acgtggctgt gtactactgt 660

cagcagtacg gaagctccct gactttcggt ggcgggacca aagtcgagat taag 714

<210> 7961

<211> 717

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7961

60

agctgcgcag tgtcgggatt cgccctgagc aaccatggaa tgtcctgggt cagaagggcc 120

cctggaaaag gcctcgaatg ggtgtcaggg atcgtgtact ccggttccac ttactacgcc 180

gcctccgtga aggggcgctt cactatctca cgggataact cccgcaatac cctgtacctc 240

caaatgaaca gcctgcggcc ggaggatacc gccatctact actgttccgc ccacggtgga 300

gagtctgacg tctggggcca gggaactacc gtgaccgtgt cctccgcgtc cggcggtgga 360

gggagcggcg gccgcgccag cggcggcgga ggctccgaga tcgtgatgac ccagagcccc 420

gctactctgt cggtgtcgcc cggagaaagg gcgaccctgt cctgccgggc gtcgcagtcc 480

gtgagcagca agctggcttg gtaccagcag aagccgggcc aggcaccacg cctgcttatg 540

tacggtgcct ccattcgggc caccggaatc ccggaccggt tctcggggtc ggggtccggt 600

accgagttca cactgaccat ttcctcgctc gagcccgagg actttgccgt ctattactgc 660

cagcagtacg gctcctcctc atggacgttc ggccagggga ccaaggtcga aatcaag 717

<210> 7962

<211> 723

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7962

60

120

cctgggaaag gacttgaatg ggtgtccggc atcgtgtact cgggttccac ctactacgcg 180

gcctcagtga agggccggtt tactattagc cgcgacaact ccagaaacac actgtacctc 240

caaatgaact cgctgcggcc ggaagatacc gctatctact actgctccgc ccatggggga 300

gagtcggacg tctggggaca gggcaccact gtcactgtgt ccagcgcttc cggcggtggt 360

ggaagcgggg gacgggcctc aggaggcggt ggcagcgaga ttgtgctgac ccagtccccc 420

gggaccctga gcctgtcccc gggagaaagg gccaccctct cctgtcgggc atcccagtcc 480

gtggggtcta ctaaccttgc atggtaccag cagaagcccg gccaggcccc tcgcctgctg 540

atctacgacg cgtccaatag agccaccggc atcccggatc gcttcagcgg aggcggatcg 600

ggcaccgact tcaccctcac catttcaagg ctggaaccgg aggacttcgc cgtgtactac 660

tgccagcagt atggttcgtc cccaccctgg acgttcggcc aggggactaa ggtcgagatc 720

aag 723

<210> 7963

<211> 717

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7963

caagtgcaac tcgtggaatc tggtggagga ctcgtgaaac ctggaggatc attgagactg 60

tcatgcgcgg cctcgggatt cacgttctcc gattactaca tgagctggat tcgccaggct 120

ccggggaagg gactggaatg ggtgtcctac atttcctcat ccggctccac catctactac 180

gcggactccg tgaaggggag attcaccatt agccgcgata acgccaagaa cagcctgtac 240

cttcagatga actccctgcg ggctgaagat actgccgtct actactgcgc aagggagagc 300

ggagatggga tggacgtctg gggacagggt accactgtga ccgtgtcgtc ggcctccggc 360

ggagggggtt cgggtggaag ggccagcggc ggcggaggca gcgacatcca gatgacccag 420

tccccctcat cgctgtccgc ctccgtgggc gaccgcgtca ccatcacatg ccgggcctca 480

cagtcgatct cctcctacct caattggtat cagcagaagc cgggaaaggc ccctaagctt 540

ctgatctacg cagcgtcctc cctgcaatcc ggggtcccat ctcggttctc cggctcgggc 600

agcggtaccg acttcactct gaccatctcg agcctgcagc cggaggactt cgccacttac 660

tactgtcagc aaagctacac cctcgcgttt ggccagggca ccaaagtgga catcaag 717

<210> 7964

<211> 717

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7964

gaagtgcaat tggtggaatc agggggagga cttgtgcagc ctggaggatc gctgagactg 60

120 tcatgtgccg tgtccggctt tgccctgtcc

cctggaaagg gcctcgaatg ggtgtcgggt attgtgtaca gcggtagcac ctactatgcc 180

gcatccgtga aggggagatt caccatcagc cgggacaact ccaggaacac tctgtacctc 240

caaatgaatt cgctgaggcc agaggacact gccatctact actgctccgc gcatggcgga 300

gagtccgacg tctggggaca ggggaccacc gtgaccgtgt ctagcgcgtc cggcgggaggc 360

ggcagcgggg gtcgggcatc agggggcggc ggatcggaca tccagctcac ccagtccccg 420

agctcgctgt ccgcctccgt gggagatcgg gtcaccatca cgtgccgcgc cagccagtcg 480

atttcctcct acctgaactg gtaccaacag aagcccggaa aagccccgaa gcttctcatc 540

tacgccgcct cgagcctgca gtcaggagtg ccctcacggt tctccggctc cggttccggt 600

actgatttca ccctgaccat ttcctccctg caaccgggagg acttcgctac ttactactgc 660

cagcagtcgt actccacccc ctacactttc ggacaaggca ccaaggtcga aatcaag 717

<210> 7965

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7965

caagtgcaac tggtgcaaag cggaggaggga ttggtcaaac ccggaggaag cctgagactg 60

tcatgcgcgg cctctggatt caccttctcc gattactaca tgtcatggat cagacaggcc 120

ccggggaagg gcctcgaatg ggtgtcctac atctcgtcct ccgggaacac catctactac 180

gccgacagcg tgaagggccg ctttaccatt tcccgcgaca acgcaaagaa ctcgctgtac 240

cttcagatga attccctgcg ggctgaagat accgcggtgt actattgcgc ccggtccact 300

atggtccggg aggactactg gggacagggc acactcgtga ccgtgtccag cgcgagcggg 360

ggtggaggca gcggtggacg cgcctccggc ggcggcggtt cagacatcgt gctgactcag 420

tcgcccctgt cgctgccggt caccctgggc caaccggcct caattagctg caagtcctcg 480

gagagcctgg tgcacaactc aggaaagact tacctgaact ggttccatca gcggcctgga 540

cagtccccac ggaggctcat ctatgaagtg tccaacaggg attcgggggt gcccgaccgc 600

ttcactggct ccgggtccgg caccgacttc accttgaaaa tctccagagt ggaagccgag 660

gacgtgggcg tgtactactg tatgcagggt acccactggc ctggaacctt tggacaagga 720

actaagctcg agattaag 738

<210> 7966

<211> 717

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7966

caagtgcaac tcgtggaatc tggtggagga ctcgtgcaac ccggtggaag ccttaggctg 60

tcgtgcgccg tcagcggggtt tgctctgagc aaccatggaa tgtcctgggt ccgccgggca 120

ccgggaaaag ggctggaatg ggtgtccggc atcgtgtaca gcgggtcaac ctattacgcc 180

gcgtccgtga agggcagatt cactatctca agagacaaca gccggaacac cctgtacttg 240

caaatgaatt ccctgcgccc cgaggacacc gccatctact actgctccgc ccacggagga 300

gagtcggacg tgtggggcca gggaacgact gtgactgtgt ccagcgcatc aggagggggt 360

ggttcgggcg gccgggcctc ggggggagga ggttccgaca ttcggctgac ccagtccccg 420

tccccactgt cggcctccgt cggcgaccgc gtgaccatca cttgtcaggc gtccgaggac 480

attaacaagt tcctgaactg gtaccaccag acccctggaa aggcccccaa gctgctgatc 540

tacgatgcct cgacccttca aactggagtg cctagccggt tctccgggtc cggctccggc 600

actgatttca ctctgaccat caactcattg cagccggaag atatcgggac ctactattgc 660

cagcagtacg aatccctccc gctcacattc ggcgggggaa ccaaggtcga gattaag 717

<210> 7967

<211> 720

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7967

gaagtgcaat tggtggaaac tggaggagga cttgtgcaac ctggaggatc attgcggctc 60

tcatgcgctg tctccggctt cgccctgtca aatcacggga tgtcgtgggt cagacgggcc 120

ccgggaaagg gtctggaatg ggtgtcgggg attgtgtaca gcggctccac ctactacgcc 180

gcttcggtca agggccgctt cactatttca cgggacaaca gccgcaacac cctctatctg 240

caaatgaact ctctccgccc ggaggatacc gccatctact actgctccgc acacggcggc 300

gaatccgacg tgtggggaca gggaaccact gtcaccgtgt cgtccgcatc cggtggcgga 360

ggatcgggtg gccgggcctc cgggggcggc ggcagcgaga ctaccctgac ccagtcccct 420

gccactctgt ccgtgagccc gggagagaga gccaccctta gctgccgggc cagccagagc 480

gtgggctcca acctggcctg gtaccagcag aagccaggac agggtcccag gctgctgatc 540

tacggagcct ccactcgcgc gaccggcatc cccgcgaggt tctccgggtc gggttccggg 600

accgagttca ccctgaccat ctcctccctc caaccgggagg acttcgcggt gtactactgt 660

cagcagtaca acgattggct gcccgtgaca tttggacagg ggacgaaggt ggaaatcaaa 720

<210> 7968

<211> 723

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 7968

gaagtgcaat tggtggaatc tggtggagga cttgtgcaac ctggaggatc actgagactg 60

tcatgcgcgg tgtccggttt tgccctgagc aatcatggga tgtcgtgggt ccggcgcgcc 120

ccgggaaagg gtctggaatg ggtgtcgggt atcgtctact ccgggagcac ttactacgcc 180

gcgagcgtga agggccgctt caccatttcc cgcgataact cccgcaacac cctgtacttg 240

caaatgaact cgctccggcc tgaggacact gccatctact actgctccgc acacggagga 300

gaatccgacg tgtggggcca gggaactacc gtgaccgtca gcagcgcctc cggcggcggg 360

ggctcaggcg gacgggctag cggcggcggt ggctccgaga tcgtgctgac ccagtcgcct 420

ggcactctct cgctgagccc cggggaaagg gcaaccctgt cctgtcgggc cagccagtcc 480

attggatcat cctccctcgc ctggtatcag cagaaaccgg gacaggctcc gcggctgctt 540

atgtatgggg ccagctcaag agcctccggc attcccgacc ggttctccgg gtccggttcc 600

ggcaccgatt tcaccctgac tatctcgagg ctggagccag aggacttcgc cgtgtactac 660

tgccagcagt acgcggggtc cccgccgttc acgttcggac agggaaccaa ggtcgagatc 720

aag 723

<210> 7969

<211> 120

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7969

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gly Trp Val

35 40 45

Ser Gly Ile Ser Arg Ser Gly Glu Asn Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Pro Ala His Tyr Tyr Gly Gly Met Asp Val Trp Gly Gln

100 105 110

Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 7970

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7970

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Glu Trp Val

35 40 45

Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ser Val His Ser Phe Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

<210> 7971

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7971

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7972

<211> 120

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7972

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Arg Lys Thr Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Asp Asn Phe

20 25 30

Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Asn Pro Lys Asn Asn Asn Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr

65 70 75 80

Met Glu Val Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Pro Tyr Tyr Tyr Gln Ser Tyr Met Asp Val Trp Gly Gln

100 105 110

Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 7973

<211> 123

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7973

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp

20 25 30

Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Val Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Leu Asp Ser Ser Gly Tyr Tyr Tyr Ala Arg Gly Pro Arg Tyr

100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 7974

<211> 118

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7974

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asn Tyr

20 25 30

Gly Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Pro Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr

100 105 110

Met Val Thr Val Ser Ser

115

<210> 7975

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7975

Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7976

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7976

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7977

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7977

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Val Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7978

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7978

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Glu Ser Gly Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser

115

<210> 7979

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7979

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7980

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7980

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Asn Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Met Val Arg Glu Asp Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser

115

<210> 7981

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7981

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7982

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7982

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7983

<211> 115

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7983

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ala Leu Ser Asn His

20 25 30

Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ser

85 90 95

Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln Gly Thr Thr Val Thr

100 105 110

Val Ser Ser

115

<210> 7984

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7984

Asp Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 7985

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7985

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 7986

<211> 111

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7986

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly

1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Arg Asn

20 25 30

Asp Gly Lys Thr Pro Leu Tyr Trp Tyr Leu Gln Lys Ala Gly Gln Pro

35 40 45

Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Ala Tyr Tyr Cys Met Gln Asn

85 90 95

Ile Gln Phe Pro Ser Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 7987

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7987

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Lys Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu His Ile

65 70 75 80

Thr Arg Val Gly Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 7988

<211> 106

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7988

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Thr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr His Phe Thr Leu Thr Ile Asn Ser Leu Gln Ser

65 70 75 80

Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Lys Arg Ala Ser

85 90 95

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7989

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7989

Glu Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser

20 25 30

Asn Gly Tyr Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Lys Leu Gln Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly

85 90 95

Arg Gln Phe Pro Tyr Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 7990

<211> 106

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7990

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly

1 5 10 15

Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala

65 70 75 80

Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr

85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7991

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7991

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Lys

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Met

35 40 45

Tyr Gly Ala Ser Ile Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Ser Ser Trp

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7992

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7992

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Thr

20 25 30

Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro

85 90 95

Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7993

<211> 105

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7993

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Leu Ala Phe

85 90 95

Gly Gln Gly Thr Lys Val Asp Ile Lys

100 105

<210> 7994

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7994

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr

85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7995

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7995

Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly

1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Glu Ser Leu Val His Asn

20 25 30

Ser Gly Lys Thr Tyr Leu Asn Trp Phe His Gln Arg Pro Gly Gln Ser

35 40 45

Pro Arg Arg Leu Ile Tyr Glu Val Ser Asn Arg Asp Ser Gly Val Pro

50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly

85 90 95

Thr His Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 7996

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7996

Asp Ile Arg Leu Thr Gln Ser Pro Ser Pro Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asp Ile Asn Lys Phe

20 25 30

Leu Asn Trp Tyr His Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Asp Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro

65 70 75 80

Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Glu Ser Leu Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7997

<211> 108

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7997

Glu Thr Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Asn

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Gly Pro Arg Leu Leu Ile

35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asp Trp Leu Pro

85 90 95

Val Thr Phe Gly Glyn Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7998

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 7998

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Ser Ser

20 25 30

Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Met Tyr Gly Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Gly Ser Pro

85 90 95

Pro Phe Thr Phe Gly Glyn Gly Thr Lys Val Glu Ile Lys

100 105

<210> 7999

<400> 7999

000

<210> 8000

<400> 8000

000

<210> 8001

<400> 8001

000

<210> 8002

<400> 8002

000

<210> 8003

<400> 8003

000

<210> 8004

<400> 8004

000

<210> 8005

<400> 8005

000

<210> 8006

<400> 8006

000

<210> 8007

<400> 8007

000

<210> 8008

<400> 8008

000

<210> 8009

<400> 8009

000

<210> 8010

<400> 8010

000

<210> 8011

<400> 8011

000

<210> 8012

<400> 8012

000

<210> 8013

<400> 8013

000

<210> 8014

<400> 8014

000

<210> 8015

<400> 8015

000

<210> 8016

<400> 8016

000

<210> 8017

<400> 8017

000

<210> 8018

<400> 8018

000

<210> 8019

<400> 8019

000

<210> 8020

<400> 8020

000

<210> 8021

<400> 8021

000

<210> 8022

<400> 8022

000

<210> 8023

<400> 8023

000

<210> 8024

<400> 8024

000

<210> 8025

<400> 8025

000

<210> 8026

<400> 8026

000

<210> 8027

<400> 8027

000

<210> 8028

<400> 8028

000

<210> 8029

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8029

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Tyr Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Ala Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg His Trp Gln Glu Trp Pro Asp Ala Phe Asp Ile Trp Gly

100 105 110

Gly Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Glu Thr Thr Leu Thr Gln Ser Pro

130 135 140

Ala Phe Met Ser Ala Thr Pro Gly Asp Lys Val Ile Ile Ser Cys Lys

145 150 155 160

Ala Ser Gln Asp Ile Asp Asp Ala Met Asn Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Glu Ala Pro Leu Phe Ile Ile Gln Ser Ala Thr Ser Pro Val Pro

180 185 190

Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Ser

195 200 205

Leu Thr Ile Asn Asn Ile Glu Ser Glu Asp Ala Ala Tyr Tyr Phe Cys

210 215 220

Leu Gln His Asp Asn Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 8030

<211> 245

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8030

Gln Val Asn Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln

1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Arg Thr Ser

20 25 30

Gly Met Cys Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu

35 40 45

Trp Leu Ala Arg Ile Asp Trp Asp Glu Asp Lys Phe Tyr Ser Thr Ser

50 55 60

Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Asp Asn Gln Val

65 70 75 80

Val Leu Arg Met Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr

85 90 95

Cys Ala Arg Ser Gly Ala Gly Gly Thr Ser Ala Thr Ala Phe Asp Ile

100 105 110

Trp Gly Pro Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln

130 135 140

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr

145 150 155 160

Cys Arg Ala Ser Gln Asp Ile Tyr Asn Asn Leu Ala Trp Phe Gln Leu

165 170 175

Lys Pro Gly Ser Ala Pro Arg Ser Leu Met Tyr Ala Ala Asn Lys Ser

180 185 190

Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp

195 200 205

Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr

210 215 220

Tyr Cys Gln His Tyr Tyr Arg Phe Pro Tyr Ser Phe Gly Gln Gly Thr

225 230 235 240

Lys Leu Glu Ile Lys

245

<210> 8031

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8031

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ser Ile Ser Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Thr Ile Ala Ala Val Tyr Ala Phe Asp Ile Trp Gly Gln Gly

100 105 110

Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

115 120 125

Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Leu Ser

130 135 140

Leu Pro Val Thr Pro Glu Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser

145 150 155 160

Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu

165 170 175

Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn

180 185 190

Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr

195 200 205

Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val

210 215 220

Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly

225 230 235 240

Thr Lys Leu Glu Ile Lys

245

<210> 8032

<211> 240

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8032

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Leu Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met

100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Ser Pro Ser Val Ser Ala

130 135 140

Ala Pro Gly Tyr Thr Ala Thr Ile Ser Cys Gly Gly Asn Asn Ile Gly

145 150 155 160

Thr Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Leu

165 170 175

Leu Val Ile Arg Asp Asp Ser Val Arg Pro Ser Lys Ile Pro Gly Arg

180 185 190

Phe Ser Gly Ser Asn Ser Gly Asn Met Ala Thr Leu Thr Ile Ser Gly

195 200 205

Val Gln Ala Gly Asp Glu Ala Asp Phe Tyr Cys Gln Val Trp Asp Ser

210 215 220

Asp Ser Glu His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

225 230 235 240

<210> 8033

<211> 241

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8033

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Pro Ser Gly Tyr Thr Val Thr Ser His

20 25 30

Tyr Ile His Trp Val Arg Arg Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Met Ile Asn Pro Ser Gly Val Thr Ala Tyr Ser Gln Thr Leu

50 55 60

Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ser Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys

85 90 95

Ala Arg Glu Gly Ser Gly Ser Gly Trp Tyr Phe Asp Phe Trp Gly Arg

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser

130 135 140

Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp

145 150 155 160

Gly Leu Ser Lys Lys Tyr Val Ser Trp Tyr Gln Gln Lys Ala Gly Gln

165 170 175

Ser Pro Val Val Leu Ile Ser Arg Asp Lys Glu Arg Pro Ser Gly Ile

180 185 190

Pro Asp Arg Phe Ser Gly Ser Asn Ser Ala Asp Thr Ala Thr Leu Thr

195 200 205

Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala

210 215 220

Trp Asp Asp Thr Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val

225 230 235 240

Leu

<210> 8034

<211> 245

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8034

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly

20 25 30

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Ala Gly Ile Ala Ala Arg Leu Arg Gly Ala Phe Asp Ile

100 105 110

Trp Gly Glyn Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln

130 135 140

Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Ile Ile Thr

145 150 155 160

Cys Arg Ala Ser Gln Gly Ile Arg Asn Trp Leu Ala Trp Tyr Gln Gln

165 170 175

Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Asn Leu

180 185 190

Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp

195 200 205

Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr

210 215 220

Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr

225 230 235 240

Lys Val Asp Ile Lys

245

<210> 8035

<211> 253

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8035

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr

20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Gly Gly Tyr Gln Leu Leu Arg Trp Asp Val Gly Leu Leu

100 105 110

Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser

115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

130 135 140

Ser Tyr Val Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Gln

145 150 155 160

Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val

165 170 175

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Leu Tyr

180 185 190

Gly Lys Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser

195 200 205

Arg Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu

210 215 220

Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Arg Asp Ser Ser Gly Asp His

225 230 235 240

Leu Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu

245 250

<210> 8036

<211> 248

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8036

Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn

20 25 30

Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu

35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Phe Tyr Ala

50 55 60

Ile Ser Leu Lys Ser Arg Ile Ile Ile Asn Pro Asp Thr Ser Lys Asn

65 70 75 80

Gln Phe Ser Leu Gln Leu Lys Ser Val Thr Pro Glu Asp Thr Ala Val

85 90 95

Tyr Tyr Cys Ala Arg Ser Ser Pro Glu Gly Leu Phe Leu Tyr Trp Phe

100 105 110

Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Asp

115 120 125

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Ser Glu Leu

130 135 140

Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Ile Arg Ile

145 150 155 160

Thr Cys Gln Gly Asp Ser Leu Gly Asn Tyr Tyr Ala Thr Trp Tyr Gln

165 170 175

Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Gly Thr Asn Asn

180 185 190

Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala Ser Ser Ser Gly Asn

195 200 205

Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp

210 215 220

Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly His His Leu Leu Phe Gly

225 230 235 240

Thr Gly Thr Lys Val Thr Val Leu

245

<210> 8037

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8037

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Glu Gly Ser Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu

130 135 140

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

145 150 155 160

Ser Val Ser Ser Ala Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln

165 170 175

Pro Pro Arg Leu Leu Ile Ser Gly Ala Ser Thr Arg Ala Thr Gly Ile

180 185 190

Pro Asp Arg Phe Gly Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr

195 200 205

Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His

210 215 220

Tyr Gly Ser Ser Phe Asn Gly Ser Ser Leu Phe Thr Phe Gly Gln Gly

225 230 235 240

Thr Arg Leu Glu Ile Lys

245

<210> 8038

<211> 241

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8038

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Arg Tyr

20 25 30

Pro Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Ser Asp Ser Gly Val Ser Thr Tyr Tyr Ala Asp Ser Ala

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Thr Arg Ala Gly Ser Glu Ala Ser Asp Ile Trp Gly Gln Gly Thr

100 105 110

Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu

130 135 140

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

145 150 155 160

Ser Val Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala

165 170 175

Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro

180 185 190

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile

195 200 205

Ser Arg Leu Glu Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Phe

210 215 220

Gly Thr Ser Ser Gly Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile

225 230 235 240

Lys

<210> 8039

<211> 248

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8039

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys

85 90 95

Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Glyn Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly

115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr

130 135 140

Gln Ser Pro Gly Thr Val Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu

145 150 155 160

Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser

180 185 190

Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala

210 215 220

Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro Ser Trp Thr Phe Gly

225 230 235 240

Gln Gly Thr Arg Leu Glu Ile Lys

245

<210> 8040

<211> 248

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8040

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly

115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr

130 135 140

Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu

145 150 155 160

Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Thr Phe Leu Ala Trp Tyr

165 170 175

Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ser Ser

180 185 190

Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Phe Thr Leu Thr Ile Arg Arg Leu Glu Pro Glu Asp Phe Ala

210 215 220

Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro Ser Trp Thr Phe Gly

225 230 235 240

Gln Gly Thr Lys Val Glu Ile Lys

245

<210> 8041

<211> 239

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8041

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Glu Trp Val

35 40 45

Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Val Gly Lys Ala Val Pro Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser

130 135 140

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser

145 150 155 160

Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro

165 170 175

Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser

180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

195 200 205

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr

210 215 220

Ser Thr Pro Tyr Ser Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys

225 230 235

<210> 8042

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8042

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Ser Ile Asn Trp Lys Gly Asn Ser Leu Ala Tyr Gly Asp Ser Val

50 55 60

Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Ser His Gln Gly Val Ala Tyr Tyr Asn Tyr Ala Met Asp Val Trp

100 105 110

Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

130 135 140

Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

145 150 155 160

Arg Ala Thr Gln Ser Ile Gly Ser Ser Phe Leu Ala Trp Tyr Gln Gln

165 170 175

Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Gln Arg

180 185 190

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp

195 200 205

Phe Thr Leu Thr Ile Ser Arg Val Glu Pro Glu Asp Ser Ala Val Tyr

210 215 220

Tyr Cys Gln His Tyr Glu Ser Ser Pro Ser Trp Thr Phe Gly Gln Gly

225 230 235 240

Thr Lys Val Glu Ile Lys

245

<210> 8043

<211> 241

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8043

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Val Arg Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser

130 135 140

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

145 150 155 160

Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala

165 170 175

Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro

180 185 190

Asp Arg Phe Ser Gly Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile

195 200 205

Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr

210 215 220

Gly Ser Pro Pro Arg Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile

225 230 235 240

Lys

<210> 8044

<211> 242

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8044

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Ile Pro Gln Thr Gly Thr Phe Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

115 120 125

Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu

130 135 140

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln

145 150 155 160

Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln

165 170 175

Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile

180 185 190

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr

195 200 205

Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His

210 215 220

Tyr Gly Ser Ser Pro Ser Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu

225 230 235 240

Ile Lys

<210> 8045

<211> 248

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8045

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Met Ser Arg Glu Asn Asp Lys Asn Ser Val Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Val Tyr Tyr Cys

85 90 95

Ala Arg Ala Asn Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Glyn Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly

115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr

130 135 140

Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu

145 150 155 160

Ser Cys Arg Ala Ser Gln Arg Val Ala Ser Asn Tyr Leu Ala Trp Tyr

165 170 175

Gln His Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Ser Gly Ala Ser

180 185 190

Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly

195 200 205

Thr Asp Phe Thr Leu Ala Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala

210 215 220

Val Tyr Tyr Cys Gln His Tyr Asp Ser Ser Pro Ser Trp Thr Phe Gly

225 230 235 240

Gln Gly Thr Lys Val Glu Ile Lys

245

<210> 8046

<211> 244

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8046

Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Ala Leu Val Gly Ala Thr Gly Ala Phe Asp Ile Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly

130 135 140

Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala

145 150 155 160

Ser Gln Ser Leu Ser Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Gln Ala Pro Gly Leu Leu Ile Tyr Gly Ala Ser Asn Trp Ala Thr

180 185 190

Gly Thr Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

195 200 205

Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys

210 215 220

Gln Tyr Tyr Gly Thr Ser Pro Met Tyr Thr Phe Gly Gln Gly Thr Lys

225 230 235 240

Val Glu Ile Lys

<210> 8047

<211> 244

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8047

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Leu Trp Phe Gly Glu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro

130 135 140

Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser

145 150 155 160

Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys

165 170 175

Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala

180 185 190

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

195 200 205

Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr

210 215 220

Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys

225 230 235 240

Val Asp Ile Lys

<210> 8048

<211> 251

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8048

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Gly Tyr Asp Ser Ser Gly Tyr Tyr Arg Asp Tyr Tyr Gly

100 105 110

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly

115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val

130 135 140

Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala

145 150 155 160

Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

165 170 175

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly

180 185 190

Thr Ser Ser Arg Ala Thr Gly Ile Ser Asp Arg Phe Ser Gly Ser Gly

195 200 205

Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp

210 215 220

Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Asn Ser Pro Pro Lys Phe

225 230 235 240

Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys

245 250

<210> 8049

<211> 246

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8049

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Met Gly Trp Ser Ser Gly Tyr Leu Gly Ala Phe Asp Ile Trp

100 105 110

Gly Glyn Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

130 135 140

Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

145 150 155 160

Arg Ala Ser Gln Ser Val Ala Ser Ser Phe Leu Ala Trp Tyr Gln Gln

165 170 175

Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Gly Arg

180 185 190

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp

195 200 205

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr

210 215 220

Tyr Cys Gln His Tyr Gly Gly Ser Pro Arg Leu Thr Phe Gly Gly Gly

225 230 235 240

Thr Lys Val Asp Ile Lys

245

<210> 8050

<211> 729

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8050

caagtgcagc ttcaggaaag cggaccgggc ctggtcaagc catccgaaac tctctccctg 60

acttgcactg tgtctggcgg ttccatctca tcgtcgtact actactgggg ctggattagg 120

cagccgcccg gaaagggact ggagtggatc ggaagcatct actattccgg ctcggcgtac 180

tacaacccta gcctcaagtc gagagtgacc atctccgtgg atacctccaa gaaccagttt 240

tccctgcgcc tgagctccgt gaccgccgct gacaccgccg tgtactactg tgctcggcat 300

tggcaggaat ggcccgatgc cttcgacatt tggggccagg gcactatggt cactgtgtca 360

tccggggggtg gaggcagcgg gggaggaggg tccgggggggg gaggttcaga gacaaccttg 420

acccagtcac ccgcattcat gtccgccact ccgggagaca aggtcatcat ctcgtgcaaa 480

gcgtcccagg atatcgacga tgccatgaat tggtaccagc agaagcctgg cgaagcgccg 540

ctgttcatta tccaatccgc aacctcgccc gtgcctggaa tcccaccgcg gttcagcggc 600

agcggtttcg gaaccgactt ttccctgacc attaacaaca ttgagtccga ggacgccgcc 660

tactacttct gcctgcaaca cgacaacttc cctctcacgt tcggccaggg aaccaagctg 720

gaaatcaag 729

<210> 8051

<211> 735

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8051

caagtcaatc tgcgcgaatc cggccccgcc ttggtcaagc ctacccagac cctcactctg 60

acctgtactt tctccggctt ctccctgcgg acttccggga tgtgcgtgtc ctggatcaga 120

cagcctccgg gaaaggccct ggagtggctc gctcgcattg actgggatga ggacaagttc 180

tactccacct cactcaagac caggctgacc atcagcaaag atacctctga caaccaagtg 240

gtgctccgca tgaccaacat ggacccagcc gacactgcca cttactactg cgcgaggagc 300

ggagcggggcg gaacctccgc caccgccttc gatatttggg gcccgggtac catggtcacc 360

gtgtcaagcg gaggaggggg gtccggggggc ggcggttccg ggggaggcgg atcggacatt 420

cagatgactc agtcaccatc gtccctgagc gctagcgtgg gcgacagagt gacaatcact 480

tgccgggcat cccaggacat ctataacaac cttgcgtggt tccagctgaa gcctggttcc 540

gcaccgcggt cacttatgta cgccgccaac aagagccagt cgggagtgcc gtcccggttt 600

tccggttcgg ccctcgggaac tgacttcacc ctgacgatct ccagcctgca acccgaggat 660

ttcgccacct actactgcca gcactactac cgctttccct actcgttcgg acagggaacc 720

aagctggaaa tcaag 735

<210> 8052

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8052

gaagtgcagc ttgtcgaatc cgggggggga ctggtcaagc cgggcggatc actgagactg 60

tcctgcgccg cgagcggctt cacgttctcc tcctactcca tgaactgggt ccgccaagcc 120

cccgggaagg gactggaatg ggtgtcctct atctcctcgt cgtcgtccta catctactac 180

gccgactccg tgaagggaag attcaccatt tcccgcgaca acgcaaagaa ctcactgtac 240

ttgcaaatga actcactccg ggccgaagat actgctgtgt actattgcgc caagactatt 300

gccgccgtct acgctttcga catctggggc cagggaacca ccgtgactgt gtcgtccggt 360

ggtggtggct cgggcgggagg aggaagcggc ggcggggggt ccgagattgt gctgacccag 420

tcgccactga gcctccctgt gacccccgag gaacccgcca gcatcagctg ccggtccagc 480

cagtccctgc tccactccaa cggatacaat tacctcgatt ggtaccttca gaagcctgga 540

caaagcccgc agctgctcat ctacttggga tcaaaccgcg cgtcaggagt gcctgaccgg 600

ttctccggct cgggcagcgg taccgatttc accctgaaaa tctccagggt ggaggcagag 660

gacgtgggag tgtattactg tatgcaggcg ctgcagactc cgtacacatt tgggcaggggc 720

accaagctgg agatcaag 738

<210> 8053

<211> 720

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8053

gaagtccagc tcgtggagtc cggcggaggc cttgtgaagc ctggaggttc gctgagactg 60

tcctgcgccg cctccggctt caccttctcc gactactaca tgtcctggat cagacaggcc 120

ccgggaaagg gcctggaatg ggtgtcctac atctcgtcat cgggcagcac tatctactac 180

gcggactcag tgaaggggcg gttcaccatt tcccgggata acgcgaagaa ctcgctgtat 240

ctgcaaatga actcactgag ggccgaggac accgccgtgt actactgcgc ccgcgatctc 300

cgcggggcat ttgacatctg gggacaggga accatggtca cagtgtccag cggaggggga 360

ggatcgggtg gcggaggttc cggggggtgga ggctcctcct acgtgctgac tcagagccca 420

agcgtcagcg ctgcgccgg ttacacggca accatctcct gtggcggaaa caacattggg 480

accaagtctg tgcactggta tcagcagaag ccgggccaag ctcccctgtt ggtgatccgc 540

gatgactccg tgcggcctag caaaattccg ggacggttct ccggctccaa cagcggcaat 600

atggccactc tcaccatctc gggagtgcag gccggagatg aagccgactt ctactgccaa 660

gtctgggact cagactccga gcatgtggtg ttcgggggcg gaaccaagct gactgtgctc 720

<210> 8054

<211> 723

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8054

caagtgcagc tggtgcagag cggggccgaa gtcaagaagc cgggagcctc cgtgaaagtg 60

tcctgcaagc cttcgggata caccgtgacc tcccactaca ttcattgggt ccgccgcgcc 120

cccggccaag gactcgagtg gatgggcatg atcaacccta gcggcggagt gaccgcgtac 180

agccagacgc tgcagggacg cgtgactatg acctcggata cctcctcctc caccgtctat 240

atggaactgt ccagcctgcg gtccgaggat accgccatgt actactgcgc ccgggaagga 300

tcaggctccg ggtggtattt cgacttctgg ggaagaggca ccctcgtgac tgtgtcatct 360

gggggagggg gttccggtgg tggcggatcg ggaggaggcg gttcatccta cgtgctgacc 420

cagccaccct ccgtgtccgt gagccccggc cagactgcat cgattacatg tagcggcgac 480

ggcctctcca agaaatacgt gtcgtggtac cagcagaagg ccggacagag cccggtggtg 540

ctgatctcaa gagataagga gcggcctagc ggaatcccgg acaggttctc gggttccaac 600

tccgcggaca ctgctactct gaccatctcg gggacccagg ctatggacga agccgattac 660

tactgccaag cctgggacga cactactgtc gtgtttggag ggggcaccaa gttgaccgtc 720

ctt 723

<210> 8055

<211> 735

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8055

caagtgcagc ttcaggagag cggcccggga ctcgtgaagc cgtcccagac cctgtccctg 60

acttgcaccg tgtcgggagg aagcatctcg agcggaggct actattggtc gtggattcgg 120

cagcaccctg gaaagggcct ggaatggatc ggctacatct actactccgg ctcgacctac 180

tacaacccat cgctgaagtc cagagtgaca atctcagtgg acacgtccaa gaatcagttc 240

agcctgaagc tctcttccgt gactgcggcc gacaccgccg tgtactactg cgcacgcgct 300

ggaattgccg cccggctgag gggtgccttc gacatttggg gacaggggcac catggtcacc 360

gtgtcctccg gcggcggagg ttccgggggt ggaggctcag gaggaggggg gtccgacatc 420

gtcatgactc agtcgccctc aagcgtcagc gcgtccgtcg gggacagagt gatcatcacc 480

tgtcgggcgt cccagggaat tcgcaactgg ctggcctggt atcagcagaa gccgggaaag 540

gcccccaacc tgttgatcta cgccgcctca aacctccaat ccggggtgcc gagccgcttc 600

agcggctccg gttcgggtgc cgatttcact ctgaccatct cctccctgca acctgaagat 660

gtggctacct actactgcca aaagtacaac tccgcacctt ttactttcgg accggggacc 720

aaagtggaca ttaag 735

<210> 8056

<211> 759

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8056

caagtgcagc tggtccagtc gggcgccgag gtcaagaagc ccgggagctc tgtgaaagtg 60

tcctgcaagg cctccggggg cacctttagc tcctacgcca tctcctgggt ccgccaagca 120

ccgggtcaag gcctggagtg gatgggggga attatcccta tcttcggcac tgccaactac 180

gcccagaagt tccagggacg cgtgaccatt accgcggacg aatccacctc caccgcttat 240

atggagctgt ccagcttgcg ctcggaagat accgccgtgt actactgcgc ccggaggggt 300

ggataccagc tgctgagatg ggacgtgggc ctcctgcggt cggcgttcga catctggggc 360

cagggcacta tggtcactgt gtccagcgga ggaggcggat cgggaggcgg cggatcaggg 420

ggaggcggtt ccagctacgt gcttactcaa cccccttcgg tgtccgtggc cccgggacag 480

accgccagaa tcacttgcgg aggaaacaac attgggtcca agagcgtgca ttggtaccag 540

cagaagccag gacaggcccc tgtgctggtg ctctacggga agaacaatcg gcccagcgga 600

gtgccggaca ggttctcggg ttcacgctcc ggtacaaccg cttcactgac tatcaccggg 660

gcccaggcag aggatgaagc ggactactac tgttcctccc gggattcatc cggcgaccac 720

ctccgggtgt tcggaaccgg aacgaaggtc accgtgctg 759

<210> 8057

<211> 744

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8057

gaagtgcagc tccaacagtc aggaccgggg ctcgtgaagc catcccagac cctgtccctg 60

acttgtgcca tctcgggaga tagcgtgtca tcgaactccg ccgcctggaa ctggattcgg 120

cagagcccgt cccgcggact ggagtggctt ggaaggacct actaccggtc caagtggtac 180

tctttctacg cgatctcgct gaagtcccgc attatcatta accctgatac ctccaagaat 240

cagttctccc tccaactgaa atccgtcacc cccgaggaca cagcagtgta ttactgcgca 300

cggagcagcc ccgaaggact gttcctgtat tggtttgacc cctggggcca ggggactctt 360

gtgaccgtgt cgagcggcgg agatgggtcc ggtggcggtg gttcgggggg cggcggatca 420

tcatccgaac tgacccagga cccggctgtg tccgtggcgc tgggacaaac catccgcatt 480

acgtgccagg gagactccct gggcaactac tacgccactt ggtaccagca gaagccggggc 540

caagcccctg tgttggtcat ctacgggacc aacaacagac cttccggcat ccccgaccgg 600

ttcagcgctt cgtcctccgg caacactgcc agcctgacca tcactggagc gcaggccgaa 660

gatgaggccg actactactg caacagcaga gactcctcgg gtcatcacct cttgttcgga 720

actggaacca aggtcaccgt gctg 744

<210> 8058

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8058

gaagtgcagc tcgtggagtc aggaggcggc ctggtccagc cgggagggtc ccttagactg 60

tcatgcgccg caagcggatt cactttctcc tcctatgcca tgagctgggt ccgccaagcc 120

ccgggaaagg gactggaatg ggtgtccgcc atctcggggt ctggaggctc aacttactac 180

gctgactccg tgaagggacg gttcaccatt agccgcgaca actccaagaa caccctctac 240

ctccaaatga actccctgcg ggccgaggat accgccgtct actactgcgc caaagtggaa 300

ggttcaggat cgctggacta ctggggacag ggtactctcg tgaccgtgtc atcgggcgga 360

ggaggttccg gcggtggcgg ctccggcggc ggagggtcgg agatcgtgat gacccagagc 420

cctggtactc tgagcctttc gccgggagaa agggccaccc tgtcctgccg cgcttcccaa 480

tccgtgtcct ccgcgtactt ggcgtggtac cagcagaagc cgggacagcc ccctcggctg 540

ctgatcagcg gggccagcac ccgggcaacc ggaatcccag acagattcgg gggttccggc 600

agcggcacag atttcaccct gactatttcg aggttggagc ccgaggactt tgcggtgtat 660

tactgtcagc actacgggtc gtcctttaat ggctccagcc tgttcacgtt cggacagggg 720

acccgcctgg aaatcaag 738

<210> 8059

<211> 723

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8059

gaagtgcaac tggtggaaac cggtggcggc ctggtgcagc ctggaggatc attgaggctg 60

tcatgcgcgg ccagcggtat taccttctcc cggtacccca tgtcctggggt cagacaggcc 120

ccggggaaag ggcttgaatg ggtgtccggg atctcggact ccggtgtcag cacttactac 180

gccgactccg ccaagggacg cttcaccatt tcccgggaca actcgaagaa caccctgttc 240

ctccaaatga gctccctccg ggacgaggat actgcagtgt actactgcgt gacccgcgcc 300

gggtccgagg cgtctgacat ttggggacag ggcactatgg tcaccgtgtc gtccggcgga 360

gggggctcgg gaggcggtgg cagcggagga ggagggtccg agatcgtgct gacccaatcc 420

ccggccaccc tctcgctgag ccctggagaa agggcaacct tgtcctgtcg cgcgagccag 480

tccgtgagca actccctggc ctggtaccag cagaagcccg gacaggctcc gagacttctg 540

atctacgacg cttcgagccg ggccactgga atccccgacc gcttttcggg gtccggctca 600

ggaaccgatt tcaccctgac aatctcacgg ctggagccag aggatttcgc catctattac 660

tgccagcagt tcggtacttc ctccggcctg actttcggag gcggcacgaa gctcgaaatc 720

aag 723

<210> 8060

<211> 744

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8060

caagtgcagc tcgtggaatc gggtggcgga ctggtgcagc cggggggctc acttagactg 60

tcctgcgcgg ccagcggatt cactttctcc tcctacgcca tgtcctggggt cagacaggcc 120

cctggaaagg gcctggaatg ggtgtccgca atcagcggca gcggcggctc gacctattac 180

gcggattcag tgaagggcag attcaccatt tcccgggaca acgccaagaa ctccttgtac 240

cttcaaatga actccctccg cgcggaagat accgcaatct actactgcgc tcgggccact 300

tacaagaggg aactgcgcta ctactacggg atggacgtct ggggccaggg aaccatggtc 360

accgtgtcca gcggaggagg aggatcggga ggaggcggta gcgggggtgg agggtcggag 420

atcgtgatga cccagtcccc cggcactgtg tcgctgtccc ccggcgaacg ggccaccctg 480

tcatgtcggg ccagccagtc agtgtcgtca agcttcctcg cctggtacca gcagaaaccg 540

ggacaagctc cccgcctgct gatctacgga gccagcagcc gggccaccgg tattcctgac 600

cggttctccg gttcggggtc cgggaccgac tttactctga ctatctctcg cctcgagcca 660

gaggactccg ccgtgtatta ctgccagcag taccactcct ccccgtcctg gacgttcgga 720

cagggcacaa ggctggagat taag 744

<210> 8061

<211> 744

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8061

60

tcctgcgccg cgtccggctt caccttctcc tcgtacgcca tgtcctggggt ccgccaggcc 120

ccgggaaagg gcctggaatg ggtgtccgcc atctctggaa gcgggaggttc cacgtactac 180

gcggacagcg tcaagggaag gttcacaatc tcccgcgata attcgaagaa cactctgtac 240

cttcaaatga acaccctgaa ggccgaggac actgctgtgt actactgcgc acggggccacc 300

tacaagagag agctccggta ctactacgga atggacgtct ggggccaggg aactactgtg 360

accgtgtcct cgggggggg tggctccgggg gggggcggct ccggcgggagg cggttccgag 420

attgtgctga cccagtcacc ttcaactctg tcgctgtccc cggggagagag cgctactctg 480

agctgccggg ccagccagtc cgtgtccacc accttcctcg cctggtatca gcagaagccg 540

gggcaggcac cacggctctt gatctacggg tcaagcaaca gagcgaccgg aattcctgac 600

cgcttctcgg ggagcggttc aggcaccgac ttcaccctga ctatccggcg cctggaaccc 660

gaagatttcg ccgtgtatta ctgtcaacag taccactcct cgccgtcctg gacctttggc 720

caaggaacca aagtggaaat caag 744

<210> 8062

<211> 717

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8062

gaagtgcagc tcgtggaaac tggaggtgga ctcgtgcagc ctggacggtc gctgcggctg 60

agctgcgctg catccggctt caccttcgac gattatgcca tgcactgggt cagacaggcg 120

ccagggaagg gacttgagtg ggtgtccggt atcagctgga atagcggctc aatcggatac 180

gcggactccg tgaagggaag gttcaccatt tcccgcgaca acgccaagaa ctccctgtac 240

ttgcaaatga acagcctccg ggatgaggac actgccgtgt actactgcgc ccgcgtcgga 300

aaagctgtgc ccgacgtctg gggccaggga accactgtga ccgtgtccag cggcgggggt 360

ggatcgggcg gtggagggtc cggtggaggg ggctcagata ttgtgatgac cggaccccc 420

tcgtccctgt ccgcctcggt cggcgaccgc gtgactatca catgtagagc ctcgcagagc 480

atctccagct acctgaactg gtatcagcag aagccgggga aggccccgaa gctcctgatc 540

tacgcggcat catcactgca atcgggagtg ccgagccggt tttccgggtc cggctccggc 600

accgacttca cgctgaccat ttcttccctg caacccgagg acttcgccac ttactactgc 660

cagcagtcct actccacccc ttactccttc ggccaaggaa ccaggctgga aatcaag 717

<210> 8063

<211> 738

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8063

60

tcctgcactg cgtctggctt caccttcgac gactacgcga tgcactgggt cagacagcgc 120

ccgggaaagg gcctggaatg ggtcgcctca atcaactgga agggaaactc cctggcctat 180

ggcgacagcg tgaagggccg cttcgccatt tcgcgcgaca acgccaagaa caccgtgttt 240

ctgcaaatga attccctgcg gaccgaggat accgctgtgt actactgcgc cagccaccag 300

ggcgtggcat actataacta cgccatggac gtgtggggaa gagggacgct cgtcaccgtg 360

tcctccgggg gcggtggatc gggtggagga ggaagcggtg gcgggggcag cgaaatcgtg 420

ctgactcaga gcccgggaac tctttcactg tccccgggag aacgggccac tctctcgtgc 480

cgggccaccc agtccatcgg ctcctccttc cttgcctggt accagcagag gccaggacag 540

gcgccccgcc tgctgatcta cggtgcttcc caacgcgcca ctggcattcc tgaccggttc 600

agcggcagag ggtcgggaac cgatttcaca ctgaccattt cccgggtgga gcccgaagat 660

tcggcagtct actactgtca gcattacgag tcctcccctt catggacctt cggtcaaggg 720

accaaagtgg agatcaag 738

<210> 8064

<211> 723

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8064

gaggtgcagt tggtcgaaag cggggggcggg cttgtgcagc ctggcggatc actgcggctg 60

tcctgcgcgg catcaggctt cacgttttct tcctacgcca tgtcctggggt gcgccaggcc 120

cctggaaagg gactggaatg ggtgtccgcg atttcggggt ccggcgggag cacctactac 180

gccgattccg tgaagggccg cttcactatc tcgcgggaca actccaagaa caccctctac 240

ctccaaatga atagcctgcg ggccgaggat accgccgtct actattgcgc taaggtcgtg 300

cgcgacggaa tggacgtgtg gggacagggt accaccgtga cagtgtcctc ggggggaggc 360

ggtagcggcg gaggaggaag cggtggtgga ggttccgaga ttgtgctgac tcaatcaccc 420

gcgaccctga gcctgtcccc cggcgaaagg gccactctgt cctgtcgggc cagccaatca 480

gtctcctcct cgtacctggc ctggtaccag cagaagccag gacaggctcc gagactcctt 540

atctatggcg catcctcccg cgccaccgga atcccggata ggttctcggg aaacggatcg 600

gggaccgact tcactctcac catctcccgg ctggaaccgg aggacttcgc cgtgtactac 660

tgccagcagt acggcagccc gcctagattc actttcggcc ccggcaccaa agtggacatc 720

aag 723

<210> 8065

<211> 726

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8065

gaagtgcagc tgctggagtc cggcggtgga ttggtgcaac cggggggatc gctcagactg 60

tcctgtgcgg cgtcaggctt caccttctcg agctacgcca tgtcatgggt cagacaggcc 120

cctggaaagg gtctggaatg ggtgtccgcc atttccggga gcgggggatc tacatactac 180

gccgatagcg tgaagggccg cttcaccatt tcccgggaca actccaagaa cactctctat 240

ctgcaaatga actccctccg cgctgaggac actgccgtgt actactgcgc caaaatccct 300

cagaccggca ccttcgacta ctggggacag gggactctgg tcaccgtcag cagcggtggc 360

ggaggttcgg ggggaggagg aagcggcggc ggagggtccg agattgtgct gacccagtca 420

cccggcactt tgtccctgtc gcctggagaa agggccaccc tttcctgccg ggcatcccaa 480

tccgtgtcct cctcgtacct ggcctggtac cagcagaggc ccggacaggc cccacggctt 540

ctgatctacg gagcaagcag ccgcgcgacc ggtatcccgg accggttttc gggctcgggc 600

tcaggaactg acttcaccct caccatctcc cgcctggaac ccgaagattt cgctgtgtat 660

tactgccagc actacggcag ctccccgtcc tggacgttcg gccagggaac tcggctggag 720

atcaag 726

<210> 8066

<211> 744

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8066

gaagtgcaac tggtggaaac cggtggagga ctcgtgcagc ctggcggcag cctccggctg 60

agctgcgccg cttcgggatt caccttttcc tcctacgcga tgtcttgggt cagacaggcc 120

ccgggaaagg ggctggaatg ggtgtcagcc atctccggct ccggcggatc aacgtactac 180

gccgactccg tgaaaggccg gttcaccatg tcgcgcgaga atgacaagaa ctccgtgttc 240

ctgcaaatga actccctgag ggtggaggac accggagtgt actattgtgc gcgcgccaac 300

tacaagagag agctgcggta ctactacgga atggacgtct ggggacaggg aactatggtg 360

accgtgtcat ccggtggagg gggaagcggc ggtggaggca gcgggggcgg gggttcagaa 420

attgtcatga cccagtcccc gggaactctt tccctctccc ccggggaatc cgcgactttg 480

tcctgccggg ccagccagcg cgtggcctcg aactacctcg catggtacca gcataagcca 540

ggccaagccc cttccctgct gatttccggg gctagcagcc gcgccactgg cgtgccggat 600

aggttctcgg gaagcggctc gggtaccgat ttcaccctgg caatctcgcg gctggaaccg 660

gaggattcgg ccgtgtacta ctgccagcac tatgactcat ccccctcctg gacattcgga 720

cagggcacca aggtcgagat caag 744

<210> 8067

<211> 732

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8067

gaagtgcagc tgctcgaaac cggtggaggg ctggtgcagc cagggggctc cctgaggctt 60

tcatgcgccg ctagcggatt ctccttctcc tcttacgcca tgtcgtgggt ccgccaagcc 120

cctggaaaag gcctggaatg ggtgtccgcg atttccggga gcggaggttc gacctattac 180

gccgactccg tgaagggccg ctttaccatc tcccgggata actccaagaa cactctgtac 240

ctccaaatga actcgctgag agccgaggac accgccgtgt attactgcgc gaaggcgctg 300

gtcggcgcga ctggggcatt cgacatctgg ggacagggaa ctcttgtgac cgtgtcgagc 360

ggaggcggcg gctccggcgg aggagggagc gggggcggtg gttccgaaat cgtgttgact 420

cagtccccgg gaaccctgag cttgtcaccc ggggagcggg ccactctctc ctgtcgcgcc 480

tcccaatcgc tctcatccaa tttcctggcc tggtaccagc agaagccgg acaggccccg 540

ggcctgctca tctacggcgc ttcaaactgg gcaacgggaa cccctgatcg gttcagcgga 600

agcggatcgg gtactgactt taccctgacc atcaccagac tggaaccggga ggacttcgcc 660

gtgtactact gccagtacta cggcacctcc cccatgtaca cattcggaca gggtaccaag 720

gtcgagatta ag 732

<210> 8068

<211> 733

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8068

gaagtgcagc tgcttgagag cggtggaggt ctggtgcagc ccgggggatc actgcgcctg 60

tcctgtgccg cgtccggttt cactttctcc tcgtacgcca tgtcgtgggt cagacaggca 120

ccgggaaagg gactggaatg ggtgtcagcc atttcgggtt cggggggcag cacctactac 180

gctgactccg tgaagggccg gttcaccatt tcccgcgaca actccaagaa caccttgtac 240

ctccaaatga actccctgcg ggccgaagat accgccgtgt attactgcgt gctgtggttc 300

ggagagggat tcgacccgtg gggacaagga acactcgtga ctgtgtcatc cggcggaggc 360

ggcagcggtg gcggcggttc cggcggcggc ggatctgaca tcgtgttgac ccagtcccct 420

ctgagcctgc cggtcactcc tggcgaacca gccagcatct cctgccggtc gagccagtcc 480

ctcctgcact ccaatgggta caactacctc gattggtatc tgcaaaagcc gggccagagc 540

ccccagctgc tgatctacct tgggtcaaac cgcgcttccg gggtgcctga tagattctcc 600

gggtccggga gcggaaccga ctttaccctg aaaatctcga gggtggaggc cgaggacgtc 660

ggagtgtact actgcatgca ggcgctccag actcccctga ccttcgggagg aggaacgaag 720

gtcgacatca aga 733

<210> 8069

<211> 753

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8069

caagtgcagc tcgtggagtc aggcggagga ctggtgcagc ccgggggctc cctgagactt 60

tcctgcgcgg catcgggttt taccttctcc tcctatgcta tgtcctgggt gcgccaggcc 120

ccgggaaagg gactggaatg ggtgtccgca atcagcggta gcgggggctc aacatactac 180

gccgactccg tcaagggtcg cttcactatt tcccgggaca actccaagaa taccctgtac 240

ctccaaatga acagcctcag ggccgaggat actgccgtgt actactgcgc caaagtcgga 300

tacgatagct ccggttacta ccgggactac tacggaatgg acgtgtgggg acagggcacc 360

accgtgaccg tgtcaagcgg cggaggcggt tcaggagggg gaggctccgg cggtggaggg 420

tccgaaatcg tcctgactca gtcgcctggc actctgtcgt tgtccccgggg ggagcgcgct 480

accctgtcgt gtcgggcgtc gcagtccgtg tcgagctcct acctcgcgtg gtaccagcag 540

aagcccggac aggcccctag acttctgatc tacggcactt cttcacgcgc caccgggatc 600

agcgacaggt tcagcggctc cggctccggg accgacttca ccctgaccat tagccggctg 660

gagcctgaag atttcgccgt gtattactgc caacactacg gaaactcgcc gccaaagttc 720

acgttcggac ccggaaccaa gctggaaatc aag 753

<210> 8070

<211> 739

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8070

gaagtccaac tggtggagtc cgggggagggg ctcgtgcagc ccggaggcag ccttcggctg

tcgtgcgccg cctccgggtt cacgttctca tcctacgcga tgtcgtgggt cagacaggca 120

cgggaaagg gactggaatg ggtgtccgcc attagcggct ccggcggtag cacctactat 180

gccgactcag tgaagggaag gttcactatc tcccgcgaca acagcaagaa caccctgtac 240

ctccaaatga actctctgcg ggccgaggat accgcggtgt actattgcgc caagatgggt 300

tggtccagcg gatacttggg agccttcgac atttggggac agggcactac tgtgaccgtg 360

tcctccgggg gtggcggatc gggaggcggc ggctcgggtg gagggggttc cgaaatcgtg 420

ttgacccagt caccgggaac cctctcgctg tccccgggag aacgggctac actgtcatgt 480

agagcgtccc agtccgtggc ttcctcgttc ctggcctggt accagcagaa gccgggacag 540

gcaccccgcc tgctcatcta cggagccagc ggccgggcga ccggcatccc tgaccgcttc 600

tccggttccg gctcgggcac cgactttact ctgaccatta gcaggcttga gcccgaggat 660

tttgccgtgt actactgcca acactacggg gggagccctc gcctgacctt cggaggcgga 720

actaaggtcg atatcaaaa 739

<210> 8071

<211> 121

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8071

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser

20 25 30

Tyr Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Ala Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg His Trp Gln Glu Trp Pro Asp Ala Phe Asp Ile Trp Gly

100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 8072

<211> 123

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8072

Gln Val Asn Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln

1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Arg Thr Ser

20 25 30

Gly Met Cys Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu

35 40 45

Trp Leu Ala Arg Ile Asp Trp Asp Glu Asp Lys Phe Tyr Ser Thr Ser

50 55 60

Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Asp Asn Gln Val

65 70 75 80

Val Leu Arg Met Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr

85 90 95

Cys Ala Arg Ser Gly Ala Gly Gly Thr Ser Ala Thr Ala Phe Asp Ile

100 105 110

Trp Gly Pro Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 8073

<211> 119

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8073

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ser Ile Ser Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Thr Ile Ala Ala Val Tyr Ala Phe Asp Ile Trp Gly Gln Gly

100 105 110

Thr Thr Val Thr Val Ser Ser

115

<210> 8074

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8074

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr

20 25 30

Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Asp Leu Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met

100 105 110

Val Thr Val Ser Ser

115

<210> 8075

<211> 120

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8075

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Pro Ser Gly Tyr Thr Val Thr Ser His

20 25 30

Tyr Ile His Trp Val Arg Arg Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Met Ile Asn Pro Ser Gly Val Thr Ala Tyr Ser Gln Thr Leu

50 55 60

Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ser Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys

85 90 95

Ala Arg Glu Gly Ser Gly Ser Gly Trp Tyr Phe Asp Phe Trp Gly Arg

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 8076

<211> 123

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8076

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly

20 25 30

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu

35 40 45

Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe

65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr

85 90 95

Cys Ala Arg Ala Gly Ile Ala Ala Arg Leu Arg Gly Ala Phe Asp Ile

100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 8077

<211> 129

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8077

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr

20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe

50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Gly Gly Tyr Gln Leu Leu Arg Trp Asp Val Gly Leu Leu

100 105 110

Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser

115 120 125

Ser

<210> 8078

<211> 125

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8078

Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn

20 25 30

Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu

35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Phe Tyr Ala

50 55 60

Ile Ser Leu Lys Ser Arg Ile Ile Ile Asn Pro Asp Thr Ser Lys Asn

65 70 75 80

Gln Phe Ser Leu Gln Leu Lys Ser Val Thr Pro Glu Asp Thr Ala Val

85 90 95

Tyr Tyr Cys Ala Arg Ser Ser Pro Glu Gly Leu Phe Leu Tyr Trp Phe

100 105 110

Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

115 120 125

<210> 8079

<211> 118

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8079

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Glu Gly Ser Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser

115

<210> 8080

<211> 118

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8080

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Arg Tyr

20 25 30

Pro Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Gly Ile Ser Asp Ser Gly Val Ser Thr Tyr Tyr Ala Asp Ser Ala

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Thr Arg Ala Gly Ser Glu Ala Ser Asp Ile Trp Gly Gln Gly Thr

100 105 110

Met Val Thr Val Ser Ser

115

<210> 8081

<211> 124

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8081

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys

85 90 95

Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 8082

<211> 124

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8082

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Thr Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 8083

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8083

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Glu Trp Val

35 40 45

Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Val Gly Lys Ala Val Pro Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser

115

<210> 8084

<211> 122

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8084

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Asp Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Ser Ile Asn Trp Lys Gly Asn Ser Leu Ala Tyr Gly Asp Ser Val

50 55 60

Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Ser His Gln Gly Val Ala Tyr Tyr Asn Tyr Ala Met Asp Val Trp

100 105 110

Gly Arg Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 8085

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8085

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Val Arg Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr

100 105 110

Val Thr Val Ser Ser

115

<210> 8086

<211> 118

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8086

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Ile Pro Gln Thr Gly Thr Phe Asp Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ser

115

<210> 8087

<211> 124

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8087

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Met Ser Arg Glu Asn Asp Lys Asn Ser Val Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Val Tyr Tyr Cys

85 90 95

Ala Arg Ala Asn Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp

100 105 110

Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

115 120

<210> 8088

<211> 120

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8088

Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Ala Leu Val Gly Ala Thr Gly Ala Phe Asp Ile Trp Gly Gln

100 105 110

Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 8089

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8089

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Leu Trp Phe Gly Glu Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser

115

<210> 8090

<211> 126

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8090

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Val Gly Tyr Asp Ser Ser Gly Tyr Tyr Arg Asp Tyr Tyr Gly

100 105 110

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120 125

<210> 8091

<211> 122

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8091

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Lys Met Gly Trp Ser Ser Gly Tyr Leu Gly Ala Phe Asp Ile Trp

100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 8092

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8092

Glu Thr Thr Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Thr Pro Gly

1 5 10 15

Asp Lys Val Ile Ile Ser Cys Lys Ala Ser Gln Asp Ile Asp Asp Ala

20 25 30

Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Leu Phe Ile Ile

35 40 45

Gln Ser Ala Thr Ser Pro Val Pro Gly Ile Pro Pro Arg Phe Ser Gly

50 55 60

Ser Gly Phe Gly Thr Asp Phe Ser Leu Thr Ile Asn Asn Ile Glu Ser

65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Leu Gln His Asp Asn Phe Pro Leu

85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 8093

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8093

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Tyr Asn Asn

20 25 30

Leu Ala Trp Phe Gln Leu Lys Pro Gly Ser Ala Pro Arg Ser Leu Met

35 40 45

Tyr Ala Ala Asn Lys Ser Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Tyr Arg Phe Pro Tyr

85 90 95

Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 8094

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8094

Glu Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Glu

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 8095

<211> 108

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8095

Ser Tyr Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Tyr

1 5 10 15

Thr Ala Thr Ile Ser Cys Gly Gly Asn Asn Ile Gly Thr Lys Ser Val

20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Leu Leu Val Ile Arg

35 40 45

Asp Asp Ser Val Arg Pro Ser Lys Ile Pro Gly Arg Phe Ser Gly Ser

50 55 60

Asn Ser Gly Asn Met Ala Thr Leu Thr Ile Ser Gly Val Gln Ala Gly

65 70 75 80

Asp Glu Ala Asp Phe Tyr Cys Gln Val Trp Asp Ser Asp Ser Glu His

85 90 95

Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105

<210> 8096

<211> 106

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8096

Ser Tyr Val Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln

1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Gly Leu Ser Lys Lys Tyr Val

20 25 30

Ser Trp Tyr Gln Gln Lys Ala Gly Gln Ser Pro Val Val Leu Ile Ser

35 40 45

Arg Asp Lys Glu Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser

50 55 60

Asn Ser Ala Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met

65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Asp Thr Thr Val Val

85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105

<210> 8097

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8097

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Trp

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe

85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys

100 105

<210> 8098

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8098

Ser Tyr Val Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Gln

1 5 10 15

Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val

20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Leu Tyr

35 40 45

Gly Lys Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser

50 55 60

Arg Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu

65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Arg Asp Ser Ser Gly Asp His

85 90 95

Leu Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu

100 105

<210> 8099

<211> 108

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8099

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln

1 5 10 15

Thr Ile Arg Ile Thr Cys Gln Gly Asp Ser Leu Gly Asn Tyr Tyr Ala

20 25 30

Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr

35 40 45

Gly Thr Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala Ser

50 55 60

Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu

65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly His His

85 90 95

Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu

100 105

<210> 8100

<211> 113

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8100

Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ala

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu

35 40 45

Ile Ser Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Gly

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Phe

85 90 95

Asn Gly Ser Ser Leu Phe Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile

100 105 110

Lys

<210> 8101

<211> 108

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8101

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Ser

20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile

35 40 45

Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro

65 70 75 80

Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Phe Gly Thr Ser Ser Gly

85 90 95

Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 8102

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8102

Glu Ile Val Met Thr Gln Ser Pro Gly Thr Val Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys

100 105

<210> 8103

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8103

Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Thr

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ser Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 8104

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8104

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr

85 90 95

Ser Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys

100 105

<210> 8105

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8105

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Thr Gln Ser Ile Gly Ser Ser

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Gln Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Val Glu

65 70 75 80

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Glu Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 8106

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8106

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Pro

85 90 95

Arg Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys

100 105

<210> 8107

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8107

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys

100 105

<210> 8108

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8108

Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ala Ser Asn

20 25 30

Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Ser Leu Leu

35 40 45

Ile Ser Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ala Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Asp Ser Ser Pro

85 90 95

Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 8109

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8109

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Ser Ser Asn

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Gly Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Asn Trp Ala Thr Gly Thr Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Tyr Tyr Gly Thr Ser Pro

85 90 95

Met Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 8110

<211> 112

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8110

Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser

20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

85 90 95

Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys

100 105 110

<210> 8111

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8111

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Thr Ser Ser Arg Ala Thr Gly Ile Ser Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Asn Ser Pro

85 90 95

Pro Lys Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 8112

<211> 109

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8112

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser

20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

35 40 45

Ile Tyr Gly Ala Ser Gly Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Gly Ser Pro

85 90 95

Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys

100 105

<210> 8113

<400> 8113

000

<210> 8114

<400> 8114

000

<210> 8115

<400> 8115

000

<210> 8116

<400> 8116

000

<210> 8117

<400> 8117

000

<210> 8118

<400> 8118

000

<210> 8119

<400> 8119

000

<210> 8120

<400> 8120

000

<210> 8121

<400> 8121

000

<210> 8122

<400> 8122

000

<210> 8123

<400> 8123

000

<210> 8124

<400> 8124

000

<210> 8125

<400> 8125

000

<210> 8126

<400> 8126

000

<210> 8127

<400> 8127

000

<210> 8128

<400> 8128

000

<210> 8129

<400> 8129

000

<210> 8130

<400> 8130

000

<210> 8131

<400> 8131

000

<210> 8132

<400> 8132

000

<210> 8133

<400> 8133

000

<210> 8134

<400> 8134

000

<210> 8135

<400> 8135

000

<210> 8136

<400> 8136

000

<210> 8137

<400> 8137

000

<210> 8138

<400> 8138

000

<210> 8139

<400> 8139

000

<210> 8140

<400> 8140

000

<210> 8141

<400> 8141

000

<210> 8142

<400> 8142

000

<210> 8143

<400> 8143

000

<210> 8144

<400> 8144

000

<210> 8145

<400> 8145

000

<210> 8146

<400> 8146

000

<210> 8147

<400> 8147

000

<210> 8148

<400> 8148

000

<210> 8149

<400> 8149

000

<210> 8150

<400> 8150

000

<210> 8151

<400> 8151

000

<210> 8152

<400> 8152

000

<210> 8153

<400> 8153

000

<210> 8154

<400> 8154

000

<210> 8155

<211> 122

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8155

Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe

20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met

35 40 45

Ala Trp Ile Asn Thr Tyr Thr Gly Glu Ser Tyr Phe Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Val Glu Thr Ser Ala Thr Thr Ala Tyr

65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Thr Glu Asp Thr Ala Thr Tyr Phe Cys

85 90 95

Ala Arg Gly Glu Ile Tyr Tyr Gly Tyr Asp Gly Gly Phe Ala Tyr Trp

100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ala

115 120

<210> 8156

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8156

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

20 25 30

Ser Ile Asn Trp Val Lys Arg Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Trp Ile Asn Thr Glu Thr Arg Glu Pro Ala Tyr Ala Tyr Asp Phe

50 55 60

Arg Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Tyr Glu Asp Thr Ala Thr Tyr Phe Cys

85 90 95

Ala Leu Asp Tyr Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser

100 105 110

Val Thr Val Ser Ser

115

<210> 8157

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8157

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Arg His Tyr

20 25 30

Ser Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Arg Ile Asn Thr Glu Ser Gly Val Pro Ile Tyr Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Val Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Val Ile Asn Asn Leu Lys Asp Glu Asp Thr Ala Ser Tyr Phe Cys

85 90 95

Ser Asn Asp Tyr Leu Tyr Ser Leu Asp Phe Trp Gly Gln Gly Thr Ala

100 105 110

Leu Thr Val Ser Ser

115

<210> 8158

<211> 117

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8158

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr His Tyr

20 25 30

Ser Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Arg Ile Asn Thr Glu Thr Gly Glu Pro Leu Tyr Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Val Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Phe Phe Cys

85 90 95

Ser Asn Asp Tyr Leu Tyr Ser Cys Asp Tyr Trp Gly Gln Gly Thr Thr

100 105 110

Leu Thr Val Ser Ser

115

<210> 8159

<211> 107

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8159

Asp Val Val Met Thr Gln Ser His Arg Phe Met Ser Thr Ser Val Gly

1 5 10 15

Asp Arg Val Ser Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala

20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile

35 40 45

Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly

50 55 60

Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala

65 70 75 80

Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Asp Ile Lys

100 105

<210> 8160

<211> 111

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8160

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly

1 5 10 15

Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Val Ile

20 25 30

Gly Ala His Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Thr Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asp

65 70 75 80

Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Ser Cys Leu Gln Ser Arg

85 90 95

Ile Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 8161

<211> 111

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8161

Asp Ile Val Leu Thr Gln Ser Pro Pro Ser Leu Ala Met Ser Leu Gly

1 5 10 15

Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Thr Ile Leu

20 25 30

Gly Ser His Leu Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Thr Leu Leu Ile Gln Leu Ala Ser Asn Val Gln Thr Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp

65 70 75 80

Pro Val Glu Glu Asp Asp Val Ala Val Tyr Tyr Cys Leu Gln Ser Arg

85 90 95

Thr Ile Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 8162

<211> 111

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8162

Asp Ile Val Leu Thr Gln Ser Pro Pro Ser Leu Ala Met Ser Leu Gly

1 5 10 15

Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Thr Ile Leu

20 25 30

Gly Ser His Leu Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Thr Leu Leu Ile Gln Leu Ala Ser Asn Val Gln Thr Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp

65 70 75 80

Pro Val Glu Glu Asp Asp Val Ala Val Tyr Tyr Cys Leu Gln Ser Arg

85 90 95

Thr Ile Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 8163

<211> 244

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8163

Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Phe

20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met

35 40 45

Ala Trp Ile Asn Thr Tyr Thr Gly Glu Ser Tyr Phe Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Val Glu Thr Ser Ala Thr Thr Ala Tyr

65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Thr Glu Asp Thr Ala Thr Tyr Phe Cys

85 90 95

Ala Arg Gly Glu Ile Tyr Tyr Gly Tyr Asp Gly Gly Phe Ala Tyr Trp

100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser

130 135 140

His Arg Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys

145 150 155 160

Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ser Trp Tyr Gln Gln Lys

165 170 175

Pro Gly Gln Ser Pro Lys Leu Leu Ile Phe Ser Ala Ser Tyr Arg Tyr

180 185 190

Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Ala Asp Phe

195 200 205

Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr

210 215 220

Cys Gln Gln His Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys

225 230 235 240

Leu Asp Ile Lys

<210> 8164

<211> 249

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8164

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

20 25 30

Ser Ile Asn Trp Val Lys Arg Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Trp Ile Asn Thr Glu Thr Arg Glu Pro Ala Tyr Ala Tyr Asp Phe

50 55 60

Arg Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Tyr Glu Asp Thr Ala Thr Tyr Phe Cys

85 90 95

Ala Leu Asp Tyr Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser

100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys

130 135 140

Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr

145 150 155 160

Phe Thr Asp Tyr Ser Ile Asn Trp Val Lys Arg Ala Pro Gly Lys Gly

165 170 175

Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Arg Glu Pro Ala Tyr

180 185 190

Ala Tyr Asp Phe Arg Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala

195 200 205

Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Tyr Glu Asp Thr Ala

210 215 220

Thr Tyr Phe Cys Ala Leu Asp Tyr Ser Tyr Ala Met Asp Tyr Trp Gly

225 230 235 240

Gln Gly Thr Ser Val Thr Val Ser Ser

245

<210> 8165

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8165

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Arg His Tyr

20 25 30

Ser Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Arg Ile Asn Thr Glu Ser Gly Val Pro Ile Tyr Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Val Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Val Ile Asn Asn Leu Lys Asp Glu Asp Thr Ala Ser Tyr Phe Cys

85 90 95

Ser Asn Asp Tyr Leu Tyr Ser Leu Asp Phe Trp Gly Gln Gly Thr Ala

100 105 110

Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Pro Ser Leu Ala

130 135 140

Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser

145 150 155 160

Val Thr Ile Leu Gly Ser His Leu Ile Tyr Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Gln Pro Pro Thr Leu Leu Ile Gln Leu Ala Ser Asn Val Gln Thr

180 185 190

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr

195 200 205

Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Val Tyr Tyr Cys

210 215 220

Leu Gln Ser Arg Thr Ile Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 8166

<211> 243

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8166

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr His Tyr

20 25 30

Ser Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Arg Ile Asn Thr Glu Thr Gly Glu Pro Leu Tyr Ala Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Val Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Phe Phe Cys

85 90 95

Ser Asn Asp Tyr Leu Tyr Ser Cys Asp Tyr Trp Gly Gln Gly Thr Thr

100 105 110

Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

115 120 125

Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Pro Ser Leu Ala

130 135 140

Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser

145 150 155 160

Val Thr Ile Leu Gly Ser His Leu Ile Tyr Trp Tyr Gln Gln Lys Pro

165 170 175

Gly Gln Pro Pro Thr Leu Leu Ile Gln Leu Ala Ser Asn Val Gln Thr

180 185 190

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr

195 200 205

Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Val Tyr Tyr Cys

210 215 220

Leu Gln Ser Arg Thr Ile Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu

225 230 235 240

Glu Ile Lys

<210> 8167

<211> 18

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8167

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr

1 5 10 15

Lys Gly

<210> 8168

<400> 8168

000

<210> 8169

<400> 8169

000

<210> 8170

<400> 8170

000

<210> 8171

<400> 8171

000

<210> 8172

<400> 8172

000

<210> 8173

<400> 8173

000

<210> 8174

<400> 8174

000

<210> 8175

<400> 8175

000

<210> 8176

<400> 8176

000

<210> 8177

<400> 8177

000

<210> 8178

<400> 8178

000

<210> 8179

<400> 8179

000

<210> 8180

<400> 8180

000

<210> 8181

<400> 8181

000

<210> 8182

<400> 8182

000

<210> 8183

<400> 8183

000

<210> 8184

<400> 8184

000

<210> 8185

<400> 8185

000

<210> 8186

<400> 8186

000

<210> 8187

<400> 8187

000

<210> 8188

<400> 8188

000

<210> 8189

<400> 8189

000

<210> 8190

<400> 8190

000

<210> 8191

<400> 8191

000

<210> 8192

<400> 8192

000

<210> 8193

<400> 8193

000

<210> 8194

<400> 8194

000

<210> 8195

<400> 8195

000

<210> 8196

<400> 8196

000

<210> 8197

<400> 8197

000

<210> 8198

<400> 8198

000

<210> 8199

<400> 8199

000

<210> 8200

<400> 8200

000

<210> 8201

<400> 8201

000

<210> 8202

<400> 8202

000

<210> 8203

<400> 8203

000

<210> 8204

<400> 8204

000

<210> 8205

<400> 8205

000

<210> 8206

<400> 8206

000

<210> 8207

<400> 8207

000

<210> 8208

<400> 8208

000

<210> 8209

<400> 8209

000

<210> 8210

<400> 8210

000

<210> 8211

<400> 8211

000

<210> 8212

<400> 8212

000

<210> 8213

<400> 8213

000

<210> 8214

<400> 8214

000

<210> 8215

<400> 8215

000

<210> 8216

<400> 8216

000

<210> 8217

<400> 8217

000

<210> 8218

<400> 8218

000

<210> 8219

<400> 8219

000

<210> 8220

<400> 8220

000

<210> 8221

<400> 8221

000

<210> 8222

<400> 8222

000

<210> 8223

<400> 8223

000

<210> 8224

<400> 8224

000

<210> 8225

<400> 8225

000

<210> 8226

<400> 8226

000

<210> 8227

<400> 8227

000

<210> 8228

<400> 8228

000

<210> 8229

<400> 8229

000

<210> 8230

<400> 8230

000

<210> 8231

<400> 8231

000

<210> 8232

<400> 8232

000

<210> 8233

<400> 8233

000

<210> 8234

<400> 8234

000

<210> 8235

<400> 8235

000

<210> 8236

<400> 8236

000

<210> 8237

<400> 8237

000

<210> 8238

<400> 8238

000

<210> 8239

<400> 8239

000

<210> 8240

<400> 8240

000

<210> 8241

<400> 8241

000

<210> 8242

<400> 8242

000

<210> 8243

<400> 8243

000

<210> 8244

<400> 8244

000

<210> 8245

<400> 8245

000

<210> 8246

<400> 8246

000

<210> 8247

<400> 8247

000

<210> 8248

<400> 8248

000

<210> 8249

<400> 8249

000

<210> 8250

<400> 8250

000

<210> 8251

<400> 8251

000

<210> 8252

<400> 8252

000

<210> 8253

<400> 8253

000

<210> 8254

<400> 8254

000

<210> 8255

<400> 8255

000

<210> 8256

<400> 8256

000

<210> 8257

<400> 8257

000

<210> 8258

<400> 8258

000

<210> 8259

<400> 8259

000

<210> 8260

<400> 8260

000

<210> 8261

<400> 8261

000

<210> 8262

<400> 8262

000

<210> 8263

<400> 8263

000

<210> 8264

<400> 8264

000

<210> 8265

<400> 8265

000

<210> 8266

<400> 8266

000

<210> 8267

<400> 8267

000

<210> 8268

<400> 8268

000

<210> 8269

<400> 8269

000

<210> 8270

<400> 8270

000

<210> 8271

<400> 8271

000

<210> 8272

<400> 8272

000

<210> 8273

<400> 8273

000

<210> 8274

<400> 8274

000

<210> 8275

<400> 8275

000

<210> 8276

<400> 8276

000

<210> 8277

<400> 8277

000

<210> 8278

<400> 8278

000

<210> 8279

<400> 8279

000

<210> 8280

<400> 8280

000

<210> 8281

<400> 8281

000

<210> 8282

<400> 8282

000

<210> 8283

<400> 8283

000

<210> 8284

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8284

Asn Tyr Ala Met Ser

fifteen

<210> 8285

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8285

Asp Tyr Ala Met His

fifteen

<210> 8286

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8286

Asn His Gly Met Ser

fifteen

<210> 8287

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8287

Asn Phe Gly Ile Asn

fifteen

<210> 8288

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8288

Ser Asp Ala Met Thr

fifteen

<210> 8289

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8289

Asn Tyr Gly Ile Thr

fifteen

<210> 8290

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8290

Asn His Gly Met Ser

fifteen

<210> 8291

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8291

Asn His Gly Met Ser

fifteen

<210> 8292

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8292

Asn His Gly Met Ser

fifteen

<210> 8293

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8293

Asp Tyr Tyr Met Ser

fifteen

<210> 8294

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8294

Asn His Gly Met Ser

fifteen

<210> 8295

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8295

Asp Tyr Tyr Met Ser

fifteen

<210> 8296

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8296

Asn His Gly Met Ser

fifteen

<210> 8297

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8297

Asn His Gly Met Ser

fifteen

<210> 8298

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8298

Asn His Gly Met Ser

fifteen

<210> 8299

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8299

Ser Ser Tyr Tyr Tyr Trp Gly

fifteen

<210> 8300

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8300

Thr Ser Gly Met Cys Val Ser

fifteen

<210> 8301

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8301

Ser Tyr Ser Met Asn

fifteen

<210> 8302

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8302

Asp Tyr Tyr Met Ser

fifteen

<210> 8303

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8303

Ser His Tyr Ile His

fifteen

<210> 8304

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8304

Ser Gly Gly Tyr Tyr Trp Ser

fifteen

<210> 8305

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8305

Ser Tyr Ala Ile Ser

fifteen

<210> 8306

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8306

Ser Asn Ser Ala Ala Trp Asn

fifteen

<210> 8307

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8307

Ser Tyr Ala Met Ser

fifteen

<210> 8308

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8308

Arg Tyr Pro Met Ser

fifteen

<210> 8309

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8309

Ser Tyr Ala Met Ser

fifteen

<210> 8310

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8310

Ser Tyr Ala Met Ser

fifteen

<210> 8311

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8311

Asp Tyr Ala Met His

fifteen

<210> 8312

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8312

Asp Tyr Ala Met His

fifteen

<210> 8313

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8313

Ser Tyr Ala Met Ser

fifteen

<210> 8314

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8314

Ser Tyr Ala Met Ser

fifteen

<210> 8315

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8315

Ser Tyr Ala Met Ser

fifteen

<210> 8316

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8316

Ser Tyr Ala Met Ser

fifteen

<210> 8317

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8317

Ser Tyr Ala Met Ser

fifteen

<210> 8318

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8318

Ser Tyr Ala Met Ser

fifteen

<210> 8319

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8319

Ser Tyr Ala Met Ser

fifteen

<210> 8320

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8320

Asn Phe Gly Met Asn

fifteen

<210> 8321

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8321

Asp Tyr Ser Ile Asn

fifteen

<210> 8322

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8322

His Tyr Ser Met Asn

fifteen

<210> 8323

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8323

His Tyr Ser Met Asn

fifteen

<210> 8324

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8324

Gly Ile Ser Arg Ser Gly Glu Asn Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8325

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8325

Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8326

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8326

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8327

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8327

Trp Ile Asn Pro Lys Asn Asn Asn Thr Asn Tyr Ala Gln Lys Phe Gln

1 5 10 15

gly

<210> 8328

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8328

Val Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8329

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8329

Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln

1 5 10 15

gly

<210> 8330

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8330

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8331

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8331

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8332

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8332

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8333

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8333

Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8334

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8334

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8335

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8335

Tyr Ile Ser Ser Ser Gly Asn Thr Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8336

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8336

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8337

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8337

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8338

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8338

Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr Ala Ala Ser Val Lys Gly

1 5 10 15

<210> 8339

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8339

Ser Ile Tyr Tyr Ser Gly Ser Ala Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 8340

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8340

Arg Ile Asp Trp Asp Glu Asp Lys Phe Tyr Ser Thr Ser Leu Lys Thr

1 5 10 15

<210> 8341

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8341

Ser Ile Ser Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8342

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8342

Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8343

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8343

Met Ile Asn Pro Ser Gly Gly Val Thr Ala Tyr Ser Gln Thr Leu Gln

1 5 10 15

gly

<210> 8344

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8344

Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

<210> 8345

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8345

Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln

1 5 10 15

gly

<210> 8346

<211> 18

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8346

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Phe Tyr Ala Ile Ser Leu

1 5 10 15

Lys Ser

<210> 8347

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8347

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8348

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8348

Gly Ile Ser Asp Ser Gly Val Ser Thr Tyr Tyr Ala Asp Ser Ala Lys

1 5 10 15

gly

<210> 8349

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8349

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8350

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8350

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8351

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8351

Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8352

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8352

Ser Ile Asn Trp Lys Gly Asn Ser Leu Ala Tyr Gly Asp Ser Val Lys

1 5 10 15

gly

<210> 8353

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8353

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8354

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8354

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8355

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8355

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8356

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8356

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8357

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8357

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8358

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8358

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8359

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8359

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

gly

<210> 8360

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8360

Trp Ile Asn Thr Tyr Thr Gly Glu Ser Tyr Phe Ala Asp Asp Phe Lys

1 5 10 15

gly

<210> 8361

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8361

Trp Ile Asn Thr Glu Thr Arg Glu Pro Ala Tyr Ala Tyr Asp Phe Arg

1 5 10 15

gly

<210> 8362

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8362

Arg Ile Asn Thr Glu Ser Gly Val Pro Ile Tyr Ala Asp Asp Phe Lys

1 5 10 15

gly

<210> 8363

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8363

Arg Ile Asn Thr Glu Thr Gly Glu Pro Leu Tyr Ala Asp Asp Phe Lys

1 5 10 15

gly

<210> 8364

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8364

Ser Pro Ala His Tyr Tyr Gly Gly Met Asp Val

1 5 10

<210> 8365

<211> 6

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8365

His Ser Phe Leu Ala Tyr

fifteen

<210> 8366

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8366

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8367

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8367

Gly Pro Tyr Tyr Tyr Gln Ser Tyr Met Asp Val

1 5 10

<210> 8368

<211> 14

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8368

Leu Asp Ser Ser Gly Tyr Tyr Tyr Ala Arg Gly Pro Arg Tyr

1 5 10

<210> 8369

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8369

Gly Pro Tyr Tyr Tyr Tyr Met Asp Val

fifteen

<210> 8370

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8370

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8371

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8371

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8372

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8372

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8373

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8373

Glu Ser Gly Asp Gly Met Asp Val

fifteen

<210> 8374

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8374

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8375

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8375

Ser Thr Met Val Arg Glu Asp Tyr

fifteen

<210> 8376

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8376

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8377

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8377

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8378

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8378

His Gly Gly Glu Ser Asp Val

fifteen

<210> 8379

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8379

His Trp Gln Glu Trp Pro Asp Ala Phe Asp Ile

1 5 10

<210> 8380

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8380

Ser Gly Ala Gly Gly Thr Ser Ala Thr Ala Phe Asp Ile

1 5 10

<210> 8381

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8381

Thr Ile Ala Ala Val Tyr Ala Phe Asp Ile

1 5 10

<210> 8382

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8382

Asp Leu Arg Gly Ala Phe Asp Ile

fifteen

<210> 8383

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8383

Glu Gly Ser Gly Ser Gly Trp Tyr Phe Asp Phe

1 5 10

<210> 8384

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8384

Ala Gly Ile Ala Ala Arg Leu Arg Gly Ala Phe Asp Ile

1 5 10

<210> 8385

<211> 20

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8385

Arg Gly Gly Tyr Gln Leu Leu Arg Trp Asp Val Gly Leu Leu Arg Ser

1 5 10 15

Ala Phe Asp Ile

20

<210> 8386

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8386

Ser Ser Pro Glu Gly Leu Phe Leu Tyr Trp Phe Asp Pro

1 5 10

<210> 8387

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8387

Val Glu Gly Ser Gly Ser Leu Asp Tyr

fifteen

<210> 8388

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8388

Arg Ala Gly Ser Glu Ala Ser Asp Ile

fifteen

<210> 8389

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8389

Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp Val

1 5 10 15

<210> 8390

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8390

Ala Thr Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp Val

1 5 10 15

<210> 8391

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8391

Val Gly Lys Ala Val Pro Asp Val

fifteen

<210> 8392

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8392

His Gln Gly Val Ala Tyr Tyr Asn Tyr Ala Met Asp Val

1 5 10

<210> 8393

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8393

Val Val Arg Asp Gly Met Asp Val

fifteen

<210> 8394

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8394

Ile Pro Gln Thr Gly Thr Phe Asp Tyr

fifteen

<210> 8395

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8395

Ala Asn Tyr Lys Arg Glu Leu Arg Tyr Tyr Tyr Gly Met Asp Val

1 5 10 15

<210> 8396

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8396

Ala Leu Val Gly Ala Thr Gly Ala Phe Asp Ile

1 5 10

<210> 8397

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8397

Trp Phe Gly Glu Gly Phe Asp Pro

fifteen

<210> 8398

<211> 17

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8398

Val Gly Tyr Asp Ser Ser Gly Tyr Tyr Arg Asp Tyr Tyr Gly Met Asp

1 5 10 15

Val

<210> 8399

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8399

Met Gly Trp Ser Ser Gly Tyr Leu Gly Ala Phe Asp Ile

1 5 10

<210> 8400

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8400

Gly Glu Ile Tyr Tyr Gly Tyr Asp Gly Gly Phe Ala Tyr

1 5 10

<210> 8401

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8401

Asp Tyr Ser Tyr Ala Met Asp Tyr

fifteen

<210> 8402

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8402

Asp Tyr Leu Tyr Ser Leu Asp Phe

fifteen

<210> 8403

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8403

Asp Tyr Leu Tyr Ser Cys Asp Tyr

fifteen

<210> 8404

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8404

Arg Ala Ser Gln Ser Ile Ser Ser Ser Phe Leu Ala

1 5 10

<210> 8405

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8405

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

1 5 10 15

<210> 8406

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8406

Lys Ser Ser Gln Ser Leu Leu Arg Asn Asp Gly Lys Thr Pro Leu Tyr

1 5 10 15

<210> 8407

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8407

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asn

1 5 10 15

<210> 8408

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8408

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

1 5 10

<210> 8409

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8409

Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn Tyr Val Asp

1 5 10 15

<210> 8410

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8410

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala

1 5 10

<210> 8411

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8411

Arg Ala Ser Gln Ser Val Ser Ser Lys Leu Ala

1 5 10

<210> 8412

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8412

Arg Ala Ser Gln Ser Val Gly Ser Thr Asn Leu Ala

1 5 10

<210> 8413

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8413

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

1 5 10

<210> 8414

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8414

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

1 5 10

<210> 8415

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8415

Lys Ser Ser Glu Ser Leu Val His Asn Ser Gly Lys Thr Tyr Leu Asn

1 5 10 15

<210> 8416

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8416

Gln Ala Ser Glu Asp Ile Asn Lys Phe Leu Asn

1 5 10

<210> 8417

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8417

Arg Ala Ser Gln Ser Val Gly Ser Asn Leu Ala

1 5 10

<210> 8418

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8418

Arg Ala Ser Gln Ser Ile Gly Ser Ser Ser Leu Ala

1 5 10

<210> 8419

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8419

Lys Ala Ser Gln Asp Ile Asp Asp Ala Met Asn

1 5 10

<210> 8420

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8420

Arg Ala Ser Gln Asp Ile Tyr Asn Asn Leu Ala

1 5 10

<210> 8421

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8421

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

1 5 10 15

<210> 8422

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8422

Gly Gly Asn Asn Ile Gly Thr Lys Ser Val His

1 5 10

<210> 8423

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8423

Ser Gly Asp Gly Leu Ser Lys Lys Tyr Val Ser

1 5 10

<210> 8424

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8424

Arg Ala Ser Gln Gly Ile Arg Asn Trp Leu Ala

1 5 10

<210> 8425

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8425

Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His

1 5 10

<210> 8426

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8426

Gln Gly Asp Ser Leu Gly Asn Tyr Tyr Ala Thr

1 5 10

<210> 8427

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8427

Arg Ala Ser Gln Ser Val Ser Ser Ala Tyr Leu Ala

1 5 10

<210> 8428

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8428

Arg Ala Ser Gln Ser Val Ser Asn Ser Leu Ala

1 5 10

<210> 8429

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8429

Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala

1 5 10

<210> 8430

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8430

Arg Ala Ser Gln Ser Val Ser Thr Thr Phe Leu Ala

1 5 10

<210> 8431

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8431

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

1 5 10

<210> 8432

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8432

Arg Ala Thr Gln Ser Ile Gly Ser Ser Phe Leu Ala

1 5 10

<210> 8433

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8433

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 8434

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8434

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 8435

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8435

Arg Ala Ser Gln Arg Val Ala Ser Asn Tyr Leu Ala

1 5 10

<210> 8436

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8436

Arg Ala Ser Gln Ser Leu Ser Ser Asn Phe Leu Ala

1 5 10

<210> 8437

<211> 16

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8437

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

1 5 10 15

<210> 8438

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8438

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala

1 5 10

<210> 8439

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8439

Arg Ala Ser Gln Ser Val Ala Ser Ser Phe Leu Ala

1 5 10

<210> 8440

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8440

Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ser

1 5 10

<210> 8441

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8441

Arg Ala Ser Glu Ser Val Ser Val Ile Gly Ala His Leu Ile His

1 5 10 15

<210> 8442

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8442

Arg Ala Ser Glu Ser Val Thr Ile Leu Gly Ser His Leu Ile Tyr

1 5 10 15

<210> 8443

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8443

Arg Ala Ser Glu Ser Val Thr Ile Leu Gly Ser His Leu Ile Tyr

1 5 10 15

<210> 8444

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8444

Gly Ala Ser Arg Arg Ala Thr

fifteen

<210> 8445

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8445

Leu Gly Ser Asn Arg Ala Ser

fifteen

<210> 8446

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8446

Glu Val Ser Asn Arg Phe Ser

fifteen

<210> 8447

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8447

Leu Gly Ser Lys Arg Ala Ser

fifteen

<210> 8448

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8448

Gly Ala Ser Thr Leu Ala Ser

fifteen

<210> 8449

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8449

Leu Gly Ser Asn Arg Ala Ser

fifteen

<210> 8450

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8450

Gly Ala Ser Thr Arg Ala Ser

fifteen

<210> 8451

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8451

Gly Ala Ser Ile Arg Ala Thr

fifteen

<210> 8452

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8452

Asp Ala Ser Asn Arg Ala Thr

fifteen

<210> 8453

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8453

Ala Ala Ser Ser Leu Gln Ser

fifteen

<210> 8454

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8454

Ala Ala Ser Ser Leu Gln Ser

fifteen

<210> 8455

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8455

Glu Val Ser Asn Arg Asp Ser

fifteen

<210> 8456

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8456

Asp Ala Ser Thr Leu Gln Thr

fifteen

<210> 8457

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8457

Gly Ala Ser Thr Arg Ala Thr

fifteen

<210> 8458

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8458

Gly Ala Ser Ser Arg Ala Ser

fifteen

<210> 8459

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8459

Ser Ala Thr Ser Pro Val Pro

fifteen

<210> 8460

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8460

Ala Ala Asn Lys Ser Gln Ser

fifteen

<210> 8461

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8461

Leu Gly Ser Asn Arg Ala Ser

fifteen

<210> 8462

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8462

Asp Asp Ser Val Arg Pro Ser

fifteen

<210> 8463

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8463

Arg Asp Lys Glu Arg Pro Ser

fifteen

<210> 8464

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8464

Ala Ala Ser Asn Leu Gln Ser

fifteen

<210> 8465

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8465

Gly Lys Asn Asn Arg Pro Ser

fifteen

<210> 8466

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8466

Gly Thr Asn Asn Arg Pro Ser

fifteen

<210> 8467

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8467

Gly Ala Ser Thr Arg Ala Thr

fifteen

<210> 8468

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8468

Asp Ala Ser Ser Arg Ala Thr

fifteen

<210> 8469

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8469

Gly Ala Ser Ser Arg Ala Thr

fifteen

<210> 8470

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8470

Gly Ser Ser Asn Arg Ala Thr

fifteen

<210> 8471

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8471

Ala Ala Ser Ser Leu Gln Ser

fifteen

<210> 8472

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8472

Gly Ala Ser Gln Arg Ala Thr

fifteen

<210> 8473

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8473

Gly Ala Ser Ser Arg Ala Thr

fifteen

<210> 8474

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8474

Gly Ala Ser Ser Arg Ala Thr

fifteen

<210> 8475

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8475

Gly Ala Ser Ser Arg Ala Thr

fifteen

<210> 8476

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8476

Gly Ala Ser Asn Trp Ala Thr

fifteen

<210> 8477

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8477

Leu Gly Ser Asn Arg Ala Ser

fifteen

<210> 8478

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8478

Gly Thr Ser Ser Arg Ala Thr

fifteen

<210> 8479

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8479

Gly Ala Ser Gly Arg Ala Thr

fifteen

<210> 8480

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8480

Ser Ala Ser Tyr Arg Tyr Thr

fifteen

<210> 8481

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8481

Leu Ala Ser Asn Leu Glu Thr

fifteen

<210> 8482

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8482

Leu Ala Ser Asn Val Gln Thr

fifteen

<210> 8483

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8483

Leu Ala Ser Asn Val Gln Thr

fifteen

<210> 8484

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8484

Gln Gln Tyr His Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8485

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8485

Met Gln Ala Leu Gln Thr Pro Tyr Thr

fifteen

<210> 8486

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8486

Met Gln Asn Ile Gln Phe Pro Ser

fifteen

<210> 8487

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8487

Met Gln Ala Leu Gln Thr Pro Tyr Thr

fifteen

<210> 8488

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8488

Gln Gln Ser Tyr Lys Arg Ala Ser

fifteen

<210> 8489

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8489

Met Gln Gly Arg Gln Phe Pro Tyr Ser

fifteen

<210> 8490

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8490

Gln Gln Tyr Gly Ser Ser Leu Thr

fifteen

<210> 8491

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8491

Gln Gln Tyr Gly Ser Ser Ser Trp Thr

fifteen

<210> 8492

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8492

Gln Gln Tyr Gly Ser Ser Pro Pro Trp Thr

1 5 10

<210> 8493

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8493

Gln Gln Ser Tyr Thr Leu Ala

fifteen

<210> 8494

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8494

Gln Gln Ser Tyr Ser Thr Pro Tyr Thr

fifteen

<210> 8495

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8495

Met Gln Gly Thr His Trp Pro Gly Thr

fifteen

<210> 8496

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8496

Gln Gln Tyr Glu Ser Leu Pro Leu Thr

fifteen

<210> 8497

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8497

Gln Gln Tyr Asn Asp Trp Leu Pro Val Thr

1 5 10

<210> 8498

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8498

Gln Gln Tyr Ala Gly Ser Pro Pro Phe Thr

1 5 10

<210> 8499

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8499

Leu Gln His Asp Asn Phe Pro Leu Thr

fifteen

<210> 8500

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8500

Gln His Tyr Tyr Arg Phe Pro Tyr Ser

fifteen

<210> 8501

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8501

Met Gln Ala Leu Gln Thr Pro Tyr Thr

fifteen

<210> 8502

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8502

Gln Val Trp Asp Ser Asp Ser Glu His Val Val

1 5 10

<210> 8503

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8503

Gln Ala Trp Asp Asp Thr Thr Val Val

fifteen

<210> 8504

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8504

Gln Lys Tyr Asn Ser Ala Pro Phe Thr

fifteen

<210> 8505

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8505

Ser Ser Arg Asp Ser Ser Gly Asp His Leu Arg Val

1 5 10

<210> 8506

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8506

Asn Ser Arg Asp Ser Ser Gly His His Leu Leu

1 5 10

<210> 8507

<211> 14

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8507

Gln His Tyr Gly Ser Ser Phe Asn Gly Ser Ser Leu Phe Thr

1 5 10

<210> 8508

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8508

Gln Gln Phe Gly Thr Ser Ser Gly Leu Thr

1 5 10

<210> 8509

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8509

Gln Gln Tyr His Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8510

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8510

Gln Gln Tyr His Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8511

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8511

Gln Gln Ser Tyr Ser Thr Pro Tyr Ser

fifteen

<210> 8512

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8512

Gln His Tyr Glu Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8513

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8513

Gln Gln Tyr Gly Ser Pro Arg Phe Thr

1 5 10

<210> 8514

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8514

Gln His Tyr Gly Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8515

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8515

Gln His Tyr Asp Ser Ser Pro Ser Trp Thr

1 5 10

<210> 8516

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8516

Gln Tyr Tyr Gly Thr Ser Pro Met Tyr Thr

1 5 10

<210> 8517

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8517

Met Gln Ala Leu Gln Thr Pro Leu Thr

fifteen

<210> 8518

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8518

Gln His Tyr Gly Asn Ser Pro Pro Lys Phe Thr

1 5 10

<210> 8519

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8519

Gln His Tyr Gly Gly Ser Pro Arg Leu Thr

1 5 10

<210> 8520

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8520

Gln Gln His Tyr Ser Thr Pro Trp Thr

fifteen

<210> 8521

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8521

Leu Gln Ser Arg Ile Phe Pro Arg Thr

fifteen

<210> 8522

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8522

Leu Gln Ser Arg Thr Ile Pro Arg Thr

fifteen

<210> 8523

<211> 9

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

peptide"

<400> 8523

Leu Gln Ser Arg Thr Ile Pro Arg Thr

fifteen

<210> 8524

<400> 8524

000

<210> 8525

<400> 8525

000

<210> 8526

<400> 8526

000

<210> 8527

<400> 8527

000

<210> 8528

<400> 8528

000

<210> 8529

<400> 8529

000

<210> 8530

<400> 8530

000

<210> 8531

<400> 8531

000

<210> 8532

<400> 8532

000

<210> 8533

<400> 8533

000

<210> 8534

<400> 8534

000

<210> 8535

<400> 8535

000

<210> 8536

<400> 8536

000

<210> 8537

<400> 8537

000

<210> 8538

<400> 8538

000

<210> 8539

<400> 8539

000

<210> 8540

<400> 8540

000

<210> 8541

<400> 8541

000

<210> 8542

<400> 8542

000

<210> 8543

<400> 8543

000

<210> 8544

<400> 8544

000

<210> 8545

<400> 8545

000

<210> 8546

<400> 8546

000

<210> 8547

<400> 8547

000

<210> 8548

<400> 8548

000

<210> 8549

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8549

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Gly Trp Val Ser Gly Ile Ser Arg Ser Gly Glu Asn Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ser Pro Ala His Tyr Tyr Gly Gly Met

115 120 125

Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile

145 150 155 160

Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg

165 170 175

Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Phe Leu

180 185 190

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr

195 200 205

Gly Ala Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser

210 215 220

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu

225 230 235 240

Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro Ser Trp

245 250 255

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8550

<211> 488

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8550

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Leu Tyr Tyr Cys Ser Val His Ser Phe Leu Ala Tyr Trp Gly Gln

115 120 125

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr

145 150 155 160

Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys

165 170 175

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

180 185 190

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu

195 200 205

Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

210 215 220

Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp

225 230 235 240

Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Tyr Thr Phe

245 250 255

Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg

260 265 270

Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg

275 280 285

Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly

290 295 300

Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr

305 310 315 320

Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg

325 330 335

Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro

340 345 350

Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu

355 360 365

Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala

370 375 380

Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu

385 390 395 400

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly

405 410 415

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu

420 425 430

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser

435 440 445

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly

450 455 460

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu

465 470 475 480

His Met Gln Ala Leu Pro Pro Arg

485

<210> 8551

<211> 487

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8551

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr

145 150 155 160

Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys

165 170 175

Lys Ser Ser Gln Ser Leu Leu Arg Asn Asp Gly Lys Thr Pro Leu Tyr

180 185 190

Trp Tyr Leu Gln Lys Ala Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu

195 200 205

Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

210 215 220

Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp

225 230 235 240

Val Gly Ala Tyr Tyr Cys Met Gln Asn Ile Gln Phe Pro Ser Phe Gly

245 250 255

Gly Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro

260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro

275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys

305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly

325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val

340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu

355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370 375 380

Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn

385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg

405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly

420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu

435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu

450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His

465 470 475 480

Met Gln Ala Leu Pro Pro Arg

485

<210> 8552

<211> 493

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8552

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Arg Lys Thr Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Ile Phe Asp Asn Phe Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Asn Asn Asn Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser

85 90 95

Thr Asn Thr Ala Tyr Met Glu Val Ser Ser Leu Arg Ser Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Gly Pro Tyr Tyr Tyr Gln Ser Tyr Met

115 120 125

Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile

145 150 155 160

Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro

165 170 175

Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly

180 185 190

Tyr Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln

195 200 205

Leu Leu Ile Tyr Leu Gly Ser Lys Arg Ala Ser Gly Val Pro Asp Arg

210 215 220

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu His Ile Thr Arg

225 230 235 240

Val Gly Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln

245 250 255

Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr

260 265 270

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln

275 280 285

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala

290 295 300

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala

305 310 315 320

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr

325 330 335

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln

340 345 350

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser

355 360 365

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys

370 375 380

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln

385 390 395 400

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu

405 410 415

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg

420 425 430

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met

435 440 445

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly

450 455 460

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp

465 470 475 480

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8553

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8553

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Asp Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Thr Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Leu Asp Ser Ser Gly Tyr Tyr Tyr Ala

115 120 125

Arg Gly Pro Arg Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

130 135 140

Ala Ser Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly

145 150 155 160

Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val

165 170 175

Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser

180 185 190

Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu

195 200 205

Ile Tyr Gly Ala Ser Thr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr His Phe Thr Leu Thr Ile Asn Ser Leu Gln

225 230 235 240

Ser Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Lys Arg Ala

245 250 255

Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8554

<211> 491

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8554

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr

35 40 45

Thr Phe Ser Asn Tyr Gly Ile Thr Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser

85 90 95

Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Gly Pro Tyr Tyr Tyr Tyr Met Asp Val

115 120 125

Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser Ala Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Met

145 150 155 160

Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser

165 170 175

Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn

180 185 190

Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu

195 200 205

Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Lys Leu Gln Ile Ser Arg Val Glu

225 230 235 240

Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly Arg Gln Phe Pro

245 250 255

Tyr Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro

260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu

275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His

290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu

305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr

325 330 335

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe

340 345 350

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg

355 360 365

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser

370 375 380

Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr

385 390 395 400

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys

405 410 415

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn

420 425 430

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu

435 440 445

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly

450 455 460

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr

465 470 475 480

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8555

<211> 482

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8555

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Ser Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys

180 185 190

Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala

195 200 205

Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr

225 230 235 240

Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val

245 250 255

Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro

260 265 270

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro

275 280 285

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp

290 295 300

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu

305 310 315 320

Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu

325 330 335

Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu

340 345 350

Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys

355 360 365

Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys

370 375 380

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu

385 390 395 400

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly

405 410 415

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu

420 425 430

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly

435 440 445

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser

450 455 460

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro

465 470 475 480

Pro Arg

<210> 8556

<211> 483

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8556

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser

145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Lys Leu Ala Trp Tyr Gln Gln Lys

180 185 190

Pro Gly Gln Ala Pro Arg Leu Leu Met Tyr Gly Ala Ser Ile Arg Ala

195 200 205

Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe

210 215 220

Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr

225 230 235 240

Cys Gln Gln Tyr Gly Ser Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys

245 250 255

Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala

260 265 270

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg

275 280 285

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys

290 295 300

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu

305 310 315 320

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu

325 330 335

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

340 345 350

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly

355 360 365

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr

370 375 380

Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg

385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met

405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu

420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465 470 475 480

Pro Pro Arg

<210> 8557

<211> 485

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8557

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Val

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

145 150 155 160

Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Val Gly Ser Thr Asn Leu Ala Trp Tyr Gln Gln

180 185 190

Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg

195 200 205

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp

210 215 220

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr

225 230 235 240

Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly

245 250 255

Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

260 265 270

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

275 280 285

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

290 295 300

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

305 310 315 320

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

325 330 335

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

340 345 350

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

355 360 365

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

370 375 380

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

385 390 395 400

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

405 410 415

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

420 425 430

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

435 440 445

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

450 455 460

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

465 470 475 480

Ala Leu Pro Pro Arg

485

<210> 8558

<211> 483

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8558

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Glu Ser Gly Asp Gly Met Asp Val Trp

115 120 125

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly

130 135 140

Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr

145 150 155 160

Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile

165 170 175

Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln

180 185 190

Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser

195 200 205

Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr

210 215 220

Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr

225 230 235 240

Tyr Tyr Cys Gln Gln Ser Tyr Thr Leu Ala Phe Gly Gln Gly Thr Lys

245 250 255

Val Asp Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala

260 265 270

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg

275 280 285

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys

290 295 300

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu

305 310 315 320

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu

325 330 335

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

340 345 350

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly

355 360 365

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr

370 375 380

Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg

385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met

405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu

420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465 470 475 480

Pro Pro Arg

<210> 8559

<211> 483

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8559

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser

145 150 155 160

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys

165 170 175

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys

180 185 190

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln

195 200 205

Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr

225 230 235 240

Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys

245 250 255

Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala

260 265 270

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg

275 280 285

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys

290 295 300

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu

305 310 315 320

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu

325 330 335

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

340 345 350

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly

355 360 365

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr

370 375 380

Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg

385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met

405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu

420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465 470 475 480

Pro Pro Arg

<210> 8560

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8560

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu

20 25 30

Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Asn Thr Ile Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ser Thr Met Val Arg Glu Asp Tyr Trp

115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly

130 135 140

Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Val Leu Thr

145 150 155 160

Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile

165 170 175

Ser Cys Lys Ser Ser Glu Ser Leu Val His Asn Ser Gly Lys Thr Tyr

180 185 190

Leu Asn Trp Phe His Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile

195 200 205

Tyr Glu Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Thr Gly

210 215 220

Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala

225 230 235 240

Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Gly

245 250 255

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8561

<211> 483

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8561

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Arg Leu Thr Gln Ser

145 150 155 160

Pro Ser Pro Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys

165 170 175

Gln Ala Ser Glu Asp Ile Asn Lys Phe Leu Asn Trp Tyr His Gln Thr

180 185 190

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln

195 200 205

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

210 215 220

Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Ile Gly Thr Tyr Tyr

225 230 235 240

Cys Gln Gln Tyr Glu Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys

245 250 255

Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala

260 265 270

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg

275 280 285

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys

290 295 300

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu

305 310 315 320

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu

325 330 335

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

340 345 350

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly

355 360 365

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr

370 375 380

Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg

385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met

405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu

420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465 470 475 480

Pro Pro Arg

<210> 8562

<211> 484

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8562

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Thr Thr Leu Thr Gln Ser

145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Val Gly Ser Asn Leu Ala Trp Tyr Gln Gln Lys

180 185 190

Pro Gly Gln Gly Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala

195 200 205

Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe

210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr

225 230 235 240

Cys Gln Gln Tyr Asn Asp Trp Leu Pro Val Thr Phe Gly Gln Gly Thr

245 250 255

Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro

260 265 270

Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys

275 280 285

Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala

290 295 300

Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu

305 310 315 320

Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys

325 330 335

Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr

340 345 350

Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly

355 360 365

Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala

370 375 380

Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg

385 390 395 400

Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu

405 410 415

Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn

420 425 430

Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met

435 440 445

Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly

450 455 460

Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala

465 470 475 480

Leu Pro Pro Arg

<210> 8563

<211> 485

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8563

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe

35 40 45

Ala Leu Ser Asn His Gly Met Ser Trp Val Arg Arg Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Val Tyr Ser Gly Ser Thr Tyr Tyr

65 70 75 80

Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg

85 90 95

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala

100 105 110

Ile Tyr Tyr Cys Ser Ala His Gly Gly Glu Ser Asp Val Trp Gly Gln

115 120 125

Gly Thr Thr Val Thr Val Ser Ser Ala Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

145 150 155 160

Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Ile Gly Ser Ser Ser Leu Ala Trp Tyr Gln Gln

180 185 190

Lys Pro Gly Gln Ala Pro Arg Leu Leu Met Tyr Gly Ala Ser Ser Arg

195 200 205

Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp

210 215 220

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr

225 230 235 240

Tyr Cys Gln Gln Tyr Ala Gly Ser Pro Pro Phe Thr Phe Gly Gln Gly

245 250 255

Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

260 265 270

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

275 280 285

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

290 295 300

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

305 310 315 320

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

325 330 335

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

340 345 350

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

355 360 365

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

370 375 380

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

385 390 395 400

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

405 410 415

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

420 425 430

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

435 440 445

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

450 455 460

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

465 470 475 480

Ala Leu Pro Pro Arg

485

<210> 8564

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8564

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aactcgtgga atctggtgga ggactcgtgc aacccggaag atcgcttaga 120

ctgtcgtgtg ccgccagcgg gttcactttc tcgaactacg cgatgtcctg ggtccgccag 180

gcaccgggaa agggactcgg ttgggtgtcc ggcatttccc ggtccggcga aaatacctac 240

tacgccgact ccgtgaaggg ccgcttcacc atctcaaggg acaacagcaa aaacaccctg 300

tacttgcaaa tgaactccct gcgggatgaa gatacagccg tgtactattg cgcccggtcg 360

cctgcccatt actacggcgg aatggacgtc tggggacagg gaaccactgt gactgtcagc 420

agcgcgtcgg gtggcggcgg ctcaggggggt cgggcctccg gggggggagg gtccgacatc 480

gtgctgaccc agtccccggg aaccctgagc ctgagcccgg gagagcgcgc gaccctgtca 540

tgccgggcat ccgagcat tagctcctcc tttctcgcct ggtatcagca gaagccggga 600

caggccccga ggctgctgat ctacggcgct agcagaaggg ctaccgggaat cccagaccgg 660

ttctccggct ccggttccgg gaccgatttc acccttacta tctcgcgcct ggaacctgag 720

gactccgccg tctactactg ccagcagtac cactcatccc cgtcgtggac gttcggacag 780

ggcaccaagc tggagattaa gaccactacc ccagcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8565

<211> 1464

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8565

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aactcgtcga atccggtgga ggtctggtcc aacctggtag aagcctgaga 120

ctgtcgtgtg cggccagcgg attcaccttt gatgactatg ctatgcactg ggtgcggcag 180

gccccaggaa agggcctgga atgggtgtcg ggaattagct ggaactccgg gtccattggc 240

tacgccgact ccgtgaaggg ccgcttcacc atctcccgcg acaacgcaaa gaactccctg 300

tacttgcaaa tgaactcgct cagggctgag gataccgcgc tgtactactg ctccgtgcat 360

tccttcctgg cctactgggg acagggaact ctggtcaccg tgtcgagcgc ctccggcggc 420

gggggctcgg gtggacgggc ctcgggcggga ggggggtccg acatcgtgat gacccagacc 480

ccgctgagct tgcccgtgac tcccggagag cctgcatcca tctcctgccg gtcatcccag 540

tcccttctcc actccaacgg atacaactac ctcgactggt acctccagaa gccgggacag 600

agccctcagc ttctgatcta cctggggtca aatagagcct caggagtgcc ggatcggttc 660

agcggatctg gttcgggaac tgatttcact ctgaagattt cccgcgtgga agccgaggac 720

gtgggcgtct actactgtat gcaggcgctg cagaccccct ataccttcgg ccaagggacg 780

aaagtggaga tcaagaccac taccccagca ccgaggccac ccaccccggc tcctaccatc 840

gcctcccagc ctctgtccct gcgtccggag gcatgtagac ccgcagctgg tggggccgtg 900

catacccggg gtcttgactt cgcctgcgat atctacattt gggcccctct ggctggtact 960

tgcggggtcc tgctgctttc actcgtgatc actctttact gtaagcgcgg tcggaagaag 1020

ctgctgtaca tctttaagca acccttcatg aggcctgtgc agactactca agaggaggac 1080

ggctgttcat gccggttccc agaggaggag gaaggcggct gcgaactgcg cgtgaaattc 1140

agccgcagcg cagatgctcc agcctacaag caggggcaga accagctcta caacgaactc 1200

1260

1320

gataagatgg cagaagccta tagcgagatt ggtatgaaag gggaacgcag aagaggcaaa 1380

ggccacgacg gactgtacca gggactcagc accgccacca aggacaccta tgacgctctt 1440

cacatgcagg ccctgccgcc tcgg 1464

<210> 8566

<211> 1461

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8566

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattgttgga atctggagga ggacttgtgc agcctggagg atcactgaga 120

ctttcgtgtg cggtgtcagg cttcgccctg agcaaccacg gcatgagctg ggtgcggaga 180

gccccgggga agggtctgga atgggtgtcc gggatcgtct actccggttc aacttactac 240

gccgcaagcg tgaagggtcg cttcaccatt tcccgcgata actcccggaa caccctgtac 300

ctccaaatga actccctgcg gcccgaggac accgccatct actactgttc cgcgcatgga 360

ggagagtccg atgtctgggg acagggcact accgtgaccg tgtcgagcgc ctcgggggga 420

ggaggctccg gcggtcgcgc ctccgggggg ggtggcagcg acattgtgat gacgcagact 480

ccactctcgc tgtccgtgac cccgggacag cccgcgtcca tctcgtgcaa gagctcccag 540

agcctgctga ggaacgacgg aaagactcct ctgtattggt acctccagaa ggctggacag 600

cccccgcaac tgctcatcta cgaagtgtca aatcgcttct ccggggtgcc ggatcggttt 660

tccggctcgg gatcgggcac cgacttcacc ctgaaaatct ccaggggtcga ggccgaggac 720

gtgggagcct actactgcat gcaaaacatc cagttccctt ccttcggcgg cggcacaaag 780

ctggagatta agaccactac cccagcaccg aggccaccca ccccggctcc taccatcgcc 840

tcccagcctc tgtccctgcg tcgggaggca tgtagacccg cagctggtgg ggccgtgcat 900

acccggggtc ttgacttcgc ctgcgatatc tacatttggg cccctctggc tggtacttgc 960

ggggtcctgc tgctttcact cgtgatcact ctttactgta agcgcggtcg gaagaagctg 1020

ctgtacatct ttaagcaacc cttcatgagg cctgtgcaga ctactcaaga ggaggacggc 1080

tgttcatgcc ggttcccaga ggaggaggaa ggcggctgcg aactgcgcgt gaaattcagc 1140

cgcagcgcag atgctccagc ctacaagcag gggcagaacc agctctacaa cgaactcaat 1200

1260

ggcgggaagc cgcgcagaaa gaatccccaa gagggcctgt acaacgagct ccaaaaggat 1320

aagatggcag aagcctatag cgagattggt atgaaagggg aacgcagaag aggcaaaggc 1380

cacgacggac tgtaccaggg actcagcacc gccaccaagg acacctatga cgctcttcac 1440

atgcaggccc tgccgcctcg g 1461

<210> 8567

<211> 1479

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8567

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtcc aactcgtcca gtccggcgca gaagtcagaa aaaccggtgc tagcgtgaaa 120

gtgtcctgca aggcctccgg ctacattttc gataacttcg gaatcaactg ggtcagacag 180

gccccgggcc aggggctgga atggatggga tggatcaacc ccaagaacaa caacaccaac 240

tacgcacaga agttccaggg ccgcgtgact atcaccgccg atgaatcgac caataccgcc 300

tacatggagg tgtcctccct gcggtcggag gacactgccg tgtattactg cgcgaggggc 360

ccatactact accaaagcta catggacgtc tggggacagg gaaccatggt gaccgtgtca 420

tccgcctccg gtggtggagg ctccgggggg cgggcttcag gaggcggagg aagcgatatt 480

gtgatgaccc agactccgct tagcctgccc gtgactcctg gagaaccggc ctccatttcc 540

tgccggtcct cgcaatcact cctgcattcc aacggttaca actacctgaa ttggtacctc 600

cagaagcctg gccagtcgcc ccagttgctg atctatctgg gctcgaagcg cgcctccggg 660

gtgcctgacc ggtttagcgg atctgggagc ggcacggact tcactctcca catcacccgc 720

gtgggagcgg aggacgtggg agtgtactac tgtatgcagg cgctgcagac tccgtacaca 780

ttcggacagg gcaccaagct ggagatcaag accactaccc cagcaccgag gccacccacc 840

ccggctccta ccatcgcctc ccagcctctg tccctgcgtc cggaggcatg tagacccgca 900

gctggtgggg ccgtgcatac ccggggtctt gacttcgcct gcgatatcta catttgggcc 960

cctctggctg gtacttgcgg ggtcctgctg ctttcactcg tgatcactct ttactgtaag 1020

cgcggtcgga agaagctgct gtacatcttt aagcaaccct tcatgaggcc tgtgcagact 1080

actcaagagg aggacggctg ttcatgccgg ttcccagagg aggaggaagg cggctgcgaa 1140

ctgcgcgtga aattcagccg cagcgcagat gctccagcct acaagcaggg gcagaaccag 1200

ctctacaacg aactcaatct tggtcggaga gaggagtacg acgtgctgga caagcggaga 1260

ggacgggacc cagaaatggg cgggaagccg cgcagaaaga atccccaaga gggcctgtac 1320

aacgagctcc aaaaggataa gatggcagaa gcctatagcg agattggtat gaaaggggaa 1380

cgcagaagag gcaaaggcca cgacggactg taccagggac tcagcaccgc caccaaggac 1440

acctatgacg ctcttcacat gcaggccctg ccgcctcgg 1479

<210> 8568

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8568

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aacttcaaga atcaggcggga ggactcgtgc agcccgggagg atcattgcgg 120

ctctcgtgcg ccgcctcggg cttcaccttc tcgagcgacg ccatgacctg ggtccgccag 180

gccccgggga aggggctgga atgggtgtct gtgatttccg gctccggggg aactacgtac 240

tacgccgatt ccgtgaaagg tcgcttcact atctcccggg acaacagcaa gaacaccctt 300

tatctgcaaa tgaattccct ccgcgccgag gacaccgccg tgtactactg cgccaagctg 360

gactcctcgg gctactacta tgcccggggt ccgagatact ggggacaggg aaccctcgtg 420

accgtgtcct ccgcgtccgg cggaggaggg tcgggagggc gggcctccgg cggcggcggt 480

tcggacatcc agctgaccca gtccccatcc tcactgagcg caagcgtggg cgacagagtc 540

accattacat gcagggcgtc ccagagcatc agctcctacc tgaactggta ccaacagaag 600

ccctggaaagg ctcctaagct gttgatctac ggggcttcga ccctggcatc cggggtgccc 660

gcgaggttta gcggaagcgg tagcggcact cacttcactc tgaccattaa cagcctccag 720

tccgaggatt cagccactta ctactgtcag cagtcctaca agcgggccag cttcggacag 780

ggcactaagg tcgagatcaa gaccactacc cgcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8569

<211> 1473

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8569

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtcc aactggtcca gagcggtgca gaagtgaaga agcccggagc gagcgtgaaa 120

gtgtcctgca aggcttccgg gtacaccttc tccaactacg gcatcacttg ggtgcgccag 180

gccccgggac agggcctgga atggatgggg tggatttccg cgtacaacgg caatacgaac 240

tacgctcaga agttcgggg tagagtgacc atgactagga acacctccat ttccaccgcc 300

tacatggaac tgtcctccct gcggagcgag gacaccgccg tgtactattg cgcccggggga 360

ccatactact actacatgga tgtctggggg aaggggacta tggtcaccgt gtcatccgcc 420

tcgggaggcg gcggatcagg aggacgcgcc tctggtggtg gaggatcgga gatcgtgatg 480

acccagagcc ctctctcctt gcccgtgact cctggggagc ccgcatccat ttcatgccgg 540

agctcccagt cacttctcta ctccaacggc tataactacg tggattggta cctccaaaag 600

ccggggccaga gcccgcagct gctgatctac ctgggctcga acagggccag cggagtgcct 660

gaccggttct ccgggtcggg aagcgggacc gacttcaagc tgcaaatctc gagagtggag 720

gccgaggacg tgggaatcta ctactgtatg cagggccgcc agtttccgta ctcgttcgga 780

cagggcacca aagtggaaat caagaccact accccagcac cgaggccacc caccccggct 840

cctaccatcg cctcccagcc tctgtccctg cgtccgggagg catgtagacc cgcagctggt 900

ggggccgtgc atacccgggg tcttgacttc gcctgcgata tctacatttg ggcccctctg 960

gctggtactt gcggggtcct gctgctttca ctcgtgatca ctctttactg taagcgcggt 1020

cggaagaagc tgctgtacat ctttaagcaa cccttcatga ggcctgtgca gactactcaa 1080

gaggaggacg gctgttcatg ccggttccca gaggaggagg aaggcggctg cgaactgcgc 1140

gtgaaattca gccgcagcgc agatgctcca gcctacaagc aggggcagaa ccagctctac 1200

aacgaactca atcttggtcg gagagaggag tacgacgtgc tggacaagcg gagaggacgg 1260

gacccagaaa tgggcgggaa gccgcgcaga aagaatcccc aaggggcct gtacaacgag 1320

ctccaaaagg ataagatggc agaagcctat agcgagattg gtatgaaagg ggaacgcaga 1380

agaggcaaag gccacgacgg actgtaccag ggactcagca ccgccaccaa ggacacctat 1440

gacgctcttc acatgcaggc cctgccgcct cgg 1473

<210> 8570

<211> 1446

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8570

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattgctcga aactggagga ggtctggtgc aacctggagg atcacttcgc 120

ctgtcctgcg ccgtgtcggg ctttgccctg tccaaccatg gaatgagctg ggtccgccgc 180

gcgccgggga agggcctcga atgggtgtcc ggcatcgtct actccggctc cacctactac 240

gccgcgtccg tgaagggccg gttcacgatt tcacgggaca actcgcggaa caccctgtac 300

ctccaaatga attcccttcg gccggaggat actgccatct actactgctc cgccccggt 360

ggcgaatccg acgtctgggg ccagggaacc accgtgaccg tgtccagcgc gtccggggga 420

ggaggaagcg ggggtagagc atcgggtgga ggcggatcag agatcgtgct gacccagtcc 480

cccgccacct tgagcgtgtc accaggagag tccgccaccc tgtcatgccg cgccagccag 540

tccgtgtcct ccaacctggc ttggtaccag cagaagccgg ggcaggcccc tagactcctg 600

atctatgggg cgtcgacccg ggcatctgga attcccgata ggttcagcgg atcgggctcg 660

ggcactgact tcactctgac catctcctcg ctgcaagccg aggacgtggc tgtgtactac 720

tgtcagcagt acggaagctc cctgactttc ggtggcggga ccaaagtcga gattaagacc 780

actaccccag caccgaggcc acccaccccg gctcctacca tcgcctccca gcctctgtcc 840

ctgcgtccgg aggcatgtag acccgcagct ggtggggccg tgcatacccg gggtcttgac 900

ttcgcctgcg atatctacat ttgggcccct ctggctggta cttgcggggt cctgctgctt 960

tcactcgtga tcactcttta ctgtaagcgc ggtcggaaga agctgctgta catctttaag 1020

caacccttca tgaggcctgt gcagactact caagggagg acggctgttc atgccggttc 1080

cggaggagg aggaaggcgg ctgcgaactg cgcgtgaaat tcagccgcag cgcagatgct 1140

ccagcctaca agcaggggca gaaccagctc tacaacgaac tcaatcttgg tcggagagag 1200

1260

agaaagaatc cccaagggg cctgtacaac gagctccaaa aggataagat ggcagaagcc 1320

1380

cagggactca gcaccgccac caaggacacc tatgacgctc ttcacatgca ggccctgccg 1440

cctcgg 1446

<210> 8571

<211> 1449

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8571

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattggtgga aactggagga ggacttgtgc aacctggagg atcattgaga 120

ctgagctgcg cagtgtcggg attcgccctg agcaaccatg gaatgtcctg ggtcagaagg 180

gcccctggaa aaggcctcga atgggtgtca gggatcgtgt actccggttc cacttactac 240

gccgcctccg tgaaggggcg cttcactatc tcacgggata actcccgcaa taccctgtac 300

ctccaaatga acagcctgcg gccggaggat accgccatct actactgttc cgcccacggt 360

ggagagtctg acgtctgggg ccagggaact accgtgaccg tgtcctccgc gtccggcggt 420

ggagggagcg gcggccgcgc cagcggcggc ggaggctccg agatcgtgat gacccagagc 480

cccgctactc tgtcggtgtc gcccggagaa agggcgaccc tgtcctgccg ggcgtcgcag 540

tccgtgagca gcaagctggc ttggtaccag cagaagccgg gccaggcacc acgcctgctt 600

atgtacggtg cctccattcg ggccaccgga atcccggacc ggttctcggg gtcggggtcc 660

ggtaccgagt tcacactgac catttcctcg ctcgagcccg aggactttgc cgtctattac 720

tgccagcagt acggctcctc ctcatggacg ttcggccagg ggaccaaggt cgaaatcaag 780

accactaccc cagcaccgag gccacccacc ccggctccta ccatcgcctc ccagcctctg 840

tccctgcgtc cggaggcatg tagacccgca gctggtgggg ccgtgcatac ccggggtctt 900

gacttcgcct gcgatatcta catttgggcc cctctggctg gtacttgcgg ggtcctgctg 960

ctttcactcg tgatcactct ttactgtaag cgcggtcgga agaagctgct gtacatcttt 1020

aagcaaccct tcatgaggcc tgtgcagact actcaagagg aggacggctg ttcatgccgg 1080

ttcccagagg aggaggaagg cggctgcgaa ctgcgcgtga aattcagccg cagcgcagat 1140

gctccagcct acaagcaggg gcagaaccag ctctacaacg aactcaatct tggtcggaga 1200

gaggagtacg acgtgctgga caagcggaga ggacgggacc cagaaatgggg cgggaagccg 1260

cgcagaaaga atccccaaga gggcctgtac aacgagctcc aaaaggataa gatggcagaa 1320

gcctatagcg agattggtat gaaaggggaa cgcagaagag gcaaaggcca cgacggactg 1380

taccagggac tcagcaccgc caccaaggac acctatgacg ctcttcacat gcaggccctg 1440

ccgcctcgg 1449

<210> 8572

<211> 1455

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8572

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattggtgga gactggagga ggagtggtgc aacctggagg aagcctgaga 120

ctgtcatgcg cggtgtcggg cttcgccctc tccaaccacg gaatgtcctg ggtccgccgg 180

gcccctggga aaggacttga atgggtgtcc ggcatcgtgt actcgggttc cacctactac 240

gcggcctcag tgaagggccg gtttactatt agccgcgaca actccagaaa cacactgtac 300

ctccaaatga actcgctgcg gccggaagat accgctatct actactgctc cgcccatggg 360

ggagagtcgg acgtctgggg acagggcacc actgtcactg tgtccagcgc ttccggcggt 420

ggtggaagcg ggggacgggc ctcaggaggc ggtggcagcg agattgtgct gacccagtcc 480

cccgggaccc tgagcctgtc cccgggagaa agggccaccc tctcctgtcg ggcatcccag 540

tccgtggggt ctactaacct tgcatggtac cagcagaagc ccggccaggc ccctcgcctg 600

ctgatctacg acgcgtccaa tagagccacc ggcatcccgg atcgcttcag cggaggcgga 660

tcgggcaccg acttcaccct caccatttca aggctggaac cggaggactt cgccgtgtac 720

tactgccagc agtatggttc gtccccaccc tggacgttcg gccaggggac taaggtcgag 780

atcaagacca ctaccccagc accgaggcca cccaccccgg ctcctaccat cgcctcccag 840

cctctgtccc tgcgtccggga ggcatgtaga cccgcagctg gtggggccgt gcatacccgg 900

ggtcttgact tcgcctgcga tatctacatt tgggcccctc tggctggtac ttgcggggtc 960

ctgctgcttt cactcgtgat cactctttac tgtaagcgcg gtcggaagaa gctgctgtac 1020

atctttaagc aacccttcat gaggcctgtg cagactactc aagaggagga cggctgttca 1080

tgccggttcc cagaggagga ggaaggcggc tgcgaactgc gcgtgaaatt cagccgcagc 1140

gcagatgctc cagcctacaa gcaggggcag aaccagctct acaacgaact caatcttggt 1200

cggagagagg agtacgacgt gctggacaag cggagaggac gggacccaga aatgggcggg 1260

aagccgcgca gaaagaatcc ccaaggggc ctgtacaacg agctccaaaa ggataagatg 1320

gcagaagcct atagcgagat tggtatgaaa ggggaacgca gaagaggcaa aggccacgac 1380

ggactgtacc agggactcag caccgccacc aaggacacct atgacgctct tcacatgcag 1440

gccctgccgc ctcgg 1455

<210> 8573

<211> 1449

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8573

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aactcgtgga atctggtgga ggactcgtga aacctggagg atcattgaga 120

ctgtcatgcg cggcctcggg attcacgttc tccgattact acatgagctg gattcgccag 180

gctccgggga agggactgga atgggtgtcc tacatttcct catccggctc caccatctac 240

tacgcggact ccgtgaaggg gagattcacc attagccgcg ataacgccaa gaacagcctg 300

taccttcaga tgaactccct gcgggctgaa gatactgccg tctactactg cgcaagggag 360

agcggagatg ggatggacgt ctggggacag ggtaccactg tgaccgtgtc gtcggcctcc 420

ggcgggagggg gttcgggtgg aagggccagc ggcggcggag gcagcgacat ccagatgacc 480

cagtccccct catcgctgtc cgcctccgtg ggcgaccgcg tcaccatcac atgccgggcc 540

tcacagtcga tctcctccta cctcaattgg tatcagcaga agcccggaaa ggcccctaag 600

cttctgatct acgcagcgtc ctccctgcaa tccggggtcc catctcggtt ctccggctcg 660

ggcagcggta ccgacttcac tctgaccatc tcgagcctgc agccggagga cttcgccact 720

tactactgtc agcaaagcta caccctcgcg tttggccagg gcaccaaagt ggacatcaag 780

accactaccc cagcaccgag gccacccacc ccggctccta ccatcgcctc ccagcctctg 840

tccctgcgtc cggaggcatg tagacccgca gctggtgggg ccgtgcatac ccggggtctt 900

gacttcgcct gcgatatcta catttgggcc cctctggctg gtacttgcgg ggtcctgctg 960

ctttcactcg tgatcactct ttactgtaag cgcggtcgga agaagctgct gtacatcttt 1020

aagcaaccct tcatgaggcc tgtgcagact actcaagagg aggacggctg ttcatgccgg 1080

ttcccagagg aggaggaagg cggctgcgaa ctgcgcgtga aattcagccg cagcgcagat 1140

gctccagcct acaagcaggg gcagaaccag ctctacaacg aactcaatct tggtcggaga 1200

gaggagtacg acgtgctgga caagcggaga ggacgggacc cagaaatgggg cgggaagccg 1260

cgcagaaaga atccccaaga gggcctgtac aacgagctcc aaaaggataa gatggcagaa 1320

gcctatagcg agattggtat gaaaggggaa cgcagaagag gcaaaggcca cgacggactg 1380

taccagggac tcagcaccgc caccaaggac acctatgacg ctcttcacat gcaggccctg 1440

cgcctcgg 1449

<210> 8574

<211> 1449

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8574

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattggtgga atcaggggga ggacttgtgc agcctggagg atcgctgaga 120

ctgtcatgtg ccgtgtccgg ctttgccctg tccaaccacg ggatgtcctg ggtccgccgc 180

gcgcctggaa agggcctcga atgggtgtcg ggtattgtgt acagcggtag cacctactat 240

gccgcatccg tgaaggggag attcaccatc agccgggaca actccaggaa cactctgtac 300

ctccaaatga attcgctgag gccagaggac actgccatct actactgctc cgcgcatggc 360

ggagagtccg acgtctgggg acaggggacc accgtgaccg tgtctagcgc gtccggcgga 420

ggcggcagcg ggggtcgggc atcaggggggc ggcggatcgg acatccagct cacccagtcc 480

ccgagctcgc tgtccgcctc cgtgggagat cgggtcacca tcacgtgccg cgccagccag 540

tcgatttcct cctacctgaa ctggtaccaa cagaagcccg gaaaagcccc gaagcttctc 600

atctacgccg cctcgagcct gcagtcagga gtgccctcac ggttctccgg ctccggttcc 660

ggtactgatt tcaccctgac catttcctcc ctgcaaccgg aggacttcgc tacttactac 720

tgccagcagt cgtactccac cccctacact ttcggacaag gcaccaaggt cgaaatcaag 780

accactaccc cagcaccgag gccacccacc ccggctccta ccatcgcctc ccagcctctg 840

tccctgcgtc cggaggcatg tagacccgca gctggtgggg ccgtgcatac ccggggtctt 900

gacttcgcct gcgatatcta catttgggcc cctctggctg gtacttgcgg ggtcctgctg 960

ctttcactcg tgatcactct ttactgtaag cgcggtcgga agaagctgct gtacatcttt 1020

aagcaaccct tcatgaggcc tgtgcagact actcaagagg aggacggctg ttcatgccgg 1080

ttcccagagg aggaggaagg cggctgcgaa ctgcgcgtga aattcagccg cagcgcagat 1140

gctccagcct acaagcaggg gcagaaccag ctctacaacg aactcaatct tggtcggaga 1200

gaggagtacg acgtgctgga caagcggaga ggacgggacc cagaaatgggg cgggaagccg 1260

cgcagaaaga atccccaaga gggcctgtac aacgagctcc aaaaggataa gatggcagaa 1320

gcctatagcg agattggtat gaaaggggaa cgcagaagag gcaaaggcca cgacggactg 1380

taccagggac tcagcaccgc caccaaggac acctatgacg ctcttcacat gcaggccctg 1440

cgcctcgg 1449

<210> 8575

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8575

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aactggtgca aagcggagga ggattggtca aacccgggagg aagcctgaga 120

ctgtcatgcg cggcctctgg attcaccttc tccgattact acatgtcatg gatcagacag 180

gccccgggga agggcctcga atgggtgtcc tacatctcgt cctccgggaa caccatctac 240

tacgccgaca gcgtgaaggg ccgctttacc atttcccgcg acaacgcaaa gaactcgctg 300

taccttcaga tgaattccct gcgggctgaa gataccgcgg tgtactattg cgcccggtcc 360

actatggtcc gggaggacta ctggggacag ggcacactcg tgaccgtgtc cagcgcgagc 420

gggggtggag gcagcggtgg acgcgcctcc ggcggcggcg gttcagacat cgtgctgact 480

cagtcgcccc tgtcgctgcc ggtcaccctg ggccaaccgg cctcaattag ctgcaagtcc 540

tcggagagcc tggtgcacaa ctcaggaaag acttacctga actggttcca tcagcggcct 600

ggacagtccc cacggaggct catctatgaa gtgtccaaca gggattcggg ggtgcccgac 660

cgcttcactg gctccgggtc cggcaccgac ttcaccttga aaatctccag agtggaagcc 720

gaggacgtgg gcgtgtacta ctgtatgcag ggtacccact ggcctggaac ctttggacaa 780

ggaactaagc tcgagattaa gaccactacc ccagcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8576

<211> 1449

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8576

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc aactcgtgga atctggtgga ggactcgtgc aacccggtgg aagccttagg 120

ctgtcgtgcg ccgtcagcgg gtttgctctg agcaaccatg gaatgtcctg ggtccgccgg 180

gcaccgggaa aagggctgga atgggtgtcc ggcatcgtgt acagcgggtc aacctattac 240

gccgcgtccg tgaagggcag attcactatc tcaagagaca acagccggaa caccctgtac 300

ttgcaaatga attccctgcg ccccgaggac accgccatct actactgctc cgcccacgga 360

ggagagtcgg acgtgtgggg ccagggaacg actgtgactg tgtccagcgc atcaggaggg 420

ggtggttcgg gcggccgggc ctcggggggga ggaggttccg acattcggct gacccagtcc 480

ccgtccccac tgtcggcctc cgtcggcgac cgcgtgacca tcacttgtca ggcgtccgag 540

gacattaaca agttcctgaa ctggtaccac cagacccctg gaaaggcccc caagctgctg 600

atctacgatg cctcgaccct tcaaactgga gtgcctagcc ggttctccgg gtccggctcc 660

ggcactgatt tcactctgac catcaactca ttgcagccgg aagatatcgg gacctactat 720

tgccagcagt acgaatccct cccgctcaca ttcggcgggg gaaccaaggt cgagattaag 780

accactaccc cagcaccgag gccacccacc ccggctccta ccatcgcctc ccagcctctg 840

tccctgcgtc cggaggcatg tagacccgca gctggtgggg ccgtgcatac ccggggtctt 900

gacttcgcct gcgatatcta catttgggcc cctctggctg gtacttgcgg ggtcctgctg 960

ctttcactcg tgatcactct ttactgtaag cgcggtcgga agaagctgct gtacatcttt 1020

aagcaaccct tcatgaggcc tgtgcagact actcaagagg aggacggctg ttcatgccgg 1080

ttcccagagg aggaggaagg cggctgcgaa ctgcgcgtga aattcagccg cagcgcagat 1140

gctccagcct acaagcaggg gcagaaccag ctctacaacg aactcaatct tggtcggaga 1200

gaggagtacg acgtgctgga caagcggaga ggacgggacc cagaaatgggg cgggaagccg 1260

cgcagaaaga atccccaaga gggcctgtac aacgagctcc aaaaggataa gatggcagaa 1320

gcctatagcg agattggtat gaaaggggaa cgcagaagag gcaaaggcca cgacggactg 1380

taccagggac tcagcaccgc caccaaggac acctatgacg ctcttcacat gcaggccctg 1440

cgcctcgg 1449

<210> 8577

<211> 1452

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8577

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattggtgga aactggagga ggacttgtgc aacctggagg atcattgcgg 120

ctctcatgcg ctgtctccgg cttcgccctg tcaaatcacg ggatgtcgtg ggtcagacgg 180

gccccgggaa agggtctgga atgggtgtcg gggattgtgt acagcggctc cacctactac 240

gccgcttcgg tcaagggccg cttcactatt tcacgggaca acagccgcaa caccctctat 300

ctgcaaatga actctctccg cccggaggat accgccatct actactgctc cgcacacggc 360

ggcgaatccg acgtgtgggg acagggaacc actgtcaccg tgtcgtccgc atccggtggc 420

ggaggatcgg gtggccgggc ctccgggggc ggcggcagcg agactaccct gacccagtcc 480

cctgccactc tgtccgtgag cccgggagag agagccaccc ttagctgccg ggccagccag 540

agcgtgggct ccaacctggc ctggtaccag cagaagccag gacagggtcc caggctgctg 600

atctacggag cctccactcg cgcgaccggc atccccgcga ggttctccgg gtcgggttcc 660

gggaccgagt tcaccctgac catctcctcc ctccaaccgg aggacttcgc ggtgtactac 720

tgtcagcagt acaacgattg gctgcccgtg acatttggac aggggacgaa ggtggaaatc 780

aaaaccacta ccccagcacc gaggccaccc accccggctc ctaccatcgc ctcccagcct 840

ctgtccctgc gtccgggaggc atgtagaccc gcagctggtg gggccgtgca tacccggggt 900

cttgacttcg cctgcgatat ctacatttgg gcccctctgg ctggtacttg cggggtcctg 960

ctgctttcac tcgtgatcac tctttactgt aagcgcggtc ggaagaagct gctgtacatc 1020

tttaagcaac ccttcatgag gcctgtgcag actactcaag aggaggacgg ctgttcatgc 1080

1140

gatgctccag cctacaagca ggggcagaac cagctctaca acgaactcaa tcttggtcgg 1200

agagaggagt acgacgtgct ggacaagcgg agaggacggg acccagaaat gggcgggaag 1260

1320

1380

ctgtaccagg gactcagcac cgccaccaag gacacctatg acgctcttca catgcaggcc 1440

ctgccgcctc gg 1452

<210> 8578

<211> 1455

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8578

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aattggtgga atctggtgga ggacttgtgc aacctggagg atcactgaga 120

ctgtcatgcg cggtgtccgg ttttgccctg agcaatcatg ggatgtcgtg ggtccggcgc 180

gccccgggaa agggtctgga atgggtgtcg ggtatcgtct actccgggag cacttactac 240

gccgcgagcg tgaagggccg cttcaccatt tcccgcgata actcccgcaa caccctgtac 300

ttgcaaatga actcgctccg gcctgaggac actgccatct actactgctc cgcacacgga 360

ggagaatccg acgtgtgggg ccagggaact accgtgaccg tcagcagcgc ctccggcggc 420

gggggctcag gcggacgggc tagcggcggc ggtggctccg agatcgtgct gacccagtcg 480

cctggcactc tctcgctgag ccccggggaa agggcaaccc tgtcctgtcg ggccagccag 540

tccattggat catcctccct cgcctggtat cagcagaaac cgggacaggc tccgcggctg 600

cttatgtatg gggccagctc aagagcctcc ggcattcccg accggttctc cgggtccggt 660

tccggcaccg atttcaccct gactatctcg aggctggagc cagaggactt cgccgtgtac 720

tactgccagc agtacgcggg gtccccgccg ttcacgttcg gacagggaac caaggtcgag 780

atcaagacca ctaccccagc accgaggcca cccaccccgg ctcctaccat cgcctcccag 840

cctctgtccc tgcgtccggga ggcatgtaga cccgcagctg gtggggccgt gcatacccgg 900

ggtcttgact tcgcctgcga tatctacatt tgggcccctc tggctggtac ttgcggggtc 960

ctgctgcttt cactcgtgat cactctttac tgtaagcgcg gtcggaagaa gctgctgtac 1020

atctttaagc aacccttcat gaggcctgtg cagactactc aagaggagga cggctgttca 1080

tgccggttcc cagaggagga ggaaggcggc tgcgaactgc gcgtgaaatt cagccgcagc 1140

gcagatgctc cagcctacaa gcaggggcag aaccagctct acaacgaact caatcttggt 1200

cggagagagg agtacgacgt gctggacaag cggagaggac gggacccaga aatgggcggg 1260

aagccgcgca gaaagaatcc ccaaggggc ctgtacaacg agctccaaaa ggataagatg 1320

gcagaagcct atagcgagat tggtatgaaa ggggaacgca gaagaggcaa aggccacgac 1380

ggactgtacc agggactcag caccgccacc aaggacacct atgacgctct tcacatgcag 1440

gccctgccgc ctcgg 1455

<210> 8579

<211> 487

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8579

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly

35 40 45

Ser Ile Ser Ser Ser Tyr Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro

50 55 60

Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Ala

65 70 75 80

Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr

85 90 95

Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp

100 105 110

Thr Ala Val Tyr Tyr Cys Ala Arg His Trp Gln Glu Trp Pro Asp Ala

115 120 125

Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly

130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Thr

145 150 155 160

Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Thr Pro Gly Asp Lys Val

165 170 175

Ile Ile Ser Cys Lys Ala Ser Gln Asp Ile Asp Asp Ala Met Asn Trp

180 185 190

Tyr Gln Gln Lys Pro Gly Glu Ala Pro Leu Phe Ile Ile Gln Ser Ala

195 200 205

Thr Ser Pro Val Pro Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Phe

210 215 220

Gly Thr Asp Phe Ser Leu Thr Ile Asn Asn Ile Glu Ser Glu Asp Ala

225 230 235 240

Ala Tyr Tyr Phe Cys Leu Gln His Asp Asn Phe Pro Leu Thr Phe Gly

245 250 255

Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro

260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro

275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys

305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly

325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val

340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu

355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370 375 380

Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn

385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg

405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly

420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu

435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu

450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His

465 470 475 480

Met Gln Ala Leu Pro Pro Arg

485

<210> 8580

<211> 489

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8580

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Asn Leu Arg Glu Ser Gly Pro Ala Leu

20 25 30

Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe

35 40 45

Ser Leu Arg Thr Ser Gly Met Cys Val Ser Trp Ile Arg Gln Pro Pro

50 55 60

Gly Lys Ala Leu Glu Trp Leu Ala Arg Ile Asp Trp Asp Glu Asp Lys

65 70 75 80

Phe Tyr Ser Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr

85 90 95

Ser Asp Asn Gln Val Val Leu Arg Met Thr Asn Met Asp Pro Ala Asp

100 105 110

Thr Ala Thr Tyr Tyr Cys Ala Arg Ser Gly Ala Gly Gly Thr Ser Ala

115 120 125

Thr Ala Phe Asp Ile Trp Gly Pro Gly Thr Met Val Thr Val Ser Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp

145 150 155 160

Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp

165 170 175

Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Tyr Asn Asn Leu

180 185 190

Ala Trp Phe Gln Leu Lys Pro Gly Ser Ala Pro Arg Ser Leu Met Tyr

195 200 205

Ala Ala Asn Lys Ser Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser

210 215 220

Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu

225 230 235 240

Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Tyr Arg Phe Pro Tyr Ser

245 250 255

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro

260 265 270

Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu

275 280 285

Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg

290 295 300

Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly

305 310 315 320

Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys

325 330 335

Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg

340 345 350

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro

355 360 365

Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser

370 375 380

Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu

385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg

405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln

420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr

435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp

450 455 460

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala

465 470 475 480

Leu His Met Gln Ala Leu Pro Pro Arg

485

<210> 8581

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8581

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Thr Ile Ala Ala Val Tyr Ala Phe Asp

115 120 125

Ile Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly

130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr

145 150 155 160

Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Glu Glu Pro Ala Ser Ile

165 170 175

Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr

180 185 190

Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile

195 200 205

Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly

210 215 220

Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala

225 230 235 240

Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Tyr

245 250 255

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8582

<211> 484

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8582

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Ala Phe Asp Ile Trp

115 120 125

Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Ser

145 150 155 160

Pro Ser Val Ser Ala Ala Pro Gly Tyr Thr Ala Thr Ile Ser Cys Gly

165 170 175

Gly Asn Asn Ile Gly Thr Lys Ser Val His Trp Tyr Gln Gln Lys Pro

180 185 190

Gly Gln Ala Pro Leu Leu Val Ile Arg Asp Asp Ser Val Arg Pro Ser

195 200 205

Lys Ile Pro Gly Arg Phe Ser Gly Ser Asn Ser Gly Asn Met Ala Thr

210 215 220

Leu Thr Ile Ser Gly Val Gln Ala Gly Asp Glu Ala Asp Phe Tyr Cys

225 230 235 240

Gln Val Trp Asp Ser Asp Ser Glu His Val Val Phe Gly Gly Gly Thr

245 250 255

Lys Leu Thr Val Leu Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro

260 265 270

Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys

275 280 285

Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala

290 295 300

Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu

305 310 315 320

Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys

325 330 335

Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr

340 345 350

Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly

355 360 365

Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala

370 375 380

Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg

385 390 395 400

Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu

405 410 415

Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn

420 425 430

Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met

435 440 445

Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly

450 455 460

Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala

465 470 475 480

Leu Pro Pro Arg

<210> 8583

<211> 485

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8583

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Pro Ser Gly Tyr

35 40 45

Thr Val Thr Ser His Tyr Ile His Trp Val Arg Arg Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Met Ile Asn Pro Ser Gly Gly Val Thr Ala

65 70 75 80

Tyr Ser Gln Thr Leu Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser

85 90 95

Ser Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr

100 105 110

Ala Met Tyr Tyr Cys Ala Arg Glu Gly Ser Gly Ser Gly Trp Tyr Phe

115 120 125

Asp Phe Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu

145 150 155 160

Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile

165 170 175

Thr Cys Ser Gly Asp Gly Leu Ser Lys Lys Tyr Val Ser Trp Tyr Gln

180 185 190

Gln Lys Ala Gly Gln Ser Pro Val Val Leu Ile Ser Arg Asp Lys Glu

195 200 205

Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn Ser Ala Asp

210 215 220

Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp

225 230 235 240

Tyr Tyr Cys Gln Ala Trp Asp Asp Thr Thr Val Val Phe Gly Gly Gly

245 250 255

Thr Lys Leu Thr Val Leu Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

260 265 270

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

275 280 285

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

290 295 300

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

305 310 315 320

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

325 330 335

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

340 345 350

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

355 360 365

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

370 375 380

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

385 390 395 400

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

405 410 415

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

420 425 430

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

435 440 445

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

450 455 460

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

465 470 475 480

Ala Leu Pro Pro Arg

485

<210> 8584

<211> 489

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8584

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly

35 40 45

Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro

50 55 60

Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr

65 70 75 80

Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr

85 90 95

Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp

100 105 110

Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Ile Ala Ala Arg Leu Arg

115 120 125

Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp

145 150 155 160

Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp

165 170 175

Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Trp Leu

180 185 190

Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr

195 200 205

Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser

210 215 220

Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu

225 230 235 240

Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe Thr

245 250 255

Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Thr Thr Thr Pro Ala Pro

260 265 270

Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu

275 280 285

Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg

290 295 300

Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly

305 310 315 320

Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys

325 330 335

Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg

340 345 350

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro

355 360 365

Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser

370 375 380

Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu

385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg

405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln

420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr

435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp

450 455 460

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala

465 470 475 480

Leu His Met Gln Ala Leu Pro Pro Arg

485

<210> 8585

<211> 497

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8585

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val

20 25 30

Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly

35 40 45

Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln

50 55 60

Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn

65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser

85 90 95

Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Arg Gly Gly Tyr Gln Leu Leu Arg Trp

115 120 125

Asp Val Gly Leu Leu Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr

130 135 140

Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

145 150 155 160

Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser

165 170 175

Val Ala Pro Gly Gln Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile

180 185 190

Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

195 200 205

Val Leu Val Leu Tyr Gly Lys Asn Asn Arg Pro Ser Gly Val Pro Asp

210 215 220

Arg Phe Ser Gly Ser Arg Ser Gly Thr Thr Ala Ser Leu Thr Ile Thr

225 230 235 240

Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Arg Asp

245 250 255

Ser Ser Gly Asp His Leu Arg Val Phe Gly Thr Gly Thr Lys Val Thr

260 265 270

Val Leu Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr

275 280 285

Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala

290 295 300

Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile

305 310 315 320

Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser

325 330 335

Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr

340 345 350

Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu

355 360 365

Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu

370 375 380

Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln

385 390 395 400

Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu

405 410 415

Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly

420 425 430

Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln

435 440 445

Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu

450 455 460

Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr

465 470 475 480

Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro

485 490 495

Arg

<210> 8586

<211> 492

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8586

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu

20 25 30

Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp

35 40 45

Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro

50 55 60

Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp

65 70 75 80

Tyr Ser Phe Tyr Ala Ile Ser Leu Lys Ser Arg Ile Ile Ile Asn Pro

85 90 95

Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Lys Ser Val Thr Pro

100 105 110

Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ser Pro Glu Gly Leu

115 120 125

Phe Leu Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val

130 135 140

Ser Ser Gly Gly Asp Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly

145 150 155 160

Ser Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly

165 170 175

Gln Thr Ile Arg Ile Thr Cys Gln Gly Asp Ser Leu Gly Asn Tyr Tyr

180 185 190

Ala Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile

195 200 205

Tyr Gly Thr Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala

210 215 220

Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala

225 230 235 240

Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly His

245 250 255

His Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Thr Thr Thr

260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro

275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val

290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro

305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu

325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro

340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys

355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe

370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu

385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp

405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys

420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala

435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys

450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr

465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8587

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8587

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Val Glu Gly Ser Gly Ser Leu Asp Tyr

115 120 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln

145 150 155 160

Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser

165 170 175

Cys Arg Ala Ser Gln Ser Val Ser Ser Ala Tyr Leu Ala Trp Tyr Gln

180 185 190

Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile Ser Gly Ala Ser Thr

195 200 205

Arg Ala Thr Gly Ile Pro Asp Arg Phe Gly Gly Ser Gly Ser Gly Thr

210 215 220

Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val

225 230 235 240

Tyr Tyr Cys Gln His Tyr Gly Ser Ser Phe Asn Gly Ser Ser Leu Phe

245 250 255

Thr Phe Gly Glyn Gly Thr Arg Leu Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8588

<211> 485

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8588

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile

35 40 45

Thr Phe Ser Arg Tyr Pro Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Ser Asp Ser Gly Val Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Phe Leu Gln Met Ser Ser Leu Arg Asp Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Val Thr Arg Ala Gly Ser Glu Ala Ser Asp Ile

115 120 125

Trp Gly Glyn Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln

145 150 155 160

Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser

165 170 175

Cys Arg Ala Ser Gln Ser Val Ser Asn Ser Leu Ala Trp Tyr Gln Gln

180 185 190

Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg

195 200 205

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp

210 215 220

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Ile Tyr

225 230 235 240

Tyr Cys Gln Gln Phe Gly Thr Ser Ser Gly Leu Thr Phe Gly Gly Gly

245 250 255

Thr Lys Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

260 265 270

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

275 280 285

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

290 295 300

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

305 310 315 320

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

325 330 335

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

340 345 350

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

355 360 365

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

370 375 380

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

385 390 395 400

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

405 410 415

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

420 425 430

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

435 440 445

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

450 455 460

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

465 470 475 480

Ala Leu Pro Pro Arg

485

<210> 8589

<211> 492

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8589

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Ile Tyr Tyr Cys Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr

115 120 125

Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser

130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

145 150 155 160

Glu Ile Val Met Thr Gln Ser Pro Gly Thr Val Ser Leu Ser Pro Gly

165 170 175

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser

180 185 190

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

195 200 205

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu

225 230 235 240

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro

245 250 255

Ser Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Thr Thr Thr

260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro

275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val

290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro

305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu

325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro

340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys

355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe

370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu

385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp

405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys

420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala

435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys

450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr

465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8590

<211> 492

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8590

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Thr Leu Lys Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ala Thr Tyr Lys Arg Glu Leu Arg Tyr

115 120 125

Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser

130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

145 150 155 160

Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly

165 170 175

Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Thr

180 185 190

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

195 200 205

Ile Tyr Gly Ser Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Arg Leu Glu

225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Ser Pro

245 250 255

Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr

260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro

275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val

290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro

305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu

325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro

340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys

355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe

370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu

385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp

405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys

420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala

435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys

450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr

465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8591

<211> 483

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8591

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Arg Val Gly Lys Ala Val Pro Asp Val Trp

115 120 125

Gly Glyn Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Thr

145 150 155 160

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys

165 170 175

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys

180 185 190

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln

195 200 205

Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr

225 230 235 240

Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Ser Phe Gly Gln Gly Thr Arg

245 250 255

Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala

260 265 270

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg

275 280 285

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys

290 295 300

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu

305 310 315 320

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu

325 330 335

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

340 345 350

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly

355 360 365

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr

370 375 380

Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg

385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met

405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu

420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465 470 475 480

Pro Pro Arg

<210> 8592

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8592

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe

35 40 45

Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Arg Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ala Ser Ile Asn Trp Lys Gly Asn Ser Leu Ala

65 70 75 80

Tyr Gly Asp Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala

85 90 95

Lys Asn Thr Val Phe Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Ser His Gln Gly Val Ala Tyr Tyr Asn Tyr

115 120 125

Ala Met Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile

145 150 155 160

Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg

165 170 175

Ala Thr Leu Ser Cys Arg Ala Thr Gln Ser Ile Gly Ser Ser Phe Leu

180 185 190

Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr

195 200 205

Gly Ala Ser Gln Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Arg

210 215 220

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Val Glu Pro Glu

225 230 235 240

Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Glu Ser Ser Pro Ser Trp

245 250 255

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8593

<211> 485

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8593

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Val Val Arg Asp Gly Met Asp Val Trp

115 120 125

Gly Glyn Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser

145 150 155 160

Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys

165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln

180 185 190

Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg

195 200 205

Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Asn Gly Ser Gly Thr Asp

210 215 220

Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr

225 230 235 240

Tyr Cys Gln Gln Tyr Gly Ser Pro Arg Phe Thr Phe Gly Pro Gly

245 250 255

Thr Lys Val Asp Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr

260 265 270

Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala

275 280 285

Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe

290 295 300

Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val

305 310 315 320

Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys

325 330 335

Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr

340 345 350

Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu

355 360 365

Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro

370 375 380

Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly

385 390 395 400

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro

405 410 415

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr

420 425 430

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly

435 440 445

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln

450 455 460

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln

465 470 475 480

Ala Leu Pro Pro Arg

485

<210> 8594

<211> 486

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8594

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Ile Pro Gln Thr Gly Thr Phe Asp Tyr

115 120 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser

130 135 140

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu Thr Gln

145 150 155 160

Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser

165 170 175

Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln

180 185 190

Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser

195 200 205

Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr

210 215 220

Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val

225 230 235 240

Tyr Tyr Cys Gln His Tyr Gly Ser Ser Pro Ser Trp Thr Phe Gly Gln

245 250 255

Gly Thr Arg Leu Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro

260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp

290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly

305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg

325 330 335

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln

340 345 350

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

355 360 365

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala

370 375 380

Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu

385 390 395 400

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

405 410 415

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu

420 425 430

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile

435 440 445

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr

450 455 460

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met

465 470 475 480

Gln Ala Leu Pro Pro Arg

485

<210> 8595

<211> 492

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8595

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Glu Asn Asp

85 90 95

Lys Asn Ser Val Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr

100 105 110

Gly Val Tyr Tyr Cys Ala Arg Ala Asn Tyr Lys Arg Glu Leu Arg Tyr

115 120 125

Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser

130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

145 150 155 160

Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly

165 170 175

Glu Ser Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ala Ser Asn

180 185 190

Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Ser Leu Leu

195 200 205

Ile Ser Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser

210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ala Ile Ser Arg Leu Glu

225 230 235 240

Pro Glu Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Asp Ser Ser Pro

245 250 255

Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr

260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro

275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val

290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro

305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu

325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro

340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys

355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe

370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu

385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp

405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys

420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala

435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys

450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr

465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8596

<211> 488

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8596

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Thr Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Ser Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Ala Leu Val Gly Ala Thr Gly Ala Phe

115 120 125

Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly

130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu

145 150 155 160

Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr

165 170 175

Leu Ser Cys Arg Ala Ser Gln Ser Leu Ser Ser Asn Phe Leu Ala Trp

180 185 190

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Gly Leu Leu Ile Tyr Gly Ala

195 200 205

Ser Asn Trp Ala Thr Gly Thr Pro Asp Arg Phe Ser Gly Ser Gly Ser

210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Phe

225 230 235 240

Ala Val Tyr Tyr Cys Gln Tyr Tyr Gly Thr Ser Pro Met Tyr Thr Phe

245 250 255

Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Thr Thr Pro Ala Pro Arg

260 265 270

Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg

275 280 285

Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly

290 295 300

Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr

305 310 315 320

Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg

325 330 335

Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro

340 345 350

Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu

355 360 365

Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala

370 375 380

Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu

385 390 395 400

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly

405 410 415

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu

420 425 430

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser

435 440 445

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly

450 455 460

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu

465 470 475 480

His Met Gln Ala Leu Pro Pro Arg

485

<210> 8597

<211> 488

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8597

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Val Leu Trp Phe Gly Glu Gly Phe Asp Pro Trp

115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser

145 150 155 160

Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys

165 170 175

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp

180 185 190

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu

195 200 205

Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

210 215 220

Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp

225 230 235 240

Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe

245 250 255

Gly Gly Gly Thr Lys Val Asp Ile Lys Thr Thr Thr Pro Ala Pro Arg

260 265 270

Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg

275 280 285

Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly

290 295 300

Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr

305 310 315 320

Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg

325 330 335

Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro

340 345 350

Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu

355 360 365

Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala

370 375 380

Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu

385 390 395 400

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly

405 410 415

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu

420 425 430

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser

435 440 445

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly

450 455 460

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu

465 470 475 480

His Met Gln Ala Leu Pro Pro Arg

485

<210> 8598

<211> 495

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8598

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Val Gly Tyr Asp Ser Ser Gly Tyr Tyr

115 120 125

Arg Asp Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr

130 135 140

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly

145 150 155 160

Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser

165 170 175

Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser

180 185 190

Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg

195 200 205

Leu Leu Ile Tyr Gly Thr Ser Ser Arg Ala Thr Gly Ile Ser Asp Arg

210 215 220

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg

225 230 235 240

Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Asn

245 250 255

Ser Pro Pro Lys Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys

260 265 270

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala

275 280 285

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly

290 295 300

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile

305 310 315 320

Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val

325 330 335

Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe

340 345 350

Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly

355 360 365

Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg

370 375 380

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln

385 390 395 400

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp

405 410 415

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro

420 425 430

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp

435 440 445

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg

450 455 460

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr

465 470 475 480

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490 495

<210> 8599

<211> 490

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 8599

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu

20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys

50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr

65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr

100 105 110

Ala Val Tyr Tyr Cys Ala Lys Met Gly Trp Ser Ser Gly Tyr Leu Gly

115 120 125

Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly

130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile

145 150 155 160

Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg

165 170 175

Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Ser Phe Leu

180 185 190

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr

195 200 205

Gly Ala Ser Gly Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser

210 215 220

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu

225 230 235 240

Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Gly Ser Pro Arg Leu

245 250 255

Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Thr Thr Thr Pro Ala

260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser

275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr

290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala

305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

325 330 335

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met

340 345 350

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe

355 360 365

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg

370 375 380

Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn

385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg

405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro

420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala

435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His

450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp

465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg

485 490

<210> 8600

<400> 8600

000

<210> 8601

<211> 1461

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8601

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agcttcagga aagcggaccg ggcctggtca agccatccga aactctctcc 120

ctgacttgca ctgtgtctgg cggttccatc tcatcgtcgt actactactg gggctggatt 180

aggcagccgc ccggaaaggg actggagtgg atcggaagca tctactattc cggctcggcg 240

tactacaacc ctagcctcaa gtcgagagtg accatctccg tggatacctc caagaaccag 300

ttttccctgc gcctgagctc cgtgaccgcc gctgacaccg ccgtgtacta ctgtgctcgg 360

cattggcagg aatggcccga tgccttcgac atttggggcc agggcactat ggtcactgtg 420

tcatccgggg gtggaggcag cgggggagga gggtccgggg ggggaggttc agagacaacc 480

ttgacccagt cacccgcatt catgtccgcc actccgggag acaaggtcat catctcgtgc 540

aaagcgtccc aggatatcga cgatgccatg aattggtacc agcagaagcc tggcgaagcg 600

ccgctgttca ttatccaatc cgcaacctcg cccgtgcctg gaatcccacc gcggttcagc 660

ggcagcggtt tcggaaccga ctttttccctg accattaaca acattgagtc cgaggacgcc 720

gcctactact tctgcctgca acacgacaac ttccctctca cgttcggcca gggaaccaag 780

ctggaaatca agaccactac cccagcaccg aggccaccca ccccggctcc taccatcgcc 840

tcccagcctc tgtccctgcg tcgggaggca tgtagacccg cagctggtgg ggccgtgcat 900

acccggggtc ttgacttcgc ctgcgatatc tacatttggg cccctctggc tggtacttgc 960

ggggtcctgc tgctttcact cgtgatcact ctttactgta agcgcggtcg gaagaagctg 1020

ctgtacatct ttaagcaacc cttcatgagg cctgtgcaga ctactcaaga ggaggacggc 1080

tgttcatgcc ggttcccaga ggaggaggaa ggcggctgcg aactgcgcgt gaaattcagc 1140

cgcagcgcag atgctccagc ctacaagcag gggcagaacc agctctacaa cgaactcaat 1200

1260

ggcgggaagc cgcgcagaaa gaatccccaa gagggcctgt acaacgagct ccaaaaggat 1320

aagatggcag aagcctatag cgagattggt atgaaagggg aacgcagaag aggcaaaggc 1380

cacgacggac tgtaccaggg actcagcacc gccaccaagg acacctatga cgctcttcac 1440

atgcaggccc tgccgcctcg g 1461

<210> 8602

<211> 1467

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8602

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtca atctgcgcga atccggcccc gccttggtca agcctaccca gaccctcact 120

ctgacctgta ctttctccgg cttctccctg cggacttccg ggatgtgcgt gtcctggatc 180

agacagcctc cgggaaaggc cctggagtgg ctcgctcgca ttgactggga tgaggacaag 240

ttctactcca cctcactcaa gaccaggctg accatcagca aagatacctc tgacaaccaa 300

gtggtgctcc gcatgaccaa catggaccca gccgacactg ccacttacta ctgcgcgagg 360

agcggagcgg gcggaacctc cgccaccgcc ttcgatattt ggggcccgggg taccatggtc 420

accgtgtcaa gcggaggagg ggggtccggg ggcggcggtt ccgggggagg cggatcggac 480

attcagatga ctcagtcacc atcgtccctg agcgctagcg tgggcgacag agtgacaatc 540

acttgccggg catccgga catctataac aaccttgcgt ggttccagct gaagcctggt 600

tccgcaccgc ggtcacttat gtacgccgcc aacaagagcc agtcgggagt gccgtcccgg 660

ttttccggtt cggcctcggg aactgacttc accctgacga tctccagcct gcaacccgag 720

gatttcgcca cctactactg ccagcactac taccgctttc cctactcgtt cggacagggga 780

accaagctgg aaatcaagac cactaccca gcaccgaggc cacccacccc ggctcctacc 840

atcgcctccc agcctctgtc cctgcgtccg gaggcatgta gacccgcagc tggtggggcc 900

gtgcataccc ggggtcttga cttcgcctgc gatatctaca tttgggcccc tctggctggt 960

acttgcgggg tcctgctgct ttcactcgtg atcactcttt actgtaagcg cggtcggaag 1020

aagctgctgt acatctttaa gcaacccttc atgaggcctg tgcagactac tcaagaggag 1080

gacggctgtt catgccggtt cccagaggag gaggaaggcg gctgcgaact gcgcgtgaaa 1140

ttcagccgca gcgcagatgc tccagcctac aagcaggggc agaaccagct ctacaacgaa 1200

ctcaatcttg gtcggagaga ggagtacgac gtgctggaca agcggagagg acgggaccca 1260

gaaatgggcg ggaagccgcg cagaaagaat ccccaagagg gcctgtacaa cgagctccaa 1320

aaggataaga tggcagaagc ctatagcgag attggtatga aaggggaacg cagaagaggc 1380

aaaggccacg acggactgta ccagggactc agcaccgcca ccaaggacac ctatgacgct 1440

cttcacatgc aggccctgcc gcctcgg 1467

<210> 8603

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8603

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agcttgtcga atccgggggg ggactggtca agccggggcgg atcactgaga 120

ctgtcctgcg ccgcgagcgg cttcacgttc tcctcctact ccatgaactg ggtccgccaa 180

gcccccggga agggactgga atgggtgtcc tctatctcct cgtcgtcgtc ctacatctac 240

tacgccgact ccgtgaaggg aagattcacc atttcccgcg acaacgcaaa gaactcactg 300

tacttgcaaa tgaactcact ccgggccgaa gatactgctg tgtactattg cgccaagact 360

attgccgccg tctacgcttt cgacatctgg ggccagggaa ccaccgtgac tgtgtcgtcc 420

ggtggtggtg gctcgggcgg aggaggaagc ggcggcgggg ggtccgagat tgtgctgacc 480

cagtcgccac tgagcctccc tgtgaccccc gaggaacccg ccagcatcag ctgccggtcc 540

agccagtccc tgctccactc caacggatac aattacctcg attggtacct tcagaagcct 600

ggacaaagcc cgcagctgct catctacttg ggatcaaacc gcgcgtcagg agtgcctgac 660

cggttctccg gctcgggcag cggtaccgat ttcaccctga aaatctccag ggtggaggca 720

gaggacgtgg gagtgtatta ctgtatgcag gcgctgcaga ctccgtacac atttgggcag 780

ggcaccaagc tggagatcaa gaccactacc ccagcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8604

<211> 1452

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8604

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtcc agctcgtgga gtccggcgga ggccttgtga agcctggagg ttcgctgaga 120

ctgtcctgcg ccgcctccgg cttcaccttc tccgactact acatgtcctg gatcagacag 180

gccccgggaa agggcctgga atgggtgtcc tacatctcgt catcggggcag cactatctac 240

tacgcggact cagtgaaggg gcggttcacc atttcccggg ataacgcgaa gaactcgctg 300

tatctgcaaa tgaactcact gagggccgag gacaccgccg tgtactactg cgcccgcgat 360

ctccgcgggg catttgacat ctggggacag ggaaccatgg tcacagtgtc cagcggaggg 420

ggaggatcgg gtggcggagg ttccgggggt ggaggctcct cctacgtgct gactcagagc 480

ccaagcgtca gcgctgcgcc cggttacacg gcaaccatct cctgtggcgg aaacaacatt 540

gggaccaagt ctgtgcactg gtatcagcag aagccgggcc aagctcccct gttggtgatc 600

cgcgatgact ccgtgcggcc tagcaaaatt ccgggacggt tctccggctc caacagcggc 660

aatatggcca ctctcaccat ctcgggagtg caggccggag atgaagccga cttctactgc 720

caagtctggg actcagactc cgagcatgtg gtgttcgggg gcggaaccaa gctgactgtg 780

ctcaccacta ccccagcacc gaggccaccc accccggctc ctaccatcgc ctcccagcct 840

ctgtccctgc gtccgggaggc atgtagaccc gcagctggtg gggccgtgca tacccggggt 900

cttgacttcg cctgcgatat ctacatttgg gcccctctgg ctggtacttg cggggtcctg 960

ctgctttcac tcgtgatcac tctttactgt aagcgcggtc ggaagaagct gctgtacatc 1020

tttaagcaac ccttcatgag gcctgtgcag actactcaag aggaggacgg ctgttcatgc 1080

1140

gatgctccag cctacaagca ggggcagaac cagctctaca acgaactcaa tcttggtcgg 1200

agagaggagt acgacgtgct ggacaagcgg agaggacggg acccagaaat gggcgggaag 1260

1320

1380

ctgtaccagg gactcagcac cgccaccaag gacacctatg acgctcttca catgcaggcc 1440

ctgccgcctc gg 1452

<210> 8605

<211> 1455

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8605

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agctggtgca gagcggggcc gaagtcaaga agccgggagc ctccgtgaaa 120

gtgtcctgca agccttcggg atacaccgtg acctcccact acattcattg ggtccgccgc 180

gcccccggcc aaggactcga gtggatgggc atgatcaacc ctagcggcgg agtgaccgcg 240

tacagccaga cgctgcaggg acgcgtgact atgacctcgg atacctcctc ctccaccgtc 300

tatatggaac tgtccagcct gcggtccgag gataccgcca tgtactactg cgcccgggaa 360

ggatcaggct ccgggtggta tttcgacttc tggggaagag gcaccctcgt gactgtgtca 420

tctgggggag ggggttccgg tggtggcgga tcgggaggag gcggttcatc ctacgtgctg 480

acccagccac cctccgtgtc cgtgagcccc ggccagactg catcgattac atgtagcggc 540

gacggcctct ccaagaaata cgtgtcgtgg taccagcaga aggccggaca gagcccggtg 600

660 gtgctgatct caagagataa

aactccgcgg acactgctac tctgaccatc tcggggaccc aggctatgga cgaagccgat 720

tactactgcc aagcctggga cgacactact gtcgtgtttg gagggggcac caagttgacc 780

gtccttacca ctaccccagc accgaggcca cccaccccgg ctcctaccat cgcctcccag 840

cctctgtccc tgcgtccggga ggcatgtaga cccgcagctg gtggggccgt gcatacccgg 900

ggtcttgact tcgcctgcga tatctacatt tgggcccctc tggctggtac ttgcggggtc 960

ctgctgcttt cactcgtgat cactctttac tgtaagcgcg gtcggaagaa gctgctgtac 1020

atctttaagc aacccttcat gaggcctgtg cagactactc aagaggagga cggctgttca 1080

tgccggttcc cagaggagga ggaaggcggc tgcgaactgc gcgtgaaatt cagccgcagc 1140

gcagatgctc cagcctacaa gcaggggcag aaccagctct acaacgaact caatcttggt 1200

cggagagagg agtacgacgt gctggacaag cggagaggac gggacccaga aatgggcggg 1260

aagccgcgca gaaagaatcc ccaaggggc ctgtacaacg agctccaaaa ggataagatg 1320

gcagaagcct atagcgagat tggtatgaaa ggggaacgca gaagaggcaa aggccacgac 1380

ggactgtacc agggactcag caccgccacc aaggacacct atgacgctct tcacatgcag 1440

gccctgccgc ctcgg 1455

<210> 8606

<211> 1467

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8606

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agcttcagga gagcggcccg ggactcgtga agccgtccca gaccctgtcc 120

ctgacttgca ccgtgtcggg aggaagcatc tcgagcggag gctactattg gtcgtggatt 180

cggcagcacc ctggaaaggg cctggaatgg atcggctaca tctactactc cggctcgacc 240

tactacacc catcgctgaa gtccagagtg acaatctcag tggacacgtc caagaatcag 300

ttcagcctga agctctcttc cgtgactgcg gccgacaccg ccgtgtacta ctgcgcacgc 360

gctggaattg cgcccggct gaggggtgcc ttcgacattt ggggacaggg caccatggtc 420

accgtgtcct ccggcggcgg aggttccggg ggtggaggct caggaggagg ggggtccgac 480

atcgtcatga ctcagtcgcc ctcaagcgtc agcgcgtccg tcggggacag agtgatcatc 540

acctgtcggg cgtcccaggg aattcgcaac tggctggcct ggtatcagca gaagccggga 600

aaggccccca acctgttgat ctacgccgcc tcaaacctcc aatccggggt gccgagccgc 660

ttcagcggct ccggttcggg tgccgatttc actctgacca tctcctccct gcaacctgaa 720

gatgtggcta cctactactg ccaaaagtac aactccgcac cttttacttt cggaccgggg 780

accaaagtgg acattaagac cactaccca gcaccgaggc cacccacccc ggctcctacc 840

atcgcctccc agcctctgtc cctgcgtccg gaggcatgta gacccgcagc tggtggggcc 900

gtgcataccc ggggtcttga cttcgcctgc gatatctaca tttgggcccc tctggctggt 960

acttgcgggg tcctgctgct ttcactcgtg atcactcttt actgtaagcg cggtcggaag 1020

aagctgctgt acatctttaa gcaacccttc atgaggcctg tgcagactac tcaagaggag 1080

gacggctgtt catgccggtt cccagaggag gaggaaggcg gctgcgaact gcgcgtgaaa 1140

ttcagccgca gcgcagatgc tccagcctac aagcaggggc agaaccagct ctacaacgaa 1200

ctcaatcttg gtcggagaga ggagtacgac gtgctggaca agcggagagg acgggaccca 1260

gaaatgggcg ggaagccgcg cagaaagaat ccccaagagg gcctgtacaa cgagctccaa 1320

aaggataaga tggcagaagc ctatagcgag attggtatga aaggggaacg cagaagaggc 1380

aaaggccacg acggactgta ccagggactc agcaccgcca ccaaggacac ctatgacgct 1440

cttcacatgc aggccctgcc gcctcgg 1467

<210> 8607

<211> 1491

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8607

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agctggtcca gtcgggcgcc gaggtcaaga agcccgggag ctctgtgaaa 120

gtgtcctgca aggcctccgg gggcaccttt agctcctacg ccatctcctg ggtccgccaa 180

gcaccgggtc aaggcctgga gtggatgggg ggaattatcc ctatcttcgg cactgccaac 240

tacgcccaga agttccaggg acgcgtgacc attaccgcgg acgaatccac ctccaccgct 300

360

ggtggatacc agctgctgag atgggacgtg ggcctcctgc ggtcggcgtt cgacatctgg 420

ggccagggca ctatggtcac tgtgtccagc ggaggaggcg gatcgggagg cggcggatca 480

gggggaggcg gttccagcta cgtgcttact caaccccctt cggtgtccgt ggccccggga 540

cagaccgcca gaatcacttg cggaggaaac aacattgggt ccaagagcgt gcattggtac 600

cagcagaagc caggacaggc ccctgtgctg gtgctctacg ggaagaacaa tcggcccagc 660

ggagtgccgg acaggttctc gggttcacgc tccggtacaa ccgcttcact gactatcacc 720

ggggcccagg cagaggatga agcggactac tactgttcct cccgggattc atccggcgac 780

cacctccggg tgttcggaac cggaacgaag gtcaccgtgc tgaccactac cccagcaccg 840

aggccaccca ccccggctcc taccatcgcc tcccagcctc tgtccctgcg tcgggaggca 900

tgtagacccg cagctggtgg ggccgtgcat acccggggtc ttgacttcgc ctgcgatatc 960

tacatttggg cccctctggc tggtacttgc ggggtcctgc tgctttcact cgtgatcact 1020

ctttactgta agcgcggtcg gaagaagctg ctgtacatct ttaagcaacc cttcatgagg 1080

cctgtgcaga ctactcaaga ggaggacggc tgttcatgcc ggttcccaga ggaggaggaa 1140

ggcggctgcg aactgcgcgt gaaattcagc cgcagcgcag atgctccagc ctacaagcag 1200

gggcagaacc agctctacaa cgaactcaat cttggtcgga gagaggagta cgacgtgctg 1260

gacaagcgga gaggacggga cccagaaatg ggcgggaagc cgcgcagaaa gaatccccaa 1320

gagggcctgt acaacgagct ccaaaaggat aagatggcag aagcctatag cgagattggt 1380

atgaaagggg aacgcagaag aggcaaaggc cacgacggac tgtaccaggg actcagcacc 1440

gccaccaagg acacctatga cgctcttcac atgcaggccc tgccgcctcg g 1491

<210> 8608

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8608

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctccaaca gtcaggaccg gggctcgtga agccatccca gaccctgtcc 120

ctgacttgtg ccatctcggg agatagcgtg tcatcgaact ccgccgcctg gaactggatt 180

cggcagagcc cgtcccgcgg actggagtgg cttggaagga cctactaccg gtccaagtgg 240

tactctttct acgcgatctc gctgaagtcc cgcattatca ttaaccctga tacctccaag 300

aatcagttct ccctccaact gaaatccgtc acccccgagg acacagcagt gtattactgc 360

gcacggagca gccccgaagg actgttcctg tattggtttg acccctgggg ccaggggact 420

cttgtgaccg tgtcgagcgg cggagatggg tccggtggcg gtggttcggg gggcggcggga 480

tcatcatccg aactgaccca ggacccggct gtgtccgtgg cgctgggaca aaccatccgc 540

attacgtgcc agggagactc cctgggcaac tactacgcca cttggtacca gcagaagccg 600

ggccaagccc ctgtgttggt catctacggg accaacaaca gaccttccgg catccccgac 660

cggttcagcg cttcgtcctc cggcaacact gccagcctga ccatcactgg agcgcaggcc 720

gaagatgagg ccgactacta ctgcaacagc agagactcct cgggtcatca cctcttgttc 780

ggaactggaa ccaaggtcac cgtgctgacc actaccccag caccgaggcc acccaccccg 840

gctcctacca tcgcctccca gcctctgtcc ctgcgtccgg aggcatgtag acccgcagct 900

ggtggggccg tgcatacccg gggtcttgac ttcgcctgcg atatctacat ttgggcccct 960

ctggctggta cttgcggggt cctgctgctt tcactcgtga tcactcttta ctgtaagcgc 1020

ggtcggaaga agctgctgta catctttaag caacccttca tgaggcctgt gcagactact 1080

caagagggagg acggctgttc atgccggttc ccagaggagg aggaaggcgg ctgcgaactg 1140

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 1200

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 1260

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagggg cctgtacaac 1320

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 1380

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 1440

tatgacgctc ttcacatgca ggccctgccg cctcgg 1476

<210> 8609

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8609

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctcgtgga gtcaggaggc ggcctggtcc agccgggagg gtcccttaga 120

ctgtcatgcg ccgcaagcgg attcactttc tcctcctatg ccatgagctg ggtccgccaa 180

gccccgggaa agggactgga atgggtgtcc gccatctcgg ggtctggagg ctcaacttac 240

tacgctgact ccgtgaaggg acggttcacc attagccgcg acaactccaa gaacaccctc 300

tacctccaaa tgaactccct gcgggccgag gataccgccg tctactactg cgccaaagtg 360

gaaggttcag gatcgctgga ctactgggga cagggtactc tcgtgaccgt gtcatcgggc 420

ggaggaggtt ccggcggtgg cggctccggc ggcggagggt cggagatcgt gatgacccag 480

agccctggta ctctgagcct ttcgccggga gaaagggcca ccctgtcctg ccgcgcttcc 540

caatccgtgt cctccgcgta cttggcgtgg taccagcaga agccgggaca gccccctcgg 600

ctgctgatca gcggggccag cacccgggca accggaatcc cagacagatt cgggggttcc 660

ggcagcggca cagatttcac cctgactatt tcgaggttgg agcccgagga ctttgcggtg 720

tattactgtc agcactacgg gtcgtccttt aatggctcca gcctgttcac gttcggacag 780

gggacccgcc tggaaatcaa gaccactacc cggcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8610

<211> 1455

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8610

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aactggtgga aaccggtggc ggcctggtgc agcctggagg atcattgagg 120

ctgtcatgcg cggccagcgg tattaccttc tcccggtacc ccatgtcctg ggtcagacag 180

gccccgggga aagggcttga atgggtgtcc gggatctcgg actccggtgt cagcacttac 240

tacgccgact ccgccaaggg acgcttcacc atttcccggg acaactcgaa gaacaccctg 300

ttcctccaaa tgagctccct ccgggacgag gatactgcag tgtactactg cgtgacccgc 360

gccgggtccg aggcgtctga catttgggga cagggcacta tggtcaccgt gtcgtccggc 420

ggagggggct cgggaggcgg tggcagcgga ggaggagggt ccgagatcgt gctgacccaa 480

tccccggcca ccctctcgct gagccctgga gaaagggcaa ccttgtcctg tcgcgcgagc 540

cagtccgtga gcaactccct ggcctggtac cagcagaagc ccggacaggc tccgagactt 600

ctgatctacg acgcttcgag ccgggccact ggaatccccg accgcttttc ggggtccggc 660

tcaggaaccg atttcaccct gacaatctca cggctggagc cagaggattt cgccatctat 720

tactgccagc agttcggtac ttcctccggc ctgactttcg gaggcggcac gaagctcgaa 780

atcaagacca ctaccccagc accgaggcca cccaccccgg ctcctaccat cgcctcccag 840

cctctgtccc tgcgtccggga ggcatgtaga cccgcagctg gtggggccgt gcatacccgg 900

ggtcttgact tcgcctgcga tatctacatt tgggcccctc tggctggtac ttgcggggtc 960

ctgctgcttt cactcgtgat cactctttac tgtaagcgcg gtcggaagaa gctgctgtac 1020

atctttaagc aacccttcat gaggcctgtg cagactactc aagaggagga cggctgttca 1080

tgccggttcc cagaggagga ggaaggcggc tgcgaactgc gcgtgaaatt cagccgcagc 1140

gcagatgctc cagcctacaa gcaggggcag aaccagctct acaacgaact caatcttggt 1200

cggagagagg agtacgacgt gctggacaag cggagaggac gggacccaga aatgggcggg 1260

aagccgcgca gaaagaatcc ccaaggggc ctgtacaacg agctccaaaa ggataagatg 1320

gcagaagcct atagcgagat tggtatgaaa ggggaacgca gaagaggcaa aggccacgac 1380

ggactgtacc agggactcag caccgccacc aaggacacct atgacgctct tcacatgcag 1440

gccctgccgc ctcgg 1455

<210> 8611

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8611

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agctcgtgga atcgggtggc ggactggtgc agccgggggg ctcacttaga 120

ctgtcctgcg cggccagcgg attcactttc tcctcctacg ccatgtcctg ggtcagacag 180

gcccctggaa agggcctgga atgggtgtcc gcaatcagcg gcagcggcgg ctcgacctat 240

tacgcggatt cagtgaaggg cagattcacc atttcccggg acaacgccaa gaactccttg 300

taccttcaaa tgaactccct ccgcgcggaa gataccgcaa tctactactg cgctcgggcc 360

acttacaaga gggaactgcg ctactactac gggatggacg tctggggcca gggaaccatg 420

480

gagatcgtga tgacccagtc ccccggcact gtgtcgctgt cccccggcga acgggccacc 540

ctgtcatgtc gggccagcca gtcagtgtcg tcaagcttcc tcgcctggta ccagcagaaa 600

ccgggacaag ctccccgcct gctgatctac ggagccagca gccgggccac cggtattcct 660

gaccggttct ccggttcggg gtccgggacc gactttactc tgactatctc tcgcctcgag 720

ccagaggact ccgccgtgta ttactgccag cagtaccact cctccccgtc ctggacgttc 780

ggacagggca caaggctgga gattaagacc actaccccag caccgaggcc acccaccccg 840

gctcctacca tcgcctccca gcctctgtcc ctgcgtccgg aggcatgtag acccgcagct 900

ggtggggccg tgcatacccg gggtcttgac ttcgcctgcg atatctacat ttgggcccct 960

ctggctggta cttgcggggt cctgctgctt tcactcgtga tcactcttta ctgtaagcgc 1020

ggtcggaaga agctgctgta catctttaag caacccttca tgaggcctgt gcagactact 1080

caagagggagg acggctgttc atgccggttc ccagaggagg aggaaggcgg ctgcgaactg 1140

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 1200

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 1260

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagggg cctgtacaac 1320

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 1380

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 1440

tatgacgctc ttcacatgca ggccctgccg cctcgg 1476

<210> 8612

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8612

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaggtgc agcttgtgga aaccggtggc ggactggtgc agcccgggagg aagcctcagg

ctgtcctgcg ccgcgtccgg cttcaccttc tcctcgtacg ccatgtcctg ggtccgccag 180

gccccgggaa agggcctgga atgggtgtcc gccatctctg gaagcgggagg ttccacgtac 240

tacgcggaca gcgtcaaggg aaggttcaca atctcccgcg ataattcgaa gaacactctg 300

taccttcaaa tgaacaccct gaaggccgag gacactgctg tgtactactg cgcacgggcc 360

acctacaaga gagagctccg gtactactac ggaatggacg tctggggcca gggaactact 420

gtgaccgtgt cctcgggagg gggtggctcc ggggggggcg gctccggcgg aggcggttcc 480

gagattgtgc tgacccagtc accttcaact ctgtcgctgt ccccgggaga gagcgctact 540

ctgagctgcc gggccagcca gtccgtgtcc accaccttcc tcgcctggta tcagcagaag 600

ccggggcagg caccacggct cttgatctac gggtcaagca acagagcgac cggaattcct 660

gaccgcttct cggggagcgg ttcaggcacc gacttcaccc tgactatccg gcgcctggaa 720

cccgaagatt tcgccgtgta ttactgtcaa cagtaccact cctcgccgtc ctggaccttt 780

ggccaaggaa ccaaagtgga aatcaagacc actaccccag caccgaggcc acccaccccg 840

gctcctacca tcgcctccca gcctctgtcc ctgcgtccgg aggcatgtag acccgcagct 900

ggtggggccg tgcatacccg gggtcttgac ttcgcctgcg atatctacat ttgggcccct 960

ctggctggta cttgcggggt cctgctgctt tcactcgtga tcactcttta ctgtaagcgc 1020

ggtcggaaga agctgctgta catctttaag caacccttca tgaggcctgt gcagactact 1080

caagagggagg acggctgttc atgccggttc ccagaggagg aggaaggcgg ctgcgaactg 1140

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 1200

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 1260

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagggg cctgtacaac 1320

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 1380

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 1440

tatgacgctc ttcacatgca ggccctgccg cctcgg 1476

<210> 8613

<211> 1449

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8613

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctcgtgga aactggaggt ggactcgtgc agcctggacg gtcgctgcgg 120

ctgagctgcg ctgcatccgg cttcaccttc gacgattatg ccatgcactg ggtcagacag 180

gcgccaggga agggacttga gtgggtgtcc ggtatcagct ggaatagcgg ctcaatcgga 240

tacgcggact ccgtgaaggg aaggttcacc atttcccgcg acaacgccaa gaactccctg 300

tacttgcaaa tgaacagcct ccgggatgag gacactgccg tgtactactg cgcccgcgtc 360

ggaaaagctg tgcccgacgt ctggggccag ggaaccactg tgaccgtgtc cagcggcggg 420

ggtggatcgg gcggtggagg gtccggtgga gggggctcag atattgtgat gacccagacc 480

ccctcgtccc tgtccgcctc ggtcggcgac cgcgtgacta tcacatgtag agcctcgcag 540

agcatctcca gctacctgaa ctggtatcag cagaagccgg ggaaggcccc gaagctcctg 600

atctacgcgg catcatcact gcaatcggga gtgccgagcc ggttttccgg gtccggctcc 660

ggcaccgact tcacgctgac catttcttcc ctgcaacccg aggacttcgc cacttactac 720

tgccagcagt cctactccac cccttactcc ttcggccaag gaaccaggct ggaaatcaag 780

accactaccc cagcaccgag gccacccacc ccggctccta ccatcgcctc ccagcctctg 840

tccctgcgtc cggaggcatg tagacccgca gctggtgggg ccgtgcatac ccggggtctt 900

gacttcgcct gcgatatcta catttgggcc cctctggctg gtacttgcgg ggtcctgctg 960

ctttcactcg tgatcactct ttactgtaag cgcggtcgga agaagctgct gtacatcttt 1020

aagcaaccct tcatgaggcc tgtgcagact actcaagagg aggacggctg ttcatgccgg 1080

ttcccagagg aggaggaagg cggctgcgaa ctgcgcgtga aattcagccg cagcgcagat 1140

gctccagcct acaagcaggg gcagaaccag ctctacaacg aactcaatct tggtcggaga 1200

gaggagtacg acgtgctgga caagcggaga ggacgggacc cagaaatgggg cgggaagccg 1260

cgcagaaaga atccccaaga gggcctgtac aacgagctcc aaaaggataa gatggcagaa 1320

gcctatagcg agattggtat gaaaggggaa cgcagaagag gcaaaggcca cgacggactg 1380

taccagggac tcagcaccgc caccaaggac acctatgacg ctcttcacat gcaggccctg 1440

cgcctcgg 1449

<210> 8614

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8614

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctcgtgga gagcggggga ggattggtgc agcccggaag gtccctgcgg 120

ctctcctgca ctgcgtctgg cttcaccttc gacgactacg cgatgcactg ggtcagacag 180

cgcccgggaa agggcctgga atgggtcgcc tcaatcaact ggaagggaaa ctccctggcc 240

tatggcgaca gcgtgaaggg ccgcttcgcc atttcgcgcg acaacgccaa gaacaccgtg 300

tttctgcaaa tgaattccct gcggaccgag gataccgctg tgtactactg cgccagccac 360

cagggcgtgg catactataa ctacgccatg gacgtgtggg gaagagggac gctcgtcacc 420

gtgtcctccg ggggcggtgg atcgggtgga ggaggaagcg gtggcggggg cagcgaaatc 480

gtgctgactc agagcccggg aactctttca ctgtccccgg gagaacggggc cactctctcg 540

tgccgggcca cccagtccat cggctcctcc ttccttgcct ggtaccagca gaggccagga 600

caggcgcccc gcctgctgat ctacggtgct tcccaacgcg ccactggcat tcctgaccgg 660

ttcagcggca gagggtcggg aaccgatttc acactgacca tttcccgggt ggagcccgaa 720

gattcggcag tctactactg tcagcattac gagtcctccc cttcatggac cttcggtcaa 780

gggaccaaag tggagatcaa gaccactacc ccagcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8615

<211> 1455

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8615

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaggtgc agttggtcga aagcgggggc gggcttgtgc agcctggcgg atcactgcgg 120

ctgtcctgcg cggcatcagg cttcacgttt tcttcctacg ccatgtcctg ggtgcgccag 180

gcccctggaa agggactgga atgggtgtcc gcgatttcgg ggtccggcgg gagcacctac 240

tacgccgatt ccgtgaaggg ccgcttcact atctcgcggg acaactccaa gaacaccctc 300

tacctccaaa tgaatagcct gcgggccgag gataccgccg tctactattg cgctaaggtc 360

gtgcgcgacg gaatggacgt gtggggacag ggtaccaccg tgacagtgtc ctcgggggga 420

ggcggtagcg gcggaggagg aagcggtggt ggaggttccg agattgtgct gactcaatca 480

cccgcgaccc tgagcctgtc ccccggcgaa agggccactc tgtcctgtcg ggccagccaa 540

tcagtctcct cctcgtacct ggcctggtac cagcagaagc caggacaggc tccgagactc 600

cttatctatg gcgcatcctc ccgcgccacc ggaatcccgg ataggttctc gggaaacgga 660

tcggggaccg acttcactct caccatctcc cggctggaac cggaggactt cgccgtgtac 720

tactgccagc agtacggcag cccgcctaga ttcactttcg gccccggcac caaagtggac 780

atcaagacca ctaccccagc accgaggcca cccaccccgg ctcctaccat cgcctcccag 840

cctctgtccc tgcgtccggga ggcatgtaga cccgcagctg gtggggccgt gcatacccgg 900

ggtcttgact tcgcctgcga tatctacatt tgggcccctc tggctggtac ttgcggggtc 960

ctgctgcttt cactcgtgat cactctttac tgtaagcgcg gtcggaagaa gctgctgtac 1020

atctttaagc aacccttcat gaggcctgtg cagactactc aagaggagga cggctgttca 1080

tgccggttcc cagaggagga ggaaggcggc tgcgaactgc gcgtgaaatt cagccgcagc 1140

gcagatgctc cagcctacaa gcaggggcag aaccagctct acaacgaact caatcttggt 1200

cggagagagg agtacgacgt gctggacaag cggagaggac gggacccaga aatgggcggg 1260

aagccgcgca gaaagaatcc ccaaggggc ctgtacaacg agctccaaaa ggataagatg 1320

gcagaagcct atagcgagat tggtatgaaa ggggaacgca gaagaggcaa aggccacgac 1380

ggactgtacc agggactcag caccgccacc aaggacacct atgacgctct tcacatgcag 1440

gccctgccgc ctcgg 1455

<210> 8616

<211> 1458

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8616

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctgctgga gtccggcggt ggattggtgc aaccgggggg atcgctcaga 120

ctgtcctgtg cggcgtcagg cttcaccttc tcgagctacg ccatgtcatg ggtcagacag 180

gcccctggaa agggtctgga atgggtgtcc gccatttccg ggagcggggg atctacatac 240

tacgccgata gcgtgaaggg ccgcttcacc atttcccggg acaactccaa gaacactctc 300

tatctgcaaa tgaactccct ccgcgctgag gacactgccg tgtactactg cgccaaaatc 360

cctcagaccg gcaccttcga ctactgggga caggggactc tggtcaccgt cagcagcggt 420

ggcgggaggtt cgggggggagg aggaagcggc ggcggagggt ccgagattgt gctgacccag 480

tcacccggca ctttgtccct gtcgcctgga gaaagggcca ccctttcctg ccgggcatcc 540

600

cttctgatct acggagcaag cagccgcgcg accggtatcc cggaccggtt ttcgggctcg 660

ggctcaggaa ctgacttcac cctcaccatc tcccgcctgg aacccgaaga tttcgctgtg 720

tattactgcc agcactacgg cagctccccg tcctggacgt tcggccaggg aactcggctg 780

gagatcaaga ccactacccc agcaccgagg ccacccaccc cggctcctac catcgcctcc 840

cagcctctgt ccctgcgtcc ggaggcatgt agacccgcag ctggtggggc cgtgcatacc 900

cggggtcttg acttcgcctg cgatatctac atttgggccc ctctggctgg tacttgcggg 960

gtcctgctgc tttcactcgt gatcactctt tactgtaagc gcggtcggaa gaagctgctg 1020

tacatcttta agcaaccctt catgaggcct gtgcagacta ctcaagagga ggacggctgt 1080

tcatgccggt tcccagagga ggaggaaggc ggctgcgaac tgcgcgtgaa attcagccgc 1140

agcgcagatg ctccagccta caagcagggg cagaaccagc tctacaacga actcaatctt 1200

ggtcggagag aggagtacga cgtgctggac aagcggagag gacgggaccc agaaatgggc 1260

gggaagccgc gcagaaagaa tccccaagag ggcctgtaca acgagctcca aaaggataag 1320

atggcagaag cctatagcga gattggtatg aaaggggaac gcagaagagg caaaggccac 1380

gacggactgt accagggact cagcaccgcc accaaggaca cctatgacgc tcttcacatg 1440

caggccctgc cgcctcgg 1458

<210> 8617

<211> 1476

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8617

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc aactggtgga aaccggtgga ggactcgtgc agcctggcgg cagcctccgg 120

ctgagctgcg ccgcttcggg attcaccttt tcctcctacg cgatgtcttg ggtcagacag 180

gccccgggaa aggggctgga atgggtgtca gccatctccg gctccggcgg atcaacgtac 240

tacgccgact ccgtgaaagg ccggttcacc atgtcgcgcg agaatgacaa gaactccgtg 300

ttcctgcaaa tgaactccct gagggtggag gacaccggag tgtactattg tgcgcgcgcc 360

aactacaaga gagagctgcg gtactactac ggaatggacg tctggggaca gggaactatg 420

gtgaccgtgt catccggtgg agggggaagc ggcggtggag gcagcggggg cggggttca 480

gaaattgtca tgacccagtc cccgggaact ctttccctct cccccgggga atccgcgact 540

ttgtcctgcc gggccagcca gcgcgtggcc tcgaactacc tcgcatggta cgcataag 600

ccaggccaag ccccttccct gctgatttcc ggggctagca gccgcgccac tggcgtgccg 660

gataggttct cgggaagcgg ctcgggtacc gatttcaccc tggcaatctc gcggctggaa 720

ccggaggatt cggccgtgta ctactgccag cactatgact catccccctc ctggacattc 780

ggacagggca ccaaggtcga gatcaagacc actaccccag caccgaggcc acccaccccg 840

gctcctacca tcgcctccca gcctctgtcc ctgcgtccgg aggcatgtag acccgcagct 900

ggtggggccg tgcatacccg gggtcttgac ttcgcctgcg atatctacat ttgggcccct 960

ctggctggta cttgcggggt cctgctgctt tcactcgtga tcactcttta ctgtaagcgc 1020

ggtcggaaga agctgctgta catctttaag caacccttca tgaggcctgt gcagactact 1080

caagagggagg acggctgttc atgccggttc ccagaggagg aggaaggcgg ctgcgaactg 1140

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 1200

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 1260

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagggg cctgtacaac 1320

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 1380

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 1440

tatgacgctc ttcacatgca ggccctgccg cctcgg 1476

<210> 8618

<211> 1464

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8618

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctgctcga aaccggtgga gggctggtgc agccaggggg ctccctgagg 120

ctttcatgcg ccgctagcgg attctccttc tcctcttacg ccatgtcgtg ggtccgccaa 180

gcccctggaa aaggcctgga atgggtgtcc gcgatttccg ggagcggagg ttcgacctat 240

tacgccgact ccgtgaaggg ccgctttacc atctcccggg ataactccaa gaacactctg 300

tacctccaaa tgaactcgct gagagccgag gacaccgccg tgtattactg cgcgaaggcg 360

ctggtcggcg cgactggggc attcgacatc tggggacagg gaactcttgt gaccgtgtcg 420

agcgggaggcg gcggctccgg cggaggaggg agcgggggcg gtggttccga aatcgtgttg 480

actcagtccc cgggaaccct gagcttgtca cccggggagc gggccactct ctcctgtcgc 540

gcctcccaat cgctctcatc caatttcctg gcctggtacc agcagaagcc cggacaggcc 600

660

ggaagcggat cgggtactga ctttaccctg accatcacca gactggaacc ggaggacttc 720

gccgtgtact actgccagta ctacggcacc tcccccatgt acacattcgg acagggtacc 780

aaggtcgaga ttaagaccac taccccagca ccgaggccac ccaccccggc tcctaccatc 840

gcctcccagc ctctgtccct gcgtccggag gcatgtagac ccgcagctgg tggggccgtg 900

catacccggg gtcttgactt cgcctgcgat atctacattt gggcccctct ggctggtact 960

tgcggggtcc tgctgctttc actcgtgatc actctttact gtaagcgcgg tcggaagaag 1020

ctgctgtaca tctttaagca acccttcatg aggcctgtgc agactactca agaggaggac 1080

ggctgttcat gccggttccc agaggaggag gaaggcggct gcgaactgcg cgtgaaattc 1140

agccgcagcg cagatgctcc agcctacaag caggggcaga accagctcta caacgaactc 1200

1260

atgggcggga agccgcgcag aaagaatccc caagagggcc tgtacaacga gctccaaaag 1320

gataagatgg cagaagccta tagcgagatt ggtatgaaag gggaacgcag aagaggcaaa 1380

ggccacgacg gactgtacca gggactcagc accgccacca aggacaccta tgacgctctt 1440

cacatgcagg ccctgccgcc tcgg 1464

<210> 8619

<211> 1464

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8619

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtgc agctgcttga gagcggtgga ggtctggtgc agcccggggg atcactgcgc 120

ctgtcctgtg ccgcgtccgg tttcactttc tcctcgtacg ccatgtcgtg ggtcagacag 180

gcaccgggaa agggactgga atgggtgtca gccatttcgg gttcgggggg cagcacctac 240

tacgctgact ccgtgaaggg ccggttcacc atttcccgcg acaactccaa gaacaccttg 300

tacctccaaa tgaactccct gcgggccgaa gataccgccg tgtattactg cgtgctgtgg 360

ttcggagagg gattcgaccc gtggggacaa ggaacactcg tgactgtgtc atccggcgga 420

ggcggcagcg gtggcggcgg ttccggcggc ggcggatctg acatcgtgtt gacccagtcc 480

cctctgagcc tgccggtcac tcctggcgaa ccagccagca tctcctgccg gtcgagccag 540

tccctcctgc actccaatgg gtacaactac ctcgattggt atctgcaaaa gccgggccag 600

agcccccagc tgctgatcta ccttgggtca aaccgcgctt ccggggtgcc tgatagattc 660

tccgggtccg ggagcggaac cgactttacc ctgaaaatct cgagggtgga ggccgaggac 720

gtcggagtgt actactgcat gcaggcgctc cagactcccc tgaccttcgg aggaggaacg 780

aaggtcgaca tcaagaccac taccccagca ccgaggccac ccaccccggc tcctaccatc 840

gcctcccagc ctctgtccct gcgtccggag gcatgtagac ccgcagctgg tggggccgtg 900

catacccggg gtcttgactt cgcctgcgat atctacattt gggcccctct ggctggtact 960

tgcggggtcc tgctgctttc actcgtgatc actctttact gtaagcgcgg tcggaagaag 1020

ctgctgtaca tctttaagca acccttcatg aggcctgtgc agactactca agaggaggac 1080

ggctgttcat gccggttccc agaggaggag gaaggcggct gcgaactgcg cgtgaaattc 1140

agccgcagcg cagatgctcc agcctacaag caggggcaga accagctcta caacgaactc 1200

1260

1320

gataagatgg cagaagccta tagcgagatt ggtatgaaag gggaacgcag aagaggcaaa 1380

ggccacgacg gactgtacca gggactcagc accgccacca aggacaccta tgacgctctt 1440

cacatgcagg ccctgccgcc tcgg 1464

<210> 8620

<211> 1485

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8620

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccccaagtgc agctcgtgga gtcaggcgga ggactggtgc agcccgggggg ctccctgaga 120

ctttcctgcg cggcatcggg tttaccttc tcctcctatg ctatgtcctg ggtgcgccag 180

gccccgggaa agggactgga atgggtgtcc gcaatcagcg gtagcgggggg ctcaacatac 240

tacgccgact ccgtcaaggg tcgcttcact atttcccggg acaactccaa gaataccctg 300

tacctccaaa tgaacagcct cagggccgag gatactgccg tgtactactg cgccaaagtc 360

ggatacgata gctccggtta ctaccgggac tactacggaa tggacgtgtg gggacagggc 420

acccgtga ccgtgtcaag cggcgggaggc ggttcaggag ggggaggctc cggcggtgga 480

gggtccgaaa tcgtcctgac tcagtcgcct ggcactctgt cgttgtcccc gggggagcgc 540

gctaccctgt cgtgtcgggc gtcgcagtcc gtgtcgagct cctacctcgc gtggtaccag 600

cagaagcccg gacaggcccc tagacttctg atctacggca cttcttcacg cgccaccggg 660

atcagcgaca ggttcagcgg ctccggctcc gggaccgact tcaccctgac cattagccgg 720

ctggagcctg aagatttcgc cgtgtattac tgccaacact acggaaactc gccgccaaag 780

ttcacgttcg gaccgggaac caagctggaa atcaagacca ctaccccagc accgaggcca 840

cccaccccgg ctcctaccat cgcctcccag cctctgtccc tgcgtccgga ggcatgtaga 900

cccgcagctg gtggggccgt gcatacccgg ggtcttgact tcgcctgcga tatctacatt 960

tgggcccctc tggctggtac ttgcggggtc ctgctgcttt cactcgtgat cactctttac 1020

tgtaagcgcg gtcggaagaa gctgctgtac atctttaagc aacccttcat gaggcctgtg 1080

cagactactc aagaggagga cggctgttca tgccggttcc cagaggagga ggaaggcggc 1140

tgcgaactgc gcgtgaaatt cagccgcagc gcagatgctc cagcctacaa gcaggggcag 1200

aaccagctct acaacgaact caatcttggt cggagagagg agtacgacgt gctggacaag 1260

1320

ctgtacaacg agctccaaaa ggataagatg gcagaagcct atagcgagat tggtatgaaa 1380

ggggaacgca gaagaggcaa aggccacgac ggactgtacc agggactcag caccgccacc 1440

aaggacacct atgacgctct tcacatgcag gccctgccgc ctcgg 1485

<210> 8621

<211> 1470

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 8621

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

cccgaagtcc aactggtgga gtccggggga gggctcgtgc agcccgggagg cagccttcgg 120

ctgtcgtgcg ccgcctccgg gttcacgttc tcatcctacg cgatgtcgtg ggtcagacag 180

gcaccaggaa agggactgga atgggtgtcc gccattagcg gctccggcgg tagcacctac 240

tatgccgact cagtgaaggg aaggttcact atctcccgcg acaacagcaa gaacaccctg 300

tacctccaaa tgaactctct gcggggccgag gataccgcgg tgtactattg cgccaagatg 360

ggttggtcca gcggatactt gggagccttc gacatttggg gacagggcac tactgtgacc 420

gtgtcctccg ggggtggcgg atcgggaggc ggcggctcgg gtggaggggg ttccgaaatc 480

gtgttgaccc agtcaccggg aaccctctcg ctgtccccgg gagaacgggc tacactgtca 540

tgtagagcgt cccagtccgt ggcttcctcg ttcctggcct ggtaccagca gaagccggga 600

caggcacccc gcctgctcat ctacggagcc agcggccggg cgaccggcat ccctgaccgc 660

ttctccggtt ccggctcggg caccgacttt actctgacca ttagcaggct tgagcccgag 720

gattttgccg tgtactactg ccaacactac ggggggagcc ctcgcctgac cttcggaggc 780

ggaactaagg tcgatatcaa aaccactacc cggcaccga ggccacccac cccggctcct 840

accatcgcct cccagcctct gtccctgcgt cgggaggcat gtagacccgc agctggtggg 900

gccgtgcata cccggggtct tgacttcgcc tgcgatatct acatttgggc ccctctggct 960

ggtacttgcg gggtcctgct gctttcactc gtgatcactc tttactgtaa gcgcggtcgg 1020

aagaagctgc tgtacatctt taagcaaccc ttcatgaggc ctgtgcagac tactcaagag 1080

gaggacggct gttcatgccg gttcccagag gaggaggaag gcggctgcga actgcgcgtg 1140

aaattcagcc gcagcgcaga tgctccagcc tacaagcagg ggcagaacca gctctacaac 1200

gaactcaatc ttggtcggag agaggagtac gacgtgctgg acaagcggag aggacgggac 1260

ccagaaatgg gcgggaagcc gcgcagaaag aatccccaag agggcctgta caacgagctc 1320

1380

ggcaaaggcc acgacggact gtaccaggga ctcagcaccg ccaccaagga cacctatgac 1440

gctcttcaca tgcaggccct gccgcctcgg 1470

<210> 8622

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8622

ccccuuagga gucugcacua 20

<210> 8623

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8623

caaccuguca auccagcuca 20

<210> 8624

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8624

cacccaugag acccucuccg 20

<210> 8625

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8625

acccaugaga cccucuccgu 20

<210> 8626

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8626

cccaugagac ccucccgug 20

<210> 8627

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8627

uagagcaccu aucaugaacg 20

<210> 8628

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8628

caugaacgag gagaccaagu 20

<210> 8629

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8629

cuccuaaggg gagagaagac 20

<210> 8630

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8630

ccauagugca gacuccuaag 20

<210> 8631

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8631

uccauaguc agacucuaa 20

<210> 8632

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8632

uuccauagug cagacuccua 20

<210> 8633

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8633

gugccuugag cuggauugac 20

<210> 8634

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8634

gggcuaugug ugccuugagc 20

<210> 8635

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8635

aggggucuc agggugucu 20

<210> 8636

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8636

gagagggucu cauggguguc 20

<210> 8637

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8637

ccccacggag agggucucau 20

<210> 8638

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8638

uccccacgga gagggucuca 20

<210> 8639

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8639

cucuaggguc cccacggaga 20

<210> 8640

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8640

gcucuagggu ccccacggag 20

<210> 8641

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8641

uaggugcucu agggucccca 20

<210> 8642

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8642

cguucaugau aggugcucua 20

<210> 8643

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8643

ucguucauga uaggugcucu 20

<210> 8644

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8644

uuggucuccu cguucaugau 20

<210> 8645

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8645

ggagagaaaa aucaccuacu 20

<210> 8646

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8646

cuucccuguc cuccagggc 20

<210> 8647

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8647

ccuccagggc uggcuccuca 20

<210> 8648

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8648

uggcuccuca uggacccgu 20

<210> 8649

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8649

gaccccguug gccuccagcu 20

<210> 8650

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8650

agcucggcaa caagaaccug 20

<210> 8651

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8651

accuguggag cugucuugug 20

<210> 8652

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8652

ugcucaccaa agacccagaa 20

<210> 8653

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8653

gaaguucuuc cuccccaaca 20

<210> 8654

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8654

cuuccucccc aacacggacc 20

<210> 8655

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8655

ccaacacgga ccuggauucc 20

<210> 8656

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8656

ggauuccagg aacgagaccu 20

<210> 8657

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8657

acucaacaag cugcaugucc 20

<210> 8658

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8658

cucaacaagc ugcaugucca 20

<210> 8659

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8659

caagcugcau guccaggguu 20

<210> 8660

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8660

auguccaggg uucggacacc 20

<210> 8661

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8661

gugcugcugc ugaguacuuuu 20

<210> 8662

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8662

aguacuuuug gcuaugauga 20

<210> 8663

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8663

uuuuggcuau gaugauggua 20

<210> 8664

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8664

uuuggcuaug augaugguaa 20

<210> 8665

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8665

gcuaugauga ugguaagggc 20

<210> 8666

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8666

gagccagccc uggagggaca 20

<210> 8667

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8667

ggagccagcc cuggagggac 20

<210> 8668

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8668

caugaggagc cagcccugga 20

<210> 8669

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8669

ccaugaggag ccaggccugg 20

<210> 8670

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8670

gugccaugag gagccagccc 20

<210> 8671

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8671

ggaggccaac gggguccaug 20

<210> 8672

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8672

ugccgagcug gaggccaacg 20

<210> 8673

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8673

uugccgagcu ggaggccaac 20

<210> 8674

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8674

guugccgagc uggaggccaa 20

<210> 8675

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8675

gguucuuguu gccgagcugg 20

<210> 8676

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8676

acagguucuu guugccgagc 20

<210> 8677

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8677

gccucacaag acagcuccac 20

<210> 8678

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8678

guucagccau ucugggucuu 20

<210> 8679

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8679

ucuuggcguu cagccauucu 20

<210> 8680

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8680

aucuuggcgu ucagccauuc 20

<210> 8681

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8681

ggggaggaag aacuucaucu 20

<210> 8682

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8682

aauccagguc cguguugggg 20

<210> 8683

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8683

uggauccag guccguguug 20

<210> 8684

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8684

cuggaaucca gguccguguu 20

<210> 8685

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8685

ccuggaaucc agguccgugu 20

<210> 8686

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8686

aggucucguu cuggaaucc 20

<210> 8687

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8687

aggguccaag gucucguucc 20

<210> 8688

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8688

gacucucugu ucagggucca 20

<210> 8689

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8689

gcaggauac ucucuguuca 20

<210> 8690

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8690

ugcaggauga cucucuguuc 20

<210> 8691

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8691

caugcagcuu guugaguugc 20

<210> 8692

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8692

acugccaggu guccgaaccc 20

<210> 8693

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8693

acaaugaaug aaagacugcc 20

<210> 8694

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8694

ugcaggguuc accagccagc 20

<210> 8695

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8695

gcaggguuca cgccagcu 20

<210> 8696

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8696

caccagccag cugggagcug 20

<210> 8697

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8697

accagccagc ugggagcuga 20

<210> 8698

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8698

ccagccagcu gggagcugag 20

<210> 8699

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8699

ccugaaucuc agcuccacca 20

<210> 8700

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8700

aucucagcuc caccauggug 20

<210> 8701

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8701

agcuccacca uggugaggac 20

<210> 8702

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8702

accaugguga ggacuggagu 20

<210> 8703

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8703

ccaggugag gacuggaguu 20

<210> 8704

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8704

cauggugagg acuggaguug 20

<210> 8705

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8705

aggugagga cuggaguugg 20

<210> 8706

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8706

uggugaaccc ugcaagagag 20

<210> 8707

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8707

cuggugaacc cugcaagaga 20

<210> 8708

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8708

gcuggugaac ccugcaagag 20

<210> 8709

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8709

ccccucagcu ccagcuggc 20

<210> 8710

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8710

uuuuccccuc agcuccagc 20

<210> 8711

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8711

gguggagcug agauucaggu 20

<210> 8712

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8712

ccaugggga gcugagauuc 20

<210> 8713

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8713

aacuccaguc cucaccaugg 20

<210> 8714

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8714

cccaacucca guccicacca 20

<210> 8715

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8715

aagcgcccac aucagagcug 20

<210> 8716

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8716

agcgcccaca ucagagcugu 20

<210> 8717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8717

gcuggggguc cucaccccgc 20

<210> 8718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8718

cagugcaaga agcagcagcu 20

<210> 8719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8719

ugcaagaagc agcagcuagg 20

<210> 8720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8720

gcaagaagca gcagcuaggu 20

<210> 8721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8721

cagcuaggug gguaccagug 20

<210> 8722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8722

agcuaggugg guaccagugu 20

<210> 8723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8723

gcuagggggg uaccagugug 20

<210> 8724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8724

ggccugaaaa agcaaaggaa 20

<210> 8725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8725

aggccugaaa aagcaaagga 20

<210> 8726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8726

cuucaggccu gaaaaagcaa 20

<210> 8727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8727

agcucugaug ugggcgcuuc 20

<210> 8728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8728

aggacccaca gcucugaugu 20

<210> 8729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8729

gaggacccac agcucugaug 20

<210> 8730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8730

gcacugcuuc cggcggggug 20

<210> 8731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8731

uucuugcacu gcuuccggcg 20

<210> 8732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8732

cuucuugcac ugcuuccggc 20

<210> 8733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8733

gcuucuugca cugcuuccgg 20

<210> 8734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8734

gcugcuucuu gcacugcuuc 20

<210> 8735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8735

gucccugccc cuugcagagu 20

<210> 8736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8736

agaaguaccu gcagcuccug 20

<210> 8737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8737

ccucugccca gcagcgcuac 20

<210> 8738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8738

cgcuacagga gccaaauccc 20

<210> 8739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8739

gcuacaggag ccaaaucccu 20

<210> 8740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8740

aggagccaaa ucccuggguc 20

<210> 8741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8741

ggagccaaau cccggguca 20

<210> 8742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8742

gcagccccac gccuuccacc 20

<210> 8743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8743

augucccucc aauccugcgc 20

<210> 8744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8744

ugucccucca auccucgcc 20

<210> 8745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8745

cacagcaucc uuagacacuc 20

<210> 8746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8746

agcauccuua gacacuccgg 20

<210> 8747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8747

gcauccuuag acacuccgga 20

<210> 8748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8748

cauccuuaga cacuccggag 20

<210> 8749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8749

auccuuagacacuccgggagg 20

<210> 8750

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8750

cacuccggag ggggccauua 20

<210> 8751

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8751

acuccgggagg gggccaauuau 20

<210> 8752

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8752

cuccggaggg ggccauuaug 20

<210> 8753

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8753

uccgggagggg gccauuaugg 20

<210> 8754

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8754

ggccauuaug ggggacguca 20

<210> 8755

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8755

cauuaugggg gacgucaagg 20

<210> 8756

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8756

ggggacguca agguggaaga 20

<210> 8757

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8757

uggugcugac gugagcaucu 20

<210> 8758

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8758

ucucggaccu cuucaacacc 20

<210> 8759

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8759

cucggaccuc uucaacacca 20

<210> 8760

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8760

cuucaacacc aggguuaaca 20

<210> 8761

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8761

uucaacacca ggguuaacaa 20

<210> 8762

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8762

ccaggguuaa caagggcccg 20

<210> 8763

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8763

caggguuaac aagggcccga 20

<210> 8764

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8764

cccgaggggug accgugcuuu 20

<210> 8765

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8765

ccgaggguga ccgugcuuuu 20

<210> 8766

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8766

cgagggugac cgugcuuuug 20

<210> 8767

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8767

ggugaccgug cuuuugggga 20

<210> 8768

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8768

accgugcuuu ugggaaggc 20

<210> 8769

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8769

gcuuuugggg aaggcuggca 20

<210> 8770

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8770

cuuuugggga aggcuggcau 20

<210> 8771

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8771

uggcaugggc aagccacgc 20

<210> 8772

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8772

gcaagaccac gcuggcccac 20

<210> 8773

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8773

cccaccggcu cugccagaag 20

<210> 8774

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8774

ccaccggcuc ugccagaagu 20

<210> 8775

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8775

gcucugccag aagugggcag 20

<210> 8776

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8776

cucugccaga aggggcaga 20

<210> 8777

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8777

gggccaucug aacuguuucc 20

<210> 8778

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8778

gccagcucaa cuugaucacg 20

<210> 8779

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8779

ucuguaccug agccugaau 20

<210> 8780

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8780

cgacacuguc uuccaguacc 20

<210> 8781

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8781

caaguccugc ugaucuuuga 20

<210> 8782

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8782

aaguccugcu gaucuuugau 20

<210> 8783

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8783

gaucuuugau gggcuagaug 20

<210> 8784

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8784

agaugaggcc cuccagccua 20

<210> 8785

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8785

gaugaggccc uccagccuau 20

<210> 8786

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8786

cuccagccua uggguccuga 20

<210> 8787

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8787

ccuauggguc cugauggccc 20

<210> 8788

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8788

cuuuucuccc aucucugcaa 20

<210> 8789

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8789

uuuucuccca ucucugcaau 20

<210> 8790

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8790

gccugccugc cugccugcag 20

<210> 8791

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8791

ccugccugca gaggcagcca 20

<210> 8792

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8792

ggcagccaug guccacaugu 20

<210> 8793

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8793

gcagccaugg uccacauguu 20

<210> 8794

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8794

guccacaugu uggcuuuga 20

<210> 8795

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8795

uccacauguu gggcuuugau 20

<210> 8796

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8796

uguugggcuu ugaggggcca 20

<210> 8797

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8797

guugggcuuu gaugggccac 20

<210> 8798

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8798

gggcuuugau gggcccggg 20

<210> 8799

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8799

ucuucagcgc cgccaucg 20

<210> 8800

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8800

cuucagcgcc cagccaucgc 20

<210> 8801

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8801

cagcgcccag ccaucgcggg 20

<210> 8802

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8802

agcgcccagc caucgcggga 20

<210> 8803

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8803

gcgcccagcc aucgcgggag 20

<210> 8804

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8804

cgccggcca ucgcgggagg 20

<210> 8805

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8805

gccaucgcgg gagggggccc 20

<210> 8806

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8806

aucgcgggag ggggccgg 20

<210> 8807

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8807

cugguggagu uacagacaaa 20

<210> 8808

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8808

acgucuccga agccugugug 20

<210> 8809

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8809

cugcuuccug accacgcccc 20

<210> 8810

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8810

ccacgcccca ggccagucug 20

<210> 8811

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8811

gacucagcuc uauaugcaga 20

<210> 8812

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8812

gugcucgccc ucagcccccc 20

<210> 8813

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8813

ugcucgcccu cagccccccu 20

<210> 8814

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8814

cuugcccacc ucgucccuac 20

<210> 8815

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8815

caccucgucc cuacuggacc 20

<210> 8816

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8816

accucguccc uacuggaccu 20

<210> 8817

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8817

ccucgucccu acuggaccug 20

<210> 8818

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8818

cuggucccua cuggaccugg 20

<210> 8819

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8819

gucccuacug gaccuggggg 20

<210> 8820

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8820

ccuacuggac cugggggagg 20

<210> 8821

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8821

accuggggga gguggccug 20

<210> 8822

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8822

ccugggggag guggccuga 20

<210> 8823

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8823

cugggggagg uggcccugag 20

<210> 8824

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8824

ggaggggcc cugaggggcc 20

<210> 8825

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8825

gcccugaggg gccuggagac 20

<210> 8826

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8826

ccggagagga 20

<210> 8827

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8827

gaggggccug gagacaggga 20

<210> 8828

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8828

gcuccacccu ugauagcuuu 20

<210> 8829

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8829

cuccacccuu gauagcuuuu 20

<210> 8830

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8830

uccacccuug auagcuuuug 20

<210> 8831

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8831

acuuccuucu gcgucugcac 20

<210> 8832

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8832

uucugcgucu gcacaggccc 20

<210> 8833

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8833

ucugcgucug cacaggcccu 20

<210> 8834

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8834

ggccggggc accagcagac 20

<210> 8835

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8835

uuucacccac cucagccugc 20

<210> 8836

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8836

ucuugcugcc cugcaccuga 20

<210> 8837

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8837

gcaccugaug gccagcccca 20

<210> 8838

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8838

auguuacccu ccauucccgc 20

<210> 8839

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8839

uguuacccuc cauucccgcu 20

<210> 8840

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8840

uccauucccg cuggguacag 20

<210> 8841

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8841

acagcggacc aaagcuagac 20

<210> 8842

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8842

cagcggacca aagcuagacu 20

<210> 8843

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8843

agaccaccuc ccaccuucc 20

<210> 8844

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8844

ccaccucccc accuuccugg 20

<210> 8845

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8845

caccucccca ccuuccuggc 20

<210> 8846

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8846

ccccaccuuc cuggcgggcc 20

<210> 8847

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8847

ccgcccccuuc cuuagccacc 20

<210> 8848

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8848

cuuccuuagc caccuggcgc 20

<210> 8849

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8849

uuccuuagcc accuggcgca 20

<210> 8850

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8850

ccaccuggcg cagggcaaug 20

<210> 8851

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8851

gcagggcaau gaggacugug 20

<210> 8852

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8852

cagggcaaug aggacuggugu 20

<210> 8853

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8853

ggacugugugggugccaagc 20

<210> 8854

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8854

caagcaggcu gcuguagugc 20

<210> 8855

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8855

agugcaggug uugaagaagu 20

<210> 8856

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8856

uuggcccc gcaagcucac 20

<210> 8857

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8857

uggccaccg caagcucaca 20

<210> 8858

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8858

ccgcaagcuc acagggccaa 20

<210> 8859

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8859

ugucacugug 20

<210> 8860

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8860

ucacuguguggaugagacac 20

<210> 8861

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8861

ugagacacag gagccugagc 20

<210> 8862

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8862

cccacugacc ugcaccgacc 20

<210> 8863

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8863

ugaccaacau ccuagagcac 20

<210> 8864

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8864

gaccaacauc cuagagcaca 20

<210> 8865

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8865

caacauccua gagcacaggg 20

<210> 8866

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8866

cagggaggcc cccauccacc 20

<210> 8867

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8867

cccauccacc uggauuuuga 20

<210> 8868

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8868

ggauuuugau ggcugucccc 20

<210> 8869

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8869

ccuggagccc cacugcccug 20

<210> 8870

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8870

gccccacugc ccugaggcuc 20

<210> 8871

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8871

cacugccug aggcucuggu 20

<210> 8872

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8872

ccugaggcuc ugguaggcug 20

<210> 8873

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8873

cugaggcucu gguaggcugu 20

<210> 8874

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8874

gugggcagau agagaaucuc 20

<210> 8875

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8875

gaaucucagg ugaguaagag 20

<210> 8876

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8876

ucucagguga guaagagugg 20

<210> 8877

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8877

caggugagua agaguggagg 20

<210> 8878

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8878

ggccaacucu gcaaggggca 20

<210> 8879

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8879

uggccaacuc ugcaaggggc 20

<210> 8880

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8880

uucuuggcca acucugcaag 20

<210> 8881

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8881

cuucuuggcc aacucugcaa 20

<210> 8882

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8882

acuucuuggc caacucugca 20

<210> 8883

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8883

caggagcugc agguacuucu 20

<210> 8884

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8884

caggugccg caggagcugc 20

<210> 8885

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8885

gcugcugggc agagguccgc 20

<210> 8886

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8886

ccuguagcgc ugcugggcag 20

<210> 8887

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8887

uuggcuccug uagcgcugcu 20

<210> 8888

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8888

uuuggcuccu guagcgcugc 20

<210> 8889

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8889

gcugccuga cccagggauu 20

<210> 8890

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8890

cguggggcug cccugaccca 20

<210> 8891

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8891

gcguggggcu gcccugaccc 20

<210> 8892

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8892

uagaccuggu ggaaggcgug 20

<210> 8893

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8893

auagaccugg uggaaggcgu 20

<210> 8894

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8894

cauagaccug guggaaggcg 20

<210> 8895

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8895

agggacauag accuggugga 20

<210> 8896

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8896

uuggagggac auagaccugg 20

<210> 8897

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8897

ggauuggagg gacauagacc 20

<210> 8898

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8898

uggcccggcg caggauugga 20

<210> 8899

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8899

guggcccggc gcaggauugg 20

<210> 8900

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8900

gcugggccc ggcgcaggau 20

<210> 8901

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8901

aggaugcugu ggcccggcgc 20

<210> 8902

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8902

ugucuaagga ugcuggggcc 20

<210> 8903

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8903

cggagugucu aaggaugcug 20

<210> 8904

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8904

ggcccccucc ggagugucuua 20

<210> 8905

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8905

ucccccauaa uggccccuc 20

<210> 8906

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8906

caccuugacg ucccccauaa 20

<210> 8907

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8907

uguuaacccu gguguugaag 20

<210> 8908

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8908

ccucgggccc uuguuaaccc 20

<210> 8909

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8909

ccaaaagcac ggucacccuc 20

<210> 8910

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8910

cccaaaagca cggucacccu 20

<210> 8911

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8911

gccagccuuc cccaaaagca 20

<210> 8912

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8912

gcagagccgg ugggccagcg 20

<210> 8913

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8913

ccacuucugg cagagccggu 20

<210> 8914

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8914

cccacuucug gcagagccgg 20

<210> 8915

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8915

cugcccacuu cuggcagagc 20

<210> 8916

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8916

gauggcccuc ugcccacuuc 20

<210> 8917

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8917

gggcugga acaguucaga 20

<210> 8918

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8918

auucaaaaag gaacagggcc 20

<210> 8919

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8919

gcggaauuca aaaaggaaca 20

<210> 8920

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8920

ggcggaauuc aaaaaggaac 20

<210> 8921

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8921

ugagcuggcg gaauucaaaa 20

<210> 8922

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8922

ucgugaucaa guugagcugg 20

<210> 8923

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8923

accucgugau caaguugagc 20

<210> 8924

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8924

aaaggagcuc ggacgguguc 20

<210> 8925

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8925

agaucaaaaa ggagcucgga 20

<210> 8926

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8926

guacagauca aaaaggagcu 20

<210> 8927

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8927

ggcucaggua cagaucaaaa 20

<210> 8928

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8928

cgugguccga uucagggcuc 20

<210> 8929

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8929

cagugucgug guccgauuca 20

<210> 8930

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8930

acagugucgu gguccgauuc 20

<210> 8931

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8931

gguacuggaa gacagugucg 20

<210> 8932

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8932

cagcguucuu cuccagguac 20

<210> 8933

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8933

cuuggucagc guucuucucc 20

<210> 8934

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8934

caucaaagau cagcaggacu 20

<210> 8935

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8935

cuagcccauc aaagaucagc 20

<210> 8936

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8936

aucaggaccc auaggcugga 20

<210> 8937

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8937

caucaggacc cauaggcugg 20

<210> 8938

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8938

ggccaucagg acccauaggc 20

<210> 8939

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8939

ccugggccau caggacccau 20

<210> 8940

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8940

aggacugggc cugggccauc 20

<210> 8941

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8941

aaaggggugag gacugggccu 20

<210> 8942

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8942

aaaagggguga ggacugggcc 20

<210> 8943

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8943

gggagaaaag ggugaggacu 20

<210> 8944

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8944

ugggagaaaa ggggugaggac 20

<210> 8945

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8945

agagauggga gaaaagggug 20

<210> 8946

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8946

auugcagaga ugggagaaaa 20

<210> 8947

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8947

cauugcagag augggagaaa 20

<210> 8948

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8948

cuccgucca uugcagagau 20

<210> 8949

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8949

ccuccgccc auugcagaga 20

<210> 8950

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8950

aaagccaac auguggacca 20

<210> 8951

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8951

gcccaucaaa gcccaacaug 20

<210> 8952

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8952

uucacauauu cuuccacccg 20

<210> 8953

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8953

ggcccccucc cgcgauggcu 20

<210> 8954

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8954

gggcccccuc ccgcgauggc 20

<210> 8955

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8955

accagggccc ccccccgcga 20

<210> 8956

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8956

auuugucugu aacuccacca 20

<210> 8957

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8957

cauuugucug uaacuccacc 20

<210> 8958

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8958

cgggcaccgc acacaggcuu 20

<210> 8959

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8959

acagugcggg caccgcacac 20

<210> 8960

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8960

caggcgacuu ggcacagugc 20

<210> 8961

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8961

acaggcgacu uggcacagug 20

<210> 8962

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8962

ggaggcagag acaggcgacu 20

<210> 8963

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8963

cagaggugg aggcagac 20

<210> 8964

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8964

ggucaggaag cagauggugg 20

<210> 8965

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8965

cguggucagg aagcagaugg 20

<210> 8966

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8966

gggcgugguc aggaagcaga 20

<210> 8967

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8967

gacuggccug gggcgugguc 20

<210> 8968

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8968

ccacagacug gccuggggcg 20

<210> 8969

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8969

gagggccaca gacuggccug 20

<210> 8970

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8970

ggagggccac agacuggccu 20

<210> 8971

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8971

aggagggcca cagacuggcc 20

<210> 8972

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8972

ugggcaggag ggccacagac 20

<210> 8973

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8973

cugagucaug uugggcagga 20

<210> 8974

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8974

gcugagucau guugggcagg 20

<210> 8975

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8975

agagcugagu cauguugggc 20

<210> 8976

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8976

auauagagcu gagucauguu 20

<210> 8977

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8977

cauauagagc ugagucaugugu 20

<210> 8978

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8978

caagugccca ggggggcuga 20

<210> 8979

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8979

gcaagugccc aggggggcug 20

<210> 8980

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8980

agggggcaa gugccgggg 20

<210> 8981

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8981

gaggugggca agugcccagg 20

<210> 8982

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8982

cgaggugggc aagugcccag 20

<210> 8983

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8983

acgagguggg caagugccca 20

<210> 8984

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8984

gacgaggugg gcaagugccc 20

<210> 8985

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8985

agguccagua gggacgaggu 20

<210> 8986

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8986

cagguccagu agggacgagg 20

<210> 8987

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8987

ccccagggucc aguagggacg 20

<210> 8988

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8988

caccuccccc agguccagua 20

<210> 8989

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8989

caccucccc cagguccagu 20

<210> 8990

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8990

cccuggggc caccuccccc 20

<210> 8991

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8991

cccugucucc aggcccccuca 20

<210> 8992

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8992

ucccugucuc caggccccuc 20

<210> 8993

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8993

agauaaccuu cccugucucc 20

<210> 8994

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8994

gccccaaaag cuaucaaggg 20

<210> 8995

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8995

guggccccaa aagcuaucaa 20

<210> 8996

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8996

aguggcccca aaagcuauca 20

<210> 8997

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8997

ggaagucagc aggcugugag 20

<210> 8998

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8998

agacgcagaa ggaagucagc 20

<210> 8999

<211> 20

<212> RNA

<213> Homo sapiens

<400> 8999

agggccugug cagacgcaga 20

<210> 9000

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9000

agccugucug cuggugccca 20

<210> 9001

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9001

uagccugucu gcuggugccc 20

<210> 9002

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9002

ugaaagcaua gccugucugc 20

<210> 9003

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9003

aaacuccugc aggcugaggu 20

<210> 9004

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9004

gaaacuccug caggcugagg 20

<210> 9005

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9005

caagaaacuc cugcaggcug 20

<210> 9006

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9006

gggcagcaag aaacuccugc 20

<210> 9007

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9007

ggggcuggcc aucaggugca 20

<210> 9008

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9008

uggggcuggc caucaggugc 20

<210> 9009

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9009

ucaccuuggg gcuggccauc 20

<210> 9010

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9010

gucuuuguuc accuuggggc 20

<210> 9011

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9011

gugugucuuu guucaccuug 20

<210> 9012

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9012

agugugucuu uguucaccuu 20

<210> 9013

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9013

aagugugucu uuguucaccu 20

<210> 9014

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9014

ggaauggagg guaacauacu 20

<210> 9015

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9015

gggaauggag gguaacauac 20

<210> 9016

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9016

cuguacccag cgggaaugga 20

<210> 9017

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9017

gcuguaccca gcgggaaugg 20

<210> 9018

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9018

uccgcuguac ccagcgggaa 20

<210> 9019

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9019

uuugguccgc uguacccagc 20

<210> 9020

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9020

cuuugguccg cuguacccag 20

<210> 9021

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9021

ugagaggccc agucuagcuu 20

<210> 9022

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9022

agguggggag guggucugag 20

<210> 9023

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9023

ccgccaggaa gguggggagg 20

<210> 9024

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9024

ggcccgccag gaaggugggg 20

<210> 9025

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9025

ccaggcccgc caggaaggug 20

<210> 9026

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9026

gccaggccg cggaaggu 20

<210> 9027

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9027

ugccaggccc gccaggaagg 20

<210> 9028

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9028

ggaugccagg ccgccagga 20

<210> 9029

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9029

ugcaggaugc caggcccgcc 20

<210> 9030

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9030

ggcggcaggu gcaggaugcc 20

<210> 9031

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9031

aaggaagggg cggcaggugc 20

<210> 9032

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9032

guggcuaagg aaggggcggc 20

<210> 9033

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9033

ccagguggcu aaggaagggg 20

<210> 9034

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9034

gcgccaggug gcuaaggaag 20

<210> 9035

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9035

ugcgccaggu ggcuaaggaa 20

<210> 9036

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9036

cugcgccagg uggcuaagga 20

<210> 9037

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9037

ugcccucgc cagguggcua 20

<210> 9038

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9038

ccucauugcc cugcgccagg 20

<210> 9039

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9039

aguccucauu gcccugcgcc 20

<210> 9040

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9040

cugcacuaca gcagccugcu 20

<210> 9041

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9041

uggccugug agcuugcggg 20

<210> 9042

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9042

cuuuggcccu gugagcuugc 20

<210> 9043

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9043

ccuuuggccc ugugagcuug 20

<210> 9044

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9044

ugacacagcu cuacaaccuu 20

<210> 9045

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9045

gcggugagac uggccagcuc 20

<210> 9046

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9046

gaggcuuugu gcggugagac 20

<210> 9047

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9047

uugauagggg aggcuuugug 20

<210> 9048

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9048

ggaagggcag uugauagggg 20

<210> 9049

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9049

uguggaaggg caguugauag 20

<210> 9050

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9050

uuguggaagg gcaguugaua 20

<210> 9051

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9051

auuguggaag ggcaguugau 20

<210> 9052

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9052

gucaguggga aauuguggaa 20

<210> 9053

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9053

ggucaguggg aaauugugga 20

<210> 9054

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9054

ugcaggucag ugggaaauug 20

<210> 9055

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9055

ccaggucggu gcaggucagu 20

<210> 9056

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9056

gccaggucgg ugcaggucag 20

<210> 9057

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9057

caggggggcc aggucggugc 20

<210> 9058

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9058

guuggucagg guggccaggu 20

<210> 9059

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9059

ggauguuggu cagggguggcc 20

<210> 9060

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9060

cucuaggaug uuggucaggg 20

<210> 9061

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9061

gugcucuagg auguugguca 20

<210> 9062

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9062

ugugcucuag gauguugguc 20

<210> 9063

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9063

cucccuguc ucuaggaugu 20

<210> 9064

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9064

uggggccuc ccugugcucu 20

<210> 9065

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9065

aucaaaaucc agguggaugg 20

<210> 9066

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9066

caucaaaauc cagguggaug 20

<210> 9067

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9067

ccaucaaaau ccagguggau 20

<210> 9068

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9068

gccaucaaaa uccaggugga 20

<210> 9069

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9069

gacagccauc aaaauccagg 20

<210> 9070

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9070

ggggacagcc aucaaaaucc 20

<210> 9071

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9071

ucagggcagu ggggcuccag 20

<210> 9072

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9072

cucaggggcag uggggcucca 20

<210> 9073

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9073

ccucagggca guggggcucc 20

<210> 9074

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9074

accagagccu cagggcagug 20

<210> 9075

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9075

uacgagcc ucagggcagu 20

<210> 9076

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9076

cuaccagagc cucaggggcag 20

<210> 9077

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9077

cacagccuac cagagccuca 20

<210> 9078

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9078

ccacagccua ccagagccuc 20

<210> 9079

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9079

cuuauggcag cuuuaagagc 20

<210> 9080

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9080

agcuuuaaga gcaggaagug 20

<210> 9081

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9081

gcuuuaagag caggaagugugugu 20

<210> 9082

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9082

cuuuaagagc aggaagugug 20

<210> 9083

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9083

ccuuugcaga agcccucucc 20

<210> 9084

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9084

cuccaggagc uugccgacaa 20

<210> 9085

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9085

uccaggagcu ugccgacaau 20

<210> 9086

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9086

ccaggagcuu gccgacaaug 20

<210> 9087

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9087

ggagcuugcc gacaaugggg 20

<210> 9088

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9088

aauggggagg cugcagaugc 20

<210> 9089

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9089

auggggaggc ugcagaugcu 20

<210> 9090

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9090

ugggaggcu gcagaugcug 20

<210> 9091

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9091

ugcagaugcu ggggugagcc 20

<210> 9092

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9092

ugcuggggug agccaggccu 20

<210> 9093

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9093

ccuggagagg gcuucugcaa 20

<210> 9094

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9094

ugucggcaag cuccuggaga 20

<210> 9095

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9095

uugucggcaa gcuccuggag 20

<210> 9096

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9096

ccccauuguc ggcaagcucc 20

<210> 9097

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9097

aucugcagcc uccccauugu 20

<210> 9098

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9098

ugcuuacucu guagguuagc 20

<210> 9099

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9099

ggaaguaaaa ucacugcccg 20

<210> 9100

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9100

ugcccgaggc aucagccacc 20

<210> 9101

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9101

guccacagcu gaaagaaguc 20

<210> 9102

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9102

aagucaggug agugaucucc 20

<210> 9103

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9103

ucaggugagu gaucuccagg 20

<210> 9104

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9104

caggugagug aucuccagga 20

<210> 9105

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9105

caccaggugg cugaugccuc 20

<210> 9106

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9106

ucaccaggug gcugaugccu 20

<210> 9107

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9107

gaggcaaagc uuucaccagg 20

<210> 9108

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9108

agagaggcaa agcuuucacc 20

<210> 9109

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9109

ucuuucagcu guggacagag 20

<210> 9110

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9110

caccugacuu cuuucagcug 20

<210> 9111

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9111

cuuggucucc ucgcaguuuu 20

<210> 9112

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9112

uuggucuccu cgcaguuuuc 20

<210> 9113

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9113

ggacaaccag cucagugacc 20

<210> 9114

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9114

caaccagcuc agugaccagg 20

<210> 9115

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9115

ccaggggug cugaacauug 20

<210> 9116

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9116

gguggugcug aacauugugg 20

<210> 9117

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9117

agguucuccc ucaccuacca 20

<210> 9118

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9118

ucccucaccu accacggcuc 20

<210> 9119

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9119

cgaaaacugc gaggagacca 20

<210> 9120

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9120

ugguuguccc gaaaacugcg 20

<210> 9121

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9121

gcaccaccug gucacugagc 20

<210> 9122

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9122

ccacaauguu cagcaccacc 20

<210> 9123

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9123

uccggagccg ugguagguga 20

<210> 9124

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9124

uuccggagcc gugguaggug 20

<210> 9125

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9125

caagcuuccg gagccguggu 20

<210> 9126

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9126

uacucaagcu uccggagccg 20

<210> 9127

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9127

agaucacuua cucaagcuuc 20

<210> 9128

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9128

cgugucaacc cuacucugcu 20

<210> 9129

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9129

caacccuacu cugcuuggca 20

<210> 9130

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9130

aacccuacuc ugcuuggcaa 20

<210> 9131

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9131

ccuacucugc uuggcaaggg 20

<210> 9132

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9132

cagucacgug uccuaccguc 20

<210> 9133

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9133

uccuaccguc aggaugcuuc 20

<210> 9134

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9134

ccgucaggau gcuucaggcc 20

<210> 9135

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9135

cuucaggcca ggugagcaga 20

<210> 9136

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9136

ggccagguga ggagaaggaa 20

<210> 9137

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9137

gccaggugag cagaaggaaa 20

<210> 9138

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9138

aggcugcaag auuguggcaa 20

<210> 9139

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9139

cugcucaggc ugcaagauug 20

<210> 9140

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9140

cgcagaugcu guugcugcuc 20

<210> 9141

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9141

cacccuugcc aagcagagua 20

<210> 9142

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9142

ccacccuugc caagcagagu 20

<210> 9143

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9143

gccugaagca uccugacggu 20

<210> 9144

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9144

ccuggccuga agcauccuga 20

<210> 9145

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9145

ucccuuuccu ucugcucacc 20

<210> 9146

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9146

ugguaucuga uccuggcaggg 20

<210> 9147

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9147

uaucugaucc ugcagggagg 20

<210> 9148

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9148

agacaacugc agagcuacaa 20

<210> 9149

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9149

uacaaaggua agaagccaag 20

<210> 9150

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9150

aaagguaaga agccaagagg 20

<210> 9151

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9151

gaugaggucc gccucccugc 20

<210> 9152

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9152

gcggggaaag aaggaagaug 20

<210> 9153

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9153

ucucugugggg cggggaaaga 20

<210> 9154

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9154

ugcaguuguc ucugugggcg 20

<210> 9155

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9155

cugcaguugu cucugugggc 20

<210> 9156

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9156

ucuccaguug ucucuguggg 20

<210> 9157

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9157

agcucucag uugucucugu 20

<210> 9158

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9158

uagcucuca guugucucug 20

<210> 9159

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9159

ugccagagcu ccagaccugc 20

<210> 9160

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9160

ccagaccugc aggaaaguga 20

<210> 9161

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9161

ugcaggaaag ugacggccag 20

<210> 9162

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9162

gaaagugacg gccagaggaa 20

<210> 9163

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9163

aaagugacgg ccagaggaaa 20

<210> 9164

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9164

aagugacggc cagaggaaag 20

<210> 9165

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9165

agagcagaag cuugacgcuc 20

<210> 9166

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9166

agcuugacgc ucagguaccu 20

<210> 9167

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9167

uugacgcuca gguaccuugg 20

<210> 9168

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9168

ugacgcucag guaccuugga 20

<210> 9169

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9169

uuccugcagg ucggagcuc 20

<210> 9170

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9170

ccgucacuuu ccugcagguc 20

<210> 9171

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9171

ucuggccguc acuuuccugc 20

<210> 9172

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9172

ugcucugagc cccuuuccuc 20

<210> 9173

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9173

gcuggagaag ugucagcucc 20

<210> 9174

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9174

ucagcuccag guccacgaug 20

<210> 9175

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9175

gcuccagguc cacgaugcgg 20

<210> 9176

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9176

ggcccucaua gccugcucc 20

<210> 9177

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9177

cucauagccc ugcuccagga 20

<210> 9178

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9178

gcuccaggaa ggcccucacc 20

<210> 9179

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9179

ccaggaaggc ccucaccugg 20

<210> 9180

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9180

aggccucac cuggaggaag 20

<210> 9181

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9181

aggaagugga gugaguauca 20

<210> 9182

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9182

ggaaguggag ugaguaucac 20

<210> 9183

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9183

gcagccuugg guaggagugg 20

<210> 9184

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9184

ugcagccuug gguaggagug 20

<210> 9185

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9185

cugcagccuu ggguaggagu 20

<210> 9186

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9186

ucugcagccu uggguaggag 20

<210> 9187

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9187

acacuucugc agccuugggu 20

<210> 9188

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9188

gcugacacuu cugcagccuu 20

<210> 9189

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9189

agcugacacu ucugcagccu 20

<210> 9190

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9190

gggccuccgc aucguggacc 20

<210> 9191

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9191

cuaugagggccuccgcaucg 20

<210> 9192

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9192

uuccuggagc agggcuauga 20

<210> 9193

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9193

cuuccuggag cagggcuaug 20

<210> 9194

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9194

gugagggccu uccuggagca 20

<210> 9195

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9195

ggugaggggcc uuccuggagc 20

<210> 9196

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9196

ccuccaggug aggccuucc 20

<210> 9197

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9197

acuccacuuc cuccagguga 20

<210> 9198

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9198

cacuccacuu ccuccaggug 20

<210> 9199

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9199

auacucacuc cacuuccucc 20

<210> 9200

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9200

gccccccguc ucagccucuc 20

<210> 9201

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9201

ccccccgucu cagccucuca 20

<210> 9202

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9202

cagccucuca gggaaccagc 20

<210> 9203

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9203

gggaaccagc uggaagauga 20

<210> 9204

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9204

agcuggaaga ugaaggcugu 20

<210> 9205

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9205

agaugaaggc ugucggcuga 20

<210> 9206

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9206

aggcugucgg cugauggcag 20

<210> 9207

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9207

caucccagcu gcacaucgcc 20

<210> 9208

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9208

gcugcacauc gccaggaagc 20

<210> 9209

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9209

cccugagagg cugagacggg 20

<210> 9210

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9210

ucccugag gcugagacgg 20

<210> 9211

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9211

uucccugaga ggcugagacg 20

<210> 9212

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9212

guucccugag aggcugagac 20

<210> 9213

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9213

gguucccuga gaggcugaga 20

<210> 9214

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9214

cuuccagcug guucccugag 20

<210> 9215

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9215

gacagccuuc aucuuccagc 20

<210> 9216

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9216

cuuccuggcg augugcagcu 20

<210> 9217

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9217

gcuuccuggc gaugugcagc 20

<210> 9218

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9218

gacaacucac uccagcuucc 20

<210> 9219

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9219

cuccacagcc ucaguaacaa 20

<210> 9220

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9220

uccacagccu caguaacaac 20

<210> 9221

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9221

caguaacaac gggcuuucug 20

<210> 9222

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9222

aacaacgggc uuucuguggc 20

<210> 9223

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9223

acaacgggcu uucuguggcc 20

<210> 9224

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9224

caacgggcuu ucuguggccg 20

<210> 9225

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9225

ccggggugca uugugugcug 20

<210> 9226

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9226

cggggugcau ugugugcuga 20

<210> 9227

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9227

ugaggggccgu gagugcgugc 20

<210> 9228

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9228

cgugagugcg ugcuggaccc 20

<210> 9229

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9229

cccggcaga gcugcacauc 20

<210> 9230

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9230

uggcagagcu gcacaucagg 20

<210> 9231

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9231

ggcagagcug cacaucaggu 20

<210> 9232

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9232

aggcugga gagcaggaga 20

<210> 9233

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9233

uuacugaggc ugggagagc 20

<210> 9234

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9234

gcccguuguu acugaggcug 20

<210> 9235

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9235

cagaaagccc guuguuacug 20

<210> 9236

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9236

ccucagcaca caaugcaccc 20

<210> 9237

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9237

caggguccag cacgcacuca 20

<210> 9238

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9238

ccugaugugc agcucugcca 20

<210> 9239

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9239

accugaugug cagcucugcc 20

<210> 9240

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9240

ugugaucuuc auguuugccc 20

<210> 9241

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9241

cauguuugcc caggagccag 20

<210> 9242

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9242

ccaggagcca gaggagcaga 20

<210> 9243

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9243

caggagccag aggaggcagaa 20

<210> 9244

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9244

aggagccaga ggagcagaag 20

<210> 9245

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9245

agaggagcag aaggggcccc 20

<210> 9246

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9246

agcagaaggg gccccaggag 20

<210> 9247

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9247

gaaggggccc caggagaggu 20

<210> 9248

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9248

aaggggcccc aggagaggua 20

<210> 9249

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9249

aggcugugaa gacaaaagag 20

<210> 9250

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9250

caggcuguga agacaaaaga 20

<210> 9251

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9251

gcaggcugug aagacaaaag 20

<210> 9252

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9252

agaucacagu uuugugcugc 20

<210> 9253

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9253

cuucugcucc ucuggcuccu 20

<210> 9254

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9254

ccuucugcuc cucuggcucc 20

<210> 9255

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9255

uggggccccu ucugcuccuc 20

<210> 9256

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9256

aucggggcccu accucuccug 20

<210> 9257

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9257

aaucgggccc uaccucuccu 20

<210> 9258

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9258

aaaucgggcc cuaccucucc 20

<210> 9259

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9259

agcugccucu gagcuccga 20

<210> 9260

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9260

cucugagcuc ccgaaggaug 20

<210> 9261

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9261

cgaaggauga gguacaguga 20

<210> 9262

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9262

gcccuggagg gacaucacca 20

<210> 9263

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9263

ucaagaaaug cagccugga 20

<210> 9264

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9264

gucaagaaau gcagcccugg 20

<210> 9265

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9265

gcugucaaga aaugcagccc 20

<210> 9266

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9266

cagagggcau cuggagcaug 20

<210> 9267

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9267

gaggcagcuc agaggggcauc 20

<210> 9268

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9268

gagcucagag gcagcucaga 20

<210> 9269

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9269

ggagcucaga ggcagcucag 20

<210> 9270

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9270

cucauccuuc gggagcucag 20

<210> 9271

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9271

aucacuguac cucauccuuc 20

<210> 9272

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9272

caucacugua ccucauccuu 20

<210> 9273

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9273

cugggcaggc ugacacauug 20

<210> 9274

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9274

gcaccuagag cagcucugca 20

<210> 9275

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9275

agagcagcuc ugcaaggcuc 20

<210> 9276

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9276

gagcagcucu gcaaggcucu 20

<210> 9277

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9277

cagcucugca aggcucuggg 20

<210> 9278

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9278

cugggaggaa gcugccaccu 20

<210> 9279

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9279

ucaccuccac cucgagugag 20

<210> 9280

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9280

cgagugagug guuugugugugu 20

<210> 9281

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9281

acaauguguc agccugccca 20

<210> 9282

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9282

cacaaugugu cagccugccc 20

<210> 9283

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9283

gcucuaggug cuuuucuugg 20

<210> 9284

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9284

gcucucuag gugcuuuucu 20

<210> 9285

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9285

gagccuugca gagcugcucu 20

<210> 9286

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9286

cgaggggag gugaccgagg 20

<210> 9287

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9287

acucgagguggaggugaccg 20

<210> 9288

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9288

aaaccacuca cucgaggugg 20

<210> 9289

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9289

cacaaaccac ucacucgagg 20

<210> 9290

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9290

acacacaaac cacucacucg 20

<210> 9291

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9291

cuccccaccc cagcuucuc 20

<210> 9292

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9292

cagcuucuca ggcaaugcuc 20

<210> 9293

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9293

agcuucucag gcaaugcucu 20

<210> 9294

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9294

gcuucucagg caaugcucug 20

<210> 9295

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9295

cuucucaggc aaugcucugg 20

<210> 9296

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9296

ggcaaugcuc ugggggauga 20

<210> 9297

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9297

ugggggauga aggugcagcc 20

<210> 9298

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9298

ggaugaaggu gcagcccggc 20

<210> 9299

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9299

cggcuggcuc agcugcuccc 20

<210> 9300

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9300

ggcuggcuca gcugcuccca 20

<210> 9301

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9301

ggcucagcug cucccagggc 20

<210> 9302

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9302

gcucagcugc ucccagggcu 20

<210> 9303

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9303

cuugaaguga guagcccgcu 20

<210> 9304

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9304

gaagcugggg guggggagaa 20

<210> 9305

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9305

agaagcuggggguggggaga 20

<210> 9306

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9306

ugccugagaa gcugggggug 20

<210> 9307

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9307

uugccugaga agcugggggu 20

<210> 9308

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9308

auugccugag aagcugggg 20

<210> 9309

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9309

agcauugccu gagaagcugg 20

<210> 9310

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9310

gagcauugcc ugagaagcug 20

<210> 9311

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9311

agagcauugc cugagaagcu 20

<210> 9312

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9312

cagagcauug ccugagaagc 20

<210> 9313

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9313

ugggagcagc ugagccagcc 20

<210> 9314

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9314

cugggagcag cugagccagc 20

<210> 9315

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9315

acugcagagc ucccagcccu 20

<210> 9316

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9316

gacugcagag cucccagccc 20

<210> 9317

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9317

cuagcgggcu acucacuuca 20

<210> 9318

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9318

aucuccagcc ucagugagaa 20

<210> 9319

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9319

cagugagaac gguuuguccc 20

<210> 9320

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9320

uuugucccug gaugccgugu 20

<210> 9321

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9321

uugucccugg augccguguu 20

<210> 9322

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9322

ccuggaugcc guguuggguu 20

<210> 9323

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9323

augccguguu ggguuugguu 20

<210> 9324

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9324

ggugcuucuc cacucugcag 20

<210> 9325

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9325

ucugcagugg cucuuccgcu 20

<210> 9326

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9326

ggcucuuccg cuuggacauc 20

<210> 9327

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9327

gaggcuggag aucacagggg 20

<210> 9328

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9328

acugaggcug gagaucacag 20

<210> 9329

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9329

cacugaggcu ggagaucaca 20

<210> 9330

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9330

ucacugaggc uggagaucac 20

<210> 9331

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9331

caaaccguuc ucacugaggc 20

<210> 9332

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9332

gggacaaacc guucucacug 20

<210> 9333

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9333

caaacccaac acggcaucca 20

<210> 9334

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9334

ccaaacccaa cacggcaucc 20

<210> 9335

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9335

gcaccgaacc aaacccaaca 20

<210> 9336

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9336

gcggaagagc cacugcagag 20

<210> 9337

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9337

acgcucaccu gauguccaag 20

<210> 9338

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9338

agccaacaca uccuccugag 20

<210> 9339

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9339

gccaacacau ccuccugaga 20

<210> 9340

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9340

ccaacacauc cuccugag 20

<210> 9341

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9341

ugagagggga caagacaagc 20

<210> 9342

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9342

ggggacaaga caagcaggug 20

<210> 9343

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9343

gacaagacaa gcaggugagg 20

<210> 9344

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9344

acaagacaag caggugagga 20

<210> 9345

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9345

gcaggugagg agggaacgcu 20

<210> 9346

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9346

caggugagga gggaacgcuc 20

<210> 9347

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9347

uuucaaagcu ggaagcagag 20

<210> 9348

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9348

gauguguugg cuuucaaagc 20

<210> 9349

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9349

ccccucucaggaggaugugugugu 20

<210> 9350

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9350

uugucuuguc cccucucagg 20

<210> 9351

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9351

ugcuugucuu guccccucuc 20

<210> 9352

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9352

aucccccccc uagggauaug 20

<210> 9353

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9353

ucccccuccu agggauaugugu 20

<210> 9354

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9354

ccuagggaua ugugggccac 20

<210> 9355

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9355

ccagcugcag ccaaguucuu 20

<210> 9356

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9356

cagcugcagc caaguucuua 20

<210> 9357

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9357

uccgucagcg cugcaucccc 20

<210> 9358

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9358

gcugcauccc caggagccuc 20

<210> 9359

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9359

gcccacaauau cccuaggagg 20

<210> 9360

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9360

ggcccacaua ucccuaggag 20

<210> 9361

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9361

uggcccacaau aucccuagga 20

<210> 9362

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9362

guggcccaca uaucccuagg 20

<210> 9363

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9363

ccaguggccc acauaucccu 20

<210> 9364

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9364

gaagucuggc aaagauccag 20

<210> 9365

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9365

uuggcugcag cugggaaguc 20

<210> 9366

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9366

cuaagaacuu ggcugcagcu 20

<210> 9367

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9367

ccuaagaacu uggcugcagc 20

<210> 9368

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9368

cugacgaac ccuagaacu 20

<210> 9369

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9369

uccggggau gcagcgcuga 20

<210> 9370

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9370

gacaguacca gaggcuccug 20

<210> 9371

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9371

ggacaguacc agaggcuccu 20

<210> 9372

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9372

gggacaguac cagaggcucc 20

<210> 9373

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9373

aagggcuggg acaguaccag 20

<210> 9374

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9374

cagccucagu gaguguccuc 20

<210> 9375

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9375

ccgccucugu gccacucuga 20

<210> 9376

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9376

ugccacucug aaggacugcc 20

<210> 9377

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9377

gccacucuga aggacugccc 20

<210> 9378

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9378

gaaggacugc ccgggacccc 20

<210> 9379

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9379

uggaacugca guaaguaacg 20

<210> 9380

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9380

ugaggcugca aaggggcaau 20

<210> 9381

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9381

cugaggcugc aaaggggcaa 20

<210> 9382

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9382

cacucacuga ggcugcaaag 20

<210> 9383

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9383

acacucacug aggcugcaaa 20

<210> 9384

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9384

gacacucacu gaggcugcaa 20

<210> 9385

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9385

gcuccagagg acacucacug 20

<210> 9386

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9386

gugaggcuug ggggcuccag 20

<210> 9387

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9387

cagaggcggg ugaggcuugg 20

<210> 9388

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9388

acagaggcgg gugaggcuug 20

<210> 9389

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9389

cacagaggcg ggugaggcuu 20

<210> 9390

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9390

gcacagaggc gggugaggcu 20

<210> 9391

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9391

gaggggcaca gaggcggggug 20

<210> 9392

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9392

cuucagagug gcacagaggc 20

<210> 9393

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9393

ccuucagagu ggcacagagg 20

<210> 9394

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9394

aguccuucag aguggcacag 20

<210> 9395

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9395

ucccgggcag uccuucagag 20

<210> 9396

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9396

acugcaguuc cagggguccc 20

<210> 9397

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9397

uacugcaguu ccaggggucc 20

<210> 9398

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9398

guuacuuacu gcaguuccag 20

<210> 9399

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9399

cguuacuuac ugcaguucca 20

<210> 9400

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9400

ucguuacuua cugcaguucc 20

<210> 9401

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9401

guuccugagu gaccagagcc 20

<210> 9402

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9402

ccagagccug gagacucuac 20

<210> 9403

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9403

aaucuguga acaaagcagg 20

<210> 9404

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9404

gacaaucugu gaaacaaagc 20

<210> 9405

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9405

cuggucacuc aggaacucac 20

<210> 9406

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9406

ucuccaggcu cuggucacuc 20

<210> 9407

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9407

ccaguagagu cuccaggcuc 20

<210> 9408

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9408

agcaguccag uagagucucc 20

<210> 9409

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9409

aggcucagcu gagggaguug 20

<210> 9410

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9410

acugcagcag gcucagcuga 20

<210> 9411

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9411

uacugcagca ggcucagcug 20

<210> 9412

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9412

aacucucguc uuacugcagc 20

<210> 9413

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9413

ccuuuucagg cugagccaga 20

<210> 9414

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9414

cuuuucaggc ugagccagac 20

<210> 9415

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9415

cccgaaaagc cccuuccugc 20

<210> 9416

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9416

acaccuuaag ccugugucca 20

<210> 9417

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9417

caccuuaagc cuguguccac 20

<210> 9418

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9418

ccugugucca cggguuaaaa 20

<210> 9419

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9419

guguccacgg guuaaaaagg 20

<210> 9420

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9420

ggguuaaaaa gguggaucuc 20

<210> 9421

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9421

uuaaaaaggu ggaucucagg 20

<210> 9422

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9422

uaaaaaggug gaucucaggu 20

<210> 9423

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9423

aucucaggugggcauucccc 20

<210> 9424

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9424

ucucaggugg gcauuccccu 20

<210> 9425

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9425

cucagccuga aaaggaaagg 20

<210> 9426

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9426

gcucagccug aaaaggaaag 20

<210> 9427

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9427

ggcucagccu gaaaaggaaa 20

<210> 9428

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9428

uggcucagcc ugaaaaggaa 20

<210> 9429

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9429

ccgucuggcu cagccugaaa 20

<210> 9430

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9430

uuuucgggga caguccccguc 20

<210> 9431

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9431

cagcaggaag gggcuuuucg 20

<210> 9432

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9432

ccagcaggaa ggggcuuuuc 20

<210> 9433

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9433

gccagcagga aggggcuuuu 20

<210> 9434

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9434

agguguuggc cagcaggaag 20

<210> 9435

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9435

aagguguugg ccagcaggaa 20

<210> 9436

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9436

uaagguguug gccagcagga 20

<210> 9437

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9437

ggcuuaaggu guuggccagc 20

<210> 9438

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9438

uggacagg cuuaaggugu 20

<210> 9439

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9439

aacccgugga cacaggcuua 20

<210> 9440

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9440

ccuuuuuaac ccguggacac 20

<210> 9441

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9441

agauccaccu uuuuaacccg 20

<210> 9442

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9442

uuugcacuuc agauccaacg 20

<210> 9443

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9443

gcacuucaga uccaacgagg 20

<210> 9444

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9444

cuucagaucc aacgaggagg 20

<210> 9445

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9445

agauccaacg aggaggagga 20

<210> 9446

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9446

gaggaggaag gcgugugcug 20

<210> 9447

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9447

aggaggaagg cgugugcugu 20

<210> 9448

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9448

gaccuggauc agacaggacc 20

<210> 9449

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9449

ugcaggacc uggaucagac 20

<210> 9450

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9450

aguugcaugg ugcagggacc 20

<210> 9451

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9451

gugcaaaguu gcauggugca 20

<210> 9452

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9452

agugcaaagu ugcauggugc 20

<210> 9453

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9453

aucugaagug caaaguugca 20

<210> 9454

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9454

cacgccuucc uccuccucgu 20

<210> 9455

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9455

ccccuuuacc uccguccagc 20

<210> 9456

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9456

ccuccgucca gcagguucac 20

<210> 9457

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9457

cacaggcugc agccucagcc 20

<210> 9458

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9458

agcacguaga gucacucugc 20

<210> 9459

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9459

ccugcuggac ggagguaaag 20

<210> 9460

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9460

accugcugga cggagguaaa 20

<210> 9461

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9461

aaccugcugg acggagguaa 20

<210> 9462

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9462

ccugugaacc ugcuggacgg 20

<210> 9463

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9463

cagccuguga accugcugga 20

<210> 9464

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9464

gcugcagccu gugaaccugc 20

<210> 9465

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9465

acucuacgug cuccuggcug 20

<210> 9466

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9466

agagugacuc uacgugcucc 20

<210> 9467

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9467

guugaaugag guggaggcug 20

<210> 9468

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9468

gagggaguug aaugaggugg 20

<210> 9469

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9469

cagucucuca gcaaaccugc 20

<210> 9470

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9470

agucucucag caaaccugcu 20

<210> 9471

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9471

gcaaaccugc ugggcgacag 20

<210> 9472

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9472

cagcggacuc agaugccuuc 20

<210> 9473

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9473

ccuucuggaa ugucugccgc 20

<210> 9474

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9474

cugccgcagg ugcccaucuc 20

<210> 9475

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9475

cuccgguuug cuugaguaag 20

<210> 9476

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9476

cugagagacu guagggggua 20

<210> 9477

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9477

guuugcugag agacuguagg 20

<210> 9478

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9478

gguuugcuga gagacuguag 20

<210> 9479

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9479

agguuugcug agagacugua 20

<210> 9480

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9480

cagguuugcu gagagacugu 20

<210> 9481

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9481

ugaguccgcu gucgcccagc 20

<210> 9482

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9482

ccugcggcag acauuccaga 20

<210> 9483

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9483

aaaccggaga ugggcaccug 20

<210> 9484

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9484

uacucaagca aaccggagau 20

<210> 9485

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9485

uuacucaagc aaaccggaga 20

<210> 9486

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9486

uuccacuuac ucaagcaaac 20

<210> 9487

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9487

gagucacaac agcauuucuc 20

<210> 9488

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9488

ggaaagugcc cuguaccugc 20

<210> 9489

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9489

ugcccuccug cccacguguc 20

<210> 9490

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9490

gcccuccuc ccacgugucc 20

<210> 9491

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9491

cuccuccca cguguccgggg 20

<210> 9492

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9492

cgggaggccu cagugaagua 20

<210> 9493

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9493

gggaggccuc agugaaguaa 20

<210> 9494

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9494

ggaggccuca gugaaguaag 20

<210> 9495

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9495

ucagugaagu aaggggaugu 20

<210> 9496

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9496

gacucagacu agaagggaaa 20

<210> 9497

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9497

uguugugacu cagacuagaa 20

<210> 9498

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9498

cuguugugac ucagacuaga 20

<210> 9499

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9499

cagugucucc agcagguaca 20

<210> 9500

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9500

gcagugucuc cagcagguac 20

<210> 9501

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9501

aggagggcag ugucuccagc 20

<210> 9502

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9502

ucccggacac gugggcagga 20

<210> 9503

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9503

cucccggaca cgugggcagg 20

<210> 9504

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9504

ggccccccgg acacguggggc 20

<210> 9505

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9505

cugaggccuc ccggacacgu 20

<210> 9506

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9506

acugaggccu cccggacacg 20

<210> 9507

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9507

cuuacuucac ugaggccucc 20

<210> 9508

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9508

aacauccccu uacuucacug 20

<210> 9509

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9509

aggcccuucu cucugcagcc 20

<210> 9510

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9510

ggcccuucuc ucugcagccu 20

<210> 9511

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9511

ugggcucuga gcagagcuuc 20

<210> 9512

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9512

ccggauucac uucuccagag 20

<210> 9513

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9513

ucacuucucc agagaggacc 20

<210> 9514

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9514

uucuccagag aggaccaggc 20

<210> 9515

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9515

ucuccagaga ggaccaggcu 20

<210> 9516

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9516

accaggcugg gaagacacuc 20

<210> 9517

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9517

gacacucagg uaauucccugc 20

<210> 9518

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9518

acacucaggu aaucccugca 20

<210> 9519

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9519

aggcugcaga gagaagggcc 20

<210> 9520

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9520

agcccaggcu gcagagagaa 20

<210> 9521

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9521

gagcccaggc ugcagagaga 20

<210> 9522

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9522

ggaagcucug cucagagccc 20

<210> 9523

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9523

ccucucugga gaagugaauc 20

<210> 9524

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9524

cuucccagcc ugguccucuc 20

<210> 9525

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9525

accugagugu cuucccagcc 20

<210> 9526

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9526

ggcuaaguga gugcagcuuc 20

<210> 9527

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9527

uccggccaga gcacgugucc 20

<210> 9528

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9528

gccagagcac guguccaggc 20

<210> 9529

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9529

cacgugucca ggcuggccac 20

<210> 9530

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9530

gagcaagucc cugcagcuga 20

<210> 9531

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9531

agccugggg cagaaagcca 20

<210> 9532

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9532

uagccugagg gcagaaagcc 20

<210> 9533

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9533

gcugcacuca cuuagccuga 20

<210> 9534

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9534

agcugcacuc acuuagccug 20

<210> 9535

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9535

gccuggacac gugcucuggc 20

<210> 9536

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9536

gccagccugg aacacgugcuc 20

<210> 9537

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9537

gcucaagccg guggccagcc 20

<210> 9538

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9538

cagggacuug cucaagccgg 20

<210> 9539

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9539

cugcaggac uugcucaagc 20

<210> 9540

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9540

cgugagcucc gucagcugca 20

<210> 9541

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9541

acgugagcuc cgucagcugc 20

<210> 9542

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9542

caggcugacc cagugcugcc 20

<210> 9543

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9543

aggcugaccc agugcugccu 20

<210> 9544

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9544

cugccugggc cagaagcagc 20

<210> 9545

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9545

gcuggccauc cuccuagcu 20

<210> 9546

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9546

ggccauccuc cugagcuugg 20

<210> 9547

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9547

gccauccucc ugagcuuggu 20

<210> 9548

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9548

ccauccuccu gagcuuggug 20

<210> 9549

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9549

agcuugggg ggcgacccgc 20

<210> 9550

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9550

gcuuggggg gcgacccgca 20

<210> 9551

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9551

cgcagggcu guucagccuc 20

<210> 9552

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9552

cugggucagc cuggagacag 20

<210> 9553

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9553

caggcagcac ugggucagcc 20

<210> 9554

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9554

cuucuggccc aggcagcacu 20

<210> 9555

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9555

gcuucuggcc caggcagcac 20

<210> 9556

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9556

uggccagcug cuucuggccc 20

<210> 9557

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9557

ggaggauggc cagcugcuuc 20

<210> 9558

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9558

ccccaccaag cucaggagga 20

<210> 9559

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9559

gucgccccac caagcucagg 20

<210> 9560

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9560

cgggucgccc caccaagcuc 20

<210> 9561

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9561

cugaggcuga acagcccugc 20

<210> 9562

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9562

ccugaggcug aacagccug 20

<210> 9563

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9563

agcgggggag gagguaccug 20

<210> 9564

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9564

ccccuucugu gacaggggugc 20

<210> 9565

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9565

gugacagggu gcaggagccg 20

<210> 9566

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9566

ugacaggggug caggagccgu 20

<210> 9567

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9567

cagggugcag gagccguggg 20

<210> 9568

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9568

agccgugggc ggacagagcc 20

<210> 9569

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9569

gccgugggcg gacagagcca 20

<210> 9570

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9570

ccuguuagaa gucugcgccc 20

<210> 9571

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9571

gaagucugcg cccaggccuc 20

<210> 9572

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9572

caggcagugu cacugaaauc 20

<210> 9573

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9573

aucaggugag uccagagaag 20

<210> 9574

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9574

ccugcacccu gucacagaag 20

<210> 9575

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9575

Uccugcaccc ugucacagaa 20

<210> 9576

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9576

cuccugcacc cugucacaga 20

<210> 9577

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9577

acccuggcuc uguccgccca 20

<210> 9578

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9578

uucuaacagg gagagaaccc 20

<210> 9579

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9579

cugggcgcag acuucuaaca 20

<210> 9580

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9580

ccugggcgca gacuucuaac 20

<210> 9581

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9581

agugacacug ccugaggccu 20

<210> 9582

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9582

cagugacacu gccugaggcc 20

<210> 9583

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9583

gauuucagug acacugccug 20

<210> 9584

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9584

gcagcagcuc uguguccagc 20

<210> 9585

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9585

ccagcuggaa uuuccucgcc 20

<210> 9586

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9586

ggaagagaau ccagaagcug 20

<210> 9587

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9587

aucgaagc uguggcacuc 20

<210> 9588

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9588

cagaagcugu ggcacucagg 20

<210> 9589

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9589

agaagcugug gcacucaggu 20

<210> 9590

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9590

cucagguggg acccagcacc 20

<210> 9591

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9591

ucagggggga ccagcacca 20

<210> 9592

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9592

gcugggucuc ggagaugcug 20

<210> 9593

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9593

acagagcugc ugcugggucu 20

<210> 9594

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9594

cuggacacag agcugcugcu 20

<210> 9595

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9595

gcuggacaca gagcugcugc 20

<210> 9596

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9596

ccuggcgagg aaauuccagc 20

<210> 9597

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9597

ucuggauucu cuuccuggcg 20

<210> 9598

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9598

cagcuucugg auucucuucc 20

<210> 9599

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9599

caccugagug ccacagcuuc 20

<210> 9600

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9600

cucccugucu guguccaggu 20

<210> 9601

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9601

agguuggcuc acugugaccu 20

<210> 9602

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9602

gcccaccaca gccuucuugu 20

<210> 9603

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9603

cccaccacag ccuucuuguc 20

<210> 9604

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9604

ccuucuuguc gggcagcuga 20

<210> 9605

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9605

agcugaugga gacaugugcc 20

<210> 9606

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9606

gugccaggcu gcagcagcuc 20

<210> 9607

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9607

cagcagcuca ggucagcgcc 20

<210> 9608

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9608

agccaaccug gacacagaca 20

<210> 9609

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9609

gagccaaccu ggacacagac 20

<210> 9610

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9610

aaggucacag ugagccaacc 20

<210> 9611

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9611

gaaggcugug gugggcucca 20

<210> 9612

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9612

cccgacaaga aggcuguggu 20

<210> 9613

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9613

gcccgacaag aaggcuggugg 20

<210> 9614

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9614

gcugccgac aagaaggcug 20

<210> 9615

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9615

ccaucagcug cccgacaaga 20

<210> 9616

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9616

ugaccuagc ugcugcagcc 20

<210> 9617

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9617

ggaccuuuuc agcuugucuc 20

<210> 9618

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9618

gucucagguu aaccucugug 20

<210> 9619

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9619

ucucugagcu gaagacauuu 20

<210> 9620

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9620

agacaagcug aaaaggucca 20

<210> 9621

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9621

uaaccugaga caagcugaaa 20

<210> 9622

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9622

uggcaucauc guccucacag 20

<210> 9623

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9623

gcucugcagc agcagggaac 20

<210> 9624

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9624

caggaggcuc ugcagcagca 20

<210> 9625

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9625

gcaggaggcu cugcagcagc 20

<210> 9626

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9626

gcucagagag ggacagcagg 20

<210> 9627

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9627

ucagcucaga gagggacagc 20

<210> 9628

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9628

aaaugucuuc agcucagaga 20

<210> 9629

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9629

gaaaugucuu cagcucagag 20

<210> 9630

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9630

cuccagcugu gugagcaccg 20

<210> 9631

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9631

Uccagcugugugagcaccga 20

<210> 9632

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9632

caccgagggc cucgcccacc 20

<210> 9633

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9633

ggccucgccc accuggcauc 20

<210> 9634

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9634

cgcccaccug gcaucugguc 20

<210> 9635

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9635

gcccaccugg caucuggucu 20

<210> 9636

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9636

ucggggcac ugccaccacu 20

<210> 9637

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9637

gggccacugc caccacuugg 20

<210> 9638

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9638

cugccaccac uuggaggagc 20

<210> 9639

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9639

agcuggagug aguugcagag 20

<210> 9640

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9640

uggagugagu ugcagagugg 20

<210> 9641

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9641

ggagugaguu ggagagugga 20

<210> 9642

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9642

ucagccuggu gggggucaaa 20

<210> 9643

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9643

gucagccugg ugggggucaa 20

<210> 9644

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9644

gcuggagguc agccuggugg 20

<210> 9645

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9645

agcuggaggu cagccuggug 20

<210> 9646

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9646

cagcuggagg ucagccuggu 20

<210> 9647

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9647

acagcuggag gucagccugg 20

<210> 9648

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9648

cacacagcug gaggucagcc 20

<210> 9649

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9649

cucggugcuc acacagcugg 20

<210> 9650

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9650

gcccucggug cucacacagc 20

<210> 9651

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9651

ugccaggugg gcgaggcccu 20

<210> 9652

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9652

gaccagaugc caggugggcg 20

<210> 9653

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9653

gcccagacca gaugccaggu 20

<210> 9654

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9654

ggccgacc agaugccagg 20

<210> 9655

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9655

aguggcccag accagaugcc 20

<210> 9656

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9656

gcuccuccaa gugguggcag 20

<210> 9657

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9657

acuccagcuc cuccaagugg 20

<210> 9658

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9658

cuccuccaag cuccuccaag 20

<210> 9659

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9659

gucuaacaau caauuugaug 20

<210> 9660

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9660

uuugaugagg 20

<210> 9661

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9661

aacaaucaau uugaugagga 20

<210> 9662

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9662

auuugaugag gagggcacca 20

<210> 9663

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9663

agggcaccaa ggcgcugaug 20

<210> 9664

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9664

gggcaccaag gcgcugauga 20

<210> 9665

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9665

ggcgcugaug agggcccuug 20

<210> 9666

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9666

gcgcugauga gggcccuuga 20

<210> 9667

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9667

cgcugaugag ggcccuugag 20

<210> 9668

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9668

ugaggggcccu ugagggggaaa 20

<210> 9669

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9669

aggggaaaug gaugcuaaag 20

<210> 9670

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9670

gaaauggaug cuaaagaggc 20

<210> 9671

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9671

gaggcuggag uaaguugaguga 20

<210> 9672

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9672

gcuggaguaa guagugaugg 20

<210> 9673

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9673

uagacaagcu gcagaagacc 20

<210> 9674

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9674

aagggcccuc aucagcgccu 20

<210> 9675

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9675

uagcauccau uuccccucaa 20

<210> 9676

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9676

uuagcaucca uuuccccuca 20

<210> 9677

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9677

ucugcugaac agcuccaccu 20

<210> 9678

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9678

ugaccugccu gcagagccuc 20

<210> 9679

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9679

gccucaggug agugaccgag 20

<210> 9680

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9680

aggcuggaga aggagaggcc 20

<210> 9681

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9681

gacugaggcu ggagaagagg 20

<210> 9682

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9682

ggugacugag gcuggagaag 20

<210> 9683

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9683

cagcagaagg ugacugaggc 20

<210> 9684

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9684

uguucagcag aaggugacug 20

<210> 9685

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9685

agguggagcu guucagcaga 20

<210> 9686

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9686

gugaguaagc aaggccaagg 20

<210> 9687

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9687

ucugugagua agcaaggcca 20

<210> 9688

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9688

gcuuagucug ugaguaagca 20

<210> 9689

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9689

ggcucugcag gcaggucauc 20

<210> 9690

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9690

ucaccugagg cucugcaggc 20

<210> 9691

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9691

ucacucaccu gaggcucugc 20

<210> 9692

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9692

gccgcucggu cacucaccug 20

<210> 9693

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9693

ccugcuuuuc cagacugaac 20

<210> 9694

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9694

agacugaaca ggaacaguau 20

<210> 9695

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9695

aggaacagua ucggugaugugu 20

<210> 9696

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9696

cgguugcugc caccuuucug 20

<210> 9697

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9697

gccaccuuuc ugaggcucuc 20

<210> 9698

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9698

ccaccuuucu gaggcucuca 20

<210> 9699

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9699

cagggcugcc accagccuag 20

<210> 9700

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9700

ugccaccagc cuagaggagc 20

<210> 9701

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9701

cuguucaguc uggaaaagca 20

<210> 9702

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9702

ccuguucagu cuggaaaagc 20

<210> 9703

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9703

gauacuguuc cuguucaguc 20

<210> 9704

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9704

cccugagagc cucagaaagg 20

<210> 9705

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9705

cagcccugag agccucagaa 20

<210> 9706

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9706

cuccagcucc ucuaggcugg 20

<210> 9707

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9707

ucacuccagc uccucuaggc 20

<210> 9708

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9708

caacucacuc cagcuccucu 20

<210> 9709

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9709

agcuugagcc acaaccagau 20

<210> 9710

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9710

cacaaccaga uuggagacgc 20

<210> 9711

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9711

cacuuagcua ccauccugcc 20

<210> 9712

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9712

acuuagcuac cauccuccu 20

<210> 9713

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9713

ugccugggcu gccagagcuc 20

<210> 9714

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9714

ugguuguggc ucaagcuugg 20

<210> 9715

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9715

cugguugugg cucaagcuug 20

<210> 9716

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9716

ucugguugug gcucaagcuu 20

<210> 9717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9717

aucugguugu ggcucaagcu 20

<210> 9718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9718

cagcgucucc aaucugguug 20

<210> 9719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9719

ggacaccagc gucuccaauc 20

<210> 9720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9720

gcaggauggu agcuaagugc 20

<210> 9721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9721

cucuggcagc ccaggcagga 20

<210> 9722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9722

ugagcucugg cagcccaggc 20

<210> 9723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9723

uuccugagcu cuggcagccc 20

<210> 9724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9724

cacucuaucu uccugagcuc 20

<210> 9725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9725

ccccccuccc acagccucuc 20

<210> 9726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9726

cccccucca cagccucuca 20

<210> 9727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9727

gggaauagca ucagcucagc 20

<210> 9728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9728

ggaauagcau cagcucagcc 20

<210> 9729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9729

gaauagcauc agcucagccg 20

<210> 9730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9730

aauagcauca gcucagccgg 20

<210> 9731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9731

cucagccgggggagugcagu 20

<210> 9732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9732

cagagucucu cguucuuugc 20

<210> 9733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9733

ucucguucuu ugcaggcgcc 20

<210> 9734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9734

cguucuuugc aggcgccugg 20

<210> 9735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9735

guugauguga gugucugccc 20

<210> 9736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9736

gaugugagug ucugcccagg 20

<210> 9737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9737

ccugagaggc ugugggagg 20

<210> 9738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9738

cccugagagg cugugggagg 20

<210> 9739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9739

ucccugag gcugggggag 20

<210> 9740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9740

uucccugaga ggcuggggga 20

<210> 9741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9741

auucccugag aggcugggg 20

<210> 9742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9742

gcuauucccu gagaggcugu 20

<210> 9743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9743

ugcuauuccc ugagaggcug 20

<210> 9744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9744

agcugaugcu auucccugag 20

<210> 9745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9745

cucugccaac ugcacucccc 20

<210> 9746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9746

acacucacau caacuccucc 20

<210> 9747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9747

uuccucuccu cuuccaggcu 20

<210> 9748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9748

caggcuuggc ugcaaugcc 20

<210> 9749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9749

aggcuuggcu gcaaugcccu 20

<210> 9750

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9750

ggcuuggcug caaugccug 20

<210> 9751

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9751

gcuuggcugc aaugccuggg 20

<210> 9752

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9752

ccugggggau cccacagccc 20

<210> 9753

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9753

cugggggauc ccacagcccu 20

<210> 9754

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9754

ugggggaucc cacagcccug 20

<210> 9755

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9755

ggaucccaca gcccuggggc 20

<210> 9756

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9756

cacagccug gggcuggcuc 20

<210> 9757

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9757

aggagcugcc ccagcaccug 20

<210> 9758

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9758

ggagcugccc cagcaccuga 20

<210> 9759

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9759

ccugaggguc cuacagugag 20

<210> 9760

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9760

agccaagccu ggaagaggag 20

<210> 9761

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9761

auugcagcca agcuggaag 20

<210> 9762

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9762

cagggcauug cagccaagcc 20

<210> 9763

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9763

cagggcugug ggauccccca 20

<210> 9764

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9764

ccaggggcugu gggauccccc 20

<210> 9765

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9765

ugagccagcc cggggcugu 20

<210> 9766

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9766

cugaggccagc cccagggcug 20

<210> 9767

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9767

cagcuccuga gccagcccca 20

<210> 9768

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9768

gcagcuccug agccagcccc 20

<210> 9769

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9769

uguaggaccc ucaggugcug 20

<210> 9770

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9770

cuguaggacc cucaggugcu 20

<210> 9771

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9771

acuguaggac ccucaggugc 20

<210> 9772

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9772

ccacucacug uaggacccuc 20

<210> 9773

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9773

ggcaggggggc cacucacugu 20

<210> 9774

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9774

cagccuacca uucagccauc 20

<210> 9775

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9775

agccuaccau ucagccaucu 20

<210> 9776

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9776

ccauucagcc aucugggccc 20

<210> 9777

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9777

uucagccauc ugggcccagg 20

<210> 9778

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9778

ucagccaucu gggcccaggu 20

<210> 9779

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9779

cagccaucug ggcccaggug 20

<210> 9780

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9780

cccaggggg gcccugagcc 20

<210> 9781

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9781

uggggccug agccuggccc 20

<210> 9782

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9782

ccugagccug gcccaggccc 20

<210> 9783

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9783

agccuggccc agcccugga 20

<210> 9784

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9784

ccuggaugga uccccccauu 20

<210> 9785

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9785

ccccccauuu ggaagagauc 20

<210> 9786

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9786

uuggaagaga ucagguaagu 20

<210> 9787

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9787

uggaagagau cagguaagua 20

<210> 9788

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9788

ggaagauc agguaaguag 20

<210> 9789

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9789

uaggcugggg aaagaggaga 20

<210> 9790

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9790

guaggcuggg gaaagaggag 20

<210> 9791

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9791

gaaugguagg cuggggaaag 20

<210> 9792

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9792

gauggcugaa ugguaggcug 20

<210> 9793

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9793

agauggcuga ugguaggcu 20

<210> 9794

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9794

cagauggcug aaugguaggc 20

<210> 9795

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9795

ggcccagaug gcugaauggu 20

<210> 9796

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9796

ccugggccca gauggcugaa 20

<210> 9797

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9797

gggccccacc ugggcccaga 20

<210> 9798

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9798

ccaggcucag ggccccaccu 20

<210> 9799

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9799

gccaggcuca gggccccacc 20

<210> 9800

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9800

cagggccugg gccaggcuca 20

<210> 9801

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9801

ccaggggcug ggccaggcuc 20

<210> 9802

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9802

auccauccag ggccugggcc 20

<210> 9803

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9803

ggggaucca uccaggggccu 20

<210> 9804

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9804

ggggggaucc aucggggcc 20

<210> 9805

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9805

caaaugggggg gauccaucca 20

<210> 9806

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9806

ccaaauggggggauccaucc 20

<210> 9807

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9807

ccugaucucu uccaaauggg 20

<210> 9808

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9808

accugaucuc uuccaaaugg 20

<210> 9809

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9809

uaccuaucu cuuccaaaug 20

<210> 9810

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9810

uuaccugauc ucuuccaaau 20

<210> 9811

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9811

cuuaccuau cucuuccaaa 20

<210> 9812

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9812

aucuccccua cccugcagcu 20

<210> 9813

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9813

uccccuaccc ugcagcuugg 20

<210> 9814

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9814

cagcuuggcg gaaaacaacc 20

<210> 9815

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9815

uuggcggaaa acaaccuggc 20

<210> 9816

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9816

gcggaaaaca accuggcugg 20

<210> 9817

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9817

cggaaaacaa ccuggcugga 20

<210> 9818

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9818

ggaaaacaac cuggcuggag 20

<210> 9819

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9819

agggguccug cguuucugua 20

<210> 9820

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9820

uccgccaagc ugcaggguag 20

<210> 9821

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9821

uuccgccaag cugcagggua 20

<210> 9822

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9822

uuuccgccaa gcugcagggu 20

<210> 9823

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9823

uuguuuuccg ccaagcugca 20

<210> 9824

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9824

guuguuuucc gccaagcugc 20

<210> 9825

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9825

aacgcaggac cccuccagcc 20

<210> 9826

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9826

ggagcuccau acagaaacgc 20

<210> 9827

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9827

acucuaucug ucugagcagc 20

<210> 9828

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9828

uacucuaucu gucugagcag 20

<210> 9829

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9829

gcccuucucc auccccagcc 20

<210> 9830

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9830

ugucaaucuu acaggaaacc 20

<210> 9831

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9831

agucugguug ucaaucuuac 20

<210> 9832

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9832

aggugaggag cuuggcaguc 20

<210> 9833

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9833

gaagcuggag gugaggagcu 20

<210> 9834

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9834

agcuggugaa gcuggaggug 20

<210> 9835

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9835

agggcagcuc gugaagcugg 20

<210> 9836

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9836

ggcaggggcag cucgugaagc 20

<210> 9837

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9837

uguucuaaug aagcaggca 20

<210> 9838

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9838

guguucuaau gaagcagggc 20

<210> 9839

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9839

gugaguguuc uaaugaagca 20

<210> 9840

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9840

agugaguguu cuaaugaagc 20

<210> 9841

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9841

cccuacccug caggcugucc 20

<210> 9842

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9842

aggcuguccu ggaaucuccu 20

<210> 9843

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9843

ggcuguccug gaaucuccuc 20

<210> 9844

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9844

gcuguccugg aaucuccucg 20

<210> 9845

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9845

cuggaaucuc cucggggaug 20

<210> 9846

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9846

ggaugaggca gcugccgagc 20

<210> 9847

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9847

ggcagcugcc gagcuggccc 20

<210> 9848

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9848

ggcccaggug cugccgcaga 20

<210> 9849

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9849

gcccaggugc ugccgcagau 20

<210> 9850

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9850

aggugcugcc gcagaugggc 20

<210> 9851

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9851

gaugggccgg cugaagagag 20

<210> 9852

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9852

gcugaagaga guggaguaug 20

<210> 9853

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9853

cugaagagag uggaguauga 20

<210> 9854

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9854

ugaagagagu ggaguaugag 20

<210> 9855

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9855

gagaguggag uaugaggggc 20

<210> 9856

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9856

agguggagu augaggggcc 20

<210> 9857

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9857

gaguggagua ugaggggccg 20

<210> 9858

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9858

aguggaguau gaggggccgg 20

<210> 9859

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9859

ggaguaugag gggccggggg 20

<210> 9860

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9860

caggacagcc ugcaggguag 20

<210> 9861

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9861

ccaggacagc cugcagggua 20

<210> 9862

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9862

uccaggacag ccugcagggu 20

<210> 9863

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9863

agauuccagg acagccugca 20

<210> 9864

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9864

gagauuccag gacagccugc 20

<210> 9865

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9865

cucauccccg aggagauucc 20

<210> 9866

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9866

cggcagcugc cucauccccg 20

<210> 9867

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9867

cggcagcacc ugggccagcu 20

<210> 9868

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9868

gcccaucugc ggcagcaccu 20

<210> 9869

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9869

ggcccaucug cggcagcacc 20

<210> 9870

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9870

cucuucagcc ggcccaucug 20

<210> 9871

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9871

cauacuccac ucucuucagc 20

<210> 9872

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9872

ucacugucca cugagaagcc 20

<210> 9873

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9873

gaagaaucag aucacagcuu 20

<210> 9874

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9874

aagaaucaga ucacagcuuu 20

<210> 9875

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9875

agaaucagau cacagcuuug 20

<210> 9876

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9876

gaaucagauc acagcuuugg 20

<210> 9877

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9877

agaucacagc uuuggggggcc 20

<210> 9878

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9878

agcuuugggg gccuggcucc 20

<210> 9879

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9879

ggggccuggc uccuggcuga 20

<210> 9880

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9880

cuggcuccug gcugaaggac 20

<210> 9881

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9881

ccuggcugaa ggacuggccc 20

<210> 9882

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9882

cuggcugaag gacuggccca 20

<210> 9883

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9883

uggcugaagg acuggcccag 20

<210> 9884

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9884

ggucuagcau ccaagucauc 20

<210> 9885

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9885

uccaagucau ccgguaacag 20

<210> 9886

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9886

auccgguaac agaggccugc 20

<210> 9887

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9887

uccgguaaca gaggccugca 20

<210> 9888

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9888

ccgguaacag aggccugcag 20

<210> 9889

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9889

aggcuucuca guggacagug 20

<210> 9890

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9890

uucuucucca ggcuucucag 20

<210> 9891

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9891

cugugaucug auucuucucc 20

<210> 9892

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9892

caguccuuca gccaggagcc 20

<210> 9893

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9893

ccugggccag uccuucagcc 20

<210> 9894

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9894

gacuuggaug cuagaccccu 20

<210> 9895

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9895

ugacuuggau gcuagacccc 20

<210> 9896

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9896

gccucuguua ccggaugacu 20

<210> 9897

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9897

ccccugcagg ccucuguuac 20

<210> 9898

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9898

uaucugugcc ccacagccuc 20

<210> 9899

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9899

uaaccccauu ccgcgaca 20

<210> 9900

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9900

ggccagcac cugaagagcc 20

<210> 9901

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9901

accugaagag ccaggagccc 20

<210> 9902

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9902

gaagagccag gagcccaggc 20

<210> 9903

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9903

cuucuuugac aaccagcccc 20

<210> 9904

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9904

acaaccagcc ccaggccccu 20

<210> 9905

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9905

caaccagccc caggccccuu 20

<210> 9906

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9906

aaccagcccc aggccccuug 20

<210> 9907

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9907

aggccccuug ggguacuuga 20

<210> 9908

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9908

gauggccccc ucaagaccuu 20

<210> 9909

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9909

augauccacc uuucgcccac 20

<210> 9910

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9910

ugauccaccu uucgcccacu 20

<210> 9911

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9911

cccacggga uaauugacuc 20

<210> 9912

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9912

gacucaggaa agaagagccu 20

<210> 9913

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9913

caggaaagaa gagccucggc 20

<210> 9914

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9914

aggaaagaag agccucggca 20

<210> 9915

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9915

gggcgcucug cacuccaccc 20

<210> 9916

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9916

cgcucugcac uccacccagg 20

<210> 9917

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9917

cugcacucca cccaggagga 20

<210> 9918

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9918

uguguccucc ugcaguccuc 20

<210> 9919

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9919

guguccugcu gcaguccuca 20

<210> 9920

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9920

guccucaggg agaacuuuuu 20

<210> 9921

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9921

uccucaggga gaacuuuuuu 20

<210> 9922

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9922

ggagaacuuuuuugggaacc 20

<210> 9923

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9923

cuuuuuuggg aaccaggagc 20

<210> 9924

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9924

uuuuuuggga accaggagcu 20

<210> 9925

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9925

ugggaaccag gagcuggguc 20

<210> 9926

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9926

caggagcugg gucuggacaa 20

<210> 9927

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9927

aaggaguacc cugcauuacg 20

<210> 9928

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9928

aggaguaccc ugcauuacgu 20

<210> 9929

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9929

gugggauaug ugugaucau 20

<210> 9930

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9930

uggauaugugugaucaauu 20

<210> 9931

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9931

ggauauugugugaucaauug 20

<210> 9932

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9932

gggacaugcg acacacaaug 20

<210> 9933

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9933

ggacaugcga cacacaauga 20

<210> 9934

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9934

augacaaugc augacacgua 20

<210> 9935

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9935

augacacgua cgguuauaug 20

<210> 9936

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9936

cagugugacc ccuugacaug 20

<210> 9937

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9937

gcguuacaug aaagucagug 20

<210> 9938

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9938

ucaguguggc acguguucug 20

<210> 9939

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9939

guggcacgug uucuguggca 20

<210> 9940

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9940

uggcacgugu ucuguggcau 20

<210> 9941

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9941

guguucugug gcaugggugc 20

<210> 9942

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9942

gugcuggcau cccaaguagc 20

<210> 9943

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9943

guagcaggau acaugauugu 20

<210> 9944

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9944

augacaaaug uccaugucac 20

<210> 9945

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9945

uguccauguc acaggacuca 20

<210> 9946

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9946

caugucacag gacucauggc 20

<210> 9947

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9947

auggcuggcc agaugaccuc 20

<210> 9948

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9948

cuggccagau gaccucaggc 20

<210> 9949

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9949

auauuuauag auugugugua 20

<210> 9950

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9950

guguauggag cagcuaaguc 20

<210> 9951

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9951

gaaaagucuu ccgcccgagc 20

<210> 9952

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9952

aaaagucuuc cgcccgagcu 20

<210> 9953

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9953

agucuuccgc ccgagcuggg 20

<210> 9954

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9954

gucuuccgcc cgagcuggga 20

<210> 9955

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9955

ucuuccgccc gagcugggag 20

<210> 9956

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9956

guccaugcac ugaccagucc 20

<210> 9957

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9957

uccaugcacu gaccagucca 20

<210> 9958

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9958

ccaugcacug accaguccag 20

<210> 9959

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9959

cugaccaguc caggggcuca 20

<210> 9960

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9960

ugaccagucc aggggcucaa 20

<210> 9961

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9961

aguccagggg cucaagggcc 20

<210> 9962

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9962

guccaggggc ucaagggcca 20

<210> 9963

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9963

gggcucaagg gccagggcuc 20

<210> 9964

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9964

ccagggcucu ggaacaagcc 20

<210> 9965

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9965

cagggcucug gaacaagcca 20

<210> 9966

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9966

uacuuacaua cuagcuucca 20

<210> 9967

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9967

acauacuagc uuccaaggac 20

<210> 9968

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9968

uacuagcuuc caaggacagg 20

<210> 9969

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9969

uagcuuccaa ggacaggugg 20

<210> 9970

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9970

uuccaaggac agguggaggu 20

<210> 9971

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9971

uccaaggaca gguggaggua 20

<210> 9972

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9972

agguggaggu aggggccagcc 20

<210> 9973

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9973

uggagguagg gccagccugg 20

<210> 9974

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9974

ggagguaggg ccagccuggc 20

<210> 9975

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9975

uagggccagc cuggcgggag 20

<210> 9976

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9976

agcccagucu guccuaugua 20

<210> 9977

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9977

gccagucug uccuauguaa 20

<210> 9978

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9978

ccuauguaag ggacaaagcc 20

<210> 9979

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9979

agggacaaag ccaggucuaa 20

<210> 9980

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9980

aaagccaggu cuaaugguac 20

<210> 9981

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9981

aagccagguc uaaugguacu 20

<210> 9982

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9982

caggucuaau gguacugggu 20

<210> 9983

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9983

aggucuaug guacugggua 20

<210> 9984

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9984

ggucuaugg uacuggguag 20

<210> 9985

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9985

gucuaauggu acggguagg 20

<210> 9986

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9986

cacugccaag acauaagcu 20

<210> 9987

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9987

aagacaauaa gcuaggcuac 20

<210> 9988

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9988

agacaauaag cuaggcuacu 20

<210> 9989

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9989

acugggucca gcuacuacuu 20

<210> 9990

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9990

ggguccagcu acuacuuugg 20

<210> 9991

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9991

gguccagcua cuacuuuggu 20

<210> 9992

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9992

cuacuacuuu ggugggauuc 20

<210> 9993

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9993

caguguucuu guuacuucca 20

<210> 9994

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9994

cuuccaagga gaaccaagaa 20

<210> 9995

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9995

gcucugucac acucgaagcc 20

<210> 9996

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9996

ggcuugauca auaaacacaa 20

<210> 9997

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9997

aggcuggggggcacagauau 20

<210> 9998

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9998

ggguuauucc agaggcugug 20

<210> 9999

<211> 20

<212> RNA

<213> Homo sapiens

<400> 9999

gggguuauuc cagaggcugu 20

<210> 10000

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10000

ugggguuauu ccagaggcug 20

<210> 10001

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10001

agggaauggg guuauuccag 20

<210> 10002

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10002

gggccauguc gcagggaaug 20

<210> 10003

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10003

uggggcaugu cgcagggaau 20

<210> 10004

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10004

cugggccaug ucgcagggaa 20

<210> 10005

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10005

aggugcuggg ccaugucgca 20

<210> 10006

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10006

caggugcugg gccaugucgc 20

<210> 10007

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10007

cuccuggcuc uucaggugcu 20

<210> 10008

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10008

gcuccuggcu cuucaggugc 20

<210> 10009

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10009

gccugggcuc cuggcucuuc 20

<210> 10010

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10010

caaaguccag ccugggcucc 20

<210> 10011

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10011

aagaaggcaa aguccagccu 20

<210> 10012

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10012

aaagaaggca aaguccagcc 20

<210> 10013

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10013

cuggggcugg uugucaaaga 20

<210> 10014

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10014

uaccccaagg ggccuggggc 20

<210> 10015

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10015

caaguacccc aaggggccug 20

<210> 10016

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10016

ucaaguaccc caaggggccu 20

<210> 10017

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10017

aucaaguacc ccaaggggcc 20

<210> 10018

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10018

gggccaucaa guaccccaag 20

<210> 10019

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10019

ggggccauca aguaccccaa 20

<210> 10020

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10020

gggggccauc aaguacccca 20

<210> 10021

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10021

ggauuccaaa ggucuugagg 20

<210> 10022

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10022

uggauuccaa aggucuugag 20

<210> 10023

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10023

cuggauucca aaggucuuga 20

<210> 10024

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10024

gcuggauucc aaaggucuug 20

<210> 10025

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10025

aucacuuggc uggauuccaa 20

<210> 10026

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10026

auuugggugc aucacuuggc 20

<210> 10027

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10027

gaucauuugg gugcaucacu 20

<210> 10028

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10028

gggcgaaagg uggaucauuu 20

<210> 10029

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10029

ugggcgaaag guggaucauu 20

<210> 10030

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10030

uuaucccagu gggcgaaagg 20

<210> 10031

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10031

caauuauccc aggggcgaa 20

<210> 10032

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10032

ccugagucaa uuaucccagu 20

<210> 10033

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10033

uccugaguca auuaucccag 20

<210> 10034

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10034

gagugcagag cgcccugccg 20

<210> 10035

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10035

cacguauccu uccuccuggg 20

<210> 10036

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10036

acacacguau ccuuccuccu 20

<210> 10037

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10037

gacacacgua uccuuccucc 20

<210> 10038

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10038

uucucccuga ggacugcagc 20

<210> 10039

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10039

ucccaaaaaa guucucccug 20

<210> 10040

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10040

cuuuguccag acccagcucc 20

<210> 10041

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10041

cacauauccc acguaaugca 20

<210> 10042

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10042

acacauaucc cacguaaugc 20

<210> 10043

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10043

auguaacgcc acaugucaag 20

<210> 10044

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10044

cauguaacgc cacaugucaa 20

<210> 10045

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10045

ucauguaacg ccacauguca 20

<210> 10046

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10046

aaucauguau ccugcuacuu 20

<210> 10047

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10047

caaucaugua uccucuacu 20

<210> 10048

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10048

cagccaugag uccugugaca 20

<210> 10049

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10049

ugggccagcc ugaggucauc 20

<210> 10050

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10050

uuagaucuug ggccagccug 20

<210> 10051

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10051

aaauuaauaaauuagaucuu 20

<210> 10052

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10052

aaaauuaaua aauuagaucu 20

<210> 10053

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10053

cucuccccuc ccagcucggg 20

<210> 10054

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10054

acacucuccc cuccagcuc 20

<210> 10055

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10055

gacacucucc ccucccagcu 20

<210> 10056

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10056

ccccuggacu ggucagugca 20

<210> 10057

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10057

uggcccuuga gccccuggac 20

<210> 10058

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10058

agccggcc cuugagcccc 20

<210> 10059

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10059

ccuggcuugu uccagagccc 20

<210> 10060

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10060

ggacuuaaug gcugaguccc 20

<210> 10061

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10061

ugaggcagga ggggacuuaa 20

<210> 10062

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10062

gcugaggauu gaggcaggag 20

<210> 10063

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10063

ggcugaggau ugaggcagga 20

<210> 10064

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10064

aggcugga uugaggcagg 20

<210> 10065

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10065

gguaggcuga ggauugaggc 20

<210> 10066

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10066

gauggguagg cugaggauug 20

<210> 10067

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10067

guuuauagau ggguaggcug 20

<210> 10068

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10068

caucaaguuu auagaugggu 20

<210> 10069

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10069

gagucaucaa guuuauagau 20

<210> 10070

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10070

ggagucauca aguuuauaga 20

<210> 10071

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10071

agcuaguaug uaaguaaggg 20

<210> 10072

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10072

ggaagcuagu auguaaguaa 20

<210> 10073

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10073

uggaagcuag uauguaagua 20

<210> 10074

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10074

gcccuaccuc caccuguccu 20

<210> 10075

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10075

cuucuccacu ccgccaggc 20

<210> 10076

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10076

uggcuucuc cacucccgcc 20

<210> 10077

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10077

ucccuuacau aggacagacu 20

<210> 10078

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10078

gucccuuaca uaggacagac 20

<210> 10079

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10079

ccuggcuuug ucccuuacau 20

<210> 10080

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10080

cuacccagua ccauuagacc 20

<210> 10081

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10081

aguagccuag cuuauugucu 20

<210> 10082

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10082

aaucccacca aaguaguagc 20

<210> 10083

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10083

uggguaacau gugaagugca 20

<210> 10084

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10084

uuggaaguaa caagaacacu 20

<210> 10085

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10085

cuuggaagua acaagaacac 20

<210> 10086

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10086

gagccauucu ugguucuccu 20

<210> 10087

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10087

gagugugaca gagccauucu 20

<210> 10088

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10088

uuguguuuau ugaucaagcc 20

<210> 10089

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10089

cauuggauuc acgcuagacg 20

<210> 10090

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10090

uaaaaagggg aaguuaagag 20

<210> 10091

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10091

gaaguuaaga ggggacuauu 20

<210> 10092

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10092

cugccacacg cagcucagcc 20

<210> 10093

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10093

ugccacacgc agcucagccu 20

<210> 10094

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10094

cacacgcagc ucagccuggg 20

<210> 10095

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10095

aucugagucu gccugcagca 20

<210> 10096

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10096

gucugccugc agcauggacc 20

<210> 10097

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10097

ucugccugca gcauggaccu 20

<210> 10098

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10098

gucuucccug aagcaucucc 20

<210> 10099

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10099

ucuuccuga agcaucucca 20

<210> 10100

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10100

cccugaagca ucuccagggc 20

<210> 10101

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10101

ugaagcaucu ccagggcugg 20

<210> 10102

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10102

gaagcaucuc cagggcugga 20

<210> 10103

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10103

ggcuggaggg acgacugcca 20

<210> 10104

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10104

gagggacgac ugccauggua 20

<210> 10105

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10105

cuuucuugac acuggauugu 20

<210> 10106

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10106

ucuuucuuga cacuggauug 20

<210> 10107

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10107

guugacuucu uucuugacac 20

<210> 10108

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10108

aagagaaaug cagggaaaua 20

<210> 10109

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10109

gaagagaaau gcagggaaau 20

<210> 10110

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10110

gagcacagaa gagaaaugca 20

<210> 10111

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10111

ugagcacaga agagaaaugc 20

<210> 10112

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10112

cgcccaggcu gagcugcgug 20

<210> 10113

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10113

cgcaucuggc ugugccgccc 20

<210> 10114

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10114

gcagagacgc aucucgcauc 20

<210> 10115

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10115

aagacccagg uccaugcugc 20

<210> 10116

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10116

agaugcuuca gggaagaccc 20

<210> 10117

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10117

ccagcccugg agaugcuuca 20

<210> 10118

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10118

uccagcccug gagaugcuuc 20

<210> 10119

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10119

ggcagucguc ccuccagccc 20

<210> 10120

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10120

guguugugg guccuuacca 20

<210> 10121

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10121

ucucuauccu gccagcaccg 20

<210> 10122

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10122

cucuauccug ccagcaccga 20

<210> 10123

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10123

ggcucaucca uccacagagc 20

<210> 10124

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10124

gcucauccau ccacagagca 20

<210> 10125

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10125

ccauccacag agcaggggcag 20

<210> 10126

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10126

cauccacaga gcagggcagu 20

<210> 10127

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10127

ccacagagca gggcagggg 20

<210> 10128

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10128

cgccaugacc cccauccuca 20

<210> 10129

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10129

cucacgggucc ugaucugucu 20

<210> 10130

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10130

gucucgguga gauuugaaga 20

<210> 10131

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10131

ucggugau uugaagaagg 20

<210> 10132

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10132

gaugagcccu cggugcuggc 20

<210> 10133

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10133

guggaugag cccucggugc 20

<210> 10134

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10134

ucuguggaug gaugagcccu 20

<210> 10135

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10135

ccacugcccu gcucugga 20

<210> 10136

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10136

cccccacug cccugcucug 20

<210> 10137

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10137

gaccgugagg auggggguca 20

<210> 10138

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10138

gaucaggacc gugaggaugg 20

<210> 10139

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10139

agaucaggac cgugaggaug 20

<210> 10140

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10140

cagaucagga ccgugaggau 20

<210> 10141

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10141

acagaucagg accgugagga 20

<210> 10142

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10142

cgagacagau caggaccgug 20

<210> 10143

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10143

aaaucucacc gagacagauc 20

<210> 10144

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10144

cucucuucca gggcugaguc 20

<210> 10145

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10145

ucucuuccag ggcugagucu 20

<210> 10146

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10146

cagggcugag ucugggcccc 20

<210> 10147

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10147

gggcccccgg acccacgugc 20

<210> 10148

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10148

ccccggaccc acgugcaggc 20

<210> 10149

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10149

cagccugga agagaguucc 20

<210> 10150

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10150

cgggggccca gacucagccc 20

<210> 10151

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10151

cugccugcac guggguccgg 20

<210> 10152

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10152

ccugccugca cguggguccg 20

<210> 10153

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10153

accugccugc accgugggucc 20

<210> 10154

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10154

caccugccug cacguggguc 20

<210> 10155

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10155

agacucaccu gccugcacgu 20

<210> 10156

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10156

cagacucacc ugccugcacg 20

<210> 10157

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10157

accuccccaa gccacccuc 20

<210> 10158

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10158

cccccccaag cccacccucu 20

<210> 10159

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10159

cccacccucu gggcugaacc 20

<210> 10160

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10160

accaggcucugugaucaccc 20

<210> 10161

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10161

ccaggcucug ugaucaccca 20

<210> 10162

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10162

caggcucugu gaucacccag 20

<210> 10163

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10163

aggggagucc ugugacccuc 20

<210> 10164

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10164

uccugugacc cucagguguc 20

<210> 10165

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10165

ccugugaccc ucagguguca 20

<210> 10166

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10166

cugugacccu caggugucag 20

<210> 10167

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10167

ugugacccuc aggugucagg 20

<210> 10168

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10168

gugacccuca ggugucaggg 20

<210> 10169

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10169

ccucaggugucaggggggcc 20

<210> 10170

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10170

ucaggggggc caggagaccc 20

<210> 10171

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10171

gagaaaagaa aacagcaccc 20

<210> 10172

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10172

aaacagcacc cuggauuaca 20

<210> 10173

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10173

cuggauuaca cggauccac 20

<210> 10174

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10174

cccacaggag cuugugaaga 20

<210> 10175

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10175

ccacaggagc uugugaagaa 20

<210> 10176

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10176

ucccauccc auccaucacc 20

<210> 10177

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10177

ccccauccca uccaucaccu 20

<210> 10178

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10178

uccaucaccu gggaacacac 20

<210> 10179

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10179

ccaucaccug ggaacacaca 20

<210> 10180

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10180

ucaccggga acacacaggg 20

<210> 10181

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10181

gggcgguauc gcuguuacua 20

<210> 10182

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10182

uacuauggua gcgacacugc 20

<210> 10183

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10183

cucagagagc agugaccccc 20

<210> 10184

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10184

gagcagugac ccccuggagc 20

<210> 10185

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10185

cagugacccc cuggagcugg 20

<210> 10186

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10186

ccccuggagc uggggugac 20

<210> 10187

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10187

ugacagguga gcugacacuc 20

<210> 10188

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10188

gacaggugag cugacacuca 20

<210> 10189

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10189

acaggugagc ugacacucag 20

<210> 10190

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10190

aggugccug gaaggaaauc 20

<210> 10191

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10191

gcuggggag gugcccugga 20

<210> 10192

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10192

gugggcuugg ggaggugccc 20

<210> 10193

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10193

cccagagggu gggcuugggg 20

<210> 10194

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10194

cagccgagggugggcuug 20

<210> 10195

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10195

ucagcccaga gggugggcuu 20

<210> 10196

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10196

uucagcccag aggggggcu 20

<210> 10197

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10197

ccugguucag ccgagggu 20

<210> 10198

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10198

gccugguuca gccgagggg 20

<210> 10199

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10199

agagccuggu ucagcccaga 20

<210> 10200

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10200

cagagccugg uucagcccag 20

<210> 10201

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10201

ccgggguga ucacagagcc 20

<210> 10202

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10202

gagggucaca ggacuccccu 20

<210> 10203

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10203

ugagggucac aggacucccc 20

<210> 10204

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10204

cccugacacc ugagggucac 20

<210> 10205

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10205

cuggcccccc ugacaccuga 20

<210> 10206

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10206

ccuggccccc cugacaccug 20

<210> 10207

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10207

gacgguacuc cugggucucc 20

<210> 10208

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10208

ucuauauaga cgguaacuccu 20

<210> 10209

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10209

cucuauauag acgguacucc 20

<210> 10210

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10210

uuuucuuuuc ucuauauaga 20

<210> 10211

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10211

uggggaucc guguaaucca 20

<210> 10212

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10212

cugggggauc cguguaaucc 20

<210> 10213

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10213

ccuucuucac aagcuccugu 20

<210> 10214

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10214

cccuucuuca caagcuccug 20

<210> 10215

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10215

ugaggaugg gaugggaac 20

<210> 10216

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10216

cccaggugau ggaugggaug 20

<210> 10217

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10217

ucccagguga uggaugggau 20

<210> 10218

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10218

uucccaggug uggauggga 20

<210> 10219

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10219

uguguuccca ggugauggau 20

<210> 10220

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10220

guguguuccc aggugaugga 20

<210> 10221

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10221

cccugugugu ucccagguga 20

<210> 10222

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10222

auaccgcccu guguguuccc 20

<210> 10223

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10223

gggggucacu gcucucugag 20

<210> 10224

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10224

cugcuccagg 20

<210> 10225

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10225

ccugucacca cgcuccag 20

<210> 10226

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10226

accugucacc accagcucca 20

<210> 10227

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10227

caccugucac caccagcucc 20

<210> 10228

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10228

cucagcccag cccagccccg 20

<210> 10229

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10229

cccagccccg uggugaacuc 20

<210> 10230

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10230

agccccgugg ugaacucagg 20

<210> 10231

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10231

gccccguggu gaacucagga 20

<210> 10232

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10232

aacccuccag ugugacucac 20

<210> 10233

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10233

ccuccagugugacucacagg 20

<210> 10234

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10234

gacucacagg uggcauuuga 20

<210> 10235

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10235

ugaggcuuc auucugugua 20

<210> 10236

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10236

ggcuucauuc uguguaagga 20

<210> 10237

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10237

aacucccagc cccaugcccg 20

<210> 10238

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10238

acuccagcc ccaugcccgu 20

<210> 10239

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10239

gucccgcgcc aucuucuccg 20

<210> 10240

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10240

ucccgcgcca ucucuccgu 20

<210> 10241

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10241

gccccgugag cccgagucgc 20

<210> 10242

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10242

ccgugagcccgagucgcagg 20

<210> 10243

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10243

ugagcccgag ucgcaggugg 20

<210> 10244

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10244

cgagucgcag guggugguac 20

<210> 10245

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10245

acucgaacuc ucccuaugag 20

<210> 10246

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10246

gucucuaccc agugaucucc 20

<210> 10247

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10247

cagugaucuc cuggagcucc 20

<210> 10248

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10248

cuccuggagc uccugguccu 20

<210> 10249

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10249

uaggcuccua ggagagaagg 20

<210> 10250

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10250

auguaggcuc cuaggagaga 20

<210> 10251

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10251

uggguuugau guaggcuccu 20

<210> 10252

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10252

ugagagggg gguuugaugu 20

<210> 10253

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10253

cugggcuggg cugagagggu 20

<210> 10254

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10254

gcugggcugg gcugagaggg 20

<210> 10255

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10255

ggggcugggc ugggcugaga 20

<210> 10256

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10256

cggggcuggg cugggcugag 20

<210> 10257

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10257

guucaccacg gggcugggcu 20

<210> 10258

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10258

aguucaccac ggggcugggc 20

<210> 10259

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10259

ccugaguuca ccacggggcu 20

<210> 10260

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10260

uccugaguuc accacggggc 20

<210> 10261

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10261

ucccuccuga guucaccacg 20

<210> 10262

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10262

uucccuccug aguucaccac 20

<210> 10263

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10263

auucccuccu gaguucacca 20

<210> 10264

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10264

caccugugag ucacacugga 20

<210> 10265

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10265

ccaccuguga gucacacugg 20

<210> 10266

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10266

augccaccug ugagucacac 20

<210> 10267

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10267

gcugggaguu caggcauugu 20

<210> 10268

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10268

ggcgggagu ucaggcauug 20

<210> 10269

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10269

gggcaugggg cugggaguuc 20

<210> 10270

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10270

cgaccacgg gcauggggcu 20

<210> 10271

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10271

acgacccg ggcauggggc 20

<210> 10272

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10272

cgggacgacc cacggggcaug 20

<210> 10273

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10273

gcgggacgac ccacgggcau 20

<210> 10274

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10274

cgcgggacga cccacgggca 20

<210> 10275

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10275

gauggcgcgg gacgacccac 20

<210> 10276

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10276

agauggcgcg ggacgaccca 20

<210> 10277

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10277

gccccggag aagauggcgc 20

<210> 10278

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10278

ggcccggga gaagauggcg 20

<210> 10279

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10279

cacggggccc acggagaaga 20

<210> 10280

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10280

acucgggcuc acggggccca 20

<210> 10281

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10281

accugcgacu cgggcucacg 20

<210> 10282

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10282

caccugcgac ucgggcucac 20

<210> 10283

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10283

ccaccugcga cucgggcuca 20

<210> 10284

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10284

uguaccacca ccugcgacuc 20

<210> 10285

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10285

cuguaccacc accugcgacu 20

<210> 10286

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10286

cuggguagag accacucaua 20

<210> 10287

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10287

acggguaga gaccacucau 20

<210> 10288

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10288

aggagcucca ggagaucacu 20

<210> 10289

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10289

caggagcucc aggagaucac 20

<210> 10290

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10290

caccuaggac caggagcucc 20

<210> 10291

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10291

ugaauuucuc accuaggacc 20

<210> 10292

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10292

augcugugaa uuucucaccu 20

<210> 10293

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10293

ccaucacucu cagugcagcc 20

<210> 10294

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10294

agugcagcca gguccuaucg 20

<210> 10295

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10295

agguccuauc guggccccug 20

<210> 10296

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10296

gagacccuga cucugcagug 20

<210> 10297

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10297

cugcagugug gcucugaugc 20

<210> 10298

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10298

caacagauuu guucuguaua 20

<210> 10299

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10299

agauuuguuc uguauaagga 20

<210> 10300

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10300

gauuuguucu guauaaggac 20

<210> 10301

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10301

auuuguucug uauaaggacg 20

<210> 10302

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10302

cgugacuucc uucagcucgc 20

<210> 10303

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10303

gcucgcuggc gcacagcccc 20

<210> 10304

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10304

gcuggcgcac agccccaggc 20

<210> 10305

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10305

cuggcgcaca gccccaggcu 20

<210> 10306

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10306

gccccaggcu gggcucuccc 20

<210> 10307

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10307

cucccaggcc aacuucaccc 20

<210> 10308

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10308

ucccaggcca acuucacccu 20

<210> 10309

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10309

ggccuguga gccgcuccua 20

<210> 10310

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10310

gcccugugag ccgcuccuac 20

<210> 10311

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10311

cccugugagc cgcuccuacg 20

<210> 10312

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10312

ccugugagcc gcuccuacgg 20

<210> 10313

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10313

gggggccagu acagaugcua 20

<210> 10314

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10314

cacacaaccu cuccuccgag 20

<210> 10315

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10315

caaccucucc uccgaguggu 20

<210> 10316

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10316

gucggccccc agcgaccccc 20

<210> 10317

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10317

ccccuggaca uccugaucgc 20

<210> 10318

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10318

ggacauccug aucgcaggug 20

<210> 10319

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10319

aucgcaggug aggagcccag 20

<210> 10320

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10320

ucgcagguga ggagcccagc 20

<210> 10321

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10321

caccugggaa aagguggguca 20

<210> 10322

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10322

uagaaacacc ugggaaaagg 20

<210> 10323

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10323

ucuuagaaac accugggaaa 20

<210> 10324

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10324

auggcuucuu agaaacaccu 20

<210> 10325

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10325

gauggcuucu uagaaacacc 20

<210> 10326

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10326

ccuggcugca cugagaguga 20

<210> 10327

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10327

ucaggggcca cgauaggacc 20

<210> 10328

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10328

gucuccucag gggccacgau 20

<210> 10329

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10329

cagagucagg gucuccucag 20

<210> 10330

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10330

gcagagucag ggucuccuca 20

<210> 10331

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10331

ugcagaguca gggucuccuc 20

<210> 10332

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10332

agagccacac ugcagaguca 20

<210> 10333

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10333

cagagccaca cugcagaguc 20

<210> 10334

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10334

gcugugcgcc agcgagcuga 20

<210> 10335

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10335

gccgggaga gccgccug 20

<210> 10336

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10336

ggccgggag agcccagccu 20

<210> 10337

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10337

uggccuggga gagccgcc 20

<210> 10338

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10338

gccggggug aaguuggccu 20

<210> 10339

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10339

ggcccagggu gaaguuggcc 20

<210> 10340

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10340

cacagggccc aggggugaagu 20

<210> 10341

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10341

ggagcggcuc acagggccca 20

<210> 10342

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10342

aggagcggcu cacagggccc 20

<210> 10343

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10343

ccccguagga gcggcucaca 20

<210> 10344

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10344

cccccguagg agcggcucac 20

<210> 10345

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10345

uguacuggcc cccguaggag 20

<210> 10346

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10346

gcaucuguac uggccccgu 20

<210> 10347

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10347

gugcaccgua gcaucuguac 20

<210> 10348

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10348

gggccgacca cucggaggag 20

<210> 10349

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10349

gcugggggcc gaccuccgg 20

<210> 10350

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10350

gucgcugggg gccgaccacu 20

<210> 10351

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10351

gauguccagg gggucgcugg 20

<210> 10352

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10352

ggauguccag ggggucgcug 20

<210> 10353

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10353

aggaugucca gggggucgcu 20

<210> 10354

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10354

caggaugucc agggggucgc 20

<210> 10355

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10355

cugcgaucag gauguccagg 20

<210> 10356

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10356

ccugcgauca ggauguccag 20

<210> 10357

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10357

accugcgauc aggaugucca 20

<210> 10358

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10358

caccugcgau caggaugucc 20

<210> 10359

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10359

ugggcuccuc accugcgauc 20

<210> 10360

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10360

cuaugacaga gucucccucu 20

<210> 10361

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10361

agucucccuc ucggugcagc 20

<210> 10362

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10362

gucucccucu cggugcagcc 20

<210> 10363

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10363

cucggugcag cggggcccca 20

<210> 10364

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10364

ggugcagccg ggccccgg 20

<210> 10365

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10365

cggggcccca cgguggccuc 20

<210> 10366

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10366

gacccugcug ugucagucac 20

<210> 10367

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10367

acccugugu gucagucaca 20

<210> 10368

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10368

ugcuguguca gucacaggga 20

<210> 10369

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10369

gcaaacuuuc cuucugacca 20

<210> 10370

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10370

aacuuuccuu cugaccaagg 20

<210> 10371

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10371

acuuuccuuc ugaccaagga 20

<210> 10372

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10372

cuuuccuucu gaccaaggag 20

<210> 10373

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10373

uuuccuucug accaaggagg 20

<210> 10374

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10374

aggggcagc ugaugaccca 20

<210> 10375

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10375

guaccaaucu caaaaauacc 20

<210> 10376

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10376

auaccaggcu gaauucccca 20

<210> 10377

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10377

uaccaggcug aauuccccau 20

<210> 10378

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10378

ucugugacc ucagcccaug 20

<210> 10379

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10379

ccugugaccu cagcccaugc 20

<210> 10380

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10380

cugugaccuc agcccaugcg 20

<210> 10381

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10381

cagcccaugc ggggaccuac 20

<210> 10382

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10382

gcggggaccu acaggugcua 20

<210> 10383

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10383

gacucacccc agugaccccc 20

<210> 10384

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10384

cagugacccc cuggagcucg 20

<210> 10385

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10385

ccccggagc ucguggucuc 20

<210> 10386

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10386

cuggagcucg uggucucagg 20

<210> 10387

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10387

uggagcucgu ggucucaggu 20

<210> 10388

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10388

ggagcucgug gucucaggug 20

<210> 10389

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10389

gagcucgugg ucucaggugg 20

<210> 10390

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10390

guccuggaga gaagaaggau 20

<210> 10391

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10391

uguccuggag agaagaagga 20

<210> 10392

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10392

gaacuguccu ggagagaaga 20

<210> 10393

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10393

acucugucau agaacugucc 20

<210> 10394

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10394

ggggcccggc ugcaccgaga 20

<210> 10395

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10395

uggggccgg cugcaccgag 20

<210> 10396

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10396

ccugaggcca ccguggggcc 20

<210> 10397

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10397

ucucuccuga ggccaccgug 20

<210> 10398

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10398

uucucuccug aggccaccgu 20

<210> 10399

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10399

guucucuccu gaggccaccg 20

<210> 10400

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10400

cagggucacg uucucuccug 20

<210> 10401

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10401

ucccugugac ugacacagca 20

<210> 10402

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10402

aucccuguga cugacacagc 20

<210> 10403

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10403

cuggucaga 20

<210> 10404

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10404

gucaucagcu gcccccuccu 20

<210> 10405

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10405

acguugaucu uagacgccau 20

<210> 10406

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10406

uacguugauc uuagacgcca 20

<210> 10407

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10407

cagccuggua uuuuugagau 20

<210> 10408

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10408

gaccauggg gaauucagcc 20

<210> 10409

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10409

cugaggucac aggacccaug 20

<210> 10410

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10410

gcugagguca caggacccau 20

<210> 10411

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10411

ggcugagguc acaggaccca 20

<210> 10412

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10412

cccgcauggg cugaggucac 20

<210> 10413

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10413

guaggucccc gcaugggcug 20

<210> 10414

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10414

gcaccuguag guccccgcau 20

<210> 10415

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10415

agcaccugua gguccccgca 20

<210> 10416

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10416

cugugagccg uagcaccugu 20

<210> 10417

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10417

gugagucagc agguaggguu 20

<210> 10418

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10418

cuggggugag ucagcaggua 20

<210> 10419

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10419

acugggguga gucagcaggu 20

<210> 10420

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10420

ggucacuggg gugagucagc 20

<210> 10421

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10421

cgagcuccag ggggucacug 20

<210> 10422

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10422

acgagcucca gggggucacu 20

<210> 10423

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10423

cacgagcucc agggggucac 20

<210> 10424

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10424

cugagaccac gagcuccagg 20

<210> 10425

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10425

ccugagacca cgagcuccag 20

<210> 10426

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10426

accugagacc acgagcucca 20

<210> 10427

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10427

caccugac cacgagcucc 20

<210> 10428

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10428

uucuuuuacc caggaccguc 20

<210> 10429

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10429

ucuuuuaccc aggaccgucu 20

<210> 10430

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10430

cuuuuaccca ggaccgucug 20

<210> 10431

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10431

uuuuacccag gaccgucugg 20

<210> 10432

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10432

ggccccagcu ccccgacaac 20

<210> 10433

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10433

acaggcccca ccuccacauc 20

<210> 10434

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10434

ccacaucugg ugagucccug 20

<210> 10435

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10435

guccugggua aaagaaugag 20

<210> 10436

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10436

uggggcccc agacgguccu 20

<210> 10437

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10437

cuggggcccc cagacgggucc 20

<210> 10438

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10438

ggggagcugg ggcccccaga 20

<210> 10439

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10439

ggccuguugu cggggagcug 20

<210> 10440

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10440

gggccuguug ucggggagcu 20

<210> 10441

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10441

ggggccuguu gucggggagc 20

<210> 10442

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10442

ggagggggg ccuguugucg 20

<210> 10443

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10443

uggaggggg gccuguuguc 20

<210> 10444

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10444

guggaggugg ggccuguugugu 20

<210> 10445

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10445

acucaccaga uguggaggug 20

<210> 10446

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10446

gacucaccag auguggaggu 20

<210> 10447

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10447

ggacucacca gauguggagg 20

<210> 10448

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10448

cagggacuca ccagaugugg 20

<210> 10449

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10449

ccucagggac ucaccagaug 20

<210> 10450

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10450

ccuccccguc cugacccagc 20

<210> 10451

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10451

uccugaccca gcaggccug 20

<210> 10452

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10452

gaccagcccc ucacccccac 20

<210> 10453

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10453

accagccccu cacccccacc 20

<210> 10454

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10454

gccccucacc cccaccgggu 20

<210> 10455

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10455

accggggcgg auccccagag 20

<210> 10456

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10456

aucccagag uggugaguga 20

<210> 10457

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10457

uccccagagu ggugagugac 20

<210> 10458

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10458

gggugugac gggcucugag 20

<210> 10459

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10459

gugagugacg ggcucugagu 20

<210> 10460

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10460

agugacggggc ucugaggggg 20

<210> 10461

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10461

gacggggcucu gagugggagg 20

<210> 10462

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10462

acgggcucug aggggaggu 20

<210> 10463

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10463

gcucugagug ggaggugggc 20

<210> 10464

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10464

cucugaggugg gaggugggca 20

<210> 10465

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10465

ccugcugggu caggacgggg 20

<210> 10466

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10466

gggccugcug ggucaggacg 20

<210> 10467

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10467

agggccugcu gggucaggac 20

<210> 10468

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10468

cagggccugc ugggucagga 20

<210> 10469

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10469

uccucagggc cugcuggguc 20

<210> 10470

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10470

gcugguccuc agggccugcu 20

<210> 10471

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10471

ggcgguccu cagggccugc 20

<210> 10472

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10472

gggugagggg cugguccuca 20

<210> 10473

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10473

ggggugaggg gcugguccuc 20

<210> 10474

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10474

acccggggggggugaggggc 20

<210> 10475

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10475

uccgacccgg ugggggugag 20

<210> 10476

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10476

auccgaccg guggggguga 20

<210> 10477

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10477

gauccgaccc ggugggggg 20

<210> 10478

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10478

cuggggaucc gacccggugg 20

<210> 10479

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10479

ucuggggauc cgacccggug 20

<210> 10480

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10480

cucuggggau ccgacccggu 20

<210> 10481

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10481

acucugggga uccgacccgg 20

<210> 10482

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10482

accacucugg ggauccgacc 20

<210> 10483

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10483

gcccgucacu caccacucug 20

<210> 10484

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10484

agcccgucac ucaccacucu 20

<210> 10485

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10485

gagcccguca cucaccacuc 20

<210> 10486

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10486

cuugggggggacggagggc 20

<210> 10487

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10487

acaucaucgu gcucaagguc 20

<210> 10488

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10488

caucaucgug cucaaggucu 20

<210> 10489

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10489

aucgugcuca aggucuggga 20

<210> 10490

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10490

ucaaggucug ggaaggcacc 20

<210> 10491

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10491

caaggucugg gaaggcaccu 20

<210> 10492

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10492

aaggucuggg aaggcaccug 20

<210> 10493

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10493

aggucuggga aggcaccugg 20

<210> 10494

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10494

aggcaccugg ggguugugau 20

<210> 10495

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10495

ggggguugug aucggcaucu 20

<210> 10496

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10496

gguugugauc ggcaucuugg 20

<210> 10497

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10497

cauccuccga caucgacguc 20

<210> 10498

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10498

auccuccgac aucgacguca 20

<210> 10499

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10499

aucgacguca gggcaaacac 20

<210> 10500

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10500

acacuggaca ucgagugagu 20

<210> 10501

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10501

cacuggacau cgagugagua 20

<210> 10502

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10502

gacaucgagu gaguagggaa 20

<210> 10503

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10503

acaucgagug aguagggaau 20

<210> 10504

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10504

caucgaguga guagggaaug 20

<210> 10505

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10505

aucgagugag uagggaaugg 20

<210> 10506

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10506

ucgagugagu agggaauggg 20

<210> 10507

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10507

agaugccgau cacaaccccc 20

<210> 10508

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10508

cuccuccucc aguaggauga 20

<210> 10509

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10509

cuccuccuc cuccuccagu 20

<210> 10510

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10510

ucuuccccca gccagagaa 20

<210> 10511

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10511

gcugauuucc aacauccugc 20

<210> 10512

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10512

cugauuucca acauccuca 20

<210> 10513

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10513

ugauuuccaa cauccucag 20

<210> 10514

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10514

ccaacauccu gcaggggcug 20

<210> 10515

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10515

caacauccug caggggcugu 20

<210> 10516

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10516

aacauccugc aggggcugug 20

<210> 10517

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10517

gggccagagc ccacagacag 20

<210> 10518

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10518

ccacagacag aggccugcag 20

<210> 10519

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10519

cagacagagg ccugcagugg 20

<210> 10520

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10520

uucucugggc ugggggaaga 20

<210> 10521

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10521

ucagccuuuc ucugggcugg 20

<210> 10522

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10522

aucagccuuu cucugggcug 20

<210> 10523

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10523

aaucagccuu ucucugggcu 20

<210> 10524

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10524

aaaucagccu uucucugggc 20

<210> 10525

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10525

uuggaaauca gccuuucucu 20

<210> 10526

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10526

guuggaaauc agccuuucuc 20

<210> 10527

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10527

ccacagcccc ugcaggaugu 20

<210> 10528

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10528

ucuggcccca cagccccugc 20

<210> 10529

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10529

aggccucugu cugugggcuc 20

<210> 10530

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10530

cacugcaggc cucugucugu 20

<210> 10531

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10531

ccacugcagg ccucugucug 20

<210> 10532

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10532

ggcagaauua ccuccacugc 20

<210> 10533

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10533

cagccagcu gccgaugccc 20

<210> 10534

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10534

agaaaaccuc ugugagugag 20

<210> 10535

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10535

ccucugugag ugagaggaag 20

<210> 10536

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10536

gcuggaccug ggggaagaau 20

<210> 10537

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10537

ggcuggaccu gggggaagaa 20

<210> 10538

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10538

ggcagcuggg cuggaccugg 20

<210> 10539

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10539

cggcagcugg gcuggaccug 20

<210> 10540

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10540

ucggcagcug ggcuggaccu 20

<210> 10541

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10541

aucggcagcu gggcuggacc 20

<210> 10542

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10542

cugggcaucg gcagcugggc 20

<210> 10543

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10543

cuuccugggc aucggcagcu 20

<210> 10544

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10544

ucuuccuggg caucggcagc 20

<210> 10545

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10545

gagguuuucu uccugggcau 20

<210> 10546

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10546

cucacagagg uuuucuuccu 20

<210> 10547

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10547

acucacatag guuuucuucc 20

<210> 10548

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10548

ccucuuccuc ucacucacag 20

<210> 10549

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10549

cgugaagcac acacagccug 20

<210> 10550

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10550

aagcacacac agccugagga 20

<210> 10551

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10551

agcacacaca gccugaggau 20

<210> 10552

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10552

gcacacacag ccugaggaug 20

<210> 10553

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10553

cacacagccu gaggaugggg 20

<210> 10554

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10554

gccugaggau gggguggaga 20

<210> 10555

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10555

aggggugga gauggacacu 20

<210> 10556

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10556

uggggggag uggacacuc 20

<210> 10557

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10557

caucugcugg ggcagagcaa 20

<210> 10558

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10558

gcaucugcug gggcagagca 20

<210> 10559

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10559

cuucacggca gcaucugcug 20

<210> 10560

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10560

gcuucacggc agcaucugcu 20

<210> 10561

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10561

ugcuucacgg cagcaucugc 20

<210> 10562

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10562

cucaggcugu gugugcuuca 20

<210> 10563

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10563

uccaucucca ccccauccuc 20

<210> 10564

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10564

cccacacgau gaagaccccc 20

<210> 10565

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10565

ccaggcagug acguaugccg 20

<210> 10566

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10566

aggugaaaca cuccagaccu 20

<210> 10567

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10567

cuccagaccu aggagagaaa 20

<210> 10568

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10568

ucuccuccuu ccccacuguc 20

<210> 10569

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10569

cuccuccuuc cccacugucu 20

<210> 10570

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10570

uccuccuucc ccacugucug 20

<210> 10571

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10571

cccacugucu ggggaauucc 20

<210> 10572

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10572

ugggaauuc cuggacacaa 20

<210> 10573

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10573

ccuggacaca aggacagac 20

<210> 10574

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10574

ggacacaaag gacagacagg 20

<210> 10575

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10575

aaaggacaga caggcggaag 20

<210> 10576

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10576

acagacaggc ggaagaggac 20

<210> 10577

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10577

ggcggaagag gacaggcaga 20

<210> 10578

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10578

ggacaggcag auggacacug 20

<210> 10579

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10579

cugcuggaga gagacagugg 20

<210> 10580

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10580

gcucugcugg aggagacag 20

<210> 10581

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10581

cuucaucgug ugggcucugc 20

<210> 10582

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10582

ccggggguc uucaucgugu 20

<210> 10583

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10583

gccugggggu cuucaucgug 20

<210> 10584

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10584

cggcauacgu cacugccugg 20

<210> 10585

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10585

ucggcauacg ucacugccug 20

<210> 10586

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10586

cucggcauac gucacugccu 20

<210> 10587

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10587

ccucggcaua cgucacugcc 20

<210> 10588

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10588

aggucuggag uguuucaccu 20

<210> 10589

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10589

ggccauuucu cuccuagguc 20

<210> 10590

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10590

ggagaggcca uuucucuccu 20

<210> 10591

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10591

agacaguggg gaaggaggag 20

<210> 10592

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10592

ucccagaca guggggaagg 20

<210> 10593

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10593

aauuccccag acagugggga 20

<210> 10594

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10594

caggaauucc ccagacagug 20

<210> 10595

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10595

cggaauuc cccagacagu 20

<210> 10596

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10596

uccaggaauu ccccagacag 20

<210> 10597

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10597

cuuugugucc 20

<210> 10598

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10598

ugcugcaucu gaagcccccc 20

<210> 10599

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10599

ugcacagcuu gacccucaga 20

<210> 10600

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10600

gcacagcuug acccucagac 20

<210> 10601

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10601

cagcuugacc cucagacggg 20

<210> 10602

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10602

aacugagccu ccuccauccc 20

<210> 10603

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10603

gagccuccuc cauccagga 20

<210> 10604

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10604

agccuccucc aucccaggaa 20

<210> 10605

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10605

gccagcauc uacgccacuc 20

<210> 10606

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10606

cucuggccau ccacuagccc 20

<210> 10607

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10607

ucuggccauc cacuagccca 20

<210> 10608

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10608

cuggccaucc acuagcccag 20

<210> 10609

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10609

uggccaucca cuagcccagg 20

<210> 10610

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10610

ggccauccac uagccgggg 20

<210> 10611

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10611

gccauccacu agcccagggg 20

<210> 10612

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10612

gacgcagacc ccacacucca 20

<210> 10613

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10613

accccacacu ccauggaguc 20

<210> 10614

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10614

uccauggagu cuggaaugca 20

<210> 10615

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10615

ccauggaguc uggaugcau 20

<210> 10616

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10616

caugggagcu gcccccccag 20

<210> 10617

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10617

gcccccccag uggacaccau 20

<210> 10618

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10618

ccauuggacc ccacccagcc 20

<210> 10619

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10619

acccagccug gaucuacccc 20

<210> 10620

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10620

ggaucuaccc caggagacuc 20

<210> 10621

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10621

gaucuacccc aggagacucu 20

<210> 10622

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10622

aggagacucu gggaacuuuu 20

<210> 10623

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10623

ggaacucug ggaacuuuua 20

<210> 10624

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10624

gagacucugg gaacuuuuag 20

<210> 10625

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10625

gaugcagcag ccugcagcgg 20

<210> 10626

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10626

agaugcagca gccugcagcg 20

<210> 10627

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10627

cagaugcagc agccugcagc 20

<210> 10628

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10628

ucagaugcag cagccugcag 20

<210> 10629

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10629

ggcguagguc acauccuggg 20

<210> 10630

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10630

gggcguaggu cacauccugg 20

<210> 10631

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10631

ugggcguagg ucacauccug 20

<210> 10632

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10632

cugggcguag gucacauccu 20

<210> 10633

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10633

gcugggcgua ggucacaucc 20

<210> 10634

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10634

caagcugugc agcugggcgu 20

<210> 10635

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10635

gagggucaag cugugcagcu 20

<210> 10636

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10636

ugagggucaa gcugugcagc 20

<210> 10637

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10637

cucaguugcc ucccgucuga 20

<210> 10638

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10638

gcucaguugc cucccgucug 20

<210> 10639

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10639

ggcccuuccu gggauggagg 20

<210> 10640

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10640

gagggcccuu ccugggaugg 20

<210> 10641

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10641

ggagaggggcc cuuccuggga 20

<210> 10642

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10642

agcuggagag ggcccuuccu 20

<210> 10643

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10643

cagcuggaga gggcccuucc 20

<210> 10644

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10644

augcuggca cagcuggaga 20

<210> 10645

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10645

gaugcugggc acagcuggag 20

<210> 10646

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10646

gcguagaugc ugggcacagc 20

<210> 10647

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10647

gccagaggg cguagaugcu 20

<210> 10648

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10648

ggccagagug gcguagaugc 20

<210> 10649

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10649

gggcuagugg aggccagag 20

<210> 10650

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10650

ucccccccug ggcuagugga 20

<210> 10651

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10651

ugcgcccccc ccugggcuag 20

<210> 10652

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10652

uggggucugc gucccccccu 20

<210> 10653

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10653

guggggucug cguccccccc 20

<210> 10654

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10654

uccagacucc aggagugug 20

<210> 10655

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10655

uuccagacuc cauggagugu 20

<210> 10656

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10656

auuccagacu ccauggagug 20

<210> 10657

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10657

cccaugcauu ccagacucca 20

<210> 10658

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10658

uccaauggug uccacugggg 20

<210> 10659

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10659

guccaauggu guccacuggg 20

<210> 10660

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10660

gguccaaugg uguccacugg 20

<210> 10661

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10661

ggguccaaug guguccacug 20

<210> 10662

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10662

gggguccaau gguguccacu 20

<210> 10663

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10663

uggguccaa ugguguccac 20

<210> 10664

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10664

ccaggcuggg ugggguccaa 20

<210> 10665

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10665

ggguagaucc aggcugggug 20

<210> 10666

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10666

gggguagauc caggcugggu 20

<210> 10667

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10667

ugggguagau ccaggcuggg 20

<210> 10668

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10668

uccggggua gauccaggcu 20

<210> 10669

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10669

cuccuggggu agauccaggc 20

<210> 10670

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10670

gagucuccug ggguagaucc 20

<210> 10671

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10671

aaaguuccca gagucuccug 20

<210> 10672

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10672

aaaaguuccc agagucuccu 20

<210> 10673

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10673

uaaaaguucc cagagucucc 20

<210> 10674

<211> 448

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 10674

Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser

1 5 10 15

Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg

20 25 30

His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser

35 40 45

Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu

50 55 60

Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp

65 70 75 80

Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp

85 90 95

Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile

100 105 110

Val Lys Trp Asp Arg Asp Met Gly Gly Gly Gly Ser Gly Gly Gly Gly

115 120 125

Ser Gly Gly Gly Gly Ser Gly Ser His Ser Met Arg Tyr Phe Ser Ala

130 135 140

Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala Met Gly

145 150 155 160

Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser Ala Cys

165 170 175

Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly Pro Glu

180 185 190

Tyr Trp Glu Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln Thr Asp

195 200 205

Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala

210 215 220

Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly Ser Asp

225 230 235 240

Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly Lys Asp

245 250 255

Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr

260 265 270

Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val Ala Glu

275 280 285

Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu His Arg

290 295 300

Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro Pro Lys

305 310 315 320

Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr Leu Arg

325 330 335

Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr Trp Gln

340 345 350

Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu Thr Arg

355 360 365

Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val Val Pro

370 375 380

Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu Gly Leu

385 390 395 400

Pro Glu Pro Leu Met Leu Arg Trp Lys Gln Ser Ser Leu Pro Thr Ile

405 410 415

Pro Ile Met Gly Ile Val Ala Gly Leu Val Val Leu Ala Ala Val Val

420 425 430

Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser Ser Asp

435 440 445

<210> 10675

<211> 1353

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 10675

gccaccatga gcagatctgt ggccctggct gtgctggccc tgctgtctct gtctggcctg 60

gaagccatcc agcggacccc caagatccag gtgtacagca gacaccccgc cgaaaacggc 120

aagagcaact tcctgaactg ctacgtgtcc ggcttccacc ccagcgacat cgaggtggac 180

ctgctgaaga acggcgagcg gatcgaaaag gtggaacata gcgacctgag cttcagcaag 240

gactggtcct tctacctgct gtactacacc gagttcaccc ccaccgaaaa ggacgagtac 300

gcctgcagag tgaaccacgt gaccctgagc cagcccaaga tcgtgaagtg ggaccgggat 360

atgggcggag gcggatccgg cggcggagga tcagggggggg gagggtccgg atcccacagc 420

atgcggtact tctctgccgc cgtgtccaga cctggaagag gcgagccccg gtttatcgcc 480

atgggctacg tggacgacac ccagttcgtc agattcgaca gcgacagcgc ctgcccccgg 540

atggaaccta gagcaccttg ggtggaacag gaaggccccg agtactggga ggaagagaca 600

cggaacacca aggccccgc ccagaccgac agaatgaacc tgcagaccct gcggggctac 660

tacaaccaga gcgaggccag cagccacacc ctgcagtgga tgatcggctg cgatctgggc 720

agcgacggca gactgctgag aggttacgaa cagtacgcct acgacggcaa ggactacctg 780

gccctgaacg aggacctgcg gtcttggaca gccgccgata cagccgccca gatcagcaag 840

agaaagtgcg aggccgccaa cgtggccgag cagagaaggg cttacctgga aggcacctgt 900

gtggaatggc tgcatagata cctggaaaac ggcaaagaga tgctgcagcg ggccgacccc 960

cctaagacac acgtgacaca ccaccccgtg ttcgactacg aggccaccct gagatgttgg 1020

gccctgggct tctatcctgc cgagatcatc ctgacctggc agagggatgg cgaggaccag 1080

acccaggacg tggaactggt ggaaaccaga cctgccggcg acggcacctt ccagaaatgg 1140

gctgctgtgg tggtgcccag cggcgaagaa cagagataca cctgtcacgt gcagcacgag 1200

ggcctgcccg aacccctgat gctgagatgg aagcagagca gcctgcccac catccccatc 1260

atgggaatcg tggccggact ggtggtgctg gccgctgtcg tgacaggcgc tgcagtggcc 1320

gccgtgctgt ggcggaagaa gtccagcgac taa 1353

<210> 10676

<211> 338

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<400> 10676

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala

1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe

20 25 30

Ser Ala Ala Val Ser Arg Pro Ser Arg Gly Glu Pro Arg Phe Ile Ala

35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser

50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Arg Glu Gly

65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln

85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser

100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly

115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly

130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala

145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val

165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu

180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro

195 200 205

Pro Lys Thr His Val Thr His Pro Val Phe Asp Tyr Glu Ala Thr

210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr

225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu

245 250 255

Thr Lys Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val

260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

275 280 285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Lys Gln Ser Ser Leu Pro

290 295 300

Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val Val Leu Ala Ala

305 310 315 320

Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser

325 330 335

Ser Asp

<210> 10677

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10677

aggccucucu acuuccugug 20

<210> 10678

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10678

ggccucucua cuuccugugu 20

<210> 10679

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10679

gccucucuac uuccugugug 20

<210> 10680

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10680

gacucugaca auaccuggag 20

<210> 10681

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10681

ggacucugac aauaccugga 20

<210> 10682

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10682

aagaggacuc ugacaauacc 20

<210> 10683

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10683

uuccuagaag gccaaacaag 20

<210> 10684

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10684

ggucccacag ccuuccuaga 20

<210> 10685

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10685

uggacugguu gaagaaagcu 20

<210> 10686

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10686

gcagaggccu ccaccuggac 20

<210> 10687

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10687

cuuggaaacg uucaaggcag 20

<210> 10688

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10688

accucacuug gaaacguuca 20

<210> 10689

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10689

ccugcggguu uuaccucacu 20

<210> 10690

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10690

agagaggccu cugggccugc 20

<210> 10691

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10691

caggaaguag agaggccucu 20

<210> 10692

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10692

accccacaca ggaaaguagag 20

<210> 10693

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10693

aggguuucug aaccccacac 20

<210> 10694

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10694

ccugaggcug ggaggggagg 20

<210> 10695

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10695

ugaagcaggc accugaggcu 20

<210> 10696

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10696

cugaagcagg caccugaggc 20

<210> 10697

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10697

uuuucugaag caggcaccug 20

<210> 10698

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10698

uccagaagua guaagucucuc 20

<210> 10699

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10699

ccaugaaaca aagaugcagu 20

<210> 10700

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10700

caugaaacaa agaugcaguc 20

<210> 10701

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10701

agaugcaguc gggcacucac 20

<210> 10702

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10702

gggcacucac uggagaguuc 20

<210> 10703

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10703

ggcacucacu ggagaguucu 20

<210> 10704

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10704

uuacuuuacu aagauggcgg 20

<210> 10705

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10705

cuguuacuuu acuaagaugg 20

<210> 10706

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10706

ggacuguuac uuuacuaaga 20

<210> 10707

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10707

cgacugcauc uuuguuucau 20

<210> 10708

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10708

ccgacugcau cuuuguuuca 20

<210> 10709

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10709

acucaccuga uaagaggcag 20

<210> 10710

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10710

cauccuacuc accugauaag 20

<210> 10711

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10711

uuuuuuuuu auuuucuagu 20

<210> 10712

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10712

uuuauuuucu aguuggcguu 20

<210> 10713

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10713

uuauuuucua guuggcguuu 20

<210> 10714

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10714

uauuuucuag uuggcguuug 20

<210> 10715

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10715

auuuucuagu uggcguuugg 20

<210> 10716

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10716

cuuuucaggu aaugaagaaa 20

<210> 10717

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10717

gcauauaaag ucuccaucuc 20

<210> 10718

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10718

uugacaugcc cucaguaucc 20

<210> 10719

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10719

auccuggauc ugaaauacua 20

<210> 10720

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10720

cacaaugaua aaaacauagg 20

<210> 10721

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10721

uaaaaacaua ggcggugaug 20

<210> 10722

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10722

gaugaggaug auaaaaacau 20

<210> 10723

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10723

uaaaaacaua ggcagugaug 20

<210> 10724

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10724

ugaggaucac cugucacuga 20

<210> 10725

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10725

acugaaggaa uuuucagaau 20

<210> 10726

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10726

uuuucagaau uggagcaaag 20

<210> 10727

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10727

gaacuuuuau cucuaccuga 20

<210> 10728

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10728

uauuacugug guuccagaga 20

<210> 10729

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10729

agggcauguc aauauuuacug 20

<210> 10730

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10730

uuucagaucc aggauacuga 20

<210> 10731

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10731

auuucagauc caggauacug 20

<210> 10732

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10732

ugccauagua uuucagaucc 20

<210> 10733

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10733

cugaaaauuc cuucagugac 20

<210> 10734

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10734

cuucugguuu gcuuccucug 20

<210> 10735

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10735

ucuucugguu ugcuuccucu 20

<210> 10736

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10736

aucuucuggu uugcuuccuc 20

<210> 10737

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10737

agauaaaagu ucgcaucuuc 20

<210> 10738

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10738

cuggauuacc ucuugcccuc 20

<210> 10739

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10739

cauggagaug gaugugaugu 20

<210> 10740

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10740

uaguggacau cugcaucacu 20

<210> 10741

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10741

guggacaucu gcaucacugg 20

<210> 10742

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10742

cacugggggc uugcugcugc 20

<210> 10743

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10743

cuacuggagc aagaauagaa 20

<210> 10744

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10744

gagcaagaau agaaaggcca 20

<210> 10745

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10745

aaggccaagc cugugacacg 20

<210> 10746

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10746

caagccugug acacgaggag 20

<210> 10747

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10747

gauguccacu augacaauug 20

<210> 10748

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10748

ucgugucaca ggcuuggccu 20

<210> 10749

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10749

cgcuccucgu gucacaggcu 20

<210> 10750

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10750

gcacccgcuc cucgugucac 20

<210> 10751

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10751

ccgcaggaca aaacaaggag 20

<210> 10752

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10752

ucggguugg gaacaggugg 20

<210> 10753

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10753

uagucugggu ugggaacagg 20

<210> 10754

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10754

ucauagucug gguugggaac 20

<210> 10755

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10755

guuaccucau agucuggguu 20

<210> 10756

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10756

cguuaccuca uagucugggu 20

<210> 10757

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10757

cccacguuac cucauagucu 20

<210> 10758

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10758

ucccacguua ccucauaguc 20

<210> 10759

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10759

uauuucaccc cgcccauc 20

<210> 10760

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10760

cacccccagc ccauccggaa 20

<210> 10761

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10761

agcccauccg gaaaaggccag 20

<210> 10762

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10762

gcccauccgg aaaggccagc 20

<210> 10763

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10763

ggccagcggg accuguauuc 20

<210> 10764

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10764

cagagacgca ucugacccuc 20

<210> 10765

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10765

uuacacugau acaucccucg 20

<210> 10766

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10766

gcauucuuuu accucucgac 20

<210> 10767

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10767

uacacugaua caucccucga 20

<210> 10768

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10768

auacaucccu cgaggguccu 20

<210> 10769

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10769

uaccugguag agcuggucau 20

<210> 10770

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10770

cgagggaugu aucaguguaa 20

<210> 10771

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10771

ggucuacuuc auugcuggac 20

<210> 10772

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10772

guaaugccaa ggacccucga 20

<210> 10773

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10773

accugguaga gcuggucauu 20

<210> 10774

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10774

gcauuuucgu ccuugcuguu 20

<210> 10775

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10775

guuggggucu acuucauugc 20

<210> 10776

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10776

gucaucuucu cgauccuuga 20

<210> 10777

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10777

ucaucuucuc gauccuugag 20

<210> 10778

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10778

guguaugacu aucaagaaga 20

<210> 10779

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10779

uucaggaaac cacuugguua 20

<210> 10780

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10780

acuucgauaa ugaacuugca 20

<210> 10781

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10781

agcaucaucu cgaucucgga 20

<210> 10782

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10782

gagcaucauc ucgaucucgg 20

<210> 10783

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10783

ggacggga aaacgcaucc 20

<210> 10784

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10784

gacauuacaa gacuggaccu 20

<210> 10785

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10785

aaacgcaucc uggaccacg 20

<210> 10786

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10786

ggcgagaucc caagcaaguc 20

<210> 10787

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10787

acugagcauc aucucgaucu 20

<210> 10788

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10788

gcaucucuc gaucucggag 20

<210> 10789

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10789

ccgacacaca agcucuguug 20

<210> 10790

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10790

uaucacuaua uauuccucgu 20

<210> 10791

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10791

gauaccuaua gaggaacuug 20

<210> 10792

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10792

acaacuccca cgccuugccc 20

<210> 10793

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10793

uuacaccuau auauuccucg 20

<210> 10794

<211> 20

<212> RNA

<213> Homo sapiens

<400> 10794

ggaacaagug aaccugagac 20

<210> 10795

<211> 6

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial sequence description: Synthetic

6xHis label"

<400> 10795

His His His His His His His

fifteen

<210> 10796

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial sequence description: Synthetic

8xHis label"

<400> 10796

His His His His His His His His His

fifteen

<210> 10797

<211> 36

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<220>

<221> modified_base

<222> (1)..(20)

<223> a, c, u, g, unknown or other

<400> 10797

nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcu 36

<210> 10798

<211> 74

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10798

aacagcauag caaguuaaaa uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag 60

ucggugcuuuuuuu 74

<210> 10799

<211> 100

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<220>

<221> modified_base

<222> (1)..(20)

<223> a, c, u, g, unknown or other

<400> 10799

nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100

<210> 10800

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial sequence description: Synthetic

His label"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(10)

<223> /note="This sequence can contain 3-10 residues"

<400> 10800

His His His His His His His His His His His

1 5 10

<210> 10801

<211> 30

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polypeptide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(30)

<223> /note="This sequence may include 1-6 'Gly-Gly-Gly-Gly-Ser'

repeating units"

<400> 10801

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

20 25 30

<210> 10802

<211> 63

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10802

atggccctcc ctgtcaccgc cctgctgctt ccgctggctc ttctgctcca cgccgctcgg 60

ccc 63

<210> 10803

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10803

atctacattt gggcccctct ggctggtact tgcggggtcc tgctgctttc actcgtgatc 60

actcttact gt 72

<210> 10804

<211> 126

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 10804

aagcgcggtc ggaagaagct gctgtacatc tttaagcaac ccttcatgag gcctgtgcag 60

actactcaag aggaggacgg ctgttcatgc cggttcccag aggaggagga aggcggctgc 120

gaactg 126

<210> 10805

<211> 336

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

polynucleotide"

<400> 10805

cgcgtgaaat tcagccgcag cgcagatgct ccagcctaca agcaggggca gaaccagctc 60

tacaacgaac tcaatcttgg tcggagagag gagtacgacg tgctggacaa gcggagagga 120

cgggacccag aaatgggcgg gaagccgcgc agaaagaatc cccaagaggg cctgtacaac 180

gagctccaaa aggataagat ggcagaagcc tatagcgaga ttggtatgaa aggggaacgc 240

agaagaggca aaggccacga cggactgtac cagggactca gcaccgccac caaggacacc 300

tatgacgctc ttcacatgca ggccctgccg cctcgg 336

<210> 10806

<211> 10

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(10)

<223> /note="This sequence can include 1-10 nucleotides"

<400> 10806

uuuuuuuuuu 10

<210> 10807

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10807

cagacagcaa actcaccag t 21

<210> 10808

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10808

ctgacgctta tcgacgccct 20

<210> 10809

<211> 10

<212> RNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<220>

<221> OTHER_SIGNIFICANTS

<222> (1)..(10)

<223> /note="This sequence can include 1-10 nucleotides"

<400> 10809

aaaaaaaaaa 10

<210> 10810

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10810

tcgtcggcag cgtcagatgt gtataagaga cag 33

<210> 10811

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10811

gtctcgtggg ctcggagatg tgtataagag acag 34

<210> 10812

<211> 51

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<220>

<221> modified_base

<222> (30)..(37)

<223> a, c, t, g, unknown or other

<400> 10812

aatgatacgg cgaccaccga gatctacacn nnnnnnntcg tcggcagcgt c 51

<210> 10813

<211> 47

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<220>

<221> modified_base

<222> (25)..(32)

<223> a, c, t, g, unknown or other

<400> 10813

caagcagaag acggcatacg agatnnnnnn nngtctcgtg ggctcgg 47

<210> 10814

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10814

caagcagaag acggcatacg a 21

<210> 10815

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10815

aatgatacgg cgaccaccga ga 22

<210> 10816

<211> 23

<212> DNA

<213> Homo sapiens

<400> 10816

ggcaacagag cgagacaact ggg 23

<210> 10817

<211> 23

<212> DNA

<213> Homo sapiens

<400> 10817

ggcgacagaa cgagacatct cgg 23

<210> 10818

<211> 23

<212> DNA

<213> Homo sapiens

<400> 10818

aaagtcacac agctggtaca tgg 23

<210> 10819

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10819

gcacgcgttt aatataagtg gagg 24

<210> 10820

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10820

cctcatctgt gcagcgggca t 21

<210> 10821

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10821

catcacgagc agctggtttc 20

<210> 10822

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10822

gagccgaggt atcggtcctg 20

<210> 10823

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10823

tgtttgtaag gggatatgca caga 24

<210> 10824

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10824

tgttgtaggt gtcaattttc tgcc 24

<210> 10825

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10825

ccctctttcc agaaatttcc ttcttc 26

<210> 10826

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10826

aatatagagact caccttggggc tttc 24

<210> 10827

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10827

gccttcagtt agaccttgtt gatt 24

<210> 10828

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10828

tccttcttca tccaagggac tttt 24

<210> 10829

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10829

ttcttcatcc aagggacttt tcct 24

<210> 10830

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10830

tgttgtaggt gtcaattttc tgcc 24

<210> 10831

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10831

tgtaggtgtc aatttttctgc ctct 24

<210> 10832

<211> 15

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10832

gaccctcccg tcgcc 15

<210> 10833

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10833

cgaggtacta ggcagagccg tgg 23

<210> 10834

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10834

ggactgccag aacaaggctc 20

<210> 10835

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10835

attcaggaga gaccccaccc 20

<210> 10836

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10836

gtttcaggcc attattattg caca 24

<210> 10837

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10837

aatttcccct gattgccgtc tcta 24

<210> 10838

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10838

gactgacgtg gctcatgatg aat 23

<210> 10839

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10839

gtacatttta aggctcctgt tggc 24

<210> 10840

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10840

gagtctctat tgtacccacc ttgg 24

<210> 10841

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10841

cccttgcaat gatttctgtg gg 22

<210> 10842

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10842

gactgacgtg gctcatgatg aat 23

<210> 10843

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10843

aatttcccct gattgccgtc tcta 24

<210> 10844

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

primer"

<400> 10844

gaatttcccc tgattgccgt ct 22

<210> 10845

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10845

ccctgatcct cttgtcccac agatatccag aaccctgacc ctgccgtacc agctgagaga 60

ctctaaatcc agtgacaa 78

<210> 10846

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10846

ccctgatcct cttgtcccac agatatccag aaccctgacc ctgcctgtac cagctgagag 60

actctaaatc cagtgacaa 79

<210> 10847

<211> 56

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10847

ccctgatcct cttgtcccac agatatccag ctgagagact ctaaatccag tgacaa 56

<210> 10848

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10848

ccctgatcct cttgtcccac agatatccag aaccctgacc agctgagaga ctctaaatcc 60

agtgacaa 68

<210> 10849

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10849

ccctgatcct cttgtcccac agatatccag aaccctgaga gactctaaat ccagtgacaa 60

<210> 10850

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10850

gatcctcttg tcccacagat atccagaacc ctgaccctgc cgtgtaacca gctgagagac 60

tctaaatcca gtgacaagtc t 81

<210> 10851

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10851

gatcctcttg tcccacagat atccagaacc ctgaccctgc cgtgttacca gctgagagac 60

tctaaatcca gtgacaagtc t 81

<210> 10852

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10852

gatcctcttg tcccacagat atccagaacc ctgacccagc tgagagactc taaatccagt 60

gacaagtct 69

<210> 10853

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10853

gatcctcttg tcccacagat atccagtgac aagtct 36

<210> 10854

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10854

gatcctcttg tcccacagat atccagaacc ctgaccctgc tgagagactc taaatccagt 60

gacaagtct 69

<210> 10855

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10855

aacaacagca ttattccaga agacaccttc ttccccagcc cagggcagct ttggtgcctt 60

cgcaggctgt ttcct 75

<210> 10856

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10856

aacaacagca ttattccaga agacaccttc ttccccagct ttggtgcctt cgcaggctgt 60

ttcct 65

<210> 10857

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10857

aacaacagca ttattccaga agacaccttc ttccccagcc caggtagggc agctttggtg 60

ccttcgcagg ctgttttcct 79

<210> 10858

<211> 70

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10858

aacaacagca ttattccaga agacaccttc ttccccagcc cagctttggt gccttcgcag 60

gctgtttcct 70

<210> 10859

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10859

aacaacagca ttattccaga agacaccttc ttccccagcc caggtgcctt cgcaggctgt 60

ttcct 65

<210> 10860

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10860

tgtttttcct tttgaaagt tcctgtgatg tcaaagctgg tcgagaaaag ctttgaaaca

ggtaagacag gggtctagcc t 81

<210> 10861

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10861

tgtttttcct tttgaaagt tcctgtgatg tcagctggtc gagaaaagct ttgaaacagg 60

taagacaggg gtctagcct 79

<210> 10862

<211> 67

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10862

tgtttttcct tttagaaagt tcctggtcga gaaaagcttt gaaacaggta agacaggggt

ctagcct 67

<210> 10863

<211> 71

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10863

tgtttttcct tttgaaagt tcctgtgatg tcgagaaaag ctttgaaaca ggtaagacag 60

gggtctagcc t 71

<210> 10864

<211> 45

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10864

tgtttttcct tttagaaaga aacaggtaag acaggggtct agcct 45

<210> 10865

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10865

gcctcttggt tttacagata cgaacctaaa ctttcaaaac ctgtcaagtg attgggttcc 60

gaatcctcct cctgaaagtg g 81

<210> 10866

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10866

gcctcttggt tttacagata cgaacctaaa ctttcaaaac ctgtcatgat tgggttccga 60

atcctcctcc tgaaagtgg 79

<210> 10867

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10867

gcctcttggt tttacagata cgaacctaaa ctttcaaaac ctgtcgtgat tgggttccga 60

atcctcctcc tgaaagtgg 79

<210> 10868

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10868

gcctcttggt tttacagata cgaacctaaa ctttcaaaac ctgtcattgg gttccgaatc 60

ctcctcctga aagtgg 76

<210> 10869

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10869

gcctcttggt tttacagata cgaacctaaa ctttcaaaac ctgtcagatt gggttccgaa 60

tcctcctcct gaaagtgg 78

<210> 10870

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10870

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggttttaa tctgctcatg 60

acgctgcggc tgtggtccag c 81

<210> 10871

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10871

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggttaatc tgctcatgac 60

gctgcggctg tggtccagc 79

<210> 10872

<211> 80

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10872

tgtcagtgat tgggttccga atccgcctcc tgaaagtggc cgggtttaat ctgctcatga 60

cgctgcggct gtggtccagc 80

<210> 10873

<211> 80

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10873

tgtcagtgat tgggttccga atcctccgcc tgaaagtggc cgggtttaat ctgctcatga 60

cgctgcggct gtggtccagc 80

<210> 10874

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10874

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc tcatgacgct gcggctgtgg 60

tccagc 66

<210> 10875

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10875

gatcctcttg tcccacagat atccagaacc ctgaccctgc cgtgtaacca gctgagagac 60

tctaaatcca gtgacaagtc t 81

<210> 10876

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10876

gatcctcttg tcccacagat atccagaacc ctgaccctgc cgtgttacca gctgagagac 60

tctaaatcca gtgacaagtc t 81

<210> 10877

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10877

gatcctcttg tcccacagat atccagaacc ctgacccagc tgagagactc taaatccagt 60

gacaagtct 69

<210> 10878

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10878

gatcctcttg tcccacagat atccagaacc ctgaccctgc cagctgagag actctaaatc 60

cagtgacaag tct 73

<210> 10879

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10879

gatcctcttg tcccacagat atccagaacc ctgaccctgc cgtgtgacca gctgagagac 60

tctaaatcca gtgacaagtc t 81

<210> 10880

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10880

aacaacagca ttattccaga agacaccttc ttccccagcc cagggcagct ttggtgcctt 60

cgcaggctgt ttcct 75

<210> 10881

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10881

aacaacagca ttattccaga agacaccttc ttccccagct ttggtgcctt cgcaggctgt 60

ttcct 65

<210> 10882

<211> 70

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10882

aacaacagca ttattccaga agacaccttc ttccccagcc cagctttggt gccttcgcag 60

gctgtttcct 70

<210> 10883

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10883

aacaacagca ttattccaga agacaccttc ttccccagcc caggtagggc agctttggtg 60

ccttcgcagg ctgttttcct 79

<210> 10884

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10884

aacaacagca ttattccaga agacaccttc ttccccagcc caggtgcctt cgcaggctgt 60

ttcct 65

<210> 10885

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10885

ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc ctgaagtggc cgggtttaat 60

ctgctcatga cgctgcggc 79

<210> 10886

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10886

ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc ctgaaatggc cgggtttaat 60

ctgctcatga cgctgcggc 79

<210> 10887

<211> 82

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10887

60

aatctgctca tgacgctgcg gc 82

<210> 10888

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10888

ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc ctgaatggcc gggtttaatc 60

tgctcatgac gctgcggc 78

<210> 10889

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10889

ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc ctgaaaagtg gccgggttta 60

atctgctcat gacgctgcgg c 81

<210> 10890

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10890

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggttaatc tgctcatgac 60

gctgcggctg tggtccagc 79

<210> 10891

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10891

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggttttaa tctgctcatg 60

acgctgcggc tgtggtccag c 81

<210> 10892

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10892

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggtaatct gctcatgacg 60

ctgcggctgt ggtccagc 78

<210> 10893

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10893

tgtcagtgat tgggttccga atcctcctcc tgaaagtggc tcatgacgct gcggctgtgg 60

tccagc 66

<210> 10894

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10894

tgtcagtgat tgggttccga atcctcctcc tgaaagtgct catgacgctg cggctgtggt 60

ccagc 65

<210> 10895

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10895

ctcctgaaag tggccgggtt taatctgcgg ctgtggtcca gctgaggtga ggggccttga 60

agctggga 68

<210> 10896

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10896

ctcctgaaag tggccggggtt taatctgctc atgacggctg cggctgtggt ccagctgagg 60

tgaggggcct tgaagctggg a 81

<210> 10897

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10897

ctcctgaaag tggccgggtt taatctgctc atgactgcgg ctgtggtcca gctgaggtga 60

ggggccttga agctggga 78

<210> 10898

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10898

ctcctgaaag tggccgggtt taatctgctc atgacctgcg gctgtggtcc agctgaggtg 60

aggggccttg aagctggga 79

<210> 10899

<211> 74

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10899

ctcctgaaag tggccggggtt taatctgctc atgcggctgt ggtccagctg aggtgagggg 60

ccttgaagct ggga 74

<210> 10900

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10900

gaagctgaca gcattcgggc cgagatgtct cgcgctactc tctctttctg gcctgga 57

<210> 10901

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10901

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ccttagcctg tgctcgcgct 60

actctctctt tctggcctgg a 81

<210> 10902

<211> 63

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10902

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ctactctctc tttctggcct 60

gga 63

<210> 10903

<211> 55

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10903

gaagctgaca gcattcgggc cgagatgtct cgctactctc tctttctggc ctgga 55

<210> 10904

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10904

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ccttagtgct cgcgctactc 60

tctctttctg gcctgga 77

<210> 10905

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10905

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ctcgcgctac tctctctttc 60

tggcctgga 69

<210> 10906

<211> 61

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10906

gaagctgaca gcattcgggc cgagatgtct cgctcgcgct actctctctt tctggcctgg 60

a 61

<210> 10907

<211> 82

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10907

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ccttagctct gtgctcgcgc 60

tactctctct ttctggcctg ga 82

<210> 10908

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10908

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg cgctactctc tctttctggc 60

ctgga 65

<210> 10909

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10909

gaagctgaca gcattcgggc cgagatgtct cgctccgtgg ccttagctcg cgctactctc 60

tctttctggc ctgga 75

<210> 10910

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10910

ccgtgtgaac catgtgactt tgtcacagcc caagttaagt ggggtaagtc ttacattctt 60

ttgtaagctg ctgaaa 76

<210> 10911

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10911

ccgtgtgaac catgtgactt tgtcacagcc caagaatagt taagtggggt aagtcttaca 60

ttcttttgta agctgctgaa a 81

<210> 10912

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10912

ccgtgtgaac catgtgactt tgttaagtgg ggtaagtctt acattctttt gtaagctgct 60

gaaa 64

<210> 10913

<211> 71

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10913

ccgtgtgaac catgtgactt tgtcacagcc caagtggggt aagtcttaca ttcttttgta 60

agctgctgaa a 71

<210> 10914

<211> 50

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10914

ccgtgtgaac catgtgactt tgtcttacat tcttttgtaa gctgctgaaa 50

<210> 10915

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10915

ccgtgtgaac catgtgactt tgtggggtaa gtcttacatt cttttgtaag ctgctgaaa 59

<210> 10916

<211> 44

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10916

ccgtgtgaac catgtgactt acattctttt gtaagctgct gaaa 44

<210> 10917

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10917

ccgtgtgaac catgtgactt tgtcacagcc caagtagtta agtggggtaa gtcttacatt 60

cttttgtaag ctgctgaaa 79

<210> 10918

<211> 51

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10918

ccgtgtgaac catgtggggt aagtcttaca ttcttttgta agctgctgaa a 51

<210> 10919

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10919

ccgtgtgaac catgtgactt tgtcacagcc caagagttaa gtggggtaag tcttacattc 60

ttttgtaagc tgctgaaa 78

<210> 10920

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10920

agctcacagt gtgccaccat ggagttgggg ccccttagaa ggtggctacc tggagcttct 60

taacagcgat gctgaccccc t 81

<210> 10921

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10921

agctcacagt gtgccaccat ggagttggct acctggagct tcttaacagc gatgctgacc 60

ccct 64

<210> 10922

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10922

agctcacagt gtgccaccat ggagttgggg ctacctggag cttcttaaca gcgatgctga 60

ccccct 66

<210> 10923

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10923

agctcacagt gtgccaccat ggagttgggg tagaaggtgg ctacctggag cttcttaaca 60

gcgatgctga ccccct 76

<210> 10924

<211> 50

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10924

agctcacagt gtgccaccat ggagcttctt aacagcgatg ctgaccccct 50

<210> 10925

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10925

aactgcgacc agttcagcag gctgttgtgt gacattggaa ggtgatgaag agaccaggga 60

ggcttatgcc aatatcggtg a 81

<210> 10926

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10926

aactgcgacc agttcagcag gctgttgtgt gatgaagaga ccagggaggc ttatgccaat 60

atcggtga 68

<210> 10927

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10927

aactgcgacc agttcagcag gctgttgtgt gactggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 10928

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10928

aactgcgacc agttcagcag gctgttgtgt gacaggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 10929

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10929

aactgcgacc agttcagcag gctgttgtgt gatggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 10930

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10930

caggctgttg tgtgacatgg aaggtgatga agagccaggg aggcttatgc caatatcggt 60

gaggaagcac ctgagccca 79

<210> 10931

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10931

caggctgttg tgtgacatgg aaggtgatga agagaaccag ggaggcttat gccaatatcg 60

gtgaggaagc acctgagccc a 81

<210> 10932

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10932

caggctgttg tgtgacatgg aaggcttatg ccaatatcgg tgaggaagca cctgagccca 60

<210> 10933

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10933

caggctgttg tgtgacaggg aggcttatgc caatatcggt gaggaagcac ctgagccca 59

<210> 10934

<211> 44

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10934

caggctgttg tgtgacatgg aaggtgagga ggcacctgag ccca 44

<210> 10935

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10935

tttctcaaag tagagcacat aggaccagat gaagttgatc ggtgagagta tggagatgcc 60

agcagaagtt gggcagaaaa g 81

<210> 10936

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10936

tttctcaaag tagagcacat aggaccagat gagagtatgg agatgccagc agaagttggg 60

cagaaaag 68

<210> 10937

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10937

tttctcaaag tagagcacat aggaccagat cggtgagagt atggagatgc cagcagaagt 60

tgggcagaaa ag 72

<210> 10938

<211> 63

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10938

tttctcaaag tagagcacat aggaccagag tatggagatg ccagcagaag ttgggcagaa

aag 63

<210> 10939

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10939

tttctcaaag tagagcacat aggaccagat gatcggtgag agtatggaga tgccagcaga 60

agttgggcag aaaag 75

<210> 10940

<211> 63

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10940

tgagcattgt cttccctccc aggcagctca cagtgtgccc ctagaaggtg gctacctgga 60

gct 63

<210> 10941

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10941

tgagcattgt cttccctccc aggcagctca cagtgtgcca ccattggagt tggggcccct 60

agaaggtggc tacctggagc t 81

<210> 10942

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10942

tgagcattgt cttccctccc aggcagctca cagtgtgcca ccaggagttg gggcccctag 60

aaggtggcta cctggagct 79

<210> 10943

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10943

tgagcattgt cttccctccc aggcagctca cagtgtgcca ccagagttgg ggcccctaga 60

aggtggctac ctggagct 78

<210> 10944

<211> 49

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10944

tgagcattgt cttccctccc aggcccctag aaggtggcta cctggagct 49

<210> 10945

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10945

gggggtcagc atcgctgtta agaagctcca ggtagccacc tctagggggcc ccaactccat 60

ggtggcacac tgtgagctg 79

<210> 10946

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10946

gggggtcagc atcgctgtta agaagctcca ggtagccact ctaggggccc caactccatg 60

gtggcacact gtgagctg 78

<210> 10947

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10947

gggggtcagc atcgctgtta agaagctcca ggtagcccca actccatggt ggcacactgt 60

gagctg 66

<210> 10948

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10948

gggggtcagc atcgctgtta agaagctcca ggtagccacc tttctaggggg ccccaactcc 60

atggtggcac actgtgagct g 81

<210> 10949

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10949

gggggtcagc atcgctgtta agaagctcca ggtagccatc taggggcccc aactccatgg 60

tggcacactg tgagctg 77

<210> 10950

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10950

ggtggctacc tggagcttct taacagcgat gctgaccccc tgtggcctct accacttcta 60

tgaccagatg gacctggctg g 81

<210> 10951

<211> 74

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10951

ggtggctacc tggagcttct taacagcgat gctgaccccc tctaccactt ctatgaccag 60

atggacctgg ctgg 74

<210> 10952

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10952

ggtggctacc tggagcttct taacagcgat gctgaccact tctatgacca gatggacctg 60

gctgg 65

<210> 10953

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10953

ggtggctacc tggagcttct taacagcgat gctgaccccc tgtgctctac cacttctatg 60

accagatgga cctggctgg 79

<210> 10954

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10954

ggtggctacc tggagcttct taacagcgat gctgaccccc tgtgctacca cttctatgac 60

cagatggacc tggctgg 77

<210> 10955

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10955

agcttcttaa cagcgatgct gaccccctgt gcctctacca gatggacctg gctggagaag 60

aagagatt 68

<210> 10956

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10956

agcttcttaa cagcgatgct gaccccctgt gcctctacca ctatgaccag atggacctgg 60

ctggagaaga agagatt 77

<210> 10957

<211> 62

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10957

agcttcttaa cagcgatgct gaccccctgt gccagatgga cctggctgga gaagaagaga 60

tt62

<210> 10958

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10958

agcttcttaa cagcgatgct gaccccctgt gcctctacca cttatgacca gatggacctg 60

gctggagaag aagagatt 78

<210> 10959

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10959

agcttcttaa cagcgatgct gaccccctgt gcctctacca ctttatgacc agatggacct 60

ggctggagaa gaagagatt 79

<210> 10960

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10960

tttttctcaa agtagagcac ataggaccag atgaagttga tcggtgagag tatggagatg 60

ccagcagaag ttgggcagaa a 81

<210> 10961

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10961

tttttctcaa agtagagcac ataggaccag atgagagtat ggagatgcca gcagaagttg 60

ggcagaaa 68

<210> 10962

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10962

tttttctcaa agtagagcac ataggaccag atcggtgaga gtatggagat gccagcagaa 60

gttgggcaga aa 72

<210> 10963

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10963

tttttctcaa agtagagcac ataggaccag atgatgatcg gtgagagtat ggagatgcca 60

gcagaagttgggcagaaa 78

<210> 10964

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10964

tttttctcaa agtagagcac ataggaccag atgtgatcgg tgagagtatg gagatgccag 60

cagaagttgg gcagaaa 77

<210> 10965

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10965

gcattgtctt ccctcccagg cagctcacag tgtgccatgg agttggggcc cctagaaggt 60

ggctacctgg agcttct 77

<210> 10966

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10966

gcattgtctt ccctcccagg cagctcacag tgtgccaacc atggagttgg ggcccctaga 60

aggtggctac ctggagcttc t 81

<210> 10967

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10967

gcattgtctt ccctcccagg cagctcacag tgtgccaatg gagttggggc ccctagaagg 60

tggctacctg gagcttct 78

<210> 10968

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10968

gcattgtctt ccctcccagg cagctcacag tgtgccccat ggagttgggg cccctagaag 60

gtggctacct ggagcttct 79

<210> 10969

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10969

gcattgtctt ccctcccagg cagctcacag tgtgccacat ggagttgggg cccctagaag 60

gtggctacct ggagcttct 79

<210> 10970

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10970

gcagctcaca gtgtgccacc atggagttgg ggccccttag aaggtggcta cctggagctt 60

cttaacagcg atgctgaccc c 81

<210> 10971

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10971

gcagctcaca gtgtgccacc atggagttgg ggccccagaa ggtggctacc tggagcttct 60

taacagcgat gctgacccc 79

<210> 10972

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10972

gcagctcaca gtgtgccacc atggagttgg ggtagaaggt ggctacctgg agcttcttaa 60

cagcgatgct gacccc 76

<210> 10973

<211> 50

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10973

gcagctcaca gtgtgccacc atggagcttc ttaacagcga tgctgacccc 50

<210> 10974

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10974

gcagctcaca gtgtgccacc atggagttgg ctacctggag cttcttaaca gcgatgctga 60

cccc 64

<210> 10975

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10975

gcagctcaca gtgtgccacc atggagttgg ggccccttag aaggtggcta cctggagctt 60

cttaacagcg atgctgaccc c 81

<210> 10976

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10976

gcagctcaca gtgtgccacc atggagttgg ggtagaaggt ggctacctgg agcttcttaa 60

cagcgatgct gacccc 76

<210> 10977

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10977

gcagctcaca gtgtgccacc atggagttgg ggccccagaa ggtggctacc tggagcttct 60

taacagcgat gctgacccc 79

<210> 10978

<211> 50

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10978

gcagctcaca gtgtgccacc atggagcttc ttaacagcga tgctgacccc 50

<210> 10979

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10979

gcagctcaca gtgtgccacc atggagttgg ggctacctgg agcttcttaa cagcgatgct 60

gacccc 66

<210> 10980

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10980

gcagctcaca gtgtgccacc atggagttgg gtagaaggtg gctacctgga gcttcttaac 60

agcgatgctg acccc 75

<210> 10981

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10981

gcagctcaca gtgtgccacc atggagttgg ctacctggag cttcttaaca gcgatgctga 60

cccc 64

<210> 10982

<211> 49

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10982

gcagctcaca gtgtgccacc tggagcttct taacagcgat gctgacccc 49

<210> 10983

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10983

gcagctcaca gtgtgccacc atggagttgg ggccctagaa ggtggctacc tggagcttct 60

taacagcgat gctgacccc 79

<210> 10984

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10984

gcagctcaca gtgtgccacc atggagttgg ggagaaggtg gctacctgga gcttcttaac 60

agcgatgctg acccc 75

<210> 10985

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10985

cagcaggctg ttgtgtgaca tggaaggtga tgaagaccag ggaggcttat gccaatatcg 60

gtgaggaagc acctgagc 78

<210> 10986

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10986

cagcaggctg ttgtgtgaca tggaaggtga tgaagaacca gggaggctta tgccaatatc 60

ggtgaggaag cacctgagc 79

<210> 10987

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10987

cagcaggctg ttgtgtgaca tggaagggag gcttatgcca atatcggtga ggaagcacct 60

gagc 64

<210> 10988

<211> 71

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10988

cagcaggctg ttgtgtgaca tggaaggtga tgaagaggct tatgccaata tcggtgagga

agcacctgag c 71

<210> 10989

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10989

cagcaggctg ttgtgtgaca tggaaggctt atgccaatat cggtgaggaa gcacctgagc 60

<210> 10990

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10990

cagcaggctg ttgtgtgaca tggaaggtga tgaagagcag ggaggcttat gccaatatcg 60

gtgaggaagc acctgagc 78

<210> 10991

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10991

cagcaggctg ttgtgtgaca tggaaggtga tgaagggagg cttatgccaa tatcggtgag 60

gaagcacctg agc 73

<210> 10992

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10992

cagcaggctg ttgtgtgaca gggaggctta tgccaatatc ggtgaggaag cacctgagc 59

<210> 10993

<211> 44

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10993

cagcaggctg ttgtgtgaca tggaaggtga ggaagcacct gagc 44

<210> 10994

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10994

cagcaggctg ttgtgtgaca tggaaggtga tgaaccaggg aggcttatgc caatatcggt 60

gaggaagcac ctgagc 76

<210> 10995

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10995

agcaggctgt tgtgtgacat ggaaggtgat gaagagccag ggaggcttat gccaatatcg 60

gtgaggaagc acctgagcc 79

<210> 10996

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10996

agcaggctgt tgtgtgacat ggaaggtgat gaagagaacc agggaggctt atgccaatat 60

cggtgaggaa gcacctgagc c 81

<210> 10997

<211> 44

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10997

agcaggctgt tgtgtgacat ggaaggtgag gaagcacctg agcc 44

<210> 10998

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10998

agcaggctgt tgtgtgacat ggaaggctta tgccaatatc ggtgaggaag cacctgagcc 60

<210> 10999

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 10999

agcaggctgt tgtgtgacat ggaaggtgat gccaatatcg gtgaggaagc acctgagcc 59

<210> 11000

<211> 71

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11000

agcaggctgt tgtgtgacat ggaaggtgat gaagaggctt atgccaatat cggtgaggaa 60

gcacctgagc c 71

<210> 11001

<211> 64

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11001

agcaggctgt tgtgtgacat ggaagggagg cttatgccaa tatcggtgag gaagcacctg 60

agcc 64

<210> 11002

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11002

agcaggctgt tgtgtgacat ggaaggtgat gaagaccagg gaggcttatg ccaatatcgg 60

tgaggaagca cctgagcc 78

<210> 11003

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11003

agcaggctgt tgtgtgacat ggaaggtgat gaagggaggc ttatgccaat atcggtgagg 60

aagcacctga gcc 73

<210> 11004

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11004

agcaggctgt tgtgtgacat ggaaggtgat gaagagacag ggaggcttat gccaatatcg 60

gtgaggaagc acctgagcc 79

<210> 11005

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11005

tttttctcaa agtagagcac ataggaccag atgaagttga tcggtgagag tatggagatg 60

ccagcagaag ttgggcagaa a 81

<210> 11006

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11006

tttttctcaa agtagagcac ataggaccag atcggtgaga gtatggagat gccagcagaa 60

gttgggcaga aa 72

<210> 11007

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11007

tttttctcaa agtagagcac ataggaccag atgatgatcg gtgagagtat ggagatgcca 60

gcagaagttgggcagaaa 78

<210> 11008

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11008

tttttctcaa agtagagcac ataggaccag atgatcggtg agagtatgga gatgccagca 60

gaagttgggc agaaa 75

<210> 11009

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11009

tttttctcaa agtagagcac ataggaccag atgagagtat ggagatgcca gcagaagttg 60

ggcagaaa 68

<210> 11010

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11010

tttttctcaa agtagagcac ataggaccag atgaagatcg gtgagagtat ggagatgcca 60

gcagaagttgggcagaaa 78

<210> 11011

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11011

tttttctcaa agtagagcac ataggaccag atgaatgatc ggtgagagta tggagatgcc 60

agcagaagtt gggcagaaa 79

<210> 11012

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11012

tttttctcaa agtagagcac ataggaccag atgtgatcgg tgagagtatg gagatgccag 60

cagaagttgg gcagaaa 77

<210> 11013

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11013

tttttctcaa agtagagcac ataggaccag attgatcggt gagagtatgg agatgccagc 60

agaagttgggg cagaaa 76

<210> 11014

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11014

tttttctcaa agtagagcac ataggaccag atgagatcgg tgagagtatg gagatgccag 60

cagaagttgg gcagaaa 77

<210> 11015

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11015

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagattgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11016

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11016

gtcgcgctgg cgggcattcc tgaagctgac agcattcgct ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11017

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11017

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11018

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11018

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccttagctgt gctcgcgct 59

<210> 11019

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11019

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagagtct cgctccgtgg 60

ccttagctgt gctcgcgct 79

<210> 11020

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11020

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagatctc gctccgtggc 60

cttagctgtg ctcgcgct 78

<210> 11021

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11021

gtcgcgctgg cgggcattcc tgaagctgac agctccgtgg ccttagctgt gctcgcgct 59

<210> 11022

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11022

gtcgcgctgg cgggcattcc tgaagctgac agcattcgtg gccttagctg tgctcgcgct 60

<210> 11023

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11023

gtcgcgctgg cgggcattcc tgaagctgac agcatccgtg gccttagctg tgctcgcgct 60

<210> 11024

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11024

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagaatgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11025

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11025

gtcgcgctgg cgggcattcc tgaagctgac agcattcgct ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11026

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11026

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagattgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11027

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11027

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11028

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11028

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccttagctgt gctcgcgct 59

<210> 11029

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11029

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagagtct cgctccgtgg 60

ccttagctgt gctcgcgct 79

<210> 11030

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11030

gtcgcgctgg cgggcattcc tgaagctgac agctccgtgg ccttagctgt gctcgcgct 59

<210> 11031

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11031

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagatctc gctccgtggc 60

cttagctgtg ctcgcgct 78

<210> 11032

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11032

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagaatgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11033

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11033

gtcgcgctgg cgggcattcc tgaagctgac agcatccgtg gccttagctg tgctcgcgct 60

<210> 11034

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11034

gtcgcgctgg cgggcattcc tgaagctgac agcattcgtg gccttagctg tgctcgcgct 60

<210> 11035

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11035

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagattgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11036

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11036

gtcgcgctgg cgggcattcc tgaagctgac agcattcgct ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11037

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11037

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11038

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11038

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccttagctgt gctcgcgct 59

<210> 11039

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11039

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagagtct cgctccgtgg 60

ccttagctgt gctcgcgct 79

<210> 11040

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11040

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagatctc gctccgtggc 60

cttagctgtg ctcgcgct 78

<210> 11041

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11041

gtcgcgctgg cgggcattcc tgaagctgac agctccgtgg ccttagctgt gctcgcgct 59

<210> 11042

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11042

gtcgcgctgg cgggcattcc tgaagctgac agcattcgtg gccttagctg tgctcgcgct 60

<210> 11043

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11043

gtcgcgctgg cgggcattcc tgaagctgac agcatccgtg gccttagctg tgctcgcgct 60

<210> 11044

<211> 67

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11044

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ctccgtggcc ttagctgtgc 60

tcgcgct 67

<210> 11045

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11045

gtcgcgctgg cgggcattcc tgaagctgac agcattcgct ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11046

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11046

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagattgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11047

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11047

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgtggcctt agctgtgctc 60

gcgct 65

<210> 11048

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11048

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccttagctgt gctcgcgct 59

<210> 11049

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11049

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagagtct cgctccgtgg 60

ccttagctgt gctcgcgct 79

<210> 11050

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11050

gtcgcgctgg cgggcattcc tgaagctgac agctccgtgg ccttagctgt gctcgcgct 59

<210> 11051

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11051

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagatctc gctccgtggc 60

cttagctgtg ctcgcgct 78

<210> 11052

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11052

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ccgagaatgt ctcgctccgt 60

ggccttagct gtgctcgcgc t 81

<210> 11053

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11053

gtcgcgctgg cgggcattcc tgaagctgac agcattcgtg gccttagctg tgctcgcgct 60

<210> 11054

<211> 67

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11054

gtcgcgctgg cgggcattcc tgaagctgac agcattcggg ctccgtggcc ttagctgtgc 60

tcgcgct 67

<210> 11055

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11055

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtaacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11056

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11056

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgttacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11057

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11057

tgatcctctt gtcccacaga tatccagaac cctgacccag ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11058

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11058

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtgacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11059

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11059

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccagctgaga gactctaaat 60

ccagtgacaa gtc 73

<210> 11060

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11060

tgatcctctt gtcccacaga tatccagaac cctgaccctg ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11061

<211> 56

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11061

tgatcctctt gtcccacaga tatccagaac cctgactcta aatccagtga caagtc 56

<210> 11062

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11062

tgatcctctt gtcccacaga tatccagaac cctgaccagc tgagagactc taaatccagt 60

gacaagtc 68

<210> 11063

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11063

tgatcctctt gtcccacaga tatccagaac cctgaccctg agagactcta aatccagtga 60

caagtc 66

<210> 11064

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11064

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtcagc tgagagactc 60

taaatccagt gacaagtc 78

<210> 11065

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11065

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtaacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11066

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11066

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgttacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11067

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11067

tgatcctctt gtcccacaga tatccagaac cctgacccag ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11068

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11068

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtgacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11069

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11069

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccagctgaga gactctaaat 60

ccagtgacaa gtc 73

<210> 11070

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11070

tgatcctctt gtcccacaga tatccagaac cctgaccctg ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11071

<211> 77

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11071

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtagct gagagactct 60

aaatccagtg acaagtc 77

<210> 11072

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11072

tgatcctctt gtcccacaga tatccagaac cctgaccagc tgagagactc taaatccagt 60

gacaagtc 68

<210> 11073

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11073

tgatcctctt gtcccacaga tatccagaac cctgaccctg agagactcta aatccagtga 60

caagtc 66

<210> 11074

<211> 82

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11074

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtatac cagctgagag 60

actctaaatc cagtgacaag tc 82

<210> 11075

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11075

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtaacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11076

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11076

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgttacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11077

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11077

tgatcctctt gtcccacaga tatccagaac cctgacccag ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11078

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11078

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccagctgaga gactctaaat 60

ccagtgacaa gtc 73

<210> 11079

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11079

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtgacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11080

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11080

tgatcctctt gtcccacaga tatccagaac cctgaccctg ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11081

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11081

tgatcctctt gtcccacaga tatccagaac cctgaccagc tgagagactc taaatccagt 60

gacaagtc 68

<210> 11082

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11082

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtcagc tgagagactc 60

taaatccagt gacaagtc 78

<210> 11083

<211> 82

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11083

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtatac cagctgagag 60

actctaaatc cagtgacaag tc 82

<210> 11084

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11084

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgaccag ctgagagact 60

ctaaatccag tgacaagtc 79

<210> 11085

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11085

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtaacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11086

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11086

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgttacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11087

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11087

tgatcctctt gtcccacaga tatccagaac cctgacccag ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11088

<211> 73

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11088

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccagctgaga gactctaaat 60

ccagtgacaa gtc 73

<210> 11089

<211> 69

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11089

tgatcctctt gtcccacaga tatccagaac cctgaccctg ctgagagact ctaaatccag 60

tgacaagtc 69

<210> 11090

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11090

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgtgacc agctgagaga 60

ctctaaatcc agtgacaagt c 81

<210> 11091

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11091

tgatcctctt gtcccacaga tatccagaac cctgaccctg ccgtgaccag ctgagagact 60

ctaaatccag tgacaagtc 79

<210> 11092

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11092

tgatcctctt gtcccacaga tatccagaac cctgaccctg agagactcta aatccagtga 60

caagtc 66

<210> 11093

<211> 56

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11093

tgatcctctt gtcccacaga tatccagaac cctgactcta aatccagtga caagtc 56

<210> 11094

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11094

tgatcctctt gtcccacaga tatccagaac cctgaccagc tgagagactc taaatccagt 60

gacaagtc 68

<210> 11095

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11095

aactgcgacc agttcagcag gctgttgtgt gacattggaa ggtgatgaag agaccaggga 60

ggcttatgcc aatatcggtg a 81

<210> 11096

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11096

aactgcgacc agttcagcag gctgttgtgt gatgaagaga ccagggaggc ttatgccaat 60

atcggtga 68

<210> 11097

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11097

aactgcgacc agttcagcag gctgttgtgt gacaggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11098

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11098

aactgcgacc agttcagcag gctgttgtgt gactggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11099

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11099

aactgcgacc agttcagcag gctgttgtga tgaagagacc agggaggctt atgccaatat 60

cggtga 66

<210> 11100

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11100

aactgcgacc agttcagcag gctgttgtgt gacggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11101

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11101

aactgcgacc agttcagcag gctgttgtgt gaagagacca gggaggctta tgccaatatc 60

ggga 65

<210> 11102

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11102

aactgcgacc agttcagcag gctgttgtgt gatggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11103

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11103

aactgcgacc agttcagcag gctgttgtgt ggaaggtgat gaagagacca gggaggctta 60

tgccaatatc ggtga 75

<210> 11104

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11104

aactgcgacc agttcagcag gtgatgaaga gaccagggag gcttatgcca atatcggtga 60

<210> 11105

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11105

aactgcgacc agttcagcag gctgttgtgt gacattggaa ggtgatgaag agaccaggga 60

ggcttatgcc aatatcggtg a 81

<210> 11106

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11106

aactgcgacc agttcagcag gctgttgtgt gatgaagaga ccagggaggc ttatgccaat 60

atcggtga 68

<210> 11107

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11107

aactgcgacc agttcagcag gctgttgtgt gacaggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11108

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11108

aactgcgacc agttcagcag gctgttgtgt gactggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11109

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11109

aactgcgacc agttcagcag gctgttgtga tgaagagacc agggaggctt atgccaatat 60

cggtga 66

<210> 11110

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11110

aactgcgacc agttcagcag gctgttgtgt gaagagacca gggaggctta tgccaatatc 60

ggga 65

<210> 11111

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11111

aactgcgacc agttcagcag gctgttgtgt gacggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11112

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11112

aactgcgacc agggaggctt atgccaatat cggtga 36

<210> 11113

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11113

aactgcgacc agttcagcag gctgttgtgt ggaaggtgat gaagagacca gggaggctta 60

tgccaatatc ggtga 75

<210> 11114

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11114

aactgcgacc agttcagcag gctgttgtgt gatggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11115

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11115

aactgcgacc agttcagcag gctgttgtgt gacattggaa ggtgatgaag agaccaggga 60

ggcttatgcc aatatcggtg a 81

<210> 11116

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11116

aactgcgacc agttcagcag gctgttgtgt gatgaagaga ccagggaggc ttatgccaat 60

atcggtga 68

<210> 11117

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11117

aactgcgacc agttcagcag gctgttgtgt gacaggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11118

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11118

aactgcgacc agttcagcag gctgttgtgt gactggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11119

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11119

aactgcgacc agttcagcag gctgttgtga tgaagagacc agggaggctt atgccaatat 60

cggtga 66

<210> 11120

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11120

aactgcgacc agttcagcag gctgttgtgt gacggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11121

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11121

aactgcgacc agttcagcag gctgttgtgt gaagagacca gggaggctta tgccaatatc 60

ggga 65

<210> 11122

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11122

aactgcgacc agttcagcag gctgttgtgt gatggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11123

<211> 44

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11123

aactgcgacc agttcagcag ggaggcttat gccaatatcg gtga 44

<210> 11124

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11124

aactgcgacc agggaggctt atgccaatat cggtga 36

<210> 11125

<211> 81

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11125

aactgcgacc agttcagcag gctgttgtgt gacattggaa ggtgatgaag agaccaggga 60

ggcttatgcc aatatcggtg a 81

<210> 11126

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11126

aactgcgacc agttcagcag gctgttgtgt gatgaagaga ccagggaggc ttatgccaat 60

atcggtga 68

<210> 11127

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11127

aactgcgacc agttcagcag gctgttgtgt gacaggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11128

<211> 79

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11128

aactgcgacc agttcagcag gctgttgtgt gactggaagg tgatgaagag accagggagg 60

cttatgccaa tatcggtga 79

<210> 11129

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11129

aactgcgacc agttcagcag gctgttgtgt gacggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11130

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11130

aactgcgacc agttcagcag gctgttgtga tgaagagacc agggaggctt atgccaatat 60

cggtga 66

<210> 11131

<211> 78

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11131

aactgcgacc agttcagcag gctgttgtgt gatggaaggt gatgaagaga ccagggaggc 60

ttatgccaat atcggtga 78

<210> 11132

<211> 76

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11132

aactgcgacc agttcagcag gctgttgtgt gggaaggtga tgaagagacc agggaggctt 60

atgccaatat cggtga 76

<210> 11133

<211> 65

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11133

aactgcgacc agttcagcag gctgttgtgt gaagagacca gggaggctta tgccaatatc 60

ggga 65

<210> 11134

<211> 74

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11134

aactgcgacc agttcagcag gctgttgtgt gaaggtgatg aagagaccag ggaggcttat 60

gccaatatcg gtga 74

<210> 11135

<211> 61

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11135

60

t61

<210> 11136

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11136

cccctccccg ctgggcccc gatcaccggt gtagtgcacc acgcaggtct ggccgcgct 59

<210> 11137

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11137

cccctccccg ctgggccccc gacaccggtg tagtgcacca cgcaggtctg gccgcgct 58

<210> 11138

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11138

cccctccccg ctgggcccc gtcaccggtg tagtgcacca cgcaggtctg gccgcgct 58

<210> 11139

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11139

cccctccccg gtgtagtgca ccacgcaggt ctggccgcgc t 41

<210> 11140

<211> 61

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11140

ctgggcccc gactcaccgg tgtagtgcac cacgcaaggt ctggccgcgc ttggggaagg 60

t61

<210> 11141

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11141

ctgggcccc gactcaccgg tgtagtgcac cacgcactgg ccgcgcttgg ggaaggt 57

<210> 11142

<211> 56

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11142

ctgggcccc gactcaccgg tgtagtgcac cacgcatggc cgcgcttgggg gaaggt 56

<210> 11143

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11143

ctgggcccc gactcaccgg tgtagtgcac cacgcatctg gccgcgcttg gggaaggt 58

<210> 11144

<211> 46

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11144

ctgggcccc gactcaccgg tgtagtgcac cacgcttggg gaaggt 46

<210> 11145

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11145

caggtctggc cgcgcttggg gaaggtgcgc cctgagagac agagacgggc atgctgagc 59

<210> 11146

<211> 61

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11146

caggtctggc cgcgcttggg gaaggtgcgc cctgagggag acagagacgg gcatgctgag 60

c 61

<210> 11147

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11147

caggtctggc cgcgcttggg gaaggtgcgc cctgagacag agacgggcat gctgagc 57

<210> 11148

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11148

caggtctggc cgcgcttggg gaaggtgcgc cctgggagac agagacgggc atgctgagc 59

<210> 11149

<211> 55

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11149

caggtctggc cgcgcttggg gaaggtgcgc cctgacagag acgggcatgc tgagc 55

<210> 11150

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11150

gagccgccgc gcgccactac tcaccgtctc ctgggagatg gtttccacct gcactccca 59

<210> 11151

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11151

gagccgccgc gcgccactac tcaccgtctc ctgggatggt ttccacctgc actccca 57

<210> 11152

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11152

gagccgccgc gcgccactac tcaccgtctc ctggagatgg tttccacctg cactccca 58

<210> 11153

<211> 35

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11153

gagccgccgc gcgccactac tcacctgcac tccca 35

<210> 11154

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11154

gagccgccgc gcgccactac tcaccgtctc ctgcactccc a 41

<210> 11155

<211> 59

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11155

gggagatggt ttccacctgc actccatggc ggcggcggac gctgagcggg cgggcggcg 59

<210> 11156

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11156

gggagatggt ttccacctgc actcatggcg gcggcggacg ctgagcgggc gggcggcg 58

<210> 11157

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11157

gggagatggt ttccacctgc acttccatgg cggcggcgga cgctgagcgg gcgggcggcg 60

<210> 11158

<211> 58

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial Sequence Description: Synthetic

oligonucleotide"

<400> 11158

gggagatggt ttccacctgc acccatggcg gcggcggacg ctgagcgggc gggcggcg 58

<210> 11159

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<221> source

<223> /note="Artificial sequence description: Synthetic

oligonucleotide"

<400> 11159

gggagatggt ttccacctgc accatggcgg cggcggacgc tgagcgggcg ggcggcg 57

<---

Claims (127)

1. An nRNA molecule for mediating B2M editing in a cell by Cas9, wherein the nRNA molecule includes tracr and crRNA, where the crRNA includes a guide domain comprising any of SEQ ID NO: 1 - SEQ ID NO: 83 or SEQ ID NO: 5492 - SEQ ID NO: 5527, and wherein the cell is not a human germ cell or a human embryonic cell. 2. An nRNA molecule according to claim 1, where the targeting domain includes SEQ ID NO: 5519, SEQ ID NO: 5497, SEQ ID NO: 5499, SEQ ID NO: 5498, SEQ ID NO: 5503, SEQ ID NO: 5496, SEQ ID NO: 5507, SEQ ID NO: 5515 , SEQ ID NO: 5493, SEQ ID NO: 5506, SEQ ID NO: 5509, SEQ ID NO: 5517, SEQ ID NO: 5521, SEQ ID NO: 5520, SEQ ID NO: 5500, SEQ ID NO: 5494, SEQ ID NO: 5508, SEQ ID NO: 5514, or SEQ ID NO: 5492. 3. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5519. 4. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5497. 5. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5499. 6. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5498. 7. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5503. 8. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5496. 9. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5507. 10. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5515. 11. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5493. 12. The nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5506. 13. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5509. 14. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5517. 15. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5521. 16. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5520. 17. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5500. 18. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5494. 19. An nRNA molecule according to claim 2, wherein the target domain contains SEQ ID NO: 5508. 20. An nRNA molecule according to claim 2, wherein the targeting domain contains SEQ ID NO: 5514. 21. An nRNA molecule according to claim 2, wherein the targeting domain contains or SEQ ID NO: 5492. 22. The nRNA molecule according to any one of the preceding claims, wherein the targeting domain and tracr are located on separate nucleic acid molecules, and wherein the nucleic acid molecule including the targeting domain comprises SEQ ID NO: 6607, optionally located immediately 3' from the targeting domain, and the molecule nucleic acid including tracr includes SEQ ID NO: 6660. 23. An nRNA molecule according to any one of paragraphs. 1-22, where the nRNA molecule contains SEQ ID NO: 7858 or 7853. 24. The nRNA molecule according to any one of the previous paragraphs, where the nRNA molecule includes: a) one or more phosphothioate modifications at the 3' end of said nucleic acid molecule or molecules; b) one or more phosphothioate modifications at the 5' end of said nucleic acid molecule or molecules; c) one or more 2'-O-methyl modifications at the 3' end of said nucleic acid molecule or molecules; d) one or more 2'-O-methyl modifications at the 5' end of said nucleic acid molecule or molecules; e) one or more 2'-O-methyl modifications on each of the 4th from the end, 3rd from the end and 2nd from the end of the 3'-residues of the indicated nucleic acid molecule or molecules; or f) any combination of them. 25. A composition for editing B2M in a cell, comprising a first nRNA molecule according to any one of the preceding claims and a Cas9 molecule or a nucleic acid encoding a Cas9 molecule, wherein the cell is not a human germ cell or a human embryonic cell. 26. The composition of claim 25, wherein the Cas9 molecule comprises any of SEQ ID NO: 6611 or SEQ ID NO: 7821 to SEQ ID NO: 7831, or a sequence having at least 95% homology thereto. 27. The composition according to claim 25 or 26, wherein the first nRNA molecule and the Cas9 molecule are present in a ribonucleoprotein complex (RNP). 28. Composition according to any one of paragraphs. 25-27, further comprising a second nRNA molecule; a second nRNA molecule and a third nRNA molecule, or a second nRNA molecule, a third nRNA molecule and a fourth nRNA molecule, wherein each nRNA molecule in the composition is complementary to a specific target sequence. 29. Composition for editing B2M in a cell, containing a Cas9 molecule or a nucleic acid encoding a Cas9 molecule, the first nRNA molecule according to any one of paragraphs. 1-24 and a second nRNA molecule comprising tracr and crRNA, wherein the crRNA of the second nRNA molecule contains a guide domain that is complementary to the target sequence in (i) TRAC, where the directing domain includes any of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965; (ii) TRBC1, where the directing domain includes any of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097; (iii) TRBC2, where the directing domain includes any of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226; (iv) CD3D, where the directing domain includes any of SEQ ID NO: 393 - SEQ ID NO: 532 or SEQ ID NO: 10780 - SEQ ID NO: 10794; (v) CD3E, where the directing domain includes any of SEQ ID NO: 533 - SEQ ID NO: 839 or SEQ ID NO: 10677 - SEQ ID NO: 10764; (vi) CD3G, where the directing domain includes any of SEQ ID NO: 840 - SEQ ID NO: 968 or SEQ ID NO: 10765 - SEQ ID NO: 10779; or (vii) HLA-A, where the guide domain includes any of SEQ ID NO: 969 - SEQ ID NO: 1345, where the cell is not a human germ cell or a human embryonic cell. 30. The composition of claim 29, wherein the targeting domain of the second nRNA molecule is complementary to the target sequence in TRAC, wherein the targeting domain includes any of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965 . 31. The composition according to claim 29 or 30, further comprising a third nRNA molecule containing tracr and crRNA, where the crRNA contains a guide domain that is complementary to the target sequence in (i) FKBP1A, where the directing domain includes any of SEQ ID NO: 6325 - SEQ ID NO: 6583 or SEQ ID NO: 6662 - SEQ ID NO: 6749; (ii) CIITA, where the directing domain includes any of SEQ ID NO: 6750 - SEQ ID NO: 7716 or SEQ ID NO: 7717 - SEQ ID NO: 7804; or (iii) NLRC5, where the targeting domain includes any of SEQ ID NO: 8622 - SEQ ID NO: 10089. 32. The composition of claim 31, wherein the targeting domain of said third nRNA molecule is complementary to the target sequence in CIITA, wherein the targeting domain comprises any of SEQ ID NO: 6750 - SEQ ID NO: 7716 or SEQ ID NO: 7717 - SEQ ID NO: 7804. 33. Composition according to paragraphs. 31, 32, further comprising a fourth nRNA molecule containing tracr and crRNA, wherein the crRNA contains a guide domain that is complementary to the target sequence of the target of the NK inhibitory molecule. 34. The composition of claim 33 wherein the target of the NK inhibitory molecule is LILRB1. 35. The composition according to claim 33, where the directing domain of the specified fourth nRNA molecule includes: a) any of SEQ ID NO: 10090 - SEQ ID NO: 10673; b) 17, 18, 19, 20, 21, 22, 23 or 24 consecutive nucleotides, preferably 20 consecutive nucleotides, any of SEQ ID NO: 10090 - SEQ ID NO: 10673; c) 5' 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides, preferably 20 nucleotides, any of SEQ ID NO: 10090 - SEQ ID NO: 10673; or d) 3' 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides, preferably 20 nucleotides, any of SEQ ID NO: 10090 - SEQ ID NO: 10673. 36. Nucleic acid for the expression of an nRNA molecule, where the nucleic acid has a sequence that encodes an nRNA molecule according to any one of paragraphs. 1-23. 37. An expression vector containing a nucleic acid having a sequence that encodes an nRNA molecule according to any one of paragraphs. 1-23. 38. Composition according to any one of paragraphs. 25-35, further comprising a template nucleic acid. 39. The composition of claim 38, wherein the template nucleic acid comprises a nucleic acid encoding a chimeric antigen receptor (CAR). 40. The composition according to claim 39, where CAR is: (a) CD19CAR; (b) BCMA CAR; (c) CD20CAR; (d) CD22CAR; (e) CD123CAR; (f) EGFRvIII CAR; or (g) mesothelin CAR. 41. The composition according to any one of paragraphs. 25-35 or 38-40, where the composition is prepared in a medium suitable for electroporation. 42. A method for changing a target sequence in a cell, including contacting said cell with: a) an nRNA molecule according to any one of paragraphs. 1-24 and a Cas9 molecule; b) an nRNA molecule according to any one of paragraphs. 1-24 and a nucleic acid encoding a Cas9 molecule; c) a nucleic acid encoding an nRNA molecule according to any one of paragraphs. 1-23, and the Cas9 molecule; d) a nucleic acid encoding an nRNA molecule according to any one of paragraphs. 1-23 and a nucleic acid encoding a Cas9 molecule; e) any one of a) to d) above and one or more additional nRNA molecules; f) any one of a) to e) above and a template nucleic acid; or g) any one of a) to e) above and a nucleic acid comprising a template nucleic acid, wherein the cell is not a human germ cell or a human embryonic cell. 43. The method of claim 42, wherein the template nucleic acid comprises a nucleic acid encoding a chimeric antigen receptor (CAR). 44. The method according to claim 43, where CAR is: (a) CD19CAR; (b) BCMA CAR; (c) CD20CAR; (d) CD22CAR; (e) CD123CAR; (f) EGFRvIII CAR; or (g) mesothelin CAR. 45. The method according to any one of paragraphs. 42-44, where the contact of the specified cell with the nRNA molecule according to any one of paragraphs. 1-24 or a nucleic acid encoding said nRNA molecule and a Cas9 molecule or a nucleic acid encoding a Cas9 molecule reduces or abolishes B2M expression, and wherein the method further comprises propagating said cell. 46. The method according to any one of paragraphs. 42-45, where the nRNA molecule according to any one of paragraphs. 1-24, or a nucleic acid encoding said nRNA molecule, a Cas9 molecule, or a nucleic acid encoding a Cas9 molecule and a template nucleic acid, if present, is introduced into the cell ex vivo. 47. The method according to any one of paragraphs. 42-46, where the nRNA molecule or nucleic acid encoding the nRNA molecule and the Cas9 molecule or nucleic acid encoding the Cas9 molecule are included in one composition. 48. Cell for use in the treatment of a disease associated with the expression of a tumor antigen, where the cell contains an nRNA molecule according to any one of paragraphs. 1-24, the composition according to any one of paragraphs. 25-35 or 38-41, the nucleic acid of claim 36 and/or the vector of claim 37, wherein the cell is not a human germ cell or a human embryonic cell. 49. The cell for use according to claim 48, where the cell contains an indel at or near the target sequence of the nRNA molecule according to any one of paragraphs. 1-24 and wherein the cell exhibits reduced or abolished B2M expression and/or function. 50. A cell for use according to claim 48 or 49, wherein the cell contains an indel at or near the target sequence of the nRNA molecule according to claim 2, and wherein the cell exhibits reduced or abolished B2M expression and/or function. 51. Cage for use according to any one of paragraphs. 48-50, where the cell is an allogeneic cell. 52. Cage for use according to any one of paragraphs. 48-51, where the cell contains a second nRNA molecule containing crRNA and tracr, where crRNA contains a guide domain that is complementary to the target sequence in: (i) TRAC, where the directing domain contains any of SEQ ID NO: 5528 - SEQ ID NO: 5623 or SEQ ID NO: 5816 - SEQ ID NO: 5965; (ii) TRBC1, where the directing domain contains any of SEQ ID NO: 5624 - SEQ ID NO: 5643 or SEQ ID NO: 5966 - SEQ ID NO: 6097; (iii) TRBC2, where the directing domain contains any of SEQ ID NO: 5644 - SEQ ID NO: 5719 or SEQ ID NO: 6098 - SEQ ID NO: 6226; (iv) CD3D, where the directing domain contains any of SEQ ID NO: 393 - SEQ ID NO: 532 or SEQ ID NO: 10780 - SEQ ID NO: 10794; (v) CD3E, where the directing domain contains any of SEQ ID NO: 533 - SEQ ID NO: 839 or SEQ ID NO: 10677 - SEQ ID NO: 10764; or (vi) CD3G, where the directing domain contains any of SEQ ID NO: 840 - SEQ ID NO: 968 or SEQ ID NO: 10765 - SEQ ID NO: 10779, or where the cell contains an indel at or near a target sequence that is complementary to the targeting domain of any of (i)-(vi). 53. A cell for use according to claim 52, wherein the cell further comprises an indel in CIITA at or near a target sequence that is complementary to any of SEQ ID NOs: 6750-7716 or 7717-7804. 54. Cage for use according to any one of paragraphs. 48-53, where the cell further comprises a nucleic acid sequence or sequences encoding a CAR, where CAR is: (a) CD19CAR; (b) BCMA CAR; (c) CD20CAR; (d) CD22CAR; (e) CD123CAR; (f) EGFRvIII CAR; or (g) mesothelin CAR. 55. Cage for use according to any one of paragraphs. 48-54, wherein the disease is a proliferative disease, a precancerous condition, a cancer, and a non-cancer related indication associated with tumor antigen expression. 56. The cell for use according to claim 55, wherein the cancer is colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung carcinoma, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma , Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penile cancer, childhood solid tumors, bladder cancer, kidney or ureter cancer, renal pelvis carcinoma , neoplasia of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal canal tumor, brainstem glioma, hi adenoma pituitary gland, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, an environmental form of cancer, chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B- ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, blast plasmacytoid dendritic cell neoplasia, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone cell lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasia, macroglobulinemia Waldenström or preleukemia, a combination of these cancers and whether metastatic lesions of these forms of cancer. 57. Cell for use in transplantation, where the cell contains an nRNA molecule according to any one of paragraphs. 1-24, the composition according to any one of paragraphs. 25-35 or 38-41, the nucleic acid of claim 36 and/or the vector of claim 37, wherein the cell is not a human germ cell or a human embryonic cell. 58. A cell for use according to claim 57, where the cell contains an indel at or near the target sequence of the nRNA molecule according to any one of paragraphs. 1-24 and wherein the cell exhibits reduced or abolished B2M expression and/or function. 59. A cell for use according to claim 57 or 58, wherein the cell contains an indel at or near the target sequence of the nRNA molecule according to claim 2, and wherein the cell exhibits reduced or abolished B2M expression and/or function. 60. Cage for use according to any one of paragraphs. 57-59, where the cell is an allogeneic cell. 61. Cage for use according to any one of paragraphs. 57-60, where transplantation includes the administration of an immunosuppressant. 62. A cell for use in the treatment of a disease associated with the expression of a tumor antigen, comprising: (a) a nucleic acid sequence or sequences encoding a CAR, where CAR is a CD19 CAR or a BCMA CAR; (b) optionally, a nucleic acid sequence encoding an HLA-G or HLA-G:B2M fusion protein; (c) one or more indels at or near the sequence of one or more genes encoding a TCR component, where the TCR component is TRAC, TRBC1 TRBC2, CD3E, CD3D, and/or CD3G, optionally at or near a target nRNA sequence that contains any of SEQ ID NOs: 5528-5623, 5816-5965, 5624-5643, 5966-6097, 5644-5719, 6098-6226, 533-839, 10677-10764, 393-532, 10780-10794, 840-968 or 10765-10779; (d) an nRNA molecule according to any one of paragraphs. 1-24; (e) optionally, an indel at or near a CIITA-encoding gene sequence at or near an nRNA target sequence comprising any of SEQ ID NOs: 7739, 7769, 7771, 6750-7716, or 7717-7804; and (f) optionally, an indel at or near the sequence of the gene encoding LILRB1, at or near the target sequence of an nRNA comprising a targeting domain that is complementary to the target sequence in LILRB1; wherein the cell expresses a CAR and optionally an HLA-G or HLA-G:B2M fusion construct and exhibits reduced or abolished expression and/or function of B2M and one or more of: i) one or more TCR components selected from TRAC, TRBC1 TRBC2 , CD3D, CD3E and/or CD3G, ii) CIITA and/or iv) LILRB1, where the cell is not a human germ cell or a human embryonic cell. 63. The cell of claim 62, wherein the cell contains an indel at or near the sequence of the gene encoding B2M, at or near the target nRNA sequence that contains any of SEQ ID NOs: 1-83 or 5492-5527.

Images